Name	MOA	Target	Disease Area	Indication	SMILES	InChIKey	Phase
(R)-(-)-apomorphine	dopamine receptor agonist	ADRA2A, ADRA2B, ADRA2C, CALY, DRD1, DRD2, DRD3, DRD4, DRD5, HTR1A, HTR1B, HTR1D, HTR2A, HTR2B, HTR2C, HTR5A	neurology/psychiatry	Parkinson's Disease	CN1CCc2cccc-3c2[C@H]1Cc1ccc(O)c(O)c-31, CN1CCc2cccc-3c2[C@H]1Cc1ccc(O)c(O)c-31, CN1CCc2cccc-3c2[C@H]1Cc1ccc(O)c(O)c-31, CN1CCc2cccc-3c2[C@H]1Cc1ccc(O)c(O)c-31	VMWNQDUVQKEIOC-CYBMUJFWSA-N, VMWNQDUVQKEIOC-CYBMUJFWSA-N, VMWNQDUVQKEIOC-CYBMUJFWSA-N, VMWNQDUVQKEIOC-CYBMUJFWSA-N	Launched
(R)-(-)-rolipram	phosphodiesterase inhibitor	PDE4A, PDE4B, PDE4C, PDE4D, PDE5A			COc1ccc(cc1OC1CCCC1)[C@@H]1CNC(=O)C1, COc1ccc(cc1OC1CCCC1)[C@@H]1CNC(=O)C1, COc1ccc(cc1OC1CCCC1)[C@@H]1CNC(=O)C1, COc1ccc(cc1OC1CCCC1)[C@@H]1CNC(=O)C1, COc1ccc(cc1OC1CCCC1)[C@@H]1CNC(=O)C1	HJORMJIFDVBMOB-LBPRGKRZSA-N, HJORMJIFDVBMOB-LBPRGKRZSA-N, HJORMJIFDVBMOB-LBPRGKRZSA-N, HJORMJIFDVBMOB-LBPRGKRZSA-N, HJORMJIFDVBMOB-LBPRGKRZSA-N	Phase 1
(R)-baclofen	benzodiazepine receptor agonist	GABBR1, GABBR2			NC[C@H](CC(O)=O)c1ccc(Cl)cc1, NC[C@H](CC(O)=O)c1ccc(Cl)cc1, NC[C@H](CC(O)=O)c1ccc(Cl)cc1	KPYSYYIEGFHWSV-QMMMGPOBSA-N, KPYSYYIEGFHWSV-QMMMGPOBSA-N, KPYSYYIEGFHWSV-QMMMGPOBSA-N	Phase 3
(S)-(+)-rolipram	phosphodiesterase inhibitor	PDE4B, PDE4D			COc1ccc(cc1OC1CCCC1)[C@H]1CNC(=O)C1, COc1ccc(cc1OC1CCCC1)[C@H]1CNC(=O)C1, COc1ccc(cc1OC1CCCC1)[C@H]1CNC(=O)C1, COc1ccc(cc1OC1CCCC1)[C@H]1CNC(=O)C1, COc1ccc(cc1OC1CCCC1)[C@H]1CNC(=O)C1, COc1ccc(cc1OC1CCCC1)[C@H]1CNC(=O)C1	HJORMJIFDVBMOB-GFCCVEGCSA-N, HJORMJIFDVBMOB-GFCCVEGCSA-N, HJORMJIFDVBMOB-GFCCVEGCSA-N, HJORMJIFDVBMOB-GFCCVEGCSA-N, HJORMJIFDVBMOB-GFCCVEGCSA-N, HJORMJIFDVBMOB-GFCCVEGCSA-N	Phase 1
[sar9,met(o2)11]-substance-p	tachykinin antagonist	TACR1			CC(C)C[C@H](NC(=O)CN(C)C(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCN)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CCS(C)(=O)=O)C(N)=O	OUPXSLGGCPUZJJ-SARDKLJWSA-N	Preclinical
A-1070722	glycogen synthase kinase inhibitor	GSK3A, GSK3B			COc1ccc2c(NC(=O)Nc3cccc(n3)C(F)(F)F)ccnc2c1, COc1ccc2c(NC(=O)Nc3cccc(n3)C(F)(F)F)ccnc2c1, COc1ccc2c(NC(=O)Nc3cccc(n3)C(F)(F)F)ccnc2c1, COc1ccc2c(NC(=O)Nc3cccc(n3)C(F)(F)F)ccnc2c1, COc1ccc2c(NC(=O)Nc3cccc(n3)C(F)(F)F)ccnc2c1, COc1ccc2c(NC(=O)Nc3cccc(n3)C(F)(F)F)ccnc2c1	VQPBIJGXSXEOCU-UHFFFAOYSA-N, VQPBIJGXSXEOCU-UHFFFAOYSA-N, VQPBIJGXSXEOCU-UHFFFAOYSA-N, VQPBIJGXSXEOCU-UHFFFAOYSA-N, VQPBIJGXSXEOCU-UHFFFAOYSA-N, VQPBIJGXSXEOCU-UHFFFAOYSA-N	Preclinical
A-1120	retinoid receptor ligand	RBP4			OC(=O)c1ccccc1NC(=O)N1CCC(CC1)c1ccccc1C(F)(F)F	MEAQCLPMSVEOQF-UHFFFAOYSA-N	Preclinical
A-317491	purinergic receptor antagonist	P2RX3			OC(=O)c1cc(C(O)=O)c(cc1C(O)=O)C(=O)N(Cc1cccc(Oc2ccccc2)c1)[C@H]1CCCc2ccccc12, OC(=O)c1cc(C(O)=O)c(cc1C(O)=O)C(=O)N(Cc1cccc(Oc2ccccc2)c1)[C@H]1CCCc2ccccc12, OC(=O)c1cc(C(O)=O)c(cc1C(O)=O)C(=O)N(Cc1cccc(Oc2ccccc2)c1)[C@H]1CCCc2ccccc12	VQGBOYBIENNKMI-LJAQVGFWSA-N, VQGBOYBIENNKMI-LJAQVGFWSA-N, VQGBOYBIENNKMI-LJAQVGFWSA-N	Preclinical
A-33903					CC(=O)N[C@@H]1N=C(c2ccccc2)c2ccccc2NC1=O |&1:4,r,t:5|	MMXSDWJOQSEPSM-MRXNPFEDSA-N	Phase 2
A-366	histone lysine methyltransferase inhibitor	EHMT1, EHMT2			COc1cc2c(cc1OCCCN1CCCC1)N=C(N)C21CCC1 |t:19|, COc1cc2c(cc1OCCCN1CCCC1)N=C(N)C21CCC1 |t:19|, COc1cc2c(cc1OCCCN1CCCC1)N=C(N)C21CCC1 |t:19|, COc1cc2c(cc1OCCCN1CCCC1)N=C(N)C21CCC1 |t:19|, COc1cc2c(cc1OCCCN1CCCC1)N=C(N)C21CCC1 |t:19|, COc1cc2c(cc1OCCCN1CCCC1)N=C(N)C21CCC1 |t:19|	BKCDJTRMYWSXMC-UHFFFAOYSA-N, BKCDJTRMYWSXMC-UHFFFAOYSA-N, BKCDJTRMYWSXMC-UHFFFAOYSA-N, BKCDJTRMYWSXMC-UHFFFAOYSA-N, BKCDJTRMYWSXMC-UHFFFAOYSA-N, BKCDJTRMYWSXMC-UHFFFAOYSA-N	Preclinical
A-381393	dopamine receptor antagonist				Cc1ccc(cc1C)N1CCN(Cc2nc3ccccc3[nH]2)CC1	SAQMCVDGOIRQTC-UHFFFAOYSA-N	Preclinical
A-412997	dopamine receptor agonist	DRD4			Cc1cccc(NC(=O)CN2CCC(CC2)c2ccccn2)c1, Cc1cccc(NC(=O)CN2CCC(CC2)c2ccccn2)c1, Cc1cccc(NC(=O)CN2CCC(CC2)c2ccccn2)c1, Cc1cccc(NC(=O)CN2CCC(CC2)c2ccccn2)c1	JFCDMGGMCUKHST-UHFFFAOYSA-N, JFCDMGGMCUKHST-UHFFFAOYSA-N, JFCDMGGMCUKHST-UHFFFAOYSA-N, JFCDMGGMCUKHST-UHFFFAOYSA-N	Preclinical
A-438079	purinergic receptor antagonist	P2RX7			Clc1cccc(-c2nnnn2Cc2cccnc2)c1Cl, Clc1cccc(-c2nnnn2Cc2cccnc2)c1Cl, Clc1cccc(-c2nnnn2Cc2cccnc2)c1Cl	MMPAULQSJLVKHP-UHFFFAOYSA-N, MMPAULQSJLVKHP-UHFFFAOYSA-N, MMPAULQSJLVKHP-UHFFFAOYSA-N	Preclinical
A-485	histone acetyltransferase inhibitor				CNC(=O)Nc1ccc2c(CC[C@@]22OC(=O)N(CC(=O)N(Cc3ccc(F)cc3)[C@@H](C)C(F)(F)F)C2=O)c1, CNC(=O)Nc1ccc2c(CC[C@@]22OC(=O)N(CC(=O)N(Cc3ccc(F)cc3)[C@@H](C)C(F)(F)F)C2=O)c1	VRVJKILQRBSEAG-LFPIHBKWSA-N, VRVJKILQRBSEAG-LFPIHBKWSA-N	Preclinical
A-582941	nicotinic receptor agonist	CHRNA7			CN1C[C@H]2CN(C[C@H]2C1)c1ccc(nn1)-c1ccccc1, CN1C[C@H]2CN(C[C@H]2C1)c1ccc(nn1)-c1ccccc1	GTMRUYCIJSNXGB-GASCZTMLSA-N, GTMRUYCIJSNXGB-GASCZTMLSA-N	Preclinical
A-61603	adrenergic receptor agonist	ADRA1A, ADRA1B, ADRA1D			CS(=O)(=O)Nc1c(O)ccc2[C@H](CCCc12)C1=NCCN1 |&1:11,r,t:18|, CS(=O)(=O)Nc1c(O)ccc2[C@H](CCCc12)C1=NCCN1 |&1:11,r,t:18|	OQFCXJDXHCDLHX-NSHDSACASA-N, OQFCXJDXHCDLHX-NSHDSACASA-N	Preclinical
A-674563	AKT inhibitor	AKT1, PKIA, PRKACA			Cc1[nH]nc2ccc(cc12)-c1cncc(OC[C@@H](N)Cc2ccccc2)c1, Cc1[nH]nc2ccc(cc12)-c1cncc(OC[C@@H](N)Cc2ccccc2)c1, Cc1[nH]nc2ccc(cc12)-c1cncc(OC[C@@H](N)Cc2ccccc2)c1	BPNUQXPIQBZCMR-IBGZPJMESA-N, BPNUQXPIQBZCMR-IBGZPJMESA-N, BPNUQXPIQBZCMR-IBGZPJMESA-N	Preclinical
A-7	calmodulin antagonist				NCCCCCCCCCCNS(=O)(=O)c1cccc2c(Cl)cccc12, NCCCCCCCCCCNS(=O)(=O)c1cccc2c(Cl)cccc12, NCCCCCCCCCCNS(=O)(=O)c1cccc2c(Cl)cccc12, NCCCCCCCCCCNS(=O)(=O)c1cccc2c(Cl)cccc12, NCCCCCCCCCCNS(=O)(=O)c1cccc2c(Cl)cccc12, NCCCCCCCCCCNS(=O)(=O)c1cccc2c(Cl)cccc12	JLUUJHIQVIXTGT-UHFFFAOYSA-N, JLUUJHIQVIXTGT-UHFFFAOYSA-N, JLUUJHIQVIXTGT-UHFFFAOYSA-N, JLUUJHIQVIXTGT-UHFFFAOYSA-N, JLUUJHIQVIXTGT-UHFFFAOYSA-N, JLUUJHIQVIXTGT-UHFFFAOYSA-N	Preclinical
A-769662	AMPK activator				Oc1ccccc1-c1ccc(cc1)-c1csc2[nH]c(=O)c(C#N)c(O)c12, Oc1ccccc1-c1ccc(cc1)-c1csc2[nH]c(=O)c(C#N)c(O)c12, Oc1ccccc1-c1ccc(cc1)-c1csc2[nH]c(=O)c(C#N)c(O)c12	CTESJDQKVOEUOY-UHFFFAOYSA-N, CTESJDQKVOEUOY-UHFFFAOYSA-N, CTESJDQKVOEUOY-UHFFFAOYSA-N	Preclinical
A-784168	transient receptor potential channel antagonist	TRPV1			FC(F)(F)c1cccnc1N1CCC(=CC1)C(=O)Nc1ccc(cc1)S(=O)(=O)C(F)(F)F |c:14|, FC(F)(F)c1cccnc1N1CCC(=CC1)C(=O)Nc1ccc(cc1)S(=O)(=O)C(F)(F)F |c:14|	SDUAWRFBHRAFBM-UHFFFAOYSA-N, SDUAWRFBHRAFBM-UHFFFAOYSA-N	Preclinical
A-803467	sodium channel blocker	SCN10A			COc1cc(NC(=O)c2ccc(o2)-c2ccc(Cl)cc2)cc(OC)c1, COc1cc(NC(=O)c2ccc(o2)-c2ccc(Cl)cc2)cc(OC)c1	VHKBTPQDHDSBSP-UHFFFAOYSA-N, VHKBTPQDHDSBSP-UHFFFAOYSA-N	Preclinical
A-804598	purinergic receptor antagonist	P2RX7			C[C@H](N\C(NC#N)=N/c1cccc2ncccc12)c1ccccc1, C[C@H](\N=C(\NC#N)Nc1cccc2ncccc12)c1ccccc1, C[C@H](\N=C(\NC#N)Nc1cccc2ncccc12)c1ccccc1	PQYCRDPLPKGSME-AWEZNQCLSA-N, PQYCRDPLPKGSME-AWEZNQCLSA-N, PQYCRDPLPKGSME-AWEZNQCLSA-N	Preclinical
A-839977	purinergic receptor antagonist	P2RX7			Clc1cccc(c1Cl)-n1nnnc1NCc1ccccc1Oc1ccccn1, Clc1cccc(c1Cl)-n1nnnc1NCc1ccccc1Oc1ccccn1	GMVNBKZQJFRFAR-UHFFFAOYSA-N, GMVNBKZQJFRFAR-UHFFFAOYSA-N	Preclinical
A-867744	acetylcholine receptor allosteric modulator	CHRNA3, CHRNA4, CHRNA7			CCC(=O)c1cc(-c2ccc(Cl)cc2)n(c1C)-c1ccc(cc1)S(N)(=O)=O, CCC(=O)c1cc(-c2ccc(Cl)cc2)n(c1C)-c1ccc(cc1)S(N)(=O)=O, CCC(=O)c1cc(-c2ccc(Cl)cc2)n(c1C)-c1ccc(cc1)S(N)(=O)=O, CCC(=O)c1cc(-c2ccc(Cl)cc2)n(c1C)-c1ccc(cc1)S(N)(=O)=O, CCC(=O)c1cc(-c2ccc(Cl)cc2)n(c1C)-c1ccc(cc1)S(N)(=O)=O	ABACVOXFUHDKNZ-UHFFFAOYSA-N, ABACVOXFUHDKNZ-UHFFFAOYSA-N, ABACVOXFUHDKNZ-UHFFFAOYSA-N, ABACVOXFUHDKNZ-UHFFFAOYSA-N, ABACVOXFUHDKNZ-UHFFFAOYSA-N	Preclinical
A-887826	sodium channel blocker	SCN10A			CCCCOc1ccc(cc1Cl)-c1cncc(c1)C(=O)NCc1cccnc1N1CCOCC1, CCCCOc1ccc(cc1Cl)-c1cncc(c1)C(=O)NCc1cccnc1N1CCOCC1	JPJGFWKHSMUKFO-UHFFFAOYSA-N, JPJGFWKHSMUKFO-UHFFFAOYSA-N	Preclinical
A-922500	diacylglycerol O acyltransferase inhibitor	DGAT1			OC(=O)[C@@H]1CCC[C@H]1C(=O)c1ccc(cc1)-c1ccc(NC(=O)Nc2ccccc2)cc1, OC(=O)[C@@H]1CCC[C@H]1C(=O)c1ccc(cc1)-c1ccc(NC(=O)Nc2ccccc2)cc1, OC(=O)[C@@H]1CCC[C@H]1C(=O)c1ccc(cc1)-c1ccc(NC(=O)Nc2ccccc2)cc1	BOZRFEQDOFSZBV-DHIUTWEWSA-N, BOZRFEQDOFSZBV-DHIUTWEWSA-N, BOZRFEQDOFSZBV-DHIUTWEWSA-N	Preclinical
A-939572	stearoyl-CoA desaturase inhibitor	SCD			CNC(=O)c1cccc(NC(=O)N2CCC(CC2)Oc2ccccc2Cl)c1, CNC(=O)c1cccc(NC(=O)N2CCC(CC2)Oc2ccccc2Cl)c1, CNC(=O)c1cccc(NC(=O)N2CCC(CC2)Oc2ccccc2Cl)c1	DPYTYQFYDLYWHZ-UHFFFAOYSA-N, DPYTYQFYDLYWHZ-UHFFFAOYSA-N, DPYTYQFYDLYWHZ-UHFFFAOYSA-N	Preclinical
A-967079	transient receptor potential channel antagonist	TRPA1			CC\C(=N/O)\C(\C)=C\c1ccc(F)cc1, CC\C(=N/O)\C(\C)=C\c1ccc(F)cc1	HKROEBDHHKMNBZ-CHBKHGQFSA-N, HKROEBDHHKMNBZ-CHBKHGQFSA-N	Preclinical
A-987306	histamine receptor antagonist	ADORA1, AVPR1A, CCR1, CHRM1, CHRM2, CHRM3, CHRM4, DRD3, HTR1A, HTR1B, HTR2A, HTR2B, HTR3A, TACR2			Nc1nc(N2CCNCC2)c2CCC3=C([C@@H]4CCCC[C@@H]4O3)c2n1 |t:14|, Nc1nc(N2CCNCC2)c2CCC3=C([C@@H]4CCCC[C@@H]4O3)c2n1 |t:14|	DJKJVWJQAVGLHJ-YPMHNXCESA-N, DJKJVWJQAVGLHJ-YPMHNXCESA-N	Preclinical
AA-29504	GABA receptor positive allosteric modulator	GABRA1, GABRA4, GABRB3			CCOC(=O)Nc1ccc(NCc2c(C)cc(C)cc2C)cc1N, CCOC(=O)Nc1ccc(NCc2c(C)cc(C)cc2C)cc1N, CCOC(=O)Nc1ccc(NCc2c(C)cc(C)cc2C)cc1N	SCOOTUMXCXKEAD-UHFFFAOYSA-N, SCOOTUMXCXKEAD-UHFFFAOYSA-N, SCOOTUMXCXKEAD-UHFFFAOYSA-N	Preclinical
AAI101	lactamase inhibitor				[H][C@@]12CC(=O)N1[C@@H](C(O)=O)[C@](C)(Cn1cc[n+](C)n1)S2(=O)=O	HFZITXBUTWITPT-YWVKMMECSA-O	Phase 3
AB-423	HBV capsid assembly inhibitor				CC[C@@H](C)NS(=O)(=O)c1ccc(F)c(c1)C(=O)Nc1ccc(F)c(F)c1	BBLXLHYPDOMJMO-SNVBAGLBSA-N	Preclinical
abacavir	nucleoside reverse transcriptase inhibitor		infectious disease	human immunodeficiency virus (HIV-1)	Nc1nc(NC2CC2)c2ncn([C@@H]3C[C@H](CO)C=C3)c2n1 |c:18|, Nc1nc(NC2CC2)c2ncn([C@@H]3C[C@H](CO)C=C3)c2n1 |c:18|, Nc1nc(NC2CC2)c2ncn([C@@H]3C[C@H](CO)C=C3)c2n1 |c:18|, Nc1nc(NC2CC2)c2ncn([C@@H]3C[C@H](CO)C=C3)c2n1 |c:18|, Nc1nc(NC2CC2)c2ncn([C@@H]3C[C@H](CO)C=C3)c2n1 |c:18|, Nc1nc(NC2CC2)c2ncn([C@@H]3C[C@H](CO)C=C3)c2n1 |c:18|	MCGSCOLBFJQGHM-SCZZXKLOSA-N, MCGSCOLBFJQGHM-SCZZXKLOSA-N, MCGSCOLBFJQGHM-SCZZXKLOSA-N, MCGSCOLBFJQGHM-SCZZXKLOSA-N, MCGSCOLBFJQGHM-SCZZXKLOSA-N, MCGSCOLBFJQGHM-SCZZXKLOSA-N	Launched
abafungin	sterol methyltransferase inhibitor				Cc1ccc(Oc2ccccc2-c2csc(NC3=NCCCN3)n2)c(C)c1 |t:18|	TYBHXIFFPVFXQW-UHFFFAOYSA-N	Phase 3
abamectin	benzodiazepine receptor agonist	GABBR1, GABBR2	infectious disease	gastrointestinal parasites	[H][C@@]12OC\C3=C/C=C/[C@H](C)[C@H](O[C@@]4([H])C[C@H](OC)[C@@H](O[C@@]5([H])C[C@H](OC)[C@@H](O)[C@H](C)O5)[C@H](C)O4)\C(C)=C\C[C@]4([H])C[C@@]([H])(C[C@@]5(O[C@H](C(C)C)[C@@H](C)C=C5)O4)OC(=O)[C@]([H])(C=C(C)[C@H]1O)[C@@]23O |c:4,54,t:6,37,64|	ZFUKERYTFURFGA-PVVXTEPVSA-N	Launched
abametapir	metalloproteinase inhibitor	MMP9			Cc1ccc(nc1)-c1ccc(C)cn1, Cc1ccc(nc1)-c1ccc(C)cn1	PTRATZCAGVBFIQ-UHFFFAOYSA-N, PTRATZCAGVBFIQ-UHFFFAOYSA-N	Phase 3
abarelix	gonadotropin releasing factor hormone receptor antagonist	GNRHR			CC(C)C[C@H](NC(=O)[C@@H](CC(N)=O)NC(=O)[C@H](Cc1ccc(O)cc1)N(C)C(=O)[C@H](CO)NC(=O)[C@@H](Cc1cccnc1)NC(=O)[C@@H](Cc1ccc(Cl)cc1)NC(=O)[C@@H](Cc1ccc2ccccc2c1)NC(C)=O)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(N)=O	AIWRTTMUVOZGPW-HSPKUQOVSA-N	Phase 3
ABBV-744	bromodomain inhibitor				CCNC(=O)c1cc2c(cn(C)c(O)c2n1)-c1cc(ccc1Oc1c(C)cc(F)cc1C)C(C)(C)O	LQPFCYWRBQRRGE-UHFFFAOYSA-N	Phase 1
ABC-294640	sphingosine kinase inhibitor	SPHK2			Clc1ccc(cc1)[C@]12C[C@H]3C[C@H](C[C@](C3)(C1)C(=O)NCc1ccncc1)C2 |&1:7,9,11,13|	CAOTVXGYTWCKQE-BRNYJPRKSA-N	Phase 2
abemaciclib	CDK inhibitor	CDK4, CDK6	oncology	breast cancer	CCN1CCN(Cc2ccc(Nc3ncc(F)c(n3)-c3cc(F)c4nc(C)n(C(C)C)c4c3)nc2)CC1, CCN1CCN(Cc2ccc(Nc3ncc(F)c(n3)-c3cc(F)c4nc(C)n(C(C)C)c4c3)nc2)CC1, CCN1CCN(Cc2ccc(Nc3ncc(F)c(n3)-c3cc(F)c4nc(C)n(C(C)C)c4c3)nc2)CC1, CCN1CCN(Cc2ccc(Nc3ncc(F)c(n3)-c3cc(F)c4nc(C)n(C(C)C)c4c3)nc2)CC1, CCN1CCN(Cc2ccc(Nc3ncc(F)c(n3)-c3cc(F)c4nc(C)n(C(C)C)c4c3)nc2)CC1, CCN1CCN(Cc2ccc(Nc3ncc(F)c(n3)-c3cc(F)c4nc(C)n(C(C)C)c4c3)nc2)CC1, CCN1CCN(Cc2ccc(Nc3ncc(F)c(n3)-c3cc(F)c4nc(C)n(C(C)C)c4c3)nc2)CC1, CCN1CCN(Cc2ccc(Nc3ncc(F)c(n3)-c3cc(F)c4nc(C)n(C(C)C)c4c3)nc2)CC1	UZWDCWONPYILKI-UHFFFAOYSA-N, UZWDCWONPYILKI-UHFFFAOYSA-N, UZWDCWONPYILKI-UHFFFAOYSA-N, UZWDCWONPYILKI-UHFFFAOYSA-N, UZWDCWONPYILKI-UHFFFAOYSA-N, UZWDCWONPYILKI-UHFFFAOYSA-N, UZWDCWONPYILKI-UHFFFAOYSA-N, UZWDCWONPYILKI-UHFFFAOYSA-N	Launched
abiraterone	androgen biosynthesis inhibitor	CYP11B1, CYP17A1	oncology	prostate cancer	C[C@]12CC[C@H]3[C@@H](CC=C4C[C@@H](O)CC[C@]34C)[C@@H]1CC=C2c1cccnc1 |c:21,t:7|, C[C@]12CC[C@H]3[C@@H](CC=C4C[C@@H](O)CC[C@]34C)[C@@H]1CC=C2c1cccnc1 |c:21,t:7|, C[C@]12CC[C@H]3[C@@H](CC=C4C[C@@H](O)CC[C@]34C)[C@@H]1CC=C2c1cccnc1 |c:21,t:7|	GZOSMCIZMLWJML-VJLLXTKPSA-N, GZOSMCIZMLWJML-VJLLXTKPSA-N, GZOSMCIZMLWJML-VJLLXTKPSA-N	Launched
abiraterone-acetate	androgen biosynthesis inhibitor	CYP17A1	oncology	prostate cancer	CC(=O)O[C@H]1CC[C@]2(C)[C@H]3CC[C@@]4(C)[C@@H](CC=C4c4cccnc4)[C@@H]3CC=C2C1 |c:16,29|, CC(=O)O[C@H]1CC[C@]2(C)[C@H]3CC[C@@]4(C)[C@@H](CC=C4c4cccnc4)[C@@H]3CC=C2C1 |c:16,29|, CC(=O)O[C@H]1CC[C@]2(C)[C@H]3CC[C@@]4(C)[C@@H](CC=C4c4cccnc4)[C@@H]3CC=C2C1 |c:16,29|, CC(=O)O[C@H]1CC[C@]2(C)[C@H]3CC[C@@]4(C)[C@@H](CC=C4c4cccnc4)[C@@H]3CC=C2C1 |c:16,29|, CC(=O)O[C@H]1CC[C@]2(C)[C@H]3CC[C@@]4(C)[C@@H](CC=C4c4cccnc4)[C@@H]3CC=C2C1 |c:16,29|	UVIQSJCZCSLXRZ-UBUQANBQSA-N, UVIQSJCZCSLXRZ-UBUQANBQSA-N, UVIQSJCZCSLXRZ-UBUQANBQSA-N, UVIQSJCZCSLXRZ-UBUQANBQSA-N, UVIQSJCZCSLXRZ-UBUQANBQSA-N	Launched
ABT-072	RNA polymerase inhibitor				COc1c(\C=C\c2ccc(NS(C)(=O)=O)cc2)cc(cc1C(C)(C)C)-n1ccc(=O)[nH]c1=O	XMZSTQYSBYEENY-RMKNXTFCSA-N	Phase 2
ABT-202	acetylcholine receptor agonist				N[C@H]1CCN(C1)c1cccnc1 |&1:1|	LVGMMVAWLISWJD-QMMMGPOBSA-N	Phase 1
ABT-239	histamine receptor antagonist	HRH1, HRH2, HRH3			C[C@@H]1CCCN1CCc1cc2cc(ccc2o1)-c1ccc(cc1)C#N	KFHYZKCRXNRKRC-MRXNPFEDSA-N	Phase 1
ABT-491	platelet activating factor receptor antagonist	PTAFR			CN(C)C(=O)n1cc(C(=O)c2ccc(Cn3c(C)nc4cnccc34)c(F)c2)c2c(cccc12)C#C, CN(C)C(=O)n1cc(C(=O)c2ccc(Cn3c(C)nc4cnccc34)c(F)c2)c2c(cccc12)C#C, CN(C)C(=O)n1cc(C(=O)c2ccc(Cn3c(C)nc4cnccc34)c(F)c2)c2c(cccc12)C#C	GDLNHSUSOZEAOR-UHFFFAOYSA-N, GDLNHSUSOZEAOR-UHFFFAOYSA-N, GDLNHSUSOZEAOR-UHFFFAOYSA-N	Phase 1
ABT-639	calcium channel blocker	CACNA1G, CACNA1H, CACNA1I			Fc1ccccc1NS(=O)(=O)c1cc(C(=O)N2CCN3CCC[C@@H]3C2)c(Cl)cc1F, Fc1ccccc1NS(=O)(=O)c1cc(C(=O)N2CCN3CCC[C@@H]3C2)c(Cl)cc1F	AGPIHNZOZNKRGT-CYBMUJFWSA-N, AGPIHNZOZNKRGT-CYBMUJFWSA-N	Phase 2
ABT-702	adenosine kinase inhibitor	ADK			Nc1ncnc2nc(cc(-c3cccc(Br)c3)c12)-c1ccc(nc1)N1CCOCC1, Nc1ncnc2nc(cc(-c3cccc(Br)c3)c12)-c1ccc(nc1)N1CCOCC1	RQCXKDWOCUJWQZ-UHFFFAOYSA-N, RQCXKDWOCUJWQZ-UHFFFAOYSA-N	Preclinical
ABT-724	dopamine receptor agonist	DRD4			C(N1CCN(CC1)c1ccccn1)c1nc2ccccc2[nH]1, C(N1CCN(CC1)c1ccccn1)c1nc2ccccc2[nH]1, C(N1CCN(CC1)c1ccccn1)c1nc2ccccc2[nH]1, C(N1CCN(CC1)c1ccccn1)c1nc2ccccc2[nH]1	FRPJGTNLZNXQEX-UHFFFAOYSA-N, FRPJGTNLZNXQEX-UHFFFAOYSA-N, FRPJGTNLZNXQEX-UHFFFAOYSA-N, FRPJGTNLZNXQEX-UHFFFAOYSA-N	Phase 2
ABT-737	BCL inhibitor	BCL2, BCL2L1, BCL2L2			CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(cc1[N+]([O-])=O)S(=O)(=O)NC(=O)c1ccc(cc1)N1CCN(Cc2ccccc2-c2ccc(Cl)cc2)CC1, CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(cc1[N+]([O-])=O)S(=O)(=O)NC(=O)c1ccc(cc1)N1CCN(Cc2ccccc2-c2ccc(Cl)cc2)CC1, CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(cc1[N+]([O-])=O)S(=O)(=O)NC(=O)c1ccc(cc1)N1CCN(Cc2ccccc2-c2ccc(Cl)cc2)CC1, CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(cc1[N+]([O-])=O)S(=O)(=O)NC(=O)c1ccc(cc1)N1CCN(Cc2ccccc2-c2ccc(Cl)cc2)CC1, CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(cc1[N+]([O-])=O)S(=O)(=O)NC(=O)c1ccc(cc1)N1CCN(Cc2ccccc2-c2ccc(Cl)cc2)CC1, CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(cc1[N+]([O-])=O)S(=O)(=O)NC(=O)c1ccc(cc1)N1CCN(Cc2ccccc2-c2ccc(Cl)cc2)CC1, CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(cc1[N+]([O-])=O)S(=O)(=O)NC(=O)c1ccc(cc1)N1CCN(Cc2ccccc2-c2ccc(Cl)cc2)CC1, CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(cc1[N+]([O-])=O)S(=O)(=O)NC(=O)c1ccc(cc1)N1CCN(Cc2ccccc2-c2ccc(Cl)cc2)CC1, CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(cc1[N+]([O-])=O)S(=O)(=O)NC(=O)c1ccc(cc1)N1CCN(Cc2ccccc2-c2ccc(Cl)cc2)CC1, CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(cc1[N+]([O-])=O)S(=O)(=O)NC(=O)c1ccc(cc1)N1CCN(Cc2ccccc2-c2ccc(Cl)cc2)CC1, CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(cc1[N+]([O-])=O)S(=O)(=O)NC(=O)c1ccc(cc1)N1CCN(Cc2ccccc2-c2ccc(Cl)cc2)CC1, CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(cc1[N+]([O-])=O)S(=O)(=O)NC(=O)c1ccc(cc1)N1CCN(Cc2ccccc2-c2ccc(Cl)cc2)CC1, CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(cc1[N+]([O-])=O)S(=O)(=O)NC(=O)c1ccc(cc1)N1CCN(Cc2ccccc2-c2ccc(Cl)cc2)CC1, CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(cc1[N+]([O-])=O)S(=O)(=O)NC(=O)c1ccc(cc1)N1CCN(Cc2ccccc2-c2ccc(Cl)cc2)CC1, CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(cc1[N+]([O-])=O)S(=O)(=O)NC(=O)c1ccc(cc1)N1CCN(Cc2ccccc2-c2ccc(Cl)cc2)CC1, CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(cc1[N+]([O-])=O)S(=O)(=O)NC(=O)c1ccc(cc1)N1CCN(Cc2ccccc2-c2ccc(Cl)cc2)CC1, CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(cc1[N+]([O-])=O)S(=O)(=O)NC(=O)c1ccc(cc1)N1CCN(Cc2ccccc2-c2ccc(Cl)cc2)CC1	HPLNQCPCUACXLM-PGUFJCEWSA-N, HPLNQCPCUACXLM-PGUFJCEWSA-N, HPLNQCPCUACXLM-PGUFJCEWSA-N, HPLNQCPCUACXLM-PGUFJCEWSA-N, HPLNQCPCUACXLM-PGUFJCEWSA-N, HPLNQCPCUACXLM-PGUFJCEWSA-N, HPLNQCPCUACXLM-PGUFJCEWSA-N, HPLNQCPCUACXLM-PGUFJCEWSA-N, HPLNQCPCUACXLM-PGUFJCEWSA-N, HPLNQCPCUACXLM-PGUFJCEWSA-N, HPLNQCPCUACXLM-PGUFJCEWSA-N, HPLNQCPCUACXLM-PGUFJCEWSA-N, HPLNQCPCUACXLM-PGUFJCEWSA-N, HPLNQCPCUACXLM-PGUFJCEWSA-N, HPLNQCPCUACXLM-PGUFJCEWSA-N, InChI=1S/C42H45ClN6O5S2/c1-46(2)23-22-35(30-55-37-9-4-3-5-10-37)44-40-21-20-38(28-41(40)49(51)52)56(53,54)45-42(50)32-14-18-36(19-15-32)48-26-24-47(25-27-48)29-33-8-6-7-11-39(33)31-12-16-34(43)17-13-31/h3-21,28,35,44H,22-27,29-30H2,1-2H3,(H,45,50)/t35-/m1/s1, InChI=1S/C42H45ClN6O5S2/c1-46(2)23-22-35(30-55-37-9-4-3-5-10-37)44-40-21-20-38(28-41(40)49(51)52)56(53,54)45-42(50)32-14-18-36(19-15-32)48-26-24-47(25-27-48)29-33-8-6-7-11-39(33)31-12-16-34(43)17-13-31/h3-21,28,35,44H,22-27,29-30H2,1-2H3,(H,45,50)/t35-/m1/s1	Phase 1/Phase 2
ABT-751	tubulin polymerization inhibitor	TUBB			COc1ccc(cc1)S(=O)(=O)Nc1cccnc1Nc1ccc(O)cc1, COc1ccc(cc1)S(=O)(=O)Nc1cccnc1Nc1ccc(O)cc1, COc1ccc(cc1)S(=O)(=O)Nc1cccnc1Nc1ccc(O)cc1, COc1ccc(cc1)S(=O)(=O)Nc1cccnc1Nc1ccc(O)cc1, COc1ccc(cc1)S(=O)(=O)Nc1cccnc1Nc1ccc(O)cc1, COc1ccc(cc1)S(=O)(=O)Nc1cccnc1Nc1ccc(O)cc1, COc1ccc(cc1)S(=O)(=O)Nc1cccnc1Nc1ccc(O)cc1, COc1ccc(cc1)S(=O)(=O)Nc1cccnc1Nc1ccc(O)cc1, COc1ccc(cc1)S(=O)(=O)Nc1cccnc1Nc1ccc(O)cc1	URCVCIZFVQDVPM-UHFFFAOYSA-N, URCVCIZFVQDVPM-UHFFFAOYSA-N, URCVCIZFVQDVPM-UHFFFAOYSA-N, URCVCIZFVQDVPM-UHFFFAOYSA-N, URCVCIZFVQDVPM-UHFFFAOYSA-N, URCVCIZFVQDVPM-UHFFFAOYSA-N, URCVCIZFVQDVPM-UHFFFAOYSA-N, URCVCIZFVQDVPM-UHFFFAOYSA-N, URCVCIZFVQDVPM-UHFFFAOYSA-N	Phase 2
ABX-1431	monoacylglycerol lipase inhibitor				FC(F)(F)C(OC(=O)N1CCN(Cc2ccc(cc2N2CCCC2)C(F)(F)F)CC1)C(F)(F)F	SQZJGTOZFRNWCX-UHFFFAOYSA-N	Phase 2
ABX464	antiviral				FC(F)(F)Oc1ccc(Nc2ccc3cccc(Cl)c3n2)cc1	OZOGDCZJYVSUBR-UHFFFAOYSA-N	Phase 2
AC-186	estrogen receptor agonist	ESR2			Oc1ccc(cc1)C1(CCC(F)(F)CC1)c1ccccc1F, Oc1ccc(cc1)C1(CCC(F)(F)CC1)c1ccccc1F, Oc1ccc(cc1)C1(CCC(F)(F)CC1)c1ccccc1F	HSMUKSLNDJOZQG-UHFFFAOYSA-N, HSMUKSLNDJOZQG-UHFFFAOYSA-N, HSMUKSLNDJOZQG-UHFFFAOYSA-N	Preclinical
AC-261066	retinoid receptor agonist	RARB			CCCCOCCOc1nc(sc1C)-c1ccc(C(O)=O)c(F)c1, CCCCOCCOc1nc(sc1C)-c1ccc(C(O)=O)c(F)c1	HSAOETBFVAWNRP-UHFFFAOYSA-N, HSAOETBFVAWNRP-UHFFFAOYSA-N	Preclinical
AC-264613	PAR agonist	F2RL1			C\C(=N/NC(=O)[C@H]1[C@@H](CNC1=O)c1ccccc1)c1cccc(Br)c1, C\C(=N/NC(=O)[C@H]1[C@@H](CNC1=O)c1ccccc1)c1cccc(Br)c1, C\C(=N/NC(=O)[C@H]1[C@@H](CNC1=O)c1ccccc1)c1cccc(Br)c1, C\C(=N/NC(=O)[C@H]1[C@@H](CNC1=O)c1ccccc1)c1cccc(Br)c1	RQKXQCSEZPQBNZ-QSBCOWLBSA-N, RQKXQCSEZPQBNZ-QSBCOWLBSA-N, RQKXQCSEZPQBNZ-QSBCOWLBSA-N, RQKXQCSEZPQBNZ-QSBCOWLBSA-N	Preclinical
AC-55541	PARP inhibitor	PARP2			C\C(=N/NC(=O)[C@@H](NC(=O)c1ccccc1)c1n[nH]c(=O)c2ccccc12)c1cccc(Br)c1 |&1:6,r|, C\C(=N/NC(=O)[C@@H](NC(=O)c1ccccc1)c1n[nH]c(=O)c2ccccc12)c1cccc(Br)c1 |&1:6,r|	UCUHFWIFSHROPY-SQEMJAKJSA-N, UCUHFWIFSHROPY-SQEMJAKJSA-N	Preclinical
AC-55649	retinoid receptor agonist	RARA, RARB			CCCCCCCCc1ccc(cc1)-c1ccc(cc1)C(O)=O, CCCCCCCCc1ccc(cc1)-c1ccc(cc1)C(O)=O, CCCCCCCCc1ccc(cc1)-c1ccc(cc1)C(O)=O, CCCCCCCCc1ccc(cc1)-c1ccc(cc1)C(O)=O	HXBKPYIEQLLNBK-UHFFFAOYSA-N, HXBKPYIEQLLNBK-UHFFFAOYSA-N, HXBKPYIEQLLNBK-UHFFFAOYSA-N, HXBKPYIEQLLNBK-UHFFFAOYSA-N	Preclinical
AC-710	PDGFR tyrosine kinase receptor inhibitor	CSF1R, FLT3, KIT, PDGFRA, PDGFRB			CCN1C(C)(C)CC(CC1(C)C)Oc1ccc(nc1)C(=O)Nc1ccc(NC(=O)Nc2cc(on2)C(C)(C)C)cc1, CCN1C(C)(C)CC(CC1(C)C)Oc1ccc(nc1)C(=O)Nc1ccc(NC(=O)Nc2cc(on2)C(C)(C)C)cc1, CCN1C(C)(C)CC(CC1(C)C)Oc1ccc(nc1)C(=O)Nc1ccc(NC(=O)Nc2cc(on2)C(C)(C)C)cc1	JVCWPUFNLFSKFS-UHFFFAOYSA-N, JVCWPUFNLFSKFS-UHFFFAOYSA-N, JVCWPUFNLFSKFS-UHFFFAOYSA-N	Preclinical
AC-7954-(+/-)	urotensin receptor agonist	UTS2R			CN(C)CC[C@]1(Cc2ccccc2C(=O)O1)c1ccc(Cl)cc1 |&1:5|, CN(C)CC[C@]1(Cc2ccccc2C(=O)O1)c1ccc(Cl)cc1 |&1:5|, CN(C)CC[C@]1(Cc2ccccc2C(=O)O1)c1ccc(Cl)cc1 |&1:5|, CN(C)CC[C@]1(Cc2ccccc2C(=O)O1)c1ccc(Cl)cc1 |&1:5|	HIVBATDUVFEJFZ-IBGZPJMESA-N, HIVBATDUVFEJFZ-IBGZPJMESA-N, HIVBATDUVFEJFZ-IBGZPJMESA-N, HIVBATDUVFEJFZ-IBGZPJMESA-N	Preclinical
acadesine	AMPK activator				NC(=O)c1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c1N, NC(=O)c1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c1N, NC(=O)c1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c1N	RTRQQBHATOEIAF-UUOKFMHZSA-N, RTRQQBHATOEIAF-UUOKFMHZSA-N, RTRQQBHATOEIAF-UUOKFMHZSA-N	Phase 3
acalabrutinib	Bruton's tyrosine kinase (BTK) inhibitor	BTK	hematologic malignancy	mantle cell lymphoma (MCL)	CC#CC(=O)N1CCC[C@H]1c1nc(-c2ccc(cc2)C(=O)Nc2ccccn2)c2c(N)nccn12, CC#CC(=O)N1CCC[C@H]1c1nc(-c2ccc(cc2)C(=O)Nc2ccccn2)c2c(N)nccn12, CC#CC(=O)N1CCC[C@H]1c1nc(-c2ccc(cc2)C(=O)Nc2ccccn2)c2c(N)nccn12, CC#CC(=O)N1CCC[C@H]1c1nc(-c2ccc(cc2)C(=O)Nc2ccccn2)c2c(N)nccn12	WDENQIQQYWYTPO-IBGZPJMESA-N, WDENQIQQYWYTPO-IBGZPJMESA-N, WDENQIQQYWYTPO-IBGZPJMESA-N, WDENQIQQYWYTPO-IBGZPJMESA-N	Launched
acalisib	PI3K inhibitor	PIK3CB, PIK3CD			C[C@H](Nc1ncnc2nc[nH]c12)c1nc2ccc(F)cc2c(=O)n1-c1ccccc1, C[C@H](Nc1ncnc2nc[nH]c12)c1nc2ccc(F)cc2c(=O)n1-c1ccccc1	DOCINCLJNAXZQF-LBPRGKRZSA-N, DOCINCLJNAXZQF-LBPRGKRZSA-N	Phase 1
acamprosate	glutamate receptor antagonist	GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D, GRIN3A, GRIN3B, GRM5	neurology/psychiatry	abstinence from alcohol	CC(=O)NCCCS(O)(=O)=O, CC(=O)NCCCS(O)(=O)=O, CC(=O)NCCCS(O)(=O)=O	AFCGFAGUEYAMAO-UHFFFAOYSA-N, AFCGFAGUEYAMAO-UHFFFAOYSA-N, AFCGFAGUEYAMAO-UHFFFAOYSA-N	Launched
acarbose	glucosidase inhibitor	AMY2A, MGAM	endocrinology	diabetes mellitus	C[C@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@H](O[C@@H]3[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]3O)[C@H](O)[C@H]2O)[C@H](O)[C@@H](O)[C@@H]1N[C@H]1C=C(CO)[C@@H](O)[C@H](O)[C@H]1O |t:37|, C[C@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@H](O[C@@H]3[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]3O)[C@H](O)[C@H]2O)[C@H](O)[C@@H](O)[C@@H]1N[C@H]1C=C(CO)[C@@H](O)[C@H](O)[C@H]1O |t:37|, C[C@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@H](O[C@@H]3[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]3O)[C@H](O)[C@H]2O)[C@H](O)[C@@H](O)[C@@H]1N[C@H]1C=C(CO)[C@@H](O)[C@H](O)[C@H]1O |t:37|, C[C@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@H](O[C@@H]3[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]3O)[C@H](O)[C@H]2O)[C@H](O)[C@@H](O)[C@@H]1N[C@H]1C=C(CO)[C@@H](O)[C@H](O)[C@H]1O |t:37|, C[C@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@H](O[C@@H]3[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]3O)[C@H](O)[C@H]2O)[C@H](O)[C@@H](O)[C@@H]1N[C@H]1C=C(CO)[C@@H](O)[C@H](O)[C@H]1O |t:37|, C[C@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@H](O[C@@H]3[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]3O)[C@H](O)[C@H]2O)[C@H](O)[C@@H](O)[C@@H]1N[C@H]1C=C(CO)[C@@H](O)[C@H](O)[C@H]1O |t:37|, C[C@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@H](O[C@@H]3[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]3O)[C@H](O)[C@H]2O)[C@H](O)[C@@H](O)[C@@H]1N[C@H]1C=C(CO)[C@@H](O)[C@H](O)[C@H]1O |t:37|	XUFXOAAUWZOOIT-SXARVLRPSA-N, XUFXOAAUWZOOIT-SXARVLRPSA-N, XUFXOAAUWZOOIT-SXARVLRPSA-N, XUFXOAAUWZOOIT-SXARVLRPSA-N, XUFXOAAUWZOOIT-SXARVLRPSA-N, XUFXOAAUWZOOIT-SXARVLRPSA-N, XUFXOAAUWZOOIT-SXARVLRPSA-N	Launched
ACDPP	glutamate receptor antagonist	GRM5			CN(C)c1nc(N)c(nc1Cl)C(=O)Nc1cccnc1, CN(C)c1nc(N)c(nc1Cl)C(=O)Nc1cccnc1, CN(C)c1nc(N)c(nc1Cl)C(=O)Nc1cccnc1	RNGRUHWJJPTYNR-UHFFFAOYSA-N, RNGRUHWJJPTYNR-UHFFFAOYSA-N, RNGRUHWJJPTYNR-UHFFFAOYSA-N	Preclinical
acebilustat	leukotriene inhibitor				[H][C@]12CN(Cc3ccc(cc3)C(O)=O)[C@]([H])(CN1Cc1ccc(Oc3ccc(cc3)-c3ncco3)cc1)C2	GERJIEKMNDGSCS-DQEYMECFSA-N	Phase 2
acebutolol	adrenergic receptor antagonist	ADRB1	cardiology	hypertension, ventricular arrhythmias	CCCC(=O)Nc1ccc(OCC(O)CNC(C)C)c(c1)C(C)=O, CCCC(=O)Nc1ccc(OCC(O)CNC(C)C)c(c1)C(C)=O, CCCC(=O)Nc1ccc(OCC(O)CNC(C)C)c(c1)C(C)=O, CCCC(=O)Nc1ccc(OCC(O)CNC(C)C)c(c1)C(C)=O	GOEMGAFJFRBGGG-UHFFFAOYSA-N, GOEMGAFJFRBGGG-UHFFFAOYSA-N, GOEMGAFJFRBGGG-UHFFFAOYSA-N, GOEMGAFJFRBGGG-UHFFFAOYSA-N	Launched
acecainide	polarization inhibitor	SCN5A			CCN(CC)CCNC(=O)c1ccc(NC(C)=O)cc1, CCN(CC)CCNC(=O)c1ccc(NC(C)=O)cc1, CCN(CC)CCNC(=O)c1ccc(NC(C)=O)cc1	KEECCEWTUVWFCV-UHFFFAOYSA-N, KEECCEWTUVWFCV-UHFFFAOYSA-N, KEECCEWTUVWFCV-UHFFFAOYSA-N	Phase 3
aceclidine	acetylcholine receptor agonist	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5	ophthalmology	glaucoma	CC(=O)O[C@H]1CN2CCC1CC2 |&1:4,r|	WRJPSSPFHGNBMG-VIFPVBQESA-N	Launched
aceclofenac	prostanoid receptor antagonist	PTGS2	rheumatology	rheumatoid arthritis, ankylosing spondylitis, osteoarthritis, periarthritis, lumbago, ischiadynia	OC(=O)COC(=O)Cc1ccccc1Nc1c(Cl)cccc1Cl, OC(=O)COC(=O)Cc1ccccc1Nc1c(Cl)cccc1Cl, OC(=O)COC(=O)Cc1ccccc1Nc1c(Cl)cccc1Cl, OC(=O)COC(=O)Cc1ccccc1Nc1c(Cl)cccc1Cl	MNIPYSSQXLZQLJ-UHFFFAOYSA-N, MNIPYSSQXLZQLJ-UHFFFAOYSA-N, MNIPYSSQXLZQLJ-UHFFFAOYSA-N, MNIPYSSQXLZQLJ-UHFFFAOYSA-N	Launched
acedapsone			infectious disease	leprosy	CC(=O)Nc1ccc(cc1)S(=O)(=O)c1ccc(NC(C)=O)cc1, CC(=O)Nc1ccc(cc1)S(=O)(=O)c1ccc(NC(C)=O)cc1	AMTPYFGPPVFBBI-UHFFFAOYSA-N, AMTPYFGPPVFBBI-UHFFFAOYSA-N	Launched
acedoben					CC(=O)Nc1ccc(cc1)C(O)=O, CC(=O)Nc1ccc(cc1)C(O)=O	QCXJEYYXVJIFCE-UHFFFAOYSA-N, QCXJEYYXVJIFCE-UHFFFAOYSA-N	Phase 2
acefylline	adenosine receptor agonist	ADORA1	pulmonary	asthma	Cn1c2ncn(CC(O)=O)c2c(=O)n(C)c1=O, Cn1c2ncn(CC(O)=O)c2c(=O)n(C)c1=O	HCYFGRCYSCXKNQ-UHFFFAOYSA-N, HCYFGRCYSCXKNQ-UHFFFAOYSA-N	Launched
aceglutamide			gastroenterology	peptic ulcer disease (PUD)	CC(=O)N[C@@H](CCC(N)=O)C(O)=O, CC(=O)N[C@@H](CCC(N)=O)C(O)=O, CC(=O)N[C@@H](CCC(N)=O)C(O)=O	KSMRODHGGIIXDV-YFKPBYRVSA-N, KSMRODHGGIIXDV-YFKPBYRVSA-N, KSMRODHGGIIXDV-YFKPBYRVSA-N	Launched
acelarin	anticancer agent				C[C@H](N[P@@](=O)(OC[C@H]1O[C@@H](n2ccc(N)nc2=O)C(F)(F)[C@@H]1O)Oc1ccccc1)C(=O)OCc1ccccc1 |a:1,7,9,21,&1:3|	NHTKGYOMICWFQZ-LHFSRKHSSA-N	Phase 2/Phase 3
acemetacin	cyclooxygenase inhibitor	PTGS1, PTGS2	rheumatology	osteoarthritis	COc1ccc2n(C(=O)c3ccc(Cl)cc3)c(C)c(CC(=O)OCC(O)=O)c2c1, COc1ccc2n(C(=O)c3ccc(Cl)cc3)c(C)c(CC(=O)OCC(O)=O)c2c1, COc1ccc2n(C(=O)c3ccc(Cl)cc3)c(C)c(CC(=O)OCC(O)=O)c2c1, COc1ccc2n(C(=O)c3ccc(Cl)cc3)c(C)c(CC(=O)OCC(O)=O)c2c1, COc1ccc2n(C(=O)c3ccc(Cl)cc3)c(C)c(CC(=O)OCC(O)=O)c2c1	FSQKKOOTNAMONP-UHFFFAOYSA-N, FSQKKOOTNAMONP-UHFFFAOYSA-N, FSQKKOOTNAMONP-UHFFFAOYSA-N, FSQKKOOTNAMONP-UHFFFAOYSA-N, FSQKKOOTNAMONP-UHFFFAOYSA-N	Launched
aceneuramic-acid		CES1, SELE, SELP			CC(=O)N[C@@H]1[C@@H](O)C[C@](O)(O[C@H]1[C@H](O)[C@H](O)CO)C(O)=O	SQVRNKJHWKZAKO-PFQGKNLYSA-N	Phase 3
acenocoumarol	vitamin K antagonist	VKORC1	hematology	deep vein thrombosis (DVT)	CC(=O)C[C@@H](c1ccc(cc1)[N+]([O-])=O)c1c(O)c2ccccc2oc1=O |&1:4,r|, CC(=O)C[C@@H](c1ccc(cc1)[N+]([O-])=O)c1c(O)c2ccccc2oc1=O |&1:4,r|	VABCILAOYCMVPS-HNNXBMFYSA-N, VABCILAOYCMVPS-HNNXBMFYSA-N	Launched
acepromazine	dopamine receptor antagonist	ADRA1A, ADRA1B, DRD1, DRD2, HTR1A, HTR2A	neurology/psychiatry	sedative	CN(C)CCCN1c2ccccc2Sc2ccc(cc12)C(C)=O, CN(C)CCCN1c2ccccc2Sc2ccc(cc12)C(C)=O, CN(C)CCCN1c2ccccc2Sc2ccc(cc12)C(C)=O	NOSIYYJFMPDDSA-UHFFFAOYSA-N, NOSIYYJFMPDDSA-UHFFFAOYSA-N, NOSIYYJFMPDDSA-UHFFFAOYSA-N	Launched
acesulfame-potassium					CC1=CC(=O)NS(=O)(=O)O1 |t:1|, CC1=CC(=O)NS(=O)(=O)O1 |t:1|, CC1=CC(=O)NS(=O)(=O)O1 |t:1|	YGCFIWIQZPHFLU-UHFFFAOYSA-N, YGCFIWIQZPHFLU-UHFFFAOYSA-N, YGCFIWIQZPHFLU-UHFFFAOYSA-N	Phase 3
acetanilide	hydrogen peroxide decomposition inhibitor				CC(=O)Nc1ccccc1, CC(=O)Nc1ccccc1, CC(=O)Nc1ccccc1	FZERHIULMFGESH-UHFFFAOYSA-N, FZERHIULMFGESH-UHFFFAOYSA-N, FZERHIULMFGESH-UHFFFAOYSA-N	Preclinical
acetarsol			gastroenterology	diarrhea	CC(=O)Nc1cc(ccc1O)[As](O)(O)=O, CC(=O)Nc1cc(ccc1O)[As](O)(O)=O, CC(=O)Nc1cc(ccc1O)[As](O)(O)=O	ODFJOVXVLFUVNQ-UHFFFAOYSA-N, ODFJOVXVLFUVNQ-UHFFFAOYSA-N, ODFJOVXVLFUVNQ-UHFFFAOYSA-N	Launched
acetazolamide	carbonic anhydrase inhibitor	AQP1, CA1, CA12, CA14, CA2, CA3, CA4, CA7	ophthalmology	glaucoma	CC(=O)Nc1nnc(s1)S(N)(=O)=O, CC(=O)Nc1nnc(s1)S(N)(=O)=O	BZKPWHYZMXOIDC-UHFFFAOYSA-N, BZKPWHYZMXOIDC-UHFFFAOYSA-N	Launched
acetohexamide	ATP channel blocker	ABCC8, KCNJ1, KCNJ10, KCNJ11	endocrinology	diabetes mellitus	CC(=O)c1ccc(cc1)S(=O)(=O)NC(=O)NC1CCCCC1, CC(=O)c1ccc(cc1)S(=O)(=O)NC(=O)NC1CCCCC1	VGZSUPCWNCWDAN-UHFFFAOYSA-N, VGZSUPCWNCWDAN-UHFFFAOYSA-N	Launched
acetohydroxamic-acid	urease inhibitor	MMP12	infectious disease	urinary tract infections	CC(=O)NO	RRUDCFGSUDOHDG-UHFFFAOYSA-N	Launched
acetophenazine	dopamine receptor antagonist	DRD1, DRD2	neurology/psychiatry	psychosis	CC(=O)c1ccc2Sc3ccccc3N(CCCN3CCN(CCO)CC3)c2c1, CC(=O)c1ccc2Sc3ccccc3N(CCCN3CCN(CCO)CC3)c2c1	WNTYBHLDCKXEOT-UHFFFAOYSA-N, WNTYBHLDCKXEOT-UHFFFAOYSA-N	Launched
acetriazoic-acid					CC(=O)Nc1c(I)cc(I)c(C(O)=O)c1I, CC(=O)Nc1c(I)cc(I)c(C(O)=O)c1I, CC(=O)Nc1c(I)cc(I)c(C(O)=O)c1I	GNOGSFBXBWBTIG-UHFFFAOYSA-N, GNOGSFBXBWBTIG-UHFFFAOYSA-N, GNOGSFBXBWBTIG-UHFFFAOYSA-N	Preclinical
acetyl-farnesyl-cysteine	methyltransferase inhibitor	PPARG	dermatology	acne vulgaris (AV)	CC(C)=CCC\C(C)=C\CC\C(C)=C\CSC[C@H](NC(C)=O)C(O)=O, CC(C)=CCC\C(C)=C\CC\C(C)=C\CSC[C@H](NC(C)=O)C(O)=O, CC(C)=CCC\C(C)=C\CC\C(C)=C\CSC[C@H](NC(C)=O)C(O)=O, CC(C)=CCC\C(C)=C\CC\C(C)=C\CSC[C@H](NC(C)=O)C(O)=O	XTURYZYJYQRJDO-BNAHBJSTSA-N, XTURYZYJYQRJDO-BNAHBJSTSA-N, XTURYZYJYQRJDO-BNAHBJSTSA-N, XTURYZYJYQRJDO-BNAHBJSTSA-N	Launched
acetyl-l-leucine			neurology/psychiatry	vertigo	CC(C)C[C@H](NC(C)=O)C(O)=O, CC(C)C[C@H](NC(C)=O)C(O)=O	WXNXCEHXYPACJF-ZETCQYMHSA-N, WXNXCEHXYPACJF-ZETCQYMHSA-N	Launched
acetyl-11-keto-beta-boswellic-acid	lipoxygenase inhibitor	HSD11B1, HSD11B2			C[C@@H]1CC[C@]2(C)CC[C@]3(C)C(=CC(=O)[C@H]4[C@@]5(C)CC[C@@H](OC(C)=O)[C@@](C)([C@@H]5CC[C@@]34C)C(O)=O)[C@@H]2[C@H]1C |a:1,4,8,15,19,24,29,34,35,&1:14,&2:26,c:10|	HMMGKOVEOFBCAU-OQJDUFEHSA-N	Phase 2
acetylcholine	acetylcholine receptor agonist	ACHE, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, CHRNA2	neurology/psychiatry, gastroenterology, pulmonary	drowsiness, fatigue, headache, indigestion, chest congestion	CC(=O)OCC[N+](C)(C)C, CC(=O)OCC[N+](C)(C)C, CC(=O)OCC[N+](C)(C)C	OIPILFWXSMYKGL-UHFFFAOYSA-N, OIPILFWXSMYKGL-UHFFFAOYSA-N, OIPILFWXSMYKGL-UHFFFAOYSA-N	Launched
acetylcysteine	mucolytic agent	ACY1, CHUK, GRIN1, GRIN2A, GRIN2B, GRIN2D, GRIN3A, GSS, IKBKB, RELA, SLC7A11	gastroenterology	acetaminophen overdose, hepatic injury	CC(=O)N[C@@H](CS)C(O)=O, CC(=O)N[C@@H](CS)C(O)=O, CC(=O)N[C@@H](CS)C(O)=O	PWKSKIMOESPYIA-BYPYZUCNSA-N, PWKSKIMOESPYIA-BYPYZUCNSA-N, PWKSKIMOESPYIA-BYPYZUCNSA-N	Launched
acetylsalicylsalicylic-acid	cyclooxygenase inhibitor				CC(=O)Oc1ccccc1C(=O)Oc1ccccc1C(O)=O, CC(=O)Oc1ccccc1C(=O)Oc1ccccc1C(O)=O, CC(=O)Oc1ccccc1C(=O)Oc1ccccc1C(O)=O	DDSFKIFGAPZBSR-UHFFFAOYSA-N, DDSFKIFGAPZBSR-UHFFFAOYSA-N, DDSFKIFGAPZBSR-UHFFFAOYSA-N	Preclinical
acetylspiramycin	other antibiotic				[H][C@@]1(C[C@@](C)(O)[C@@H](O)[C@H](C)O1)O[C@@H]1[C@@H](C)O[C@@]([H])(O[C@H]2[C@@H](CC=O)C[C@@H](C)[C@@H](O[C@@]3([H])CC[C@@H]([C@@H](C)O3)N(C)C)\C=C\C=C\C[C@@H](C)OC(=O)C[C@@]([H])(OC(C)=O)[C@@H]2OC)[C@H](O)[C@H]1N(C)C |t:42,44|	ZPCCSZFPOXBNDL-VGQMBGNASA-N	Preclinical
acexamic-acid	5 alpha reductase inhibitor	GAST	dermatology	wound healing	CC(=O)NCCCCCC(O)=O, CC(=O)NCCCCCC(O)=O, CC(=O)NCCCCCC(O)=O, CC(=O)NCCCCCC(O)=O, CC(=O)NCCCCCC(O)=O, CC(=O)NCCCCCC(O)=O, CC(=O)NCCCCCC(O)=O	WDSCBUNMANHPFH-UHFFFAOYSA-N, WDSCBUNMANHPFH-UHFFFAOYSA-N, WDSCBUNMANHPFH-UHFFFAOYSA-N, WDSCBUNMANHPFH-UHFFFAOYSA-N, WDSCBUNMANHPFH-UHFFFAOYSA-N, WDSCBUNMANHPFH-UHFFFAOYSA-N, WDSCBUNMANHPFH-UHFFFAOYSA-N	Launched
acifran	cholesterol inhibitor	HCAR2, HCAR3			C[C@]1(OC(=CC1=O)C(O)=O)c1ccccc1 |&1:1,r,c:3|, C[C@]1(OC(=CC1=O)C(O)=O)c1ccccc1 |&1:1,r,c:3|, C[C@]1(OC(=CC1=O)C(O)=O)c1ccccc1 |&1:1,r,c:3|, C[C@]1(OC(=CC1=O)C(O)=O)c1ccccc1 |&1:1,r,c:3|	DFDGRKNOFOJBAJ-LBPRGKRZSA-N, DFDGRKNOFOJBAJ-LBPRGKRZSA-N, DFDGRKNOFOJBAJ-LBPRGKRZSA-N, DFDGRKNOFOJBAJ-LBPRGKRZSA-N	Phase 3
acipimox	cholesterol inhibitor	HCAR2	endocrinology	hyperlipidemia	Cc1cnc(c[n+]1[O-])C(O)=O, Cc1cnc(c[n+]1[O-])C(O)=O, Cc1cnc(c[n+]1[O-])C(O)=O, Cc1cnc(c[n+]1[O-])C(O)=O, Cc1cnc(c[n+]1[O-])C(O)=O, Cc1cnc(c[n+]1[O-])C(O)=O, Cc1cnc(c[n+]1[O-])C(O)=O	DJQOOSBJCLSSEY-UHFFFAOYSA-N, DJQOOSBJCLSSEY-UHFFFAOYSA-N, DJQOOSBJCLSSEY-UHFFFAOYSA-N, DJQOOSBJCLSSEY-UHFFFAOYSA-N, DJQOOSBJCLSSEY-UHFFFAOYSA-N, DJQOOSBJCLSSEY-UHFFFAOYSA-N, DJQOOSBJCLSSEY-UHFFFAOYSA-N	Launched
acitazanolast	mediator release inhibitor		allergy	allergic rhinitis	OC(=O)C(=O)Nc1cccc(c1)-c1nn[nH]n1, OC(=O)C(=O)Nc1cccc(c1)-c1nn[nH]n1, OC(=O)C(=O)Nc1cccc(c1)-c1nn[nH]n1	VWQZJJZGISNFOE-UHFFFAOYSA-N, VWQZJJZGISNFOE-UHFFFAOYSA-N, VWQZJJZGISNFOE-UHFFFAOYSA-N	Launched
acitretin	retinoid receptor agonist	RARA, RARB, RARG, RBP1, RXRA, RXRB, RXRG, STAT3	dermatology	psoriasis	COc1cc(C)c(\C=C\C(\C)=C\C=C\C(\C)=C\C(O)=O)c(C)c1C, COc1cc(C)c(\C=C\C(\C)=C\C=C\C(\C)=C\C(O)=O)c(C)c1C, COc1cc(C)c(\C=C\C(\C)=C\C=C\C(\C)=C\C(O)=O)c(C)c1C, COc1cc(C)c(\C=C\C(\C)=C\C=C\C(\C)=C\C(O)=O)c(C)c1C, COc1cc(C)c(\C=C\C(\C)=C\C=C\C(\C)=C\C(O)=O)c(C)c1C	IHUNBGSDBOWDMA-AQFIFDHZSA-N, IHUNBGSDBOWDMA-AQFIFDHZSA-N, IHUNBGSDBOWDMA-AQFIFDHZSA-N, IHUNBGSDBOWDMA-AQFIFDHZSA-N, IHUNBGSDBOWDMA-AQFIFDHZSA-N	Launched
acivicin	gamma glutamyltransferase inhibitor	CTPS1			N[C@H]([C@@H]1CC(Cl)=NO1)C(O)=O |c:5|, N[C@H]([C@@H]1CC(Cl)=NO1)C(O)=O |c:5|	QAWIHIJWNYOLBE-ZAFYKAAXSA-N, QAWIHIJWNYOLBE-ZAFYKAAXSA-N	Phase 2
aclarubicin	topoisomerase inhibitor	TOP1, TOP2A	hematologic malignancy	acute myeloid leukemia (AML)	CC[C@@]1(O)C[C@H](O[C@H]2C[C@@H]([C@H](O[C@H]3C[C@H](O)[C@H](O[C@H]4CCC(=O)[C@H](C)O4)[C@H](C)O3)[C@H](C)O2)N(C)C)c2c(O)c3C(=O)c4c(O)cccc4C(=O)c3cc2[C@H]1C(=O)OC	USZYSDMBJDPRIF-SVEJIMAYSA-N	Launched
aclidinium	acetylcholine receptor antagonist	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5	pulmonary	bronchitis, emphysema, chronic obstructive pulmonary disease (COPD)	OC(C(=O)O[C@H]1C[N+]2(CCCOc3ccccc3)CCC1CC2)(c1cccs1)c1cccs1, OC(C(=O)O[C@H]1C[N+]2(CCCOc3ccccc3)CCC1CC2)(c1cccs1)c1cccs1	ASMXXROZKSBQIH-VITNCHFBSA-N, ASMXXROZKSBQIH-VITNCHFBSA-N	Launched
acolbifene	estrogen receptor antagonist				CC1=C([C@@H](Oc2cc(O)ccc12)c1ccc(OCCN2CCCCC2)cc1)c1ccc(O)cc1 |t:1|	DUYNJNWVGIWJRI-LJAQVGFWSA-N	Phase 3
acoziborole	antitrypanosomal				CC1(C)OB(O)c2cc(NC(=O)c3ccc(F)cc3C(F)(F)F)ccc12	PTYGDEXEGLDNAZ-UHFFFAOYSA-N	Preclinical
ACPC	glutamate receptor antagonist				NC1(CC1)C(O)=O, NC1(CC1)C(O)=O	PAJPWUMXBYXFCZ-UHFFFAOYSA-N, PAJPWUMXBYXFCZ-UHFFFAOYSA-N	Phase 1
acriflavine	hypoxia inducible factor inhibitor	HIF1A	infectious disease	fungal infection	Nc1ccc2cc3ccc(N)cc3nc2c1.C[n+]1c2cc(N)ccc2cc2ccc(N)cc12, Nc1ccc2cc3ccc(N)cc3nc2c1.C[n+]1c2cc(N)ccc2cc2ccc(N)cc12	BCBIBQWDFMQRSJ-UHFFFAOYSA-O, BCBIBQWDFMQRSJ-UHFFFAOYSA-O	Launched
acriflavinium	hypoxia inducible factor inhibitor	HIF1A	infectious disease	fungal infection	C[n+]1c2cc(N)ccc2cc2ccc(N)cc12, C[n+]1c2cc(N)ccc2cc2ccc(N)cc12	XSIOKTWDEOJMGG-UHFFFAOYSA-O, XSIOKTWDEOJMGG-UHFFFAOYSA-O	Launched
acrisorcin	other antifungal		infectious disease	fungal infection	CCCCCCc1ccc(O)cc1O.Nc1c2ccccc2nc2ccccc12	YZODJQFXMFEJRM-UHFFFAOYSA-N	Launched
acrivastine	histamine receptor antagonist	HRH1	allergy	allergic rhinitis	Cc1ccc(cc1)C(=C/CN1CCCC1)\c1cccc(\C=C\C(O)=O)n1, Cc1ccc(cc1)C(=C/CN1CCCC1)\c1cccc(\C=C\C(O)=O)n1, Cc1ccc(cc1)C(=C/CN1CCCC1)\c1cccc(\C=C\C(O)=O)n1, Cc1ccc(cc1)C(=C/CN1CCCC1)\c1cccc(\C=C\C(O)=O)n1, Cc1ccc(cc1)C(=C/CN1CCCC1)\c1cccc(\C=C\C(O)=O)n1	PWACSDKDOHSSQD-IUTFFREVSA-N, PWACSDKDOHSSQD-IUTFFREVSA-N, PWACSDKDOHSSQD-IUTFFREVSA-N, PWACSDKDOHSSQD-IUTFFREVSA-N, PWACSDKDOHSSQD-IUTFFREVSA-N	Launched
acrylate	mucus protecting agent				[Na].OC(=O)C=C	MNNFZYTXMPWOTA-UHFFFAOYSA-N	Phase 3
ACT-132577	endothelin receptor antagonist	EDNRA, EDNRB	pulmonary	pulmonary arterial hypertension (PAH)	NS(=O)(=O)Nc1ncnc(OCCOc2ncc(Br)cn2)c1-c1ccc(Br)cc1, NS(=O)(=O)Nc1ncnc(OCCOc2ncc(Br)cn2)c1-c1ccc(Br)cc1, NS(=O)(=O)Nc1ncnc(OCCOc2ncc(Br)cn2)c1-c1ccc(Br)cc1	DKULOVKANLVDEA-UHFFFAOYSA-N, DKULOVKANLVDEA-UHFFFAOYSA-N, DKULOVKANLVDEA-UHFFFAOYSA-N	Launched
ACT-462206	orexin receptor antagonist	HCRTR1, HCRTR2			COc1ccc(cc1)S(=O)(=O)N1CCC[C@H]1C(=O)Nc1cc(C)cc(C)c1, COc1ccc(cc1)S(=O)(=O)N1CCC[C@H]1C(=O)Nc1cc(C)cc(C)c1	NHPQGZOBHSVTAQ-IBGZPJMESA-N, NHPQGZOBHSVTAQ-IBGZPJMESA-N	Phase 1
actarit	interleukin receptor agonist		rheumatology	rheumatoid arthritis	CC(=O)Nc1ccc(CC(O)=O)cc1, CC(=O)Nc1ccc(CC(O)=O)cc1	MROJXXOCABQVEF-UHFFFAOYSA-N, MROJXXOCABQVEF-UHFFFAOYSA-N	Launched
ACTB-1003	FGFR inhibitor, VEGFR inhibitor	KDR, TEK			COCc1c(CN2CCOCC2)n2ncnc(N)c2c1-c1ccc(NC(=O)Nc2cc(ccc2F)C(F)(F)F)c(F)c1, COCc1c(CN2CCOCC2)n2ncnc(N)c2c1-c1ccc(NC(=O)Nc2cc(ccc2F)C(F)(F)F)c(F)c1, COCc1c(CN2CCOCC2)n2ncnc(N)c2c1-c1ccc(NC(=O)Nc2cc(ccc2F)C(F)(F)F)c(F)c1, COCc1c(CN2CCOCC2)n2ncnc(N)c2c1-c1ccc(NC(=O)Nc2cc(ccc2F)C(F)(F)F)c(F)c1	GZPJCJKUZPUFAL-UHFFFAOYSA-N, GZPJCJKUZPUFAL-UHFFFAOYSA-N, GZPJCJKUZPUFAL-UHFFFAOYSA-N, GZPJCJKUZPUFAL-UHFFFAOYSA-N	Phase 1
actinomycin-d	RNA polymerase inhibitor		oncology	Wilm's tumor, Ewing's sarcoma, rhabdomyosarcoma, testicular carcinoma	CC(C)[C@@H]1NC(=O)[C@@H](NC(=O)c2ccc(C)c3oc4c(C)c(=O)c(N)c(C(=O)N[C@H]5[C@@H](C)OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]6CCCN6C(=O)[C@@H](NC5=O)C(C)C)c4nc23)[C@@H](C)OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C1=O, CC(C)[C@@H]1NC(=O)[C@@H](NC(=O)c2ccc(C)c3oc4c(C)c(=O)c(N)c(C(=O)N[C@H]5[C@@H](C)OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]6CCCN6C(=O)[C@@H](NC5=O)C(C)C)c4nc23)[C@@H](C)OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C1=O, CC(C)[C@@H]1NC(=O)[C@@H](NC(=O)c2ccc(C)c3oc4c(C)c(=O)c(N)c(C(=O)N[C@H]5[C@@H](C)OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]6CCCN6C(=O)[C@@H](NC5=O)C(C)C)c4nc23)[C@@H](C)OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C1=O	RJURFGZVJUQBHK-DCUCITLNSA-N, RJURFGZVJUQBHK-DCUCITLNSA-N, RJURFGZVJUQBHK-DCUCITLNSA-N	Launched
actinoquinol					CCOc1ccc(c2cccnc12)S(O)(=O)=O, CCOc1ccc(c2cccnc12)S(O)(=O)=O	YAMVZYRZAMBCED-UHFFFAOYSA-N, YAMVZYRZAMBCED-UHFFFAOYSA-N	Preclinical
acumapimod	p38 MAPK inhibitor				Cc1ccc(cc1-n1ncc(C(=O)c2cccc(c2)C#N)c1N)C(=O)NC1CC1	VGUSQKZDZHAAEE-UHFFFAOYSA-N	Phase 1
ACY-1215	HDAC inhibitor	HDAC1, HDAC2, HDAC3, HDAC6, HDAC8			ONC(=O)CCCCCCNC(=O)c1cnc(nc1)N(c1ccccc1)c1ccccc1, ONC(=O)CCCCCCNC(=O)c1cnc(nc1)N(c1ccccc1)c1ccccc1, ONC(=O)CCCCCCNC(=O)c1cnc(nc1)N(c1ccccc1)c1ccccc1, ONC(=O)CCCCCCNC(=O)c1cnc(nc1)N(c1ccccc1)c1ccccc1, ONC(=O)CCCCCCNC(=O)c1cnc(nc1)N(c1ccccc1)c1ccccc1, ONC(=O)CCCCCCNC(=O)c1cnc(nc1)N(c1ccccc1)c1ccccc1	QGZYDVAGYRLSKP-UHFFFAOYSA-N, QGZYDVAGYRLSKP-UHFFFAOYSA-N, QGZYDVAGYRLSKP-UHFFFAOYSA-N, QGZYDVAGYRLSKP-UHFFFAOYSA-N, QGZYDVAGYRLSKP-UHFFFAOYSA-N, QGZYDVAGYRLSKP-UHFFFAOYSA-N	Phase 1/Phase 2
acyclovir	DNA polymerase inhibitor	PNP	infectious disease	genitial herpes, shingles, chicken pox	Nc1nc(=O)c2ncn(COCCO)c2[nH]1, Nc1nc(=O)c2ncn(COCCO)c2[nH]1, Nc1nc(=O)c2ncn(COCCO)c2[nH]1, Nc1nc(=O)c2ncn(COCCO)c2[nH]1, Nc1nc(=O)c2ncn(COCCO)c2[nH]1, Nc1nc(=O)c2ncn(COCCO)c2[nH]1, Nc1nc(=O)c2ncn(COCCO)c2[nH]1	MKUXAQIIEYXACX-UHFFFAOYSA-N, MKUXAQIIEYXACX-UHFFFAOYSA-N, MKUXAQIIEYXACX-UHFFFAOYSA-N, MKUXAQIIEYXACX-UHFFFAOYSA-N, MKUXAQIIEYXACX-UHFFFAOYSA-N, MKUXAQIIEYXACX-UHFFFAOYSA-N, MKUXAQIIEYXACX-UHFFFAOYSA-N	Launched
AC1NDSS5					CCCCCCCCCCCCCCCCCC[S+](CCC)c1ccccc1C(=O)OCC, CCCCCCCCCCCCCCCCCC[S+](CCC)c1ccccc1C(=O)OCC	VZXULFIUJKSVJY-UHFFFAOYSA-N, VZXULFIUJKSVJY-UHFFFAOYSA-N	Phase 1
AC260584	cholinergic receptor agonist				CCCCC1CCN(CCCN2C(=O)COc3cc(F)ccc23)CC1	BWAKMLKESHKOHK-UHFFFAOYSA-N	Preclinical
AD-5467	aldose reductase inhibitor	AKR1B1			CC(C)[C@H]1Oc2c(cccc2N(CC(O)=O)C1=S)C(C)C |&1:3,r|, CC(C)[C@H]1Oc2c(cccc2N(CC(O)=O)C1=S)C(C)C |&1:3,r|	CLDJCRWXLDLJLO-CQSZACIVSA-N, CLDJCRWXLDLJLO-CQSZACIVSA-N	Phase 2
adapalene	retinoid receptor agonist	RARA, RARB, RARG, RXRA, RXRB, RXRG	dermatology	acne vulgaris (AV)	COc1ccc(cc1C12CC3CC(CC(C3)C1)C2)-c1ccc2cc(ccc2c1)C(O)=O, COc1ccc(cc1C12CC3CC(CC(C3)C1)C2)-c1ccc2cc(ccc2c1)C(O)=O, COc1ccc(cc1C12CC3CC(CC(C3)C1)C2)-c1ccc2cc(ccc2c1)C(O)=O, COc1ccc(cc1C12CC3CC(CC(C3)C1)C2)-c1ccc2cc(ccc2c1)C(O)=O, COc1ccc(cc1C12CC3CC(CC(C3)C1)C2)-c1ccc2cc(ccc2c1)C(O)=O, COc1ccc(cc1C12CC3CC(CC(C3)C1)C2)-c1ccc2cc(ccc2c1)C(O)=O, COc1ccc(cc1C12CC3CC(CC(C3)C1)C2)-c1ccc2cc(ccc2c1)C(O)=O, COc1ccc(cc1C12CC3CC(CC(C3)C1)C2)-c1ccc2cc(ccc2c1)C(O)=O	LZCDAPDGXCYOEH-UHFFFAOYSA-N, LZCDAPDGXCYOEH-UHFFFAOYSA-N, LZCDAPDGXCYOEH-UHFFFAOYSA-N, LZCDAPDGXCYOEH-UHFFFAOYSA-N, LZCDAPDGXCYOEH-UHFFFAOYSA-N, LZCDAPDGXCYOEH-UHFFFAOYSA-N, LZCDAPDGXCYOEH-UHFFFAOYSA-N, LZCDAPDGXCYOEH-UHFFFAOYSA-N	Launched
adaprev	TGF beta receptor inhibitor	AKR1B1, GPI, HK1, M6PR, PYGM			O[C@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H](O)[C@H]1O |a:3,10,12,14,&1:1|, O[C@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H](O)[C@H]1O |a:3,10,12,14,&1:1|	NBSCHQHZLSJFNQ-DVKNGEFBSA-N, NBSCHQHZLSJFNQ-DVKNGEFBSA-N	Phase 3
adaptavir	CC chemokine receptor antagonist	CCR5			C[C@@H](O)[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@@H](C)N)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)C(N)=O, C[C@@H](O)[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@@H](C)N)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)C(N)=O, C[C@@H](O)[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@@H](C)N)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)C(N)=O, C[C@@H](O)[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@@H](C)N)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)C(N)=O	AKWRNBWMGFUAMF-ZESMOPTKSA-N, AKWRNBWMGFUAMF-ZESMOPTKSA-N, AKWRNBWMGFUAMF-ZESMOPTKSA-N, AKWRNBWMGFUAMF-ZESMOPTKSA-N	Phase 2
adarotene	retinoid receptor agonist	RARB, RARG			OC(=O)\C=C\c1ccc(cc1)-c1ccc(O)c(c1)C12CC3CC(CC(C3)C1)C2, OC(=O)\C=C\c1ccc(cc1)-c1ccc(O)c(c1)C12CC3CC(CC(C3)C1)C2, OC(=O)\C=C\c1ccc(cc1)-c1ccc(O)c(c1)C12CC3CC(CC(C3)C1)C2, OC(=O)\C=C\c1ccc(cc1)-c1ccc(O)c(c1)C12CC3CC(CC(C3)C1)C2	QAWBIEIZDDIEMW-FPYGCLRLSA-N, QAWBIEIZDDIEMW-FPYGCLRLSA-N, QAWBIEIZDDIEMW-FPYGCLRLSA-N, QAWBIEIZDDIEMW-FPYGCLRLSA-N	Phase 1
adatanserin	serotonin receptor agonist, serotonin receptor antagonist	HTR1A, HTR2A			O=C(NCCN1CCN(CC1)c1ncccn1)C12CC3CC(CC(C3)C1)C2, O=C(NCCN1CCN(CC1)c1ncccn1)C12CC3CC(CC(C3)C1)C2, O=C(NCCN1CCN(CC1)c1ncccn1)C12CC3CC(CC(C3)C1)C2	HPFLVTSWRFCPCV-UHFFFAOYSA-N, HPFLVTSWRFCPCV-UHFFFAOYSA-N, HPFLVTSWRFCPCV-UHFFFAOYSA-N	Phase 2
adavivint	WNT pathway inhibitor				CC(C)CC(=O)Nc1cncc(c1)-c1ccc2[nH]nc(-c3nc4cncc(-c5cccc(F)c5)c4[nH]3)c2c1	AQDWDWAYVBQMAM-UHFFFAOYSA-N	Phase 1
ADD-233089	benzodiazepine receptor agonist				Clc1ccc(cc1)-n1cc([nH]c1=O)N1CCOCC1, Clc1ccc(cc1)-n1cc([nH]c1=O)N1CCOCC1, Clc1ccc(cc1)-n1cc([nH]c1=O)N1CCOCC1	OKVOKULYZXODKU-UHFFFAOYSA-N, OKVOKULYZXODKU-UHFFFAOYSA-N, OKVOKULYZXODKU-UHFFFAOYSA-N	Phase 1
adefovir	DNA polymerase inhibitor		infectious disease	hepatitis B	Nc1ncnc2n(CCOCP(O)(O)=O)cnc12, Nc1ncnc2n(CCOCP(O)(O)=O)cnc12	SUPKOOSCJHTBAH-UHFFFAOYSA-N, SUPKOOSCJHTBAH-UHFFFAOYSA-N	Launched
adefovir-dipivoxil	DNA polymerase inhibitor		infectious disease	hepatitis B	CC(C)(C)C(=O)OCOP(=O)(COCCn1cnc2c(N)ncnc12)OCOC(=O)C(C)(C)C, CC(C)(C)C(=O)OCOP(=O)(COCCn1cnc2c(N)ncnc12)OCOC(=O)C(C)(C)C, CC(C)(C)C(=O)OCOP(=O)(COCCn1cnc2c(N)ncnc12)OCOC(=O)C(C)(C)C	WOZSCQDILHKSGG-UHFFFAOYSA-N, WOZSCQDILHKSGG-UHFFFAOYSA-N, WOZSCQDILHKSGG-UHFFFAOYSA-N	Launched
adelmidrol	anti-inflammatory agent		dermatology	dermatitis	OCCNC(=O)CCCCCCCC(=O)NCCO, OCCNC(=O)CCCCCCCC(=O)NCCO	PAHZPHDAJQIETD-UHFFFAOYSA-N, PAHZPHDAJQIETD-UHFFFAOYSA-N	Launched
ademetionine	methyltransferase stimulant, phosphodiesterase inhibitor		neurology/psychiatry	depression, attention-deficit/hyperactivity disorder (ADHD)	C[S+](CC[C@H](N)C(O)=O)C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(N)ncnc12, C[S+](CC[C@H](N)C(O)=O)C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(N)ncnc12	MEFKEPWMEQBLKI-AIRLBKTGSA-O, MEFKEPWMEQBLKI-AIRLBKTGSA-O	Launched
adenine	protein synthesis stimulant	ACACB, ACP1, APRT, MTAP, PECR, SRPK2			Nc1ncnc2nc[nH]c12, Nc1ncnc2nc[nH]c12, Nc1ncnc2nc[nH]c12, Nc1ncnc2nc[nH]c12, Nc1ncnc2nc[nH]c12	GFFGJBXGBJISGV-UHFFFAOYSA-N, GFFGJBXGBJISGV-UHFFFAOYSA-N, GFFGJBXGBJISGV-UHFFFAOYSA-N, GFFGJBXGBJISGV-UHFFFAOYSA-N, GFFGJBXGBJISGV-UHFFFAOYSA-N	Preclinical
adenosine	adenosine receptor agonist	ADORA1, ADORA2A, ADORA2B, ADORA3, PI4K2A, PI4K2B, TRPM4	cardiology	Wolff-Parkinson-White Syndrome (WPW)	Nc1ncnc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O, Nc1ncnc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O, Nc1ncnc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O, Nc1ncnc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O	OIRDTQYFTABQOQ-KQYNXXCUSA-N, OIRDTQYFTABQOQ-KQYNXXCUSA-N, OIRDTQYFTABQOQ-KQYNXXCUSA-N, OIRDTQYFTABQOQ-KQYNXXCUSA-N	Launched
adenosine-phosphate	adenosine receptor agonist	ACSL1, ACSS1, ACSS2, ADCY1, ADK, CREB1, FBP1, HINT1, PDE4B, PDE4D, PIM1, PRKAA1, PRKAB1, PRKAB2, PYGL, TRPM4			Nc1ncnc2n(cnc12)[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O	UDMBCSSLTHHNCD-KQYNXXCUSA-N	Launched
adenosine-triphosphate	adenosine receptor agonist	ABCA1, ABCB1, ABCB11, ABCC2, ABCC8, ABCC9, ABCG1, ABL1, ABL2, ACSL1, ACSS1, ACSS2, ACVR1, ACVR1B, ACVRL1, ADCY1, ADRBK1, ADRBK2, AFG3L2, AKT1, ALK, AMHR2, APAF1, ARAF, ASNA1, ASNS, ASS1, CDK15, GPR17, ITPR1, NAE1, NT5C2, P2RY1, P2RY11, P2RY13, P2RY2, P2RY4, PRKAA1, RYR1, RYR2, RYR3, SLC25A4, TNK2, TRPM4, TRPM7			Nc1ncnc2n(cnc12)[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O	ZKHQWZAMYRWXGA-KQYNXXCUSA-N	Phase 2
adiphenine	acetylcholine receptor antagonist	CHRNA1	neurology/psychiatry	spasms	CCN(CC)CCOC(=O)C(c1ccccc1)c1ccccc1, CCN(CC)CCOC(=O)C(c1ccccc1)c1ccccc1, CCN(CC)CCOC(=O)C(c1ccccc1)c1ccccc1, CCN(CC)CCOC(=O)C(c1ccccc1)c1ccccc1	JGOAIQNSOGZNBX-UHFFFAOYSA-N, JGOAIQNSOGZNBX-UHFFFAOYSA-N, JGOAIQNSOGZNBX-UHFFFAOYSA-N, JGOAIQNSOGZNBX-UHFFFAOYSA-N	Launched
adipic-acid	solute carrier family member inhibitor	SLC22A6			OC(=O)CCCCC(O)=O	WNLRTRBMVRJNCN-UHFFFAOYSA-N	Preclinical
adiporon	adiponectin receptor agonist	ADIPOR1, ADIPOR2			O=C(COc1ccc(cc1)C(=O)c1ccccc1)NC1CCN(Cc2ccccc2)CC1, O=C(COc1ccc(cc1)C(=O)c1ccccc1)NC1CCN(Cc2ccccc2)CC1, O=C(COc1ccc(cc1)C(=O)c1ccccc1)NC1CCN(Cc2ccccc2)CC1, O=C(COc1ccc(cc1)C(=O)c1ccccc1)NC1CCN(Cc2ccccc2)CC1, O=C(COc1ccc(cc1)C(=O)c1ccccc1)NC1CCN(Cc2ccccc2)CC1	SHHUPGSHGSNPDB-UHFFFAOYSA-N, SHHUPGSHGSNPDB-UHFFFAOYSA-N, SHHUPGSHGSNPDB-UHFFFAOYSA-N, SHHUPGSHGSNPDB-UHFFFAOYSA-N, SHHUPGSHGSNPDB-UHFFFAOYSA-N	Preclinical
ADL5859	opioid receptor agonist	OPRD1			CCN(CC)C(=O)c1ccc(cc1)C1=CC2(CCNCC2)Oc2cccc(O)c12 |t:14|, CCN(CC)C(=O)c1ccc(cc1)C1=CC2(CCNCC2)Oc2cccc(O)c12 |t:14|, CCN(CC)C(=O)c1ccc(cc1)C1=CC2(CCNCC2)Oc2cccc(O)c12 |t:14|, CCN(CC)C(=O)c1ccc(cc1)C1=CC2(CCNCC2)Oc2cccc(O)c12 |t:14|, CCN(CC)C(=O)c1ccc(cc1)C1=CC2(CCNCC2)Oc2cccc(O)c12 |t:14|, CCN(CC)C(=O)c1ccc(cc1)C1=CC2(CCNCC2)Oc2cccc(O)c12 |t:14|, CCN(CC)C(=O)c1ccc(cc1)C1=CC2(CCNCC2)Oc2cccc(O)c12 |t:14|	OPIKUXLJQFYMSC-UHFFFAOYSA-N, OPIKUXLJQFYMSC-UHFFFAOYSA-N, OPIKUXLJQFYMSC-UHFFFAOYSA-N, OPIKUXLJQFYMSC-UHFFFAOYSA-N, OPIKUXLJQFYMSC-UHFFFAOYSA-N, OPIKUXLJQFYMSC-UHFFFAOYSA-N, OPIKUXLJQFYMSC-UHFFFAOYSA-N	Phase 2
adomeglivant	glucagon receptor antagonist				Cc1cc(O[C@@H](CCC(F)(F)F)c2ccc(cc2)C(=O)NCCC(O)=O)cc(C)c1-c1ccc(cc1)C(C)(C)C	FASLTMSUPQDLIB-MHZLTWQESA-N	Preclinical
adoprazine	dopamine receptor antagonist, serotonin receptor agonist	DRD2, HTR1A			Fc1ccc(cc1)-c1cncc(CN2CCN(CC2)c2cccc3OCCOc23)c1, Fc1ccc(cc1)-c1cncc(CN2CCN(CC2)c2cccc3OCCOc23)c1, Fc1ccc(cc1)-c1cncc(CN2CCN(CC2)c2cccc3OCCOc23)c1	IUVSEUFHPNITEQ-UHFFFAOYSA-N, IUVSEUFHPNITEQ-UHFFFAOYSA-N, IUVSEUFHPNITEQ-UHFFFAOYSA-N	Phase 2
adrafinil	adrenergic receptor agonist		neurology/psychiatry	fatigue	ONC(=O)C[S@@](=O)C(c1ccccc1)c1ccccc1 |r|, ONC(=O)C[S@@](=O)C(c1ccccc1)c1ccccc1 |r|, ONC(=O)C[S@@](=O)C(c1ccccc1)c1ccccc1 |r|	CGNMLOKEMNBUAI-HXUWFJFHSA-N, CGNMLOKEMNBUAI-HXUWFJFHSA-N, CGNMLOKEMNBUAI-HXUWFJFHSA-N	Launched
adrenalone	adrenergic receptor agonist	ADRA1A	hematology	hemorrhage	CNCC(=O)c1ccc(O)c(O)c1, CNCC(=O)c1ccc(O)c(O)c1, CNCC(=O)c1ccc(O)c(O)c1, CNCC(=O)c1ccc(O)c(O)c1	PZMVOUYYNKPMSI-UHFFFAOYSA-N, PZMVOUYYNKPMSI-UHFFFAOYSA-N, PZMVOUYYNKPMSI-UHFFFAOYSA-N, PZMVOUYYNKPMSI-UHFFFAOYSA-N	Launched
adrenosterone	11-beta hydroxysteroid dehydrogenase inhibitor	HSD11B1, HSD11B2			C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CCC2=O |t:9|, C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CCC2=O |t:9|	RZRPTBIGEANTGU-IRIMSJTPSA-N, RZRPTBIGEANTGU-IRIMSJTPSA-N	Preclinical
ADX-10059	glutamate receptor negative allosteric modulator	GRM5			Cc1cc(C)c(N)c(n1)C#Cc1cccc(F)c1, Cc1cc(C)c(N)c(n1)C#Cc1cccc(F)c1, Cc1cc(C)c(N)c(n1)C#Cc1cccc(F)c1, Cc1cc(C)c(N)c(n1)C#Cc1cccc(F)c1, Cc1cc(C)c(N)c(n1)C#Cc1cccc(F)c1	MEDCLNYIYBERKO-UHFFFAOYSA-N, MEDCLNYIYBERKO-UHFFFAOYSA-N, MEDCLNYIYBERKO-UHFFFAOYSA-N, MEDCLNYIYBERKO-UHFFFAOYSA-N, MEDCLNYIYBERKO-UHFFFAOYSA-N	Phase 2
ADX-47273	glutamate receptor modulator	GRM5			Fc1ccc(cc1)C(=O)N1CCC[C@@H](C1)c1nc(no1)-c1ccc(F)cc1, Fc1ccc(cc1)C(=O)N1CCC[C@@H](C1)c1nc(no1)-c1ccc(F)cc1	VXQCCZHCFBHTTD-HNNXBMFYSA-N, VXQCCZHCFBHTTD-HNNXBMFYSA-N	Preclinical
AEE788	EGFR inhibitor, VEGFR inhibitor	EGFR, ERBB2, ERBB4, FGFR2, FGFR3, KDR			CCN1CCN(Cc2ccc(cc2)-c2cc3c(N[C@H](C)c4ccccc4)ncnc3[nH]2)CC1, CCN1CCN(Cc2ccc(cc2)-c2cc3c(N[C@H](C)c4ccccc4)ncnc3[nH]2)CC1, CCN1CCN(Cc2ccc(cc2)-c2cc3c(N[C@H](C)c4ccccc4)ncnc3[nH]2)CC1, CCN1CCN(Cc2ccc(cc2)-c2cc3c(N[C@H](C)c4ccccc4)ncnc3[nH]2)CC1, CCN1CCN(Cc2ccc(cc2)-c2cc3c(N[C@H](C)c4ccccc4)ncnc3[nH]2)CC1	OONFNUWBHFSNBT-HXUWFJFHSA-N, OONFNUWBHFSNBT-HXUWFJFHSA-N, OONFNUWBHFSNBT-HXUWFJFHSA-N, OONFNUWBHFSNBT-HXUWFJFHSA-N, OONFNUWBHFSNBT-HXUWFJFHSA-N	Phase 1/Phase 2
AEG3482	HSP inducer				NS(=O)(=O)c1nn2cc(nc2s1)-c1ccccc1, NS(=O)(=O)c1nn2cc(nc2s1)-c1ccccc1, NS(=O)(=O)c1nn2cc(nc2s1)-c1ccccc1	MQUYTXDAVCOCMX-UHFFFAOYSA-N, MQUYTXDAVCOCMX-UHFFFAOYSA-N, MQUYTXDAVCOCMX-UHFFFAOYSA-N	Preclinical
afalanine	dopamine receptor agonist	DRD2			CC(=O)N[C@@H](Cc1ccccc1)C(O)=O, CC(=O)N[C@@H](Cc1ccccc1)C(O)=O, CC(=O)N[C@@H](Cc1ccccc1)C(O)=O	CBQJSKKFNMDLON-JTQLQIEISA-N, CBQJSKKFNMDLON-JTQLQIEISA-N, CBQJSKKFNMDLON-JTQLQIEISA-N	Phase 3
afamelanotide	melanocyte-stimulating hormone mimetic				CCCC[C@H](NC(=O)[C@H](CO)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(C)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(N)=O	UAHFGYDRQSXQEB-LEBBXHLNSA-N	Launched
afatinib	EGFR inhibitor	EGFR, ERBB2, ERBB4	oncology	non-small cell lung cancer (NSCLC)	CN(C)C\C=C\C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1, CN(C)C\C=C\C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1, CN(C)C\C=C\C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1, CN(C)C\C=C\C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1, CN(C)C\C=C\C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1, CN(C)C\C=C\C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1, CN(C)C\C=C\C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1, CN(C)C\C=C\C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1, CN(C)C\C=C\C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1, CN(C)C\C=C\C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1	ULXXDDBFHOBEHA-CWDCEQMOSA-N, ULXXDDBFHOBEHA-CWDCEQMOSA-N, ULXXDDBFHOBEHA-CWDCEQMOSA-N, ULXXDDBFHOBEHA-CWDCEQMOSA-N, ULXXDDBFHOBEHA-CWDCEQMOSA-N, ULXXDDBFHOBEHA-CWDCEQMOSA-N, ULXXDDBFHOBEHA-CWDCEQMOSA-N, ULXXDDBFHOBEHA-CWDCEQMOSA-N, ULXXDDBFHOBEHA-CWDCEQMOSA-N, ULXXDDBFHOBEHA-CWDCEQMOSA-N	Launched
afimoxifene	estrogen receptor antagonist	ESR1, ESR2, ESRRG, PLD1, PRKCD, PRKCE, PRKCQ, PRKCZ			CC\C(=C(/c1ccc(O)cc1)c1ccc(OCCN(C)C)cc1)c1ccccc1	TXUZVZSFRXZGTL-QPLCGJKRSA-N	Phase 2
afloqualone	acetylcholine receptor antagonist		neurology/psychiatry	sedative	Cc1ccccc1-n1c(CF)nc2ccc(N)cc2c1=O, Cc1ccccc1-n1c(CF)nc2ccc(N)cc2c1=O, Cc1ccccc1-n1c(CF)nc2ccc(N)cc2c1=O	VDOSWXIDETXFET-UHFFFAOYSA-N, VDOSWXIDETXFET-UHFFFAOYSA-N, VDOSWXIDETXFET-UHFFFAOYSA-N	Launched
AFN-1252	FABI inhibitor				CN(Cc1oc2ccccc2c1C)C(=O)\C=C\c1cnc2NC(=O)CCc2c1	QXTWSUQCXCWEHF-JXMROGBWSA-N	Phase 2
afobazole	anxiolytic		neurology/psychiatry	anxiety	CCOc1ccc2nc(SCCN3CCOCC3)[nH]c2c1, CCOc1ccc2nc(SCCN3CCOCC3)[nH]c2c1	WWNUCVSRRUDYPP-UHFFFAOYSA-N, WWNUCVSRRUDYPP-UHFFFAOYSA-N	Launched
AF38469	sortilin inhibitor	SORT1			Cc1cccc(NC(=O)c2ccc(cc2C(O)=O)C(F)(F)F)n1, Cc1cccc(NC(=O)c2ccc(cc2C(O)=O)C(F)(F)F)n1, Cc1cccc(NC(=O)c2ccc(cc2C(O)=O)C(F)(F)F)n1, Cc1cccc(NC(=O)c2ccc(cc2C(O)=O)C(F)(F)F)n1	JWCUSQCZMQIBMR-UHFFFAOYSA-N, JWCUSQCZMQIBMR-UHFFFAOYSA-N, JWCUSQCZMQIBMR-UHFFFAOYSA-N, JWCUSQCZMQIBMR-UHFFFAOYSA-N	Preclinical
AG-1024	insulin growth factor receptor inhibitor	IGF1R			CC(C)(C)c1cc(C=C(C#N)C#N)cc(Br)c1O, CC(C)(C)c1cc(C=C(C#N)C#N)cc(Br)c1O	ABBADGFSRBWENF-UHFFFAOYSA-N, ABBADGFSRBWENF-UHFFFAOYSA-N	Preclinical
AG-14361	PARP inhibitor	PARP1			CN(C)Cc1ccc(cc1)-c1nc2cccc3C(=O)NCCn1c23, CN(C)Cc1ccc(cc1)-c1nc2cccc3C(=O)NCCn1c23, CN(C)Cc1ccc(cc1)-c1nc2cccc3C(=O)NCCn1c23, CN(C)Cc1ccc(cc1)-c1nc2cccc3C(=O)NCCn1c23, CN(C)Cc1ccc(cc1)-c1nc2cccc3C(=O)NCCn1c23, CN(C)Cc1ccc(cc1)-c1nc2cccc3C(=O)NCCn1c23, CN(C)Cc1ccc(cc1)-c1nc2cccc3C(=O)NCCn1c23, CN(C)Cc1ccc(cc1)-c1nc2cccc3C(=O)NCCn1c23, CN(C)Cc1ccc(cc1)-c1nc2cccc3C(=O)NCCn1c23, CN(C)Cc1ccc(cc1)-c1nc2cccc3C(=O)NCCn1c23, CN(C)Cc1ccc(cc1)-c1nc2cccc3C(=O)NCCn1c23	SEKJSSBJKFLZIT-UHFFFAOYSA-N, SEKJSSBJKFLZIT-UHFFFAOYSA-N, SEKJSSBJKFLZIT-UHFFFAOYSA-N, SEKJSSBJKFLZIT-UHFFFAOYSA-N, SEKJSSBJKFLZIT-UHFFFAOYSA-N, SEKJSSBJKFLZIT-UHFFFAOYSA-N, SEKJSSBJKFLZIT-UHFFFAOYSA-N, SEKJSSBJKFLZIT-UHFFFAOYSA-N, SEKJSSBJKFLZIT-UHFFFAOYSA-N, SEKJSSBJKFLZIT-UHFFFAOYSA-N, SEKJSSBJKFLZIT-UHFFFAOYSA-N	Preclinical
AG-490	EGFR inhibitor, JAK inhibitor	EGFR, JAK2, JAK3			Oc1ccc(\C=C(/C#N)C(=O)NCc2ccccc2)cc1O, Oc1ccc(\C=C(/C#N)C(=O)NCc2ccccc2)cc1O, Oc1ccc(\C=C(/C#N)C(=O)NCc2ccccc2)cc1O, Oc1ccc(\C=C(/C#N)C(=O)NCc2ccccc2)cc1O	TUCIOBMMDDOEMM-RIYZIHGNSA-N, TUCIOBMMDDOEMM-RIYZIHGNSA-N, TUCIOBMMDDOEMM-RIYZIHGNSA-N, TUCIOBMMDDOEMM-RIYZIHGNSA-N	Preclinical
AG-555	tyrosine kinase inhibitor	CDK2			Oc1ccc(\C=C(/C#N)C(=O)NCCCc2ccccc2)cc1O	GSQOBTOAOGXIFL-LFIBNONCSA-N	Preclinical
AG-556	tyrosine kinase inhibitor				Oc1ccc(\C=C(/C#N)C(=O)NCCCCc2ccccc2)cc1O, Oc1ccc(\C=C(/C#N)C(=O)NCCCCc2ccccc2)cc1O	GWCNJMUSWLTSCW-SFQUDFHCSA-N, GWCNJMUSWLTSCW-SFQUDFHCSA-N	Preclinical
AGI-5198	isocitrate dehydrogenase inhibitor	IDH1			Cc1nccn1CC(=O)N([C@@H](C(=O)NC1CCCCC1)c1ccccc1C)c1cccc(F)c1 |&1:10,r|, Cc1nccn1CC(=O)N([C@@H](C(=O)NC1CCCCC1)c1ccccc1C)c1cccc(F)c1 |&1:10,r|, Cc1nccn1CC(=O)N([C@@H](C(=O)NC1CCCCC1)c1ccccc1C)c1cccc(F)c1 |&1:10,r|	FNYGWXSATBUBER-AREMUKBSSA-N, FNYGWXSATBUBER-AREMUKBSSA-N, FNYGWXSATBUBER-AREMUKBSSA-N	Preclinical
AGI-6780	isocitrate dehydrogenase inhibitor	IDH2			FC(F)(F)c1cccc(NC(=O)Nc2cc(ccc2-c2ccsc2)S(=O)(=O)NC2CC2)c1, FC(F)(F)c1cccc(NC(=O)Nc2cc(ccc2-c2ccsc2)S(=O)(=O)NC2CC2)c1, FC(F)(F)c1cccc(NC(=O)Nc2cc(ccc2-c2ccsc2)S(=O)(=O)NC2CC2)c1	CCAWRGNYALGPQH-UHFFFAOYSA-N, CCAWRGNYALGPQH-UHFFFAOYSA-N, CCAWRGNYALGPQH-UHFFFAOYSA-N	Preclinical
AGM-1470	cell cycle inhibitor	METAP2			CO[C@@H]1[C@@H](CC[C@]2(CO2)[C@@H]1[C@@]1(C)O[C@@H]1CC=C(C)C)OC(=O)NC(=O)CCl |a:2,3,6,10,13,&1:9|	MSHZHSPISPJWHW-FRDQJGBZSA-N	Phase 2
agmatine	nitric oxide synthase inhibitor	ADRA2C, ASIC3, CACNA1B, CHRNA1, GRIN1, KCNJ1, NISCH			NCCCCNC(N)=N, NCCCCNC(N)=N	QYPPJABKJHAVHS-UHFFFAOYSA-N, QYPPJABKJHAVHS-UHFFFAOYSA-N	Phase 3
AGN-192403	imidazoline receptor ligand	NISCH			CC(C)[C@@H]1[C@H]2CC[C@@H](C2)[C@H]1N |a:3,9,&1:4,&2:7|, CC(C)[C@@H]1[C@H]2CC[C@@H](C2)[C@H]1N |a:3,9,&1:4,&2:7|, CC(C)[C@@H]1[C@H]2CC[C@@H](C2)[C@H]1N |a:3,9,&1:4,&2:7|	SHXVJSFOJHMEEQ-AXTSPUMRSA-N, SHXVJSFOJHMEEQ-AXTSPUMRSA-N, SHXVJSFOJHMEEQ-AXTSPUMRSA-N	Preclinical
AGN-194310	retinoid receptor antagonist	RXRA, RXRB, RXRG			CCc1ccc(cc1)C1=CC(C)(C)Sc2ccc(cc12)C#Cc1ccc(cc1)C(O)=O |t:9|, CCc1ccc(cc1)C1=CC(C)(C)Sc2ccc(cc12)C#Cc1ccc(cc1)C(O)=O |t:9|, CCc1ccc(cc1)C1=CC(C)(C)Sc2ccc(cc12)C#Cc1ccc(cc1)C(O)=O |t:9|	LHUPKWKWYWOMSK-UHFFFAOYSA-N, LHUPKWKWYWOMSK-UHFFFAOYSA-N, LHUPKWKWYWOMSK-UHFFFAOYSA-N	Phase 3
AGN-195183	retinoid receptor agonist	RARA			CC1(C)CCC(C)(C)c2c(Cl)c(O)c(cc12)C(=O)Nc1cc(F)c(C(O)=O)c(F)c1, CC1(C)CCC(C)(C)c2c(Cl)c(O)c(cc12)C(=O)Nc1cc(F)c(C(O)=O)c(F)c1	PNAWUIKCVQSLFG-UHFFFAOYSA-N, PNAWUIKCVQSLFG-UHFFFAOYSA-N	Phase 1/Phase 2
agomelatine	melatonin receptor agonist, serotonin receptor antagonist	HTR2A, HTR2B, HTR2C, MTNR1A, MTNR1B	neurology/psychiatry	depression	COc1ccc2cccc(CCNC(C)=O)c2c1, COc1ccc2cccc(CCNC(C)=O)c2c1, COc1ccc2cccc(CCNC(C)=O)c2c1	YJYPHIXNFHFHND-UHFFFAOYSA-N, YJYPHIXNFHFHND-UHFFFAOYSA-N, YJYPHIXNFHFHND-UHFFFAOYSA-N	Launched
AGP-103	membrane permeability inhibitor				CCCCCCCCCCCCCCCCCCCCCC(O)=O, CCCCCCCCCCCCCCCCCCCCCC(O)=O, CCCCCCCCCCCCCCCCCCCCCC(O)=O	UKMSUNONTOPOIO-UHFFFAOYSA-N, UKMSUNONTOPOIO-UHFFFAOYSA-N, UKMSUNONTOPOIO-UHFFFAOYSA-N	Launched
AH-7614	free fatty acid receptor antagonist	FFAR4			Cc1ccc(cc1)S(=O)(=O)NC1c2ccccc2Oc2ccccc12, Cc1ccc(cc1)S(=O)(=O)NC1c2ccccc2Oc2ccccc12, Cc1ccc(cc1)S(=O)(=O)NC1c2ccccc2Oc2ccccc12	OZCQEUZTOAAWDK-UHFFFAOYSA-N, OZCQEUZTOAAWDK-UHFFFAOYSA-N, OZCQEUZTOAAWDK-UHFFFAOYSA-N	Preclinical
AH11110	adrenergic receptor ligand	ADRA1B			O[C@@H](COc1ccccc1-c1ccccc1)CC(=N)N1CCCCC1 |&1:1|, O[C@@H](COc1ccccc1-c1ccccc1)CC(=N)N1CCCCC1 |&1:1|, O[C@@H](COc1ccccc1-c1ccccc1)CC(=N)N1CCCCC1 |&1:1|	HSVZQQYIMKLNLN-GOSISDBHSA-N, HSVZQQYIMKLNLN-GOSISDBHSA-N, HSVZQQYIMKLNLN-GOSISDBHSA-N	Preclinical
AH6809	prostanoid receptor antagonist	PTGDR, PTGER1, PTGER2, PTGER3			CC(C)Oc1ccc2c(c1)oc1ccc(cc1c2=O)C(O)=O, CC(C)Oc1ccc2c(c1)oc1ccc(cc1c2=O)C(O)=O, CC(C)Oc1ccc2c(c1)oc1ccc(cc1c2=O)C(O)=O	AQFFXPQJLZFABJ-UHFFFAOYSA-N, AQFFXPQJLZFABJ-UHFFFAOYSA-N, AQFFXPQJLZFABJ-UHFFFAOYSA-N	Preclinical
AI-10-49	core binding factor inhibitor	CBFB			FC(F)(F)Oc1ccc2nc([nH]c2c1)-c1ccc(OCCOCCOc2ccc(nc2)-c2nc3ccc(OC(F)(F)F)cc3[nH]2)cn1	WJBSSBFGPKTMQQ-UHFFFAOYSA-N	Preclinical
AIM-100	tyrosine kinase inhibitor	TNK2			C(Nc1ncnc2oc(c(-c3ccccc3)c12)-c1ccccc1)[C@@H]1CCCO1, C(Nc1ncnc2oc(c(-c3ccccc3)c12)-c1ccccc1)[C@@H]1CCCO1	XNFHHOXCDUAYSR-SFHVURJKSA-N, XNFHHOXCDUAYSR-SFHVURJKSA-N	Preclinical
ajmaline	sodium channel blocker		cardiology	Wolff-Parkinson-White Syndrome (WPW)	[H][C@]12C[C@]34[C@H](O)[C@@]1([H])[C@]1([H])C[C@]([H])(N2[C@H](O)[C@@]1([H])CC)[C@]3([H])N(C)c1ccccc41, [H][C@]12C[C@]34[C@H](O)[C@@]1([H])[C@]1([H])C[C@]([H])(N2[C@H](O)[C@@]1([H])CC)[C@]3([H])N(C)c1ccccc41	CJDRUOGAGYHKKD-BDXZSHBPSA-N, CJDRUOGAGYHKKD-BDXZSHBPSA-N	Launched
AJ76-(+)	dopamine receptor antagonist	DRD2, DRD3, DRD4			CCCN[C@@H]1CCc2c(OC)cccc2[C@@H]1C, CCCN[C@@H]1CCc2c(OC)cccc2[C@@H]1C	YGHLYBIUVOLKCV-SMDDNHRTSA-N, YGHLYBIUVOLKCV-SMDDNHRTSA-N	Preclinical
AK-7	SIRT inhibitor	SIRT2			Brc1cccc(NC(=O)c2cccc(c2)S(=O)(=O)N2CCCCCC2)c1, Brc1cccc(NC(=O)c2cccc(c2)S(=O)(=O)N2CCCCCC2)c1	IYAYHZZWYNXHEQ-UHFFFAOYSA-N, IYAYHZZWYNXHEQ-UHFFFAOYSA-N	Preclinical
AKBA	lipoxygenase inhibitor	ALOX5			C[C@@H]1CC[C@]2(C)CC[C@]3(C)C(=CC(=O)[C@@H]4[C@@]5(C)CC[C@@H](OC(C)=O)[C@@](C)([C@@H]5CC[C@@]34C)C(O)=O)[C@@H]2[C@H]1C |c:10|, C[C@@H]1CC[C@]2(C)CC[C@]3(C)C(=CC(=O)[C@@H]4[C@@]5(C)CC[C@@H](OC(C)=O)[C@@](C)([C@@H]5CC[C@@]34C)C(O)=O)[C@@H]2[C@H]1C |c:10|, C[C@@H]1CC[C@]2(C)CC[C@]3(C)C(=CC(=O)[C@@H]4[C@@]5(C)CC[C@@H](OC(C)=O)[C@@](C)([C@@H]5CC[C@@]34C)C(O)=O)[C@@H]2[C@H]1C |c:10|, C[C@@H]1CC[C@]2(C)CC[C@]3(C)C(=CC(=O)[C@@H]4[C@@]5(C)CC[C@@H](OC(C)=O)[C@@](C)([C@@H]5CC[C@@]34C)C(O)=O)[C@@H]2[C@H]1C |c:10|	HMMGKOVEOFBCAU-BCDBGHSCSA-N, HMMGKOVEOFBCAU-BCDBGHSCSA-N, HMMGKOVEOFBCAU-BCDBGHSCSA-N, HMMGKOVEOFBCAU-BCDBGHSCSA-N	Phase 3
aklomide			infectious disease	coccidiosis	NC(=O)c1ccc(cc1Cl)[N+]([O-])=O	GFGSZUNNBQXGMK-UHFFFAOYSA-N	Launched
AL-8697	p38 MAPK inhibitor	MAPK14			Cc1c(F)cc(cc1-c1c(F)cn2c(nnc2c1F)C(C)(C)C)C(=O)NC1CC1, Cc1c(F)cc(cc1-c1c(F)cn2c(nnc2c1F)C(C)(C)C)C(=O)NC1CC1	ZVBTZTQYHOXIBC-UHFFFAOYSA-N, ZVBTZTQYHOXIBC-UHFFFAOYSA-N	Preclinical
alacepril	angiotensin converting enzyme inhibitor	ACE	cardiology	hypertension	C[C@H](CSC(C)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1ccccc1)C(O)=O, C[C@H](CSC(C)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1ccccc1)C(O)=O, C[C@H](CSC(C)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1ccccc1)C(O)=O, C[C@H](CSC(C)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1ccccc1)C(O)=O	FHHHOYXPRDYHEZ-COXVUDFISA-N, FHHHOYXPRDYHEZ-COXVUDFISA-N, FHHHOYXPRDYHEZ-COXVUDFISA-N, FHHHOYXPRDYHEZ-COXVUDFISA-N	Launched
alafosfalin	bacterial cell wall synthesis inhibitor				C[C@H](N)C(=O)N[C@@H](C)P(O)(O)=O, C[C@H](N)C(=O)N[C@@H](C)P(O)(O)=O	BHAYDBSYOBONRV-IUYQGCFVSA-N, BHAYDBSYOBONRV-IUYQGCFVSA-N	Phase 1
alagebrium	glycosylation inhibitor				Cc1sc[n+](CC(=O)c2ccccc2)c1C	LYLFQLCLUXOFOL-UHFFFAOYSA-N	Phase 2/Phase 3
alanine					C[C@@H](N)C(O)=O |&1:1,r|	QNAYBMKLOCPYGJ-UWTATZPHSA-N	Launched
alanosine	antimetabolite				N[C@@H](CN(O)[N+][O-])C(O)=O	MLFKVJCWGUZWNV-REOHCLBHSA-N	Phase 2
alantolactone	apoptosis stimulant, STAT inhibitor	STAT3			C[C@H]1CCC[C@]2(C)C[C@H]3OC(=O)C(=C)[C@H]3C=C12 |t:16|, C[C@H]1CCC[C@]2(C)C[C@H]3OC(=O)C(=C)[C@H]3C=C12 |t:16|	PXOYOCNNSUAQNS-AGNJHWRGSA-N, PXOYOCNNSUAQNS-AGNJHWRGSA-N	Preclinical
alaproclate	serotonin receptor antagonist	SLC6A4			C[C@@H](N)C(=O)OC(C)(C)Cc1ccc(Cl)cc1 |&1:1|	FZSPJBYOKQPKCD-SECBINFHSA-N	Phase 2
alarelin	gonadotropin releasing factor hormone receptor antagonist	GNRH1			CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@@H]1CCC(=O)N1, CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@@H]1CCC(=O)N1	QLGKMLRGKPKGKI-QWQCQAQZSA-N, QLGKMLRGKPKGKI-QWQCQAQZSA-N	Launched
albendazole	tubulin polymerization inhibitor	TUBA1A, TUBB, TUBB4B	infectious disease	cystic hydatid disease, parenchymal neurocysticercosis	CCCSc1ccc2nc(NC(=O)OC)[nH]c2c1, CCCSc1ccc2nc(NC(=O)OC)[nH]c2c1, CCCSc1ccc2nc(NC(=O)OC)[nH]c2c1, CCCSc1ccc2nc(NC(=O)OC)[nH]c2c1, CCCSc1ccc2nc(NC(=O)OC)[nH]c2c1	HXHWSAZORRCQMX-UHFFFAOYSA-N, HXHWSAZORRCQMX-UHFFFAOYSA-N, HXHWSAZORRCQMX-UHFFFAOYSA-N, HXHWSAZORRCQMX-UHFFFAOYSA-N, HXHWSAZORRCQMX-UHFFFAOYSA-N	Launched
albendazole-oxide	anthelmintic agent		infectious disease	cystic hydatid disease, parenchymal neurocysticercosis	CCC[S@@](=O)c1ccc2nc(NC(=O)OC)[nH]c2c1 |r|, CCC[S@@](=O)c1ccc2nc(NC(=O)OC)[nH]c2c1 |r|	VXTGHWHFYNYFFV-LJQANCHMSA-N, VXTGHWHFYNYFFV-LJQANCHMSA-N	Launched
albuterol	adrenergic receptor agonist	ADRB2	pulmonary	asthma	CC(C)(C)NC[C@@H](O)c1ccc(O)c(CO)c1 |&1:6|, CC(C)(C)NC[C@@H](O)c1ccc(O)c(CO)c1 |&1:6|	NDAUXUAQIAJITI-GFCCVEGCSA-N, NDAUXUAQIAJITI-GFCCVEGCSA-N	Launched
alcaftadine	histamine receptor antagonist	HRH1	allergy	allergic conjunctivitis	CN1CCC(CC1)=C1c2ncc(C=O)n2CCc2ccccc12	MWTBKTRZPHJQLH-UHFFFAOYSA-N	Launched
alclofenac	cyclooxygenase inhibitor	PTGS1	rheumatology	rheumatoid arthritis	OC(=O)Cc1ccc(OCC=C)c(Cl)c1, OC(=O)Cc1ccc(OCC=C)c(Cl)c1	ARHWPKZXBHOEEE-UHFFFAOYSA-N, ARHWPKZXBHOEEE-UHFFFAOYSA-N	Launched
alclometasone-dipropionate	glucocorticoid receptor agonist	CYP3A4, NR3C1, SERPINA6	dermatology	corticosteroid-responsive dermatoses	CCC(=O)OCC(=O)[C@@]1(OC(=O)CC)[C@H](C)C[C@H]2[C@H]3[C@H](Cl)CC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]12C |a:14,17,19,28,30,31,34,&1:8,&2:18,c:26,t:22|	DJHCCTTVDRAMEH-FQEREKBASA-N	Launched
alcuronium	muscle relaxant	CHRM1, CHRM2, CHRM3, CHRM4, CHRNA7	neurology/psychiatry	muscle relaxant	OC\C=C1/C[N@+]2(CC=C)CC[C@@]34[C@@H]2C[C@@H]1\C1=C\N2[C@@H]5\C(=C/N([C@@H]31)c1ccccc41)[C@H]1C[C@H]3[C@@]5(CC[N@@+]3(CC=C)C\C1=C/CO)c1ccccc21 |a:5,11,12,14,29,31,32,35,&1:18,&2:22,c:21,t:17,TLB:2:3:13:11.15.22,20:19:30:35.39.40,10:11:3.4.5:13,41:40:30:18.19.32,28:11:3.4.5:13,THB:34:35:30:18.19.32,16:15:3.4.5:13,33:32:30:35.39.40,36:35:30:18.19.32,6:5:13:11.15.22,9:5:13:11.15.22,44:32:30:35.39.40|	MUQUYTSLDVKIOF-JGNNFNAWSA-N	Launched
alda-1	aldehyde dehydrogenase activator	ALDH2			Clc1cccc(Cl)c1C(=O)NCc1ccc2OCOc2c1, Clc1cccc(Cl)c1C(=O)NCc1ccc2OCOc2c1	NMKJFZCBCIUYHI-UHFFFAOYSA-N, NMKJFZCBCIUYHI-UHFFFAOYSA-N	Preclinical
aldoxorubicin	topoisomerase inhibitor	TOP2A			COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(\CO)=N\NC(=O)CCCCCN1C(=O)C=CC1=O |c:55|, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(\CO)=N\NC(=O)CCCCCN1C(=O)C=CC1=O |c:55|, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(\CO)=N\NC(=O)CCCCCN1C(=O)C=CC1=O |c:55|	OBMJQRLIQQTJLR-USGQOSEYSA-N, OBMJQRLIQQTJLR-USGQOSEYSA-N, OBMJQRLIQQTJLR-USGQOSEYSA-N	Phase 3
alectinib	ALK tyrosine kinase receptor inhibitor	ALK, MET	oncology	non-small cell lung cancer (NSCLC)	CCc1cc2C(=O)c3c([nH]c4cc(ccc34)C#N)C(C)(C)c2cc1N1CCC(CC1)N1CCOCC1, CCc1cc2C(=O)c3c([nH]c4cc(ccc34)C#N)C(C)(C)c2cc1N1CCC(CC1)N1CCOCC1, CCc1cc2C(=O)c3c([nH]c4cc(ccc34)C#N)C(C)(C)c2cc1N1CCC(CC1)N1CCOCC1	KDGFLJKFZUIJMX-UHFFFAOYSA-N, KDGFLJKFZUIJMX-UHFFFAOYSA-N, KDGFLJKFZUIJMX-UHFFFAOYSA-N	Launched
alendronate	bone resorption inhibitor	ATP6V1A, FDPS, PTPN4, PTPRE, PTPRS	orthopedics	osteoporosis	NCCCC(O)(P(O)(O)=O)P(O)(O)=O, NCCCC(O)(P(O)(O)=O)P(O)(O)=O, NCCCC(O)(P(O)(O)=O)P(O)(O)=O, NCCCC(O)(P(O)(O)=O)P(O)(O)=O, NCCCC(O)(P(O)(O)=O)P(O)(O)=O	OGSPWJRAVKPPFI-UHFFFAOYSA-N, OGSPWJRAVKPPFI-UHFFFAOYSA-N, OGSPWJRAVKPPFI-UHFFFAOYSA-N, OGSPWJRAVKPPFI-UHFFFAOYSA-N, OGSPWJRAVKPPFI-UHFFFAOYSA-N	Launched
alexidine	phosphatidylglycerophosphatase inhibitor	PTPMT1			CCCC[C@H](CC)CNC(=N)N=C(N)NCCCCCCNC(N)=NC(=N)NC[C@H](CC)CCCC |&1:29,&2:4,&3:11,&4:24,w:11.10,24.24|, CCCC[C@H](CC)CNC(=N)N=C(N)NCCCCCCNC(N)=NC(=N)NC[C@H](CC)CCCC |&1:29,&2:4,&3:11,&4:24,w:11.10,24.24|, CCCC[C@H](CC)CNC(=N)N=C(N)NCCCCCCNC(N)=NC(=N)NC[C@H](CC)CCCC |&1:29,&2:4,&3:11,&4:24,w:11.10,24.24|, CCCC[C@H](CC)CNC(=N)N=C(N)NCCCCCCNC(N)=NC(=N)NC[C@H](CC)CCCC |&1:29,&2:4,&3:11,&4:24,w:11.10,24.24|, CCCC[C@H](CC)CNC(=N)N=C(N)NCCCCCCNC(N)=NC(=N)NC[C@H](CC)CCCC |&1:29,&2:4,&3:11,&4:24,w:11.10,24.24|, CCCC[C@H](CC)CNC(=N)N=C(N)NCCCCCCNC(N)=NC(=N)NC[C@H](CC)CCCC |&1:29,&2:4,&3:11,&4:24,w:11.10,24.24|, CCCC[C@H](CC)CNC(=N)N=C(N)NCCCCCCNC(N)=NC(=N)NC[C@H](CC)CCCC |&1:29,&2:4,&3:11,&4:24,w:11.10,24.24|	LFVVNPBBFUSSHL-SZPZYZBQSA-N, LFVVNPBBFUSSHL-SZPZYZBQSA-N, LFVVNPBBFUSSHL-SZPZYZBQSA-N, LFVVNPBBFUSSHL-SZPZYZBQSA-N, LFVVNPBBFUSSHL-SZPZYZBQSA-N, LFVVNPBBFUSSHL-SZPZYZBQSA-N, LFVVNPBBFUSSHL-SZPZYZBQSA-N	Preclinical
alfacalcidol	vitamin D receptor agonist	CYP27B1, VDR	endocrinology	vitamin D deficiency	CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C, CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C, CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C, CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C, CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C, CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C	OFHCOWSQAMBJIW-AVJTYSNKSA-N, OFHCOWSQAMBJIW-AVJTYSNKSA-N, OFHCOWSQAMBJIW-AVJTYSNKSA-N, OFHCOWSQAMBJIW-AVJTYSNKSA-N, OFHCOWSQAMBJIW-AVJTYSNKSA-N, OFHCOWSQAMBJIW-AVJTYSNKSA-N	Launched
alfadolone-acetate	benzodiazepine receptor agonist				CC(=O)OCC(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4C[C@H](O)CC[C@]4(C)[C@H]3C(=O)C[C@]12C	QRJOQYLXZPQQMX-FWROMSNXSA-N	Phase 2
alfuzosin	adrenergic receptor antagonist	ADRA1A, ADRA1B, ADRA1D, SCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A	urology	benign prostatic hyperplasia (BPH)	COc1cc2nc(nc(N)c2cc1OC)N(C)CCCNC(=O)[C@H]1CCCO1 |&1:23|, COc1cc2nc(nc(N)c2cc1OC)N(C)CCCNC(=O)[C@H]1CCCO1 |&1:23|	WNMJYKCGWZFFKR-CQSZACIVSA-N, WNMJYKCGWZFFKR-CQSZACIVSA-N	Launched
algestone-acetophenide			endocrinology	contraceptive	CC(=O)[C@@]12O[C@@](C)(O[C@@H]1C[C@H]1[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]21C)c1ccccc1 |t:15|	AHBKIEXBQNRDNL-FVCOMRFXSA-N	Launched
alibendol	antispasmodic		gastroenterology	bile stimulation	COc1cc(CC=C)cc(C(=O)NCCO)c1O	UMJHTFHIQDEGKB-UHFFFAOYSA-N	Launched
alimemazine	histamine receptor agonist, histamine receptor antagonist	HRH1	neurology/psychiatry, allergy, pulmonary	sedative, urticaria, itching, cough suppressant	C[C@@H](CN(C)C)CN1c2ccccc2Sc2ccccc12 |&3:1|, C[C@@H](CN(C)C)CN1c2ccccc2Sc2ccccc12 |&3:1|, C[C@@H](CN(C)C)CN1c2ccccc2Sc2ccccc12 |&3:1|	ZZHLYYDVIOPZBE-AWEZNQCLSA-N, ZZHLYYDVIOPZBE-AWEZNQCLSA-N, ZZHLYYDVIOPZBE-AWEZNQCLSA-N	Launched
alinidine	bradycardic effect 				Clc1cccc(Cl)c1N(CC=C)C1=NCCN1 |t:13|	OXTYVEUAQHPPMV-UHFFFAOYSA-N	Phase 3
alisertib	Aurora kinase inhibitor	AURKA			COc1cc(Nc2ncc3CN=C(c4cc(Cl)ccc4-c3n2)c2c(F)cccc2OC)ccc1C(O)=O |c:11|, COc1cc(Nc2ncc3CN=C(c4cc(Cl)ccc4-c3n2)c2c(F)cccc2OC)ccc1C(O)=O |c:11|, COc1cc(Nc2ncc3CN=C(c4cc(Cl)ccc4-c3n2)c2c(F)cccc2OC)ccc1C(O)=O |c:11|, COc1cc(Nc2ncc3CN=C(c4cc(Cl)ccc4-c3n2)c2c(F)cccc2OC)ccc1C(O)=O |c:11|, COc1cc(Nc2ncc3CN=C(c4cc(Cl)ccc4-c3n2)c2c(F)cccc2OC)ccc1C(O)=O |c:11|, COc1cc(Nc2ncc3CN=C(c4cc(Cl)ccc4-c3n2)c2c(F)cccc2OC)ccc1C(O)=O |c:11|, COc1cc(Nc2ncc3CN=C(c4cc(Cl)ccc4-c3n2)c2c(F)cccc2OC)ccc1C(O)=O |c:11|, COc1cc(Nc2ncc3CN=C(c4cc(Cl)ccc4-c3n2)c2c(F)cccc2OC)ccc1C(O)=O |c:11|, COc1cc(Nc2ncc3CN=C(c4cc(Cl)ccc4-c3n2)c2c(F)cccc2OC)ccc1C(O)=O |c:11|, COc1cc(Nc2ncc3CN=C(c4cc(Cl)ccc4-c3n2)c2c(F)cccc2OC)ccc1C(O)=O |c:11|, COc1cc(Nc2ncc3CN=C(c4cc(Cl)ccc4-c3n2)c2c(F)cccc2OC)ccc1C(O)=O |c:11|, COc1cc(Nc2ncc3CN=C(c4cc(Cl)ccc4-c3n2)c2c(F)cccc2OC)ccc1C(O)=O |c:11|, COc1cc(Nc2ncc3CN=C(c4cc(Cl)ccc4-c3n2)c2c(F)cccc2OC)ccc1C(O)=O |c:11|	ZLHFILGSQDJULK-UHFFFAOYSA-N, ZLHFILGSQDJULK-UHFFFAOYSA-N, ZLHFILGSQDJULK-UHFFFAOYSA-N, ZLHFILGSQDJULK-UHFFFAOYSA-N, ZLHFILGSQDJULK-UHFFFAOYSA-N, InChI=1S/C27H20ClFN4O4/c1-36-21-5-3-4-20(29)23(21)25-19-10-15(28)6-8-17(19)24-14(12-30-25)13-31-27(33-24)32-16-7-9-18(26(34)35)22(11-16)37-2/h3-11,13H,12H2,1-2H3,(H,34,35)(H,31,32,33), InChI=1S/C27H20ClFN4O4/c1-36-21-5-3-4-20(29)23(21)25-19-10-15(28)6-8-17(19)24-14(12-30-25)13-31-27(33-24)32-16-7-9-18(26(34)35)22(11-16)37-2/h3-11,13H,12H2,1-2H3,(H,34,35)(H,31,32,33), InChI=1S/C27H20ClFN4O4/c1-36-21-5-3-4-20(29)23(21)25-19-10-15(28)6-8-17(19)24-14(12-30-25)13-31-27(33-24)32-16-7-9-18(26(34)35)22(11-16)37-2/h3-11,13H,12H2,1-2H3,(H,34,35)(H,31,32,33), InChI=1S/C27H20ClFN4O4/c1-36-21-5-3-4-20(29)23(21)25-19-10-15(28)6-8-17(19)24-14(12-30-25)13-31-27(33-24)32-16-7-9-18(26(34)35)22(11-16)37-2/h3-11,13H,12H2,1-2H3,(H,34,35)(H,31,32,33), InChI=1S/C27H20ClFN4O4/c1-36-21-5-3-4-20(29)23(21)25-19-10-15(28)6-8-17(19)24-14(12-30-25)13-31-27(33-24)32-16-7-9-18(26(34)35)22(11-16)37-2/h3-11,13H,12H2,1-2H3,(H,34,35)(H,31,32,33), InChI=1S/C27H20ClFN4O4/c1-36-21-5-3-4-20(29)23(21)25-19-10-15(28)6-8-17(19)24-14(12-30-25)13-31-27(33-24)32-16-7-9-18(26(34)35)22(11-16)37-2/h3-11,13H,12H2,1-2H3,(H,34,35)(H,31,32,33), InChI=1S/C27H20ClFN4O4/c1-36-21-5-3-4-20(29)23(21)25-19-10-15(28)6-8-17(19)24-14(12-30-25)13-31-27(33-24)32-16-7-9-18(26(34)35)22(11-16)37-2/h3-11,13H,12H2,1-2H3,(H,34,35)(H,31,32,33), InChI=1S/C27H20ClFN4O4/c1-36-21-5-3-4-20(29)23(21)25-19-10-15(28)6-8-17(19)24-14(12-30-25)13-31-27(33-24)32-16-7-9-18(26(34)35)22(11-16)37-2/h3-11,13H,12H2,1-2H3,(H,34,35)(H,31,32,33)	Phase 3
aliskiren-hemifumarate	renin inhibitor	REN	cardiology	hypertension	COCCCOc1cc(C[C@@H](C[C@H](N)[C@@H](O)C[C@@H](C(C)C)C(=O)NCC(C)(C)C(N)=O)C(C)C)ccc1OC, COCCCOc1cc(C[C@@H](C[C@H](N)[C@@H](O)C[C@@H](C(C)C)C(=O)NCC(C)(C)C(N)=O)C(C)C)ccc1OC, COCCCOc1cc(C[C@@H](C[C@H](N)[C@@H](O)C[C@@H](C(C)C)C(=O)NCC(C)(C)C(N)=O)C(C)C)ccc1OC, COCCCOc1cc(C[C@@H](C[C@H](N)[C@@H](O)C[C@@H](C(C)C)C(=O)NCC(C)(C)C(N)=O)C(C)C)ccc1OC, COCCCOc1cc(C[C@@H](C[C@H](N)[C@@H](O)C[C@@H](C(C)C)C(=O)NCC(C)(C)C(N)=O)C(C)C)ccc1OC, COCCCOc1cc(C[C@@H](C[C@H](N)[C@@H](O)C[C@@H](C(C)C)C(=O)NCC(C)(C)C(N)=O)C(C)C)ccc1OC	UXOWGYHJODZGMF-QORCZRPOSA-N, UXOWGYHJODZGMF-QORCZRPOSA-N, UXOWGYHJODZGMF-QORCZRPOSA-N, UXOWGYHJODZGMF-QORCZRPOSA-N, UXOWGYHJODZGMF-QORCZRPOSA-N, UXOWGYHJODZGMF-QORCZRPOSA-N	Launched
alisporivir	cyclophilin inhibitor				[H][C@]1(C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(CC)C(=O)[C@@H](C)N(C)C(=O)[C@H](CC)NC(=O)[C@]([H])([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@]([H])(CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C1=O)C(C)C	OLROWHGDTNFZBH-XEMWPYQTSA-N	Phase 3
alizapride	dopamine receptor antagonist		gastroenterology	nausea	COc1cc2[nH]nnc2cc1C(=O)NC[C@H]1CCCN1CC=C |&1:15,r|	KSEYRUGYKHXGFW-LLVKDONJSA-N	Launched
alizarin					Oc1ccc2C(=O)c3ccccc3C(=O)c2c1O, Oc1ccc2C(=O)c3ccccc3C(=O)c2c1O, Oc1ccc2C(=O)c3ccccc3C(=O)c2c1O	RGCKGOZRHPZPFP-UHFFFAOYSA-N, RGCKGOZRHPZPFP-UHFFFAOYSA-N, RGCKGOZRHPZPFP-UHFFFAOYSA-N	Preclinical
allantoin	cosmetic		dermatology	skin protectant	NC(=O)N[C@H]1NC(=O)NC1=O |r|	POJWUDADGALRAB-SFOWXEAESA-N	Launched
allicin	cytokine production inhibitor	TRPA1, TRPV1			C=CCS[S@@](=O)CC=C |&1:4,r|	JDLKFOPOAOFWQN-SECBINFHSA-N	Phase 2
allopurinol	xanthine oxidase inhibitor	XDH	rheumatology, urology	gout, kidney stones	O=c1nc[nH]c2n[nH]cc12, O=c1nc[nH]c2n[nH]cc12, O=c1nc[nH]c2n[nH]cc12, O=c1nc[nH]c2n[nH]cc12	OFCNXPDARWKPPY-UHFFFAOYSA-N, OFCNXPDARWKPPY-UHFFFAOYSA-N, OFCNXPDARWKPPY-UHFFFAOYSA-N, OFCNXPDARWKPPY-UHFFFAOYSA-N	Launched
allopurinol-riboside	anti-leishmanial agent, phosphorylase inhibitor				OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1ncc2c(O)ncnc12, OC[C@H]1O[C@H]([C@@H](O)[C@H]1O)n1ncc2c1[nH]cnc2=O |a:2,4,7,&1:5|	KFQUAMTWOJHPEJ-DAGMQNCNSA-N, KFQUAMTWOJHPEJ-NBBQQVJHSA-N	Phase 2
allylestrenol	steroidal progestin	ESR1, PGR, SLC6A9	obstetrics/gynecology	premature labor	C[C@]12CC[C@H]3[C@@H](CCC4=CCCC[C@H]34)[C@@H]1CC[C@@]2(O)CC=C |t:8|	ATXHVCQZZJYMCF-XUDSTZEESA-N	Launched
allylisothiocyanate	TRPV agonist	TRPA1			C=CCN=C=S, C=CCN=C=S	ZOJBYZNEUISWFT-UHFFFAOYSA-N, ZOJBYZNEUISWFT-UHFFFAOYSA-N	Preclinical
allylthiourea	nitrification inhibitor				NC(=S)NCC=C, NC(=S)NCC=C, NC(=S)NCC=C	HTKFORQRBXIQHD-UHFFFAOYSA-N, HTKFORQRBXIQHD-UHFFFAOYSA-N, HTKFORQRBXIQHD-UHFFFAOYSA-N	Preclinical
almitrine	neurotransmitter agonist	ATP1A1	pulmonary	chronic obstructive pulmonary disease (COPD)	Fc1ccc(cc1)C(N1CCN(CC1)c1nc(NCC=C)nc(NCC=C)n1)c1ccc(F)cc1, Fc1ccc(cc1)C(N1CCN(CC1)c1nc(NCC=C)nc(NCC=C)n1)c1ccc(F)cc1	OBDOVFRMEYHSQB-UHFFFAOYSA-N, OBDOVFRMEYHSQB-UHFFFAOYSA-N	Launched
almorexant	orexin receptor antagonist	HCRTR1, HCRTR2			CNC(=O)[C@H](N1CCc2cc(OC)c(OC)cc2[C@@H]1CCc1ccc(cc1)C(F)(F)F)c1ccccc1, CNC(=O)[C@H](N1CCc2cc(OC)c(OC)cc2[C@@H]1CCc1ccc(cc1)C(F)(F)F)c1ccccc1	DKMACHNQISHMDN-RPLLCQBOSA-N, DKMACHNQISHMDN-RPLLCQBOSA-N	Phase 3
almotriptan	serotonin receptor agonist	HTR1B, HTR1D	neurology/psychiatry	migraine headache	CN(C)CCc1c[nH]c2ccc(CS(=O)(=O)N3CCCC3)cc12, CN(C)CCc1c[nH]c2ccc(CS(=O)(=O)N3CCCC3)cc12, CN(C)CCc1c[nH]c2ccc(CS(=O)(=O)N3CCCC3)cc12	WKEMJKQOLOHJLZ-UHFFFAOYSA-N, WKEMJKQOLOHJLZ-UHFFFAOYSA-N, WKEMJKQOLOHJLZ-UHFFFAOYSA-N	Launched
aloe-emodin	anticancer agent	CASP8			OCc1cc(O)c2C(=O)c3c(O)cccc3C(=O)c2c1	YDQWDHRMZQUTBA-UHFFFAOYSA-N	Preclinical
alogliptin	dipeptidyl peptidase inhibitor	DPP4	endocrinology	diabetes mellitus	Cn1c(=O)cc(N2CCC[C@@H](N)C2)n(Cc2ccccc2C#N)c1=O, Cn1c(=O)cc(N2CCC[C@@H](N)C2)n(Cc2ccccc2C#N)c1=O, Cn1c(=O)cc(N2CCC[C@@H](N)C2)n(Cc2ccccc2C#N)c1=O, Cn1c(=O)cc(N2CCC[C@@H](N)C2)n(Cc2ccccc2C#N)c1=O, Cn1c(=O)cc(N2CCC[C@@H](N)C2)n(Cc2ccccc2C#N)c1=O	ZSBOMTDTBDDKMP-OAHLLOKOSA-N, ZSBOMTDTBDDKMP-OAHLLOKOSA-N, ZSBOMTDTBDDKMP-OAHLLOKOSA-N, ZSBOMTDTBDDKMP-OAHLLOKOSA-N, ZSBOMTDTBDDKMP-OAHLLOKOSA-N	Launched
aloin	angiogenesis inhibitor				OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)[C@H]1c2cccc(O)c2C(=O)c2c(O)cc(CO)cc12, OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)[C@H]1c2cccc(O)c2C(=O)c2c(O)cc(CO)cc12, OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)[C@H]1c2cccc(O)c2C(=O)c2c(O)cc(CO)cc12, OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)[C@H]1c2cccc(O)c2C(=O)c2c(O)cc(CO)cc12	AFHJQYHRLPMKHU-OSYMLPPYSA-N, AFHJQYHRLPMKHU-OSYMLPPYSA-N, AFHJQYHRLPMKHU-OSYMLPPYSA-N, AFHJQYHRLPMKHU-OSYMLPPYSA-N	Preclinical
aloperine					C1CCN2C[C@H]3C[C@H](C=C4CCCN[C@@H]34)[C@H]2C1 |t:8|, C1CCN2C[C@H]3C[C@H](C=C4CCCN[C@@H]34)[C@H]2C1 |t:8|	SKOLRLSBMUGVOY-GBJTYRQASA-N, SKOLRLSBMUGVOY-GBJTYRQASA-N	Preclinical
alosetron	serotonin receptor antagonist	HTR3A			Cc1nc[nH]c1CN1CCc2c(C1=O)c1ccccc1n2C, Cc1nc[nH]c1CN1CCc2c(C1=O)c1ccccc1n2C, Cc1nc[nH]c1CN1CCc2c(C1=O)c1ccccc1n2C	JSWZEAMFRNKZNL-UHFFFAOYSA-N, JSWZEAMFRNKZNL-UHFFFAOYSA-N, JSWZEAMFRNKZNL-UHFFFAOYSA-N	Withdrawn
alovudine	DNA synthesis marker				Cc1cn([C@H]2C[C@H](F)[C@@H](CO)O2)c(=O)[nH]c1=O	UXCAQJAQSWSNPQ-XLPZGREQSA-N	Phase 2
aloxistatin	protease inhibitor	CTSG			CCOC(=O)[C@H]1O[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)NCCC(C)C, CCOC(=O)[C@H]1O[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)NCCC(C)C, CCOC(=O)[C@H]1O[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)NCCC(C)C, CCOC(=O)[C@H]1O[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)NCCC(C)C, CCOC(=O)[C@H]1O[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)NCCC(C)C, CCOC(=O)[C@H]1O[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)NCCC(C)C, CCOC(=O)[C@H]1O[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)NCCC(C)C	SRVFFFJZQVENJC-IHRRRGAJSA-N, SRVFFFJZQVENJC-IHRRRGAJSA-N, SRVFFFJZQVENJC-IHRRRGAJSA-N, SRVFFFJZQVENJC-IHRRRGAJSA-N, SRVFFFJZQVENJC-IHRRRGAJSA-N, SRVFFFJZQVENJC-IHRRRGAJSA-N, SRVFFFJZQVENJC-IHRRRGAJSA-N	Phase 3
alpelisib	PI3K inhibitor	PIK3CA, PIK3CB, PIK3CD, PIK3CG	oncology	breast cancer	Cc1nc(NC(=O)N2CCC[C@H]2C(N)=O)sc1-c1ccnc(c1)C(C)(C)C(F)(F)F, Cc1nc(NC(=O)N2CCC[C@H]2C(N)=O)sc1-c1ccnc(c1)C(C)(C)C(F)(F)F, Cc1nc(NC(=O)N2CCC[C@H]2C(N)=O)sc1-c1ccnc(c1)C(C)(C)C(F)(F)F, Cc1nc(NC(=O)N2CCC[C@H]2C(N)=O)sc1-c1ccnc(c1)C(C)(C)C(F)(F)F, Cc1nc(NC(=O)N2CCC[C@H]2C(N)=O)sc1-c1ccnc(c1)C(C)(C)C(F)(F)F, Cc1nc(NC(=O)N2CCC[C@H]2C(N)=O)sc1-c1ccnc(c1)C(C)(C)C(F)(F)F	STUWGJZDJHPWGZ-LBPRGKRZSA-N, STUWGJZDJHPWGZ-LBPRGKRZSA-N, STUWGJZDJHPWGZ-LBPRGKRZSA-N, STUWGJZDJHPWGZ-LBPRGKRZSA-N, STUWGJZDJHPWGZ-LBPRGKRZSA-N, STUWGJZDJHPWGZ-LBPRGKRZSA-N	Launched
alpha-asarone	cytochrome P450 inhibitor, HMGCR inhibitor	HMGCR			COc1cc(OC)c(\C=C\C)cc1OC	RKFAZBXYICVSKP-AATRIKPKSA-N	Preclinical
alpha-D-glucopyranose					OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@@H]1O	WQZGKKKJIJFFOK-DVKNGEFBSA-N	Preclinical
alpha-glucosyl-hesperidin	antioxidant				COc1ccc(cc1O)[C@@H]1CC(=O)c2c(O)cc(O[C@@H]3O[C@H](CO[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@@H](O[C@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)[C@H](O)[C@H]3O)cc2O1	IMMBLRJLSYJQIZ-RBWYFKFWSA-N	Preclinical
alpha-linolenic-acid	omega 3 fatty acid stimulant	ELOVL4, FADS1, FADS2, FFAR1, FFAR4, PTGS2, SLC8A1, TRPV1			CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O, CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O, CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O, CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O, CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O	DTOSIQBPPRVQHS-PDBXOOCHSA-N, DTOSIQBPPRVQHS-PDBXOOCHSA-N, DTOSIQBPPRVQHS-PDBXOOCHSA-N, DTOSIQBPPRVQHS-PDBXOOCHSA-N, DTOSIQBPPRVQHS-PDBXOOCHSA-N	Phase 3
alpha-methylhistamine-dihydrobromide-(R)-(-)	histamine receptor agonist	HRH3			C[C@@H](N)Cc1cnc[nH]1, C[C@@H](N)Cc1cnc[nH]1	XNQIOISZPFVUFG-RXMQYKEDSA-N, XNQIOISZPFVUFG-RXMQYKEDSA-N	Preclinical
alpha-methylhistamine-dihydrobromide-(S)-(+)	histamine receptor agonist	HRH3			C[C@H](N)Cc1cnc[nH]1, C[C@H](N)Cc1cnc[nH]1	XNQIOISZPFVUFG-YFKPBYRVSA-N, XNQIOISZPFVUFG-YFKPBYRVSA-N	Preclinical
alpha-methylserotonin	serotonin receptor agonist	HTR1D, HTR1E, HTR1F, HTR2A, HTR2B, HTR2C, HTR4			C[C@@H](N)Cc1c[nH]c2ccc(O)cc12 |&1:1|	LYPCGXKCQDYTFV-SSDOTTSWSA-N	Preclinical
alpha-tochopherol	antioxidant		endocrinology	vitamin E deficiency	CC(C)CCC[C@@H](C)CCC[C@@H](C)CCC[C@@]1(C)CCc2c(C)c(O)c(C)c(C)c2O1 |&1:6,&2:11,&3:16,r|, CC(C)CCC[C@@H](C)CCC[C@@H](C)CCC[C@@]1(C)CCc2c(C)c(O)c(C)c(C)c2O1 |&1:6,&2:11,&3:16,r|	GVJHHUAWPYXKBD-QLVXXPONSA-N, GVJHHUAWPYXKBD-QLVXXPONSA-N	Launched
alpha-tochopheryl-acetate	antioxidant		endocrinology	vitamin E deficiency	CC(C)CCC[C@@H](C)CCC[C@@H](C)CCC[C@@]1(C)CCc2c(C)c(OC(C)=O)c(C)c(C)c2O1 |&1:6,&2:11,&3:16,r|	ZAKOWWREFLAJOT-PKIAKLFDSA-N	Launched
alpidem	benzodiazepine receptor agonist	GABRA1			CCCN(CCC)C(=O)Cc1c(nc2ccc(Cl)cn12)-c1ccc(Cl)cc1, CCCN(CCC)C(=O)Cc1c(nc2ccc(Cl)cn12)-c1ccc(Cl)cc1, CCCN(CCC)C(=O)Cc1c(nc2ccc(Cl)cn12)-c1ccc(Cl)cc1	JRTIDHTUMYMPRU-UHFFFAOYSA-N, JRTIDHTUMYMPRU-UHFFFAOYSA-N, JRTIDHTUMYMPRU-UHFFFAOYSA-N	Withdrawn
alprenolol	adrenergic receptor antagonist	ADRB1, ADRB2	cardiology	angina pectoris	CC(C)NC[C@@H](O)COc1ccccc1CC=C |&1:5,r|, CC(C)NC[C@@H](O)COc1ccccc1CC=C |&1:5,r|	PAZJSJFMUHDSTF-CQSZACIVSA-N, PAZJSJFMUHDSTF-CQSZACIVSA-N	Launched
alprostadil	prostanoid receptor agonist	CATSPER1, CATSPER2, CATSPER3, CATSPER4, PTGDR, PTGER1, PTGER2, PTGER4, PTGIR	cardiology	congenital heart defects	CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O, CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O, CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O, CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O	GMVPRGQOIOIIMI-DWKJAMRDSA-N, GMVPRGQOIOIIMI-DWKJAMRDSA-N, GMVPRGQOIOIIMI-DWKJAMRDSA-N, GMVPRGQOIOIIMI-DWKJAMRDSA-N	Launched
alrestatin	aldose reductase inhibitor	AKR1B1			OC(=O)CN1C(=O)c2cccc3cccc(C1=O)c23, OC(=O)CN1C(=O)c2cccc3cccc(C1=O)c23, OC(=O)CN1C(=O)c2cccc3cccc(C1=O)c23	GCUCIFQCGJIRNT-UHFFFAOYSA-N, GCUCIFQCGJIRNT-UHFFFAOYSA-N, GCUCIFQCGJIRNT-UHFFFAOYSA-N	Preclinical
ALS-8112					Nc1ccn([C@@H]2O[C@@](CO)(CCl)[C@@H](O)[C@H]2F)c(=O)n1, Nc1ccn([C@@H]2O[C@@](CO)(CCl)[C@@H](O)[C@H]2F)c(=O)n1, Nc1ccn([C@@H]2O[C@@](CO)(CCl)[C@@H](O)[C@H]2F)c(=O)n1	AWSRKKBIPSQHOJ-IBCQBUCCSA-N, AWSRKKBIPSQHOJ-IBCQBUCCSA-N, AWSRKKBIPSQHOJ-IBCQBUCCSA-N	Phase 1
ALS-8176	RNA polymerase inhibitor				CC(C)C(=O)OC[C@@]1(CCl)O[C@H]([C@H](F)[C@@H]1OC(=O)C(C)C)n1ccc(N)nc1=O	MJVKYGMNSQJLIN-KYZVSKTDSA-N	Phase 1
altanserin	serotonin receptor antagonist	HTR2A			Fc1ccc(cc1)C(=O)C1CCN(CCn2c(=S)[nH]c3ccccc3c2=O)CC1, Fc1ccc(cc1)C(=O)C1CCN(CCn2c(=S)[nH]c3ccccc3c2=O)CC1, Fc1ccc(cc1)C(=O)C1CCN(CCn2c(=S)[nH]c3ccccc3c2=O)CC1, Fc1ccc(cc1)C(=O)C1CCN(CCn2c(=S)[nH]c3ccccc3c2=O)CC1, Fc1ccc(cc1)C(=O)C1CCN(CCn2c(=S)[nH]c3ccccc3c2=O)CC1	SMYALUSCZJXWHG-UHFFFAOYSA-N, SMYALUSCZJXWHG-UHFFFAOYSA-N, SMYALUSCZJXWHG-UHFFFAOYSA-N, SMYALUSCZJXWHG-UHFFFAOYSA-N, SMYALUSCZJXWHG-UHFFFAOYSA-N	Phase 2
althiazide	diuretic		cardiology	hypertension	NS(=O)(=O)c1cc2c(N[C@@H](CSCC=C)NS2(=O)=O)cc1Cl |&1:9,r|, NS(=O)(=O)c1cc2c(N[C@@H](CSCC=C)NS2(=O)=O)cc1Cl |&1:9,r|, NS(=O)(=O)c1cc2c(N[C@@H](CSCC=C)NS2(=O)=O)cc1Cl |&1:9,r|	VGLGVJVUHYTIIU-LLVKDONJSA-N, VGLGVJVUHYTIIU-LLVKDONJSA-N, VGLGVJVUHYTIIU-LLVKDONJSA-N	Launched
altinicline	nicotinic receptor agonist	CHRNA4, CHRNB2			CN1CCC[C@H]1c1cncc(c1)C#C, CN1CCC[C@H]1c1cncc(c1)C#C	NUPUDYKEEJNZRG-LBPRGKRZSA-N, NUPUDYKEEJNZRG-LBPRGKRZSA-N	Phase 2
altiratinib	MET inhibitor, VEGFR inhibitor	KDR, MET, TEK			Fc1ccc(NC(=O)C2(CC2)C(=O)Nc2cc(F)c(Oc3ccnc(NC(=O)C4CC4)c3)cc2F)cc1, Fc1ccc(NC(=O)C2(CC2)C(=O)Nc2cc(F)c(Oc3ccnc(NC(=O)C4CC4)c3)cc2F)cc1, Fc1ccc(NC(=O)C2(CC2)C(=O)Nc2cc(F)c(Oc3ccnc(NC(=O)C4CC4)c3)cc2F)cc1, Fc1ccc(NC(=O)C2(CC2)C(=O)Nc2cc(F)c(Oc3ccnc(NC(=O)C4CC4)c3)cc2F)cc1, Fc1ccc(NC(=O)C2(CC2)C(=O)Nc2cc(F)c(Oc3ccnc(NC(=O)C4CC4)c3)cc2F)cc1, Fc1ccc(NC(=O)C2(CC2)C(=O)Nc2cc(F)c(Oc3ccnc(NC(=O)C4CC4)c3)cc2F)cc1, Fc1ccc(NC(=O)C2(CC2)C(=O)Nc2cc(F)c(Oc3ccnc(NC(=O)C4CC4)c3)cc2F)cc1	GNNDEPIMDAZHRQ-UHFFFAOYSA-N, GNNDEPIMDAZHRQ-UHFFFAOYSA-N, GNNDEPIMDAZHRQ-UHFFFAOYSA-N, GNNDEPIMDAZHRQ-UHFFFAOYSA-N, GNNDEPIMDAZHRQ-UHFFFAOYSA-N, GNNDEPIMDAZHRQ-UHFFFAOYSA-N, GNNDEPIMDAZHRQ-UHFFFAOYSA-N	Phase 1
altrenogest	progestogen hormone	PGR	endocrinology	estrus	C[C@]12C=CC3=C4CCC(=O)C=C4CC[C@H]3[C@@H]1CC[C@@]2(O)CC=C |c:2,4,10|, C[C@]12C=CC3=C4CCC(=O)C=C4CC[C@H]3[C@@H]1CC[C@@]2(O)CC=C |c:2,4,10|	VWAUPFMBXBWEQY-ANULTFPQSA-N, VWAUPFMBXBWEQY-ANULTFPQSA-N	Launched
altretamine	DNA synthesis inhibitor		oncology	ovarian cancer	CN(C)c1nc(nc(n1)N(C)C)N(C)C, CN(C)c1nc(nc(n1)N(C)C)N(C)C	UUVWYPNAQBNQJQ-UHFFFAOYSA-N, UUVWYPNAQBNQJQ-UHFFFAOYSA-N	Launched
alverine	muscle relaxant	HTR1A	gastroenterology	irritable bowel syndrome, diverticular disease	CCN(CCCc1ccccc1)CCCc1ccccc1, CCN(CCCc1ccccc1)CCCc1ccccc1, CCN(CCCc1ccccc1)CCCc1ccccc1	ZPFXAOWNKLFJDN-UHFFFAOYSA-N, ZPFXAOWNKLFJDN-UHFFFAOYSA-N, ZPFXAOWNKLFJDN-UHFFFAOYSA-N	Launched
alvespimycin	HSP inhibitor	HSP90AA1			CO[C@H]1C[C@H](C)CC2=C(NCCN(C)C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O |c:7,25,t:17,23,36|, CO[C@H]1C[C@H](C)CC2=C(NCCN(C)C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O |c:7,25,t:17,23,36|, CO[C@H]1C[C@H](C)CC2=C(NCCN(C)C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O |c:7,25,t:17,23,36|, CO[C@H]1C[C@H](C)CC2=C(NCCN(C)C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O |c:7,25,t:17,23,36|, CO[C@H]1C[C@H](C)CC2=C(NCCN(C)C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O |c:7,25,t:17,23,36|, CO[C@H]1C[C@H](C)CC2=C(NCCN(C)C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O |c:7,25,t:17,23,36|, CO[C@H]1C[C@H](C)CC2=C(NCCN(C)C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O |c:7,25,t:17,23,36|, CO[C@H]1C[C@H](C)CC2=C(NCCN(C)C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O |c:7,25,t:17,23,36|	KUFRQPKVAWMTJO-UBNVGODQSA-N, KUFRQPKVAWMTJO-UBNVGODQSA-N, KUFRQPKVAWMTJO-UBNVGODQSA-N, KUFRQPKVAWMTJO-UBNVGODQSA-N, KUFRQPKVAWMTJO-UBNVGODQSA-N, KUFRQPKVAWMTJO-UBNVGODQSA-N, KUFRQPKVAWMTJO-UBNVGODQSA-N, KUFRQPKVAWMTJO-UBNVGODQSA-N	Phase 2
alvimopan	opioid receptor antagonist	OPRD1, OPRK1, OPRM1	gastroenterology	postoperative ileus	C[C@H]1CN(C[C@H](Cc2ccccc2)C(=O)NCC(O)=O)CC[C@@]1(C)c1cccc(O)c1, C[C@H]1CN(C[C@H](Cc2ccccc2)C(=O)NCC(O)=O)CC[C@@]1(C)c1cccc(O)c1, C[C@H]1CN(C[C@H](Cc2ccccc2)C(=O)NCC(O)=O)CC[C@@]1(C)c1cccc(O)c1, C[C@H]1CN(C[C@H](Cc2ccccc2)C(=O)NCC(O)=O)CC[C@@]1(C)c1cccc(O)c1	UPNUIXSCZBYVBB-JVFUWBCBSA-N, UPNUIXSCZBYVBB-JVFUWBCBSA-N, UPNUIXSCZBYVBB-JVFUWBCBSA-N, UPNUIXSCZBYVBB-JVFUWBCBSA-N	Launched
alvocidib	CDK inhibitor	CDK1, CDK2, CDK4, CDK5, CDK6, CDK7, CDK8, CDK9, EGFR, PYGM			CN1CC[C@@H]([C@H](O)C1)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl, CN1CC[C@@H]([C@H](O)C1)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl, CN1CC[C@@H]([C@H](O)C1)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl, CN1CC[C@@H]([C@H](O)C1)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl, CN1CC[C@@H]([C@H](O)C1)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl, CN1CC[C@@H]([C@H](O)C1)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl, CN1CC[C@@H]([C@H](O)C1)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl, CN1CC[C@@H]([C@H](O)C1)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl, CN1CC[C@@H]([C@H](O)C1)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl	BIIVYFLTOXDAOV-YVEFUNNKSA-N, BIIVYFLTOXDAOV-YVEFUNNKSA-N, BIIVYFLTOXDAOV-YVEFUNNKSA-N, BIIVYFLTOXDAOV-YVEFUNNKSA-N, BIIVYFLTOXDAOV-YVEFUNNKSA-N, BIIVYFLTOXDAOV-YVEFUNNKSA-N, BIIVYFLTOXDAOV-YVEFUNNKSA-N, BIIVYFLTOXDAOV-YVEFUNNKSA-N, BIIVYFLTOXDAOV-YVEFUNNKSA-N	Phase 2
ALX-40-4C	CC chemokine receptor antagonist				CC(=O)N[C@H](CCCNC(N)=N)C(=O)N[C@H](CCCNC(N)=N)C(=O)N[C@H](CCCNC(N)=N)C(=O)N[C@H](CCCNC(N)=N)C(=O)N[C@H](CCCNC(N)=N)C(=O)N[C@H](CCCNC(N)=N)C(=O)N[C@H](CCCNC(N)=N)C(=O)N[C@H](CCCNC(N)=N)C(=O)N[C@H](CCCNC(N)=N)C(N)=O	LGLVVVCSQBZONM-HCCLCSBVSA-N	Preclinical
ALX-5407	glycine transporter inhibitor	SLC6A9			CN(CC[C@@H](Oc1ccc(cc1)-c1ccccc1)c1ccc(F)cc1)CC(O)=O, CN(CC[C@@H](Oc1ccc(cc1)-c1ccccc1)c1ccc(F)cc1)CC(O)=O, CN(CC[C@@H](Oc1ccc(cc1)-c1ccccc1)c1ccc(F)cc1)CC(O)=O	FDORQEIHOKEJNX-HSZRJFAPSA-N, FDORQEIHOKEJNX-HSZRJFAPSA-N, FDORQEIHOKEJNX-HSZRJFAPSA-N	Phase 1
AM-1241	cannabinoid receptor agonist	CNR1, CNR2			CN1CCCC[C@@H]1Cn1cc(C(=O)c2cc(ccc2I)[N+]([O-])=O)c2ccccc12 |&1:6,r|, CN1CCCC[C@@H]1Cn1cc(C(=O)c2cc(ccc2I)[N+]([O-])=O)c2ccccc12 |&1:6,r|, CN1CCCC[C@@H]1Cn1cc(C(=O)c2cc(ccc2I)[N+]([O-])=O)c2ccccc12 |&1:6,r|	ZUHIXXCLLBMBDW-MRXNPFEDSA-N, ZUHIXXCLLBMBDW-MRXNPFEDSA-N, ZUHIXXCLLBMBDW-MRXNPFEDSA-N	Preclinical
AM-24	lipoxygenase inhibitor	ALOX5			Oc1c(I)cc(I)cc1I, Oc1c(I)cc(I)cc1I, Oc1c(I)cc(I)cc1I	VAPDZNUFNKUROY-UHFFFAOYSA-N, VAPDZNUFNKUROY-UHFFFAOYSA-N, VAPDZNUFNKUROY-UHFFFAOYSA-N	Phase 2
AM-251	cannabinoid receptor antagonist	CNR1, GPR18, GPR55			Cc1c(nn(c1-c1ccc(I)cc1)-c1ccc(Cl)cc1Cl)C(=O)NN1CCCCC1, Cc1c(nn(c1-c1ccc(I)cc1)-c1ccc(Cl)cc1Cl)C(=O)NN1CCCCC1, Cc1c(nn(c1-c1ccc(I)cc1)-c1ccc(Cl)cc1Cl)C(=O)NN1CCCCC1, Cc1c(nn(c1-c1ccc(I)cc1)-c1ccc(Cl)cc1Cl)C(=O)NN1CCCCC1	BUZAJRPLUGXRAB-UHFFFAOYSA-N, BUZAJRPLUGXRAB-UHFFFAOYSA-N, BUZAJRPLUGXRAB-UHFFFAOYSA-N, BUZAJRPLUGXRAB-UHFFFAOYSA-N	Preclinical
AM-281	cannabinoid receptor antagonist	CNR1, CNR2, GPR55			Cc1c(nn(c1-c1ccc(I)cc1)-c1ccc(Cl)cc1Cl)C(=O)NN1CCOCC1, Cc1c(nn(c1-c1ccc(I)cc1)-c1ccc(Cl)cc1Cl)C(=O)NN1CCOCC1	AJFFBPZYXRNAIC-UHFFFAOYSA-N, AJFFBPZYXRNAIC-UHFFFAOYSA-N	Preclinical
AM-404	cyclooxygenase inhibitor, FAAH inhibitor, TRPV antagonist	CNR1, CNR2, FAAH, TRPV1			CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)Nc1ccc(O)cc1, CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)Nc1ccc(O)cc1, CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)Nc1ccc(O)cc1, CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)Nc1ccc(O)cc1, CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)Nc1ccc(O)cc1	IJBZOOZRAXHERC-DOFZRALJSA-N, IJBZOOZRAXHERC-DOFZRALJSA-N, IJBZOOZRAXHERC-DOFZRALJSA-N, IJBZOOZRAXHERC-DOFZRALJSA-N, IJBZOOZRAXHERC-DOFZRALJSA-N	Preclinical
AM-580	retinoid receptor agonist	RARA			CC1(C)CCC(C)(C)c2cc(ccc12)C(=O)Nc1ccc(cc1)C(O)=O, CC1(C)CCC(C)(C)c2cc(ccc12)C(=O)Nc1ccc(cc1)C(O)=O, CC1(C)CCC(C)(C)c2cc(ccc12)C(=O)Nc1ccc(cc1)C(O)=O, CC1(C)CCC(C)(C)c2cc(ccc12)C(=O)Nc1ccc(cc1)C(O)=O, CC1(C)CCC(C)(C)c2cc(ccc12)C(=O)Nc1ccc(cc1)C(O)=O	SZWKGOZKRMMLAJ-UHFFFAOYSA-N, SZWKGOZKRMMLAJ-UHFFFAOYSA-N, SZWKGOZKRMMLAJ-UHFFFAOYSA-N, SZWKGOZKRMMLAJ-UHFFFAOYSA-N, SZWKGOZKRMMLAJ-UHFFFAOYSA-N	Preclinical
AM-630	cannabinoid receptor antagonist	CNR1, CNR2			COc1ccc(cc1)C(=O)c1c(C)n(CCN2CCOCC2)c2cc(I)ccc12, COc1ccc(cc1)C(=O)c1c(C)n(CCN2CCOCC2)c2cc(I)ccc12, COc1ccc(cc1)C(=O)c1c(C)n(CCN2CCOCC2)c2cc(I)ccc12, COc1ccc(cc1)C(=O)c1c(C)n(CCN2CCOCC2)c2cc(I)ccc12, COc1ccc(cc1)C(=O)c1c(C)n(CCN2CCOCC2)c2cc(I)ccc12, COc1ccc(cc1)C(=O)c1c(C)n(CCN2CCOCC2)c2cc(I)ccc12	JHOTYHDSLIUKCJ-UHFFFAOYSA-N, JHOTYHDSLIUKCJ-UHFFFAOYSA-N, JHOTYHDSLIUKCJ-UHFFFAOYSA-N, JHOTYHDSLIUKCJ-UHFFFAOYSA-N, JHOTYHDSLIUKCJ-UHFFFAOYSA-N, JHOTYHDSLIUKCJ-UHFFFAOYSA-N	Preclinical
AM-92016	potassium channel blocker	GRIN1			CN(CCc1ccc(Cl)c(Cl)c1)C[C@@H](O)COc1ccc(NS(C)(=O)=O)cc1 |&1:13|, CN(CCc1ccc(Cl)c(Cl)c1)C[C@@H](O)COc1ccc(NS(C)(=O)=O)cc1 |&1:13|, CN(CCc1ccc(Cl)c(Cl)c1)C[C@@H](O)COc1ccc(NS(C)(=O)=O)cc1 |&1:13|	BQBSHJUQVIWEFM-MRXNPFEDSA-N, BQBSHJUQVIWEFM-MRXNPFEDSA-N, BQBSHJUQVIWEFM-MRXNPFEDSA-N	Preclinical
amantadine	glutamate receptor antagonist	DRD2, GRIN2A, GRIN2B, GRIN2C, GRIN2D, GRIN3A	infectious disease, neurology/psychiatry	influenza A virus infection, Parkinson's Disease	NC12CC3CC(CC(C3)C1)C2, NC12CC3CC(CC(C3)C1)C2, NC12CC3CC(CC(C3)C1)C2	DKNWSYNQZKUICI-UHFFFAOYSA-N, DKNWSYNQZKUICI-UHFFFAOYSA-N, DKNWSYNQZKUICI-UHFFFAOYSA-N	Launched
ambazone	DNA damage inducer				NC(=S)NNc1ccc(cc1)N=NC(N)=N, NC(=S)NNc1ccc(cc1)N=NC(N)=N, NC(=S)NNc1ccc(cc1)N=NC(N)=N	HQDSAVMTLKVTGJ-UHFFFAOYSA-N, HQDSAVMTLKVTGJ-UHFFFAOYSA-N, HQDSAVMTLKVTGJ-UHFFFAOYSA-N	Phase 1
ambenonium	cholinesterase inhibitor	ACHE	neurology/psychiatry	myasthenia gravis	CC[N+](CC)(CCNC(=O)C(=O)NCC[N+](CC)(CC)Cc1ccccc1Cl)Cc1ccccc1Cl, CC[N+](CC)(CCNC(=O)C(=O)NCC[N+](CC)(CC)Cc1ccccc1Cl)Cc1ccccc1Cl, CC[N+](CC)(CCNC(=O)C(=O)NCC[N+](CC)(CC)Cc1ccccc1Cl)Cc1ccccc1Cl, CC[N+](CC)(CCNC(=O)C(=O)NCC[N+](CC)(CC)Cc1ccccc1Cl)Cc1ccccc1Cl	OMHBPUNFVFNHJK-UHFFFAOYSA-P, OMHBPUNFVFNHJK-UHFFFAOYSA-P, OMHBPUNFVFNHJK-UHFFFAOYSA-P, OMHBPUNFVFNHJK-UHFFFAOYSA-P	Launched
ambrisentan	endothelin receptor antagonist	EDNRA, EDNRB	pulmonary	pulmonary arterial hypertension (PAH)	COC([C@H](Oc1nc(C)cc(C)n1)C(O)=O)(c1ccccc1)c1ccccc1, COC([C@H](Oc1nc(C)cc(C)n1)C(O)=O)(c1ccccc1)c1ccccc1	OUJTZYPIHDYQMC-LJQANCHMSA-N, OUJTZYPIHDYQMC-LJQANCHMSA-N	Launched
ambroxol	sodium channel blocker	CYP3A4	pulmonary	bronchitis	Nc1c(Br)cc(Br)cc1CN[C@H]1CC[C@H](O)CC1 |r|, Nc1c(Br)cc(Br)cc1CN[C@H]1CC[C@H](O)CC1 |r|, Nc1c(Br)cc(Br)cc1CN[C@H]1CC[C@H](O)CC1 |r|, Nc1c(Br)cc(Br)cc1CN[C@H]1CC[C@H](O)CC1 |r|, Nc1c(Br)cc(Br)cc1CN[C@H]1CC[C@H](O)CC1 |r|, Nc1c(Br)cc(Br)cc1CN[C@H]1CC[C@H](O)CC1 |r|	JBDGDEWWOUBZPM-XYPYZODXSA-N, JBDGDEWWOUBZPM-XYPYZODXSA-N, JBDGDEWWOUBZPM-XYPYZODXSA-N, JBDGDEWWOUBZPM-XYPYZODXSA-N, JBDGDEWWOUBZPM-XYPYZODXSA-N, JBDGDEWWOUBZPM-XYPYZODXSA-N	Launched
amcasertib	kinase inhibitor				CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2\C(=O)Nc3ccc(cc23)-c2csc(n2)-c2ccccc2)c1C	QDWKGEFGLQMDAM-JJIBRWJFSA-N	Phase 2
amcinonide	glucocorticoid receptor agonist	NR3C1	dermatology	corticosteroid-responsive dermatoses	CC(=O)OCC(=O)[C@@]12OC3(CCCC3)O[C@@H]1C[C@H]1[C@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]21C |a:7,15,27,29,31,34,&1:17,&2:18,c:27,t:23|	ILKJAFIWWBXGDU-KNPIAJNZSA-N	Launched
AMD-3465	CC chemokine receptor antagonist	CXCR4			C(NCc1ccccn1)c1ccc(CN2CCCNCCNCCCNCC2)cc1, C(NCc1ccccn1)c1ccc(CN2CCCNCCNCCCNCC2)cc1, C(NCc1ccccn1)c1ccc(CN2CCCNCCNCCCNCC2)cc1	CWJJHESJXJQCJA-UHFFFAOYSA-N, CWJJHESJXJQCJA-UHFFFAOYSA-N, CWJJHESJXJQCJA-UHFFFAOYSA-N	Preclinical
amdinocillin	bacterial cell wall synthesis inhibitor		infectious disease	urinary tract infections, gram-negative bacterial infections	CC1(C)S[C@@H]2[C@H](\N=C\N3CCCCCC3)C(=O)N2[C@H]1C(O)=O, CC1(C)S[C@@H]2[C@H](\N=C\N3CCCCCC3)C(=O)N2[C@H]1C(O)=O	BWWVAEOLVKTZFQ-ISVUSNJMSA-N, BWWVAEOLVKTZFQ-ISVUSNJMSA-N	Launched
AMD11070	CC chemokine receptor antagonist	CCR5, CXCR4			NCCCCN(Cc1nc2ccccc2[nH]1)[C@H]1CCCc2cccnc12, NCCCCN(Cc1nc2ccccc2[nH]1)[C@H]1CCCc2cccnc12, NCCCCN(Cc1nc2ccccc2[nH]1)[C@H]1CCCc2cccnc12	WVLHHLRVNDMIAR-IBGZPJMESA-N, WVLHHLRVNDMIAR-IBGZPJMESA-N, WVLHHLRVNDMIAR-IBGZPJMESA-N	Phase 3
ameltolide	anticonvulsant				Cc1cccc(C)c1NC(=O)c1ccc(N)cc1, Cc1cccc(C)c1NC(=O)c1ccc(N)cc1	HZIWGOAXOBPQGY-UHFFFAOYSA-N, HZIWGOAXOBPQGY-UHFFFAOYSA-N	Preclinical
amenamevir	helicase primase inhibitor				Cc1cccc(C)c1N(CC(=O)Nc1ccc(cc1)-c1ncon1)C(=O)C1CCS(=O)(=O)CC1, Cc1cccc(C)c1N(CC(=O)Nc1ccc(cc1)-c1ncon1)C(=O)C1CCS(=O)(=O)CC1	MNHNIVNAFBSLLX-UHFFFAOYSA-N, MNHNIVNAFBSLLX-UHFFFAOYSA-N	Phase 1
ametantrone	anticancer agent				OCCNCCNc1ccc(NCCNCCO)c2C(=O)c3ccccc3C(=O)c12	FFGSXKJJVBXWCY-UHFFFAOYSA-N	Preclinical
amezinium	adrenergic receptor agonist	ADRB2	cardiology	hypotension	COc1cc(N)cn[n+]1-c1ccccc1, COc1cc(N)cn[n+]1-c1ccccc1	VXROHTDSRBRJLN-UHFFFAOYSA-O, VXROHTDSRBRJLN-UHFFFAOYSA-O	Launched
amfenac	cyclooxygenase inhibitor	PTGS1, PTGS2	neurology/psychiatry	pain relief	Nc1c(CC(O)=O)cccc1C(=O)c1ccccc1, Nc1c(CC(O)=O)cccc1C(=O)c1ccccc1	SOYCMDCMZDHQFP-UHFFFAOYSA-N, SOYCMDCMZDHQFP-UHFFFAOYSA-N	Launched
amflutizole	xanthine oxidase inhibitor	XDH			Nc1c(snc1-c1cccc(c1)C(F)(F)F)C(O)=O, Nc1c(snc1-c1cccc(c1)C(F)(F)F)C(O)=O, Nc1c(snc1-c1cccc(c1)C(F)(F)F)C(O)=O	KVMCEGAWQYTFKC-UHFFFAOYSA-N, KVMCEGAWQYTFKC-UHFFFAOYSA-N, KVMCEGAWQYTFKC-UHFFFAOYSA-N	Phase 2
AMG-PERK-44	PERK inhibitor	EIF2AK4			Cc1ccc2cc(ccc2n1)-c1c(C)ccc(C(=O)c2c(-c3ccccc3)n(C)n(-c3ccccc3)c2=O)c1N, Cc1ccc2cc(ccc2n1)-c1c(C)ccc(C(=O)c2c(-c3ccccc3)n(C)n(-c3ccccc3)c2=O)c1N, Cc1ccc2cc(ccc2n1)-c1c(C)ccc(C(=O)c2c(-c3ccccc3)n(C)n(-c3ccccc3)c2=O)c1N	YPPSMYLMSKHYAY-UHFFFAOYSA-N, YPPSMYLMSKHYAY-UHFFFAOYSA-N, YPPSMYLMSKHYAY-UHFFFAOYSA-N	Preclinical
AMG-176	MCL1 inhibitor				CO[C@H]1\C=C\C[C@H](C)[C@@H](C)S(=O)(=O)NC(=O)c2ccc3OC[C@]4(CCCc5cc(Cl)ccc45)CN(C[C@@H]4CC[C@@H]14)c3c2 |t:3|	JQNINBDKGLWYMU-PTJFNUENSA-N	Phase 1
AMG-208	tyrosine kinase inhibitor	MET			COc1ccc2c(OCc3nnc4ccc(nn34)-c3ccccc3)ccnc2c1, COc1ccc2c(OCc3nnc4ccc(nn34)-c3ccccc3)ccnc2c1	HEAIZQNMNCHNFD-UHFFFAOYSA-N, HEAIZQNMNCHNFD-UHFFFAOYSA-N	Phase 1
AMG-232	MDM inhibitor	MDM2			CC(C)[C@@H](CS(=O)(=O)C(C)C)N1[C@@H]([C@H](C[C@](C)(CC(O)=O)C1=O)c1cccc(Cl)c1)c1ccc(Cl)cc1, CC(C)[C@@H](CS(=O)(=O)C(C)C)N1[C@@H]([C@H](C[C@](C)(CC(O)=O)C1=O)c1cccc(Cl)c1)c1ccc(Cl)cc1, CC(C)[C@@H](CS(=O)(=O)C(C)C)N1[C@@H]([C@H](C[C@](C)(CC(O)=O)C1=O)c1cccc(Cl)c1)c1ccc(Cl)cc1, CC(C)[C@@H](CS(=O)(=O)C(C)C)N1[C@@H]([C@H](C[C@](C)(CC(O)=O)C1=O)c1cccc(Cl)c1)c1ccc(Cl)cc1, CC(C)[C@@H](CS(=O)(=O)C(C)C)N1[C@@H]([C@H](C[C@](C)(CC(O)=O)C1=O)c1cccc(Cl)c1)c1ccc(Cl)cc1, CC(C)[C@@H](CS(=O)(=O)C(C)C)N1[C@@H]([C@H](C[C@](C)(CC(O)=O)C1=O)c1cccc(Cl)c1)c1ccc(Cl)cc1, CC(C)[C@@H](CS(=O)(=O)C(C)C)N1[C@@H]([C@H](C[C@](C)(CC(O)=O)C1=O)c1cccc(Cl)c1)c1ccc(Cl)cc1, CC(C)[C@@H](CS(=O)(=O)C(C)C)N1[C@@H]([C@H](C[C@](C)(CC(O)=O)C1=O)c1cccc(Cl)c1)c1ccc(Cl)cc1, CC(C)[C@@H](CS(=O)(=O)C(C)C)N1[C@@H]([C@H](C[C@](C)(CC(O)=O)C1=O)c1cccc(Cl)c1)c1ccc(Cl)cc1	DRLCSJFKKILATL-YWCVFVGNSA-N, DRLCSJFKKILATL-YWCVFVGNSA-N, DRLCSJFKKILATL-YWCVFVGNSA-N, DRLCSJFKKILATL-YWCVFVGNSA-N, DRLCSJFKKILATL-YWCVFVGNSA-N, DRLCSJFKKILATL-YWCVFVGNSA-N, DRLCSJFKKILATL-YWCVFVGNSA-N, DRLCSJFKKILATL-YWCVFVGNSA-N, DRLCSJFKKILATL-YWCVFVGNSA-N	Phase 2
AMG-319	PI3K inhibitor	PIK3CD			C[C@H](Nc1ncnc2nc[nH]c12)c1cc2ccc(F)cc2nc1-c1ccccn1	KWRYMZHCQIOOEB-LBPRGKRZSA-N	Phase 2
AMG-337	MET inhibitor	MET			COCCOc1cnc2ccn([C@H](C)c3nnc4c(F)cc(cn34)-c3cnn(C)c3)c(=O)c2c1, COCCOc1cnc2ccn([C@H](C)c3nnc4c(F)cc(cn34)-c3cnn(C)c3)c(=O)c2c1, COCCOc1cnc2ccn([C@H](C)c3nnc4c(F)cc(cn34)-c3cnn(C)c3)c(=O)c2c1	DWHXUGDWKAIASB-CQSZACIVSA-N, DWHXUGDWKAIASB-CQSZACIVSA-N, DWHXUGDWKAIASB-CQSZACIVSA-N	Phase 2
AMG-487	CC chemokine receptor antagonist				CCOc1ccc(cc1)-n1c(nc2ncccc2c1=O)[C@@H](C)N(Cc1cccnc1)C(=O)Cc1ccc(OC(F)(F)F)cc1, CCOc1ccc(cc1)-n1c(nc2ncccc2c1=O)[C@@H](C)N(Cc1cccnc1)C(=O)Cc1ccc(OC(F)(F)F)cc1, CCOc1ccc(cc1)-n1c(nc2ncccc2c1=O)[C@@H](C)N(Cc1cccnc1)C(=O)Cc1ccc(OC(F)(F)F)cc1, CCOc1ccc(cc1)-n1c(nc2ncccc2c1=O)[C@@H](C)N(Cc1cccnc1)C(=O)Cc1ccc(OC(F)(F)F)cc1	WQTKNBPCJKRYPA-OAQYLSRUSA-N, WQTKNBPCJKRYPA-OAQYLSRUSA-N, WQTKNBPCJKRYPA-OAQYLSRUSA-N, WQTKNBPCJKRYPA-OAQYLSRUSA-N	Phase 2
AMG-487-(+/-)	CC chemokine receptor antagonist	CXCR3			CCOc1ccc(cc1)-n1c(nc2ncccc2c1=O)[C@@H](C)N(Cc1cccnc1)C(=O)Cc1ccc(OC(F)(F)F)cc1 |&1:20,r|, CCOc1ccc(cc1)-n1c(nc2ncccc2c1=O)[C@@H](C)N(Cc1cccnc1)C(=O)Cc1ccc(OC(F)(F)F)cc1 |&1:20,r|, CCOc1ccc(cc1)-n1c(nc2ncccc2c1=O)[C@@H](C)N(Cc1cccnc1)C(=O)Cc1ccc(OC(F)(F)F)cc1 |&1:20,r|	WQTKNBPCJKRYPA-OAQYLSRUSA-N, WQTKNBPCJKRYPA-OAQYLSRUSA-N, WQTKNBPCJKRYPA-OAQYLSRUSA-N	Phase 2
AMG-510	K-Ras inhibitor				CC(C)c1nccc(C)c1-n1c2nc(c(F)cc2c(nc1=O)N1CCN(C[C@@H]1C)C(=O)C=C)-c1c(O)cccc1F, CC(C)c1nccc(C)c1-n1c2nc(c(F)cc2c(nc1=O)N1CCN(C[C@@H]1C)C(=O)C=C)-c1c(O)cccc1F	NXQKSXLFSAEQCZ-SFHVURJKSA-N, NXQKSXLFSAEQCZ-SFHVURJKSA-N	Phase 1/Phase 2
AMG-517	TRPV antagonist	TRPV1			CC(=O)Nc1nc2c(Oc3cc(ncn3)-c3ccc(cc3)C(F)(F)F)cccc2s1, CC(=O)Nc1nc2c(Oc3cc(ncn3)-c3ccc(cc3)C(F)(F)F)cccc2s1, CC(=O)Nc1nc2c(Oc3cc(ncn3)-c3ccc(cc3)C(F)(F)F)cccc2s1, CC(=O)Nc1nc2c(Oc3cc(ncn3)-c3ccc(cc3)C(F)(F)F)cccc2s1	YUTIXVXZQIQWGY-UHFFFAOYSA-N, YUTIXVXZQIQWGY-UHFFFAOYSA-N, YUTIXVXZQIQWGY-UHFFFAOYSA-N, YUTIXVXZQIQWGY-UHFFFAOYSA-N	Phase 1
AMG-548	MAP kinase inhibitor	MAPK11, MAPK12, MAPK13, MAPK14			Cn1c(NC[C@@H](N)Cc2ccccc2)nc(-c2ccncc2)c(-c2ccc3ccccc3c2)c1=O, Cn1c(NC[C@@H](N)Cc2ccccc2)nc(-c2ccncc2)c(-c2ccc3ccccc3c2)c1=O, Cn1c(NC[C@@H](N)Cc2ccccc2)nc(-c2ccncc2)c(-c2ccc3ccccc3c2)c1=O	RQVKVJIRFKVPBF-VWLOTQADSA-N, RQVKVJIRFKVPBF-VWLOTQADSA-N, RQVKVJIRFKVPBF-VWLOTQADSA-N	Phase 1
AMG-837	free fatty acid receptor agonist	FFAR1			CC#C[C@@H](CC(O)=O)c1ccc(OCc2cccc(c2)-c2ccc(cc2)C(F)(F)F)cc1, CC#C[C@@H](CC(O)=O)c1ccc(OCc2cccc(c2)-c2ccc(cc2)C(F)(F)F)cc1, CC#C[C@@H](CC(O)=O)c1ccc(OCc2cccc(c2)-c2ccc(cc2)C(F)(F)F)cc1, CC#C[C@@H](CC(O)=O)c1ccc(OCc2cccc(c2)-c2ccc(cc2)C(F)(F)F)cc1, CC#C[C@@H](CC(O)=O)c1ccc(OCc2cccc(c2)-c2ccc(cc2)C(F)(F)F)cc1	ZOPNBMMVVZRSGH-NRFANRHFSA-N, ZOPNBMMVVZRSGH-NRFANRHFSA-N, ZOPNBMMVVZRSGH-NRFANRHFSA-N, ZOPNBMMVVZRSGH-NRFANRHFSA-N, ZOPNBMMVVZRSGH-NRFANRHFSA-N	Phase 1
AMG-925	CDK inhibitor, FLT3 inhibitor	CDK4, CDK6, FLT3			C[C@H]1CC[C@@H](CC1)n1c2cnccc2c2cnc(Nc3ccc4CN(CCc4n3)C(=O)CO)nc12 |r|, C[C@H]1CC[C@@H](CC1)n1c2cnccc2c2cnc(Nc3ccc4CN(CCc4n3)C(=O)CO)nc12 |r|, C[C@H]1CC[C@@H](CC1)n1c2cnccc2c2cnc(Nc3ccc4CN(CCc4n3)C(=O)CO)nc12 |r|, C[C@H]1CC[C@@H](CC1)n1c2cnccc2c2cnc(Nc3ccc4CN(CCc4n3)C(=O)CO)nc12 |r|	BBUVDDPUURMFOX-SAABIXHNSA-N, BBUVDDPUURMFOX-SAABIXHNSA-N, BBUVDDPUURMFOX-SAABIXHNSA-N, BBUVDDPUURMFOX-SAABIXHNSA-N	Phase 1
AMG-9810	TRPV antagonist	TRPV1			CC(C)(C)c1ccc(\C=C\C(=O)Nc2ccc3OCCOc3c2)cc1, CC(C)(C)c1ccc(\C=C\C(=O)Nc2ccc3OCCOc3c2)cc1, CC(C)(C)c1ccc(\C=C\C(=O)Nc2ccc3OCCOc3c2)cc1, CC(C)(C)c1ccc(\C=C\C(=O)Nc2ccc3OCCOc3c2)cc1, CC(C)(C)c1ccc(\C=C\C(=O)Nc2ccc3OCCOc3c2)cc1	GZTFUVZVLYUPRG-IZZDOVSWSA-N, GZTFUVZVLYUPRG-IZZDOVSWSA-N, GZTFUVZVLYUPRG-IZZDOVSWSA-N, GZTFUVZVLYUPRG-IZZDOVSWSA-N, GZTFUVZVLYUPRG-IZZDOVSWSA-N	Preclinical
AMG319	PI3K inhibitor	PIK3CD			C[C@@H](Nc1ncnc2nc[nH]c12)c1cc2ccc(F)cc2nc1-c1ccccn1 |&1:1,r|	KWRYMZHCQIOOEB-GFCCVEGCSA-N	Phase 2
AMG458	MET inhibitor	MET			COc1ccc2c(Oc3ccc(NC(=O)c4c(C)n(CC(C)(C)O)n(-c5ccccc5)c4=O)nc3)ccnc2c1, COc1ccc2c(Oc3ccc(NC(=O)c4c(C)n(CC(C)(C)O)n(-c5ccccc5)c4=O)nc3)ccnc2c1, COc1ccc2c(Oc3ccc(NC(=O)c4c(C)n(CC(C)(C)O)n(-c5ccccc5)c4=O)nc3)ccnc2c1	GLBZSOQDAOLMGC-UHFFFAOYSA-N, GLBZSOQDAOLMGC-UHFFFAOYSA-N, GLBZSOQDAOLMGC-UHFFFAOYSA-N	Preclinical
AMG900	Aurora kinase inhibitor	AURKA, AURKB, AURKC			Cc1csc(c1)-c1nnc(Nc2ccc(Oc3ncccc3-c3ccnc(N)n3)cc2)c2ccccc12, Cc1csc(c1)-c1nnc(Nc2ccc(Oc3ncccc3-c3ccnc(N)n3)cc2)c2ccccc12, Cc1csc(c1)-c1nnc(Nc2ccc(Oc3ncccc3-c3ccnc(N)n3)cc2)c2ccccc12, Cc1csc(c1)-c1nnc(Nc2ccc(Oc3ncccc3-c3ccnc(N)n3)cc2)c2ccccc12, Cc1csc(c1)-c1nnc(Nc2ccc(Oc3ncccc3-c3ccnc(N)n3)cc2)c2ccccc12	IVUGFMLRJOCGAS-UHFFFAOYSA-N, IVUGFMLRJOCGAS-UHFFFAOYSA-N, IVUGFMLRJOCGAS-UHFFFAOYSA-N, IVUGFMLRJOCGAS-UHFFFAOYSA-N, IVUGFMLRJOCGAS-UHFFFAOYSA-N	Phase 1
AMI-1	protein arginine N-methyltransferase inhibitor	PRMT1			Oc1cc(cc2cc(NC(=O)Nc3ccc4c(O)cc(cc4c3)S(O)(=O)=O)ccc12)S(O)(=O)=O	PCGISRHGYLRXSR-UHFFFAOYSA-N	Preclinical
amibegron	adrenergic receptor agonist	ADRB3			CCOC(=O)COc1ccc2CC[C@@H](Cc2c1)NC[C@H](O)c1cccc(Cl)c1, CCOC(=O)COc1ccc2CC[C@@H](Cc2c1)NC[C@H](O)c1cccc(Cl)c1, CCOC(=O)COc1ccc2CC[C@@H](Cc2c1)NC[C@H](O)c1cccc(Cl)c1	RDJQCOBTKKAQAH-FPOVZHCZSA-N, RDJQCOBTKKAQAH-FPOVZHCZSA-N, RDJQCOBTKKAQAH-FPOVZHCZSA-N	Phase 3
amidopyrine	analgesic agent		dermatology	dermatitis herpetiformis (DH)	CN(C)c1c(C)n(C)n(-c2ccccc2)c1=O, CN(C)c1c(C)n(C)n(-c2ccccc2)c1=O, CN(C)c1c(C)n(C)n(-c2ccccc2)c1=O, CN(C)c1c(C)n(C)n(-c2ccccc2)c1=O, CN(C)c1c(C)n(C)n(-c2ccccc2)c1=O	RMMXTBMQSGEXHJ-UHFFFAOYSA-N, RMMXTBMQSGEXHJ-UHFFFAOYSA-N, RMMXTBMQSGEXHJ-UHFFFAOYSA-N, RMMXTBMQSGEXHJ-UHFFFAOYSA-N, RMMXTBMQSGEXHJ-UHFFFAOYSA-N	Launched
amifampridine	potassium channel blocker		neurology/psychiatry	Lambert-Eaton myasthenic syndrome (LEMS)	Nc1ccncc1N, Nc1ccncc1N	OYTKINVCDFNREN-UHFFFAOYSA-N, OYTKINVCDFNREN-UHFFFAOYSA-N	Launched
amiflamine	monoamine oxidase inhibitor	MAOA, SLC6A2			C[C@@H](N)Cc1ccc(cc1C)N(C)C |&1:1,r|, C[C@@H](N)Cc1ccc(cc1C)N(C)C |&1:1,r|	HFQMYSHATTXRTC-SNVBAGLBSA-N, HFQMYSHATTXRTC-SNVBAGLBSA-N	Phase 1
amifostine	reducing agent	ALPPL2, ENPP1	nephrology	renal toxicity	NCCCNCCSP(O)(O)=O	JKOQGQFVAUAYPM-UHFFFAOYSA-N	Launched
amikacin	bacterial 30S ribosomal subunit inhibitor		infectious disease	gram-negative bacterial infections	NCC[C@H](O)C(=O)N[C@@H]1C[C@H](N)[C@@H](O[C@H]2O[C@H](CN)[C@@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@H]1O[C@H]1O[C@H](CO)[C@@H](O)[C@H](N)[C@H]1O, NCC[C@H](O)C(=O)N[C@@H]1C[C@H](N)[C@@H](O[C@H]2O[C@H](CN)[C@@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@H]1O[C@H]1O[C@H](CO)[C@@H](O)[C@H](N)[C@H]1O, NCC[C@H](O)C(=O)N[C@@H]1C[C@H](N)[C@@H](O[C@H]2O[C@H](CN)[C@@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@H]1O[C@H]1O[C@H](CO)[C@@H](O)[C@H](N)[C@H]1O, NCC[C@H](O)C(=O)N[C@@H]1C[C@H](N)[C@@H](O[C@H]2O[C@H](CN)[C@@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@H]1O[C@H]1O[C@H](CO)[C@@H](O)[C@H](N)[C@H]1O, NCC[C@H](O)C(=O)N[C@@H]1C[C@H](N)[C@@H](O[C@H]2O[C@H](CN)[C@@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@H]1O[C@H]1O[C@H](CO)[C@@H](O)[C@H](N)[C@H]1O, NCC[C@H](O)C(=O)N[C@@H]1C[C@H](N)[C@@H](O[C@H]2O[C@H](CN)[C@@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@H]1O[C@H]1O[C@H](CO)[C@@H](O)[C@H](N)[C@H]1O	LKCWBDHBTVXHDL-RMDFUYIESA-N, LKCWBDHBTVXHDL-RMDFUYIESA-N, LKCWBDHBTVXHDL-RMDFUYIESA-N, LKCWBDHBTVXHDL-RMDFUYIESA-N, LKCWBDHBTVXHDL-RMDFUYIESA-N, LKCWBDHBTVXHDL-RMDFUYIESA-N	Launched
amiloride	sodium channel blocker	AOC1, ASIC1, ASIC2, ASIC3, PKD2, PKD2L1, PLAU, SCNN1A, SCNN1B, SCNN1D, SCNN1G, SLC9A1, TRPC7, TRPV2	cardiology	hypertension, congestive heart failure	NC(=N)NC(=O)c1nc(Cl)c(N)nc1N, NC(=N)NC(=O)c1nc(Cl)c(N)nc1N, NC(=N)NC(=O)c1nc(Cl)c(N)nc1N, NC(=N)NC(=O)c1nc(Cl)c(N)nc1N, NC(=N)NC(=O)c1nc(Cl)c(N)nc1N, NC(=N)NC(=O)c1nc(Cl)c(N)nc1N, NC(=N)NC(=O)c1nc(Cl)c(N)nc1N	XSDQTOBWRPYKKA-UHFFFAOYSA-N, XSDQTOBWRPYKKA-UHFFFAOYSA-N, XSDQTOBWRPYKKA-UHFFFAOYSA-N, XSDQTOBWRPYKKA-UHFFFAOYSA-N, XSDQTOBWRPYKKA-UHFFFAOYSA-N, XSDQTOBWRPYKKA-UHFFFAOYSA-N, XSDQTOBWRPYKKA-UHFFFAOYSA-N	Launched
amineptine	dopamine receptor agonist	SLC6A2, SLC6A4			OC(=O)CCCCCCNC1c2ccccc2CCc2ccccc12, OC(=O)CCCCCCNC1c2ccccc2CCc2ccccc12, OC(=O)CCCCCCNC1c2ccccc2CCc2ccccc12	ONNOFKFOZAJDHT-UHFFFAOYSA-N, ONNOFKFOZAJDHT-UHFFFAOYSA-N, ONNOFKFOZAJDHT-UHFFFAOYSA-N	Withdrawn
aminocaproic-acid	plasminogen activator inhibitor	LPA, PLAT, PLG	hematology	fibrinolytic bleeding	NCCCCCC(O)=O, NCCCCCC(O)=O, NCCCCCC(O)=O	SLXKOJJOQWFEFD-UHFFFAOYSA-N, SLXKOJJOQWFEFD-UHFFFAOYSA-N, SLXKOJJOQWFEFD-UHFFFAOYSA-N	Launched
aminoglutethimide	glucocorticoid receptor antagonist	CYP11A1, CYP19A1	endocrinology, oncology	Cushing's syndrome, breast cancer	CC[C@]1(CCC(=O)NC1=O)c1ccc(N)cc1 |&1:2,r|, CC[C@]1(CCC(=O)NC1=O)c1ccc(N)cc1 |&1:2,r|, CC[C@]1(CCC(=O)NC1=O)c1ccc(N)cc1 |&1:2,r|, CC[C@]1(CCC(=O)NC1=O)c1ccc(N)cc1 |&1:2,r|, CC[C@]1(CCC(=O)NC1=O)c1ccc(N)cc1 |&1:2,r|	ROBVIMPUHSLWNV-ZDUSSCGKSA-N, ROBVIMPUHSLWNV-ZDUSSCGKSA-N, ROBVIMPUHSLWNV-ZDUSSCGKSA-N, ROBVIMPUHSLWNV-ZDUSSCGKSA-N, ROBVIMPUHSLWNV-ZDUSSCGKSA-N	Launched
aminoguanidine	nitric oxide synthase inhibitor	AKR1B1, NOS2, TIMP3			NN=C(N)N, NN=C(N)N, NN=C(N)N	HAMNKKUPIHEESI-UHFFFAOYSA-N, HAMNKKUPIHEESI-UHFFFAOYSA-N, HAMNKKUPIHEESI-UHFFFAOYSA-N	Phase 3
aminohydroxybutyric-acid			neurology/psychiatry	epilepsy	NC[C@@H](O)CC(O)=O |&1:2,r|, NC[C@@H](O)CC(O)=O |&1:2,r|	YQGDEPYYFWUPGO-VKHMYHEASA-N, YQGDEPYYFWUPGO-VKHMYHEASA-N	Launched
aminolevulinic-acid-benzyl-ester					NCC(=O)CCC(=O)OCc1ccccc1	AFFZCQDLQIEQGB-UHFFFAOYSA-N	Phase 1
aminomethyltransferase	nitric oxide synthase inhibitor	NOS2			C[C@H]1CCN=C(N)S1 |&1:1,t:4|, C[C@H]1CCN=C(N)S1 |&1:1,t:4|, C[C@H]1CCN=C(N)S1 |&1:1,t:4|	BATVOUKHGLKDGQ-BYPYZUCNSA-N, BATVOUKHGLKDGQ-BYPYZUCNSA-N, BATVOUKHGLKDGQ-BYPYZUCNSA-N	Preclinical
aminopentamide	acetylcholine receptor antagonist	CHRM1	gastroenterology	acute abdominal visceral spasm, hypertrophic gastritis (GHG), nausea	CC(CC(C(N)=O)(c1ccccc1)c1ccccc1)N(C)C	NARHAGIVSFTMIG-UHFFFAOYSA-N	Launched
aminophylline	adenosine receptor antagonist	ADORA1, ADORA2A, ADORA2B, ADORA3, HDAC2, PDE3A, PDE3B, PDE4A, PDE4B, PDE4C, PDE4D, PDE5A	pulmonary	asthma, bronchitis, emphysema	Cn1c2nc[nH]c2c(=O)n(C)c1=O, Cn1c2nc[nH]c2c(=O)n(C)c1=O, Cn1c2nc[nH]c2c(=O)n(C)c1=O, Cn1c2nc[nH]c2c(=O)n(C)c1=O, Cn1c2nc[nH]c2c(=O)n(C)c1=O, Cn1c2nc[nH]c2c(=O)n(C)c1=O	ZFXYFBGIUFBOJW-UHFFFAOYSA-N, ZFXYFBGIUFBOJW-UHFFFAOYSA-N, ZFXYFBGIUFBOJW-UHFFFAOYSA-N, ZFXYFBGIUFBOJW-UHFFFAOYSA-N, ZFXYFBGIUFBOJW-UHFFFAOYSA-N, ZFXYFBGIUFBOJW-UHFFFAOYSA-N	Launched
aminopterin	dihydrofolate reductase inhibitor	DHFR, SLC46A1			Nc1nc(N)c2nc(CNc3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)cnc2n1, Nc1nc(N)c2nc(CNc3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)cnc2n1	TVZGACDUOSZQKY-LBPRGKRZSA-N, TVZGACDUOSZQKY-LBPRGKRZSA-N	Phase 3
aminopurvalanol-a	CDK inhibitor, tyrosine kinase inhibitor	CDK1, CDK2, CDK5			CC(C)[C@H](CO)Nc1nc(Nc2cc(N)cc(Cl)c2)c2ncn(C(C)C)c2n1, CC(C)[C@H](CO)Nc1nc(Nc2cc(N)cc(Cl)c2)c2ncn(C(C)C)c2n1, CC(C)[C@H](CO)Nc1nc(Nc2cc(N)cc(Cl)c2)c2ncn(C(C)C)c2n1	RAMROQQYRRQPDL-HNNXBMFYSA-N, RAMROQQYRRQPDL-HNNXBMFYSA-N, RAMROQQYRRQPDL-HNNXBMFYSA-N	Preclinical
aminosalicylate	cyclooxygenase inhibitor	ALOX5, CHUK, PLA2G2E, PTGS1, PTGS2	gastroenterology	inflammatory bowel disease, ulcerative colitis	Nc1ccc(C(O)=O)c(O)c1, Nc1ccc(C(O)=O)c(O)c1, Nc1ccc(C(O)=O)c(O)c1, Nc1ccc(C(O)=O)c(O)c1	WUBBRNOQWQTFEX-UHFFFAOYSA-N, WUBBRNOQWQTFEX-UHFFFAOYSA-N, WUBBRNOQWQTFEX-UHFFFAOYSA-N, WUBBRNOQWQTFEX-UHFFFAOYSA-N	Launched
aminothiadiazole	inosine monophosphate dehydrogenase inhibitor	ADORA3, IMPDH1			Nc1nncs1, Nc1nncs1	QUKGLNCXGVWCJX-UHFFFAOYSA-N, QUKGLNCXGVWCJX-UHFFFAOYSA-N	Phase 2
aminothiazole	cyclin D inhibitor	NOS2			Nc1nccs1, Nc1nccs1, Nc1nccs1	RAIPHJJURHTUIC-UHFFFAOYSA-N, RAIPHJJURHTUIC-UHFFFAOYSA-N, RAIPHJJURHTUIC-UHFFFAOYSA-N	Preclinical
amiodarone	potassium channel blocker	ADRB1, CACNA1H, CACNA2D2, KCNA7, KCNH2	cardiology	ventricular arrhythmias	CCCCc1oc2ccccc2c1C(=O)c1cc(I)c(OCCN(CC)CC)c(I)c1, CCCCc1oc2ccccc2c1C(=O)c1cc(I)c(OCCN(CC)CC)c(I)c1, CCCCc1oc2ccccc2c1C(=O)c1cc(I)c(OCCN(CC)CC)c(I)c1, CCCCc1oc2ccccc2c1C(=O)c1cc(I)c(OCCN(CC)CC)c(I)c1, CCCCc1oc2ccccc2c1C(=O)c1cc(I)c(OCCN(CC)CC)c(I)c1, CCCCc1oc2ccccc2c1C(=O)c1cc(I)c(OCCN(CC)CC)c(I)c1, CCCCc1oc2ccccc2c1C(=O)c1cc(I)c(OCCN(CC)CC)c(I)c1, CCCCc1oc2ccccc2c1C(=O)c1cc(I)c(OCCN(CC)CC)c(I)c1	IYIKLHRQXLHMJQ-UHFFFAOYSA-N, IYIKLHRQXLHMJQ-UHFFFAOYSA-N, IYIKLHRQXLHMJQ-UHFFFAOYSA-N, IYIKLHRQXLHMJQ-UHFFFAOYSA-N, IYIKLHRQXLHMJQ-UHFFFAOYSA-N, IYIKLHRQXLHMJQ-UHFFFAOYSA-N, IYIKLHRQXLHMJQ-UHFFFAOYSA-N, IYIKLHRQXLHMJQ-UHFFFAOYSA-N	Launched
amiprilose	CD antagonist				CN(C)CCCO[C@H]1[C@H](O[C@@H]2OC(C)(C)O[C@H]12)[C@H](O)CO	YXBQLONCIPUQKO-UJPOAAIJSA-N	Phase 3
amiselimod	sphingosine 1-phosphate receptor modulator				CCCCCCCOc1ccc(CCC(N)(CO)CO)cc1C(F)(F)F	JVCPIJKPAKAIIP-UHFFFAOYSA-N	Phase 2
amisulpride	dopamine receptor antagonist	DRD2	neurology/psychiatry	psychosis, bipolar disorder, schizophrenia	CCN1CCC[C@@H]1CNC(=O)c1cc(c(N)cc1OC)S(=O)(=O)CC |&1:6,r|, CCN1CCC[C@@H]1CNC(=O)c1cc(c(N)cc1OC)S(=O)(=O)CC |&1:6,r|	NTJOBXMMWNYJFB-GFCCVEGCSA-N, NTJOBXMMWNYJFB-GFCCVEGCSA-N	Launched
amitifadine	serotonin transporter (SERT) inhibitor	SLC6A2, SLC6A3, SLC6A4			Clc1ccc(cc1Cl)[C@@]12C[C@@H]1CNC2 |&1:8,&2:10|, Clc1ccc(cc1Cl)[C@@]12C[C@@H]1CNC2 |&1:8,&2:10|	BSMNRYCSBFHEMQ-KCJUWKMLSA-N, BSMNRYCSBFHEMQ-KCJUWKMLSA-N	Phase 3
amitraz	adrenergic receptor agonist	ADRA1A, ADRA2A	infectious disease	generalized demodicosis	CN(\C=N\c1ccc(C)cc1C)\C=N\c1ccc(C)cc1C, CN(\C=N\c1ccc(C)cc1C)\C=N\c1ccc(C)cc1C	QXAITBQSYVNQDR-ZIOPAAQOSA-N, QXAITBQSYVNQDR-ZIOPAAQOSA-N	Launched
amitriptyline	norepinephrine inhibitor, norepinephrine reuptake inhibitor, serotonin receptor antagonist, serotoninnorepinephrine reuptake inhibitor (SNRI)	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRB1, ADRB2, ADRB3, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, HRH1, HRH2, HRH4, HTR1A, HTR1B, HTR1D, HTR2A, HTR2C, HTR6, HTR7, KCNA1, KCND2, KCND3, KCNQ2, KCNQ3, NTRK1, NTRK2, OPRD1, OPRK1, OPRM1, SIGMAR1, SLC6A2, SLC6A4	neurology/psychiatry	depression	CN(C)CCC=C1c2ccccc2CCc2ccccc12, CN(C)CCC=C1c2ccccc2CCc2ccccc12	KRMDCWKBEZIMAB-UHFFFAOYSA-N, KRMDCWKBEZIMAB-UHFFFAOYSA-N	Launched
amlexanox	histamine receptor modulator	FGF1, IL3, PDE4A, PDE4B, PDE4C, PDE4D, S100A12, S100A13	dental, pulmonary, ophthalmology, allergy	aphthous ulcers, asthma, conjunctivitis, allergic rhinitis	CC(C)c1ccc2oc3nc(N)c(cc3c(=O)c2c1)C(O)=O, CC(C)c1ccc2oc3nc(N)c(cc3c(=O)c2c1)C(O)=O, CC(C)c1ccc2oc3nc(N)c(cc3c(=O)c2c1)C(O)=O, CC(C)c1ccc2oc3nc(N)c(cc3c(=O)c2c1)C(O)=O	SGRYPYWGNKJSDL-UHFFFAOYSA-N, SGRYPYWGNKJSDL-UHFFFAOYSA-N, SGRYPYWGNKJSDL-UHFFFAOYSA-N, SGRYPYWGNKJSDL-UHFFFAOYSA-N	Launched
amlodipine	calcium channel blocker	CACNA1C, CACNA1D, CACNA1F, CACNA1S, CACNA2D1	cardiology	hypertension, chronic stable angina, vasospastic angina, coronary artery disease (CAD)	CCOC(=O)C1=C(COCCN)NC(C)=C([C@H]1c1ccccc1Cl)C(=O)OC |&1:16,r,c:5,14|, CCOC(=O)C1=C(COCCN)NC(C)=C([C@H]1c1ccccc1Cl)C(=O)OC |&1:16,r,c:5,14|, CCOC(=O)C1=C(COCCN)NC(C)=C([C@H]1c1ccccc1Cl)C(=O)OC |&1:16,r,c:5,14|, CCOC(=O)C1=C(COCCN)NC(C)=C([C@H]1c1ccccc1Cl)C(=O)OC |&1:16,r,c:5,14|	HTIQEAQVCYTUBX-QGZVFWFLSA-N, HTIQEAQVCYTUBX-QGZVFWFLSA-N, HTIQEAQVCYTUBX-QGZVFWFLSA-N, HTIQEAQVCYTUBX-QGZVFWFLSA-N	Launched
ammonium-glycyrrhizinate	thrombin inhibitor	HSD11B1, HSD11B2, SLCO1B1, SLCO1B3	dermatology	cosmetic	CC1(C)[C@H](CC[C@@]2(C)[C@H]1CC[C@]1(C)[C@@H]2C(=O)C=C2[C@@H]3C[C@](C)(CC[C@]3(C)CC[C@@]12C)C(O)=O)O[C@H]1O[C@@H]([C@@H](O)[C@H](O)[C@H]1O[C@@H]1O[C@@H]([C@@H](O)[C@H](O)[C@H]1O)C(O)=O)C(O)=O |t:18|	LPLVUJXQOOQHMX-QWBHMCJMSA-N	Launched
ammonium-lactate		HCAR1	dermatology	xerosis cutis, ichthyosis vulgaris	N.C[C@@H](O)C(O)=O |&1:2,r|, N.C[C@@H](O)C(O)=O |&1:2,r|	RZOBLYBZQXQGFY-HSHFZTNMSA-N, RZOBLYBZQXQGFY-HSHFZTNMSA-N	Launched
ammonium-perfluorocaprylate	Pim kinase inhibitor	PIM1			OC(=O)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F, OC(=O)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F	SNGREZUHAYWORS-UHFFFAOYSA-N, SNGREZUHAYWORS-UHFFFAOYSA-N	Phase 1
AMN-082	glutamate receptor modulator	GRM7			C(CNC(c1ccccc1)c1ccccc1)NC(c1ccccc1)c1ccccc1, C(CNC(c1ccccc1)c1ccccc1)NC(c1ccccc1)c1ccccc1, C(CNC(c1ccccc1)c1ccccc1)NC(c1ccccc1)c1ccccc1, C(CNC(c1ccccc1)c1ccccc1)NC(c1ccccc1)c1ccccc1	DTZDSNQYNPNCPK-UHFFFAOYSA-N, DTZDSNQYNPNCPK-UHFFFAOYSA-N, DTZDSNQYNPNCPK-UHFFFAOYSA-N, DTZDSNQYNPNCPK-UHFFFAOYSA-N	Preclinical
amodiaquine	histamine receptor agonist	HNMT	infectious disease	malaria	CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O, CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O, CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O, CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O, CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O, CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O	OVCDSSHSILBFBN-UHFFFAOYSA-N, OVCDSSHSILBFBN-UHFFFAOYSA-N, OVCDSSHSILBFBN-UHFFFAOYSA-N, OVCDSSHSILBFBN-UHFFFAOYSA-N, OVCDSSHSILBFBN-UHFFFAOYSA-N, OVCDSSHSILBFBN-UHFFFAOYSA-N	Launched
amonafide	topoisomerase inhibitor	TOP2A, TOP2B			CN(C)CCN1C(=O)c2cccc3cc(N)cc(C1=O)c23, CN(C)CCN1C(=O)c2cccc3cc(N)cc(C1=O)c23	UPALIKSFLSVKIS-UHFFFAOYSA-N, UPALIKSFLSVKIS-UHFFFAOYSA-N	Phase 3
amorolfine	membrane integrity inhibitor		infectious disease	onychomycosis	CCC(C)(C)c1ccc(C[C@@H](C)CN2C[C@H](C)O[C@H](C)C2)cc1 |a:15,18,&1:10|, CCC(C)(C)c1ccc(C[C@@H](C)CN2C[C@H](C)O[C@H](C)C2)cc1 |a:15,18,&1:10|, CCC(C)(C)c1ccc(C[C@@H](C)CN2C[C@H](C)O[C@H](C)C2)cc1 |a:15,18,&1:10|, CCC(C)(C)c1ccc(C[C@@H](C)CN2C[C@H](C)O[C@H](C)C2)cc1 |a:15,18,&1:10|	MQHLMHIZUIDKOO-KURKYZTESA-N, MQHLMHIZUIDKOO-KURKYZTESA-N, MQHLMHIZUIDKOO-KURKYZTESA-N, MQHLMHIZUIDKOO-KURKYZTESA-N	Launched
amoxapine	norepinephrine reputake inhibitor	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, DRD1, DRD2, DRD3, DRD4, DRD5, GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, HRH1, HRH4, HTR1A, HTR1B, HTR2A, HTR2B, HTR2C, HTR3A, HTR6, HTR7, SLC6A2, SLC6A3, SLC6A4	neurology/psychiatry	depression	Clc1ccc2Oc3ccccc3N=C(N3CCNCC3)c2c1 |t:13|, Clc1ccc2Oc3ccccc3N=C(N3CCNCC3)c2c1 |t:13|, Clc1ccc2Oc3ccccc3N=C(N3CCNCC3)c2c1 |t:13|	QWGDMFLQWFTERH-UHFFFAOYSA-N, QWGDMFLQWFTERH-UHFFFAOYSA-N, QWGDMFLQWFTERH-UHFFFAOYSA-N	Launched
amoxicillin	penicillin binding protein inhibitor	CYP2C19, SLC15A1, SLC15A2, SLC22A6	infectious disease, gastroenterology	skin infections, duodenal ulcer disease, gonorrhea, ear infections, throat infections, genitourinary tract infections, respiratory tract infections	CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccc(O)cc3)C(=O)N2[C@H]1C(O)=O, CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccc(O)cc3)C(=O)N2[C@H]1C(O)=O, CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccc(O)cc3)C(=O)N2[C@H]1C(O)=O, CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccc(O)cc3)C(=O)N2[C@H]1C(O)=O, CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccc(O)cc3)C(=O)N2[C@H]1C(O)=O, CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccc(O)cc3)C(=O)N2[C@H]1C(O)=O	LSQZJLSUYDQPKJ-NJBDSQKTSA-N, LSQZJLSUYDQPKJ-NJBDSQKTSA-N, LSQZJLSUYDQPKJ-NJBDSQKTSA-N, LSQZJLSUYDQPKJ-NJBDSQKTSA-N, LSQZJLSUYDQPKJ-NJBDSQKTSA-N, LSQZJLSUYDQPKJ-NJBDSQKTSA-N	Launched
AMPA-(RS)	glutamate receptor agonist	GRIN1			Cc1o[nH]c(=O)c1C[C@@H](N)C(O)=O |&1:8|, Cc1o[nH]c(=O)c1C[C@@H](N)C(O)=O |&1:8|	UUDAMDVQRQNNHZ-RXMQYKEDSA-N, UUDAMDVQRQNNHZ-RXMQYKEDSA-N	Preclinical
AMPA-(S)	glutamate receptor agonist	GRIA2, GRIN1			Cc1o[nH]c(=O)c1C[C@H](N)C(O)=O, Cc1o[nH]c(=O)c1C[C@H](N)C(O)=O, Cc1o[nH]c(=O)c1C[C@H](N)C(O)=O	UUDAMDVQRQNNHZ-YFKPBYRVSA-N, UUDAMDVQRQNNHZ-YFKPBYRVSA-N, UUDAMDVQRQNNHZ-YFKPBYRVSA-N	Preclinical
ampalex	glutamate receptor agonist	GRIA1, GRIA2, GRIA3, GRIA4			O=C(N1CCCCC1)c1ccc2nccnc2c1, O=C(N1CCCCC1)c1ccc2nccnc2c1, O=C(N1CCCCC1)c1ccc2nccnc2c1, O=C(N1CCCCC1)c1ccc2nccnc2c1	ANDGGVOPIJEHOF-UHFFFAOYSA-N, ANDGGVOPIJEHOF-UHFFFAOYSA-N, ANDGGVOPIJEHOF-UHFFFAOYSA-N, ANDGGVOPIJEHOF-UHFFFAOYSA-N	Phase 2
amperozide	dopamine receptor antagonist	FAAH, HTR2A	neurology/psychiatry	psychosis	CCNC(=O)N1CCN(CCCC(c2ccc(F)cc2)c2ccc(F)cc2)CC1, CCNC(=O)N1CCN(CCCC(c2ccc(F)cc2)c2ccc(F)cc2)CC1, CCNC(=O)N1CCN(CCCC(c2ccc(F)cc2)c2ccc(F)cc2)CC1	NNAIYOXJNVGUOM-UHFFFAOYSA-N, NNAIYOXJNVGUOM-UHFFFAOYSA-N, NNAIYOXJNVGUOM-UHFFFAOYSA-N	Launched
amphotericin-b	membrane permeability enhancer		infectious disease	fungal infection	C[C@H]1O[C@@H](O[C@@H]2C[C@@H]3O[C@@](O)(C[C@H](O)[C@H]3C(O)=O)C[C@@H](O)C[C@@H](O)[C@H](O)CC[C@@H](O)C[C@@H](O)CC(=O)O[C@@H](C)[C@H](C)[C@H](O)[C@@H](C)\C=C\C=C\C=C\C=C\C=C\C=C\C=C\2)[C@@H](O)[C@@H](N)[C@@H]1O |t:46,48,50,52,54,56,58|, C[C@H]1O[C@@H](O[C@@H]2C[C@@H]3O[C@@](O)(C[C@H](O)[C@H]3C(O)=O)C[C@@H](O)C[C@@H](O)[C@H](O)CC[C@@H](O)C[C@@H](O)CC(=O)O[C@@H](C)[C@H](C)[C@H](O)[C@@H](C)\C=C\C=C\C=C\C=C\C=C\C=C\C=C\2)[C@@H](O)[C@@H](N)[C@@H]1O |t:46,48,50,52,54,56,58|, C[C@H]1O[C@@H](O[C@@H]2C[C@@H]3O[C@@](O)(C[C@H](O)[C@H]3C(O)=O)C[C@@H](O)C[C@@H](O)[C@H](O)CC[C@@H](O)C[C@@H](O)CC(=O)O[C@@H](C)[C@H](C)[C@H](O)[C@@H](C)\C=C\C=C\C=C\C=C\C=C\C=C\C=C\2)[C@@H](O)[C@@H](N)[C@@H]1O |t:46,48,50,52,54,56,58|, C[C@H]1O[C@@H](O[C@@H]2C[C@@H]3O[C@@](O)(C[C@H](O)[C@H]3C(O)=O)C[C@@H](O)C[C@@H](O)[C@H](O)CC[C@@H](O)C[C@@H](O)CC(=O)O[C@@H](C)[C@H](C)[C@H](O)[C@@H](C)\C=C\C=C\C=C\C=C\C=C\C=C\C=C\2)[C@@H](O)[C@@H](N)[C@@H]1O |t:46,48,50,52,54,56,58|, C[C@H]1O[C@@H](O[C@@H]2C[C@@H]3O[C@@](O)(C[C@H](O)[C@H]3C(O)=O)C[C@@H](O)C[C@@H](O)[C@H](O)CC[C@@H](O)C[C@@H](O)CC(=O)O[C@@H](C)[C@H](C)[C@H](O)[C@@H](C)\C=C\C=C\C=C\C=C\C=C\C=C\C=C\2)[C@@H](O)[C@@H](N)[C@@H]1O |t:46,48,50,52,54,56,58|	APKFDSVGJQXUKY-ZNVUZQDLSA-N, APKFDSVGJQXUKY-ZNVUZQDLSA-N, APKFDSVGJQXUKY-ZNVUZQDLSA-N, APKFDSVGJQXUKY-ZNVUZQDLSA-N, APKFDSVGJQXUKY-ZNVUZQDLSA-N	Launched
ampicillin	bacterial cell wall synthesis inhibitor		infectious disease	respiratory tract infections, meningitis, bacterial septicemia, endocarditis, urinary tract infections, gastrointestinal infections	CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccccc3)C(=O)N2[C@H]1C(O)=O, CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccccc3)C(=O)N2[C@H]1C(O)=O, CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccccc3)C(=O)N2[C@H]1C(O)=O, CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccccc3)C(=O)N2[C@H]1C(O)=O, CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccccc3)C(=O)N2[C@H]1C(O)=O, CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccccc3)C(=O)N2[C@H]1C(O)=O, CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccccc3)C(=O)N2[C@H]1C(O)=O, CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccccc3)C(=O)N2[C@H]1C(O)=O, CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccccc3)C(=O)N2[C@H]1C(O)=O	AVKUERGKIZMTKX-NJBDSQKTSA-N, AVKUERGKIZMTKX-NJBDSQKTSA-N, AVKUERGKIZMTKX-NJBDSQKTSA-N, AVKUERGKIZMTKX-NJBDSQKTSA-N, AVKUERGKIZMTKX-NJBDSQKTSA-N, AVKUERGKIZMTKX-NJBDSQKTSA-N, AVKUERGKIZMTKX-NJBDSQKTSA-N, AVKUERGKIZMTKX-NJBDSQKTSA-N, AVKUERGKIZMTKX-NJBDSQKTSA-N	Launched
ampiroxicam	cyclooxygenase inhibitor	PTGS1, PTGS2	neurology/psychiatry	pain relief	CCOC(=O)O[C@@H](C)OC1=C(N(C)S(=O)(=O)c2ccccc12)C(=O)Nc1ccccn1 |&1:6,r,t:9|, CCOC(=O)O[C@@H](C)OC1=C(N(C)S(=O)(=O)c2ccccc12)C(=O)Nc1ccccn1 |&1:6,r,t:9|, CCOC(=O)O[C@@H](C)OC1=C(N(C)S(=O)(=O)c2ccccc12)C(=O)Nc1ccccn1 |&1:6,r,t:9|, CCOC(=O)O[C@@H](C)OC1=C(N(C)S(=O)(=O)c2ccccc12)C(=O)Nc1ccccn1 |&1:6,r,t:9|, CCOC(=O)O[C@@H](C)OC1=C(N(C)S(=O)(=O)c2ccccc12)C(=O)Nc1ccccn1 |&1:6,r,t:9|	LSNWBKACGXCGAJ-ZDUSSCGKSA-N, LSNWBKACGXCGAJ-ZDUSSCGKSA-N, LSNWBKACGXCGAJ-ZDUSSCGKSA-N, LSNWBKACGXCGAJ-ZDUSSCGKSA-N, LSNWBKACGXCGAJ-ZDUSSCGKSA-N	Launched
amprenavir	HIV protease inhibitor		infectious disease	human immunodeficiency virus (HIV-1)	CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1CCOC1)S(=O)(=O)c1ccc(N)cc1, CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1CCOC1)S(=O)(=O)c1ccc(N)cc1, CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1CCOC1)S(=O)(=O)c1ccc(N)cc1	YMARZQAQMVYCKC-OEMFJLHTSA-N, YMARZQAQMVYCKC-OEMFJLHTSA-N, YMARZQAQMVYCKC-OEMFJLHTSA-N	Launched
amprolium	thiamine uptake blocker		infectious disease	coccidiosis	CCCc1ncc(C[n+]2ccccc2C)c(N)n1, CCCc1ncc(C[n+]2ccccc2C)c(N)n1, CCCc1ncc(C[n+]2ccccc2C)c(N)n1	IPZFPROOBOUEIG-UHFFFAOYSA-N, IPZFPROOBOUEIG-UHFFFAOYSA-N, IPZFPROOBOUEIG-UHFFFAOYSA-N	Launched
ampyrone	cyclooxygenase inhibitor				Cc1c(N)c(=O)n(-c2ccccc2)n1C, Cc1c(N)c(=O)n(-c2ccccc2)n1C	RLFWWDJHLFCNIJ-UHFFFAOYSA-N, RLFWWDJHLFCNIJ-UHFFFAOYSA-N	Preclinical
amrinone	phosphodiesterase inhibitor	PDE3A, PDE3B, PDE4B, TNF	cardiology	congestive heart failure	Nc1cc(c[nH]c1=O)-c1ccncc1, Nc1cc(c[nH]c1=O)-c1ccncc1, Nc1cc(c[nH]c1=O)-c1ccncc1, Nc1cc(c[nH]c1=O)-c1ccncc1, Nc1cc(c[nH]c1=O)-c1ccncc1	RNLQIBCLLYYYFJ-UHFFFAOYSA-N, RNLQIBCLLYYYFJ-UHFFFAOYSA-N, RNLQIBCLLYYYFJ-UHFFFAOYSA-N, RNLQIBCLLYYYFJ-UHFFFAOYSA-N, RNLQIBCLLYYYFJ-UHFFFAOYSA-N	Launched
amrubicin	topoisomerase inhibitor	TOP2A, TOP2B	oncology	small cell lung cancer	CC(=O)[C@@]1(N)C[C@H](O[C@H]2C[C@H](O)[C@H](O)CO2)c2c(O)c3C(=O)c4ccccc4C(=O)c3c(O)c2C1, CC(=O)[C@@]1(N)C[C@H](O[C@H]2C[C@H](O)[C@H](O)CO2)c2c(O)c3C(=O)c4ccccc4C(=O)c3c(O)c2C1, CC(=O)[C@@]1(N)C[C@H](O[C@H]2C[C@H](O)[C@H](O)CO2)c2c(O)c3C(=O)c4ccccc4C(=O)c3c(O)c2C1	VJZITPJGSQKZMX-XDPRQOKASA-N, VJZITPJGSQKZMX-XDPRQOKASA-N, VJZITPJGSQKZMX-XDPRQOKASA-N	Launched
amsacrine	topoisomerase inhibitor	KCNH2, TOP2A	hematologic malignancy	acute lymphoblastic leukemia (ALL)	COc1cc(NS(C)(=O)=O)ccc1Nc1c2ccccc2nc2ccccc12, COc1cc(NS(C)(=O)=O)ccc1Nc1c2ccccc2nc2ccccc12, COc1cc(NS(C)(=O)=O)ccc1Nc1c2ccccc2nc2ccccc12, COc1cc(NS(C)(=O)=O)ccc1Nc1c2ccccc2nc2ccccc12	XCPGHVQEEXUHNC-UHFFFAOYSA-N, XCPGHVQEEXUHNC-UHFFFAOYSA-N, XCPGHVQEEXUHNC-UHFFFAOYSA-N, XCPGHVQEEXUHNC-UHFFFAOYSA-N	Launched
amthamine	histamine receptor agonist	HRH2			Cc1nc(N)sc1CCN, Cc1nc(N)sc1CCN	LHVRFUVVRXGZPV-UHFFFAOYSA-N, LHVRFUVVRXGZPV-UHFFFAOYSA-N	Preclinical
amtolmetin-guacil	cyclooxygenase inhibitor	PTGS1, PTGS2	rheumatology	rheumatoid arthritis, osteoarthritis	COc1ccccc1OC(=O)CNC(=O)Cc1ccc(C(=O)c2ccc(C)cc2)n1C, COc1ccccc1OC(=O)CNC(=O)Cc1ccc(C(=O)c2ccc(C)cc2)n1C, COc1ccccc1OC(=O)CNC(=O)Cc1ccc(C(=O)c2ccc(C)cc2)n1C	CWJNMKKMGIAGDK-UHFFFAOYSA-N, CWJNMKKMGIAGDK-UHFFFAOYSA-N, CWJNMKKMGIAGDK-UHFFFAOYSA-N	Launched
amuvatinib	FLT3 inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RAD51 inhibitor, RET tyrosine kinase inhibitor	KIT, MET			S=C(NCc1ccc2OCOc2c1)N1CCN(CC1)c1ncnc2c3ccccc3oc12, S=C(NCc1ccc2OCOc2c1)N1CCN(CC1)c1ncnc2c3ccccc3oc12, S=C(NCc1ccc2OCOc2c1)N1CCN(CC1)c1ncnc2c3ccccc3oc12, S=C(NCc1ccc2OCOc2c1)N1CCN(CC1)c1ncnc2c3ccccc3oc12, S=C(NCc1ccc2OCOc2c1)N1CCN(CC1)c1ncnc2c3ccccc3oc12, S=C(NCc1ccc2OCOc2c1)N1CCN(CC1)c1ncnc2c3ccccc3oc12, S=C(NCc1ccc2OCOc2c1)N1CCN(CC1)c1ncnc2c3ccccc3oc12, S=C(NCc1ccc2OCOc2c1)N1CCN(CC1)c1ncnc2c3ccccc3oc12	FOFDIMHVKGYHRU-UHFFFAOYSA-N, FOFDIMHVKGYHRU-UHFFFAOYSA-N, FOFDIMHVKGYHRU-UHFFFAOYSA-N, FOFDIMHVKGYHRU-UHFFFAOYSA-N, FOFDIMHVKGYHRU-UHFFFAOYSA-N, FOFDIMHVKGYHRU-UHFFFAOYSA-N, InChI=1S/C23H21N5O3S/c32-23(24-12-15-5-6-18-19(11-15)30-14-29-18)28-9-7-27(8-10-28)22-21-20(25-13-26-22)16-3-1-2-4-17(16)31-21/h1-6,11,13H,7-10,12,14H2,(H,24,32), InChI=1S/C23H21N5O3S/c32-23(24-12-15-5-6-18-19(11-15)30-14-29-18)28-9-7-27(8-10-28)22-21-20(25-13-26-22)16-3-1-2-4-17(16)31-21/h1-6,11,13H,7-10,12,14H2,(H,24,32)	Phase 2
amygdalin	caspase activator	CASP3			OC[C@H]1O[C@@H](OC[C@H]2O[C@@H](O[C@@H](C#N)c3ccccc3)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@@H](O)[C@@H]1O, OC[C@H]1O[C@@H](OC[C@H]2O[C@@H](O[C@@H](C#N)c3ccccc3)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@@H](O)[C@@H]1O, OC[C@H]1O[C@@H](OC[C@H]2O[C@@H](O[C@@H](C#N)c3ccccc3)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@@H](O)[C@@H]1O, OC[C@H]1O[C@@H](OC[C@H]2O[C@@H](O[C@@H](C#N)c3ccccc3)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@@H](O)[C@@H]1O, OC[C@H]1O[C@@H](OC[C@H]2O[C@@H](O[C@@H](C#N)c3ccccc3)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@@H](O)[C@@H]1O, OC[C@H]1O[C@@H](OC[C@H]2O[C@@H](O[C@@H](C#N)c3ccccc3)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@@H](O)[C@@H]1O	XUCIJNAGGSZNQT-JHSLDZJXSA-N, XUCIJNAGGSZNQT-JHSLDZJXSA-N, XUCIJNAGGSZNQT-JHSLDZJXSA-N, XUCIJNAGGSZNQT-JHSLDZJXSA-N, XUCIJNAGGSZNQT-JHSLDZJXSA-N, XUCIJNAGGSZNQT-JHSLDZJXSA-N	Phase 2
amyl-nitrite	atrial natriuretic peptide receptor agonist				CCCCCO[NH2+][O-]	GVGUCRAJNQYOSE-UHFFFAOYSA-N	Preclinical
amyleine	local anesthetic				CC[C@@](C)(CN(C)C)OC(=O)c1ccccc1 |&1:2|, CC[C@@](C)(CN(C)C)OC(=O)c1ccccc1 |&1:2|, CC[C@@](C)(CN(C)C)OC(=O)c1ccccc1 |&1:2|, CC[C@@](C)(CN(C)C)OC(=O)c1ccccc1 |&1:2|	FDMBBCOBEAVDAO-AWEZNQCLSA-N, FDMBBCOBEAVDAO-AWEZNQCLSA-N, FDMBBCOBEAVDAO-AWEZNQCLSA-N, FDMBBCOBEAVDAO-AWEZNQCLSA-N	Preclinical
amylene-hydrate	local anesthetic				CCC(C)(C)O, CCC(C)(C)O	MSXVEPNJUHWQHW-UHFFFAOYSA-N, MSXVEPNJUHWQHW-UHFFFAOYSA-N	Preclinical
AMZ30	protein phosphatase inhibitor				[O-][N+](=O)c1cccc(c1)S(=O)(=O)n1cccc1\C=C(/C#N)S(=O)(=O)c1ccc(F)cc1	GUCUORSUHTZMBW-YBFXNURJSA-N	Preclinical
AM095	lysophosphatidic acid receptor antagonist				C[C@@H](OC(=O)Nc1c(C)noc1-c1ccc(cc1)-c1ccc(CC(O)=O)cc1)c1ccccc1, C[C@@H](OC(=O)Nc1c(C)noc1-c1ccc(cc1)-c1ccc(CC(O)=O)cc1)c1ccccc1, C[C@@H](OC(=O)Nc1c(C)noc1-c1ccc(cc1)-c1ccc(CC(O)=O)cc1)c1ccccc1, C[C@@H](OC(=O)Nc1c(C)noc1-c1ccc(cc1)-c1ccc(CC(O)=O)cc1)c1ccccc1, C[C@@H](OC(=O)Nc1c(C)noc1-c1ccc(cc1)-c1ccc(CC(O)=O)cc1)c1ccccc1, C[C@@H](OC(=O)Nc1c(C)noc1-c1ccc(cc1)-c1ccc(CC(O)=O)cc1)c1ccccc1, C[C@@H](OC(=O)Nc1c(C)noc1-c1ccc(cc1)-c1ccc(CC(O)=O)cc1)c1ccccc1, C[C@@H](OC(=O)Nc1c(C)noc1-c1ccc(cc1)-c1ccc(CC(O)=O)cc1)c1ccccc1, C[C@@H](OC(=O)Nc1c(C)noc1-c1ccc(cc1)-c1ccc(CC(O)=O)cc1)c1ccccc1, C[C@@H](OC(=O)Nc1c(C)noc1-c1ccc(cc1)-c1ccc(CC(O)=O)cc1)c1ccccc1	LNDDRUPAICPXIN-GOSISDBHSA-N, LNDDRUPAICPXIN-GOSISDBHSA-N, LNDDRUPAICPXIN-GOSISDBHSA-N, LNDDRUPAICPXIN-GOSISDBHSA-N, LNDDRUPAICPXIN-GOSISDBHSA-N, LNDDRUPAICPXIN-GOSISDBHSA-N, LNDDRUPAICPXIN-GOSISDBHSA-N, LNDDRUPAICPXIN-GOSISDBHSA-N, LNDDRUPAICPXIN-GOSISDBHSA-N, LNDDRUPAICPXIN-GOSISDBHSA-N	Preclinical
AM211	prostaglandin inhibitor				CCN(Cc1cc(ccc1-c1cc(CC(O)=O)ccc1OC)C(F)(F)F)C(=O)NCc1ccccc1	OPXIRFWNLBDKQB-UHFFFAOYSA-N	Preclinical
AM679	cannabinoid receptor agonist, lipoxygenase inhibitor	ALOX5AP, CNR1, CNR2			COc1cnc(nc1)-c1ccc(Cn2c(CC(C)(C)C(O)=O)c(SC(C)(C)C)c3cc(OC[C@@H]4Cc5ccccc5N4C(C)=O)ccc23)cc1	VYXWHVDEWWHDLH-LJAQVGFWSA-N	Preclinical
ANA-12	tropomyosin receptor kinase inhibitor	NTRK2			O=C(Nc1ccccc1C(=O)N[C@H]1CCCCNC1=O)c1cc2ccccc2s1 |&1:12,r|, O=C(Nc1ccccc1C(=O)N[C@H]1CCCCNC1=O)c1cc2ccccc2s1 |&1:12,r|	TUSCYCAIGRVBMD-KRWDZBQOSA-N, TUSCYCAIGRVBMD-KRWDZBQOSA-N	Preclinical
anabasine	acetylcholine receptor agonist				C1CC[C@@H](NC1)c1cccnc1 |&1:3,r|	MTXSIJUGVMTTMU-SNVBAGLBSA-N	Preclinical
anacetrapib	cholesteryl ester transfer protein inhibitor	CETP			COc1cc(F)c(cc1-c1ccc(cc1CN1[C@@H](C)[C@H](OC1=O)c1cc(cc(c1)C(F)(F)F)C(F)(F)F)C(F)(F)F)C(C)C	MZZLGJHLQGUVPN-HAWMADMCSA-N	Phase 3
anagliptin	dipeptidyl peptidase inhibitor	DPP4	endocrinology	diabetes mellitus	Cc1cc2ncc(cn2n1)C(=O)NCC(C)(C)NCC(=O)N1CCC[C@H]1C#N, Cc1cc2ncc(cn2n1)C(=O)NCC(C)(C)NCC(=O)N1CCC[C@H]1C#N	LDXYBEHACFJIEL-HNNXBMFYSA-N, LDXYBEHACFJIEL-HNNXBMFYSA-N	Launched
anagrelide	phosphodiesterase inhibitor	PDE3A	hematology, hematologic malignancy	thrombocythemia, myeloproliferative neoplasms	Clc1ccc2N=C3NC(=O)CN3Cc2c1Cl |t:5|, Clc1ccc2N=C3NC(=O)CN3Cc2c1Cl |t:5|, Clc1ccc2N=C3NC(=O)CN3Cc2c1Cl |t:5|, Clc1ccc2N=C3NC(=O)CN3Cc2c1Cl |t:5|, Clc1ccc2N=C3NC(=O)CN3Cc2c1Cl |t:5|, Clc1ccc2N=C3NC(=O)CN3Cc2c1Cl |t:5|, Clc1ccc2N=C3NC(=O)CN3Cc2c1Cl |t:5|, Clc1ccc2N=C3NC(=O)CN3Cc2c1Cl |t:5|	OTBXOEAOVRKTNQ-UHFFFAOYSA-N, OTBXOEAOVRKTNQ-UHFFFAOYSA-N, OTBXOEAOVRKTNQ-UHFFFAOYSA-N, OTBXOEAOVRKTNQ-UHFFFAOYSA-N, OTBXOEAOVRKTNQ-UHFFFAOYSA-N, OTBXOEAOVRKTNQ-UHFFFAOYSA-N, OTBXOEAOVRKTNQ-UHFFFAOYSA-N, OTBXOEAOVRKTNQ-UHFFFAOYSA-N	Launched
anamorelin	growth hormone secretagogue receptor agonist	GHSR			CN(C)N(C)C(=O)[C@@]1(Cc2ccccc2)CCCN(C1)C(=O)[C@@H](Cc1c[nH]c2ccccc12)NC(=O)C(C)(C)N, CN(C)N(C)C(=O)[C@@]1(Cc2ccccc2)CCCN(C1)C(=O)[C@@H](Cc1c[nH]c2ccccc12)NC(=O)C(C)(C)N	VQPFSIRUEPQQPP-MXBOTTGLSA-N, VQPFSIRUEPQQPP-MXBOTTGLSA-N	Phase 3
anandamide	cannabinoid receptor agonist	CACNA1G, CACNA1H, CACNA1I, CNR1, CNR2, GLRA1, GPR18, GPR55, KCNA2, KCNK3, KCNK9, TRPM8, TRPV1			CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)NCCO, CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)NCCO, CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)NCCO, CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)NCCO, CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)NCCO	LGEQQWMQCRIYKG-DOFZRALJSA-N, LGEQQWMQCRIYKG-DOFZRALJSA-N, LGEQQWMQCRIYKG-DOFZRALJSA-N, LGEQQWMQCRIYKG-DOFZRALJSA-N, LGEQQWMQCRIYKG-DOFZRALJSA-N	Phase 2
anastrozole	aromatase inhibitor	CYP19A1	oncology	breast cancer	CC(C)(C#N)c1cc(Cn2cncn2)cc(c1)C(C)(C)C#N, CC(C)(C#N)c1cc(Cn2cncn2)cc(c1)C(C)(C)C#N, CC(C)(C#N)c1cc(Cn2cncn2)cc(c1)C(C)(C)C#N	YBBLVLTVTVSKRW-UHFFFAOYSA-N, YBBLVLTVTVSKRW-UHFFFAOYSA-N, YBBLVLTVTVSKRW-UHFFFAOYSA-N	Launched
andarine	androgen receptor modulator	AR			CC(=O)Nc1ccc(OC[C@](C)(O)C(=O)Nc2ccc(c(c2)C(F)(F)F)[N+]([O-])=O)cc1, CC(=O)Nc1ccc(OC[C@](C)(O)C(=O)Nc2ccc(c(c2)C(F)(F)F)[N+]([O-])=O)cc1, CC(=O)Nc1ccc(OC[C@](C)(O)C(=O)Nc2ccc(c(c2)C(F)(F)F)[N+]([O-])=O)cc1, CC(=O)Nc1ccc(OC[C@](C)(O)C(=O)Nc2ccc(c(c2)C(F)(F)F)[N+]([O-])=O)cc1	YVXVTLGIDOACBJ-SFHVURJKSA-N, YVXVTLGIDOACBJ-SFHVURJKSA-N, YVXVTLGIDOACBJ-SFHVURJKSA-N, YVXVTLGIDOACBJ-SFHVURJKSA-N	Phase 1
andrographolide	tumor necrosis factor production inhibitor	IL1B, IL6, NFKB1, NFKB2, TNF			C[C@@]1(CO)[C@H](O)CC[C@@]2(C)[C@H](C\C=C3/[C@H](O)COC3=O)C(=C)CC[C@H]12	BOJKULTULYSRAS-OTESTREVSA-N	Phase 2
androstenone	steroid				C[C@@]12CC[C@H]3[C@@H](CC[C@H]4CC(=O)CC[C@@]34C)[C@@H]1CC=C2 |&1:1,&2:4,&3:5,&4:8,&5:14,&6:16,r,c:21|, C[C@@]12CC[C@H]3[C@@H](CC[C@H]4CC(=O)CC[C@@]34C)[C@@H]1CC=C2 |&1:1,&2:4,&3:5,&4:8,&5:14,&6:16,r,c:21|, C[C@@]12CC[C@H]3[C@@H](CC[C@H]4CC(=O)CC[C@@]34C)[C@@H]1CC=C2 |&1:1,&2:4,&3:5,&4:8,&5:14,&6:16,r,c:21|	HFVMLYAGWXSTQI-UGRKVPRCSA-N, HFVMLYAGWXSTQI-UGRKVPRCSA-N, HFVMLYAGWXSTQI-UGRKVPRCSA-N	Preclinical
androsterone	androgen receptor agonist				C[C@]12CC[C@H]3[C@@H](CC[C@H]4C[C@H](O)CC[C@]34C)[C@@H]1CCC2=O, C[C@]12CC[C@H]3[C@@H](CC[C@H]4C[C@H](O)CC[C@]34C)[C@@H]1CCC2=O, C[C@]12CC[C@H]3[C@@H](CC[C@H]4C[C@H](O)CC[C@]34C)[C@@H]1CCC2=O	QGXBDMJGAMFCBF-HLUDHZFRSA-N, QGXBDMJGAMFCBF-HLUDHZFRSA-N, QGXBDMJGAMFCBF-HLUDHZFRSA-N	Preclinical
anecortave-acetate	angiogenesis inhibitor		ophthalmology	macular degeneration	CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)C3=CC[C@]12C |c:25,t:15|	YUWPMEXLKGOSBF-GACAOOTBSA-N	Launched
anethole	glutathione transferase stimulant				COc1ccc(\C=C\C)cc1, COc1ccc(\C=C\C)cc1, COc1ccc(\C=C\C)cc1	RUVINXPYWBROJD-ONEGZZNKSA-N, RUVINXPYWBROJD-ONEGZZNKSA-N, RUVINXPYWBROJD-ONEGZZNKSA-N	Launched
anethole-trithione	glutathione transferase stimulant		dental	xerostomia	COc1ccc(cc1)-c1cc(=S)ss1, COc1ccc(cc1)-c1cc(=S)ss1, COc1ccc(cc1)-c1cc(=S)ss1	KYLIZBIRMBGUOP-UHFFFAOYSA-N, KYLIZBIRMBGUOP-UHFFFAOYSA-N, KYLIZBIRMBGUOP-UHFFFAOYSA-N	Launched
anguidine	protein synthesis inhibitor	SLC5A1			CC(=O)OC[C@]12CCC(C)=C[C@H]1O[C@@H]1[C@H](O)[C@@H](OC(C)=O)[C@@]2(C)[C@@]11CO1 |c:9|, CC(=O)OC[C@]12CCC(C)=C[C@H]1O[C@@H]1[C@H](O)[C@@H](OC(C)=O)[C@@]2(C)[C@@]11CO1 |c:9|, CC(=O)OC[C@]12CCC(C)=C[C@H]1O[C@@H]1[C@H](O)[C@@H](OC(C)=O)[C@@]2(C)[C@@]11CO1 |c:9|, CC(=O)OC[C@]12CCC(C)=C[C@H]1O[C@@H]1[C@H](O)[C@@H](OC(C)=O)[C@@]2(C)[C@@]11CO1 |c:9|	AUGQEEXBDZWUJY-ZLJUKNTDSA-N, AUGQEEXBDZWUJY-ZLJUKNTDSA-N, AUGQEEXBDZWUJY-ZLJUKNTDSA-N, AUGQEEXBDZWUJY-ZLJUKNTDSA-N	Phase 2
anidulafungin	fungal 1,3-beta-D-glucan synthase inhibitor		infectious disease	candidemia, fungal infection, esophageal candidiasis	CCCCCOc1ccc(cc1)-c1ccc(cc1)-c1ccc(cc1)C(=O)N[C@H]1C[C@@H](O)[C@@H](O)NC(=O)[C@@H]2[C@@H](O)[C@@H](C)CN2C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC1=O)[C@@H](C)O)[C@H](O)[C@@H](O)c1ccc(O)cc1)[C@@H](C)O |r|	JHVAMHSQVVQIOT-MFAJLEFUSA-N	Launched
aniracetam	glutamate receptor agonist	DRD2, GRIA1, GRIA2, GRIA3, GRIA4, HTR2A			COc1ccc(cc1)C(=O)N1CCCC1=O, COc1ccc(cc1)C(=O)N1CCCC1=O, COc1ccc(cc1)C(=O)N1CCCC1=O, COc1ccc(cc1)C(=O)N1CCCC1=O, COc1ccc(cc1)C(=O)N1CCCC1=O	ZXNRTKGTQJPIJK-UHFFFAOYSA-N, ZXNRTKGTQJPIJK-UHFFFAOYSA-N, ZXNRTKGTQJPIJK-UHFFFAOYSA-N, ZXNRTKGTQJPIJK-UHFFFAOYSA-N, ZXNRTKGTQJPIJK-UHFFFAOYSA-N	Launched
anisindione	vitamin K antagonist	GGCX	hematology	deep vein thrombosis (DVT)	COc1ccc(cc1)C1C(=O)c2ccccc2C1=O, COc1ccc(cc1)C1C(=O)c2ccccc2C1=O, COc1ccc(cc1)C1C(=O)c2ccccc2C1=O, COc1ccc(cc1)C1C(=O)c2ccccc2C1=O, COc1ccc(cc1)C1C(=O)c2ccccc2C1=O, COc1ccc(cc1)C1C(=O)c2ccccc2C1=O, COc1ccc(cc1)C1C(=O)c2ccccc2C1=O	XRCFXMGQEVUZFC-UHFFFAOYSA-N, XRCFXMGQEVUZFC-UHFFFAOYSA-N, XRCFXMGQEVUZFC-UHFFFAOYSA-N, XRCFXMGQEVUZFC-UHFFFAOYSA-N, XRCFXMGQEVUZFC-UHFFFAOYSA-N, XRCFXMGQEVUZFC-UHFFFAOYSA-N, XRCFXMGQEVUZFC-UHFFFAOYSA-N	Launched
anisodamine	lipid peroxidase inhibitor	ADRA1A			CN1[C@H]2C[C@H](O)[C@H]1C[C@H](C2)OC(=O)[C@H](CO)c1ccccc1 |a:4,6,8,13,&1:2,THB:5:4:1:7.8.9|, CN1[C@H]2C[C@H](O)[C@H]1C[C@H](C2)OC(=O)[C@H](CO)c1ccccc1 |a:4,6,8,13,&1:2,THB:5:4:1:7.8.9|	WTQYWNWRJNXDEG-JKJDWNRSSA-N, WTQYWNWRJNXDEG-JKJDWNRSSA-N	Phase 3
anisomycin	DNA synthesis inhibitor	NHP2L1, RPL10L, RPL11, RPL13A, RPL15, RPL19, RPL23, RPL23A, RPL26L1, RPL3, RPL37, RPL8, RSL24D1			COc1ccc(C[C@H]2NC[C@H](O)[C@H]2OC(C)=O)cc1, COc1ccc(C[C@H]2NC[C@H](O)[C@H]2OC(C)=O)cc1, COc1ccc(C[C@H]2NC[C@H](O)[C@H]2OC(C)=O)cc1, COc1ccc(C[C@H]2NC[C@H](O)[C@H]2OC(C)=O)cc1, COc1ccc(C[C@H]2NC[C@H](O)[C@H]2OC(C)=O)cc1	YKJYKKNCCRKFSL-RDBSUJKOSA-N, YKJYKKNCCRKFSL-RDBSUJKOSA-N, YKJYKKNCCRKFSL-RDBSUJKOSA-N, YKJYKKNCCRKFSL-RDBSUJKOSA-N, YKJYKKNCCRKFSL-RDBSUJKOSA-N	Preclinical
anisotropine	acetylcholine receptor antagonist		gastroenterology	peptic ulcer disease (PUD)	CCCC(CCC)C(=O)O[C@@H]1C[C@@H]2CC[C@H](C1)[N+]2(C)C	XGGHHHBGPSNXFE-ZSHCYNCHSA-N	Launched
anlotinib	PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	KDR, PDGFRB			COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ccnc2cc1OCC1(N)CC1, COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ccnc2cc1OCC1(N)CC1, COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ccnc2cc1OCC1(N)CC1, COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ccnc2cc1OCC1(N)CC1, COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ccnc2cc1OCC1(N)CC1	KSMZEXLVHXZPEF-UHFFFAOYSA-N, KSMZEXLVHXZPEF-UHFFFAOYSA-N, KSMZEXLVHXZPEF-UHFFFAOYSA-N, KSMZEXLVHXZPEF-UHFFFAOYSA-N, KSMZEXLVHXZPEF-UHFFFAOYSA-N	Launched
anpirtoline	serotonin receptor agonist	HTR1B			Clc1cccc(SC2CCNCC2)n1, Clc1cccc(SC2CCNCC2)n1, Clc1cccc(SC2CCNCC2)n1, Clc1cccc(SC2CCNCC2)n1, Clc1cccc(SC2CCNCC2)n1	GGALEXMXDMUMDM-UHFFFAOYSA-N, GGALEXMXDMUMDM-UHFFFAOYSA-N, GGALEXMXDMUMDM-UHFFFAOYSA-N, GGALEXMXDMUMDM-UHFFFAOYSA-N, GGALEXMXDMUMDM-UHFFFAOYSA-N	Phase 1
ANR-94	adenosine receptor antagonist	ADORA2A			CCOc1nc2c(N)ncnc2n1CC, CCOc1nc2c(N)ncnc2n1CC	QUGDTMONBLMLLD-UHFFFAOYSA-N, QUGDTMONBLMLLD-UHFFFAOYSA-N	Preclinical
ansamitocin-p-3	apoptosis stimulant				[H][C@@]12O[C@@]1(C)[C@H](CC(=O)N(C)c1cc(C\C(C)=C\C=C\[C@@H](OC)[C@@]3(O)C[C@]([H])(OC(=O)N3)[C@H]2C)cc(OC)c1Cl)OC(=O)C(C)C |t:17,19|	OPQNCARIZFLNLF-HSBZPDDFSA-N	Preclinical
antagonist-g	neuropeptide receptor antagonist	MAPK8			CSCC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1ccccc1)N(C)C(=O)[C@@H](Cc1c[nH]c2ccccc12)NC(=O)[C@@H](N)CCCNC(N)=N)C(N)=O, CSCC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1ccccc1)N(C)C(=O)[C@@H](Cc1c[nH]c2ccccc12)NC(=O)[C@@H](N)CCCNC(N)=N)C(N)=O	CUCSSYAUKKIDJV-FAXBSAIASA-N, CUCSSYAUKKIDJV-FAXBSAIASA-N	Phase 1
antalarmin	corticotropin releasing factor receptor antagonist	CRHR1			CCCCN(CC)c1nc(C)nc2n(c(C)c(C)c12)-c1c(C)cc(C)cc1C, CCCCN(CC)c1nc(C)nc2n(c(C)c(C)c12)-c1c(C)cc(C)cc1C, CCCCN(CC)c1nc(C)nc2n(c(C)c(C)c12)-c1c(C)cc(C)cc1C	IXPROWGEHNVJOY-UHFFFAOYSA-N, IXPROWGEHNVJOY-UHFFFAOYSA-N, IXPROWGEHNVJOY-UHFFFAOYSA-N	Preclinical
antazoline	antihistamine	HRH1	ophthalmology, otolaryngology	conjunctivitis, nasal congestion	C(N(Cc1ccccc1)c1ccccc1)C1=NCCN1 |t:17|, C(N(Cc1ccccc1)c1ccccc1)C1=NCCN1 |t:17|, C(N(Cc1ccccc1)c1ccccc1)C1=NCCN1 |t:17|, C(N(Cc1ccccc1)c1ccccc1)C1=NCCN1 |t:17|	REYFJDPCWQRWAA-UHFFFAOYSA-N, REYFJDPCWQRWAA-UHFFFAOYSA-N, REYFJDPCWQRWAA-UHFFFAOYSA-N, REYFJDPCWQRWAA-UHFFFAOYSA-N	Launched
anthralin	DNA synthesis inhibitor		dermatology	psoriasis	Oc1cccc2Cc3cccc(O)c3C(=O)c12, Oc1cccc2Cc3cccc(O)c3C(=O)c12, Oc1cccc2Cc3cccc(O)c3C(=O)c12, Oc1cccc2Cc3cccc(O)c3C(=O)c12	NUZWLKWWNNJHPT-UHFFFAOYSA-N, NUZWLKWWNNJHPT-UHFFFAOYSA-N, NUZWLKWWNNJHPT-UHFFFAOYSA-N, NUZWLKWWNNJHPT-UHFFFAOYSA-N	Launched
anthraquinone	CDC inhibitor	CDC25B			O=C1c2ccccc2C(=O)c2ccccc12, O=C1c2ccccc2C(=O)c2ccccc12	RZVHIXYEVGDQDX-UHFFFAOYSA-N, RZVHIXYEVGDQDX-UHFFFAOYSA-N	Preclinical
antimony-potassium					[H][C@]12O[SbH]3(OC1=O)OC(=O)[C@]([H])(O3)[C@@]1([H])O[SbH]3(OC(=O)[C@]2([H])O3)OC1=O |r|	ZCIXFSVENQDMCK-SOMOIXMJSA-J	Phase 2
antimonyl					O=C1O[SbH]23OC1C1O[SbH]4(OC(C(O2)C(=O)O3)C(=O)O4)OC1=O, O=C1O[SbH]23OC1C1O[SbH]4(OC(C(O2)C(=O)O3)C(=O)O4)OC1=O	ZCIXFSVENQDMCK-UHFFFAOYSA-J, ZCIXFSVENQDMCK-UHFFFAOYSA-J	Phase 1
antimycin-A	ATP synthase inhibitor	CYCS			CCCCCC[C@@H]1[C@@H](OC(=O)CC(C)C)[C@H](C)OC(=O)[C@@H](NC(=O)c2cccc(NC=O)c2O)[C@@H](C)OC1=O	UIFFUZWRFRDZJC-SBOOETFBSA-N	Preclinical
antioxine					CC(C)c1ccc(C)c(O)c1, CC(C)c1ccc(C)c(O)c1	RECUKUPTGUEGMW-UHFFFAOYSA-N, RECUKUPTGUEGMW-UHFFFAOYSA-N	Launched
AN2718	leucyl-tRNA synthetase inhibitor				OB1OCc2cc(Cl)ccc12, OB1OCc2cc(Cl)ccc12	HMAFTPZYFJFEHK-UHFFFAOYSA-N, HMAFTPZYFJFEHK-UHFFFAOYSA-N	Phase 1
AP-18	transient receptor potential channel antagonist	TRPA1			C\C(=C/c1ccc(Cl)cc1)\C(\C)=N\O, C\C(=C/c1ccc(Cl)cc1)\C(\C)=N\O	MHTJEUOFLVQMCL-NJHPPEEMSA-N, MHTJEUOFLVQMCL-NJHPPEEMSA-N	Preclinical
apabetalone	apolipoprotein expression enhancer	BRD3			COc1cc(OC)c2c(c1)[nH]c(nc2=O)-c1cc(C)c(OCCO)c(C)c1, COc1cc(OC)c2c(c1)[nH]c(nc2=O)-c1cc(C)c(OCCO)c(C)c1	NETXMUIMUZJUTB-UHFFFAOYSA-N, NETXMUIMUZJUTB-UHFFFAOYSA-N	Phase 3
apafant	platelet activating factor receptor antagonist	PTAFR			Cc1nnc2CN=C(c3cc(CCC(=O)N4CCOCC4)sc3-n12)c1ccccc1Cl |c:6|, Cc1nnc2CN=C(c3cc(CCC(=O)N4CCOCC4)sc3-n12)c1ccccc1Cl |c:6|, Cc1nnc2CN=C(c3cc(CCC(=O)N4CCOCC4)sc3-n12)c1ccccc1Cl |c:6|	JGPJQFOROWSRRS-UHFFFAOYSA-N, JGPJQFOROWSRRS-UHFFFAOYSA-N, JGPJQFOROWSRRS-UHFFFAOYSA-N	Phase 3
apalutamide	androgen receptor antagonist		oncology	prostate cancer	CNC(=O)c1ccc(cc1F)N1C(=S)N(C(=O)C11CCC1)c1cnc(C#N)c(c1)C(F)(F)F, CNC(=O)c1ccc(cc1F)N1C(=S)N(C(=O)C11CCC1)c1cnc(C#N)c(c1)C(F)(F)F, CNC(=O)c1ccc(cc1F)N1C(=S)N(C(=O)C11CCC1)c1cnc(C#N)c(c1)C(F)(F)F, CNC(=O)c1ccc(cc1F)N1C(=S)N(C(=O)C11CCC1)c1cnc(C#N)c(c1)C(F)(F)F	HJBWBFZLDZWPHF-UHFFFAOYSA-N, HJBWBFZLDZWPHF-UHFFFAOYSA-N, HJBWBFZLDZWPHF-UHFFFAOYSA-N, HJBWBFZLDZWPHF-UHFFFAOYSA-N	Launched
apararenone	mineralocorticoid receptor antagonist				CC1(C)Oc2cc(NS(C)(=O)=O)ccc2N(C1=O)c1ccc(F)cc1	AZNHWXAFPBYFGH-UHFFFAOYSA-N	Preclinical
apatinib	RET tyrosine kinase inhibitor	CSK, KDR, KIT, RET			O=C(Nc1ccc(cc1)C1(CCCC1)C#N)c1cccnc1NCc1ccncc1, O=C(Nc1ccc(cc1)C1(CCCC1)C#N)c1cccnc1NCc1ccncc1, O=C(Nc1ccc(cc1)C1(CCCC1)C#N)c1cccnc1NCc1ccncc1	WPEWQEMJFLWMLV-UHFFFAOYSA-N, WPEWQEMJFLWMLV-UHFFFAOYSA-N, WPEWQEMJFLWMLV-UHFFFAOYSA-N	Phase 3
APC-100	androgen receptor antagonist, anti-inflammatory agent	AR			Cc1c(C)c2OC(C)(C)CCc2c(C)c1O, Cc1c(C)c2OC(C)(C)CCc2c(C)c1O	SEBPXHSZHLFWRL-UHFFFAOYSA-N, SEBPXHSZHLFWRL-UHFFFAOYSA-N	Phase 1/Phase 2
APcK-110	KIT inhibitor	KIT, STAT3			COc1cc(OC)cc(c1)-c1ccc2c([nH]nc2n1)-c1ccc(F)cc1, COc1cc(OC)cc(c1)-c1ccc2c([nH]nc2n1)-c1ccc(F)cc1, COc1cc(OC)cc(c1)-c1ccc2c([nH]nc2n1)-c1ccc(F)cc1	CAMGZGMEPKFVMF-UHFFFAOYSA-N, CAMGZGMEPKFVMF-UHFFFAOYSA-N, CAMGZGMEPKFVMF-UHFFFAOYSA-N	Preclinical
APD597	glucose dependent insulinotropic receptor agonist	GPR119			COc1c(Nc2ccc(nc2C)S(C)(=O)=O)ncnc1OC1CCN(CC1)C(=O)OC(C)C	WPDCHTSXOPUOII-UHFFFAOYSA-N	Phase 1
APD668	glucose dependent insulinotropic receptor agonist	GPR119			CC(C)OC(=O)N1CCC(CC1)Oc1ncnc2n(ncc12)-c1ccc(cc1F)S(C)(=O)=O, CC(C)OC(=O)N1CCC(CC1)Oc1ncnc2n(ncc12)-c1ccc(cc1F)S(C)(=O)=O	XTRUQJBVQBUKSQ-UHFFFAOYSA-N, XTRUQJBVQBUKSQ-UHFFFAOYSA-N	Phase 1
aphidicolin	RNA synthesis inhibitor				C[C@@]1(CO)[C@H](O)CC[C@@]2(C)[C@H]1CC[C@H]1C[C@@H]3C[C@]21CC[C@]3(O)CO, C[C@@]1(CO)[C@H](O)CC[C@@]2(C)[C@H]1CC[C@H]1C[C@@H]3C[C@]21CC[C@]3(O)CO, C[C@@]1(CO)[C@H](O)CC[C@@]2(C)[C@H]1CC[C@H]1C[C@@H]3C[C@]21CC[C@]3(O)CO	NOFOAYPPHIUXJR-APNQCZIXSA-N, NOFOAYPPHIUXJR-APNQCZIXSA-N, NOFOAYPPHIUXJR-APNQCZIXSA-N	Phase 1
API-001	sigma receptor antagonist	SIGMAR1			Cc1cc(OCCN2CCOCC2)nn1-c1ccc2ccccc2c1, Cc1cc(OCCN2CCOCC2)nn1-c1ccc2ccccc2c1, Cc1cc(OCCN2CCOCC2)nn1-c1ccc2ccccc2c1	DGPGXHRHNRYVDH-UHFFFAOYSA-N, DGPGXHRHNRYVDH-UHFFFAOYSA-N, DGPGXHRHNRYVDH-UHFFFAOYSA-N	Phase 2
API-1	AKT inhibitor	AKT1, AKT2, AKT3			NC(=O)c1cn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c2ncnc(N)c2c1=O, NC(=O)c1cn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c2ncnc(N)c2c1=O, NC(=O)c1cn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c2ncnc(N)c2c1=O	SPBWHPXCWJLQRU-FITJORAGSA-N, SPBWHPXCWJLQRU-FITJORAGSA-N, SPBWHPXCWJLQRU-FITJORAGSA-N	Preclinical
apigenin	casein kinase inhibitor, cell proliferation inhibitor	AKR1B1, AR, CDK6, CFTR, CYP19A1, CYP1B1, HSD17B1			Oc1ccc(cc1)-c1cc(=O)c2c(O)cc(O)cc2o1, Oc1ccc(cc1)-c1cc(=O)c2c(O)cc(O)cc2o1, Oc1ccc(cc1)-c1cc(=O)c2c(O)cc(O)cc2o1, Oc1ccc(cc1)-c1cc(=O)c2c(O)cc(O)cc2o1	KZNIFHPLKGYRTM-UHFFFAOYSA-N, KZNIFHPLKGYRTM-UHFFFAOYSA-N, KZNIFHPLKGYRTM-UHFFFAOYSA-N, KZNIFHPLKGYRTM-UHFFFAOYSA-N	Preclinical
apixaban	coagulation factor inhibitor	F10	neurology/psychiatry, hematology, cardiology	stroke, systemic embolism, pulmonary embolism (PE), atrial fibrillation (AF), deep vein thrombosis (DVT)	COc1ccc(cc1)-n1nc(C(N)=O)c2CCN(C(=O)c12)c1ccc(cc1)N1CCCCC1=O, COc1ccc(cc1)-n1nc(C(N)=O)c2CCN(C(=O)c12)c1ccc(cc1)N1CCCCC1=O, COc1ccc(cc1)-n1nc(C(N)=O)c2CCN(C(=O)c12)c1ccc(cc1)N1CCCCC1=O, COc1ccc(cc1)-n1nc(C(N)=O)c2CCN(C(=O)c12)c1ccc(cc1)N1CCCCC1=O	QNZCBYKSOIHPEH-UHFFFAOYSA-N, QNZCBYKSOIHPEH-UHFFFAOYSA-N, QNZCBYKSOIHPEH-UHFFFAOYSA-N, QNZCBYKSOIHPEH-UHFFFAOYSA-N	Launched
apocynin	NADPH oxidase inhibitor	NOX4			COc1cc(ccc1O)C(C)=O, COc1cc(ccc1O)C(C)=O, COc1cc(ccc1O)C(C)=O, COc1cc(ccc1O)C(C)=O	DFYRUELUNQRZTB-UHFFFAOYSA-N, DFYRUELUNQRZTB-UHFFFAOYSA-N, DFYRUELUNQRZTB-UHFFFAOYSA-N, DFYRUELUNQRZTB-UHFFFAOYSA-N	Phase 1
apoptosis-activator-II	carboxylesterase inhibitor	BCHE, CES1			Clc1ccc(CN2C(=O)C(=O)c3ccccc23)cc1Cl, Clc1ccc(CN2C(=O)C(=O)c3ccccc23)cc1Cl, Clc1ccc(CN2C(=O)C(=O)c3ccccc23)cc1Cl, Clc1ccc(CN2C(=O)C(=O)c3ccccc23)cc1Cl	KGRJPLRFGLMQMV-UHFFFAOYSA-N, KGRJPLRFGLMQMV-UHFFFAOYSA-N, KGRJPLRFGLMQMV-UHFFFAOYSA-N, KGRJPLRFGLMQMV-UHFFFAOYSA-N	Preclinical
APR-246	p53 activator	TP53			COC[C@@]1(CO)N2CCC(CC2)C1=O |&1:3,r,TLB:2:3:7.8:10.11|	BGBNULCRKBVAKL-SNVBAGLBSA-N	Phase 3
apraclonidine	adrenergic receptor agonist	ADRA1A, ADRA2A, ADRA2B, ADRA2C	ophthalmology	glaucoma, intraocular pressure	Nc1cc(Cl)c(NC2=NCCN2)c(Cl)c1 |t:7|	IEJXVRYNEISIKR-UHFFFAOYSA-N	Launched
apramycin	bacterial 30S ribosomal subunit inhibitor		infectious disease	gram-negative bacterial infections	CN[C@H]1[C@@H](O)[C@H]2O[C@H](O[C@@H]3[C@@H](N)C[C@@H](N)[C@H](O)[C@H]3O)[C@H](N)C[C@@H]2O[C@@H]1O[C@H]1O[C@H](CO)[C@@H](N)[C@H](O)[C@H]1O	XZNUGFQTQHRASN-XQENGBIVSA-N	Launched
apratastat	matrix metalloprotease inhibitor, tumor necrosis factor production inhibitor	ADAM17, MMP1, MMP13, MMP9			CC1(C)SCCN([C@H]1C(=O)NO)S(=O)(=O)c1ccc(OCC#CCO)cc1, CC1(C)SCCN([C@H]1C(=O)NO)S(=O)(=O)c1ccc(OCC#CCO)cc1, CC1(C)SCCN([C@H]1C(=O)NO)S(=O)(=O)c1ccc(OCC#CCO)cc1, CC1(C)SCCN([C@H]1C(=O)NO)S(=O)(=O)c1ccc(OCC#CCO)cc1	MAVDNGWEBZTACC-HNNXBMFYSA-N, MAVDNGWEBZTACC-HNNXBMFYSA-N, MAVDNGWEBZTACC-HNNXBMFYSA-N, MAVDNGWEBZTACC-HNNXBMFYSA-N	Phase 2
apremilast	phosphodiesterase inhibitor	PDE4A, PDE4B, PDE4C, PDE4D	dermatology, rheumatology	psoriasis, psoriatic arthritis	CCOc1cc(ccc1OC)[C@@H](CS(C)(=O)=O)N1C(=O)c2cccc(NC(C)=O)c2C1=O, CCOc1cc(ccc1OC)[C@@H](CS(C)(=O)=O)N1C(=O)c2cccc(NC(C)=O)c2C1=O, CCOc1cc(ccc1OC)[C@@H](CS(C)(=O)=O)N1C(=O)c2cccc(NC(C)=O)c2C1=O, CCOc1cc(ccc1OC)[C@@H](CS(C)(=O)=O)N1C(=O)c2cccc(NC(C)=O)c2C1=O	IMOZEMNVLZVGJZ-QGZVFWFLSA-N, IMOZEMNVLZVGJZ-QGZVFWFLSA-N, IMOZEMNVLZVGJZ-QGZVFWFLSA-N, IMOZEMNVLZVGJZ-QGZVFWFLSA-N	Launched
aprepitant	tachykinin antagonist	TACR1	gastroenterology	nausea, vomiting	C[C@@H](O[C@H]1OCCN(Cc2n[nH]c(=O)[nH]2)[C@H]1c1ccc(F)cc1)c1cc(cc(c1)C(F)(F)F)C(F)(F)F	ATALOFNDEOCMKK-OITMNORJSA-N	Launched
apricitabine	nucleoside reverse transcriptase inhibitor				Nc1ccn([C@H]2CO[C@@H](CO)S2)c(=O)n1	RYMCFYKJDVMSIR-RNFRBKRXSA-N	Phase 3
aprindine	voltage-gated sodium channel blocker	CALM1, SCN5A	cardiology	cardiac arrythmia	CCN(CC)CCCN(C1Cc2ccccc2C1)c1ccccc1, CCN(CC)CCCN(C1Cc2ccccc2C1)c1ccccc1	NZLBHDRPUJLHCE-UHFFFAOYSA-N, NZLBHDRPUJLHCE-UHFFFAOYSA-N	Launched
apronal	cytochrome P450 modulator				CC(C)[C@H](CC=C)C(=O)NC(N)=O |&1:3,r|	KSUUMAWCGDNLFK-ZETCQYMHSA-N	Preclinical
aptiganel	glutamate receptor antagonist	GRIN1			CCc1cccc(c1)N(C)C(=N)Nc1cccc2ccccc12, CCc1cccc(c1)N(C)C(=N)Nc1cccc2ccccc12, CCc1cccc(c1)N(C)C(=N)Nc1cccc2ccccc12	BFNCJMURTMZBTE-UHFFFAOYSA-N, BFNCJMURTMZBTE-UHFFFAOYSA-N, BFNCJMURTMZBTE-UHFFFAOYSA-N	Phase 3
APTO-253	krppel-like factor expression enhancer	KLF4			Cc1[nH]c2ccc(F)cc2c1-c1nc2c([nH]1)c1cccnc1c1ncccc21, Cc1[nH]c2ccc(F)cc2c1-c1nc2c([nH]1)c1cccnc1c1ncccc21, Cc1[nH]c2ccc(F)cc2c1-c1nc2c([nH]1)c1cccnc1c1ncccc21, Cc1[nH]c2ccc(F)cc2c1-c1nc2c([nH]1)c1cccnc1c1ncccc21	NIRXBXIPHUTNNI-UHFFFAOYSA-N, NIRXBXIPHUTNNI-UHFFFAOYSA-N, NIRXBXIPHUTNNI-UHFFFAOYSA-N, NIRXBXIPHUTNNI-UHFFFAOYSA-N	Phase 1
APY-29	serine/threonine kinase inhibitor	ERN1			C1CC1c1cc(Nc2ccnc(Nc3ccc4nc[nH]c4c3)n2)[nH]n1, C1CC1c1cc(Nc2ccnc(Nc3ccc4nc[nH]c4c3)n2)[nH]n1, C1CC1c1cc(Nc2ccnc(Nc3ccc4nc[nH]c4c3)n2)[nH]n1	WJNBSTLIALIIEW-UHFFFAOYSA-N, WJNBSTLIALIIEW-UHFFFAOYSA-N, WJNBSTLIALIIEW-UHFFFAOYSA-N	Preclinical
apyramide	cyclooxygenase inhibitor				COc1ccc2n(C(=O)c3ccc(Cl)cc3)c(C)c(CC(=O)Oc3ccc(NC(C)=O)cc3)c2c1	KWUFTKVMXUYTBF-UHFFFAOYSA-N	Preclinical
APY0201	phosphoinositide dependent kinase inhibitor	IL12A, IL12B, PIKFYVE			Cc1cccc(\C=N\Nc2cc(N3CCOCC3)n3nc(cc3n2)-c2ccncc2)c1, Cc1cccc(\C=N\Nc2cc(N3CCOCC3)n3nc(cc3n2)-c2ccncc2)c1, Cc1cccc(\C=N\Nc2cc(N3CCOCC3)n3nc(cc3n2)-c2ccncc2)c1	RFZQYGBLRIKROZ-PCLIKHOPSA-N, RFZQYGBLRIKROZ-PCLIKHOPSA-N, RFZQYGBLRIKROZ-PCLIKHOPSA-N	Preclinical
AP1903		MTOR			CC[C@H](C(=O)N1CCCC[C@H]1C(=O)O[C@H](CCc1ccc(OC)c(OC)c1)c1cccc(OCC(=O)NCCNC(=O)COc2cccc(c2)[C@@H](CCc2ccc(OC)c(OC)c2)OC(=O)[C@@H]2CCCCN2C(=O)[C@@H](CC)c2cc(OC)c(OC)c(OC)c2)c1)c1cc(OC)c(OC)c(OC)c1, CC[C@H](C(=O)N1CCCC[C@H]1C(=O)O[C@H](CCc1ccc(OC)c(OC)c1)c1cccc(OCC(=O)NCCNC(=O)COc2cccc(c2)[C@@H](CCc2ccc(OC)c(OC)c2)OC(=O)[C@@H]2CCCCN2C(=O)[C@@H](CC)c2cc(OC)c(OC)c(OC)c2)c1)c1cc(OC)c(OC)c(OC)c1	GQLCLPLEEOUJQC-ZTQDTCGGSA-N, GQLCLPLEEOUJQC-ZTQDTCGGSA-N	Phase 1/Phase 2
AP26113	ALK tyrosine kinase receptor inhibitor	ALK, EGFR			COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2P(C)(C)=O)n1)N1CCC(CC1)N(C)C, COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2P(C)(C)=O)n1)N1CCC(CC1)N(C)C, COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2P(C)(C)=O)n1)N1CCC(CC1)N(C)C, COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2P(C)(C)=O)n1)N1CCC(CC1)N(C)C, COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2P(C)(C)=O)n1)N1CCC(CC1)N(C)C	OVDSPTSBIQCAIN-UHFFFAOYSA-N, OVDSPTSBIQCAIN-UHFFFAOYSA-N, OVDSPTSBIQCAIN-UHFFFAOYSA-N, OVDSPTSBIQCAIN-UHFFFAOYSA-N, OVDSPTSBIQCAIN-UHFFFAOYSA-N	Phase 2
AQ-RA741	acetylcholine receptor antagonist	CHRM2			CCN(CC)CCCCC1CCN(CC(=O)N2c3ccccc3C(=O)Nc3cccnc23)CC1, CCN(CC)CCCCC1CCN(CC(=O)N2c3ccccc3C(=O)Nc3cccnc23)CC1, CCN(CC)CCCCC1CCN(CC(=O)N2c3ccccc3C(=O)Nc3cccnc23)CC1	BCUGCHZRMKTPMU-UHFFFAOYSA-N, BCUGCHZRMKTPMU-UHFFFAOYSA-N, BCUGCHZRMKTPMU-UHFFFAOYSA-N	Preclinical
AQ-13	antimalarial agent				CCN(CC)CCCNc1ccnc2cc(Cl)ccc12	NCPLTAGJJVCHOW-UHFFFAOYSA-N	Phase 2
AQW-051	nicotinic receptor agonist				Cc1ccc(cc1)-c1ccc(O[C@H]2CN3CCC2CC3)cn1	NPDLTEZXGWRMLQ-IBGZPJMESA-N	Preclinical
AR-A014418	glycogen synthase kinase inhibitor	GSK3B			COc1ccc(CNC(=O)Nc2ncc(s2)[N+]([O-])=O)cc1, COc1ccc(CNC(=O)Nc2ncc(s2)[N+]([O-])=O)cc1, COc1ccc(CNC(=O)Nc2ncc(s2)[N+]([O-])=O)cc1, COc1ccc(CNC(=O)Nc2ncc(s2)[N+]([O-])=O)cc1, COc1ccc(CNC(=O)Nc2ncc(s2)[N+]([O-])=O)cc1	YAEMHJKFIIIULI-UHFFFAOYSA-N, YAEMHJKFIIIULI-UHFFFAOYSA-N, YAEMHJKFIIIULI-UHFFFAOYSA-N, YAEMHJKFIIIULI-UHFFFAOYSA-N, YAEMHJKFIIIULI-UHFFFAOYSA-N	Preclinical
AR-C155858	monocarboxylate transporter inhibitor	SLC16A1, SLC16A7			CC(C)Cn1c2sc(Cc3c(C)n[nH]c3C)c(C(=O)N3C[C@H](O)CO3)c2c(=O)n(C)c1=O, CC(C)Cn1c2sc(Cc3c(C)n[nH]c3C)c(C(=O)N3C[C@H](O)CO3)c2c(=O)n(C)c1=O	ISIVOJWVBJIOFM-ZDUSSCGKSA-N, ISIVOJWVBJIOFM-ZDUSSCGKSA-N	Preclinical
AR-12	phosphoinositide dependent kinase inhibitor	PDPK1			NCC(=O)Nc1ccc(cc1)-n1nc(cc1-c1ccc2c(ccc3ccccc23)c1)C(F)(F)F, NCC(=O)Nc1ccc(cc1)-n1nc(cc1-c1ccc2c(ccc3ccccc23)c1)C(F)(F)F, NCC(=O)Nc1ccc(cc1)-n1nc(cc1-c1ccc2c(ccc3ccccc23)c1)C(F)(F)F, NCC(=O)Nc1ccc(cc1)-n1nc(cc1-c1ccc2c(ccc3ccccc23)c1)C(F)(F)F	YULUCECVQOCQFQ-UHFFFAOYSA-N, YULUCECVQOCQFQ-UHFFFAOYSA-N, YULUCECVQOCQFQ-UHFFFAOYSA-N, YULUCECVQOCQFQ-UHFFFAOYSA-N	Phase 1
AR-42	HDAC inhibitor	HDAC1			CC(C)[C@H](C(=O)Nc1ccc(cc1)C(=O)NO)c1ccccc1, CC(C)[C@H](C(=O)Nc1ccc(cc1)C(=O)NO)c1ccccc1, CC(C)[C@H](C(=O)Nc1ccc(cc1)C(=O)NO)c1ccccc1	LAMIXXKAWNLXOC-INIZCTEOSA-N, LAMIXXKAWNLXOC-INIZCTEOSA-N, LAMIXXKAWNLXOC-INIZCTEOSA-N	Phase 1
arachidonic-acid	cytochrome P450 inhibitor	CLCN2, KCNJ4, KCNK10, KCNK18, KCNK2, PRKCZ, PTGS1, TRPC6, TRPM2			CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O, CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O	YZXBAPSDXZZRGB-DOFZRALJSA-N, YZXBAPSDXZZRGB-DOFZRALJSA-N	Phase 1
aramchol	stearoyl-CoA desaturase inhibitor				CCCCCCCCCCCCCCCCCCCC(=O)N[C@H]1CC[C@@]2(C)[C@H](C[C@@H](O)[C@H]3[C@@H]4CC[C@H]([C@H](C)CCC(O)=O)[C@@]4(C)[C@@H](O)C[C@H]23)C1	SHKXZIQNFMOPBS-OOMQYRRCSA-N	Phase 2/Phase 3
arbidol	cytochrome P450 inhibitor	CYP3A4	infectious disease	influenza A virus infection	CCOC(=O)c1c(CSc2ccccc2)n(C)c2cc(Br)c(O)c(CN(C)C)c12, CCOC(=O)c1c(CSc2ccccc2)n(C)c2cc(Br)c(O)c(CN(C)C)c12, CCOC(=O)c1c(CSc2ccccc2)n(C)c2cc(Br)c(O)c(CN(C)C)c12, CCOC(=O)c1c(CSc2ccccc2)n(C)c2cc(Br)c(O)c(CN(C)C)c12	KCFYEAOKVJSACF-UHFFFAOYSA-N, KCFYEAOKVJSACF-UHFFFAOYSA-N, KCFYEAOKVJSACF-UHFFFAOYSA-N, KCFYEAOKVJSACF-UHFFFAOYSA-N	Launched
arbutin	melanin inhibitor	TYR			OC[C@H]1O[C@@H](Oc2ccc(O)cc2)[C@H](O)[C@@H](O)[C@@H]1O, OC[C@H]1O[C@@H](Oc2ccc(O)cc2)[C@H](O)[C@@H](O)[C@@H]1O	BJRNKVDFDLYUGJ-RMPHRYRLSA-N, BJRNKVDFDLYUGJ-RMPHRYRLSA-N	Phase 2/Phase 3
ARC-239	adrenergic receptor antagonist	ADRA2A, ADRA2B, ADRA2C			COc1ccccc1N1CCN(CCN2C(=O)c3ccccc3C(C)(C)C2=O)CC1, COc1ccccc1N1CCN(CCN2C(=O)c3ccccc3C(C)(C)C2=O)CC1	JFNKXGOEOQCXDM-UHFFFAOYSA-N, JFNKXGOEOQCXDM-UHFFFAOYSA-N	Preclinical
arctigenin	MEK inhibitor	CHUK, MAP2K1			COc1ccc(C[C@H]2COC(=O)[C@@H]2Cc2ccc(O)c(OC)c2)cc1OC, COc1ccc(C[C@H]2COC(=O)[C@@H]2Cc2ccc(O)c(OC)c2)cc1OC	NQWVSMVXKMHKTF-JKSUJKDBSA-N, NQWVSMVXKMHKTF-JKSUJKDBSA-N	Preclinical
arcyriaflavin-a	CDK inhibitor	CCND1, CDK4			O=C1NC(=O)c2c1c1c3ccccc3[nH]c1c1[nH]c3ccccc3c21, O=C1NC(=O)c2c1c1c3ccccc3[nH]c1c1[nH]c3ccccc3c21, O=C1NC(=O)c2c1c1c3ccccc3[nH]c1c1[nH]c3ccccc3c21, O=C1NC(=O)c2c1c1c3ccccc3[nH]c1c1[nH]c3ccccc3c21, O=C1NC(=O)c2c1c1c3ccccc3[nH]c1c1[nH]c3ccccc3c21, O=C1NC(=O)c2c1c1c3ccccc3[nH]c1c1[nH]c3ccccc3c21, O=C1NC(=O)c2c1c1c3ccccc3[nH]c1c1[nH]c3ccccc3c21, O=C1NC(=O)c2c1c1c3ccccc3[nH]c1c1[nH]c3ccccc3c21, O=C1NC(=O)c2c1c1c3ccccc3[nH]c1c1[nH]c3ccccc3c21	KAJXOWFGKYKMMZ-UHFFFAOYSA-N, KAJXOWFGKYKMMZ-UHFFFAOYSA-N, KAJXOWFGKYKMMZ-UHFFFAOYSA-N, KAJXOWFGKYKMMZ-UHFFFAOYSA-N, KAJXOWFGKYKMMZ-UHFFFAOYSA-N, KAJXOWFGKYKMMZ-UHFFFAOYSA-N, KAJXOWFGKYKMMZ-UHFFFAOYSA-N, KAJXOWFGKYKMMZ-UHFFFAOYSA-N, KAJXOWFGKYKMMZ-UHFFFAOYSA-N	Preclinical
ardeparin	thrombin inhibitor	SERPIND1			CO[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](O[C@@H]2O[C@H]([C@@H](OC)[C@H](O)[C@H]2OS(O)(=O)=O)C(O)=O)[C@H](O)[C@H]1NS(O)(=O)=O	HXSDFQWQRCUQHF-IDOMHHBZSA-N	Withdrawn
arecaidine-but-2-ynyl-ester	acetylcholine receptor agonist	CHRM2			CC#CCOC(=O)C1=CCCN(C)C1 |t:7|	LBFWTPRSXIRKMZ-UHFFFAOYSA-N	Preclinical
arecaidine-propargyl-ester	acetylcholine receptor agonist	CHRM1, CHRM2, CHRM3, CHRM4			CN1CCC=C(C1)C(=O)OCC#C |c:4|, CN1CCC=C(C1)C(=O)OCC#C |c:4|, CN1CCC=C(C1)C(=O)OCC#C |c:4|, CN1CCC=C(C1)C(=O)OCC#C |c:4|, CN1CCC=C(C1)C(=O)OCC#C |c:4|, CN1CCC=C(C1)C(=O)OCC#C |c:4|	SPHRJZBOFYIKMC-UHFFFAOYSA-N, SPHRJZBOFYIKMC-UHFFFAOYSA-N, SPHRJZBOFYIKMC-UHFFFAOYSA-N, SPHRJZBOFYIKMC-UHFFFAOYSA-N, SPHRJZBOFYIKMC-UHFFFAOYSA-N, SPHRJZBOFYIKMC-UHFFFAOYSA-N	Preclinical
arecoline	acetylcholine receptor agonist	CHRM1, CHRM2, CHRM3, CHRM4			COC(=O)C1=CCCN(C)C1 |t:4|, COC(=O)C1=CCCN(C)C1 |t:4|, COC(=O)C1=CCCN(C)C1 |t:4|	HJJPJSXJAXAIPN-UHFFFAOYSA-N, HJJPJSXJAXAIPN-UHFFFAOYSA-N, HJJPJSXJAXAIPN-UHFFFAOYSA-N	Phase 1
argatroban	thrombin inhibitor	F2	hematology	heparin-induced thrombocytopenia (HIT)	C[C@@H]1CCN([C@H](C1)C(O)=O)C(=O)[C@H](CCCNC(N)=N)NS(=O)(=O)c1cccc2C[C@@H](C)CNc12 |a:1,5,12,&1:30|, C[C@@H]1CCN([C@H](C1)C(O)=O)C(=O)[C@H](CCCNC(N)=N)NS(=O)(=O)c1cccc2C[C@@H](C)CNc12 |a:1,5,12,&1:30|, C[C@@H]1CCN([C@H](C1)C(O)=O)C(=O)[C@H](CCCNC(N)=N)NS(=O)(=O)c1cccc2C[C@@H](C)CNc12 |a:1,5,12,&1:30|, C[C@@H]1CCN([C@H](C1)C(O)=O)C(=O)[C@H](CCCNC(N)=N)NS(=O)(=O)c1cccc2C[C@@H](C)CNc12 |a:1,5,12,&1:30|	KXNPVXPOPUZYGB-XYVMCAHJSA-N, KXNPVXPOPUZYGB-XYVMCAHJSA-N, KXNPVXPOPUZYGB-XYVMCAHJSA-N, KXNPVXPOPUZYGB-XYVMCAHJSA-N	Launched
argireline	neurotransmitter release inhibitor				CSCC[C@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(C)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(N)=O	RJZNPROJTJSYLC-LLINQDLYSA-N	Phase 3
arglabin	farnesyltransferase inhibitor	FNTA, NFKB1			CC1=CC[C@]23O[C@@]2(C)CC[C@@H]2[C@H](OC(=O)C2=C)[C@@H]13 |t:1|, CC1=CC[C@]23O[C@@]2(C)CC[C@@H]2[C@H](OC(=O)C2=C)[C@@H]13 |t:1|, CC1=CC[C@]23O[C@@]2(C)CC[C@@H]2[C@H](OC(=O)C2=C)[C@@H]13 |t:1|, CC1=CC[C@]23O[C@@]2(C)CC[C@@H]2[C@H](OC(=O)C2=C)[C@@H]13 |t:1|, CC1=CC[C@]23O[C@@]2(C)CC[C@@H]2[C@H](OC(=O)C2=C)[C@@H]13 |t:1|, CC1=CC[C@]23O[C@@]2(C)CC[C@@H]2[C@H](OC(=O)C2=C)[C@@H]13 |t:1|	UVJYAKBJSGRTHA-CUZKYEQNSA-N, UVJYAKBJSGRTHA-CUZKYEQNSA-N, UVJYAKBJSGRTHA-CUZKYEQNSA-N, UVJYAKBJSGRTHA-CUZKYEQNSA-N, UVJYAKBJSGRTHA-CUZKYEQNSA-N, UVJYAKBJSGRTHA-CUZKYEQNSA-N	Launched
aripiprazole	serotonin receptor agonist, serotonin receptor antagonist	ADRA1A, ADRA1B, ADRA2A, ADRA2B, ADRA2C, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, DRD1, DRD2, DRD3, DRD4, DRD5, HRH1, HTR1A, HTR1B, HTR1D, HTR1E, HTR2A, HTR2C, HTR3A, HTR6, HTR7	neurology/psychiatry	depression, schizophrenia, bipolar disorder	Clc1cccc(N2CCN(CCCCOc3ccc4CCC(=O)Nc4c3)CC2)c1Cl, Clc1cccc(N2CCN(CCCCOc3ccc4CCC(=O)Nc4c3)CC2)c1Cl, Clc1cccc(N2CCN(CCCCOc3ccc4CCC(=O)Nc4c3)CC2)c1Cl	CEUORZQYGODEFX-UHFFFAOYSA-N, CEUORZQYGODEFX-UHFFFAOYSA-N, CEUORZQYGODEFX-UHFFFAOYSA-N	Launched
aripiprazole-lauroxil	serotonin receptor agonist		neurology/psychiatry	schizophrenia	CCCCCCCCCCCC(=O)OCN1C(=O)CCc2ccc(OCCCCN3CCN(CC3)c3cccc(Cl)c3Cl)cc12	DDINXHAORAAYAD-UHFFFAOYSA-N	Launched
arofylline	phosphodiesterase inhibitor	PDE4A			CCCn1c(=O)n(-c2ccc(Cl)cc2)c2nc[nH]c2c1=O, CCCn1c(=O)n(-c2ccc(Cl)cc2)c2nc[nH]c2c1=O	GVTLDPJNRVMCAL-UHFFFAOYSA-N, GVTLDPJNRVMCAL-UHFFFAOYSA-N	Phase 3
arotinolol	adrenergic receptor antagonist	ADRB3	cardiology, neurology/psychiatry	hypertension, tremors	CC(C)(C)NC[C@@H](O)CSc1nc(cs1)-c1ccc(s1)C(N)=O |&1:6,r|, CC(C)(C)NC[C@@H](O)CSc1nc(cs1)-c1ccc(s1)C(N)=O |&1:6,r|	BHIAIPWSVYSKJS-SECBINFHSA-N, BHIAIPWSVYSKJS-SECBINFHSA-N	Launched
ARQ-092	AKT inhibitor	AKT2			Nc1ncccc1-c1nc2ccc(nc2n1-c1ccc(cc1)C1(N)CCC1)-c1ccccc1, Nc1ncccc1-c1nc2ccc(nc2n1-c1ccc(cc1)C1(N)CCC1)-c1ccccc1	HNFMVVHMKGFCMB-UHFFFAOYSA-N, HNFMVVHMKGFCMB-UHFFFAOYSA-N	Phase 1
ARQ-621	kinesin-like spindle protein inhibitor	KIF11			NCCCN([C@H](CC#C)c1nc2cc(Cl)ccc2c(=O)n1Nc1ccccc1)C(=O)c1cccc(Cl)c1F, NCCCN([C@H](CC#C)c1nc2cc(Cl)ccc2c(=O)n1Nc1ccccc1)C(=O)c1cccc(Cl)c1F, NCCCN([C@H](CC#C)c1nc2cc(Cl)ccc2c(=O)n1Nc1ccccc1)C(=O)c1cccc(Cl)c1F	UPJSUQWHUVLLNW-XMMPIXPASA-N, UPJSUQWHUVLLNW-XMMPIXPASA-N, UPJSUQWHUVLLNW-XMMPIXPASA-N	Phase 1
ARRY-334543	EGFR inhibitor	ERBB2			C[C@@H]1COC(Nc2ccc3ncnc(Nc4ccc(OCc5nccs5)c(Cl)c4)c3c2)=N1 |c:34|, C[C@@H]1COC(Nc2ccc3ncnc(Nc4ccc(OCc5nccs5)c(Cl)c4)c3c2)=N1 |c:34|, C[C@@H]1COC(Nc2ccc3ncnc(Nc4ccc(OCc5nccs5)c(Cl)c4)c3c2)=N1 |c:34|	UWXSAYUXVSFDBQ-CYBMUJFWSA-N, UWXSAYUXVSFDBQ-CYBMUJFWSA-N, UWXSAYUXVSFDBQ-CYBMUJFWSA-N	Phase 2/Phase 3
arsanilic-acid		LYZ			Nc1ccc(cc1)[As](O)(O)=O, Nc1ccc(cc1)[As](O)(O)=O	XKNKHVGWJDPIRJ-UHFFFAOYSA-N, XKNKHVGWJDPIRJ-UHFFFAOYSA-N	Phase 1
arsenic-trioxide	apoptosis stimulant	AKT1, CCND1, IKBKB, JUN, MAPK1, MAPK3, TXNRD1	gastroenterology	diarrhea	O=[As]O[As]=O	IKWTVSLWAPBBKU-UHFFFAOYSA-N	Launched
artemether	antimalarial agent	ATP1A1	infectious disease	malaria	CO[C@H]1O[C@@H]2O[C@@]3(C)CC[C@H]4[C@H](C)CC[C@@H]([C@H]1C)[C@@]24OO3, CO[C@H]1O[C@@H]2O[C@@]3(C)CC[C@H]4[C@H](C)CC[C@@H]([C@H]1C)[C@@]24OO3, CO[C@H]1O[C@@H]2O[C@@]3(C)CC[C@H]4[C@H](C)CC[C@@H]([C@H]1C)[C@@]24OO3, CO[C@H]1O[C@@H]2O[C@@]3(C)CC[C@H]4[C@H](C)CC[C@@H]([C@H]1C)[C@@]24OO3, CO[C@H]1O[C@@H]2O[C@@]3(C)CC[C@H]4[C@H](C)CC[C@@H]([C@H]1C)[C@@]24OO3	SXYIRMFQILZOAM-HVNFFKDJSA-N, SXYIRMFQILZOAM-HVNFFKDJSA-N, SXYIRMFQILZOAM-HVNFFKDJSA-N, SXYIRMFQILZOAM-HVNFFKDJSA-N, SXYIRMFQILZOAM-HVNFFKDJSA-N	Launched
artemisinin	DNA synthesis inhibitor	CYP2B6	infectious disease	malaria	C[C@@H]1CC[C@H]2[C@@H](C)C(=O)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@@]23OO4, C[C@@H]1CC[C@H]2[C@@H](C)C(=O)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@@]23OO4, C[C@@H]1CC[C@H]2[C@@H](C)C(=O)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@@]23OO4, C[C@@H]1CC[C@H]2[C@@H](C)C(=O)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@@]23OO4, C[C@@H]1CC[C@H]2[C@@H](C)C(=O)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@@]23OO4, C[C@@H]1CC[C@H]2[C@@H](C)C(=O)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@@]23OO4	BLUAFEHZUWYNDE-NNWCWBAJSA-N, BLUAFEHZUWYNDE-NNWCWBAJSA-N, BLUAFEHZUWYNDE-NNWCWBAJSA-N, BLUAFEHZUWYNDE-NNWCWBAJSA-N, BLUAFEHZUWYNDE-NNWCWBAJSA-N, BLUAFEHZUWYNDE-NNWCWBAJSA-N	Launched
artemotil			infectious disease	malaria	CCO[C@H]1O[C@@H]2O[C@@]3(C)CC[C@H]4[C@H](C)CC[C@@H]([C@H]1C)[C@@]24OO3, CCO[C@H]1O[C@@H]2O[C@@]3(C)CC[C@H]4[C@H](C)CC[C@@H]([C@H]1C)[C@@]24OO3, CCO[C@H]1O[C@@H]2O[C@@]3(C)CC[C@H]4[C@H](C)CC[C@@H]([C@H]1C)[C@@]24OO3	NLYNIRQVMRLPIQ-XQLAAWPRSA-N, NLYNIRQVMRLPIQ-XQLAAWPRSA-N, NLYNIRQVMRLPIQ-XQLAAWPRSA-N	Launched
artesunate	DNA synthesis inhibitor		infectious disease	malaria	C[C@@H]1CC[C@H]2[C@@H](C)[C@H](OC(=O)CCC(O)=O)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@@]23OO4, C[C@@H]1CC[C@H]2[C@@H](C)[C@H](OC(=O)CCC(O)=O)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@@]23OO4, C[C@@H]1CC[C@H]2[C@@H](C)[C@H](OC(=O)CCC(O)=O)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@@]23OO4, C[C@@H]1CC[C@H]2[C@@H](C)[C@H](OC(=O)CCC(O)=O)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@@]23OO4, C[C@@H]1CC[C@H]2[C@@H](C)[C@H](OC(=O)CCC(O)=O)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@@]23OO4	FIHJKUPKCHIPAT-AHIGJZGOSA-N, FIHJKUPKCHIPAT-AHIGJZGOSA-N, FIHJKUPKCHIPAT-AHIGJZGOSA-N, FIHJKUPKCHIPAT-AHIGJZGOSA-N, FIHJKUPKCHIPAT-AHIGJZGOSA-N	Launched
articaine	local anesthetic		neurology/psychiatry	local anesthetic	CCCN[C@@H](C)C(=O)Nc1c(C)csc1C(=O)OC |&1:4|, CCCN[C@@H](C)C(=O)Nc1c(C)csc1C(=O)OC |&1:4|	QTGIAADRBBLJGA-VIFPVBQESA-N, QTGIAADRBBLJGA-VIFPVBQESA-N	Launched
arundic-acid	astrocyte modulating agent	PTGS2, S100B			CCCCCC[C@@H](CCC)C(O)=O	YCYMCMYLORLIJX-SNVBAGLBSA-N	Phase 2/Phase 3
ARV-825	bromodomain inhibitor	BRD4			Cc1sc-2c(c1C)C(=N[C@@H](CC(=O)Nc1ccc(OCCOCCOCCOCCNc3cccc4C(=O)N([C@H]5CCC(=O)NC5=O)C(=O)c34)cc1)c1nnc(C)n-21)c1ccc(Cl)cc1 |a:9,&1:39,c:8|, Cc1sc-2c(c1C)C(=N[C@@H](CC(=O)Nc1ccc(OCCOCCOCCOCCNc3cccc4C(=O)N([C@H]5CCC(=O)NC5=O)C(=O)c34)cc1)c1nnc(C)n-21)c1ccc(Cl)cc1 |a:9,&1:39,c:8|	RWLOGRLTDKDANT-ZPGRZCPFSA-N, RWLOGRLTDKDANT-ZPGRZCPFSA-N	Preclinical
AS-1269574	glucose dependent insulinotropic receptor agonist	GPR119			Cc1cc(NCCO)nc(n1)-c1ccc(Br)cc1, Cc1cc(NCCO)nc(n1)-c1ccc(Br)cc1, Cc1cc(NCCO)nc(n1)-c1ccc(Br)cc1, Cc1cc(NCCO)nc(n1)-c1ccc(Br)cc1	DUKPGOOUJNUIOI-UHFFFAOYSA-N, DUKPGOOUJNUIOI-UHFFFAOYSA-N, DUKPGOOUJNUIOI-UHFFFAOYSA-N, DUKPGOOUJNUIOI-UHFFFAOYSA-N	Preclinical
AS-1892802	rho associated kinase inhibitor	ROCK1			OC[C@@H](NC(=O)Nc1ccc(cc1)-c1ccncc1)c1ccccc1, OC[C@@H](NC(=O)Nc1ccc(cc1)-c1ccncc1)c1ccccc1, OC[C@@H](NC(=O)Nc1ccc(cc1)-c1ccncc1)c1ccccc1, OC[C@@H](NC(=O)Nc1ccc(cc1)-c1ccncc1)c1ccccc1, OC[C@@H](NC(=O)Nc1ccc(cc1)-c1ccncc1)c1ccccc1	WDTFYYZHMRBVHK-LJQANCHMSA-N, WDTFYYZHMRBVHK-LJQANCHMSA-N, WDTFYYZHMRBVHK-LJQANCHMSA-N, WDTFYYZHMRBVHK-LJQANCHMSA-N, WDTFYYZHMRBVHK-LJQANCHMSA-N	Preclinical
AS-1949490	SHIP2 phosphatase inhibitor	INPP5D			C[C@H](NC(=O)c1sccc1OCc1ccc(Cl)cc1)c1ccccc1, C[C@H](NC(=O)c1sccc1OCc1ccc(Cl)cc1)c1ccccc1, C[C@H](NC(=O)c1sccc1OCc1ccc(Cl)cc1)c1ccccc1, C[C@H](NC(=O)c1sccc1OCc1ccc(Cl)cc1)c1ccccc1	RFZPGNRLOKVZJY-AWEZNQCLSA-N, RFZPGNRLOKVZJY-AWEZNQCLSA-N, RFZPGNRLOKVZJY-AWEZNQCLSA-N, RFZPGNRLOKVZJY-AWEZNQCLSA-N	Preclinical
AS-2034178	free fatty acid receptor agonist	FFAR1			OC(=O)CCc1ccc(NCc2cccc3N(CCOc4ccccc4)CCCc23)cc1F, OC(=O)CCc1ccc(NCc2cccc3N(CCOc4ccccc4)CCCc23)cc1F, OC(=O)CCc1ccc(NCc2cccc3N(CCOc4ccccc4)CCCc23)cc1F	VENOXIKBBUVHRY-UHFFFAOYSA-N, VENOXIKBBUVHRY-UHFFFAOYSA-N, VENOXIKBBUVHRY-UHFFFAOYSA-N	Preclinical
AS-2444697	interleukin inhibitor	IRAK4			Cc1cc(ccn1)-c1nc(co1)C(=O)Nc1cn(nc1C(N)=O)C1CCOCC1, Cc1cc(ccn1)-c1nc(co1)C(=O)Nc1cn(nc1C(N)=O)C1CCOCC1, Cc1cc(ccn1)-c1nc(co1)C(=O)Nc1cn(nc1C(N)=O)C1CCOCC1, Cc1cc(ccn1)-c1nc(co1)C(=O)Nc1cn(nc1C(N)=O)C1CCOCC1, Cc1cc(ccn1)-c1nc(co1)C(=O)Nc1cn(nc1C(N)=O)C1CCOCC1	JANBIXNDYNRYQP-UHFFFAOYSA-N, JANBIXNDYNRYQP-UHFFFAOYSA-N, JANBIXNDYNRYQP-UHFFFAOYSA-N, JANBIXNDYNRYQP-UHFFFAOYSA-N, JANBIXNDYNRYQP-UHFFFAOYSA-N	Preclinical
AS-252424	PI3K inhibitor	PIK3CG			Oc1cc(F)ccc1-c1ccc(\C=C2/SC(=O)NC2=O)o1, Oc1cc(F)ccc1-c1ccc(\C=C2/SC(=O)NC2=O)o1, Oc1cc(F)ccc1-c1ccc(\C=C2/SC(=O)NC2=O)o1	OYYVWNDMOQPMGE-SDQBBNPISA-N, OYYVWNDMOQPMGE-SDQBBNPISA-N, OYYVWNDMOQPMGE-SDQBBNPISA-N	Preclinical
AS-604850	PI3K inhibitor	PIK3CA, PIK3CG			FC1(F)Oc2ccc(\C=C3/SC(=O)NC3=O)cc2O1	SRLVNYDXMUGOFI-YWEYNIOJSA-N	Preclinical
AS-703026	MEK inhibitor	MAP2K1, MAP2K2			OC[C@@H](O)CNC(=O)c1ccncc1Nc1ccc(I)cc1F, OC[C@@H](O)CNC(=O)c1ccncc1Nc1ccc(I)cc1F, OC[C@@H](O)CNC(=O)c1ccncc1Nc1ccc(I)cc1F, OC[C@@H](O)CNC(=O)c1ccncc1Nc1ccc(I)cc1F, OC[C@@H](O)CNC(=O)c1ccncc1Nc1ccc(I)cc1F, OC[C@@H](O)CNC(=O)c1ccncc1Nc1ccc(I)cc1F, OC[C@@H](O)CNC(=O)c1ccncc1Nc1ccc(I)cc1F	VIUAUNHCRHHYNE-JTQLQIEISA-N, VIUAUNHCRHHYNE-JTQLQIEISA-N, VIUAUNHCRHHYNE-JTQLQIEISA-N, VIUAUNHCRHHYNE-JTQLQIEISA-N, VIUAUNHCRHHYNE-JTQLQIEISA-N, VIUAUNHCRHHYNE-JTQLQIEISA-N, VIUAUNHCRHHYNE-JTQLQIEISA-N	Phase 2
AS-77	potassium channel blocker	KCNA3, KCNA5, KCNN4			O=c1ccc2c(OCCCCOc3ccccc3)c3ccoc3cc2o1, O=c1ccc2c(OCCCCOc3ccccc3)c3ccoc3cc2o1, O=c1ccc2c(OCCCCOc3ccccc3)c3ccoc3cc2o1	KINMYBBFQRSVLL-UHFFFAOYSA-N, KINMYBBFQRSVLL-UHFFFAOYSA-N, KINMYBBFQRSVLL-UHFFFAOYSA-N	Phase 1
ASA-404	angiogenesis inhibitor				Cc1ccc2c(oc3c(CC(O)=O)cccc3c2=O)c1C, Cc1ccc2c(oc3c(CC(O)=O)cccc3c2=O)c1C	XGOYIMQSIKSOBS-UHFFFAOYSA-N, XGOYIMQSIKSOBS-UHFFFAOYSA-N	Phase 3
asapiprant	prostaglandin inhibitor				CC(C)Oc1ccc(cc1)S(=O)(=O)N1CCN(CC1)c1ccc(-c2ncco2)c(OCC(O)=O)c1	ZMZNWNTZRWXTJU-UHFFFAOYSA-N	Preclinical
asaraldehyde	cyclooxygenase inhibitor	PTGS2			COc1cc(OC)c(C=O)cc1OC, COc1cc(OC)c(C=O)cc1OC	IAJBQAYHSQIQRE-UHFFFAOYSA-N, IAJBQAYHSQIQRE-UHFFFAOYSA-N	Preclinical
ASC-J9	androgen receptor enhancer	AR			COc1ccc(\C=C\C(O)=CC(=O)\C=C\c2ccc(OC)c(OC)c2)cc1OC, COc1ccc(\C=C\C(O)=CC(=O)\C=C\c2ccc(OC)c(OC)c2)cc1OC, COc1ccc(\C=C\C(O)=CC(=O)\C=C\c2ccc(OC)c(OC)c2)cc1OC, COc1ccc(\C=C\C(O)=CC(=O)\C=C\c2ccc(OC)c(OC)c2)cc1OC	ZMGUKFHHNQMKJI-URFDALOKSA-N, ZMGUKFHHNQMKJI-URFDALOKSA-N, ZMGUKFHHNQMKJI-URFDALOKSA-N, ZMGUKFHHNQMKJI-URFDALOKSA-N	Phase 2
asciminib	Bcr-Abl kinase inhibitor				O[C@@H]1CCN(C1)c1ncc(cc1-c1cc[nH]n1)C(=O)Nc1ccc(OC(F)(F)Cl)cc1	VOVZXURTCKPRDQ-CQSZACIVSA-N	Phase 2
ascomycin	calcineurin inhibitor	FKBP1A			CC[C@@H]1\C=C(C)\C[C@H](C)C[C@H](OC)[C@H]2O[C@](O)([C@H](C)C[C@@H]2OC)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@@H]([C@H](C)[C@@H](O)CC1=O)C(\C)=C\[C@@H]1CC[C@@H](O)[C@@H](C1)OC |c:3|	ZDQSOHOQTUFQEM-MONOPTSESA-N	Preclinical
ascorbic-acid	antioxidant	SLC23A1, SLC23A2	endocrinology	scurvy	OC[C@H](O)[C@H]1OC(=O)C(=O)[C@@H]1O |a:2,4,&1:10|, OC[C@H](O)[C@H]1OC(=O)C(=O)[C@@H]1O |a:2,4,&1:10|, OC[C@H](O)[C@H]1OC(=O)C(=O)[C@@H]1O |a:2,4,&1:10|, OC[C@H](O)[C@H]1OC(=O)C(=O)[C@@H]1O |a:2,4,&1:10|, OC[C@H](O)[C@H]1OC(=O)C(=O)[C@@H]1O |a:2,4,&1:10|, OC[C@H](O)[C@H]1OC(=O)C(=O)[C@@H]1O |a:2,4,&1:10|	KRGQEOSDQHTZMX-TXQLHFEISA-N, KRGQEOSDQHTZMX-TXQLHFEISA-N, KRGQEOSDQHTZMX-TXQLHFEISA-N, KRGQEOSDQHTZMX-TXQLHFEISA-N, KRGQEOSDQHTZMX-TXQLHFEISA-N, KRGQEOSDQHTZMX-TXQLHFEISA-N	Launched
asenapine	dopamine receptor antagonist, serotonin receptor antagonist	DRD2, HRH1, HTR1A, HTR1B, HTR1D, HTR1E, HTR2A	neurology/psychiatry	schizophrenia, bipolar disorder	[H][C@]12CN(C)C[C@]1([H])c1cc(Cl)ccc1Oc1ccccc21 |&1:1,6|, [H][C@]12CN(C)C[C@]1([H])c1cc(Cl)ccc1Oc1ccccc21 |&1:1,6|	VSWBSWWIRNCQIJ-HUUCEWRRSA-N, VSWBSWWIRNCQIJ-HUUCEWRRSA-N	Launched
asiatic-acid	apoptosis stimulant	PYGM			C[C@@H]1CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)C[C@@H](O)[C@H](O)[C@@](C)(CO)[C@@H]5CC[C@@]34C)[C@@H]2[C@H]1C)C(O)=O |c:9|, C[C@@H]1CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)C[C@@H](O)[C@H](O)[C@@](C)(CO)[C@@H]5CC[C@@]34C)[C@@H]2[C@H]1C)C(O)=O |c:9|, C[C@@H]1CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)C[C@@H](O)[C@H](O)[C@@](C)(CO)[C@@H]5CC[C@@]34C)[C@@H]2[C@H]1C)C(O)=O |c:9|, C[C@@H]1CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)C[C@@H](O)[C@H](O)[C@@](C)(CO)[C@@H]5CC[C@@]34C)[C@@H]2[C@H]1C)C(O)=O |c:9|, C[C@@H]1CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)C[C@@H](O)[C@H](O)[C@@](C)(CO)[C@@H]5CC[C@@]34C)[C@@H]2[C@H]1C)C(O)=O |c:9|, C[C@@H]1CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)C[C@@H](O)[C@H](O)[C@@](C)(CO)[C@@H]5CC[C@@]34C)[C@@H]2[C@H]1C)C(O)=O |c:9|, C[C@@H]1CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)C[C@@H](O)[C@H](O)[C@@](C)(CO)[C@@H]5CC[C@@]34C)[C@@H]2[C@H]1C)C(O)=O |c:9|, C[C@@H]1CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)C[C@@H](O)[C@H](O)[C@@](C)(CO)[C@@H]5CC[C@@]34C)[C@@H]2[C@H]1C)C(O)=O |c:9|	JXSVIVRDWWRQRT-UYDOISQJSA-N, JXSVIVRDWWRQRT-UYDOISQJSA-N, JXSVIVRDWWRQRT-UYDOISQJSA-N, JXSVIVRDWWRQRT-UYDOISQJSA-N, JXSVIVRDWWRQRT-UYDOISQJSA-N, JXSVIVRDWWRQRT-UYDOISQJSA-N, JXSVIVRDWWRQRT-UYDOISQJSA-N, JXSVIVRDWWRQRT-UYDOISQJSA-N	Preclinical
asimadoline	opioid receptor agonist	OPRK1			CN([C@H](CN1CC[C@H](O)C1)c1ccccc1)C(=O)C(c1ccccc1)c1ccccc1	JHLHNYVMZCADTC-LOSJGSFVSA-N	Phase 3
asivatrep	transient receptor potential channel antagonist				CCCc1nc(ccc1\C=C\C(=O)N[C@H](C)c1cc(F)c(NS(C)(=O)=O)c(F)c1)C(F)(F)F	UKGJZDSUJSPAJL-YPUOHESYSA-N	Phase 3
ASP-2535	glycine transporter inhibitor	SLC6A9			CC(C)c1nnc(-c2ccc(nc2)-c2ccccc2)n1-c1cccc2nonc12, CC(C)c1nnc(-c2ccc(nc2)-c2ccccc2)n1-c1cccc2nonc12	FQGLDGKVKDPVLO-UHFFFAOYSA-N, FQGLDGKVKDPVLO-UHFFFAOYSA-N	Phase 1
ASP-6537	cyclooxygenase inhibitor				COc1nc(-c2ccc(OC)cc2)n(n1)-c1ccc(OC)cc1	OBAICMYWONZOSZ-UHFFFAOYSA-N	Preclinical
ASP-9521	aldo-keto reductase inhibitor				COc1ccc2[nH]c(cc2c1)C(=O)N1CCC(CC(C)(C)O)CC1	OXSCPDKUZWPWFR-UHFFFAOYSA-N	Preclinical
aspartame		TAS1R2, TRPV1			COC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](N)CC(O)=O, COC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](N)CC(O)=O, COC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](N)CC(O)=O, COC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](N)CC(O)=O, COC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](N)CC(O)=O	IAOZJIPTCAWIRG-QWRGUYRKSA-N, IAOZJIPTCAWIRG-QWRGUYRKSA-N, IAOZJIPTCAWIRG-QWRGUYRKSA-N, IAOZJIPTCAWIRG-QWRGUYRKSA-N, IAOZJIPTCAWIRG-QWRGUYRKSA-N	Launched
aspirin	cyclooxygenase inhibitor	AKR1C1, ASIC3, EDNRA, HSPA5, IKBKB, NFKB1, NFKB2, NFKBIA, PRKAA1, PRKAA2, PRKAB1, PRKAB2, PRKAG1, PRKAG2, PRKAG3, PTGS1, PTGS2, RPS6KA3, TP53	neurology/psychiatry, endocrinology, dental	headache, fever, toothache, muscle pain	CC(=O)Oc1ccccc1C(O)=O, CC(=O)Oc1ccccc1C(O)=O, CC(=O)Oc1ccccc1C(O)=O, CC(=O)Oc1ccccc1C(O)=O, CC(=O)Oc1ccccc1C(O)=O	BSYNRYMUTXBXSQ-UHFFFAOYSA-N, BSYNRYMUTXBXSQ-UHFFFAOYSA-N, BSYNRYMUTXBXSQ-UHFFFAOYSA-N, BSYNRYMUTXBXSQ-UHFFFAOYSA-N, BSYNRYMUTXBXSQ-UHFFFAOYSA-N	Launched
ASP3026	ALK tyrosine kinase receptor inhibitor	ALK			COc1cc(ccc1Nc1ncnc(Nc2ccccc2S(=O)(=O)C(C)C)n1)N1CCC(CC1)N1CCN(C)CC1, COc1cc(ccc1Nc1ncnc(Nc2ccccc2S(=O)(=O)C(C)C)n1)N1CCC(CC1)N1CCN(C)CC1, COc1cc(ccc1Nc1ncnc(Nc2ccccc2S(=O)(=O)C(C)C)n1)N1CCC(CC1)N1CCN(C)CC1, COc1cc(ccc1Nc1ncnc(Nc2ccccc2S(=O)(=O)C(C)C)n1)N1CCC(CC1)N1CCN(C)CC1, COc1cc(ccc1Nc1ncnc(Nc2ccccc2S(=O)(=O)C(C)C)n1)N1CCC(CC1)N1CCN(C)CC1, COc1cc(ccc1Nc1ncnc(Nc2ccccc2S(=O)(=O)C(C)C)n1)N1CCC(CC1)N1CCN(C)CC1	MGGBYMDAPCCKCT-UHFFFAOYSA-N, MGGBYMDAPCCKCT-UHFFFAOYSA-N, MGGBYMDAPCCKCT-UHFFFAOYSA-N, MGGBYMDAPCCKCT-UHFFFAOYSA-N, MGGBYMDAPCCKCT-UHFFFAOYSA-N, MGGBYMDAPCCKCT-UHFFFAOYSA-N	Phase 1
AST-1306	EGFR inhibitor	EGFR, ERBB2			Fc1cccc(COc2ccc(Nc3ncnc4ccc(NC(=O)C=C)cc34)cc2Cl)c1, Fc1cccc(COc2ccc(Nc3ncnc4ccc(NC(=O)C=C)cc34)cc2Cl)c1, Fc1cccc(COc2ccc(Nc3ncnc4ccc(NC(=O)C=C)cc34)cc2Cl)c1, Fc1cccc(COc2ccc(Nc3ncnc4ccc(NC(=O)C=C)cc34)cc2Cl)c1	MVZGYPSXNDCANY-UHFFFAOYSA-N, MVZGYPSXNDCANY-UHFFFAOYSA-N, MVZGYPSXNDCANY-UHFFFAOYSA-N, MVZGYPSXNDCANY-UHFFFAOYSA-N	Phase 1
astaxanthin	antioxidant				C\C(\C=C\C=C(/C)\C=C\C1=C(C)C(=O)[C@@H](O)CC1(C)C)=C/C=C/C=C(\C)/C=C/C=C(\C)/C=C/C1=C(C)C(=O)[C@@H](O)CC1(C)C |c:9,34|	MQZIGYBFDRPAKN-UWFIBFSHSA-N	Launched
astemizole	histamine receptor antagonist	HRH1, KCNH1, KCNH2			COc1ccc(CCN2CCC(CC2)Nc2nc3ccccc3n2Cc2ccc(F)cc2)cc1, COc1ccc(CCN2CCC(CC2)Nc2nc3ccccc3n2Cc2ccc(F)cc2)cc1, COc1ccc(CCN2CCC(CC2)Nc2nc3ccccc3n2Cc2ccc(F)cc2)cc1, COc1ccc(CCN2CCC(CC2)Nc2nc3ccccc3n2Cc2ccc(F)cc2)cc1	GXDALQBWZGODGZ-UHFFFAOYSA-N, GXDALQBWZGODGZ-UHFFFAOYSA-N, GXDALQBWZGODGZ-UHFFFAOYSA-N, GXDALQBWZGODGZ-UHFFFAOYSA-N	Withdrawn
astilbin	nuclear factor erythroid derived, like (NRF2) activator				C[C@@H]1O[C@@H](O[C@@H]2[C@H](Oc3cc(O)cc(O)c3C2=O)c2ccc(O)c(O)c2)[C@H](O)[C@H](O)[C@H]1O	ZROGCCBNZBKLEL-MPRHSVQHSA-N	Preclinical
astragaloside-a	anti-inflammatory agent				CC(C)(O)[C@H]1CC[C@](C)(O1)[C@H]1[C@@H](O)C[C@@]2(C)[C@@H]3C[C@H](O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)[C@@H]4[C@]5(C[C@@]35CC[C@]12C)CC[C@H](O[C@@H]1OC[C@@H](O)[C@H](O)[C@H]1O)C4(C)C, CC(C)(O)[C@H]1CC[C@](C)(O1)[C@H]1[C@@H](O)C[C@@]2(C)[C@@H]3C[C@H](O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)[C@@H]4[C@]5(C[C@@]35CC[C@]12C)CC[C@H](O[C@@H]1OC[C@@H](O)[C@H](O)[C@H]1O)C4(C)C	QMNWISYXSJWHRY-AUJDEUPOSA-N, QMNWISYXSJWHRY-AUJDEUPOSA-N	Preclinical
ASTX660	apoptosis inhibitor				C[C@@H]1CN(CC(=O)N2CC(C)(C)c3nc(CO)c(Cc4ccc(F)cc4)cc23)[C@@H](CN2CCOC[C@H]2C)CN1	YCXOHEXZVKOGEV-DNRQZRRGSA-N	Phase 1/Phase 2
asunaprevir	HCV inhibitor				COc1cnc(O[C@@H]2C[C@H](N(C2)C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)C(=O)N[C@@]2(C[C@H]2C=C)C(=O)NS(=O)(=O)C2CC2)c2cc(Cl)ccc12, COc1cnc(O[C@@H]2C[C@H](N(C2)C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)C(=O)N[C@@]2(C[C@H]2C=C)C(=O)NS(=O)(=O)C2CC2)c2cc(Cl)ccc12, COc1cnc(O[C@@H]2C[C@H](N(C2)C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)C(=O)N[C@@]2(C[C@H]2C=C)C(=O)NS(=O)(=O)C2CC2)c2cc(Cl)ccc12, COc1cnc(O[C@@H]2C[C@H](N(C2)C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)C(=O)N[C@@]2(C[C@H]2C=C)C(=O)NS(=O)(=O)C2CC2)c2cc(Cl)ccc12, COc1cnc(O[C@@H]2C[C@H](N(C2)C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)C(=O)N[C@@]2(C[C@H]2C=C)C(=O)NS(=O)(=O)C2CC2)c2cc(Cl)ccc12, COc1cnc(O[C@@H]2C[C@H](N(C2)C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)C(=O)N[C@@]2(C[C@H]2C=C)C(=O)NS(=O)(=O)C2CC2)c2cc(Cl)ccc12	XRWSZZJLZRKHHD-WVWIJVSJSA-N, XRWSZZJLZRKHHD-WVWIJVSJSA-N, XRWSZZJLZRKHHD-WVWIJVSJSA-N, XRWSZZJLZRKHHD-WVWIJVSJSA-N, XRWSZZJLZRKHHD-WVWIJVSJSA-N, XRWSZZJLZRKHHD-WVWIJVSJSA-N	Phase 3
asymmetrical-dimethylarginine	nitric oxide synthase inhibitor	NOS2, NOS3			CN(C)C(=N)NCCC[C@H](N)C(O)=O, CN(C)C(=N)NCCC[C@H](N)C(O)=O	YDGMGEXADBMOMJ-LURJTMIESA-N, YDGMGEXADBMOMJ-LURJTMIESA-N	Phase 1
AT-1015	serotonin receptor antagonist	HTR2A			O=CN1CCC(CC1)C(=O)NCCN1CCC(CC1)=C1c2ccccc2C=Cc2ccccc12 |c:29|, O=CN1CCC(CC1)C(=O)NCCN1CCC(CC1)=C1c2ccccc2C=Cc2ccccc12 |c:29|	BSPMYKLEFGUTSI-UHFFFAOYSA-N, BSPMYKLEFGUTSI-UHFFFAOYSA-N	Preclinical
AT-406	IAP antagonist 				CN[C@@H](C)C(=O)N[C@H]1CN(CC[C@H]2CC[C@H](N2C1=O)C(=O)NC(c1ccccc1)c1ccccc1)C(=O)CC(C)C	LSXUTRRVVSPWDZ-MKKUMYSQSA-N	Phase 1
AT-7519	CDK inhibitor	CDK1, CDK2, CDK4, CDK5, CDK6, CDK9			Clc1cccc(Cl)c1C(=O)Nc1cn[nH]c1C(=O)NC1CCNCC1, Clc1cccc(Cl)c1C(=O)Nc1cn[nH]c1C(=O)NC1CCNCC1, Clc1cccc(Cl)c1C(=O)Nc1cn[nH]c1C(=O)NC1CCNCC1, Clc1cccc(Cl)c1C(=O)Nc1cn[nH]c1C(=O)NC1CCNCC1, Clc1cccc(Cl)c1C(=O)Nc1cn[nH]c1C(=O)NC1CCNCC1, Clc1cccc(Cl)c1C(=O)Nc1cn[nH]c1C(=O)NC1CCNCC1, Clc1cccc(Cl)c1C(=O)Nc1cn[nH]c1C(=O)NC1CCNCC1	OVPNQJVDAFNBDN-UHFFFAOYSA-N, OVPNQJVDAFNBDN-UHFFFAOYSA-N, OVPNQJVDAFNBDN-UHFFFAOYSA-N, OVPNQJVDAFNBDN-UHFFFAOYSA-N, OVPNQJVDAFNBDN-UHFFFAOYSA-N, OVPNQJVDAFNBDN-UHFFFAOYSA-N, OVPNQJVDAFNBDN-UHFFFAOYSA-N	Phase 2
AT-9283	Aurora kinase inhibitor, JAK inhibitor	AURKA, AURKB, JAK2, JAK3, RPS6KA6, STK17A			O=C(NC1CC1)Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1, O=C(NC1CC1)Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1, O=C(NC1CC1)Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1, O=C(NC1CC1)Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1, O=C(NC1CC1)Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1, O=C(NC1CC1)Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1, O=C(NC1CC1)Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1, O=C(NC1CC1)Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1	LOLPPWBBNUVNQZ-UHFFFAOYSA-N, LOLPPWBBNUVNQZ-UHFFFAOYSA-N, LOLPPWBBNUVNQZ-UHFFFAOYSA-N, LOLPPWBBNUVNQZ-UHFFFAOYSA-N, LOLPPWBBNUVNQZ-UHFFFAOYSA-N, InChI=1S/C19H23N7O2/c27-19(21-13-2-3-13)24-16-10-20-25-17(16)18-22-14-4-1-12(9-15(14)23-18)11-26-5-7-28-8-6-26/h1,4,9-10,13H,2-3,5-8,11H2,(H,20,25)(H,22,23)(H2,21,24,27), InChI=1S/C19H23N7O2/c27-19(21-13-2-3-13)24-16-10-20-25-17(16)18-22-14-4-1-12(9-15(14)23-18)11-26-5-7-28-8-6-26/h1,4,9-10,13H,2-3,5-8,11H2,(H,20,25)(H,22,23)(H2,21,24,27), InChI=1S/C19H23N7O2/c27-19(21-13-2-3-13)24-16-10-20-25-17(16)18-22-14-4-1-12(9-15(14)23-18)11-26-5-7-28-8-6-26/h1,4,9-10,13H,2-3,5-8,11H2,(H,20,25)(H,22,23)(H2,21,24,27)	Phase 2
ataluren	CFTR channel agonist, dystrophin stimulant	DMD	genetics, pulmonary	duchenne muscular dystrophy (DMD), cystic fibrosis	OC(=O)c1cccc(c1)-c1noc(n1)-c1ccccc1F, OC(=O)c1cccc(c1)-c1noc(n1)-c1ccccc1F	OOUGLTULBSNHNF-UHFFFAOYSA-N, OOUGLTULBSNHNF-UHFFFAOYSA-N	Launched
atazanavir	HIV protease inhibitor		infectious disease	human immunodeficiency virus (HIV-1)	COC(=O)N[C@H](C(=O)N[C@@H](Cc1ccccc1)[C@@H](O)CN(Cc1ccc(cc1)-c1ccccn1)NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)C(C)(C)C, COC(=O)N[C@H](C(=O)N[C@@H](Cc1ccccc1)[C@@H](O)CN(Cc1ccc(cc1)-c1ccccn1)NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)C(C)(C)C, COC(=O)N[C@H](C(=O)N[C@@H](Cc1ccccc1)[C@@H](O)CN(Cc1ccc(cc1)-c1ccccn1)NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)C(C)(C)C	AXRYRYVKAWYZBR-GASGPIRDSA-N, AXRYRYVKAWYZBR-GASGPIRDSA-N, AXRYRYVKAWYZBR-GASGPIRDSA-N	Launched
ATB-346	cyclooxygenase inhibitor	PTGER2			COc1ccc2cc(ccc2c1)[C@@H](C)C(=O)Oc1ccc(cc1)C(N)=S |&1:12,r|, COc1ccc2cc(ccc2c1)[C@@H](C)C(=O)Oc1ccc(cc1)C(N)=S |&1:12,r|	YCNMAPLPQYQJFC-CYBMUJFWSA-N, YCNMAPLPQYQJFC-CYBMUJFWSA-N	Phase 2
atenolol-(+)	adrenergic receptor antagonist				CC(C)NC[C@@H](O)COc1ccc(CC(N)=O)cc1	METKIMKYRPQLGS-GFCCVEGCSA-N	Preclinical
atenolol-(+/-)	adrenergic receptor antagonist	ADRB1, ADRB2, LTF, PLA2G2E	cardiology	hypertension, angina pectoris	CC(C)NC[C@@H](O)COc1ccc(CC(N)=O)cc1 |&1:5,r|, CC(C)NC[C@@H](O)COc1ccc(CC(N)=O)cc1 |&1:5,r|, CC(C)NC[C@@H](O)COc1ccc(CC(N)=O)cc1 |&1:5,r|	METKIMKYRPQLGS-GFCCVEGCSA-N, METKIMKYRPQLGS-GFCCVEGCSA-N, METKIMKYRPQLGS-GFCCVEGCSA-N	Launched
atenolol-(-)	adrenergic receptor antagonist		cardiology	hypertension	CC(C)NC[C@H](O)COc1ccc(CC(N)=O)cc1, CC(C)NC[C@H](O)COc1ccc(CC(N)=O)cc1, CC(C)NC[C@H](O)COc1ccc(CC(N)=O)cc1	METKIMKYRPQLGS-LBPRGKRZSA-N, METKIMKYRPQLGS-LBPRGKRZSA-N, METKIMKYRPQLGS-LBPRGKRZSA-N	Launched
atglistatin	adipose triglyceride lipase inhibitor				CN(C)C(=O)Nc1cccc(c1)-c1ccc(cc1)N(C)C, CN(C)C(=O)Nc1cccc(c1)-c1ccc(cc1)N(C)C, CN(C)C(=O)Nc1cccc(c1)-c1ccc(cc1)N(C)C, CN(C)C(=O)Nc1cccc(c1)-c1ccc(cc1)N(C)C	AWOPBSAJHCUSAS-UHFFFAOYSA-N, AWOPBSAJHCUSAS-UHFFFAOYSA-N, AWOPBSAJHCUSAS-UHFFFAOYSA-N, AWOPBSAJHCUSAS-UHFFFAOYSA-N	Preclinical
aticaprant	opioid receptor antagonist				Cc1cc(C)cc(c1)[C@@H]1CCCN1Cc1ccc(Oc2ccc(cc2F)C(N)=O)cc1	ZHPMYDSXGRRERG-DEOSSOPVSA-N	Phase 2
atipamezole	adrenergic receptor antagonist		neurology/psychiatry	reverse sedative	CCC1(Cc2ccccc2C1)c1cnc[nH]1, CCC1(Cc2ccccc2C1)c1cnc[nH]1, CCC1(Cc2ccccc2C1)c1cnc[nH]1, CCC1(Cc2ccccc2C1)c1cnc[nH]1, CCC1(Cc2ccccc2C1)c1cnc[nH]1	HSWPZIDYAHLZDD-UHFFFAOYSA-N, HSWPZIDYAHLZDD-UHFFFAOYSA-N, HSWPZIDYAHLZDD-UHFFFAOYSA-N, HSWPZIDYAHLZDD-UHFFFAOYSA-N, HSWPZIDYAHLZDD-UHFFFAOYSA-N	Launched
atiprimod	JAK inhibitor, STAT inhibitor	JAK2, STAT3			CCCC1(CCC)CCC2(CCN(CCCN(CC)CC)C2)CC1, CCCC1(CCC)CCC2(CCN(CCCN(CC)CC)C2)CC1, CCCC1(CCC)CCC2(CCN(CCCN(CC)CC)C2)CC1, CCCC1(CCC)CCC2(CCN(CCCN(CC)CC)C2)CC1, CCCC1(CCC)CCC2(CCN(CCCN(CC)CC)C2)CC1, CCCC1(CCC)CCC2(CCN(CCCN(CC)CC)C2)CC1, CCCC1(CCC)CCC2(CCN(CCCN(CC)CC)C2)CC1	SERHTTSLBVGRBY-UHFFFAOYSA-N, SERHTTSLBVGRBY-UHFFFAOYSA-N, SERHTTSLBVGRBY-UHFFFAOYSA-N, SERHTTSLBVGRBY-UHFFFAOYSA-N, SERHTTSLBVGRBY-UHFFFAOYSA-N, SERHTTSLBVGRBY-UHFFFAOYSA-N, SERHTTSLBVGRBY-UHFFFAOYSA-N	Phase 2
atizoram	phosphodiesterase inhibitor	PDE4A, PDE4B, PDE4C, PDE4D			COc1ccc(cc1O[C@H]1C[C@@H]2CC[C@H]1C2)C1CNC(=O)NC1, COc1ccc(cc1O[C@H]1C[C@@H]2CC[C@H]1C2)C1CNC(=O)NC1	LITNEAPWQHVPOK-FFSVYQOJSA-N, LITNEAPWQHVPOK-FFSVYQOJSA-N	Phase 2
ATN-161	integrin antagonist	ITGA5, ITGAV, ITGB1, ITGB3			CC(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(N)=O, CC(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(N)=O, CC(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(N)=O, CC(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(N)=O, CC(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(N)=O	MMHDBUJXLOFTLC-WOYTXXSLSA-N, MMHDBUJXLOFTLC-WOYTXXSLSA-N, MMHDBUJXLOFTLC-WOYTXXSLSA-N, MMHDBUJXLOFTLC-WOYTXXSLSA-N, MMHDBUJXLOFTLC-WOYTXXSLSA-N	Phase 2
atomoxetine	norepinephrine transporter inhibitor	GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D, GRIN3A, GRIN3B, SLC6A2, SLC6A3, SLC6A4	neurology/psychiatry	attention-deficit/hyperactivity disorder (ADHD)	CNCC[C@@H](Oc1ccccc1C)c1ccccc1, CNCC[C@@H](Oc1ccccc1C)c1ccccc1, CNCC[C@@H](Oc1ccccc1C)c1ccccc1, CNCC[C@@H](Oc1ccccc1C)c1ccccc1	VHGCDTVCOLNTBX-QGZVFWFLSA-N, VHGCDTVCOLNTBX-QGZVFWFLSA-N, VHGCDTVCOLNTBX-QGZVFWFLSA-N, VHGCDTVCOLNTBX-QGZVFWFLSA-N	Launched
atorvastatin	HMGCR inhibitor	AHR, DPP4, HMGCR	neurology/psychiatry, cardiology	stroke, heart attack	CC(C)c1c(C(=O)Nc2ccccc2)c(c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(O)=O)-c1ccccc1, CC(C)c1c(C(=O)Nc2ccccc2)c(c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(O)=O)-c1ccccc1, CC(C)c1c(C(=O)Nc2ccccc2)c(c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(O)=O)-c1ccccc1, CC(C)c1c(C(=O)Nc2ccccc2)c(c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(O)=O)-c1ccccc1, CC(C)c1c(C(=O)Nc2ccccc2)c(c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(O)=O)-c1ccccc1, CC(C)c1c(C(=O)Nc2ccccc2)c(c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(O)=O)-c1ccccc1, CC(C)c1c(C(=O)Nc2ccccc2)c(c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(O)=O)-c1ccccc1, CC(C)c1c(C(=O)Nc2ccccc2)c(c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(O)=O)-c1ccccc1, CC(C)c1c(C(=O)Nc2ccccc2)c(c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(O)=O)-c1ccccc1, CC(C)c1c(C(=O)Nc2ccccc2)c(c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(O)=O)-c1ccccc1, CC(C)c1c(C(=O)Nc2ccccc2)c(c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(O)=O)-c1ccccc1	XUKUURHRXDUEBC-KAYWLYCHSA-N, XUKUURHRXDUEBC-KAYWLYCHSA-N, XUKUURHRXDUEBC-KAYWLYCHSA-N, XUKUURHRXDUEBC-KAYWLYCHSA-N, XUKUURHRXDUEBC-KAYWLYCHSA-N, XUKUURHRXDUEBC-KAYWLYCHSA-N, XUKUURHRXDUEBC-KAYWLYCHSA-N, XUKUURHRXDUEBC-KAYWLYCHSA-N, XUKUURHRXDUEBC-KAYWLYCHSA-N, XUKUURHRXDUEBC-KAYWLYCHSA-N, XUKUURHRXDUEBC-KAYWLYCHSA-N	Launched
atosiban	oxytocin receptor antagonist	AVPR1A, AVPR1B, AVPR2, OXTR	neurology/psychiatry, cardiology, endocrinology	stroke, angina pectoris, myocardial infarction, hyperlipidemia	CCOc1ccc(C[C@H]2NC(=O)CCSSC[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](NC2=O)[C@@H](C)CC)[C@@H](C)O)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CCCN)C(=O)NCC(N)=O)cc1 |a:8,17,21,33,37,41,50,54,&1:29|, CCOc1ccc(C[C@H]2NC(=O)CCSSC[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](NC2=O)[C@@H](C)CC)[C@@H](C)O)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CCCN)C(=O)NCC(N)=O)cc1 |a:8,17,21,33,37,41,50,54,&1:29|, CCOc1ccc(C[C@H]2NC(=O)CCSSC[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](NC2=O)[C@@H](C)CC)[C@@H](C)O)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CCCN)C(=O)NCC(N)=O)cc1 |a:8,17,21,33,37,41,50,54,&1:29|, CCOc1ccc(C[C@H]2NC(=O)CCSSC[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](NC2=O)[C@@H](C)CC)[C@@H](C)O)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CCCN)C(=O)NCC(N)=O)cc1 |a:8,17,21,33,37,41,50,54,&1:29|	VWXRQYYUEIYXCZ-ZJBFWUDNSA-N, VWXRQYYUEIYXCZ-ZJBFWUDNSA-N, VWXRQYYUEIYXCZ-ZJBFWUDNSA-N, VWXRQYYUEIYXCZ-ZJBFWUDNSA-N	Launched
atovaquone	mitochondrial electron transport inhibitor		infectious disease	pneumonia	Clc1ccc(cc1)[C@H]1CC[C@@H](CC1)[C@H]1C(=O)C(=O)c2ccccc2C1=O |a:7,10,&1:13,wU:7.7,wD:10.14,13.15,(-11.75,6.01,;-10.68,5.39,;-10.68,3.85,;-9.35,3.08,;-8.02,3.85,;-8.01,5.39,;-9.35,6.16,;-6.68,3.08,;-5.35,3.85,;-4.01,3.08,;-4.01,1.54,;-5.35,.77,;-6.68,1.54,;-2.68,.77,;-2.68,-.77,;-3.75,-1.39,;-1.33,-1.54,;-1.33,-2.77,;,-.77,;1.33,-1.54,;2.66,-.77,;2.66,.77,;1.33,1.54,;,.77,;-1.33,1.54,;-1.33,2.77,)|, Clc1ccc(cc1)[C@H]1CC[C@@H](CC1)[C@H]1C(=O)C(=O)c2ccccc2C1=O |a:7,10,&1:13,wU:7.7,wD:10.14,13.15,(-11.75,6.01,;-10.68,5.39,;-10.68,3.85,;-9.35,3.08,;-8.02,3.85,;-8.01,5.39,;-9.35,6.16,;-6.68,3.08,;-5.35,3.85,;-4.01,3.08,;-4.01,1.54,;-5.35,.77,;-6.68,1.54,;-2.68,.77,;-2.68,-.77,;-3.75,-1.39,;-1.33,-1.54,;-1.33,-2.77,;,-.77,;1.33,-1.54,;2.66,-.77,;2.66,.77,;1.33,1.54,;,.77,;-1.33,1.54,;-1.33,2.77,)|	UYFLKEIEOREOFC-ZXYWRSMDSA-N, UYFLKEIEOREOFC-ZXYWRSMDSA-N	Launched
ATPA	glutamate receptor agonist	GRIK1			CC(C)(C)c1o[nH]c(=O)c1C[C@@H](N)C(O)=O |&1:11,r|, CC(C)(C)c1o[nH]c(=O)c1C[C@@H](N)C(O)=O |&1:11,r|, CC(C)(C)c1o[nH]c(=O)c1C[C@@H](N)C(O)=O |&1:11,r|, CC(C)(C)c1o[nH]c(=O)c1C[C@@H](N)C(O)=O |&1:11,r|, CC(C)(C)c1o[nH]c(=O)c1C[C@@H](N)C(O)=O |&1:11,r|	PIXJURSCCVBKRF-ZCFIWIBFSA-N, PIXJURSCCVBKRF-ZCFIWIBFSA-N, PIXJURSCCVBKRF-ZCFIWIBFSA-N, PIXJURSCCVBKRF-ZCFIWIBFSA-N, PIXJURSCCVBKRF-ZCFIWIBFSA-N	Preclinical
atractylenolide-i	JAK inhibitor				[H][C@@]12CC3=C(C)C(=O)OC3=C[C@@]1(C)CCCC2=C |c:3,10|	ZTVSGQPHMUYCRS-SWLSCSKDSA-N	Preclinical
atracurium	acetylcholine receptor antagonist		critical care, neurology/psychiatry	endotracheal intubation, muscle relaxant	COc1ccc(C[C@H]2c3cc(OC)c(OC)cc3CC[N@@+]2(C)CCC(=O)OCCCCCOC(=O)CC[N@@+]2(C)CCc3cc(OC)c(OC)cc3[C@@H]2Cc2ccc(OC)c(OC)c2)cc1OC |&1:7,&2:20,&3:37,&4:51|	YXSLJKQTIDHPOT-MWAPPURBSA-N	Launched
atrasentan	endothelin receptor antagonist	EDNRA			CCCCN(CCCC)C(=O)CN1C[C@@H]([C@H]([C@@H]1c1ccc(OC)cc1)C(O)=O)c1ccc2OCOc2c1, CCCCN(CCCC)C(=O)CN1C[C@@H]([C@H]([C@@H]1c1ccc(OC)cc1)C(O)=O)c1ccc2OCOc2c1, CCCCN(CCCC)C(=O)CN1C[C@@H]([C@H]([C@@H]1c1ccc(OC)cc1)C(O)=O)c1ccc2OCOc2c1, CCCCN(CCCC)C(=O)CN1C[C@@H]([C@H]([C@@H]1c1ccc(OC)cc1)C(O)=O)c1ccc2OCOc2c1	MOTJMGVDPWRKOC-QPVYNBJUSA-N, MOTJMGVDPWRKOC-QPVYNBJUSA-N, MOTJMGVDPWRKOC-QPVYNBJUSA-N, MOTJMGVDPWRKOC-QPVYNBJUSA-N	Phase 3
atropine	acetylcholine receptor antagonist	CHRM1, CHRM2, CHRM3	ophthalmology	cycloplegia, mydriasis, amblyopia	CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)[C@@H](CO)c1ccccc1 |a:2,5,7,&1:12,THB:9:7:1:3.4|, CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)[C@@H](CO)c1ccccc1 |a:2,5,7,&1:12,THB:9:7:1:3.4|, CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)[C@@H](CO)c1ccccc1 |a:2,5,7,&1:12,THB:9:7:1:3.4|	RKUNBYITZUJHSG-JJXSEGSLSA-N, RKUNBYITZUJHSG-JJXSEGSLSA-N, RKUNBYITZUJHSG-JJXSEGSLSA-N	Launched
atropine-oxide	acetylcholine receptor antagonist	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5			C[N@@+]1([O-])[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)[C@H](CO)c1ccccc1 |&1:3,6,8,&2:1,&3:13|	HGWPFSBHDACWNL-JFBPSJKJSA-N	Preclinical
atuveciclib	CDK9 inhibitor				COc1cc(F)ccc1-c1ncnc(Nc2cccc(C[S@](C)(=N)=O)c2)n1	ACWKGTGIJRCOOM-HHHXNRCGSA-N	Phase 1
AT13148	protein kinase inhibitor	AKT1, AKT2, AKT3, ROCK1, ROCK2, SGK3			NC[C@@](O)(c1ccc(Cl)cc1)c1ccc(cc1)-c1cn[nH]c1, NC[C@@](O)(c1ccc(Cl)cc1)c1ccc(cc1)-c1cn[nH]c1, NC[C@@](O)(c1ccc(Cl)cc1)c1ccc(cc1)-c1cn[nH]c1, NC[C@@](O)(c1ccc(Cl)cc1)c1ccc(cc1)-c1cn[nH]c1, NC[C@@](O)(c1ccc(Cl)cc1)c1ccc(cc1)-c1cn[nH]c1	IIRWNGPLJQXWFJ-KRWDZBQOSA-N, IIRWNGPLJQXWFJ-KRWDZBQOSA-N, IIRWNGPLJQXWFJ-KRWDZBQOSA-N, IIRWNGPLJQXWFJ-KRWDZBQOSA-N, IIRWNGPLJQXWFJ-KRWDZBQOSA-N	Phase 1
AT13387	HSP inhibitor	HSP90AA1			CC(C)c1cc(C(=O)N2Cc3ccc(CN4CCN(C)CC4)cc3C2)c(O)cc1O, CC(C)c1cc(C(=O)N2Cc3ccc(CN4CCN(C)CC4)cc3C2)c(O)cc1O, CC(C)c1cc(C(=O)N2Cc3ccc(CN4CCN(C)CC4)cc3C2)c(O)cc1O, CC(C)c1cc(C(=O)N2Cc3ccc(CN4CCN(C)CC4)cc3C2)c(O)cc1O, CC(C)c1cc(C(=O)N2Cc3ccc(CN4CCN(C)CC4)cc3C2)c(O)cc1O, CC(C)c1cc(C(=O)N2Cc3ccc(CN4CCN(C)CC4)cc3C2)c(O)cc1O	IFRGXKKQHBVPCQ-UHFFFAOYSA-N, IFRGXKKQHBVPCQ-UHFFFAOYSA-N, IFRGXKKQHBVPCQ-UHFFFAOYSA-N, IFRGXKKQHBVPCQ-UHFFFAOYSA-N, IFRGXKKQHBVPCQ-UHFFFAOYSA-N, IFRGXKKQHBVPCQ-UHFFFAOYSA-N	Phase 2
AT7867	AKT inhibitor	AKT2, GSK3B, PKIA, PRKACA			Clc1ccc(cc1)C1(CCNCC1)c1ccc(cc1)-c1cn[nH]c1, Clc1ccc(cc1)C1(CCNCC1)c1ccc(cc1)-c1cn[nH]c1, Clc1ccc(cc1)C1(CCNCC1)c1ccc(cc1)-c1cn[nH]c1, Clc1ccc(cc1)C1(CCNCC1)c1ccc(cc1)-c1cn[nH]c1, Clc1ccc(cc1)C1(CCNCC1)c1ccc(cc1)-c1cn[nH]c1, Clc1ccc(cc1)C1(CCNCC1)c1ccc(cc1)-c1cn[nH]c1, Clc1ccc(cc1)C1(CCNCC1)c1ccc(cc1)-c1cn[nH]c1, Clc1ccc(cc1)C1(CCNCC1)c1ccc(cc1)-c1cn[nH]c1	LZMOSYUFVYJEPY-UHFFFAOYSA-N, LZMOSYUFVYJEPY-UHFFFAOYSA-N, LZMOSYUFVYJEPY-UHFFFAOYSA-N, LZMOSYUFVYJEPY-UHFFFAOYSA-N, LZMOSYUFVYJEPY-UHFFFAOYSA-N, LZMOSYUFVYJEPY-UHFFFAOYSA-N, LZMOSYUFVYJEPY-UHFFFAOYSA-N, LZMOSYUFVYJEPY-UHFFFAOYSA-N	Preclinical
auranofin	NFkB pathway inhibitor	IKBKB, PRDX5, TRPA1	rheumatology	rheumatoid arthritis	CCP(CC)(CC)=[Au]S[C@@H]1O[C@H](COC(C)=O)[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H]1OC(C)=O, CCP(CC)(CC)=[Au]S[C@@H]1O[C@H](COC(C)=O)[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H]1OC(C)=O, CCP(CC)(CC)=[Au]S[C@@H]1O[C@H](COC(C)=O)[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H]1OC(C)=O, CCP(CC)(CC)=[Au]S[C@@H]1O[C@H](COC(C)=O)[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H]1OC(C)=O	AUJRCFUBUPVWSZ-XTZHGVARSA-M, AUJRCFUBUPVWSZ-XTZHGVARSA-M, AUJRCFUBUPVWSZ-XTZHGVARSA-M, AUJRCFUBUPVWSZ-XTZHGVARSA-M	Launched
aurora-a-inhibitor-i	Aurora kinase inhibitor	AURKA			CCN1CCN(CC1)C(=O)Cc1ccc(Nc2ncc(F)c(Nc3ccc(cc3)C(=O)Nc3ccccc3Cl)n2)cc1, CCN1CCN(CC1)C(=O)Cc1ccc(Nc2ncc(F)c(Nc3ccc(cc3)C(=O)Nc3ccccc3Cl)n2)cc1, CCN1CCN(CC1)C(=O)Cc1ccc(Nc2ncc(F)c(Nc3ccc(cc3)C(=O)Nc3ccccc3Cl)n2)cc1, CCN1CCN(CC1)C(=O)Cc1ccc(Nc2ncc(F)c(Nc3ccc(cc3)C(=O)Nc3ccccc3Cl)n2)cc1, CCN1CCN(CC1)C(=O)Cc1ccc(Nc2ncc(F)c(Nc3ccc(cc3)C(=O)Nc3ccccc3Cl)n2)cc1	AKSIZPIFQAYJGF-UHFFFAOYSA-N, AKSIZPIFQAYJGF-UHFFFAOYSA-N, AKSIZPIFQAYJGF-UHFFFAOYSA-N, AKSIZPIFQAYJGF-UHFFFAOYSA-N, AKSIZPIFQAYJGF-UHFFFAOYSA-N	Preclinical
aurothioglucose	PKC inhibitor	PRKCI	rheumatology	rheumatoid arthritis	OC[C@H]1O[C@H](S[Au])[C@H](O)[C@@H](O)[C@@H]1O, OC[C@H]1O[C@H](S[Au])[C@H](O)[C@@H](O)[C@@H]1O	XHVAWZZCDCWGBK-WYRLRVFGSA-M, XHVAWZZCDCWGBK-WYRLRVFGSA-M	Launched
AUT-1	potassium channel activator				CC[C@H]1NC(=O)N(C1=O)c1ccc(Oc2ccc(C)c(OC)c2)nc1	AMAOXEGBJHLCSF-CQSZACIVSA-N	Preclinical
autotaxin-modulator-1	autotaxin inhibitor	ENPP2			C[C@@H](N1[C@H]2CC[C@@H]1C[C@@H](C2)C(O)=O)c1ccc2ccc(O[C@H]3CC[C@H](CC3)C(F)(F)F)c(c2c1)C(F)(F)F |a:1,21,24,&1:3,&2:6,&3:8,wU:8.11,21.22,24.29,wD:1.0,3.2,6.6,(6.23,2.09,;5.61,1.02,;4.07,1.02,;3.25,-.38,;2.26,.16,;2.26,1.96,;3.29,2.4,;1.65,2.4,;.83,1.02,;1.62,-.38,;-.71,1.02,;-1.33,2.09,;-1.33,-.04,;6.38,-.31,;5.62,-1.65,;6.4,-2.98,;7.94,-2.98,;8.71,-4.31,;10.25,-4.31,;11.01,-2.97,;12.56,-2.97,;13.33,-4.31,;14.87,-4.31,;15.64,-5.64,;14.86,-6.98,;13.32,-6.97,;12.56,-5.64,;15.63,-8.31,;16.86,-8.31,;15.02,-9.38,;16.25,-9.38,;10.24,-1.64,;8.71,-1.65,;7.94,-.32,;11.01,-.31,;12.24,-.3,;10.39,.76,;11.62,.76,)|, C[C@@H](N1[C@H]2CC[C@@H]1C[C@@H](C2)C(O)=O)c1ccc2ccc(O[C@H]3CC[C@H](CC3)C(F)(F)F)c(c2c1)C(F)(F)F |a:1,21,24,&1:3,&2:6,&3:8,wU:8.11,21.22,24.29,wD:1.0,3.2,6.6,(6.23,2.09,;5.61,1.02,;4.07,1.02,;3.25,-.38,;2.26,.16,;2.26,1.96,;3.29,2.4,;1.65,2.4,;.83,1.02,;1.62,-.38,;-.71,1.02,;-1.33,2.09,;-1.33,-.04,;6.38,-.31,;5.62,-1.65,;6.4,-2.98,;7.94,-2.98,;8.71,-4.31,;10.25,-4.31,;11.01,-2.97,;12.56,-2.97,;13.33,-4.31,;14.87,-4.31,;15.64,-5.64,;14.86,-6.98,;13.32,-6.97,;12.56,-5.64,;15.63,-8.31,;16.86,-8.31,;15.02,-9.38,;16.25,-9.38,;10.24,-1.64,;8.71,-1.65,;7.94,-.32,;11.01,-.31,;12.24,-.3,;10.39,.76,;11.62,.76,)|	PZASAAIJIFDWSB-PQGZPOPSSA-N, PZASAAIJIFDWSB-PQGZPOPSSA-N	Preclinical
AV-412	protein tyrosine kinase inhibitor	EGFR, ERBB2			CN1CCN(CC1)C(C)(C)C#Cc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)C=C, CN1CCN(CC1)C(C)(C)C#Cc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)C=C, CN1CCN(CC1)C(C)(C)C#Cc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)C=C	ZAJXXUDARPGGOC-UHFFFAOYSA-N, ZAJXXUDARPGGOC-UHFFFAOYSA-N, ZAJXXUDARPGGOC-UHFFFAOYSA-N	Phase 1
AV-608	tachykinin antagonist	TACR1			FC(F)(F)c1cc(cc(c1)C(F)(F)F)C(=O)N1CC[C@@H](C[C@H]1Cc1ccc(Cl)cc1)NC(=O)c1ccnc2ccccc12, FC(F)(F)c1cc(cc(c1)C(F)(F)F)C(=O)N1CC[C@@H](C[C@H]1Cc1ccc(Cl)cc1)NC(=O)c1ccnc2ccccc12	NXLUTEDAEFXMQR-BJKOFHAPSA-N, NXLUTEDAEFXMQR-BJKOFHAPSA-N	Phase 2
avacopan	complement inhibitor				Cc1ccc(NC(=O)[C@H]2CCCN([C@H]2c2ccc(NC3CCCC3)cc2)C(=O)c2c(C)cccc2F)cc1C(F)(F)F	PUKBOVABABRILL-YZNIXAGQSA-N	Phase 2
avadomide	antitumor agent				Cc1nc2cccc(N)c2c(=O)n1[C@H]1CCC(=O)NC1=O |&1:13,r|	RSNPAKAFCAAMBH-JTQLQIEISA-N	Phase 2
avagacestat	gamma secretase inhibitor	PSEN1			NC(=O)[C@@H](CCC(F)(F)F)N(Cc1ccc(cc1F)-c1ncon1)S(=O)(=O)c1ccc(Cl)cc1, NC(=O)[C@@H](CCC(F)(F)F)N(Cc1ccc(cc1F)-c1ncon1)S(=O)(=O)c1ccc(Cl)cc1, NC(=O)[C@@H](CCC(F)(F)F)N(Cc1ccc(cc1F)-c1ncon1)S(=O)(=O)c1ccc(Cl)cc1, NC(=O)[C@@H](CCC(F)(F)F)N(Cc1ccc(cc1F)-c1ncon1)S(=O)(=O)c1ccc(Cl)cc1	XEAOPVUAMONVLA-QGZVFWFLSA-N, XEAOPVUAMONVLA-QGZVFWFLSA-N, XEAOPVUAMONVLA-QGZVFWFLSA-N, XEAOPVUAMONVLA-QGZVFWFLSA-N	Phase 2
avanafil	phosphodiesterase inhibitor	PDE5A	urology	erectile dysfunction	COc1ccc(CNc2nc(ncc2C(=O)NCc2ncccn2)N2CCC[C@H]2CO)cc1Cl, COc1ccc(CNc2nc(ncc2C(=O)NCc2ncccn2)N2CCC[C@H]2CO)cc1Cl, COc1ccc(CNc2nc(ncc2C(=O)NCc2ncccn2)N2CCC[C@H]2CO)cc1Cl, COc1ccc(CNc2nc(ncc2C(=O)NCc2ncccn2)N2CCC[C@H]2CO)cc1Cl	WEAJZXNPAWBCOA-INIZCTEOSA-N, WEAJZXNPAWBCOA-INIZCTEOSA-N, WEAJZXNPAWBCOA-INIZCTEOSA-N, WEAJZXNPAWBCOA-INIZCTEOSA-N	Launched
avapritinib	KIT inhibitor				Cn1cc(cn1)-c1cc2c(ncnn2c1)N1CCN(CC1)c1ncc(cn1)[C@@](C)(N)c1ccc(F)cc1	DWYRIWUZIJHQKQ-SANMLTNESA-N	Launched
avasimibe	ACAT inhibitor	CES1			CC(C)c1cc(C(C)C)c(CC(=O)NS(=O)(=O)Oc2c(cccc2C(C)C)C(C)C)c(c1)C(C)C, CC(C)c1cc(C(C)C)c(CC(=O)NS(=O)(=O)Oc2c(cccc2C(C)C)C(C)C)c(c1)C(C)C, CC(C)c1cc(C(C)C)c(CC(=O)NS(=O)(=O)Oc2c(cccc2C(C)C)C(C)C)c(c1)C(C)C, CC(C)c1cc(C(C)C)c(CC(=O)NS(=O)(=O)Oc2c(cccc2C(C)C)C(C)C)c(c1)C(C)C, CC(C)c1cc(C(C)C)c(CC(=O)NS(=O)(=O)Oc2c(cccc2C(C)C)C(C)C)c(c1)C(C)C, CC(C)c1cc(C(C)C)c(CC(=O)NS(=O)(=O)Oc2c(cccc2C(C)C)C(C)C)c(c1)C(C)C	PTQXTEKSNBVPQJ-UHFFFAOYSA-N, PTQXTEKSNBVPQJ-UHFFFAOYSA-N, PTQXTEKSNBVPQJ-UHFFFAOYSA-N, PTQXTEKSNBVPQJ-UHFFFAOYSA-N, PTQXTEKSNBVPQJ-UHFFFAOYSA-N, PTQXTEKSNBVPQJ-UHFFFAOYSA-N	Phase 3
avatrombopag	thrombopoietin receptor agonist	MPL	hematology	thrombocytopenia	OC(=O)C1CCN(CC1)c1ncc(cc1Cl)C(=O)Nc1nc(-c2cc(Cl)cs2)c(s1)N1CCN(CC1)C1CCCCC1	OFZJKCQENFPZBH-UHFFFAOYSA-N	Launched
AVE-0991	angiotensin receptor agonist	MRGPRX1			CCNC(=O)NS(=O)(=O)c1sc(CC(C)C)cc1-c1ccc(Cn2c(C=O)c(OC)nc2-c2ccccc2)cc1, CCNC(=O)NS(=O)(=O)c1sc(CC(C)C)cc1-c1ccc(Cn2c(C=O)c(OC)nc2-c2ccccc2)cc1	QTOZBSNPDCWHPV-UHFFFAOYSA-N, QTOZBSNPDCWHPV-UHFFFAOYSA-N	Preclinical
AVE-3085	nitric oxide synthase stimulant				FC1(F)Oc2ccc(cc2O1)C(=O)NC1Cc2ccccc2C1	OKCJNSDIVCXYAL-UHFFFAOYSA-N	Preclinical
AVex-73	sigma receptor agonist				CN(C)C[C@H]1CCOC1(c1ccccc1)c1ccccc1 |&1:4,r|	BOTHKNZTGGXFEQ-GOSISDBHSA-N	Preclinical
avibactam	beta lactamase inhibitor		infectious disease	intra-abdominal infections, urinary tract infections, pyelonephritis	NC(=O)[C@@H]1CC[C@@H]2CN1C(=O)N2OS(O)(=O)=O, NC(=O)[C@@H]1CC[C@@H]2CN1C(=O)N2OS(O)(=O)=O, NC(=O)[C@@H]1CC[C@@H]2CN1C(=O)N2OS(O)(=O)=O	NDCUAPJVLWFHHB-UHNVWZDZSA-N, NDCUAPJVLWFHHB-UHNVWZDZSA-N, NDCUAPJVLWFHHB-UHNVWZDZSA-N	Launched
avitinib	EGFR inhibitor				CN1CCN(CC1)c1ccc(Nc2nc(Oc3cccc(NC(=O)C=C)c3)c3cc[nH]c3n2)cc1F	UOFYSRZSLXWIQB-UHFFFAOYSA-N	Phase 2
AVL-292	Bruton's tyrosine kinase (BTK) inhibitor	BTK, YES1			COCCOc1ccc(Nc2ncc(F)c(Nc3cccc(NC(=O)C=C)c3)n2)cc1, COCCOc1ccc(Nc2ncc(F)c(Nc3cccc(NC(=O)C=C)c3)n2)cc1, COCCOc1ccc(Nc2ncc(F)c(Nc3cccc(NC(=O)C=C)c3)n2)cc1, COCCOc1ccc(Nc2ncc(F)c(Nc3cccc(NC(=O)C=C)c3)n2)cc1, COCCOc1ccc(Nc2ncc(F)c(Nc3cccc(NC(=O)C=C)c3)n2)cc1, COCCOc1ccc(Nc2ncc(F)c(Nc3cccc(NC(=O)C=C)c3)n2)cc1, COCCOc1ccc(Nc2ncc(F)c(Nc3cccc(NC(=O)C=C)c3)n2)cc1	KXBDTLQSDKGAEB-UHFFFAOYSA-N, KXBDTLQSDKGAEB-UHFFFAOYSA-N, KXBDTLQSDKGAEB-UHFFFAOYSA-N, KXBDTLQSDKGAEB-UHFFFAOYSA-N, KXBDTLQSDKGAEB-UHFFFAOYSA-N, KXBDTLQSDKGAEB-UHFFFAOYSA-N, KXBDTLQSDKGAEB-UHFFFAOYSA-N	Phase 2
AVN-492	serotonin receptor antagonist				CNc1nn2c(C)c(N(C)C)c(C)nc2c1S(=O)(=O)c1ccccc1, CNc1nn2c(C)c(N(C)C)c(C)nc2c1S(=O)(=O)c1ccccc1	SNPPEHMSSOEYDH-UHFFFAOYSA-N, SNPPEHMSSOEYDH-UHFFFAOYSA-N	Preclinical
AVN-944	inosine monophosphate dehydrogenase inhibitor	IMPDH1, IMPDH2			CC[C@H](CC#N)OC(=O)N[C@@H](C)c1cccc(NC(=O)Nc2ccc(-c3cnco3)c(OC)c2)c1, CC[C@H](CC#N)OC(=O)N[C@@H](C)c1cccc(NC(=O)Nc2ccc(-c3cnco3)c(OC)c2)c1, CC[C@H](CC#N)OC(=O)N[C@@H](C)c1cccc(NC(=O)Nc2ccc(-c3cnco3)c(OC)c2)c1, CC[C@H](CC#N)OC(=O)N[C@@H](C)c1cccc(NC(=O)Nc2ccc(-c3cnco3)c(OC)c2)c1, CC[C@H](CC#N)OC(=O)N[C@@H](C)c1cccc(NC(=O)Nc2ccc(-c3cnco3)c(OC)c2)c1, CC[C@H](CC#N)OC(=O)N[C@@H](C)c1cccc(NC(=O)Nc2ccc(-c3cnco3)c(OC)c2)c1	GYCPCOJTCINIFZ-OXJNMPFZSA-N, GYCPCOJTCINIFZ-OXJNMPFZSA-N, GYCPCOJTCINIFZ-OXJNMPFZSA-N, GYCPCOJTCINIFZ-OXJNMPFZSA-N, GYCPCOJTCINIFZ-OXJNMPFZSA-N, GYCPCOJTCINIFZ-OXJNMPFZSA-N	Phase 2
avobenzone	topical sunscreen agent		dermatology	cosmetic, sunscreen lotion	COc1ccc(cc1)C(=O)C=C(O)c1ccc(cc1)C(C)(C)C, COc1ccc(cc1)C(=O)C=C(O)c1ccc(cc1)C(C)(C)C, COc1ccc(cc1)C(=O)C=C(O)c1ccc(cc1)C(C)(C)C	LKIIIESDXWZZRE-UHFFFAOYSA-N, LKIIIESDXWZZRE-UHFFFAOYSA-N, LKIIIESDXWZZRE-UHFFFAOYSA-N	Launched
avoralstat	kallikrein inhibitor				COc1cc(c(cc1C=C)C(=O)Nc1ccc(cc1)C(N)=N)-c1ccc(nc1C(O)=O)C(=O)NCC1CC1	TUWMKPVJGGWGNL-UHFFFAOYSA-N	Phase 3
avridine	immunostimulant				CCCCCCCCCCCCCCCCCCN(CCCCCCCCCCCCCCCCCC)CCCN(CCO)CCO	WXNRAKRZUCLRBP-UHFFFAOYSA-N	Preclinical
AX-024	cytokine production inhibitor				COc1ccc2OCC(CN3CCCC3)=C(c3ccc(F)cc3)c2c1 |t:15|	VMMKGVRPILDZML-UHFFFAOYSA-N	Preclinical
axitinib	PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	CSF1, FLT1, FLT4, KDR, PLK4	oncology	renal cell carcinoma (RCC)	CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)[nH]nc2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)[nH]nc2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)[nH]nc2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)[nH]nc2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)[nH]nc2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)[nH]nc2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)[nH]nc2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)[nH]nc2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)[nH]nc2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)[nH]nc2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)[nH]nc2c1	RITAVMQDGBJQJZ-FMIVXFBMSA-N, RITAVMQDGBJQJZ-FMIVXFBMSA-N, RITAVMQDGBJQJZ-FMIVXFBMSA-N, RITAVMQDGBJQJZ-FMIVXFBMSA-N, RITAVMQDGBJQJZ-FMIVXFBMSA-N, RITAVMQDGBJQJZ-FMIVXFBMSA-N, RITAVMQDGBJQJZ-FMIVXFBMSA-N, RITAVMQDGBJQJZ-FMIVXFBMSA-N, RITAVMQDGBJQJZ-FMIVXFBMSA-N, RITAVMQDGBJQJZ-FMIVXFBMSA-N, RITAVMQDGBJQJZ-FMIVXFBMSA-N	Launched
AY-9944	hedgehog pathway modulator				Clc1ccccc1CNC[C@H]1CC[C@H](CNCc2ccccc2Cl)CC1 |r|, Clc1ccccc1CNC[C@H]1CC[C@H](CNCc2ccccc2Cl)CC1 |r|, Clc1ccccc1CNC[C@H]1CC[C@H](CNCc2ccccc2Cl)CC1 |r|, Clc1ccccc1CNC[C@H]1CC[C@H](CNCc2ccccc2Cl)CC1 |r|	RZRPZWGIOOZIBE-IYARVYRRSA-N, RZRPZWGIOOZIBE-IYARVYRRSA-N, RZRPZWGIOOZIBE-IYARVYRRSA-N, RZRPZWGIOOZIBE-IYARVYRRSA-N	Preclinical
AZ-10417808	caspase inhibitor	CASP3			[O-][N+](=O)c1cc(C(=O)NCC=C)c2[nH]c(Nc3ccc(Cl)c(Cl)c3)nc(=O)c2c1, [O-][N+](=O)c1cc(C(=O)NCC=C)c2[nH]c(Nc3ccc(Cl)c(Cl)c3)nc(=O)c2c1	VUBILPOZTRGZJK-UHFFFAOYSA-N, VUBILPOZTRGZJK-UHFFFAOYSA-N	Preclinical
AZ-10606120	purinergic receptor antagonist	P2RX7			OCCNCCNc1ccc2c(NC(=O)CC34CC5CC(CC(C5)C3)C4)cccc2n1, OCCNCCNc1ccc2c(NC(=O)CC34CC5CC(CC(C5)C3)C4)cccc2n1	FQMZXMVHHKXGTM-UHFFFAOYSA-N, FQMZXMVHHKXGTM-UHFFFAOYSA-N	Preclinical
AZ-12080282	hedgehog pathway inhibitor	DHH			Cc1ccc(cc1NC(=O)c1ccc(OCc2ccccn2)cc1)-c1ncc[nH]1, Cc1ccc(cc1NC(=O)c1ccc(OCc2ccccn2)cc1)-c1ncc[nH]1	KMSKKYBHDQYHMC-UHFFFAOYSA-N, KMSKKYBHDQYHMC-UHFFFAOYSA-N	Preclinical
AZ-628	RAF inhibitor	BRAF, RAF1			Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1	ZGBGPEDJXCYQPH-UHFFFAOYSA-N, ZGBGPEDJXCYQPH-UHFFFAOYSA-N, ZGBGPEDJXCYQPH-UHFFFAOYSA-N, ZGBGPEDJXCYQPH-UHFFFAOYSA-N, ZGBGPEDJXCYQPH-UHFFFAOYSA-N, ZGBGPEDJXCYQPH-UHFFFAOYSA-N, ZGBGPEDJXCYQPH-UHFFFAOYSA-N, ZGBGPEDJXCYQPH-UHFFFAOYSA-N, ZGBGPEDJXCYQPH-UHFFFAOYSA-N, ZGBGPEDJXCYQPH-UHFFFAOYSA-N, ZGBGPEDJXCYQPH-UHFFFAOYSA-N, ZGBGPEDJXCYQPH-UHFFFAOYSA-N	Preclinical
AZ-7371	antibacterial 				COc1ncnc(Cn2cc(C(=O)NCCO)c3ncc(C)cc23)c1C	VDRYGTNDKXIPSK-UHFFFAOYSA-N	Preclinical
azacitidine	DNA methyltransferase inhibitor	DNMT1, DNMT3A	hematologic malignancy, hematology	myelodysplastic diseases (MDS), anemia, chronic myelomonocytic leukemia (CMMoL)	Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1	NMUSYJAQQFHJEW-KVTDHHQDSA-N, NMUSYJAQQFHJEW-KVTDHHQDSA-N, NMUSYJAQQFHJEW-KVTDHHQDSA-N, NMUSYJAQQFHJEW-KVTDHHQDSA-N, NMUSYJAQQFHJEW-KVTDHHQDSA-N, NMUSYJAQQFHJEW-KVTDHHQDSA-N, NMUSYJAQQFHJEW-KVTDHHQDSA-N, NMUSYJAQQFHJEW-KVTDHHQDSA-N, NMUSYJAQQFHJEW-KVTDHHQDSA-N, NMUSYJAQQFHJEW-KVTDHHQDSA-N, NMUSYJAQQFHJEW-KVTDHHQDSA-N	Launched
azacyclonol	histamine receptor antagonist	HRH1			OC(C1CCNCC1)(c1ccccc1)c1ccccc1, OC(C1CCNCC1)(c1ccccc1)c1ccccc1, OC(C1CCNCC1)(c1ccccc1)c1ccccc1	ZMISODWVFHHWNR-UHFFFAOYSA-N, ZMISODWVFHHWNR-UHFFFAOYSA-N, ZMISODWVFHHWNR-UHFFFAOYSA-N	Preclinical
azaguanine-8	purine antagonist	PNP			Nc1nc2nn[nH]c2c(=O)[nH]1, Nc1nc2nn[nH]c2c(=O)[nH]1	LPXQRXLUHJKZIE-UHFFFAOYSA-N, LPXQRXLUHJKZIE-UHFFFAOYSA-N	Preclinical
azalomycin-B	bacterial 50S ribosomal subunit inhibitor				CC[C@@H]1[C@@H](C)O[C@](O)(C[C@H]1O[C@H]1C[C@H](O)[C@H](O)[C@H](C)O1)[C@@H](C)[C@H](O)[C@H](C)[C@H]1OC(=O)\C=C\C=C\[C@H](C)[C@H](OC(=O)\C=C\C=C\[C@@H]1C)[C@@H](C)[C@@H](O)[C@H](C)[C@@]1(O)C[C@@H](O[C@H]2C[C@H](O)[C@H](O)[C@H](C)O2)[C@H](CC)[C@@H](C)O1 |t:32,34,42,44|	OSERMIPXNLXAPD-MJMYBOKFSA-N	Preclinical
azaperone	dopamine receptor antagonist	DRD2, DRD3	neurology/psychiatry	sedative	Fc1ccc(cc1)C(=O)CCCN1CCN(CC1)c1ccccn1, Fc1ccc(cc1)C(=O)CCCN1CCN(CC1)c1ccccn1, Fc1ccc(cc1)C(=O)CCCN1CCN(CC1)c1ccccn1, Fc1ccc(cc1)C(=O)CCCN1CCN(CC1)c1ccccn1	XTKDAFGWCDAMPY-UHFFFAOYSA-N, XTKDAFGWCDAMPY-UHFFFAOYSA-N, XTKDAFGWCDAMPY-UHFFFAOYSA-N, XTKDAFGWCDAMPY-UHFFFAOYSA-N	Launched
azapropazone	cyclooxygenase inhibitor	PTGS2			CCC[C@H]1C(=O)N2N(C1=O)c1cc(C)ccc1N=C2N(C)C |r,c:19|, CCC[C@H]1C(=O)N2N(C1=O)c1cc(C)ccc1N=C2N(C)C |r,c:19|	MPHPHYZQRGLTBO-LLVKDONJSA-N, MPHPHYZQRGLTBO-LLVKDONJSA-N	Withdrawn
azaserine	purine antagonist				N[C@@H](COC(=O)C[N+]#N)C(O)=O	YXEASJLRXGZRHS-VKHMYHEASA-O	Preclinical
azasetron	serotonin receptor antagonist	HTR3A, HTR3B	infectious disease	genitial herpes	CN1C(=O)COc2c1cc(Cl)cc2C(=O)N[C@H]1CN2CCC1CC2 |&1:16|, CN1C(=O)COc2c1cc(Cl)cc2C(=O)N[C@H]1CN2CCC1CC2 |&1:16|	WUKZPHOXUVCQOR-ZDUSSCGKSA-N, WUKZPHOXUVCQOR-ZDUSSCGKSA-N	Launched
azatadine	histamine receptor antagonist	HRH1	allergy	allergic rhinitis	CN1CCC(CC1)=C1c2ccccc2CCc2cccnc12, CN1CCC(CC1)=C1c2ccccc2CCc2cccnc12, CN1CCC(CC1)=C1c2ccccc2CCc2cccnc12	SEBMTIQKRHYNIT-UHFFFAOYSA-N, SEBMTIQKRHYNIT-UHFFFAOYSA-N, SEBMTIQKRHYNIT-UHFFFAOYSA-N	Launched
azathioprine	dehydrogenase inhibitor	HPRT1, IMPDH1, PPAT	transplant, rheumatology	renal homotransplantation, rheumatoid arthritis	Cn1cnc(c1Sc1ncnc2nc[nH]c12)[N+]([O-])=O, Cn1cnc(c1Sc1ncnc2nc[nH]c12)[N+]([O-])=O, Cn1cnc(c1Sc1ncnc2nc[nH]c12)[N+]([O-])=O, Cn1cnc(c1Sc1ncnc2nc[nH]c12)[N+]([O-])=O, Cn1cnc(c1Sc1ncnc2nc[nH]c12)[N+]([O-])=O, Cn1cnc(c1Sc1ncnc2nc[nH]c12)[N+]([O-])=O, Cn1cnc(c1Sc1ncnc2nc[nH]c12)[N+]([O-])=O	LMEKQMALGUDUQG-UHFFFAOYSA-N, LMEKQMALGUDUQG-UHFFFAOYSA-N, LMEKQMALGUDUQG-UHFFFAOYSA-N, LMEKQMALGUDUQG-UHFFFAOYSA-N, LMEKQMALGUDUQG-UHFFFAOYSA-N, LMEKQMALGUDUQG-UHFFFAOYSA-N, LMEKQMALGUDUQG-UHFFFAOYSA-N	Launched
AZD0156	ATM kinase inhibitor				CN(C)CCCOc1ccc(cn1)-c1ccc2ncc3n(C)c(=O)n(C4CCOCC4)c3c2c1	AOTRIQLYUAFVSC-UHFFFAOYSA-N	Phase 1
AZD1080	glycogen synthase kinase inhibitor	GSK3A, GSK3B			O=C1Nc2ccc(cc2C1c1ccc(CN2CCOCC2)cn1)C#N, O=C1Nc2ccc(cc2C1c1ccc(CN2CCOCC2)cn1)C#N, O=C1Nc2ccc(cc2C1c1ccc(CN2CCOCC2)cn1)C#N, O=C1Nc2ccc(cc2C1c1ccc(CN2CCOCC2)cn1)C#N, O=C1Nc2ccc(cc2C1c1ccc(CN2CCOCC2)cn1)C#N	RDXUCTYBYOIJGA-UHFFFAOYSA-N, RDXUCTYBYOIJGA-UHFFFAOYSA-N, RDXUCTYBYOIJGA-UHFFFAOYSA-N, RDXUCTYBYOIJGA-UHFFFAOYSA-N, RDXUCTYBYOIJGA-UHFFFAOYSA-N	Phase 1
AZD1208	Pim kinase inhibitor	PIM1, PIM2, PIM3			N[C@@H]1CCCN(C1)c1c(\C=C2/SC(=O)NC2=O)cccc1-c1ccccc1, N[C@@H]1CCCN(C1)c1c(\C=C2/SC(=O)NC2=O)cccc1-c1ccccc1, N[C@@H]1CCCN(C1)c1c(\C=C2/SC(=O)NC2=O)cccc1-c1ccccc1, N[C@@H]1CCCN(C1)c1c(\C=C2/SC(=O)NC2=O)cccc1-c1ccccc1, N[C@@H]1CCCN(C1)c1c(\C=C2/SC(=O)NC2=O)cccc1-c1ccccc1	MCUJKPPARUPFJM-UWCCDQBKSA-N, MCUJKPPARUPFJM-UWCCDQBKSA-N, MCUJKPPARUPFJM-UWCCDQBKSA-N, MCUJKPPARUPFJM-UWCCDQBKSA-N, MCUJKPPARUPFJM-UWCCDQBKSA-N	Phase 1
AZD1283	purinergic receptor antagonist	P2RY12			CCOC(=O)c1cc(C#N)c(nc1C)N1CCC(CC1)C(=O)NS(=O)(=O)Cc1ccccc1, CCOC(=O)c1cc(C#N)c(nc1C)N1CCC(CC1)C(=O)NS(=O)(=O)Cc1ccccc1, CCOC(=O)c1cc(C#N)c(nc1C)N1CCC(CC1)C(=O)NS(=O)(=O)Cc1ccccc1	NEMHKCNXXRQYRF-UHFFFAOYSA-N, NEMHKCNXXRQYRF-UHFFFAOYSA-N, NEMHKCNXXRQYRF-UHFFFAOYSA-N	Preclinical
AZD1390	ATM kinase inhibitor				CC(C)n1c2c(cnc3cc(F)c(cc23)-c2ccc(OCCCN3CCCCC3)nc2)n(C)c1=O, CC(C)n1c2c(cnc3cc(F)c(cc23)-c2ccc(OCCCN3CCCCC3)nc2)n(C)c1=O	VQSZIPCGAGVRRP-UHFFFAOYSA-N, VQSZIPCGAGVRRP-UHFFFAOYSA-N	Phase 1
AZD1446	acetylcholine receptor agonist	CHRNA4, CHRNB2			Clc1ccc(o1)C(=O)N1C[C@H]2CNC[C@@H]2C1 |&1:10,&2:14,r|	GTUIQNHJSXQMKW-HTQZYQBOSA-N	Phase 2
AZD1480	JAK inhibitor	JAK1, JAK2, JAK3			C[C@H](Nc1ncc(Cl)c(Nc2cc(C)n[nH]2)n1)c1ncc(F)cn1, C[C@H](Nc1ncc(Cl)c(Nc2cc(C)n[nH]2)n1)c1ncc(F)cn1, C[C@H](Nc1ncc(Cl)c(Nc2cc(C)n[nH]2)n1)c1ncc(F)cn1	PDOQBOJDRPLBQU-QMMMGPOBSA-N, PDOQBOJDRPLBQU-QMMMGPOBSA-N, PDOQBOJDRPLBQU-QMMMGPOBSA-N	Phase 1
AZD1981	CRTH receptor antagonist	PTGDR2			CC(=O)Nc1cccc2n(CC(O)=O)c(C)c(Sc3ccc(Cl)cc3)c12, CC(=O)Nc1cccc2n(CC(O)=O)c(C)c(Sc3ccc(Cl)cc3)c12, CC(=O)Nc1cccc2n(CC(O)=O)c(C)c(Sc3ccc(Cl)cc3)c12	JWYIGNODXSRKGP-UHFFFAOYSA-N, JWYIGNODXSRKGP-UHFFFAOYSA-N, JWYIGNODXSRKGP-UHFFFAOYSA-N	Phase 2
AZD2014	mTOR inhibitor	MTOR			CNC(=O)c1cccc(c1)-c1ccc2c(nc(nc2n1)N1CCOC[C@@H]1C)N1CCOC[C@@H]1C, CNC(=O)c1cccc(c1)-c1ccc2c(nc(nc2n1)N1CCOC[C@@H]1C)N1CCOC[C@@H]1C, CNC(=O)c1cccc(c1)-c1ccc2c(nc(nc2n1)N1CCOC[C@@H]1C)N1CCOC[C@@H]1C, CNC(=O)c1cccc(c1)-c1ccc2c(nc(nc2n1)N1CCOC[C@@H]1C)N1CCOC[C@@H]1C	JUSFANSTBFGBAF-IRXDYDNUSA-N, JUSFANSTBFGBAF-IRXDYDNUSA-N, JUSFANSTBFGBAF-IRXDYDNUSA-N, JUSFANSTBFGBAF-IRXDYDNUSA-N	Phase 2
AZD2461	PARP inhibitor				COC1CCN(CC1)C(=O)c1cc(Cc2n[nH]c(=O)c3ccccc23)ccc1F, COC1CCN(CC1)C(=O)c1cc(Cc2n[nH]c(=O)c3ccccc23)ccc1F, COC1CCN(CC1)C(=O)c1cc(Cc2n[nH]c(=O)c3ccccc23)ccc1F, COC1CCN(CC1)C(=O)c1cc(Cc2n[nH]c(=O)c3ccccc23)ccc1F	HYNBNUYQTQIHJK-UHFFFAOYSA-N, HYNBNUYQTQIHJK-UHFFFAOYSA-N, HYNBNUYQTQIHJK-UHFFFAOYSA-N, HYNBNUYQTQIHJK-UHFFFAOYSA-N	Phase 1
AZD2858	glycogen synthase kinase inhibitor	GSK3B			CN1CCN(CC1)S(=O)(=O)c1ccc(cc1)-c1cnc(N)c(n1)C(=O)Nc1cccnc1, CN1CCN(CC1)S(=O)(=O)c1ccc(cc1)-c1cnc(N)c(n1)C(=O)Nc1cccnc1, CN1CCN(CC1)S(=O)(=O)c1ccc(cc1)-c1cnc(N)c(n1)C(=O)Nc1cccnc1, CN1CCN(CC1)S(=O)(=O)c1ccc(cc1)-c1cnc(N)c(n1)C(=O)Nc1cccnc1, CN1CCN(CC1)S(=O)(=O)c1ccc(cc1)-c1cnc(N)c(n1)C(=O)Nc1cccnc1	FHCSBLWRGCOVPT-UHFFFAOYSA-N, FHCSBLWRGCOVPT-UHFFFAOYSA-N, FHCSBLWRGCOVPT-UHFFFAOYSA-N, FHCSBLWRGCOVPT-UHFFFAOYSA-N, FHCSBLWRGCOVPT-UHFFFAOYSA-N	Preclinical
AZD3264	IKK inhibitor	IKBKB			Cc1noc(C)c1-c1ccc(-c2cc(C(N)=O)c(NC(N)=O)s2)c(O[C@H]2CCNC2)c1, Cc1noc(C)c1-c1ccc(-c2cc(C(N)=O)c(NC(N)=O)s2)c(O[C@H]2CCNC2)c1	NMFIXEFNQPDISY-ZDUSSCGKSA-N, NMFIXEFNQPDISY-ZDUSSCGKSA-N	Preclinical
AZD3463	ALK tyrosine kinase receptor inhibitor, insulin growth factor receptor inhibitor	ALK, IGF1R			COc1cc(ccc1Nc1ncc(Cl)c(n1)-c1c[nH]c2ccccc12)N1CCC(N)CC1, COc1cc(ccc1Nc1ncc(Cl)c(n1)-c1c[nH]c2ccccc12)N1CCC(N)CC1, COc1cc(ccc1Nc1ncc(Cl)c(n1)-c1c[nH]c2ccccc12)N1CCC(N)CC1, COc1cc(ccc1Nc1ncc(Cl)c(n1)-c1c[nH]c2ccccc12)N1CCC(N)CC1, COc1cc(ccc1Nc1ncc(Cl)c(n1)-c1c[nH]c2ccccc12)N1CCC(N)CC1, COc1cc(ccc1Nc1ncc(Cl)c(n1)-c1c[nH]c2ccccc12)N1CCC(N)CC1, COc1cc(ccc1Nc1ncc(Cl)c(n1)-c1c[nH]c2ccccc12)N1CCC(N)CC1, COc1cc(ccc1Nc1ncc(Cl)c(n1)-c1c[nH]c2ccccc12)N1CCC(N)CC1, COc1cc(ccc1Nc1ncc(Cl)c(n1)-c1c[nH]c2ccccc12)N1CCC(N)CC1	GCYIGMXOIWJGBU-UHFFFAOYSA-N, GCYIGMXOIWJGBU-UHFFFAOYSA-N, GCYIGMXOIWJGBU-UHFFFAOYSA-N, GCYIGMXOIWJGBU-UHFFFAOYSA-N, GCYIGMXOIWJGBU-UHFFFAOYSA-N, GCYIGMXOIWJGBU-UHFFFAOYSA-N, GCYIGMXOIWJGBU-UHFFFAOYSA-N, GCYIGMXOIWJGBU-UHFFFAOYSA-N, GCYIGMXOIWJGBU-UHFFFAOYSA-N	Preclinical
AZD3514	androgen receptor modulator	AR			CC(=O)N1CCN(CCOc2ccc(cc2)C2CCN(CC2)C2=Nn3c(CC2)nnc3C(F)(F)F)CC1 |t:24|, CC(=O)N1CCN(CCOc2ccc(cc2)C2CCN(CC2)C2=Nn3c(CC2)nnc3C(F)(F)F)CC1 |t:24|, CC(=O)N1CCN(CCOc2ccc(cc2)C2CCN(CC2)C2=Nn3c(CC2)nnc3C(F)(F)F)CC1 |t:24|, CC(=O)N1CCN(CCOc2ccc(cc2)C2CCN(CC2)C2=Nn3c(CC2)nnc3C(F)(F)F)CC1 |t:24|, CC(=O)N1CCN(CCOc2ccc(cc2)C2CCN(CC2)C2=Nn3c(CC2)nnc3C(F)(F)F)CC1 |t:24|, CC(=O)N1CCN(CCOc2ccc(cc2)C2CCN(CC2)C2=Nn3c(CC2)nnc3C(F)(F)F)CC1 |t:24|, CC(=O)N1CCN(CCOc2ccc(cc2)C2CCN(CC2)C2=Nn3c(CC2)nnc3C(F)(F)F)CC1 |t:24|, CC(=O)N1CCN(CCOc2ccc(cc2)C2CCN(CC2)C2=Nn3c(CC2)nnc3C(F)(F)F)CC1 |t:24|	JMEYDSHPKCSIJC-UHFFFAOYSA-N, JMEYDSHPKCSIJC-UHFFFAOYSA-N, JMEYDSHPKCSIJC-UHFFFAOYSA-N, JMEYDSHPKCSIJC-UHFFFAOYSA-N, JMEYDSHPKCSIJC-UHFFFAOYSA-N, JMEYDSHPKCSIJC-UHFFFAOYSA-N, JMEYDSHPKCSIJC-UHFFFAOYSA-N, JMEYDSHPKCSIJC-UHFFFAOYSA-N	Phase 1
AZD3759	EGFR inhibitor	EGFR			COc1cc2ncnc(Nc3cccc(Cl)c3F)c2cc1OC(=O)N1CCN(C)C[C@H]1C	MXDSJQHFFDGFDK-CYBMUJFWSA-N	Phase 2/Phase 3
AZD3839	beta-secretase inhibitor	BACE1			NC1=N[C@@](c2cccc(F)c12)(c1cccc(c1)-c1cncnc1)c1ccnc(c1)C(F)F |t:1|, NC1=N[C@@](c2cccc(F)c12)(c1cccc(c1)-c1cncnc1)c1ccnc(c1)C(F)F |t:1|	MRXBCEQZNKUUIP-DEOSSOPVSA-N, MRXBCEQZNKUUIP-DEOSSOPVSA-N	Phase 1
AZD3965	monocarboxylate transporter inhibitor	SLC16A1			CC(C)n1c2sc(Cc3c(C)[nH]nc3C(F)(F)F)c(C(=O)N3C[C@](C)(O)CO3)c2c(=O)n(C)c1=O	PRNXOFBDXNTIFG-FQEVSTJZSA-N	Phase 1
AZD3988	diacylglycerol kinase inhibitor	DGAT1			OC(=O)C[C@H]1CC[C@@H](CC1)c1ccc(NC(=O)c2nnc(Nc3ccc(F)c(F)c3)o2)cc1 |r|, OC(=O)C[C@H]1CC[C@@H](CC1)c1ccc(NC(=O)c2nnc(Nc3ccc(F)c(F)c3)o2)cc1 |r|	NGEBYTLALFOQKI-HDJSIYSDSA-N, NGEBYTLALFOQKI-HDJSIYSDSA-N	Preclinical
AZD4282	glutamate receptor antagonist	AGXT, AGXT2, ALAS1, ALAS2, BAAT, GARS, GATM, GCAT, GCSH, GLDC, GLRA1, GLRA2, GLRA3, GLRB, GLYAT, GLYATL1, GLYATL2, GNMT, GPR18, GPRC6A, GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D, GRIN3B, GSS, PIPOX, SHMT1, SHMT2, SLC32A1, SLC36A1, SLC6A5, SLC6A9			NCC(O)=O	DHMQDGOQFOQNFH-UHFFFAOYSA-N	Phase 1
AZD4547	FGFR inhibitor	FGFR1, FGFR2, FGFR3, FGFR4, IGF1R, KDR			COc1cc(CCc2cc(NC(=O)c3ccc(cc3)N3C[C@H](C)N[C@H](C)C3)[nH]n2)cc(OC)c1, COc1cc(CCc2cc(NC(=O)c3ccc(cc3)N3C[C@H](C)N[C@H](C)C3)[nH]n2)cc(OC)c1	VRQMAABPASPXMW-HDICACEKSA-N, InChI=1S/C26H33N5O3/c1-17-15-31(16-18(2)27-17)22-9-6-20(7-10-22)26(32)28-25-13-21(29-30-25)8-5-19-11-23(33-3)14-24(12-19)34-4/h6-7,9-14,17-18,27H,5,8,15-16H2,1-4H3,(H2,28,29,30,32)/t17-,18+	Phase 2/Phase 3
AZD4573	CDK9 inhibitor				CC(=O)N[C@@H]1CCC[C@@H](C1)C(=O)Nc1cc(-c2cnn3CC(C)(C)Cc23)c(Cl)cn1	AVIWDYSJSPOOAR-LSDHHAIUSA-N	Phase 1
AZD4635	adenosine receptor antagonist				Cc1cc(cc(Cl)n1)-c1nnc(N)nc1-c1ccc(F)cc1	NCWQLHHDGDXIJN-UHFFFAOYSA-N	Phase 1/Phase 2
AZD5069	CC chemokine receptor antagonist	CXCR2			C[C@@H](Oc1cc(NS(=O)(=O)N2CCC2)nc(SCc2cccc(F)c2F)n1)[C@@H](O)CO	QZECRCLSIGFCIO-RISCZKNCSA-N	Phase 2
AZD5153	bromodomain inhibitor				[H][C@]1(C)N(CCOc2ccc(cc2)C2CCN(CC2)c2ccc3nnc(OC)n3n2)CCN(C)C1=O |r|	RSMYFSPOTCDHHJ-GOSISDBHSA-N	Phase 1
AZD5363	AKT inhibitor	AKT1, AKT2, AKT3			NC1(CCN(CC1)c1ncnc2[nH]ccc12)C(=O)N[C@@H](CCO)c1ccc(Cl)cc1, NC1(CCN(CC1)c1ncnc2[nH]ccc12)C(=O)N[C@@H](CCO)c1ccc(Cl)cc1, NC1(CCN(CC1)c1ncnc2[nH]ccc12)C(=O)N[C@@H](CCO)c1ccc(Cl)cc1	JDUBGYFRJFOXQC-KRWDZBQOSA-N, JDUBGYFRJFOXQC-KRWDZBQOSA-N, JDUBGYFRJFOXQC-KRWDZBQOSA-N	Phase 3
AZD5438	CDK inhibitor	KCNH2			CC(C)n1c(C)ncc1-c1ccnc(Nc2ccc(cc2)S(C)(=O)=O)n1, CC(C)n1c(C)ncc1-c1ccnc(Nc2ccc(cc2)S(C)(=O)=O)n1, CC(C)n1c(C)ncc1-c1ccnc(Nc2ccc(cc2)S(C)(=O)=O)n1, CC(C)n1c(C)ncc1-c1ccnc(Nc2ccc(cc2)S(C)(=O)=O)n1, CC(C)n1c(C)ncc1-c1ccnc(Nc2ccc(cc2)S(C)(=O)=O)n1, CC(C)n1c(C)ncc1-c1ccnc(Nc2ccc(cc2)S(C)(=O)=O)n1, CC(C)n1c(C)ncc1-c1ccnc(Nc2ccc(cc2)S(C)(=O)=O)n1, CC(C)n1c(C)ncc1-c1ccnc(Nc2ccc(cc2)S(C)(=O)=O)n1, CC(C)n1c(C)ncc1-c1ccnc(Nc2ccc(cc2)S(C)(=O)=O)n1	WJRRGYBTGDJBFX-UHFFFAOYSA-N, WJRRGYBTGDJBFX-UHFFFAOYSA-N, WJRRGYBTGDJBFX-UHFFFAOYSA-N, WJRRGYBTGDJBFX-UHFFFAOYSA-N, WJRRGYBTGDJBFX-UHFFFAOYSA-N, WJRRGYBTGDJBFX-UHFFFAOYSA-N, WJRRGYBTGDJBFX-UHFFFAOYSA-N, InChI=1S/C18H21N5O2S/c1-12(2)23-13(3)20-11-17(23)16-9-10-19-18(22-16)21-14-5-7-15(8-6-14)26(4,24)25/h5-12H,1-4H3,(H,19,21,22), InChI=1S/C18H21N5O2S/c1-12(2)23-13(3)20-11-17(23)16-9-10-19-18(22-16)21-14-5-7-15(8-6-14)26(4,24)25/h5-12H,1-4H3,(H,19,21,22)	Phase 1
AZD5582	XIAP inhibitor	BIRC2, BIRC3, XIAP			CN[C@@H](C)C(=O)N[C@@H](C1CCCCC1)C(=O)N1CCC[C@H]1C(=O)N[C@@H]1[C@@H](Cc2ccccc12)OCC#CC#CCO[C@@H]1Cc2ccccc2[C@@H]1NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H](C)NC)C1CCCCC1, CN[C@@H](C)C(=O)N[C@@H](C1CCCCC1)C(=O)N1CCC[C@H]1C(=O)N[C@@H]1[C@@H](Cc2ccccc12)OCC#CC#CCO[C@@H]1Cc2ccccc2[C@@H]1NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H](C)NC)C1CCCCC1, CN[C@@H](C)C(=O)N[C@@H](C1CCCCC1)C(=O)N1CCC[C@H]1C(=O)N[C@@H]1[C@@H](Cc2ccccc12)OCC#CC#CCO[C@@H]1Cc2ccccc2[C@@H]1NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H](C)NC)C1CCCCC1, CN[C@@H](C)C(=O)N[C@@H](C1CCCCC1)C(=O)N1CCC[C@H]1C(=O)N[C@@H]1[C@@H](Cc2ccccc12)OCC#CC#CCO[C@@H]1Cc2ccccc2[C@@H]1NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H](C)NC)C1CCCCC1	WLMCRYCCYXHPQF-ZVMUOSSASA-N, WLMCRYCCYXHPQF-ZVMUOSSASA-N, WLMCRYCCYXHPQF-ZVMUOSSASA-N, WLMCRYCCYXHPQF-ZVMUOSSASA-N	Preclinical
AZD5991	MCL1 inhibitor				Cc1c-2c(CSCc3cc(CSc4cc(OCCCc5c(C(O)=O)n(C)c6c-2c(Cl)ccc56)c2ccccc2c4)n(C)n3)nn1C	KBQCEQAXHPIRTF-UHFFFAOYSA-N	Phase 1
AZD6482	PI3K inhibitor	PIK3CA, PIK3CB, PIK3CD, PIK3CG			C[C@@H](Nc1ccccc1C(O)=O)c1cc(C)cn2c1nc(cc2=O)N1CCOCC1, C[C@@H](Nc1ccccc1C(O)=O)c1cc(C)cn2c1nc(cc2=O)N1CCOCC1, C[C@@H](Nc1ccccc1C(O)=O)c1cc(C)cn2c1nc(cc2=O)N1CCOCC1, C[C@@H](Nc1ccccc1C(O)=O)c1cc(C)cn2c1nc(cc2=O)N1CCOCC1, C[C@@H](Nc1ccccc1C(O)=O)c1cc(C)cn2c1nc(cc2=O)N1CCOCC1, C[C@@H](Nc1ccccc1C(O)=O)c1cc(C)cn2c1nc(cc2=O)N1CCOCC1, C[C@@H](Nc1ccccc1C(O)=O)c1cc(C)cn2c1nc(cc2=O)N1CCOCC1	IRTDIKMSKMREGO-OAHLLOKOSA-N, IRTDIKMSKMREGO-OAHLLOKOSA-N, IRTDIKMSKMREGO-OAHLLOKOSA-N, IRTDIKMSKMREGO-OAHLLOKOSA-N, IRTDIKMSKMREGO-OAHLLOKOSA-N, IRTDIKMSKMREGO-OAHLLOKOSA-N, IRTDIKMSKMREGO-OAHLLOKOSA-N	Phase 1
AZD6738	ATR kinase inhibitor	ATR			C[C@@H]1COCCN1c1cc(nc(n1)-c1ccnc2[nH]ccc12)C1(CC1)[S@@](C)(=N)=O |a:1,&1:25|	OHUHVTCQTUDPIJ-MUWSIPGASA-N	Phase 2
AZD6765	glutamate receptor antagonist	GRIN1			N[C@@H](Cc1ccccn1)c1ccccc1 |&1:1,r|, N[C@@H](Cc1ccccn1)c1ccccc1 |&1:1,r|	FWUQWDCOOWEXRY-ZDUSSCGKSA-N, FWUQWDCOOWEXRY-ZDUSSCGKSA-N	Phase 2
AZD7545	pyruvate dehydrogenase kinase inhibitor	PDK1			CN(C)C(=O)c1ccc(cc1)S(=O)(=O)c1ccc(NC(=O)[C@@](C)(O)C(F)(F)F)c(Cl)c1	DTDZLJHKVNTQGZ-GOSISDBHSA-N	Phase 1
AZD7594	glucocorticoid receptor modulator				C[C@H](NC(=O)C(C)(F)F)[C@H](Oc1ccc2n(ncc2c1)-c1cccc(c1)C(=O)N[C@@H]1CCOC1)c1ccc2OCCOc2c1	ZZWJKLGCDHYVMB-BWGXUDETSA-N	Phase 2
AZD7687	diacylglycerol O acyltransferase inhibitor	DGAT1			Cc1nc(C)c(nc1C(N)=O)-c1ccc(cc1)[C@H]1CC[C@H](CC(O)=O)CC1 |r|, Cc1nc(C)c(nc1C(N)=O)-c1ccc(cc1)[C@H]1CC[C@H](CC(O)=O)CC1 |r|	YXFNPRHZMOGREC-SHTZXODSSA-N, YXFNPRHZMOGREC-SHTZXODSSA-N	Phase 1
AZD7762	CHK inhibitor	CHEK1, CHEK2			NC(=O)Nc1cc(sc1C(=O)N[C@H]1CCCNC1)-c1cccc(F)c1, NC(=O)Nc1cc(sc1C(=O)N[C@H]1CCCNC1)-c1cccc(F)c1, NC(=O)Nc1cc(sc1C(=O)N[C@H]1CCCNC1)-c1cccc(F)c1, NC(=O)Nc1cc(sc1C(=O)N[C@H]1CCCNC1)-c1cccc(F)c1, NC(=O)Nc1cc(sc1C(=O)N[C@H]1CCCNC1)-c1cccc(F)c1, NC(=O)Nc1cc(sc1C(=O)N[C@H]1CCCNC1)-c1cccc(F)c1, NC(=O)Nc1cc(sc1C(=O)N[C@H]1CCCNC1)-c1cccc(F)c1, NC(=O)Nc1cc(sc1C(=O)N[C@H]1CCCNC1)-c1cccc(F)c1, NC(=O)Nc1cc(sc1C(=O)N[C@H]1CCCNC1)-c1cccc(F)c1	IAYGCINLNONXHY-LBPRGKRZSA-N, IAYGCINLNONXHY-LBPRGKRZSA-N, IAYGCINLNONXHY-LBPRGKRZSA-N, IAYGCINLNONXHY-LBPRGKRZSA-N, IAYGCINLNONXHY-LBPRGKRZSA-N, IAYGCINLNONXHY-LBPRGKRZSA-N, IAYGCINLNONXHY-LBPRGKRZSA-N, IAYGCINLNONXHY-LBPRGKRZSA-N, IAYGCINLNONXHY-LBPRGKRZSA-N	Phase 1
AZD7986	dipeptidyl peptidase inhibitor				Cn1c2cc(ccc2oc1=O)-c1ccc(C[C@H](NC(=O)[C@@H]2CNCCCO2)C#N)cc1	AEXFXNFMSAAELR-RXVVDRJESA-N	Phase 1
AZD8055	mTOR inhibitor	MTOR			COc1ccc(cc1CO)-c1ccc2c(nc(nc2n1)N1CCOC[C@@H]1C)N1CCOC[C@@H]1C, COc1ccc(cc1CO)-c1ccc2c(nc(nc2n1)N1CCOC[C@@H]1C)N1CCOC[C@@H]1C, COc1ccc(cc1CO)-c1ccc2c(nc(nc2n1)N1CCOC[C@@H]1C)N1CCOC[C@@H]1C, COc1ccc(cc1CO)-c1ccc2c(nc(nc2n1)N1CCOC[C@@H]1C)N1CCOC[C@@H]1C, COc1ccc(cc1CO)-c1ccc2c(nc(nc2n1)N1CCOC[C@@H]1C)N1CCOC[C@@H]1C, COc1ccc(cc1CO)-c1ccc2c(nc(nc2n1)N1CCOC[C@@H]1C)N1CCOC[C@@H]1C, COc1ccc(cc1CO)-c1ccc2c(nc(nc2n1)N1CCOC[C@@H]1C)N1CCOC[C@@H]1C, COc1ccc(cc1CO)-c1ccc2c(nc(nc2n1)N1CCOC[C@@H]1C)N1CCOC[C@@H]1C	KVLFRAWTRWDEDF-IRXDYDNUSA-N, KVLFRAWTRWDEDF-IRXDYDNUSA-N, KVLFRAWTRWDEDF-IRXDYDNUSA-N, KVLFRAWTRWDEDF-IRXDYDNUSA-N, KVLFRAWTRWDEDF-IRXDYDNUSA-N, KVLFRAWTRWDEDF-IRXDYDNUSA-N, KVLFRAWTRWDEDF-IRXDYDNUSA-N, KVLFRAWTRWDEDF-IRXDYDNUSA-N	Phase 1
AZD8186	PI3K inhibitor	PIK3CB, PIK3CD			C[C@@H](Nc1cc(F)cc(F)c1)c1cc(cc2c1oc(cc2=O)N1CCOCC1)C(=O)N(C)C, C[C@@H](Nc1cc(F)cc(F)c1)c1cc(cc2c1oc(cc2=O)N1CCOCC1)C(=O)N(C)C, C[C@@H](Nc1cc(F)cc(F)c1)c1cc(cc2c1oc(cc2=O)N1CCOCC1)C(=O)N(C)C, C[C@@H](Nc1cc(F)cc(F)c1)c1cc(cc2c1oc(cc2=O)N1CCOCC1)C(=O)N(C)C	LMJFJIDLEAWOQJ-CQSZACIVSA-N, LMJFJIDLEAWOQJ-CQSZACIVSA-N, LMJFJIDLEAWOQJ-CQSZACIVSA-N, LMJFJIDLEAWOQJ-CQSZACIVSA-N	Phase 1
AZD8330	MEK inhibitor	MAP3K1			Cc1cc(C(=O)NOCCO)c(Nc2ccc(I)cc2F)n(C)c1=O, Cc1cc(C(=O)NOCCO)c(Nc2ccc(I)cc2F)n(C)c1=O, Cc1cc(C(=O)NOCCO)c(Nc2ccc(I)cc2F)n(C)c1=O, Cc1cc(C(=O)NOCCO)c(Nc2ccc(I)cc2F)n(C)c1=O, Cc1cc(C(=O)NOCCO)c(Nc2ccc(I)cc2F)n(C)c1=O	RWEVIPRMPFNTLO-UHFFFAOYSA-N, RWEVIPRMPFNTLO-UHFFFAOYSA-N, RWEVIPRMPFNTLO-UHFFFAOYSA-N, RWEVIPRMPFNTLO-UHFFFAOYSA-N, RWEVIPRMPFNTLO-UHFFFAOYSA-N	Phase 1
AZD8797	CC chemokine receptor antagonist				CC(C)C[C@H](CO)Nc1nc(S[C@@H](C)c2ccccc2)nc2nc(N)sc12	ZMQSLMZOWVGBSM-GXTWGEPZSA-N	Preclinical
AZD8835	PI3K inhibitor	PIK3CA, PIK3CD			CCn1nc(nc1-c1cnc(N)c(n1)-c1nnc(o1)C(C)(C)C)C1CCN(CC1)C(=O)CCO, CCn1nc(nc1-c1cnc(N)c(n1)-c1nnc(o1)C(C)(C)C)C1CCN(CC1)C(=O)CCO, CCn1nc(nc1-c1cnc(N)c(n1)-c1nnc(o1)C(C)(C)C)C1CCN(CC1)C(=O)CCO	ZGRDYKFVDCFJCZ-UHFFFAOYSA-N, ZGRDYKFVDCFJCZ-UHFFFAOYSA-N, ZGRDYKFVDCFJCZ-UHFFFAOYSA-N	Phase 1
AZD8931	EGFR inhibitor	EGFR, ERBB2, ERBB3			CNC(=O)CN1CCC(CC1)Oc1cc2c(Nc3cccc(Cl)c3F)ncnc2cc1OC, CNC(=O)CN1CCC(CC1)Oc1cc2c(Nc3cccc(Cl)c3F)ncnc2cc1OC, CNC(=O)CN1CCC(CC1)Oc1cc2c(Nc3cccc(Cl)c3F)ncnc2cc1OC, CNC(=O)CN1CCC(CC1)Oc1cc2c(Nc3cccc(Cl)c3F)ncnc2cc1OC, CNC(=O)CN1CCC(CC1)Oc1cc2c(Nc3cccc(Cl)c3F)ncnc2cc1OC	DFJSJLGUIXFDJP-UHFFFAOYSA-N, DFJSJLGUIXFDJP-UHFFFAOYSA-N, DFJSJLGUIXFDJP-UHFFFAOYSA-N, DFJSJLGUIXFDJP-UHFFFAOYSA-N, DFJSJLGUIXFDJP-UHFFFAOYSA-N	Phase 2
AZD9056	purinergic receptor antagonist				OCCCNCCCc1ccc(Cl)c(c1)C(=O)NCC12CC3CC(CC(C3)C1)C2	HSQAARMBHJCUOK-UHFFFAOYSA-N	Phase 2
AZD9272	glutamate receptor antagonist	GRM5			Fc1ccc(nc1)-c1noc(n1)-c1cc(F)cc(c1)C#N, Fc1ccc(nc1)-c1noc(n1)-c1cc(F)cc(c1)C#N, Fc1ccc(nc1)-c1noc(n1)-c1cc(F)cc(c1)C#N	RBSPCALDSNXWEP-UHFFFAOYSA-N, RBSPCALDSNXWEP-UHFFFAOYSA-N, RBSPCALDSNXWEP-UHFFFAOYSA-N	Preclinical
AZD9496	estrogen receptor agonist	ESR1			C[C@@H]1Cc2c([nH]c3ccccc23)[C@H](N1CC(C)(C)F)c1c(F)cc(\C=C\C(O)=O)cc1F, C[C@@H]1Cc2c([nH]c3ccccc23)[C@H](N1CC(C)(C)F)c1c(F)cc(\C=C\C(O)=O)cc1F, C[C@@H]1Cc2c([nH]c3ccccc23)[C@H](N1CC(C)(C)F)c1c(F)cc(\C=C\C(O)=O)cc1F	DFBDRVGWBHBJNR-BBNFHIFMSA-N, DFBDRVGWBHBJNR-BBNFHIFMSA-N, DFBDRVGWBHBJNR-BBNFHIFMSA-N	Phase 1
AZD9668	elastase inhibitor	ELANE			Cc1c(cc(C(=O)NCc2ccc(cn2)S(C)(=O)=O)c(=O)n1-c1cccc(c1)C(F)(F)F)-c1ccnn1C, Cc1c(cc(C(=O)NCc2ccc(cn2)S(C)(=O)=O)c(=O)n1-c1cccc(c1)C(F)(F)F)-c1ccnn1C, Cc1c(cc(C(=O)NCc2ccc(cn2)S(C)(=O)=O)c(=O)n1-c1cccc(c1)C(F)(F)F)-c1ccnn1C	QNQZWEGMKJBHEM-UHFFFAOYSA-N, QNQZWEGMKJBHEM-UHFFFAOYSA-N, QNQZWEGMKJBHEM-UHFFFAOYSA-N	Phase 2
azelaic-acid	tyrosinase inhibitor	AKR1D1, SRD5A2, TYR	dermatology	rosacea	OC(=O)CCCCCCCC(O)=O, OC(=O)CCCCCCCC(O)=O	BDJRBEYXGGNYIS-UHFFFAOYSA-N, BDJRBEYXGGNYIS-UHFFFAOYSA-N	Launched
azelastine	histamine receptor antagonist	HRH1	ophthalmology	conjunctivitis	CN1CCC[C@@H](CC1)n1nc(Cc2ccc(Cl)cc2)c2ccccc2c1=O |&1:5|, CN1CCC[C@@H](CC1)n1nc(Cc2ccc(Cl)cc2)c2ccccc2c1=O |&1:5|, CN1CCC[C@@H](CC1)n1nc(Cc2ccc(Cl)cc2)c2ccccc2c1=O |&1:5|, CN1CCC[C@@H](CC1)n1nc(Cc2ccc(Cl)cc2)c2ccccc2c1=O |&1:5|	MBUVEWMHONZEQD-SFHVURJKSA-N, MBUVEWMHONZEQD-SFHVURJKSA-N, MBUVEWMHONZEQD-SFHVURJKSA-N, MBUVEWMHONZEQD-SFHVURJKSA-N	Launched
azeliragon	RAGE receptor antagonist	AGER			CCCCc1nc(cn1-c1ccc(Oc2ccc(Cl)cc2)cc1)-c1ccc(OCCCN(CC)CC)cc1, CCCCc1nc(cn1-c1ccc(Oc2ccc(Cl)cc2)cc1)-c1ccc(OCCCN(CC)CC)cc1, CCCCc1nc(cn1-c1ccc(Oc2ccc(Cl)cc2)cc1)-c1ccc(OCCCN(CC)CC)cc1, CCCCc1nc(cn1-c1ccc(Oc2ccc(Cl)cc2)cc1)-c1ccc(OCCCN(CC)CC)cc1, CCCCc1nc(cn1-c1ccc(Oc2ccc(Cl)cc2)cc1)-c1ccc(OCCCN(CC)CC)cc1	KJNNWYBAOPXVJY-UHFFFAOYSA-N, KJNNWYBAOPXVJY-UHFFFAOYSA-N, KJNNWYBAOPXVJY-UHFFFAOYSA-N, KJNNWYBAOPXVJY-UHFFFAOYSA-N, KJNNWYBAOPXVJY-UHFFFAOYSA-N	Phase 3
azelnidipine	calcium channel blocker	CACNA1C	cardiology	hypertension	CC(C)OC(=O)C1=C(C)NC(N)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OC1CN(C1)C(c1ccccc1)c1ccccc1 |r,c:6,11|, CC(C)OC(=O)C1=C(C)NC(N)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OC1CN(C1)C(c1ccccc1)c1ccccc1 |r,c:6,11|, CC(C)OC(=O)C1=C(C)NC(N)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OC1CN(C1)C(c1ccccc1)c1ccccc1 |r,c:6,11|, CC(C)OC(=O)C1=C(C)NC(N)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OC1CN(C1)C(c1ccccc1)c1ccccc1 |r,c:6,11|, CC(C)OC(=O)C1=C(C)NC(N)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OC1CN(C1)C(c1ccccc1)c1ccccc1 |r,c:6,11|, CC(C)OC(=O)C1=C(C)NC(N)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OC1CN(C1)C(c1ccccc1)c1ccccc1 |r,c:6,11|, CC(C)OC(=O)C1=C(C)NC(N)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OC1CN(C1)C(c1ccccc1)c1ccccc1 |r,c:6,11|	ZKFQEACEUNWPMT-MUUNZHRXSA-N, ZKFQEACEUNWPMT-MUUNZHRXSA-N, ZKFQEACEUNWPMT-MUUNZHRXSA-N, ZKFQEACEUNWPMT-MUUNZHRXSA-N, ZKFQEACEUNWPMT-MUUNZHRXSA-N, ZKFQEACEUNWPMT-MUUNZHRXSA-N, ZKFQEACEUNWPMT-MUUNZHRXSA-N	Launched
azilsartan	angiotensin receptor antagonist	AGTR1, AGTR2	cardiology	hypertension	CCOc1nc2cccc(C(O)=O)c2n1Cc1ccc(cc1)-c1ccccc1-c1nc(=O)o[nH]1, CCOc1nc2cccc(C(O)=O)c2n1Cc1ccc(cc1)-c1ccccc1-c1nc(=O)o[nH]1, CCOc1nc2cccc(C(O)=O)c2n1Cc1ccc(cc1)-c1ccccc1-c1nc(=O)o[nH]1, CCOc1nc2cccc(C(O)=O)c2n1Cc1ccc(cc1)-c1ccccc1-c1nc(=O)o[nH]1, CCOc1nc2cccc(C(O)=O)c2n1Cc1ccc(cc1)-c1ccccc1-c1nc(=O)o[nH]1	KGSXMPPBFPAXLY-UHFFFAOYSA-N, KGSXMPPBFPAXLY-UHFFFAOYSA-N, KGSXMPPBFPAXLY-UHFFFAOYSA-N, KGSXMPPBFPAXLY-UHFFFAOYSA-N, KGSXMPPBFPAXLY-UHFFFAOYSA-N	Launched
azilsartan-medoxomil	angiotensin receptor antagonist	AGTR1, AGTR2	cardiology	hypertension	CCOc1nc2cccc(C(=O)OCc3oc(=O)oc3C)c2n1Cc1ccc(cc1)-c1ccccc1-c1nc(=O)o[nH]1, CCOc1nc2cccc(C(=O)OCc3oc(=O)oc3C)c2n1Cc1ccc(cc1)-c1ccccc1-c1nc(=O)o[nH]1, CCOc1nc2cccc(C(=O)OCc3oc(=O)oc3C)c2n1Cc1ccc(cc1)-c1ccccc1-c1nc(=O)o[nH]1, CCOc1nc2cccc(C(=O)OCc3oc(=O)oc3C)c2n1Cc1ccc(cc1)-c1ccccc1-c1nc(=O)o[nH]1, CCOc1nc2cccc(C(=O)OCc3oc(=O)oc3C)c2n1Cc1ccc(cc1)-c1ccccc1-c1nc(=O)o[nH]1, CCOc1nc2cccc(C(=O)OCc3oc(=O)oc3C)c2n1Cc1ccc(cc1)-c1ccccc1-c1nc(=O)o[nH]1, CCOc1nc2cccc(C(=O)OCc3oc(=O)oc3C)c2n1Cc1ccc(cc1)-c1ccccc1-c1nc(=O)o[nH]1	QJFSABGVXDWMIW-UHFFFAOYSA-N, QJFSABGVXDWMIW-UHFFFAOYSA-N, QJFSABGVXDWMIW-UHFFFAOYSA-N, QJFSABGVXDWMIW-UHFFFAOYSA-N, QJFSABGVXDWMIW-UHFFFAOYSA-N, QJFSABGVXDWMIW-UHFFFAOYSA-N, QJFSABGVXDWMIW-UHFFFAOYSA-N	Launched
azimilide	potassium channel blocker	KCNA5			CN1CCN(CCCCN2C(=O)CN(\N=C\c3ccc(o3)-c3ccc(Cl)cc3)C2=O)CC1, CN1CCN(CCCCN2C(=O)CN(\N=C\c3ccc(o3)-c3ccc(Cl)cc3)C2=O)CC1, CN1CCN(CCCCN2C(=O)CN(\N=C\c3ccc(o3)-c3ccc(Cl)cc3)C2=O)CC1	MREBEPTUUMTTIA-PCLIKHOPSA-N, MREBEPTUUMTTIA-PCLIKHOPSA-N, MREBEPTUUMTTIA-PCLIKHOPSA-N	Phase 3
azithromycin	bacterial 50S ribosomal subunit inhibitor	MLNR	infectious disease	pelvic inflammatory disease, pneumonia	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O, CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O, CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O, CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O, CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O, CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O, CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O	MQTOSJVFKKJCRP-CBLJCGFISA-N, MQTOSJVFKKJCRP-CBLJCGFISA-N, MQTOSJVFKKJCRP-CBLJCGFISA-N, MQTOSJVFKKJCRP-CBLJCGFISA-N, MQTOSJVFKKJCRP-CBLJCGFISA-N, MQTOSJVFKKJCRP-CBLJCGFISA-N, MQTOSJVFKKJCRP-CBLJCGFISA-N	Launched
azlocillin	bacterial cell wall synthesis inhibitor		infectious disease	gram-positive bacterial infections, gram-negative bacterial infections	CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](NC(=O)N3CCNC3=O)c3ccccc3)C(=O)N2[C@H]1C(O)=O, CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](NC(=O)N3CCNC3=O)c3ccccc3)C(=O)N2[C@H]1C(O)=O, CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](NC(=O)N3CCNC3=O)c3ccccc3)C(=O)N2[C@H]1C(O)=O, CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](NC(=O)N3CCNC3=O)c3ccccc3)C(=O)N2[C@H]1C(O)=O, CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](NC(=O)N3CCNC3=O)c3ccccc3)C(=O)N2[C@H]1C(O)=O	JTWOMNBEOCYFNV-NFFDBFGFSA-N, JTWOMNBEOCYFNV-NFFDBFGFSA-N, JTWOMNBEOCYFNV-NFFDBFGFSA-N, JTWOMNBEOCYFNV-NFFDBFGFSA-N, JTWOMNBEOCYFNV-NFFDBFGFSA-N	Launched
AZM-475271	SRC inhibitor	SRC			COc1ccc(Cl)c(Nc2ncnc3cc(OCC4CCN(C)CC4)c(OC)cc23)c1, COc1ccc(Cl)c(Nc2ncnc3cc(OCC4CCN(C)CC4)c(OC)cc23)c1, COc1ccc(Cl)c(Nc2ncnc3cc(OCC4CCN(C)CC4)c(OC)cc23)c1, COc1ccc(Cl)c(Nc2ncnc3cc(OCC4CCN(C)CC4)c(OC)cc23)c1	WPOXAFXHRJYEIC-UHFFFAOYSA-N, WPOXAFXHRJYEIC-UHFFFAOYSA-N, WPOXAFXHRJYEIC-UHFFFAOYSA-N, WPOXAFXHRJYEIC-UHFFFAOYSA-N	Preclinical
azodicarbonamide	DNA synthesis inhibitor				NC(=O)\N=N\C(N)=O, NC(=O)\N=N\C(N)=O	XOZUGNYVDXMRKW-AATRIKPKSA-N, XOZUGNYVDXMRKW-AATRIKPKSA-N	Phase 2
azomycin-(2-nitroimidazole)	protein synthesis inhibitor				[O-][N+](=O)c1ncc[nH]1, [O-][N+](=O)c1ncc[nH]1	YZEUHQHUFTYLPH-UHFFFAOYSA-N, YZEUHQHUFTYLPH-UHFFFAOYSA-N	Preclinical
azosemide	electrolyte reabsorption inhibitor	SLC12A1, SLC12A2	cardiology	edema	NS(=O)(=O)c1cc(-c2nn[nH]n2)c(NCc2cccs2)cc1Cl, NS(=O)(=O)c1cc(-c2nn[nH]n2)c(NCc2cccs2)cc1Cl, NS(=O)(=O)c1cc(-c2nn[nH]n2)c(NCc2cccs2)cc1Cl	HMEDEBAJARCKCT-UHFFFAOYSA-N, HMEDEBAJARCKCT-UHFFFAOYSA-N, HMEDEBAJARCKCT-UHFFFAOYSA-N	Launched
aztreonam	bacterial cell wall synthesis inhibitor		infectious disease	urinary tract infections, respiratory tract infections, bacterial septicemia, skin infections, intra-abdominal infections, gynecologic infections	C[C@H]1[C@H](NC(=O)C(=N/OC(C)(C)C(O)=O)\c2csc(N)n2)C(=O)N1S(O)(=O)=O, C[C@H]1[C@H](NC(=O)C(=N/OC(C)(C)C(O)=O)\c2csc(N)n2)C(=O)N1S(O)(=O)=O, C[C@H]1[C@H](NC(=O)C(=N/OC(C)(C)C(O)=O)\c2csc(N)n2)C(=O)N1S(O)(=O)=O, C[C@H]1[C@H](NC(=O)C(=N/OC(C)(C)C(O)=O)\c2csc(N)n2)C(=O)N1S(O)(=O)=O, C[C@H]1[C@H](NC(=O)C(=N/OC(C)(C)C(O)=O)\c2csc(N)n2)C(=O)N1S(O)(=O)=O	WZPBZJONDBGPKJ-VEHQQRBSSA-N, WZPBZJONDBGPKJ-VEHQQRBSSA-N, WZPBZJONDBGPKJ-VEHQQRBSSA-N, WZPBZJONDBGPKJ-VEHQQRBSSA-N, WZPBZJONDBGPKJ-VEHQQRBSSA-N	Launched
AZ191	DYRK inhibitor	DYRK1B			COc1cc(ccc1Nc1nccc(n1)-c1cn(C)c2cnccc12)N1CCN(C)CC1, COc1cc(ccc1Nc1nccc(n1)-c1cn(C)c2cnccc12)N1CCN(C)CC1, COc1cc(ccc1Nc1nccc(n1)-c1cn(C)c2cnccc12)N1CCN(C)CC1, COc1cc(ccc1Nc1nccc(n1)-c1cn(C)c2cnccc12)N1CCN(C)CC1, COc1cc(ccc1Nc1nccc(n1)-c1cn(C)c2cnccc12)N1CCN(C)CC1, COc1cc(ccc1Nc1nccc(n1)-c1cn(C)c2cnccc12)N1CCN(C)CC1	ZYVXTMKTGDARKR-UHFFFAOYSA-N, ZYVXTMKTGDARKR-UHFFFAOYSA-N, ZYVXTMKTGDARKR-UHFFFAOYSA-N, ZYVXTMKTGDARKR-UHFFFAOYSA-N, ZYVXTMKTGDARKR-UHFFFAOYSA-N, ZYVXTMKTGDARKR-UHFFFAOYSA-N	Preclinical
AZ20	ATR kinase inhibitor	ATR, MTOR			C[C@@H]1COCCN1c1cc(nc(n1)-c1cccc2[nH]ccc12)C1(CC1)S(C)(=O)=O, C[C@@H]1COCCN1c1cc(nc(n1)-c1cccc2[nH]ccc12)C1(CC1)S(C)(=O)=O	SCGCBAAYLFTIJU-CQSZACIVSA-N, SCGCBAAYLFTIJU-CQSZACIVSA-N	Preclinical
AZ3146	monopolar spindle 1 kinase inhibitor				COc1cc(OC2CCN(C)CC2)ccc1Nc1ncc2n(C)c(=O)n(C3CCCC3)c2n1, COc1cc(OC2CCN(C)CC2)ccc1Nc1ncc2n(C)c(=O)n(C3CCCC3)c2n1, COc1cc(OC2CCN(C)CC2)ccc1Nc1ncc2n(C)c(=O)n(C3CCCC3)c2n1, COc1cc(OC2CCN(C)CC2)ccc1Nc1ncc2n(C)c(=O)n(C3CCCC3)c2n1	YUKWVHPTFRQHMF-UHFFFAOYSA-N, YUKWVHPTFRQHMF-UHFFFAOYSA-N, YUKWVHPTFRQHMF-UHFFFAOYSA-N, YUKWVHPTFRQHMF-UHFFFAOYSA-N	Preclinical
AZ505	histone lysine methyltransferase inhibitor	SMYD2			Oc1ccc(CCNCCN(C2CCCCC2)C(=O)CCNCCc2ccc(Cl)c(Cl)c2)c2OCC(=O)Nc12, Oc1ccc(CCNCCN(C2CCCCC2)C(=O)CCNCCc2ccc(Cl)c(Cl)c2)c2OCC(=O)Nc12	LIBVHXXKHSODII-UHFFFAOYSA-N, LIBVHXXKHSODII-UHFFFAOYSA-N	Preclinical
AZ5104	EGFR inhibitor	EGFR			COc1cc(N(C)CCN(C)C)c(NC(=O)C=C)cc1Nc1nccc(n1)-c1c[nH]c2ccccc12	IQNVEOMHJHBNHC-UHFFFAOYSA-N	Preclinical
AZ7550	insulin growth factor receptor inhibitor				CNCCN(C)c1cc(OC)c(Nc2nccc(n2)-c2cn(C)c3ccccc23)cc1NC(=O)C=C	ZROCWKZRGJYPTG-UHFFFAOYSA-N	Phase 1
AZ960	JAK inhibitor	JAK2			C[C@H](Nc1nc(Nc2cc(C)n[nH]2)c(F)cc1C#N)c1ccc(F)cc1, C[C@H](Nc1nc(Nc2cc(C)n[nH]2)c(F)cc1C#N)c1ccc(F)cc1, C[C@H](Nc1nc(Nc2cc(C)n[nH]2)c(F)cc1C#N)c1ccc(F)cc1, C[C@H](Nc1nc(Nc2cc(C)n[nH]2)c(F)cc1C#N)c1ccc(F)cc1, C[C@H](Nc1nc(Nc2cc(C)n[nH]2)c(F)cc1C#N)c1ccc(F)cc1, C[C@H](Nc1nc(Nc2cc(C)n[nH]2)c(F)cc1C#N)c1ccc(F)cc1, C[C@H](Nc1nc(Nc2cc(C)n[nH]2)c(F)cc1C#N)c1ccc(F)cc1, C[C@H](Nc1nc(Nc2cc(C)n[nH]2)c(F)cc1C#N)c1ccc(F)cc1, C[C@H](Nc1nc(Nc2cc(C)n[nH]2)c(F)cc1C#N)c1ccc(F)cc1, C[C@H](Nc1nc(Nc2cc(C)n[nH]2)c(F)cc1C#N)c1ccc(F)cc1	SUNXHXDJOIXABJ-NSHDSACASA-N, SUNXHXDJOIXABJ-NSHDSACASA-N, SUNXHXDJOIXABJ-NSHDSACASA-N, SUNXHXDJOIXABJ-NSHDSACASA-N, SUNXHXDJOIXABJ-NSHDSACASA-N, SUNXHXDJOIXABJ-NSHDSACASA-N, SUNXHXDJOIXABJ-NSHDSACASA-N, SUNXHXDJOIXABJ-NSHDSACASA-N, SUNXHXDJOIXABJ-NSHDSACASA-N, SUNXHXDJOIXABJ-NSHDSACASA-N	Preclinical
A0001					CC(C)CCC[C@@H](C)CCC[C@@H](C)CCC[C@@](C)(O)CCC1=C(C)C(=O)C(C)=C(C)C1=O |c:21,t:27|, CC(C)CCC[C@@H](C)CCC[C@@H](C)CCC[C@@](C)(O)CCC1=C(C)C(=O)C(C)=C(C)C1=O |c:21,t:27|	LTVDFSLWFKLJDQ-IEOSBIPESA-N, LTVDFSLWFKLJDQ-IEOSBIPESA-N	Phase 2
A12B4C3	polynucleotide kinase/phosphatase inhibitor	PNKP			CCCCCCCCCC[C@@H](O)[C@H]1C=C[C@H]2[C@@H](N1Nc1ccc(cc1)[N+]([O-])=O)C(=O)N(C2=O)c1ccccc1 |&1:10,&2:12,r,c:13|, CCCCCCCCCC[C@@H](O)[C@H]1C=C[C@H]2[C@@H](N1Nc1ccc(cc1)[N+]([O-])=O)C(=O)N(C2=O)c1ccccc1 |&1:10,&2:12,r,c:13|	KVHGJAKTBPFFNV-KUXCXQDQSA-N, KVHGJAKTBPFFNV-KUXCXQDQSA-N	Preclinical
A205804	ICAM1 expression inhibitor	ICAM1, SELE			Cc1ccc(Sc2cncc3sc(cc23)C(N)=O)cc1, Cc1ccc(Sc2cncc3sc(cc23)C(N)=O)cc1, Cc1ccc(Sc2cncc3sc(cc23)C(N)=O)cc1, Cc1ccc(Sc2cncc3sc(cc23)C(N)=O)cc1, Cc1ccc(Sc2cncc3sc(cc23)C(N)=O)cc1, Cc1ccc(Sc2cncc3sc(cc23)C(N)=O)cc1, Cc1ccc(Sc2cncc3sc(cc23)C(N)=O)cc1	QQGWEXFLMJGCAL-UHFFFAOYSA-N, QQGWEXFLMJGCAL-UHFFFAOYSA-N, QQGWEXFLMJGCAL-UHFFFAOYSA-N, QQGWEXFLMJGCAL-UHFFFAOYSA-N, QQGWEXFLMJGCAL-UHFFFAOYSA-N, QQGWEXFLMJGCAL-UHFFFAOYSA-N, QQGWEXFLMJGCAL-UHFFFAOYSA-N	Preclinical
A61603	adrenergic receptor agonist	ADRA1A			CS(=O)(=O)Nc1c(O)ccc2[C@@H](CCCc12)C1=NCCN1 |r,t:18|, CS(=O)(=O)Nc1c(O)ccc2[C@@H](CCCc12)C1=NCCN1 |r,t:18|	OQFCXJDXHCDLHX-LLVKDONJSA-N, OQFCXJDXHCDLHX-LLVKDONJSA-N	Preclinical
A66	PI3K inhibitor	PIK3CA			Cc1nc(NC(=O)N2CCC[C@H]2C(N)=O)sc1-c1csc(n1)C(C)(C)C, Cc1nc(NC(=O)N2CCC[C@H]2C(N)=O)sc1-c1csc(n1)C(C)(C)C, Cc1nc(NC(=O)N2CCC[C@H]2C(N)=O)sc1-c1csc(n1)C(C)(C)C	HBPXWEPKNBHKAX-NSHDSACASA-N, HBPXWEPKNBHKAX-NSHDSACASA-N, HBPXWEPKNBHKAX-NSHDSACASA-N	Preclinical
A740003	purinergic receptor antagonist	P2RX7			COc1ccc(CC(=O)N[C@@H](N\C(Nc2cccc3ncccc23)=N\C#N)C(C)(C)C)cc1OC |&1:10,r|, COc1ccc(CC(=O)N[C@@H](N\C(Nc2cccc3ncccc23)=N\C#N)C(C)(C)C)cc1OC |&1:10,r|, COc1ccc(CC(=O)N[C@@H](N\C(Nc2cccc3ncccc23)=N\C#N)C(C)(C)C)cc1OC |&1:10,r|, COc1ccc(CC(=O)N[C@@H](N\C(Nc2cccc3ncccc23)=N\C#N)C(C)(C)C)cc1OC |&1:10,r|, COc1ccc(CC(=O)N[C@@H](N\C(Nc2cccc3ncccc23)=N\C#N)C(C)(C)C)cc1OC |&1:10,r|, COc1ccc(CC(=O)N[C@@H](N\C(Nc2cccc3ncccc23)=N\C#N)C(C)(C)C)cc1OC |&1:10,r|, COc1ccc(CC(=O)N[C@@H](N\C(Nc2cccc3ncccc23)=N\C#N)C(C)(C)C)cc1OC |&1:10,r|	PUHSRMSFDASMAE-DEOSSOPVSA-N, PUHSRMSFDASMAE-DEOSSOPVSA-N, PUHSRMSFDASMAE-DEOSSOPVSA-N, PUHSRMSFDASMAE-DEOSSOPVSA-N, PUHSRMSFDASMAE-DEOSSOPVSA-N, PUHSRMSFDASMAE-DEOSSOPVSA-N, PUHSRMSFDASMAE-DEOSSOPVSA-N	Preclinical
A77636	dopamine receptor agonist	CALY			NC[C@@H]1O[C@@H](Cc2c(O)c(O)ccc12)[C@@]12CC3CC(CC(C3)C1)C2, NC[C@@H]1O[C@@H](Cc2c(O)c(O)ccc12)[C@@]12CC3CC(CC(C3)C1)C2, NC[C@@H]1O[C@@H](Cc2c(O)c(O)ccc12)[C@@]12CC3CC(CC(C3)C1)C2	QLJOSZATCBCBDR-KLONBWLYSA-N, QLJOSZATCBCBDR-KLONBWLYSA-N, QLJOSZATCBCBDR-KLONBWLYSA-N	Preclinical
A922500	diacylglycerol O acyltransferase inhibitor	DGAT1			OC(=O)[C@H]1CCC[C@H]1C(=O)c1ccc(cc1)-c1ccc(NC(=O)Nc2ccccc2)cc1	BOZRFEQDOFSZBV-PKTZIBPZSA-N	Preclinical
bacampicillin	bacterial cell wall synthesis inhibitor		infectious disease	gram-positive bacterial infections, gram-negative bacterial infections	CCOC(=O)O[C@@H](C)OC(=O)[C@@H]1N2[C@H](SC1(C)C)[C@H](NC(=O)[C@H](N)c1ccccc1)C2=O |a:11,13,18,22,&1:6|, CCOC(=O)O[C@@H](C)OC(=O)[C@@H]1N2[C@H](SC1(C)C)[C@H](NC(=O)[C@H](N)c1ccccc1)C2=O |a:11,13,18,22,&1:6|, CCOC(=O)O[C@@H](C)OC(=O)[C@@H]1N2[C@H](SC1(C)C)[C@H](NC(=O)[C@H](N)c1ccccc1)C2=O |a:11,13,18,22,&1:6|	PFOLLRNADZZWEX-XIJZRVNUSA-N, PFOLLRNADZZWEX-XIJZRVNUSA-N, PFOLLRNADZZWEX-XIJZRVNUSA-N	Launched
bacitracin	bacterial cell wall synthesis inhibitor	IDE	infectious disease	first-aid antibiotic	CC[C@H](C)[C@H](N)C1=N[C@@H](CS1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H]1CCCCNC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](CC(O)=O)NC(=O)[C@H](Cc2cnc[nH]2)NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@@H](NC(=O)[C@@H](CCCN)NC1=O)[C@@H](C)CC |t:6|	CLKOFPXJLQSYAH-BBLSSJOMSA-N	Launched
bacitracin-zinc	bacterial cell wall synthesis inhibitor		infectious disease	first-aid antibiotic	CC[C@H](C)[C@H](N)C1=N[C@@H](CS1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]1CCC(=O)O[Zn]OC(=O)C[C@H]2NC(=O)[C@H](Cc3c[nH]cn3)NC(=O)[C@@H](Cc3ccccc3)NC(=O)[C@@H](NC(=O)[C@@H](CCCN)NC(=O)[C@H](CCCCNC(=O)[C@H](CC(N)=O)NC2=O)NC(=O)[C@@H](NC1=O)[C@@H](C)CC)[C@@H](C)CC |t:6|	UCRLQOPRDMGYOA-PIGMFEANSA-L	Launched
baclofen	benzodiazepine receptor agonist	GABBR1, GABBR2, KCTD12, KCTD16, KCTD8	neurology/psychiatry	multiple sclerosis, spasms	NC[C@@H](CC(O)=O)c1ccc(Cl)cc1 |&1:2|, NC[C@@H](CC(O)=O)c1ccc(Cl)cc1 |&1:2|	KPYSYYIEGFHWSV-MRVPVSSYSA-N, KPYSYYIEGFHWSV-MRVPVSSYSA-N	Launched
BADGE	PPAR receptor antagonist	PPARG			CC(C)(c1ccc(OC[C@H]2CO2)cc1)c1ccc(OC[C@H]2CO2)cc1 |&1:9,&2:20,r|, CC(C)(c1ccc(OC[C@H]2CO2)cc1)c1ccc(OC[C@H]2CO2)cc1 |&1:9,&2:20,r|	LCFVJGUPQDGYKZ-PMACEKPBSA-N, LCFVJGUPQDGYKZ-PMACEKPBSA-N	Preclinical
bafetinib	Bcr-Abl kinase inhibitor, LYN tyrosine kinase inhibitor	ABL1, BCR, LYN			CN(C)[C@H]1CCN(Cc2ccc(cc2C(F)(F)F)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cncnc3)c2)C1, CN(C)[C@H]1CCN(Cc2ccc(cc2C(F)(F)F)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cncnc3)c2)C1, CN(C)[C@H]1CCN(Cc2ccc(cc2C(F)(F)F)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cncnc3)c2)C1, CN(C)[C@H]1CCN(Cc2ccc(cc2C(F)(F)F)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cncnc3)c2)C1, CN(C)[C@H]1CCN(Cc2ccc(cc2C(F)(F)F)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cncnc3)c2)C1, CN(C)[C@H]1CCN(Cc2ccc(cc2C(F)(F)F)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cncnc3)c2)C1	ZGBAJMQHJDFTQJ-DEOSSOPVSA-N, ZGBAJMQHJDFTQJ-DEOSSOPVSA-N, ZGBAJMQHJDFTQJ-DEOSSOPVSA-N, ZGBAJMQHJDFTQJ-DEOSSOPVSA-N, ZGBAJMQHJDFTQJ-DEOSSOPVSA-N, ZGBAJMQHJDFTQJ-DEOSSOPVSA-N	Phase 2
bafilomycin-a1	ATPase inhibitor				[H][C@@]1(OC(=O)\C(OC)=C\C(\C)=C/[C@@H](C)[C@@H](O)[C@@H](C)C\C(C)=C\C=C\[C@@H]1OC)[C@@H](C)[C@@H](O)[C@H](C)[C@@]1(O)C[C@@H](O)[C@H](C)[C@H](O1)C(C)C |c:10,t:7,20,22|, [H][C@@]1(OC(=O)\C(OC)=C\C(\C)=C/[C@@H](C)[C@@H](O)[C@@H](C)C\C(C)=C\C=C\[C@@H]1OC)[C@@H](C)[C@@H](O)[C@H](C)[C@@]1(O)C[C@@H](O)[C@H](C)[C@H](O1)C(C)C |c:10,t:7,20,22|	XDHNQDDQEHDUTM-UTRUWJARSA-N, XDHNQDDQEHDUTM-UTRUWJARSA-N	Preclinical
BAG-956	phosphoinositide dependent kinase inhibitor	PIK3CG			Cc1nc2cnc3ccc(cc3c2n1-c1ccc(cc1)C(C)(C)C#N)C#Cc1cccnc1, Cc1nc2cnc3ccc(cc3c2n1-c1ccc(cc1)C(C)(C)C#N)C#Cc1cccnc1, Cc1nc2cnc3ccc(cc3c2n1-c1ccc(cc1)C(C)(C)C#N)C#Cc1cccnc1	GVPAGJWVBUZHNQ-UHFFFAOYSA-N, GVPAGJWVBUZHNQ-UHFFFAOYSA-N, GVPAGJWVBUZHNQ-UHFFFAOYSA-N	Preclinical
baicalein	lipoxygenase inhibitor	ALOX5, GLO1, PREP, SELL, SELP, TNF, XDH			Oc1cc2oc(cc(O)c2c(=O)c1O)-c1ccccc1, Oc1cc2oc(cc(O)c2c(=O)c1O)-c1ccccc1, Oc1cc2oc(cc(O)c2c(=O)c1O)-c1ccccc1, Oc1cc2oc(cc(O)c2c(=O)c1O)-c1ccccc1, Oc1cc2oc(cc(O)c2c(=O)c1O)-c1ccccc1, Oc1cc2oc(cc(O)c2c(=O)c1O)-c1ccccc1	WTNAEULBGCSUSK-UHFFFAOYSA-N, WTNAEULBGCSUSK-UHFFFAOYSA-N, WTNAEULBGCSUSK-UHFFFAOYSA-N, WTNAEULBGCSUSK-UHFFFAOYSA-N, WTNAEULBGCSUSK-UHFFFAOYSA-N, WTNAEULBGCSUSK-UHFFFAOYSA-N	Preclinical
baicalin	beta glucuronidase inhibitor	PREP	neurology/psychiatry	anxiety	O[C@H]1[C@H](Oc2cc3oc(cc(O)c3c(=O)c2O)-c2ccccc2)O[C@@H]([C@@H](O)[C@@H]1O)C(O)=O, O[C@H]1[C@H](Oc2cc3oc(cc(O)c3c(=O)c2O)-c2ccccc2)O[C@@H]([C@@H](O)[C@@H]1O)C(O)=O, O[C@H]1[C@H](Oc2cc3oc(cc(O)c3c(=O)c2O)-c2ccccc2)O[C@@H]([C@@H](O)[C@@H]1O)C(O)=O, O[C@H]1[C@H](Oc2cc3oc(cc(O)c3c(=O)c2O)-c2ccccc2)O[C@@H]([C@@H](O)[C@@H]1O)C(O)=O, O[C@H]1[C@H](Oc2cc3oc(cc(O)c3c(=O)c2O)-c2ccccc2)O[C@@H]([C@@H](O)[C@@H]1O)C(O)=O	DAIGSUHCWOZEQG-ZFORQUDYSA-N, DAIGSUHCWOZEQG-ZFORQUDYSA-N, DAIGSUHCWOZEQG-ZFORQUDYSA-N, DAIGSUHCWOZEQG-ZFORQUDYSA-N, DAIGSUHCWOZEQG-ZFORQUDYSA-N	Launched
bakuchiol	DNA polymerase inhibitor	HIF1A			CC(C)=CCC[C@@](C)(C=C)\C=C\c1ccc(O)cc1, CC(C)=CCC[C@@](C)(C=C)\C=C\c1ccc(O)cc1, CC(C)=CCC[C@@](C)(C=C)\C=C\c1ccc(O)cc1, CC(C)=CCC[C@@](C)(C=C)\C=C\c1ccc(O)cc1	LFYJSSARVMHQJB-QIXNEVBVSA-N, LFYJSSARVMHQJB-QIXNEVBVSA-N, LFYJSSARVMHQJB-QIXNEVBVSA-N, LFYJSSARVMHQJB-QIXNEVBVSA-N	Phase 2
balaglitazone	insulin sensitizer, PPAR receptor partial agonist	PPARG			Cn1c(COc2ccc(C[C@H]3SC(=O)NC3=O)cc2)nc2ccccc2c1=O |r|, Cn1c(COc2ccc(C[C@H]3SC(=O)NC3=O)cc2)nc2ccccc2c1=O |r|	IETKPTYAGKZLKY-MRXNPFEDSA-N, IETKPTYAGKZLKY-MRXNPFEDSA-N	Phase 3
balapiravir	RNA polymerase inhibitor				CC(C)C(=O)OC[C@]1(O[C@H]([C@H](OC(=O)C(C)C)[C@@H]1OC(=O)C(C)C)n1ccc(N)nc1=O)N=[N+]=[N-], CC(C)C(=O)OC[C@]1(O[C@H]([C@H](OC(=O)C(C)C)[C@@H]1OC(=O)C(C)C)n1ccc(N)nc1=O)N=[N+]=[N-], CC(C)C(=O)OC[C@]1(O[C@H]([C@H](OC(=O)C(C)C)[C@@H]1OC(=O)C(C)C)n1ccc(N)nc1=O)N=[N+]=[N-], CC(C)C(=O)OC[C@]1(O[C@H]([C@H](OC(=O)C(C)C)[C@@H]1OC(=O)C(C)C)n1ccc(N)nc1=O)N=[N+]=[N-]	VKXWOLCNTHXCLF-DXEZIKHYSA-N, VKXWOLCNTHXCLF-DXEZIKHYSA-N, VKXWOLCNTHXCLF-DXEZIKHYSA-N, VKXWOLCNTHXCLF-DXEZIKHYSA-N	Phase 2
balicatib	cathepsin inhibitor	CTSK			CCCN1CCN(CC1)c1ccc(cc1)C(=O)NC1(CCCCC1)C(=O)NCC#N, CCCN1CCN(CC1)c1ccc(cc1)C(=O)NC1(CCCCC1)C(=O)NCC#N, CCCN1CCN(CC1)c1ccc(cc1)C(=O)NC1(CCCCC1)C(=O)NCC#N, CCCN1CCN(CC1)c1ccc(cc1)C(=O)NC1(CCCCC1)C(=O)NCC#N, CCCN1CCN(CC1)c1ccc(cc1)C(=O)NC1(CCCCC1)C(=O)NCC#N	LLCRBOWRJOUJAE-UHFFFAOYSA-N, LLCRBOWRJOUJAE-UHFFFAOYSA-N, LLCRBOWRJOUJAE-UHFFFAOYSA-N, LLCRBOWRJOUJAE-UHFFFAOYSA-N, LLCRBOWRJOUJAE-UHFFFAOYSA-N	Phase 2
balofloxacin	bacterial DNA gyrase inhibitor		infectious disease	gram-negative bacterial infections	CN[C@H]1CCCN(C1)c1c(F)cc2c(c1OC)n(cc(C(O)=O)c2=O)C1CC1 |&1:2,r|, CN[C@H]1CCCN(C1)c1c(F)cc2c(c1OC)n(cc(C(O)=O)c2=O)C1CC1 |&1:2,r|, CN[C@H]1CCCN(C1)c1c(F)cc2c(c1OC)n(cc(C(O)=O)c2=O)C1CC1 |&1:2,r|	MGQLHRYJBWGORO-NSHDSACASA-N, MGQLHRYJBWGORO-NSHDSACASA-N, MGQLHRYJBWGORO-NSHDSACASA-N	Launched
baloxavir	endonuclease inhibitor				[H][C@@]12COCCN1C(=O)c1c(O)c(=O)ccn1N2[C@@H]1c2ccccc2SCc2c(F)c(F)ccc12	FIDLLEYNNRGVFR-CTNGQTDRSA-N	Phase 3
baloxavir-marboxil	endonuclease inhibitor		infectious disease	influenza A virus infection	[H][C@@]12COCCN1C(=O)c1c(OCOC(=O)OC)c(=O)ccn1N2[C@H]1c2ccc(F)c(F)c2CSc2ccccc12	RZVPBGBYGMDSBG-GGAORHGYSA-N	Launched
balsalazide	cyclooxygenase inhibitor	ALOX5, PPARG, PTGS1, PTGS2	gastroenterology	ulcerative colitis	OC(=O)CCNC(=O)c1ccc(cc1)\N=N\c1ccc(O)c(c1)C(O)=O	IPOKCKJONYRRHP-FMQUCBEESA-N	Launched
bamaquimast	proton pump inhibitor				CCCn1c2ccccc2nc(CCCOC(=O)NC)c1=O	HNQSZPBGDAJIJO-UHFFFAOYSA-N	Preclinical
bambuterol	adrenergic receptor agonist	ADRB2, BCHE	pulmonary	asthma	CN(C)C(=O)Oc1cc(OC(=O)N(C)C)cc(c1)C(O)CNC(C)(C)C	ANZXOIAKUNOVQU-UHFFFAOYSA-N	Launched
BAM7	BAX activator	BAX			CCOc1ccccc1N\N=C1/C(C)=NN(C1=O)c1nc(cs1)-c1ccccc1 |c:14|, CCOc1ccccc1N\N=C1/C(C)=NN(C1=O)c1nc(cs1)-c1ccccc1 |c:14|, CCOc1ccccc1N\N=C1/C(C)=NN(C1=O)c1nc(cs1)-c1ccccc1 |c:14|, CCOc1ccccc1N\N=C1/C(C)=NN(C1=O)c1nc(cs1)-c1ccccc1 |c:14|, CCOc1ccccc1N\N=C1/C(C)=NN(C1=O)c1nc(cs1)-c1ccccc1 |c:14|, CCOc1ccccc1N\N=C1/C(C)=NN(C1=O)c1nc(cs1)-c1ccccc1 |c:14|	KOCVKGYKBLJEPK-LYBHJNIJSA-N, KOCVKGYKBLJEPK-LYBHJNIJSA-N, KOCVKGYKBLJEPK-LYBHJNIJSA-N, KOCVKGYKBLJEPK-LYBHJNIJSA-N, KOCVKGYKBLJEPK-LYBHJNIJSA-N, KOCVKGYKBLJEPK-LYBHJNIJSA-N	Preclinical
BAN-ORL-24	nociceptin/orphanin FQ receptor antagonist	OPRL1			O=C(NCCCN1CCC2(CC1)OCc1ccccc21)[C@H]1CCCN1Cc1ccccc1, O=C(NCCCN1CCC2(CC1)OCc1ccccc21)[C@H]1CCCN1Cc1ccccc1, O=C(NCCCN1CCC2(CC1)OCc1ccccc21)[C@H]1CCCN1Cc1ccccc1, O=C(NCCCN1CCC2(CC1)OCc1ccccc21)[C@H]1CCCN1Cc1ccccc1	MAKMQGKJURAJEN-RUZDIDTESA-N, MAKMQGKJURAJEN-RUZDIDTESA-N, MAKMQGKJURAJEN-RUZDIDTESA-N, MAKMQGKJURAJEN-RUZDIDTESA-N	Preclinical
banoxantrone	topoisomerase inhibitor	TOP2A			C[N+](C)([O-])CCNc1ccc(NCC[N+](C)(C)[O-])c2C(=O)c3c(O)ccc(O)c3C(=O)c12	YZBAXVICWUUHGG-UHFFFAOYSA-N	Phase 1/Phase 2
barasertib	Aurora kinase inhibitor	AURKA, AURKB			CCN(CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)n[nH]3)ncnc2c1)CCOP(O)(O)=O, CCN(CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)n[nH]3)ncnc2c1)CCOP(O)(O)=O, CCN(CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)n[nH]3)ncnc2c1)CCOP(O)(O)=O	GBJVVSCPOBPEIT-UHFFFAOYSA-N, GBJVVSCPOBPEIT-UHFFFAOYSA-N, GBJVVSCPOBPEIT-UHFFFAOYSA-N	Phase 2/Phase 3
barasertib-HQPA	Aurora kinase inhibitor	AURKB			CCN(CCO)CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)n[nH]3)ncnc2c1, CCN(CCO)CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)n[nH]3)ncnc2c1, CCN(CCO)CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)n[nH]3)ncnc2c1, CCN(CCO)CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)n[nH]3)ncnc2c1, CCN(CCO)CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)n[nH]3)ncnc2c1, CCN(CCO)CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)n[nH]3)ncnc2c1, CCN(CCO)CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)n[nH]3)ncnc2c1, CCN(CCO)CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)n[nH]3)ncnc2c1, CCN(CCO)CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)n[nH]3)ncnc2c1	QYZOGCMHVIGURT-UHFFFAOYSA-N, QYZOGCMHVIGURT-UHFFFAOYSA-N, QYZOGCMHVIGURT-UHFFFAOYSA-N, QYZOGCMHVIGURT-UHFFFAOYSA-N, QYZOGCMHVIGURT-UHFFFAOYSA-N, QYZOGCMHVIGURT-UHFFFAOYSA-N, QYZOGCMHVIGURT-UHFFFAOYSA-N, QYZOGCMHVIGURT-UHFFFAOYSA-N, InChI=1S/C26H30FN7O3/c1-2-34(10-11-35)9-4-12-37-21-7-8-22-23(16-21)28-17-29-26(22)31-24-14-20(32-33-24)15-25(36)30-19-6-3-5-18(27)13-19/h3,5-8,13-14,16-17,35H,2,4,9-12,15H2,1H3,(H,30,36)(H2,28,29,31,32,33)	Phase 2/Phase 3
bardoxolone	nuclear factor erythroid derived, like (NRF2) activator	NOS2, PPARG			CC1(C)CC[C@@]2(CC[C@]3(C)[C@@H]([C@@H]2C1)C(=O)C=C1[C@@]2(C)C=C(C#N)C(=O)C(C)(C)[C@@H]2CC[C@@]31C)C(O)=O |t:17,21|, CC1(C)CC[C@@]2(CC[C@]3(C)[C@@H]([C@@H]2C1)C(=O)C=C1[C@@]2(C)C=C(C#N)C(=O)C(C)(C)[C@@H]2CC[C@@]31C)C(O)=O |t:17,21|, CC1(C)CC[C@@]2(CC[C@]3(C)[C@@H]([C@@H]2C1)C(=O)C=C1[C@@]2(C)C=C(C#N)C(=O)C(C)(C)[C@@H]2CC[C@@]31C)C(O)=O |t:17,21|, CC1(C)CC[C@@]2(CC[C@]3(C)[C@@H]([C@@H]2C1)C(=O)C=C1[C@@]2(C)C=C(C#N)C(=O)C(C)(C)[C@@H]2CC[C@@]31C)C(O)=O |t:17,21|, CC1(C)CC[C@@]2(CC[C@]3(C)[C@@H]([C@@H]2C1)C(=O)C=C1[C@@]2(C)C=C(C#N)C(=O)C(C)(C)[C@@H]2CC[C@@]31C)C(O)=O |t:17,21|	TXGZJQLMVSIZEI-UQMAOPSPSA-N, TXGZJQLMVSIZEI-UQMAOPSPSA-N, TXGZJQLMVSIZEI-UQMAOPSPSA-N, TXGZJQLMVSIZEI-UQMAOPSPSA-N, TXGZJQLMVSIZEI-UQMAOPSPSA-N	Phase 1
bardoxolone-methyl	nuclear factor erythroid derived, like (NRF2) activator	PPARG, STAT3			COC(=O)[C@]12CCC(C)(C)C[C@H]1[C@H]1C(=O)C=C3[C@@]4(C)C=C(C#N)C(=O)C(C)(C)[C@@H]4CC[C@@]3(C)[C@]1(C)CC2 |t:16,20|, COC(=O)[C@]12CCC(C)(C)C[C@H]1[C@H]1C(=O)C=C3[C@@]4(C)C=C(C#N)C(=O)C(C)(C)[C@@H]4CC[C@@]3(C)[C@]1(C)CC2 |t:16,20|, COC(=O)[C@]12CCC(C)(C)C[C@H]1[C@H]1C(=O)C=C3[C@@]4(C)C=C(C#N)C(=O)C(C)(C)[C@@H]4CC[C@@]3(C)[C@]1(C)CC2 |t:16,20|, COC(=O)[C@]12CCC(C)(C)C[C@H]1[C@H]1C(=O)C=C3[C@@]4(C)C=C(C#N)C(=O)C(C)(C)[C@@H]4CC[C@@]3(C)[C@]1(C)CC2 |t:16,20|	WPTTVJLTNAWYAO-KPOXMGGZSA-N, WPTTVJLTNAWYAO-KPOXMGGZSA-N, WPTTVJLTNAWYAO-KPOXMGGZSA-N, InChI=1S/C32H43NO4/c1-27(2)11-13-32(26(36)37-8)14-12-31(7)24(20(32)17-27)21(34)15-23-29(5)16-19(18-33)25(35)28(3,4)22(29)9-10-30(23,31)6/h15-16,20,22,24H,9-14,17H2,1-8H3/t20-,22-,24-,29-,30+,31+,32-/m0/s1	Phase 3
baricitinib	JAK inhibitor	JAK1, JAK2	rheumatology	rheumatoid arthritis	CCS(=O)(=O)N1CC(CC#N)(C1)n1cc(cn1)-c1ncnc2[nH]ccc12, CCS(=O)(=O)N1CC(CC#N)(C1)n1cc(cn1)-c1ncnc2[nH]ccc12, CCS(=O)(=O)N1CC(CC#N)(C1)n1cc(cn1)-c1ncnc2[nH]ccc12, CCS(=O)(=O)N1CC(CC#N)(C1)n1cc(cn1)-c1ncnc2[nH]ccc12	XUZMWHLSFXCVMG-UHFFFAOYSA-N, XUZMWHLSFXCVMG-UHFFFAOYSA-N, XUZMWHLSFXCVMG-UHFFFAOYSA-N, XUZMWHLSFXCVMG-UHFFFAOYSA-N	Launched
barium-6-O-phosphonato-D-glucose					O[C@H](COP(O)(O)=O)[C@@H](O)[C@H](O)[C@@H](O)C=O	VFRROHXSMXFLSN-SLPGGIOYSA-N	Preclinical
barnidipine	calcium channel blocker		cardiology	hypertension	COC(=O)C1=C(C)NC(C)=C([C@H]1c1cccc(c1)[N+]([O-])=O)C(=O)O[C@H]1CCN(Cc2ccccc2)C1 |c:4,9|, COC(=O)C1=C(C)NC(C)=C([C@H]1c1cccc(c1)[N+]([O-])=O)C(=O)O[C@H]1CCN(Cc2ccccc2)C1 |c:4,9|	VXMOONUMYLCFJD-DHLKQENFSA-N, VXMOONUMYLCFJD-DHLKQENFSA-N	Launched
basic-fuchsin					CC1=CC(C=CC1=N)=C(c1ccc(N)cc1)c1ccc(N)cc1 |c:4,t:1|	YDCMWLQSPFTWCS-UHFFFAOYSA-N	Preclinical
basimglurant	glutamate receptor antagonist	GRM5			Cc1nc(C#Cc2ccnc(Cl)c2)c(C)n1-c1ccc(F)cc1	UPZWINBEAHDTLA-UHFFFAOYSA-N	Phase 2
basmisanil	GABA receptor inverse agonist				Cc1onc(c1COc1ccc(cn1)C(=O)N1CCS(=O)(=O)CC1)-c1ccc(F)cc1	VCGRFBXVSFAGGA-UHFFFAOYSA-N	Phase 2
batefenterol	acetylcholine receptor antagonist, adrenergic receptor agonist				COc1cc(NC(=O)CCN2CCC(CC2)OC(=O)Nc2ccccc2-c2ccccc2)c(Cl)cc1CNC[C@H](O)c1ccc(O)c2nc(O)ccc12	URWYQGVSPQJGGB-DHUJRADRSA-N	Phase 2
batimastat	matrix metalloprotease inhibitor	ADAM28, ADAMTS5, MMP12, MMP16, MMP2, MMP8			CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)[C@H](CSc1cccs1)C(=O)NO, CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)[C@H](CSc1cccs1)C(=O)NO, CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)[C@H](CSc1cccs1)C(=O)NO, CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)[C@H](CSc1cccs1)C(=O)NO, CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)[C@H](CSc1cccs1)C(=O)NO, CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)[C@H](CSc1cccs1)C(=O)NO, CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)[C@H](CSc1cccs1)C(=O)NO, CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)[C@H](CSc1cccs1)C(=O)NO, CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)[C@H](CSc1cccs1)C(=O)NO, CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)[C@H](CSc1cccs1)C(=O)NO, CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)[C@H](CSc1cccs1)C(=O)NO, CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)[C@H](CSc1cccs1)C(=O)NO	XFILPEOLDIKJHX-QYZOEREBSA-N, XFILPEOLDIKJHX-QYZOEREBSA-N, XFILPEOLDIKJHX-QYZOEREBSA-N, XFILPEOLDIKJHX-QYZOEREBSA-N, XFILPEOLDIKJHX-QYZOEREBSA-N, XFILPEOLDIKJHX-QYZOEREBSA-N, XFILPEOLDIKJHX-QYZOEREBSA-N, XFILPEOLDIKJHX-QYZOEREBSA-N, XFILPEOLDIKJHX-QYZOEREBSA-N, XFILPEOLDIKJHX-QYZOEREBSA-N, XFILPEOLDIKJHX-QYZOEREBSA-N, XFILPEOLDIKJHX-QYZOEREBSA-N	Phase 3
bavisant	histamine receptor antagonist	HRH3			O=C(N1CCN(CC1)C1CC1)c1ccc(CN2CCOCC2)cc1, O=C(N1CCN(CC1)C1CC1)c1ccc(CN2CCOCC2)cc1, O=C(N1CCN(CC1)C1CC1)c1ccc(CN2CCOCC2)cc1	BGBVSGSIXIIREO-UHFFFAOYSA-N, BGBVSGSIXIIREO-UHFFFAOYSA-N, BGBVSGSIXIIREO-UHFFFAOYSA-N	Phase 2
BAX-channel-blocker	cytochrome C release inhibitor	BAX			O[C@@H](CN1CCNCC1)Cn1c2ccc(Br)cc2c2cc(Br)ccc12 |&1:1|	KUUJEXLRLIPQQJ-HNNXBMFYSA-N	Preclinical
BAY-K-8644-(+/-)	L-type calcium channel blocker				COC(=O)C1=C(C)NC(C)=C([C@@H]1c1ccccc1C(F)(F)F)[N+]([O-])=O |r,c:4,9|, COC(=O)C1=C(C)NC(C)=C([C@@H]1c1ccccc1C(F)(F)F)[N+]([O-])=O |r,c:4,9|, COC(=O)C1=C(C)NC(C)=C([C@@H]1c1ccccc1C(F)(F)F)[N+]([O-])=O |r,c:4,9|	ZFLWDHHVRRZMEI-CYBMUJFWSA-N, ZFLWDHHVRRZMEI-CYBMUJFWSA-N, ZFLWDHHVRRZMEI-CYBMUJFWSA-N	Preclinical
BAY-K-8644-(s)-(-)	L-type calcium channel activator	CACNA1C			COC(=O)C1=C(C)NC(C)=C([C@H]1c1ccccc1C(F)(F)F)[N+]([O-])=O |c:4,9|	ZFLWDHHVRRZMEI-ZDUSSCGKSA-N	Preclinical
BAY-W-9798	antioxidant				COC(=O)C1=C(C)N(C)C(C)=C(C1c1ccc(cc1)C(F)(F)F)C(=O)OC |c:4,10|	AVFYPHPSIBAAME-UHFFFAOYSA-N	Phase 2
BAY-11-7082	NFkB pathway inhibitor	RELA			Cc1ccc(cc1)S(=O)(=O)\C=C\C#N, Cc1ccc(cc1)S(=O)(=O)\C=C\C#N, Cc1ccc(cc1)S(=O)(=O)\C=C\C#N, Cc1ccc(cc1)S(=O)(=O)\C=C\C#N, Cc1ccc(cc1)S(=O)(=O)\C=C\C#N, Cc1ccc(cc1)S(=O)(=O)\C=C\C#N, Cc1ccc(cc1)S(=O)(=O)\C=C\C#N, Cc1ccc(cc1)S(=O)(=O)\C=C\C#N, Cc1ccc(cc1)S(=O)(=O)\C=C\C#N, Cc1ccc(cc1)S(=O)(=O)\C=C\C#N, Cc1ccc(cc1)S(=O)(=O)\C=C\C#N, Cc1ccc(cc1)S(=O)(=O)\C=C\C#N, Cc1ccc(cc1)S(=O)(=O)\C=C\C#N	DOEWDSDBFRHVAP-KRXBUXKQSA-N, DOEWDSDBFRHVAP-KRXBUXKQSA-N, DOEWDSDBFRHVAP-KRXBUXKQSA-N, DOEWDSDBFRHVAP-KRXBUXKQSA-N, DOEWDSDBFRHVAP-KRXBUXKQSA-N, DOEWDSDBFRHVAP-KRXBUXKQSA-N, DOEWDSDBFRHVAP-KRXBUXKQSA-N, DOEWDSDBFRHVAP-KRXBUXKQSA-N, DOEWDSDBFRHVAP-KRXBUXKQSA-N, DOEWDSDBFRHVAP-KRXBUXKQSA-N, DOEWDSDBFRHVAP-KRXBUXKQSA-N, DOEWDSDBFRHVAP-KRXBUXKQSA-N, DOEWDSDBFRHVAP-KRXBUXKQSA-N	Preclinical
BAY-11-7085	NFkB pathway inhibitor	NFKBIA			CC(C)(C)c1ccc(cc1)S(=O)(=O)\C=C\C#N, CC(C)(C)c1ccc(cc1)S(=O)(=O)\C=C\C#N	VHKZGNPOHPFPER-ONNFQVAWSA-N, VHKZGNPOHPFPER-ONNFQVAWSA-N	Preclinical
BAY-1251152	CDK9 inhibitor				COc1cc(F)ccc1-c1cc(Nc2cc(C[S@](C)(=N)=O)ccn2)ncc1F |r|	YZCUMZWULWOUMD-MUUNZHRXSA-N	Phase 1
BAY-1436032	isocitrate dehydrogenase inhibitor				C[C@H]1C[C@H](CC(C)(C)C1)n1c(Nc2ccc(OC(F)(F)F)cc2)nc2cc(CCC(O)=O)ccc12	RNMAUIMMNAHKQR-QFBILLFUSA-N	Phase 1
BAY-1895344	ATR kinase inhibitor				C[C@@H]1COCCN1c1cc(-c2ccnn2C)c2ccnc(-c3ccn[nH]3)c2n1	YBXRSCXGRPSTMW-CYBMUJFWSA-N	Phase 1
BAY-2402234	dihydroorotate dehydrogenase inhibitor				CCn1c(CO)nn(-c2cc(O[C@@H](C)C(F)(F)F)c(cc2F)C(=O)Nc2c(F)cccc2Cl)c1=O, CCn1c(CO)nn(-c2cc(O[C@@H](C)C(F)(F)F)c(cc2F)C(=O)Nc2c(F)cccc2Cl)c1=O	KNVJMHHAXCPZHF-JTQLQIEISA-N, KNVJMHHAXCPZHF-JTQLQIEISA-N	Phase 1
BAY-41-2272	guanylyl cyclase activator	GUCY1A3, GUCY1B3			Nc1nc(ncc1C1CC1)-c1nn(Cc2ccccc2F)c2ncccc12, Nc1nc(ncc1C1CC1)-c1nn(Cc2ccccc2F)c2ncccc12, Nc1nc(ncc1C1CC1)-c1nn(Cc2ccccc2F)c2ncccc12, Nc1nc(ncc1C1CC1)-c1nn(Cc2ccccc2F)c2ncccc12	ATOAHNRJAXSBOR-UHFFFAOYSA-N, ATOAHNRJAXSBOR-UHFFFAOYSA-N, ATOAHNRJAXSBOR-UHFFFAOYSA-N, ATOAHNRJAXSBOR-UHFFFAOYSA-N	Preclinical
BAY-60-6583	adenosine receptor agonist	ADORA1, ADORA2A, ADORA2B, ADORA3			NC(=O)CSc1nc(N)c(C#N)c(-c2ccc(OCC3CC3)cc2)c1C#N, NC(=O)CSc1nc(N)c(C#N)c(-c2ccc(OCC3CC3)cc2)c1C#N	ZTYHZMAZUWOXNC-UHFFFAOYSA-N, ZTYHZMAZUWOXNC-UHFFFAOYSA-N	Preclinical
BAY-60-7550	phosphodiesterase inhibitor	PDE2A			COc1ccc(Cc2nc(=O)c3c(C)nc([C@@H](CCCc4ccccc4)[C@@H](C)O)n3[nH]2)cc1OC	MYTWFJKBZGMYCS-NQIIRXRSSA-N	Preclinical
BAY-61-3606	SYK inhibitor	SYK			COc1ccc(cc1OC)-c1cc2nccn2c(Nc2ncccc2C(N)=O)n1, COc1ccc(cc1OC)-c1cc2nccn2c(Nc2ncccc2C(N)=O)n1, COc1ccc(cc1OC)-c1cc2nccn2c(Nc2ncccc2C(N)=O)n1, COc1ccc(cc1OC)-c1cc2nccn2c(Nc2ncccc2C(N)=O)n1, COc1ccc(cc1OC)-c1cc2nccn2c(Nc2ncccc2C(N)=O)n1	JWQOJVOKBAAAAR-UHFFFAOYSA-N, JWQOJVOKBAAAAR-UHFFFAOYSA-N, JWQOJVOKBAAAAR-UHFFFAOYSA-N, JWQOJVOKBAAAAR-UHFFFAOYSA-N, JWQOJVOKBAAAAR-UHFFFAOYSA-N	Preclinical
BAY-8002	monocarboxylate transporter inhibitor				OC(=O)c1ccccc1NC(=O)c1cc(ccc1Cl)S(=O)(=O)c1ccccc1	CLAUJSRBKSRTGQ-UHFFFAOYSA-N	Preclinical
BAY-85-8050					N[C@@H](C[C@@H](F)C(O)=O)C(O)=O |&1:1,&2:3,r|	JPSHPWJJSVEEAX-GBXIJSLDSA-N	Phase 1
BAY-87-2243	hypoxia inducible factor inhibitor	HIF1A			Cc1cc(nn1Cc1ccnc(c1)N1CCN(CC1)C1CC1)-c1nc(no1)-c1ccc(OC(F)(F)F)cc1, Cc1cc(nn1Cc1ccnc(c1)N1CCN(CC1)C1CC1)-c1nc(no1)-c1ccc(OC(F)(F)F)cc1, Cc1cc(nn1Cc1ccnc(c1)N1CCN(CC1)C1CC1)-c1nc(no1)-c1ccc(OC(F)(F)F)cc1, Cc1cc(nn1Cc1ccnc(c1)N1CCN(CC1)C1CC1)-c1nc(no1)-c1ccc(OC(F)(F)F)cc1, Cc1cc(nn1Cc1ccnc(c1)N1CCN(CC1)C1CC1)-c1nc(no1)-c1ccc(OC(F)(F)F)cc1, Cc1cc(nn1Cc1ccnc(c1)N1CCN(CC1)C1CC1)-c1nc(no1)-c1ccc(OC(F)(F)F)cc1, Cc1cc(nn1Cc1ccnc(c1)N1CCN(CC1)C1CC1)-c1nc(no1)-c1ccc(OC(F)(F)F)cc1	CDJNNOJINJAXPV-UHFFFAOYSA-N, CDJNNOJINJAXPV-UHFFFAOYSA-N, CDJNNOJINJAXPV-UHFFFAOYSA-N, CDJNNOJINJAXPV-UHFFFAOYSA-N, CDJNNOJINJAXPV-UHFFFAOYSA-N, CDJNNOJINJAXPV-UHFFFAOYSA-N, CDJNNOJINJAXPV-UHFFFAOYSA-N	Phase 1
BAY1125976	AKT inhibitor				NC(=O)c1ccc2nc(c(-c3ccccc3)n2n1)-c1ccc(cc1)C1(N)CCC1	JBGYKRAZYDNCNV-UHFFFAOYSA-N	Phase 1
BAY1217389	kinase inhibitor				COc1ccc(Oc2cc(NCCC(F)(F)F)c3ncc(-c4ccc(C(=O)NC5CC5)c(C)c4)n3n2)c(F)c1F	WNEILUNVMHVMPH-UHFFFAOYSA-N	Phase 1
bazedoxifene	selective estrogen receptor modulator (SERM)	ESR1, ESR2	orthopedics, endocrinology	osteoporosis, menopause	Cc1c(-c2ccc(O)cc2)n(Cc2ccc(OCCN3CCCCCC3)cc2)c2ccc(O)cc12, Cc1c(-c2ccc(O)cc2)n(Cc2ccc(OCCN3CCCCCC3)cc2)c2ccc(O)cc12, Cc1c(-c2ccc(O)cc2)n(Cc2ccc(OCCN3CCCCCC3)cc2)c2ccc(O)cc12, Cc1c(-c2ccc(O)cc2)n(Cc2ccc(OCCN3CCCCCC3)cc2)c2ccc(O)cc12, Cc1c(-c2ccc(O)cc2)n(Cc2ccc(OCCN3CCCCCC3)cc2)c2ccc(O)cc12, Cc1c(-c2ccc(O)cc2)n(Cc2ccc(OCCN3CCCCCC3)cc2)c2ccc(O)cc12, Cc1c(-c2ccc(O)cc2)n(Cc2ccc(OCCN3CCCCCC3)cc2)c2ccc(O)cc12, Cc1c(-c2ccc(O)cc2)n(Cc2ccc(OCCN3CCCCCC3)cc2)c2ccc(O)cc12, Cc1c(-c2ccc(O)cc2)n(Cc2ccc(OCCN3CCCCCC3)cc2)c2ccc(O)cc12, Cc1c(-c2ccc(O)cc2)n(Cc2ccc(OCCN3CCCCCC3)cc2)c2ccc(O)cc12, Cc1c(-c2ccc(O)cc2)n(Cc2ccc(OCCN3CCCCCC3)cc2)c2ccc(O)cc12, Cc1c(-c2ccc(O)cc2)n(Cc2ccc(OCCN3CCCCCC3)cc2)c2ccc(O)cc12, Cc1c(-c2ccc(O)cc2)n(Cc2ccc(OCCN3CCCCCC3)cc2)c2ccc(O)cc12, Cc1c(-c2ccc(O)cc2)n(Cc2ccc(OCCN3CCCCCC3)cc2)c2ccc(O)cc12	UCJGJABZCDBEDK-UHFFFAOYSA-N, UCJGJABZCDBEDK-UHFFFAOYSA-N, UCJGJABZCDBEDK-UHFFFAOYSA-N, UCJGJABZCDBEDK-UHFFFAOYSA-N, UCJGJABZCDBEDK-UHFFFAOYSA-N, UCJGJABZCDBEDK-UHFFFAOYSA-N, UCJGJABZCDBEDK-UHFFFAOYSA-N, UCJGJABZCDBEDK-UHFFFAOYSA-N, UCJGJABZCDBEDK-UHFFFAOYSA-N, UCJGJABZCDBEDK-UHFFFAOYSA-N, UCJGJABZCDBEDK-UHFFFAOYSA-N, UCJGJABZCDBEDK-UHFFFAOYSA-N, UCJGJABZCDBEDK-UHFFFAOYSA-N, UCJGJABZCDBEDK-UHFFFAOYSA-N	Launched
BAZ2-ICR	bromodomain inhibitor	ZNF215			Cn1cc(CCn2cnc(-c3cnn(C)c3)c2-c2ccc(cc2)C#N)cn1, Cn1cc(CCn2cnc(-c3cnn(C)c3)c2-c2ccc(cc2)C#N)cn1, Cn1cc(CCn2cnc(-c3cnn(C)c3)c2-c2ccc(cc2)C#N)cn1	RRZVGDGTWNQAPW-UHFFFAOYSA-N, RRZVGDGTWNQAPW-UHFFFAOYSA-N, RRZVGDGTWNQAPW-UHFFFAOYSA-N	Preclinical
BC-11	urokinase inhibitor	PLAU			NC(=N)SCc1ccc(cc1)B(O)O, NC(=N)SCc1ccc(cc1)B(O)O	KDQVMGQHPAKJAN-UHFFFAOYSA-N, KDQVMGQHPAKJAN-UHFFFAOYSA-N	Preclinical
BCI-540	glutamate receptor agonist				Cc1oc2nc3CCCCc3c(NC(=O)CN3CCCC3=O)c2c1C, Cc1oc2nc3CCCCc3c(NC(=O)CN3CCCC3=O)c2c1C, Cc1oc2nc3CCCCc3c(NC(=O)CN3CCCC3=O)c2c1C	PSPGQHXMUKWNDI-UHFFFAOYSA-N, PSPGQHXMUKWNDI-UHFFFAOYSA-N, PSPGQHXMUKWNDI-UHFFFAOYSA-N	Phase 2
BCTC	TRPV antagonist	TRPV1			CC(C)(C)c1ccc(NC(=O)N2CCN(CC2)c2ncccc2Cl)cc1, CC(C)(C)c1ccc(NC(=O)N2CCN(CC2)c2ncccc2Cl)cc1	ROGUAPYLUCHQGK-UHFFFAOYSA-N, ROGUAPYLUCHQGK-UHFFFAOYSA-N	Preclinical
BCX-1470	complement inhibitor, serine protease inhibitor	CFD			NC(=N)c1cc2ccc(OC(=O)c3cccs3)cc2s1, NC(=N)c1cc2ccc(OC(=O)c3cccs3)cc2s1	OTGQTQBPQCRNRG-UHFFFAOYSA-N, OTGQTQBPQCRNRG-UHFFFAOYSA-N	Phase 1
BD-1008	sigma receptor antagonist				CN(CCN1CCCC1)CCc1ccc(Cl)c(Cl)c1, CN(CCN1CCCC1)CCc1ccc(Cl)c(Cl)c1	ASGIQUHBAVIOTI-UHFFFAOYSA-N, ASGIQUHBAVIOTI-UHFFFAOYSA-N	Preclinical
BD-1047	adrenergic receptor antagonist	SIGMAR1			CN(C)CCN(C)CCc1ccc(Cl)c(Cl)c1, CN(C)CCN(C)CCc1ccc(Cl)c(Cl)c1, CN(C)CCN(C)CCc1ccc(Cl)c(Cl)c1	MGVRNMUKTZOQOW-UHFFFAOYSA-N, MGVRNMUKTZOQOW-UHFFFAOYSA-N, MGVRNMUKTZOQOW-UHFFFAOYSA-N	Preclinical
BD-1063	sigma receptor antagonist	SIGMAR1			CN1CCN(CCc2ccc(Cl)c(Cl)c2)CC1	SUIZRDJCBVPASY-UHFFFAOYSA-N	Preclinical
BE-2254	adrenergic receptor antagonist	ADRA1A			Oc1ccc(CCNC[C@H]2CCc3ccccc3C2=O)cc1 |r|, Oc1ccc(CCNC[C@H]2CCc3ccccc3C2=O)cc1 |r|	PZZOEXPDTYIBPI-MRXNPFEDSA-N, PZZOEXPDTYIBPI-MRXNPFEDSA-N	Phase 2
BEBT-908	PI3K inhibitor				CNc1ccc(cn1)-c1nc(N2CCOCC2)c2sc(CN(C)c3ncc(cn3)C(=O)NO)cc2n1	TWJZFXHSPBBPNI-UHFFFAOYSA-N	Preclinical
beclabuvir	antiviral				COc1ccc2-c3c(C4CCCCC4)c4ccc(cc4n3C[C@]3(C[C@H]3c2c1)C(=O)N1[C@H]2CC[C@@H]1CN(C)C2)C(=O)NS(=O)(=O)N(C)C |THB:27:29:31.32:34.35.37|	ZTTKEBYSXUCBSE-QDFUAKMASA-N	Phase 2
beclamide	anticonvulsant		neurology/psychiatry	sedative, seizures	ClCCC(=O)NCc1ccccc1, ClCCC(=O)NCc1ccccc1	JPYQFYIEOUVJDU-UHFFFAOYSA-N, JPYQFYIEOUVJDU-UHFFFAOYSA-N	Launched
beclomethasone	glucocorticoid receptor agonist	NR3C1, SERPINA6	allergy	allergic rhinitis	C[C@H]1C[C@H]2[C@H]3CCC4=CC(=O)C=C[C@@]4(C)[C@@]3(Cl)[C@@H](O)C[C@@]2(C)[C@@]1(O)C(=O)CO |&1:1,&2:3,&3:4,&4:13,&5:15,&6:17,&7:20,&8:22,r,c:11,t:7|, C[C@H]1C[C@H]2[C@H]3CCC4=CC(=O)C=C[C@@]4(C)[C@@]3(Cl)[C@@H](O)C[C@@]2(C)[C@@]1(O)C(=O)CO |&1:1,&2:3,&3:4,&4:13,&5:15,&6:17,&7:20,&8:22,r,c:11,t:7|, C[C@H]1C[C@H]2[C@H]3CCC4=CC(=O)C=C[C@@]4(C)[C@@]3(Cl)[C@@H](O)C[C@@]2(C)[C@@]1(O)C(=O)CO |&1:1,&2:3,&3:4,&4:13,&5:15,&6:17,&7:20,&8:22,r,c:11,t:7|	NBMKJKDGKREAPL-DGLOSGAVSA-N, NBMKJKDGKREAPL-DGLOSGAVSA-N, NBMKJKDGKREAPL-DGLOSGAVSA-N	Launched
beclomethasone-dipropionate	glucocorticoid receptor agonist	GPR97, NR3C1	allergy	allergic rhinitis	CCC(=O)OCC(=O)[C@@]1(OC(=O)CC)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]12C |c:25,t:21|, CCC(=O)OCC(=O)[C@@]1(OC(=O)CC)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]12C |c:25,t:21|, CCC(=O)OCC(=O)[C@@]1(OC(=O)CC)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]12C |c:25,t:21|, CCC(=O)OCC(=O)[C@@]1(OC(=O)CC)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]12C |c:25,t:21|, CCC(=O)OCC(=O)[C@@]1(OC(=O)CC)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]12C |c:25,t:21|, CCC(=O)OCC(=O)[C@@]1(OC(=O)CC)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]12C |c:25,t:21|	KUVIULQEHSCUHY-XYWKZLDCSA-N, KUVIULQEHSCUHY-XYWKZLDCSA-N, KUVIULQEHSCUHY-XYWKZLDCSA-N, KUVIULQEHSCUHY-XYWKZLDCSA-N, KUVIULQEHSCUHY-XYWKZLDCSA-N, KUVIULQEHSCUHY-XYWKZLDCSA-N	Launched
bedaquiline	ATPase inhibitor		infectious disease	tuberculosis	COc1nc2ccc(Br)cc2cc1[C@@H](c1ccccc1)[C@@](O)(CCN(C)C)c1cccc2ccccc12, COc1nc2ccc(Br)cc2cc1[C@@H](c1ccccc1)[C@@](O)(CCN(C)C)c1cccc2ccccc12, COc1nc2ccc(Br)cc2cc1[C@@H](c1ccccc1)[C@@](O)(CCN(C)C)c1cccc2ccccc12, COc1nc2ccc(Br)cc2cc1[C@@H](c1ccccc1)[C@@](O)(CCN(C)C)c1cccc2ccccc12	QUIJNHUBAXPXFS-XLJNKUFUSA-N, QUIJNHUBAXPXFS-XLJNKUFUSA-N, QUIJNHUBAXPXFS-XLJNKUFUSA-N, QUIJNHUBAXPXFS-XLJNKUFUSA-N	Launched
befuraline					O=C(N1CCN(Cc2ccccc2)CC1)c1cc2ccccc2o1	SRIJFPBZWUFLFD-UHFFFAOYSA-N	Phase 2
begacestat	gamma secretase inhibitor	PSEN1			OC[C@@H](NS(=O)(=O)c1ccc(Cl)s1)C(C(F)(F)F)C(F)(F)F, OC[C@@H](NS(=O)(=O)c1ccc(Cl)s1)C(C(F)(F)F)C(F)(F)F, OC[C@@H](NS(=O)(=O)c1ccc(Cl)s1)C(C(F)(F)F)C(F)(F)F	PSXOKXJMVRSARX-SCSAIBSYSA-N, PSXOKXJMVRSARX-SCSAIBSYSA-N, PSXOKXJMVRSARX-SCSAIBSYSA-N	Phase 1
bekanamycin	bacterial 30S ribosomal subunit inhibitor		infectious disease	gram-negative bacterial infections	NC[C@H]1O[C@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O)[C@H]2O)[C@H](N)[C@@H](O)[C@@H]1O, NC[C@H]1O[C@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O)[C@H]2O)[C@H](N)[C@@H](O)[C@@H]1O, NC[C@H]1O[C@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O)[C@H]2O)[C@H](N)[C@@H](O)[C@@H]1O, NC[C@H]1O[C@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O)[C@H]2O)[C@H](N)[C@@H](O)[C@@H]1O	SKKLOUVUUNMCJE-FQSMHNGLSA-N, SKKLOUVUUNMCJE-FQSMHNGLSA-N, SKKLOUVUUNMCJE-FQSMHNGLSA-N, SKKLOUVUUNMCJE-FQSMHNGLSA-N	Launched
belinostat	HDAC inhibitor	HDAC1, HDAC10, HDAC11, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9	hematologic malignancy	peripheral T-cell lymphoma (PTCL)	ONC(=O)\C=C\c1cccc(c1)S(=O)(=O)Nc1ccccc1, ONC(=O)\C=C\c1cccc(c1)S(=O)(=O)Nc1ccccc1, ONC(=O)\C=C\c1cccc(c1)S(=O)(=O)Nc1ccccc1, ONC(=O)\C=C\c1cccc(c1)S(=O)(=O)Nc1ccccc1, ONC(=O)\C=C\c1cccc(c1)S(=O)(=O)Nc1ccccc1, ONC(=O)\C=C\c1cccc(c1)S(=O)(=O)Nc1ccccc1, ONC(=O)\C=C\c1cccc(c1)S(=O)(=O)Nc1ccccc1	NCNRHFGMJRPRSK-MDZDMXLPSA-N, NCNRHFGMJRPRSK-MDZDMXLPSA-N, NCNRHFGMJRPRSK-MDZDMXLPSA-N, NCNRHFGMJRPRSK-MDZDMXLPSA-N, InChI=1S/C15H14N2O4S/c18-15(16-19)10-9-12-5-4-8-14(11-12)22(20,21)17-13-6-2-1-3-7-13/h1-11,17,19H,(H,16,18)/b10-9+, InChI=1S/C15H14N2O4S/c18-15(16-19)10-9-12-5-4-8-14(11-12)22(20,21)17-13-6-2-1-3-7-13/h1-11,17,19H,(H,16,18)/b10-9+, InChI=1S/C15H14N2O4S/c18-15(16-19)10-9-12-5-4-8-14(11-12)22(20,21)17-13-6-2-1-3-7-13/h1-11,17,19H,(H,16,18)/b10-9+	Launched
belizatinib	receptor tyrosine protein kinase inhibitor				CC(C)NC(=O)[C@H]1CC[C@H](CC1)n1c(NC(=O)c2ccc(F)cc2)nc2ccc(CN3CCC(CC3)C(C)(C)O)cc12 |r|	WSTUJEXAPHIEIM-FEGDYQJNSA-N	Preclinical
belotecan	topoisomerase inhibitor				CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccccc4c(CCNC(C)C)c3Cn1c2=O	LNHWXBUNXOXMRL-VWLOTQADSA-N	Phase 3
bemegride	chemoreceptor agonist	GABRA1	critical care	poison antidote	CCC1(C)CC(=O)NC(=O)C1, CCC1(C)CC(=O)NC(=O)C1, CCC1(C)CC(=O)NC(=O)C1	ORRZGUBHBVWWOP-UHFFFAOYSA-N, ORRZGUBHBVWWOP-UHFFFAOYSA-N, ORRZGUBHBVWWOP-UHFFFAOYSA-N	Launched
bemesetron	serotonin receptor antagonist	HTR3A, HTR3B			CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)c1cc(Cl)cc(Cl)c1 |r,THB:0:1:3.4:6.7.8|	MNJNPLVXBISNSX-WDNDVIMCSA-N	Phase 3
bemotrizinol			dermatology	sunscreen lotion	CCCC[C@H](CC)COc1ccc(c(O)c1)-c1nc(nc(n1)-c1ccc(OC[C@H](CC)CCCC)cc1O)-c1ccc(OC)cc1 |&1:28,&2:4|, CCCC[C@H](CC)COc1ccc(c(O)c1)-c1nc(nc(n1)-c1ccc(OC[C@H](CC)CCCC)cc1O)-c1ccc(OC)cc1 |&1:28,&2:4|	XVAMCHGMPYWHNL-MKPDMIMOSA-N, XVAMCHGMPYWHNL-MKPDMIMOSA-N	Launched
bempedoic-acid	AMPK inhibitor	ACLY			CC(C)(CCCCCC(O)CCCCCC(C)(C)C(O)=O)C(O)=O	HYHMLYSLQUKXKP-UHFFFAOYSA-N	Launched
benactyzine	butyrylcholinesterase inhibitor				CCN(CC)CCOC(=O)C(O)(c1ccccc1)c1ccccc1	IVQOFBKHQCTVQV-UHFFFAOYSA-N	Preclinical
benaxibine					OC[C@H]1O[C@@H](Nc2ccc(cc2)C(O)=O)[C@H](O)[C@@H](O)[C@@H]1O	VXMVXDITZWJXJN-RMPHRYRLSA-N	Phase 1
benazepril	angiotensin converting enzyme inhibitor	ACE	cardiology	hypertension	CCOC(=O)[C@H](CCc1ccccc1)N[C@H]1CCc2ccccc2N(CC(O)=O)C1=O, CCOC(=O)[C@H](CCc1ccccc1)N[C@H]1CCc2ccccc2N(CC(O)=O)C1=O, CCOC(=O)[C@H](CCc1ccccc1)N[C@H]1CCc2ccccc2N(CC(O)=O)C1=O, CCOC(=O)[C@H](CCc1ccccc1)N[C@H]1CCc2ccccc2N(CC(O)=O)C1=O, CCOC(=O)[C@H](CCc1ccccc1)N[C@H]1CCc2ccccc2N(CC(O)=O)C1=O, CCOC(=O)[C@H](CCc1ccccc1)N[C@H]1CCc2ccccc2N(CC(O)=O)C1=O	XPCFTKFZXHTYIP-PMACEKPBSA-N, XPCFTKFZXHTYIP-PMACEKPBSA-N, XPCFTKFZXHTYIP-PMACEKPBSA-N, XPCFTKFZXHTYIP-PMACEKPBSA-N, XPCFTKFZXHTYIP-PMACEKPBSA-N, XPCFTKFZXHTYIP-PMACEKPBSA-N	Launched
bendamustine	DNA inhibitor		hematologic malignancy	chronic lymphocytic leukemia (CLL), non-Hodgkin lymphoma (NHL)	Cn1c(CCCC(O)=O)nc2cc(ccc12)N(CCCl)CCCl, Cn1c(CCCC(O)=O)nc2cc(ccc12)N(CCCl)CCCl, Cn1c(CCCC(O)=O)nc2cc(ccc12)N(CCCl)CCCl	YTKUWDBFDASYHO-UHFFFAOYSA-N, YTKUWDBFDASYHO-UHFFFAOYSA-N, YTKUWDBFDASYHO-UHFFFAOYSA-N	Launched
bendazac	cyclooxygenase inhibitor	PTGS1, PTGS2	neurology/psychiatry, rheumatology	muscle pain, joint pain	OC(=O)COc1nn(Cc2ccccc2)c2ccccc12	BYFMCKSPFYVMOU-UHFFFAOYSA-N	Launched
bendazol	nitric oxide synthase stimulant				C(c1nc2ccccc2[nH]1)c1ccccc1	YTLQFZVCLXFFRK-UHFFFAOYSA-N	Launched
bendroflumethiazide	sodium/potassium/chloride transporter inhibitor	SLC12A1, SLC12A3	cardiology	hypertension	NS(=O)(=O)c1cc2c(N[C@@H](Cc3ccccc3)NS2(=O)=O)cc1C(F)(F)F |&1:9,r|, NS(=O)(=O)c1cc2c(N[C@@H](Cc3ccccc3)NS2(=O)=O)cc1C(F)(F)F |&1:9,r|, NS(=O)(=O)c1cc2c(N[C@@H](Cc3ccccc3)NS2(=O)=O)cc1C(F)(F)F |&1:9,r|, NS(=O)(=O)c1cc2c(N[C@@H](Cc3ccccc3)NS2(=O)=O)cc1C(F)(F)F |&1:9,r|	HDWIHXWEUNVBIY-CQSZACIVSA-N, HDWIHXWEUNVBIY-CQSZACIVSA-N, HDWIHXWEUNVBIY-CQSZACIVSA-N, HDWIHXWEUNVBIY-CQSZACIVSA-N	Launched
benethamine					C(Cc1ccccc1)NCc1ccccc1	UPABQMWFWCMOFV-UHFFFAOYSA-N	Preclinical
benfluorex	gluconeogenesis inhibitor	HMGCR			C[C@@H](Cc1cccc(c1)C(F)(F)F)NCCOC(=O)c1ccccc1 |r|	CJAVTWRYCDNHSM-AWEZNQCLSA-N	Withdrawn
benfluralin		CYP1A1, CYP1A2, CYP2B6, CYP3A4, ESR1, MMP1, SULT2A1, UGT1A1			CCCCN(CC)c1c(cc(cc1[N+]([O-])=O)C(F)(F)F)[N+]([O-])=O, CCCCN(CC)c1c(cc(cc1[N+]([O-])=O)C(F)(F)F)[N+]([O-])=O	SMDHCQAYESWHAE-UHFFFAOYSA-N, SMDHCQAYESWHAE-UHFFFAOYSA-N	Phase 3
benfotiamine	antioxidant	AGER	rheumatology	lumbago	C\C(N(Cc1cnc(C)nc1N)C=O)=C(/CCOP(O)(O)=O)SC(=O)c1ccccc1, C\C(N(Cc1cnc(C)nc1N)C=O)=C(/CCOP(O)(O)=O)SC(=O)c1ccccc1, C\C(N(Cc1cnc(C)nc1N)C=O)=C(/CCOP(O)(O)=O)SC(=O)c1ccccc1, C\C(N(Cc1cnc(C)nc1N)C=O)=C(/CCOP(O)(O)=O)SC(=O)c1ccccc1	BTNNPSLJPBRMLZ-LGMDPLHJSA-N, BTNNPSLJPBRMLZ-LGMDPLHJSA-N, BTNNPSLJPBRMLZ-LGMDPLHJSA-N, BTNNPSLJPBRMLZ-LGMDPLHJSA-N	Launched
benidipine	calcium channel blocker	CACNA1C, CACNA1G	cardiology	hypertension	COC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)O[C@@H]1CCCN(Cc2ccccc2)C1, COC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)O[C@@H]1CCCN(Cc2ccccc2)C1, COC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)O[C@@H]1CCCN(Cc2ccccc2)C1, COC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)O[C@@H]1CCCN(Cc2ccccc2)C1, COC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)O[C@@H]1CCCN(Cc2ccccc2)C1, COC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)O[C@@H]1CCCN(Cc2ccccc2)C1, COC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)O[C@@H]1CCCN(Cc2ccccc2)C1	QZVNQOLPLYWLHQ-ZEQKJWHPSA-N, QZVNQOLPLYWLHQ-ZEQKJWHPSA-N, QZVNQOLPLYWLHQ-ZEQKJWHPSA-N, QZVNQOLPLYWLHQ-ZEQKJWHPSA-N, QZVNQOLPLYWLHQ-ZEQKJWHPSA-N, QZVNQOLPLYWLHQ-ZEQKJWHPSA-N, QZVNQOLPLYWLHQ-ZEQKJWHPSA-N	Launched
benperidol	dopamine receptor antagonist	DRD2	neurology/psychiatry	schizophrenia	Fc1ccc(cc1)C(=O)CCCN1CCC(CC1)n1c2ccccc2[nH]c1=O, Fc1ccc(cc1)C(=O)CCCN1CCC(CC1)n1c2ccccc2[nH]c1=O	FEBOTPHFXYHVPL-UHFFFAOYSA-N, FEBOTPHFXYHVPL-UHFFFAOYSA-N	Launched
benproperine	antitussive	SCN5A	pulmonary	cough suppressant	C[C@@H](COc1ccccc1Cc1ccccc1)N1CCCCC1 |&1:1,r|	JTUQXGZRVLWBCR-SFHVURJKSA-N	Launched
benserazide	DOPA decarboxylase inhibitor	DDC	neurology/psychiatry	Parkinson's Disease	NC(CO)C(=O)NNCc1ccc(O)c(O)c1O, NC(CO)C(=O)NNCc1ccc(O)c(O)c1O	BNQDCRGUHNALGH-UHFFFAOYSA-N, BNQDCRGUHNALGH-UHFFFAOYSA-N	Launched
bentiromide		HPN	gastroenterology	pancreas diagnostic agent	OC(=O)c1ccc(NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)c2ccccc2)cc1, OC(=O)c1ccc(NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)c2ccccc2)cc1, OC(=O)c1ccc(NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)c2ccccc2)cc1	SPPTWHFVYKCNNK-FQEVSTJZSA-N, SPPTWHFVYKCNNK-FQEVSTJZSA-N, SPPTWHFVYKCNNK-FQEVSTJZSA-N	Launched
benurestat	urease inhibitor				ONC(=O)CNC(=O)c1ccc(Cl)cc1, ONC(=O)CNC(=O)c1ccc(Cl)cc1	JFZGBMJPJZDNNT-UHFFFAOYSA-N, JFZGBMJPJZDNNT-UHFFFAOYSA-N	Phase 1
benzalkonium	cationic surfactant		dermatology	abrasions, superficial cuts	CCCCCCCCCCCCC[N+](C)(C)Cc1ccccc1, CCCCCCCCCCCCC[N+](C)(C)Cc1ccccc1	VVZBFOKBSDGVGZ-UHFFFAOYSA-N, VVZBFOKBSDGVGZ-UHFFFAOYSA-N	Launched
benzamil	sodium channel blocker	ASIC1, PKD2L1, SCNN1A, SCNN1B, SCNN1D, SCNN1G, SLC8A1			NC(NCc1ccccc1)=NC(=O)c1nc(Cl)c(N)nc1N, NC(NCc1ccccc1)=NC(=O)c1nc(Cl)c(N)nc1N, NC(NCc1ccccc1)=NC(=O)c1nc(Cl)c(N)nc1N	KXDROGADUISDGY-UHFFFAOYSA-N, KXDROGADUISDGY-UHFFFAOYSA-N, KXDROGADUISDGY-UHFFFAOYSA-N	Phase 2
benzbromarone	chloride channel blocker	ABCC1	rheumatology	gout	CCc1oc2ccccc2c1C(=O)c1cc(Br)c(O)c(Br)c1, CCc1oc2ccccc2c1C(=O)c1cc(Br)c(O)c(Br)c1, CCc1oc2ccccc2c1C(=O)c1cc(Br)c(O)c(Br)c1	WHQCHUCQKNIQEC-UHFFFAOYSA-N, WHQCHUCQKNIQEC-UHFFFAOYSA-N, WHQCHUCQKNIQEC-UHFFFAOYSA-N	Launched
benzenemethanol,-2,5-dimethyl-[[(1-methylethyl)amino]methyl]					CC(C)NC[C@@H](O)c1cc(C)ccc1C |&1:5,r|	PHFWPIKQCFQPJY-CYBMUJFWSA-N	Preclinical
benzethonium	sodium channel blocker	SCN10A	infectious disease	first-aid antiseptic	CC(C)(C)CC(C)(C)c1ccc(OCCOCC[N+](C)(C)Cc2ccccc2)cc1, CC(C)(C)CC(C)(C)c1ccc(OCCOCC[N+](C)(C)Cc2ccccc2)cc1, CC(C)(C)CC(C)(C)c1ccc(OCCOCC[N+](C)(C)Cc2ccccc2)cc1, CC(C)(C)CC(C)(C)c1ccc(OCCOCC[N+](C)(C)Cc2ccccc2)cc1, CC(C)(C)CC(C)(C)c1ccc(OCCOCC[N+](C)(C)Cc2ccccc2)cc1, CC(C)(C)CC(C)(C)c1ccc(OCCOCC[N+](C)(C)Cc2ccccc2)cc1, CC(C)(C)CC(C)(C)c1ccc(OCCOCC[N+](C)(C)Cc2ccccc2)cc1, CC(C)(C)CC(C)(C)c1ccc(OCCOCC[N+](C)(C)Cc2ccccc2)cc1, CC(C)(C)CC(C)(C)c1ccc(OCCOCC[N+](C)(C)Cc2ccccc2)cc1, CC(C)(C)CC(C)(C)c1ccc(OCCOCC[N+](C)(C)Cc2ccccc2)cc1, CC(C)(C)CC(C)(C)c1ccc(OCCOCC[N+](C)(C)Cc2ccccc2)cc1, CC(C)(C)CC(C)(C)c1ccc(OCCOCC[N+](C)(C)Cc2ccccc2)cc1, CC(C)(C)CC(C)(C)c1ccc(OCCOCC[N+](C)(C)Cc2ccccc2)cc1	SIYLLGKDQZGJHK-UHFFFAOYSA-N, SIYLLGKDQZGJHK-UHFFFAOYSA-N, SIYLLGKDQZGJHK-UHFFFAOYSA-N, SIYLLGKDQZGJHK-UHFFFAOYSA-N, SIYLLGKDQZGJHK-UHFFFAOYSA-N, SIYLLGKDQZGJHK-UHFFFAOYSA-N, SIYLLGKDQZGJHK-UHFFFAOYSA-N, SIYLLGKDQZGJHK-UHFFFAOYSA-N, SIYLLGKDQZGJHK-UHFFFAOYSA-N, SIYLLGKDQZGJHK-UHFFFAOYSA-N, SIYLLGKDQZGJHK-UHFFFAOYSA-N, SIYLLGKDQZGJHK-UHFFFAOYSA-N, SIYLLGKDQZGJHK-UHFFFAOYSA-N	Launched
benznidazole	DNA synthesis inhibitor		infectious disease	Chagas disease	[O-][N+](=O)c1nccn1CC(=O)NCc1ccccc1	CULUWZNBISUWAS-UHFFFAOYSA-N	Launched
benzo[d]thiazole-2(3H)-thione					S=c1[nH]c2ccccc2s1	YXIWHUQXZSMYRE-UHFFFAOYSA-N	Phase 1
benzocaine	sodium channel blocker	SCN10A	infectious disease	first-aid antiseptic	CCOC(=O)c1ccc(N)cc1, CCOC(=O)c1ccc(N)cc1, CCOC(=O)c1ccc(N)cc1, CCOC(=O)c1ccc(N)cc1	BLFLLBZGZJTVJG-UHFFFAOYSA-N, BLFLLBZGZJTVJG-UHFFFAOYSA-N, BLFLLBZGZJTVJG-UHFFFAOYSA-N, BLFLLBZGZJTVJG-UHFFFAOYSA-N	Launched
benzoclidine					O=C(O[C@H]1CN2CCC1CC2)c1ccccc1 |&1:3,r|	AHKAOMZZTQULDS-ZDUSSCGKSA-N	Preclinical
benzofenac					OC(=O)Cc1ccc(OCc2ccccc2)c(Cl)c1, OC(=O)Cc1ccc(OCc2ccccc2)c(Cl)c1, OC(=O)Cc1ccc(OCc2ccccc2)c(Cl)c1	DFHBBMJTBBLQSA-UHFFFAOYSA-N, DFHBBMJTBBLQSA-UHFFFAOYSA-N, DFHBBMJTBBLQSA-UHFFFAOYSA-N	Phase 1
benzoic-acid	food preservative	DAO, HRSP12, PRDX5, RAB9A	infectious disease	tinea pedis	OC(=O)c1ccccc1, OC(=O)c1ccccc1, OC(=O)c1ccccc1, OC(=O)c1ccccc1	WPYMKLBDIGXBTP-UHFFFAOYSA-N, WPYMKLBDIGXBTP-UHFFFAOYSA-N, WPYMKLBDIGXBTP-UHFFFAOYSA-N, WPYMKLBDIGXBTP-UHFFFAOYSA-N	Launched
benzoin		CES1			O[C@@H](C(=O)c1ccccc1)c1ccccc1 |&1:1,r|, O[C@@H](C(=O)c1ccccc1)c1ccccc1 |&1:1,r|	ISAOCJYIOMOJEB-CYBMUJFWSA-N, ISAOCJYIOMOJEB-CYBMUJFWSA-N	Preclinical
benzonatate	local anesthetic	SCN5A	pulmonary	cough suppressant	CCCCNc1ccc(cc1)C(=O)OCCOCCOCCOCCOCCOCCOCCOCCOCCOC	MAFMQEKGGFWBAB-UHFFFAOYSA-N	Launched
benzoquinonium-dibromide	cholinergic receptor antagonist	CHRNA1			CC[N+](CC)(CCCNC1=CC(=O)C(NCCC[N+](CC)(CC)Cc2ccccc2)=CC1=O)Cc1ccccc1 |c:30,t:9|, CC[N+](CC)(CCCNC1=CC(=O)C(NCCC[N+](CC)(CC)Cc2ccccc2)=CC1=O)Cc1ccccc1 |c:30,t:9|, CC[N+](CC)(CCCNC1=CC(=O)C(NCCC[N+](CC)(CC)Cc2ccccc2)=CC1=O)Cc1ccccc1 |c:30,t:9|	YERABYSOHUZTPQ-UHFFFAOYSA-P, YERABYSOHUZTPQ-UHFFFAOYSA-P, YERABYSOHUZTPQ-UHFFFAOYSA-P	Preclinical
benzotript	CCK receptor antagonist	CCKAR, CCKBR			OC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)c1ccc(Cl)cc1	QJERBBQXOMUURJ-INIZCTEOSA-N	Phase 1
benzoxiquine	antiinfective drug				O=C(Oc1cccc2cccnc12)c1ccccc1	BHKPHCKISVSDGV-UHFFFAOYSA-N	Preclinical
benzoyl-peroxide	oxidizing agent		dermatology	acne vulgaris (AV)	O=C(OOC(=O)c1ccccc1)c1ccccc1, O=C(OOC(=O)c1ccccc1)c1ccccc1	OMPJBNCRMGITSC-UHFFFAOYSA-N, OMPJBNCRMGITSC-UHFFFAOYSA-N	Launched
benzoylpas					OC(=O)c1ccc(NC(=O)c2ccccc2)cc1O, OC(=O)c1ccc(NC(=O)c2ccccc2)cc1O, OC(=O)c1ccc(NC(=O)c2ccccc2)cc1O	GNZCRYWFWKFIDM-UHFFFAOYSA-N, GNZCRYWFWKFIDM-UHFFFAOYSA-N, GNZCRYWFWKFIDM-UHFFFAOYSA-N	Preclinical
benzthiazide	carbonic anhydrase inhibitor	CA2	cardiology	hypertension, edema	NS(=O)(=O)c1cc2c(NC(NS2(=O)=O)=CSCc2ccccc2)cc1Cl, NS(=O)(=O)c1cc2c(NC(NS2(=O)=O)=CSCc2ccccc2)cc1Cl, NS(=O)(=O)c1cc2c(NC(NS2(=O)=O)=CSCc2ccccc2)cc1Cl, NS(=O)(=O)c1cc2c(NC(NS2(=O)=O)=CSCc2ccccc2)cc1Cl, NS(=O)(=O)c1cc2c(NC(NS2(=O)=O)=CSCc2ccccc2)cc1Cl, NS(=O)(=O)c1cc2c(NC(NS2(=O)=O)=CSCc2ccccc2)cc1Cl, NS(=O)(=O)c1cc2c(NC(NS2(=O)=O)=CSCc2ccccc2)cc1Cl	MQMCZGVMQZPYQA-UHFFFAOYSA-N, MQMCZGVMQZPYQA-UHFFFAOYSA-N, MQMCZGVMQZPYQA-UHFFFAOYSA-N, MQMCZGVMQZPYQA-UHFFFAOYSA-N, MQMCZGVMQZPYQA-UHFFFAOYSA-N, MQMCZGVMQZPYQA-UHFFFAOYSA-N, MQMCZGVMQZPYQA-UHFFFAOYSA-N	Launched
benztropine-mesylate	acetylcholine receptor antagonist	CHRM1, HRH1, SLC6A3	neurology/psychiatry	extrapyramidal symptoms (EPS), Parkinson's Disease	CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(c1ccccc1)c1ccccc1	GIJXKZJWITVLHI-PMOLBWCYSA-N	Launched
benzydamine	prostanoid receptor antagonist		dental, otolaryngology	mouth inflammation, throat inflammation	CN(C)CCCOc1nn(Cc2ccccc2)c2ccccc12, CN(C)CCCOc1nn(Cc2ccccc2)c2ccccc12	CNBGNNVCVSKAQZ-UHFFFAOYSA-N, CNBGNNVCVSKAQZ-UHFFFAOYSA-N	Launched
benzyl-alcohol	local anesthetic		infectious disease	virus herpes simplex (HSV)	OCc1ccccc1, OCc1ccccc1	WVDDGKGOMKODPV-UHFFFAOYSA-N, WVDDGKGOMKODPV-UHFFFAOYSA-N	Launched
benzyl-benzoate	lipase inhibitor	LIPE	allergy	sweet itch	O=C(OCc1ccccc1)c1ccccc1, O=C(OCc1ccccc1)c1ccccc1, O=C(OCc1ccccc1)c1ccccc1	SESFRYSPDFLNCH-UHFFFAOYSA-N, SESFRYSPDFLNCH-UHFFFAOYSA-N, SESFRYSPDFLNCH-UHFFFAOYSA-N	Launched
benzyl-isothiocyanate	methylazoxymethanol acetate inhibitor				S=C=NCc1ccccc1, S=C=NCc1ccccc1	MDKCFLQDBWCQCV-UHFFFAOYSA-N, MDKCFLQDBWCQCV-UHFFFAOYSA-N	Preclinical
benzyldimethylhexadecylammonium	cationic surfactant				CCCCCCCCCCCCCCCC[N+](C)(C)Cc1ccccc1, CCCCCCCCCCCCCCCC[N+](C)(C)Cc1ccccc1, CCCCCCCCCCCCCCCC[N+](C)(C)Cc1ccccc1	QDYLMAYUEZBUFO-UHFFFAOYSA-N, QDYLMAYUEZBUFO-UHFFFAOYSA-N, QDYLMAYUEZBUFO-UHFFFAOYSA-N	Preclinical
benzyldimethyloctylammonium					CCCCCCCC[N+](C)(C)Cc1ccccc1	SHFLYPPECXRCFO-UHFFFAOYSA-N	Preclinical
benzylpenicillin	penicillin binding protein inhibitor		infectious disease	celluitis, meningitis, endocarditis, syphilis, pneumonia, bacterial septicemia	CC1(C)S[C@@H]2[C@H](NC(=O)Cc3ccccc3)C(=O)N2[C@H]1C(O)=O, CC1(C)S[C@@H]2[C@H](NC(=O)Cc3ccccc3)C(=O)N2[C@H]1C(O)=O, CC1(C)S[C@@H]2[C@H](NC(=O)Cc3ccccc3)C(=O)N2[C@H]1C(O)=O	JGSARLDLIJGVTE-MBNYWOFBSA-N, JGSARLDLIJGVTE-MBNYWOFBSA-N, JGSARLDLIJGVTE-MBNYWOFBSA-N	Launched
bephenium-hydroxynaphthoate	anthelmintic agent		infectious disease	ascariasis	C[N+](C)(CCOc1ccccc1)Cc1ccccc1, C[N+](C)(CCOc1ccccc1)Cc1ccccc1, C[N+](C)(CCOc1ccccc1)Cc1ccccc1, C[N+](C)(CCOc1ccccc1)Cc1ccccc1	AVWWVJUMXRXPNF-UHFFFAOYSA-N, AVWWVJUMXRXPNF-UHFFFAOYSA-N, AVWWVJUMXRXPNF-UHFFFAOYSA-N, AVWWVJUMXRXPNF-UHFFFAOYSA-N	Launched
bepotastine	histamine receptor antagonist	HRH1	ophthalmology	conjunctivitis	OC(=O)CCCN1CCC(CC1)O[C@@H](c1ccc(Cl)cc1)c1ccccn1, OC(=O)CCCN1CCC(CC1)O[C@@H](c1ccc(Cl)cc1)c1ccccn1, OC(=O)CCCN1CCC(CC1)O[C@@H](c1ccc(Cl)cc1)c1ccccn1	YWGDOWXRIALTES-NRFANRHFSA-N, YWGDOWXRIALTES-NRFANRHFSA-N, YWGDOWXRIALTES-NRFANRHFSA-N	Launched
bepridil	calcium channel blocker	KCNQ4	cardiology	angina pectoris	CC(C)COCC(CN(Cc1ccccc1)c1ccccc1)N1CCCC1, CC(C)COCC(CN(Cc1ccccc1)c1ccccc1)N1CCCC1, CC(C)COCC(CN(Cc1ccccc1)c1ccccc1)N1CCCC1, CC(C)COCC(CN(Cc1ccccc1)c1ccccc1)N1CCCC1, CC(C)COCC(CN(Cc1ccccc1)c1ccccc1)N1CCCC1	UIEATEWHFDRYRU-UHFFFAOYSA-N, UIEATEWHFDRYRU-UHFFFAOYSA-N, UIEATEWHFDRYRU-UHFFFAOYSA-N, UIEATEWHFDRYRU-UHFFFAOYSA-N, UIEATEWHFDRYRU-UHFFFAOYSA-N	Launched
berberine	LDL receptor activator	LDLR			COc1ccc2cc3-c4cc5OCOc5cc4CC[n+]3cc2c1OC, COc1ccc2cc3-c4cc5OCOc5cc4CC[n+]3cc2c1OC, COc1ccc2cc3-c4cc5OCOc5cc4CC[n+]3cc2c1OC, COc1ccc2cc3-c4cc5OCOc5cc4CC[n+]3cc2c1OC, COc1ccc2cc3-c4cc5OCOc5cc4CC[n+]3cc2c1OC	YBHILYKTIRIUTE-UHFFFAOYSA-N, YBHILYKTIRIUTE-UHFFFAOYSA-N, YBHILYKTIRIUTE-UHFFFAOYSA-N, YBHILYKTIRIUTE-UHFFFAOYSA-N, YBHILYKTIRIUTE-UHFFFAOYSA-N	Launched
bergapten					COc1c2ccoc2cc2oc(=O)ccc12, COc1c2ccoc2cc2oc(=O)ccc12, COc1c2ccoc2cc2oc(=O)ccc12	BGEBZHIAGXMEMV-UHFFFAOYSA-N, BGEBZHIAGXMEMV-UHFFFAOYSA-N, BGEBZHIAGXMEMV-UHFFFAOYSA-N	Phase 3
bergenin	interleukin inhibitor	IL1B, TNF			COc1c(O)cc2C(=O)O[C@@H]3[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]3c2c1O, COc1c(O)cc2C(=O)O[C@@H]3[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]3c2c1O, COc1c(O)cc2C(=O)O[C@@H]3[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]3c2c1O	YWJXCIXBAKGUKZ-HJJNZUOJSA-N, YWJXCIXBAKGUKZ-HJJNZUOJSA-N, YWJXCIXBAKGUKZ-HJJNZUOJSA-N	Preclinical
besifloxacin	bacterial DNA gyrase inhibitor		ophthalmology	conjunctivitis	N[C@@H]1CCCCN(C1)c1c(F)cc2c(c1Cl)n(cc(C(O)=O)c2=O)C1CC1, N[C@@H]1CCCCN(C1)c1c(F)cc2c(c1Cl)n(cc(C(O)=O)c2=O)C1CC1	QFFGVLORLPOAEC-SNVBAGLBSA-N, QFFGVLORLPOAEC-SNVBAGLBSA-N	Launched
BET-BAY-002	bromodomain inhibitor				Cc1nnc(C[C@@H]2C=C(c3ccc(Cl)cc3)c3ccccc3-n3c(C)nnc23)o1 |t:7|, Cc1nnc(C[C@@H]2C=C(c3ccc(Cl)cc3)c3ccccc3-n3c(C)nnc23)o1 |t:7|, Cc1nnc(C[C@@H]2C=C(c3ccc(Cl)cc3)c3ccccc3-n3c(C)nnc23)o1 |t:7|, Cc1nnc(C[C@@H]2C=C(c3ccc(Cl)cc3)c3ccccc3-n3c(C)nnc23)o1 |t:7|, Cc1nnc(C[C@@H]2C=C(c3ccc(Cl)cc3)c3ccccc3-n3c(C)nnc23)o1 |t:7|, Cc1nnc(C[C@@H]2C=C(c3ccc(Cl)cc3)c3ccccc3-n3c(C)nnc23)o1 |t:7|	AGYIAWHWIUZNSD-INIZCTEOSA-N, AGYIAWHWIUZNSD-INIZCTEOSA-N, AGYIAWHWIUZNSD-INIZCTEOSA-N, AGYIAWHWIUZNSD-INIZCTEOSA-N, AGYIAWHWIUZNSD-INIZCTEOSA-N, AGYIAWHWIUZNSD-INIZCTEOSA-N	Preclinical
beta-amyloid-synthesis-inhibitor	beta amyloid synthesis inhibitor	APP			Oc1cccc(Nc2ccc(Nc3cccc(O)c3)nn2)c1	GYNDFOLSPPBBIK-UHFFFAOYSA-N	Preclinical
beta-carotene					C\C(\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C=C(\C)/C=C/C=C(\C)/C=C/C1=C(C)CCCC1(C)C |c:9,32|, C\C(\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C=C(\C)/C=C/C=C(\C)/C=C/C1=C(C)CCCC1(C)C |c:9,32|, C\C(\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C=C(\C)/C=C/C=C(\C)/C=C/C1=C(C)CCCC1(C)C |c:9,32|, C\C(\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C=C(\C)/C=C/C=C(\C)/C=C/C1=C(C)CCCC1(C)C |c:9,32|	OENHQHLEOONYIE-JLTXGRSLSA-N, OENHQHLEOONYIE-JLTXGRSLSA-N, OENHQHLEOONYIE-JLTXGRSLSA-N, OENHQHLEOONYIE-JLTXGRSLSA-N	Launched
beta-CCB	benzodiazepine receptor ligand	GABRA1, GABRG2			CCCCOC(=O)c1cc2c(cn1)[nH]c1ccccc21, CCCCOC(=O)c1cc2c(cn1)[nH]c1ccccc21	WGNGIELOOKACSB-UHFFFAOYSA-N, WGNGIELOOKACSB-UHFFFAOYSA-N	Launched
beta-elemene	apoptosis stimulant	MMP2, MMP9			CC(=C)[C@@H]1CC[C@@](C)(C=C)[C@@H](C1)C(C)=C	OPFTUNCRGUEPRZ-QLFBSQMISA-N	Launched
beta-funaltrexamine	opioid receptor antagonist	OPRD1, OPRK1, OPRM1			COC(=O)\C=C\C(=O)N[C@@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5O[C@@H]1[C@]2(CCN3CC1CC1)c45, COC(=O)\C=C\C(=O)N[C@@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5O[C@@H]1[C@]2(CCN3CC1CC1)c45, COC(=O)\C=C\C(=O)N[C@@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5O[C@@H]1[C@]2(CCN3CC1CC1)c45, COC(=O)\C=C\C(=O)N[C@@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5O[C@@H]1[C@]2(CCN3CC1CC1)c45, COC(=O)\C=C\C(=O)N[C@@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5O[C@@H]1[C@]2(CCN3CC1CC1)c45	PQKHESYTSKMWFP-WZJCLRDWSA-N, PQKHESYTSKMWFP-WZJCLRDWSA-N, PQKHESYTSKMWFP-WZJCLRDWSA-N, PQKHESYTSKMWFP-WZJCLRDWSA-N, PQKHESYTSKMWFP-WZJCLRDWSA-N	Preclinical
beta-glycerophosphoric-acid					OCC(CO)OP(O)(O)=O	DHCLVCXQIBBOPH-UHFFFAOYSA-N	Preclinical
beta-hydroxy-beta-methylbutyrate	protein synthesis stimulant	MTOR			CC(C)(O)CC(O)=O.CC(C)(O)CC(O)=O	KORPMXSVHOHPMS-UHFFFAOYSA-N	Launched
beta-hydroxybutyrate		HCAR2			CC(O)CC(O)=O	WHBMMWSBFZVSSR-UHFFFAOYSA-N	Phase 1
beta-lapachone	topoisomerase inhibitor	TOP1			CC1(C)CCC2=C(O1)c1ccccc1C(=O)C2=O |c:5|, CC1(C)CCC2=C(O1)c1ccccc1C(=O)C2=O |c:5|, CC1(C)CCC2=C(O1)c1ccccc1C(=O)C2=O |c:5|, CC1(C)CCC2=C(O1)c1ccccc1C(=O)C2=O |c:5|, CC1(C)CCC2=C(O1)c1ccccc1C(=O)C2=O |c:5|, CC1(C)CCC2=C(O1)c1ccccc1C(=O)C2=O |c:5|, CC1(C)CCC2=C(O1)c1ccccc1C(=O)C2=O |c:5|	QZPQTZZNNJUOLS-UHFFFAOYSA-N, QZPQTZZNNJUOLS-UHFFFAOYSA-N, QZPQTZZNNJUOLS-UHFFFAOYSA-N, QZPQTZZNNJUOLS-UHFFFAOYSA-N, QZPQTZZNNJUOLS-UHFFFAOYSA-N, QZPQTZZNNJUOLS-UHFFFAOYSA-N, QZPQTZZNNJUOLS-UHFFFAOYSA-N	Phase 2
beta-naphthol					Oc1ccc2ccccc2c1	JWAZRIHNYRIHIV-UHFFFAOYSA-N	Preclinical
betahistine	histamine receptor agonist, histamine receptor antagonist	HRH1, HRH3	neurology/psychiatry	Meniere's disease	CNCCc1ccccn1, CNCCc1ccccn1, CNCCc1ccccn1	UUQMNUMQCIQDMZ-UHFFFAOYSA-N, UUQMNUMQCIQDMZ-UHFFFAOYSA-N, UUQMNUMQCIQDMZ-UHFFFAOYSA-N	Launched
betaine	nitric oxide donor		metabolism	homocystinuria	C[N+](C)(C)CC(O)=O	KWIUHFFTVRNATP-UHFFFAOYSA-O	Launched
betamethasone	glucocorticoid receptor agonist	NR3C1	dermatology	corticosteroid-responsive dermatoses	C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO |c:11,t:7|	UREBDLICKHMUKA-DVTGEIKXSA-N	Launched
betamethasone-acetate	glucocorticoid receptor agonist	NR3C1	dermatology	corticosteroid-responsive dermatoses	C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)COC(C)=O |c:11,t:7|	AKUJBENLRBOFTD-QZIXMDIESA-N	Launched
betamethasone-butyrate-propionate			rheumatology	rheumatoid arthritis	CCCC(=O)O[C@@]1([C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)COC(=O)CC |c:18,t:14|	VXOWJCTXWVWLLC-REGDIAEZSA-N	Launched
betamethasone-dipropionate	anti-inflammatory agent	NR3C1	dermatology	corticosteroid-responsive dermatoses	CCC(=O)OCC(=O)[C@@]1(OC(=O)CC)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C |c:25,t:21|, CCC(=O)OCC(=O)[C@@]1(OC(=O)CC)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C |c:25,t:21|, CCC(=O)OCC(=O)[C@@]1(OC(=O)CC)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C |c:25,t:21|, CCC(=O)OCC(=O)[C@@]1(OC(=O)CC)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C |c:25,t:21|	CIWBQSYVNNPZIQ-XYWKZLDCSA-N, CIWBQSYVNNPZIQ-XYWKZLDCSA-N, CIWBQSYVNNPZIQ-XYWKZLDCSA-N, CIWBQSYVNNPZIQ-XYWKZLDCSA-N	Launched
betamethasone-phosphate			rheumatology	rheumatoid arthritis	C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)COP(O)(O)=O |c:11,t:7|	VQODGRNSFPNSQE-DVTGEIKXSA-N	Launched
betamethasone-valerate	glucocorticoid receptor agonist	NR3C1	dermatology	corticosteroid-responsive dermatoses	CCCCC(=O)O[C@@]1([C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)CO |c:19,t:15|, CCCCC(=O)O[C@@]1([C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)CO |c:19,t:15|, CCCCC(=O)O[C@@]1([C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)CO |c:19,t:15|, CCCCC(=O)O[C@@]1([C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)CO |c:19,t:15|	SNHRLVCMMWUAJD-SUYDQAKGSA-N, SNHRLVCMMWUAJD-SUYDQAKGSA-N, SNHRLVCMMWUAJD-SUYDQAKGSA-N, SNHRLVCMMWUAJD-SUYDQAKGSA-N	Launched
betamipron	panipenem uptake inhibitor		nephrology	renal toxicity	OC(=O)CCNC(=O)c1ccccc1, OC(=O)CCNC(=O)c1ccccc1, OC(=O)CCNC(=O)c1ccccc1	CWXYHOHYCJXYFQ-UHFFFAOYSA-N, CWXYHOHYCJXYFQ-UHFFFAOYSA-N, CWXYHOHYCJXYFQ-UHFFFAOYSA-N	Launched
betaxolol	adrenergic receptor antagonist	ADRB1, ADRB2	ophthalmology	intraocular pressure, glaucoma, ocular hypertension	CC(C)NC[C@@H](O)COc1ccc(CCOCC2CC2)cc1 |&1:5,r|, CC(C)NC[C@@H](O)COc1ccc(CCOCC2CC2)cc1 |&1:5,r|	NWIUTZDMDHAVTP-QGZVFWFLSA-N, NWIUTZDMDHAVTP-QGZVFWFLSA-N	Launched
betazole	histamine receptor agonist	HRH2	gastroenterology	gastric hypersecretion diagnostic	NCCc1ccn[nH]1	JXDFEQONERDKSS-UHFFFAOYSA-N	Launched
bethanechol	acetylcholine receptor agonist	CHRM1, CHRM2, CHRM3, CHRM4	urology	urinary retention	C[C@@H](C[N+](C)(C)C)OC(N)=O |r|	NZUPCNDJBJXXRF-LURJTMIESA-O	Launched
BETP	GLP receptor positive allosteric modulator	GLP1R			CC[S@](=O)c1nc(cc(n1)C(F)(F)F)-c1cccc(OCc2ccccc2)c1 |&1:2,r|	NTDFYGSSDDMNHI-NDEPHWFRSA-N	Preclinical
betrixaban	coagulation factor inhibitor	KCNH2	hematology	deep vein thrombosis (DVT)	COc1ccc(NC(=O)c2ccc(cc2)C(=N)N(C)C)c(c1)C(=O)Nc1ccc(Cl)cn1, COc1ccc(NC(=O)c2ccc(cc2)C(=N)N(C)C)c(c1)C(=O)Nc1ccc(Cl)cn1, COc1ccc(NC(=O)c2ccc(cc2)C(=N)N(C)C)c(c1)C(=O)Nc1ccc(Cl)cn1, COc1ccc(NC(=O)c2ccc(cc2)C(=N)N(C)C)c(c1)C(=O)Nc1ccc(Cl)cn1	XHOLNRLADUSQLD-UHFFFAOYSA-N, XHOLNRLADUSQLD-UHFFFAOYSA-N, XHOLNRLADUSQLD-UHFFFAOYSA-N, XHOLNRLADUSQLD-UHFFFAOYSA-N	Launched
betulinic-acid	apoptosis stimulant, NFkB pathway inhibitor	GPBAR1			CC(=C)[C@@H]1CC[C@@]2(CC[C@]3(C)[C@H](CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]12)C(O)=O, CC(=C)[C@@H]1CC[C@@]2(CC[C@]3(C)[C@H](CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]12)C(O)=O, CC(=C)[C@@H]1CC[C@@]2(CC[C@]3(C)[C@H](CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]12)C(O)=O	QGJZLNKBHJESQX-FZFNOLFKSA-N, QGJZLNKBHJESQX-FZFNOLFKSA-N, QGJZLNKBHJESQX-FZFNOLFKSA-N	Phase 1/Phase 2
bevantolol	adrenergic receptor antagonist		cardiology	angina pectoris, hypertension	COc1ccc(CCNC[C@@H](O)COc2cccc(C)c2)cc1OC |&1:10|, COc1ccc(CCNC[C@@H](O)COc2cccc(C)c2)cc1OC |&1:10|	HXLAFSUPPDYFEO-QGZVFWFLSA-N, HXLAFSUPPDYFEO-QGZVFWFLSA-N	Launched
bevenopran	opioid receptor antagonist				COc1cc(CNCCC2CCOCC2)ccc1Oc1cnc(cn1)C(N)=O	ZGCYVRNZWGUXNQ-UHFFFAOYSA-N	Phase 1
bevirimat-dimeglumine	HIV capsid assembly inhibitor				CC(=C)[C@@H]1CC[C@@]2(CC[C@]3(C)[C@H](CC[C@@H]4[C@@]5(C)CC[C@H](OC(=O)CC(C)(C)C(O)=O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]12)C(O)=O, CC(=C)[C@@H]1CC[C@@]2(CC[C@]3(C)[C@H](CC[C@@H]4[C@@]5(C)CC[C@H](OC(=O)CC(C)(C)C(O)=O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]12)C(O)=O, CC(=C)[C@@H]1CC[C@@]2(CC[C@]3(C)[C@H](CC[C@@H]4[C@@]5(C)CC[C@H](OC(=O)CC(C)(C)C(O)=O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]12)C(O)=O	YJEJKUQEXFSVCJ-WRFMNRASSA-N, YJEJKUQEXFSVCJ-WRFMNRASSA-N, YJEJKUQEXFSVCJ-WRFMNRASSA-N	Phase 2
bexagliflozin	solute carrier family member inhibitor				OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)c1ccc(Cl)c(Cc2ccc(OCCOC3CC3)cc2)c1	BTCRKOKVYTVOLU-SJSRKZJXSA-N	Phase 3
bexarotene	retinoid receptor agonist	RXRA, RXRB, RXRG	hematologic malignancy	cutaneous T-cell lymphoma (CTCL)	Cc1cc2c(cc1C(=C)c1ccc(cc1)C(O)=O)C(C)(C)CCC2(C)C, Cc1cc2c(cc1C(=C)c1ccc(cc1)C(O)=O)C(C)(C)CCC2(C)C, Cc1cc2c(cc1C(=C)c1ccc(cc1)C(O)=O)C(C)(C)CCC2(C)C, Cc1cc2c(cc1C(=C)c1ccc(cc1)C(O)=O)C(C)(C)CCC2(C)C	NAVMQTYZDKMPEU-UHFFFAOYSA-N, NAVMQTYZDKMPEU-UHFFFAOYSA-N, NAVMQTYZDKMPEU-UHFFFAOYSA-N, NAVMQTYZDKMPEU-UHFFFAOYSA-N	Launched
bezafibrate	PPAR receptor agonist	PPARA, PPARD, PPARG	cardiology	cholesterol	CC(C)(Oc1ccc(CCNC(=O)c2ccc(Cl)cc2)cc1)C(O)=O, CC(C)(Oc1ccc(CCNC(=O)c2ccc(Cl)cc2)cc1)C(O)=O, CC(C)(Oc1ccc(CCNC(=O)c2ccc(Cl)cc2)cc1)C(O)=O, CC(C)(Oc1ccc(CCNC(=O)c2ccc(Cl)cc2)cc1)C(O)=O	IIBYAHWJQTYFKB-UHFFFAOYSA-N, IIBYAHWJQTYFKB-UHFFFAOYSA-N, IIBYAHWJQTYFKB-UHFFFAOYSA-N, IIBYAHWJQTYFKB-UHFFFAOYSA-N	Launched
BFH772	VEGFR inhibitor				OCc1cc(Oc2ccc3c(cccc3c2)C(=O)Nc2cccc(c2)C(F)(F)F)ncn1	JNLSTLQFDDAULK-UHFFFAOYSA-N	Phase 2
BGP-15	PARP inhibitor				O[C@H](CONC(=N)c1cccnc1)CN1CCCCC1 |&1:1,r|	MVLOQULXIYSERZ-ZDUSSCGKSA-N	Phase 2
BGT226	PI3K inhibitor	MTOR, PIK3CA, PIK3CB, PIK3CG			COc1ccc(cn1)-c1ccc2ncc3n(C)c(=O)n(-c4ccc(N5CCNCC5)c(c4)C(F)(F)F)c3c2c1, COc1ccc(cn1)-c1ccc2ncc3n(C)c(=O)n(-c4ccc(N5CCNCC5)c(c4)C(F)(F)F)c3c2c1, COc1ccc(cn1)-c1ccc2ncc3n(C)c(=O)n(-c4ccc(N5CCNCC5)c(c4)C(F)(F)F)c3c2c1, COc1ccc(cn1)-c1ccc2ncc3n(C)c(=O)n(-c4ccc(N5CCNCC5)c(c4)C(F)(F)F)c3c2c1, COc1ccc(cn1)-c1ccc2ncc3n(C)c(=O)n(-c4ccc(N5CCNCC5)c(c4)C(F)(F)F)c3c2c1, COc1ccc(cn1)-c1ccc2ncc3n(C)c(=O)n(-c4ccc(N5CCNCC5)c(c4)C(F)(F)F)c3c2c1	BMMXYEBLEBULND-UHFFFAOYSA-N, BMMXYEBLEBULND-UHFFFAOYSA-N, BMMXYEBLEBULND-UHFFFAOYSA-N, BMMXYEBLEBULND-UHFFFAOYSA-N, BMMXYEBLEBULND-UHFFFAOYSA-N, BMMXYEBLEBULND-UHFFFAOYSA-N	Phase 1/Phase 2
BHQ	ATPase inhibitor	ATP2A1			CC(C)(C)c1cc(O)c(cc1O)C(C)(C)C, CC(C)(C)c1cc(O)c(cc1O)C(C)(C)C	JZODKRWQWUWGCD-UHFFFAOYSA-N, JZODKRWQWUWGCD-UHFFFAOYSA-N	Preclinical
BI-D1870	ribosomal protein inhibitor	RPS6KA1, RPS6KA2, RPS6KA3, RPS6KA6			CC(C)CCN1[C@@H](C)C(=O)N(C)c2cnc(Nc3cc(F)c(O)c(F)c3)nc12 |&1:6,r|, CC(C)CCN1[C@@H](C)C(=O)N(C)c2cnc(Nc3cc(F)c(O)c(F)c3)nc12 |&1:6,r|, CC(C)CCN1[C@@H](C)C(=O)N(C)c2cnc(Nc3cc(F)c(O)c(F)c3)nc12 |&1:6,r|, CC(C)CCN1[C@@H](C)C(=O)N(C)c2cnc(Nc3cc(F)c(O)c(F)c3)nc12 |&1:6,r|, CC(C)CCN1[C@@H](C)C(=O)N(C)c2cnc(Nc3cc(F)c(O)c(F)c3)nc12 |&1:6,r|, CC(C)CCN1[C@@H](C)C(=O)N(C)c2cnc(Nc3cc(F)c(O)c(F)c3)nc12 |&1:6,r|, CC(C)CCN1[C@@H](C)C(=O)N(C)c2cnc(Nc3cc(F)c(O)c(F)c3)nc12 |&1:6,r|, CC(C)CCN1[C@@H](C)C(=O)N(C)c2cnc(Nc3cc(F)c(O)c(F)c3)nc12 |&1:6,r|	DTEKTGDVSARYDS-NSHDSACASA-N, DTEKTGDVSARYDS-NSHDSACASA-N, DTEKTGDVSARYDS-NSHDSACASA-N, DTEKTGDVSARYDS-NSHDSACASA-N, DTEKTGDVSARYDS-NSHDSACASA-N, DTEKTGDVSARYDS-NSHDSACASA-N, DTEKTGDVSARYDS-NSHDSACASA-N, DTEKTGDVSARYDS-NSHDSACASA-N	Preclinical
BI-224436	HIV integrase inhibitor				Cc1nc2ccccc2c(-c2ccc3OCCc4ccnc2c34)c1[C@H](OC(C)(C)C)C(O)=O, Cc1nc2ccccc2c(-c2ccc3OCCc4ccnc2c34)c1[C@H](OC(C)(C)C)C(O)=O	MIXIIJCBELCMCZ-VWLOTQADSA-N, MIXIIJCBELCMCZ-VWLOTQADSA-N	Phase 1
BI-2536	PLK inhibitor	BRD4, PLK1, PLK2, PLK3			CC[C@H]1N(C2CCCC2)c2nc(Nc3ccc(cc3OC)C(=O)NC3CCN(C)CC3)ncc2N(C)C1=O, CC[C@H]1N(C2CCCC2)c2nc(Nc3ccc(cc3OC)C(=O)NC3CCN(C)CC3)ncc2N(C)C1=O, CC[C@H]1N(C2CCCC2)c2nc(Nc3ccc(cc3OC)C(=O)NC3CCN(C)CC3)ncc2N(C)C1=O, CC[C@H]1N(C2CCCC2)c2nc(Nc3ccc(cc3OC)C(=O)NC3CCN(C)CC3)ncc2N(C)C1=O, CC[C@H]1N(C2CCCC2)c2nc(Nc3ccc(cc3OC)C(=O)NC3CCN(C)CC3)ncc2N(C)C1=O, CC[C@H]1N(C2CCCC2)c2nc(Nc3ccc(cc3OC)C(=O)NC3CCN(C)CC3)ncc2N(C)C1=O, CC[C@H]1N(C2CCCC2)c2nc(Nc3ccc(cc3OC)C(=O)NC3CCN(C)CC3)ncc2N(C)C1=O, CC[C@H]1N(C2CCCC2)c2nc(Nc3ccc(cc3OC)C(=O)NC3CCN(C)CC3)ncc2N(C)C1=O, CC[C@H]1N(C2CCCC2)c2nc(Nc3ccc(cc3OC)C(=O)NC3CCN(C)CC3)ncc2N(C)C1=O	XQVVPGYIWAGRNI-JOCHJYFZSA-N, XQVVPGYIWAGRNI-JOCHJYFZSA-N, XQVVPGYIWAGRNI-JOCHJYFZSA-N, XQVVPGYIWAGRNI-JOCHJYFZSA-N, XQVVPGYIWAGRNI-JOCHJYFZSA-N, InChI=1S/C28H39N7O3/c1-5-22-27(37)34(3)23-17-29-28(32-25(23)35(22)20-8-6-7-9-20)31-21-11-10-18(16-24(21)38-4)26(36)30-19-12-14-33(2)15-13-19/h10-11,16-17,19-20,22H,5-9,12-15H2,1-4H3,(H,30,36)(H,29,31,32)/t22-/m1/s1, InChI=1S/C28H39N7O3/c1-5-22-27(37)34(3)23-17-29-28(32-25(23)35(22)20-8-6-7-9-20)31-21-11-10-18(16-24(21)38-4)26(36)30-19-12-14-33(2)15-13-19/h10-11,16-17,19-20,22H,5-9,12-15H2,1-4H3,(H,30,36)(H,29,31,32)/t22-/m1/s1, InChI=1S/C28H39N7O3/c1-5-22-27(37)34(3)23-17-29-28(32-25(23)35(22)20-8-6-7-9-20)31-21-11-10-18(16-24(21)38-4)26(36)30-19-12-14-33(2)15-13-19/h10-11,16-17,19-20,22H,5-9,12-15H2,1-4H3,(H,30,36)(H,29,31,32)/t22-/m1/s1, InChI=1S/C28H39N7O3/c1-5-22-27(37)34(3)23-17-29-28(32-25(23)35(22)20-8-6-7-9-20)31-21-11-10-18(16-24(21)38-4)26(36)30-19-12-14-33(2)15-13-19/h10-11,16-17,19-20,22H,5-9,12-15H2,1-4H3,(H,30,36)(H,29,31,32)/t22-/m1/s1	Phase 2
BI-409306	phosphodiesterase inhibitor				Oc1nc(Cc2ccccn2)nc2n(ncc12)C1CCOCC1	BZTIJCSHNVZMES-UHFFFAOYSA-N	Phase 1
BI-78D3	JNK inhibitor	MAPK8			[O-][N+](=O)c1cnc(Sc2n[nH]c(=O)n2-c2ccc3OCCOc3c2)s1, [O-][N+](=O)c1cnc(Sc2n[nH]c(=O)n2-c2ccc3OCCOc3c2)s1, [O-][N+](=O)c1cnc(Sc2n[nH]c(=O)n2-c2ccc3OCCOc3c2)s1, [O-][N+](=O)c1cnc(Sc2n[nH]c(=O)n2-c2ccc3OCCOc3c2)s1, [O-][N+](=O)c1cnc(Sc2n[nH]c(=O)n2-c2ccc3OCCOc3c2)s1, [O-][N+](=O)c1cnc(Sc2n[nH]c(=O)n2-c2ccc3OCCOc3c2)s1, [O-][N+](=O)c1cnc(Sc2n[nH]c(=O)n2-c2ccc3OCCOc3c2)s1, [O-][N+](=O)c1cnc(Sc2n[nH]c(=O)n2-c2ccc3OCCOc3c2)s1, [O-][N+](=O)c1cnc(Sc2n[nH]c(=O)n2-c2ccc3OCCOc3c2)s1	QFRLDZGQEZCCJZ-UHFFFAOYSA-N, QFRLDZGQEZCCJZ-UHFFFAOYSA-N, QFRLDZGQEZCCJZ-UHFFFAOYSA-N, QFRLDZGQEZCCJZ-UHFFFAOYSA-N, QFRLDZGQEZCCJZ-UHFFFAOYSA-N, QFRLDZGQEZCCJZ-UHFFFAOYSA-N, QFRLDZGQEZCCJZ-UHFFFAOYSA-N, QFRLDZGQEZCCJZ-UHFFFAOYSA-N, QFRLDZGQEZCCJZ-UHFFFAOYSA-N	Preclinical
BI-847325	Aurora kinase inhibitor, MEK inhibitor	AURKA, AURKB, AURKC, MAP2K1, MAP2K2			CCNC(=O)C#Cc1ccc2\C(=C(/Nc3ccc(CN(C)C)cc3)c3ccccc3)C(=O)Nc2c1, CCNC(=O)C#Cc1ccc2\C(=C(/Nc3ccc(CN(C)C)cc3)c3ccccc3)C(=O)Nc2c1, CCNC(=O)C#Cc1ccc2\C(=C(/Nc3ccc(CN(C)C)cc3)c3ccccc3)C(=O)Nc2c1, CCNC(=O)C#Cc1ccc2\C(=C(/Nc3ccc(CN(C)C)cc3)c3ccccc3)C(=O)Nc2c1, CCNC(=O)C#Cc1ccc2\C(=C(/Nc3ccc(CN(C)C)cc3)c3ccccc3)C(=O)Nc2c1	FLBNLJLONKAPLR-BYYHNAKLSA-N, FLBNLJLONKAPLR-BYYHNAKLSA-N, FLBNLJLONKAPLR-BYYHNAKLSA-N, FLBNLJLONKAPLR-BYYHNAKLSA-N, FLBNLJLONKAPLR-BYYHNAKLSA-N	Phase 1
BIA-10-2474	Fatty acid hydrolase inhibitor				CN(C1CCCCC1)C(=O)n1cnc(c1)-c1ccc[n+]([O-])c1	DOWVMJFBDGWVML-UHFFFAOYSA-N	Preclinical
biapenem	bacterial cell wall synthesis inhibitor		infectious disease	bacterial septicemia, pneumonia, urinary tract infections	C[C@@H](O)[C@@H]1[C@H]2[C@@H](C)C(SC3Cn4cnc[n+]4C3)=C(N2C1=O)C(O)=O |a:1,3,4,5,&1:9,c:18|, C[C@@H](O)[C@@H]1[C@H]2[C@@H](C)C(SC3Cn4cnc[n+]4C3)=C(N2C1=O)C(O)=O |a:1,3,4,5,&1:9,c:18|, C[C@@H](O)[C@@H]1[C@H]2[C@@H](C)C(SC3Cn4cnc[n+]4C3)=C(N2C1=O)C(O)=O |a:1,3,4,5,&1:9,c:18|, C[C@@H](O)[C@@H]1[C@H]2[C@@H](C)C(SC3Cn4cnc[n+]4C3)=C(N2C1=O)C(O)=O |a:1,3,4,5,&1:9,c:18|, C[C@@H](O)[C@@H]1[C@H]2[C@@H](C)C(SC3Cn4cnc[n+]4C3)=C(N2C1=O)C(O)=O |a:1,3,4,5,&1:9,c:18|, C[C@@H](O)[C@@H]1[C@H]2[C@@H](C)C(SC3Cn4cnc[n+]4C3)=C(N2C1=O)C(O)=O |a:1,3,4,5,&1:9,c:18|, C[C@@H](O)[C@@H]1[C@H]2[C@@H](C)C(SC3Cn4cnc[n+]4C3)=C(N2C1=O)C(O)=O |a:1,3,4,5,&1:9,c:18|	MRMBZHPJVKCOMA-YJFSRANCSA-O, MRMBZHPJVKCOMA-YJFSRANCSA-O, MRMBZHPJVKCOMA-YJFSRANCSA-O, MRMBZHPJVKCOMA-YJFSRANCSA-O, MRMBZHPJVKCOMA-YJFSRANCSA-O, MRMBZHPJVKCOMA-YJFSRANCSA-O, MRMBZHPJVKCOMA-YJFSRANCSA-O	Launched
BIBN4096	calcitonin antagonist	CALCA, CALCRL, RAMP1			NCCCC[C@H](NC(=O)[C@@H](Cc1cc(Br)c(O)c(Br)c1)NC(=O)N1CCC(CC1)N1Cc2ccccc2NC1=O)C(=O)N1CCN(CC1)c1ccncc1, NCCCC[C@H](NC(=O)[C@@H](Cc1cc(Br)c(O)c(Br)c1)NC(=O)N1CCC(CC1)N1Cc2ccccc2NC1=O)C(=O)N1CCN(CC1)c1ccncc1, NCCCC[C@H](NC(=O)[C@@H](Cc1cc(Br)c(O)c(Br)c1)NC(=O)N1CCC(CC1)N1Cc2ccccc2NC1=O)C(=O)N1CCN(CC1)c1ccncc1, NCCCC[C@H](NC(=O)[C@@H](Cc1cc(Br)c(O)c(Br)c1)NC(=O)N1CCC(CC1)N1Cc2ccccc2NC1=O)C(=O)N1CCN(CC1)c1ccncc1	ITIXDWVDFFXNEG-JHOUSYSJSA-N, ITIXDWVDFFXNEG-JHOUSYSJSA-N, ITIXDWVDFFXNEG-JHOUSYSJSA-N, ITIXDWVDFFXNEG-JHOUSYSJSA-N	Phase 2
BIBR-1532	telomerase inhibitor	TERT			C\C(=C/C(=O)Nc1ccccc1C(O)=O)c1ccc2ccccc2c1, C\C(=C/C(=O)Nc1ccccc1C(O)=O)c1ccc2ccccc2c1, C\C(=C/C(=O)Nc1ccccc1C(O)=O)c1ccc2ccccc2c1, C\C(=C/C(=O)Nc1ccccc1C(O)=O)c1ccc2ccccc2c1, C\C(=C/C(=O)Nc1ccccc1C(O)=O)c1ccc2ccccc2c1	PGFQXGLPJUCTOI-WYMLVPIESA-N, PGFQXGLPJUCTOI-WYMLVPIESA-N, PGFQXGLPJUCTOI-WYMLVPIESA-N, PGFQXGLPJUCTOI-WYMLVPIESA-N, PGFQXGLPJUCTOI-WYMLVPIESA-N	Preclinical
BIBU-1361	EGFR inhibitor	EGFR			CCN(CC)CC1CCN(CC1)c1ncc2ncnc(Nc3ccc(F)c(Cl)c3)c2n1, CCN(CC)CC1CCN(CC1)c1ncc2ncnc(Nc3ccc(F)c(Cl)c3)c2n1, CCN(CC)CC1CCN(CC1)c1ncc2ncnc(Nc3ccc(F)c(Cl)c3)c2n1	JUGSLZCFNSTKBN-UHFFFAOYSA-N, JUGSLZCFNSTKBN-UHFFFAOYSA-N, JUGSLZCFNSTKBN-UHFFFAOYSA-N	Preclinical
BIBX-1382	EGFR inhibitor	EGFR, ERBB2			CN1CCC(CC1)Nc1ncc2ncnc(Nc3ccc(F)c(Cl)c3)c2n1, CN1CCC(CC1)Nc1ncc2ncnc(Nc3ccc(F)c(Cl)c3)c2n1, CN1CCC(CC1)Nc1ncc2ncnc(Nc3ccc(F)c(Cl)c3)c2n1	FTFRZXFNZVCRSK-UHFFFAOYSA-N, FTFRZXFNZVCRSK-UHFFFAOYSA-N, FTFRZXFNZVCRSK-UHFFFAOYSA-N	Phase 1
bicalutamide	androgen receptor antagonist	AR	oncology	prostate cancer	CC(O)(CS(=O)(=O)c1ccc(F)cc1)C(=O)Nc1ccc(C#N)c(c1)C(F)(F)F |&1:1|, CC(O)(CS(=O)(=O)c1ccc(F)cc1)C(=O)Nc1ccc(C#N)c(c1)C(F)(F)F |&1:1|, CC(O)(CS(=O)(=O)c1ccc(F)cc1)C(=O)Nc1ccc(C#N)c(c1)C(F)(F)F |&1:1|	LKJPYSCBVHEWIU-UHFFFAOYSA-N, LKJPYSCBVHEWIU-UHFFFAOYSA-N, LKJPYSCBVHEWIU-UHFFFAOYSA-N	Launched
bicifadine	dopamine reuptake inhibitor, serotonin receptor antagonist				[H][C@@]12C[C@@]1(CNC2)c1ccc(C)cc1 |&1:1,3,r|	OFYVIGTWSQPCLF-NWDGAFQWSA-N	Phase 3
bictegravir	HIV integrase inhibitor		infectious disease	human immunodeficiency virus (HIV-1)	[H][C@@]12CC[C@@]([H])(C1)N1C(=O)c3c(O)c(=O)c(cn3C[C@@]1([H])O2)C(=O)NCc1c(F)cc(F)cc1F	SOLUWJRYJLAZCX-LYOVBCGYSA-N	Launched
bicuculline-(+)	GABA receptor antagonist	GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, KCNN1			CN1CCc2cc3OCOc3cc2[C@H]1[C@@H]1OC(=O)c2c1ccc1OCOc21	IYGYMKDQCDOMRE-ZWKOTPCHSA-N	Preclinical
bicuculline-methochloride-(-)	GABA receptor antagonist				C[N+]1(C)CCc2cc3OCOc3cc2[C@H]1[C@@H]1OC(=O)c2c1ccc1OCOc21	WDIQXKYUSINZME-RBUKOAKNSA-N	Preclinical
bicyclol	NFkB pathway inhibitor	HSPA1A, HSPB1	infectious disease	hepatitis B, hepatitis C	COC(=O)c1cc(OC)c2OCOc2c1-c1c2OCOc2c(OC)cc1CO	KXMTXZACPVCDMH-UHFFFAOYSA-N	Launched
bifemelane	acetylcholine release enhancer	MAOA, MAOB	ophthalmology, neurology/psychiatry	glaucoma, senile dementia	CNCCCCOc1ccccc1Cc1ccccc1, CNCCCCOc1ccccc1Cc1ccccc1, CNCCCCOc1ccccc1Cc1ccccc1	QSQQPMHPCBLLGX-UHFFFAOYSA-N, QSQQPMHPCBLLGX-UHFFFAOYSA-N, QSQQPMHPCBLLGX-UHFFFAOYSA-N	Launched
bifendate			infectious disease	hepatitis B, hepatitis C	COC(=O)c1cc(OC)c2OCOc2c1-c1c2OCOc2c(OC)cc1C(=O)OC, COC(=O)c1cc(OC)c2OCOc2c1-c1c2OCOc2c(OC)cc1C(=O)OC	JMZOMFYRADAWOG-UHFFFAOYSA-N, JMZOMFYRADAWOG-UHFFFAOYSA-N	Launched
bifonazole	sterol demethylase inhibitor		infectious disease	tinea pedis, tinea cruris	c1cn(cn1)[C@@H](c1ccccc1)c1ccc(cc1)-c1ccccc1 |&1:5,r|, c1cn(cn1)[C@@H](c1ccccc1)c1ccc(cc1)-c1ccccc1 |&1:5,r|, c1cn(cn1)[C@@H](c1ccccc1)c1ccc(cc1)-c1ccccc1 |&1:5,r|, c1cn(cn1)[C@@H](c1ccccc1)c1ccc(cc1)-c1ccccc1 |&1:5,r|, c1cn(cn1)[C@@H](c1ccccc1)c1ccc(cc1)-c1ccccc1 |&1:5,r|, c1cn(cn1)[C@@H](c1ccccc1)c1ccc(cc1)-c1ccccc1 |&1:5,r|	OCAPBUJLXMYKEJ-QFIPXVFZSA-N, OCAPBUJLXMYKEJ-QFIPXVFZSA-N, OCAPBUJLXMYKEJ-QFIPXVFZSA-N, OCAPBUJLXMYKEJ-QFIPXVFZSA-N, OCAPBUJLXMYKEJ-QFIPXVFZSA-N, OCAPBUJLXMYKEJ-QFIPXVFZSA-N	Launched
BIIB021	HSP inhibitor	HSP90AA1			COc1c(C)cnc(Cn2cnc3c(Cl)nc(N)nc23)c1C, COc1c(C)cnc(Cn2cnc3c(Cl)nc(N)nc23)c1C, COc1c(C)cnc(Cn2cnc3c(Cl)nc(N)nc23)c1C, COc1c(C)cnc(Cn2cnc3c(Cl)nc(N)nc23)c1C, COc1c(C)cnc(Cn2cnc3c(Cl)nc(N)nc23)c1C	QULDDKSCVCJTPV-UHFFFAOYSA-N, QULDDKSCVCJTPV-UHFFFAOYSA-N, QULDDKSCVCJTPV-UHFFFAOYSA-N, QULDDKSCVCJTPV-UHFFFAOYSA-N, QULDDKSCVCJTPV-UHFFFAOYSA-N	Phase 2
bilastine	histamine receptor antagonist	HRH1	ophthalmology	conjunctivitis	CCOCCn1c(nc2ccccc12)C1CCN(CCc2ccc(cc2)C(C)(C)C(O)=O)CC1, CCOCCn1c(nc2ccccc12)C1CCN(CCc2ccc(cc2)C(C)(C)C(O)=O)CC1	ACCMWZWAEFYUGZ-UHFFFAOYSA-N, ACCMWZWAEFYUGZ-UHFFFAOYSA-N	Launched
bilobalide	GABA receptor modulator	GLRA1, GLRA2, GLRB, HTR3A, HTR3B			CC(C)(C)[C@]1(O)C[C@@H]2OC(=O)C[C@@]22C(=O)O[C@@H]3OC(=O)[C@H](O)[C@]123	MOLPUWBMSBJXER-YDGSQGCISA-N	Preclinical
bimatoprost	prostanoid receptor agonist	AKR1C3, PTGER1, PTGER3, PTGFR	ophthalmology	intraocular pressure, glaucoma, ocular hypertension	CCNC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\[C@@H](O)CCc1ccccc1	AQOKCDNYWBIDND-FTOWTWDKSA-N	Launched
BIMU-8	serotonin receptor agonist	HTR4			CC(C)n1c2ccccc2n(C(=O)N[C@@H]2C[C@@H]3CC[C@H](C2)N3C)c1=O |&1:14,16,19|	AFOFVIBWSLOHFR-QDMKHBRRSA-N	Preclinical
BINA	glutamate receptor positive allosteric modulator	GRM2			Cc1c2C(=O)[C@H](Cc2cc(OCc2cccc(c2)-c2ccc(cc2)C(O)=O)c1C)C1CCCC1 |&1:5,r|	KMKBEESNZAPKMP-AREMUKBSSA-N	Preclinical
bindarit	NFkB pathway inhibitor	CCL2, CCL7, CCL8			CC(C)(OCc1nn(Cc2ccccc2)c2ccccc12)C(O)=O, CC(C)(OCc1nn(Cc2ccccc2)c2ccccc12)C(O)=O	MTHORRSSURHQPZ-UHFFFAOYSA-N, MTHORRSSURHQPZ-UHFFFAOYSA-N	Phase 2
binimetinib	MEK inhibitor	MAP2K1, MAP2K2	oncology	melanoma	Cn1cnc2c(F)c(Nc3ccc(Br)cc3F)c(cc12)C(=O)NOCCO, Cn1cnc2c(F)c(Nc3ccc(Br)cc3F)c(cc12)C(=O)NOCCO, Cn1cnc2c(F)c(Nc3ccc(Br)cc3F)c(cc12)C(=O)NOCCO, Cn1cnc2c(F)c(Nc3ccc(Br)cc3F)c(cc12)C(=O)NOCCO, Cn1cnc2c(F)c(Nc3ccc(Br)cc3F)c(cc12)C(=O)NOCCO	ACWZRVQXLIRSDF-UHFFFAOYSA-N, ACWZRVQXLIRSDF-UHFFFAOYSA-N, ACWZRVQXLIRSDF-UHFFFAOYSA-N, ACWZRVQXLIRSDF-UHFFFAOYSA-N, ACWZRVQXLIRSDF-UHFFFAOYSA-N	Launched
BIO-1211	integrin antagonist	ITGA4, ITGB1			CC(C)C[C@H](NC(=O)Cc1ccc(NC(=O)Nc2ccccc2C)cc1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(O)=O, CC(C)C[C@H](NC(=O)Cc1ccc(NC(=O)Nc2ccccc2C)cc1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(O)=O	NVVGCQABIHSJSQ-KFZSMJGVSA-N, NVVGCQABIHSJSQ-KFZSMJGVSA-N	Phase 2
BIO-5192	integrin inhibitor	ITGA4, ITGB1			CC(C)C[C@H](N(C)C(=O)Cc1ccc(NC(=O)Nc2ccccc2C)cc1)C(=O)NCC[C@H](NC(=O)[C@@H]1CCCN1S(=O)(=O)c1cc(Cl)cc(Cl)c1)C(O)=O, CC(C)C[C@H](N(C)C(=O)Cc1ccc(NC(=O)Nc2ccccc2C)cc1)C(=O)NCC[C@H](NC(=O)[C@@H]1CCCN1S(=O)(=O)c1cc(Cl)cc(Cl)c1)C(O)=O, CC(C)C[C@H](N(C)C(=O)Cc1ccc(NC(=O)Nc2ccccc2C)cc1)C(=O)NCC[C@H](NC(=O)[C@@H]1CCCN1S(=O)(=O)c1cc(Cl)cc(Cl)c1)C(O)=O	MNQBPRHHZPXCKZ-ZDCRTTOTSA-N, MNQBPRHHZPXCKZ-ZDCRTTOTSA-N, MNQBPRHHZPXCKZ-ZDCRTTOTSA-N	Preclinical
biotin	vitamin B	ACACA, ACACB, HLCS, MCCC1, MCCC2, PC, PCCA, PCCB, SLC5A6			OC(=O)CCCC[C@@H]1SC[C@@H]2NC(=O)N[C@H]12, OC(=O)CCCC[C@@H]1SC[C@@H]2NC(=O)N[C@H]12, OC(=O)CCCC[C@@H]1SC[C@@H]2NC(=O)N[C@H]12	YBJHBAHKTGYVGT-ZKWXMUAHSA-N, YBJHBAHKTGYVGT-ZKWXMUAHSA-N, YBJHBAHKTGYVGT-ZKWXMUAHSA-N	Launched
bipenamol	dipeptidyl peptidase inhibitor	CTSC			NCc1ccccc1Sc1ccccc1CO, NCc1ccccc1Sc1ccccc1CO	HLAFSNJRKZLMPT-UHFFFAOYSA-N, HLAFSNJRKZLMPT-UHFFFAOYSA-N	Phase 2
biperiden	acetylcholine receptor antagonist	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5	neurology/psychiatry	Parkinson's Disease	O[C@@](CCN1CCCCC1)([C@@H]1C[C@@H]2C[C@H]1C=C2)c1ccccc1 |&1:12,14,&2:10,&3:1,c:17|, O[C@@](CCN1CCCCC1)([C@@H]1C[C@@H]2C[C@H]1C=C2)c1ccccc1 |&1:12,14,&2:10,&3:1,c:17|, O[C@@](CCN1CCCCC1)([C@@H]1C[C@@H]2C[C@H]1C=C2)c1ccccc1 |&1:12,14,&2:10,&3:1,c:17|	YSXKPIUOCJLQIE-UYWIDEMCSA-N, YSXKPIUOCJLQIE-UYWIDEMCSA-N, YSXKPIUOCJLQIE-UYWIDEMCSA-N	Launched
birinapant	XIAP inhibitor	BIRC2, XIAP			CC[C@H](NC(=O)[C@H](C)NC)C(=O)N1C[C@@H](O)C[C@H]1Cc1c([nH]c2cc(F)ccc12)-c1[nH]c2cc(F)ccc2c1C[C@@H]1C[C@H](O)CN1C(=O)[C@H](CC)NC(=O)[C@H](C)NC, CC[C@H](NC(=O)[C@H](C)NC)C(=O)N1C[C@@H](O)C[C@H]1Cc1c([nH]c2cc(F)ccc12)-c1[nH]c2cc(F)ccc2c1C[C@@H]1C[C@H](O)CN1C(=O)[C@H](CC)NC(=O)[C@H](C)NC, CC[C@H](NC(=O)[C@H](C)NC)C(=O)N1C[C@@H](O)C[C@H]1Cc1c([nH]c2cc(F)ccc12)-c1[nH]c2cc(F)ccc2c1C[C@@H]1C[C@H](O)CN1C(=O)[C@H](CC)NC(=O)[C@H](C)NC, CC[C@H](NC(=O)[C@H](C)NC)C(=O)N1C[C@@H](O)C[C@H]1Cc1c([nH]c2cc(F)ccc12)-c1[nH]c2cc(F)ccc2c1C[C@@H]1C[C@H](O)CN1C(=O)[C@H](CC)NC(=O)[C@H](C)NC, CC[C@H](NC(=O)[C@H](C)NC)C(=O)N1C[C@@H](O)C[C@H]1Cc1c([nH]c2cc(F)ccc12)-c1[nH]c2cc(F)ccc2c1C[C@@H]1C[C@H](O)CN1C(=O)[C@H](CC)NC(=O)[C@H](C)NC, CC[C@H](NC(=O)[C@H](C)NC)C(=O)N1C[C@@H](O)C[C@H]1Cc1c([nH]c2cc(F)ccc12)-c1[nH]c2cc(F)ccc2c1C[C@@H]1C[C@H](O)CN1C(=O)[C@H](CC)NC(=O)[C@H](C)NC, CC[C@H](NC(=O)[C@H](C)NC)C(=O)N1C[C@@H](O)C[C@H]1Cc1c([nH]c2cc(F)ccc12)-c1[nH]c2cc(F)ccc2c1C[C@@H]1C[C@H](O)CN1C(=O)[C@H](CC)NC(=O)[C@H](C)NC, CC[C@H](NC(=O)[C@H](C)NC)C(=O)N1C[C@@H](O)C[C@H]1Cc1c([nH]c2cc(F)ccc12)-c1[nH]c2cc(F)ccc2c1C[C@@H]1C[C@H](O)CN1C(=O)[C@H](CC)NC(=O)[C@H](C)NC, CC[C@H](NC(=O)[C@H](C)NC)C(=O)N1C[C@@H](O)C[C@H]1Cc1c([nH]c2cc(F)ccc12)-c1[nH]c2cc(F)ccc2c1C[C@@H]1C[C@H](O)CN1C(=O)[C@H](CC)NC(=O)[C@H](C)NC	PKWRMUKBEYJEIX-DXXQBUJASA-N, PKWRMUKBEYJEIX-DXXQBUJASA-N, PKWRMUKBEYJEIX-DXXQBUJASA-N, PKWRMUKBEYJEIX-DXXQBUJASA-N, PKWRMUKBEYJEIX-DXXQBUJASA-N, PKWRMUKBEYJEIX-DXXQBUJASA-N, PKWRMUKBEYJEIX-DXXQBUJASA-N, InChI=1S/C42H56F2N8O6/c1-7-33(49-39(55)21(3)45-5)41(57)51-19-27(53)15-25(51)17-31-29-11-9-23(43)13-35(29)47-37(31)38-32(30-12-10-24(44)14-36(30)48-38)18-26-16-28(54)20-52(26)42(58)34(8-2)50-40(56)22(4)46-6/h9-14,21-22,25-28,33-34,45-48,53-54H,7-8,15-20H2,1-6H3,(H,49,55)(H,50,56)/t21-,22-,25-,26-,27-,28-,33-,34-/m0/s1, InChI=1S/C42H56F2N8O6/c1-7-33(49-39(55)21(3)45-5)41(57)51-19-27(53)15-25(51)17-31-29-11-9-23(43)13-35(29)47-37(31)38-32(30-12-10-24(44)14-36(30)48-38)18-26-16-28(54)20-52(26)42(58)34(8-2)50-40(56)22(4)46-6/h9-14,21-22,25-28,33-34,45-48,53-54H,7-8,15-20H2,1-6H3,(H,49,55)(H,50,56)/t21-,22-,25-,26-,27-,28-,33-,34-/m0/s1	Phase 2
BIRT-377	lymphocyte function-associated antigen negative modulator	ICAM1			CN1C(=O)N(C(=O)[C@@]1(C)Cc1ccc(Br)cc1)c1cc(Cl)cc(Cl)c1, CN1C(=O)N(C(=O)[C@@]1(C)Cc1ccc(Br)cc1)c1cc(Cl)cc(Cl)c1	FJNJHZQMQRVZEE-GOSISDBHSA-N, FJNJHZQMQRVZEE-GOSISDBHSA-N	Preclinical
bis(maltolato)oxovanadium(IV)	tyrosine phosphatase inhibitor	PTPN1			Cc1occc(=O)c1O[V](=O)Oc1c(C)occc1=O, Cc1occc(=O)c1O[V](=O)Oc1c(C)occc1=O, Cc1occc(=O)c1O[V](=O)Oc1c(C)occc1=O, Cc1occc(=O)c1O[V](=O)Oc1c(C)occc1=O	XUOLEICXAPEOSI-UHFFFAOYSA-L, XUOLEICXAPEOSI-UHFFFAOYSA-L, XUOLEICXAPEOSI-UHFFFAOYSA-L, XUOLEICXAPEOSI-UHFFFAOYSA-L	Phase 2
bisacodyl	laxative		gastroenterology	constipation	CC(=O)Oc1ccc(cc1)C(c1ccc(OC(C)=O)cc1)c1ccccn1, CC(=O)Oc1ccc(cc1)C(c1ccc(OC(C)=O)cc1)c1ccccn1, CC(=O)Oc1ccc(cc1)C(c1ccc(OC(C)=O)cc1)c1ccccn1	KHOITXIGCFIULA-UHFFFAOYSA-N, KHOITXIGCFIULA-UHFFFAOYSA-N, KHOITXIGCFIULA-UHFFFAOYSA-N	Launched
bisantrene	topoisomerase inhibitor				C1CN=C(N\N=C\c2c3ccccc3c(\C=N\NC3=NCCN3)c3ccccc23)N1 |t:2,19|	NJSMWLQOCQIOPE-OCHFTUDZSA-N	Phase 2
bisindolylmaleimide-IX	PKC inhibitor	AKT1, GSK3B, LCK, MAPK1, MAPK11, MAPK12, MAPK14, MAPK8, PRKCA, ROCK1, RPS6KB1, SIRT1			Cn1cc(C2=C(C(=O)NC2=O)c2cn(CCCSC(N)=N)c3ccccc23)c2ccccc12 |t:4|, Cn1cc(C2=C(C(=O)NC2=O)c2cn(CCCSC(N)=N)c3ccccc23)c2ccccc12 |t:4|, Cn1cc(C2=C(C(=O)NC2=O)c2cn(CCCSC(N)=N)c3ccccc23)c2ccccc12 |t:4|, Cn1cc(C2=C(C(=O)NC2=O)c2cn(CCCSC(N)=N)c3ccccc23)c2ccccc12 |t:4|	DSXXEELGXBCYNQ-UHFFFAOYSA-N, DSXXEELGXBCYNQ-UHFFFAOYSA-N, DSXXEELGXBCYNQ-UHFFFAOYSA-N, DSXXEELGXBCYNQ-UHFFFAOYSA-N	Preclinical
bismuth(III)-trifluoromethanesulfonate	direct substitution catalyst				[Bi].OS(=O)(=O)C(F)(F)F.OS(=O)(=O)C(F)(F)F.OS(=O)(=O)C(F)(F)F	BQFARKYNYLKHRD-UHFFFAOYSA-N	Preclinical
bismuth-oxalate					[Bi].[Bi].OC(=O)C(O)=O.OC(=O)C(O)=O.OC(=O)C(O)=O	PEBMBOMJLWXKFI-UHFFFAOYSA-N	Preclinical
bismuth-subcitrate-potassium			gastroenterology	duodenal ulcer disease	OC(=O)C[C@](O)(CC(=O)O[Bi]1OC(=O)C[C@@](O)(CC(O)=O)C(=O)O1)C(O)=O |&1:4,&2:15|	KNOSZBQOKCZXTI-UHFFFAOYSA-K	Launched
bismuth-subgallate	nitric oxide synthase inhibitor	NOS1	gastroenterology	internal deoderant	O[Bi]1Oc2cc(cc(O)c2O1)C(O)=O	JAONZGLTYYUPCT-UHFFFAOYSA-K	Launched
bismuth-subsalicylate	antacid		gastroenterology	diarrhea	O[Bi]1OC(=O)c2ccccc2O1, O[Bi]1OC(=O)c2ccccc2O1, O[Bi]1OC(=O)c2ccccc2O1, O[Bi]1OC(=O)c2ccccc2O1, O[Bi]1OC(=O)c2ccccc2O1	ZREIPSZUJIFJNP-UHFFFAOYSA-K, ZREIPSZUJIFJNP-UHFFFAOYSA-K, ZREIPSZUJIFJNP-UHFFFAOYSA-K, ZREIPSZUJIFJNP-UHFFFAOYSA-K, ZREIPSZUJIFJNP-UHFFFAOYSA-K	Launched
bisoctrizole					CC(C)(C)CC(C)(C)c1cc(Cc2cc(cc(c2O)-n2nc3ccccc3n2)C(C)(C)CC(C)(C)C)c(O)c(c1)-n1nc2ccccc2n1, CC(C)(C)CC(C)(C)c1cc(Cc2cc(cc(c2O)-n2nc3ccccc3n2)C(C)(C)CC(C)(C)C)c(O)c(c1)-n1nc2ccccc2n1	FQUNFJULCYSSOP-UHFFFAOYSA-N, FQUNFJULCYSSOP-UHFFFAOYSA-N	Phase 2
bisoprolol	adrenergic receptor antagonist	ADRB1	cardiology	hypertension	CC(C)NC[C@@H](O)COc1ccc(COCCOC(C)C)cc1 |&1:5|, CC(C)NC[C@@H](O)COc1ccc(COCCOC(C)C)cc1 |&1:5|, CC(C)NC[C@@H](O)COc1ccc(COCCOC(C)C)cc1 |&1:5|, CC(C)NC[C@@H](O)COc1ccc(COCCOC(C)C)cc1 |&1:5|, CC(C)NC[C@@H](O)COc1ccc(COCCOC(C)C)cc1 |&1:5|	VHYCDWMUTMEGQY-QGZVFWFLSA-N, VHYCDWMUTMEGQY-QGZVFWFLSA-N, VHYCDWMUTMEGQY-QGZVFWFLSA-N, VHYCDWMUTMEGQY-QGZVFWFLSA-N, VHYCDWMUTMEGQY-QGZVFWFLSA-N	Launched
bisphenol-A	synthetic estrogen	AR, ESR1, ESR2, ESRRG, PPARG			CC(C)(c1ccc(O)cc1)c1ccc(O)cc1, CC(C)(c1ccc(O)cc1)c1ccc(O)cc1	IISBACLAFKSPIT-UHFFFAOYSA-N, IISBACLAFKSPIT-UHFFFAOYSA-N	Phase 1
bithionol	autotaxin inhibitor	ESR1, ESR2, MCL1			Oc1c(Cl)cc(Cl)cc1Sc1cc(Cl)cc(Cl)c1O, Oc1c(Cl)cc(Cl)cc1Sc1cc(Cl)cc(Cl)c1O, Oc1c(Cl)cc(Cl)cc1Sc1cc(Cl)cc(Cl)c1O, Oc1c(Cl)cc(Cl)cc1Sc1cc(Cl)cc(Cl)c1O, Oc1c(Cl)cc(Cl)cc1Sc1cc(Cl)cc(Cl)c1O, Oc1c(Cl)cc(Cl)cc1Sc1cc(Cl)cc(Cl)c1O, Oc1c(Cl)cc(Cl)cc1Sc1cc(Cl)cc(Cl)c1O, Oc1c(Cl)cc(Cl)cc1Sc1cc(Cl)cc(Cl)c1O	JFIOVJDNOJYLKP-UHFFFAOYSA-N, JFIOVJDNOJYLKP-UHFFFAOYSA-N, JFIOVJDNOJYLKP-UHFFFAOYSA-N, JFIOVJDNOJYLKP-UHFFFAOYSA-N, JFIOVJDNOJYLKP-UHFFFAOYSA-N, JFIOVJDNOJYLKP-UHFFFAOYSA-N, JFIOVJDNOJYLKP-UHFFFAOYSA-N, InChI=1S/C12H6Cl4O2S/c13-5-1-7(15)11(17)9(3-5)19-10-4-6(14)2-8(16)12(10)18/h1-4,17-18H	Withdrawn
bitopertin	glycine transporter inhibitor	SLC6A5, SLC6A9			C[C@H](Oc1ccc(cc1C(=O)N1CCN(CC1)c1ncc(cc1F)C(F)(F)F)S(C)(=O)=O)C(F)(F)F, C[C@H](Oc1ccc(cc1C(=O)N1CCN(CC1)c1ncc(cc1F)C(F)(F)F)S(C)(=O)=O)C(F)(F)F	YUUGYIUSCYNSQR-LBPRGKRZSA-N, YUUGYIUSCYNSQR-LBPRGKRZSA-N	Phase 3
bitoscanate	anthelmintic agent				S=C=Nc1ccc(cc1)N=C=S, S=C=Nc1ccc(cc1)N=C=S	OMWQUXGVXQELIX-UHFFFAOYSA-N, OMWQUXGVXQELIX-UHFFFAOYSA-N	Preclinical
bivalirudin	thrombin inhibitor	F2	cardiology	angina pectoris	CC[C@H](C)[C@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)CNC(=O)CNC(=O)CNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](N)Cc1ccccc1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CC(C)C)C(O)=O, CC[C@H](C)[C@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)CNC(=O)CNC(=O)CNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](N)Cc1ccccc1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CC(C)C)C(O)=O, CC[C@H](C)[C@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)CNC(=O)CNC(=O)CNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](N)Cc1ccccc1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CC(C)C)C(O)=O, CC[C@H](C)[C@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)CNC(=O)CNC(=O)CNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](N)Cc1ccccc1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CC(C)C)C(O)=O, CC[C@H](C)[C@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)CNC(=O)CNC(=O)CNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](N)Cc1ccccc1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CC(C)C)C(O)=O, CC[C@H](C)[C@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)CNC(=O)CNC(=O)CNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](N)Cc1ccccc1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CC(C)C)C(O)=O	OIRCOABEOLEUMC-GEJPAHFPSA-N, OIRCOABEOLEUMC-GEJPAHFPSA-N, OIRCOABEOLEUMC-GEJPAHFPSA-N, OIRCOABEOLEUMC-GEJPAHFPSA-N, OIRCOABEOLEUMC-GEJPAHFPSA-N, OIRCOABEOLEUMC-GEJPAHFPSA-N	Launched
BIX-01294	histone lysine methyltransferase inhibitor	EHMT1, EHMT2			COc1cc2nc(nc(NC3CCN(Cc4ccccc4)CC3)c2cc1OC)N1CCCN(C)CC1, COc1cc2nc(nc(NC3CCN(Cc4ccccc4)CC3)c2cc1OC)N1CCCN(C)CC1, COc1cc2nc(nc(NC3CCN(Cc4ccccc4)CC3)c2cc1OC)N1CCCN(C)CC1, COc1cc2nc(nc(NC3CCN(Cc4ccccc4)CC3)c2cc1OC)N1CCCN(C)CC1, COc1cc2nc(nc(NC3CCN(Cc4ccccc4)CC3)c2cc1OC)N1CCCN(C)CC1, COc1cc2nc(nc(NC3CCN(Cc4ccccc4)CC3)c2cc1OC)N1CCCN(C)CC1, COc1cc2nc(nc(NC3CCN(Cc4ccccc4)CC3)c2cc1OC)N1CCCN(C)CC1, COc1cc2nc(nc(NC3CCN(Cc4ccccc4)CC3)c2cc1OC)N1CCCN(C)CC1, COc1cc2nc(nc(NC3CCN(Cc4ccccc4)CC3)c2cc1OC)N1CCCN(C)CC1, COc1cc2nc(nc(NC3CCN(Cc4ccccc4)CC3)c2cc1OC)N1CCCN(C)CC1, COc1cc2nc(nc(NC3CCN(Cc4ccccc4)CC3)c2cc1OC)N1CCCN(C)CC1, COc1cc2nc(nc(NC3CCN(Cc4ccccc4)CC3)c2cc1OC)N1CCCN(C)CC1	OSXFATOLZGZLSK-UHFFFAOYSA-N, OSXFATOLZGZLSK-UHFFFAOYSA-N, OSXFATOLZGZLSK-UHFFFAOYSA-N, OSXFATOLZGZLSK-UHFFFAOYSA-N, OSXFATOLZGZLSK-UHFFFAOYSA-N, OSXFATOLZGZLSK-UHFFFAOYSA-N, OSXFATOLZGZLSK-UHFFFAOYSA-N, OSXFATOLZGZLSK-UHFFFAOYSA-N, OSXFATOLZGZLSK-UHFFFAOYSA-N, OSXFATOLZGZLSK-UHFFFAOYSA-N, OSXFATOLZGZLSK-UHFFFAOYSA-N, OSXFATOLZGZLSK-UHFFFAOYSA-N	Preclinical
BIX-02188	MEK inhibitor	MAP2K5			CN(C)Cc1cccc(N\C(=C2/C(=O)Nc3cc(ccc23)C(N)=O)c2ccccc2)c1, CN(C)Cc1cccc(N\C(=C2/C(=O)Nc3cc(ccc23)C(N)=O)c2ccccc2)c1, CN(C)Cc1cccc(N\C(=C2/C(=O)Nc3cc(ccc23)C(N)=O)c2ccccc2)c1, CN(C)Cc1cccc(N\C(=C2/C(=O)Nc3cc(ccc23)C(N)=O)c2ccccc2)c1, CN(C)Cc1cccc(N\C(=C2/C(=O)Nc3cc(ccc23)C(N)=O)c2ccccc2)c1, CN(C)Cc1cccc(N\C(=C2/C(=O)Nc3cc(ccc23)C(N)=O)c2ccccc2)c1	FSZPIAXLCCQFCM-FCQUAONHSA-N, FSZPIAXLCCQFCM-FCQUAONHSA-N, FSZPIAXLCCQFCM-FCQUAONHSA-N, FSZPIAXLCCQFCM-FCQUAONHSA-N, FSZPIAXLCCQFCM-FCQUAONHSA-N, FSZPIAXLCCQFCM-FCQUAONHSA-N	Preclinical
BIX-02189	MEK inhibitor	MAP2K5, MAPK7			CN(C)Cc1cccc(N\C(=C2/C(=O)Nc3cc(ccc23)C(=O)N(C)C)c2ccccc2)c1, CN(C)Cc1cccc(N\C(=C2/C(=O)Nc3cc(ccc23)C(=O)N(C)C)c2ccccc2)c1, CN(C)Cc1cccc(N\C(=C2/C(=O)Nc3cc(ccc23)C(=O)N(C)C)c2ccccc2)c1	HOMJAAIVTDVQJA-IZHYLOQSSA-N, HOMJAAIVTDVQJA-IZHYLOQSSA-N, HOMJAAIVTDVQJA-IZHYLOQSSA-N	Preclinical
BL-5583	hypercalcaemic agent				OC(=O)c1cc2ccccc2s1, OC(=O)c1cc2ccccc2s1, OC(=O)c1cc2ccccc2s1, OC(=O)c1cc2ccccc2s1	DYSJMQABFPKAQM-UHFFFAOYSA-N, DYSJMQABFPKAQM-UHFFFAOYSA-N, DYSJMQABFPKAQM-UHFFFAOYSA-N, DYSJMQABFPKAQM-UHFFFAOYSA-N	Preclinical
blebbistatin-(+/-)	ATPase inhibitor	MYH14, MYH2			Cc1ccc2N=C3N(CC[C@@]3(O)C(=O)c2c1)c1ccccc1 |&1:10,r,t:5|	LZAXPYOBKSJSEX-GOSISDBHSA-N	Preclinical
blebbistatin-(-)	ATPase inhibitor				Cc1ccc2N=C3N(CC[C@@]3(O)C(=O)c2c1)c1ccccc1 |t:5|, Cc1ccc2N=C3N(CC[C@@]3(O)C(=O)c2c1)c1ccccc1 |t:5|	LZAXPYOBKSJSEX-GOSISDBHSA-N, LZAXPYOBKSJSEX-GOSISDBHSA-N	Preclinical
bleomycetin	EGFR expression inhibitor				C[C@@H](O)[C@H](NC(=O)[C@@H](C)[C@H](O)[C@@H](C)NC(=O)[C@@H](NC(=O)c1nc(nc(N)c1C)[C@H](CC(N)=O)NC[C@H](N)C(N)=O)[C@@H](O[C@@H]1O[C@@H](CO)[C@@H](O)[C@H](O)[C@@H]1O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](OC(N)=O)[C@@H]1O)c1c[nH]cn1)C(=O)NCCc1nc(cs1)-c1nc(cs1)C(=O)NCCCNCCCCN	QYOAUOAXCQAEMW-DDZPZTJXSA-N	Launched
bleomycin	DNA synthesis inhibitor		hematologic malignancy, pulmonary, oncology	non-Hodgkin lymphoma (NHL), Hodgkin's lymphoma, pleural effusion, testicular carcinoma, squamous cell carcinoma	[H][C@]1(O[C@H]2O[C@H](CO)[C@@H](O)[C@H](OC(N)=O)[C@@H]2O)[C@@H](O[C@H]([C@H](NC(=O)c2nc(nc(N)c2C)[C@H](CC(N)=O)NC[C@@H](N)C(N)=O)C(=O)N[C@@H](C)[C@H](O)[C@@H](C)C(=O)N[C@H]([C@@H](C)O)C(=O)NCCc2nc(cs2)-c2nc(cs2)C(=O)NCCC[S+](C)C)c2c[nH]cn2)O[C@H](CO)[C@H](O)[C@H]1O	OYVAGSVQBOHSSS-WMBAVFRVSA-O	Launched
blonanserin	dopamine receptor antagonist, serotonin receptor antagonist	DRD2, HTR2A	neurology/psychiatry	schizophrenia	CCN1CCN(CC1)c1cc(-c2ccc(F)cc2)c2CCCCCCc2n1, CCN1CCN(CC1)c1cc(-c2ccc(F)cc2)c2CCCCCCc2n1, CCN1CCN(CC1)c1cc(-c2ccc(F)cc2)c2CCCCCCc2n1, CCN1CCN(CC1)c1cc(-c2ccc(F)cc2)c2CCCCCCc2n1	XVGOZDAJGBALKS-UHFFFAOYSA-N, XVGOZDAJGBALKS-UHFFFAOYSA-N, XVGOZDAJGBALKS-UHFFFAOYSA-N, XVGOZDAJGBALKS-UHFFFAOYSA-N	Launched
BLU9931	FGFR inhibitor	FGFR4			COc1cc(OC)c(Cl)c(c1Cl)-c1ccc2nc(Nc3c(C)cccc3NC(=O)C=C)ncc2c1, COc1cc(OC)c(Cl)c(c1Cl)-c1ccc2nc(Nc3c(C)cccc3NC(=O)C=C)ncc2c1, COc1cc(OC)c(Cl)c(c1Cl)-c1ccc2nc(Nc3c(C)cccc3NC(=O)C=C)ncc2c1, COc1cc(OC)c(Cl)c(c1Cl)-c1ccc2nc(Nc3c(C)cccc3NC(=O)C=C)ncc2c1	TXEBNKKOLVBTFK-UHFFFAOYSA-N, TXEBNKKOLVBTFK-UHFFFAOYSA-N, TXEBNKKOLVBTFK-UHFFFAOYSA-N, TXEBNKKOLVBTFK-UHFFFAOYSA-N	Preclinical
BLZ945	CSF1R inhibitor				CNC(=O)c1cc(Oc2ccc3nc(N[C@@H]4CCCC[C@H]4O)sc3c2)ccn1	ADZBMFGQQWPHMJ-RHSMWYFYSA-N	Phase 1/Phase 2
BML-190	cannabinoid receptor inverse agonist	CNR2			COc1ccc2n(C(=O)c3ccc(Cl)cc3)c(C)c(CC(=O)N3CCOCC3)c2c1, COc1ccc2n(C(=O)c3ccc(Cl)cc3)c(C)c(CC(=O)N3CCOCC3)c2c1, COc1ccc2n(C(=O)c3ccc(Cl)cc3)c(C)c(CC(=O)N3CCOCC3)c2c1, COc1ccc2n(C(=O)c3ccc(Cl)cc3)c(C)c(CC(=O)N3CCOCC3)c2c1, COc1ccc2n(C(=O)c3ccc(Cl)cc3)c(C)c(CC(=O)N3CCOCC3)c2c1	BJSDNVVWJYDOLK-UHFFFAOYSA-N, BJSDNVVWJYDOLK-UHFFFAOYSA-N, BJSDNVVWJYDOLK-UHFFFAOYSA-N, BJSDNVVWJYDOLK-UHFFFAOYSA-N, BJSDNVVWJYDOLK-UHFFFAOYSA-N	Preclinical
BML-284	WNT agonist				COc1cccc(c1)-c1cc(NCc2ccc3OCOc3c2)nc(N)n1, COc1cccc(c1)-c1cc(NCc2ccc3OCOc3c2)nc(N)n1, COc1cccc(c1)-c1cc(NCc2ccc3OCOc3c2)nc(N)n1	FABQUVYDAXWUQP-UHFFFAOYSA-N, FABQUVYDAXWUQP-UHFFFAOYSA-N, FABQUVYDAXWUQP-UHFFFAOYSA-N	Preclinical
BMS-CCR2-22	CC chemokine receptor antagonist	CCR2			CSc1ccc(cc1)C(=O)N[C@@H]1CCCC[C@@H]1NC(=O)CNC(=O)c1cc(ccc1NC(=O)NC(C)C)C(F)(F)F, CSc1ccc(cc1)C(=O)N[C@@H]1CCCC[C@@H]1NC(=O)CNC(=O)c1cc(ccc1NC(=O)NC(C)C)C(F)(F)F, CSc1ccc(cc1)C(=O)N[C@@H]1CCCC[C@@H]1NC(=O)CNC(=O)c1cc(ccc1NC(=O)NC(C)C)C(F)(F)F, CSc1ccc(cc1)C(=O)N[C@@H]1CCCC[C@@H]1NC(=O)CNC(=O)c1cc(ccc1NC(=O)NC(C)C)C(F)(F)F	IBPXYDUJQWENPM-XZOQPEGZSA-N, IBPXYDUJQWENPM-XZOQPEGZSA-N, IBPXYDUJQWENPM-XZOQPEGZSA-N, IBPXYDUJQWENPM-XZOQPEGZSA-N	Preclinical
BMS-182874	endothelin receptor antagonist	EDNRA			CN(C)c1cccc2c(cccc12)S(=O)(=O)Nc1onc(C)c1C, CN(C)c1cccc2c(cccc12)S(=O)(=O)Nc1onc(C)c1C, CN(C)c1cccc2c(cccc12)S(=O)(=O)Nc1onc(C)c1C	MJRGSRRZKSJHOE-UHFFFAOYSA-N, MJRGSRRZKSJHOE-UHFFFAOYSA-N, MJRGSRRZKSJHOE-UHFFFAOYSA-N	Phase 2
BMS-191011	potassium channel activator	KCNMA1			Oc1ccc(Cl)cc1Cn1nc(oc1=O)-c1ccc(cc1)C(F)(F)F, Oc1ccc(Cl)cc1Cn1nc(oc1=O)-c1ccc(cc1)C(F)(F)F, Oc1ccc(Cl)cc1Cn1nc(oc1=O)-c1ccc(cc1)C(F)(F)F, Oc1ccc(Cl)cc1Cn1nc(oc1=O)-c1ccc(cc1)C(F)(F)F, Oc1ccc(Cl)cc1Cn1nc(oc1=O)-c1ccc(cc1)C(F)(F)F	QKOWACXSXTXRKA-UHFFFAOYSA-N, QKOWACXSXTXRKA-UHFFFAOYSA-N, QKOWACXSXTXRKA-UHFFFAOYSA-N, QKOWACXSXTXRKA-UHFFFAOYSA-N, QKOWACXSXTXRKA-UHFFFAOYSA-N	Preclinical
BMS-191095	KATP activator, potassium channel agonist				CC1(C)Oc2ccc(cc2[C@@H]([C@H]1O)N(Cc1ncc[nH]1)c1ccc(Cl)cc1)C#N, CC1(C)Oc2ccc(cc2[C@@H]([C@H]1O)N(Cc1ncc[nH]1)c1ccc(Cl)cc1)C#N	SMIKIPXIDLITMP-LEWJYISDSA-N, SMIKIPXIDLITMP-LEWJYISDSA-N	Phase 1
BMS-207940	endothelin receptor antagonist				CN(Cc1cc(ccc1-c1ccccc1S(=O)(=O)Nc1noc(C)c1C)-c1ncco1)C(=O)CC(C)(C)C	ORJRYNKVKJAJPY-UHFFFAOYSA-N	Preclinical
BMS-214662	farnesyltransferase inhibitor				O=S(=O)(N1Cc2cc(ccc2N(Cc2cnc[nH]2)C[C@H]1Cc1ccccc1)C#N)c1cccs1	OLCWFLWEHWLBTO-HSZRJFAPSA-N	Phase 1
BMS-265246	CDK inhibitor	CDK1, CDK2			CCCCOc1c(cnc2n[nH]cc12)C(=O)c1c(F)cc(C)cc1F, CCCCOc1c(cnc2n[nH]cc12)C(=O)c1c(F)cc(C)cc1F, CCCCOc1c(cnc2n[nH]cc12)C(=O)c1c(F)cc(C)cc1F, CCCCOc1c(cnc2n[nH]cc12)C(=O)c1c(F)cc(C)cc1F, CCCCOc1c(cnc2n[nH]cc12)C(=O)c1c(F)cc(C)cc1F, CCCCOc1c(cnc2n[nH]cc12)C(=O)c1c(F)cc(C)cc1F, CCCCOc1c(cnc2n[nH]cc12)C(=O)c1c(F)cc(C)cc1F, CCCCOc1c(cnc2n[nH]cc12)C(=O)c1c(F)cc(C)cc1F, CCCCOc1c(cnc2n[nH]cc12)C(=O)c1c(F)cc(C)cc1F, CCCCOc1c(cnc2n[nH]cc12)C(=O)c1c(F)cc(C)cc1F	SCFMWQIQBVZOQR-UHFFFAOYSA-N, SCFMWQIQBVZOQR-UHFFFAOYSA-N, SCFMWQIQBVZOQR-UHFFFAOYSA-N, SCFMWQIQBVZOQR-UHFFFAOYSA-N, SCFMWQIQBVZOQR-UHFFFAOYSA-N, SCFMWQIQBVZOQR-UHFFFAOYSA-N, SCFMWQIQBVZOQR-UHFFFAOYSA-N, SCFMWQIQBVZOQR-UHFFFAOYSA-N, SCFMWQIQBVZOQR-UHFFFAOYSA-N, SCFMWQIQBVZOQR-UHFFFAOYSA-N	Preclinical
BMS-299897	gamma secretase inhibitor				C[C@@H](N(c1cc(F)ccc1F)S(=O)(=O)c1ccc(Cl)cc1)c1ccc(F)cc1CCCC(O)=O, C[C@@H](N(c1cc(F)ccc1F)S(=O)(=O)c1ccc(Cl)cc1)c1ccc(F)cc1CCCC(O)=O, C[C@@H](N(c1cc(F)ccc1F)S(=O)(=O)c1ccc(Cl)cc1)c1ccc(F)cc1CCCC(O)=O, C[C@@H](N(c1cc(F)ccc1F)S(=O)(=O)c1ccc(Cl)cc1)c1ccc(F)cc1CCCC(O)=O	IZAOBRWCUGOKNH-OAHLLOKOSA-N, IZAOBRWCUGOKNH-OAHLLOKOSA-N, IZAOBRWCUGOKNH-OAHLLOKOSA-N, IZAOBRWCUGOKNH-OAHLLOKOSA-N	Phase 1
BMS-309403	fatty acid binding protein inhibitor	FABP4			CCc1c(c(nn1-c1ccccc1-c1cccc(OCC(O)=O)c1)-c1ccccc1)-c1ccccc1, CCc1c(c(nn1-c1ccccc1-c1cccc(OCC(O)=O)c1)-c1ccccc1)-c1ccccc1	SJRVJRYZAQYCEE-UHFFFAOYSA-N, SJRVJRYZAQYCEE-UHFFFAOYSA-N	Preclinical
BMS-345541	IKK inhibitor	CHUK, IKBKB			Cc1cnc2c(NCCN)nc3ccc(C)cc3n12, Cc1cnc2c(NCCN)nc3ccc(C)cc3n12, Cc1cnc2c(NCCN)nc3ccc(C)cc3n12, Cc1cnc2c(NCCN)nc3ccc(C)cc3n12, Cc1cnc2c(NCCN)nc3ccc(C)cc3n12, Cc1cnc2c(NCCN)nc3ccc(C)cc3n12, Cc1cnc2c(NCCN)nc3ccc(C)cc3n12	PSPFQEBFYXJZEV-UHFFFAOYSA-N, PSPFQEBFYXJZEV-UHFFFAOYSA-N, PSPFQEBFYXJZEV-UHFFFAOYSA-N, PSPFQEBFYXJZEV-UHFFFAOYSA-N, PSPFQEBFYXJZEV-UHFFFAOYSA-N, PSPFQEBFYXJZEV-UHFFFAOYSA-N, PSPFQEBFYXJZEV-UHFFFAOYSA-N	Preclinical
BMS-387032	CDK inhibitor, cell cycle inhibitor, MCL1 inhibitor	CDK2, CDK7, CDK9			CC(C)(C)c1cnc(CSc2cnc(NC(=O)C3CCNCC3)s2)o1, CC(C)(C)c1cnc(CSc2cnc(NC(=O)C3CCNCC3)s2)o1, CC(C)(C)c1cnc(CSc2cnc(NC(=O)C3CCNCC3)s2)o1, CC(C)(C)c1cnc(CSc2cnc(NC(=O)C3CCNCC3)s2)o1	OUSFTKFNBAZUKL-UHFFFAOYSA-N, OUSFTKFNBAZUKL-UHFFFAOYSA-N, OUSFTKFNBAZUKL-UHFFFAOYSA-N, OUSFTKFNBAZUKL-UHFFFAOYSA-N	Phase 1
BMS-470539	melanocortin receptor agonist	MC1R			CCCC(=O)C1(CCN(CC1)C(=O)[C@@H](Cc1ccc(OC)cc1)NC(=O)[C@@H](N)Cc1cncn1C)c1ccccc1, CCCC(=O)C1(CCN(CC1)C(=O)[C@@H](Cc1ccc(OC)cc1)NC(=O)[C@@H](N)Cc1cncn1C)c1ccccc1	GULVVTHHUIIMRL-WUFINQPMSA-N, GULVVTHHUIIMRL-WUFINQPMSA-N	Preclinical
BMS-536924	IGF-1 inhibitor	AKT1, CCNE1, CDK2, CYP3A4, ERBB2, IGF1R, KDR, LCK, MAPK1, MET, PDGFRA, PDGFRB			Cc1cc(cc2[nH]c(nc12)-c1c(NC[C@@H](O)c2cccc(Cl)c2)cc[nH]c1=O)N1CCOCC1, Cc1cc(cc2[nH]c(nc12)-c1c(NC[C@@H](O)c2cccc(Cl)c2)cc[nH]c1=O)N1CCOCC1, Cc1cc(cc2[nH]c(nc12)-c1c(NC[C@@H](O)c2cccc(Cl)c2)cc[nH]c1=O)N1CCOCC1, Cc1cc(cc2[nH]c(nc12)-c1c(NC[C@@H](O)c2cccc(Cl)c2)cc[nH]c1=O)N1CCOCC1, Cc1cc(cc2[nH]c(nc12)-c1c(NC[C@@H](O)c2cccc(Cl)c2)cc[nH]c1=O)N1CCOCC1	ZWVZORIKUNOTCS-OAQYLSRUSA-N, ZWVZORIKUNOTCS-OAQYLSRUSA-N, ZWVZORIKUNOTCS-OAQYLSRUSA-N, ZWVZORIKUNOTCS-OAQYLSRUSA-N, ZWVZORIKUNOTCS-OAQYLSRUSA-N	Preclinical
BMS-566419	inosine monophosphate dehydrogenase inhibitor	IMPDH1, IMPDH2			CCN1CCN(CC1)c1ccc(cn1)C(C)(C)NC(=O)c1cc2[nH]c3ccccc3c(=O)c2cc1F, CCN1CCN(CC1)c1ccc(cn1)C(C)(C)NC(=O)c1cc2[nH]c3ccccc3c(=O)c2cc1F, CCN1CCN(CC1)c1ccc(cn1)C(C)(C)NC(=O)c1cc2[nH]c3ccccc3c(=O)c2cc1F, CCN1CCN(CC1)c1ccc(cn1)C(C)(C)NC(=O)c1cc2[nH]c3ccccc3c(=O)c2cc1F, CCN1CCN(CC1)c1ccc(cn1)C(C)(C)NC(=O)c1cc2[nH]c3ccccc3c(=O)c2cc1F	XEVJUIZOZCFECP-UHFFFAOYSA-N, XEVJUIZOZCFECP-UHFFFAOYSA-N, XEVJUIZOZCFECP-UHFFFAOYSA-N, XEVJUIZOZCFECP-UHFFFAOYSA-N, XEVJUIZOZCFECP-UHFFFAOYSA-N	Preclinical
BMS-582949	p38 MAPK inhibitor				CCCNC(=O)c1cn2ncnc(Nc3cc(ccc3C)C(=O)NC3CC3)c2c1C	GDTQLZHHDRRBEB-UHFFFAOYSA-N	Phase 2
BMS-587101	integrin antagonist	ITGAL, ITGB2			CN1C(=O)N(C(=O)[C@]11CN(Cc2cc(cs2)C(O)=O)C[C@H]1c1ccc(cc1)C#N)c1cc(Cl)cc(Cl)c1	NXNKJLOEGWSJGI-BKMJKUGQSA-N	Phase 2
BMS-599626	EGFR inhibitor, protein tyrosine kinase inhibitor	EGFR, ERBB2, ERBB4			Cc1c(NC(=O)OC[C@@H]2COCCN2)cn2ncnc(Nc3ccc4n(Cc5cccc(F)c5)ncc4c3)c12, Cc1c(NC(=O)OC[C@@H]2COCCN2)cn2ncnc(Nc3ccc4n(Cc5cccc(F)c5)ncc4c3)c12, Cc1c(NC(=O)OC[C@@H]2COCCN2)cn2ncnc(Nc3ccc4n(Cc5cccc(F)c5)ncc4c3)c12	LUJZZYWHBDHDQX-QFIPXVFZSA-N, LUJZZYWHBDHDQX-QFIPXVFZSA-N, LUJZZYWHBDHDQX-QFIPXVFZSA-N	Phase 1
BMS-626529	HIV attachment inhibitor				COc1cnc(-n2cnc(C)n2)c2[nH]cc(C(=O)C(=O)N3CCN(CC3)C(=O)c3ccccc3)c12, COc1cnc(-n2cnc(C)n2)c2[nH]cc(C(=O)C(=O)N3CCN(CC3)C(=O)c3ccccc3)c12	QRPZBKAMSFHVRW-UHFFFAOYSA-N, QRPZBKAMSFHVRW-UHFFFAOYSA-N	Phase 3
BMS-626531	p38 MAPK inhibitor				Cc1c(cnn1-c1ncccc1C(F)(F)F)C(=O)Nc1cc(ccc1C)C(=O)NC1CC1	ZZZJRULMCGMYRH-UHFFFAOYSA-N	Phase 1
BMS-649	retinoid receptor agonist	RXRA			CC1(C)CCC(C)(C)c2cc(ccc12)C1(OCCO1)c1ccc(cc1)C(O)=O, CC1(C)CCC(C)(C)c2cc(ccc12)C1(OCCO1)c1ccc(cc1)C(O)=O, CC1(C)CCC(C)(C)c2cc(ccc12)C1(OCCO1)c1ccc(cc1)C(O)=O, CC1(C)CCC(C)(C)c2cc(ccc12)C1(OCCO1)c1ccc(cc1)C(O)=O, CC1(C)CCC(C)(C)c2cc(ccc12)C1(OCCO1)c1ccc(cc1)C(O)=O	ZZUKALQMHNSWTK-UHFFFAOYSA-N, ZZUKALQMHNSWTK-UHFFFAOYSA-N, ZZUKALQMHNSWTK-UHFFFAOYSA-N, ZZUKALQMHNSWTK-UHFFFAOYSA-N, ZZUKALQMHNSWTK-UHFFFAOYSA-N	Preclinical
BMS-688521	ICAM1 antagonist, leukocyte function-associated antigen receptor antagonist	ICAM1			CN1C(=O)N(C(=O)[C@]11CN(C[C@H]1c1ccc(cc1)C#N)c1ccc(cn1)C(O)=O)c1cc(Cl)cc(Cl)c1	LILGMDXLRPEBNH-HFZDXXHNSA-N	Preclinical
BMS-690514	EGFR inhibitor, VEGFR inhibitor	EGFR, ERBB2, FLT3, KDR			COc1cccc(Nc2ncnn3ccc(CN4CC[C@@H](N)[C@H](O)C4)c23)c1, COc1cccc(Nc2ncnn3ccc(CN4CC[C@@H](N)[C@H](O)C4)c23)c1, COc1cccc(Nc2ncnn3ccc(CN4CC[C@@H](N)[C@H](O)C4)c23)c1, COc1cccc(Nc2ncnn3ccc(CN4CC[C@@H](N)[C@H](O)C4)c23)c1, COc1cccc(Nc2ncnn3ccc(CN4CC[C@@H](N)[C@H](O)C4)c23)c1, COc1cccc(Nc2ncnn3ccc(CN4CC[C@@H](N)[C@H](O)C4)c23)c1	CSGQVNMSRKWUSH-IAGOWNOFSA-N, CSGQVNMSRKWUSH-IAGOWNOFSA-N, CSGQVNMSRKWUSH-IAGOWNOFSA-N, CSGQVNMSRKWUSH-IAGOWNOFSA-N, CSGQVNMSRKWUSH-IAGOWNOFSA-N, CSGQVNMSRKWUSH-IAGOWNOFSA-N	Phase 2
BMS-707035	HIV integrase inhibitor				Cn1c(nc(C(=O)NCc2ccc(F)cc2)c(O)c1=O)N1CCCCS1(=O)=O	VNIWZCGZPBJWBI-UHFFFAOYSA-N	Phase 2
BMS-754807	IGF-1 inhibitor	AKT1, IGF1R			C[C@]1(CCCN1c1nc(Nc2cc(n[nH]2)C2CC2)c2cccn2n1)C(=O)Nc1ccc(F)nc1, C[C@]1(CCCN1c1nc(Nc2cc(n[nH]2)C2CC2)c2cccn2n1)C(=O)Nc1ccc(F)nc1, C[C@]1(CCCN1c1nc(Nc2cc(n[nH]2)C2CC2)c2cccn2n1)C(=O)Nc1ccc(F)nc1, C[C@]1(CCCN1c1nc(Nc2cc(n[nH]2)C2CC2)c2cccn2n1)C(=O)Nc1ccc(F)nc1, C[C@]1(CCCN1c1nc(Nc2cc(n[nH]2)C2CC2)c2cccn2n1)C(=O)Nc1ccc(F)nc1, C[C@]1(CCCN1c1nc(Nc2cc(n[nH]2)C2CC2)c2cccn2n1)C(=O)Nc1ccc(F)nc1, C[C@]1(CCCN1c1nc(Nc2cc(n[nH]2)C2CC2)c2cccn2n1)C(=O)Nc1ccc(F)nc1, C[C@]1(CCCN1c1nc(Nc2cc(n[nH]2)C2CC2)c2cccn2n1)C(=O)Nc1ccc(F)nc1, C[C@]1(CCCN1c1nc(Nc2cc(n[nH]2)C2CC2)c2cccn2n1)C(=O)Nc1ccc(F)nc1, C[C@]1(CCCN1c1nc(Nc2cc(n[nH]2)C2CC2)c2cccn2n1)C(=O)Nc1ccc(F)nc1, C[C@]1(CCCN1c1nc(Nc2cc(n[nH]2)C2CC2)c2cccn2n1)C(=O)Nc1ccc(F)nc1	LQVXSNNAFNGRAH-QHCPKHFHSA-N, LQVXSNNAFNGRAH-QHCPKHFHSA-N, LQVXSNNAFNGRAH-QHCPKHFHSA-N, LQVXSNNAFNGRAH-QHCPKHFHSA-N, LQVXSNNAFNGRAH-QHCPKHFHSA-N, LQVXSNNAFNGRAH-QHCPKHFHSA-N, LQVXSNNAFNGRAH-QHCPKHFHSA-N, LQVXSNNAFNGRAH-QHCPKHFHSA-N, LQVXSNNAFNGRAH-QHCPKHFHSA-N, LQVXSNNAFNGRAH-QHCPKHFHSA-N, LQVXSNNAFNGRAH-QHCPKHFHSA-N	Phase 2
BMS-770767	11-beta-HSD1 inhibitor				O[C@@]12CC[C@@](CC1)(C2)c1nnc2c(Oc3ccccc3Cl)cccn12 |r|	HNXGIFYHJKEXNA-KDURUIRLSA-N	Phase 2
BMS-777607	AXL kinase inhibitor, c-Met inhibitor, FLT3 inhibitor, hepatocyte growth factor receptor inhibitor, macrophage migration inhibiting factor inhibitor, tyrosine kinase inhibitor	AXL, MERTK, MET, MST1R, TYRO3			CCOc1ccn(-c2ccc(F)cc2)c(=O)c1C(=O)Nc1ccc(Oc2ccnc(N)c2Cl)c(F)c1, CCOc1ccn(-c2ccc(F)cc2)c(=O)c1C(=O)Nc1ccc(Oc2ccnc(N)c2Cl)c(F)c1	VNBRGSXVFBYQNN-UHFFFAOYSA-N, VNBRGSXVFBYQNN-UHFFFAOYSA-N	Phase 1/Phase 2
BMS-779788	LXR agonist				CC(C)(O)c1cn(c(n1)C(C)(C)c1ccccc1Cl)-c1ccc(cc1)-c1cccc(c1)S(C)(=O)=O	JLPURTXCSILYLW-UHFFFAOYSA-N	Phase 1
BMS-806	HIV attachment inhibitor				COc1ccnc2[nH]cc(C(=O)C(=O)N3CCN(C[C@H]3C)C(=O)c3ccccc3)c12, COc1ccnc2[nH]cc(C(=O)C(=O)N3CCN(C[C@H]3C)C(=O)c3ccccc3)c12, COc1ccnc2[nH]cc(C(=O)C(=O)N3CCN(C[C@H]3C)C(=O)c3ccccc3)c12	OKGPFTLYBPQBIX-CQSZACIVSA-N, OKGPFTLYBPQBIX-CQSZACIVSA-N, OKGPFTLYBPQBIX-CQSZACIVSA-N	Phase 1
BMS-813160	CC chemokine receptor antagonist				CC(=O)N[C@@H]1C[C@@H](CC[C@@H]1N1CC[C@H](Nc2ncnc3cc(nn23)C(C)(C)C)C1=O)NC(C)(C)C	CMVHFGNTABZQJU-HCXYKTFWSA-N	Phase 2
BMS-817378	c-Met inhibitor, VEGFR inhibitor	KDR, MET			Nc1nccc(Oc2ccc(NC(=O)c3cn(COP(O)(O)=O)cc(-c4ccc(F)cc4)c3=O)cc2F)c1Cl	KXDZWUPUSDCGDD-UHFFFAOYSA-N	Phase 1
BMS-833923	smoothened receptor antagonist	SMO			CNCc1ccc(C)c(NC(=O)c2ccc(Nc3nc(-c4ccccc4)c4ccccc4n3)cc2)c1, CNCc1ccc(C)c(NC(=O)c2ccc(Nc3nc(-c4ccccc4)c4ccccc4n3)cc2)c1, CNCc1ccc(C)c(NC(=O)c2ccc(Nc3nc(-c4ccccc4)c4ccccc4n3)cc2)c1, CNCc1ccc(C)c(NC(=O)c2ccc(Nc3nc(-c4ccccc4)c4ccccc4n3)cc2)c1, CNCc1ccc(C)c(NC(=O)c2ccc(Nc3nc(-c4ccccc4)c4ccccc4n3)cc2)c1, CNCc1ccc(C)c(NC(=O)c2ccc(Nc3nc(-c4ccccc4)c4ccccc4n3)cc2)c1, CNCc1ccc(C)c(NC(=O)c2ccc(Nc3nc(-c4ccccc4)c4ccccc4n3)cc2)c1	KLRRGBHZCJLIEL-UHFFFAOYSA-N, KLRRGBHZCJLIEL-UHFFFAOYSA-N, KLRRGBHZCJLIEL-UHFFFAOYSA-N, KLRRGBHZCJLIEL-UHFFFAOYSA-N, KLRRGBHZCJLIEL-UHFFFAOYSA-N, KLRRGBHZCJLIEL-UHFFFAOYSA-N, KLRRGBHZCJLIEL-UHFFFAOYSA-N	Phase 2
BMS-863233	CDC inhibitor	CDC7, PIM1			Clc1ccc2oc3c(nc([nH]c3=O)[C@@H]3CCCN3)c2c1, Clc1ccc2oc3c(nc([nH]c3=O)[C@@H]3CCCN3)c2c1, Clc1ccc2oc3c(nc([nH]c3=O)[C@@H]3CCCN3)c2c1, Clc1ccc2oc3c(nc([nH]c3=O)[C@@H]3CCCN3)c2c1, Clc1ccc2oc3c(nc([nH]c3=O)[C@@H]3CCCN3)c2c1	JJWLXRKVUJDJKG-VIFPVBQESA-N, JJWLXRKVUJDJKG-VIFPVBQESA-N, JJWLXRKVUJDJKG-VIFPVBQESA-N, JJWLXRKVUJDJKG-VIFPVBQESA-N, JJWLXRKVUJDJKG-VIFPVBQESA-N	Phase 1/Phase 2
BMS-906024	gamma secretase inhibitor				CN1c2ccccc2C(=N[C@H](NC(=O)[C@H](CCC(F)(F)F)[C@H](CCC(F)(F)F)C(N)=O)C1=O)c1ccccc1 |c:9|	AYOUDDAETNMCBW-GSHUGGBRSA-N	Phase 1
BMS-911543	JAK inhibitor				CCn1c(cc2c1nc(Nc1cc(C)n(C)n1)c1ncn(C)c21)C(=O)N(C1CC1)C1CC1	JCINBYQJBYJGDM-UHFFFAOYSA-N	Phase 1/Phase 2
BMS-935177	Bruton's tyrosine kinase (BTK) inhibitor				Cc1c(cccc1-n1cnc2ccccc2c1=O)-c1ccc(C(N)=O)c2[nH]c3cc(ccc3c12)C(C)(C)O	TVJRDCQUZMGBAB-UHFFFAOYSA-N	Preclinical
BMS-983970	notch signaling inhibitor				NC(=O)[C@@H](CC1CC1)[C@@H](CCC(F)(F)F)C(=O)N[C@H]1N=C(c2ccccc2)c2cccc(F)c2NC1=O |t:20|, NC(=O)[C@@H](CC1CC1)[C@@H](CCC(F)(F)F)C(=O)N[C@H]1N=C(c2ccccc2)c2cccc(F)c2NC1=O |t:20|, NC(=O)[C@@H](CC1CC1)[C@@H](CCC(F)(F)F)C(=O)N[C@H]1N=C(c2ccccc2)c2cccc(F)c2NC1=O |t:20|, NC(=O)[C@@H](CC1CC1)[C@@H](CCC(F)(F)F)C(=O)N[C@H]1N=C(c2ccccc2)c2cccc(F)c2NC1=O |t:20|	RANYIWAZSQWERN-WLENULPWSA-N, RANYIWAZSQWERN-WLENULPWSA-N, RANYIWAZSQWERN-WLENULPWSA-N, RANYIWAZSQWERN-WLENULPWSA-N	Phase 1
BMS-986020	lysophosphatidic acid receptor antagonist	LPAR1			C[C@@H](OC(=O)Nc1c(C)noc1-c1ccc(cc1)-c1ccc(cc1)C1(CC1)C(O)=O)c1ccccc1	GQBRZBHEPUQRPL-LJQANCHMSA-N	Phase 2
BMS-986142	Bruton's tyrosine kinase (BTK) inhibitor				Cc1c(cccc1-n1c(=O)n(C)c2c(F)cccc2c1=O)-c1c(F)cc(C(N)=O)c2[nH]c3C[C@H](CCc3c12)C(C)(C)O	ZRYMMWAJAFUANM-INIZCTEOSA-N	Phase 2
BMS-986158	bromodomain inhibitor				Cc1nnn(C)c1-c1cnc2c(c1)n([C@@H](C1CCOCC1)c1ccccc1)c1cc(ccc21)C(C)(C)O, Cc1nnn(C)c1-c1cnc2c(c1)n([C@@H](C1CCOCC1)c1ccccc1)c1cc(ccc21)C(C)(C)O	KGERZPVQIRYWRK-GDLZYMKVSA-N, KGERZPVQIRYWRK-GDLZYMKVSA-N	Phase 1/Phase 2
BMS-986195	Bruton's tyrosine kinase (BTK) inhibitor				CC#CC(=O)N[C@H]1CCCN(C1)c1c(F)cc(C(N)=O)c2[nH]c(C)c(C)c12	VJPPLCNBDLZIFG-ZDUSSCGKSA-N	Phase 1
BMS-986205	indoleamine 2,3-dioxygenase inhibitor				[H][C@]1(CC[C@@H](CC1)c1ccnc2ccc(F)cc12)[C@@H](C)C(=O)Nc1ccc(Cl)cc1	KRTIYQIPSAGSBP-ZACQAIPSSA-N	Phase 3
BMY-14802	sigma receptor antagonist	HTR1A			O[C@@H](CCCN1CCN(CC1)c1ncc(F)cn1)c1ccc(F)cc1 |&1:1|, O[C@@H](CCCN1CCN(CC1)c1ncc(F)cn1)c1ccc(F)cc1 |&1:1|, O[C@@H](CCCN1CCN(CC1)c1ncc(F)cn1)c1ccc(F)cc1 |&1:1|, O[C@@H](CCCN1CCN(CC1)c1ncc(F)cn1)c1ccc(F)cc1 |&1:1|, O[C@@H](CCCN1CCN(CC1)c1ncc(F)cn1)c1ccc(F)cc1 |&1:1|, O[C@@H](CCCN1CCN(CC1)c1ncc(F)cn1)c1ccc(F)cc1 |&1:1|	ZXUYYZPJUGQHLQ-KRWDZBQOSA-N, ZXUYYZPJUGQHLQ-KRWDZBQOSA-N, ZXUYYZPJUGQHLQ-KRWDZBQOSA-N, ZXUYYZPJUGQHLQ-KRWDZBQOSA-N, ZXUYYZPJUGQHLQ-KRWDZBQOSA-N, ZXUYYZPJUGQHLQ-KRWDZBQOSA-N	Phase 2
BMY-45778	IP1 prostacyclin receptor agonist	PTGIR			OC(=O)COc1cccc(c1)-c1ocnc1-c1nc(c(o1)-c1ccccc1)-c1ccccc1, OC(=O)COc1cccc(c1)-c1ocnc1-c1nc(c(o1)-c1ccccc1)-c1ccccc1	DSRSEEYZGWTODH-UHFFFAOYSA-N, DSRSEEYZGWTODH-UHFFFAOYSA-N	Preclinical
BMY-7378	adrenergic receptor antagonist, serotonin receptor antagonist	ADRA1A, ADRA1B, ADRA1D, HTR1A			COc1ccccc1N1CCN(CCN2C(=O)CC3(CCCC3)CC2=O)CC1, COc1ccccc1N1CCN(CCN2C(=O)CC3(CCCC3)CC2=O)CC1, COc1ccccc1N1CCN(CCN2C(=O)CC3(CCCC3)CC2=O)CC1, COc1ccccc1N1CCN(CCN2C(=O)CC3(CCCC3)CC2=O)CC1	AYYCFGDXLUPJAQ-UHFFFAOYSA-N, AYYCFGDXLUPJAQ-UHFFFAOYSA-N, AYYCFGDXLUPJAQ-UHFFFAOYSA-N, AYYCFGDXLUPJAQ-UHFFFAOYSA-N	Preclinical
BNC105	tubulin polymerization inhibitor				COc1ccc2c(C(=O)c3cc(OC)c(OC)c(OC)c3)c(C)oc2c1O, COc1ccc2c(C(=O)c3cc(OC)c(OC)c(OC)c3)c(C)oc2c1O, COc1ccc2c(C(=O)c3cc(OC)c(OC)c(OC)c3)c(C)oc2c1O, COc1ccc2c(C(=O)c3cc(OC)c(OC)c(OC)c3)c(C)oc2c1O	RADMJHVVIZTENA-UHFFFAOYSA-N, RADMJHVVIZTENA-UHFFFAOYSA-N, RADMJHVVIZTENA-UHFFFAOYSA-N, RADMJHVVIZTENA-UHFFFAOYSA-N	Phase 2
BNTX	opioid receptor antagonist	OPRD1, OPRK1, OPRM1					Preclinical
boceprevir	HCV inhibitor	CMA1, CTSA, CTSF, CTSK, CTSL, CTSS	infectious disease	hepatitis C	CC(C)(C)NC(=O)N[C@H](C(=O)N1C[C@H]2[C@@H]([C@H]1C(=O)N[C@@H](CC1CCC1)C(=O)C(N)=O)C2(C)C)C(C)(C)C |a:8,13,14,15,&1:19|, CC(C)(C)NC(=O)N[C@H](C(=O)N1C[C@H]2[C@@H]([C@H]1C(=O)N[C@@H](CC1CCC1)C(=O)C(N)=O)C2(C)C)C(C)(C)C |a:8,13,14,15,&1:19|, CC(C)(C)NC(=O)N[C@H](C(=O)N1C[C@H]2[C@@H]([C@H]1C(=O)N[C@@H](CC1CCC1)C(=O)C(N)=O)C2(C)C)C(C)(C)C |a:8,13,14,15,&1:19|, CC(C)(C)NC(=O)N[C@H](C(=O)N1C[C@H]2[C@@H]([C@H]1C(=O)N[C@@H](CC1CCC1)C(=O)C(N)=O)C2(C)C)C(C)(C)C |a:8,13,14,15,&1:19|	LHHCSNFAOIFYRV-ZYNAIFEFSA-N, LHHCSNFAOIFYRV-ZYNAIFEFSA-N, LHHCSNFAOIFYRV-ZYNAIFEFSA-N, LHHCSNFAOIFYRV-ZYNAIFEFSA-N	Launched
bonaphthone					Brc1ccc2C(=O)C(=O)C=Cc2c1 |c:9|, Brc1ccc2C(=O)C(=O)C=Cc2c1 |c:9|	MXWZRRPNVLCHMY-UHFFFAOYSA-N, MXWZRRPNVLCHMY-UHFFFAOYSA-N	Phase 3
bopindolol	adrenergic receptor antagonist		cardiology	hypertension, coronary artery disease (CAD)	Cc1cc2c(OC[C@@H](CNC(C)(C)C)OC(=O)c3ccccc3)cccc2[nH]1 |&1:7|, Cc1cc2c(OC[C@@H](CNC(C)(C)C)OC(=O)c3ccccc3)cccc2[nH]1 |&1:7|	UUOJIACWOAYWEZ-GOSISDBHSA-N, UUOJIACWOAYWEZ-GOSISDBHSA-N	Launched
bornyl-acetate					CC(=O)O[C@H]1C[C@H]2CC[C@@]1(C)C2(C)C |&1:4,&2:6,&3:9,r,TLB:3:4:7.8:11|, CC(=O)O[C@H]1C[C@H]2CC[C@@]1(C)C2(C)C |&1:4,&2:6,&3:9,r,TLB:3:4:7.8:11|	KGEKLUUHTZCSIP-JFGNBEQYSA-N, KGEKLUUHTZCSIP-JFGNBEQYSA-N	Preclinical
boronophenylalanine					N[C@@H](Cc1ccc(cc1)B(O)O)C(O)=O, N[C@@H](Cc1ccc(cc1)B(O)O)C(O)=O	NFIVJOSXJDORSP-QMMMGPOBSA-N, NFIVJOSXJDORSP-QMMMGPOBSA-N	Phase 2
bortezomib	NFkB pathway inhibitor, proteasome inhibitor	PSMA1, PSMA2, PSMA3, PSMA4, PSMA5, PSMA6, PSMA7, PSMA8, PSMB1, PSMB10, PSMB11, PSMB2, PSMB3, PSMB4, PSMB5, PSMB6, PSMB7, PSMB8, PSMB9, PSMD1, PSMD2, RELA	hematologic malignancy	multiple myeloma, mantle cell lymphoma (MCL)	CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O	GXJABQQUPOEUTA-RDJZCZTQSA-N, GXJABQQUPOEUTA-RDJZCZTQSA-N, GXJABQQUPOEUTA-RDJZCZTQSA-N, GXJABQQUPOEUTA-RDJZCZTQSA-N, GXJABQQUPOEUTA-RDJZCZTQSA-N, GXJABQQUPOEUTA-RDJZCZTQSA-N, GXJABQQUPOEUTA-RDJZCZTQSA-N, GXJABQQUPOEUTA-RDJZCZTQSA-N, GXJABQQUPOEUTA-RDJZCZTQSA-N, GXJABQQUPOEUTA-RDJZCZTQSA-N, GXJABQQUPOEUTA-RDJZCZTQSA-N, GXJABQQUPOEUTA-RDJZCZTQSA-N, GXJABQQUPOEUTA-RDJZCZTQSA-N, GXJABQQUPOEUTA-RDJZCZTQSA-N, GXJABQQUPOEUTA-RDJZCZTQSA-N, GXJABQQUPOEUTA-RDJZCZTQSA-N, GXJABQQUPOEUTA-RDJZCZTQSA-N	Launched
BOS-172722	monopolar spindle 1 kinase inhibitor				CCOc1cc(ccc1Nc1ncc2cc(C)nc(NCC(C)(C)C)c2n1)-c1nncn1C	SGWLRDAOCLITOM-UHFFFAOYSA-N	Phase 1
bosentan	endothelin receptor antagonist	EDNRA, EDNRB	pulmonary	pulmonary arterial hypertension (PAH)	COc1ccccc1Oc1c(NS(=O)(=O)c2ccc(cc2)C(C)(C)C)nc(nc1OCCO)-c1ncccn1	GJPICJJJRGTNOD-UHFFFAOYSA-N	Launched
bosutinib	Abl kinase inhibitor, Bcr-Abl kinase inhibitor, SRC inhibitor	ABL1, BCR, CAMK1D, CAMK2G, CDK2, FRK, FYN, HCK, LYN, MAP2K1, MAP2K2, MAP3K2, MAP4K5, SRC, STK10, STK24, STK4, TNK2, TXK	hematologic malignancy	chronic myeloid leukemia (CML)	COc1cc(Nc2c(cnc3cc(OCCCN4CCN(C)CC4)c(OC)cc23)C#N)c(Cl)cc1Cl, COc1cc(Nc2c(cnc3cc(OCCCN4CCN(C)CC4)c(OC)cc23)C#N)c(Cl)cc1Cl, COc1cc(Nc2c(cnc3cc(OCCCN4CCN(C)CC4)c(OC)cc23)C#N)c(Cl)cc1Cl, COc1cc(Nc2c(cnc3cc(OCCCN4CCN(C)CC4)c(OC)cc23)C#N)c(Cl)cc1Cl, COc1cc(Nc2c(cnc3cc(OCCCN4CCN(C)CC4)c(OC)cc23)C#N)c(Cl)cc1Cl, COc1cc(Nc2c(cnc3cc(OCCCN4CCN(C)CC4)c(OC)cc23)C#N)c(Cl)cc1Cl, COc1cc(Nc2c(cnc3cc(OCCCN4CCN(C)CC4)c(OC)cc23)C#N)c(Cl)cc1Cl	UBPYILGKFZZVDX-UHFFFAOYSA-N, UBPYILGKFZZVDX-UHFFFAOYSA-N, UBPYILGKFZZVDX-UHFFFAOYSA-N, UBPYILGKFZZVDX-UHFFFAOYSA-N, UBPYILGKFZZVDX-UHFFFAOYSA-N, UBPYILGKFZZVDX-UHFFFAOYSA-N, UBPYILGKFZZVDX-UHFFFAOYSA-N	Launched
BP-554	serotonin receptor agonist	HTR1A			C(COc1ccc2OCOc2c1)CN1CCN(CC1)c1ccccc1, C(COc1ccc2OCOc2c1)CN1CCN(CC1)c1ccccc1, C(COc1ccc2OCOc2c1)CN1CCN(CC1)c1ccccc1, C(COc1ccc2OCOc2c1)CN1CCN(CC1)c1ccccc1, C(COc1ccc2OCOc2c1)CN1CCN(CC1)c1ccccc1	VUSNBQDZGKZEDL-UHFFFAOYSA-N, VUSNBQDZGKZEDL-UHFFFAOYSA-N, VUSNBQDZGKZEDL-UHFFFAOYSA-N, VUSNBQDZGKZEDL-UHFFFAOYSA-N, VUSNBQDZGKZEDL-UHFFFAOYSA-N	Preclinical
BP-897	dopamine receptor agonist	ADRA1A, ADRA1D, ADRA2A, DRD1, DRD2, DRD3, DRD4, HTR1A, HTR2B			COc1ccccc1N1CCN(CCCCNC(=O)c2ccc3ccccc3c2)CC1, COc1ccccc1N1CCN(CCCCNC(=O)c2ccc3ccccc3c2)CC1	MNHDKMDLOJSCGN-UHFFFAOYSA-N, MNHDKMDLOJSCGN-UHFFFAOYSA-N	Phase 2
BQ-123	endothelin receptor antagonist	EDNRA			[H][C@@]12CCCN1C(=O)[C@@]([H])(CC(O)=O)NC(=O)[C@@H](Cc1c[nH]c3ccccc13)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](NC2=O)C(C)C	VYCMAAOURFJIHD-PJNXIOHISA-N	Phase 2
BQ-788	endothelin receptor antagonist	EDNRB			CCCC[C@@H](NC(=O)[C@@H](Cc1cn(C(=O)OC)c2ccccc12)NC(=O)[C@H](CC(C)(C)C)NC(=O)N1[C@@H](C)CCC[C@H]1C)C(O)=O, CCCC[C@@H](NC(=O)[C@@H](Cc1cn(C(=O)OC)c2ccccc12)NC(=O)[C@H](CC(C)(C)C)NC(=O)N1[C@@H](C)CCC[C@H]1C)C(O)=O, CCCC[C@@H](NC(=O)[C@@H](Cc1cn(C(=O)OC)c2ccccc12)NC(=O)[C@H](CC(C)(C)C)NC(=O)N1[C@@H](C)CCC[C@H]1C)C(O)=O	LPAHKJMGDSJDRG-DJYQTOCQSA-N, LPAHKJMGDSJDRG-DJYQTOCQSA-N, LPAHKJMGDSJDRG-DJYQTOCQSA-N	Phase 1
BQU57	Ras GTPase inhibitor	RALA, RALB			Cc1nn(C)c2OC(=N)C(C#N)[C@@H](c12)c1ccc(cc1)C(F)(F)F |&1:12,r|, Cc1nn(C)c2OC(=N)C(C#N)[C@@H](c12)c1ccc(cc1)C(F)(F)F |&1:12,r|	QFUFJOJDXRWBNA-YUZLPWPTSA-N, QFUFJOJDXRWBNA-YUZLPWPTSA-N	Preclinical
BRD4770	histone lysine methyltransferase inhibitor	EHMT2			COC(=O)c1ccc2n(CCCc3ccccc3)c(NC(=O)c3ccccc3)nc2c1, COC(=O)c1ccc2n(CCCc3ccccc3)c(NC(=O)c3ccccc3)nc2c1, COC(=O)c1ccc2n(CCCc3ccccc3)c(NC(=O)c3ccccc3)nc2c1	UCGWYCMPZXDHNR-UHFFFAOYSA-N, UCGWYCMPZXDHNR-UHFFFAOYSA-N, UCGWYCMPZXDHNR-UHFFFAOYSA-N	Preclinical
BRD7389	ribosomal protein inhibitor	RPS6KA1, RPS6KA2, RPS6KA3			O=C1c2ccccc2-c2c(NCCc3ccccc3)c(=O)[nH]c3cccc1c23, O=C1c2ccccc2-c2c(NCCc3ccccc3)c(=O)[nH]c3cccc1c23, O=C1c2ccccc2-c2c(NCCc3ccccc3)c(=O)[nH]c3cccc1c23, O=C1c2ccccc2-c2c(NCCc3ccccc3)c(=O)[nH]c3cccc1c23	XASCINRGTHLHGM-UHFFFAOYSA-N, InChI=1S/C24H18N2O2/c27-23-17-10-5-4-9-16(17)21-20-18(23)11-6-12-19(20)26-24(28)22(21)25-14-13-15-7-2-1-3-8-15/h1-12,25H,13-14H2,(H,26,28), InChI=1S/C24H18N2O2/c27-23-17-10-5-4-9-16(17)21-20-18(23)11-6-12-19(20)26-24(28)22(21)25-14-13-15-7-2-1-3-8-15/h1-12,25H,13-14H2,(H,26,28), InChI=1S/C24H18N2O2/c27-23-17-10-5-4-9-16(17)21-20-18(23)11-6-12-19(20)26-24(28)22(21)25-14-13-15-7-2-1-3-8-15/h1-12,25H,13-14H2,(H,26,28)	Preclinical
BRD9876	kinesin inhibitor	KIF11			CC(C)(C)c1ccc2cc(C#N)c(cc2c1)C#N, CC(C)(C)c1ccc2cc(C#N)c(cc2c1)C#N	MKILROQBJOOZKC-UHFFFAOYSA-N, MKILROQBJOOZKC-UHFFFAOYSA-N	Preclinical
brefeldin-A	protein synthesis inhibitor	ARF1, CYTH2			C[C@H]1CCC\C=C\[C@@H]2C[C@H](O)C[C@H]2[C@H](O)\C=C\C(=O)O1 |t:5,16|, C[C@H]1CCC\C=C\[C@@H]2C[C@H](O)C[C@H]2[C@H](O)\C=C\C(=O)O1 |t:5,16|, C[C@H]1CCC\C=C\[C@@H]2C[C@H](O)C[C@H]2[C@H](O)\C=C\C(=O)O1 |t:5,16|, C[C@H]1CCC\C=C\[C@@H]2C[C@H](O)C[C@H]2[C@H](O)\C=C\C(=O)O1 |t:5,16|, C[C@H]1CCC\C=C\[C@@H]2C[C@H](O)C[C@H]2[C@H](O)\C=C\C(=O)O1 |t:5,16|, C[C@H]1CCC\C=C\[C@@H]2C[C@H](O)C[C@H]2[C@H](O)\C=C\C(=O)O1 |t:5,16|	KQNZDYYTLMIZCT-KQPMLPITSA-N, KQNZDYYTLMIZCT-KQPMLPITSA-N, KQNZDYYTLMIZCT-KQPMLPITSA-N, KQNZDYYTLMIZCT-KQPMLPITSA-N, KQNZDYYTLMIZCT-KQPMLPITSA-N, KQNZDYYTLMIZCT-KQPMLPITSA-N	Preclinical
bremelanotide	melanocortin receptor agonist	MC1R, MC2R, MC3R, MC4R, MC5R	neurology/psychiatry	hypoactive sexual desire disorder	CCCC[C@H](NC(C)=O)C(=O)N[C@H]1CC(=O)NCCCC[C@H](NC(=O)[C@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@H](Cc2cnc[nH]2)NC1=O)C(O)=O, CCCC[C@H](NC(C)=O)C(=O)N[C@H]1CC(=O)NCCCC[C@H](NC(=O)[C@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@H](Cc2cnc[nH]2)NC1=O)C(O)=O	FFHBJDQSGDNCIV-VEUPWBLKSA-N, FFHBJDQSGDNCIV-VEUPWBLKSA-N	Launched
brequinar	dihydroorotate dehydrogenase inhibitor	DHODH			Cc1c(nc2ccc(F)cc2c1C(O)=O)-c1ccc(cc1)-c1ccccc1F, Cc1c(nc2ccc(F)cc2c1C(O)=O)-c1ccc(cc1)-c1ccccc1F, Cc1c(nc2ccc(F)cc2c1C(O)=O)-c1ccc(cc1)-c1ccccc1F	PHEZJEYUWHETKO-UHFFFAOYSA-N, PHEZJEYUWHETKO-UHFFFAOYSA-N, PHEZJEYUWHETKO-UHFFFAOYSA-N	Phase 2
bretazenil	GABA benzodiazepine site receptor partial agonist	GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6			CC(C)(C)OC(=O)c1ncn-2c1[C@@H]1CCCN1C(=O)c1c(Br)cccc-21, CC(C)(C)OC(=O)c1ncn-2c1[C@@H]1CCCN1C(=O)c1c(Br)cccc-21, CC(C)(C)OC(=O)c1ncn-2c1[C@@H]1CCCN1C(=O)c1c(Br)cccc-21	LWUDDYHYYNNIQI-ZDUSSCGKSA-N, LWUDDYHYYNNIQI-ZDUSSCGKSA-N, LWUDDYHYYNNIQI-ZDUSSCGKSA-N	Phase 2
bretylium	norepinephrine inhibitor	ATP1A1	cardiology	ventricular arrhythmias, ventricular fibrillation (VF), ventricular tachycardia (VT)	CC[N+](C)(C)Cc1ccccc1Br, CC[N+](C)(C)Cc1ccccc1Br, CC[N+](C)(C)Cc1ccccc1Br, CC[N+](C)(C)Cc1ccccc1Br	AAQOQKQBGPPFNS-UHFFFAOYSA-N, AAQOQKQBGPPFNS-UHFFFAOYSA-N, AAQOQKQBGPPFNS-UHFFFAOYSA-N, AAQOQKQBGPPFNS-UHFFFAOYSA-N	Launched
brexpiprazole	dopamine receptor partial agonist	DRD2	neurology/psychiatry	depression, schizophrenia	O=c1ccc2ccc(OCCCCN3CCN(CC3)c3cccc4sccc34)cc2[nH]1, O=c1ccc2ccc(OCCCCN3CCN(CC3)c3cccc4sccc34)cc2[nH]1, O=c1ccc2ccc(OCCCCN3CCN(CC3)c3cccc4sccc34)cc2[nH]1, O=c1ccc2ccc(OCCCCN3CCN(CC3)c3cccc4sccc34)cc2[nH]1, O=c1ccc2ccc(OCCCCN3CCN(CC3)c3cccc4sccc34)cc2[nH]1, O=c1ccc2ccc(OCCCCN3CCN(CC3)c3cccc4sccc34)cc2[nH]1	ZKIAIYBUSXZPLP-UHFFFAOYSA-N, ZKIAIYBUSXZPLP-UHFFFAOYSA-N, ZKIAIYBUSXZPLP-UHFFFAOYSA-N, ZKIAIYBUSXZPLP-UHFFFAOYSA-N, ZKIAIYBUSXZPLP-UHFFFAOYSA-N, ZKIAIYBUSXZPLP-UHFFFAOYSA-N	Launched
briciclib	cyclin D inhibitor	CCND1			COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(OP(O)(O)=O)c2)c(OC)c1, COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(OP(O)(O)=O)c2)c(OC)c1, COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(OP(O)(O)=O)c2)c(OC)c1	LXENKEWVEVKKGV-BQYQJAHWSA-N, LXENKEWVEVKKGV-BQYQJAHWSA-N, LXENKEWVEVKKGV-BQYQJAHWSA-N	Phase 1
brigatinib	ALK tyrosine kinase receptor inhibitor, EGFR inhibitor	ALK, EGFR	oncology	non-small cell lung cancer (NSCLC)	COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2P(C)(C)=O)n1)N1CCC(CC1)N1CCN(C)CC1, COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2P(C)(C)=O)n1)N1CCC(CC1)N1CCN(C)CC1, COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2P(C)(C)=O)n1)N1CCC(CC1)N1CCN(C)CC1, COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2P(C)(C)=O)n1)N1CCC(CC1)N1CCN(C)CC1, COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2P(C)(C)=O)n1)N1CCC(CC1)N1CCN(C)CC1, COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2P(C)(C)=O)n1)N1CCC(CC1)N1CCN(C)CC1, COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2P(C)(C)=O)n1)N1CCC(CC1)N1CCN(C)CC1, COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2P(C)(C)=O)n1)N1CCC(CC1)N1CCN(C)CC1	AILRADAXUVEEIR-UHFFFAOYSA-N, AILRADAXUVEEIR-UHFFFAOYSA-N, AILRADAXUVEEIR-UHFFFAOYSA-N, AILRADAXUVEEIR-UHFFFAOYSA-N, AILRADAXUVEEIR-UHFFFAOYSA-N, AILRADAXUVEEIR-UHFFFAOYSA-N, AILRADAXUVEEIR-UHFFFAOYSA-N, AILRADAXUVEEIR-UHFFFAOYSA-N	Launched
brilliant-green			infectious disease	antiseptic	CCN(CC)c1ccc(cc1)[C+](c1ccccc1)c1ccc(cc1)N(CC)CC, CCN(CC)c1ccc(cc1)[C+](c1ccccc1)c1ccc(cc1)N(CC)CC, CCN(CC)c1ccc(cc1)[C+](c1ccccc1)c1ccc(cc1)N(CC)CC, CCN(CC)c1ccc(cc1)[C+](c1ccccc1)c1ccc(cc1)N(CC)CC	HXCILVUBKWANLN-UHFFFAOYSA-N, HXCILVUBKWANLN-UHFFFAOYSA-N, HXCILVUBKWANLN-UHFFFAOYSA-N, HXCILVUBKWANLN-UHFFFAOYSA-N	Launched
brimonidine	adrenergic receptor agonist	ADRA2A, ADRA2B, ADRA2C	ophthalmology	intraocular pressure, glaucoma, ocular hypertension	Brc1c(NC2=NCCN2)ccc2nccnc12 |t:4|, Brc1c(NC2=NCCN2)ccc2nccnc12 |t:4|, Brc1c(NC2=NCCN2)ccc2nccnc12 |t:4|, Brc1c(NC2=NCCN2)ccc2nccnc12 |t:4|, Brc1c(NC2=NCCN2)ccc2nccnc12 |t:4|, Brc1c(NC2=NCCN2)ccc2nccnc12 |t:4|	XYLJNLCSTIOKRM-UHFFFAOYSA-N, XYLJNLCSTIOKRM-UHFFFAOYSA-N, XYLJNLCSTIOKRM-UHFFFAOYSA-N, XYLJNLCSTIOKRM-UHFFFAOYSA-N, XYLJNLCSTIOKRM-UHFFFAOYSA-N, XYLJNLCSTIOKRM-UHFFFAOYSA-N	Launched
brincidofovir	antiviral				CCCCCCCCCCCCCCCCOCCCOP(O)(=O)CO[C@H](CO)Cn1ccc(N)nc1=O	WXJFKKQWPMNTIM-VWLOTQADSA-N	Phase 3
brinzolamide	carbonic anhydrase inhibitor	CA1, CA12, CA14, CA2, CA4, CA5A, CA7	ophthalmology	intraocular pressure, glaucoma, ocular hypertension	CCN[C@H]1CN(CCCOC)S(=O)(=O)c2sc(cc12)S(N)(=O)=O, CCN[C@H]1CN(CCCOC)S(=O)(=O)c2sc(cc12)S(N)(=O)=O, CCN[C@H]1CN(CCCOC)S(=O)(=O)c2sc(cc12)S(N)(=O)=O, CCN[C@H]1CN(CCCOC)S(=O)(=O)c2sc(cc12)S(N)(=O)=O	HCRKCZRJWPKOAR-JTQLQIEISA-N, HCRKCZRJWPKOAR-JTQLQIEISA-N, HCRKCZRJWPKOAR-JTQLQIEISA-N, HCRKCZRJWPKOAR-JTQLQIEISA-N	Launched
brivanib	FGFR inhibitor, VEGFR inhibitor	CYP3A4, FGFR1, FLT1, KCNH2, KDR			C[C@@H](O)COc1cn2ncnc(Oc3ccc4[nH]c(C)cc4c3F)c2c1C, C[C@@H](O)COc1cn2ncnc(Oc3ccc4[nH]c(C)cc4c3F)c2c1C, C[C@@H](O)COc1cn2ncnc(Oc3ccc4[nH]c(C)cc4c3F)c2c1C, C[C@@H](O)COc1cn2ncnc(Oc3ccc4[nH]c(C)cc4c3F)c2c1C	WCWUXEGQKLTGDX-LLVKDONJSA-N, WCWUXEGQKLTGDX-LLVKDONJSA-N, WCWUXEGQKLTGDX-LLVKDONJSA-N, WCWUXEGQKLTGDX-LLVKDONJSA-N	Phase 3
brivanib-alaninate	FGFR inhibitor, VEGFR inhibitor	FGFR3			C[C@H](COc1cn2ncnc(Oc3ccc4[nH]c(C)cc4c3F)c2c1C)OC(=O)[C@H](C)N, C[C@H](COc1cn2ncnc(Oc3ccc4[nH]c(C)cc4c3F)c2c1C)OC(=O)[C@H](C)N, C[C@H](COc1cn2ncnc(Oc3ccc4[nH]c(C)cc4c3F)c2c1C)OC(=O)[C@H](C)N, C[C@H](COc1cn2ncnc(Oc3ccc4[nH]c(C)cc4c3F)c2c1C)OC(=O)[C@H](C)N, C[C@H](COc1cn2ncnc(Oc3ccc4[nH]c(C)cc4c3F)c2c1C)OC(=O)[C@H](C)N, C[C@H](COc1cn2ncnc(Oc3ccc4[nH]c(C)cc4c3F)c2c1C)OC(=O)[C@H](C)N	LTEJRLHKIYCEOX-OCCSQVGLSA-N, LTEJRLHKIYCEOX-OCCSQVGLSA-N, LTEJRLHKIYCEOX-OCCSQVGLSA-N, LTEJRLHKIYCEOX-OCCSQVGLSA-N, LTEJRLHKIYCEOX-OCCSQVGLSA-N, LTEJRLHKIYCEOX-OCCSQVGLSA-N	Phase 3
brivudine	DNA directed DNA polymerase inhibitor		infectious disease	shingles	OC[C@H]1O[C@H](C[C@@H]1O)n1cc(\C=C\Br)c(=O)[nH]c1=O |a:2,4,&1:6|	ODZBBRURCPAEIQ-PIXDULNESA-N	Launched
BRL-15572	serotonin receptor antagonist	HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2B, HTR2C, HTR6			O[C@@H](CN1CCN(CC1)c1cccc(Cl)c1)C(c1ccccc1)c1ccccc1 |&1:1|, O[C@@H](CN1CCN(CC1)c1cccc(Cl)c1)C(c1ccccc1)c1ccccc1 |&1:1|, O[C@@H](CN1CCN(CC1)c1cccc(Cl)c1)C(c1ccccc1)c1ccccc1 |&1:1|, O[C@@H](CN1CCN(CC1)c1cccc(Cl)c1)C(c1ccccc1)c1ccccc1 |&1:1|	QJHCTHPYUOXOGM-DEOSSOPVSA-N, QJHCTHPYUOXOGM-DEOSSOPVSA-N, QJHCTHPYUOXOGM-DEOSSOPVSA-N, QJHCTHPYUOXOGM-DEOSSOPVSA-N	Preclinical
BRL-26314	cholesterol inhibitor	LPL			OC(=O)[C@@H](Cc1ccccc1)NCc1ccc(Cl)cc1 |&1:3,r|, OC(=O)[C@@H](Cc1ccccc1)NCc1ccc(Cl)cc1 |&1:3,r|, OC(=O)[C@@H](Cc1ccccc1)NCc1ccc(Cl)cc1 |&1:3,r|	SAOHCSVJQIAGDD-OAHLLOKOSA-N, SAOHCSVJQIAGDD-OAHLLOKOSA-N, SAOHCSVJQIAGDD-OAHLLOKOSA-N	Phase 1
BRL-37344	adrenergic receptor agonist	ADRB1, ADRB2, ADRB3			C[C@H](Cc1ccc(OCC(O)=O)cc1)NC[C@H](O)c1cccc(Cl)c1, C[C@H](Cc1ccc(OCC(O)=O)cc1)NC[C@H](O)c1cccc(Cl)c1, C[C@H](Cc1ccc(OCC(O)=O)cc1)NC[C@H](O)c1cccc(Cl)c1, C[C@H](Cc1ccc(OCC(O)=O)cc1)NC[C@H](O)c1cccc(Cl)c1	ZGGNJJJYUVRADP-ACJLOTCBSA-N, ZGGNJJJYUVRADP-ACJLOTCBSA-N, ZGGNJJJYUVRADP-ACJLOTCBSA-N, ZGGNJJJYUVRADP-ACJLOTCBSA-N	Phase 2
BRL-44408	adrenergic receptor antagonist	ADRA2A, ADRA2B, ADRA2C			C[C@H]1N(CC2=NCCN2)Cc2ccccc12 |&1:1,t:4|, C[C@H]1N(CC2=NCCN2)Cc2ccccc12 |&1:1,t:4|	SGOFAUSEYBZKDQ-SNVBAGLBSA-N, SGOFAUSEYBZKDQ-SNVBAGLBSA-N	Preclinical
BRL-50481	phosphodiesterase inhibitor	PDE7A, PDE7B			CN(C)S(=O)(=O)c1cc(ccc1C)[N+]([O-])=O, CN(C)S(=O)(=O)c1cc(ccc1C)[N+]([O-])=O, CN(C)S(=O)(=O)c1cc(ccc1C)[N+]([O-])=O, CN(C)S(=O)(=O)c1cc(ccc1C)[N+]([O-])=O	IFIUFCJFLGCQPH-UHFFFAOYSA-N, IFIUFCJFLGCQPH-UHFFFAOYSA-N, IFIUFCJFLGCQPH-UHFFFAOYSA-N, IFIUFCJFLGCQPH-UHFFFAOYSA-N	Preclinical
BRL-52537	opioid receptor agonist	OPRK1			Clc1ccc(CC(=O)N2CCCC[C@@H]2CN2CCCC2)cc1Cl |&1:13|, Clc1ccc(CC(=O)N2CCCC[C@@H]2CN2CCCC2)cc1Cl |&1:13|, Clc1ccc(CC(=O)N2CCCC[C@@H]2CN2CCCC2)cc1Cl |&1:13|	GHCCBWMZKJQGLS-OAHLLOKOSA-N, GHCCBWMZKJQGLS-OAHLLOKOSA-N, GHCCBWMZKJQGLS-OAHLLOKOSA-N	Preclinical
BRL-54443	serotonin receptor agonist	HTR1E, HTR1F			CN1CCC(CC1)c1c[nH]c2ccc(O)cc12, CN1CCC(CC1)c1c[nH]c2ccc(O)cc12, CN1CCC(CC1)c1c[nH]c2ccc(O)cc12, CN1CCC(CC1)c1c[nH]c2ccc(O)cc12	WKNFADCGOAHBPG-UHFFFAOYSA-N, WKNFADCGOAHBPG-UHFFFAOYSA-N, WKNFADCGOAHBPG-UHFFFAOYSA-N, WKNFADCGOAHBPG-UHFFFAOYSA-N	Preclinical
brolitene	muscle relaxant	RYR1	rheumatology	lumbago	OCCNC(=O)\C=C\c1ccccc1, OCCNC(=O)\C=C\c1ccccc1	OSCTXCOERRNGLW-VOTSOKGWSA-N, OSCTXCOERRNGLW-VOTSOKGWSA-N	Launched
bromantan	dopamine reuptake inhibitor, serotonin reuptake inhibitor		neurology/psychiatry	neurasthenia	Brc1ccc(NC2C3CC4CC(C3)CC2C4)cc1, Brc1ccc(NC2C3CC4CC(C3)CC2C4)cc1, Brc1ccc(NC2C3CC4CC(C3)CC2C4)cc1, Brc1ccc(NC2C3CC4CC(C3)CC2C4)cc1	LWJALJDRFBXHKX-UHFFFAOYSA-N, LWJALJDRFBXHKX-UHFFFAOYSA-N, LWJALJDRFBXHKX-UHFFFAOYSA-N, LWJALJDRFBXHKX-UHFFFAOYSA-N	Launched
bromebric-acid	DNA synthesis inhibitor, purine antagonist				COc1ccc(cc1)C(=O)C(\Br)=C\C(O)=O	UPZFHUODAYGHDZ-TWGQIWQCSA-N	Preclinical
bromfenac	cyclooxygenase inhibitor	PTGS1, PTGS2			Nc1c(CC(O)=O)cccc1C(=O)c1ccc(Br)cc1	ZBPLOVFIXSTCRZ-UHFFFAOYSA-N	Withdrawn
bromhexine	mucolytic agent		pulmonary	chest congestion	CN(Cc1cc(Br)cc(Br)c1N)C1CCCCC1, CN(Cc1cc(Br)cc(Br)c1N)C1CCCCC1, CN(Cc1cc(Br)cc(Br)c1N)C1CCCCC1, CN(Cc1cc(Br)cc(Br)c1N)C1CCCCC1, CN(Cc1cc(Br)cc(Br)c1N)C1CCCCC1, CN(Cc1cc(Br)cc(Br)c1N)C1CCCCC1	OJGDCBLYJGHCIH-UHFFFAOYSA-N, OJGDCBLYJGHCIH-UHFFFAOYSA-N, OJGDCBLYJGHCIH-UHFFFAOYSA-N, OJGDCBLYJGHCIH-UHFFFAOYSA-N, OJGDCBLYJGHCIH-UHFFFAOYSA-N, OJGDCBLYJGHCIH-UHFFFAOYSA-N	Launched
bromindione	anticoagulant				Brc1ccc(cc1)C1C(=O)c2ccccc2C1=O, Brc1ccc(cc1)C1C(=O)c2ccccc2C1=O	NPUZIGSOEWMFKK-UHFFFAOYSA-N, NPUZIGSOEWMFKK-UHFFFAOYSA-N	Phase 2
bromisoval	anti-inflammatory agent				CC(C)[C@@H](Br)C(=O)NC(N)=O |&1:3,r|	CMCCHHWTTBEZNM-SCSAIBSYSA-N	Preclinical
bromocriptine	dopamine receptor agonist	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, DRD4, DRD5, HTR1A, HTR1B, HTR1D, HTR2A, HTR2B, HTR2C, HTR6, HTR7	endocrinology, neurology/psychiatry	hyperprolactinemia, Parkinson's Disease, acromegaly	CC(C)C[C@@H]1N2C(=O)[C@](NC(=O)[C@H]3CN(C)[C@@H]4Cc5c(Br)[nH]c6cccc(C4=C3)c56)(O[C@@]2(O)[C@@H]2CCCN2C1=O)C(C)C |c:28|, CC(C)C[C@@H]1N2C(=O)[C@](NC(=O)[C@H]3CN(C)[C@@H]4Cc5c(Br)[nH]c6cccc(C4=C3)c56)(O[C@@]2(O)[C@@H]2CCCN2C1=O)C(C)C |c:28|, CC(C)C[C@@H]1N2C(=O)[C@](NC(=O)[C@H]3CN(C)[C@@H]4Cc5c(Br)[nH]c6cccc(C4=C3)c56)(O[C@@]2(O)[C@@H]2CCCN2C1=O)C(C)C |c:28|, CC(C)C[C@@H]1N2C(=O)[C@](NC(=O)[C@H]3CN(C)[C@@H]4Cc5c(Br)[nH]c6cccc(C4=C3)c56)(O[C@@]2(O)[C@@H]2CCCN2C1=O)C(C)C |c:28|	OZVBMTJYIDMWIL-AYFBDAFISA-N, OZVBMTJYIDMWIL-AYFBDAFISA-N, OZVBMTJYIDMWIL-AYFBDAFISA-N, OZVBMTJYIDMWIL-AYFBDAFISA-N	Launched
bromopride	dopamine receptor antagonist	DRD2	gastroenterology	nausea, vomiting, gastroesophageal reflux disease (GERD)	CCN(CC)CCNC(=O)c1cc(Br)c(N)cc1OC, CCN(CC)CCNC(=O)c1cc(Br)c(N)cc1OC, CCN(CC)CCNC(=O)c1cc(Br)c(N)cc1OC	GIYAQDDTCWHPPL-UHFFFAOYSA-N, GIYAQDDTCWHPPL-UHFFFAOYSA-N, GIYAQDDTCWHPPL-UHFFFAOYSA-N	Launched
bromosporine	bromodomain inhibitor				CCOC(=O)Nc1cc(nn2c(C)nnc12)-c1ccc(C)c(NS(C)(=O)=O)c1, CCOC(=O)Nc1cc(nn2c(C)nnc12)-c1ccc(C)c(NS(C)(=O)=O)c1, CCOC(=O)Nc1cc(nn2c(C)nnc12)-c1ccc(C)c(NS(C)(=O)=O)c1, CCOC(=O)Nc1cc(nn2c(C)nnc12)-c1ccc(C)c(NS(C)(=O)=O)c1, CCOC(=O)Nc1cc(nn2c(C)nnc12)-c1ccc(C)c(NS(C)(=O)=O)c1, CCOC(=O)Nc1cc(nn2c(C)nnc12)-c1ccc(C)c(NS(C)(=O)=O)c1, CCOC(=O)Nc1cc(nn2c(C)nnc12)-c1ccc(C)c(NS(C)(=O)=O)c1	UYBRROMMFMPJAN-UHFFFAOYSA-N, UYBRROMMFMPJAN-UHFFFAOYSA-N, UYBRROMMFMPJAN-UHFFFAOYSA-N, UYBRROMMFMPJAN-UHFFFAOYSA-N, UYBRROMMFMPJAN-UHFFFAOYSA-N, UYBRROMMFMPJAN-UHFFFAOYSA-N, UYBRROMMFMPJAN-UHFFFAOYSA-N	Preclinical
bromperidol	dopamine receptor antagonist	DRD2	neurology/psychiatry	schizophrenia	OC1(CCN(CCCC(=O)c2ccc(F)cc2)CC1)c1ccc(Br)cc1, OC1(CCN(CCCC(=O)c2ccc(F)cc2)CC1)c1ccc(Br)cc1, OC1(CCN(CCCC(=O)c2ccc(F)cc2)CC1)c1ccc(Br)cc1, OC1(CCN(CCCC(=O)c2ccc(F)cc2)CC1)c1ccc(Br)cc1	RKLNONIVDFXQRX-UHFFFAOYSA-N, RKLNONIVDFXQRX-UHFFFAOYSA-N, RKLNONIVDFXQRX-UHFFFAOYSA-N, RKLNONIVDFXQRX-UHFFFAOYSA-N	Launched
brompheniramine	histamine receptor antagonist	HRH1	allergy, otolaryngology	allergic rhinitis, common cold	CN(C)CC[C@@H](c1ccc(Br)cc1)c1ccccn1 |&1:5|	ZDIGNSYAACHWNL-HNNXBMFYSA-N	Launched
bronopol			obstetrics/gynecology	mastitis	OCC(Br)(CO)[N+]([O-])=O, OCC(Br)(CO)[N+]([O-])=O	LVDKZNITIUWNER-UHFFFAOYSA-N, LVDKZNITIUWNER-UHFFFAOYSA-N	Launched
bropirimine	interferon inducer				Nc1nc(=O)c(Br)c([nH]1)-c1ccccc1, Nc1nc(=O)c(Br)c([nH]1)-c1ccccc1, Nc1nc(=O)c(Br)c([nH]1)-c1ccccc1	CIUUIPMOFZIWIZ-UHFFFAOYSA-N, CIUUIPMOFZIWIZ-UHFFFAOYSA-N, CIUUIPMOFZIWIZ-UHFFFAOYSA-N	Phase 3
broxaldine					Cc1ccc2c(Br)cc(Br)c(OC(=O)c3ccccc3)c2n1, Cc1ccc2c(Br)cc(Br)c(OC(=O)c3ccccc3)c2n1, Cc1ccc2c(Br)cc(Br)c(OC(=O)c3ccccc3)c2n1	IJTPLVAAROHGGB-UHFFFAOYSA-N, IJTPLVAAROHGGB-UHFFFAOYSA-N, IJTPLVAAROHGGB-UHFFFAOYSA-N	Preclinical
broxaterol	adrenergic receptor agonist	ADRB2			CC(C)(C)NC[C@@H](O)c1cc(Br)no1 |&1:6,r|	JBRBWHCVRGURBA-ZCFIWIBFSA-N	Phase 3
broxuridine	antimetabolite				OC[C@H]1O[C@H](C[C@@H]1O)n1cc(Br)c(=O)[nH]c1=O, OC[C@H]1O[C@H](C[C@@H]1O)n1cc(Br)c(=O)[nH]c1=O	WOVKYSAHUYNSMH-RRKCRQDMSA-N, WOVKYSAHUYNSMH-RRKCRQDMSA-N	Phase 2
broxyquinoline	antiprotozoal agent				Oc1c(Br)cc(Br)c2cccnc12, Oc1c(Br)cc(Br)c2cccnc12, Oc1c(Br)cc(Br)c2cccnc12, Oc1c(Br)cc(Br)c2cccnc12	ZDASUJMDVPTNTF-UHFFFAOYSA-N, ZDASUJMDVPTNTF-UHFFFAOYSA-N, ZDASUJMDVPTNTF-UHFFFAOYSA-N, ZDASUJMDVPTNTF-UHFFFAOYSA-N	Phase 1
bruceantin	protein synthesis inhibitor				COC(=O)[C@]12OC[C@@]34[C@H]1[C@@H](OC(=O)\C=C(/C)C(C)C)C(=O)O[C@@H]3C[C@H]1[C@@H](C)C(=O)C(=O)C[C@]1(C)[C@H]4[C@@H](O)[C@@H]2O |a:4,7,8,9,22,24,32,34,35,37,&1:25|, COC(=O)[C@]12OC[C@@]34[C@H]1[C@@H](OC(=O)\C=C(/C)C(C)C)C(=O)O[C@@H]3C[C@H]1[C@@H](C)C(=O)C(=O)C[C@]1(C)[C@H]4[C@@H](O)[C@@H]2O |a:4,7,8,9,22,24,32,34,35,37,&1:25|, COC(=O)[C@]12OC[C@@]34[C@H]1[C@@H](OC(=O)\C=C(/C)C(C)C)C(=O)O[C@@H]3C[C@H]1[C@@H](C)C(=O)C(=O)C[C@]1(C)[C@H]4[C@@H](O)[C@@H]2O |a:4,7,8,9,22,24,32,34,35,37,&1:25|, COC(=O)[C@]12OC[C@@]34[C@H]1[C@@H](OC(=O)\C=C(/C)C(C)C)C(=O)O[C@@H]3C[C@H]1[C@@H](C)C(=O)C(=O)C[C@]1(C)[C@H]4[C@@H](O)[C@@H]2O |a:4,7,8,9,22,24,32,34,35,37,&1:25|, COC(=O)[C@]12OC[C@@]34[C@H]1[C@@H](OC(=O)\C=C(/C)C(C)C)C(=O)O[C@@H]3C[C@H]1[C@@H](C)C(=O)C(=O)C[C@]1(C)[C@H]4[C@@H](O)[C@@H]2O |a:4,7,8,9,22,24,32,34,35,37,&1:25|	KMCZIPGKKBSLEX-AOHBHZTBSA-N, KMCZIPGKKBSLEX-AOHBHZTBSA-N, KMCZIPGKKBSLEX-AOHBHZTBSA-N, KMCZIPGKKBSLEX-AOHBHZTBSA-N, KMCZIPGKKBSLEX-AOHBHZTBSA-N	Phase 2
brucine	glycine receptor antagonist	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5			COc1cc2N3[C@H]4[C@@H]5[C@H](CC3=O)OCC=C3CN6CC[C@]4([C@@H]6C[C@H]53)c2cc1OC |t:15|	RRKTZKIUPZVBMF-IBTVXLQLSA-N	Preclinical
BS-181	CDK inhibitor	CDK7			CC(C)c1cnn2c(NCc3ccccc3)cc(NCCCCCCN)nc12, CC(C)c1cnn2c(NCc3ccccc3)cc(NCCCCCCN)nc12, CC(C)c1cnn2c(NCc3ccccc3)cc(NCCCCCCN)nc12, CC(C)c1cnn2c(NCc3ccccc3)cc(NCCCCCCN)nc12, CC(C)c1cnn2c(NCc3ccccc3)cc(NCCCCCCN)nc12, CC(C)c1cnn2c(NCc3ccccc3)cc(NCCCCCCN)nc12, CC(C)c1cnn2c(NCc3ccccc3)cc(NCCCCCCN)nc12	DNYBIOICMDTDAP-UHFFFAOYSA-N, DNYBIOICMDTDAP-UHFFFAOYSA-N, DNYBIOICMDTDAP-UHFFFAOYSA-N, DNYBIOICMDTDAP-UHFFFAOYSA-N, DNYBIOICMDTDAP-UHFFFAOYSA-N, DNYBIOICMDTDAP-UHFFFAOYSA-N, DNYBIOICMDTDAP-UHFFFAOYSA-N	Preclinical
BT-11	cAMP stimulant				O=C(N1CCN(CC1)C(=O)c1cccc(n1)-c1nc2ccccc2[nH]1)c1cccc(n1)-c1nc2ccccc2[nH]1	MVHWZNBAQIGPOQ-UHFFFAOYSA-N	Phase 2
BTB06584	ATPase inhibitor	ATP5F1			[O-][N+](=O)c1ccc(cc1OC(=O)c1ccc(Cl)cc1)S(=O)(=O)c1ccccc1, [O-][N+](=O)c1ccc(cc1OC(=O)c1ccc(Cl)cc1)S(=O)(=O)c1ccccc1, [O-][N+](=O)c1ccc(cc1OC(=O)c1ccc(Cl)cc1)S(=O)(=O)c1ccccc1	WNDWKKPBLAKXMI-UHFFFAOYSA-N, WNDWKKPBLAKXMI-UHFFFAOYSA-N, WNDWKKPBLAKXMI-UHFFFAOYSA-N	Preclinical
BTB1	mitotic kinesin inhibitor	KIF18A			[O-][N+](=O)c1cc(Cl)ccc1S(=O)(=O)c1ccccc1, [O-][N+](=O)c1cc(Cl)ccc1S(=O)(=O)c1ccccc1, [O-][N+](=O)c1cc(Cl)ccc1S(=O)(=O)c1ccccc1	VZDUQPHKUBZMLW-UHFFFAOYSA-N, VZDUQPHKUBZMLW-UHFFFAOYSA-N, VZDUQPHKUBZMLW-UHFFFAOYSA-N	Preclinical
BTK-IN-1	Bruton's tyrosine kinase (BTK) inhibitor				Clc1cccc(NCC(=O)N[C@@H]2CCCN(C2)c2ncnc3[nH]ccc23)c1 |&1:11,r|	SPSNKQVUYDXOGY-OAHLLOKOSA-N	Preclinical
BTS					Cc1ccc(cc1)S(=O)(=O)NCc1ccccc1, Cc1ccc(cc1)S(=O)(=O)NCc1ccccc1, Cc1ccc(cc1)S(=O)(=O)NCc1ccccc1	WTHKAJZQYNKTCJ-UHFFFAOYSA-N, WTHKAJZQYNKTCJ-UHFFFAOYSA-N, WTHKAJZQYNKTCJ-UHFFFAOYSA-N	Preclinical
BTS-54505	dopamine reuptake inhibitor	SLC6A2, SLC6A3, SLC6A4			CC(C)C[C@@H](N)C1(CCC1)c1ccc(Cl)cc1 |&1:4|, CC(C)C[C@@H](N)C1(CCC1)c1ccc(Cl)cc1 |&1:4|, CC(C)C[C@@H](N)C1(CCC1)c1ccc(Cl)cc1 |&1:4|, CC(C)C[C@@H](N)C1(CCC1)c1ccc(Cl)cc1 |&1:4|, CC(C)C[C@@H](N)C1(CCC1)c1ccc(Cl)cc1 |&1:4|	WQSACWZKKZPCHN-CQSZACIVSA-N, WQSACWZKKZPCHN-CQSZACIVSA-N, WQSACWZKKZPCHN-CQSZACIVSA-N, WQSACWZKKZPCHN-CQSZACIVSA-N, WQSACWZKKZPCHN-CQSZACIVSA-N	Withdrawn
BTS-71321					CC(C)(NCCCn1ccnc1)c1ccc(Cl)cc1	GRKYRJREJPZXIU-UHFFFAOYSA-N	Phase 2
BTS-72664	GABA receptor antagonist	GABBR1			C[C@@H](Oc1ccc(Cl)cc1)c1ccnc2ncnn12 |&1:1,r|	FCEPUTGEUCVRRI-SECBINFHSA-N	Phase 1
BTT-3033	integrin inhibitor	ITGA2, ITGB1			CN(c1ccc(NC(=O)Nc2ccccc2)cc1)S(=O)(=O)c1cnn(c1)-c1ccc(F)cc1, CN(c1ccc(NC(=O)Nc2ccccc2)cc1)S(=O)(=O)c1cnn(c1)-c1ccc(F)cc1, CN(c1ccc(NC(=O)Nc2ccccc2)cc1)S(=O)(=O)c1cnn(c1)-c1ccc(F)cc1	NSLIQOPYDUKWTA-UHFFFAOYSA-N, NSLIQOPYDUKWTA-UHFFFAOYSA-N, NSLIQOPYDUKWTA-UHFFFAOYSA-N	Preclinical
BTZ043-racemate	DPRE1 inhibitor				C[C@H]1COC2(CCN(CC2)c2nc(=O)c3cc(cc([N+]([O-])=O)c3s2)C(F)(F)F)O1 |&1:1,r|, C[C@H]1COC2(CCN(CC2)c2nc(=O)c3cc(cc([N+]([O-])=O)c3s2)C(F)(F)F)O1 |&1:1,r|	GTUIRORNXIOHQR-VIFPVBQESA-N, GTUIRORNXIOHQR-VIFPVBQESA-N	Phase 1/Phase 2
BU-224	imidazoline receptor ligand	MAOA, MAOB			C1CN=C(N1)c1ccc2ccccc2n1 |c:2|, C1CN=C(N1)c1ccc2ccccc2n1 |c:2|, C1CN=C(N1)c1ccc2ccccc2n1 |c:2|	OSUVWJGCKQEMHK-UHFFFAOYSA-N, OSUVWJGCKQEMHK-UHFFFAOYSA-N, OSUVWJGCKQEMHK-UHFFFAOYSA-N	Preclinical
BU-239	imidazoline receptor agonist, imidazoline receptor ligand				C1CN=C(N1)c1cnc2ccccc2n1 |c:2|, C1CN=C(N1)c1cnc2ccccc2n1 |c:2|, C1CN=C(N1)c1cnc2ccccc2n1 |c:2|, C1CN=C(N1)c1cnc2ccccc2n1 |c:2|, C1CN=C(N1)c1cnc2ccccc2n1 |c:2|, C1CN=C(N1)c1cnc2ccccc2n1 |c:2|, C1CN=C(N1)c1cnc2ccccc2n1 |c:2|	MQSSFHXQKUSFIW-UHFFFAOYSA-N, MQSSFHXQKUSFIW-UHFFFAOYSA-N, MQSSFHXQKUSFIW-UHFFFAOYSA-N, MQSSFHXQKUSFIW-UHFFFAOYSA-N, MQSSFHXQKUSFIW-UHFFFAOYSA-N, MQSSFHXQKUSFIW-UHFFFAOYSA-N, InChI=1S/C11H10N4/c1-2-4-9-8(3-1)14-7-10(15-9)11-12-5-6-13-11/h1-4,7H,5-6H2,(H,12,13)	Preclinical
bucetin	analgesic agent				CCOc1ccc(NC(=O)C[C@@H](C)O)cc1 |&1:11,r|, CCOc1ccc(NC(=O)C[C@@H](C)O)cc1 |&1:11,r|	LIAWQASKBFCRNR-SECBINFHSA-N, LIAWQASKBFCRNR-SECBINFHSA-N	Withdrawn
bucillamine	immunosuppressant		rheumatology	rheumatoid arthritis	CC(C)(S)C(=O)N[C@@H](CS)C(O)=O, CC(C)(S)C(=O)N[C@@H](CS)C(O)=O	VUAFHZCUKUDDBC-BYPYZUCNSA-N, VUAFHZCUKUDDBC-BYPYZUCNSA-N	Launched
bucladesine	adenosine receptor agonist, cAMP stimulant	PRKACA	dermatology	skin ulcer	CCCC(=O)Nc1ncnc2n(cnc12)[C@@H]1O[C@@H]2CO[P@](O)(=O)O[C@H]2[C@H]1OC(=O)CCC |a:15,17,24,25,&1:20|, CCCC(=O)Nc1ncnc2n(cnc12)[C@@H]1O[C@@H]2CO[P@](O)(=O)O[C@H]2[C@H]1OC(=O)CCC |a:15,17,24,25,&1:20|, CCCC(=O)Nc1ncnc2n(cnc12)[C@@H]1O[C@@H]2CO[P@](O)(=O)O[C@H]2[C@H]1OC(=O)CCC |a:15,17,24,25,&1:20|, CCCC(=O)Nc1ncnc2n(cnc12)[C@@H]1O[C@@H]2CO[P@](O)(=O)O[C@H]2[C@H]1OC(=O)CCC |a:15,17,24,25,&1:20|, CCCC(=O)Nc1ncnc2n(cnc12)[C@@H]1O[C@@H]2CO[P@](O)(=O)O[C@H]2[C@H]1OC(=O)CCC |a:15,17,24,25,&1:20|, CCCC(=O)Nc1ncnc2n(cnc12)[C@@H]1O[C@@H]2CO[P@](O)(=O)O[C@H]2[C@H]1OC(=O)CCC |a:15,17,24,25,&1:20|	CJGYSWNGNKCJSB-YVLZZHOMSA-N, CJGYSWNGNKCJSB-YVLZZHOMSA-N, CJGYSWNGNKCJSB-YVLZZHOMSA-N, CJGYSWNGNKCJSB-YVLZZHOMSA-N, CJGYSWNGNKCJSB-YVLZZHOMSA-N, CJGYSWNGNKCJSB-YVLZZHOMSA-N	Launched
buclizine	histamine receptor antagonist	HRH1	neurology/psychiatry	migraine headache	CC(C)(C)c1ccc(CN2CCN(CC2)[C@@H](c2ccccc2)c2ccc(Cl)cc2)cc1 |&1:15|, CC(C)(C)c1ccc(CN2CCN(CC2)[C@@H](c2ccccc2)c2ccc(Cl)cc2)cc1 |&1:15|	MOYGZHXDRJNJEP-MHZLTWQESA-N, MOYGZHXDRJNJEP-MHZLTWQESA-N	Launched
budesonide	glucocorticoid receptor agonist	NR3C1	gastroenterology	Crohn's disease	CCC[C@H]1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO |a:5,7,8,17,19,20,23,25,&1:3,c:15,t:11|, CCC[C@H]1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO |a:5,7,8,17,19,20,23,25,&1:3,c:15,t:11|, CCC[C@H]1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO |a:5,7,8,17,19,20,23,25,&1:3,c:15,t:11|, CCC[C@H]1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO |a:5,7,8,17,19,20,23,25,&1:3,c:15,t:11|, CCC[C@H]1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO |a:5,7,8,17,19,20,23,25,&1:3,c:15,t:11|, CCC[C@H]1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO |a:5,7,8,17,19,20,23,25,&1:3,c:15,t:11|, CCC[C@H]1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO |a:5,7,8,17,19,20,23,25,&1:3,c:15,t:11|, CCC[C@H]1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO |a:5,7,8,17,19,20,23,25,&1:3,c:15,t:11|, CCC[C@H]1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO |a:5,7,8,17,19,20,23,25,&1:3,c:15,t:11|	VOVIALXJUBGFJZ-AMTWPJRWSA-N, VOVIALXJUBGFJZ-AMTWPJRWSA-N, VOVIALXJUBGFJZ-AMTWPJRWSA-N, VOVIALXJUBGFJZ-AMTWPJRWSA-N, VOVIALXJUBGFJZ-AMTWPJRWSA-N, VOVIALXJUBGFJZ-AMTWPJRWSA-N, VOVIALXJUBGFJZ-AMTWPJRWSA-N, VOVIALXJUBGFJZ-AMTWPJRWSA-N, VOVIALXJUBGFJZ-AMTWPJRWSA-N	Launched
budipine	glutamate receptor antagonist	GRIN1	neurology/psychiatry	Parkinson's Disease	CC(C)(C)N1CCC(CC1)(c1ccccc1)c1ccccc1, CC(C)(C)N1CCC(CC1)(c1ccccc1)c1ccccc1	QIHLUZAFSSMXHQ-UHFFFAOYSA-N, QIHLUZAFSSMXHQ-UHFFFAOYSA-N	Launched
bufexamac	cyclooxygenase inhibitor	HDAC10, HDAC6			CCCCOc1ccc(CC(=O)NO)cc1, CCCCOc1ccc(CC(=O)NO)cc1, CCCCOc1ccc(CC(=O)NO)cc1, CCCCOc1ccc(CC(=O)NO)cc1	MXJWRABVEGLYDG-UHFFFAOYSA-N, MXJWRABVEGLYDG-UHFFFAOYSA-N, MXJWRABVEGLYDG-UHFFFAOYSA-N, MXJWRABVEGLYDG-UHFFFAOYSA-N	Withdrawn
buflomedil	adrenergic receptor antagonist, calcium channel blocker	ADRA1A	cardiology	peripheral artery disease (PAD)	COc1cc(OC)c(C(=O)CCCN2CCCC2)c(OC)c1, COc1cc(OC)c(C(=O)CCCN2CCCC2)c(OC)c1, COc1cc(OC)c(C(=O)CCCN2CCCC2)c(OC)c1, COc1cc(OC)c(C(=O)CCCN2CCCC2)c(OC)c1, COc1cc(OC)c(C(=O)CCCN2CCCC2)c(OC)c1, COc1cc(OC)c(C(=O)CCCN2CCCC2)c(OC)c1	OWYLAEYXIQKAOL-UHFFFAOYSA-N, OWYLAEYXIQKAOL-UHFFFAOYSA-N, OWYLAEYXIQKAOL-UHFFFAOYSA-N, OWYLAEYXIQKAOL-UHFFFAOYSA-N, OWYLAEYXIQKAOL-UHFFFAOYSA-N, OWYLAEYXIQKAOL-UHFFFAOYSA-N	Launched
bumetanide	solute carrier family member inhibitor	CFTR, GPR35, SLC12A1, SLC12A2, SLC12A4, SLC12A5	cardiology	edema, congestive heart failure	CCCCNc1cc(cc(c1Oc1ccccc1)S(N)(=O)=O)C(O)=O, CCCCNc1cc(cc(c1Oc1ccccc1)S(N)(=O)=O)C(O)=O, CCCCNc1cc(cc(c1Oc1ccccc1)S(N)(=O)=O)C(O)=O, CCCCNc1cc(cc(c1Oc1ccccc1)S(N)(=O)=O)C(O)=O, CCCCNc1cc(cc(c1Oc1ccccc1)S(N)(=O)=O)C(O)=O	MAEIEVLCKWDQJH-UHFFFAOYSA-N, MAEIEVLCKWDQJH-UHFFFAOYSA-N, MAEIEVLCKWDQJH-UHFFFAOYSA-N, MAEIEVLCKWDQJH-UHFFFAOYSA-N, MAEIEVLCKWDQJH-UHFFFAOYSA-N	Launched
bunazosin	adrenergic receptor antagonist	ADRA1A	ophthalmology	glaucoma, intraocular pressure	CCCC(=O)N1CCCN(CC1)c1nc(N)c2cc(OC)c(OC)cc2n1, CCCC(=O)N1CCCN(CC1)c1nc(N)c2cc(OC)c(OC)cc2n1	RHLJLALHBZGAFM-UHFFFAOYSA-N, RHLJLALHBZGAFM-UHFFFAOYSA-N	Launched
buparlisib	PI3K inhibitor	PIK3CA, PIK3CG			Nc1cc(c(cn1)-c1cc(nc(n1)N1CCOCC1)N1CCOCC1)C(F)(F)F, Nc1cc(c(cn1)-c1cc(nc(n1)N1CCOCC1)N1CCOCC1)C(F)(F)F, Nc1cc(c(cn1)-c1cc(nc(n1)N1CCOCC1)N1CCOCC1)C(F)(F)F	CWHUFRVAEUJCEF-UHFFFAOYSA-N, CWHUFRVAEUJCEF-UHFFFAOYSA-N, CWHUFRVAEUJCEF-UHFFFAOYSA-N	Phase 3
buparvaquone	antiprotozoal agent		infectious disease	protozoan infection	CC(C)(C)C1CCC(C[C@H]2C(=O)C(=O)c3ccccc3C2=O)CC1 |&1:9,r|, CC(C)(C)C1CCC(C[C@H]2C(=O)C(=O)c3ccccc3C2=O)CC1 |&1:9,r|	OMMKCJLAGTXGLC-MQBCKMQZSA-N, OMMKCJLAGTXGLC-MQBCKMQZSA-N	Launched
buphenine	adrenergic receptor agonist	ADRB2	rheumatology	Raynaud's disease	CC(CCc1ccccc1)NC(C)C(O)c1ccc(O)cc1, CC(CCc1ccccc1)NC(C)C(O)c1ccc(O)cc1	PTGXAUBQBSGPKF-UHFFFAOYSA-N, PTGXAUBQBSGPKF-UHFFFAOYSA-N	Launched
bupicomide	adrenergic receptor antagonist	ADRB1			CCCCc1ccc(nc1)C(N)=O, CCCCc1ccc(nc1)C(N)=O	VKSPIPWLHGKJQO-UHFFFAOYSA-N, VKSPIPWLHGKJQO-UHFFFAOYSA-N	Phase 1
bupivacaine	sodium channel blocker	KCNA5, SCN10A	neurology/psychiatry	peripheral nerve block, caudal epidural block, lumbar epidural block	CCCCN1CCCC[C@H]1C(=O)Nc1c(C)cccc1C |&1:9,r|	LEBVLXFERQHONN-INIZCTEOSA-N	Launched
bupranolol	adrenergic receptor antagonist	ADRB1, ADRB2, ADRB3	cardiology, ophthalmology	hypertension, glaucoma	Cc1ccc(Cl)c(OC[C@@H](O)CNC(C)(C)C)c1 |&1:9,r|, Cc1ccc(Cl)c(OC[C@@H](O)CNC(C)(C)C)c1 |&1:9,r|, Cc1ccc(Cl)c(OC[C@@H](O)CNC(C)(C)C)c1 |&1:9,r|, Cc1ccc(Cl)c(OC[C@@H](O)CNC(C)(C)C)c1 |&1:9,r|, Cc1ccc(Cl)c(OC[C@@H](O)CNC(C)(C)C)c1 |&1:9,r|	HQIRNZOQPUAHHV-NSHDSACASA-N, HQIRNZOQPUAHHV-NSHDSACASA-N, HQIRNZOQPUAHHV-NSHDSACASA-N, HQIRNZOQPUAHHV-NSHDSACASA-N, HQIRNZOQPUAHHV-NSHDSACASA-N	Launched
bupropion	dopamine reuptake inhibitor	SLC6A2, SLC6A3	neurology/psychiatry	depression	C[C@@H](NC(C)(C)C)C(=O)c1cccc(Cl)c1 |&1:1,r|	SNPPWIUOZRMYNY-SECBINFHSA-N	Launched
buramate	antiepileptic				OCCOC(=O)NCc1ccccc1, OCCOC(=O)NCc1ccccc1	YFLRYAVDPKONNX-UHFFFAOYSA-N, YFLRYAVDPKONNX-UHFFFAOYSA-N	Preclinical
buserelin	gonadotropin releasing factor hormone receptor agonist		oncology, obstetrics/gynecology	prostate cancer, endometriosis	CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H]1CCC(=O)N1	CUWODFFVMXJOKD-UVLQAERKSA-N	Launched
buspirone	serotonin receptor agonist	DRD2, HTR1A	neurology/psychiatry	generalized anxiety disorder (GAD)	O=C1CC2(CCCC2)CC(=O)N1CCCCN1CCN(CC1)c1ncccn1, O=C1CC2(CCCC2)CC(=O)N1CCCCN1CCN(CC1)c1ncccn1, O=C1CC2(CCCC2)CC(=O)N1CCCCN1CCN(CC1)c1ncccn1, O=C1CC2(CCCC2)CC(=O)N1CCCCN1CCN(CC1)c1ncccn1	QWCRAEMEVRGPNT-UHFFFAOYSA-N, QWCRAEMEVRGPNT-UHFFFAOYSA-N, QWCRAEMEVRGPNT-UHFFFAOYSA-N, QWCRAEMEVRGPNT-UHFFFAOYSA-N	Launched
busulfan	DNA inhibitor		hematologic malignancy	chronic myeloid leukemia (CML)	CS(=O)(=O)OCCCCOS(C)(=O)=O, CS(=O)(=O)OCCCCOS(C)(=O)=O, CS(=O)(=O)OCCCCOS(C)(=O)=O	COVZYZSDYWQREU-UHFFFAOYSA-N, COVZYZSDYWQREU-UHFFFAOYSA-N, COVZYZSDYWQREU-UHFFFAOYSA-N	Launched
butabindide	tripeptidyl peptidase inhibitor	TPP2			CCCCNC(=O)[C@@H]1Cc2ccccc2N1C(=O)[C@@H](N)CC, CCCCNC(=O)[C@@H]1Cc2ccccc2N1C(=O)[C@@H](N)CC	HAQIRIMIVLFYIX-ZFWWWQNUSA-N, HAQIRIMIVLFYIX-ZFWWWQNUSA-N	Preclinical
butacaine	local anesthetic		neurology/psychiatry	local anesthetic	CCCCN(CCCC)CCCOC(=O)c1ccc(N)cc1, CCCCN(CCCC)CCCOC(=O)c1ccc(N)cc1, CCCCN(CCCC)CCCOC(=O)c1ccc(N)cc1	HQFWVSGBVLEQGA-UHFFFAOYSA-N, HQFWVSGBVLEQGA-UHFFFAOYSA-N, HQFWVSGBVLEQGA-UHFFFAOYSA-N	Launched
butaclamol	dopamine receptor antagonist	DRD1, DRD2, DRD3, DRD4, DRD5, HTR1A, HTR2A			CC(C)(C)[C@]1(O)CCN2C[C@H]3c4ccccc4CCc4cccc([C@@H]2C1)c34	ZZJYIKPMDIWRSN-HWBMXIPRSA-N	Phase 2
butalbital	GABA receptor antagonist	CHRNA4, CHRNA7, GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, GRIA2, GRIK2	neurology/psychiatry	headache, muscle relaxant	CC(C)CC1(CC=C)C(=O)NC(=O)NC1=O, CC(C)CC1(CC=C)C(=O)NC(=O)NC1=O	UZVHFVZFNXBMQJ-UHFFFAOYSA-N, UZVHFVZFNXBMQJ-UHFFFAOYSA-N	Launched
butamben	sodium channel blocker				CCCCOC(=O)c1ccc(N)cc1, CCCCOC(=O)c1ccc(N)cc1, CCCCOC(=O)c1ccc(N)cc1	IUWVALYLNVXWKX-UHFFFAOYSA-N, IUWVALYLNVXWKX-UHFFFAOYSA-N, IUWVALYLNVXWKX-UHFFFAOYSA-N	Withdrawn
butaprost	prostaglandin receptor agonist				CCCC1(CCC1)[C@H](O)C\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(=O)OC	XRISENIKJUKIHD-LHQZMKCDSA-N	Preclinical
butein	EGFR inhibitor, SRC inhibitor	ACE			Oc1ccc(C(=O)\C=C\c2ccc(O)c(O)c2)c(O)c1, Oc1ccc(C(=O)\C=C\c2ccc(O)c(O)c2)c(O)c1, Oc1ccc(C(=O)\C=C\c2ccc(O)c(O)c2)c(O)c1, Oc1ccc(C(=O)\C=C\c2ccc(O)c(O)c2)c(O)c1	AYMYWHCQALZEGT-ORCRQEGFSA-N, AYMYWHCQALZEGT-ORCRQEGFSA-N, AYMYWHCQALZEGT-ORCRQEGFSA-N, AYMYWHCQALZEGT-ORCRQEGFSA-N	Preclinical
butenafine	fungal squalene epoxidase inhibitor	SQLE	infectious disease	tinea pedis, tinea cruris, tinea corporis	CN(Cc1ccc(cc1)C(C)(C)C)Cc1cccc2ccccc12, CN(Cc1ccc(cc1)C(C)(C)C)Cc1cccc2ccccc12, CN(Cc1ccc(cc1)C(C)(C)C)Cc1cccc2ccccc12, CN(Cc1ccc(cc1)C(C)(C)C)Cc1cccc2ccccc12	ABJKWBDEJIDSJZ-UHFFFAOYSA-N, ABJKWBDEJIDSJZ-UHFFFAOYSA-N, ABJKWBDEJIDSJZ-UHFFFAOYSA-N, ABJKWBDEJIDSJZ-UHFFFAOYSA-N	Launched
buthionine-sulfoximine	glutathione transferase inhibitor	GCLM			CCCCS(=N)(=O)CC[C@H](N)C(O)=O |a:9,&1:4|	KJQFBVYMGADDTQ-CVSPRKDYSA-N	Phase 1
butibufen	cyclooxygenase inhibitor				CC[C@@H](C(O)=O)c1ccc(CC(C)C)cc1 |&1:2,r|, CC[C@@H](C(O)=O)c1ccc(CC(C)C)cc1 |&1:2,r|, CC[C@@H](C(O)=O)c1ccc(CC(C)C)cc1 |&1:2,r|	UULSXYSSHHRCQK-CYBMUJFWSA-N, UULSXYSSHHRCQK-CYBMUJFWSA-N, UULSXYSSHHRCQK-CYBMUJFWSA-N	Withdrawn
butoconazole	bacterial cell wall synthesis inhibitor		infectious disease	vulvovaginal candidiasis	Clc1ccc(CC[C@@H](Cn2ccnc2)Sc2c(Cl)cccc2Cl)cc1 |&1:7,r|, Clc1ccc(CC[C@@H](Cn2ccnc2)Sc2c(Cl)cccc2Cl)cc1 |&1:7,r|	SWLMUYACZKCSHZ-INIZCTEOSA-N, SWLMUYACZKCSHZ-INIZCTEOSA-N	Launched
butofilolol	adrenergic receptor antagonist				CCCC(=O)c1cc(F)ccc1OC[C@@H](O)CNC(C)(C)C |&1:14,r|	NMBNQRJDEPOXCP-ZDUSSCGKSA-N	Phase 2
butyl-paraben	DNA synthesis inhibitor				CCCCOC(=O)c1ccc(O)cc1, CCCCOC(=O)c1ccc(O)cc1	QFOHBWFCKVYLES-UHFFFAOYSA-N, QFOHBWFCKVYLES-UHFFFAOYSA-N	Preclinical
butylated-hydroxyanisole	antioxidant				COc1ccc(O)c(c1)C(C)(C)C, COc1ccc(O)c(c1)C(C)(C)C	MRBKEAMVRSLQPH-UHFFFAOYSA-N, MRBKEAMVRSLQPH-UHFFFAOYSA-N	Preclinical
butylated-hydroxytoluene	carbonic anhydrase inhibitor	CA2			Cc1cc(c(O)c(c1)C(C)(C)C)C(C)(C)C, Cc1cc(c(O)c(c1)C(C)(C)C)C(C)(C)C, Cc1cc(c(O)c(c1)C(C)(C)C)C(C)(C)C	NLZUEZXRPGMBCV-UHFFFAOYSA-N, NLZUEZXRPGMBCV-UHFFFAOYSA-N, NLZUEZXRPGMBCV-UHFFFAOYSA-N	Phase 1
butylidenephthalide	cyclooxygenase inhibitor				CCC\C=C1/OC(=O)c2ccccc12	WMBOCUXXNSOQHM-FLIBITNWSA-N	Phase 1/Phase 2
butylphthalide	potassium channel antagonist	KCNK2	neurology/psychiatry	stroke	CCCC[C@H]1OC(=O)c2ccccc12 |&1:4,r|	HJXMNVQARNZTEE-LLVKDONJSA-N	Launched
butylscopolamine-bromide	cholinergic receptor antagonist		gastroenterology	abdominal pain	CCCC[N@@+]1(C)[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)c1ccccc1 |a:6,8,10,11,13,17,&1:4,TLB:3:4:7.8.9:11.13,12:11:4:7.8.9,12:13:4:7.8.9,THB:5:4:7.8.9:11.13,14:8:4:11.13|	YBCNXCRZPWQOBR-FRNBUXIHSA-N	Launched
BU226	imidazoline receptor ligand				C1CN=C(N1)c1cc2ccccc2cn1 |c:2|, C1CN=C(N1)c1cc2ccccc2cn1 |c:2|, C1CN=C(N1)c1cc2ccccc2cn1 |c:2|, C1CN=C(N1)c1cc2ccccc2cn1 |c:2|	ZXRSVNHYTSSFMN-UHFFFAOYSA-N, ZXRSVNHYTSSFMN-UHFFFAOYSA-N, ZXRSVNHYTSSFMN-UHFFFAOYSA-N, ZXRSVNHYTSSFMN-UHFFFAOYSA-N	Preclinical
BVD-523	MAP kinase inhibitor				CC(C)Nc1cc(-c2c[nH]c(c2)C(=O)N[C@H](CO)c2cccc(Cl)c2)c(Cl)cn1, CC(C)Nc1cc(-c2c[nH]c(c2)C(=O)N[C@H](CO)c2cccc(Cl)c2)c(Cl)cn1, CC(C)Nc1cc(-c2c[nH]c(c2)C(=O)N[C@H](CO)c2cccc(Cl)c2)c(Cl)cn1	KSERXGMCDHOLSS-LJQANCHMSA-N, KSERXGMCDHOLSS-LJQANCHMSA-N, KSERXGMCDHOLSS-LJQANCHMSA-N	Phase 2
BVT-2733	11-beta hydroxysteroid dehydrogenase inhibitor	HSD17B1			CN1CCN(CC1)C(=O)Cc1csc(NS(=O)(=O)c2cccc(Cl)c2C)n1	YDPRNGAPPNPYQQ-UHFFFAOYSA-N	Preclinical
BVT-948	tyrosine phosphatase inhibitor	PTPN1, PTPN11, PTPN2			CC1(C)C(=O)NC2=C1C(=O)C(=O)c1ccccc21 |c:6|, CC1(C)C(=O)NC2=C1C(=O)C(=O)c1ccccc21 |c:6|	LLPBUXODFQZPFH-UHFFFAOYSA-N, LLPBUXODFQZPFH-UHFFFAOYSA-N	Preclinical
BW-A4C	lipoxygenase inhibitor	ALOX5			CC(=O)N(O)C\C=C\c1cccc(Oc2ccccc2)c1, CC(=O)N(O)C\C=C\c1cccc(Oc2ccccc2)c1	CEUDWZXMLMKPNN-SOFGYWHQSA-N, CEUDWZXMLMKPNN-SOFGYWHQSA-N	Phase 1
BW-B70C	lipoxygenase inhibitor	ALOX5			C[C@@H](\C=C\c1cccc(Oc2ccc(F)cc2)c1)N(O)C(N)=O |&1:1,r|, C[C@@H](\C=C\c1cccc(Oc2ccc(F)cc2)c1)N(O)C(N)=O |&1:1,r|	UAIYNMRLUHHRMF-FYJFLYSWSA-N, UAIYNMRLUHHRMF-FYJFLYSWSA-N	Preclinical
BW-180C	opioid receptor agonist	OPRD1, OPRM1			CC(C)C[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)[C@@H](C)NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(O)=O	ZHUJMSMQIPIPTF-IBURTVSXSA-N	Phase 2
BW-348U87	antiviral				C\C(=N/NC(=S)NNC(=S)Nc1ccccc1Cl)c1ccccn1	YYLKOELWSMRYHV-VXLYETTFSA-N	Preclinical
BW-373U86	opioid receptor agonist	OPRD1			CCN(CC)C(=O)c1ccc(cc1)[C@@H](N1C[C@@H](C)N(CC=C)C[C@@H]1C)c1cccc(O)c1, CCN(CC)C(=O)c1ccc(cc1)[C@@H](N1C[C@@H](C)N(CC=C)C[C@@H]1C)c1cccc(O)c1, CCN(CC)C(=O)c1ccc(cc1)[C@@H](N1C[C@@H](C)N(CC=C)C[C@@H]1C)c1cccc(O)c1	LBLDMHBSVIVJPM-YZIHRLCOSA-N, LBLDMHBSVIVJPM-YZIHRLCOSA-N, LBLDMHBSVIVJPM-YZIHRLCOSA-N	Preclinical
BW-616U	monoamine oxidase inhibitor	MAOA			CNC(=O)c1ccc2C(=O)c3ccccc3S(=O)(=O)c2c1, CNC(=O)c1ccc2C(=O)c3ccccc3S(=O)(=O)c2c1	MLPSDBJCWIYSEA-UHFFFAOYSA-N, MLPSDBJCWIYSEA-UHFFFAOYSA-N	Preclinical
BW-723C86	serotonin receptor agonist	HTR2A, HTR2B, HTR2C			C[C@@H](N)Cc1c[nH]c2ccc(OCc3cccs3)cc12 |&1:1|, C[C@@H](N)Cc1c[nH]c2ccc(OCc3cccs3)cc12 |&1:1|, C[C@@H](N)Cc1c[nH]c2ccc(OCc3cccs3)cc12 |&1:1|	ALFGDCNSEBJYSP-LLVKDONJSA-N, ALFGDCNSEBJYSP-LLVKDONJSA-N, ALFGDCNSEBJYSP-LLVKDONJSA-N	Preclinical
BX-795	IKK inhibitor	CDK2, CHEK1, GSK3B, KDR, PDK1, PDPK1			Ic1cnc(Nc2cccc(NC(=O)N3CCCC3)c2)nc1NCCCNC(=O)c1cccs1, Ic1cnc(Nc2cccc(NC(=O)N3CCCC3)c2)nc1NCCCNC(=O)c1cccs1, Ic1cnc(Nc2cccc(NC(=O)N3CCCC3)c2)nc1NCCCNC(=O)c1cccs1, Ic1cnc(Nc2cccc(NC(=O)N3CCCC3)c2)nc1NCCCNC(=O)c1cccs1	VAVXGGRQQJZYBL-UHFFFAOYSA-N, VAVXGGRQQJZYBL-UHFFFAOYSA-N, VAVXGGRQQJZYBL-UHFFFAOYSA-N, VAVXGGRQQJZYBL-UHFFFAOYSA-N	Preclinical
BX-912	pyruvate dehydrogenase kinase inhibitor	CDK2, CHEK1, GSK3B, KDR, PDK1, PDPK1			Brc1cnc(Nc2cccc(NC(=O)N3CCCC3)c2)nc1NCCc1cnc[nH]1, Brc1cnc(Nc2cccc(NC(=O)N3CCCC3)c2)nc1NCCc1cnc[nH]1	DMMILYKXNCVKOJ-UHFFFAOYSA-N, DMMILYKXNCVKOJ-UHFFFAOYSA-N	Preclinical
BYK-204165	PARP inhibitor	PARP1			Cn1cccc1\C=C1/C(=O)NC(=O)c2ccccc12, Cn1cccc1\C=C1/C(=O)NC(=O)c2ccccc12, Cn1cccc1\C=C1/C(=O)NC(=O)c2ccccc12, Cn1cccc1\C=C1/C(=O)NC(=O)c2ccccc12, Cn1cccc1\C=C1/C(=O)NC(=O)c2ccccc12, Cn1cccc1\C=C1/C(=O)NC(=O)c2ccccc12, Cn1cccc1\C=C1/C(=O)NC(=O)c2ccccc12	BTYSIDSTHDDAJW-LCYFTJDESA-N, BTYSIDSTHDDAJW-LCYFTJDESA-N, BTYSIDSTHDDAJW-LCYFTJDESA-N, BTYSIDSTHDDAJW-LCYFTJDESA-N, BTYSIDSTHDDAJW-LCYFTJDESA-N, BTYSIDSTHDDAJW-LCYFTJDESA-N, BTYSIDSTHDDAJW-LCYFTJDESA-N	Preclinical
C-021	CC chemokine receptor antagonist	CCR4			COc1cc2nc(nc(NC3CCCCCC3)c2cc1OC)N1CCC(CC1)N1CCCCC1, COc1cc2nc(nc(NC3CCCCCC3)c2cc1OC)N1CCC(CC1)N1CCCCC1, COc1cc2nc(nc(NC3CCCCCC3)c2cc1OC)N1CCC(CC1)N1CCCCC1, COc1cc2nc(nc(NC3CCCCCC3)c2cc1OC)N1CCC(CC1)N1CCCCC1, COc1cc2nc(nc(NC3CCCCCC3)c2cc1OC)N1CCC(CC1)N1CCCCC1, COc1cc2nc(nc(NC3CCCCCC3)c2cc1OC)N1CCC(CC1)N1CCCCC1	WYVBISCFCHREDA-UHFFFAOYSA-N, WYVBISCFCHREDA-UHFFFAOYSA-N, WYVBISCFCHREDA-UHFFFAOYSA-N, WYVBISCFCHREDA-UHFFFAOYSA-N, WYVBISCFCHREDA-UHFFFAOYSA-N, WYVBISCFCHREDA-UHFFFAOYSA-N	Preclinical
C-1	protein kinase inhibitor	PRKCA			O=S(=O)(N1CCNCC1)c1cccc2cnccc12, O=S(=O)(N1CCNCC1)c1cccc2cnccc12, O=S(=O)(N1CCNCC1)c1cccc2cnccc12, O=S(=O)(N1CCNCC1)c1cccc2cnccc12	UPTYCYWTFGTCCG-UHFFFAOYSA-N, UPTYCYWTFGTCCG-UHFFFAOYSA-N, UPTYCYWTFGTCCG-UHFFFAOYSA-N, UPTYCYWTFGTCCG-UHFFFAOYSA-N	Preclinical
C-751					CCOC(=O)c1cnc[nH]1	KLWYPRNPRNPORS-UHFFFAOYSA-N	Preclinical
CA-4948	kinase inhibitor				Nc1ccc(cn1)-c1cccc(n1)C(=O)Nc1cnc2nc(oc2c1)N1CCOCC1	RWIMETUXCNDSLE-UHFFFAOYSA-N	Phase 1
cabagin			gastroenterology	dyspepsia	C[S+](C)CC[C@H](N)C(O)=O, C[S+](C)CC[C@H](N)C(O)=O	YDBYJHTYSHBBAU-YFKPBYRVSA-O, YDBYJHTYSHBBAU-YFKPBYRVSA-O	Launched
cabaletta	pharmacological chaperone				OC[C@H]1O[C@H](O[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@@H](O)[C@@H]1O	HDTRYLNUVZCQOY-LIZSDCNHSA-N	Phase 2
cabazitaxel	microtubule inhibitor	TUBA1A, TUBA1B, TUBA1C, TUBA3C, TUBA3D, TUBA3E, TUBA4A, TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8	oncology	prostate cancer	CO[C@H]1C[C@H]2OC[C@@]2(OC(C)=O)[C@H]2[C@H](OC(=O)c3ccccc3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c4ccccc4)C(C)=C([C@@H](OC)C(=O)[C@]12C)C3(C)C |t:51|	BMQGVNUXMIRLCK-OAGWZNDDSA-N	Launched
cabergoline	dopamine receptor agonist	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, DRD1, DRD2, DRD3, DRD4, DRD5, HTR1A, HTR1B, HTR1D, HTR2A, HTR2B, HTR2C, HTR7	endocrinology	hyperprolactinemia	CCNC(=O)N(CCCN(C)C)C(=O)[C@@H]1C[C@H]2[C@@H](Cc3c[nH]c4cccc2c34)N(CC=C)C1, CCNC(=O)N(CCCN(C)C)C(=O)[C@@H]1C[C@H]2[C@@H](Cc3c[nH]c4cccc2c34)N(CC=C)C1, CCNC(=O)N(CCCN(C)C)C(=O)[C@@H]1C[C@H]2[C@@H](Cc3c[nH]c4cccc2c34)N(CC=C)C1, CCNC(=O)N(CCCN(C)C)C(=O)[C@@H]1C[C@H]2[C@@H](Cc3c[nH]c4cccc2c34)N(CC=C)C1, CCNC(=O)N(CCCN(C)C)C(=O)[C@@H]1C[C@H]2[C@@H](Cc3c[nH]c4cccc2c34)N(CC=C)C1, CCNC(=O)N(CCCN(C)C)C(=O)[C@@H]1C[C@H]2[C@@H](Cc3c[nH]c4cccc2c34)N(CC=C)C1	KORNTPPJEAJQIU-KJXAQDMKSA-N, KORNTPPJEAJQIU-KJXAQDMKSA-N, KORNTPPJEAJQIU-KJXAQDMKSA-N, KORNTPPJEAJQIU-KJXAQDMKSA-N, KORNTPPJEAJQIU-KJXAQDMKSA-N, KORNTPPJEAJQIU-KJXAQDMKSA-N	Launched
cabotegravir	HIV integrase inhibitor				C[C@H]1CO[C@@H]2Cn3cc(C(=O)NCc4ccc(F)cc4F)c(=O)c(O)c3C(=O)N12, C[C@H]1CO[C@@H]2Cn3cc(C(=O)NCc4ccc(F)cc4F)c(=O)c(O)c3C(=O)N12	WCWSTNLSLKSJPK-LKFCYVNXSA-N, WCWSTNLSLKSJPK-LKFCYVNXSA-N	Phase 3
cabozantinib	RET tyrosine kinase inhibitor, VEGFR inhibitor	KDR, MET, RET	oncology	medullary thyroid cancer (MTC)	COc1cc2nccc(Oc3ccc(NC(=O)C4(CC4)C(=O)Nc4ccc(F)cc4)cc3)c2cc1OC, COc1cc2nccc(Oc3ccc(NC(=O)C4(CC4)C(=O)Nc4ccc(F)cc4)cc3)c2cc1OC, COc1cc2nccc(Oc3ccc(NC(=O)C4(CC4)C(=O)Nc4ccc(F)cc4)cc3)c2cc1OC, COc1cc2nccc(Oc3ccc(NC(=O)C4(CC4)C(=O)Nc4ccc(F)cc4)cc3)c2cc1OC, COc1cc2nccc(Oc3ccc(NC(=O)C4(CC4)C(=O)Nc4ccc(F)cc4)cc3)c2cc1OC, COc1cc2nccc(Oc3ccc(NC(=O)C4(CC4)C(=O)Nc4ccc(F)cc4)cc3)c2cc1OC, COc1cc2nccc(Oc3ccc(NC(=O)C4(CC4)C(=O)Nc4ccc(F)cc4)cc3)c2cc1OC, COc1cc2nccc(Oc3ccc(NC(=O)C4(CC4)C(=O)Nc4ccc(F)cc4)cc3)c2cc1OC, COc1cc2nccc(Oc3ccc(NC(=O)C4(CC4)C(=O)Nc4ccc(F)cc4)cc3)c2cc1OC, COc1cc2nccc(Oc3ccc(NC(=O)C4(CC4)C(=O)Nc4ccc(F)cc4)cc3)c2cc1OC	ONIQOQHATWINJY-UHFFFAOYSA-N, ONIQOQHATWINJY-UHFFFAOYSA-N, ONIQOQHATWINJY-UHFFFAOYSA-N, ONIQOQHATWINJY-UHFFFAOYSA-N, ONIQOQHATWINJY-UHFFFAOYSA-N, ONIQOQHATWINJY-UHFFFAOYSA-N, InChI=1S/C28H24FN3O5/c1-35-24-15-21-22(16-25(24)36-2)30-14-11-23(21)37-20-9-7-19(8-10-20)32-27(34)28(12-13-28)26(33)31-18-5-3-17(29)4-6-18/h3-11,14-16H,12-13H2,1-2H3,(H,31,33)(H,32,34), InChI=1S/C28H24FN3O5/c1-35-24-15-21-22(16-25(24)36-2)30-14-11-23(21)37-20-9-7-19(8-10-20)32-27(34)28(12-13-28)26(33)31-18-5-3-17(29)4-6-18/h3-11,14-16H,12-13H2,1-2H3,(H,31,33)(H,32,34), InChI=1S/C28H24FN3O5/c1-35-24-15-21-22(16-25(24)36-2)30-14-11-23(21)37-20-9-7-19(8-10-20)32-27(34)28(12-13-28)26(33)31-18-5-3-17(29)4-6-18/h3-11,14-16H,12-13H2,1-2H3,(H,31,33)(H,32,34), InChI=1S/C28H24FN3O5/c1-35-24-15-21-22(16-25(24)36-2)30-14-11-23(21)37-20-9-7-19(8-10-20)32-27(34)28(12-13-28)26(33)31-18-5-3-17(29)4-6-18/h3-11,14-16H,12-13H2,1-2H3,(H,31,33)(H,32,34)	Launched
CaCCinh-A01	calcium-activated chloride channel inhibitor	CLCA1			CC(C)(C)[C@H]1CCc2c(C1)sc(NC(=O)c1ccco1)c2C(O)=O |&1:4,r|, CC(C)(C)[C@H]1CCc2c(C1)sc(NC(=O)c1ccco1)c2C(O)=O |&1:4,r|	ACLUEOBQFRYTQS-JTQLQIEISA-N, ACLUEOBQFRYTQS-JTQLQIEISA-N	Preclinical
cadazolid	antibacterial 				OC[C@H]1CN(C(=O)O1)c1ccc(OCC2(O)CCN(CC2)c2cc3n(cc(C(O)=O)c(=O)c3cc2F)C2CC2)c(F)c1	XWFCFMXQTBGXQW-GOSISDBHSA-N	Phase 3
cadralazine	adrenergic receptor antagonist		cardiology	hypertension	CCOC(=O)NNc1ccc(nn1)N(CC)C[C@@H](C)O |&1:17,r|, CCOC(=O)NNc1ccc(nn1)N(CC)C[C@@H](C)O |&1:17,r|	QLTVVOATEHFXLT-SECBINFHSA-N, QLTVVOATEHFXLT-SECBINFHSA-N	Launched
cafestol	pregnane X receptor agonist				C[C@@]12CCc3occc3[C@H]1CC[C@@]13C[C@@H](CC[C@@H]21)[C@@](O)(CO)C3	DNJVYWXIDISQRD-HWUKTEKMSA-N	Launched
caffeic-acid	HIV integrase inhibitor, lipoxygenase inhibitor, nitric oxide production inhibitor, tumor necrosis factor production inhibitor	ALOX5, MIF			OC(=O)\C=C\c1ccc(O)c(O)c1, OC(=O)\C=C\c1ccc(O)c(O)c1, OC(=O)\C=C\c1ccc(O)c(O)c1, OC(=O)\C=C\c1ccc(O)c(O)c1	QAIPRVGONGVQAS-DUXPYHPUSA-N, QAIPRVGONGVQAS-DUXPYHPUSA-N, QAIPRVGONGVQAS-DUXPYHPUSA-N, QAIPRVGONGVQAS-DUXPYHPUSA-N	Preclinical
caffeic-acid-phenethyl-ester	HIV integrase inhibitor	RELA			Oc1ccc(\C=C\C(=O)OCCc2ccccc2)cc1O, Oc1ccc(\C=C\C(=O)OCCc2ccccc2)cc1O, Oc1ccc(\C=C\C(=O)OCCc2ccccc2)cc1O	SWUARLUWKZWEBQ-VQHVLOKHSA-N, SWUARLUWKZWEBQ-VQHVLOKHSA-N, SWUARLUWKZWEBQ-VQHVLOKHSA-N	Preclinical
caffeine	adenosine receptor antagonist, phosphodiesterase inhibitor	ADORA1, ADORA2A, ADORA2B, ADORA3, ATM, ITPR1, ITPR2, ITPR3, PDE10A, PDE11A, PDE1A, PDE1B, PDE1C, PDE2A, PDE3A, PDE3B, PDE4A, PDE4B, PDE4C, PDE4D, PDE5A, PDE6A, PDE6B, PDE6C, PDE7A, PDE7B, PDE8A, PDE8B, PDE9A, PIK3CA, PIK3CB, PIK3CD, PRKDC, RYR1, RYR2, RYR3	neurology/psychiatry	fatigue, drowsiness	Cn1cnc2n(C)c(=O)n(C)c(=O)c12, Cn1cnc2n(C)c(=O)n(C)c(=O)c12, Cn1cnc2n(C)c(=O)n(C)c(=O)c12	RYYVLZVUVIJVGH-UHFFFAOYSA-N, RYYVLZVUVIJVGH-UHFFFAOYSA-N, RYYVLZVUVIJVGH-UHFFFAOYSA-N	Launched
calcifediol	vitamin D receptor agonist	VDR	endocrinology	hyperparathyroidism	C[C@H](CCCC(C)(C)O)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)CCC1=C, C[C@H](CCCC(C)(C)O)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)CCC1=C, C[C@H](CCCC(C)(C)O)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)CCC1=C, C[C@H](CCCC(C)(C)O)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)CCC1=C, C[C@H](CCCC(C)(C)O)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)CCC1=C, C[C@H](CCCC(C)(C)O)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)CCC1=C	JWUBBDSIWDLEOM-DTOXIADCSA-N, JWUBBDSIWDLEOM-DTOXIADCSA-N, JWUBBDSIWDLEOM-DTOXIADCSA-N, JWUBBDSIWDLEOM-DTOXIADCSA-N, JWUBBDSIWDLEOM-DTOXIADCSA-N, JWUBBDSIWDLEOM-DTOXIADCSA-N	Launched
calcipotriol	vitamin D receptor agonist	VDR	dermatology	psoriasis	C[C@H](\C=C\[C@@H](O)C1CC1)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C, C[C@H](\C=C\[C@@H](O)C1CC1)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C, C[C@H](\C=C\[C@@H](O)C1CC1)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C, C[C@H](\C=C\[C@@H](O)C1CC1)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C, C[C@H](\C=C\[C@@H](O)C1CC1)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C, C[C@H](\C=C\[C@@H](O)C1CC1)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C, C[C@H](\C=C\[C@@H](O)C1CC1)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C, C[C@H](\C=C\[C@@H](O)C1CC1)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C	LWQQLNNNIPYSNX-UROSTWAQSA-N, LWQQLNNNIPYSNX-UROSTWAQSA-N, LWQQLNNNIPYSNX-UROSTWAQSA-N, LWQQLNNNIPYSNX-UROSTWAQSA-N, LWQQLNNNIPYSNX-UROSTWAQSA-N, LWQQLNNNIPYSNX-UROSTWAQSA-N, LWQQLNNNIPYSNX-UROSTWAQSA-N, LWQQLNNNIPYSNX-UROSTWAQSA-N	Launched
calcitonin	calcitonin agonist		orthopedics	osteoporosis	[H]N[C@H]1CSSC[C@H](NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CO)NC1=O)[C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](Cc1c[nH]cn1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(N)=O |r|	JDJALSWDQPEHEJ-XXZWWZJQSA-N	Launched
calcitriol	vitamin D receptor agonist	VDR	endocrinology, orthopedics	hypocalcemia, hypoparathyroidism, osteoporosis	C[C@H](CCCC(C)(C)O)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C, C[C@H](CCCC(C)(C)O)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C, C[C@H](CCCC(C)(C)O)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C, C[C@H](CCCC(C)(C)O)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C, C[C@H](CCCC(C)(C)O)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C, C[C@H](CCCC(C)(C)O)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C, C[C@H](CCCC(C)(C)O)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C, C[C@H](CCCC(C)(C)O)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C, C[C@H](CCCC(C)(C)O)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C, C[C@H](CCCC(C)(C)O)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C	GMRQFYUYWCNGIN-NKMMMXOESA-N, GMRQFYUYWCNGIN-NKMMMXOESA-N, GMRQFYUYWCNGIN-NKMMMXOESA-N, GMRQFYUYWCNGIN-NKMMMXOESA-N, GMRQFYUYWCNGIN-NKMMMXOESA-N, GMRQFYUYWCNGIN-NKMMMXOESA-N, GMRQFYUYWCNGIN-NKMMMXOESA-N, GMRQFYUYWCNGIN-NKMMMXOESA-N, GMRQFYUYWCNGIN-NKMMMXOESA-N, GMRQFYUYWCNGIN-NKMMMXOESA-N	Launched
calcium-gluceptate					OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O)C(O)=O, OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O)C(O)=O, OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O)C(O)=O, OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O)C(O)=O, OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O)C(O)=O	KWMLJOLKUYYJFJ-VFUOTHLCSA-N, KWMLJOLKUYYJFJ-VFUOTHLCSA-N, KWMLJOLKUYYJFJ-VFUOTHLCSA-N, KWMLJOLKUYYJFJ-VFUOTHLCSA-N, KWMLJOLKUYYJFJ-VFUOTHLCSA-N	Launched
calcium-levofolinate					Nc1nc(=O)c2N(C=O)[C@@H](CNc3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)CNc2[nH]1, Nc1nc(=O)c2N(C=O)[C@@H](CNc3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)CNc2[nH]1, Nc1nc(=O)c2N(C=O)[C@@H](CNc3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)CNc2[nH]1, Nc1nc(=O)c2N(C=O)[C@@H](CNc3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)CNc2[nH]1	VVIAGPKUTFNRDU-STQMWFEESA-N, VVIAGPKUTFNRDU-STQMWFEESA-N, VVIAGPKUTFNRDU-STQMWFEESA-N, VVIAGPKUTFNRDU-STQMWFEESA-N	Launched
Calhex-231	calcium sensing receptor negative allosteric modulator	CASR			C[C@@H](N[C@H]1CCCC[C@@H]1NC(=O)c1ccc(Cl)cc1)c1cccc2ccccc12, C[C@@H](N[C@H]1CCCC[C@@H]1NC(=O)c1ccc(Cl)cc1)c1cccc2ccccc12, C[C@@H](N[C@H]1CCCC[C@@H]1NC(=O)c1ccc(Cl)cc1)c1cccc2ccccc12	YTFUQWWKTIWYEY-CQLNOVPUSA-N, YTFUQWWKTIWYEY-CQLNOVPUSA-N, YTFUQWWKTIWYEY-CQLNOVPUSA-N	Preclinical
calpeptin	calpain inhibitor				CCCC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)OCc1ccccc1)C=O, CCCC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)OCc1ccccc1)C=O, CCCC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)OCc1ccccc1)C=O, CCCC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)OCc1ccccc1)C=O, CCCC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)OCc1ccccc1)C=O, CCCC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)OCc1ccccc1)C=O, CCCC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)OCc1ccccc1)C=O, CCCC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)OCc1ccccc1)C=O	PGGUOGKHUUUWAF-ROUUACIJSA-N, PGGUOGKHUUUWAF-ROUUACIJSA-N, PGGUOGKHUUUWAF-ROUUACIJSA-N, PGGUOGKHUUUWAF-ROUUACIJSA-N, PGGUOGKHUUUWAF-ROUUACIJSA-N, PGGUOGKHUUUWAF-ROUUACIJSA-N, PGGUOGKHUUUWAF-ROUUACIJSA-N, PGGUOGKHUUUWAF-ROUUACIJSA-N	Preclinical
camicinal	motilin receptor agonist	MLNR			C[C@H]1CN(Cc2ccc(CC(=O)N3CCC(CC3)Nc3cccc(F)c3)cc2)CCN1, C[C@H]1CN(Cc2ccc(CC(=O)N3CCC(CC3)Nc3cccc(F)c3)cc2)CCN1, C[C@H]1CN(Cc2ccc(CC(=O)N3CCC(CC3)Nc3cccc(F)c3)cc2)CCN1	RZKDEGZIFSJVNA-IBGZPJMESA-N, RZKDEGZIFSJVNA-IBGZPJMESA-N, RZKDEGZIFSJVNA-IBGZPJMESA-N	Phase 2
CaMKII-IN-1	calcium/calmodulin dependent protein kinase inhibitor	AKT1, CAMK2A, CAMK4, MYLK			Cc1c(Cl)cccc1S(=O)(=O)Nc1nc(NCCc2ccccc2)nc2CCN(Cc3ccccc3)Cc12, Cc1c(Cl)cccc1S(=O)(=O)Nc1nc(NCCc2ccccc2)nc2CCN(Cc3ccccc3)Cc12	LGUUETDTMQTHML-UHFFFAOYSA-N, LGUUETDTMQTHML-UHFFFAOYSA-N	Preclinical
camobucol	anti-inflammatory agent				CC(C)(C)c1cc(SC(C)(C)Sc2cc(c(OCC(O)=O)c(c2)C(C)(C)C)C(C)(C)C)cc(c1O)C(C)(C)C	FGBGXESDYFKUFX-UHFFFAOYSA-N	Preclinical
camostat-mesilate	protease inhibitor	PRSS1	gastroenterology	pancreatitis	CN(C)C(=O)COC(=O)Cc1ccc(OC(=O)c2ccc(NC(N)=N)cc2)cc1, CN(C)C(=O)COC(=O)Cc1ccc(OC(=O)c2ccc(NC(N)=N)cc2)cc1, CN(C)C(=O)COC(=O)Cc1ccc(OC(=O)c2ccc(NC(N)=N)cc2)cc1	XASIMHXSUQUHLV-UHFFFAOYSA-N, XASIMHXSUQUHLV-UHFFFAOYSA-N, XASIMHXSUQUHLV-UHFFFAOYSA-N	Launched
camphor-(+)					CC1(C)[C@@H]2CC[C@@]1(C)C(=O)C2, CC1(C)[C@@H]2CC[C@@]1(C)C(=O)C2	DSSYKIVIOFKYAU-XCBNKYQSSA-N, DSSYKIVIOFKYAU-XCBNKYQSSA-N	Phase 2
camphor-(1R)	TRPV activator	TRPV1			CC1(C)[C@@H]2CC[C@]1(C)C(=O)C2	DSSYKIVIOFKYAU-GMSGAONNSA-N	Phase 1
camptothecin	topoisomerase inhibitor	TOP1			CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccccc4cc3Cn1c2=O, CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccccc4cc3Cn1c2=O, CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccccc4cc3Cn1c2=O, CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccccc4cc3Cn1c2=O, CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccccc4cc3Cn1c2=O, CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccccc4cc3Cn1c2=O	VSJKWCGYPAHWDS-FQEVSTJZSA-N, VSJKWCGYPAHWDS-FQEVSTJZSA-N, VSJKWCGYPAHWDS-FQEVSTJZSA-N, VSJKWCGYPAHWDS-FQEVSTJZSA-N, VSJKWCGYPAHWDS-FQEVSTJZSA-N, VSJKWCGYPAHWDS-FQEVSTJZSA-N	Phase 3
camylofine-chlorhydrate			gastroenterology	abdominal pain	CCN(CC)CCN[C@@H](C(=O)OCCC(C)C)c1ccccc1 |&1:8|, CCN(CC)CCN[C@@H](C(=O)OCCC(C)C)c1ccccc1 |&1:8|, CCN(CC)CCN[C@@H](C(=O)OCCC(C)C)c1ccccc1 |&1:8|	RYOOHIUJEJZCFT-GOSISDBHSA-N, RYOOHIUJEJZCFT-GOSISDBHSA-N, RYOOHIUJEJZCFT-GOSISDBHSA-N	Launched
canagliflozin	sodium/glucose cotransporter inhibitor	SLC5A1, SLC5A2	endocrinology	diabetes mellitus	Cc1ccc(cc1Cc1ccc(s1)-c1ccc(F)cc1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O, Cc1ccc(cc1Cc1ccc(s1)-c1ccc(F)cc1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O, Cc1ccc(cc1Cc1ccc(s1)-c1ccc(F)cc1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O	XTNGUQKDFGDXSJ-ZXGKGEBGSA-N, XTNGUQKDFGDXSJ-ZXGKGEBGSA-N, XTNGUQKDFGDXSJ-ZXGKGEBGSA-N	Launched
candesartan	angiotensin receptor antagonist	AGTR1	cardiology	hypertension, congestive heart failure	CCOc1nc2cccc(C(O)=O)c2n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1, CCOc1nc2cccc(C(O)=O)c2n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1, CCOc1nc2cccc(C(O)=O)c2n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1, CCOc1nc2cccc(C(O)=O)c2n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1, CCOc1nc2cccc(C(O)=O)c2n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1, CCOc1nc2cccc(C(O)=O)c2n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1	HTQMVQVXFRQIKW-UHFFFAOYSA-N, HTQMVQVXFRQIKW-UHFFFAOYSA-N, HTQMVQVXFRQIKW-UHFFFAOYSA-N, HTQMVQVXFRQIKW-UHFFFAOYSA-N, HTQMVQVXFRQIKW-UHFFFAOYSA-N, HTQMVQVXFRQIKW-UHFFFAOYSA-N	Launched
candesartan-cilexetil	angiotensin receptor antagonist		cardiology	hypertension, congestive heart failure, hypertension	CCOc1nc2cccc(C(=O)O[C@@H](C)OC(=O)OC3CCCCC3)c2n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1 |&1:13,r|, CCOc1nc2cccc(C(=O)O[C@@H](C)OC(=O)OC3CCCCC3)c2n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1 |&1:13,r|, CCOc1nc2cccc(C(=O)O[C@@H](C)OC(=O)OC3CCCCC3)c2n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1 |&1:13,r|, CCOc1nc2cccc(C(=O)O[C@@H](C)OC(=O)OC3CCCCC3)c2n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1 |&1:13,r|, CCOc1nc2cccc(C(=O)O[C@@H](C)OC(=O)OC3CCCCC3)c2n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1 |&1:13,r|, CCOc1nc2cccc(C(=O)O[C@@H](C)OC(=O)OC3CCCCC3)c2n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1 |&1:13,r|, CCOc1nc2cccc(C(=O)O[C@@H](C)OC(=O)OC3CCCCC3)c2n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1 |&1:13,r|	GHOSNRCGJFBJIB-OAQYLSRUSA-N, GHOSNRCGJFBJIB-OAQYLSRUSA-N, GHOSNRCGJFBJIB-OAQYLSRUSA-N, GHOSNRCGJFBJIB-OAQYLSRUSA-N, GHOSNRCGJFBJIB-OAQYLSRUSA-N, GHOSNRCGJFBJIB-OAQYLSRUSA-N, GHOSNRCGJFBJIB-OAQYLSRUSA-N	Launched
candicidin	fungal ergosterol inhibitor		infectious disease	vulvovaginal candidiasis	C[C@@H](C[C@@H](C)[C@H]1OC(=O)CC(=O)CCCC(=O)C[C@@H](O)C[C@@H](O)C[C@@H](O)CC(=O)C[C@@H](O)[C@@H]([C@@H](O)C[C@@H](O[C@@H]2O[C@H](C)[C@H](O)[C@@H](O)[C@@H]2N)\C=C\C=C\C=C\C=C\C=C\C=C\C=C\[C@@H]1C)C(O)=O)[C@@H](O)CC(=O)c1ccc(N)cc1 |a:38,40,42,44,46,&1:1,&2:3,&3:5,&4:18,&5:21,&6:24,&7:30,&8:32,&9:33,&10:36,&11:62,&12:67,t:49,51,53,55,57,59,61|	HYIZCDMXFDRDFE-RGXQRFNASA-N	Launched
canertinib	EGFR inhibitor	AKT1, EGFR, ERBB2, ERBB4			Fc1ccc(Nc2ncnc3cc(OCCCN4CCOCC4)c(NC(=O)C=C)cc23)cc1Cl, Fc1ccc(Nc2ncnc3cc(OCCCN4CCOCC4)c(NC(=O)C=C)cc23)cc1Cl, Fc1ccc(Nc2ncnc3cc(OCCCN4CCOCC4)c(NC(=O)C=C)cc23)cc1Cl, Fc1ccc(Nc2ncnc3cc(OCCCN4CCOCC4)c(NC(=O)C=C)cc23)cc1Cl, Fc1ccc(Nc2ncnc3cc(OCCCN4CCOCC4)c(NC(=O)C=C)cc23)cc1Cl, Fc1ccc(Nc2ncnc3cc(OCCCN4CCOCC4)c(NC(=O)C=C)cc23)cc1Cl, Fc1ccc(Nc2ncnc3cc(OCCCN4CCOCC4)c(NC(=O)C=C)cc23)cc1Cl	OMZCMEYTWSXEPZ-UHFFFAOYSA-N, OMZCMEYTWSXEPZ-UHFFFAOYSA-N, OMZCMEYTWSXEPZ-UHFFFAOYSA-N, OMZCMEYTWSXEPZ-UHFFFAOYSA-N, InChI=1S/C24H25ClFN5O3/c1-2-23(32)30-21-13-17-20(14-22(21)34-9-3-6-31-7-10-33-11-8-31)27-15-28-24(17)29-16-4-5-19(26)18(25)12-16/h2,4-5,12-15H,1,3,6-11H2,(H,30,32)(H,27,28,29), InChI=1S/C24H25ClFN5O3/c1-2-23(32)30-21-13-17-20(14-22(21)34-9-3-6-31-7-10-33-11-8-31)27-15-28-24(17)29-16-4-5-19(26)18(25)12-16/h2,4-5,12-15H,1,3,6-11H2,(H,30,32)(H,27,28,29), InChI=1S/C24H25ClFN5O3/c1-2-23(32)30-21-13-17-20(14-22(21)34-9-3-6-31-7-10-33-11-8-31)27-15-28-24(17)29-16-4-5-19(26)18(25)12-16/h2,4-5,12-15H,1,3,6-11H2,(H,30,32)(H,27,28,29)	Phase 3
cangrelor	purinergic receptor antagonist		cardiology	myocardial infarction	CSCCNc1nc(SCCC(F)(F)F)nc2n(cnc12)[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)C(Cl)(Cl)P(O)(O)=O)[C@@H](O)[C@H]1O	PAEBIVWUMLRPSK-IDTAVKCVSA-N	Launched
canrenone	mineralocorticoid receptor antagonist	NR3C2			C[C@]12CC[C@H]3[C@@H](C=CC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@@]21CCC(=O)O1 |c:6,t:8|	UJVLDDZCTMKXJK-WNHSNXHDSA-N	Withdrawn
cantharidin	protein phosphatase inhibitor		dermatology	blisters	C[C@]12[C@@H]3CC[C@@H](O3)[C@@]1(C)C(=O)OC2=O, C[C@]12[C@@H]3CC[C@@H](O3)[C@@]1(C)C(=O)OC2=O, C[C@]12[C@@H]3CC[C@@H](O3)[C@@]1(C)C(=O)OC2=O, C[C@]12[C@@H]3CC[C@@H](O3)[C@@]1(C)C(=O)OC2=O	DHZBEENLJMYSHQ-XCVPVQRUSA-N, DHZBEENLJMYSHQ-XCVPVQRUSA-N, DHZBEENLJMYSHQ-XCVPVQRUSA-N, DHZBEENLJMYSHQ-XCVPVQRUSA-N	Launched
capadenoson	adenosine receptor agonist	ADORA1			Nc1nc(SCc2csc(n2)-c2ccc(Cl)cc2)c(C#N)c(-c2ccc(OCCO)cc2)c1C#N, Nc1nc(SCc2csc(n2)-c2ccc(Cl)cc2)c(C#N)c(-c2ccc(OCCO)cc2)c1C#N, Nc1nc(SCc2csc(n2)-c2ccc(Cl)cc2)c(C#N)c(-c2ccc(OCCO)cc2)c1C#N	CITWCLNVRIKQAF-UHFFFAOYSA-N, CITWCLNVRIKQAF-UHFFFAOYSA-N, CITWCLNVRIKQAF-UHFFFAOYSA-N	Phase 2
capecitabine	DNA synthesis inhibitor, thymidylate synthase inhibitor	TYMS	oncology	breast cancer, colorectal cancer	CCCCCOC(=O)Nc1nc(=O)n(cc1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O, CCCCCOC(=O)Nc1nc(=O)n(cc1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O, CCCCCOC(=O)Nc1nc(=O)n(cc1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O, CCCCCOC(=O)Nc1nc(=O)n(cc1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O, CCCCCOC(=O)Nc1nc(=O)n(cc1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O, CCCCCOC(=O)Nc1nc(=O)n(cc1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O, CCCCCOC(=O)Nc1nc(=O)n(cc1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O	GAGWJHPBXLXJQN-UORFTKCHSA-N, GAGWJHPBXLXJQN-UORFTKCHSA-N, GAGWJHPBXLXJQN-UORFTKCHSA-N, GAGWJHPBXLXJQN-UORFTKCHSA-N, GAGWJHPBXLXJQN-UORFTKCHSA-N, GAGWJHPBXLXJQN-UORFTKCHSA-N, GAGWJHPBXLXJQN-UORFTKCHSA-N	Launched
capobenic-acid					COc1cc(cc(OC)c1OC)C(=O)NCCCCCC(O)=O	MPTXLVRHYGBOQY-UHFFFAOYSA-N	Preclinical
capreomycin	protein synthesis inhibitor		infectious disease	tuberculosis	C[C@@H]1NC(=O)[C@@H](N)CNC(=O)[C@@H](NC(=O)\C(NC(=O)[C@H](CNC(=O)C[C@@H](N)CCCN)NC1=O)=C/NC(N)=O)[C@H]1CCN=C(N)N1 |t:43|	FRXNXDHFQYZYNA-GJTMSUEESA-N	Launched
capromorelin	growth hormone secretagogue receptor agonist				CN1N=C2CCN(C[C@@]2(Cc2ccccc2)C1=O)C(=O)[C@@H](COCc1ccccc1)NC(=O)C(C)(C)N |t:2|	KVLLHLWBPNCVNR-SKCUWOTOSA-N	Preclinical
caprylic-acid					CCCCCCCC(O)=O, CCCCCCCC(O)=O	WWZKQHOCKIZLMA-UHFFFAOYSA-N, WWZKQHOCKIZLMA-UHFFFAOYSA-N	Launched
capsaicin	TRPV agonist	CFTR, TRPV1	neurology/psychiatry, rheumatology	muscle pain, rheumatoid arthritis	COc1cc(CNC(=O)CCCC\C=C\C(C)C)ccc1O, COc1cc(CNC(=O)CCCC\C=C\C(C)C)ccc1O	YKPUWZUDDOIDPM-SOFGYWHQSA-N, YKPUWZUDDOIDPM-SOFGYWHQSA-N	Launched
capsazepine	TRPV agonist	TRPV1, TRPV4			Oc1cc2CCCN(Cc2cc1O)C(=S)NCCc1ccc(Cl)cc1, Oc1cc2CCCN(Cc2cc1O)C(=S)NCCc1ccc(Cl)cc1, Oc1cc2CCCN(Cc2cc1O)C(=S)NCCc1ccc(Cl)cc1, Oc1cc2CCCN(Cc2cc1O)C(=S)NCCc1ccc(Cl)cc1	DRCMAZOSEIMCHM-UHFFFAOYSA-N, DRCMAZOSEIMCHM-UHFFFAOYSA-N, DRCMAZOSEIMCHM-UHFFFAOYSA-N, DRCMAZOSEIMCHM-UHFFFAOYSA-N	Preclinical
captamine					CN(C)CCS, CN(C)CCS	DENMGZODXQRYAR-UHFFFAOYSA-N, DENMGZODXQRYAR-UHFFFAOYSA-N	Preclinical
captan					ClC(Cl)(Cl)SN1C(=O)[C@H]2CC=CC[C@@H]2C1=O |r,c:10|	LDVVMCZRFWMZSG-WDSKDSINSA-N	Phase 1
captopril	angiotensin converting enzyme inhibitor	ACE, LTA4H, MMP2, MMP9	cardiology, endocrinology, nephrology	hypertension, congestive heart failure, myocardial infarction, diabetes mellitus, diabetic nephropathy	C[C@H](CS)C(=O)N1CCC[C@H]1C(O)=O, C[C@H](CS)C(=O)N1CCC[C@H]1C(O)=O, C[C@H](CS)C(=O)N1CCC[C@H]1C(O)=O, C[C@H](CS)C(=O)N1CCC[C@H]1C(O)=O, C[C@H](CS)C(=O)N1CCC[C@H]1C(O)=O	FAKRSMQSSFJEIM-RQJHMYQMSA-N, FAKRSMQSSFJEIM-RQJHMYQMSA-N, FAKRSMQSSFJEIM-RQJHMYQMSA-N, FAKRSMQSSFJEIM-RQJHMYQMSA-N, FAKRSMQSSFJEIM-RQJHMYQMSA-N	Launched
caracemide	ribonucleotide reductase inhibitor	RRM1			CNC(=O)ON(C(C)=O)C(=O)NC, CNC(=O)ON(C(C)=O)C(=O)NC	JURAJLFHWXNPHG-UHFFFAOYSA-N, JURAJLFHWXNPHG-UHFFFAOYSA-N	Phase 2
caramiphen	cholinergic receptor antagonist	CHRM1, CHRM2	neurology/psychiatry	Parkinson's Disease	CCN(CC)CCOC(=O)C1(CCCC1)c1ccccc1, CCN(CC)CCOC(=O)C1(CCCC1)c1ccccc1	OFAIGZWCDGNZGT-UHFFFAOYSA-N, OFAIGZWCDGNZGT-UHFFFAOYSA-N	Launched
carazolol	adrenergic receptor antagonist	ADRB1, ADRB2, ADRB3	cardiology	angina pectoris, cardiac arrythmia, hypertension, myocardial infarction	CC(C)NC[C@@H](O)COc1cccc2[nH]c3ccccc3c12 |&1:5,r|, CC(C)NC[C@@H](O)COc1cccc2[nH]c3ccccc3c12 |&1:5,r|	BQXQGZPYHWWCEB-CYBMUJFWSA-N, BQXQGZPYHWWCEB-CYBMUJFWSA-N	Launched
carbachol	cholinergic receptor agonist	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, CHRNA2	ophthalmology	intraocular pressure	C[N+](C)(C)CCOC(N)=O, C[N+](C)(C)CCOC(N)=O, C[N+](C)(C)CCOC(N)=O	VPJXQGSRWJZDOB-UHFFFAOYSA-O, VPJXQGSRWJZDOB-UHFFFAOYSA-O, VPJXQGSRWJZDOB-UHFFFAOYSA-O	Launched
carbadox	other antibiotic		infectious disease, gastroenterology	dysentry, enteritis	COC(=O)N\N=C\c1c[n+]([O-])c2ccccc2[n+]1[O-], COC(=O)N\N=C\c1c[n+]([O-])c2ccccc2[n+]1[O-], COC(=O)N\N=C\c1c[n+]([O-])c2ccccc2[n+]1[O-], COC(=O)N\N=C\c1c[n+]([O-])c2ccccc2[n+]1[O-], COC(=O)N\N=C\c1c[n+]([O-])c2ccccc2[n+]1[O-], COC(=O)N\N=C\c1c[n+]([O-])c2ccccc2[n+]1[O-]	OVGGLBAWFMIPPY-WUXMJOGZSA-N, OVGGLBAWFMIPPY-WUXMJOGZSA-N, OVGGLBAWFMIPPY-WUXMJOGZSA-N, OVGGLBAWFMIPPY-WUXMJOGZSA-N, OVGGLBAWFMIPPY-WUXMJOGZSA-N, OVGGLBAWFMIPPY-WUXMJOGZSA-N	Launched
carbamazepine	carboxamide antiepileptic	SCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A	neurology/psychiatry	seizures	NC(=O)N1c2ccccc2C=Cc2ccccc12 |c:11|, NC(=O)N1c2ccccc2C=Cc2ccccc12 |c:11|, NC(=O)N1c2ccccc2C=Cc2ccccc12 |c:11|, NC(=O)N1c2ccccc2C=Cc2ccccc12 |c:11|	FFGPTBGBLSHEPO-UHFFFAOYSA-N, FFGPTBGBLSHEPO-UHFFFAOYSA-N, FFGPTBGBLSHEPO-UHFFFAOYSA-N, FFGPTBGBLSHEPO-UHFFFAOYSA-N	Launched
carbaril	acetylcholinesterase inhibitor				CNC(=O)Oc1cccc2ccccc12, CNC(=O)Oc1cccc2ccccc12	CVXBEEMKQHEXEN-UHFFFAOYSA-N, CVXBEEMKQHEXEN-UHFFFAOYSA-N	Launched
carbarsone	antiprotozoal agent		infectious disease	amebiasis	NC(=O)Nc1ccc(cc1)[As](O)(O)=O, NC(=O)Nc1ccc(cc1)[As](O)(O)=O	WWXBHTZSYYGCSG-UHFFFAOYSA-N, WWXBHTZSYYGCSG-UHFFFAOYSA-N	Launched
carbazochrome			hematology	hemorrhage	CN1[C@@H](CC2=C\C(=N\NC(N)=O)C(=O)C=C12)S(O)(=O)=O |&1:2,t:4,14|, CN1[C@@H](CC2=C\C(=N\NC(N)=O)C(=O)C=C12)S(O)(=O)=O |&1:2,t:4,14|, CN1[C@@H](CC2=C\C(=N\NC(N)=O)C(=O)C=C12)S(O)(=O)=O |&1:2,t:4,14|	OZCACMPSTYQSMM-DKBJHAQFSA-N, OZCACMPSTYQSMM-DKBJHAQFSA-N, OZCACMPSTYQSMM-DKBJHAQFSA-N	Launched
carbendazim	microtubule inhibitor, tubulin polymerization inhibitor	TP53, TUBB	infectious disease	fungicide	COC(=O)Nc1nc2ccccc2[nH]1, COC(=O)Nc1nc2ccccc2[nH]1	TWFZGCMQGLPBSX-UHFFFAOYSA-N, TWFZGCMQGLPBSX-UHFFFAOYSA-N	Launched
carbenicillin	bacterial cell wall synthesis inhibitor		infectious disease	gram-negative bacterial infections	CC1(C)S[C@@H]2[C@H](NC(=O)[C@@H](C(O)=O)c3ccccc3)C(=O)N2[C@H]1C(O)=O |a:4,5,22,&1:9|, CC1(C)S[C@@H]2[C@H](NC(=O)[C@@H](C(O)=O)c3ccccc3)C(=O)N2[C@H]1C(O)=O |a:4,5,22,&1:9|, CC1(C)S[C@@H]2[C@H](NC(=O)[C@@H](C(O)=O)c3ccccc3)C(=O)N2[C@H]1C(O)=O |a:4,5,22,&1:9|, CC1(C)S[C@@H]2[C@H](NC(=O)[C@@H](C(O)=O)c3ccccc3)C(=O)N2[C@H]1C(O)=O |a:4,5,22,&1:9|, CC1(C)S[C@@H]2[C@H](NC(=O)[C@@H](C(O)=O)c3ccccc3)C(=O)N2[C@H]1C(O)=O |a:4,5,22,&1:9|	FPPNZSSZRUTDAP-BBGACYKPSA-N, FPPNZSSZRUTDAP-BBGACYKPSA-N, FPPNZSSZRUTDAP-BBGACYKPSA-N, FPPNZSSZRUTDAP-BBGACYKPSA-N, FPPNZSSZRUTDAP-BBGACYKPSA-N	Launched
carbenoxolone	11-beta hydroxysteroid dehydrogenase inhibitor	GJA1, GJA10, GJA3, GJA4, GJA5, GJA8, GJA9, GJB1, GJB2, GJB3, GJB4, GJB5, GJB6, GJB7, GJC1, GJC2, GJC3, GJD2, GJD3, GJD4, GJE1, HSD11B1, PANX1, PANX2, PANX3	gastroenterology, dental	peptic ulcer disease (PUD), mouth inflammation	CC1(C)[C@H](CC[C@@]2(C)[C@H]1CC[C@]1(C)[C@@H]2C(=O)C=C2[C@@H]3C[C@](C)(CC[C@]3(C)CC[C@@]12C)C(O)=O)OC(=O)CCC(O)=O |t:18|	OBZHEBDUNPOCJG-WBXJDKIVSA-N	Launched
carbetapentane	acetylcholine receptor antagonist	CHRM2	otolaryngology, pulmonary	common cold, nasal congestion, bronchitis	CCN(CC)CCOCCOC(=O)C1(CCCC1)c1ccccc1, CCN(CC)CCOCCOC(=O)C1(CCCC1)c1ccccc1	CFJMRBQWBDQYMK-UHFFFAOYSA-N, CFJMRBQWBDQYMK-UHFFFAOYSA-N	Launched
carbetocin	oxytocin receptor agonist	OXTR	hematology	hemorrhage	CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(OC)cc2)NC(=O)CCCSC[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC1=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O	NSTRIRCPWQHTIA-CPWZVOFUSA-N	Launched
carbidopa	aromatic L-amino acid decarboxylase inhibitor	DDC	neurology/psychiatry	Parkinson's Disease	C[C@@](Cc1ccc(O)c(O)c1)(NN)C(O)=O, C[C@@](Cc1ccc(O)c(O)c1)(NN)C(O)=O, C[C@@](Cc1ccc(O)c(O)c1)(NN)C(O)=O, C[C@@](Cc1ccc(O)c(O)c1)(NN)C(O)=O, C[C@@](Cc1ccc(O)c(O)c1)(NN)C(O)=O	TZFNLOMSOLWIDK-JTQLQIEISA-N, TZFNLOMSOLWIDK-JTQLQIEISA-N, TZFNLOMSOLWIDK-JTQLQIEISA-N, TZFNLOMSOLWIDK-JTQLQIEISA-N, TZFNLOMSOLWIDK-JTQLQIEISA-N	Launched
carbimazole	antithyroid agent	TPO	endocrinology	hyperthyroidism	CCOC(=O)n1ccn(C)c1=S, CCOC(=O)n1ccn(C)c1=S, CCOC(=O)n1ccn(C)c1=S, CCOC(=O)n1ccn(C)c1=S	CFOYWRHIYXMDOT-UHFFFAOYSA-N, CFOYWRHIYXMDOT-UHFFFAOYSA-N, CFOYWRHIYXMDOT-UHFFFAOYSA-N, CFOYWRHIYXMDOT-UHFFFAOYSA-N	Launched
carbinoxamine	histamine receptor antagonist	HRH1	allergy, ophthalmology, otolaryngology, dermatology	allergic rhinitis, conjunctivitis, vasomotor rhinitis, dermatographism	CN(C)CCO[C@@H](c1ccc(Cl)cc1)c1ccccn1 |&1:6|	OJFSXZCBGQGRNV-INIZCTEOSA-N	Launched
carboplatin	DNA alkylating agent, DNA inhibitor		oncology	ovarian cancer	N[Pt]1(N)OC(=O)C2(CCC2)C(=O)O1, N[Pt]1(N)OC(=O)C2(CCC2)C(=O)O1, N[Pt]1(N)OC(=O)C2(CCC2)C(=O)O1, N[Pt]1(N)OC(=O)C2(CCC2)C(=O)O1, N[Pt]1(N)OC(=O)C2(CCC2)C(=O)O1, N[Pt]1(N)OC(=O)C2(CCC2)C(=O)O1, N[Pt]1(N)OC(=O)C2(CCC2)C(=O)O1	YAYRGNWWLMLWJE-UHFFFAOYSA-L, YAYRGNWWLMLWJE-UHFFFAOYSA-L, YAYRGNWWLMLWJE-UHFFFAOYSA-L, YAYRGNWWLMLWJE-UHFFFAOYSA-L, YAYRGNWWLMLWJE-UHFFFAOYSA-L, YAYRGNWWLMLWJE-UHFFFAOYSA-L, YAYRGNWWLMLWJE-UHFFFAOYSA-L	Launched
carboxyamidotriazole	calcium channel blocker	CXCL8			NC(=O)c1nnn(Cc2cc(Cl)c(C(=O)c3ccc(Cl)cc3)c(Cl)c2)c1N, NC(=O)c1nnn(Cc2cc(Cl)c(C(=O)c3ccc(Cl)cc3)c(Cl)c2)c1N, NC(=O)c1nnn(Cc2cc(Cl)c(C(=O)c3ccc(Cl)cc3)c(Cl)c2)c1N, NC(=O)c1nnn(Cc2cc(Cl)c(C(=O)c3ccc(Cl)cc3)c(Cl)c2)c1N	WNRZHQBJSXRYJK-UHFFFAOYSA-N, WNRZHQBJSXRYJK-UHFFFAOYSA-N, WNRZHQBJSXRYJK-UHFFFAOYSA-N, WNRZHQBJSXRYJK-UHFFFAOYSA-N	Phase 3
carboxylosartan	angiotensin antagonist	AGTR1			CCCCc1nc(Cl)c(C(O)=O)n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1	ZEUXAIYYDDCIRX-UHFFFAOYSA-N	Phase 1
carboxypyridine-disulfide					OC(=O)c1ccc(SSc2ccc(cn2)C(O)=O)nc1, OC(=O)c1ccc(SSc2ccc(cn2)C(O)=O)nc1, OC(=O)c1ccc(SSc2ccc(cn2)C(O)=O)nc1	GSASOFRDSIKDSN-UHFFFAOYSA-N, GSASOFRDSIKDSN-UHFFFAOYSA-N, GSASOFRDSIKDSN-UHFFFAOYSA-N	Phase 2
cardiogenol-C	cardiomyogenesis inducer				COc1ccc(Nc2nccc(NCCO)n2)cc1, COc1ccc(Nc2nccc(NCCO)n2)cc1, COc1ccc(Nc2nccc(NCCO)n2)cc1	LKBSMPFEKIBRGC-UHFFFAOYSA-N, LKBSMPFEKIBRGC-UHFFFAOYSA-N, LKBSMPFEKIBRGC-UHFFFAOYSA-N	Preclinical
cardionogen-1	WNT signaling inhibitor	CTNNB1			C1CCC(CC1)c1nn2c(nnc2s1)-c1ccco1, C1CCC(CC1)c1nn2c(nnc2s1)-c1ccco1	SWTUPSNBTSPBIH-UHFFFAOYSA-N, SWTUPSNBTSPBIH-UHFFFAOYSA-N	Preclinical
carebastine	histamine receptor antagonist	HRH1			CC(C)(C(O)=O)c1ccc(cc1)C(=O)CCCN1CCC(CC1)OC(c1ccccc1)c1ccccc1	XGHOVGYJHWQGCC-UHFFFAOYSA-N	Phase 1
carfilzomib	proteasome inhibitor	PSMA1, PSMA2, PSMA3, PSMA4, PSMA5, PSMA6, PSMA7, PSMA8, PSMB1, PSMB10, PSMB11, PSMB2, PSMB3, PSMB4, PSMB5, PSMB6, PSMB7, PSMB8, PSMB9	hematologic malignancy	multiple myeloma	CC(C)C[C@H](NC(=O)[C@H](CCc1ccccc1)NC(=O)CN1CCOCC1)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC(C)C)C(=O)[C@@]1(C)CO1, CC(C)C[C@H](NC(=O)[C@H](CCc1ccccc1)NC(=O)CN1CCOCC1)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC(C)C)C(=O)[C@@]1(C)CO1, CC(C)C[C@H](NC(=O)[C@H](CCc1ccccc1)NC(=O)CN1CCOCC1)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC(C)C)C(=O)[C@@]1(C)CO1, CC(C)C[C@H](NC(=O)[C@H](CCc1ccccc1)NC(=O)CN1CCOCC1)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC(C)C)C(=O)[C@@]1(C)CO1, CC(C)C[C@H](NC(=O)[C@H](CCc1ccccc1)NC(=O)CN1CCOCC1)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC(C)C)C(=O)[C@@]1(C)CO1, CC(C)C[C@H](NC(=O)[C@H](CCc1ccccc1)NC(=O)CN1CCOCC1)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC(C)C)C(=O)[C@@]1(C)CO1, CC(C)C[C@H](NC(=O)[C@H](CCc1ccccc1)NC(=O)CN1CCOCC1)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC(C)C)C(=O)[C@@]1(C)CO1, CC(C)C[C@H](NC(=O)[C@H](CCc1ccccc1)NC(=O)CN1CCOCC1)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC(C)C)C(=O)[C@@]1(C)CO1	BLMPQMFVWMYDKT-NZTKNTHTSA-N, BLMPQMFVWMYDKT-NZTKNTHTSA-N, BLMPQMFVWMYDKT-NZTKNTHTSA-N, BLMPQMFVWMYDKT-NZTKNTHTSA-N, BLMPQMFVWMYDKT-NZTKNTHTSA-N, BLMPQMFVWMYDKT-NZTKNTHTSA-N, BLMPQMFVWMYDKT-NZTKNTHTSA-N, BLMPQMFVWMYDKT-NZTKNTHTSA-N	Launched
carglumic-acid	carbamoyl phosphate synthase activator	CPS1	metabolism	hyperammonemia	NC(=O)N[C@@H](CCC(O)=O)C(O)=O, NC(=O)N[C@@H](CCC(O)=O)C(O)=O	LCQLHJZYVOQKHU-VKHMYHEASA-N, LCQLHJZYVOQKHU-VKHMYHEASA-N	Launched
caricotamide	NADPH quinone oxidoreductase inhibitor	NQO2			NC(=O)CN1C=CCC(=C1)C(N)=O |c:5,8|	WEJRSYKFMCUCRQ-UHFFFAOYSA-N	Phase 2
cariporide	sodium/hydrogen exchanger inhibitor	SLC9A1			CC(C)c1ccc(cc1S(C)(=O)=O)C(=O)N=C(N)N	IWXNYAIICFKCTM-UHFFFAOYSA-N	Phase 3
cariprazine	dopamine receptor antagonist	DRD2, DRD3	neurology/psychiatry	schizophrenia	CN(C)C(=O)N[C@H]1CC[C@H](CCN2CCN(CC2)c2cccc(Cl)c2Cl)CC1 |r|, CN(C)C(=O)N[C@H]1CC[C@H](CCN2CCN(CC2)c2cccc(Cl)c2Cl)CC1 |r|	KPWSJANDNDDRMB-QAQDUYKDSA-N, KPWSJANDNDDRMB-QAQDUYKDSA-N	Launched
carmofur	thymidylate synthase inhibitor	TYMS	oncology	breast cancer, colorectal cancer	CCCCCCNC(=O)n1cc(F)c(=O)[nH]c1=O, CCCCCCNC(=O)n1cc(F)c(=O)[nH]c1=O, CCCCCCNC(=O)n1cc(F)c(=O)[nH]c1=O, CCCCCCNC(=O)n1cc(F)c(=O)[nH]c1=O	AOCCBINRVIKJHY-UHFFFAOYSA-N, AOCCBINRVIKJHY-UHFFFAOYSA-N, AOCCBINRVIKJHY-UHFFFAOYSA-N, AOCCBINRVIKJHY-UHFFFAOYSA-N	Launched
carmoterol	adrenergic receptor agonist	ADRB2			COc1ccc(C[C@@H](C)NC[C@H](O)c2ccc(O)c3[nH]c(=O)ccc23)cc1	IHOXNOQMRZISPV-YJYMSZOUSA-N	Phase 2
carmoxirole	dopamine receptor agonist	DRD2			OC(=O)c1ccc2[nH]cc(CCCCN3CCC(=CC3)c3ccccc3)c2c1 |c:17|, OC(=O)c1ccc2[nH]cc(CCCCN3CCC(=CC3)c3ccccc3)c2c1 |c:17|, OC(=O)c1ccc2[nH]cc(CCCCN3CCC(=CC3)c3ccccc3)c2c1 |c:17|	AFSOIHMEOKEZJF-UHFFFAOYSA-N, AFSOIHMEOKEZJF-UHFFFAOYSA-N, AFSOIHMEOKEZJF-UHFFFAOYSA-N	Phase 2
carmustine	DNA alkylating agent, DNA inhibitor	GSR	hematologic malignancy, oncology	non-Hodgkin lymphoma (NHL), Hodgkin's lymphoma, multiple myeloma, glioblastoma, brainstem glioma, medulloblastoma, astrocytoma, ependymoma	[O-][NH2+]N(CCCl)C(=O)NCCCl, [O-][NH2+]N(CCCl)C(=O)NCCCl	IIJOAQBKDPUMEO-UHFFFAOYSA-N, IIJOAQBKDPUMEO-UHFFFAOYSA-N	Launched
carnitine-(D/L)					C[N+](C)(C)C[C@@H](O)CC(O)=O |&1:5|, C[N+](C)(C)C[C@@H](O)CC(O)=O |&1:5|, C[N+](C)(C)C[C@@H](O)CC(O)=O |&1:5|, C[N+](C)(C)C[C@@H](O)CC(O)=O |&1:5|	PHIQHXFUZVPYII-LURJTMIESA-O, PHIQHXFUZVPYII-LURJTMIESA-O, PHIQHXFUZVPYII-LURJTMIESA-O, PHIQHXFUZVPYII-LURJTMIESA-O	Phase 3
carnosine	antiglycating agent				NCCC(=O)N[C@@H](Cc1cnc[nH]1)C(O)=O |&1:6,r|	CQOVPNPJLQNMDC-ZETCQYMHSA-N	Phase 2
caroverin	cytochrome P450 inhibitor				CCN(CC)CCn1c2ccccc2nc(Cc2ccc(OC)cc2)c1=O, CCN(CC)CCn1c2ccccc2nc(Cc2ccc(OC)cc2)c1=O	MSPRUJDUTKRMLM-UHFFFAOYSA-N, MSPRUJDUTKRMLM-UHFFFAOYSA-N	Phase 3
caroxazone	monoamine oxidase inhibitor	MAOA, MAOB			NC(=O)CN1Cc2ccccc2OC1=O, NC(=O)CN1Cc2ccccc2OC1=O, NC(=O)CN1Cc2ccccc2OC1=O	KYCBWEZLKCTALM-UHFFFAOYSA-N, KYCBWEZLKCTALM-UHFFFAOYSA-N, KYCBWEZLKCTALM-UHFFFAOYSA-N	Withdrawn
carprofen	cyclooxygenase inhibitor	PTGS2	rheumatology	osteoarthritis	C[C@@H](C(O)=O)c1ccc2c(c1)[nH]c1ccc(Cl)cc21 |&1:1,r|, C[C@@H](C(O)=O)c1ccc2c(c1)[nH]c1ccc(Cl)cc21 |&1:1,r|, C[C@@H](C(O)=O)c1ccc2c(c1)[nH]c1ccc(Cl)cc21 |&1:1,r|	PUXBGTOOZJQSKH-MRVPVSSYSA-N, PUXBGTOOZJQSKH-MRVPVSSYSA-N, PUXBGTOOZJQSKH-MRVPVSSYSA-N	Launched
carsalam	analgesic agent				O=c1[nH]c(=O)c2ccccc2o1, O=c1[nH]c(=O)c2ccccc2o1	OAYRYNVEFFWSHK-UHFFFAOYSA-N, OAYRYNVEFFWSHK-UHFFFAOYSA-N	Preclinical
carteolol	adrenergic receptor antagonist	ADRB1, ADRB2, ADRB3	ophthalmology	intraocular pressure, glaucoma, ocular hypertension	CC(C)(C)NCC(O)COc1cccc2NC(=O)CCc12	LWAFSWPYPHEXKX-UHFFFAOYSA-N	Launched
carumonam	bacterial cell wall synthesis inhibitor		infectious disease	urinary tract infections, gram-negative bacterial infections	NC(=O)OC[C@@H]1[C@H](NC(=O)C(=N/OCC(O)=O)\c2csc(N)n2)C(=O)N1S(O)(=O)=O	UIMOJFJSJSIGLV-JNHMLNOCSA-N	Launched
carvedilol	adrenergic receptor antagonist	ADRB1, ADRB2, ADRB3	cardiology	myocardial infarction, hypertension	COc1ccccc1OCCNC[C@@H](O)COc1cccc2[nH]c3ccccc3c12 |&1:13|, COc1ccccc1OCCNC[C@@H](O)COc1cccc2[nH]c3ccccc3c12 |&1:13|	OGHNVEJMJSYVRP-QGZVFWFLSA-N, OGHNVEJMJSYVRP-QGZVFWFLSA-N	Launched
carzenide		CA1, CA12, CA14, CA2, CA6, CA9			NS(=O)(=O)c1ccc(cc1)C(O)=O	UCAGLBKTLXCODC-UHFFFAOYSA-N	Preclinical
casanthranol-variant			gastroenterology	constipation	OC[C@H]1O[C@@H](Oc2c3cccc(O)c3c(O)c3c(O)cc(CO)cc23)[C@H](O)[C@H](O)[C@H]1O, OC[C@H]1O[C@@H](Oc2c3cccc(O)c3c(O)c3c(O)cc(CO)cc23)[C@H](O)[C@H](O)[C@H]1O	XMCJWIFCIIXRGI-BAEVKLAGSA-N, XMCJWIFCIIXRGI-BAEVKLAGSA-N	Launched
casin	GTPase inhibitor	CDC42			OCCN[C@H]1CCCc2c1[nH]c1ccc(cc21)-c1ccccc1 |&1:4,r|, OCCN[C@H]1CCCc2c1[nH]c1ccc(cc21)-c1ccccc1 |&1:4,r|	RXIUMAOXORBRCY-IBGZPJMESA-N, RXIUMAOXORBRCY-IBGZPJMESA-N	Preclinical
caspofungin	bacterial cell wall synthesis inhibitor, fungal 1,3-beta-D-glucan synthase inhibitor		infectious disease	candidemia, esophageal candidiasis, aspergillosis, peritonitis, fungal infection	[H][C@@]12C[C@@H](O)CN1C(=O)[C@@H](NC(=O)[C@H](C[C@@H](O)[C@@H](NCCN)NC(=O)[C@@H]1[C@@H](O)CCN1C(=O)[C@@H](NC(=O)[C@@H](NC2=O)[C@H](O)[C@@H](O)c1ccc(O)cc1)[C@H](O)CCN)NC(=O)CCCCCCCC[C@@H](C)C[C@@H](C)CC)[C@@H](C)O	JYIKNQVWKBUSNH-WVDDFWQHSA-N	Launched
castanospermine	glucosidase inhibitor	GAA, GBA			O[C@H]1CCN2C[C@H](O)[C@@H](O)[C@H](O)[C@@H]12, O[C@H]1CCN2C[C@H](O)[C@@H](O)[C@H](O)[C@@H]12	JDVVGAQPNNXQDW-TVNFTVLESA-N, JDVVGAQPNNXQDW-TVNFTVLESA-N	Phase 2
catharanthine	tubulin polymerization inhibitor				CCC1=C[C@@H]2CN3CCc4c([nH]c5ccccc45)[C@@](C2)([C@@H]13)C(=O)OC |t:2|, CCC1=C[C@@H]2CN3CCc4c([nH]c5ccccc45)[C@@](C2)([C@@H]13)C(=O)OC |t:2|, CCC1=C[C@@H]2CN3CCc4c([nH]c5ccccc45)[C@@](C2)([C@@H]13)C(=O)OC |t:2|	CMKFQVZJOWHHDV-NQZBTDCJSA-N, CMKFQVZJOWHHDV-NQZBTDCJSA-N, CMKFQVZJOWHHDV-NQZBTDCJSA-N	Preclinical
cathepsin-inhibitor-1	cathepsin inhibitor	CTSB, CTSL, CTSV			Cn1nc(cc1C(=O)N[C@@H](Cc1cccc(Cl)c1)C(=O)NCC#N)C(C)(C)C, Cn1nc(cc1C(=O)N[C@@H](Cc1cccc(Cl)c1)C(=O)NCC#N)C(C)(C)C	MZRVIHRERYCHBL-HNNXBMFYSA-N, MZRVIHRERYCHBL-HNNXBMFYSA-N	Preclinical
CAY10505	PI3K inhibitor	PIK3CG			Fc1ccc(cc1)-c1ccc(\C=C2\SC(=O)NC2=O)o1, Fc1ccc(cc1)-c1ccc(\C=C2\SC(=O)NC2=O)o1, Fc1ccc(cc1)-c1ccc(\C=C2\SC(=O)NC2=O)o1, Fc1ccc(cc1)-c1ccc(\C=C2\SC(=O)NC2=O)o1	UFBTYTGRUBUUIL-KPKJPENVSA-N, UFBTYTGRUBUUIL-KPKJPENVSA-N, UFBTYTGRUBUUIL-KPKJPENVSA-N, UFBTYTGRUBUUIL-KPKJPENVSA-N	Preclinical
CB-03-01	androgen receptor antagonist	AR			CCC(=O)O[C@@]1(CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C)C(=O)CO |t:12|, CCC(=O)O[C@@]1(CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C)C(=O)CO |t:12|, CCC(=O)O[C@@]1(CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C)C(=O)CO |t:12|, CCC(=O)O[C@@]1(CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C)C(=O)CO |t:12|, CCC(=O)O[C@@]1(CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C)C(=O)CO |t:12|	GPNHMOZDMYNCPO-PDUMRIMRSA-N, GPNHMOZDMYNCPO-PDUMRIMRSA-N, GPNHMOZDMYNCPO-PDUMRIMRSA-N, GPNHMOZDMYNCPO-PDUMRIMRSA-N, GPNHMOZDMYNCPO-PDUMRIMRSA-N	Phase 3
CB-10-277	DNA synthesis inhibitor				CN(C)\N=N\c1ccc(cc1)C(O)=O, CN(C)\N=N\c1ccc(cc1)C(O)=O, CN(C)\N=N\c1ccc(cc1)C(O)=O	GUAZPUYTLMUTMA-ZHACJKMWSA-N, GUAZPUYTLMUTMA-ZHACJKMWSA-N, GUAZPUYTLMUTMA-ZHACJKMWSA-N	Phase 1
CB-5083	valosin-containing protein inhibitor	VCP			Cc1cc2c(cccc2n1-c1nc2CCOCc2c(NCc2ccccc2)n1)C(N)=O, Cc1cc2c(cccc2n1-c1nc2CCOCc2c(NCc2ccccc2)n1)C(N)=O, Cc1cc2c(cccc2n1-c1nc2CCOCc2c(NCc2ccccc2)n1)C(N)=O	RDALZZCKQFLGJP-UHFFFAOYSA-N, RDALZZCKQFLGJP-UHFFFAOYSA-N, RDALZZCKQFLGJP-UHFFFAOYSA-N	Phase 1
CB-839	glutaminase inhibitor	GLS			FC(F)(F)Oc1cccc(CC(=O)Nc2ccc(CCCCc3nnc(NC(=O)Cc4ccccn4)s3)nn2)c1, FC(F)(F)Oc1cccc(CC(=O)Nc2ccc(CCCCc3nnc(NC(=O)Cc4ccccn4)s3)nn2)c1, FC(F)(F)Oc1cccc(CC(=O)Nc2ccc(CCCCc3nnc(NC(=O)Cc4ccccn4)s3)nn2)c1, FC(F)(F)Oc1cccc(CC(=O)Nc2ccc(CCCCc3nnc(NC(=O)Cc4ccccn4)s3)nn2)c1, FC(F)(F)Oc1cccc(CC(=O)Nc2ccc(CCCCc3nnc(NC(=O)Cc4ccccn4)s3)nn2)c1	PRAAPINBUWJLGA-UHFFFAOYSA-N, PRAAPINBUWJLGA-UHFFFAOYSA-N, PRAAPINBUWJLGA-UHFFFAOYSA-N, PRAAPINBUWJLGA-UHFFFAOYSA-N, PRAAPINBUWJLGA-UHFFFAOYSA-N	Phase 2
CBiPES	glutamate receptor positive allosteric modulator	GRM2			CCS(=O)(=O)N(Cc1cccnc1)c1cccc(c1)-c1ccc(cc1)C#N, CCS(=O)(=O)N(Cc1cccnc1)c1cccc(c1)-c1ccc(cc1)C#N, CCS(=O)(=O)N(Cc1cccnc1)c1cccc(c1)-c1ccc(cc1)C#N	HDVYXILCBYGKGU-UHFFFAOYSA-N, HDVYXILCBYGKGU-UHFFFAOYSA-N, HDVYXILCBYGKGU-UHFFFAOYSA-N	Preclinical
cbl0137	histone chaperone inhibitor				CC(C)NCCn1c2ccc(cc2c2cc(ccc12)C(C)=O)C(C)=O	JKCSODVERGVDLT-UHFFFAOYSA-N	Phase 1
CBS-1114	lipoxygenase inhibitor	ALOX5			NC(=NNc1ccccc1)c1ccccc1	ZOBKPJRHDMKXQG-UHFFFAOYSA-N	Phase 1
CC-115	DNA protein kinase inhibitor, mTOR inhibitor	MTOR			CCN1C(=O)CN=C2NC=C(N=C12)c1ccc(nc1C)-c1nnc[nH]1 |c:9,t:6,11|, CCN1C(=O)CN=C2NC=C(N=C12)c1ccc(nc1C)-c1nnc[nH]1 |c:9,t:6,11|, CCN1C(=O)CN=C2NC=C(N=C12)c1ccc(nc1C)-c1nnc[nH]1 |c:9,t:6,11|, CCN1C(=O)CN=C2NC=C(N=C12)c1ccc(nc1C)-c1nnc[nH]1 |c:9,t:6,11|	GMYLVKUGJMYTFB-UHFFFAOYSA-N, GMYLVKUGJMYTFB-UHFFFAOYSA-N, GMYLVKUGJMYTFB-UHFFFAOYSA-N, GMYLVKUGJMYTFB-UHFFFAOYSA-N	Phase 2
CC-223	mTOR inhibitor	MTOR			CO[C@H]1CC[C@@H](CC1)N1C(=O)CNc2ncc(nc12)-c1ccc(nc1)C(C)(C)O |r|, CO[C@H]1CC[C@@H](CC1)N1C(=O)CNc2ncc(nc12)-c1ccc(nc1)C(C)(C)O |r|	UFKLYTOEMRFKAD-SHTZXODSSA-N, UFKLYTOEMRFKAD-SHTZXODSSA-N	Phase 2
CC-401	JNK inhibitor	MAPK8			C(CN1CCCCC1)Oc1cccc(c1)-c1n[nH]c2ccc(cc12)-c1nnc[nH]1	XDJCLCLBSGGNKS-UHFFFAOYSA-N	Phase 1
CC-90003	MAP kinase inhibitor				COc1cc(Nc2ncc(c(Nc3ccc(C)cc3NC(=O)C=C)n2)C(F)(F)F)c(C)cn1	ILUKRINUNLAVMH-UHFFFAOYSA-N	Phase 1
CC-930	JNK inhibitor				O[C@H]1CC[C@@H](CC1)Nc1ncc2nc(Nc3c(F)cc(F)cc3F)n([C@H]3CCOC3)c2n1, O[C@H]1CC[C@@H](CC1)Nc1ncc2nc(Nc3c(F)cc(F)cc3F)n([C@H]3CCOC3)c2n1, O[C@H]1CC[C@@H](CC1)Nc1ncc2nc(Nc3c(F)cc(F)cc3F)n([C@H]3CCOC3)c2n1, O[C@H]1CC[C@@H](CC1)Nc1ncc2nc(Nc3c(F)cc(F)cc3F)n([C@H]3CCOC3)c2n1, O[C@H]1CC[C@@H](CC1)Nc1ncc2nc(Nc3c(F)cc(F)cc3F)n([C@H]3CCOC3)c2n1	IBGLGMOPHJQDJB-IHRRRGAJSA-N, IBGLGMOPHJQDJB-IHRRRGAJSA-N, IBGLGMOPHJQDJB-IHRRRGAJSA-N, IBGLGMOPHJQDJB-IHRRRGAJSA-N, IBGLGMOPHJQDJB-IHRRRGAJSA-N	Phase 2
CCG-1423	apoptosis stimulant	RHOC, SRF			C[C@@H](ONC(=O)c1cc(cc(c1)C(F)(F)F)C(F)(F)F)C(=O)Nc1ccc(Cl)cc1 |&1:1,r|, C[C@@H](ONC(=O)c1cc(cc(c1)C(F)(F)F)C(F)(F)F)C(=O)Nc1ccc(Cl)cc1 |&1:1,r|	DSMXVSGJIDFLKP-SECBINFHSA-N, DSMXVSGJIDFLKP-SECBINFHSA-N	Preclinical
CCG-50014	G protein signaling inhibitor	RGS4, RGS8			Cc1ccc(cc1)-n1sc(=O)n(Cc2ccc(F)cc2)c1=O, Cc1ccc(cc1)-n1sc(=O)n(Cc2ccc(F)cc2)c1=O, Cc1ccc(cc1)-n1sc(=O)n(Cc2ccc(F)cc2)c1=O, Cc1ccc(cc1)-n1sc(=O)n(Cc2ccc(F)cc2)c1=O, Cc1ccc(cc1)-n1sc(=O)n(Cc2ccc(F)cc2)c1=O, Cc1ccc(cc1)-n1sc(=O)n(Cc2ccc(F)cc2)c1=O	QUIIIYITNGOFEI-UHFFFAOYSA-N, QUIIIYITNGOFEI-UHFFFAOYSA-N, QUIIIYITNGOFEI-UHFFFAOYSA-N, QUIIIYITNGOFEI-UHFFFAOYSA-N, QUIIIYITNGOFEI-UHFFFAOYSA-N, QUIIIYITNGOFEI-UHFFFAOYSA-N	Preclinical
CCG-63802	G protein signaling inhibitor	RGS4			Cc1cccc(Oc2nc3c(C)cccn3c(=O)c2\C=C(/C#N)c2nc3ccccc3s2)c1, Cc1cccc(Oc2nc3c(C)cccn3c(=O)c2\C=C(/C#N)c2nc3ccccc3s2)c1	VFSVKVQMZDJFQX-NBVRZTHBSA-N, VFSVKVQMZDJFQX-NBVRZTHBSA-N	Preclinical
CCG-63808	G protein signaling inhibitor	RGS4			Cc1cccn2c1nc(Oc1ccc(F)cc1)c(\C=C(/C#N)c1nc3ccccc3s1)c2=O, Cc1cccn2c1nc(Oc1ccc(F)cc1)c(\C=C(/C#N)c1nc3ccccc3s1)c2=O	IPZHFKHGSYRBNT-DTQAZKPQSA-N, IPZHFKHGSYRBNT-DTQAZKPQSA-N	Preclinical
CCMI	acetylcholine receptor allosteric modulator	CHRNA7			Cc1cc(on1)C(=CNc1ccc(Cl)cc1)C(=O)Nc1ccc(Cl)cc1, Cc1cc(on1)C(=CNc1ccc(Cl)cc1)C(=O)Nc1ccc(Cl)cc1, Cc1cc(on1)C(=CNc1ccc(Cl)cc1)C(=O)Nc1ccc(Cl)cc1, Cc1cc(on1)C(=CNc1ccc(Cl)cc1)C(=O)Nc1ccc(Cl)cc1, Cc1cc(on1)C(=CNc1ccc(Cl)cc1)C(=O)Nc1ccc(Cl)cc1	VMAKIACTLSBBIY-UHFFFAOYSA-N, VMAKIACTLSBBIY-UHFFFAOYSA-N, VMAKIACTLSBBIY-UHFFFAOYSA-N, VMAKIACTLSBBIY-UHFFFAOYSA-N, VMAKIACTLSBBIY-UHFFFAOYSA-N	Preclinical
CCMQ	homoquinolinic acid binding inhibitor				OC(=O)Cc1cc2ccccc2nc1C(O)=O, OC(=O)Cc1cc2ccccc2nc1C(O)=O	IFXJDEHFADWURH-UHFFFAOYSA-N, IFXJDEHFADWURH-UHFFFAOYSA-N	Preclinical
CCT-031374	WNT signaling inhibitor	CTNNB1			O=C(CN1C2=NCCN2c2ccccc12)c1ccc(cc1)-c1ccccc1 |t:4|, O=C(CN1C2=NCCN2c2ccccc12)c1ccc(cc1)-c1ccccc1 |t:4|	JPCYSKNELCOPKJ-UHFFFAOYSA-N, JPCYSKNELCOPKJ-UHFFFAOYSA-N	Preclinical
CCT018159	HSP inhibitor	HSP90AA1, HSP90AB1			CCc1cc(-c2n[nH]c(C)c2-c2ccc3OCCOc3c2)c(O)cc1O, CCc1cc(-c2n[nH]c(C)c2-c2ccc3OCCOc3c2)c(O)cc1O, CCc1cc(-c2n[nH]c(C)c2-c2ccc3OCCOc3c2)c(O)cc1O	OWPMENVYXDJDOW-UHFFFAOYSA-N, OWPMENVYXDJDOW-UHFFFAOYSA-N, OWPMENVYXDJDOW-UHFFFAOYSA-N	Preclinical
CCT128930	AKT inhibitor				NC1(Cc2ccc(Cl)cc2)CCN(CC1)c1ncnc2[nH]ccc12, NC1(Cc2ccc(Cl)cc2)CCN(CC1)c1ncnc2[nH]ccc12, NC1(Cc2ccc(Cl)cc2)CCN(CC1)c1ncnc2[nH]ccc12, NC1(Cc2ccc(Cl)cc2)CCN(CC1)c1ncnc2[nH]ccc12, NC1(Cc2ccc(Cl)cc2)CCN(CC1)c1ncnc2[nH]ccc12	RZIDZIGAXXNODG-UHFFFAOYSA-N, RZIDZIGAXXNODG-UHFFFAOYSA-N, RZIDZIGAXXNODG-UHFFFAOYSA-N, RZIDZIGAXXNODG-UHFFFAOYSA-N, RZIDZIGAXXNODG-UHFFFAOYSA-N	Preclinical
CCT129202	Aurora kinase inhibitor	AURKA, AURKB, AURKC			CN(C)c1ccc(cc1)-c1nc2ncc(Cl)c(N3CCN(CC(=O)Nc4nccs4)CC3)c2[nH]1, CN(C)c1ccc(cc1)-c1nc2ncc(Cl)c(N3CCN(CC(=O)Nc4nccs4)CC3)c2[nH]1, CN(C)c1ccc(cc1)-c1nc2ncc(Cl)c(N3CCN(CC(=O)Nc4nccs4)CC3)c2[nH]1	QYKHWEFPFAGNEV-UHFFFAOYSA-N, QYKHWEFPFAGNEV-UHFFFAOYSA-N, QYKHWEFPFAGNEV-UHFFFAOYSA-N	Preclinical
CCT137690	Aurora kinase inhibitor	AURKA, AURKB, AURKC			CN1CCN(CC1)c1ccc(cc1)-c1nc2ncc(Br)c(N3CCN(Cc4cc(C)on4)CC3)c2[nH]1, CN1CCN(CC1)c1ccc(cc1)-c1nc2ncc(Br)c(N3CCN(Cc4cc(C)on4)CC3)c2[nH]1, CN1CCN(CC1)c1ccc(cc1)-c1nc2ncc(Br)c(N3CCN(Cc4cc(C)on4)CC3)c2[nH]1, CN1CCN(CC1)c1ccc(cc1)-c1nc2ncc(Br)c(N3CCN(Cc4cc(C)on4)CC3)c2[nH]1	GFLQCBTXTRCREJ-UHFFFAOYSA-N, GFLQCBTXTRCREJ-UHFFFAOYSA-N, GFLQCBTXTRCREJ-UHFFFAOYSA-N, GFLQCBTXTRCREJ-UHFFFAOYSA-N	Preclinical
CCT196969	RAF inhibitor				CC(C)(C)c1cc(NC(=O)Nc2ccc(Oc3ccnc4nc(O)cnc34)cc2F)n(n1)-c1ccccc1, CC(C)(C)c1cc(NC(=O)Nc2ccc(Oc3ccnc4nc(O)cnc34)cc2F)n(n1)-c1ccccc1	KYYKGSDLXXKQCR-UHFFFAOYSA-N, KYYKGSDLXXKQCR-UHFFFAOYSA-N	Preclinical
CCT245737	kinase inhibitor				FC(F)(F)c1cnc(Nc2cnc(cn2)C#N)cc1NC[C@H]1CNCCO1	YBYYWUUUGCNAHQ-LLVKDONJSA-N	Preclinical
CC4	nicotinic receptor agonist	CHRNB2			O=c1cccc2[C@@H]3C[C@@H](CN(CCN4C[C@@H]5C[C@H](C4)c4cccc(=O)n4C5)C3)Cn12, O=c1cccc2[C@@H]3C[C@@H](CN(CCN4C[C@@H]5C[C@H](C4)c4cccc(=O)n4C5)C3)Cn12	LEXDAVFCJPDCNA-VNTMZGSJSA-N, LEXDAVFCJPDCNA-VNTMZGSJSA-N	Preclinical
CD-1530	retinoid receptor agonist	RARG			OC(=O)c1ccc(cc1)-c1ccc2cc(O)c(cc2c1)C12CC3CC(CC(C3)C1)C2, OC(=O)c1ccc(cc1)-c1ccc2cc(O)c(cc2c1)C12CC3CC(CC(C3)C1)C2, OC(=O)c1ccc(cc1)-c1ccc2cc(O)c(cc2c1)C12CC3CC(CC(C3)C1)C2, OC(=O)c1ccc(cc1)-c1ccc2cc(O)c(cc2c1)C12CC3CC(CC(C3)C1)C2, OC(=O)c1ccc(cc1)-c1ccc2cc(O)c(cc2c1)C12CC3CC(CC(C3)C1)C2, OC(=O)c1ccc(cc1)-c1ccc2cc(O)c(cc2c1)C12CC3CC(CC(C3)C1)C2	VCQGNUWOMLYNNG-UHFFFAOYSA-N, VCQGNUWOMLYNNG-UHFFFAOYSA-N, VCQGNUWOMLYNNG-UHFFFAOYSA-N, VCQGNUWOMLYNNG-UHFFFAOYSA-N, VCQGNUWOMLYNNG-UHFFFAOYSA-N, VCQGNUWOMLYNNG-UHFFFAOYSA-N	Preclinical
CD-437	retinoid receptor agonist	RARG			OC(=O)c1ccc2cc(ccc2c1)-c1ccc(O)c(c1)C12CC3CC(CC(C3)C1)C2, OC(=O)c1ccc2cc(ccc2c1)-c1ccc(O)c(c1)C12CC3CC(CC(C3)C1)C2, OC(=O)c1ccc2cc(ccc2c1)-c1ccc(O)c(c1)C12CC3CC(CC(C3)C1)C2, OC(=O)c1ccc2cc(ccc2c1)-c1ccc(O)c(c1)C12CC3CC(CC(C3)C1)C2, OC(=O)c1ccc2cc(ccc2c1)-c1ccc(O)c(c1)C12CC3CC(CC(C3)C1)C2, OC(=O)c1ccc2cc(ccc2c1)-c1ccc(O)c(c1)C12CC3CC(CC(C3)C1)C2, OC(=O)c1ccc2cc(ccc2c1)-c1ccc(O)c(c1)C12CC3CC(CC(C3)C1)C2	LDGIHZJOIQSHPB-UHFFFAOYSA-N, LDGIHZJOIQSHPB-UHFFFAOYSA-N, LDGIHZJOIQSHPB-UHFFFAOYSA-N, LDGIHZJOIQSHPB-UHFFFAOYSA-N, LDGIHZJOIQSHPB-UHFFFAOYSA-N, LDGIHZJOIQSHPB-UHFFFAOYSA-N, LDGIHZJOIQSHPB-UHFFFAOYSA-N	Preclinical
CDBA					OC[C@H]1O[C@H]2O[C@H]3[C@@H](CO)O[C@@H](O[C@H]4[C@@H](CO)O[C@@H](O[C@H]5[C@@H](CO)O[C@@H](O[C@H]6[C@@H](CO)O[C@@H](O[C@H]7[C@@H](CO)O[C@@H](O[C@H]8[C@@H](CO)O[C@@H](O[C@@H]1[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]8O)[C@@H](O)[C@@H]7O)[C@@H](O)[C@@H]6O)[C@@H](O)[C@@H]5O)[C@@H](O)[C@@H]4O)[C@@H](O)[C@@H]3O |&1:2,&2:4,&3:6,&4:7,&5:11,&6:13,&7:14,&8:18,&9:20,&10:21,&11:25,&12:27,&13:28,&14:32,&15:34,&16:35,&17:39,&18:41,&19:42,&20:46,&21:48,&22:49,&23:51,&24:53,&25:55,&26:57,&27:59,&28:61,&29:63,&30:65,&31:67,&32:69,&33:71,&34:73,&35:75,r|, OC[C@H]1O[C@H]2O[C@H]3[C@@H](CO)O[C@@H](O[C@H]4[C@@H](CO)O[C@@H](O[C@H]5[C@@H](CO)O[C@@H](O[C@H]6[C@@H](CO)O[C@@H](O[C@H]7[C@@H](CO)O[C@@H](O[C@H]8[C@@H](CO)O[C@@H](O[C@@H]1[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]8O)[C@@H](O)[C@@H]7O)[C@@H](O)[C@@H]6O)[C@@H](O)[C@@H]5O)[C@@H](O)[C@@H]4O)[C@@H](O)[C@@H]3O |&1:2,&2:4,&3:6,&4:7,&5:11,&6:13,&7:14,&8:18,&9:20,&10:21,&11:25,&12:27,&13:28,&14:32,&15:34,&16:35,&17:39,&18:41,&19:42,&20:46,&21:48,&22:49,&23:51,&24:53,&25:55,&26:57,&27:59,&28:61,&29:63,&30:65,&31:67,&32:69,&33:71,&34:73,&35:75,r|, OC[C@H]1O[C@H]2O[C@H]3[C@@H](CO)O[C@@H](O[C@H]4[C@@H](CO)O[C@@H](O[C@H]5[C@@H](CO)O[C@@H](O[C@H]6[C@@H](CO)O[C@@H](O[C@H]7[C@@H](CO)O[C@@H](O[C@H]8[C@@H](CO)O[C@@H](O[C@@H]1[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]8O)[C@@H](O)[C@@H]7O)[C@@H](O)[C@@H]6O)[C@@H](O)[C@@H]5O)[C@@H](O)[C@@H]4O)[C@@H](O)[C@@H]3O |&1:2,&2:4,&3:6,&4:7,&5:11,&6:13,&7:14,&8:18,&9:20,&10:21,&11:25,&12:27,&13:28,&14:32,&15:34,&16:35,&17:39,&18:41,&19:42,&20:46,&21:48,&22:49,&23:51,&24:53,&25:55,&26:57,&27:59,&28:61,&29:63,&30:65,&31:67,&32:69,&33:71,&34:73,&35:75,r|	WHGYBXFWUBPSRW-GUJBRCDDSA-N, WHGYBXFWUBPSRW-GUJBRCDDSA-N, WHGYBXFWUBPSRW-GUJBRCDDSA-N	Phase 3
CDK1-5-inhibitor	CDK inhibitor, glycogen synthase kinase inhibitor	CDK1, CDK5, GSK3B			Nc1[nH]nc2nc3ccccc3nc12, Nc1[nH]nc2nc3ccccc3nc12, Nc1[nH]nc2nc3ccccc3nc12, Nc1[nH]nc2nc3ccccc3nc12	DWHVZCLBMTZRQM-UHFFFAOYSA-N, DWHVZCLBMTZRQM-UHFFFAOYSA-N, DWHVZCLBMTZRQM-UHFFFAOYSA-N, DWHVZCLBMTZRQM-UHFFFAOYSA-N	Preclinical
CDK9-IN-6	CDK inhibitor	CDK9			COC[C@H](C)N[C@H]1CC[C@@H](CC1)Nc1cc(c(Cl)cn1)-c1cccc(NCC2(CCOCC2)C#N)n1, COC[C@H](C)N[C@H]1CC[C@@H](CC1)Nc1cc(c(Cl)cn1)-c1cccc(NCC2(CCOCC2)C#N)n1, COC[C@H](C)N[C@H]1CC[C@@H](CC1)Nc1cc(c(Cl)cn1)-c1cccc(NCC2(CCOCC2)C#N)n1	XWQVQSXLXAXOPJ-ACRUOGEOSA-N, XWQVQSXLXAXOPJ-ACRUOGEOSA-N, XWQVQSXLXAXOPJ-ACRUOGEOSA-N	Preclinical
CDPPB	glutamate receptor positive allosteric modulator	GRM5			O=C(Nc1cc(nn1-c1ccccc1)-c1ccccc1)c1cccc(c1)C#N, O=C(Nc1cc(nn1-c1ccccc1)-c1ccccc1)c1cccc(c1)C#N	BKUIZWILNWHFHD-UHFFFAOYSA-N, BKUIZWILNWHFHD-UHFFFAOYSA-N	Preclinical
cebranopadol	opioid receptor agonist	OPRL1, OPRM1			CN(C)[C@]1(CC[C@@]2(CC1)OCCc1c2[nH]c2ccc(F)cc12)c1ccccc1 |r|, CN(C)[C@]1(CC[C@@]2(CC1)OCCc1c2[nH]c2ccc(F)cc12)c1ccccc1 |r|, CN(C)[C@]1(CC[C@@]2(CC1)OCCc1c2[nH]c2ccc(F)cc12)c1ccccc1 |r|	CSMVOZKEWSOFER-RQNOJGIXSA-N, CSMVOZKEWSOFER-RQNOJGIXSA-N, CSMVOZKEWSOFER-RQNOJGIXSA-N	Phase 3
cediranib	KIT inhibitor, VEGFR inhibitor	CSF1R, FLT1, FLT3, FLT4, KDR, KIT, PDGFRA, PDGFRB			COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1, COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1, COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1, COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1, COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1	XXJWYDDUDKYVKI-UHFFFAOYSA-N, XXJWYDDUDKYVKI-UHFFFAOYSA-N, XXJWYDDUDKYVKI-UHFFFAOYSA-N, XXJWYDDUDKYVKI-UHFFFAOYSA-N, XXJWYDDUDKYVKI-UHFFFAOYSA-N	Phase 3
cedrol					C[C@H]1CC[C@H]2C(C)(C)[C@H]3C[C@@]12CC[C@@]3(C)O |&1:1,&2:4,&3:8,&4:10,&5:13,r|	SVURIXNDRWRAFU-OBORUHMCSA-N	Phase 2
cedrol-(+)	sedative				C[C@@H]1CC[C@H]2C(C)(C)[C@H]3C[C@@]12CC[C@@]3(C)O, C[C@@H]1CC[C@H]2C(C)(C)[C@H]3C[C@@]12CC[C@@]3(C)O	SVURIXNDRWRAFU-OGMFBOKVSA-N, SVURIXNDRWRAFU-OGMFBOKVSA-N	Phase 2
cefaclor	bacterial cell wall synthesis inhibitor		infectious disease, otolaryngology	pneumonia, skin infections, urinary tract infections, respiratory tract infections, tonsillitis, pharyngitis	N[C@@H](C(=O)N[C@H]1[C@H]2SCC(Cl)=C(N2C1=O)C(O)=O)c1ccccc1 |c:10|, N[C@@H](C(=O)N[C@H]1[C@H]2SCC(Cl)=C(N2C1=O)C(O)=O)c1ccccc1 |c:10|, N[C@@H](C(=O)N[C@H]1[C@H]2SCC(Cl)=C(N2C1=O)C(O)=O)c1ccccc1 |c:10|, N[C@@H](C(=O)N[C@H]1[C@H]2SCC(Cl)=C(N2C1=O)C(O)=O)c1ccccc1 |c:10|	QYIYFLOTGYLRGG-GPCCPHFNSA-N, QYIYFLOTGYLRGG-GPCCPHFNSA-N, QYIYFLOTGYLRGG-GPCCPHFNSA-N, QYIYFLOTGYLRGG-GPCCPHFNSA-N	Launched
cefadroxil	bacterial cell wall synthesis inhibitor	SLC15A1, SLC15A2, SLC22A6, SLC22A8	infectious disease, otolaryngology	urinary tract infections, skin infections, tonsillitis, pharyngitis	CC1=C(N2[C@H](SC1)[C@H](NC(=O)[C@H](N)c1ccc(O)cc1)C2=O)C(O)=O |t:1|	BOEGTKLJZSQCCD-UEKVPHQBSA-N	Launched
cefalonium	bacterial cell wall synthesis inhibitor		infectious disease	gram-positive bacterial infections	NC(=O)c1cc[n+](CC2=C(N3[C@H](SC2)[C@H](NC(=O)Cc2cccs2)C3=O)C(O)=O)cc1 |t:8|, NC(=O)c1cc[n+](CC2=C(N3[C@H](SC2)[C@H](NC(=O)Cc2cccs2)C3=O)C(O)=O)cc1 |t:8|	FMZXNVLFJHCSAF-DNVCBOLYSA-O, FMZXNVLFJHCSAF-DNVCBOLYSA-O	Launched
cefamandole	bacterial cell wall synthesis inhibitor		infectious disease	skin infections, urinary tract infections, respiratory tract infections	Cn1nnnc1SCC1=C(N2[C@H](SC1)[C@H](NC(=O)[C@H](O)c1ccccc1)C2=O)C(O)=O |t:9|, Cn1nnnc1SCC1=C(N2[C@H](SC1)[C@H](NC(=O)[C@H](O)c1ccccc1)C2=O)C(O)=O |t:9|	OLVCFLKTBJRLHI-AXAPSJFSSA-N, OLVCFLKTBJRLHI-AXAPSJFSSA-N	Launched
cefamandole-nafate	bacterial cell wall synthesis inhibitor		infectious disease	skin infections, urinary tract infections, respiratory tract infections	Cn1nnnc1SCC1=C(N2[C@H](SC1)[C@H](NC(=O)[C@H](OC=O)c1ccccc1)C2=O)C(O)=O |t:9|, Cn1nnnc1SCC1=C(N2[C@H](SC1)[C@H](NC(=O)[C@H](OC=O)c1ccccc1)C2=O)C(O)=O |t:9|, Cn1nnnc1SCC1=C(N2[C@H](SC1)[C@H](NC(=O)[C@H](OC=O)c1ccccc1)C2=O)C(O)=O |t:9|	RRJHESVQVSRQEX-SUYBPPKGSA-N, RRJHESVQVSRQEX-SUYBPPKGSA-N, RRJHESVQVSRQEX-SUYBPPKGSA-N	Launched
cefathiamidine	bacterial cell wall synthesis inhibitor		infectious disease	gram-positive bacterial infections	CC(C)N\C(SCC(=O)N[C@H]1[C@H]2SCC(COC(C)=O)=C(N2C1=O)C(O)=O)=N/C(C)C |c:19|	JYXACOFERDBGGQ-RHSMWYFYSA-N	Launched
cefazolin	bacterial cell wall synthesis inhibitor	PON1	infectious disease	urinary tract infections, skin infections, bacterial septicemia, endocarditis, surgical prophylaxis, bone and joint infections	Cc1nnc(SCC2=C(N3[C@H](SC2)[C@H](NC(=O)Cn2cnnn2)C3=O)C(O)=O)s1 |t:7|, Cc1nnc(SCC2=C(N3[C@H](SC2)[C@H](NC(=O)Cn2cnnn2)C3=O)C(O)=O)s1 |t:7|, Cc1nnc(SCC2=C(N3[C@H](SC2)[C@H](NC(=O)Cn2cnnn2)C3=O)C(O)=O)s1 |t:7|	MLYYVTUWGNIJIB-BXKDBHETSA-N, MLYYVTUWGNIJIB-BXKDBHETSA-N, MLYYVTUWGNIJIB-BXKDBHETSA-N	Launched
cefcapene-pivoxil	bacterial cell wall synthesis inhibitor		infectious disease	skin infections, pneumonia, urinary tract infections	CC\C=C(/C(=O)N[C@H]1[C@H]2SCC(COC(N)=O)=C(N2C1=O)C(=O)OCOC(=O)C(C)(C)C)c1csc(N)n1 |c:16|, CC\C=C(/C(=O)N[C@H]1[C@H]2SCC(COC(N)=O)=C(N2C1=O)C(=O)OCOC(=O)C(C)(C)C)c1csc(N)n1 |c:16|, CC\C=C(/C(=O)N[C@H]1[C@H]2SCC(COC(N)=O)=C(N2C1=O)C(=O)OCOC(=O)C(C)(C)C)c1csc(N)n1 |c:16|, CC\C=C(/C(=O)N[C@H]1[C@H]2SCC(COC(N)=O)=C(N2C1=O)C(=O)OCOC(=O)C(C)(C)C)c1csc(N)n1 |c:16|	WVPAABNYMHNFJG-QDVBXLKVSA-N, WVPAABNYMHNFJG-QDVBXLKVSA-N, WVPAABNYMHNFJG-QDVBXLKVSA-N, WVPAABNYMHNFJG-QDVBXLKVSA-N	Launched
cefdinir	bacterial cell wall synthesis inhibitor	MPO	infectious disease, otolaryngology, pulmonary	pneumonia, tonsillitis, pharyngitis, bronchitis, skin infections, otitis, sinusitis	Nc1nc(cs1)C(=N\O)\C(=O)N[C@H]1[C@H]2SCC(C=C)=C(N2C1=O)C(O)=O |c:19|, Nc1nc(cs1)C(=N\O)\C(=O)N[C@H]1[C@H]2SCC(C=C)=C(N2C1=O)C(O)=O |c:19|, Nc1nc(cs1)C(=N\O)\C(=O)N[C@H]1[C@H]2SCC(C=C)=C(N2C1=O)C(O)=O |c:19|, Nc1nc(cs1)C(=N\O)\C(=O)N[C@H]1[C@H]2SCC(C=C)=C(N2C1=O)C(O)=O |c:19|	RTXOFQZKPXMALH-GHXIOONMSA-N, RTXOFQZKPXMALH-GHXIOONMSA-N, RTXOFQZKPXMALH-GHXIOONMSA-N, RTXOFQZKPXMALH-GHXIOONMSA-N	Launched
cefditoren-pivoxil	bacterial cell wall synthesis inhibitor		infectious disease, pulmonary, otolaryngology	pneumonia, bronchitis, skin infections, tonsillitis, pharyngitis	CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(\C=C/c3scnc3C)=C(N2C1=O)C(=O)OCOC(=O)C(C)(C)C)c1csc(N)n1 |c:20|, CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(\C=C/c3scnc3C)=C(N2C1=O)C(=O)OCOC(=O)C(C)(C)C)c1csc(N)n1 |c:20|, CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(\C=C/c3scnc3C)=C(N2C1=O)C(=O)OCOC(=O)C(C)(C)C)c1csc(N)n1 |c:20|, CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(\C=C/c3scnc3C)=C(N2C1=O)C(=O)OCOC(=O)C(C)(C)C)c1csc(N)n1 |c:20|	AFZFFLVORLEPPO-UVYJNCLZSA-N, AFZFFLVORLEPPO-UVYJNCLZSA-N, AFZFFLVORLEPPO-UVYJNCLZSA-N, AFZFFLVORLEPPO-UVYJNCLZSA-N	Launched
cefepime	bacterial cell wall synthesis inhibitor		infectious disease	pneumonia, urinary tract infections, skin infections, intra-abdominal infections	CO\N=C(\C(=O)N[C@H]1[C@H]2SCC(C[N+]3(C)CCCC3)=C(N2C1=O)C(O)=O)c1csc(N)n1 |&1:7,&2:8,c:19|	HVFLCNVBZFFHBT-FKULVZFESA-O	Launched
cefetamet	bacterial cell wall synthesis inhibitor		infectious disease, otolaryngology, pulmonary	ear infections, pneumonia, otitis, sinusitis, bronchitis, urinary tract infections	CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(C)=C(N2C1=O)C(O)=O)c1csc(N)n1 |c:12|, CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(C)=C(N2C1=O)C(O)=O)c1csc(N)n1 |c:12|	MQLRYUCJDNBWMV-GHXIOONMSA-N, MQLRYUCJDNBWMV-GHXIOONMSA-N	Launched
cefetamet-pivoxil	bacterial cell wall synthesis inhibitor		infectious disease	gram-positive bacterial infections	CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(C)=C(N2C1=O)C(=O)OCOC(=O)C(C)(C)C)c1csc(N)n1 |c:12|, CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(C)=C(N2C1=O)C(=O)OCOC(=O)C(C)(C)C)c1csc(N)n1 |c:12|, CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(C)=C(N2C1=O)C(=O)OCOC(=O)C(C)(C)C)c1csc(N)n1 |c:12|	DASYMCLQENWCJG-XUKDPADISA-N, DASYMCLQENWCJG-XUKDPADISA-N, DASYMCLQENWCJG-XUKDPADISA-N	Launched
cefiderocol	antibacterial 				[H][C@]12SCC(C[N+]3(CCNC(=O)c4ccc(O)c(O)c4Cl)CCCC3)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC(C)(C)C(O)=O)\c1csc(N)n1)C(O)=O |c:26|	DBPPRLRVDVJOCL-FQRUVTKNSA-O	Launched
cefixime	bacterial cell wall synthesis inhibitor		infectious disease, otolaryngology, pulmonary	urinary tract infections, otitis, pharyngitis, tonsillitis, gonorrhea, bronchitis	Nc1nc(cs1)C(=N\OCC(O)=O)\C(=O)N[C@H]1[C@H]2SCC(C=C)=C(N2C1=O)C(O)=O |c:23|, Nc1nc(cs1)C(=N\OCC(O)=O)\C(=O)N[C@H]1[C@H]2SCC(C=C)=C(N2C1=O)C(O)=O |c:23|, Nc1nc(cs1)C(=N\OCC(O)=O)\C(=O)N[C@H]1[C@H]2SCC(C=C)=C(N2C1=O)C(O)=O |c:23|	OKBVVJOGVLARMR-QSWIMTSFSA-N, OKBVVJOGVLARMR-QSWIMTSFSA-N, OKBVVJOGVLARMR-QSWIMTSFSA-N	Launched
cefmenoxime	bacterial cell wall synthesis inhibitor		infectious disease	gram-negative bacterial infections	[H][C@]12SCC(CSc3nnnn3C)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\c1csc(N)n1)C(O)=O |c:13|	HJJDBAOLQAWBMH-YCRCPZNHSA-N	Launched
cefmetazole	bacterial cell wall synthesis inhibitor		infectious disease	urinary tract infections, skin infections	CO[C@]1(NC(=O)CSCC#N)[C@H]2SCC(CSc3nnnn3C)=C(N2C1=O)C(O)=O |c:23|, CO[C@]1(NC(=O)CSCC#N)[C@H]2SCC(CSc3nnnn3C)=C(N2C1=O)C(O)=O |c:23|, CO[C@]1(NC(=O)CSCC#N)[C@H]2SCC(CSc3nnnn3C)=C(N2C1=O)C(O)=O |c:23|	SNBUBQHDYVFSQF-HIFRSBDPSA-N, SNBUBQHDYVFSQF-HIFRSBDPSA-N, SNBUBQHDYVFSQF-HIFRSBDPSA-N	Launched
cefminox	bacterial cell wall synthesis inhibitor		infectious disease	gram-negative bacterial infections	CO[C@]1(NC(=O)CSC[C@@H](N)C(O)=O)[C@H]2SCC(CSc3nnnn3C)=C(N2C1=O)C(O)=O |c:26|, CO[C@]1(NC(=O)CSC[C@@H](N)C(O)=O)[C@H]2SCC(CSc3nnnn3C)=C(N2C1=O)C(O)=O |c:26|	JSDXOWVAHXDYCU-VXSYNFHWSA-N, JSDXOWVAHXDYCU-VXSYNFHWSA-N	Launched
cefodizime	bacterial cell wall synthesis inhibitor		infectious disease	respiratory tract infections, skin infections, gonorrhea	CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(CSc3nc(C)c(CC(O)=O)s3)=C(N2C1=O)C(O)=O)c1csc(N)n1 |c:24|, CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(CSc3nc(C)c(CC(O)=O)s3)=C(N2C1=O)C(O)=O)c1csc(N)n1 |c:24|, CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(CSc3nc(C)c(CC(O)=O)s3)=C(N2C1=O)C(O)=O)c1csc(N)n1 |c:24|	XDZKBRJLTGRPSS-BGZQYGJUSA-N, XDZKBRJLTGRPSS-BGZQYGJUSA-N, XDZKBRJLTGRPSS-BGZQYGJUSA-N	Launched
cefonicid	bacterial cell wall synthesis inhibitor		infectious disease	gram-positive bacterial infections	O[C@@H](C(=O)N[C@H]1[C@H]2SCC(CSc3nnnn3CS(O)(=O)=O)=C(N2C1=O)C(O)=O)c1ccccc1 |c:22|, O[C@@H](C(=O)N[C@H]1[C@H]2SCC(CSc3nnnn3CS(O)(=O)=O)=C(N2C1=O)C(O)=O)c1ccccc1 |c:22|, O[C@@H](C(=O)N[C@H]1[C@H]2SCC(CSc3nnnn3CS(O)(=O)=O)=C(N2C1=O)C(O)=O)c1ccccc1 |c:22|	DYAIAHUQIPBDIP-AXAPSJFSSA-N, DYAIAHUQIPBDIP-AXAPSJFSSA-N, DYAIAHUQIPBDIP-AXAPSJFSSA-N	Launched
cefoperazone	bacterial cell wall synthesis inhibitor		infectious disease	gram-negative bacterial infections	CCN1CCN(C(=O)N[C@@H](C(=O)N[C@H]2[C@H]3SCC(CSc4nnnn4C)=C(N3C2=O)C(O)=O)c2ccc(O)cc2)C(=O)C1=O |c:26|, CCN1CCN(C(=O)N[C@@H](C(=O)N[C@H]2[C@H]3SCC(CSc4nnnn4C)=C(N3C2=O)C(O)=O)c2ccc(O)cc2)C(=O)C1=O |c:26|, CCN1CCN(C(=O)N[C@@H](C(=O)N[C@H]2[C@H]3SCC(CSc4nnnn4C)=C(N3C2=O)C(O)=O)c2ccc(O)cc2)C(=O)C1=O |c:26|	GCFBRXLSHGKWDP-XCGNWRKASA-N, GCFBRXLSHGKWDP-XCGNWRKASA-N, GCFBRXLSHGKWDP-XCGNWRKASA-N	Launched
ceforanide	penicillin binding protein inhibitor		infectious disease	gram-negative bacterial infections	NCc1ccccc1CC(=O)N[C@H]1[C@H]2SCC(CSc3nnnn3CC(O)=O)=C(N2C1=O)C(O)=O |c:29|, NCc1ccccc1CC(=O)N[C@H]1[C@H]2SCC(CSc3nnnn3CC(O)=O)=C(N2C1=O)C(O)=O |c:29|, NCc1ccccc1CC(=O)N[C@H]1[C@H]2SCC(CSc3nnnn3CC(O)=O)=C(N2C1=O)C(O)=O |c:29|	SLAYUXIURFNXPG-CRAIPNDOSA-N, SLAYUXIURFNXPG-CRAIPNDOSA-N, SLAYUXIURFNXPG-CRAIPNDOSA-N	Launched
cefoselis	bacterial cell wall synthesis inhibitor		infectious disease	gram-negative bacterial infections, gram-positive bacterial infections	CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(Cn3ccc(=N)n3CCO)=C(N2C1=O)C(O)=O)c1csc(N)n1 |c:22|, CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(Cn3ccc(=N)n3CCO)=C(N2C1=O)C(O)=O)c1csc(N)n1 |c:22|, CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(Cn3ccc(=N)n3CCO)=C(N2C1=O)C(O)=O)c1csc(N)n1 |c:22|, CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(Cn3ccc(=N)n3CCO)=C(N2C1=O)C(O)=O)c1csc(N)n1 |c:22|	ZINFAXPQMLDEEJ-GFVOIPPFSA-N, ZINFAXPQMLDEEJ-GFVOIPPFSA-N, ZINFAXPQMLDEEJ-GFVOIPPFSA-N, ZINFAXPQMLDEEJ-GFVOIPPFSA-N	Launched
cefotaxime	bacterial cell wall synthesis inhibitor		infectious disease	respiratory tract infections, bone and joint infections, pelvic inflammatory disease, intra-abdominal infections, skin infections, meningitis, urinary tract infections, bacterial septicemia, gynecologic infections	CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(COC(C)=O)=C(N2C1=O)C(O)=O)c1csc(N)n1 |c:16|, CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(COC(C)=O)=C(N2C1=O)C(O)=O)c1csc(N)n1 |c:16|, CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(COC(C)=O)=C(N2C1=O)C(O)=O)c1csc(N)n1 |c:16|, CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(COC(C)=O)=C(N2C1=O)C(O)=O)c1csc(N)n1 |c:16|	GPRBEKHLDVQUJE-QSWIMTSFSA-N, GPRBEKHLDVQUJE-QSWIMTSFSA-N, GPRBEKHLDVQUJE-QSWIMTSFSA-N, GPRBEKHLDVQUJE-QSWIMTSFSA-N	Launched
cefotetan	bacterial cell wall synthesis inhibitor		infectious disease	urinary tract infections, respiratory tract infections, skin infections, gynecologic infections, chlamydia, intra-abdominal infections, bone and joint infections, surgical prophylaxis	CO[C@]1(NC(=O)C2SC(S2)=C(C(N)=O)C(O)=O)[C@H]2SCC(CSc3nnnn3C)=C(N2C1=O)C(O)=O |a:2,&1:17,c:30|, CO[C@]1(NC(=O)C2SC(S2)=C(C(N)=O)C(O)=O)[C@H]2SCC(CSc3nnnn3C)=C(N2C1=O)C(O)=O |a:2,&1:17,c:30|	SRZNHPXWXCNNDU-IXOPCIAXSA-N, SRZNHPXWXCNNDU-IXOPCIAXSA-N	Launched
cefotiam	bacterial cell wall synthesis inhibitor		infectious disease	bacterial septicemia, bone and joint infections, respiratory tract infections, skin infections, urinary tract infections	CN(C)CCn1nnnc1SCC1=C(N2[C@H](SC1)[C@H](NC(=O)Cc1csc(N)n1)C2=O)C(O)=O |t:13|, CN(C)CCn1nnnc1SCC1=C(N2[C@H](SC1)[C@H](NC(=O)Cc1csc(N)n1)C2=O)C(O)=O |t:13|	QYQDKDWGWDOFFU-IUODEOHRSA-N, QYQDKDWGWDOFFU-IUODEOHRSA-N	Launched
cefotiam-cilexetil	bacterial cell wall synthesis inhibitor		infectious disease	gram-negative bacterial infections, gram-positive bacterial infections	C[C@@H](OC(=O)OC1CCCCC1)OC(=O)C1=C(CSc2nnnn2CCN(C)C)CS[C@H]2[C@@H](NC(=O)Cc3csc(N)n3)C(=O)N12 |&1:1,&2:31,&3:32,c:16|, C[C@@H](OC(=O)OC1CCCCC1)OC(=O)C1=C(CSc2nnnn2CCN(C)C)CS[C@H]2[C@@H](NC(=O)Cc3csc(N)n3)C(=O)N12 |&1:1,&2:31,&3:32,c:16|	VVFDMWZLBPUKTD-XLHILCRZSA-N, VVFDMWZLBPUKTD-XLHILCRZSA-N	Launched
cefoxitin	bacterial cell wall synthesis inhibitor		infectious disease	respiratory tract infections, urinary tract infections, intra-abdominal infections, gynecologic infections, bacterial septicemia, bone and joint infections, skin infections	CO[C@]1(NC(=O)Cc2cccs2)[C@H]2SCC(COC(N)=O)=C(N2C1=O)C(O)=O |c:21|, CO[C@]1(NC(=O)Cc2cccs2)[C@H]2SCC(COC(N)=O)=C(N2C1=O)C(O)=O |c:21|, CO[C@]1(NC(=O)Cc2cccs2)[C@H]2SCC(COC(N)=O)=C(N2C1=O)C(O)=O |c:21|, CO[C@]1(NC(=O)Cc2cccs2)[C@H]2SCC(COC(N)=O)=C(N2C1=O)C(O)=O |c:21|	WZOZEZRFJCJXNZ-ZBFHGGJFSA-N, WZOZEZRFJCJXNZ-ZBFHGGJFSA-N, WZOZEZRFJCJXNZ-ZBFHGGJFSA-N, WZOZEZRFJCJXNZ-ZBFHGGJFSA-N	Launched
cefozopran	bacterial cell wall synthesis inhibitor		infectious disease	gram-negative bacterial infections, gram-positive bacterial infections	CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(C[n+]3ccn4ncccc34)=C(N2C1=O)C(O)=O)c1nsc(N)n1 |c:23|, CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(C[n+]3ccn4ncccc34)=C(N2C1=O)C(O)=O)c1nsc(N)n1 |c:23|, CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(C[n+]3ccn4ncccc34)=C(N2C1=O)C(O)=O)c1nsc(N)n1 |c:23|	QDUIJCOKQCCXQY-WHJQOFBOSA-O, QDUIJCOKQCCXQY-WHJQOFBOSA-O, QDUIJCOKQCCXQY-WHJQOFBOSA-O	Launched
cefpiramide	bacterial cell wall synthesis inhibitor		infectious disease	gram-negative bacterial infections	Cc1cc(=O)c(c[nH]1)C(=O)N[C@@H](C(=O)N[C@H]1[C@H]2SCC(CSc3nnnn3C)=C(N2C1=O)C(O)=O)c1ccc(O)cc1 |c:29|, Cc1cc(=O)c(c[nH]1)C(=O)N[C@@H](C(=O)N[C@H]1[C@H]2SCC(CSc3nnnn3C)=C(N2C1=O)C(O)=O)c1ccc(O)cc1 |c:29|, Cc1cc(=O)c(c[nH]1)C(=O)N[C@@H](C(=O)N[C@H]1[C@H]2SCC(CSc3nnnn3C)=C(N2C1=O)C(O)=O)c1ccc(O)cc1 |c:29|	PWAUCHMQEXVFJR-PMAPCBKXSA-N, PWAUCHMQEXVFJR-PMAPCBKXSA-N, PWAUCHMQEXVFJR-PMAPCBKXSA-N	Launched
cefpirome	bacterial cell wall synthesis inhibitor		infectious disease	gram-negative bacterial infections	CO\N=C(\C(=O)N[C@H]1[C@H]2SCC(C[n+]3cccc4CCCc34)=C(N2C1=O)C(O)=O)c1csc(N)n1 |c:23|, CO\N=C(\C(=O)N[C@H]1[C@H]2SCC(C[n+]3cccc4CCCc34)=C(N2C1=O)C(O)=O)c1csc(N)n1 |c:23|, CO\N=C(\C(=O)N[C@H]1[C@H]2SCC(C[n+]3cccc4CCCc34)=C(N2C1=O)C(O)=O)c1csc(N)n1 |c:23|	DKOQGJHPHLTOJR-PUIFZAHNSA-O, DKOQGJHPHLTOJR-PUIFZAHNSA-O, DKOQGJHPHLTOJR-PUIFZAHNSA-O	Launched
cefpodoxime	bacterial cell wall synthesis inhibitor		otolaryngology, infectious disease, pulmonary	pharyngitis, pneumonia, bronchitis, gonorrhea, skin infections, urinary tract infections, sinusitis, tonsillitis	COCC1=C(N2[C@H](SC1)[C@H](NC(=O)C(=N/OC)\c1csc(N)n1)C2=O)C(=O)O[C@@H](C)OC(=O)OC(C)C |a:6,9,&1:28,t:3|, COCC1=C(N2[C@H](SC1)[C@H](NC(=O)C(=N/OC)\c1csc(N)n1)C2=O)C(=O)O[C@@H](C)OC(=O)OC(C)C |a:6,9,&1:28,t:3|, COCC1=C(N2[C@H](SC1)[C@H](NC(=O)C(=N/OC)\c1csc(N)n1)C2=O)C(=O)O[C@@H](C)OC(=O)OC(C)C |a:6,9,&1:28,t:3|	LTINZAODLRIQIX-OLEGMKQCSA-N, LTINZAODLRIQIX-OLEGMKQCSA-N, LTINZAODLRIQIX-OLEGMKQCSA-N	Launched
cefprozil	bacterial cell wall synthesis inhibitor		otolaryngology, infectious disease, pulmonary	pharyngitis, tonsillitis, otitis, sinusitis, respiratory tract infections, skin infections, bronchitis	C\C=C\C1=C(N2[C@H](SC1)[C@H](NC(=O)[C@H](N)c1ccc(O)cc1)C2=O)C(O)=O |t:3|, C\C=C\C1=C(N2[C@H](SC1)[C@H](NC(=O)[C@H](N)c1ccc(O)cc1)C2=O)C(O)=O |t:3|, C\C=C\C1=C(N2[C@H](SC1)[C@H](NC(=O)[C@H](N)c1ccc(O)cc1)C2=O)C(O)=O |t:3|, C\C=C\C1=C(N2[C@H](SC1)[C@H](NC(=O)[C@H](N)c1ccc(O)cc1)C2=O)C(O)=O |t:3|, C\C=C\C1=C(N2[C@H](SC1)[C@H](NC(=O)[C@H](N)c1ccc(O)cc1)C2=O)C(O)=O |t:3|	WDLWHQDACQUCJR-ZAMMOSSLSA-N, WDLWHQDACQUCJR-ZAMMOSSLSA-N, WDLWHQDACQUCJR-ZAMMOSSLSA-N, WDLWHQDACQUCJR-ZAMMOSSLSA-N, WDLWHQDACQUCJR-ZAMMOSSLSA-N	Launched
cefradine	bacterial cell wall synthesis inhibitor	CYP3A4	infectious disease, otolaryngology	respiratory tract infections, otitis, skin infections, urinary tract infections, tonsillitis, pharyngitis, pneumonia	CC1=C(N2[C@H](SC1)[C@H](NC(=O)[C@H](N)C1=CCC=CC1)C2=O)C(O)=O |c:17,t:1,14|, CC1=C(N2[C@H](SC1)[C@H](NC(=O)[C@H](N)C1=CCC=CC1)C2=O)C(O)=O |c:17,t:1,14|, CC1=C(N2[C@H](SC1)[C@H](NC(=O)[C@H](N)C1=CCC=CC1)C2=O)C(O)=O |c:17,t:1,14|	RDLPVSKMFDYCOR-UEKVPHQBSA-N, RDLPVSKMFDYCOR-UEKVPHQBSA-N, RDLPVSKMFDYCOR-UEKVPHQBSA-N	Launched
cefsulodin	bacterial cell wall synthesis inhibitor		infectious disease	gram-negative bacterial infections	NC(=O)c1cc[n+](CC2=C(N3[C@H](SC2)[C@H](NC(=O)[C@@H](c2ccccc2)S(O)(=O)=O)C3=O)C(O)=O)cc1 |t:8|, NC(=O)c1cc[n+](CC2=C(N3[C@H](SC2)[C@H](NC(=O)[C@@H](c2ccccc2)S(O)(=O)=O)C3=O)C(O)=O)cc1 |t:8|, NC(=O)c1cc[n+](CC2=C(N3[C@H](SC2)[C@H](NC(=O)[C@@H](c2ccccc2)S(O)(=O)=O)C3=O)C(O)=O)cc1 |t:8|, NC(=O)c1cc[n+](CC2=C(N3[C@H](SC2)[C@H](NC(=O)[C@@H](c2ccccc2)S(O)(=O)=O)C3=O)C(O)=O)cc1 |t:8|	SYLKGLMBLAAGSC-QLVMHMETSA-O, SYLKGLMBLAAGSC-QLVMHMETSA-O, SYLKGLMBLAAGSC-QLVMHMETSA-O, SYLKGLMBLAAGSC-QLVMHMETSA-O	Launched
ceftaroline-fosamil	bacterial cell wall synthesis inhibitor		infectious disease	skin infections, pneumonia	CCO\N=C(\C(=O)N[C@H]1[C@H]2SCC(Sc3nc(cs3)-c3cc[n+](C)cc3)=C(N2C1=O)C(O)=O)c1nc(=NP(O)(O)=O)s[nH]1 |c:27|	ZCCUWMICIWSJIX-XHNDKCDBSA-O	Launched
ceftazidime	bacterial cell wall synthesis inhibitor		infectious disease	respiratory tract infections, skin infections, bacterial septicemia, bone and joint infections, gynecologic infections, intra-abdominal infections, meningitis	CC(C)(O\N=C(/C(=O)N[C@H]1[C@H]2SCC(C[n+]3ccccc3)=C(N2C1=O)C(O)=O)c1csc(N)n1)C(O)=O |c:21|, CC(C)(O\N=C(/C(=O)N[C@H]1[C@H]2SCC(C[n+]3ccccc3)=C(N2C1=O)C(O)=O)c1csc(N)n1)C(O)=O |c:21|, CC(C)(O\N=C(/C(=O)N[C@H]1[C@H]2SCC(C[n+]3ccccc3)=C(N2C1=O)C(O)=O)c1csc(N)n1)C(O)=O |c:21|, CC(C)(O\N=C(/C(=O)N[C@H]1[C@H]2SCC(C[n+]3ccccc3)=C(N2C1=O)C(O)=O)c1csc(N)n1)C(O)=O |c:21|, CC(C)(O\N=C(/C(=O)N[C@H]1[C@H]2SCC(C[n+]3ccccc3)=C(N2C1=O)C(O)=O)c1csc(N)n1)C(O)=O |c:21|	ORFOPKXBNMVMKC-DWVKKRMSSA-O, ORFOPKXBNMVMKC-DWVKKRMSSA-O, ORFOPKXBNMVMKC-DWVKKRMSSA-O, ORFOPKXBNMVMKC-DWVKKRMSSA-O, ORFOPKXBNMVMKC-DWVKKRMSSA-O	Launched
ceftibuten	bacterial cell wall synthesis inhibitor		pulmonary, otolaryngology	bronchitis, otitis, pharyngitis, tonsillitis	Nc1nc(cs1)C(=C\CC(O)=O)\C(=O)N[C@H]1[C@H]2SCC=C(N2C1=O)C(O)=O |c:20|, Nc1nc(cs1)C(=C\CC(O)=O)\C(=O)N[C@H]1[C@H]2SCC=C(N2C1=O)C(O)=O |c:20|, Nc1nc(cs1)C(=C\CC(O)=O)\C(=O)N[C@H]1[C@H]2SCC=C(N2C1=O)C(O)=O |c:20|, Nc1nc(cs1)C(=C\CC(O)=O)\C(=O)N[C@H]1[C@H]2SCC=C(N2C1=O)C(O)=O |c:20|, Nc1nc(cs1)C(=C\CC(O)=O)\C(=O)N[C@H]1[C@H]2SCC=C(N2C1=O)C(O)=O |c:20|	UNJFKXSSGBWRBZ-BJCIPQKHSA-N, UNJFKXSSGBWRBZ-BJCIPQKHSA-N, UNJFKXSSGBWRBZ-BJCIPQKHSA-N, UNJFKXSSGBWRBZ-BJCIPQKHSA-N, UNJFKXSSGBWRBZ-BJCIPQKHSA-N	Launched
ceftiofur	bacterial cell wall synthesis inhibitor		infectious disease	pneumonia, respiratory tract infections	CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(CSC(=O)c3ccco3)=C(N2C1=O)C(O)=O)c1csc(N)n1 |c:21|, CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(CSC(=O)c3ccco3)=C(N2C1=O)C(O)=O)c1csc(N)n1 |c:21|, CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(CSC(=O)c3ccco3)=C(N2C1=O)C(O)=O)c1csc(N)n1 |c:21|, CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(CSC(=O)c3ccco3)=C(N2C1=O)C(O)=O)c1csc(N)n1 |c:21|	ZBHXIWJRIFEVQY-IHMPYVIRSA-N, ZBHXIWJRIFEVQY-IHMPYVIRSA-N, ZBHXIWJRIFEVQY-IHMPYVIRSA-N, ZBHXIWJRIFEVQY-IHMPYVIRSA-N	Launched
ceftizoxim	bacterial cell wall synthesis inhibitor		infectious disease	respiratory tract infections, urinary tract infections, gonorrhea, pelvic inflammatory disease, intra-abdominal infections, bacterial septicemia, skin infections, bone and joint infections, meningitis	CO\N=C(/C(=O)N[C@H]1[C@H]2SCC=C(N2C1=O)C(O)=O)c1csc(N)n1 |c:11|, CO\N=C(/C(=O)N[C@H]1[C@H]2SCC=C(N2C1=O)C(O)=O)c1csc(N)n1 |c:11|, CO\N=C(/C(=O)N[C@H]1[C@H]2SCC=C(N2C1=O)C(O)=O)c1csc(N)n1 |c:11|	NNULBSISHYWZJU-LLKWHZGFSA-N, NNULBSISHYWZJU-LLKWHZGFSA-N, NNULBSISHYWZJU-LLKWHZGFSA-N	Launched
ceftobiprole	antiinfective drug				[H][C@]12SCC(\C=C3/CCN([C@@H]4CCNC4)C3=O)=C(N1C(=O)[C@H]2NC(=O)C(=N/O)\c1nsc(N)n1)C(O)=O |c:18|	VOAZJEPQLGBXGO-SDAWRPRTSA-N	Phase 3
ceftriaxone	bacterial cell wall synthesis inhibitor		infectious disease, otolaryngology	gonorrhea, pneumonia, otitis, skin infections, urinary tract infections, pelvic inflammatory disease, bacterial septicemia, bone and joint infections, intra-abdominal infections, meningitis, surgical prophylaxis	CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(CSc3nc(=O)c(O)nn3C)=C(N2C1=O)C(O)=O)c1csc(N)n1 |c:23|, CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(CSc3nc(=O)c(O)nn3C)=C(N2C1=O)C(O)=O)c1csc(N)n1 |c:23|	VAAUVRVFOQPIGI-SPQHTLEESA-N, VAAUVRVFOQPIGI-SPQHTLEESA-N	Launched
cefuroxime	bacterial cell wall synthesis inhibitor		infectious disease	gram-negative bacterial infections	CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(COC(N)=O)=C(N2C1=O)C(O)=O)c1ccco1 |c:16|, CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(COC(N)=O)=C(N2C1=O)C(O)=O)c1ccco1 |c:16|, CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(COC(N)=O)=C(N2C1=O)C(O)=O)c1ccco1 |c:16|	JFPVXVDWJQMJEE-IZRZKJBUSA-N, JFPVXVDWJQMJEE-IZRZKJBUSA-N, JFPVXVDWJQMJEE-IZRZKJBUSA-N	Launched
cefuroxime-axetil	bacterial cell wall synthesis inhibitor		otolaryngology	pharyngitis, tonsillitis, otitis, sinusitis	CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(COC(N)=O)=C(N2C1=O)C(=O)O[C@@H](C)OC(C)=O)c1ccco1 |a:7,8,&1:24,c:16|, CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(COC(N)=O)=C(N2C1=O)C(=O)O[C@@H](C)OC(C)=O)c1ccco1 |a:7,8,&1:24,c:16|, CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(COC(N)=O)=C(N2C1=O)C(=O)O[C@@H](C)OC(C)=O)c1ccco1 |a:7,8,&1:24,c:16|	KEJCWVGMRLCZQQ-QFDKGRJDSA-N, KEJCWVGMRLCZQQ-QFDKGRJDSA-N, KEJCWVGMRLCZQQ-QFDKGRJDSA-N	Launched
celecoxib	cyclooxygenase inhibitor	CA12, PDPK1, PTGS2	rheumatology, endocrinology	osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, primary dysmenorrhea (PD)	Cc1ccc(cc1)-c1cc(nn1-c1ccc(cc1)S(N)(=O)=O)C(F)(F)F, Cc1ccc(cc1)-c1cc(nn1-c1ccc(cc1)S(N)(=O)=O)C(F)(F)F, Cc1ccc(cc1)-c1cc(nn1-c1ccc(cc1)S(N)(=O)=O)C(F)(F)F	RZEKVGVHFLEQIL-UHFFFAOYSA-N, RZEKVGVHFLEQIL-UHFFFAOYSA-N, RZEKVGVHFLEQIL-UHFFFAOYSA-N	Launched
celgosivir	glucosidase inhibitor				[H][C@]12[C@@H](O)CCN1C[C@H](OC(=O)CCC)[C@@H](O)[C@@H]2O	HTJGLYIJVSDQAE-VWNXEWBOSA-N	Phase 2
celiprolol	adrenergic receptor antagonist	ADRA2A, ADRB1, ADRB2	genetics	Ehlers-Danlos syndrome (EDS)	CCN(CC)C(=O)Nc1ccc(OC[C@@H](O)CNC(C)(C)C)c(c1)C(C)=O |&1:14|, CCN(CC)C(=O)Nc1ccc(OC[C@@H](O)CNC(C)(C)C)c(c1)C(C)=O |&1:14|	JOATXPAWOHTVSZ-INIZCTEOSA-N, JOATXPAWOHTVSZ-INIZCTEOSA-N	Launched
cenerimod	sphingosine 1-phosphate receptor modulator				CCc1cc(cc(C)c1OC[C@@H](O)CO)-c1noc(n1)-c1cc(OC)nc(c1)C1CCCC1	KJKKMMMRWISKRF-FQEVSTJZSA-N	Phase 2
cenicriviroc	CC chemokine receptor antagonist				CCCCOCCOc1ccc(cc1)-c1ccc2N(CC(C)C)CCC\C(=C/c2c1)C(=O)Nc1ccc(cc1)[S@@](=O)Cc1cncn1CCC |c:27|	PNDKCRDVVKJPKG-WHERJAGFSA-N	Phase 3
cenobamate	GABA receptor modulator, voltage-gated sodium channel blocker				NC(=O)O[C@@H](Cn1ncnn1)c1ccccc1Cl	GFHAXPJGXSQLPT-VIFPVBQESA-N	Launched
centanafadine	dopamine reuptake inhibitor				C1[C@@H]2CNC[C@]12c1ccc2ccccc2c1	HKHCSWPSUSWGLI-CABCVRRESA-N	Phase 3
centazolone	monoamine oxidase inhibitor				Nn1cnc2cc3ccccc3cc2c1=O, Nn1cnc2cc3ccccc3cc2c1=O, Nn1cnc2cc3ccccc3cc2c1=O	CZXUQBVMAUWSBX-UHFFFAOYSA-N, CZXUQBVMAUWSBX-UHFFFAOYSA-N, CZXUQBVMAUWSBX-UHFFFAOYSA-N	Phase 1
centhaquin	analgesic agent				Cc1cccc(c1)N1CCN(CCc2ccc3ccccc3n2)CC1	UJNWGFBJUHIJKK-UHFFFAOYSA-N	Phase 1
centpropazine	inositol monophosphatase inhibitor				CCC(=O)c1ccc(OC[C@@H](O)CN2CCN(CC2)c2ccccc2)cc1 |&1:10,r|, CCC(=O)c1ccc(OC[C@@H](O)CN2CCN(CC2)c2ccccc2)cc1 |&1:10,r|, CCC(=O)c1ccc(OC[C@@H](O)CN2CCN(CC2)c2ccccc2)cc1 |&1:10,r|, CCC(=O)c1ccc(OC[C@@H](O)CN2CCN(CC2)c2ccccc2)cc1 |&1:10,r|	ZQPXSRTZFYHSFB-FQEVSTJZSA-N, ZQPXSRTZFYHSFB-FQEVSTJZSA-N, ZQPXSRTZFYHSFB-FQEVSTJZSA-N, ZQPXSRTZFYHSFB-FQEVSTJZSA-N	Phase 3
CEP-32496	RAF inhibitor	BRAF, RAF1			COc1cc2ncnc(Oc3cccc(NC(=O)Nc4cc(on4)C(C)(C)C(F)(F)F)c3)c2cc1OC, COc1cc2ncnc(Oc3cccc(NC(=O)Nc4cc(on4)C(C)(C)C(F)(F)F)c3)c2cc1OC, COc1cc2ncnc(Oc3cccc(NC(=O)Nc4cc(on4)C(C)(C)C(F)(F)F)c3)c2cc1OC, COc1cc2ncnc(Oc3cccc(NC(=O)Nc4cc(on4)C(C)(C)C(F)(F)F)c3)c2cc1OC, COc1cc2ncnc(Oc3cccc(NC(=O)Nc4cc(on4)C(C)(C)C(F)(F)F)c3)c2cc1OC, COc1cc2ncnc(Oc3cccc(NC(=O)Nc4cc(on4)C(C)(C)C(F)(F)F)c3)c2cc1OC, COc1cc2ncnc(Oc3cccc(NC(=O)Nc4cc(on4)C(C)(C)C(F)(F)F)c3)c2cc1OC	DKNUPRMJNUQNHR-UHFFFAOYSA-N, DKNUPRMJNUQNHR-UHFFFAOYSA-N, DKNUPRMJNUQNHR-UHFFFAOYSA-N, DKNUPRMJNUQNHR-UHFFFAOYSA-N, DKNUPRMJNUQNHR-UHFFFAOYSA-N, DKNUPRMJNUQNHR-UHFFFAOYSA-N, DKNUPRMJNUQNHR-UHFFFAOYSA-N	Phase 1/Phase 2
CEP-33779	JAK inhibitor	JAK2			CN1CCN(CC1)c1cccc(Nc2nc3c(cccn3n2)-c2ccc(cc2)S(C)(=O)=O)c1, CN1CCN(CC1)c1cccc(Nc2nc3c(cccn3n2)-c2ccc(cc2)S(C)(=O)=O)c1, CN1CCN(CC1)c1cccc(Nc2nc3c(cccn3n2)-c2ccc(cc2)S(C)(=O)=O)c1, CN1CCN(CC1)c1cccc(Nc2nc3c(cccn3n2)-c2ccc(cc2)S(C)(=O)=O)c1, CN1CCN(CC1)c1cccc(Nc2nc3c(cccn3n2)-c2ccc(cc2)S(C)(=O)=O)c1, CN1CCN(CC1)c1cccc(Nc2nc3c(cccn3n2)-c2ccc(cc2)S(C)(=O)=O)c1, CN1CCN(CC1)c1cccc(Nc2nc3c(cccn3n2)-c2ccc(cc2)S(C)(=O)=O)c1	RFZKSQIFOZZIAQ-UHFFFAOYSA-N, RFZKSQIFOZZIAQ-UHFFFAOYSA-N, RFZKSQIFOZZIAQ-UHFFFAOYSA-N, RFZKSQIFOZZIAQ-UHFFFAOYSA-N, RFZKSQIFOZZIAQ-UHFFFAOYSA-N, RFZKSQIFOZZIAQ-UHFFFAOYSA-N, RFZKSQIFOZZIAQ-UHFFFAOYSA-N	Preclinical
CEP-37440	ALK tyrosine kinase receptor inhibitor	ALK			CNC(=O)c1ccccc1Nc1nc(Nc2ccc3C[C@H](CCCc3c2OC)N2CCN(CCO)CC2)ncc1Cl, CNC(=O)c1ccccc1Nc1nc(Nc2ccc3C[C@H](CCCc3c2OC)N2CCN(CCO)CC2)ncc1Cl, CNC(=O)c1ccccc1Nc1nc(Nc2ccc3C[C@H](CCCc3c2OC)N2CCN(CCO)CC2)ncc1Cl, CNC(=O)c1ccccc1Nc1nc(Nc2ccc3C[C@H](CCCc3c2OC)N2CCN(CCO)CC2)ncc1Cl, CNC(=O)c1ccccc1Nc1nc(Nc2ccc3C[C@H](CCCc3c2OC)N2CCN(CCO)CC2)ncc1Cl, CNC(=O)c1ccccc1Nc1nc(Nc2ccc3C[C@H](CCCc3c2OC)N2CCN(CCO)CC2)ncc1Cl	BCSHRERPHLTPEE-NRFANRHFSA-N, BCSHRERPHLTPEE-NRFANRHFSA-N, BCSHRERPHLTPEE-NRFANRHFSA-N, BCSHRERPHLTPEE-NRFANRHFSA-N, InChI=1S/C30H38ClN7O3/c1-32-29(40)23-7-3-4-9-25(23)34-28-24(31)19-33-30(36-28)35-26-11-10-20-18-21(6-5-8-22(20)27(26)41-2)38-14-12-37(13-15-38)16-17-39/h3-4,7,9-11,19,21,39H,5-6,8,12-18H2,1-2H3,(H,32,40)(H2,33,34,35,36)/t21-/m0/s1, InChI=1S/C30H38ClN7O3/c1-32-29(40)23-7-3-4-9-25(23)34-28-24(31)19-33-30(36-28)35-26-11-10-20-18-21(6-5-8-22(20)27(26)41-2)38-14-12-37(13-15-38)16-17-39/h3-4,7,9-11,19,21,39H,5-6,8,12-18H2,1-2H3,(H,32,40)(H2,33,34,35,36)/t21-/m0/s1	Phase 1
CEP-40783	AXL kinase inhibitor				COc1cc2nccc(Oc3ccc(NC(=O)c4cn(C(C)C)c(=O)n(-c5ccc(F)cc5)c4=O)cc3F)c2cc1OC	FKCWHHYUMFGOPY-UHFFFAOYSA-N	Preclinical
cephalexin	bacterial cell wall synthesis inhibitor		infectious disease, otolaryngology	respiratory tract infections, otitis, skin infections, bone and joint infections, genitourinary tract infections	CC1=C(N2[C@H](SC1)[C@H](NC(=O)[C@H](N)c1ccccc1)C2=O)C(O)=O |t:1|, CC1=C(N2[C@H](SC1)[C@H](NC(=O)[C@H](N)c1ccccc1)C2=O)C(O)=O |t:1|, CC1=C(N2[C@H](SC1)[C@H](NC(=O)[C@H](N)c1ccccc1)C2=O)C(O)=O |t:1|, CC1=C(N2[C@H](SC1)[C@H](NC(=O)[C@H](N)c1ccccc1)C2=O)C(O)=O |t:1|, CC1=C(N2[C@H](SC1)[C@H](NC(=O)[C@H](N)c1ccccc1)C2=O)C(O)=O |t:1|, CC1=C(N2[C@H](SC1)[C@H](NC(=O)[C@H](N)c1ccccc1)C2=O)C(O)=O |t:1|	ZAIPMKNFIOOWCQ-UEKVPHQBSA-N, ZAIPMKNFIOOWCQ-UEKVPHQBSA-N, ZAIPMKNFIOOWCQ-UEKVPHQBSA-N, ZAIPMKNFIOOWCQ-UEKVPHQBSA-N, ZAIPMKNFIOOWCQ-UEKVPHQBSA-N, ZAIPMKNFIOOWCQ-UEKVPHQBSA-N	Launched
cephalomannine	DNA polymerase inhibitor				C\C=C(/C)C(=O)N[C@H]([C@@H](O)C(=O)O[C@H]1C[C@@]2(O)[C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C(=O)[C@H](OC(C)=O)C(=C1C)C2(C)C)OC(C)=O)c1ccccc1 |t:47|, C\C=C(/C)C(=O)N[C@H]([C@@H](O)C(=O)O[C@H]1C[C@@]2(O)[C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C(=O)[C@H](OC(C)=O)C(=C1C)C2(C)C)OC(C)=O)c1ccccc1 |t:47|, C\C=C(/C)C(=O)N[C@H]([C@@H](O)C(=O)O[C@H]1C[C@@]2(O)[C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C(=O)[C@H](OC(C)=O)C(=C1C)C2(C)C)OC(C)=O)c1ccccc1 |t:47|	DBXFAPJCZABTDR-WBYYIXQISA-N, DBXFAPJCZABTDR-WBYYIXQISA-N, DBXFAPJCZABTDR-WBYYIXQISA-N	Preclinical
cephalosporin-c-zn	bacterial cell wall synthesis inhibitor				CC(=O)OCC1=C2N3[C@H](SC1)[C@H](NC(=O)CCC[C@H](N)C(=O)O[Zn]OC2=O)C3=O |t:5|	TVMXJQZBKOMFQK-JFEXGKLBSA-L	Preclinical
cephalothin	bacterial cell wall synthesis inhibitor		infectious disease	skin infections, surgical prophylaxis	CC(=O)OCC1=C(N2[C@H](SC1)[C@H](NC(=O)Cc1cccs1)C2=O)C(O)=O |t:5|, CC(=O)OCC1=C(N2[C@H](SC1)[C@H](NC(=O)Cc1cccs1)C2=O)C(O)=O |t:5|	XIURVHNZVLADCM-IUODEOHRSA-N, XIURVHNZVLADCM-IUODEOHRSA-N	Launched
cephapirin	bacterial cell wall synthesis inhibitor		obstetrics/gynecology	mastitis	CC(=O)OCC1=C(N2[C@H](SC1)[C@H](NC(=O)CSc1ccncc1)C2=O)C(O)=O |t:5|, CC(=O)OCC1=C(N2[C@H](SC1)[C@H](NC(=O)CSc1ccncc1)C2=O)C(O)=O |t:5|, CC(=O)OCC1=C(N2[C@H](SC1)[C@H](NC(=O)CSc1ccncc1)C2=O)C(O)=O |t:5|	UQLLWWBDSUHNEB-CZUORRHYSA-N, UQLLWWBDSUHNEB-CZUORRHYSA-N, UQLLWWBDSUHNEB-CZUORRHYSA-N	Launched
cepharanthine	NFkB pathway inhibitor				COc1ccc2C[C@H]3N(C)CCc4cc(OC)c(Oc5c6OCOc6cc6CCN(C)[C@@H](Cc7ccc(Oc1c2)cc7)c56)cc34, COc1ccc2C[C@H]3N(C)CCc4cc(OC)c(Oc5c6OCOc6cc6CCN(C)[C@@H](Cc7ccc(Oc1c2)cc7)c56)cc34, COc1ccc2C[C@H]3N(C)CCc4cc(OC)c(Oc5c6OCOc6cc6CCN(C)[C@@H](Cc7ccc(Oc1c2)cc7)c56)cc34, COc1ccc2C[C@H]3N(C)CCc4cc(OC)c(Oc5c6OCOc6cc6CCN(C)[C@@H](Cc7ccc(Oc1c2)cc7)c56)cc34, COc1ccc2C[C@H]3N(C)CCc4cc(OC)c(Oc5c6OCOc6cc6CCN(C)[C@@H](Cc7ccc(Oc1c2)cc7)c56)cc34, COc1ccc2C[C@H]3N(C)CCc4cc(OC)c(Oc5c6OCOc6cc6CCN(C)[C@@H](Cc7ccc(Oc1c2)cc7)c56)cc34, COc1ccc2C[C@H]3N(C)CCc4cc(OC)c(Oc5c6OCOc6cc6CCN(C)[C@@H](Cc7ccc(Oc1c2)cc7)c56)cc34	YVPXVXANRNDGTA-WDYNHAJCSA-N, YVPXVXANRNDGTA-WDYNHAJCSA-N, YVPXVXANRNDGTA-WDYNHAJCSA-N, YVPXVXANRNDGTA-WDYNHAJCSA-N, YVPXVXANRNDGTA-WDYNHAJCSA-N, YVPXVXANRNDGTA-WDYNHAJCSA-N, YVPXVXANRNDGTA-WDYNHAJCSA-N	Phase 2
cephradine	bacterial cell wall synthesis inhibitor		infectious disease	skin infections, respiratory tract infections, urinary tract infections	CC1=C(N2[C@@H](SC1)[C@H](NC(=O)[C@H](N)C1=CCC=CC1)C2=O)C(O)=O |a:7,11,&1:4,c:17,t:1,14|	RDLPVSKMFDYCOR-HFAKWTLXSA-N	Launched
ceramide	phosphoenolpyruvate carboxylase activator, serine/threonine protein phosphatase activator		dermatology	cosmetic	CCCCCCCCCCCCC\C=C\[C@@H](O)[C@H](CO)NC(C)=O	BLTCBVOJNNKFKC-QUDYQQOWSA-N	Launched
ceritinib	ALK tyrosine kinase receptor inhibitor	ALK, FLT3, IGF1R, INSR, TSSK1B	oncology	non-small cell lung cancer (NSCLC)	CC(C)Oc1cc(C2CCNCC2)c(C)cc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1, CC(C)Oc1cc(C2CCNCC2)c(C)cc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1, CC(C)Oc1cc(C2CCNCC2)c(C)cc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1, CC(C)Oc1cc(C2CCNCC2)c(C)cc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1, CC(C)Oc1cc(C2CCNCC2)c(C)cc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1, CC(C)Oc1cc(C2CCNCC2)c(C)cc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1, CC(C)Oc1cc(C2CCNCC2)c(C)cc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1, CC(C)Oc1cc(C2CCNCC2)c(C)cc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1, CC(C)Oc1cc(C2CCNCC2)c(C)cc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1, CC(C)Oc1cc(C2CCNCC2)c(C)cc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1, CC(C)Oc1cc(C2CCNCC2)c(C)cc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1, CC(C)Oc1cc(C2CCNCC2)c(C)cc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1, CC(C)Oc1cc(C2CCNCC2)c(C)cc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1, CC(C)Oc1cc(C2CCNCC2)c(C)cc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1, CC(C)Oc1cc(C2CCNCC2)c(C)cc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1, CC(C)Oc1cc(C2CCNCC2)c(C)cc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1	VERWOWGGCGHDQE-UHFFFAOYSA-N, VERWOWGGCGHDQE-UHFFFAOYSA-N, VERWOWGGCGHDQE-UHFFFAOYSA-N, VERWOWGGCGHDQE-UHFFFAOYSA-N, VERWOWGGCGHDQE-UHFFFAOYSA-N, VERWOWGGCGHDQE-UHFFFAOYSA-N, VERWOWGGCGHDQE-UHFFFAOYSA-N, VERWOWGGCGHDQE-UHFFFAOYSA-N, VERWOWGGCGHDQE-UHFFFAOYSA-N, VERWOWGGCGHDQE-UHFFFAOYSA-N, VERWOWGGCGHDQE-UHFFFAOYSA-N, VERWOWGGCGHDQE-UHFFFAOYSA-N, VERWOWGGCGHDQE-UHFFFAOYSA-N, VERWOWGGCGHDQE-UHFFFAOYSA-N, VERWOWGGCGHDQE-UHFFFAOYSA-N, VERWOWGGCGHDQE-UHFFFAOYSA-N	Launched
cerulenin	fatty acid synthase inhibitor	FASN	infectious disease	fungal infection	C\C=C\C\C=C\CCC(=O)[C@H]1O[C@H]1C(N)=O, C\C=C\C\C=C\CCC(=O)[C@H]1O[C@H]1C(N)=O, C\C=C\C\C=C\CCC(=O)[C@H]1O[C@H]1C(N)=O	GVEZIHKRYBHEFX-NQQPLRFYSA-N, GVEZIHKRYBHEFX-NQQPLRFYSA-N, GVEZIHKRYBHEFX-NQQPLRFYSA-N	Launched
ceruletide	CCK receptor agonist	CCKAR			[H][C@](NC(=O)[C@H](Cc1ccc(OS(O)(=O)=O)cc1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H]1CCC(=O)N1)([C@@H](C)O)C(=O)NCC(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](Cc1ccccc1)C(N)=O	YRALAIOMGQZKOW-HYAOXDFASA-N	Preclinical
cetaben	ACAT inhibitor, cholesterol inhibitor	PPARA			CCCCCCCCCCCCCCCCNc1ccc(cc1)C(O)=O, CCCCCCCCCCCCCCCCNc1ccc(cc1)C(O)=O, CCCCCCCCCCCCCCCCNc1ccc(cc1)C(O)=O	QXWKHSSBFQDQPR-UHFFFAOYSA-N, QXWKHSSBFQDQPR-UHFFFAOYSA-N, QXWKHSSBFQDQPR-UHFFFAOYSA-N	Phase 2
cetilistat	triacylglycerol lipase inhibitor	PNLIP			CCCCCCCCCCCCCCCCOc1nc2ccc(C)cc2c(=O)o1, CCCCCCCCCCCCCCCCOc1nc2ccc(C)cc2c(=O)o1	MVCQKIKWYUURMU-UHFFFAOYSA-N, MVCQKIKWYUURMU-UHFFFAOYSA-N	Phase 3
cetirizine	histamine receptor antagonist	HRH1	allergy	allergic rhinitis	OC(=O)COCCN1CCN(CC1)[C@@H](c1ccccc1)c1ccc(Cl)cc1 |&1:13|, OC(=O)COCCN1CCN(CC1)[C@@H](c1ccccc1)c1ccc(Cl)cc1 |&1:13|, OC(=O)COCCN1CCN(CC1)[C@@H](c1ccccc1)c1ccc(Cl)cc1 |&1:13|	ZKLPARSLTMPFCP-NRFANRHFSA-N, ZKLPARSLTMPFCP-NRFANRHFSA-N, ZKLPARSLTMPFCP-NRFANRHFSA-N	Launched
cetrimonium			dermatology	cosmetic	CCCCCCCCCCCCCCCC[N+](C)(C)C, CCCCCCCCCCCCCCCC[N+](C)(C)C, CCCCCCCCCCCCCCCC[N+](C)(C)C, CCCCCCCCCCCCCCCC[N+](C)(C)C, CCCCCCCCCCCCCCCC[N+](C)(C)C, CCCCCCCCCCCCCCCC[N+](C)(C)C, CCCCCCCCCCCCCCCC[N+](C)(C)C	RLGQACBPNDBWTB-UHFFFAOYSA-N, RLGQACBPNDBWTB-UHFFFAOYSA-N, RLGQACBPNDBWTB-UHFFFAOYSA-N, RLGQACBPNDBWTB-UHFFFAOYSA-N, RLGQACBPNDBWTB-UHFFFAOYSA-N, RLGQACBPNDBWTB-UHFFFAOYSA-N, RLGQACBPNDBWTB-UHFFFAOYSA-N	Launched
cetrorelix	gonadotropin releasing factor hormone receptor antagonist	GNRHR, LHCGR	endocrinology	premature luteinizing hormone surges	CC(C)C[C@H](NC(=O)[C@@H](CCCNC(N)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@@H](Cc1cccnc1)NC(=O)[C@@H](Cc1ccc(Cl)cc1)NC(=O)[C@@H](Cc1ccc2ccccc2c1)NC(C)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(N)=O, CC(C)C[C@H](NC(=O)[C@@H](CCCNC(N)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@@H](Cc1cccnc1)NC(=O)[C@@H](Cc1ccc(Cl)cc1)NC(=O)[C@@H](Cc1ccc2ccccc2c1)NC(C)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(N)=O, CC(C)C[C@H](NC(=O)[C@@H](CCCNC(N)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@@H](Cc1cccnc1)NC(=O)[C@@H](Cc1ccc(Cl)cc1)NC(=O)[C@@H](Cc1ccc2ccccc2c1)NC(C)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(N)=O	SBNPWPIBESPSIF-MHWMIDJBSA-N, SBNPWPIBESPSIF-MHWMIDJBSA-N, SBNPWPIBESPSIF-MHWMIDJBSA-N	Launched
cetylpyridinium			dental	gingivitis, mouth inflammation	CCCCCCCCCCCCCCCC[n+]1ccccc1, CCCCCCCCCCCCCCCC[n+]1ccccc1, CCCCCCCCCCCCCCCC[n+]1ccccc1, CCCCCCCCCCCCCCCC[n+]1ccccc1, CCCCCCCCCCCCCCCC[n+]1ccccc1, CCCCCCCCCCCCCCCC[n+]1ccccc1, CCCCCCCCCCCCCCCC[n+]1ccccc1, CCCCCCCCCCCCCCCC[n+]1ccccc1, CCCCCCCCCCCCCCCC[n+]1ccccc1, CCCCCCCCCCCCCCCC[n+]1ccccc1	NEUSVAOJNUQRTM-UHFFFAOYSA-N, NEUSVAOJNUQRTM-UHFFFAOYSA-N, NEUSVAOJNUQRTM-UHFFFAOYSA-N, NEUSVAOJNUQRTM-UHFFFAOYSA-N, NEUSVAOJNUQRTM-UHFFFAOYSA-N, NEUSVAOJNUQRTM-UHFFFAOYSA-N, NEUSVAOJNUQRTM-UHFFFAOYSA-N, NEUSVAOJNUQRTM-UHFFFAOYSA-N, NEUSVAOJNUQRTM-UHFFFAOYSA-N, NEUSVAOJNUQRTM-UHFFFAOYSA-N	Launched
cevimeline	acetylcholine receptor agonist	CHRM3	rheumatology	sjogren's syndrome	C[C@H]1O[C@]2(CS1)CN1CCC2CC1 |&1:1,3|	WUTYZMFRCNBCHQ-WPRPVWTQSA-N	Launched
cevipabulin	microtubule stimulant, tubulin polymerization inhibitor	TUBB			[H][C@@](C)(Nc1c(c(Cl)nc2ncnn12)-c1c(F)cc(OCCCNC)cc1F)C(F)(F)F	ZUZPCOQWSYNWLU-VIFPVBQESA-N	Phase 1
CE3F4	rap guanine nucleotide exchange factor inhibitor	RAPGEF3			C[C@H]1CCc2c(Br)c(F)c(Br)cc2N1C=O |&1:1,r|, C[C@H]1CCc2c(Br)c(F)c(Br)cc2N1C=O |&1:1,r|	ZZLQPWXVZCPUGC-LURJTMIESA-N, ZZLQPWXVZCPUGC-LURJTMIESA-N	Preclinical
CFI-400945	serine/threonine kinase inhibitor				COc1ccc2NC(=O)[C@@]3(C[C@H]3c3ccc4c(\C=C\c5ccc(CN6C[C@H](C)O[C@H](C)C6)cc5)[nH]nc4c3)c2c1	DADASRPKWOGKCU-FVTQAUBDSA-N	Phase 2
CFI-402257	dual specificity protein kinase inhibitor				Cc1cc(ccc1C(=O)NC1CC1)-c1cnn2c(NC[C@H]3C[C@@](C)(O)C3)cc(Oc3cccnc3)nc12 |r|	PMQUGSPFUBGJCZ-CHOKWEPUSA-N	Phase 1/Phase 2
CFM-1571	guanylate cyclase activator				COc1ccc(NC(=O)c2cc(OCCCN(C)C)nn2Cc2ccccc2)cc1, COc1ccc(NC(=O)c2cc(OCCCN(C)C)nn2Cc2ccccc2)cc1	YZCSJBGQLATPMH-UHFFFAOYSA-N, YZCSJBGQLATPMH-UHFFFAOYSA-N	Preclinical
CFM-2	glutamate receptor antagonist				COc1cc2CC(=O)NN=C(c3ccc(N)cc3)c2cc1OC |t:9|, COc1cc2CC(=O)NN=C(c3ccc(N)cc3)c2cc1OC |t:9|	MJKADKZSYQWGLL-UHFFFAOYSA-N, MJKADKZSYQWGLL-UHFFFAOYSA-N	Preclinical
CFTRinh-172	chloride channel blocker	CFTR			OC(=O)c1ccc(\C=C2\SC(=S)N(C2=O)c2cccc(c2)C(F)(F)F)cc1, OC(=O)c1ccc(\C=C2\SC(=S)N(C2=O)c2cccc(c2)C(F)(F)F)cc1, OC(=O)c1ccc(\C=C2\SC(=S)N(C2=O)c2cccc(c2)C(F)(F)F)cc1, OC(=O)c1ccc(\C=C2\SC(=S)N(C2=O)c2cccc(c2)C(F)(F)F)cc1, OC(=O)c1ccc(\C=C2\SC(=S)N(C2=O)c2cccc(c2)C(F)(F)F)cc1	JIMHYXZZCWVCMI-RIYZIHGNSA-N, JIMHYXZZCWVCMI-RIYZIHGNSA-N, JIMHYXZZCWVCMI-RIYZIHGNSA-N, JIMHYXZZCWVCMI-RIYZIHGNSA-N, JIMHYXZZCWVCMI-RIYZIHGNSA-N	Preclinical
CF102	adenosine receptor agonist	ADORA1, ADORA2A, ADORA2B, ADORA3			CNC(=O)[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(NCc3cccc(I)c3)nc(Cl)nc12, CNC(=O)[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(NCc3cccc(I)c3)nc(Cl)nc12, CNC(=O)[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(NCc3cccc(I)c3)nc(Cl)nc12, CNC(=O)[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(NCc3cccc(I)c3)nc(Cl)nc12	IPSYPUKKXMNCNQ-PFHKOEEOSA-N, IPSYPUKKXMNCNQ-PFHKOEEOSA-N, IPSYPUKKXMNCNQ-PFHKOEEOSA-N, IPSYPUKKXMNCNQ-PFHKOEEOSA-N	Phase 2
CG-400549	FABI inhibitor				Cc1c(N)cccc1Cn1ccc(OCCc2cccs2)cc1=O, Cc1c(N)cccc1Cn1ccc(OCCc2cccs2)cc1=O	YCLREGRRHGLOAK-UHFFFAOYSA-N, YCLREGRRHGLOAK-UHFFFAOYSA-N	Phase 2
CGH2466	adenosine receptor antagonist	ADORA1, ADORA2B, ADORA3			Nc1nc(c(s1)-c1ccncc1)-c1ccc(Cl)c(Cl)c1, Nc1nc(c(s1)-c1ccncc1)-c1ccc(Cl)c(Cl)c1, Nc1nc(c(s1)-c1ccncc1)-c1ccc(Cl)c(Cl)c1, Nc1nc(c(s1)-c1ccncc1)-c1ccc(Cl)c(Cl)c1, Nc1nc(c(s1)-c1ccncc1)-c1ccc(Cl)c(Cl)c1	BEPGKLOHQTXUHX-UHFFFAOYSA-N, BEPGKLOHQTXUHX-UHFFFAOYSA-N, BEPGKLOHQTXUHX-UHFFFAOYSA-N, BEPGKLOHQTXUHX-UHFFFAOYSA-N, BEPGKLOHQTXUHX-UHFFFAOYSA-N	Preclinical
CGK-733	ATM kinase inhibitor, ATR kinase inhibitor	ATM, ATR			[O-][N+](=O)c1cc(NC(=S)N[C@@H](NC(=O)C(c2ccccc2)c2ccccc2)C(Cl)(Cl)Cl)ccc1F |&1:10,r|, [O-][N+](=O)c1cc(NC(=S)N[C@@H](NC(=O)C(c2ccccc2)c2ccccc2)C(Cl)(Cl)Cl)ccc1F |&1:10,r|, [O-][N+](=O)c1cc(NC(=S)N[C@@H](NC(=O)C(c2ccccc2)c2ccccc2)C(Cl)(Cl)Cl)ccc1F |&1:10,r|, [O-][N+](=O)c1cc(NC(=S)N[C@@H](NC(=O)C(c2ccccc2)c2ccccc2)C(Cl)(Cl)Cl)ccc1F |&1:10,r|, [O-][N+](=O)c1cc(NC(=S)N[C@@H](NC(=O)C(c2ccccc2)c2ccccc2)C(Cl)(Cl)Cl)ccc1F |&1:10,r|, [O-][N+](=O)c1cc(NC(=S)N[C@@H](NC(=O)C(c2ccccc2)c2ccccc2)C(Cl)(Cl)Cl)ccc1F |&1:10,r|	HLCDNLNLQNYZTK-OAQYLSRUSA-N, HLCDNLNLQNYZTK-OAQYLSRUSA-N, HLCDNLNLQNYZTK-OAQYLSRUSA-N, HLCDNLNLQNYZTK-OAQYLSRUSA-N, HLCDNLNLQNYZTK-OAQYLSRUSA-N, HLCDNLNLQNYZTK-OAQYLSRUSA-N	Preclinical
CGM097	MDM inhibitor	MDM2			COc1cc2CC(=O)N([C@@H](c3ccc(Cl)cc3)c2cc1OC(C)C)c1ccc(cc1)N(C)C[C@H]1CC[C@@H](CC1)N1CCN(C)C(=O)C1, COc1cc2CC(=O)N([C@@H](c3ccc(Cl)cc3)c2cc1OC(C)C)c1ccc(cc1)N(C)C[C@H]1CC[C@@H](CC1)N1CCN(C)C(=O)C1, COc1cc2CC(=O)N([C@@H](c3ccc(Cl)cc3)c2cc1OC(C)C)c1ccc(cc1)N(C)C[C@H]1CC[C@@H](CC1)N1CCN(C)C(=O)C1, COc1cc2CC(=O)N([C@@H](c3ccc(Cl)cc3)c2cc1OC(C)C)c1ccc(cc1)N(C)C[C@H]1CC[C@@H](CC1)N1CCN(C)C(=O)C1, COc1cc2CC(=O)N([C@@H](c3ccc(Cl)cc3)c2cc1OC(C)C)c1ccc(cc1)N(C)C[C@H]1CC[C@@H](CC1)N1CCN(C)C(=O)C1, COc1cc2CC(=O)N([C@@H](c3ccc(Cl)cc3)c2cc1OC(C)C)c1ccc(cc1)N(C)C[C@H]1CC[C@@H](CC1)N1CCN(C)C(=O)C1, COc1cc2CC(=O)N([C@@H](c3ccc(Cl)cc3)c2cc1OC(C)C)c1ccc(cc1)N(C)C[C@H]1CC[C@@H](CC1)N1CCN(C)C(=O)C1	CLRSLRWKONPSRQ-IIPSPAQQSA-N, CLRSLRWKONPSRQ-IIPSPAQQSA-N, CLRSLRWKONPSRQ-IIPSPAQQSA-N, CLRSLRWKONPSRQ-IIPSPAQQSA-N, CLRSLRWKONPSRQ-IIPSPAQQSA-N, CLRSLRWKONPSRQ-IIPSPAQQSA-N, CLRSLRWKONPSRQ-IIPSPAQQSA-N	Phase 1
CGP-12177	adrenergic receptor agonist	ADRB1, ADRB2, ADRB3			CC(C)(C)NC[C@@H](O)COc1cccc2[nH]c(=O)[nH]c12 |&1:6|, CC(C)(C)NC[C@@H](O)COc1cccc2[nH]c(=O)[nH]c12 |&1:6|	UMQUQWCJKFOUGV-SECBINFHSA-N, UMQUQWCJKFOUGV-SECBINFHSA-N	Phase 1
CGP-13501	GABA receptor modulator	GABBR1			CC(C)(C)c1cc(CC(C)(C)C=O)cc(c1O)C(C)(C)C, CC(C)(C)c1cc(CC(C)(C)C=O)cc(c1O)C(C)(C)C, CC(C)(C)c1cc(CC(C)(C)C=O)cc(c1O)C(C)(C)C, CC(C)(C)c1cc(CC(C)(C)C=O)cc(c1O)C(C)(C)C	XGWATTXMMMANFJ-UHFFFAOYSA-N, XGWATTXMMMANFJ-UHFFFAOYSA-N, XGWATTXMMMANFJ-UHFFFAOYSA-N, XGWATTXMMMANFJ-UHFFFAOYSA-N	Preclinical
CGP-20712A	adrenergic receptor antagonist	ADRB1, ADRB3			CS(O)(=O)=O.Cn1cc(nc1-c1ccc(OC[C@H](O)CNCCOc2ccc(O)c(c2)C(N)=O)cc1)C(F)(F)F |&1:17,r|	VFPOVCXWKBYDNF-XFULWGLBSA-N	Preclinical
CGP-25454A	dopamine receptor antagonist				CCN(CC)CCNC(=O)c1cc(C#N)c(Cl)cc1OC	JEMKCYHUYUPGFN-UHFFFAOYSA-N	Preclinical
CGP-37157	mitochondrial Na+/Ca2+ exchanger antagonist, sodium/calcium exchange inhibitor	SLC8A1			Clc1ccc2NC(=O)CS[C@@H](c3ccccc3Cl)c2c1 |&1:10,r|, Clc1ccc2NC(=O)CS[C@@H](c3ccccc3Cl)c2c1 |&1:10,r|, Clc1ccc2NC(=O)CS[C@@H](c3ccccc3Cl)c2c1 |&1:10,r|, Clc1ccc2NC(=O)CS[C@@H](c3ccccc3Cl)c2c1 |&1:10,r|, Clc1ccc2NC(=O)CS[C@@H](c3ccccc3Cl)c2c1 |&1:10,r|	KQEPIRKXSUIUTH-HNNXBMFYSA-N, KQEPIRKXSUIUTH-HNNXBMFYSA-N, KQEPIRKXSUIUTH-HNNXBMFYSA-N, KQEPIRKXSUIUTH-HNNXBMFYSA-N, KQEPIRKXSUIUTH-HNNXBMFYSA-N	Preclinical
CGP-37849	glutamate receptor antagonist	GRIN2A, GRIN2B, GRIN2C, GRIN2D			C\C(CP(O)(O)=O)=C/[C@@H](N)C(O)=O |&1:8,r|, C\C(CP(O)(O)=O)=C/[C@@H](N)C(O)=O |&1:8,r|	BDYHNCZIGYIOGJ-XWCPEMDWSA-N, BDYHNCZIGYIOGJ-XWCPEMDWSA-N	Phase 1
CGP-39551	NMDA receptor antagonist				CCOC(=O)[C@H](N)\C=C(/C)CP(O)(O)=O |&1:5,r|	OKDOWCKDTWNRCB-PTYLAXBQSA-N	Preclinical
CGP-52411	EGFR inhibitor	EGFR			O=C1NC(=O)c2cc(Nc3ccccc3)c(Nc3ccccc3)cc12, O=C1NC(=O)c2cc(Nc3ccccc3)c(Nc3ccccc3)cc12, O=C1NC(=O)c2cc(Nc3ccccc3)c(Nc3ccccc3)cc12, O=C1NC(=O)c2cc(Nc3ccccc3)c(Nc3ccccc3)cc12	AAALVYBICLMAMA-UHFFFAOYSA-N, AAALVYBICLMAMA-UHFFFAOYSA-N, AAALVYBICLMAMA-UHFFFAOYSA-N, AAALVYBICLMAMA-UHFFFAOYSA-N	Preclinical
CGP-53353	EGFR inhibitor, PKC inhibitor	EGFR, PRKCB			Fc1ccc(Nc2cc3C(=O)NC(=O)c3cc2Nc2ccc(F)cc2)cc1, Fc1ccc(Nc2cc3C(=O)NC(=O)c3cc2Nc2ccc(F)cc2)cc1	RONQPWQYDRPRGG-UHFFFAOYSA-N, RONQPWQYDRPRGG-UHFFFAOYSA-N	Preclinical
CGP-54626	GABA receptor antagonist	GABBR1, GABBR2, KCTD12, KCTD16, KCTD8			C[C@H](NC[C@H](O)CP(O)(=O)CC1CCCCC1)c1ccc(Cl)c(Cl)c1 |a:1,4,&1:7|, C[C@H](NC[C@H](O)CP(O)(=O)CC1CCCCC1)c1ccc(Cl)c(Cl)c1 |a:1,4,&1:7|, C[C@H](NC[C@H](O)CP(O)(=O)CC1CCCCC1)c1ccc(Cl)c(Cl)c1 |a:1,4,&1:7|	JGGVBBYJRQOPPA-BBRMVZONSA-N, JGGVBBYJRQOPPA-BBRMVZONSA-N, JGGVBBYJRQOPPA-BBRMVZONSA-N	Preclinical
CGP-55845	GABA receptor antagonist	GABBR1, GABBR2, KCTD12, KCTD16, KCTD8			C[C@H](NC[C@H](O)CP(O)(=O)Cc1ccccc1)c1ccc(Cl)c(Cl)c1, C[C@H](NC[C@H](O)CP(O)(=O)Cc1ccccc1)c1ccc(Cl)c(Cl)c1	ZODSPDOOCZZEIM-BBRMVZONSA-N, ZODSPDOOCZZEIM-BBRMVZONSA-N	Preclinical
CGP-57380	MAP kinase inhibitor	AURKB, LCK, MKNK1, MKNK2, SGK1			Nc1ncnc2n[nH]c(Nc3ccc(F)cc3)c12, Nc1ncnc2n[nH]c(Nc3ccc(F)cc3)c12, Nc1ncnc2n[nH]c(Nc3ccc(F)cc3)c12	UQPMANVRZYYQMD-UHFFFAOYSA-N, UQPMANVRZYYQMD-UHFFFAOYSA-N, UQPMANVRZYYQMD-UHFFFAOYSA-N	Preclinical
CGP-60474	CDK inhibitor	CDK1, CDK2			OCCCNc1cc(ccn1)-c1ccnc(Nc2cccc(Cl)c2)n1, OCCCNc1cc(ccn1)-c1ccnc(Nc2cccc(Cl)c2)n1, OCCCNc1cc(ccn1)-c1ccnc(Nc2cccc(Cl)c2)n1, OCCCNc1cc(ccn1)-c1ccnc(Nc2cccc(Cl)c2)n1	IYNDTACKOAXKBJ-UHFFFAOYSA-N, IYNDTACKOAXKBJ-UHFFFAOYSA-N, IYNDTACKOAXKBJ-UHFFFAOYSA-N, IYNDTACKOAXKBJ-UHFFFAOYSA-N	Preclinical
CGP-71683	neuropeptide receptor antagonist	NPY5R			Nc1nc(NC[C@H]2CC[C@H](CNS(=O)(=O)c3cccc4ccccc34)CC2)nc2ccccc12 |r|, Nc1nc(NC[C@H]2CC[C@H](CNS(=O)(=O)c3cccc4ccccc34)CC2)nc2ccccc12 |r|, Nc1nc(NC[C@H]2CC[C@H](CNS(=O)(=O)c3cccc4ccccc34)CC2)nc2ccccc12 |r|, Nc1nc(NC[C@H]2CC[C@H](CNS(=O)(=O)c3cccc4ccccc34)CC2)nc2ccccc12 |r|	UULIGRNKXHCLQN-WGSAOQKQSA-N, UULIGRNKXHCLQN-WGSAOQKQSA-N, UULIGRNKXHCLQN-WGSAOQKQSA-N, UULIGRNKXHCLQN-WGSAOQKQSA-N	Preclinical
CGP-74514	CDK inhibitor	CDK1			CCn1cnc2c(Nc3cccc(Cl)c3)nc(N[C@@H]3CCCC[C@@H]3N)nc12, CCn1cnc2c(Nc3cccc(Cl)c3)nc(N[C@@H]3CCCC[C@@H]3N)nc12, CCn1cnc2c(Nc3cccc(Cl)c3)nc(N[C@@H]3CCCC[C@@H]3N)nc12, CCn1cnc2c(Nc3cccc(Cl)c3)nc(N[C@@H]3CCCC[C@@H]3N)nc12	UTBSBSOBZHXMHI-LSDHHAIUSA-N, UTBSBSOBZHXMHI-LSDHHAIUSA-N, UTBSBSOBZHXMHI-LSDHHAIUSA-N, UTBSBSOBZHXMHI-LSDHHAIUSA-N	Preclinical
CGP-78608	glutamate receptor antagonist				C[C@@H](NCc1cc(Br)cc2[nH]c(=O)c(=O)[nH]c12)P(O)(O)=O, C[C@@H](NCc1cc(Br)cc2[nH]c(=O)c(=O)[nH]c12)P(O)(O)=O	DPFHVUSPVHRVFL-YFKPBYRVSA-N, DPFHVUSPVHRVFL-YFKPBYRVSA-N	Preclinical
CGP-7930	GABA receptor modulator	GABBR1			CC(C)(CO)Cc1cc(c(O)c(c1)C(C)(C)C)C(C)(C)C, CC(C)(CO)Cc1cc(c(O)c(c1)C(C)(C)C)C(C)(C)C, CC(C)(CO)Cc1cc(c(O)c(c1)C(C)(C)C)C(C)(C)C, CC(C)(CO)Cc1cc(c(O)c(c1)C(C)(C)C)C(C)(C)C, CC(C)(CO)Cc1cc(c(O)c(c1)C(C)(C)C)C(C)(C)C, CC(C)(CO)Cc1cc(c(O)c(c1)C(C)(C)C)C(C)(C)C, CC(C)(CO)Cc1cc(c(O)c(c1)C(C)(C)C)C(C)(C)C	XLWJPQQFJNGUPA-UHFFFAOYSA-N, XLWJPQQFJNGUPA-UHFFFAOYSA-N, XLWJPQQFJNGUPA-UHFFFAOYSA-N, XLWJPQQFJNGUPA-UHFFFAOYSA-N, XLWJPQQFJNGUPA-UHFFFAOYSA-N, XLWJPQQFJNGUPA-UHFFFAOYSA-N, XLWJPQQFJNGUPA-UHFFFAOYSA-N	Preclinical
CGS-15943	adenosine receptor antagonist	ADORA1, ADORA2A, ADORA2B, ADORA3			Nc1nc2ccc(Cl)cc2c2nc(nn12)-c1ccco1, Nc1nc2ccc(Cl)cc2c2nc(nn12)-c1ccco1, Nc1nc2ccc(Cl)cc2c2nc(nn12)-c1ccco1, Nc1nc2ccc(Cl)cc2c2nc(nn12)-c1ccco1, Nc1nc2ccc(Cl)cc2c2nc(nn12)-c1ccco1, Nc1nc2ccc(Cl)cc2c2nc(nn12)-c1ccco1, Nc1nc2ccc(Cl)cc2c2nc(nn12)-c1ccco1, Nc1nc2ccc(Cl)cc2c2nc(nn12)-c1ccco1, Nc1nc2ccc(Cl)cc2c2nc(nn12)-c1ccco1, Nc1nc2ccc(Cl)cc2c2nc(nn12)-c1ccco1, Nc1nc2ccc(Cl)cc2c2nc(nn12)-c1ccco1, Nc1nc2ccc(Cl)cc2c2nc(nn12)-c1ccco1, Nc1nc2ccc(Cl)cc2c2nc(nn12)-c1ccco1, Nc1nc2ccc(Cl)cc2c2nc(nn12)-c1ccco1, Nc1nc2ccc(Cl)cc2c2nc(nn12)-c1ccco1, Nc1nc2ccc(Cl)cc2c2nc(nn12)-c1ccco1, Nc1nc2ccc(Cl)cc2c2nc(nn12)-c1ccco1	MSJODEOZODDVGW-UHFFFAOYSA-N, MSJODEOZODDVGW-UHFFFAOYSA-N, MSJODEOZODDVGW-UHFFFAOYSA-N, MSJODEOZODDVGW-UHFFFAOYSA-N, MSJODEOZODDVGW-UHFFFAOYSA-N, MSJODEOZODDVGW-UHFFFAOYSA-N, MSJODEOZODDVGW-UHFFFAOYSA-N, MSJODEOZODDVGW-UHFFFAOYSA-N, MSJODEOZODDVGW-UHFFFAOYSA-N, MSJODEOZODDVGW-UHFFFAOYSA-N, MSJODEOZODDVGW-UHFFFAOYSA-N, MSJODEOZODDVGW-UHFFFAOYSA-N, MSJODEOZODDVGW-UHFFFAOYSA-N, MSJODEOZODDVGW-UHFFFAOYSA-N, MSJODEOZODDVGW-UHFFFAOYSA-N, MSJODEOZODDVGW-UHFFFAOYSA-N, MSJODEOZODDVGW-UHFFFAOYSA-N	Preclinical
CGS-20625	benzodiazepine receptor agonist, GABA benzodiazepine site receptor partial agonist	GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6			COc1ccc(cc1)-n1[nH]c2c3CCCCCc3ncc2c1=O, COc1ccc(cc1)-n1[nH]c2c3CCCCCc3ncc2c1=O, COc1ccc(cc1)-n1[nH]c2c3CCCCCc3ncc2c1=O, COc1ccc(cc1)-n1[nH]c2c3CCCCCc3ncc2c1=O, COc1ccc(cc1)-n1[nH]c2c3CCCCCc3ncc2c1=O	UBLXQFIFWUEVGJ-UHFFFAOYSA-N, UBLXQFIFWUEVGJ-UHFFFAOYSA-N, UBLXQFIFWUEVGJ-UHFFFAOYSA-N, UBLXQFIFWUEVGJ-UHFFFAOYSA-N, UBLXQFIFWUEVGJ-UHFFFAOYSA-N	Phase 1
CGS-21680	adenosine receptor agonist	ADORA1, ADORA2A, ADORA2B, ADORA3			CCNC(=O)[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(N)nc(NCCc3ccc(CCC(O)=O)cc3)nc12	PAOANWZGLPPROA-RQXXJAGISA-N	Preclinical
CGS-9896	GABA receptor antagonist	GABRA1, GABRB2, GABRG2			Clc1ccc(cc1)-n1[nH]c2c(cnc3ccccc23)c1=O, Clc1ccc(cc1)-n1[nH]c2c(cnc3ccccc23)c1=O	QCBUAKLOWCOUCR-UHFFFAOYSA-N, QCBUAKLOWCOUCR-UHFFFAOYSA-N	Preclinical
CH-170					Cc1nc(Cn2cnc3n(C)c(=O)n(C)c(=O)c23)no1	JBXSBZBZASARMY-UHFFFAOYSA-N	Phase 1
CH-5183284	fibroblast growth factor inhibitor	FGFR1, FGFR2, FGFR3			Cc1nc2ccc(cc2[nH]1)-n1ncc(C(=O)c2cc3ccccc3[nH]2)c1N, Cc1nc2ccc(cc2[nH]1)-n1ncc(C(=O)c2cc3ccccc3[nH]2)c1N, Cc1nc2ccc(cc2[nH]1)-n1ncc(C(=O)c2cc3ccccc3[nH]2)c1N	BEMNJULZEQTDJY-UHFFFAOYSA-N, BEMNJULZEQTDJY-UHFFFAOYSA-N, BEMNJULZEQTDJY-UHFFFAOYSA-N	Phase 2
CHC	monocarboxylate transporter inhibitor	SLC16A1			OC(=O)C(=C\c1ccc(O)cc1)\C#N, OC(=O)C(=C\c1ccc(O)cc1)\C#N	AFVLVVWMAFSXCK-VMPITWQZSA-N, InChI=1S/C10H7NO3/c11-6-8(10(13)14)5-7-1-3-9(12)4-2-7/h1-5,12H,(H,13,14)/b8-5+	Preclinical
chenodeoxycholic-acid	11-beta hydroxysteroid dehydrogenase inhibitor, FXR agonist	HSD11B1, NR1H4	cardiology, gastroenterology	cerebral cholesterosis, gallstones	C[C@H](CCC(O)=O)[C@H]1CC[C@H]2[C@@H]3[C@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C, C[C@H](CCC(O)=O)[C@H]1CC[C@H]2[C@@H]3[C@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C, C[C@H](CCC(O)=O)[C@H]1CC[C@H]2[C@@H]3[C@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C, C[C@H](CCC(O)=O)[C@H]1CC[C@H]2[C@@H]3[C@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C, C[C@H](CCC(O)=O)[C@H]1CC[C@H]2[C@@H]3[C@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C	RUDATBOHQWOJDD-BSWAIDMHSA-N, RUDATBOHQWOJDD-BSWAIDMHSA-N, RUDATBOHQWOJDD-BSWAIDMHSA-N, RUDATBOHQWOJDD-BSWAIDMHSA-N, RUDATBOHQWOJDD-BSWAIDMHSA-N	Launched
CHF5074	gamma secretase modulator	PSEN1			OC(=O)C1(CC1)c1ccc(c(F)c1)-c1ccc(Cl)c(Cl)c1	LIYLTQQDABRNRX-UHFFFAOYSA-N	Phase 2
chicago-sky-blue-6b	glutamate inhibitor, macrophage migration inhibiting factor inhibitor	MIF			COc1cc(ccc1NN=C1C=Cc2c(cc(c(N)c2C1=O)S(O)(=O)=O)S(O)(=O)=O)-c1ccc(NN=C2C=Cc3c(cc(c(N)c3C2=O)S(O)(=O)=O)S(O)(=O)=O)c(OC)c1 |c:12,40|, COc1cc(ccc1NN=C1C=Cc2c(cc(c(N)c2C1=O)S(O)(=O)=O)S(O)(=O)=O)-c1ccc(NN=C2C=Cc3c(cc(c(N)c3C2=O)S(O)(=O)=O)S(O)(=O)=O)c(OC)c1 |c:12,40|	BGULJNMSWJQIEK-UHFFFAOYSA-N, BGULJNMSWJQIEK-UHFFFAOYSA-N	Preclinical
chidamide	HDAC inhibitor	HDAC10, HDAC3	hematologic malignancy	peripheral T-cell lymphoma (PTCL)	Nc1ccc(F)cc1NC(=O)c1ccc(CNC(=O)\C=C\c2cccnc2)cc1, Nc1ccc(F)cc1NC(=O)c1ccc(CNC(=O)\C=C\c2cccnc2)cc1, Nc1ccc(F)cc1NC(=O)c1ccc(CNC(=O)\C=C\c2cccnc2)cc1, Nc1ccc(F)cc1NC(=O)c1ccc(CNC(=O)\C=C\c2cccnc2)cc1	WXHHICFWKXDFOW-BJMVGYQFSA-N, WXHHICFWKXDFOW-BJMVGYQFSA-N, WXHHICFWKXDFOW-BJMVGYQFSA-N, WXHHICFWKXDFOW-BJMVGYQFSA-N	Launched
chiniofon	antiprotozoal agent		infectious disease	amebiasis	Oc1c(I)cc(c2cccnc12)S(O)(=O)=O, Oc1c(I)cc(c2cccnc12)S(O)(=O)=O	ZBJWWKFMHOAPNS-UHFFFAOYSA-N, ZBJWWKFMHOAPNS-UHFFFAOYSA-N	Launched
CHIR-124	CHK inhibitor	CHEK1			Clc1ccc2[nH]c(=O)c(-c3nc4ccccc4[nH]3)c(N[C@@H]3CN4CCC3CC4)c2c1, Clc1ccc2[nH]c(=O)c(-c3nc4ccccc4[nH]3)c(N[C@@H]3CN4CCC3CC4)c2c1, Clc1ccc2[nH]c(=O)c(-c3nc4ccccc4[nH]3)c(N[C@@H]3CN4CCC3CC4)c2c1	MOVBBVMDHIRCTG-LJQANCHMSA-N, MOVBBVMDHIRCTG-LJQANCHMSA-N, MOVBBVMDHIRCTG-LJQANCHMSA-N	Preclinical
CHIR-98014	glycogen synthase kinase inhibitor	GSK3A, GSK3B			Nc1nc(NCCNc2ncc(c(n2)-c2ccc(Cl)cc2Cl)-n2ccnc2)ccc1[N+]([O-])=O, Nc1nc(NCCNc2ncc(c(n2)-c2ccc(Cl)cc2Cl)-n2ccnc2)ccc1[N+]([O-])=O, Nc1nc(NCCNc2ncc(c(n2)-c2ccc(Cl)cc2Cl)-n2ccnc2)ccc1[N+]([O-])=O, Nc1nc(NCCNc2ncc(c(n2)-c2ccc(Cl)cc2Cl)-n2ccnc2)ccc1[N+]([O-])=O	MDZCSIDIPDZWKL-UHFFFAOYSA-N, MDZCSIDIPDZWKL-UHFFFAOYSA-N, MDZCSIDIPDZWKL-UHFFFAOYSA-N, MDZCSIDIPDZWKL-UHFFFAOYSA-N	Preclinical
CHIR-99021	glycogen synthase kinase inhibitor	CDK1, GSK3A, GSK3B, MAPK1			Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl	AQGNHMOJWBZFQQ-UHFFFAOYSA-N, AQGNHMOJWBZFQQ-UHFFFAOYSA-N, AQGNHMOJWBZFQQ-UHFFFAOYSA-N, AQGNHMOJWBZFQQ-UHFFFAOYSA-N, AQGNHMOJWBZFQQ-UHFFFAOYSA-N, AQGNHMOJWBZFQQ-UHFFFAOYSA-N, AQGNHMOJWBZFQQ-UHFFFAOYSA-N, AQGNHMOJWBZFQQ-UHFFFAOYSA-N, AQGNHMOJWBZFQQ-UHFFFAOYSA-N, AQGNHMOJWBZFQQ-UHFFFAOYSA-N, AQGNHMOJWBZFQQ-UHFFFAOYSA-N, AQGNHMOJWBZFQQ-UHFFFAOYSA-N, AQGNHMOJWBZFQQ-UHFFFAOYSA-N, AQGNHMOJWBZFQQ-UHFFFAOYSA-N, AQGNHMOJWBZFQQ-UHFFFAOYSA-N, AQGNHMOJWBZFQQ-UHFFFAOYSA-N, AQGNHMOJWBZFQQ-UHFFFAOYSA-N, AQGNHMOJWBZFQQ-UHFFFAOYSA-N, AQGNHMOJWBZFQQ-UHFFFAOYSA-N, AQGNHMOJWBZFQQ-UHFFFAOYSA-N, AQGNHMOJWBZFQQ-UHFFFAOYSA-N, AQGNHMOJWBZFQQ-UHFFFAOYSA-N, AQGNHMOJWBZFQQ-UHFFFAOYSA-N, AQGNHMOJWBZFQQ-UHFFFAOYSA-N, AQGNHMOJWBZFQQ-UHFFFAOYSA-N, AQGNHMOJWBZFQQ-UHFFFAOYSA-N, AQGNHMOJWBZFQQ-UHFFFAOYSA-N, AQGNHMOJWBZFQQ-UHFFFAOYSA-N, AQGNHMOJWBZFQQ-UHFFFAOYSA-N, AQGNHMOJWBZFQQ-UHFFFAOYSA-N, AQGNHMOJWBZFQQ-UHFFFAOYSA-N, AQGNHMOJWBZFQQ-UHFFFAOYSA-N, AQGNHMOJWBZFQQ-UHFFFAOYSA-N, AQGNHMOJWBZFQQ-UHFFFAOYSA-N, AQGNHMOJWBZFQQ-UHFFFAOYSA-N, AQGNHMOJWBZFQQ-UHFFFAOYSA-N, AQGNHMOJWBZFQQ-UHFFFAOYSA-N, AQGNHMOJWBZFQQ-UHFFFAOYSA-N, AQGNHMOJWBZFQQ-UHFFFAOYSA-N, AQGNHMOJWBZFQQ-UHFFFAOYSA-N, AQGNHMOJWBZFQQ-UHFFFAOYSA-N, AQGNHMOJWBZFQQ-UHFFFAOYSA-N, AQGNHMOJWBZFQQ-UHFFFAOYSA-N, AQGNHMOJWBZFQQ-UHFFFAOYSA-N, AQGNHMOJWBZFQQ-UHFFFAOYSA-N, AQGNHMOJWBZFQQ-UHFFFAOYSA-N, AQGNHMOJWBZFQQ-UHFFFAOYSA-N, AQGNHMOJWBZFQQ-UHFFFAOYSA-N, AQGNHMOJWBZFQQ-UHFFFAOYSA-N, AQGNHMOJWBZFQQ-UHFFFAOYSA-N, AQGNHMOJWBZFQQ-UHFFFAOYSA-N, AQGNHMOJWBZFQQ-UHFFFAOYSA-N, AQGNHMOJWBZFQQ-UHFFFAOYSA-N, AQGNHMOJWBZFQQ-UHFFFAOYSA-N, AQGNHMOJWBZFQQ-UHFFFAOYSA-N, AQGNHMOJWBZFQQ-UHFFFAOYSA-N, AQGNHMOJWBZFQQ-UHFFFAOYSA-N, AQGNHMOJWBZFQQ-UHFFFAOYSA-N, AQGNHMOJWBZFQQ-UHFFFAOYSA-N, AQGNHMOJWBZFQQ-UHFFFAOYSA-N, AQGNHMOJWBZFQQ-UHFFFAOYSA-N, AQGNHMOJWBZFQQ-UHFFFAOYSA-N, AQGNHMOJWBZFQQ-UHFFFAOYSA-N, AQGNHMOJWBZFQQ-UHFFFAOYSA-N, AQGNHMOJWBZFQQ-UHFFFAOYSA-N, AQGNHMOJWBZFQQ-UHFFFAOYSA-N, AQGNHMOJWBZFQQ-UHFFFAOYSA-N, AQGNHMOJWBZFQQ-UHFFFAOYSA-N, AQGNHMOJWBZFQQ-UHFFFAOYSA-N, AQGNHMOJWBZFQQ-UHFFFAOYSA-N	Preclinical
chloralose					OC[C@@H](O)[C@H]1O[C@@H]2O[C@@H](O[C@@H]2[C@H]1O)C(Cl)(Cl)Cl	OJYGBLRPYBAHRT-IPQSZEQASA-N	Preclinical
chlorambucil	DNA inhibitor		hematologic malignancy	chronic lymphocytic leukemia (CLL), Hodgkin's lymphoma	OC(=O)CCCc1ccc(cc1)N(CCCl)CCCl	JCKYGMPEJWAADB-UHFFFAOYSA-N	Launched
chloramine-T			infectious disease	bacterial gill disease	Cc1ccc(cc1)S(=O)(=O)NCl, Cc1ccc(cc1)S(=O)(=O)NCl	NXTVQNIVUKXOIL-UHFFFAOYSA-N, NXTVQNIVUKXOIL-UHFFFAOYSA-N	Launched
chloramphenicol	bacterial 50S ribosomal subunit inhibitor	CD55	infectious disease, endocrinology	meningitis, fever, cholera	OC[C@@H](NC(=O)C(Cl)Cl)[C@H](O)c1ccc(cc1)[N+]([O-])=O, OC[C@@H](NC(=O)C(Cl)Cl)[C@H](O)c1ccc(cc1)[N+]([O-])=O, OC[C@@H](NC(=O)C(Cl)Cl)[C@H](O)c1ccc(cc1)[N+]([O-])=O, OC[C@@H](NC(=O)C(Cl)Cl)[C@H](O)c1ccc(cc1)[N+]([O-])=O	WIIZWVCIJKGZOK-RKDXNWHRSA-N, WIIZWVCIJKGZOK-RKDXNWHRSA-N, WIIZWVCIJKGZOK-RKDXNWHRSA-N, WIIZWVCIJKGZOK-RKDXNWHRSA-N	Launched
chloramphenicol-palmitate	protein synthesis inhibitor		infectious disease, endocrinology	meningitis, fever, cholera	CCCCCCCCCCCCCCCC(=O)OC[C@@H](NC(=O)C(Cl)Cl)[C@H](O)c1ccc(cc1)[N+]([O-])=O	PXKHGMGELZGJQE-ILBGXUMGSA-N	Launched
chloramphenicol-sodium-succinate	protein synthesis inhibitor		infectious disease	gram-negative bacterial infections	O[C@@H]([C@@H](COC(=O)CCC(O)=O)NC(=O)C(Cl)Cl)c1ccc(cc1)[N+]([O-])=O	LIRCDOVJWUGTMW-ZWNOBZJWSA-N	Launched
chlorazanil					Nc1ncnc(Nc2ccc(Cl)cc2)n1	YRZQHIVOIFJEEE-UHFFFAOYSA-N	Preclinical
chlorcyclizine	histamine receptor antagonist		allergy	allergic rhinitis	CN1CCN(CC1)[C@@H](c1ccccc1)c1ccc(Cl)cc1 |&1:7|, CN1CCN(CC1)[C@@H](c1ccccc1)c1ccc(Cl)cc1 |&1:7|, CN1CCN(CC1)[C@@H](c1ccccc1)c1ccc(Cl)cc1 |&1:7|	WFNAKBGANONZEQ-SFHVURJKSA-N, WFNAKBGANONZEQ-SFHVURJKSA-N, WFNAKBGANONZEQ-SFHVURJKSA-N	Launched
chlorfenson	other antifungal				Clc1ccc(OS(=O)(=O)c2ccc(Cl)cc2)cc1	RZXLPPRPEOUENN-UHFFFAOYSA-N	Phase 2
chlorhexidine	membrane integrity inhibitor		dermatology, infectious disease, dental	cosmetic, skin infections, gingivitis	NC(Nc1ccc(Cl)cc1)=NC(=N)NCCCCCCNC(=N)N=C(N)Nc1ccc(Cl)cc1, NC(Nc1ccc(Cl)cc1)=NC(=N)NCCCCCCNC(=N)N=C(N)Nc1ccc(Cl)cc1, NC(Nc1ccc(Cl)cc1)=NC(=N)NCCCCCCNC(=N)N=C(N)Nc1ccc(Cl)cc1, NC(Nc1ccc(Cl)cc1)=NC(=N)NCCCCCCNC(=N)N=C(N)Nc1ccc(Cl)cc1, NC(Nc1ccc(Cl)cc1)=NC(=N)NCCCCCCNC(=N)N=C(N)Nc1ccc(Cl)cc1, NC(Nc1ccc(Cl)cc1)=NC(=N)NCCCCCCNC(=N)N=C(N)Nc1ccc(Cl)cc1, NC(Nc1ccc(Cl)cc1)=NC(=N)NCCCCCCNC(=N)N=C(N)Nc1ccc(Cl)cc1	GHXZTYHSJHQHIJ-UHFFFAOYSA-N, GHXZTYHSJHQHIJ-UHFFFAOYSA-N, GHXZTYHSJHQHIJ-UHFFFAOYSA-N, GHXZTYHSJHQHIJ-UHFFFAOYSA-N, GHXZTYHSJHQHIJ-UHFFFAOYSA-N, InChI=1S/C22H30Cl2N10/c23-15-5-9-17(10-6-15)31-21(27)33-19(25)29-13-3-1-2-4-14-30-20(26)34-22(28)32-18-11-7-16(24)8-12-18/h5-12H,1-4,13-14H2,(H5,25,27,29,31,33)(H5,26,28,30,32,34), InChI=1S/C22H30Cl2N10/c23-15-5-9-17(10-6-15)31-21(27)33-19(25)29-13-3-1-2-4-14-30-20(26)34-22(28)32-18-11-7-16(24)8-12-18/h5-12H,1-4,13-14H2,(H5,25,27,29,31,33)(H5,26,28,30,32,34)	Launched
chlorindanol					Oc1ccc(Cl)c2CCCc12, Oc1ccc(Cl)c2CCCc12	ATAJVFBUUIBIEO-UHFFFAOYSA-N, ATAJVFBUUIBIEO-UHFFFAOYSA-N	Preclinical
chlorindione					Clc1ccc(cc1)C1C(=O)c2ccccc2C1=O, Clc1ccc(cc1)C1C(=O)c2ccccc2C1=O	NJDUWAXIURWWLN-UHFFFAOYSA-N, NJDUWAXIURWWLN-UHFFFAOYSA-N	Preclinical
chlorisondamine-diiodide	acetylcholine receptor antagonist	CHRNA1			C[N+](C)(C)CC[N+]1(C)Cc2c(C1)c(Cl)c(Cl)c(Cl)c2Cl, C[N+](C)(C)CC[N+]1(C)Cc2c(C1)c(Cl)c(Cl)c(Cl)c2Cl	IXWDUZLHWJKVPX-UHFFFAOYSA-N, IXWDUZLHWJKVPX-UHFFFAOYSA-N	Preclinical
chlormadinone-acetate	5 alpha reductase inhibitor	PGR	endocrinology	hypermenorrhea, amenorrhea, oligomenorrhea, polymenorrhea	CC(=O)O[C@@]1(CC[C@H]2[C@@H]3C=C(Cl)C4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)=O |t:9,12|	QMBJSIBWORFWQT-DFXBJWIESA-N	Launched
chlormezanone	GABA receptor modulator	GABRA1			CN1[C@@H](c2ccc(Cl)cc2)S(=O)(=O)CCC1=O |&1:2,r|, CN1[C@@H](c2ccc(Cl)cc2)S(=O)(=O)CCC1=O |&1:2,r|, CN1[C@@H](c2ccc(Cl)cc2)S(=O)(=O)CCC1=O |&1:2,r|, CN1[C@@H](c2ccc(Cl)cc2)S(=O)(=O)CCC1=O |&1:2,r|, CN1[C@@H](c2ccc(Cl)cc2)S(=O)(=O)CCC1=O |&1:2,r|	WEQAYVWKMWHEJO-LLVKDONJSA-N, WEQAYVWKMWHEJO-LLVKDONJSA-N, WEQAYVWKMWHEJO-LLVKDONJSA-N, WEQAYVWKMWHEJO-LLVKDONJSA-N, WEQAYVWKMWHEJO-LLVKDONJSA-N	Withdrawn
chlormidazole	fungal lanosterol demethylase inhibitor		infectious disease	fungal infection	Cc1nc2ccccc2n1Cc1ccc(Cl)cc1, Cc1nc2ccccc2n1Cc1ccc(Cl)cc1, Cc1nc2ccccc2n1Cc1ccc(Cl)cc1, Cc1nc2ccccc2n1Cc1ccc(Cl)cc1	WNAQOLSMVPFGTE-UHFFFAOYSA-N, WNAQOLSMVPFGTE-UHFFFAOYSA-N, WNAQOLSMVPFGTE-UHFFFAOYSA-N, WNAQOLSMVPFGTE-UHFFFAOYSA-N	Launched
chlorobutanol			neurology/psychiatry	anesthetic, sedative	CC(C)(O)C(Cl)(Cl)Cl, CC(C)(O)C(Cl)(Cl)Cl, CC(C)(O)C(Cl)(Cl)Cl	OSASVXMJTNOKOY-UHFFFAOYSA-N, OSASVXMJTNOKOY-UHFFFAOYSA-N, OSASVXMJTNOKOY-UHFFFAOYSA-N	Launched
chlorocresol	ryanodine receptor activator		infectious disease	first-aid antiseptic	Cc1cc(O)ccc1Cl, Cc1cc(O)ccc1Cl, Cc1cc(O)ccc1Cl	CFKMVGJGLGKFKI-UHFFFAOYSA-N, CFKMVGJGLGKFKI-UHFFFAOYSA-N, CFKMVGJGLGKFKI-UHFFFAOYSA-N	Launched
chlorogenic-acid	antioxidant	SLC37A4	neurology/psychiatry, pulmonary, allergy	headache, chest congestion, allergic rhinitis	O[C@@H]1C[C@](O)(C[C@@H](OC(=O)\C=C\c2ccc(O)c(O)c2)[C@@H]1O)C(O)=O, O[C@@H]1C[C@](O)(C[C@@H](OC(=O)\C=C\c2ccc(O)c(O)c2)[C@@H]1O)C(O)=O, O[C@@H]1C[C@](O)(C[C@@H](OC(=O)\C=C\c2ccc(O)c(O)c2)[C@@H]1O)C(O)=O, O[C@@H]1C[C@](O)(C[C@@H](OC(=O)\C=C\c2ccc(O)c(O)c2)[C@@H]1O)C(O)=O	CWVRJTMFETXNAD-JUHZACGLSA-N, CWVRJTMFETXNAD-JUHZACGLSA-N, CWVRJTMFETXNAD-JUHZACGLSA-N, CWVRJTMFETXNAD-JUHZACGLSA-N	Launched
chlorophyllin			urology	urinary incontinence	CCc1c(C)c2cc3nc(cc4[nH]c([C@@H](CCC(O)=O)[C@@H]4C)c(CC(O)=O)c4[nH]c(cc1n2)c(C)c4C(O)=O)c(C)c3C=C	HZDQUOWQHHSPIE-HASICPNOSA-N	Preclinical
chlorophyllin-copper	cytochrome P450 inhibitor				CCC1=C(C)\C2=C\c3c(C=C)c(C)c4\C=C5/N=C([C@@H](CCC(O)=O)[C@@H]5C)/C(/CC(O)=O)=c5/c(C(O)=O)c(C)\c(=C\C1=N2)n5[Cu]n34 |&1:18,&2:24,r,c:2,14,16,42,t:5,31,39|, CCC1=C(C)\C2=C\c3c(C=C)c(C)c4\C=C5/N=C([C@@H](CCC(O)=O)[C@@H]5C)/C(/CC(O)=O)=c5/c(C(O)=O)c(C)\c(=C\C1=N2)n5[Cu]n34 |&1:18,&2:24,r,c:2,14,16,42,t:5,31,39|	ZDOYGJNADZJRFB-PVMVIUQGSA-L, ZDOYGJNADZJRFB-PVMVIUQGSA-L	Phase 1
chloroprocaine	sodium channel blocker	ATP1A1, CHRNA10, GRIN3A, HTR3A, SCN10A, SLC6A3	neurology/psychiatry	local anesthetic	CCN(CC)CCOC(=O)c1ccc(N)cc1Cl	VDANGULDQQJODZ-UHFFFAOYSA-N	Launched
chloropyramine	histamine receptor antagonist	HRH1	cardiology, ophthalmology, allergy, pulmonary	edema, conjunctivitis, allergic rhinitis, asthma	CN(C)CCN(Cc1ccc(Cl)cc1)c1ccccn1, CN(C)CCN(Cc1ccc(Cl)cc1)c1ccccn1, CN(C)CCN(Cc1ccc(Cl)cc1)c1ccccn1, CN(C)CCN(Cc1ccc(Cl)cc1)c1ccccn1, CN(C)CCN(Cc1ccc(Cl)cc1)c1ccccn1, CN(C)CCN(Cc1ccc(Cl)cc1)c1ccccn1	ICKFFNBDFNZJSX-UHFFFAOYSA-N, ICKFFNBDFNZJSX-UHFFFAOYSA-N, ICKFFNBDFNZJSX-UHFFFAOYSA-N, ICKFFNBDFNZJSX-UHFFFAOYSA-N, ICKFFNBDFNZJSX-UHFFFAOYSA-N, ICKFFNBDFNZJSX-UHFFFAOYSA-N	Launched
chloroquine	antimalarial agent	MRGPRX1	infectious disease	malaria, amebiasis	CCN(CC)CCC[C@@H](C)Nc1ccnc2cc(Cl)ccc12 |&1:8|, CCN(CC)CCC[C@@H](C)Nc1ccnc2cc(Cl)ccc12 |&1:8|, CCN(CC)CCC[C@@H](C)Nc1ccnc2cc(Cl)ccc12 |&1:8|, CCN(CC)CCC[C@@H](C)Nc1ccnc2cc(Cl)ccc12 |&1:8|, CCN(CC)CCC[C@@H](C)Nc1ccnc2cc(Cl)ccc12 |&1:8|, CCN(CC)CCC[C@@H](C)Nc1ccnc2cc(Cl)ccc12 |&1:8|	WHTVZRBIWZFKQO-CQSZACIVSA-N, WHTVZRBIWZFKQO-CQSZACIVSA-N, WHTVZRBIWZFKQO-CQSZACIVSA-N, WHTVZRBIWZFKQO-CQSZACIVSA-N, WHTVZRBIWZFKQO-CQSZACIVSA-N, WHTVZRBIWZFKQO-CQSZACIVSA-N	Launched
chlorothiazide	diuretic	CA1, CA2, CA4, SLC12A3	cardiology	hypertension	NS(=O)(=O)c1cc2c(cc1Cl)N=CNS2(=O)=O |c:12|, NS(=O)(=O)c1cc2c(cc1Cl)N=CNS2(=O)=O |c:12|, NS(=O)(=O)c1cc2c(cc1Cl)N=CNS2(=O)=O |c:12|, NS(=O)(=O)c1cc2c(cc1Cl)N=CNS2(=O)=O |c:12|	JBMKAUGHUNFTOL-UHFFFAOYSA-N, JBMKAUGHUNFTOL-UHFFFAOYSA-N, JBMKAUGHUNFTOL-UHFFFAOYSA-N, JBMKAUGHUNFTOL-UHFFFAOYSA-N	Launched
chlorothymol					CC(C)c1cc(Cl)c(C)cc1O, CC(C)c1cc(Cl)c(C)cc1O	KFZXVMNBUMVKLN-UHFFFAOYSA-N, KFZXVMNBUMVKLN-UHFFFAOYSA-N	Launched
chlorotrianisene	estrogenic hormone	ESR1, ESR2	endocrinology, oncology	menopause, prostate cancer	COc1ccc(cc1)C(Cl)=C(c1ccc(OC)cc1)c1ccc(OC)cc1, COc1ccc(cc1)C(Cl)=C(c1ccc(OC)cc1)c1ccc(OC)cc1, COc1ccc(cc1)C(Cl)=C(c1ccc(OC)cc1)c1ccc(OC)cc1, COc1ccc(cc1)C(Cl)=C(c1ccc(OC)cc1)c1ccc(OC)cc1	BFPSDSIWYFKGBC-UHFFFAOYSA-N, BFPSDSIWYFKGBC-UHFFFAOYSA-N, BFPSDSIWYFKGBC-UHFFFAOYSA-N, BFPSDSIWYFKGBC-UHFFFAOYSA-N	Launched
chloroxine	opioid receptor antagonist	OPRK1	gastroenterology, infectious disease, dermatology	diarrhea, inflammatory bowel disease, giardiasis, dandruff	Oc1c(Cl)cc(Cl)c2cccnc12, Oc1c(Cl)cc(Cl)c2cccnc12, Oc1c(Cl)cc(Cl)c2cccnc12, Oc1c(Cl)cc(Cl)c2cccnc12, Oc1c(Cl)cc(Cl)c2cccnc12, Oc1c(Cl)cc(Cl)c2cccnc12, Oc1c(Cl)cc(Cl)c2cccnc12, Oc1c(Cl)cc(Cl)c2cccnc12	WDFKMLRRRCGAKS-UHFFFAOYSA-N, WDFKMLRRRCGAKS-UHFFFAOYSA-N, WDFKMLRRRCGAKS-UHFFFAOYSA-N, WDFKMLRRRCGAKS-UHFFFAOYSA-N, WDFKMLRRRCGAKS-UHFFFAOYSA-N, WDFKMLRRRCGAKS-UHFFFAOYSA-N, WDFKMLRRRCGAKS-UHFFFAOYSA-N, WDFKMLRRRCGAKS-UHFFFAOYSA-N	Launched
chloroxoquinoline					Clc1ccc2c(c1)[nH]ccc2=O	XMFXTXKSWIDMER-UHFFFAOYSA-N	Launched
chloroxylenol	ATP synthase inhibitor		infectious disease	skin infections	Cc1cc(O)cc(C)c1Cl, Cc1cc(O)cc(C)c1Cl	OSDLLIBGSJNGJE-UHFFFAOYSA-N, OSDLLIBGSJNGJE-UHFFFAOYSA-N	Launched
chlorphenamine	histamine receptor antagonist		allergy	allergic rhinitis, urticaria	CN(C)CC[C@@H](c1ccc(Cl)cc1)c1ccccn1 |&1:5|	SOYKEARSMXGVTM-HNNXBMFYSA-N	Launched
chlorphenesin	muscle relaxant		neurology/psychiatry	muscle relaxant, sedative	OC[C@@H](O)COc1ccc(Cl)cc1 |&1:2,r|, OC[C@@H](O)COc1ccc(Cl)cc1 |&1:2,r|	MXOAEAUPQDYUQM-MRVPVSSYSA-N, MXOAEAUPQDYUQM-MRVPVSSYSA-N	Launched
chlorphenoxamine	histamine receptor antagonist				CN(C)CCO[C@@](C)(c1ccccc1)c1ccc(Cl)cc1 |r|	KKHPNPMTPORSQE-SFHVURJKSA-N	Preclinical
chlorphensin-carbamate	muscle relaxant		neurology/psychiatry	spasms	NC(=O)OC[C@@H](O)COc1ccc(Cl)cc1 |&1:5,r|	SKPLBLUECSEIFO-QMMMGPOBSA-N	Launched
chlorproguanil	dihydrofolate reductase inhibitor	DHFR	infectious disease	malaria	CC(C)NC(=N)N=C(N)Nc1ccc(Cl)c(Cl)c1, CC(C)NC(=N)N=C(N)Nc1ccc(Cl)c(Cl)c1	ISZNZKHCRKXXAU-UHFFFAOYSA-N, ISZNZKHCRKXXAU-UHFFFAOYSA-N	Launched
chlorpromazine	dopamine receptor antagonist	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, CALM1, CHRM1, CHRM3, DRD1, DRD2, DRD3, DRD4, DRD5, HRH1, HRH4, HTR1A, HTR2A, HTR2B, HTR2C, HTR6, HTR7, KCNH2, ORM1, ORM2, SMPD1, TRPC5	neurology/psychiatry, gastroenterology, hematology, infectious disease	schizophrenia, nausea, vomiting, acute intermittent porphyria (AIP), tetanus	CN(C)CCCN1c2ccccc2Sc2ccc(Cl)cc12, CN(C)CCCN1c2ccccc2Sc2ccc(Cl)cc12, CN(C)CCCN1c2ccccc2Sc2ccc(Cl)cc12, CN(C)CCCN1c2ccccc2Sc2ccc(Cl)cc12, CN(C)CCCN1c2ccccc2Sc2ccc(Cl)cc12	ZPEIMTDSQAKGNT-UHFFFAOYSA-N, ZPEIMTDSQAKGNT-UHFFFAOYSA-N, ZPEIMTDSQAKGNT-UHFFFAOYSA-N, ZPEIMTDSQAKGNT-UHFFFAOYSA-N, ZPEIMTDSQAKGNT-UHFFFAOYSA-N	Launched
chlorpropamide	ATP channel blocker	ABCC8, KCNJ10	endocrinology	diabetes mellitus	CCCNC(=O)NS(=O)(=O)c1ccc(Cl)cc1, CCCNC(=O)NS(=O)(=O)c1ccc(Cl)cc1, CCCNC(=O)NS(=O)(=O)c1ccc(Cl)cc1, CCCNC(=O)NS(=O)(=O)c1ccc(Cl)cc1, CCCNC(=O)NS(=O)(=O)c1ccc(Cl)cc1	RKWGIWYCVPQPMF-UHFFFAOYSA-N, RKWGIWYCVPQPMF-UHFFFAOYSA-N, RKWGIWYCVPQPMF-UHFFFAOYSA-N, RKWGIWYCVPQPMF-UHFFFAOYSA-N, RKWGIWYCVPQPMF-UHFFFAOYSA-N	Launched
chlorpropham	antiviral				CC(C)OC(=O)Nc1cccc(Cl)c1, CC(C)OC(=O)Nc1cccc(Cl)c1	CWJSHJJYOPWUGX-UHFFFAOYSA-N, CWJSHJJYOPWUGX-UHFFFAOYSA-N	Phase 1
chlorprothixene	dopamine receptor antagonist	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, DRD1, DRD2, DRD3, HRH1, HTR2A, HTR2B, HTR2C	neurology/psychiatry	schizophrenia, bipolar disorder	CN(C)CC\C=C1\c2ccccc2Sc2ccc(Cl)cc12, CN(C)CC\C=C1\c2ccccc2Sc2ccc(Cl)cc12, CN(C)CC\C=C1\c2ccccc2Sc2ccc(Cl)cc12, CN(C)CC\C=C1\c2ccccc2Sc2ccc(Cl)cc12, CN(C)CC\C=C1\c2ccccc2Sc2ccc(Cl)cc12, CN(C)CC\C=C1\c2ccccc2Sc2ccc(Cl)cc12, CN(C)CC\C=C1\c2ccccc2Sc2ccc(Cl)cc12	WSPOMRSOLSGNFJ-AUWJEWJLSA-N, WSPOMRSOLSGNFJ-AUWJEWJLSA-N, WSPOMRSOLSGNFJ-AUWJEWJLSA-N, WSPOMRSOLSGNFJ-AUWJEWJLSA-N, WSPOMRSOLSGNFJ-AUWJEWJLSA-N, WSPOMRSOLSGNFJ-AUWJEWJLSA-N, WSPOMRSOLSGNFJ-AUWJEWJLSA-N	Launched
chlorpyrifos	acetylcholinesterase inhibitor	ACHE			CCOP(=S)(OCC)Oc1nc(Cl)c(Cl)cc1Cl, CCOP(=S)(OCC)Oc1nc(Cl)c(Cl)cc1Cl, CCOP(=S)(OCC)Oc1nc(Cl)c(Cl)cc1Cl	SBPBAQFWLVIOKP-UHFFFAOYSA-N, SBPBAQFWLVIOKP-UHFFFAOYSA-N, SBPBAQFWLVIOKP-UHFFFAOYSA-N	Launched
chlorquinaldol	other antibiotic		infectious disease	fungal infection	Cc1ccc2c(Cl)cc(Cl)c(O)c2n1, Cc1ccc2c(Cl)cc(Cl)c(O)c2n1, Cc1ccc2c(Cl)cc(Cl)c(O)c2n1, Cc1ccc2c(Cl)cc(Cl)c(O)c2n1, Cc1ccc2c(Cl)cc(Cl)c(O)c2n1, Cc1ccc2c(Cl)cc(Cl)c(O)c2n1, Cc1ccc2c(Cl)cc(Cl)c(O)c2n1	GPTXWRGISTZRIO-UHFFFAOYSA-N, GPTXWRGISTZRIO-UHFFFAOYSA-N, GPTXWRGISTZRIO-UHFFFAOYSA-N, GPTXWRGISTZRIO-UHFFFAOYSA-N, GPTXWRGISTZRIO-UHFFFAOYSA-N, GPTXWRGISTZRIO-UHFFFAOYSA-N, GPTXWRGISTZRIO-UHFFFAOYSA-N	Launched
chlortetracycline	protein synthesis inhibitor		ophthalmology	conjunctivitis	[H][C@@]12C[C@@]3([H])[C@H](C(=O)c4c(O)ccc(Cl)c4[C@@]3(C)O)C(=O)[C@]1(O)C(=O)[C@H](C(N)=O)C(=O)[C@H]2N(C)C |&1:25,&2:5|, [H][C@@]12C[C@@]3([H])[C@H](C(=O)c4c(O)ccc(Cl)c4[C@@]3(C)O)C(=O)[C@]1(O)C(=O)[C@H](C(N)=O)C(=O)[C@H]2N(C)C |&1:25,&2:5|	RNPLSXLZRGPQCU-YPOKJENWSA-N, RNPLSXLZRGPQCU-YPOKJENWSA-N	Launched
chlorthalidone	carbonic anhydrase inhibitor	CA1, CA12, CA14, CA2, CA4, CA7, SLC12A1	cardiology, gastroenterology, rheumatology, nephrology	hypertension, edema, congestive heart failure, hepatic cirrhosis, nephrotic syndrome, acute glomerulonephritis (AGN), chronic renal failure	NS(=O)(=O)c1cc(ccc1Cl)[C@@]1(O)NC(=O)c2ccccc12 |&1:11,r|, NS(=O)(=O)c1cc(ccc1Cl)[C@@]1(O)NC(=O)c2ccccc12 |&1:11,r|, NS(=O)(=O)c1cc(ccc1Cl)[C@@]1(O)NC(=O)c2ccccc12 |&1:11,r|	JIVPVXMEBJLZRO-AWEZNQCLSA-N, JIVPVXMEBJLZRO-AWEZNQCLSA-N, JIVPVXMEBJLZRO-AWEZNQCLSA-N	Launched
chlorzoxazone	bacterial 30S ribosomal subunit inhibitor	KCNMA1, KCNN4	neurology/psychiatry	muscle relaxant	Clc1ccc2oc(=O)[nH]c2c1, Clc1ccc2oc(=O)[nH]c2c1, Clc1ccc2oc(=O)[nH]c2c1	TZFWDZFKRBELIQ-UHFFFAOYSA-N, TZFWDZFKRBELIQ-UHFFFAOYSA-N, TZFWDZFKRBELIQ-UHFFFAOYSA-N	Launched
cholecalciferol		VDR	endocrinology	vitamin D deficiency	CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)CCC1=C, CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)CCC1=C, CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)CCC1=C, CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)CCC1=C	QYSXJUFSXHHAJI-YRZJJWOYSA-N, QYSXJUFSXHHAJI-YRZJJWOYSA-N, QYSXJUFSXHHAJI-YRZJJWOYSA-N, QYSXJUFSXHHAJI-YRZJJWOYSA-N	Launched
cholesterol		RORA			CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C |t:14|	HVYWMOMLDIMFJA-DPAQBDIFSA-N	Preclinical
cholic-acid	bile acid	ADH1C, CES1, COX4I1, COX5A, COX5B, COX6A2, COX6B1, COX6C, COX7A1, COX7B, COX7C, COX8A, ESRRG, FABP6, FECH, GPBAR1, MT-CO1, MT-CO2, MT-CO3, PLA2G1B	gastroenterology, neurology/psychiatry, genetics	bile acid synthesis disorders, peroxisomal disorders, Zellweger syndrome	C[C@H](CCC(O)=O)[C@H]1CC[C@H]2[C@@H]3[C@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3C[C@H](O)[C@]12C, C[C@H](CCC(O)=O)[C@H]1CC[C@H]2[C@@H]3[C@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3C[C@H](O)[C@]12C	BHQCQFFYRZLCQQ-OELDTZBJSA-N, BHQCQFFYRZLCQQ-OELDTZBJSA-N	Launched
choline	acetylcholine precursor	ACHE, BCHE, CHRNA2, PCYT1A, PCYT1B, PHOSPHO1, PLD1, PLD2			C[N+](C)(C)CCO, C[N+](C)(C)CCO, C[N+](C)(C)CCO	OEYIOHPDSNJKLS-UHFFFAOYSA-N, OEYIOHPDSNJKLS-UHFFFAOYSA-N, OEYIOHPDSNJKLS-UHFFFAOYSA-N	Phase 3
choline-alfoscerate	acetylcholine precursor				C[N+](C)(C)CCOP(O)(=O)OC[C@H](O)CO	SUHOQUVVVLNYQR-MRVPVSSYSA-O	Launched
CHPG	glutamate receptor agonist	GRM5			N[C@@H](C(O)=O)c1cc(O)ccc1Cl |&1:1,r|, N[C@@H](C(O)=O)c1cc(O)ccc1Cl |&1:1,r|, N[C@@H](C(O)=O)c1cc(O)ccc1Cl |&1:1,r|	UNIDAFCQFPGYJJ-SSDOTTSWSA-N, UNIDAFCQFPGYJJ-SSDOTTSWSA-N, UNIDAFCQFPGYJJ-SSDOTTSWSA-N	Preclinical
CHR-6494	serine/threonine kinase inhibitor	GSG2			CCCNc1ccc2ncc(-c3ccc4n[nH]cc4c3)n2n1, CCCNc1ccc2ncc(-c3ccc4n[nH]cc4c3)n2n1, CCCNc1ccc2ncc(-c3ccc4n[nH]cc4c3)n2n1, CCCNc1ccc2ncc(-c3ccc4n[nH]cc4c3)n2n1, CCCNc1ccc2ncc(-c3ccc4n[nH]cc4c3)n2n1	CZZCAOGIEGXMBZ-UHFFFAOYSA-N, CZZCAOGIEGXMBZ-UHFFFAOYSA-N, CZZCAOGIEGXMBZ-UHFFFAOYSA-N, CZZCAOGIEGXMBZ-UHFFFAOYSA-N, CZZCAOGIEGXMBZ-UHFFFAOYSA-N	Preclinical
chromanol-(+/-)	potassium channel blocker				CCS(=O)(=O)N(C)[C@@H]1[C@@H](O)C(C)(C)Oc2ccc(cc12)C#N.CCS(=O)(=O)N(C)[C@H]1[C@H](O)C(C)(C)Oc2ccc(cc12)C#N	VCIPBXUEKWCJAU-DZYJZKBLSA-N	Preclinical
chromanol-293B-(-)-[3R,4S]	potassium channel blocker				CCS(=O)(=O)N(C)[C@@H]1[C@@H](O)C(C)(C)Oc2ccc(cc12)C#N, CCS(=O)(=O)N(C)[C@@H]1[C@@H](O)C(C)(C)Oc2ccc(cc12)C#N	HVSJHHXUORMCGK-UONOGXRCSA-N, HVSJHHXUORMCGK-UONOGXRCSA-N	Preclinical
chromium-picolinate	insulin sensitizer		endocrinology	diabetes mellitus	O=C(O[Cr](OC(=O)c1ccccn1)OC(=O)c1ccccn1)c1ccccn1, O=C(O[Cr](OC(=O)c1ccccn1)OC(=O)c1ccccn1)c1ccccn1	CBDQOLKNTOMMTL-UHFFFAOYSA-K, CBDQOLKNTOMMTL-UHFFFAOYSA-K	Launched
chromocarb	antispasmodic				OC(=O)c1cc(=O)c2ccccc2o1, OC(=O)c1cc(=O)c2ccccc2o1, OC(=O)c1cc(=O)c2ccccc2o1, OC(=O)c1cc(=O)c2ccccc2o1	RVMGXWBCQGAWBR-UHFFFAOYSA-N, RVMGXWBCQGAWBR-UHFFFAOYSA-N, RVMGXWBCQGAWBR-UHFFFAOYSA-N, RVMGXWBCQGAWBR-UHFFFAOYSA-N	Launched
chrysin	breast cancer resistance protein inhibitor	AKR1B1, CDK6, CYP19A1, CYP1B1			Oc1cc(O)c2c(c1)oc(cc2=O)-c1ccccc1, Oc1cc(O)c2c(c1)oc(cc2=O)-c1ccccc1, Oc1cc(O)c2c(c1)oc(cc2=O)-c1ccccc1, Oc1cc(O)c2c(c1)oc(cc2=O)-c1ccccc1	RTIXKCRFFJGDFG-UHFFFAOYSA-N, RTIXKCRFFJGDFG-UHFFFAOYSA-N, RTIXKCRFFJGDFG-UHFFFAOYSA-N, RTIXKCRFFJGDFG-UHFFFAOYSA-N	Phase 1
chrysophanic-acid	EGFR inhibitor	EGFR, MTOR			Cc1cc(O)c2C(=O)c3c(O)cccc3C(=O)c2c1, Cc1cc(O)c2C(=O)c3c(O)cccc3C(=O)c2c1	LQGUBLBATBMXHT-UHFFFAOYSA-N, LQGUBLBATBMXHT-UHFFFAOYSA-N	Preclinical
chuanxiongzine					Cc1nc(C)c(C)nc1C, Cc1nc(C)c(C)nc1C	FINHMKGKINIASC-UHFFFAOYSA-N, FINHMKGKINIASC-UHFFFAOYSA-N	Phase 2
CH223191	aryl hydrocarbon receptor antagonist	AHR			Cc1ccccc1\N=N\c1ccc(NC(=O)c2ccnn2C)c(C)c1	LKTNEXPODAWWFM-GHVJWSGMSA-N	Preclinical
CH5132799	PI3K inhibitor	MTOR, PIK3CA, PIK3CB, PIK3CD, PIK3CG			CS(=O)(=O)N1CCc2c1nc(nc2-c1cnc(N)nc1)N1CCOCC1, CS(=O)(=O)N1CCc2c1nc(nc2-c1cnc(N)nc1)N1CCOCC1, CS(=O)(=O)N1CCc2c1nc(nc2-c1cnc(N)nc1)N1CCOCC1, CS(=O)(=O)N1CCc2c1nc(nc2-c1cnc(N)nc1)N1CCOCC1	JEGHXKRHKHPBJD-UHFFFAOYSA-N, JEGHXKRHKHPBJD-UHFFFAOYSA-N, JEGHXKRHKHPBJD-UHFFFAOYSA-N, JEGHXKRHKHPBJD-UHFFFAOYSA-N	Phase 1
CH55	retinoid receptor binder	RARA, RARB			CC(C)(C)c1cc(cc(c1)C(C)(C)C)C(=O)\C=C\c1ccc(cc1)C(O)=O, CC(C)(C)c1cc(cc(c1)C(C)(C)C)C(=O)\C=C\c1ccc(cc1)C(O)=O	FOUVTBKPJRMLPE-FMIVXFBMSA-N, FOUVTBKPJRMLPE-FMIVXFBMSA-N	Preclinical
CI-844					O(c1ccccc1)c1cccnc1	KDGUIKPOZGYLQJ-UHFFFAOYSA-N	Phase 2
CI-923	acetylcholine receptor antagonist				CCN[C@@H](C)CN1CCc2c(C1)c(=O)oc1ccccc21 |&1:3,r|, CCN[C@@H](C)CN1CCc2c(C1)c(=O)oc1ccccc21 |&1:3,r|	MJRICTKAEYTJAV-LBPRGKRZSA-N, MJRICTKAEYTJAV-LBPRGKRZSA-N	Phase 1
CI-953	voltage-gated sodium channel blocker				Cc1cccc(Cl)c1NC(=O)Nc1ccncc1	ZSBWDKCIIZYQIR-UHFFFAOYSA-N	Phase 1
CI-966	GAT inhibitor	SLC6A1			OC(=O)C1=CCCN(CCOC(c2ccc(cc2)C(F)(F)F)c2ccc(cc2)C(F)(F)F)C1 |t:3|, OC(=O)C1=CCCN(CCOC(c2ccc(cc2)C(F)(F)F)c2ccc(cc2)C(F)(F)F)C1 |t:3|, OC(=O)C1=CCCN(CCOC(c2ccc(cc2)C(F)(F)F)c2ccc(cc2)C(F)(F)F)C1 |t:3|, OC(=O)C1=CCCN(CCOC(c2ccc(cc2)C(F)(F)F)c2ccc(cc2)C(F)(F)F)C1 |t:3|	CMHQDSBIBSKHFP-UHFFFAOYSA-N, CMHQDSBIBSKHFP-UHFFFAOYSA-N, CMHQDSBIBSKHFP-UHFFFAOYSA-N, CMHQDSBIBSKHFP-UHFFFAOYSA-N	Phase 1
CI-976	ACAT inhibitor	ACAT1, CES1			CCCCCCCCCCC(C)(C)C(=O)Nc1c(OC)cc(OC)cc1OC, CCCCCCCCCCC(C)(C)C(=O)Nc1c(OC)cc(OC)cc1OC, CCCCCCCCCCC(C)(C)C(=O)Nc1c(OC)cc(OC)cc1OC, CCCCCCCCCCC(C)(C)C(=O)Nc1c(OC)cc(OC)cc1OC, CCCCCCCCCCC(C)(C)C(=O)Nc1c(OC)cc(OC)cc1OC, CCCCCCCCCCC(C)(C)C(=O)Nc1c(OC)cc(OC)cc1OC, CCCCCCCCCCC(C)(C)C(=O)Nc1c(OC)cc(OC)cc1OC	WAFNZAURAWBNDZ-UHFFFAOYSA-N, WAFNZAURAWBNDZ-UHFFFAOYSA-N, WAFNZAURAWBNDZ-UHFFFAOYSA-N, WAFNZAURAWBNDZ-UHFFFAOYSA-N, WAFNZAURAWBNDZ-UHFFFAOYSA-N, WAFNZAURAWBNDZ-UHFFFAOYSA-N, WAFNZAURAWBNDZ-UHFFFAOYSA-N	Phase 1
ciaftalan-zinc	reactive oxygen species stimulant				[Zn]1n2c3\N=C4/N=C(/N=c5\n1\c(=N/C1=N/C(=N\c2c2ccccc32)/c2ccccc12)c1ccccc51)c1ccccc41 |c:3,7,11,15,t:5,13|	PODBBOVVOGJETB-UHFFFAOYSA-N	Phase 1
cianidanol	fatty acid synthase inhibitor	PTGS1			O[C@H]1Cc2c(O)cc(O)cc2O[C@@H]1c1ccc(O)c(O)c1, O[C@H]1Cc2c(O)cc(O)cc2O[C@@H]1c1ccc(O)c(O)c1	PFTAWBLQPZVEMU-DZGCQCFKSA-N, PFTAWBLQPZVEMU-DZGCQCFKSA-N	Withdrawn
cibenzoline	sodium channel blocker		cardiology	cardiac arrythmia	C1[C@@H](C2=NCCN2)C1(c1ccccc1)c1ccccc1 |r,t:2|, C1[C@@H](C2=NCCN2)C1(c1ccccc1)c1ccccc1 |r,t:2|, C1[C@@H](C2=NCCN2)C1(c1ccccc1)c1ccccc1 |r,t:2|	IPOBOOXFSRWSHL-INIZCTEOSA-N, IPOBOOXFSRWSHL-INIZCTEOSA-N, IPOBOOXFSRWSHL-INIZCTEOSA-N	Launched
ciclesonide	glucocorticoid receptor agonist	NR3C1, SERPINA6	allergy	allergic rhinitis	CC(C)C(=O)OCC(=O)[C@@]12O[C@@H](O[C@@H]1C[C@H]1[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]21C)C1CCCCC1 |c:24,t:20|, CC(C)C(=O)OCC(=O)[C@@]12O[C@@H](O[C@@H]1C[C@H]1[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]21C)C1CCCCC1 |c:24,t:20|, CC(C)C(=O)OCC(=O)[C@@]12O[C@@H](O[C@@H]1C[C@H]1[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]21C)C1CCCCC1 |c:24,t:20|, CC(C)C(=O)OCC(=O)[C@@]12O[C@@H](O[C@@H]1C[C@H]1[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]21C)C1CCCCC1 |c:24,t:20|	LUKZNWIVRBCLON-GXOBDPJESA-N, LUKZNWIVRBCLON-GXOBDPJESA-N, LUKZNWIVRBCLON-GXOBDPJESA-N, LUKZNWIVRBCLON-GXOBDPJESA-N	Launched
ciclopirox	membrane integrity inhibitor	ATP1A1	infectious disease	onychomycosis	Cc1cc(C2CCCCC2)n(O)c(=O)c1, Cc1cc(C2CCCCC2)n(O)c(=O)c1, Cc1cc(C2CCCCC2)n(O)c(=O)c1, Cc1cc(C2CCCCC2)n(O)c(=O)c1, Cc1cc(C2CCCCC2)n(O)c(=O)c1, Cc1cc(C2CCCCC2)n(O)c(=O)c1, Cc1cc(C2CCCCC2)n(O)c(=O)c1, Cc1cc(C2CCCCC2)n(O)c(=O)c1, Cc1cc(C2CCCCC2)n(O)c(=O)c1	SCKYRAXSEDYPSA-UHFFFAOYSA-N, SCKYRAXSEDYPSA-UHFFFAOYSA-N, SCKYRAXSEDYPSA-UHFFFAOYSA-N, SCKYRAXSEDYPSA-UHFFFAOYSA-N, SCKYRAXSEDYPSA-UHFFFAOYSA-N, SCKYRAXSEDYPSA-UHFFFAOYSA-N, SCKYRAXSEDYPSA-UHFFFAOYSA-N, SCKYRAXSEDYPSA-UHFFFAOYSA-N, SCKYRAXSEDYPSA-UHFFFAOYSA-N	Launched
cicloprofen	cyclooxygenase inhibitor	PTGS1, PTGS2			C[C@@H](C(O)=O)c1ccc-2c(Cc3ccccc-23)c1 |&1:1,r|, C[C@@H](C(O)=O)c1ccc-2c(Cc3ccccc-23)c1 |&1:1,r|	LRXFKKPEBXIPMW-SNVBAGLBSA-N, LRXFKKPEBXIPMW-SNVBAGLBSA-N	Preclinical
CID-16020046	G protein-coupled receptor antagonist	GPR55			Cc1ccc(cc1)-c1n[nH]c2C(=O)N([C@H](c12)c1cccc(O)c1)c1ccc(cc1)C(O)=O |&1:14,r|	VGUQVYZXABOXCX-QHCPKHFHSA-N	Preclinical
CID-2011756	protein kinase inhibitor	PKD1			Clc1cccc(c1)-c1ccc(o1)C(=O)Nc1ccc(CN2CCOCC2)cc1, Clc1cccc(c1)-c1ccc(o1)C(=O)Nc1ccc(CN2CCOCC2)cc1	XQJWTJLJEYIUDZ-UHFFFAOYSA-N, XQJWTJLJEYIUDZ-UHFFFAOYSA-N	Preclinical
CID-2745687	G protein-coupled receptor antagonist	GPR35			COC(=O)c1cnn(c1\C=N\NC(=S)NC(C)(C)C)-c1ccc(F)cc1F, COC(=O)c1cnn(c1\C=N\NC(=S)NC(C)(C)C)-c1ccc(F)cc1F	CYNLZIBKERMMOA-AWQFTUOYSA-N, CYNLZIBKERMMOA-AWQFTUOYSA-N	Preclinical
CID-5458317	MAP kinase phosphatase inhibitor	MAPK3			OC1=c2ccccc2=C(NC2CCCCC2)\C1=C/c1ccccc1 |c:1,t:8|, OC1=c2ccccc2=C(NC2CCCCC2)\C1=C/c1ccccc1 |c:1,t:8|	BJJVCNWHNQAAGB-HMMYKYKNSA-N, BJJVCNWHNQAAGB-HMMYKYKNSA-N	Preclinical
cidofovir	DNA polymerase inhibitor		infectious disease	acquired immunodeficiency syndrome (AIDS), cytomegalovirus retinitis	Nc1ccn(C[C@@H](CO)OCP(O)(O)=O)c(=O)n1, Nc1ccn(C[C@@H](CO)OCP(O)(O)=O)c(=O)n1, Nc1ccn(C[C@@H](CO)OCP(O)(O)=O)c(=O)n1	VWFCHDSQECPREK-LURJTMIESA-N, VWFCHDSQECPREK-LURJTMIESA-N, VWFCHDSQECPREK-LURJTMIESA-N	Launched
ciglitazone	PPAR receptor agonist	PPARG			CC1(COc2ccc(C[C@H]3SC(=O)NC3=O)cc2)CCCCC1 |r|, CC1(COc2ccc(C[C@H]3SC(=O)NC3=O)cc2)CCCCC1 |r|, CC1(COc2ccc(C[C@H]3SC(=O)NC3=O)cc2)CCCCC1 |r|	YZFWTZACSRHJQD-OAHLLOKOSA-N, YZFWTZACSRHJQD-OAHLLOKOSA-N, YZFWTZACSRHJQD-OAHLLOKOSA-N	Phase 2
cilastatin	dehydropeptidase inhibitor	DPEP1			CC1(C)C[C@@H]1C(=O)N\C(=C/CCCCSC[C@H](N)C(O)=O)C(O)=O, CC1(C)C[C@@H]1C(=O)N\C(=C/CCCCSC[C@H](N)C(O)=O)C(O)=O	DHSUYTOATWAVLW-WFVMDLQDSA-N, DHSUYTOATWAVLW-WFVMDLQDSA-N	Launched
cilazapril	angiotensin converting enzyme inhibitor	ACE	cardiology	hypertension, congestive heart failure	CCOC(=O)[C@H](CCc1ccccc1)N[C@H]1CCCN2CCC[C@H](N2C1=O)C(O)=O, CCOC(=O)[C@H](CCc1ccccc1)N[C@H]1CCCN2CCC[C@H](N2C1=O)C(O)=O	HHHKFGXWKKUNCY-FHWLQOOXSA-N, HHHKFGXWKKUNCY-FHWLQOOXSA-N	Launched
cilengitide	integrin antagonist	ITGAV, ITGB3			CC(C)[C@@H]1N(C)C(=O)[C@@H](Cc2ccccc2)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CCCNC(N)=N)NC1=O, CC(C)[C@@H]1N(C)C(=O)[C@@H](Cc2ccccc2)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CCCNC(N)=N)NC1=O, CC(C)[C@@H]1N(C)C(=O)[C@@H](Cc2ccccc2)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CCCNC(N)=N)NC1=O	AMLYAMJWYAIXIA-VWNVYAMZSA-N, AMLYAMJWYAIXIA-VWNVYAMZSA-N, AMLYAMJWYAIXIA-VWNVYAMZSA-N	Phase 3
cilnidipine	calcium channel blocker	CACNA1B	cardiology	hypertension	COCCOC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OC\C=C\c1ccccc1 |&1:14,r,c:7,12|, COCCOC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OC\C=C\c1ccccc1 |&1:14,r,c:7,12|	KJEBULYHNRNJTE-HGJFNOKFSA-N, KJEBULYHNRNJTE-HGJFNOKFSA-N	Launched
cilofexor	FXR agonist				OC(=O)c1ccnc(c1)N1CC(O)(C1)c1ccc(OCc2c(onc2-c2c(Cl)cccc2Cl)C2CC2)cc1Cl	KZSKGLFYQAYZCO-UHFFFAOYSA-N	Phase 3
cilomilast	phosphodiesterase inhibitor	PDE4A, PDE4B, PDE4D			COc1ccc(cc1OC1CCCC1)[C@]1(CC[C@@H](CC1)C(O)=O)C#N |r|	CFBUZOUXXHZCFB-OYOVHJISSA-N	Phase 3
cilostamide	phosphodiesterase inhibitor	PDE3A, PDE3B			CN(C1CCCCC1)C(=O)CCCOc1ccc2[nH]c(=O)ccc2c1, CN(C1CCCCC1)C(=O)CCCOc1ccc2[nH]c(=O)ccc2c1, CN(C1CCCCC1)C(=O)CCCOc1ccc2[nH]c(=O)ccc2c1	UIAYVIIHMORPSJ-UHFFFAOYSA-N, UIAYVIIHMORPSJ-UHFFFAOYSA-N, UIAYVIIHMORPSJ-UHFFFAOYSA-N	Preclinical
cilostazol	phosphodiesterase inhibitor	PDE3A, PDE3B	cardiology	claudication	O=C1CCc2cc(OCCCCc3nnnn3C3CCCCC3)ccc2N1, O=C1CCc2cc(OCCCCc3nnnn3C3CCCCC3)ccc2N1, O=C1CCc2cc(OCCCCc3nnnn3C3CCCCC3)ccc2N1, O=C1CCc2cc(OCCCCc3nnnn3C3CCCCC3)ccc2N1, O=C1CCc2cc(OCCCCc3nnnn3C3CCCCC3)ccc2N1, O=C1CCc2cc(OCCCCc3nnnn3C3CCCCC3)ccc2N1	RRGUKTPIGVIEKM-UHFFFAOYSA-N, RRGUKTPIGVIEKM-UHFFFAOYSA-N, RRGUKTPIGVIEKM-UHFFFAOYSA-N, RRGUKTPIGVIEKM-UHFFFAOYSA-N, RRGUKTPIGVIEKM-UHFFFAOYSA-N, RRGUKTPIGVIEKM-UHFFFAOYSA-N	Launched
ciluprevir	serine protease inhibitor				COc1ccc2c(O[C@@H]3C[C@@H]4N(C3)C(=O)[C@H](CCCCC\C=C/[C@@H]3C[C@]3(NC4=O)C(O)=O)NC(=O)OC3CCCC3)cc(nc2c1)-c1csc(NC(C)C)n1 |c:22|, COc1ccc2c(O[C@@H]3C[C@@H]4N(C3)C(=O)[C@H](CCCCC\C=C/[C@@H]3C[C@]3(NC4=O)C(O)=O)NC(=O)OC3CCCC3)cc(nc2c1)-c1csc(NC(C)C)n1 |c:22|	PJZPDFUUXKKDNB-KNINVFKUSA-N, PJZPDFUUXKKDNB-KNINVFKUSA-N	Preclinical
CIM-0216	transient receptor potential channel agonist	TRPM3			Cc1cc(NC(=O)[C@@H](N2CCCc3ccccc23)c2ccccc2)no1 |&1:7,r|, Cc1cc(NC(=O)[C@@H](N2CCCc3ccccc23)c2ccccc2)no1 |&1:7,r|, Cc1cc(NC(=O)[C@@H](N2CCCc3ccccc23)c2ccccc2)no1 |&1:7,r|	KSEXDSJYVSEVGF-FQEVSTJZSA-N, KSEXDSJYVSEVGF-FQEVSTJZSA-N, KSEXDSJYVSEVGF-FQEVSTJZSA-N	Preclinical
cimaterol	adrenergic receptor agonist	ADRB1, ADRB2, ADRB3			CC(C)NC[C@@H](O)c1ccc(N)c(c1)C#N |&1:5,r|, CC(C)NC[C@@H](O)c1ccc(N)c(c1)C#N |&1:5,r|	BUXRLJCGHZZYNE-GFCCVEGCSA-N, BUXRLJCGHZZYNE-GFCCVEGCSA-N	Preclinical
cimetidine	histamine receptor antagonist	HRH2, SLC29A4, SLC47A1, SLC47A2	gastroenterology, hematologic malignancy, endocrinology	duodenal ulcer disease, peptic ulcer disease (PUD), gastroesophageal reflux disease (GERD), aggressive systemic mastocytosis (ASM), Zollinger-Ellison syndrome, endocrine adenoma	CN\C(NCCSCc1[nH]cnc1C)=N/C#N, CN\C(NCCSCc1[nH]cnc1C)=N/C#N, CN\C(NCCSCc1[nH]cnc1C)=N/C#N, CN\C(NCCSCc1[nH]cnc1C)=N/C#N, CN\C(NCCSCc1[nH]cnc1C)=N/C#N	AQIXAKUUQRKLND-UHFFFAOYSA-N, AQIXAKUUQRKLND-UHFFFAOYSA-N, AQIXAKUUQRKLND-UHFFFAOYSA-N, AQIXAKUUQRKLND-UHFFFAOYSA-N, AQIXAKUUQRKLND-UHFFFAOYSA-N	Launched
cimetropium	acetylcholine receptor antagonist	CHRM1	gastroenterology	irritable bowel syndrome	C[N@@+]1(CC2CC2)[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)c1ccccc1 |a:6,8,10,11,13,17,&1:1,TLB:0:1:7.8.9:11.13,THB:2:1:7.8.9:11.13,12:11:1:7.8.9,12:13:1:7.8.9,14:8:1:11.13|	QVVOZYKELHAIPX-IGDPVYPXSA-N	Launched
cinacalcet	calcium channel activator	CASR	endocrinology, nephrology, oncology	hyperparathyroidism, chronic kidney disease (CKD), parathyroid carcinoma, hypercalcemia	C[C@@H](NCCCc1cccc(c1)C(F)(F)F)c1cccc2ccccc12, C[C@@H](NCCCc1cccc(c1)C(F)(F)F)c1cccc2ccccc12, C[C@@H](NCCCc1cccc(c1)C(F)(F)F)c1cccc2ccccc12, C[C@@H](NCCCc1cccc(c1)C(F)(F)F)c1cccc2ccccc12, C[C@@H](NCCCc1cccc(c1)C(F)(F)F)c1cccc2ccccc12, C[C@@H](NCCCc1cccc(c1)C(F)(F)F)c1cccc2ccccc12, C[C@@H](NCCCc1cccc(c1)C(F)(F)F)c1cccc2ccccc12	VDHAWDNDOKGFTD-MRXNPFEDSA-N, VDHAWDNDOKGFTD-MRXNPFEDSA-N, VDHAWDNDOKGFTD-MRXNPFEDSA-N, VDHAWDNDOKGFTD-MRXNPFEDSA-N, VDHAWDNDOKGFTD-MRXNPFEDSA-N, VDHAWDNDOKGFTD-MRXNPFEDSA-N, InChI=1S/C22H22F3N/c1-16(20-13-5-10-18-9-2-3-12-21(18)20)26-14-6-8-17-7-4-11-19(15-17)22(23,24)25/h2-5,7,9-13,15-16,26H,6,8,14H2,1H3/t16-/m1/s1	Launched
cinaciguat	guanylate cyclase activator	GUCY1A3, GUCY1B3			OC(=O)CCCCN(CCc1ccccc1OCc1ccc(CCc2ccccc2)cc1)Cc1ccc(cc1)C(O)=O, OC(=O)CCCCN(CCc1ccccc1OCc1ccc(CCc2ccccc2)cc1)Cc1ccc(cc1)C(O)=O, OC(=O)CCCCN(CCc1ccccc1OCc1ccc(CCc2ccccc2)cc1)Cc1ccc(cc1)C(O)=O	WPYWMXNXEZFMAK-UHFFFAOYSA-N, WPYWMXNXEZFMAK-UHFFFAOYSA-N, WPYWMXNXEZFMAK-UHFFFAOYSA-N	Phase 2
cinalukast	leukotriene receptor antagonist	CYSLTR1			CCC(CC)(CC(=O)Nc1cccc(\C=C\c2nc(cs2)C2CCC2)c1)C(O)=O, CCC(CC)(CC(=O)Nc1cccc(\C=C\c2nc(cs2)C2CCC2)c1)C(O)=O, CCC(CC)(CC(=O)Nc1cccc(\C=C\c2nc(cs2)C2CCC2)c1)C(O)=O	BZMKNPGKXJAIDV-VAWYXSNFSA-N, BZMKNPGKXJAIDV-VAWYXSNFSA-N, BZMKNPGKXJAIDV-VAWYXSNFSA-N	Phase 2
cinanserin	serotonin receptor antagonist	HTR2A			CN(C)CCCSc1ccccc1NC(=O)\C=C\c1ccccc1, CN(C)CCCSc1ccccc1NC(=O)\C=C\c1ccccc1	RSUVYMGADVXGOU-BUHFOSPRSA-N, RSUVYMGADVXGOU-BUHFOSPRSA-N	Preclinical
cinchocaine	sodium channel blocker	CALM1, SCN10A, SCN5A	neurology/psychiatry	local anesthetic	CCCCOc1cc(C(=O)NCCN(CC)CC)c2ccccc2n1, CCCCOc1cc(C(=O)NCCN(CC)CC)c2ccccc2n1, CCCCOc1cc(C(=O)NCCN(CC)CC)c2ccccc2n1	PUFQVTATUTYEAL-UHFFFAOYSA-N, PUFQVTATUTYEAL-UHFFFAOYSA-N, PUFQVTATUTYEAL-UHFFFAOYSA-N	Launched
cinchonidine	P glycoprotein inhibitor				O[C@@H]([C@@H]1C[C@@H]2CC[N@]1C[C@@H]2C=C)c1ccnc2ccccc12, O[C@@H]([C@@H]1C[C@@H]2CC[N@]1C[C@@H]2C=C)c1ccnc2ccccc12, O[C@@H]([C@@H]1C[C@@H]2CC[N@]1C[C@@H]2C=C)c1ccnc2ccccc12, O[C@@H]([C@@H]1C[C@@H]2CC[N@]1C[C@@H]2C=C)c1ccnc2ccccc12	KMPWYEUPVWOPIM-KODHJQJWSA-N, KMPWYEUPVWOPIM-KODHJQJWSA-N, KMPWYEUPVWOPIM-KODHJQJWSA-N, KMPWYEUPVWOPIM-KODHJQJWSA-N	Phase 1
cinchonine	P glycoprotein inhibitor	CYP2D6			O[C@H]([C@H]1C[C@@H]2CC[N@]1C[C@@H]2C=C)c1ccnc2ccccc12	KMPWYEUPVWOPIM-QAMTZSDWSA-N	Preclinical
cinchophen	analgesic agent		rheumatology	gout	OC(=O)c1cc(nc2ccccc12)-c1ccccc1, OC(=O)c1cc(nc2ccccc12)-c1ccccc1, OC(=O)c1cc(nc2ccccc12)-c1ccccc1	YTRMTPPVNRALON-UHFFFAOYSA-N, YTRMTPPVNRALON-UHFFFAOYSA-N, YTRMTPPVNRALON-UHFFFAOYSA-N	Launched
cinepazet	vasodilator				CCOC(=O)CN1CCN(CC1)C(=O)\C=C\c1cc(OC)c(OC)c(OC)c1	XDUOTWNXVDBCDY-VOTSOKGWSA-N	Launched
cinepazide	calcium channel activator				COc1cc(\C=C\C(=O)N2CCN(CC(=O)N3CCCC3)CC2)cc(OC)c1OC, COc1cc(\C=C\C(=O)N2CCN(CC(=O)N3CCCC3)CC2)cc(OC)c1OC, COc1cc(\C=C\C(=O)N2CCN(CC(=O)N3CCCC3)CC2)cc(OC)c1OC	RCUDFXMNPQNBDU-VOTSOKGWSA-N, RCUDFXMNPQNBDU-VOTSOKGWSA-N, RCUDFXMNPQNBDU-VOTSOKGWSA-N	Withdrawn
cinflumide	muscle relaxant				Fc1cccc(\C=C\C(=O)NC2CC2)c1	NCOOUEIQXVWKTO-QPJJXVBHSA-N	Phase 2
cinnamaldehyde	aldose reductase inhibitor, TRPV agonist	TRPA1			O=C\C=C\c1ccccc1	KJPRLNWUNMBNBZ-QPJJXVBHSA-N	Preclinical
cinnarazine	calcium channel blocker		neurology/psychiatry, gastroenterology, ophthalmology	Meniere's disease, nausea, vomiting, Cogan's syndrome	C(\C=C\c1ccccc1)N1CCN(CC1)C(c1ccccc1)c1ccccc1, C(\C=C\c1ccccc1)N1CCN(CC1)C(c1ccccc1)c1ccccc1, C(\C=C\c1ccccc1)N1CCN(CC1)C(c1ccccc1)c1ccccc1, C(\C=C\c1ccccc1)N1CCN(CC1)C(c1ccccc1)c1ccccc1	DERZBLKQOCDDDZ-JLHYYAGUSA-N, DERZBLKQOCDDDZ-JLHYYAGUSA-N, DERZBLKQOCDDDZ-JLHYYAGUSA-N, DERZBLKQOCDDDZ-JLHYYAGUSA-N	Launched
cinobufotalin	anticancer agent				[H][C@@]12CC[C@]3(O)C[C@@H](O)CC[C@]3(C)[C@@]1([H])CC[C@]1(C)[C@H]([C@@H](OC(C)=O)[C@H]3O[C@@]213)c1ccc(=O)oc1	KBKUJJFDSHBPPA-ZNCGZLKOSA-N	Phase 1
cinoctramide					COc1cc(\C=C\C(=O)N2CCCCCCC2)cc(OC)c1OC, COc1cc(\C=C\C(=O)N2CCCCCCC2)cc(OC)c1OC	MDGVCMGGLSOVIQ-MDZDMXLPSA-N, MDGVCMGGLSOVIQ-MDZDMXLPSA-N	Preclinical
cinoxacin	topoisomerase inhibitor		infectious disease	urinary tract infections	CCn1nc(C(O)=O)c(=O)c2cc3OCOc3cc12, CCn1nc(C(O)=O)c(=O)c2cc3OCOc3cc12	VDUWPHTZYNWKRN-UHFFFAOYSA-N, VDUWPHTZYNWKRN-UHFFFAOYSA-N	Launched
cinoxate			dermatology	sunscreen lotion	CCOCCOC(=O)\C=C\c1ccc(OC)cc1, CCOCCOC(=O)\C=C\c1ccc(OC)cc1, CCOCCOC(=O)\C=C\c1ccc(OC)cc1	CMDKPGRTAQVGFQ-RMKNXTFCSA-N, CMDKPGRTAQVGFQ-RMKNXTFCSA-N, CMDKPGRTAQVGFQ-RMKNXTFCSA-N	Launched
CINPA-1	CAR antagonist	NR1H4, NR1I3, PPARG			CCOC(=O)Nc1ccc2CCc3ccccc3N(C(=O)CN(CC)CC)c2c1, CCOC(=O)Nc1ccc2CCc3ccccc3N(C(=O)CN(CC)CC)c2c1	AYQBYSPEGRYKFA-UHFFFAOYSA-N, AYQBYSPEGRYKFA-UHFFFAOYSA-N	Preclinical
cinromide					CCNC(=O)\C=C\c1cccc(Br)c1, CCNC(=O)\C=C\c1cccc(Br)c1	LDCXGZCEMNMWIL-VOTSOKGWSA-N, LDCXGZCEMNMWIL-VOTSOKGWSA-N	Phase 3
cintirorgon	ROR agonist				CC(C)(C[C@H]1CN(c2cc(ccc2O1)-c1cc(F)cc(OC(F)F)c1)S(=O)(=O)c1cccc(c1)C(F)(F)F)C(O)=O	GULSIMHVQYBADX-FQEVSTJZSA-N	Phase 1/Phase 2
cintriamide					COc1cc(\C=C\C(N)=O)cc(OC)c1OC	LRLKZVMLJBNNPE-SNAWJCMRSA-N	Preclinical
cipamfylline	phosphodiesterase inhibitor				Nc1nc2n(CC3CC3)c(=O)n(CC3CC3)c(=O)c2[nH]1	KSPYMJJKQMWWNB-UHFFFAOYSA-N	Phase 2
cipargamin	antimalarial agent				C[C@H]1Cc2c([nH]c3cc(Cl)c(F)cc23)[C@@]2(N1)C(=O)Nc1ccc(Cl)cc21	CKLPLPZSUQEDRT-WPCRTTGESA-N	Phase 2
cipemastat	metalloproteinase inhibitor	ADAM17, MMP1, MMP13, MMP2, MMP3, MMP8, MMP9			CN1C(=O)N(C[C@@H]([C@@H](CC2CCCC2)C(=O)N2CCCCC2)C(=O)NO)C(=O)C1(C)C	GFUITADOEPNRML-SJORKVTESA-N	Phase 3
ciprofibrate	PPAR receptor agonist	PPARA	endocrinology	hyperlipidemia	CC(C)(Oc1ccc(cc1)[C@H]1CC1(Cl)Cl)C(O)=O |&1:10,r|, CC(C)(Oc1ccc(cc1)[C@H]1CC1(Cl)Cl)C(O)=O |&1:10,r|, CC(C)(Oc1ccc(cc1)[C@H]1CC1(Cl)Cl)C(O)=O |&1:10,r|	KPSRODZRAIWAKH-SNVBAGLBSA-N, KPSRODZRAIWAKH-SNVBAGLBSA-N, KPSRODZRAIWAKH-SNVBAGLBSA-N	Launched
ciprofloxacin	bacterial DNA gyrase inhibitor	TOP2A	otolaryngology	otitis	OC(=O)c1cn(C2CC2)c2cc(N3CCNCC3)c(F)cc2c1=O, OC(=O)c1cn(C2CC2)c2cc(N3CCNCC3)c(F)cc2c1=O, OC(=O)c1cn(C2CC2)c2cc(N3CCNCC3)c(F)cc2c1=O	MYSWGUAQZAJSOK-UHFFFAOYSA-N, MYSWGUAQZAJSOK-UHFFFAOYSA-N, MYSWGUAQZAJSOK-UHFFFAOYSA-N	Launched
ciproxifan	histamine receptor antagonist	ADRA2A, ADRA2C, HRH3, HRH4, HTR3A			O=C(C1CC1)c1ccc(OCCCc2cnc[nH]2)cc1, O=C(C1CC1)c1ccc(OCCCc2cnc[nH]2)cc1	ACQBHJXEAYTHCY-UHFFFAOYSA-N, ACQBHJXEAYTHCY-UHFFFAOYSA-N	Preclinical
CIQ	glutamate receptor potentiator	GRIN2C, GRIN2D			COc1ccc(OC[C@H]2N(CCc3cc(OC)c(OC)cc23)C(=O)c2cccc(Cl)c2)cc1 |&1:8,r|, COc1ccc(OC[C@H]2N(CCc3cc(OC)c(OC)cc23)C(=O)c2cccc(Cl)c2)cc1 |&1:8,r|, COc1ccc(OC[C@H]2N(CCc3cc(OC)c(OC)cc23)C(=O)c2cccc(Cl)c2)cc1 |&1:8,r|	VYMILMYEENZHAR-HSZRJFAPSA-N, VYMILMYEENZHAR-HSZRJFAPSA-N, VYMILMYEENZHAR-HSZRJFAPSA-N	Preclinical
cirazoline	adrenergic receptor agonist	ADRA1A			C(Oc1ccccc1C1CC1)C1=NCCN1 |t:13|, C(Oc1ccccc1C1CC1)C1=NCCN1 |t:13|	YAORIDZYZDUZCM-UHFFFAOYSA-N, YAORIDZYZDUZCM-UHFFFAOYSA-N	Preclinical
cis-aconitic-acid		ACO2			OC(=O)C\C(=C\C(O)=O)C(O)=O	GTZCVFVGUGFEME-IWQZZHSRSA-N	Preclinical
cis-ACPD	glutamate receptor agonist	GRM2, GRM3, GRM6, GRM7, GRM8			[H][C@]1(CC[C@@](N)(C1)C(O)=O)C(O)=O |&1:1,4,r|	YFYNOWXBIBKGHB-CLZZGJSISA-N	Preclinical
cis-exo-camphanediol-2,3	nitric oxide stimulant	NOS3			CC1(C)[C@H]2CC[C@]1(C)[C@@H](O)[C@H]2O	AYEOSGBMQHXVER-AZQAYCESSA-N	Phase 1
cis-urocanic-acid	serotonin receptor agonist	HTR2A			OC(=O)\C=C\c1cnc[nH]1, OC(=O)\C=C\c1cnc[nH]1, OC(=O)\C=C\c1cnc[nH]1, OC(=O)\C=C/c1cnc[nH]1	LOIYMIARKYCTBW-OWOJBTEDSA-N, LOIYMIARKYCTBW-OWOJBTEDSA-N, LOIYMIARKYCTBW-OWOJBTEDSA-N, LOIYMIARKYCTBW-UPHRSURJSA-N	Phase 2
cis-9,trans-11-conjugated-linoleic-acid					CCCCCC\C=C\C=C/CCCCCCCC(O)=O, CCCCCC\C=C\C=C/CCCCCCCC(O)=O, CCCCCC\C=C\C=C/CCCCCCCC(O)=O	JBYXPOFIGCOSSB-GOJKSUSPSA-N, JBYXPOFIGCOSSB-GOJKSUSPSA-N, JBYXPOFIGCOSSB-GOJKSUSPSA-N	Launched
cisapride	serotonin receptor agonist	HTR2A, HTR3A, HTR4, KCNH2			CO[C@H]1CN(CCCOc2ccc(F)cc2)CC[C@H]1NC(=O)c1cc(Cl)c(N)cc1OC, CO[C@H]1CN(CCCOc2ccc(F)cc2)CC[C@H]1NC(=O)c1cc(Cl)c(N)cc1OC, CO[C@H]1CN(CCCOc2ccc(F)cc2)CC[C@H]1NC(=O)c1cc(Cl)c(N)cc1OC	DCSUBABJRXZOMT-IRLDBZIGSA-N, DCSUBABJRXZOMT-IRLDBZIGSA-N, DCSUBABJRXZOMT-IRLDBZIGSA-N	Withdrawn
cisatracurium	acetylcholine receptor antagonist	CHRNA2	neurology/psychiatry, critical care	muscle relaxant, endotracheal intubation	COc1ccc(C[C@@H]2c3cc(OC)c(OC)cc3CC[N@+]2(C)CCC(=O)OCCCCCOC(=O)CC[N@@+]2(C)CCc3cc(OC)c(OC)cc3[C@H]2Cc2ccc(OC)c(OC)c2)cc1OC, COc1ccc(C[C@@H]2c3cc(OC)c(OC)cc3CC[N@+]2(C)CCC(=O)OCCCCCOC(=O)CC[N@@+]2(C)CCc3cc(OC)c(OC)cc3[C@H]2Cc2ccc(OC)c(OC)c2)cc1OC, COc1ccc(C[C@@H]2c3cc(OC)c(OC)cc3CC[N@+]2(C)CCC(=O)OCCCCCOC(=O)CC[N@@+]2(C)CCc3cc(OC)c(OC)cc3[C@H]2Cc2ccc(OC)c(OC)c2)cc1OC	YXSLJKQTIDHPOT-LJCJQEJUSA-N, YXSLJKQTIDHPOT-LJCJQEJUSA-N, YXSLJKQTIDHPOT-LJCJQEJUSA-N	Launched
cisplatin	DNA alkylating agent, DNA synthesis inhibitor	XIAP	oncology	testicular carcinoma, ovarian cancer, bladder cancer	N[Pt](N)(Cl)Cl, N[Pt](N)(Cl)Cl, N[Pt](N)(Cl)Cl, N[Pt](N)(Cl)Cl, N[Pt](N)(Cl)Cl	DQLATGHUWYMOKM-UHFFFAOYSA-L, DQLATGHUWYMOKM-UHFFFAOYSA-L, DQLATGHUWYMOKM-UHFFFAOYSA-L, DQLATGHUWYMOKM-UHFFFAOYSA-L, DQLATGHUWYMOKM-UHFFFAOYSA-L	Launched
citalopram	selective serotonin reuptake inhibitor (SSRI)	ADRA1A, CHRM1, HRH1, SLC6A2, SLC6A3, SLC6A4	neurology/psychiatry	depression	CN(C)CCC[C@]1(OCc2cc(ccc12)C#N)c1ccc(F)cc1 |&1:6|, CN(C)CCC[C@]1(OCc2cc(ccc12)C#N)c1ccc(F)cc1 |&1:6|, CN(C)CCC[C@]1(OCc2cc(ccc12)C#N)c1ccc(F)cc1 |&1:6|	WSEQXVZVJXJVFP-FQEVSTJZSA-N, WSEQXVZVJXJVFP-FQEVSTJZSA-N, WSEQXVZVJXJVFP-FQEVSTJZSA-N	Launched
citarinostat	HDAC inhibitor				ONC(=O)CCCCCCNC(=O)c1cnc(nc1)N(c1ccccc1)c1ccccc1Cl	VLIUIBXPEDFJRF-UHFFFAOYSA-N	Phase 1
CITCO	constitutive androstane receptor (CAR) agonist	NR1I3			Clc1ccc(cc1)-c1nc2sccn2c1\C=N\OCc1ccc(Cl)c(Cl)c1, Clc1ccc(cc1)-c1nc2sccn2c1\C=N\OCc1ccc(Cl)c(Cl)c1, Clc1ccc(cc1)-c1nc2sccn2c1\C=N\OCc1ccc(Cl)c(Cl)c1, Clc1ccc(cc1)-c1nc2sccn2c1\C=N\OCc1ccc(Cl)c(Cl)c1	ZQWBOKJVVYNKTL-AUEPDCJTSA-N, ZQWBOKJVVYNKTL-AUEPDCJTSA-N, ZQWBOKJVVYNKTL-AUEPDCJTSA-N, ZQWBOKJVVYNKTL-AUEPDCJTSA-N	Preclinical
citicoline	glutathione transferase stimulant, membrane permeability enhancer	ACHE, SLC1A2	neurology/psychiatry, ophthalmology	stroke, Alzheimer's disease, senile dementia, Parkinson's Disease, attention-deficit/hyperactivity disorder (ADHD), glaucoma	C[N+](C)(C)CCOP(O)(=O)OP(O)(=O)OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1ccc(N)nc1=O |a:16,18,19,21,&1:7,&2:11|, C[N+](C)(C)CCOP(O)(=O)OP(O)(=O)OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1ccc(N)nc1=O |a:16,18,19,21,&1:7,&2:11|, C[N+](C)(C)CCOP(O)(=O)OP(O)(=O)OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1ccc(N)nc1=O |a:16,18,19,21,&1:7,&2:11|	RZZPDXZPRHQOCG-OJAKKHQRSA-O, RZZPDXZPRHQOCG-OJAKKHQRSA-O, RZZPDXZPRHQOCG-OJAKKHQRSA-O	Launched
citiolone	lipotropic, mucolytic agent				CC(=O)N[C@H]1CCSC1=O |&1:4,r|	NRFJZTXWLKPZAV-YFKPBYRVSA-N	Preclinical
citric-acid	coagulation factor inhibitor	AKR1B1, ANG, APRT, BHMT, C8G, CA4, CPB1, CS, CTDSP1, GNMT, HGS, HS3ST3A1, IL4I1, ITPA, LSM6, MDH2, MIF, PDE5A, PKD2L1, PLEKHA1, RNASE1, RNASE3, SRC, TNFSF13B, UCK2			OC(=O)CC(O)(CC(O)=O)C(O)=O	KRKNYBCHXYNGOX-UHFFFAOYSA-N	Preclinical
CJ-033466	serotonin receptor agonist	HTR4			CC(C)CN1CCC(CNC(=O)c2cc(Cl)c(N)n3cc(C)nc23)CC1, CC(C)CN1CCC(CNC(=O)c2cc(Cl)c(N)n3cc(C)nc23)CC1	ISKHMDNIWXPUGR-UHFFFAOYSA-N, ISKHMDNIWXPUGR-UHFFFAOYSA-N	Preclinical
CJ-13610	lipoxygenase inhibitor				Cc1nccn1-c1ccc(Sc2cccc(c2)C2(CCOCC2)C(N)=O)cc1	VPTONMHDLLMOOV-UHFFFAOYSA-N	Phase 2
CK-101	EGFR inhibitor				OCCN1CCN(CC1)c1ccc(Nc2ncc3cccc(-c4cccc(NC(=O)C=C)c4)c3n2)c(F)c1F	IDRGFNPZDVBSSE-UHFFFAOYSA-N	Preclinical
CK-636	actin related protein inhibitor	ACTR2, ACTR3, ARPC1B, ARPC2, ARPC3, ARPC4, ARPC5			Cc1[nH]c2ccccc2c1CCNC(=O)c1cccs1, Cc1[nH]c2ccccc2c1CCNC(=O)c1cccs1, Cc1[nH]c2ccccc2c1CCNC(=O)c1cccs1	ACAKNPKRLPMONU-UHFFFAOYSA-N, ACAKNPKRLPMONU-UHFFFAOYSA-N, ACAKNPKRLPMONU-UHFFFAOYSA-N	Preclinical
CKD-712	NFkB pathway inhibitor	JAK2, STAT1			Oc1cc2CCN[C@@H](Cc3cccc4ccccc34)c2cc1O |&1:7|, Oc1cc2CCN[C@@H](Cc3cccc4ccccc34)c2cc1O |&1:7|, Oc1cc2CCN[C@@H](Cc3cccc4ccccc34)c2cc1O |&1:7|	YGCQFKVNIBDJFW-SFHVURJKSA-N, YGCQFKVNIBDJFW-SFHVURJKSA-N, YGCQFKVNIBDJFW-SFHVURJKSA-N	Phase 1
CKI-7	casein kinase inhibitor	CSNK1G2			NCCNS(=O)(=O)c1ccc(Cl)c2ccncc12	OGKYMFFYOWUTKV-UHFFFAOYSA-N	Preclinical
CL-218872	benzodiazepine receptor agonist	GABRA1, GABRA2, GABRA3, GABRA5, GABRB2, GABRG2			Cc1nnc2ccc(nn12)-c1cccc(c1)C(F)(F)F, Cc1nnc2ccc(nn12)-c1cccc(c1)C(F)(F)F, Cc1nnc2ccc(nn12)-c1cccc(c1)C(F)(F)F	GUOQUXNJZHGPQF-UHFFFAOYSA-N, GUOQUXNJZHGPQF-UHFFFAOYSA-N, GUOQUXNJZHGPQF-UHFFFAOYSA-N	Phase 1
CL-225385					O=C(CC#N)c1ccccc1	ZJRCIQAMTAINCB-UHFFFAOYSA-N	Phase 2
cladribine	adenosine deaminase inhibitor, ribonucleotide reductase inhibitor	ADA, PNP, POLA1, POLE, POLE2, POLE3, POLE4, RRM1, RRM2, RRM2B	hematologic malignancy	hairy cell leukemia	Nc1nc(Cl)nc2n(cnc12)[C@H]1C[C@H](O)[C@@H](CO)O1, Nc1nc(Cl)nc2n(cnc12)[C@H]1C[C@H](O)[C@@H](CO)O1, Nc1nc(Cl)nc2n(cnc12)[C@H]1C[C@H](O)[C@@H](CO)O1, Nc1nc(Cl)nc2n(cnc12)[C@H]1C[C@H](O)[C@@H](CO)O1, Nc1nc(Cl)nc2n(cnc12)[C@H]1C[C@H](O)[C@@H](CO)O1, Nc1nc(Cl)nc2n(cnc12)[C@H]1C[C@H](O)[C@@H](CO)O1	PTOAARAWEBMLNO-KVQBGUIXSA-N, PTOAARAWEBMLNO-KVQBGUIXSA-N, PTOAARAWEBMLNO-KVQBGUIXSA-N, PTOAARAWEBMLNO-KVQBGUIXSA-N, PTOAARAWEBMLNO-KVQBGUIXSA-N, PTOAARAWEBMLNO-KVQBGUIXSA-N	Launched
clamikalant	ATP-sensitive potassium channel antagonist				CNC(=S)NS(=O)(=O)c1cc(CCNC(=O)c2cc(Cl)ccc2OC)ccc1OC	VXTKXGKPBOLHRY-UHFFFAOYSA-N	Preclinical
clanfenur	anticancer agent				CN(C)c1cccc(F)c1C(=O)NC(=O)Nc1ccc(Cl)cc1	SRLPZQAEBMZCIJ-UHFFFAOYSA-N	Preclinical
clarithromycin	bacterial 50S ribosomal subunit inhibitor	CYP3A4	otolaryngology, pulmonary, infectious disease	pharyngitis, tonsillitis, sinusitis, bronchitis, pneumonia, skin infections, otitis	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@@](C)(C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O)OC, CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@@](C)(C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O)OC, CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@@](C)(C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O)OC, CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@@](C)(C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O)OC, CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@@](C)(C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O)OC	AGOYDEPGAOXOCK-AAFHZFQRSA-N, AGOYDEPGAOXOCK-AAFHZFQRSA-N, AGOYDEPGAOXOCK-AAFHZFQRSA-N, AGOYDEPGAOXOCK-AAFHZFQRSA-N, AGOYDEPGAOXOCK-AAFHZFQRSA-N	Launched
clavulanate	beta lactamase inhibitor		otolaryngology	otitis	OC\C=C1/O[C@@H]2CC(=O)N2[C@H]1C(O)=O, OC\C=C1/O[C@@H]2CC(=O)N2[C@H]1C(O)=O	HZZVJAQRINQKSD-PBFISZAISA-N, HZZVJAQRINQKSD-PBFISZAISA-N	Launched
clebopride	dopamine receptor antagonist	ACHE, DRD2	gastroenterology	nausea	COc1cc(N)c(Cl)cc1C(=O)NC1CCN(Cc2ccccc2)CC1, COc1cc(N)c(Cl)cc1C(=O)NC1CCN(Cc2ccccc2)CC1, COc1cc(N)c(Cl)cc1C(=O)NC1CCN(Cc2ccccc2)CC1	BVPWJMCABCPUQY-UHFFFAOYSA-N, BVPWJMCABCPUQY-UHFFFAOYSA-N, BVPWJMCABCPUQY-UHFFFAOYSA-N	Launched
clemastine	histamine receptor antagonist	HRH1	allergy	allergic rhinitis, urticaria	CN1CCC[C@@H]1CCO[C@](C)(c1ccccc1)c1ccc(Cl)cc1, CN1CCC[C@@H]1CCO[C@](C)(c1ccccc1)c1ccc(Cl)cc1, CN1CCC[C@@H]1CCO[C@](C)(c1ccccc1)c1ccc(Cl)cc1, CN1CCC[C@@H]1CCO[C@](C)(c1ccccc1)c1ccc(Cl)cc1, CN1CCC[C@@H]1CCO[C@](C)(c1ccccc1)c1ccc(Cl)cc1	YNNUSGIPVFPVBX-NHCUHLMSSA-N, YNNUSGIPVFPVBX-NHCUHLMSSA-N, YNNUSGIPVFPVBX-NHCUHLMSSA-N, YNNUSGIPVFPVBX-NHCUHLMSSA-N, YNNUSGIPVFPVBX-NHCUHLMSSA-N	Launched
clemizole	HCV inhibitor		allergy	allergic rhinitis	Clc1ccc(Cn2c(CN3CCCC3)nc3ccccc23)cc1, Clc1ccc(Cn2c(CN3CCCC3)nc3ccccc23)cc1, Clc1ccc(Cn2c(CN3CCCC3)nc3ccccc23)cc1, Clc1ccc(Cn2c(CN3CCCC3)nc3ccccc23)cc1	CJXAEXPPLWQRFR-UHFFFAOYSA-N, CJXAEXPPLWQRFR-UHFFFAOYSA-N, CJXAEXPPLWQRFR-UHFFFAOYSA-N, CJXAEXPPLWQRFR-UHFFFAOYSA-N	Launched
clenbuterol	adrenergic receptor agonist	ABCC8, ADRB2, KCNJ11	pulmonary	chronic obstructive pulmonary disease (COPD), asthma	CC(C)(C)NC[C@@H](O)c1cc(Cl)c(N)c(Cl)c1 |r|	STJMRWALKKWQGH-SNVBAGLBSA-N	Launched
cleviprex	calcium channel blocker	CACNA1C, CACNA1D, CACNA1F, CACNA1S	cardiology	hypertension	CCCC(=O)OCOC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(Cl)c1Cl)C(=O)OC |&1:17,r,c:10,15|, CCCC(=O)OCOC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(Cl)c1Cl)C(=O)OC |&1:17,r,c:10,15|, CCCC(=O)OCOC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(Cl)c1Cl)C(=O)OC |&1:17,r,c:10,15|, CCCC(=O)OCOC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(Cl)c1Cl)C(=O)OC |&1:17,r,c:10,15|	KPBZROQVTHLCDU-SFHVURJKSA-N, KPBZROQVTHLCDU-SFHVURJKSA-N, KPBZROQVTHLCDU-SFHVURJKSA-N, KPBZROQVTHLCDU-SFHVURJKSA-N	Launched
clevudine	DNA polymerase inhibitor		infectious disease	hepatitis B	Cc1cn([C@H]2O[C@@H](CO)[C@H](O)[C@H]2F)c(=O)[nH]c1=O	GBBJCSTXCAQSSJ-XQXXSGGOSA-N	Launched
clidinium	acetylcholine receptor antagonist	CHRM1, CHRM3	gastroenterology	peptic ulcer disease (PUD), irritable bowel syndrome, enterocolitis	C[N+]12CCC(CC1)[C@@H](C2)OC(=O)C(O)(c1ccccc1)c1ccccc1 |&1:7,THB:9:7:2.3:5.6|, C[N+]12CCC(CC1)[C@@H](C2)OC(=O)C(O)(c1ccccc1)c1ccccc1 |&1:7,THB:9:7:2.3:5.6|, C[N+]12CCC(CC1)[C@@H](C2)OC(=O)C(O)(c1ccccc1)c1ccccc1 |&1:7,THB:9:7:2.3:5.6|, C[N+]12CCC(CC1)[C@@H](C2)OC(=O)C(O)(c1ccccc1)c1ccccc1 |&1:7,THB:9:7:2.3:5.6|	HOOSGZJRQIVJSZ-WEQDKIBNSA-N, HOOSGZJRQIVJSZ-WEQDKIBNSA-N, HOOSGZJRQIVJSZ-WEQDKIBNSA-N, HOOSGZJRQIVJSZ-WEQDKIBNSA-N	Launched
climbazole	enzyme inducer		dermatology	dandruff, eczema	CC(C)(C)C(=O)[C@@H](Oc1ccc(Cl)cc1)n1ccnc1 |&1:6,r|, CC(C)(C)C(=O)[C@@H](Oc1ccc(Cl)cc1)n1ccnc1 |&1:6,r|	OWEGWHBOCFMBLP-CQSZACIVSA-N, OWEGWHBOCFMBLP-CQSZACIVSA-N	Launched
clinafloxacin	bacterial DNA gyrase inhibitor				N[C@H]1CCN(C1)c1c(F)cc2c(c1Cl)n(cc(C(O)=O)c2=O)C1CC1 |&1:1|, N[C@H]1CCN(C1)c1c(F)cc2c(c1Cl)n(cc(C(O)=O)c2=O)C1CC1 |&1:1|	QGPKADBNRMWEQR-QMMMGPOBSA-N, QGPKADBNRMWEQR-QMMMGPOBSA-N	Phase 3
clindamycin	protein synthesis inhibitor		infectious disease	respiratory tract infections, pneumonia, skin infections, gynecologic infections, intra-abdominal infections, bacterial septicemia, bone and joint infections	CCC[C@@H]1C[C@H](N(C)C1)C(=O)N[C@H]([C@H](C)Cl)[C@H]1O[C@H](SC)[C@H](O)[C@@H](O)[C@H]1O, CCC[C@@H]1C[C@H](N(C)C1)C(=O)N[C@H]([C@H](C)Cl)[C@H]1O[C@H](SC)[C@H](O)[C@@H](O)[C@H]1O, CCC[C@@H]1C[C@H](N(C)C1)C(=O)N[C@H]([C@H](C)Cl)[C@H]1O[C@H](SC)[C@H](O)[C@@H](O)[C@H]1O, CCC[C@@H]1C[C@H](N(C)C1)C(=O)N[C@H]([C@H](C)Cl)[C@H]1O[C@H](SC)[C@H](O)[C@@H](O)[C@H]1O, CCC[C@@H]1C[C@H](N(C)C1)C(=O)N[C@H]([C@H](C)Cl)[C@H]1O[C@H](SC)[C@H](O)[C@@H](O)[C@H]1O, CCC[C@@H]1C[C@H](N(C)C1)C(=O)N[C@H]([C@H](C)Cl)[C@H]1O[C@H](SC)[C@H](O)[C@@H](O)[C@H]1O	KDLRVYVGXIQJDK-AWPVFWJPSA-N, KDLRVYVGXIQJDK-AWPVFWJPSA-N, KDLRVYVGXIQJDK-AWPVFWJPSA-N, KDLRVYVGXIQJDK-AWPVFWJPSA-N, KDLRVYVGXIQJDK-AWPVFWJPSA-N, KDLRVYVGXIQJDK-AWPVFWJPSA-N	Launched
clindamycin-palmitate	bacterial 50S ribosomal subunit inhibitor		infectious disease	intra-abdominal infections, skin infections, pneumonia, peritonitis, gynecologic infections	CCCCCCCCCCCCCCCC(=O)O[C@@H]1[C@@H](O)[C@@H](O)[C@H](O[C@@H]1SC)[C@H](NC(=O)[C@@H]1C[C@@H](CCC)CN1C)[C@H](C)Cl	OYSKUZDIHNKWLV-PRUAPSLNSA-N	Launched
clindamycin-phosphate	protein synthesis inhibitor		obstetrics/gynecology	bacterial vaginosis	CCC[C@@H]1C[C@H](N(C)C1)C(=O)N[C@H]([C@H](C)Cl)[C@H]1O[C@H](SC)[C@H](OP(O)(O)=O)[C@@H](O)[C@H]1O, CCC[C@@H]1C[C@H](N(C)C1)C(=O)N[C@H]([C@H](C)Cl)[C@H]1O[C@H](SC)[C@H](OP(O)(O)=O)[C@@H](O)[C@H]1O	UFUVLHLTWXBHGZ-MGZQPHGTSA-N, UFUVLHLTWXBHGZ-MGZQPHGTSA-N	Launched
clinofibrate	lipase clearing factor inhibitor	LPL	endocrinology	hypertriglyceridemia	CCC(C)(Oc1ccc(cc1)C1(CCCCC1)c1ccc(O[C@](C)(CC)C(O)=O)cc1)C(O)=O |&1:22,&2:2,r|, CCC(C)(Oc1ccc(cc1)C1(CCCCC1)c1ccc(O[C@](C)(CC)C(O)=O)cc1)C(O)=O |&1:22,&2:2,r|	BMOVQUBVGICXQN-AVJYQCBHSA-N, BMOVQUBVGICXQN-AVJYQCBHSA-N	Launched
clioquinol	chelating agent	OPRK1			Oc1c(I)cc(Cl)c2cccnc12, Oc1c(I)cc(Cl)c2cccnc12, Oc1c(I)cc(Cl)c2cccnc12	QCDFBFJGMNKBDO-UHFFFAOYSA-N, QCDFBFJGMNKBDO-UHFFFAOYSA-N, QCDFBFJGMNKBDO-UHFFFAOYSA-N	Withdrawn
clobenpropit	histamine receptor antagonist	HRH1, HRH2, HRH3, HRH4			Clc1ccc(CNC(=N)SCCCc2cnc[nH]2)cc1, Clc1ccc(CNC(=N)SCCCc2cnc[nH]2)cc1, Clc1ccc(CNC(=N)SCCCc2cnc[nH]2)cc1, Clc1ccc(CNC(=N)SCCCc2cnc[nH]2)cc1, Clc1ccc(CNC(=N)SCCCc2cnc[nH]2)cc1	UCAIEVHKDLMIFL-UHFFFAOYSA-N, UCAIEVHKDLMIFL-UHFFFAOYSA-N, UCAIEVHKDLMIFL-UHFFFAOYSA-N, UCAIEVHKDLMIFL-UHFFFAOYSA-N, UCAIEVHKDLMIFL-UHFFFAOYSA-N	Preclinical
clobetasol-propionate	glucocorticoid receptor agonist	NR3C1, PLA2G1B	dermatology	corticosteroid-responsive dermatoses	CCC(=O)O[C@@]1([C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)CCl |c:17,t:13|, CCC(=O)O[C@@]1([C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)CCl |c:17,t:13|, CCC(=O)O[C@@]1([C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)CCl |c:17,t:13|, CCC(=O)O[C@@]1([C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)CCl |c:17,t:13|, CCC(=O)O[C@@]1([C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)CCl |c:17,t:13|	CBGUOGMQLZIXBE-XGQKBEPLSA-N, CBGUOGMQLZIXBE-XGQKBEPLSA-N, CBGUOGMQLZIXBE-XGQKBEPLSA-N, CBGUOGMQLZIXBE-XGQKBEPLSA-N, CBGUOGMQLZIXBE-XGQKBEPLSA-N	Launched
clobetasone-butyrate	corticosteroid agonist	NR3C1	dermatology	eczema, psoriasis, dermatitis	CCCC(=O)O[C@@]1([C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)C(=O)C[C@]12C)C(=O)CCl |c:18,t:14|, CCCC(=O)O[C@@]1([C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)C(=O)C[C@]12C)C(=O)CCl |c:18,t:14|	FBRAWBYQGRLCEK-AVVSTMBFSA-N, FBRAWBYQGRLCEK-AVVSTMBFSA-N	Launched
clobutinol	antitussive				C[C@@H](CN(C)C)C(C)(O)Cc1ccc(Cl)cc1 |&1:1,&2:6|	KVHHQGIIZCJATJ-ZSOXZCCMSA-N	Withdrawn
clocortolone-pivalate	steroid	NR3C1, PLA2G1B	dermatology	corticosteroid-responsive dermatoses	C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@H]1C(=O)COC(=O)C(C)(C)C |c:12,t:8|, C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@H]1C(=O)COC(=O)C(C)(C)C |c:12,t:8|, C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@H]1C(=O)COC(=O)C(C)(C)C |c:12,t:8|, C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@H]1C(=O)COC(=O)C(C)(C)C |c:12,t:8|, C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@H]1C(=O)COC(=O)C(C)(C)C |c:12,t:8|	SXYZQZLHAIHKKY-GSTUPEFVSA-N, SXYZQZLHAIHKKY-GSTUPEFVSA-N, SXYZQZLHAIHKKY-GSTUPEFVSA-N, SXYZQZLHAIHKKY-GSTUPEFVSA-N, SXYZQZLHAIHKKY-GSTUPEFVSA-N	Launched
clodronic-acid	bone resorption inhibitor	SLC25A4, SLC25A5, SLC25A6	orthopedics, endocrinology, hematologic malignancy	osteoporosis, hyperparathyroidism, hypercalcemia, multiple myeloma	OP(O)(=O)C(Cl)(Cl)P(O)(O)=O, OP(O)(=O)C(Cl)(Cl)P(O)(O)=O, OP(O)(=O)C(Cl)(Cl)P(O)(O)=O	ACSIXWWBWUQEHA-UHFFFAOYSA-N, ACSIXWWBWUQEHA-UHFFFAOYSA-N, ACSIXWWBWUQEHA-UHFFFAOYSA-N	Launched
clofarabine	ribonucleotide reductase inhibitor	POLA1, POLD1, POLE, RRM1, RRM2, RRM2B	hematologic malignancy	acute lymphoblastic leukemia (ALL)	Nc1nc(Cl)nc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F, Nc1nc(Cl)nc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F, Nc1nc(Cl)nc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F, Nc1nc(Cl)nc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F, Nc1nc(Cl)nc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F, Nc1nc(Cl)nc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F, Nc1nc(Cl)nc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F, Nc1nc(Cl)nc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F	WDDPHFBMKLOVOX-AYQXTPAHSA-N, WDDPHFBMKLOVOX-AYQXTPAHSA-N, WDDPHFBMKLOVOX-AYQXTPAHSA-N, WDDPHFBMKLOVOX-AYQXTPAHSA-N, WDDPHFBMKLOVOX-AYQXTPAHSA-N, WDDPHFBMKLOVOX-AYQXTPAHSA-N, WDDPHFBMKLOVOX-AYQXTPAHSA-N, WDDPHFBMKLOVOX-AYQXTPAHSA-N	Launched
clofazimine	GK0582 inhibitor		infectious disease	leprosy	CC(C)\N=c1/cc2n(-c3ccc(Cl)cc3)c3ccccc3nc2cc1Nc1ccc(Cl)cc1, CC(C)\N=c1/cc2n(-c3ccc(Cl)cc3)c3ccccc3nc2cc1Nc1ccc(Cl)cc1, CC(C)\N=c1/cc2n(-c3ccc(Cl)cc3)c3ccccc3nc2cc1Nc1ccc(Cl)cc1, CC(C)\N=c1/cc2n(-c3ccc(Cl)cc3)c3ccccc3nc2cc1Nc1ccc(Cl)cc1	WDQPAMHFFCXSNU-BGABXYSRSA-N, WDQPAMHFFCXSNU-BGABXYSRSA-N, WDQPAMHFFCXSNU-BGABXYSRSA-N, WDQPAMHFFCXSNU-BGABXYSRSA-N	Launched
clofedanol	histamine receptor antagonist	HRH1	pulmonary	cough suppressant	CN(C)CC[C@@](O)(c1ccccc1)c1ccccc1Cl |&1:5,r|	WRCHFMBCVFFYEQ-QGZVFWFLSA-N	Launched
clofibrate	PPAR receptor agonist	LPL, PPARA	endocrinology, cardiology	hyperlipidemia, cholesterol	CCOC(=O)C(C)(C)Oc1ccc(Cl)cc1, CCOC(=O)C(C)(C)Oc1ccc(Cl)cc1, CCOC(=O)C(C)(C)Oc1ccc(Cl)cc1, CCOC(=O)C(C)(C)Oc1ccc(Cl)cc1	KNHUKKLJHYUCFP-UHFFFAOYSA-N, KNHUKKLJHYUCFP-UHFFFAOYSA-N, KNHUKKLJHYUCFP-UHFFFAOYSA-N, KNHUKKLJHYUCFP-UHFFFAOYSA-N	Launched
clofibric-acid	PPAR receptor agonist	PPARA	endocrinology	hyperlipidemia	CC(C)(Oc1ccc(Cl)cc1)C(O)=O, CC(C)(Oc1ccc(Cl)cc1)C(O)=O, CC(C)(Oc1ccc(Cl)cc1)C(O)=O, CC(C)(Oc1ccc(Cl)cc1)C(O)=O	TXCGAZHTZHNUAI-UHFFFAOYSA-N, TXCGAZHTZHNUAI-UHFFFAOYSA-N, TXCGAZHTZHNUAI-UHFFFAOYSA-N, TXCGAZHTZHNUAI-UHFFFAOYSA-N	Launched
clofilium	potassium channel blocker	KCNA5, KCNH1			CCCCCCC[N+](CC)(CC)CCCCc1ccc(Cl)cc1, CCCCCCC[N+](CC)(CC)CCCCc1ccc(Cl)cc1, CCCCCCC[N+](CC)(CC)CCCCc1ccc(Cl)cc1	WPSYTTKBGAZSCX-UHFFFAOYSA-N, WPSYTTKBGAZSCX-UHFFFAOYSA-N, WPSYTTKBGAZSCX-UHFFFAOYSA-N	Phase 2
clofoctol	protein synthesis inhibitor		infectious disease	gram-positive bacterial infections	CC(C)(C)CC(C)(C)c1ccc(O)c(Cc2ccc(Cl)cc2Cl)c1, CC(C)(C)CC(C)(C)c1ccc(O)c(Cc2ccc(Cl)cc2Cl)c1, CC(C)(C)CC(C)(C)c1ccc(O)c(Cc2ccc(Cl)cc2Cl)c1, CC(C)(C)CC(C)(C)c1ccc(O)c(Cc2ccc(Cl)cc2Cl)c1	HQVZOORKDNCGCK-UHFFFAOYSA-N, HQVZOORKDNCGCK-UHFFFAOYSA-N, HQVZOORKDNCGCK-UHFFFAOYSA-N, HQVZOORKDNCGCK-UHFFFAOYSA-N	Launched
clomesone	DNA inhibitor				CS(=O)(=O)CS(=O)(=O)OCCCl	SEHSPJCWCBQHPF-UHFFFAOYSA-N	Phase 1
clomethiazole	GABA receptor antagonist, GABA receptor modulator	GABRA1	neurology/psychiatry	Parkinson's Disease, sedative, muscle relaxant	Cc1ncsc1CCCl, Cc1ncsc1CCCl, Cc1ncsc1CCCl	PCLITLDOTJTVDJ-UHFFFAOYSA-N, PCLITLDOTJTVDJ-UHFFFAOYSA-N, PCLITLDOTJTVDJ-UHFFFAOYSA-N	Launched
clomifene	estrogen receptor antagonist	ESR1	obstetrics/gynecology	infertility	CCN(CC)CCOc1ccc(cc1)C(=C(/Cl)c1ccccc1)\c1ccccc1, CCN(CC)CCOc1ccc(cc1)C(=C(/Cl)c1ccccc1)\c1ccccc1, CCN(CC)CCOc1ccc(cc1)C(=C(/Cl)c1ccccc1)\c1ccccc1, CCN(CC)CCOc1ccc(cc1)C(=C(/Cl)c1ccccc1)\c1ccccc1, CCN(CC)CCOc1ccc(cc1)C(=C(/Cl)c1ccccc1)\c1ccccc1, CCN(CC)CCOc1ccc(cc1)C(=C(/Cl)c1ccccc1)\c1ccccc1, CCN(CC)CCOc1ccc(cc1)C(=C(/Cl)c1ccccc1)\c1ccccc1, CCN(CC)CCOc1ccc(cc1)C(=C(/Cl)c1ccccc1)\c1ccccc1, CCN(CC)CCOc1ccc(cc1)C(=C(/Cl)c1ccccc1)\c1ccccc1, CCN(CC)CCOc1ccc(cc1)C(=C(/Cl)c1ccccc1)\c1ccccc1	GKIRPKYJQBWNGO-QPLCGJKRSA-N, GKIRPKYJQBWNGO-QPLCGJKRSA-N, GKIRPKYJQBWNGO-QPLCGJKRSA-N, GKIRPKYJQBWNGO-QPLCGJKRSA-N, GKIRPKYJQBWNGO-QPLCGJKRSA-N, GKIRPKYJQBWNGO-QPLCGJKRSA-N, GKIRPKYJQBWNGO-QPLCGJKRSA-N, GKIRPKYJQBWNGO-QPLCGJKRSA-N, GKIRPKYJQBWNGO-QPLCGJKRSA-N, GKIRPKYJQBWNGO-QPLCGJKRSA-N	Launched
clomipramine	serotonin transporter (SERT) inhibitor	GSTP1, HTR2A, HTR2B, HTR2C, SLC6A2, SLC6A3, SLC6A4	neurology/psychiatry	obsessive compulsive disorder (OCD)	CN(C)CCCN1c2ccccc2CCc2ccc(Cl)cc12, CN(C)CCCN1c2ccccc2CCc2ccc(Cl)cc12, CN(C)CCCN1c2ccccc2CCc2ccc(Cl)cc12, CN(C)CCCN1c2ccccc2CCc2ccc(Cl)cc12, CN(C)CCCN1c2ccccc2CCc2ccc(Cl)cc12	GDLIGKIOYRNHDA-UHFFFAOYSA-N, GDLIGKIOYRNHDA-UHFFFAOYSA-N, GDLIGKIOYRNHDA-UHFFFAOYSA-N, GDLIGKIOYRNHDA-UHFFFAOYSA-N, GDLIGKIOYRNHDA-UHFFFAOYSA-N	Launched
clonidine	adrenergic receptor agonist	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C	cardiology, neurology/psychiatry	hypertension, attention-deficit/hyperactivity disorder (ADHD)	Clc1cccc(Cl)c1NC1=NCCN1 |t:10|, Clc1cccc(Cl)c1NC1=NCCN1 |t:10|, Clc1cccc(Cl)c1NC1=NCCN1 |t:10|, Clc1cccc(Cl)c1NC1=NCCN1 |t:10|, Clc1cccc(Cl)c1NC1=NCCN1 |t:10|	GJSURZIOUXUGAL-UHFFFAOYSA-N, GJSURZIOUXUGAL-UHFFFAOYSA-N, GJSURZIOUXUGAL-UHFFFAOYSA-N, GJSURZIOUXUGAL-UHFFFAOYSA-N, GJSURZIOUXUGAL-UHFFFAOYSA-N	Launched
clonixin	cyclooxygenase inhibitor	PTGS1, PTGS2	rheumatology, infectious disease	rheumatoid arthritis, soft tissue infection	Cc1c(Cl)cccc1Nc1ncccc1C(O)=O	CLOMYZFHNHFSIQ-UHFFFAOYSA-N	Preclinical
clonixin-lysinate	cyclooxygenase inhibitor		neurology/psychiatry	pain relief	NCCCC[C@H](N)C(O)=O.Cc1c(Cl)cccc1Nc1ncccc1C(O)=O, NCCCC[C@H](N)C(O)=O.Cc1c(Cl)cccc1Nc1ncccc1C(O)=O, NCCCC[C@H](N)C(O)=O.Cc1c(Cl)cccc1Nc1ncccc1C(O)=O	CVNFYQCHAWFYQI-ZSCHJXSPSA-N, CVNFYQCHAWFYQI-ZSCHJXSPSA-N, CVNFYQCHAWFYQI-ZSCHJXSPSA-N	Launched
clopamide	sodium/chloride cotransporter inhibitor		cardiology	hypertension	C[C@H]1CCC[C@@H](C)N1NC(=O)c1ccc(Cl)c(c1)S(N)(=O)=O, C[C@H]1CCC[C@@H](C)N1NC(=O)c1ccc(Cl)c(c1)S(N)(=O)=O	LBXHRAWDUMTPSE-AOOOYVTPSA-N, LBXHRAWDUMTPSE-AOOOYVTPSA-N	Launched
cloperastine	antitussive		pulmonary	cough suppressant	Clc1ccc(cc1)[C@@H](OCCN1CCCCC1)c1ccccc1 |&1:7|, Clc1ccc(cc1)[C@@H](OCCN1CCCCC1)c1ccccc1 |&1:7|	FLNXBVJLPJNOSI-FQEVSTJZSA-N, FLNXBVJLPJNOSI-FQEVSTJZSA-N	Launched
cloperastine-fendizoate	potassium channel antagonist						Preclinical
clopidogrel	purinergic receptor antagonist	P2RY12	cardiology, neurology/psychiatry	myocardial infarction, stroke, peripheral artery disease (PAD), acute coronary syndrome (ACS)	COC(=O)[C@@H](N1CCc2sccc2C1)c1ccccc1Cl, COC(=O)[C@@H](N1CCc2sccc2C1)c1ccccc1Cl, COC(=O)[C@@H](N1CCc2sccc2C1)c1ccccc1Cl, COC(=O)[C@@H](N1CCc2sccc2C1)c1ccccc1Cl, COC(=O)[C@@H](N1CCc2sccc2C1)c1ccccc1Cl, COC(=O)[C@@H](N1CCc2sccc2C1)c1ccccc1Cl	GKTWGGQPFAXNFI-HNNXBMFYSA-N, GKTWGGQPFAXNFI-HNNXBMFYSA-N, GKTWGGQPFAXNFI-HNNXBMFYSA-N, GKTWGGQPFAXNFI-HNNXBMFYSA-N, GKTWGGQPFAXNFI-HNNXBMFYSA-N, GKTWGGQPFAXNFI-HNNXBMFYSA-N	Launched
clopidol			infectious disease	coccidiosis	Cc1[nH]c(C)c(Cl)c(=O)c1Cl, Cc1[nH]c(C)c(Cl)c(=O)c1Cl	ZDPIZLCVJAAHHR-UHFFFAOYSA-N, ZDPIZLCVJAAHHR-UHFFFAOYSA-N	Launched
cloprostenol-(+/-)	prostaglandin receptor agonist	PTGDR, PTGER1, PTGER3, PTGFR, TBXA2R	obstetrics/gynecology	endometriosis	O[C@@H](COc1cccc(Cl)c1)\C=C\[C@H]1[C@H](O)C[C@H](O)[C@@H]1C\C=C/CCCC(O)=O	VJGGHXVGBSZVMZ-QIZQQNKQSA-N	Launched
cloranolol	adrenergic receptor antagonist	ADRB1, ADRB2, ADRB3	cardiology	hypertension	CC(C)(C)NC[C@@H](O)COc1cc(Cl)ccc1Cl |&1:6|	XYCMOTOFHFTUIU-SNVBAGLBSA-N	Launched
clorgiline	monoamine oxidase inhibitor	MAOA			CN(CCCOc1ccc(Cl)cc1Cl)CC#C, CN(CCCOc1ccc(Cl)cc1Cl)CC#C, CN(CCCOc1ccc(Cl)cc1Cl)CC#C, CN(CCCOc1ccc(Cl)cc1Cl)CC#C	BTFHLQRNAMSNLC-UHFFFAOYSA-N, BTFHLQRNAMSNLC-UHFFFAOYSA-N, BTFHLQRNAMSNLC-UHFFFAOYSA-N, BTFHLQRNAMSNLC-UHFFFAOYSA-N	Phase 2
clorotepine	adrenergic receptor antagonist, dopamine receptor antagonist	ADRA1A, ADRA1B, ADRA1D, DRD2, HRH1, HTR2C, HTR6	neurology/psychiatry	psychosis	CN1CCN(CC1)[C@H]1Cc2ccccc2Sc2ccc(Cl)cc12 |&1:7|, CN1CCN(CC1)[C@H]1Cc2ccccc2Sc2ccc(Cl)cc12 |&1:7|	XRYLGRGAWQSVQW-KRWDZBQOSA-N, XRYLGRGAWQSVQW-KRWDZBQOSA-N	Launched
clorprenaline	adrenergic receptor agonist	ADRB1, ADRB2	pulmonary	asthma	CC(C)NC[C@@H](O)c1ccccc1Cl |&1:5|	SSMSBSWKLKKXGG-LLVKDONJSA-N	Launched
clorsulon	glycolysis inhibitor		infectious disease	gastrointestinal roundworms, lungworms, liver flukes, lice, mites	Nc1cc(C(Cl)=C(Cl)Cl)c(cc1S(N)(=O)=O)S(N)(=O)=O, Nc1cc(C(Cl)=C(Cl)Cl)c(cc1S(N)(=O)=O)S(N)(=O)=O, Nc1cc(C(Cl)=C(Cl)Cl)c(cc1S(N)(=O)=O)S(N)(=O)=O	QOVTVIYTBRHADL-UHFFFAOYSA-N, QOVTVIYTBRHADL-UHFFFAOYSA-N, QOVTVIYTBRHADL-UHFFFAOYSA-N	Launched
closantel	chitinase inhibitor, NFkB pathway inhibitor		infectious disease	liver flukes	Cc1cc([C@@H](C#N)c2ccc(Cl)cc2)c(Cl)cc1NC(=O)c1cc(I)cc(I)c1O |&1:4|, Cc1cc([C@@H](C#N)c2ccc(Cl)cc2)c(Cl)cc1NC(=O)c1cc(I)cc(I)c1O |&1:4|	JMPFSEBWVLAJKM-KRWDZBQOSA-N, JMPFSEBWVLAJKM-KRWDZBQOSA-N	Launched
clotiapine			neurology/psychiatry	psychosis	CN1CCN(CC1)C1=Nc2ccccc2Sc2ccc(Cl)cc12 |t:8|, CN1CCN(CC1)C1=Nc2ccccc2Sc2ccc(Cl)cc12 |t:8|	KAAZGXDPUNNEFN-UHFFFAOYSA-N, KAAZGXDPUNNEFN-UHFFFAOYSA-N	Launched
clotrimazole	cytochrome P450 inhibitor, imidazoline receptor ligand	CYP3A4, KCNN4, NR1I2, NR1I3, TRPM2, TRPM4, TRPM8	infectious disease	vulvovaginal candidiasis, oropharyngeal candidiasis	Clc1ccccc1C(c1ccccc1)(c1ccccc1)n1ccnc1, Clc1ccccc1C(c1ccccc1)(c1ccccc1)n1ccnc1, Clc1ccccc1C(c1ccccc1)(c1ccccc1)n1ccnc1, Clc1ccccc1C(c1ccccc1)(c1ccccc1)n1ccnc1	VNFPBHJOKIVQEB-UHFFFAOYSA-N, VNFPBHJOKIVQEB-UHFFFAOYSA-N, VNFPBHJOKIVQEB-UHFFFAOYSA-N, VNFPBHJOKIVQEB-UHFFFAOYSA-N	Launched
cloxacillin	bacterial cell wall synthesis inhibitor		infectious disease	gram-positive bacterial infections	Cc1onc(c1C(=O)N[C@H]1[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O)-c1ccccc1Cl, Cc1onc(c1C(=O)N[C@H]1[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O)-c1ccccc1Cl, Cc1onc(c1C(=O)N[C@H]1[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O)-c1ccccc1Cl, Cc1onc(c1C(=O)N[C@H]1[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O)-c1ccccc1Cl, Cc1onc(c1C(=O)N[C@H]1[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O)-c1ccccc1Cl	LQOLIRLGBULYKD-JKIFEVAISA-N, LQOLIRLGBULYKD-JKIFEVAISA-N, LQOLIRLGBULYKD-JKIFEVAISA-N, LQOLIRLGBULYKD-JKIFEVAISA-N, LQOLIRLGBULYKD-JKIFEVAISA-N	Launched
cloxyquin	potassium channel activator	KCNK18			Oc1ccc(Cl)c2cccnc12, Oc1ccc(Cl)c2cccnc12, Oc1ccc(Cl)c2cccnc12	CTQMJYWDVABFRZ-UHFFFAOYSA-N, CTQMJYWDVABFRZ-UHFFFAOYSA-N, CTQMJYWDVABFRZ-UHFFFAOYSA-N	Preclinical
clozapine	dopamine receptor antagonist, serotonin receptor antagonist	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, CALY, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, DRD1, DRD2, DRD3, DRD4, DRD5, HRH1, HRH4, HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2B, HTR2C, HTR3A, HTR5A, HTR6, HTR7	neurology/psychiatry	schizophrenia	CN1CCN(CC1)C1=Nc2cc(Cl)ccc2Nc2ccccc12 |t:8|, CN1CCN(CC1)C1=Nc2cc(Cl)ccc2Nc2ccccc12 |t:8|, CN1CCN(CC1)C1=Nc2cc(Cl)ccc2Nc2ccccc12 |t:8|, CN1CCN(CC1)C1=Nc2cc(Cl)ccc2Nc2ccccc12 |t:8|	QZUDBNBUXVUHMW-UHFFFAOYSA-N, QZUDBNBUXVUHMW-UHFFFAOYSA-N, QZUDBNBUXVUHMW-UHFFFAOYSA-N, QZUDBNBUXVUHMW-UHFFFAOYSA-N	Launched
CL316243	adrenergic receptor agonist	ADRB3, UCP1, UCP2, UCP3			C[C@H](Cc1ccc2OC(Oc2c1)(C(O)=O)C(O)=O)NC[C@H](O)c1cccc(Cl)c1	JEDJMKTVUPSHFW-ABAIWWIYSA-N	Phase 2
CM-4620	calcium release activated channel modulator				Cc1cccc(F)c1C(=O)Nc1cnc(cn1)-c1cc2OC(F)(F)Oc2cc1Cl	QQMKTHUGOQDEIL-UHFFFAOYSA-N	Phase 2
CMPD-1	p38 MAPK inhibitor	GNRHR, MAPK14			Oc1ccc(NC(=O)CCCc2ccc(cc2)-c2ccccc2F)cc1, Oc1ccc(NC(=O)CCCc2ccc(cc2)-c2ccccc2F)cc1, Oc1ccc(NC(=O)CCCc2ccc(cc2)-c2ccccc2F)cc1	ODYAQBDIXCVKAE-UHFFFAOYSA-N, ODYAQBDIXCVKAE-UHFFFAOYSA-N, ODYAQBDIXCVKAE-UHFFFAOYSA-N	Preclinical
CNQX	glutamate receptor antagonist	GRIA1, GRIA2, GRIA3, GRIA4			[O-][N+](=O)c1cc2[nH]c(=O)c(=O)[nH]c2cc1C#N, [O-][N+](=O)c1cc2[nH]c(=O)c(=O)[nH]c2cc1C#N, [O-][N+](=O)c1cc2[nH]c(=O)c(=O)[nH]c2cc1C#N	RPXVIAFEQBNEAX-UHFFFAOYSA-N, RPXVIAFEQBNEAX-UHFFFAOYSA-N, RPXVIAFEQBNEAX-UHFFFAOYSA-N	Phase 1
CNX-2006	EGFR inhibitor	EGFR			COc1cc(NC2CN(CCF)C2)ccc1Nc1ncc(c(Nc2cccc(NC(=O)C=C)c2)n1)C(F)(F)F, COc1cc(NC2CN(CCF)C2)ccc1Nc1ncc(c(Nc2cccc(NC(=O)C=C)c2)n1)C(F)(F)F	BFSRTTWIPACGMI-UHFFFAOYSA-N, BFSRTTWIPACGMI-UHFFFAOYSA-N	Preclinical
CNX-774	Bruton's tyrosine kinase (BTK) inhibitor	BTK			CNC(=O)c1cc(Oc2ccc(Nc3ncc(F)c(Nc4cccc(NC(=O)C=C)c4)n3)cc2)ccn1, CNC(=O)c1cc(Oc2ccc(Nc3ncc(F)c(Nc4cccc(NC(=O)C=C)c4)n3)cc2)ccn1, CNC(=O)c1cc(Oc2ccc(Nc3ncc(F)c(Nc4cccc(NC(=O)C=C)c4)n3)cc2)ccn1, CNC(=O)c1cc(Oc2ccc(Nc3ncc(F)c(Nc4cccc(NC(=O)C=C)c4)n3)cc2)ccn1, CNC(=O)c1cc(Oc2ccc(Nc3ncc(F)c(Nc4cccc(NC(=O)C=C)c4)n3)cc2)ccn1	VVLHQJDAUIPZFH-UHFFFAOYSA-N, VVLHQJDAUIPZFH-UHFFFAOYSA-N, VVLHQJDAUIPZFH-UHFFFAOYSA-N, VVLHQJDAUIPZFH-UHFFFAOYSA-N, VVLHQJDAUIPZFH-UHFFFAOYSA-N	Preclinical
CO-101244	glutamate receptor antagonist	GRIN2B			Cc1ccc(CC2(O)CCN(CCOc3ccc(O)cc3)CC2)cc1, Cc1ccc(CC2(O)CCN(CCOc3ccc(O)cc3)CC2)cc1, Cc1ccc(CC2(O)CCN(CCOc3ccc(O)cc3)CC2)cc1, Cc1ccc(CC2(O)CCN(CCOc3ccc(O)cc3)CC2)cc1	VKMFDKYCIKEDMR-UHFFFAOYSA-N, VKMFDKYCIKEDMR-UHFFFAOYSA-N, VKMFDKYCIKEDMR-UHFFFAOYSA-N, VKMFDKYCIKEDMR-UHFFFAOYSA-N	Preclinical
CO-102862	sodium channel blocker	SCN4A, SCN9A			NC(=O)N\N=C\c1ccc(Oc2ccc(F)cc2)cc1, NC(=O)N\N=C\c1ccc(Oc2ccc(F)cc2)cc1, NC(=O)N\N=C\c1ccc(Oc2ccc(F)cc2)cc1	MHUUDVZSPFRUSK-RQZCQDPDSA-N, MHUUDVZSPFRUSK-RQZCQDPDSA-N, MHUUDVZSPFRUSK-RQZCQDPDSA-N	Phase 1
cobicistat	cytochrome P450 inhibitor	CYP3A4, CYP3A43, CYP3A5, CYP3A7	infectious disease	human immunodeficiency virus (HIV-1)	CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1, CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1, CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1, CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1	ZCIGNRJZKPOIKD-CQXVEOKZSA-N, ZCIGNRJZKPOIKD-CQXVEOKZSA-N, ZCIGNRJZKPOIKD-CQXVEOKZSA-N, ZCIGNRJZKPOIKD-CQXVEOKZSA-N	Launched
cobimetinib	MEK inhibitor	MAP2K1	oncology	melanoma	OC1(CN(C1)C(=O)c1ccc(F)c(F)c1Nc1ccc(I)cc1F)[C@@H]1CCCCN1, OC1(CN(C1)C(=O)c1ccc(F)c(F)c1Nc1ccc(I)cc1F)[C@@H]1CCCCN1, OC1(CN(C1)C(=O)c1ccc(F)c(F)c1Nc1ccc(I)cc1F)[C@@H]1CCCCN1, OC1(CN(C1)C(=O)c1ccc(F)c(F)c1Nc1ccc(I)cc1F)[C@@H]1CCCCN1, OC1(CN(C1)C(=O)c1ccc(F)c(F)c1Nc1ccc(I)cc1F)[C@@H]1CCCCN1, OC1(CN(C1)C(=O)c1ccc(F)c(F)c1Nc1ccc(I)cc1F)[C@@H]1CCCCN1, OC1(CN(C1)C(=O)c1ccc(F)c(F)c1Nc1ccc(I)cc1F)[C@@H]1CCCCN1, OC1(CN(C1)C(=O)c1ccc(F)c(F)c1Nc1ccc(I)cc1F)[C@@H]1CCCCN1	BSMCAPRUBJMWDF-KRWDZBQOSA-N, BSMCAPRUBJMWDF-KRWDZBQOSA-N, BSMCAPRUBJMWDF-KRWDZBQOSA-N, BSMCAPRUBJMWDF-KRWDZBQOSA-N, BSMCAPRUBJMWDF-KRWDZBQOSA-N, BSMCAPRUBJMWDF-KRWDZBQOSA-N, BSMCAPRUBJMWDF-KRWDZBQOSA-N, BSMCAPRUBJMWDF-KRWDZBQOSA-N	Launched
coenzyme-A		ACAT2, CRAT, CS, DBI, HMGCR, KAT2A, KAT2B, KAT5			CC(C)(COP(O)(=O)OP(O)(=O)OC[C@H]1O[C@H]([C@H](O)[C@@H]1OP(O)(O)=O)n1cnc2c(N)ncnc12)[C@@H](O)C(=O)NCCC(=O)NCCS |a:14,16,17,19,35,&1:5,&2:9|	RGJOEKWQDUBAIZ-IBOSZNHHSA-N	Launched
coenzyme-I		AASS, ACADS, ADH1A, ADH1B, ADH1C, ADH4, ADH5, ADH7, AKR1B1, AKR1C1, AKR1C2, AKR1C3, AKR1C4, ALDH1A1, ALDH1A2, ALDH1A3, ALDH1B1, ALDH2, ALDH3A1, ALDH3A2, ALDH3B1, ALDH3B2, ALDH4A1, ALDH5A1, ALDH6A1, ALDH7A1, ALDH9A1, AMT, BDH1, BLVRA, BLVRB, CDO1, CYB5R3, CYP17A1, CYP4A11, DHCR7, DHFR, DLAT, DLD, EHHADH, GAPDH, GAPDHS, GLUD1, GLUD2, GPD1, GSR, H6PD, HADH, HADHA, HIBADH, HMGCR, HMOX1, HMOX2, HPGD, HSD11B1, HSD11B2, HSD17B1, HSD17B10, HSD17B2, HSD17B3, HSD17B4, HSD17B7, HSD17B8, HSD3B1, HSD3B2, IDH3A, IDH3B, IDH3G, IMPDH1, IMPDH2, LDHA, LDHAL6A, LDHAL6B, LDHB, LDHC, MDH1, MDH2, ME1, ME2, ME3, MSMO1, MT-ND1, MT-ND2, MT-ND3, MT-ND4, MT-ND4L, MT-ND5, MT-ND6, MTHFD1, MTHFD2, NDUFA1, NDUFA10, NDUFA11, NDUFA12, NDUFA13, NDUFA2, NDUFA3, NDUFA4, NDUFA4L2, NDUFA5, NDUFA6, NDUFA7, NDUFA8, NDUFA9, NDUFAB1, NDUFB1, NDUFB10, NDUFB2, NDUFB3, NDUFB4, NDUFB5, NDUFB6, NDUFB7, NDUFB8, NDUFB9, NDUFC1, NDUFC2, NDUFS1, NDUFS2, NDUFS3, NDUFS4, NDUFS5, NDUFS6, NDUFS7, NDUFS8, NDUFV1, NDUFV2, NDUFV3, NNT, NQO2, NSDHL, OGDH, PDHA1, PDHA2, PDHB, PHGDH, PYCR1, PYCR2, QDPR, RDH5, SORD, TSTA3, TYR, UGDH			NC(=O)C1=CN(C=CC1)[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@H](O)[C@@H]2O)n2cnc3c(N)ncnc23)[C@@H](O)[C@H]1O |a:9,11,23,25,26,28,40,42,&1:14,&2:18,c:6,t:3|, NC(=O)C1=CN(C=CC1)[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@H](O)[C@@H]2O)n2cnc3c(N)ncnc23)[C@@H](O)[C@H]1O |a:9,11,23,25,26,28,40,42,&1:14,&2:18,c:6,t:3|	BOPGDPNILDQYTO-NNYOXOHSSA-N, BOPGDPNILDQYTO-NNYOXOHSSA-N	Phase 2
coenzyme-Q10					COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O |c:2,t:58|, COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O |c:2,t:58|, COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O |c:2,t:58|	ACTIUHUUMQJHFO-UPTCCGCDSA-N, ACTIUHUUMQJHFO-UPTCCGCDSA-N, ACTIUHUUMQJHFO-UPTCCGCDSA-N	Launched
COH29	ribonucleotide reductase inhibitor				Oc1ccc(cc1O)C(=O)Nc1nc(c(s1)-c1ccccc1)-c1ccc(O)c(O)c1	LGGDLPSXAGQFSG-UHFFFAOYSA-N	Phase 1
colchicine	microtubule inhibitor	GLRA1, GLRA2, TUBA1A, TUBA1B, TUBA1C, TUBA3C, TUBA3D, TUBA3E, TUBA4A, TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8	rheumatology, endocrinology	gout, fever	COc1cc2CC[C@H](NC(C)=O)c3cc(=O)c(OC)ccc3-c2c(OC)c1OC, COc1cc2CC[C@H](NC(C)=O)c3cc(=O)c(OC)ccc3-c2c(OC)c1OC, COc1cc2CC[C@H](NC(C)=O)c3cc(=O)c(OC)ccc3-c2c(OC)c1OC	IAKHMKGGTNLKSZ-INIZCTEOSA-N, IAKHMKGGTNLKSZ-INIZCTEOSA-N, IAKHMKGGTNLKSZ-INIZCTEOSA-N	Launched
colforsin	adenylyl cyclase activator	ADCY2, ADCY5			CC(=O)O[C@H]1[C@@H](O)[C@H]2C(C)(C)CC[C@H](O)[C@]2(C)[C@@]2(O)C(=O)C[C@@](C)(O[C@]12C)C=C |a:4,5,13,15,17,22,25,&1:7|, CC(=O)O[C@H]1[C@@H](O)[C@H]2C(C)(C)CC[C@H](O)[C@]2(C)[C@@]2(O)C(=O)C[C@@](C)(O[C@]12C)C=C |a:4,5,13,15,17,22,25,&1:7|	OHCQJHSOBUTRHG-KGGHGJDLSA-N, OHCQJHSOBUTRHG-KGGHGJDLSA-N	Phase 2
colforsin-daproate	adenylyl cyclase activator				CN(C)CCC(=O)O[C@@H]1[C@H](OC(C)=O)[C@@]2(C)O[C@](C)(CC(=O)[C@]2(O)[C@@]2(C)[C@@H](O)CCC(C)(C)[C@H]12)C=C, CN(C)CCC(=O)O[C@@H]1[C@H](OC(C)=O)[C@@]2(C)O[C@](C)(CC(=O)[C@]2(O)[C@@]2(C)[C@@H](O)CCC(C)(C)[C@H]12)C=C, CN(C)CCC(=O)O[C@@H]1[C@H](OC(C)=O)[C@@]2(C)O[C@](C)(CC(=O)[C@]2(O)[C@@]2(C)[C@@H](O)CCC(C)(C)[C@H]12)C=C, CN(C)CCC(=O)O[C@@H]1[C@H](OC(C)=O)[C@@]2(C)O[C@](C)(CC(=O)[C@]2(O)[C@@]2(C)[C@@H](O)CCC(C)(C)[C@H]12)C=C, CN(C)CCC(=O)O[C@@H]1[C@H](OC(C)=O)[C@@]2(C)O[C@](C)(CC(=O)[C@]2(O)[C@@]2(C)[C@@H](O)CCC(C)(C)[C@H]12)C=C, CN(C)CCC(=O)O[C@@H]1[C@H](OC(C)=O)[C@@]2(C)O[C@](C)(CC(=O)[C@]2(O)[C@@]2(C)[C@@H](O)CCC(C)(C)[C@H]12)C=C	RSOZZQTUMVBTMR-XGUNBQNXSA-N, RSOZZQTUMVBTMR-XGUNBQNXSA-N, RSOZZQTUMVBTMR-XGUNBQNXSA-N, RSOZZQTUMVBTMR-XGUNBQNXSA-N, RSOZZQTUMVBTMR-XGUNBQNXSA-N, RSOZZQTUMVBTMR-XGUNBQNXSA-N	Launched
colfosceril-palmitate	pulmonary surfactant		pulmonary	respiratory distress syndrome (RDS)	CCCCCCCCCCCCCCCC(=O)OC[C@H](CO[P@](O)(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC |a:19,&1:22|, CCCCCCCCCCCCCCCC(=O)OC[C@H](CO[P@](O)(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC |a:19,&1:22|	KILNVBDSWZSGLL-KXQOOQHDSA-O, KILNVBDSWZSGLL-KXQOOQHDSA-O	Launched
colistimethate	bacterial permeability inducer		infectious disease	gram-negative bacterial infections	[H][C@@](CCNCS(O)(=O)=O)(NC(=O)CCCC(C)C)C(=O)N[C@@]([H])([C@@H](C)O)C(=O)N[C@@]([H])(CCNCS(O)(=O)=O)C(=O)N[C@@]1([H])CCNC(=O)[C@@]([H])(NC(=O)[C@]([H])(CCNCS(O)(=O)=O)NC(=O)[C@]([H])(CCNCS(O)(=O)=O)NC(=O)[C@]([H])(CC(C)C)NC(=O)[C@]([H])(CC(C)C)NC(=O)[C@]([H])(CCNCS(O)(=O)=O)NC1=O)[C@@H](C)O	PTQGBRPUALXNCZ-INRRNNIXSA-N	Launched
colistin	bacterial permeability inducer		infectious disease	gram-negative bacterial infections, gram-negative bacterial infections	CC[C@@H](C)CCCC(=O)N[C@@H](CCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O)[C@@H](C)O |a:10,17,18,24,31,37,41,48,55,63,71,78,&1:2|, CC[C@@H](C)CCCC(=O)N[C@@H](CCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O)[C@@H](C)O |a:10,17,18,24,31,37,41,48,55,63,71,78,&1:2|	YKQOSKADJPQZHB-TULBBYNTSA-N, YKQOSKADJPQZHB-TULBBYNTSA-N	Launched
combretastatin-A-4	tubulin polymerization inhibitor				COc1ccc(\C=C/c2cc(OC)c(OC)c(OC)c2)cc1O, COc1ccc(\C=C/c2cc(OC)c(OC)c(OC)c2)cc1O	HVXBOLULGPECHP-WAYWQWQTSA-N, HVXBOLULGPECHP-WAYWQWQTSA-N	Phase 2
compound-w	beta-secretase inhibitor	BACE1			OC(=O)c1cc(Oc2ccc(cc2)[N+]([O-])=O)cc(Oc2ccc(cc2)[N+]([O-])=O)c1, OC(=O)c1cc(Oc2ccc(cc2)[N+]([O-])=O)cc(Oc2ccc(cc2)[N+]([O-])=O)c1, OC(=O)c1cc(Oc2ccc(cc2)[N+]([O-])=O)cc(Oc2ccc(cc2)[N+]([O-])=O)c1	JOSXKPZXMVHRKU-UHFFFAOYSA-N, JOSXKPZXMVHRKU-UHFFFAOYSA-N, JOSXKPZXMVHRKU-UHFFFAOYSA-N	Preclinical
compound-401	DNA dependent protein kinase inhibitor	MTOR, PRKDC			O=c1cc(nc2c3ccccc3ccn12)N1CCOCC1, O=c1cc(nc2c3ccccc3ccn12)N1CCOCC1, O=c1cc(nc2c3ccccc3ccn12)N1CCOCC1	BVRDQVRQVGRNHG-UHFFFAOYSA-N, BVRDQVRQVGRNHG-UHFFFAOYSA-N, BVRDQVRQVGRNHG-UHFFFAOYSA-N	Preclinical
compound-58112					COc1cccc(CN2C[Si](C)(C)O[Si](C)(C)C2)c1, COc1cccc(CN2C[Si](C)(C)O[Si](C)(C)C2)c1	CUYLJVJMQPPTOS-UHFFFAOYSA-N, CUYLJVJMQPPTOS-UHFFFAOYSA-N	Preclinical
conivaptan	vasopressin receptor antagonist	AVPR1A, AVPR2	endocrinology	hyponatremia	Cc1nc-2c(CCN(C(=O)c3ccc(NC(=O)c4ccccc4-c4ccccc4)cc3)c3ccccc-23)[nH]1, Cc1nc-2c(CCN(C(=O)c3ccc(NC(=O)c4ccccc4-c4ccccc4)cc3)c3ccccc-23)[nH]1	IKENVDNFQMCRTR-UHFFFAOYSA-N, IKENVDNFQMCRTR-UHFFFAOYSA-N	Launched
convallatoxin	cardiac glycoside				C[C@@H]1O[C@@H](O[C@H]2CC[C@]3(C=O)[C@H]4CC[C@]5(C)[C@H](CC[C@]5(O)[C@@H]4CC[C@]3(O)C2)C2=CC(=O)OC2)[C@H](O)[C@H](O)[C@H]1O |t:31|	HULMNSIAKWANQO-JQKSAQOKSA-N	Preclinical
copanlisib	PI3K inhibitor	PIK3CA, PIK3CB, PIK3CD, PIK3CG	hematologic malignancy	follicular lymphoma	COc1c(OCCCN2CCOCC2)ccc2C3=NCCN3C(NC(=O)c3cnc(N)nc3)=Nc12 |c:35,t:18|, COc1c(OCCCN2CCOCC2)ccc2C3=NCCN3C(NC(=O)c3cnc(N)nc3)=Nc12 |c:35,t:18|, COc1c(OCCCN2CCOCC2)ccc2C3=NCCN3C(NC(=O)c3cnc(N)nc3)=Nc12 |c:35,t:18|, COc1c(OCCCN2CCOCC2)ccc2C3=NCCN3C(NC(=O)c3cnc(N)nc3)=Nc12 |c:35,t:18|, COc1c(OCCCN2CCOCC2)ccc2C3=NCCN3C(NC(=O)c3cnc(N)nc3)=Nc12 |c:35,t:18|, COc1c(OCCCN2CCOCC2)ccc2C3=NCCN3C(NC(=O)c3cnc(N)nc3)=Nc12 |c:35,t:18|, COc1c(OCCCN2CCOCC2)ccc2C3=NCCN3C(NC(=O)c3cnc(N)nc3)=Nc12 |c:35,t:18|	PZBCKZWLPGJMAO-UHFFFAOYSA-N, PZBCKZWLPGJMAO-UHFFFAOYSA-N, PZBCKZWLPGJMAO-UHFFFAOYSA-N, PZBCKZWLPGJMAO-UHFFFAOYSA-N, PZBCKZWLPGJMAO-UHFFFAOYSA-N, PZBCKZWLPGJMAO-UHFFFAOYSA-N, PZBCKZWLPGJMAO-UHFFFAOYSA-N	Launched
copper-histidine		SLC15A3, SLC15A4, SLC38A5			N[C@H](Cc1cnc[nH]1)C(O)=O, N[C@H](Cc1cnc[nH]1)C(O)=O	HNDVDQJCIGZPNO-RXMQYKEDSA-N, HNDVDQJCIGZPNO-RXMQYKEDSA-N	Phase 3
COR-170	cannabinoid receptor inverse agonist	CNR2			CCCCCn1cc(C(=O)NC23CC4CC(CC(C4)C2)C3)c(=O)c2cc(ccc12)-c1ccccc1, CCCCCn1cc(C(=O)NC23CC4CC(CC(C4)C2)C3)c(=O)c2cc(ccc12)-c1ccccc1	MSJISJDTJJYBFT-UHFFFAOYSA-N, MSJISJDTJJYBFT-UHFFFAOYSA-N	Preclinical
cordycepin	DNA inhibitor				Nc1ncnc2n(cnc12)[C@@H]1O[C@H](CO)C[C@H]1O, Nc1ncnc2n(cnc12)[C@@H]1O[C@H](CO)C[C@H]1O, Nc1ncnc2n(cnc12)[C@@H]1O[C@H](CO)C[C@H]1O, Nc1ncnc2n(cnc12)[C@@H]1O[C@H](CO)C[C@H]1O	OFEZSBMBBKLLBJ-BAJZRUMYSA-N, OFEZSBMBBKLLBJ-BAJZRUMYSA-N, OFEZSBMBBKLLBJ-BAJZRUMYSA-N, OFEZSBMBBKLLBJ-BAJZRUMYSA-N	Phase 1/Phase 2
corosolic-acid	PKC inhibitor, protein tyrosine kinase inhibitor	HSD11B1, PTPN1			C[C@@H]1CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)C[C@@H](O)[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]2[C@H]1C)C(O)=O |c:9|, C[C@@H]1CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)C[C@@H](O)[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]2[C@H]1C)C(O)=O |c:9|, C[C@@H]1CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)C[C@@H](O)[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]2[C@H]1C)C(O)=O |c:9|	HFGSQOYIOKBQOW-ZSDYHTTISA-N, HFGSQOYIOKBQOW-ZSDYHTTISA-N, HFGSQOYIOKBQOW-ZSDYHTTISA-N	Phase 2
CORT-108297	glucocorticoid receptor antagonist				CCOC[C@@]12CN(CCC1=Cc1c(C2)cnn1-c1ccc(F)cc1)S(=O)(=O)c1ccc(cc1)C(F)(F)F |c:10|	SLKURXRZHJOZOD-RUZDIDTESA-N	Preclinical
corticosterone	mineralocorticoid receptor agonist	HSD11B1, NCOA1, NR3C2			C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@@H]2C(=O)CO |t:9|, C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@@H]2C(=O)CO |t:9|, C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@@H]2C(=O)CO |t:9|	OMFXVFTZEKFJBZ-HJTSIMOOSA-N, OMFXVFTZEKFJBZ-HJTSIMOOSA-N, OMFXVFTZEKFJBZ-HJTSIMOOSA-N	Preclinical
cortisone	glucocorticoid receptor agonist	NR3C1	gastroenterology, rheumatology, dermatology	ulcerative colitis, rheumatoid arthritis, psoriasis, joint inflammation, eczema	C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO |t:9|	MFYSYFVPBJMHGN-ZPOLXVRWSA-N	Launched
cortisone-acetate	glucocorticoid receptor agonist	NR3C1	pulmonary, rheumatology, allergy, dermatology, ophthalmology, gastroenterology, infectious disease	asthma, rheumatoid arthritis, urticaria, osteoarthritis, psoriasis, allergic rhinitis, conjunctivitis, ulcerative colitis, meningitis	CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3C(=O)C[C@]12C |t:15|, CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3C(=O)C[C@]12C |t:15|, CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3C(=O)C[C@]12C |t:15|, CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3C(=O)C[C@]12C |t:15|, CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3C(=O)C[C@]12C |t:15|	ITRJWOMZKQRYTA-RFZYENFJSA-N, ITRJWOMZKQRYTA-RFZYENFJSA-N, ITRJWOMZKQRYTA-RFZYENFJSA-N, ITRJWOMZKQRYTA-RFZYENFJSA-N, ITRJWOMZKQRYTA-RFZYENFJSA-N	Launched
cortodoxone	androgen receptor antagonist	AR			C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO |t:8|, C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO |t:8|, C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO |t:8|	WHBHBVVOGNECLV-OBQKJFGGSA-N, WHBHBVVOGNECLV-OBQKJFGGSA-N, WHBHBVVOGNECLV-OBQKJFGGSA-N	Phase 3
costunolide	telomerase inhibitor				C\C1=C/CC\C(C)=C\[C@H]2OC(=O)C(=C)[C@@H]2CC1 |c:1,t:6|, C\C1=C/CC\C(C)=C\[C@H]2OC(=O)C(=C)[C@@H]2CC1 |c:1,t:6|, C\C1=C/CC\C(C)=C\[C@H]2OC(=O)C(=C)[C@@H]2CC1 |c:1,t:6|, C\C1=C/CC\C(C)=C\[C@H]2OC(=O)C(=C)[C@@H]2CC1 |c:1,t:6|, C\C1=C/CC\C(C)=C\[C@H]2OC(=O)C(=C)[C@@H]2CC1 |c:1,t:6|, C\C1=C/CC\C(C)=C\[C@H]2OC(=O)C(=C)[C@@H]2CC1 |c:1,t:6|, C\C1=C/CC\C(C)=C\[C@H]2OC(=O)C(=C)[C@@H]2CC1 |c:1,t:6|	HRYLQFBHBWLLLL-AHNJNIBGSA-N, HRYLQFBHBWLLLL-AHNJNIBGSA-N, HRYLQFBHBWLLLL-AHNJNIBGSA-N, HRYLQFBHBWLLLL-AHNJNIBGSA-N, HRYLQFBHBWLLLL-AHNJNIBGSA-N, HRYLQFBHBWLLLL-AHNJNIBGSA-N, HRYLQFBHBWLLLL-AHNJNIBGSA-N	Preclinical
cot-inhibitor-1	MAPK-interacting kinase inhibitor	MAP3K8			Fc1ccc(Nc2c(cnc3c(Cl)cc(NCc4cn(CCN5CCCCCC5)nn4)cc23)C#N)cc1Cl	ZWFKJFUFYPOTKL-UHFFFAOYSA-N	Preclinical
cot-inhibitor-2	MAPK-interacting kinase inhibitor	MAP3K8			CCN1CCC(CC1)n1cc(CNc2cc(Cl)c3ncc(C#N)c(Nc4ccc(F)c(Cl)c4)c3c2)nn1, CCN1CCC(CC1)n1cc(CNc2cc(Cl)c3ncc(C#N)c(Nc4ccc(F)c(Cl)c4)c3c2)nn1	PHNZIIMWDVXPGG-UHFFFAOYSA-N, PHNZIIMWDVXPGG-UHFFFAOYSA-N	Preclinical
COTI-2	anticancer agent				S=C(N\N=C1/CCCc2cccnc12)N1CCN(CC1)c1ccccn1	UTDAKQMBNSHJJB-CJLVFECKSA-N	Phase 1
cotinine	nicotine metabolite				CN1[C@@H](CCC1=O)c1cccnc1, CN1[C@@H](CCC1=O)c1cccnc1	UIKROCXWUNQSPJ-VIFPVBQESA-N, UIKROCXWUNQSPJ-VIFPVBQESA-N	Phase 2
coumarin	vitamin K antagonist	CA1, CA12, CA14, CA2, CA4, CA6, CA9, CYP2A6	gastroenterology, pulmonary	ulcerative colitis, asthma, celiac disease	O=c1ccc2ccccc2o1, O=c1ccc2ccccc2o1, O=c1ccc2ccccc2o1	ZYGHJZDHTFUPRJ-UHFFFAOYSA-N, ZYGHJZDHTFUPRJ-UHFFFAOYSA-N, ZYGHJZDHTFUPRJ-UHFFFAOYSA-N	Launched
coumophos	cholinesterase inhibitor				CCOP(=S)(OCC)Oc1ccc2c(C)c(Cl)c(=O)oc2c1, CCOP(=S)(OCC)Oc1ccc2c(C)c(Cl)c(=O)oc2c1, CCOP(=S)(OCC)Oc1ccc2c(C)c(Cl)c(=O)oc2c1	BXNANOICGRISHX-UHFFFAOYSA-N, BXNANOICGRISHX-UHFFFAOYSA-N, BXNANOICGRISHX-UHFFFAOYSA-N	Preclinical
CP-105,696	leukotriene receptor antagonist				O[C@@H]1[C@@H](Cc2ccc(cc2)-c2ccccc2)COc2cc(ccc12)C1(CCCC1)C(O)=O	KMNLXCBYBKHKSK-BKMJKUGQSA-N	Preclinical
CP-316819	glycogen phosphorylase inhibitor	PYGL			CON(C)C(=O)[C@H](O)[C@H](Cc1ccccc1)NC(=O)c1cc2cc(Cl)ccc2[nH]1, CON(C)C(=O)[C@H](O)[C@H](Cc1ccccc1)NC(=O)c1cc2cc(Cl)ccc2[nH]1, CON(C)C(=O)[C@H](O)[C@H](Cc1ccccc1)NC(=O)c1cc2cc(Cl)ccc2[nH]1	WEQLRDLTRCEUHG-PKOBYXMFSA-N, WEQLRDLTRCEUHG-PKOBYXMFSA-N, WEQLRDLTRCEUHG-PKOBYXMFSA-N	Preclinical
CP-339818	potassium channel blocker	KCNA3			CCCCC\N=c1/ccn(Cc2ccccc2)c2ccccc12	MMGAVKCAGQCFHS-LSDHQDQOSA-N	Preclinical
CP-376395	corticotropin releasing factor receptor antagonist	CRHR1			CCC(CC)Nc1cc(C)nc(Oc2c(C)cc(C)cc2C)c1C, CCC(CC)Nc1cc(C)nc(Oc2c(C)cc(C)cc2C)c1C	VIZBSVDBNLAVAW-UHFFFAOYSA-N, VIZBSVDBNLAVAW-UHFFFAOYSA-N	Phase 1
CP-471474	matrix metalloprotease inhibitor	MMP1, MMP13, MMP2, MMP3, MMP9			CC(C)(NS(=O)(=O)c1ccc(Oc2ccc(F)cc2)cc1)C(=O)NO, CC(C)(NS(=O)(=O)c1ccc(Oc2ccc(F)cc2)cc1)C(=O)NO, CC(C)(NS(=O)(=O)c1ccc(Oc2ccc(F)cc2)cc1)C(=O)NO	QCOQJYRPDUMCNP-UHFFFAOYSA-N, QCOQJYRPDUMCNP-UHFFFAOYSA-N, QCOQJYRPDUMCNP-UHFFFAOYSA-N	Preclinical
CP-532623	cholesteryl ester transfer protein inhibitor	CETP			CC[C@@H]1C[C@H](N(Cc2cc(cc(c2)C(F)(F)F)C(F)(F)F)C(C)=O)c2cc(ccc2N1C(=O)OC(C)C)C(F)(F)F	TUPKOWFPVAXQFP-OFNKIYASSA-N	Phase 1
CP-547632	kinase inhibitor				NC(=O)c1c(NC(=O)NCCCCN2CCCC2)snc1OCc1c(F)cc(Br)cc1F	HXHAJRMTJXHJJZ-UHFFFAOYSA-N	Phase 2
CP-640186	acetyl-CoA carboxylase inhibitor	ACACA, ACACB			O=C([C@@H]1CCCN(C1)C1CCN(CC1)C(=O)c1c2ccccc2cc2ccccc12)N1CCOCC1, O=C([C@@H]1CCCN(C1)C1CCN(CC1)C(=O)c1c2ccccc2cc2ccccc12)N1CCOCC1	LDQKDRLEMKIYMC-XMMPIXPASA-N, LDQKDRLEMKIYMC-XMMPIXPASA-N	Preclinical
CP-673451	PDGFR tyrosine kinase receptor inhibitor	KIT, PDGFRA, PDGFRB			COCCOc1ccc2n(cnc2c1)-c1ccc2cccc(N3CCC(N)CC3)c2n1, COCCOc1ccc2n(cnc2c1)-c1ccc2cccc(N3CCC(N)CC3)c2n1, COCCOc1ccc2n(cnc2c1)-c1ccc2cccc(N3CCC(N)CC3)c2n1, COCCOc1ccc2n(cnc2c1)-c1ccc2cccc(N3CCC(N)CC3)c2n1, COCCOc1ccc2n(cnc2c1)-c1ccc2cccc(N3CCC(N)CC3)c2n1, COCCOc1ccc2n(cnc2c1)-c1ccc2cccc(N3CCC(N)CC3)c2n1, COCCOc1ccc2n(cnc2c1)-c1ccc2cccc(N3CCC(N)CC3)c2n1, COCCOc1ccc2n(cnc2c1)-c1ccc2cccc(N3CCC(N)CC3)c2n1, COCCOc1ccc2n(cnc2c1)-c1ccc2cccc(N3CCC(N)CC3)c2n1, COCCOc1ccc2n(cnc2c1)-c1ccc2cccc(N3CCC(N)CC3)c2n1, COCCOc1ccc2n(cnc2c1)-c1ccc2cccc(N3CCC(N)CC3)c2n1	DEEOXSOLTLIWMG-UHFFFAOYSA-N, DEEOXSOLTLIWMG-UHFFFAOYSA-N, DEEOXSOLTLIWMG-UHFFFAOYSA-N, DEEOXSOLTLIWMG-UHFFFAOYSA-N, DEEOXSOLTLIWMG-UHFFFAOYSA-N, DEEOXSOLTLIWMG-UHFFFAOYSA-N, DEEOXSOLTLIWMG-UHFFFAOYSA-N, DEEOXSOLTLIWMG-UHFFFAOYSA-N, DEEOXSOLTLIWMG-UHFFFAOYSA-N, DEEOXSOLTLIWMG-UHFFFAOYSA-N, DEEOXSOLTLIWMG-UHFFFAOYSA-N	Preclinical
CP-724714	EGFR inhibitor, protein tyrosine kinase inhibitor	ERBB2			COCC(=O)NC\C=C\c1ccc2ncnc(Nc3ccc(Oc4ccc(C)nc4)c(C)c3)c2c1, COCC(=O)NC\C=C\c1ccc2ncnc(Nc3ccc(Oc4ccc(C)nc4)c(C)c3)c2c1, COCC(=O)NC\C=C\c1ccc2ncnc(Nc3ccc(Oc4ccc(C)nc4)c(C)c3)c2c1, COCC(=O)NC\C=C\c1ccc2ncnc(Nc3ccc(Oc4ccc(C)nc4)c(C)c3)c2c1, COCC(=O)NC\C=C\c1ccc2ncnc(Nc3ccc(Oc4ccc(C)nc4)c(C)c3)c2c1	LLVZBTWPGQVVLW-SNAWJCMRSA-N, LLVZBTWPGQVVLW-SNAWJCMRSA-N, LLVZBTWPGQVVLW-SNAWJCMRSA-N, LLVZBTWPGQVVLW-SNAWJCMRSA-N, LLVZBTWPGQVVLW-SNAWJCMRSA-N	Phase 2
CP-775146	PPAR receptor agonist	PPARA			CC(C)c1ccc(CC(=O)N2CCC[C@H](C2)c2cccc(OC(C)(C)C(O)=O)c2)cc1, CC(C)c1ccc(CC(=O)N2CCC[C@H](C2)c2cccc(OC(C)(C)C(O)=O)c2)cc1	OISHBINQIFNIPV-JOCHJYFZSA-N, OISHBINQIFNIPV-JOCHJYFZSA-N	Preclinical
CP-91149	glycogen phosphorylase inhibitor	PYGL			CN(C)C(=O)[C@H](O)[C@H](Cc1ccccc1)NC(=O)c1cc2cc(Cl)ccc2[nH]1, CN(C)C(=O)[C@H](O)[C@H](Cc1ccccc1)NC(=O)c1cc2cc(Cl)ccc2[nH]1, CN(C)C(=O)[C@H](O)[C@H](Cc1ccccc1)NC(=O)c1cc2cc(Cl)ccc2[nH]1, CN(C)C(=O)[C@H](O)[C@H](Cc1ccccc1)NC(=O)c1cc2cc(Cl)ccc2[nH]1	HINJNZFCMLSBCI-PKOBYXMFSA-N, HINJNZFCMLSBCI-PKOBYXMFSA-N, HINJNZFCMLSBCI-PKOBYXMFSA-N, HINJNZFCMLSBCI-PKOBYXMFSA-N	Preclinical
CP-93129	serotonin receptor agonist	HTR1A			O=c1ccc2[nH]cc(C3=CCNCC3)c2[nH]1 |t:8|, O=c1ccc2[nH]cc(C3=CCNCC3)c2[nH]1 |t:8|, O=c1ccc2[nH]cc(C3=CCNCC3)c2[nH]1 |t:8|	PJYVGMRFPFNZCT-UHFFFAOYSA-N, PJYVGMRFPFNZCT-UHFFFAOYSA-N, PJYVGMRFPFNZCT-UHFFFAOYSA-N	Preclinical
CP-94253	serotonin receptor agonist	HTR1B			CCCOc1ccc2[nH]cc(C3=CCNCC3)c2n1 |t:11|, CCCOc1ccc2[nH]cc(C3=CCNCC3)c2n1 |t:11|	KWQWBZIGHIOKIO-UHFFFAOYSA-N, KWQWBZIGHIOKIO-UHFFFAOYSA-N	Preclinical
CP-945,598	cannabinoid receptor antagonist	CNR1			CCNC1(CCN(CC1)c1ncnc2n(c(nc12)-c1ccccc1Cl)-c1ccc(Cl)cc1)C(N)=O, CCNC1(CCN(CC1)c1ncnc2n(c(nc12)-c1ccccc1Cl)-c1ccc(Cl)cc1)C(N)=O, CCNC1(CCN(CC1)c1ncnc2n(c(nc12)-c1ccccc1Cl)-c1ccc(Cl)cc1)C(N)=O	UNAZAADNBYXMIV-UHFFFAOYSA-N, UNAZAADNBYXMIV-UHFFFAOYSA-N, UNAZAADNBYXMIV-UHFFFAOYSA-N	Phase 3
CP-99994	tachykinin antagonist	TACR1			COc1ccccc1CN[C@H]1CCCN[C@H]1c1ccccc1, COc1ccccc1CN[C@H]1CCCN[C@H]1c1ccccc1, COc1ccccc1CN[C@H]1CCCN[C@H]1c1ccccc1	DTQNEFOKTXXQKV-HKUYNNGSSA-N, DTQNEFOKTXXQKV-HKUYNNGSSA-N, DTQNEFOKTXXQKV-HKUYNNGSSA-N	Phase 2
CPA-inhibitor	carboxypeptidase inhibitor	CPA1, CPA2			ON(C[C@@H](Cc1ccccc1)C(O)=O)C(=O)Cc1ccccc1 |&1:3,r|, ON(C[C@@H](Cc1ccccc1)C(O)=O)C(=O)Cc1ccccc1 |&1:3,r|	PONANXDRJJIGPG-MRXNPFEDSA-N, PONANXDRJJIGPG-MRXNPFEDSA-N	Preclinical
CPCCOEt	glutamate receptor antagonist	GRM1			CCOC(=O)[C@]12C[C@H]1\C(=N/O)c1ccccc1O2 |&1:5,7,r|	FXCTZFMSAHZQTR-PFJVYOFESA-N	Preclinical
CPI-0610	bromodomain inhibitor	BRD4			Cc1noc2[C@H](CC(N)=O)N=C(c3ccc(Cl)cc3)c3ccccc3-c12 |t:10|, Cc1noc2[C@H](CC(N)=O)N=C(c3ccc(Cl)cc3)c3ccccc3-c12 |t:10|, Cc1noc2[C@H](CC(N)=O)N=C(c3ccc(Cl)cc3)c3ccccc3-c12 |t:10|, Cc1noc2[C@H](CC(N)=O)N=C(c3ccc(Cl)cc3)c3ccccc3-c12 |t:10|, Cc1noc2[C@H](CC(N)=O)N=C(c3ccc(Cl)cc3)c3ccccc3-c12 |t:10|, Cc1noc2[C@H](CC(N)=O)N=C(c3ccc(Cl)cc3)c3ccccc3-c12 |t:10|	GCWIQUVXWZWCLE-INIZCTEOSA-N, GCWIQUVXWZWCLE-INIZCTEOSA-N, GCWIQUVXWZWCLE-INIZCTEOSA-N, GCWIQUVXWZWCLE-INIZCTEOSA-N, GCWIQUVXWZWCLE-INIZCTEOSA-N, GCWIQUVXWZWCLE-INIZCTEOSA-N	Phase 2
CPI-1189	tumor necrosis factor release inhibitor	TNF			CC(=O)Nc1ccc(cc1)C(=O)NC(C)(C)C, CC(=O)Nc1ccc(cc1)C(=O)NC(C)(C)C, CC(=O)Nc1ccc(cc1)C(=O)NC(C)(C)C, CC(=O)Nc1ccc(cc1)C(=O)NC(C)(C)C	DJKNRCWSXSZACF-UHFFFAOYSA-N, DJKNRCWSXSZACF-UHFFFAOYSA-N, DJKNRCWSXSZACF-UHFFFAOYSA-N, DJKNRCWSXSZACF-UHFFFAOYSA-N	Phase 2
CPI-1205	EZH2 inhibitor				COc1cc(C)[nH]c(=O)c1CNC(=O)c1c(C)n([C@H](C)C2CCN(CC(F)(F)F)CC2)c2ccccc12	HPODOLXTMDHLLC-QGZVFWFLSA-N	Phase 1/Phase 2
CPI-169	histone lysine methyltransferase inhibitor	EZH2			CCS(=O)(=O)N1CCC(CC1)[C@@H](C)n1c(C)c(C(=O)NCc2c(OC)cc(C)[nH]c2=O)c2ccccc12	LHGUZCKPFXXVPV-GOSISDBHSA-N	Preclinical
CPI-203	bromodomain inhibitor	BRD4			Cc1nnc2[C@H](CC(N)=O)N=C(c3c(C)c(C)sc3-n12)c1ccc(Cl)cc1 |c:10|, Cc1nnc2[C@H](CC(N)=O)N=C(c3c(C)c(C)sc3-n12)c1ccc(Cl)cc1 |c:10|, Cc1nnc2[C@H](CC(N)=O)N=C(c3c(C)c(C)sc3-n12)c1ccc(Cl)cc1 |c:10|, Cc1nnc2[C@H](CC(N)=O)N=C(c3c(C)c(C)sc3-n12)c1ccc(Cl)cc1 |c:10|, Cc1nnc2[C@H](CC(N)=O)N=C(c3c(C)c(C)sc3-n12)c1ccc(Cl)cc1 |c:10|	QECMENZMDBOLDR-AWEZNQCLSA-N, QECMENZMDBOLDR-AWEZNQCLSA-N, QECMENZMDBOLDR-AWEZNQCLSA-N, QECMENZMDBOLDR-AWEZNQCLSA-N, QECMENZMDBOLDR-AWEZNQCLSA-N	Preclinical
CPI-360	histone lysine methyltransferase inhibitor	EZH2			COc1cc(C)[nH]c(=O)c1CNC(=O)c1c(C)n([C@H](C)C2CCOCC2)c2ccccc12, COc1cc(C)[nH]c(=O)c1CNC(=O)c1c(C)n([C@H](C)C2CCOCC2)c2ccccc12	PFPSFENQCNMITC-MRXNPFEDSA-N, PFPSFENQCNMITC-MRXNPFEDSA-N	Preclinical
CPI-444	adenosine receptor antagonist				Cc1ccc(o1)-c1nc(N)nc2n(Cc3cccc(CO[C@H]4CCOC4)n3)nnc12	KURQKNMKCGYWRJ-HNNXBMFYSA-N	Phase 1/Phase 2
CPI-613	pyruvate dehydrogenase inhibitor	PDHA1			OC(=O)CCCC[C@@H](CCSCc1ccccc1)SCc1ccccc1 |&1:7,r|, OC(=O)CCCC[C@@H](CCSCc1ccccc1)SCc1ccccc1 |&1:7,r|, OC(=O)CCCC[C@@H](CCSCc1ccccc1)SCc1ccccc1 |&1:7,r|	ZYRLHJIMTROTBO-NRFANRHFSA-N, ZYRLHJIMTROTBO-NRFANRHFSA-N, ZYRLHJIMTROTBO-NRFANRHFSA-N	Phase 3
CPP	glutamate receptor antagonist	GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D			OC(=O)[C@H]1CN(CCCP(O)(O)=O)CCN1, OC(=O)[C@H]1CN(CCCP(O)(O)=O)CCN1, OC(=O)[C@H]1CN(CCCP(O)(O)=O)CCN1	CUVGUPIVTLGRGI-SSDOTTSWSA-N, CUVGUPIVTLGRGI-SSDOTTSWSA-N, CUVGUPIVTLGRGI-SSDOTTSWSA-N	Phase 2
CPSI-1306-(+/-)	macrophage migration inhibiting factor inhibitor	MIF			Fc1ccc(C2=NO[C@@H](CC(=O)N3CCOCC3)C2)c(F)c1 |&1:8,r,t:5|, Fc1ccc(C2=NO[C@@H](CC(=O)N3CCOCC3)C2)c(F)c1 |&1:8,r,t:5|, Fc1ccc(C2=NO[C@@H](CC(=O)N3CCOCC3)C2)c(F)c1 |&1:8,r,t:5|	GUWOSEVHCSNYFK-LLVKDONJSA-N, GUWOSEVHCSNYFK-LLVKDONJSA-N, GUWOSEVHCSNYFK-LLVKDONJSA-N	Preclinical
CQS					Nc1ccc(cc1)S(=O)(=O)Nc1cnc2c(Cl)cccc2n1	CTSNHMQGVWXIEG-UHFFFAOYSA-N	Preclinical
creatine		CKB, CKM, CKMT1A, CKMT2, GAMT, SLC6A8			CN(CC(O)=O)C(N)=N	CVSVTCORWBXHQV-UHFFFAOYSA-N	Launched
creatinine					CN1CC(=O)NC1=N, CN1CC(=O)NC1=N, CN1CC(=O)NC1=N	DDRJAANPRJIHGJ-UHFFFAOYSA-N, DDRJAANPRJIHGJ-UHFFFAOYSA-N, DDRJAANPRJIHGJ-UHFFFAOYSA-N	Preclinical
creatinol-phosphate					CN(CCOP(O)(O)=O)C(N)=N, CN(CCOP(O)(O)=O)C(N)=N	FOIPWTMKYXWFGC-UHFFFAOYSA-N, FOIPWTMKYXWFGC-UHFFFAOYSA-N	Launched
crenigacestat	notch signaling inhibitor				C[C@H](NC(=O)CCC(F)(F)F)C(=O)N[C@H]1c2ccccc2-c2cccnc2N(CCO)C1=O	YCBAQKQAINQRFW-UGSOOPFHSA-N	Preclinical
crenolanib	PDGFR tyrosine kinase receptor inhibitor	CSF1R, FLT3, KIT, PDGFRA, PDGFRB			CC1(COc2ccc3n(cnc3c2)-c2ccc3cccc(N4CCC(N)CC4)c3n2)COC1, CC1(COc2ccc3n(cnc3c2)-c2ccc3cccc(N4CCC(N)CC4)c3n2)COC1, CC1(COc2ccc3n(cnc3c2)-c2ccc3cccc(N4CCC(N)CC4)c3n2)COC1, CC1(COc2ccc3n(cnc3c2)-c2ccc3cccc(N4CCC(N)CC4)c3n2)COC1, CC1(COc2ccc3n(cnc3c2)-c2ccc3cccc(N4CCC(N)CC4)c3n2)COC1, CC1(COc2ccc3n(cnc3c2)-c2ccc3cccc(N4CCC(N)CC4)c3n2)COC1, CC1(COc2ccc3n(cnc3c2)-c2ccc3cccc(N4CCC(N)CC4)c3n2)COC1	DYNHJHQFHQTFTP-UHFFFAOYSA-N, DYNHJHQFHQTFTP-UHFFFAOYSA-N, DYNHJHQFHQTFTP-UHFFFAOYSA-N, DYNHJHQFHQTFTP-UHFFFAOYSA-N, DYNHJHQFHQTFTP-UHFFFAOYSA-N, DYNHJHQFHQTFTP-UHFFFAOYSA-N, DYNHJHQFHQTFTP-UHFFFAOYSA-N	Phase 3
cresol					Cc1ccc(O)cc1	IWDCLRJOBJJRNH-UHFFFAOYSA-N	Launched
cresopirine					CC(=O)Oc1c(C)cccc1C(O)=O, CC(=O)Oc1c(C)cccc1C(O)=O	XRBMKGUDDJPAMH-UHFFFAOYSA-N, XRBMKGUDDJPAMH-UHFFFAOYSA-N	Preclinical
cridanimod	progesterone receptor agonist	PGR	infectious disease	influenza A virus infection	OC(=O)Cn1c2ccccc2c(=O)c2ccccc12, OC(=O)Cn1c2ccccc2c(=O)c2ccccc12	UOMKBIIXHQIERR-UHFFFAOYSA-N, UOMKBIIXHQIERR-UHFFFAOYSA-N	Launched
crisaborole	phosphodiesterase inhibitor	PDE4A, PDE4B, PDE4C, PDE4D	dermatology	dermatitis	OB1OCc2cc(Oc3ccc(cc3)C#N)ccc12, OB1OCc2cc(Oc3ccc(cc3)C#N)ccc12	USZAGAREISWJDP-UHFFFAOYSA-N, USZAGAREISWJDP-UHFFFAOYSA-N	Launched
crisdesalazine	free radical scavenger				OC(=O)c1cc(NCCc2ccc(cc2)C(F)(F)F)ccc1O	UTMVACIBQLDZLP-UHFFFAOYSA-N	Preclinical
crizotinib	ALK tyrosine kinase receptor inhibitor	ALK, MET	oncology	non-small cell lung cancer (NSCLC)	C[C@@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl, C[C@@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl, C[C@@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl, C[C@@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl, C[C@@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl, C[C@@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl, C[C@@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl, C[C@@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl, C[C@@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl, C[C@@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl, C[C@@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl, C[C@@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl	KTEIFNKAUNYNJU-GFCCVEGCSA-N, KTEIFNKAUNYNJU-GFCCVEGCSA-N, KTEIFNKAUNYNJU-GFCCVEGCSA-N, KTEIFNKAUNYNJU-GFCCVEGCSA-N, KTEIFNKAUNYNJU-GFCCVEGCSA-N, KTEIFNKAUNYNJU-GFCCVEGCSA-N, KTEIFNKAUNYNJU-GFCCVEGCSA-N, KTEIFNKAUNYNJU-GFCCVEGCSA-N, KTEIFNKAUNYNJU-GFCCVEGCSA-N, KTEIFNKAUNYNJU-GFCCVEGCSA-N, KTEIFNKAUNYNJU-GFCCVEGCSA-N, KTEIFNKAUNYNJU-GFCCVEGCSA-N	Launched
crizotinib-(S)	MTH1 inhibitor	NUDT1			C[C@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl, C[C@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl, C[C@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl, C[C@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl, C[C@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl, C[C@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl, C[C@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl, C[C@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl, C[C@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl, C[C@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl	KTEIFNKAUNYNJU-LBPRGKRZSA-N, KTEIFNKAUNYNJU-LBPRGKRZSA-N, KTEIFNKAUNYNJU-LBPRGKRZSA-N, KTEIFNKAUNYNJU-LBPRGKRZSA-N, KTEIFNKAUNYNJU-LBPRGKRZSA-N, KTEIFNKAUNYNJU-LBPRGKRZSA-N, KTEIFNKAUNYNJU-LBPRGKRZSA-N, KTEIFNKAUNYNJU-LBPRGKRZSA-N, KTEIFNKAUNYNJU-LBPRGKRZSA-N, KTEIFNKAUNYNJU-LBPRGKRZSA-N	Preclinical
croconazole	bacterial cell wall synthesis inhibitor		infectious disease	fungal infection	Clc1cccc(COc2ccccc2C(=C)n2ccnc2)c1, Clc1cccc(COc2ccccc2C(=C)n2ccnc2)c1	WHPAGCJNPTUGGD-UHFFFAOYSA-N, WHPAGCJNPTUGGD-UHFFFAOYSA-N	Launched
crolibulin	tubulin polymerization inhibitor				COc1cc(cc(Br)c1OC)[C@H]1C(C#N)=C(N)Oc2c(N)c(N)ccc12 |t:15|	JXONINOYTKKXQQ-CQSZACIVSA-N	Phase 1/Phase 2
cromakalim		KCNJ8			CC1(C)Oc2ccc(cc2[C@H]([C@@H]1O)N1CCCC1=O)C#N.CC1(C)Oc2ccc(cc2[C@@H]([C@H]1O)N1CCCC1=O)C#N, CC1(C)Oc2ccc(cc2[C@H]([C@@H]1O)N1CCCC1=O)C#N.CC1(C)Oc2ccc(cc2[C@@H]([C@H]1O)N1CCCC1=O)C#N	BVMDRSUIADWFLV-PNSAJKJISA-N, BVMDRSUIADWFLV-PNSAJKJISA-N	Phase 2
cromoglicic-acid	immunosuppressant	KCNMA1, S100P	pulmonary, ophthalmology, allergy, gastroenterology	asthma, conjunctivitis, urticaria, ulcerative colitis	OC(COc1cccc2oc(cc(=O)c12)C(O)=O)COc1cccc2oc(cc(=O)c12)C(O)=O, OC(COc1cccc2oc(cc(=O)c12)C(O)=O)COc1cccc2oc(cc(=O)c12)C(O)=O, OC(COc1cccc2oc(cc(=O)c12)C(O)=O)COc1cccc2oc(cc(=O)c12)C(O)=O	IMZMKUWMOSJXDT-UHFFFAOYSA-N, IMZMKUWMOSJXDT-UHFFFAOYSA-N, IMZMKUWMOSJXDT-UHFFFAOYSA-N	Launched
crotamiton	antipruritic		infectious disease	scabies	CCN(C(=O)\C=C\C)c1ccccc1C, CCN(C(=O)\C=C\C)c1ccccc1C	DNTGGZPQPQTDQF-XBXARRHUSA-N, DNTGGZPQPQTDQF-XBXARRHUSA-N	Launched
CRT0044876					OC(=O)c1cc2cccc([N+]([O-])=O)c2[nH]1, OC(=O)c1cc2cccc([N+]([O-])=O)c2[nH]1, OC(=O)c1cc2cccc([N+]([O-])=O)c2[nH]1	BIUCOFQROHIAEO-UHFFFAOYSA-N, BIUCOFQROHIAEO-UHFFFAOYSA-N, BIUCOFQROHIAEO-UHFFFAOYSA-N	Preclinical
cryptotanshinone	acetylcholinesterase inhibitor, STAT inhibitor	STAT3			C[C@H]1COC2=C1C(=O)C(=O)c1c3CCCC(C)(C)c3ccc21 |c:4|, C[C@H]1COC2=C1C(=O)C(=O)c1c3CCCC(C)(C)c3ccc21 |c:4|, C[C@H]1COC2=C1C(=O)C(=O)c1c3CCCC(C)(C)c3ccc21 |c:4|, C[C@H]1COC2=C1C(=O)C(=O)c1c3CCCC(C)(C)c3ccc21 |c:4|	GVKKJJOMQCNPGB-JTQLQIEISA-N, GVKKJJOMQCNPGB-JTQLQIEISA-N, GVKKJJOMQCNPGB-JTQLQIEISA-N, GVKKJJOMQCNPGB-JTQLQIEISA-N	Preclinical
crystal-violet	other antibiotic				CN(C)c1ccc(cc1)C(=C1C=CC(C=C1)=[N+](C)C)c1ccc(cc1)N(C)C |c:12,15|	LGLFFNDHMLKUMI-UHFFFAOYSA-N	Launched
CR8-(R)	CDK inhibitor	CCNA2			CC[C@H](CO)Nc1nc(NCc2ccc(cc2)-c2ccccn2)c2ncn(C(C)C)c2n1, CC[C@H](CO)Nc1nc(NCc2ccc(cc2)-c2ccccn2)c2ncn(C(C)C)c2n1, CC[C@H](CO)Nc1nc(NCc2ccc(cc2)-c2ccccn2)c2ncn(C(C)C)c2n1, CC[C@H](CO)Nc1nc(NCc2ccc(cc2)-c2ccccn2)c2ncn(C(C)C)c2n1, CC[C@H](CO)Nc1nc(NCc2ccc(cc2)-c2ccccn2)c2ncn(C(C)C)c2n1, CC[C@H](CO)Nc1nc(NCc2ccc(cc2)-c2ccccn2)c2ncn(C(C)C)c2n1, CC[C@H](CO)Nc1nc(NCc2ccc(cc2)-c2ccccn2)c2ncn(C(C)C)c2n1	HOCBJBNQIQQQGT-LJQANCHMSA-N, HOCBJBNQIQQQGT-LJQANCHMSA-N, HOCBJBNQIQQQGT-LJQANCHMSA-N, HOCBJBNQIQQQGT-LJQANCHMSA-N, HOCBJBNQIQQQGT-LJQANCHMSA-N, HOCBJBNQIQQQGT-LJQANCHMSA-N, HOCBJBNQIQQQGT-LJQANCHMSA-N	Preclinical
CS-110266	dopamine receptor agonist	SLC6A3			C1CCN(CC1)C1(CCCCC1)c1cc2ccccc2s1, C1CCN(CC1)C1(CCCCC1)c1cc2ccccc2s1, C1CCN(CC1)C1(CCCCC1)c1cc2ccccc2s1, C1CCN(CC1)C1(CCCCC1)c1cc2ccccc2s1, C1CCN(CC1)C1(CCCCC1)c1cc2ccccc2s1, C1CCN(CC1)C1(CCCCC1)c1cc2ccccc2s1	RGSVXQJPSWZXOP-UHFFFAOYSA-N, RGSVXQJPSWZXOP-UHFFFAOYSA-N, RGSVXQJPSWZXOP-UHFFFAOYSA-N, RGSVXQJPSWZXOP-UHFFFAOYSA-N, RGSVXQJPSWZXOP-UHFFFAOYSA-N, RGSVXQJPSWZXOP-UHFFFAOYSA-N	Preclinical
CS-917	fructose biphosphate inhibitor	FBP1			CC(C)Cc1sc(N)nc1-c1ccc(o1)P(O)(O)=O, CC(C)Cc1sc(N)nc1-c1ccc(o1)P(O)(O)=O, CC(C)Cc1sc(N)nc1-c1ccc(o1)P(O)(O)=O, CC(C)Cc1sc(N)nc1-c1ccc(o1)P(O)(O)=O	XJMYIJPPDSZOPN-UHFFFAOYSA-N, XJMYIJPPDSZOPN-UHFFFAOYSA-N, XJMYIJPPDSZOPN-UHFFFAOYSA-N, XJMYIJPPDSZOPN-UHFFFAOYSA-N	Phase 2
CT-7758	integrin antagonist	ITGA4			OC(=O)[C@H](Cc1ccc(Nc2nccc3ccncc23)cc1)NC1=C(Br)C(=O)C11CCCCC1 |c:26|, OC(=O)[C@H](Cc1ccc(Nc2nccc3ccncc23)cc1)NC1=C(Br)C(=O)C11CCCCC1 |c:26|, OC(=O)[C@H](Cc1ccc(Nc2nccc3ccncc23)cc1)NC1=C(Br)C(=O)C11CCCCC1 |c:26|, OC(=O)[C@H](Cc1ccc(Nc2nccc3ccncc23)cc1)NC1=C(Br)C(=O)C11CCCCC1 |c:26|, OC(=O)[C@H](Cc1ccc(Nc2nccc3ccncc23)cc1)NC1=C(Br)C(=O)C11CCCCC1 |c:26|, OC(=O)[C@H](Cc1ccc(Nc2nccc3ccncc23)cc1)NC1=C(Br)C(=O)C11CCCCC1 |c:26|	KYHVWHYLKOHLKA-FQEVSTJZSA-N, KYHVWHYLKOHLKA-FQEVSTJZSA-N, KYHVWHYLKOHLKA-FQEVSTJZSA-N, KYHVWHYLKOHLKA-FQEVSTJZSA-N, KYHVWHYLKOHLKA-FQEVSTJZSA-N, KYHVWHYLKOHLKA-FQEVSTJZSA-N	Phase 2
CTEP	glutamate receptor antagonist	GRM5			Cc1nc(C#Cc2ccnc(Cl)c2)c(C)n1-c1ccc(OC(F)(F)F)cc1, Cc1nc(C#Cc2ccnc(Cl)c2)c(C)n1-c1ccc(OC(F)(F)F)cc1, Cc1nc(C#Cc2ccnc(Cl)c2)c(C)n1-c1ccc(OC(F)(F)F)cc1, Cc1nc(C#Cc2ccnc(Cl)c2)c(C)n1-c1ccc(OC(F)(F)F)cc1	GOHCTCOGYKAJLZ-UHFFFAOYSA-N, GOHCTCOGYKAJLZ-UHFFFAOYSA-N, GOHCTCOGYKAJLZ-UHFFFAOYSA-N, GOHCTCOGYKAJLZ-UHFFFAOYSA-N	Preclinical
CTS-1027	metalloproteinase inhibitor	MMP1, MMP13, MMP2, MMP3, MMP9			ONC(=O)C1(CS(=O)(=O)c2ccc(Oc3ccc(Cl)cc3)cc2)CCOCC1, ONC(=O)C1(CS(=O)(=O)c2ccc(Oc3ccc(Cl)cc3)cc2)CCOCC1, ONC(=O)C1(CS(=O)(=O)c2ccc(Oc3ccc(Cl)cc3)cc2)CCOCC1, ONC(=O)C1(CS(=O)(=O)c2ccc(Oc3ccc(Cl)cc3)cc2)CCOCC1	ROSNVSQTEGHUKU-UHFFFAOYSA-N, ROSNVSQTEGHUKU-UHFFFAOYSA-N, ROSNVSQTEGHUKU-UHFFFAOYSA-N, ROSNVSQTEGHUKU-UHFFFAOYSA-N	Phase 2
CTS21166	beta-secretase inhibitor	BACE1			CC(C)C[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CCC(O)=O)C(C)C)[C@@H](O)C[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](Cc1ccccc1)C(O)=O, CC(C)C[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CCC(O)=O)C(C)C)[C@@H](O)C[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](Cc1ccccc1)C(O)=O	NIOCOJFPGCXNKL-ZKZXETMPSA-N, NIOCOJFPGCXNKL-ZKZXETMPSA-N	Phase 1
CT7001	CDK inhibitor				CC(C)c1cnn2c(NCc3ccccc3)cc(NC[C@H]3CCNC[C@@H]3O)nc12	YCVGLKWJKIKVBI-MJGOQNOKSA-N	Phase 1/Phase 2
CU-CPT-4a	toll-like receptor inhibitor	TLR3			OC(=O)[C@@H](Cc1ccccc1)NC(=O)c1sc2cc(F)ccc2c1Cl, OC(=O)[C@@H](Cc1ccccc1)NC(=O)c1sc2cc(F)ccc2c1Cl	IAASQMCXDRISAV-CYBMUJFWSA-N, IAASQMCXDRISAV-CYBMUJFWSA-N	Preclinical
CU-T12-9	toll-like receptor agonist	TLR1, TLR2			CNc1ccc(cc1-n1cnc(c1)-c1ccc(cc1)C(F)(F)F)[N+]([O-])=O, CNc1ccc(cc1-n1cnc(c1)-c1ccc(cc1)C(F)(F)F)[N+]([O-])=O	LITXVDAFEYLWQE-UHFFFAOYSA-N, LITXVDAFEYLWQE-UHFFFAOYSA-N	Preclinical
CUDC-101	EGFR inhibitor	EGFR, ERBB2			COc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCCCCCC(=O)NO, COc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCCCCCC(=O)NO, COc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCCCCCC(=O)NO	PLIVFNIUGLLCEK-UHFFFAOYSA-N, PLIVFNIUGLLCEK-UHFFFAOYSA-N, PLIVFNIUGLLCEK-UHFFFAOYSA-N	Phase 1
CUDC-427	apoptosis inhibitor	XIAP			CN[C@@H](C)C(=O)N[C@@H](C1CCCCC1)C(=O)N1CCC[C@H]1C(=O)Nc1sc(nc1-c1ccccc1)-c1ncco1, CN[C@@H](C)C(=O)N[C@@H](C1CCCCC1)C(=O)N1CCC[C@H]1C(=O)Nc1sc(nc1-c1ccccc1)-c1ncco1, CN[C@@H](C)C(=O)N[C@@H](C1CCCCC1)C(=O)N1CCC[C@H]1C(=O)Nc1sc(nc1-c1ccccc1)-c1ncco1, CN[C@@H](C)C(=O)N[C@@H](C1CCCCC1)C(=O)N1CCC[C@H]1C(=O)Nc1sc(nc1-c1ccccc1)-c1ncco1	HSHPBORBOJIXSQ-HARLFGEKSA-N, HSHPBORBOJIXSQ-HARLFGEKSA-N, HSHPBORBOJIXSQ-HARLFGEKSA-N, HSHPBORBOJIXSQ-HARLFGEKSA-N	Phase 1
CUDC-907	PI3K inhibitor	HDAC2, PIK3R1			COc1ccc(cn1)-c1nc(N2CCOCC2)c2sc(CN(C)c3ncc(cn3)C(=O)NO)cc2n1, COc1ccc(cn1)-c1nc(N2CCOCC2)c2sc(CN(C)c3ncc(cn3)C(=O)NO)cc2n1, COc1ccc(cn1)-c1nc(N2CCOCC2)c2sc(CN(C)c3ncc(cn3)C(=O)NO)cc2n1, COc1ccc(cn1)-c1nc(N2CCOCC2)c2sc(CN(C)c3ncc(cn3)C(=O)NO)cc2n1, COc1ccc(cn1)-c1nc(N2CCOCC2)c2sc(CN(C)c3ncc(cn3)C(=O)NO)cc2n1	JOWXJLIFIIOYMS-UHFFFAOYSA-N, JOWXJLIFIIOYMS-UHFFFAOYSA-N, JOWXJLIFIIOYMS-UHFFFAOYSA-N, JOWXJLIFIIOYMS-UHFFFAOYSA-N, JOWXJLIFIIOYMS-UHFFFAOYSA-N	Phase 2
CUR-61414	smoothened receptor antagonist	DHH, IHH, SMO			COc1cccc(CN([C@H]2C[C@H](N(Cc3ccc4OCOc4c3)C2)C(=O)N2CCNCC2)C(=O)CC(C)(C)C)c1	WPHXYKUPFJRJDK-AHWVRZQESA-N	Phase 1
curcumin	cyclooxygenase inhibitor, histone acetyltransferase inhibitor, lipoxygenase inhibitor, NFkB pathway inhibitor	APP, CA1, CA12, CA14, CA2, CA4, CA6, CA9, CHRM3, CYP3A4, DNMT3B, EP300, MMP13, MMP9, NOS2, PTGS1, PTGS2, XDH			COc1cc(\C=C\C(O)=CC(=O)\C=C\c2ccc(O)c(OC)c2)ccc1O, COc1cc(\C=C\C(O)=CC(=O)\C=C\c2ccc(O)c(OC)c2)ccc1O, COc1cc(\C=C\C(O)=CC(=O)\C=C\c2ccc(O)c(OC)c2)ccc1O, COc1cc(\C=C\C(O)=CC(=O)\C=C\c2ccc(O)c(OC)c2)ccc1O, COc1cc(\C=C\C(O)=CC(=O)\C=C\c2ccc(O)c(OC)c2)ccc1O, COc1cc(\C=C\C(O)=CC(=O)\C=C\c2ccc(O)c(OC)c2)ccc1O	ZIUSSTSXXLLKKK-SMSFQYLMSA-N, ZIUSSTSXXLLKKK-SMSFQYLMSA-N, ZIUSSTSXXLLKKK-SMSFQYLMSA-N, ZIUSSTSXXLLKKK-SMSFQYLMSA-N, ZIUSSTSXXLLKKK-SMSFQYLMSA-N, ZIUSSTSXXLLKKK-SMSFQYLMSA-N	Launched
curcumol	JAK inhibitor	JAK1, JAK2, JAK3			CC(C)[C@@H]1C[C@@]23O[C@]1(O)CC(=C)[C@@H]2CC[C@@H]3C, CC(C)[C@@H]1C[C@@]23O[C@]1(O)CC(=C)[C@@H]2CC[C@@H]3C, CC(C)[C@@H]1C[C@@]23O[C@]1(O)CC(=C)[C@@H]2CC[C@@H]3C, CC(C)[C@@H]1C[C@@]23O[C@]1(O)CC(=C)[C@@H]2CC[C@@H]3C, CC(C)[C@@H]1C[C@@]23O[C@]1(O)CC(=C)[C@@H]2CC[C@@H]3C	QRMPRVXWPCLVNI-YYFQZIEXSA-N, QRMPRVXWPCLVNI-YYFQZIEXSA-N, QRMPRVXWPCLVNI-YYFQZIEXSA-N, QRMPRVXWPCLVNI-YYFQZIEXSA-N, QRMPRVXWPCLVNI-YYFQZIEXSA-N	Phase 1
cutamesine	sigma receptor agonist	SIGMAR1			COc1ccc(CCN2CCN(CCCc3ccccc3)CC2)cc1OC, COc1ccc(CCN2CCN(CCCc3ccccc3)CC2)cc1OC, COc1ccc(CCN2CCN(CCCc3ccccc3)CC2)cc1OC, COc1ccc(CCN2CCN(CCCc3ccccc3)CC2)cc1OC, COc1ccc(CCN2CCN(CCCc3ccccc3)CC2)cc1OC	UVSWWUWQVAQPJR-UHFFFAOYSA-N, UVSWWUWQVAQPJR-UHFFFAOYSA-N, UVSWWUWQVAQPJR-UHFFFAOYSA-N, UVSWWUWQVAQPJR-UHFFFAOYSA-N, UVSWWUWQVAQPJR-UHFFFAOYSA-N	Phase 2
CV-1808	adenosine receptor agonist	ADORA2A			Nc1nc(Nc2ccccc2)nc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O, Nc1nc(Nc2ccccc2)nc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O, Nc1nc(Nc2ccccc2)nc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O, Nc1nc(Nc2ccccc2)nc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O	SCNILGOVBBRMBK-SDBHATRESA-N, SCNILGOVBBRMBK-SDBHATRESA-N, SCNILGOVBBRMBK-SDBHATRESA-N, SCNILGOVBBRMBK-SDBHATRESA-N	Preclinical
CVT-10216	aldehyde dehydrogenase inhibitor	ALDH2			CS(=O)(=O)Nc1ccc(cc1)-c1coc2cc(OCc3cccc(c3)C(O)=O)ccc2c1=O, CS(=O)(=O)Nc1ccc(cc1)-c1coc2cc(OCc3cccc(c3)C(O)=O)ccc2c1=O	YYOOFJZTRCPVFD-UHFFFAOYSA-N, YYOOFJZTRCPVFD-UHFFFAOYSA-N	Phase 1
CW-008	PKA activator	PRKACA			COc1ccn2ncc(-c3nc4n[nH]c(NC(=O)c5ccc(F)cc5)c4cc3F)c2c1, COc1ccn2ncc(-c3nc4n[nH]c(NC(=O)c5ccc(F)cc5)c4cc3F)c2c1, COc1ccn2ncc(-c3nc4n[nH]c(NC(=O)c5ccc(F)cc5)c4cc3F)c2c1	KCIMKTNQCUDTFI-UHFFFAOYSA-N, KCIMKTNQCUDTFI-UHFFFAOYSA-N, KCIMKTNQCUDTFI-UHFFFAOYSA-N	Preclinical
CX-4945	casein kinase inhibitor	CSNK2A1, CSNK2A2, DAPK3, HIPK3			OC(=O)c1ccc2c(c1)nc(Nc1cccc(Cl)c1)c1ccncc21, OC(=O)c1ccc2c(c1)nc(Nc1cccc(Cl)c1)c1ccncc21, OC(=O)c1ccc2c(c1)nc(Nc1cccc(Cl)c1)c1ccncc21, OC(=O)c1ccc2c(c1)nc(Nc1cccc(Cl)c1)c1ccncc21, OC(=O)c1ccc2c(c1)nc(Nc1cccc(Cl)c1)c1ccncc21	MUOKSQABCJCOPU-UHFFFAOYSA-N, MUOKSQABCJCOPU-UHFFFAOYSA-N, MUOKSQABCJCOPU-UHFFFAOYSA-N, MUOKSQABCJCOPU-UHFFFAOYSA-N, MUOKSQABCJCOPU-UHFFFAOYSA-N	Phase 1/Phase 2
CX-516	glutamate receptor modulator				O=C(N1CCCCC1)c1ccc2OCOc2c1, O=C(N1CCCCC1)c1ccc2OCOc2c1	BXBNADAPIHHXJQ-UHFFFAOYSA-N, BXBNADAPIHHXJQ-UHFFFAOYSA-N	Phase 2/Phase 3
CX-5461	RNA polymerase inhibitor				CN1CCCN(CC1)c1ccc2c(n1)n1c3ccccc3sc1c(C(=O)NCc1cnc(C)cn1)c2=O, CN1CCCN(CC1)c1ccc2c(n1)n1c3ccccc3sc1c(C(=O)NCc1cnc(C)cn1)c2=O	XGPBJCHFROADCK-UHFFFAOYSA-N, XGPBJCHFROADCK-UHFFFAOYSA-N	Phase 1
CXD101	HDAC inhibitor				Cc1nn(C)cc1CN1CCC(CC1)c1ccc(cc1)C(=O)Nc1ccccc1N	JHDZMASHNBKTPS-UHFFFAOYSA-N	Phase 1/Phase 2
cyacetacide					NNC(=O)CC#N, NNC(=O)CC#N	HPHBOJANXDKUQD-UHFFFAOYSA-N, HPHBOJANXDKUQD-UHFFFAOYSA-N	Preclinical
cyamemazine	serotonin receptor antagonist	HTR1A, HTR2A, HTR2C, HTR7	neurology/psychiatry	schizophrenia, anxiety	C[C@@H](CN(C)C)CN1c2ccccc2Sc2ccc(cc12)C#N |&1:1,r|	SLFGIOIONGJGRT-AWEZNQCLSA-N	Launched
cyanocobalamin	methylmalonyl CoA mutase stimulant, vitamin B	MUT	hematology, infectious disease, gastroenterology	anemia, fish tapeworm infestation, celiac disease	C[C@H](CNC(=O)CC[C@]1(C)[C@@H](CC(N)=O)[C@H]2N=C1\C(C)=C1/N=C(/C=C3\N=C(\C(\C)=C4\[C@@H](CCC(N)=O)[C@](C)(CC(N)=O)[C@@]2(C)N4[Co+]C#N)[C@@](C)(CC(N)=O)[C@@H]3CCC(N)=O)C(C)(C)[C@@H]1CCC(N)=O)O[P@@](O)(=O)O[C@@H]1[C@@H](CO)O[C@@H]([C@@H]1O)n1cnc2cc(C)c(C)cc12 |a:1,8,10,15,30,36,42,48,54,63,74,75,79,80,&1:70,c:16,20,24,t:22,26,29|, C[C@H](CNC(=O)CC[C@]1(C)[C@@H](CC(N)=O)[C@H]2N=C1\C(C)=C1/N=C(/C=C3\N=C(\C(\C)=C4\[C@@H](CCC(N)=O)[C@](C)(CC(N)=O)[C@@]2(C)N4[Co+]C#N)[C@@](C)(CC(N)=O)[C@@H]3CCC(N)=O)C(C)(C)[C@@H]1CCC(N)=O)O[P@@](O)(=O)O[C@@H]1[C@@H](CO)O[C@@H]([C@@H]1O)n1cnc2cc(C)c(C)cc12 |a:1,8,10,15,30,36,42,48,54,63,74,75,79,80,&1:70,c:16,20,24,t:22,26,29|, C[C@H](CNC(=O)CC[C@]1(C)[C@@H](CC(N)=O)[C@H]2N=C1\C(C)=C1/N=C(/C=C3\N=C(\C(\C)=C4\[C@@H](CCC(N)=O)[C@](C)(CC(N)=O)[C@@]2(C)N4[Co+]C#N)[C@@](C)(CC(N)=O)[C@@H]3CCC(N)=O)C(C)(C)[C@@H]1CCC(N)=O)O[P@@](O)(=O)O[C@@H]1[C@@H](CO)O[C@@H]([C@@H]1O)n1cnc2cc(C)c(C)cc12 |a:1,8,10,15,30,36,42,48,54,63,74,75,79,80,&1:70,c:16,20,24,t:22,26,29|, C[C@H](CNC(=O)CC[C@]1(C)[C@@H](CC(N)=O)[C@H]2N=C1\C(C)=C1/N=C(/C=C3\N=C(\C(\C)=C4\[C@@H](CCC(N)=O)[C@](C)(CC(N)=O)[C@@]2(C)N4[Co+]C#N)[C@@](C)(CC(N)=O)[C@@H]3CCC(N)=O)C(C)(C)[C@@H]1CCC(N)=O)O[P@@](O)(=O)O[C@@H]1[C@@H](CO)O[C@@H]([C@@H]1O)n1cnc2cc(C)c(C)cc12 |a:1,8,10,15,30,36,42,48,54,63,74,75,79,80,&1:70,c:16,20,24,t:22,26,29|, C[C@H](CNC(=O)CC[C@]1(C)[C@@H](CC(N)=O)[C@H]2N=C1\C(C)=C1/N=C(/C=C3\N=C(\C(\C)=C4\[C@@H](CCC(N)=O)[C@](C)(CC(N)=O)[C@@]2(C)N4[Co+]C#N)[C@@](C)(CC(N)=O)[C@@H]3CCC(N)=O)C(C)(C)[C@@H]1CCC(N)=O)O[P@@](O)(=O)O[C@@H]1[C@@H](CO)O[C@@H]([C@@H]1O)n1cnc2cc(C)c(C)cc12 |a:1,8,10,15,30,36,42,48,54,63,74,75,79,80,&1:70,c:16,20,24,t:22,26,29|	RMRCNWBMXRMIRW-WZHZPDAFSA-M, RMRCNWBMXRMIRW-WZHZPDAFSA-M, RMRCNWBMXRMIRW-WZHZPDAFSA-M, RMRCNWBMXRMIRW-WZHZPDAFSA-M, RMRCNWBMXRMIRW-WZHZPDAFSA-M	Launched
cyanopindolol	adrenergic receptor antagonist	ADRB1, HTR1A, HTR1D			CC(C)(C)NC[C@@H](O)COc1cccc2[nH]c(cc12)C#N |&1:6|, CC(C)(C)NC[C@@H](O)COc1cccc2[nH]c(cc12)C#N |&1:6|, CC(C)(C)NC[C@@H](O)COc1cccc2[nH]c(cc12)C#N |&1:6|	QXIUMMLTJVHILT-GFCCVEGCSA-N, QXIUMMLTJVHILT-GFCCVEGCSA-N, QXIUMMLTJVHILT-GFCCVEGCSA-N	Phase 2
cyclamic-acid					OS(=O)(=O)NC1CCCCC1, OS(=O)(=O)NC1CCCCC1, OS(=O)(=O)NC1CCCCC1, OS(=O)(=O)NC1CCCCC1	HCAJEUSONLESMK-UHFFFAOYSA-N, HCAJEUSONLESMK-UHFFFAOYSA-N, HCAJEUSONLESMK-UHFFFAOYSA-N, HCAJEUSONLESMK-UHFFFAOYSA-N	Preclinical
cyclandelate	calcium channel blocker		cardiology, rheumatology	claudication, arteriosclerosis, Raynaud's disease	C[C@H]1C[C@@H](CC(C)(C)C1)OC(=O)[C@@H](O)c1ccccc1 |&1:1,&2:3,&3:12,r|, C[C@H]1C[C@@H](CC(C)(C)C1)OC(=O)[C@@H](O)c1ccccc1 |&1:1,&2:3,&3:12,r|, C[C@H]1C[C@@H](CC(C)(C)C1)OC(=O)[C@@H](O)c1ccccc1 |&1:1,&2:3,&3:12,r|, C[C@H]1C[C@@H](CC(C)(C)C1)OC(=O)[C@@H](O)c1ccccc1 |&1:1,&2:3,&3:12,r|, C[C@H]1C[C@@H](CC(C)(C)C1)OC(=O)[C@@H](O)c1ccccc1 |&1:1,&2:3,&3:12,r|	WZHCOOQXZCIUNC-QEJZJMRPSA-N, WZHCOOQXZCIUNC-QEJZJMRPSA-N, WZHCOOQXZCIUNC-QEJZJMRPSA-N, WZHCOOQXZCIUNC-QEJZJMRPSA-N, WZHCOOQXZCIUNC-QEJZJMRPSA-N	Launched
cyclic-AMP		CNGA3, TRPM7			Nc1ncnc2n(cnc12)[C@H]1O[C@H]2CO[P@](O)(=O)O[C@@H]2[C@@H]1O |&1:10,&2:12,&3:15,&4:19,&5:20,r|, Nc1ncnc2n(cnc12)[C@H]1O[C@H]2CO[P@](O)(=O)O[C@@H]2[C@@H]1O |&1:10,&2:12,&3:15,&4:19,&5:20,r|	IVOMOUWHDPKRLL-DEGSGYPDSA-N, IVOMOUWHDPKRLL-DEGSGYPDSA-N	Preclinical
cyclizine	histamine receptor modulator	HRH1, SULT1E1	gastroenterology, neurology/psychiatry	nausea, vomiting, vertigo, motion sickness	CN1CCN(CC1)C(c1ccccc1)c1ccccc1, CN1CCN(CC1)C(c1ccccc1)c1ccccc1, CN1CCN(CC1)C(c1ccccc1)c1ccccc1	UVKZSORBKUEBAZ-UHFFFAOYSA-N, UVKZSORBKUEBAZ-UHFFFAOYSA-N, UVKZSORBKUEBAZ-UHFFFAOYSA-N	Launched
cyclobenzaprine	adrenergic receptor agonist, serotonin receptor agonist	HTR2A	neurology/psychiatry	spasms	CN(C)CCC=C1c2ccccc2C=Cc2ccccc12 |c:14|, CN(C)CCC=C1c2ccccc2C=Cc2ccccc12 |c:14|, CN(C)CCC=C1c2ccccc2C=Cc2ccccc12 |c:14|	JURKNVYFZMSNLP-UHFFFAOYSA-N, JURKNVYFZMSNLP-UHFFFAOYSA-N, JURKNVYFZMSNLP-UHFFFAOYSA-N	Launched
cyclocreatine	creatine kinase substrate				NC1=NCCN1CC(O)=O |t:1|	AMHZIUVRYRVYBA-UHFFFAOYSA-N	Phase 1
cyclocytidine	DNA synthesis inhibitor, RNA synthesis inhibitor				OC[C@H]1O[C@@H]2[C@@H](Oc3nc(=N)ccn23)[C@@H]1O, OC[C@H]1O[C@@H]2[C@@H](Oc3nc(=N)ccn23)[C@@H]1O, OC[C@H]1O[C@@H]2[C@@H](Oc3nc(=N)ccn23)[C@@H]1O, OC[C@H]1O[C@@H]2[C@@H](Oc3nc(=N)ccn23)[C@@H]1O	BBDAGFIXKZCXAH-CCXZUQQUSA-N, BBDAGFIXKZCXAH-CCXZUQQUSA-N, BBDAGFIXKZCXAH-CCXZUQQUSA-N, BBDAGFIXKZCXAH-CCXZUQQUSA-N	Preclinical
cycloheximide	protein synthesis inhibitor	RPL3			C[C@H]1C[C@H](C)C(=O)[C@@H](C1)[C@H](O)CC1CC(=O)NC(=O)C1, C[C@H]1C[C@H](C)C(=O)[C@@H](C1)[C@H](O)CC1CC(=O)NC(=O)C1, C[C@H]1C[C@H](C)C(=O)[C@@H](C1)[C@H](O)CC1CC(=O)NC(=O)C1, C[C@H]1C[C@H](C)C(=O)[C@@H](C1)[C@H](O)CC1CC(=O)NC(=O)C1	YPHMISFOHDHNIV-FSZOTQKASA-N, YPHMISFOHDHNIV-FSZOTQKASA-N, YPHMISFOHDHNIV-FSZOTQKASA-N, YPHMISFOHDHNIV-FSZOTQKASA-N	Preclinical
cyclopamine	hedgehog pathway inhibitor				C[C@@H]1[C@@H]2NC[C@@H](C)C[C@H]2O[C@]11CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC2=C1C |c:32,t:18|	QASFUMOKHFSJGL-LAFRSMQTSA-N	Preclinical
cyclopenthiazide	thiazide diuretic		cardiology	hypertension, congestive heart failure	NS(=O)(=O)c1cc2c(N[C@@H](CC3CCCC3)NS2(=O)=O)cc1Cl |&1:9,r|, NS(=O)(=O)c1cc2c(N[C@@H](CC3CCCC3)NS2(=O)=O)cc1Cl |&1:9,r|, NS(=O)(=O)c1cc2c(N[C@@H](CC3CCCC3)NS2(=O)=O)cc1Cl |&1:9,r|	BKYKPTRYDKTTJY-CYBMUJFWSA-N, BKYKPTRYDKTTJY-CYBMUJFWSA-N, BKYKPTRYDKTTJY-CYBMUJFWSA-N	Launched
cyclopentolate	acetylcholine receptor antagonist		ophthalmology	mydriasis, cycloplegia	CN(C)CCOC(=O)[C@@H](c1ccccc1)C1(O)CCCC1 |&1:8|, CN(C)CCOC(=O)[C@@H](c1ccccc1)C1(O)CCCC1 |&1:8|	SKYSRIRYMSLOIN-OAHLLOKOSA-N, SKYSRIRYMSLOIN-OAHLLOKOSA-N	Launched
cyclophosphamide	DNA alkylating agent	CYP2A6, CYP2B6, CYP2C18, CYP2C19, CYP2C8, CYP2C9, CYP2D6, CYP3A4, CYP3A5, CYP3A7	hematologic malignancy, oncology	Hodgkin's lymphoma, small lymphocytic lymphoma (SLL), breast cancer, neuroblastoma, Burkitt's lymphoma, multiple myeloma, chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), chronic myeloid leukemia (CML), true histiocytic lymphoma (THL), retinoblastoma, ovarian cancer	ClCCN(CCCl)[P@@]1(=O)NCCCO1 |r|, ClCCN(CCCl)[P@@]1(=O)NCCCO1 |r|, ClCCN(CCCl)[P@@]1(=O)NCCCO1 |r|, ClCCN(CCCl)[P@@]1(=O)NCCCO1 |r|	CMSMOCZEIVJLDB-CQSZACIVSA-N, CMSMOCZEIVJLDB-CQSZACIVSA-N, CMSMOCZEIVJLDB-CQSZACIVSA-N, CMSMOCZEIVJLDB-CQSZACIVSA-N	Launched
cyclopiazonic-acid	ATPase inhibitor	ATP2A1			CC(=O)C1=C(O)[C@@H]2[C@@H]3[C@@H](Cc4cccc5[nH]cc3c45)C(C)(C)N2C1=O |a:6,7,8,&1:3,c:3|, CC(=O)C1=C(O)[C@@H]2[C@@H]3[C@@H](Cc4cccc5[nH]cc3c45)C(C)(C)N2C1=O |a:6,7,8,&1:3,c:3|, CC(=O)C1=C(O)[C@@H]2[C@@H]3[C@@H](Cc4cccc5[nH]cc3c45)C(C)(C)N2C1=O |a:6,7,8,&1:3,c:3|	SZINUGQCTHLQAZ-DQYPLSBCSA-N, SZINUGQCTHLQAZ-DQYPLSBCSA-N, SZINUGQCTHLQAZ-DQYPLSBCSA-N	Preclinical
cycloserine-(D)	bacterial cell wall synthesis inhibitor	GRIN1	infectious disease	tuberculosis, tuberculosis	N[C@@H]1CONC1=O, N[C@@H]1CONC1=O, N[C@@H]1CONC1=O, N[C@@H]1CONC1=O, N[C@@H]1CONC1=O	DYDCUQKUCUHJBH-UWTATZPHSA-N, DYDCUQKUCUHJBH-UWTATZPHSA-N, DYDCUQKUCUHJBH-UWTATZPHSA-N, DYDCUQKUCUHJBH-UWTATZPHSA-N, DYDCUQKUCUHJBH-UWTATZPHSA-N	Launched
cyclosporin-A	calcineurin inhibitor	ABCB11, CAMLG, FPR1, PPIA, PPIF, PPP3CA, PPP3R2, SLC10A1, SLCO1B1, SLCO1B3	rheumatology, dermatology	rheumatoid arthritis, psoriasis	CC[C@H]1NC(=O)[C@@H]([C@@H](O)[C@@H](C)C\C=C\C)N(C)C(=O)[C@@H](C(C)C)N(C)C(=O)[C@@H](CC(C)C)N(C)C(=O)[C@@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@@H](C)NC(=O)[C@@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C |&1:2,&2:6,&3:7,&4:9,&5:19,&6:27,&7:36,&8:45,&9:50,&10:55,&11:64,&12:68,r|, CC[C@H]1NC(=O)[C@@H]([C@@H](O)[C@@H](C)C\C=C\C)N(C)C(=O)[C@@H](C(C)C)N(C)C(=O)[C@@H](CC(C)C)N(C)C(=O)[C@@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@@H](C)NC(=O)[C@@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C |&1:2,&2:6,&3:7,&4:9,&5:19,&6:27,&7:36,&8:45,&9:50,&10:55,&11:64,&12:68,r|, CC[C@H]1NC(=O)[C@@H]([C@@H](O)[C@@H](C)C\C=C\C)N(C)C(=O)[C@@H](C(C)C)N(C)C(=O)[C@@H](CC(C)C)N(C)C(=O)[C@@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@@H](C)NC(=O)[C@@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C |&1:2,&2:6,&3:7,&4:9,&5:19,&6:27,&7:36,&8:45,&9:50,&10:55,&11:64,&12:68,r|, CC[C@H]1NC(=O)[C@@H]([C@@H](O)[C@@H](C)C\C=C\C)N(C)C(=O)[C@@H](C(C)C)N(C)C(=O)[C@@H](CC(C)C)N(C)C(=O)[C@@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@@H](C)NC(=O)[C@@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C |&1:2,&2:6,&3:7,&4:9,&5:19,&6:27,&7:36,&8:45,&9:50,&10:55,&11:64,&12:68,r|, CC[C@H]1NC(=O)[C@@H]([C@@H](O)[C@@H](C)C\C=C\C)N(C)C(=O)[C@@H](C(C)C)N(C)C(=O)[C@@H](CC(C)C)N(C)C(=O)[C@@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@@H](C)NC(=O)[C@@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C |&1:2,&2:6,&3:7,&4:9,&5:19,&6:27,&7:36,&8:45,&9:50,&10:55,&11:64,&12:68,r|, CC[C@H]1NC(=O)[C@@H]([C@@H](O)[C@@H](C)C\C=C\C)N(C)C(=O)[C@@H](C(C)C)N(C)C(=O)[C@@H](CC(C)C)N(C)C(=O)[C@@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@@H](C)NC(=O)[C@@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C |&1:2,&2:6,&3:7,&4:9,&5:19,&6:27,&7:36,&8:45,&9:50,&10:55,&11:64,&12:68,r|, CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C, CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C, CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C, CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C, CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C, CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C, CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C, CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C	PMATZTZNYRCHOR-MAYCVHQQSA-N, PMATZTZNYRCHOR-MAYCVHQQSA-N, PMATZTZNYRCHOR-MAYCVHQQSA-N, PMATZTZNYRCHOR-MAYCVHQQSA-N, PMATZTZNYRCHOR-MAYCVHQQSA-N, PMATZTZNYRCHOR-MAYCVHQQSA-N, PMATZTZNYRCHOR-CGLBZJNRSA-N, PMATZTZNYRCHOR-CGLBZJNRSA-N, PMATZTZNYRCHOR-CGLBZJNRSA-N, PMATZTZNYRCHOR-CGLBZJNRSA-N, PMATZTZNYRCHOR-CGLBZJNRSA-N, PMATZTZNYRCHOR-CGLBZJNRSA-N, PMATZTZNYRCHOR-CGLBZJNRSA-N, PMATZTZNYRCHOR-CGLBZJNRSA-N	Launched
cyclothiazide	glutamate receptor modulator	CA2, GRIA1, GRIA2, GRIA3, GRIA4, SLC12A3	cardiology	hypertension	NS(=O)(=O)c1cc2c(N[C@@H](NS2(=O)=O)[C@H]2C[C@H]3C[C@@H]2C=C3)cc1Cl |&1:9,&2:14,&3:16,&4:18,r,c:21|, NS(=O)(=O)c1cc2c(N[C@@H](NS2(=O)=O)[C@H]2C[C@H]3C[C@@H]2C=C3)cc1Cl |&1:9,&2:14,&3:16,&4:18,r,c:21|, NS(=O)(=O)c1cc2c(N[C@@H](NS2(=O)=O)[C@H]2C[C@H]3C[C@@H]2C=C3)cc1Cl |&1:9,&2:14,&3:16,&4:18,r,c:21|, NS(=O)(=O)c1cc2c(N[C@@H](NS2(=O)=O)[C@H]2C[C@H]3C[C@@H]2C=C3)cc1Cl |&1:9,&2:14,&3:16,&4:18,r,c:21|, NS(=O)(=O)c1cc2c(N[C@@H](NS2(=O)=O)[C@H]2C[C@H]3C[C@@H]2C=C3)cc1Cl |&1:9,&2:14,&3:16,&4:18,r,c:21|, NS(=O)(=O)c1cc2c(N[C@@H](NS2(=O)=O)[C@H]2C[C@H]3C[C@@H]2C=C3)cc1Cl |&1:9,&2:14,&3:16,&4:18,r,c:21|	BOCUKUHCLICSIY-JWUFEOHASA-N, BOCUKUHCLICSIY-JWUFEOHASA-N, BOCUKUHCLICSIY-JWUFEOHASA-N, BOCUKUHCLICSIY-JWUFEOHASA-N, BOCUKUHCLICSIY-JWUFEOHASA-N, BOCUKUHCLICSIY-JWUFEOHASA-N	Launched
cyclovalone	breast cancer resistance protein inhibitor	ABCG2	gastroenterology	bile stimulation	COc1cc(\C=C2/CCC\C(=C/c3ccc(O)c(OC)c3)C2=O)ccc1O, COc1cc(\C=C2/CCC\C(=C/c3ccc(O)c(OC)c3)C2=O)ccc1O, COc1cc(\C=C2/CCC\C(=C/c3ccc(O)c(OC)c3)C2=O)ccc1O, COc1cc(\C=C2/CCC\C(=C/c3ccc(O)c(OC)c3)C2=O)ccc1O, COc1cc(\C=C2/CCC\C(=C/c3ccc(O)c(OC)c3)C2=O)ccc1O	DHKKONBXGAAFTB-OTYYAQKOSA-N, DHKKONBXGAAFTB-OTYYAQKOSA-N, DHKKONBXGAAFTB-OTYYAQKOSA-N, DHKKONBXGAAFTB-OTYYAQKOSA-N, DHKKONBXGAAFTB-OTYYAQKOSA-N	Launched
cyclovirobuxin-D	calcium channel modulator				CN[C@@H](C)[C@H]1[C@H](O)C[C@@]2(C)[C@@H]3CC[C@@H]4[C@]5(C[C@@]35CC[C@]12C)CC[C@H](NC)C4(C)C, CN[C@@H](C)[C@H]1[C@H](O)C[C@@]2(C)[C@@H]3CC[C@@H]4[C@]5(C[C@@]35CC[C@]12C)CC[C@H](NC)C4(C)C, CN[C@@H](C)[C@H]1[C@H](O)C[C@@]2(C)[C@@H]3CC[C@@H]4[C@]5(C[C@@]35CC[C@]12C)CC[C@H](NC)C4(C)C	GMNAPBAUIVITMI-ABNIRSKTSA-N, GMNAPBAUIVITMI-ABNIRSKTSA-N, GMNAPBAUIVITMI-ABNIRSKTSA-N	Preclinical
CycLuc1					OC(=O)[C@H]1CSC(=N1)c1nc2cc3CCNc3cc2s1 |c:6|	HBZBAMXERPYTFS-SECBINFHSA-N	Preclinical
CYC065	CDK inhibitor				CC[C@H](Nc1nc(NCc2cnc(C)cc2C)c2ncn(C(C)C)c2n1)[C@@H](C)O	DLPIYBKBHMZCJI-WBVHZDCISA-N	Phase 1
CYC116	Aurora kinase inhibitor	AURKA, AURKB, KDR			Cc1nc(N)sc1-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1, Cc1nc(N)sc1-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1, Cc1nc(N)sc1-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1, Cc1nc(N)sc1-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1, Cc1nc(N)sc1-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1	GPSZYOIFQZPWEJ-UHFFFAOYSA-N, GPSZYOIFQZPWEJ-UHFFFAOYSA-N, GPSZYOIFQZPWEJ-UHFFFAOYSA-N, GPSZYOIFQZPWEJ-UHFFFAOYSA-N, GPSZYOIFQZPWEJ-UHFFFAOYSA-N	Phase 1
CYM-50260	sphingosine 1-phosphate receptor agonist	S1PR4			FCc1ccc(OCCOc2ccc(Cl)cc2Cl)c(Cl)n1, FCc1ccc(OCCOc2ccc(Cl)cc2Cl)c(Cl)n1	FHPOTBQOUBMMCI-UHFFFAOYSA-N, FHPOTBQOUBMMCI-UHFFFAOYSA-N	Preclinical
CYM-50358	sphingosine 1-phosphate receptor antagonist	S1PR4			Cc1cc(CN)cc(C)c1NC(=O)c1ccc(o1)-c1cc(Cl)ccc1Cl, Cc1cc(CN)cc(C)c1NC(=O)c1ccc(o1)-c1cc(Cl)ccc1Cl	QWJOPXDAQCDRRM-UHFFFAOYSA-N, QWJOPXDAQCDRRM-UHFFFAOYSA-N	Preclinical
CYM-50769	neuropeptide receptor antagonist	NPBWR1			COc1ccc(Oc2c(Cl)cnn(C3c4ccccc4-c4ccccc34)c2=O)cc1, COc1ccc(Oc2c(Cl)cnn(C3c4ccccc4-c4ccccc34)c2=O)cc1	QHVSQUYCVUHYKT-UHFFFAOYSA-N, QHVSQUYCVUHYKT-UHFFFAOYSA-N	Preclinical
CYM-5442	sphingosine 1-phosphate receptor agonist	S1PR1			CCOc1ccc(cc1OCC)-c1nc(no1)-c1cccc2[C@@H](CCc12)NCCO |&1:22|, CCOc1ccc(cc1OCC)-c1nc(no1)-c1cccc2[C@@H](CCc12)NCCO |&1:22|	NUIKTBLZSPQGCP-LJQANCHMSA-N, NUIKTBLZSPQGCP-LJQANCHMSA-N	Preclinical
CYM-5520	sphingosine 1-phosphate receptor agonist	S1PR2			Cc1cc(C(=O)Cn2cc(ccc2=O)C#N)c(C)n1Cc1ccccc1, Cc1cc(C(=O)Cn2cc(ccc2=O)C#N)c(C)n1Cc1ccccc1	FMYGNANMYYHBSU-UHFFFAOYSA-N, FMYGNANMYYHBSU-UHFFFAOYSA-N	Preclinical
CYM-5541	sphingosine 1-phosphate receptor agonist	S1PR3			O=C(N(C1CCCCC1)C1CCCCC1)c1cc(on1)C1CC1, O=C(N(C1CCCCC1)C1CCCCC1)c1cc(on1)C1CC1, O=C(N(C1CCCCC1)C1CCCCC1)c1cc(on1)C1CC1	NDKGACIWVAOUQH-UHFFFAOYSA-N, NDKGACIWVAOUQH-UHFFFAOYSA-N, NDKGACIWVAOUQH-UHFFFAOYSA-N	Preclinical
cypermethrin			infectious disease	flea control	CC1(C)[C@@H](C=C(Cl)Cl)[C@@H]1C(=O)O[C@@H](C#N)c1cccc(Oc2ccccc2)c1 |&1:3,&2:8,&3:12,r|, CC1(C)[C@@H](C=C(Cl)Cl)[C@@H]1C(=O)O[C@@H](C#N)c1cccc(Oc2ccccc2)c1 |&1:3,&2:8,&3:12,r|	KAATUXNTWXVJKI-CMKODMSKSA-N, KAATUXNTWXVJKI-CMKODMSKSA-N	Launched
cyproheptadine	histamine receptor antagonist	ADRA1A, ADRA1B, ADRA1D, CHRM1, CHRM2, CHRM3, HRH1, HTR2A, HTR2C, HTR6, HTR7	allergy, otolaryngology, ophthalmology, dermatology	allergic rhinitis, vasomotor rhinitis, conjunctivitis, urticaria, dermatographism	CN1CCC(CC1)=C1c2ccccc2C=Cc2ccccc12 |c:16|, CN1CCC(CC1)=C1c2ccccc2C=Cc2ccccc12 |c:16|, CN1CCC(CC1)=C1c2ccccc2C=Cc2ccccc12 |c:16|, CN1CCC(CC1)=C1c2ccccc2C=Cc2ccccc12 |c:16|, CN1CCC(CC1)=C1c2ccccc2C=Cc2ccccc12 |c:16|, CN1CCC(CC1)=C1c2ccccc2C=Cc2ccccc12 |c:16|, CN1CCC(CC1)=C1c2ccccc2C=Cc2ccccc12 |c:16|, CN1CCC(CC1)=C1c2ccccc2C=Cc2ccccc12 |c:16|	JJCFRYNCJDLXIK-UHFFFAOYSA-N, JJCFRYNCJDLXIK-UHFFFAOYSA-N, JJCFRYNCJDLXIK-UHFFFAOYSA-N, JJCFRYNCJDLXIK-UHFFFAOYSA-N, JJCFRYNCJDLXIK-UHFFFAOYSA-N, JJCFRYNCJDLXIK-UHFFFAOYSA-N, JJCFRYNCJDLXIK-UHFFFAOYSA-N, JJCFRYNCJDLXIK-UHFFFAOYSA-N	Launched
cyproterone-acetate	androgen receptor antagonist	ADORA1, AR	oncology	prostate cancer	CC(=O)O[C@@]1(CC[C@H]2[C@@H]3C=C(Cl)C4=CC(=O)[C@@H]5C[C@@H]5[C@]4(C)[C@H]3CC[C@]12C)C(C)=O |t:9,12|, CC(=O)O[C@@]1(CC[C@H]2[C@@H]3C=C(Cl)C4=CC(=O)[C@@H]5C[C@@H]5[C@]4(C)[C@H]3CC[C@]12C)C(C)=O |t:9,12|, CC(=O)O[C@@]1(CC[C@H]2[C@@H]3C=C(Cl)C4=CC(=O)[C@@H]5C[C@@H]5[C@]4(C)[C@H]3CC[C@]12C)C(C)=O |t:9,12|, CC(=O)O[C@@]1(CC[C@H]2[C@@H]3C=C(Cl)C4=CC(=O)[C@@H]5C[C@@H]5[C@]4(C)[C@H]3CC[C@]12C)C(C)=O |t:9,12|	UWFYSQMTEOIJJG-FDTZYFLXSA-N, UWFYSQMTEOIJJG-FDTZYFLXSA-N, UWFYSQMTEOIJJG-FDTZYFLXSA-N, UWFYSQMTEOIJJG-FDTZYFLXSA-N	Launched
cyromazine					Nc1nc(N)nc(NC2CC2)n1, Nc1nc(N)nc(NC2CC2)n1	LVQDKIWDGQRHTE-UHFFFAOYSA-N, LVQDKIWDGQRHTE-UHFFFAOYSA-N	Launched
cysteamine	tissue transglutaminase inhibitor	NPY2R, SST	metabolism	cystinosis	NCCS, NCCS	UFULAYFCSOUIOV-UHFFFAOYSA-N, UFULAYFCSOUIOV-UHFFFAOYSA-N	Launched
CYT-997	tubulin polymerization inhibitor	TUBB			CCC[C@H](Nc1nc(ncc1C)-c1ccc(NC(=O)NCC)c(OC)c1)c1cccnc1	MTJHLONVHHPNSI-IBGZPJMESA-N	Phase 2
cytarabine	ribonucleotide reductase inhibitor	POLA1, POLB, POLD1, POLE	hematologic malignancy	acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL)	Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1	UHDGCWIWMRVCDJ-CCXZUQQUSA-N, UHDGCWIWMRVCDJ-CCXZUQQUSA-N	Launched
cytidine		UCK2			Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1	UHDGCWIWMRVCDJ-XVFCMESISA-N, UHDGCWIWMRVCDJ-XVFCMESISA-N, InChI=1S/C9H13N3O5/c10-5-1-2-12(9(16)11-5)8-7(15)6(14)4(3-13)17-8/h1-2,4,6-8,13-15H,3H2,(H2,10,11,16)/t4-,6-,7-,8-/m1/s1, InChI=1S/C9H13N3O5/c10-5-1-2-12(9(16)11-5)8-7(15)6(14)4(3-13)17-8/h1-2,4,6-8,13-15H,3H2,(H2,10,11,16)/t4-,6-,7-,8-/m1/s1	Launched
cytisine	acetylcholine receptor agonist	CHRNA2, CHRNA3, CHRNA4, CHRNA6, CHRNA7, CHRNB2, CHRNB4	neurology/psychiatry	nicotinism	O=c1cccc2[C@H]3CNC[C@H](C3)Cn12, O=c1cccc2[C@H]3CNC[C@H](C3)Cn12, O=c1cccc2[C@H]3CNC[C@H](C3)Cn12, O=c1cccc2[C@H]3CNC[C@H](C3)Cn12, O=c1cccc2[C@H]3CNC[C@H](C3)Cn12	ANJTVLIZGCUXLD-DTWKUNHWSA-N, ANJTVLIZGCUXLD-DTWKUNHWSA-N, ANJTVLIZGCUXLD-DTWKUNHWSA-N, ANJTVLIZGCUXLD-DTWKUNHWSA-N, ANJTVLIZGCUXLD-DTWKUNHWSA-N	Launched
cytochalasin-B	microtubule inhibitor	ACTB			C[C@H]1[C@H]2[C@H](Cc3ccccc3)NC(=O)[C@]22OC(=O)\C=C\[C@H](O)CCC[C@@H](C)C\C=C\[C@H]2[C@H](O)C1=C |t:20,30|	GBOGMAARMMDZGR-TYHYBEHESA-N	Phase 2
cytochlor					Nc1nc(=O)n(cc1Cl)[C@H]1C[C@@H](O)[C@@H](CO)O1	NGGRGTWYSXYVDK-FSDSQADBSA-N	Phase 1
cyt387	JAK inhibitor	JAK1, JAK2, JAK3			O=C(NCC#N)c1ccc(cc1)-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1, O=C(NCC#N)c1ccc(cc1)-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1, O=C(NCC#N)c1ccc(cc1)-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1, O=C(NCC#N)c1ccc(cc1)-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1, O=C(NCC#N)c1ccc(cc1)-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1, O=C(NCC#N)c1ccc(cc1)-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1	ZVHNDZWQTBEVRY-UHFFFAOYSA-N, ZVHNDZWQTBEVRY-UHFFFAOYSA-N, ZVHNDZWQTBEVRY-UHFFFAOYSA-N, ZVHNDZWQTBEVRY-UHFFFAOYSA-N, ZVHNDZWQTBEVRY-UHFFFAOYSA-N, ZVHNDZWQTBEVRY-UHFFFAOYSA-N	Phase 3
CY208-243	dopamine receptor agonist	CALY			CN1Cc2ccccc2[C@H]2[C@H]1Cc1c[nH]c3cccc2c13, CN1Cc2ccccc2[C@H]2[C@H]1Cc1c[nH]c3cccc2c13	WRNKIDLXXXIELU-IEBWSBKVSA-N, WRNKIDLXXXIELU-IEBWSBKVSA-N	Phase 2
CZC-54252	leucine rich repeat kinase inhibitor	LRRK2			COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2NS(C)(=O)=O)n1)N1CCOCC1, COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2NS(C)(=O)=O)n1)N1CCOCC1, COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2NS(C)(=O)=O)n1)N1CCOCC1, COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2NS(C)(=O)=O)n1)N1CCOCC1	CLGWUCNXOBLWFM-UHFFFAOYSA-N, CLGWUCNXOBLWFM-UHFFFAOYSA-N, CLGWUCNXOBLWFM-UHFFFAOYSA-N, CLGWUCNXOBLWFM-UHFFFAOYSA-N	Preclinical
CZC24832	PI3K inhibitor	PIK3CG			CC(C)(C)NS(=O)(=O)c1cncc(c1)-c1cc(F)c2nc(N)nn2c1, CC(C)(C)NS(=O)(=O)c1cncc(c1)-c1cc(F)c2nc(N)nn2c1	RXRZPHQBTHQXSV-UHFFFAOYSA-N, RXRZPHQBTHQXSV-UHFFFAOYSA-N	Preclinical
C106					CN1CCC[C@@H]1c1cccnc1.Cc1ccc(cc1)C(=O)O[C@@H]([C@@H](OC(=O)c1ccc(C)cc1)C(O)=O)C(O)=O |&1:5,&2:22,&3:23,r|	GEGPCGHEPLKDLY-DRHSTVBOSA-N	Phase 3
C11-Acetate		ABAT, ACE, AKR1C3, CA2, CELA1, ESR2, FFAR2, FFAR3, HPRT1, LTA4H, MMP12, NOS1, NOS3, PLA2G1B, PTPN1, SOD1, TXN			[Y+3]	GRTBAGCGDOYUBE-UHFFFAOYSA-N	Phase 3
C188-9	STAT inhibitor				COc1ccc(cc1)S(=O)(=O)Nc1cc(c(O)c2ccccc12)-c1c(O)ccc2ccccc12	QDCJDYWGYVPBDO-UHFFFAOYSA-N	Preclinical
C34	toll-like receptor inhibitor	TLR4			CC(C)O[C@H]1O[C@H](COC(C)=O)[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H]1NC(C)=O, CC(C)O[C@H]1O[C@H](COC(C)=O)[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H]1NC(C)=O	KMIQMFHPUJUDMC-HHARLNAUSA-N, KMIQMFHPUJUDMC-HHARLNAUSA-N	Preclinical
C646	histone acetyltransferase inhibitor	EP300			CC1=NN(C(=O)C1=Cc1ccc(o1)-c1cc(C)c(C)cc1[N+]([O-])=O)c1ccc(cc1)C(O)=O |t:1|, CC1=NN(C(=O)C1=Cc1ccc(o1)-c1cc(C)c(C)cc1[N+]([O-])=O)c1ccc(cc1)C(O)=O |t:1|, CC1=NN(C(=O)C1=Cc1ccc(o1)-c1cc(C)c(C)cc1[N+]([O-])=O)c1ccc(cc1)C(O)=O |t:1|, CC1=NN(C(=O)C1=Cc1ccc(o1)-c1cc(C)c(C)cc1[N+]([O-])=O)c1ccc(cc1)C(O)=O |t:1|, CC1=NN(C(=O)C1=Cc1ccc(o1)-c1cc(C)c(C)cc1[N+]([O-])=O)c1ccc(cc1)C(O)=O |t:1|, CC1=NN(C(=O)C1=Cc1ccc(o1)-c1cc(C)c(C)cc1[N+]([O-])=O)c1ccc(cc1)C(O)=O |t:1|, CC1=NN(C(=O)C1=Cc1ccc(o1)-c1cc(C)c(C)cc1[N+]([O-])=O)c1ccc(cc1)C(O)=O |t:1|, CC1=NN(C(=O)C1=Cc1ccc(o1)-c1cc(C)c(C)cc1[N+]([O-])=O)c1ccc(cc1)C(O)=O |t:1|, CC1=NN(C(=O)C1=Cc1ccc(o1)-c1cc(C)c(C)cc1[N+]([O-])=O)c1ccc(cc1)C(O)=O |t:1|	HEKJYZZSCQBJGB-UHFFFAOYSA-N, HEKJYZZSCQBJGB-UHFFFAOYSA-N, HEKJYZZSCQBJGB-UHFFFAOYSA-N, HEKJYZZSCQBJGB-UHFFFAOYSA-N, HEKJYZZSCQBJGB-UHFFFAOYSA-N, HEKJYZZSCQBJGB-UHFFFAOYSA-N, HEKJYZZSCQBJGB-UHFFFAOYSA-N, HEKJYZZSCQBJGB-UHFFFAOYSA-N, HEKJYZZSCQBJGB-UHFFFAOYSA-N	Preclinical
D,L-mevalonic-acid-lactone					C[C@@]1(O)CCOC(=O)C1 |&1:1,r|	JYVXNLLUYHCIIH-ZCFIWIBFSA-N	Preclinical
D-(+)-maltose		MGAM			OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O, OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O	GUBGYTABKSRVRQ-QUYVBRFLSA-N, GUBGYTABKSRVRQ-QUYVBRFLSA-N	Preclinical
D-alpha-tocopheryl-succinate					CC(C)CCC[C@@H](C)CCC[C@@H](C)CCC[C@]1(C)CCc2c(C)c(OC(=O)CCC(O)=O)c(C)c(C)c2O1, CC(C)CCC[C@@H](C)CCC[C@@H](C)CCC[C@]1(C)CCc2c(C)c(OC(=O)CCC(O)=O)c(C)c(C)c2O1	IELOKBJPULMYRW-NJQVLOCASA-N, IELOKBJPULMYRW-NJQVLOCASA-N	Launched
D-delta-tocopherol					CC(C)CCC[C@@H](C)CCC[C@@H](C)CCC[C@]1(C)CCc2cc(O)cc(C)c2O1	GZIFEOYASATJEH-VHFRWLAGSA-N	Launched
D-limonene					CC(=C)[C@@H]1CCC(C)=CC1 |c:7|, CC(=C)[C@@H]1CCC(C)=CC1 |c:7|	XMGQYMWWDOXHJM-JTQLQIEISA-N, XMGQYMWWDOXHJM-JTQLQIEISA-N	Phase 1
D-phenylalanine	enkephalinase inhibitor	CCBL1, CRH, HCAR3			N[C@H](Cc1ccccc1)C(O)=O, N[C@H](Cc1ccccc1)C(O)=O, N[C@H](Cc1ccccc1)C(O)=O	COLNVLDHVKWLRT-MRVPVSSYSA-N, COLNVLDHVKWLRT-MRVPVSSYSA-N, COLNVLDHVKWLRT-MRVPVSSYSA-N	Preclinical
D-serine	glutamate receptor agonist	GLRA1, GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D, SERPINB3			N[C@H](CO)C(O)=O, N[C@H](CO)C(O)=O	MTCFGRXMJLQNBG-UWTATZPHSA-N, MTCFGRXMJLQNBG-UWTATZPHSA-N	Launched
D-157495	decapping scavenger enzyme inhibitor				Nc1nc(N)c2c(OCC3CCN(Cc4c(Cl)cccc4Cl)CC3)cccc2n1	MNLHFGXIUJNDAF-UHFFFAOYSA-N	Preclinical
D-3263	transient receptor potential channel agonist				COc1ccc2n(C(=O)[C@@H]3C[C@H](C)CC[C@H]3C(C)C)c(=O)n(CCN)c2c1	ZGTYTFYRCIRWBL-HYVNUMGLSA-N	Phase 1
D-4476	TGF beta receptor inhibitor	CSNK1A1, CSNK1D, TGFB1			NC(=O)c1ccc(cc1)-c1nc(c([nH]1)-c1ccc2OCCOc2c1)-c1ccccn1, NC(=O)c1ccc(cc1)-c1nc(c([nH]1)-c1ccc2OCCOc2c1)-c1ccccn1, NC(=O)c1ccc(cc1)-c1nc(c([nH]1)-c1ccc2OCCOc2c1)-c1ccccn1	DPDZHVCKYBCJHW-UHFFFAOYSA-N, DPDZHVCKYBCJHW-UHFFFAOYSA-N, DPDZHVCKYBCJHW-UHFFFAOYSA-N	Preclinical
D-64131	microtubule inhibitor	TUBB			COc1ccc2[nH]c(cc2c1)C(=O)c1ccccc1, COc1ccc2[nH]c(cc2c1)C(=O)c1ccccc1, COc1ccc2[nH]c(cc2c1)C(=O)c1ccccc1, COc1ccc2[nH]c(cc2c1)C(=O)c1ccccc1, COc1ccc2[nH]c(cc2c1)C(=O)c1ccccc1, COc1ccc2[nH]c(cc2c1)C(=O)c1ccccc1	ICMIJSRDISNKOC-UHFFFAOYSA-N, ICMIJSRDISNKOC-UHFFFAOYSA-N, ICMIJSRDISNKOC-UHFFFAOYSA-N, ICMIJSRDISNKOC-UHFFFAOYSA-N, ICMIJSRDISNKOC-UHFFFAOYSA-N, ICMIJSRDISNKOC-UHFFFAOYSA-N	Preclinical
D-7193					CC(=O)N[C@@H](CSSC[C@H](NC(C)=O)C(O)=O)C(O)=O	YTPQSLLEROSACP-YUMQZZPRSA-N	Phase 2
DAA-1106	benzodiazepine receptor agonist	TSPO			COc1ccc(OC)c(CN(C(C)=O)c2cc(F)ccc2Oc2ccccc2)c1, COc1ccc(OC)c(CN(C(C)=O)c2cc(F)ccc2Oc2ccccc2)c1	DCRZYADKQRHHSF-UHFFFAOYSA-N, DCRZYADKQRHHSF-UHFFFAOYSA-N	Preclinical
dabigatran	thrombin inhibitor	F2	neurology/psychiatry, hematology	stroke, systemic embolism, pulmonary embolism (PE), deep vein thrombosis (DVT)	Cn1c(CNc2ccc(cc2)C(N)=N)nc2cc(ccc12)C(=O)N(CCC(O)=O)c1ccccn1, Cn1c(CNc2ccc(cc2)C(N)=N)nc2cc(ccc12)C(=O)N(CCC(O)=O)c1ccccn1, Cn1c(CNc2ccc(cc2)C(N)=N)nc2cc(ccc12)C(=O)N(CCC(O)=O)c1ccccn1, Cn1c(CNc2ccc(cc2)C(N)=N)nc2cc(ccc12)C(=O)N(CCC(O)=O)c1ccccn1, Cn1c(CNc2ccc(cc2)C(N)=N)nc2cc(ccc12)C(=O)N(CCC(O)=O)c1ccccn1, Cn1c(CNc2ccc(cc2)C(N)=N)nc2cc(ccc12)C(=O)N(CCC(O)=O)c1ccccn1	YBSJFWOBGCMAKL-UHFFFAOYSA-N, YBSJFWOBGCMAKL-UHFFFAOYSA-N, YBSJFWOBGCMAKL-UHFFFAOYSA-N, YBSJFWOBGCMAKL-UHFFFAOYSA-N, YBSJFWOBGCMAKL-UHFFFAOYSA-N, YBSJFWOBGCMAKL-UHFFFAOYSA-N	Launched
dabigatran-etexilate	thrombin inhibitor	F2	neurology/psychiatry, hematology	stroke, systemic embolism, pulmonary embolism (PE), deep vein thrombosis (DVT)	CCCCCCOC(=O)\N=C(\N)c1ccc(NCc2nc3cc(ccc3n2C)C(=O)N(CCC(=O)OCC)c2ccccn2)cc1, CCCCCCOC(=O)\N=C(\N)c1ccc(NCc2nc3cc(ccc3n2C)C(=O)N(CCC(=O)OCC)c2ccccn2)cc1, CCCCCCOC(=O)\N=C(\N)c1ccc(NCc2nc3cc(ccc3n2C)C(=O)N(CCC(=O)OCC)c2ccccn2)cc1	KSGXQBZTULBEEQ-UHFFFAOYSA-N, KSGXQBZTULBEEQ-UHFFFAOYSA-N, KSGXQBZTULBEEQ-UHFFFAOYSA-N	Launched
dabrafenib	RAF inhibitor	BRAF, LIMK1, NEK11, RAF1, SIK1	oncology	melanoma	CC(C)(C)c1nc(c(s1)-c1ccnc(N)n1)-c1cccc(NS(=O)(=O)c2c(F)cccc2F)c1F, CC(C)(C)c1nc(c(s1)-c1ccnc(N)n1)-c1cccc(NS(=O)(=O)c2c(F)cccc2F)c1F, CC(C)(C)c1nc(c(s1)-c1ccnc(N)n1)-c1cccc(NS(=O)(=O)c2c(F)cccc2F)c1F, CC(C)(C)c1nc(c(s1)-c1ccnc(N)n1)-c1cccc(NS(=O)(=O)c2c(F)cccc2F)c1F, CC(C)(C)c1nc(c(s1)-c1ccnc(N)n1)-c1cccc(NS(=O)(=O)c2c(F)cccc2F)c1F, CC(C)(C)c1nc(c(s1)-c1ccnc(N)n1)-c1cccc(NS(=O)(=O)c2c(F)cccc2F)c1F, CC(C)(C)c1nc(c(s1)-c1ccnc(N)n1)-c1cccc(NS(=O)(=O)c2c(F)cccc2F)c1F, CC(C)(C)c1nc(c(s1)-c1ccnc(N)n1)-c1cccc(NS(=O)(=O)c2c(F)cccc2F)c1F	BFSMGDJOXZAERB-UHFFFAOYSA-N, BFSMGDJOXZAERB-UHFFFAOYSA-N, BFSMGDJOXZAERB-UHFFFAOYSA-N, BFSMGDJOXZAERB-UHFFFAOYSA-N, BFSMGDJOXZAERB-UHFFFAOYSA-N, BFSMGDJOXZAERB-UHFFFAOYSA-N, BFSMGDJOXZAERB-UHFFFAOYSA-N, BFSMGDJOXZAERB-UHFFFAOYSA-N	Launched
dacarbazine	DNA alkylating agent	PGD, POLA2	oncology, hematologic malignancy	melanoma, Hodgkin's lymphoma	CN(C)\N=N\c1nc[nH]c1C(N)=O, CN(C)\N=N\c1nc[nH]c1C(N)=O, CN(C)\N=N\c1nc[nH]c1C(N)=O	FDKXTQMXEQVLRF-ZHACJKMWSA-N, FDKXTQMXEQVLRF-ZHACJKMWSA-N, FDKXTQMXEQVLRF-ZHACJKMWSA-N	Launched
dacinostat	HDAC inhibitor	HDAC1, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9			OCCN(CCc1c[nH]c2ccccc12)Cc1ccc(\C=C\C(=O)NO)cc1, OCCN(CCc1c[nH]c2ccccc12)Cc1ccc(\C=C\C(=O)NO)cc1, OCCN(CCc1c[nH]c2ccccc12)Cc1ccc(\C=C\C(=O)NO)cc1, OCCN(CCc1c[nH]c2ccccc12)Cc1ccc(\C=C\C(=O)NO)cc1, OCCN(CCc1c[nH]c2ccccc12)Cc1ccc(\C=C\C(=O)NO)cc1, OCCN(CCc1c[nH]c2ccccc12)Cc1ccc(\C=C\C(=O)NO)cc1	BWDQBBCUWLSASG-MDZDMXLPSA-N, BWDQBBCUWLSASG-MDZDMXLPSA-N, BWDQBBCUWLSASG-MDZDMXLPSA-N, BWDQBBCUWLSASG-MDZDMXLPSA-N, BWDQBBCUWLSASG-MDZDMXLPSA-N, BWDQBBCUWLSASG-MDZDMXLPSA-N	Phase 1
daclatasvir	HCV inhibitor		infectious disease	hepatitis C	COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1c1nc(c[nH]1)-c1ccc(cc1)-c1ccc(cc1)-c1c[nH]c(n1)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)OC)C(C)C, COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1c1nc(c[nH]1)-c1ccc(cc1)-c1ccc(cc1)-c1c[nH]c(n1)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)OC)C(C)C, COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1c1nc(c[nH]1)-c1ccc(cc1)-c1ccc(cc1)-c1c[nH]c(n1)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)OC)C(C)C	FKRSSPOQAMALKA-CUPIEXAXSA-N, FKRSSPOQAMALKA-CUPIEXAXSA-N, FKRSSPOQAMALKA-CUPIEXAXSA-N	Launched
dacomitinib	EGFR inhibitor	EGFR, ERBB2, ERBB4			COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)\C=C\CN1CCCCC1, COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)\C=C\CN1CCCCC1, COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)\C=C\CN1CCCCC1, COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)\C=C\CN1CCCCC1, COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)\C=C\CN1CCCCC1, COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)\C=C\CN1CCCCC1, COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)\C=C\CN1CCCCC1	LVXJQMNHJWSHET-AATRIKPKSA-N, LVXJQMNHJWSHET-AATRIKPKSA-N, LVXJQMNHJWSHET-AATRIKPKSA-N, LVXJQMNHJWSHET-AATRIKPKSA-N, LVXJQMNHJWSHET-AATRIKPKSA-N, LVXJQMNHJWSHET-AATRIKPKSA-N, LVXJQMNHJWSHET-AATRIKPKSA-N	Launched
dactinomycin	RNA polymerase inhibitor	POLR2A	oncology	testicular carcinoma, Wilm's tumor, rhabdomyosarcoma, Ewing's sarcoma, gestational trophoblastic disease (GTD)	CC(C)[C@H]1NC(=O)[C@@H](NC(=O)c2ccc(C)c3oc4c(C)c(=O)c(N)c(C(=O)N[C@H]5[C@@H](C)OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]6CCCN6C(=O)[C@H](NC5=O)C(C)C)c4nc23)[C@@H](C)OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C1=O, CC(C)[C@H]1NC(=O)[C@@H](NC(=O)c2ccc(C)c3oc4c(C)c(=O)c(N)c(C(=O)N[C@H]5[C@@H](C)OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]6CCCN6C(=O)[C@H](NC5=O)C(C)C)c4nc23)[C@@H](C)OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C1=O	RJURFGZVJUQBHK-IIXSONLDSA-N, RJURFGZVJUQBHK-IIXSONLDSA-N	Launched
daidzein	estrogen receptor agonist	ESRRA, ESRRB, ESRRG, TRPC5			Oc1ccc(cc1)-c1coc2cc(O)ccc2c1=O, Oc1ccc(cc1)-c1coc2cc(O)ccc2c1=O, Oc1ccc(cc1)-c1coc2cc(O)ccc2c1=O, Oc1ccc(cc1)-c1coc2cc(O)ccc2c1=O, Oc1ccc(cc1)-c1coc2cc(O)ccc2c1=O, Oc1ccc(cc1)-c1coc2cc(O)ccc2c1=O	ZQSIJRDFPHDXIC-UHFFFAOYSA-N, ZQSIJRDFPHDXIC-UHFFFAOYSA-N, ZQSIJRDFPHDXIC-UHFFFAOYSA-N, ZQSIJRDFPHDXIC-UHFFFAOYSA-N, ZQSIJRDFPHDXIC-UHFFFAOYSA-N, ZQSIJRDFPHDXIC-UHFFFAOYSA-N	Phase 2
daidzin	antioxidant	ALDH2			OC[C@H]1O[C@@H](Oc2ccc3c(c2)occ(-c2ccc(O)cc2)c3=O)[C@H](O)[C@@H](O)[C@@H]1O	KYQZWONCHDNPDP-QNDFHXLGSA-N	Phase 1
dalargin	opioid receptor agonist	OPRM1			CC(C)C[C@@H](NC(=O)[C@@H](Cc1ccccc1)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)N[C@H](CCCNC(N)=N)C(O)=O |a:23,41,&1:4,&2:8,&3:28|, CC(C)C[C@@H](NC(=O)[C@@H](Cc1ccccc1)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)N[C@H](CCCNC(N)=N)C(O)=O |a:23,41,&1:4,&2:8,&3:28|	GDPHPXYFLPDZGH-ABDYMBPTSA-N, GDPHPXYFLPDZGH-ABDYMBPTSA-N	Phase 2
dalbavancin	bacterial cell wall synthesis inhibitor	PNLIP	infectious disease	skin infections	CN[C@@H]1c2ccc(O)c(Oc3cc(O)c(Cl)c(c3)[C@@H]3NC(=O)[C@@H](Cc4ccc(Oc5cc6cc(Oc7ccc(cc7Cl)[C@@H](O)[C@@H]7NC(=O)[C@H](NC(=O)[C@@H]6NC3=O)c3ccc(O)c(c3)-c3c(O[C@H]6O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]6O)cc(O)cc3[C@H](NC7=O)C(=O)NCCCN(C)C)c5O[C@@H]3O[C@@H]([C@@H](O)[C@H](O)[C@H]3NC(=O)CCCCCCCCC(C)C)C(O)=O)cc4)NC1=O)c2, CN[C@@H]1c2ccc(O)c(Oc3cc(O)c(Cl)c(c3)[C@@H]3NC(=O)[C@@H](Cc4ccc(Oc5cc6cc(Oc7ccc(cc7Cl)[C@@H](O)[C@@H]7NC(=O)[C@H](NC(=O)[C@@H]6NC3=O)c3ccc(O)c(c3)-c3c(O[C@H]6O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]6O)cc(O)cc3[C@H](NC7=O)C(=O)NCCCN(C)C)c5O[C@@H]3O[C@@H]([C@@H](O)[C@H](O)[C@H]3NC(=O)CCCCCCCCC(C)C)C(O)=O)cc4)NC1=O)c2	KGPGQDLTDHGEGT-SZUNQUCBSA-N, KGPGQDLTDHGEGT-SZUNQUCBSA-N	Launched
dalcetrapib	cholesteryl ester transfer protein inhibitor	CETP			CCC(CC)CC1(CCCCC1)C(=O)Nc1ccccc1SC(=O)C(C)C, CCC(CC)CC1(CCCCC1)C(=O)Nc1ccccc1SC(=O)C(C)C, CCC(CC)CC1(CCCCC1)C(=O)Nc1ccccc1SC(=O)C(C)C	YZQLWPMZQVHJED-UHFFFAOYSA-N, YZQLWPMZQVHJED-UHFFFAOYSA-N, YZQLWPMZQVHJED-UHFFFAOYSA-N	Phase 3
dalfampridine	potassium channel blocker	KCNA1, KCNA10, KCNA2, KCNA3, KCNA4, KCNA5, KCNA6, KCNA7, KCNB1, KCNB2, KCNC1, KCNC2, KCNC3, KCNC4, KCND1, KCND2, KCND3, KCNF1, KCNG1, KCNG2, KCNG3, KCNG4, KCNH1, KCNH2, KCNH3, KCNH4, KCNH5, KCNH6, KCNH7, KCNH8, KCNJ13, KCNJ5, KCNQ1, KCNQ2, KCNQ3, KCNQ4, KCNQ5, KCNS1, KCNS2, KCNS3, KCNV1, KCNV2	neurology/psychiatry	multiple sclerosis	Nc1ccncc1, Nc1ccncc1, Nc1ccncc1	NUKYPUAOHBNCPY-UHFFFAOYSA-N, NUKYPUAOHBNCPY-UHFFFAOYSA-N, NUKYPUAOHBNCPY-UHFFFAOYSA-N	Launched
dalfopristin	antibacterial 				[H][C@]12[C@@H](CCN1C(=O)c1coc(CC(=O)C[C@H](O)\C=C(/C)\C=C/CNC(=O)\C=C\[C@@H](C)[C@@H](OC2=O)C(C)C)n1)S(=O)(=O)CCN(CC)CC |c:19,22,t:28|	SUYRLXYYZQTJHF-FENKCRFESA-N	Preclinical
daltroban	thromboxane receptor antagonist	TBXA2R			OC(=O)Cc1ccc(CCNS(=O)(=O)c2ccc(Cl)cc2)cc1	IULOBWFWYDMECP-UHFFFAOYSA-N	Phase 3
daminozide	KDM2A inhibitor	KDM2A, KDM7A, PHF8			CN(C)NC(=O)CCC(O)=O, CN(C)NC(=O)CCC(O)=O	NOQGZXFMHARMLW-UHFFFAOYSA-N, NOQGZXFMHARMLW-UHFFFAOYSA-N	Preclinical
danazol	estrogen receptor antagonist, progesterone receptor agonist	AR, CCL2, ESR1, GNRHR, GNRHR2, PGR	obstetrics/gynecology, cardiology	endometriosis, angioedema	C[C@]12CC[C@H]3[C@@H](CCC4=Cc5oncc5C[C@]34C)[C@@H]1CC[C@@]2(O)C#C |t:8|, C[C@]12CC[C@H]3[C@@H](CCC4=Cc5oncc5C[C@]34C)[C@@H]1CC[C@@]2(O)C#C |t:8|	POZRVZJJTULAOH-LHZXLZLDSA-N, POZRVZJJTULAOH-LHZXLZLDSA-N	Launched
danegaptide	gap junction modulator				NCC(=O)N1C[C@@H](C[C@H]1C(O)=O)NC(=O)c1ccccc1, NCC(=O)N1C[C@@H](C[C@H]1C(O)=O)NC(=O)c1ccccc1	BIZKIHUJGMSVFD-MNOVXSKESA-N, BIZKIHUJGMSVFD-MNOVXSKESA-N	Phase 2
danirixin	CC chemokine receptor antagonist	CXCR2			Cc1c(F)cccc1NC(=O)Nc1ccc(Cl)c(c1O)S(=O)(=O)[C@H]1CCCNC1, Cc1c(F)cccc1NC(=O)Nc1ccc(Cl)c(c1O)S(=O)(=O)[C@H]1CCCNC1	NGYNBSHYFOFVLS-LBPRGKRZSA-N, NGYNBSHYFOFVLS-LBPRGKRZSA-N	Phase 2
danofloxacin	bacterial DNA gyrase inhibitor		pulmonary	bovine respiratory disease (BRD)	CN1C[C@@H]2C[C@H]1CN2c1cc2n(cc(C(O)=O)c(=O)c2cc1F)C1CC1, CN1C[C@@H]2C[C@H]1CN2c1cc2n(cc(C(O)=O)c(=O)c2cc1F)C1CC1, CN1C[C@@H]2C[C@H]1CN2c1cc2n(cc(C(O)=O)c(=O)c2cc1F)C1CC1	QMLVECGLEOSESV-RYUDHWBXSA-N, QMLVECGLEOSESV-RYUDHWBXSA-N, QMLVECGLEOSESV-RYUDHWBXSA-N	Launched
danoprevir	HCV inhibitor				CC(C)(C)OC(=O)N[C@H]1CCCCC\C=C/[C@@H]2C[C@]2(NC(=O)[C@@H]2C[C@H](CN2C1=O)OC(=O)N1Cc2cccc(F)c2C1)C(=O)NS(=O)(=O)C1CC1 |c:14|, CC(C)(C)OC(=O)N[C@H]1CCCCC\C=C/[C@@H]2C[C@]2(NC(=O)[C@@H]2C[C@H](CN2C1=O)OC(=O)N1Cc2cccc(F)c2C1)C(=O)NS(=O)(=O)C1CC1 |c:14|, CC(C)(C)OC(=O)N[C@H]1CCCCC\C=C/[C@@H]2C[C@]2(NC(=O)[C@@H]2C[C@H](CN2C1=O)OC(=O)N1Cc2cccc(F)c2C1)C(=O)NS(=O)(=O)C1CC1 |c:14|	ZVTDLPBHTSMEJZ-JSZLBQEHSA-N, ZVTDLPBHTSMEJZ-JSZLBQEHSA-N, ZVTDLPBHTSMEJZ-JSZLBQEHSA-N	Phase 3
dantrolene	calcium channel blocker	RYR1, RYR3	neurology/psychiatry, endocrinology	spasms, malignant hyperthermia (MH)	[O-][N+](=O)c1ccc(cc1)-c1ccc(\C=N\N2CC(=O)NC2=O)o1, [O-][N+](=O)c1ccc(cc1)-c1ccc(\C=N\N2CC(=O)NC2=O)o1, [O-][N+](=O)c1ccc(cc1)-c1ccc(\C=N\N2CC(=O)NC2=O)o1, [O-][N+](=O)c1ccc(cc1)-c1ccc(\C=N\N2CC(=O)NC2=O)o1	OZOMQRBLCMDCEG-VIZOYTHASA-N, OZOMQRBLCMDCEG-VIZOYTHASA-N, OZOMQRBLCMDCEG-VIZOYTHASA-N, OZOMQRBLCMDCEG-VIZOYTHASA-N	Launched
dantron	laxative				Oc1cccc2C(=O)c3cccc(O)c3C(=O)c12, Oc1cccc2C(=O)c3cccc(O)c3C(=O)c12, Oc1cccc2C(=O)c3cccc(O)c3C(=O)c12, Oc1cccc2C(=O)c3cccc(O)c3C(=O)c12	QBPFLULOKWLNNW-UHFFFAOYSA-N, QBPFLULOKWLNNW-UHFFFAOYSA-N, QBPFLULOKWLNNW-UHFFFAOYSA-N, QBPFLULOKWLNNW-UHFFFAOYSA-N	Withdrawn
danusertib	Aurora kinase inhibitor, growth factor receptor inhibitor	AURKA, AURKB, AURKC, FGFR1, NTRK1, RET, SLK			CO[C@@H](C(=O)N1Cc2n[nH]c(NC(=O)c3ccc(cc3)N3CCN(C)CC3)c2C1)c1ccccc1, CO[C@@H](C(=O)N1Cc2n[nH]c(NC(=O)c3ccc(cc3)N3CCN(C)CC3)c2C1)c1ccccc1, CO[C@@H](C(=O)N1Cc2n[nH]c(NC(=O)c3ccc(cc3)N3CCN(C)CC3)c2C1)c1ccccc1, CO[C@@H](C(=O)N1Cc2n[nH]c(NC(=O)c3ccc(cc3)N3CCN(C)CC3)c2C1)c1ccccc1	XKFTZKGMDDZMJI-HSZRJFAPSA-N, XKFTZKGMDDZMJI-HSZRJFAPSA-N, XKFTZKGMDDZMJI-HSZRJFAPSA-N, XKFTZKGMDDZMJI-HSZRJFAPSA-N	Phase 2
dapagliflozin	sodium/glucose cotransporter inhibitor	SLC5A1, SLC5A2	endocrinology	diabetes mellitus	CCOc1ccc(Cc2cc(ccc2Cl)[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)cc1, CCOc1ccc(Cc2cc(ccc2Cl)[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)cc1, CCOc1ccc(Cc2cc(ccc2Cl)[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)cc1	JVHXJTBJCFBINQ-ADAARDCZSA-N, JVHXJTBJCFBINQ-ADAARDCZSA-N, JVHXJTBJCFBINQ-ADAARDCZSA-N	Launched
dapansutrile	anti-inflammatory agent				CS(=O)(=O)CCC#N	LQFRYKBDZNPJSW-UHFFFAOYSA-N	Phase 2
daphnetin	protein kinase inhibitor				Oc1ccc2ccc(=O)oc2c1O, Oc1ccc2ccc(=O)oc2c1O	ATEFPOUAMCWAQS-UHFFFAOYSA-N, ATEFPOUAMCWAQS-UHFFFAOYSA-N	Preclinical
dapiprazole	adrenergic receptor antagonist	ADRA1A, ADRA1B, ADRA1D	ophthalmology	mydriasis	Cc1ccccc1N1CCN(CCc2nnc3CCCCn23)CC1, Cc1ccccc1N1CCN(CCc2nnc3CCCCn23)CC1	RFWZESUMWJKKRN-UHFFFAOYSA-N, RFWZESUMWJKKRN-UHFFFAOYSA-N	Launched
dapivirine	non-nucleoside reverse transcriptase inhibitor	CYP3A4, CYP3A5			Cc1cc(C)c(Nc2ccnc(Nc3ccc(cc3)C#N)n2)c(C)c1, Cc1cc(C)c(Nc2ccnc(Nc3ccc(cc3)C#N)n2)c(C)c1, Cc1cc(C)c(Nc2ccnc(Nc3ccc(cc3)C#N)n2)c(C)c1, Cc1cc(C)c(Nc2ccnc(Nc3ccc(cc3)C#N)n2)c(C)c1, Cc1cc(C)c(Nc2ccnc(Nc3ccc(cc3)C#N)n2)c(C)c1	ILAYIAGXTHKHNT-UHFFFAOYSA-N, ILAYIAGXTHKHNT-UHFFFAOYSA-N, ILAYIAGXTHKHNT-UHFFFAOYSA-N, ILAYIAGXTHKHNT-UHFFFAOYSA-N, ILAYIAGXTHKHNT-UHFFFAOYSA-N	Phase 3
dapoxetine	selective serotonin reuptake inhibitor (SSRI)	HTR1A, HTR1B, HTR2C, SLC6A4	urology	premature ejaculation (PE)	CN(C)[C@@H](CCOc1cccc2ccccc12)c1ccccc1, CN(C)[C@@H](CCOc1cccc2ccccc12)c1ccccc1, CN(C)[C@@H](CCOc1cccc2ccccc12)c1ccccc1, CN(C)[C@@H](CCOc1cccc2ccccc12)c1ccccc1	USRHYDPUVLEVMC-FQEVSTJZSA-N, USRHYDPUVLEVMC-FQEVSTJZSA-N, USRHYDPUVLEVMC-FQEVSTJZSA-N, USRHYDPUVLEVMC-FQEVSTJZSA-N	Launched
daprodustat	hypoxia inducible factor inhibitor	EGLN1			OC(=O)CNC(=O)c1c(O)n(C2CCCCC2)c(=O)n(C2CCCCC2)c1=O, OC(=O)CNC(=O)c1c(O)n(C2CCCCC2)c(=O)n(C2CCCCC2)c1=O, OC(=O)CNC(=O)c1c(O)n(C2CCCCC2)c(=O)n(C2CCCCC2)c1=O	NVTKJBXOBFRPLQ-UHFFFAOYSA-N, NVTKJBXOBFRPLQ-UHFFFAOYSA-N, NVTKJBXOBFRPLQ-UHFFFAOYSA-N	Phase 3
dapsone	bacterial antifolate	DHFR	dermatology, infectious disease	dermatitis herpetiformis (DH), leprosy	Nc1ccc(cc1)S(=O)(=O)c1ccc(N)cc1, Nc1ccc(cc1)S(=O)(=O)c1ccc(N)cc1	MQJKPEGWNLWLTK-UHFFFAOYSA-N, MQJKPEGWNLWLTK-UHFFFAOYSA-N	Launched
DAPT	gamma secretase inhibitor				C[C@H](NC(=O)Cc1cc(F)cc(F)c1)C(=O)N[C@H](C(=O)OC(C)(C)C)c1ccccc1, C[C@H](NC(=O)Cc1cc(F)cc(F)c1)C(=O)N[C@H](C(=O)OC(C)(C)C)c1ccccc1, C[C@H](NC(=O)Cc1cc(F)cc(F)c1)C(=O)N[C@H](C(=O)OC(C)(C)C)c1ccccc1, C[C@H](NC(=O)Cc1cc(F)cc(F)c1)C(=O)N[C@H](C(=O)OC(C)(C)C)c1ccccc1, C[C@H](NC(=O)Cc1cc(F)cc(F)c1)C(=O)N[C@H](C(=O)OC(C)(C)C)c1ccccc1	DWJXYEABWRJFSP-XOBRGWDASA-N, DWJXYEABWRJFSP-XOBRGWDASA-N, DWJXYEABWRJFSP-XOBRGWDASA-N, DWJXYEABWRJFSP-XOBRGWDASA-N, DWJXYEABWRJFSP-XOBRGWDASA-N	Preclinical
daptomycin	bacterial cell wall synthesis inhibitor		infectious disease	skin infections, endocarditis	[H][C@]1(CO)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](C)NC(=O)[C@]([H])(CC(O)=O)NC(=O)[C@H](CCCN)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](CC(N)=O)NC(=O)[C@H](Cc2c[nH]c3ccccc23)NC(=O)CCCCCCCCC)[C@@H](C)OC(=O)[C@]([H])(CC(=O)c2ccccc2N)NC(=O)[C@@]([H])(NC1=O)[C@H](C)CC(O)=O	DOAKLVKFURWEDJ-QCMAZARJSA-N	Launched
darapladib	phospholipase inhibitor	PLA2G7			CCN(CC)CCN(Cc1ccc(cc1)-c1ccc(cc1)C(F)(F)F)C(=O)Cn1c2CCCc2c(=O)nc1SCc1ccc(F)cc1, CCN(CC)CCN(Cc1ccc(cc1)-c1ccc(cc1)C(F)(F)F)C(=O)Cn1c2CCCc2c(=O)nc1SCc1ccc(F)cc1, CCN(CC)CCN(Cc1ccc(cc1)-c1ccc(cc1)C(F)(F)F)C(=O)Cn1c2CCCc2c(=O)nc1SCc1ccc(F)cc1, CCN(CC)CCN(Cc1ccc(cc1)-c1ccc(cc1)C(F)(F)F)C(=O)Cn1c2CCCc2c(=O)nc1SCc1ccc(F)cc1, CCN(CC)CCN(Cc1ccc(cc1)-c1ccc(cc1)C(F)(F)F)C(=O)Cn1c2CCCc2c(=O)nc1SCc1ccc(F)cc1, CCN(CC)CCN(Cc1ccc(cc1)-c1ccc(cc1)C(F)(F)F)C(=O)Cn1c2CCCc2c(=O)nc1SCc1ccc(F)cc1, CCN(CC)CCN(Cc1ccc(cc1)-c1ccc(cc1)C(F)(F)F)C(=O)Cn1c2CCCc2c(=O)nc1SCc1ccc(F)cc1, CCN(CC)CCN(Cc1ccc(cc1)-c1ccc(cc1)C(F)(F)F)C(=O)Cn1c2CCCc2c(=O)nc1SCc1ccc(F)cc1	WDPFJWLDPVQCAJ-UHFFFAOYSA-N, WDPFJWLDPVQCAJ-UHFFFAOYSA-N, WDPFJWLDPVQCAJ-UHFFFAOYSA-N, WDPFJWLDPVQCAJ-UHFFFAOYSA-N, WDPFJWLDPVQCAJ-UHFFFAOYSA-N, WDPFJWLDPVQCAJ-UHFFFAOYSA-N, WDPFJWLDPVQCAJ-UHFFFAOYSA-N, WDPFJWLDPVQCAJ-UHFFFAOYSA-N	Phase 3
darglitazone	PPAR receptor antagonist	PPARG			Cc1oc(nc1CCC(=O)c1ccc(CC2SC(=O)NC2=O)cc1)-c1ccccc1, Cc1oc(nc1CCC(=O)c1ccc(CC2SC(=O)NC2=O)cc1)-c1ccccc1	QQKNSPHAFATFNQ-UHFFFAOYSA-N, QQKNSPHAFATFNQ-UHFFFAOYSA-N	Phase 2
darifenacin	acetylcholine receptor antagonist	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5	urology	urinary incontinence	NC(=O)C([C@@H]1CCN(CCc2ccc3OCCc3c2)C1)(c1ccccc1)c1ccccc1, NC(=O)C([C@@H]1CCN(CCc2ccc3OCCc3c2)C1)(c1ccccc1)c1ccccc1, NC(=O)C([C@@H]1CCN(CCc2ccc3OCCc3c2)C1)(c1ccccc1)c1ccccc1	HXGBXQDTNZMWGS-RUZDIDTESA-N, HXGBXQDTNZMWGS-RUZDIDTESA-N, HXGBXQDTNZMWGS-RUZDIDTESA-N	Launched
darolutamide	androgen receptor antagonist	AR	oncology	prostate cancer	C[C@@H](Cn1ccc(n1)-c1ccc(C#N)c(Cl)c1)NC(=O)c1cc(n[nH]1)[C@@H](C)O |a:1,&1:25|, C[C@@H](Cn1ccc(n1)-c1ccc(C#N)c(Cl)c1)NC(=O)c1cc(n[nH]1)[C@@H](C)O |a:1,&1:25|	BLIJXOOIHRSQRB-NWDGAFQWSA-N, BLIJXOOIHRSQRB-NWDGAFQWSA-N	Launched
darunavir	HIV protease inhibitor	CYP3A4	infectious disease	human immunodeficiency virus (HIV-1)	CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1CO[C@H]2OCC[C@@H]12)S(=O)(=O)c1ccc(N)cc1, CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1CO[C@H]2OCC[C@@H]12)S(=O)(=O)c1ccc(N)cc1, CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1CO[C@H]2OCC[C@@H]12)S(=O)(=O)c1ccc(N)cc1, CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1CO[C@H]2OCC[C@@H]12)S(=O)(=O)c1ccc(N)cc1, CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1CO[C@H]2OCC[C@@H]12)S(=O)(=O)c1ccc(N)cc1	CJBJHOAVZSMMDJ-HEXNFIEUSA-N, CJBJHOAVZSMMDJ-HEXNFIEUSA-N, CJBJHOAVZSMMDJ-HEXNFIEUSA-N, CJBJHOAVZSMMDJ-HEXNFIEUSA-N, CJBJHOAVZSMMDJ-HEXNFIEUSA-N	Launched
darusentan	endothelin receptor antagonist	EDNRA			COc1cc(OC)nc(O[C@H](C(O)=O)C(OC)(c2ccccc2)c2ccccc2)n1, COc1cc(OC)nc(O[C@H](C(O)=O)C(OC)(c2ccccc2)c2ccccc2)n1	FEJVSJIALLTFRP-LJQANCHMSA-N, FEJVSJIALLTFRP-LJQANCHMSA-N	Phase 3
dasabuvir	HCV inhibitor		infectious disease	hepatitis C	COc1c(cc(cc1C(C)(C)C)-n1ccc(=O)[nH]c1=O)-c1ccc2cc(NS(C)(=O)=O)ccc2c1, COc1c(cc(cc1C(C)(C)C)-n1ccc(=O)[nH]c1=O)-c1ccc2cc(NS(C)(=O)=O)ccc2c1, COc1c(cc(cc1C(C)(C)C)-n1ccc(=O)[nH]c1=O)-c1ccc2cc(NS(C)(=O)=O)ccc2c1, COc1c(cc(cc1C(C)(C)C)-n1ccc(=O)[nH]c1=O)-c1ccc2cc(NS(C)(=O)=O)ccc2c1, COc1c(cc(cc1C(C)(C)C)-n1ccc(=O)[nH]c1=O)-c1ccc2cc(NS(C)(=O)=O)ccc2c1	NBRBXGKOEOGLOI-UHFFFAOYSA-N, NBRBXGKOEOGLOI-UHFFFAOYSA-N, NBRBXGKOEOGLOI-UHFFFAOYSA-N, NBRBXGKOEOGLOI-UHFFFAOYSA-N, NBRBXGKOEOGLOI-UHFFFAOYSA-N	Launched
dasatinib	Bcr-Abl kinase inhibitor, ephrin inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, SRC inhibitor, tyrosine kinase inhibitor	ABL1, ABL2, BLK, EPHA2, FGR, FRK, FYN, HCK, KIT, LCK, LYN, PDGFRB, SRC, SRMS, STAT5B, YES1	hematologic malignancy	chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL)	Cc1nc(Nc2ncc(s2)C(=O)Nc2c(C)cccc2Cl)cc(n1)N1CCN(CCO)CC1, Cc1nc(Nc2ncc(s2)C(=O)Nc2c(C)cccc2Cl)cc(n1)N1CCN(CCO)CC1, Cc1nc(Nc2ncc(s2)C(=O)Nc2c(C)cccc2Cl)cc(n1)N1CCN(CCO)CC1, Cc1nc(Nc2ncc(s2)C(=O)Nc2c(C)cccc2Cl)cc(n1)N1CCN(CCO)CC1	ZBNZXTGUTAYRHI-UHFFFAOYSA-N, ZBNZXTGUTAYRHI-UHFFFAOYSA-N, ZBNZXTGUTAYRHI-UHFFFAOYSA-N, ZBNZXTGUTAYRHI-UHFFFAOYSA-N	Launched
dasotraline	dopamine-norepinephrine-serotonin reuptake inhibitor				N[C@@H]1CC[C@@H](c2ccc(Cl)c(Cl)c2)c2ccccc12	SRPXSILJHWNFMK-MEDUHNTESA-N	Phase 3
DAU-5884	acetylcholine receptor antagonist	CHRM3			CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)N1Cc2ccccc2NC1=O, CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)N1Cc2ccccc2NC1=O, CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)N1Cc2ccccc2NC1=O	NWXCDQHBVVPPTL-WDNDVIMCSA-N, NWXCDQHBVVPPTL-WDNDVIMCSA-N, NWXCDQHBVVPPTL-WDNDVIMCSA-N	Preclinical
daucosterol	apoptosis stimulant				CC[C@H](CC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@H](CC[C@]4(C)[C@H]3CC[C@]12C)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O)C(C)C |t:13|	NPJICTMALKLTFW-OFUAXYCQSA-N	Phase 2
daunorubicin	RNA synthesis inhibitor, topoisomerase inhibitor	TOP2A, TOP2B	hematologic malignancy	acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL)	COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O	STQGQHZAVUOBTE-VGBVRHCVSA-N, STQGQHZAVUOBTE-VGBVRHCVSA-N, STQGQHZAVUOBTE-VGBVRHCVSA-N, STQGQHZAVUOBTE-VGBVRHCVSA-N, STQGQHZAVUOBTE-VGBVRHCVSA-N, STQGQHZAVUOBTE-VGBVRHCVSA-N, STQGQHZAVUOBTE-VGBVRHCVSA-N, STQGQHZAVUOBTE-VGBVRHCVSA-N, STQGQHZAVUOBTE-VGBVRHCVSA-N, STQGQHZAVUOBTE-VGBVRHCVSA-N, STQGQHZAVUOBTE-VGBVRHCVSA-N, STQGQHZAVUOBTE-VGBVRHCVSA-N, STQGQHZAVUOBTE-VGBVRHCVSA-N, STQGQHZAVUOBTE-VGBVRHCVSA-N	Launched
dazmegrel	thromboxane synthase inhibitor	TBXAS1			Cc1c(Cn2ccnc2)c2ccccc2n1CCC(O)=O	DEQLGSOHGTZKFB-UHFFFAOYSA-N	Phase 2
dazoxiben	thromboxane synthase inhibitor	TBXAS1			OC(=O)c1ccc(OCCn2ccnc2)cc1	XQGZSYKGWHUSDH-UHFFFAOYSA-N	Phase 2
DBeQ	ATPase inhibitor	CASP3			C(Nc1nc(NCc2ccccc2)c2ccccc2n1)c1ccccc1, C(Nc1nc(NCc2ccccc2)c2ccccc2n1)c1ccccc1, C(Nc1nc(NCc2ccccc2)c2ccccc2n1)c1ccccc1, C(Nc1nc(NCc2ccccc2)c2ccccc2n1)c1ccccc1	QAIMUUJJAJBPCL-UHFFFAOYSA-N, QAIMUUJJAJBPCL-UHFFFAOYSA-N, QAIMUUJJAJBPCL-UHFFFAOYSA-N, QAIMUUJJAJBPCL-UHFFFAOYSA-N	Preclinical
DBPR-211	cannabinoid receptor antagonist				FC(F)(F)c1ccc(cc1)C#Cc1ccc(s1)-c1c(CNS(=O)(=O)N2CCCC2)c(nn1-c1ccc(Cl)cc1Cl)C(=O)NN1CCCCC1	KAIYFJUWIBTYPK-UHFFFAOYSA-N	Preclinical
DBPR108	dipeptidyl peptidase inhibitor	DPP4			CC(C)(CC(=O)N1CCCC1)NCC(=O)N1C[C@@H](F)C[C@H]1C#N, CC(C)(CC(=O)N1CCCC1)NCC(=O)N1C[C@@H](F)C[C@H]1C#N, CC(C)(CC(=O)N1CCCC1)NCC(=O)N1C[C@@H](F)C[C@H]1C#N	VQKSCYBKUIDZEI-STQMWFEESA-N, VQKSCYBKUIDZEI-STQMWFEESA-N, VQKSCYBKUIDZEI-STQMWFEESA-N	Phase 1
DC-260126	free fatty acid receptor antagonist	FFAR1			CCCCc1ccc(NS(=O)(=O)c2ccc(F)cc2)cc1, CCCCc1ccc(NS(=O)(=O)c2ccc(F)cc2)cc1, CCCCc1ccc(NS(=O)(=O)c2ccc(F)cc2)cc1	CNGHPXKWPGIDSK-UHFFFAOYSA-N, CNGHPXKWPGIDSK-UHFFFAOYSA-N, CNGHPXKWPGIDSK-UHFFFAOYSA-N	Preclinical
DCC-2618	KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor	KIT, PDGFRA			Cn1cc(cn1)-c1cc(Oc2cc(F)c(NC(=O)C3(CC3)C(=O)Nc3ccccc3)cc2F)ccn1, Cn1cc(cn1)-c1cc(Oc2cc(F)c(NC(=O)C3(CC3)C(=O)Nc3ccccc3)cc2F)ccn1	WWOXKWLDMLMYQY-UHFFFAOYSA-N, WWOXKWLDMLMYQY-UHFFFAOYSA-N	Phase 1
DCEBIO	potassium channel activator	KCNN2, KCNN3, KCNN4			CCn1c2cc(Cl)c(Cl)cc2[nH]c1=O, CCn1c2cc(Cl)c(Cl)cc2[nH]c1=O, CCn1c2cc(Cl)c(Cl)cc2[nH]c1=O, CCn1c2cc(Cl)c(Cl)cc2[nH]c1=O, CCn1c2cc(Cl)c(Cl)cc2[nH]c1=O, CCn1c2cc(Cl)c(Cl)cc2[nH]c1=O, CCn1c2cc(Cl)c(Cl)cc2[nH]c1=O	LKHRMULASXZCLG-UHFFFAOYSA-N, LKHRMULASXZCLG-UHFFFAOYSA-N, LKHRMULASXZCLG-UHFFFAOYSA-N, LKHRMULASXZCLG-UHFFFAOYSA-N, LKHRMULASXZCLG-UHFFFAOYSA-N, LKHRMULASXZCLG-UHFFFAOYSA-N, LKHRMULASXZCLG-UHFFFAOYSA-N	Preclinical
DCP-LA	protein kinase activator				CCCCC[C@H]1C[C@H]1C[C@H]1C[C@H]1CCCCCCCC(O)=O |&1:11,&2:9,&3:7,&4:5,r|	CONYTTFKIUJZOF-ZSYWTGECSA-N	Preclinical
DCPIB	chloride channel blocker, gap junction modulator, glutamate inhibitor	SLC1A2			CCCC[C@]1(Cc2cc(OCCCC(O)=O)c(Cl)c(Cl)c2C1=O)C1CCCC1 |&1:4,r|	KHKGTPJPBOQECW-QFIPXVFZSA-N	Preclinical
DDR1-IN-1	discoidin domain receptor inhibitor	DDR1, DDR2			CCN1CCN(Cc2ccc(cc2C(F)(F)F)C(=O)Nc2ccc(C)c(Oc3ccc4NC(=O)Cc4c3)c2)CC1, CCN1CCN(Cc2ccc(cc2C(F)(F)F)C(=O)Nc2ccc(C)c(Oc3ccc4NC(=O)Cc4c3)c2)CC1	AOZPVMOOEJAZGK-UHFFFAOYSA-N, AOZPVMOOEJAZGK-UHFFFAOYSA-N	Preclinical
deazaguanine	DNA synthesis inhibitor				Nc1cc2[nH]cnc2c(O)n1	KXBCLNRMQPRVTP-UHFFFAOYSA-N	Preclinical
Debio-0932	HSP inhibitor				CN(C)c1cc2OCOc2cc1Sc1nc2c(N)nccc2n1CCNCC(C)(C)C	RVJIQAYFTOPTKK-UHFFFAOYSA-N	Phase 1
debrisoquin	adrenergic neuron blocker	SLC6A2	cardiology	hypertension	NC(=N)N1CCc2ccccc2C1, NC(=N)N1CCc2ccccc2C1, NC(=N)N1CCc2ccccc2C1	JWPGJSVJDAJRLW-UHFFFAOYSA-N, JWPGJSVJDAJRLW-UHFFFAOYSA-N, JWPGJSVJDAJRLW-UHFFFAOYSA-N	Launched
decamethonium	acetylcholine receptor agonist	ACHE, CHRNA2	neurology/psychiatry	muscle relaxant	C[N+](C)(C)CCCCCCCCCC[N+](C)(C)C, C[N+](C)(C)CCCCCCCCCC[N+](C)(C)C, C[N+](C)(C)CCCCCCCCCC[N+](C)(C)C, C[N+](C)(C)CCCCCCCCCC[N+](C)(C)C	MTCUAOILFDZKCO-UHFFFAOYSA-N, MTCUAOILFDZKCO-UHFFFAOYSA-N, MTCUAOILFDZKCO-UHFFFAOYSA-N, MTCUAOILFDZKCO-UHFFFAOYSA-N	Launched
decamethoxine	antiseptic				CC(C)[C@H]1CC[C@H](C)C[C@@H]1OC(=O)C[N+](C)(C)CCCCCCCCCC[N+](C)(C)CC(=O)O[C@H]1C[C@H](C)CC[C@@H]1C(C)C |&1:40,&2:36,&3:34,&4:9,&5:6,&6:3|	ZADGGFKUEYIBJC-BPBUSIJASA-N	Phase 2
decernotinib	JAK inhibitor	JAK3			CC[C@@](C)(Nc1ccnc(n1)-c1c[nH]c2ncccc12)C(=O)NCC(F)(F)F |&1:2,r|, CC[C@@](C)(Nc1ccnc(n1)-c1c[nH]c2ncccc12)C(=O)NCC(F)(F)F |&1:2,r|	ASUGUQWIHMTFJL-QGZVFWFLSA-N, ASUGUQWIHMTFJL-QGZVFWFLSA-N	Phase 2/Phase 3
decitabine	DNA methyltransferase inhibitor	DNMT1, DNMT3A	hematologic malignancy, hematology	myelodysplastic diseases (MDS), anemia, chronic myeloid leukemia (CML)	Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1, Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1, Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1, Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1, Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1, Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1	XAUDJQYHKZQPEU-KVQBGUIXSA-N, XAUDJQYHKZQPEU-KVQBGUIXSA-N, XAUDJQYHKZQPEU-KVQBGUIXSA-N, XAUDJQYHKZQPEU-KVQBGUIXSA-N, XAUDJQYHKZQPEU-KVQBGUIXSA-N, XAUDJQYHKZQPEU-KVQBGUIXSA-N	Launched
declopramide	cell cycle inhibitor				CCN(CC)CCNC(=O)c1ccc(N)c(Cl)c1	YEYAKZXEBSVURO-UHFFFAOYSA-N	Preclinical
decloxizine	histamine receptor antagonist				OCCOCCN1CCN(CC1)C(c1ccccc1)c1ccccc1	OXBBIHZWNDPBMQ-UHFFFAOYSA-N	Preclinical
decoquinate	antiprotozoal agent		infectious disease	coccidiosis	CCCCCCCCCCOc1cc2c(cc1OCC)[nH]cc(C(=O)OCC)c2=O, CCCCCCCCCCOc1cc2c(cc1OCC)[nH]cc(C(=O)OCC)c2=O, CCCCCCCCCCOc1cc2c(cc1OCC)[nH]cc(C(=O)OCC)c2=O, CCCCCCCCCCOc1cc2c(cc1OCC)[nH]cc(C(=O)OCC)c2=O, CCCCCCCCCCOc1cc2c(cc1OCC)[nH]cc(C(=O)OCC)c2=O	JHAYEQICABJSTP-UHFFFAOYSA-N, JHAYEQICABJSTP-UHFFFAOYSA-N, JHAYEQICABJSTP-UHFFFAOYSA-N, JHAYEQICABJSTP-UHFFFAOYSA-N, JHAYEQICABJSTP-UHFFFAOYSA-N	Launched
defactinib	focal adhesion kinase inhibitor	PTK2			CNC(=O)c1ccc(Nc2ncc(c(NCc3nccnc3N(C)S(C)(=O)=O)n2)C(F)(F)F)cc1, CNC(=O)c1ccc(Nc2ncc(c(NCc3nccnc3N(C)S(C)(=O)=O)n2)C(F)(F)F)cc1, CNC(=O)c1ccc(Nc2ncc(c(NCc3nccnc3N(C)S(C)(=O)=O)n2)C(F)(F)F)cc1, CNC(=O)c1ccc(Nc2ncc(c(NCc3nccnc3N(C)S(C)(=O)=O)n2)C(F)(F)F)cc1, CNC(=O)c1ccc(Nc2ncc(c(NCc3nccnc3N(C)S(C)(=O)=O)n2)C(F)(F)F)cc1, CNC(=O)c1ccc(Nc2ncc(c(NCc3nccnc3N(C)S(C)(=O)=O)n2)C(F)(F)F)cc1, CNC(=O)c1ccc(Nc2ncc(c(NCc3nccnc3N(C)S(C)(=O)=O)n2)C(F)(F)F)cc1, CNC(=O)c1ccc(Nc2ncc(c(NCc3nccnc3N(C)S(C)(=O)=O)n2)C(F)(F)F)cc1, CNC(=O)c1ccc(Nc2ncc(c(NCc3nccnc3N(C)S(C)(=O)=O)n2)C(F)(F)F)cc1, CNC(=O)c1ccc(Nc2ncc(c(NCc3nccnc3N(C)S(C)(=O)=O)n2)C(F)(F)F)cc1	FWLMVFUGMHIOAA-UHFFFAOYSA-N, FWLMVFUGMHIOAA-UHFFFAOYSA-N, FWLMVFUGMHIOAA-UHFFFAOYSA-N, FWLMVFUGMHIOAA-UHFFFAOYSA-N, FWLMVFUGMHIOAA-UHFFFAOYSA-N, FWLMVFUGMHIOAA-UHFFFAOYSA-N, FWLMVFUGMHIOAA-UHFFFAOYSA-N, FWLMVFUGMHIOAA-UHFFFAOYSA-N, FWLMVFUGMHIOAA-UHFFFAOYSA-N, FWLMVFUGMHIOAA-UHFFFAOYSA-N	Phase 2
deferasirox	chelating agent	CYP3A4	hematology	transfusional hemosiderosis, thalassemia, iron overload	OC(=O)c1ccc(cc1)-n1nc(nc1-c1ccccc1O)-c1ccccc1O, OC(=O)c1ccc(cc1)-n1nc(nc1-c1ccccc1O)-c1ccccc1O, OC(=O)c1ccc(cc1)-n1nc(nc1-c1ccccc1O)-c1ccccc1O, OC(=O)c1ccc(cc1)-n1nc(nc1-c1ccccc1O)-c1ccccc1O	BOFQWVMAQOTZIW-UHFFFAOYSA-N, BOFQWVMAQOTZIW-UHFFFAOYSA-N, BOFQWVMAQOTZIW-UHFFFAOYSA-N, BOFQWVMAQOTZIW-UHFFFAOYSA-N	Launched
deferasirox-iron-chelate					OC(=O)c1ccc(cc1)-n1nc-2nc1-c1ccccc1O[Fe]Oc1ccccc-21	XLHBYAVMDSNIEM-UHFFFAOYSA-L	Launched
deferiprone	chelating agent	UGT1A6	hematology	transfusional hemosiderosis, thalassemia, iron overload	Cc1c(O)c(=O)ccn1C, Cc1c(O)c(=O)ccn1C, Cc1c(O)c(=O)ccn1C	TZXKOCQBRNJULO-UHFFFAOYSA-N, TZXKOCQBRNJULO-UHFFFAOYSA-N, TZXKOCQBRNJULO-UHFFFAOYSA-N	Launched
deferoxamine-mesylate	chelating agent		hematology	acute iron intoxication, iron overload	CC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCN, CC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCN, CC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCN	UBQYURCVBFRUQT-UHFFFAOYSA-N, UBQYURCVBFRUQT-UHFFFAOYSA-N, UBQYURCVBFRUQT-UHFFFAOYSA-N	Launched
deflazacort	glucocorticoid receptor agonist	NR3C1	rheumatology	joint inflammation	CC(=O)OCC(=O)[C@@]12N=C(C)O[C@@H]1C[C@H]1[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]21C |c:23,t:8,19|	FBHSPRKOSMHSIF-GRMWVWQJSA-N	Launched
deforolimus	mTOR inhibitor	MTOR			CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1OP(C)(C)=O |c:14,33,t:29,31|, CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1OP(C)(C)=O |c:14,33,t:29,31|, CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1OP(C)(C)=O |c:14,33,t:29,31|	BUROJSBIWGDYCN-LKLUGXJSSA-N, BUROJSBIWGDYCN-LKLUGXJSSA-N, BUROJSBIWGDYCN-LKLUGXJSSA-N	Phase 3
degarelix	gonadotropin releasing factor hormone receptor antagonist	GNRHR	oncology	prostate cancer	CC(C)C[C@H](NC(=O)[C@@H](Cc1ccc(NC(N)=O)cc1)NC(=O)[C@H](Cc1ccc(NC(=O)[C@@H]2CC(=O)NC(=O)N2)cc1)NC(=O)[C@H](CO)NC(=O)[C@@H](Cc1cccnc1)NC(=O)[C@@H](Cc1ccc(Cl)cc1)NC(=O)[C@@H](Cc1ccc2ccccc2c1)NC(C)=O)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(N)=O	MEUCPCLKGZSHTA-XYAYPHGZSA-N	Launched
dehydroacetic-acid					CC(=O)c1c(O)cc(C)oc1=O, CC(=O)c1c(O)cc(C)oc1=O	PKLPQOJFHFGVBS-UHFFFAOYSA-N, PKLPQOJFHFGVBS-UHFFFAOYSA-N	Preclinical
dehydrocholate					C[C@H](CCC(O)=O)[C@H]1CC[C@H]2[C@H]3[C@@H](CC(=O)[C@]12C)[C@@]1(C)CCC(=O)C[C@@H]1CC3=O |a:1,7,16,18,&1:10,&2:11,&3:12,&4:25|	OHXPGWPVLFPUSM-IVFZZBRKSA-N	Preclinical
dehydrocholate-acid					C[C@H](CCC(O)=O)[C@H]1CC[C@H]2[C@H]3[C@H](CC(=O)[C@]12C)[C@@]1(C)CCC(=O)C[C@H]1CC3=O, C[C@H](CCC(O)=O)[C@H]1CC[C@H]2[C@H]3[C@H](CC(=O)[C@]12C)[C@@]1(C)CCC(=O)C[C@H]1CC3=O	OHXPGWPVLFPUSM-KLRNGDHRSA-N, OHXPGWPVLFPUSM-KLRNGDHRSA-N	Preclinical
dehydrocorydaline	acetylcholinesterase inhibitor	ACHE			COc1ccc2c(C)c3-c4cc(OC)c(OC)cc4CC[n+]3cc2c1OC, COc1ccc2c(C)c3-c4cc(OC)c(OC)cc4CC[n+]3cc2c1OC, COc1ccc2c(C)c3-c4cc(OC)c(OC)cc4CC[n+]3cc2c1OC	RFKQJTRWODZPHF-UHFFFAOYSA-N, RFKQJTRWODZPHF-UHFFFAOYSA-N, RFKQJTRWODZPHF-UHFFFAOYSA-N	Phase 3
dehydroepiandrosterone	protein synthesis stimulant	ESR1, ESR2, G6PD, GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D, GRIN3A, GRIN3B, HSD17B1, NR1I2, NR1I3, PPARA, SIGMAR1, SULT2A1, SULT2B1	endocrinology	menopause	C[C@]12CC[C@H]3[C@@H](CC=C4C[C@@H](O)CC[C@]34C)[C@@H]1CCC2=O |t:7|, C[C@]12CC[C@H]3[C@@H](CC=C4C[C@@H](O)CC[C@]34C)[C@@H]1CCC2=O |t:7|	FMGSKLZLMKYGDP-USOAJAOKSA-N, FMGSKLZLMKYGDP-USOAJAOKSA-N	Launched
dehydroepiandrosterone-sulfate	androgen receptor agonist, estrogen receptor agonist	AR, ESR1, ESR2	endocrinology	menopause	C[C@]12CC[C@H]3[C@@H](CC=C4C[C@H](CC[C@]34C)OS(O)(=O)=O)[C@@H]1CCC2=O |t:7|	CZWCKYRVOZZJNM-USOAJAOKSA-N	Launched
delafloxacin	antiinfective drug				Nc1nc(c(F)cc1F)-n1cc(C(O)=O)c(=O)c2cc(F)c(N3CC(O)C3)c(Cl)c12	DYDCPNMLZGFQTM-UHFFFAOYSA-N	Phase 3
delamanid	bacterial cell wall synthesis inhibitor		infectious disease	tuberculosis	C[C@]1(COc2ccc(cc2)N2CCC(CC2)Oc2ccc(OC(F)(F)F)cc2)Cn2cc(nc2O1)[N+]([O-])=O, C[C@]1(COc2ccc(cc2)N2CCC(CC2)Oc2ccc(OC(F)(F)F)cc2)Cn2cc(nc2O1)[N+]([O-])=O	XDAOLTSRNUSPPH-XMMPIXPASA-N, XDAOLTSRNUSPPH-XMMPIXPASA-N	Launched
delanzomib	proteasome inhibitor	CMA1, CTSG, CYP3A4, ELANE			CC(C)C[C@H](NC(=O)[C@@H](NC(=O)c1cccc(n1)-c1ccccc1)[C@@H](C)O)B(O)O, CC(C)C[C@H](NC(=O)[C@@H](NC(=O)c1cccc(n1)-c1ccccc1)[C@@H](C)O)B(O)O, CC(C)C[C@H](NC(=O)[C@@H](NC(=O)c1cccc(n1)-c1ccccc1)[C@@H](C)O)B(O)O, CC(C)C[C@H](NC(=O)[C@@H](NC(=O)c1cccc(n1)-c1ccccc1)[C@@H](C)O)B(O)O, CC(C)C[C@H](NC(=O)[C@@H](NC(=O)c1cccc(n1)-c1ccccc1)[C@@H](C)O)B(O)O, CC(C)C[C@H](NC(=O)[C@@H](NC(=O)c1cccc(n1)-c1ccccc1)[C@@H](C)O)B(O)O, CC(C)C[C@H](NC(=O)[C@@H](NC(=O)c1cccc(n1)-c1ccccc1)[C@@H](C)O)B(O)O, CC(C)C[C@H](NC(=O)[C@@H](NC(=O)c1cccc(n1)-c1ccccc1)[C@@H](C)O)B(O)O, CC(C)C[C@H](NC(=O)[C@@H](NC(=O)c1cccc(n1)-c1ccccc1)[C@@H](C)O)B(O)O	SJFBTAPEPRWNKH-CCKFTAQKSA-N, SJFBTAPEPRWNKH-CCKFTAQKSA-N, SJFBTAPEPRWNKH-CCKFTAQKSA-N, SJFBTAPEPRWNKH-CCKFTAQKSA-N, SJFBTAPEPRWNKH-CCKFTAQKSA-N, SJFBTAPEPRWNKH-CCKFTAQKSA-N, SJFBTAPEPRWNKH-CCKFTAQKSA-N, SJFBTAPEPRWNKH-CCKFTAQKSA-N, SJFBTAPEPRWNKH-CCKFTAQKSA-N	Phase 1/Phase 2
delapril	angiotensin converting enzyme inhibitor	ACE	cardiology	hypertension	CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N(CC(O)=O)C1Cc2ccccc2C1, CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N(CC(O)=O)C1Cc2ccccc2C1, CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N(CC(O)=O)C1Cc2ccccc2C1	WOUOLAUOZXOLJQ-MBSDFSHPSA-N, WOUOLAUOZXOLJQ-MBSDFSHPSA-N, WOUOLAUOZXOLJQ-MBSDFSHPSA-N	Launched
delavirdine	non-nucleoside reverse transcriptase inhibitor	CYP3A4	infectious disease	human immunodeficiency virus (HIV-1)	CC(C)Nc1cccnc1N1CCN(CC1)C(=O)c1cc2cc(NS(C)(=O)=O)ccc2[nH]1, CC(C)Nc1cccnc1N1CCN(CC1)C(=O)c1cc2cc(NS(C)(=O)=O)ccc2[nH]1, CC(C)Nc1cccnc1N1CCN(CC1)C(=O)c1cc2cc(NS(C)(=O)=O)ccc2[nH]1, CC(C)Nc1cccnc1N1CCN(CC1)C(=O)c1cc2cc(NS(C)(=O)=O)ccc2[nH]1	WHBIGIKBNXZKFE-UHFFFAOYSA-N, WHBIGIKBNXZKFE-UHFFFAOYSA-N, WHBIGIKBNXZKFE-UHFFFAOYSA-N, WHBIGIKBNXZKFE-UHFFFAOYSA-N	Launched
delcasertib	PKC inhibitor				CC(C)C[C@H](NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CSSC[C@H](N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(O)=O	XPXZTVWPRKJTAA-PJKOMPQUSA-N	Phase 1
delgocitinib	JAK inhibitor				C[C@H]1CN(C(=O)CC#N)[C@]11CCN(C1)c1ncnc2[nH]ccc12	LOWWYYZBZNSPDT-ZBEGNZNMSA-N	Phase 2
delivert	angiotensin receptor agonist	AGTR1, AGTR2	critical care	sepsis	CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)[C@@H](CCCNC(N)=N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N1CCC[C@@H]1C(=O)N[C@H](Cc1ccccc1)C(O)=O, CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)[C@@H](CCCNC(N)=N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N1CCC[C@@H]1C(=O)N[C@H](Cc1ccccc1)C(O)=O	CZGUSIXMZVURDU-FCWOTDAASA-N, CZGUSIXMZVURDU-FCWOTDAASA-N	Launched
delpazolid	antibacterial				CN1CCN(C=N1)c1ccc(cc1F)N1C[C@H](CO)OC1=O |c:5|	QLUWQAFDTNAYPN-LLVKDONJSA-N	Phase 2
delphinidin	membrane permeability inhibitor	GLO1			Oc1cc(O)c2cc(O)c([o+]c2c1)-c1cc(O)c(O)c(O)c1, Oc1cc(O)c2cc(O)c([o+]c2c1)-c1cc(O)c(O)c(O)c1, Oc1cc(O)c2cc(O)c([o+]c2c1)-c1cc(O)c(O)c(O)c1	JKHRCGUTYDNCLE-UHFFFAOYSA-O, JKHRCGUTYDNCLE-UHFFFAOYSA-O, JKHRCGUTYDNCLE-UHFFFAOYSA-O	Phase 2
delta-tocotrienol	HMGCR inhibitor	HMGCR			CC(C)=CCC\C(C)=C\CC\C(C)=C\CC[C@]1(C)CCc2cc(O)cc(C)c2O1, CC(C)=CCC\C(C)=C\CC\C(C)=C\CC[C@]1(C)CCc2cc(O)cc(C)c2O1	ODADKLYLWWCHNB-LDYBVBFYSA-N, ODADKLYLWWCHNB-LDYBVBFYSA-N	Phase 1
deltarasin	phosphodiesterase inhibitor	KRAS			C(Oc1ccc(cc1)-c1nc2ccccc2n1Cc1ccccc1)[C@H](C1CCNCC1)n1c(nc2ccccc12)-c1ccccc1, C(Oc1ccc(cc1)-c1nc2ccccc2n1Cc1ccccc1)[C@H](C1CCNCC1)n1c(nc2ccccc12)-c1ccccc1, C(Oc1ccc(cc1)-c1nc2ccccc2n1Cc1ccccc1)[C@H](C1CCNCC1)n1c(nc2ccccc12)-c1ccccc1, C(Oc1ccc(cc1)-c1nc2ccccc2n1Cc1ccccc1)[C@H](C1CCNCC1)n1c(nc2ccccc12)-c1ccccc1, C(Oc1ccc(cc1)-c1nc2ccccc2n1Cc1ccccc1)[C@H](C1CCNCC1)n1c(nc2ccccc12)-c1ccccc1	LTZKEDSUXKTTTC-KXQOOQHDSA-N, LTZKEDSUXKTTTC-KXQOOQHDSA-N, LTZKEDSUXKTTTC-KXQOOQHDSA-N, LTZKEDSUXKTTTC-KXQOOQHDSA-N, LTZKEDSUXKTTTC-KXQOOQHDSA-N	Preclinical
demecarium	acetylcholinesterase inhibitor	ACHE, BCHE	ophthalmology	intraocular pressure, glaucoma	CN(CCCCCCCCCCN(C)C(=O)Oc1cccc(c1)[N+](C)(C)C)C(=O)Oc1cccc(c1)[N+](C)(C)C, CN(CCCCCCCCCCN(C)C(=O)Oc1cccc(c1)[N+](C)(C)C)C(=O)Oc1cccc(c1)[N+](C)(C)C, CN(CCCCCCCCCCN(C)C(=O)Oc1cccc(c1)[N+](C)(C)C)C(=O)Oc1cccc(c1)[N+](C)(C)C, CN(CCCCCCCCCCN(C)C(=O)Oc1cccc(c1)[N+](C)(C)C)C(=O)Oc1cccc(c1)[N+](C)(C)C, CN(CCCCCCCCCCN(C)C(=O)Oc1cccc(c1)[N+](C)(C)C)C(=O)Oc1cccc(c1)[N+](C)(C)C	RWZVPVOZTJJMNU-UHFFFAOYSA-N, RWZVPVOZTJJMNU-UHFFFAOYSA-N, RWZVPVOZTJJMNU-UHFFFAOYSA-N, RWZVPVOZTJJMNU-UHFFFAOYSA-N, RWZVPVOZTJJMNU-UHFFFAOYSA-N	Launched
demeclocycline	bacterial 30S ribosomal subunit inhibitor		endocrinology, infectious disease, ophthalmology, urology	fever, respiratory tract infections, psittacosis, trachoma, conjunctivitis, urethritis, chancroid, cholera, syphilis, listeria, anthrax, actinomycosis, tularemia, brucellosis	[H][C@]12C[C@@]3([H])[C@H](N(C)C)C(=O)[C@@H](C(N)=O)C(=O)[C@@]3(O)C(=O)[C@H]1C(=O)c1c(O)ccc(Cl)c1[C@H]2O |&1:11,&2:21|	JHOHXJYRVSLQCB-AWLLFJHESA-N	Launched
denatonium-benzoate					CC[N+](CC)(CC(=O)Nc1c(C)cccc1C)Cc1ccccc1, CC[N+](CC)(CC(=O)Nc1c(C)cccc1C)Cc1ccccc1	ZFQMTVNLDNXRNQ-UHFFFAOYSA-O, ZFQMTVNLDNXRNQ-UHFFFAOYSA-O	Preclinical
denopamine	adrenergic receptor agonist		cardiology	angina pectoris	COc1ccc(CCNC[C@H](O)c2ccc(O)cc2)cc1OC	VHSBBVZJABQOSG-INIZCTEOSA-N	Launched
denotivir	antiviral		infectious disease	virus herpes simplex (HSV), skin infections	Cc1nsc(NC(=O)c2ccccc2)c1C(=O)Nc1ccc(Cl)cc1, Cc1nsc(NC(=O)c2ccccc2)c1C(=O)Nc1ccc(Cl)cc1, Cc1nsc(NC(=O)c2ccccc2)c1C(=O)Nc1ccc(Cl)cc1	ZPBLNADJHWHOEP-UHFFFAOYSA-N, ZPBLNADJHWHOEP-UHFFFAOYSA-N, ZPBLNADJHWHOEP-UHFFFAOYSA-N	Launched
deoxyarbutin	tyrosinase inhibitor				Oc1ccc(O[C@H]2CCCCO2)cc1 |&1:6,r|, Oc1ccc(O[C@H]2CCCCO2)cc1 |&1:6,r|	GFBCWCDNXDKFRH-NSHDSACASA-N, GFBCWCDNXDKFRH-NSHDSACASA-N	Preclinical
deoxycholic-acid	biliverdin reductase A activator, G protein-coupled receptor agonist	FPR1, GPBAR1	endocrinology	submental fat	C[C@H](CCC(O)=O)[C@H]1CC[C@H]2[C@@H]3CC[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3C[C@H](O)[C@]12C	KXGVEGMKQFWNSR-LLQZFEROSA-N	Launched
deoxycorticosterone-acetate	progestogen hormone	NR3C2			CC(=O)OCC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C |t:14|, CC(=O)OCC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C |t:14|, CC(=O)OCC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C |t:14|, CC(=O)OCC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C |t:14|, CC(=O)OCC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C |t:14|, CC(=O)OCC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C |t:14|, CC(=O)OCC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C |t:14|, CC(=O)OCC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C |t:14|	VPGRYOFKCNULNK-ACXQXYJUSA-N, VPGRYOFKCNULNK-ACXQXYJUSA-N, VPGRYOFKCNULNK-ACXQXYJUSA-N, VPGRYOFKCNULNK-ACXQXYJUSA-N, VPGRYOFKCNULNK-ACXQXYJUSA-N, VPGRYOFKCNULNK-ACXQXYJUSA-N, VPGRYOFKCNULNK-ACXQXYJUSA-N, VPGRYOFKCNULNK-ACXQXYJUSA-N	Preclinical
deoxyepinephrine	adrenergic receptor agonist, dopamine receptor agonist	ADRA1A, DRD1, DRD2			CNCCc1ccc(O)c(O)c1, CNCCc1ccc(O)c(O)c1	NGKZFDYBISXGGS-UHFFFAOYSA-N, NGKZFDYBISXGGS-UHFFFAOYSA-N	Preclinical
deptropine	histamine receptor antagonist	HRH1			CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC1c2ccccc2CCc2ccccc12 |r,THB:0:1:3.4:6.7.8|	ZWPODSUQWXAZNC-PMOLBWCYSA-N	Preclinical
dequalinium	PKC inhibitor	KCNN1, KCNN3	infectious disease	first-aid antiseptic	Cc1cc(N)c2ccccc2[n+]1CCCCCCCCCC[n+]1c(C)cc(N)c2ccccc12, Cc1cc(N)c2ccccc2[n+]1CCCCCCCCCC[n+]1c(C)cc(N)c2ccccc12, Cc1cc(N)c2ccccc2[n+]1CCCCCCCCCC[n+]1c(C)cc(N)c2ccccc12, Cc1cc(N)c2ccccc2[n+]1CCCCCCCCCC[n+]1c(C)cc(N)c2ccccc12, Cc1cc(N)c2ccccc2[n+]1CCCCCCCCCC[n+]1c(C)cc(N)c2ccccc12, Cc1cc(N)c2ccccc2[n+]1CCCCCCCCCC[n+]1c(C)cc(N)c2ccccc12	PCSWXVJAIHCTMO-UHFFFAOYSA-P, PCSWXVJAIHCTMO-UHFFFAOYSA-P, PCSWXVJAIHCTMO-UHFFFAOYSA-P, PCSWXVJAIHCTMO-UHFFFAOYSA-P, PCSWXVJAIHCTMO-UHFFFAOYSA-P, PCSWXVJAIHCTMO-UHFFFAOYSA-P	Launched
deracoxib	cyclooxygenase inhibitor	PTGS2	rheumatology	osteoarthritis	COc1ccc(cc1F)-c1cc(nn1-c1ccc(cc1)S(N)(=O)=O)C(F)F, COc1ccc(cc1F)-c1cc(nn1-c1ccc(cc1)S(N)(=O)=O)C(F)F	WAZQAZKAZLXFMK-UHFFFAOYSA-N, WAZQAZKAZLXFMK-UHFFFAOYSA-N	Launched
derazantinib	tyrosine kinase inhibitor				COCCNCCc1cccc(Nc2ncc3C[C@@H](c4ccccc4F)c4ccccc4-c3n2)c1	KPJDVVCDVBFRMU-AREMUKBSSA-N	Phase 2
deserpidine	angiotensin converting enzyme inhibitor	ACE, SLC18A2	cardiology	hypertension	CO[C@H]1[C@@H](C[C@@H]2CN3CCc4c([nH]c5ccccc45)[C@H]3C[C@@H]2[C@@H]1C(=O)OC)OC(=O)c1cc(OC)c(OC)c(OC)c1, CO[C@H]1[C@@H](C[C@@H]2CN3CCc4c([nH]c5ccccc45)[C@H]3C[C@@H]2[C@@H]1C(=O)OC)OC(=O)c1cc(OC)c(OC)c(OC)c1, CO[C@H]1[C@@H](C[C@@H]2CN3CCc4c([nH]c5ccccc45)[C@H]3C[C@@H]2[C@@H]1C(=O)OC)OC(=O)c1cc(OC)c(OC)c(OC)c1, CO[C@H]1[C@@H](C[C@@H]2CN3CCc4c([nH]c5ccccc45)[C@H]3C[C@@H]2[C@@H]1C(=O)OC)OC(=O)c1cc(OC)c(OC)c(OC)c1, CO[C@H]1[C@@H](C[C@@H]2CN3CCc4c([nH]c5ccccc45)[C@H]3C[C@@H]2[C@@H]1C(=O)OC)OC(=O)c1cc(OC)c(OC)c(OC)c1, CO[C@H]1[C@@H](C[C@@H]2CN3CCc4c([nH]c5ccccc45)[C@H]3C[C@@H]2[C@@H]1C(=O)OC)OC(=O)c1cc(OC)c(OC)c(OC)c1, CO[C@H]1[C@@H](C[C@@H]2CN3CCc4c([nH]c5ccccc45)[C@H]3C[C@@H]2[C@@H]1C(=O)OC)OC(=O)c1cc(OC)c(OC)c(OC)c1	CVBMAZKKCSYWQR-WCGOZPBSSA-N, CVBMAZKKCSYWQR-WCGOZPBSSA-N, CVBMAZKKCSYWQR-WCGOZPBSSA-N, CVBMAZKKCSYWQR-WCGOZPBSSA-N, CVBMAZKKCSYWQR-WCGOZPBSSA-N, CVBMAZKKCSYWQR-WCGOZPBSSA-N, CVBMAZKKCSYWQR-WCGOZPBSSA-N	Launched
desidustat	hypoxia inducible factor prolyl hydroxylase inhibitor				OC(=O)CNC(=O)c1c(O)c2ccccc2n(OCC2CC2)c1=O	IKRKQQLJYBAPQT-UHFFFAOYSA-N	Preclinical
desipramine	tricyclic antidepressant	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, DRD2, HRH1, HTR1A, HTR2A, HTR2C, SLC6A2, SLC6A4, SMPD1	neurology/psychiatry	depression	CNCCCN1c2ccccc2CCc2ccccc12, CNCCCN1c2ccccc2CCc2ccccc12	HCYAFALTSJYZDH-UHFFFAOYSA-N, HCYAFALTSJYZDH-UHFFFAOYSA-N	Launched
desisobutyryl-ciclesonide	cytochrome P450 inhibitor		allergy	allergic rhinitis	[H][C@]12C[C@@]3([H])[C@]4([H])CCC5=CC(=O)C=C[C@]5(C)[C@@]4([H])[C@@H](O)C[C@]3(C)[C@@]1(O[C@@H](O2)C1CCCCC1)C(=O)CO |c:13,t:9|	OXPLANUPKBHPMS-FYSAVPLMSA-N	Launched
deslanoside	Na/K-ATPase inhibitor	ATP1A1, ATP1A2, ATP1A3, ATP1A4, ATP1B1, ATP1B2, ATP1B3, FXYD2	cardiology	congestive heart failure, cardiac arrythmia	C[C@H]1O[C@H](C[C@H](O)[C@@H]1O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)[C@@H](C)O2)[C@@H](C)O1)O[C@H]1CC[C@@]2(C)[C@H](CC[C@@H]3[C@@H]2C[C@@H](O)[C@]2(C)[C@H](CC[C@]32O)C2=CC(=O)OC2)C1 |t:66|, C[C@H]1O[C@H](C[C@H](O)[C@@H]1O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)[C@@H](C)O2)[C@@H](C)O1)O[C@H]1CC[C@@]2(C)[C@H](CC[C@@H]3[C@@H]2C[C@@H](O)[C@]2(C)[C@H](CC[C@]32O)C2=CC(=O)OC2)C1 |t:66|, C[C@H]1O[C@H](C[C@H](O)[C@@H]1O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)[C@@H](C)O2)[C@@H](C)O1)O[C@H]1CC[C@@]2(C)[C@H](CC[C@@H]3[C@@H]2C[C@@H](O)[C@]2(C)[C@H](CC[C@]32O)C2=CC(=O)OC2)C1 |t:66|, C[C@H]1O[C@H](C[C@H](O)[C@@H]1O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)[C@@H](C)O2)[C@@H](C)O1)O[C@H]1CC[C@@]2(C)[C@H](CC[C@@H]3[C@@H]2C[C@@H](O)[C@]2(C)[C@H](CC[C@]32O)C2=CC(=O)OC2)C1 |t:66|	OBATZBGFDSVCJD-LALPQLPRSA-N, OBATZBGFDSVCJD-LALPQLPRSA-N, OBATZBGFDSVCJD-LALPQLPRSA-N, OBATZBGFDSVCJD-LALPQLPRSA-N	Launched
desloratadine	histamine receptor antagonist	HRH1	allergy	allergic rhinitis, urticaria	Clc1ccc2c(CCc3cccnc3C2=C2CCNCC2)c1, Clc1ccc2c(CCc3cccnc3C2=C2CCNCC2)c1, Clc1ccc2c(CCc3cccnc3C2=C2CCNCC2)c1, Clc1ccc2c(CCc3cccnc3C2=C2CCNCC2)c1, Clc1ccc2c(CCc3cccnc3C2=C2CCNCC2)c1, Clc1ccc2c(CCc3cccnc3C2=C2CCNCC2)c1, Clc1ccc2c(CCc3cccnc3C2=C2CCNCC2)c1	JAUOIFJMECXRGI-UHFFFAOYSA-N, JAUOIFJMECXRGI-UHFFFAOYSA-N, JAUOIFJMECXRGI-UHFFFAOYSA-N, JAUOIFJMECXRGI-UHFFFAOYSA-N, JAUOIFJMECXRGI-UHFFFAOYSA-N, JAUOIFJMECXRGI-UHFFFAOYSA-N, JAUOIFJMECXRGI-UHFFFAOYSA-N	Launched
deslorelin	gonadotropin releasing factor hormone receptor agonist				CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H]1CCC(=O)N1	GJKXGJCSJWBJEZ-XRSSZCMZSA-N	Phase 2
desmethylclozapine	acetylcholine receptor agonist	HTR2C			Clc1ccc2Nc3ccccc3C(=Nc2c1)N1CCNCC1 |c:13|	JNNOSTQEZICQQP-UHFFFAOYSA-N	Phase 2
desmopressin-acetate	vasopressin receptor agonist	AVPR1A, AVPR1B, AVPR2, OXTR	endocrinology, urology	central diabetes insipidus, nocturnal enuresis	NC(=O)CC[C@@H]1NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)CCSSC[C@@H](NC(=O)[C@H](CC(N)=O)NC1=O)C(=O)N1CCC[C@H]1C(=O)N[C@H](CCCNC(N)=N)C(=O)NCC(N)=O |r|	NFLWUMRGJYTJIN-AIOUAYLGSA-N	Launched
desogestrel	progesterone receptor agonist	ESR1, PGR	endocrinology	contraceptive	CC[C@]12CC(=C)[C@H]3[C@@H](CCC4=CCCC[C@H]34)[C@@H]1CC[C@@]2(O)C#C |t:10|, CC[C@]12CC(=C)[C@H]3[C@@H](CCC4=CCCC[C@H]34)[C@@H]1CC[C@@]2(O)C#C |t:10|, CC[C@]12CC(=C)[C@H]3[C@@H](CCC4=CCCC[C@H]34)[C@@H]1CC[C@@]2(O)C#C |t:10|, CC[C@]12CC(=C)[C@H]3[C@@H](CCC4=CCCC[C@H]34)[C@@H]1CC[C@@]2(O)C#C |t:10|, CC[C@]12CC(=C)[C@H]3[C@@H](CCC4=CCCC[C@H]34)[C@@H]1CC[C@@]2(O)C#C |t:10|	RPLCPCMSCLEKRS-BPIQYHPVSA-N, RPLCPCMSCLEKRS-BPIQYHPVSA-N, RPLCPCMSCLEKRS-BPIQYHPVSA-N, RPLCPCMSCLEKRS-BPIQYHPVSA-N, RPLCPCMSCLEKRS-BPIQYHPVSA-N	Launched
desonide	glucocorticoid receptor agonist	NR3C1, PLA2G1B	gastroenterology	Crohn's disease	CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO |c:14,t:10|, CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO |c:14,t:10|, CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO |c:14,t:10|, CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO |c:14,t:10|, CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO |c:14,t:10|, CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO |c:14,t:10|, CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO |c:14,t:10|	WBGKWQHBNHJJPZ-LECWWXJVSA-N, WBGKWQHBNHJJPZ-LECWWXJVSA-N, WBGKWQHBNHJJPZ-LECWWXJVSA-N, WBGKWQHBNHJJPZ-LECWWXJVSA-N, WBGKWQHBNHJJPZ-LECWWXJVSA-N, WBGKWQHBNHJJPZ-LECWWXJVSA-N, WBGKWQHBNHJJPZ-LECWWXJVSA-N	Launched
desoximetasone	glucocorticoid receptor agonist	NR3C1, PLA2G1B	dermatology	corticosteroid-responsive dermatoses	C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@H]1C(=O)CO |c:11,t:7|	VWVSBHGCDBMOOT-IIEHVVJPSA-N	Launched
desoxycorticosterone-pivalate	corticosteroid agonist	NR3C2	endocrinology	Addison's disease	CC(C)(C)C(=O)OCC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C |t:17|	VVOIQBFMTVCINR-WWMZEODYSA-N	Launched
desoxycortone	mineralocorticoid receptor agonist	NR3C1, NR3C2			C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@@H]2C(=O)CO |t:8|, C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@@H]2C(=O)CO |t:8|, C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@@H]2C(=O)CO |t:8|, C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@@H]2C(=O)CO |t:8|	ZESRJSPZRDMNHY-YFWFAHHUSA-N, ZESRJSPZRDMNHY-YFWFAHHUSA-N, ZESRJSPZRDMNHY-YFWFAHHUSA-N, ZESRJSPZRDMNHY-YFWFAHHUSA-N	Preclinical
desoxypeganine	acetylcholinesterase inhibitor, monoamine oxidase inhibitor	ACHE			C1CN2Cc3ccccc3N=C2C1 |c:11|, C1CN2Cc3ccccc3N=C2C1 |c:11|, C1CN2Cc3ccccc3N=C2C1 |c:11|, C1CN2Cc3ccccc3N=C2C1 |c:11|	WUFQLZTXIWKION-UHFFFAOYSA-N, WUFQLZTXIWKION-UHFFFAOYSA-N, WUFQLZTXIWKION-UHFFFAOYSA-N, WUFQLZTXIWKION-UHFFFAOYSA-N	Phase 1
desvenlafaxine	serotoninnorepinephrine reuptake inhibitor (SNRI)	SLC6A2, SLC6A3, SLC6A4	neurology/psychiatry	depression	CN(C)C[C@@H](c1ccc(O)cc1)C1(O)CCCCC1 |&1:4|, CN(C)C[C@@H](c1ccc(O)cc1)C1(O)CCCCC1 |&1:4|, CN(C)C[C@@H](c1ccc(O)cc1)C1(O)CCCCC1 |&1:4|, CN(C)C[C@@H](c1ccc(O)cc1)C1(O)CCCCC1 |&1:4|, CN(C)C[C@@H](c1ccc(O)cc1)C1(O)CCCCC1 |&1:4|	KYYIDSXMWOZKMP-HNNXBMFYSA-N, KYYIDSXMWOZKMP-HNNXBMFYSA-N, KYYIDSXMWOZKMP-HNNXBMFYSA-N, KYYIDSXMWOZKMP-HNNXBMFYSA-N, KYYIDSXMWOZKMP-HNNXBMFYSA-N	Launched
detomidine	adrenergic receptor agonist	ADRA2A	neurology/psychiatry	sedative	Cc1cccc(Cc2cnc[nH]2)c1C, Cc1cccc(Cc2cnc[nH]2)c1C, Cc1cccc(Cc2cnc[nH]2)c1C	RHDJRPPFURBGLQ-UHFFFAOYSA-N, RHDJRPPFURBGLQ-UHFFFAOYSA-N, RHDJRPPFURBGLQ-UHFFFAOYSA-N	Launched
devazepide	CCK receptor antagonist				CN1c2ccccc2C(=N[C@H](NC(=O)c2cc3ccccc3[nH]2)C1=O)c1ccccc1 |c:9|, CN1c2ccccc2C(=N[C@H](NC(=O)c2cc3ccccc3[nH]2)C1=O)c1ccccc1 |c:9|	NFHRQQKPEBFUJK-HSZRJFAPSA-N, NFHRQQKPEBFUJK-HSZRJFAPSA-N	Preclinical
dexamethasone	glucocorticoid receptor agonist	ANXA1, NOS2, NR0B1, NR3C1, NR3C2	endocrinology, rheumatology, allergy, gastroenterology, hematology, neurology/psychiatry, dermatology	hypercalcemia, rheumatoid arthritis, psoriatic arthritis, osteoarthritis, allergic rhinitis, ulcerative colitis, anemia, multiple sclerosis, enteritis, lupus, dermatitis herpetiformis (DH), nephrotic syndrome, psoriasis	C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO |c:11,t:7|, C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO |c:11,t:7|, C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO |c:11,t:7|, C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO |c:11,t:7|, C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO |c:11,t:7|, C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO |c:11,t:7|, C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO |c:11,t:7|	UREBDLICKHMUKA-CXSFZGCWSA-N, UREBDLICKHMUKA-CXSFZGCWSA-N, UREBDLICKHMUKA-CXSFZGCWSA-N, UREBDLICKHMUKA-CXSFZGCWSA-N, UREBDLICKHMUKA-CXSFZGCWSA-N, UREBDLICKHMUKA-CXSFZGCWSA-N, UREBDLICKHMUKA-CXSFZGCWSA-N	Launched
dexamethasone-acetate	glucocorticoid receptor agonist		endocrinology, rheumatology, allergy, gastroenterology, hematology, neurology/psychiatry, dermatology	hypercalcemia, rheumatoid arthritis, psoriatic arthritis, osteoarthritis, allergic rhinitis, ulcerative colitis, anemia, multiple sclerosis, enteritis, lupus, dermatitis herpetiformis (DH), nephrotic syndrome, psoriasis	C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)COC(C)=O |c:11,t:7|, C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)COC(C)=O |c:11,t:7|, C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)COC(C)=O |c:11,t:7|, C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)COC(C)=O |c:11,t:7|, C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)COC(C)=O |c:11,t:7|	AKUJBENLRBOFTD-RPRRAYFGSA-N, AKUJBENLRBOFTD-RPRRAYFGSA-N, AKUJBENLRBOFTD-RPRRAYFGSA-N, AKUJBENLRBOFTD-RPRRAYFGSA-N, AKUJBENLRBOFTD-RPRRAYFGSA-N	Launched
dexchlorpheniramine	histamine receptor antagonist		allergy, cardiology	allergic conjunctivitis, allergic rhinitis, urticaria, angioedema	CN(C)CC[C@@H](c1ccc(Cl)cc1)c1ccccn1, CN(C)CC[C@@H](c1ccc(Cl)cc1)c1ccccn1, CN(C)CC[C@@H](c1ccc(Cl)cc1)c1ccccn1	SOYKEARSMXGVTM-HNNXBMFYSA-N, SOYKEARSMXGVTM-HNNXBMFYSA-N, SOYKEARSMXGVTM-HNNXBMFYSA-N	Launched
dexfosfoserine	membrane integrity inhibitor	CFTR, GRM4, GRM6, GRM7, GRM8, KCNC4, PDPK1, PIM1, PRKACA, PRKCQ, PYGL, PYGM, REG1A, RHO, SERPINB3, SMAD2, TAOK2			N[C@@H](COP(O)(O)=O)C(O)=O, N[C@@H](COP(O)(O)=O)C(O)=O	BZQFBWGGLXLEPQ-REOHCLBHSA-N, BZQFBWGGLXLEPQ-REOHCLBHSA-N	Preclinical
dexlansoprazole	ATPase inhibitor	ATP4A	gastroenterology	gastroesophageal reflux disease (GERD), erosive esophagitis (EE)	Cc1c(OCC(F)(F)F)ccnc1C[S@@](=O)c1nc2ccccc2[nH]1, Cc1c(OCC(F)(F)F)ccnc1C[S@@](=O)c1nc2ccccc2[nH]1, Cc1c(OCC(F)(F)F)ccnc1C[S@@](=O)c1nc2ccccc2[nH]1, Cc1c(OCC(F)(F)F)ccnc1C[S@@](=O)c1nc2ccccc2[nH]1	MJIHNNLFOKEZEW-RUZDIDTESA-N, MJIHNNLFOKEZEW-RUZDIDTESA-N, MJIHNNLFOKEZEW-RUZDIDTESA-N, MJIHNNLFOKEZEW-RUZDIDTESA-N	Launched
dexloxiglumide	CCK receptor antagonist	CCKAR			CCCCCN(CCCOC)C(=O)[C@@H](CCC(O)=O)NC(=O)c1ccc(Cl)c(Cl)c1	QNQZBKQEIFTHFZ-GOSISDBHSA-N	Phase 3
dexmedetomidine	adrenergic receptor agonist	ADRA2A, ADRA2B, ADRA2C	neurology/psychiatry	sedative	C[C@H](c1cnc[nH]1)c1cccc(C)c1C, C[C@H](c1cnc[nH]1)c1cccc(C)c1C, C[C@H](c1cnc[nH]1)c1cccc(C)c1C, C[C@H](c1cnc[nH]1)c1cccc(C)c1C	CUHVIMMYOGQXCV-NSHDSACASA-N, CUHVIMMYOGQXCV-NSHDSACASA-N, CUHVIMMYOGQXCV-NSHDSACASA-N, CUHVIMMYOGQXCV-NSHDSACASA-N	Launched
dexniguldipine	calmodulin antagonist	ADORA3			COC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OCCCN1CCC(CC1)(c1ccccc1)c1ccccc1 |c:4,9|, COC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OCCCN1CCC(CC1)(c1ccccc1)c1ccccc1 |c:4,9|, COC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OCCCN1CCC(CC1)(c1ccccc1)c1ccccc1 |c:4,9|, COC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OCCCN1CCC(CC1)(c1ccccc1)c1ccccc1 |c:4,9|, COC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OCCCN1CCC(CC1)(c1ccccc1)c1ccccc1 |c:4,9|	SVJMLYUFVDMUHP-MGBGTMOVSA-N, SVJMLYUFVDMUHP-MGBGTMOVSA-N, SVJMLYUFVDMUHP-MGBGTMOVSA-N, SVJMLYUFVDMUHP-MGBGTMOVSA-N, SVJMLYUFVDMUHP-MGBGTMOVSA-N	Phase 2
dexpanthenol			gastroenterology	paralytic ileus	CC(C)(CO)[C@@H](O)C(=O)NCCCO, CC(C)(CO)[C@@H](O)C(=O)NCCCO	SNPLKNRPJHDVJA-ZETCQYMHSA-N, SNPLKNRPJHDVJA-ZETCQYMHSA-N	Launched
dexrazoxane	chelating agent, topoisomerase inhibitor	TOP2A, TOP2B	cardiology	cardiomyopathy	C[C@@H](CN1CC(=O)NC(=O)C1)N1CC(=O)NC(=O)C1, C[C@@H](CN1CC(=O)NC(=O)C1)N1CC(=O)NC(=O)C1, C[C@@H](CN1CC(=O)NC(=O)C1)N1CC(=O)NC(=O)C1, C[C@@H](CN1CC(=O)NC(=O)C1)N1CC(=O)NC(=O)C1, C[C@@H](CN1CC(=O)NC(=O)C1)N1CC(=O)NC(=O)C1	BMKDZUISNHGIBY-ZETCQYMHSA-N, BMKDZUISNHGIBY-ZETCQYMHSA-N, BMKDZUISNHGIBY-ZETCQYMHSA-N, BMKDZUISNHGIBY-ZETCQYMHSA-N, BMKDZUISNHGIBY-ZETCQYMHSA-N	Launched
dextran			hematology, critical care	thrombosis, hypovolemia	OC[C@H]1O[C@H](OC[C@H]2O[C@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@@H](O)[C@@H]1O	FZWBNHMXJMCXLU-BLAUPYHCSA-N	Launched
dextromethorphan	glutamate receptor antagonist, sigma receptor agonist	CHRNA2, CHRNA3, CHRNA4, CHRNA7, CHRNB2, CHRNB4, CYBA, CYBB, GRIN3A, NCF1, NCF2, NCF4, OPRD1, OPRK1, OPRM1, PGRMC1, RAC1, RAC2, SIGMAR1, SLC6A2, SLC6A4	pulmonary	cough suppressant	COc1ccc2C[C@H]3[C@H]4CCCC[C@@]4(CCN3C)c2c1, COc1ccc2C[C@H]3[C@H]4CCCC[C@@]4(CCN3C)c2c1, COc1ccc2C[C@H]3[C@H]4CCCC[C@@]4(CCN3C)c2c1	MKXZASYAUGDDCJ-NJAFHUGGSA-N, MKXZASYAUGDDCJ-NJAFHUGGSA-N, MKXZASYAUGDDCJ-NJAFHUGGSA-N	Launched
dextrorotation-nimorazole-phosphate-ester	antiinfective drug				Cc1ncc(n1C[C@@H](CN1CCOCC1)OP(O)(O)=O)[N+]([O-])=O	CCDHHPOGWLYHAX-SNVBAGLBSA-N	Preclinical
dextrose			endocrinology	hypoglycemia	OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O, OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O, OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O	GZCGUPFRVQAUEE-SLPGGIOYSA-N, GZCGUPFRVQAUEE-SLPGGIOYSA-N, GZCGUPFRVQAUEE-SLPGGIOYSA-N	Launched
DFB	glutamate receptor agonist	GRM5			Fc1cccc(\C=N\N=C\c2cccc(F)c2)c1, Fc1cccc(\C=N\N=C\c2cccc(F)c2)c1, Fc1cccc(\C=N\N=C\c2cccc(F)c2)c1, Fc1cccc(\C=N\N=C\c2cccc(F)c2)c1	YYMCVDNIIFNDJK-BEQMOXJMSA-N, YYMCVDNIIFNDJK-BEQMOXJMSA-N, YYMCVDNIIFNDJK-BEQMOXJMSA-N, YYMCVDNIIFNDJK-BEQMOXJMSA-N	Preclinical
DG-172	PPAR receptor inverse agonist	PPARD			CN1CCN(CC1)c1ccc(\C=C(/C#N)c2ccccc2Br)cc1, CN1CCN(CC1)c1ccc(\C=C(/C#N)c2ccccc2Br)cc1	ZJMDTBBCNMGFMS-SAPNQHFASA-N, ZJMDTBBCNMGFMS-SAPNQHFASA-N	Preclinical
DG051	leukotriene synthesis inhibitor				OC(=O)CCCN1CCC[C@H]1COc1ccc(Oc2ccc(Cl)cc2)cc1	PVCTYSQBVIGZRU-KRWDZBQOSA-N	Preclinical
DH-97	melatonin receptor antagonist	MTNR1B			CCCCC(=O)NCCc1c(Cc2ccccc2)[nH]c2ccccc12, CCCCC(=O)NCCc1c(Cc2ccccc2)[nH]c2ccccc12, CCCCC(=O)NCCc1c(Cc2ccccc2)[nH]c2ccccc12	HDOIPCLEKCEANF-UHFFFAOYSA-N, HDOIPCLEKCEANF-UHFFFAOYSA-N, HDOIPCLEKCEANF-UHFFFAOYSA-N	Preclinical
DHBP	ryanodine receptor blocker				CCCCCCC[n+]1ccc(cc1)-c1cc[n+](CCCCCCC)cc1, CCCCCCC[n+]1ccc(cc1)-c1cc[n+](CCCCCCC)cc1	XJGZGUSMZSXHJI-UHFFFAOYSA-N, XJGZGUSMZSXHJI-UHFFFAOYSA-N	Preclinical
diacerein	interleukin inhibitor	IL1B	rheumatology	osteoarthritis	CC(=O)Oc1cccc2C(=O)c3cc(cc(OC(C)=O)c3C(=O)c12)C(O)=O, CC(=O)Oc1cccc2C(=O)c3cc(cc(OC(C)=O)c3C(=O)c12)C(O)=O, CC(=O)Oc1cccc2C(=O)c3cc(cc(OC(C)=O)c3C(=O)c12)C(O)=O, CC(=O)Oc1cccc2C(=O)c3cc(cc(OC(C)=O)c3C(=O)c12)C(O)=O, CC(=O)Oc1cccc2C(=O)c3cc(cc(OC(C)=O)c3C(=O)c12)C(O)=O	TYNLGDBUJLVSMA-UHFFFAOYSA-N, TYNLGDBUJLVSMA-UHFFFAOYSA-N, TYNLGDBUJLVSMA-UHFFFAOYSA-N, TYNLGDBUJLVSMA-UHFFFAOYSA-N, TYNLGDBUJLVSMA-UHFFFAOYSA-N	Launched
diacetamate					CC(=O)Nc1ccc(OC(C)=O)cc1, CC(=O)Nc1ccc(OC(C)=O)cc1	UJAOSPFULOFZRR-UHFFFAOYSA-N, UJAOSPFULOFZRR-UHFFFAOYSA-N	Preclinical
diadenosine-tetraphosphate	adenosine kinase inhibitor	P2RY13, P2RY2			Nc1ncnc2n(cnc12)[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@H](O)[C@@H]2O)n2cnc3c(N)ncnc23)[C@@H](O)[C@H]1O |a:10,12,32,34,35,37,49,51,&1:15,&2:19,&3:23,&4:27|	YOAHKNVSNCMZGQ-XPWFQUROSA-N	Phase 1
dianhydrogalactitol	DNA alkylating agent				O[C@@H]([C@@H](O)[C@H]1CO1)[C@@H]1CO1, O[C@@H]([C@@H](O)[C@H]1CO1)[C@@H]1CO1, O[C@@H]([C@@H](O)[C@H]1CO1)[C@@H]1CO1	AAFJXZWCNVJTMK-GUCUJZIJSA-N, AAFJXZWCNVJTMK-GUCUJZIJSA-N, AAFJXZWCNVJTMK-GUCUJZIJSA-N	Phase 3
diarylpropionitrile	estrogen receptor agonist	ESR2			Oc1ccc(C[C@@H](C#N)c2ccc(O)cc2)cc1 |&1:6,r|, Oc1ccc(C[C@@H](C#N)c2ccc(O)cc2)cc1 |&1:6,r|	GHZHWDWADLAOIQ-ZDUSSCGKSA-N, GHZHWDWADLAOIQ-ZDUSSCGKSA-N	Preclinical
diatrizoic-acid			radiology	contrast agent	CC(=O)Nc1c(I)c(NC(C)=O)c(I)c(C(O)=O)c1I, CC(=O)Nc1c(I)c(NC(C)=O)c(I)c(C(O)=O)c1I	YVPYQUNUQOZFHG-UHFFFAOYSA-N, YVPYQUNUQOZFHG-UHFFFAOYSA-N	Launched
diaveridine	dihydrofolate reductase inhibitor		infectious disease	coccidiosis	COc1ccc(Cc2cnc(N)nc2N)cc1OC, COc1ccc(Cc2cnc(N)nc2N)cc1OC, COc1ccc(Cc2cnc(N)nc2N)cc1OC	LDBTVAXGKYIFHO-UHFFFAOYSA-N, LDBTVAXGKYIFHO-UHFFFAOYSA-N, LDBTVAXGKYIFHO-UHFFFAOYSA-N	Launched
diazoxide	potassium channel activator	ATP1A1, CA1, CA2, KCNJ11, KCNJ8, KCNMA1, SLC12A3	endocrinology	hypoglycemia	CC1=Nc2ccc(Cl)cc2S(=O)(=O)N1 |t:1|, CC1=Nc2ccc(Cl)cc2S(=O)(=O)N1 |t:1|, CC1=Nc2ccc(Cl)cc2S(=O)(=O)N1 |t:1|, CC1=Nc2ccc(Cl)cc2S(=O)(=O)N1 |t:1|, CC1=Nc2ccc(Cl)cc2S(=O)(=O)N1 |t:1|	GDLBFKVLRPITMI-UHFFFAOYSA-N, GDLBFKVLRPITMI-UHFFFAOYSA-N, GDLBFKVLRPITMI-UHFFFAOYSA-N, GDLBFKVLRPITMI-UHFFFAOYSA-N, GDLBFKVLRPITMI-UHFFFAOYSA-N	Launched
dibekacin	bacterial 30S ribosomal subunit inhibitor		infectious disease	gram-negative bacterial infections	NC[C@@H]1CC[C@@H](N)[C@@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O)[C@H]2O)O1	JJCQSGDBDPYCEO-XVZSLQNASA-N	Launched
dibenzepine	norepinephrine reputake inhibitor				CN(C)CCN1c2ccccc2N(C)c2ccccc2C1=O, CN(C)CCN1c2ccccc2N(C)c2ccccc2C1=O	QPGGEKPRGVJKQB-UHFFFAOYSA-N, QPGGEKPRGVJKQB-UHFFFAOYSA-N	Preclinical
dibenzothiophene					c1ccc2c(c1)sc1ccccc21, c1ccc2c(c1)sc1ccccc21, c1ccc2c(c1)sc1ccccc21	IYYZUPMFVPLQIF-UHFFFAOYSA-N, IYYZUPMFVPLQIF-UHFFFAOYSA-N, IYYZUPMFVPLQIF-UHFFFAOYSA-N	Preclinical
dibutyl-phthalate		TRPA1			CCCCOC(=O)c1ccccc1C(=O)OCCCC, CCCCOC(=O)c1ccccc1C(=O)OCCCC	DOIRQSBPFJWKBE-UHFFFAOYSA-N, DOIRQSBPFJWKBE-UHFFFAOYSA-N	Preclinical
dichlorisone-acetate					CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](Cl)C[C@]12C |c:19,t:15|, CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](Cl)C[C@]12C |c:19,t:15|, CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](Cl)C[C@]12C |c:19,t:15|, CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](Cl)C[C@]12C |c:19,t:15|	YNNURTVKPVJVEI-GSLJADNHSA-N, YNNURTVKPVJVEI-GSLJADNHSA-N, YNNURTVKPVJVEI-GSLJADNHSA-N, YNNURTVKPVJVEI-GSLJADNHSA-N	Phase 2
dichloroacetate	pyruvate dehydrogenase kinase inhibitor				[Na].OC(=O)C(Cl)Cl, [Na].OC(=O)C(Cl)Cl, [Na].OC(=O)C(Cl)Cl	FLWQSOHPGISTPX-UHFFFAOYSA-N, FLWQSOHPGISTPX-UHFFFAOYSA-N, FLWQSOHPGISTPX-UHFFFAOYSA-N	Phase 3
dichlorophen	anticestodal agent		infectious disease	hookworm, tapeworm	Oc1ccc(Cl)cc1Cc1cc(Cl)ccc1O, Oc1ccc(Cl)cc1Cc1cc(Cl)ccc1O, Oc1ccc(Cl)cc1Cc1cc(Cl)ccc1O, Oc1ccc(Cl)cc1Cc1cc(Cl)ccc1O, Oc1ccc(Cl)cc1Cc1cc(Cl)ccc1O, Oc1ccc(Cl)cc1Cc1cc(Cl)ccc1O, Oc1ccc(Cl)cc1Cc1cc(Cl)ccc1O	MDNWOSOZYLHTCG-UHFFFAOYSA-N, MDNWOSOZYLHTCG-UHFFFAOYSA-N, MDNWOSOZYLHTCG-UHFFFAOYSA-N, MDNWOSOZYLHTCG-UHFFFAOYSA-N, MDNWOSOZYLHTCG-UHFFFAOYSA-N, MDNWOSOZYLHTCG-UHFFFAOYSA-N, MDNWOSOZYLHTCG-UHFFFAOYSA-N	Launched
dichlorvos	acetylcholinesterase inhibitor				COP(=O)(OC)OC=C(Cl)Cl, COP(=O)(OC)OC=C(Cl)Cl	OEBRKCOSUFCWJD-UHFFFAOYSA-N, OEBRKCOSUFCWJD-UHFFFAOYSA-N	Launched
diclazuril	antiprotozoal agent		infectious disease	equine protozoal myeloencephalitis (EPM)	Clc1ccc(cc1)[C@@H](C#N)c1c(Cl)cc(cc1Cl)-n1ncc(=O)[nH]c1=O |&1:7,r|, Clc1ccc(cc1)[C@@H](C#N)c1c(Cl)cc(cc1Cl)-n1ncc(=O)[nH]c1=O |&1:7,r|, Clc1ccc(cc1)[C@@H](C#N)c1c(Cl)cc(cc1Cl)-n1ncc(=O)[nH]c1=O |&1:7,r|, Clc1ccc(cc1)[C@@H](C#N)c1c(Cl)cc(cc1Cl)-n1ncc(=O)[nH]c1=O |&1:7,r|	ZSZFUDFOPOMEET-GFCCVEGCSA-N, ZSZFUDFOPOMEET-GFCCVEGCSA-N, ZSZFUDFOPOMEET-GFCCVEGCSA-N, ZSZFUDFOPOMEET-GFCCVEGCSA-N	Launched
diclofenac	cyclooxygenase inhibitor	AKR1C3, ALOX5, ASIC1, ASIC3, KCNQ2, KCNQ3, PLA2G2A, PPARG, PTGS1, PTGS2, SCN4A	rheumatology, neurology/psychiatry	rheumatoid arthritis, osteoarthritis, migraine headache	OC(=O)Cc1ccccc1Nc1c(Cl)cccc1Cl, OC(=O)Cc1ccccc1Nc1c(Cl)cccc1Cl, OC(=O)Cc1ccccc1Nc1c(Cl)cccc1Cl, OC(=O)Cc1ccccc1Nc1c(Cl)cccc1Cl	DCOPUUMXTXDBNB-UHFFFAOYSA-N, DCOPUUMXTXDBNB-UHFFFAOYSA-N, DCOPUUMXTXDBNB-UHFFFAOYSA-N, DCOPUUMXTXDBNB-UHFFFAOYSA-N	Launched
diclofenamide	carbonic anhydrase inhibitor	CA1, CA12, CA2, CA4, CA7	ophthalmology, neurology/psychiatry	glaucoma, epilepsy	NS(=O)(=O)c1cc(Cl)c(Cl)c(c1)S(N)(=O)=O, NS(=O)(=O)c1cc(Cl)c(Cl)c(c1)S(N)(=O)=O	GJQPMPFPNINLKP-UHFFFAOYSA-N, GJQPMPFPNINLKP-UHFFFAOYSA-N	Launched
diclofensine	dopamine reuptake inhibitor	DRD1, MAOA, MAOB			COc1ccc2[C@@H](CN(C)Cc2c1)c1ccc(Cl)c(Cl)c1 |&1:6|, COc1ccc2[C@@H](CN(C)Cc2c1)c1ccc(Cl)c(Cl)c1 |&1:6|	ZJDCGVDEEHWEIG-HNNXBMFYSA-N, ZJDCGVDEEHWEIG-HNNXBMFYSA-N	Phase 3
dicloralurea					O[C@@H](NC(=O)N[C@@H](O)C(Cl)(Cl)Cl)C(Cl)(Cl)Cl |&1:1,&2:6,r|, O[C@@H](NC(=O)N[C@@H](O)C(Cl)(Cl)Cl)C(Cl)(Cl)Cl |&1:1,&2:6,r|	PPJXIHLNYDVTDI-XIXRPRMCSA-N, PPJXIHLNYDVTDI-XIXRPRMCSA-N	Preclinical
dicloxacillin	bacterial cell wall synthesis inhibitor		infectious disease	gram-positive bacterial infections	Cc1onc(c1C(=O)N[C@H]1[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O)-c1c(Cl)cccc1Cl, Cc1onc(c1C(=O)N[C@H]1[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O)-c1c(Cl)cccc1Cl, Cc1onc(c1C(=O)N[C@H]1[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O)-c1c(Cl)cccc1Cl, Cc1onc(c1C(=O)N[C@H]1[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O)-c1c(Cl)cccc1Cl	YFAGHNZHGGCZAX-JKIFEVAISA-N, YFAGHNZHGGCZAX-JKIFEVAISA-N, YFAGHNZHGGCZAX-JKIFEVAISA-N, YFAGHNZHGGCZAX-JKIFEVAISA-N	Launched
dicoumarol	NADPH inhibitor	CRYZ, NQO1, VKORC1	hematology	deep vein thrombosis (DVT)	Oc1c(Cc2c(O)c3ccccc3oc2=O)c(=O)oc2ccccc12, Oc1c(Cc2c(O)c3ccccc3oc2=O)c(=O)oc2ccccc12	DOBMPNYZJYQDGZ-UHFFFAOYSA-N, DOBMPNYZJYQDGZ-UHFFFAOYSA-N	Launched
dicyclohexylamine					C1CCC(CC1)NC1CCCCC1, C1CCC(CC1)NC1CCCCC1	XBPCUCUWBYBCDP-UHFFFAOYSA-N, XBPCUCUWBYBCDP-UHFFFAOYSA-N	Preclinical
dicycloverine	acetylcholine receptor antagonist	CHRM1, CHRM2, CHRM3	gastroenterology	irritable bowel syndrome	CCN(CC)CCOC(=O)C1(CCCCC1)C1CCCCC1, CCN(CC)CCOC(=O)C1(CCCCC1)C1CCCCC1, CCN(CC)CCOC(=O)C1(CCCCC1)C1CCCCC1	CURUTKGFNZGFSE-UHFFFAOYSA-N, CURUTKGFNZGFSE-UHFFFAOYSA-N, CURUTKGFNZGFSE-UHFFFAOYSA-N	Launched
didanosine	nucleoside reverse transcriptase inhibitor	PNP	infectious disease	human immunodeficiency virus (HIV-1)	OC[C@@H]1CC[C@@H](O1)n1cnc2c1[nH]cnc2=O, OC[C@@H]1CC[C@@H](O1)n1cnc2c1[nH]cnc2=O, OC[C@@H]1CC[C@@H](O1)n1cnc2c1[nH]cnc2=O, OC[C@@H]1CC[C@@H](O1)n1cnc2c1[nH]cnc2=O, OC[C@@H]1CC[C@@H](O1)n1cnc2c1[nH]cnc2=O, OC[C@@H]1CC[C@@H](O1)n1cnc2c1[nH]cnc2=O	BXZVVICBKDXVGW-NKWVEPMBSA-N, BXZVVICBKDXVGW-NKWVEPMBSA-N, BXZVVICBKDXVGW-NKWVEPMBSA-N, BXZVVICBKDXVGW-NKWVEPMBSA-N, BXZVVICBKDXVGW-NKWVEPMBSA-N, BXZVVICBKDXVGW-NKWVEPMBSA-N	Launched
dideoxyadenosine	nucleoside reverse transcriptase inhibitor				Nc1ncnc2n(cnc12)[C@H]1CC[C@@H](CO)O1, Nc1ncnc2n(cnc12)[C@H]1CC[C@@H](CO)O1	WVXRAFOPTSTNLL-NKWVEPMBSA-N, WVXRAFOPTSTNLL-NKWVEPMBSA-N	Phase 1
didox	ribonucleotide reductase inhibitor	RRM1	oncology	breast cancer	ONC(=O)c1ccc(O)c(O)c1	QJMCKEPOKRERLN-UHFFFAOYSA-N	Launched
dienestrol	estrogen receptor agonist	ESR1	endocrinology	menopause	C\C=C(\C(=C\C)\c1ccc(O)cc1)/c1ccc(O)cc1, C\C=C(\C(=C\C)\c1ccc(O)cc1)/c1ccc(O)cc1, C\C=C(\C(=C\C)\c1ccc(O)cc1)/c1ccc(O)cc1, C\C=C(\C(=C\C)\c1ccc(O)cc1)/c1ccc(O)cc1	NFDFQCUYFHCNBW-SCGPFSFSSA-N, NFDFQCUYFHCNBW-SCGPFSFSSA-N, NFDFQCUYFHCNBW-SCGPFSFSSA-N, NFDFQCUYFHCNBW-SCGPFSFSSA-N	Launched
dienogest	progesterone receptor agonist	PGR	endocrinology, obstetrics/gynecology	contraceptive, endometriosis	C[C@]12CCC3=C4CCC(=O)C=C4CC[C@H]3[C@@H]1CC[C@@]2(O)CC#N |c:4,10|, C[C@]12CCC3=C4CCC(=O)C=C4CC[C@H]3[C@@H]1CC[C@@]2(O)CC#N |c:4,10|, C[C@]12CCC3=C4CCC(=O)C=C4CC[C@H]3[C@@H]1CC[C@@]2(O)CC#N |c:4,10|	AZFLJNIPTRTECV-FUMNGEBKSA-N, AZFLJNIPTRTECV-FUMNGEBKSA-N, AZFLJNIPTRTECV-FUMNGEBKSA-N	Launched
diethylcarbamazine	lipoxygenase inhibitor	ALOX5, PTGS1	infectious disease	filariasis	CCN(CC)C(=O)N1CCN(C)CC1, CCN(CC)C(=O)N1CCN(C)CC1, CCN(CC)C(=O)N1CCN(C)CC1	RCKMWOKWVGPNJF-UHFFFAOYSA-N, RCKMWOKWVGPNJF-UHFFFAOYSA-N, RCKMWOKWVGPNJF-UHFFFAOYSA-N	Launched
diethylstilbestrol	estrogen receptor agonist	ESR1, ESR2, ESRRB, ESRRG			CC\C(=C(\CC)c1ccc(O)cc1)c1ccc(O)cc1, CC\C(=C(\CC)c1ccc(O)cc1)c1ccc(O)cc1, CC\C(=C(\CC)c1ccc(O)cc1)c1ccc(O)cc1	RGLYKWWBQGJZGM-ISLYRVAYSA-N, RGLYKWWBQGJZGM-ISLYRVAYSA-N, RGLYKWWBQGJZGM-ISLYRVAYSA-N	Withdrawn
diethyltoluamide	ionotropic receptor IR40a activator		dermatology	sunscreen lotion	CCN(CC)C(=O)c1cccc(C)c1, CCN(CC)C(=O)c1cccc(C)c1, CCN(CC)C(=O)c1cccc(C)c1	MMOXZBCLCQITDF-UHFFFAOYSA-N, MMOXZBCLCQITDF-UHFFFAOYSA-N, MMOXZBCLCQITDF-UHFFFAOYSA-N	Launched
difenpiramide	cyclooxygenase inhibitor, prostaglandin inhibitor		neurology/psychiatry	pain relief	O=C(Cc1ccc(cc1)-c1ccccc1)Nc1ccccn1	PWHROYKAGRUWDQ-UHFFFAOYSA-N	Launched
diflorasone-diacetate	glucocorticoid receptor agonist	NR3C1	dermatology	corticosteroid-responsive dermatoses			Launched
difloxacin	bacterial DNA gyrase inhibitor		infectious disease	skin infections, urinary tract infections	CN1CCN(CC1)c1cc2n(cc(C(O)=O)c(=O)c2cc1F)-c1ccc(F)cc1, CN1CCN(CC1)c1cc2n(cc(C(O)=O)c(=O)c2cc1F)-c1ccc(F)cc1, CN1CCN(CC1)c1cc2n(cc(C(O)=O)c(=O)c2cc1F)-c1ccc(F)cc1	NOCJXYPHIIZEHN-UHFFFAOYSA-N, NOCJXYPHIIZEHN-UHFFFAOYSA-N, NOCJXYPHIIZEHN-UHFFFAOYSA-N	Launched
diflunisal	prostanoid receptor antagonist	PTGS1, PTGS2	rheumatology	rheumatoid arthritis, osteoarthritis	OC(=O)c1cc(ccc1O)-c1ccc(F)cc1F	HUPFGZXOMWLGNK-UHFFFAOYSA-N	Launched
difluprednate	glucocorticoid receptor agonist	NR3C1	ophthalmology	endogenous uveitis	CCCC(=O)O[C@@]1(CC[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)COC(C)=O |c:18,t:14|	WYQPLTPSGFELIB-JTQPXKBDSA-N	Launched
diftalone	cyclooxygenase inhibitor		endocrinology	thyroiditis	O=C1N2Cc3ccccc3C(=O)N2Cc2ccccc12, O=C1N2Cc3ccccc3C(=O)N2Cc2ccccc12	CXSJGNHRBWJXEA-UHFFFAOYSA-N, CXSJGNHRBWJXEA-UHFFFAOYSA-N	Launched
digitoxigenin	ATPase inhibitor	ATP1A1			C[C@]12CC[C@H]3[C@@H](CC[C@@H]4C[C@@H](O)CC[C@]34C)[C@@]1(O)CC[C@@H]2C1=CC(=O)OC1 |t:25|, C[C@]12CC[C@H]3[C@@H](CC[C@@H]4C[C@@H](O)CC[C@]34C)[C@@]1(O)CC[C@@H]2C1=CC(=O)OC1 |t:25|, C[C@]12CC[C@H]3[C@@H](CC[C@@H]4C[C@@H](O)CC[C@]34C)[C@@]1(O)CC[C@@H]2C1=CC(=O)OC1 |t:25|, C[C@]12CC[C@H]3[C@@H](CC[C@@H]4C[C@@H](O)CC[C@]34C)[C@@]1(O)CC[C@@H]2C1=CC(=O)OC1 |t:25|, C[C@]12CC[C@H]3[C@@H](CC[C@@H]4C[C@@H](O)CC[C@]34C)[C@@]1(O)CC[C@@H]2C1=CC(=O)OC1 |t:25|	XZTUSOXSLKTKJQ-CESUGQOBSA-N, XZTUSOXSLKTKJQ-CESUGQOBSA-N, XZTUSOXSLKTKJQ-CESUGQOBSA-N, XZTUSOXSLKTKJQ-CESUGQOBSA-N, XZTUSOXSLKTKJQ-CESUGQOBSA-N	Preclinical
digitoxin	ATPase inhibitor	ATP1A1, ATP1A2, ATP1A3, ATP1A4, ATP1B1, ATP1B2, ATP1B3, FXYD2	cardiology	congestive heart failure, cardiac arrythmia	C[C@H]1O[C@H](C[C@H](O)[C@@H]1O)O[C@H]1[C@@H](O)C[C@H](O[C@H]2[C@@H](O)C[C@H](O[C@H]3CC[C@@]4(C)[C@H](CC[C@@H]5[C@@H]4CC[C@]4(C)[C@H](CC[C@]54O)C4=CC(=O)OC4)C3)O[C@@H]2C)O[C@@H]1C |t:45|, C[C@H]1O[C@H](C[C@H](O)[C@@H]1O)O[C@H]1[C@@H](O)C[C@H](O[C@H]2[C@@H](O)C[C@H](O[C@H]3CC[C@@]4(C)[C@H](CC[C@@H]5[C@@H]4CC[C@]4(C)[C@H](CC[C@]54O)C4=CC(=O)OC4)C3)O[C@@H]2C)O[C@@H]1C |t:45|	WDJUZGPOPHTGOT-XUDUSOBPSA-N, WDJUZGPOPHTGOT-XUDUSOBPSA-N	Launched
digoxigenin	steroid				C[C@@]12[C@H](CC[C@]1(O)[C@@H]1CC[C@@H]3C[C@@H](O)CC[C@]3(C)[C@H]1C[C@H]2O)C1=CC(=O)OC1 |t:26|, C[C@@]12[C@H](CC[C@]1(O)[C@@H]1CC[C@@H]3C[C@@H](O)CC[C@]3(C)[C@H]1C[C@H]2O)C1=CC(=O)OC1 |t:26|, C[C@@]12[C@H](CC[C@]1(O)[C@@H]1CC[C@@H]3C[C@@H](O)CC[C@]3(C)[C@H]1C[C@H]2O)C1=CC(=O)OC1 |t:26|	SHIBSTMRCDJXLN-KCZCNTNESA-N, SHIBSTMRCDJXLN-KCZCNTNESA-N, SHIBSTMRCDJXLN-KCZCNTNESA-N	Preclinical
digoxin	ATPase inhibitor	ATP1A1	cardiology	congestive heart failure, atrial fibrillation (AF)	[H][C@@]1(C[C@H](O)[C@H](O[C@@]2([H])C[C@H](O)[C@H](O[C@@]3([H])C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1)O[C@H]1CC[C@@]2(C)[C@]([H])(CC[C@]3([H])[C@]2([H])C[C@@H](O)[C@@]2(C)[C@H](CC[C@]32O)C2=CC(=O)OC2)C1 |t:60|, [H][C@@]1(C[C@H](O)[C@H](O[C@@]2([H])C[C@H](O)[C@H](O[C@@]3([H])C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1)O[C@H]1CC[C@@]2(C)[C@]([H])(CC[C@]3([H])[C@]2([H])C[C@@H](O)[C@@]2(C)[C@H](CC[C@]32O)C2=CC(=O)OC2)C1 |t:60|	LTMHDMANZUZIPE-SYUUTQQWSA-N, LTMHDMANZUZIPE-SYUUTQQWSA-N	Launched
dihomo-gamma-linolenic-acid	prostanoid receptor agonist	PTGS1, PTGS2			CCCCC\C=C/C\C=C/C\C=C/CCCCCCC(O)=O, CCCCC\C=C/C\C=C/C\C=C/CCCCCCC(O)=O, CCCCC\C=C/C\C=C/C\C=C/CCCCCCC(O)=O	HOBAELRKJCKHQD-QNEBEIHSSA-N, HOBAELRKJCKHQD-QNEBEIHSSA-N, HOBAELRKJCKHQD-QNEBEIHSSA-N	Phase 2
dihydrexidine	dopamine receptor agonist	DRD1, DRD2, DRD3, DRD4, DRD5			Oc1cc2CC[C@H]3NCc4ccccc4[C@@H]3c2cc1O, Oc1cc2CC[C@H]3NCc4ccccc4[C@@H]3c2cc1O, Oc1cc2CC[C@H]3NCc4ccccc4[C@@H]3c2cc1O, Oc1cc2CC[C@H]3NCc4ccccc4[C@@H]3c2cc1O	BGOQGUHWXBGXJW-RHSMWYFYSA-N, BGOQGUHWXBGXJW-RHSMWYFYSA-N, BGOQGUHWXBGXJW-RHSMWYFYSA-N, BGOQGUHWXBGXJW-RHSMWYFYSA-N	Phase 2
dihydroartemisinin	antimalarial agent		infectious disease	malaria	C[C@@H]1CC[C@H]2[C@@H](C)[C@@H](O)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@@]23OO4, C[C@@H]1CC[C@H]2[C@@H](C)[C@@H](O)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@@]23OO4, C[C@@H]1CC[C@H]2[C@@H](C)[C@@H](O)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@@]23OO4, C[C@@H]1CC[C@H]2[C@@H](C)[C@@H](O)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@@]23OO4	BJDCWCLMFKKGEE-ISOSDAIHSA-N, BJDCWCLMFKKGEE-ISOSDAIHSA-N, BJDCWCLMFKKGEE-ISOSDAIHSA-N, BJDCWCLMFKKGEE-ISOSDAIHSA-N	Launched
dihydroergocristine	adrenergic receptor antagonist, prolactin inhibitor	ADRA1A, ADRB1, DRD1, DRD2, DRD3, DRD4, DRD5, HTR1A, HTR2A, HTR3A, HTR4, HTR5A, HTR6, HTR7	neurology/psychiatry	senile dementia, cerebrovascular insufficiency	CC(C)[C@@]1(NC(=O)[C@@H]2C[C@H]3[C@@H](Cc4c[nH]c5cccc3c45)N(C)C2)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](Cc3ccccc3)N2C1=O, CC(C)[C@@]1(NC(=O)[C@@H]2C[C@H]3[C@@H](Cc4c[nH]c5cccc3c45)N(C)C2)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](Cc3ccccc3)N2C1=O, CC(C)[C@@]1(NC(=O)[C@@H]2C[C@H]3[C@@H](Cc4c[nH]c5cccc3c45)N(C)C2)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](Cc3ccccc3)N2C1=O, CC(C)[C@@]1(NC(=O)[C@@H]2C[C@H]3[C@@H](Cc4c[nH]c5cccc3c45)N(C)C2)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](Cc3ccccc3)N2C1=O, CC(C)[C@@]1(NC(=O)[C@@H]2C[C@H]3[C@@H](Cc4c[nH]c5cccc3c45)N(C)C2)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](Cc3ccccc3)N2C1=O, CC(C)[C@@]1(NC(=O)[C@@H]2C[C@H]3[C@@H](Cc4c[nH]c5cccc3c45)N(C)C2)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](Cc3ccccc3)N2C1=O, CC(C)[C@@]1(NC(=O)[C@@H]2C[C@H]3[C@@H](Cc4c[nH]c5cccc3c45)N(C)C2)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](Cc3ccccc3)N2C1=O	DEQITUUQPICUMR-HJPBWRTMSA-N, DEQITUUQPICUMR-HJPBWRTMSA-N, DEQITUUQPICUMR-HJPBWRTMSA-N, DEQITUUQPICUMR-HJPBWRTMSA-N, DEQITUUQPICUMR-HJPBWRTMSA-N, DEQITUUQPICUMR-HJPBWRTMSA-N, DEQITUUQPICUMR-HJPBWRTMSA-N	Launched
dihydroergotamine	serotonin receptor agonist	ADRA2A, DRD2, HTR1B, HTR1D, HTR1E, HTR1F, HTR2B, HTR7	neurology/psychiatry	migraine headache	CN1C[C@@H](C[C@H]2[C@H]1Cc1c[nH]c3cccc2c13)C(=O)N[C@]1(C)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](Cc3ccccc3)N2C1=O, CN1C[C@@H](C[C@H]2[C@H]1Cc1c[nH]c3cccc2c13)C(=O)N[C@]1(C)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](Cc3ccccc3)N2C1=O, CN1C[C@@H](C[C@H]2[C@H]1Cc1c[nH]c3cccc2c13)C(=O)N[C@]1(C)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](Cc3ccccc3)N2C1=O, CN1C[C@@H](C[C@H]2[C@H]1Cc1c[nH]c3cccc2c13)C(=O)N[C@]1(C)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](Cc3ccccc3)N2C1=O	LUZRJRNZXALNLM-JGRZULCMSA-N, LUZRJRNZXALNLM-JGRZULCMSA-N, LUZRJRNZXALNLM-JGRZULCMSA-N, LUZRJRNZXALNLM-JGRZULCMSA-N	Launched
dihydromyricetin					O[C@@H]1[C@H](Oc2cc(O)cc(O)c2C1=O)c1cc(O)c(O)c(O)c1, O[C@@H]1[C@H](Oc2cc(O)cc(O)c2C1=O)c1cc(O)c(O)c(O)c1, O[C@@H]1[C@H](Oc2cc(O)cc(O)c2C1=O)c1cc(O)c(O)c(O)c1, O[C@@H]1[C@H](Oc2cc(O)cc(O)c2C1=O)c1cc(O)c(O)c(O)c1	KJXSIXMJHKAJOD-LSDHHAIUSA-N, KJXSIXMJHKAJOD-LSDHHAIUSA-N, KJXSIXMJHKAJOD-LSDHHAIUSA-N, KJXSIXMJHKAJOD-LSDHHAIUSA-N	Preclinical
dihydrostreptomycin	bacterial 30S ribosomal subunit inhibitor				CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@H]1[C@H](O[C@@H]2[C@@H](O)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]2NC(N)=N)O[C@@H](C)[C@]1(O)CO.CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@H]1[C@H](O[C@@H]2[C@@H](O)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]2NC(N)=N)O[C@@H](C)[C@]1(O)CO	DLNWBHHJUACHNB-SNGKZNBCSA-N	Withdrawn
dihydrotachysterol	vitamin analog	VDR	orthopedics, endocrinology	rickets, hypocalcemia, osteomalacia	CC(C)[C@@H](C)\C=C\[C@@H](C)[C@H]1CC[C@@H]2\C(CCC[C@@]12C)=C\C=C1/C[C@@H](O)CC[C@@H]1C |&1:3,&2:7,&3:9,&4:12,&5:17,&6:23,&7:27,r|	ILYCWAKSDCYMBB-CEQNRCNESA-N	Launched
dihydroxyacetone			dermatology	skin protectant	OCC(=O)CO	RXKJFZQQPQGTFL-UHFFFAOYSA-N	Launched
dihydroxyphenylglycine	glutamate receptor agonist	GRM1, GRM5			N[C@@H](C(O)=O)c1cc(O)cc(O)c1 |&1:1,r|, N[C@@H](C(O)=O)c1cc(O)cc(O)c1 |&1:1,r|	HOOWCUZPEFNHDT-SSDOTTSWSA-N, HOOWCUZPEFNHDT-SSDOTTSWSA-N	Preclinical
diiodothyropropionic-acid	thyroid hormone stimulant				OC(=O)CCc1cc(I)c(Oc2ccc(O)cc2)c(I)c1	WONYMNWUJVKVII-UHFFFAOYSA-N	Phase 2
dilazep	adenosine reuptake inhibitor	SLC29A1	cardiology	coronary heart disease	COc1cc(cc(OC)c1OC)C(=O)OCCCN1CCCN(CCCOC(=O)c2cc(OC)c(OC)c(OC)c2)CC1, COc1cc(cc(OC)c1OC)C(=O)OCCCN1CCCN(CCCOC(=O)c2cc(OC)c(OC)c(OC)c2)CC1	QVZCXCJXTMIDME-UHFFFAOYSA-N, QVZCXCJXTMIDME-UHFFFAOYSA-N	Launched
dilmapimod	p38 MAPK inhibitor				Cc1cc(F)ccc1-c1nc(NC(CO)CO)nc2n(-c3c(F)cccc3F)c(=O)ccc12	ORVNHOYNEHYKJG-UHFFFAOYSA-N	Phase 1
diloxanide	protein synthesis inhibitor		infectious disease	amebiasis	CN(C(=O)C(Cl)Cl)c1ccc(OC(=O)c2ccco2)cc1	BDYYDXJSHYEDGB-UHFFFAOYSA-N	Launched
diltiazem	calcium channel blocker	CACNA1C, CACNA1S, CACNA2D1, CACNG1, HTR3A, KCNA5	cardiology	hypertension, angina pectoris	COc1ccc(cc1)[C@@H]1Sc2ccccc2N(CCN(C)C)C(=O)[C@@H]1OC(C)=O, COc1ccc(cc1)[C@@H]1Sc2ccccc2N(CCN(C)C)C(=O)[C@@H]1OC(C)=O, COc1ccc(cc1)[C@@H]1Sc2ccccc2N(CCN(C)C)C(=O)[C@@H]1OC(C)=O, COc1ccc(cc1)[C@@H]1Sc2ccccc2N(CCN(C)C)C(=O)[C@@H]1OC(C)=O, COc1ccc(cc1)[C@@H]1Sc2ccccc2N(CCN(C)C)C(=O)[C@@H]1OC(C)=O, COc1ccc(cc1)[C@@H]1Sc2ccccc2N(CCN(C)C)C(=O)[C@@H]1OC(C)=O	HSUGRBWQSSZJOP-RTWAWAEBSA-N, HSUGRBWQSSZJOP-RTWAWAEBSA-N, HSUGRBWQSSZJOP-RTWAWAEBSA-N, HSUGRBWQSSZJOP-RTWAWAEBSA-N, HSUGRBWQSSZJOP-RTWAWAEBSA-N, HSUGRBWQSSZJOP-RTWAWAEBSA-N	Launched
DIM-C-pPhCO2Me	nuclear receptor antagonist				COC(=O)c1ccc(cc1)C(c1c[nH]c2ccccc12)c1c[nH]c2ccccc12	BBAOKSZCULLDIW-UHFFFAOYSA-N	Preclinical
dimaprit	histamine receptor agonist	HRH2, HRH3, HRH4			CN(C)CCCSC(N)=N, CN(C)CCCSC(N)=N, CN(C)CCCSC(N)=N, CN(C)CCCSC(N)=N	OLHQOJYVQUNWPL-UHFFFAOYSA-N, OLHQOJYVQUNWPL-UHFFFAOYSA-N, OLHQOJYVQUNWPL-UHFFFAOYSA-N, OLHQOJYVQUNWPL-UHFFFAOYSA-N	Preclinical
dimemorfan	sigma receptor agonist	SIGMAR1	pulmonary	cough suppressant	CN1CC[C@@]23CCCC[C@@H]2[C@@H]1Cc1ccc(C)cc31, CN1CC[C@@]23CCCC[C@@H]2[C@@H]1Cc1ccc(C)cc31, CN1CC[C@@]23CCCC[C@@H]2[C@@H]1Cc1ccc(C)cc31	KBEZZLAAKIIPFK-NJAFHUGGSA-N, KBEZZLAAKIIPFK-NJAFHUGGSA-N, KBEZZLAAKIIPFK-NJAFHUGGSA-N	Launched
dimenhydrinate	histamine receptor antagonist	HRH1	neurology/psychiatry, gastroenterology	motion sickness, nausea, vomiting			Launched
dimercaprol	chelating agent		neurology/psychiatry	metal toxicity	OC[C@@H](S)CS |&1:2,r|, OC[C@@H](S)CS |&1:2,r|	WQABCVAJNWAXTE-GSVOUGTGSA-N, WQABCVAJNWAXTE-GSVOUGTGSA-N	Launched
dimercaptosuccinic-acid	chelating agent	DNMT1	neurology/psychiatry	metal toxicity	OC(=O)[C@@H](S)[C@@H](S)C(O)=O, OC(=O)[C@@H](S)[C@@H](S)C(O)=O, OC(=O)[C@@H](S)[C@@H](S)C(O)=O, OC(=O)[C@@H](S)[C@@H](S)C(O)=O	ACTRVOBWPAIOHC-XIXRPRMCSA-N, ACTRVOBWPAIOHC-XIXRPRMCSA-N, ACTRVOBWPAIOHC-XIXRPRMCSA-N, ACTRVOBWPAIOHC-XIXRPRMCSA-N	Launched
dimesna	tubulin polymerization inhibitor				OS(=O)(=O)CCSSCCS(O)(=O)=O, OS(=O)(=O)CCSSCCS(O)(=O)=O, OS(=O)(=O)CCSSCCS(O)(=O)=O	BYUKOOOZTSTOOH-UHFFFAOYSA-N, BYUKOOOZTSTOOH-UHFFFAOYSA-N, BYUKOOOZTSTOOH-UHFFFAOYSA-N	Phase 3
dimethadione	oxazolidine antiepileptic				CC1(C)OC(=O)NC1=O	JYJFNDQBESEHJQ-UHFFFAOYSA-N	Preclinical
dimethicone			dermatology	cosmetic	C[Si](C)(C)O[Si](C)(C)C	UQEAIHBTYFGYIE-UHFFFAOYSA-N	Launched
dimethindene-(S)-(+)	acetylcholine receptor antagonist	HRH1			C[C@@H](C1=C(CCN(C)C)Cc2ccccc12)c1ccccn1 |c:2|, C[C@@H](C1=C(CCN(C)C)Cc2ccccc12)c1ccccn1 |c:2|, C[C@@H](C1=C(CCN(C)C)Cc2ccccc12)c1ccccn1 |c:2|, C[C@@H](C1=C(CCN(C)C)Cc2ccccc12)c1ccccn1 |c:2|, C[C@@H](C1=C(CCN(C)C)Cc2ccccc12)c1ccccn1 |c:2|	MVMQESMQSYOVGV-OAHLLOKOSA-N, MVMQESMQSYOVGV-OAHLLOKOSA-N, MVMQESMQSYOVGV-OAHLLOKOSA-N, MVMQESMQSYOVGV-OAHLLOKOSA-N, MVMQESMQSYOVGV-OAHLLOKOSA-N	Preclinical
dimethisoquin	local anesthetic		neurology/psychiatry	local anesthetic	CCCCc1cc2ccccc2c(OCCN(C)C)n1, CCCCc1cc2ccccc2c(OCCN(C)C)n1	XNMYNYSCEJBRPZ-UHFFFAOYSA-N, XNMYNYSCEJBRPZ-UHFFFAOYSA-N	Launched
dimethyl-fumarate	nuclear factor erythroid derived, like (NRF2) activator	KEAP1	neurology/psychiatry	multiple sclerosis	COC(=O)\C=C\C(=O)OC, COC(=O)\C=C\C(=O)OC, COC(=O)\C=C\C(=O)OC, COC(=O)\C=C\C(=O)OC, COC(=O)\C=C\C(=O)OC	LDCRTTXIJACKKU-ONEGZZNKSA-N, LDCRTTXIJACKKU-ONEGZZNKSA-N, LDCRTTXIJACKKU-ONEGZZNKSA-N, LDCRTTXIJACKKU-ONEGZZNKSA-N, LDCRTTXIJACKKU-ONEGZZNKSA-N	Launched
dimethyl-isosorbide	cosmetic moisturizer				CO[C@@H]1CO[C@H]2[C@H](CO[C@@H]12)OC |&1:6,&2:9,&3:2,&4:5,r|	MEJYDZQQVZJMPP-YWIQKCBGSA-N	Preclinical
dimetindene	cholinergic receptor antagonist, histamine receptor antagonist	HRH1	allergy	allergic rhinitis	C[C@@H](C1=C(CCN(C)C)Cc2ccccc12)c1ccccn1 |&1:1,r,c:2|	MVMQESMQSYOVGV-OAHLLOKOSA-N	Launched
dimetridazole	bacterial DNA inhibitor		infectious disease	protozoan infection	Cc1ncc(n1C)[N+]([O-])=O	IBXPYPUJPLLOIN-UHFFFAOYSA-N	Launched
diminazene-aceturate	angiotensin converting enzyme activator	AOC1, PRDX5, PRSS1			NC(=N)c1ccc(N\N=N\c2ccc(cc2)C(N)=N)cc1, NC(=N)c1ccc(N\N=N\c2ccc(cc2)C(N)=N)cc1, NC(=N)c1ccc(N\N=N\c2ccc(cc2)C(N)=N)cc1, NC(=N)c1ccc(N\N=N\c2ccc(cc2)C(N)=N)cc1	XNYZHCFCZNMTFY-UHFFFAOYSA-N, XNYZHCFCZNMTFY-UHFFFAOYSA-N, XNYZHCFCZNMTFY-UHFFFAOYSA-N, XNYZHCFCZNMTFY-UHFFFAOYSA-N	Phase 3
dimpylate	acetylcholinesterase inhibitor	ACHE	infectious disease	flea control	CCOP(=S)(OCC)Oc1cc(C)nc(n1)C(C)C, CCOP(=S)(OCC)Oc1cc(C)nc(n1)C(C)C, CCOP(=S)(OCC)Oc1cc(C)nc(n1)C(C)C	FHIVAFMUCKRCQO-UHFFFAOYSA-N, FHIVAFMUCKRCQO-UHFFFAOYSA-N, FHIVAFMUCKRCQO-UHFFFAOYSA-N	Launched
dinaciclib	CDK inhibitor	CDK1, CDK2, CDK5, CDK9			CCc1cnn2c(NCc3ccc[n+]([O-])c3)cc(nc12)N1CCCC[C@H]1CCO, CCc1cnn2c(NCc3ccc[n+]([O-])c3)cc(nc12)N1CCCC[C@H]1CCO, CCc1cnn2c(NCc3ccc[n+]([O-])c3)cc(nc12)N1CCCC[C@H]1CCO, CCc1cnn2c(NCc3ccc[n+]([O-])c3)cc(nc12)N1CCCC[C@H]1CCO, CCc1cnn2c(NCc3ccc[n+]([O-])c3)cc(nc12)N1CCCC[C@H]1CCO, CCc1cnn2c(NCc3ccc[n+]([O-])c3)cc(nc12)N1CCCC[C@H]1CCO	PIMQWRZWLQKKBJ-SFHVURJKSA-N, PIMQWRZWLQKKBJ-SFHVURJKSA-N, PIMQWRZWLQKKBJ-SFHVURJKSA-N, PIMQWRZWLQKKBJ-SFHVURJKSA-N, InChI=1S/C21H28N6O2/c1-2-17-14-23-27-19(22-13-16-6-5-9-25(29)15-16)12-20(24-21(17)27)26-10-4-3-7-18(26)8-11-28/h5-6,9,12,14-15,18,22,28H,2-4,7-8,10-11,13H2,1H3/t18-/m0/s1, InChI=1S/C21H28N6O2/c1-2-17-14-23-27-19(22-13-16-6-5-9-25(29)15-16)12-20(24-21(17)27)26-10-4-3-7-18(26)8-11-28/h5-6,9,12,14-15,18,22,28H,2-4,7-8,10-11,13H2,1H3/t18-/m0/s1	Phase 3
dinitolmide			infectious disease	coccidiosis	Cc1c(cc(cc1[N+]([O-])=O)[N+]([O-])=O)C(N)=O, Cc1c(cc(cc1[N+]([O-])=O)[N+]([O-])=O)C(N)=O	ZEFNOZRLAWVAQF-UHFFFAOYSA-N, ZEFNOZRLAWVAQF-UHFFFAOYSA-N	Launched
dinoprost	prostacyclin analog	PTGDR, PTGDR2, PTGER1, PTGER2, PTGER3, PTGER4, PTGFR, TBXA2R	obstetrics/gynecology	labor induction	CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)C[C@H](O)[C@@H]1C\C=C/CCCC(O)=O, CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)C[C@H](O)[C@@H]1C\C=C/CCCC(O)=O, CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)C[C@H](O)[C@@H]1C\C=C/CCCC(O)=O	PXGPLTODNUVGFL-YNNPMVKQSA-N, PXGPLTODNUVGFL-YNNPMVKQSA-N, PXGPLTODNUVGFL-YNNPMVKQSA-N	Launched
dinoprostone	prostanoid receptor agonist	CATSPER1, CATSPER2, CATSPER3, CATSPER4, PTGDR, PTGDR2, PTGER1, PTGER2, PTGER3, PTGER4, PTGFR, TBXA2R			CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O, CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O	XEYBRNLFEZDVAW-ARSRFYASSA-N, XEYBRNLFEZDVAW-ARSRFYASSA-N	Withdrawn
dioscin	apoptosis stimulant	CXCR3			C[C@H]1[C@H]2[C@H](C[C@H]3[C@@H]4CC=C5C[C@H](CC[C@]5(C)[C@H]4CC[C@]23C)O[C@@H]2O[C@H](CO)[C@@H](O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](O)[C@H]3O)[C@H](O)[C@H]2O[C@@H]2O[C@@H](C)[C@H](O)[C@@H](O)[C@H]2O)O[C@]11CC[C@@H](C)CO1 |t:8|	VNONINPVFQTJOC-ZGXDEBHDSA-N	Preclinical
diosgenin	steroid				C[C@H]1[C@H]2[C@H](C[C@H]3[C@@H]4CC=C5C[C@@H](O)CC[C@]5(C)[C@H]4CC[C@]23C)O[C@]11CC[C@@H](C)CO1 |t:8|, C[C@H]1[C@H]2[C@H](C[C@H]3[C@@H]4CC=C5C[C@@H](O)CC[C@]5(C)[C@H]4CC[C@]23C)O[C@]11CC[C@@H](C)CO1 |t:8|	WQLVFSAGQJTQCK-VKROHFNGSA-N, WQLVFSAGQJTQCK-VKROHFNGSA-N	Preclinical
diosmetin	aryl hydrocarbon receptor agonist	CYP1B1	dermatology	cosmetic	COc1ccc(cc1O)-c1cc(=O)c2c(O)cc(O)cc2o1, COc1ccc(cc1O)-c1cc(=O)c2c(O)cc(O)cc2o1, COc1ccc(cc1O)-c1cc(=O)c2c(O)cc(O)cc2o1, COc1ccc(cc1O)-c1cc(=O)c2c(O)cc(O)cc2o1, COc1ccc(cc1O)-c1cc(=O)c2c(O)cc(O)cc2o1	MBNGWHIJMBWFHU-UHFFFAOYSA-N, MBNGWHIJMBWFHU-UHFFFAOYSA-N, MBNGWHIJMBWFHU-UHFFFAOYSA-N, MBNGWHIJMBWFHU-UHFFFAOYSA-N, MBNGWHIJMBWFHU-UHFFFAOYSA-N	Launched
diosmin	aryl hydrocarbon receptor agonist, capillary stabilizing agent	AHR	cardiology, hematology, dermatology	chronic venous insufficiency (CVI), edema, deep vein thrombosis (DVT), statis dermatitis, heavy leg syndrome	COc1ccc(cc1O)-c1cc(=O)c2c(O)cc(O[C@@H]3O[C@H](CO[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@@H](O)[C@H](O)[C@H]3O)cc2o1, COc1ccc(cc1O)-c1cc(=O)c2c(O)cc(O[C@@H]3O[C@H](CO[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@@H](O)[C@H](O)[C@H]3O)cc2o1, COc1ccc(cc1O)-c1cc(=O)c2c(O)cc(O[C@@H]3O[C@H](CO[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@@H](O)[C@H](O)[C@H]3O)cc2o1, COc1ccc(cc1O)-c1cc(=O)c2c(O)cc(O[C@@H]3O[C@H](CO[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@@H](O)[C@H](O)[C@H]3O)cc2o1, COc1ccc(cc1O)-c1cc(=O)c2c(O)cc(O[C@@H]3O[C@H](CO[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@@H](O)[C@H](O)[C@H]3O)cc2o1	GZSOSUNBTXMUFQ-YFAPSIMESA-N, GZSOSUNBTXMUFQ-YFAPSIMESA-N, GZSOSUNBTXMUFQ-YFAPSIMESA-N, GZSOSUNBTXMUFQ-YFAPSIMESA-N, GZSOSUNBTXMUFQ-YFAPSIMESA-N	Launched
dioxybenzone	topical sunscreen agent				COc1ccc(C(=O)c2ccccc2O)c(O)c1, COc1ccc(C(=O)c2ccccc2O)c(O)c1	MEZZCSHVIGVWFI-UHFFFAOYSA-N, MEZZCSHVIGVWFI-UHFFFAOYSA-N	Preclinical
dipeptamin					C[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(O)=O, C[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(O)=O	HJCMDXDYPOUFDY-WHFBIAKZSA-N, HJCMDXDYPOUFDY-WHFBIAKZSA-N	Launched
diperodon	local anesthetic				O=C(Nc1ccccc1)OC[C@@H](CN1CCCCC1)OC(=O)Nc1ccccc1 |&1:11|, O=C(Nc1ccccc1)OC[C@@H](CN1CCCCC1)OC(=O)Nc1ccccc1 |&1:11|, O=C(Nc1ccccc1)OC[C@@H](CN1CCCCC1)OC(=O)Nc1ccccc1 |&1:11|, O=C(Nc1ccccc1)OC[C@@H](CN1CCCCC1)OC(=O)Nc1ccccc1 |&1:11|	YUGZHQHSNYIFLG-HXUWFJFHSA-N, YUGZHQHSNYIFLG-HXUWFJFHSA-N, YUGZHQHSNYIFLG-HXUWFJFHSA-N, YUGZHQHSNYIFLG-HXUWFJFHSA-N	Preclinical
diphemanil	acetylcholine receptor antagonist	CHRM3	neurology/psychiatry	spasms	C[N+]1(C)CCC(CC1)=C(c1ccccc1)c1ccccc1, C[N+]1(C)CCC(CC1)=C(c1ccccc1)c1ccccc1, C[N+]1(C)CCC(CC1)=C(c1ccccc1)c1ccccc1	LCTZPQRFOZKZNK-UHFFFAOYSA-N, LCTZPQRFOZKZNK-UHFFFAOYSA-N, LCTZPQRFOZKZNK-UHFFFAOYSA-N	Launched
diphencyprone	immunostimulant				O=c1c(c1-c1ccccc1)-c1ccccc1, O=c1c(c1-c1ccccc1)-c1ccccc1	HCIBTBXNLVOFER-UHFFFAOYSA-N, HCIBTBXNLVOFER-UHFFFAOYSA-N	Phase 2
diphenhydramine	histamine receptor antagonist	HRH1	neurology/psychiatry	headache	CN(C)CCOC(c1ccccc1)c1ccccc1, CN(C)CCOC(c1ccccc1)c1ccccc1, CN(C)CCOC(c1ccccc1)c1ccccc1	ZZVUWRFHKOJYTH-UHFFFAOYSA-N, ZZVUWRFHKOJYTH-UHFFFAOYSA-N, ZZVUWRFHKOJYTH-UHFFFAOYSA-N	Launched
diphenidol	acetylcholine receptor agonist	CHRM1, CHRM2, CHRM3, CHRM4	neurology/psychiatry	vertigo	OC(CCCN1CCCCC1)(c1ccccc1)c1ccccc1, OC(CCCN1CCCCC1)(c1ccccc1)c1ccccc1, OC(CCCN1CCCCC1)(c1ccccc1)c1ccccc1, OC(CCCN1CCCCC1)(c1ccccc1)c1ccccc1, OC(CCCN1CCCCC1)(c1ccccc1)c1ccccc1	OGAKLTJNUQRZJU-UHFFFAOYSA-N, OGAKLTJNUQRZJU-UHFFFAOYSA-N, OGAKLTJNUQRZJU-UHFFFAOYSA-N, OGAKLTJNUQRZJU-UHFFFAOYSA-N, OGAKLTJNUQRZJU-UHFFFAOYSA-N	Launched
diphenyleneiodonium	nitric oxide synthase inhibitor	NOS2, NOS3			[I]1c2ccccc2-c2ccccc12 |^1:0|, [I]1c2ccccc2-c2ccccc12 |^1:0|, [I]1c2ccccc2-c2ccccc12 |^1:0|	ZSZPLBNCHKXQRY-UHFFFAOYSA-N, ZSZPLBNCHKXQRY-UHFFFAOYSA-N, ZSZPLBNCHKXQRY-UHFFFAOYSA-N	Preclinical
diphenylguanidine					N=C(Nc1ccccc1)Nc1ccccc1, N=C(Nc1ccccc1)Nc1ccccc1	OWRCNXZUPFZXOS-UHFFFAOYSA-N, OWRCNXZUPFZXOS-UHFFFAOYSA-N	Preclinical
diphenylpyraline	dopamine reuptake inhibitor	HRH1, SLC6A3	allergy	allergic rhinitis	CN1CCC(CC1)OC(c1ccccc1)c1ccccc1, CN1CCC(CC1)OC(c1ccccc1)c1ccccc1, CN1CCC(CC1)OC(c1ccccc1)c1ccccc1, CN1CCC(CC1)OC(c1ccccc1)c1ccccc1	OWQUZNMMYNAXSL-UHFFFAOYSA-N, OWQUZNMMYNAXSL-UHFFFAOYSA-N, OWQUZNMMYNAXSL-UHFFFAOYSA-N, OWQUZNMMYNAXSL-UHFFFAOYSA-N	Launched
dipivefrine	adrenergic receptor agonist		ophthalmology	glaucoma, intraocular pressure	CNC[C@@H](O)c1ccc(OC(=O)C(C)(C)C)c(OC(=O)C(C)(C)C)c1 |&1:3|	OCUJLLGVOUDECM-CYBMUJFWSA-N	Launched
dipraglurant	glutamate receptor negative allosteric modulator	GRM5			Fc1ccc2nc(CCC#Cc3ccccn3)cn2c1, Fc1ccc2nc(CCC#Cc3ccccn3)cn2c1	LZXMUJCJAWVHPZ-UHFFFAOYSA-N, LZXMUJCJAWVHPZ-UHFFFAOYSA-N	Phase 2
DIPT	dopamine reuptake inhibitor, serotonin reuptake inhibitor	HTR1A, HTR2A, HTR2C			CC(C)N(CCc1c[nH]c2ccccc12)C(C)C	ZRVAAGAZUWXRIP-UHFFFAOYSA-N	Launched
dipyridamole	phosphodiesterase inhibitor	ADA, PDE10A, PDE1A, PDE1B, PDE1C, PDE2A, PDE3A, PDE3B, PDE4A, PDE4B, PDE4C, PDE4D, PDE5A, PDE6A, PDE6B, PDE6C, PDE6D, PDE6G, PDE6H, PDE7A, PDE7B, PDE8A, PDE8B, PDE9A, SLC29A1	cardiology	coronary artery disease (CAD), peripheral artery disease (PAD), hypertension	OCCN(CCO)c1nc(N2CCCCC2)c2nc(nc(N3CCCCC3)c2n1)N(CCO)CCO, OCCN(CCO)c1nc(N2CCCCC2)c2nc(nc(N3CCCCC3)c2n1)N(CCO)CCO, OCCN(CCO)c1nc(N2CCCCC2)c2nc(nc(N3CCCCC3)c2n1)N(CCO)CCO, OCCN(CCO)c1nc(N2CCCCC2)c2nc(nc(N3CCCCC3)c2n1)N(CCO)CCO, OCCN(CCO)c1nc(N2CCCCC2)c2nc(nc(N3CCCCC3)c2n1)N(CCO)CCO, OCCN(CCO)c1nc(N2CCCCC2)c2nc(nc(N3CCCCC3)c2n1)N(CCO)CCO, OCCN(CCO)c1nc(N2CCCCC2)c2nc(nc(N3CCCCC3)c2n1)N(CCO)CCO, OCCN(CCO)c1nc(N2CCCCC2)c2nc(nc(N3CCCCC3)c2n1)N(CCO)CCO	IZEKFCXSFNUWAM-UHFFFAOYSA-N, IZEKFCXSFNUWAM-UHFFFAOYSA-N, IZEKFCXSFNUWAM-UHFFFAOYSA-N, IZEKFCXSFNUWAM-UHFFFAOYSA-N, IZEKFCXSFNUWAM-UHFFFAOYSA-N, IZEKFCXSFNUWAM-UHFFFAOYSA-N, IZEKFCXSFNUWAM-UHFFFAOYSA-N, IZEKFCXSFNUWAM-UHFFFAOYSA-N	Launched
dipyrocetyl	chelating agent		endocrinology, neurology/psychiatry	fever, pain relief	CC(=O)Oc1cccc(C(O)=O)c1OC(C)=O, CC(=O)Oc1cccc(C(O)=O)c1OC(C)=O	NYIZXMGNIUSNKL-UHFFFAOYSA-N, NYIZXMGNIUSNKL-UHFFFAOYSA-N	Launched
diquafosol	purinergic receptor activator				O[C@@H]1[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@H](O)[C@@H]2O)n2ccc(=O)[nH]c2=O)O[C@H]([C@@H]1O)n1ccc(=O)[nH]c1=O	NMLMACJWHPHKGR-NCOIDOBVSA-N	Phase 3
dirithromycin	bacterial 50S ribosomal subunit inhibitor		pulmonary	bronchitis	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)[C@@H]2N[C@@H](COCCOC)O[C@H]([C@H]2C)[C@]1(C)O, CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)[C@@H]2N[C@@H](COCCOC)O[C@H]([C@H]2C)[C@]1(C)O, CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)[C@@H]2N[C@@H](COCCOC)O[C@H]([C@H]2C)[C@]1(C)O, CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)[C@@H]2N[C@@H](COCCOC)O[C@H]([C@H]2C)[C@]1(C)O, CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)[C@@H]2N[C@@H](COCCOC)O[C@H]([C@H]2C)[C@]1(C)O, CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)[C@@H]2N[C@@H](COCCOC)O[C@H]([C@H]2C)[C@]1(C)O, CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)[C@@H]2N[C@@H](COCCOC)O[C@H]([C@H]2C)[C@]1(C)O, CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)[C@@H]2N[C@@H](COCCOC)O[C@H]([C@H]2C)[C@]1(C)O, CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)[C@@H]2N[C@@H](COCCOC)O[C@H]([C@H]2C)[C@]1(C)O, CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)[C@@H]2N[C@@H](COCCOC)O[C@H]([C@H]2C)[C@]1(C)O	WLOHNSSYAXHWNR-FDEBZETHSA-N, WLOHNSSYAXHWNR-FDEBZETHSA-N, WLOHNSSYAXHWNR-FDEBZETHSA-N, WLOHNSSYAXHWNR-FDEBZETHSA-N, WLOHNSSYAXHWNR-FDEBZETHSA-N, WLOHNSSYAXHWNR-FDEBZETHSA-N, WLOHNSSYAXHWNR-FDEBZETHSA-N, WLOHNSSYAXHWNR-FDEBZETHSA-N, WLOHNSSYAXHWNR-FDEBZETHSA-N, WLOHNSSYAXHWNR-FDEBZETHSA-N	Launched
diroximel-fumarate	anti-inflammatory agent				COC(=O)\C=C\C(=O)OCCN1C(=O)CCC1=O	YIMYDTCOUQIDMT-SNAWJCMRSA-N	Phase 3
disodium-sebacate		HBB			OC(=O)CCCCCCCCC(O)=O	CXMXRPHRNRROMY-UHFFFAOYSA-N	Phase 1
disopyramide	sodium channel blocker	CHRM1, CHRM2, CHRM3, KCND2, KCND3, KCNH2, SCN5A	cardiology	ventricular tachycardia (VT), ventricular arrhythmias	CC(C)N(CCC(C(N)=O)(c1ccccc1)c1ccccn1)C(C)C |&1:6|, CC(C)N(CCC(C(N)=O)(c1ccccc1)c1ccccn1)C(C)C |&1:6|, CC(C)N(CCC(C(N)=O)(c1ccccc1)c1ccccn1)C(C)C |&1:6|, CC(C)N(CCC(C(N)=O)(c1ccccc1)c1ccccn1)C(C)C |&1:6|, CC(C)N(CCC(C(N)=O)(c1ccccc1)c1ccccn1)C(C)C |&1:6|	UVTNFZQICZKOEM-UHFFFAOYSA-N, UVTNFZQICZKOEM-UHFFFAOYSA-N, UVTNFZQICZKOEM-UHFFFAOYSA-N, UVTNFZQICZKOEM-UHFFFAOYSA-N, UVTNFZQICZKOEM-UHFFFAOYSA-N	Launched
disulfiram	aldehyde dehydrogenase inhibitor, DNA methyltransferase inhibitor, TRPV agonist	ALDH2, DBH	neurology/psychiatry	abstinence from alcohol	CCN(CC)C(=S)SSC(=S)N(CC)CC, CCN(CC)C(=S)SSC(=S)N(CC)CC, CCN(CC)C(=S)SSC(=S)N(CC)CC, CCN(CC)C(=S)SSC(=S)N(CC)CC, CCN(CC)C(=S)SSC(=S)N(CC)CC, CCN(CC)C(=S)SSC(=S)N(CC)CC, CCN(CC)C(=S)SSC(=S)N(CC)CC, CCN(CC)C(=S)SSC(=S)N(CC)CC, CCN(CC)C(=S)SSC(=S)N(CC)CC, CCN(CC)C(=S)SSC(=S)N(CC)CC, CCN(CC)C(=S)SSC(=S)N(CC)CC, CCN(CC)C(=S)SSC(=S)N(CC)CC, CCN(CC)C(=S)SSC(=S)N(CC)CC, CCN(CC)C(=S)SSC(=S)N(CC)CC	AUZONCFQVSMFAP-UHFFFAOYSA-N, AUZONCFQVSMFAP-UHFFFAOYSA-N, AUZONCFQVSMFAP-UHFFFAOYSA-N, AUZONCFQVSMFAP-UHFFFAOYSA-N, AUZONCFQVSMFAP-UHFFFAOYSA-N, AUZONCFQVSMFAP-UHFFFAOYSA-N, AUZONCFQVSMFAP-UHFFFAOYSA-N, AUZONCFQVSMFAP-UHFFFAOYSA-N, AUZONCFQVSMFAP-UHFFFAOYSA-N, AUZONCFQVSMFAP-UHFFFAOYSA-N, AUZONCFQVSMFAP-UHFFFAOYSA-N, AUZONCFQVSMFAP-UHFFFAOYSA-N, AUZONCFQVSMFAP-UHFFFAOYSA-N, AUZONCFQVSMFAP-UHFFFAOYSA-N	Launched
dithranol	DNA synthesis inhibitor		dermatology	psoriasis	Oc1cccc2cc3cccc(O)c3c(O)c12	YUTJCNNFTOIOGT-UHFFFAOYSA-N	Launched
ditiocarb-sodium-trihydrate	immunostimulant	CA1, CA2, CA4			CCN(CC)C(S)=S, CCN(CC)C(S)=S	LMBWSYZSUOEYSN-UHFFFAOYSA-N, LMBWSYZSUOEYSN-UHFFFAOYSA-N	Phase 3
ditolylguanidine	sigma receptor agonist	GRIN1, GRIN2A, GRIN2B, SIGMAR1			Cc1ccccc1NC(=N)Nc1ccccc1C, Cc1ccccc1NC(=N)Nc1ccccc1C	OPNUROKCUBTKLF-UHFFFAOYSA-N, OPNUROKCUBTKLF-UHFFFAOYSA-N	Preclinical
dixanthogen					CCOC(=S)SSC(=S)OCC, CCOC(=S)SSC(=S)OCC	FVIGODVHAVLZOO-UHFFFAOYSA-N, FVIGODVHAVLZOO-UHFFFAOYSA-N	Preclinical
dixyrazine	antipsychotic				C[C@H](CN1CCN(CCOCCO)CC1)CN1c2ccccc2Sc2ccccc12 |&1:1,r|	MSYUMPGNGDNTIQ-HXUWFJFHSA-N	Preclinical
dizocilpine-(+)	glutamate receptor antagonist	GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D			C[C@]12N[C@H](Cc3ccccc13)c1ccccc21, C[C@]12N[C@H](Cc3ccccc13)c1ccccc21, C[C@]12N[C@H](Cc3ccccc13)c1ccccc21, C[C@]12N[C@H](Cc3ccccc13)c1ccccc21, C[C@]12N[C@H](Cc3ccccc13)c1ccccc21, C[C@]12N[C@H](Cc3ccccc13)c1ccccc21	LBOJYSIDWZQNJS-CVEARBPZSA-N, LBOJYSIDWZQNJS-CVEARBPZSA-N, LBOJYSIDWZQNJS-CVEARBPZSA-N, LBOJYSIDWZQNJS-CVEARBPZSA-N, LBOJYSIDWZQNJS-CVEARBPZSA-N, LBOJYSIDWZQNJS-CVEARBPZSA-N	Preclinical
dizocilpine-(-)	glutamate receptor antagonist				C[C@@]12N[C@@H](Cc3ccccc13)c1ccccc21, C[C@@]12N[C@@H](Cc3ccccc13)c1ccccc21, C[C@@]12N[C@@H](Cc3ccccc13)c1ccccc21, C[C@@]12N[C@@H](Cc3ccccc13)c1ccccc21	LBOJYSIDWZQNJS-JKSUJKDBSA-N, LBOJYSIDWZQNJS-JKSUJKDBSA-N, LBOJYSIDWZQNJS-JKSUJKDBSA-N, LBOJYSIDWZQNJS-JKSUJKDBSA-N	Phase 1
DMAB-anabaseine	adrenergic receptor agonist	CHRNA7			CN(C)c1ccc(\C=C2/CCCN=C2c2cccnc2)cc1 |c:12|, CN(C)c1ccc(\C=C2/CCCN=C2c2cccnc2)cc1 |c:12|, CN(C)c1ccc(\C=C2/CCCN=C2c2cccnc2)cc1 |c:12|, CN(C)c1ccc(\C=C2/CCCN=C2c2cccnc2)cc1 |c:12|	KHUUTHZSRXABAC-DTQAZKPQSA-N, KHUUTHZSRXABAC-DTQAZKPQSA-N, KHUUTHZSRXABAC-DTQAZKPQSA-N, KHUUTHZSRXABAC-DTQAZKPQSA-N	Preclinical
DMeOB	glutamate receptor modulator	GRM5			COc1cccc(\C=N\N=C\c2cccc(OC)c2)c1, COc1cccc(\C=N\N=C\c2cccc(OC)c2)c1	FBNPHFBYHYNMHC-JYFOCSDGSA-N, FBNPHFBYHYNMHC-JYFOCSDGSA-N	Preclinical
DMH1	ALK tyrosine kinase receptor inhibitor	ACVR1			CC(C)Oc1ccc(cc1)-c1cnc2c(cnn2c1)-c1ccnc2ccccc12, CC(C)Oc1ccc(cc1)-c1cnc2c(cnn2c1)-c1ccnc2ccccc12, CC(C)Oc1ccc(cc1)-c1cnc2c(cnn2c1)-c1ccnc2ccccc12, CC(C)Oc1ccc(cc1)-c1cnc2c(cnn2c1)-c1ccnc2ccccc12, CC(C)Oc1ccc(cc1)-c1cnc2c(cnn2c1)-c1ccnc2ccccc12, CC(C)Oc1ccc(cc1)-c1cnc2c(cnn2c1)-c1ccnc2ccccc12	JMIFGARJSWXZSH-UHFFFAOYSA-N, JMIFGARJSWXZSH-UHFFFAOYSA-N, JMIFGARJSWXZSH-UHFFFAOYSA-N, JMIFGARJSWXZSH-UHFFFAOYSA-N, JMIFGARJSWXZSH-UHFFFAOYSA-N, JMIFGARJSWXZSH-UHFFFAOYSA-N	Preclinical
DMH4	VEGFR inhibitor	KDR			C(CN1CCOCC1)Oc1ccc(cc1)-c1cnc2c(cnn2c1)-c1ccccc1, C(CN1CCOCC1)Oc1ccc(cc1)-c1cnc2c(cnn2c1)-c1ccccc1, C(CN1CCOCC1)Oc1ccc(cc1)-c1cnc2c(cnn2c1)-c1ccccc1	SKZQZGSPYYHTQG-UHFFFAOYSA-N, SKZQZGSPYYHTQG-UHFFFAOYSA-N, SKZQZGSPYYHTQG-UHFFFAOYSA-N	Preclinical
DMNB	DNA dependent protein kinase inhibitor				COc1cc(C=O)c(cc1OC)[N+]([O-])=O, COc1cc(C=O)c(cc1OC)[N+]([O-])=O	YWSPWKXREVSQCA-UHFFFAOYSA-N, YWSPWKXREVSQCA-UHFFFAOYSA-N	Preclinical
DMP-543	acetylcholine release enhancer				Fc1cc(CC2(Cc3ccnc(F)c3)c3ccccc3C(=O)c3ccccc23)ccn1, Fc1cc(CC2(Cc3ccnc(F)c3)c3ccccc3C(=O)c3ccccc23)ccn1, Fc1cc(CC2(Cc3ccnc(F)c3)c3ccccc3C(=O)c3ccccc23)ccn1	MUJBUUDUXGDXLW-UHFFFAOYSA-N, MUJBUUDUXGDXLW-UHFFFAOYSA-N, MUJBUUDUXGDXLW-UHFFFAOYSA-N	Phase 2
DMP-777	elastase inhibitor	MPO			CCC[C@@H](NC(=O)N1[C@@H](Oc2ccc(cc2)C(=O)N2CCN(C)CC2)C(CC)(CC)C1=O)c1ccc2OCOc2c1, CCC[C@@H](NC(=O)N1[C@@H](Oc2ccc(cc2)C(=O)N2CCN(C)CC2)C(CC)(CC)C1=O)c1ccc2OCOc2c1, CCC[C@@H](NC(=O)N1[C@@H](Oc2ccc(cc2)C(=O)N2CCN(C)CC2)C(CC)(CC)C1=O)c1ccc2OCOc2c1	ZSDCIRYNTCVTMF-GIGWZHCTSA-N, ZSDCIRYNTCVTMF-GIGWZHCTSA-N, ZSDCIRYNTCVTMF-GIGWZHCTSA-N	Phase 2
DMPS	chelating agent				OS(=O)(=O)C[C@@H](S)CS |&1:5,r|	JLVSRWOIZZXQAD-VKHMYHEASA-N	Phase 1
DMSO	control vehicle				CS(C)=O.CS(C)=O	CETRZFQIITUQQL-UHFFFAOYSA-N	Preclinical
DNQX	glutamate receptor antagonist	GRIA1, GRIA2, GRIK1, GRIN1, GRIN2A, GRIN2B			[O-][N+](=O)c1cc2[nH]c(=O)c(=O)[nH]c2cc1[N+]([O-])=O, [O-][N+](=O)c1cc2[nH]c(=O)c(=O)[nH]c2cc1[N+]([O-])=O, [O-][N+](=O)c1cc2[nH]c(=O)c(=O)[nH]c2cc1[N+]([O-])=O, [O-][N+](=O)c1cc2[nH]c(=O)c(=O)[nH]c2cc1[N+]([O-])=O, [O-][N+](=O)c1cc2[nH]c(=O)c(=O)[nH]c2cc1[N+]([O-])=O, [O-][N+](=O)c1cc2[nH]c(=O)c(=O)[nH]c2cc1[N+]([O-])=O	RWVIMCIPOAXUDG-UHFFFAOYSA-N, RWVIMCIPOAXUDG-UHFFFAOYSA-N, RWVIMCIPOAXUDG-UHFFFAOYSA-N, RWVIMCIPOAXUDG-UHFFFAOYSA-N, RWVIMCIPOAXUDG-UHFFFAOYSA-N, RWVIMCIPOAXUDG-UHFFFAOYSA-N	Preclinical
dobutamine	adrenergic receptor agonist	ADRB1, ADRB2	cardiology	congestive heart failure	CC(CCc1ccc(O)cc1)NCCc1ccc(O)c(O)c1, CC(CCc1ccc(O)cc1)NCCc1ccc(O)c(O)c1, CC(CCc1ccc(O)cc1)NCCc1ccc(O)c(O)c1, CC(CCc1ccc(O)cc1)NCCc1ccc(O)c(O)c1, CC(CCc1ccc(O)cc1)NCCc1ccc(O)c(O)c1, CC(CCc1ccc(O)cc1)NCCc1ccc(O)c(O)c1, CC(CCc1ccc(O)cc1)NCCc1ccc(O)c(O)c1, CC(CCc1ccc(O)cc1)NCCc1ccc(O)c(O)c1	JRWZLRBJNMZMFE-UHFFFAOYSA-N, JRWZLRBJNMZMFE-UHFFFAOYSA-N, JRWZLRBJNMZMFE-UHFFFAOYSA-N, JRWZLRBJNMZMFE-UHFFFAOYSA-N, JRWZLRBJNMZMFE-UHFFFAOYSA-N, JRWZLRBJNMZMFE-UHFFFAOYSA-N, JRWZLRBJNMZMFE-UHFFFAOYSA-N, JRWZLRBJNMZMFE-UHFFFAOYSA-N	Launched
docebenone	lipoxygenase inhibitor	ALOX5			CC1=C(C)C(=O)C(CCCCC#CCCCC#CCO)=C(C)C1=O |c:1,t:19|	WDEABJKSGGRCQA-UHFFFAOYSA-N	Phase 2
docetaxel	tubulin polymerization inhibitor	BCL2, MAP2, MAP4, MAPT, NR1I2, TUBA1A, TUBA1B, TUBA1C, TUBA3C, TUBA3D, TUBA3E, TUBA4A, TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8	oncology	breast cancer, non-small cell lung cancer (NSCLC), prostate cancer, gastric adenocarcinoma, head and neck squamous cell carcinoma (HNSCC)	CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C([C@@H](O)C1=O)C2(C)C |t:53|, CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C([C@@H](O)C1=O)C2(C)C |t:53|, CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C([C@@H](O)C1=O)C2(C)C |t:53|, CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C([C@@H](O)C1=O)C2(C)C |t:53|, CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C([C@@H](O)C1=O)C2(C)C |t:53|, CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C([C@@H](O)C1=O)C2(C)C |t:53|, CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C([C@@H](O)C1=O)C2(C)C |t:53|	ZDZOTLJHXYCWBA-VCVYQWHSSA-N, ZDZOTLJHXYCWBA-VCVYQWHSSA-N, ZDZOTLJHXYCWBA-VCVYQWHSSA-N, ZDZOTLJHXYCWBA-VCVYQWHSSA-N, ZDZOTLJHXYCWBA-VCVYQWHSSA-N, ZDZOTLJHXYCWBA-VCVYQWHSSA-N, ZDZOTLJHXYCWBA-VCVYQWHSSA-N	Launched
doconexent	PPAR receptor agonist	FFAR1, PTGS1, PTGS2			CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O, CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O	MBMBGCFOFBJSGT-KUBAVDMBSA-N, MBMBGCFOFBJSGT-KUBAVDMBSA-N	Launched
doconexent-ethyl-ester	omega 3 fatty acid stimulant		endocrinology	hypertriglyceridemia	CCOC(=O)CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CC	ITNKVODZACVXDS-YNUSHXQLSA-N	Launched
docosanol	lipase clearing factor inhibitor	TLR7	dental	cold sore	CCCCCCCCCCCCCCCCCCCCCCO, CCCCCCCCCCCCCCCCCCCCCCO, CCCCCCCCCCCCCCCCCCCCCCO, CCCCCCCCCCCCCCCCCCCCCCO	NOPFSRXAKWQILS-UHFFFAOYSA-N, NOPFSRXAKWQILS-UHFFFAOYSA-N, NOPFSRXAKWQILS-UHFFFAOYSA-N, NOPFSRXAKWQILS-UHFFFAOYSA-N	Launched
docusate	laxative		gastroenterology	constipation	CCCC[C@@H](CC)COC(=O)C[C@@H](C(=O)OC[C@@H](CC)CCCC)S(O)(=O)=O |&1:4,&2:12,&3:17|, CCCC[C@@H](CC)COC(=O)C[C@@H](C(=O)OC[C@@H](CC)CCCC)S(O)(=O)=O |&1:4,&2:12,&3:17|	HNSDLXPSAYFUHK-SQNIBIBYSA-N, HNSDLXPSAYFUHK-SQNIBIBYSA-N	Launched
dodecyl-sulfate		LYZ			CCCCCCCCCCCCOS(O)(=O)=O	MOTZDAYCYVMXPC-UHFFFAOYSA-N	Preclinical
dofequidar	MRP inhibitor, P glycoprotein inhibitor	ABCB1			OC(COc1cccc2ncccc12)CN1CCN(CC1)C(=O)C(c1ccccc1)c1ccccc1, OC(COc1cccc2ncccc12)CN1CCN(CC1)C(=O)C(c1ccccc1)c1ccccc1	KLWUUPVJTLHYIM-UHFFFAOYSA-N, KLWUUPVJTLHYIM-UHFFFAOYSA-N	Phase 3
dofetilide	potassium channel blocker	KCNH1, KCNH2, KCNJ12, KCNK2			CN(CCOc1ccc(NS(C)(=O)=O)cc1)CCc1ccc(NS(C)(=O)=O)cc1, CN(CCOc1ccc(NS(C)(=O)=O)cc1)CCc1ccc(NS(C)(=O)=O)cc1, CN(CCOc1ccc(NS(C)(=O)=O)cc1)CCc1ccc(NS(C)(=O)=O)cc1, CN(CCOc1ccc(NS(C)(=O)=O)cc1)CCc1ccc(NS(C)(=O)=O)cc1, CN(CCOc1ccc(NS(C)(=O)=O)cc1)CCc1ccc(NS(C)(=O)=O)cc1	IXTMWRCNAAVVAI-UHFFFAOYSA-N, IXTMWRCNAAVVAI-UHFFFAOYSA-N, IXTMWRCNAAVVAI-UHFFFAOYSA-N, IXTMWRCNAAVVAI-UHFFFAOYSA-N, IXTMWRCNAAVVAI-UHFFFAOYSA-N	Withdrawn
dolasetron	serotonin receptor antagonist	HTR3A	gastroenterology	nausea, vomiting	O=C(O[C@H]1C[C@H]2C[C@H]3C[C@@H](C1)N2CC3=O)c1c[nH]c2ccccc12, O=C(O[C@H]1C[C@H]2C[C@H]3C[C@@H](C1)N2CC3=O)c1c[nH]c2ccccc12, O=C(O[C@H]1C[C@H]2C[C@H]3C[C@@H](C1)N2CC3=O)c1c[nH]c2ccccc12	UKTAZPQNNNJVKR-YXSUXZIUSA-N, UKTAZPQNNNJVKR-YXSUXZIUSA-N, UKTAZPQNNNJVKR-YXSUXZIUSA-N	Launched
dolastatin-10	tubulin polymerization inhibitor	TUBB			CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@@H](Cc1ccccc1)c1nccs1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C)C(C)C, CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@@H](Cc1ccccc1)c1nccs1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C)C(C)C, CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@@H](Cc1ccccc1)c1nccs1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C)C(C)C, CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@@H](Cc1ccccc1)c1nccs1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C)C(C)C, CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@@H](Cc1ccccc1)c1nccs1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C)C(C)C, CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@@H](Cc1ccccc1)c1nccs1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C)C(C)C, CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@@H](Cc1ccccc1)c1nccs1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C)C(C)C	OFDNQWIFNXBECV-VFSYNPLYSA-N, OFDNQWIFNXBECV-VFSYNPLYSA-N, OFDNQWIFNXBECV-VFSYNPLYSA-N, OFDNQWIFNXBECV-VFSYNPLYSA-N, OFDNQWIFNXBECV-VFSYNPLYSA-N, OFDNQWIFNXBECV-VFSYNPLYSA-N, OFDNQWIFNXBECV-VFSYNPLYSA-N	Phase 2
dolutegravir	HIV integrase inhibitor	CYP3A4, CYP3A5, CYP3A7, POU2F2, UGT1A1	infectious disease	human immunodeficiency virus (HIV-1)	C[C@@H]1CCO[C@H]2Cn3cc(C(=O)NCc4ccc(F)cc4F)c(=O)c(O)c3C(=O)N12	RHWKPHLQXYSBKR-BMIGLBTASA-N	Launched
domiphen					CCCCCCCCCCCC[N+](C)(C)CCOc1ccccc1, CCCCCCCCCCCC[N+](C)(C)CCOc1ccccc1, CCCCCCCCCCCC[N+](C)(C)CCOc1ccccc1, CCCCCCCCCCCC[N+](C)(C)CCOc1ccccc1, CCCCCCCCCCCC[N+](C)(C)CCOc1ccccc1, CCCCCCCCCCCC[N+](C)(C)CCOc1ccccc1	YXUPZGKORWTXID-UHFFFAOYSA-N, YXUPZGKORWTXID-UHFFFAOYSA-N, YXUPZGKORWTXID-UHFFFAOYSA-N, YXUPZGKORWTXID-UHFFFAOYSA-N, YXUPZGKORWTXID-UHFFFAOYSA-N, YXUPZGKORWTXID-UHFFFAOYSA-N	Preclinical
domperidone	dopamine receptor antagonist	DRD2, DRD3	infectious disease	fescue toxicosis	Clc1ccc2n(C3CCN(CCCn4c5ccccc5[nH]c4=O)CC3)c(=O)[nH]c2c1, Clc1ccc2n(C3CCN(CCCn4c5ccccc5[nH]c4=O)CC3)c(=O)[nH]c2c1, Clc1ccc2n(C3CCN(CCCn4c5ccccc5[nH]c4=O)CC3)c(=O)[nH]c2c1, Clc1ccc2n(C3CCN(CCCn4c5ccccc5[nH]c4=O)CC3)c(=O)[nH]c2c1	FGXWKSZFVQUSTL-UHFFFAOYSA-N, FGXWKSZFVQUSTL-UHFFFAOYSA-N, FGXWKSZFVQUSTL-UHFFFAOYSA-N, FGXWKSZFVQUSTL-UHFFFAOYSA-N	Launched
donepezil	acetylcholinesterase inhibitor	ACHE	neurology/psychiatry	Alzheimer's disease	COc1cc2C[C@@H](CC3CCN(Cc4ccccc4)CC3)C(=O)c2cc1OC |r|, COc1cc2C[C@@H](CC3CCN(Cc4ccccc4)CC3)C(=O)c2cc1OC |r|	ADEBPBSSDYVVLD-HXUWFJFHSA-N, ADEBPBSSDYVVLD-HXUWFJFHSA-N	Launched
donitriptan	serotonin receptor agonist	HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR5A, HTR6			NCCc1c[nH]c2ccc(OCC(=O)N3CCN(CC3)c3ccc(cc3)C#N)cc12, NCCc1c[nH]c2ccc(OCC(=O)N3CCN(CC3)c3ccc(cc3)C#N)cc12, NCCc1c[nH]c2ccc(OCC(=O)N3CCN(CC3)c3ccc(cc3)C#N)cc12	SOHCKWZVTCTQBG-UHFFFAOYSA-N, SOHCKWZVTCTQBG-UHFFFAOYSA-N, SOHCKWZVTCTQBG-UHFFFAOYSA-N	Phase 2
dopamine	dopamine receptor agonist	DBH, DRD1, DRD2, DRD3, DRD4, DRD5, HTR1A, HTR7, SLC6A2, SLC6A3, SLC6A4	cardiology, neurology/psychiatry	ventricular arrhythmias, depression, headache, tremors	NCCc1ccc(O)c(O)c1, NCCc1ccc(O)c(O)c1, NCCc1ccc(O)c(O)c1, NCCc1ccc(O)c(O)c1	VYFYYTLLBUKUHU-UHFFFAOYSA-N, VYFYYTLLBUKUHU-UHFFFAOYSA-N, VYFYYTLLBUKUHU-UHFFFAOYSA-N, VYFYYTLLBUKUHU-UHFFFAOYSA-N	Launched
doramapimod	p38 MAPK inhibitor	MAPK11, MAPK12, MAPK13, MAPK14			Cc1ccc(cc1)-n1nc(cc1NC(=O)Nc1ccc(OCCN2CCOCC2)c2ccccc12)C(C)(C)C, Cc1ccc(cc1)-n1nc(cc1NC(=O)Nc1ccc(OCCN2CCOCC2)c2ccccc12)C(C)(C)C, Cc1ccc(cc1)-n1nc(cc1NC(=O)Nc1ccc(OCCN2CCOCC2)c2ccccc12)C(C)(C)C, Cc1ccc(cc1)-n1nc(cc1NC(=O)Nc1ccc(OCCN2CCOCC2)c2ccccc12)C(C)(C)C, Cc1ccc(cc1)-n1nc(cc1NC(=O)Nc1ccc(OCCN2CCOCC2)c2ccccc12)C(C)(C)C	MVCOAUNKQVWQHZ-UHFFFAOYSA-N, MVCOAUNKQVWQHZ-UHFFFAOYSA-N, MVCOAUNKQVWQHZ-UHFFFAOYSA-N, MVCOAUNKQVWQHZ-UHFFFAOYSA-N, MVCOAUNKQVWQHZ-UHFFFAOYSA-N	Phase 2
doramectin			infectious disease	gastrointestinal roundworms	[H][C@@]12OC\C3=C/C=C/[C@H](C)[C@H](O[C@@]4([H])C[C@H](OC)[C@@H](O[C@@]5([H])C[C@H](OC)[C@@H](O)[C@H](C)O5)[C@H](C)O4)\C(C)=C\C[C@]4([H])C[C@@]([H])(C[C@@]5(O[C@H](C6CCCCC6)[C@@H](C)C=C5)O4)OC(=O)[C@]([H])(C=C(C)[C@H]1O)[C@@]23O |c:4,58,t:6,37,68|	QLFZZSKTJWDQOS-YDBLARSUSA-N	Launched
doravirine	non-nucleoside reverse transcriptase inhibitor				Cn1c(Cn2ccc(c(Oc3cc(Cl)cc(c3)C#N)c2=O)C(F)(F)F)n[nH]c1=O	ZIAOVIPSKUPPQW-UHFFFAOYSA-N	Launched
doripenem	bacterial cell wall synthesis inhibitor	DPEP1	infectious disease	intra-abdominal infections, urinary tract infections, pyelonephritis	C[C@@H](O)[C@@H]1[C@H]2[C@@H](C)C(S[C@@H]3CN[C@H](CNS(N)(=O)=O)C3)=C(N2C1=O)C(O)=O |c:20|, C[C@@H](O)[C@@H]1[C@H]2[C@@H](C)C(S[C@@H]3CN[C@H](CNS(N)(=O)=O)C3)=C(N2C1=O)C(O)=O |c:20|, C[C@@H](O)[C@@H]1[C@H]2[C@@H](C)C(S[C@@H]3CN[C@H](CNS(N)(=O)=O)C3)=C(N2C1=O)C(O)=O |c:20|, C[C@@H](O)[C@@H]1[C@H]2[C@@H](C)C(S[C@@H]3CN[C@H](CNS(N)(=O)=O)C3)=C(N2C1=O)C(O)=O |c:20|, C[C@@H](O)[C@@H]1[C@H]2[C@@H](C)C(S[C@@H]3CN[C@H](CNS(N)(=O)=O)C3)=C(N2C1=O)C(O)=O |c:20|	AVAACINZEOAHHE-VFZPANTDSA-N, AVAACINZEOAHHE-VFZPANTDSA-N, AVAACINZEOAHHE-VFZPANTDSA-N, AVAACINZEOAHHE-VFZPANTDSA-N, AVAACINZEOAHHE-VFZPANTDSA-N	Launched
dorsomorphin	AMPK inhibitor	ACVR1, BMPR1A, BMPR1B, EPHA2, FKBP1A, FLT1, FLT3, KDR, LCK, MKNK1, PRKAA1, RPS6KA1, SRC			C(CN1CCCCC1)Oc1ccc(cc1)-c1cnc2c(cnn2c1)-c1ccncc1, C(CN1CCCCC1)Oc1ccc(cc1)-c1cnc2c(cnn2c1)-c1ccncc1, C(CN1CCCCC1)Oc1ccc(cc1)-c1cnc2c(cnn2c1)-c1ccncc1, C(CN1CCCCC1)Oc1ccc(cc1)-c1cnc2c(cnn2c1)-c1ccncc1, C(CN1CCCCC1)Oc1ccc(cc1)-c1cnc2c(cnn2c1)-c1ccncc1, C(CN1CCCCC1)Oc1ccc(cc1)-c1cnc2c(cnn2c1)-c1ccncc1	XHBVYDAKJHETMP-UHFFFAOYSA-N, XHBVYDAKJHETMP-UHFFFAOYSA-N, InChI=1S/C24H25N5O/c1-2-12-28(13-3-1)14-15-30-22-6-4-19(5-7-22)21-16-26-24-23(17-27-29(24)18-21)20-8-10-25-11-9-20/h4-11,16-18H,1-3,12-15H2, InChI=1S/C24H25N5O/c1-2-12-28(13-3-1)14-15-30-22-6-4-19(5-7-22)21-16-26-24-23(17-27-29(24)18-21)20-8-10-25-11-9-20/h4-11,16-18H,1-3,12-15H2, InChI=1S/C24H25N5O/c1-2-12-28(13-3-1)14-15-30-22-6-4-19(5-7-22)21-16-26-24-23(17-27-29(24)18-21)20-8-10-25-11-9-20/h4-11,16-18H,1-3,12-15H2, InChI=1S/C24H25N5O/c1-2-12-28(13-3-1)14-15-30-22-6-4-19(5-7-22)21-16-26-24-23(17-27-29(24)18-21)20-8-10-25-11-9-20/h4-11,16-18H,1-3,12-15H2	Preclinical
dorzolamide	carbonic anhydrase inhibitor	CA1, CA12, CA14, CA2, CA4, CA7	ophthalmology	intraocular pressure, glaucoma	CCN[C@H]1C[C@H](C)S(=O)(=O)c2sc(cc12)S(N)(=O)=O	IAVUPMFITXYVAF-XPUUQOCRSA-N	Launched
dosulepin	norepinephrine reuptake inhibitor, serotoninnorepinephrine reuptake inhibitor (SNRI), tricyclic antidepressant	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, HRH1, SLC6A2, SLC6A4	neurology/psychiatry	depression	CN(C)CC\C=C1/c2ccccc2CSc2ccccc12, CN(C)CC\C=C1/c2ccccc2CSc2ccccc12, CN(C)CC\C=C1/c2ccccc2CSc2ccccc12	PHTUQLWOUWZIMZ-GZTJUZNOSA-N, PHTUQLWOUWZIMZ-GZTJUZNOSA-N, PHTUQLWOUWZIMZ-GZTJUZNOSA-N	Launched
DOTMP					OP(O)(=O)CN1CCN(CP(O)(O)=O)CCN(CP(O)(O)=O)CCN(CP(O)(O)=O)CC1	RCXMQNIDOFXYDO-UHFFFAOYSA-N	Preclinical
dovitinib	EGFR inhibitor, FGFR inhibitor, FLT3 inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	CSF1R, EGFR, FGFR1, FGFR2, FGFR3, FLT1, FLT3, FLT4, INSR, KDR, KIT, PDGFRA, PDGFRB			CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O	PIQCTGMSNWUMAF-UHFFFAOYSA-N, PIQCTGMSNWUMAF-UHFFFAOYSA-N, PIQCTGMSNWUMAF-UHFFFAOYSA-N, PIQCTGMSNWUMAF-UHFFFAOYSA-N, PIQCTGMSNWUMAF-UHFFFAOYSA-N, PIQCTGMSNWUMAF-UHFFFAOYSA-N, PIQCTGMSNWUMAF-UHFFFAOYSA-N, PIQCTGMSNWUMAF-UHFFFAOYSA-N, PIQCTGMSNWUMAF-UHFFFAOYSA-N, PIQCTGMSNWUMAF-UHFFFAOYSA-N, PIQCTGMSNWUMAF-UHFFFAOYSA-N, PIQCTGMSNWUMAF-UHFFFAOYSA-N, PIQCTGMSNWUMAF-UHFFFAOYSA-N	Phase 3
doxapram	potassium channel blocker		pulmonary, neurology/psychiatry	respiratory depression, central nervous system depression, acute hypercapnia (AHC)	CCN1C[C@@H](CCN2CCOCC2)C(C1=O)(c1ccccc1)c1ccccc1 |&1:4|, CCN1C[C@@H](CCN2CCOCC2)C(C1=O)(c1ccccc1)c1ccccc1 |&1:4|, CCN1C[C@@H](CCN2CCOCC2)C(C1=O)(c1ccccc1)c1ccccc1 |&1:4|	XFDJYSQDBULQSI-JOCHJYFZSA-N, XFDJYSQDBULQSI-JOCHJYFZSA-N, XFDJYSQDBULQSI-JOCHJYFZSA-N	Launched
doxazosin	adrenergic receptor antagonist	ADRA1A, ADRA1B, ADRA1D	urology, cardiology	benign prostatic hyperplasia (BPH), hypertension	COc1cc2nc(nc(N)c2cc1OC)N1CCN(CC1)C(=O)[C@H]1COc2ccccc2O1 |&1:23,r|, COc1cc2nc(nc(N)c2cc1OC)N1CCN(CC1)C(=O)[C@H]1COc2ccccc2O1 |&1:23,r|	RUZYUOTYCVRMRZ-HXUWFJFHSA-N, RUZYUOTYCVRMRZ-HXUWFJFHSA-N	Launched
doxepin	histamine receptor antagonist	HRH1, SLC6A2, SLC6A4	neurology/psychiatry	depression, anxiety	CN(C)CC\C=C1\c2ccccc2COc2ccccc12, CN(C)CC\C=C1\c2ccccc2COc2ccccc12	ODQWQRRAPPTVAG-BOPFTXTBSA-N, ODQWQRRAPPTVAG-BOPFTXTBSA-N	Launched
doxercalciferol	vitamin D receptor agonist	VDR	nephrology, endocrinology	chronic kidney disease (CKD), hyperparathyroidism	CC(C)[C@H](C)\C=C\[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1/C[C@@H](O)C[C@H](O)C1=C, CC(C)[C@H](C)\C=C\[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1/C[C@@H](O)C[C@H](O)C1=C, CC(C)[C@H](C)\C=C\[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1/C[C@@H](O)C[C@H](O)C1=C, CC(C)[C@H](C)\C=C\[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1/C[C@@H](O)C[C@H](O)C1=C	HKXBNHCUPKIYDM-ZKVKAWQFSA-N, HKXBNHCUPKIYDM-ZKVKAWQFSA-N, HKXBNHCUPKIYDM-ZKVKAWQFSA-N, HKXBNHCUPKIYDM-ZKVKAWQFSA-N	Launched
doxifluridine	thymidylate synthase inhibitor	TYMS	oncology	colorectal cancer	C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cc(F)c(=O)[nH]c1=O, C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cc(F)c(=O)[nH]c1=O, C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cc(F)c(=O)[nH]c1=O, C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cc(F)c(=O)[nH]c1=O, C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cc(F)c(=O)[nH]c1=O	ZWAOHEXOSAUJHY-ZIYNGMLESA-N, ZWAOHEXOSAUJHY-ZIYNGMLESA-N, ZWAOHEXOSAUJHY-ZIYNGMLESA-N, ZWAOHEXOSAUJHY-ZIYNGMLESA-N, ZWAOHEXOSAUJHY-ZIYNGMLESA-N	Launched
doxofylline	adenosine receptor antagonist	ADORA1, PDE4A, PDE4B, PDE4C, PDE4D	pulmonary	asthma	Cn1c2ncn(CC3OCCO3)c2c(=O)n(C)c1=O, Cn1c2ncn(CC3OCCO3)c2c(=O)n(C)c1=O, Cn1c2ncn(CC3OCCO3)c2c(=O)n(C)c1=O, Cn1c2ncn(CC3OCCO3)c2c(=O)n(C)c1=O, Cn1c2ncn(CC3OCCO3)c2c(=O)n(C)c1=O	HWXIGFIVGWUZAO-UHFFFAOYSA-N, HWXIGFIVGWUZAO-UHFFFAOYSA-N, HWXIGFIVGWUZAO-UHFFFAOYSA-N, HWXIGFIVGWUZAO-UHFFFAOYSA-N, HWXIGFIVGWUZAO-UHFFFAOYSA-N	Launched
doxorubicin	topoisomerase inhibitor	TOP2A	hematologic malignancy, oncology	acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), Wilm's tumor, breast cancer, ovarian cancer, Hodgkin's lymphoma, bladder cancer, multiple myeloma			Launched
doxycycline	bacterial 30S ribosomal subunit inhibitor, metalloproteinase inhibitor	MMP8	dental	periodontitis	C[C@@H]1[C@H]2[C@H](O)[C@H]3[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]3(O)C(O)=C2C(=O)c2c(O)cccc12 |a:1,2,3,5,6,18,&1:12,&2:22,c:22,t:11|, C[C@@H]1[C@H]2[C@H](O)[C@H]3[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]3(O)C(O)=C2C(=O)c2c(O)cccc12 |a:1,2,3,5,6,18,&1:12,&2:22,c:22,t:11|, C[C@@H]1[C@H]2[C@H](O)[C@H]3[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]3(O)C(O)=C2C(=O)c2c(O)cccc12 |a:1,2,3,5,6,18,&1:12,&2:22,c:22,t:11|, C[C@@H]1[C@H]2[C@H](O)[C@H]3[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]3(O)C(O)=C2C(=O)c2c(O)cccc12 |a:1,2,3,5,6,18,&1:12,&2:22,c:22,t:11|, C[C@@H]1[C@H]2[C@H](O)[C@H]3[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]3(O)C(O)=C2C(=O)c2c(O)cccc12 |a:1,2,3,5,6,18,&1:12,&2:22,c:22,t:11|	JBIWCJUYHHGXTC-AKNGSSGZSA-N, JBIWCJUYHHGXTC-AKNGSSGZSA-N, JBIWCJUYHHGXTC-AKNGSSGZSA-N, JBIWCJUYHHGXTC-AKNGSSGZSA-N, JBIWCJUYHHGXTC-AKNGSSGZSA-N	Launched
doxylamine	histamine receptor antagonist	HRH1	neurology/psychiatry	sedative	CN(C)CCOC(C)(c1ccccc1)c1ccccn1, CN(C)CCOC(C)(c1ccccc1)c1ccccn1	HCFDWZZGGLSKEP-UHFFFAOYSA-N, HCFDWZZGGLSKEP-UHFFFAOYSA-N	Launched
DpC					CN(C1CCCCC1)C(=S)NN=C(c1ccccn1)c1ccccn1	GNLZNQJBZNOUBM-UHFFFAOYSA-N	Phase 1
DPC-681	HIV protease inhibitor				CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)CNCc1cccc(F)c1)C(C)(C)C)S(=O)(=O)c1cccc(N)c1	PNIFFZXGBAYVMQ-RKKDRKJOSA-N	Phase 1
DPCPX	adenosine receptor antagonist	ADORA1, ADORA2A, ADORA2B, ADORA3			CCCn1c2nc([nH]c2c(=O)n(CCC)c1=O)C1CCCC1, CCCn1c2nc([nH]c2c(=O)n(CCC)c1=O)C1CCCC1, CCCn1c2nc([nH]c2c(=O)n(CCC)c1=O)C1CCCC1	FFBDFADSZUINTG-UHFFFAOYSA-N, FFBDFADSZUINTG-UHFFFAOYSA-N, FFBDFADSZUINTG-UHFFFAOYSA-N	Phase 1
DPI-201106	sodium channel activator	ADRB2			O[C@@H](COc1cccc2[nH]c(cc12)C#N)CN1CCN(CC1)C(c1ccccc1)c1ccccc1 |&1:1,r|	BYBYHCOEAFHGJL-RUZDIDTESA-N	Phase 2
DPO-1	potassium channel blocker	KCNA5			CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1P(=O)(c1ccccc1)c1ccccc1, CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1P(=O)(c1ccccc1)c1ccccc1, CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1P(=O)(c1ccccc1)c1ccccc1	BPCNGVCAHAIZEE-COPCDDAFSA-N, BPCNGVCAHAIZEE-COPCDDAFSA-N, BPCNGVCAHAIZEE-COPCDDAFSA-N	Preclinical
DPPE	histamine receptor antagonist	ABCB1, HRH1			CCN(CC)CCOc1ccc(Cc2ccccc2)cc1, CCN(CC)CCOc1ccc(Cc2ccccc2)cc1, CCN(CC)CCOc1ccc(Cc2ccccc2)cc1	NFIXBCVWIPOYCD-UHFFFAOYSA-N, NFIXBCVWIPOYCD-UHFFFAOYSA-N, NFIXBCVWIPOYCD-UHFFFAOYSA-N	Phase 3
DQP-1105	glutamate receptor antagonist	GRIN2C, GRIN2D			Cc1ccc2[nH]c(=O)c(C3=NN([C@@H](C3)c3ccc(Br)cc3)C(=O)CCC(O)=O)c(-c3ccccc3)c2c1 |&1:12,r,t:9|, Cc1ccc2[nH]c(=O)c(C3=NN([C@@H](C3)c3ccc(Br)cc3)C(=O)CCC(O)=O)c(-c3ccccc3)c2c1 |&1:12,r,t:9|, Cc1ccc2[nH]c(=O)c(C3=NN([C@@H](C3)c3ccc(Br)cc3)C(=O)CCC(O)=O)c(-c3ccccc3)c2c1 |&1:12,r,t:9|	MVYNQMRZRULRIE-DEOSSOPVSA-N, MVYNQMRZRULRIE-DEOSSOPVSA-N, MVYNQMRZRULRIE-DEOSSOPVSA-N	Preclinical
DR-2313	PARP inhibitor	PARP1, PARP3			Cc1nc(=O)c2CSCCc2[nH]1, Cc1nc(=O)c2CSCCc2[nH]1	HRYKZAKEAVZGJD-UHFFFAOYSA-N, HRYKZAKEAVZGJD-UHFFFAOYSA-N	Preclinical
DR-4485	serotonin receptor antagonist	HTR7			Clc1ccc(cc1)C1=CCN(CCCC[C@@]23CCCc4c2c(NC3=O)ccc4Cl)CC1 |&1:15,t:8|, Clc1ccc(cc1)C1=CCN(CCCC[C@@]23CCCc4c2c(NC3=O)ccc4Cl)CC1 |&1:15,t:8|, Clc1ccc(cc1)C1=CCN(CCCC[C@@]23CCCc4c2c(NC3=O)ccc4Cl)CC1 |&1:15,t:8|	SBTRHJHOLCAPFT-AREMUKBSSA-N, SBTRHJHOLCAPFT-AREMUKBSSA-N, SBTRHJHOLCAPFT-AREMUKBSSA-N	Preclinical
DRF053-(R)	CDK inhibitor	CSNK1A1			CC[C@H](CO)Nc1nc(Nc2cccc(c2)-c2ccccn2)c2ncn(C(C)C)c2n1, CC[C@H](CO)Nc1nc(Nc2cccc(c2)-c2ccccn2)c2ncn(C(C)C)c2n1, CC[C@H](CO)Nc1nc(Nc2cccc(c2)-c2ccccn2)c2ncn(C(C)C)c2n1	LWANFAFTTOKZAX-QGZVFWFLSA-N, LWANFAFTTOKZAX-QGZVFWFLSA-N, LWANFAFTTOKZAX-QGZVFWFLSA-N	Preclinical
drofenine			neurology/psychiatry	spasms	CCN(CC)CCOC(=O)[C@@H](C1CCCCC1)c1ccccc1 |&1:10|, CCN(CC)CCOC(=O)[C@@H](C1CCCCC1)c1ccccc1 |&1:10|	AGJBLWCLQCKRJP-LJQANCHMSA-N, AGJBLWCLQCKRJP-LJQANCHMSA-N	Launched
droloxifene	selective estrogen receptor modulator (SERM)	ESR1			CC\C(=C(\c1ccc(OCCN(C)C)cc1)c1cccc(O)c1)c1ccccc1	ZQZFYGIXNQKOAV-OCEACIFDSA-N	Phase 3
dromostanolone-propionate	androgen receptor modulator	AR	oncology	breast cancer	CCC(=O)O[C@H]1CC[C@H]2[C@H]3CC[C@H]4CC(=O)[C@@H](C)C[C@@]4(C)[C@@H]3CC[C@@]12C |&1:5,&2:8,&3:9,&4:12,&5:16,&6:19,&7:21,&8:24,r|, CCC(=O)O[C@H]1CC[C@H]2[C@H]3CC[C@H]4CC(=O)[C@@H](C)C[C@@]4(C)[C@@H]3CC[C@@]12C |&1:5,&2:8,&3:9,&4:12,&5:16,&6:19,&7:21,&8:24,r|	NOTIQUSPUUHHEH-QOMQUSCHSA-N, NOTIQUSPUUHHEH-QOMQUSCHSA-N	Launched
dronedarone	adrenergic receptor antagonist	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, CACNA1C, CACNA1D, CACNA1F, CACNA1S, CACNB1, CACNB2, CACNB3, CACNB4, KCNA5, KCNH2, KCNK2, SCN1A	cardiology	atrial fibrillation (AF)	CCCCN(CCCC)CCCOc1ccc(cc1)C(=O)c1c(CCCC)oc2ccc(NS(C)(=O)=O)cc12, CCCCN(CCCC)CCCOc1ccc(cc1)C(=O)c1c(CCCC)oc2ccc(NS(C)(=O)=O)cc12, CCCCN(CCCC)CCCOc1ccc(cc1)C(=O)c1c(CCCC)oc2ccc(NS(C)(=O)=O)cc12, CCCCN(CCCC)CCCOc1ccc(cc1)C(=O)c1c(CCCC)oc2ccc(NS(C)(=O)=O)cc12, CCCCN(CCCC)CCCOc1ccc(cc1)C(=O)c1c(CCCC)oc2ccc(NS(C)(=O)=O)cc12	ZQTNQVWKHCQYLQ-UHFFFAOYSA-N, ZQTNQVWKHCQYLQ-UHFFFAOYSA-N, ZQTNQVWKHCQYLQ-UHFFFAOYSA-N, ZQTNQVWKHCQYLQ-UHFFFAOYSA-N, ZQTNQVWKHCQYLQ-UHFFFAOYSA-N	Launched
droperidol	dopamine receptor antagonist	ADRA1A, DRD2, DRD3, DRD4, HTR2A	gastroenterology	nausea, vomiting	Fc1ccc(cc1)C(=O)CCCN1CCC(=CC1)n1c2ccccc2[nH]c1=O |c:16|, Fc1ccc(cc1)C(=O)CCCN1CCC(=CC1)n1c2ccccc2[nH]c1=O |c:16|, Fc1ccc(cc1)C(=O)CCCN1CCC(=CC1)n1c2ccccc2[nH]c1=O |c:16|	RMEDXOLNCUSCGS-UHFFFAOYSA-N, RMEDXOLNCUSCGS-UHFFFAOYSA-N, RMEDXOLNCUSCGS-UHFFFAOYSA-N	Launched
dropropizine	antitussive		pulmonary	cough suppressant	OC[C@@H](O)CN1CCN(CC1)c1ccccc1 |&1:2,r|, OC[C@@H](O)CN1CCN(CC1)c1ccccc1 |&1:2,r|, OC[C@@H](O)CN1CCN(CC1)c1ccccc1 |&1:2,r|, OC[C@@H](O)CN1CCN(CC1)c1ccccc1 |&1:2,r|	PTVWPYVOOKLBCG-ZDUSSCGKSA-N, PTVWPYVOOKLBCG-ZDUSSCGKSA-N, PTVWPYVOOKLBCG-ZDUSSCGKSA-N, PTVWPYVOOKLBCG-ZDUSSCGKSA-N	Launched
drospirenone	mineralocorticoid receptor antagonist	AR, NR3C2, PGR	endocrinology	contraceptive	C[C@]12CC[C@H]3[C@@H]([C@H]4C[C@H]4C4=CC(=O)CC[C@]34C)[C@@H]1[C@@H]1C[C@@H]1[C@@]21CCC(=O)O1 |t:10|, C[C@]12CC[C@H]3[C@@H]([C@H]4C[C@H]4C4=CC(=O)CC[C@]34C)[C@@H]1[C@@H]1C[C@@H]1[C@@]21CCC(=O)O1 |t:10|, C[C@]12CC[C@H]3[C@@H]([C@H]4C[C@H]4C4=CC(=O)CC[C@]34C)[C@@H]1[C@@H]1C[C@@H]1[C@@]21CCC(=O)O1 |t:10|, C[C@]12CC[C@H]3[C@@H]([C@H]4C[C@H]4C4=CC(=O)CC[C@]34C)[C@@H]1[C@@H]1C[C@@H]1[C@@]21CCC(=O)O1 |t:10|, C[C@]12CC[C@H]3[C@@H]([C@H]4C[C@H]4C4=CC(=O)CC[C@]34C)[C@@H]1[C@@H]1C[C@@H]1[C@@]21CCC(=O)O1 |t:10|, C[C@]12CC[C@H]3[C@@H]([C@H]4C[C@H]4C4=CC(=O)CC[C@]34C)[C@@H]1[C@@H]1C[C@@H]1[C@@]21CCC(=O)O1 |t:10|, C[C@]12CC[C@H]3[C@@H]([C@H]4C[C@H]4C4=CC(=O)CC[C@]34C)[C@@H]1[C@@H]1C[C@@H]1[C@@]21CCC(=O)O1 |t:10|	METQSPRSQINEEU-HXCATZOESA-N, METQSPRSQINEEU-HXCATZOESA-N, METQSPRSQINEEU-HXCATZOESA-N, METQSPRSQINEEU-HXCATZOESA-N, METQSPRSQINEEU-HXCATZOESA-N, METQSPRSQINEEU-HXCATZOESA-N, METQSPRSQINEEU-HXCATZOESA-N	Launched
drotaverine	phosphodiesterase inhibitor		obstetrics/gynecology	labor induction	CCOc1ccc(CC2=NCCc3cc(OCC)c(OCC)cc23)cc1OCC |t:8|, CCOc1ccc(CC2=NCCc3cc(OCC)c(OCC)cc23)cc1OCC |t:8|, CCOc1ccc(CC2=NCCc3cc(OCC)c(OCC)cc23)cc1OCC |t:8|, CCOc1ccc(CC2=NCCc3cc(OCC)c(OCC)cc23)cc1OCC |t:8|	NCVXEYAKRVJMTQ-UHFFFAOYSA-N, NCVXEYAKRVJMTQ-UHFFFAOYSA-N, NCVXEYAKRVJMTQ-UHFFFAOYSA-N, NCVXEYAKRVJMTQ-UHFFFAOYSA-N	Launched
droxicam	cyclooxygenase inhibitor	PTGS1	rheumatology	rheumatoid arthritis, osteoarthritis	CN1c2c(oc(=O)n(-c3ccccn3)c2=O)-c2ccccc2S1(=O)=O, CN1c2c(oc(=O)n(-c3ccccn3)c2=O)-c2ccccc2S1(=O)=O	OEHFRZLKGRKFAS-UHFFFAOYSA-N, OEHFRZLKGRKFAS-UHFFFAOYSA-N	Launched
droxidopa	norepinephrine precursor	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3, PAH	cardiology, neurology/psychiatry	hypertension, Parkinson's Disease	N[C@@H]([C@H](O)c1ccc(O)c(O)c1)C(O)=O, N[C@@H]([C@H](O)c1ccc(O)c(O)c1)C(O)=O, N[C@@H]([C@H](O)c1ccc(O)c(O)c1)C(O)=O, N[C@@H]([C@H](O)c1ccc(O)c(O)c1)C(O)=O, N[C@@H]([C@H](O)c1ccc(O)c(O)c1)C(O)=O	QXWYKJLNLSIPIN-JGVFFNPUSA-N, QXWYKJLNLSIPIN-JGVFFNPUSA-N, QXWYKJLNLSIPIN-JGVFFNPUSA-N, QXWYKJLNLSIPIN-JGVFFNPUSA-N, QXWYKJLNLSIPIN-JGVFFNPUSA-N	Launched
droxinostat	HDAC inhibitor	HDAC6, HDAC8			Cc1cc(Cl)ccc1OCCCC(=O)NO, Cc1cc(Cl)ccc1OCCCC(=O)NO, Cc1cc(Cl)ccc1OCCCC(=O)NO, Cc1cc(Cl)ccc1OCCCC(=O)NO	JHSXDAWGLCZYSM-UHFFFAOYSA-N, JHSXDAWGLCZYSM-UHFFFAOYSA-N, JHSXDAWGLCZYSM-UHFFFAOYSA-N, JHSXDAWGLCZYSM-UHFFFAOYSA-N	Preclinical
DSM265	dihydroorotate dehydrogenase inhibitor				Cc1cc(Nc2ccc(cc2)S(F)(F)(F)(F)F)n2nc(nc2n1)C(C)(F)F	OIZSVTOIBNSVOS-UHFFFAOYSA-N	Phase 2
DSPC					CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](COP(O)(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC |&1:21,r|	NRJAVPSFFCBXDT-WBCKFURZSA-O	Preclinical
DSR-6434	toll-like receptor agonist	TLR7			CCCCNc1nc(N)c2[nH]c(=O)n(Cc3ccc(OCCN(C)C)nc3)c2n1, CCCCNc1nc(N)c2[nH]c(=O)n(Cc3ccc(OCCN(C)C)nc3)c2n1	SSZHESNDOMBSRV-UHFFFAOYSA-N, SSZHESNDOMBSRV-UHFFFAOYSA-N	Preclinical
DS2-(806622)					Clc1ccc(cc1)C(=O)Nc1c(nc2ccccn12)-c1cccs1, Clc1ccc(cc1)C(=O)Nc1c(nc2ccccn12)-c1cccs1, Clc1ccc(cc1)C(=O)Nc1c(nc2ccccn12)-c1cccs1	AZKMWHRDICVYEI-UHFFFAOYSA-N, AZKMWHRDICVYEI-UHFFFAOYSA-N, AZKMWHRDICVYEI-UHFFFAOYSA-N	Preclinical
DU-728	structural glycoprotein antagonist	ITGA2B, ITGB3			N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(O)=O, N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(O)=O	NNRFRJQMBSBXGO-CIUDSAMLSA-N, NNRFRJQMBSBXGO-CIUDSAMLSA-N	Phase 1
duloxetine	norepinephrine reuptake inhibitor, serotoninnorepinephrine reuptake inhibitor (SNRI)	HTR2A, HTR2C, HTR6, SLC6A2, SLC6A3, SLC6A4	neurology/psychiatry	depression, generalized anxiety disorder (GAD), muscle pain, peripheral neuropathy	CNCC[C@H](Oc1cccc2ccccc12)c1cccs1, CNCC[C@H](Oc1cccc2ccccc12)c1cccs1, CNCC[C@H](Oc1cccc2ccccc12)c1cccs1, CNCC[C@H](Oc1cccc2ccccc12)c1cccs1, CNCC[C@H](Oc1cccc2ccccc12)c1cccs1, CNCC[C@H](Oc1cccc2ccccc12)c1cccs1	ZEUITGRIYCTCEM-KRWDZBQOSA-N, ZEUITGRIYCTCEM-KRWDZBQOSA-N, ZEUITGRIYCTCEM-KRWDZBQOSA-N, ZEUITGRIYCTCEM-KRWDZBQOSA-N, ZEUITGRIYCTCEM-KRWDZBQOSA-N, ZEUITGRIYCTCEM-KRWDZBQOSA-N	Launched
DUP-697	cyclooxygenase inhibitor	PTGS2			CS(=O)(=O)c1ccc(cc1)-c1cc(Br)sc1-c1ccc(F)cc1, CS(=O)(=O)c1ccc(cc1)-c1cc(Br)sc1-c1ccc(F)cc1, CS(=O)(=O)c1ccc(cc1)-c1cc(Br)sc1-c1ccc(F)cc1	AJFTZWGGHJXZOB-UHFFFAOYSA-N, AJFTZWGGHJXZOB-UHFFFAOYSA-N, AJFTZWGGHJXZOB-UHFFFAOYSA-N	Phase 1
dutasteride	5 alpha reductase inhibitor	SRD5A1, SRD5A2, SRD5A3	urology	benign prostatic hyperplasia (BPH)	C[C@]12CC[C@H]3[C@@H](CC[C@H]4NC(=O)C=C[C@]34C)[C@@H]1CC[C@@H]2C(=O)Nc1cc(ccc1C(F)(F)F)C(F)(F)F |c:12|, C[C@]12CC[C@H]3[C@@H](CC[C@H]4NC(=O)C=C[C@]34C)[C@@H]1CC[C@@H]2C(=O)Nc1cc(ccc1C(F)(F)F)C(F)(F)F |c:12|, C[C@]12CC[C@H]3[C@@H](CC[C@H]4NC(=O)C=C[C@]34C)[C@@H]1CC[C@@H]2C(=O)Nc1cc(ccc1C(F)(F)F)C(F)(F)F |c:12|	JWJOTENAMICLJG-QWBYCMEYSA-N, JWJOTENAMICLJG-QWBYCMEYSA-N, JWJOTENAMICLJG-QWBYCMEYSA-N	Launched
duvelisib	PI3K inhibitor	PIK3CA, PIK3CB, PIK3CD, PIK3CG			C[C@H](Nc1ncnc2nc[nH]c12)c1cc2cccc(Cl)c2c(=O)n1-c1ccccc1, C[C@H](Nc1ncnc2nc[nH]c12)c1cc2cccc(Cl)c2c(=O)n1-c1ccccc1, C[C@H](Nc1ncnc2nc[nH]c12)c1cc2cccc(Cl)c2c(=O)n1-c1ccccc1, C[C@H](Nc1ncnc2nc[nH]c12)c1cc2cccc(Cl)c2c(=O)n1-c1ccccc1	SJVQHLPISAIATJ-ZDUSSCGKSA-N, SJVQHLPISAIATJ-ZDUSSCGKSA-N, SJVQHLPISAIATJ-ZDUSSCGKSA-N, SJVQHLPISAIATJ-ZDUSSCGKSA-N	Launched
DVD-111					CCOC(=O)CNC(=O)[C@@H]1CCCN1C(=O)Cc1ccccc1, CCOC(=O)CNC(=O)[C@@H]1CCCN1C(=O)Cc1ccccc1	PJNSMUBMSNAEEN-AWEZNQCLSA-N, PJNSMUBMSNAEEN-AWEZNQCLSA-N	Phase 2
DWK-1339	beta amyloid aggregation inhibitor				COCCCc1ccc2oc(cc2c1)-c1ccc(OC)c(OC)c1	CUEPJIGXQLIOIK-UHFFFAOYSA-N	Preclinical
dyclonine	sodium channel blocker	SCN10A, SCN5A	neurology/psychiatry	local anesthetic	CCCCOc1ccc(cc1)C(=O)CCN1CCCCC1, CCCCOc1ccc(cc1)C(=O)CCN1CCCCC1, CCCCOc1ccc(cc1)C(=O)CCN1CCCCC1, CCCCOc1ccc(cc1)C(=O)CCN1CCCCC1, CCCCOc1ccc(cc1)C(=O)CCN1CCCCC1, CCCCOc1ccc(cc1)C(=O)CCN1CCCCC1, CCCCOc1ccc(cc1)C(=O)CCN1CCCCC1	BZEWSEKUUPWQDQ-UHFFFAOYSA-N, BZEWSEKUUPWQDQ-UHFFFAOYSA-N, BZEWSEKUUPWQDQ-UHFFFAOYSA-N, BZEWSEKUUPWQDQ-UHFFFAOYSA-N, BZEWSEKUUPWQDQ-UHFFFAOYSA-N, BZEWSEKUUPWQDQ-UHFFFAOYSA-N, BZEWSEKUUPWQDQ-UHFFFAOYSA-N	Launched
dydrogesterone	progesterone receptor agonist	PGR	obstetrics/gynecology	infertility	CC(=O)[C@H]1CC[C@H]2[C@@H]3C=CC4=CC(=O)CC[C@@]4(C)[C@@H]3CC[C@]12C |c:8,t:10|, CC(=O)[C@H]1CC[C@H]2[C@@H]3C=CC4=CC(=O)CC[C@@]4(C)[C@@H]3CC[C@]12C |c:8,t:10|, CC(=O)[C@H]1CC[C@H]2[C@@H]3C=CC4=CC(=O)CC[C@@]4(C)[C@@H]3CC[C@]12C |c:8,t:10|, CC(=O)[C@H]1CC[C@H]2[C@@H]3C=CC4=CC(=O)CC[C@@]4(C)[C@@H]3CC[C@]12C |c:8,t:10|	JGMOKGBVKVMRFX-HQZYFCCVSA-N, JGMOKGBVKVMRFX-HQZYFCCVSA-N, JGMOKGBVKVMRFX-HQZYFCCVSA-N, JGMOKGBVKVMRFX-HQZYFCCVSA-N	Launched
dynasore	dynamin inhibitor	DNM1, DNM1L, DNM2			Oc1ccc(\C=N\NC(=O)c2cc3ccccc3cc2O)cc1O, Oc1ccc(\C=N\NC(=O)c2cc3ccccc3cc2O)cc1O, Oc1ccc(\C=N\NC(=O)c2cc3ccccc3cc2O)cc1O, Oc1ccc(\C=N\NC(=O)c2cc3ccccc3cc2O)cc1O, Oc1ccc(\C=N\NC(=O)c2cc3ccccc3cc2O)cc1O, Oc1ccc(\C=N\NC(=O)c2cc3ccccc3cc2O)cc1O	SYNDQCRDGGCQRZ-VXLYETTFSA-N, SYNDQCRDGGCQRZ-VXLYETTFSA-N, SYNDQCRDGGCQRZ-VXLYETTFSA-N, SYNDQCRDGGCQRZ-VXLYETTFSA-N, SYNDQCRDGGCQRZ-VXLYETTFSA-N, SYNDQCRDGGCQRZ-VXLYETTFSA-N	Preclinical
dynole-34-2	dynamin inhibitor	DNM1			CCCCCCCCNC(=O)C(=C\c1cn(CCCN(C)C)c2ccccc12)\C#N, CCCCCCCCNC(=O)C(=C\c1cn(CCCN(C)C)c2ccccc12)\C#N	MYIMRONQBLZJFI-DYTRJAOYSA-N, MYIMRONQBLZJFI-DYTRJAOYSA-N	Preclinical
dyphylline	adenosine receptor antagonist, phosphodiesterase inhibitor	PDE4A	pulmonary	asthma, bronchitis, emphysema	Cn1c2ncn(C[C@@H](O)CO)c2c(=O)n(C)c1=O |&1:7,r|, Cn1c2ncn(C[C@@H](O)CO)c2c(=O)n(C)c1=O |&1:7,r|, Cn1c2ncn(C[C@@H](O)CO)c2c(=O)n(C)c1=O |&1:7,r|	KSCFJBIXMNOVSH-ZCFIWIBFSA-N, KSCFJBIXMNOVSH-ZCFIWIBFSA-N, KSCFJBIXMNOVSH-ZCFIWIBFSA-N	Launched
DY131	estrogen-related receptor agonist	ESRRB, ESRRG			CCN(CC)c1ccc(\C=N\NC(=O)c2ccc(O)cc2)cc1, CCN(CC)c1ccc(\C=N\NC(=O)c2ccc(O)cc2)cc1, CCN(CC)c1ccc(\C=N\NC(=O)c2ccc(O)cc2)cc1	WLKOCYWYAWBGKY-CPNJWEJPSA-N, WLKOCYWYAWBGKY-CPNJWEJPSA-N, WLKOCYWYAWBGKY-CPNJWEJPSA-N	Preclinical
D609	phospholipase inhibitor				SC(=S)OC1CC2CC1C1CCCC21, SC(=S)OC1CC2CC1C1CCCC21, SC(=S)OC1CC2CC1C1CCCC21, SC(=S)OC1CC2CC1C1CCCC21	PWLXJBSAUKKGCM-UHFFFAOYSA-N, PWLXJBSAUKKGCM-UHFFFAOYSA-N, PWLXJBSAUKKGCM-UHFFFAOYSA-N, PWLXJBSAUKKGCM-UHFFFAOYSA-N	Preclinical
E-2001	antioxidant				Fc1ccc(cc1)C(=O)C1CCN(CC(=O)c2ccc3ccccc3c2)CC1	WPFPDSUMDURRRW-UHFFFAOYSA-N	Preclinical
E-2012	gamma secretase modulator	APH1A, APH1B, PSENEN			COc1cc(\C=C2/CCCN([C@@H](C)c3ccc(F)cc3)C2=O)ccc1-n1cnc(C)c1, COc1cc(\C=C2/CCCN([C@@H](C)c3ccc(F)cc3)C2=O)ccc1-n1cnc(C)c1	PUOAETJYKQITMO-LANLRWRYSA-N, PUOAETJYKQITMO-LANLRWRYSA-N	Phase 1
E-4031	potassium channel blocker	KCNH1, KCNH2			Cc1cccc(CCN2CCC(CC2)C(=O)c2ccc(NS(C)(=O)=O)cc2)n1, Cc1cccc(CCN2CCC(CC2)C(=O)c2ccc(NS(C)(=O)=O)cc2)n1, Cc1cccc(CCN2CCC(CC2)C(=O)c2ccc(NS(C)(=O)=O)cc2)n1, Cc1cccc(CCN2CCC(CC2)C(=O)c2ccc(NS(C)(=O)=O)cc2)n1	SRUISGSHWFJION-UHFFFAOYSA-N, SRUISGSHWFJION-UHFFFAOYSA-N, SRUISGSHWFJION-UHFFFAOYSA-N, SRUISGSHWFJION-UHFFFAOYSA-N	Phase 1
E-64	calpain inhibitor, cysteine protease inhibitor	CTSS			CC(C)C[C@H](NC(=O)[C@H]1O[C@@H]1C(O)=O)C(=O)NCCCCNC(N)=N, CC(C)C[C@H](NC(=O)[C@H]1O[C@@H]1C(O)=O)C(=O)NCCCCNC(N)=N	LTLYEAJONXGNFG-DCAQKATOSA-N, LTLYEAJONXGNFG-DCAQKATOSA-N	Preclinical
eact	calcium-activated chloride channel inhibitor	ANO1			COCCN(C(=O)c1cc(OC)c(OC)c(OC)c1)c1nc(cs1)-c1ccccc1, COCCN(C(=O)c1cc(OC)c(OC)c(OC)c1)c1nc(cs1)-c1ccccc1	ZUXNHFFVQWADJL-UHFFFAOYSA-N, ZUXNHFFVQWADJL-UHFFFAOYSA-N	Preclinical
EB-47	PARP inhibitor	PARP1			Nc1ncnc2n(cnc12)[C@H]1O[C@H]([C@H](O)[C@@H]1O)C(=O)N1CCN(CC(=O)Nc2cccc3C(=O)NCc23)CC1, Nc1ncnc2n(cnc12)[C@H]1O[C@H]([C@H](O)[C@@H]1O)C(=O)N1CCN(CC(=O)Nc2cccc3C(=O)NCc23)CC1, Nc1ncnc2n(cnc12)[C@H]1O[C@H]([C@H](O)[C@@H]1O)C(=O)N1CCN(CC(=O)Nc2cccc3C(=O)NCc23)CC1, Nc1ncnc2n(cnc12)[C@H]1O[C@H]([C@H](O)[C@@H]1O)C(=O)N1CCN(CC(=O)Nc2cccc3C(=O)NCc23)CC1	DDFLFKTXUWPNMV-LFALDJFMSA-N, DDFLFKTXUWPNMV-LFALDJFMSA-N, DDFLFKTXUWPNMV-LFALDJFMSA-N, DDFLFKTXUWPNMV-LFALDJFMSA-N	Preclinical
ebastine	histamine receptor antagonist	CYP3A4, HRH1	allergy	allergic rhinitis, urticaria	CC(C)(C)c1ccc(cc1)C(=O)CCCN1CCC(CC1)OC(c1ccccc1)c1ccccc1, CC(C)(C)c1ccc(cc1)C(=O)CCCN1CCC(CC1)OC(c1ccccc1)c1ccccc1, CC(C)(C)c1ccc(cc1)C(=O)CCCN1CCC(CC1)OC(c1ccccc1)c1ccccc1, CC(C)(C)c1ccc(cc1)C(=O)CCCN1CCC(CC1)OC(c1ccccc1)c1ccccc1	MJJALKDDGIKVBE-UHFFFAOYSA-N, MJJALKDDGIKVBE-UHFFFAOYSA-N, MJJALKDDGIKVBE-UHFFFAOYSA-N, MJJALKDDGIKVBE-UHFFFAOYSA-N	Launched
EBPC	aldose reductase inhibitor	AKR1B1			CCOC(=O)[C@@H]1CN(Cc2ccccc2)C(=O)C1=O |&1:5,r|	FQMSSTZJKSWSMP-LLVKDONJSA-N	Preclinical
ebrotidine	histamine receptor antagonist	HRH2			NC(=N)Nc1nc(CSCCN\C=N\S(=O)(=O)c2ccc(Br)cc2)cs1, NC(=N)Nc1nc(CSCCN\C=N\S(=O)(=O)c2ccc(Br)cc2)cs1, NC(=N)Nc1nc(CSCCN\C=N\S(=O)(=O)c2ccc(Br)cc2)cs1, NC(=N)Nc1nc(CSCCN\C=N\S(=O)(=O)c2ccc(Br)cc2)cs1	ZQHFZHPUZXNPMF-UHFFFAOYSA-N, ZQHFZHPUZXNPMF-UHFFFAOYSA-N, ZQHFZHPUZXNPMF-UHFFFAOYSA-N, ZQHFZHPUZXNPMF-UHFFFAOYSA-N	Withdrawn
ebselen	cyclooxygenase inhibitor, glutathione peroxidase agonist, H+/K+-ATPase inhibitor, nitric oxide synthase inhibitor	ALB			O=c1n([se]c2ccccc12)-c1ccccc1, O=c1n([se]c2ccccc12)-c1ccccc1, O=c1n([se]c2ccccc12)-c1ccccc1	DYEFUKCXAQOFHX-UHFFFAOYSA-N, DYEFUKCXAQOFHX-UHFFFAOYSA-N, DYEFUKCXAQOFHX-UHFFFAOYSA-N	Phase 2/Phase 3
EC-144	HSP inhibitor	HSP90AA1, HSP90AB1			COc1c(C)cnc(Cn2cc(C#CCC(C)(C)O)c3c(Cl)nc(N)nc23)c1C, COc1c(C)cnc(Cn2cc(C#CCC(C)(C)O)c3c(Cl)nc(N)nc23)c1C, COc1c(C)cnc(Cn2cc(C#CCC(C)(C)O)c3c(Cl)nc(N)nc23)c1C, COc1c(C)cnc(Cn2cc(C#CCC(C)(C)O)c3c(Cl)nc(N)nc23)c1C	VOASEWXFCTZRDF-UHFFFAOYSA-N, VOASEWXFCTZRDF-UHFFFAOYSA-N, VOASEWXFCTZRDF-UHFFFAOYSA-N, VOASEWXFCTZRDF-UHFFFAOYSA-N	Preclinical
EC-23	retinoid receptor agonist	RARA, RARB, RARG			CC1(C)CCC(C)(C)c2cc(ccc12)C#Cc1ccc(cc1)C(O)=O, CC1(C)CCC(C)(C)c2cc(ccc12)C#Cc1ccc(cc1)C(O)=O, CC1(C)CCC(C)(C)c2cc(ccc12)C#Cc1ccc(cc1)C(O)=O	OQVLOWLEEHYBJH-UHFFFAOYSA-N, OQVLOWLEEHYBJH-UHFFFAOYSA-N, OQVLOWLEEHYBJH-UHFFFAOYSA-N	Preclinical
ecabapide					CNC(=O)c1cccc(NCC(=O)NCCc2ccc(OC)c(OC)c2)c1, CNC(=O)c1cccc(NCC(=O)NCCc2ccc(OC)c(OC)c2)c1, CNC(=O)c1cccc(NCC(=O)NCCc2ccc(OC)c(OC)c2)c1	JTAGHJPZEDNHHA-UHFFFAOYSA-N, JTAGHJPZEDNHHA-UHFFFAOYSA-N, JTAGHJPZEDNHHA-UHFFFAOYSA-N	Phase 3
ecabet	gastrin inhibitor, urease inhibitor	NOXO1	ophthalmology	dry eye syndrome	CC(C)c1cc2CC[C@H]3[C@@](C)(CCC[C@]3(C)c2cc1S(O)(=O)=O)C(O)=O, CC(C)c1cc2CC[C@H]3[C@@](C)(CCC[C@]3(C)c2cc1S(O)(=O)=O)C(O)=O	IWCWQNVIUXZOMJ-MISYRCLQSA-N, IWCWQNVIUXZOMJ-MISYRCLQSA-N	Launched
ecamsule-triethanolamine			dermatology	skin protectant, sunscreen lotion	CC1(C)[C@H]2CC[C@]1(CS(O)(=O)=O)C(=O)C2=Cc1ccc(C=C2[C@@H]3CC[C@](CS(O)(=O)=O)(C2=O)C3(C)C)cc1 |&1:3,6,&2:22,25,r|	HEAHZSUCFKFERC-MPPVQRIUSA-N	Launched
echinomycin	DNA intercalating agent				[H][C@]1(COC(=O)[C@]([H])(C(C)C)N(C)C(=O)[C@]2([H])N(C)C(=O)[C@H](C)NC(=O)[C@@]([H])(COC(=O)[C@]([H])(C(C)C)N(C)C(=O)[C@]([H])(CS[C@]2([H])SC)N(C)C(=O)[C@H](C)NC1=O)NC(=O)c1cnc2ccccc2n1)NC(=O)c1cnc2ccccc2n1 |&1:45,@:8,34|	AUJXLBOHYWTPFV-DYWXRLDNSA-N	Phase 2
econazole	lanosterol demethylase inhibitor, sterol demethylase inhibitor	NPY1R, NPY2R, TRPM2, TRPV5	infectious disease	tinea pedis, tinea cruris, tinea corporis, tinea versicolor, cutaneous candidiasis	Clc1ccc(CO[C@@H](Cn2ccnc2)c2ccc(Cl)cc2Cl)cc1 |&1:7|, Clc1ccc(CO[C@@H](Cn2ccnc2)c2ccc(Cl)cc2Cl)cc1 |&1:7|, Clc1ccc(CO[C@@H](Cn2ccnc2)c2ccc(Cl)cc2Cl)cc1 |&1:7|, Clc1ccc(CO[C@@H](Cn2ccnc2)c2ccc(Cl)cc2Cl)cc1 |&1:7|, Clc1ccc(CO[C@@H](Cn2ccnc2)c2ccc(Cl)cc2Cl)cc1 |&1:7|, Clc1ccc(CO[C@@H](Cn2ccnc2)c2ccc(Cl)cc2Cl)cc1 |&1:7|, Clc1ccc(CO[C@@H](Cn2ccnc2)c2ccc(Cl)cc2Cl)cc1 |&1:7|, Clc1ccc(CO[C@@H](Cn2ccnc2)c2ccc(Cl)cc2Cl)cc1 |&1:7|	LEZWWPYKPKIXLL-SFHVURJKSA-N, LEZWWPYKPKIXLL-SFHVURJKSA-N, LEZWWPYKPKIXLL-SFHVURJKSA-N, LEZWWPYKPKIXLL-SFHVURJKSA-N, LEZWWPYKPKIXLL-SFHVURJKSA-N, LEZWWPYKPKIXLL-SFHVURJKSA-N, LEZWWPYKPKIXLL-SFHVURJKSA-N, LEZWWPYKPKIXLL-SFHVURJKSA-N	Launched
ectoine	anti-inflammatory agent				CC1=NCC[C@H](N1)C(O)=O |t:1|, CC1=NCC[C@H](N1)C(O)=O |t:1|	WQXNXVUDBPYKBA-YFKPBYRVSA-N, WQXNXVUDBPYKBA-YFKPBYRVSA-N	Launched
edaglitazone	PPAR receptor agonist	PPARG			Cc1oc(nc1CCOc1ccc(C[C@@H]2SC(=O)NC2=O)c2sccc12)-c1ccccc1 |&1:14,r|	HAAXAFNSRADSMK-FQEVSTJZSA-N	Phase 2
edaravone	nootropic agent	BCL2	neurology/psychiatry	stroke	Cc1cc(=O)n([nH]1)-c1ccccc1, Cc1cc(=O)n([nH]1)-c1ccccc1, Cc1cc(=O)n([nH]1)-c1ccccc1, Cc1cc(=O)n([nH]1)-c1ccccc1, Cc1cc(=O)n([nH]1)-c1ccccc1, Cc1cc(=O)n([nH]1)-c1ccccc1, Cc1cc(=O)n([nH]1)-c1ccccc1	KZQYIMCESJLPQH-UHFFFAOYSA-N, KZQYIMCESJLPQH-UHFFFAOYSA-N, KZQYIMCESJLPQH-UHFFFAOYSA-N, KZQYIMCESJLPQH-UHFFFAOYSA-N, KZQYIMCESJLPQH-UHFFFAOYSA-N, KZQYIMCESJLPQH-UHFFFAOYSA-N, KZQYIMCESJLPQH-UHFFFAOYSA-N	Launched
edasalonexent	NFkB pathway inhibitor				CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(=O)NCCNC(=O)c1ccccc1O	JQLBBYLGWHUHRW-KUBAVDMBSA-N	Phase 3
edelfosine	phospholipase inhibitor				CCCCCCCCCCCCCCCCCCOC[C@H](COP(O)(=O)OCC[N+](C)(C)C)OC |a:20,&1:23|, CCCCCCCCCCCCCCCCCCOC[C@H](COP(O)(=O)OCC[N+](C)(C)C)OC |a:20,&1:23|	MHFRGQHAERHWKZ-HHHXNRCGSA-O, MHFRGQHAERHWKZ-HHHXNRCGSA-O	Phase 2
editol					C[C@@H](O)CN(CCN(C[C@@H](C)O)C[C@@H](C)O)C[C@@H](C)O |&1:1,&2:9,&3:13,&4:17,r|, C[C@@H](O)CN(CCN(C[C@@H](C)O)C[C@@H](C)O)C[C@@H](C)O |&1:1,&2:9,&3:13,&4:17,r|	NSOXQYCFHDMMGV-AAVRWANBSA-N, NSOXQYCFHDMMGV-AAVRWANBSA-N	Preclinical
EDO-S101	HDAC inhibitor				Cn1c(CCCCCCC(=O)NO)nc2cc(ccc12)N(CCCl)CCCl	GISXTRIGVCKQBX-UHFFFAOYSA-N	Phase 1/Phase 2
edonerpic-maleate	beta amyloid inhibitor				OC1CN(CCCOCCc2ccc3sccc3c2)C1	HQNACSFBDBYLJP-UHFFFAOYSA-N	Preclinical
edoxaban	coagulation factor inhibitor	F10	neurology/psychiatry, hematology, cardiology	stroke, pulmonary embolism (PE), systemic embolism, deep vein thrombosis (DVT), atrial fibrillation (AF)	CN(C)C(=O)[C@H]1CC[C@H](NC(=O)C(=O)Nc2ccc(Cl)cn2)[C@@H](C1)NC(=O)c1nc2CCN(C)Cc2s1, CN(C)C(=O)[C@H]1CC[C@H](NC(=O)C(=O)Nc2ccc(Cl)cn2)[C@@H](C1)NC(=O)c1nc2CCN(C)Cc2s1	HGVDHZBSSITLCT-JLJPHGGASA-N, HGVDHZBSSITLCT-JLJPHGGASA-N	Launched
edoxudine	DNA directed DNA polymerase inhibitor		infectious disease	virus herpes simplex (HSV)	CCc1cn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)[nH]c1=O, CCc1cn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)[nH]c1=O	XACKNLSZYYIACO-DJLDLDEBSA-N, XACKNLSZYYIACO-DJLDLDEBSA-N	Launched
edrophonium	acetylcholinesterase inhibitor	ACHE, BCHE	neurology/psychiatry	myasthenia gravis	CC[N+](C)(C)c1cccc(O)c1, CC[N+](C)(C)c1cccc(O)c1, CC[N+](C)(C)c1cccc(O)c1	VWLHWLSRQJQWRG-UHFFFAOYSA-O, VWLHWLSRQJQWRG-UHFFFAOYSA-O, VWLHWLSRQJQWRG-UHFFFAOYSA-O	Launched
EDTMP	chelating agent				OP(O)(=O)CN(CCN(CP(O)(O)=O)CP(O)(O)=O)CP(O)(O)=O, OP(O)(=O)CN(CCN(CP(O)(O)=O)CP(O)(O)=O)CP(O)(O)=O	NFDRPXJGHKJRLJ-UHFFFAOYSA-N, NFDRPXJGHKJRLJ-UHFFFAOYSA-N	Preclinical
EED226	polycomb protein inhibitor	EED			CS(=O)(=O)c1ccc(cc1)-c1cnc(NCc2ccco2)n2cnnc12, CS(=O)(=O)c1ccc(cc1)-c1cnc(NCc2ccco2)n2cnnc12	DYIRSNMPIZZNBK-UHFFFAOYSA-N, DYIRSNMPIZZNBK-UHFFFAOYSA-N	Preclinical
efaproxiral	hemoglobin oxygen release stimulant	HBA1, HBB			Cc1cc(C)cc(NC(=O)Cc2ccc(OC(C)(C)C(O)=O)cc2)c1, Cc1cc(C)cc(NC(=O)Cc2ccc(OC(C)(C)C(O)=O)cc2)c1, Cc1cc(C)cc(NC(=O)Cc2ccc(OC(C)(C)C(O)=O)cc2)c1	BNFRJXLZYUTIII-UHFFFAOYSA-N, BNFRJXLZYUTIII-UHFFFAOYSA-N, BNFRJXLZYUTIII-UHFFFAOYSA-N	Phase 3
efaroxan	adrenergic receptor antagonist	ADORA2A			CCC1(Cc2ccccc2O1)C1=NCCN1, CCC1(Cc2ccccc2O1)C1=NCCN1, CCC1(Cc2ccccc2O1)C1=NCCN1	RATZLMXRALDSJW-UHFFFAOYSA-N, RATZLMXRALDSJW-UHFFFAOYSA-N, RATZLMXRALDSJW-UHFFFAOYSA-N	Phase 2
efatutazone	PPAR receptor agonist	PPARG			Cc1cc(Oc2ccc3nc(COc4ccc(C[C@H]5SC(=O)NC5=O)cc4)n(C)c3c2)cc(C)c1N |r|, Cc1cc(Oc2ccc3nc(COc4ccc(C[C@H]5SC(=O)NC5=O)cc4)n(C)c3c2)cc(C)c1N |r|, Cc1cc(Oc2ccc3nc(COc4ccc(C[C@H]5SC(=O)NC5=O)cc4)n(C)c3c2)cc(C)c1N |r|	JCYNMRJCUYVDBC-HSZRJFAPSA-N, JCYNMRJCUYVDBC-HSZRJFAPSA-N, JCYNMRJCUYVDBC-HSZRJFAPSA-N	Phase 2
efavirenz	HIV protease inhibitor	CYP1A2, CYP2B6, CYP2C19, CYP2C9, CYP2D6, CYP3A4	infectious disease	human immunodeficiency virus (HIV-1)	FC(F)(F)[C@]1(OC(=O)Nc2ccc(Cl)cc12)C#CC1CC1, FC(F)(F)[C@]1(OC(=O)Nc2ccc(Cl)cc12)C#CC1CC1, FC(F)(F)[C@]1(OC(=O)Nc2ccc(Cl)cc12)C#CC1CC1	XPOQHMRABVBWPR-ZDUSSCGKSA-N, XPOQHMRABVBWPR-ZDUSSCGKSA-N, XPOQHMRABVBWPR-ZDUSSCGKSA-N	Launched
efinaconazole	lanosterol demethylase inhibitor	CYP51A1	infectious disease	onychomycosis	C[C@@H](N1CCC(=C)CC1)[C@@](O)(Cn1cncn1)c1ccc(F)cc1F |a:1,&1:9|	NFEZZTICAUWDHU-KDOFPFPSSA-N	Launched
efletirizine	antihistamine				OC(=O)COCCN1CCN(CC1)C(c1ccc(F)cc1)c1ccc(F)cc1	BAWMMJAUVBLLEE-UHFFFAOYSA-N	Phase 3
eflornithine	ornithine decarboxylase inhibitor	ARG2, ODC1	dermatology	facial hair reduction	NCCCC(N)(C(F)F)C(O)=O |&1:4|	VLCYCQAOQCDTCN-UHFFFAOYSA-N	Launched
efloxate	vasodilator				CCOC(=O)COc1ccc2c(c1)oc(cc2=O)-c1ccccc1	ZVXBAHLOGZCFTP-UHFFFAOYSA-N	Preclinical
efonidipine	calcium channel blocker		cardiology	hypertension	CC1=C([C@@H](C(=C(C)N1)P1(=O)OCC(C)(C)CO1)c1cccc(c1)[N+]([O-])=O)C(=O)OCCN(Cc1ccccc1)c1ccccc1 |&1:3,r,t:1,4|, CC1=C([C@@H](C(=C(C)N1)P1(=O)OCC(C)(C)CO1)c1cccc(c1)[N+]([O-])=O)C(=O)OCCN(Cc1ccccc1)c1ccccc1 |&1:3,r,t:1,4|	NSVFSAJIGAJDMR-HKBQPEDESA-N, NSVFSAJIGAJDMR-HKBQPEDESA-N	Launched
EF5	cytochrome P450 activator				[O-][N+](=O)c1nccn1CC(=O)NCC(F)(F)C(F)(F)F	JGGDSDPOPRWSCX-UHFFFAOYSA-N	Phase 2
EGF816	EGFR inhibitor	EGFR			CN(C)C\C=C\C(=O)N1CCCC[C@H](C1)n1c(NC(=O)c2ccnc(C)c2)nc2cccc(Cl)c12, CN(C)C\C=C\C(=O)N1CCCC[C@H](C1)n1c(NC(=O)c2ccnc(C)c2)nc2cccc(Cl)c12, CN(C)C\C=C\C(=O)N1CCCC[C@H](C1)n1c(NC(=O)c2ccnc(C)c2)nc2cccc(Cl)c12	IOMMMLWIABWRKL-WUTDNEBXSA-N, IOMMMLWIABWRKL-WUTDNEBXSA-N, IOMMMLWIABWRKL-WUTDNEBXSA-N	Phase 2
eglumetad	glutamate receptor agonist	GRM2, GRM3, GRM6, GRM8			N[C@]1(CC[C@H]2[C@@H]([C@@H]12)C(O)=O)C(O)=O, N[C@]1(CC[C@H]2[C@@H]([C@@H]12)C(O)=O)C(O)=O, N[C@]1(CC[C@H]2[C@@H]([C@@H]12)C(O)=O)C(O)=O	VTAARTQTOOYTES-RGDLXGNYSA-N, VTAARTQTOOYTES-RGDLXGNYSA-N, VTAARTQTOOYTES-RGDLXGNYSA-N	Phase 2
EG00229	neuropilin receptor antagonist	NRP1			NC(=N)NCCC[C@H](NC(=O)c1sccc1NS(=O)(=O)c1cccc2nsnc12)C(O)=O, NC(=N)NCCC[C@H](NC(=O)c1sccc1NS(=O)(=O)c1cccc2nsnc12)C(O)=O	ZWWMEDURALZMEV-NSHDSACASA-N, ZWWMEDURALZMEV-NSHDSACASA-N	Preclinical
EHop-016	Ras GTPase inhibitor	RAC1, RAC3			CCn1c2ccccc2c2cc(Nc3ccnc(NCCCN4CCOCC4)n3)ccc12, CCn1c2ccccc2c2cc(Nc3ccnc(NCCCN4CCOCC4)n3)ccc12, CCn1c2ccccc2c2cc(Nc3ccnc(NCCCN4CCOCC4)n3)ccc12, CCn1c2ccccc2c2cc(Nc3ccnc(NCCCN4CCOCC4)n3)ccc12, CCn1c2ccccc2c2cc(Nc3ccnc(NCCCN4CCOCC4)n3)ccc12, CCn1c2ccccc2c2cc(Nc3ccnc(NCCCN4CCOCC4)n3)ccc12, CCn1c2ccccc2c2cc(Nc3ccnc(NCCCN4CCOCC4)n3)ccc12	AFTZZRFCMOAFCR-UHFFFAOYSA-N, AFTZZRFCMOAFCR-UHFFFAOYSA-N, AFTZZRFCMOAFCR-UHFFFAOYSA-N, AFTZZRFCMOAFCR-UHFFFAOYSA-N, AFTZZRFCMOAFCR-UHFFFAOYSA-N, AFTZZRFCMOAFCR-UHFFFAOYSA-N, AFTZZRFCMOAFCR-UHFFFAOYSA-N	Preclinical
EIPA	sodium/hydrogen exchanger inhibitor, transient receptor potential polycystic inhibitor	ADRA2A, ASIC1, PKD2L1			CCN(C(C)C)c1nc(N)c(nc1Cl)C(=O)N=C(N)N, CCN(C(C)C)c1nc(N)c(nc1Cl)C(=O)N=C(N)N	QDERNBXNXJCIQK-UHFFFAOYSA-N, QDERNBXNXJCIQK-UHFFFAOYSA-N	Preclinical
EIT-hydrobromide	nitric oxide synthase inhibitor	NOS2, NOS3			CCSC(N)=N, CCSC(N)=N	VFIZBHJTOHUOEK-UHFFFAOYSA-N, VFIZBHJTOHUOEK-UHFFFAOYSA-N	Preclinical
EI1	histone lysine methyltransferase inhibitor	EZH2			CCC(CC)n1ccc2c(cc(cc12)C#N)C(=O)NCc1c(C)cc(C)[nH]c1=O	PFHDWRIVDDIFRP-UHFFFAOYSA-N	Preclinical
elacestrant	estrogen receptor degrader				CCNCCc1ccc(CN(CC)c2cc(OC)ccc2[C@@H]2CCc3cc(O)ccc3C2)cc1, CCNCCc1ccc(CN(CC)c2cc(OC)ccc2[C@@H]2CCc3cc(O)ccc3C2)cc1	SIFNOOUKXBRGGB-AREMUKBSSA-N, SIFNOOUKXBRGGB-AREMUKBSSA-N	Phase 3
elacridar	P glycoprotein inhibitor	ABCB1			COc1cc2CCN(CCc3ccc(NC(=O)c4cccc5c4[nH]c4c(OC)cccc4c5=O)cc3)Cc2cc1OC, COc1cc2CCN(CCc3ccc(NC(=O)c4cccc5c4[nH]c4c(OC)cccc4c5=O)cc3)Cc2cc1OC, COc1cc2CCN(CCc3ccc(NC(=O)c4cccc5c4[nH]c4c(OC)cccc4c5=O)cc3)Cc2cc1OC, COc1cc2CCN(CCc3ccc(NC(=O)c4cccc5c4[nH]c4c(OC)cccc4c5=O)cc3)Cc2cc1OC, COc1cc2CCN(CCc3ccc(NC(=O)c4cccc5c4[nH]c4c(OC)cccc4c5=O)cc3)Cc2cc1OC, COc1cc2CCN(CCc3ccc(NC(=O)c4cccc5c4[nH]c4c(OC)cccc4c5=O)cc3)Cc2cc1OC, COc1cc2CCN(CCc3ccc(NC(=O)c4cccc5c4[nH]c4c(OC)cccc4c5=O)cc3)Cc2cc1OC, COc1cc2CCN(CCc3ccc(NC(=O)c4cccc5c4[nH]c4c(OC)cccc4c5=O)cc3)Cc2cc1OC, COc1cc2CCN(CCc3ccc(NC(=O)c4cccc5c4[nH]c4c(OC)cccc4c5=O)cc3)Cc2cc1OC, COc1cc2CCN(CCc3ccc(NC(=O)c4cccc5c4[nH]c4c(OC)cccc4c5=O)cc3)Cc2cc1OC, COc1cc2CCN(CCc3ccc(NC(=O)c4cccc5c4[nH]c4c(OC)cccc4c5=O)cc3)Cc2cc1OC	OSFCMRGOZNQUSW-UHFFFAOYSA-N, OSFCMRGOZNQUSW-UHFFFAOYSA-N, OSFCMRGOZNQUSW-UHFFFAOYSA-N, OSFCMRGOZNQUSW-UHFFFAOYSA-N, OSFCMRGOZNQUSW-UHFFFAOYSA-N, OSFCMRGOZNQUSW-UHFFFAOYSA-N, OSFCMRGOZNQUSW-UHFFFAOYSA-N, OSFCMRGOZNQUSW-UHFFFAOYSA-N, OSFCMRGOZNQUSW-UHFFFAOYSA-N, OSFCMRGOZNQUSW-UHFFFAOYSA-N, OSFCMRGOZNQUSW-UHFFFAOYSA-N	Phase 1
elactocin	exportin antagonist	XPO1					Phase 1
elacytarabine	antineoplastic agent	DCK			CCCCCCCC\C=C\CCCCCCCC(=O)OC[C@H]1O[C@H]([C@@H](O)[C@@H]1O)n1ccc(N)nc1=O	FLFGNMFWNBOBGE-FNNZEKJRSA-N	Phase 3
elafibranor	PPAR receptor agonist	PPARA, PPARD, PPARG			CSc1ccc(cc1)C(=O)\C=C\c1cc(C)c(OC(C)(C)C(O)=O)c(C)c1, CSc1ccc(cc1)C(=O)\C=C\c1cc(C)c(OC(C)(C)C(O)=O)c(C)c1	AFLFKFHDSCQHOL-IZZDOVSWSA-N, AFLFKFHDSCQHOL-IZZDOVSWSA-N	Phase 3
elagolix	gonadotropin releasing factor hormone receptor antagonist	GNRHR			COc1cccc(c1F)-c1c(C)n(Cc2c(F)cccc2C(F)(F)F)c(=O)n(C[C@H](NCCCC(O)=O)c2ccccc2)c1=O, COc1cccc(c1F)-c1c(C)n(Cc2c(F)cccc2C(F)(F)F)c(=O)n(C[C@H](NCCCC(O)=O)c2ccccc2)c1=O	HEAUOKZIVMZVQL-VWLOTQADSA-N, HEAUOKZIVMZVQL-VWLOTQADSA-N	Launched
elbasvir	HCV inhibitor		infectious disease	hepatitis C	COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1c1nc(c[nH]1)-c1ccc2-c3cc4cc(ccc4n3[C@@H](Oc2c1)c1ccccc1)-c1c[nH]c(n1)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)OC)C(C)C, COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1c1nc(c[nH]1)-c1ccc2-c3cc4cc(ccc4n3[C@@H](Oc2c1)c1ccccc1)-c1c[nH]c(n1)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)OC)C(C)C	BVAZQCUMNICBAQ-PZHYSIFUSA-N, BVAZQCUMNICBAQ-PZHYSIFUSA-N	Launched
eldecalcitol	bone formation stimulant	VDR			[H][C@@]12CC[C@H]([C@H](C)CCCC(C)(C)O)[C@@]1(C)CCC\C2=C/C=C1/C[C@@H](O)[C@@H](OCCCO)[C@H](O)C1=C	FZEXGDDBXLBRTD-AYIMTCTASA-N	Phase 3
eleclazine	late sodium current inhibitor				FC(F)(F)Oc1ccc(cc1)-c1ccc2OCCN(Cc3ncccn3)C(=O)c2c1	YNUAEEJQYHYLMS-UHFFFAOYSA-N	Phase 3
elemene	VEGFR inhibitor				CC(=C)[C@@H]1CC[C@@](C)(C=C)[C@H](C1)C(C)=C	OPFTUNCRGUEPRZ-RBSFLKMASA-N	Phase 3
elesclomol	oxidative stress inducer	HSPA1A			CN(NC(=O)CC(=O)NN(C)C(=S)c1ccccc1)C(=S)c1ccccc1, CN(NC(=O)CC(=O)NN(C)C(=S)c1ccccc1)C(=S)c1ccccc1, CN(NC(=O)CC(=O)NN(C)C(=S)c1ccccc1)C(=S)c1ccccc1, CN(NC(=O)CC(=O)NN(C)C(=S)c1ccccc1)C(=S)c1ccccc1	BKJIXTWSNXCKJH-UHFFFAOYSA-N, BKJIXTWSNXCKJH-UHFFFAOYSA-N, BKJIXTWSNXCKJH-UHFFFAOYSA-N, BKJIXTWSNXCKJH-UHFFFAOYSA-N	Phase 3
eletriptan	serotonin receptor agonist	HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2B, HTR7	neurology/psychiatry	migraine headache	CN1CCC[C@@H]1Cc1c[nH]c2ccc(CCS(=O)(=O)c3ccccc3)cc12, CN1CCC[C@@H]1Cc1c[nH]c2ccc(CCS(=O)(=O)c3ccccc3)cc12, CN1CCC[C@@H]1Cc1c[nH]c2ccc(CCS(=O)(=O)c3ccccc3)cc12, CN1CCC[C@@H]1Cc1c[nH]c2ccc(CCS(=O)(=O)c3ccccc3)cc12, CN1CCC[C@@H]1Cc1c[nH]c2ccc(CCS(=O)(=O)c3ccccc3)cc12, CN1CCC[C@@H]1Cc1c[nH]c2ccc(CCS(=O)(=O)c3ccccc3)cc12	PWVXXGRKLHYWKM-LJQANCHMSA-N, PWVXXGRKLHYWKM-LJQANCHMSA-N, PWVXXGRKLHYWKM-LJQANCHMSA-N, PWVXXGRKLHYWKM-LJQANCHMSA-N, PWVXXGRKLHYWKM-LJQANCHMSA-N, PWVXXGRKLHYWKM-LJQANCHMSA-N	Launched
eliglustat	glycosyl transferase inhibitor	UGCG	hematology	Gaucher disease	CCCCCCCC(=O)N[C@H](CN1CCCC1)[C@H](O)c1ccc2OCCOc2c1, CCCCCCCC(=O)N[C@H](CN1CCCC1)[C@H](O)c1ccc2OCCOc2c1, CCCCCCCC(=O)N[C@H](CN1CCCC1)[C@H](O)c1ccc2OCCOc2c1, CCCCCCCC(=O)N[C@H](CN1CCCC1)[C@H](O)c1ccc2OCCOc2c1, CCCCCCCC(=O)N[C@H](CN1CCCC1)[C@H](O)c1ccc2OCCOc2c1	FJZZPCZKBUKGGU-AUSIDOKSSA-N, FJZZPCZKBUKGGU-AUSIDOKSSA-N, FJZZPCZKBUKGGU-AUSIDOKSSA-N, FJZZPCZKBUKGGU-AUSIDOKSSA-N, FJZZPCZKBUKGGU-AUSIDOKSSA-N	Launched
elinogrel	purinergic receptor antagonist	P2RY12			CNc1cc2[nH]c(=O)n(-c3ccc(NC(=O)NS(=O)(=O)c4ccc(Cl)s4)cc3)c(=O)c2cc1F, CNc1cc2[nH]c(=O)n(-c3ccc(NC(=O)NS(=O)(=O)c4ccc(Cl)s4)cc3)c(=O)c2cc1F	LGSDFTPAICUONK-UHFFFAOYSA-N, LGSDFTPAICUONK-UHFFFAOYSA-N	Phase 2
eliprodil	glutamate receptor antagonist	GRIN1, GRIN2B			O[C@@H](CN1CCC(Cc2ccc(F)cc2)CC1)c1ccc(Cl)cc1 |&1:1,r|, O[C@@H](CN1CCC(Cc2ccc(F)cc2)CC1)c1ccc(Cl)cc1 |&1:1,r|, O[C@@H](CN1CCC(Cc2ccc(F)cc2)CC1)c1ccc(Cl)cc1 |&1:1,r|, O[C@@H](CN1CCC(Cc2ccc(F)cc2)CC1)c1ccc(Cl)cc1 |&1:1,r|	GGUSQTSTQSHJAH-FQEVSTJZSA-N, GGUSQTSTQSHJAH-FQEVSTJZSA-N, GGUSQTSTQSHJAH-FQEVSTJZSA-N, GGUSQTSTQSHJAH-FQEVSTJZSA-N	Phase 3
ellagic-acid	glutathione transferase inhibitor, non-nucleoside reverse transcriptase inhibitor	CA1, CA12, CA14, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9, CSNK2A1, GSK3B, PRKACA, PRKCA, PRKCB, SQLE, SYK			Oc1cc2c3c(oc(=O)c4cc(O)c(O)c(oc2=O)c34)c1O, Oc1cc2c3c(oc(=O)c4cc(O)c(O)c(oc2=O)c34)c1O, Oc1cc2c3c(oc(=O)c4cc(O)c(O)c(oc2=O)c34)c1O, Oc1cc2c3c(oc(=O)c4cc(O)c(O)c(oc2=O)c34)c1O, Oc1cc2c3c(oc(=O)c4cc(O)c(O)c(oc2=O)c34)c1O	AFSDNFLWKVMVRB-UHFFFAOYSA-N, AFSDNFLWKVMVRB-UHFFFAOYSA-N, AFSDNFLWKVMVRB-UHFFFAOYSA-N, AFSDNFLWKVMVRB-UHFFFAOYSA-N, AFSDNFLWKVMVRB-UHFFFAOYSA-N	Phase 2
ELN-441958	bradykinin receptor antagonist	BDKRB1			Clc1cccc2CN(C(=O)c12)c1cccc(c1)C(=O)N1CCC2(CC1)CCN(CC2)c1ccncc1, Clc1cccc2CN(C(=O)c12)c1cccc(c1)C(=O)N1CCC2(CC1)CCN(CC2)c1ccncc1	ARYQHSWJGHCGJS-UHFFFAOYSA-N, ARYQHSWJGHCGJS-UHFFFAOYSA-N	Preclinical
eltanexor	exportin inhibitor				NC(=O)C(=C/n1cnc(n1)-c1cc(cc(c1)C(F)(F)F)C(F)(F)F)\c1cncnc1	JFBAVWVBLRIWHM-MLPAPPSSSA-N	Preclinical
eltanolone	GABA receptor positive allosteric modulator	GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB2, GABRG2			CC(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C, CC(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C	AURFZBICLPNKBZ-YZRLXODZSA-N, AURFZBICLPNKBZ-YZRLXODZSA-N	Phase 3
eltoprazine	serotonin receptor agonist	HTR1A, HTR1B			C1CN(CCN1)c1cccc2OCCOc12, C1CN(CCN1)c1cccc2OCCOc12, C1CN(CCN1)c1cccc2OCCOc12	WVLHGCRWEHCIOT-UHFFFAOYSA-N, WVLHGCRWEHCIOT-UHFFFAOYSA-N, WVLHGCRWEHCIOT-UHFFFAOYSA-N	Phase 2
eltrombopag	thrombopoietin receptor agonist	MPL	hematology, infectious disease	anemia, hepatitis C, thrombocytopenia	CC1=NN(C(=O)\C1=N/Nc1cccc(-c2cccc(c2)C(O)=O)c1O)c1ccc(C)c(C)c1 |t:1|	XDXWLKQMMKQXPV-QYQHSDTDSA-N	Launched
eluxadoline	opioid receptor agonist, opioid receptor antagonist	OPRD1, OPRK1, OPRM1	gastroenterology	irritable bowel syndrome	COc1ccc(CN([C@@H](C)c2nc(c[nH]2)-c2ccccc2)C(=O)[C@@H](N)Cc2c(C)cc(cc2C)C(N)=O)cc1C(O)=O	QFNHIDANIVGXPE-FNZWTVRRSA-N	Launched
elvitegravir	HIV integrase inhibitor		infectious disease	human immunodeficiency virus (HIV-1)	COc1cc2n(cc(C(O)=O)c(=O)c2cc1Cc1cccc(Cl)c1F)[C@H](CO)C(C)C	JUZYLCPPVHEVSV-LJQANCHMSA-N	Launched
emamectin	GABA receptor agonist				[H][C@@]12OC\C3=C/C=C/[C@H](C)[C@]([H])(O[C@H]4C[C@H](OC)[C@@]([H])(O[C@H]5C[C@@H](OC)[C@H](NC)[C@@H](C)O5)[C@H](C)O4)\C(C)=C\C[C@@H]4C[C@@H](C[C@]5(O4)O[C@H](C(C)C)[C@@H](C)C=C5)OC(=O)[C@H](C=C(C)[C@H]1O)[C@@]23O |c:4,55,t:6,38,62|	DXIOOXFZLKCVHK-HGIWSLISSA-N	Preclinical
embelin	HCV inhibitor, XIAP inhibitor	XIAP			CCCCCCCCCCCC1C(=O)C(O)=CC(=O)C1=O |c:15|, CCCCCCCCCCCC1C(=O)C(O)=CC(=O)C1=O |c:15|, CCCCCCCCCCCC1C(=O)C(O)=CC(=O)C1=O |c:15|, CCCCCCCCCCCC1C(=O)C(O)=CC(=O)C1=O |c:15|, CCCCCCCCCCCC1C(=O)C(O)=CC(=O)C1=O |c:15|, CCCCCCCCCCCC1C(=O)C(O)=CC(=O)C1=O |c:15|, CCCCCCCCCCCC1C(=O)C(O)=CC(=O)C1=O |c:15|, CCCCCCCCCCCC1C(=O)C(O)=CC(=O)C1=O |c:15|	HQWGBIUMYSOPFP-UHFFFAOYSA-N, HQWGBIUMYSOPFP-UHFFFAOYSA-N, HQWGBIUMYSOPFP-UHFFFAOYSA-N, HQWGBIUMYSOPFP-UHFFFAOYSA-N, HQWGBIUMYSOPFP-UHFFFAOYSA-N, HQWGBIUMYSOPFP-UHFFFAOYSA-N, HQWGBIUMYSOPFP-UHFFFAOYSA-N, HQWGBIUMYSOPFP-UHFFFAOYSA-N	Preclinical
EMD-1214063	hepatocyte growth factor receptor inhibitor	MET			CN1CCC(COc2cnc(nc2)-c2cccc(Cn3nc(ccc3=O)-c3cccc(c3)C#N)c2)CC1, CN1CCC(COc2cnc(nc2)-c2cccc(Cn3nc(ccc3=O)-c3cccc(c3)C#N)c2)CC1, CN1CCC(COc2cnc(nc2)-c2cccc(Cn3nc(ccc3=O)-c3cccc(c3)C#N)c2)CC1, CN1CCC(COc2cnc(nc2)-c2cccc(Cn3nc(ccc3=O)-c3cccc(c3)C#N)c2)CC1	AHYMHWXQRWRBKT-UHFFFAOYSA-N, AHYMHWXQRWRBKT-UHFFFAOYSA-N, AHYMHWXQRWRBKT-UHFFFAOYSA-N, AHYMHWXQRWRBKT-UHFFFAOYSA-N	Phase 2
EMD-386088	serotonin receptor agonist	HTR6			Cc1[nH]c2ccc(Cl)cc2c1C1=CCNCC1 |t:13|, Cc1[nH]c2ccc(Cl)cc2c1C1=CCNCC1 |t:13|, Cc1[nH]c2ccc(Cl)cc2c1C1=CCNCC1 |t:13|, Cc1[nH]c2ccc(Cl)cc2c1C1=CCNCC1 |t:13|	BPPGPYJBCVXILI-UHFFFAOYSA-N, BPPGPYJBCVXILI-UHFFFAOYSA-N, BPPGPYJBCVXILI-UHFFFAOYSA-N, BPPGPYJBCVXILI-UHFFFAOYSA-N	Preclinical
EMD-53998	phosphodiesterase inhibitor	TNNC1			COc1ccc(cc1OC)C(=O)N1CCCc2cc(ccc12)C1=NNC(=O)S[C@@H]1C |r,t:25|, COc1ccc(cc1OC)C(=O)N1CCCc2cc(ccc12)C1=NNC(=O)S[C@@H]1C |r,t:25|, COc1ccc(cc1OC)C(=O)N1CCCc2cc(ccc12)C1=NNC(=O)S[C@@H]1C |r,t:25|, COc1ccc(cc1OC)C(=O)N1CCCc2cc(ccc12)C1=NNC(=O)S[C@@H]1C |r,t:25|	IZLRMTJLQCLMKF-CYBMUJFWSA-N, IZLRMTJLQCLMKF-CYBMUJFWSA-N, IZLRMTJLQCLMKF-CYBMUJFWSA-N, IZLRMTJLQCLMKF-CYBMUJFWSA-N	Phase 1
EMD-66684	angiotensin receptor antagonist	AGTR1			CCCCc1nc2ccn(CC(=O)N(C)C)c(=O)c2n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1, CCCCc1nc2ccn(CC(=O)N(C)C)c(=O)c2n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1, CCCCc1nc2ccn(CC(=O)N(C)C)c(=O)c2n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1, CCCCc1nc2ccn(CC(=O)N(C)C)c(=O)c2n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1	CQVJTTOZTTVVBK-UHFFFAOYSA-N, CQVJTTOZTTVVBK-UHFFFAOYSA-N, CQVJTTOZTTVVBK-UHFFFAOYSA-N, CQVJTTOZTTVVBK-UHFFFAOYSA-N	Preclinical
EMD534085	kinesin inhibitor				[H][C@@]12CC[C@H](CNC(=O)NCCN(C)C)O[C@]1([H])c1cc(ccc1N[C@H]2c1ccccc1)C(F)(F)F	MARIUIDCPUZLKZ-FUKQBSRTSA-N	Preclinical
emedastine	histamine receptor antagonist	HRH1	ophthalmology	conjunctivitis	CCOCCn1c(nc2ccccc12)N1CCCN(C)CC1, CCOCCn1c(nc2ccccc12)N1CCCN(C)CC1	KBUZBQVCBVDWKX-UHFFFAOYSA-N, KBUZBQVCBVDWKX-UHFFFAOYSA-N	Launched
emeramide	antioxidant				SCCNC(=O)c1cccc(c1)C(=O)NCCS	JUTBAVRYDAKVGQ-UHFFFAOYSA-N	Phase 2
emetine	protein synthesis inhibitor	RPS2			CC[C@H]1CN2CCc3cc(OC)c(OC)cc3[C@@H]2C[C@@H]1C[C@H]1NCCc2cc(OC)c(OC)cc12, CC[C@H]1CN2CCc3cc(OC)c(OC)cc3[C@@H]2C[C@@H]1C[C@H]1NCCc2cc(OC)c(OC)cc12, CC[C@H]1CN2CCc3cc(OC)c(OC)cc3[C@@H]2C[C@@H]1C[C@H]1NCCc2cc(OC)c(OC)cc12, CC[C@H]1CN2CCc3cc(OC)c(OC)cc3[C@@H]2C[C@@H]1C[C@H]1NCCc2cc(OC)c(OC)cc12, CC[C@H]1CN2CCc3cc(OC)c(OC)cc3[C@@H]2C[C@@H]1C[C@H]1NCCc2cc(OC)c(OC)cc12, CC[C@H]1CN2CCc3cc(OC)c(OC)cc3[C@@H]2C[C@@H]1C[C@H]1NCCc2cc(OC)c(OC)cc12, CC[C@H]1CN2CCc3cc(OC)c(OC)cc3[C@@H]2C[C@@H]1C[C@H]1NCCc2cc(OC)c(OC)cc12	AUVVAXYIELKVAI-CKBKHPSWSA-N, AUVVAXYIELKVAI-CKBKHPSWSA-N, AUVVAXYIELKVAI-CKBKHPSWSA-N, AUVVAXYIELKVAI-CKBKHPSWSA-N, AUVVAXYIELKVAI-CKBKHPSWSA-N, AUVVAXYIELKVAI-CKBKHPSWSA-N, AUVVAXYIELKVAI-CKBKHPSWSA-N	Phase 2
emiglitate	alpha glucoside inhibitor				CCOC(=O)c1ccc(OCCN2C[C@H](O)[C@@H](O)[C@H](O)[C@H]2CO)cc1	NWWORXYTJRPSMC-QKPAOTATSA-N	Preclinical
emixustat	retinoid isomerohydrolase inhibitor				NCC[C@@H](O)c1cccc(OCC2CCCCC2)c1	WJIGGYYSZBWCGC-MRXNPFEDSA-N	Phase 3
emodepside	nematocide				[H][C@]1(C)OC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](Cc2ccc(cc2)N2CCOCC2)OC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)OC(=O)[C@@H](CC(C)C)N(C)C(=O)[C@@H](Cc2ccc(cc2)N2CCOCC2)OC(=O)[C@H](CC(C)C)N(C)C1=O	ZMQMTKVVAMWKNY-CZOLZNPPSA-N	Phase 1
emodin	11-beta hydroxysteroid dehydrogenase inhibitor	CSNK2A1			Cc1cc(O)c2C(=O)c3c(O)cc(O)cc3C(=O)c2c1, Cc1cc(O)c2C(=O)c3c(O)cc(O)cc3C(=O)c2c1	RHMXXJGYXNZAPX-UHFFFAOYSA-N, RHMXXJGYXNZAPX-UHFFFAOYSA-N	Preclinical
emorfazone	anti-inflammatory agent, cyclooxygenase inhibitor		dental	mouth inflammation	CCOc1c(cnn(C)c1=O)N1CCOCC1	URJQOOISAKEBKW-UHFFFAOYSA-N	Launched
emoxipin					CCc1nc(C)ccc1O	JPGDYIGSCHWQCC-UHFFFAOYSA-N	Phase 3
empagliflozin	sodium/glucose cotransporter inhibitor	SLC5A1, SLC5A2	endocrinology	diabetes mellitus	OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)c1ccc(Cl)c(Cc2ccc(O[C@H]3CCOC3)cc2)c1, OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)c1ccc(Cl)c(Cc2ccc(O[C@H]3CCOC3)cc2)c1, OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)c1ccc(Cl)c(Cc2ccc(O[C@H]3CCOC3)cc2)c1	OBWASQILIWPZMG-QZMOQZSNSA-N, OBWASQILIWPZMG-QZMOQZSNSA-N, OBWASQILIWPZMG-QZMOQZSNSA-N	Launched
emricasan	caspase inhibitor	CASP1, CASP3, CASP7			C[C@H](NC(=O)C(=O)Nc1ccccc1C(C)(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)COc1c(F)c(F)cc(F)c1F, C[C@H](NC(=O)C(=O)Nc1ccccc1C(C)(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)COc1c(F)c(F)cc(F)c1F, C[C@H](NC(=O)C(=O)Nc1ccccc1C(C)(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)COc1c(F)c(F)cc(F)c1F	SCVHJVCATBPIHN-SJCJKPOMSA-N, SCVHJVCATBPIHN-SJCJKPOMSA-N, SCVHJVCATBPIHN-SJCJKPOMSA-N	Phase 2
emtricitabine	nucleoside reverse transcriptase inhibitor		infectious disease	human immunodeficiency virus (HIV-1)	Nc1nc(=O)n(cc1F)[C@@H]1CS[C@H](CO)O1, Nc1nc(=O)n(cc1F)[C@@H]1CS[C@H](CO)O1	XQSPYNMVSIKCOC-NTSWFWBYSA-N, XQSPYNMVSIKCOC-NTSWFWBYSA-N	Launched
enalapril	angiotensin converting enzyme inhibitor	ACE	cardiology	hypertension, congestive heart failure, left ventricular systolic dysfunction (LVSD)	CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O, CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O, CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O, CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O, CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O	GBXSMTUPTTWBMN-XIRDDKMYSA-N, GBXSMTUPTTWBMN-XIRDDKMYSA-N, GBXSMTUPTTWBMN-XIRDDKMYSA-N, GBXSMTUPTTWBMN-XIRDDKMYSA-N, GBXSMTUPTTWBMN-XIRDDKMYSA-N	Launched
enalaprilat	angiotensin converting enzyme inhibitor	ACE	cardiology	hypertension	C[C@H](N[C@@H](CCc1ccccc1)C(O)=O)C(=O)N1CCC[C@H]1C(O)=O, C[C@H](N[C@@H](CCc1ccccc1)C(O)=O)C(=O)N1CCC[C@H]1C(O)=O, C[C@H](N[C@@H](CCc1ccccc1)C(O)=O)C(=O)N1CCC[C@H]1C(O)=O, C[C@H](N[C@@H](CCc1ccccc1)C(O)=O)C(=O)N1CCC[C@H]1C(O)=O, C[C@H](N[C@@H](CCc1ccccc1)C(O)=O)C(=O)N1CCC[C@H]1C(O)=O, C[C@H](N[C@@H](CCc1ccccc1)C(O)=O)C(=O)N1CCC[C@H]1C(O)=O, C[C@H](N[C@@H](CCc1ccccc1)C(O)=O)C(=O)N1CCC[C@H]1C(O)=O	LZFZMUMEGBBDTC-QEJZJMRPSA-N, LZFZMUMEGBBDTC-QEJZJMRPSA-N, LZFZMUMEGBBDTC-QEJZJMRPSA-N, LZFZMUMEGBBDTC-QEJZJMRPSA-N, LZFZMUMEGBBDTC-QEJZJMRPSA-N, LZFZMUMEGBBDTC-QEJZJMRPSA-N, LZFZMUMEGBBDTC-QEJZJMRPSA-N	Launched
enasidenib	isocitrate dehydrogenase inhibitor	IDH1	hematologic malignancy	acute myeloid leukemia (AML)	CC(C)(O)CNc1nc(Nc2ccnc(c2)C(F)(F)F)nc(n1)-c1cccc(n1)C(F)(F)F, CC(C)(O)CNc1nc(Nc2ccnc(c2)C(F)(F)F)nc(n1)-c1cccc(n1)C(F)(F)F, CC(C)(O)CNc1nc(Nc2ccnc(c2)C(F)(F)F)nc(n1)-c1cccc(n1)C(F)(F)F, CC(C)(O)CNc1nc(Nc2ccnc(c2)C(F)(F)F)nc(n1)-c1cccc(n1)C(F)(F)F	DYLUUSLLRIQKOE-UHFFFAOYSA-N, DYLUUSLLRIQKOE-UHFFFAOYSA-N, DYLUUSLLRIQKOE-UHFFFAOYSA-N, DYLUUSLLRIQKOE-UHFFFAOYSA-N	Launched
enbucrilate			dermatology	skin lacerations, tissue adhesive	CCCCOC(=O)C(=C)C#N	JJJFUHOGVZWXNQ-UHFFFAOYSA-N	Launched
enciprazine	GABA receptor modulator	GABRA1			COc1ccccc1N1CCN(C[C@@H](O)COc2cc(OC)c(OC)c(OC)c2)CC1 |&1:13,r|, COc1ccccc1N1CCN(C[C@@H](O)COc2cc(OC)c(OC)c(OC)c2)CC1 |&1:13,r|, COc1ccccc1N1CCN(C[C@@H](O)COc2cc(OC)c(OC)c(OC)c2)CC1 |&1:13,r|	KSQCNASWXSCJTD-QGZVFWFLSA-N, KSQCNASWXSCJTD-QGZVFWFLSA-N, KSQCNASWXSCJTD-QGZVFWFLSA-N	Phase 3
encorafenib	RAF inhibitor	BRAF	oncology	melanoma	COC(=O)N[C@@H](C)CNc1nccc(n1)-c1cn(nc1-c1cc(Cl)cc(NS(C)(=O)=O)c1F)C(C)C	CMJCXYNUCSMDBY-ZDUSSCGKSA-N	Launched
endo-IWR-1	PARP inhibitor	TNKS, TNKS2			O=C(Nc1cccc2cccnc12)c1ccc(cc1)N1C(=O)[C@H]2[C@@H]3C[C@@H](C=C3)[C@H]2C1=O |c:29|, O=C(Nc1cccc2cccnc12)c1ccc(cc1)N1C(=O)[C@H]2[C@@H]3C[C@@H](C=C3)[C@H]2C1=O |c:29|, O=C(Nc1cccc2cccnc12)c1ccc(cc1)N1C(=O)[C@H]2[C@@H]3C[C@@H](C=C3)[C@H]2C1=O |c:29|, O=C(Nc1cccc2cccnc12)c1ccc(cc1)N1C(=O)[C@H]2[C@@H]3C[C@@H](C=C3)[C@H]2C1=O |c:29|, O=C(Nc1cccc2cccnc12)c1ccc(cc1)N1C(=O)[C@H]2[C@@H]3C[C@@H](C=C3)[C@H]2C1=O |c:29|, O=C(Nc1cccc2cccnc12)c1ccc(cc1)N1C(=O)[C@H]2[C@@H]3C[C@@H](C=C3)[C@H]2C1=O |c:29|, O=C(Nc1cccc2cccnc12)c1ccc(cc1)N1C(=O)[C@H]2[C@@H]3C[C@@H](C=C3)[C@H]2C1=O |c:29|, O=C(Nc1cccc2cccnc12)c1ccc(cc1)N1C(=O)[C@H]2[C@@H]3C[C@@H](C=C3)[C@H]2C1=O |c:29|	ZGSXEXBYLJIOGF-ALFLXDJESA-N, ZGSXEXBYLJIOGF-ALFLXDJESA-N, ZGSXEXBYLJIOGF-ALFLXDJESA-N, ZGSXEXBYLJIOGF-ALFLXDJESA-N, ZGSXEXBYLJIOGF-ALFLXDJESA-N, ZGSXEXBYLJIOGF-ALFLXDJESA-N, ZGSXEXBYLJIOGF-ALFLXDJESA-N, ZGSXEXBYLJIOGF-ALFLXDJESA-N	Preclinical
endoxifen	estrogen receptor antagonist	ESR1			CC\C(=C(/c1ccc(O)cc1)c1ccc(OCCNC)cc1)c1ccccc1, CC\C(=C(/c1ccc(O)cc1)c1ccc(OCCNC)cc1)c1ccccc1	MHJBZVSGOZTKRH-IZHYLOQSSA-N, MHJBZVSGOZTKRH-IZHYLOQSSA-N	Phase 2
enflurane	membrane permeability inhibitor	GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, GLRA1, GLRB, KCNK10, KCNK18, KCNK2, KCNK3, KCNK9	neurology/psychiatry	anesthetic	FC(F)OC(F)(F)[C@@H](F)Cl |&1:7,r|, FC(F)OC(F)(F)[C@@H](F)Cl |&1:7,r|, FC(F)OC(F)(F)[C@@H](F)Cl |&1:7,r|	JPGQOUSTVILISH-PVQJCKRUSA-N, JPGQOUSTVILISH-PVQJCKRUSA-N, JPGQOUSTVILISH-PVQJCKRUSA-N	Launched
enilconazole	sterol demethylase inhibitor	CYP19A1, CYP1A2, CYP2B6, CYP2C9, CYP2J2, CYP3A4, CYP3A5, NR1I2, PPARA, PTGER2	infectious disease	skin infections	Clc1ccc([C@@H](Cn2ccnc2)OCC=C)c(Cl)c1 |&1:5|, Clc1ccc([C@@H](Cn2ccnc2)OCC=C)c(Cl)c1 |&1:5|	PZBPKYOVPCNPJY-CQSZACIVSA-N, PZBPKYOVPCNPJY-CQSZACIVSA-N	Launched
eniluracil	dihydropyrimidine dehydrogenase inhibitor	AOX1, DPYD, XDH			O=c1[nH]cc(C#C)c(=O)[nH]1	JOZGNYDSEBIJDH-UHFFFAOYSA-N	Phase 3
eniporide	sodium/hydrogen antiport inhibitor				Cc1cc(c(cc1C(=O)NC(N)=N)S(C)(=O)=O)-n1cccc1	UADMBZFZZOBWBB-UHFFFAOYSA-N	Preclinical
enisamium-iodide					C[n+]1ccc(cc1)C(=O)NCc1ccccc1, C[n+]1ccc(cc1)C(=O)NCc1ccccc1	QOEJDHLJOKRPJG-UHFFFAOYSA-O, QOEJDHLJOKRPJG-UHFFFAOYSA-O	Launched
ENMD-2076	Aurora kinase inhibitor, FLT3 inhibitor, VEGFR inhibitor	AURKA, FLT3, KDR, PDGFRA, PTK2, SRC			CN1CCN(CC1)c1cc(Nc2cc(C)n[nH]2)nc(\C=C\c2ccccc2)n1, CN1CCN(CC1)c1cc(Nc2cc(C)n[nH]2)nc(\C=C\c2ccccc2)n1, CN1CCN(CC1)c1cc(Nc2cc(C)n[nH]2)nc(\C=C\c2ccccc2)n1	BLQYVHBZHAISJM-CMDGGOBGSA-N, BLQYVHBZHAISJM-CMDGGOBGSA-N, BLQYVHBZHAISJM-CMDGGOBGSA-N	Phase 2
enocitabine	DNA synthesis inhibitor	CMPK1, RRM1, TYMS	hematologic malignancy	acute myeloid leukemia (AML)	CCCCCCCCCCCCCCCCCCCCCC(=O)Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1, CCCCCCCCCCCCCCCCCCCCCC(=O)Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1	SAMRUMKYXPVKPA-VFKOLLTISA-N, SAMRUMKYXPVKPA-VFKOLLTISA-N	Launched
enoxacin	topoisomerase inhibitor	TOP2A	infectious disease	urinary tract infections, gonorrhea	CCn1cc(C(O)=O)c(=O)c2cc(F)c(nc12)N1CCNCC1, CCn1cc(C(O)=O)c(=O)c2cc(F)c(nc12)N1CCNCC1, CCn1cc(C(O)=O)c(=O)c2cc(F)c(nc12)N1CCNCC1, CCn1cc(C(O)=O)c(=O)c2cc(F)c(nc12)N1CCNCC1	IDYZIJYBMGIQMJ-UHFFFAOYSA-N, IDYZIJYBMGIQMJ-UHFFFAOYSA-N, IDYZIJYBMGIQMJ-UHFFFAOYSA-N, IDYZIJYBMGIQMJ-UHFFFAOYSA-N	Launched
enoximone	phosphodiesterase inhibitor	PDE3A	cardiology	congestive heart failure	CSc1ccc(cc1)C(=O)c1[nH]c(=O)[nH]c1C, CSc1ccc(cc1)C(=O)c1[nH]c(=O)[nH]c1C, CSc1ccc(cc1)C(=O)c1[nH]c(=O)[nH]c1C, CSc1ccc(cc1)C(=O)c1[nH]c(=O)[nH]c1C, CSc1ccc(cc1)C(=O)c1[nH]c(=O)[nH]c1C, CSc1ccc(cc1)C(=O)c1[nH]c(=O)[nH]c1C, CSc1ccc(cc1)C(=O)c1[nH]c(=O)[nH]c1C	ZJKNESGOIKRXQY-UHFFFAOYSA-N, ZJKNESGOIKRXQY-UHFFFAOYSA-N, ZJKNESGOIKRXQY-UHFFFAOYSA-N, ZJKNESGOIKRXQY-UHFFFAOYSA-N, ZJKNESGOIKRXQY-UHFFFAOYSA-N, ZJKNESGOIKRXQY-UHFFFAOYSA-N, ZJKNESGOIKRXQY-UHFFFAOYSA-N	Launched
enoxolone	gap junction modulator	HSD11B1	gastroenterology, otolaryngology	peptic ulcer disease (PUD), common cold	CC1(C)[C@@H](O)CC[C@@]2(C)[C@H]1CC[C@]1(C)[C@@H]2C(=O)C=C2[C@@H]3C[C@](C)(CC[C@]3(C)CC[C@@]12C)C(O)=O |t:19|, CC1(C)[C@@H](O)CC[C@@]2(C)[C@H]1CC[C@]1(C)[C@@H]2C(=O)C=C2[C@@H]3C[C@](C)(CC[C@]3(C)CC[C@@]12C)C(O)=O |t:19|, CC1(C)[C@@H](O)CC[C@@]2(C)[C@H]1CC[C@]1(C)[C@@H]2C(=O)C=C2[C@@H]3C[C@](C)(CC[C@]3(C)CC[C@@]12C)C(O)=O |t:19|, CC1(C)[C@@H](O)CC[C@@]2(C)[C@H]1CC[C@]1(C)[C@@H]2C(=O)C=C2[C@@H]3C[C@](C)(CC[C@]3(C)CC[C@@]12C)C(O)=O |t:19|, CC1(C)[C@@H](O)CC[C@@]2(C)[C@H]1CC[C@]1(C)[C@@H]2C(=O)C=C2[C@@H]3C[C@](C)(CC[C@]3(C)CC[C@@]12C)C(O)=O |t:19|	MPDGHEJMBKOTSU-YKLVYJNSSA-N, MPDGHEJMBKOTSU-YKLVYJNSSA-N, MPDGHEJMBKOTSU-YKLVYJNSSA-N, MPDGHEJMBKOTSU-YKLVYJNSSA-N, MPDGHEJMBKOTSU-YKLVYJNSSA-N	Launched
enprofylline	phosphodiesterase inhibitor	ADORA1, ADORA2A, ADORA2B, ADORA3, PDE4A, PDE4B			CCCn1c2nc[nH]c2c(=O)[nH]c1=O, CCCn1c2nc[nH]c2c(=O)[nH]c1=O, CCCn1c2nc[nH]c2c(=O)[nH]c1=O, CCCn1c2nc[nH]c2c(=O)[nH]c1=O, CCCn1c2nc[nH]c2c(=O)[nH]c1=O, CCCn1c2nc[nH]c2c(=O)[nH]c1=O	SIQPXVQCUCHWDI-UHFFFAOYSA-N, SIQPXVQCUCHWDI-UHFFFAOYSA-N, SIQPXVQCUCHWDI-UHFFFAOYSA-N, SIQPXVQCUCHWDI-UHFFFAOYSA-N, SIQPXVQCUCHWDI-UHFFFAOYSA-N, SIQPXVQCUCHWDI-UHFFFAOYSA-N	Phase 3
enrofloxacin	bacterial DNA gyrase inhibitor		infectious disease	gram-negative bacterial infections	CCN1CCN(CC1)c1cc2n(cc(C(O)=O)c(=O)c2cc1F)C1CC1, CCN1CCN(CC1)c1cc2n(cc(C(O)=O)c(=O)c2cc1F)C1CC1, CCN1CCN(CC1)c1cc2n(cc(C(O)=O)c(=O)c2cc1F)C1CC1	SPFYMRJSYKOXGV-UHFFFAOYSA-N, SPFYMRJSYKOXGV-UHFFFAOYSA-N, SPFYMRJSYKOXGV-UHFFFAOYSA-N	Launched
entacapone	catechol O methyltransferase inhibitor	COMT	neurology/psychiatry	Parkinson's Disease	CCN(CC)C(=O)C(=C\c1cc(O)c(O)c(c1)[N+]([O-])=O)\C#N, CCN(CC)C(=O)C(=C\c1cc(O)c(O)c(c1)[N+]([O-])=O)\C#N, CCN(CC)C(=O)C(=C\c1cc(O)c(O)c(c1)[N+]([O-])=O)\C#N, CCN(CC)C(=O)C(=C\c1cc(O)c(O)c(c1)[N+]([O-])=O)\C#N, CCN(CC)C(=O)C(=C\c1cc(O)c(O)c(c1)[N+]([O-])=O)\C#N	JRURYQJSLYLRLN-BJMVGYQFSA-N, JRURYQJSLYLRLN-BJMVGYQFSA-N, JRURYQJSLYLRLN-BJMVGYQFSA-N, JRURYQJSLYLRLN-BJMVGYQFSA-N, JRURYQJSLYLRLN-BJMVGYQFSA-N	Launched
entasobulin	tubulin polymerization inhibitor				Clc1ccc(Cn2cc(C(=O)C(=O)Nc3ccc4ncccc4c3)c3ccccc23)cc1	LJIUXAHLYIPHOK-UHFFFAOYSA-N	Preclinical
entecavir	DNA replication inhibitor, nucleoside reverse transcriptase inhibitor		infectious disease	hepatitis B	Nc1nc(=O)c2ncn([C@H]3C[C@H](O)[C@@H](CO)C3=C)c2[nH]1	QDGZDCVAUDNJFG-FXQIFTODSA-N	Launched
entinostat	HDAC inhibitor	HDAC1, HDAC2, HDAC3, HDAC9			Nc1ccccc1NC(=O)c1ccc(CNC(=O)OCc2cccnc2)cc1, Nc1ccccc1NC(=O)c1ccc(CNC(=O)OCc2cccnc2)cc1, Nc1ccccc1NC(=O)c1ccc(CNC(=O)OCc2cccnc2)cc1, Nc1ccccc1NC(=O)c1ccc(CNC(=O)OCc2cccnc2)cc1, Nc1ccccc1NC(=O)c1ccc(CNC(=O)OCc2cccnc2)cc1, Nc1ccccc1NC(=O)c1ccc(CNC(=O)OCc2cccnc2)cc1, Nc1ccccc1NC(=O)c1ccc(CNC(=O)OCc2cccnc2)cc1, Nc1ccccc1NC(=O)c1ccc(CNC(=O)OCc2cccnc2)cc1, Nc1ccccc1NC(=O)c1ccc(CNC(=O)OCc2cccnc2)cc1	INVTYAOGFAGBOE-UHFFFAOYSA-N, INVTYAOGFAGBOE-UHFFFAOYSA-N, INVTYAOGFAGBOE-UHFFFAOYSA-N, INVTYAOGFAGBOE-UHFFFAOYSA-N, INVTYAOGFAGBOE-UHFFFAOYSA-N, INVTYAOGFAGBOE-UHFFFAOYSA-N, INVTYAOGFAGBOE-UHFFFAOYSA-N, INVTYAOGFAGBOE-UHFFFAOYSA-N, INVTYAOGFAGBOE-UHFFFAOYSA-N	Phase 3
entrectinib	ALK tyrosine kinase receptor inhibitor, proto-oncogene tyrosine protein kinase inhibitor	ALK, NTRK1, NTRK2, NTRK3, ROS1	oncology	non-small cell lung cancer (NSCLC)	CN1CCN(CC1)c1ccc(C(=O)Nc2[nH]nc3ccc(Cc4cc(F)cc(F)c4)cc23)c(NC2CCOCC2)c1, CN1CCN(CC1)c1ccc(C(=O)Nc2[nH]nc3ccc(Cc4cc(F)cc(F)c4)cc23)c(NC2CCOCC2)c1	HAYYBYPASCDWEQ-UHFFFAOYSA-N, HAYYBYPASCDWEQ-UHFFFAOYSA-N	Launched
enzalutamide	androgen receptor antagonist	AR	oncology	prostate cancer	CNC(=O)c1ccc(cc1F)N1C(=S)N(C(=O)C1(C)C)c1ccc(C#N)c(c1)C(F)(F)F	WXCXUHSOUPDCQV-UHFFFAOYSA-N	Launched
enzastaurin	PKC inhibitor	AKT1, GSK3B, PRKCA, PRKCB, PRKCD, PRKCG			Cn1cc(C2=C(C(=O)NC2=O)c2cn(C3CCN(Cc4ccccn4)CC3)c3ccccc23)c2ccccc12 |t:4|, Cn1cc(C2=C(C(=O)NC2=O)c2cn(C3CCN(Cc4ccccn4)CC3)c3ccccc23)c2ccccc12 |t:4|, Cn1cc(C2=C(C(=O)NC2=O)c2cn(C3CCN(Cc4ccccn4)CC3)c3ccccc23)c2ccccc12 |t:4|	AXRCEOKUDYDWLF-UHFFFAOYSA-N, AXRCEOKUDYDWLF-UHFFFAOYSA-N, AXRCEOKUDYDWLF-UHFFFAOYSA-N	Phase 3
EN460	endoplasmic reticulum oxidation inhibitor	ERO1A			OC(=O)c1cc(ccc1Cl)N1N=C(\C(=C\c2ccc(o2)-c2ccccc2)C1=O)C(F)(F)F |c:12|, OC(=O)c1cc(ccc1Cl)N1N=C(\C(=C\c2ccc(o2)-c2ccccc2)C1=O)C(F)(F)F |c:12|	RSLFQCNAOMQAIH-WJDWOHSUSA-N, RSLFQCNAOMQAIH-WJDWOHSUSA-N	Preclinical
EO-1428	p38 MAPK inhibitor	MAPK11, MAPK14			Cc1ccccc1C(=O)c1ccc(Nc2ccc(Br)cc2N)cc1Cl, Cc1ccccc1C(=O)c1ccc(Nc2ccc(Br)cc2N)cc1Cl, Cc1ccccc1C(=O)c1ccc(Nc2ccc(Br)cc2N)cc1Cl, Cc1ccccc1C(=O)c1ccc(Nc2ccc(Br)cc2N)cc1Cl	HDCLCHNAEZNGNV-UHFFFAOYSA-N, HDCLCHNAEZNGNV-UHFFFAOYSA-N, HDCLCHNAEZNGNV-UHFFFAOYSA-N, HDCLCHNAEZNGNV-UHFFFAOYSA-N	Preclinical
epacadostat	indoleamine 2,3-dioxygenase inhibitor	IDO1			NS(=O)(=O)NCCNc1nonc1C(NO)=Nc1ccc(F)c(Br)c1, NS(=O)(=O)NCCNc1nonc1C(NO)=Nc1ccc(F)c(Br)c1, NS(=O)(=O)NCCNc1nonc1C(NO)=Nc1ccc(F)c(Br)c1, NS(=O)(=O)NCCNc1nonc1C(NO)=Nc1ccc(F)c(Br)c1	FBKMWOJEPMPVTQ-UHFFFAOYSA-N, FBKMWOJEPMPVTQ-UHFFFAOYSA-N, FBKMWOJEPMPVTQ-UHFFFAOYSA-N, FBKMWOJEPMPVTQ-UHFFFAOYSA-N	Phase 3
epalrestat	aldose reductase inhibitor	AKR1B1	nephrology	diabetic nephropathy	C\C(\C=C1/SC(=S)N(CC(O)=O)C1=O)=C/c1ccccc1, C\C(\C=C1/SC(=S)N(CC(O)=O)C1=O)=C/c1ccccc1, C\C(\C=C1/SC(=S)N(CC(O)=O)C1=O)=C/c1ccccc1, C\C(\C=C1/SC(=S)N(CC(O)=O)C1=O)=C/c1ccccc1, C\C(\C=C1/SC(=S)N(CC(O)=O)C1=O)=C/c1ccccc1	CHNUOJQWGUIOLD-NFZZJPOKSA-N, CHNUOJQWGUIOLD-NFZZJPOKSA-N, CHNUOJQWGUIOLD-NFZZJPOKSA-N, CHNUOJQWGUIOLD-NFZZJPOKSA-N, CHNUOJQWGUIOLD-NFZZJPOKSA-N	Launched
eperezolid	bacterial 30S ribosomal subunit inhibitor				CC(=O)NC[C@H]1CN(C(=O)O1)c1ccc(N2CCN(CC2)C(=O)CO)c(F)c1, CC(=O)NC[C@H]1CN(C(=O)O1)c1ccc(N2CCN(CC2)C(=O)CO)c(F)c1, CC(=O)NC[C@H]1CN(C(=O)O1)c1ccc(N2CCN(CC2)C(=O)CO)c(F)c1, CC(=O)NC[C@H]1CN(C(=O)O1)c1ccc(N2CCN(CC2)C(=O)CO)c(F)c1	SIMWTRCFFSTNMG-AWEZNQCLSA-N, SIMWTRCFFSTNMG-AWEZNQCLSA-N, SIMWTRCFFSTNMG-AWEZNQCLSA-N, SIMWTRCFFSTNMG-AWEZNQCLSA-N	Phase 1
eperisone	acetylcholine receptor antagonist	CYP2J2	neurology/psychiatry	amyotrophic lateral sclerosis (ALS), spasms, head injury, spinal injury	CCc1ccc(cc1)C(=O)[C@@H](C)CN1CCCCC1 |r|	SQUNAWUMZGQQJD-AWEZNQCLSA-N	Launched
epetraborole	leucyl-tRNA synthetase inhibitor				NC[C@H]1OB(O)c2c1cccc2OCCCO	FXQIIDINBDJDKL-SNVBAGLBSA-N	Preclinical
ephedrine	adrenergic receptor agonist	ACHE, ADRA1A, ADRB2, SLC18A2, SLC6A2	cardiology, pulmonary, neurology/psychiatry, endocrinology	hypotension, asthma, narcolepsy, obesity	CN[C@@H](C)[C@H](O)c1ccccc1, CN[C@@H](C)[C@H](O)c1ccccc1	KWGRBVOPPLSCSI-WPRPVWTQSA-N, KWGRBVOPPLSCSI-WPRPVWTQSA-N	Launched
ephedrine-(racemic)	adrenergic receptor agonist	ADRA1A, ADRA2A, ADRB1, ADRB2, ATF1, ATF2, ATF3, ATF4, ATF5, ATF6, ATF7, FOS, IL2, JDP2, JUN, NFATC1, SLC6A2, SLC6A3, SLC6A4, TNF	cardiology, pulmonary, neurology/psychiatry, endocrinology	hypotension, asthma, narcolepsy, obesity	CN[C@@H](C)[C@@H](O)c1ccccc1 |&1:2,&2:4|, CN[C@@H](C)[C@@H](O)c1ccccc1 |&1:2,&2:4|	KWGRBVOPPLSCSI-WCBMZHEXSA-N, KWGRBVOPPLSCSI-WCBMZHEXSA-N	Launched
epiandrosterone	steroid	G6PD			C[C@]12CC[C@H]3[C@@H](CC[C@H]4C[C@@H](O)CC[C@]34C)[C@@H]1CCC2=O	QGXBDMJGAMFCBF-LUJOEAJASA-N	Preclinical
epicatechin-gallate-(-)	bacterial DNA gyrase inhibitor	BACE1, FASN			Oc1cc(O)c2C[C@@H](OC(=O)c3cc(O)c(O)c(O)c3)[C@H](Oc2c1)c1ccc(O)c(O)c1, Oc1cc(O)c2C[C@@H](OC(=O)c3cc(O)c(O)c(O)c3)[C@H](Oc2c1)c1ccc(O)c(O)c1	LSHVYAFMTMFKBA-TZIWHRDSSA-N, LSHVYAFMTMFKBA-TZIWHRDSSA-N	Phase 2
epiestriol					C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1C[C@H](O)[C@@H]2O	PROQIPRRNZUXQM-ZMSHIADSSA-N	Preclinical
epigallocatechin-(-)					O[C@@H]1Cc2c(O)cc(O)cc2O[C@@H]1c1cc(O)c(O)c(O)c1	XMOCLSLCDHWDHP-IUODEOHRSA-N	Phase 2
epigallocatechin-gallate-(-)	bacterial DNA gyrase inhibitor	ELANE, EP300, FASN, KAT2B, MMP14, MMP2			Oc1cc(O)c2C[C@@H](OC(=O)c3cc(O)c(O)c(O)c3)[C@H](Oc2c1)c1cc(O)c(O)c(O)c1, Oc1cc(O)c2C[C@@H](OC(=O)c3cc(O)c(O)c(O)c3)[C@H](Oc2c1)c1cc(O)c(O)c(O)c1, Oc1cc(O)c2C[C@@H](OC(=O)c3cc(O)c(O)c(O)c3)[C@H](Oc2c1)c1cc(O)c(O)c(O)c1, Oc1cc(O)c2C[C@@H](OC(=O)c3cc(O)c(O)c(O)c3)[C@H](Oc2c1)c1cc(O)c(O)c(O)c1, Oc1cc(O)c2C[C@@H](OC(=O)c3cc(O)c(O)c(O)c3)[C@H](Oc2c1)c1cc(O)c(O)c(O)c1	WMBWREPUVVBILR-WIYYLYMNSA-N, WMBWREPUVVBILR-WIYYLYMNSA-N, WMBWREPUVVBILR-WIYYLYMNSA-N, WMBWREPUVVBILR-WIYYLYMNSA-N, WMBWREPUVVBILR-WIYYLYMNSA-N	Phase 2/Phase 3
epinastine	histamine receptor antagonist	HRH1	ophthalmology	conjunctivitis	NC1=NC[C@H]2N1c1ccccc1Cc1ccccc21 |&1:4,t:1|, NC1=NC[C@H]2N1c1ccccc1Cc1ccccc21 |&1:4,t:1|	WHWZLSFABNNENI-OAHLLOKOSA-N, WHWZLSFABNNENI-OAHLLOKOSA-N	Launched
epinephrine	adrenergic receptor agonist, carbonic anhydrase activator, neurotransmitter	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3, PAH, TNF	cardiology, allergy, pulmonary	cardiac arrest, anaphylactic shock, asthma	CNC[C@H](O)c1ccc(O)c(O)c1, CNC[C@H](O)c1ccc(O)c(O)c1, CNC[C@H](O)c1ccc(O)c(O)c1, CNC[C@H](O)c1ccc(O)c(O)c1, CNC[C@H](O)c1ccc(O)c(O)c1, CNC[C@H](O)c1ccc(O)c(O)c1, CNC[C@H](O)c1ccc(O)c(O)c1, CNC[C@H](O)c1ccc(O)c(O)c1	UCTWMZQNUQWSLP-VIFPVBQESA-N, UCTWMZQNUQWSLP-VIFPVBQESA-N, UCTWMZQNUQWSLP-VIFPVBQESA-N, UCTWMZQNUQWSLP-VIFPVBQESA-N, UCTWMZQNUQWSLP-VIFPVBQESA-N, UCTWMZQNUQWSLP-VIFPVBQESA-N, UCTWMZQNUQWSLP-VIFPVBQESA-N, UCTWMZQNUQWSLP-VIFPVBQESA-N	Launched
epirizole	cyclooxygenase inhibitor	PTGS1, PTGS2	neurology/psychiatry	pain relief	COc1cc(C)nn1-c1nc(C)cc(OC)n1, COc1cc(C)nn1-c1nc(C)cc(OC)n1	RHAXSHUQNIEUEY-UHFFFAOYSA-N, RHAXSHUQNIEUEY-UHFFFAOYSA-N	Launched
epirubicin	topoisomerase inhibitor	CHD1, TOP2A	oncology	breast cancer	COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(=O)CO, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(=O)CO, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(=O)CO, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(=O)CO, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(=O)CO, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(=O)CO, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(=O)CO, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(=O)CO, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(=O)CO	AOJJSUZBOXZQNB-VTZDEGQISA-N, AOJJSUZBOXZQNB-VTZDEGQISA-N, AOJJSUZBOXZQNB-VTZDEGQISA-N, AOJJSUZBOXZQNB-VTZDEGQISA-N, AOJJSUZBOXZQNB-VTZDEGQISA-N, InChI=1S/C27H29NO11/c1-10-22(31)13(28)6-17(38-10)39-15-8-27(36,16(30)9-29)7-12-19(15)26(35)21-20(24(12)33)23(32)11-4-3-5-14(37-2)18(11)25(21)34/h3-5,10,13,15,17,22,29,31,33,35-36H,6-9,28H2,1-2H3/t10-,13-,15-,17-,22-,27-/m0/s1, InChI=1S/C27H29NO11/c1-10-22(31)13(28)6-17(38-10)39-15-8-27(36,16(30)9-29)7-12-19(15)26(35)21-20(24(12)33)23(32)11-4-3-5-14(37-2)18(11)25(21)34/h3-5,10,13,15,17,22,29,31,33,35-36H,6-9,28H2,1-2H3/t10-,13-,15-,17-,22-,27-/m0/s1, InChI=1S/C27H29NO11/c1-10-22(31)13(28)6-17(38-10)39-15-8-27(36,16(30)9-29)7-12-19(15)26(35)21-20(24(12)33)23(32)11-4-3-5-14(37-2)18(11)25(21)34/h3-5,10,13,15,17,22,29,31,33,35-36H,6-9,28H2,1-2H3/t10-,13-,15-,17-,22-,27-/m0/s1, InChI=1S/C27H29NO11/c1-10-22(31)13(28)6-17(38-10)39-15-8-27(36,16(30)9-29)7-12-19(15)26(35)21-20(24(12)33)23(32)11-4-3-5-14(37-2)18(11)25(21)34/h3-5,10,13,15,17,22,29,31,33,35-36H,6-9,28H2,1-2H3/t10-,13-,15-,17-,22-,27-/m0/s1	Launched
epitiostanol	androgen receptor agonist	AR	oncology	breast cancer	C[C@]12CC[C@H]3[C@@H](CC[C@H]4C[C@@H]5S[C@@H]5C[C@]34C)[C@@H]1CC[C@@H]2O, C[C@]12CC[C@H]3[C@@H](CC[C@H]4C[C@@H]5S[C@@H]5C[C@]34C)[C@@H]1CC[C@@H]2O, C[C@]12CC[C@H]3[C@@H](CC[C@H]4C[C@@H]5S[C@@H]5C[C@]34C)[C@@H]1CC[C@@H]2O	OBMLHUPNRURLOK-XGRAFVIBSA-N, OBMLHUPNRURLOK-XGRAFVIBSA-N, OBMLHUPNRURLOK-XGRAFVIBSA-N	Launched
eplerenone	cytochrome P450 inhibitor	NR3C2	cardiology	congestive heart failure, hypertension	COC(=O)[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@@]23O[C@@H]2C[C@@]2(C)[C@@H](CC[C@@]22CCC(=O)O2)[C@H]13 |t:6|, COC(=O)[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@@]23O[C@@H]2C[C@@]2(C)[C@@H](CC[C@@]22CCC(=O)O2)[C@H]13 |t:6|, COC(=O)[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@@]23O[C@@H]2C[C@@]2(C)[C@@H](CC[C@@]22CCC(=O)O2)[C@H]13 |t:6|, COC(=O)[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@@]23O[C@@H]2C[C@@]2(C)[C@@H](CC[C@@]22CCC(=O)O2)[C@H]13 |t:6|, COC(=O)[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@@]23O[C@@H]2C[C@@]2(C)[C@@H](CC[C@@]22CCC(=O)O2)[C@H]13 |t:6|, COC(=O)[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@@]23O[C@@H]2C[C@@]2(C)[C@@H](CC[C@@]22CCC(=O)O2)[C@H]13 |t:6|, COC(=O)[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@@]23O[C@@H]2C[C@@]2(C)[C@@H](CC[C@@]22CCC(=O)O2)[C@H]13 |t:6|, COC(=O)[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@@]23O[C@@H]2C[C@@]2(C)[C@@H](CC[C@@]22CCC(=O)O2)[C@H]13 |t:6|	JUKPWJGBANNWMW-VWBFHTRKSA-N, JUKPWJGBANNWMW-VWBFHTRKSA-N, JUKPWJGBANNWMW-VWBFHTRKSA-N, JUKPWJGBANNWMW-VWBFHTRKSA-N, JUKPWJGBANNWMW-VWBFHTRKSA-N, JUKPWJGBANNWMW-VWBFHTRKSA-N, JUKPWJGBANNWMW-VWBFHTRKSA-N, JUKPWJGBANNWMW-VWBFHTRKSA-N	Launched
epomediol	cholesterol inhibitor	CYP7A1	neurology/psychiatry	itching	CC1(C)OC2(C)[C@@H](O)C[C@H]1C[C@@H]2O |&1:11,&2:9,&3:6,r,THB:12:11:1.3:8.6,7:6:1.3:11.10|	JSNQSLSBBZFGBM-XAKJDZQGSA-N	Launched
epoprostenol	prostacyclin analog	P2RY12, PTGER1, PTGER4, PTGIR, PTGIS	cardiology	hypertension	CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)C[C@@H]2O\C(C[C@H]12)=C/CCCC(O)=O, CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)C[C@@H]2O\C(C[C@H]12)=C/CCCC(O)=O, CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)C[C@@H]2O\C(C[C@H]12)=C/CCCC(O)=O, CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)C[C@@H]2O\C(C[C@H]12)=C/CCCC(O)=O	KAQKFAOMNZTLHT-OZUDYXHBSA-N, InChI=1S/C20H32O5/c1-2-3-4-7-14(21)10-11-16-17-12-15(8-5-6-9-20(23)24)25-19(17)13-18(16)22/h8,10-11,14,16-19,21-22H,2-7,9,12-13H2,1H3,(H,23,24)/b11-10+,15-8-/t14-,16+,17+,18+,19-/m0/s1, InChI=1S/C20H32O5/c1-2-3-4-7-14(21)10-11-16-17-12-15(8-5-6-9-20(23)24)25-19(17)13-18(16)22/h8,10-11,14,16-19,21-22H,2-7,9,12-13H2,1H3,(H,23,24)/b11-10+,15-8-/t14-,16+,17+,18+,19-/m0/s1, InChI=1S/C20H32O5/c1-2-3-4-7-14(21)10-11-16-17-12-15(8-5-6-9-20(23)24)25-19(17)13-18(16)22/h8,10-11,14,16-19,21-22H,2-7,9,12-13H2,1H3,(H,23,24)/b11-10+,15-8-/t14-,16+,17+,18+,19-/m0/s1	Launched
epothilone-A	microtubule stabilizing agent				C[C@H]1CCC[C@H]2O[C@H]2C[C@H](OC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@H]1O)C(\C)=C\c1csc(C)n1, C[C@H]1CCC[C@H]2O[C@H]2C[C@H](OC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@H]1O)C(\C)=C\c1csc(C)n1	HESCAJZNRMSMJG-QJCAGBKWSA-N, HESCAJZNRMSMJG-QJCAGBKWSA-N	Preclinical
epothilone-B	microtubule stabilizing agent, tubulin polymerization inhibitor	TUBB			C[C@H]1CCC[C@@]2(C)O[C@H]2C[C@H](OC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@H]1O)C(\C)=C\c1csc(C)n1	QXRSDHAAWVKZLJ-QBNZTRRJSA-N	Phase 3
epothilone-D	microtubule stabilizing agent, tubulin polymerization inhibitor	TUBB			C[C@H]1CCC\C(C)=C/C[C@H](OC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@H]1O)C(\C)=C\c1csc(C)n1 |c:6|, C[C@H]1CCC\C(C)=C/C[C@H](OC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@H]1O)C(\C)=C\c1csc(C)n1 |c:6|	XOZIUKBZLSUILX-HFHFCCBWSA-N, XOZIUKBZLSUILX-HFHFCCBWSA-N	Phase 2
EPPTB	trace amine associated receptor antagonist	TAAR1			CCOc1cccc(NC(=O)c2ccc(N3CCCC3)c(c2)C(F)(F)F)c1, CCOc1cccc(NC(=O)c2ccc(N3CCCC3)c(c2)C(F)(F)F)c1, CCOc1cccc(NC(=O)c2ccc(N3CCCC3)c(c2)C(F)(F)F)c1	KLFVWQCQUXXLOU-UHFFFAOYSA-N, KLFVWQCQUXXLOU-UHFFFAOYSA-N, KLFVWQCQUXXLOU-UHFFFAOYSA-N	Preclinical
eprazinone	mucolytic agent		pulmonary	bronchospasm	CCO[C@@H](CN1CCN(C[C@@H](C)C(=O)c2ccccc2)CC1)c1ccccc1 |a:10,&1:3|, CCO[C@@H](CN1CCN(C[C@@H](C)C(=O)c2ccccc2)CC1)c1ccccc1 |a:10,&1:3|, CCO[C@@H](CN1CCN(C[C@@H](C)C(=O)c2ccccc2)CC1)c1ccccc1 |a:10,&1:3|	BSHWLCACYCVCJE-OFNKIYASSA-N, BSHWLCACYCVCJE-OFNKIYASSA-N, BSHWLCACYCVCJE-OFNKIYASSA-N	Launched
eprinomectin	benzodiazepine receptor agonist		infectious disease	gastrointestinal roundworms, lungworms	[H][C@@]12OC\C3=C/C=C/[C@]([H])(C)[C@]([H])(O[C@@]4([H])C[C@H](OC)[C@@H](O[C@@]5([H])C[C@H](OC)[C@@H](NC(C)=O)[C@H](C)O5)[C@H](C)O4)\C(C)=C\C[C@]4([H])C[C@@]([H])(C[C@]5(O4)O[C@]([H])([C@@H](C)CC)[C@@]([H])(C)C=C5)OC(=O)[C@]([H])(C=C(C)[C@@]1([H])O)[C@@]23O |c:4,64,t:6,42,72|	ZKWQQXZUCOBISE-NQMKODOQSA-N	Launched
epristeride	5 alpha reductase inhibitor				[H][C@@]12CC[C@H](C(=O)NC(C)(C)C)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C=C(CC[C@]12C)C(O)=O |c:25,t:23|	VAPSMQAHNAZRKC-PQWRYPMOSA-N	Preclinical
eprobemide	monoamine oxidase inhibitor	MAOA	neurology/psychiatry	depression	Clc1ccc(cc1)C(=O)NCCCN1CCOCC1, Clc1ccc(cc1)C(=O)NCCCN1CCOCC1, Clc1ccc(cc1)C(=O)NCCCN1CCOCC1	YYFGRAGNYHYWEZ-UHFFFAOYSA-N, YYFGRAGNYHYWEZ-UHFFFAOYSA-N, YYFGRAGNYHYWEZ-UHFFFAOYSA-N	Launched
eprodisate	amyloid protein inhibitor, antiamyloidogenic agent	SAA1			OS(=O)(=O)CCCS(O)(=O)=O, OS(=O)(=O)CCCS(O)(=O)=O, OS(=O)(=O)CCCS(O)(=O)=O	MGNVWUDMMXZUDI-UHFFFAOYSA-N, MGNVWUDMMXZUDI-UHFFFAOYSA-N, MGNVWUDMMXZUDI-UHFFFAOYSA-N	Phase 3
eprosartan	angiotensin receptor antagonist	AGTR1	cardiology	hypertension	CCCCc1ncc(\C=C(/Cc2cccs2)C(O)=O)n1Cc1ccc(cc1)C(O)=O, CCCCc1ncc(\C=C(/Cc2cccs2)C(O)=O)n1Cc1ccc(cc1)C(O)=O, CCCCc1ncc(\C=C(/Cc2cccs2)C(O)=O)n1Cc1ccc(cc1)C(O)=O, CCCCc1ncc(\C=C(/Cc2cccs2)C(O)=O)n1Cc1ccc(cc1)C(O)=O, CCCCc1ncc(\C=C(/Cc2cccs2)C(O)=O)n1Cc1ccc(cc1)C(O)=O	OROAFUQRIXKEMV-LDADJPATSA-N, OROAFUQRIXKEMV-LDADJPATSA-N, OROAFUQRIXKEMV-LDADJPATSA-N, OROAFUQRIXKEMV-LDADJPATSA-N, OROAFUQRIXKEMV-LDADJPATSA-N	Launched
eptifibatide	platelet aggregation inhibitor	ITGA2B, ITGB3	cardiology	acute coronary syndrome (ACS), percutaneous coronary intervention (PCI)	NC(=N)NCCCC[C@@H]1NC(=O)CCSSC[C@H](NC(=O)[C@@H]2CCCN2C(=O)[C@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](CC(O)=O)NC(=O)CNC1=O)C(N)=O, NC(=N)NCCCC[C@@H]1NC(=O)CCSSC[C@H](NC(=O)[C@@H]2CCCN2C(=O)[C@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](CC(O)=O)NC(=O)CNC1=O)C(N)=O	CZKPOZZJODAYPZ-IQENKEMDSA-N, CZKPOZZJODAYPZ-IQENKEMDSA-N	Launched
EPZ-5676	histone lysine methyltransferase inhibitor	DOT1L			CC(C)N(C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(N)ncnc12)[C@@H]1C[C@H](CCc2nc3ccc(cc3[nH]2)C(C)(C)C)C1, CC(C)N(C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(N)ncnc12)[C@@H]1C[C@H](CCc2nc3ccc(cc3[nH]2)C(C)(C)C)C1, CC(C)N(C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(N)ncnc12)[C@@H]1C[C@H](CCc2nc3ccc(cc3[nH]2)C(C)(C)C)C1, CC(C)N(C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(N)ncnc12)[C@@H]1C[C@H](CCc2nc3ccc(cc3[nH]2)C(C)(C)C)C1, CC(C)N(C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(N)ncnc12)[C@@H]1C[C@H](CCc2nc3ccc(cc3[nH]2)C(C)(C)C)C1, CC(C)N(C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(N)ncnc12)[C@@H]1C[C@H](CCc2nc3ccc(cc3[nH]2)C(C)(C)C)C1, CC(C)N(C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(N)ncnc12)[C@@H]1C[C@H](CCc2nc3ccc(cc3[nH]2)C(C)(C)C)C1, CC(C)N(C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(N)ncnc12)[C@@H]1C[C@H](CCc2nc3ccc(cc3[nH]2)C(C)(C)C)C1, CC(C)N(C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(N)ncnc12)[C@@H]1C[C@H](CCc2nc3ccc(cc3[nH]2)C(C)(C)C)C1, CC(C)N(C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(N)ncnc12)[C@@H]1C[C@H](CCc2nc3ccc(cc3[nH]2)C(C)(C)C)C1	LXFOLMYKSYSZQS-LURJZOHASA-N, LXFOLMYKSYSZQS-LURJZOHASA-N, LXFOLMYKSYSZQS-LURJZOHASA-N, LXFOLMYKSYSZQS-LURJZOHASA-N, LXFOLMYKSYSZQS-LURJZOHASA-N, LXFOLMYKSYSZQS-LURJZOHASA-N, LXFOLMYKSYSZQS-LURJZOHASA-N, LXFOLMYKSYSZQS-LURJZOHASA-N, LXFOLMYKSYSZQS-LURJZOHASA-N, LXFOLMYKSYSZQS-LURJZOHASA-N	Phase 1
EPZ004777	histone lysine methyltransferase inhibitor	DOT1L			CC(C)N(CCCNC(=O)Nc1ccc(cc1)C(C)(C)C)C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1ccc2c(N)ncnc12, CC(C)N(CCCNC(=O)Nc1ccc(cc1)C(C)(C)C)C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1ccc2c(N)ncnc12, CC(C)N(CCCNC(=O)Nc1ccc(cc1)C(C)(C)C)C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1ccc2c(N)ncnc12, CC(C)N(CCCNC(=O)Nc1ccc(cc1)C(C)(C)C)C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1ccc2c(N)ncnc12, CC(C)N(CCCNC(=O)Nc1ccc(cc1)C(C)(C)C)C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1ccc2c(N)ncnc12	WXRGFPHDRFQODR-ICLZECGLSA-N, WXRGFPHDRFQODR-ICLZECGLSA-N, WXRGFPHDRFQODR-ICLZECGLSA-N, WXRGFPHDRFQODR-ICLZECGLSA-N, WXRGFPHDRFQODR-ICLZECGLSA-N	Preclinical
EPZ005687	histone lysine methyltransferase inhibitor	EZH2			Cc1cc(C)c(CNC(=O)c2cc(cc3n(ncc23)C2CCCC2)-c2ccc(CN3CCOCC3)cc2)c(=O)[nH]1	ZOIBZSZLMJDVDQ-UHFFFAOYSA-N	Preclinical
EPZ011989	histone lysine methyltransferase inhibitor	EZH2			CCN([C@H]1CC[C@@H](CC1)N(C)CCOC)c1cc(cc(C(=O)NCc2c(C)cc(C)[nH]c2=O)c1C)C#CCN1CCOCC1 |r|, CCN([C@H]1CC[C@@H](CC1)N(C)CCOC)c1cc(cc(C(=O)NCc2c(C)cc(C)[nH]c2=O)c1C)C#CCN1CCOCC1 |r|, CCN([C@H]1CC[C@@H](CC1)N(C)CCOC)c1cc(cc(C(=O)NCc2c(C)cc(C)[nH]c2=O)c1C)C#CCN1CCOCC1 |r|	XQFINGFCBFHOPE-WXUXXXNLSA-N, XQFINGFCBFHOPE-WXUXXXNLSA-N, XQFINGFCBFHOPE-WXUXXXNLSA-N	Preclinical
EPZ015666	protein arginine N-methyltransferase inhibitor	PRMT5			O[C@@H](CNC(=O)c1cc(NC2COC2)ncn1)CN1CCc2ccccc2C1, O[C@@H](CNC(=O)c1cc(NC2COC2)ncn1)CN1CCc2ccccc2C1, O[C@@H](CNC(=O)c1cc(NC2COC2)ncn1)CN1CCc2ccccc2C1, O[C@@H](CNC(=O)c1cc(NC2COC2)ncn1)CN1CCc2ccccc2C1, O[C@@H](CNC(=O)c1cc(NC2COC2)ncn1)CN1CCc2ccccc2C1, O[C@@H](CNC(=O)c1cc(NC2COC2)ncn1)CN1CCc2ccccc2C1, O[C@@H](CNC(=O)c1cc(NC2COC2)ncn1)CN1CCc2ccccc2C1, O[C@@H](CNC(=O)c1cc(NC2COC2)ncn1)CN1CCc2ccccc2C1, O[C@@H](CNC(=O)c1cc(NC2COC2)ncn1)CN1CCc2ccccc2C1	ZKXZLIFRWWKZRY-KRWDZBQOSA-N, ZKXZLIFRWWKZRY-KRWDZBQOSA-N, ZKXZLIFRWWKZRY-KRWDZBQOSA-N, ZKXZLIFRWWKZRY-KRWDZBQOSA-N, ZKXZLIFRWWKZRY-KRWDZBQOSA-N, ZKXZLIFRWWKZRY-KRWDZBQOSA-N, ZKXZLIFRWWKZRY-KRWDZBQOSA-N, ZKXZLIFRWWKZRY-KRWDZBQOSA-N, ZKXZLIFRWWKZRY-KRWDZBQOSA-N	Preclinical
EPZ020411	protein arginine N-methyltransferase inhibitor	PRMT6			CNCCN(C)Cc1c[nH]nc1-c1ccc(O[C@H]2C[C@@H](C2)OCCC2CCOCC2)cc1 |r|, CNCCN(C)Cc1c[nH]nc1-c1ccc(O[C@H]2C[C@@H](C2)OCCC2CCOCC2)cc1 |r|, CNCCN(C)Cc1c[nH]nc1-c1ccc(O[C@H]2C[C@@H](C2)OCCC2CCOCC2)cc1 |r|, CNCCN(C)Cc1c[nH]nc1-c1ccc(O[C@H]2C[C@@H](C2)OCCC2CCOCC2)cc1 |r|	QMDKVNSQXPVCRD-RQNOJGIXSA-N, QMDKVNSQXPVCRD-RQNOJGIXSA-N, QMDKVNSQXPVCRD-RQNOJGIXSA-N, QMDKVNSQXPVCRD-RQNOJGIXSA-N	Preclinical
equilin	estrogen receptor agonist	HSD17B1			C[C@@]12CC[C@H]3C(=CCc4cc(O)ccc34)[C@@H]1CCC2=O |&1:1,&2:4,&3:15,r,c:5|, C[C@@]12CC[C@H]3C(=CCc4cc(O)ccc34)[C@@H]1CCC2=O |&1:1,&2:4,&3:15,r,c:5|, C[C@@]12CC[C@H]3C(=CCc4cc(O)ccc34)[C@@H]1CCC2=O |&1:1,&2:4,&3:15,r,c:5|	WKRLQDKEXYKHJB-UWWQBHOKSA-N, WKRLQDKEXYKHJB-UWWQBHOKSA-N, WKRLQDKEXYKHJB-UWWQBHOKSA-N	Preclinical
equol	estrogen receptor agonist	ESR1, ESR2			Oc1ccc(cc1)[C@H]1COc2cc(O)ccc2C1, Oc1ccc(cc1)[C@H]1COc2cc(O)ccc2C1, Oc1ccc(cc1)[C@H]1COc2cc(O)ccc2C1	ADFCQWZHKCXPAJ-GFCCVEGCSA-N, ADFCQWZHKCXPAJ-GFCCVEGCSA-N, ADFCQWZHKCXPAJ-GFCCVEGCSA-N	Launched
ER-27319	mediator release inhibitor, SYK inhibitor	SYK			Cc1ccc2c(c1C)n(CCCN)c1ccccc1c2=O, Cc1ccc2c(c1C)n(CCCN)c1ccccc1c2=O, Cc1ccc2c(c1C)n(CCCN)c1ccccc1c2=O, Cc1ccc2c(c1C)n(CCCN)c1ccccc1c2=O, Cc1ccc2c(c1C)n(CCCN)c1ccccc1c2=O, Cc1ccc2c(c1C)n(CCCN)c1ccccc1c2=O	CFPDEQBPNROZDC-UHFFFAOYSA-N, CFPDEQBPNROZDC-UHFFFAOYSA-N, CFPDEQBPNROZDC-UHFFFAOYSA-N, CFPDEQBPNROZDC-UHFFFAOYSA-N, CFPDEQBPNROZDC-UHFFFAOYSA-N, CFPDEQBPNROZDC-UHFFFAOYSA-N	Preclinical
ER-50891	retinoid receptor antagonist	RARA			CC(C)c1cccc2c(cc(nc12)-c1ccc([nH]1)-c1ccc(cc1)C(O)=O)-c1ccccc1, CC(C)c1cccc2c(cc(nc12)-c1ccc([nH]1)-c1ccc(cc1)C(O)=O)-c1ccccc1	LSGNKLDHMQVTEK-UHFFFAOYSA-N, LSGNKLDHMQVTEK-UHFFFAOYSA-N	Preclinical
erastin	ion channel antagonist	VDAC2			CCOc1ccccc1-n1c(nc2ccccc2c1=O)[C@@H](C)N1CCN(CC1)C(=O)COc1ccc(Cl)cc1 |&1:20,r|, CCOc1ccccc1-n1c(nc2ccccc2c1=O)[C@@H](C)N1CCN(CC1)C(=O)COc1ccc(Cl)cc1 |&1:20,r|, CCOc1ccccc1-n1c(nc2ccccc2c1=O)[C@@H](C)N1CCN(CC1)C(=O)COc1ccc(Cl)cc1 |&1:20,r|, CCOc1ccccc1-n1c(nc2ccccc2c1=O)[C@@H](C)N1CCN(CC1)C(=O)COc1ccc(Cl)cc1 |&1:20,r|, CCOc1ccccc1-n1c(nc2ccccc2c1=O)[C@@H](C)N1CCN(CC1)C(=O)COc1ccc(Cl)cc1 |&1:20,r|	BKQFRNYHFIQEKN-OAQYLSRUSA-N, BKQFRNYHFIQEKN-OAQYLSRUSA-N, BKQFRNYHFIQEKN-OAQYLSRUSA-N, BKQFRNYHFIQEKN-OAQYLSRUSA-N, BKQFRNYHFIQEKN-OAQYLSRUSA-N	Preclinical
eravacycline	antibacterial				[H][C@@]12Cc3c(F)cc(NC(=O)CN4CCCC4)c(O)c3C(=O)[C@H]1C(=O)[C@]1(O)C(=O)[C@H](C(N)=O)C(=O)[C@@H](N(C)C)[C@]1([H])C2 |&1:29,&2:22|	LSZZJAUTRJAFCO-KKCFVTAMSA-N	Launched
erbstatin-analog	EGFR inhibitor, tyrosine kinase inhibitor	EGFR			COC(=O)\C=C\c1cc(O)ccc1O	BQCNSTFWSKOWMA-GORDUTHDSA-N	Preclinical
ercalcitriol	vitamin D receptor agonist	VDR			C[C@H](\C=C\[C@H](C)C(C)(C)O)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C, C[C@H](\C=C\[C@H](C)C(C)(C)O)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C, C[C@H](\C=C\[C@H](C)C(C)(C)O)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C, C[C@H](\C=C\[C@H](C)C(C)(C)O)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C	ZGLHBRQAEXKACO-XJRQOBMKSA-N, ZGLHBRQAEXKACO-XJRQOBMKSA-N, ZGLHBRQAEXKACO-XJRQOBMKSA-N, ZGLHBRQAEXKACO-XJRQOBMKSA-N	Phase 1
erdafitinib	FGFR inhibitor	FGFR1, FGFR2, FGFR3, FGFR4			COc1cc(OC)cc(c1)N(CCNC(C)C)c1ccc2ncc(nc2c1)-c1cnn(C)c1, COc1cc(OC)cc(c1)N(CCNC(C)C)c1ccc2ncc(nc2c1)-c1cnn(C)c1, COc1cc(OC)cc(c1)N(CCNC(C)C)c1ccc2ncc(nc2c1)-c1cnn(C)c1, COc1cc(OC)cc(c1)N(CCNC(C)C)c1ccc2ncc(nc2c1)-c1cnn(C)c1, COc1cc(OC)cc(c1)N(CCNC(C)C)c1ccc2ncc(nc2c1)-c1cnn(C)c1	OLAHOMJCDNXHFI-UHFFFAOYSA-N, OLAHOMJCDNXHFI-UHFFFAOYSA-N, OLAHOMJCDNXHFI-UHFFFAOYSA-N, OLAHOMJCDNXHFI-UHFFFAOYSA-N, OLAHOMJCDNXHFI-UHFFFAOYSA-N	Launched
erdosteine	mucolytic agent		pulmonary, infectious disease	bronchitis, cough suppressant, chronic obstructive pulmonary disease (COPD), respiratory tract infections	OC(=O)CSCC(=O)N[C@H]1CCSC1=O |&1:9,r|, OC(=O)CSCC(=O)N[C@H]1CCSC1=O |&1:9,r|, OC(=O)CSCC(=O)N[C@H]1CCSC1=O |&1:9,r|, OC(=O)CSCC(=O)N[C@H]1CCSC1=O |&1:9,r|	QGFORSXNKQLDNO-YFKPBYRVSA-N, QGFORSXNKQLDNO-YFKPBYRVSA-N, QGFORSXNKQLDNO-YFKPBYRVSA-N, QGFORSXNKQLDNO-YFKPBYRVSA-N	Launched
ergocalciferol	vitamin analog	VDR	endocrinology, orthopedics	hypoparathyroidism, rickets, hypophosphatemia	CC(C)[C@@H](C)\C=C\[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)CCC1=C, CC(C)[C@@H](C)\C=C\[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)CCC1=C, CC(C)[C@@H](C)\C=C\[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)CCC1=C, CC(C)[C@@H](C)\C=C\[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)CCC1=C, CC(C)[C@@H](C)\C=C\[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)CCC1=C, CC(C)[C@@H](C)\C=C\[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)CCC1=C, CC(C)[C@@H](C)\C=C\[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)CCC1=C, CC(C)[C@@H](C)\C=C\[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)CCC1=C, CC(C)[C@@H](C)\C=C\[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)CCC1=C	MECHNRXZTMCUDQ-RKHKHRCZSA-N, MECHNRXZTMCUDQ-RKHKHRCZSA-N, MECHNRXZTMCUDQ-RKHKHRCZSA-N, MECHNRXZTMCUDQ-RKHKHRCZSA-N, MECHNRXZTMCUDQ-RKHKHRCZSA-N, MECHNRXZTMCUDQ-RKHKHRCZSA-N, MECHNRXZTMCUDQ-RKHKHRCZSA-N, MECHNRXZTMCUDQ-RKHKHRCZSA-N, MECHNRXZTMCUDQ-RKHKHRCZSA-N	Launched
ergonovine	adrenergic receptor agonist, serotonin receptor agonist	ADRA1A, HTR1E	hematology	postpartum hemorrhage (PPH)	C[C@@H](CO)NC(=O)[C@H]1CN(C)[C@@H]2Cc3c[nH]c4cccc(C2=C1)c34 |c:22|	WVVSZNPYNCNODU-XTQGRXLLSA-N	Launched
ergosterol	vitamin D precursor				CC(C)[C@@H](C)\C=C\[C@@H](C)[C@H]1CC[C@H]2C3=CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C |t:13,15|, CC(C)[C@@H](C)\C=C\[C@@H](C)[C@H]1CC[C@H]2C3=CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C |t:13,15|, CC(C)[C@@H](C)\C=C\[C@@H](C)[C@H]1CC[C@H]2C3=CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C |t:13,15|, CC(C)[C@@H](C)\C=C\[C@@H](C)[C@H]1CC[C@H]2C3=CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C |t:13,15|, CC(C)[C@@H](C)\C=C\[C@@H](C)[C@H]1CC[C@H]2C3=CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C |t:13,15|	DNVPQKQSNYMLRS-APGDWVJJSA-N, DNVPQKQSNYMLRS-APGDWVJJSA-N, DNVPQKQSNYMLRS-APGDWVJJSA-N, DNVPQKQSNYMLRS-APGDWVJJSA-N, DNVPQKQSNYMLRS-APGDWVJJSA-N	Preclinical
ergotamine	adrenergic receptor antagonist	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, DRD1, DRD2, DRD5, HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2B, HTR2C, HTR5A, HTR6, SLC6A2	neurology/psychiatry	migraine headache	CN1C[C@@H](C=C2[C@H]1Cc1c[nH]c3cccc2c13)C(=O)N[C@]1(C)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](Cc3ccccc3)N2C1=O |c:4|, CN1C[C@@H](C=C2[C@H]1Cc1c[nH]c3cccc2c13)C(=O)N[C@]1(C)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](Cc3ccccc3)N2C1=O |c:4|	XCGSFFUVFURLIX-VFGNJEKYSA-N, XCGSFFUVFURLIX-VFGNJEKYSA-N	Launched
eribulin	microtubule inhibitor		oncology	breast cancer	[H][C@@]12CC(=C)[C@]([H])(CC[C@@]3([H])C[C@@H](C)C(=C)[C@@]([H])(C[C@]4([H])O[C@H](C[C@H](O)CN)[C@H](OC)[C@@]4([H])CC(=O)C[C@@]4([H])CC[C@]5([H])O[C@@]6([H])[C@@]7([H])O[C@@]8(C[C@@]7([H])O[C@@]6([H])[C@@]([H])(O8)[C@@]5([H])O4)CC1)O3)O2 |THB:43:44:51.53:48.49.56.58,50:49:44:51.53,50:51:44:48.49.56.58,53:54:46.48.49.58:41.43.59,59:56:44:51.53|	UFNVPOGXISZXJD-JBQZKEIOSA-N	Launched
ERK5-IN-1	MAP kinase inhibitor	MAPK7			COc1cc(ccc1Nc1ncc2N(C)C(=O)c3ccccc3N(C)c2n1)N1CCN(C)CC1, COc1cc(ccc1Nc1ncc2N(C)C(=O)c3ccccc3N(C)c2n1)N1CCN(C)CC1, COc1cc(ccc1Nc1ncc2N(C)C(=O)c3ccccc3N(C)c2n1)N1CCN(C)CC1	DDTPGANIPBKTNU-UHFFFAOYSA-N, DDTPGANIPBKTNU-UHFFFAOYSA-N, DDTPGANIPBKTNU-UHFFFAOYSA-N	Preclinical
erlotinib	EGFR inhibitor	EGFR, NR1I2	oncology	non-small cell lung cancer (NSCLC), pancreatic cancer	COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC, COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC, COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC, COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC, COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC, COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC, COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC, COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC, COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC, COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC, COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC, COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC, COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC, COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC, COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC, COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC, COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC	AAKJLRGGTJKAMG-UHFFFAOYSA-N, AAKJLRGGTJKAMG-UHFFFAOYSA-N, AAKJLRGGTJKAMG-UHFFFAOYSA-N, AAKJLRGGTJKAMG-UHFFFAOYSA-N, AAKJLRGGTJKAMG-UHFFFAOYSA-N, AAKJLRGGTJKAMG-UHFFFAOYSA-N, AAKJLRGGTJKAMG-UHFFFAOYSA-N, AAKJLRGGTJKAMG-UHFFFAOYSA-N, AAKJLRGGTJKAMG-UHFFFAOYSA-N, AAKJLRGGTJKAMG-UHFFFAOYSA-N, InChI=1S/C22H23N3O4/c1-4-16-6-5-7-17(12-16)25-22-18-13-20(28-10-8-26-2)21(29-11-9-27-3)14-19(18)23-15-24-22/h1,5-7,12-15H,8-11H2,2-3H3,(H,23,24,25), InChI=1S/C22H23N3O4/c1-4-16-6-5-7-17(12-16)25-22-18-13-20(28-10-8-26-2)21(29-11-9-27-3)14-19(18)23-15-24-22/h1,5-7,12-15H,8-11H2,2-3H3,(H,23,24,25), InChI=1S/C22H23N3O4/c1-4-16-6-5-7-17(12-16)25-22-18-13-20(28-10-8-26-2)21(29-11-9-27-3)14-19(18)23-15-24-22/h1,5-7,12-15H,8-11H2,2-3H3,(H,23,24,25), InChI=1S/C22H23N3O4/c1-4-16-6-5-7-17(12-16)25-22-18-13-20(28-10-8-26-2)21(29-11-9-27-3)14-19(18)23-15-24-22/h1,5-7,12-15H,8-11H2,2-3H3,(H,23,24,25), InChI=1S/C22H23N3O4/c1-4-16-6-5-7-17(12-16)25-22-18-13-20(28-10-8-26-2)21(29-11-9-27-3)14-19(18)23-15-24-22/h1,5-7,12-15H,8-11H2,2-3H3,(H,23,24,25), InChI=1S/C22H23N3O4/c1-4-16-6-5-7-17(12-16)25-22-18-13-20(28-10-8-26-2)21(29-11-9-27-3)14-19(18)23-15-24-22/h1,5-7,12-15H,8-11H2,2-3H3,(H,23,24,25), InChI=1S/C22H23N3O4/c1-4-16-6-5-7-17(12-16)25-22-18-13-20(28-10-8-26-2)21(29-11-9-27-3)14-19(18)23-15-24-22/h1,5-7,12-15H,8-11H2,2-3H3,(H,23,24,25)	Launched
ertapenem	bacterial cell wall synthesis inhibitor		infectious disease	intra-abdominal infections, skin infections, pneumonia, urinary tract infections, gynecologic infections, postpartum endomyometritis	C[C@@H](O)[C@H]1[C@H]2[C@@H](C)C(S[C@@H]3CN[C@@H](C3)C(=O)Nc3cccc(c3)C(O)=O)=C(N2C1=O)C(O)=O |a:1,4,5,9,12,&1:3,c:27|	JUZNIMUFDBIJCM-FKTXGUMASA-N	Launched
erteberel	estrogen receptor agonist	ESR1, ESR2			Oc1ccc(cc1)[C@@H]1Oc2ccc(O)cc2[C@@H]2CCC[C@H]12, Oc1ccc(cc1)[C@@H]1Oc2ccc(O)cc2[C@@H]2CCC[C@H]12	XIESSJVMWNJCGZ-VKJFTORMSA-N, XIESSJVMWNJCGZ-VKJFTORMSA-N	Phase 2
ertugliflozin	sodium/glucose cotransporter inhibitor	SLC5A2	endocrinology	diabetes mellitus	CCOc1ccc(Cc2cc(ccc2Cl)[C@]23OC[C@](CO)(O2)[C@@H](O)[C@H](O)[C@H]3O)cc1	MCIACXAZCBVDEE-CUUWFGFTSA-N	Launched
erythritol					OC[C@H](O)[C@H](O)CO, OC[C@H](O)[C@H](O)CO, OC[C@H](O)[C@H](O)CO, OC[C@H](O)[C@H](O)CO	UNXHWFMMPAWVPI-ZXZARUISSA-N, UNXHWFMMPAWVPI-ZXZARUISSA-N, UNXHWFMMPAWVPI-ZXZARUISSA-N, UNXHWFMMPAWVPI-ZXZARUISSA-N	Launched
erythromycin	NFkB pathway inhibitor	MLNR	infectious disease	listeria, respiratory tract infections, skin infections, syphilis, amebiasis, pelvic inflammatory disease, chlamydia, diphtheria, erythrasma	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O, CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O, CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O, CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O, CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O	ULGZDMOVFRHVEP-BCQGSPHWSA-N, ULGZDMOVFRHVEP-BCQGSPHWSA-N, ULGZDMOVFRHVEP-BCQGSPHWSA-N, ULGZDMOVFRHVEP-BCQGSPHWSA-N, ULGZDMOVFRHVEP-BCQGSPHWSA-N	Launched
erythromycin-estolate	bacterial 50S ribosomal subunit inhibitor	ABCB1, ALB, CYP3A4, CYP51A1, KCNH2, MLNR, SLC47A1	infectious disease	listeria, respiratory tract infections, skin infections, syphilis, amebiasis, pelvic inflammatory disease, chlamydia, diphtheria, erythrasma	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2OC(=O)CC)N(C)C)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O, CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2OC(=O)CC)N(C)C)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O	TYQXKHPOXXXCTP-JKQIPHDKSA-N, TYQXKHPOXXXCTP-JKQIPHDKSA-N	Launched
erythromycin-ethylsuccinate	cytochrome P450 inhibitor, protein synthesis inhibitor	ABCB1, ALB, CYP3A4, CYP51A1, KCNH2, MLNR, SLC47A1	infectious disease	listeria, respiratory tract infections, skin infections, syphilis, amebiasis, pelvic inflammatory disease, chlamydia, diphtheria, erythrasma	CCOC(=O)CCC(=O)O[C@H]1[C@H](O[C@@H]2[C@@H](C)[C@H](O[C@H]3C[C@@](C)(OC)[C@@H](O)[C@H](C)O3)[C@@H](C)C(=O)O[C@H](CC)[C@@](C)(O)[C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@]2(C)O)O[C@H](C)C[C@@H]1N(C)C, CCOC(=O)CCC(=O)O[C@H]1[C@H](O[C@@H]2[C@@H](C)[C@H](O[C@H]3C[C@@](C)(OC)[C@@H](O)[C@H](C)O3)[C@@H](C)C(=O)O[C@H](CC)[C@@](C)(O)[C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@]2(C)O)O[C@H](C)C[C@@H]1N(C)C, CCOC(=O)CCC(=O)O[C@H]1[C@H](O[C@@H]2[C@@H](C)[C@H](O[C@H]3C[C@@](C)(OC)[C@@H](O)[C@H](C)O3)[C@@H](C)C(=O)O[C@H](CC)[C@@](C)(O)[C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@]2(C)O)O[C@H](C)C[C@@H]1N(C)C, CCOC(=O)CCC(=O)O[C@H]1[C@H](O[C@@H]2[C@@H](C)[C@H](O[C@H]3C[C@@](C)(OC)[C@@H](O)[C@H](C)O3)[C@@H](C)C(=O)O[C@H](CC)[C@@](C)(O)[C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@]2(C)O)O[C@H](C)C[C@@H]1N(C)C	NSYZCCDSJNWWJL-ZBFNRKITSA-N, NSYZCCDSJNWWJL-ZBFNRKITSA-N, NSYZCCDSJNWWJL-ZBFNRKITSA-N, NSYZCCDSJNWWJL-ZBFNRKITSA-N	Launched
erythrosine	coloring agent				Oc1c(I)cc2c(Oc3c(I)c(O)c(I)cc3C22OC(=O)c3ccccc23)c1I	OALHHIHQOFIMEF-UHFFFAOYSA-N	Preclinical
esaprazole					O=C(CN1CCNCC1)NC1CCCCC1, O=C(CN1CCNCC1)NC1CCCCC1	RTFADALJKSFJDZ-UHFFFAOYSA-N, RTFADALJKSFJDZ-UHFFFAOYSA-N	Phase 2
esaxerenone	mineralocorticoid receptor antagonist				Cc1c(cn(CCO)c1-c1ccccc1C(F)(F)F)C(=O)Nc1ccc(cc1)S(C)(=O)=O	NOSNHVJANRODGR-UHFFFAOYSA-N	Preclinical
escin	nitric oxide synthase stimulant		dermatology	varicose veins	CC=C(C)C(=O)O[C@H]1[C@H](OC(C)=O)[C@]2(CO)[C@H](O)C[C@]3(C)C(=CC[C@@H]4[C@@]5(C)CC[C@H](O[C@@H]6O[C@@H]([C@@H](O[C@@H]7O[C@H](CO)[C@@H](O)[C@H](O)[C@H]7O)[C@H](O)[C@H]6O[C@@H]6O[C@H](CO)[C@@H](O)[C@H](O)[C@H]6O)C(O)=O)[C@](C)(CO)[C@@H]5CC[C@@]34C)[C@@H]2CC1(C)C |c:21|	AXNVHPCVMSNXNP-FDGZCRRKSA-N	Launched
escitalopram	selective serotonin reuptake inhibitor (SSRI)	SLC6A4	neurology/psychiatry	depression, generalized anxiety disorder (GAD)	CN(C)CCC[C@]1(OCc2cc(ccc12)C#N)c1ccc(F)cc1, CN(C)CCC[C@]1(OCc2cc(ccc12)C#N)c1ccc(F)cc1, CN(C)CCC[C@]1(OCc2cc(ccc12)C#N)c1ccc(F)cc1, CN(C)CCC[C@]1(OCc2cc(ccc12)C#N)c1ccc(F)cc1, OC(=O)C(O)=O.CN(C)CCC[C@]1(OCc2cc(ccc12)C#N)c1ccc(F)cc1 |&1:12,r|	WSEQXVZVJXJVFP-FQEVSTJZSA-N, WSEQXVZVJXJVFP-FQEVSTJZSA-N, WSEQXVZVJXJVFP-FQEVSTJZSA-N, WSEQXVZVJXJVFP-FQEVSTJZSA-N, KTGRHKOEFSJQNS-BDQAORGHSA-N	Launched
esculin	antioxidant				OC[C@H]1O[C@@H](Oc2cc3ccc(=O)oc3cc2O)[C@H](O)[C@@H](O)[C@@H]1O	XHCADAYNFIFUHF-TVKJYDDYSA-N	Phase 1
eseroline-(-)	acetylcholinesterase inhibitor	OPRD1, OPRM1			CN1CC[C@]2(C)[C@H]1N(C)c1ccc(O)cc21	HKGWQUVGHPDEBZ-OLZOCXBDSA-N	Preclinical
ESI-09	EPAC inhibitor	RAPGEF3, RAPGEF4			CC(C)(C)c1cc(no1)C(=O)C(=N\Nc1cccc(Cl)c1)\C#N, CC(C)(C)c1cc(no1)C(=O)C(=N\Nc1cccc(Cl)c1)\C#N	DXEATJQGQHDURZ-DEDYPNTBSA-N, DXEATJQGQHDURZ-DEDYPNTBSA-N	Preclinical
eslicarbazepine-acetate	sodium channel blocker	SCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A	neurology/psychiatry	seizures	CC(=O)O[C@H]1Cc2ccccc2N(C(N)=O)c2ccccc12, CC(=O)O[C@H]1Cc2ccccc2N(C(N)=O)c2ccccc12	QIALRBLEEWJACW-INIZCTEOSA-N, QIALRBLEEWJACW-INIZCTEOSA-N	Launched
esmolol	adrenergic receptor antagonist	ADRB1	cardiology	ventricular tachycardia (VT), hypertension	COC(=O)CCc1ccc(OC[C@@H](O)CNC(C)C)cc1 |&1:12,r|, COC(=O)CCc1ccc(OC[C@@H](O)CNC(C)C)cc1 |&1:12,r|	AQNDDEOPVVGCPG-AWEZNQCLSA-N, AQNDDEOPVVGCPG-AWEZNQCLSA-N	Launched
esomeprazole	ATPase inhibitor	ATP4A	gastroenterology	gastroesophageal reflux disease (GERD), Zollinger-Ellison syndrome, peptic ulcer disease (PUD)	COc1ccc2nc([nH]c2c1)[S@@](=O)Cc1ncc(C)c(OC)c1C, COc1ccc2nc([nH]c2c1)[S@@](=O)Cc1ncc(C)c(OC)c1C, COc1ccc2nc([nH]c2c1)[S@@](=O)Cc1ncc(C)c(OC)c1C, COc1ccc2nc([nH]c2c1)[S@@](=O)Cc1ncc(C)c(OC)c1C	SUBDBMMJDZJVOS-DEOSSOPVSA-N, SUBDBMMJDZJVOS-DEOSSOPVSA-N, SUBDBMMJDZJVOS-DEOSSOPVSA-N, SUBDBMMJDZJVOS-DEOSSOPVSA-N	Launched
esonarimod	antirheumatic drug				CC(=O)SC[C@H](CC(=O)c1ccc(C)cc1)C(O)=O |&1:5,r|	YRSSFEUQNAXQMX-LBPRGKRZSA-N	Preclinical
estetrol	selective estrogen receptor modulator (SERM)	ESR1			C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1[C@@H](O)[C@@H](O)[C@@H]2O	AJIPIJNNOJSSQC-NYLIRDPKSA-N	Phase 3
estradiol	estrogen receptor agonist	ESR1, ESR2, GPER1, KCNMA1, NR1I2	endocrinology	contraceptive	C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@H]2O, C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@H]2O, C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@H]2O, C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@H]2O, C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@H]2O, C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@H]2O, C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@H]2O, C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@H]2O, C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@H]2O, C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@H]2O	VOXZDWNPVJITMN-ZBRFXRBCSA-N, VOXZDWNPVJITMN-ZBRFXRBCSA-N, VOXZDWNPVJITMN-ZBRFXRBCSA-N, VOXZDWNPVJITMN-ZBRFXRBCSA-N, VOXZDWNPVJITMN-ZBRFXRBCSA-N, VOXZDWNPVJITMN-ZBRFXRBCSA-N, VOXZDWNPVJITMN-ZBRFXRBCSA-N, VOXZDWNPVJITMN-ZBRFXRBCSA-N, VOXZDWNPVJITMN-ZBRFXRBCSA-N, VOXZDWNPVJITMN-ZBRFXRBCSA-N	Launched
estradiol-acetate	estrogen receptor agonist	ESR1	endocrinology, obstetrics/gynecology	menopause, vaginal atrophy	CC(=O)Oc1ccc2[C@H]3CC[C@]4(C)[C@@H](O)CC[C@H]4[C@@H]3CCc2c1	FHXBMXJMKMWVRG-SLHNCBLASA-N	Launched
estradiol-benzoate	contraceptive agent	ESR1			C[C@]12CC[C@H]3[C@@H](CCc4cc(OC(=O)c5ccccc5)ccc34)[C@@H]1CC[C@@H]2O	UYIFTLBWAOGQBI-BZDYCCQFSA-N	Preclinical
estradiol-cypionate	estrogen receptor agonist	ESR1	endocrinology	hypoestrogenism, menopause	C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@H]2OC(=O)CCC1CCCC1	UOACKFBJUYNSLK-XRKIENNPSA-N	Launched
estradiol-valerate	estrogen receptor agonist	ESR1	oncology, endocrinology, obstetrics/gynecology	prostate cancer, hypoestrogenism, menopause, vaginal atrophy	CCCCC(=O)O[C@H]1CC[C@H]2[C@@H]3CCc4cc(O)ccc4[C@H]3CC[C@]12C, CCCCC(=O)O[C@H]1CC[C@H]2[C@@H]3CCc4cc(O)ccc4[C@H]3CC[C@]12C, CCCCC(=O)O[C@H]1CC[C@H]2[C@@H]3CCc4cc(O)ccc4[C@H]3CC[C@]12C, CCCCC(=O)O[C@H]1CC[C@H]2[C@@H]3CCc4cc(O)ccc4[C@H]3CC[C@]12C, CCCCC(=O)O[C@H]1CC[C@H]2[C@@H]3CCc4cc(O)ccc4[C@H]3CC[C@]12C, CCCCC(=O)O[C@H]1CC[C@H]2[C@@H]3CCc4cc(O)ccc4[C@H]3CC[C@]12C, CCCCC(=O)O[C@H]1CC[C@H]2[C@@H]3CCc4cc(O)ccc4[C@H]3CC[C@]12C	RSEPBGGWRJCQGY-RBRWEJTLSA-N, RSEPBGGWRJCQGY-RBRWEJTLSA-N, RSEPBGGWRJCQGY-RBRWEJTLSA-N, RSEPBGGWRJCQGY-RBRWEJTLSA-N, RSEPBGGWRJCQGY-RBRWEJTLSA-N, RSEPBGGWRJCQGY-RBRWEJTLSA-N, RSEPBGGWRJCQGY-RBRWEJTLSA-N	Launched
estradiol-3-O-sulfamate	steryl sulfatase inhibitor				C[C@]12CC[C@H]3[C@@H](CCc4cc(OS(N)(=O)=O)ccc34)[C@@H]1CC[C@@H]2O	YXYXCSOJKUAPJI-ZBRFXRBCSA-N	Phase 2
estramustine	DNA alkylating agent	ESR1, ESR2, MAP1A, MAP2	oncology	prostate cancer			Launched
estramustine-phosphate	DNA synthesis inhibitor, microtubule inhibitor	ESR1, ESR2, MAP1A, MAP2	oncology	prostate cancer	C[C@]12CC[C@H]3[C@@H](CCc4cc(OC(=O)N(CCCl)CCCl)ccc34)[C@@H]1CC[C@@H]2OP(O)(O)=O, C[C@]12CC[C@H]3[C@@H](CCc4cc(OC(=O)N(CCCl)CCCl)ccc34)[C@@H]1CC[C@@H]2OP(O)(O)=O, C[C@]12CC[C@H]3[C@@H](CCc4cc(OC(=O)N(CCCl)CCCl)ccc34)[C@@H]1CC[C@@H]2OP(O)(O)=O	ADFOJJHRTBFFOF-RBRWEJTLSA-N, ADFOJJHRTBFFOF-RBRWEJTLSA-N, ADFOJJHRTBFFOF-RBRWEJTLSA-N	Launched
estriol	estrogen receptor agonist	ESR1, ESR2	endocrinology, obstetrics/gynecology, infectious disease	menopause, vaginal atrophy, urinary tract infections	C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1C[C@@H](O)[C@@H]2O, C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1C[C@@H](O)[C@@H]2O, C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1C[C@@H](O)[C@@H]2O, C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1C[C@@H](O)[C@@H]2O	PROQIPRRNZUXQM-ZXXIGWHRSA-N, PROQIPRRNZUXQM-ZXXIGWHRSA-N, PROQIPRRNZUXQM-ZXXIGWHRSA-N, PROQIPRRNZUXQM-ZXXIGWHRSA-N	Launched
estrone	estrogen receptor agonist, estrogenic hormone	ESR1, ESR2	endocrinology	menopause	C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CCC2=O, C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CCC2=O, C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CCC2=O, C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CCC2=O, C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CCC2=O, C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CCC2=O	DNXHEGUUPJUMQT-CBZIJGRNSA-N, DNXHEGUUPJUMQT-CBZIJGRNSA-N, DNXHEGUUPJUMQT-CBZIJGRNSA-N, DNXHEGUUPJUMQT-CBZIJGRNSA-N, DNXHEGUUPJUMQT-CBZIJGRNSA-N, DNXHEGUUPJUMQT-CBZIJGRNSA-N	Launched
estropipate	estrogen receptor agonist	ESR1, ESR2	orthopedics, endocrinology, obstetrics/gynecology	osteoporosis, menopause, vaginal atrophy, hypoestrogenism	C[C@]12CC[C@H]3[C@@H](CCc4cc(OS(O)(=O)=O)ccc34)[C@@H]1CCC2=O	JKKFKPJIXZFSSB-CBZIJGRNSA-N	Launched
etacrynic-acid	sodium/potassium/chloride transporter inhibitor	ATP1A1, SLC12A1	cardiology, gastroenterology, nephrology, rheumatology	hypertension, congestive heart failure, edema, hepatic cirrhosis, chronic renal failure, nephrotic syndrome	CCC(=C)C(=O)c1ccc(OCC(O)=O)c(Cl)c1Cl, CCC(=C)C(=O)c1ccc(OCC(O)=O)c(Cl)c1Cl, CCC(=C)C(=O)c1ccc(OCC(O)=O)c(Cl)c1Cl	AVOLMBLBETYQHX-UHFFFAOYSA-N, AVOLMBLBETYQHX-UHFFFAOYSA-N, AVOLMBLBETYQHX-UHFFFAOYSA-N	Launched
etafenone	calcium channel blocker				CCN(CC)CCOc1ccccc1C(=O)CCc1ccccc1, CCN(CC)CCOc1ccccc1C(=O)CCc1ccccc1, CCN(CC)CCOc1ccccc1C(=O)CCc1ccccc1, CCN(CC)CCOc1ccccc1C(=O)CCc1ccccc1, CCN(CC)CCOc1ccccc1C(=O)CCc1ccccc1, CCN(CC)CCOc1ccccc1C(=O)CCc1ccccc1	OEGDFSLNGABBKJ-UHFFFAOYSA-N, OEGDFSLNGABBKJ-UHFFFAOYSA-N, OEGDFSLNGABBKJ-UHFFFAOYSA-N, OEGDFSLNGABBKJ-UHFFFAOYSA-N, OEGDFSLNGABBKJ-UHFFFAOYSA-N, OEGDFSLNGABBKJ-UHFFFAOYSA-N	Launched
etamsylate	hemostatic agent		hematology	hemorrhage	Oc1ccc(O)c(c1)S(O)(=O)=O, Oc1ccc(O)c(c1)S(O)(=O)=O, Oc1ccc(O)c(c1)S(O)(=O)=O, Oc1ccc(O)c(c1)S(O)(=O)=O	IKQCSJBQLWJEPU-UHFFFAOYSA-N, IKQCSJBQLWJEPU-UHFFFAOYSA-N, IKQCSJBQLWJEPU-UHFFFAOYSA-N, IKQCSJBQLWJEPU-UHFFFAOYSA-N	Launched
etanidazole	bacterial cell wall synthesis inhibitor				OCCNC(=O)Cn1ccnc1[N+]([O-])=O, OCCNC(=O)Cn1ccnc1[N+]([O-])=O	WCDWBPCFGJXFJZ-UHFFFAOYSA-N, WCDWBPCFGJXFJZ-UHFFFAOYSA-N	Phase 3
etazolate	phosphodiesterase inhibitor	GABRB3, PDE4A			CCOC(=O)c1cnc2n(CC)ncc2c1NN=C(C)C, CCOC(=O)c1cnc2n(CC)ncc2c1NN=C(C)C, CCOC(=O)c1cnc2n(CC)ncc2c1NN=C(C)C	OPQRBXUBWHDHPQ-UHFFFAOYSA-N, OPQRBXUBWHDHPQ-UHFFFAOYSA-N, OPQRBXUBWHDHPQ-UHFFFAOYSA-N	Phase 2
ETC-159	beta catenin inhibitor, porcupine inhibitor	PORCN			Cn1c2ncn(CC(=O)Nc3ccc(nn3)-c3ccccc3)c2c(=O)n(C)c1=O	QTRXIFVSTWXRJJ-UHFFFAOYSA-N	Phase 1
ETC-206	MAPK-interacting kinase inhibitor				O=C(N1CCOCC1)c1ccc(cc1)-c1ccc2ncc(-c3ccc(cc3)C#N)n2c1	FWRFPHJSGLYXTD-UHFFFAOYSA-N	Phase 1
etebenecid	uricosuric blocker				CCN(CC)S(=O)(=O)c1ccc(cc1)C(O)=O	UACOQEQOBAQRDQ-UHFFFAOYSA-N	Preclinical
eterobarb	anticonvulsant				CCC1(C(=O)N(COC)C(=O)N(COC)C1=O)c1ccccc1, CCC1(C(=O)N(COC)C(=O)N(COC)C1=O)c1ccccc1	DACOQFZGGLCXMA-UHFFFAOYSA-N, DACOQFZGGLCXMA-UHFFFAOYSA-N	Phase 2
ethacizin	anticonvulsant		cardiology	ventricular tachycardia (VT), Wolff-Parkinson-White Syndrome (WPW)	CCOC(=O)Nc1ccc2Sc3ccccc3N(C(=O)CCN(CC)CC)c2c1, CCOC(=O)Nc1ccc2Sc3ccccc3N(C(=O)CCN(CC)CC)c2c1	PQXGNJKJMFUPPM-UHFFFAOYSA-N, PQXGNJKJMFUPPM-UHFFFAOYSA-N	Launched
ethacridine-lactate-monohydrate	DNA intercalating agent				CCOc1ccc2nc3cc(N)ccc3c(N)c2c1, CCOc1ccc2nc3cc(N)ccc3c(N)c2c1, CCOc1ccc2nc3cc(N)ccc3c(N)c2c1, CCOc1ccc2nc3cc(N)ccc3c(N)c2c1, CCOc1ccc2nc3cc(N)ccc3c(N)c2c1, CCOc1ccc2nc3cc(N)ccc3c(N)c2c1, CCOc1ccc2nc3cc(N)ccc3c(N)c2c1, CCOc1ccc2nc3cc(N)ccc3c(N)c2c1	CIKWKGFPFXJVGW-UHFFFAOYSA-N, CIKWKGFPFXJVGW-UHFFFAOYSA-N, CIKWKGFPFXJVGW-UHFFFAOYSA-N, CIKWKGFPFXJVGW-UHFFFAOYSA-N, CIKWKGFPFXJVGW-UHFFFAOYSA-N, CIKWKGFPFXJVGW-UHFFFAOYSA-N, CIKWKGFPFXJVGW-UHFFFAOYSA-N, CIKWKGFPFXJVGW-UHFFFAOYSA-N	Preclinical
ethambutol	bacterial cell wall synthesis inhibitor		infectious disease	tuberculosis	CC[C@@H](CO)NCCN[C@@H](CC)CO, CC[C@@H](CO)NCCN[C@@H](CC)CO, CC[C@@H](CO)NCCN[C@@H](CC)CO	AEUTYOVWOVBAKS-UWVGGRQHSA-N, AEUTYOVWOVBAKS-UWVGGRQHSA-N, AEUTYOVWOVBAKS-UWVGGRQHSA-N	Launched
ethamivan	respiratory stimulant				CCN(CC)C(=O)c1ccc(O)c(OC)c1, CCN(CC)C(=O)c1ccc(O)c(OC)c1	BQJODPIMMWWMFC-UHFFFAOYSA-N, BQJODPIMMWWMFC-UHFFFAOYSA-N	Preclinical
ethanolamine-oleate	immunostimulant	F12, FABP4, FFAR1, FFAR4, PLD2	gastroenterology	esophageal varices	NCCO.CCCCCCCC\C=C/CCCCCCCC(O)=O	KGWDUNBJIMUFAP-KVVVOXFISA-N	Launched
ethaverine	calcium channel blocker		neurology/psychiatry	muscle relaxant, spasms	CCOc1ccc(Cc2nccc3cc(OCC)c(OCC)cc23)cc1OCC, CCOc1ccc(Cc2nccc3cc(OCC)c(OCC)cc23)cc1OCC	ZOWYFYXTIWQBEP-UHFFFAOYSA-N, ZOWYFYXTIWQBEP-UHFFFAOYSA-N	Launched
ethenzamide	analgesic agent		neurology/psychiatry, endocrinology, otolaryngology	headache, fever, common cold	CCOc1ccccc1C(N)=O, CCOc1ccccc1C(N)=O, CCOc1ccccc1C(N)=O	SBNKFTQSBPKMBZ-UHFFFAOYSA-N, SBNKFTQSBPKMBZ-UHFFFAOYSA-N, SBNKFTQSBPKMBZ-UHFFFAOYSA-N	Launched
ethimizol					CCn1cnc(C(=O)NC)c1C(=O)NC, CCn1cnc(C(=O)NC)c1C(=O)NC	RYRFAMRQBZNEPX-UHFFFAOYSA-N, RYRFAMRQBZNEPX-UHFFFAOYSA-N	Phase 1
ethinyl-estradiol	estrogen receptor agonist, estrogenic hormone	ESR1, ESR2, NR1I2	endocrinology	contraceptive	C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@]2(O)C#C, C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@]2(O)C#C, C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@]2(O)C#C, C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@]2(O)C#C, C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@]2(O)C#C, C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@]2(O)C#C	BFPYWIDHMRZLRN-SLHNCBLASA-N, BFPYWIDHMRZLRN-SLHNCBLASA-N, BFPYWIDHMRZLRN-SLHNCBLASA-N, BFPYWIDHMRZLRN-SLHNCBLASA-N, BFPYWIDHMRZLRN-SLHNCBLASA-N, BFPYWIDHMRZLRN-SLHNCBLASA-N	Launched
ethionamide	mycolic synthesis inhibitor		infectious disease	tuberculosis	CCc1cc(ccn1)C(N)=S, CCc1cc(ccn1)C(N)=S, CCc1cc(ccn1)C(N)=S	AEOCXXJPGCBFJA-UHFFFAOYSA-N, AEOCXXJPGCBFJA-UHFFFAOYSA-N, AEOCXXJPGCBFJA-UHFFFAOYSA-N	Launched
ethisterone	progestogen hormone	TYR	endocrinology	amenorrhea	C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@@]2(O)C#C |t:8|, C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@@]2(O)C#C |t:8|, C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@@]2(O)C#C |t:8|	CHNXZKVNWQUJIB-CEGNMAFCSA-N, CHNXZKVNWQUJIB-CEGNMAFCSA-N, CHNXZKVNWQUJIB-CEGNMAFCSA-N	Launched
ethopabate	antiprotozoal agent		infectious disease	coccidiosis	CCOc1cc(NC(C)=O)ccc1C(=O)OC, CCOc1cc(NC(C)=O)ccc1C(=O)OC, CCOc1cc(NC(C)=O)ccc1C(=O)OC	GOVWOKSKFSBNGD-UHFFFAOYSA-N, GOVWOKSKFSBNGD-UHFFFAOYSA-N, GOVWOKSKFSBNGD-UHFFFAOYSA-N	Launched
ethosuximide	succinimide antiepileptic	CACNA1G, CACNA1H, CACNA1I	neurology/psychiatry	epilepsy	CC[C@@]1(C)CC(=O)NC1=O |&1:2,r|, CC[C@@]1(C)CC(=O)NC1=O |&1:2,r|	HAPOVYFOVVWLRS-ZETCQYMHSA-N, HAPOVYFOVVWLRS-ZETCQYMHSA-N	Launched
ethotoin	hydantoin antiepileptic	SCN5A	neurology/psychiatry	seizures	CCN1C(=O)N[C@@H](C1=O)c1ccccc1 |r|, CCN1C(=O)N[C@@H](C1=O)c1ccccc1 |r|, CCN1C(=O)N[C@@H](C1=O)c1ccccc1 |r|	SZQIFWWUIBRPBZ-SECBINFHSA-N, SZQIFWWUIBRPBZ-SECBINFHSA-N, SZQIFWWUIBRPBZ-SECBINFHSA-N	Launched
ethoxyquin	antioxidant				CCOc1ccc2NC(C)(C)C=C(C)c2c1 |t:11|, CCOc1ccc2NC(C)(C)C=C(C)c2c1 |t:11|	DECIPOUIJURFOJ-UHFFFAOYSA-N, DECIPOUIJURFOJ-UHFFFAOYSA-N	Preclinical
ethoxzolamide	carbonic anhydrase inhibitor	CA1, CA12, CA13, CA14, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9	ophthalmology, gastroenterology	glaucoma, duodenal ulcer disease	CCOc1ccc2nc(sc2c1)S(N)(=O)=O, CCOc1ccc2nc(sc2c1)S(N)(=O)=O, CCOc1ccc2nc(sc2c1)S(N)(=O)=O	OUZWUKMCLIBBOG-UHFFFAOYSA-N, OUZWUKMCLIBBOG-UHFFFAOYSA-N, OUZWUKMCLIBBOG-UHFFFAOYSA-N	Launched
ethyl-paraben					CCOC(=O)c1ccc(O)cc1, CCOC(=O)c1ccc(O)cc1	NUVBSKCKDOMJSU-UHFFFAOYSA-N, NUVBSKCKDOMJSU-UHFFFAOYSA-N	Preclinical
ethyl-pyruvate	tumor necrosis factor production inhibitor				CCOC(=O)C(O)=C, CCOC(=O)C(O)=C	PSYUBHDPOIZRST-UHFFFAOYSA-N, PSYUBHDPOIZRST-UHFFFAOYSA-N	Phase 2
ethyl-vanillin					CCOc1cc(C=O)ccc1O, CCOc1cc(C=O)ccc1O	CBOQJANXLMLOSS-UHFFFAOYSA-N, CBOQJANXLMLOSS-UHFFFAOYSA-N	Preclinical
ethyl-2-(carbamoyloxy)benzoate					CCOC(=O)c1ccccc1OC(N)=O	JFMIIMPCFQKAAD-UHFFFAOYSA-N	Phase 1
ethylenediaminetetraacetic-acid	PKC inhibitor		neurology/psychiatry	metal toxicity	OC(=O)CN(CCN(CC(O)=O)CC(O)=O)CC(O)=O, OC(=O)CN(CCN(CC(O)=O)CC(O)=O)CC(O)=O	KCXVZYZYPLLWCC-UHFFFAOYSA-N, KCXVZYZYPLLWCC-UHFFFAOYSA-N	Launched
ethylnorepinephrine	bronchodilator				CC[C@@H](N)[C@@H](O)c1ccc(O)c(O)c1 |&1:2,&2:4|	LENNRXOJHWNHSD-XCBNKYQSSA-N	Preclinical
ethynodiol-diacetate		ESR1, PGR	endocrinology	contraceptive	CC(=O)O[C@H]1CC[C@@H]2[C@H]3CC[C@@]4(C)[C@@H](CC[C@@]4(OC(C)=O)C#C)[C@@H]3CCC2=C1 |c:29|, CC(=O)O[C@H]1CC[C@@H]2[C@H]3CC[C@@]4(C)[C@@H](CC[C@@]4(OC(C)=O)C#C)[C@@H]3CCC2=C1 |c:29|, CC(=O)O[C@H]1CC[C@@H]2[C@H]3CC[C@@]4(C)[C@@H](CC[C@@]4(OC(C)=O)C#C)[C@@H]3CCC2=C1 |c:29|, CC(=O)O[C@H]1CC[C@@H]2[C@H]3CC[C@@]4(C)[C@@H](CC[C@@]4(OC(C)=O)C#C)[C@@H]3CCC2=C1 |c:29|, CC(=O)O[C@H]1CC[C@@H]2[C@H]3CC[C@@]4(C)[C@@H](CC[C@@]4(OC(C)=O)C#C)[C@@H]3CCC2=C1 |c:29|	ONKUMRGIYFNPJW-KIEAKMPYSA-N, ONKUMRGIYFNPJW-KIEAKMPYSA-N, ONKUMRGIYFNPJW-KIEAKMPYSA-N, ONKUMRGIYFNPJW-KIEAKMPYSA-N, ONKUMRGIYFNPJW-KIEAKMPYSA-N	Launched
ethynylcytidine	antimetabolite				Nc1ccn([C@@H]2O[C@H](CO)[C@](O)(C#C)[C@H]2O)c(=O)n1	JFIWEPHGRUDAJN-DYUFWOLASA-N	Preclinical
eticlopride	dopamine receptor antagonist	DRD2, DRD3, DRD4			CCN1CCC[C@H]1CNC(=O)c1c(O)c(CC)cc(Cl)c1OC, CCN1CCC[C@H]1CNC(=O)c1c(O)c(CC)cc(Cl)c1OC, CCN1CCC[C@H]1CNC(=O)c1c(O)c(CC)cc(Cl)c1OC	AADCDMQTJNYOSS-LBPRGKRZSA-N, AADCDMQTJNYOSS-LBPRGKRZSA-N, AADCDMQTJNYOSS-LBPRGKRZSA-N	Preclinical
etidronic-acid	bone resorption inhibitor	ATP6V1A, PTPRS	endocrinology, orthopedics	Paget's disease, heterotopic ossification	CC(O)(P(O)(O)=O)P(O)(O)=O, CC(O)(P(O)(O)=O)P(O)(O)=O, CC(O)(P(O)(O)=O)P(O)(O)=O, CC(O)(P(O)(O)=O)P(O)(O)=O, CC(O)(P(O)(O)=O)P(O)(O)=O	DBVJJBKOTRCVKF-UHFFFAOYSA-N, DBVJJBKOTRCVKF-UHFFFAOYSA-N, DBVJJBKOTRCVKF-UHFFFAOYSA-N, DBVJJBKOTRCVKF-UHFFFAOYSA-N, DBVJJBKOTRCVKF-UHFFFAOYSA-N	Launched
etifenin	renal function diagnostic agent				CCc1cccc(CC)c1NC(=O)CN(CC(O)=O)CC(O)=O, CCc1cccc(CC)c1NC(=O)CN(CC(O)=O)CC(O)=O	WNIDXAKKFOKNEF-UHFFFAOYSA-N, WNIDXAKKFOKNEF-UHFFFAOYSA-N	Preclinical
etifoxine	GABA receptor modulator	GABRA1, GABRA2, GABRA3, GABRA5	neurology/psychiatry	anxiety	CCNC1=Nc2ccc(Cl)cc2[C@@](C)(O1)c1ccccc1 |&1:12,r,t:3|	IBYCYJFUEJQSMK-KRWDZBQOSA-N	Launched
etilefrine	adrenergic receptor agonist	ADRA1A, ADRB1	neurology/psychiatry, otolaryngology, endocrinology, pulmonary	headache, nasal congestion, fever, cough suppressant, common cold	CCNCC(O)c1cccc(O)c1	SQVIAVUSQAWMKL-UHFFFAOYSA-N	Launched
etilevodopa	dopamine receptor agonist	DRD3			CCOC(=O)[C@@H](N)Cc1ccc(O)c(O)c1, CCOC(=O)[C@@H](N)Cc1ccc(O)c(O)c1, CCOC(=O)[C@@H](N)Cc1ccc(O)c(O)c1	NULMGOSOSZBEQL-QMMMGPOBSA-N, NULMGOSOSZBEQL-QMMMGPOBSA-N, NULMGOSOSZBEQL-QMMMGPOBSA-N	Phase 3
etizolam	benzodiazepine receptor agonist	GABRA1	neurology/psychiatry	insomnia, anxiety	CCc1cc2c(s1)-n1c(C)nnc1CN=C2c1ccccc1Cl |c:16|, CCc1cc2c(s1)-n1c(C)nnc1CN=C2c1ccccc1Cl |c:16|, CCc1cc2c(s1)-n1c(C)nnc1CN=C2c1ccccc1Cl |c:16|, CCc1cc2c(s1)-n1c(C)nnc1CN=C2c1ccccc1Cl |c:16|	VMZUTJCNQWMAGF-UHFFFAOYSA-N, VMZUTJCNQWMAGF-UHFFFAOYSA-N, VMZUTJCNQWMAGF-UHFFFAOYSA-N, VMZUTJCNQWMAGF-UHFFFAOYSA-N	Launched
etodolac	cyclooxygenase inhibitor	PTGS2	rheumatology	osteoarthritis, rheumatoid arthritis	CCc1cccc2c3CCO[C@@](CC)(CC(O)=O)c3[nH]c12 |&1:11,r|, CCc1cccc2c3CCO[C@@](CC)(CC(O)=O)c3[nH]c12 |&1:11,r|, CCc1cccc2c3CCO[C@@](CC)(CC(O)=O)c3[nH]c12 |&1:11,r|	NNYBQONXHNTVIJ-KRWDZBQOSA-N, NNYBQONXHNTVIJ-KRWDZBQOSA-N, NNYBQONXHNTVIJ-KRWDZBQOSA-N	Launched
etofenamate	cyclooxygenase inhibitor	PTGS1, PTGS2	neurology/psychiatry, rheumatology	muscle pain, joint pain	OCCOCCOC(=O)c1ccccc1Nc1cccc(c1)C(F)(F)F, OCCOCCOC(=O)c1ccccc1Nc1cccc(c1)C(F)(F)F	XILVEPYQJIOVNB-UHFFFAOYSA-N, XILVEPYQJIOVNB-UHFFFAOYSA-N	Launched
etofibrate	PPAR receptor agonist	PPARA	endocrinology	hypertriglyceridemia	CC(C)(Oc1ccc(Cl)cc1)C(=O)OCCOC(=O)c1cccnc1	XXRVYAFBUDSLJX-UHFFFAOYSA-N	Launched
etofylline	adenosine receptor antagonist	ADORA1	pulmonary	asthma, bronchitis	Cn1c2ncn(CCO)c2c(=O)n(C)c1=O, Cn1c2ncn(CCO)c2c(=O)n(C)c1=O, Cn1c2ncn(CCO)c2c(=O)n(C)c1=O, Cn1c2ncn(CCO)c2c(=O)n(C)c1=O, Cn1c2ncn(CCO)c2c(=O)n(C)c1=O	NWPRCRWQMGIBOT-UHFFFAOYSA-N, NWPRCRWQMGIBOT-UHFFFAOYSA-N, NWPRCRWQMGIBOT-UHFFFAOYSA-N, NWPRCRWQMGIBOT-UHFFFAOYSA-N, NWPRCRWQMGIBOT-UHFFFAOYSA-N	Launched
etofylline-clofibrate	platelet aggregation inhibitor	PPARA	endocrinology	hyperlipidemia	Cn1c2ncn(CCOC(=O)C(C)(C)Oc3ccc(Cl)cc3)c2c(=O)n(C)c1=O, Cn1c2ncn(CCOC(=O)C(C)(C)Oc3ccc(Cl)cc3)c2c(=O)n(C)c1=O, Cn1c2ncn(CCOC(=O)C(C)(C)Oc3ccc(Cl)cc3)c2c(=O)n(C)c1=O	KYAKGJDISSNVPZ-UHFFFAOYSA-N, KYAKGJDISSNVPZ-UHFFFAOYSA-N, KYAKGJDISSNVPZ-UHFFFAOYSA-N	Launched
etomidate	GABA receptor modulator	ADRA2B, GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ	neurology/psychiatry	general anaesthetic	CCOC(=O)c1cncn1[C@H](C)c1ccccc1, CCOC(=O)c1cncn1[C@H](C)c1ccccc1, CCOC(=O)c1cncn1[C@H](C)c1ccccc1	NPUKDXXFDDZOKR-LLVKDONJSA-N, NPUKDXXFDDZOKR-LLVKDONJSA-N, NPUKDXXFDDZOKR-LLVKDONJSA-N	Launched
etomoxir	carnitine palmitoyltransferase inhibitor	CPT1A			CCOC(=O)[C@@]1(CCCCCCOc2ccc(Cl)cc2)CO1, CCOC(=O)[C@@]1(CCCCCCOc2ccc(Cl)cc2)CO1	DZLOHEOHWICNIL-QGZVFWFLSA-N, DZLOHEOHWICNIL-QGZVFWFLSA-N	Phase 2
etonogestrel	progesterone receptor agonist	ESR1, PGR	endocrinology	contraceptive	[H][C@@]12CC[C@@](O)(C#C)[C@@]1(CC)CC(=C)[C@]1([H])[C@@]3([H])CCC(=O)C=C3CC[C@@]21[H] |c:23|	GCKFUYQCUCGESZ-BPIQYHPVSA-N	Launched
etoposide	topoisomerase inhibitor	TOP2A, TOP2B	oncology	non-small cell lung cancer (NSCLC)	COc1cc(cc(OC)c1O)[C@H]1[C@@H]2[C@H](COC2=O)[C@H](O[C@@H]2O[C@@H]3CO[C@@H](C)O[C@H]3[C@H](O)[C@H]2O)c2cc3OCOc3cc12, COc1cc(cc(OC)c1O)[C@H]1[C@@H]2[C@H](COC2=O)[C@H](O[C@@H]2O[C@@H]3CO[C@@H](C)O[C@H]3[C@H](O)[C@H]2O)c2cc3OCOc3cc12, COc1cc(cc(OC)c1O)[C@H]1[C@@H]2[C@H](COC2=O)[C@H](O[C@@H]2O[C@@H]3CO[C@@H](C)O[C@H]3[C@H](O)[C@H]2O)c2cc3OCOc3cc12, COc1cc(cc(OC)c1O)[C@H]1[C@@H]2[C@H](COC2=O)[C@H](O[C@@H]2O[C@@H]3CO[C@@H](C)O[C@H]3[C@H](O)[C@H]2O)c2cc3OCOc3cc12, COc1cc(cc(OC)c1O)[C@H]1[C@@H]2[C@H](COC2=O)[C@H](O[C@@H]2O[C@@H]3CO[C@@H](C)O[C@H]3[C@H](O)[C@H]2O)c2cc3OCOc3cc12, COc1cc(cc(OC)c1O)[C@H]1[C@@H]2[C@H](COC2=O)[C@H](O[C@@H]2O[C@@H]3CO[C@@H](C)O[C@H]3[C@H](O)[C@H]2O)c2cc3OCOc3cc12, COc1cc(cc(OC)c1O)[C@H]1[C@@H]2[C@H](COC2=O)[C@H](O[C@@H]2O[C@@H]3CO[C@@H](C)O[C@H]3[C@H](O)[C@H]2O)c2cc3OCOc3cc12	VJJPUSNTGOMMGY-MRVIYFEKSA-N, VJJPUSNTGOMMGY-MRVIYFEKSA-N, VJJPUSNTGOMMGY-MRVIYFEKSA-N, VJJPUSNTGOMMGY-MRVIYFEKSA-N, VJJPUSNTGOMMGY-MRVIYFEKSA-N, VJJPUSNTGOMMGY-MRVIYFEKSA-N, VJJPUSNTGOMMGY-MRVIYFEKSA-N	Launched
etoposide-phosphate	topoisomerase inhibitor	TOP2A	oncology	testicular carcinoma, small cell lung cancer	COc1cc(cc(OC)c1OP(O)(O)=O)[C@H]1[C@@H]2[C@H](COC2=O)[C@H](O[C@@H]2O[C@@H]3CO[C@@H](C)O[C@H]3[C@H](O)[C@H]2O)c2cc3OCOc3cc12, COc1cc(cc(OC)c1OP(O)(O)=O)[C@H]1[C@@H]2[C@H](COC2=O)[C@H](O[C@@H]2O[C@@H]3CO[C@@H](C)O[C@H]3[C@H](O)[C@H]2O)c2cc3OCOc3cc12, COc1cc(cc(OC)c1OP(O)(O)=O)[C@H]1[C@@H]2[C@H](COC2=O)[C@H](O[C@@H]2O[C@@H]3CO[C@@H](C)O[C@H]3[C@H](O)[C@H]2O)c2cc3OCOc3cc12	LIQODXNTTZAGID-OCBXBXKTSA-N, LIQODXNTTZAGID-OCBXBXKTSA-N, LIQODXNTTZAGID-OCBXBXKTSA-N	Launched
etoricoxib	cyclooxygenase inhibitor	PTGS2	rheumatology	rheumatoid arthritis, psoriatic arthritis, osteoarthritis, gout, ankylosing spondylitis	Cc1ccc(cn1)-c1ncc(Cl)cc1-c1ccc(cc1)S(C)(=O)=O, Cc1ccc(cn1)-c1ncc(Cl)cc1-c1ccc(cc1)S(C)(=O)=O	MNJVRJDLRVPLFE-UHFFFAOYSA-N, MNJVRJDLRVPLFE-UHFFFAOYSA-N	Launched
etosalamide	anti-inflammatory agent				CCOCCOc1ccccc1C(N)=O, CCOCCOc1ccccc1C(N)=O	XBNRCMFFZFCWMH-UHFFFAOYSA-N, XBNRCMFFZFCWMH-UHFFFAOYSA-N	Preclinical
etoxybamide					OCCCC(=O)NCCO	MFHPPMMWHSHDSI-UHFFFAOYSA-N	Phase 2
ETP-45658	PI3K inhibitor	PIK3CA, PIK3CB, PIK3CD, PIK3CG			Cn1ncc2c(nc(nc12)-c1cccc(O)c1)N1CCOCC1, Cn1ncc2c(nc(nc12)-c1cccc(O)c1)N1CCOCC1, Cn1ncc2c(nc(nc12)-c1cccc(O)c1)N1CCOCC1	BJVRNXSHJLDZJR-UHFFFAOYSA-N, BJVRNXSHJLDZJR-UHFFFAOYSA-N, BJVRNXSHJLDZJR-UHFFFAOYSA-N	Preclinical
ETP-46464	ATR kinase inhibitor				CC(C)(C#N)c1ccc(cc1)N1C(=O)OCc2cnc3ccc(cc3c12)-c1cnc2ccccc2c1, CC(C)(C#N)c1ccc(cc1)N1C(=O)OCc2cnc3ccc(cc3c12)-c1cnc2ccccc2c1, CC(C)(C#N)c1ccc(cc1)N1C(=O)OCc2cnc3ccc(cc3c12)-c1cnc2ccccc2c1, CC(C)(C#N)c1ccc(cc1)N1C(=O)OCc2cnc3ccc(cc3c12)-c1cnc2ccccc2c1, CC(C)(C#N)c1ccc(cc1)N1C(=O)OCc2cnc3ccc(cc3c12)-c1cnc2ccccc2c1, CC(C)(C#N)c1ccc(cc1)N1C(=O)OCc2cnc3ccc(cc3c12)-c1cnc2ccccc2c1, CC(C)(C#N)c1ccc(cc1)N1C(=O)OCc2cnc3ccc(cc3c12)-c1cnc2ccccc2c1, CC(C)(C#N)c1ccc(cc1)N1C(=O)OCc2cnc3ccc(cc3c12)-c1cnc2ccccc2c1, CC(C)(C#N)c1ccc(cc1)N1C(=O)OCc2cnc3ccc(cc3c12)-c1cnc2ccccc2c1, CC(C)(C#N)c1ccc(cc1)N1C(=O)OCc2cnc3ccc(cc3c12)-c1cnc2ccccc2c1, CC(C)(C#N)c1ccc(cc1)N1C(=O)OCc2cnc3ccc(cc3c12)-c1cnc2ccccc2c1	DPLMXAYKJZOTKO-UHFFFAOYSA-N, DPLMXAYKJZOTKO-UHFFFAOYSA-N, DPLMXAYKJZOTKO-UHFFFAOYSA-N, DPLMXAYKJZOTKO-UHFFFAOYSA-N, DPLMXAYKJZOTKO-UHFFFAOYSA-N, DPLMXAYKJZOTKO-UHFFFAOYSA-N, DPLMXAYKJZOTKO-UHFFFAOYSA-N, DPLMXAYKJZOTKO-UHFFFAOYSA-N, InChI=1S/C30H22N4O2/c1-30(2,18-31)23-8-10-24(11-9-23)34-28-22(17-36-29(34)35)16-33-27-12-7-19(14-25(27)28)21-13-20-5-3-4-6-26(20)32-15-21/h3-16H,17H2,1-2H3, InChI=1S/C30H22N4O2/c1-30(2,18-31)23-8-10-24(11-9-23)34-28-22(17-36-29(34)35)16-33-27-12-7-19(14-25(27)28)21-13-20-5-3-4-6-26(20)32-15-21/h3-16H,17H2,1-2H3, InChI=1S/C30H22N4O2/c1-30(2,18-31)23-8-10-24(11-9-23)34-28-22(17-36-29(34)35)16-33-27-12-7-19(14-25(27)28)21-13-20-5-3-4-6-26(20)32-15-21/h3-16H,17H2,1-2H3	Preclinical
etrabamine	dopamine receptor agonist				CN[C@H]1CCc2ncsc2C1 |&1:2,r|	YDSVAKPJAOSZJA-LURJTMIESA-N	Phase 2
etrasimod	sphingosine 1-phosphate receptor antagonist				OC(=O)C[C@H]1CCc2c1[nH]c1ccc(OCc3ccc(C4CCCC4)c(c3)C(F)(F)F)cc21	MVGWUTBTXDYMND-QGZVFWFLSA-N	Phase 3
etravirine	non-nucleoside reverse transcriptase inhibitor	CYP2C19, CYP2C9, CYP3A4	infectious disease	human immunodeficiency virus (HIV-1)	Cc1cc(cc(C)c1Oc1nc(Nc2ccc(cc2)C#N)nc(N)c1Br)C#N, Cc1cc(cc(C)c1Oc1nc(Nc2ccc(cc2)C#N)nc(N)c1Br)C#N, Cc1cc(cc(C)c1Oc1nc(Nc2ccc(cc2)C#N)nc(N)c1Br)C#N, Cc1cc(cc(C)c1Oc1nc(Nc2ccc(cc2)C#N)nc(N)c1Br)C#N	PYGWGZALEOIKDF-UHFFFAOYSA-N, PYGWGZALEOIKDF-UHFFFAOYSA-N, PYGWGZALEOIKDF-UHFFFAOYSA-N, PYGWGZALEOIKDF-UHFFFAOYSA-N	Launched
etretinate	protein synthesis inhibitor	RARA, RXRG			CCOC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\c1c(C)cc(OC)c(C)c1C, CCOC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\c1c(C)cc(OC)c(C)c1C, CCOC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\c1c(C)cc(OC)c(C)c1C, CCOC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\c1c(C)cc(OC)c(C)c1C	HQMNCQVAMBCHCO-DJRRULDNSA-N, HQMNCQVAMBCHCO-DJRRULDNSA-N, HQMNCQVAMBCHCO-DJRRULDNSA-N, HQMNCQVAMBCHCO-DJRRULDNSA-N	Withdrawn
eucalyptol	acetylcholinesterase inhibitor	ACHE	dental	gingivitis	CC12CCC(CC1)C(C)(C)O2, CC12CCC(CC1)C(C)(C)O2	WEEGYLXZBRQIMU-UHFFFAOYSA-N, WEEGYLXZBRQIMU-UHFFFAOYSA-N	Launched
eucatropine	acetylcholine receptor antagonist				C[C@H]1C[C@@H](CC(C)(C)N1C)OC(=O)[C@@H](O)c1ccccc1 |&1:1,&2:3,&3:13|, C[C@H]1C[C@@H](CC(C)(C)N1C)OC(=O)[C@@H](O)c1ccccc1 |&1:1,&2:3,&3:13|	QSAVEGSLJISCDF-QEJZJMRPSA-N, QSAVEGSLJISCDF-QEJZJMRPSA-N	Preclinical
eugenol	androgen receptor antagonist	AR	dental	toothache	COc1cc(CC=C)ccc1O, COc1cc(CC=C)ccc1O	RRAFCDWBNXTKKO-UHFFFAOYSA-N, RRAFCDWBNXTKKO-UHFFFAOYSA-N	Launched
EUK-134	catalase stimulant	APP, SOD2			COc1cccc2C=[N+]3CC[N+]4=Cc5cccc(OC)c5O[Mn]34(Cl)Oc12 |t:7,11|, COc1cccc2C=[N+]3CC[N+]4=Cc5cccc(OC)c5O[Mn]34(Cl)Oc12 |t:7,11|, COc1cccc2C=[N+]3CC[N+]4=Cc5cccc(OC)c5O[Mn]34(Cl)Oc12 |t:7,11|, COc1cccc2C=[N+]3CC[N+]4=Cc5cccc(OC)c5O[Mn]34(Cl)Oc12 |t:7,11|	QCAWBJDECIOVBU-GAMUHHASSA-K, QCAWBJDECIOVBU-GAMUHHASSA-K, QCAWBJDECIOVBU-GAMUHHASSA-K, QCAWBJDECIOVBU-GAMUHHASSA-K	Preclinical
eupatilin	mucus protecting agent				COc1ccc(cc1OC)-c1cc(=O)c2c(O)c(OC)c(O)cc2o1, COc1ccc(cc1OC)-c1cc(=O)c2c(O)c(OC)c(O)cc2o1, COc1ccc(cc1OC)-c1cc(=O)c2c(O)c(OC)c(O)cc2o1	DRRWBCNQOKKKOL-UHFFFAOYSA-N, DRRWBCNQOKKKOL-UHFFFAOYSA-N, DRRWBCNQOKKKOL-UHFFFAOYSA-N	Launched
evacetrapib	cholesteryl ester transfer protein inhibitor	CETP			Cc1cc(C)c2N(C[C@H]3CC[C@@H](CC3)C(O)=O)CCC[C@H](N(Cc3cc(cc(c3)C(F)(F)F)C(F)(F)F)c3nnn(C)n3)c2c1, Cc1cc(C)c2N(C[C@H]3CC[C@@H](CC3)C(O)=O)CCC[C@H](N(Cc3cc(cc(c3)C(F)(F)F)C(F)(F)F)c3nnn(C)n3)c2c1, Cc1cc(C)c2N(C[C@H]3CC[C@@H](CC3)C(O)=O)CCC[C@H](N(Cc3cc(cc(c3)C(F)(F)F)C(F)(F)F)c3nnn(C)n3)c2c1, Cc1cc(C)c2N(C[C@H]3CC[C@@H](CC3)C(O)=O)CCC[C@H](N(Cc3cc(cc(c3)C(F)(F)F)C(F)(F)F)c3nnn(C)n3)c2c1	IHIUGIVXARLYHP-YBXDKENTSA-N, IHIUGIVXARLYHP-YBXDKENTSA-N, IHIUGIVXARLYHP-YBXDKENTSA-N, IHIUGIVXARLYHP-YBXDKENTSA-N	Phase 3
evans-blue	glutamate receptor negative allosteric modulator	GRIA1, PTPN1			Cc1cc(ccc1NN=C1C=Cc2c(cc(c(N)c2C1=O)S(O)(=O)=O)S(O)(=O)=O)-c1ccc(NN=C2C=Cc3c(cc(c(N)c3C2=O)S(O)(=O)=O)S(O)(=O)=O)c(C)c1 |c:11,39|, Cc1cc(ccc1NN=C1C=Cc2c(cc(c(N)c2C1=O)S(O)(=O)=O)S(O)(=O)=O)-c1ccc(NN=C2C=Cc3c(cc(c(N)c3C2=O)S(O)(=O)=O)S(O)(=O)=O)c(C)c1 |c:11,39|, Cc1cc(ccc1NN=C1C=Cc2c(cc(c(N)c2C1=O)S(O)(=O)=O)S(O)(=O)=O)-c1ccc(NN=C2C=Cc3c(cc(c(N)c3C2=O)S(O)(=O)=O)S(O)(=O)=O)c(C)c1 |c:11,39|, Cc1cc(ccc1NN=C1C=Cc2c(cc(c(N)c2C1=O)S(O)(=O)=O)S(O)(=O)=O)-c1ccc(NN=C2C=Cc3c(cc(c(N)c3C2=O)S(O)(=O)=O)S(O)(=O)=O)c(C)c1 |c:11,39|, Cc1cc(ccc1NN=C1C=Cc2c(cc(c(N)c2C1=O)S(O)(=O)=O)S(O)(=O)=O)-c1ccc(NN=C2C=Cc3c(cc(c(N)c3C2=O)S(O)(=O)=O)S(O)(=O)=O)c(C)c1 |c:11,39|	LIRUWPZKVZZTHC-UHFFFAOYSA-N, LIRUWPZKVZZTHC-UHFFFAOYSA-N, LIRUWPZKVZZTHC-UHFFFAOYSA-N, LIRUWPZKVZZTHC-UHFFFAOYSA-N, LIRUWPZKVZZTHC-UHFFFAOYSA-N	Launched
evatanepag	prostaglandin inhibitor	PTGER2, PTGER4			CC(C)(C)c1ccc(CN(Cc2cccc(OCC(O)=O)c2)S(=O)(=O)c2cccnc2)cc1, CC(C)(C)c1ccc(CN(Cc2cccc(OCC(O)=O)c2)S(=O)(=O)c2cccnc2)cc1	WOHRHWDYFNWPNG-UHFFFAOYSA-N, WOHRHWDYFNWPNG-UHFFFAOYSA-N	Phase 2
evenamide	voltage-gated sodium channel blocker				CCCCOc1cccc(CCNCC(=O)N(C)C)c1	GRHBODILPPXVKN-UHFFFAOYSA-N	Phase 2
everolimus	mTOR inhibitor	MTOR	oncology, neurology/psychiatry, genetics, urology	breast cancer, neuroendocrine tumors of pancreatic origin (PNET), renal cell carcinoma (RCC), subependymal giant cell astrocytoma (SEGA), tuberous sclerosis complex (TSC), renal angiomyolipoma	CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1OCCO |c:14,33,t:29,31|, CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1OCCO |c:14,33,t:29,31|, CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1OCCO |c:14,33,t:29,31|, CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1OCCO |c:14,33,t:29,31|, CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1OCCO |c:14,33,t:29,31|, CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1OCCO |c:14,33,t:29,31|, CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1OCCO |c:14,33,t:29,31|, CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1OCCO |c:14,33,t:29,31|, CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1OCCO |c:14,33,t:29,31|, CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1OCCO |c:14,33,t:29,31|	HKVAMNSJSFKALM-FLOWVUKKSA-N, HKVAMNSJSFKALM-FLOWVUKKSA-N, HKVAMNSJSFKALM-FLOWVUKKSA-N, HKVAMNSJSFKALM-FLOWVUKKSA-N, HKVAMNSJSFKALM-FLOWVUKKSA-N, HKVAMNSJSFKALM-FLOWVUKKSA-N, HKVAMNSJSFKALM-FLOWVUKKSA-N, HKVAMNSJSFKALM-FLOWVUKKSA-N, HKVAMNSJSFKALM-FLOWVUKKSA-N, HKVAMNSJSFKALM-FLOWVUKKSA-N	Launched
evobrutinib	Bruton's tyrosine kinase (BTK) inhibitor				Nc1ncnc(NCC2CCN(CC2)C(=O)C=C)c1-c1ccc(Oc2ccccc2)cc1	QUIWHXQETADMGN-UHFFFAOYSA-N	Phase 2
evocalcet	calcium sensitizer				C[C@@H](N[C@H]1CCN(C1)c1ccc(CC(O)=O)cc1)c1cccc2ccccc12	RZNUIYPHQFXBAN-XLIONFOSSA-N	Phase 3
evodiamine	ATPase inhibitor, TRPV agonist	TRPV1			CN1[C@H]2N(CCc3c2[nH]c2ccccc32)C(=O)c2ccccc12 |&1:2,r|, CN1[C@H]2N(CCc3c2[nH]c2ccccc32)C(=O)c2ccccc12 |&1:2,r|, CN1[C@H]2N(CCc3c2[nH]c2ccccc32)C(=O)c2ccccc12 |&1:2,r|, CN1[C@H]2N(CCc3c2[nH]c2ccccc32)C(=O)c2ccccc12 |&1:2,r|	TXDUTHBFYKGSAH-SFHVURJKSA-N, TXDUTHBFYKGSAH-SFHVURJKSA-N, TXDUTHBFYKGSAH-SFHVURJKSA-N, TXDUTHBFYKGSAH-SFHVURJKSA-N	Preclinical
EVP-6124	acetylcholine receptor agonist	CHRNA7			Clc1cccc2cc(sc12)C(=O)N[C@H]1CN2CCC1CC2, Clc1cccc2cc(sc12)C(=O)N[C@H]1CN2CCC1CC2, Clc1cccc2cc(sc12)C(=O)N[C@H]1CN2CCC1CC2, Clc1cccc2cc(sc12)C(=O)N[C@H]1CN2CCC1CC2	SSRDSYXGYPJKRR-ZDUSSCGKSA-N, SSRDSYXGYPJKRR-ZDUSSCGKSA-N, SSRDSYXGYPJKRR-ZDUSSCGKSA-N, SSRDSYXGYPJKRR-ZDUSSCGKSA-N	Phase 3
EVP4593	NFkB pathway inhibitor				Nc1ccc2ncnc(NCCc3ccc(Oc4ccccc4)cc3)c2c1, Nc1ccc2ncnc(NCCc3ccc(Oc4ccccc4)cc3)c2c1, Nc1ccc2ncnc(NCCc3ccc(Oc4ccccc4)cc3)c2c1, Nc1ccc2ncnc(NCCc3ccc(Oc4ccccc4)cc3)c2c1	IBAKVEUZKHOWNG-UHFFFAOYSA-N, IBAKVEUZKHOWNG-UHFFFAOYSA-N, IBAKVEUZKHOWNG-UHFFFAOYSA-N, IBAKVEUZKHOWNG-UHFFFAOYSA-N	Preclinical
EW-7197	TGF beta receptor inhibitor	ACVR1B, TGFBR1			Cc1cccc(n1)-c1nc(CNc2ccccc2F)[nH]c1-c1ccc2ncnn2c1, Cc1cccc(n1)-c1nc(CNc2ccccc2F)[nH]c1-c1ccc2ncnn2c1, Cc1cccc(n1)-c1nc(CNc2ccccc2F)[nH]c1-c1ccc2ncnn2c1, Cc1cccc(n1)-c1nc(CNc2ccccc2F)[nH]c1-c1ccc2ncnn2c1, Cc1cccc(n1)-c1nc(CNc2ccccc2F)[nH]c1-c1ccc2ncnn2c1	FJCDSQATIJKQKA-UHFFFAOYSA-N, FJCDSQATIJKQKA-UHFFFAOYSA-N, FJCDSQATIJKQKA-UHFFFAOYSA-N, FJCDSQATIJKQKA-UHFFFAOYSA-N, FJCDSQATIJKQKA-UHFFFAOYSA-N	Phase 2
EX-527	SIRT inhibitor	SIRT1			NC(=O)[C@H]1CCCc2c1[nH]c1ccc(Cl)cc21 |&1:3,r|, NC(=O)[C@H]1CCCc2c1[nH]c1ccc(Cl)cc21 |&1:3,r|, NC(=O)[C@H]1CCCc2c1[nH]c1ccc(Cl)cc21 |&1:3,r|	FUZYTVDVLBBXDL-VIFPVBQESA-N, FUZYTVDVLBBXDL-VIFPVBQESA-N, FUZYTVDVLBBXDL-VIFPVBQESA-N	Phase 2
exalamide	membrane permeability inhibitor				CCCCCCOc1ccccc1C(N)=O, CCCCCCOc1ccccc1C(N)=O	CKSJXOVLXUMMFF-UHFFFAOYSA-N, CKSJXOVLXUMMFF-UHFFFAOYSA-N	Launched
examorelin	growth hormone releasing factor agonist	GHRHR, GHSR			C[C@H](NC(=O)[C@@H](Cc1c(C)[nH]c2ccccc12)NC(=O)[C@@H](N)Cc1cnc[nH]1)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@H](Cc1ccccc1)C(=O)N[C@@H](CCCCN)C(N)=O	RVWNMGKSNGWLOL-GIIHNPQRSA-N	Phase 2
exatecan-mesylate	topoisomerase inhibitor	TOP1			CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4cc(F)c(C)c5CC[C@H](N)c(c3Cn1c2=O)c45, CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4cc(F)c(C)c5CC[C@H](N)c(c3Cn1c2=O)c45, CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4cc(F)c(C)c5CC[C@H](N)c(c3Cn1c2=O)c45, CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4cc(F)c(C)c5CC[C@H](N)c(c3Cn1c2=O)c45	ZVYVPGLRVWUPMP-FYSMJZIKSA-N, ZVYVPGLRVWUPMP-FYSMJZIKSA-N, ZVYVPGLRVWUPMP-FYSMJZIKSA-N, ZVYVPGLRVWUPMP-FYSMJZIKSA-N	Phase 3
exemestane	aromatase inhibitor	CYP19A1	oncology	breast cancer	C[C@]12CC[C@H]3[C@@H](CC(=C)C4=CC(=O)C=C[C@]34C)[C@@H]1CCC2=O |c:13,t:9|, C[C@]12CC[C@H]3[C@@H](CC(=C)C4=CC(=O)C=C[C@]34C)[C@@H]1CCC2=O |c:13,t:9|, C[C@]12CC[C@H]3[C@@H](CC(=C)C4=CC(=O)C=C[C@]34C)[C@@H]1CCC2=O |c:13,t:9|, C[C@]12CC[C@H]3[C@@H](CC(=C)C4=CC(=O)C=C[C@]34C)[C@@H]1CCC2=O |c:13,t:9|	BFYIZQONLCFLEV-DAELLWKTSA-N, BFYIZQONLCFLEV-DAELLWKTSA-N, BFYIZQONLCFLEV-DAELLWKTSA-N, BFYIZQONLCFLEV-DAELLWKTSA-N	Launched
exenatide	GLP receptor agonist	GLP1R	endocrinology	diabetes mellitus	[H]N[C@@H](Cc1c[nH]cn1)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(N)=O |r|	HTQBXNHDCUEHJF-XWLPCZSASA-N	Launched
exherin	cadherin antagonist	CDH2			CC(C)[C@@H]1NC(=O)[C@H](C)NC(=O)[C@H](Cc2cnc[nH]2)NC(=O)[C@H](CSSC[C@H](NC1=O)C(N)=O)NC(C)=O, CC(C)[C@@H]1NC(=O)[C@H](C)NC(=O)[C@H](Cc2cnc[nH]2)NC(=O)[C@H](CSSC[C@H](NC1=O)C(N)=O)NC(C)=O, CC(C)[C@@H]1NC(=O)[C@H](C)NC(=O)[C@H](Cc2cnc[nH]2)NC(=O)[C@H](CSSC[C@H](NC1=O)C(N)=O)NC(C)=O, CC(C)[C@@H]1NC(=O)[C@H](C)NC(=O)[C@H](Cc2cnc[nH]2)NC(=O)[C@H](CSSC[C@H](NC1=O)C(N)=O)NC(C)=O, CC(C)[C@@H]1NC(=O)[C@H](C)NC(=O)[C@H](Cc2cnc[nH]2)NC(=O)[C@H](CSSC[C@H](NC1=O)C(N)=O)NC(C)=O	FQVLRGLGWNWPSS-XDKAFHOCSA-N, FQVLRGLGWNWPSS-XDKAFHOCSA-N, FQVLRGLGWNWPSS-XDKAFHOCSA-N, FQVLRGLGWNWPSS-XDKAFHOCSA-N, FQVLRGLGWNWPSS-XDKAFHOCSA-N	Phase 2
exifone	nootropic agent	TYR			Oc1ccc(C(=O)c2cc(O)c(O)c(O)c2)c(O)c1O, Oc1ccc(C(=O)c2cc(O)c(O)c(O)c2)c(O)c1O	XEDWWPGWIXPVRQ-UHFFFAOYSA-N, XEDWWPGWIXPVRQ-UHFFFAOYSA-N	Withdrawn
exisulind	phosphodiesterase inhibitor	PDE5A			CC1=C(CC(O)=O)c2cc(F)ccc2\C1=C/c1ccc(cc1)S(C)(=O)=O |c:1|, CC1=C(CC(O)=O)c2cc(F)ccc2\C1=C/c1ccc(cc1)S(C)(=O)=O |c:1|, CC1=C(CC(O)=O)c2cc(F)ccc2\C1=C/c1ccc(cc1)S(C)(=O)=O |c:1|	MVGSNCBCUWPVDA-MFOYZWKCSA-N, MVGSNCBCUWPVDA-MFOYZWKCSA-N, MVGSNCBCUWPVDA-MFOYZWKCSA-N	Phase 3
exo-IWR-1	WNT signaling inhibitor negative control	TNKS			O=C(Nc1cccc2cccnc12)c1ccc(cc1)N1C(=O)[C@H]2[C@H]3C[C@H](C=C3)[C@H]2C1=O |c:29|, O=C(Nc1cccc2cccnc12)c1ccc(cc1)N1C(=O)[C@H]2[C@H]3C[C@H](C=C3)[C@H]2C1=O |c:29|	ZGSXEXBYLJIOGF-BTYSMDAFSA-N, ZGSXEXBYLJIOGF-BTYSMDAFSA-N	Preclinical
EXO-1	ARF inhibitor				COC(=O)c1ccccc1NC(=O)c1ccc(F)cc1, COC(=O)c1ccccc1NC(=O)c1ccc(F)cc1, COC(=O)c1ccccc1NC(=O)c1ccc(F)cc1	KIAPWMKFHIKQOZ-UHFFFAOYSA-N, KIAPWMKFHIKQOZ-UHFFFAOYSA-N, KIAPWMKFHIKQOZ-UHFFFAOYSA-N	Preclinical
ezatiostat	glutathione transferase inhibitor	GSTP1			CCOC(=O)[C@@H](N)CCC(=O)N[C@@H](CSCc1ccccc1)C(=O)N[C@@H](C(=O)OCC)c1ccccc1, CCOC(=O)[C@@H](N)CCC(=O)N[C@@H](CSCc1ccccc1)C(=O)N[C@@H](C(=O)OCC)c1ccccc1, CCOC(=O)[C@@H](N)CCC(=O)N[C@@H](CSCc1ccccc1)C(=O)N[C@@H](C(=O)OCC)c1ccccc1, CCOC(=O)[C@@H](N)CCC(=O)N[C@@H](CSCc1ccccc1)C(=O)N[C@@H](C(=O)OCC)c1ccccc1	GWEJFLVSOGNLSS-WPFOTENUSA-N, GWEJFLVSOGNLSS-WPFOTENUSA-N, GWEJFLVSOGNLSS-WPFOTENUSA-N, GWEJFLVSOGNLSS-WPFOTENUSA-N	Phase 2
ezetimibe	cholesterol inhibitor, Niemann-Pick C1-like 1 protein antagonist	ANPEP, NPC1L1, SOAT1	endocrinology, metabolism	hyperlipidemia, hypercholesterolemia, sitosterolemia	O[C@@H](CC[C@@H]1[C@H](N(C1=O)c1ccc(F)cc1)c1ccc(O)cc1)c1ccc(F)cc1, O[C@@H](CC[C@@H]1[C@H](N(C1=O)c1ccc(F)cc1)c1ccc(O)cc1)c1ccc(F)cc1, O[C@@H](CC[C@@H]1[C@H](N(C1=O)c1ccc(F)cc1)c1ccc(O)cc1)c1ccc(F)cc1, O[C@@H](CC[C@@H]1[C@H](N(C1=O)c1ccc(F)cc1)c1ccc(O)cc1)c1ccc(F)cc1, O[C@@H](CC[C@@H]1[C@H](N(C1=O)c1ccc(F)cc1)c1ccc(O)cc1)c1ccc(F)cc1, O[C@@H](CC[C@@H]1[C@H](N(C1=O)c1ccc(F)cc1)c1ccc(O)cc1)c1ccc(F)cc1, O[C@@H](CC[C@@H]1[C@H](N(C1=O)c1ccc(F)cc1)c1ccc(O)cc1)c1ccc(F)cc1, O[C@@H](CC[C@@H]1[C@H](N(C1=O)c1ccc(F)cc1)c1ccc(O)cc1)c1ccc(F)cc1	OLNTVTPDXPETLC-XPWALMASSA-N, OLNTVTPDXPETLC-XPWALMASSA-N, OLNTVTPDXPETLC-XPWALMASSA-N, OLNTVTPDXPETLC-XPWALMASSA-N, OLNTVTPDXPETLC-XPWALMASSA-N, OLNTVTPDXPETLC-XPWALMASSA-N, OLNTVTPDXPETLC-XPWALMASSA-N, OLNTVTPDXPETLC-XPWALMASSA-N	Launched
ezutromid	utrophin enhancer	UTRN			CCN(CC)c1ccc(cc1)-n1nc2cc(C)c(N)cc2n1	WRIPKYOZKAJHRL-UHFFFAOYSA-N	Phase 2
E3330	NFkB pathway inhibitor				CCCCCCCCC\C(=C/C1=C(C)C(=O)C(OC)=C(OC)C1=O)C(O)=O |c:11,t:18|	AALSSIXXBDPENJ-FYWRMAATSA-N	Preclinical
E7046	prostanoid receptor antagonist				C[C@H](NC(=O)c1c(nn(C)c1Oc1cccc(c1)C(F)(F)F)C(F)F)c1ccc(cc1)C(O)=O	MKLKAQMPKHNQPR-NSHDSACASA-N	Phase 1
E7449	PARP inhibitor	PARP1, PARP2, TNKS, TNKS2			O=c1[nH][nH]c2nc(CN3Cc4ccccc4C3)nc3cccc1c23, O=c1[nH][nH]c2nc(CN3Cc4ccccc4C3)nc3cccc1c23, O=c1[nH][nH]c2nc(CN3Cc4ccccc4C3)nc3cccc1c23, O=c1[nH][nH]c2nc(CN3Cc4ccccc4C3)nc3cccc1c23	JLFSBHQQXIAQEC-UHFFFAOYSA-N, JLFSBHQQXIAQEC-UHFFFAOYSA-N, JLFSBHQQXIAQEC-UHFFFAOYSA-N, JLFSBHQQXIAQEC-UHFFFAOYSA-N	Phase 2
E7820	angiogenesis inhibitor				Cc1ccc(NS(=O)(=O)c2cccc(c2)C#N)c2[nH]cc(C#N)c12	LWGUASZLXHYWIV-UHFFFAOYSA-N	Phase 2
F-11440	serotonin receptor agonist	HTR1A			Cn1c(=O)cnn(CCCCN2CCN(CC2)c2ncccn2)c1=O, Cn1c(=O)cnn(CCCCN2CCN(CC2)c2ncccn2)c1=O	NMYAHEULKSYAPP-UHFFFAOYSA-N, NMYAHEULKSYAPP-UHFFFAOYSA-N	Phase 2
F-16915					CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(=O)OCc1cccnc1	BUWVEXMRBAWBPJ-KUBAVDMBSA-N	Preclinical
fadrozole	aromatase inhibitor	CYP11B1, CYP19A1	oncology	breast cancer	N#Cc1ccc(cc1)[C@H]1CCCc2cncn12 |&1:8|, N#Cc1ccc(cc1)[C@H]1CCCc2cncn12 |&1:8|	CLPFFLWZZBQMAO-CQSZACIVSA-N, CLPFFLWZZBQMAO-CQSZACIVSA-N	Launched
fagomine	glucosidase inhibitor	GLB1			OC[C@H]1NCC[C@@H](O)[C@@H]1O	YZNNBIPIQWYLDM-HSUXUTPPSA-N	Phase 2
falecalcitriol	vitamin D receptor agonist	VDR	endocrinology	hyperparathyroidism	C[C@H](CCCC(O)(C(F)(F)F)C(F)(F)F)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C, C[C@H](CCCC(O)(C(F)(F)F)C(F)(F)F)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C, C[C@H](CCCC(O)(C(F)(F)F)C(F)(F)F)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C, C[C@H](CCCC(O)(C(F)(F)F)C(F)(F)F)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C, C[C@H](CCCC(O)(C(F)(F)F)C(F)(F)F)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C, C[C@H](CCCC(O)(C(F)(F)F)C(F)(F)F)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C	XPYGGHVSFMUHLH-UUSULHAXSA-N, XPYGGHVSFMUHLH-UUSULHAXSA-N, XPYGGHVSFMUHLH-UUSULHAXSA-N, XPYGGHVSFMUHLH-UUSULHAXSA-N, XPYGGHVSFMUHLH-UUSULHAXSA-N, XPYGGHVSFMUHLH-UUSULHAXSA-N	Launched
famciclovir	DNA polymerase inhibitor		dental, infectious disease	cold sore, genitial herpes, shingles	CC(=O)OCC(CCn1cnc2cnc(N)nc12)COC(C)=O, CC(=O)OCC(CCn1cnc2cnc(N)nc12)COC(C)=O, CC(=O)OCC(CCn1cnc2cnc(N)nc12)COC(C)=O	GGXKWVWZWMLJEH-UHFFFAOYSA-N, GGXKWVWZWMLJEH-UHFFFAOYSA-N, GGXKWVWZWMLJEH-UHFFFAOYSA-N	Launched
famotidine	histamine receptor antagonist	HRH2	gastroenterology	heartburn	NC(=N)Nc1nc(CSCC\C(N)=N/S(N)(=O)=O)cs1, NC(=N)Nc1nc(CSCC\C(N)=N/S(N)(=O)=O)cs1	XUFQPHANEAPEMJ-UHFFFAOYSA-N, XUFQPHANEAPEMJ-UHFFFAOYSA-N	Launched
famprofazone	cyclooxygenase inhibitor				CC(C)c1c(CN(C)[C@@H](C)Cc2ccccc2)n(C)n(-c2ccccc2)c1=O |&1:8,r|, CC(C)c1c(CN(C)[C@@H](C)Cc2ccccc2)n(C)n(-c2ccccc2)c1=O |&1:8,r|, CC(C)c1c(CN(C)[C@@H](C)Cc2ccccc2)n(C)n(-c2ccccc2)c1=O |&1:8,r|	GNUXVOXXWGNPIV-IBGZPJMESA-N, GNUXVOXXWGNPIV-IBGZPJMESA-N, GNUXVOXXWGNPIV-IBGZPJMESA-N	Preclinical
fananserin	dopamine receptor antagonist, serotonin receptor antagonist	HTR2A			Fc1ccc(cc1)N1CCN(CCCN2c3cccc4cccc(c34)S2(=O)=O)CC1, Fc1ccc(cc1)N1CCN(CCCN2c3cccc4cccc(c34)S2(=O)=O)CC1	VGIGHGMPMUCLIQ-UHFFFAOYSA-N, VGIGHGMPMUCLIQ-UHFFFAOYSA-N	Phase 2
fanetizole	neutrophil superoxide production				C(Cc1ccccc1)Nc1nc(cs1)-c1ccccc1	WEEYMMXMBFJUAI-UHFFFAOYSA-N	Phase 3
fantofarone	calcium channel blocker				COc1ccc(CCN(C)CCCOc2ccc(cc2)S(=O)(=O)c2c(cn3ccccc23)C(C)C)cc1OC	ITAMRBIZWGDOHW-UHFFFAOYSA-N	Preclinical
farampator	ionotropic glutamate receptor agonist				O=C(N1CCCCC1)c1ccc2nonc2c1	XFVRBYKKGGDPAJ-UHFFFAOYSA-N	Preclinical
farnesyl-thiosalicylic-acid-amide	Ras GTPase inhibitor	HRAS			CC(C)=CCC\C(C)=C\CC\C(C)=C\CSc1ccccc1C(N)=O, CC(C)=CCC\C(C)=C\CC\C(C)=C\CSc1ccccc1C(N)=O, CC(C)=CCC\C(C)=C\CC\C(C)=C\CSc1ccccc1C(N)=O	GZTMFRUGZMZCRD-CFBAGHHKSA-N, GZTMFRUGZMZCRD-CFBAGHHKSA-N, GZTMFRUGZMZCRD-CFBAGHHKSA-N	Phase 1
faropenem	lactamase inhibitor		infectious disease, pulmonary, otolaryngology	pneumonia, bronchitis, skin infections, urinary tract infections, sinusitis	C[C@@H](O)[C@H]1[C@H]2SC([C@H]3CCCO3)=C(N2C1=O)C(O)=O |&1:1,&2:3,&3:4,&4:7,r,c:12|	HGGAKXAHAYOLDJ-OJKLQORTSA-N	Launched
faropenem-medoxomil	lactamase inhibitor		otolaryngology, infectious disease, pulmonary	sinusitis, pneumonia, bronchitis, skin infections, urinary tract infections	C[C@@H](O)[C@@H]1[C@H]2SC([C@H]3CCCO3)=C(N2C1=O)C(=O)OCc1oc(=O)oc1C |c:12|, C[C@@H](O)[C@@H]1[C@H]2SC([C@H]3CCCO3)=C(N2C1=O)C(=O)OCc1oc(=O)oc1C |c:12|, C[C@@H](O)[C@@H]1[C@H]2SC([C@H]3CCCO3)=C(N2C1=O)C(=O)OCc1oc(=O)oc1C |c:12|	JQBKWZPHJOEQAO-DVPVEWDBSA-N, JQBKWZPHJOEQAO-DVPVEWDBSA-N, JQBKWZPHJOEQAO-DVPVEWDBSA-N	Launched
fasoracetam	GABA receptor antagonist				O=C([C@H]1CCC(=O)N1)N1CCCCC1	GOWRRBABHQUJMX-MRVPVSSYSA-N	Preclinical
fasudil	rho associated kinase inhibitor	PKIA, PRKACA, ROCK1, ROCK2	neurology/psychiatry	cerebral vasospasm	O=S(=O)(N1CCCNCC1)c1cccc2cnccc12, O=S(=O)(N1CCCNCC1)c1cccc2cnccc12, O=S(=O)(N1CCCNCC1)c1cccc2cnccc12, O=S(=O)(N1CCCNCC1)c1cccc2cnccc12, O=S(=O)(N1CCCNCC1)c1cccc2cnccc12, O=S(=O)(N1CCCNCC1)c1cccc2cnccc12, O=S(=O)(N1CCCNCC1)c1cccc2cnccc12	NGOGFTYYXHNFQH-UHFFFAOYSA-N, NGOGFTYYXHNFQH-UHFFFAOYSA-N, NGOGFTYYXHNFQH-UHFFFAOYSA-N, NGOGFTYYXHNFQH-UHFFFAOYSA-N, NGOGFTYYXHNFQH-UHFFFAOYSA-N, NGOGFTYYXHNFQH-UHFFFAOYSA-N, NGOGFTYYXHNFQH-UHFFFAOYSA-N	Launched
favipiravir	RNA polymerase inhibitor				NC(=O)c1nc(F)c[nH]c1=O, NC(=O)c1nc(F)c[nH]c1=O	ZCGNOVWYSGBHAU-UHFFFAOYSA-N, ZCGNOVWYSGBHAU-UHFFFAOYSA-N	Phase 3
FCE-22250	DNA directed DNA polymerase inhibitor				CO[C@H]1\C=C\O[C@@]2(C)Oc3c(C2=O)c2c(O)c(\C=N\N=C\N4CCCCC4)c(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)c(O)c2c(O)c3C |c:34,t:3,36|	JEGGQYICWGMXOZ-KLZPLVFYSA-N	Phase 1
fdcyd	DNA methyltransferase inhibitor				Nc1nc(=O)n(cc1F)[C@H]1C[C@H](O)[C@@H](CO)O1, Nc1nc(=O)n(cc1F)[C@H]1C[C@H](O)[C@@H](CO)O1	IDYKCXHJJGMAEV-RRKCRQDMSA-N, IDYKCXHJJGMAEV-RRKCRQDMSA-N	Phase 2
febuprol	choleretic agent				CCCCOC[C@@H](O)COc1ccccc1 |&1:6,r|	WBLXZPHICYCDGN-GFCCVEGCSA-N	Launched
febuxostat	xanthine oxidase inhibitor	XDH	nephrology	hyperuricemia	CC(C)COc1ccc(cc1C#N)-c1nc(C)c(s1)C(O)=O, CC(C)COc1ccc(cc1C#N)-c1nc(C)c(s1)C(O)=O, CC(C)COc1ccc(cc1C#N)-c1nc(C)c(s1)C(O)=O, CC(C)COc1ccc(cc1C#N)-c1nc(C)c(s1)C(O)=O	BQSJTQLCZDPROO-UHFFFAOYSA-N, BQSJTQLCZDPROO-UHFFFAOYSA-N, BQSJTQLCZDPROO-UHFFFAOYSA-N, BQSJTQLCZDPROO-UHFFFAOYSA-N	Launched
fedratinib	FLT3 inhibitor, JAK inhibitor	BRD4, JAK1, JAK2, JAK3, TYK2	hematologic malignancy	myelofibrosis	Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(c1)S(=O)(=O)NC(C)(C)C, Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(c1)S(=O)(=O)NC(C)(C)C, Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(c1)S(=O)(=O)NC(C)(C)C, Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(c1)S(=O)(=O)NC(C)(C)C, Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(c1)S(=O)(=O)NC(C)(C)C, Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(c1)S(=O)(=O)NC(C)(C)C, Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(c1)S(=O)(=O)NC(C)(C)C, Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(c1)S(=O)(=O)NC(C)(C)C, Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(c1)S(=O)(=O)NC(C)(C)C, Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(c1)S(=O)(=O)NC(C)(C)C, Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(c1)S(=O)(=O)NC(C)(C)C	JOOXLOJCABQBSG-UHFFFAOYSA-N, JOOXLOJCABQBSG-UHFFFAOYSA-N, JOOXLOJCABQBSG-UHFFFAOYSA-N, JOOXLOJCABQBSG-UHFFFAOYSA-N, JOOXLOJCABQBSG-UHFFFAOYSA-N, JOOXLOJCABQBSG-UHFFFAOYSA-N, JOOXLOJCABQBSG-UHFFFAOYSA-N, JOOXLOJCABQBSG-UHFFFAOYSA-N, JOOXLOJCABQBSG-UHFFFAOYSA-N, JOOXLOJCABQBSG-UHFFFAOYSA-N, JOOXLOJCABQBSG-UHFFFAOYSA-N	Launched
felbamate	glutamate receptor antagonist	GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D, GRIN3A, GRIN3B	neurology/psychiatry	epilepsy	NC(=O)OCC(COC(N)=O)c1ccccc1, NC(=O)OCC(COC(N)=O)c1ccccc1, NC(=O)OCC(COC(N)=O)c1ccccc1, NC(=O)OCC(COC(N)=O)c1ccccc1, NC(=O)OCC(COC(N)=O)c1ccccc1, NC(=O)OCC(COC(N)=O)c1ccccc1, NC(=O)OCC(COC(N)=O)c1ccccc1, NC(=O)OCC(COC(N)=O)c1ccccc1, NC(=O)OCC(COC(N)=O)c1ccccc1, NC(=O)OCC(COC(N)=O)c1ccccc1	WKGXYQFOCVYPAC-UHFFFAOYSA-N, WKGXYQFOCVYPAC-UHFFFAOYSA-N, WKGXYQFOCVYPAC-UHFFFAOYSA-N, WKGXYQFOCVYPAC-UHFFFAOYSA-N, WKGXYQFOCVYPAC-UHFFFAOYSA-N, WKGXYQFOCVYPAC-UHFFFAOYSA-N, WKGXYQFOCVYPAC-UHFFFAOYSA-N, WKGXYQFOCVYPAC-UHFFFAOYSA-N, WKGXYQFOCVYPAC-UHFFFAOYSA-N, WKGXYQFOCVYPAC-UHFFFAOYSA-N	Launched
felbinac	cyclooxygenase inhibitor	CTSL	rheumatology, neurology/psychiatry	rheumatoid arthritis, muscle pain	OC(=O)Cc1ccc(cc1)-c1ccccc1, OC(=O)Cc1ccc(cc1)-c1ccccc1	QRZAKQDHEVVFRX-UHFFFAOYSA-N, QRZAKQDHEVVFRX-UHFFFAOYSA-N	Launched
felbinac-ethyl	cyclooxygenase inhibitor	PTGS1, PTGS2			CCOC(=O)Cc1ccc(cc1)-c1ccccc1	NPPJLSILDPVHCM-UHFFFAOYSA-N	Launched
felodipine	calcium channel blocker	CFTR	cardiology	hypertension	CCOC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(Cl)c1Cl)C(=O)OC |&1:12,r,c:5,10|, CCOC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(Cl)c1Cl)C(=O)OC |&1:12,r,c:5,10|, CCOC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(Cl)c1Cl)C(=O)OC |&1:12,r,c:5,10|, CCOC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(Cl)c1Cl)C(=O)OC |&1:12,r,c:5,10|	RZTAMFZIAATZDJ-HNNXBMFYSA-N, RZTAMFZIAATZDJ-HNNXBMFYSA-N, RZTAMFZIAATZDJ-HNNXBMFYSA-N, RZTAMFZIAATZDJ-HNNXBMFYSA-N	Launched
felypressin	vasopressin receptor agonist				[H][C@@]1(Cc2ccccc2)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@@H](N)CSSC[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC1=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(=O)NCC(N)=O	SFKQVVDKFKYTNA-HLQBGFAYSA-N	Preclinical
fenaclon					ClCCC(=O)NCCc1ccccc1, ClCCC(=O)NCCc1ccccc1, ClCCC(=O)NCCc1ccccc1	BITWVVLBVUMFHU-UHFFFAOYSA-N, BITWVVLBVUMFHU-UHFFFAOYSA-N, BITWVVLBVUMFHU-UHFFFAOYSA-N	Preclinical
fenbendazole	tubulin polymerization inhibitor	TUBB	infectious disease	gastrointestinal parasites, gastrointestinal roundworms	COC(=O)Nc1nc2ccc(Sc3ccccc3)cc2[nH]1, COC(=O)Nc1nc2ccc(Sc3ccccc3)cc2[nH]1, COC(=O)Nc1nc2ccc(Sc3ccccc3)cc2[nH]1	HDDSHPAODJUKPD-UHFFFAOYSA-N, HDDSHPAODJUKPD-UHFFFAOYSA-N, HDDSHPAODJUKPD-UHFFFAOYSA-N	Launched
fenbufen	cyclooxygenase inhibitor	PTGS1, PTGS2	neurology/psychiatry	pain relief	OC(=O)CCC(=O)c1ccc(cc1)-c1ccccc1, OC(=O)CCC(=O)c1ccc(cc1)-c1ccccc1	ZPAKPRAICRBAOD-UHFFFAOYSA-N, ZPAKPRAICRBAOD-UHFFFAOYSA-N	Launched
fenclonine-(+/-)	tryptophan hydroxylase inhibitor	PAH, TPH1, TPH2			N[C@@H](Cc1ccc(Cl)cc1)C(O)=O |&1:1|, N[C@@H](Cc1ccc(Cl)cc1)C(O)=O |&1:1|	NIGWMJHCCYYCSF-QMMMGPOBSA-N, NIGWMJHCCYYCSF-QMMMGPOBSA-N	Preclinical
fendiline	calcium channel blocker	HTR2B			C[C@@H](NCCC(c1ccccc1)c1ccccc1)c1ccccc1 |&1:1|, C[C@@H](NCCC(c1ccccc1)c1ccccc1)c1ccccc1 |&1:1|, C[C@@H](NCCC(c1ccccc1)c1ccccc1)c1ccccc1 |&1:1|, C[C@@H](NCCC(c1ccccc1)c1ccccc1)c1ccccc1 |&1:1|, C[C@@H](NCCC(c1ccccc1)c1ccccc1)c1ccccc1 |&1:1|, C[C@@H](NCCC(c1ccccc1)c1ccccc1)c1ccccc1 |&1:1|	NMKSAYKQLCHXDK-LJQANCHMSA-N, NMKSAYKQLCHXDK-LJQANCHMSA-N, NMKSAYKQLCHXDK-LJQANCHMSA-N, NMKSAYKQLCHXDK-LJQANCHMSA-N, NMKSAYKQLCHXDK-LJQANCHMSA-N, NMKSAYKQLCHXDK-LJQANCHMSA-N	Preclinical
fenebrutinib	Bruton's tyrosine kinase (BTK) inhibitor				C[C@H]1CN(CCN1c1ccc(Nc2cc(cn(C)c2=O)-c2ccnc(N3CCn4c5CC(C)(C)Cc5cc4C3=O)c2CO)nc1)C1COC1	WNEODWDFDXWOLU-QHCPKHFHSA-N	Phase 2
fenigam	benzodiazepine receptor agonist	GABBR1, GABBR2	neurology/psychiatry	posttraumatic stress disorder, anxiety, depression	NC[C@@H](CC(O)=O)c1ccccc1 |&1:2,r|, NC[C@@H](CC(O)=O)c1ccccc1 |&1:2,r|, NC[C@@H](CC(O)=O)c1ccccc1 |&1:2,r|	DAFOCGYVTAOKAJ-SECBINFHSA-N, DAFOCGYVTAOKAJ-SECBINFHSA-N, DAFOCGYVTAOKAJ-SECBINFHSA-N	Launched
fenipentol	choleretic agent		gastroenterology	bile stimulation	CCCC[C@@H](O)c1ccccc1 |&1:4,r|, CCCC[C@@H](O)c1ccccc1 |&1:4,r|	OVGORFFCBUIFIA-LLVKDONJSA-N, OVGORFFCBUIFIA-LLVKDONJSA-N	Launched
fenobam	glutamate receptor antagonist	GRM5			CN1CC(=O)N=C1NC(=O)Nc1cccc(Cl)c1 |c:5|, CN1CC(=O)N=C1NC(=O)Nc1cccc(Cl)c1 |c:5|, CN1CC(=O)N=C1NC(=O)Nc1cccc(Cl)c1 |c:5|, CN1CC(=O)N=C1NC(=O)Nc1cccc(Cl)c1 |c:5|	DWPQODZAOSWNHB-UHFFFAOYSA-N, DWPQODZAOSWNHB-UHFFFAOYSA-N, DWPQODZAOSWNHB-UHFFFAOYSA-N, DWPQODZAOSWNHB-UHFFFAOYSA-N	Phase 2
fenofibrate	PPAR receptor agonist	MMP25, PPARA	endocrinology	hypercholesterolemia, hypertriglyceridemia	CC(C)OC(=O)C(C)(C)Oc1ccc(cc1)C(=O)c1ccc(Cl)cc1, CC(C)OC(=O)C(C)(C)Oc1ccc(cc1)C(=O)c1ccc(Cl)cc1, CC(C)OC(=O)C(C)(C)Oc1ccc(cc1)C(=O)c1ccc(Cl)cc1	YMTINGFKWWXKFG-UHFFFAOYSA-N, YMTINGFKWWXKFG-UHFFFAOYSA-N, YMTINGFKWWXKFG-UHFFFAOYSA-N	Launched
fenofibric-acid	cytochrome P450 inhibitor	CLCN1, PPARA	cardiology	dyslipidemia	CC(C)(Oc1ccc(cc1)C(=O)c1ccc(Cl)cc1)C(O)=O, CC(C)(Oc1ccc(cc1)C(=O)c1ccc(Cl)cc1)C(O)=O, CC(C)(Oc1ccc(cc1)C(=O)c1ccc(Cl)cc1)C(O)=O	MQOBSOSZFYZQOK-UHFFFAOYSA-N, MQOBSOSZFYZQOK-UHFFFAOYSA-N, MQOBSOSZFYZQOK-UHFFFAOYSA-N	Launched
fenoldopam	dopamine receptor agonist	DRD1, DRD4	cardiology	hypertension	Oc1ccc(cc1)[C@H]1CNCCc2c(Cl)c(O)c(O)cc12 |&1:7|, Oc1ccc(cc1)[C@H]1CNCCc2c(Cl)c(O)c(O)cc12 |&1:7|	TVURRHSHRRELCG-CYBMUJFWSA-N, TVURRHSHRRELCG-CYBMUJFWSA-N	Launched
fenoprofen	prostaglandin inhibitor	PTGS1, SLC5A8	rheumatology	rheumatoid arthritis, osteoarthritis	C[C@@H](C(O)=O)c1cccc(Oc2ccccc2)c1 |&1:1|	RDJGLLICXDHJDY-LLVKDONJSA-N	Launched
fenoterol	adrenergic receptor agonist	ADRB2			C[C@@H](Cc1ccc(O)cc1)NC[C@@H](O)c1cc(O)cc(O)c1 |&1:1,12,r|	LSLYOANBFKQKPT-APPDUMDISA-N	Withdrawn
fenoverine	acetylcholine receptor antagonist		neurology/psychiatry	spasms	O=C(CN1CCN(Cc2ccc3OCOc3c2)CC1)N1c2ccccc2Sc2ccccc12	UBAJTZKNDCEGKL-UHFFFAOYSA-N	Launched
fenoxaprop-p-ethyl		NOS3			CCOC(=O)[C@@H](C)Oc1ccc(Oc2nc3ccc(Cl)cc3o2)cc1	PQKBPHSEKWERTG-LLVKDONJSA-N	Preclinical
fenretinide	apoptosis stimulant, retinoid receptor agonist	RARA			C\C(\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C/C(=O)Nc1ccc(O)cc1 |c:4|, C\C(\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C/C(=O)Nc1ccc(O)cc1 |c:4|, C\C(\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C/C(=O)Nc1ccc(O)cc1 |c:4|, C\C(\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C/C(=O)Nc1ccc(O)cc1 |c:4|, C\C(\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C/C(=O)Nc1ccc(O)cc1 |c:4|, C\C(\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C/C(=O)Nc1ccc(O)cc1 |c:4|	AKJHMTWEGVYYSE-FXILSDISSA-N, AKJHMTWEGVYYSE-FXILSDISSA-N, AKJHMTWEGVYYSE-FXILSDISSA-N, AKJHMTWEGVYYSE-FXILSDISSA-N, AKJHMTWEGVYYSE-FXILSDISSA-N, AKJHMTWEGVYYSE-FXILSDISSA-N	Phase 3
fenspiride	bronchodilator		pulmonary, otolaryngology	asthma, otitis, sinusitis, rhinopharyngitis, laryngitis	O=C1NCC2(CCN(CCc3ccccc3)CC2)O1, O=C1NCC2(CCN(CCc3ccccc3)CC2)O1, O=C1NCC2(CCN(CCc3ccccc3)CC2)O1	FVNFBBAOMBJTST-UHFFFAOYSA-N, FVNFBBAOMBJTST-UHFFFAOYSA-N, FVNFBBAOMBJTST-UHFFFAOYSA-N	Launched
fenthion	cholinesterase inhibitor				COP(=S)(OC)Oc1ccc(SC)c(C)c1	PNVJTZOFSHSLTO-UHFFFAOYSA-N	Launched
fentiazac	cyclooxygenase inhibitor	PTGS1, PTGS2	neurology/psychiatry, rheumatology	muscle pain, joint pain	OC(=O)Cc1sc(nc1-c1ccc(Cl)cc1)-c1ccccc1, OC(=O)Cc1sc(nc1-c1ccc(Cl)cc1)-c1ccccc1	JIEKMACRVQTPRC-UHFFFAOYSA-N, JIEKMACRVQTPRC-UHFFFAOYSA-N	Launched
fenticonazole	bacterial cell wall synthesis inhibitor		infectious disease	vulvovaginal candidiasis	Clc1ccc([C@@H](Cn2ccnc2)OCc2ccc(Sc3ccccc3)cc2)c(Cl)c1 |&1:5|, Clc1ccc([C@@H](Cn2ccnc2)OCc2ccc(Sc3ccccc3)cc2)c(Cl)c1 |&1:5|, Clc1ccc([C@@H](Cn2ccnc2)OCc2ccc(Sc3ccccc3)cc2)c(Cl)c1 |&1:5|	ZCJYUTQZBAIHBS-XMMPIXPASA-N, ZCJYUTQZBAIHBS-XMMPIXPASA-N, ZCJYUTQZBAIHBS-XMMPIXPASA-N	Launched
FERb-033	EGFR inhibitor	ERBB2			O\N=C\c1ccc(c(Cl)c1O)-c1ccc(O)c(F)c1, O\N=C\c1ccc(c(Cl)c1O)-c1ccc(O)c(F)c1, O\N=C\c1ccc(c(Cl)c1O)-c1ccc(O)c(F)c1	LRRMQNGSYOUANY-OMCISZLKSA-N, LRRMQNGSYOUANY-OMCISZLKSA-N, LRRMQNGSYOUANY-OMCISZLKSA-N	Preclinical
ferroquine	antimalarial agent				CN(C)CC1=CC=C[C@@]1(CNc1ccnc2cc(Cl)ccc12)[Fe]C1C=CC=C1 |&1:8,r,c:6,27,29,t:4|	UZTPLPOYSVSMBU-UHFFFAOYSA-N	Phase 2
ferrostatin-1	ferroptosis inhibitor				CCOC(=O)c1ccc(NC2CCCCC2)c(N)c1, CCOC(=O)c1ccc(NC2CCCCC2)c(N)c1, CCOC(=O)c1ccc(NC2CCCCC2)c(N)c1, CCOC(=O)c1ccc(NC2CCCCC2)c(N)c1	UJHBVMHOBZBWMX-UHFFFAOYSA-N, UJHBVMHOBZBWMX-UHFFFAOYSA-N, UJHBVMHOBZBWMX-UHFFFAOYSA-N, UJHBVMHOBZBWMX-UHFFFAOYSA-N	Preclinical
ferulic-acid	antioxidant	CA1, CA12, CA14, CA2, CA4, CA6, CA9			COc1cc(\C=C\C(O)=O)ccc1O, COc1cc(\C=C\C(O)=O)ccc1O, COc1cc(\C=C\C(O)=O)ccc1O, COc1cc(\C=C\C(O)=O)ccc1O, COc1cc(\C=C\C(O)=O)ccc1O	KSEBMYQBYZTDHS-HWKANZROSA-N, KSEBMYQBYZTDHS-HWKANZROSA-N, KSEBMYQBYZTDHS-HWKANZROSA-N, KSEBMYQBYZTDHS-HWKANZROSA-N, KSEBMYQBYZTDHS-HWKANZROSA-N	Phase 2
fesoterodine	acetylcholine receptor antagonist	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5	urology	urinary incontinence	CC(C)N(CC[C@H](c1ccccc1)c1cc(CO)ccc1OC(=O)C(C)C)C(C)C, CC(C)N(CC[C@H](c1ccccc1)c1cc(CO)ccc1OC(=O)C(C)C)C(C)C, CC(C)N(CC[C@H](c1ccccc1)c1cc(CO)ccc1OC(=O)C(C)C)C(C)C	DCCSDBARQIPTGU-HSZRJFAPSA-N, DCCSDBARQIPTGU-HSZRJFAPSA-N, DCCSDBARQIPTGU-HSZRJFAPSA-N	Launched
fevipiprant	prostaglandin inhibitor				Cc1c(CC(O)=O)c2cccnc2n1Cc1ccc(cc1C(F)(F)F)S(C)(=O)=O	GFPPXZDRVCSVNR-UHFFFAOYSA-N	Phase 2
fexaramine	FXR agonist	NR1H4			COC(=O)\C=C\c1cccc(c1)N(Cc1ccc(cc1)-c1ccc(cc1)N(C)C)C(=O)C1CCCCC1, COC(=O)\C=C\c1cccc(c1)N(Cc1ccc(cc1)-c1ccc(cc1)N(C)C)C(=O)C1CCCCC1, COC(=O)\C=C\c1cccc(c1)N(Cc1ccc(cc1)-c1ccc(cc1)N(C)C)C(=O)C1CCCCC1	VLQTUNDJHLEFEQ-KGENOOAVSA-N, VLQTUNDJHLEFEQ-KGENOOAVSA-N, VLQTUNDJHLEFEQ-KGENOOAVSA-N	Preclinical
fexinidazole					CSc1ccc(OCc2ncc(n2C)[N+]([O-])=O)cc1	MIWWSGDADVMLTG-UHFFFAOYSA-N	Phase 3
fexofenadine	histamine receptor antagonist	HRH1	allergy	allergic rhinitis, urticaria	CC(C)(C(O)=O)c1ccc(cc1)[C@@H](O)CCCN1CCC(CC1)C(O)(c1ccccc1)c1ccccc1 |&1:12|, CC(C)(C(O)=O)c1ccc(cc1)[C@@H](O)CCCN1CCC(CC1)C(O)(c1ccccc1)c1ccccc1 |&1:12|, CC(C)(C(O)=O)c1ccc(cc1)[C@@H](O)CCCN1CCC(CC1)C(O)(c1ccccc1)c1ccccc1 |&1:12|, CC(C)(C(O)=O)c1ccc(cc1)[C@@H](O)CCCN1CCC(CC1)C(O)(c1ccccc1)c1ccccc1 |&1:12|	RWTNPBWLLIMQHL-LJAQVGFWSA-N, RWTNPBWLLIMQHL-LJAQVGFWSA-N, RWTNPBWLLIMQHL-LJAQVGFWSA-N, RWTNPBWLLIMQHL-LJAQVGFWSA-N	Launched
fezolinetant	neurokinin receptor antagonist				C[C@H]1N(CCn2c1nnc2-c1nc(C)ns1)C(=O)c1ccc(F)cc1	PPSNFPASKFYPMN-SECBINFHSA-N	Phase 2
FG-2216	hypoxia inducible factor prolyl hydroxylase inhibitor	EGLN1, EGLN2, HIF1A			OC(=O)CNC(=O)c1nc(Cl)c2ccccc2c1O	OUQVKRKGTAUJQA-UHFFFAOYSA-N	Phase 2
FG-4592	hypoxia inducible factor prolyl hydroxylase inhibitor	EGLN1, EGLN2, EGLN3			Cc1nc(C(=O)NCC(O)=O)c(O)c2ccc(Oc3ccccc3)cc12, Cc1nc(C(=O)NCC(O)=O)c(O)c2ccc(Oc3ccccc3)cc12, Cc1nc(C(=O)NCC(O)=O)c(O)c2ccc(Oc3ccccc3)cc12, Cc1nc(C(=O)NCC(O)=O)c(O)c2ccc(Oc3ccccc3)cc12, Cc1nc(C(=O)NCC(O)=O)c(O)c2ccc(Oc3ccccc3)cc12	YOZBGTLTNGAVFU-UHFFFAOYSA-N, YOZBGTLTNGAVFU-UHFFFAOYSA-N, YOZBGTLTNGAVFU-UHFFFAOYSA-N, YOZBGTLTNGAVFU-UHFFFAOYSA-N, YOZBGTLTNGAVFU-UHFFFAOYSA-N	Phase 3
FG-7142	GABA benzodiazepine site receptor inverse agonist				CNC(=O)c1cc2c(cn1)[nH]c1ccccc21, CNC(=O)c1cc2c(cn1)[nH]c1ccccc21, CNC(=O)c1cc2c(cn1)[nH]c1ccccc21, CNC(=O)c1cc2c(cn1)[nH]c1ccccc21	QMCOPDWHWYSJSA-UHFFFAOYSA-N, QMCOPDWHWYSJSA-UHFFFAOYSA-N, QMCOPDWHWYSJSA-UHFFFAOYSA-N, QMCOPDWHWYSJSA-UHFFFAOYSA-N	Preclinical
FGIN-1-27	inositol monophosphatase inhibitor	TSPO			CCCCCCN(CCCCCC)C(=O)Cc1c([nH]c2ccccc12)-c1ccc(F)cc1, CCCCCCN(CCCCCC)C(=O)Cc1c([nH]c2ccccc12)-c1ccc(F)cc1, CCCCCCN(CCCCCC)C(=O)Cc1c([nH]c2ccccc12)-c1ccc(F)cc1, CCCCCCN(CCCCCC)C(=O)Cc1c([nH]c2ccccc12)-c1ccc(F)cc1	VUWXAQFLTSBUDB-UHFFFAOYSA-N, VUWXAQFLTSBUDB-UHFFFAOYSA-N, VUWXAQFLTSBUDB-UHFFFAOYSA-N, VUWXAQFLTSBUDB-UHFFFAOYSA-N	Preclinical
FGIN-1-43	benzodiazepine receptor agonist	TSPO			CCCCCCN(CCCCCC)C(=O)Cc1c([nH]c2ccc(Cl)cc12)-c1ccc(Cl)cc1, CCCCCCN(CCCCCC)C(=O)Cc1c([nH]c2ccc(Cl)cc12)-c1ccc(Cl)cc1, CCCCCCN(CCCCCC)C(=O)Cc1c([nH]c2ccc(Cl)cc12)-c1ccc(Cl)cc1, CCCCCCN(CCCCCC)C(=O)Cc1c([nH]c2ccc(Cl)cc12)-c1ccc(Cl)cc1, CCCCCCN(CCCCCC)C(=O)Cc1c([nH]c2ccc(Cl)cc12)-c1ccc(Cl)cc1	XTZUPNNVXIMWAR-UHFFFAOYSA-N, XTZUPNNVXIMWAR-UHFFFAOYSA-N, XTZUPNNVXIMWAR-UHFFFAOYSA-N, XTZUPNNVXIMWAR-UHFFFAOYSA-N, XTZUPNNVXIMWAR-UHFFFAOYSA-N	Preclinical
FH-535	PPAR receptor antagonist, WNT signaling inhibitor	PPARD, PPARG			Cc1cc(ccc1NS(=O)(=O)c1cc(Cl)ccc1Cl)[N+]([O-])=O, Cc1cc(ccc1NS(=O)(=O)c1cc(Cl)ccc1Cl)[N+]([O-])=O	AXNUEXXEQGQWPA-UHFFFAOYSA-N, AXNUEXXEQGQWPA-UHFFFAOYSA-N	Preclinical
FH1	hepatocyte function enhancer				CC(=O)Nc1ccc(Cc2ccc(NC(C)=O)cc2)cc1, CC(=O)Nc1ccc(Cc2ccc(NC(C)=O)cc2)cc1	OEXMNSOPAKOPEF-UHFFFAOYSA-N, OEXMNSOPAKOPEF-UHFFFAOYSA-N	Preclinical
fiacitabine	DNA synthesis inhibitor				Nc1nc(=O)n(cc1I)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F, Nc1nc(=O)n(cc1I)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F	GIMSJJHKKXRFGV-BYPJNBLXSA-N, GIMSJJHKKXRFGV-BYPJNBLXSA-N	Phase 2
fidarestat	aldose reductase inhibitor	AKR1B1			NC(=O)[C@H]1C[C@]2(NC(=O)NC2=O)c2cc(F)ccc2O1 |&1:3,&2:5,r|, NC(=O)[C@H]1C[C@]2(NC(=O)NC2=O)c2cc(F)ccc2O1 |&1:3,&2:5,r|	WAAPEIZFCHNLKK-PELKAZGASA-N, WAAPEIZFCHNLKK-PELKAZGASA-N	Phase 3
fidaxomicin	RNA polymerase inhibitor		gastroenterology	diarrhea	CC[C@H]1\C=C(C)\[C@@H](O)C\C=C\C=C(CO[C@@H]2O[C@H](C)[C@@H](OC(=O)c3c(O)c(Cl)c(O)c(Cl)c3CC)[C@H](O)[C@@H]2OC)\C(=O)O[C@@H](C\C=C(/C)\C=C(C)\[C@@H]1O[C@@H]1OC(C)(C)[C@@H](OC(=O)C(C)C)[C@H](O)[C@@H]1O)[C@@H](C)O |c:3,11,47,50,t:9|	ZVGNESXIJDCBKN-UUEYKCAUSA-N	Launched
filanesib	kinesin inhibitor, kinesin-like spindle protein inhibitor	KIF11			CON(C)C(=O)N1N=C(S[C@@]1(CCCN)c1ccccc1)c1cc(F)ccc1F |c:7|, CON(C)C(=O)N1N=C(S[C@@]1(CCCN)c1ccccc1)c1cc(F)ccc1F |c:7|, CON(C)C(=O)N1N=C(S[C@@]1(CCCN)c1ccccc1)c1cc(F)ccc1F |c:7|, CON(C)C(=O)N1N=C(S[C@@]1(CCCN)c1ccccc1)c1cc(F)ccc1F |c:7|, CON(C)C(=O)N1N=C(S[C@@]1(CCCN)c1ccccc1)c1cc(F)ccc1F |c:7|, CON(C)C(=O)N1N=C(S[C@@]1(CCCN)c1ccccc1)c1cc(F)ccc1F |c:7|	LLXISKGBWFTGEI-FQEVSTJZSA-N, LLXISKGBWFTGEI-FQEVSTJZSA-N, LLXISKGBWFTGEI-FQEVSTJZSA-N, LLXISKGBWFTGEI-FQEVSTJZSA-N, LLXISKGBWFTGEI-FQEVSTJZSA-N, LLXISKGBWFTGEI-FQEVSTJZSA-N	Phase 3
filgotinib	JAK inhibitor	JAK1, JAK2, JAK3, TYK2			O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1, O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1, O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1, O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1, O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1	RIJLVEAXPNLDTC-UHFFFAOYSA-N, RIJLVEAXPNLDTC-UHFFFAOYSA-N, RIJLVEAXPNLDTC-UHFFFAOYSA-N, RIJLVEAXPNLDTC-UHFFFAOYSA-N, RIJLVEAXPNLDTC-UHFFFAOYSA-N	Phase 3
fimasartan	angiotensin receptor antagonist	AGTR1	cardiology	hypertension, congestive heart failure	CCCCc1nc(C)c(CC(=S)N(C)C)c(=O)n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1, CCCCc1nc(C)c(CC(=S)N(C)C)c(=O)n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1, CCCCc1nc(C)c(CC(=S)N(C)C)c(=O)n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1	AMEROGPZOLAFBN-UHFFFAOYSA-N, AMEROGPZOLAFBN-UHFFFAOYSA-N, AMEROGPZOLAFBN-UHFFFAOYSA-N	Launched
finafloxacin	bacterial DNA gyrase inhibitor		infectious disease, pulmonary	intra-abdominal infections, chronic obstructive pulmonary disease (COPD), cystic fibrosis	OC(=O)c1cn(C2CC2)c2c(C#N)c(N3C[C@@H]4NCCO[C@H]4C3)c(F)cc2c1=O, OC(=O)c1cn(C2CC2)c2c(C#N)c(N3C[C@@H]4NCCO[C@H]4C3)c(F)cc2c1=O, OC(=O)c1cn(C2CC2)c2c(C#N)c(N3C[C@@H]4NCCO[C@H]4C3)c(F)cc2c1=O	FYMHQCNFKNMJAV-HOTGVXAUSA-N, FYMHQCNFKNMJAV-HOTGVXAUSA-N, FYMHQCNFKNMJAV-HOTGVXAUSA-N	Launched
finasteride	5 alpha reductase inhibitor	AKR1D1, SRD5A1, SRD5A2	endocrinology	androgenetic alopecia	CC(C)(C)NC(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4NC(=O)C=C[C@]4(C)[C@H]3CC[C@]12C |c:18|, CC(C)(C)NC(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4NC(=O)C=C[C@]4(C)[C@H]3CC[C@]12C |c:18|, CC(C)(C)NC(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4NC(=O)C=C[C@]4(C)[C@H]3CC[C@]12C |c:18|, CC(C)(C)NC(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4NC(=O)C=C[C@]4(C)[C@H]3CC[C@]12C |c:18|, CC(C)(C)NC(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4NC(=O)C=C[C@]4(C)[C@H]3CC[C@]12C |c:18|	DBEPLOCGEIEOCV-WSBQPABSSA-N, DBEPLOCGEIEOCV-WSBQPABSSA-N, DBEPLOCGEIEOCV-WSBQPABSSA-N, DBEPLOCGEIEOCV-WSBQPABSSA-N, DBEPLOCGEIEOCV-WSBQPABSSA-N	Launched
fingolimod	immunosuppressant, sphingosine 1-phosphate receptor agonist	S1PR1, S1PR5	neurology/psychiatry	multiple sclerosis	CCCCCCCCc1ccc(CCC(N)(CO)CO)cc1, CCCCCCCCc1ccc(CCC(N)(CO)CO)cc1, CCCCCCCCc1ccc(CCC(N)(CO)CO)cc1, CCCCCCCCc1ccc(CCC(N)(CO)CO)cc1, CCCCCCCCc1ccc(CCC(N)(CO)CO)cc1, CCCCCCCCc1ccc(CCC(N)(CO)CO)cc1, CCCCCCCCc1ccc(CCC(N)(CO)CO)cc1, CCCCCCCCc1ccc(CCC(N)(CO)CO)cc1, CCCCCCCCc1ccc(CCC(N)(CO)CO)cc1, CCCCCCCCc1ccc(CCC(N)(CO)CO)cc1, CCCCCCCCc1ccc(CCC(N)(CO)CO)cc1	KKGQTZUTZRNORY-UHFFFAOYSA-N, KKGQTZUTZRNORY-UHFFFAOYSA-N, KKGQTZUTZRNORY-UHFFFAOYSA-N, KKGQTZUTZRNORY-UHFFFAOYSA-N, KKGQTZUTZRNORY-UHFFFAOYSA-N, KKGQTZUTZRNORY-UHFFFAOYSA-N, KKGQTZUTZRNORY-UHFFFAOYSA-N, KKGQTZUTZRNORY-UHFFFAOYSA-N, KKGQTZUTZRNORY-UHFFFAOYSA-N, KKGQTZUTZRNORY-UHFFFAOYSA-N, KKGQTZUTZRNORY-UHFFFAOYSA-N	Launched
fipexide	psychoactive drug				Clc1ccc(OCC(=O)N2CCN(Cc3ccc4OCOc4c3)CC2)cc1	BFUJHVVEMMWLHC-UHFFFAOYSA-N	Withdrawn
FIPI	phospholipase inhibitor	PLD1, PLD2			Fc1ccc2[nH]c(cc2c1)C(=O)NCCN1CCC(CC1)n1c2ccccc2[nH]c1=O, Fc1ccc2[nH]c(cc2c1)C(=O)NCCN1CCC(CC1)n1c2ccccc2[nH]c1=O	LHABRXRGDLASIH-UHFFFAOYSA-N, LHABRXRGDLASIH-UHFFFAOYSA-N	Preclinical
fipronil	chloride channel blocker, GABA gated chloride channel blocker		infectious disease	flea control	Nc1c(c(nn1-c1c(Cl)cc(cc1Cl)C(F)(F)F)C#N)[S@@](=O)C(F)(F)F |&1:20,r|, Nc1c(c(nn1-c1c(Cl)cc(cc1Cl)C(F)(F)F)C#N)[S@@](=O)C(F)(F)F |&1:20,r|	ZOCSXAVNDGMNBV-AREMUKBSSA-N, ZOCSXAVNDGMNBV-AREMUKBSSA-N	Launched
firategrast	integrin antagonist	ITGA4			CCOCc1cc(OC)c(c(OC)c1)-c1ccc(C[C@H](NC(=O)c2c(F)cccc2F)C(O)=O)cc1, CCOCc1cc(OC)c(c(OC)c1)-c1ccc(C[C@H](NC(=O)c2c(F)cccc2F)C(O)=O)cc1, CCOCc1cc(OC)c(c(OC)c1)-c1ccc(C[C@H](NC(=O)c2c(F)cccc2F)C(O)=O)cc1, CCOCc1cc(OC)c(c(OC)c1)-c1ccc(C[C@H](NC(=O)c2c(F)cccc2F)C(O)=O)cc1, CCOCc1cc(OC)c(c(OC)c1)-c1ccc(C[C@H](NC(=O)c2c(F)cccc2F)C(O)=O)cc1, CCOCc1cc(OC)c(c(OC)c1)-c1ccc(C[C@H](NC(=O)c2c(F)cccc2F)C(O)=O)cc1, CCOCc1cc(OC)c(c(OC)c1)-c1ccc(C[C@H](NC(=O)c2c(F)cccc2F)C(O)=O)cc1, CCOCc1cc(OC)c(c(OC)c1)-c1ccc(C[C@H](NC(=O)c2c(F)cccc2F)C(O)=O)cc1	YLFZHHDVRSYTKT-NRFANRHFSA-N, YLFZHHDVRSYTKT-NRFANRHFSA-N, YLFZHHDVRSYTKT-NRFANRHFSA-N, YLFZHHDVRSYTKT-NRFANRHFSA-N, YLFZHHDVRSYTKT-NRFANRHFSA-N, YLFZHHDVRSYTKT-NRFANRHFSA-N, YLFZHHDVRSYTKT-NRFANRHFSA-N, YLFZHHDVRSYTKT-NRFANRHFSA-N	Phase 2
firocoxib	cyclooxygenase inhibitor	PTGS2	rheumatology	osteoarthritis	CC1(C)OC(=O)C(OCC2CC2)=C1c1ccc(cc1)S(C)(=O)=O |c:12|	FULAPETWGIGNMT-UHFFFAOYSA-N	Launched
firsocostat	acetyl-CoA carboxylase inhibitor				COc1ccccc1[C@H](Cn1c2sc(c(C)c2c(=O)n(c1=O)C(C)(C)C(O)=O)-c1ncco1)OC1CCOCC1	ZZWWXIBKLBMSCS-FQEVSTJZSA-N	Phase 2
fisetin	Aurora kinase inhibitor	CDK6, FASN			Oc1ccc2c(c1)oc(-c1ccc(O)c(O)c1)c(O)c2=O, Oc1ccc2c(c1)oc(-c1ccc(O)c(O)c1)c(O)c2=O, Oc1ccc2c(c1)oc(-c1ccc(O)c(O)c1)c(O)c2=O, Oc1ccc2c(c1)oc(-c1ccc(O)c(O)c1)c(O)c2=O	XHEFDIBZLJXQHF-UHFFFAOYSA-N, XHEFDIBZLJXQHF-UHFFFAOYSA-N, XHEFDIBZLJXQHF-UHFFFAOYSA-N, XHEFDIBZLJXQHF-UHFFFAOYSA-N	Preclinical
fisogatinib	fibroblast growth factor inhibitor				COc1cc(OC)c(Cl)c(c1Cl)-c1ccc2nc(N[C@@H]3COCC[C@@H]3NC(=O)C=C)ncc2c1	MGZKYOAQVGSSGC-DLBZAZTESA-N	Phase 1
FIT	opioid receptor agonist	OPRD1			CCC(=O)N(C1CCN(CCc2ccc(cc2)N=C=S)CC1)c1ccccc1	VDKBIFPJULZUPU-UHFFFAOYSA-N	Preclinical
FK-33-824	opioid receptor agonist	OPRM1			C[C@H](NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)NCC(=O)N(C)[C@@H](Cc1ccccc1)C(=O)N[C@H](CO)CC[S@@](C)=O |a:1,5,23,34,&1:39|, C[C@H](NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)NCC(=O)N(C)[C@@H](Cc1ccccc1)C(=O)N[C@H](CO)CC[S@@](C)=O |a:1,5,23,34,&1:39|	HYZHONGSQNXMPH-YJRDZJJMSA-N, HYZHONGSQNXMPH-YJRDZJJMSA-N	Phase 2
FK-3311	cyclooxygenase inhibitor	PTGS2			CC(=O)c1ccc(NS(C)(=O)=O)c(Oc2ccc(F)cc2F)c1, CC(=O)c1ccc(NS(C)(=O)=O)c(Oc2ccc(F)cc2F)c1, CC(=O)c1ccc(NS(C)(=O)=O)c(Oc2ccc(F)cc2F)c1	DIIYLGZNZGPXRR-UHFFFAOYSA-N, DIIYLGZNZGPXRR-UHFFFAOYSA-N, DIIYLGZNZGPXRR-UHFFFAOYSA-N	Phase 2
FK-409	guanylyl cyclase activator				CC\C(=C/C(=N/O)/C(N)=O)[C@@H](C)[N+]([O-])=O |&1:10,r|	MZAGXDHQGXUDDX-FGCOBAPNSA-N	Phase 2
FK-866	niacinamide phosphoribosyltransferase inhibitor	NAMPT			O=C(NCCCCC1CCN(CC1)C(=O)c1ccccc1)\C=C\c1cccnc1, O=C(NCCCCC1CCN(CC1)C(=O)c1ccccc1)\C=C\c1cccnc1	KPBNHDGDUADAGP-VAWYXSNFSA-N, KPBNHDGDUADAGP-VAWYXSNFSA-N	Phase 2
FK-888	tachykinin antagonist	TACR1, TACR2			CN(Cc1ccccc1)C(=O)[C@H](Cc1ccc2ccccc2c1)NC(=O)[C@@H]1C[C@@H](O)CN1C(=O)c1cn(C)c2ccccc12, CN(Cc1ccccc1)C(=O)[C@H](Cc1ccc2ccccc2c1)NC(=O)[C@@H]1C[C@@H](O)CN1C(=O)c1cn(C)c2ccccc12, CN(Cc1ccccc1)C(=O)[C@H](Cc1ccc2ccccc2c1)NC(=O)[C@@H]1C[C@@H](O)CN1C(=O)c1cn(C)c2ccccc12, CN(Cc1ccccc1)C(=O)[C@H](Cc1ccc2ccccc2c1)NC(=O)[C@@H]1C[C@@H](O)CN1C(=O)c1cn(C)c2ccccc12	BFNKQTIJVFGCKQ-PDJGWCFMSA-N, BFNKQTIJVFGCKQ-PDJGWCFMSA-N, BFNKQTIJVFGCKQ-PDJGWCFMSA-N, BFNKQTIJVFGCKQ-PDJGWCFMSA-N	Phase 2
FK-962	somatostatin receptor agonist				CC(=O)N1CCC(CC1)NC(=O)c1ccc(F)cc1, CC(=O)N1CCC(CC1)NC(=O)c1ccc(F)cc1	VBHVOHJOTMCSBQ-UHFFFAOYSA-N, VBHVOHJOTMCSBQ-UHFFFAOYSA-N	Phase 2
flavin-adenine-dinucleotide		ACAD8, ACADM, ACADS, ACOX1, AIFM1, CYB5R1, CYB5R3, DAO, DLD, DPYD, ERO1LB, FDXR, GCDH, GFER, GSR, IL4I1, IVD, MAOA, MAOB, NOS1, NQO1, NQO2, POR, TXNRD1, XDH			Cc1cc2nc3c(nc(=O)[nH]c3=O)n(C[C@H](O)[C@H](O)[C@H](O)CO[P@@](O)(=O)O[P@@](O)(=O)OC[C@H]3O[C@H]([C@H](O)[C@@H]3O)n3cnc4c(N)ncnc34)c2cc1C |a:15,17,19,32,34,35,37,&1:23,&2:27|	VWWQXMAJTJZDQX-UYBVJOGSSA-N	Preclinical
flavoxate	acetylcholine receptor antagonist	CHRM1, CHRM2	urology	urinary incontinence, interstitial cystitis (IC), urethritis, prostatitis	Cc1c(oc2c(cccc2c1=O)C(=O)OCCN1CCCCC1)-c1ccccc1, Cc1c(oc2c(cccc2c1=O)C(=O)OCCN1CCCCC1)-c1ccccc1	SPIUTQOUKAMGCX-UHFFFAOYSA-N, SPIUTQOUKAMGCX-UHFFFAOYSA-N	Launched
flecainide	sodium channel blocker	KCNA5, KCNA7, SCN5A	cardiology	ventricular tachycardia (VT), atrial fibrillation (AF), ventricular arrhythmias	FC(F)(F)COc1ccc(OCC(F)(F)F)c(c1)C(=O)NCC1CCCCN1, FC(F)(F)COc1ccc(OCC(F)(F)F)c(c1)C(=O)NCC1CCCCN1, FC(F)(F)COc1ccc(OCC(F)(F)F)c(c1)C(=O)NCC1CCCCN1, FC(F)(F)COc1ccc(OCC(F)(F)F)c(c1)C(=O)NCC1CCCCN1, FC(F)(F)COc1ccc(OCC(F)(F)F)c(c1)C(=O)NCC1CCCCN1, FC(F)(F)COc1ccc(OCC(F)(F)F)c(c1)C(=O)NCC1CCCCN1	DJBNUMBKLMJRSA-UHFFFAOYSA-N, DJBNUMBKLMJRSA-UHFFFAOYSA-N, DJBNUMBKLMJRSA-UHFFFAOYSA-N, DJBNUMBKLMJRSA-UHFFFAOYSA-N, DJBNUMBKLMJRSA-UHFFFAOYSA-N, DJBNUMBKLMJRSA-UHFFFAOYSA-N	Launched
fleroxacin	topoisomerase inhibitor	TOP2A	infectious disease, gastroenterology	gonorrhea, enteritis, diarrhea, respiratory tract infections	CN1CCN(CC1)c1c(F)cc2c(c1F)n(CCF)cc(C(O)=O)c2=O, CN1CCN(CC1)c1c(F)cc2c(c1F)n(CCF)cc(C(O)=O)c2=O, CN1CCN(CC1)c1c(F)cc2c(c1F)n(CCF)cc(C(O)=O)c2=O, CN1CCN(CC1)c1c(F)cc2c(c1F)n(CCF)cc(C(O)=O)c2=O	XBJBPGROQZJDOJ-UHFFFAOYSA-N, XBJBPGROQZJDOJ-UHFFFAOYSA-N, XBJBPGROQZJDOJ-UHFFFAOYSA-N, XBJBPGROQZJDOJ-UHFFFAOYSA-N	Launched
FLI-06	notch signaling inhibitor				CC1=NC2=C([C@@H](C1C(=O)OC1CCCCC1)c1ccc(cc1)[N+]([O-])=O)C(=O)CC(C)(C)C2 |&1:5,r,c:3,t:1|, CC1=NC2=C([C@@H](C1C(=O)OC1CCCCC1)c1ccc(cc1)[N+]([O-])=O)C(=O)CC(C)(C)C2 |&1:5,r,c:3,t:1|, CC1=NC2=C([C@@H](C1C(=O)OC1CCCCC1)c1ccc(cc1)[N+]([O-])=O)C(=O)CC(C)(C)C2 |&1:5,r,c:3,t:1|, CC1=NC2=C([C@@H](C1C(=O)OC1CCCCC1)c1ccc(cc1)[N+]([O-])=O)C(=O)CC(C)(C)C2 |&1:5,r,c:3,t:1|, CC1=NC2=C([C@@H](C1C(=O)OC1CCCCC1)c1ccc(cc1)[N+]([O-])=O)C(=O)CC(C)(C)C2 |&1:5,r,c:3,t:1|, CC1=NC2=C([C@@H](C1C(=O)OC1CCCCC1)c1ccc(cc1)[N+]([O-])=O)C(=O)CC(C)(C)C2 |&1:5,r,c:3,t:1|, CC1=NC2=C([C@@H](C1C(=O)OC1CCCCC1)c1ccc(cc1)[N+]([O-])=O)C(=O)CC(C)(C)C2 |&1:5,r,c:3,t:1|, CC1=NC2=C([C@@H](C1C(=O)OC1CCCCC1)c1ccc(cc1)[N+]([O-])=O)C(=O)CC(C)(C)C2 |&1:5,r,c:3,t:1|	DUGBYNJMBYPWGS-FOIFJWKZSA-N, DUGBYNJMBYPWGS-FOIFJWKZSA-N, DUGBYNJMBYPWGS-FOIFJWKZSA-N, DUGBYNJMBYPWGS-FOIFJWKZSA-N, DUGBYNJMBYPWGS-FOIFJWKZSA-N, DUGBYNJMBYPWGS-FOIFJWKZSA-N, DUGBYNJMBYPWGS-FOIFJWKZSA-N, DUGBYNJMBYPWGS-FOIFJWKZSA-N	Preclinical
flibanserin	serotonin receptor agonist	DRD4, HTR1A, HTR2A	neurology/psychiatry	hypoactive sexual desire disorder	FC(F)(F)c1cccc(c1)N1CCN(CCn2c3ccccc3[nH]c2=O)CC1	PPRRDFIXUUSXRA-UHFFFAOYSA-N	Launched
flindokalner	potassium channel agonist	KCNMA1, KCNN4, KCNQ2, KCNQ4, KCNQ5			COc1ccc(Cl)cc1[C@]1(F)C(=O)Nc2cc(ccc12)C(F)(F)F, COc1ccc(Cl)cc1[C@]1(F)C(=O)Nc2cc(ccc12)C(F)(F)F, COc1ccc(Cl)cc1[C@]1(F)C(=O)Nc2cc(ccc12)C(F)(F)F	ULYONBAOIMCNEH-HNNXBMFYSA-N, ULYONBAOIMCNEH-HNNXBMFYSA-N, ULYONBAOIMCNEH-HNNXBMFYSA-N	Phase 3
floctafenine	cyclooxygenase inhibitor	PTGS1, PTGS2	neurology/psychiatry	pain relief	OC[C@@H](O)COC(=O)c1ccccc1Nc1ccnc2c(cccc12)C(F)(F)F |&1:2,r|, OC[C@@H](O)COC(=O)c1ccccc1Nc1ccnc2c(cccc12)C(F)(F)F |&1:2,r|, OC[C@@H](O)COC(=O)c1ccccc1Nc1ccnc2c(cccc12)C(F)(F)F |&1:2,r|	APQPGQGAWABJLN-GFCCVEGCSA-N, APQPGQGAWABJLN-GFCCVEGCSA-N, APQPGQGAWABJLN-GFCCVEGCSA-N	Launched
flopropione	serotonin receptor antagonist	HTR1A	neurology/psychiatry	spasms	CCC(=O)c1c(O)cc(O)cc1O, CCC(=O)c1c(O)cc(O)cc1O, CCC(=O)c1c(O)cc(O)cc1O, CCC(=O)c1c(O)cc(O)cc1O	PTHLEKANMPKYDB-UHFFFAOYSA-N, PTHLEKANMPKYDB-UHFFFAOYSA-N, PTHLEKANMPKYDB-UHFFFAOYSA-N, PTHLEKANMPKYDB-UHFFFAOYSA-N	Launched
florfenicol	protein synthesis inhibitor		pulmonary	bovine respiratory disease (BRD)	CS(=O)(=O)c1ccc(cc1)[C@@H](O)[C@@H](CF)NC(=O)C(Cl)Cl, CS(=O)(=O)c1ccc(cc1)[C@@H](O)[C@@H](CF)NC(=O)C(Cl)Cl, CS(=O)(=O)c1ccc(cc1)[C@@H](O)[C@@H](CF)NC(=O)C(Cl)Cl	AYIRNRDRBQJXIF-NXEZZACHSA-N, AYIRNRDRBQJXIF-NXEZZACHSA-N, AYIRNRDRBQJXIF-NXEZZACHSA-N	Launched
florifenine	anti-inflammatory agent				FC(F)(F)c1ccc2c(Nc3ccccc3C(=O)OCCN3CCCC3)ccnc2c1	DQOYUDHAZMAVLD-UHFFFAOYSA-N	Preclinical
flosequinan	phosphodiesterase inhibitor				Cn1cc([S@@](C)=O)c(=O)c2ccc(F)cc12 |r|	UYGONJYYUKVHDD-MRXNPFEDSA-N	Withdrawn
floxuridine	DNA synthesis inhibitor	TYMS	oncology	colorectal cancer	OC[C@H]1O[C@H](C[C@@H]1O)n1cc(F)c(=O)[nH]c1=O, OC[C@H]1O[C@H](C[C@@H]1O)n1cc(F)c(=O)[nH]c1=O, OC[C@H]1O[C@H](C[C@@H]1O)n1cc(F)c(=O)[nH]c1=O	ODKNJVUHOIMIIZ-RRKCRQDMSA-N, ODKNJVUHOIMIIZ-RRKCRQDMSA-N, ODKNJVUHOIMIIZ-RRKCRQDMSA-N	Launched
FLT3-IN-1	FLT3 inhibitor				CCCNc1nc(Nc2ccc(cc2)C#N)ncc1C#CCCCNC(=O)[C@H](C)N(C)C(=O)\C=C\CN(C)C	HJFSVYUFOXAVAA-YUAYGMJFSA-N	Preclinical
flubendazole	tubulin polymerization inhibitor	TUBB	infectious disease	gastrointestinal parasites	COC(=O)Nc1nc2ccc(cc2[nH]1)C(=O)c1ccc(F)cc1, COC(=O)Nc1nc2ccc(cc2[nH]1)C(=O)c1ccc(F)cc1, COC(=O)Nc1nc2ccc(cc2[nH]1)C(=O)c1ccc(F)cc1, COC(=O)Nc1nc2ccc(cc2[nH]1)C(=O)c1ccc(F)cc1, COC(=O)Nc1nc2ccc(cc2[nH]1)C(=O)c1ccc(F)cc1	CPEUVMUXAHMANV-UHFFFAOYSA-N, CPEUVMUXAHMANV-UHFFFAOYSA-N, CPEUVMUXAHMANV-UHFFFAOYSA-N, CPEUVMUXAHMANV-UHFFFAOYSA-N, CPEUVMUXAHMANV-UHFFFAOYSA-N	Launched
flucloxacillin	bacterial cell wall synthesis inhibitor		infectious disease, otolaryngology, dermatology, gastroenterology	gram-positive bacterial infections, tonsillitis, sinusitis, pneumonia, eczema, endocarditis, meningitis, enteritis, bacterial septicemia	Cc1onc(c1C(=O)N[C@H]1[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O)-c1c(F)cccc1Cl, Cc1onc(c1C(=O)N[C@H]1[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O)-c1c(F)cccc1Cl	UIOFUWFRIANQPC-JKIFEVAISA-N, UIOFUWFRIANQPC-JKIFEVAISA-N	Launched
fluconazole	sterol demethylase inhibitor	CYP51A1	infectious disease	esophageal candidiasis, meningitis	OC(Cn1cncn1)(Cn1cncn1)c1ccc(F)cc1F, OC(Cn1cncn1)(Cn1cncn1)c1ccc(F)cc1F, OC(Cn1cncn1)(Cn1cncn1)c1ccc(F)cc1F	RFHAOTPXVQNOHP-UHFFFAOYSA-N, RFHAOTPXVQNOHP-UHFFFAOYSA-N, RFHAOTPXVQNOHP-UHFFFAOYSA-N	Launched
flucytosine	other antifungal	DNMT1	infectious disease	bacterial septicemia, endocarditis, urinary tract infections, meningitis	Nc1nc(=O)[nH]cc1F, Nc1nc(=O)[nH]cc1F, Nc1nc(=O)[nH]cc1F, Nc1nc(=O)[nH]cc1F	XRECTZIEBJDKEO-UHFFFAOYSA-N, XRECTZIEBJDKEO-UHFFFAOYSA-N, XRECTZIEBJDKEO-UHFFFAOYSA-N, XRECTZIEBJDKEO-UHFFFAOYSA-N	Launched
fludarabine	ribonucleotide reductase inhibitor	ADA, DCK, POLA1, RRM1, RRM2	hematologic malignancy	chronic lymphocytic leukemia (CLL)	Nc1nc(F)nc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O, Nc1nc(F)nc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O, Nc1nc(F)nc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O, Nc1nc(F)nc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O, Nc1nc(F)nc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O, Nc1nc(F)nc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O	HBUBKKRHXORPQB-FJFJXFQQSA-N, HBUBKKRHXORPQB-FJFJXFQQSA-N, HBUBKKRHXORPQB-FJFJXFQQSA-N, HBUBKKRHXORPQB-FJFJXFQQSA-N, HBUBKKRHXORPQB-FJFJXFQQSA-N, HBUBKKRHXORPQB-FJFJXFQQSA-N	Launched
fludarabine-phosphate	ribonucleotide reductase inhibitor	POLA1, POLD1, POLE, RRM1, RRM2, RRM2B	hematologic malignancy	chronic lymphocytic leukemia (CLL)	Nc1nc(F)nc2n(cnc12)[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O, Nc1nc(F)nc2n(cnc12)[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O, Nc1nc(F)nc2n(cnc12)[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O, Nc1nc(F)nc2n(cnc12)[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O	GIUYCYHIANZCFB-FJFJXFQQSA-N, GIUYCYHIANZCFB-FJFJXFQQSA-N, GIUYCYHIANZCFB-FJFJXFQQSA-N, GIUYCYHIANZCFB-FJFJXFQQSA-N	Launched
fludrocortisone-acetate		NR3C2	endocrinology	Addison's disease, adrenogenital syndrome	CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C |t:15|, CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C |t:15|, CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C |t:15|, CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C |t:15|, CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C |t:15|	SYWHXTATXSMDSB-GSLJADNHSA-N, SYWHXTATXSMDSB-GSLJADNHSA-N, SYWHXTATXSMDSB-GSLJADNHSA-N, SYWHXTATXSMDSB-GSLJADNHSA-N, SYWHXTATXSMDSB-GSLJADNHSA-N	Launched
fludroxycortide	glucocorticoid receptor agonist	NR3C1, SERPINA6	infectious disease, dermatology	skin infections, psoriasis	CC1(C)O[C@@H]2C[C@H]3[C@@H]4C[C@H](F)C5=CC(=O)CC[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO |t:11|	POPFMWWJOGLOIF-XWCQMRHXSA-N	Launched
flufenamic-acid	chloride channel blocker	AKR1C3, ANO1, AR, GJA1, GJA10, GJA3, GJA4, GJA5, GJA8, GJA9, GJB1, GJB2, GJB3, GJB4, GJB5, GJB6, GJB7, GJC1, GJC2, GJC3, GJD2, GJD3, GJD4, GJE1, PANX1, PANX2, PANX3, PKD2L1, PTGS1, PTGS2, TRPC5, TRPM2, TRPM5			OC(=O)c1ccccc1Nc1cccc(c1)C(F)(F)F, OC(=O)c1ccccc1Nc1cccc(c1)C(F)(F)F	LPEPZBJOKDYZAD-UHFFFAOYSA-N, LPEPZBJOKDYZAD-UHFFFAOYSA-N	Preclinical
flumatinib	Bcr-Abl kinase inhibitor	ABL1, PDGFRB			CN1CCN(Cc2ccc(cc2C(F)(F)F)C(=O)Nc2cnc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2C(F)(F)F)C(=O)Nc2cnc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2C(F)(F)F)C(=O)Nc2cnc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2C(F)(F)F)C(=O)Nc2cnc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2C(F)(F)F)C(=O)Nc2cnc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2C(F)(F)F)C(=O)Nc2cnc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1	BJCJYEYYYGBROF-UHFFFAOYSA-N, BJCJYEYYYGBROF-UHFFFAOYSA-N, BJCJYEYYYGBROF-UHFFFAOYSA-N, BJCJYEYYYGBROF-UHFFFAOYSA-N, BJCJYEYYYGBROF-UHFFFAOYSA-N, BJCJYEYYYGBROF-UHFFFAOYSA-N	Phase 3
flumazenil	benzodiazepine receptor antagonist	GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ	neurology/psychiatry	sedative	CCOC(=O)c1ncn-2c1CN(C)C(=O)c1cc(F)ccc-21, CCOC(=O)c1ncn-2c1CN(C)C(=O)c1cc(F)ccc-21, CCOC(=O)c1ncn-2c1CN(C)C(=O)c1cc(F)ccc-21, CCOC(=O)c1ncn-2c1CN(C)C(=O)c1cc(F)ccc-21, CCOC(=O)c1ncn-2c1CN(C)C(=O)c1cc(F)ccc-21	OFBIFZUFASYYRE-UHFFFAOYSA-N, OFBIFZUFASYYRE-UHFFFAOYSA-N, OFBIFZUFASYYRE-UHFFFAOYSA-N, OFBIFZUFASYYRE-UHFFFAOYSA-N, OFBIFZUFASYYRE-UHFFFAOYSA-N	Launched
flumecinol					CC[C@@](O)(c1ccccc1)c1cccc(c1)C(F)(F)F |&1:2,r|	DVASNQYQOZHAJN-OAHLLOKOSA-N	Launched
flumequine	topoisomerase inhibitor		infectious disease	urinary tract infections	C[C@H]1CCc2cc(F)cc3c2n1cc(C(O)=O)c3=O |&1:1,r|, C[C@H]1CCc2cc(F)cc3c2n1cc(C(O)=O)c3=O |&1:1,r|, C[C@H]1CCc2cc(F)cc3c2n1cc(C(O)=O)c3=O |&1:1,r|, C[C@H]1CCc2cc(F)cc3c2n1cc(C(O)=O)c3=O |&1:1,r|, C[C@H]1CCc2cc(F)cc3c2n1cc(C(O)=O)c3=O |&1:1,r|	DPSPPJIUMHPXMA-ZETCQYMHSA-N, DPSPPJIUMHPXMA-ZETCQYMHSA-N, DPSPPJIUMHPXMA-ZETCQYMHSA-N, DPSPPJIUMHPXMA-ZETCQYMHSA-N, DPSPPJIUMHPXMA-ZETCQYMHSA-N	Launched
flumethasone	glucocorticoid receptor agonist	NR3C1, PLA2G1B	otolaryngology, infectious disease, dermatology	otitis, ear infections, corticosteroid-responsive dermatoses	C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO |c:12,t:8|, C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO |c:12,t:8|, C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO |c:12,t:8|, C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO |c:12,t:8|, C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO |c:12,t:8|, C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO |c:12,t:8|	WXURHACBFYSXBI-GQKYHHCASA-N, WXURHACBFYSXBI-GQKYHHCASA-N, WXURHACBFYSXBI-GQKYHHCASA-N, WXURHACBFYSXBI-GQKYHHCASA-N, WXURHACBFYSXBI-GQKYHHCASA-N, WXURHACBFYSXBI-GQKYHHCASA-N	Launched
flumethasone-pivalate	glucocorticoid receptor agonist	NR3C1, SERPINA6	allergy	allergic rhinitis	C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)COC(=O)C(C)(C)C |c:12,t:8|	JWRMHDSINXPDHB-OJAGFMMFSA-N	Launched
flumexadol					FC(F)(F)c1cccc(c1)[C@H]1CNCCO1 |&1:10,r|, FC(F)(F)c1cccc(c1)[C@H]1CNCCO1 |&1:10,r|	GXPYCYWPUGKQIJ-SNVBAGLBSA-N, GXPYCYWPUGKQIJ-SNVBAGLBSA-N	Preclinical
flunarizine	calcium channel blocker	CACNA1G, CACNA1H, CACNA1I, CALM1, HRH1	neurology/psychiatry, cardiology	migraine headache, vertigo, peripheral artery disease (PAD)	Fc1ccc(cc1)C(N1CCN(C\C=C\c2ccccc2)CC1)c1ccc(F)cc1, Fc1ccc(cc1)C(N1CCN(C\C=C\c2ccccc2)CC1)c1ccc(F)cc1, Fc1ccc(cc1)C(N1CCN(C\C=C\c2ccccc2)CC1)c1ccc(F)cc1, Fc1ccc(cc1)C(N1CCN(C\C=C\c2ccccc2)CC1)c1ccc(F)cc1, Fc1ccc(cc1)C(N1CCN(C\C=C\c2ccccc2)CC1)c1ccc(F)cc1, Fc1ccc(cc1)C(N1CCN(C\C=C\c2ccccc2)CC1)c1ccc(F)cc1, Fc1ccc(cc1)C(N1CCN(C\C=C\c2ccccc2)CC1)c1ccc(F)cc1, Fc1ccc(cc1)C(N1CCN(C\C=C\c2ccccc2)CC1)c1ccc(F)cc1	SMANXXCATUTDDT-QPJJXVBHSA-N, SMANXXCATUTDDT-QPJJXVBHSA-N, SMANXXCATUTDDT-QPJJXVBHSA-N, SMANXXCATUTDDT-QPJJXVBHSA-N, SMANXXCATUTDDT-QPJJXVBHSA-N, SMANXXCATUTDDT-QPJJXVBHSA-N, SMANXXCATUTDDT-QPJJXVBHSA-N, SMANXXCATUTDDT-QPJJXVBHSA-N	Launched
flunisolide	cytochrome P450 inhibitor	NR3C1	allergy	allergic rhinitis	CC1(C)O[C@@H]2C[C@H]3[C@@H]4C[C@H](F)C5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO |c:15,t:11|	XSFJVAJPIHIPKU-XWCQMRHXSA-N	Launched
flunixin-meglumin	prostanoid receptor antagonist		pulmonary	bovine respiratory disease (BRD)	Cc1c(Nc2ncccc2C(O)=O)cccc1C(F)(F)F, Cc1c(Nc2ncccc2C(O)=O)cccc1C(F)(F)F, Cc1c(Nc2ncccc2C(O)=O)cccc1C(F)(F)F	NOOCSNJCXJYGPE-UHFFFAOYSA-N, NOOCSNJCXJYGPE-UHFFFAOYSA-N, NOOCSNJCXJYGPE-UHFFFAOYSA-N	Launched
fluocinolone-acetonide	glucocorticoid receptor agonist	NR3C1, SERPINA6	dermatology	seborrheic dermatitis	CC1(C)O[C@@H]2C[C@H]3[C@@H]4C[C@H](F)C5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO |c:15,t:11|, CC1(C)O[C@@H]2C[C@H]3[C@@H]4C[C@H](F)C5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO |c:15,t:11|, CC1(C)O[C@@H]2C[C@H]3[C@@H]4C[C@H](F)C5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO |c:15,t:11|, CC1(C)O[C@@H]2C[C@H]3[C@@H]4C[C@H](F)C5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO |c:15,t:11|, CC1(C)O[C@@H]2C[C@H]3[C@@H]4C[C@H](F)C5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO |c:15,t:11|	FEBLZLNTKCEFIT-VSXGLTOVSA-N, FEBLZLNTKCEFIT-VSXGLTOVSA-N, FEBLZLNTKCEFIT-VSXGLTOVSA-N, FEBLZLNTKCEFIT-VSXGLTOVSA-N, FEBLZLNTKCEFIT-VSXGLTOVSA-N	Launched
fluocinonide	glucocorticoid receptor agonist	NR3C1, SERPINA6, SMO	dermatology	seborrheic dermatitis, eczema	CC(=O)OCC(=O)[C@@]12OC(C)(C)O[C@@H]1C[C@H]1[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]21C |c:25,t:21|, CC(=O)OCC(=O)[C@@]12OC(C)(C)O[C@@H]1C[C@H]1[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]21C |c:25,t:21|, CC(=O)OCC(=O)[C@@]12OC(C)(C)O[C@@H]1C[C@H]1[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]21C |c:25,t:21|, CC(=O)OCC(=O)[C@@]12OC(C)(C)O[C@@H]1C[C@H]1[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]21C |c:25,t:21|, CC(=O)OCC(=O)[C@@]12OC(C)(C)O[C@@H]1C[C@H]1[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]21C |c:25,t:21|, CC(=O)OCC(=O)[C@@]12OC(C)(C)O[C@@H]1C[C@H]1[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]21C |c:25,t:21|, CC(=O)OCC(=O)[C@@]12OC(C)(C)O[C@@H]1C[C@H]1[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]21C |c:25,t:21|	WJOHZNCJWYWUJD-IUGZLZTKSA-N, WJOHZNCJWYWUJD-IUGZLZTKSA-N, WJOHZNCJWYWUJD-IUGZLZTKSA-N, WJOHZNCJWYWUJD-IUGZLZTKSA-N, WJOHZNCJWYWUJD-IUGZLZTKSA-N, WJOHZNCJWYWUJD-IUGZLZTKSA-N, WJOHZNCJWYWUJD-IUGZLZTKSA-N	Launched
fluorescein		SLC22A6	ophthalmology	ophthalmology diagnostic	Oc1ccc2c(Oc3cc(O)ccc3C22OC(=O)c3ccccc23)c1, Oc1ccc2c(Oc3cc(O)ccc3C22OC(=O)c3ccccc23)c1	GNBHRKFJIUUOQI-UHFFFAOYSA-N, GNBHRKFJIUUOQI-UHFFFAOYSA-N	Launched
fluorometholone	glucocorticoid receptor agonist	NR3C1	ophthalmology	eye inflammation			Launched
fluorometholone-acetate		NR3C1	ophthalmology	eye inflammation	C[C@H]1C[C@H]2[C@@H]3CC[C@](OC(C)=O)(C(C)=O)[C@@]3(C)C[C@H](O)[C@]2(F)[C@@]2(C)C=CC(=O)C=C12 |c:26,t:30|, C[C@H]1C[C@H]2[C@@H]3CC[C@](OC(C)=O)(C(C)=O)[C@@]3(C)C[C@H](O)[C@]2(F)[C@@]2(C)C=CC(=O)C=C12 |c:26,t:30|, C[C@H]1C[C@H]2[C@@H]3CC[C@](OC(C)=O)(C(C)=O)[C@@]3(C)C[C@H](O)[C@]2(F)[C@@]2(C)C=CC(=O)C=C12 |c:26,t:30|, C[C@H]1C[C@H]2[C@@H]3CC[C@](OC(C)=O)(C(C)=O)[C@@]3(C)C[C@H](O)[C@]2(F)[C@@]2(C)C=CC(=O)C=C12 |c:26,t:30|	YRFXGQHBPBMFHW-SBTZIJSASA-N, YRFXGQHBPBMFHW-SBTZIJSASA-N, YRFXGQHBPBMFHW-SBTZIJSASA-N, YRFXGQHBPBMFHW-SBTZIJSASA-N	Launched
fluoromethylcholine					C[N+](C)(CF)CCO	PBVFROWIWWGIFK-UHFFFAOYSA-N	Launched
fluoxetine	selective serotonin reuptake inhibitor (SSRI)	ANO1, HTR2B, SLC6A4	neurology/psychiatry	depression, obsessive compulsive disorder (OCD), bulimia nervosa, panic disorders, bipolar disorder	CNCCC(Oc1ccc(cc1)C(F)(F)F)c1ccccc1, CNCCC(Oc1ccc(cc1)C(F)(F)F)c1ccccc1, CNCCC(Oc1ccc(cc1)C(F)(F)F)c1ccccc1, CNCCC(Oc1ccc(cc1)C(F)(F)F)c1ccccc1	RTHCYVBBDHJXIQ-UHFFFAOYSA-N, RTHCYVBBDHJXIQ-UHFFFAOYSA-N, RTHCYVBBDHJXIQ-UHFFFAOYSA-N, RTHCYVBBDHJXIQ-UHFFFAOYSA-N	Launched
flupentixol	dopamine receptor antagonist	ADRA1A, CHRM1, DRD1, DRD2, DRD3, DRD5, HTR2A	neurology/psychiatry	schizophrenia, depression	OCCN1CCN(CC\C=C2\c3ccccc3Sc3ccc(cc23)C(F)(F)F)CC1, OCCN1CCN(CC\C=C2\c3ccccc3Sc3ccc(cc23)C(F)(F)F)CC1	NJMYODHXAKYRHW-DVZOWYKESA-N, NJMYODHXAKYRHW-DVZOWYKESA-N	Launched
fluphenazine	dopamine receptor antagonist	CALM1, DRD1, DRD2, DRD5, HRH1, HTR2A, HTR6, HTR7	neurology/psychiatry	schizophrenia	OCCN1CCN(CCCN2c3ccccc3Sc3ccc(cc23)C(F)(F)F)CC1, OCCN1CCN(CCCN2c3ccccc3Sc3ccc(cc23)C(F)(F)F)CC1, OCCN1CCN(CCCN2c3ccccc3Sc3ccc(cc23)C(F)(F)F)CC1	PLDUPXSUYLZYBN-UHFFFAOYSA-N, PLDUPXSUYLZYBN-UHFFFAOYSA-N, PLDUPXSUYLZYBN-UHFFFAOYSA-N	Launched
fluphenazine-decanoate	dopamine receptor antagonist	DRD2, HTR1B, HTR4	neurology/psychiatry	schizophrenia	CCCCCCCCCC(=O)OCCN1CCN(CCCN2c3ccccc3Sc3ccc(cc23)C(F)(F)F)CC1	VIQCGTZFEYDQMR-UHFFFAOYSA-N	Launched
flupirtine	glutamate receptor antagonist	ADRA2A, KCNQ1, KCNQ2	neurology/psychiatry	pain relief	CCOC(=O)Nc1ccc(NCc2ccc(F)cc2)nc1N, CCOC(=O)Nc1ccc(NCc2ccc(F)cc2)nc1N, CCOC(=O)Nc1ccc(NCc2ccc(F)cc2)nc1N, CCOC(=O)Nc1ccc(NCc2ccc(F)cc2)nc1N, CCOC(=O)Nc1ccc(NCc2ccc(F)cc2)nc1N, CCOC(=O)Nc1ccc(NCc2ccc(F)cc2)nc1N	JUUFBMODXQKSTD-UHFFFAOYSA-N, JUUFBMODXQKSTD-UHFFFAOYSA-N, JUUFBMODXQKSTD-UHFFFAOYSA-N, JUUFBMODXQKSTD-UHFFFAOYSA-N, JUUFBMODXQKSTD-UHFFFAOYSA-N, JUUFBMODXQKSTD-UHFFFAOYSA-N	Launched
fluprazine	serotonin receptor agonist	HTR1A, HTR1B			NC(=O)NCCN1CCN(CC1)c1cccc(c1)C(F)(F)F, NC(=O)NCCN1CCN(CC1)c1cccc(c1)C(F)(F)F	CHQKHXJPWDSTPY-UHFFFAOYSA-N, CHQKHXJPWDSTPY-UHFFFAOYSA-N	Phase 1
fluralaner	GABA receptor antagonist				Cc1cc(ccc1C(=O)NCC(=O)NCC(F)(F)F)C1=NO[C@](C1)(c1cc(Cl)cc(Cl)c1)C(F)(F)F |&1:22,r,t:20|	MLBZKOGAMRTSKP-HXUWFJFHSA-N	Preclinical
flurbiprofen-(+/-)	cyclooxygenase inhibitor		rheumatology	rheumatoid arthritis, osteoarthritis	C[C@@H](C(O)=O)c1ccc(c(F)c1)-c1ccccc1 |&1:1,r|, C[C@@H](C(O)=O)c1ccc(c(F)c1)-c1ccccc1 |&1:1,r|, C[C@@H](C(O)=O)c1ccc(c(F)c1)-c1ccccc1 |&1:1,r|	SYTBZMRGLBWNTM-SNVBAGLBSA-N, SYTBZMRGLBWNTM-SNVBAGLBSA-N, SYTBZMRGLBWNTM-SNVBAGLBSA-N	Launched
flurbiprofen-(S)-(+)	cyclooxygenase inhibitor	PTGS1, PTGS2	rheumatology	rheumatoid arthritis, osteoarthritis	C[C@H](C(O)=O)c1ccc(c(F)c1)-c1ccccc1, C[C@H](C(O)=O)c1ccc(c(F)c1)-c1ccccc1	SYTBZMRGLBWNTM-JTQLQIEISA-N, SYTBZMRGLBWNTM-JTQLQIEISA-N	Launched
flurbiprofen-axetil	analgesic agent				C[C@H](OC(C)=O)OC(=O)[C@H](C)c1ccc(c(F)c1)-c1ccccc1 |&1:9,&2:1,r|	ALIVXCSEERJYHU-TZMCWYRMSA-N	Launched
flurizan	gamma secretase inhibitor	APH1B, BACE1, IKBKG, PSEN1, PSEN2, PTGS1, PTGS2			C[C@@H](C(O)=O)c1ccc(c(F)c1)-c1ccccc1, C[C@@H](C(O)=O)c1ccc(c(F)c1)-c1ccccc1, C[C@@H](C(O)=O)c1ccc(c(F)c1)-c1ccccc1, C[C@@H](C(O)=O)c1ccc(c(F)c1)-c1ccccc1	SYTBZMRGLBWNTM-SNVBAGLBSA-N, SYTBZMRGLBWNTM-SNVBAGLBSA-N, SYTBZMRGLBWNTM-SNVBAGLBSA-N, SYTBZMRGLBWNTM-SNVBAGLBSA-N	Phase 3
flurofamide	urease inhibitor				NP(N)(=O)NC(=O)c1ccc(F)cc1, NP(N)(=O)NC(=O)c1ccc(F)cc1, NP(N)(=O)NC(=O)c1ccc(F)cc1	QWZFVMCWPLMLTL-UHFFFAOYSA-N, QWZFVMCWPLMLTL-UHFFFAOYSA-N, QWZFVMCWPLMLTL-UHFFFAOYSA-N	Preclinical
flurothyl					FC(F)(F)COCC(F)(F)F, FC(F)(F)COCC(F)(F)F, FC(F)(F)COCC(F)(F)F	KGPPDNUWZNWPSI-UHFFFAOYSA-N, KGPPDNUWZNWPSI-UHFFFAOYSA-N, KGPPDNUWZNWPSI-UHFFFAOYSA-N	Preclinical
fluroxene	local anesthetic				FC(F)(F)COC=C, FC(F)(F)COC=C	DLEGDLSLRSOURQ-UHFFFAOYSA-N, DLEGDLSLRSOURQ-UHFFFAOYSA-N	Preclinical
fluspirilene	dopamine receptor antagonist	CACNG1, DRD2, HRH1, HTR1A, HTR1D, HTR1E, HTR2A	neurology/psychiatry	schizophrenia	Fc1ccc(cc1)C(CCCN1CCC2(CC1)N(CNC2=O)c1ccccc1)c1ccc(F)cc1, Fc1ccc(cc1)C(CCCN1CCC2(CC1)N(CNC2=O)c1ccccc1)c1ccc(F)cc1, Fc1ccc(cc1)C(CCCN1CCC2(CC1)N(CNC2=O)c1ccccc1)c1ccc(F)cc1, Fc1ccc(cc1)C(CCCN1CCC2(CC1)N(CNC2=O)c1ccccc1)c1ccc(F)cc1	QOYHHIBFXOOADH-UHFFFAOYSA-N, QOYHHIBFXOOADH-UHFFFAOYSA-N, QOYHHIBFXOOADH-UHFFFAOYSA-N, QOYHHIBFXOOADH-UHFFFAOYSA-N	Launched
flutamide	androgen receptor antagonist	AHR, AR	oncology	prostate cancer	CC(C)C(=O)Nc1ccc(c(c1)C(F)(F)F)[N+]([O-])=O, CC(C)C(=O)Nc1ccc(c(c1)C(F)(F)F)[N+]([O-])=O, CC(C)C(=O)Nc1ccc(c(c1)C(F)(F)F)[N+]([O-])=O	MKXKFYHWDHIYRV-UHFFFAOYSA-N, MKXKFYHWDHIYRV-UHFFFAOYSA-N, MKXKFYHWDHIYRV-UHFFFAOYSA-N	Launched
fluticasone-propionate	glucocorticoid receptor agonist	NR3C1, NR3C2, PGR, PLA2G4A	dermatology	corticosteroid-responsive dermatoses	CCC(=O)O[C@@]1([C@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)SCF |c:18,t:14|, CCC(=O)O[C@@]1([C@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)SCF |c:18,t:14|, CCC(=O)O[C@@]1([C@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)SCF |c:18,t:14|, CCC(=O)O[C@@]1([C@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)SCF |c:18,t:14|, CCC(=O)O[C@@]1([C@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)SCF |c:18,t:14|, CCC(=O)O[C@@]1([C@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)SCF |c:18,t:14|	WMWTYOKRWGGJOA-CENSZEJFSA-N, WMWTYOKRWGGJOA-CENSZEJFSA-N, WMWTYOKRWGGJOA-CENSZEJFSA-N, WMWTYOKRWGGJOA-CENSZEJFSA-N, WMWTYOKRWGGJOA-CENSZEJFSA-N, WMWTYOKRWGGJOA-CENSZEJFSA-N	Launched
flutrimazole	sterol demethylase inhibitor		infectious disease	mycosis	Fc1ccc(cc1)C(c1ccccc1)(c1ccccc1F)n1ccnc1 |&1:7|	QHMWCHQXCUNUAK-UHFFFAOYSA-N	Launched
fluvastatin	HMGCR inhibitor	HMGCR	endocrinology, cardiology	hypercholesterolemia, congenital heart defects	CC(C)n1c(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)c(-c2ccc(F)cc2)c2ccccc12, CC(C)n1c(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)c(-c2ccc(F)cc2)c2ccccc12, CC(C)n1c(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)c(-c2ccc(F)cc2)c2ccccc12, CC(C)n1c(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)c(-c2ccc(F)cc2)c2ccccc12, CC(C)n1c(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)c(-c2ccc(F)cc2)c2ccccc12, CC(C)n1c(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)c(-c2ccc(F)cc2)c2ccccc12, CC(C)n1c(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)c(-c2ccc(F)cc2)c2ccccc12, CC(C)n1c(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)c(-c2ccc(F)cc2)c2ccccc12, CC(C)n1c(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)c(-c2ccc(F)cc2)c2ccccc12, CC(C)n1c(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)c(-c2ccc(F)cc2)c2ccccc12	FJLGEFLZQAZZCD-MCBHFWOFSA-N, FJLGEFLZQAZZCD-MCBHFWOFSA-N, FJLGEFLZQAZZCD-MCBHFWOFSA-N, FJLGEFLZQAZZCD-MCBHFWOFSA-N, FJLGEFLZQAZZCD-MCBHFWOFSA-N, FJLGEFLZQAZZCD-MCBHFWOFSA-N, FJLGEFLZQAZZCD-MCBHFWOFSA-N, FJLGEFLZQAZZCD-MCBHFWOFSA-N, FJLGEFLZQAZZCD-MCBHFWOFSA-N, FJLGEFLZQAZZCD-MCBHFWOFSA-N	Launched
fluvoxamine	selective serotonin reuptake inhibitor (SSRI)	SLC6A4	neurology/psychiatry	obsessive compulsive disorder (OCD)	COCCCC\C(=N/OCCN)c1ccc(cc1)C(F)(F)F, COCCCC\C(=N/OCCN)c1ccc(cc1)C(F)(F)F, COCCCC\C(=N/OCCN)c1ccc(cc1)C(F)(F)F, COCCCC\C(=N/OCCN)c1ccc(cc1)C(F)(F)F, COCCCC\C(=N/OCCN)c1ccc(cc1)C(F)(F)F	CJOFXWAVKWHTFT-XSFVSMFZSA-N, CJOFXWAVKWHTFT-XSFVSMFZSA-N, CJOFXWAVKWHTFT-XSFVSMFZSA-N, CJOFXWAVKWHTFT-XSFVSMFZSA-N, CJOFXWAVKWHTFT-XSFVSMFZSA-N	Launched
fmoc-L-leucine	PPAR receptor agonist				CC(C)C[C@H](NC(=O)OCC1c2ccccc2-c2ccccc12)C(O)=O, CC(C)C[C@H](NC(=O)OCC1c2ccccc2-c2ccccc12)C(O)=O	CBPJQFCAFFNICX-IBGZPJMESA-N, CBPJQFCAFFNICX-IBGZPJMESA-N	Phase 2
FN-1501	tyrosine kinase inhibitor				CN1CCN(Cc2ccc(NC(=O)c3[nH]ncc3Nc3ncnc4[nH]ccc34)cc2)CC1, CN1CCN(Cc2ccc(NC(=O)c3[nH]ncc3Nc3ncnc4[nH]ccc34)cc2)CC1	VXLAKHWYGRKCGI-UHFFFAOYSA-N, VXLAKHWYGRKCGI-UHFFFAOYSA-N	Phase 1
folic-acid	folate receptor ligand	FOLR2, FOLR3, SLC19A1, SLC46A1	hematology	megaloblastic anemia	Nc1nc(=O)c2nc(CNc3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)cnc2[nH]1	OVBPIULPVIDEAO-LBPRGKRZSA-N	Launched
fomepizole	alcohol dehydrogenase inhibitor	ADH1A, ADH1B, ADH1C, AKR1A1, CAT	critical care	poison antidote	Cc1cn[nH]c1, Cc1cn[nH]c1, Cc1cn[nH]c1, Cc1cn[nH]c1, Cc1cn[nH]c1	RIKMMFOAQPJVMX-UHFFFAOYSA-N, RIKMMFOAQPJVMX-UHFFFAOYSA-N, RIKMMFOAQPJVMX-UHFFFAOYSA-N, RIKMMFOAQPJVMX-UHFFFAOYSA-N, RIKMMFOAQPJVMX-UHFFFAOYSA-N	Launched
fomocaine	voltage-gated sodium channel modulator		neurology/psychiatry	local anesthetic	C(CN1CCOCC1)Cc1ccc(COc2ccccc2)cc1, C(CN1CCOCC1)Cc1ccc(COc2ccccc2)cc1	CVHGCWVMTZWGAY-UHFFFAOYSA-N, CVHGCWVMTZWGAY-UHFFFAOYSA-N	Launched
fondaparinux	coagulation factor inhibitor	F10, SERPINC1	hematology	deep vein thrombosis (DVT)	[H][C@@]1(O[C@@H]2[C@@H](COS(O)(=O)=O)O[C@H](O[C@@]3([H])[C@H](O)[C@@H](OS(O)(=O)=O)[C@H](O[C@@]4([H])[C@H](O)[C@@H](NS(O)(=O)=O)[C@@H](OC)O[C@@H]4COS(O)(=O)=O)O[C@H]3C(O)=O)[C@H](NS(O)(=O)=O)[C@H]2OS(O)(=O)=O)O[C@@H]([C@@H](O[C@@]2([H])O[C@H](COS(O)(=O)=O)[C@@H](O)[C@H](O)[C@H]2NS(O)(=O)=O)[C@H](O)[C@H]1O)C(O)=O	KANJSNBRCNMZMV-ABRZTLGGSA-N	Launched
foretinib	VEGFR inhibitor	FLT1, FLT4, KDR, MET			COc1cc2c(Oc3ccc(NC(=O)C4(CC4)C(=O)Nc4ccc(F)cc4)cc3F)ccnc2cc1OCCCN1CCOCC1, COc1cc2c(Oc3ccc(NC(=O)C4(CC4)C(=O)Nc4ccc(F)cc4)cc3F)ccnc2cc1OCCCN1CCOCC1, COc1cc2c(Oc3ccc(NC(=O)C4(CC4)C(=O)Nc4ccc(F)cc4)cc3F)ccnc2cc1OCCCN1CCOCC1, COc1cc2c(Oc3ccc(NC(=O)C4(CC4)C(=O)Nc4ccc(F)cc4)cc3F)ccnc2cc1OCCCN1CCOCC1, COc1cc2c(Oc3ccc(NC(=O)C4(CC4)C(=O)Nc4ccc(F)cc4)cc3F)ccnc2cc1OCCCN1CCOCC1, COc1cc2c(Oc3ccc(NC(=O)C4(CC4)C(=O)Nc4ccc(F)cc4)cc3F)ccnc2cc1OCCCN1CCOCC1, COc1cc2c(Oc3ccc(NC(=O)C4(CC4)C(=O)Nc4ccc(F)cc4)cc3F)ccnc2cc1OCCCN1CCOCC1	CXQHYVUVSFXTMY-UHFFFAOYSA-N, CXQHYVUVSFXTMY-UHFFFAOYSA-N, CXQHYVUVSFXTMY-UHFFFAOYSA-N, CXQHYVUVSFXTMY-UHFFFAOYSA-N, CXQHYVUVSFXTMY-UHFFFAOYSA-N, InChI=1S/C34H34F2N4O6/c1-43-30-20-25-27(21-31(30)45-16-2-13-40-14-17-44-18-15-40)37-12-9-28(25)46-29-8-7-24(19-26(29)36)39-33(42)34(10-11-34)32(41)38-23-5-3-22(35)4-6-23/h3-9,12,19-21H,2,10-11,13-18H2,1H3,(H,38,41)(H,39,42), InChI=1S/C34H34F2N4O6/c1-43-30-20-25-27(21-31(30)45-16-2-13-40-14-17-44-18-15-40)37-12-9-28(25)46-29-8-7-24(19-26(29)36)39-33(42)34(10-11-34)32(41)38-23-5-3-22(35)4-6-23/h3-9,12,19-21H,2,10-11,13-18H2,1H3,(H,38,41)(H,39,42)	Phase 2
formestane	aromatase inhibitor	CYP19A1	oncology	breast cancer	C[C@]12CC[C@H]3[C@@H](CC[C@H]4C(=O)C(=O)CC[C@]34C)[C@@H]1CCC2=O |a:1,4,5,15,17,&1:8|, C[C@]12CC[C@H]3[C@@H](CC[C@H]4C(=O)C(=O)CC[C@]34C)[C@@H]1CCC2=O |a:1,4,5,15,17,&1:8|, C[C@]12CC[C@H]3[C@@H](CC[C@H]4C(=O)C(=O)CC[C@]34C)[C@@H]1CCC2=O |a:1,4,5,15,17,&1:8|, C[C@]12CC[C@H]3[C@@H](CC[C@H]4C(=O)C(=O)CC[C@]34C)[C@@H]1CCC2=O |a:1,4,5,15,17,&1:8|	ZMEULISFKSVRLQ-LZBOESDWSA-N, ZMEULISFKSVRLQ-LZBOESDWSA-N, ZMEULISFKSVRLQ-LZBOESDWSA-N, ZMEULISFKSVRLQ-LZBOESDWSA-N	Launched
formononetin	alcohol dehydrogenase inhibitor	ADH1C, SLC5A2			COc1ccc(cc1)-c1coc2cc(O)ccc2c1=O, COc1ccc(cc1)-c1coc2cc(O)ccc2c1=O, COc1ccc(cc1)-c1coc2cc(O)ccc2c1=O	HKQYGTCOTHHOMP-UHFFFAOYSA-N, HKQYGTCOTHHOMP-UHFFFAOYSA-N, HKQYGTCOTHHOMP-UHFFFAOYSA-N	Preclinical
formoterol	adrenergic receptor agonist	ADRB2	pulmonary	asthma, chronic obstructive pulmonary disease (COPD), bronchospasm	COc1ccc(C[C@H](C)NC[C@@H](O)c2ccc(O)c(NC=O)c2)cc1, COc1ccc(C[C@H](C)NC[C@@H](O)c2ccc(O)c(NC=O)c2)cc1, COc1ccc(C[C@H](C)NC[C@@H](O)c2ccc(O)c(NC=O)c2)cc1, COc1ccc(C[C@H](C)NC[C@@H](O)c2ccc(O)c(NC=O)c2)cc1, COc1ccc(C[C@H](C)NC[C@@H](O)c2ccc(O)c(NC=O)c2)cc1, COc1ccc(C[C@H](C)NC[C@@H](O)c2ccc(O)c(NC=O)c2)cc1, COc1ccc(C[C@H](C)NC[C@@H](O)c2ccc(O)c(NC=O)c2)cc1	BPZSYCZIITTYBL-ORAYPTAESA-N, BPZSYCZIITTYBL-ORAYPTAESA-N, BPZSYCZIITTYBL-ORAYPTAESA-N, BPZSYCZIITTYBL-ORAYPTAESA-N, BPZSYCZIITTYBL-ORAYPTAESA-N, BPZSYCZIITTYBL-ORAYPTAESA-N, BPZSYCZIITTYBL-ORAYPTAESA-N	Launched
forodesine	purinergic receptor antagonist	PNP	hematologic malignancy	peripheral T-cell lymphoma (PTCL)	OC[C@H]1N[C@H]([C@H](O)[C@@H]1O)c1c[nH]c2c1[nH]cnc2=O, OC[C@H]1N[C@H]([C@H](O)[C@@H]1O)c1c[nH]c2c1[nH]cnc2=O, OC[C@H]1N[C@H]([C@H](O)[C@@H]1O)c1c[nH]c2c1[nH]cnc2=O, OC[C@H]1N[C@H]([C@H](O)[C@@H]1O)c1c[nH]c2c1[nH]cnc2=O	IWKXDMQDITUYRK-KUBHLMPHSA-N, IWKXDMQDITUYRK-KUBHLMPHSA-N, IWKXDMQDITUYRK-KUBHLMPHSA-N, IWKXDMQDITUYRK-KUBHLMPHSA-N	Launched
foropafant	platelet activating factor receptor antagonist	PTAFR			CC(C)c1cc(C(C)C)c(-c2csc(n2)N(CCN(C)C)Cc2cccnc2)c(c1)C(C)C, CC(C)c1cc(C(C)C)c(-c2csc(n2)N(CCN(C)C)Cc2cccnc2)c(c1)C(C)C, CC(C)c1cc(C(C)C)c(-c2csc(n2)N(CCN(C)C)Cc2cccnc2)c(c1)C(C)C	VVBFISAUNSXQGZ-UHFFFAOYSA-N, VVBFISAUNSXQGZ-UHFFFAOYSA-N, VVBFISAUNSXQGZ-UHFFFAOYSA-N	Phase 3
forskolin	adenylyl cyclase activator	ADCY2, ADCY5, GNAS			CC(=O)O[C@H]1[C@@H](O)[C@H]2C(C)(C)CC[C@H](O)[C@]2(C)[C@@]2(O)C(=O)C[C@@](C)(O[C@]12C)C=C, CC(=O)O[C@H]1[C@@H](O)[C@H]2C(C)(C)CC[C@H](O)[C@]2(C)[C@@]2(O)C(=O)C[C@@](C)(O[C@]12C)C=C, CC(=O)O[C@H]1[C@@H](O)[C@H]2C(C)(C)CC[C@H](O)[C@]2(C)[C@@]2(O)C(=O)C[C@@](C)(O[C@]12C)C=C, CC(=O)O[C@H]1[C@@H](O)[C@H]2C(C)(C)CC[C@H](O)[C@]2(C)[C@@]2(O)C(=O)C[C@@](C)(O[C@]12C)C=C, CC(=O)O[C@H]1[C@@H](O)[C@H]2C(C)(C)CC[C@H](O)[C@]2(C)[C@@]2(O)C(=O)C[C@@](C)(O[C@]12C)C=C, CC(=O)O[C@H]1[C@@H](O)[C@H]2C(C)(C)CC[C@H](O)[C@]2(C)[C@@]2(O)C(=O)C[C@@](C)(O[C@]12C)C=C	OHCQJHSOBUTRHG-KGGHGJDLSA-N, OHCQJHSOBUTRHG-KGGHGJDLSA-N, OHCQJHSOBUTRHG-KGGHGJDLSA-N, OHCQJHSOBUTRHG-KGGHGJDLSA-N, OHCQJHSOBUTRHG-KGGHGJDLSA-N, OHCQJHSOBUTRHG-KGGHGJDLSA-N	Launched
fosamprenavir	HIV protease inhibitor		infectious disease	human immunodeficiency virus (HIV-1)	CC(C)CN(C[C@@H](OP(O)(O)=O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1CCOC1)S(=O)(=O)c1ccc(N)cc1, CC(C)CN(C[C@@H](OP(O)(O)=O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1CCOC1)S(=O)(=O)c1ccc(N)cc1, CC(C)CN(C[C@@H](OP(O)(O)=O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1CCOC1)S(=O)(=O)c1ccc(N)cc1, CC(C)CN(C[C@@H](OP(O)(O)=O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1CCOC1)S(=O)(=O)c1ccc(N)cc1	MLBVMOWEQCZNCC-OEMFJLHTSA-N, MLBVMOWEQCZNCC-OEMFJLHTSA-N, MLBVMOWEQCZNCC-OEMFJLHTSA-N, MLBVMOWEQCZNCC-OEMFJLHTSA-N	Launched
fosaprepitant-dimeglumine	tachykinin antagonist	TACR1	gastroenterology	nausea, vomiting	C[C@@H](O[C@H]1OCCN(Cc2nn(c(=O)[nH]2)P(O)(O)=O)[C@H]1c1ccc(F)cc1)c1cc(cc(c1)C(F)(F)F)C(F)(F)F, C[C@@H](O[C@H]1OCCN(Cc2nn(c(=O)[nH]2)P(O)(O)=O)[C@H]1c1ccc(F)cc1)c1cc(cc(c1)C(F)(F)F)C(F)(F)F, C[C@@H](O[C@H]1OCCN(Cc2nn(c(=O)[nH]2)P(O)(O)=O)[C@H]1c1ccc(F)cc1)c1cc(cc(c1)C(F)(F)F)C(F)(F)F, C[C@@H](O[C@H]1OCCN(Cc2nn(c(=O)[nH]2)P(O)(O)=O)[C@H]1c1ccc(F)cc1)c1cc(cc(c1)C(F)(F)F)C(F)(F)F, C[C@@H](O[C@H]1OCCN(Cc2nn(c(=O)[nH]2)P(O)(O)=O)[C@H]1c1ccc(F)cc1)c1cc(cc(c1)C(F)(F)F)C(F)(F)F	BARDROPHSZEBKC-OITMNORJSA-N, BARDROPHSZEBKC-OITMNORJSA-N, BARDROPHSZEBKC-OITMNORJSA-N, BARDROPHSZEBKC-OITMNORJSA-N, BARDROPHSZEBKC-OITMNORJSA-N	Launched
fosbretabulin	tubulin polymerization inhibitor, VE-cadherin antagonist	CDH5			COc1ccc(\C=C/c2cc(OC)c(OC)c(OC)c2)cc1OP(O)(O)=O, COc1ccc(\C=C/c2cc(OC)c(OC)c(OC)c2)cc1OP(O)(O)=O, COc1ccc(\C=C/c2cc(OC)c(OC)c(OC)c2)cc1OP(O)(O)=O, COc1ccc(\C=C/c2cc(OC)c(OC)c(OC)c2)cc1OP(O)(O)=O	WDOGQTQEKVLZIJ-WAYWQWQTSA-N, WDOGQTQEKVLZIJ-WAYWQWQTSA-N, WDOGQTQEKVLZIJ-WAYWQWQTSA-N, WDOGQTQEKVLZIJ-WAYWQWQTSA-N	Phase 3
foscarnet	DNA polymerase inhibitor		infectious disease	cytomegalovirus retinitis, acquired immunodeficiency syndrome (AIDS), virus herpes simplex (HSV)	OC(=O)P(O)(O)=O, OC(=O)P(O)(O)=O, OC(=O)P(O)(O)=O, OC(=O)P(O)(O)=O	ZJAOAACCNHFJAH-UHFFFAOYSA-N, ZJAOAACCNHFJAH-UHFFFAOYSA-N, ZJAOAACCNHFJAH-UHFFFAOYSA-N, ZJAOAACCNHFJAH-UHFFFAOYSA-N	Launched
fosfestrol	synthetic estrogen	ESR1, ESR2	oncology	prostate cancer	CC\C(=C(\CC)c1ccc(OP(O)(O)=O)cc1)c1ccc(OP(O)(O)=O)cc1	NLORYLAYLIXTID-ISLYRVAYSA-N	Launched
fosfluconazole	other antifungal				OP(O)(=O)OC(Cn1cncn1)(Cn1cncn1)c1ccc(F)cc1F	GHJWNRRCRIGGIO-UHFFFAOYSA-N	Preclinical
fosfomycin	bacterial cell wall synthesis inhibitor		infectious disease	urinary tract infections	C[C@@H]1O[C@@H]1P(O)(O)=O, C[C@@H]1O[C@@H]1P(O)(O)=O, C[C@@H]1O[C@@H]1P(O)(O)=O	YMDXZJFXQJVXBF-STHAYSLISA-N, YMDXZJFXQJVXBF-STHAYSLISA-N, YMDXZJFXQJVXBF-STHAYSLISA-N	Launched
fosfosal	phosphodiesterase inhibitor	PTGS1, PTGS2	neurology/psychiatry	pain relief	OC(=O)c1ccccc1OP(O)(O)=O, OC(=O)c1ccccc1OP(O)(O)=O, OC(=O)c1ccccc1OP(O)(O)=O	FFKUDWZICMJVPA-UHFFFAOYSA-N, FFKUDWZICMJVPA-UHFFFAOYSA-N, FFKUDWZICMJVPA-UHFFFAOYSA-N	Launched
fosfructose	fructose diphosphate stimulant				O[C@H](COP(O)(O)=O)[C@@H](O)[C@H](O)C(=O)COP(O)(O)=O	XPYBSIWDXQFNMH-UYFOZJQFSA-N	Phase 3
fosinopril	angiotensin converting enzyme inhibitor	ACE	cardiology	hypertension, congestive heart failure	CCC(=O)O[C@@H](OP(=O)(CCCCc1ccccc1)CC(=O)N1C[C@@H](C[C@H]1C(O)=O)C1CCCCC1)C(C)C |a:5,24,26,&1:7|, CCC(=O)O[C@@H](OP(=O)(CCCCc1ccccc1)CC(=O)N1C[C@@H](C[C@H]1C(O)=O)C1CCCCC1)C(C)C |a:5,24,26,&1:7|, CCC(=O)O[C@@H](OP(=O)(CCCCc1ccccc1)CC(=O)N1C[C@@H](C[C@H]1C(O)=O)C1CCCCC1)C(C)C |a:5,24,26,&1:7|, CCC(=O)O[C@@H](OP(=O)(CCCCc1ccccc1)CC(=O)N1C[C@@H](C[C@H]1C(O)=O)C1CCCCC1)C(C)C |a:5,24,26,&1:7|, CCC(=O)O[C@@H](OP(=O)(CCCCc1ccccc1)CC(=O)N1C[C@@H](C[C@H]1C(O)=O)C1CCCCC1)C(C)C |a:5,24,26,&1:7|	BIDNLKIUORFRQP-AJTMIRJTSA-N, BIDNLKIUORFRQP-AJTMIRJTSA-N, BIDNLKIUORFRQP-AJTMIRJTSA-N, BIDNLKIUORFRQP-AJTMIRJTSA-N, BIDNLKIUORFRQP-AJTMIRJTSA-N	Launched
fosinoprilat	angiotensin converting enzyme inhibitor	ACE	cardiology	hypertension	OC(=O)[C@@H]1C[C@H](CN1C(=O)C[P@](O)(=O)CCCCc1ccccc1)C1CCCCC1 |a:3,5,&1:11|	WOIWWYDXDVSWAZ-RTWAWAEBSA-N	Launched
fosphenytoin	sodium channel blocker	SCN5A	neurology/psychiatry	epilepsy, seizures	OP(O)(=O)OCN1C(=O)NC(C1=O)(c1ccccc1)c1ccccc1, OP(O)(=O)OCN1C(=O)NC(C1=O)(c1ccccc1)c1ccccc1, OP(O)(=O)OCN1C(=O)NC(C1=O)(c1ccccc1)c1ccccc1	XWLUWCNOOVRFPX-UHFFFAOYSA-N, XWLUWCNOOVRFPX-UHFFFAOYSA-N, XWLUWCNOOVRFPX-UHFFFAOYSA-N	Launched
fostamatinib	SYK inhibitor	SYK	hematology	chronic immune thrombocytopenia (ITP)	COc1cc(Nc2ncc(F)c(Nc3ccc4OC(C)(C)C(=O)N(COP(O)(O)=O)c4n3)n2)cc(OC)c1OC, COc1cc(Nc2ncc(F)c(Nc3ccc4OC(C)(C)C(=O)N(COP(O)(O)=O)c4n3)n2)cc(OC)c1OC, COc1cc(Nc2ncc(F)c(Nc3ccc4OC(C)(C)C(=O)N(COP(O)(O)=O)c4n3)n2)cc(OC)c1OC	GKDRMWXFWHEQQT-UHFFFAOYSA-N, GKDRMWXFWHEQQT-UHFFFAOYSA-N, GKDRMWXFWHEQQT-UHFFFAOYSA-N	Launched
fostemsavir	antiviral				COc1cnc(-n2cnc(C)n2)c2n(COP(O)(O)=O)cc(C(=O)C(=O)N3CCN(CC3)C(=O)c3ccccc3)c12	SWMDAPWAQQTBOG-UHFFFAOYSA-N	Phase 3
fotemustine	thioredoxin inhibitor		oncology	melanoma	CCOP(=O)(OCC)[C@@H](C)NC(=O)N(CCCl)[NH2+][O-] |&1:8,r|, CCOP(=O)(OCC)[C@@H](C)NC(=O)N(CCCl)[NH2+][O-] |&1:8,r|	UETIXAMLWBFWOE-QMMMGPOBSA-N, UETIXAMLWBFWOE-QMMMGPOBSA-N	Launched
foxy-5	WNT5a peptide mimetic	WNT5A			CSCC[C@H](NC=O)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O, CSCC[C@H](NC=O)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O	WFZPJYYCTSHDJI-ATIWLJMLSA-N, WFZPJYYCTSHDJI-ATIWLJMLSA-N	Phase 2
FPA-124	AKT inhibitor						Preclinical
FPH1-(BRD-6125)	hepatocyte function enhancer				Cc1ccc(Cl)cc1N(CC(=O)Nc1c(F)cccc1F)S(C)(=O)=O, Cc1ccc(Cl)cc1N(CC(=O)Nc1c(F)cccc1F)S(C)(=O)=O	WAOBCCBUTHNTFO-UHFFFAOYSA-N, WAOBCCBUTHNTFO-UHFFFAOYSA-N	Preclinical
FPL-12495	glutamate receptor antagonist				CC(N)(Cc1ccccc1)c1ccccc1 |&1:1|, CC(N)(Cc1ccccc1)c1ccccc1 |&1:1|, CC(N)(Cc1ccccc1)c1ccccc1 |&1:1|	JINQHBRSXWQJAZ-UHFFFAOYSA-N, JINQHBRSXWQJAZ-UHFFFAOYSA-N, JINQHBRSXWQJAZ-UHFFFAOYSA-N	Phase 1
FPL-55712	leukotriene receptor antagonist				CCCc1c(OC[C@@H](O)COc2ccc3c(oc(cc3=O)C(O)=O)c2CCC)ccc(C(C)=O)c1O |&1:7,r|, CCCc1c(OC[C@@H](O)COc2ccc3c(oc(cc3=O)C(O)=O)c2CCC)ccc(C(C)=O)c1O |&1:7,r|, CCCc1c(OC[C@@H](O)COc2ccc3c(oc(cc3=O)C(O)=O)c2CCC)ccc(C(C)=O)c1O |&1:7,r|, CCCc1c(OC[C@@H](O)COc2ccc3c(oc(cc3=O)C(O)=O)c2CCC)ccc(C(C)=O)c1O |&1:7,r|	LMQBMWHHGVZWMR-MRXNPFEDSA-N, LMQBMWHHGVZWMR-MRXNPFEDSA-N, LMQBMWHHGVZWMR-MRXNPFEDSA-N, LMQBMWHHGVZWMR-MRXNPFEDSA-N	Phase 1
FPL-62064	cyclooxygenase inhibitor, lipoxygenase inhibitor				COc1ccc(Nc2ccn(n2)-c2ccccc2)cc1, COc1ccc(Nc2ccn(n2)-c2ccccc2)cc1, COc1ccc(Nc2ccn(n2)-c2ccccc2)cc1	WKLGNFJHVJIZPK-UHFFFAOYSA-N, WKLGNFJHVJIZPK-UHFFFAOYSA-N, WKLGNFJHVJIZPK-UHFFFAOYSA-N	Phase 2
FPL-64176	calcium channel activator	CACNA1C, CACNA1S			COC(=O)c1c(C)[nH]c(C)c1C(=O)c1ccccc1Cc1ccccc1, COC(=O)c1c(C)[nH]c(C)c1C(=O)c1ccccc1Cc1ccccc1, COC(=O)c1c(C)[nH]c(C)c1C(=O)c1ccccc1Cc1ccccc1, COC(=O)c1c(C)[nH]c(C)c1C(=O)c1ccccc1Cc1ccccc1, COC(=O)c1c(C)[nH]c(C)c1C(=O)c1ccccc1Cc1ccccc1	MDMWHKZANMNXTF-UHFFFAOYSA-N, MDMWHKZANMNXTF-UHFFFAOYSA-N, MDMWHKZANMNXTF-UHFFFAOYSA-N, MDMWHKZANMNXTF-UHFFFAOYSA-N, MDMWHKZANMNXTF-UHFFFAOYSA-N	Preclinical
FPS-ZM1	RAGE receptor antagonist	AGER			Clc1ccc(cc1)C(=O)N(Cc1ccccc1)C1CCCCC1, Clc1ccc(cc1)C(=O)N(Cc1ccccc1)C1CCCCC1	XDFKWGIBQMHSOH-UHFFFAOYSA-N, XDFKWGIBQMHSOH-UHFFFAOYSA-N	Preclinical
FR-122047	cyclooxygenase inhibitor				COc1ccc(cc1)-c1nc(sc1-c1ccc(OC)cc1)C(=O)N1CCN(C)CC1, COc1ccc(cc1)-c1nc(sc1-c1ccc(OC)cc1)C(=O)N1CCN(C)CC1	UBHKJRYGKOSQDJ-UHFFFAOYSA-N, UBHKJRYGKOSQDJ-UHFFFAOYSA-N	Preclinical
FR-139317	endothelin receptor antagonist	EDNRA			CC(C)C[C@H](NC(=O)N1CCCCCC1)C(=O)N[C@H](Cc1cn(C)c2ccccc12)C(=O)N[C@H](Cc1ccccn1)C(O)=O, CC(C)C[C@H](NC(=O)N1CCCCCC1)C(=O)N[C@H](Cc1cn(C)c2ccccc12)C(=O)N[C@H](Cc1ccccn1)C(O)=O, CC(C)C[C@H](NC(=O)N1CCCCCC1)C(=O)N[C@H](Cc1cn(C)c2ccccc12)C(=O)N[C@H](Cc1ccccn1)C(O)=O, CC(C)C[C@H](NC(=O)N1CCCCCC1)C(=O)N[C@H](Cc1cn(C)c2ccccc12)C(=O)N[C@H](Cc1ccccn1)C(O)=O	LIOKMIQQPDDTNO-UPRLRBBYSA-N, LIOKMIQQPDDTNO-UPRLRBBYSA-N, LIOKMIQQPDDTNO-UPRLRBBYSA-N, LIOKMIQQPDDTNO-UPRLRBBYSA-N	Phase 1
FR-180204	MAP kinase inhibitor	MAPK1, MAPK3			Nc1[nH]nc2nnc(cc12)-c1c(nn2ccccc12)-c1ccccc1, Nc1[nH]nc2nnc(cc12)-c1c(nn2ccccc12)-c1ccccc1, Nc1[nH]nc2nnc(cc12)-c1c(nn2ccccc12)-c1ccccc1, Nc1[nH]nc2nnc(cc12)-c1c(nn2ccccc12)-c1ccccc1	XVECMUKVOMUNLE-UHFFFAOYSA-N, XVECMUKVOMUNLE-UHFFFAOYSA-N, XVECMUKVOMUNLE-UHFFFAOYSA-N, XVECMUKVOMUNLE-UHFFFAOYSA-N	Preclinical
FRAX486	serine/threonine kinase inhibitor	PAK1, PAK2, PAK3, PAK4			CCn1c2nc(Nc3ccc(N4CCNCC4)c(F)c3)ncc2cc(-c2ccc(Cl)cc2Cl)c1=O, CCn1c2nc(Nc3ccc(N4CCNCC4)c(F)c3)ncc2cc(-c2ccc(Cl)cc2Cl)c1=O, CCn1c2nc(Nc3ccc(N4CCNCC4)c(F)c3)ncc2cc(-c2ccc(Cl)cc2Cl)c1=O, CCn1c2nc(Nc3ccc(N4CCNCC4)c(F)c3)ncc2cc(-c2ccc(Cl)cc2Cl)c1=O, CCn1c2nc(Nc3ccc(N4CCNCC4)c(F)c3)ncc2cc(-c2ccc(Cl)cc2Cl)c1=O	DHKFOIHIUYFSOF-UHFFFAOYSA-N, DHKFOIHIUYFSOF-UHFFFAOYSA-N, DHKFOIHIUYFSOF-UHFFFAOYSA-N, DHKFOIHIUYFSOF-UHFFFAOYSA-N, DHKFOIHIUYFSOF-UHFFFAOYSA-N	Preclinical
frentizole	immunosuppressant				COc1ccc2nc(NC(=O)Nc3ccccc3)sc2c1, COc1ccc2nc(NC(=O)Nc3ccccc3)sc2c1, COc1ccc2nc(NC(=O)Nc3ccccc3)sc2c1	JHBWYQRKOUBPCA-UHFFFAOYSA-N, JHBWYQRKOUBPCA-UHFFFAOYSA-N, JHBWYQRKOUBPCA-UHFFFAOYSA-N	Phase 1
freselestat	elastase inhibitor	CELA1, ELANE			CC(C)[C@@H](NC(=O)Cn1c(ncc(N)c1=O)-c1ccccc1)[C@@H](O)c1nnc(o1)C(C)(C)C	HMPQTEPEMQZWQH-QZTJIDSGSA-N	Preclinical
frovatriptan	serotonin receptor agonist	HTR1A, HTR1B, HTR1D	neurology/psychiatry	migraine headache	CN[C@@H]1CCc2[nH]c3ccc(cc3c2C1)C(N)=O	XPSQPHWEGNHMSK-SECBINFHSA-N	Launched
fruquintinib	VEGFR inhibitor	KDR	oncology	colorectal cancer	CNC(=O)c1c(C)oc2cc(Oc3ncnc4cc(OC)c(OC)cc34)ccc12, CNC(=O)c1c(C)oc2cc(Oc3ncnc4cc(OC)c(OC)cc34)ccc12, CNC(=O)c1c(C)oc2cc(Oc3ncnc4cc(OC)c(OC)cc34)ccc12	BALLNEJQLSTPIO-UHFFFAOYSA-N, BALLNEJQLSTPIO-UHFFFAOYSA-N, BALLNEJQLSTPIO-UHFFFAOYSA-N	Launched
ftaxilide					Cc1cccc(C)c1NC(=O)c1ccccc1C(O)=O, Cc1cccc(C)c1NC(=O)c1ccccc1C(O)=O	LLECMGGNFBKPRH-UHFFFAOYSA-N, LLECMGGNFBKPRH-UHFFFAOYSA-N	Preclinical
ftorafur	thymidylate synthase inhibitor	TYMS	oncology	colorectal cancer	Fc1cn([C@H]2CCCO2)c(=O)[nH]c1=O, Fc1cn([C@H]2CCCO2)c(=O)[nH]c1=O, Fc1cn([C@H]2CCCO2)c(=O)[nH]c1=O, Fc1cn([C@H]2CCCO2)c(=O)[nH]c1=O, Fc1cn([C@H]2CCCO2)c(=O)[nH]c1=O	WFWLQNSHRPWKFK-ZCFIWIBFSA-N, WFWLQNSHRPWKFK-ZCFIWIBFSA-N, WFWLQNSHRPWKFK-ZCFIWIBFSA-N, WFWLQNSHRPWKFK-ZCFIWIBFSA-N, WFWLQNSHRPWKFK-ZCFIWIBFSA-N	Launched
FT011	TGF beta receptor inhibitor				COc1cc(\C=C\C(=O)Nc2ccccc2C(O)=O)ccc1OCC#C	UIWZIDIJCUEOMT-PKNBQFBNSA-N	Preclinical
fucoxanthin	anticancer agent				[H]C(=[C@@]=C1C(C)(C)C[C@@H](C[C@@]1(C)O)OC(C)=O)C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)C(=O)C[C@]12O[C@@]1(C)C[C@H](O)CC2(C)C	SJWWTRQNNRNTPU-BWRPRJLXSA-N	Phase 2
fudosteine	mucolytic agent		pulmonary	chest congestion	N[C@@H](CSCCCO)C(O)=O, N[C@@H](CSCCCO)C(O)=O, N[C@@H](CSCCCO)C(O)=O	KINWYTAUPKOPCQ-YFKPBYRVSA-N, KINWYTAUPKOPCQ-YFKPBYRVSA-N, KINWYTAUPKOPCQ-YFKPBYRVSA-N	Launched
fulvestrant	estrogen receptor antagonist	ESR1, ESR2, GPER1	oncology	breast cancer	C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)[C@H](CCCCCCCCC[S@@](=O)CCCC(F)(F)C(F)(F)F)Cc1cc(O)ccc31 |a:1,4,5,6,9,11,&1:21|, C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)[C@H](CCCCCCCCC[S@@](=O)CCCC(F)(F)C(F)(F)F)Cc1cc(O)ccc31 |a:1,4,5,6,9,11,&1:21|, C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)[C@H](CCCCCCCCC[S@@](=O)CCCC(F)(F)C(F)(F)F)Cc1cc(O)ccc31 |a:1,4,5,6,9,11,&1:21|, C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)[C@H](CCCCCCCCC[S@@](=O)CCCC(F)(F)C(F)(F)F)Cc1cc(O)ccc31 |a:1,4,5,6,9,11,&1:21|, C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)[C@H](CCCCCCCCC[S@@](=O)CCCC(F)(F)C(F)(F)F)Cc1cc(O)ccc31 |a:1,4,5,6,9,11,&1:21|, C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)[C@H](CCCCCCCCC[S@@](=O)CCCC(F)(F)C(F)(F)F)Cc1cc(O)ccc31 |a:1,4,5,6,9,11,&1:21|, C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)[C@H](CCCCCCCCC[S@@](=O)CCCC(F)(F)C(F)(F)F)Cc1cc(O)ccc31 |a:1,4,5,6,9,11,&1:21|, C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)[C@H](CCCCCCCCC[S@@](=O)CCCC(F)(F)C(F)(F)F)Cc1cc(O)ccc31 |a:1,4,5,6,9,11,&1:21|, C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)[C@H](CCCCCCCCC[S@@](=O)CCCC(F)(F)C(F)(F)F)Cc1cc(O)ccc31 |a:1,4,5,6,9,11,&1:21|, C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)[C@H](CCCCCCCCC[S@@](=O)CCCC(F)(F)C(F)(F)F)Cc1cc(O)ccc31 |a:1,4,5,6,9,11,&1:21|, C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)[C@H](CCCCCCCCC[S@@](=O)CCCC(F)(F)C(F)(F)F)Cc1cc(O)ccc31 |a:1,4,5,6,9,11,&1:21|, C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)[C@H](CCCCCCCCC[S@@](=O)CCCC(F)(F)C(F)(F)F)Cc1cc(O)ccc31 |a:1,4,5,6,9,11,&1:21|, C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)[C@H](CCCCCCCCC[S@@](=O)CCCC(F)(F)C(F)(F)F)Cc1cc(O)ccc31 |a:1,4,5,6,9,11,&1:21|	VWUXBMIQPBEWFH-CIAKRVSBSA-N, VWUXBMIQPBEWFH-CIAKRVSBSA-N, VWUXBMIQPBEWFH-CIAKRVSBSA-N, VWUXBMIQPBEWFH-CIAKRVSBSA-N, VWUXBMIQPBEWFH-CIAKRVSBSA-N, VWUXBMIQPBEWFH-CIAKRVSBSA-N, VWUXBMIQPBEWFH-CIAKRVSBSA-N, VWUXBMIQPBEWFH-CIAKRVSBSA-N, VWUXBMIQPBEWFH-CIAKRVSBSA-N, VWUXBMIQPBEWFH-CIAKRVSBSA-N, VWUXBMIQPBEWFH-CIAKRVSBSA-N, VWUXBMIQPBEWFH-CIAKRVSBSA-N, VWUXBMIQPBEWFH-CIAKRVSBSA-N	Launched
fumagillin	methionine aminopeptidase inhibitor	METAP2	infectious disease	microsporidiosis	CO[C@@H]1[C@@H](CC[C@]2(CO2)[C@@H]1[C@@]1(C)O[C@@H]1CC=C(C)C)OC(=O)\C=C\C=C\C=C\C=C\C(O)=O |a:2,3,6,10,13,&1:9|, CO[C@@H]1[C@@H](CC[C@]2(CO2)[C@@H]1[C@@]1(C)O[C@@H]1CC=C(C)C)OC(=O)\C=C\C=C\C=C\C=C\C(O)=O |a:2,3,6,10,13,&1:9|, CO[C@@H]1[C@@H](CC[C@]2(CO2)[C@@H]1[C@@]1(C)O[C@@H]1CC=C(C)C)OC(=O)\C=C\C=C\C=C\C=C\C(O)=O |a:2,3,6,10,13,&1:9|, CO[C@@H]1[C@@H](CC[C@]2(CO2)[C@@H]1[C@@]1(C)O[C@@H]1CC=C(C)C)OC(=O)\C=C\C=C\C=C\C=C\C(O)=O |a:2,3,6,10,13,&1:9|	NGGMYCMLYOUNGM-FKSJYSFPSA-N, NGGMYCMLYOUNGM-FKSJYSFPSA-N, NGGMYCMLYOUNGM-FKSJYSFPSA-N, NGGMYCMLYOUNGM-FKSJYSFPSA-N	Launched
fumonisin-B1		CERS1			CCCC[C@@H](C)[C@@H](OC(=O)C[C@@H](CC(O)=O)C(O)=O)[C@H](C[C@@H](C)C[C@H](O)CCCC[C@@H](O)C[C@H](O)[C@H](C)N)OC(=O)C[C@@H](CC(O)=O)C(O)=O	UVBUBMSSQKOIBE-DSLOAKGESA-N	Preclinical
funapide	sodium channel blocker				FC(F)(F)c1ccc(CN2C(=O)[C@@]3(COc4cc5OCOc5cc34)c3ccccc23)o1	NEBUOXBYNAHKFV-NRFANRHFSA-N	Preclinical
furagin	antibacterial				[O-][N+](=O)c1ccc(\C=C\C=N\N2CC(=O)NC2=O)o1	DECBQELQORZLLP-UAIOPKHMSA-N	Preclinical
furaltadone	bacterial DNA inhibitor		infectious disease	gram-negative bacterial infections	[O-][N+](=O)c1ccc(\C=N\N2C[C@@H](CN3CCOCC3)OC2=O)o1 |&1:11,r|, [O-][N+](=O)c1ccc(\C=N\N2C[C@@H](CN3CCOCC3)OC2=O)o1 |&1:11,r|	YVQVOQKFMFRVGR-LLUUXILJSA-N, YVQVOQKFMFRVGR-LLUUXILJSA-N	Launched
furamidine	protein arginine N-methyltransferase inhibitor	PRMT1			NC(=N)c1ccc(cc1)-c1ccc(o1)-c1ccc(cc1)C(N)=N, NC(=N)c1ccc(cc1)-c1ccc(o1)-c1ccc(cc1)C(N)=N	ZJHZBDRZEZEDGB-UHFFFAOYSA-N, ZJHZBDRZEZEDGB-UHFFFAOYSA-N	Preclinical
furazolidone	bacterial DNA inhibitor		gastroenterology, infectious disease	diarrhea, enteritis, cholera	[O-][N+](=O)c1ccc(\C=N\N2CCOC2=O)o1, [O-][N+](=O)c1ccc(\C=N\N2CCOC2=O)o1	PLHJDBGFXBMTGZ-WEVVVXLNSA-N, PLHJDBGFXBMTGZ-WEVVVXLNSA-N	Launched
furegrelate	thromboxane synthase inhibitor	TBXAS1			OC(=O)c1cc2cc(Cc3cccnc3)ccc2o1, OC(=O)c1cc2cc(Cc3cccnc3)ccc2o1	VHWFITPGPFLBGT-UHFFFAOYSA-N, VHWFITPGPFLBGT-UHFFFAOYSA-N	Phase 1
furosemide	diuretic	CA2, GPR35, SLC12A1, SLC12A2	cardiology, rheumatology	edema, hypertension, congestive heart failure, nephrotic syndrome	NS(=O)(=O)c1cc(C(O)=O)c(NCc2ccco2)cc1Cl, NS(=O)(=O)c1cc(C(O)=O)c(NCc2ccco2)cc1Cl, NS(=O)(=O)c1cc(C(O)=O)c(NCc2ccco2)cc1Cl, NS(=O)(=O)c1cc(C(O)=O)c(NCc2ccco2)cc1Cl, NS(=O)(=O)c1cc(C(O)=O)c(NCc2ccco2)cc1Cl, NS(=O)(=O)c1cc(C(O)=O)c(NCc2ccco2)cc1Cl	ZZUFCTLCJUWOSV-UHFFFAOYSA-N, ZZUFCTLCJUWOSV-UHFFFAOYSA-N, ZZUFCTLCJUWOSV-UHFFFAOYSA-N, ZZUFCTLCJUWOSV-UHFFFAOYSA-N, ZZUFCTLCJUWOSV-UHFFFAOYSA-N, ZZUFCTLCJUWOSV-UHFFFAOYSA-N	Launched
fursultiamine	vitamin B		metabolism	thiamine deficiency	C\C(N(Cc1cnc(C)nc1N)C=O)=C(\CCO)SSC[C@H]1CCCO1 |&1:21|, C\C(N(Cc1cnc(C)nc1N)C=O)=C(\CCO)SSC[C@H]1CCCO1 |&1:21|	JTLXCMOFVBXEKD-XYGUXCPDSA-N, JTLXCMOFVBXEKD-XYGUXCPDSA-N	Launched
furvina	quorum sensing signaling inhibitor				[O-][N+](=O)C(\Br)=C/c1ccc(Br)o1	MJPPGVVIDGQOQT-HYXAFXHYSA-N	Preclinical
fusidic-acid	bacterial 30S ribosomal subunit inhibitor		dermatology	acne vulgaris (AV)	C[C@@H]1[C@H](O)CC[C@@]2(C)[C@H]1CC[C@@]1(C)[C@H]2[C@H](O)C[C@H]2\C([C@H](C[C@]12C)OC(C)=O)=C(/CCC=C(C)C)C(O)=O	IECPWNUMDGFDKC-MZJAQBGESA-N	Launched
futibatinib	FGFR inhibitor				COc1cc(OC)cc(c1)C#Cc1nn([C@H]2CCN(C2)C(=O)C=C)c2ncnc(N)c12	KEIPNCCJPRMIAX-HNNXBMFYSA-N	Phase 3
F351	TGF beta receptor inhibitor	TGFB1			Cc1ccc(=O)n(c1)-c1ccc(O)cc1, Cc1ccc(=O)n(c1)-c1ccc(O)cc1	NETTXQJYJRFTFS-UHFFFAOYSA-N, NETTXQJYJRFTFS-UHFFFAOYSA-N	Phase 2
g-caryophyllene	acetylcholinesterase inhibitor	ACHE			C\C1=C/CCC(=C)[C@H]2CC(C)(C)[C@@H]2CC1 |c:1|, C\C1=C/CCC(=C)[C@H]2CC(C)(C)[C@@H]2CC1 |c:1|	NPNUFJAVOOONJE-GFUGXAQUSA-N, NPNUFJAVOOONJE-GFUGXAQUSA-N	Preclinical
G-1	G protein-coupled receptor agonist	GPER1			CC(=O)c1ccc2N[C@H]([C@H]3CC=C[C@H]3c2c1)c1cc2OCOc2cc1Br |c:11|, CC(=O)c1ccc2N[C@H]([C@H]3CC=C[C@H]3c2c1)c1cc2OCOc2cc1Br |c:11|	VHSVKVWHYFBIFJ-HKZYLEAXSA-N, VHSVKVWHYFBIFJ-HKZYLEAXSA-N	Preclinical
G-15	estrogen receptor antagonist	GPER1			Brc1cc2OCOc2cc1[C@H]1Nc2ccccc2[C@H]2C=CC[C@@H]12 |&1:10,18,22,c:22|	YOLTZIVRJAPVPH-MVBJNABHSA-N	Preclinical
G-749	tyrosine kinase inhibitor				CN1CCC(CC1)Nc1nc(Nc2ccc(Oc3ccccc3)cc2)c2c(O)ncc(Br)c2n1	SXWMIXPJPNCXQQ-UHFFFAOYSA-N	Preclinical
GABA-linoleamide	benzodiazepine receptor agonist				CCCCC\C=C/C\C=C/CCCCCCCC(=O)NCCCC(O)=O	YGFYZZQGVSUXJE-HZJYTTRNSA-N	Phase 2
gabapentin	calcium channel blocker	ADORA1, CACNA1A, CACNA1B, CACNA1C, CACNA1D, CACNA1E, CACNA1F, CACNA1G, CACNA1H, CACNA1I, CACNA1S, CACNA2D1, CACNA2D2, CACNA2D3, CACNA2D4, CACNB1, CACNB2, CACNB3, CACNB4, CACNG1, CACNG2, CACNG3, CACNG4, CACNG5, CACNG6, CACNG7, CACNG8, GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D, GRIN3A, GRIN3B	infectious disease, neurology/psychiatry	virus herpes simplex (HSV), shingles, seizures, restless leg syndrome	NCC1(CC(O)=O)CCCCC1, NCC1(CC(O)=O)CCCCC1, NCC1(CC(O)=O)CCCCC1, NCC1(CC(O)=O)CCCCC1	UGJMXCAKCUNAIE-UHFFFAOYSA-N, UGJMXCAKCUNAIE-UHFFFAOYSA-N, UGJMXCAKCUNAIE-UHFFFAOYSA-N, UGJMXCAKCUNAIE-UHFFFAOYSA-N	Launched
gabapentin-enacarbil	adrenergic receptor agonist	CACNA1G	neurology/psychiatry	restless leg syndrome, postherpetic neuralgia	CC(C)C(=O)O[C@@H](C)OC(=O)NCC1(CC(O)=O)CCCCC1 |&1:6,r|	TZDUHAJSIBHXDL-GFCCVEGCSA-N	Launched
gabazine	GABA receptor antagonist	GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRG2			COc1ccc(cc1)-c1ccc(=N)n(CCCC(O)=O)n1, COc1ccc(cc1)-c1ccc(=N)n(CCCC(O)=O)n1, COc1ccc(cc1)-c1ccc(=N)n(CCCC(O)=O)n1, COc1ccc(cc1)-c1ccc(=N)n(CCCC(O)=O)n1, COc1ccc(cc1)-c1ccc(=N)n(CCCC(O)=O)n1	ACVGNKYJVGNLIL-UHFFFAOYSA-N, ACVGNKYJVGNLIL-UHFFFAOYSA-N, ACVGNKYJVGNLIL-UHFFFAOYSA-N, ACVGNKYJVGNLIL-UHFFFAOYSA-N, ACVGNKYJVGNLIL-UHFFFAOYSA-N	Preclinical
gabexate	serine protease inhibitor	PRSS1, TPSAB1	gastroenterology	pancreatitis	CCOC(=O)c1ccc(OC(=O)CCCCCNC(N)=N)cc1, CCOC(=O)c1ccc(OC(=O)CCCCCNC(N)=N)cc1, CCOC(=O)c1ccc(OC(=O)CCCCCNC(N)=N)cc1, CCOC(=O)c1ccc(OC(=O)CCCCCNC(N)=N)cc1, CCOC(=O)c1ccc(OC(=O)CCCCCNC(N)=N)cc1, CCOC(=O)c1ccc(OC(=O)CCCCCNC(N)=N)cc1	YKGYIDJEEQRWQH-UHFFFAOYSA-N, YKGYIDJEEQRWQH-UHFFFAOYSA-N, YKGYIDJEEQRWQH-UHFFFAOYSA-N, YKGYIDJEEQRWQH-UHFFFAOYSA-N, YKGYIDJEEQRWQH-UHFFFAOYSA-N, YKGYIDJEEQRWQH-UHFFFAOYSA-N	Launched
gaboxadol	benzodiazepine receptor agonist	GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRD, GABRR1, GABRR2, GABRR3			O=c1[nH]oc2CNCCc12, O=c1[nH]oc2CNCCc12, O=c1[nH]oc2CNCCc12, O=c1[nH]oc2CNCCc12, O=c1[nH]oc2CNCCc12	ZXRVKCBLGJOCEE-UHFFFAOYSA-N, ZXRVKCBLGJOCEE-UHFFFAOYSA-N, ZXRVKCBLGJOCEE-UHFFFAOYSA-N, ZXRVKCBLGJOCEE-UHFFFAOYSA-N, ZXRVKCBLGJOCEE-UHFFFAOYSA-N	Phase 3
gadobutrol	radiopaque medium		radiology	MRI contrast agent	[H]O[C@@H](CO)[C@H](CO)N1CCN2CCN3CCN(CC1)CC(=O)O[Gd](OC(=O)C3)OC(=O)C2 |&1:2,5|	ZPDFIIGFYAHNSK-YYLIZZNMSA-K	Launched
gadodiamide	radiopaque medium		radiology	MRI contrast agent	CNC(=O)CN1CCN2CCN(CC(=O)NC)CC(=O)O[Gd](OC(=O)C1)OC(=O)C2, CNC(=O)CN1CCN2CCN(CC(=O)NC)CC(=O)O[Gd](OC(=O)C1)OC(=O)C2	HZHFFEYYPYZMNU-UHFFFAOYSA-K, HZHFFEYYPYZMNU-UHFFFAOYSA-K	Launched
gadopentetic-acid	contrast agent	PGD	radiology	contrast agent	OC(=O)CN1CCN2CCN(CC(O)=O)CC(=O)O[Gd](OC(=O)C1)OC(=O)C2	IZOOGPBRAOKZFK-UHFFFAOYSA-K	Launched
gadoterate-meglumine	radiopaque medium		radiology	MRI contrast agent	OC(=O)CN1CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC1, OC(=O)CN1CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC1	WDLRUFUQRNWCPK-UHFFFAOYSA-N, WDLRUFUQRNWCPK-UHFFFAOYSA-N	Launched
gadoteridol	radiopaque medium		radiology	MRI contrast agent	C[C@@H](O)CN1CCN2CCN3CCN(CC1)CC(=O)O[Gd](OC(=O)C2)OC(=O)C3 |&1:1,r|, C[C@@H](O)CN1CCN2CCN3CCN(CC1)CC(=O)O[Gd](OC(=O)C2)OC(=O)C3 |&1:1,r|	DPNNNPAKRZOSMO-PFEQFJNWSA-K, DPNNNPAKRZOSMO-PFEQFJNWSA-K	Launched
GAL-021	calcium channel blocker				CCCNc1nc(NCCC)nc(n1)N(C)OC	FJNLCHNQVJVCPY-UHFFFAOYSA-N	Preclinical
galantamine	acetylcholinesterase inhibitor	ACHE, BCHE, CHRNA1, CHRNA10, CHRNA2, CHRNA3, CHRNA4, CHRNA5, CHRNA6, CHRNA7, CHRNA9, CHRNB1, CHRNB2, CHRNB3, CHRNB4, CHRND, CHRNE, CHRNG	neurology/psychiatry	senile dementia	COc1ccc2CN(C)CC[C@@]34C=C[C@H](O)C[C@@H]3Oc1c24 |c:12|, COc1ccc2CN(C)CC[C@@]34C=C[C@H](O)C[C@@H]3Oc1c24 |c:12|, COc1ccc2CN(C)CC[C@@]34C=C[C@H](O)C[C@@H]3Oc1c24 |c:12|, COc1ccc2CN(C)CC[C@@]34C=C[C@H](O)C[C@@H]3Oc1c24 |c:12|	ASUTZQLVASHGKV-JDFRZJQESA-N, ASUTZQLVASHGKV-JDFRZJQESA-N, ASUTZQLVASHGKV-JDFRZJQESA-N, ASUTZQLVASHGKV-JDFRZJQESA-N	Launched
galeterone	androgen receptor modulator	AR, CYP17A1			[H][C@@]12CC=C(n3cnc4ccccc34)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@@H](O)CC[C@]12C |t:3,27|	PAFKTGFSEFKSQG-PAASFTFBSA-N	Phase 3
galidesivir	antiviral				Nc1ncnc2c(c[nH]c12)[C@@H]1N[C@H](CO)[C@@H](O)[C@H]1O	AMFDITJFBUXZQN-KUBHLMPHSA-N	Phase 1
gallamine-triethiodide	acetylcholine receptor antagonist	CHRM2, CHRNA1	neurology/psychiatry	muscle relaxant	CC[N+](CC)(CC)CCOc1cccc(OCC[N+](CC)(CC)CC)c1OCC[N+](CC)(CC)CC, CC[N+](CC)(CC)CCOc1cccc(OCC[N+](CC)(CC)CC)c1OCC[N+](CC)(CC)CC, CC[N+](CC)(CC)CCOc1cccc(OCC[N+](CC)(CC)CC)c1OCC[N+](CC)(CC)CC, CC[N+](CC)(CC)CCOc1cccc(OCC[N+](CC)(CC)CC)c1OCC[N+](CC)(CC)CC, CC[N+](CC)(CC)CCOc1cccc(OCC[N+](CC)(CC)CC)c1OCC[N+](CC)(CC)CC, CC[N+](CC)(CC)CCOc1cccc(OCC[N+](CC)(CC)CC)c1OCC[N+](CC)(CC)CC	OZLPUNFFCJDMJD-UHFFFAOYSA-N, OZLPUNFFCJDMJD-UHFFFAOYSA-N, OZLPUNFFCJDMJD-UHFFFAOYSA-N, OZLPUNFFCJDMJD-UHFFFAOYSA-N, OZLPUNFFCJDMJD-UHFFFAOYSA-N, OZLPUNFFCJDMJD-UHFFFAOYSA-N	Launched
gallic-acid	beta amyloid protein neurotoxicity inhibitor, PPAR receptor agonist	CA1, CA12, CA14, CA2, CA4, CA6, CA9, SELP			OC(=O)c1cc(O)c(O)c(O)c1, OC(=O)c1cc(O)c(O)c(O)c1	LNTHITQWFMADLM-UHFFFAOYSA-N, LNTHITQWFMADLM-UHFFFAOYSA-N	Preclinical
gallium-triquinolin-8-olate					O([Ga](Oc1cccc2cccnc12)Oc1cccc2cccnc12)c1cccc2cccnc12	KWQNQSDKCINQQP-UHFFFAOYSA-K	Phase 1
gallopamil	L-type calcium channel blocker	ATP2A2	cardiology	hypertension, cardiac arrythmia	COc1ccc(CCN(C)CCCC(C#N)(C(C)C)c2cc(OC)c(OC)c(OC)c2)cc1OC |&1:13|, COc1ccc(CCN(C)CCCC(C#N)(C(C)C)c2cc(OC)c(OC)c(OC)c2)cc1OC |&1:13|, COc1ccc(CCN(C)CCCC(C#N)(C(C)C)c2cc(OC)c(OC)c(OC)c2)cc1OC |&1:13|, COc1ccc(CCN(C)CCCC(C#N)(C(C)C)c2cc(OC)c(OC)c(OC)c2)cc1OC |&1:13|, COc1ccc(CCN(C)CCCC(C#N)(C(C)C)c2cc(OC)c(OC)c(OC)c2)cc1OC |&1:13|	XQLWNAFCTODIRK-UHFFFAOYSA-N, XQLWNAFCTODIRK-UHFFFAOYSA-N, XQLWNAFCTODIRK-UHFFFAOYSA-N, XQLWNAFCTODIRK-UHFFFAOYSA-N, XQLWNAFCTODIRK-UHFFFAOYSA-N	Launched
gambogic-acid	caspase activator	BCL2			CC(C)=CCC[C@@]1(C)Oc2c(CC=C(C)C)c3O[C@@]45[C@H]6C[C@@H](C=C4C(=O)c3c(O)c2C=C1)C(=O)[C@]5(C\C=C(\C)C(O)=O)OC6(C)C |c:22,33|, CC(C)=CCC[C@@]1(C)Oc2c(CC=C(C)C)c3O[C@@]45[C@H]6C[C@@H](C=C4C(=O)c3c(O)c2C=C1)C(=O)[C@]5(C\C=C(\C)C(O)=O)OC6(C)C |c:22,33|, CC(C)=CCC[C@@]1(C)Oc2c(CC=C(C)C)c3O[C@@]45[C@H]6C[C@@H](C=C4C(=O)c3c(O)c2C=C1)C(=O)[C@]5(C\C=C(\C)C(O)=O)OC6(C)C |c:22,33|, CC(C)=CCC[C@@]1(C)Oc2c(CC=C(C)C)c3O[C@@]45[C@H]6C[C@@H](C=C4C(=O)c3c(O)c2C=C1)C(=O)[C@]5(C\C=C(\C)C(O)=O)OC6(C)C |c:22,33|, CC(C)=CCC[C@@]1(C)Oc2c(CC=C(C)C)c3O[C@@]45[C@H]6C[C@@H](C=C4C(=O)c3c(O)c2C=C1)C(=O)[C@]5(C\C=C(\C)C(O)=O)OC6(C)C |c:22,33|	GEZHEQNLKAOMCA-RRZNCOCZSA-N, GEZHEQNLKAOMCA-RRZNCOCZSA-N, GEZHEQNLKAOMCA-RRZNCOCZSA-N, GEZHEQNLKAOMCA-RRZNCOCZSA-N, GEZHEQNLKAOMCA-RRZNCOCZSA-N	Phase 2
gamithromycin	antibacterial 				[H][C@@]1(C[C@@](C)(OC)[C@@H](O)[C@H](C)O1)O[C@H]1[C@H](C)[C@@H](O[C@]2([H])O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)N(CCC)C[C@H](C)[C@@H](O)[C@](C)(O)[C@@H](CC)OC(=O)[C@@H]1C	VWAMTBXLZPEDQO-RHJMDXJBSA-N	Preclinical
gamma-aminobutyric-acid	benzodiazepine receptor agonist	GABBR1, GABBR2, GABRA1, GABRA2, GABRA3, GABRA5, GABRB2, GABRG2, GATM, KCTD12, KCTD16, KCTD8, SLC6A1			NCCCC(O)=O, NCCCC(O)=O, NCCCC(O)=O, NCCCC(O)=O	BTCSSZJGUNDROE-UHFFFAOYSA-N, BTCSSZJGUNDROE-UHFFFAOYSA-N, BTCSSZJGUNDROE-UHFFFAOYSA-N, BTCSSZJGUNDROE-UHFFFAOYSA-N	Preclinical
gamma-linolenic-acid	cyclooxygenase inhibitor, prostanoid receptor agonist	PTGS1, PTGS2			CCCCC\C=C/C\C=C/C\C=C/CCCCC(O)=O, CCCCC\C=C/C\C=C/C\C=C/CCCCC(O)=O, CCCCC\C=C/C\C=C/C\C=C/CCCCC(O)=O, CCCCC\C=C/C\C=C/C\C=C/CCCCC(O)=O, CCCCC\C=C/C\C=C/C\C=C/CCCCC(O)=O	VZCCETWTMQHEPK-QNEBEIHSSA-N, VZCCETWTMQHEPK-QNEBEIHSSA-N, VZCCETWTMQHEPK-QNEBEIHSSA-N, VZCCETWTMQHEPK-QNEBEIHSSA-N, VZCCETWTMQHEPK-QNEBEIHSSA-N	Phase 2
ganaxolone	GABA receptor modulator	GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6			CC(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4C[C@](C)(O)CC[C@]4(C)[C@H]3CC[C@]12C, CC(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4C[C@](C)(O)CC[C@]4(C)[C@H]3CC[C@]12C, CC(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4C[C@](C)(O)CC[C@]4(C)[C@H]3CC[C@]12C	PGTVWKLGGCQMBR-FLBATMFCSA-N, PGTVWKLGGCQMBR-FLBATMFCSA-N, PGTVWKLGGCQMBR-FLBATMFCSA-N	Phase 3
ganciclovir	DNA polymerase inhibitor		infectious disease	cytomegalovirus (CMV)	Nc1nc(=O)c2ncn(COC(CO)CO)c2[nH]1, Nc1nc(=O)c2ncn(COC(CO)CO)c2[nH]1, Nc1nc(=O)c2ncn(COC(CO)CO)c2[nH]1, Nc1nc(=O)c2ncn(COC(CO)CO)c2[nH]1	IRSCQMHQWWYFCW-UHFFFAOYSA-N, IRSCQMHQWWYFCW-UHFFFAOYSA-N, IRSCQMHQWWYFCW-UHFFFAOYSA-N, IRSCQMHQWWYFCW-UHFFFAOYSA-N	Launched
ganetespib	HSP inhibitor	HSP90AA1			CC(C)c1cc(-c2n[nH]c(=O)n2-c2ccc3n(C)ccc3c2)c(O)cc1O, CC(C)c1cc(-c2n[nH]c(=O)n2-c2ccc3n(C)ccc3c2)c(O)cc1O, CC(C)c1cc(-c2n[nH]c(=O)n2-c2ccc3n(C)ccc3c2)c(O)cc1O, CC(C)c1cc(-c2n[nH]c(=O)n2-c2ccc3n(C)ccc3c2)c(O)cc1O, CC(C)c1cc(-c2n[nH]c(=O)n2-c2ccc3n(C)ccc3c2)c(O)cc1O, CC(C)c1cc(-c2n[nH]c(=O)n2-c2ccc3n(C)ccc3c2)c(O)cc1O, CC(C)c1cc(-c2n[nH]c(=O)n2-c2ccc3n(C)ccc3c2)c(O)cc1O	RVAQIUULWULRNW-UHFFFAOYSA-N, RVAQIUULWULRNW-UHFFFAOYSA-N, RVAQIUULWULRNW-UHFFFAOYSA-N, RVAQIUULWULRNW-UHFFFAOYSA-N, RVAQIUULWULRNW-UHFFFAOYSA-N, RVAQIUULWULRNW-UHFFFAOYSA-N, RVAQIUULWULRNW-UHFFFAOYSA-N	Phase 3
ganoderic-acid-a	JAK inhibitor				[H][C@@]12C[C@H](O)C3=C(C(=O)C[C@]4(C)[C@H](C[C@H](O)[C@@]34C)[C@H](C)CC(=O)C[C@@H](C)C(O)=O)[C@@]1(C)CCC(=O)C2(C)C |t:5|	DYOKDAQBNHPJFD-JNTBEZBXSA-N	Preclinical
GANT-58	GLI antagonist	GLI1			c1cc(ccn1)-c1sc(c(c1-c1ccncc1)-c1ccncc1)-c1ccncc1, c1cc(ccn1)-c1sc(c(c1-c1ccncc1)-c1ccncc1)-c1ccncc1	USWLOKMMUTWFMD-UHFFFAOYSA-N, USWLOKMMUTWFMD-UHFFFAOYSA-N	Preclinical
GANT-61	GLI antagonist	GLI1, GLI2			CN(C)c1ccccc1CN1CCCN(Cc2ccccc2N(C)C)C1c1ccncc1, CN(C)c1ccccc1CN1CCCN(Cc2ccccc2N(C)C)C1c1ccncc1, CN(C)c1ccccc1CN1CCCN(Cc2ccccc2N(C)C)C1c1ccncc1, CN(C)c1ccccc1CN1CCCN(Cc2ccccc2N(C)C)C1c1ccncc1, CN(C)c1ccccc1CN1CCCN(Cc2ccccc2N(C)C)C1c1ccncc1, CN(C)c1ccccc1CN1CCCN(Cc2ccccc2N(C)C)C1c1ccncc1, CN(C)c1ccccc1CN1CCCN(Cc2ccccc2N(C)C)C1c1ccncc1, CN(C)c1ccccc1CN1CCCN(Cc2ccccc2N(C)C)C1c1ccncc1	KVQOGDQTWWCZFX-UHFFFAOYSA-N, KVQOGDQTWWCZFX-UHFFFAOYSA-N, KVQOGDQTWWCZFX-UHFFFAOYSA-N, KVQOGDQTWWCZFX-UHFFFAOYSA-N, KVQOGDQTWWCZFX-UHFFFAOYSA-N, KVQOGDQTWWCZFX-UHFFFAOYSA-N, KVQOGDQTWWCZFX-UHFFFAOYSA-N, KVQOGDQTWWCZFX-UHFFFAOYSA-N	Preclinical
garenoxacin	topoisomerase inhibitor	TOP2A	infectious disease	respiratory tract infections	C[C@H]1NCc2cc(ccc12)-c1ccc2c(c1OC(F)F)n(cc(C(O)=O)c2=O)C1CC1, C[C@H]1NCc2cc(ccc12)-c1ccc2c(c1OC(F)F)n(cc(C(O)=O)c2=O)C1CC1	NJDRXTDGYFKORP-LLVKDONJSA-N, NJDRXTDGYFKORP-LLVKDONJSA-N	Launched
gastrodin					OC[C@H]1O[C@@H](Oc2ccc(CO)cc2)[C@H](O)[C@@H](O)[C@@H]1O	PUQSUZTXKPLAPR-UJPOAAIJSA-N	Phase 2
gatifloxacin	bacterial DNA gyrase inhibitor				COc1c(N2CCN[C@@H](C)C2)c(F)cc2c1n(cc(C(O)=O)c2=O)C1CC1 |&1:8|, COc1c(N2CCN[C@@H](C)C2)c(F)cc2c1n(cc(C(O)=O)c2=O)C1CC1 |&1:8|	XUBOMFCQGDBHNK-JTQLQIEISA-N, XUBOMFCQGDBHNK-JTQLQIEISA-N	Withdrawn
gavestinel	glutamate receptor antagonist	GLRB, GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D, GRIN3A, GRIN3B			OC(=O)c1[nH]c2cc(Cl)cc(Cl)c2c1\C=C\C(=O)Nc1ccccc1, OC(=O)c1[nH]c2cc(Cl)cc(Cl)c2c1\C=C\C(=O)Nc1ccccc1, OC(=O)c1[nH]c2cc(Cl)cc(Cl)c2c1\C=C\C(=O)Nc1ccccc1, OC(=O)c1[nH]c2cc(Cl)cc(Cl)c2c1\C=C\C(=O)Nc1ccccc1	WZBNEZWCNKUOSM-VOTSOKGWSA-N, WZBNEZWCNKUOSM-VOTSOKGWSA-N, WZBNEZWCNKUOSM-VOTSOKGWSA-N, WZBNEZWCNKUOSM-VOTSOKGWSA-N	Phase 3
GBR-12783	dopamine reuptake inhibitor				C(CN1CCN(C\C=C\c2ccccc2)CC1)OC(c1ccccc1)c1ccccc1, C(CN1CCN(C\C=C\c2ccccc2)CC1)OC(c1ccccc1)c1ccccc1, C(CN1CCN(C\C=C\c2ccccc2)CC1)OC(c1ccccc1)c1ccccc1, C(CN1CCN(C\C=C\c2ccccc2)CC1)OC(c1ccccc1)c1ccccc1, C(CN1CCN(C\C=C\c2ccccc2)CC1)OC(c1ccccc1)c1ccccc1, C(CN1CCN(C\C=C\c2ccccc2)CC1)OC(c1ccccc1)c1ccccc1	XFBDGHFDKJITGC-JLHYYAGUSA-N, XFBDGHFDKJITGC-JLHYYAGUSA-N, XFBDGHFDKJITGC-JLHYYAGUSA-N, XFBDGHFDKJITGC-JLHYYAGUSA-N, XFBDGHFDKJITGC-JLHYYAGUSA-N, XFBDGHFDKJITGC-JLHYYAGUSA-N	Preclinical
GBR-12935	dopamine reuptake inhibitor	AGTR1, SLC6A3			C(CN1CCN(CCOC(c2ccccc2)c2ccccc2)CC1)Cc1ccccc1, C(CN1CCN(CCOC(c2ccccc2)c2ccccc2)CC1)Cc1ccccc1	RAQPOZGWANIDQT-UHFFFAOYSA-N, RAQPOZGWANIDQT-UHFFFAOYSA-N	Preclinical
GBR-13069	dopamine reuptake inhibitor	SLC6A3			Fc1ccc(cc1)C(OCCN1CCN(C\C=C\c2ccccc2)CC1)c1ccc(F)cc1, Fc1ccc(cc1)C(OCCN1CCN(C\C=C\c2ccccc2)CC1)c1ccc(F)cc1, Fc1ccc(cc1)C(OCCN1CCN(C\C=C\c2ccccc2)CC1)c1ccc(F)cc1, Fc1ccc(cc1)C(OCCN1CCN(C\C=C\c2ccccc2)CC1)c1ccc(F)cc1	DASHZBBQOARCMQ-QPJJXVBHSA-N, DASHZBBQOARCMQ-QPJJXVBHSA-N, DASHZBBQOARCMQ-QPJJXVBHSA-N, DASHZBBQOARCMQ-QPJJXVBHSA-N	Preclinical
GDC-0068	AKT inhibitor	AKT1, AKT2, AKT3, PRKG1			CC(C)NC[C@@H](C(=O)N1CCN(CC1)c1ncnc2[C@H](O)C[C@@H](C)c12)c1ccc(Cl)cc1	GRZXWCHAXNAUHY-NSISKUIASA-N	Phase 3
GDC-0077	PI3K inhibitor				C[C@H](Nc1ccc2-c3nc(cn3CCOc2c1)N1[C@@H](COC1=O)C(F)F)C(N)=O	SGEUNORSOZVTOL-CABZTGNLSA-N	Phase 1
GDC-0084	mTOR inhibitor, PI3K inhibitor				CC1(C)OCCn2c1nc1c(nc(nc21)-c1cnc(N)nc1)N1CCOCC1	LGWACEZVCMBSKW-UHFFFAOYSA-N	Phase 2
GDC-0152	XIAP inhibitor	BIRC2, BIRC3, BIRC7, XIAP			CN[C@@H](C)C(=O)N[C@@H](C1CCCCC1)C(=O)N1CCC[C@H]1C(=O)Nc1snnc1-c1ccccc1, CN[C@@H](C)C(=O)N[C@@H](C1CCCCC1)C(=O)N1CCC[C@H]1C(=O)Nc1snnc1-c1ccccc1, CN[C@@H](C)C(=O)N[C@@H](C1CCCCC1)C(=O)N1CCC[C@H]1C(=O)Nc1snnc1-c1ccccc1, CN[C@@H](C)C(=O)N[C@@H](C1CCCCC1)C(=O)N1CCC[C@H]1C(=O)Nc1snnc1-c1ccccc1, CN[C@@H](C)C(=O)N[C@@H](C1CCCCC1)C(=O)N1CCC[C@H]1C(=O)Nc1snnc1-c1ccccc1, CN[C@@H](C)C(=O)N[C@@H](C1CCCCC1)C(=O)N1CCC[C@H]1C(=O)Nc1snnc1-c1ccccc1	WZRFLSDVFPIXOV-LRQRDZAKSA-N, WZRFLSDVFPIXOV-LRQRDZAKSA-N, WZRFLSDVFPIXOV-LRQRDZAKSA-N, WZRFLSDVFPIXOV-LRQRDZAKSA-N, WZRFLSDVFPIXOV-LRQRDZAKSA-N, WZRFLSDVFPIXOV-LRQRDZAKSA-N	Phase 1
GDC-0349	Pim kinase inhibitor	PIK3CA			CCNC(=O)Nc1ccc(cc1)-c1nc2CN(CCc2c(n1)N1CCOC[C@@H]1C)C1COC1, CCNC(=O)Nc1ccc(cc1)-c1nc2CN(CCc2c(n1)N1CCOC[C@@H]1C)C1COC1, CCNC(=O)Nc1ccc(cc1)-c1nc2CN(CCc2c(n1)N1CCOC[C@@H]1C)C1COC1, CCNC(=O)Nc1ccc(cc1)-c1nc2CN(CCc2c(n1)N1CCOC[C@@H]1C)C1COC1, CCNC(=O)Nc1ccc(cc1)-c1nc2CN(CCc2c(n1)N1CCOC[C@@H]1C)C1COC1, CCNC(=O)Nc1ccc(cc1)-c1nc2CN(CCc2c(n1)N1CCOC[C@@H]1C)C1COC1, CCNC(=O)Nc1ccc(cc1)-c1nc2CN(CCc2c(n1)N1CCOC[C@@H]1C)C1COC1	RGJOJUGRHPQXGF-INIZCTEOSA-N, RGJOJUGRHPQXGF-INIZCTEOSA-N, RGJOJUGRHPQXGF-INIZCTEOSA-N, RGJOJUGRHPQXGF-INIZCTEOSA-N, RGJOJUGRHPQXGF-INIZCTEOSA-N, RGJOJUGRHPQXGF-INIZCTEOSA-N, RGJOJUGRHPQXGF-INIZCTEOSA-N	Phase 1
GDC-0575	CHK inhibitor				N[C@@H]1CCCN(C1)c1c(Br)cnc2[nH]cc(NC(=O)C3CC3)c12	BAZRWWGASYWYGB-SNVBAGLBSA-N	Phase 1
GDC-0623	MEK inhibitor				OCCONC(=O)c1ccc2cncn2c1Nc1ccc(I)cc1F, OCCONC(=O)c1ccc2cncn2c1Nc1ccc(I)cc1F, OCCONC(=O)c1ccc2cncn2c1Nc1ccc(I)cc1F, OCCONC(=O)c1ccc2cncn2c1Nc1ccc(I)cc1F, OCCONC(=O)c1ccc2cncn2c1Nc1ccc(I)cc1F	RFWVETIZUQEJEF-UHFFFAOYSA-N, RFWVETIZUQEJEF-UHFFFAOYSA-N, RFWVETIZUQEJEF-UHFFFAOYSA-N, RFWVETIZUQEJEF-UHFFFAOYSA-N, RFWVETIZUQEJEF-UHFFFAOYSA-N	Phase 1
GDC-0810	selective estrogen receptor destabilizer	ESR1			CC\C(=C(\c1ccc(\C=C\C(O)=O)cc1)c1ccc2n[nH]cc2c1)c1ccc(F)cc1Cl, CC\C(=C(\c1ccc(\C=C\C(O)=O)cc1)c1ccc2n[nH]cc2c1)c1ccc(F)cc1Cl	BURHGPHDEVGCEZ-KJGLQBJMSA-N, BURHGPHDEVGCEZ-KJGLQBJMSA-N	Phase 2
GDC-0834	Bruton's tyrosine kinase (BTK) inhibitor	BTK			CN1CCN(C)C(=O)[C@@H]1c1ccc(Nc2nc(cn(C)c2=O)-c2cccc(NC(=O)c3cc4CCCCc4s3)c2C)cc1 |&1:8,r|, CN1CCN(C)C(=O)[C@@H]1c1ccc(Nc2nc(cn(C)c2=O)-c2cccc(NC(=O)c3cc4CCCCc4s3)c2C)cc1 |&1:8,r|, CN1CCN(C)C(=O)[C@@H]1c1ccc(Nc2nc(cn(C)c2=O)-c2cccc(NC(=O)c3cc4CCCCc4s3)c2C)cc1 |&1:8,r|, CN1CCN(C)C(=O)[C@@H]1c1ccc(Nc2nc(cn(C)c2=O)-c2cccc(NC(=O)c3cc4CCCCc4s3)c2C)cc1 |&1:8,r|, CN1CCN(C)C(=O)[C@@H]1c1ccc(Nc2nc(cn(C)c2=O)-c2cccc(NC(=O)c3cc4CCCCc4s3)c2C)cc1 |&1:8,r|, CN1CCN(C)C(=O)[C@@H]1c1ccc(Nc2nc(cn(C)c2=O)-c2cccc(NC(=O)c3cc4CCCCc4s3)c2C)cc1 |&1:8,r|, CN1CCN(C)C(=O)[C@@H]1c1ccc(Nc2nc(cn(C)c2=O)-c2cccc(NC(=O)c3cc4CCCCc4s3)c2C)cc1 |&1:8,r|, CN1CCN(C)C(=O)[C@@H]1c1ccc(Nc2nc(cn(C)c2=O)-c2cccc(NC(=O)c3cc4CCCCc4s3)c2C)cc1 |&1:8,r|	CDOOFZZILLRUQH-LJAQVGFWSA-N, CDOOFZZILLRUQH-LJAQVGFWSA-N, CDOOFZZILLRUQH-LJAQVGFWSA-N, CDOOFZZILLRUQH-LJAQVGFWSA-N, CDOOFZZILLRUQH-LJAQVGFWSA-N, CDOOFZZILLRUQH-LJAQVGFWSA-N, CDOOFZZILLRUQH-LJAQVGFWSA-N, CDOOFZZILLRUQH-LJAQVGFWSA-N	Phase 1
GDC-0879	RAF inhibitor	BRAF			OCCn1cc(c(n1)-c1ccncc1)-c1ccc2\C(CCc2c1)=N\O, OCCn1cc(c(n1)-c1ccncc1)-c1ccc2\C(CCc2c1)=N\O, OCCn1cc(c(n1)-c1ccncc1)-c1ccc2\C(CCc2c1)=N\O, OCCn1cc(c(n1)-c1ccncc1)-c1ccc2\C(CCc2c1)=N\O	DEZZLWQELQORIU-RELWKKBWSA-N, DEZZLWQELQORIU-RELWKKBWSA-N, DEZZLWQELQORIU-RELWKKBWSA-N, DEZZLWQELQORIU-RELWKKBWSA-N	Preclinical
GDC-0927	estrogen receptor antagonist				CC1=C([C@@H](Oc2ccc(O)cc12)c1ccc(OCCN2CC(CF)C2)cc1)c1cccc(O)c1 |t:1|, CC1=C([C@@H](Oc2ccc(O)cc12)c1ccc(OCCN2CC(CF)C2)cc1)c1cccc(O)c1 |t:1|	KJAAPZIFCQQQKX-NDEPHWFRSA-N, KJAAPZIFCQQQKX-NDEPHWFRSA-N	Phase 1
GDC-0941	PI3K inhibitor	PIK3CA, PIK3CB, PIK3CD, PIK3CG			CS(=O)(=O)N1CCN(Cc2cc3nc(nc(N4CCOCC4)c3s2)-c2cccc3n[nH]cc23)CC1, CS(=O)(=O)N1CCN(Cc2cc3nc(nc(N4CCOCC4)c3s2)-c2cccc3n[nH]cc23)CC1, CS(=O)(=O)N1CCN(Cc2cc3nc(nc(N4CCOCC4)c3s2)-c2cccc3n[nH]cc23)CC1, CS(=O)(=O)N1CCN(Cc2cc3nc(nc(N4CCOCC4)c3s2)-c2cccc3n[nH]cc23)CC1, CS(=O)(=O)N1CCN(Cc2cc3nc(nc(N4CCOCC4)c3s2)-c2cccc3n[nH]cc23)CC1, CS(=O)(=O)N1CCN(Cc2cc3nc(nc(N4CCOCC4)c3s2)-c2cccc3n[nH]cc23)CC1, CS(=O)(=O)N1CCN(Cc2cc3nc(nc(N4CCOCC4)c3s2)-c2cccc3n[nH]cc23)CC1	LHNIIDJUOCFXAP-UHFFFAOYSA-N, LHNIIDJUOCFXAP-UHFFFAOYSA-N, LHNIIDJUOCFXAP-UHFFFAOYSA-N, LHNIIDJUOCFXAP-UHFFFAOYSA-N, InChI=1S/C23H27N7O3S2/c1-35(31,32)30-7-5-28(6-8-30)15-16-13-20-21(34-16)23(29-9-11-33-12-10-29)26-22(25-20)17-3-2-4-19-18(17)14-24-27-19/h2-4,13-14H,5-12,15H2,1H3,(H,24,27), InChI=1S/C23H27N7O3S2/c1-35(31,32)30-7-5-28(6-8-30)15-16-13-20-21(34-16)23(29-9-11-33-12-10-29)26-22(25-20)17-3-2-4-19-18(17)14-24-27-19/h2-4,13-14H,5-12,15H2,1H3,(H,24,27), InChI=1S/C23H27N7O3S2/c1-35(31,32)30-7-5-28(6-8-30)15-16-13-20-21(34-16)23(29-9-11-33-12-10-29)26-22(25-20)17-3-2-4-19-18(17)14-24-27-19/h2-4,13-14H,5-12,15H2,1H3,(H,24,27)	Phase 2
GDC-0980	mTOR inhibitor, PI3K inhibitor	FGR, MAP3K9, MTOR, PIK3CA, PIK3CB, PIK3CD, PIK3CG, SYK			C[C@H](O)C(=O)N1CCN(Cc2sc3c(nc(nc3c2C)-c2cnc(N)nc2)N2CCOCC2)CC1, C[C@H](O)C(=O)N1CCN(Cc2sc3c(nc(nc3c2C)-c2cnc(N)nc2)N2CCOCC2)CC1, C[C@H](O)C(=O)N1CCN(Cc2sc3c(nc(nc3c2C)-c2cnc(N)nc2)N2CCOCC2)CC1, C[C@H](O)C(=O)N1CCN(Cc2sc3c(nc(nc3c2C)-c2cnc(N)nc2)N2CCOCC2)CC1, C[C@H](O)C(=O)N1CCN(Cc2sc3c(nc(nc3c2C)-c2cnc(N)nc2)N2CCOCC2)CC1, C[C@H](O)C(=O)N1CCN(Cc2sc3c(nc(nc3c2C)-c2cnc(N)nc2)N2CCOCC2)CC1, C[C@H](O)C(=O)N1CCN(Cc2sc3c(nc(nc3c2C)-c2cnc(N)nc2)N2CCOCC2)CC1, C[C@H](O)C(=O)N1CCN(Cc2sc3c(nc(nc3c2C)-c2cnc(N)nc2)N2CCOCC2)CC1, C[C@H](O)C(=O)N1CCN(Cc2sc3c(nc(nc3c2C)-c2cnc(N)nc2)N2CCOCC2)CC1	YOVVNQKCSKSHKT-HNNXBMFYSA-N, YOVVNQKCSKSHKT-HNNXBMFYSA-N, YOVVNQKCSKSHKT-HNNXBMFYSA-N, YOVVNQKCSKSHKT-HNNXBMFYSA-N, YOVVNQKCSKSHKT-HNNXBMFYSA-N, YOVVNQKCSKSHKT-HNNXBMFYSA-N, YOVVNQKCSKSHKT-HNNXBMFYSA-N, YOVVNQKCSKSHKT-HNNXBMFYSA-N, YOVVNQKCSKSHKT-HNNXBMFYSA-N	Phase 2
GDC-0994	MAP kinase inhibitor	MAPK1, MAPK3			Cn1nccc1Nc1nccc(n1)-c1ccn([C@@H](CO)c2ccc(Cl)c(F)c2)c(=O)c1 |&1:17,r|, Cn1nccc1Nc1nccc(n1)-c1ccn([C@@H](CO)c2ccc(Cl)c(F)c2)c(=O)c1 |&1:17,r|	RZUOCXOYPYGSKL-SFHVURJKSA-N, RZUOCXOYPYGSKL-SFHVURJKSA-N	Phase 1
gedunin	HSP inhibitor	HSP90AA1			CC(=O)O[C@@H]1C[C@H]2C(C)(C)C(=O)C=C[C@]2(C)[C@H]2CC[C@@]3(C)[C@@H](OC(=O)[C@H]4O[C@@]34[C@]12C)c1ccoc1 |c:12|	YJXDGWUNRYLINJ-BHAPSIHVSA-N	Preclinical
gefapixant	purinergic receptor antagonist				COc1cc(C(C)C)c(Oc2cnc(N)nc2N)cc1S(N)(=O)=O	HLWURFKMDLAKOD-UHFFFAOYSA-N	Phase 3
gefitinib	EGFR inhibitor	EGFR	oncology	non-small cell lung cancer (NSCLC)	COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1, COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1, COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1, COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1, COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1, COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1, COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1, COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1, COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1, COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1, COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1, COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1	XGALLCVXEZPNRQ-UHFFFAOYSA-N, XGALLCVXEZPNRQ-UHFFFAOYSA-N, XGALLCVXEZPNRQ-UHFFFAOYSA-N, XGALLCVXEZPNRQ-UHFFFAOYSA-N, XGALLCVXEZPNRQ-UHFFFAOYSA-N, XGALLCVXEZPNRQ-UHFFFAOYSA-N, XGALLCVXEZPNRQ-UHFFFAOYSA-N, XGALLCVXEZPNRQ-UHFFFAOYSA-N, XGALLCVXEZPNRQ-UHFFFAOYSA-N, XGALLCVXEZPNRQ-UHFFFAOYSA-N, XGALLCVXEZPNRQ-UHFFFAOYSA-N, XGALLCVXEZPNRQ-UHFFFAOYSA-N	Launched
geldanamycin	HSP inhibitor	HSP90AA1			CO[C@H]1C[C@H](C)CC2=C(OC)C(=O)C=C(NC(=O)\C(C)=C\C=C\[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O |c:7,t:13,19,21,32|, CO[C@H]1C[C@H](C)CC2=C(OC)C(=O)C=C(NC(=O)\C(C)=C\C=C\[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O |c:7,t:13,19,21,32|, CO[C@H]1C[C@H](C)CC2=C(OC)C(=O)C=C(NC(=O)\C(C)=C\C=C\[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O |c:7,t:13,19,21,32|, CO[C@H]1C[C@H](C)CC2=C(OC)C(=O)C=C(NC(=O)\C(C)=C\C=C\[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O |c:7,t:13,19,21,32|	QTQAWLPCGQOSGP-SLOAUYBXSA-N, QTQAWLPCGQOSGP-SLOAUYBXSA-N, QTQAWLPCGQOSGP-SLOAUYBXSA-N, QTQAWLPCGQOSGP-SLOAUYBXSA-N	Preclinical
gemcadiol	antilipemic				CC(C)(CO)CCCCCCC(C)(C)CO, CC(C)(CO)CCCCCCC(C)(C)CO, CC(C)(CO)CCCCCCC(C)(C)CO	DJKWDKJYFYUEBQ-UHFFFAOYSA-N, DJKWDKJYFYUEBQ-UHFFFAOYSA-N, DJKWDKJYFYUEBQ-UHFFFAOYSA-N	Phase 2
gemcitabine	ribonucleotide reductase inhibitor	CMPK1, RRM1, RRM2, TYMS	oncology	ovarian cancer, breast cancer, non-small cell lung cancer (NSCLC), pancreatic cancer	Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1	SDUQYLNIPVEERB-QPPQHZFASA-N, SDUQYLNIPVEERB-QPPQHZFASA-N, SDUQYLNIPVEERB-QPPQHZFASA-N, SDUQYLNIPVEERB-QPPQHZFASA-N, SDUQYLNIPVEERB-QPPQHZFASA-N, SDUQYLNIPVEERB-QPPQHZFASA-N, SDUQYLNIPVEERB-QPPQHZFASA-N, SDUQYLNIPVEERB-QPPQHZFASA-N, SDUQYLNIPVEERB-QPPQHZFASA-N, SDUQYLNIPVEERB-QPPQHZFASA-N, SDUQYLNIPVEERB-QPPQHZFASA-N, SDUQYLNIPVEERB-QPPQHZFASA-N	Launched
gemcitabine-elaidate	apoptosis inhibitor, DNA synthesis inhibitor	CMPK1, RRM1, TYMS			CCCCCCCC\C=C\CCCCCCCC(=O)OC[C@H]1O[C@@H](n2ccc(N)nc2=O)C(F)(F)[C@@H]1O, CCCCCCCC\C=C\CCCCCCCC(=O)OC[C@H]1O[C@@H](n2ccc(N)nc2=O)C(F)(F)[C@@H]1O, CCCCCCCC\C=C\CCCCCCCC(=O)OC[C@H]1O[C@@H](n2ccc(N)nc2=O)C(F)(F)[C@@H]1O, CCCCCCCC\C=C\CCCCCCCC(=O)OC[C@H]1O[C@@H](n2ccc(N)nc2=O)C(F)(F)[C@@H]1O	HESSNRGIEVBPRB-QDDPNBLJSA-N, HESSNRGIEVBPRB-QDDPNBLJSA-N, HESSNRGIEVBPRB-QDDPNBLJSA-N, HESSNRGIEVBPRB-QDDPNBLJSA-N	Phase 1
gemfibrozil	lipoprotein lipase activator	LPL, PPARA, SLCO1B1, SLCO1B3, SLCO2B1	endocrinology, cardiology	hyperlipidemia, coronary heart disease	Cc1ccc(C)c(OCCCC(C)(C)C(O)=O)c1, Cc1ccc(C)c(OCCCC(C)(C)C(O)=O)c1, Cc1ccc(C)c(OCCCC(C)(C)C(O)=O)c1, Cc1ccc(C)c(OCCCC(C)(C)C(O)=O)c1	HEMJJKBWTPKOJG-UHFFFAOYSA-N, HEMJJKBWTPKOJG-UHFFFAOYSA-N, HEMJJKBWTPKOJG-UHFFFAOYSA-N, HEMJJKBWTPKOJG-UHFFFAOYSA-N	Launched
gemifloxacin	bacterial DNA gyrase inhibitor		pulmonary, infectious disease	bronchitis, pneumonia	CO\N=C1/CN(C[C@@H]1CN)c1nc2n(cc(C(O)=O)c(=O)c2cc1F)C1CC1 |&1:7|	ZRCVYEYHRGVLOC-NOTZLVJDSA-N	Launched
gemigliptin	dipeptidyl peptidase inhibitor				N[C@H](CN1CC(F)(F)CCC1=O)CC(=O)N1CCc2c(C1)nc(nc2C(F)(F)F)C(F)(F)F	ZWPRRQZNBDYKLH-VIFPVBQESA-N	Launched
genipin	choleretic agent				COC(=O)C1=CO[C@@H](O)[C@H]2[C@@H]1CC=C2CO |c:13,t:4|, COC(=O)C1=CO[C@@H](O)[C@H]2[C@@H]1CC=C2CO |c:13,t:4|, COC(=O)C1=CO[C@@H](O)[C@H]2[C@@H]1CC=C2CO |c:13,t:4|, COC(=O)C1=CO[C@@H](O)[C@H]2[C@@H]1CC=C2CO |c:13,t:4|	AZKVWQKMDGGDSV-BCMRRPTOSA-N, AZKVWQKMDGGDSV-BCMRRPTOSA-N, AZKVWQKMDGGDSV-BCMRRPTOSA-N, AZKVWQKMDGGDSV-BCMRRPTOSA-N	Preclinical
geniposide	GLP receptor agonist	GLP1R			COC(=O)C1=CO[C@@H](O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@H]2[C@@H]1CC=C2CO |c:25,t:4|, COC(=O)C1=CO[C@@H](O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@H]2[C@@H]1CC=C2CO |c:25,t:4|, COC(=O)C1=CO[C@@H](O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@H]2[C@@H]1CC=C2CO |c:25,t:4|, COC(=O)C1=CO[C@@H](O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@H]2[C@@H]1CC=C2CO |c:25,t:4|	IBFYXTRXDNAPMM-BVTMAQQCSA-N, IBFYXTRXDNAPMM-BVTMAQQCSA-N, IBFYXTRXDNAPMM-BVTMAQQCSA-N, IBFYXTRXDNAPMM-BVTMAQQCSA-N	Preclinical
geniposidic-acid	cyclooxygenase inhibitor				OC[C@H]1O[C@@H](O[C@@H]2OC=C([C@H]3CC=C(CO)[C@@H]23)C(O)=O)[C@H](O)[C@@H](O)[C@@H]1O |c:8,t:12|, OC[C@H]1O[C@@H](O[C@@H]2OC=C([C@H]3CC=C(CO)[C@@H]23)C(O)=O)[C@H](O)[C@@H](O)[C@@H]1O |c:8,t:12|, OC[C@H]1O[C@@H](O[C@@H]2OC=C([C@H]3CC=C(CO)[C@@H]23)C(O)=O)[C@H](O)[C@@H](O)[C@@H]1O |c:8,t:12|, OC[C@H]1O[C@@H](O[C@@H]2OC=C([C@H]3CC=C(CO)[C@@H]23)C(O)=O)[C@H](O)[C@@H](O)[C@@H]1O |c:8,t:12|	ZJDOESGVOWAULF-OGJQONSISA-N, ZJDOESGVOWAULF-OGJQONSISA-N, ZJDOESGVOWAULF-OGJQONSISA-N, ZJDOESGVOWAULF-OGJQONSISA-N	Preclinical
genistein	tyrosine kinase inhibitor	CFTR, ESR1, ESR2, ESRRA, ESRRB, ESRRG, NCOA1, NCOA2, PPARG, PTK2B, TOP2A, TRPC5			Oc1ccc(cc1)-c1coc2cc(O)cc(O)c2c1=O, Oc1ccc(cc1)-c1coc2cc(O)cc(O)c2c1=O, Oc1ccc(cc1)-c1coc2cc(O)cc(O)c2c1=O, Oc1ccc(cc1)-c1coc2cc(O)cc(O)c2c1=O, Oc1ccc(cc1)-c1coc2cc(O)cc(O)c2c1=O	TZBJGXHYKVUXJN-UHFFFAOYSA-N, TZBJGXHYKVUXJN-UHFFFAOYSA-N, TZBJGXHYKVUXJN-UHFFFAOYSA-N, TZBJGXHYKVUXJN-UHFFFAOYSA-N, TZBJGXHYKVUXJN-UHFFFAOYSA-N	Phase 2/Phase 3
gentamycin	bacterial 50S ribosomal subunit inhibitor	HSPA8	infectious disease, critical care	bone and joint infections, endocarditis, pelvic inflammatory disease, meningitis, pneumonia, urinary tract infections, sepsis	CN[C@H](C)[C@@H]1CC[C@@H](N)[C@@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3OC[C@](C)(O)[C@H](NC)[C@H]3O)[C@H]2O)O1	CEAZRRDELHUEMR-CAMVTXANSA-N	Launched
gentiopicrin	glutamate receptor downregulator	GRIN2B			OC[C@H]1O[C@@H](O[C@@H]2OC=C3C(=O)OCC=C3[C@H]2C=C)[C@H](O)[C@@H](O)[C@@H]1O |c:14,t:8|	DUAGQYUORDTXOR-GPQRQXLASA-N	Phase 3
genz-123346	glucosylceramidase inhibitor	UGCG			CCCCCCCCC(=O)N[C@H](CN1CCCC1)[C@H](O)c1ccc2OCCOc2c1, CCCCCCCCC(=O)N[C@H](CN1CCCC1)[C@H](O)c1ccc2OCCOc2c1	JMNXWOFCUJJYEO-HYBUGGRVSA-N, JMNXWOFCUJJYEO-HYBUGGRVSA-N	Preclinical
genz-644282	topoisomerase inhibitor	TOP1			CNCCn1c2c3cc4OCOc4cc3ncc2c2cc(OC)c(OC)cc2c1=O, CNCCn1c2c3cc4OCOc4cc3ncc2c2cc(OC)c(OC)cc2c1=O, CNCCn1c2c3cc4OCOc4cc3ncc2c2cc(OC)c(OC)cc2c1=O	BAORCAMWLWRZQG-UHFFFAOYSA-N, BAORCAMWLWRZQG-UHFFFAOYSA-N, BAORCAMWLWRZQG-UHFFFAOYSA-N	Phase 1
gepefrine	adrenergic receptor agonist		cardiology	hypotension	C[C@@H](N)Cc1cccc(O)c1 |&1:1,r|, C[C@@H](N)Cc1cccc(O)c1 |&1:1,r|	WTDGMHYYGNJEKQ-SSDOTTSWSA-N, WTDGMHYYGNJEKQ-SSDOTTSWSA-N	Launched
gepon					CC(C)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](CCCNC(N)=N)NC(=O)[C@@H](CCCCN)NC(=O)[C@@H](CCCCN)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@H](N)[C@@H](C)O)[C@@H](C)O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(O)=O |a:3,11,20,51,69,80,100,118,&1:7,&2:31,&3:42,&4:60,&5:71,&6:74,&7:89,&8:109|, CC(C)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](CCCNC(N)=N)NC(=O)[C@@H](CCCCN)NC(=O)[C@@H](CCCCN)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@H](N)[C@@H](C)O)[C@@H](C)O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(O)=O |a:3,11,20,51,69,80,100,118,&1:7,&2:31,&3:42,&4:60,&5:71,&6:74,&7:89,&8:109|	HTQONPPEZULJKY-MUPFFGQUSA-N, HTQONPPEZULJKY-MUPFFGQUSA-N	Phase 1
gepotidacin	topoisomerase inhibitor				O=c1ccc2ncc(=O)n3[C@H](CN4CCC(CC4)NCc4cc5CCCOc5cn4)Cn1c23	PZFAZQUREQIODZ-LJQANCHMSA-N	Phase 2
geranyl-farnesylacetate	mucin production enhancer				CC(C)=CCC\C(C)=C\CC\C(C)=C\CCC(=O)OC\C=C(/C)CCC=C(C)C, CC(C)=CCC\C(C)=C\CC\C(C)=C\CCC(=O)OC\C=C(/C)CCC=C(C)C	ZPACYDRSPFRDHO-ROBAGEODSA-N, ZPACYDRSPFRDHO-ROBAGEODSA-N	Phase 2
gestodene	contraceptive agent		endocrinology	contraceptive	CC[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1C=C[C@@]2(O)C#C |c:20,t:9|, CC[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1C=C[C@@]2(O)C#C |c:20,t:9|	SIGSPDASOTUPFS-XUDSTZEESA-N, SIGSPDASOTUPFS-XUDSTZEESA-N	Launched
gestrinone	progesterone receptor antagonist	AR, ESR1, PGR	obstetrics/gynecology	endometriosis	CC[C@]12C=CC3=C4CCC(=O)C=C4CC[C@H]3[C@@H]1CC[C@@]2(O)C#C |c:3,5,11|, CC[C@]12C=CC3=C4CCC(=O)C=C4CC[C@H]3[C@@H]1CC[C@@]2(O)C#C |c:3,5,11|, CC[C@]12C=CC3=C4CCC(=O)C=C4CC[C@H]3[C@@H]1CC[C@@]2(O)C#C |c:3,5,11|, CC[C@]12C=CC3=C4CCC(=O)C=C4CC[C@H]3[C@@H]1CC[C@@]2(O)C#C |c:3,5,11|, CC[C@]12C=CC3=C4CCC(=O)C=C4CC[C@H]3[C@@H]1CC[C@@]2(O)C#C |c:3,5,11|	BJJXHLWLUDYTGC-ANULTFPQSA-N, BJJXHLWLUDYTGC-ANULTFPQSA-N, BJJXHLWLUDYTGC-ANULTFPQSA-N, BJJXHLWLUDYTGC-ANULTFPQSA-N, BJJXHLWLUDYTGC-ANULTFPQSA-N	Launched
GF109203X	PKC inhibitor	PDPK1, PIM1, PRKCI, PRKCZ			CN(C)CCCn1cc(C2=C(C(=O)NC2=O)c2c[nH]c3ccccc23)c2ccccc12 |t:9|, CN(C)CCCn1cc(C2=C(C(=O)NC2=O)c2c[nH]c3ccccc23)c2ccccc12 |t:9|, CN(C)CCCn1cc(C2=C(C(=O)NC2=O)c2c[nH]c3ccccc23)c2ccccc12 |t:9|, CN(C)CCCn1cc(C2=C(C(=O)NC2=O)c2c[nH]c3ccccc23)c2ccccc12 |t:9|, CN(C)CCCn1cc(C2=C(C(=O)NC2=O)c2c[nH]c3ccccc23)c2ccccc12 |t:9|, CN(C)CCCn1cc(C2=C(C(=O)NC2=O)c2c[nH]c3ccccc23)c2ccccc12 |t:9|, CN(C)CCCn1cc(C2=C(C(=O)NC2=O)c2c[nH]c3ccccc23)c2ccccc12 |t:9|	QMGUOJYZJKLOLH-UHFFFAOYSA-N, QMGUOJYZJKLOLH-UHFFFAOYSA-N, QMGUOJYZJKLOLH-UHFFFAOYSA-N, InChI=1S/C25H24N4O2/c1-28(2)12-7-13-29-15-19(17-9-4-6-11-21(17)29)23-22(24(30)27-25(23)31)18-14-26-20-10-5-3-8-16(18)20/h3-6,8-11,14-15,26H,7,12-13H2,1-2H3,(H,27,30,31), InChI=1S/C25H24N4O2/c1-28(2)12-7-13-29-15-19(17-9-4-6-11-21(17)29)23-22(24(30)27-25(23)31)18-14-26-20-10-5-3-8-16(18)20/h3-6,8-11,14-15,26H,7,12-13H2,1-2H3,(H,27,30,31), InChI=1S/C25H24N4O2/c1-28(2)12-7-13-29-15-19(17-9-4-6-11-21(17)29)23-22(24(30)27-25(23)31)18-14-26-20-10-5-3-8-16(18)20/h3-6,8-11,14-15,26H,7,12-13H2,1-2H3,(H,27,30,31), InChI=1S/C25H24N4O2/c1-28(2)12-7-13-29-15-19(17-9-4-6-11-21(17)29)23-22(24(30)27-25(23)31)18-14-26-20-10-5-3-8-16(18)20/h3-6,8-11,14-15,26H,7,12-13H2,1-2H3,(H,27,30,31)	Preclinical
GGsTop	gamma glutamyltransferase Inhibitor	GGT1			COP(=O)(CC[C@@H](N)C(O)=O)Oc1cccc(CC(O)=O)c1 |&1:2,&2:6,r|, COP(=O)(CC[C@@H](N)C(O)=O)Oc1cccc(CC(O)=O)c1 |&1:2,&2:6,r|	NTFPDEDRMYYPAC-FAYKFVSFSA-N, NTFPDEDRMYYPAC-FAYKFVSFSA-N	Preclinical
GGTI-298	GGTase inhibitor	CDKN1A			COC(=O)[C@H](CC(C)C)NC(=O)c1ccc(NC[C@@H](N)CS)cc1-c1cccc2ccccc12, COC(=O)[C@H](CC(C)C)NC(=O)c1ccc(NC[C@@H](N)CS)cc1-c1cccc2ccccc12	XVWPFYDMUFBHBF-CLOONOSVSA-N, XVWPFYDMUFBHBF-CLOONOSVSA-N	Preclinical
gilteritinib	FLT3 inhibitor	FLT3			CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(CC3)N3CCN(C)CC3)c(OC)c2)nc1NC1CCOCC1, CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(CC3)N3CCN(C)CC3)c(OC)c2)nc1NC1CCOCC1, CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(CC3)N3CCN(C)CC3)c(OC)c2)nc1NC1CCOCC1, CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(CC3)N3CCN(C)CC3)c(OC)c2)nc1NC1CCOCC1	GYQYAJJFPNQOOW-UHFFFAOYSA-N, GYQYAJJFPNQOOW-UHFFFAOYSA-N, GYQYAJJFPNQOOW-UHFFFAOYSA-N, GYQYAJJFPNQOOW-UHFFFAOYSA-N	Launched
gimeracil	dihydropyrimidine dehydrogenase inhibitor	DPYD	oncology	gastric adenocarcinoma	Oc1cc(=O)[nH]cc1Cl, Oc1cc(=O)[nH]cc1Cl	ZPLQIPFOCGIIHV-UHFFFAOYSA-N, ZPLQIPFOCGIIHV-UHFFFAOYSA-N	Launched
ginkgolide-A	GABA receptor antagonist	GLRA1, GLRB			C[C@@H]1C(=O)O[C@H]2C[C@@]34[C@H]5C[C@@H](C(C)(C)C)[C@@]33[C@@H](O)C(=O)O[C@H]3O[C@@]4(C(=O)O5)[C@@]12O	FPUXKXIZEIDQKW-UEHATNFXSA-N	Preclinical
ginkgolide-B	platelet activating factor receptor antagonist	GLRA1, GLRA2, GLRA3, GLRB, HTR3A, HTR3B			C[C@@H]1C(=O)O[C@H]2[C@H](O)[C@@]34[C@H]5C[C@@H](C(C)(C)C)[C@@]33[C@@H](O)C(=O)O[C@H]3O[C@@]4(C(=O)O5)[C@@]12O, C[C@@H]1C(=O)O[C@H]2[C@H](O)[C@@]34[C@H]5C[C@@H](C(C)(C)C)[C@@]33[C@@H](O)C(=O)O[C@H]3O[C@@]4(C(=O)O5)[C@@]12O, C[C@@H]1C(=O)O[C@H]2[C@H](O)[C@@]34[C@H]5C[C@@H](C(C)(C)C)[C@@]33[C@@H](O)C(=O)O[C@H]3O[C@@]4(C(=O)O5)[C@@]12O, C[C@@H]1C(=O)O[C@H]2[C@H](O)[C@@]34[C@H]5C[C@@H](C(C)(C)C)[C@@]33[C@@H](O)C(=O)O[C@H]3O[C@@]4(C(=O)O5)[C@@]12O, C[C@@H]1C(=O)O[C@H]2[C@H](O)[C@@]34[C@H]5C[C@@H](C(C)(C)C)[C@@]33[C@@H](O)C(=O)O[C@H]3O[C@@]4(C(=O)O5)[C@@]12O, C[C@@H]1C(=O)O[C@H]2[C@H](O)[C@@]34[C@H]5C[C@@H](C(C)(C)C)[C@@]33[C@@H](O)C(=O)O[C@H]3O[C@@]4(C(=O)O5)[C@@]12O	SQOJOAFXDQDRGF-AIQFLADASA-N, SQOJOAFXDQDRGF-AIQFLADASA-N, SQOJOAFXDQDRGF-AIQFLADASA-N, SQOJOAFXDQDRGF-AIQFLADASA-N, SQOJOAFXDQDRGF-AIQFLADASA-N, SQOJOAFXDQDRGF-AIQFLADASA-N	Phase 3
ginsenoside-C-K	NFkB pathway inhibitor, nitric oxide synthase inhibitor	PTGS2			CC(C)=CCC[C@](C)(O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O)[C@H]1CC[C@]2(C)[C@@H]1[C@H](O)C[C@@H]1[C@@]3(C)CC[C@H](O)C(C)(C)[C@@H]3CC[C@@]21C, CC(C)=CCC[C@](C)(O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O)[C@H]1CC[C@]2(C)[C@@H]1[C@H](O)C[C@@H]1[C@@]3(C)CC[C@H](O)C(C)(C)[C@@H]3CC[C@@]21C	FVIZARNDLVOMSU-IRFFNABBSA-N, FVIZARNDLVOMSU-IRFFNABBSA-N	Phase 1
ginsenoside-RD	calcium channel blocker				CC(C)=CCC[C@@](C)(O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O)[C@H]1CC[C@]2(C)[C@@H]1[C@H](O)C[C@@H]1[C@@]3(C)CC[C@H](O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)C(C)(C)[C@@H]3CC[C@@]21C |a:9,11,14,16,18,20,23,25,26,29,30,34,36,38,41,43,45,47,49,52,54,56,61,64,&1:6|, CC(C)=CCC[C@@](C)(O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O)[C@H]1CC[C@]2(C)[C@@H]1[C@H](O)C[C@@H]1[C@@]3(C)CC[C@H](O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)C(C)(C)[C@@H]3CC[C@@]21C |a:9,11,14,16,18,20,23,25,26,29,30,34,36,38,41,43,45,47,49,52,54,56,61,64,&1:6|	RLDVZILFNVRJTL-ZMHPOSLNSA-N, RLDVZILFNVRJTL-ZMHPOSLNSA-N	Phase 3
ginsenoside-RE	anti-inflammatory agent				[H][C@@]1(CC[C@]2(C)[C@]1([H])[C@H](O)C[C@]1([H])[C@@]3(C)CC[C@H](O)C(C)(C)[C@]3([H])[C@H](C[C@@]21C)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O[C@@H]1O[C@@H](C)[C@H](O)[C@@H](O)[C@H]1O)[C@](C)(CCC=C(C)C)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O	PWAOOJDMFUQOKB-WCZZMFLVSA-N	Phase 1
ginsenoside-RE3	angiogenesis inhibitor, apoptosis stimulant	KCNH2			CC(C)=CCC[C@@](C)(O)[C@H]1CC[C@]2(C)[C@@H]1[C@H](O)C[C@@H]1[C@@]3(C)CC[C@H](O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)C(C)(C)[C@@H]3CC[C@@]21C |a:9,12,14,15,18,19,23,25,27,30,32,34,36,38,41,43,45,50,53,&1:6|	RWXIFXNRCLMQCD-CZIWJLDFSA-N	Launched
givinostat	HDAC inhibitor	HDAC1, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9			CCN(CC)Cc1ccc2cc(COC(=O)Nc3ccc(cc3)C(=O)NO)ccc2c1, CCN(CC)Cc1ccc2cc(COC(=O)Nc3ccc(cc3)C(=O)NO)ccc2c1, CCN(CC)Cc1ccc2cc(COC(=O)Nc3ccc(cc3)C(=O)NO)ccc2c1, CCN(CC)Cc1ccc2cc(COC(=O)Nc3ccc(cc3)C(=O)NO)ccc2c1, CCN(CC)Cc1ccc2cc(COC(=O)Nc3ccc(cc3)C(=O)NO)ccc2c1, CCN(CC)Cc1ccc2cc(COC(=O)Nc3ccc(cc3)C(=O)NO)ccc2c1, CCN(CC)Cc1ccc2cc(COC(=O)Nc3ccc(cc3)C(=O)NO)ccc2c1, CCN(CC)Cc1ccc2cc(COC(=O)Nc3ccc(cc3)C(=O)NO)ccc2c1, CCN(CC)Cc1ccc2cc(COC(=O)Nc3ccc(cc3)C(=O)NO)ccc2c1, CCN(CC)Cc1ccc2cc(COC(=O)Nc3ccc(cc3)C(=O)NO)ccc2c1, CCN(CC)Cc1ccc2cc(COC(=O)Nc3ccc(cc3)C(=O)NO)ccc2c1, CCN(CC)Cc1ccc2cc(COC(=O)Nc3ccc(cc3)C(=O)NO)ccc2c1	YALNUENQHAQXEA-UHFFFAOYSA-N, YALNUENQHAQXEA-UHFFFAOYSA-N, YALNUENQHAQXEA-UHFFFAOYSA-N, YALNUENQHAQXEA-UHFFFAOYSA-N, YALNUENQHAQXEA-UHFFFAOYSA-N, YALNUENQHAQXEA-UHFFFAOYSA-N, YALNUENQHAQXEA-UHFFFAOYSA-N, InChI=1S/C24H27N3O4/c1-3-27(4-2)15-17-5-7-21-14-18(6-8-20(21)13-17)16-31-24(29)25-22-11-9-19(10-12-22)23(28)26-30/h5-14,30H,3-4,15-16H2,1-2H3,(H,25,29)(H,26,28), InChI=1S/C24H27N3O4/c1-3-27(4-2)15-17-5-7-21-14-18(6-8-20(21)13-17)16-31-24(29)25-22-11-9-19(10-12-22)23(28)26-30/h5-14,30H,3-4,15-16H2,1-2H3,(H,25,29)(H,26,28), InChI=1S/C24H27N3O4/c1-3-27(4-2)15-17-5-7-21-14-18(6-8-20(21)13-17)16-31-24(29)25-22-11-9-19(10-12-22)23(28)26-30/h5-14,30H,3-4,15-16H2,1-2H3,(H,25,29)(H,26,28), InChI=1S/C24H27N3O4/c1-3-27(4-2)15-17-5-7-21-14-18(6-8-20(21)13-17)16-31-24(29)25-22-11-9-19(10-12-22)23(28)26-30/h5-14,30H,3-4,15-16H2,1-2H3,(H,25,29)(H,26,28), InChI=1S/C24H27N3O4/c1-3-27(4-2)15-17-5-7-21-14-18(6-8-20(21)13-17)16-31-24(29)25-22-11-9-19(10-12-22)23(28)26-30/h5-14,30H,3-4,15-16H2,1-2H3,(H,25,29)(H,26,28)	Phase 3
GKA-50	glucokinase activator	GCK			COC[C@H](C)Oc1cc(O[C@@H](C)Cc2ccccc2)cc(c1)C(=O)Nc1ccc(cn1)C(O)=O, COC[C@H](C)Oc1cc(O[C@@H](C)Cc2ccccc2)cc(c1)C(=O)Nc1ccc(cn1)C(O)=O, COC[C@H](C)Oc1cc(O[C@@H](C)Cc2ccccc2)cc(c1)C(=O)Nc1ccc(cn1)C(O)=O	OCBMECSFDVUYQN-ROUUACIJSA-N, OCBMECSFDVUYQN-ROUUACIJSA-N, OCBMECSFDVUYQN-ROUUACIJSA-N	Preclinical
GKT137831	NADPH oxidase inhibitor	NOX1, NOX4			CN(C)c1cccc(c1)-c1n(C)c(=O)cc2[nH]n(-c3ccccc3Cl)c(=O)c12, CN(C)c1cccc(c1)-c1n(C)c(=O)cc2[nH]n(-c3ccccc3Cl)c(=O)c12, CN(C)c1cccc(c1)-c1n(C)c(=O)cc2[nH]n(-c3ccccc3Cl)c(=O)c12	RGYQPQARIQKJKH-UHFFFAOYSA-N, RGYQPQARIQKJKH-UHFFFAOYSA-N, RGYQPQARIQKJKH-UHFFFAOYSA-N	Phase 2
GK921	transglutaminase inhibitor	TGM2			C(CN1CCCC1)Oc1nc2cccnc2nc1C#Cc1ccccc1, C(CN1CCCC1)Oc1nc2cccnc2nc1C#Cc1ccccc1	MNYJJHBAEYKXEG-UHFFFAOYSA-N, MNYJJHBAEYKXEG-UHFFFAOYSA-N	Preclinical
glafenine	DeltaF508-CFTR Correctors	CFTR			OC[C@@H](O)COC(=O)c1ccccc1Nc1ccnc2cc(Cl)ccc12 |&1:2|, OC[C@@H](O)COC(=O)c1ccccc1Nc1ccnc2cc(Cl)ccc12 |&1:2|	GWOFUCIGLDBNKM-CYBMUJFWSA-N, GWOFUCIGLDBNKM-CYBMUJFWSA-N	Withdrawn
glasdegib	hedgehog pathway inhibitor	SMO	hematologic malignancy	acute myeloid leukemia (AML)	CN1CC[C@H](C[C@@H]1c1nc2ccccc2[nH]1)NC(=O)Nc1ccc(cc1)C#N, CN1CC[C@H](C[C@@H]1c1nc2ccccc2[nH]1)NC(=O)Nc1ccc(cc1)C#N, CN1CC[C@H](C[C@@H]1c1nc2ccccc2[nH]1)NC(=O)Nc1ccc(cc1)C#N, CN1CC[C@H](C[C@@H]1c1nc2ccccc2[nH]1)NC(=O)Nc1ccc(cc1)C#N, CN1CC[C@H](C[C@@H]1c1nc2ccccc2[nH]1)NC(=O)Nc1ccc(cc1)C#N	SFNSLLSYNZWZQG-VQIMIIECSA-N, SFNSLLSYNZWZQG-VQIMIIECSA-N, SFNSLLSYNZWZQG-VQIMIIECSA-N, SFNSLLSYNZWZQG-VQIMIIECSA-N, SFNSLLSYNZWZQG-VQIMIIECSA-N	Launched
glecaprevir	serine protease inhibitor		infectious disease	hepatitis C	[H]\C1=C([H])/C(F)(F)c2nc3ccccc3nc2O[C@@]2([H])CN(C(=O)[C@@]([H])(NC(=O)O[C@]3([H])CCC[C@@]3([H])OC1)C(C)(C)C)[C@@]([H])(C2)C(=O)N[C@@]1(C[C@@]1([H])C(F)F)C(=O)NS(=O)(=O)C1(C)CC1 |t:1|, [H]\C1=C([H])/C(F)(F)c2nc3ccccc3nc2O[C@@]2([H])CN(C(=O)[C@@]([H])(NC(=O)O[C@]3([H])CCC[C@@]3([H])OC1)C(C)(C)C)[C@@]([H])(C2)C(=O)N[C@@]1(C[C@@]1([H])C(F)F)C(=O)NS(=O)(=O)C1(C)CC1 |t:1|	MLSQGNCUYAMAHD-ITNVBOSISA-N, MLSQGNCUYAMAHD-ITNVBOSISA-N	Launched
glesatinib	tyrosine kinase inhibitor				COCCNCc1ccc(nc1)-c1cc2nccc(Oc3ccc(NC(=S)NC(=O)Cc4ccc(F)cc4)cc3F)c2s1	YRCHYHRCBXNYNU-UHFFFAOYSA-N	Phase 2
gliclazide	ATP channel blocker, insulin secretagogue		endocrinology	diabetes mellitus	Cc1ccc(cc1)S(=O)(=O)NC(=O)NN1C[C@H]2CCC[C@@H]2C1 |&1:16,&2:20,r|, Cc1ccc(cc1)S(=O)(=O)NC(=O)NN1C[C@H]2CCC[C@@H]2C1 |&1:16,&2:20,r|, Cc1ccc(cc1)S(=O)(=O)NC(=O)NN1C[C@H]2CCC[C@@H]2C1 |&1:16,&2:20,r|, Cc1ccc(cc1)S(=O)(=O)NC(=O)NN1C[C@H]2CCC[C@@H]2C1 |&1:16,&2:20,r|	BOVGTQGAOIONJV-CHWSQXEVSA-N, BOVGTQGAOIONJV-CHWSQXEVSA-N, BOVGTQGAOIONJV-CHWSQXEVSA-N, BOVGTQGAOIONJV-CHWSQXEVSA-N	Launched
glimepiride	insulin secretagogue	ABCC8, KCNJ1, KCNJ11	endocrinology	diabetes mellitus	CCC1=C(C)CN(C(=O)NCCc2ccc(cc2)S(=O)(=O)NC(=O)N[C@H]2CC[C@H](C)CC2)C1=O |r,c:2|, CCC1=C(C)CN(C(=O)NCCc2ccc(cc2)S(=O)(=O)NC(=O)N[C@H]2CC[C@H](C)CC2)C1=O |r,c:2|, CCC1=C(C)CN(C(=O)NCCc2ccc(cc2)S(=O)(=O)NC(=O)N[C@H]2CC[C@H](C)CC2)C1=O |r,c:2|, CCC1=C(C)CN(C(=O)NCCc2ccc(cc2)S(=O)(=O)NC(=O)N[C@H]2CC[C@H](C)CC2)C1=O |r,c:2|, CCC1=C(C)CN(C(=O)NCCc2ccc(cc2)S(=O)(=O)NC(=O)N[C@H]2CC[C@H](C)CC2)C1=O |r,c:2|, CCC1=C(C)CN(C(=O)NCCc2ccc(cc2)S(=O)(=O)NC(=O)N[C@H]2CC[C@H](C)CC2)C1=O |r,c:2|	WIGIZIANZCJQQY-RUCARUNLSA-N, WIGIZIANZCJQQY-RUCARUNLSA-N, WIGIZIANZCJQQY-RUCARUNLSA-N, WIGIZIANZCJQQY-RUCARUNLSA-N, WIGIZIANZCJQQY-RUCARUNLSA-N, WIGIZIANZCJQQY-RUCARUNLSA-N	Launched
glipizide	sulfonylurea	ABCC8, KCNJ10, KCNJ11, PPARG	endocrinology	diabetes mellitus, hyperglycemia	Cc1cnc(cn1)C(=O)NCCc1ccc(cc1)S(=O)(=O)NC(=O)NC1CCCCC1, Cc1cnc(cn1)C(=O)NCCc1ccc(cc1)S(=O)(=O)NC(=O)NC1CCCCC1, Cc1cnc(cn1)C(=O)NCCc1ccc(cc1)S(=O)(=O)NC(=O)NC1CCCCC1	ZJJXGWJIGJFDTL-UHFFFAOYSA-N, ZJJXGWJIGJFDTL-UHFFFAOYSA-N, ZJJXGWJIGJFDTL-UHFFFAOYSA-N	Launched
gliquidone	sulfonylurea	ABCC8, KCNJ10, KCNJ8	endocrinology	diabetes mellitus	COc1ccc2c(c1)C(=O)N(CCc1ccc(cc1)S(=O)(=O)NC(=O)NC1CCCCC1)C(=O)C2(C)C, COc1ccc2c(c1)C(=O)N(CCc1ccc(cc1)S(=O)(=O)NC(=O)NC1CCCCC1)C(=O)C2(C)C, COc1ccc2c(c1)C(=O)N(CCc1ccc(cc1)S(=O)(=O)NC(=O)NC1CCCCC1)C(=O)C2(C)C, COc1ccc2c(c1)C(=O)N(CCc1ccc(cc1)S(=O)(=O)NC(=O)NC1CCCCC1)C(=O)C2(C)C	LLJFMFZYVVLQKT-UHFFFAOYSA-N, LLJFMFZYVVLQKT-UHFFFAOYSA-N, LLJFMFZYVVLQKT-UHFFFAOYSA-N, LLJFMFZYVVLQKT-UHFFFAOYSA-N	Launched
Gln-1062	cholinesterase inhibitor				COc1ccc2CN(C)CC[C@@]34C=C[C@@H](C[C@@H]3Oc1c24)OC(=O)c1ccccc1 |c:12|	JKVNJTYHRABHIY-WXVUKLJWSA-N	Preclinical
GLPG0187	integrin antagonist				COc1ccc(cc1)S(=O)(=O)N[C@@H](CNc1nc(C)nc(N2CCC(CC2)c2ccc3CCCNc3n2)c1C)C(O)=O	CXHCNOMGODVIKB-VWLOTQADSA-N	Phase 1
GLPG0492	androgen receptor modulator	AR			CN1C(=O)N(C(=O)[C@@]1(CO)c1ccccc1)c1ccc(C#N)c(c1)C(F)(F)F, CN1C(=O)N(C(=O)[C@@]1(CO)c1ccccc1)c1ccc(C#N)c(c1)C(F)(F)F	VAJGULUVTFDTAS-GOSISDBHSA-N, VAJGULUVTFDTAS-GOSISDBHSA-N	Phase 1
GLPG0492-R-enantiomer	androgen receptor modulator	AR			CN1C(=O)N(C(=O)[C@]1(CO)c1ccccc1)c1ccc(C#N)c(c1)C(F)(F)F, CN1C(=O)N(C(=O)[C@]1(CO)c1ccccc1)c1ccc(C#N)c(c1)C(F)(F)F	VAJGULUVTFDTAS-SFHVURJKSA-N, VAJGULUVTFDTAS-SFHVURJKSA-N	Phase 1
GLPG1837	CFTR channel potentiator				CC1(C)Cc2c(sc(NC(=O)c3cc[nH]n3)c2C(N)=O)C(C)(C)O1	GHTGYZMBQPXTCQ-UHFFFAOYSA-N	Phase 2
glucaric-acid					O[C@@H]([C@H](O)[C@@H](O)C(O)=O)[C@H](O)C(O)=O	DSLZVSRJTYRBFB-LLEIAEIESA-N	Phase 1
gluconolactone		LCT			OC[C@@H]1OC(=O)[C@@H](O)[C@H](O)[C@H]1O	PHOQVHQSTUBQQK-KLVWXMOXSA-N	Launched
glucosamine	glycosylated protein precursor	IL1B	neurology/psychiatry, rheumatology	muscle pain, rheumatoid arthritis, joint pain, backache	N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O, N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O, N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O	MSWZFWKMSRAUBD-QZABAPFNSA-N, MSWZFWKMSRAUBD-QZABAPFNSA-N, MSWZFWKMSRAUBD-QZABAPFNSA-N	Launched
glutathione	antioxidant	ESD, GGT1, GLO1, GLRX, GLRX2, GPX1, GPX2, GPX3, GPX4, GPX5, GPX6, GPX7, GPX8, GSR, GSS, GSTA1, GSTA2, GSTA3, GSTA4, GSTA5, GSTK1, GSTM1, GSTM2, GSTM3, GSTM4, GSTM5, GSTO1, GSTO2, GSTP1, GSTT1, GSTZ1, HAGH, HPGDS, LTC4S, MGST1, MGST2, MGST3, TXNDC12			N[C@@H](CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O)C(O)=O	RWSXRVCMGQZWBV-WDSKDSINSA-N	Phase 3
glutathione-monoisopropyl-ester	lipid peroxidase inhibitor				CC(C)OC(=O)CNC(=O)[C@H](CS)NC(=O)CC[C@H](N)C(O)=O, CC(C)OC(=O)CNC(=O)[C@H](CS)NC(=O)CC[C@H](N)C(O)=O	MVNCPACIPXNJIW-IUCAKERBSA-N, MVNCPACIPXNJIW-IUCAKERBSA-N	Phase 2
gly-gln					NCC(=O)N[C@@H](CCC(N)=O)C(O)=O	PNMUAGGSDZXTHX-BYPYZUCNSA-N	Phase 2
glyburide	ATP channel blocker, insulin secretagogue, sulfonylurea	ABCA1, ABCB11, ABCC8, ABCC9, CFTR, CPT1A, KCNJ1, KCNJ11, KCNJ5, KCNJ8, SLCO2B1	endocrinology	diabetes mellitus, hyperglycemia	COc1ccc(Cl)cc1C(=O)NCCc1ccc(cc1)S(=O)(=O)NC(=O)NC1CCCCC1, COc1ccc(Cl)cc1C(=O)NCCc1ccc(cc1)S(=O)(=O)NC(=O)NC1CCCCC1, COc1ccc(Cl)cc1C(=O)NCCc1ccc(cc1)S(=O)(=O)NC(=O)NC1CCCCC1, COc1ccc(Cl)cc1C(=O)NCCc1ccc(cc1)S(=O)(=O)NC(=O)NC1CCCCC1, COc1ccc(Cl)cc1C(=O)NCCc1ccc(cc1)S(=O)(=O)NC(=O)NC1CCCCC1	ZNNLBTZKUZBEKO-UHFFFAOYSA-N, ZNNLBTZKUZBEKO-UHFFFAOYSA-N, ZNNLBTZKUZBEKO-UHFFFAOYSA-N, ZNNLBTZKUZBEKO-UHFFFAOYSA-N, ZNNLBTZKUZBEKO-UHFFFAOYSA-N	Launched
glycerol-monolaurate	beta lactamase inhibitor				CCCCCCCCCCCC(=O)OC[C@@H](O)CO |&1:15,r|	ARIWANIATODDMH-AWEZNQCLSA-N	Launched
glycerol-phenylbutyrate	sigma receptor ligand				O=C(CCCc1ccccc1)OCC(COC(=O)CCCc1ccccc1)OC(=O)CCCc1ccccc1	ZSDBFLMJVAGKOU-UHFFFAOYSA-N	Phase 1
glycitein	tumor necrosis factor release inhibitor	TNF			COc1cc2c(cc1O)occ(-c1ccc(O)cc1)c2=O, COc1cc2c(cc1O)occ(-c1ccc(O)cc1)c2=O	DXYUAIFZCFRPTH-UHFFFAOYSA-N, DXYUAIFZCFRPTH-UHFFFAOYSA-N	Phase 3
glycopyrrolate	acetylcholine receptor antagonist	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5	gastroenterology	peptic ulcer disease (PUD)	C[N+]1(C)CC[C@@H](C1)OC(=O)[C@@](O)(C1CCCC1)c1ccccc1 |&1:5,&2:10|, C[N+]1(C)CC[C@@H](C1)OC(=O)[C@@](O)(C1CCCC1)c1ccccc1 |&1:5,&2:10|	ANGKOCUUWGHLCE-HKUYNNGSSA-N, ANGKOCUUWGHLCE-HKUYNNGSSA-N	Launched
GM-1485	immunophilin ligand	FKBP1A			CCC(C)(C)C(=O)C(=O)N1CCC[C@H]1C(O)=O	FOPALECPEUVCTL-QMMMGPOBSA-N	Preclinical
GMX1778	NAMPT inhibitor	NAMPT			Clc1ccc(OCCCCCCN\C(NC#N)=N\c2ccncc2)cc1, Clc1ccc(OCCCCCCN\C(NC#N)=N\c2ccncc2)cc1, Clc1ccc(OCCCCCCN\C(NC#N)=N\c2ccncc2)cc1	BOIPLTNGIAPDBY-UHFFFAOYSA-N, BOIPLTNGIAPDBY-UHFFFAOYSA-N, BOIPLTNGIAPDBY-UHFFFAOYSA-N	Phase 1/Phase 2
GNE-7915	leucine rich repeat kinase inhibitor				CCNc1nc(Nc2cc(F)c(cc2OC)C(=O)N2CCOCC2)ncc1C(F)(F)F	XCFLWTZSJYBCPF-UHFFFAOYSA-N	Preclinical
GNF-2	Bcr-Abl kinase inhibitor	ABL1, BCR			NC(=O)c1cccc(c1)-c1cc(Nc2ccc(OC(F)(F)F)cc2)ncn1, NC(=O)c1cccc(c1)-c1cc(Nc2ccc(OC(F)(F)F)cc2)ncn1, NC(=O)c1cccc(c1)-c1cc(Nc2ccc(OC(F)(F)F)cc2)ncn1, NC(=O)c1cccc(c1)-c1cc(Nc2ccc(OC(F)(F)F)cc2)ncn1	WEVYNIUIFUYDGI-UHFFFAOYSA-N, WEVYNIUIFUYDGI-UHFFFAOYSA-N, WEVYNIUIFUYDGI-UHFFFAOYSA-N, WEVYNIUIFUYDGI-UHFFFAOYSA-N	Preclinical
GNF-5	Bcr-Abl kinase inhibitor	ABL1, BCR			OCCNC(=O)c1cccc(c1)-c1cc(Nc2ccc(OC(F)(F)F)cc2)ncn1, OCCNC(=O)c1cccc(c1)-c1cc(Nc2ccc(OC(F)(F)F)cc2)ncn1, OCCNC(=O)c1cccc(c1)-c1cc(Nc2ccc(OC(F)(F)F)cc2)ncn1	IIQUYGWWHIHOCF-UHFFFAOYSA-N, IIQUYGWWHIHOCF-UHFFFAOYSA-N, IIQUYGWWHIHOCF-UHFFFAOYSA-N	Preclinical
GNF-5837	growth factor receptor inhibitor	NTRK1, NTRK2, NTRK3			Cc1ccc(NC(=O)Nc2cc(ccc2F)C(F)(F)F)cc1Nc1ccc2\C(=C\c3ccc[nH]3)C(=O)Nc2c1, Cc1ccc(NC(=O)Nc2cc(ccc2F)C(F)(F)F)cc1Nc1ccc2\C(=C\c3ccc[nH]3)C(=O)Nc2c1	YYDUWLSETXNJJT-MTJSOVHGSA-N, InChI=1S/C28H21F4N5O2/c1-15-4-6-19(35-27(39)37-25-11-16(28(30,31)32)5-9-22(25)29)13-23(15)34-18-7-8-20-21(12-17-3-2-10-33-17)26(38)36-24(20)14-18/h2-14,33-34H,1H3,(H,36,38)(H2,35,37,39)/b21-12-	Preclinical
GNF-7	glucokinase inhibitor, protein kinase inhibitor	GCK, TNK2			CN1C(=O)N(Cc2cnc(Nc3ccc(C)nc3)nc12)c1cc(NC(=O)c2cccc(c2)C(F)(F)F)ccc1C, CN1C(=O)N(Cc2cnc(Nc3ccc(C)nc3)nc12)c1cc(NC(=O)c2cccc(c2)C(F)(F)F)ccc1C, CN1C(=O)N(Cc2cnc(Nc3ccc(C)nc3)nc12)c1cc(NC(=O)c2cccc(c2)C(F)(F)F)ccc1C	SZNYUUZOQHNEKB-UHFFFAOYSA-N, SZNYUUZOQHNEKB-UHFFFAOYSA-N, SZNYUUZOQHNEKB-UHFFFAOYSA-N	Preclinical
GNTI	opioid receptor antagonist	OPRK1, OPRM1			NC(=N)Nc1ccc2[nH]c3[C@@H]4Oc5c6c(C[C@H]7N(CC8CC8)CC[C@@]46[C@@]7(O)Cc3c2c1)ccc5O, NC(=N)Nc1ccc2[nH]c3[C@@H]4Oc5c6c(C[C@H]7N(CC8CC8)CC[C@@]46[C@@]7(O)Cc3c2c1)ccc5O	VLNHDKDBGWXJEE-GYHUNEDQSA-N, VLNHDKDBGWXJEE-GYHUNEDQSA-N	Preclinical
go-6983	protein kinase inhibitor	PRKCA, PRKCB, PRKCD, PRKCG, PRKCZ			COc1ccc2n(CCCN(C)C)cc(C3=C(C(=O)NC3=O)c3c[nH]c4ccccc34)c2c1 |t:15|, COc1ccc2n(CCCN(C)C)cc(C3=C(C(=O)NC3=O)c3c[nH]c4ccccc34)c2c1 |t:15|, COc1ccc2n(CCCN(C)C)cc(C3=C(C(=O)NC3=O)c3c[nH]c4ccccc34)c2c1 |t:15|	LLJJDLHGZUOMQP-UHFFFAOYSA-N, LLJJDLHGZUOMQP-UHFFFAOYSA-N, LLJJDLHGZUOMQP-UHFFFAOYSA-N	Preclinical
golgicide-A	ARF inhibitor	GBF1			Fc1cc(F)c2N[C@@H]([C@@H]3CC=C[C@@H]3c2c1)c1cccnc1 |a:8,12,&1:7,c:10|, Fc1cc(F)c2N[C@@H]([C@@H]3CC=C[C@@H]3c2c1)c1cccnc1 |a:8,12,&1:7,c:10|, Fc1cc(F)c2N[C@@H]([C@@H]3CC=C[C@@H]3c2c1)c1cccnc1 |a:8,12,&1:7,c:10|, Fc1cc(F)c2N[C@@H]([C@@H]3CC=C[C@@H]3c2c1)c1cccnc1 |a:8,12,&1:7,c:10|, Fc1cc(F)c2N[C@@H]([C@@H]3CC=C[C@@H]3c2c1)c1cccnc1 |a:8,12,&1:7,c:10|	NJZHEQOUHLZCOX-WOSRLPQWSA-N, NJZHEQOUHLZCOX-WOSRLPQWSA-N, NJZHEQOUHLZCOX-WOSRLPQWSA-N, NJZHEQOUHLZCOX-WOSRLPQWSA-N, NJZHEQOUHLZCOX-WOSRLPQWSA-N	Preclinical
golvatinib	VEGFR inhibitor	KDR, MET			CN1CCN(CC1)C1CCN(CC1)C(=O)Nc1cc(Oc2ccc(NC(=O)C3(CC3)C(=O)Nc3ccc(F)cc3)c(F)c2)ccn1, CN1CCN(CC1)C1CCN(CC1)C(=O)Nc1cc(Oc2ccc(NC(=O)C3(CC3)C(=O)Nc3ccc(F)cc3)c(F)c2)ccn1, CN1CCN(CC1)C1CCN(CC1)C(=O)Nc1cc(Oc2ccc(NC(=O)C3(CC3)C(=O)Nc3ccc(F)cc3)c(F)c2)ccn1, CN1CCN(CC1)C1CCN(CC1)C(=O)Nc1cc(Oc2ccc(NC(=O)C3(CC3)C(=O)Nc3ccc(F)cc3)c(F)c2)ccn1	UQRCJCNVNUFYDX-UHFFFAOYSA-N, UQRCJCNVNUFYDX-UHFFFAOYSA-N, UQRCJCNVNUFYDX-UHFFFAOYSA-N, UQRCJCNVNUFYDX-UHFFFAOYSA-N	Phase 2
gonadorelin	gonadotropin releasing factor hormone receptor agonist	GNRHR	obstetrics/gynecology	cystic ovaries, reproductive synchrony	CC(C)C[C@H](NC(=O)CNC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)NCC(N)=O	XLXSAKCOAKORKW-AQJXLSMYSA-N	Launched
goserelin-acetate	gonadotropin releasing factor hormone receptor agonist	GNRHR, LHCGR	oncology, obstetrics/gynecology	prostate cancer, breast cancer, endometriosis	CC(C)C[C@H](NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)NNC(N)=O, CC(C)C[C@H](NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)NNC(N)=O	BLCLNMBMMGCOAS-URPVMXJPSA-N, BLCLNMBMMGCOAS-URPVMXJPSA-N	Launched
gossypol	BCL inhibitor, MCL1 inhibitor	BCL2			CC(C)c1c(O)c(O)c(C=O)c2c(O)c(c(C)cc12)-c1c(C)cc2c(C(C)C)c(O)c(O)c(C=O)c2c1O, CC(C)c1c(O)c(O)c(C=O)c2c(O)c(c(C)cc12)-c1c(C)cc2c(C(C)C)c(O)c(O)c(C=O)c2c1O, CC(C)c1c(O)c(O)c(C=O)c2c(O)c(c(C)cc12)-c1c(C)cc2c(C(C)C)c(O)c(O)c(C=O)c2c1O, CC(C)c1c(O)c(O)c(C=O)c2c(O)c(c(C)cc12)-c1c(C)cc2c(C(C)C)c(O)c(O)c(C=O)c2c1O, CC(C)c1c(O)c(O)c(C=O)c2c(O)c(c(C)cc12)-c1c(C)cc2c(C(C)C)c(O)c(O)c(C=O)c2c1O, CC(C)c1c(O)c(O)c(C=O)c2c(O)c(c(C)cc12)-c1c(C)cc2c(C(C)C)c(O)c(O)c(C=O)c2c1O, CC(C)c1c(O)c(O)c(C=O)c2c(O)c(c(C)cc12)-c1c(C)cc2c(C(C)C)c(O)c(O)c(C=O)c2c1O, CC(C)c1c(O)c(O)c(C=O)c2c(O)c(c(C)cc12)-c1c(C)cc2c(C(C)C)c(O)c(O)c(C=O)c2c1O	QBKSWRVVCFFDOT-UHFFFAOYSA-N, QBKSWRVVCFFDOT-UHFFFAOYSA-N, QBKSWRVVCFFDOT-UHFFFAOYSA-N, QBKSWRVVCFFDOT-UHFFFAOYSA-N, QBKSWRVVCFFDOT-UHFFFAOYSA-N, QBKSWRVVCFFDOT-UHFFFAOYSA-N, QBKSWRVVCFFDOT-UHFFFAOYSA-N, QBKSWRVVCFFDOT-UHFFFAOYSA-N	Phase 2
GPBAR-A	G protein-coupled receptor agonist	GPBAR1			Fc1ccccc1-c1ccnc2OCC(=O)N(Cc3cc(cc(c3)C(F)(F)F)C(F)(F)F)Cc12, Fc1ccccc1-c1ccnc2OCC(=O)N(Cc3cc(cc(c3)C(F)(F)F)C(F)(F)F)Cc12, Fc1ccccc1-c1ccnc2OCC(=O)N(Cc3cc(cc(c3)C(F)(F)F)C(F)(F)F)Cc12	ZIXNJVGTAXRKAP-UHFFFAOYSA-N, ZIXNJVGTAXRKAP-UHFFFAOYSA-N, ZIXNJVGTAXRKAP-UHFFFAOYSA-N	Preclinical
GPI-1046	FKBP inhibitor	FKBP1A			CCC(C)(C)C(=O)C(=O)N1CCC[C@H]1C(=O)OCCCc1cccnc1	OQAHHWOPVDDWHD-INIZCTEOSA-N	Preclinical
GPi-688	glycogen phosphorylase inhibitor				OC[C@H](O)CN1C(=O)[C@@H](Cc2ccccc12)NC(=O)c1cc2cc(Cl)sc2[nH]1 |a:2,&1:8|, OC[C@H](O)CN1C(=O)[C@@H](Cc2ccccc12)NC(=O)c1cc2cc(Cl)sc2[nH]1 |a:2,&1:8|	UICNBXVDHCBKCE-TZMCWYRMSA-N, UICNBXVDHCBKCE-TZMCWYRMSA-N	Preclinical
GPP-78	NAMPT inhibitor	NAMPT			O=C(CCCCCCCn1cc(nn1)-c1cccnc1)Nc1ccccc1-c1ccccc1, O=C(CCCCCCCn1cc(nn1)-c1cccnc1)Nc1ccccc1-c1ccccc1, O=C(CCCCCCCn1cc(nn1)-c1cccnc1)Nc1ccccc1-c1ccccc1	SJOLTIOPWDLDEB-UHFFFAOYSA-N, SJOLTIOPWDLDEB-UHFFFAOYSA-N, SJOLTIOPWDLDEB-UHFFFAOYSA-N	Preclinical
GPR120-modulator-1	G protein-coupled receptor modulator	FFAR4			Cc1cc(OCc2nc(cs2)-c2ccccc2Cl)ccc1OCC(O)=O	FONSSTYHKIFEBM-UHFFFAOYSA-N	Preclinical
GP1a	cannabinoid receptor agonist	CNR2			Cc1ccc-2c(Cc3c(nn(c-23)-c2ccc(Cl)cc2Cl)C(=O)NN2CCCCC2)c1, Cc1ccc-2c(Cc3c(nn(c-23)-c2ccc(Cl)cc2Cl)C(=O)NN2CCCCC2)c1, Cc1ccc-2c(Cc3c(nn(c-23)-c2ccc(Cl)cc2Cl)C(=O)NN2CCCCC2)c1, Cc1ccc-2c(Cc3c(nn(c-23)-c2ccc(Cl)cc2Cl)C(=O)NN2CCCCC2)c1, Cc1ccc-2c(Cc3c(nn(c-23)-c2ccc(Cl)cc2Cl)C(=O)NN2CCCCC2)c1, Cc1ccc-2c(Cc3c(nn(c-23)-c2ccc(Cl)cc2Cl)C(=O)NN2CCCCC2)c1	FNOMTMVRTBHRET-UHFFFAOYSA-N, FNOMTMVRTBHRET-UHFFFAOYSA-N, FNOMTMVRTBHRET-UHFFFAOYSA-N, FNOMTMVRTBHRET-UHFFFAOYSA-N, FNOMTMVRTBHRET-UHFFFAOYSA-N, FNOMTMVRTBHRET-UHFFFAOYSA-N	Preclinical
GP2a	cannabinoid receptor agonist	CNR2			Cc1ccc-2c(Cc3c(nn(c-23)-c2ccc(Cl)cc2Cl)C(=O)NC2CCCCC2)c1, Cc1ccc-2c(Cc3c(nn(c-23)-c2ccc(Cl)cc2Cl)C(=O)NC2CCCCC2)c1, Cc1ccc-2c(Cc3c(nn(c-23)-c2ccc(Cl)cc2Cl)C(=O)NC2CCCCC2)c1	SPEFJYZGXZENAF-UHFFFAOYSA-N, SPEFJYZGXZENAF-UHFFFAOYSA-N, SPEFJYZGXZENAF-UHFFFAOYSA-N	Preclinical
GR-103691	dopamine receptor antagonist	DRD3			COc1ccccc1N1CCN(CCCCNC(=O)c2ccc(cc2)-c2ccc(cc2)C(C)=O)CC1, COc1ccccc1N1CCN(CCCCNC(=O)c2ccc(cc2)-c2ccc(cc2)C(C)=O)CC1	JARNORYOPMINDY-UHFFFAOYSA-N, JARNORYOPMINDY-UHFFFAOYSA-N	Preclinical
GR-113808	serotonin receptor antagonist	HTR4			Cn1cc(C(=O)OCC2CCN(CCNS(C)(=O)=O)CC2)c2ccccc12, Cn1cc(C(=O)OCC2CCN(CCNS(C)(=O)=O)CC2)c2ccccc12	MOZPSIXKYJUTKI-UHFFFAOYSA-N, MOZPSIXKYJUTKI-UHFFFAOYSA-N	Preclinical
GR-127935	serotonin receptor antagonist	HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2B, HTR2C, HTR6			COc1ccc(NC(=O)c2ccc(cc2)-c2ccc(cc2C)-c2noc(C)n2)cc1N1CCN(C)CC1, COc1ccc(NC(=O)c2ccc(cc2)-c2ccc(cc2C)-c2noc(C)n2)cc1N1CCN(C)CC1, COc1ccc(NC(=O)c2ccc(cc2)-c2ccc(cc2C)-c2noc(C)n2)cc1N1CCN(C)CC1, COc1ccc(NC(=O)c2ccc(cc2)-c2ccc(cc2C)-c2noc(C)n2)cc1N1CCN(C)CC1, COc1ccc(NC(=O)c2ccc(cc2)-c2ccc(cc2C)-c2noc(C)n2)cc1N1CCN(C)CC1	YDBCEBYHYKAFRX-UHFFFAOYSA-N, YDBCEBYHYKAFRX-UHFFFAOYSA-N, YDBCEBYHYKAFRX-UHFFFAOYSA-N, YDBCEBYHYKAFRX-UHFFFAOYSA-N, YDBCEBYHYKAFRX-UHFFFAOYSA-N	Preclinical
GR-135531	melatonin receptor agonist				COC(=O)Nc1ccc2[nH]cc(CCNC(C)=O)c2c1, COC(=O)Nc1ccc2[nH]cc(CCNC(C)=O)c2c1	MPZVHKLZCUEJFO-UHFFFAOYSA-N, MPZVHKLZCUEJFO-UHFFFAOYSA-N	Preclinical
GR-144053	integrin antagonist	ITGA2B, ITGB3			NC(=N)c1ccc(cc1)N1CCN(CC1)C1CCN(CC(O)=O)CC1, NC(=N)c1ccc(cc1)N1CCN(CC1)C1CCN(CC(O)=O)CC1, NC(=N)c1ccc(cc1)N1CCN(CC1)C1CCN(CC(O)=O)CC1	QGEGSJUSWLLZLH-UHFFFAOYSA-N, QGEGSJUSWLLZLH-UHFFFAOYSA-N, QGEGSJUSWLLZLH-UHFFFAOYSA-N	Preclinical
GR-159897	tachykinin antagonist	TAC1, TACR2			COC1(C[S@@](=O)c2ccccc2)CCN(CCc2c[nH]c3ccc(F)cc23)CC1, COC1(C[S@@](=O)c2ccccc2)CCN(CCc2c[nH]c3ccc(F)cc23)CC1, COC1(C[S@@](=O)c2ccccc2)CCN(CCc2c[nH]c3ccc(F)cc23)CC1, COC1(C[S@@](=O)c2ccccc2)CCN(CCc2c[nH]c3ccc(F)cc23)CC1, COC1(C[S@@](=O)c2ccccc2)CCN(CCc2c[nH]c3ccc(F)cc23)CC1	BANYJBHWTOJQDU-GDLZYMKVSA-N, BANYJBHWTOJQDU-GDLZYMKVSA-N, BANYJBHWTOJQDU-GDLZYMKVSA-N, BANYJBHWTOJQDU-GDLZYMKVSA-N, BANYJBHWTOJQDU-GDLZYMKVSA-N	Preclinical
GR-235	estrogen receptor agonist, FXR antagonist, progesterone receptor agonist	NR1H4			[H][C@@]12CC(=O)C(=CC)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C |t:20|	WDXRGPWQVHZTQJ-NRJJLHBYSA-N	Launched
GR-79236	adenosine receptor agonist	ADORA1, ADORA2A			OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(N[C@H]3CCC[C@@H]3O)ncnc12, OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(N[C@H]3CCC[C@@H]3O)ncnc12, OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(N[C@H]3CCC[C@@H]3O)ncnc12	GYWXTRVEUURNEW-TVDBPQCTSA-N, GYWXTRVEUURNEW-TVDBPQCTSA-N, GYWXTRVEUURNEW-TVDBPQCTSA-N	Phase 1
gramicidin	bacterial permeability inducer		infectious disease	first-aid antibiotic	CC(C)C[C@@H](NC(=O)[C@H](C)NC(=O)CNC(=O)[C@@H](NC=O)C(C)C)C(=O)N[C@@H](C)C(=O)N[C@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(C)C)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)NCCO	ZWCXYZRRTRDGQE-LUPIJMBPSA-N	Launched
gramine	norepinephrine reputake inhibitor				CN(C)Cc1c[nH]c2ccccc12	OCDGBSUVYYVKQZ-UHFFFAOYSA-N	Preclinical
granisetron	serotonin receptor antagonist	HTR3A	gastroenterology	nausea, vomiting	CN1[C@H]2CCC[C@@H]1C[C@@H](C2)NC(=O)c1nn(C)c2ccccc12 |&1:2,&2:6,&3:8|, CN1[C@H]2CCC[C@@H]1C[C@@H](C2)NC(=O)c1nn(C)c2ccccc12 |&1:2,&2:6,&3:8|	MFWNKCLOYSRHCJ-BTTYYORXSA-N, MFWNKCLOYSRHCJ-BTTYYORXSA-N	Launched
grapiprant	prostaglandin inhibitor	PTGER4	rheumatology	osteoarthritis	CCc1nc2c(C)nc(C)cc2n1-c1ccc(CCNC(=O)NS(=O)(=O)c2ccc(C)cc2)cc1, CCc1nc2c(C)nc(C)cc2n1-c1ccc(CCNC(=O)NS(=O)(=O)c2ccc(C)cc2)cc1	HZVLFTCYCLXTGV-UHFFFAOYSA-N, HZVLFTCYCLXTGV-UHFFFAOYSA-N	Launched
grazoprevir	HCV inhibitor		infectious disease	hepatitis C	COc1ccc2nc3CCCCC[C@@H]4C[C@H]4OC(=O)N[C@H](C(=O)N4C[C@@H](C[C@H]4C(=O)N[C@@]4(C[C@H]4C=C)C(=O)NS(=O)(=O)C4CC4)Oc3nc2c1)C(C)(C)C, COc1ccc2nc3CCCCC[C@@H]4C[C@H]4OC(=O)N[C@H](C(=O)N4C[C@@H](C[C@H]4C(=O)N[C@@]4(C[C@H]4C=C)C(=O)NS(=O)(=O)C4CC4)Oc3nc2c1)C(C)(C)C, COc1ccc2nc3CCCCC[C@@H]4C[C@H]4OC(=O)N[C@H](C(=O)N4C[C@@H](C[C@H]4C(=O)N[C@@]4(C[C@H]4C=C)C(=O)NS(=O)(=O)C4CC4)Oc3nc2c1)C(C)(C)C, COc1ccc2nc3CCCCC[C@@H]4C[C@H]4OC(=O)N[C@H](C(=O)N4C[C@@H](C[C@H]4C(=O)N[C@@]4(C[C@H]4C=C)C(=O)NS(=O)(=O)C4CC4)Oc3nc2c1)C(C)(C)C, COc1ccc2nc3CCCCC[C@@H]4C[C@H]4OC(=O)N[C@H](C(=O)N4C[C@@H](C[C@H]4C(=O)N[C@@]4(C[C@H]4C=C)C(=O)NS(=O)(=O)C4CC4)Oc3nc2c1)C(C)(C)C	OBMNJSNZOWALQB-NCQNOWPTSA-N, OBMNJSNZOWALQB-NCQNOWPTSA-N, OBMNJSNZOWALQB-NCQNOWPTSA-N, OBMNJSNZOWALQB-NCQNOWPTSA-N, OBMNJSNZOWALQB-NCQNOWPTSA-N	Launched
griseofulvin	tubulin polymerization inhibitor	KRT12	infectious disease	ringworm, tinea pedis	COC1=CC(=O)C[C@@H](C)[C@]11Oc2c(C1=O)c(OC)cc(OC)c2Cl |t:2|, COC1=CC(=O)C[C@@H](C)[C@]11Oc2c(C1=O)c(OC)cc(OC)c2Cl |t:2|, COC1=CC(=O)C[C@@H](C)[C@]11Oc2c(C1=O)c(OC)cc(OC)c2Cl |t:2|	DDUHZTYCFQRHIY-RBHXEPJQSA-N, DDUHZTYCFQRHIY-RBHXEPJQSA-N, DDUHZTYCFQRHIY-RBHXEPJQSA-N	Launched
GR125487	serotonin receptor antagonist	HTR4			COc1[nH]c2ccc(F)cc2c1C(=O)OCC1CCN(CCNS(C)(=O)=O)CC1, COc1[nH]c2ccc(F)cc2c1C(=O)OCC1CCN(CCNS(C)(=O)=O)CC1, COc1[nH]c2ccc(F)cc2c1C(=O)OCC1CCN(CCNS(C)(=O)=O)CC1, COc1[nH]c2ccc(F)cc2c1C(=O)OCC1CCN(CCNS(C)(=O)=O)CC1	SSPCCAYAIDNNJX-UHFFFAOYSA-N, SSPCCAYAIDNNJX-UHFFFAOYSA-N, SSPCCAYAIDNNJX-UHFFFAOYSA-N, SSPCCAYAIDNNJX-UHFFFAOYSA-N	Preclinical
GR46611	serotonin receptor agonist	HTR1D			COc1ccc(CNC(=O)\C=C\c2ccc3[nH]cc(CCN(C)C)c3c2)cc1, COc1ccc(CNC(=O)\C=C\c2ccc3[nH]cc(CCN(C)C)c3c2)cc1, COc1ccc(CNC(=O)\C=C\c2ccc3[nH]cc(CCN(C)C)c3c2)cc1, COc1ccc(CNC(=O)\C=C\c2ccc3[nH]cc(CCN(C)C)c3c2)cc1	LBVZWEWTNUDWNS-YRNVUSSQSA-N, LBVZWEWTNUDWNS-YRNVUSSQSA-N, LBVZWEWTNUDWNS-YRNVUSSQSA-N, LBVZWEWTNUDWNS-YRNVUSSQSA-N	Preclinical
GS-143	ubiquitin ligase inhibitor	BTRC, NFKBIA			OC(=O)c1ccc(cc1)N1N=C(Cc2ccccc2)\C(=C/c2ccc(o2)-c2ccccc2F)C1=O |t:11|, OC(=O)c1ccc(cc1)N1N=C(Cc2ccccc2)\C(=C/c2ccc(o2)-c2ccccc2F)C1=O |t:11|, OC(=O)c1ccc(cc1)N1N=C(Cc2ccccc2)\C(=C/c2ccc(o2)-c2ccccc2F)C1=O |t:11|, OC(=O)c1ccc(cc1)N1N=C(Cc2ccccc2)\C(=C/c2ccc(o2)-c2ccccc2F)C1=O |t:11|	IZPMWFSVTDOCDI-HAVVHWLPSA-N, IZPMWFSVTDOCDI-HAVVHWLPSA-N, IZPMWFSVTDOCDI-HAVVHWLPSA-N, IZPMWFSVTDOCDI-HAVVHWLPSA-N	Preclinical
GS-39783	GABA receptor modulator	GABBR1			CSc1nc(NC2CCCC2)c(c(NC2CCCC2)n1)[N+]([O-])=O, CSc1nc(NC2CCCC2)c(c(NC2CCCC2)n1)[N+]([O-])=O, CSc1nc(NC2CCCC2)c(c(NC2CCCC2)n1)[N+]([O-])=O	GSGVDKOCBKBMGG-UHFFFAOYSA-N, GSGVDKOCBKBMGG-UHFFFAOYSA-N, GSGVDKOCBKBMGG-UHFFFAOYSA-N	Preclinical
GS-6201	adenosine receptor antagonist	ADORA1, ADORA2A, ADORA2B, ADORA3			CCCn1c(=O)n(CC)c2nc([nH]c2c1=O)-c1cnn(Cc2cccc(c2)C(F)(F)F)c1, CCCn1c(=O)n(CC)c2nc([nH]c2c1=O)-c1cnn(Cc2cccc(c2)C(F)(F)F)c1, CCCn1c(=O)n(CC)c2nc([nH]c2c1=O)-c1cnn(Cc2cccc(c2)C(F)(F)F)c1	KOYXXLLNCXWUNF-UHFFFAOYSA-N, KOYXXLLNCXWUNF-UHFFFAOYSA-N, KOYXXLLNCXWUNF-UHFFFAOYSA-N	Phase 1
GS-9620	toll-like receptor agonist	TLR7			CCCCOc1nc(N)c2NC(=O)CN(Cc3cccc(CN4CCCC4)c3)c2n1, CCCCOc1nc(N)c2NC(=O)CN(Cc3cccc(CN4CCCC4)c3)c2n1	VFOKSTCIRGDTBR-UHFFFAOYSA-N, VFOKSTCIRGDTBR-UHFFFAOYSA-N	Phase 2
GS-967	voltage-gated sodium channel blocker				FC(F)(F)Oc1ccc(cc1)-c1ccc2nnc(n2c1)C(F)(F)F	FEVBKJITJDHASC-UHFFFAOYSA-N	Preclinical
GS-9973	SYK inhibitor	SYK			C1CN(CCO1)c1ccc(Nc2nc(cn3ccnc23)-c2ccc3c[nH]nc3c2)cc1, C1CN(CCO1)c1ccc(Nc2nc(cn3ccnc23)-c2ccc3c[nH]nc3c2)cc1, C1CN(CCO1)c1ccc(Nc2nc(cn3ccnc23)-c2ccc3c[nH]nc3c2)cc1, C1CN(CCO1)c1ccc(Nc2nc(cn3ccnc23)-c2ccc3c[nH]nc3c2)cc1, C1CN(CCO1)c1ccc(Nc2nc(cn3ccnc23)-c2ccc3c[nH]nc3c2)cc1, C1CN(CCO1)c1ccc(Nc2nc(cn3ccnc23)-c2ccc3c[nH]nc3c2)cc1, C1CN(CCO1)c1ccc(Nc2nc(cn3ccnc23)-c2ccc3c[nH]nc3c2)cc1, C1CN(CCO1)c1ccc(Nc2nc(cn3ccnc23)-c2ccc3c[nH]nc3c2)cc1	XSMSNFMDVXXHGJ-UHFFFAOYSA-N, XSMSNFMDVXXHGJ-UHFFFAOYSA-N, XSMSNFMDVXXHGJ-UHFFFAOYSA-N, XSMSNFMDVXXHGJ-UHFFFAOYSA-N, XSMSNFMDVXXHGJ-UHFFFAOYSA-N, XSMSNFMDVXXHGJ-UHFFFAOYSA-N, XSMSNFMDVXXHGJ-UHFFFAOYSA-N, XSMSNFMDVXXHGJ-UHFFFAOYSA-N	Phase 2
GSK-J1	histone demethylase inhibitor	KDM6B			OC(=O)CCNc1cc(nc(n1)-c1ccccn1)N1CCc2ccccc2CC1, OC(=O)CCNc1cc(nc(n1)-c1ccccn1)N1CCc2ccccc2CC1, OC(=O)CCNc1cc(nc(n1)-c1ccccn1)N1CCc2ccccc2CC1	AVZCPICCWKMZDT-UHFFFAOYSA-N, AVZCPICCWKMZDT-UHFFFAOYSA-N, AVZCPICCWKMZDT-UHFFFAOYSA-N	Preclinical
GSK-J2	histone demethylase inhibitor				OC(=O)CCNc1cc(nc(n1)-c1cccnc1)N1CCc2ccccc2CC1, OC(=O)CCNc1cc(nc(n1)-c1cccnc1)N1CCc2ccccc2CC1, OC(=O)CCNc1cc(nc(n1)-c1cccnc1)N1CCc2ccccc2CC1	LJIFOCRGDDQFJF-UHFFFAOYSA-N, LJIFOCRGDDQFJF-UHFFFAOYSA-N, LJIFOCRGDDQFJF-UHFFFAOYSA-N	Preclinical
GSK-J4	histone lysine demethylase inhibitor	KDM6A, KDM6B			CCOC(=O)CCNc1cc(nc(n1)-c1ccccn1)N1CCc2ccccc2CC1, CCOC(=O)CCNc1cc(nc(n1)-c1ccccn1)N1CCc2ccccc2CC1, CCOC(=O)CCNc1cc(nc(n1)-c1ccccn1)N1CCc2ccccc2CC1, CCOC(=O)CCNc1cc(nc(n1)-c1ccccn1)N1CCc2ccccc2CC1, CCOC(=O)CCNc1cc(nc(n1)-c1ccccn1)N1CCc2ccccc2CC1, CCOC(=O)CCNc1cc(nc(n1)-c1ccccn1)N1CCc2ccccc2CC1, CCOC(=O)CCNc1cc(nc(n1)-c1ccccn1)N1CCc2ccccc2CC1, CCOC(=O)CCNc1cc(nc(n1)-c1ccccn1)N1CCc2ccccc2CC1	WBKCKEHGXNWYMO-UHFFFAOYSA-N, WBKCKEHGXNWYMO-UHFFFAOYSA-N, WBKCKEHGXNWYMO-UHFFFAOYSA-N, WBKCKEHGXNWYMO-UHFFFAOYSA-N, WBKCKEHGXNWYMO-UHFFFAOYSA-N, WBKCKEHGXNWYMO-UHFFFAOYSA-N, WBKCKEHGXNWYMO-UHFFFAOYSA-N, WBKCKEHGXNWYMO-UHFFFAOYSA-N	Preclinical
GSK-J5	histone demethylase control				CCOC(=O)CCNc1cc(nc(n1)-c1cccnc1)N1CCc2ccccc2CC1, CCOC(=O)CCNc1cc(nc(n1)-c1cccnc1)N1CCc2ccccc2CC1	LQPGVGSKBNXQDU-UHFFFAOYSA-N, LQPGVGSKBNXQDU-UHFFFAOYSA-N	Preclinical
GSK-LSD-1	histone lysine demethylase inhibitor	KDM1A			C1[C@@H](NC2CCNCC2)[C@@H]1c1ccccc1, C1[C@@H](NC2CCNCC2)[C@@H]1c1ccccc1	BASFYRLYJAZPPL-UONOGXRCSA-N, InChI=1S/C14H20N2/c1-2-4-11(5-3-1)13-10-14(13)16-12-6-8-15-9-7-12/h1-5,12-16H,6-10H2/t13-,14+/m0/s1	Preclinical
GSK-3-inhibitor-IX	glycogen synthase kinase inhibitor, lipoxygenase inhibitor	GSK3A, GSK3B			O\N=C1/C(/Nc2ccccc/12)=C1/C(=O)Nc2cc(Br)ccc12, O\N=C1/C(/Nc2ccccc/12)=C1/C(=O)Nc2cc(Br)ccc12, O\N=C1/C(/Nc2ccccc/12)=C1/C(=O)Nc2cc(Br)ccc12, O\N=C1/C(/Nc2ccccc/12)=C1/C(=O)Nc2cc(Br)ccc12, O\N=C1/C(/Nc2ccccc/12)=C1/C(=O)Nc2cc(Br)ccc12, O\N=C1/C(/Nc2ccccc/12)=C1/C(=O)Nc2cc(Br)ccc12, O\N=C1/C(/Nc2ccccc/12)=C1/C(=O)Nc2cc(Br)ccc12, O\N=C1/C(/Nc2ccccc/12)=C1/C(=O)Nc2cc(Br)ccc12, O\N=C1/C(/Nc2ccccc/12)=C1/C(=O)Nc2cc(Br)ccc12	DDLZLOKCJHBUHD-UJZLGWIISA-N, DDLZLOKCJHBUHD-UJZLGWIISA-N, DDLZLOKCJHBUHD-UJZLGWIISA-N, DDLZLOKCJHBUHD-UJZLGWIISA-N, DDLZLOKCJHBUHD-UJZLGWIISA-N, DDLZLOKCJHBUHD-UJZLGWIISA-N, DDLZLOKCJHBUHD-UJZLGWIISA-N, DDLZLOKCJHBUHD-UJZLGWIISA-N, DDLZLOKCJHBUHD-UJZLGWIISA-N	Preclinical
GSK0660	PPAR receptor antagonist	PPARD			COC(=O)c1sccc1S(=O)(=O)Nc1ccc(Nc2ccccc2)cc1OC, COC(=O)c1sccc1S(=O)(=O)Nc1ccc(Nc2ccccc2)cc1OC, COC(=O)c1sccc1S(=O)(=O)Nc1ccc(Nc2ccccc2)cc1OC	NDFKBGWLUHKMFY-UHFFFAOYSA-N, NDFKBGWLUHKMFY-UHFFFAOYSA-N, NDFKBGWLUHKMFY-UHFFFAOYSA-N	Preclinical
GSK1059615	PI3K inhibitor	PIK3CG			O=C1NC(=O)\C(S1)=C\c1ccc2nccc(-c3ccncc3)c2c1, O=C1NC(=O)\C(S1)=C\c1ccc2nccc(-c3ccncc3)c2c1, O=C1NC(=O)\C(S1)=C\c1ccc2nccc(-c3ccncc3)c2c1	QDITZBLZQQZVEE-YBEGLDIGSA-N, QDITZBLZQQZVEE-YBEGLDIGSA-N, QDITZBLZQQZVEE-YBEGLDIGSA-N	Phase 1
GSK1070916	Aurora kinase inhibitor	AURKA, AURKB, AURKC, CYP2D6, CYP3A4			CCn1cc(c(n1)-c1ccc(NC(=O)N(C)C)cc1)-c1ccnc2[nH]c(cc12)-c1cccc(CN(C)C)c1, CCn1cc(c(n1)-c1ccc(NC(=O)N(C)C)cc1)-c1ccnc2[nH]c(cc12)-c1cccc(CN(C)C)c1, CCn1cc(c(n1)-c1ccc(NC(=O)N(C)C)cc1)-c1ccnc2[nH]c(cc12)-c1cccc(CN(C)C)c1, CCn1cc(c(n1)-c1ccc(NC(=O)N(C)C)cc1)-c1ccnc2[nH]c(cc12)-c1cccc(CN(C)C)c1	QTBWCSQGBMPECM-UHFFFAOYSA-N, QTBWCSQGBMPECM-UHFFFAOYSA-N, QTBWCSQGBMPECM-UHFFFAOYSA-N, QTBWCSQGBMPECM-UHFFFAOYSA-N	Phase 1
GSK1292263	glucose dependent insulinotropic receptor agonist	GRPR			CC(C)c1noc(n1)N1CCC(COc2ccc(nc2)-c2ccc(cc2)S(C)(=O)=O)CC1, CC(C)c1noc(n1)N1CCC(COc2ccc(nc2)-c2ccc(cc2)S(C)(=O)=O)CC1	AYJRTVVIBJSSKN-UHFFFAOYSA-N, AYJRTVVIBJSSKN-UHFFFAOYSA-N	Phase 2
GSK1562590	urotensin receptor antagonist	UTS2R			CN([C@@H](CN1CCCC1)c1ccc(cc1)-c1cccc(c1)C(N)=O)C(=O)CN1C(=O)COc2cc(Cl)c(Cl)cc12, CN([C@@H](CN1CCCC1)c1ccc(cc1)-c1cccc(c1)C(N)=O)C(=O)CN1C(=O)COc2cc(Cl)c(Cl)cc12	QDUMEBKFKOODFN-SANMLTNESA-N, QDUMEBKFKOODFN-SANMLTNESA-N	Preclinical
GSK163090	serotonin receptor antagonist	HTR1A, HTR1B, HTR1D			Cc1ccc2c(cccc2n1)N1CCN(CCc2cccc(c2)N2CCNC2=O)CC1, Cc1ccc2c(cccc2n1)N1CCN(CCc2cccc(c2)N2CCNC2=O)CC1	ANGUXJDGJCHGOG-UHFFFAOYSA-N, ANGUXJDGJCHGOG-UHFFFAOYSA-N	Phase 2
GSK1838705A	insulin growth factor receptor inhibitor	ALK, IGF1R, INSR, RPS6KA1			CNC(=O)c1c(F)cccc1Nc1nc(Nc2cc3N(CCc3cc2OC)C(=O)CN(C)C)nc2[nH]ccc12, CNC(=O)c1c(F)cccc1Nc1nc(Nc2cc3N(CCc3cc2OC)C(=O)CN(C)C)nc2[nH]ccc12, CNC(=O)c1c(F)cccc1Nc1nc(Nc2cc3N(CCc3cc2OC)C(=O)CN(C)C)nc2[nH]ccc12, CNC(=O)c1c(F)cccc1Nc1nc(Nc2cc3N(CCc3cc2OC)C(=O)CN(C)C)nc2[nH]ccc12, CNC(=O)c1c(F)cccc1Nc1nc(Nc2cc3N(CCc3cc2OC)C(=O)CN(C)C)nc2[nH]ccc12, CNC(=O)c1c(F)cccc1Nc1nc(Nc2cc3N(CCc3cc2OC)C(=O)CN(C)C)nc2[nH]ccc12, CNC(=O)c1c(F)cccc1Nc1nc(Nc2cc3N(CCc3cc2OC)C(=O)CN(C)C)nc2[nH]ccc12	HZTYDQRUAWIZRE-UHFFFAOYSA-N, HZTYDQRUAWIZRE-UHFFFAOYSA-N, HZTYDQRUAWIZRE-UHFFFAOYSA-N, HZTYDQRUAWIZRE-UHFFFAOYSA-N, HZTYDQRUAWIZRE-UHFFFAOYSA-N, HZTYDQRUAWIZRE-UHFFFAOYSA-N, HZTYDQRUAWIZRE-UHFFFAOYSA-N	Preclinical
GSK189254	histamine receptor antagonist				CNC(=O)c1ccc(Oc2ccc3CCN(CCc3c2)C2CCC2)nc1	WROHEWWOCPRMIA-UHFFFAOYSA-N	Phase 2
GSK1904529A	IGF-1 inhibitor, insulin growth factor receptor inhibitor, insulin receptor ligand	IGF1R, INSR			CCc1cc(Nc2nccc(n2)-c2c(nc3ccccn23)-c2ccc(OC)c(c2)C(=O)Nc2c(F)cccc2F)c(OC)cc1N1CCC(CC1)N1CCN(CC1)S(C)(=O)=O, CCc1cc(Nc2nccc(n2)-c2c(nc3ccccn23)-c2ccc(OC)c(c2)C(=O)Nc2c(F)cccc2F)c(OC)cc1N1CCC(CC1)N1CCN(CC1)S(C)(=O)=O, CCc1cc(Nc2nccc(n2)-c2c(nc3ccccn23)-c2ccc(OC)c(c2)C(=O)Nc2c(F)cccc2F)c(OC)cc1N1CCC(CC1)N1CCN(CC1)S(C)(=O)=O	MOSKATHMXWSZTQ-UHFFFAOYSA-N, MOSKATHMXWSZTQ-UHFFFAOYSA-N, MOSKATHMXWSZTQ-UHFFFAOYSA-N	Preclinical
GSK2110183	AKT inhibitor	AKT1, AKT2, AKT3			Cn1ncc(Cl)c1-c1cc(sc1Cl)C(=O)N[C@H](CN)Cc1cccc(F)c1, Cn1ncc(Cl)c1-c1cc(sc1Cl)C(=O)N[C@H](CN)Cc1cccc(F)c1, Cn1ncc(Cl)c1-c1cc(sc1Cl)C(=O)N[C@H](CN)Cc1cccc(F)c1, Cn1ncc(Cl)c1-c1cc(sc1Cl)C(=O)N[C@H](CN)Cc1cccc(F)c1, Cn1ncc(Cl)c1-c1cc(sc1Cl)C(=O)N[C@H](CN)Cc1cccc(F)c1	AFJRDFWMXUECEW-LBPRGKRZSA-N, AFJRDFWMXUECEW-LBPRGKRZSA-N, AFJRDFWMXUECEW-LBPRGKRZSA-N, AFJRDFWMXUECEW-LBPRGKRZSA-N, AFJRDFWMXUECEW-LBPRGKRZSA-N	Phase 2
GSK2126458	mTOR inhibitor, PI3K inhibitor	MTOR, PIK3CA, PIK3CB, PIK3CD, PIK3CG			COc1ncc(cc1NS(=O)(=O)c1ccc(F)cc1F)-c1ccc2nccc(-c3ccnnc3)c2c1, COc1ncc(cc1NS(=O)(=O)c1ccc(F)cc1F)-c1ccc2nccc(-c3ccnnc3)c2c1, COc1ncc(cc1NS(=O)(=O)c1ccc(F)cc1F)-c1ccc2nccc(-c3ccnnc3)c2c1, COc1ncc(cc1NS(=O)(=O)c1ccc(F)cc1F)-c1ccc2nccc(-c3ccnnc3)c2c1, COc1ncc(cc1NS(=O)(=O)c1ccc(F)cc1F)-c1ccc2nccc(-c3ccnnc3)c2c1, COc1ncc(cc1NS(=O)(=O)c1ccc(F)cc1F)-c1ccc2nccc(-c3ccnnc3)c2c1, COc1ncc(cc1NS(=O)(=O)c1ccc(F)cc1F)-c1ccc2nccc(-c3ccnnc3)c2c1	CGBJSGAELGCMKE-UHFFFAOYSA-N, CGBJSGAELGCMKE-UHFFFAOYSA-N, CGBJSGAELGCMKE-UHFFFAOYSA-N, CGBJSGAELGCMKE-UHFFFAOYSA-N, CGBJSGAELGCMKE-UHFFFAOYSA-N, CGBJSGAELGCMKE-UHFFFAOYSA-N, CGBJSGAELGCMKE-UHFFFAOYSA-N	Phase 1
GSK2190915	lipoxygenase inhibitor	ALOX5AP			CCOc1ccc(cn1)-c1ccc(Cn2c(CC(C)(C)C(O)=O)c(SC(C)(C)C)c3cc(OCc4ccc(C)cn4)ccc23)cc1	DFQGDHBGRSTTHX-UHFFFAOYSA-N	Phase 2
GSK2193874	transient receptor potential channel antagonist	TRPV4			FC(F)(F)c1cccc(c1)-c1nc2cc(Br)ccc2c(C(=O)NC2(CC2)c2ccccc2)c1CN1CCC(CC1)N1CCCCC1, FC(F)(F)c1cccc(c1)-c1nc2cc(Br)ccc2c(C(=O)NC2(CC2)c2ccccc2)c1CN1CCC(CC1)N1CCCCC1, FC(F)(F)c1cccc(c1)-c1nc2cc(Br)ccc2c(C(=O)NC2(CC2)c2ccccc2)c1CN1CCC(CC1)N1CCCCC1	UIVOZBSCHXCGPS-UHFFFAOYSA-N, UIVOZBSCHXCGPS-UHFFFAOYSA-N, UIVOZBSCHXCGPS-UHFFFAOYSA-N	Preclinical
GSK2194069	fatty acid synthase inhibitor	FASN			O=C(C1CC1)N1CC[C@@H](Cc2n[nH]c(=O)n2-c2ccc(cc2)-c2ccc3occc3c2)C1, O=C(C1CC1)N1CC[C@@H](Cc2n[nH]c(=O)n2-c2ccc(cc2)-c2ccc3occc3c2)C1, O=C(C1CC1)N1CC[C@@H](Cc2n[nH]c(=O)n2-c2ccc(cc2)-c2ccc3occc3c2)C1, O=C(C1CC1)N1CC[C@@H](Cc2n[nH]c(=O)n2-c2ccc(cc2)-c2ccc3occc3c2)C1	AQTPWCUIYUOEMG-INIZCTEOSA-N, AQTPWCUIYUOEMG-INIZCTEOSA-N, AQTPWCUIYUOEMG-INIZCTEOSA-N, AQTPWCUIYUOEMG-INIZCTEOSA-N	Preclinical
GSK2239633A	CC chemokine receptor antagonist				COc1cccc2n(Cc3cccc(CNC(=O)C(C)(C)O)c3)nc(NS(=O)(=O)c3ccc(Cl)s3)c12	YTEVTHHGQMUPHC-UHFFFAOYSA-N	Preclinical
GSK2256098	kinase inhibitor				CONC(=O)c1ccccc1Nc1cc(Nc2cc(C)nn2C(C)C)ncc1Cl	BVAHPPKGOOJSPU-UHFFFAOYSA-N	Phase 2
GSK2256294A	epoxide hydolase inhibitor	EPHX2			CNc1nc(C)nc(N[C@H]2CCC[C@H](C2)C(=O)NCc2ccc(cc2C(F)(F)F)C#N)n1	LQHDJQIMETZMPH-ZBFHGGJFSA-N	Phase 1
GSK2330672	bile acid transporter inhibitor	SLC10A2			CCCC[C@]1(CC)CS(=O)(=O)c2cc(CNC(CC(O)=O)CC(O)=O)c(OC)cc2[C@H](N1)c1ccccc1	CZGVOBIGEBDYTP-VSGBNLITSA-N	Phase 2
GSK2334470	phosphoinositide dependent kinase inhibitor	AURKA, AURKB, PDPK1			CNc1nc(cc(n1)-c1ccc2c(N)[nH]nc2c1)N1C[C@H](CC[C@H]1C)C(=O)NC1CCCCC1, CNc1nc(cc(n1)-c1ccc2c(N)[nH]nc2c1)N1C[C@H](CC[C@H]1C)C(=O)NC1CCCCC1, CNc1nc(cc(n1)-c1ccc2c(N)[nH]nc2c1)N1C[C@H](CC[C@H]1C)C(=O)NC1CCCCC1	QLPHOXTXAKOFMU-WBVHZDCISA-N, QLPHOXTXAKOFMU-WBVHZDCISA-N, QLPHOXTXAKOFMU-WBVHZDCISA-N	Preclinical
GSK239512	histamine receptor antagonist				O=C1CCCN1c1ccc(Oc2ccc3CCN(CCc3c2)C2CCC2)nc1	YFRBKEVUUCQYOW-UHFFFAOYSA-N	Preclinical
GSK256066	phosphodiesterase inhibitor	PDE4A			COc1cccc(Nc2c(cnc3c(C)cc(cc23)S(=O)(=O)c2cccc(c2)C(=O)N(C)C)C(N)=O)c1, COc1cccc(Nc2c(cnc3c(C)cc(cc23)S(=O)(=O)c2cccc(c2)C(=O)N(C)C)C(N)=O)c1, COc1cccc(Nc2c(cnc3c(C)cc(cc23)S(=O)(=O)c2cccc(c2)C(=O)N(C)C)C(N)=O)c1	JFHROPTYMMSOLG-UHFFFAOYSA-N, JFHROPTYMMSOLG-UHFFFAOYSA-N, JFHROPTYMMSOLG-UHFFFAOYSA-N	Phase 2
GSK2578215A	leucine rich repeat kinase inhibitor	LRRK2			Fc1cc(ccn1)-c1ccc(OCc2ccccc2)c(c1)C(=O)Nc1cccnc1, Fc1cc(ccn1)-c1ccc(OCc2ccccc2)c(c1)C(=O)Nc1cccnc1	WCIGMFCFPXZRMQ-UHFFFAOYSA-N, WCIGMFCFPXZRMQ-UHFFFAOYSA-N	Preclinical
GSK2606414	protein kinase inhibitor	EIF2AK3, MYLK2			Cn1cc(-c2ccc3N(CCc3c2)C(=O)Cc2cccc(c2)C(F)(F)F)c2c(N)ncnc12, Cn1cc(-c2ccc3N(CCc3c2)C(=O)Cc2cccc(c2)C(F)(F)F)c2c(N)ncnc12, Cn1cc(-c2ccc3N(CCc3c2)C(=O)Cc2cccc(c2)C(F)(F)F)c2c(N)ncnc12, Cn1cc(-c2ccc3N(CCc3c2)C(=O)Cc2cccc(c2)C(F)(F)F)c2c(N)ncnc12, Cn1cc(-c2ccc3N(CCc3c2)C(=O)Cc2cccc(c2)C(F)(F)F)c2c(N)ncnc12	SIXVRXARNAVBTC-UHFFFAOYSA-N, SIXVRXARNAVBTC-UHFFFAOYSA-N, SIXVRXARNAVBTC-UHFFFAOYSA-N, SIXVRXARNAVBTC-UHFFFAOYSA-N, SIXVRXARNAVBTC-UHFFFAOYSA-N	Preclinical
GSK2636771	PI3K inhibitor	PIK3CB			Cc1nc2c(cc(cc2n1Cc1cccc(c1C)C(F)(F)F)N1CCOCC1)C(O)=O, Cc1nc2c(cc(cc2n1Cc1cccc(c1C)C(F)(F)F)N1CCOCC1)C(O)=O, Cc1nc2c(cc(cc2n1Cc1cccc(c1C)C(F)(F)F)N1CCOCC1)C(O)=O, Cc1nc2c(cc(cc2n1Cc1cccc(c1C)C(F)(F)F)N1CCOCC1)C(O)=O	XTKLTGBKIDQGQL-UHFFFAOYSA-N, XTKLTGBKIDQGQL-UHFFFAOYSA-N, XTKLTGBKIDQGQL-UHFFFAOYSA-N, XTKLTGBKIDQGQL-UHFFFAOYSA-N	Phase 2
GSK2656157	PERK inhibitor				Cc1cccc(CC(=O)N2CCc3c2ccc(-c2cn(C)c4ncnc(N)c24)c3F)n1	PRWSIEBRGXYXAJ-UHFFFAOYSA-N	Preclinical
GSK269962	rho associated kinase inhibitor	ROCK1, ROCK2			CCn1c(nc2cnc(Oc3cccc(NC(=O)c4ccc(OCCN5CCOCC5)cc4)c3)cc12)-c1nonc1N, CCn1c(nc2cnc(Oc3cccc(NC(=O)c4ccc(OCCN5CCOCC5)cc4)c3)cc12)-c1nonc1N, CCn1c(nc2cnc(Oc3cccc(NC(=O)c4ccc(OCCN5CCOCC5)cc4)c3)cc12)-c1nonc1N, CCn1c(nc2cnc(Oc3cccc(NC(=O)c4ccc(OCCN5CCOCC5)cc4)c3)cc12)-c1nonc1N	YOVNFNXUCOWYSG-UHFFFAOYSA-N, YOVNFNXUCOWYSG-UHFFFAOYSA-N, YOVNFNXUCOWYSG-UHFFFAOYSA-N, YOVNFNXUCOWYSG-UHFFFAOYSA-N	Preclinical
GSK2801	bromodomain inhibitor	BAZ2A, BAZ2B			CCCOc1ccn2c(cc(-c3ccccc3S(C)(=O)=O)c2c1)C(C)=O, CCCOc1ccn2c(cc(-c3ccccc3S(C)(=O)=O)c2c1)C(C)=O	KHWCPNJRJCNVRI-UHFFFAOYSA-N, KHWCPNJRJCNVRI-UHFFFAOYSA-N	Preclinical
GSK2816126	histone lysine methyltransferase inhibitor	EZH2			CC[C@H](C)n1cc(C)c2c(cc(cc12)-c1ccc(nc1)N1CCNCC1)C(=O)NCc1c(C)cc(C)[nH]c1=O, CC[C@H](C)n1cc(C)c2c(cc(cc12)-c1ccc(nc1)N1CCNCC1)C(=O)NCc1c(C)cc(C)[nH]c1=O	FKSFKBQGSFSOSM-QFIPXVFZSA-N, FKSFKBQGSFSOSM-QFIPXVFZSA-N	Phase 1
GSK2830371	protein phosphatase inhibitor	PPM1D			Cc1ncc(Cl)cc1NCc1ccc(s1)C(=O)N[C@@H](CC1CCCC1)C(=O)NC1CC1, Cc1ncc(Cl)cc1NCc1ccc(s1)C(=O)N[C@@H](CC1CCCC1)C(=O)NC1CC1, Cc1ncc(Cl)cc1NCc1ccc(s1)C(=O)N[C@@H](CC1CCCC1)C(=O)NC1CC1	IVDUVEGCMXCMSO-FQEVSTJZSA-N, IVDUVEGCMXCMSO-FQEVSTJZSA-N, IVDUVEGCMXCMSO-FQEVSTJZSA-N	Preclinical
GSK2837808A	lactate dehydrogenase inhibitor	LDHA			COc1ncc(-c2ccc3c(Nc4cc(Oc5cc(F)cc(F)c5)cc(c4)C(O)=O)c(cnc3c2)S(=O)(=O)NC2CC2)c(OC)n1, COc1ncc(-c2ccc3c(Nc4cc(Oc5cc(F)cc(F)c5)cc(c4)C(O)=O)c(cnc3c2)S(=O)(=O)NC2CC2)c(OC)n1	RZBCPMYJIARMGV-UHFFFAOYSA-N, RZBCPMYJIARMGV-UHFFFAOYSA-N	Preclinical
GSK2838232	HIV gag inhibitor				CC(C)C1=C2[C@H]3CC[C@@H]4[C@@]5(C)CC[C@H](OC(=O)CC(C)(C)C(O)=O)C(C)(C)[C@@H]5CC[C@@]4(C)[C@]3(C)CC[C@]2(CC1=O)[C@@H](O)CN(CCN(C)C)Cc1ccc(Cl)cc1 |c:3|, CC(C)C1=C2[C@H]3CC[C@@H]4[C@@]5(C)CC[C@H](OC(=O)CC(C)(C)C(O)=O)C(C)(C)[C@@H]5CC[C@@]4(C)[C@]3(C)CC[C@]2(CC1=O)[C@@H](O)CN(CCN(C)C)Cc1ccc(Cl)cc1 |c:3|, CC(C)C1=C2[C@H]3CC[C@@H]4[C@@]5(C)CC[C@H](OC(=O)CC(C)(C)C(O)=O)C(C)(C)[C@@H]5CC[C@@]4(C)[C@]3(C)CC[C@]2(CC1=O)[C@@H](O)CN(CCN(C)C)Cc1ccc(Cl)cc1 |c:3|	MEOWKUXNVNJAMY-PZFKGGKESA-N, MEOWKUXNVNJAMY-PZFKGGKESA-N, MEOWKUXNVNJAMY-PZFKGGKESA-N	Phase 2
GSK2879552	histone lysine demethylase inhibitor	KDM1A			OC(=O)c1ccc(CN2CCC(CN[C@@H]3C[C@H]3c3ccccc3)CC2)cc1, OC(=O)c1ccc(CN2CCC(CN[C@@H]3C[C@H]3c3ccccc3)CC2)cc1, OC(=O)c1ccc(CN2CCC(CN[C@@H]3C[C@H]3c3ccccc3)CC2)cc1, OC(=O)c1ccc(CN2CCC(CN[C@@H]3C[C@H]3c3ccccc3)CC2)cc1	LRULVYSBRWUVGR-FCHUYYIVSA-N, LRULVYSBRWUVGR-FCHUYYIVSA-N, LRULVYSBRWUVGR-FCHUYYIVSA-N, LRULVYSBRWUVGR-FCHUYYIVSA-N	Phase 1/Phase 2
GSK2881078	androgen receptor modulator				C[C@H](CS(C)(=O)=O)n1ccc2c(c(ccc12)C#N)C(F)(F)F	SKDVMPZQJMZEAC-SECBINFHSA-N	Phase 2
GSK2981278	ROR modulator				CCc1ccc(cc1)N(CC(C)C)S(=O)(=O)c1ccc(OCC2CCOCC2)c(CO)c1	LZLBRISQTJVZNP-UHFFFAOYSA-N	Phase 1/Phase 2
GSK2982772	RIPK inhibitor				CN1c2ccccc2OC[C@H](NC(=O)c2nc(Cc3ccccc3)n[nH]2)C1=O	LYPAFUINURXJSG-AWEZNQCLSA-N	Phase 2
GSK3117391	HDAC inhibitor				ONC(=O)CCc1ccc(CN[C@@H](C2CCCCC2)C(=O)OC2CCCC2)cn1	AFDPFLDWOXXHQM-NRFANRHFSA-N	Phase 1/Phase 2
GSK3179106	RET tyrosine kinase inhibitor				CCOc1cc(=O)[nH]cc1-c1ccc(CC(=O)Nc2cc(on2)C(C)(C)C(F)(F)F)c(F)c1	IDXKJSSOUXWLDB-UHFFFAOYSA-N	Phase 1
GSK3326595	protein arginine N-methyltransferase inhibitor				CC(=O)N1CCC(CC1)Nc1cc(ncn1)C(=O)NC[C@H](O)CN1CCc2ccccc2C1	JLCCNYVTIWRPIZ-NRFANRHFSA-N	Phase 1/Phase 2
GSK356278	phosphodiesterase inhibitor				CCn1ncc2c(NC3CCOCC3)c(cnc12)-c1nnc(Cc2sc(C)nc2C)o1	AWDJJMXJUOHGLC-UHFFFAOYSA-N	Preclinical
GSK369796	potassium channel antagonist				CC(C)(C)NCc1ccc(Nc2ccnc3cc(Cl)ccc23)cc1O	ZVMMVSSEAMUNGI-UHFFFAOYSA-N	Phase 1
GSK37647	free fatty acid receptor agonist	FFAR4			COc1ccc(cc1)S(=O)(=O)Nc1c(C)cc(C)cc1C, COc1ccc(cc1)S(=O)(=O)Nc1c(C)cc(C)cc1C, COc1ccc(cc1)S(=O)(=O)Nc1c(C)cc(C)cc1C	FQUAFMNPXPXOJE-UHFFFAOYSA-N, FQUAFMNPXPXOJE-UHFFFAOYSA-N, FQUAFMNPXPXOJE-UHFFFAOYSA-N	Preclinical
GSK3787	PPAR receptor antagonist	PPARD			FC(F)(F)c1ccc(nc1)S(=O)(=O)CCNC(=O)c1ccc(Cl)cc1, FC(F)(F)c1ccc(nc1)S(=O)(=O)CCNC(=O)c1ccc(Cl)cc1, FC(F)(F)c1ccc(nc1)S(=O)(=O)CCNC(=O)c1ccc(Cl)cc1	JFUIMTGOQCQTPF-UHFFFAOYSA-N, JFUIMTGOQCQTPF-UHFFFAOYSA-N, JFUIMTGOQCQTPF-UHFFFAOYSA-N	Preclinical
GSK429286A	rho associated kinase inhibitor	ROCK1			CC1=C([C@@H](CC(=O)N1)c1ccc(cc1)C(F)(F)F)C(=O)Nc1cc2c[nH]nc2cc1F |&1:3,r,t:1|, CC1=C([C@@H](CC(=O)N1)c1ccc(cc1)C(F)(F)F)C(=O)Nc1cc2c[nH]nc2cc1F |&1:3,r,t:1|, CC1=C([C@@H](CC(=O)N1)c1ccc(cc1)C(F)(F)F)C(=O)Nc1cc2c[nH]nc2cc1F |&1:3,r,t:1|	OLIIUAHHAZEXEX-AWEZNQCLSA-N, OLIIUAHHAZEXEX-AWEZNQCLSA-N, OLIIUAHHAZEXEX-AWEZNQCLSA-N	Preclinical
GSK461364	PLK inhibitor	PLK1			C[C@@H](Oc1cc(sc1C(N)=O)-n1cnc2ccc(CN3CCN(C)CC3)cc12)c1ccccc1C(F)(F)F, C[C@@H](Oc1cc(sc1C(N)=O)-n1cnc2ccc(CN3CCN(C)CC3)cc12)c1ccccc1C(F)(F)F, C[C@@H](Oc1cc(sc1C(N)=O)-n1cnc2ccc(CN3CCN(C)CC3)cc12)c1ccccc1C(F)(F)F, C[C@@H](Oc1cc(sc1C(N)=O)-n1cnc2ccc(CN3CCN(C)CC3)cc12)c1ccccc1C(F)(F)F	ZHJGWYRLJUCMRT-QGZVFWFLSA-N, ZHJGWYRLJUCMRT-QGZVFWFLSA-N, ZHJGWYRLJUCMRT-QGZVFWFLSA-N, ZHJGWYRLJUCMRT-QGZVFWFLSA-N	Phase 1
GSK503	histone lysine methyltransferase inhibitor	EZH2			CC(C)n1cc(C)c2c(cc(cc12)-c1ccc(nc1)N1CCN(C)CC1)C(=O)NCc1c(C)cc(C)[nH]c1=O, CC(C)n1cc(C)c2c(cc(cc12)-c1ccc(nc1)N1CCN(C)CC1)C(=O)NCc1c(C)cc(C)[nH]c1=O	HRDQQHUKUIKFHT-UHFFFAOYSA-N, HRDQQHUKUIKFHT-UHFFFAOYSA-N	Preclinical
GSK650394	serum/glucocorticoid regulated kinase inhibitor	SGK1, SGK2			OC(=O)c1ccc(cc1C1CCCC1)-c1c[nH]c2ncc(cc12)-c1ccccc1, OC(=O)c1ccc(cc1C1CCCC1)-c1c[nH]c2ncc(cc12)-c1ccccc1, OC(=O)c1ccc(cc1C1CCCC1)-c1c[nH]c2ncc(cc12)-c1ccccc1, OC(=O)c1ccc(cc1C1CCCC1)-c1c[nH]c2ncc(cc12)-c1ccccc1, OC(=O)c1ccc(cc1C1CCCC1)-c1c[nH]c2ncc(cc12)-c1ccccc1, OC(=O)c1ccc(cc1C1CCCC1)-c1c[nH]c2ncc(cc12)-c1ccccc1, OC(=O)c1ccc(cc1C1CCCC1)-c1c[nH]c2ncc(cc12)-c1ccccc1, OC(=O)c1ccc(cc1C1CCCC1)-c1c[nH]c2ncc(cc12)-c1ccccc1	WVSBGSNVCDAMCF-UHFFFAOYSA-N, WVSBGSNVCDAMCF-UHFFFAOYSA-N, WVSBGSNVCDAMCF-UHFFFAOYSA-N, WVSBGSNVCDAMCF-UHFFFAOYSA-N, WVSBGSNVCDAMCF-UHFFFAOYSA-N, WVSBGSNVCDAMCF-UHFFFAOYSA-N, WVSBGSNVCDAMCF-UHFFFAOYSA-N, WVSBGSNVCDAMCF-UHFFFAOYSA-N	Preclinical
GSK656	leucyl-tRNA synthetase inhibitor				NC[C@H]1OB(O)c2c1c(Cl)ccc2OCCO	DJUOWOXTPXUHDQ-MRVPVSSYSA-N	Preclinical
GSK690693	AKT inhibitor	AKT1, AKT2, AKT3, PAK4, PAK6, PAK7, PRKCQ, PRKG1, PRKX			CCn1c(nc2c(ncc(OC[C@H]3CCCNC3)c12)C#CC(C)(C)O)-c1nonc1N, CCn1c(nc2c(ncc(OC[C@H]3CCCNC3)c12)C#CC(C)(C)O)-c1nonc1N, CCn1c(nc2c(ncc(OC[C@H]3CCCNC3)c12)C#CC(C)(C)O)-c1nonc1N, CCn1c(nc2c(ncc(OC[C@H]3CCCNC3)c12)C#CC(C)(C)O)-c1nonc1N, CCn1c(nc2c(ncc(OC[C@H]3CCCNC3)c12)C#CC(C)(C)O)-c1nonc1N, CCn1c(nc2c(ncc(OC[C@H]3CCCNC3)c12)C#CC(C)(C)O)-c1nonc1N	KGPGFQWBCSZGEL-ZDUSSCGKSA-N, KGPGFQWBCSZGEL-ZDUSSCGKSA-N, KGPGFQWBCSZGEL-ZDUSSCGKSA-N, KGPGFQWBCSZGEL-ZDUSSCGKSA-N, KGPGFQWBCSZGEL-ZDUSSCGKSA-N, KGPGFQWBCSZGEL-ZDUSSCGKSA-N	Phase 1
GSK9027	glucocorticoid receptor agonist	NR3C1			Fc1ccc(cc1)-n1ncc2cc(ccc12)-c1ccc(NS(=O)(=O)Cc2ccccc2)cc1C(F)(F)F, Fc1ccc(cc1)-n1ncc2cc(ccc12)-c1ccc(NS(=O)(=O)Cc2ccccc2)cc1C(F)(F)F, Fc1ccc(cc1)-n1ncc2cc(ccc12)-c1ccc(NS(=O)(=O)Cc2ccccc2)cc1C(F)(F)F	DXBJGDVBQPEMOB-UHFFFAOYSA-N, DXBJGDVBQPEMOB-UHFFFAOYSA-N, DXBJGDVBQPEMOB-UHFFFAOYSA-N	Preclinical
GSK923295	centromere associated protein inhibitor	CENPE			CC(C)Oc1ccc(cc1Cl)C(=O)N[C@H](CNC(=O)CN(C)C)Cc1ccc(cc1)-c1cn2cccc([C@H](C)O)c2n1, CC(C)Oc1ccc(cc1Cl)C(=O)N[C@H](CNC(=O)CN(C)C)Cc1ccc(cc1)-c1cn2cccc([C@H](C)O)c2n1	WHMXDBPHBVLYRC-OFVILXPXSA-N, WHMXDBPHBVLYRC-OFVILXPXSA-N	Phase 1
GTP-14564	FLT3 inhibitor, tyrosine kinase inhibitor	CSF1R, FLT3, KIT, PDGFRB			c1ccc(cc1)-c1[nH]nc2c3ccccc3oc12, c1ccc(cc1)-c1[nH]nc2c3ccccc3oc12, c1ccc(cc1)-c1[nH]nc2c3ccccc3oc12, c1ccc(cc1)-c1[nH]nc2c3ccccc3oc12, c1ccc(cc1)-c1[nH]nc2c3ccccc3oc12	DZQLVVLATXPWBK-UHFFFAOYSA-N, DZQLVVLATXPWBK-UHFFFAOYSA-N, DZQLVVLATXPWBK-UHFFFAOYSA-N, DZQLVVLATXPWBK-UHFFFAOYSA-N, DZQLVVLATXPWBK-UHFFFAOYSA-N	Preclinical
GTS21	cholinergic receptor agonist	CHRNA7			COc1ccc(\C=C2/CCCN=C2c2cccnc2)c(OC)c1 |c:11|, COc1ccc(\C=C2/CCCN=C2c2cccnc2)c(OC)c1 |c:11|	RPYWXZCFYPVCNQ-RVDMUPIBSA-N, RPYWXZCFYPVCNQ-RVDMUPIBSA-N	Phase 1/Phase 2
guacetisal	immunosuppressant		pulmonary	cough suppressant	COc1ccccc1OC(=O)c1ccccc1OC(C)=O	HSJFYRYGGKLQBT-UHFFFAOYSA-N	Launched
guadecitabine	DNA methyltransferase inhibitor				Nc1ncn([C@H]2C[C@H](OP(O)(=O)OC[C@H]3O[C@H](C[C@@H]3O)n3cnc4c3[nH]c(N)nc4=O)[C@@H](CO)O2)c(=O)n1	GUWXKKAWLCENJA-WGWHJZDNSA-N	Phase 3
guaiacol	local anesthetic	CA2	pulmonary	cough suppressant	COc1ccccc1O, COc1ccccc1O	LHGVFZTZFXWLCP-UHFFFAOYSA-N, LHGVFZTZFXWLCP-UHFFFAOYSA-N	Launched
guaifenesin	expectorant		pulmonary	cough suppressant	COc1ccccc1OC[C@@H](O)CO |&1:10,r|, COc1ccccc1OC[C@@H](O)CO |&1:10,r|, COc1ccccc1OC[C@@H](O)CO |&1:10,r|	HSRJKNPTNIJEKV-QMMMGPOBSA-N, HSRJKNPTNIJEKV-QMMMGPOBSA-N, HSRJKNPTNIJEKV-QMMMGPOBSA-N	Launched
guanaben-acetate	adrenergic receptor agonist	ADRA2A, ADRA2B, ADRA2C	cardiology	hypertension	NC(=N)N\N=C\c1c(Cl)cccc1Cl, NC(=N)N\N=C\c1c(Cl)cccc1Cl, NC(=N)N\N=C\c1c(Cl)cccc1Cl, NC(=N)N\N=C\c1c(Cl)cccc1Cl, NC(=N)N\N=C\c1c(Cl)cccc1Cl	WDZVGELJXXEGPV-YIXHJXPBSA-N, WDZVGELJXXEGPV-YIXHJXPBSA-N, WDZVGELJXXEGPV-YIXHJXPBSA-N, WDZVGELJXXEGPV-YIXHJXPBSA-N, WDZVGELJXXEGPV-YIXHJXPBSA-N	Launched
guanadrel	adrenergic inhibitor		cardiology	hypertension	NC(=N)NC[C@H]1COC2(CCCCC2)O1 |&1:5|, NC(=N)NC[C@H]1COC2(CCCCC2)O1 |&1:5|, NC(=N)NC[C@H]1COC2(CCCCC2)O1 |&1:5|, NC(=N)NC[C@H]1COC2(CCCCC2)O1 |&1:5|, NC(=N)NC[C@H]1COC2(CCCCC2)O1 |&1:5|	HPBNRIOWIXYZFK-QMMMGPOBSA-N, HPBNRIOWIXYZFK-QMMMGPOBSA-N, HPBNRIOWIXYZFK-QMMMGPOBSA-N, HPBNRIOWIXYZFK-QMMMGPOBSA-N, HPBNRIOWIXYZFK-QMMMGPOBSA-N	Launched
guancydine	antihypertensive agent				CCC(C)(C)NC(=N)NC#N	VZVGEDRCVUKSEL-UHFFFAOYSA-N	Preclinical
guanethidine	adrenergic inhibitor	SLC6A2	cardiology	hypertension	NC(=N)NCCN1CCCCCCC1, NC(=N)NCCN1CCCCCCC1, NC(=N)NCCN1CCCCCCC1, NC(=N)NCCN1CCCCCCC1, NC(=N)NCCN1CCCCCCC1	ACGDKVXYNVEAGU-UHFFFAOYSA-N, ACGDKVXYNVEAGU-UHFFFAOYSA-N, ACGDKVXYNVEAGU-UHFFFAOYSA-N, ACGDKVXYNVEAGU-UHFFFAOYSA-N, ACGDKVXYNVEAGU-UHFFFAOYSA-N	Launched
guanfacine	adrenergic receptor agonist	ADRA2A, ADRA2B, ADRA2C	cardiology	hypertension	NC(=N)NC(=O)Cc1c(Cl)cccc1Cl, NC(=N)NC(=O)Cc1c(Cl)cccc1Cl, NC(=N)NC(=O)Cc1c(Cl)cccc1Cl, NC(=N)NC(=O)Cc1c(Cl)cccc1Cl, NC(=N)NC(=O)Cc1c(Cl)cccc1Cl	INJOMKTZOLKMBF-UHFFFAOYSA-N, INJOMKTZOLKMBF-UHFFFAOYSA-N, INJOMKTZOLKMBF-UHFFFAOYSA-N, INJOMKTZOLKMBF-UHFFFAOYSA-N, INJOMKTZOLKMBF-UHFFFAOYSA-N	Launched
guanidine	HSP inhibitor	ALDH2, DLG4, GAMT, RNASE1	neurology/psychiatry	Lambert-Eaton myasthenic syndrome (LEMS)	NC(N)=N, NC(N)=N, NC(N)=N	ZRALSGWEFCBTJO-UHFFFAOYSA-N, ZRALSGWEFCBTJO-UHFFFAOYSA-N, ZRALSGWEFCBTJO-UHFFFAOYSA-N	Launched
guanidinoethyldisulfide-bicarbonate	nitric oxide synthase inhibitor	NOS2			NC(=N)NCCSSCCNC(N)=N	IRMTXMJNHRISQH-UHFFFAOYSA-N	Phase 2
guanidinopropionic-acid	creatine kinase inhibitor	CKM			NC(=N)NCCC(O)=O	KMXXSJLYVJEBHI-UHFFFAOYSA-N	Phase 2
guanosine		PNP			Nc1nc(=O)c2ncn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c2[nH]1	NYHBQMYGNKIUIF-UUOKFMHZSA-N	Preclinical
Gue-1654	oxoeicosanoid receptor modulator	OXER1			CSc1nc2ccc3nc(NC(=O)C(c4ccccc4)c4ccccc4)sc3c2s1, CSc1nc2ccc3nc(NC(=O)C(c4ccccc4)c4ccccc4)sc3c2s1	UFOBDFMYJABXGK-UHFFFAOYSA-N, UFOBDFMYJABXGK-UHFFFAOYSA-N	Preclinical
guvacine	GABA uptake inhibitor	SLC6A1, SLC6A11, SLC6A12, SLC6A13			OC(=O)C1=CCCNC1 |t:3|, OC(=O)C1=CCCNC1 |t:3|, OC(=O)C1=CCCNC1 |t:3|, OC(=O)C1=CCCNC1 |t:3|	QTDZOWFRBNTPQR-UHFFFAOYSA-N, QTDZOWFRBNTPQR-UHFFFAOYSA-N, QTDZOWFRBNTPQR-UHFFFAOYSA-N, QTDZOWFRBNTPQR-UHFFFAOYSA-N	Preclinical
GW-0742	PPAR receptor agonist	PPARD			Cc1nc(sc1CSc1ccc(OCC(O)=O)c(C)c1)-c1ccc(c(F)c1)C(F)(F)F, Cc1nc(sc1CSc1ccc(OCC(O)=O)c(C)c1)-c1ccc(c(F)c1)C(F)(F)F, Cc1nc(sc1CSc1ccc(OCC(O)=O)c(C)c1)-c1ccc(c(F)c1)C(F)(F)F, Cc1nc(sc1CSc1ccc(OCC(O)=O)c(C)c1)-c1ccc(c(F)c1)C(F)(F)F, Cc1nc(sc1CSc1ccc(OCC(O)=O)c(C)c1)-c1ccc(c(F)c1)C(F)(F)F	HWVNEWGKWRGSRK-UHFFFAOYSA-N, HWVNEWGKWRGSRK-UHFFFAOYSA-N, HWVNEWGKWRGSRK-UHFFFAOYSA-N, HWVNEWGKWRGSRK-UHFFFAOYSA-N, HWVNEWGKWRGSRK-UHFFFAOYSA-N	Preclinical
GW-1100	G protein-coupled receptor agonist	FFAR1			CCOC(=O)c1ccc(cc1)-n1cc(Cc2cnc(OCC)nc2)c(=O)nc1SCc1ccc(F)cc1	PTPNCCWOTBBVJR-UHFFFAOYSA-N	Preclinical
GW-1929	PPAR receptor agonist	PPARG			CN(CCOc1ccc(C[C@H](Nc2ccccc2C(=O)c2ccccc2)C(O)=O)cc1)c1ccccn1	QTQMRBZOBKYXCG-MHZLTWQESA-N	Preclinical
GW-2580	cFMS kinase inhibitor	CSF1R			COc1ccc(COc2ccc(Cc3cnc(N)nc3N)cc2OC)cc1, COc1ccc(COc2ccc(Cc3cnc(N)nc3N)cc2OC)cc1	MYQAUKPBNJWPIE-UHFFFAOYSA-N, MYQAUKPBNJWPIE-UHFFFAOYSA-N	Preclinical
GW-311616	elastase inhibitor, leukocyte elastase inhibitor	ELANE			CC(C)[C@H]1[C@H]2[C@@H](CCN2C(=O)\C=C\CN2CCCCC2)N(C1=O)S(C)(=O)=O, CC(C)[C@H]1[C@H]2[C@@H](CCN2C(=O)\C=C\CN2CCCCC2)N(C1=O)S(C)(=O)=O, CC(C)[C@H]1[C@H]2[C@@H](CCN2C(=O)\C=C\CN2CCCCC2)N(C1=O)S(C)(=O)=O	NDNKNUMSTIMSHQ-URZKGLGPSA-N, NDNKNUMSTIMSHQ-URZKGLGPSA-N, NDNKNUMSTIMSHQ-URZKGLGPSA-N	Phase 1
GW-3965	LXR agonist	NR1H2, NR1H3			OC(=O)Cc1cccc(OCCCN(CC(c2ccccc2)c2ccccc2)Cc2cccc(c2Cl)C(F)(F)F)c1, OC(=O)Cc1cccc(OCCCN(CC(c2ccccc2)c2ccccc2)Cc2cccc(c2Cl)C(F)(F)F)c1, OC(=O)Cc1cccc(OCCCN(CC(c2ccccc2)c2ccccc2)Cc2cccc(c2Cl)C(F)(F)F)c1, OC(=O)Cc1cccc(OCCCN(CC(c2ccccc2)c2ccccc2)Cc2cccc(c2Cl)C(F)(F)F)c1, OC(=O)Cc1cccc(OCCCN(CC(c2ccccc2)c2ccccc2)Cc2cccc(c2Cl)C(F)(F)F)c1, OC(=O)Cc1cccc(OCCCN(CC(c2ccccc2)c2ccccc2)Cc2cccc(c2Cl)C(F)(F)F)c1	NAXSRXHZFIBFMI-UHFFFAOYSA-N, NAXSRXHZFIBFMI-UHFFFAOYSA-N, NAXSRXHZFIBFMI-UHFFFAOYSA-N, NAXSRXHZFIBFMI-UHFFFAOYSA-N, NAXSRXHZFIBFMI-UHFFFAOYSA-N, NAXSRXHZFIBFMI-UHFFFAOYSA-N	Preclinical
GW-405833	cannabinoid receptor agonist	CNR2			COc1ccc2n(C(=O)c3cccc(Cl)c3Cl)c(C)c(CCN3CCOCC3)c2c1	FSFZRNZSZYDVLI-UHFFFAOYSA-N	Preclinical
GW-4064	FXR agonist	NR1H4			CC(C)c1onc(c1COc1ccc(\C=C\c2cccc(c2)C(O)=O)c(Cl)c1)-c1c(Cl)cccc1Cl, CC(C)c1onc(c1COc1ccc(\C=C\c2cccc(c2)C(O)=O)c(Cl)c1)-c1c(Cl)cccc1Cl, CC(C)c1onc(c1COc1ccc(\C=C\c2cccc(c2)C(O)=O)c(Cl)c1)-c1c(Cl)cccc1Cl, CC(C)c1onc(c1COc1ccc(\C=C\c2cccc(c2)C(O)=O)c(Cl)c1)-c1c(Cl)cccc1Cl, CC(C)c1onc(c1COc1ccc(\C=C\c2cccc(c2)C(O)=O)c(Cl)c1)-c1c(Cl)cccc1Cl, CC(C)c1onc(c1COc1ccc(\C=C\c2cccc(c2)C(O)=O)c(Cl)c1)-c1c(Cl)cccc1Cl	BYTNEISLBIENSA-MDZDMXLPSA-N, BYTNEISLBIENSA-MDZDMXLPSA-N, BYTNEISLBIENSA-MDZDMXLPSA-N, BYTNEISLBIENSA-MDZDMXLPSA-N, BYTNEISLBIENSA-MDZDMXLPSA-N, BYTNEISLBIENSA-MDZDMXLPSA-N	Preclinical
GW-438014A	neuropeptide receptor antagonist	NPY5R			O=C(Nc1nc2ccccc2n1CCc1ccccc1)c1ccccc1, O=C(Nc1nc2ccccc2n1CCc1ccccc1)c1ccccc1, O=C(Nc1nc2ccccc2n1CCc1ccccc1)c1ccccc1	CDUDZZGLFOFINU-UHFFFAOYSA-N, CDUDZZGLFOFINU-UHFFFAOYSA-N, CDUDZZGLFOFINU-UHFFFAOYSA-N	Preclinical
GW-441756	growth factor receptor inhibitor	NTRK1			Cn1cc(\C=C2/C(=O)Nc3cccnc23)c2ccccc12, Cn1cc(\C=C2/C(=O)Nc3cccnc23)c2ccccc12	NXNQLECPAXXYTR-LCYFTJDESA-N, NXNQLECPAXXYTR-LCYFTJDESA-N	Preclinical
GW-501516	PPAR receptor agonist	PPARA, PPARD			Cc1nc(sc1CSc1ccc(OCC(O)=O)c(C)c1)-c1ccc(cc1)C(F)(F)F, Cc1nc(sc1CSc1ccc(OCC(O)=O)c(C)c1)-c1ccc(cc1)C(F)(F)F, Cc1nc(sc1CSc1ccc(OCC(O)=O)c(C)c1)-c1ccc(cc1)C(F)(F)F, Cc1nc(sc1CSc1ccc(OCC(O)=O)c(C)c1)-c1ccc(cc1)C(F)(F)F, Cc1nc(sc1CSc1ccc(OCC(O)=O)c(C)c1)-c1ccc(cc1)C(F)(F)F, Cc1nc(sc1CSc1ccc(OCC(O)=O)c(C)c1)-c1ccc(cc1)C(F)(F)F	YDBLKRPLXZNVNB-UHFFFAOYSA-N, YDBLKRPLXZNVNB-UHFFFAOYSA-N, YDBLKRPLXZNVNB-UHFFFAOYSA-N, YDBLKRPLXZNVNB-UHFFFAOYSA-N, YDBLKRPLXZNVNB-UHFFFAOYSA-N, YDBLKRPLXZNVNB-UHFFFAOYSA-N	Phase 2
GW-5074	leucine rich repeat kinase inhibitor, RAF inhibitor	NTRK1, RAF1			Oc1c(Br)cc(C=C2C(=O)Nc3ccc(I)cc23)cc1Br, Oc1c(Br)cc(C=C2C(=O)Nc3ccc(I)cc23)cc1Br, Oc1c(Br)cc(C=C2C(=O)Nc3ccc(I)cc23)cc1Br, Oc1c(Br)cc(C=C2C(=O)Nc3ccc(I)cc23)cc1Br, Oc1c(Br)cc(C=C2C(=O)Nc3ccc(I)cc23)cc1Br, Oc1c(Br)cc(C=C2C(=O)Nc3ccc(I)cc23)cc1Br	LMXYVLFTZRPNRV-UHFFFAOYSA-N, LMXYVLFTZRPNRV-UHFFFAOYSA-N, LMXYVLFTZRPNRV-UHFFFAOYSA-N, LMXYVLFTZRPNRV-UHFFFAOYSA-N, LMXYVLFTZRPNRV-UHFFFAOYSA-N, LMXYVLFTZRPNRV-UHFFFAOYSA-N	Phase 1/Phase 2
GW-542573X	calcium channel activator	KCNN1			COc1ccccc1NC(=O)OCC1CCN(CC1)C(=O)OC(C)(C)C, COc1ccccc1NC(=O)OCC1CCN(CC1)C(=O)OC(C)(C)C, COc1ccccc1NC(=O)OCC1CCN(CC1)C(=O)OC(C)(C)C	SAXGSDIZIYFNKD-UHFFFAOYSA-N, SAXGSDIZIYFNKD-UHFFFAOYSA-N, SAXGSDIZIYFNKD-UHFFFAOYSA-N	Preclinical
GW-583340	EGFR inhibitor	EGFR, ERBB2			CS(=O)(=O)CCNCc1nc(cs1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1, CS(=O)(=O)CCNCc1nc(cs1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1, CS(=O)(=O)CCNCc1nc(cs1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1	MNNXRVSQOABRRP-UHFFFAOYSA-N, MNNXRVSQOABRRP-UHFFFAOYSA-N, MNNXRVSQOABRRP-UHFFFAOYSA-N	Preclinical
GW-627368	prostanoid receptor antagonist	PTGER4			CCOc1c2CN(C(=O)c2c(OCC)c2ccccc12)c1ccc(CC(=O)NS(=O)(=O)c2ccccc2)cc1, CCOc1c2CN(C(=O)c2c(OCC)c2ccccc12)c1ccc(CC(=O)NS(=O)(=O)c2ccccc2)cc1	XREWXJVMYAXCJV-UHFFFAOYSA-N, XREWXJVMYAXCJV-UHFFFAOYSA-N	Preclinical
GW-6471	PPAR receptor antagonist	PPARA			CCC(=O)NC[C@H](Cc1ccc(OCCc2nc(oc2C)-c2ccccc2)cc1)N\C(C)=C/C(=O)c1ccc(cc1)C(F)(F)F, CCC(=O)NC[C@H](Cc1ccc(OCCc2nc(oc2C)-c2ccccc2)cc1)N\C(C)=C/C(=O)c1ccc(cc1)C(F)(F)F, CCC(=O)NC[C@H](Cc1ccc(OCCc2nc(oc2C)-c2ccccc2)cc1)N\C(C)=C/C(=O)c1ccc(cc1)C(F)(F)F, CCC(=O)NC[C@H](Cc1ccc(OCCc2nc(oc2C)-c2ccccc2)cc1)N\C(C)=C/C(=O)c1ccc(cc1)C(F)(F)F	TYEFSRMOUXWTDN-DYQICHDWSA-N, TYEFSRMOUXWTDN-DYQICHDWSA-N, TYEFSRMOUXWTDN-DYQICHDWSA-N, TYEFSRMOUXWTDN-DYQICHDWSA-N	Preclinical
GW-7647	PPAR receptor agonist	PPARA			CC(C)(Sc1ccc(CCN(CCCCC2CCCCC2)C(=O)NC2CCCCC2)cc1)C(O)=O, CC(C)(Sc1ccc(CCN(CCCCC2CCCCC2)C(=O)NC2CCCCC2)cc1)C(O)=O, CC(C)(Sc1ccc(CCN(CCCCC2CCCCC2)C(=O)NC2CCCCC2)cc1)C(O)=O	PKNYXWMTHFMHKD-UHFFFAOYSA-N, PKNYXWMTHFMHKD-UHFFFAOYSA-N, PKNYXWMTHFMHKD-UHFFFAOYSA-N	Preclinical
GW-788388	ALK tyrosine kinase receptor inhibitor	LCK, MAPK14, TGFBR1			O=C(NC1CCOCC1)c1ccc(cc1)-c1cc(ccn1)-c1c[nH]nc1-c1ccccn1, O=C(NC1CCOCC1)c1ccc(cc1)-c1cc(ccn1)-c1c[nH]nc1-c1ccccn1, O=C(NC1CCOCC1)c1ccc(cc1)-c1cc(ccn1)-c1c[nH]nc1-c1ccccn1, O=C(NC1CCOCC1)c1ccc(cc1)-c1cc(ccn1)-c1c[nH]nc1-c1ccccn1	SAGZIBJAQGBRQA-UHFFFAOYSA-N, SAGZIBJAQGBRQA-UHFFFAOYSA-N, SAGZIBJAQGBRQA-UHFFFAOYSA-N, SAGZIBJAQGBRQA-UHFFFAOYSA-N	Preclinical
GW-803430	melanin inhibitor	KCNH2, MCHR1			COc1cc(ccc1OCCN1CCCC1)-n1cnc2cc(sc2c1=O)-c1ccc(Cl)cc1, COc1cc(ccc1OCCN1CCCC1)-n1cnc2cc(sc2c1=O)-c1ccc(Cl)cc1	MWULMTACIBZPGN-UHFFFAOYSA-N, MWULMTACIBZPGN-UHFFFAOYSA-N	Phase 1
GW-842166	cannabinoid receptor agonist	CNR2			FC(F)(F)c1nc(Nc2ccc(Cl)cc2Cl)ncc1C(=O)NCC1CCOCC1, FC(F)(F)c1nc(Nc2ccc(Cl)cc2Cl)ncc1C(=O)NCC1CCOCC1, FC(F)(F)c1nc(Nc2ccc(Cl)cc2Cl)ncc1C(=O)NCC1CCOCC1	TWQYWUXBZHPIIV-UHFFFAOYSA-N, TWQYWUXBZHPIIV-UHFFFAOYSA-N, TWQYWUXBZHPIIV-UHFFFAOYSA-N	Phase 2
GW-843682X	PLK inhibitor	PLK1, PLK3			COc1cc2ncn(-c3cc(OCc4ccccc4C(F)(F)F)c(s3)C(N)=O)c2cc1OC, COc1cc2ncn(-c3cc(OCc4ccccc4C(F)(F)F)c(s3)C(N)=O)c2cc1OC, COc1cc2ncn(-c3cc(OCc4ccccc4C(F)(F)F)c(s3)C(N)=O)c2cc1OC, COc1cc2ncn(-c3cc(OCc4ccccc4C(F)(F)F)c(s3)C(N)=O)c2cc1OC, COc1cc2ncn(-c3cc(OCc4ccccc4C(F)(F)F)c(s3)C(N)=O)c2cc1OC	JSKUWFIZUALZLX-UHFFFAOYSA-N, JSKUWFIZUALZLX-UHFFFAOYSA-N, JSKUWFIZUALZLX-UHFFFAOYSA-N, JSKUWFIZUALZLX-UHFFFAOYSA-N, JSKUWFIZUALZLX-UHFFFAOYSA-N	Preclinical
GW-9508	free fatty acid receptor agonist, G protein-coupled receptor agonist	FFAR1, FFAR4			OC(=O)CCc1ccc(NCc2cccc(Oc3ccccc3)c2)cc1, OC(=O)CCc1ccc(NCc2cccc(Oc3ccccc3)c2)cc1, OC(=O)CCc1ccc(NCc2cccc(Oc3ccccc3)c2)cc1, OC(=O)CCc1ccc(NCc2cccc(Oc3ccccc3)c2)cc1	DGENZVKCTGIDRZ-UHFFFAOYSA-N, DGENZVKCTGIDRZ-UHFFFAOYSA-N, DGENZVKCTGIDRZ-UHFFFAOYSA-N, DGENZVKCTGIDRZ-UHFFFAOYSA-N	Preclinical
GW-9662	PPAR receptor antagonist	NCOA2, PPARG, RXRA			[O-][N+](=O)c1ccc(Cl)c(c1)C(=O)Nc1ccccc1, [O-][N+](=O)c1ccc(Cl)c(c1)C(=O)Nc1ccccc1, [O-][N+](=O)c1ccc(Cl)c(c1)C(=O)Nc1ccccc1	DNTSIBUQMRRYIU-UHFFFAOYSA-N, DNTSIBUQMRRYIU-UHFFFAOYSA-N, DNTSIBUQMRRYIU-UHFFFAOYSA-N	Preclinical
GW274150	nitric oxide synthase inhibitor				CC(=N)NCCSCC[C@H](N)C(O)=O	MOLOJNHYNHBPCW-ZETCQYMHSA-N	Phase 2
GYKI-52466	glutamate receptor antagonist	GRIA1, GRIA2, GRIA3, GRIA4			CC1=NN=C(c2ccc(N)cc2)c2cc3OCOc3cc2C1 |t:1,3|, CC1=NN=C(c2ccc(N)cc2)c2cc3OCOc3cc2C1 |t:1,3|, CC1=NN=C(c2ccc(N)cc2)c2cc3OCOc3cc2C1 |t:1,3|, CC1=NN=C(c2ccc(N)cc2)c2cc3OCOc3cc2C1 |t:1,3|	LFBZZHVSGAHQPP-UHFFFAOYSA-N, LFBZZHVSGAHQPP-UHFFFAOYSA-N, InChI=1S/C17H15N3O2/c1-10-6-12-7-15-16(22-9-21-15)8-14(12)17(20-19-10)11-2-4-13(18)5-3-11/h2-5,7-8H,6,9,18H2,1H3, InChI=1S/C17H15N3O2/c1-10-6-12-7-15-16(22-9-21-15)8-14(12)17(20-19-10)11-2-4-13(18)5-3-11/h2-5,7-8H,6,9,18H2,1H3	Preclinical
gynostemma-extract	calcium channel modulator				CC(C)=CCC[C@](C)(O[C@@H]1O[C@H](CO[C@@H]2OC[C@@H](O)[C@H](O)[C@H]2O)[C@@H](O)[C@H](O)[C@H]1O)[C@H]1CC[C@]2(C)[C@@H]1[C@H](O)C[C@@H]1[C@@]3(C)CC[C@H](O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)C(C)(C)[C@@H]3CC[C@@]21C, CC(C)=CCC[C@](C)(O[C@@H]1O[C@H](CO[C@@H]2OC[C@@H](O)[C@H](O)[C@H]2O)[C@@H](O)[C@H](O)[C@H]1O)[C@H]1CC[C@]2(C)[C@@H]1[C@H](O)C[C@@H]1[C@@]3(C)CC[C@H](O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)C(C)(C)[C@@H]3CC[C@@]21C, CC(C)=CCC[C@](C)(O[C@@H]1O[C@H](CO[C@@H]2OC[C@@H](O)[C@H](O)[C@H]2O)[C@@H](O)[C@H](O)[C@H]1O)[C@H]1CC[C@]2(C)[C@@H]1[C@H](O)C[C@@H]1[C@@]3(C)CC[C@H](O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)C(C)(C)[C@@H]3CC[C@@]21C	ZTQSADJAYQOCDD-HUGMCNGHSA-N, ZTQSADJAYQOCDD-HUGMCNGHSA-N, ZTQSADJAYQOCDD-HUGMCNGHSA-N	Phase 2
GZD824	Bcr-Abl kinase inhibitor	ABL1, BCR			CN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(c3)C#Cc3cnc4n[nH]cc4c3)cc2C(F)(F)F)CC1, CN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(c3)C#Cc3cnc4n[nH]cc4c3)cc2C(F)(F)F)CC1, CN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(c3)C#Cc3cnc4n[nH]cc4c3)cc2C(F)(F)F)CC1, CN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(c3)C#Cc3cnc4n[nH]cc4c3)cc2C(F)(F)F)CC1, CN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(c3)C#Cc3cnc4n[nH]cc4c3)cc2C(F)(F)F)CC1, CN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(c3)C#Cc3cnc4n[nH]cc4c3)cc2C(F)(F)F)CC1, CN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(c3)C#Cc3cnc4n[nH]cc4c3)cc2C(F)(F)F)CC1	TZKBVRDEOITLRB-UHFFFAOYSA-N, TZKBVRDEOITLRB-UHFFFAOYSA-N, TZKBVRDEOITLRB-UHFFFAOYSA-N, TZKBVRDEOITLRB-UHFFFAOYSA-N, TZKBVRDEOITLRB-UHFFFAOYSA-N, TZKBVRDEOITLRB-UHFFFAOYSA-N, TZKBVRDEOITLRB-UHFFFAOYSA-N	Preclinical
G007-LK	tankyrase inhibitor	TNKS, TNKS2			CS(=O)(=O)c1ccc(nc1)-c1nnc(\C=C\c2nnc(o2)-c2ccc(cc2)C#N)n1-c1ccccc1Cl	HIWVLHPKZNBSBE-OUKQBFOZSA-N	Preclinical
H-151	STING antagonist				CCc1ccc(NC(=O)Nc2c[nH]c3ccccc23)cc1	UJZDIKVQFMCLBE-UHFFFAOYSA-N	Preclinical
H-89	PKA inhibitor	GSG2, PKIA, PRKACA			Brc1ccc(\C=C\CNCCNS(=O)(=O)c2cccc3cnccc23)cc1, Brc1ccc(\C=C\CNCCNS(=O)(=O)c2cccc3cnccc23)cc1, Brc1ccc(\C=C\CNCCNS(=O)(=O)c2cccc3cnccc23)cc1, Brc1ccc(\C=C\CNCCNS(=O)(=O)c2cccc3cnccc23)cc1, Brc1ccc(\C=C\CNCCNS(=O)(=O)c2cccc3cnccc23)cc1, Brc1ccc(\C=C\CNCCNS(=O)(=O)c2cccc3cnccc23)cc1, Brc1ccc(\C=C\CNCCNS(=O)(=O)c2cccc3cnccc23)cc1	ZKZXNDJNWUTGDK-NSCUHMNNSA-N, ZKZXNDJNWUTGDK-NSCUHMNNSA-N, ZKZXNDJNWUTGDK-NSCUHMNNSA-N, ZKZXNDJNWUTGDK-NSCUHMNNSA-N, ZKZXNDJNWUTGDK-NSCUHMNNSA-N, ZKZXNDJNWUTGDK-NSCUHMNNSA-N, ZKZXNDJNWUTGDK-NSCUHMNNSA-N	Preclinical
HA-1004	calcium channel blocker				NC(=N)NCCNS(=O)(=O)c1cccc2cnccc12, NC(=N)NCCNS(=O)(=O)c1cccc2cnccc12, NC(=N)NCCNS(=O)(=O)c1cccc2cnccc12	MZNDNBFMSVMUCX-UHFFFAOYSA-N, MZNDNBFMSVMUCX-UHFFFAOYSA-N, MZNDNBFMSVMUCX-UHFFFAOYSA-N	Phase 2
HA-130	autotaxin inhibitor	ENPP2			OB(O)c1cccc(COc2ccc(\C=C3/SC(=O)N(Cc4ccc(F)cc4)C3=O)cc2)c1, OB(O)c1cccc(COc2ccc(\C=C3/SC(=O)N(Cc4ccc(F)cc4)C3=O)cc2)c1	VTNKMYWFWQTEHE-XKZIYDEJSA-N, VTNKMYWFWQTEHE-XKZIYDEJSA-N	Preclinical
HA-966-(R)-(+)	glutamate receptor agonist	GRIA1			N[C@@H]1CCN(O)C1=O, N[C@@H]1CCN(O)C1=O, N[C@@H]1CCN(O)C1=O	HCKUBNLZMKAEIN-GSVOUGTGSA-N, HCKUBNLZMKAEIN-GSVOUGTGSA-N, HCKUBNLZMKAEIN-GSVOUGTGSA-N	Preclinical
HA-966-(S)-(-)	glutamate receptor antagonist	GRIA1			N[C@H]1CCN(O)C1=O, N[C@H]1CCN(O)C1=O	HCKUBNLZMKAEIN-VKHMYHEASA-N, HCKUBNLZMKAEIN-VKHMYHEASA-N	Preclinical
halazone			infectious disease	disinfectant	OC(=O)c1ccc(cc1)S(=O)(=O)N(Cl)Cl, OC(=O)c1ccc(cc1)S(=O)(=O)N(Cl)Cl	XPDVQPODLRGWPL-UHFFFAOYSA-N, XPDVQPODLRGWPL-UHFFFAOYSA-N	Launched
halcinonide	glucocorticoid receptor agonist	NR3C1	dermatology	corticosteroid-responsive dermatoses	CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)CC[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CCl |t:10|, CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)CC[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CCl |t:10|, CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)CC[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CCl |t:10|, CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)CC[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CCl |t:10|, CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)CC[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CCl |t:10|, CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)CC[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CCl |t:10|	MUQNGPZZQDCDFT-JNQJZLCISA-N, MUQNGPZZQDCDFT-JNQJZLCISA-N, MUQNGPZZQDCDFT-JNQJZLCISA-N, MUQNGPZZQDCDFT-JNQJZLCISA-N, MUQNGPZZQDCDFT-JNQJZLCISA-N, MUQNGPZZQDCDFT-JNQJZLCISA-N	Launched
halobetasol-propionate	glucocorticoid receptor agonist	NR3C1, PLA2G1B	dermatology	corticosteroid-responsive dermatoses	CCC(=O)O[C@@]1([C@@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)CCl |c:18,t:14|	BDSYKGHYMJNPAB-LICBFIPMSA-N	Launched
halofantrine	antimalarial agent	KCNN4	infectious disease	malaria	CCCCN(CCCC)CC[C@@H](O)c1cc2c(Cl)cc(Cl)cc2c2cc(ccc12)C(F)(F)F |&1:11|, CCCCN(CCCC)CC[C@@H](O)c1cc2c(Cl)cc(Cl)cc2c2cc(ccc12)C(F)(F)F |&1:11|	FOHHNHSLJDZUGQ-RUZDIDTESA-N, FOHHNHSLJDZUGQ-RUZDIDTESA-N	Launched
halofuginone	collagenase inhibitor	COL1A1, MMP2	rheumatology	scleroderma	O[C@H]1CCCN[C@@H]1CC(=O)Cn1cnc2cc(Br)c(Cl)cc2c1=O, O[C@H]1CCCN[C@@H]1CC(=O)Cn1cnc2cc(Br)c(Cl)cc2c1=O, O[C@H]1CCCN[C@@H]1CC(=O)Cn1cnc2cc(Br)c(Cl)cc2c1=O, O[C@H]1CCCN[C@@H]1CC(=O)Cn1cnc2cc(Br)c(Cl)cc2c1=O, O[C@H]1CCCN[C@@H]1CC(=O)Cn1cnc2cc(Br)c(Cl)cc2c1=O	LVASCWIMLIKXLA-CABCVRRESA-N, LVASCWIMLIKXLA-CABCVRRESA-N, LVASCWIMLIKXLA-CABCVRRESA-N, LVASCWIMLIKXLA-CABCVRRESA-N, LVASCWIMLIKXLA-CABCVRRESA-N	Launched
halopemide	phospholipase inhibitor	PLD1, PLD2			Fc1ccc(cc1)C(=O)NCCN1CCC(CC1)n1c2ccc(Cl)cc2[nH]c1=O, Fc1ccc(cc1)C(=O)NCCN1CCC(CC1)n1c2ccc(Cl)cc2[nH]c1=O, Fc1ccc(cc1)C(=O)NCCN1CCC(CC1)n1c2ccc(Cl)cc2[nH]c1=O, Fc1ccc(cc1)C(=O)NCCN1CCC(CC1)n1c2ccc(Cl)cc2[nH]c1=O	NBHPRWLFLUBAIE-UHFFFAOYSA-N, NBHPRWLFLUBAIE-UHFFFAOYSA-N, NBHPRWLFLUBAIE-UHFFFAOYSA-N, NBHPRWLFLUBAIE-UHFFFAOYSA-N	Phase 2
haloperidol	dopamine receptor antagonist	DRD1, DRD2, DRD3, DRD4, DRD5, GRIN2B, HRH1, HTR1A, HTR1D, HTR2A, HTR2B, HTR7, KCNH1	neurology/psychiatry	schizophrenia, Tourette's disorder	OC1(CCN(CCCC(=O)c2ccc(F)cc2)CC1)c1ccc(Cl)cc1, OC1(CCN(CCCC(=O)c2ccc(F)cc2)CC1)c1ccc(Cl)cc1, OC1(CCN(CCCC(=O)c2ccc(F)cc2)CC1)c1ccc(Cl)cc1, OC1(CCN(CCCC(=O)c2ccc(F)cc2)CC1)c1ccc(Cl)cc1	LNEPOXFFQSENCJ-UHFFFAOYSA-N, LNEPOXFFQSENCJ-UHFFFAOYSA-N, LNEPOXFFQSENCJ-UHFFFAOYSA-N, LNEPOXFFQSENCJ-UHFFFAOYSA-N	Launched
haloperidol-decanoate	psychoactive drug	DRD2, DRD3, DRD4, HTR2A	neurology/psychiatry	schizophrenia	CCCCCCCCCC(=O)OC1(CCN(CCCC(=O)c2ccc(F)cc2)CC1)c1ccc(Cl)cc1, CCCCCCCCCC(=O)OC1(CCN(CCCC(=O)c2ccc(F)cc2)CC1)c1ccc(Cl)cc1	GUTXTARXLVFHDK-UHFFFAOYSA-N, GUTXTARXLVFHDK-UHFFFAOYSA-N	Launched
haloprogin	other antifungal		infectious disease	tinea pedis	Clc1cc(Cl)c(OCC#CI)cc1Cl, Clc1cc(Cl)c(OCC#CI)cc1Cl, Clc1cc(Cl)c(OCC#CI)cc1Cl	CTETYYAZBPJBHE-UHFFFAOYSA-N, CTETYYAZBPJBHE-UHFFFAOYSA-N, CTETYYAZBPJBHE-UHFFFAOYSA-N	Launched
halothane	glutamate receptor antagonist	GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, GLRA1, GLRB, KCNK10, KCNK12, KCNK13, KCNK15, KCNK18, KCNK2, KCNK3, KCNK9	neurology/psychiatry	general anaesthetic	FC(F)(F)[C@@H](Cl)Br |&1:4,r|, FC(F)(F)[C@@H](Cl)Br |&1:4,r|	BCQZXOMGPXTTIC-PVQJCKRUSA-N, BCQZXOMGPXTTIC-PVQJCKRUSA-N	Launched
harmane	monoamine oxidase inhibitor	MAOA, MAOB			Cc1nccc2c3ccccc3[nH]c12	PSFDQSOCUJVVGF-UHFFFAOYSA-N	Preclinical
harringtonine	protein synthesis inhibitor				[H][C@@]12[C@H](OC(=O)[C@@](O)(CCC(C)(C)O)CC(=O)OC)C(OC)=C[C@@]11CCCN1CCc1cc3OCOc3cc21 |c:21|, [H][C@@]12[C@H](OC(=O)[C@@](O)(CCC(C)(C)O)CC(=O)OC)C(OC)=C[C@@]11CCCN1CCc1cc3OCOc3cc21 |c:21|	HAVJATCHLFRDHY-KSZYUSJVSA-N, HAVJATCHLFRDHY-KSZYUSJVSA-N	Phase 3
HA14-1	BCL inhibitor	BCL2			CCOC(=O)[C@@H](C#N)[C@H]1C(C(=O)OCC)=C(N)Oc2ccc(Br)cc12 |&1:5,8,r,t:14|, CCOC(=O)[C@@H](C#N)[C@H]1C(C(=O)OCC)=C(N)Oc2ccc(Br)cc12 |&1:5,8,r,t:14|, CCOC(=O)[C@@H](C#N)[C@H]1C(C(=O)OCC)=C(N)Oc2ccc(Br)cc12 |&1:5,8,r,t:14|	SXJDCULZDFWMJC-AAEUAGOBSA-N, SXJDCULZDFWMJC-AAEUAGOBSA-N, SXJDCULZDFWMJC-AAEUAGOBSA-N	Preclinical
HBED	chelating agent				OC(=O)CN(CCN(CC(O)=O)Cc1ccccc1O)Cc1ccccc1O	GRUVVLWKPGIYEG-UHFFFAOYSA-N	Phase 3
HC-030031	TRPA1 channel blocker	TRPA1			CC(C)c1ccc(NC(=O)Cn2cnc3n(C)c(=O)n(C)c(=O)c23)cc1, CC(C)c1ccc(NC(=O)Cn2cnc3n(C)c(=O)n(C)c(=O)c23)cc1, CC(C)c1ccc(NC(=O)Cn2cnc3n(C)c(=O)n(C)c(=O)c23)cc1, CC(C)c1ccc(NC(=O)Cn2cnc3n(C)c(=O)n(C)c(=O)c23)cc1, CC(C)c1ccc(NC(=O)Cn2cnc3n(C)c(=O)n(C)c(=O)c23)cc1, CC(C)c1ccc(NC(=O)Cn2cnc3n(C)c(=O)n(C)c(=O)c23)cc1	HEQDZPHDVAOBLN-UHFFFAOYSA-N, HEQDZPHDVAOBLN-UHFFFAOYSA-N, HEQDZPHDVAOBLN-UHFFFAOYSA-N, HEQDZPHDVAOBLN-UHFFFAOYSA-N, HEQDZPHDVAOBLN-UHFFFAOYSA-N, HEQDZPHDVAOBLN-UHFFFAOYSA-N	Phase 1
HC-067047	transient receptor potential channel antagonist	TRPV4			Cc1c(cc(-c2ccccc2)n1CCCN1CCOCC1)C(=O)Nc1cccc(c1)C(F)(F)F, Cc1c(cc(-c2ccccc2)n1CCCN1CCOCC1)C(=O)Nc1cccc(c1)C(F)(F)F, Cc1c(cc(-c2ccccc2)n1CCCN1CCOCC1)C(=O)Nc1cccc(c1)C(F)(F)F, Cc1c(cc(-c2ccccc2)n1CCCN1CCOCC1)C(=O)Nc1cccc(c1)C(F)(F)F, Cc1c(cc(-c2ccccc2)n1CCCN1CCOCC1)C(=O)Nc1cccc(c1)C(F)(F)F, Cc1c(cc(-c2ccccc2)n1CCCN1CCOCC1)C(=O)Nc1cccc(c1)C(F)(F)F, Cc1c(cc(-c2ccccc2)n1CCCN1CCOCC1)C(=O)Nc1cccc(c1)C(F)(F)F, Cc1c(cc(-c2ccccc2)n1CCCN1CCOCC1)C(=O)Nc1cccc(c1)C(F)(F)F, Cc1c(cc(-c2ccccc2)n1CCCN1CCOCC1)C(=O)Nc1cccc(c1)C(F)(F)F	NCZYSQOTAYFTNM-UHFFFAOYSA-N, NCZYSQOTAYFTNM-UHFFFAOYSA-N, NCZYSQOTAYFTNM-UHFFFAOYSA-N, NCZYSQOTAYFTNM-UHFFFAOYSA-N, NCZYSQOTAYFTNM-UHFFFAOYSA-N, NCZYSQOTAYFTNM-UHFFFAOYSA-N, NCZYSQOTAYFTNM-UHFFFAOYSA-N, NCZYSQOTAYFTNM-UHFFFAOYSA-N, NCZYSQOTAYFTNM-UHFFFAOYSA-N	Preclinical
HC-070	transient receptor potential channel antagonist				Cn1c2nc(Oc3cccc(Cl)c3)n(Cc3ccc(Cl)cc3)c2c(=O)n(CCCO)c1=O	VYJPVPHNGWEIBT-UHFFFAOYSA-N	Preclinical
heclin	ubiquitin ligase inhibitor	NEDD4, SMURF2, WWP1			CCc1ccc(\C=C\C(=O)Nc2ccc(cc2)C(C)=O)o1, CCc1ccc(\C=C\C(=O)Nc2ccc(cc2)C(C)=O)o1, CCc1ccc(\C=C\C(=O)Nc2ccc(cc2)C(C)=O)o1, CCc1ccc(\C=C\C(=O)Nc2ccc(cc2)C(C)=O)o1	SPTWXRJNCFIDRQ-ZHACJKMWSA-N, SPTWXRJNCFIDRQ-ZHACJKMWSA-N, SPTWXRJNCFIDRQ-ZHACJKMWSA-N, SPTWXRJNCFIDRQ-ZHACJKMWSA-N	Preclinical
HEMADO	adenosine receptor agonist	ADORA1, ADORA2A, ADORA2B, ADORA3			CCCCC#Cc1nc(NC)c2ncn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c2n1, CCCCC#Cc1nc(NC)c2ncn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c2n1, CCCCC#Cc1nc(NC)c2ncn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c2n1	KOCIMZNSNPOGOP-IWCJZZDYSA-N, KOCIMZNSNPOGOP-IWCJZZDYSA-N, KOCIMZNSNPOGOP-IWCJZZDYSA-N	Preclinical
hematoporphyrin			neurology/psychiatry	depression, psychosis	C[C@@H](O)c1c(C)c2cc3[nH]c(cc4[nH]c(cc5nc(cc1n2)c(C)c5[C@@H](C)O)c(C)c4CCC(O)=O)c(CCC(O)=O)c3C |&1:25,&2:1,r|, C[C@@H](O)c1c(C)c2cc3[nH]c(cc4[nH]c(cc5nc(cc1n2)c(C)c5[C@@H](C)O)c(C)c4CCC(O)=O)c(CCC(O)=O)c3C |&1:25,&2:1,r|	DWZDGMDDUHAIQA-XEAGYAAOSA-N, DWZDGMDDUHAIQA-XEAGYAAOSA-N	Launched
hematoxylin					Oc1ccc2[C@H]3c4cc(O)c(O)cc4C[C@@]3(O)COc2c1O, Oc1ccc2[C@H]3c4cc(O)c(O)cc4C[C@@]3(O)COc2c1O, Oc1ccc2[C@H]3c4cc(O)c(O)cc4C[C@@]3(O)COc2c1O	WZUVPPKBWHMQCE-XJKSGUPXSA-N, WZUVPPKBWHMQCE-XJKSGUPXSA-N, WZUVPPKBWHMQCE-XJKSGUPXSA-N	Preclinical
hemin	enzyme inducer		hematology, cardiology	acute intermittent porphyria (AIP), hypertension, ventricular tachycardia (VT)	CC1=C(CCC(O)=O)\C2=C\c3c(CCC(O)=O)c(C)c4\C=C5/N=C(/C=c6/c(C=C)c(C)\c(=C\C1=N2)n6[Fe](O)n34)C(C)=C5C=C |c:1,20,34,45,t:8,22,24,31|, CC1=C(CCC(O)=O)\C2=C\c3c(CCC(O)=O)c(C)c4\C=C5/N=C(/C=c6/c(C=C)c(C)\c(=C\C1=N2)n6[Fe](O)n34)C(C)=C5C=C |c:1,20,34,45,t:8,22,24,31|, CC1=C(CCC(O)=O)\C2=C\c3c(CCC(O)=O)c(C)c4\C=C5/N=C(/C=c6/c(C=C)c(C)\c(=C\C1=N2)n6[Fe](O)n34)C(C)=C5C=C |c:1,20,34,45,t:8,22,24,31|	BMUDPLZKKRQECS-HXFTUNQESA-K, BMUDPLZKKRQECS-HXFTUNQESA-K, BMUDPLZKKRQECS-HXFTUNQESA-K	Launched
hemomex-s		PPARG			CC(C)=CCC[C@](C)(O)[C@H]1CC[C@]2(C)[C@@H]1[C@H](O)C[C@@H]1[C@@]3(C)CC[C@H](O)C(C)(C)[C@@H]3[C@@H](O)C[C@@]21C, CC(C)=CCC[C@](C)(O)[C@H]1CC[C@]2(C)[C@@H]1[C@H](O)C[C@@H]1[C@@]3(C)CC[C@H](O)C(C)(C)[C@@H]3[C@@H](O)C[C@@]21C, CC(C)=CCC[C@](C)(O)[C@H]1CC[C@]2(C)[C@@H]1[C@H](O)C[C@@H]1[C@@]3(C)CC[C@H](O)C(C)(C)[C@@H]3[C@@H](O)C[C@@]21C	SHCBCKBYTHZQGZ-CJPZEJHVSA-N, SHCBCKBYTHZQGZ-CJPZEJHVSA-N, SHCBCKBYTHZQGZ-CJPZEJHVSA-N	Launched
hepsulfam	DNA cross-linking				NS(=O)(=O)OCCCCCCCOS(N)(=O)=O	GOJJWDOZNKBUSR-UHFFFAOYSA-N	Preclinical
heptaminol	vasoconstrictor		cardiology	hypotension	C[C@@H](N)CCCC(C)(C)O |&1:1|, C[C@@H](N)CCCC(C)(C)O |&1:1|, C[C@@H](N)CCCC(C)(C)O |&1:1|	LREQLEBVOXIEOM-SSDOTTSWSA-N, LREQLEBVOXIEOM-SSDOTTSWSA-N, LREQLEBVOXIEOM-SSDOTTSWSA-N	Launched
HER2-Inhibitor-1	EGFR inhibitor				Cc1cc(Nc2ncnc3ccc(cc23)-c2ccc(CNCCS(C)(=O)=O)o2)ccc1Oc1ccn2ncnc2c1, Cc1cc(Nc2ncnc3ccc(cc23)-c2ccc(CNCCS(C)(=O)=O)o2)ccc1Oc1ccn2ncnc2c1	QVMNYGOVNWWFKF-UHFFFAOYSA-N, QVMNYGOVNWWFKF-UHFFFAOYSA-N	Preclinical
hesperadin	Aurora kinase inhibitor	AURKB			CCS(=O)(=O)Nc1ccc2NC(=O)\C(=C(/Nc3ccc(CN4CCCCC4)cc3)c3ccccc3)c2c1, CCS(=O)(=O)Nc1ccc2NC(=O)\C(=C(/Nc3ccc(CN4CCCCC4)cc3)c3ccccc3)c2c1, CCS(=O)(=O)Nc1ccc2NC(=O)\C(=C(/Nc3ccc(CN4CCCCC4)cc3)c3ccccc3)c2c1, CCS(=O)(=O)Nc1ccc2NC(=O)\C(=C(/Nc3ccc(CN4CCCCC4)cc3)c3ccccc3)c2c1, CCS(=O)(=O)Nc1ccc2NC(=O)\C(=C(/Nc3ccc(CN4CCCCC4)cc3)c3ccccc3)c2c1, CCS(=O)(=O)Nc1ccc2NC(=O)\C(=C(/Nc3ccc(CN4CCCCC4)cc3)c3ccccc3)c2c1, CCS(=O)(=O)Nc1ccc2NC(=O)\C(=C(/Nc3ccc(CN4CCCCC4)cc3)c3ccccc3)c2c1, CCS(=O)(=O)Nc1ccc2NC(=O)\C(=C(/Nc3ccc(CN4CCCCC4)cc3)c3ccccc3)c2c1	GLDSKRNGVVYJAB-DQSJHHFOSA-N, GLDSKRNGVVYJAB-DQSJHHFOSA-N, GLDSKRNGVVYJAB-DQSJHHFOSA-N, GLDSKRNGVVYJAB-DQSJHHFOSA-N, GLDSKRNGVVYJAB-DQSJHHFOSA-N, GLDSKRNGVVYJAB-DQSJHHFOSA-N, GLDSKRNGVVYJAB-DQSJHHFOSA-N, GLDSKRNGVVYJAB-DQSJHHFOSA-N	Preclinical
hesperetin	ACAT inhibitor	DGAT1, MTTP, SOAT1, SOAT2			COc1ccc(cc1O)[C@@H]1CC(=O)c2c(O)cc(O)cc2O1, COc1ccc(cc1O)[C@@H]1CC(=O)c2c(O)cc(O)cc2O1, COc1ccc(cc1O)[C@@H]1CC(=O)c2c(O)cc(O)cc2O1, COc1ccc(cc1O)[C@@H]1CC(=O)c2c(O)cc(O)cc2O1	AIONOLUJZLIMTK-AWEZNQCLSA-N, AIONOLUJZLIMTK-AWEZNQCLSA-N, AIONOLUJZLIMTK-AWEZNQCLSA-N, AIONOLUJZLIMTK-AWEZNQCLSA-N	Launched
hesperidin	flavanone glycoside	AURKB, CACNA1B			COc1ccc(cc1O)[C@@H]1CC(=O)c2c(O)cc(O[C@@H]3O[C@H](CO[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@@H](O)[C@H](O)[C@H]3O)cc2O1, COc1ccc(cc1O)[C@@H]1CC(=O)c2c(O)cc(O[C@@H]3O[C@H](CO[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@@H](O)[C@H](O)[C@H]3O)cc2O1, COc1ccc(cc1O)[C@@H]1CC(=O)c2c(O)cc(O[C@@H]3O[C@H](CO[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@@H](O)[C@H](O)[C@H]3O)cc2O1, COc1ccc(cc1O)[C@@H]1CC(=O)c2c(O)cc(O[C@@H]3O[C@H](CO[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@@H](O)[C@H](O)[C@H]3O)cc2O1, COc1ccc(cc1O)[C@@H]1CC(=O)c2c(O)cc(O[C@@H]3O[C@H](CO[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@@H](O)[C@H](O)[C@H]3O)cc2O1, COc1ccc(cc1O)[C@@H]1CC(=O)c2c(O)cc(O[C@@H]3O[C@H](CO[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@@H](O)[C@H](O)[C@H]3O)cc2O1	QUQPHWDTPGMPEX-QJBIFVCTSA-N, QUQPHWDTPGMPEX-QJBIFVCTSA-N, QUQPHWDTPGMPEX-QJBIFVCTSA-N, QUQPHWDTPGMPEX-QJBIFVCTSA-N, QUQPHWDTPGMPEX-QJBIFVCTSA-N, QUQPHWDTPGMPEX-QJBIFVCTSA-N	Launched
hetacillin	bacterial cell wall synthesis inhibitor		obstetrics/gynecology	mastitis	CC1(C)S[C@@H]2[C@H](N3C(=O)[C@H](NC3(C)C)c3ccccc3)C(=O)N2[C@H]1C(O)=O	DXVUYOAEDJXBPY-NFFDBFGFSA-N	Launched
hexachlorophene	potassium channel activator	GLUD1, SDHD	infectious disease	gram-positive bacterial infections	Oc1c(Cl)cc(Cl)c(Cl)c1Cc1c(O)c(Cl)cc(Cl)c1Cl, Oc1c(Cl)cc(Cl)c(Cl)c1Cc1c(O)c(Cl)cc(Cl)c1Cl, Oc1c(Cl)cc(Cl)c(Cl)c1Cc1c(O)c(Cl)cc(Cl)c1Cl, Oc1c(Cl)cc(Cl)c(Cl)c1Cc1c(O)c(Cl)cc(Cl)c1Cl, Oc1c(Cl)cc(Cl)c(Cl)c1Cc1c(O)c(Cl)cc(Cl)c1Cl, Oc1c(Cl)cc(Cl)c(Cl)c1Cc1c(O)c(Cl)cc(Cl)c1Cl, Oc1c(Cl)cc(Cl)c(Cl)c1Cc1c(O)c(Cl)cc(Cl)c1Cl, Oc1c(Cl)cc(Cl)c(Cl)c1Cc1c(O)c(Cl)cc(Cl)c1Cl, Oc1c(Cl)cc(Cl)c(Cl)c1Cc1c(O)c(Cl)cc(Cl)c1Cl, Oc1c(Cl)cc(Cl)c(Cl)c1Cc1c(O)c(Cl)cc(Cl)c1Cl, Oc1c(Cl)cc(Cl)c(Cl)c1Cc1c(O)c(Cl)cc(Cl)c1Cl, Oc1c(Cl)cc(Cl)c(Cl)c1Cc1c(O)c(Cl)cc(Cl)c1Cl, Oc1c(Cl)cc(Cl)c(Cl)c1Cc1c(O)c(Cl)cc(Cl)c1Cl	ACGUYXCXAPNIKK-UHFFFAOYSA-N, ACGUYXCXAPNIKK-UHFFFAOYSA-N, ACGUYXCXAPNIKK-UHFFFAOYSA-N, ACGUYXCXAPNIKK-UHFFFAOYSA-N, ACGUYXCXAPNIKK-UHFFFAOYSA-N, ACGUYXCXAPNIKK-UHFFFAOYSA-N, ACGUYXCXAPNIKK-UHFFFAOYSA-N, ACGUYXCXAPNIKK-UHFFFAOYSA-N, ACGUYXCXAPNIKK-UHFFFAOYSA-N, ACGUYXCXAPNIKK-UHFFFAOYSA-N, ACGUYXCXAPNIKK-UHFFFAOYSA-N, ACGUYXCXAPNIKK-UHFFFAOYSA-N, ACGUYXCXAPNIKK-UHFFFAOYSA-N	Launched
hexamethonium	cholinergic receptor antagonist	CHRNA2, CHRNA3, CHRNA4, CHRNA6			C[N+](C)(C)CCCCCC[N+](C)(C)C, C[N+](C)(C)CCCCCC[N+](C)(C)C, C[N+](C)(C)CCCCCC[N+](C)(C)C, C[N+](C)(C)CCCCCC[N+](C)(C)C, C[N+](C)(C)CCCCCC[N+](C)(C)C, C[N+](C)(C)CCCCCC[N+](C)(C)C	VZJFGSRCJCXDSG-UHFFFAOYSA-N, VZJFGSRCJCXDSG-UHFFFAOYSA-N, VZJFGSRCJCXDSG-UHFFFAOYSA-N, VZJFGSRCJCXDSG-UHFFFAOYSA-N, VZJFGSRCJCXDSG-UHFFFAOYSA-N, VZJFGSRCJCXDSG-UHFFFAOYSA-N	Preclinical
hexamethylenebisacetamide	AKT inhibitor, differentiation inducer, NFKB pathway inhibitor	AKT1			CC(=O)NCCCCCCNC(C)=O, CC(=O)NCCCCCCNC(C)=O, CC(=O)NCCCCCCNC(C)=O	BNQSTAOJRULKNX-UHFFFAOYSA-N, BNQSTAOJRULKNX-UHFFFAOYSA-N, BNQSTAOJRULKNX-UHFFFAOYSA-N	Phase 2
hexaminolevulinate			radiology	diagnostic agent	CCCCCCOC(=O)CCC(=O)CN, CCCCCCOC(=O)CCC(=O)CN	RYQOILLJDKPETL-UHFFFAOYSA-N, RYQOILLJDKPETL-UHFFFAOYSA-N	Launched
hexasodium-phytate					OP(O)(=O)O[C@H]1[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@@H]1OP(O)(O)=O	IMQLKJBTEOYOSI-GPIVLXJGSA-N	Phase 2
hexestrol	synthetic estrogen	AKR1C1, ESR1, ESR2	endocrinology	hypoestrogenism	CC[C@@H]([C@@H](CC)c1ccc(O)cc1)c1ccc(O)cc1, CC[C@@H]([C@@H](CC)c1ccc(O)cc1)c1ccc(O)cc1, CC[C@@H]([C@@H](CC)c1ccc(O)cc1)c1ccc(O)cc1, CC[C@@H]([C@@H](CC)c1ccc(O)cc1)c1ccc(O)cc1	PBBGSZCBWVPOOL-HDICACEKSA-N, PBBGSZCBWVPOOL-HDICACEKSA-N, PBBGSZCBWVPOOL-HDICACEKSA-N, PBBGSZCBWVPOOL-HDICACEKSA-N	Launched
hexetidine	local anesthetic		otolaryngology, infectious disease, dental, gastroenterology	pharyngitis, meningitis, laryngitis, gingivitis, ulcerative colitis	CCCC[C@H](CC)CN1CN(C[C@H](CC)CCCC)C[C@](C)(N)C1 |&1:12,&2:4,&3:20,r|, CCCC[C@H](CC)CN1CN(C[C@H](CC)CCCC)C[C@](C)(N)C1 |&1:12,&2:4,&3:20,r|, CCCC[C@H](CC)CN1CN(C[C@H](CC)CCCC)C[C@](C)(N)C1 |&1:12,&2:4,&3:20,r|	DTOUUUZOYKYHEP-AERCQKQUSA-N, DTOUUUZOYKYHEP-AERCQKQUSA-N, DTOUUUZOYKYHEP-AERCQKQUSA-N	Launched
hexonic-acid					OC[C@@H](O)[C@@H](O)[C@@H](O)[C@@H](O)C(O)=O |&1:2,&2:4,&3:6,&4:8,r|, OC[C@@H](O)[C@@H](O)[C@@H](O)[C@@H](O)C(O)=O |&1:2,&2:4,&3:6,&4:8,r|	RGHNJXZEOKUKBD-TXICZTDVSA-N, RGHNJXZEOKUKBD-TXICZTDVSA-N	Preclinical
hexoprenaline	adrenergic receptor agonist	ADRB2	pulmonary	asthma	O[C@@H](CNCCCCCCNC[C@@H](O)c1ccc(O)c(O)c1)c1ccc(O)c(O)c1 |&1:1,&2:12|	OXLZNBCNGJWPRV-SZPZYZBQSA-N	Launched
hexylcaine	sodium channel blocker	SCN5A	neurology/psychiatry	local anesthetic	C[C@@H](CNC1CCCCC1)OC(=O)c1ccccc1 |&1:1|, C[C@@H](CNC1CCCCC1)OC(=O)c1ccccc1 |&1:1|	DKLKMKYDWHYZTD-ZDUSSCGKSA-N, DKLKMKYDWHYZTD-ZDUSSCGKSA-N	Launched
hexylene-glycol		AKR1C3, CTPS1, DLG4, HSP90AA1, NOS3, PGF, PLA2G1B, PTPN1, SELP			C[C@@H](O)CC(C)(C)O |&1:1,r|, C[C@@H](O)CC(C)(C)O |&1:1,r|	SVTBMSDMJJWYQN-RXMQYKEDSA-N, SVTBMSDMJJWYQN-RXMQYKEDSA-N	Preclinical
hexylresorcinol	local anesthetic	TYR	infectious disease	skin infections, first-aid antiseptic	CCCCCCc1ccc(O)cc1O, CCCCCCc1ccc(O)cc1O, CCCCCCc1ccc(O)cc1O, CCCCCCc1ccc(O)cc1O	WFJIVOKAWHGMBH-UHFFFAOYSA-N, WFJIVOKAWHGMBH-UHFFFAOYSA-N, WFJIVOKAWHGMBH-UHFFFAOYSA-N, WFJIVOKAWHGMBH-UHFFFAOYSA-N	Launched
higenamine	adrenergic receptor agonist	ADRB2			Oc1ccc(C[C@H]2NCCc3cc(O)c(O)cc23)cc1 |&1:6|, Oc1ccc(C[C@H]2NCCc3cc(O)c(O)cc23)cc1 |&1:6|, Oc1ccc(C[C@H]2NCCc3cc(O)c(O)cc23)cc1 |&1:6|, Oc1ccc(C[C@H]2NCCc3cc(O)c(O)cc23)cc1 |&1:6|	WZRCQWQRFZITDX-CQSZACIVSA-N, WZRCQWQRFZITDX-CQSZACIVSA-N, WZRCQWQRFZITDX-CQSZACIVSA-N, WZRCQWQRFZITDX-CQSZACIVSA-N	Phase 1
hippuric-acid					OC(=O)CNC(=O)c1ccccc1	QIAFMBKCNZACKA-UHFFFAOYSA-N	Preclinical
histamine	histamine receptor agonist	HRH1, HRH2, HRH3, HRH4	allergy	allergic rhinitis	NCCc1cnc[nH]1, NCCc1cnc[nH]1, NCCc1cnc[nH]1, NCCc1cnc[nH]1, NCCc1cnc[nH]1, NCCc1cnc[nH]1	NTYJJOPFIAHURM-UHFFFAOYSA-N, NTYJJOPFIAHURM-UHFFFAOYSA-N, NTYJJOPFIAHURM-UHFFFAOYSA-N, NTYJJOPFIAHURM-UHFFFAOYSA-N, NTYJJOPFIAHURM-UHFFFAOYSA-N, NTYJJOPFIAHURM-UHFFFAOYSA-N	Launched
HJC-0350	GTPase inhibitor	RAPGEF4			Cc1cc(C)n(c1)S(=O)(=O)c1c(C)cc(C)cc1C, Cc1cc(C)n(c1)S(=O)(=O)c1c(C)cc(C)cc1C, Cc1cc(C)n(c1)S(=O)(=O)c1c(C)cc(C)cc1C	AFZWZVLPIMHLSE-UHFFFAOYSA-N, AFZWZVLPIMHLSE-UHFFFAOYSA-N, AFZWZVLPIMHLSE-UHFFFAOYSA-N	Preclinical
HKI-357	EGFR inhibitor	EGFR			CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2cc1NC(=O)\C=C\CN(C)C, CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2cc1NC(=O)\C=C\CN(C)C	NERXPXBELDBEPZ-RMKNXTFCSA-N, NERXPXBELDBEPZ-RMKNXTFCSA-N	Phase 1
HLCL-61	protein arginine N-methyltransferase inhibitor	PRMT5			CCn1c2ccccc2c2cc(CNCc3ccccc3OC)ccc12, CCn1c2ccccc2c2cc(CNCc3ccccc3OC)ccc12, CCn1c2ccccc2c2cc(CNCc3ccccc3OC)ccc12	FIOIJUCPVZEPFX-UHFFFAOYSA-N, FIOIJUCPVZEPFX-UHFFFAOYSA-N, FIOIJUCPVZEPFX-UHFFFAOYSA-N	Preclinical
HM-30181	P glycoprotein inhibitor				COc1cc2CCN(CCc3ccc(cc3)-n3nnc(n3)-c3cc(OC)c(OC)cc3NC(=O)c3cc(=O)c4ccccc4o3)Cc2cc1OC	AHJUHHDDCJQACA-UHFFFAOYSA-N	Phase 1
HMN-214	PLK inhibitor	PLK1			COc1ccc(cc1)S(=O)(=O)N(C(C)=O)c1ccccc1\C=C\c1cc[n+]([O-])cc1	OCKHRKSTDPOHEN-BQYQJAHWSA-N	Phase 1
HOKU-81	bronchodilator				CC(C)(C)NC[C@H](O)c1ccc(O)cc1Cl |r|	LIXBJWRFCNRAPA-NSHDSACASA-N	Preclinical
homatropine	acetylcholine receptor antagonist	CHRM1	ophthalmology	uveal tract inflammation, pupil dilation	CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)[C@@H](O)c1ccccc1 |a:2,5,7,&1:12,THB:9:7:1:3.4|, CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)[C@@H](O)c1ccccc1 |a:2,5,7,&1:12,THB:9:7:1:3.4|, CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)[C@@H](O)c1ccccc1 |a:2,5,7,&1:12,THB:9:7:1:3.4|, CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)[C@@H](O)c1ccccc1 |a:2,5,7,&1:12,THB:9:7:1:3.4|, CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)[C@@H](O)c1ccccc1 |a:2,5,7,&1:12,THB:9:7:1:3.4|	ZTVIKZXZYLEVOL-YJNKXOJESA-N, ZTVIKZXZYLEVOL-YJNKXOJESA-N, ZTVIKZXZYLEVOL-YJNKXOJESA-N, ZTVIKZXZYLEVOL-YJNKXOJESA-N, ZTVIKZXZYLEVOL-YJNKXOJESA-N	Launched
homatropine-methylbromide	acetylcholine receptor antagonist	CHRM5	ophthalmology	uveal tract inflammation	C[N+]1(C)[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)[C@@H](O)c1ccccc1 |a:3,6,8,&1:13,THB:10:8:1:4.5|	WKWOJBUWWZTUQV-JJXSEGSLSA-N	Launched
homidium					CC[n+]1c(-c2ccccc2)c2cc(N)ccc2c2ccc(N)cc12, CC[n+]1c(-c2ccccc2)c2cc(N)ccc2c2ccc(N)cc12	QTANTQQOYSUMLC-UHFFFAOYSA-O, QTANTQQOYSUMLC-UHFFFAOYSA-O	Preclinical
homochlorcyclizine	antihistamine	HRH1	allergy	allergic rhinitis			Launched
homoharringtonine	protein synthesis inhibitor	RPL3	hematologic malignancy	chronic myeloid leukemia (CML)	COC(=O)C[C@](O)(CCCC(C)(C)O)C(=O)O[C@H]1[C@H]2c3cc4OCOc4cc3CCN3CCC[C@]23C=C1OC |c:39|, COC(=O)C[C@](O)(CCCC(C)(C)O)C(=O)O[C@H]1[C@H]2c3cc4OCOc4cc3CCN3CCC[C@]23C=C1OC |c:39|, COC(=O)C[C@](O)(CCCC(C)(C)O)C(=O)O[C@H]1[C@H]2c3cc4OCOc4cc3CCN3CCC[C@]23C=C1OC |c:39|, COC(=O)C[C@](O)(CCCC(C)(C)O)C(=O)O[C@H]1[C@H]2c3cc4OCOc4cc3CCN3CCC[C@]23C=C1OC |c:39|, COC(=O)C[C@](O)(CCCC(C)(C)O)C(=O)O[C@H]1[C@H]2c3cc4OCOc4cc3CCN3CCC[C@]23C=C1OC |c:39|, COC(=O)C[C@](O)(CCCC(C)(C)O)C(=O)O[C@H]1[C@H]2c3cc4OCOc4cc3CCN3CCC[C@]23C=C1OC |c:39|	HYFHYPWGAURHIV-JFIAXGOJSA-N, HYFHYPWGAURHIV-JFIAXGOJSA-N, HYFHYPWGAURHIV-JFIAXGOJSA-N, HYFHYPWGAURHIV-JFIAXGOJSA-N, HYFHYPWGAURHIV-JFIAXGOJSA-N, HYFHYPWGAURHIV-JFIAXGOJSA-N	Launched
homoquinolinic-acid	glutamate receptor agonist	GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D			OC(=O)Cc1cccnc1C(O)=O, OC(=O)Cc1cccnc1C(O)=O, OC(=O)Cc1cccnc1C(O)=O	HQPMJFFEXJELOQ-UHFFFAOYSA-N, HQPMJFFEXJELOQ-UHFFFAOYSA-N, HQPMJFFEXJELOQ-UHFFFAOYSA-N	Preclinical
homosalate	HSP inducer				C[C@H]1C[C@@H](CC(C)(C)C1)OC(=O)c1ccccc1O |&1:1,&2:3,r|, C[C@H]1C[C@@H](CC(C)(C)C1)OC(=O)c1ccccc1O |&1:1,&2:3,r|	WSSJONWNBBTCMG-RYUDHWBXSA-N, WSSJONWNBBTCMG-RYUDHWBXSA-N	Preclinical
homoveratrylamine	monoamine oxidase inhibitor				COc1ccc(CCN)cc1OC, COc1ccc(CCN)cc1OC	ANOUKFYBOAKOIR-UHFFFAOYSA-N, ANOUKFYBOAKOIR-UHFFFAOYSA-N	Preclinical
honokiol	AKT inhibitor	ALOX5, PTGS1, PTGS2			Oc1ccc(cc1CC=C)-c1cc(CC=C)ccc1O, Oc1ccc(cc1CC=C)-c1cc(CC=C)ccc1O, Oc1ccc(cc1CC=C)-c1cc(CC=C)ccc1O	FVYXIJYOAGAUQK-UHFFFAOYSA-N, FVYXIJYOAGAUQK-UHFFFAOYSA-N, FVYXIJYOAGAUQK-UHFFFAOYSA-N	Phase 3
hordenine					CN(C)CCc1ccc(O)cc1, CN(C)CCc1ccc(O)cc1	KUBCEEMXQZUPDQ-UHFFFAOYSA-N, KUBCEEMXQZUPDQ-UHFFFAOYSA-N	Preclinical
HP-228	nitric oxide synthase inhibitor				CCCC[C@H](NC(C)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](Cc1c[nH]cn1)C(=O)N[C@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](Cc1c[nH]c2ccccc12)C(=O)NCC(N)=O	UHKZNDVUBSEJJO-XAYNKGEHSA-N	Preclinical
hPGDS-IN-1	prostaglandin inhibitor				CC(C)(O)c1nc(no1)-c1cccc(CNC(=O)c2cnc(nc2)-c2ccccn2)c1	VJCLAPUACUQZOV-UHFFFAOYSA-N	Preclinical
HPPH	photosensitizing agent				CCCCCCO[C@H](C)c1c(C)c2cc3nc([C@@H](CCC(O)=O)[C@@H]3C)c3CC(=O)c4c(C)c(cc5nc(cc1[nH]2)c(C)c5CC)[nH]c34 |&1:7|	PVXGCBZIVFCMJK-AUSGGWNYSA-N	Phase 2
HQK-1001					CCC(C)(C)C(O)=O, CCC(C)(C)C(O)=O	VUAXHMVRKOTJKP-UHFFFAOYSA-N, VUAXHMVRKOTJKP-UHFFFAOYSA-N	Phase 2
HSR6071	antiallergic agent				O=C(Nc1nnn[nH]1)c1cncc(n1)N1CCCC1	LUJDHCXCWJFNOJ-UHFFFAOYSA-N	Preclinical
HT-2157	galanin receptor 3 antagonist				FC(F)(F)c1cccc(c1)\N=C1/C(=O)N(c2ccccc12)c1ccccc1	TXCGMRVPXUBHAL-PLRJNAJWSA-N	Phase 1/Phase 2
HTH-01-015	protein kinase inhibitor	NUAK1			CN1c2cc3ccccc3cc2C(=O)N(C)c2c(C)nc(Nc3cnn(c3)C3CCNCC3)nc12, CN1c2cc3ccccc3cc2C(=O)N(C)c2c(C)nc(Nc3cnn(c3)C3CCNCC3)nc12	CHSDJDLAKKAWCI-UHFFFAOYSA-N, CHSDJDLAKKAWCI-UHFFFAOYSA-N	Preclinical
HTHQ	antioxidant				CCCCCCOc1cc(C)c(O)c(C)c1C	ATMNQRRJNBCQJO-UHFFFAOYSA-N	Preclinical
HTMT	histamine receptor agonist	HRH4			C[C@@H](CCCCC(=O)Nc1ccc(cc1)C(F)(F)F)NCCc1cnc[nH]1 |&1:1|, C[C@@H](CCCCC(=O)Nc1ccc(cc1)C(F)(F)F)NCCc1cnc[nH]1 |&1:1|	PMKJGGBYYNEYPA-AWEZNQCLSA-N, PMKJGGBYYNEYPA-AWEZNQCLSA-N	Preclinical
huperzine-A	acetylcholinesterase inhibitor	ACHE			C\C=C1/[C@@H]2Cc3[nH]c(=O)ccc3[C@@]1(N)CC(C)=C2 |c:18|, C\C=C1/[C@@H]2Cc3[nH]c(=O)ccc3[C@@]1(N)CC(C)=C2 |c:18|, C\C=C1/[C@@H]2Cc3[nH]c(=O)ccc3[C@@]1(N)CC(C)=C2 |c:18|, C\C=C1/[C@@H]2Cc3[nH]c(=O)ccc3[C@@]1(N)CC(C)=C2 |c:18|, C\C=C1/[C@@H]2Cc3[nH]c(=O)ccc3[C@@]1(N)CC(C)=C2 |c:18|, C\C=C1/[C@@H]2Cc3[nH]c(=O)ccc3[C@@]1(N)CC(C)=C2 |c:18|	ZRJBHWIHUMBLCN-YQEJDHNASA-N, ZRJBHWIHUMBLCN-YQEJDHNASA-N, ZRJBHWIHUMBLCN-YQEJDHNASA-N, ZRJBHWIHUMBLCN-YQEJDHNASA-N, ZRJBHWIHUMBLCN-YQEJDHNASA-N, ZRJBHWIHUMBLCN-YQEJDHNASA-N	Phase 2
hyaluronic-acid		C1QBP, CD44, HABP2, HAPLN1, HAPLN3, HAPLN4, HMMR, ICAM1, NCAN, VCAN	rheumatology, urology	osteoarthritis, interstitial cystitis (IC)	CC(=O)N[C@@H]1C[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)O[C@@H]1C(O)=O	WCDDVEOXEIYWFB-VXORFPGASA-N	Launched
hycanthone	RNA synthesis inhibitor		infectious disease	schistosomiasis	CCN(CC)CCNc1ccc(CO)c2sc3ccccc3c(=O)c12, CCN(CC)CCNc1ccc(CO)c2sc3ccccc3c(=O)c12	MFZWMTSUNYWVBU-UHFFFAOYSA-N, MFZWMTSUNYWVBU-UHFFFAOYSA-N	Launched
hydralazine	vasodilator		cardiology	hypertension	NNc1nncc2ccccc12, NNc1nncc2ccccc12, NNc1nncc2ccccc12, N\N=c1/[nH]ncc2ccccc12, N\N=c1/[nH]ncc2ccccc12	RPTUSVTUFVMDQK-UHFFFAOYSA-N, RPTUSVTUFVMDQK-UHFFFAOYSA-N, RPTUSVTUFVMDQK-UHFFFAOYSA-N, RPTUSVTUFVMDQK-UHFFFAOYSA-N, RPTUSVTUFVMDQK-UHFFFAOYSA-N	Launched
hydrastine-(1R,9S)	tyrosine hydroxylase inhibitor				COc1ccc2[C@H](OC(=O)c2c1OC)[C@@H]1N(C)CCc2cc3OCOc3cc12, COc1ccc2[C@H](OC(=O)c2c1OC)[C@@H]1N(C)CCc2cc3OCOc3cc12, COc1ccc2[C@H](OC(=O)c2c1OC)[C@@H]1N(C)CCc2cc3OCOc3cc12	JZUTXVTYJDCMDU-MOPGFXCFSA-N, JZUTXVTYJDCMDU-MOPGFXCFSA-N, JZUTXVTYJDCMDU-MOPGFXCFSA-N	Preclinical
hydrastinine	hemostatic agent				C[N+]1=Cc2cc3OCOc3cc2CC1 |t:1|	LGDCROILDUSHQX-UHFFFAOYSA-N	Preclinical
hydrochlorothiazide	thiazide diuretic	CA1, CA12, CA2, CA4, CA9, KCNMA1, SLC12A3	cardiology	hypertension, congestive heart failure	NS(=O)(=O)c1cc2c(NCNS2(=O)=O)cc1Cl, NS(=O)(=O)c1cc2c(NCNS2(=O)=O)cc1Cl, NS(=O)(=O)c1cc2c(NCNS2(=O)=O)cc1Cl	JZUFKLXOESDKRF-UHFFFAOYSA-N, JZUFKLXOESDKRF-UHFFFAOYSA-N, JZUFKLXOESDKRF-UHFFFAOYSA-N	Launched
hydrocortisone	glucocorticoid receptor agonist	ANXA1, NOS2, NR3C1, NR3C2	dermatology, neurology/psychiatry	eczema, psoriasis, seborrheic dermatitis, itching	C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO |t:9|, C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO |t:9|, C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO |t:9|, C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO |t:9|, C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO |t:9|, C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO |t:9|	JYGXADMDTFJGBT-VWUMJDOOSA-N, JYGXADMDTFJGBT-VWUMJDOOSA-N, JYGXADMDTFJGBT-VWUMJDOOSA-N, JYGXADMDTFJGBT-VWUMJDOOSA-N, JYGXADMDTFJGBT-VWUMJDOOSA-N, JYGXADMDTFJGBT-VWUMJDOOSA-N	Launched
hydrocortisone-acetate	glucocorticoid receptor agonist	NR3C1	dermatology	corticosteroid-responsive dermatoses	CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3[C@@H](O)C[C@]12C |t:15|	ALEXXDVDDISNDU-JZYPGELDSA-N	Launched
hydrocortisone-butyrate	glucocorticoid receptor agonist	NR3C1	dermatology	corticosteroid-responsive dermatoses, eczema	CCCC(=O)O[C@@]1(CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3[C@@H](O)C[C@]12C)C(=O)CO |t:13|, CCCC(=O)O[C@@]1(CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3[C@@H](O)C[C@]12C)C(=O)CO |t:13|	BMCQMVFGOVHVNG-TUFAYURCSA-N, BMCQMVFGOVHVNG-TUFAYURCSA-N	Launched
hydrocortisone-hemisuccinate					C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@]2(O)C(=O)COC(=O)CCC(O)=O |t:9|	VWQWXZAWFPZJDA-CGVGKPPMSA-N	Phase 2/Phase 3
hydrocortisone-phosphate			pulmonary, gastroenterology, hematologic malignancy, ophthalmology	asthma, nausea, vomiting, multiple myeloma, contact dermatitis, enteritis, colitis	C[C@@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]34C)[C@@H]1CC[C@]2(O)C(=O)COP(O)(O)=O |a:3,20,&1:1,&2:5,&3:6,&4:15,&5:17,t:9|	BGSOJVFOEQLVMH-SBXZOHCASA-N	Launched
hydrocortisone-valerate	glucocorticoid receptor agonist	NR3C1	dermatology	corticosteroid-responsive dermatoses	CCCCC(=O)O[C@@]1(CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3[C@@H](O)C[C@]12C)C(=O)CO |t:14|	FZCHYNWYXKICIO-FZNHGJLXSA-N	Launched
hydroflumethiazide	sodium/potassium/chloride transporter inhibitor	ATP1A1, CA1, CA12, CA2, CA4, CA9, KCNMA1, SLC12A1, SLC12A3	cardiology, gastroenterology, rheumatology, nephrology	edema, congestive heart failure, hepatic cirrhosis, nephrotic syndrome, chronic renal failure, acute glomerulonephritis (AGN), hypertension	NS(=O)(=O)c1cc2c(NCNS2(=O)=O)cc1C(F)(F)F, NS(=O)(=O)c1cc2c(NCNS2(=O)=O)cc1C(F)(F)F, NS(=O)(=O)c1cc2c(NCNS2(=O)=O)cc1C(F)(F)F	DMDGGSIALPNSEE-UHFFFAOYSA-N, DMDGGSIALPNSEE-UHFFFAOYSA-N, DMDGGSIALPNSEE-UHFFFAOYSA-N	Launched
hydroquinidine	antiarrhythmic		cardiology	cardiac arrythmia	CC[C@H]1C[N@@]2CC[C@H]1C[C@@H]2[C@@H](O)c1ccnc2ccc(OC)cc12, CC[C@H]1C[N@@]2CC[C@H]1C[C@@H]2[C@@H](O)c1ccnc2ccc(OC)cc12	LJOQGZACKSYWCH-LHHVKLHASA-N, LJOQGZACKSYWCH-LHHVKLHASA-N	Launched
hydroquinone	melanin inhibitor	TYR	dermatology	dyschromia	Oc1ccc(O)cc1, Oc1ccc(O)cc1	QIGBRXMKCJKVMJ-UHFFFAOYSA-N, QIGBRXMKCJKVMJ-UHFFFAOYSA-N	Launched
hydroxocobalamin	vitamin B				[H]O[Co+]N1\C2=C(C)/C3=N/C(=C/C4=N/C(=C(C)\C5=N[C@@](C)([C@@]1([H])[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@@H]1[C@@H](CO)O[C@@H]([C@@H]1O)n1cnc2cc(C)c(C)cc12)[C@@](C)(CC(N)=O)[C@@H]5CCC(N)=O)/[C@@](C)(CC(N)=O)[C@@H]4CCC(N)=O)/C(C)(C)[C@@H]3CCC(N)=O |r,t:4,7,9,11,13,16|	YOZNUFWCRFCGIH-WZHZPDAFSA-L	Launched
hydroxyamphetamine	trace amine associated receptor agonist	TAAR1	ophthalmology	mydriasis	C[C@@H](N)Cc1ccc(O)cc1 |&1:1|, C[C@@H](N)Cc1ccc(O)cc1 |&1:1|, C[C@@H](N)Cc1ccc(O)cc1 |&1:1|	GIKNHHRFLCDOEU-SSDOTTSWSA-N, GIKNHHRFLCDOEU-SSDOTTSWSA-N, GIKNHHRFLCDOEU-SSDOTTSWSA-N	Launched
hydroxychloroquine	antimalarial agent	TLR7, TLR9	infectious disease	malaria	CCN(CCO)CCCC(C)Nc1ccnc2cc(Cl)ccc12, CCN(CCO)CCCC(C)Nc1ccnc2cc(Cl)ccc12, CCN(CCO)CCCC(C)Nc1ccnc2cc(Cl)ccc12	XXSMGPRMXLTPCZ-UHFFFAOYSA-N, XXSMGPRMXLTPCZ-UHFFFAOYSA-N, XXSMGPRMXLTPCZ-UHFFFAOYSA-N	Launched
hydroxyfasudil	rho associated kinase inhibitor	PKIA, PRKACA, ROCK1			O=c1[nH]ccc2c(cccc12)S(=O)(=O)N1CCCNCC1, O=c1[nH]ccc2c(cccc12)S(=O)(=O)N1CCCNCC1, O=c1[nH]ccc2c(cccc12)S(=O)(=O)N1CCCNCC1, O=c1[nH]ccc2c(cccc12)S(=O)(=O)N1CCCNCC1	ZAVGJDAFCZAWSZ-UHFFFAOYSA-N, ZAVGJDAFCZAWSZ-UHFFFAOYSA-N, ZAVGJDAFCZAWSZ-UHFFFAOYSA-N, ZAVGJDAFCZAWSZ-UHFFFAOYSA-N	Preclinical
hydroxyprogesterone	progesterone receptor agonist	PGR	obstetrics/gynecology	spontaneous preterm birth	CC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C |t:11|	DBPWSSGDRRHUNT-CEGNMAFCSA-N	Launched
hydroxyprogesterone-acetate	progesterone receptor agonist	PGR			CC(=O)O[C@@]1(CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)=O |t:11|	VTHUYJIXSMGYOQ-KOORYGTMSA-N	Launched
hydroxypropyl-beta-cyclodextrin					C[C@@H](O)COC[C@H]1O[C@@H]2O[C@@H]3[C@@H](COC[C@@H](C)O)O[C@H](O[C@@H]4[C@@H](COC[C@@H](C)O)O[C@H](O[C@@H]5[C@@H](COC[C@@H](C)O)O[C@H](O[C@@H]6[C@@H](COC[C@@H](C)O)O[C@H](O[C@@H]7[C@@H](COC[C@@H](C)O)O[C@H](O[C@@H]8[C@@H](COC[C@@H](C)O)O[C@H](O[C@H]1[C@H](O)[C@H]2O)[C@H](O)[C@H]8O)[C@H](O)[C@H]7O)[C@H](O)[C@H]6O)[C@H](O)[C@H]5O)[C@H](O)[C@H]4O)[C@H](O)[C@H]3O |a:6,8,10,11,19,21,22,30,32,33,41,43,44,52,54,55,63,65,66,74,76,77,79,81,83,85,87,89,91,93,95,97,99,101,103,&1:1,&2:15,&3:26,&4:37,&5:48,&6:59,&7:70|, C[C@@H](O)COC[C@H]1O[C@@H]2O[C@@H]3[C@@H](COC[C@@H](C)O)O[C@H](O[C@@H]4[C@@H](COC[C@@H](C)O)O[C@H](O[C@@H]5[C@@H](COC[C@@H](C)O)O[C@H](O[C@@H]6[C@@H](COC[C@@H](C)O)O[C@H](O[C@@H]7[C@@H](COC[C@@H](C)O)O[C@H](O[C@@H]8[C@@H](COC[C@@H](C)O)O[C@H](O[C@H]1[C@H](O)[C@H]2O)[C@H](O)[C@H]8O)[C@H](O)[C@H]7O)[C@H](O)[C@H]6O)[C@H](O)[C@H]5O)[C@H](O)[C@H]4O)[C@H](O)[C@H]3O |a:6,8,10,11,19,21,22,30,32,33,41,43,44,52,54,55,63,65,66,74,76,77,79,81,83,85,87,89,91,93,95,97,99,101,103,&1:1,&2:15,&3:26,&4:37,&5:48,&6:59,&7:70|, C[C@@H](O)COC[C@H]1O[C@@H]2O[C@@H]3[C@@H](COC[C@@H](C)O)O[C@H](O[C@@H]4[C@@H](COC[C@@H](C)O)O[C@H](O[C@@H]5[C@@H](COC[C@@H](C)O)O[C@H](O[C@@H]6[C@@H](COC[C@@H](C)O)O[C@H](O[C@@H]7[C@@H](COC[C@@H](C)O)O[C@H](O[C@@H]8[C@@H](COC[C@@H](C)O)O[C@H](O[C@H]1[C@H](O)[C@H]2O)[C@H](O)[C@H]8O)[C@H](O)[C@H]7O)[C@H](O)[C@H]6O)[C@H](O)[C@H]5O)[C@H](O)[C@H]4O)[C@H](O)[C@H]3O |a:6,8,10,11,19,21,22,30,32,33,41,43,44,52,54,55,63,65,66,74,76,77,79,81,83,85,87,89,91,93,95,97,99,101,103,&1:1,&2:15,&3:26,&4:37,&5:48,&6:59,&7:70|	ODLHGICHYURWBS-LWHSBNEASA-N, ODLHGICHYURWBS-LWHSBNEASA-N, ODLHGICHYURWBS-LWHSBNEASA-N	Phase 2/Phase 3
hydroxysafflor-yellow-A	antitumor agent				[H][C@]1(O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O)[C@]1(O)C(=O)[C@@H]([C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)C(=O)[C@H](C(=O)\C=C\c2ccc(O)cc2)C1=O |&1:12,&2:30,&3:16|	DKEZDPGUJMMUCC-GJVNFNJISA-N	Preclinical
hydroxystilbamidine					NC(=N)c1ccc(\C=C\c2ccc(cc2O)C(N)=N)cc1	TUESWZZJYCLFNL-DAFODLJHSA-N	Launched
hydroxytacrine-maleate-(R,S)	cholinesterase inhibitor	ACHE			Nc1c2[C@@H](O)CCCc2nc2ccccc12 |&1:3|	HLVVITIHAZBPKB-NSHDSACASA-N	Preclinical
hydroxytoluic-acid					Cc1cccc(C(O)=O)c1O, Cc1cccc(C(O)=O)c1O, Cc1cccc(C(O)=O)c1O	WHSXTWFYRGOBGO-UHFFFAOYSA-N, WHSXTWFYRGOBGO-UHFFFAOYSA-N, WHSXTWFYRGOBGO-UHFFFAOYSA-N	Preclinical
hydroxyurea	ribonucleotide reductase inhibitor	RRM1, RRM2, RRM2B	hematologic malignancy, oncology	chronic myeloid leukemia (CML), head and neck squamous cell carcinoma (HNSCC)	NC(=O)NO, NC(=O)NO, NC(=O)NO, NC(=O)NO, NC(=O)NO, NC(=O)NO	VSNHCAURESNICA-UHFFFAOYSA-N, VSNHCAURESNICA-UHFFFAOYSA-N, VSNHCAURESNICA-UHFFFAOYSA-N, VSNHCAURESNICA-UHFFFAOYSA-N, VSNHCAURESNICA-UHFFFAOYSA-N, VSNHCAURESNICA-UHFFFAOYSA-N	Launched
hydroxyzine	antihistamine	HRH1	neurology/psychiatry, allergy, dermatology	anxiety, urticaria, itching, dermatosis	OCCOCCN1CCN(CC1)[C@@H](c1ccccc1)c1ccc(Cl)cc1 |&1:12|, OCCOCCN1CCN(CC1)[C@@H](c1ccccc1)c1ccc(Cl)cc1 |&1:12|	ZQDWXGKKHFNSQK-NRFANRHFSA-N, ZQDWXGKKHFNSQK-NRFANRHFSA-N	Launched
hygromycin-B	polypeptide synthesis inhibitor				CN[C@H]1C[C@@H](N)[C@H](O)[C@@H](O[C@@H]2O[C@H](CO)[C@H](O)[C@@H]3O[C@@]4(O[C@H]23)O[C@H]([C@@H](N)CO)[C@H](O)[C@H](O)[C@H]4O)[C@@H]1O |a:2,4,6,8,10,12,15,17,21,23,24,28,30,32,34,&1:19|	GRRNUXAQVGOGFE-SIGCQSELSA-N	Preclinical
hymecromone	monoamine oxidase inhibitor	MAOA, MAOB			Cc1cc(=O)oc2cc(O)ccc12, Cc1cc(=O)oc2cc(O)ccc12, Cc1cc(=O)oc2cc(O)ccc12, Cc1cc(=O)oc2cc(O)ccc12	HSHNITRMYYLLCV-UHFFFAOYSA-N, HSHNITRMYYLLCV-UHFFFAOYSA-N, HSHNITRMYYLLCV-UHFFFAOYSA-N, HSHNITRMYYLLCV-UHFFFAOYSA-N	Phase 2
hyodeoxycholic-acid	atherosclerosis formation inhibitor				C[C@H](CCC(O)=O)[C@H]1CC[C@H]2[C@@H]3C[C@H](O)[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C, C[C@H](CCC(O)=O)[C@H]1CC[C@H]2[C@@H]3C[C@H](O)[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C, C[C@H](CCC(O)=O)[C@H]1CC[C@H]2[C@@H]3C[C@H](O)[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C	DGABKXLVXPYZII-SIBKNCMHSA-N, DGABKXLVXPYZII-SIBKNCMHSA-N, DGABKXLVXPYZII-SIBKNCMHSA-N	Phase 1
hyoscyamine	acetylcholine receptor antagonist	CHRM1, CHRM2, CHRM3, CHRM4	gastroenterology, urology, neurology/psychiatry, allergy	peptic ulcer disease (PUD), acute abdominal visceral spasm, ulcerative colitis, interstitial cystitis (IC), enterocolitis, irritable bowel syndrome, tremors, allergic rhinitis	CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)[C@H](CO)c1ccccc1, CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)[C@H](CO)c1ccccc1, CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)[C@H](CO)c1ccccc1	RKUNBYITZUJHSG-FXUDXRNXSA-N, RKUNBYITZUJHSG-FXUDXRNXSA-N, RKUNBYITZUJHSG-FXUDXRNXSA-N	Launched
hypericin	tyrosine kinase inhibitor				Cc1cc(O)c2c3c1c1c(C)cc(O)c4c1c1c3c3c(c(O)cc(O)c3c2=O)c2c(O)cc(O)c(c12)c4=O, Cc1cc(O)c2c3c1c1c(C)cc(O)c4c1c1c3c3c(c(O)cc(O)c3c2=O)c2c(O)cc(O)c(c12)c4=O, Cc1cc(O)c2c3c1c1c(C)cc(O)c4c1c1c3c3c(c(O)cc(O)c3c2=O)c2c(O)cc(O)c(c12)c4=O, Cc1cc(O)c2c3c1c1c(C)cc(O)c4c1c1c3c3c(c(O)cc(O)c3c2=O)c2c(O)cc(O)c(c12)c4=O	BTXNYTINYBABQR-UHFFFAOYSA-N, BTXNYTINYBABQR-UHFFFAOYSA-N, BTXNYTINYBABQR-UHFFFAOYSA-N, BTXNYTINYBABQR-UHFFFAOYSA-N	Phase 3
hyperin	aldose reductase inhibitor	ACE, AKR1B1			OC[C@H]1O[C@@H](Oc2c(oc3cc(O)cc(O)c3c2=O)-c2ccc(O)c(O)c2)[C@@H](O)[C@@H](O)[C@@H]1O |&1:2,&2:4,&3:27,&4:29,&5:31,r|, OC[C@H]1O[C@@H](Oc2c(oc3cc(O)cc(O)c3c2=O)-c2ccc(O)c(O)c2)[C@@H](O)[C@@H](O)[C@@H]1O |&1:2,&2:4,&3:27,&4:29,&5:31,r|, OC[C@H]1O[C@@H](Oc2c(oc3cc(O)cc(O)c3c2=O)-c2ccc(O)c(O)c2)[C@@H](O)[C@@H](O)[C@@H]1O |&1:2,&2:4,&3:27,&4:29,&5:31,r|, OC[C@H]1O[C@@H](Oc2c(oc3cc(O)cc(O)c3c2=O)-c2ccc(O)c(O)c2)[C@@H](O)[C@@H](O)[C@@H]1O |&1:2,&2:4,&3:27,&4:29,&5:31,r|	OVSQVDMCBVZWGM-FHYQVQSVSA-N, OVSQVDMCBVZWGM-FHYQVQSVSA-N, OVSQVDMCBVZWGM-FHYQVQSVSA-N, OVSQVDMCBVZWGM-FHYQVQSVSA-N	Preclinical
hypoestoxide	IKK inhibitor	IKBKB, IL1B, TNF			CC(=O)O[C@@H]1C[C@]2(C)O[C@H]2CC[C@]2(C)O[C@H]2C[C@@H]2CC(=O)C(=C)[C@@H]1C2(C)C	HNPAHGHFONBTLV-KSJQNFQUSA-N	Phase 1
hypoxanthine	PARP inhibitor	PNP			O=c1nc[nH]c2nc[nH]c12, O=c1nc[nH]c2nc[nH]c12	FDGQSTZJBFJUBT-UHFFFAOYSA-N, FDGQSTZJBFJUBT-UHFFFAOYSA-N	Preclinical
H2L-5765834	lysophosphatidic acid receptor antagonist	LPAR1, LPAR3			OC(=O)c1ccc2C(=O)N(C(=O)c2c1)c1cccc(Oc2ccc(cc2)[N+]([O-])=O)c1, OC(=O)c1ccc2C(=O)N(C(=O)c2c1)c1cccc(Oc2ccc(cc2)[N+]([O-])=O)c1, OC(=O)c1ccc2C(=O)N(C(=O)c2c1)c1cccc(Oc2ccc(cc2)[N+]([O-])=O)c1	HFYPTENHTPNXGP-UHFFFAOYSA-N, HFYPTENHTPNXGP-UHFFFAOYSA-N, HFYPTENHTPNXGP-UHFFFAOYSA-N	Preclinical
I-BET-762	bromodomain inhibitor	BRD2, BRD3, BRD4			CCNC(=O)C[C@@H]1N=C(c2ccc(Cl)cc2)c2cc(OC)ccc2-n2c(C)nnc12 |t:7|, CCNC(=O)C[C@@H]1N=C(c2ccc(Cl)cc2)c2cc(OC)ccc2-n2c(C)nnc12 |t:7|, CCNC(=O)C[C@@H]1N=C(c2ccc(Cl)cc2)c2cc(OC)ccc2-n2c(C)nnc12 |t:7|, CCNC(=O)C[C@@H]1N=C(c2ccc(Cl)cc2)c2cc(OC)ccc2-n2c(C)nnc12 |t:7|, CCNC(=O)C[C@@H]1N=C(c2ccc(Cl)cc2)c2cc(OC)ccc2-n2c(C)nnc12 |t:7|, CCNC(=O)C[C@@H]1N=C(c2ccc(Cl)cc2)c2cc(OC)ccc2-n2c(C)nnc12 |t:7|, CCNC(=O)C[C@@H]1N=C(c2ccc(Cl)cc2)c2cc(OC)ccc2-n2c(C)nnc12 |t:7|	AAAQFGUYHFJNHI-SFHVURJKSA-N, AAAQFGUYHFJNHI-SFHVURJKSA-N, AAAQFGUYHFJNHI-SFHVURJKSA-N, InChI=1S/C22H22ClN5O2/c1-4-24-20(29)12-18-22-27-26-13(2)28(22)19-10-9-16(30-3)11-17(19)21(25-18)14-5-7-15(23)8-6-14/h5-11,18H,4,12H2,1-3H3,(H,24,29)/t18-/m0/s1, InChI=1S/C22H22ClN5O2/c1-4-24-20(29)12-18-22-27-26-13(2)28(22)19-10-9-16(30-3)11-17(19)21(25-18)14-5-7-15(23)8-6-14/h5-11,18H,4,12H2,1-3H3,(H,24,29)/t18-/m0/s1, InChI=1S/C22H22ClN5O2/c1-4-24-20(29)12-18-22-27-26-13(2)28(22)19-10-9-16(30-3)11-17(19)21(25-18)14-5-7-15(23)8-6-14/h5-11,18H,4,12H2,1-3H3,(H,24,29)/t18-/m0/s1, InChI=1S/C22H22ClN5O2/c1-4-24-20(29)12-18-22-27-26-13(2)28(22)19-10-9-16(30-3)11-17(19)21(25-18)14-5-7-15(23)8-6-14/h5-11,18H,4,12H2,1-3H3,(H,24,29)/t18-/m0/s1	Phase 2
I-BET151	bromodomain inhibitor	BRD2, BRD3, BRD4			COc1cc2c3n([C@H](C)c4ccccn4)c(=O)[nH]c3cnc2cc1-c1c(C)noc1C, COc1cc2c3n([C@H](C)c4ccccn4)c(=O)[nH]c3cnc2cc1-c1c(C)noc1C, COc1cc2c3n([C@H](C)c4ccccn4)c(=O)[nH]c3cnc2cc1-c1c(C)noc1C, COc1cc2c3n([C@H](C)c4ccccn4)c(=O)[nH]c3cnc2cc1-c1c(C)noc1C, COc1cc2c3n([C@H](C)c4ccccn4)c(=O)[nH]c3cnc2cc1-c1c(C)noc1C, COc1cc2c3n([C@H](C)c4ccccn4)c(=O)[nH]c3cnc2cc1-c1c(C)noc1C	VUVUVNZRUGEAHB-CYBMUJFWSA-N, VUVUVNZRUGEAHB-CYBMUJFWSA-N, VUVUVNZRUGEAHB-CYBMUJFWSA-N, VUVUVNZRUGEAHB-CYBMUJFWSA-N, VUVUVNZRUGEAHB-CYBMUJFWSA-N, VUVUVNZRUGEAHB-CYBMUJFWSA-N	Preclinical
I-BRD9	bromodomain inhibitor	BRD9			CCn1cc(-c2cccc(c2)C(F)(F)F)c2sc(cc2c1=O)C(=N)NC1CCS(=O)(=O)CC1, CCn1cc(-c2cccc(c2)C(F)(F)F)c2sc(cc2c1=O)C(=N)NC1CCS(=O)(=O)CC1, CCn1cc(-c2cccc(c2)C(F)(F)F)c2sc(cc2c1=O)C(=N)NC1CCS(=O)(=O)CC1, CCn1cc(-c2cccc(c2)C(F)(F)F)c2sc(cc2c1=O)C(=N)NC1CCS(=O)(=O)CC1, CCn1cc(-c2cccc(c2)C(F)(F)F)c2sc(cc2c1=O)C(=N)NC1CCS(=O)(=O)CC1, CCn1cc(-c2cccc(c2)C(F)(F)F)c2sc(cc2c1=O)C(=N)NC1CCS(=O)(=O)CC1	WRUWGLUCNBMGPS-UHFFFAOYSA-N, WRUWGLUCNBMGPS-UHFFFAOYSA-N, WRUWGLUCNBMGPS-UHFFFAOYSA-N, WRUWGLUCNBMGPS-UHFFFAOYSA-N, WRUWGLUCNBMGPS-UHFFFAOYSA-N, WRUWGLUCNBMGPS-UHFFFAOYSA-N	Preclinical
I-BZA					CCN(CC)CCNC(=O)c1ccc(I)cc1, CCN(CC)CCNC(=O)c1ccc(I)cc1	HRVWCNMOEFNEON-UHFFFAOYSA-N, HRVWCNMOEFNEON-UHFFFAOYSA-N	Phase 2
I-BZA2					CCN(CC)CCNC(=O)c1ccccc1I, CCN(CC)CCNC(=O)c1ccccc1I	WNSWOZIBBVUJBI-UHFFFAOYSA-N, WNSWOZIBBVUJBI-UHFFFAOYSA-N	Phase 3
I-CBP-112	bromodomain inhibitor	CREBBP, EP300			CCC(=O)N1CCOc2c(C1)cc(cc2OC[C@H]1CCCN(C)C1)-c1ccc(OC)c(OC)c1, CCC(=O)N1CCOc2c(C1)cc(cc2OC[C@H]1CCCN(C)C1)-c1ccc(OC)c(OC)c1	YKNAKDFZAWQEEO-IBGZPJMESA-N, YKNAKDFZAWQEEO-IBGZPJMESA-N	Preclinical
IACS-10759	mitochondrial complex I inhibitor				Cc1nc(nn1Cc1cccc(c1)N1CCC(CC1)S(C)(=O)=O)-c1nc(no1)-c1ccc(OC(F)(F)F)cc1	HWJWNWZJUYCGKV-UHFFFAOYSA-N	Preclinical
IB-MECA	adenosine receptor agonist	ADORA1, ADORA2A, ADORA2B, ADORA3			CNC(=O)[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(NCc3cccc(I)c3)ncnc12, CNC(=O)[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(NCc3cccc(I)c3)ncnc12, CNC(=O)[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(NCc3cccc(I)c3)ncnc12	HUJXGQILHAUCCV-MOROJQBDSA-N, HUJXGQILHAUCCV-MOROJQBDSA-N, HUJXGQILHAUCCV-MOROJQBDSA-N	Phase 3
ibandronate	bone resorption inhibitor	FDPS	orthopedics	osteoporosis	CCCCCN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O, CCCCCN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O, CCCCCN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O, CCCCCN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O	MPBVHIBUJCELCL-UHFFFAOYSA-N, MPBVHIBUJCELCL-UHFFFAOYSA-N, MPBVHIBUJCELCL-UHFFFAOYSA-N, MPBVHIBUJCELCL-UHFFFAOYSA-N	Launched
IBC-293	hydroxycarboxylic acid receptor agonist	HCAR3			CC(C)n1nnc2cc(ccc12)C(O)=O, CC(C)n1nnc2cc(ccc12)C(O)=O	RUTVRAJKELSHCC-UHFFFAOYSA-N, RUTVRAJKELSHCC-UHFFFAOYSA-N	Preclinical
iberdomide	cereblon modulator				O=C1N(Cc2c1cccc2OCc1ccc(CN2CCOCC2)cc1)[C@H]1CCC(=O)NC1=O	IXZOHGPZAQLIBH-NRFANRHFSA-N	Preclinical
ibiglustat	glucosylceramidase inhibitor				CC(C)(NC(=O)O[C@@H]1CN2CCC1CC2)c1csc(n1)-c1ccc(F)cc1	YFHRCLAKZBDRHN-MRXNPFEDSA-N	Preclinical
IBMX	phosphodiesterase inhibitor	ADORA1, PDE2A, PDE3B, PDE4D, PDE5A, PDE6G, PDE7A, PDE8A, PDE9A			CC(C)Cn1c2nc[nH]c2c(=O)n(C)c1=O, CC(C)Cn1c2nc[nH]c2c(=O)n(C)c1=O, CC(C)Cn1c2nc[nH]c2c(=O)n(C)c1=O, CC(C)Cn1c2nc[nH]c2c(=O)n(C)c1=O	APIXJSLKIYYUKG-UHFFFAOYSA-N, APIXJSLKIYYUKG-UHFFFAOYSA-N, APIXJSLKIYYUKG-UHFFFAOYSA-N, APIXJSLKIYYUKG-UHFFFAOYSA-N	Preclinical
ibotenic-acid	glutamate receptor agonist	GRIN1			N[C@@H](C(O)=O)c1cc(=O)[nH]o1 |&1:1,r|, N[C@@H](C(O)=O)c1cc(=O)[nH]o1 |&1:1,r|	IRJCBFDCFXCWGO-SCSAIBSYSA-N, IRJCBFDCFXCWGO-SCSAIBSYSA-N	Preclinical
ibrolipim	lipoprotein lipase activator	LPL			CCOP(=O)(Cc1ccc(cc1)C(=O)Nc1ccc(Br)cc1C#N)OCC, CCOP(=O)(Cc1ccc(cc1)C(=O)Nc1ccc(Br)cc1C#N)OCC	KPRTURMJVWXURQ-UHFFFAOYSA-N, KPRTURMJVWXURQ-UHFFFAOYSA-N	Phase 2
ibrutinib	Bruton's tyrosine kinase (BTK) inhibitor	BLK, BMX, BTK	hematologic malignancy	chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), Waldenstrom's macroglobulinemia (WM)	Nc1ncnc2n(nc(-c3ccc(Oc4ccccc4)cc3)c12)[C@@H]1CCCN(C1)C(=O)C=C, Nc1ncnc2n(nc(-c3ccc(Oc4ccccc4)cc3)c12)[C@@H]1CCCN(C1)C(=O)C=C, Nc1ncnc2n(nc(-c3ccc(Oc4ccccc4)cc3)c12)[C@@H]1CCCN(C1)C(=O)C=C, Nc1ncnc2n(nc(-c3ccc(Oc4ccccc4)cc3)c12)[C@@H]1CCCN(C1)C(=O)C=C, Nc1ncnc2n(nc(-c3ccc(Oc4ccccc4)cc3)c12)[C@@H]1CCCN(C1)C(=O)C=C, Nc1ncnc2n(nc(-c3ccc(Oc4ccccc4)cc3)c12)[C@@H]1CCCN(C1)C(=O)C=C, Nc1ncnc2n(nc(-c3ccc(Oc4ccccc4)cc3)c12)[C@@H]1CCCN(C1)C(=O)C=C, Nc1ncnc2n(nc(-c3ccc(Oc4ccccc4)cc3)c12)[C@@H]1CCCN(C1)C(=O)C=C, Nc1ncnc2n(nc(-c3ccc(Oc4ccccc4)cc3)c12)[C@@H]1CCCN(C1)C(=O)C=C	XYFPWWZEPKGCCK-GOSISDBHSA-N, XYFPWWZEPKGCCK-GOSISDBHSA-N, XYFPWWZEPKGCCK-GOSISDBHSA-N, XYFPWWZEPKGCCK-GOSISDBHSA-N, XYFPWWZEPKGCCK-GOSISDBHSA-N, XYFPWWZEPKGCCK-GOSISDBHSA-N, XYFPWWZEPKGCCK-GOSISDBHSA-N, XYFPWWZEPKGCCK-GOSISDBHSA-N, InChI=1S/C25H24N6O2/c1-2-21(32)30-14-6-7-18(15-30)31-25-22(24(26)27-16-28-25)23(29-31)17-10-12-20(13-11-17)33-19-8-4-3-5-9-19/h2-5,8-13,16,18H,1,6-7,14-15H2,(H2,26,27,28)/t18-/m1/s1	Launched
ibudilast	leukotriene receptor antagonist, phosphodiesterase inhibitor	IL1B, IL6, PDE3A, PDE4A, PDE4B, PDE4C, PDE4D, PDE5A	pulmonary, neurology/psychiatry	asthma, stroke	CC(C)C(=O)c1c(nn2ccccc12)C(C)C, CC(C)C(=O)c1c(nn2ccccc12)C(C)C, CC(C)C(=O)c1c(nn2ccccc12)C(C)C, CC(C)C(=O)c1c(nn2ccccc12)C(C)C	ZJVFLBOZORBYFE-UHFFFAOYSA-N, ZJVFLBOZORBYFE-UHFFFAOYSA-N, ZJVFLBOZORBYFE-UHFFFAOYSA-N, ZJVFLBOZORBYFE-UHFFFAOYSA-N	Launched
ibuprofen	cyclooxygenase inhibitor		neurology/psychiatry, rheumatology, otolaryngology, obstetrics/gynecology, endocrinology, dental	headache, muscle pain, rheumatoid arthritis, backache, common cold, menstrual pain, fever, toothache	CC(C)Cc1ccc(cc1)[C@@H](C)C(O)=O |&1:10,r|, CC(C)Cc1ccc(cc1)[C@@H](C)C(O)=O |&1:10,r|	HEFNNWSXXWATRW-SNVBAGLBSA-N, HEFNNWSXXWATRW-SNVBAGLBSA-N	Launched
ibuprofen-(S)	cyclooxygenase inhibitor	ASIC1, PTGS1, PTGS2, SLC5A8	neurology/psychiatry	pain relief	CC(C)Cc1ccc(cc1)[C@H](C)C(O)=O, CC(C)Cc1ccc(cc1)[C@H](C)C(O)=O, CC(C)Cc1ccc(cc1)[C@H](C)C(O)=O	HEFNNWSXXWATRW-JTQLQIEISA-N, HEFNNWSXXWATRW-JTQLQIEISA-N, HEFNNWSXXWATRW-JTQLQIEISA-N	Launched
ibuprofen-lysine	cyclooxygenase inhibitor		cardiology	patent ductus arteriosus (PDA)	NCCCC[C@H](N)C(O)=O.CC(C)Cc1ccc(cc1)[C@@H](C)C(O)=O |a:5,&1:20|, NCCCC[C@H](N)C(O)=O.CC(C)Cc1ccc(cc1)[C@@H](C)C(O)=O |a:5,&1:20|, NCCCC[C@H](N)C(O)=O.CC(C)Cc1ccc(cc1)[C@@H](C)C(O)=O |a:5,&1:20|, NCCCC[C@H](N)C(O)=O.CC(C)Cc1ccc(cc1)[C@@H](C)C(O)=O |a:5,&1:20|	IHHXIUAEPKVVII-APFIOPMWSA-N, IHHXIUAEPKVVII-APFIOPMWSA-N, IHHXIUAEPKVVII-APFIOPMWSA-N, IHHXIUAEPKVVII-APFIOPMWSA-N	Launched
ibuprofen-piconol	cyclooxygenase inhibitor	PTGS1, PTGS2	neurology/psychiatry	pain relief	CC(C)Cc1ccc(cc1)[C@@H](C)C(=O)OCc1ccccn1 |&1:10,r|, CC(C)Cc1ccc(cc1)[C@@H](C)C(=O)OCc1ccccn1 |&1:10,r|, CC(C)Cc1ccc(cc1)[C@@H](C)C(=O)OCc1ccccn1 |&1:10,r|	ACEWLPOYLGNNHV-OAHLLOKOSA-N, ACEWLPOYLGNNHV-OAHLLOKOSA-N, ACEWLPOYLGNNHV-OAHLLOKOSA-N	Launched
ibuproxam	cyclooxygenase inhibitor, prostaglandin inhibitor	ALOX5	endocrinology, rheumatology, neurology/psychiatry	fever, joint inflammation, pain relief	CC(C)Cc1ccc(cc1)[C@@H](C)C(=O)NO |r|	BYPIURIATSUHDW-SNVBAGLBSA-N	Launched
ibutamoren	growth hormone secretagogue receptor agonist	GHR, GHSR			CC(C)(N)C(=O)N[C@H](COCc1ccccc1)C(=O)N1CCC2(CN(c3ccccc23)S(C)(=O)=O)CC1, CC(C)(N)C(=O)N[C@H](COCc1ccccc1)C(=O)N1CCC2(CN(c3ccccc23)S(C)(=O)=O)CC1, CC(C)(N)C(=O)N[C@H](COCc1ccccc1)C(=O)N1CCC2(CN(c3ccccc23)S(C)(=O)=O)CC1	UMUPQWIGCOZEOY-JOCHJYFZSA-N, UMUPQWIGCOZEOY-JOCHJYFZSA-N, UMUPQWIGCOZEOY-JOCHJYFZSA-N	Phase 2
ibutilide	potassium channel blocker	CACNA1C, KCNH2	cardiology	atrial fibrillation (AF)	CCCCCCCN(CC)CCC[C@@H](O)c1ccc(NS(C)(=O)=O)cc1 |&1:13|, CCCCCCCN(CC)CCC[C@@H](O)c1ccc(NS(C)(=O)=O)cc1 |&1:13|, CCCCCCCN(CC)CCC[C@@H](O)c1ccc(NS(C)(=O)=O)cc1 |&1:13|, CCCCCCCN(CC)CCC[C@@H](O)c1ccc(NS(C)(=O)=O)cc1 |&1:13|, CCCCCCCN(CC)CCC[C@@H](O)c1ccc(NS(C)(=O)=O)cc1 |&1:13|, CCCCCCCN(CC)CCC[C@@H](O)c1ccc(NS(C)(=O)=O)cc1 |&1:13|, CCCCCCCN(CC)CCC[C@@H](O)c1ccc(NS(C)(=O)=O)cc1 |&1:13|	ALOBUEHUHMBRLE-HXUWFJFHSA-N, ALOBUEHUHMBRLE-HXUWFJFHSA-N, ALOBUEHUHMBRLE-HXUWFJFHSA-N, ALOBUEHUHMBRLE-HXUWFJFHSA-N, ALOBUEHUHMBRLE-HXUWFJFHSA-N, ALOBUEHUHMBRLE-HXUWFJFHSA-N, ALOBUEHUHMBRLE-HXUWFJFHSA-N	Launched
ICA-069673	voltage-gated potassium channel activator	KCNQ2, KCNQ3			Fc1ccc(cc1F)C(=O)Nc1cnc(Cl)nc1, Fc1ccc(cc1F)C(=O)Nc1cnc(Cl)nc1, Fc1ccc(cc1F)C(=O)Nc1cnc(Cl)nc1	IIBSHMFXVWTQSJ-UHFFFAOYSA-N, IIBSHMFXVWTQSJ-UHFFFAOYSA-N, IIBSHMFXVWTQSJ-UHFFFAOYSA-N	Preclinical
ICA-110381	voltage-gated potassium channel activator	KCNQ2			Clc1ccc(cc1)C(=O)Nc1ccc(Cl)nc1, Clc1ccc(cc1)C(=O)Nc1ccc(Cl)nc1, Clc1ccc(cc1)C(=O)Nc1ccc(Cl)nc1	FOYOGIUAMYSVIT-UHFFFAOYSA-N, FOYOGIUAMYSVIT-UHFFFAOYSA-N, FOYOGIUAMYSVIT-UHFFFAOYSA-N	Preclinical
ICA-121431	sodium channel blocker	SCN1A, SCN3A			O=C(Nc1ccc(cc1)S(=O)(=O)Nc1nccs1)C(c1ccccc1)c1ccccc1, O=C(Nc1ccc(cc1)S(=O)(=O)Nc1nccs1)C(c1ccccc1)c1ccccc1, O=C(Nc1ccc(cc1)S(=O)(=O)Nc1nccs1)C(c1ccccc1)c1ccccc1, O=C(Nc1ccc(cc1)S(=O)(=O)Nc1nccs1)C(c1ccccc1)c1ccccc1	URSQNPPONHUJDL-UHFFFAOYSA-N, URSQNPPONHUJDL-UHFFFAOYSA-N, URSQNPPONHUJDL-UHFFFAOYSA-N, URSQNPPONHUJDL-UHFFFAOYSA-N	Preclinical
icariin	phosphodiesterase inhibitor	PDE5A			COc1ccc(cc1)-c1oc2c(CC=C(C)C)c(O[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)cc(O)c2c(=O)c1O[C@@H]1O[C@@H](C)[C@H](O)[C@@H](O)[C@H]1O, COc1ccc(cc1)-c1oc2c(CC=C(C)C)c(O[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)cc(O)c2c(=O)c1O[C@@H]1O[C@@H](C)[C@H](O)[C@@H](O)[C@H]1O, COc1ccc(cc1)-c1oc2c(CC=C(C)C)c(O[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)cc(O)c2c(=O)c1O[C@@H]1O[C@@H](C)[C@H](O)[C@@H](O)[C@H]1O, COc1ccc(cc1)-c1oc2c(CC=C(C)C)c(O[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)cc(O)c2c(=O)c1O[C@@H]1O[C@@H](C)[C@H](O)[C@@H](O)[C@H]1O, COc1ccc(cc1)-c1oc2c(CC=C(C)C)c(O[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)cc(O)c2c(=O)c1O[C@@H]1O[C@@H](C)[C@H](O)[C@@H](O)[C@H]1O, COc1ccc(cc1)-c1oc2c(CC=C(C)C)c(O[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)cc(O)c2c(=O)c1O[C@@H]1O[C@@H](C)[C@H](O)[C@@H](O)[C@H]1O, COc1ccc(cc1)-c1oc2c(CC=C(C)C)c(O[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)cc(O)c2c(=O)c1O[C@@H]1O[C@@H](C)[C@H](O)[C@@H](O)[C@H]1O, COc1ccc(cc1)-c1oc2c(CC=C(C)C)c(O[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)cc(O)c2c(=O)c1O[C@@H]1O[C@@H](C)[C@H](O)[C@@H](O)[C@H]1O	TZJALUIVHRYQQB-XLRXWWTNSA-N, TZJALUIVHRYQQB-XLRXWWTNSA-N, TZJALUIVHRYQQB-XLRXWWTNSA-N, TZJALUIVHRYQQB-XLRXWWTNSA-N, TZJALUIVHRYQQB-XLRXWWTNSA-N, TZJALUIVHRYQQB-XLRXWWTNSA-N, TZJALUIVHRYQQB-XLRXWWTNSA-N, TZJALUIVHRYQQB-XLRXWWTNSA-N	Phase 3
icaritin	PPAR receptor antagonist	PDE5A			COc1ccc(cc1)-c1oc2c(CC=C(C)C)c(O)cc(O)c2c(=O)c1O, COc1ccc(cc1)-c1oc2c(CC=C(C)C)c(O)cc(O)c2c(=O)c1O, COc1ccc(cc1)-c1oc2c(CC=C(C)C)c(O)cc(O)c2c(=O)c1O	TUUXBSASAQJECY-UHFFFAOYSA-N, TUUXBSASAQJECY-UHFFFAOYSA-N, TUUXBSASAQJECY-UHFFFAOYSA-N	Phase 3
icatibant-acetate	bradykinin receptor antagonist	BDKRB2	cardiology	angioedema	N[C@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)N1C[C@H](O)C[C@H]1C(=O)NCC(=O)N[C@@H](Cc1cccs1)C(=O)N[C@@H](CO)C(=O)N1Cc2ccccc2C[C@@H]1C(=O)N1[C@H]2CCCC[C@H]2C[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(O)=O, N[C@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)N1C[C@H](O)C[C@H]1C(=O)NCC(=O)N[C@@H](Cc1cccs1)C(=O)N[C@@H](CO)C(=O)N1Cc2ccccc2C[C@@H]1C(=O)N1[C@H]2CCCC[C@H]2C[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(O)=O, N[C@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)N1C[C@H](O)C[C@H]1C(=O)NCC(=O)N[C@@H](Cc1cccs1)C(=O)N[C@@H](CO)C(=O)N1Cc2ccccc2C[C@@H]1C(=O)N1[C@H]2CCCC[C@H]2C[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(O)=O, N[C@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)N1C[C@H](O)C[C@H]1C(=O)NCC(=O)N[C@@H](Cc1cccs1)C(=O)N[C@@H](CO)C(=O)N1Cc2ccccc2C[C@@H]1C(=O)N1[C@H]2CCCC[C@H]2C[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(O)=O	QURWXBZNHXJZBE-SKXRKSCCSA-N, QURWXBZNHXJZBE-SKXRKSCCSA-N, QURWXBZNHXJZBE-SKXRKSCCSA-N, QURWXBZNHXJZBE-SKXRKSCCSA-N	Launched
ICG-001	beta-catenin inhibitor	CTNNB1			Oc1ccc(C[C@@H]2N3[C@H](CN(Cc4cccc5ccccc45)C2=O)N(CCC3=O)C(=O)NCc2ccccc2)cc1	HQWTUOLCGKIECB-XZWHSSHBSA-N	Preclinical
ICI-118,551	adrenergic receptor antagonist	ADRB2, ADRB3			CC(C)N[C@@H](C)[C@H](O)COc1ccc(C)c2CCCc12, CC(C)N[C@@H](C)[C@H](O)COc1ccc(C)c2CCCc12, CC(C)N[C@@H](C)[C@H](O)COc1ccc(C)c2CCCc12	VFIDUCMKNJIJTO-XJKSGUPXSA-N, VFIDUCMKNJIJTO-XJKSGUPXSA-N, VFIDUCMKNJIJTO-XJKSGUPXSA-N	Phase 2
ICI-162846	histamine receptor antagonist	HRH2			NC(=O)CCCCn1ccc(NC(=N)NCC(F)(F)F)n1, NC(=O)CCCCn1ccc(NC(=N)NCC(F)(F)F)n1	ALCSGJCIESECFD-UHFFFAOYSA-N, ALCSGJCIESECFD-UHFFFAOYSA-N	Phase 1
ICI-169369	serotonin receptor antagonist				CN(C)CCSc1nc2ccccc2cc1-c1ccccc1	HYOLQGVNMQNERE-UHFFFAOYSA-N	Phase 2
ICI-185,282	thromboxane receptor antagonist				OC(=O)CCC\C=C/C[C@@H]1CO[C@@H](O[C@@H]1c1ccccc1O)C(F)(F)F, OC(=O)CCC\C=C/C[C@@H]1CO[C@@H](O[C@@H]1c1ccccc1O)C(F)(F)F, OC(=O)CCC\C=C/C[C@@H]1CO[C@@H](O[C@@H]1c1ccccc1O)C(F)(F)F	ZWAVGFSZMACJHA-PMNBYGLBSA-N, ZWAVGFSZMACJHA-PMNBYGLBSA-N, ZWAVGFSZMACJHA-PMNBYGLBSA-N	Phase 1
ICI-192605	thromboxane receptor antagonist	TBXA2R			OC(=O)CC\C=C/C[C@@H]1CO[C@@H](O[C@@H]1c1ccccc1O)c1ccccc1Cl, OC(=O)CC\C=C/C[C@@H]1CO[C@@H](O[C@@H]1c1ccccc1O)c1ccccc1Cl, OC(=O)CC\C=C/C[C@@H]1CO[C@@H](O[C@@H]1c1ccccc1O)c1ccccc1Cl	WHUIENZXNGAHQI-GKZDNZBASA-N, WHUIENZXNGAHQI-GKZDNZBASA-N, WHUIENZXNGAHQI-GKZDNZBASA-N	Phase 2
ICI-199441	opioid receptor agonist	CYP2D6, OPRD1, OPRK1, OPRM1, UTS2R			CN([C@H](CN1CCCC1)c1ccccc1)C(=O)Cc1ccc(Cl)c(Cl)c1, CN([C@H](CN1CCCC1)c1ccccc1)C(=O)Cc1ccc(Cl)c(Cl)c1, CN([C@H](CN1CCCC1)c1ccccc1)C(=O)Cc1ccc(Cl)c(Cl)c1	AEJOEPSMZCEYJN-HXUWFJFHSA-N, AEJOEPSMZCEYJN-HXUWFJFHSA-N, AEJOEPSMZCEYJN-HXUWFJFHSA-N	Preclinical
ICI-215,001	adrenergic receptor agonist	ADRB3			O[C@@H](CNCCOc1ccc(OCC(O)=O)cc1)COc1ccccc1	MXWICZOXPUWAHY-HNNXBMFYSA-N	Preclinical
ICI-63197	phosphodiesterase inhibitor				CCCn1c2nc(N)nn2cc(C)c1=O, CCCn1c2nc(N)nn2cc(C)c1=O, CCCn1c2nc(N)nn2cc(C)c1=O, CCCn1c2nc(N)nn2cc(C)c1=O	UQDVRVNMIJAGRK-UHFFFAOYSA-N, UQDVRVNMIJAGRK-UHFFFAOYSA-N, UQDVRVNMIJAGRK-UHFFFAOYSA-N, UQDVRVNMIJAGRK-UHFFFAOYSA-N	Preclinical
ICI-89406	adrenergic receptor antagonist	ADRB1, ADRB2			O[C@@H](CNCCNC(=O)Nc1ccccc1)COc1ccccc1C#N |&1:1,r|, O[C@@H](CNCCNC(=O)Nc1ccccc1)COc1ccccc1C#N |&1:1,r|	HTLWRKRZKFAAAH-KRWDZBQOSA-N, HTLWRKRZKFAAAH-KRWDZBQOSA-N	Phase 1
icilin	TRPV agonist	TRPA1, TRPM8			Oc1ccccc1N1CC=C(NC1=O)c1cccc(c1)[N+]([O-])=O |c:10|	RCEFMOGVOYEGJN-UHFFFAOYSA-N	Phase 1
iclaprim	dihydrofolate reductase inhibitor				COc1cc(Cc2cnc(N)nc2N)c2C=C[C@H](Oc2c1OC)C1CC1 |&1:17,r,c:16|	HWJPWWYTGBZDEG-AWEZNQCLSA-N	Phase 3
icomucret	mucin production enhancer	LTB4R2			CCCCC[C@H](O)\C=C\C=C/C\C=C/C\C=C/CCCC(O)=O	JSFATNQSLKRBCI-VAEKSGALSA-N	Phase 3
icosapent	platelet aggregation inhibitor	ACSL3, ACSL4, FADS1, FFAR1, PPARD, PPARG, PTGS1, PTGS2, SLC8A1, TRPV1	endocrinology	hypertriglyceridemia	CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O, CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O, CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O, CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O	JAZBEHYOTPTENJ-JLNKQSITSA-N, JAZBEHYOTPTENJ-JLNKQSITSA-N, JAZBEHYOTPTENJ-JLNKQSITSA-N, JAZBEHYOTPTENJ-JLNKQSITSA-N	Launched
icotinib	EGFR inhibitor	EGFR	oncology	non-small cell lung cancer (NSCLC)	C#Cc1cccc(Nc2ncnc3cc4OCCOCCOCCOc4cc23)c1, C#Cc1cccc(Nc2ncnc3cc4OCCOCCOCCOc4cc23)c1, C#Cc1cccc(Nc2ncnc3cc4OCCOCCOCCOc4cc23)c1, C#Cc1cccc(Nc2ncnc3cc4OCCOCCOCCOc4cc23)c1	QQLKULDARVNMAL-UHFFFAOYSA-N, QQLKULDARVNMAL-UHFFFAOYSA-N, QQLKULDARVNMAL-UHFFFAOYSA-N, QQLKULDARVNMAL-UHFFFAOYSA-N	Launched
iCRT-14	beta catenin inhibitor, WNT signaling inhibitor	CTNNB1, TCF4			Cc1cc(\C=C2/SC(=O)N(C2=O)c2ccccc2)c(C)n1-c1cccnc1, Cc1cc(\C=C2/SC(=O)N(C2=O)c2ccccc2)c(C)n1-c1cccnc1	NCSHZXNGQYSKLR-UNOMPAQXSA-N, NCSHZXNGQYSKLR-UNOMPAQXSA-N	Preclinical
IC261	casein kinase inhibitor	CSNK1A1, CSNK1D, CSNK1E, CSNK1G2			COc1cc(OC)c(\C=C2\C(=O)Nc3ccccc23)c(OC)c1, COc1cc(OC)c(\C=C2\C(=O)Nc3ccccc23)c(OC)c1	JBJYTZXCZDNOJW-JLHYYAGUSA-N, JBJYTZXCZDNOJW-JLHYYAGUSA-N	Preclinical
ID-1101	insulin sensitizer	INS			C[C@H](O)[C@H](C)[C@H](N)C(O)=O, C[C@H](O)[C@H](C)[C@H](N)C(O)=O	OSCCDBFHNMXNME-YUPRTTJUSA-N, OSCCDBFHNMXNME-YUPRTTJUSA-N	Phase 1
ID-8					COc1ccc(cc1)-n1c(C)c([N+]([O-])=O)c2ccc(O)cc12, COc1ccc(cc1)-n1c(C)c([N+]([O-])=O)c2ccc(O)cc12, COc1ccc(cc1)-n1c(C)c([N+]([O-])=O)c2ccc(O)cc12, COc1ccc(cc1)-n1c(C)c([N+]([O-])=O)c2ccc(O)cc12, COc1ccc(cc1)-n1c(C)c([N+]([O-])=O)c2ccc(O)cc12, COc1ccc(cc1)-n1c(C)c([N+]([O-])=O)c2ccc(O)cc12, COc1ccc(cc1)-n1c(C)c([N+]([O-])=O)c2ccc(O)cc12	VVZNWYXIOADGSW-UHFFFAOYSA-N, VVZNWYXIOADGSW-UHFFFAOYSA-N, VVZNWYXIOADGSW-UHFFFAOYSA-N, VVZNWYXIOADGSW-UHFFFAOYSA-N, VVZNWYXIOADGSW-UHFFFAOYSA-N, VVZNWYXIOADGSW-UHFFFAOYSA-N, VVZNWYXIOADGSW-UHFFFAOYSA-N	Preclinical
idalopirdine	serotonin receptor antagonist	HTR6			FC(F)C(F)(F)COc1cccc(CNCCc2c[nH]c3cc(F)ccc23)c1, FC(F)C(F)(F)COc1cccc(CNCCc2c[nH]c3cc(F)ccc23)c1, FC(F)C(F)(F)COc1cccc(CNCCc2c[nH]c3cc(F)ccc23)c1, FC(F)C(F)(F)COc1cccc(CNCCc2c[nH]c3cc(F)ccc23)c1, FC(F)C(F)(F)COc1cccc(CNCCc2c[nH]c3cc(F)ccc23)c1	YBAWYTYNMZWMMJ-UHFFFAOYSA-N, YBAWYTYNMZWMMJ-UHFFFAOYSA-N, YBAWYTYNMZWMMJ-UHFFFAOYSA-N, YBAWYTYNMZWMMJ-UHFFFAOYSA-N, YBAWYTYNMZWMMJ-UHFFFAOYSA-N	Phase 3
idarubicin	topoisomerase inhibitor	TOP2A	hematologic malignancy	acute myeloid leukemia (AML)	C[C@@H]1O[C@H](C[C@H](N)[C@@H]1O)O[C@H]1C[C@@](O)(Cc2c(O)c3C(=O)c4ccccc4C(=O)c3c(O)c12)C(C)=O, C[C@@H]1O[C@H](C[C@H](N)[C@@H]1O)O[C@H]1C[C@@](O)(Cc2c(O)c3C(=O)c4ccccc4C(=O)c3c(O)c12)C(C)=O, C[C@@H]1O[C@H](C[C@H](N)[C@@H]1O)O[C@H]1C[C@@](O)(Cc2c(O)c3C(=O)c4ccccc4C(=O)c3c(O)c12)C(C)=O, C[C@@H]1O[C@H](C[C@H](N)[C@@H]1O)O[C@H]1C[C@@](O)(Cc2c(O)c3C(=O)c4ccccc4C(=O)c3c(O)c12)C(C)=O, C[C@@H]1O[C@H](C[C@H](N)[C@@H]1O)O[C@H]1C[C@@](O)(Cc2c(O)c3C(=O)c4ccccc4C(=O)c3c(O)c12)C(C)=O	XDXDZDZNSLXDNA-TZNDIEGXSA-N, XDXDZDZNSLXDNA-TZNDIEGXSA-N, XDXDZDZNSLXDNA-TZNDIEGXSA-N, XDXDZDZNSLXDNA-TZNDIEGXSA-N, XDXDZDZNSLXDNA-TZNDIEGXSA-N	Launched
idasanutlin	MDM inhibitor	MDM2, TP53			COc1cc(ccc1NC(=O)[C@@H]1N[C@@H](CC(C)(C)C)[C@@](C#N)([C@H]1c1cccc(Cl)c1F)c1ccc(Cl)cc1F)C(O)=O, COc1cc(ccc1NC(=O)[C@@H]1N[C@@H](CC(C)(C)C)[C@@](C#N)([C@H]1c1cccc(Cl)c1F)c1ccc(Cl)cc1F)C(O)=O, COc1cc(ccc1NC(=O)[C@@H]1N[C@@H](CC(C)(C)C)[C@@](C#N)([C@H]1c1cccc(Cl)c1F)c1ccc(Cl)cc1F)C(O)=O, COc1cc(ccc1NC(=O)[C@@H]1N[C@@H](CC(C)(C)C)[C@@](C#N)([C@H]1c1cccc(Cl)c1F)c1ccc(Cl)cc1F)C(O)=O, COc1cc(ccc1NC(=O)[C@@H]1N[C@@H](CC(C)(C)C)[C@@](C#N)([C@H]1c1cccc(Cl)c1F)c1ccc(Cl)cc1F)C(O)=O, COc1cc(ccc1NC(=O)[C@@H]1N[C@@H](CC(C)(C)C)[C@@](C#N)([C@H]1c1cccc(Cl)c1F)c1ccc(Cl)cc1F)C(O)=O, COc1cc(ccc1NC(=O)[C@@H]1N[C@@H](CC(C)(C)C)[C@@](C#N)([C@H]1c1cccc(Cl)c1F)c1ccc(Cl)cc1F)C(O)=O, COc1cc(ccc1NC(=O)[C@@H]1N[C@@H](CC(C)(C)C)[C@@](C#N)([C@H]1c1cccc(Cl)c1F)c1ccc(Cl)cc1F)C(O)=O	TVTXCJFHQKSQQM-LJQIRTBHSA-N, TVTXCJFHQKSQQM-LJQIRTBHSA-N, TVTXCJFHQKSQQM-LJQIRTBHSA-N, TVTXCJFHQKSQQM-LJQIRTBHSA-N, TVTXCJFHQKSQQM-LJQIRTBHSA-N, TVTXCJFHQKSQQM-LJQIRTBHSA-N, InChI=1S/C31H29Cl2F2N3O4/c1-30(2,3)14-24-31(15-36,19-10-9-17(32)13-21(19)34)25(18-6-5-7-20(33)26(18)35)27(38-24)28(39)37-22-11-8-16(29(40)41)12-23(22)42-4/h5-13,24-25,27,38H,14H2,1-4H3,(H,37,39)(H,40,41)/t24-,25-,27+,31-/m0/s1, InChI=1S/C31H29Cl2F2N3O4/c1-30(2,3)14-24-31(15-36,19-10-9-17(32)13-21(19)34)25(18-6-5-7-20(33)26(18)35)27(38-24)28(39)37-22-11-8-16(29(40)41)12-23(22)42-4/h5-13,24-25,27,38H,14H2,1-4H3,(H,37,39)(H,40,41)/t24-,25-,27+,31-/m0/s1	Phase 3
idazoxan	adrenergic receptor antagonist	ADRA2A, PTGS2			C1CN=C(N1)[C@H]1COc2ccccc2O1 |r,c:2|, C1CN=C(N1)[C@H]1COc2ccccc2O1 |r,c:2|, C1CN=C(N1)[C@H]1COc2ccccc2O1 |r,c:2|	HPMRFMKYPGXPEP-SNVBAGLBSA-N, HPMRFMKYPGXPEP-SNVBAGLBSA-N, HPMRFMKYPGXPEP-SNVBAGLBSA-N	Phase 3
idebenone	calcium channel modulator		neurology/psychiatry, ophthalmology	Alzheimer's disease, Friedreich's ataxia, Leber hereditary optic neuropathy (LHON)	COC1=C(OC)C(=O)C(CCCCCCCCCCO)=C(C)C1=O |c:2,t:19|, COC1=C(OC)C(=O)C(CCCCCCCCCCO)=C(C)C1=O |c:2,t:19|, COC1=C(OC)C(=O)C(CCCCCCCCCCO)=C(C)C1=O |c:2,t:19|, COC1=C(OC)C(=O)C(CCCCCCCCCCO)=C(C)C1=O |c:2,t:19|, COC1=C(OC)C(=O)C(CCCCCCCCCCO)=C(C)C1=O |c:2,t:19|, COC1=C(OC)C(=O)C(CCCCCCCCCCO)=C(C)C1=O |c:2,t:19|, COC1=C(OC)C(=O)C(CCCCCCCCCCO)=C(C)C1=O |c:2,t:19|	JGPMMRGNQUBGND-UHFFFAOYSA-N, JGPMMRGNQUBGND-UHFFFAOYSA-N, JGPMMRGNQUBGND-UHFFFAOYSA-N, JGPMMRGNQUBGND-UHFFFAOYSA-N, JGPMMRGNQUBGND-UHFFFAOYSA-N, JGPMMRGNQUBGND-UHFFFAOYSA-N, JGPMMRGNQUBGND-UHFFFAOYSA-N	Launched
idelalisib	PI3K inhibitor	PIK3CA, PIK3CB, PIK3CD, PIK3CG	hematologic malignancy	chronic lymphocytic leukemia (CLL)	CC[C@H](Nc1ncnc2nc[nH]c12)c1nc2cccc(F)c2c(=O)n1-c1ccccc1, CC[C@H](Nc1ncnc2nc[nH]c12)c1nc2cccc(F)c2c(=O)n1-c1ccccc1, CC[C@H](Nc1ncnc2nc[nH]c12)c1nc2cccc(F)c2c(=O)n1-c1ccccc1, CC[C@H](Nc1ncnc2nc[nH]c12)c1nc2cccc(F)c2c(=O)n1-c1ccccc1	IFSDAJWBUCMOAH-HNNXBMFYSA-N, IFSDAJWBUCMOAH-HNNXBMFYSA-N, InChI=1S/C22H18FN7O/c1-2-15(28-20-18-19(25-11-24-18)26-12-27-20)21-29-16-10-6-9-14(23)17(16)22(31)30(21)13-7-4-3-5-8-13/h3-12,15H,2H2,1H3,(H2,24,25,26,27,28)/t15-/m0/s1, InChI=1S/C22H18FN7O/c1-2-15(28-20-18-19(25-11-24-18)26-12-27-20)21-29-16-10-6-9-14(23)17(16)22(31)30(21)13-7-4-3-5-8-13/h3-12,15H,2H2,1H3,(H2,24,25,26,27,28)/t15-/m0/s1	Launched
IDF-11774	hypoxia inducible factor inhibitor				CN1CCN(CC1)C(=O)COc1ccc(cc1)C12CC3CC(CC(C3)C1)C2	QGBBBLPWBSWERZ-UHFFFAOYSA-N	Preclinical
IDH-305	isocitrate dehydrogenase inhibitor				C[C@H](F)[C@H]1COC(=O)N1c1ccnc(N[C@@H](C)c2cc(C)c(cn2)-c2ccnc(c2)C(F)(F)F)n1	DCGDPJCUIKLTDU-SUNYJGFJSA-N	Phase 2
idoxuridine	DNA directed DNA polymerase inhibitor, DNA synthesis inhibitor		infectious disease	virus herpes simplex (HSV)	OC[C@H]1O[C@H](C[C@@H]1O)n1cc(I)c(=O)[nH]c1=O, OC[C@H]1O[C@H](C[C@@H]1O)n1cc(I)c(=O)[nH]c1=O, OC[C@H]1O[C@H](C[C@@H]1O)n1cc(I)c(=O)[nH]c1=O, OC[C@H]1O[C@H](C[C@@H]1O)n1cc(I)c(=O)[nH]c1=O, OC[C@H]1O[C@H](C[C@@H]1O)n1cc(I)c(=O)[nH]c1=O	XQFRJNBWHJMXHO-RRKCRQDMSA-N, XQFRJNBWHJMXHO-RRKCRQDMSA-N, XQFRJNBWHJMXHO-RRKCRQDMSA-N, XQFRJNBWHJMXHO-RRKCRQDMSA-N, XQFRJNBWHJMXHO-RRKCRQDMSA-N	Launched
IDO5L	indoleamine 2,3-dioxygenase inhibitor	IDO1			Nc1nonc1\C(NO)=N/c1ccc(F)c(Cl)c1, Nc1nonc1\C(NO)=N/c1ccc(F)c(Cl)c1, Nc1nonc1\C(NO)=N/c1ccc(F)c(Cl)c1	HGXSLPIXNPASGZ-UHFFFAOYSA-N, HGXSLPIXNPASGZ-UHFFFAOYSA-N, HGXSLPIXNPASGZ-UHFFFAOYSA-N	Preclinical
IDRA-21	glutamate receptor positive allosteric modulator	GRIA1, GRIA2, GRIA3, GRIA4			C[C@H]1Nc2ccc(Cl)cc2S(=O)(=O)N1 |&1:1,r|, C[C@H]1Nc2ccc(Cl)cc2S(=O)(=O)N1 |&1:1,r|, C[C@H]1Nc2ccc(Cl)cc2S(=O)(=O)N1 |&1:1,r|, C[C@H]1Nc2ccc(Cl)cc2S(=O)(=O)N1 |&1:1,r|, C[C@H]1Nc2ccc(Cl)cc2S(=O)(=O)N1 |&1:1,r|	VZRNTCHTJRLTMU-YFKPBYRVSA-N, VZRNTCHTJRLTMU-YFKPBYRVSA-N, VZRNTCHTJRLTMU-YFKPBYRVSA-N, VZRNTCHTJRLTMU-YFKPBYRVSA-N, VZRNTCHTJRLTMU-YFKPBYRVSA-N	Preclinical
idramantone					[H][C@@]12C[C@@]3([H])C[C@@](O)(C1)C[C@@]([H])(C2)C3=O |&1:1,3,6,10|	TZBDEVBNMSLVKT-XYYXLIQBSA-N	Preclinical
idronoxil	XIAP inhibitor	ENOX2, SPHK1			Oc1ccc(cc1)C1=Cc2ccc(O)cc2OC1 |t:8|, Oc1ccc(cc1)C1=Cc2ccc(O)cc2OC1 |t:8|, Oc1ccc(cc1)C1=Cc2ccc(O)cc2OC1 |t:8|	ZZUBHVMHNVYXRR-UHFFFAOYSA-N, ZZUBHVMHNVYXRR-UHFFFAOYSA-N, ZZUBHVMHNVYXRR-UHFFFAOYSA-N	Phase 3
IEM1460	glutamate receptor antagonist	GRIA2			C[N+](C)(C)CCCCCNCC12CC3CC(CC(C3)C1)C2, C[N+](C)(C)CCCCCNCC12CC3CC(CC(C3)C1)C2, C[N+](C)(C)CCCCCNCC12CC3CC(CC(C3)C1)C2, C[N+](C)(C)CCCCCNCC12CC3CC(CC(C3)C1)C2, C[N+](C)(C)CCCCCNCC12CC3CC(CC(C3)C1)C2	IWYZMMIPAJDJBN-UHFFFAOYSA-N, IWYZMMIPAJDJBN-UHFFFAOYSA-N, IWYZMMIPAJDJBN-UHFFFAOYSA-N, IWYZMMIPAJDJBN-UHFFFAOYSA-N, IWYZMMIPAJDJBN-UHFFFAOYSA-N	Preclinical
IEM1754	glutamate receptor antagonist	GRIA1			NCCCCCNCC12CC3CC(CC(C3)C1)C2, NCCCCCNCC12CC3CC(CC(C3)C1)C2, NCCCCCNCC12CC3CC(CC(C3)C1)C2, NCCCCCNCC12CC3CC(CC(C3)C1)C2	UWWMQHVWAYFCDT-UHFFFAOYSA-N, UWWMQHVWAYFCDT-UHFFFAOYSA-N, UWWMQHVWAYFCDT-UHFFFAOYSA-N, UWWMQHVWAYFCDT-UHFFFAOYSA-N	Preclinical
ifenprodil	adrenergic receptor antagonist, glutamate receptor antagonist	GRIN2B			C[C@@H]([C@H](O)c1ccc(O)cc1)N1CCC(Cc2ccccc2)CC1 |&1:1,2|	UYNVMODNBIQBMV-KKSFZXQISA-N	Launched
ifosfamide	DNA alkylating agent	CYP2A6, CYP2B6, CYP2C18, CYP2C19, CYP2C8, CYP2C9, CYP3A4, CYP3A5, CYP3A7, PTGS1	oncology, urology	testicular carcinoma, hemorrhagic cystitis	ClCCN[P@@]1(=O)OCCCN1CCCl |r|, ClCCN[P@@]1(=O)OCCCN1CCCl |r|	HOMGKSMUEGBAAB-CQSZACIVSA-N, HOMGKSMUEGBAAB-CQSZACIVSA-N	Launched
igmesine	sigma receptor agonist	SIGMAR1			CCC(C\C=C\c1ccccc1)(N(C)CC1CC1)c1ccccc1 |&1:2|, CCC(C\C=C\c1ccccc1)(N(C)CC1CC1)c1ccccc1 |&1:2|	VCZSWYIFCKGTJI-JLHYYAGUSA-N, VCZSWYIFCKGTJI-JLHYYAGUSA-N	Phase 2
iguratimod	cyclooxygenase inhibitor, NFkB pathway inhibitor	PTGS2	rheumatology	rheumatoid arthritis	CS(=O)(=O)Nc1cc2occ(NC=O)c(=O)c2cc1Oc1ccccc1, CS(=O)(=O)Nc1cc2occ(NC=O)c(=O)c2cc1Oc1ccccc1	ANMATWQYLIFGOK-UHFFFAOYSA-N, ANMATWQYLIFGOK-UHFFFAOYSA-N	Launched
IKK-16	IKK inhibitor	IKBKB			O=C(N1CCC(CC1)N1CCCC1)c1ccc(Nc2nccc(n2)-c2cc3ccccc3s2)cc1, O=C(N1CCC(CC1)N1CCCC1)c1ccc(Nc2nccc(n2)-c2cc3ccccc3s2)cc1, O=C(N1CCC(CC1)N1CCCC1)c1ccc(Nc2nccc(n2)-c2cc3ccccc3s2)cc1, O=C(N1CCC(CC1)N1CCCC1)c1ccc(Nc2nccc(n2)-c2cc3ccccc3s2)cc1, O=C(N1CCC(CC1)N1CCCC1)c1ccc(Nc2nccc(n2)-c2cc3ccccc3s2)cc1, O=C(N1CCC(CC1)N1CCCC1)c1ccc(Nc2nccc(n2)-c2cc3ccccc3s2)cc1, O=C(N1CCC(CC1)N1CCCC1)c1ccc(Nc2nccc(n2)-c2cc3ccccc3s2)cc1, O=C(N1CCC(CC1)N1CCCC1)c1ccc(Nc2nccc(n2)-c2cc3ccccc3s2)cc1	BWZJBXAPRCVCKQ-UHFFFAOYSA-N, BWZJBXAPRCVCKQ-UHFFFAOYSA-N, BWZJBXAPRCVCKQ-UHFFFAOYSA-N, BWZJBXAPRCVCKQ-UHFFFAOYSA-N, BWZJBXAPRCVCKQ-UHFFFAOYSA-N, BWZJBXAPRCVCKQ-UHFFFAOYSA-N, BWZJBXAPRCVCKQ-UHFFFAOYSA-N, BWZJBXAPRCVCKQ-UHFFFAOYSA-N	Preclinical
IKK-2-inhibitor	IKK inhibitor, SYK inhibitor	IKBKB			NC(=O)c1sc(cc1N)-c1ccsc1, NC(=O)c1sc(cc1N)-c1ccsc1, NC(=O)c1sc(cc1N)-c1ccsc1, NC(=O)c1sc(cc1N)-c1ccsc1	BMUACLADCKCNKZ-UHFFFAOYSA-N, BMUACLADCKCNKZ-UHFFFAOYSA-N, BMUACLADCKCNKZ-UHFFFAOYSA-N, BMUACLADCKCNKZ-UHFFFAOYSA-N	Preclinical
IKK-2-inhibitor-V	IKK inhibitor, NFkB pathway inhibitor	IKBKB			Oc1ccc(Cl)cc1C(=O)Nc1cc(cc(c1)C(F)(F)F)C(F)(F)F, Oc1ccc(Cl)cc1C(=O)Nc1cc(cc(c1)C(F)(F)F)C(F)(F)F, Oc1ccc(Cl)cc1C(=O)Nc1cc(cc(c1)C(F)(F)F)C(F)(F)F, Oc1ccc(Cl)cc1C(=O)Nc1cc(cc(c1)C(F)(F)F)C(F)(F)F, Oc1ccc(Cl)cc1C(=O)Nc1cc(cc(c1)C(F)(F)F)C(F)(F)F	CHILCFMQWMQVAL-UHFFFAOYSA-N, CHILCFMQWMQVAL-UHFFFAOYSA-N, CHILCFMQWMQVAL-UHFFFAOYSA-N, CHILCFMQWMQVAL-UHFFFAOYSA-N, CHILCFMQWMQVAL-UHFFFAOYSA-N	Phase 1
ilaprazole	proton pump inhibitor		gastroenterology	gastroesophageal reflux disease (GERD)	COc1ccnc(C[S@@](=O)c2nc3ccc(cc3[nH]2)-n2cccc2)c1C |&1:8,r|	HRRXCXABAPSOCP-AREMUKBSSA-N	Launched
ilepcimide	anticonvulsant				O=C(\C=C\c1ccc2OCOc2c1)N1CCCCC1	BLPUOQGPBJPXRL-FNORWQNLSA-N	Phase 3
ilomastat	matrix metalloprotease inhibitor	ACAN, ADAM28, MMP1, MMP12, MMP13, MMP14, MMP2, MMP3, MMP8, MMP9			CNC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CC(C)C)CC(=O)NO, CNC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CC(C)C)CC(=O)NO, CNC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CC(C)C)CC(=O)NO, CNC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CC(C)C)CC(=O)NO, CNC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CC(C)C)CC(=O)NO, CNC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CC(C)C)CC(=O)NO, CNC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CC(C)C)CC(=O)NO	NITYDPDXAAFEIT-DYVFJYSZSA-N, NITYDPDXAAFEIT-DYVFJYSZSA-N, NITYDPDXAAFEIT-DYVFJYSZSA-N, NITYDPDXAAFEIT-DYVFJYSZSA-N, NITYDPDXAAFEIT-DYVFJYSZSA-N, NITYDPDXAAFEIT-DYVFJYSZSA-N, NITYDPDXAAFEIT-DYVFJYSZSA-N	Phase 3
iloperidone	dopamine receptor antagonist, serotonin receptor antagonist	ADRA1A, ADRA2C, DRD1, DRD2, DRD3, DRD4, HRH1, HTR1A, HTR2A, HTR6, HTR7	neurology/psychiatry	schizophrenia	COc1cc(ccc1OCCCN1CCC(CC1)c1noc2cc(F)ccc12)C(C)=O	XMXHEBAFVSFQEX-UHFFFAOYSA-N	Launched
iloprost	platelet aggregation inhibitor, prostanoid receptor agonist	PTGDR, PTGER1, PTGER2, PTGER3, PTGER4, PTGFR, PTGIR, TBXA2R	pulmonary	pulmonary arterial hypertension (PAH)	CC#CC[C@@H](C)[C@H](O)\C=C\[C@H]1[C@H](O)C[C@@H]2C\C(C[C@H]12)=C/CCCC(O)=O |a:6,10,11,14,18,&1:4|	HIFJCPQKFCZDDL-GBSCXWAGSA-N	Launched
imatinib	Bcr-Abl kinase inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor	ABL1, CSF1R, DDR1, KIT, NTRK1, PDGFRA, PDGFRB, RET	hematologic malignancy, oncology	chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL), myelodysplastic diseases (MDS), aggressive systemic mastocytosis (ASM), hypereosinophilic syndrome (HES), chronic eosinophilic leukemia (CEL), dermatofibrosarcoma protuberans (DFSP), gastrointestinal stromal tumors (GIST)	CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1	KTUFNOKKBVMGRW-UHFFFAOYSA-N, KTUFNOKKBVMGRW-UHFFFAOYSA-N, KTUFNOKKBVMGRW-UHFFFAOYSA-N, KTUFNOKKBVMGRW-UHFFFAOYSA-N, KTUFNOKKBVMGRW-UHFFFAOYSA-N, KTUFNOKKBVMGRW-UHFFFAOYSA-N, KTUFNOKKBVMGRW-UHFFFAOYSA-N, KTUFNOKKBVMGRW-UHFFFAOYSA-N, KTUFNOKKBVMGRW-UHFFFAOYSA-N, KTUFNOKKBVMGRW-UHFFFAOYSA-N	Launched
Imazodan	phosphodiesterase inhibitor				O=C1CCC(=NN1)c1ccc(cc1)-n1ccnc1 |c:4|	VXMYWVMXSWJFCV-UHFFFAOYSA-N	Phase 1
imeglimin	gluconeogenesis inhibitor				C[C@H]1NC(=NC(N)=N1)N(C)C |c:3,6|, C[C@H]1NC(=NC(N)=N1)N(C)C |c:3,6|, C[C@H]1NC(=NC(N)=N1)N(C)C |c:3,6|	GFICWFZTBXUVIG-SCSAIBSYSA-N, GFICWFZTBXUVIG-SCSAIBSYSA-N, GFICWFZTBXUVIG-SCSAIBSYSA-N	Phase 2
imetit	histamine receptor agonist	HRH3, HRH4			NC(=N)SCCc1cnc[nH]1, NC(=N)SCCc1cnc[nH]1	PEHSVUKQDJULKE-UHFFFAOYSA-N, PEHSVUKQDJULKE-UHFFFAOYSA-N	Preclinical
imexon	apoptosis stimulant, ribonucleotide reductase inhibitor				NC1=NC(=O)N2C[C@@H]12 |r,t:1|, NC1=NC(=O)N2C[C@@H]12 |r,t:1|, NC1=NC(=O)N2C[C@@H]12 |r,t:1|, NC1=NC(=O)N2C[C@@H]12 |r,t:1|	BIXBBIPTYBJTRY-VBMBUWLQSA-N, BIXBBIPTYBJTRY-VBMBUWLQSA-N, BIXBBIPTYBJTRY-VBMBUWLQSA-N, BIXBBIPTYBJTRY-VBMBUWLQSA-N	Phase 2
imidacloprid	acetylcholine receptor antagonist				[O-][N+](=O)N=C1NCCN1Cc1ccc(Cl)nc1	YWTYJOPNNQFBPC-UHFFFAOYSA-N	Launched
imidafenacin	acetylcholine receptor antagonist	CHRM1, CHRM3	neurology/psychiatry	spasms	Cc1nccn1CCC(C(N)=O)(c1ccccc1)c1ccccc1, Cc1nccn1CCC(C(N)=O)(c1ccccc1)c1ccccc1, Cc1nccn1CCC(C(N)=O)(c1ccccc1)c1ccccc1	SQKXYSGRELMAAU-UHFFFAOYSA-N, SQKXYSGRELMAAU-UHFFFAOYSA-N, SQKXYSGRELMAAU-UHFFFAOYSA-N	Launched
imidapril	angiotensin converting enzyme inhibitor	ACE	cardiology	hypertension, congestive heart failure	CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1[C@@H](CN(C)C1=O)C(O)=O, CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1[C@@H](CN(C)C1=O)C(O)=O	KLZWOWYOHUKJIG-BPUTZDHNSA-N, KLZWOWYOHUKJIG-BPUTZDHNSA-N	Launched
imidazoacridinone	anticancer agent				CCN(CC)CCNc1ccc2ncn3c2c1c(=O)c1cc(O)ccc31	CUNDRHORZHFPLY-UHFFFAOYSA-N	Preclinical
imidurea	other antibiotic				OCN1[C@@H](NC(=O)NCNC(=O)N[C@@H]2N(CO)C(=O)NC2=O)C(=O)NC1=O |&1:3,&2:13,r|	ZCTXEAQXZGPWFG-RFZPGFLSSA-N	Preclinical
imiloxan	adrenergic receptor antagonist	ADRA2A, ADRA2B			CCn1ccnc1C[C@H]1COc2ccccc2O1 |&1:8|, CCn1ccnc1C[C@H]1COc2ccccc2O1 |&1:8|	UXABARREKCJULM-NSHDSACASA-N, UXABARREKCJULM-NSHDSACASA-N	Phase 1
imipenem	bacterial cell wall synthesis inhibitor		infectious disease	pneumonia, urinary tract infections, intra-abdominal infections, gynecologic infections, bacterial septicemia, bone and joint infections, skin infections, endocarditis	C[C@@H](O)[C@@H]1[C@H]2CC(SCCNC=N)=C(N2C1=O)C(O)=O |c:12|, C[C@@H](O)[C@@H]1[C@H]2CC(SCCNC=N)=C(N2C1=O)C(O)=O |c:12|	ZSKVGTPCRGIANV-ZXFLCMHBSA-N, ZSKVGTPCRGIANV-ZXFLCMHBSA-N	Launched
imipramine	norepinephrine reputake inhibitor, serotonin reuptake inhibitor	ADRA1A, ADRA1B, ADRA1D, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, DRD1, DRD2, DRD5, HRH1, HTR1A, HTR2A, HTR2C, HTR6, HTR7, KCND2, KCND3, KCNH1, KCNH2, SLC6A2, SLC6A3, SLC6A4	neurology/psychiatry, urology	depression, nocturnal enuresis	CN(C)CCCN1c2ccccc2CCc2ccccc12, CN(C)CCCN1c2ccccc2CCc2ccccc12, CN(C)CCCN1c2ccccc2CCc2ccccc12, CN(C)CCCN1c2ccccc2CCc2ccccc12, CN(C)CCCN1c2ccccc2CCc2ccccc12	BCGWQEUPMDMJNV-UHFFFAOYSA-N, BCGWQEUPMDMJNV-UHFFFAOYSA-N, BCGWQEUPMDMJNV-UHFFFAOYSA-N, BCGWQEUPMDMJNV-UHFFFAOYSA-N, BCGWQEUPMDMJNV-UHFFFAOYSA-N	Launched
imiquimod	interferon inducer, toll-like receptor agonist	TLR7, TLR8	dermatology, infectious disease, oncology	actinic keratosis (AK), genital warts, basal cell carcinoma (BCC)	CC(C)Cn1cnc2c(N)nc3ccccc3c12, CC(C)Cn1cnc2c(N)nc3ccccc3c12, CC(C)Cn1cnc2c(N)nc3ccccc3c12, CC(C)Cn1cnc2c(N)nc3ccccc3c12, CC(C)Cn1cnc2c(N)nc3ccccc3c12	DOUYETYNHWVLEO-UHFFFAOYSA-N, DOUYETYNHWVLEO-UHFFFAOYSA-N, DOUYETYNHWVLEO-UHFFFAOYSA-N, DOUYETYNHWVLEO-UHFFFAOYSA-N, DOUYETYNHWVLEO-UHFFFAOYSA-N	Launched
imirestat	aldose reductase inhibitor				Fc1ccc2-c3ccc(F)cc3C3(NC(=O)NC3=O)c2c1	QCCHBHSAIQIQGO-UHFFFAOYSA-N	Preclinical
imisopasem-manganese	superoxide dismutase mimetic				[H][C@@]12CCCC[C@@]1([H])N1Cc3cccc(CN4[C@]5([H])CCCC[C@@]5([H])N5CCN2[Mn]145(Cl)Cl)n3	UWYSKLMRWPKZES-XNPJUPKFSA-L	Preclinical
immepip	histamine receptor agonist	HRH3, HRH4			C(C1CCNCC1)c1cnc[nH]1, C(C1CCNCC1)c1cnc[nH]1	MCNGUYXRBCIGOV-UHFFFAOYSA-N, MCNGUYXRBCIGOV-UHFFFAOYSA-N	Preclinical
immethridine	histamine receptor agonist	HRH3			C(c1cnc[nH]1)c1ccncc1, C(c1cnc[nH]1)c1ccncc1, C(c1cnc[nH]1)c1ccncc1	DFVSGZHJSIEEQQ-UHFFFAOYSA-N, DFVSGZHJSIEEQQ-UHFFFAOYSA-N, DFVSGZHJSIEEQQ-UHFFFAOYSA-N	Phase 1
impentamine	histamine receptor antagonist	HRH3			NCCCCCc1cnc[nH]1, NCCCCCc1cnc[nH]1, NCCCCCc1cnc[nH]1	MZCJWLAXZRFUPI-UHFFFAOYSA-N, MZCJWLAXZRFUPI-UHFFFAOYSA-N, MZCJWLAXZRFUPI-UHFFFAOYSA-N	Preclinical
IMREG-1					N[C@@H](Cc1ccc(O)cc1)C(=O)NCC(=O)NCC(O)=O, N[C@@H](Cc1ccc(O)cc1)C(=O)NCC(=O)NCC(O)=O	HIINQLBHPIQYHN-JTQLQIEISA-N, HIINQLBHPIQYHN-JTQLQIEISA-N	Phase 3
inarigivir	antiviral				CO[C@@H]1[C@H](O[P@](S)(=O)OC[C@H]2O[C@H](C[C@@H]2O)n2cnc3c(N)ncnc23)[C@@H](CO)O[C@H]1n1ccc(=O)[nH]c1=O |a:2,3,10,12,14,26,30,&1:5|	LYMICVBGNUEHGE-NLKZJYKHSA-N	Phase 2
inarigivir-soproxil	antiviral				[H][C@]1(O)C[C@@]([H])(O[C@]1([H])CO[P@](=O)(O[C@]1([H])[C@@]([H])(CO)O[C@@]([H])(n2ccc(=O)[nH]c2=O)[C@]1([H])OC)SCOC(=O)OC(C)C)n1cnc2c(N)ncnc12 |&1:11,r|	CJCYTUJOSMYXLE-NHMFLIHISA-N	Phase 2
INC-280	c-Met inhibitor	MET			CNC(=O)c1ccc(cc1F)-c1cnc2ncc(Cc3ccc4ncccc4c3)n2n1, CNC(=O)c1ccc(cc1F)-c1cnc2ncc(Cc3ccc4ncccc4c3)n2n1, CNC(=O)c1ccc(cc1F)-c1cnc2ncc(Cc3ccc4ncccc4c3)n2n1, CNC(=O)c1ccc(cc1F)-c1cnc2ncc(Cc3ccc4ncccc4c3)n2n1, CNC(=O)c1ccc(cc1F)-c1cnc2ncc(Cc3ccc4ncccc4c3)n2n1	LIOLIMKSCNQPLV-UHFFFAOYSA-N, LIOLIMKSCNQPLV-UHFFFAOYSA-N, LIOLIMKSCNQPLV-UHFFFAOYSA-N, LIOLIMKSCNQPLV-UHFFFAOYSA-N, LIOLIMKSCNQPLV-UHFFFAOYSA-N	Phase 3
INCA-6	calcineurin inhibitor	NFATC1			O=C1C=CC(=O)C2=C1C1c3ccccc3C2c2ccccc12 |c:2,6|, O=C1C=CC(=O)C2=C1C1c3ccccc3C2c2ccccc12 |c:2,6|, O=C1C=CC(=O)C2=C1C1c3ccccc3C2c2ccccc12 |c:2,6|	GCHPUOHXXCNSQL-UHFFFAOYSA-N, GCHPUOHXXCNSQL-UHFFFAOYSA-N, GCHPUOHXXCNSQL-UHFFFAOYSA-N	Preclinical
INCB-003284	CC chemokine receptor antagonist				COc1ccc(cn1)C1(O)CCC(CC1)N1CC[C@H](C1)NC(=O)CNC(=O)c1cccc(c1)C(F)(F)F	NXZNYBUBXWWKCP-JMOWIOHXSA-N	Phase 2
INCB-057643	bromodomain inhibitor				CN1C(=O)C(C)(C)Oc2c1cc(cc2-c1cn(C)c(O)c2nccc12)S(C)(=O)=O	ZNFWPFHSBWLNSO-UHFFFAOYSA-N	Phase 1/Phase 2
INCB-3284	CC chemokine receptor antagonist	CCR2			COc1ccc(cn1)[C@]1(O)CC[C@@H](CC1)N1CC[C@H](C1)NC(=O)CNC(=O)c1cccc(c1)C(F)(F)F, COc1ccc(cn1)[C@]1(O)CC[C@@H](CC1)N1CC[C@H](C1)NC(=O)CNC(=O)c1cccc(c1)C(F)(F)F	NXZNYBUBXWWKCP-DNRQZRRGSA-N, NXZNYBUBXWWKCP-DNRQZRRGSA-N	Phase 2
incyclinide	matrix metalloprotease inhibitor				[H][C@@]12Cc3cccc(O)c3C(=O)[C@@H]1C(=O)[C@]1(O)C(=O)[C@H](C(N)=O)C(=O)C[C@]1([H])C2 |&1:19,&2:12|	MDYVZYDNBUAVCN-WCAKBIDQSA-N	Phase 2
indacaterol	adrenergic receptor agonist	ADRB1, ADRB2	pulmonary	chronic obstructive pulmonary disease (COPD)	CCc1cc2CC(Cc2cc1CC)NC[C@H](O)c1ccc(O)c2[nH]c(=O)ccc12, CCc1cc2CC(Cc2cc1CC)NC[C@H](O)c1ccc(O)c2[nH]c(=O)ccc12	QZZUEBNBZAPZLX-QFIPXVFZSA-N, QZZUEBNBZAPZLX-QFIPXVFZSA-N	Launched
indalpine	selective serotonin reuptake inhibitor (SSRI)	SLC6A4			C(Cc1c[nH]c2ccccc12)C1CCNCC1, C(Cc1c[nH]c2ccccc12)C1CCNCC1	SADQVAVFGNTEOD-UHFFFAOYSA-N, SADQVAVFGNTEOD-UHFFFAOYSA-N	Withdrawn
indapamide	thiazide diuretic	CA2, HTR3A, KCNQ1	cardiology	hypertension, congestive heart failure	C[C@H]1Cc2ccccc2N1NC(=O)c1ccc(Cl)c(c1)S(N)(=O)=O |&1:1,r|, C[C@H]1Cc2ccccc2N1NC(=O)c1ccc(Cl)c(c1)S(N)(=O)=O |&1:1,r|, C[C@H]1Cc2ccccc2N1NC(=O)c1ccc(Cl)c(c1)S(N)(=O)=O |&1:1,r|, C[C@H]1Cc2ccccc2N1NC(=O)c1ccc(Cl)c(c1)S(N)(=O)=O |&1:1,r|	NDDAHWYSQHTHNT-JTQLQIEISA-N, NDDAHWYSQHTHNT-JTQLQIEISA-N, NDDAHWYSQHTHNT-JTQLQIEISA-N, NDDAHWYSQHTHNT-JTQLQIEISA-N	Launched
indatraline	norepinephrine transporter inhibitor	MAOA, MAOB			CN[C@@H]1C[C@H](c2ccccc12)c1ccc(Cl)c(Cl)c1, CN[C@@H]1C[C@H](c2ccccc12)c1ccc(Cl)c(Cl)c1, CN[C@@H]1C[C@H](c2ccccc12)c1ccc(Cl)c(Cl)c1, CN[C@@H]1C[C@H](c2ccccc12)c1ccc(Cl)c(Cl)c1, CN[C@@H]1C[C@H](c2ccccc12)c1ccc(Cl)c(Cl)c1	SVFXPTLYMIXFRX-XJKSGUPXSA-N, SVFXPTLYMIXFRX-XJKSGUPXSA-N, SVFXPTLYMIXFRX-XJKSGUPXSA-N, SVFXPTLYMIXFRX-XJKSGUPXSA-N, SVFXPTLYMIXFRX-XJKSGUPXSA-N	Preclinical
indeglitazar	PPAR receptor agonist	NCOA1, PPARA, PPARD, PPARG			COc1ccc(cc1)S(=O)(=O)n1cc(CCC(O)=O)c2cc(OC)ccc12	YMPALHOKRBVHOJ-UHFFFAOYSA-N	Phase 2
indeloxazine	norepinephrine reuptake inhibitor, serotonin reuptake inhibitor				C(Oc1cccc2C=CCc12)[C@H]1CNCCO1 |&1:11,c:7|	MADRVGBADLFHMO-GFCCVEGCSA-N	Withdrawn
indibulin	tubulin polymerization inhibitor				Clc1ccc(Cn2cc(C(=O)C(=O)Nc3ccncc3)c3ccccc23)cc1, Clc1ccc(Cn2cc(C(=O)C(=O)Nc3ccncc3)c3ccccc23)cc1, Clc1ccc(Cn2cc(C(=O)C(=O)Nc3ccncc3)c3ccccc23)cc1, Clc1ccc(Cn2cc(C(=O)C(=O)Nc3ccncc3)c3ccccc23)cc1	SOLIIYNRSAWTSQ-UHFFFAOYSA-N, SOLIIYNRSAWTSQ-UHFFFAOYSA-N, SOLIIYNRSAWTSQ-UHFFFAOYSA-N, SOLIIYNRSAWTSQ-UHFFFAOYSA-N	Phase 1/Phase 2
indinavir	HIV protease inhibitor	CYP3A4, CYP3A5, CYP3A7	infectious disease	human immunodeficiency virus (HIV-1)	CC(C)(C)NC(=O)[C@@H]1CN(Cc2cccnc2)CCN1C[C@@H](O)C[C@@H](Cc1ccccc1)C(=O)N[C@@H]1[C@H](O)Cc2ccccc12, CC(C)(C)NC(=O)[C@@H]1CN(Cc2cccnc2)CCN1C[C@@H](O)C[C@@H](Cc1ccccc1)C(=O)N[C@@H]1[C@H](O)Cc2ccccc12, CC(C)(C)NC(=O)[C@@H]1CN(Cc2cccnc2)CCN1C[C@@H](O)C[C@@H](Cc1ccccc1)C(=O)N[C@@H]1[C@H](O)Cc2ccccc12, CC(C)(C)NC(=O)[C@@H]1CN(Cc2cccnc2)CCN1C[C@@H](O)C[C@@H](Cc1ccccc1)C(=O)N[C@@H]1[C@H](O)Cc2ccccc12, CC(C)(C)NC(=O)[C@@H]1CN(Cc2cccnc2)CCN1C[C@@H](O)C[C@@H](Cc1ccccc1)C(=O)N[C@@H]1[C@H](O)Cc2ccccc12, CC(C)(C)NC(=O)[C@@H]1CN(Cc2cccnc2)CCN1C[C@@H](O)C[C@@H](Cc1ccccc1)C(=O)N[C@@H]1[C@H](O)Cc2ccccc12, CC(C)(C)NC(=O)[C@@H]1CN(Cc2cccnc2)CCN1C[C@@H](O)C[C@@H](Cc1ccccc1)C(=O)N[C@@H]1[C@H](O)Cc2ccccc12	CBVCZFGXHXORBI-PXQQMZJSSA-N, CBVCZFGXHXORBI-PXQQMZJSSA-N, CBVCZFGXHXORBI-PXQQMZJSSA-N, CBVCZFGXHXORBI-PXQQMZJSSA-N, CBVCZFGXHXORBI-PXQQMZJSSA-N, CBVCZFGXHXORBI-PXQQMZJSSA-N, InChI=1S/C36H47N5O4/c1-36(2,3)39-35(45)31-24-40(22-26-12-9-15-37-21-26)16-17-41(31)23-29(42)19-28(18-25-10-5-4-6-11-25)34(44)38-33-30-14-8-7-13-27(30)20-32(33)43/h4-15,21,28-29,31-33,42-43H,16-20,22-24H2,1-3H3,(H,38,44)(H,39,45)/t28-,29+,31+,32-,33+/m1/s1	Launched
indiplon	benzodiazepine receptor agonist	GABRA1			CN(C(C)=O)c1cccc(c1)-c1ccnc2c(cnn12)C(=O)c1cccs1, CN(C(C)=O)c1cccc(c1)-c1ccnc2c(cnn12)C(=O)c1cccs1, CN(C(C)=O)c1cccc(c1)-c1ccnc2c(cnn12)C(=O)c1cccs1, CN(C(C)=O)c1cccc(c1)-c1ccnc2c(cnn12)C(=O)c1cccs1, CN(C(C)=O)c1cccc(c1)-c1ccnc2c(cnn12)C(=O)c1cccs1	CBIAWPMZSFFRGN-UHFFFAOYSA-N, CBIAWPMZSFFRGN-UHFFFAOYSA-N, CBIAWPMZSFFRGN-UHFFFAOYSA-N, CBIAWPMZSFFRGN-UHFFFAOYSA-N, CBIAWPMZSFFRGN-UHFFFAOYSA-N	Phase 3
indirubin	CDK inhibitor, glycogen synthase kinase inhibitor	CDK1, CDK5, GSK3A			O=C1Nc2ccccc2\C1=C1\Nc2ccccc2C1=O, O=C1Nc2ccccc2\C1=C1\Nc2ccccc2C1=O, O=C1Nc2ccccc2\C1=C1\Nc2ccccc2C1=O	CRDNMYFJWFXOCH-YPKPFQOOSA-N, CRDNMYFJWFXOCH-YPKPFQOOSA-N, CRDNMYFJWFXOCH-YPKPFQOOSA-N	Phase 2/Phase 3
indirubin-3-monoxime	CDK inhibitor, glycogen synthase kinase inhibitor	CDK1, CDK2, CDK5, CDK5R1, GSK3B			O\N=C1\C(\Nc2ccccc\12)=C1\C(=O)Nc2ccccc12, O\N=C1\C(\Nc2ccccc\12)=C1\C(=O)Nc2ccccc12, O\N=C1\C(\Nc2ccccc\12)=C1\C(=O)Nc2ccccc12	HBDSHCUSXQATPO-BGBJRWHRSA-N, HBDSHCUSXQATPO-BGBJRWHRSA-N, HBDSHCUSXQATPO-BGBJRWHRSA-N	Preclinical
indisulam	CDK inhibitor	CA1, CA12, CA14, CA2, CA6, CA7, CA9			NS(=O)(=O)c1ccc(cc1)S(=O)(=O)Nc1cccc2c(Cl)c[nH]c12, NS(=O)(=O)c1ccc(cc1)S(=O)(=O)Nc1cccc2c(Cl)c[nH]c12, NS(=O)(=O)c1ccc(cc1)S(=O)(=O)Nc1cccc2c(Cl)c[nH]c12, NS(=O)(=O)c1ccc(cc1)S(=O)(=O)Nc1cccc2c(Cl)c[nH]c12	SETFNECMODOHTO-UHFFFAOYSA-N, SETFNECMODOHTO-UHFFFAOYSA-N, SETFNECMODOHTO-UHFFFAOYSA-N, SETFNECMODOHTO-UHFFFAOYSA-N	Phase 2
indium(III)-isopropoxide					[In].CC(C)O.CC(C)O.CC(C)O	JUUUERJZVKCDOT-UHFFFAOYSA-N	Preclinical
indium-tri(2-propanolate)					CC(C)O[In](OC(C)C)OC(C)C	OVZUSPADPSOQQN-UHFFFAOYSA-N	Preclinical
indobufen	cyclooxygenase inhibitor, platelet aggregation inhibitor	PTGS1, PTGS2	hematology	thrombosis	CC[C@@H](C(O)=O)c1ccc(cc1)N1Cc2ccccc2C1=O |&1:2,r|	AYDXAULLCROVIT-OAHLLOKOSA-N	Launched
indocyanine-green	contrast agent	SLCO1B1	cardiology	vascular imaging agent	CC1(C)\C(=C/C=C/C=C/C=C/C2=[N+](CCCCS(O)(=O)=O)c3ccc4ccccc4c3C2(C)C)N(CCCCS(O)(=O)=O)c2ccc3ccccc3c12 |c:11|, CC1(C)\C(=C/C=C/C=C/C=C/C2=[N+](CCCCS(O)(=O)=O)c3ccc4ccccc4c3C2(C)C)N(CCCCS(O)(=O)=O)c2ccc3ccccc3c12 |c:11|, CC1(C)\C(=C/C=C/C=C/C=C/C2=[N+](CCCCS(O)(=O)=O)c3ccc4ccccc4c3C2(C)C)N(CCCCS(O)(=O)=O)c2ccc3ccccc3c12 |c:11|, CC1(C)\C(=C/C=C/C=C/C=C/C2=[N+](CCCCS(O)(=O)=O)c3ccc4ccccc4c3C2(C)C)N(CCCCS(O)(=O)=O)c2ccc3ccccc3c12 |c:11|	BDBMLMBYCXNVMC-UHFFFAOYSA-O, BDBMLMBYCXNVMC-UHFFFAOYSA-O, BDBMLMBYCXNVMC-UHFFFAOYSA-O, BDBMLMBYCXNVMC-UHFFFAOYSA-O	Launched
indole-3-carbinol	aryl hydrocarbon receptor agonist, indoleamine 2,3-dioxygenase inhibitor	AHR			OCc1c[nH]c2ccccc12, OCc1c[nH]c2ccccc12	IVYPNXXAYMYVSP-UHFFFAOYSA-N, IVYPNXXAYMYVSP-UHFFFAOYSA-N	Phase 2/Phase 3
indole-3-pyrubate	melatonin receptor agonist				OC(=O)C(O)=Cc1c[nH]c2ccccc12	KDCSRTPNDBPWQZ-UHFFFAOYSA-N	Phase 2
indomethacin	cyclooxygenase inhibitor	GLO1, PLA2G2A, PPARA, PPARG, PTGDR2, PTGR2, PTGS1, PTGS2, SLC46A1	rheumatology, orthopedics	rheumatoid arthritis, ankylosing spondylitis, osteoarthritis, bursitis, tendinitis	COc1ccc2n(C(=O)c3ccc(Cl)cc3)c(C)c(CC(O)=O)c2c1, COc1ccc2n(C(=O)c3ccc(Cl)cc3)c(C)c(CC(O)=O)c2c1, COc1ccc2n(C(=O)c3ccc(Cl)cc3)c(C)c(CC(O)=O)c2c1, COc1ccc2n(C(=O)c3ccc(Cl)cc3)c(C)c(CC(O)=O)c2c1	CGIGDMFJXJATDK-UHFFFAOYSA-N, CGIGDMFJXJATDK-UHFFFAOYSA-N, CGIGDMFJXJATDK-UHFFFAOYSA-N, CGIGDMFJXJATDK-UHFFFAOYSA-N	Launched
indoprofen	cyclooxygenase inhibitor, prostanoid receptor antagonist	CXCR1, CXCR2, PTGS1, PTGS2			C[C@@H](C(O)=O)c1ccc(cc1)N1Cc2ccccc2C1=O |&1:1,r|, C[C@@H](C(O)=O)c1ccc(cc1)N1Cc2ccccc2C1=O |&1:1,r|, C[C@@H](C(O)=O)c1ccc(cc1)N1Cc2ccccc2C1=O |&1:1,r|, C[C@@H](C(O)=O)c1ccc(cc1)N1Cc2ccccc2C1=O |&1:1,r|, C[C@@H](C(O)=O)c1ccc(cc1)N1Cc2ccccc2C1=O |&1:1,r|	RJMIEHBSYVWVIN-LLVKDONJSA-N, RJMIEHBSYVWVIN-LLVKDONJSA-N, RJMIEHBSYVWVIN-LLVKDONJSA-N, RJMIEHBSYVWVIN-LLVKDONJSA-N, RJMIEHBSYVWVIN-LLVKDONJSA-N	Withdrawn
indoramin	adrenergic receptor antagonist	ADRA1A, ADRA1B, ADRA1D, ADRA2B, ADRA2C	urology, cardiology	benign prostatic hyperplasia (BPH), hypertension	O=C(NC1CCN(CCc2c[nH]c3ccccc23)CC1)c1ccccc1, O=C(NC1CCN(CCc2c[nH]c3ccccc23)CC1)c1ccccc1, O=C(NC1CCN(CCc2c[nH]c3ccccc23)CC1)c1ccccc1	JXZZEXZZKAWDSP-UHFFFAOYSA-N, JXZZEXZZKAWDSP-UHFFFAOYSA-N, JXZZEXZZKAWDSP-UHFFFAOYSA-N	Launched
indoximod	indoleamine 2,3-dioxygenase inhibitor	IDO1			Cn1cc(C[C@@H](N)C(O)=O)c2ccccc12, Cn1cc(C[C@@H](N)C(O)=O)c2ccccc12, Cn1cc(C[C@@H](N)C(O)=O)c2ccccc12, Cn1cc(C[C@@H](N)C(O)=O)c2ccccc12	ZADWXFSZEAPBJS-SNVBAGLBSA-N, ZADWXFSZEAPBJS-SNVBAGLBSA-N, ZADWXFSZEAPBJS-SNVBAGLBSA-N, ZADWXFSZEAPBJS-SNVBAGLBSA-N	Phase 2
ingenol	PKC activator	PRKCD, PRKCE	dermatology	keratosis	[H][C@]12C=C(CO)[C@@H](O)[C@]3(O)[C@@H](O)C(C)=C[C@]3([C@H](C)C[C@@H]3[C@H]1C3(C)C)C2=O |c:13,t:2|	VEBVPUXQAPLADL-POYOOMFHSA-N	Launched
ingenol-mebutate	PKC activator	PRKCA, PRKCB, PRKCD, PRKCE, PRKCG	dermatology	actinic keratosis (AK)	C\C=C(\C)C(=O)O[C@H]1C(C)=C[C@@]23[C@H](C)C[C@@H]4[C@H]([C@H](C=C(CO)[C@@H](O)[C@]12O)C3=O)C4(C)C |c:9,t:18|, C\C=C(\C)C(=O)O[C@H]1C(C)=C[C@@]23[C@H](C)C[C@@H]4[C@H]([C@H](C=C(CO)[C@@H](O)[C@]12O)C3=O)C4(C)C |c:9,t:18|, C\C=C(\C)C(=O)O[C@H]1C(C)=C[C@@]23[C@H](C)C[C@@H]4[C@H]([C@H](C=C(CO)[C@@H](O)[C@]12O)C3=O)C4(C)C |c:9,t:18|, C\C=C(\C)C(=O)O[C@H]1C(C)=C[C@@]23[C@H](C)C[C@@H]4[C@H]([C@H](C=C(CO)[C@@H](O)[C@]12O)C3=O)C4(C)C |c:9,t:18|, C\C=C(\C)C(=O)O[C@H]1C(C)=C[C@@]23[C@H](C)C[C@@H]4[C@H]([C@H](C=C(CO)[C@@H](O)[C@]12O)C3=O)C4(C)C |c:9,t:18|, C\C=C(\C)C(=O)O[C@H]1C(C)=C[C@@]23[C@H](C)C[C@@H]4[C@H]([C@H](C=C(CO)[C@@H](O)[C@]12O)C3=O)C4(C)C |c:9,t:18|	VDJHFHXMUKFKET-WDUFCVPESA-N, VDJHFHXMUKFKET-WDUFCVPESA-N, VDJHFHXMUKFKET-WDUFCVPESA-N, VDJHFHXMUKFKET-WDUFCVPESA-N, VDJHFHXMUKFKET-WDUFCVPESA-N, VDJHFHXMUKFKET-WDUFCVPESA-N	Launched
INH1	Hec1 inhibitor	NDC80			Cc1ccc(-c2csc(NC(=O)c3ccccc3)n2)c(C)c1, Cc1ccc(-c2csc(NC(=O)c3ccccc3)n2)c(C)c1, Cc1ccc(-c2csc(NC(=O)c3ccccc3)n2)c(C)c1, Cc1ccc(-c2csc(NC(=O)c3ccccc3)n2)c(C)c1	JPMOKRWIYQGMJL-UHFFFAOYSA-N, JPMOKRWIYQGMJL-UHFFFAOYSA-N, JPMOKRWIYQGMJL-UHFFFAOYSA-N, JPMOKRWIYQGMJL-UHFFFAOYSA-N	Preclinical
inimur	other antifungal				CSC[C@H]1CN(\N=C\c2ccc(o2)[N+]([O-])=O)C(=O)O1 |&1:3,r|, CSC[C@H]1CN(\N=C\c2ccc(o2)[N+]([O-])=O)C(=O)O1 |&1:3,r|	SRQKTCXJCCHINN-ORMNHXAVSA-N, SRQKTCXJCCHINN-ORMNHXAVSA-N	Launched
iniparib	PARP inhibitor	PARP1			NC(=O)c1ccc(I)c(c1)[N+]([O-])=O, NC(=O)c1ccc(I)c(c1)[N+]([O-])=O, NC(=O)c1ccc(I)c(c1)[N+]([O-])=O	MDOJTZQKHMAPBK-UHFFFAOYSA-N, MDOJTZQKHMAPBK-UHFFFAOYSA-N, MDOJTZQKHMAPBK-UHFFFAOYSA-N	Phase 3
inosine	neurotrophic agent	PARP1, PNP			OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c1[nH]cnc2=O, OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c1[nH]cnc2=O, OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c1[nH]cnc2=O, OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c1[nH]cnc2=O	UGQMRVRMYYASKQ-KQYNXXCUSA-N, UGQMRVRMYYASKQ-KQYNXXCUSA-N, UGQMRVRMYYASKQ-KQYNXXCUSA-N, UGQMRVRMYYASKQ-KQYNXXCUSA-N	Launched
inositol	insulin sensitizer	CDIPT	obstetrics/gynecology	polycystic ovary syndrom (PCOS)	O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O, O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O	CDAISMWEOUEBRE-GPIVLXJGSA-N, CDAISMWEOUEBRE-GPIVLXJGSA-N	Launched
inositol-hexanicotinate			dermatology, cardiology, rheumatology, neurology/psychiatry	statis dermatitis, claudication, Raynaud's disease, hypertension, insomnia, atherosclerosis, restless leg syndrome, schizophrenia, psoriasis, acne vulgaris (AV)	O=C(O[C@H]1[C@H](OC(=O)c2cccnc2)[C@@H](OC(=O)c2cccnc2)[C@H](OC(=O)c2cccnc2)[C@H](OC(=O)c2cccnc2)[C@@H]1OC(=O)c1cccnc1)c1cccnc1, O=C(O[C@H]1[C@H](OC(=O)c2cccnc2)[C@@H](OC(=O)c2cccnc2)[C@H](OC(=O)c2cccnc2)[C@H](OC(=O)c2cccnc2)[C@@H]1OC(=O)c1cccnc1)c1cccnc1, O=C(O[C@H]1[C@H](OC(=O)c2cccnc2)[C@@H](OC(=O)c2cccnc2)[C@H](OC(=O)c2cccnc2)[C@H](OC(=O)c2cccnc2)[C@@H]1OC(=O)c1cccnc1)c1cccnc1	MFZCIDXOLLEMOO-GYSGTQPESA-N, MFZCIDXOLLEMOO-GYSGTQPESA-N, MFZCIDXOLLEMOO-GYSGTQPESA-N	Launched
INS316	purinergic receptor antagonist				O[C@H]1[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O[C@H]([C@@H]1O)n1ccc(=O)[nH]c1=O |a:2,18,&1:1,&2:5,&3:9,&4:19|	PGAVKCOVUIYSFO-PXBUCIJWSA-N	Phase 2
INT-747	FXR agonist				CC[C@H]1[C@@H](O)[C@H]2[C@@H]3CC[C@H]([C@H](C)CCC(O)=O)[C@@]3(C)CC[C@@H]2[C@@]2(C)CC[C@@H](O)C[C@@H]12, CC[C@H]1[C@@H](O)[C@H]2[C@@H]3CC[C@H]([C@H](C)CCC(O)=O)[C@@]3(C)CC[C@@H]2[C@@]2(C)CC[C@@H](O)C[C@@H]12	ZXERDUOLZKYMJM-ZWECCWDJSA-N, ZXERDUOLZKYMJM-ZWECCWDJSA-N	Phase 3
INT-767	FXR agonist	GPBAR1			CC[C@H]1[C@@H](O)[C@H]2[C@@H]3CC[C@H]([C@H](C)CCOS(O)(=O)=O)[C@@]3(C)CC[C@@H]2[C@@]2(C)CC[C@@H](O)C[C@@H]12, CC[C@H]1[C@@H](O)[C@H]2[C@@H]3CC[C@H]([C@H](C)CCOS(O)(=O)=O)[C@@]3(C)CC[C@@H]2[C@@]2(C)CC[C@@H](O)C[C@@H]12	XGIYOABXZNJOHV-APIYUPOTSA-N, XGIYOABXZNJOHV-APIYUPOTSA-N	Phase 1
integrin-antagonist-1	integrin antagonist	ITGAV, ITGB6			Cc1cc(C)n(n1)-c1cccc(c1)[C@@H](CN1CC[C@@H](CCc2ccc3CCCNc3n2)C1)CC(O)=O, Cc1cc(C)n(n1)-c1cccc(c1)[C@@H](CN1CC[C@@H](CCc2ccc3CCCNc3n2)C1)CC(O)=O	ZMXBIIQMSGOIRZ-RCZVLFRGSA-N, ZMXBIIQMSGOIRZ-RCZVLFRGSA-N	Phase 1
INX-08189	antiviral				[H][C@@](C)(N[P@](=O)(OC[C@@]1([H])O[C@@]([H])(n2cnc3c(OC)nc(N)nc23)[C@](C)(O)[C@]1([H])O)Oc1cccc2ccccc12)C(=O)OCC(C)(C)C |r|	YFXGICNMLCGLHJ-KGSOWIGMSA-N	Phase 2
iobenguane	antineoplastic agent		oncology, cardiology, endocrinology	neuroblastoma, congestive heart failure, pheochromocytoma	NC(=N)NCc1cccc(I)c1, NC(=N)NCc1cccc(I)c1, NC(=N)NCc1cccc(I)c1	PDWUPXJEEYOOTR-UHFFFAOYSA-N, PDWUPXJEEYOOTR-UHFFFAOYSA-N, PDWUPXJEEYOOTR-UHFFFAOYSA-N	Launched
iocetamic-acid	radiopaque medium		radiology	contrast agent	C[C@@H](CN(C(C)=O)c1c(I)cc(I)c(N)c1I)C(O)=O |&1:1,r|	GSVQIUGOUKJHRC-YFKPBYRVSA-N	Launched
iodipamide	radiopaque medium	ALB	radiology	contrast agent	OC(=O)c1c(I)cc(I)c(NC(=O)CCCCC(=O)Nc2c(I)cc(I)c(C(O)=O)c2I)c1I, OC(=O)c1c(I)cc(I)c(NC(=O)CCCCC(=O)Nc2c(I)cc(I)c(C(O)=O)c2I)c1I	FFINMCNLQNTKLU-UHFFFAOYSA-N, FFINMCNLQNTKLU-UHFFFAOYSA-N	Launched
iodixanol	radiopaque medium		radiology	contrast agent	CC(=O)N(CC(O)CN(C(C)=O)c1c(I)c(C(=O)NC[C@@H](O)CO)c(I)c(C(=O)NC[C@@H](O)CO)c1I)c1c(I)c(C(=O)NC[C@@H](O)CO)c(I)c(C(=O)NC[C@@H](O)CO)c1I |&1:20,&2:31,&3:45,&4:56,r|, CC(=O)N(CC(O)CN(C(C)=O)c1c(I)c(C(=O)NC[C@@H](O)CO)c(I)c(C(=O)NC[C@@H](O)CO)c1I)c1c(I)c(C(=O)NC[C@@H](O)CO)c(I)c(C(=O)NC[C@@H](O)CO)c1I |&1:20,&2:31,&3:45,&4:56,r|, CC(=O)N(CC(O)CN(C(C)=O)c1c(I)c(C(=O)NC[C@@H](O)CO)c(I)c(C(=O)NC[C@@H](O)CO)c1I)c1c(I)c(C(=O)NC[C@@H](O)CO)c(I)c(C(=O)NC[C@@H](O)CO)c1I |&1:20,&2:31,&3:45,&4:56,r|	NBQNWMBBSKPBAY-BRSBDYLESA-N, NBQNWMBBSKPBAY-BRSBDYLESA-N, NBQNWMBBSKPBAY-BRSBDYLESA-N	Launched
iodoantipyrine					Cc1c(I)c(=O)n(-c2ccccc2)n1C	ZZOBLCHCPLOXCE-UHFFFAOYSA-N	Preclinical
iododexetimide	acetylcholine receptor antagonist				Ic1ccc(CN2CCC(CC2)[C@]2(CCC(=O)NC2=O)c2ccccc2)cc1 |&1:12,r|, Ic1ccc(CN2CCC(CC2)[C@]2(CCC(=O)NC2=O)c2ccccc2)cc1 |&1:12,r|	WJLRTFJPHDSXAF-QHCPKHFHSA-N, WJLRTFJPHDSXAF-QHCPKHFHSA-N	Phase 2
iodophenpropit	histamine receptor antagonist	HRH3, HRH4			Ic1ccc(CCNC(=N)SCCCc2cnc[nH]2)cc1	UBHYDQAARZKHEZ-UHFFFAOYSA-N	Preclinical
iodoquinol	antiseptic		infectious disease	amebiasis	Oc1c(I)cc(I)c2cccnc12, Oc1c(I)cc(I)c2cccnc12, Oc1c(I)cc(I)c2cccnc12, Oc1c(I)cc(I)c2cccnc12	UXZFQZANDVDGMM-UHFFFAOYSA-N, UXZFQZANDVDGMM-UHFFFAOYSA-N, UXZFQZANDVDGMM-UHFFFAOYSA-N, UXZFQZANDVDGMM-UHFFFAOYSA-N	Launched
iohexol	radiopaque medium		radiology	contrast agent	CC(=O)N(C[C@@H](O)CO)c1c(I)c(C(=O)NC[C@@H](O)CO)c(I)c(C(=O)NC[C@@H](O)CO)c1I |&1:5,&2:17,&3:28,r|, CC(=O)N(C[C@@H](O)CO)c1c(I)c(C(=O)NC[C@@H](O)CO)c(I)c(C(=O)NC[C@@H](O)CO)c1I |&1:5,&2:17,&3:28,r|	NTHXOOBQLCIOLC-GMTAPVOTSA-N, NTHXOOBQLCIOLC-GMTAPVOTSA-N	Launched
iopamidol	radiopaque medium		radiology	contrast agent	C[C@H](O)C(=O)Nc1c(I)c(C(=O)NC(CO)CO)c(I)c(C(=O)NC(CO)CO)c1I, C[C@H](O)C(=O)Nc1c(I)c(C(=O)NC(CO)CO)c(I)c(C(=O)NC(CO)CO)c1I	XQZXYNRDCRIARQ-LURJTMIESA-N, XQZXYNRDCRIARQ-LURJTMIESA-N	Launched
iopanic-acid	thyroid hormone inhibitor				CC[C@@H](Cc1c(I)cc(I)c(N)c1I)C(O)=O |&1:2,r|, CC[C@@H](Cc1c(I)cc(I)c(N)c1I)C(O)=O |&1:2,r|	OIRFJRBSRORBCM-YFKPBYRVSA-N, OIRFJRBSRORBCM-YFKPBYRVSA-N	Withdrawn
iopodic-acid			radiology	contrast agent	CN(C)\C=N\c1c(I)cc(I)c(CCC(O)=O)c1I, CN(C)\C=N\c1c(I)cc(I)c(CCC(O)=O)c1I, CN(C)\C=N\c1c(I)cc(I)c(CCC(O)=O)c1I	YQNFBOJPTAXAKV-OMCISZLKSA-N, YQNFBOJPTAXAKV-OMCISZLKSA-N, YQNFBOJPTAXAKV-OMCISZLKSA-N	Launched
iopromide	radiopaque medium		radiology	contrast agent	COCC(=O)Nc1c(I)c(C(=O)NC[C@@H](O)CO)c(I)c(C(=O)N(C)C[C@@H](O)CO)c1I |&1:14,&2:26,r|, COCC(=O)Nc1c(I)c(C(=O)NC[C@@H](O)CO)c(I)c(C(=O)N(C)C[C@@H](O)CO)c1I |&1:14,&2:26,r|, COCC(=O)Nc1c(I)c(C(=O)NC[C@@H](O)CO)c(I)c(C(=O)N(C)C[C@@H](O)CO)c1I |&1:14,&2:26,r|	DGAIEPBNLOQYER-RKDXNWHRSA-N, DGAIEPBNLOQYER-RKDXNWHRSA-N, DGAIEPBNLOQYER-RKDXNWHRSA-N	Launched
iothalamic-acid-d3	radiopaque medium				CNC(=O)c1c(I)c(NC(C)=O)c(I)c(C(O)=O)c1I	UXIGWFXRQKWHHA-UHFFFAOYSA-N	Preclinical
ioversol	radiopaque medium		radiology	contrast agent	OCCN(C(=O)CO)c1c(I)c(C(=O)NC[C@@H](O)CO)c(I)c(C(=O)NC[C@@H](O)CO)c1I |&1:16,&2:27,r|, OCCN(C(=O)CO)c1c(I)c(C(=O)NC[C@@H](O)CO)c(I)c(C(=O)NC[C@@H](O)CO)c1I |&1:16,&2:27,r|	AMDBBAQNWSUWGN-RKDXNWHRSA-N, AMDBBAQNWSUWGN-RKDXNWHRSA-N	Launched
IOWH032	CFTR channel antagonist	CFTR			Oc1c(Br)cc(cc1Br)-c1noc(n1)C(=O)NCc1ccc(Oc2ccccc2)cc1, Oc1c(Br)cc(cc1Br)-c1noc(n1)C(=O)NCc1ccc(Oc2ccccc2)cc1, Oc1c(Br)cc(cc1Br)-c1noc(n1)C(=O)NCc1ccc(Oc2ccccc2)cc1, Oc1c(Br)cc(cc1Br)-c1noc(n1)C(=O)NCc1ccc(Oc2ccccc2)cc1	DSFNLJXHXBIKDS-UHFFFAOYSA-N, DSFNLJXHXBIKDS-UHFFFAOYSA-N, DSFNLJXHXBIKDS-UHFFFAOYSA-N, DSFNLJXHXBIKDS-UHFFFAOYSA-N	Phase 2
ioxaglic-acid	radiopaque medium		radiology	contrast agent	CNC(=O)c1c(I)c(N(C)C(C)=O)c(I)c(C(=O)NCC(=O)Nc2c(I)c(C(O)=O)c(I)c(C(=O)NCCO)c2I)c1I, CNC(=O)c1c(I)c(N(C)C(C)=O)c(I)c(C(=O)NCC(=O)Nc2c(I)c(C(O)=O)c(I)c(C(=O)NCCO)c2I)c1I	TYYBFXNZMFNZJT-UHFFFAOYSA-N, TYYBFXNZMFNZJT-UHFFFAOYSA-N	Launched
ioxilan	radiopaque medium		radiology	angiography	CC(=O)N(C[C@@H](O)CO)c1c(I)c(C(=O)NCCO)c(I)c(C(=O)NC[C@@H](O)CO)c1I |&1:5,&2:26,r|, CC(=O)N(C[C@@H](O)CO)c1c(I)c(C(=O)NCCO)c(I)c(C(=O)NC[C@@H](O)CO)c1I |&1:5,&2:26,r|, CC(=O)N(C[C@@H](O)CO)c1c(I)c(C(=O)NCCO)c(I)c(C(=O)NC[C@@H](O)CO)c1I |&1:5,&2:26,r|	UUMLTINZBQPNGF-NXEZZACHSA-N, UUMLTINZBQPNGF-NXEZZACHSA-N, UUMLTINZBQPNGF-NXEZZACHSA-N	Launched
IOX1	histone demethylase inhibitor	EGLN1, KDM3A, KDM4C, KDM6B			OC(=O)c1ccc(O)c2ncccc12, OC(=O)c1ccc(O)c2ncccc12	JGRPKOGHYBAVMW-UHFFFAOYSA-N, JGRPKOGHYBAVMW-UHFFFAOYSA-N	Preclinical
IOX2	hypoxia inducible factor inhibitor	EGLN1, KDM2A, KDM5C			OC(=O)CNC(=O)c1c(O)c2ccccc2n(Cc2ccccc2)c1=O, OC(=O)CNC(=O)c1c(O)c2ccccc2n(Cc2ccccc2)c1=O, OC(=O)CNC(=O)c1c(O)c2ccccc2n(Cc2ccccc2)c1=O, OC(=O)CNC(=O)c1c(O)c2ccccc2n(Cc2ccccc2)c1=O, OC(=O)CNC(=O)c1c(O)c2ccccc2n(Cc2ccccc2)c1=O	CAOSCCRYLYQBES-UHFFFAOYSA-N, CAOSCCRYLYQBES-UHFFFAOYSA-N, CAOSCCRYLYQBES-UHFFFAOYSA-N, CAOSCCRYLYQBES-UHFFFAOYSA-N, CAOSCCRYLYQBES-UHFFFAOYSA-N	Preclinical
IPA-3	p21 activated kinase inhibitor	PAK1			Oc1ccc2ccccc2c1SSc1c(O)ccc2ccccc12, Oc1ccc2ccccc2c1SSc1c(O)ccc2ccccc12, Oc1ccc2ccccc2c1SSc1c(O)ccc2ccccc12, Oc1ccc2ccccc2c1SSc1c(O)ccc2ccccc12	RFAXLXKIAKIUDT-UHFFFAOYSA-N, RFAXLXKIAKIUDT-UHFFFAOYSA-N, RFAXLXKIAKIUDT-UHFFFAOYSA-N, RFAXLXKIAKIUDT-UHFFFAOYSA-N	Preclinical
IPAG					Ic1ccc(NC(=N)NC2C3CC4CC(C3)CC2C4)cc1, Ic1ccc(NC(=N)NC2C3CC4CC(C3)CC2C4)cc1, Ic1ccc(NC(=N)NC2C3CC4CC(C3)CC2C4)cc1, Ic1ccc(NC(=N)NC2C3CC4CC(C3)CC2C4)cc1	UUKPIWYXWLJPJF-UHFFFAOYSA-N, UUKPIWYXWLJPJF-UHFFFAOYSA-N, UUKPIWYXWLJPJF-UHFFFAOYSA-N, UUKPIWYXWLJPJF-UHFFFAOYSA-N	Preclinical
ipidacrine	acetylcholinesterase inhibitor	ACHE			Nc1c2CCCc2nc2CCCCc12, Nc1c2CCCc2nc2CCCCc12	YLUSMKAJIQOXPV-UHFFFAOYSA-N, YLUSMKAJIQOXPV-UHFFFAOYSA-N	Phase 3
IPI549	PI3K inhibitor				C[C@H](NC(=O)c1c(N)nn2cccnc12)c1cc2cccc(C#Cc3cnn(C)c3)c2c(=O)n1-c1ccccc1	XUMALORDVCFWKV-IBGZPJMESA-N	Phase 2
ipragliflozin-L-proline	sodium/glucose cotransporter inhibitor	SLC5A2	endocrinology	diabetes mellitus	OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)c1ccc(F)c(Cc2cc3ccccc3s2)c1, OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)c1ccc(F)c(Cc2cc3ccccc3s2)c1, OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)c1ccc(F)c(Cc2cc3ccccc3s2)c1	AHFWIQIYAXSLBA-RQXATKFSSA-N, AHFWIQIYAXSLBA-RQXATKFSSA-N, AHFWIQIYAXSLBA-RQXATKFSSA-N	Launched
ipratropium	acetylcholine receptor antagonist	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5	pulmonary	bronchospasm, chronic obstructive pulmonary disease (COPD), bronchitis, emphysema	CC(C)[N@@+]1(C)[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)[C@@H](CO)c1ccccc1 |a:5,8,10,&1:3,&2:15,TLB:4:3:6.7:9.10.11,THB:1:3:6.7:9.10.11,12:10:3:6.7|	OEXHQOGQTVQTAT-KKKDIUQISA-N	Launched
ipriflavone	bone resorption inhibitor		orthopedics	osteoporosis	CC(C)Oc1ccc2c(c1)occ(-c1ccccc1)c2=O, CC(C)Oc1ccc2c(c1)occ(-c1ccccc1)c2=O, CC(C)Oc1ccc2c(c1)occ(-c1ccccc1)c2=O	SFBODOKJTYAUCM-UHFFFAOYSA-N, SFBODOKJTYAUCM-UHFFFAOYSA-N, SFBODOKJTYAUCM-UHFFFAOYSA-N	Launched
iproniazid	monoamine oxidase inhibitor	MAOA, MAOB			CC(C)NNC(=O)c1ccncc1, CC(C)NNC(=O)c1ccncc1, CC(C)NNC(=O)c1ccncc1	NYMGNSNKLVNMIA-UHFFFAOYSA-N, NYMGNSNKLVNMIA-UHFFFAOYSA-N, NYMGNSNKLVNMIA-UHFFFAOYSA-N	Withdrawn
ipsapirone	serotonin receptor agonist	HTR1A			O=C1N(CCCCN2CCN(CC2)c2ncccn2)S(=O)(=O)c2ccccc12, O=C1N(CCCCN2CCN(CC2)c2ncccn2)S(=O)(=O)c2ccccc12	TZJUVVIWVWFLCD-UHFFFAOYSA-N, TZJUVVIWVWFLCD-UHFFFAOYSA-N	Phase 3
irbesartan	angiotensin receptor antagonist	AGTR1, JUN, SLC10A1	cardiology, nephrology	hypertension, diabetic nephropathy	CCCCC1=NC2(CCCC2)C(=O)N1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1 |t:4|, CCCCC1=NC2(CCCC2)C(=O)N1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1 |t:4|, CCCCC1=NC2(CCCC2)C(=O)N1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1 |t:4|, CCCCC1=NC2(CCCC2)C(=O)N1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1 |t:4|, CCCCC1=NC2(CCCC2)C(=O)N1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1 |t:4|	YOSHYTLCDANDAN-UHFFFAOYSA-N, YOSHYTLCDANDAN-UHFFFAOYSA-N, YOSHYTLCDANDAN-UHFFFAOYSA-N, YOSHYTLCDANDAN-UHFFFAOYSA-N, YOSHYTLCDANDAN-UHFFFAOYSA-N	Launched
irganox-1010	antioxidant				CC(C)(C)c1cc(CCC(=O)OCC(COC(=O)CCc2cc(c(O)c(c2)C(C)(C)C)C(C)(C)C)(COC(=O)CCc2cc(c(O)c(c2)C(C)(C)C)C(C)(C)C)COC(=O)CCc2cc(c(O)c(c2)C(C)(C)C)C(C)(C)C)cc(c1O)C(C)(C)C	BGYHLZZASRKEJE-UHFFFAOYSA-N	Preclinical
iRGD-peptide	integrin signaling activator				[H][C@@]12CCCN1C(=O)CNC(=O)[C@H](CCCCN)NC(=O)[C@]([H])(CC(O)=O)NC(=O)CNC(=O)[C@]([H])(CCCNC(N)=N)NC(=O)[C@@H](N)CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC2=O)C(O)=O	YHTTWXCDIRTOQX-YDZOEDPBSA-N	Preclinical
irinotecan	topoisomerase inhibitor	TOP1, TOP1MT	oncology	colorectal cancer	CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12	UWKQSNNFCGGAFS-XIFFEERXSA-N, UWKQSNNFCGGAFS-XIFFEERXSA-N, UWKQSNNFCGGAFS-XIFFEERXSA-N, UWKQSNNFCGGAFS-XIFFEERXSA-N, UWKQSNNFCGGAFS-XIFFEERXSA-N, UWKQSNNFCGGAFS-XIFFEERXSA-N, UWKQSNNFCGGAFS-XIFFEERXSA-N, UWKQSNNFCGGAFS-XIFFEERXSA-N, UWKQSNNFCGGAFS-XIFFEERXSA-N	Launched
IRL-2500	endothelin receptor antagonist	EDNRB			CN([C@H](Cc1ccc(cc1)-c1ccccc1)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(O)=O)C(=O)c1cc(C)cc(C)c1, CN([C@H](Cc1ccc(cc1)-c1ccccc1)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(O)=O)C(=O)c1cc(C)cc(C)c1	UZDORQWMYRRLQV-JHOUSYSJSA-N, UZDORQWMYRRLQV-JHOUSYSJSA-N	Preclinical
irosustat	steroid sulfatase inhibitor	CA2, STS			NS(=O)(=O)Oc1ccc2c3CCCCCc3c(=O)oc2c1	DSLPMJSGSBLWRE-UHFFFAOYSA-N	Phase 2
irsogladine	phosphodiesterase inhibitor	PDE4A	gastroenterology	peptic ulcer disease (PUD)	Nc1nc(N)nc(n1)-c1cc(Cl)ccc1Cl, Nc1nc(N)nc(n1)-c1cc(Cl)ccc1Cl, Nc1nc(N)nc(n1)-c1cc(Cl)ccc1Cl, Nc1nc(N)nc(n1)-c1cc(Cl)ccc1Cl, Nc1nc(N)nc(n1)-c1cc(Cl)ccc1Cl	ATCGGEJZONJOCL-UHFFFAOYSA-N, ATCGGEJZONJOCL-UHFFFAOYSA-N, ATCGGEJZONJOCL-UHFFFAOYSA-N, ATCGGEJZONJOCL-UHFFFAOYSA-N, ATCGGEJZONJOCL-UHFFFAOYSA-N	Launched
isamoltane	adrenergic receptor antagonist	HTR1A, HTR1B			CC(C)NC[C@@H](O)COc1ccccc1-n1cccc1 |&1:5|, CC(C)NC[C@@H](O)COc1ccccc1-n1cccc1 |&1:5|	XVTVPGKWYHWYAD-CQSZACIVSA-N, XVTVPGKWYHWYAD-CQSZACIVSA-N	Phase 1
isavuconazole	cytochrome P450 inhibitor	CYP3A4			C[C@@H](c1nc(cs1)-c1ccc(cc1)C#N)[C@@](O)(Cn1cncn1)c1cc(F)ccc1F |a:1,&1:15|	DDFOUSQFMYRUQK-FPTDNZKUSA-N	Phase 3
isaxonine	nerve growth factor agonist				CC(C)Nc1ncccn1, CC(C)Nc1ncccn1	FTCYIGBVOHNHCD-UHFFFAOYSA-N, FTCYIGBVOHNHCD-UHFFFAOYSA-N	Withdrawn
isbufylline	phosphodiesterase inhibitor				CC(C)Cn1cnc2n(C)c(=O)n(C)c(=O)c12, CC(C)Cn1cnc2n(C)c(=O)n(C)c(=O)c12, CC(C)Cn1cnc2n(C)c(=O)n(C)c(=O)c12	WHUWQSQEVISUMC-UHFFFAOYSA-N, WHUWQSQEVISUMC-UHFFFAOYSA-N, WHUWQSQEVISUMC-UHFFFAOYSA-N	Phase 2
isepamicin	protein synthesis inhibitor		infectious disease	pneumonia, peritonitis	CN[C@@H]1[C@@H](O)[C@@H](O[C@H]2[C@@H](C[C@H](N)[C@@H](O[C@H]3O[C@H](CN)[C@@H](O)[C@H](O)[C@H]3O)[C@@H]2O)NC(=O)[C@@H](O)CN)OC[C@]1(C)O, CN[C@@H]1[C@@H](O)[C@@H](O[C@H]2[C@@H](C[C@H](N)[C@@H](O[C@H]3O[C@H](CN)[C@@H](O)[C@H](O)[C@H]3O)[C@@H]2O)NC(=O)[C@@H](O)CN)OC[C@]1(C)O	UDIIBEDMEYAVNG-ZKFPOVNWSA-N, UDIIBEDMEYAVNG-ZKFPOVNWSA-N	Launched
ISO-1	macrophage migration inhibiting factor inhibitor	MIF			COC(=O)C[C@H]1CC(=NO1)c1ccc(O)cc1 |&1:5,r,c:7|, COC(=O)C[C@H]1CC(=NO1)c1ccc(O)cc1 |&1:5,r,c:7|	AIXMJTYHQHQJLU-SNVBAGLBSA-N, AIXMJTYHQHQJLU-SNVBAGLBSA-N	Preclinical
isobutamben	local anesthetic				CC(C)COC(=O)c1ccc(N)cc1, CC(C)COC(=O)c1ccc(N)cc1	PUYOAVGNCWPANW-UHFFFAOYSA-N, PUYOAVGNCWPANW-UHFFFAOYSA-N	Preclinical
isobutyramide	gene expression stimulant	HBE1, HBG1			CC(C)C(N)=O	WFKAJVHLWXSISD-UHFFFAOYSA-N	Phase 2
isocarboxazid	monoamine oxidase inhibitor	MAOA, MAOB	neurology/psychiatry	depression	Cc1cc(no1)C(=O)NNCc1ccccc1, Cc1cc(no1)C(=O)NNCc1ccccc1, Cc1cc(no1)C(=O)NNCc1ccccc1, Cc1cc(no1)C(=O)NNCc1ccccc1, Cc1cc(no1)C(=O)NNCc1ccccc1	XKFPYPQQHFEXRZ-UHFFFAOYSA-N, XKFPYPQQHFEXRZ-UHFFFAOYSA-N, XKFPYPQQHFEXRZ-UHFFFAOYSA-N, XKFPYPQQHFEXRZ-UHFFFAOYSA-N, XKFPYPQQHFEXRZ-UHFFFAOYSA-N	Launched
isoconazole	fungal lanosterol demethylase inhibitor	CYP17A1	infectious disease	gram-positive bacterial infections	Clc1ccc([C@@H](Cn2ccnc2)OCc2c(Cl)cccc2Cl)c(Cl)c1 |&1:5|, Clc1ccc([C@@H](Cn2ccnc2)OCc2c(Cl)cccc2Cl)c(Cl)c1 |&1:5|	MPIPASJGOJYODL-GOSISDBHSA-N, MPIPASJGOJYODL-GOSISDBHSA-N	Launched
isodibut	aldehyde reductase inhibitor				OC(=O)CCCN1C(=O)c2cccc3cccc(C1=O)c23, OC(=O)CCCN1C(=O)c2cccc3cccc(C1=O)c23, OC(=O)CCCN1C(=O)c2cccc3cccc(C1=O)c23	ZHXRDXTYPCPBTI-UHFFFAOYSA-N, ZHXRDXTYPCPBTI-UHFFFAOYSA-N, ZHXRDXTYPCPBTI-UHFFFAOYSA-N	Phase 2
isoetharine	adrenergic receptor agonist		pulmonary	bronchospasm, asthma	CC[C@@H](NC(C)C)[C@@H](O)c1ccc(O)c(O)c1 |&1:2,&2:7|, CC[C@@H](NC(C)C)[C@@H](O)c1ccc(O)c(O)c1 |&1:2,&2:7|, CC[C@@H](NC(C)C)[C@@H](O)c1ccc(O)c(O)c1 |&1:2,&2:7|, CC[C@@H](NC(C)C)[C@@H](O)c1ccc(O)c(O)c1 |&1:2,&2:7|	HUYWAWARQUIQLE-MFKMUULPSA-N, HUYWAWARQUIQLE-MFKMUULPSA-N, HUYWAWARQUIQLE-MFKMUULPSA-N, HUYWAWARQUIQLE-MFKMUULPSA-N	Launched
isofloxythepin	dopamine receptor antagonist				CC(C)c1ccc2Sc3cc(F)ccc3C[C@@H](N3CCN(CCO)CC3)c2c1 |&1:16,r|, CC(C)c1ccc2Sc3cc(F)ccc3C[C@@H](N3CCN(CCO)CC3)c2c1 |&1:16,r|, CC(C)c1ccc2Sc3cc(F)ccc3C[C@@H](N3CCN(CCO)CC3)c2c1 |&1:16,r|	XDBMBHVYXPBOPL-OAQYLSRUSA-N, XDBMBHVYXPBOPL-OAQYLSRUSA-N, XDBMBHVYXPBOPL-OAQYLSRUSA-N	Phase 2
isoflupredone-acetate		NR3C1			CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C |c:19,t:15|, CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C |c:19,t:15|, CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C |c:19,t:15|	ZOCUOMKMBMEYQV-GSLJADNHSA-N, ZOCUOMKMBMEYQV-GSLJADNHSA-N, ZOCUOMKMBMEYQV-GSLJADNHSA-N	Preclinical
isoflurane	inhaled anaesthetic	GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, GLRA1, GLRB, KCNK10, KCNK18, KCNK2, KCNK3, KCNK9	neurology/psychiatry	general anaesthetic	FC(F)O[C@@H](Cl)C(F)(F)F |&1:4,r|, FC(F)O[C@@H](Cl)C(F)(F)F |&1:4,r|	PIWKPBJCKXDKJR-PVQJCKRUSA-N, PIWKPBJCKXDKJR-PVQJCKRUSA-N	Launched
isoflurophate	cholinesterase inhibitor	ACHE, BCHE	ophthalmology	glaucoma	CC(C)OP(F)(=O)OC(C)C, CC(C)OP(F)(=O)OC(C)C, CC(C)OP(F)(=O)OC(C)C	MUCZHBLJLSDCSD-UHFFFAOYSA-N, MUCZHBLJLSDCSD-UHFFFAOYSA-N, MUCZHBLJLSDCSD-UHFFFAOYSA-N	Launched
isoguvacine	benzodiazepine receptor agonist	GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRR1, GABRR2, GABRR3			OC(=O)C1=CCNCC1 |t:3|, OC(=O)C1=CCNCC1 |t:3|, OC(=O)C1=CCNCC1 |t:3|	KRVDMABBKYMBHG-UHFFFAOYSA-N, KRVDMABBKYMBHG-UHFFFAOYSA-N, KRVDMABBKYMBHG-UHFFFAOYSA-N	Preclinical
isoleucine					CC[C@@H](C)[C@@H](N)C(O)=O |&1:2,&2:4,r|	AGPKZVBTJJNPAG-RFZPGFLSSA-N	Launched
isoliquiritigenin	guanylate cyclase activator	GABBR1			Oc1ccc(\C=C\C(=O)c2ccc(O)cc2O)cc1, Oc1ccc(\C=C\C(=O)c2ccc(O)cc2O)cc1	DXDRHHKMWQZJHT-FPYGCLRLSA-N, DXDRHHKMWQZJHT-FPYGCLRLSA-N	Preclinical
isometheptene-mucate			neurology/psychiatry	headache	CN[C@@H](C)CCC=C(C)C |&1:2,r|	XVQUOJBERHHONY-VIFPVBQESA-N	Launched
isoniazid	FABI inhibitor	CYP1A2, CYP2C19, CYP2C8, CYP2E1, CYP3A4	infectious disease	tuberculosis	NNC(=O)c1ccncc1, NNC(=O)c1ccncc1, NNC(=O)c1ccncc1, NNC(=O)c1ccncc1, NNC(=O)c1ccncc1	QRXWMOHMRWLFEY-UHFFFAOYSA-N, QRXWMOHMRWLFEY-UHFFFAOYSA-N, QRXWMOHMRWLFEY-UHFFFAOYSA-N, QRXWMOHMRWLFEY-UHFFFAOYSA-N, QRXWMOHMRWLFEY-UHFFFAOYSA-N	Launched
isopentyl-4-methoxycinnamate			dermatology	sunscreen lotion	COc1ccc(\C=C\C(=O)OCCC(C)C)cc1, COc1ccc(\C=C\C(=O)OCCC(C)C)cc1	UBNYRXMKIIGMKK-RMKNXTFCSA-N, UBNYRXMKIIGMKK-RMKNXTFCSA-N	Launched
isoprenaline	adrenergic receptor agonist	ADRB1, ADRB2, ADRB3	cardiology, pulmonary	bradycardia, heart block, asthma	CC(C)NC[C@@H](O)c1ccc(O)c(O)c1 |&1:5|, CC(C)NC[C@@H](O)c1ccc(O)c(O)c1 |&1:5|, CC(C)NC[C@@H](O)c1ccc(O)c(O)c1 |&1:5|, CC(C)NC[C@@H](O)c1ccc(O)c(O)c1 |&1:5|, CC(C)NC[C@@H](O)c1ccc(O)c(O)c1 |&1:5|	JWZZKOKVBUJMES-LLVKDONJSA-N, JWZZKOKVBUJMES-LLVKDONJSA-N, JWZZKOKVBUJMES-LLVKDONJSA-N, JWZZKOKVBUJMES-LLVKDONJSA-N, JWZZKOKVBUJMES-LLVKDONJSA-N	Launched
isopropamide-iodide	acetylcholine receptor antagonist	CHRM3, CHRM4	gastroenterology	peptic ulcer disease (PUD), gastrointestinal acidosis	CC(C)[N+](C)(CCC(C(N)=O)(c1ccccc1)c1ccccc1)C(C)C, CC(C)[N+](C)(CCC(C(N)=O)(c1ccccc1)c1ccccc1)C(C)C, CC(C)[N+](C)(CCC(C(N)=O)(c1ccccc1)c1ccccc1)C(C)C, CC(C)[N+](C)(CCC(C(N)=O)(c1ccccc1)c1ccccc1)C(C)C, CC(C)[N+](C)(CCC(C(N)=O)(c1ccccc1)c1ccccc1)C(C)C	JTPUMZTWMWIVPA-UHFFFAOYSA-O, JTPUMZTWMWIVPA-UHFFFAOYSA-O, JTPUMZTWMWIVPA-UHFFFAOYSA-O, JTPUMZTWMWIVPA-UHFFFAOYSA-O, JTPUMZTWMWIVPA-UHFFFAOYSA-O	Launched
isopropyl-myristate			dermatology	cosmetic	CCCCCCCCCCCCCC(=O)OC(C)C, CCCCCCCCCCCCCC(=O)OC(C)C, CCCCCCCCCCCCCC(=O)OC(C)C	AXISYYRBXTVTFY-UHFFFAOYSA-N, AXISYYRBXTVTFY-UHFFFAOYSA-N, AXISYYRBXTVTFY-UHFFFAOYSA-N	Launched
isopropyl-palmitate	cosmetic moisturizer		dermatology	cosmetic	CCCCCCCCCCCCCCCC(=O)OC(C)C, CCCCCCCCCCCCCCCC(=O)OC(C)C	XUGNVMKQXJXZCD-UHFFFAOYSA-N, XUGNVMKQXJXZCD-UHFFFAOYSA-N	Launched
isoquercitrin	antioxidant				OC[C@H]1O[C@@H](Oc2c(oc3cc(O)cc(O)c3c2=O)-c2ccc(O)c(O)c2)[C@H](O)[C@@H](O)[C@@H]1O	OVSQVDMCBVZWGM-QSOFNFLRSA-N	Phase 2/Phase 3
Isoquinoline,-6,7-dimethoxy-1-methyl-1,2,3,4-tetrahydro,					COc1cc2CCN[C@@H](C)c2cc1OC |&1:8|, COc1cc2CCN[C@@H](C)c2cc1OC |&1:8|	HMYJLVDKPJHJCF-QMMMGPOBSA-N, HMYJLVDKPJHJCF-QMMMGPOBSA-N	Preclinical
isosorbide	nitric oxide stimulant		cardiology	angina pectoris, coronary artery disease (CAD)	O[C@H]1CO[C@@H]2[C@H](O)CO[C@H]12, O[C@H]1CO[C@@H]2[C@H](O)CO[C@H]12, O[C@H]1CO[C@@H]2[C@H](O)CO[C@H]12, O[C@H]1CO[C@@H]2[C@H](O)CO[C@H]12, O[C@H]1CO[C@@H]2[C@H](O)CO[C@H]12, O[C@H]1CO[C@@H]2[C@H](O)CO[C@H]12	KLDXJTOLSGUMSJ-JGWLITMVSA-N, KLDXJTOLSGUMSJ-JGWLITMVSA-N, KLDXJTOLSGUMSJ-JGWLITMVSA-N, KLDXJTOLSGUMSJ-JGWLITMVSA-N, KLDXJTOLSGUMSJ-JGWLITMVSA-N, KLDXJTOLSGUMSJ-JGWLITMVSA-N	Launched
isosorbide-dinitrate	nitric oxide stimulant	GUCY1A2, GUCY1A3, GUCY1B2, GUCY1B3, NPR1	cardiology	angina pectoris, coronary artery disease (CAD)	[O-][N+](=O)O[C@@H]1CO[C@@H]2[C@H](CO[C@H]12)O[N+]([O-])=O, [O-][N+](=O)O[C@@H]1CO[C@@H]2[C@H](CO[C@H]12)O[N+]([O-])=O, [O-][N+](=O)O[C@@H]1CO[C@@H]2[C@H](CO[C@H]12)O[N+]([O-])=O	MOYKHGMNXAOIAT-JGWLITMVSA-N, MOYKHGMNXAOIAT-JGWLITMVSA-N, MOYKHGMNXAOIAT-JGWLITMVSA-N	Launched
isosorbide-mononitrate	nitric oxide stimulant	GUCY1A2, GUCY1A3, GUCY1B2, GUCY1B3	cardiology	angina pectoris, coronary artery disease (CAD)	O[C@H]1CO[C@@H]2[C@@H](CO[C@H]12)O[N+]([O-])=O, O[C@H]1CO[C@@H]2[C@@H](CO[C@H]12)O[N+]([O-])=O, O[C@H]1CO[C@@H]2[C@@H](CO[C@H]12)O[N+]([O-])=O	YWXYYJSYQOXTPL-SLPGGIOYSA-N, YWXYYJSYQOXTPL-SLPGGIOYSA-N, YWXYYJSYQOXTPL-SLPGGIOYSA-N	Launched
isosteviol					C[C@]12C[C@@]3(CC1=O)CC[C@H]1[C@@](C)(CCC[C@@]1(C)C(O)=O)[C@@H]3CC2 |a:1,3,9,10,15,&1:20|	KFVUFODCZDRVSS-XGBBNYNSSA-N	Phase 2
isotiquimide					Cc1ccnc2[C@@H](CCCc12)C(N)=S |&1:6,r|, Cc1ccnc2[C@@H](CCCc12)C(N)=S |&1:6,r|	PWPWEYFVLITGNU-SECBINFHSA-N, PWPWEYFVLITGNU-SECBINFHSA-N	Phase 1
isotretinoin	retinoid receptor agonist	RARA, RARB, RARG	dermatology	acne vulgaris (AV)	C\C(\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C\C(O)=O |c:4|, C\C(\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C\C(O)=O |c:4|, C\C(\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C\C(O)=O |c:4|, C\C(\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C\C(O)=O |c:4|, C\C(\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C\C(O)=O |c:4|	SHGAZHPCJJPHSC-XFYACQKRSA-N, SHGAZHPCJJPHSC-XFYACQKRSA-N, SHGAZHPCJJPHSC-XFYACQKRSA-N, SHGAZHPCJJPHSC-XFYACQKRSA-N, SHGAZHPCJJPHSC-XFYACQKRSA-N	Launched
isovaleramide	alcohol dehydrogenase inhibitor				CC(C)CC(N)=O, CC(C)CC(N)=O, CC(C)CC(N)=O, CC(C)CC(N)=O, CC(C)CC(N)=O	SANOUVWGPVYVAV-UHFFFAOYSA-N, SANOUVWGPVYVAV-UHFFFAOYSA-N, SANOUVWGPVYVAV-UHFFFAOYSA-N, SANOUVWGPVYVAV-UHFFFAOYSA-N, SANOUVWGPVYVAV-UHFFFAOYSA-N	Phase 2
isoxepac	anti-inflammatory agent				OC(=O)Cc1ccc2OCc3ccccc3C(=O)c2c1	QFGMXJOBTNZHEL-UHFFFAOYSA-N	Phase 2
isoxicam	cyclooxygenase inhibitor	PTGS1, PTGS2			CN1C(C(=O)Nc2cc(C)on2)=C(O)c2ccccc2S1(=O)=O |t:12|, CN1C(C(=O)Nc2cc(C)on2)=C(O)c2ccccc2S1(=O)=O |t:12|, CN1C(C(=O)Nc2cc(C)on2)=C(O)c2ccccc2S1(=O)=O |t:12|	YYUAYBYLJSNDCX-UHFFFAOYSA-N, YYUAYBYLJSNDCX-UHFFFAOYSA-N, YYUAYBYLJSNDCX-UHFFFAOYSA-N	Withdrawn
isoxsuprine	adrenergic receptor agonist	ADRB2	rheumatology, cardiology	Raynaud's disease, arteriosclerosis, Buerger's disease	C[C@@H](COc1ccccc1)N[C@H](C)[C@@H](O)c1ccc(O)cc1 |&1:13,&2:11,&3:1|, C[C@@H](COc1ccccc1)N[C@H](C)[C@@H](O)c1ccc(O)cc1 |&1:13,&2:11,&3:1|	BMUKKTUHUDJSNZ-PMUMKWKESA-N, BMUKKTUHUDJSNZ-PMUMKWKESA-N	Launched
ispinesib	kinesin inhibitor	KIF11			CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1nc2cc(Cl)ccc2c(=O)n1Cc1ccccc1, CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1nc2cc(Cl)ccc2c(=O)n1Cc1ccccc1, CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1nc2cc(Cl)ccc2c(=O)n1Cc1ccccc1, CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1nc2cc(Cl)ccc2c(=O)n1Cc1ccccc1, CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1nc2cc(Cl)ccc2c(=O)n1Cc1ccccc1, CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1nc2cc(Cl)ccc2c(=O)n1Cc1ccccc1, CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1nc2cc(Cl)ccc2c(=O)n1Cc1ccccc1, CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1nc2cc(Cl)ccc2c(=O)n1Cc1ccccc1	QJZRFPJCWMNVAV-HHHXNRCGSA-N, QJZRFPJCWMNVAV-HHHXNRCGSA-N, QJZRFPJCWMNVAV-HHHXNRCGSA-N, QJZRFPJCWMNVAV-HHHXNRCGSA-N, QJZRFPJCWMNVAV-HHHXNRCGSA-N, QJZRFPJCWMNVAV-HHHXNRCGSA-N, QJZRFPJCWMNVAV-HHHXNRCGSA-N, QJZRFPJCWMNVAV-HHHXNRCGSA-N	Phase 2
isradipine	calcium channel blocker	CACNA1D, CACNA1F, CACNA2D1	cardiology	hypertension	COC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc2nonc12)C(=O)OC(C)C |r,c:4,9|, COC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc2nonc12)C(=O)OC(C)C |r,c:4,9|, COC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc2nonc12)C(=O)OC(C)C |r,c:4,9|, COC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc2nonc12)C(=O)OC(C)C |r,c:4,9|, COC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc2nonc12)C(=O)OC(C)C |r,c:4,9|, COC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc2nonc12)C(=O)OC(C)C |r,c:4,9|	HMJIYCCIJYRONP-MRXNPFEDSA-N, HMJIYCCIJYRONP-MRXNPFEDSA-N, HMJIYCCIJYRONP-MRXNPFEDSA-N, HMJIYCCIJYRONP-MRXNPFEDSA-N, HMJIYCCIJYRONP-MRXNPFEDSA-N, HMJIYCCIJYRONP-MRXNPFEDSA-N	Launched
ISRIB	eukaryotic translation initiation factor inhibitor, PERK inhibitor	EIF2A, EIF2AK3			Clc1ccc(OCC(=O)N[C@H]2CC[C@@H](CC2)NC(=O)COc2ccc(Cl)cc2)cc1 |r|, Clc1ccc(OCC(=O)N[C@H]2CC[C@@H](CC2)NC(=O)COc2ccc(Cl)cc2)cc1 |r|, Clc1ccc(OCC(=O)N[C@H]2CC[C@@H](CC2)NC(=O)COc2ccc(Cl)cc2)cc1 |r|	HJGMCDHQPXTGAV-IYARVYRRSA-N, HJGMCDHQPXTGAV-IYARVYRRSA-N, HJGMCDHQPXTGAV-IYARVYRRSA-N	Preclinical
istaroxime	ATPase inhibitor	ATP1A1			C[C@]12CC[C@H]3[C@@H](CC(=O)[C@H]4C\C(CC[C@]34C)=N\OCCN)[C@@H]1CCC2=O, C[C@]12CC[C@H]3[C@@H](CC(=O)[C@H]4C\C(CC[C@]34C)=N\OCCN)[C@@H]1CCC2=O, C[C@]12CC[C@H]3[C@@H](CC(=O)[C@H]4C\C(CC[C@]34C)=N\OCCN)[C@@H]1CCC2=O, C[C@]12CC[C@H]3[C@@H](CC(=O)[C@H]4C\C(CC[C@]34C)=N\OCCN)[C@@H]1CCC2=O, C[C@]12CC[C@H]3[C@@H](CC(=O)[C@H]4C\C(CC[C@]34C)=N\OCCN)[C@@H]1CCC2=O	MPYLDWFDPHRTEG-PAAYLBSLSA-N, MPYLDWFDPHRTEG-PAAYLBSLSA-N, MPYLDWFDPHRTEG-PAAYLBSLSA-N, MPYLDWFDPHRTEG-PAAYLBSLSA-N, MPYLDWFDPHRTEG-PAAYLBSLSA-N	Phase 2
istradefylline	adenosine receptor antagonist	ADORA1, ADORA2A, ADORA2B, ADORA3	neurology/psychiatry	Parkinson's Disease, dyskinesia	CCn1c2nc(\C=C\c3ccc(OC)c(OC)c3)n(C)c2c(=O)n(CC)c1=O, CCn1c2nc(\C=C\c3ccc(OC)c(OC)c3)n(C)c2c(=O)n(CC)c1=O, CCn1c2nc(\C=C\c3ccc(OC)c(OC)c3)n(C)c2c(=O)n(CC)c1=O, CCn1c2nc(\C=C\c3ccc(OC)c(OC)c3)n(C)c2c(=O)n(CC)c1=O, CCn1c2nc(\C=C\c3ccc(OC)c(OC)c3)n(C)c2c(=O)n(CC)c1=O, CCn1c2nc(\C=C\c3ccc(OC)c(OC)c3)n(C)c2c(=O)n(CC)c1=O, CCn1c2nc(\C=C\c3ccc(OC)c(OC)c3)n(C)c2c(=O)n(CC)c1=O	IQVRBWUUXZMOPW-PKNBQFBNSA-N, IQVRBWUUXZMOPW-PKNBQFBNSA-N, IQVRBWUUXZMOPW-PKNBQFBNSA-N, IQVRBWUUXZMOPW-PKNBQFBNSA-N, IQVRBWUUXZMOPW-PKNBQFBNSA-N, IQVRBWUUXZMOPW-PKNBQFBNSA-N, IQVRBWUUXZMOPW-PKNBQFBNSA-N	Launched
ISX-9	neural stem cell inducer	NEUROD1			O=C(NC1CC1)c1cc(on1)-c1cccs1, O=C(NC1CC1)c1cc(on1)-c1cccs1, O=C(NC1CC1)c1cc(on1)-c1cccs1, O=C(NC1CC1)c1cc(on1)-c1cccs1, O=C(NC1CC1)c1cc(on1)-c1cccs1, O=C(NC1CC1)c1cc(on1)-c1cccs1	SYENTKHGMVKGAQ-UHFFFAOYSA-N, SYENTKHGMVKGAQ-UHFFFAOYSA-N, SYENTKHGMVKGAQ-UHFFFAOYSA-N, SYENTKHGMVKGAQ-UHFFFAOYSA-N, SYENTKHGMVKGAQ-UHFFFAOYSA-N, SYENTKHGMVKGAQ-UHFFFAOYSA-N	Preclinical
itacitinib	JAK inhibitor	JAK1			Fc1c(ccnc1C(F)(F)F)C(=O)N1CCC(CC1)N1CC(CC#N)(C1)n1cc(cn1)-c1ncnc2[nH]ccc12, Fc1c(ccnc1C(F)(F)F)C(=O)N1CCC(CC1)N1CC(CC#N)(C1)n1cc(cn1)-c1ncnc2[nH]ccc12	KTBSXLIQKWEBRB-UHFFFAOYSA-N, KTBSXLIQKWEBRB-UHFFFAOYSA-N	Phase 3
ITD-1	TGF beta receptor inhibitor	TGFBR2			CCOC(=O)C1=C(C)NC2=C([C@@H]1c1ccc(cc1)-c1ccccc1)C(=O)CC(C)(C)C2 |&1:11,r,c:5,9|, CCOC(=O)C1=C(C)NC2=C([C@@H]1c1ccc(cc1)-c1ccccc1)C(=O)CC(C)(C)C2 |&1:11,r,c:5,9|	ULFUJLFTRWWLPO-XMMPIXPASA-N, ULFUJLFTRWWLPO-XMMPIXPASA-N	Preclinical
ITE	aryl hydrocarbon receptor agonist	AHR			COC(=O)c1csc(n1)C(=O)c1c[nH]c2ccccc12, COC(=O)c1csc(n1)C(=O)c1c[nH]c2ccccc12, COC(=O)c1csc(n1)C(=O)c1c[nH]c2ccccc12	KDDXOGDIPZSCTM-UHFFFAOYSA-N, KDDXOGDIPZSCTM-UHFFFAOYSA-N, KDDXOGDIPZSCTM-UHFFFAOYSA-N	Preclinical
ITI214	phosphodiesterase inhibitor	PDE1A			CN1C2=N[C@@H]3CCC[C@@H]3N2c2nn(Cc3ccc(cc3)-c3cccc(F)n3)c(Nc3ccccc3)c2C1=O |t:2|, CN1C2=N[C@@H]3CCC[C@@H]3N2c2nn(Cc3ccc(cc3)-c3cccc(F)n3)c(Nc3ccccc3)c2C1=O |t:2|, CN1C2=N[C@@H]3CCC[C@@H]3N2c2nn(Cc3ccc(cc3)-c3cccc(F)n3)c(Nc3ccccc3)c2C1=O |t:2|	BBIPVJCGIASXJB-PKTZIBPZSA-N, BBIPVJCGIASXJB-PKTZIBPZSA-N, BBIPVJCGIASXJB-PKTZIBPZSA-N	Phase 1/Phase 2
itopride	dopamine receptor antagonist	CHRM3, DRD2	gastroenterology, neurology/psychiatry	dyspepsia, gastroparesis, heartburn, nausea, vomiting, anorexia	COc1ccc(cc1OC)C(=O)NCc1ccc(OCCN(C)C)cc1, COc1ccc(cc1OC)C(=O)NCc1ccc(OCCN(C)C)cc1, COc1ccc(cc1OC)C(=O)NCc1ccc(OCCN(C)C)cc1, COc1ccc(cc1OC)C(=O)NCc1ccc(OCCN(C)C)cc1, COc1ccc(cc1OC)C(=O)NCc1ccc(OCCN(C)C)cc1	QQQIECGTIMUVDS-UHFFFAOYSA-N, QQQIECGTIMUVDS-UHFFFAOYSA-N, QQQIECGTIMUVDS-UHFFFAOYSA-N, QQQIECGTIMUVDS-UHFFFAOYSA-N, QQQIECGTIMUVDS-UHFFFAOYSA-N	Launched
itraconazole	cytochrome P450 inhibitor		infectious disease	onychomycosis, histoplasmosis, blastomycosis, aspergillosis	CC[C@H](C)n1ncn(-c2ccc(cc2)N2CCN(CC2)c2ccc(OC[C@H]3CO[C@@](Cn4cncn4)(O3)c3ccc(Cl)cc3Cl)cc2)c1=O |&1:26,29,&2:2|	VHVPQPYKVGDNFY-TUJWMRSMSA-N	Launched
ITX3	GEF inhibitor	TRIO			Cc1cc(\C=c2\sc3nc4ccccc4n3c2=O)c(C)n1-c1ccccc1, Cc1cc(\C=c2\sc3nc4ccccc4n3c2=O)c(C)n1-c1ccccc1	SJMYMKPBODEZSH-DEDYPNTBSA-N, SJMYMKPBODEZSH-DEDYPNTBSA-N	Preclinical
ITX5061	SR-BI inhibitor				COc1c(NC(=O)C(=O)c2ccc(OCCN3CCOCC3)c3ccccc23)cc(cc1NS(C)(=O)=O)C(C)(C)C	UUROSJLZNDSXRF-UHFFFAOYSA-N	Phase 1
IT1t	CC chemokine receptor antagonist	CXCR4			CC1(C)CN2C(CS\C(NC3CCCCC3)=N\C3CCCCC3)=CSC2=N1 |c:24,28|, CC1(C)CN2C(CS\C(NC3CCCCC3)=N\C3CCCCC3)=CSC2=N1 |c:24,28|	OOSUDWRRWZVFEB-UHFFFAOYSA-N, OOSUDWRRWZVFEB-UHFFFAOYSA-N	Preclinical
IU1	ubiquitin C-terminal hydrolase inhibitor	USP14			Cc1cc(C(=O)CN2CCCC2)c(C)n1-c1ccc(F)cc1, Cc1cc(C(=O)CN2CCCC2)c(C)n1-c1ccc(F)cc1, Cc1cc(C(=O)CN2CCCC2)c(C)n1-c1ccc(F)cc1	JUWDSDKJBMFLHE-UHFFFAOYSA-N, JUWDSDKJBMFLHE-UHFFFAOYSA-N, JUWDSDKJBMFLHE-UHFFFAOYSA-N	Preclinical
ivabradine	HCN channel blocker, potassium channel blocker, sodium channel blocker	HCN1, HCN3, HCN4	cardiology	angina pectoris	COc1cc2C[C@H](CN(C)CCCN3CCc4cc(OC)c(OC)cc4CC3=O)c2cc1OC, COc1cc2C[C@H](CN(C)CCCN3CCc4cc(OC)c(OC)cc4CC3=O)c2cc1OC	ACRHBAYQBXXRTO-OAQYLSRUSA-N, ACRHBAYQBXXRTO-OAQYLSRUSA-N	Launched
ivacaftor	CFTR channel potentiator	CFTR	pulmonary	cystic fibrosis	CC(C)(C)c1cc(c(NC(=O)c2c[nH]c3ccccc3c2=O)cc1O)C(C)(C)C, CC(C)(C)c1cc(c(NC(=O)c2c[nH]c3ccccc3c2=O)cc1O)C(C)(C)C, CC(C)(C)c1cc(c(NC(=O)c2c[nH]c3ccccc3c2=O)cc1O)C(C)(C)C, CC(C)(C)c1cc(c(NC(=O)c2c[nH]c3ccccc3c2=O)cc1O)C(C)(C)C	PURKAOJPTOLRMP-UHFFFAOYSA-N, PURKAOJPTOLRMP-UHFFFAOYSA-N, PURKAOJPTOLRMP-UHFFFAOYSA-N, PURKAOJPTOLRMP-UHFFFAOYSA-N	Launched
ivermectin	benzodiazepine receptor agonist	CHRNA7, P2RX7	infectious disease	gastrointestinal roundworms, lungworms, cattle grubs, mites, lice, horn flies	CC[C@H](C)[C@H]1O[C@]2(CC[C@@H]1C)C[C@@H]1C[C@@H](C\C=C(C)\[C@@H](O[C@H]3C[C@H](OC)[C@@H](O[C@H]4C[C@H](OC)[C@@H](O)[C@H](C)O4)[C@H](C)O3)[C@@H](C)\C=C\C=C3/CO[C@@H]4[C@H](O)C(C)=C[C@@H](C(=O)O1)[C@]34O)O2 |c:17,48,56,t:46|, CC[C@H](C)[C@H]1O[C@]2(CC[C@@H]1C)C[C@@H]1C[C@@H](C\C=C(C)\[C@@H](O[C@H]3C[C@H](OC)[C@@H](O[C@H]4C[C@H](OC)[C@@H](O)[C@H](C)O4)[C@H](C)O3)[C@@H](C)\C=C\C=C3/CO[C@@H]4[C@H](O)C(C)=C[C@@H](C(=O)O1)[C@]34O)O2 |c:17,48,56,t:46|, CC[C@H](C)[C@H]1O[C@]2(CC[C@@H]1C)C[C@@H]1C[C@@H](C\C=C(C)\[C@@H](O[C@H]3C[C@H](OC)[C@@H](O[C@H]4C[C@H](OC)[C@@H](O)[C@H](C)O4)[C@H](C)O3)[C@@H](C)\C=C\C=C3/CO[C@@H]4[C@H](O)C(C)=C[C@@H](C(=O)O1)[C@]34O)O2 |c:17,48,56,t:46|, CC[C@H](C)[C@H]1O[C@]2(CC[C@@H]1C)C[C@@H]1C[C@@H](C\C=C(C)\[C@@H](O[C@H]3C[C@H](OC)[C@@H](O[C@H]4C[C@H](OC)[C@@H](O)[C@H](C)O4)[C@H](C)O3)[C@@H](C)\C=C\C=C3/CO[C@@H]4[C@H](O)C(C)=C[C@@H](C(=O)O1)[C@]34O)O2 |c:17,48,56,t:46|, CC[C@H](C)[C@H]1O[C@]2(CC[C@@H]1C)C[C@@H]1C[C@@H](C\C=C(C)\[C@@H](O[C@H]3C[C@H](OC)[C@@H](O[C@H]4C[C@H](OC)[C@@H](O)[C@H](C)O4)[C@H](C)O3)[C@@H](C)\C=C\C=C3/CO[C@@H]4[C@H](O)C(C)=C[C@@H](C(=O)O1)[C@]34O)O2 |c:17,48,56,t:46|, CC[C@H](C)[C@H]1O[C@]2(CC[C@@H]1C)C[C@@H]1C[C@@H](C\C=C(C)\[C@@H](O[C@H]3C[C@H](OC)[C@@H](O[C@H]4C[C@H](OC)[C@@H](O)[C@H](C)O4)[C@H](C)O3)[C@@H](C)\C=C\C=C3/CO[C@@H]4[C@H](O)C(C)=C[C@@H](C(=O)O1)[C@]34O)O2 |c:17,48,56,t:46|, CC[C@H](C)[C@H]1O[C@]2(CC[C@@H]1C)C[C@@H]1C[C@@H](C\C=C(C)\[C@@H](O[C@H]3C[C@H](OC)[C@@H](O[C@H]4C[C@H](OC)[C@@H](O)[C@H](C)O4)[C@H](C)O3)[C@@H](C)\C=C\C=C3/CO[C@@H]4[C@H](O)C(C)=C[C@@H](C(=O)O1)[C@]34O)O2 |c:17,48,56,t:46|, CC[C@H](C)[C@H]1O[C@]2(CC[C@@H]1C)C[C@@H]1C[C@@H](C\C=C(C)\[C@@H](O[C@H]3C[C@H](OC)[C@@H](O[C@H]4C[C@H](OC)[C@@H](O)[C@H](C)O4)[C@H](C)O3)[C@@H](C)\C=C\C=C3/CO[C@@H]4[C@H](O)C(C)=C[C@@H](C(=O)O1)[C@]34O)O2 |c:17,48,56,t:46|	AZSNMRSAGSSBNP-XPNPUAGNSA-N, AZSNMRSAGSSBNP-XPNPUAGNSA-N, AZSNMRSAGSSBNP-XPNPUAGNSA-N, AZSNMRSAGSSBNP-XPNPUAGNSA-N, AZSNMRSAGSSBNP-XPNPUAGNSA-N, AZSNMRSAGSSBNP-XPNPUAGNSA-N, AZSNMRSAGSSBNP-XPNPUAGNSA-N, AZSNMRSAGSSBNP-XPNPUAGNSA-N	Launched
ivosidenib	isocitrate dehydrogenase inhibitor	IDH1	hematologic malignancy	acute myeloid leukemia (AML)	Fc1cncc(c1)N([C@H](C(=O)NC1CC(F)(F)C1)c1ccccc1Cl)C(=O)[C@@H]1CCC(=O)N1c1cc(ccn1)C#N, Fc1cncc(c1)N([C@H](C(=O)NC1CC(F)(F)C1)c1ccccc1Cl)C(=O)[C@@H]1CCC(=O)N1c1cc(ccn1)C#N	WIJZXSAJMHAVGX-DHLKQENFSA-N, WIJZXSAJMHAVGX-DHLKQENFSA-N	Launched
IWP-L6	porcupine inhibitor	PORCN			O=C(CSc1nc2CCSc2c(=O)n1-c1ccccc1)Nc1ccc(cn1)-c1ccccc1, O=C(CSc1nc2CCSc2c(=O)n1-c1ccccc1)Nc1ccc(cn1)-c1ccccc1, O=C(CSc1nc2CCSc2c(=O)n1-c1ccccc1)Nc1ccc(cn1)-c1ccccc1	QESQGTFWEQMCMH-UHFFFAOYSA-N, QESQGTFWEQMCMH-UHFFFAOYSA-N, QESQGTFWEQMCMH-UHFFFAOYSA-N	Preclinical
ixabepilone	microtubule stabilizing agent	TUBB	oncology	breast cancer	C[C@H]1CCC[C@@]2(C)O[C@H]2C[C@H](NC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@H]1O)C(\C)=C\c1csc(C)n1, C[C@H]1CCC[C@@]2(C)O[C@H]2C[C@H](NC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@H]1O)C(\C)=C\c1csc(C)n1, C[C@H]1CCC[C@@]2(C)O[C@H]2C[C@H](NC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@H]1O)C(\C)=C\c1csc(C)n1	FABUFPQFXZVHFB-QBNZTRRJSA-N, FABUFPQFXZVHFB-QBNZTRRJSA-N, FABUFPQFXZVHFB-QBNZTRRJSA-N	Launched
ixazomib	proteasome inhibitor		hematologic malignancy	multiple myeloma	CC(C)C[C@H](NC(=O)CNC(=O)c1cc(Cl)ccc1Cl)B(O)O, CC(C)C[C@H](NC(=O)CNC(=O)c1cc(Cl)ccc1Cl)B(O)O, CC(C)C[C@H](NC(=O)CNC(=O)c1cc(Cl)ccc1Cl)B(O)O, CC(C)C[C@H](NC(=O)CNC(=O)c1cc(Cl)ccc1Cl)B(O)O, CC(C)C[C@H](NC(=O)CNC(=O)c1cc(Cl)ccc1Cl)B(O)O, CC(C)C[C@H](NC(=O)CNC(=O)c1cc(Cl)ccc1Cl)B(O)O, CC(C)C[C@H](NC(=O)CNC(=O)c1cc(Cl)ccc1Cl)B(O)O	MXAYKZJJDUDWDS-LBPRGKRZSA-N, MXAYKZJJDUDWDS-LBPRGKRZSA-N, MXAYKZJJDUDWDS-LBPRGKRZSA-N, MXAYKZJJDUDWDS-LBPRGKRZSA-N, MXAYKZJJDUDWDS-LBPRGKRZSA-N, MXAYKZJJDUDWDS-LBPRGKRZSA-N, MXAYKZJJDUDWDS-LBPRGKRZSA-N	Launched
ixazomib-citrate	proteasome inhibitor		hematologic malignancy	multiple myeloma	CC(C)C[C@H](NC(=O)CNC(=O)c1cc(Cl)ccc1Cl)B1OC(=O)C[C@@](CC(O)=O)(O1)C(O)=O |a:4,&1:25|, CC(C)C[C@H](NC(=O)CNC(=O)c1cc(Cl)ccc1Cl)B1OC(=O)C[C@@](CC(O)=O)(O1)C(O)=O |a:4,&1:25|, CC(C)C[C@H](NC(=O)CNC(=O)c1cc(Cl)ccc1Cl)B1OC(=O)C[C@@](CC(O)=O)(O1)C(O)=O |a:4,&1:25|, CC(C)C[C@H](NC(=O)CNC(=O)c1cc(Cl)ccc1Cl)B1OC(=O)C[C@@](CC(O)=O)(O1)C(O)=O |a:4,&1:25|	YTXSYWAKVMZICI-VBKZILBWSA-N, YTXSYWAKVMZICI-VBKZILBWSA-N, YTXSYWAKVMZICI-VBKZILBWSA-N, YTXSYWAKVMZICI-VBKZILBWSA-N	Launched
JAK3-inhibitor-V	JAK inhibitor	JAK3			C=CC(=O)c1ccc2ccccc2c1, C=CC(=O)c1ccc2ccccc2c1	FOTCGZPFSUWZBN-UHFFFAOYSA-N, FOTCGZPFSUWZBN-UHFFFAOYSA-N	Preclinical
JD-5037	cannabinoid receptor antagonist				CC(C)[C@H](\N=C(\NS(=O)(=O)c1ccc(Cl)cc1)N1C[C@@H](C(=N1)c1ccc(Cl)cc1)c1ccccc1)C(N)=O |c:21|	GTCSIQFTNPTSLO-RPWUZVMVSA-N	Preclinical
JDTic	opioid receptor antagonist	OPRK1			CC(C)[C@@H](CN1CC[C@](C)([C@@H](C)C1)c1cccc(O)c1)NC(=O)[C@H]1Cc2ccc(O)cc2CN1, CC(C)[C@@H](CN1CC[C@](C)([C@@H](C)C1)c1cccc(O)c1)NC(=O)[C@H]1Cc2ccc(O)cc2CN1	ZLVXBBHTMQJRSX-VMGNSXQWSA-N, ZLVXBBHTMQJRSX-VMGNSXQWSA-N	Phase 1
JHW-007	dopamine reuptake inhibitor	SLC6A3			CCCCN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(c1ccc(F)cc1)c1ccc(F)cc1, CCCCN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(c1ccc(F)cc1)c1ccc(F)cc1	HZEVDVGPBUFIAW-JKHIJQBDSA-N, HZEVDVGPBUFIAW-JKHIJQBDSA-N	Preclinical
JI-101	kinase inhibitor				COc1ccc(Br)cc1NC(=O)Nc1cccc2n(Cc3ccnc(N)c3)ccc12	ZXBFYBLSJMEBEP-UHFFFAOYSA-N	Phase 1/Phase 2
JIB04	histone lysine demethylase inhibitor	KDM4E			Clc1ccc(N\N=C(/c2ccccc2)c2ccccn2)nc1, Clc1ccc(N\N=C(/c2ccccc2)c2ccccn2)nc1, Clc1ccc(N\N=C(/c2ccccc2)c2ccccn2)nc1, Clc1ccc(N\N=C(/c2ccccc2)c2ccccn2)nc1, Clc1ccc(N\N=C(/c2ccccc2)c2ccccn2)nc1, Clc1ccc(N\N=C(/c2ccccc2)c2ccccn2)nc1, Clc1ccc(N\N=C(/c2ccccc2)c2ccccn2)nc1, Clc1ccc(N\N=C(/c2ccccc2)c2ccccn2)nc1, Clc1ccc(N\N=C(/c2ccccc2)c2ccccn2)nc1	YHHFKWKMXWRVTJ-OQKWZONESA-N, YHHFKWKMXWRVTJ-OQKWZONESA-N, YHHFKWKMXWRVTJ-OQKWZONESA-N, YHHFKWKMXWRVTJ-OQKWZONESA-N, YHHFKWKMXWRVTJ-OQKWZONESA-N, YHHFKWKMXWRVTJ-OQKWZONESA-N, YHHFKWKMXWRVTJ-OQKWZONESA-N, YHHFKWKMXWRVTJ-OQKWZONESA-N, YHHFKWKMXWRVTJ-OQKWZONESA-N	Preclinical
JK-184	hedgehog pathway inhibitor				CCOc1ccc(Nc2nc(cs2)-c2c(C)nc3ccccn23)cc1, CCOc1ccc(Nc2nc(cs2)-c2c(C)nc3ccccn23)cc1, CCOc1ccc(Nc2nc(cs2)-c2c(C)nc3ccccn23)cc1, CCOc1ccc(Nc2nc(cs2)-c2c(C)nc3ccccn23)cc1, CCOc1ccc(Nc2nc(cs2)-c2c(C)nc3ccccn23)cc1, CCOc1ccc(Nc2nc(cs2)-c2c(C)nc3ccccn23)cc1	ROYXIPOUVGDTAO-UHFFFAOYSA-N, ROYXIPOUVGDTAO-UHFFFAOYSA-N, ROYXIPOUVGDTAO-UHFFFAOYSA-N, ROYXIPOUVGDTAO-UHFFFAOYSA-N, ROYXIPOUVGDTAO-UHFFFAOYSA-N, ROYXIPOUVGDTAO-UHFFFAOYSA-N	Preclinical
JLK-6	gamma secretase inhibitor	PSEN1			COc1oc(=O)c2cc(N)ccc2c1Cl	AMDGKLWVCUXONP-UHFFFAOYSA-N	Preclinical
JNJ-10191584	histamine receptor antagonist	HRH4			CN1CCN(CC1)C(=O)c1nc2ccc(Cl)cc2[nH]1, CN1CCN(CC1)C(=O)c1nc2ccc(Cl)cc2[nH]1, CN1CCN(CC1)C(=O)c1nc2ccc(Cl)cc2[nH]1, CN1CCN(CC1)C(=O)c1nc2ccc(Cl)cc2[nH]1	MOIWSUQWIOVGRH-UHFFFAOYSA-N, MOIWSUQWIOVGRH-UHFFFAOYSA-N, MOIWSUQWIOVGRH-UHFFFAOYSA-N, MOIWSUQWIOVGRH-UHFFFAOYSA-N	Preclinical
JNJ-10397049	orexin receptor antagonist	HCRTR1, HCRTR2			CC1(C)OC[C@H](NC(=O)Nc2ccc(Br)cc2Br)[C@@H](O1)c1ccccc1, CC1(C)OC[C@H](NC(=O)Nc2ccc(Br)cc2Br)[C@@H](O1)c1ccccc1	RBKIJGLHFFQHBE-IRXDYDNUSA-N, RBKIJGLHFFQHBE-IRXDYDNUSA-N	Preclinical
JNJ-16259685	glutamate receptor antagonist	GRM1			CO[C@H]1CC[C@H](CC1)C(=O)c1ccc2nc3OCCCc3cc2c1 |r|, CO[C@H]1CC[C@H](CC1)C(=O)c1ccc2nc3OCCCc3cc2c1 |r|, CO[C@H]1CC[C@H](CC1)C(=O)c1ccc2nc3OCCCc3cc2c1 |r|	QOTAQTRFJWLFCR-XFHMXUHZSA-N, QOTAQTRFJWLFCR-XFHMXUHZSA-N, QOTAQTRFJWLFCR-XFHMXUHZSA-N	Preclinical
JNJ-1661010	FAAH inhibitor	FAAH			O=C(Nc1ccccc1)N1CCN(CC1)c1nc(ns1)-c1ccccc1, O=C(Nc1ccccc1)N1CCN(CC1)c1nc(ns1)-c1ccccc1, O=C(Nc1ccccc1)N1CCN(CC1)c1nc(ns1)-c1ccccc1, O=C(Nc1ccccc1)N1CCN(CC1)c1nc(ns1)-c1ccccc1	BHBOSTKQCZEAJM-UHFFFAOYSA-N, BHBOSTKQCZEAJM-UHFFFAOYSA-N, BHBOSTKQCZEAJM-UHFFFAOYSA-N, BHBOSTKQCZEAJM-UHFFFAOYSA-N	Preclinical
JNJ-17203212	TRPV antagonist	TRPV1			FC(F)(F)c1ccc(NC(=O)N2CCN(CC2)c2ncccc2C(F)(F)F)nc1, FC(F)(F)c1ccc(NC(=O)N2CCN(CC2)c2ncccc2C(F)(F)F)nc1, FC(F)(F)c1ccc(NC(=O)N2CCN(CC2)c2ncccc2C(F)(F)F)nc1, FC(F)(F)c1ccc(NC(=O)N2CCN(CC2)c2ncccc2C(F)(F)F)nc1	JFRYYGVYCWYIDQ-UHFFFAOYSA-N, JFRYYGVYCWYIDQ-UHFFFAOYSA-N, JFRYYGVYCWYIDQ-UHFFFAOYSA-N, JFRYYGVYCWYIDQ-UHFFFAOYSA-N	Preclinical
JNJ-26481585	HDAC inhibitor	HDAC1, HDAC10, HDAC11, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9, MDM2			Cn1cc(CNCC2CCN(CC2)c2ncc(cn2)C(=O)NO)c2ccccc12, Cn1cc(CNCC2CCN(CC2)c2ncc(cn2)C(=O)NO)c2ccccc12, Cn1cc(CNCC2CCN(CC2)c2ncc(cn2)C(=O)NO)c2ccccc12, Cn1cc(CNCC2CCN(CC2)c2ncc(cn2)C(=O)NO)c2ccccc12, Cn1cc(CNCC2CCN(CC2)c2ncc(cn2)C(=O)NO)c2ccccc12	PAWIYAYFNXQGAP-UHFFFAOYSA-N, PAWIYAYFNXQGAP-UHFFFAOYSA-N, PAWIYAYFNXQGAP-UHFFFAOYSA-N, PAWIYAYFNXQGAP-UHFFFAOYSA-N, PAWIYAYFNXQGAP-UHFFFAOYSA-N	Phase 2
JNJ-26990990	anticonvulsant				NS(=O)(=O)NCc1csc2ccccc12	AWSKBQNOSRREEY-UHFFFAOYSA-N	Phase 2
JNJ-27141491	CC chemokine receptor antagonist	CCR2			CC[C@@H](c1ccc(F)c(F)c1)n1c(C(=O)OC)c([nH]c1=S)-c1ccno1, CC[C@@H](c1ccc(F)c(F)c1)n1c(C(=O)OC)c([nH]c1=S)-c1ccno1	SYARXICKXVXWNA-LBPRGKRZSA-N, SYARXICKXVXWNA-LBPRGKRZSA-N	Preclinical
JNJ-37822681	dopamine receptor antagonist	DRD2			Fc1ccc(CN2CCC(CC2)Nc2ccc(nn2)C(F)(F)F)cc1F, Fc1ccc(CN2CCC(CC2)Nc2ccc(nn2)C(F)(F)F)cc1F	UVUYWJWYRLJHEN-UHFFFAOYSA-N, UVUYWJWYRLJHEN-UHFFFAOYSA-N	Phase 2
JNJ-38877605	tyrosine kinase inhibitor	MET			Cn1cc(cn1)-c1ccc2nnc(n2n1)C(F)(F)c1ccc2ncccc2c1	JRWCBEOAFGHNNU-UHFFFAOYSA-N	Phase 1
JNJ-38877618	c-Met inhibitor				FC(F)(c1nnc2ccc(nn12)-c1ccncc1)c1ccc2ncccc2c1	KOAWAWHSMVKCON-UHFFFAOYSA-N	Phase 1
JNJ-39758979	histamine receptor antagonist				CC(C)c1cc(nc(N)n1)N1CC[C@@H](N)C1	COOGVHJHSCBOQT-MRVPVSSYSA-N	Phase 2
JNJ-40411813	glutamate receptor positive allosteric modulator	GRM2			CCCCn1ccc(N2CCC(CC2)c2ccccc2)c(Cl)c1=O	HYOGJHCDLQSAHX-UHFFFAOYSA-N	Phase 2
JNJ-42041935	hypoxia inducible factor prolyl hydroxylase inhibitor	PDK2			OC(=O)c1cnn(c1)-c1nc2cc(Cl)c(OC(F)(F)F)cc2[nH]1, OC(=O)c1cnn(c1)-c1nc2cc(Cl)c(OC(F)(F)F)cc2[nH]1	FXHHASJVTYRJHH-UHFFFAOYSA-N, FXHHASJVTYRJHH-UHFFFAOYSA-N	Preclinical
JNJ-42165279	FAAH inhibitor	FAAH			FC1(F)Oc2ccc(CN3CCN(CC3)C(=O)Nc3cnccc3Cl)cc2O1, FC1(F)Oc2ccc(CN3CCN(CC3)C(=O)Nc3cnccc3Cl)cc2O1	YWGYNGCRVZLMCS-UHFFFAOYSA-N, YWGYNGCRVZLMCS-UHFFFAOYSA-N	Phase 2
JNJ-47965567	purinergic receptor antagonist	P2RX7			O=C(NCC1(CCOCC1)N1CCN(CC1)c1ccccc1)c1cccnc1Sc1ccccc1, O=C(NCC1(CCOCC1)N1CCN(CC1)c1ccccc1)c1cccnc1Sc1ccccc1	XREFXUCWSYMIOG-UHFFFAOYSA-N, XREFXUCWSYMIOG-UHFFFAOYSA-N	Preclinical
JNJ-54175446	purinergic receptor antagonist				C[C@H]1N(CCc2c1nnn2-c1ncc(F)cn1)C(=O)c1cccc(c1Cl)C(F)(F)F	CWFVVQFVGMFTBD-SECBINFHSA-N	Phase 1
JNJ-63533054	G protein-coupled receptor agonist	GPR139			C[C@H](NC(=O)CNC(=O)c1cccc(Cl)c1)c1ccccc1, C[C@H](NC(=O)CNC(=O)c1cccc(Cl)c1)c1ccccc1, C[C@H](NC(=O)CNC(=O)c1cccc(Cl)c1)c1ccccc1	MWDVCHRYCKXEBY-LBPRGKRZSA-N, MWDVCHRYCKXEBY-LBPRGKRZSA-N, MWDVCHRYCKXEBY-LBPRGKRZSA-N	Preclinical
JNJ-64619178	protein arginine N-methyltransferase inhibitor				Nc1nc2cc(CC[C@H]3C[C@H]([C@H](O)[C@@H]3O)n3ccc4c(N)ncnc34)ccc2cc1Br	DBSMLQTUDJVICQ-CJODITQLSA-N	Phase 1
JNJ-678	RSV fusion inhibitor				CS(=O)(=O)CCCn1c(Cn2c3cnccc3n(CC(F)(F)F)c2=O)cc2cc(Cl)ccc12	GTQTUABHRCWVLL-UHFFFAOYSA-N	Phase 1
JNJ-7706621	CDK inhibitor	AURKA, AURKB, CDK1, CDK2			Nc1nc(Nc2ccc(cc2)S(N)(=O)=O)nn1C(=O)c1c(F)cccc1F, Nc1nc(Nc2ccc(cc2)S(N)(=O)=O)nn1C(=O)c1c(F)cccc1F, Nc1nc(Nc2ccc(cc2)S(N)(=O)=O)nn1C(=O)c1c(F)cccc1F, Nc1nc(Nc2ccc(cc2)S(N)(=O)=O)nn1C(=O)c1c(F)cccc1F, Nc1nc(Nc2ccc(cc2)S(N)(=O)=O)nn1C(=O)c1c(F)cccc1F, Nc1nc(Nc2ccc(cc2)S(N)(=O)=O)nn1C(=O)c1c(F)cccc1F, Nc1nc(Nc2ccc(cc2)S(N)(=O)=O)nn1C(=O)c1c(F)cccc1F, Nc1nc(Nc2ccc(cc2)S(N)(=O)=O)nn1C(=O)c1c(F)cccc1F	KDKUVYLMPJIGKA-UHFFFAOYSA-N, KDKUVYLMPJIGKA-UHFFFAOYSA-N, KDKUVYLMPJIGKA-UHFFFAOYSA-N, KDKUVYLMPJIGKA-UHFFFAOYSA-N, KDKUVYLMPJIGKA-UHFFFAOYSA-N, InChI=1S/C15H12F2N6O3S/c16-10-2-1-3-11(17)12(10)13(24)23-14(18)21-15(22-23)20-8-4-6-9(7-5-8)27(19,25)26/h1-7H,(H2,19,25,26)(H3,18,20,21,22), InChI=1S/C15H12F2N6O3S/c16-10-2-1-3-11(17)12(10)13(24)23-14(18)21-15(22-23)20-8-4-6-9(7-5-8)27(19,25)26/h1-7H,(H2,19,25,26)(H3,18,20,21,22), InChI=1S/C15H12F2N6O3S/c16-10-2-1-3-11(17)12(10)13(24)23-14(18)21-15(22-23)20-8-4-6-9(7-5-8)27(19,25)26/h1-7H,(H2,19,25,26)(H3,18,20,21,22)	Preclinical
JNJ-7777120	histamine receptor antagonist	HRH4			CN1CCN(CC1)C(=O)c1cc2cc(Cl)ccc2[nH]1, CN1CCN(CC1)C(=O)c1cc2cc(Cl)ccc2[nH]1, CN1CCN(CC1)C(=O)c1cc2cc(Cl)ccc2[nH]1, CN1CCN(CC1)C(=O)c1cc2cc(Cl)ccc2[nH]1	HUQJRYMLJBBEDO-UHFFFAOYSA-N, HUQJRYMLJBBEDO-UHFFFAOYSA-N, HUQJRYMLJBBEDO-UHFFFAOYSA-N, HUQJRYMLJBBEDO-UHFFFAOYSA-N	Preclinical
josamycin	bacterial 50S ribosomal subunit inhibitor		pulmonary	bronchitis	[H][C@@]1(C[C@@](C)(O)[C@@H](OC(=O)CC(C)C)[C@H](C)O1)O[C@@H]1[C@@H](C)O[C@@]([H])(O[C@H]2[C@@H](CC=O)C[C@@H](C)[C@@H](O)\C=C\C=C\C[C@@H](C)OC(=O)C[C@@]([H])(OC(C)=O)[C@@H]2OC)[C@H](O)[C@H]1N(C)C |t:36,38|	XJSFLOJWULLJQS-MJKZEBMBSA-N	Launched
JPH203	solute carrier family member inhibitor				N[C@@H](Cc1cc(Cl)c(OCc2cc(N)cc3nc(oc23)-c2ccccc2)c(Cl)c1)C(O)=O	XNRZJPQTMQZBCE-SFHVURJKSA-N	Preclinical
JQ1-(+)	bromodomain inhibitor	BRD4, BRDT			Cc1nnc2[C@H](CC(=O)OC(C)(C)C)N=C(c3c(C)c(C)sc3-n12)c1ccc(Cl)cc1 |c:14|, Cc1nnc2[C@H](CC(=O)OC(C)(C)C)N=C(c3c(C)c(C)sc3-n12)c1ccc(Cl)cc1 |c:14|, Cc1nnc2[C@H](CC(=O)OC(C)(C)C)N=C(c3c(C)c(C)sc3-n12)c1ccc(Cl)cc1 |c:14|, Cc1nnc2[C@H](CC(=O)OC(C)(C)C)N=C(c3c(C)c(C)sc3-n12)c1ccc(Cl)cc1 |c:14|, Cc1nnc2[C@H](CC(=O)OC(C)(C)C)N=C(c3c(C)c(C)sc3-n12)c1ccc(Cl)cc1 |c:14|, Cc1nnc2[C@H](CC(=O)OC(C)(C)C)N=C(c3c(C)c(C)sc3-n12)c1ccc(Cl)cc1 |c:14|, Cc1nnc2[C@H](CC(=O)OC(C)(C)C)N=C(c3c(C)c(C)sc3-n12)c1ccc(Cl)cc1 |c:14|	DNVXATUJJDPFDM-KRWDZBQOSA-N, DNVXATUJJDPFDM-KRWDZBQOSA-N, DNVXATUJJDPFDM-KRWDZBQOSA-N, DNVXATUJJDPFDM-KRWDZBQOSA-N, DNVXATUJJDPFDM-KRWDZBQOSA-N, DNVXATUJJDPFDM-KRWDZBQOSA-N, DNVXATUJJDPFDM-KRWDZBQOSA-N	Preclinical
JTC-801	opioid receptor antagonist	OPRL1			CCc1ccc(OCc2ccccc2C(=O)Nc2ccc3nc(C)cc(N)c3c2)cc1, CCc1ccc(OCc2ccccc2C(=O)Nc2ccc3nc(C)cc(N)c3c2)cc1, CCc1ccc(OCc2ccccc2C(=O)Nc2ccc3nc(C)cc(N)c3c2)cc1, CCc1ccc(OCc2ccccc2C(=O)Nc2ccc3nc(C)cc(N)c3c2)cc1	VTGBZWHPJFMTKS-UHFFFAOYSA-N, VTGBZWHPJFMTKS-UHFFFAOYSA-N, VTGBZWHPJFMTKS-UHFFFAOYSA-N, VTGBZWHPJFMTKS-UHFFFAOYSA-N	Phase 2
JTE-013	lysophospholipid receptor antagonist	P2RY10, S1PR2			CC(C)c1cc(NNC(=O)Nc2cc(Cl)nc(Cl)c2)nc2n(C)nc(C)c12, CC(C)c1cc(NNC(=O)Nc2cc(Cl)nc(Cl)c2)nc2n(C)nc(C)c12, CC(C)c1cc(NNC(=O)Nc2cc(Cl)nc(Cl)c2)nc2n(C)nc(C)c12	RNSLRQNDXRSASX-UHFFFAOYSA-N, RNSLRQNDXRSASX-UHFFFAOYSA-N, RNSLRQNDXRSASX-UHFFFAOYSA-N	Preclinical
JTE-607	cytokine production inhibitor	IL10, IL1B, IL6, TNF			CCOC(=O)[C@H](Cc1ccccc1)NC(=O)c1cc(Cl)c(OCCN2CCN(C)CC2)c(Cl)c1O, CCOC(=O)[C@H](Cc1ccccc1)NC(=O)c1cc(Cl)c(OCCN2CCN(C)CC2)c(Cl)c1O, CCOC(=O)[C@H](Cc1ccccc1)NC(=O)c1cc(Cl)c(OCCN2CCN(C)CC2)c(Cl)c1O, CCOC(=O)[C@H](Cc1ccccc1)NC(=O)c1cc(Cl)c(OCCN2CCN(C)CC2)c(Cl)c1O, CCOC(=O)[C@H](Cc1ccccc1)NC(=O)c1cc(Cl)c(OCCN2CCN(C)CC2)c(Cl)c1O	IPSSXIMJJXSJQB-FQEVSTJZSA-N, IPSSXIMJJXSJQB-FQEVSTJZSA-N, IPSSXIMJJXSJQB-FQEVSTJZSA-N, IPSSXIMJJXSJQB-FQEVSTJZSA-N, IPSSXIMJJXSJQB-FQEVSTJZSA-N	Phase 2
JTE-907	cannabinoid receptor inverse agonist	CNR2			CCCCCOc1c(OC)ccc2cc(C(=O)NCc3ccc4OCOc4c3)c(=O)[nH]c12, CCCCCOc1c(OC)ccc2cc(C(=O)NCc3ccc4OCOc4c3)c(=O)[nH]c12, CCCCCOc1c(OC)ccc2cc(C(=O)NCc3ccc4OCOc4c3)c(=O)[nH]c12	GRAJFFFXJYFVOC-UHFFFAOYSA-N, GRAJFFFXJYFVOC-UHFFFAOYSA-N, GRAJFFFXJYFVOC-UHFFFAOYSA-N	Phase 1
JW-55	tankyrase inhibitor	TNKS, TNKS2			COc1ccc(cc1)C1(CNC(=O)c2ccc(NC(=O)c3ccco3)cc2)CCOCC1, COc1ccc(cc1)C1(CNC(=O)c2ccc(NC(=O)c3ccco3)cc2)CCOCC1, COc1ccc(cc1)C1(CNC(=O)c2ccc(NC(=O)c3ccco3)cc2)CCOCC1, COc1ccc(cc1)C1(CNC(=O)c2ccc(NC(=O)c3ccco3)cc2)CCOCC1, COc1ccc(cc1)C1(CNC(=O)c2ccc(NC(=O)c3ccco3)cc2)CCOCC1, COc1ccc(cc1)C1(CNC(=O)c2ccc(NC(=O)c3ccco3)cc2)CCOCC1, COc1ccc(cc1)C1(CNC(=O)c2ccc(NC(=O)c3ccco3)cc2)CCOCC1	ZJZWZIXSGNFWQQ-UHFFFAOYSA-N, ZJZWZIXSGNFWQQ-UHFFFAOYSA-N, ZJZWZIXSGNFWQQ-UHFFFAOYSA-N, ZJZWZIXSGNFWQQ-UHFFFAOYSA-N, ZJZWZIXSGNFWQQ-UHFFFAOYSA-N, ZJZWZIXSGNFWQQ-UHFFFAOYSA-N, ZJZWZIXSGNFWQQ-UHFFFAOYSA-N	Preclinical
JW-642	monoacylglycerol lipase inhibitor	MGLL			FC(F)(F)C(OC(=O)N1CCN(Cc2cccc(Oc3ccccc3)c2)CC1)C(F)(F)F, FC(F)(F)C(OC(=O)N1CCN(Cc2cccc(Oc3ccccc3)c2)CC1)C(F)(F)F	AVSCNEOUWSVZEY-UHFFFAOYSA-N, AVSCNEOUWSVZEY-UHFFFAOYSA-N	Preclinical
JW-67	WNT pathway inhibitor	APC, AXIN1, GSK3B			O=C1Nc2ccccc2C11OCC2(CO1)COC1(OC2)C(=O)Nc2ccccc12, O=C1Nc2ccccc2C11OCC2(CO1)COC1(OC2)C(=O)Nc2ccccc12, O=C1Nc2ccccc2C11OCC2(CO1)COC1(OC2)C(=O)Nc2ccccc12	BTXRSHKJNDFHGA-UHFFFAOYSA-N, BTXRSHKJNDFHGA-UHFFFAOYSA-N, BTXRSHKJNDFHGA-UHFFFAOYSA-N	Preclinical
JW-74	tankyrase inhibitor, WNT signaling inhibitor	TNKS, TNKS2			COc1ccc(cc1)-n1c(SCc2nc(no2)-c2ccc(C)cc2)nnc1-c1ccncc1, COc1ccc(cc1)-n1c(SCc2nc(no2)-c2ccc(C)cc2)nnc1-c1ccncc1, COc1ccc(cc1)-n1c(SCc2nc(no2)-c2ccc(C)cc2)nnc1-c1ccncc1	KRIKILRRJCIWNB-UHFFFAOYSA-N, KRIKILRRJCIWNB-UHFFFAOYSA-N, KRIKILRRJCIWNB-UHFFFAOYSA-N	Preclinical
JX-401	p38 MAPK inhibitor	MAPK14			COc1cc(SC)ccc1C(=O)N1CCC(Cc2ccccc2)CC1, COc1cc(SC)ccc1C(=O)N1CCC(Cc2ccccc2)CC1, COc1cc(SC)ccc1C(=O)N1CCC(Cc2ccccc2)CC1	OMGLGPKQUFSRNN-UHFFFAOYSA-N, OMGLGPKQUFSRNN-UHFFFAOYSA-N, OMGLGPKQUFSRNN-UHFFFAOYSA-N	Preclinical
JZL-184	monoacylglucerol lipase inhibitor	MGLL			OC(C1CCN(CC1)C(=O)Oc1ccc(cc1)[N+]([O-])=O)(c1ccc2OCOc2c1)c1ccc2OCOc2c1, OC(C1CCN(CC1)C(=O)Oc1ccc(cc1)[N+]([O-])=O)(c1ccc2OCOc2c1)c1ccc2OCOc2c1	SEGYOKHGGFKMCX-UHFFFAOYSA-N, SEGYOKHGGFKMCX-UHFFFAOYSA-N	Preclinical
JZL-195	FAAH inhibitor, monoacylglycerol lipase inhibitor	FAAH, MGLL			[O-][N+](=O)c1ccc(OC(=O)N2CCN(Cc3cccc(Oc4ccccc4)c3)CC2)cc1, [O-][N+](=O)c1ccc(OC(=O)N2CCN(Cc3cccc(Oc4ccccc4)c3)CC2)cc1	QNYRAEKLMNDRFY-UHFFFAOYSA-N, QNYRAEKLMNDRFY-UHFFFAOYSA-N	Preclinical
J147	BDNF inducer				COc1cccc(\C=N\N(C(=O)C(F)(F)F)c2ccc(C)cc2C)c1	HYMZAYGFKNNHDN-SSDVNMTOSA-N	Phase 1
K-MAP					OC[C@H]1O[C@@H](Nc2ccc(cc2)C(O)=O)[C@@H](O)[C@@H](O)[C@@H]1O |&1:2,&2:4,&3:15,&4:17,&5:19,r|	VXMVXDITZWJXJN-LDMBFOFVSA-N	Phase 2
K-Ras(G12C)-inhibitor-12	K-Ras inhibitor	KRAS			Oc1cc(Cl)c(I)cc1NCC(=O)N1CCN(CC1)C(=O)C=C, Oc1cc(Cl)c(I)cc1NCC(=O)N1CCN(CC1)C(=O)C=C, Oc1cc(Cl)c(I)cc1NCC(=O)N1CCN(CC1)C(=O)C=C	JFIFBWVNHLXJFY-UHFFFAOYSA-N, JFIFBWVNHLXJFY-UHFFFAOYSA-N, JFIFBWVNHLXJFY-UHFFFAOYSA-N	Preclinical
K-Ras(G12C)-inhibitor-6	K-Ras inhibitor				SCCCC(=O)NC1CCN(CC1)C(=O)COc1ccc(Cl)cc1Cl, SCCCC(=O)NC1CCN(CC1)C(=O)COc1ccc(Cl)cc1Cl, SCCCC(=O)NC1CCN(CC1)C(=O)COc1ccc(Cl)cc1Cl, SCCCC(=O)NC1CCN(CC1)C(=O)COc1ccc(Cl)cc1Cl	ZPXCEHMKUTXHRZ-UHFFFAOYSA-N, ZPXCEHMKUTXHRZ-UHFFFAOYSA-N, ZPXCEHMKUTXHRZ-UHFFFAOYSA-N, ZPXCEHMKUTXHRZ-UHFFFAOYSA-N	Preclinical
K-strophanthidin	ATPase inhibitor	ATP1A1			C[C@]12CC[C@H]3[C@@H](CC[C@]4(O)C[C@@H](O)CC[C@]34C=O)[C@@]1(O)CC[C@@H]2C1=CC(=O)OC1 |t:27|, C[C@]12CC[C@H]3[C@@H](CC[C@]4(O)C[C@@H](O)CC[C@]34C=O)[C@@]1(O)CC[C@@H]2C1=CC(=O)OC1 |t:27|	ODJLBQGVINUMMR-HZXDTFASSA-N, ODJLBQGVINUMMR-HZXDTFASSA-N	Phase 2
K-247					OC[C@H]1O[C@@H](Nc2ccc(cc2)C(O)=O)[C@@H](O)[C@@H]1O |&1:2,&2:4,&3:15,&4:17,r|	QNUBRHYSSHJWDH-CHWFTXMASA-N	Phase 1
K-858	kinesin-like spindle protein inhibitor	KIF11			CC(=O)NC1=NN(C(C)=O)[C@@](C)(S1)c1ccccc1 |&1:10,r,t:4|, CC(=O)NC1=NN(C(C)=O)[C@@](C)(S1)c1ccccc1 |&1:10,r,t:4|	JEFVYQYZCAVNTP-ZDUSSCGKSA-N, JEFVYQYZCAVNTP-ZDUSSCGKSA-N	Preclinical
kaempferol	bone resorption inhibitor, estrogen-related receptor inverse agonist	AKR1B1, ALOX15B, ALOX5, AR, CYP1B1, GLO1, HSD17B1, UGT3A1			Oc1ccc(cc1)-c1oc2cc(O)cc(O)c2c(=O)c1O, Oc1ccc(cc1)-c1oc2cc(O)cc(O)c2c(=O)c1O, Oc1ccc(cc1)-c1oc2cc(O)cc(O)c2c(=O)c1O, Oc1ccc(cc1)-c1oc2cc(O)cc(O)c2c(=O)c1O	IYRMWMYZSQPJKC-UHFFFAOYSA-N, IYRMWMYZSQPJKC-UHFFFAOYSA-N, IYRMWMYZSQPJKC-UHFFFAOYSA-N, IYRMWMYZSQPJKC-UHFFFAOYSA-N	Preclinical
KAF-156	antimalarial agent				CC1(C)N(CCn2c(Nc3ccc(F)cc3)c(nc12)-c1ccc(F)cc1)C(=O)CN	BUPRVECGWBHCQV-UHFFFAOYSA-N	Preclinical
kainic-acid	kainate receptor agonist	GRIA1, GRIK1, GRIK2, GRIK3, GRIK4, GRIK5			CC(=C)[C@H]1CN[C@@H]([C@H]1CC(O)=O)C(O)=O, CC(=C)[C@H]1CN[C@@H]([C@H]1CC(O)=O)C(O)=O	VLSMHEGGTFMBBZ-OOZYFLPDSA-N, VLSMHEGGTFMBBZ-OOZYFLPDSA-N	Preclinical
kakonein	GABA receptor antagonist, serotonin receptor antagonist				OC[C@H]1O[C@@H]([C@@H](O)[C@@H](O)[C@@H]1O)c1c(O)ccc2c1occ(-c1ccc(O)cc1)c2=O |&1:2,&2:4,&3:5,&4:7,&5:9,r|, OC[C@H]1O[C@@H]([C@@H](O)[C@@H](O)[C@@H]1O)c1c(O)ccc2c1occ(-c1ccc(O)cc1)c2=O |&1:2,&2:4,&3:5,&4:7,&5:9,r|	HKEAFJYKMMKDOR-YAJUCGGBSA-N, HKEAFJYKMMKDOR-YAJUCGGBSA-N	Phase 2
kanamycin	bacterial 30S ribosomal subunit inhibitor		infectious disease	gram-negative bacterial infections	NC[C@H]1O[C@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O)[C@H]2O)[C@H](O)[C@@H](O)[C@@H]1O, NC[C@H]1O[C@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O)[C@H]2O)[C@H](O)[C@@H](O)[C@@H]1O, NC[C@H]1O[C@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O)[C@H]2O)[C@H](O)[C@@H](O)[C@@H]1O	SBUJHOSQTJFQJX-NOAMYHISSA-N, SBUJHOSQTJFQJX-NOAMYHISSA-N, SBUJHOSQTJFQJX-NOAMYHISSA-N	Launched
karenitecin	topoisomerase inhibitor	TOP1			CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccccc4c(CC[Si](C)(C)C)c3Cn1c2=O	POADTFBBIXOWFJ-VWLOTQADSA-N	Phase 3
kartogenin	chondrocyte differentiation stimulator	FLNA			OC(=O)c1ccccc1C(=O)Nc1ccc(cc1)-c1ccccc1, OC(=O)c1ccccc1C(=O)Nc1ccc(cc1)-c1ccccc1	SLUINPGXGFUMLL-UHFFFAOYSA-N, SLUINPGXGFUMLL-UHFFFAOYSA-N	Preclinical
kasugamycin	bacterial 30S ribosomal subunit inhibitor				C[C@H]1O[C@H](O[C@@H]2[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@H]2O)[C@@H](N)C[C@@H]1NC(=N)C(O)=O	PVTHJAPFENJVNC-MHRBZPPQSA-N	Preclinical
KB-R7943	sodium/calcium exchange inhibitor	SLC8A1, TRPC3, TRPC5, TRPC6			NC(=N)SCCc1ccc(OCc2ccc(cc2)[N+]([O-])=O)cc1, NC(=N)SCCc1ccc(OCc2ccc(cc2)[N+]([O-])=O)cc1, NC(=N)SCCc1ccc(OCc2ccc(cc2)[N+]([O-])=O)cc1	UMJUNUMSJDTYTM-UHFFFAOYSA-N, UMJUNUMSJDTYTM-UHFFFAOYSA-N, UMJUNUMSJDTYTM-UHFFFAOYSA-N	Preclinical
KB-SRC-4	SRC inhibitor	SRC			Nc1ncnc2n(nc(-c3ccc(Cl)cc3)c12)-c1cccc(c1)-c1cnnn1Cc1cccc(c1)-c1ccccc1, Nc1ncnc2n(nc(-c3ccc(Cl)cc3)c12)-c1cccc(c1)-c1cnnn1Cc1cccc(c1)-c1ccccc1, Nc1ncnc2n(nc(-c3ccc(Cl)cc3)c12)-c1cccc(c1)-c1cnnn1Cc1cccc(c1)-c1ccccc1	UHIZYQVRKSWIFO-UHFFFAOYSA-N, UHIZYQVRKSWIFO-UHFFFAOYSA-N, UHIZYQVRKSWIFO-UHFFFAOYSA-N	Preclinical
KBG	neprilysin inhibitor	MME			O[C@H]1O[C@@H]2CO[C@@H](O[C@H]2[C@H](O)[C@H]1O)c1ccccc1 |a:3,8,9,11,&1:1,&2:6|, O[C@H]1O[C@@H]2CO[C@@H](O[C@H]2[C@H](O)[C@H]1O)c1ccccc1 |a:3,8,9,11,&1:1,&2:6|	FOLRUCXBTYDAQK-PTEOKISQSA-N, FOLRUCXBTYDAQK-PTEOKISQSA-N	Phase 2
KD-023	ACAT inhibitor	ACACA, ACACB			CCCCCCCCCCCCCCOc1ccc(o1)C(O)=O, CCCCCCCCCCCCCCOc1ccc(o1)C(O)=O	CZRCFAOMWRAFIC-UHFFFAOYSA-N, CZRCFAOMWRAFIC-UHFFFAOYSA-N	Phase 2
KD025	rho associated kinase inhibitor	ROCK2			CC(C)NC(=O)COc1cccc(c1)-c1nc(Nc2ccc3n[nH]cc3c2)c2ccccc2n1, CC(C)NC(=O)COc1cccc(c1)-c1nc(Nc2ccc3n[nH]cc3c2)c2ccccc2n1, CC(C)NC(=O)COc1cccc(c1)-c1nc(Nc2ccc3n[nH]cc3c2)c2ccccc2n1, CC(C)NC(=O)COc1cccc(c1)-c1nc(Nc2ccc3n[nH]cc3c2)c2ccccc2n1, CC(C)NC(=O)COc1cccc(c1)-c1nc(Nc2ccc3n[nH]cc3c2)c2ccccc2n1, CC(C)NC(=O)COc1cccc(c1)-c1nc(Nc2ccc3n[nH]cc3c2)c2ccccc2n1	GKHIVNAUVKXIIY-UHFFFAOYSA-N, GKHIVNAUVKXIIY-UHFFFAOYSA-N, GKHIVNAUVKXIIY-UHFFFAOYSA-N, GKHIVNAUVKXIIY-UHFFFAOYSA-N, GKHIVNAUVKXIIY-UHFFFAOYSA-N, GKHIVNAUVKXIIY-UHFFFAOYSA-N	Phase 2
kenpaullone	CDK inhibitor, glycogen synthase kinase inhibitor	CCNB1, CDK1, CDK5, GSK3B			Brc1ccc2[nH]c-3c(CC(=O)Nc4ccccc-34)c2c1, Brc1ccc2[nH]c-3c(CC(=O)Nc4ccccc-34)c2c1, Brc1ccc2[nH]c-3c(CC(=O)Nc4ccccc-34)c2c1	QQUXFYAWXPMDOE-UHFFFAOYSA-N, QQUXFYAWXPMDOE-UHFFFAOYSA-N, QQUXFYAWXPMDOE-UHFFFAOYSA-N	Preclinical
ketanserin	serotonin receptor antagonist	ADRA1A, ADRA1B, ADRA1D, DRD1, DRD5, HTR1A, HTR1B, HTR1D, HTR2A, HTR2B, HTR2C, HTR5A, HTR7, SLC18A1, SLC18A2	cardiology	hypertension	Fc1ccc(cc1)C(=O)C1CCN(CCn2c(=O)[nH]c3ccccc3c2=O)CC1, Fc1ccc(cc1)C(=O)C1CCN(CCn2c(=O)[nH]c3ccccc3c2=O)CC1, Fc1ccc(cc1)C(=O)C1CCN(CCn2c(=O)[nH]c3ccccc3c2=O)CC1, Fc1ccc(cc1)C(=O)C1CCN(CCn2c(=O)[nH]c3ccccc3c2=O)CC1, Fc1ccc(cc1)C(=O)C1CCN(CCn2c(=O)[nH]c3ccccc3c2=O)CC1	FPCCSQOGAWCVBH-UHFFFAOYSA-N, FPCCSQOGAWCVBH-UHFFFAOYSA-N, FPCCSQOGAWCVBH-UHFFFAOYSA-N, FPCCSQOGAWCVBH-UHFFFAOYSA-N, FPCCSQOGAWCVBH-UHFFFAOYSA-N	Launched
ketoconazole	sterol demethylase inhibitor	KCNA10	dermatology	seborrheic dermatitis	CC(=O)N1CCN(CC1)c1ccc(OC[C@@H]2CO[C@](Cn3ccnc3)(O2)c2ccc(Cl)cc2Cl)cc1 |&1:15,18|, CC(=O)N1CCN(CC1)c1ccc(OC[C@@H]2CO[C@](Cn3ccnc3)(O2)c2ccc(Cl)cc2Cl)cc1 |&1:15,18|, CC(=O)N1CCN(CC1)c1ccc(OC[C@@H]2CO[C@](Cn3ccnc3)(O2)c2ccc(Cl)cc2Cl)cc1 |&1:15,18|, CC(=O)N1CCN(CC1)c1ccc(OC[C@@H]2CO[C@](Cn3ccnc3)(O2)c2ccc(Cl)cc2Cl)cc1 |&1:15,18|, CC(=O)N1CCN(CC1)c1ccc(OC[C@@H]2CO[C@](Cn3ccnc3)(O2)c2ccc(Cl)cc2Cl)cc1 |&1:15,18|, CC(=O)N1CCN(CC1)c1ccc(OC[C@@H]2CO[C@](Cn3ccnc3)(O2)c2ccc(Cl)cc2Cl)cc1 |&1:15,18|, CC(=O)N1CCN(CC1)c1ccc(OC[C@@H]2CO[C@](Cn3ccnc3)(O2)c2ccc(Cl)cc2Cl)cc1 |&1:15,18|	XMAYWYJOQHXEEK-ZEQKJWHPSA-N, XMAYWYJOQHXEEK-ZEQKJWHPSA-N, XMAYWYJOQHXEEK-ZEQKJWHPSA-N, XMAYWYJOQHXEEK-ZEQKJWHPSA-N, XMAYWYJOQHXEEK-ZEQKJWHPSA-N, XMAYWYJOQHXEEK-ZEQKJWHPSA-N, XMAYWYJOQHXEEK-ZEQKJWHPSA-N	Launched
ketohexokinase-inhibitor-1	kinase inhibitor				[H][C@@]12CN(C[C@]1([H])[C@H]2CC(O)=O)c1cc(nc(n1)N1CC[C@@H]1C)C(F)(F)F	MDUYWDNWFXSMJJ-XWLWVQCSSA-N	Preclinical
ketoprofen	cyclooxygenase inhibitor	PTGS1, PTGS2, SLC5A8	rheumatology	rheumatoid arthritis, osteoarthritis	C[C@@H](C(O)=O)c1cccc(c1)C(=O)c1ccccc1 |&1:1,r|, C[C@@H](C(O)=O)c1cccc(c1)C(=O)c1ccccc1 |&1:1,r|, C[C@@H](C(O)=O)c1cccc(c1)C(=O)c1ccccc1 |&1:1,r|	DKYWVDODHFEZIM-LLVKDONJSA-N, DKYWVDODHFEZIM-LLVKDONJSA-N, DKYWVDODHFEZIM-LLVKDONJSA-N	Launched
ketorolac	cyclooxygenase inhibitor	PTGS1, PTGS2	neurology/psychiatry	pain relief	OC(=O)[C@H]1CCn2c1ccc2C(=O)c1ccccc1 |&1:3,r|, OC(=O)[C@H]1CCn2c1ccc2C(=O)c1ccccc1 |&1:3,r|, OC(=O)[C@H]1CCn2c1ccc2C(=O)c1ccccc1 |&1:3,r|	OZWKMVRBQXNZKK-NSHDSACASA-N, OZWKMVRBQXNZKK-NSHDSACASA-N, OZWKMVRBQXNZKK-NSHDSACASA-N	Launched
ketotifen	histamine receptor agonist, leukotriene receptor antagonist, phosphodiesterase inhibitor	HRH1	neurology/psychiatry	itching	CN1CCC(CC1)=C1c2ccsc2C(O)=Cc2ccccc12 |c:16|, CN1CCC(CC1)=C1c2ccsc2C(O)=Cc2ccccc12 |c:16|, CN1CCC(CC1)=C1c2ccsc2C(O)=Cc2ccccc12 |c:16|, CN1CCC(CC1)=C1c2ccsc2C(O)=Cc2ccccc12 |c:16|	OVJRNFMIYGGLDL-UHFFFAOYSA-N, OVJRNFMIYGGLDL-UHFFFAOYSA-N, OVJRNFMIYGGLDL-UHFFFAOYSA-N, OVJRNFMIYGGLDL-UHFFFAOYSA-N	Launched
kevetrin	p53 activator				NC(=N)SCCCC#N, NC(=N)SCCCC#N	PRDJGNVQBVXXEO-UHFFFAOYSA-N, PRDJGNVQBVXXEO-UHFFFAOYSA-N	Phase 1
KF-38789	P selectin inhibitor	SELP			COc1ccc([C@H]2CC(=NCCS2)c2c(O)cc(C)oc2=O)c(OC)c1 |&1:6,r,c:8|, COc1ccc([C@H]2CC(=NCCS2)c2c(O)cc(C)oc2=O)c(OC)c1 |&1:6,r,c:8|, COc1ccc([C@H]2CC(=NCCS2)c2c(O)cc(C)oc2=O)c(OC)c1 |&1:6,r,c:8|	NHFIAAAMCYVRIW-QGZVFWFLSA-N, NHFIAAAMCYVRIW-QGZVFWFLSA-N, NHFIAAAMCYVRIW-QGZVFWFLSA-N	Preclinical
KG-5	RAF inhibitor	BRAF, FLT3, KIT, PDGFRB			CSc1nc(N)cc(Oc2ccc(cc2)-c2nnc(Nc3cccc(c3)C(F)(F)F)[nH]2)n1, CSc1nc(N)cc(Oc2ccc(cc2)-c2nnc(Nc3cccc(c3)C(F)(F)F)[nH]2)n1, CSc1nc(N)cc(Oc2ccc(cc2)-c2nnc(Nc3cccc(c3)C(F)(F)F)[nH]2)n1	CMYHZFCJPORPHY-UHFFFAOYSA-N, CMYHZFCJPORPHY-UHFFFAOYSA-N, CMYHZFCJPORPHY-UHFFFAOYSA-N	Preclinical
KH-CB19	CDC inhibitor	CLK1, CLK3, DYRK1A			CCOC(=O)c1c(C(C=N)C#N)c2ccc(Cl)c(Cl)c2n1C, CCOC(=O)c1c(C(C=N)C#N)c2ccc(Cl)c(Cl)c2n1C, CCOC(=O)c1c(C(C=N)C#N)c2ccc(Cl)c(Cl)c2n1C	DXZRBHUCOHBAHP-UHFFFAOYSA-N, DXZRBHUCOHBAHP-UHFFFAOYSA-N, DXZRBHUCOHBAHP-UHFFFAOYSA-N	Preclinical
khellin	vasodilator				COc1c2ccoc2c(OC)c2oc(C)cc(=O)c12, COc1c2ccoc2c(OC)c2oc(C)cc(=O)c12	HSMPDPBYAYSOBC-UHFFFAOYSA-N, HSMPDPBYAYSOBC-UHFFFAOYSA-N	Phase 2
KHK-IN-1	hexokinase inhibitor	KHK			CSc1ccccc1Nc1nc(nc2c(NCC3CC3)ncnc12)N1CCNCC1, CSc1ccccc1Nc1nc(nc2c(NCC3CC3)ncnc12)N1CCNCC1, CSc1ccccc1Nc1nc(nc2c(NCC3CC3)ncnc12)N1CCNCC1, CSc1ccccc1Nc1nc(nc2c(NCC3CC3)ncnc12)N1CCNCC1, CSc1ccccc1Nc1nc(nc2c(NCC3CC3)ncnc12)N1CCNCC1	HFLMLZKGLUEWBU-UHFFFAOYSA-N, HFLMLZKGLUEWBU-UHFFFAOYSA-N, HFLMLZKGLUEWBU-UHFFFAOYSA-N, HFLMLZKGLUEWBU-UHFFFAOYSA-N, HFLMLZKGLUEWBU-UHFFFAOYSA-N	Preclinical
KHS-101	neural stem cell inducer	TACC3			CC(C)CNc1ccnc(NCc2csc(n2)-c2ccccc2)n1, CC(C)CNc1ccnc(NCc2csc(n2)-c2ccccc2)n1, CC(C)CNc1ccnc(NCc2csc(n2)-c2ccccc2)n1	DGRJOOOHPBSAHD-UHFFFAOYSA-N, DGRJOOOHPBSAHD-UHFFFAOYSA-N, DGRJOOOHPBSAHD-UHFFFAOYSA-N	Preclinical
KI-16425	lysophosphatidic acid receptor antagonist	LPAR1, LPAR3			C[C@@H](OC(=O)Nc1c(C)noc1-c1ccc(CSCCC(O)=O)cc1)c1ccccc1Cl |&1:1,r|	LLIFMNUXGDHTRO-OAHLLOKOSA-N	Preclinical
KI-20227	c-Fms inhibitor	CSF1R, KDR, KIT, PDGFRB			COc1cc(Oc2ccnc3cc(OC)c(OC)cc23)ccc1NC(=O)N[C@@H](C)c1nccs1 |&1:27,r|, COc1cc(Oc2ccnc3cc(OC)c(OC)cc23)ccc1NC(=O)N[C@@H](C)c1nccs1 |&1:27,r|	SHPFDGWALWEPGS-AWEZNQCLSA-N, SHPFDGWALWEPGS-AWEZNQCLSA-N	Preclinical
KI-8751	KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	KDR			COc1cc2nccc(Oc3ccc(NC(=O)Nc4ccc(F)cc4F)c(F)c3)c2cc1OC, COc1cc2nccc(Oc3ccc(NC(=O)Nc4ccc(F)cc4F)c(F)c3)c2cc1OC, COc1cc2nccc(Oc3ccc(NC(=O)Nc4ccc(F)cc4F)c(F)c3)c2cc1OC, COc1cc2nccc(Oc3ccc(NC(=O)Nc4ccc(F)cc4F)c(F)c3)c2cc1OC	LFKQSJNCVRGFCC-UHFFFAOYSA-N, LFKQSJNCVRGFCC-UHFFFAOYSA-N, LFKQSJNCVRGFCC-UHFFFAOYSA-N, LFKQSJNCVRGFCC-UHFFFAOYSA-N	Preclinical
kifunensine	mannosidase inhibitor	MAN1B1, MAN2A1			OC[C@@H]1[C@@H](O)[C@H](O)[C@H](O)[C@H]2NC(=O)C(=O)N12, OC[C@@H]1[C@@H](O)[C@H](O)[C@H](O)[C@H]2NC(=O)C(=O)N12, OC[C@@H]1[C@@H](O)[C@H](O)[C@H](O)[C@H]2NC(=O)C(=O)N12, OC[C@@H]1[C@@H](O)[C@H](O)[C@H](O)[C@H]2NC(=O)C(=O)N12	OIURYJWYVIAOCW-PQMKYFCFSA-N, OIURYJWYVIAOCW-PQMKYFCFSA-N, OIURYJWYVIAOCW-PQMKYFCFSA-N, OIURYJWYVIAOCW-PQMKYFCFSA-N	Phase 1
kinetin	cell division inducer		dermatology	sunburn	C(Nc1ncnc2nc[nH]c12)c1ccco1, C(Nc1ncnc2nc[nH]c12)c1ccco1	QANMHLXAZMSUEX-UHFFFAOYSA-N, QANMHLXAZMSUEX-UHFFFAOYSA-N	Launched
ki16198	lipoprotein antagonist	LPA			COC(=O)CCSCc1ccc(cc1)-c1onc(C)c1NC(=O)O[C@@H](C)c1ccccc1Cl |&1:24,r|, COC(=O)CCSCc1ccc(cc1)-c1onc(C)c1NC(=O)O[C@@H](C)c1ccccc1Cl |&1:24,r|, COC(=O)CCSCc1ccc(cc1)-c1onc(C)c1NC(=O)O[C@@H](C)c1ccccc1Cl |&1:24,r|	HHVJBROTJWPHHX-INIZCTEOSA-N, HHVJBROTJWPHHX-INIZCTEOSA-N, HHVJBROTJWPHHX-INIZCTEOSA-N	Preclinical
KL-001	proteasome inhibitor	CRY1, CRY2			CS(=O)(=O)N(C[C@@H](O)Cn1c2ccccc2c2ccccc12)Cc1ccco1 |&1:6,r|, CS(=O)(=O)N(C[C@@H](O)Cn1c2ccccc2c2ccccc12)Cc1ccco1 |&1:6,r|, CS(=O)(=O)N(C[C@@H](O)Cn1c2ccccc2c2ccccc12)Cc1ccco1 |&1:6,r|	OQAFDLPAPSSOHY-MRXNPFEDSA-N, OQAFDLPAPSSOHY-MRXNPFEDSA-N, OQAFDLPAPSSOHY-MRXNPFEDSA-N	Preclinical
KM-0118	anticancer agent				CN(C)CCNC(=O)COc1c2Cc3cccc(Cc4cccc(Cc5cccc(Cc1ccc2)c5OCC(=O)NCCN(C)C)c4OCC(=O)NCCN(C)C)c3OCC(=O)NCCN(C)C	CQVAQQNDZCZBSU-UHFFFAOYSA-N	Phase 1
KME-4	prostaglandin inhibitor				CC(C)(C)c1cc(\C=C2/CCOC2=O)cc(c1O)C(C)(C)C	DFPYHQJPGCODSB-UKTHLTGXSA-N	Preclinical
KML29	monoacylglucerol lipase inhibitor	MGLL			OC(C1CCN(CC1)C(=O)OC(C(F)(F)F)C(F)(F)F)(c1ccc2OCOc2c1)c1ccc2OCOc2c1	SXHQLPHDBLTFPM-UHFFFAOYSA-N	Preclinical
KN-62	calcium/calmodulin dependent protein kinase inhibitor, purinergic receptor antagonist	AKT1, CAMK2A, CHEK1, LCK, MAPK1, MAPK11, MAPK12, MAPK14, MAPK8, P2RX7, PRKCA, ROCK1, RPS6KB1, SGK1			CN([C@@H](Cc1ccc(OS(=O)(=O)c2cccc3cnccc23)cc1)C(=O)N1CCN(CC1)c1ccccc1)S(=O)(=O)c1cccc2cnccc12 |&1:2,r|	RJVLFQBBRSMWHX-DHUJRADRSA-N	Preclinical
KN-93	calcium/calmodulin dependent protein kinase inhibitor	CAMK2A			COc1ccc(cc1)S(=O)(=O)N(CCO)c1ccccc1CN(C)C\C=C\c1ccc(Cl)cc1, COc1ccc(cc1)S(=O)(=O)N(CCO)c1ccccc1CN(C)C\C=C\c1ccc(Cl)cc1, COc1ccc(cc1)S(=O)(=O)N(CCO)c1ccccc1CN(C)C\C=C\c1ccc(Cl)cc1	LLLQTDSSHZREGW-AATRIKPKSA-N, LLLQTDSSHZREGW-AATRIKPKSA-N, LLLQTDSSHZREGW-AATRIKPKSA-N	Preclinical
Ko143	BCRP inhibitor	ABCB1, ABCC1			COc1ccc2c3C[C@@H]4N([C@@H](CC(C)C)c3[nH]c2c1)C(=O)[C@H](CCC(=O)OC(C)(C)C)NC4=O, COc1ccc2c3C[C@@H]4N([C@@H](CC(C)C)c3[nH]c2c1)C(=O)[C@H](CCC(=O)OC(C)(C)C)NC4=O, COc1ccc2c3C[C@@H]4N([C@@H](CC(C)C)c3[nH]c2c1)C(=O)[C@H](CCC(=O)OC(C)(C)C)NC4=O	NXNRAECHCJZNRF-JBACZVJFSA-N, NXNRAECHCJZNRF-JBACZVJFSA-N, NXNRAECHCJZNRF-JBACZVJFSA-N	Preclinical
KP-1212					NC1=NC(=O)N(CN1)[C@H]1C[C@@H](O)[C@@H](CO)O1 |t:1|	LAOLDMMWVYDDID-HSUXUTPPSA-N	Phase 2
KPT-185	exportin antagonist	XPO1			COc1cc(cc(c1)C(F)(F)F)-c1ncn(\C=C/C(=O)OC(C)C)n1, COc1cc(cc(c1)C(F)(F)F)-c1ncn(\C=C/C(=O)OC(C)C)n1, COc1cc(cc(c1)C(F)(F)F)-c1ncn(\C=C/C(=O)OC(C)C)n1	NLNGWFLRRRYNIL-PLNGDYQASA-N, NLNGWFLRRRYNIL-PLNGDYQASA-N, NLNGWFLRRRYNIL-PLNGDYQASA-N	Preclinical
KPT-276	exportin antagonist	XPO1			FC(F)(F)c1cc(cc(c1)C(F)(F)F)-c1ncn(\C=C/C(=O)N2CC(F)(F)C2)n1, FC(F)(F)c1cc(cc(c1)C(F)(F)F)-c1ncn(\C=C/C(=O)N2CC(F)(F)C2)n1, FC(F)(F)c1cc(cc(c1)C(F)(F)F)-c1ncn(\C=C/C(=O)N2CC(F)(F)C2)n1, FC(F)(F)c1cc(cc(c1)C(F)(F)F)-c1ncn(\C=C/C(=O)N2CC(F)(F)C2)n1	JCHAWRDHMUSLMM-UPHRSURJSA-N, JCHAWRDHMUSLMM-UPHRSURJSA-N, JCHAWRDHMUSLMM-UPHRSURJSA-N, JCHAWRDHMUSLMM-UPHRSURJSA-N	Preclinical
KPT-9274	NAMPT inhibitor				Nc1ccc(\C=C\C(=O)NCc2cc3cc(cc(-c4ccc(F)cc4)c3o2)-c2ccc(cc2)C(=O)N2CCC(F)(F)CC2)cn1	MRFOPLWJZULAQD-SWGQDTFXSA-N	Phase 1
KR-33494	cell death inhibitor 				OC(=O)c1nn(CCc2ccccc2)cc1NC(=O)CSc1ccc(Br)cc1	ZRLJEHIUGYTTSZ-UHFFFAOYSA-N	Preclinical
KRCA-0008	ALK inihibitor	ALK			COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccc(cc2OC)N2CCN(CC2)C(C)=O)n1)N1CCN(CC1)C(C)=O, COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccc(cc2OC)N2CCN(CC2)C(C)=O)n1)N1CCN(CC1)C(C)=O	TXDIRJCYNAWBOS-UHFFFAOYSA-N, TXDIRJCYNAWBOS-UHFFFAOYSA-N	Preclinical
KRN-633	VEGFR inhibitor	FLT1, FLT4, KDR			CCCNC(=O)Nc1ccc(Oc2ncnc3cc(OC)c(OC)cc23)cc1Cl, CCCNC(=O)Nc1ccc(Oc2ncnc3cc(OC)c(OC)cc23)cc1Cl, CCCNC(=O)Nc1ccc(Oc2ncnc3cc(OC)c(OC)cc23)cc1Cl	VPBYZLCHOKSGRX-UHFFFAOYSA-N, VPBYZLCHOKSGRX-UHFFFAOYSA-N, VPBYZLCHOKSGRX-UHFFFAOYSA-N	Preclinical
KS-176	BCRP inhibitor	ABCG2			OCCc1ccc(NC(=O)c2ccccc2NC(=O)c2ccc(cc2)[N+]([O-])=O)cc1, OCCc1ccc(NC(=O)c2ccccc2NC(=O)c2ccc(cc2)[N+]([O-])=O)cc1	LTWQQWSXYYXVGA-UHFFFAOYSA-N, LTWQQWSXYYXVGA-UHFFFAOYSA-N	Preclinical
KT-433	uricosuric agent				CCc1oc2ccccc2c1C(=O)c1ccc(OCC(O)=O)cc1	XSDFWTIKVXKOGJ-UHFFFAOYSA-N	Phase 2
KU-0063794	mTOR inhibitor	MTOR			COc1ccc(cc1CO)-c1ccc2c(nc(nc2n1)N1C[C@H](C)O[C@H](C)C1)N1CCOCC1, COc1ccc(cc1CO)-c1ccc2c(nc(nc2n1)N1C[C@H](C)O[C@H](C)C1)N1CCOCC1, COc1ccc(cc1CO)-c1ccc2c(nc(nc2n1)N1C[C@H](C)O[C@H](C)C1)N1CCOCC1	RFSMUFRPPYDYRD-CALCHBBNSA-N, RFSMUFRPPYDYRD-CALCHBBNSA-N, RFSMUFRPPYDYRD-CALCHBBNSA-N	Preclinical
KU-55933	ATM kinase inhibitor	ATM, PRKDC			O=c1cc(oc(c1)-c1cccc2Sc3ccccc3Sc12)N1CCOCC1, O=c1cc(oc(c1)-c1cccc2Sc3ccccc3Sc12)N1CCOCC1	XRKYMMUGXMWDAO-UHFFFAOYSA-N, XRKYMMUGXMWDAO-UHFFFAOYSA-N	Preclinical
KU-60019	ATM kinase inhibitor	ATM			C[C@H]1CN(CC(=O)Nc2ccc3Sc4c(Cc3c2)cccc4-c2cc(=O)cc(o2)N2CCOCC2)C[C@@H](C)O1, C[C@H]1CN(CC(=O)Nc2ccc3Sc4c(Cc3c2)cccc4-c2cc(=O)cc(o2)N2CCOCC2)C[C@@H](C)O1, C[C@H]1CN(CC(=O)Nc2ccc3Sc4c(Cc3c2)cccc4-c2cc(=O)cc(o2)N2CCOCC2)C[C@@H](C)O1, C[C@H]1CN(CC(=O)Nc2ccc3Sc4c(Cc3c2)cccc4-c2cc(=O)cc(o2)N2CCOCC2)C[C@@H](C)O1, C[C@H]1CN(CC(=O)Nc2ccc3Sc4c(Cc3c2)cccc4-c2cc(=O)cc(o2)N2CCOCC2)C[C@@H](C)O1	SCELLOWTHJGVIC-BGYRXZFFSA-N, SCELLOWTHJGVIC-BGYRXZFFSA-N, SCELLOWTHJGVIC-BGYRXZFFSA-N, SCELLOWTHJGVIC-BGYRXZFFSA-N, SCELLOWTHJGVIC-BGYRXZFFSA-N	Preclinical
kuromanin	ribosyl cyclase inhibitor	CD38			OC[C@H]1O[C@@H](Oc2cc3c(O)cc(O)cc3[o+]c2-c2ccc(O)c(O)c2)[C@H](O)[C@@H](O)[C@@H]1O	RKWHWFONKJEUEF-GQUPQBGVSA-O	Preclinical
KU14R	imidazoline receptor antagonist				CC[C@]1(Cc2ccccc2O1)c1ncc[nH]1 |&1:2,r|, CC[C@]1(Cc2ccccc2O1)c1ncc[nH]1 |&1:2,r|, CC[C@]1(Cc2ccccc2O1)c1ncc[nH]1 |&1:2,r|, CC[C@]1(Cc2ccccc2O1)c1ncc[nH]1 |&1:2,r|, CC[C@]1(Cc2ccccc2O1)c1ncc[nH]1 |&1:2,r|	JCWVNNMJXQJVNC-ZDUSSCGKSA-N, JCWVNNMJXQJVNC-ZDUSSCGKSA-N, JCWVNNMJXQJVNC-ZDUSSCGKSA-N, JCWVNNMJXQJVNC-ZDUSSCGKSA-N, JCWVNNMJXQJVNC-ZDUSSCGKSA-N	Preclinical
KW-2449	Abl kinase inhibitor, Aurora kinase inhibitor, FLT3 inhibitor	ABL1, AURKA, AURKB, FLT3			O=C(N1CCNCC1)c1ccc(\C=C\c2[nH]nc3ccccc23)cc1, O=C(N1CCNCC1)c1ccc(\C=C\c2[nH]nc3ccccc23)cc1, O=C(N1CCNCC1)c1ccc(\C=C\c2[nH]nc3ccccc23)cc1	YYLKKYCXAOBSRM-JXMROGBWSA-N, YYLKKYCXAOBSRM-JXMROGBWSA-N, YYLKKYCXAOBSRM-JXMROGBWSA-N	Phase 1
KW-2478	HSP inhibitor				CCc1c(O)cc(O)c(C(=O)c2ccc(OCCN3CCOCC3)c(OC)c2)c1CC(=O)N(CCOC)CCOC, CCc1c(O)cc(O)c(C(=O)c2ccc(OCCN3CCOCC3)c(OC)c2)c1CC(=O)N(CCOC)CCOC, CCc1c(O)cc(O)c(C(=O)c2ccc(OCCN3CCOCC3)c(OC)c2)c1CC(=O)N(CCOC)CCOC, CCc1c(O)cc(O)c(C(=O)c2ccc(OCCN3CCOCC3)c(OC)c2)c1CC(=O)N(CCOC)CCOC	VFUXSYAXEKYYMB-UHFFFAOYSA-N, VFUXSYAXEKYYMB-UHFFFAOYSA-N, VFUXSYAXEKYYMB-UHFFFAOYSA-N, VFUXSYAXEKYYMB-UHFFFAOYSA-N	Phase 1/Phase 2
KW-3902	adenosine receptor antagonist	ADORA1, ADORA2A, ADORA2B, ADORA3			CCCn1c2nc([nH]c2c(=O)n(CCC)c1=O)C12C[C@@H]3C[C@H]1C[C@H](C2)C3 |&1:23,&2:21,&3:19,r|, CCCn1c2nc([nH]c2c(=O)n(CCC)c1=O)C12C[C@@H]3C[C@H]1C[C@H](C2)C3 |&1:23,&2:21,&3:19,r|, CCCn1c2nc([nH]c2c(=O)n(CCC)c1=O)C12C[C@@H]3C[C@H]1C[C@H](C2)C3 |&1:23,&2:21,&3:19,r|	PJBFVWGQFLYWCB-XEDLVCFGSA-N, PJBFVWGQFLYWCB-XEDLVCFGSA-N, PJBFVWGQFLYWCB-XEDLVCFGSA-N	Phase 3
KX2-391	SRC inhibitor, tubulin polymerization inhibitor	SRC			O=C(Cc1ccc(cn1)-c1ccc(OCCN2CCOCC2)cc1)NCc1ccccc1, O=C(Cc1ccc(cn1)-c1ccc(OCCN2CCOCC2)cc1)NCc1ccccc1, O=C(Cc1ccc(cn1)-c1ccc(OCCN2CCOCC2)cc1)NCc1ccccc1, O=C(Cc1ccc(cn1)-c1ccc(OCCN2CCOCC2)cc1)NCc1ccccc1	HUNGUWOZPQBXGX-UHFFFAOYSA-N, InChI=1S/C26H29N3O3/c30-26(28-19-21-4-2-1-3-5-21)18-24-9-6-23(20-27-24)22-7-10-25(11-8-22)32-17-14-29-12-15-31-16-13-29/h1-11,20H,12-19H2,(H,28,30), InChI=1S/C26H29N3O3/c30-26(28-19-21-4-2-1-3-5-21)18-24-9-6-23(20-27-24)22-7-10-25(11-8-22)32-17-14-29-12-15-31-16-13-29/h1-11,20H,12-19H2,(H,28,30), InChI=1S/C26H29N3O3/c30-26(28-19-21-4-2-1-3-5-21)18-24-9-6-23(20-27-24)22-7-10-25(11-8-22)32-17-14-29-12-15-31-16-13-29/h1-11,20H,12-19H2,(H,28,30)	Phase 3
kynurenic-acid	glutamate receptor antagonist	GPR35, GRIN1, GRIN2A, GRIN2B			OC(=O)c1cc(=O)c2ccccc2[nH]1, OC(=O)c1cc(=O)c2ccccc2[nH]1, OC(=O)c1cc(=O)c2ccccc2[nH]1	HCZHHEIFKROPDY-UHFFFAOYSA-N, HCZHHEIFKROPDY-UHFFFAOYSA-N, HCZHHEIFKROPDY-UHFFFAOYSA-N	Phase 1
KY02111	WNT pathway inhibitor	DKK1			COc1ccc(CCC(=O)Nc2nc3ccc(Cl)cc3s2)cc1OC, COc1ccc(CCC(=O)Nc2nc3ccc(Cl)cc3s2)cc1OC, COc1ccc(CCC(=O)Nc2nc3ccc(Cl)cc3s2)cc1OC, COc1ccc(CCC(=O)Nc2nc3ccc(Cl)cc3s2)cc1OC, COc1ccc(CCC(=O)Nc2nc3ccc(Cl)cc3s2)cc1OC	LXFKEVQQSKQXPR-UHFFFAOYSA-N, LXFKEVQQSKQXPR-UHFFFAOYSA-N, LXFKEVQQSKQXPR-UHFFFAOYSA-N, LXFKEVQQSKQXPR-UHFFFAOYSA-N, LXFKEVQQSKQXPR-UHFFFAOYSA-N	Preclinical
K02288	bone morphogenic protein inhibitor	BMP1			COc1cc(cc(OC)c1OC)-c1cc(cnc1N)-c1cccc(O)c1, COc1cc(cc(OC)c1OC)-c1cc(cnc1N)-c1cccc(O)c1, COc1cc(cc(OC)c1OC)-c1cc(cnc1N)-c1cccc(O)c1, COc1cc(cc(OC)c1OC)-c1cc(cnc1N)-c1cccc(O)c1, COc1cc(cc(OC)c1OC)-c1cc(cnc1N)-c1cccc(O)c1, COc1cc(cc(OC)c1OC)-c1cc(cnc1N)-c1cccc(O)c1	CJLMANFTWLNAKC-UHFFFAOYSA-N, CJLMANFTWLNAKC-UHFFFAOYSA-N, CJLMANFTWLNAKC-UHFFFAOYSA-N, CJLMANFTWLNAKC-UHFFFAOYSA-N, CJLMANFTWLNAKC-UHFFFAOYSA-N, CJLMANFTWLNAKC-UHFFFAOYSA-N	Preclinical
K145	sphingosine kinase inhibitor	SPHK2			CCCCOc1ccc(CC\C=C2/SC(=O)N(CCN)C2=O)cc1, CCCCOc1ccc(CC\C=C2/SC(=O)N(CCN)C2=O)cc1, CCCCOc1ccc(CC\C=C2/SC(=O)N(CCN)C2=O)cc1	MPZXLTZVPUSTFY-SOFYXZRVSA-N, MPZXLTZVPUSTFY-SOFYXZRVSA-N, MPZXLTZVPUSTFY-SOFYXZRVSA-N	Preclinical
L-(+)-rhamnose-monohydrate					C[C@@H]1O[C@@H](O)[C@H](O)[C@H](O)[C@H]1O	SHZGCJCMOBCMKK-HGVZOGFYSA-N	Preclinical
L-alanine		AARS, AARS2, ABAT, AGXT, AGXT2, GPRC6A, GPT, GPT2, KYNU, NFS1, PHYKPL, SLC1A4, SLC36A1, SLC7A8			C[C@H](N)C(O)=O	QNAYBMKLOCPYGJ-REOHCLBHSA-N	Launched
L-arginine	nitric oxide precursor	ARG2, ASL, ASS1, AZIN2, GPRC6A, NOS2, NOS3, SLC7A1, SLC7A3, SLC7A4	cardiology, neurology/psychiatry, urology, obstetrics/gynecology, otolaryngology	congestive heart failure, hypertension, coronary artery disease (CAD), claudication, senile dementia, erectile dysfunction, infertility, common cold	N[C@@H](CCCNC(N)=N)C(O)=O, N[C@@H](CCCNC(N)=N)C(O)=O	ODKSFYDXXFIFQN-BYPYZUCNSA-N, ODKSFYDXXFIFQN-BYPYZUCNSA-N	Launched
L-ascorbyl-6-palmitate					CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(=O)[C@@H]1O |a:19,21,&1:27|, CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(=O)[C@@H]1O |a:19,21,&1:27|, CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(=O)[C@@H]1O |a:19,21,&1:27|, CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(=O)[C@@H]1O |a:19,21,&1:27|, CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(=O)[C@@H]1O |a:19,21,&1:27|	CYJPUZLKFAUFHF-HFSMHLIXSA-N, CYJPUZLKFAUFHF-HFSMHLIXSA-N, CYJPUZLKFAUFHF-HFSMHLIXSA-N, CYJPUZLKFAUFHF-HFSMHLIXSA-N, CYJPUZLKFAUFHF-HFSMHLIXSA-N	Preclinical
L-asparagine		ASNS, ASRGL1, NARS, NARS2, SLC1A5, SLC38A3			N[C@@H](CC(N)=O)C(O)=O	DCXYFEDJOCDNAF-REOHCLBHSA-N	Phase 3
L-asparagine-N-hydroxy					N[C@@H](CC(=O)NO)C(O)=O	ZBYVTTSIVDYQSO-REOHCLBHSA-N	Preclinical
L-aspartic-acid	metallic radical formation stimulant	ACY1, ACY3, ADSS, ADSSL1, ASNS, ASPA, ASPH, ASRGL1, ASS1, CAD, DARS, DARS2, GOT1, GOT2, GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D, LYZ, PAICS, RNASE1, SLC1A1, SLC25A12, SLC25A13			N[C@@H](CC(O)=O)C(O)=O, N[C@@H](CC(O)=O)C(O)=O, N[C@@H](CC(O)=O)C(O)=O	CKLJMWTZIZZHCS-REOHCLBHSA-N, CKLJMWTZIZZHCS-REOHCLBHSA-N, CKLJMWTZIZZHCS-REOHCLBHSA-N	Launched
L-citrulline	nitric oxide stimulant	ASS1, DDAH1, DDAH2, GPRC6A, NOS1, NOS2, NOS3, OTC, PADI1, PADI2, PADI3, PADI4, PADI6	cardiology, urology	hypertension, erectile dysfunction	N[C@@H](CCCNC(N)=O)C(O)=O |&1:1,r|, N[C@@H](CCCNC(N)=O)C(O)=O |&1:1,r|, N[C@@H](CCCNC(N)=O)C(O)=O |&1:1,r|, N[C@@H](CCCNC(N)=O)C(O)=O |&1:1,r|	RHGKLRLOHDJJDR-BYPYZUCNSA-N, RHGKLRLOHDJJDR-BYPYZUCNSA-N, RHGKLRLOHDJJDR-BYPYZUCNSA-N, RHGKLRLOHDJJDR-BYPYZUCNSA-N	Launched
L-cysteine		CARS, CARS2, CBS, CDO-1, CDO1, CSAD, CTH, GCLC, GCLM, GOT1, GSS, MGMT, NFS1, SLC19A3	rheumatology	osteoarthritis, rheumatoid arthritis	N[C@@H](CS)C(O)=O	XUJNEKJLAYXESH-REOHCLBHSA-N	Launched
L-cysteinesulfinic-acid	glutamate receptor agonist	GRM1, GRM5, GSR, HMGCS2, PAPOLA, PRDX2			N[C@@H](C[S@@](O)=O)C(O)=O |a:1,&1:3|, N[C@@H](C[S@@](O)=O)C(O)=O |a:1,&1:3|	ADVPTQAUNPRNPO-REOHCLBHSA-N, ADVPTQAUNPRNPO-REOHCLBHSA-N	Preclinical
L-cystine		CTNS, SLC3A1, SLC7A11, SLC7A9			N[C@@H](CSSC[C@H](N)C(O)=O)C(O)=O	LEVWYRKDKASIDU-IMJSIDKUSA-N	Launched
L-ergothioneine	free radical scavenger				C[N+](C)(C)[C@@H](Cc1c[nH]c(=S)[nH]1)C(O)=O	SSISHJJTAXXQAX-ZETCQYMHSA-O	Phase 3
L-glutamic-acid	glutamate receptor agonist	AADAT, AASS, ABAT, ALDH18A1, ASNS, BCAT1, BCAT2, CCBL2, DNPEP, EARS2, ENPEP, EPRS, FOLH1, FPGS, FTCD, GAD1, GAD2, GATB, GCLC, GCLM, GGCX, GLS, GLS2, GLUD1, GLUD2, GLUL, GMPS, GOT1, GOT2, GPT, GPT2, GRIA1, GRIA2, GRIA3, GRIA4, GRID1, GRID2, GRIK1, GRIK2, GRIK3, GRIK4, GRIK5, GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D, GRIN3A, GRIN3B, GRM1, GRM2, GRM3, GRM4, GRM6, GRM7, GRM8, LGSN, NADSYN1, NAGS, OPLAH, PFAS, PGCP, PSAT1, SLC1A1, SLC1A2, SLC1A3, SLC1A6, SLC1A7, SLC25A18, SLC25A22, SLC7A11, TAT			N[C@@H](CCC(O)=O)C(O)=O, N[C@@H](CCC(O)=O)C(O)=O	WHUUTDBJXJRKMK-VKHMYHEASA-N, WHUUTDBJXJRKMK-VKHMYHEASA-N	Launched
L-glutamine		CTPS1, GLUL, GPRC6A, PPAT	gastroenterology, dental, neurology/psychiatry, rheumatology	diarrhea, mucositis, muscle pain, joint pain, peptic ulcer disease (PUD), ulcerative colitis, Crohn's disease, anxiety, insomnia	N[C@@H](CCC(N)=O)C(O)=O, N[C@@H](CCC(N)=O)C(O)=O	ZDXPYRJPNDTMRX-VKHMYHEASA-N, ZDXPYRJPNDTMRX-VKHMYHEASA-N	Launched
L-hydroxyproline					O[C@H]1CN[C@@H](C1)C(O)=O |&1:1,&2:4,r|	PMMYEEVYMWASQN-DMTCNVIQSA-N	Launched
L-kynurenine	aryl hydrocarbon receptor agonist				N[C@@H](CC(=O)c1ccccc1N)C(O)=O	YGPSJZOEDVAXAB-QMMMGPOBSA-N	Phase 1
L-leucine		BCAT1, BCAT2, LARS, LARS2, LCMT1, LCMT2			CC(C)C[C@H](N)C(O)=O	ROHFNLRQFUQHCH-YFKPBYRVSA-N	Phase 3
L-lysine	serotonin receptor agonist	GPRC6A, KARS, SLC7A1, SLC7A2, SLC7A3, SLC7A4			NCCCC[C@H](N)C(O)=O	KDXKERNSBIXSRK-YFKPBYRVSA-N	Phase 2
L-methionine	voltage-gated calcium channel ligand	BHMT, BHMT2, METAP2, MTR, MTRR	pulmonary, allergy, neurology/psychiatry	asthma, allergic rhinitis, depression, Parkinson's Disease, schizophrenia	CSCC[C@H](N)C(O)=O	FFEARJCKVFRZRR-BYPYZUCNSA-N	Launched
L-mimosine	dopamine beta hydroxylase inhibitor, eukaryotic translation initiation factor inhibitor	DBH, EIF5A			N[C@@H](CN1CC(=O)C(=O)C=C1)C(O)=O |c:9|	BLYDGIISUNWHLF-YFKPBYRVSA-N	Preclinical
L-monomethylarginine	nitric oxide synthase inhibitor	NOS1, NOS2			CN[C@@H](CCCNC(N)=N)C(O)=O	NTWVQPHTOUKMDI-YFKPBYRVSA-N	Phase 3
L-NAME	nitric oxide synthase inhibitor	NOS3			COC(=O)[C@@H](N)CCCNC(N)=N[N+]([O-])=O, COC(=O)[C@@H](N)CCCNC(N)=N[N+]([O-])=O, COC(=O)[C@@H](N)CCCNC(N)=N[N+]([O-])=O	KCWZGJVSDFYRIX-YFKPBYRVSA-N, KCWZGJVSDFYRIX-YFKPBYRVSA-N, KCWZGJVSDFYRIX-YFKPBYRVSA-N	Phase 2/Phase 3
L-NIL	nitric oxide synthase inhibitor	NOS1, NOS2, NOS3			CC(=N)NCCCC[C@H](N)C(O)=O, CC(=N)NCCCC[C@H](N)C(O)=O	ONYFNWIHJBLQKE-ZETCQYMHSA-N, ONYFNWIHJBLQKE-ZETCQYMHSA-N	Preclinical
L-phenylisopropyladenosine					C[C@H](Cc1ccccc1)Nc1ncnc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O	RIRGCFBBHQEQQH-SSFGXONLSA-N	Preclinical
L-proline	glutamate receptor agonist	EPRS, L3HYPDH, P3H1, P3H2, P3H3, P4HA1, P4HA2, PARS2, PPIA, PPIB, PPIC, PPIF, PPIG, PPIH, PRODH, PROSC, PYCR1, PYCR2, PYCRL, SLC6A14, SLC6A7			OC(=O)[C@@H]1CCCN1	ONIBWKKTOPOVIA-BYPYZUCNSA-N	Launched
L-quisqualic-acid	glutamate receptor agonist	FOLH1, GRIA2, GRIK1, GRIK2, GRM1, GRM2, GRM3, GRM5, GRM7, GRM8			N[C@@H](Cn1oc(=O)[nH]c1=O)C(O)=O, N[C@@H](Cn1oc(=O)[nH]c1=O)C(O)=O, N[C@@H](Cn1oc(=O)[nH]c1=O)C(O)=O, N[C@@H](Cn1oc(=O)[nH]c1=O)C(O)=O, N[C@@H](Cn1oc(=O)[nH]c1=O)C(O)=O	ASNFTDCKZKHJSW-REOHCLBHSA-N, ASNFTDCKZKHJSW-REOHCLBHSA-N, ASNFTDCKZKHJSW-REOHCLBHSA-N, ASNFTDCKZKHJSW-REOHCLBHSA-N, ASNFTDCKZKHJSW-REOHCLBHSA-N	Preclinical
L-theanine	glutamate receptor antagonist				CCNC(=O)CC[C@H](N)C(O)=O	DATAGRPVKZEWHA-YFKPBYRVSA-N	Launched
L-threonine		TARS, TARS2, THNSL1			C[C@@H](O)[C@H](N)C(O)=O	AYFVYJQAPQTCCC-GBXIJSLDSA-N	Phase 2
L-valine					CC(C)[C@@H](N)C(O)=O, CC(C)[C@@H](N)C(O)=O	KZSNJWFQEVHDMF-SCSAIBSYSA-N, KZSNJWFQEVHDMF-SCSAIBSYSA-N	Phase 2
L-152804	neuropeptide receptor antagonist	NPY5R			CC1(C)CC(=O)C([C@@H]2C3=C(CC(C)(C)CC3=O)Oc3ccccc23)C(=O)C1 |&1:7,r,t:8|, CC1(C)CC(=O)C([C@@H]2C3=C(CC(C)(C)CC3=O)Oc3ccccc23)C(=O)C1 |&1:7,r,t:8|, CC1(C)CC(=O)C([C@@H]2C3=C(CC(C)(C)CC3=O)Oc3ccccc23)C(=O)C1 |&1:7,r,t:8|	XQDXIHYKAGHZRX-LJQANCHMSA-N, XQDXIHYKAGHZRX-LJQANCHMSA-N, XQDXIHYKAGHZRX-LJQANCHMSA-N	Preclinical
L-161982	prostanoid receptor antagonist	PTGER4			CCCCc1nn(-c2ccccc2C(F)(F)F)c(=O)n1Cc1ccc(cc1)-c1ccccc1S(=O)(=O)NC(=O)c1sccc1C, CCCCc1nn(-c2ccccc2C(F)(F)F)c(=O)n1Cc1ccc(cc1)-c1ccccc1S(=O)(=O)NC(=O)c1sccc1C, CCCCc1nn(-c2ccccc2C(F)(F)F)c(=O)n1Cc1ccc(cc1)-c1ccccc1S(=O)(=O)NC(=O)c1sccc1C, CCCCc1nn(-c2ccccc2C(F)(F)F)c(=O)n1Cc1ccc(cc1)-c1ccccc1S(=O)(=O)NC(=O)c1sccc1C	MMDNKTXNUZFVKD-UHFFFAOYSA-N, MMDNKTXNUZFVKD-UHFFFAOYSA-N, MMDNKTXNUZFVKD-UHFFFAOYSA-N, MMDNKTXNUZFVKD-UHFFFAOYSA-N	Preclinical
L-165041	PPAR receptor agonist	PPARD			CCCc1c(O)c(ccc1OCCCOc1ccc(OCC(O)=O)cc1)C(C)=O, CCCc1c(O)c(ccc1OCCCOc1ccc(OCC(O)=O)cc1)C(C)=O, CCCc1c(O)c(ccc1OCCCOc1ccc(OCC(O)=O)cc1)C(C)=O, CCCc1c(O)c(ccc1OCCCOc1ccc(OCC(O)=O)cc1)C(C)=O	HBBVCKCCQCQCTJ-UHFFFAOYSA-N, HBBVCKCCQCQCTJ-UHFFFAOYSA-N, HBBVCKCCQCQCTJ-UHFFFAOYSA-N, HBBVCKCCQCQCTJ-UHFFFAOYSA-N	Preclinical
L-168049	glucagon receptor antagonist	GCGR			CCCOc1ccc(Br)cc1-c1cc([nH]c1-c1ccncc1)-c1ccc(Cl)cc1, CCCOc1ccc(Br)cc1-c1cc([nH]c1-c1ccncc1)-c1ccc(Cl)cc1, CCCOc1ccc(Br)cc1-c1cc([nH]c1-c1ccncc1)-c1ccc(Cl)cc1, CCCOc1ccc(Br)cc1-c1cc([nH]c1-c1ccncc1)-c1ccc(Cl)cc1	HHBOWXZOLYQFNY-UHFFFAOYSA-N, HHBOWXZOLYQFNY-UHFFFAOYSA-N, HHBOWXZOLYQFNY-UHFFFAOYSA-N, HHBOWXZOLYQFNY-UHFFFAOYSA-N	Preclinical
L-365260	CCK receptor antagonist	CCKAR, CCKBR, KCNQ1			CN1c2ccccc2C(=N[C@@H](NC(=O)Nc2cccc(C)c2)C1=O)c1ccccc1 |c:9|	KDFQABSFVYLGPM-QFIPXVFZSA-N	Phase 2
L-368899	oxytocin receptor antagonist	AVPR1A, AVPR2, OXTR			Cc1ccccc1N1CCN(CC1)S(=O)(=O)C[C@]12CC[C@H](C[C@@H]1NC(=O)[C@@H](N)CCS(C)(=O)=O)C2(C)C	MWIASLNTAGRGGA-ZJPWWDJASA-N	Phase 1
L-655,708	GABA receptor inverse agonist	GABRA1, GABRA2, GABRA3, GABRA5, GABRG2			CCOC(=O)c1ncn-2c1[C@@H]1CCCN1C(=O)c1cc(OC)ccc-21, CCOC(=O)c1ncn-2c1[C@@H]1CCCN1C(=O)c1cc(OC)ccc-21, CCOC(=O)c1ncn-2c1[C@@H]1CCCN1C(=O)c1cc(OC)ccc-21, CCOC(=O)c1ncn-2c1[C@@H]1CCCN1C(=O)c1cc(OC)ccc-21, CCOC(=O)c1ncn-2c1[C@@H]1CCCN1C(=O)c1cc(OC)ccc-21	YKYOQIXTECBVBB-AWEZNQCLSA-N, YKYOQIXTECBVBB-AWEZNQCLSA-N, YKYOQIXTECBVBB-AWEZNQCLSA-N, YKYOQIXTECBVBB-AWEZNQCLSA-N, YKYOQIXTECBVBB-AWEZNQCLSA-N	Preclinical
L-655240	thromboxane receptor antagonist	PTGES			Cc1c(CC(C)(C)C(O)=O)n(Cc2ccc(Cl)cc2)c2ccc(F)cc12, Cc1c(CC(C)(C)C(O)=O)n(Cc2ccc(Cl)cc2)c2ccc(F)cc12	JLPYLHLUHJOPNL-UHFFFAOYSA-N, JLPYLHLUHJOPNL-UHFFFAOYSA-N	Phase 1
L-670596	prostanoid receptor antagonist				CS(=O)(=O)c1ccc(Cn2c3[C@@H](CC(O)=O)CCCc3c3cc(F)cc(F)c23)cc1 |&1:11,r|, CS(=O)(=O)c1ccc(Cn2c3[C@@H](CC(O)=O)CCCc3c3cc(F)cc(F)c23)cc1 |&1:11,r|, CS(=O)(=O)c1ccc(Cn2c3[C@@H](CC(O)=O)CCCc3c3cc(F)cc(F)c23)cc1 |&1:11,r|	GMJWAIMJHBTYPD-CQSZACIVSA-N, GMJWAIMJHBTYPD-CQSZACIVSA-N, GMJWAIMJHBTYPD-CQSZACIVSA-N	Preclinical
L-689560	glutamate receptor antagonist	GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D			OC(=O)[C@H]1C[C@H](NC(=O)Nc2ccccc2)c2c(Cl)cc(Cl)cc2N1, OC(=O)[C@H]1C[C@H](NC(=O)Nc2ccccc2)c2c(Cl)cc(Cl)cc2N1, OC(=O)[C@H]1C[C@H](NC(=O)Nc2ccccc2)c2c(Cl)cc(Cl)cc2N1	UCKHICKHGAOGAP-UONOGXRCSA-N, UCKHICKHGAOGAP-UONOGXRCSA-N, UCKHICKHGAOGAP-UONOGXRCSA-N	Preclinical
L-690330	inositol monophosphatase inhibitor	IMPA1			CC(Oc1ccc(O)cc1)(P(O)(O)=O)P(O)(O)=O	JKOCAAWWDVHWKB-UHFFFAOYSA-N	Preclinical
L-693403	sigma receptor agonist, sigma receptor antagonist	DRD2, SIGMAR1			C(N1CCC2(CCc3ccccc23)CC1)c1ccccc1, C(N1CCC2(CCc3ccccc23)CC1)c1ccccc1, C(N1CCC2(CCc3ccccc23)CC1)c1ccccc1, C(N1CCC2(CCc3ccccc23)CC1)c1ccccc1, C(N1CCC2(CCc3ccccc23)CC1)c1ccccc1	GSXJSGMDWKPVBY-UHFFFAOYSA-N, GSXJSGMDWKPVBY-UHFFFAOYSA-N, GSXJSGMDWKPVBY-UHFFFAOYSA-N, GSXJSGMDWKPVBY-UHFFFAOYSA-N, GSXJSGMDWKPVBY-UHFFFAOYSA-N	Preclinical
L-694247	serotonin receptor agonist	HTR1A, HTR1B, HTR1D			CS(=O)(=O)Nc1ccc(Cc2noc(n2)-c2ccc3[nH]cc(CCN)c3c2)cc1, CS(=O)(=O)Nc1ccc(Cc2noc(n2)-c2ccc3[nH]cc(CCN)c3c2)cc1	HKXMQLISPYELRD-UHFFFAOYSA-N, HKXMQLISPYELRD-UHFFFAOYSA-N	Preclinical
L-701252	glutamate receptor antagonist	GRIN1			Oc1c(C(=O)C2CC2)c(=O)[nH]c2cc(Cl)ccc12	MXEFWCFPCLDOOG-UHFFFAOYSA-N	Preclinical
L-701324	glutamate receptor antagonist	GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D			Oc1c(-c2cccc(Oc3ccccc3)c2)c(=O)[nH]c2cc(Cl)ccc12, Oc1c(-c2cccc(Oc3ccccc3)c2)c(=O)[nH]c2cc(Cl)ccc12, Oc1c(-c2cccc(Oc3ccccc3)c2)c(=O)[nH]c2cc(Cl)ccc12, Oc1c(-c2cccc(Oc3ccccc3)c2)c(=O)[nH]c2cc(Cl)ccc12	FLVRDMUHUXVRET-UHFFFAOYSA-N, FLVRDMUHUXVRET-UHFFFAOYSA-N, FLVRDMUHUXVRET-UHFFFAOYSA-N, FLVRDMUHUXVRET-UHFFFAOYSA-N	Preclinical
L-732,138	tachykinin antagonist	TACR1, TACR2			CC(=O)N[C@H](Cc1c[nH]c2ccccc12)C(=O)OCc1cc(cc(c1)C(F)(F)F)C(F)(F)F, CC(=O)N[C@H](Cc1c[nH]c2ccccc12)C(=O)OCc1cc(cc(c1)C(F)(F)F)C(F)(F)F, CC(=O)N[C@H](Cc1c[nH]c2ccccc12)C(=O)OCc1cc(cc(c1)C(F)(F)F)C(F)(F)F, CC(=O)N[C@H](Cc1c[nH]c2ccccc12)C(=O)OCc1cc(cc(c1)C(F)(F)F)C(F)(F)F	BYYQYXVAWXAYQC-LJQANCHMSA-N, BYYQYXVAWXAYQC-LJQANCHMSA-N, BYYQYXVAWXAYQC-LJQANCHMSA-N, BYYQYXVAWXAYQC-LJQANCHMSA-N	Preclinical
L-733060	tachykinin antagonist	TACR1			FC(F)(F)c1cc(CO[C@H]2CCCN[C@H]2c2ccccc2)cc(c1)C(F)(F)F, FC(F)(F)c1cc(CO[C@H]2CCCN[C@H]2c2ccccc2)cc(c1)C(F)(F)F, FC(F)(F)c1cc(CO[C@H]2CCCN[C@H]2c2ccccc2)cc(c1)C(F)(F)F, FC(F)(F)c1cc(CO[C@H]2CCCN[C@H]2c2ccccc2)cc(c1)C(F)(F)F	FCDRFVCGMLUYPG-ROUUACIJSA-N, FCDRFVCGMLUYPG-ROUUACIJSA-N, FCDRFVCGMLUYPG-ROUUACIJSA-N, FCDRFVCGMLUYPG-ROUUACIJSA-N	Preclinical
L-741742	dopamine receptor antagonist	DRD3, DRD4, SCN1A, SCN3A			Cc1c(noc1-c1ccc(Cl)cc1)C1CCN(CCc2ccccc2)CC1, Cc1c(noc1-c1ccc(Cl)cc1)C1CCN(CCc2ccccc2)CC1	QDMAKDIDFJTXEL-UHFFFAOYSA-N, QDMAKDIDFJTXEL-UHFFFAOYSA-N	Preclinical
L-745870	dopamine receptor antagonist	DRD1, DRD2, DRD3, DRD4, HTR1A, HTR2A, HTR6, HTR7			Clc1ccc(cc1)N1CCN(Cc2c[nH]c3ncccc23)CC1, Clc1ccc(cc1)N1CCN(Cc2c[nH]c3ncccc23)CC1, Clc1ccc(cc1)N1CCN(Cc2c[nH]c3ncccc23)CC1	OGJGQVFWEPNYSB-UHFFFAOYSA-N, OGJGQVFWEPNYSB-UHFFFAOYSA-N, OGJGQVFWEPNYSB-UHFFFAOYSA-N	Preclinical
L-755507	adrenergic receptor agonist	ADRB1, ADRB2, ADRB3			CCCCCCNC(=O)Nc1ccc(cc1)S(=O)(=O)Nc1ccc(CCNC[C@H](O)COc2ccc(O)cc2)cc1, CCCCCCNC(=O)Nc1ccc(cc1)S(=O)(=O)Nc1ccc(CCNC[C@H](O)COc2ccc(O)cc2)cc1, CCCCCCNC(=O)Nc1ccc(cc1)S(=O)(=O)Nc1ccc(CCNC[C@H](O)COc2ccc(O)cc2)cc1	NYYJKMXNVNFOFQ-MHZLTWQESA-N, NYYJKMXNVNFOFQ-MHZLTWQESA-N, NYYJKMXNVNFOFQ-MHZLTWQESA-N	Preclinical
L-760735	tachykinin antagonist	TACR1			C[C@@H](O[C@H]1OCCN(Cc2n[nH]nc2CN(C)C)[C@H]1c1ccc(F)cc1)c1cc(cc(c1)C(F)(F)F)C(F)(F)F, C[C@@H](O[C@H]1OCCN(Cc2n[nH]nc2CN(C)C)[C@H]1c1ccc(F)cc1)c1cc(cc(c1)C(F)(F)F)C(F)(F)F	USRYEHHMJIRICK-ZNZBMKLDSA-N, USRYEHHMJIRICK-ZNZBMKLDSA-N	Preclinical
L-778123	farnesyltransferase inhibitor	FNTA, FNTB, PGGT1B			Clc1cccc(c1)N1CCN(Cc2cncn2Cc2ccc(cc2)C#N)CC1=O, Clc1cccc(c1)N1CCN(Cc2cncn2Cc2ccc(cc2)C#N)CC1=O, Clc1cccc(c1)N1CCN(Cc2cncn2Cc2ccc(cc2)C#N)CC1=O, Clc1cccc(c1)N1CCN(Cc2cncn2Cc2ccc(cc2)C#N)CC1=O, Clc1cccc(c1)N1CCN(Cc2cncn2Cc2ccc(cc2)C#N)CC1=O	JNUGFGAVPBYSHF-UHFFFAOYSA-N, JNUGFGAVPBYSHF-UHFFFAOYSA-N, JNUGFGAVPBYSHF-UHFFFAOYSA-N, JNUGFGAVPBYSHF-UHFFFAOYSA-N, JNUGFGAVPBYSHF-UHFFFAOYSA-N	Phase 1
L-798106	prostanoid receptor antagonist	PTGER3			COc1ccc(Br)cc1S(=O)(=O)NC(=O)\C=C\c1ccccc1Cc1ccc2ccccc2c1, COc1ccc(Br)cc1S(=O)(=O)NC(=O)\C=C\c1ccccc1Cc1ccc2ccccc2c1, COc1ccc(Br)cc1S(=O)(=O)NC(=O)\C=C\c1ccccc1Cc1ccc2ccccc2c1	ODTKFNUPVBULRJ-NTCAYCPXSA-N, ODTKFNUPVBULRJ-NTCAYCPXSA-N, ODTKFNUPVBULRJ-NTCAYCPXSA-N	Preclinical
L-838417	GABA receptor partial agonist	GABRA1, GABRA2, GABRA3, GABRA5			Cn1ncnc1COc1nn2c(nnc2cc1C(C)(C)C)-c1cc(F)ccc1F, Cn1ncnc1COc1nn2c(nnc2cc1C(C)(C)C)-c1cc(F)ccc1F, Cn1ncnc1COc1nn2c(nnc2cc1C(C)(C)C)-c1cc(F)ccc1F	BQDUNOMMYOKHEP-UHFFFAOYSA-N, BQDUNOMMYOKHEP-UHFFFAOYSA-N, BQDUNOMMYOKHEP-UHFFFAOYSA-N	Preclinical
labetalol	adrenergic receptor antagonist	ADRA1D, ADRB1, ADRB2	cardiology	hypertension	C[C@@H](CCc1ccccc1)NC[C@@H](O)c1ccc(O)c(c1)C(N)=O |&1:1,&2:12,r|, C[C@@H](CCc1ccccc1)NC[C@@H](O)c1ccc(O)c(c1)C(N)=O |&1:1,&2:12,r|	SGUAFYQXFOLMHL-SCLBCKFNSA-N, SGUAFYQXFOLMHL-SCLBCKFNSA-N	Launched
lacidipine	calcium channel blocker	CACNA1C	cardiology	hypertension	CCOC(=O)C1=C(C)NC(C)=C(C1c1ccccc1\C=C\C(=O)OC(C)(C)C)C(=O)OCC |c:5,10|, CCOC(=O)C1=C(C)NC(C)=C(C1c1ccccc1\C=C\C(=O)OC(C)(C)C)C(=O)OCC |c:5,10|, CCOC(=O)C1=C(C)NC(C)=C(C1c1ccccc1\C=C\C(=O)OC(C)(C)C)C(=O)OCC |c:5,10|, CCOC(=O)C1=C(C)NC(C)=C(C1c1ccccc1\C=C\C(=O)OC(C)(C)C)C(=O)OCC |c:5,10|, CCOC(=O)C1=C(C)NC(C)=C(C1c1ccccc1\C=C\C(=O)OC(C)(C)C)C(=O)OCC |c:5,10|, CCOC(=O)C1=C(C)NC(C)=C(C1c1ccccc1\C=C\C(=O)OC(C)(C)C)C(=O)OCC |c:5,10|	GKQPCPXONLDCMU-CCEZHUSRSA-N, GKQPCPXONLDCMU-CCEZHUSRSA-N, GKQPCPXONLDCMU-CCEZHUSRSA-N, GKQPCPXONLDCMU-CCEZHUSRSA-N, GKQPCPXONLDCMU-CCEZHUSRSA-N, GKQPCPXONLDCMU-CCEZHUSRSA-N	Launched
lacitol	laxative		gastroenterology	constipation	OC[C@H](O)[C@@H](O)[C@H](O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O)[C@H](O)CO, OC[C@H](O)[C@@H](O)[C@H](O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O)[C@H](O)CO, OC[C@H](O)[C@@H](O)[C@H](O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O)[C@H](O)CO	VQHSOMBJVWLPSR-JVCRWLNRSA-N, VQHSOMBJVWLPSR-JVCRWLNRSA-N, VQHSOMBJVWLPSR-JVCRWLNRSA-N	Launched
lactulose	laxative		gastroenterology	portal-systemic encephalopathy (PSE)	OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O, OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O, OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O	JCQLYHFGKNRPGE-FCVZTGTOSA-N, JCQLYHFGKNRPGE-FCVZTGTOSA-N, JCQLYHFGKNRPGE-FCVZTGTOSA-N	Launched
lafutidine	histamine receptor antagonist	HRH2	gastroenterology	duodenal ulcer disease, peptic ulcer disease (PUD)	O=C(C[S@@](=O)Cc1ccco1)NC\C=C/COc1cc(CN2CCCCC2)ccn1 |&1:3|	KMZQAVXSMUKBPD-FCRIZLRQSA-N	Launched
lamivudine	nucleoside reverse transcriptase inhibitor		infectious disease	human immunodeficiency virus (HIV-1), acquired immunodeficiency syndrome (AIDS), hepatitis B	Nc1ccn([C@@H]2CS[C@H](CO)O2)c(=O)n1, Nc1ccn([C@@H]2CS[C@H](CO)O2)c(=O)n1	JTEGQNOMFQHVDC-NKWVEPMBSA-N, JTEGQNOMFQHVDC-NKWVEPMBSA-N	Launched
lamotrigine	serotonin receptor antagonist, sodium channel blocker	SCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A	neurology/psychiatry	epilepsy, bipolar disorder	Nc1nnc(c(N)n1)-c1cccc(Cl)c1Cl, Nc1nnc(c(N)n1)-c1cccc(Cl)c1Cl, Nc1nnc(c(N)n1)-c1cccc(Cl)c1Cl, Nc1nnc(c(N)n1)-c1cccc(Cl)c1Cl	PYZRQGJRPPTADH-UHFFFAOYSA-N, PYZRQGJRPPTADH-UHFFFAOYSA-N, PYZRQGJRPPTADH-UHFFFAOYSA-N, PYZRQGJRPPTADH-UHFFFAOYSA-N	Launched
lanabecestat	beta secretase inhibitor				CO[C@H]1CC[C@@]2(Cc3ccc(cc3[C@@]22N=C(C)C(N)=N2)-c2cncc(c2)C#CC)CC1 |c:20,t:16|	WKDNQONLGXOZRG-HRNNMHKYSA-N	Phase 3
lanatoside-C	cardiac glycoside				C[C@H]1O[C@H](C[C@H](O)[C@@H]1O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](OC(C)=O)[C@H](O[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)[C@@H](C)O2)[C@@H](C)O1)O[C@H]1CC[C@@]2(C)[C@@H](CC[C@H]3[C@@H]2C[C@@H](O)[C@]2(C)[C@H](CC[C@]32O)C2=CC(=O)OC2)C1 |a:1,3,5,7,9,11,13,15,17,22,24,26,29,31,33,35,38,42,45,53,55,57,60,&1:47,&2:50,&3:51,t:69|, C[C@H]1O[C@H](C[C@H](O)[C@@H]1O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](OC(C)=O)[C@H](O[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)[C@@H](C)O2)[C@@H](C)O1)O[C@H]1CC[C@@]2(C)[C@@H](CC[C@H]3[C@@H]2C[C@@H](O)[C@]2(C)[C@H](CC[C@]32O)C2=CC(=O)OC2)C1 |a:1,3,5,7,9,11,13,15,17,22,24,26,29,31,33,35,38,42,45,53,55,57,60,&1:47,&2:50,&3:51,t:69|	JAYAGJDXJIDEKI-FUVOQQLASA-N, JAYAGJDXJIDEKI-FUVOQQLASA-N	Preclinical
landiolol	adrenergic receptor antagonist	ADRB1	cardiology	cardiac arrythmia	CC1(C)OC[C@@H](COC(=O)CCc2ccc(OC[C@@H](O)CNCCNC(=O)N3CCOCC3)cc2)O1, CC1(C)OC[C@@H](COC(=O)CCc2ccc(OC[C@@H](O)CNCCNC(=O)N3CCOCC3)cc2)O1	WMDSZGFJQKSLLH-RBBKRZOGSA-N, WMDSZGFJQKSLLH-RBBKRZOGSA-N	Launched
lanifibranor	PPAR receptor agonist				OC(=O)CCCc1cc2cc(Cl)ccc2n1S(=O)(=O)c1ccc2ncsc2c1	OQDQIFQRNZIEEJ-UHFFFAOYSA-N	Phase 2
lanoconazole	sterol demethylase inhibitor		infectious disease	fungal infection	Clc1ccccc1[C@H]1CS\C(S1)=C(\C#N)n1ccnc1 |&1:7,r|	ZRTQSJFIDWNVJW-MNWMYKRDSA-N	Launched
lansoprazole	ATPase inhibitor	ATP4A, ATP4B	gastroenterology	heartburn	Cc1c(OCC(F)(F)F)ccnc1C[S@@](=O)c1nc2ccccc2[nH]1 |&1:14,r|	MJIHNNLFOKEZEW-RUZDIDTESA-N	Launched
lapatinib	EGFR inhibitor	EGFR, ERBB2	oncology	breast cancer	CS(=O)(=O)CCNCc1ccc(o1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1, CS(=O)(=O)CCNCc1ccc(o1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1, CS(=O)(=O)CCNCc1ccc(o1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1, CS(=O)(=O)CCNCc1ccc(o1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1, CS(=O)(=O)CCNCc1ccc(o1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1, CS(=O)(=O)CCNCc1ccc(o1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1, CS(=O)(=O)CCNCc1ccc(o1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1, CS(=O)(=O)CCNCc1ccc(o1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1	BCFGMOOMADDAQU-UHFFFAOYSA-N, BCFGMOOMADDAQU-UHFFFAOYSA-N, BCFGMOOMADDAQU-UHFFFAOYSA-N, BCFGMOOMADDAQU-UHFFFAOYSA-N, BCFGMOOMADDAQU-UHFFFAOYSA-N, BCFGMOOMADDAQU-UHFFFAOYSA-N, BCFGMOOMADDAQU-UHFFFAOYSA-N, BCFGMOOMADDAQU-UHFFFAOYSA-N	Launched
lappaconite	sodium channel blocker				CCN1C[C@@]2(CC[C@H](OC)[C@@]34[C@@H]5C[C@H]6[C@H](OC)[C@]5(O)[C@](O)(C[C@@H]6OC)[C@@H](C[C@H]23)[C@@H]14)OC(=O)c1ccccc1NC(C)=O	NWBWCXBPKTTZNQ-QOQRDJBUSA-N	Phase 2
laquinimod	immunosuppressant	CXCL2			CCN(C(=O)c1c(O)c2c(Cl)cccc2n(C)c1=O)c1ccccc1, CCN(C(=O)c1c(O)c2c(Cl)cccc2n(C)c1=O)c1ccccc1, CCN(C(=O)c1c(O)c2c(Cl)cccc2n(C)c1=O)c1ccccc1, CCN(C(=O)c1c(O)c2c(Cl)cccc2n(C)c1=O)c1ccccc1, CCN(C(=O)c1c(O)c2c(Cl)cccc2n(C)c1=O)c1ccccc1	GKWPCEFFIHSJOE-UHFFFAOYSA-N, GKWPCEFFIHSJOE-UHFFFAOYSA-N, GKWPCEFFIHSJOE-UHFFFAOYSA-N, GKWPCEFFIHSJOE-UHFFFAOYSA-N, GKWPCEFFIHSJOE-UHFFFAOYSA-N	Phase 3
larazotide-acetate	tight junction regulator				CC(C)C[C@H](NC(=O)[C@@H](NC(=O)CNC(=O)CN)C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O	ORFLZNAGUTZRLQ-ZMBVWFSWSA-N	Phase 2
laropiprant	prostanoid receptor antagonist	PTGDR, PTGDR2, PTGER1, PTGER2, PTGER3, PTGFR, PTGIR, TBXA2R	cardiology	cholesterol	CS(=O)(=O)c1cc(F)cc2c3CC[C@H](CC(O)=O)c3n(Cc3ccc(Cl)cc3)c12, CS(=O)(=O)c1cc(F)cc2c3CC[C@H](CC(O)=O)c3n(Cc3ccc(Cl)cc3)c12, CS(=O)(=O)c1cc(F)cc2c3CC[C@H](CC(O)=O)c3n(Cc3ccc(Cl)cc3)c12, CS(=O)(=O)c1cc(F)cc2c3CC[C@H](CC(O)=O)c3n(Cc3ccc(Cl)cc3)c12, CS(=O)(=O)c1cc(F)cc2c3CC[C@H](CC(O)=O)c3n(Cc3ccc(Cl)cc3)c12	NXFFJDQHYLNEJK-CYBMUJFWSA-N, NXFFJDQHYLNEJK-CYBMUJFWSA-N, NXFFJDQHYLNEJK-CYBMUJFWSA-N, NXFFJDQHYLNEJK-CYBMUJFWSA-N, NXFFJDQHYLNEJK-CYBMUJFWSA-N	Launched
larotrectinib	tropomyosin receptor kinase inhibitor	NTRK1, NTRK2, NTRK3			O[C@H]1CCN(C1)C(=O)Nc1cnn2ccc(nc12)N1CCC[C@@H]1c1cc(F)ccc1F, O[C@H]1CCN(C1)C(=O)Nc1cnn2ccc(nc12)N1CCC[C@@H]1c1cc(F)ccc1F	NYNZQNWKBKUAII-KBXCAEBGSA-N, NYNZQNWKBKUAII-KBXCAEBGSA-N	Launched
lasalocid	bacterial permeability inducer		infectious disease	coccidiosis	CC[C@H]([C@H]1O[C@@](CC)(C[C@@H]1C)[C@H]1CC[C@](O)(CC)[C@H](C)O1)C(=O)[C@@H](C)[C@@H](O)[C@H](C)CCc1ccc(C)c(O)c1C(O)=O	BBMULGJBVDDDNI-OWKLGTHSSA-N	Launched
lasmiditan	serotonin receptor agonist				CN1CCC(CC1)C(=O)c1cccc(NC(=O)c2c(F)cc(F)cc2F)n1	XEDHVZKDSYZQBF-UHFFFAOYSA-N	Launched
lasofoxifene	selective estrogen receptor modulator (SERM)	ESR1, ESR2	orthopedics, oncology	osteoporosis, breast cancer	O[C@@H]([C@H](O)C(O)=O)C(O)=O.Oc1ccc2[C@H]([C@H](CCc2c1)c1ccccc1)c1ccc(OCCN2CCCC2)cc1, O[C@@H]([C@H](O)C(O)=O)C(O)=O.Oc1ccc2[C@H]([C@H](CCc2c1)c1ccccc1)c1ccc(OCCN2CCCC2)cc1	INEHJXCWEVNEDZ-LUDNRVPPSA-N, INEHJXCWEVNEDZ-LUDNRVPPSA-N	Launched
latanoprost	prostanoid receptor agonist	PTGFR	ophthalmology	ocular hypertension, glaucoma	CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCc1ccccc1, CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCc1ccccc1	GGXICVAJURFBLW-CEYXHVGTSA-N, GGXICVAJURFBLW-CEYXHVGTSA-N	Launched
latrepirdine	glutamate receptor antagonist	HRH1, HTR6			CN1CCc2c(C1)c1cc(C)ccc1n2CCc1ccc(C)nc1, CN1CCc2c(C1)c1cc(C)ccc1n2CCc1ccc(C)nc1, CN1CCc2c(C1)c1cc(C)ccc1n2CCc1ccc(C)nc1, CN1CCc2c(C1)c1cc(C)ccc1n2CCc1ccc(C)nc1, CN1CCc2c(C1)c1cc(C)ccc1n2CCc1ccc(C)nc1	JNODQFNWMXFMEV-UHFFFAOYSA-N, JNODQFNWMXFMEV-UHFFFAOYSA-N, JNODQFNWMXFMEV-UHFFFAOYSA-N, JNODQFNWMXFMEV-UHFFFAOYSA-N, JNODQFNWMXFMEV-UHFFFAOYSA-N	Phase 3
latrunculin-B	actin polymerization inhibitor	ACTA1, MKL1, SPIRE2			C[C@H]1CC[C@@H]2C[C@H](C[C@@](O)(O2)[C@@H]2CSC(=O)N2)OC(=O)\C=C(C)/CC\C=C/1 |c:27,t:22|, C[C@H]1CC[C@@H]2C[C@H](C[C@@](O)(O2)[C@@H]2CSC(=O)N2)OC(=O)\C=C(C)/CC\C=C/1 |c:27,t:22|	NSHPHXHGRHSMIK-JRIKCGFMSA-N, NSHPHXHGRHSMIK-JRIKCGFMSA-N	Phase 1
lauric-acid	bacterial permeability inducer	GPR84, HNF4A, LTF, LY96, PLA2G2A, TLR4			CCCCCCCCCCCC(O)=O	POULHZVOKOAJMA-UHFFFAOYSA-N	Phase 3
lauric-diethanolamide					CCCCCCCCCCCC(=O)N(CCO)CCO, CCCCCCCCCCCC(=O)N(CCO)CCO	AOMUHOFOVNGZAN-UHFFFAOYSA-N, AOMUHOFOVNGZAN-UHFFFAOYSA-N	Preclinical
laurocapram					CCCCCCCCCCCCN1CCCCCC1=O, CCCCCCCCCCCCN1CCCCCC1=O	AXTGDCSMTYGJND-UHFFFAOYSA-N, AXTGDCSMTYGJND-UHFFFAOYSA-N	Phase 3
lazabemide	monoamine oxidase inhibitor	MAOB			NCCNC(=O)c1ccc(Cl)cn1, NCCNC(=O)c1ccc(Cl)cn1, NCCNC(=O)c1ccc(Cl)cn1	JZXRLKWWVNUZRB-UHFFFAOYSA-N, JZXRLKWWVNUZRB-UHFFFAOYSA-N, JZXRLKWWVNUZRB-UHFFFAOYSA-N	Phase 3
lazertinib	tyrosine kinase inhibitor				COc1cc(N2CCOCC2)c(NC(=O)C=C)cc1Nc1nccc(n1)-n1cc(CN(C)C)c(n1)-c1ccccc1	RRMJMHOQSALEJJ-UHFFFAOYSA-N	Phase 1/Phase 2
LB-100	protein phosphatase inhibitor				CN1CCN(CC1)C(=O)[C@@H]1[C@H]2CC[C@H](O2)[C@@H]1C(O)=O |&1:10,13,&2:15,&3:9|	JUQMLSGOTNKJKI-YTWAJWBKSA-N	Phase 2
LB42708	farnesyltransferase inhibitor				Brc1ccc(Cn2cncc2Cn2cc(C(=O)N3CCOCC3)c(c2)-c2cccc3ccccc23)cc1, Brc1ccc(Cn2cncc2Cn2cc(C(=O)N3CCOCC3)c(c2)-c2cccc3ccccc23)cc1, Brc1ccc(Cn2cncc2Cn2cc(C(=O)N3CCOCC3)c(c2)-c2cccc3ccccc23)cc1, Brc1ccc(Cn2cncc2Cn2cc(C(=O)N3CCOCC3)c(c2)-c2cccc3ccccc23)cc1, Brc1ccc(Cn2cncc2Cn2cc(C(=O)N3CCOCC3)c(c2)-c2cccc3ccccc23)cc1, Brc1ccc(Cn2cncc2Cn2cc(C(=O)N3CCOCC3)c(c2)-c2cccc3ccccc23)cc1, Brc1ccc(Cn2cncc2Cn2cc(C(=O)N3CCOCC3)c(c2)-c2cccc3ccccc23)cc1, Brc1ccc(Cn2cncc2Cn2cc(C(=O)N3CCOCC3)c(c2)-c2cccc3ccccc23)cc1, Brc1ccc(Cn2cncc2Cn2cc(C(=O)N3CCOCC3)c(c2)-c2cccc3ccccc23)cc1, Brc1ccc(Cn2cncc2Cn2cc(C(=O)N3CCOCC3)c(c2)-c2cccc3ccccc23)cc1	GUUIRIMAQGOLHT-UHFFFAOYSA-N, GUUIRIMAQGOLHT-UHFFFAOYSA-N, GUUIRIMAQGOLHT-UHFFFAOYSA-N, GUUIRIMAQGOLHT-UHFFFAOYSA-N, GUUIRIMAQGOLHT-UHFFFAOYSA-N, GUUIRIMAQGOLHT-UHFFFAOYSA-N, GUUIRIMAQGOLHT-UHFFFAOYSA-N, GUUIRIMAQGOLHT-UHFFFAOYSA-N, GUUIRIMAQGOLHT-UHFFFAOYSA-N, GUUIRIMAQGOLHT-UHFFFAOYSA-N	Preclinical
LCL-161	XIAP inhibitor	BIRC2, XIAP			CN[C@@H](C)C(=O)N[C@@H](C1CCCCC1)C(=O)N1CCC[C@H]1c1nc(cs1)C(=O)c1ccc(F)cc1, CN[C@@H](C)C(=O)N[C@@H](C1CCCCC1)C(=O)N1CCC[C@H]1c1nc(cs1)C(=O)c1ccc(F)cc1, CN[C@@H](C)C(=O)N[C@@H](C1CCCCC1)C(=O)N1CCC[C@H]1c1nc(cs1)C(=O)c1ccc(F)cc1, CN[C@@H](C)C(=O)N[C@@H](C1CCCCC1)C(=O)N1CCC[C@H]1c1nc(cs1)C(=O)c1ccc(F)cc1, CN[C@@H](C)C(=O)N[C@@H](C1CCCCC1)C(=O)N1CCC[C@H]1c1nc(cs1)C(=O)c1ccc(F)cc1, CN[C@@H](C)C(=O)N[C@@H](C1CCCCC1)C(=O)N1CCC[C@H]1c1nc(cs1)C(=O)c1ccc(F)cc1, CN[C@@H](C)C(=O)N[C@@H](C1CCCCC1)C(=O)N1CCC[C@H]1c1nc(cs1)C(=O)c1ccc(F)cc1, CN[C@@H](C)C(=O)N[C@@H](C1CCCCC1)C(=O)N1CCC[C@H]1c1nc(cs1)C(=O)c1ccc(F)cc1	UFPFGVNKHCLJJO-SSKFGXFMSA-N, UFPFGVNKHCLJJO-SSKFGXFMSA-N, UFPFGVNKHCLJJO-SSKFGXFMSA-N, UFPFGVNKHCLJJO-SSKFGXFMSA-N, UFPFGVNKHCLJJO-SSKFGXFMSA-N, UFPFGVNKHCLJJO-SSKFGXFMSA-N, UFPFGVNKHCLJJO-SSKFGXFMSA-N, UFPFGVNKHCLJJO-SSKFGXFMSA-N	Phase 2
LCQ908	diacylglycerol O acyltransferase inhibitor	DGAT1			OC(=O)C[C@H]1CC[C@@H](CC1)c1ccc(cc1)-c1ccc(Nc2ccc(nc2)C(F)(F)F)cn1 |r|, OC(=O)C[C@H]1CC[C@@H](CC1)c1ccc(cc1)-c1ccc(Nc2ccc(nc2)C(F)(F)F)cn1 |r|, OC(=O)C[C@H]1CC[C@@H](CC1)c1ccc(cc1)-c1ccc(Nc2ccc(nc2)C(F)(F)F)cn1 |r|, OC(=O)C[C@H]1CC[C@@H](CC1)c1ccc(cc1)-c1ccc(Nc2ccc(nc2)C(F)(F)F)cn1 |r|, OC(=O)C[C@H]1CC[C@@H](CC1)c1ccc(cc1)-c1ccc(Nc2ccc(nc2)C(F)(F)F)cn1 |r|, OC(=O)C[C@H]1CC[C@@H](CC1)c1ccc(cc1)-c1ccc(Nc2ccc(nc2)C(F)(F)F)cn1 |r|	GXALXAKNHIROPE-QAQDUYKDSA-N, GXALXAKNHIROPE-QAQDUYKDSA-N, GXALXAKNHIROPE-QAQDUYKDSA-N, GXALXAKNHIROPE-QAQDUYKDSA-N, GXALXAKNHIROPE-QAQDUYKDSA-N, GXALXAKNHIROPE-QAQDUYKDSA-N	Phase 3
LCZ696	angiotensin receptor antagonist		cardiology	angioedema, hypotension			Launched
LDC1267	protein tyrosine kinase inhibitor	AXL, MERTK, TYRO3			CCOc1cn(nc1C(=O)Nc1ccc(Oc2ccnc3cc(OC)c(OC)cc23)c(F)c1)-c1ccc(F)cc1C, CCOc1cn(nc1C(=O)Nc1ccc(Oc2ccnc3cc(OC)c(OC)cc23)c(F)c1)-c1ccc(F)cc1C	ISPBCAXOSOLFME-UHFFFAOYSA-N, ISPBCAXOSOLFME-UHFFFAOYSA-N	Preclinical
LDN-209929	haspin kinase inhibitor	GSG2			COc1ccc2nc3ccc(Cl)cc3c(SCCCN)c2c1, COc1ccc2nc3ccc(Cl)cc3c(SCCCN)c2c1	XMMAOXMYUGQGJD-UHFFFAOYSA-N, XMMAOXMYUGQGJD-UHFFFAOYSA-N	Preclinical
LDN-212854	bone morphogenic protein inhibitor	ABL1, ACVR1, RIPK2			C1CN(CCN1)c1ccc(cc1)-c1cnc2c(cnn2c1)-c1cccc2ncccc12, C1CN(CCN1)c1ccc(cc1)-c1cnc2c(cnn2c1)-c1cccc2ncccc12, C1CN(CCN1)c1ccc(cc1)-c1cnc2c(cnn2c1)-c1cccc2ncccc12, C1CN(CCN1)c1ccc(cc1)-c1cnc2c(cnn2c1)-c1cccc2ncccc12, C1CN(CCN1)c1ccc(cc1)-c1cnc2c(cnn2c1)-c1cccc2ncccc12, C1CN(CCN1)c1ccc(cc1)-c1cnc2c(cnn2c1)-c1cccc2ncccc12, C1CN(CCN1)c1ccc(cc1)-c1cnc2c(cnn2c1)-c1cccc2ncccc12, C1CN(CCN1)c1ccc(cc1)-c1cnc2c(cnn2c1)-c1cccc2ncccc12, C1CN(CCN1)c1ccc(cc1)-c1cnc2c(cnn2c1)-c1cccc2ncccc12, C1CN(CCN1)c1ccc(cc1)-c1cnc2c(cnn2c1)-c1cccc2ncccc12	BBDGBGOVJPEFBT-UHFFFAOYSA-N, BBDGBGOVJPEFBT-UHFFFAOYSA-N, BBDGBGOVJPEFBT-UHFFFAOYSA-N, BBDGBGOVJPEFBT-UHFFFAOYSA-N, BBDGBGOVJPEFBT-UHFFFAOYSA-N, BBDGBGOVJPEFBT-UHFFFAOYSA-N, BBDGBGOVJPEFBT-UHFFFAOYSA-N, BBDGBGOVJPEFBT-UHFFFAOYSA-N, BBDGBGOVJPEFBT-UHFFFAOYSA-N, BBDGBGOVJPEFBT-UHFFFAOYSA-N	Preclinical
LDN-27219	tissue transglutaminase inhibitor	TGM2			NNC(=O)CSc1nc2scc(-c3ccccc3)c2c(=O)n1-c1ccccc1, NNC(=O)CSc1nc2scc(-c3ccccc3)c2c(=O)n1-c1ccccc1	WLBUICQBNZXIDJ-UHFFFAOYSA-N, WLBUICQBNZXIDJ-UHFFFAOYSA-N	Preclinical
LDN-57444	ubiquitin C-terminal hydrolase inhibitor				CC(=O)O\N=C1\C(=O)N(Cc2cc(Cl)ccc2Cl)c2ccc(Cl)cc12, CC(=O)O\N=C1\C(=O)N(Cc2cc(Cl)ccc2Cl)c2ccc(Cl)cc12, CC(=O)O\N=C1\C(=O)N(Cc2cc(Cl)ccc2Cl)c2ccc(Cl)cc12, CC(=O)O\N=C1\C(=O)N(Cc2cc(Cl)ccc2Cl)c2ccc(Cl)cc12	OPQRFPHLZZPCCH-LTGZKZEYSA-N, OPQRFPHLZZPCCH-LTGZKZEYSA-N, OPQRFPHLZZPCCH-LTGZKZEYSA-N, OPQRFPHLZZPCCH-LTGZKZEYSA-N	Preclinical
LDN193189	bone morphogenic protein inhibitor	ACVR1, BMPR1A			C1CN(CCN1)c1ccc(cc1)-c1cnc2c(cnn2c1)-c1ccnc2ccccc12, C1CN(CCN1)c1ccc(cc1)-c1cnc2c(cnn2c1)-c1ccnc2ccccc12, C1CN(CCN1)c1ccc(cc1)-c1cnc2c(cnn2c1)-c1ccnc2ccccc12, C1CN(CCN1)c1ccc(cc1)-c1cnc2c(cnn2c1)-c1ccnc2ccccc12	CDOVNWNANFFLFJ-UHFFFAOYSA-N, CDOVNWNANFFLFJ-UHFFFAOYSA-N, CDOVNWNANFFLFJ-UHFFFAOYSA-N, CDOVNWNANFFLFJ-UHFFFAOYSA-N	Preclinical
LE-135	retinoid receptor agonist	RARB			CN1c2cc3c(cc2N=C(c2ccc(cc2)C(O)=O)c2ccccc12)C(C)(C)CCC3(C)C |t:9|, CN1c2cc3c(cc2N=C(c2ccc(cc2)C(O)=O)c2ccccc12)C(C)(C)CCC3(C)C |t:9|, CN1c2cc3c(cc2N=C(c2ccc(cc2)C(O)=O)c2ccccc12)C(C)(C)CCC3(C)C |t:9|	YZZAIQOVMHVWBS-UHFFFAOYSA-N, YZZAIQOVMHVWBS-UHFFFAOYSA-N, YZZAIQOVMHVWBS-UHFFFAOYSA-N	Preclinical
ledipasvir	HCV inhibitor		infectious disease	hepatitis C	COC(=O)N[C@@H](C(C)C)C(=O)N1CC2(CC2)C[C@H]1c1nc(c[nH]1)-c1ccc2-c3ccc(cc3C(F)(F)c2c1)-c1ccc2nc([nH]c2c1)[C@@H]1[C@H]2CC[C@H](C2)N1C(=O)[C@@H](NC(=O)OC)C(C)C, COC(=O)N[C@@H](C(C)C)C(=O)N1CC2(CC2)C[C@H]1c1nc(c[nH]1)-c1ccc2-c3ccc(cc3C(F)(F)c2c1)-c1ccc2nc([nH]c2c1)[C@@H]1[C@H]2CC[C@H](C2)N1C(=O)[C@@H](NC(=O)OC)C(C)C, COC(=O)N[C@@H](C(C)C)C(=O)N1CC2(CC2)C[C@H]1c1nc(c[nH]1)-c1ccc2-c3ccc(cc3C(F)(F)c2c1)-c1ccc2nc([nH]c2c1)[C@@H]1[C@H]2CC[C@H](C2)N1C(=O)[C@@H](NC(=O)OC)C(C)C, COC(=O)N[C@@H](C(C)C)C(=O)N1CC2(CC2)C[C@H]1c1nc(c[nH]1)-c1ccc2-c3ccc(cc3C(F)(F)c2c1)-c1ccc2nc([nH]c2c1)[C@@H]1[C@H]2CC[C@H](C2)N1C(=O)[C@@H](NC(=O)OC)C(C)C	VRTWBAAJJOHBQU-KMWAZVGDSA-N, VRTWBAAJJOHBQU-KMWAZVGDSA-N, VRTWBAAJJOHBQU-KMWAZVGDSA-N, VRTWBAAJJOHBQU-KMWAZVGDSA-N	Launched
leflunomide	dihydroorotate dehydrogenase inhibitor, PDGFR tyrosine kinase receptor inhibitor	AHR, DHODH, PTK2B	rheumatology	rheumatoid arthritis	Cc1oncc1C(=O)Nc1ccc(cc1)C(F)(F)F, Cc1oncc1C(=O)Nc1ccc(cc1)C(F)(F)F, Cc1oncc1C(=O)Nc1ccc(cc1)C(F)(F)F, Cc1oncc1C(=O)Nc1ccc(cc1)C(F)(F)F	VHOGYURTWQBHIL-UHFFFAOYSA-N, VHOGYURTWQBHIL-UHFFFAOYSA-N, VHOGYURTWQBHIL-UHFFFAOYSA-N, VHOGYURTWQBHIL-UHFFFAOYSA-N	Launched
lemborexant	orexin receptor antagonist	HCRTR1, HCRTR2			Cc1ncc(OC[C@]2(C[C@H]2C(=O)Nc2ccc(F)cn2)c2cccc(F)c2)c(C)n1	MUGXRYIUWFITCP-PGRDOPGGSA-N	Launched
lenalidomide	anticancer agent	TNF	hematologic malignancy	multiple myeloma, mantle cell lymphoma (MCL), myelodysplastic diseases (MDS)	Nc1cccc2C(=O)N(Cc12)[C@H]1CCC(=O)NC1=O |&1:11,r|	GOTYRUGSSMKFNF-JTQLQIEISA-N	Launched
leniolisib	PI3K inhibitor				CCC(=O)N1CC[C@@H](C1)Nc1ncnc2CCN(Cc12)c1cnc(OC)c(c1)C(F)(F)F	MWKYMZXCGYXLPL-ZDUSSCGKSA-N	Phase 2/Phase 3
lenvatinib	FGFR inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	FLT4, KDR	oncology	thyroid cancer	COc1cc2nccc(Oc3ccc(NC(=O)NC4CC4)c(Cl)c3)c2cc1C(N)=O, COc1cc2nccc(Oc3ccc(NC(=O)NC4CC4)c(Cl)c3)c2cc1C(N)=O, COc1cc2nccc(Oc3ccc(NC(=O)NC4CC4)c(Cl)c3)c2cc1C(N)=O, COc1cc2nccc(Oc3ccc(NC(=O)NC4CC4)c(Cl)c3)c2cc1C(N)=O, COc1cc2nccc(Oc3ccc(NC(=O)NC4CC4)c(Cl)c3)c2cc1C(N)=O	WOSKHXYHFSIKNG-UHFFFAOYSA-N, WOSKHXYHFSIKNG-UHFFFAOYSA-N, WOSKHXYHFSIKNG-UHFFFAOYSA-N, WOSKHXYHFSIKNG-UHFFFAOYSA-N, WOSKHXYHFSIKNG-UHFFFAOYSA-N	Launched
leonurine	anti-inflammatory agent				COc1cc(cc(OC)c1O)C(=O)OCCCCNC(N)=N	WNGSUWLDMZFYNZ-UHFFFAOYSA-N	Preclinical
LEQ506	G protein signaling inhibitor				C[C@@H]1CN(CCN1c1cnc(cn1)C(C)(C)O)c1nnc(Cc2ccccc2)c(C)c1C	POERAARDVFVDLO-QGZVFWFLSA-N	Phase 1
lercanidipine	calcium channel blocker	CACNA2D1	cardiology	hypertension	COC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OC(C)(C)CN(C)CCC(c1ccccc1)c1ccccc1 |r,c:4,9|, COC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OC(C)(C)CN(C)CCC(c1ccccc1)c1ccccc1 |r,c:4,9|, COC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OC(C)(C)CN(C)CCC(c1ccccc1)c1ccccc1 |r,c:4,9|	ZDXUKAKRHYTAKV-MGBGTMOVSA-N, ZDXUKAKRHYTAKV-MGBGTMOVSA-N, ZDXUKAKRHYTAKV-MGBGTMOVSA-N	Launched
lerisetron	serotonin receptor antagonist	HTR3A			C(c1ccccc1)n1c(nc2ccccc12)N1CCNCC1, C(c1ccccc1)n1c(nc2ccccc12)N1CCNCC1, C(c1ccccc1)n1c(nc2ccccc12)N1CCNCC1	PWWDCRQZITYKDV-UHFFFAOYSA-N, PWWDCRQZITYKDV-UHFFFAOYSA-N, PWWDCRQZITYKDV-UHFFFAOYSA-N	Phase 3
lersivirine	non-nucleoside reverse transcriptase inhibitor				CCc1nn(CCO)c(CC)c1Oc1cc(cc(c1)C#N)C#N, CCc1nn(CCO)c(CC)c1Oc1cc(cc(c1)C#N)C#N	MCPUZZJBAHRIPO-UHFFFAOYSA-N, MCPUZZJBAHRIPO-UHFFFAOYSA-N	Phase 2
lesinurad	uric acid diuretic	SLC22A12	rheumatology	gout	OC(=O)CSc1nnc(Br)n1-c1ccc(C2CC2)c2ccccc12, OC(=O)CSc1nnc(Br)n1-c1ccc(C2CC2)c2ccccc12	FGQFOYHRJSUHMR-UHFFFAOYSA-N, FGQFOYHRJSUHMR-UHFFFAOYSA-N	Launched
lestaurtinib	FLT3 inhibitor, growth factor receptor inhibitor, JAK inhibitor	FLT3, NTRK1			C[C@]12O[C@@H](C[C@]1(O)CO)n1c3ccccc3c3c4C(=O)NCc4c4c5ccccc5n2c4c13 |a:1,5,&1:3|, C[C@]12O[C@@H](C[C@]1(O)CO)n1c3ccccc3c3c4C(=O)NCc4c4c5ccccc5n2c4c13 |a:1,5,&1:3|, C[C@]12O[C@@H](C[C@]1(O)CO)n1c3ccccc3c3c4C(=O)NCc4c4c5ccccc5n2c4c13 |a:1,5,&1:3|, C[C@]12O[C@@H](C[C@]1(O)CO)n1c3ccccc3c3c4C(=O)NCc4c4c5ccccc5n2c4c13 |a:1,5,&1:3|, C[C@]12O[C@@H](C[C@]1(O)CO)n1c3ccccc3c3c4C(=O)NCc4c4c5ccccc5n2c4c13 |a:1,5,&1:3|, C[C@]12O[C@@H](C[C@]1(O)CO)n1c3ccccc3c3c4C(=O)NCc4c4c5ccccc5n2c4c13 |a:1,5,&1:3|, C[C@]12O[C@@H](C[C@]1(O)CO)n1c3ccccc3c3c4C(=O)NCc4c4c5ccccc5n2c4c13 |a:1,5,&1:3|, C[C@]12O[C@@H](C[C@]1(O)CO)n1c3ccccc3c3c4C(=O)NCc4c4c5ccccc5n2c4c13 |a:1,5,&1:3|, C[C@]12O[C@@H](C[C@]1(O)CO)n1c3ccccc3c3c4C(=O)NCc4c4c5ccccc5n2c4c13 |a:1,5,&1:3|, C[C@]12O[C@@H](C[C@]1(O)CO)n1c3ccccc3c3c4C(=O)NCc4c4c5ccccc5n2c4c13 |a:1,5,&1:3|, C[C@]12O[C@@H](C[C@]1(O)CO)n1c3ccccc3c3c4C(=O)NCc4c4c5ccccc5n2c4c13 |a:1,5,&1:3|	UIARLYUEJFELEN-DMVVYWCZSA-N, UIARLYUEJFELEN-DMVVYWCZSA-N, UIARLYUEJFELEN-DMVVYWCZSA-N, UIARLYUEJFELEN-DMVVYWCZSA-N, UIARLYUEJFELEN-DMVVYWCZSA-N, UIARLYUEJFELEN-DMVVYWCZSA-N, UIARLYUEJFELEN-DMVVYWCZSA-N, UIARLYUEJFELEN-DMVVYWCZSA-N, UIARLYUEJFELEN-DMVVYWCZSA-N, UIARLYUEJFELEN-DMVVYWCZSA-N, UIARLYUEJFELEN-DMVVYWCZSA-N	Phase 3
leteprinim	nerve growth factor agonist				OC(=O)c1ccc(NC(=O)CCn2cnc3c2[nH]cnc3=O)cc1	JMPOIZCOJJMTHI-UHFFFAOYSA-N	Phase 2
letermovir	CMV terminase inhibitor		infectious disease	cytomegalovirus (CMV)	COc1cccc(c1)N1CCN(CC1)C1=Nc2c(F)cccc2[C@H](CC(O)=O)N1c1cc(ccc1OC)C(F)(F)F |t:16|, COc1cccc(c1)N1CCN(CC1)C1=Nc2c(F)cccc2[C@H](CC(O)=O)N1c1cc(ccc1OC)C(F)(F)F |t:16|, COc1cccc(c1)N1CCN(CC1)C1=Nc2c(F)cccc2[C@H](CC(O)=O)N1c1cc(ccc1OC)C(F)(F)F |t:16|	FWYSMLBETOMXAG-QHCPKHFHSA-N, FWYSMLBETOMXAG-QHCPKHFHSA-N, FWYSMLBETOMXAG-QHCPKHFHSA-N	Launched
letosteine	mucolytic agent		pulmonary, infectious disease	bronchitis, pneumonia	CCOC(=O)CSCC[C@H]1N[C@@H](CS1)C(O)=O |&1:9,&2:11,r|	IKOCLISPVJZJEA-YUMQZZPRSA-N	Launched
letrazuril	antiinfective drug				Fc1ccc(cc1)[C@@H](C#N)c1c(Cl)cc(cc1Cl)-n1ncc(=O)[nH]c1=O |&1:7,r|	XQKYUBTUOHHNDV-GFCCVEGCSA-N	Phase 1
letrozole	aromatase inhibitor	CYP19A1	oncology	breast cancer	N#Cc1ccc(cc1)C(c1ccc(cc1)C#N)n1cncn1, N#Cc1ccc(cc1)C(c1ccc(cc1)C#N)n1cncn1, N#Cc1ccc(cc1)C(c1ccc(cc1)C#N)n1cncn1	HPJKCIUCZWXJDR-UHFFFAOYSA-N, HPJKCIUCZWXJDR-UHFFFAOYSA-N, HPJKCIUCZWXJDR-UHFFFAOYSA-N	Launched
leucomethylene-blue	nitric oxide production inhibitor, tau aggregation inhibitor	MAPT			CN(C)c1ccc2Nc3ccc(cc3Sc2c1)N(C)C	QTWZICCBKBYHDM-UHFFFAOYSA-N	Phase 3
leucovorin	folate receptor ligand		oncology	osteosarcoma	Nc1nc(=O)c2N(C=O)[C@@H](CNc3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)CNc2[nH]1 |a:21,&1:9|, Nc1nc(=O)c2N(C=O)[C@@H](CNc3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)CNc2[nH]1 |a:21,&1:9|, Nc1nc(=O)c2N(C=O)[C@@H](CNc3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)CNc2[nH]1 |a:21,&1:9|, Nc1nc(=O)c2N(C=O)[C@@H](CNc3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)CNc2[nH]1 |a:21,&1:9|, Nc1nc(=O)c2N(C=O)[C@@H](CNc3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)CNc2[nH]1 |a:21,&1:9|	VVIAGPKUTFNRDU-STQMWFEESA-N, VVIAGPKUTFNRDU-STQMWFEESA-N, VVIAGPKUTFNRDU-STQMWFEESA-N, VVIAGPKUTFNRDU-STQMWFEESA-N, VVIAGPKUTFNRDU-STQMWFEESA-N	Launched
leucylleucine-methyl-ester					COC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC(C)C	AJMOLNFDYWTVQW-QWRGUYRKSA-N	Phase 2
leuprolide	gonadotropin releasing factor hormone receptor agonist	GNRHR	oncology	prostate cancer	CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@@H]1CCC(=O)N1, CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@@H]1CCC(=O)N1	GFIJNRVAKGFPGQ-LIJARHBVSA-N, GFIJNRVAKGFPGQ-LIJARHBVSA-N	Launched
levalbuterol	adrenergic receptor agonist	ADRB2	pulmonary	bronchospasm	CC(C)(C)NC[C@H](O)c1ccc(O)c(CO)c1, CC(C)(C)NC[C@H](O)c1ccc(O)c(CO)c1, CC(C)(C)NC[C@H](O)c1ccc(O)c(CO)c1	NDAUXUAQIAJITI-LBPRGKRZSA-N, NDAUXUAQIAJITI-LBPRGKRZSA-N, NDAUXUAQIAJITI-LBPRGKRZSA-N	Launched
levallorphan	opioid receptor antagonist	CHRNA2, OPRM1	pulmonary	respiratory depression	Oc1ccc2C[C@@H]3[C@@H]4CCCC[C@]4(CCN3CC=C)c2c1, Oc1ccc2C[C@@H]3[C@@H]4CCCC[C@]4(CCN3CC=C)c2c1, Oc1ccc2C[C@@H]3[C@@H]4CCCC[C@]4(CCN3CC=C)c2c1	OZYUPQUCAUTOBP-QXAKKESOSA-N, OZYUPQUCAUTOBP-QXAKKESOSA-N, OZYUPQUCAUTOBP-QXAKKESOSA-N	Launched
levamisole	acetylcholine receptor agonist	ALPL			C1CN2C[C@@H](N=C2S1)c1ccccc1 |c:5|, C1CN2C[C@@H](N=C2S1)c1ccccc1 |c:5|, C1CN2C[C@@H](N=C2S1)c1ccccc1 |c:5|, C1CN2C[C@@H](N=C2S1)c1ccccc1 |c:5|	HLFSDGLLUJUHTE-SNVBAGLBSA-N, HLFSDGLLUJUHTE-SNVBAGLBSA-N, HLFSDGLLUJUHTE-SNVBAGLBSA-N, HLFSDGLLUJUHTE-SNVBAGLBSA-N	Withdrawn
levamlodipine	calcium channel blocker		cardiology	hypertension	CCOC(=O)C1=C(COCCN)NC(C)=C([C@@H]1c1ccccc1Cl)C(=O)OC |c:5,14|	HTIQEAQVCYTUBX-KRWDZBQOSA-N	Launched
levcromakalim	potassium channel activator	KCNJ5			CC1(C)Oc2ccc(cc2[C@H]([C@@H]1O)N1CCCC1=O)C#N, CC1(C)Oc2ccc(cc2[C@H]([C@@H]1O)N1CCCC1=O)C#N, CC1(C)Oc2ccc(cc2[C@H]([C@@H]1O)N1CCCC1=O)C#N, CC1(C)Oc2ccc(cc2[C@H]([C@@H]1O)N1CCCC1=O)C#N, CC1(C)Oc2ccc(cc2[C@H]([C@@H]1O)N1CCCC1=O)C#N	TVZCRIROJQEVOT-CABCVRRESA-N, TVZCRIROJQEVOT-CABCVRRESA-N, TVZCRIROJQEVOT-CABCVRRESA-N, TVZCRIROJQEVOT-CABCVRRESA-N, TVZCRIROJQEVOT-CABCVRRESA-N	Phase 3
levetiracetam	calcium channel blocker	CACNA1B, SCN1A, SV2A	neurology/psychiatry	seizures	CC[C@H](N1CCCC1=O)C(N)=O, CC[C@H](N1CCCC1=O)C(N)=O, CC[C@H](N1CCCC1=O)C(N)=O, CC[C@H](N1CCCC1=O)C(N)=O, CC[C@H](N1CCCC1=O)C(N)=O, CC[C@H](N1CCCC1=O)C(N)=O	HPHUVLMMVZITSG-LURJTMIESA-N, HPHUVLMMVZITSG-LURJTMIESA-N, HPHUVLMMVZITSG-LURJTMIESA-N, HPHUVLMMVZITSG-LURJTMIESA-N, HPHUVLMMVZITSG-LURJTMIESA-N, HPHUVLMMVZITSG-LURJTMIESA-N	Launched
levo-phencynonate	acetylcholine receptor antagonist	CHRM1			CN1C[C@@H]2CCC[C@H](C1)[C@H]2OC(=O)[C@@](O)(C1CCCC1)c1ccccc1 |&1:7,&2:3,&3:9,&4:13|	ROZOEEGFKDFEFP-AXRVMRSRSA-N	Launched
levobetaxolol	adrenergic receptor antagonist	ADRB1, ADRB2	ophthalmology	intraocular pressure, glaucoma	CC(C)NC[C@H](O)COc1ccc(CCOCC2CC2)cc1, CC(C)NC[C@H](O)COc1ccc(CCOCC2CC2)cc1, CC(C)NC[C@H](O)COc1ccc(CCOCC2CC2)cc1	NWIUTZDMDHAVTP-KRWDZBQOSA-N, NWIUTZDMDHAVTP-KRWDZBQOSA-N, NWIUTZDMDHAVTP-KRWDZBQOSA-N	Launched
levobunolol	adrenergic receptor antagonist	ADRB1, ADRB2, ADRB3	ophthalmology	glaucoma, ocular hypertension	CC(C)(C)NC[C@H](O)COc1cccc2C(=O)CCCc12, CC(C)(C)NC[C@H](O)COc1cccc2C(=O)CCCc12, CC(C)(C)NC[C@H](O)COc1cccc2C(=O)CCCc12	IXHBTMCLRNMKHZ-LBPRGKRZSA-N, IXHBTMCLRNMKHZ-LBPRGKRZSA-N, IXHBTMCLRNMKHZ-LBPRGKRZSA-N	Launched
levobunolol-(+)	adrenergic receptor antagonist				CC(C)(C)NC[C@@H](O)COc1cccc2C(=O)CCCc12, CC(C)(C)NC[C@@H](O)COc1cccc2C(=O)CCCc12, CC(C)(C)NC[C@@H](O)COc1cccc2C(=O)CCCc12, CC(C)(C)NC[C@@H](O)COc1cccc2C(=O)CCCc12	IXHBTMCLRNMKHZ-GFCCVEGCSA-N, IXHBTMCLRNMKHZ-GFCCVEGCSA-N, IXHBTMCLRNMKHZ-GFCCVEGCSA-N, IXHBTMCLRNMKHZ-GFCCVEGCSA-N	Preclinical
levobunolol-(+/-)	adrenergic receptor antagonist				CC(C)(C)NC[C@@H](O)COc1cccc2C(=O)CCCc12 |&1:6|, CC(C)(C)NC[C@@H](O)COc1cccc2C(=O)CCCc12 |&1:6|	IXHBTMCLRNMKHZ-GFCCVEGCSA-N, IXHBTMCLRNMKHZ-GFCCVEGCSA-N	Preclinical
levocabastine	histamine receptor antagonist	HRH1, NTSR2	ophthalmology	conjunctivitis	C[C@@H]1CN(CC[C@]1(C(O)=O)c1ccccc1)[C@H]1CC[C@](CC1)(C#N)c1ccc(F)cc1	ZCGOMHNNNFPNMX-KYTRFIICSA-N	Launched
levocarnitine		CRAT, CROT	endocrinology	carnitine deficiency	C[N+](C)(C)C[C@H](O)CC(O)=O, C[N+](C)(C)C[C@H](O)CC(O)=O	PHIQHXFUZVPYII-ZCFIWIBFSA-O, PHIQHXFUZVPYII-ZCFIWIBFSA-O	Launched
levocarnitine-propionate	carnitine palmitoyltransferase inhibitor	CRAT	neurology/psychiatry, endocrinology	peripheral neuropathy, carnitine deficiency	CCC(=O)O[C@H](CC(O)=O)C[N+](C)(C)C	UFAHZIUFPNSHSL-MRVPVSSYSA-O	Launched
levocetirizine	histamine receptor antagonist	HRH1	allergy	allergic rhinitis, urticaria	OC(=O)COCCN1CCN(CC1)[C@H](c1ccccc1)c1ccc(Cl)cc1, OC(=O)COCCN1CCN(CC1)[C@H](c1ccccc1)c1ccc(Cl)cc1, OC(=O)COCCN1CCN(CC1)[C@H](c1ccccc1)c1ccc(Cl)cc1, OC(=O)COCCN1CCN(CC1)[C@H](c1ccccc1)c1ccc(Cl)cc1	ZKLPARSLTMPFCP-OAQYLSRUSA-N, ZKLPARSLTMPFCP-OAQYLSRUSA-N, ZKLPARSLTMPFCP-OAQYLSRUSA-N, ZKLPARSLTMPFCP-OAQYLSRUSA-N	Launched
levodopa	dopamine precursor	DRD1, DRD2, DRD3, DRD4, DRD5, GPR143	neurology/psychiatry	Parkinson's Disease	N[C@@H](Cc1ccc(O)c(O)c1)C(O)=O, N[C@@H](Cc1ccc(O)c(O)c1)C(O)=O, N[C@@H](Cc1ccc(O)c(O)c1)C(O)=O	WTDRDQBEARUVNC-LURJTMIESA-N, WTDRDQBEARUVNC-LURJTMIESA-N, WTDRDQBEARUVNC-LURJTMIESA-N	Launched
levodropropizine	antitussive		pulmonary	cough suppressant	OC[C@@H](O)CN1CCN(CC1)c1ccccc1, OC[C@@H](O)CN1CCN(CC1)c1ccccc1, OC[C@@H](O)CN1CCN(CC1)c1ccccc1	PTVWPYVOOKLBCG-ZDUSSCGKSA-N, PTVWPYVOOKLBCG-ZDUSSCGKSA-N, PTVWPYVOOKLBCG-ZDUSSCGKSA-N	Launched
levofloxacin	bacterial DNA gyrase inhibitor	TOP2A	infectious disease, otolaryngology, pulmonary, urology	pneumonia, sinusitis, bronchitis, skin infections, prostatitis, urinary tract infections, pyelonephritis, anthrax, plague	C[C@H]1COc2c(N3CCN(C)CC3)c(F)cc3c2n1cc(C(O)=O)c3=O, C[C@H]1COc2c(N3CCN(C)CC3)c(F)cc3c2n1cc(C(O)=O)c3=O	GSDSWSVVBLHKDQ-JTQLQIEISA-N, GSDSWSVVBLHKDQ-JTQLQIEISA-N	Launched
levomenol			neurology/psychiatry, infectious disease	spasms, skin infections	CC(C)=CCC[C@](C)(O)[C@H]1CCC(C)=CC1 |c:13|	RGZSQWQPBWRIAQ-CABCVRRESA-N	Launched
levomenthol		OPRK1, TRPA1, TRPM8, TRPV3	neurology/psychiatry	pain relief	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O, CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O	NOOLISFMXDJSKH-KXUCPTDWSA-N, NOOLISFMXDJSKH-KXUCPTDWSA-N	Launched
levomepromazine	dopamine receptor antagonist	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, DRD1, DRD2, DRD3, DRD4, DRD5, HRH1, HTR2A, HTR2C	neurology/psychiatry, gastroenterology	psychosis, schizophrenia, bipolar disorder, nausea, insomnia	COc1ccc2Sc3ccccc3N(C[C@H](C)CN(C)C)c2c1, COc1ccc2Sc3ccccc3N(C[C@H](C)CN(C)C)c2c1, COc1ccc2Sc3ccccc3N(C[C@H](C)CN(C)C)c2c1	VRQVVMDWGGWHTJ-CQSZACIVSA-N, VRQVVMDWGGWHTJ-CQSZACIVSA-N, VRQVVMDWGGWHTJ-CQSZACIVSA-N	Launched
levomequitazine	histamine receptor antagonist	HRH1			C([C@H]1CN2CCC1CC2)N1c2ccccc2Sc2ccccc12 |&1:1,r|, C([C@H]1CN2CCC1CC2)N1c2ccccc2Sc2ccccc12 |&1:1,r|, C([C@H]1CN2CCC1CC2)N1c2ccccc2Sc2ccccc12 |&1:1,r|, C([C@H]1CN2CCC1CC2)N1c2ccccc2Sc2ccccc12 |&1:1,r|, C([C@H]1CN2CCC1CC2)N1c2ccccc2Sc2ccccc12 |&1:1,r|	HOKDBMAJZXIPGC-MRXNPFEDSA-N, HOKDBMAJZXIPGC-MRXNPFEDSA-N, HOKDBMAJZXIPGC-MRXNPFEDSA-N, HOKDBMAJZXIPGC-MRXNPFEDSA-N, HOKDBMAJZXIPGC-MRXNPFEDSA-N	Phase 2
levonordefrin	vasodilator	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, SLC6A2	hematology	hemorrhage	C[C@H](N)[C@H](O)c1ccc(O)c(O)c1, C[C@H](N)[C@H](O)c1ccc(O)c(O)c1	GEFQWZLICWMTKF-CDUCUWFYSA-N, GEFQWZLICWMTKF-CDUCUWFYSA-N	Launched
levonorgestrel	estrogen receptor agonist, glucocorticoid receptor antagonist, progesterone receptor agonist, progesterone receptor antagonist	PGR	endocrinology	contraceptive	CC[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C |t:9|, CC[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C |t:9|, CC[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C |t:9|, CC[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C |t:9|, CC[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C |t:9|, CC[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C |t:9|, CC[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C |t:9|, CC[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C |t:9|, CC[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C |t:9|, CC[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C |t:9|	WWYNJERNGUHSAO-XUDSTZEESA-N, WWYNJERNGUHSAO-XUDSTZEESA-N, WWYNJERNGUHSAO-XUDSTZEESA-N, WWYNJERNGUHSAO-XUDSTZEESA-N, WWYNJERNGUHSAO-XUDSTZEESA-N, WWYNJERNGUHSAO-XUDSTZEESA-N, WWYNJERNGUHSAO-XUDSTZEESA-N, WWYNJERNGUHSAO-XUDSTZEESA-N, WWYNJERNGUHSAO-XUDSTZEESA-N, WWYNJERNGUHSAO-XUDSTZEESA-N	Launched
levopropoxyphene	antitussive		pulmonary	cough suppressant	CCC(=O)OC(Cc1ccccc1)([C@@H](C)CN(C)C)c1ccccc1 |&1:5,&2:13|	XLMALTXPSGQGBX-HXBUSHRASA-N	Launched
levosimendan	calcium sensitizer	KCNJ11, KCNJ8, PDE3A, TNNC1	cardiology	congestive heart failure	C[C@@H]1CC(=O)NN=C1c1ccc(NN=C(C#N)C#N)cc1 |c:6|, C[C@@H]1CC(=O)NN=C1c1ccc(NN=C(C#N)C#N)cc1 |c:6|, C[C@@H]1CC(=O)NN=C1c1ccc(NN=C(C#N)C#N)cc1 |c:6|, C[C@@H]1CC(=O)NN=C1c1ccc(NN=C(C#N)C#N)cc1 |c:6|, C[C@@H]1CC(=O)NN=C1c1ccc(NN=C(C#N)C#N)cc1 |c:6|, C[C@@H]1CC(=O)NN=C1c1ccc(NN=C(C#N)C#N)cc1 |c:6|	WHXMKTBCFHIYNQ-SECBINFHSA-N, WHXMKTBCFHIYNQ-SECBINFHSA-N, WHXMKTBCFHIYNQ-SECBINFHSA-N, WHXMKTBCFHIYNQ-SECBINFHSA-N, WHXMKTBCFHIYNQ-SECBINFHSA-N, WHXMKTBCFHIYNQ-SECBINFHSA-N	Launched
levosulpiride	dopamine receptor antagonist	CA1, CA12, CA7, DRD2, DRD3	neurology/psychiatry, gastroenterology, urology	schizophrenia, psychosis, anxiety, vertigo, dyspepsia, irritable bowel syndrome, premature ejaculation (PE)	CCN1CCC[C@H]1CNC(=O)c1cc(ccc1OC)S(N)(=O)=O, CCN1CCC[C@H]1CNC(=O)c1cc(ccc1OC)S(N)(=O)=O, CCN1CCC[C@H]1CNC(=O)c1cc(ccc1OC)S(N)(=O)=O, CCN1CCC[C@H]1CNC(=O)c1cc(ccc1OC)S(N)(=O)=O, CCN1CCC[C@H]1CNC(=O)c1cc(ccc1OC)S(N)(=O)=O, CCN1CCC[C@H]1CNC(=O)c1cc(ccc1OC)S(N)(=O)=O	BGRJTUBHPOOWDU-NSHDSACASA-N, BGRJTUBHPOOWDU-NSHDSACASA-N, BGRJTUBHPOOWDU-NSHDSACASA-N, BGRJTUBHPOOWDU-NSHDSACASA-N, BGRJTUBHPOOWDU-NSHDSACASA-N, BGRJTUBHPOOWDU-NSHDSACASA-N	Launched
levothyroxine	thyroid hormone stimulant	THRA, THRB	endocrinology	myxedema coma	N[C@@H](Cc1cc(I)c(Oc2cc(I)c(O)c(I)c2)c(I)c1)C(O)=O, N[C@@H](Cc1cc(I)c(Oc2cc(I)c(O)c(I)c2)c(I)c1)C(O)=O, N[C@@H](Cc1cc(I)c(Oc2cc(I)c(O)c(I)c2)c(I)c1)C(O)=O, N[C@@H](Cc1cc(I)c(Oc2cc(I)c(O)c(I)c2)c(I)c1)C(O)=O	XUIIKFGFIJCVMT-LBPRGKRZSA-N, XUIIKFGFIJCVMT-LBPRGKRZSA-N, XUIIKFGFIJCVMT-LBPRGKRZSA-N, XUIIKFGFIJCVMT-LBPRGKRZSA-N	Launched
LFM-A13	Bruton's tyrosine kinase (BTK) inhibitor	BTK			CC(=O)[C@@H](C#N)C(=O)Nc1cc(Br)ccc1Br |&1:3,r|, CC(=O)[C@@H](C#N)C(=O)Nc1cc(Br)ccc1Br |&1:3,r|	BQLDGDMKDYAGNE-MRVPVSSYSA-N, BQLDGDMKDYAGNE-MRVPVSSYSA-N	Preclinical
LGD-6972	glucagon receptor antagonist				Cc1cc(C)c(c(C)c1)-c1ccc(NC(=O)[C@H](Cc2ccc(cc2)C(=O)NCCS(O)(=O)=O)c2ccc(cc2)-c2ccc(cc2)C(C)(C)C)cc1, Cc1cc(C)c(c(C)c1)-c1ccc(NC(=O)[C@H](Cc2ccc(cc2)C(=O)NCCS(O)(=O)=O)c2ccc(cc2)-c2ccc(cc2)C(C)(C)C)cc1	HKJMCBYPVCGZFB-LDLOPFEMSA-N, HKJMCBYPVCGZFB-LDLOPFEMSA-N	Phase 2
LGK-974	porcupine inhibitor	PORCN			Cc1cc(ccn1)-c1ncc(CC(=O)Nc2ccc(cn2)-c2cnccn2)cc1C, Cc1cc(ccn1)-c1ncc(CC(=O)Nc2ccc(cn2)-c2cnccn2)cc1C, Cc1cc(ccn1)-c1ncc(CC(=O)Nc2ccc(cn2)-c2cnccn2)cc1C, Cc1cc(ccn1)-c1ncc(CC(=O)Nc2ccc(cn2)-c2cnccn2)cc1C, Cc1cc(ccn1)-c1ncc(CC(=O)Nc2ccc(cn2)-c2cnccn2)cc1C, Cc1cc(ccn1)-c1ncc(CC(=O)Nc2ccc(cn2)-c2cnccn2)cc1C	XXYGTCZJJLTAGH-UHFFFAOYSA-N, XXYGTCZJJLTAGH-UHFFFAOYSA-N, XXYGTCZJJLTAGH-UHFFFAOYSA-N, XXYGTCZJJLTAGH-UHFFFAOYSA-N, XXYGTCZJJLTAGH-UHFFFAOYSA-N, XXYGTCZJJLTAGH-UHFFFAOYSA-N	Phase 2
LH846	casein kinase inhibitor	CSNK1D			Cc1cc2sc(NC(=O)Cc3ccccc3)nc2cc1Cl, Cc1cc2sc(NC(=O)Cc3ccccc3)nc2cc1Cl	DYHAMRNAHTWYKY-UHFFFAOYSA-N, DYHAMRNAHTWYKY-UHFFFAOYSA-N	Preclinical
liarozole	cytochrome P450 inhibitor	CYP19A1, CYP26A1			Clc1cccc(c1)[C@H](c1ccc2nc[nH]c2c1)n1ccnc1 |&1:7,r|	UGFHIPBXIWJXNA-QGZVFWFLSA-N	Phase 2/Phase 3
licarbazepine	voltage-gated sodium channel blocker	SCN5A			NC(=O)N1c2ccccc2C[C@@H](O)c2ccccc12 |&1:11,r|, NC(=O)N1c2ccccc2C[C@@H](O)c2ccccc12 |&1:11,r|, NC(=O)N1c2ccccc2C[C@@H](O)c2ccccc12 |&1:11,r|, NC(=O)N1c2ccccc2C[C@@H](O)c2ccccc12 |&1:11,r|, NC(=O)N1c2ccccc2C[C@@H](O)c2ccccc12 |&1:11,r|	BMPDWHIDQYTSHX-CQSZACIVSA-N, BMPDWHIDQYTSHX-CQSZACIVSA-N, BMPDWHIDQYTSHX-CQSZACIVSA-N, BMPDWHIDQYTSHX-CQSZACIVSA-N, BMPDWHIDQYTSHX-CQSZACIVSA-N	Phase 3
licochalcone-A	topoisomerase inhibitor	PTPN1			COc1cc(O)c(cc1\C=C\C(=O)c1ccc(O)cc1)C(C)(C)C=C	KAZSKMJFUPEHHW-DHZHZOJOSA-N	Phase 3
licofelone	cyclooxygenase inhibitor, lipoxygenase inhibitor	ALOX5, PLA2G2E, PTGS2			CC1(C)Cc2c(c(c(CC(O)=O)n2C1)-c1ccc(Cl)cc1)-c1ccccc1, CC1(C)Cc2c(c(c(CC(O)=O)n2C1)-c1ccc(Cl)cc1)-c1ccccc1, CC1(C)Cc2c(c(c(CC(O)=O)n2C1)-c1ccc(Cl)cc1)-c1ccccc1	UAWXGRJVZSAUSZ-UHFFFAOYSA-N, UAWXGRJVZSAUSZ-UHFFFAOYSA-N, UAWXGRJVZSAUSZ-UHFFFAOYSA-N	Phase 3
licogliflozin	sodium/glucose cotransporter inhibitor				CCc1ccc(cc1Cc1ccc2OCCOc2c1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O	XFJAMQQAAMJFGB-ZQGJOIPISA-N	Preclinical
licostinel	NMDA receptor antagonist 				[O-][N+](=O)c1c(Cl)c(Cl)cc2[nH]c(=O)c(=O)[nH]c12	CHFSOFHQIZKQCR-UHFFFAOYSA-N	Phase 1
lidamidine	adrenergic receptor agonist		gastroenterology	diarrhea	CNC(=N)NC(=O)Nc1c(C)cccc1C, CNC(=N)NC(=O)Nc1c(C)cccc1C	RRHJHSBDJDZUGL-UHFFFAOYSA-N, RRHJHSBDJDZUGL-UHFFFAOYSA-N	Launched
lidocaine	histamine receptor agonist	EGFR, SCN10A, SCN5A, SCN9A	neurology/psychiatry, dermatology, hematology	itching, eczema, hemorrhage	CCN(CC)CC(=O)Nc1c(C)cccc1C, CCN(CC)CC(=O)Nc1c(C)cccc1C, CCN(CC)CC(=O)Nc1c(C)cccc1C	NNJVILVZKWQKPM-UHFFFAOYSA-N, NNJVILVZKWQKPM-UHFFFAOYSA-N, NNJVILVZKWQKPM-UHFFFAOYSA-N	Launched
lidoflazine	calcium channel blocker	SCN1A, SCN3A, SLC29A1	cardiology	coronary artery disease (CAD)	Cc1cccc(C)c1NC(=O)CN1CCN(CCCC(c2ccc(F)cc2)c2ccc(F)cc2)CC1, Cc1cccc(C)c1NC(=O)CN1CCN(CCCC(c2ccc(F)cc2)c2ccc(F)cc2)CC1, Cc1cccc(C)c1NC(=O)CN1CCN(CCCC(c2ccc(F)cc2)c2ccc(F)cc2)CC1	ZBIAKUMOEKILTF-UHFFFAOYSA-N, ZBIAKUMOEKILTF-UHFFFAOYSA-N, ZBIAKUMOEKILTF-UHFFFAOYSA-N	Launched
lifirafenib	RAF inhibitor				FC(F)(F)c1ccc2nc([nH]c2c1)[C@@H]1[C@H]2Oc3ccc(Oc4ccnc5NC(=O)CCc45)cc3[C@@H]12	NGFFVZQXSRKHBM-FKBYEOEOSA-N	Phase 1/Phase 2
lifitegrast	lymphocyte function-associated antigen negative modulator		ophthalmology	dry eye syndrome	CS(=O)(=O)c1cccc(C[C@H](NC(=O)c2c(Cl)cc3CN(CCc3c2Cl)C(=O)c2ccc3ccoc3c2)C(O)=O)c1	JFOZKMSJYSPYLN-QHCPKHFHSA-N	Launched
ligustilide	tumor necrosis factor production inhibitor	TNF			CCC\C=C1/OC(=O)C2=C1CCC=C2 |c:8,13|, CCC\C=C1/OC(=O)C2=C1CCC=C2 |c:8,13|	IQVQXVFMNOFTMU-FLIBITNWSA-N, IQVQXVFMNOFTMU-FLIBITNWSA-N	Preclinical
limaprost-alfadex	prostanoid receptor agonist	PTGER1	cardiology	claudication	CCCC[C@H](C)C[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCC\C=C\C(O)=O, CCCC[C@H](C)C[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCC\C=C\C(O)=O, CCCC[C@H](C)C[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCC\C=C\C(O)=O	OJZYRQPMEIEQFC-UAWLTFRCSA-N, OJZYRQPMEIEQFC-UAWLTFRCSA-N, OJZYRQPMEIEQFC-UAWLTFRCSA-N	Launched
LIMKi-3	LIM kinase inhibitor	LIMK1			CC(C)C(=O)Nc1ncc(s1)-c1cc(nn1-c1c(Cl)cccc1Cl)C(F)F, CC(C)C(=O)Nc1ncc(s1)-c1cc(nn1-c1c(Cl)cccc1Cl)C(F)F	IVUGBSGLHRJSSP-UHFFFAOYSA-N, IVUGBSGLHRJSSP-UHFFFAOYSA-N	Preclinical
limonin	HIV protease inhibitor				CC1(C)O[C@H]2CC(=O)OC[C@@]22[C@H]1CC(=O)[C@]1(C)[C@@H]2CC[C@@]2(C)[C@@H](OC(=O)[C@H]3O[C@@]123)c1ccoc1, CC1(C)O[C@H]2CC(=O)OC[C@@]22[C@H]1CC(=O)[C@]1(C)[C@@H]2CC[C@@]2(C)[C@@H](OC(=O)[C@H]3O[C@@]123)c1ccoc1, CC1(C)O[C@H]2CC(=O)OC[C@@]22[C@H]1CC(=O)[C@]1(C)[C@@H]2CC[C@@]2(C)[C@@H](OC(=O)[C@H]3O[C@@]123)c1ccoc1	KBDSLGBFQAGHBE-MSGMIQHVSA-N, KBDSLGBFQAGHBE-MSGMIQHVSA-N, KBDSLGBFQAGHBE-MSGMIQHVSA-N	Preclinical
linaclotide	guanylate cyclase activator	GUCY2C	gastroenterology	irritable bowel syndrome, constipation	[H][C@@]12CCCN1C(=O)[C@H](CC(N)=O)NC(=O)[C@]1([H])CSSC[C@H](N)C(=O)N[C@@]3([H])CSSC[C@]([H])(NC(=O)[C@H](C)NC2=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CSSC[C@]([H])(NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CCC(O)=O)NC3=O)C(=O)N1)C(=O)N[C@@H](Cc1ccc(O)cc1)C(O)=O	KXGCNMMJRFDFNR-WDRJZQOASA-N	Launched
linagliptin	dipeptidyl peptidase inhibitor	DPP4	endocrinology	diabetes mellitus	CC#CCn1c(nc2n(C)c(=O)n(Cc3nc(C)c4ccccc4n3)c(=O)c12)N1CCC[C@@H](N)C1, CC#CCn1c(nc2n(C)c(=O)n(Cc3nc(C)c4ccccc4n3)c(=O)c12)N1CCC[C@@H](N)C1, CC#CCn1c(nc2n(C)c(=O)n(Cc3nc(C)c4ccccc4n3)c(=O)c12)N1CCC[C@@H](N)C1, CC#CCn1c(nc2n(C)c(=O)n(Cc3nc(C)c4ccccc4n3)c(=O)c12)N1CCC[C@@H](N)C1, CC#CCn1c(nc2n(C)c(=O)n(Cc3nc(C)c4ccccc4n3)c(=O)c12)N1CCC[C@@H](N)C1, CC#CCn1c(nc2n(C)c(=O)n(Cc3nc(C)c4ccccc4n3)c(=O)c12)N1CCC[C@@H](N)C1, CC#CCn1c(nc2n(C)c(=O)n(Cc3nc(C)c4ccccc4n3)c(=O)c12)N1CCC[C@@H](N)C1	LTXREWYXXSTFRX-QGZVFWFLSA-N, LTXREWYXXSTFRX-QGZVFWFLSA-N, LTXREWYXXSTFRX-QGZVFWFLSA-N, LTXREWYXXSTFRX-QGZVFWFLSA-N, LTXREWYXXSTFRX-QGZVFWFLSA-N, LTXREWYXXSTFRX-QGZVFWFLSA-N, LTXREWYXXSTFRX-QGZVFWFLSA-N	Launched
linalool	anticonvulsant				CC(C)=CCC[C@@](C)(O)C=C |&1:6,r|, CC(C)=CCC[C@@](C)(O)C=C |&1:6,r|	CDOSHBSSFJOMGT-JTQLQIEISA-N, CDOSHBSSFJOMGT-JTQLQIEISA-N	Phase 1
linaprazan	ATP-sensitive potassium channel inhibitor				Cc1nc2c(NCc3c(C)cccc3C)cc(cn2c1C)C(=O)NCCO	GHVIMBCFLRTFHI-UHFFFAOYSA-N	Preclinical
lincomycin	bacterial 30S ribosomal subunit inhibitor		gastroenterology	enteritis	CCC[C@@H]1C[C@H](N(C)C1)C(=O)N[C@H]([C@@H](C)O)[C@H]1O[C@H](SC)[C@H](O)[C@@H](O)[C@H]1O, CCC[C@@H]1C[C@H](N(C)C1)C(=O)N[C@H]([C@@H](C)O)[C@H]1O[C@H](SC)[C@H](O)[C@@H](O)[C@H]1O	OJMMVQQUTAEWLP-KIDUDLJLSA-N, OJMMVQQUTAEWLP-KIDUDLJLSA-N	Launched
lindane		GABRB1, GLRA1, GLRA2, GLRA3, GLRB	infectious disease	scabies	Cl[C@H]1[C@H](Cl)[C@@H](Cl)[C@@H](Cl)[C@H](Cl)[C@H]1Cl, Cl[C@H]1[C@H](Cl)[C@@H](Cl)[C@@H](Cl)[C@H](Cl)[C@H]1Cl, Cl[C@H]1[C@H](Cl)[C@@H](Cl)[C@@H](Cl)[C@H](Cl)[C@H]1Cl	JLYXXMFPNIAWKQ-GNIYUCBRSA-N, JLYXXMFPNIAWKQ-GNIYUCBRSA-N, JLYXXMFPNIAWKQ-GNIYUCBRSA-N	Launched
linezolid	bacterial 50S ribosomal subunit inhibitor	MAOA, MAOB	infectious disease	pneumonia, skin infections	CC(=O)NC[C@H]1CN(C(=O)O1)c1ccc(N2CCOCC2)c(F)c1, CC(=O)NC[C@H]1CN(C(=O)O1)c1ccc(N2CCOCC2)c(F)c1, CC(=O)NC[C@H]1CN(C(=O)O1)c1ccc(N2CCOCC2)c(F)c1, CC(=O)NC[C@H]1CN(C(=O)O1)c1ccc(N2CCOCC2)c(F)c1, CC(=O)NC[C@H]1CN(C(=O)O1)c1ccc(N2CCOCC2)c(F)c1	TYZROVQLWOKYKF-ZDUSSCGKSA-N, TYZROVQLWOKYKF-ZDUSSCGKSA-N, TYZROVQLWOKYKF-ZDUSSCGKSA-N, TYZROVQLWOKYKF-ZDUSSCGKSA-N, TYZROVQLWOKYKF-ZDUSSCGKSA-N	Launched
linifanib	PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	CSF1, CSF1R, FLT1, FLT3, FLT4, KDR, KIT, PDGFRB, RET, TEK			Cc1ccc(F)c(NC(=O)Nc2ccc(cc2)-c2cccc3n[nH]c(N)c23)c1, Cc1ccc(F)c(NC(=O)Nc2ccc(cc2)-c2cccc3n[nH]c(N)c23)c1, Cc1ccc(F)c(NC(=O)Nc2ccc(cc2)-c2cccc3n[nH]c(N)c23)c1, Cc1ccc(F)c(NC(=O)Nc2ccc(cc2)-c2cccc3n[nH]c(N)c23)c1, Cc1ccc(F)c(NC(=O)Nc2ccc(cc2)-c2cccc3n[nH]c(N)c23)c1, Cc1ccc(F)c(NC(=O)Nc2ccc(cc2)-c2cccc3n[nH]c(N)c23)c1	MPVGZUGXCQEXTM-UHFFFAOYSA-N, MPVGZUGXCQEXTM-UHFFFAOYSA-N, MPVGZUGXCQEXTM-UHFFFAOYSA-N, MPVGZUGXCQEXTM-UHFFFAOYSA-N, MPVGZUGXCQEXTM-UHFFFAOYSA-N, MPVGZUGXCQEXTM-UHFFFAOYSA-N	Phase 3
linoleic-acid	oxidative stress inducer	FABP4, FFAR1, FFAR4, HNF4A, KCNB1, PPARG, TRPM8			CCCCC\C=C/C\C=C/CCCCCCCC(O)=O	OYHQOLUKZRVURQ-HZJYTTRNSA-N	Phase 3
linopirdine	potassium channel blocker	KCNQ2, KCNQ3, KCNQ4, KCNQ5			O=C1N(c2ccccc2C1(Cc1ccncc1)Cc1ccncc1)c1ccccc1, O=C1N(c2ccccc2C1(Cc1ccncc1)Cc1ccncc1)c1ccccc1, O=C1N(c2ccccc2C1(Cc1ccncc1)Cc1ccncc1)c1ccccc1, O=C1N(c2ccccc2C1(Cc1ccncc1)Cc1ccncc1)c1ccccc1	YEJCDKJIEMIWRQ-UHFFFAOYSA-N, YEJCDKJIEMIWRQ-UHFFFAOYSA-N, YEJCDKJIEMIWRQ-UHFFFAOYSA-N, YEJCDKJIEMIWRQ-UHFFFAOYSA-N	Phase 3
linsidomine	nitric oxide donor		urology	erectile dysfunction	Nc1c[n+](no1)N1CCOCC1, Nc1c[n+](no1)N1CCOCC1, Nc1c[n+](no1)N1CCOCC1	XZYRDNUZENBYFI-UHFFFAOYSA-N, XZYRDNUZENBYFI-UHFFFAOYSA-N, XZYRDNUZENBYFI-UHFFFAOYSA-N	Launched
linsitinib	IGF-1 inhibitor	IGF1R, INSR, INSRR			C[C@@]1(O)C[C@@H](C1)c1nc(-c2ccc3ccc(nc3c2)-c2ccccc2)c2c(N)nccn12 |r|, C[C@@]1(O)C[C@@H](C1)c1nc(-c2ccc3ccc(nc3c2)-c2ccccc2)c2c(N)nccn12 |r|, C[C@@]1(O)C[C@@H](C1)c1nc(-c2ccc3ccc(nc3c2)-c2ccccc2)c2c(N)nccn12 |r|, C[C@@]1(O)C[C@@H](C1)c1nc(-c2ccc3ccc(nc3c2)-c2ccccc2)c2c(N)nccn12 |r|, C[C@@]1(O)C[C@@H](C1)c1nc(-c2ccc3ccc(nc3c2)-c2ccccc2)c2c(N)nccn12 |r|, C[C@@]1(O)C[C@@H](C1)c1nc(-c2ccc3ccc(nc3c2)-c2ccccc2)c2c(N)nccn12 |r|, C[C@@]1(O)C[C@@H](C1)c1nc(-c2ccc3ccc(nc3c2)-c2ccccc2)c2c(N)nccn12 |r|, C[C@@]1(O)C[C@@H](C1)c1nc(-c2ccc3ccc(nc3c2)-c2ccccc2)c2c(N)nccn12 |r|	PKCDDUHJAFVJJB-VLZXCDOPSA-N, PKCDDUHJAFVJJB-VLZXCDOPSA-N, PKCDDUHJAFVJJB-VLZXCDOPSA-N, PKCDDUHJAFVJJB-VLZXCDOPSA-N, PKCDDUHJAFVJJB-VLZXCDOPSA-N, PKCDDUHJAFVJJB-VLZXCDOPSA-N, PKCDDUHJAFVJJB-VLZXCDOPSA-N, PKCDDUHJAFVJJB-VLZXCDOPSA-N	Phase 3
lintopride	serotonin receptor antagonist				CCN1CCN=C1CNC(=O)c1cc(Cl)c(N)cc1OC |c:5|	MJCKISCWHDATBN-UHFFFAOYSA-N	Preclinical
liothyronine	thyroid hormone stimulant	THRA, THRB	endocrinology	hypothyroidism, myxedema coma	N[C@@H](Cc1cc(I)c(Oc2ccc(O)c(I)c2)c(I)c1)C(O)=O, N[C@@H](Cc1cc(I)c(Oc2ccc(O)c(I)c2)c(I)c1)C(O)=O, N[C@@H](Cc1cc(I)c(Oc2ccc(O)c(I)c2)c(I)c1)C(O)=O, N[C@@H](Cc1cc(I)c(Oc2ccc(O)c(I)c2)c(I)c1)C(O)=O, N[C@@H](Cc1cc(I)c(Oc2ccc(O)c(I)c2)c(I)c1)C(O)=O, N[C@@H](Cc1cc(I)c(Oc2ccc(O)c(I)c2)c(I)c1)C(O)=O, N[C@@H](Cc1cc(I)c(Oc2ccc(O)c(I)c2)c(I)c1)C(O)=O	AUYYCJSJGJYCDS-LBPRGKRZSA-N, AUYYCJSJGJYCDS-LBPRGKRZSA-N, AUYYCJSJGJYCDS-LBPRGKRZSA-N, AUYYCJSJGJYCDS-LBPRGKRZSA-N, AUYYCJSJGJYCDS-LBPRGKRZSA-N, AUYYCJSJGJYCDS-LBPRGKRZSA-N, AUYYCJSJGJYCDS-LBPRGKRZSA-N	Launched
liothyronine-(isomer)					N[C@H](Cc1cc(I)c(Oc2ccc(O)c(I)c2)c(I)c1)C(O)=O	AUYYCJSJGJYCDS-GFCCVEGCSA-N	Preclinical
lipoamide					NC(=O)CCCC[C@H]1CCSS1 |&1:7,r|, NC(=O)CCCC[C@H]1CCSS1 |&1:7,r|	FCCDDURTIIUXBY-ZETCQYMHSA-N, FCCDDURTIIUXBY-ZETCQYMHSA-N	Preclinical
liquiritin	antioxidant				OC[C@H]1O[C@@H](Oc2ccc(cc2)[C@@H]2CC(=O)c3ccc(O)cc3O2)[C@H](O)[C@@H](O)[C@@H]1O	DEMKZLAVQYISIA-ZRWXNEIDSA-N	Preclinical
liraglutide	GLP receptor agonist	GLP1R	endocrinology	weight-loss aid, diabetes mellitus	CCCCCCCCCCCCCCCC(=O)N[C@@H](CCC(=O)NCCCC[C@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)Cc1cnc[nH]1)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)C(O)=O	YSDQQAXHVYUZIW-QCIJIYAXSA-N	Launched
liranaftate	fungal squalene epoxidase inhibitor		infectious disease	fungal infection	COc1cccc(n1)N(C)C(=S)Oc1ccc2CCCCc2c1, COc1cccc(n1)N(C)C(=S)Oc1ccc2CCCCc2c1	VPHPQNGOVQYUMG-UHFFFAOYSA-N, VPHPQNGOVQYUMG-UHFFFAOYSA-N	Launched
lirimilast	phosphodiesterase inhibitor				CS(=O)(=O)Oc1ccc2c(NC(N)=O)c(oc2c1)C(=O)c1ccc(Cl)cc1Cl, CS(=O)(=O)Oc1ccc2c(NC(N)=O)c(oc2c1)C(=O)c1ccc(Cl)cc1Cl	YPFLFUJKZDAXRA-UHFFFAOYSA-N, YPFLFUJKZDAXRA-UHFFFAOYSA-N	Phase 2
lisadimate	topical sunscreen agent		dermatology	sunscreen lotion	Nc1ccc(cc1)C(=O)OC[C@@H](O)CO |&1:11,r|	WHQOKFZWSDOTQP-VIFPVBQESA-N	Launched
lisinopril	angiotensin converting enzyme inhibitor	ACE, ACE2	cardiology, endocrinology	hypertension, congestive heart failure, diabetes mellitus	NCCCC[C@H](N[C@@H](CCc1ccccc1)C(O)=O)C(=O)N1CCC[C@H]1C(O)=O, NCCCC[C@H](N[C@@H](CCc1ccccc1)C(O)=O)C(=O)N1CCC[C@H]1C(O)=O, NCCCC[C@H](N[C@@H](CCc1ccccc1)C(O)=O)C(=O)N1CCC[C@H]1C(O)=O, NCCCC[C@H](N[C@@H](CCc1ccccc1)C(O)=O)C(=O)N1CCC[C@H]1C(O)=O, NCCCC[C@H](N[C@@H](CCc1ccccc1)C(O)=O)C(=O)N1CCC[C@H]1C(O)=O, NCCCC[C@H](N[C@@H](CCc1ccccc1)C(O)=O)C(=O)N1CCC[C@H]1C(O)=O, NCCCC[C@H](N[C@@H](CCc1ccccc1)C(O)=O)C(=O)N1CCC[C@H]1C(O)=O, NCCCC[C@H](N[C@@H](CCc1ccccc1)C(O)=O)C(=O)N1CCC[C@H]1C(O)=O, NCCCC[C@H](N[C@@H](CCc1ccccc1)C(O)=O)C(=O)N1CCC[C@H]1C(O)=O	RLAWWYSOJDYHDC-BZSNNMDCSA-N, RLAWWYSOJDYHDC-BZSNNMDCSA-N, RLAWWYSOJDYHDC-BZSNNMDCSA-N, RLAWWYSOJDYHDC-BZSNNMDCSA-N, RLAWWYSOJDYHDC-BZSNNMDCSA-N, RLAWWYSOJDYHDC-BZSNNMDCSA-N, RLAWWYSOJDYHDC-BZSNNMDCSA-N, RLAWWYSOJDYHDC-BZSNNMDCSA-N, RLAWWYSOJDYHDC-BZSNNMDCSA-N	Launched
lisofylline	interleukin receptor antagonist, STAT inhibitor				C[C@@H](O)CCCCn1c(=O)n(C)c2ncn(C)c2c1=O |&1:1,r|, C[C@@H](O)CCCCn1c(=O)n(C)c2ncn(C)c2c1=O |&1:1,r|	NSMXQKNUPPXBRG-SECBINFHSA-N, NSMXQKNUPPXBRG-SECBINFHSA-N	Phase 2
lisuride	dopamine receptor agonist	ADRA1A, ADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, DRD4, DRD5, HTR1A, HTR1B, HTR1D, HTR2A, HTR2B, HTR2C, HTR6	neurology/psychiatry	Parkinson's Disease	CCN(CC)C(=O)N[C@@H]1CN(C)[C@@H]2Cc3c[nH]c4cccc(C2=C1)c34 |c:23|, CCN(CC)C(=O)N[C@@H]1CN(C)[C@@H]2Cc3c[nH]c4cccc(C2=C1)c34 |c:23|, CCN(CC)C(=O)N[C@@H]1CN(C)[C@@H]2Cc3c[nH]c4cccc(C2=C1)c34 |c:23|	BKRGVLQUQGGVSM-KBXCAEBGSA-N, BKRGVLQUQGGVSM-KBXCAEBGSA-N, BKRGVLQUQGGVSM-KBXCAEBGSA-N	Launched
lithium-acetoacetate		FAH			CC(=O)CC(O)=O	WDJHALXBUFZDSR-UHFFFAOYSA-N	Preclinical
lithium-citrate			neurology/psychiatry	bipolar disorder, depression	[Li].[Li].[Li].OC(=O)CC(O)(CC(O)=O)C(O)=O, [Li].[Li].[Li].OC(=O)CC(O)(CC(O)=O)C(O)=O, [Li].[Li].[Li].OC(=O)CC(O)(CC(O)=O)C(O)=O, [Li].[Li].[Li].OC(=O)CC(O)(CC(O)=O)C(O)=O	PTYJGLZVOMGTRG-UHFFFAOYSA-N, PTYJGLZVOMGTRG-UHFFFAOYSA-N, PTYJGLZVOMGTRG-UHFFFAOYSA-N, PTYJGLZVOMGTRG-UHFFFAOYSA-N	Launched
lithocholic-acid	FXR antagonist, vitamin D receptor agonist	GPBAR1, NR1H4, NR1I2, VDR			C[C@H](CCC(O)=O)[C@H]1CC[C@H]2[C@@H]3CC[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C	SMEROWZSTRWXGI-HVATVPOCSA-N	Preclinical
litronesib	kinesin-like spindle protein inhibitor	KIF11			CCNCCS(=O)(=O)NC[C@]1(SC(NC(=O)C(C)(C)C)=NN1C(=O)C(C)(C)C)c1ccccc1 |c:19|, CCNCCS(=O)(=O)NC[C@]1(SC(NC(=O)C(C)(C)C)=NN1C(=O)C(C)(C)C)c1ccccc1 |c:19|, CCNCCS(=O)(=O)NC[C@]1(SC(NC(=O)C(C)(C)C)=NN1C(=O)C(C)(C)C)c1ccccc1 |c:19|	YVAFBXLHPINSIK-QHCPKHFHSA-N, YVAFBXLHPINSIK-QHCPKHFHSA-N, YVAFBXLHPINSIK-QHCPKHFHSA-N	Phase 2
lixivaptan	vasopressin receptor antagonist	AVPR2			Cc1ccc(F)cc1C(=O)Nc1ccc(C(=O)N2Cc3cccn3Cc3ccccc23)c(Cl)c1, Cc1ccc(F)cc1C(=O)Nc1ccc(C(=O)N2Cc3cccn3Cc3ccccc23)c(Cl)c1, Cc1ccc(F)cc1C(=O)Nc1ccc(C(=O)N2Cc3cccn3Cc3ccccc23)c(Cl)c1	PPHTXRNHTVLQED-UHFFFAOYSA-N, PPHTXRNHTVLQED-UHFFFAOYSA-N, PPHTXRNHTVLQED-UHFFFAOYSA-N	Phase 3
LM-22A4	tropomyosin receptor kinase inhibitor	NTRK2			OCCNC(=O)c1cc(cc(c1)C(=O)NCCO)C(=O)NCCO, OCCNC(=O)c1cc(cc(c1)C(=O)NCCO)C(=O)NCCO, OCCNC(=O)c1cc(cc(c1)C(=O)NCCO)C(=O)NCCO	RGWJKANXFYJKHN-UHFFFAOYSA-N, RGWJKANXFYJKHN-UHFFFAOYSA-N, RGWJKANXFYJKHN-UHFFFAOYSA-N	Preclinical
LMI070	survival motor neuron protein modulator	SMN1			CC1(C)CC(CC(C)(C)N1)Oc1ccc(nn1)-c1ccc(cc1O)-c1cn[nH]c1, CC1(C)CC(CC(C)(C)N1)Oc1ccc(nn1)-c1ccc(cc1O)-c1cn[nH]c1	STWTUEAWRAIWJG-UHFFFAOYSA-N, STWTUEAWRAIWJG-UHFFFAOYSA-N	Phase 1/Phase 2
LMK-235	HDAC inhibitor	HDAC4, HDAC5			Cc1cc(C)cc(c1)C(=O)NOCCCCCC(=O)NO, Cc1cc(C)cc(c1)C(=O)NOCCCCCC(=O)NO, Cc1cc(C)cc(c1)C(=O)NOCCCCCC(=O)NO	VRYZCEONIWEUAV-UHFFFAOYSA-N, VRYZCEONIWEUAV-UHFFFAOYSA-N, InChI=1S/C15H22N2O4/c1-11-8-12(2)10-13(9-11)15(19)17-21-7-5-3-4-6-14(18)16-20/h8-10,20H,3-7H2,1-2H3,(H,16,18)(H,17,19)	Preclinical
LM11A-31	neurotrophic agent	NGFR			CC[C@@H](C)[C@@H](N)C(=O)NCCN1CCOCC1 |&1:2,&2:4,r|, CC[C@@H](C)[C@@H](N)C(=O)NCCN1CCOCC1 |&1:2,&2:4,r|	YNMUTYLWSRFTPX-GHMZBOCLSA-N, YNMUTYLWSRFTPX-GHMZBOCLSA-N	Phase 1
lobeline	acetylcholine receptor antagonist	CHRNA10, CHRNA9, SLC18A2	neurology/psychiatry	smoking cessation	CN1[C@H](C[C@H](O)c2ccccc2)CCC[C@@H]1CC(=O)c1ccccc1, CN1[C@H](C[C@H](O)c2ccccc2)CCC[C@@H]1CC(=O)c1ccccc1, CN1[C@H](C[C@H](O)c2ccccc2)CCC[C@@H]1CC(=O)c1ccccc1, CN1[C@H](C[C@H](O)c2ccccc2)CCC[C@@H]1CC(=O)c1ccccc1, CN1[C@H](C[C@H](O)c2ccccc2)CCC[C@@H]1CC(=O)c1ccccc1	MXYUKLILVYORSK-HBMCJLEFSA-N, MXYUKLILVYORSK-HBMCJLEFSA-N, MXYUKLILVYORSK-HBMCJLEFSA-N, MXYUKLILVYORSK-HBMCJLEFSA-N, MXYUKLILVYORSK-HBMCJLEFSA-N	Launched
lobendazole	anthelmintic agent				CCOC(=O)Nc1nc2ccccc2[nH]1, CCOC(=O)Nc1nc2ccccc2[nH]1, CCOC(=O)Nc1nc2ccccc2[nH]1	OKOVSTKGUBOSTB-UHFFFAOYSA-N, OKOVSTKGUBOSTB-UHFFFAOYSA-N, OKOVSTKGUBOSTB-UHFFFAOYSA-N	Preclinical
lobenzarit	immunosuppressant		rheumatology	rheumatoid arthritis	OC(=O)c1ccccc1Nc1cc(Cl)ccc1C(O)=O	UGDPYGKWIHHBMB-UHFFFAOYSA-N	Launched
lodenosine	antiretroviral 				Nc1ncnc2n(cnc12)[C@@H]1O[C@H](CO)C[C@@H]1F	KBEMFSMODRNJHE-JFWOZONXSA-N	Phase 2
lodoxamide	histamine receptor antagonist		ophthalmology	vernal keratoconjunctivitis (VKC)	OC(=O)C(=O)Nc1cc(cc(NC(=O)C(O)=O)c1Cl)C#N, OC(=O)C(=O)Nc1cc(cc(NC(=O)C(O)=O)c1Cl)C#N, OC(=O)C(=O)Nc1cc(cc(NC(=O)C(O)=O)c1Cl)C#N	RVGLGHVJXCETIO-UHFFFAOYSA-N, RVGLGHVJXCETIO-UHFFFAOYSA-N, RVGLGHVJXCETIO-UHFFFAOYSA-N	Launched
lofemizole	cyclooxygenase inhibitor				Cc1[nH]cnc1-c1ccc(Cl)cc1, Cc1[nH]cnc1-c1ccc(Cl)cc1	MBKWNJVQSFBLQI-UHFFFAOYSA-N, MBKWNJVQSFBLQI-UHFFFAOYSA-N	Phase 3
lofepramine	norepinephrine reuptake inhibitor, serotoninnorepinephrine reuptake inhibitor (SNRI)	HTR1A, SLC6A2, SLC6A4	neurology/psychiatry	depression	CN(CCCN1c2ccccc2CCc2ccccc12)CC(=O)c1ccc(Cl)cc1, CN(CCCN1c2ccccc2CCc2ccccc12)CC(=O)c1ccc(Cl)cc1	SAPNXPWPAUFAJU-UHFFFAOYSA-N, SAPNXPWPAUFAJU-UHFFFAOYSA-N	Launched
lofexidine	adrenergic receptor agonist		neurology/psychiatry	opioid withdrawal	C[C@@H](Oc1c(Cl)cccc1Cl)C1=NCCN1 |r,t:12|, C[C@@H](Oc1c(Cl)cccc1Cl)C1=NCCN1 |r,t:12|, C[C@@H](Oc1c(Cl)cccc1Cl)C1=NCCN1 |r,t:12|, C[C@@H](Oc1c(Cl)cccc1Cl)C1=NCCN1 |r,t:12|	KSMAGQUYOIHWFS-SSDOTTSWSA-N, KSMAGQUYOIHWFS-SSDOTTSWSA-N, KSMAGQUYOIHWFS-SSDOTTSWSA-N, KSMAGQUYOIHWFS-SSDOTTSWSA-N	Launched
lomefloxacin	bacterial DNA gyrase inhibitor		infectious disease	respiratory tract infections, urinary tract infections	CCn1cc(C(O)=O)c(=O)c2cc(F)c(N3CCN[C@@H](C)C3)c(F)c12 |&1:19|, CCn1cc(C(O)=O)c(=O)c2cc(F)c(N3CCN[C@@H](C)C3)c(F)c12 |&1:19|, CCn1cc(C(O)=O)c(=O)c2cc(F)c(N3CCN[C@@H](C)C3)c(F)c12 |&1:19|	ZEKZLJVOYLTDKK-VIFPVBQESA-N, ZEKZLJVOYLTDKK-VIFPVBQESA-N, ZEKZLJVOYLTDKK-VIFPVBQESA-N	Launched
lomeguatrib	O6-alkylguanine-DNA alkyltransferase inhibitor	MGMT			Nc1nc(OCc2cc(Br)cs2)c2[nH]cnc2n1, Nc1nc(OCc2cc(Br)cs2)c2[nH]cnc2n1, Nc1nc(OCc2cc(Br)cs2)c2[nH]cnc2n1, Nc1nc(OCc2cc(Br)cs2)c2[nH]cnc2n1	JUJPKFNFCWJBCX-UHFFFAOYSA-N, JUJPKFNFCWJBCX-UHFFFAOYSA-N, JUJPKFNFCWJBCX-UHFFFAOYSA-N, JUJPKFNFCWJBCX-UHFFFAOYSA-N	Phase 2
lomerizine	calcium channel blocker	CACNA1B, SCN5A	neurology/psychiatry	migraine headache	COc1ccc(CN2CCN(CC2)C(c2ccc(F)cc2)c2ccc(F)cc2)c(OC)c1OC, COc1ccc(CN2CCN(CC2)C(c2ccc(F)cc2)c2ccc(F)cc2)c(OC)c1OC, COc1ccc(CN2CCN(CC2)C(c2ccc(F)cc2)c2ccc(F)cc2)c(OC)c1OC, COc1ccc(CN2CCN(CC2)C(c2ccc(F)cc2)c2ccc(F)cc2)c(OC)c1OC, COc1ccc(CN2CCN(CC2)C(c2ccc(F)cc2)c2ccc(F)cc2)c(OC)c1OC, COc1ccc(CN2CCN(CC2)C(c2ccc(F)cc2)c2ccc(F)cc2)c(OC)c1OC, COc1ccc(CN2CCN(CC2)C(c2ccc(F)cc2)c2ccc(F)cc2)c(OC)c1OC, COc1ccc(CN2CCN(CC2)C(c2ccc(F)cc2)c2ccc(F)cc2)c(OC)c1OC	JQSAYKKFZOSZGJ-UHFFFAOYSA-N, JQSAYKKFZOSZGJ-UHFFFAOYSA-N, JQSAYKKFZOSZGJ-UHFFFAOYSA-N, JQSAYKKFZOSZGJ-UHFFFAOYSA-N, JQSAYKKFZOSZGJ-UHFFFAOYSA-N, JQSAYKKFZOSZGJ-UHFFFAOYSA-N, JQSAYKKFZOSZGJ-UHFFFAOYSA-N, JQSAYKKFZOSZGJ-UHFFFAOYSA-N	Launched
lometrexol	glycinamide ribonucleotide formyltransferase inhibitor	GART			Nc1nc(=O)c2C[C@@H](CCc3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)CNc2[nH]1	ZUQBAQVRAURMCL-DOMZBBRYSA-N	Phase 2
lomitapide	microsomal trigylceride transfer protein inhibitor	MTTP	endocrinology	hypercholesterolemia	FC(F)(F)CNC(=O)C1(CCCCN2CCC(CC2)NC(=O)c2ccccc2-c2ccc(cc2)C(F)(F)F)c2ccccc2-c2ccccc12, FC(F)(F)CNC(=O)C1(CCCCN2CCC(CC2)NC(=O)c2ccccc2-c2ccc(cc2)C(F)(F)F)c2ccccc2-c2ccccc12, FC(F)(F)CNC(=O)C1(CCCCN2CCC(CC2)NC(=O)c2ccccc2-c2ccc(cc2)C(F)(F)F)c2ccccc2-c2ccccc12, FC(F)(F)CNC(=O)C1(CCCCN2CCC(CC2)NC(=O)c2ccccc2-c2ccc(cc2)C(F)(F)F)c2ccccc2-c2ccccc12	MBBCVAKAJPKAKM-UHFFFAOYSA-N, MBBCVAKAJPKAKM-UHFFFAOYSA-N, MBBCVAKAJPKAKM-UHFFFAOYSA-N, MBBCVAKAJPKAKM-UHFFFAOYSA-N	Launched
lomustine	DNA synthesis inhibitor		hematologic malignancy, oncology	Hodgkin's lymphoma, brain tumors	[O-][NH2+]N(CCCl)C(=O)NC1CCCCC1, [O-][NH2+]N(CCCl)C(=O)NC1CCCCC1, [O-][NH2+]N(CCCl)C(=O)NC1CCCCC1, [O-][NH2+]N(CCCl)C(=O)NC1CCCCC1, [O-][NH2+]N(CCCl)C(=O)NC1CCCCC1, [O-][NH2+]N(CCCl)C(=O)NC1CCCCC1	NEXPKUGJJKVILF-UHFFFAOYSA-N, NEXPKUGJJKVILF-UHFFFAOYSA-N, NEXPKUGJJKVILF-UHFFFAOYSA-N, NEXPKUGJJKVILF-UHFFFAOYSA-N, NEXPKUGJJKVILF-UHFFFAOYSA-N, NEXPKUGJJKVILF-UHFFFAOYSA-N	Launched
lonafarnib	farnesyltransferase inhibitor	FNTA, HRAS, KRAS, NRAS			NC(=O)N1CCC(CC(=O)N2CCC(CC2)[C@H]2c3ncc(Br)cc3CCc3cc(Cl)cc(Br)c23)CC1, NC(=O)N1CCC(CC(=O)N2CCC(CC2)[C@H]2c3ncc(Br)cc3CCc3cc(Cl)cc(Br)c23)CC1, NC(=O)N1CCC(CC(=O)N2CCC(CC2)[C@H]2c3ncc(Br)cc3CCc3cc(Cl)cc(Br)c23)CC1, NC(=O)N1CCC(CC(=O)N2CCC(CC2)[C@H]2c3ncc(Br)cc3CCc3cc(Cl)cc(Br)c23)CC1, NC(=O)N1CCC(CC(=O)N2CCC(CC2)[C@H]2c3ncc(Br)cc3CCc3cc(Cl)cc(Br)c23)CC1, NC(=O)N1CCC(CC(=O)N2CCC(CC2)[C@H]2c3ncc(Br)cc3CCc3cc(Cl)cc(Br)c23)CC1	DHMTURDWPRKSOA-RUZDIDTESA-N, DHMTURDWPRKSOA-RUZDIDTESA-N, DHMTURDWPRKSOA-RUZDIDTESA-N, DHMTURDWPRKSOA-RUZDIDTESA-N, DHMTURDWPRKSOA-RUZDIDTESA-N, InChI=1S/C27H31Br2ClN4O2/c28-20-12-19-2-1-18-13-21(30)14-22(29)24(18)25(26(19)32-15-20)17-5-9-33(10-6-17)23(35)11-16-3-7-34(8-4-16)27(31)36/h12-17,25H,1-11H2,(H2,31,36)/t25-/m1/s1	Phase 3
lonidamine	glucokinase inhibitor	GCK			OC(=O)c1nn(Cc2ccc(Cl)cc2Cl)c2ccccc12, OC(=O)c1nn(Cc2ccc(Cl)cc2Cl)c2ccccc12, OC(=O)c1nn(Cc2ccc(Cl)cc2Cl)c2ccccc12, OC(=O)c1nn(Cc2ccc(Cl)cc2Cl)c2ccccc12, OC(=O)c1nn(Cc2ccc(Cl)cc2Cl)c2ccccc12	WDRYRZXSPDWGEB-UHFFFAOYSA-N, WDRYRZXSPDWGEB-UHFFFAOYSA-N, WDRYRZXSPDWGEB-UHFFFAOYSA-N, WDRYRZXSPDWGEB-UHFFFAOYSA-N, WDRYRZXSPDWGEB-UHFFFAOYSA-N	Launched
loperamide	opioid receptor agonist	CACNA1A, CALM1, OPRD1, OPRK1, OPRM1, POMC	gastroenterology	diarrhea	CN(C)C(=O)C(CCN1CCC(O)(CC1)c1ccc(Cl)cc1)(c1ccccc1)c1ccccc1, CN(C)C(=O)C(CCN1CCC(O)(CC1)c1ccc(Cl)cc1)(c1ccccc1)c1ccccc1, CN(C)C(=O)C(CCN1CCC(O)(CC1)c1ccc(Cl)cc1)(c1ccccc1)c1ccccc1, CN(C)C(=O)C(CCN1CCC(O)(CC1)c1ccc(Cl)cc1)(c1ccccc1)c1ccccc1, CN(C)C(=O)C(CCN1CCC(O)(CC1)c1ccc(Cl)cc1)(c1ccccc1)c1ccccc1, CN(C)C(=O)C(CCN1CCC(O)(CC1)c1ccc(Cl)cc1)(c1ccccc1)c1ccccc1, CN(C)C(=O)C(CCN1CCC(O)(CC1)c1ccc(Cl)cc1)(c1ccccc1)c1ccccc1, CN(C)C(=O)C(CCN1CCC(O)(CC1)c1ccc(Cl)cc1)(c1ccccc1)c1ccccc1	RDOIQAHITMMDAJ-UHFFFAOYSA-N, RDOIQAHITMMDAJ-UHFFFAOYSA-N, RDOIQAHITMMDAJ-UHFFFAOYSA-N, RDOIQAHITMMDAJ-UHFFFAOYSA-N, RDOIQAHITMMDAJ-UHFFFAOYSA-N, RDOIQAHITMMDAJ-UHFFFAOYSA-N, RDOIQAHITMMDAJ-UHFFFAOYSA-N, RDOIQAHITMMDAJ-UHFFFAOYSA-N	Launched
lopinavir	HIV protease inhibitor		infectious disease	human immunodeficiency virus (HIV-1)	CC(C)[C@H](N1CCCNC1=O)C(=O)N[C@H](C[C@H](O)[C@H](Cc1ccccc1)NC(=O)COc1c(C)cccc1C)Cc1ccccc1, CC(C)[C@H](N1CCCNC1=O)C(=O)N[C@H](C[C@H](O)[C@H](Cc1ccccc1)NC(=O)COc1c(C)cccc1C)Cc1ccccc1, CC(C)[C@H](N1CCCNC1=O)C(=O)N[C@H](C[C@H](O)[C@H](Cc1ccccc1)NC(=O)COc1c(C)cccc1C)Cc1ccccc1, CC(C)[C@H](N1CCCNC1=O)C(=O)N[C@H](C[C@H](O)[C@H](Cc1ccccc1)NC(=O)COc1c(C)cccc1C)Cc1ccccc1, CC(C)[C@H](N1CCCNC1=O)C(=O)N[C@H](C[C@H](O)[C@H](Cc1ccccc1)NC(=O)COc1c(C)cccc1C)Cc1ccccc1	KJHKTHWMRKYKJE-SUGCFTRWSA-N, KJHKTHWMRKYKJE-SUGCFTRWSA-N, KJHKTHWMRKYKJE-SUGCFTRWSA-N, KJHKTHWMRKYKJE-SUGCFTRWSA-N, KJHKTHWMRKYKJE-SUGCFTRWSA-N	Launched
loracarbef	bacterial cell wall synthesis inhibitor		infectious disease, otolaryngology, pulmonary	ear infections, laryngitis, bronchitis, pneumonia, urinary tract infections, skin infections	N[C@@H](C(=O)N[C@H]1[C@H]2CCC(Cl)=C(N2C1=O)C(O)=O)c1ccccc1 |c:10|, N[C@@H](C(=O)N[C@H]1[C@H]2CCC(Cl)=C(N2C1=O)C(O)=O)c1ccccc1 |c:10|	JAPHQRWPEGVNBT-UTUOFQBUSA-N, JAPHQRWPEGVNBT-UTUOFQBUSA-N	Launched
loratadine	histamine receptor antagonist	HRH1	allergy, neurology/psychiatry	allergic rhinitis, itching	CCOC(=O)N1CCC(CC1)=C1c2ccc(Cl)cc2CCc2cccnc12, CCOC(=O)N1CCC(CC1)=C1c2ccc(Cl)cc2CCc2cccnc12, CCOC(=O)N1CCC(CC1)=C1c2ccc(Cl)cc2CCc2cccnc12, CCOC(=O)N1CCC(CC1)=C1c2ccc(Cl)cc2CCc2cccnc12, CCOC(=O)N1CCC(CC1)=C1c2ccc(Cl)cc2CCc2cccnc12	JCCNYMKQOSZNPW-UHFFFAOYSA-N, JCCNYMKQOSZNPW-UHFFFAOYSA-N, JCCNYMKQOSZNPW-UHFFFAOYSA-N, JCCNYMKQOSZNPW-UHFFFAOYSA-N, JCCNYMKQOSZNPW-UHFFFAOYSA-N	Launched
loreclezole	benzodiazepine receptor agonist	GABRB2, GABRB3			Cl\C(=C/n1cncn1)c1ccc(Cl)cc1Cl, Cl\C(=C/n1cncn1)c1ccc(Cl)cc1Cl	XGLHZTBDUXXHOM-WMZJFQQLSA-N, XGLHZTBDUXXHOM-WMZJFQQLSA-N	Phase 2
lorediplon	GABA receptor modulator	GABRA1			CN(C(C)=O)c1cc(ccc1F)-c1ccnc2c(cnn12)C(=O)c1cccs1	NQPOCLFSADOXBR-UHFFFAOYSA-N	Phase 2
lorglumide	CCK receptor antagonist	CCKAR, CCKBR			CCCCCN(CCCCC)C(=O)[C@@H](CCC(O)=O)NC(=O)c1ccc(Cl)c(Cl)c1 |&1:13,r|	IEKOTSCYBBDIJC-LJQANCHMSA-N	Phase 1
lorlatinib	ALK tyrosine kinase receptor inhibitor	ALK	oncology	non-small cell lung cancer (NSCLC)	C[C@H]1Oc2cc(cnc2N)-c2c(CN(C)C(=O)c3ccc(F)cc13)nn(C)c2C#N, C[C@H]1Oc2cc(cnc2N)-c2c(CN(C)C(=O)c3ccc(F)cc13)nn(C)c2C#N, C[C@H]1Oc2cc(cnc2N)-c2c(CN(C)C(=O)c3ccc(F)cc13)nn(C)c2C#N, C[C@H]1Oc2cc(cnc2N)-c2c(CN(C)C(=O)c3ccc(F)cc13)nn(C)c2C#N, C[C@H]1Oc2cc(cnc2N)-c2c(CN(C)C(=O)c3ccc(F)cc13)nn(C)c2C#N	IIXWYSCJSQVBQM-UHFFFAOYSA-N, IIXWYSCJSQVBQM-UHFFFAOYSA-N, IIXWYSCJSQVBQM-UHFFFAOYSA-N, IIXWYSCJSQVBQM-UHFFFAOYSA-N, IIXWYSCJSQVBQM-UHFFFAOYSA-N	Launched
lornoxicam	cyclooxygenase inhibitor	PTGS1, PTGS2	rheumatology, neurology/psychiatry	osteoarthritis, sciata	CN1C(C(=O)Nc2ccccn2)=C(O)c2sc(Cl)cc2S1(=O)=O |t:12|, CN1C(C(=O)Nc2ccccn2)=C(O)c2sc(Cl)cc2S1(=O)=O |t:12|, CN1C(C(=O)Nc2ccccn2)=C(O)c2sc(Cl)cc2S1(=O)=O |t:12|	WLHQHAUOOXYABV-UHFFFAOYSA-N, WLHQHAUOOXYABV-UHFFFAOYSA-N, WLHQHAUOOXYABV-UHFFFAOYSA-N	Launched
losartan	angiotensin receptor antagonist	AGTR1	cardiology, nephrology	hypertension, diabetic nephropathy, hypertension	CCCCc1nc(Cl)c(CO)n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1, CCCCc1nc(Cl)c(CO)n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1, CCCCc1nc(Cl)c(CO)n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1, CCCCc1nc(Cl)c(CO)n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1, CCCCc1nc(Cl)c(CO)n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1, CCCCc1nc(Cl)c(CO)n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1, CCCCc1nc(Cl)c(CO)n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1, CCCCc1nc(Cl)c(CO)n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1	PSIFNNKUMBGKDQ-UHFFFAOYSA-N, PSIFNNKUMBGKDQ-UHFFFAOYSA-N, PSIFNNKUMBGKDQ-UHFFFAOYSA-N, PSIFNNKUMBGKDQ-UHFFFAOYSA-N, PSIFNNKUMBGKDQ-UHFFFAOYSA-N, PSIFNNKUMBGKDQ-UHFFFAOYSA-N, PSIFNNKUMBGKDQ-UHFFFAOYSA-N, PSIFNNKUMBGKDQ-UHFFFAOYSA-N	Launched
losmapimod	p38 MAPK inhibitor	MAPK14			Cc1c(F)cc(cc1-c1ccc(cn1)C(=O)NCC(C)(C)C)C(=O)NC1CC1, Cc1c(F)cc(cc1-c1ccc(cn1)C(=O)NCC(C)(C)C)C(=O)NC1CC1, Cc1c(F)cc(cc1-c1ccc(cn1)C(=O)NCC(C)(C)C)C(=O)NC1CC1, Cc1c(F)cc(cc1-c1ccc(cn1)C(=O)NCC(C)(C)C)C(=O)NC1CC1, Cc1c(F)cc(cc1-c1ccc(cn1)C(=O)NCC(C)(C)C)C(=O)NC1CC1, Cc1c(F)cc(cc1-c1ccc(cn1)C(=O)NCC(C)(C)C)C(=O)NC1CC1	KKYABQBFGDZVNQ-UHFFFAOYSA-N, KKYABQBFGDZVNQ-UHFFFAOYSA-N, KKYABQBFGDZVNQ-UHFFFAOYSA-N, KKYABQBFGDZVNQ-UHFFFAOYSA-N, KKYABQBFGDZVNQ-UHFFFAOYSA-N, KKYABQBFGDZVNQ-UHFFFAOYSA-N	Phase 3
lotamilast	phosphodiesterase inhibitor				CNc1nc(-c2cccc(NC(=O)c3ccc(cc3)C(=O)OC)c2)c2cc(OC)c(OC)cc2n1	BBTFKAOFCSOZMB-UHFFFAOYSA-N	Preclinical
loteprednol	glucocorticoid receptor agonist, phospholipase inhibitor	NR3C1	ophthalmology	conjunctivitis	CCOC(=O)O[C@@]1(CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]12C)C(=O)OCCl |c:17,t:13|, CCOC(=O)O[C@@]1(CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]12C)C(=O)OCCl |c:17,t:13|, CCOC(=O)O[C@@]1(CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]12C)C(=O)OCCl |c:17,t:13|, CCOC(=O)O[C@@]1(CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]12C)C(=O)OCCl |c:17,t:13|, CCOC(=O)O[C@@]1(CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]12C)C(=O)OCCl |c:17,t:13|	DMKSVUSAATWOCU-HROMYWEYSA-N, DMKSVUSAATWOCU-HROMYWEYSA-N, DMKSVUSAATWOCU-HROMYWEYSA-N, DMKSVUSAATWOCU-HROMYWEYSA-N, DMKSVUSAATWOCU-HROMYWEYSA-N	Launched
lovastatin	HMGCR inhibitor	HDAC2, HMGCR, ITGAL, NR1I2	cardiology, endocrinology	coronary heart disease, myocardial infarction, hypercholesterolemia	CC[C@H](C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12 |c:13,t:11|, CC[C@H](C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12 |c:13,t:11|, CC[C@H](C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12 |c:13,t:11|, CC[C@H](C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12 |c:13,t:11|, CC[C@H](C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12 |c:13,t:11|, CC[C@H](C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12 |c:13,t:11|, CC[C@H](C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12 |c:13,t:11|, CC[C@H](C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12 |c:13,t:11|, CC[C@H](C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12 |c:13,t:11|	PCZOHLXUXFIOCF-BXMDZJJMSA-N, PCZOHLXUXFIOCF-BXMDZJJMSA-N, PCZOHLXUXFIOCF-BXMDZJJMSA-N, PCZOHLXUXFIOCF-BXMDZJJMSA-N, PCZOHLXUXFIOCF-BXMDZJJMSA-N, PCZOHLXUXFIOCF-BXMDZJJMSA-N, PCZOHLXUXFIOCF-BXMDZJJMSA-N, PCZOHLXUXFIOCF-BXMDZJJMSA-N, PCZOHLXUXFIOCF-BXMDZJJMSA-N	Launched
loxapine	dopamine receptor antagonist, serotonin receptor antagonist	ADRA1A, ADRA1B, ADRA2A, ADRA2B, ADRA2C, ADRB1, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, DRD1, DRD2, DRD3, DRD4, DRD5, HRH1, HRH2, HRH4, HTR1A, HTR1B, HTR1D, HTR1E, HTR2A, HTR2C, HTR3A, HTR5A, HTR6, HTR7, SLC6A2, SLC6A3, SLC6A4	neurology/psychiatry	schizophrenia	CN1CCN(CC1)C1=Nc2ccccc2Oc2ccc(Cl)cc12 |t:8|, CN1CCN(CC1)C1=Nc2ccccc2Oc2ccc(Cl)cc12 |t:8|, CN1CCN(CC1)C1=Nc2ccccc2Oc2ccc(Cl)cc12 |t:8|	XJGVXQDUIWGIRW-UHFFFAOYSA-N, XJGVXQDUIWGIRW-UHFFFAOYSA-N, XJGVXQDUIWGIRW-UHFFFAOYSA-N	Launched
loxistatin-acid	cysteine peptidase inhibitor	CTSB			CC(C)CCNC(=O)[C@H](CC(C)C)NC(=O)[C@H]1O[C@@H]1C(O)=O, CC(C)CCNC(=O)[C@H](CC(C)C)NC(=O)[C@H]1O[C@@H]1C(O)=O, CC(C)CCNC(=O)[C@H](CC(C)C)NC(=O)[C@H]1O[C@@H]1C(O)=O	SCMSYZJDIQPSDI-SRVKXCTJSA-N, SCMSYZJDIQPSDI-SRVKXCTJSA-N, SCMSYZJDIQPSDI-SRVKXCTJSA-N	Preclinical
loxoprofen	cyclooxygenase inhibitor, prostanoid receptor antagonist	PTGS2	neurology/psychiatry	pain relief	C[C@@H](C(O)=O)c1ccc(C[C@H]2CCCC2=O)cc1 |&1:1,&2:10,r|, C[C@@H](C(O)=O)c1ccc(C[C@H]2CCCC2=O)cc1 |&1:1,&2:10,r|, C[C@@H](C(O)=O)c1ccc(C[C@H]2CCCC2=O)cc1 |&1:1,&2:10,r|, C[C@@H](C(O)=O)c1ccc(C[C@H]2CCCC2=O)cc1 |&1:1,&2:10,r|	YMBXTVYHTMGZDW-ZWNOBZJWSA-N, YMBXTVYHTMGZDW-ZWNOBZJWSA-N, YMBXTVYHTMGZDW-ZWNOBZJWSA-N, YMBXTVYHTMGZDW-ZWNOBZJWSA-N	Launched
LP-533401	tryptophan hydroxylase inhibitor				N[C@@H](Cc1ccc(cc1)-c1cc(O[C@@H](c2ccc(cc2)-c2cccc(F)c2)C(F)(F)F)nc(N)n1)C(O)=O |&1:13|	JZWUKILTKYJLCN-URXFXBBRSA-N	Preclinical
LPA2-antagonist-1	lysophosphatidic acid receptor antagonist	LPAR2			C[C@@H](CN1CCN(CC1)S(=O)(=O)c1ccc(Cl)c(Cl)c1)Nc1ncnc2c(C)csc12, C[C@@H](CN1CCN(CC1)S(=O)(=O)c1ccc(Cl)c(Cl)c1)Nc1ncnc2c(C)csc12	BPRNMVDTWIHULJ-AWEZNQCLSA-N, BPRNMVDTWIHULJ-AWEZNQCLSA-N	Preclinical
LRRK2-IN-1	leucine rich repeat kinase inhibitor	LRRK2			COc1cc(ccc1Nc1ncc2N(C)C(=O)c3ccccc3N(C)c2n1)C(=O)N1CCC(CC1)N1CCN(C)CC1, COc1cc(ccc1Nc1ncc2N(C)C(=O)c3ccccc3N(C)c2n1)C(=O)N1CCC(CC1)N1CCN(C)CC1	IWMCPJZTADUIFX-UHFFFAOYSA-N, IWMCPJZTADUIFX-UHFFFAOYSA-N	Preclinical
LSN-2463359	glutamate receptor positive allosteric modulator	GRM5			CC(C)NC(=O)c1ccc(cn1)C#Cc1ccncc1, CC(C)NC(=O)c1ccc(cn1)C#Cc1ccncc1, CC(C)NC(=O)c1ccc(cn1)C#Cc1ccncc1	STAFRSGTRKNXHF-UHFFFAOYSA-N, STAFRSGTRKNXHF-UHFFFAOYSA-N, STAFRSGTRKNXHF-UHFFFAOYSA-N	Preclinical
LSZ-102	selective estrogen receptor modulator (SERM)				CC(F)(F)c1cc(F)ccc1-c1sc2cc(O)ccc2c1Oc1ccc(\C=C\C(O)=O)cc1, CC(F)(F)c1cc(F)ccc1-c1sc2cc(O)ccc2c1Oc1ccc(\C=C\C(O)=O)cc1	SJXNPGGVGZXKKI-NYYWCZLTSA-N, SJXNPGGVGZXKKI-NYYWCZLTSA-N	Phase 1
LTA					N=C(Nc1ccccc1)c1cccs1	RCORNHOUCUDCAC-UHFFFAOYSA-N	Phase 2
LTB4	leukocyte activator	LTB4R, LTB4R2			CCCCC\C=C/C[C@@H](O)\C=C\C=C\C=C/[C@@H](O)CCCC(O)=O	VNYSSYRCGWBHLG-AMOLWHMGSA-N	Phase 2
LTX-315	anticancer agent				NCCCC[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](C(c1ccccc1)c1ccccc1)C(=O)N[C@@H](CCCCN)C(N)=O	GGAKLYWEFZCVIT-TVEKFXMRSA-N	Phase 2
Lu-AA-47070	adenosine receptor antagonist	ADORA2A			CC(C)(C)CC(=O)Nc1c(F)cc(cc1F)C(=O)\N=c1/sccn1COP(O)(O)=O, CC(C)(C)CC(=O)Nc1c(F)cc(cc1F)C(=O)\N=c1/sccn1COP(O)(O)=O, CC(C)(C)CC(=O)Nc1c(F)cc(cc1F)C(=O)\N=c1/sccn1COP(O)(O)=O	MSWIQSFUBYCFJE-PGMHBOJBSA-N, MSWIQSFUBYCFJE-PGMHBOJBSA-N, MSWIQSFUBYCFJE-PGMHBOJBSA-N	Phase 2
lubiprostone	chloride channel activator	CLCN2	gastroenterology	constipation, irritable bowel syndrome	CCCCC(F)(F)C(=O)CC[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O, CCCCC(F)(F)C(=O)CC[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O, CCCCC(F)(F)C(=O)CC[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O	DBVFKLAGQHYVGQ-BFYDXBDKSA-N, DBVFKLAGQHYVGQ-BFYDXBDKSA-N, DBVFKLAGQHYVGQ-BFYDXBDKSA-N	Launched
lucanthone	endonuclease inhibitor	APEX1, TOP1, TOP2A			CCN(CC)CCNc1ccc(C)c2sc3ccccc3c(=O)c12	FBQPGGIHOFZRGH-UHFFFAOYSA-N	Phase 2
lucitanib	FGFR inhibitor, VEGFR inhibitor	FGFR1, FLT1, KDR, KIT, PDGFRA, PDGFRB, RET			CNC(=O)c1cccc2cc(Oc3ccnc4cc(OCC5(N)CC5)c(OC)cc34)ccc12, CNC(=O)c1cccc2cc(Oc3ccnc4cc(OCC5(N)CC5)c(OC)cc34)ccc12, CNC(=O)c1cccc2cc(Oc3ccnc4cc(OCC5(N)CC5)c(OC)cc34)ccc12, CNC(=O)c1cccc2cc(Oc3ccnc4cc(OCC5(N)CC5)c(OC)cc34)ccc12, CNC(=O)c1cccc2cc(Oc3ccnc4cc(OCC5(N)CC5)c(OC)cc34)ccc12, CNC(=O)c1cccc2cc(Oc3ccnc4cc(OCC5(N)CC5)c(OC)cc34)ccc12, CNC(=O)c1cccc2cc(Oc3ccnc4cc(OCC5(N)CC5)c(OC)cc34)ccc12, CNC(=O)c1cccc2cc(Oc3ccnc4cc(OCC5(N)CC5)c(OC)cc34)ccc12, CNC(=O)c1cccc2cc(Oc3ccnc4cc(OCC5(N)CC5)c(OC)cc34)ccc12, CNC(=O)c1cccc2cc(Oc3ccnc4cc(OCC5(N)CC5)c(OC)cc34)ccc12, CNC(=O)c1cccc2cc(Oc3ccnc4cc(OCC5(N)CC5)c(OC)cc34)ccc12, CNC(=O)c1cccc2cc(Oc3ccnc4cc(OCC5(N)CC5)c(OC)cc34)ccc12, CNC(=O)c1cccc2cc(Oc3ccnc4cc(OCC5(N)CC5)c(OC)cc34)ccc12	CUDVHEFYRIWYQD-UHFFFAOYSA-N, CUDVHEFYRIWYQD-UHFFFAOYSA-N, CUDVHEFYRIWYQD-UHFFFAOYSA-N, CUDVHEFYRIWYQD-UHFFFAOYSA-N, CUDVHEFYRIWYQD-UHFFFAOYSA-N, CUDVHEFYRIWYQD-UHFFFAOYSA-N, InChI=1S/C26H25N3O4/c1-28-25(30)19-5-3-4-16-12-17(6-7-18(16)19)33-22-8-11-29-21-14-24(23(31-2)13-20(21)22)32-15-26(27)9-10-26/h3-8,11-14H,9-10,15,27H2,1-2H3,(H,28,30), InChI=1S/C26H25N3O4/c1-28-25(30)19-5-3-4-16-12-17(6-7-18(16)19)33-22-8-11-29-21-14-24(23(31-2)13-20(21)22)32-15-26(27)9-10-26/h3-8,11-14H,9-10,15,27H2,1-2H3,(H,28,30), InChI=1S/C26H25N3O4/c1-28-25(30)19-5-3-4-16-12-17(6-7-18(16)19)33-22-8-11-29-21-14-24(23(31-2)13-20(21)22)32-15-26(27)9-10-26/h3-8,11-14H,9-10,15,27H2,1-2H3,(H,28,30), InChI=1S/C26H25N3O4/c1-28-25(30)19-5-3-4-16-12-17(6-7-18(16)19)33-22-8-11-29-21-14-24(23(31-2)13-20(21)22)32-15-26(27)9-10-26/h3-8,11-14H,9-10,15,27H2,1-2H3,(H,28,30), InChI=1S/C26H25N3O4/c1-28-25(30)19-5-3-4-16-12-17(6-7-18(16)19)33-22-8-11-29-21-14-24(23(31-2)13-20(21)22)32-15-26(27)9-10-26/h3-8,11-14H,9-10,15,27H2,1-2H3,(H,28,30), InChI=1S/C26H25N3O4/c1-28-25(30)19-5-3-4-16-12-17(6-7-18(16)19)33-22-8-11-29-21-14-24(23(31-2)13-20(21)22)32-15-26(27)9-10-26/h3-8,11-14H,9-10,15,27H2,1-2H3,(H,28,30), InChI=1S/C26H25N3O4/c1-28-25(30)19-5-3-4-16-12-17(6-7-18(16)19)33-22-8-11-29-21-14-24(23(31-2)13-20(21)22)32-15-26(27)9-10-26/h3-8,11-14H,9-10,15,27H2,1-2H3,(H,28,30)	Phase 2
LUF-5834	adenosine receptor agonist	ADORA2A, ADORA2B			Nc1nc(SCc2ncc[nH]2)c(C#N)c(-c2ccc(O)cc2)c1C#N, Nc1nc(SCc2ncc[nH]2)c(C#N)c(-c2ccc(O)cc2)c1C#N	OFHKDLYFKPBXER-UHFFFAOYSA-N, OFHKDLYFKPBXER-UHFFFAOYSA-N	Preclinical
lufenuron	chitin inhibitor		infectious disease	flea control	F[C@@H](C(F)(F)F)C(F)(F)Oc1cc(Cl)c(NC(=O)NC(=O)c2c(F)cccc2F)cc1Cl |&1:1,r|, F[C@@H](C(F)(F)F)C(F)(F)Oc1cc(Cl)c(NC(=O)NC(=O)c2c(F)cccc2F)cc1Cl |&1:1,r|, F[C@@H](C(F)(F)F)C(F)(F)Oc1cc(Cl)c(NC(=O)NC(=O)c2c(F)cccc2F)cc1Cl |&1:1,r|	PWPJGUXAGUPAHP-AWEZNQCLSA-N, PWPJGUXAGUPAHP-AWEZNQCLSA-N, PWPJGUXAGUPAHP-AWEZNQCLSA-N	Launched
luliconazole	sterol demethylase inhibitor		infectious disease	tinea pedis, tinea cruris, tinea corporis	Clc1ccc([C@@H]2CS\C(S2)=C(\C#N)n2ccnc2)c(Cl)c1, Clc1ccc([C@@H]2CS\C(S2)=C(\C#N)n2ccnc2)c(Cl)c1, Clc1ccc([C@@H]2CS\C(S2)=C(\C#N)n2ccnc2)c(Cl)c1	YTAOBBFIOAEMLL-REQDGWNSSA-N, YTAOBBFIOAEMLL-REQDGWNSSA-N, YTAOBBFIOAEMLL-REQDGWNSSA-N	Launched
lumacaftor	CFTR channel agonist	CFTR	pulmonary	cystic fibrosis	Cc1ccc(NC(=O)C2(CC2)c2ccc3OC(F)(F)Oc3c2)nc1-c1cccc(c1)C(O)=O, Cc1ccc(NC(=O)C2(CC2)c2ccc3OC(F)(F)Oc3c2)nc1-c1cccc(c1)C(O)=O	UFSKUSARDNFIRC-UHFFFAOYSA-N, UFSKUSARDNFIRC-UHFFFAOYSA-N	Launched
lumateperone	dopamine receptor modulator, serotonin receptor antagonist	DRD2, HTR2A			CN1CCN2[C@H]3CCN(CCCC(=O)c4ccc(F)cc4)C[C@H]3c3cccc1c23, CN1CCN2[C@H]3CCN(CCCC(=O)c4ccc(F)cc4)C[C@H]3c3cccc1c23, CN1CCN2[C@H]3CCN(CCCC(=O)c4ccc(F)cc4)C[C@H]3c3cccc1c23	HOIIHACBCFLJET-SFTDATJTSA-N, HOIIHACBCFLJET-SFTDATJTSA-N, HOIIHACBCFLJET-SFTDATJTSA-N	Launched
lumefantrine	antimalarial agent	ATP1A1	infectious disease	malaria	CCCCN(CCCC)C[C@@H](O)c1cc(Cl)cc2\C(=C/c3ccc(Cl)cc3)c3cc(Cl)ccc3-c12 |&1:10,r|, CCCCN(CCCC)C[C@@H](O)c1cc(Cl)cc2\C(=C/c3ccc(Cl)cc3)c3cc(Cl)ccc3-c12 |&1:10,r|, CCCCN(CCCC)C[C@@H](O)c1cc(Cl)cc2\C(=C/c3ccc(Cl)cc3)c3cc(Cl)ccc3-c12 |&1:10,r|	DYLGFOYVTXJFJP-OXTLUBNBSA-N, DYLGFOYVTXJFJP-OXTLUBNBSA-N, DYLGFOYVTXJFJP-OXTLUBNBSA-N	Launched
lumiracoxib	cyclooxygenase inhibitor	PTGS1, PTGS2			Cc1ccc(Nc2c(F)cccc2Cl)c(CC(O)=O)c1, Cc1ccc(Nc2c(F)cccc2Cl)c(CC(O)=O)c1, Cc1ccc(Nc2c(F)cccc2Cl)c(CC(O)=O)c1	KHPKQFYUPIUARC-UHFFFAOYSA-N, KHPKQFYUPIUARC-UHFFFAOYSA-N, KHPKQFYUPIUARC-UHFFFAOYSA-N	Withdrawn
lupanine	sodium channel blocker	INS			[H][C@@]12CCCCN1C[C@@H]1C[C@H]2CN2C(=O)CCC[C@]12[H]	JYIJIIVLEOETIQ-XDQVBPFNSA-N	Phase 1
lurasidone	dopamine receptor antagonist, serotonin receptor antagonist	ADRA2A, ADRA2C, DRD2, HTR1A, HTR2A, HTR7	neurology/psychiatry	schizophrenia	O=C1[C@H]2[C@@H]3CC[C@@H](C3)[C@H]2C(=O)N1C[C@@H]1CCCC[C@H]1CN1CCN(CC1)c1nsc2ccccc12, O=C1[C@H]2[C@@H]3CC[C@@H](C3)[C@H]2C(=O)N1C[C@@H]1CCCC[C@H]1CN1CCN(CC1)c1nsc2ccccc12, O=C1[C@H]2[C@@H]3CC[C@@H](C3)[C@H]2C(=O)N1C[C@@H]1CCCC[C@H]1CN1CCN(CC1)c1nsc2ccccc12, O=C1[C@H]2[C@@H]3CC[C@@H](C3)[C@H]2C(=O)N1C[C@@H]1CCCC[C@H]1CN1CCN(CC1)c1nsc2ccccc12	PQXKDMSYBGKCJA-CVTJIBDQSA-N, PQXKDMSYBGKCJA-CVTJIBDQSA-N, PQXKDMSYBGKCJA-CVTJIBDQSA-N, PQXKDMSYBGKCJA-CVTJIBDQSA-N	Launched
lurbinectedin	DNA binding agent				[H][C@@]12Cc3cc(C)c(OC)c(O)c3[C@@]([H])(N1C)[C@@]1([H])N([C@H]2O)[C@@]2([H])COC(=O)[C@]3(CS[C@]1([H])c1c(OC(C)=O)c(C)c4OCOc4c21)NCCc1c3[nH]c2ccc(OC)cc12 |THB:16:15:2.3.12:20.19.17|	YDDMIZRDDREKEP-HWTBNCOESA-N	Phase 3
lusaperidone	adrenergic receptor antagonist				Cc1nc2ccccn2c(=O)c1CCN1CCc2oc3ccccc3c2C1	ZYXHQIPQIKTEDI-UHFFFAOYSA-N	Preclinical
lusutrombopag	thrombopoietin receptor agonist				CCCCCCO[C@@H](C)c1cccc(-c2csc(NC(=O)c3cc(Cl)c(\C=C(/C)C(O)=O)c(Cl)c3)n2)c1OC	NOZIJMHMKORZBA-KJCUYJGMSA-N	Launched
lutein	antioxidant		ophthalmology	macular degeneration, cataracts, retinitis pigmentosa (RP)	C\C(\C=C\C=C(/C)\C=C\[C@H]1C(C)=C[C@H](O)CC1(C)C)=C/C=C/C=C(\C)/C=C/C=C(\C)/C=C/C1=C(C)C[C@@H](O)CC1(C)C |c:11,33|, C\C(\C=C\C=C(/C)\C=C\[C@H]1C(C)=C[C@H](O)CC1(C)C)=C/C=C/C=C(\C)/C=C/C=C(\C)/C=C/C1=C(C)C[C@@H](O)CC1(C)C |c:11,33|	KBPHJBAIARWVSC-RGZFRNHPSA-N, KBPHJBAIARWVSC-RGZFRNHPSA-N	Launched
luteolin	glucosidase inhibitor	TOP1			Oc1cc(O)c2c(c1)oc(cc2=O)-c1ccc(O)c(O)c1, Oc1cc(O)c2c(c1)oc(cc2=O)-c1ccc(O)c(O)c1	IQPNAANSBPBGFQ-UHFFFAOYSA-N, IQPNAANSBPBGFQ-UHFFFAOYSA-N	Phase 2
luzindole	melatonin receptor antagonist	MTNR1A, MTNR1B			CC(=O)NCCc1c(Cc2ccccc2)[nH]c2ccccc12, CC(=O)NCCc1c(Cc2ccccc2)[nH]c2ccccc12, CC(=O)NCCc1c(Cc2ccccc2)[nH]c2ccccc12	WVVXBPKOIZGVNS-UHFFFAOYSA-N, WVVXBPKOIZGVNS-UHFFFAOYSA-N, WVVXBPKOIZGVNS-UHFFFAOYSA-N	Preclinical
LXH254	RAF inhibitor				Cc1ccc(NC(=O)c2ccnc(c2)C(F)(F)F)cc1-c1cc(OCCO)nc(c1)N1CCOCC1	UEPXBTCUIIGYCY-UHFFFAOYSA-N	Phase 1
LXR-623	LXR agonist	AR, NR1H2, NR1H3, NR1I2, NR3C1			Fc1ccc(cc1)-c1n(Cc2ccc(F)cc2Cl)nc2c(cccc12)C(F)(F)F, Fc1ccc(cc1)-c1n(Cc2ccc(F)cc2Cl)nc2c(cccc12)C(F)(F)F	KYWWJENKIMRJBI-UHFFFAOYSA-N, KYWWJENKIMRJBI-UHFFFAOYSA-N	Phase 1
LXS196	PKC inhibitor				CC1(N)CCN(CC1)c1cccnc1NC(=O)c1nc(cnc1N)-c1ncccc1C(F)(F)F	XXJXHXJWQSCNPX-UHFFFAOYSA-N	Phase 1
LX1031	tryptophan hydroxylase inhibitor	TPH1			COc1cccc(c1)-c1ccc(cc1)[C@@H](Oc1cc(nc(N)n1)-c1ccc(C[C@H](N)C(O)=O)cc1)C(F)(F)F, COc1cccc(c1)-c1ccc(cc1)[C@@H](Oc1cc(nc(N)n1)-c1ccc(C[C@H](N)C(O)=O)cc1)C(F)(F)F	XNMUICFMGGQSMZ-WIOPSUGQSA-N, XNMUICFMGGQSMZ-WIOPSUGQSA-N	Phase 2
LX7101	LIM kinase inhibitor, rho associated kinase inhibitor	LIMK2, ROCK1, ROCK2			CN(C)C(=O)Oc1cccc(NC(=O)C2(CN)CCN(CC2)c2ncnc3[nH]cc(C)c23)c1, CN(C)C(=O)Oc1cccc(NC(=O)C2(CN)CCN(CC2)c2ncnc3[nH]cc(C)c23)c1, CN(C)C(=O)Oc1cccc(NC(=O)C2(CN)CCN(CC2)c2ncnc3[nH]cc(C)c23)c1	PWPNYABQEOGNNC-UHFFFAOYSA-N, PWPNYABQEOGNNC-UHFFFAOYSA-N, PWPNYABQEOGNNC-UHFFFAOYSA-N	Phase 1/Phase 2
lycopene	free radical scavenger				CC(C)=CCC\C(C)=C\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C=C(/C)CCC=C(C)C	OAIJSZIZWZSQBC-GYZMGTAESA-N	Launched
lylamine	cannabinoid receptor agonist	CNR1			CC(C)c1ccc2c(CC[C@H]3[C@](C)(CN)CCC[C@]23C)c1, CC(C)c1ccc2c(CC[C@H]3[C@](C)(CN)CCC[C@]23C)c1, CC(C)c1ccc2c(CC[C@H]3[C@](C)(CN)CCC[C@]23C)c1, CC(C)c1ccc2c(CC[C@H]3[C@](C)(CN)CCC[C@]23C)c1	JVVXZOOGOGPDRZ-SLFFLAALSA-N, JVVXZOOGOGPDRZ-SLFFLAALSA-N, JVVXZOOGOGPDRZ-SLFFLAALSA-N, JVVXZOOGOGPDRZ-SLFFLAALSA-N	Preclinical
lymecycline	bacterial 50S ribosomal subunit inhibitor		dermatology	acne vulgaris (AV)	CN(C)[C@H]1[C@@H]2C[C@H]3[C@@H](C(=O)c4c(O)cccc4[C@@]3(C)O)C(=O)[C@]2(O)C(=O)[C@H](C(=O)NCNCCCC[C@H](N)C(O)=O)C1=O |&1:7,&2:26|	DZTKAWPWXGIREW-KKSKXDPKSA-N	Launched
lynestrenol	progestogen hormone		endocrinology	contraceptive	C[C@]12CC[C@H]3[C@@H](CCC4=CCCC[C@H]34)[C@@H]1CC[C@@]2(O)C#C |t:8|, C[C@]12CC[C@H]3[C@@H](CCC4=CCCC[C@H]34)[C@@H]1CC[C@@]2(O)C#C |t:8|	YNVGQYHLRCDXFQ-XGXHKTLJSA-N, YNVGQYHLRCDXFQ-XGXHKTLJSA-N	Launched
lypressin	vasopressin receptor agonist	AVPR1A, AVPR1B, AVPR2	endocrinology	central diabetes insipidus	NCCCC[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N1)C(=O)NCC(N)=O, NCCCC[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N1)C(=O)NCC(N)=O, NCCCC[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N1)C(=O)NCC(N)=O	BJFIDCADFRDPIO-KKSWSVFASA-N, BJFIDCADFRDPIO-KKSWSVFASA-N, BJFIDCADFRDPIO-KKSWSVFASA-N	Launched
LY2090314	glycogen synthase kinase inhibitor	GSK3B			Fc1cc2CN(CCn3cc(C4=C(C(=O)NC4=O)c4cnc5ccccn45)c(c1)c23)C(=O)N1CCCCC1 |t:11|, Fc1cc2CN(CCn3cc(C4=C(C(=O)NC4=O)c4cnc5ccccn45)c(c1)c23)C(=O)N1CCCCC1 |t:11|, Fc1cc2CN(CCn3cc(C4=C(C(=O)NC4=O)c4cnc5ccccn45)c(c1)c23)C(=O)N1CCCCC1 |t:11|, Fc1cc2CN(CCn3cc(C4=C(C(=O)NC4=O)c4cnc5ccccn45)c(c1)c23)C(=O)N1CCCCC1 |t:11|, Fc1cc2CN(CCn3cc(C4=C(C(=O)NC4=O)c4cnc5ccccn45)c(c1)c23)C(=O)N1CCCCC1 |t:11|	HRJWTAWVFDCTGO-UHFFFAOYSA-N, HRJWTAWVFDCTGO-UHFFFAOYSA-N, HRJWTAWVFDCTGO-UHFFFAOYSA-N, HRJWTAWVFDCTGO-UHFFFAOYSA-N, HRJWTAWVFDCTGO-UHFFFAOYSA-N	Phase 2
LY2109761	TGF beta receptor inhibitor	TGFBR1, TGFBR2			C(CN1CCOCC1)Oc1ccc2c(ccnc2c1)-c1c2CCCn2nc1-c1ccccn1, C(CN1CCOCC1)Oc1ccc2c(ccnc2c1)-c1c2CCCn2nc1-c1ccccn1, C(CN1CCOCC1)Oc1ccc2c(ccnc2c1)-c1c2CCCn2nc1-c1ccccn1, C(CN1CCOCC1)Oc1ccc2c(ccnc2c1)-c1c2CCCn2nc1-c1ccccn1, C(CN1CCOCC1)Oc1ccc2c(ccnc2c1)-c1c2CCCn2nc1-c1ccccn1, C(CN1CCOCC1)Oc1ccc2c(ccnc2c1)-c1c2CCCn2nc1-c1ccccn1	IHLVSLOZUHKNMQ-UHFFFAOYSA-N, IHLVSLOZUHKNMQ-UHFFFAOYSA-N, IHLVSLOZUHKNMQ-UHFFFAOYSA-N, IHLVSLOZUHKNMQ-UHFFFAOYSA-N, IHLVSLOZUHKNMQ-UHFFFAOYSA-N, IHLVSLOZUHKNMQ-UHFFFAOYSA-N	Preclinical
LY2140023	glutamate receptor agonist	GRM3			N[C@]1(CS(=O)(=O)[C@H]2[C@@H]([C@@H]12)C(O)=O)C(O)=O, N[C@]1(CS(=O)(=O)[C@H]2[C@@H]([C@@H]12)C(O)=O)C(O)=O, N[C@]1(CS(=O)(=O)[C@H]2[C@@H]([C@@H]12)C(O)=O)C(O)=O, N[C@]1(CS(=O)(=O)[C@H]2[C@@H]([C@@H]12)C(O)=O)C(O)=O, N[C@]1(CS(=O)(=O)[C@H]2[C@@H]([C@@H]12)C(O)=O)C(O)=O	AVDUGNCTZRCAHH-MDASVERJSA-N, AVDUGNCTZRCAHH-MDASVERJSA-N, AVDUGNCTZRCAHH-MDASVERJSA-N, AVDUGNCTZRCAHH-MDASVERJSA-N, AVDUGNCTZRCAHH-MDASVERJSA-N	Phase 3
LY215490	glutamate receptor antagonist	GRIA1, GRIA2, GRIA3, GRIA4, GRIK1			OC(=O)[C@@H]1C[C@H]2C[C@@H](CCc3nn[nH]n3)CC[C@H]2CN1	ZXFRFPSZAKNPQQ-YTWAJWBKSA-N	Phase 1
LY2157299	TGF beta receptor inhibitor	TGFBR1			Cc1cccc(n1)-c1nn2CCCc2c1-c1ccnc2ccc(cc12)C(N)=O, Cc1cccc(n1)-c1nn2CCCc2c1-c1ccnc2ccc(cc12)C(N)=O, Cc1cccc(n1)-c1nn2CCCc2c1-c1ccnc2ccc(cc12)C(N)=O, Cc1cccc(n1)-c1nn2CCCc2c1-c1ccnc2ccc(cc12)C(N)=O	IVRXNBXKWIJUQB-UHFFFAOYSA-N, IVRXNBXKWIJUQB-UHFFFAOYSA-N, IVRXNBXKWIJUQB-UHFFFAOYSA-N, IVRXNBXKWIJUQB-UHFFFAOYSA-N	Phase 2/Phase 3
LY2183240	FAAH inhibitor, FAAH reuptake inhibitor	FAAH			CN(C)C(=O)n1nnnc1Cc1ccc(cc1)-c1ccccc1, CN(C)C(=O)n1nnnc1Cc1ccc(cc1)-c1ccccc1, CN(C)C(=O)n1nnnc1Cc1ccc(cc1)-c1ccccc1, CN(C)C(=O)n1nnnc1Cc1ccc(cc1)-c1ccccc1	GZNIYOXWFCDBBJ-UHFFFAOYSA-N, GZNIYOXWFCDBBJ-UHFFFAOYSA-N, GZNIYOXWFCDBBJ-UHFFFAOYSA-N, GZNIYOXWFCDBBJ-UHFFFAOYSA-N	Preclinical
LY2228820	p38 MAPK inhibitor	MAPK14			CC(C)(C)Cn1c(N)nc2ccc(nc12)-c1nc([nH]c1-c1ccc(F)cc1)C(C)(C)C, CC(C)(C)Cn1c(N)nc2ccc(nc12)-c1nc([nH]c1-c1ccc(F)cc1)C(C)(C)C, CC(C)(C)Cn1c(N)nc2ccc(nc12)-c1nc([nH]c1-c1ccc(F)cc1)C(C)(C)C, CC(C)(C)Cn1c(N)nc2ccc(nc12)-c1nc([nH]c1-c1ccc(F)cc1)C(C)(C)C, CC(C)(C)Cn1c(N)nc2ccc(nc12)-c1nc([nH]c1-c1ccc(F)cc1)C(C)(C)C	XPPBBJCBDOEXDN-UHFFFAOYSA-N, XPPBBJCBDOEXDN-UHFFFAOYSA-N, XPPBBJCBDOEXDN-UHFFFAOYSA-N, XPPBBJCBDOEXDN-UHFFFAOYSA-N, XPPBBJCBDOEXDN-UHFFFAOYSA-N	Phase 2
LY223982	leukotriene receptor antagonist	LTB4R			COc1ccc(\C=C\CCCCOc2ccc(cc2CCC(O)=O)C(=O)c2cccc(c2)C(O)=O)cc1, COc1ccc(\C=C\CCCCOc2ccc(cc2CCC(O)=O)C(=O)c2cccc(c2)C(O)=O)cc1	SYZSSLLFRVDRHL-QPJJXVBHSA-N, SYZSSLLFRVDRHL-QPJJXVBHSA-N	Phase 2
LY225910	CCK receptor antagonist	CCKBR			CC(C)Oc1cccc(c1)-n1c(CCc2c[nH]c3ccc(Br)cc23)nc2ccccc2c1=O, CC(C)Oc1cccc(c1)-n1c(CCc2c[nH]c3ccc(Br)cc23)nc2ccccc2c1=O, CC(C)Oc1cccc(c1)-n1c(CCc2c[nH]c3ccc(Br)cc23)nc2ccccc2c1=O, CC(C)Oc1cccc(c1)-n1c(CCc2c[nH]c3ccc(Br)cc23)nc2ccccc2c1=O, CC(C)Oc1cccc(c1)-n1c(CCc2c[nH]c3ccc(Br)cc23)nc2ccccc2c1=O, CC(C)Oc1cccc(c1)-n1c(CCc2c[nH]c3ccc(Br)cc23)nc2ccccc2c1=O	KUECXUACQOYKNB-UHFFFAOYSA-N, KUECXUACQOYKNB-UHFFFAOYSA-N, KUECXUACQOYKNB-UHFFFAOYSA-N, KUECXUACQOYKNB-UHFFFAOYSA-N, KUECXUACQOYKNB-UHFFFAOYSA-N, KUECXUACQOYKNB-UHFFFAOYSA-N	Preclinical
LY231617	lipid peroxidase inhibitor				CCNCc1cc(c(O)c(c1)C(C)(C)C)C(C)(C)C, CCNCc1cc(c(O)c(c1)C(C)(C)C)C(C)(C)C	WQNYIWJBDGLKEB-UHFFFAOYSA-N, WQNYIWJBDGLKEB-UHFFFAOYSA-N	Preclinical
LY2334737	antitumor agent, ribonucleotide reductase inhibitor				CCCC(CCC)C(=O)Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1, CCCC(CCC)C(=O)Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1, CCCC(CCC)C(=O)Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1	MEOYFIHNRBNEPI-UXIGCNINSA-N, MEOYFIHNRBNEPI-UXIGCNINSA-N, MEOYFIHNRBNEPI-UXIGCNINSA-N	Phase 1
LY2365109	glycine transporter inhibitor	SLC6A9			CN(CCOc1ccc(cc1C(C)(C)C)-c1ccc2OCOc2c1)CC(O)=O, CN(CCOc1ccc(cc1C(C)(C)C)-c1ccc2OCOc2c1)CC(O)=O	FKPLJWGRBCQLTL-UHFFFAOYSA-N, FKPLJWGRBCQLTL-UHFFFAOYSA-N	Preclinical
LY2452473	androgen receptor modulator	AR			CC(C)OC(=O)N[C@@H]1Cc2c(C1)c1cc(ccc1n2Cc1ccccn1)C#N	IHIWYQYVBNODSV-KRWDZBQOSA-N	Phase 2
LY2510924	CC chemokine receptor antagonist				[H][C@]1(CCCN=C(N)N)NC(=O)[C@H](CCCCNC(C)C)NC(=O)[C@@H](Cc2ccc(O)cc2)NC(=O)[C@H](Cc2ccccc2)NC(=O)CC[C@@H](NC(=O)CNC(=O)[C@H](Cc2ccc3ccccc3c2)NC1=O)C(=O)N[C@@H](CCCCNC(C)C)C(N)=O	IJHWVENTEFSNBC-FHYZPQNHSA-N	Phase 2
LY255283	leukotriene receptor antagonist	LTB4R, LTB4R2			CCc1cc(C(C)=O)c(O)cc1OCCCCCC(C)(C)c1nn[nH]n1, CCc1cc(C(C)=O)c(O)cc1OCCCCCC(C)(C)c1nn[nH]n1, CCc1cc(C(C)=O)c(O)cc1OCCCCCC(C)(C)c1nn[nH]n1, CCc1cc(C(C)=O)c(O)cc1OCCCCCC(C)(C)c1nn[nH]n1	WCGXJPFHTHQNJL-UHFFFAOYSA-N, WCGXJPFHTHQNJL-UHFFFAOYSA-N, WCGXJPFHTHQNJL-UHFFFAOYSA-N, WCGXJPFHTHQNJL-UHFFFAOYSA-N	Preclinical
LY2584702	ribosomal protein inhibitor	RPS6KB1			Cn1cc(nc1C1CCN(CC1)c1ncnc2n[nH]cc12)-c1ccc(F)c(c1)C(F)(F)F, Cn1cc(nc1C1CCN(CC1)c1ncnc2n[nH]cc12)-c1ccc(F)c(c1)C(F)(F)F	FYXRSVDHGLUMHB-UHFFFAOYSA-N, FYXRSVDHGLUMHB-UHFFFAOYSA-N	Phase 1
LY2603618	CHK inhibitor	CHEK1			Cc1cnc(NC(=O)Nc2cc(Br)c(C)cc2OC[C@@H]2CNCCO2)cn1, Cc1cnc(NC(=O)Nc2cc(Br)c(C)cc2OC[C@@H]2CNCCO2)cn1, Cc1cnc(NC(=O)Nc2cc(Br)c(C)cc2OC[C@@H]2CNCCO2)cn1, Cc1cnc(NC(=O)Nc2cc(Br)c(C)cc2OC[C@@H]2CNCCO2)cn1, Cc1cnc(NC(=O)Nc2cc(Br)c(C)cc2OC[C@@H]2CNCCO2)cn1	SYYBDNPGDKKJDU-ZDUSSCGKSA-N, SYYBDNPGDKKJDU-ZDUSSCGKSA-N, SYYBDNPGDKKJDU-ZDUSSCGKSA-N, SYYBDNPGDKKJDU-ZDUSSCGKSA-N, SYYBDNPGDKKJDU-ZDUSSCGKSA-N	Phase 2
LY2606368	CHK inhibitor	CHEK1			COc1cccc(OCCCN)c1-c1cc(Nc2cnc(cn2)C#N)[nH]n1, COc1cccc(OCCCN)c1-c1cc(Nc2cnc(cn2)C#N)[nH]n1, COc1cccc(OCCCN)c1-c1cc(Nc2cnc(cn2)C#N)[nH]n1, COc1cccc(OCCCN)c1-c1cc(Nc2cnc(cn2)C#N)[nH]n1, COc1cccc(OCCCN)c1-c1cc(Nc2cnc(cn2)C#N)[nH]n1	DOTGPNHGTYJDEP-UHFFFAOYSA-N, DOTGPNHGTYJDEP-UHFFFAOYSA-N, DOTGPNHGTYJDEP-UHFFFAOYSA-N, DOTGPNHGTYJDEP-UHFFFAOYSA-N, DOTGPNHGTYJDEP-UHFFFAOYSA-N	Phase 2
LY2608204	glucokinase activator	GCK			O=C(Nc1ncc(SCCN2CCCC2)s1)[C@@]1(C[C@H]1C1CCCCC1)c1ccc(cc1)S(=O)(=O)C1CC1, O=C(Nc1ncc(SCCN2CCCC2)s1)[C@@]1(C[C@H]1C1CCCCC1)c1ccc(cc1)S(=O)(=O)C1CC1, O=C(Nc1ncc(SCCN2CCCC2)s1)[C@@]1(C[C@H]1C1CCCCC1)c1ccc(cc1)S(=O)(=O)C1CC1, O=C(Nc1ncc(SCCN2CCCC2)s1)[C@@]1(C[C@H]1C1CCCCC1)c1ccc(cc1)S(=O)(=O)C1CC1, O=C(Nc1ncc(SCCN2CCCC2)s1)[C@@]1(C[C@H]1C1CCCCC1)c1ccc(cc1)S(=O)(=O)C1CC1, O=C(Nc1ncc(SCCN2CCCC2)s1)[C@@]1(C[C@H]1C1CCCCC1)c1ccc(cc1)S(=O)(=O)C1CC1, O=C(Nc1ncc(SCCN2CCCC2)s1)[C@@]1(C[C@H]1C1CCCCC1)c1ccc(cc1)S(=O)(=O)C1CC1	QIIVJLHCZUTGSD-CUBQBAPOSA-N, QIIVJLHCZUTGSD-CUBQBAPOSA-N, QIIVJLHCZUTGSD-CUBQBAPOSA-N, QIIVJLHCZUTGSD-CUBQBAPOSA-N, QIIVJLHCZUTGSD-CUBQBAPOSA-N, QIIVJLHCZUTGSD-CUBQBAPOSA-N, QIIVJLHCZUTGSD-CUBQBAPOSA-N	Phase 2
LY266097	serotonin receptor antagonist	HTR2B			COc1ccc(C[C@H]2NCCc3c2[nH]c2ccc(C)cc32)c(Cl)c1OC |&1:7|, COc1ccc(C[C@H]2NCCc3c2[nH]c2ccc(C)cc32)c(Cl)c1OC |&1:7|, COc1ccc(C[C@H]2NCCc3c2[nH]c2ccc(C)cc32)c(Cl)c1OC |&1:7|	NJLHHCITDFZZSE-QGZVFWFLSA-N, NJLHHCITDFZZSE-QGZVFWFLSA-N, NJLHHCITDFZZSE-QGZVFWFLSA-N	Preclinical
LY2784544	JAK inhibitor	JAK2, JAK3			Cc1cc(Nc2cc(CN3CCOCC3)c3nc(C)c(Cc4ccc(Cl)cc4F)n3n2)[nH]n1, Cc1cc(Nc2cc(CN3CCOCC3)c3nc(C)c(Cc4ccc(Cl)cc4F)n3n2)[nH]n1, Cc1cc(Nc2cc(CN3CCOCC3)c3nc(C)c(Cc4ccc(Cl)cc4F)n3n2)[nH]n1, Cc1cc(Nc2cc(CN3CCOCC3)c3nc(C)c(Cc4ccc(Cl)cc4F)n3n2)[nH]n1, Cc1cc(Nc2cc(CN3CCOCC3)c3nc(C)c(Cc4ccc(Cl)cc4F)n3n2)[nH]n1, Cc1cc(Nc2cc(CN3CCOCC3)c3nc(C)c(Cc4ccc(Cl)cc4F)n3n2)[nH]n1, Cc1cc(Nc2cc(CN3CCOCC3)c3nc(C)c(Cc4ccc(Cl)cc4F)n3n2)[nH]n1, Cc1cc(Nc2cc(CN3CCOCC3)c3nc(C)c(Cc4ccc(Cl)cc4F)n3n2)[nH]n1, Cc1cc(Nc2cc(CN3CCOCC3)c3nc(C)c(Cc4ccc(Cl)cc4F)n3n2)[nH]n1	SQSZANZGUXWJEA-UHFFFAOYSA-N, SQSZANZGUXWJEA-UHFFFAOYSA-N, SQSZANZGUXWJEA-UHFFFAOYSA-N, SQSZANZGUXWJEA-UHFFFAOYSA-N, SQSZANZGUXWJEA-UHFFFAOYSA-N, SQSZANZGUXWJEA-UHFFFAOYSA-N, InChI=1S/C23H25ClFN7O/c1-14-9-21(29-28-14)27-22-11-17(13-31-5-7-33-8-6-31)23-26-15(2)20(32(23)30-22)10-16-3-4-18(24)12-19(16)25/h3-4,9,11-12H,5-8,10,13H2,1-2H3,(H2,27,28,29,30), InChI=1S/C23H25ClFN7O/c1-14-9-21(29-28-14)27-22-11-17(13-31-5-7-33-8-6-31)23-26-15(2)20(32(23)30-22)10-16-3-4-18(24)12-19(16)25/h3-4,9,11-12H,5-8,10,13H2,1-2H3,(H2,27,28,29,30), InChI=1S/C23H25ClFN7O/c1-14-9-21(29-28-14)27-22-11-17(13-31-5-7-33-8-6-31)23-26-15(2)20(32(23)30-22)10-16-3-4-18(24)12-19(16)25/h3-4,9,11-12H,5-8,10,13H2,1-2H3,(H2,27,28,29,30)	Phase 2
LY2795050	opioid receptor antagonist				NC(=O)c1ccc(Oc2ccc(CN3CCC[C@H]3c3cccnc3)cc2)c(Cl)c1	LOOCZNLSXJHWTG-NRFANRHFSA-N	Preclinical
LY2801653	MET inhibitor	MET			Cc1ccc(C(=O)Nc2ccc(Oc3cc4cnn(C)c4cc3-c3cn[nH]c3)c(F)c2)c(=O)n1-c1ccc(F)cc1, Cc1ccc(C(=O)Nc2ccc(Oc3cc4cnn(C)c4cc3-c3cn[nH]c3)c(F)c2)c(=O)n1-c1ccc(F)cc1, Cc1ccc(C(=O)Nc2ccc(Oc3cc4cnn(C)c4cc3-c3cn[nH]c3)c(F)c2)c(=O)n1-c1ccc(F)cc1, Cc1ccc(C(=O)Nc2ccc(Oc3cc4cnn(C)c4cc3-c3cn[nH]c3)c(F)c2)c(=O)n1-c1ccc(F)cc1	QHADVLVFMKEIIP-UHFFFAOYSA-N, QHADVLVFMKEIIP-UHFFFAOYSA-N, QHADVLVFMKEIIP-UHFFFAOYSA-N, QHADVLVFMKEIIP-UHFFFAOYSA-N	Phase 2
LY2811376	beta-secretase inhibitor	BACE1			C[C@]1(CCSC(N)=N1)c1cc(c(F)cc1F)-c1cncnc1 |c:6|, C[C@]1(CCSC(N)=N1)c1cc(c(F)cc1F)-c1cncnc1 |c:6|, C[C@]1(CCSC(N)=N1)c1cc(c(F)cc1F)-c1cncnc1 |c:6|, C[C@]1(CCSC(N)=N1)c1cc(c(F)cc1F)-c1cncnc1 |c:6|, C[C@]1(CCSC(N)=N1)c1cc(c(F)cc1F)-c1cncnc1 |c:6|, C[C@]1(CCSC(N)=N1)c1cc(c(F)cc1F)-c1cncnc1 |c:6|	MJQMRGWYPNIERM-HNNXBMFYSA-N, MJQMRGWYPNIERM-HNNXBMFYSA-N, MJQMRGWYPNIERM-HNNXBMFYSA-N, MJQMRGWYPNIERM-HNNXBMFYSA-N, MJQMRGWYPNIERM-HNNXBMFYSA-N, MJQMRGWYPNIERM-HNNXBMFYSA-N	Phase 1
LY2828360	cannabinoid receptor agonist				CN1CCN(CC1)c1nc(C)nc2n(C3CCOCC3)c(nc12)-c1ccccc1Cl	UCMNDPDJRSEZPL-UHFFFAOYSA-N	Phase 2
LY2857785	CDK inhibitor	CDK9			CC(C)c1n(C)nc2ccc(cc12)-c1ccnc(N[C@H]2CC[C@@H](CC2)NC2CCOCC2)n1 |r|, CC(C)c1n(C)nc2ccc(cc12)-c1ccnc(N[C@H]2CC[C@@H](CC2)NC2CCOCC2)n1 |r|, CC(C)c1n(C)nc2ccc(cc12)-c1ccnc(N[C@H]2CC[C@@H](CC2)NC2CCOCC2)n1 |r|	LHIUZPIDLZYPRL-MXVIHJGJSA-N, LHIUZPIDLZYPRL-MXVIHJGJSA-N, LHIUZPIDLZYPRL-MXVIHJGJSA-N	Preclinical
LY2874455	FGFR antagonist	FGFR1, FGFR2, FGFR3, FGFR4, KDR			C[C@@H](Oc1ccc2n[nH]c(\C=C\c3cnn(CCO)c3)c2c1)c1c(Cl)cncc1Cl, C[C@@H](Oc1ccc2n[nH]c(\C=C\c3cnn(CCO)c3)c2c1)c1c(Cl)cncc1Cl, C[C@@H](Oc1ccc2n[nH]c(\C=C\c3cnn(CCO)c3)c2c1)c1c(Cl)cncc1Cl, C[C@@H](Oc1ccc2n[nH]c(\C=C\c3cnn(CCO)c3)c2c1)c1c(Cl)cncc1Cl, C[C@@H](Oc1ccc2n[nH]c(\C=C\c3cnn(CCO)c3)c2c1)c1c(Cl)cncc1Cl, C[C@@H](Oc1ccc2n[nH]c(\C=C\c3cnn(CCO)c3)c2c1)c1c(Cl)cncc1Cl, C[C@@H](Oc1ccc2n[nH]c(\C=C\c3cnn(CCO)c3)c2c1)c1c(Cl)cncc1Cl, C[C@@H](Oc1ccc2n[nH]c(\C=C\c3cnn(CCO)c3)c2c1)c1c(Cl)cncc1Cl	GKJCVYLDJWTWQU-CXLRFSCWSA-N, GKJCVYLDJWTWQU-CXLRFSCWSA-N, GKJCVYLDJWTWQU-CXLRFSCWSA-N, GKJCVYLDJWTWQU-CXLRFSCWSA-N, GKJCVYLDJWTWQU-CXLRFSCWSA-N, GKJCVYLDJWTWQU-CXLRFSCWSA-N, GKJCVYLDJWTWQU-CXLRFSCWSA-N, GKJCVYLDJWTWQU-CXLRFSCWSA-N	Phase 1
LY288513	CCK receptor antagonist	CCKBR			Brc1ccc(NC(=O)N2NC(=O)[C@H]([C@@H]2c2ccccc2)c2ccccc2)cc1, Brc1ccc(NC(=O)N2NC(=O)[C@H]([C@@H]2c2ccccc2)c2ccccc2)cc1	LMUQHXHWJWQXSD-PMACEKPBSA-N, LMUQHXHWJWQXSD-PMACEKPBSA-N	Preclinical
LY2886721	beta-secretase inhibitor	BACE1			NC1=N[C@]2(COC[C@H]2CS1)c1cc(NC(=O)c2ccc(F)cn2)ccc1F |t:1|	NIDRNVHMMDAAIK-YPMLDQLKSA-N	Phase 1/Phase 2
LY294002	DNA dependent protein kinase inhibitor, mTOR inhibitor, phosphodiesterase inhibitor, PI3K inhibitor, PLK inhibitor	AKT1, CHEK1, GSK3B, LCK, MAPK1, MAPK11, MAPK12, MAPK14, MAPK8, MTOR, PIK3CA, PIK3CB, PIK3CD, PIK3CG, PIM1, PLK1, PRKCA, PRKDC, ROCK1, RPS6KB1, SGK1			O=c1cc(oc2c(cccc12)-c1ccccc1)N1CCOCC1, O=c1cc(oc2c(cccc12)-c1ccccc1)N1CCOCC1, O=c1cc(oc2c(cccc12)-c1ccccc1)N1CCOCC1, O=c1cc(oc2c(cccc12)-c1ccccc1)N1CCOCC1	CZQHHVNHHHRRDU-UHFFFAOYSA-N, CZQHHVNHHHRRDU-UHFFFAOYSA-N, CZQHHVNHHHRRDU-UHFFFAOYSA-N, CZQHHVNHHHRRDU-UHFFFAOYSA-N	Preclinical
LY2979165	glutamate receptor agonist	GRM2			C[C@H](N)C(=O)N[C@]1(C[C@@H](Sc2nnc[nH]2)[C@H]2[C@@H]([C@@H]12)C(O)=O)C(O)=O, C[C@H](N)C(=O)N[C@]1(C[C@@H](Sc2nnc[nH]2)[C@H]2[C@@H]([C@@H]12)C(O)=O)C(O)=O, C[C@H](N)C(=O)N[C@]1(C[C@@H](Sc2nnc[nH]2)[C@H]2[C@@H]([C@@H]12)C(O)=O)C(O)=O, C[C@H](N)C(=O)N[C@]1(C[C@@H](Sc2nnc[nH]2)[C@H]2[C@@H]([C@@H]12)C(O)=O)C(O)=O, C[C@H](N)C(=O)N[C@]1(C[C@@H](Sc2nnc[nH]2)[C@H]2[C@@H]([C@@H]12)C(O)=O)C(O)=O	BBGHHIUQOKQCBW-LDZWZCGGSA-N, BBGHHIUQOKQCBW-LDZWZCGGSA-N, BBGHHIUQOKQCBW-LDZWZCGGSA-N, BBGHHIUQOKQCBW-LDZWZCGGSA-N, BBGHHIUQOKQCBW-LDZWZCGGSA-N	Phase 1
LY3000328	cathepsin inhibitor	CTSS			CNC(=O)O[C@H]1COc2ccc(cc2[C@@H]1NC(=O)c1ccc(F)cc1)N1CCN(CC1)C1COC1, CNC(=O)O[C@H]1COc2ccc(cc2[C@@H]1NC(=O)c1ccc(F)cc1)N1CCN(CC1)C1COC1, CNC(=O)O[C@H]1COc2ccc(cc2[C@@H]1NC(=O)c1ccc(F)cc1)N1CCN(CC1)C1COC1	NDEBZCZEAVMSQF-GOTSBHOMSA-N, NDEBZCZEAVMSQF-GOTSBHOMSA-N, NDEBZCZEAVMSQF-GOTSBHOMSA-N	Phase 1
LY3009120	RAF inhibitor	BRAF, RAF1			CNc1ncc2cc(c(C)nc2n1)-c1cc(NC(=O)NCCC(C)(C)C)c(F)cc1C, CNc1ncc2cc(c(C)nc2n1)-c1cc(NC(=O)NCCC(C)(C)C)c(F)cc1C, CNc1ncc2cc(c(C)nc2n1)-c1cc(NC(=O)NCCC(C)(C)C)c(F)cc1C	HHCBMISMPSAZBF-UHFFFAOYSA-N, HHCBMISMPSAZBF-UHFFFAOYSA-N, HHCBMISMPSAZBF-UHFFFAOYSA-N	Phase 1
LY3023414	mTOR inhibitor, PI3K inhibitor	MTOR			CO[C@@H](C)Cn1c2c(cnc3ccc(cc23)-c2cncc(c2)C(C)(C)O)n(C)c1=O, CO[C@@H](C)Cn1c2c(cnc3ccc(cc23)-c2cncc(c2)C(C)(C)O)n(C)c1=O, CO[C@@H](C)Cn1c2c(cnc3ccc(cc23)-c2cncc(c2)C(C)(C)O)n(C)c1=O	ACCFLVVUVBJNGT-AWEZNQCLSA-N, ACCFLVVUVBJNGT-AWEZNQCLSA-N, ACCFLVVUVBJNGT-AWEZNQCLSA-N	Phase 2
LY303511	casein kinase inhibitor, mTOR inhibitor, PI3K inhibitor	BRD2, BRD3, BRD4			O=c1cc(oc2c(cccc12)-c1ccccc1)N1CCNCC1, O=c1cc(oc2c(cccc12)-c1ccccc1)N1CCNCC1, O=c1cc(oc2c(cccc12)-c1ccccc1)N1CCNCC1, O=c1cc(oc2c(cccc12)-c1ccccc1)N1CCNCC1, O=c1cc(oc2c(cccc12)-c1ccccc1)N1CCNCC1, O=c1cc(oc2c(cccc12)-c1ccccc1)N1CCNCC1, O=c1cc(oc2c(cccc12)-c1ccccc1)N1CCNCC1, O=c1cc(oc2c(cccc12)-c1ccccc1)N1CCNCC1	NGAGMBNBKCDCDJ-UHFFFAOYSA-N, NGAGMBNBKCDCDJ-UHFFFAOYSA-N, NGAGMBNBKCDCDJ-UHFFFAOYSA-N, NGAGMBNBKCDCDJ-UHFFFAOYSA-N, NGAGMBNBKCDCDJ-UHFFFAOYSA-N, NGAGMBNBKCDCDJ-UHFFFAOYSA-N, NGAGMBNBKCDCDJ-UHFFFAOYSA-N, NGAGMBNBKCDCDJ-UHFFFAOYSA-N	Preclinical
LY310762	serotonin receptor antagonist	HTR1D			CC1(C)C(=O)N(CCN2CCC(CC2)C(=O)c2ccc(F)cc2)c2ccccc12, CC1(C)C(=O)N(CCN2CCC(CC2)C(=O)c2ccc(F)cc2)c2ccccc12, CC1(C)C(=O)N(CCN2CCC(CC2)C(=O)c2ccc(F)cc2)c2ccccc12, CC1(C)C(=O)N(CCN2CCC(CC2)C(=O)c2ccc(F)cc2)c2ccccc12	KDXISMANFPJVJY-UHFFFAOYSA-N, KDXISMANFPJVJY-UHFFFAOYSA-N, KDXISMANFPJVJY-UHFFFAOYSA-N, KDXISMANFPJVJY-UHFFFAOYSA-N	Preclinical
LY311727	phospholipase inhibitor				CCc1c(CC(N)=O)c2cc(OCCCP(O)(O)=O)ccc2n1Cc1ccccc1	OPWQYOUZRHDKBR-UHFFFAOYSA-N	Preclinical
LY3200882	TGF beta receptor inhibitor				CC(C)(O)c1cc(Nc2cc(Oc3cn(nc3C3CCOCC3)C3CC3)ccn2)ccn1	PNPFMWIDAKQFPY-UHFFFAOYSA-N	Phase 1
LY320135	cannabinoid receptor antagonist	CNR1			COc1ccc(cc1)-c1oc2cc(OC)ccc2c1C(=O)c1ccc(cc1)C#N, COc1ccc(cc1)-c1oc2cc(OC)ccc2c1C(=O)c1ccc(cc1)C#N, COc1ccc(cc1)-c1oc2cc(OC)ccc2c1C(=O)c1ccc(cc1)C#N	RYNSGDFWBJWWSZ-UHFFFAOYSA-N, RYNSGDFWBJWWSZ-UHFFFAOYSA-N, RYNSGDFWBJWWSZ-UHFFFAOYSA-N	Preclinical
LY3214996	ERK inhibitor				Cn1nccc1Nc1nccc(n1)-c1cc2C(=O)N(CCN3CCOCC3)C(C)(C)c2s1	JNPRPMBJODOFEC-UHFFFAOYSA-N	Phase 1
LY3295668	Aurora kinase inhibitor				C[C@@H]1C[C@@](Cc2nc(Nc3cc(C)[nH]n3)ccc2F)(CCN1Cc1cccc(Cl)c1F)C(O)=O	YQQZZYYQTCPEAS-OYLFLEFRSA-N	Phase 1/Phase 2
LY334370	serotonin receptor agonist				CN1CCC(CC1)c1c[nH]c2ccc(NC(=O)c3ccc(F)cc3)cc12	MDMJLMDBRQXOOI-UHFFFAOYSA-N	Preclinical
LY344864	serotonin receptor agonist	HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2B, HTR2C, HTR7			CN(C)[C@@H]1CCc2[nH]c3ccc(NC(=O)c4ccc(F)cc4)cc3c2C1, CN(C)[C@@H]1CCc2[nH]c3ccc(NC(=O)c4ccc(F)cc4)cc3c2C1, CN(C)[C@@H]1CCc2[nH]c3ccc(NC(=O)c4ccc(F)cc4)cc3c2C1	GKWHICIUSVVNGX-MRXNPFEDSA-N, GKWHICIUSVVNGX-MRXNPFEDSA-N, GKWHICIUSVVNGX-MRXNPFEDSA-N	Preclinical
LY364947	p38 MAPK inhibitor, TGF beta receptor inhibitor	TGFBR1			c1[nH]nc(c1-c1ccnc2ccccc12)-c1ccccn1, c1[nH]nc(c1-c1ccnc2ccccc12)-c1ccccn1, c1[nH]nc(c1-c1ccnc2ccccc12)-c1ccccn1, c1[nH]nc(c1-c1ccnc2ccccc12)-c1ccccn1, c1[nH]nc(c1-c1ccnc2ccccc12)-c1ccccn1, c1[nH]nc(c1-c1ccnc2ccccc12)-c1ccccn1	IBCXZJCWDGCXQT-UHFFFAOYSA-N, IBCXZJCWDGCXQT-UHFFFAOYSA-N, IBCXZJCWDGCXQT-UHFFFAOYSA-N, IBCXZJCWDGCXQT-UHFFFAOYSA-N, IBCXZJCWDGCXQT-UHFFFAOYSA-N, IBCXZJCWDGCXQT-UHFFFAOYSA-N	Preclinical
LY393558	serotonin receptor antagonist	HTR1B, HTR1D, HTR2A, HTR2B			CC(C)N1Cc2cc(ccc2N(CCN2CCC(=CC2)c2c[nH]c3cc(F)ccc23)S1(=O)=O)S(C)(=O)=O |c:18|, CC(C)N1Cc2cc(ccc2N(CCN2CCC(=CC2)c2c[nH]c3cc(F)ccc23)S1(=O)=O)S(C)(=O)=O |c:18|	QUSLYAPLTMMCFE-UHFFFAOYSA-N, QUSLYAPLTMMCFE-UHFFFAOYSA-N	Preclinical
LY404187	glutamate receptor positive allosteric modulator	GRIA1, GRIA2, GRIA3, GRIA4			CC(C)S(=O)(=O)NC[C@H](C)c1ccc(cc1)-c1ccc(cc1)C#N |&1:8,r|, CC(C)S(=O)(=O)NC[C@H](C)c1ccc(cc1)-c1ccc(cc1)C#N |&1:8,r|	HOQAVGZLYRYHSO-HNNXBMFYSA-N, HOQAVGZLYRYHSO-HNNXBMFYSA-N	Preclinical
LY411575	gamma secretase inhibitor				C[C@H](NC(=O)[C@@H](O)c1cc(F)cc(F)c1)C(=O)N[C@H]1c2ccccc2-c2ccccc2N(C)C1=O, C[C@H](NC(=O)[C@@H](O)c1cc(F)cc(F)c1)C(=O)N[C@H]1c2ccccc2-c2ccccc2N(C)C1=O	ULSSJYNJIZWPSB-CVRXJBIPSA-N, ULSSJYNJIZWPSB-CVRXJBIPSA-N	Preclinical
LY450108	glutamate receptor modulator				CC(C)S(=O)(=O)NC[C@H](C)c1ccc(NC(=O)c2cc(F)cc(F)c2)cc1, CC(C)S(=O)(=O)NC[C@H](C)c1ccc(NC(=O)c2cc(F)cc(F)c2)cc1	ACOXQYLJOQAHST-ZDUSSCGKSA-N, ACOXQYLJOQAHST-ZDUSSCGKSA-N	Phase 1
LY456236	glutamate receptor antagonist	GRM1			COc1ccc(Nc2ncnc3ccc(OC)cc23)cc1, COc1ccc(Nc2ncnc3ccc(OC)cc23)cc1, COc1ccc(Nc2ncnc3ccc(OC)cc23)cc1, COc1ccc(Nc2ncnc3ccc(OC)cc23)cc1	XPJOMFBGKIABQW-UHFFFAOYSA-N, XPJOMFBGKIABQW-UHFFFAOYSA-N, XPJOMFBGKIABQW-UHFFFAOYSA-N, XPJOMFBGKIABQW-UHFFFAOYSA-N	Preclinical
m-chlorophenylbiguanide	serotonin receptor agonist	HTR3A, HTR3B			NC(N)=NC(=N)Nc1cccc(Cl)c1, NC(N)=NC(=N)Nc1cccc(Cl)c1	DIHXJZHAIHGSAW-UHFFFAOYSA-N, DIHXJZHAIHGSAW-UHFFFAOYSA-N	Preclinical
m-THP					Oc1cccc(c1)-c1c2ccc(n2)c(-c2cccc(O)c2)c2ccc([nH]2)c(-c2cccc(O)c2)c2ccc([nH]2)c(-c2cccc(O)c2)c2ccc1n2	XAEPFBXVLMACNN-LWQDQPMZSA-N	Phase 1
M-14157	ATP-sensitive potassium channel antagonist	KCNQ1			CCCCCC(O)CCCC(O)=O	LMHJFKYQYDSOQO-UHFFFAOYSA-N	Phase 2
M-25	smoothened receptor antagonist	DHH, IHH, SMO			CCCC(CCC)C(=O)NCc1ccc2n(ncc2c1)-c1ccccc1OC, CCCC(CCC)C(=O)NCc1ccc2n(ncc2c1)-c1ccccc1OC	WATNXVHKRRTUFK-UHFFFAOYSA-N, WATNXVHKRRTUFK-UHFFFAOYSA-N	Preclinical
m-3M3FBS	phospholipase activator	PLCB2, PLCB3, PLCD1, PLCG1, PLCG2			Cc1cc(C)c(c(C)c1)S(=O)(=O)Nc1cccc(c1)C(F)(F)F, Cc1cc(C)c(c(C)c1)S(=O)(=O)Nc1cccc(c1)C(F)(F)F	ZIIUUSVHCHPIQD-UHFFFAOYSA-N, ZIIUUSVHCHPIQD-UHFFFAOYSA-N	Preclinical
M-344	HDAC inhibitor	HDAC8			CN(C)c1ccc(cc1)C(=O)NCCCCCCC(=O)NO, CN(C)c1ccc(cc1)C(=O)NCCCCCCC(=O)NO, CN(C)c1ccc(cc1)C(=O)NCCCCCCC(=O)NO, CN(C)c1ccc(cc1)C(=O)NCCCCCCC(=O)NO	MXWDSZWTBOCWBK-UHFFFAOYSA-N, MXWDSZWTBOCWBK-UHFFFAOYSA-N, MXWDSZWTBOCWBK-UHFFFAOYSA-N, MXWDSZWTBOCWBK-UHFFFAOYSA-N	Preclinical
mabuprofen	cyclooxygenase inhibitor		neurology/psychiatry	pain relief	CC(C)Cc1ccc(cc1)[C@@H](C)C(=O)NCCO |&1:10,r|, CC(C)Cc1ccc(cc1)[C@@H](C)C(=O)NCCO |&1:10,r|, CC(C)Cc1ccc(cc1)[C@@H](C)C(=O)NCCO |&1:10,r|	JVGUNCHERKJFCM-GFCCVEGCSA-N, JVGUNCHERKJFCM-GFCCVEGCSA-N, JVGUNCHERKJFCM-GFCCVEGCSA-N	Launched
mabuterol	adrenergic receptor agonist	ADRB2	pulmonary	asthma	CC(C)(C)NC[C@@H](O)c1cc(Cl)c(N)c(c1)C(F)(F)F |&1:6|	JSJCTEKTBOKRST-SNVBAGLBSA-N	Launched
macelignan	anti-inflammatory agent, antioxidant				COc1cc(C[C@H](C)[C@H](C)Cc2ccc3OCOc3c2)ccc1O	QDDILOVMGWUNGD-UONOGXRCSA-N	Preclinical
macitentan	endothelin receptor antagonist	EDNRA, EDNRB	endocrinology	contraceptive	CCCNS(=O)(=O)Nc1ncnc(OCCOc2ncc(Br)cn2)c1-c1ccc(Br)cc1, CCCNS(=O)(=O)Nc1ncnc(OCCOc2ncc(Br)cn2)c1-c1ccc(Br)cc1, CCCNS(=O)(=O)Nc1ncnc(OCCOc2ncc(Br)cn2)c1-c1ccc(Br)cc1, CCCNS(=O)(=O)Nc1ncnc(OCCOc2ncc(Br)cn2)c1-c1ccc(Br)cc1, CCCNS(=O)(=O)Nc1ncnc(OCCOc2ncc(Br)cn2)c1-c1ccc(Br)cc1, CCCNS(=O)(=O)Nc1ncnc(OCCOc2ncc(Br)cn2)c1-c1ccc(Br)cc1, CCCNS(=O)(=O)Nc1ncnc(OCCOc2ncc(Br)cn2)c1-c1ccc(Br)cc1, CCCNS(=O)(=O)Nc1ncnc(OCCOc2ncc(Br)cn2)c1-c1ccc(Br)cc1	JGCMEBMXRHSZKX-UHFFFAOYSA-N, JGCMEBMXRHSZKX-UHFFFAOYSA-N, JGCMEBMXRHSZKX-UHFFFAOYSA-N, JGCMEBMXRHSZKX-UHFFFAOYSA-N, JGCMEBMXRHSZKX-UHFFFAOYSA-N, JGCMEBMXRHSZKX-UHFFFAOYSA-N, JGCMEBMXRHSZKX-UHFFFAOYSA-N, JGCMEBMXRHSZKX-UHFFFAOYSA-N	Launched
macitentan-n-butyl-analogue	endothelin receptor antagonist				CCCCS(=O)(=O)Nc1ncnc(OCCOc2ncc(Br)cn2)c1-c1ccc(Br)cc1	OZBDTKLWBSATSN-UHFFFAOYSA-N	Preclinical
macozinone	DPRE1 inhibitor				[O-][N+](=O)c1cc(cc2c1sc(nc2=O)N1CCN(CC2CCCCC2)CC1)C(F)(F)F	BJDZBXGJNBMCAV-UHFFFAOYSA-N	Preclinical
madecassoside	anti-inflammatory agent				[H][C@]12CC=C3[C@]4([H])[C@@H](C)[C@H](C)CC[C@@]4(CC[C@@]3(C)[C@]1(C)C[C@@H](O)[C@@]1([H])[C@](C)(CO)[C@@H](O)[C@H](O)C[C@]21C)C(=O)O[C@@H]1O[C@H](CO[C@@H]2O[C@H](CO)[C@@H](O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](O)[C@H]3O)[C@H](O)[C@H]2O)[C@@H](O)[C@H](O)[C@H]1O |t:3|	BNMGUJRJUUDLHW-HCZMHFOYSA-N	Preclinical
madrasin	cell splicing inhibitor				COc1ccc2c(C)nc(Nc3nc(=O)c(C)c(C)[nH]3)nc2c1, COc1ccc2c(C)nc(Nc3nc(=O)c(C)c(C)[nH]3)nc2c1, COc1ccc2c(C)nc(Nc3nc(=O)c(C)c(C)[nH]3)nc2c1, COc1ccc2c(C)nc(Nc3nc(=O)c(C)c(C)[nH]3)nc2c1, COc1ccc2c(C)nc(Nc3nc(=O)c(C)c(C)[nH]3)nc2c1	QQJIYKXTEMDJFM-UHFFFAOYSA-N, QQJIYKXTEMDJFM-UHFFFAOYSA-N, QQJIYKXTEMDJFM-UHFFFAOYSA-N, QQJIYKXTEMDJFM-UHFFFAOYSA-N, QQJIYKXTEMDJFM-UHFFFAOYSA-N	Preclinical
mafenide	carbonic anhydrase inhibitor	CA12, CA14, CA2, CA4, CA6, CA9	infectious disease	first-aid antibiotic, skin infections	NCc1ccc(cc1)S(N)(=O)=O, NCc1ccc(cc1)S(N)(=O)=O	TYMRLRRVMHJFTF-UHFFFAOYSA-N, TYMRLRRVMHJFTF-UHFFFAOYSA-N	Launched
magnolol	PPAR receptor agonist	GABRA1, PPARG			Oc1ccc(CC=C)cc1-c1cc(CC=C)ccc1O, Oc1ccc(CC=C)cc1-c1cc(CC=C)ccc1O	VVOAZFWZEDHOOU-UHFFFAOYSA-N, VVOAZFWZEDHOOU-UHFFFAOYSA-N	Preclinical
malathion	cholinesterase inhibitor	ACHE	infectious disease	lice	CCOC(=O)C[C@@H](SP(=S)(OC)OC)C(=O)OCC |&1:6,r|, CCOC(=O)C[C@@H](SP(=S)(OC)OC)C(=O)OCC |&1:6,r|, CCOC(=O)C[C@@H](SP(=S)(OC)OC)C(=O)OCC |&1:6,r|, CCOC(=O)C[C@@H](SP(=S)(OC)OC)C(=O)OCC |&1:6,r|	JXSJBGJIGXNWCI-MRVPVSSYSA-N, JXSJBGJIGXNWCI-MRVPVSSYSA-N, JXSJBGJIGXNWCI-MRVPVSSYSA-N, JXSJBGJIGXNWCI-MRVPVSSYSA-N	Launched
malic-acid		PKD2L1			O[C@@H](CC(O)=O)C(O)=O |&1:1,r|, O[C@@H](CC(O)=O)C(O)=O |&1:1,r|	BJEPYKJPYRNKOW-REOHCLBHSA-N, BJEPYKJPYRNKOW-REOHCLBHSA-N	Launched
malotilate	protein synthesis stimulant		gastroenterology	hepatic cirrhosis	CC(C)OC(=O)C(C(=O)OC(C)C)=C1SC=CS1 |c:15|, CC(C)OC(=O)C(C(=O)OC(C)C)=C1SC=CS1 |c:15|	YPIQVCUJEKAZCP-UHFFFAOYSA-N, YPIQVCUJEKAZCP-UHFFFAOYSA-N	Launched
maltobionic-acid	matrix metalloprotease inhibitor		dermatology	cosmetic	OC[C@@H](O)[C@@H](O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O)[C@H](O)[C@@H](O)C(O)=O, OC[C@@H](O)[C@@H](O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O)[C@H](O)[C@@H](O)C(O)=O, OC[C@@H](O)[C@@H](O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O)[C@H](O)[C@@H](O)C(O)=O, OC[C@@H](O)[C@@H](O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O)[C@H](O)[C@@H](O)C(O)=O	JYTUSYBCFIZPBE-AMTLMPIISA-N, JYTUSYBCFIZPBE-AMTLMPIISA-N, JYTUSYBCFIZPBE-AMTLMPIISA-N, JYTUSYBCFIZPBE-AMTLMPIISA-N	Launched
mandelic-acid					O[C@@H](C(O)=O)c1ccccc1 |&1:1,r|, O[C@@H](C(O)=O)c1ccccc1 |&1:1,r|	IWYDHOAUDWTVEP-SSDOTTSWSA-N, IWYDHOAUDWTVEP-SSDOTTSWSA-N	Launched
mangafodipir	contrast agent		radiology	contrast agent	Cc1nc(COP(O)(O)=O)cc2CN(CC(O)=O)CCN(CC(O)=O)Cc3cc(COP(O)(O)=O)nc(C)c3O[Mn]Oc12, Cc1nc(COP(O)(O)=O)cc2CN(CC(O)=O)CCN(CC(O)=O)Cc3cc(COP(O)(O)=O)nc(C)c3O[Mn]Oc12, Cc1nc(COP(O)(O)=O)cc2CN(CC(O)=O)CCN(CC(O)=O)Cc3cc(COP(O)(O)=O)nc(C)c3O[Mn]Oc12	CXFKOLCMCRBYPL-UHFFFAOYSA-L, CXFKOLCMCRBYPL-UHFFFAOYSA-L, CXFKOLCMCRBYPL-UHFFFAOYSA-L	Launched
manidipine	calcium channel blocker	CACNA1C, CACNA1D	cardiology	hypertension	COC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OCCN1CCN(CC1)C(c1ccccc1)c1ccccc1 |r,c:4,9|, COC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OCCN1CCN(CC1)C(c1ccccc1)c1ccccc1 |r,c:4,9|	ANEBWFXPVPTEET-JGCGQSQUSA-N, ANEBWFXPVPTEET-JGCGQSQUSA-N	Launched
manitimus	dehydrogenase inhibitor				FC(F)(F)c1ccc(NC(=O)[C@H](C#N)C(=O)CCC#C)cc1 |&1:11,r|	MYMWDZLPEPMSCN-GFCCVEGCSA-N	Preclinical
mannitol-D	diuretic		neurology/psychiatry, ophthalmology, gastroenterology	intracranial pressure, intraocular pressure, constipation	OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO, OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO	FBPFZTCFMRRESA-KVTDHHQDSA-N, FBPFZTCFMRRESA-KVTDHHQDSA-N	Launched
maprotiline	norepinephrine reputake inhibitor, tricyclic antidepressant	SLC6A2	neurology/psychiatry	depression, dysthymic disorder	CNCCC[C@@]12CC[C@@H](c3ccccc13)c1ccccc21 |r|, CNCCC[C@@]12CC[C@@H](c3ccccc13)c1ccccc21 |r|	QSLMDECMDJKHMQ-GSXCWMCISA-N, QSLMDECMDJKHMQ-GSXCWMCISA-N	Launched
maraviroc	CC chemokine receptor antagonist	CCR5	infectious disease	human immunodeficiency virus (HIV-1)	CC(C)c1nnc(C)n1[C@H]1C[C@@H]2CC[C@H](C1)N2CC[C@H](NC(=O)C1CCC(F)(F)CC1)c1ccccc1	GSNHKUDZZFZSJB-QYOOZWMWSA-N	Launched
marbofloxacin	bacterial DNA gyrase inhibitor		infectious disease	gram-negative bacterial infections	CN1CCN(CC1)c1c(F)cc2c3c1OCN(C)n3cc(C(O)=O)c2=O, CN1CCN(CC1)c1c(F)cc2c3c1OCN(C)n3cc(C(O)=O)c2=O, CN1CCN(CC1)c1c(F)cc2c3c1OCN(C)n3cc(C(O)=O)c2=O, CN1CCN(CC1)c1c(F)cc2c3c1OCN(C)n3cc(C(O)=O)c2=O, CN1CCN(CC1)c1c(F)cc2c3c1OCN(C)n3cc(C(O)=O)c2=O, CN1CCN(CC1)c1c(F)cc2c3c1OCN(C)n3cc(C(O)=O)c2=O, CN1CCN(CC1)c1c(F)cc2c3c1OCN(C)n3cc(C(O)=O)c2=O	BPFYOAJNDMUVBL-UHFFFAOYSA-N, BPFYOAJNDMUVBL-UHFFFAOYSA-N, BPFYOAJNDMUVBL-UHFFFAOYSA-N, BPFYOAJNDMUVBL-UHFFFAOYSA-N, BPFYOAJNDMUVBL-UHFFFAOYSA-N, BPFYOAJNDMUVBL-UHFFFAOYSA-N, BPFYOAJNDMUVBL-UHFFFAOYSA-N	Launched
maribavir	cytomegalovirus inhibitor, protein kinase inhibitor	PYGM			CC(C)Nc1nc2cc(Cl)c(Cl)cc2n1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O, CC(C)Nc1nc2cc(Cl)c(Cl)cc2n1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O, CC(C)Nc1nc2cc(Cl)c(Cl)cc2n1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O	KJFBVJALEQWJBS-XUXIUFHCSA-N, KJFBVJALEQWJBS-XUXIUFHCSA-N, KJFBVJALEQWJBS-XUXIUFHCSA-N	Phase 3
marimastat	matrix metalloprotease inhibitor	MMP1, MMP10, MMP11, MMP12, MMP13, MMP14, MMP15, MMP16, MMP17, MMP19, MMP2, MMP20, MMP21, MMP23A, MMP24, MMP25, MMP26, MMP27, MMP28, MMP3, MMP7, MMP8, MMP9			CNC(=O)[C@@H](NC(=O)[C@H](CC(C)C)[C@H](O)C(=O)NO)C(C)(C)C, CNC(=O)[C@@H](NC(=O)[C@H](CC(C)C)[C@H](O)C(=O)NO)C(C)(C)C, CNC(=O)[C@@H](NC(=O)[C@H](CC(C)C)[C@H](O)C(=O)NO)C(C)(C)C, CNC(=O)[C@@H](NC(=O)[C@H](CC(C)C)[C@H](O)C(=O)NO)C(C)(C)C, CNC(=O)[C@@H](NC(=O)[C@H](CC(C)C)[C@H](O)C(=O)NO)C(C)(C)C	OCSMOTCMPXTDND-OUAUKWLOSA-N, OCSMOTCMPXTDND-OUAUKWLOSA-N, OCSMOTCMPXTDND-OUAUKWLOSA-N, OCSMOTCMPXTDND-OUAUKWLOSA-N, InChI=1S/C15H29N3O5/c1-8(2)7-9(10(19)13(21)18-23)12(20)17-11(14(22)16-6)15(3,4)5/h8-11,19,23H,7H2,1-6H3,(H,16,22)(H,17,20)(H,18,21)/t9-,10+,11-/m1/s1	Phase 3
maropitant	neurokinin receptor antagonist	TACR1	gastroenterology	vomiting	COc1ccc(cc1CN[C@H]1C2CCN(CC2)[C@H]1C(c1ccccc1)c1ccccc1)C(C)(C)C, COc1ccc(cc1CN[C@H]1C2CCN(CC2)[C@H]1C(c1ccccc1)c1ccccc1)C(C)(C)C	OMPCVMLFFSQFIX-CONSDPRKSA-N, OMPCVMLFFSQFIX-CONSDPRKSA-N	Launched
masitinib	KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, SRC inhibitor	FGFR3, KIT, PDGFRA, PDGFRB	dermatology	mastocytoma	CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nc(cs3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nc(cs3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nc(cs3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nc(cs3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nc(cs3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nc(cs3)-c3cccnc3)c2)CC1	WJEOLQLKVOPQFV-UHFFFAOYSA-N, WJEOLQLKVOPQFV-UHFFFAOYSA-N, WJEOLQLKVOPQFV-UHFFFAOYSA-N, WJEOLQLKVOPQFV-UHFFFAOYSA-N, WJEOLQLKVOPQFV-UHFFFAOYSA-N, WJEOLQLKVOPQFV-UHFFFAOYSA-N	Launched
masoprocol	lipoxygenase inhibitor	ALOX5	dermatology	actinic keratosis (AK)	C[C@@H](Cc1ccc(O)c(O)c1)[C@@H](C)Cc1ccc(O)c(O)c1 |&1:1,&2:11,r|, C[C@@H](Cc1ccc(O)c(O)c1)[C@@H](C)Cc1ccc(O)c(O)c1 |&1:1,&2:11,r|, C[C@@H](Cc1ccc(O)c(O)c1)[C@@H](C)Cc1ccc(O)c(O)c1 |&1:1,&2:11,r|, C[C@@H](Cc1ccc(O)c(O)c1)[C@@H](C)Cc1ccc(O)c(O)c1 |&1:1,&2:11,r|	HCZKYJDFEPMADG-RYUDHWBXSA-N, HCZKYJDFEPMADG-RYUDHWBXSA-N, HCZKYJDFEPMADG-RYUDHWBXSA-N, HCZKYJDFEPMADG-RYUDHWBXSA-N	Launched
matrine	opioid receptor agonist	OPRK1			O=C1CCC[C@@H]2[C@H]3CCCN4CCC[C@@H](CN12)[C@@H]34	ZSBXGIUJOOQZMP-JLNYLFASSA-N	Phase 2
mavacamten	myosin inhibitor 				CC(C)n1c(=O)cc(N[C@@H](C)c2ccccc2)[nH]c1=O	RLCLASQCAPXVLM-NSHDSACASA-N	Phase 3
mavatrep	transient receptor potential channel antagonist				CC(C)(O)c1ccccc1-c1ccc2nc(\C=C\c3ccc(cc3)C(F)(F)F)[nH]c2c1	ORDHXXHTBUZRCN-NTEUORMPSA-N	Preclinical
mavoglurant	glutamate receptor antagonist	GRM5			COC(=O)N1CC[C@@H]2[C@H]1CCC[C@@]2(O)C#Cc1cccc(C)c1, COC(=O)N1CC[C@@H]2[C@H]1CCC[C@@]2(O)C#Cc1cccc(C)c1	ZFPZEYHRWGMJCV-ZHALLVOQSA-N, ZFPZEYHRWGMJCV-ZHALLVOQSA-N	Phase 2
maxacalcitol	vitamin D receptor agonist	VDR	endocrinology	hyperparathyroidism	C[C@H](OCCC(C)(C)O)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C	DTXXSJZBSTYZKE-ZDQKKZTESA-N	Launched
maytansinol-isobutyrate					CO[C@@H]1\C=C\C=C(C)\Cc2cc(OC)c(Cl)c(c2)N(C)C(=O)C[C@H](OC(=O)C(C)C)[C@]2(C)O[C@H]2[C@H](C)[C@@H]2C[C@@]1(O)NC(=O)O2 |c:5,t:3|, CO[C@@H]1\C=C\C=C(C)\Cc2cc(OC)c(Cl)c(c2)N(C)C(=O)C[C@H](OC(=O)C(C)C)[C@]2(C)O[C@H]2[C@H](C)[C@@H]2C[C@@]1(O)NC(=O)O2 |c:5,t:3|	OPQNCARIZFLNLF-HSBZPDDFSA-N, OPQNCARIZFLNLF-HSBZPDDFSA-N	Preclinical
MBX-2982	glucose dependent insulinotropic receptor agonist	GPR119			CCc1cnc(nc1)N1CCC(CC1)c1nc(COc2ccc(cc2)-n2cnnn2)cs1, CCc1cnc(nc1)N1CCC(CC1)c1nc(COc2ccc(cc2)-n2cnnn2)cs1, CCc1cnc(nc1)N1CCC(CC1)c1nc(COc2ccc(cc2)-n2cnnn2)cs1, CCc1cnc(nc1)N1CCC(CC1)c1nc(COc2ccc(cc2)-n2cnnn2)cs1, CCc1cnc(nc1)N1CCC(CC1)c1nc(COc2ccc(cc2)-n2cnnn2)cs1, CCc1cnc(nc1)N1CCC(CC1)c1nc(COc2ccc(cc2)-n2cnnn2)cs1, CCc1cnc(nc1)N1CCC(CC1)c1nc(COc2ccc(cc2)-n2cnnn2)cs1	NFTMKHWBOINJGM-UHFFFAOYSA-N, NFTMKHWBOINJGM-UHFFFAOYSA-N, NFTMKHWBOINJGM-UHFFFAOYSA-N, NFTMKHWBOINJGM-UHFFFAOYSA-N, NFTMKHWBOINJGM-UHFFFAOYSA-N, NFTMKHWBOINJGM-UHFFFAOYSA-N, NFTMKHWBOINJGM-UHFFFAOYSA-N	Phase 2
MC-1		AADAT, ABAT, AGXT, AGXT2, ALAS1, AZIN2, BCAT1, BCAT2, CBS, CCBL1, CCBL2, CSAD, CTH, DDC, FTCD, GAD1, GAD2, GADL1, GCAT, GLDC, GOT1, GOT2, GPT, GPT2, HDC, IGSF10, KYNU, MOCOS, NFS1, OAT, ODC1, PDXDC1, PDXP, PHYKPL, PNPO, PROSC, PSAT1, PYGB, PYGL, PYGM, SCLY, SDS, SDSL, SEPSECS, SGPL1, SHMT1, SHMT2, SPTLC1, SPTLC2, SPTLC3, SRR, TAT, THNSL1			Cc1ncc(COP(O)(O)=O)c(C=O)c1O, Cc1ncc(COP(O)(O)=O)c(C=O)c1O	NGVDGCNFYWLIFO-UHFFFAOYSA-N, NGVDGCNFYWLIFO-UHFFFAOYSA-N	Phase 3
MCC950	NOD like receptor inhibitor	NLRP3			CC(C)(O)c1coc(c1)S(=O)(=O)NC(=O)Nc1c2CCCc2cc2CCCc12, CC(C)(O)c1coc(c1)S(=O)(=O)NC(=O)Nc1c2CCCc2cc2CCCc12	HUUSXLKCTQDPGL-UHFFFAOYSA-N, HUUSXLKCTQDPGL-UHFFFAOYSA-N	Preclinical
McN-5652-(+/-)	selective serotonin reuptake inhibitor (SSRI)				CSc1ccc(cc1)[C@H]1CN2CCC[C@H]2c2ccccc12, CSc1ccc(cc1)[C@H]1CN2CCC[C@H]2c2ccccc12	YVKDUIAAPBKHMJ-MOPGFXCFSA-N, YVKDUIAAPBKHMJ-MOPGFXCFSA-N	Preclinical
MCOPPB	nociceptin/orphanin FQ receptor agonist	OPRL1			CC1(CCCCCCC1)N1CCC(CC1)n1c(nc2ccccc12)[C@@H]1CCCNC1, CC1(CCCCCCC1)N1CCC(CC1)n1c(nc2ccccc12)[C@@H]1CCCNC1	CYYNMPPFEJPBJD-OAQYLSRUSA-N, CYYNMPPFEJPBJD-OAQYLSRUSA-N	Preclinical
mCPP	serotonin receptor agonist	HTR1A, HTR1D, HTR1E, HTR2A, HTR2B, HTR2C, HTR6			Clc1cccc(c1)N1CCNCC1, Clc1cccc(c1)N1CCNCC1	VHFVKMTVMIZMIK-UHFFFAOYSA-N, VHFVKMTVMIZMIK-UHFFFAOYSA-N	Phase 2
MC1568	HDAC inhibitor	HDAC2			Cn1c(\C=C\C(=O)NO)ccc1\C=C\C(=O)c1cccc(F)c1, Cn1c(\C=C\C(=O)NO)ccc1\C=C\C(=O)c1cccc(F)c1, Cn1c(\C=C\C(=O)NO)ccc1\C=C\C(=O)c1cccc(F)c1, Cn1c(\C=C\C(=O)NO)ccc1\C=C\C(=O)c1cccc(F)c1	QQDIFLSJMFDTCQ-FIFLTTCUSA-N, QQDIFLSJMFDTCQ-FIFLTTCUSA-N, QQDIFLSJMFDTCQ-FIFLTTCUSA-N, QQDIFLSJMFDTCQ-FIFLTTCUSA-N	Preclinical
MD-920	NFkB pathway inhibitor	AADACL2			C[C@@]12[C@H]3[C@H](C(O)=O)[C@@]45CC(=C)[C@@](O)(C4)CC[C@H]5[C@]3(OC1=O)C=C[C@@H]2O |c:25|, C[C@@]12[C@H]3[C@H](C(O)=O)[C@@]45CC(=C)[C@@](O)(C4)CC[C@H]5[C@]3(OC1=O)C=C[C@@H]2O |c:25|	IXORZMNAPKEEDV-OBDJNFEBSA-N, IXORZMNAPKEEDV-OBDJNFEBSA-N	Phase 1
mdivi-1	dynamin inhibitor	DNM1			COc1cc(c(Cl)cc1Cl)-n1c(=S)[nH]c2ccccc2c1=O, COc1cc(c(Cl)cc1Cl)-n1c(=S)[nH]c2ccccc2c1=O, COc1cc(c(Cl)cc1Cl)-n1c(=S)[nH]c2ccccc2c1=O	NZJKEVWTYMOYOR-UHFFFAOYSA-N, NZJKEVWTYMOYOR-UHFFFAOYSA-N, NZJKEVWTYMOYOR-UHFFFAOYSA-N	Preclinical
MDL-11939	serotonin receptor antagonist	HTR2A, HTR2B, HTR2C			O[C@@H](C1CCN(CCc2ccccc2)CC1)c1ccccc1 |&1:1,r|, O[C@@H](C1CCN(CCc2ccccc2)CC1)c1ccccc1 |&1:1,r|	AXNGJCOYCMDPQG-HXUWFJFHSA-N, AXNGJCOYCMDPQG-HXUWFJFHSA-N	Phase 2
MDL-27531	glycine receptor agonist				Cn1c(nnc1S(C)(=O)=O)-c1ccccc1	DPGDRICHXKQXEN-UHFFFAOYSA-N	Preclinical
MDL-29951	glutamate receptor antagonist	FBP1			OC(=O)CCc1c([nH]c2cc(Cl)cc(Cl)c12)C(O)=O, OC(=O)CCc1c([nH]c2cc(Cl)cc(Cl)c12)C(O)=O, OC(=O)CCc1c([nH]c2cc(Cl)cc(Cl)c12)C(O)=O, OC(=O)CCc1c([nH]c2cc(Cl)cc(Cl)c12)C(O)=O	KNBSYZNKEAWABY-UHFFFAOYSA-N, KNBSYZNKEAWABY-UHFFFAOYSA-N, KNBSYZNKEAWABY-UHFFFAOYSA-N, KNBSYZNKEAWABY-UHFFFAOYSA-N	Preclinical
MDL-72832	serotonin receptor agonist	HTR1A			O=C1CC2(CCCC2)CC(=O)N1CCCCNC[C@H]1COc2ccccc2O1 |&1:18|, O=C1CC2(CCCC2)CC(=O)N1CCCCNC[C@H]1COc2ccccc2O1 |&1:18|	HCVRCHQFYYZPHT-KRWDZBQOSA-N, HCVRCHQFYYZPHT-KRWDZBQOSA-N	Preclinical
MDL-73005EF	serotonin receptor antagonist	HTR1A			O=C1CC2(CCCC2)CC(=O)N1CCNC[C@H]1COc2ccccc2O1 |&1:16|, O=C1CC2(CCCC2)CC(=O)N1CCNC[C@H]1COc2ccccc2O1 |&1:16|	BVMYCHKQPGEOSI-HNNXBMFYSA-N, BVMYCHKQPGEOSI-HNNXBMFYSA-N	Phase 1
MDMS	DNA inhibitor				CS(=O)(=O)OCOS(C)(=O)=O	IQLZWWDXNXZGPK-UHFFFAOYSA-N	Phase 2
ME-0328	PPAR receptor antagonist	PARP3			C[C@H](NC(=O)CCc1nc(=O)c2ccccc2[nH]1)c1ccccc1, C[C@H](NC(=O)CCc1nc(=O)c2ccccc2[nH]1)c1ccccc1, C[C@H](NC(=O)CCc1nc(=O)c2ccccc2[nH]1)c1ccccc1	QIHBWVVVRYYYRO-ZDUSSCGKSA-N, QIHBWVVVRYYYRO-ZDUSSCGKSA-N, QIHBWVVVRYYYRO-ZDUSSCGKSA-N	Preclinical
mebendazole	tubulin polymerization inhibitor	TUBA1A, TUBB, TUBB4B	infectious disease	pinworm, whipworm, hookworm, ascariasis	COC(=O)Nc1nc2ccc(cc2[nH]1)C(=O)c1ccccc1, COC(=O)Nc1nc2ccc(cc2[nH]1)C(=O)c1ccccc1	OPXLLQIJSORQAM-UHFFFAOYSA-N, OPXLLQIJSORQAM-UHFFFAOYSA-N	Launched
mebeverine	acetylcholine receptor antagonist	CHRM1	gastroenterology	irritable bowel syndrome	CCN(CCCCOC(=O)c1ccc(OC)c(OC)c1)[C@@H](C)Cc1ccc(OC)cc1 |&1:20|, CCN(CCCCOC(=O)c1ccc(OC)c(OC)c1)[C@@H](C)Cc1ccc(OC)cc1 |&1:20|	VYVKHNNGDFVQGA-IBGZPJMESA-N, VYVKHNNGDFVQGA-IBGZPJMESA-N	Launched
mebhydrolin	antihistamine		allergy	allergic rhinitis, urticaria	CN1CCc2c(C1)c1ccccc1n2Cc1ccccc1, CN1CCc2c(C1)c1ccccc1n2Cc1ccccc1, CN1CCc2c(C1)c1ccccc1n2Cc1ccccc1	FQQIIPAOSKSOJM-UHFFFAOYSA-N, FQQIIPAOSKSOJM-UHFFFAOYSA-N, FQQIIPAOSKSOJM-UHFFFAOYSA-N	Launched
mebicar	anxiolytic		neurology/psychiatry	anxiety	CN1C2C(N(C)C1=O)N(C)C(=O)N2C, CN1C2C(N(C)C1=O)N(C)C(=O)N2C, CN1C2C(N(C)C1=O)N(C)C(=O)N2C	XIUUSFJTJXFNGH-UHFFFAOYSA-N, XIUUSFJTJXFNGH-UHFFFAOYSA-N, XIUUSFJTJXFNGH-UHFFFAOYSA-N	Launched
mebrofenin			radiology	diagnostic agent	Cc1cc(C)c(NC(=O)CN(CC(O)=O)CC(O)=O)c(C)c1Br	MHPZZZZLAQGTHT-UHFFFAOYSA-N	Launched
mecamylamine	acetylcholine receptor antagonist	CHRNA1, CHRNA2, CHRNA3, CHRNA4, CHRNA6, CHRNA7, CHRNB4	cardiology	hypertension	CNC1(C)C2CCC(C2)C1(C)C, CNC1(C)C2CCC(C2)C1(C)C, CNC1(C)C2CCC(C2)C1(C)C	IMYZQPCYWPFTAG-UHFFFAOYSA-N, IMYZQPCYWPFTAG-UHFFFAOYSA-N, IMYZQPCYWPFTAG-UHFFFAOYSA-N	Launched
mecarbinate					CCOC(=O)c1c(C)n(C)c2ccc(O)cc12	YTBNTDMBGXAOCG-UHFFFAOYSA-N	Preclinical
meclinertant	neurotensin receptor antagonist	NTSR1, NTSR2			COc1cccc(OC)c1-c1cc(nn1-c1ccnc2cc(Cl)ccc12)C(=O)NC1(C2CC3CC(C2)CC1C3)C(O)=O, COc1cccc(OC)c1-c1cc(nn1-c1ccnc2cc(Cl)ccc12)C(=O)NC1(C2CC3CC(C2)CC1C3)C(O)=O	DYLJVOXRWLXDIG-UHFFFAOYSA-N, DYLJVOXRWLXDIG-UHFFFAOYSA-N	Phase 2/Phase 3
meclizine	constitutive androstane receptor (CAR) agonist	NR1I3	gastroenterology, neurology/psychiatry	nausea, vomiting, motion sickness	Cc1cccc(CN2CCN(CC2)[C@@H](c2ccccc2)c2ccc(Cl)cc2)c1 |&1:13|	OCJYIGYOJCODJL-VWLOTQADSA-N	Launched
meclocycline-sulfosalicylate	bacterial 50S ribosomal subunit inhibitor		dermatology, infectious disease	acne vulgaris (AV), skin infections	CN(C)[C@H]1[C@@H]2[C@@H](O)[C@@H]3C(=C)c4c(Cl)ccc(O)c4C(=O)C3=C(O)[C@]2(O)C(O)=C(C(N)=O)C1=O |a:3,4,5,7,23,&1:20,&2:27,t:22,29|, CN(C)[C@H]1[C@@H]2[C@@H](O)[C@@H]3C(=C)c4c(Cl)ccc(O)c4C(=O)C3=C(O)[C@]2(O)C(O)=C(C(N)=O)C1=O |a:3,4,5,7,23,&1:20,&2:27,t:22,29|, CN(C)[C@H]1[C@@H]2[C@@H](O)[C@@H]3C(=C)c4c(Cl)ccc(O)c4C(=O)C3=C(O)[C@]2(O)C(O)=C(C(N)=O)C1=O |a:3,4,5,7,23,&1:20,&2:27,t:22,29|	MEFKOOXNVFALTA-IWVLMIASSA-N, MEFKOOXNVFALTA-IWVLMIASSA-N, MEFKOOXNVFALTA-IWVLMIASSA-N	Launched
meclofenamic-acid	cyclooxygenase inhibitor, prostanoid receptor antagonist	ALOX5, CNR1, KCNQ2, KCNQ3, PTGS1, PTGS2	rheumatology, neurology/psychiatry, endocrinology	joint pain, muscle pain, rheumatoid arthritis, primary dysmenorrhea (PD)	Cc1ccc(Cl)c(Nc2ccccc2C(O)=O)c1Cl, Cc1ccc(Cl)c(Nc2ccccc2C(O)=O)c1Cl	SBDNJUWAMKYJOX-UHFFFAOYSA-N, SBDNJUWAMKYJOX-UHFFFAOYSA-N	Launched
meclofenoxate	nootropic agent		neurology/psychiatry	senile dementia, Alzheimer's disease	CN(C)CCOC(=O)COc1ccc(Cl)cc1, CN(C)CCOC(=O)COc1ccc(Cl)cc1	XZTYGFHCIAKPGJ-UHFFFAOYSA-N, XZTYGFHCIAKPGJ-UHFFFAOYSA-N	Launched
mecysteine	analgesic agent		pulmonary	chest congestion	COC(=O)[C@@H](N)CS	MCYHPZGUONZRGO-VKHMYHEASA-N	Launched
medetomidine	adrenergic receptor agonist	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C	neurology/psychiatry	sedative	C[C@@H](c1cnc[nH]1)c1cccc(C)c1C |r|, C[C@@H](c1cnc[nH]1)c1cccc(C)c1C |r|, C[C@@H](c1cnc[nH]1)c1cccc(C)c1C |r|, C[C@@H](c1cnc[nH]1)c1cccc(C)c1C |r|	CUHVIMMYOGQXCV-LLVKDONJSA-N, CUHVIMMYOGQXCV-LLVKDONJSA-N, CUHVIMMYOGQXCV-LLVKDONJSA-N, CUHVIMMYOGQXCV-LLVKDONJSA-N	Launched
medica-16	ATP citrase lyase inhibitor	FFAR1			CC(C)(CCCCCCCCCCC(C)(C)CC(O)=O)CC(O)=O	HYSMCRNFENOHJH-UHFFFAOYSA-N	Phase 2
medorinone					Cc1nccc2[nH]c(=O)ccc12, Cc1nccc2[nH]c(=O)ccc12	OCCZJXAHSUCJSA-UHFFFAOYSA-N, OCCZJXAHSUCJSA-UHFFFAOYSA-N	Phase 1
medronic-acid	bone resorption inhibitor		radiology	skeletal imaging agent	OP(O)(=O)CP(O)(O)=O, OP(O)(=O)CP(O)(O)=O	MBKDYNNUVRNNRF-UHFFFAOYSA-N, MBKDYNNUVRNNRF-UHFFFAOYSA-N	Launched
medroxyprogesterone	progesterone receptor agonist	PGR	endocrinology	contraceptive	C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(C)=O)[C@@]3(C)CC[C@@H]2[C@@]2(C)CCC(=O)C=C12 |t:25|, C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(C)=O)[C@@]3(C)CC[C@@H]2[C@@]2(C)CCC(=O)C=C12 |t:25|, C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(C)=O)[C@@]3(C)CC[C@@H]2[C@@]2(C)CCC(=O)C=C12 |t:25|, C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(C)=O)[C@@]3(C)CC[C@@H]2[C@@]2(C)CCC(=O)C=C12 |t:25|, C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(C)=O)[C@@]3(C)CC[C@@H]2[C@@]2(C)CCC(=O)C=C12 |t:25|	FRQMUZJSZHZSGN-HBNHAYAOSA-N, FRQMUZJSZHZSGN-HBNHAYAOSA-N, FRQMUZJSZHZSGN-HBNHAYAOSA-N, FRQMUZJSZHZSGN-HBNHAYAOSA-N, FRQMUZJSZHZSGN-HBNHAYAOSA-N	Launched
medroxyprogesterone-acetate	progesterone receptor agonist	ESR1, PGR	endocrinology	contraceptive	C[C@H]1C[C@H]2[C@@H]3CC[C@](OC(C)=O)(C(C)=O)[C@@]3(C)CC[C@@H]2[C@@]2(C)CCC(=O)C=C12 |t:28|	PSGAAPLEWMOORI-PEINSRQWSA-N	Launched
medrysone	glucocorticoid receptor agonist	NR3C1	ophthalmology	conjunctivitis, episcleritis	C[C@H]1C[C@H]2[C@@H]3CC[C@H](C(C)=O)[C@@]3(C)C[C@H](O)[C@@H]2[C@@]2(C)CCC(=O)C=C12 |t:25|, C[C@H]1C[C@H]2[C@@H]3CC[C@H](C(C)=O)[C@@]3(C)C[C@H](O)[C@@H]2[C@@]2(C)CCC(=O)C=C12 |t:25|, C[C@H]1C[C@H]2[C@@H]3CC[C@H](C(C)=O)[C@@]3(C)C[C@H](O)[C@@H]2[C@@]2(C)CCC(=O)C=C12 |t:25|	GZENKSODFLBBHQ-ILSZZQPISA-N, GZENKSODFLBBHQ-ILSZZQPISA-N, GZENKSODFLBBHQ-ILSZZQPISA-N	Launched
mefenamic-acid	cyclooxygenase inhibitor	KCNQ1, PTGS1, PTGS2, TRPM3	endocrinology	primary dysmenorrhea (PD)	Cc1cccc(Nc2ccccc2C(O)=O)c1C, Cc1cccc(Nc2ccccc2C(O)=O)c1C, Cc1cccc(Nc2ccccc2C(O)=O)c1C	HYYBABOKPJLUIN-UHFFFAOYSA-N, HYYBABOKPJLUIN-UHFFFAOYSA-N, HYYBABOKPJLUIN-UHFFFAOYSA-N	Launched
mefexamide	psychoactive drug				CCN(CC)CCNC(=O)COc1ccc(OC)cc1, CCN(CC)CCNC(=O)COc1ccc(OC)cc1, CCN(CC)CCNC(=O)COc1ccc(OC)cc1	HUNIPYLVUPMFCZ-UHFFFAOYSA-N, HUNIPYLVUPMFCZ-UHFFFAOYSA-N, HUNIPYLVUPMFCZ-UHFFFAOYSA-N	Preclinical
mefloquine	adenosine receptor antagonist, hemoglobin antagonist		infectious disease	malaria	O[C@H]([C@H]1CCCCN1)c1cc(nc2c(cccc12)C(F)(F)F)C(F)(F)F	XEEQGYMUWCZPDN-DOMZBBRYSA-N	Launched
megestrol	progesterone receptor agonist		oncology	breast cancer	CC(=O)[C@@]1(O)CC[C@H]2[C@@H]3C=C(C)C4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C |t:9,12|	VXIMPSPISRVBPZ-NWUMPJBXSA-N	Launched
megestrol-acetate	progesterone receptor agonist	NR3C1, PGR	neurology/psychiatry, endocrinology	anorexia, cachexia	CC(=O)O[C@@]1(CC[C@H]2[C@@H]3C=C(C)C4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)=O |t:9,12|, CC(=O)O[C@@]1(CC[C@H]2[C@@H]3C=C(C)C4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)=O |t:9,12|, CC(=O)O[C@@]1(CC[C@H]2[C@@H]3C=C(C)C4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)=O |t:9,12|, CC(=O)O[C@@]1(CC[C@H]2[C@@H]3C=C(C)C4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)=O |t:9,12|, CC(=O)O[C@@]1(CC[C@H]2[C@@H]3C=C(C)C4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)=O |t:9,12|, CC(=O)O[C@@]1(CC[C@H]2[C@@H]3C=C(C)C4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)=O |t:9,12|	RQZAXGRLVPAYTJ-GQFGMJRRSA-N, RQZAXGRLVPAYTJ-GQFGMJRRSA-N, RQZAXGRLVPAYTJ-GQFGMJRRSA-N, RQZAXGRLVPAYTJ-GQFGMJRRSA-N, RQZAXGRLVPAYTJ-GQFGMJRRSA-N, RQZAXGRLVPAYTJ-GQFGMJRRSA-N	Launched
meglitinide	potassium channel blocker	CCR2			COc1ccc(Cl)cc1C(=O)NCCc1ccc(cc1)C(O)=O	SWLAMJPTOQZTAE-UHFFFAOYSA-N	Phase 2
meglumine	excipient				CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO, CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO, CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO, CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO	MBBZMMPHUWSWHV-BDVNFPICSA-N, MBBZMMPHUWSWHV-BDVNFPICSA-N, MBBZMMPHUWSWHV-BDVNFPICSA-N, MBBZMMPHUWSWHV-BDVNFPICSA-N	Launched
meglutol	HMGCR inhibitor	HMGCR			CC(O)(CC(O)=O)CC(O)=O	NPOAOTPXWNWTSH-UHFFFAOYSA-N	Launched
meisoindigo	STAT inhibitor	STAT3			CN1C(=O)\C(=C2\C(=O)Nc3ccccc23)c2ccccc12, CN1C(=O)\C(=C2\C(=O)Nc3ccccc23)c2ccccc12, CN1C(=O)\C(=C2\C(=O)Nc3ccccc23)c2ccccc12, CN1C(=O)\C(=C2\C(=O)Nc3ccccc23)c2ccccc12, CN1C(=O)\C(=C2\C(=O)Nc3ccccc23)c2ccccc12	QNOCRUSVMMAKSC-CCEZHUSRSA-N, QNOCRUSVMMAKSC-CCEZHUSRSA-N, QNOCRUSVMMAKSC-CCEZHUSRSA-N, QNOCRUSVMMAKSC-CCEZHUSRSA-N, QNOCRUSVMMAKSC-CCEZHUSRSA-N	Phase 3
MEK1-2-inhibitor	MEK inhibitor	MAP2K2			Nc1ccc(SC(=N)C(C#N)c2ccccc2C(F)(F)F)cc1, Nc1ccc(SC(=N)C(C#N)c2ccccc2C(F)(F)F)cc1	XQRVCODIGHFXKQ-UHFFFAOYSA-N, XQRVCODIGHFXKQ-UHFFFAOYSA-N	Preclinical
melanotan-ii	melanocortin receptor agonist				CCCC[C@H](NC(C)=O)C(=O)N[C@H]1CC(=O)NCCCC[C@H](NC(=O)[C@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@H](Cc2cnc[nH]2)NC1=O)C(N)=O	JDKLPDJLXHXHNV-VEUPWBLKSA-N	Launched
melatonin	melatonin receptor agonist, nitric oxide synthase inhibitor	ASMT, CALM1, CALR, EPX, ESR1, HTR2B, MPO, MTNR1A, MTNR1B, NQO2, RORB	neurology/psychiatry	sleep cycle support	COc1ccc2[nH]cc(CCNC(C)=O)c2c1, COc1ccc2[nH]cc(CCNC(C)=O)c2c1, COc1ccc2[nH]cc(CCNC(C)=O)c2c1, COc1ccc2[nH]cc(CCNC(C)=O)c2c1	DRLFMBDRBRZALE-UHFFFAOYSA-N, DRLFMBDRBRZALE-UHFFFAOYSA-N, DRLFMBDRBRZALE-UHFFFAOYSA-N, DRLFMBDRBRZALE-UHFFFAOYSA-N	Launched
meldonium	gamma butyrobetaine hydroxylase inhibitor	BBOX1	cardiology	coronary artery disease (CAD)	C[N+](C)(C)NCCC(O)=O, C[N+](C)(C)NCCC(O)=O	PVBQYTCFVWZSJK-UHFFFAOYSA-O, PVBQYTCFVWZSJK-UHFFFAOYSA-O	Launched
melengestrol-acetate	progesterone receptor agonist				CC(=O)O[C@]1(C(C)=O)C(=C)C[C@H]2[C@H]3C=C(C)C4=CC(=O)CC[C@]4(C)[C@@H]3CC[C@]12C |a:4,22,27,&1:11,&2:12,&3:24,t:13,16|	UDKABVSQKJNZBH-AKZSSJSASA-N	Preclinical
melevodopa	dopamine precursor, dopamine receptor agonist	DDC	neurology/psychiatry	Parkinson's Disease	COC(=O)[C@@H](N)Cc1ccc(O)c(O)c1, COC(=O)[C@@H](N)Cc1ccc(O)c(O)c1	XBBDACCLCFWBSI-ZETCQYMHSA-N, XBBDACCLCFWBSI-ZETCQYMHSA-N	Launched
meloxicam	cyclooxygenase inhibitor	PTGS1, PTGS2	rheumatology	osteoarthritis, rheumatoid arthritis	CN1C(C(=O)Nc2ncc(C)s2)=C(O)c2ccccc2S1(=O)=O |t:12|, CN1C(C(=O)Nc2ncc(C)s2)=C(O)c2ccccc2S1(=O)=O |t:12|, CN1C(C(=O)Nc2ncc(C)s2)=C(O)c2ccccc2S1(=O)=O |t:12|	ZRVUJXDFFKFLMG-UHFFFAOYSA-N, ZRVUJXDFFKFLMG-UHFFFAOYSA-N, ZRVUJXDFFKFLMG-UHFFFAOYSA-N	Launched
melperone	dopamine receptor antagonist, serotonin receptor antagonist	DRD2, HTR2A	neurology/psychiatry	psychosis	CC1CCN(CCCC(=O)c2ccc(F)cc2)CC1, CC1CCN(CCCC(=O)c2ccc(F)cc2)CC1, CC1CCN(CCCC(=O)c2ccc(F)cc2)CC1	DKMFBWQBDIGMHM-UHFFFAOYSA-N, DKMFBWQBDIGMHM-UHFFFAOYSA-N, DKMFBWQBDIGMHM-UHFFFAOYSA-N	Launched
melphalan	DNA alkylating agent, DNA inhibitor		hematologic malignancy	multiple myeloma	N[C@@H](Cc1ccc(cc1)N(CCCl)CCCl)C(O)=O, N[C@@H](Cc1ccc(cc1)N(CCCl)CCCl)C(O)=O, N[C@@H](Cc1ccc(cc1)N(CCCl)CCCl)C(O)=O, N[C@@H](Cc1ccc(cc1)N(CCCl)CCCl)C(O)=O	SGDBTWWWUNNDEQ-LBPRGKRZSA-N, SGDBTWWWUNNDEQ-LBPRGKRZSA-N, SGDBTWWWUNNDEQ-LBPRGKRZSA-N, SGDBTWWWUNNDEQ-LBPRGKRZSA-N	Launched
melphalan-n-oxide	hypoxia inducible factor inhibitor	HIF1A			N[C@@H](Cc1ccc(cc1)[N+]([O-])(CCCl)CCCl)C(O)=O	GSKQMLGAUOTSKT-LBPRGKRZSA-N	Phase 1
meluadrine					CC(C)(C)NC[C@@H](O)c1ccc(O)cc1Cl |&1:6,r|	LIXBJWRFCNRAPA-LLVKDONJSA-N	Preclinical
memantine	glutamate receptor antagonist		neurology/psychiatry	Alzheimer's disease, senile dementia	C[C@@]12C[C@H]3C[C@@](C)(C1)C[C@](N)(C3)C2	BUGYDGFZZOZRHP-CDECOKDKSA-N	Launched
menadione	mitochondrial DNA polymerase inhibitor, phosphatase inhibitor	AOX1, BGLAP, F10, F2, F7, F9, GGCX, NQO1, NQO2, PROC, PROS1, PROZ, VKORC1, VKORC1L1	gastroenterology, neurology/psychiatry, dermatology, rheumatology	ulcerative colitis, diarrhea, headache, varicose veins, rheumatoid arthritis	CC1=CC(=O)c2ccccc2C1=O |t:1|, CC1=CC(=O)c2ccccc2C1=O |t:1|, CC1=CC(=O)c2ccccc2C1=O |t:1|, CC1=CC(=O)c2ccccc2C1=O |t:1|, CC1=CC(=O)c2ccccc2C1=O |t:1|, CC1=CC(=O)c2ccccc2C1=O |t:1|, CC1=CC(=O)c2ccccc2C1=O |t:1|	MJVAVZPDRWSRRC-UHFFFAOYSA-N, MJVAVZPDRWSRRC-UHFFFAOYSA-N, MJVAVZPDRWSRRC-UHFFFAOYSA-N, MJVAVZPDRWSRRC-UHFFFAOYSA-N, MJVAVZPDRWSRRC-UHFFFAOYSA-N, MJVAVZPDRWSRRC-UHFFFAOYSA-N, MJVAVZPDRWSRRC-UHFFFAOYSA-N	Launched
menadione-bisulfite	vitamin K	GGCX, VKORC1, VKORC1L1			C[C@]1(CC(=O)c2ccccc2C1=O)S(O)(=O)=O |&1:1|, C[C@]1(CC(=O)c2ccccc2C1=O)S(O)(=O)=O |&1:1|	WIXFIQKTHUVFDI-LLVKDONJSA-N, WIXFIQKTHUVFDI-LLVKDONJSA-N	Phase 2
menatetrenone	bone resorption inhibitor		orthopedics	osteoporosis	CC(C)=CCC\C(C)=C\CC\C(C)=C\CC\C(C)=C\CC1=C(C)C(=O)c2ccccc2C1=O |c:20|, CC(C)=CCC\C(C)=C\CC\C(C)=C\CC\C(C)=C\CC1=C(C)C(=O)c2ccccc2C1=O |c:20|	DKHGMERMDICWDU-GHDNBGIDSA-N, DKHGMERMDICWDU-GHDNBGIDSA-N	Launched
menbutone			gastroenterology	bile stimulation	COc1ccc(C(=O)CCC(O)=O)c2ccccc12, COc1ccc(C(=O)CCC(O)=O)c2ccccc12	FHGJSJFIQNQBCK-UHFFFAOYSA-N, FHGJSJFIQNQBCK-UHFFFAOYSA-N	Launched
mepacrine	cytokine production inhibitor, NFkB pathway inhibitor, TP53 activator	PLA2G1B	infectious disease	giardiasis	CCN(CC)CCC[C@@H](C)Nc1c2ccc(Cl)cc2nc2ccc(OC)cc12 |&1:8|, CCN(CC)CCC[C@@H](C)Nc1c2ccc(Cl)cc2nc2ccc(OC)cc12 |&1:8|, CCN(CC)CCC[C@@H](C)Nc1c2ccc(Cl)cc2nc2ccc(OC)cc12 |&1:8|, CCN(CC)CCC[C@@H](C)Nc1c2ccc(Cl)cc2nc2ccc(OC)cc12 |&1:8|, CCN(CC)CCC[C@@H](C)Nc1c2ccc(Cl)cc2nc2ccc(OC)cc12 |&1:8|, CCN(CC)CCC[C@@H](C)Nc1c2ccc(Cl)cc2nc2ccc(OC)cc12 |&1:8|	GPKJTRJOBQGKQK-MRXNPFEDSA-N, GPKJTRJOBQGKQK-MRXNPFEDSA-N, GPKJTRJOBQGKQK-MRXNPFEDSA-N, GPKJTRJOBQGKQK-MRXNPFEDSA-N, GPKJTRJOBQGKQK-MRXNPFEDSA-N, GPKJTRJOBQGKQK-MRXNPFEDSA-N	Launched
meparfylon					CCC(C)(O)C#C |&1:2|	QXLPXWSKPNOQLE-UHFFFAOYSA-N	Preclinical
mepazine	MALT1 inhibitor (JH)	MALT1			CN1CCC[C@@H](CN2c3ccccc3Sc3ccccc23)C1 |&1:5,r|, CN1CCC[C@@H](CN2c3ccccc3Sc3ccccc23)C1 |&1:5,r|, CN1CCC[C@@H](CN2c3ccccc3Sc3ccccc23)C1 |&1:5,r|	CBHCDHNUZWWAPP-OAHLLOKOSA-N, CBHCDHNUZWWAPP-OAHLLOKOSA-N, CBHCDHNUZWWAPP-OAHLLOKOSA-N	Phase 2
mepenzolate	acetylcholine receptor antagonist		gastroenterology	peptic ulcer disease (PUD)	C[N+]1(C)CCC[C@@H](C1)OC(=O)C(O)(c1ccccc1)c1ccccc1 |&1:6|, C[N+]1(C)CCC[C@@H](C1)OC(=O)C(O)(c1ccccc1)c1ccccc1 |&1:6|, C[N+]1(C)CCC[C@@H](C1)OC(=O)C(O)(c1ccccc1)c1ccccc1 |&1:6|	GKNPSSNBBWDAGH-IBGZPJMESA-N, GKNPSSNBBWDAGH-IBGZPJMESA-N, GKNPSSNBBWDAGH-IBGZPJMESA-N	Launched
mephenesin	muscle relaxant		neurology/psychiatry	muscle relaxant	Cc1ccccc1OC[C@@H](O)CO |&1:9,r|, Cc1ccccc1OC[C@@H](O)CO |&1:9,r|	JWDYCNIAQWPBHD-VIFPVBQESA-N, JWDYCNIAQWPBHD-VIFPVBQESA-N	Launched
mephentermine	adrenergic receptor agonist	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3	cardiology	hypotension	CNC(C)(C)Cc1ccccc1, CNC(C)(C)Cc1ccccc1, CNC(C)(C)Cc1ccccc1	RXQCGGRTAILOIN-UHFFFAOYSA-N, RXQCGGRTAILOIN-UHFFFAOYSA-N, RXQCGGRTAILOIN-UHFFFAOYSA-N	Launched
mephenytoin	hydantoin antiepileptic	SCN5A	neurology/psychiatry	seizures	CC[C@]1(NC(=O)N(C)C1=O)c1ccccc1 |&1:2,r|, CC[C@]1(NC(=O)N(C)C1=O)c1ccccc1 |&1:2,r|, CC[C@]1(NC(=O)N(C)C1=O)c1ccccc1 |&1:2,r|, CC[C@]1(NC(=O)N(C)C1=O)c1ccccc1 |&1:2,r|	GMHKMTDVRCWUDX-LBPRGKRZSA-N, GMHKMTDVRCWUDX-LBPRGKRZSA-N, GMHKMTDVRCWUDX-LBPRGKRZSA-N, GMHKMTDVRCWUDX-LBPRGKRZSA-N	Launched
mepiroxol					OCc1ccc[n+]([O-])c1, OCc1ccc[n+]([O-])c1, OCc1ccc[n+]([O-])c1	LQYJAVWWKTWWKN-UHFFFAOYSA-N, LQYJAVWWKTWWKN-UHFFFAOYSA-N, LQYJAVWWKTWWKN-UHFFFAOYSA-N	Preclinical
mepivacaine	potassium channel blocker, sodium channel blocker		neurology/psychiatry	local anesthetic	CN1CCCC[C@@H]1C(=O)Nc1c(C)cccc1C |&1:6|, CN1CCCC[C@@H]1C(=O)Nc1c(C)cccc1C |&1:6|, CN1CCCC[C@@H]1C(=O)Nc1c(C)cccc1C |&1:6|, CN1CCCC[C@@H]1C(=O)Nc1c(C)cccc1C |&1:6|	INWLQCZOYSRPNW-CYBMUJFWSA-N, INWLQCZOYSRPNW-CYBMUJFWSA-N, INWLQCZOYSRPNW-CYBMUJFWSA-N, INWLQCZOYSRPNW-CYBMUJFWSA-N	Launched
meprednisone		NR3C1			C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3C(=O)C[C@]2(C)[C@@]1(O)C(=O)CO |c:11,t:7|, C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3C(=O)C[C@]2(C)[C@@]1(O)C(=O)CO |c:11,t:7|	PIDANAQULIKBQS-RNUIGHNZSA-N, PIDANAQULIKBQS-RNUIGHNZSA-N	Launched
meprylcaine	local anesthetic				CCCNC(C)(C)COC(=O)c1ccccc1, CCCNC(C)(C)COC(=O)c1ccccc1	VXJABHHJLXLNMP-UHFFFAOYSA-N, VXJABHHJLXLNMP-UHFFFAOYSA-N	Preclinical
meptazinol	opioid receptor agonist	BCHE	neurology/psychiatry	pain relief	CC[C@]1(CCCCN(C)C1)c1cccc(O)c1 |&1:2|, CC[C@]1(CCCCN(C)C1)c1cccc(O)c1 |&1:2|, CC[C@]1(CCCCN(C)C1)c1cccc(O)c1 |&1:2|, CC[C@]1(CCCCN(C)C1)c1cccc(O)c1 |&1:2|	JLICHNCFTLFZJN-OAHLLOKOSA-N, JLICHNCFTLFZJN-OAHLLOKOSA-N, JLICHNCFTLFZJN-OAHLLOKOSA-N, JLICHNCFTLFZJN-OAHLLOKOSA-N	Launched
mepyramine	histamine receptor antagonist	HRH1	otolaryngology, obstetrics/gynecology	common cold, menstrual pain	COc1ccc(CN(CCN(C)C)c2ccccn2)cc1, COc1ccc(CN(CCN(C)C)c2ccccn2)cc1, COc1ccc(CN(CCN(C)C)c2ccccn2)cc1, COc1ccc(CN(CCN(C)C)c2ccccn2)cc1, COc1ccc(CN(CCN(C)C)c2ccccn2)cc1, COc1ccc(CN(CCN(C)C)c2ccccn2)cc1	YECBIJXISLIIDS-UHFFFAOYSA-N, YECBIJXISLIIDS-UHFFFAOYSA-N, YECBIJXISLIIDS-UHFFFAOYSA-N, YECBIJXISLIIDS-UHFFFAOYSA-N, YECBIJXISLIIDS-UHFFFAOYSA-N, YECBIJXISLIIDS-UHFFFAOYSA-N	Launched
mequinol		TYR	dermatology	skin depigmentation	COc1ccc(O)cc1, COc1ccc(O)cc1, COc1ccc(O)cc1	NWVVVBRKAWDGAB-UHFFFAOYSA-N, NWVVVBRKAWDGAB-UHFFFAOYSA-N, NWVVVBRKAWDGAB-UHFFFAOYSA-N	Launched
merbarone	topoisomerase inhibitor	TOP2A			Oc1[nH]c(=S)[nH]c(=O)c1C(=O)Nc1ccccc1, Oc1[nH]c(=S)[nH]c(=O)c1C(=O)Nc1ccccc1	GFYRZTLCYQQVHZ-UHFFFAOYSA-N, GFYRZTLCYQQVHZ-UHFFFAOYSA-N	Phase 2
merbromin	antiseptic		infectious disease	first-aid antiseptic	O[Hg]c1c(O)c(Br)cc2c(-c3ccccc3C(O)=O)c3cc(Br)c(=O)cc3oc12	OHCFGBLQZMYRTR-UHFFFAOYSA-M	Launched
mercaptopurine	immunosuppressant, protein synthesis inhibitor, purine antagonist	HPRT1, IMPDH1, IMPDH2, PPAT	hematologic malignancy	acute lymphoblastic leukemia (ALL)	S=c1nc[nH]c2nc[nH]c12, S=c1nc[nH]c2nc[nH]c12, S=c1nc[nH]c2nc[nH]c12, S=c1nc[nH]c2nc[nH]c12	GLVAUDGFNGKCSF-UHFFFAOYSA-N, GLVAUDGFNGKCSF-UHFFFAOYSA-N, GLVAUDGFNGKCSF-UHFFFAOYSA-N, GLVAUDGFNGKCSF-UHFFFAOYSA-N	Launched
mercaptosuccinic-acid					OC(=O)C[C@@H](S)C(O)=O |&1:4,r|, OC(=O)C[C@@H](S)C(O)=O |&1:4,r|	NJRXVEJTAYWCQJ-UWTATZPHSA-N, NJRXVEJTAYWCQJ-UWTATZPHSA-N	Launched
Merck60	HDAC inhibitor	HDAC1, HDAC2					Preclinical
mericitabine	HCV inhibitor				CC(C)C(=O)OC[C@H]1O[C@@H](n2ccc(N)nc2=O)[C@](C)(F)[C@@H]1OC(=O)C(C)C, CC(C)C(=O)OC[C@H]1O[C@@H](n2ccc(N)nc2=O)[C@](C)(F)[C@@H]1OC(=O)C(C)C, CC(C)C(=O)OC[C@H]1O[C@@H](n2ccc(N)nc2=O)[C@](C)(F)[C@@H]1OC(=O)C(C)C, CC(C)C(=O)OC[C@H]1O[C@@H](n2ccc(N)nc2=O)[C@](C)(F)[C@@H]1OC(=O)C(C)C, CC(C)C(=O)OC[C@H]1O[C@@H](n2ccc(N)nc2=O)[C@](C)(F)[C@@H]1OC(=O)C(C)C, CC(C)C(=O)OC[C@H]1O[C@@H](n2ccc(N)nc2=O)[C@](C)(F)[C@@H]1OC(=O)C(C)C	MLESJYFEMSJZLZ-MAAOGQSESA-N, MLESJYFEMSJZLZ-MAAOGQSESA-N, MLESJYFEMSJZLZ-MAAOGQSESA-N, MLESJYFEMSJZLZ-MAAOGQSESA-N, MLESJYFEMSJZLZ-MAAOGQSESA-N, MLESJYFEMSJZLZ-MAAOGQSESA-N	Phase 2
merimepodib	inosine monophosphate dehydrogenase inhibitor	IMPDH1			COc1cc(NC(=O)Nc2cccc(CNC(=O)O[C@H]3CCOC3)c2)ccc1-c1cnco1, COc1cc(NC(=O)Nc2cccc(CNC(=O)O[C@H]3CCOC3)c2)ccc1-c1cnco1, COc1cc(NC(=O)Nc2cccc(CNC(=O)O[C@H]3CCOC3)c2)ccc1-c1cnco1, COc1cc(NC(=O)Nc2cccc(CNC(=O)O[C@H]3CCOC3)c2)ccc1-c1cnco1, COc1cc(NC(=O)Nc2cccc(CNC(=O)O[C@H]3CCOC3)c2)ccc1-c1cnco1, COc1cc(NC(=O)Nc2cccc(CNC(=O)O[C@H]3CCOC3)c2)ccc1-c1cnco1, COc1cc(NC(=O)Nc2cccc(CNC(=O)O[C@H]3CCOC3)c2)ccc1-c1cnco1	JBPUGFODGPKTDW-SFHVURJKSA-N, JBPUGFODGPKTDW-SFHVURJKSA-N, JBPUGFODGPKTDW-SFHVURJKSA-N, JBPUGFODGPKTDW-SFHVURJKSA-N, JBPUGFODGPKTDW-SFHVURJKSA-N, JBPUGFODGPKTDW-SFHVURJKSA-N, JBPUGFODGPKTDW-SFHVURJKSA-N	Phase 2
meropenem	bacterial cell wall synthesis inhibitor		infectious disease	skin infections, intra-abdominal infections, meningitis	C[C@@H](O)[C@@H]1[C@H]2[C@@H](C)C(S[C@@H]3CN[C@@H](C3)C(=O)N(C)C)=C(N2C1=O)C(O)=O |c:19|, C[C@@H](O)[C@@H]1[C@H]2[C@@H](C)C(S[C@@H]3CN[C@@H](C3)C(=O)N(C)C)=C(N2C1=O)C(O)=O |c:19|, C[C@@H](O)[C@@H]1[C@H]2[C@@H](C)C(S[C@@H]3CN[C@@H](C3)C(=O)N(C)C)=C(N2C1=O)C(O)=O |c:19|, C[C@@H](O)[C@@H]1[C@H]2[C@@H](C)C(S[C@@H]3CN[C@@H](C3)C(=O)N(C)C)=C(N2C1=O)C(O)=O |c:19|	DMJNNHOOLUXYBV-PQTSNVLCSA-N, DMJNNHOOLUXYBV-PQTSNVLCSA-N, DMJNNHOOLUXYBV-PQTSNVLCSA-N, DMJNNHOOLUXYBV-PQTSNVLCSA-N	Launched
mertansine	microtubule inhibitor				[H][C@@]12C[C@@](O)(NC(=O)O1)[C@]([H])(OC)\C=C\C=C(C)\Cc1cc(OC)c(Cl)c(c1)N(C)C(=O)C[C@]([H])(OC(=O)[C@H](C)N(C)C(=O)CCS)[C@]1(C)O[C@H]1[C@@H]2C |c:16,t:14|	ANZJBCHSOXCCRQ-UTOUECMYSA-N	Phase 2
mesalazine	cyclooxygenase inhibitor, lipoxygenase inhibitor, prostanoid receptor antagonist	ALOX5, CHUK, IKBKB, MPO, PPARG, PTGS1, PTGS2	gastroenterology	ulcerative colitis, inflammatory bowel disease	Nc1ccc(O)c(c1)C(O)=O, Nc1ccc(O)c(c1)C(O)=O, Nc1ccc(O)c(c1)C(O)=O, Nc1ccc(O)c(c1)C(O)=O, Nc1ccc(O)c(c1)C(O)=O	KBOPZPXVLCULAV-UHFFFAOYSA-N, KBOPZPXVLCULAV-UHFFFAOYSA-N, KBOPZPXVLCULAV-UHFFFAOYSA-N, KBOPZPXVLCULAV-UHFFFAOYSA-N, KBOPZPXVLCULAV-UHFFFAOYSA-N	Launched
mesna	antioxidant		urology	hemorrhagic cystitis	OS(=O)(=O)CCS, OS(=O)(=O)CCS, OS(=O)(=O)CCS	ZNEWHQLOPFWXOF-UHFFFAOYSA-N, ZNEWHQLOPFWXOF-UHFFFAOYSA-N, ZNEWHQLOPFWXOF-UHFFFAOYSA-N	Launched
mesoridazine	dopamine receptor antagonist	DRD2, HTR2A	neurology/psychiatry	schizophrenia	CN1CCCC[C@@H]1CCN1c2ccccc2Sc2ccc(cc12)[S@@](C)=O |a:23,&1:6|, CN1CCCC[C@@H]1CCN1c2ccccc2Sc2ccc(cc12)[S@@](C)=O |a:23,&1:6|, CN1CCCC[C@@H]1CCN1c2ccccc2Sc2ccc(cc12)[S@@](C)=O |a:23,&1:6|, CN1CCCC[C@@H]1CCN1c2ccccc2Sc2ccc(cc12)[S@@](C)=O |a:23,&1:6|, CN1CCCC[C@@H]1CCN1c2ccccc2Sc2ccc(cc12)[S@@](C)=O |a:23,&1:6|, CN1CCCC[C@@H]1CCN1c2ccccc2Sc2ccc(cc12)[S@@](C)=O |a:23,&1:6|	SLVMESMUVMCQIY-AKJBCIBTSA-N, SLVMESMUVMCQIY-AKJBCIBTSA-N, SLVMESMUVMCQIY-AKJBCIBTSA-N, SLVMESMUVMCQIY-AKJBCIBTSA-N, SLVMESMUVMCQIY-AKJBCIBTSA-N, SLVMESMUVMCQIY-AKJBCIBTSA-N	Launched
mestinon	cholinesterase inhibitor	ACHE, BCHE	neurology/psychiatry	myasthenia gravis	CN(C)C(=O)Oc1ccc[n+](C)c1, CN(C)C(=O)Oc1ccc[n+](C)c1, CN(C)C(=O)Oc1ccc[n+](C)c1, CN(C)C(=O)Oc1ccc[n+](C)c1, CN(C)C(=O)Oc1ccc[n+](C)c1	RVOLLAQWKVFTGE-UHFFFAOYSA-N, RVOLLAQWKVFTGE-UHFFFAOYSA-N, RVOLLAQWKVFTGE-UHFFFAOYSA-N, RVOLLAQWKVFTGE-UHFFFAOYSA-N, RVOLLAQWKVFTGE-UHFFFAOYSA-N	Launched
mestranol	estrogen receptor agonist	ESR1	endocrinology	contraceptive	COc1ccc2[C@H]3CC[C@@]4(C)[C@@H](CC[C@@]4(O)C#C)[C@@H]3CCc2c1, COc1ccc2[C@H]3CC[C@@]4(C)[C@@H](CC[C@@]4(O)C#C)[C@@H]3CCc2c1, COc1ccc2[C@H]3CC[C@@]4(C)[C@@H](CC[C@@]4(O)C#C)[C@@H]3CCc2c1, COc1ccc2[C@H]3CC[C@@]4(C)[C@@H](CC[C@@]4(O)C#C)[C@@H]3CCc2c1	IMSSROKUHAOUJS-MJCUULBUSA-N, IMSSROKUHAOUJS-MJCUULBUSA-N, IMSSROKUHAOUJS-MJCUULBUSA-N, IMSSROKUHAOUJS-MJCUULBUSA-N	Launched
mesulergine	dopamine receptor agonist	HTR2A, HTR2B, HTR2C, HTR3A, HTR3B, HTR6, HTR7			CN(C)S(=O)(=O)N[C@H]1C[C@H]2[C@@H](Cc3cn(C)c4cccc2c34)N(C)C1, CN(C)S(=O)(=O)N[C@H]1C[C@H]2[C@@H](Cc3cn(C)c4cccc2c34)N(C)C1	JLVHTNZNKOSCNB-YSVLISHTSA-N, JLVHTNZNKOSCNB-YSVLISHTSA-N	Phase 2
meta-cresyl-acetate					CC(=O)Oc1cccc(C)c1	OTGAHJPFNKQGAE-UHFFFAOYSA-N	Preclinical
metacetamol	analgesic agent				CC(=O)Nc1cccc(O)c1	QLNWXBAGRTUKKI-UHFFFAOYSA-N	Preclinical
metacresol		INS			Cc1cccc(O)c1, Cc1cccc(O)c1, Cc1cccc(O)c1	RLSSMJSEOOYNOY-UHFFFAOYSA-N, RLSSMJSEOOYNOY-UHFFFAOYSA-N, RLSSMJSEOOYNOY-UHFFFAOYSA-N	Launched
metafolin					CN1[C@@H](CNc2ccc(cc2)C(=O)N[C@@H](CCC(O)=O)C(O)=O)CNc2[nH]c(N)nc(=O)c12, CN1[C@@H](CNc2ccc(cc2)C(=O)N[C@@H](CCC(O)=O)C(O)=O)CNc2[nH]c(N)nc(=O)c12, CN1[C@@H](CNc2ccc(cc2)C(=O)N[C@@H](CCC(O)=O)C(O)=O)CNc2[nH]c(N)nc(=O)c12	ZNOVTXRBGFNYRX-STQMWFEESA-N, ZNOVTXRBGFNYRX-STQMWFEESA-N, ZNOVTXRBGFNYRX-STQMWFEESA-N	Launched
metamizole	cyclooxygenase inhibitor, opioid receptor agonist	PTGS1			CN(CS(O)(=O)=O)c1c(C)n(C)n(-c2ccccc2)c1=O	LVWZTYCIRDMTEY-UHFFFAOYSA-N	Withdrawn
metaphit	phencyclidine receptor acylator				S=C=Nc1cccc(c1)C1(CCCCC1)N1CCCCC1, S=C=Nc1cccc(c1)C1(CCCCC1)N1CCCCC1	FGSGBQAQSPSRJK-UHFFFAOYSA-N, FGSGBQAQSPSRJK-UHFFFAOYSA-N	Preclinical
metaproterenol	adrenergic receptor agonist	ADRB2	pulmonary	bronchospasm, asthma, bronchitis, emphysema	CC(C)NC[C@@H](O)c1cc(O)cc(O)c1 |&1:5|, CC(C)NC[C@@H](O)c1cc(O)cc(O)c1 |&1:5|, CC(C)NC[C@@H](O)c1cc(O)cc(O)c1 |&1:5|, CC(C)NC[C@@H](O)c1cc(O)cc(O)c1 |&1:5|	LMOINURANNBYCM-LLVKDONJSA-N, LMOINURANNBYCM-LLVKDONJSA-N, LMOINURANNBYCM-LLVKDONJSA-N, LMOINURANNBYCM-LLVKDONJSA-N	Launched
metaraminol	adrenergic receptor agonist	ADRA1A	cardiology	hypotension	C[C@H](N)[C@H](O)c1cccc(O)c1, C[C@H](N)[C@H](O)c1cccc(O)c1, C[C@H](N)[C@H](O)c1cccc(O)c1, C[C@H](N)[C@H](O)c1cccc(O)c1, C[C@H](N)[C@H](O)c1cccc(O)c1	WXFIGDLSSYIKKV-RCOVLWMOSA-N, WXFIGDLSSYIKKV-RCOVLWMOSA-N, WXFIGDLSSYIKKV-RCOVLWMOSA-N, WXFIGDLSSYIKKV-RCOVLWMOSA-N, WXFIGDLSSYIKKV-RCOVLWMOSA-N	Launched
metatinib	Bcr-Abl kinase inhibitor	ABL1, BCR			Nc1nccc(Oc2ccc(NC(=O)c3c[nH]cc(-c4ccc(F)cc4)c3=O)cc2F)c1Cl, Nc1nccc(Oc2ccc(NC(=O)c3c[nH]cc(-c4ccc(F)cc4)c3=O)cc2F)c1Cl, Nc1nccc(Oc2ccc(NC(=O)c3c[nH]cc(-c4ccc(F)cc4)c3=O)cc2F)c1Cl, Nc1nccc(Oc2ccc(NC(=O)c3c[nH]cc(-c4ccc(F)cc4)c3=O)cc2F)c1Cl	PDYXPCKITKHFOZ-UHFFFAOYSA-N, PDYXPCKITKHFOZ-UHFFFAOYSA-N, PDYXPCKITKHFOZ-UHFFFAOYSA-N, PDYXPCKITKHFOZ-UHFFFAOYSA-N	Phase 1
metaxalone	muscle relaxant		neurology/psychiatry	muscle pain	Cc1cc(C)cc(OC[C@H]2CNC(=O)O2)c1 |&1:9,r|	IMWZZHHPURKASS-LLVKDONJSA-N	Launched
metazosin	adrenergic receptor antagonist	ADRA1A			CO[C@@H](C)C(=O)N1CCN(CC1)c1nc(N)c2cc(OC)c(OC)cc2n1 |&1:2,r|	YEOTYALSMRNXLJ-NSHDSACASA-N	Phase 2
metenkephalin	immunostimulant	OPRD1			CSCC[C@@H](NC(=O)[C@@H](Cc1ccccc1)NC(=O)CNC(=O)CNC(=O)[C@@H](N)Cc1ccc(O)cc1)C(O)=O |&1:4,&2:8,&3:27,r|, CSCC[C@@H](NC(=O)[C@@H](Cc1ccccc1)NC(=O)CNC(=O)CNC(=O)[C@@H](N)Cc1ccc(O)cc1)C(O)=O |&1:4,&2:8,&3:27,r|	YFGBQHOOROIVKG-BHDDXSALSA-N, YFGBQHOOROIVKG-BHDDXSALSA-N	Phase 2
metergoline	dopamine receptor agonist, serotonin receptor antagonist	HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2B, HTR2C, HTR5A, HTR6, HTR7	neurology/psychiatry, endocrinology	seasonal affective disorder, anxiety, hyperprolactinemia	CN1C[C@H](CNC(=O)OCc2ccccc2)C[C@H]2[C@H]1Cc1cn(C)c3cccc2c13, CN1C[C@H](CNC(=O)OCc2ccccc2)C[C@H]2[C@H]1Cc1cn(C)c3cccc2c13, CN1C[C@H](CNC(=O)OCc2ccccc2)C[C@H]2[C@H]1Cc1cn(C)c3cccc2c13, CN1C[C@H](CNC(=O)OCc2ccccc2)C[C@H]2[C@H]1Cc1cn(C)c3cccc2c13	WZHJKEUHNJHDLS-QTGUNEKASA-N, WZHJKEUHNJHDLS-QTGUNEKASA-N, WZHJKEUHNJHDLS-QTGUNEKASA-N, WZHJKEUHNJHDLS-QTGUNEKASA-N	Launched
metformin	insulin sensitizer	ACACB, PRKAB1	endocrinology	diabetes mellitus	CN(C)C(=N)N=C(N)N, CN(C)C(=N)N=C(N)N, CN(C)C(=N)N=C(N)N, CN(C)C(=N)N=C(N)N, CN(C)C(=N)N=C(N)N, CN(C)C(=N)N=C(N)N	XZWYZXLIPXDOLR-UHFFFAOYSA-N, XZWYZXLIPXDOLR-UHFFFAOYSA-N, XZWYZXLIPXDOLR-UHFFFAOYSA-N, XZWYZXLIPXDOLR-UHFFFAOYSA-N, XZWYZXLIPXDOLR-UHFFFAOYSA-N, XZWYZXLIPXDOLR-UHFFFAOYSA-N	Launched
methacholine	acetylcholine receptor agonist	CHRM2, CHRM4	pulmonary	bronchial hyperresponsiveness diagnostic	C[C@@H](C[N+](C)(C)C)OC(C)=O |&1:1|, C[C@@H](C[N+](C)(C)C)OC(C)=O |&1:1|, C[C@@H](C[N+](C)(C)C)OC(C)=O |&1:1|	NZWOPGCLSHLLPA-ZETCQYMHSA-N, NZWOPGCLSHLLPA-ZETCQYMHSA-N, NZWOPGCLSHLLPA-ZETCQYMHSA-N	Launched
methacycline	protein synthesis inhibitor		pulmonary	bronchitis	[H][C@]12[C@H](O)[C@@]3([H])[C@H](N(C)C)C(=O)[C@H](C(N)=O)C(=O)[C@@]3(O)C(=O)[C@H]1C(=O)c1c(O)cccc1C2=C |&1:22,&2:12|	QNJKSUYWBCNWFI-IKHBEOKZSA-N	Preclinical
methanesulfonyl-fluoride	acetylcholinesterase inhibitor	ACHE			CS(F)(=O)=O, CS(F)(=O)=O	KNWQLFOXPQZGPX-UHFFFAOYSA-N, KNWQLFOXPQZGPX-UHFFFAOYSA-N	Phase 2
methantheline	acetylcholine receptor antagonist	CHRM1, HRH2	gastroenterology, neurology/psychiatry, urology	peptic ulcer disease (PUD), irritable bowel syndrome, pancreatitis, dyskinesia, neurogenic bladder	CC[N+](C)(CC)CCOC(=O)C1c2ccccc2Oc2ccccc12, CC[N+](C)(CC)CCOC(=O)C1c2ccccc2Oc2ccccc12	GZHFODJQISUKAY-UHFFFAOYSA-N, GZHFODJQISUKAY-UHFFFAOYSA-N	Launched
methapyrilene	histamine receptor antagonist	HRH1			CN(C)CCN(Cc1cccs1)c1ccccn1, CN(C)CCN(Cc1cccs1)c1ccccn1	HNJJXZKZRAWDPF-UHFFFAOYSA-N, HNJJXZKZRAWDPF-UHFFFAOYSA-N	Withdrawn
metharbital	GABA receptor modulator	CHRNA4, CHRNA7, GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, GRIA2, GRIK2	neurology/psychiatry	epilepsy	CCC1(CC)C(=O)NC(=O)N(C)C1=O, CCC1(CC)C(=O)NC(=O)N(C)C1=O, CCC1(CC)C(=O)NC(=O)N(C)C1=O, CCC1(CC)C(=O)NC(=O)N(C)C1=O	FWJKNZONDWOGMI-UHFFFAOYSA-N, FWJKNZONDWOGMI-UHFFFAOYSA-N, FWJKNZONDWOGMI-UHFFFAOYSA-N, FWJKNZONDWOGMI-UHFFFAOYSA-N	Launched
methazolamide	carbonic anhydrase inhibitor	CA1, CA12, CA14, CA2, CA4, CA7	ophthalmology	glaucoma, intraocular pressure	CC(=O)N=c1sc(nn1C)S(N)(=O)=O	FLOSMHQXBMRNHR-UHFFFAOYSA-N	Launched
methenamine	bacterial DNA inhibitor		infectious disease	urinary tract infections	C1N2CN3CN1CN(C2)C3, C1N2CN3CN1CN(C2)C3	VKYKSIONXSXAKP-UHFFFAOYSA-N, VKYKSIONXSXAKP-UHFFFAOYSA-N	Launched
methiazole	anthelmintic agent				COC(=O)Nc1nc2ccc(SC(C)C)cc2[nH]1, COC(=O)Nc1nc2ccc(SC(C)C)cc2[nH]1	SXJIZQPZESTWLD-UHFFFAOYSA-N, SXJIZQPZESTWLD-UHFFFAOYSA-N	Preclinical
methicillin	bacterial cell wall synthesis inhibitor		infectious disease	gram-negative bacterial infections, gram-positive bacterial infections	COc1cccc(OC)c1C(=O)N[C@H]1[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O, COc1cccc(OC)c1C(=O)N[C@H]1[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O	RJQXTJLFIWVMTO-TYNCELHUSA-N, RJQXTJLFIWVMTO-TYNCELHUSA-N	Launched
methimazole	antithyroid agent	TPO	endocrinology	hyperthyroidism	Cn1cc[nH]c1=S, Cn1cc[nH]c1=S, Cn1cc[nH]c1=S	PMRYVIKBURPHAH-UHFFFAOYSA-N, PMRYVIKBURPHAH-UHFFFAOYSA-N, PMRYVIKBURPHAH-UHFFFAOYSA-N	Launched
methionine		METAP2			CSCC[C@@H](N)C(O)=O |&1:4,r|	FFEARJCKVFRZRR-SCSAIBSYSA-N	Launched
methiopril	angiotensin converting enzyme inhibitor	ACE			C[C@@H]1CCC[C@@H](N1C(=O)CCSC(C)=O)C(O)=O |&1:1,5,r|	JHFOAISYWJRTIM-PSASIEDQSA-N	Phase 2
methocarbamol	muscle relaxant	CA1	neurology/psychiatry	muscle relaxant	COc1ccccc1OC[C@@H](O)COC(N)=O |&1:10,r|, COc1ccccc1OC[C@@H](O)COC(N)=O |&1:10,r|, COc1ccccc1OC[C@@H](O)COC(N)=O |&1:10,r|, COc1ccccc1OC[C@@H](O)COC(N)=O |&1:10,r|	GNXFOGHNGIVQEH-MRVPVSSYSA-N, GNXFOGHNGIVQEH-MRVPVSSYSA-N, GNXFOGHNGIVQEH-MRVPVSSYSA-N, GNXFOGHNGIVQEH-MRVPVSSYSA-N	Launched
methoprene-(s)					COC(C)(C)CCC[C@H](C)C\C=C\C(\C)=C\C(=O)OC(C)C, COC(C)(C)CCC[C@H](C)C\C=C\C(\C)=C\C(=O)OC(C)C	NFGXHKASABOEEW-GYMWBFJFSA-N, NFGXHKASABOEEW-GYMWBFJFSA-N	Preclinical
methotrexate	dihydrofolate reductase inhibitor	DHFR	oncology, hematologic malignancy, dermatology, rheumatology	gestational choriocarcinoma, hydatidiform mole, acute lymphoblastic leukemia (ALL), psoriasis, rheumatoid arthritis	CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(cc1)C(=O)N[C@@H](CCC(O)=O)C(O)=O, CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(cc1)C(=O)N[C@@H](CCC(O)=O)C(O)=O, CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(cc1)C(=O)N[C@@H](CCC(O)=O)C(O)=O, CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(cc1)C(=O)N[C@@H](CCC(O)=O)C(O)=O, CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(cc1)C(=O)N[C@@H](CCC(O)=O)C(O)=O, CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(cc1)C(=O)N[C@@H](CCC(O)=O)C(O)=O, CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(cc1)C(=O)N[C@@H](CCC(O)=O)C(O)=O, CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(cc1)C(=O)N[C@@H](CCC(O)=O)C(O)=O, CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(cc1)C(=O)N[C@@H](CCC(O)=O)C(O)=O	FBOZXECLQNJBKD-ZDUSSCGKSA-N, FBOZXECLQNJBKD-ZDUSSCGKSA-N, FBOZXECLQNJBKD-ZDUSSCGKSA-N, FBOZXECLQNJBKD-ZDUSSCGKSA-N, FBOZXECLQNJBKD-ZDUSSCGKSA-N, FBOZXECLQNJBKD-ZDUSSCGKSA-N, FBOZXECLQNJBKD-ZDUSSCGKSA-N, FBOZXECLQNJBKD-ZDUSSCGKSA-N, FBOZXECLQNJBKD-ZDUSSCGKSA-N	Launched
methoxamine	adrenergic receptor agonist	ADRA1A, ADRA1B, ADRA1D	cardiology	hypotension	COc1ccc(OC)c(c1)C(O)C(C)N, COc1ccc(OC)c(c1)C(O)C(C)N, COc1ccc(OC)c(c1)C(O)C(C)N, COc1ccc(OC)c(c1)C(O)C(C)N, COc1ccc(OC)c(c1)C(O)C(C)N	WJAJPNHVVFWKKL-UHFFFAOYSA-N, WJAJPNHVVFWKKL-UHFFFAOYSA-N, WJAJPNHVVFWKKL-UHFFFAOYSA-N, WJAJPNHVVFWKKL-UHFFFAOYSA-N, WJAJPNHVVFWKKL-UHFFFAOYSA-N	Launched
methoxsalen	DNA synthesis inhibitor	CYP1A1, CYP1A2, CYP2A13, CYP2A6, CYP3A4	dermatology	psoriasis	COc1c2occc2cc2ccc(=O)oc12, COc1c2occc2cc2ccc(=O)oc12	QXKHYNVANLEOEG-UHFFFAOYSA-N, QXKHYNVANLEOEG-UHFFFAOYSA-N	Launched
methoxyamine	DNA repair enzyme inhibitor	APEX1			CON	GMPKIPWJBDOURN-UHFFFAOYSA-N	Phase 2
methoxyflurane	membrane permeability inhibitor	ATP2C1, ATP5D, GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, GLRA1, GLRB, GRIA1, KCNA1, MT-ND1	neurology/psychiatry	general anaesthetic	COC(F)(F)C(Cl)Cl, COC(F)(F)C(Cl)Cl, COC(F)(F)C(Cl)Cl, COC(F)(F)C(Cl)Cl, COC(F)(F)C(Cl)Cl	RFKMCNOHBTXSMU-UHFFFAOYSA-N, RFKMCNOHBTXSMU-UHFFFAOYSA-N, RFKMCNOHBTXSMU-UHFFFAOYSA-N, RFKMCNOHBTXSMU-UHFFFAOYSA-N, RFKMCNOHBTXSMU-UHFFFAOYSA-N	Launched
methoxyphenamine	adrenergic receptor agonist		pulmonary	asthma	CN[C@@H](C)Cc1ccccc1OC |&1:2,r|	OEHAYUOVELTAPG-VIFPVBQESA-N	Launched
methscopolamine	acetylcholine receptor antagonist	CHRM1, CHRM2, CHRM3	gastroenterology	peptic ulcer disease (PUD)	C[N+]1(C)[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)c1ccccc1, C[N+]1(C)[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)c1ccccc1, C[N+]1(C)[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)c1ccccc1, C[N+]1(C)[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)c1ccccc1, C[N+]1(C)[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)c1ccccc1	LZCOQTDXKCNBEE-IKIFYQGPSA-N, LZCOQTDXKCNBEE-IKIFYQGPSA-N, LZCOQTDXKCNBEE-IKIFYQGPSA-N, LZCOQTDXKCNBEE-IKIFYQGPSA-N, LZCOQTDXKCNBEE-IKIFYQGPSA-N	Launched
methsuximide	T-type calcium channel blocker	CACNA1G, CACNA1H, CACNA1I	neurology/psychiatry	seizures	CN1C(=O)C[C@@](C)(C1=O)c1ccccc1 |&1:5,r|, CN1C(=O)C[C@@](C)(C1=O)c1ccccc1 |&1:5,r|, CN1C(=O)C[C@@](C)(C1=O)c1ccccc1 |&1:5,r|	AJXPJJZHWIXJCJ-GFCCVEGCSA-N, AJXPJJZHWIXJCJ-GFCCVEGCSA-N, AJXPJJZHWIXJCJ-GFCCVEGCSA-N	Launched
methyclothiazide	chloride reabsorption inhibitor	SLC12A1, SLC12A3	cardiology	hypertension, edema	CN1[C@@H](CCl)Nc2cc(Cl)c(cc2S1(=O)=O)S(N)(=O)=O |&1:2,r|, CN1[C@@H](CCl)Nc2cc(Cl)c(cc2S1(=O)=O)S(N)(=O)=O |&1:2,r|	CESYKOGBSMNBPD-VIFPVBQESA-N, CESYKOGBSMNBPD-VIFPVBQESA-N	Launched
methyl-aminolevulinate	oxidizing agent	FCGR1A, FECH	dermatology	actinic keratosis (AK)	COC(=O)CCC(=O)CN	YUUAYBAIHCDHHD-UHFFFAOYSA-N	Launched
methyl-nicotinate					COC(=O)c1cccnc1, COC(=O)c1cccnc1	YNBADRVTZLEFNH-UHFFFAOYSA-N, YNBADRVTZLEFNH-UHFFFAOYSA-N	Phase 2
methyl-salicylate			endocrinology, neurology/psychiatry	fever, pain relief	COC(=O)c1ccccc1O, COC(=O)c1ccccc1O	OSWPMRLSEDHDFF-UHFFFAOYSA-N, OSWPMRLSEDHDFF-UHFFFAOYSA-N	Launched
methyl-5-hydroxytryptamine					C[C@@H](N)Cc1c[nH]c2ccc(O)cc12 |&1:1|, C[C@@H](N)Cc1c[nH]c2ccc(O)cc12 |&1:1|	LYPCGXKCQDYTFV-SSDOTTSWSA-N, LYPCGXKCQDYTFV-SSDOTTSWSA-N	Preclinical
methylatropine-nitrate	acetylcholine receptor antagonist	CHRM1			C[N+]1(C)[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)[C@@H](CO)c1ccccc1 |&1:3,6,8,&2:13|	PIPAJLPNWZMYQA-HZMVEIRTSA-N	Preclinical
methylbenactyzium-bromide	cholinergic receptor antagonist				CC[N+](C)(CC)CCOC(=O)C(O)(c1ccccc1)c1ccccc1	HDAMOICMOAXFLJ-UHFFFAOYSA-N	Preclinical
methylbenzethonium-chloride	other antibiotic				Cc1cc(ccc1OCCOCC[N+](C)(C)Cc1ccccc1)C(C)(C)CC(C)(C)C, Cc1cc(ccc1OCCOCC[N+](C)(C)Cc1ccccc1)C(C)(C)CC(C)(C)C	UQOOPIMXBSPVJI-UHFFFAOYSA-N, UQOOPIMXBSPVJI-UHFFFAOYSA-N	Preclinical
methylcobalamin	vitamin B				[H][C@]1(CO)O[C@]([H])(n2cnc3cc(C)c(C)cc23)[C@]([H])(O)[C@]1([H])OP(O)(=O)O[C@H](C)CNC(=O)CC[C@@]1(C)\C2=C(C)\C3=N\C(=C\C4=N\C(=C(C)/C5=N[C@@](C)([C@@]([H])(N2[Co+]C)[C@]1([H])CC(N)=O)[C@@](C)(CC(N)=O)[C@]5([H])CCC(N)=O)\[C@@](C)(CC(N)=O)[C@]4([H])CCC(N)=O)\C(C)(C)[C@]3([H])CCC(N)=O |c:41,t:44,46,48,50,53|	JEWJRMKHSMTXPP-WDJKBINPSA-M	Phase 3
methyldopa	adrenergic receptor agonist	ADRA2A, ADRA2B, ADRA2C, DDC	cardiology	hypertension	C[C@](N)(Cc1ccc(O)c(O)c1)C(O)=O, C[C@](N)(Cc1ccc(O)c(O)c1)C(O)=O, C[C@](N)(Cc1ccc(O)c(O)c1)C(O)=O, C[C@](N)(Cc1ccc(O)c(O)c1)C(O)=O, C[C@](N)(Cc1ccc(O)c(O)c1)C(O)=O, C[C@](N)(Cc1ccc(O)c(O)c1)C(O)=O	CJCSPKMFHVPWAR-JTQLQIEISA-N, CJCSPKMFHVPWAR-JTQLQIEISA-N, CJCSPKMFHVPWAR-JTQLQIEISA-N, CJCSPKMFHVPWAR-JTQLQIEISA-N, CJCSPKMFHVPWAR-JTQLQIEISA-N, CJCSPKMFHVPWAR-JTQLQIEISA-N	Launched
methyldopate			cardiology	hypertension	CCOC(=O)[C@@](C)(N)Cc1ccc(O)c(O)c1, CCOC(=O)[C@@](C)(N)Cc1ccc(O)c(O)c1	SVEBYYWCXTVYCR-LBPRGKRZSA-N, SVEBYYWCXTVYCR-LBPRGKRZSA-N	Launched
methylene-blue	guanylyl cyclase inhibitor, nitric oxide production inhibitor	ACHE	hematology	methemoglobinemia	CN(C)c1ccc2nc3ccc(cc3sc2c1)=[N+](C)C, CN(C)c1ccc2nc3ccc(cc3sc2c1)=[N+](C)C	RBTBFTRPCNLSDE-UHFFFAOYSA-N, RBTBFTRPCNLSDE-UHFFFAOYSA-N	Launched
methylergometrine	dopamine receptor antagonist, serotonin receptor antagonist	DRD1, HTR1E, HTR1F, HTR2A, HTR2B, HTR2C	hematology, neurology/psychiatry	postpartum hemorrhage (PPH), migraine headache	CC[C@@H](CO)NC(=O)[C@H]1CN(C)[C@@H]2Cc3c[nH]c4cccc(C2=C1)c34 |c:23|, CC[C@@H](CO)NC(=O)[C@H]1CN(C)[C@@H]2Cc3c[nH]c4cccc(C2=C1)c34 |c:23|, CC[C@@H](CO)NC(=O)[C@H]1CN(C)[C@@H]2Cc3c[nH]c4cccc(C2=C1)c34 |c:23|	UNBRKDKAWYKMIV-QWQRMKEZSA-N, UNBRKDKAWYKMIV-QWQRMKEZSA-N, UNBRKDKAWYKMIV-QWQRMKEZSA-N	Launched
methyllycaconitine	acetylcholine receptor antagonist	CHRNA7			CCN1C[C@]2(COC(=O)c3ccccc3N3C(=O)C[C@H](C)C3=O)CC[C@H](OC)[C@@]34[C@@H]5C[C@H]6[C@H](OC)[C@@H]5[C@](O)(C[C@@H]6OC)[C@@](O)([C@@H](OC)[C@H]23)[C@@H]14, CCN1C[C@]2(COC(=O)c3ccccc3N3C(=O)C[C@H](C)C3=O)CC[C@H](OC)[C@@]34[C@@H]5C[C@H]6[C@H](OC)[C@@H]5[C@](O)(C[C@@H]6OC)[C@@](O)([C@@H](OC)[C@H]23)[C@@H]14, CCN1C[C@]2(COC(=O)c3ccccc3N3C(=O)C[C@H](C)C3=O)CC[C@H](OC)[C@@]34[C@@H]5C[C@H]6[C@H](OC)[C@@H]5[C@](O)(C[C@@H]6OC)[C@@](O)([C@@H](OC)[C@H]23)[C@@H]14, CCN1C[C@]2(COC(=O)c3ccccc3N3C(=O)C[C@H](C)C3=O)CC[C@H](OC)[C@@]34[C@@H]5C[C@H]6[C@H](OC)[C@@H]5[C@](O)(C[C@@H]6OC)[C@@](O)([C@@H](OC)[C@H]23)[C@@H]14	XLTANAWLDBYGFU-VTLKBQQISA-N, XLTANAWLDBYGFU-VTLKBQQISA-N, XLTANAWLDBYGFU-VTLKBQQISA-N, XLTANAWLDBYGFU-VTLKBQQISA-N	Preclinical
methylnaltrexone	opioid receptor antagonist	OPRD1, OPRK1, OPRM1	gastroenterology	constipation	[H][C@]12Oc3c4c(C[C@]5([H])[C@](O)(CCC1=O)[C@]24CC[N@+]5(C)CC1CC1)ccc3O	JVLBPIPGETUEET-WIXLDOGYSA-O	Launched
methylparaben	other antifungal		dermatology	cosmetic	COC(=O)c1ccc(O)cc1, COC(=O)c1ccc(O)cc1	LXCFILQKKLGQFO-UHFFFAOYSA-N, LXCFILQKKLGQFO-UHFFFAOYSA-N	Launched
methylprednisolone	glucocorticoid receptor agonist	NR3C1	endocrinology, rheumatology, dermatology, infectious disease, allergy, hematology, neurology/psychiatry, gastroenterology	hypercalcemia, thyroiditis, ankylosing spondylitis, bursitis, osteoarthritis, psoriatic arthritis, seborrheic dermatitis, mycosis, allergic rhinitis, psoriasis, anemia, multiple sclerosis, ulcerative colitis, enteritis	C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(=O)CO)[C@@]3(C)C[C@H](O)[C@@H]2[C@@]2(C)C=CC(=O)C=C12 |c:23,t:27|, C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(=O)CO)[C@@]3(C)C[C@H](O)[C@@H]2[C@@]2(C)C=CC(=O)C=C12 |c:23,t:27|, C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(=O)CO)[C@@]3(C)C[C@H](O)[C@@H]2[C@@]2(C)C=CC(=O)C=C12 |c:23,t:27|, C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(=O)CO)[C@@]3(C)C[C@H](O)[C@@H]2[C@@]2(C)C=CC(=O)C=C12 |c:23,t:27|, C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(=O)CO)[C@@]3(C)C[C@H](O)[C@@H]2[C@@]2(C)C=CC(=O)C=C12 |c:23,t:27|, C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(=O)CO)[C@@]3(C)C[C@H](O)[C@@H]2[C@@]2(C)C=CC(=O)C=C12 |c:23,t:27|	VHRSUDSXCMQTMA-PJHHCJLFSA-N, VHRSUDSXCMQTMA-PJHHCJLFSA-N, VHRSUDSXCMQTMA-PJHHCJLFSA-N, VHRSUDSXCMQTMA-PJHHCJLFSA-N, VHRSUDSXCMQTMA-PJHHCJLFSA-N, VHRSUDSXCMQTMA-PJHHCJLFSA-N	Launched
methylprednisolone-aceponate	anti-inflammatory agent, glucocorticoid receptor agonist	NR3C1	endocrinology, rheumatology, infectious disease, allergy, pulmonary, gastroenterology, dermatology, neurology/psychiatry, hematology	congenital adrenal hyperplasia, thyroiditis, hypercalcemia, rheumatoid arthritis, bursitis, epicondylitis, allergic rhinitis, asthma, ulcerative colitis, enteritis, osteoarthritis, psoriasis, multiple sclerosis, anemia	CCC(=O)O[C@@]1(CC[C@H]2[C@@H]3C[C@H](C)C4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]12C)C(=O)COC(C)=O |c:17,t:13|, CCC(=O)O[C@@]1(CC[C@H]2[C@@H]3C[C@H](C)C4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]12C)C(=O)COC(C)=O |c:17,t:13|, CCC(=O)O[C@@]1(CC[C@H]2[C@@H]3C[C@H](C)C4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]12C)C(=O)COC(C)=O |c:17,t:13|	DALKLAYLIPSCQL-YPYQNWSCSA-N, DALKLAYLIPSCQL-YPYQNWSCSA-N, DALKLAYLIPSCQL-YPYQNWSCSA-N	Launched
methylprednisolone-sodium-succinate	glucocorticoid receptor agonist		endocrinology, rheumatology, dermatology, pulmonary, allergy, infectious disease, ophthalmology, gastroenterology, hematology, neurology/psychiatry	hypercalcemia, thyroiditis, osteoarthritis, rheumatoid arthritis, seborrheic dermatitis, asthma, allergic rhinitis, shingles, conjunctivitis, ulcerative colitis, enteritis, anemia, multiple sclerosis, mycosis	[H][C@@]12CC[C@](O)(C(=O)COC(=O)CCC(O)=O)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])C[C@H](C)C2=CC(=O)C=C[C@]12C |c:35,t:31|	IMBXEJJVJRTNOW-XYMSELFBSA-N	Launched
methylthiouracil			endocrinology	hyperthyroidism	Cc1cc(=O)[nH]c(=S)[nH]1, Cc1cc(=O)[nH]c(=S)[nH]1	HWGBHCRJGXAGEU-UHFFFAOYSA-N, HWGBHCRJGXAGEU-UHFFFAOYSA-N	Launched
methysergide	serotonin receptor antagonist	HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2B, HTR2C, HTR5A, HTR6, HTR7	neurology/psychiatry	headache	CC[C@@H](CO)NC(=O)[C@H]1CN(C)[C@@H]2Cc3cn(C)c4cccc(C2=C1)c34 |c:24|, CC[C@@H](CO)NC(=O)[C@H]1CN(C)[C@@H]2Cc3cn(C)c4cccc(C2=C1)c34 |c:24|, CC[C@@H](CO)NC(=O)[C@H]1CN(C)[C@@H]2Cc3cn(C)c4cccc(C2=C1)c34 |c:24|	KPJZHOPZRAFDTN-ZRGWGRIASA-N, KPJZHOPZRAFDTN-ZRGWGRIASA-N, KPJZHOPZRAFDTN-ZRGWGRIASA-N	Launched
meticrane	diuretic		cardiology	edema	Cc1cc2CCCS(=O)(=O)c2cc1S(N)(=O)=O, Cc1cc2CCCS(=O)(=O)c2cc1S(N)(=O)=O, Cc1cc2CCCS(=O)(=O)c2cc1S(N)(=O)=O, Cc1cc2CCCS(=O)(=O)c2cc1S(N)(=O)=O	FNQQBFNIYODEMB-UHFFFAOYSA-N, FNQQBFNIYODEMB-UHFFFAOYSA-N, FNQQBFNIYODEMB-UHFFFAOYSA-N, FNQQBFNIYODEMB-UHFFFAOYSA-N	Launched
metipranolol	adrenergic receptor antagonist				CC(C)NC[C@@H](O)COc1cc(C)c(OC(C)=O)c(C)c1C |&1:5,r|	BQIPXWYNLPYNHW-OAHLLOKOSA-N	Withdrawn
metirosine	tyrosine hydroxylase inhibitor	TH	cardiology	hypertension	C[C@](N)(Cc1ccc(O)cc1)C(O)=O, C[C@](N)(Cc1ccc(O)cc1)C(O)=O, C[C@](N)(Cc1ccc(O)cc1)C(O)=O	NHTGHBARYWONDQ-JTQLQIEISA-N, NHTGHBARYWONDQ-JTQLQIEISA-N, NHTGHBARYWONDQ-JTQLQIEISA-N	Launched
metitepine	anti-HCVE2	HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2B, HTR2C, HTR5A, HTR6, HTR7			CSc1ccc2Sc3ccccc3C[C@@H](N3CCN(C)CC3)c2c1 |&1:14,r|, CSc1ccc2Sc3ccccc3C[C@@H](N3CCN(C)CC3)c2c1 |&1:14,r|	RLJFTICUTYVZDG-GOSISDBHSA-N, RLJFTICUTYVZDG-GOSISDBHSA-N	Preclinical
metixene	acetylcholine receptor antagonist	CHRM5	neurology/psychiatry	Parkinson's Disease	CN1CCC[C@@H](CC2c3ccccc3Sc3ccccc23)C1 |&1:5|	MJFJKKXQDNNUJF-HNNXBMFYSA-N	Launched
metoclopramide	dopamine receptor antagonist, serotonin receptor antagonist	CHRM1, DRD2, HTR3A, HTR3B, HTR4	gastroenterology	gastroparesis, nausea, vomiting	CCN(CC)CCNC(=O)c1cc(Cl)c(N)cc1OC, CCN(CC)CCNC(=O)c1cc(Cl)c(N)cc1OC	TTWJBBZEZQICBI-UHFFFAOYSA-N, TTWJBBZEZQICBI-UHFFFAOYSA-N	Launched
metocurine	acetylcholine receptor antagonist	CHRM2, CHRNA2	neurology/psychiatry	muscle relaxant	COc1ccc2C[C@@H]3c4c(CC[N+]3(C)C)cc(OC)c(OC)c4Oc3ccc(C[C@H]4c5cc(Oc1c2)c(OC)cc5CC[N+]4(C)C)cc3	JFXBEKISTKFVAB-AJQTZOPKSA-N	Launched
metolazone	carbonic anhydrase inhibitor	SLC12A3	cardiology	edema, hypertension	C[C@H]1Nc2cc(Cl)c(cc2C(=O)N1c1ccccc1C)S(N)(=O)=O |&1:1,r|, C[C@H]1Nc2cc(Cl)c(cc2C(=O)N1c1ccccc1C)S(N)(=O)=O |&1:1,r|, C[C@H]1Nc2cc(Cl)c(cc2C(=O)N1c1ccccc1C)S(N)(=O)=O |&1:1,r|, C[C@H]1Nc2cc(Cl)c(cc2C(=O)N1c1ccccc1C)S(N)(=O)=O |&1:1,r|, C[C@H]1Nc2cc(Cl)c(cc2C(=O)N1c1ccccc1C)S(N)(=O)=O |&1:1,r|	AQCHWTWZEMGIFD-JTQLQIEISA-N, AQCHWTWZEMGIFD-JTQLQIEISA-N, AQCHWTWZEMGIFD-JTQLQIEISA-N, AQCHWTWZEMGIFD-JTQLQIEISA-N, AQCHWTWZEMGIFD-JTQLQIEISA-N	Launched
metoprolol	adrenergic receptor antagonist	ADRB1, ADRB2	cardiology	hypertension, angina pectoris, myocardial infarction	COCCc1ccc(OC[C@@H](O)CNC(C)C)cc1 |&1:10|, COCCc1ccc(OC[C@@H](O)CNC(C)C)cc1 |&1:10|, COCCc1ccc(OC[C@@H](O)CNC(C)C)cc1 |&1:10|	IUBSYMUCCVWXPE-AWEZNQCLSA-N, IUBSYMUCCVWXPE-AWEZNQCLSA-N, IUBSYMUCCVWXPE-AWEZNQCLSA-N	Launched
metoxibutropate	cyclooxygenase inhibitor	PTGS1, PTGS2			COc1ccccc1OC(=O)[C@@H](C)c1ccc(CC(C)C)cc1 |&1:11,r|, COc1ccccc1OC(=O)[C@@H](C)c1ccc(CC(C)C)cc1 |&1:11,r|	FVRWRGBTEHAPDI-HNNXBMFYSA-N, FVRWRGBTEHAPDI-HNNXBMFYSA-N	Launched
metrifonate	acetylcholinesterase inhibitor	ACHE			COP(=O)(OC)[C@@H](O)C(Cl)(Cl)Cl |&1:6,r|, COP(=O)(OC)[C@@H](O)C(Cl)(Cl)Cl |&1:6,r|, COP(=O)(OC)[C@@H](O)C(Cl)(Cl)Cl |&1:6,r|, COP(=O)(OC)[C@@H](O)C(Cl)(Cl)Cl |&1:6,r|	NFACJZMKEDPNKN-GSVOUGTGSA-N, NFACJZMKEDPNKN-GSVOUGTGSA-N, NFACJZMKEDPNKN-GSVOUGTGSA-N, NFACJZMKEDPNKN-GSVOUGTGSA-N	Phase 3
metrizamide	radiopaque medium		radiology	contrast agent	CN(C(C)=O)c1c(I)c(NC(C)=O)c(I)c(C(=O)N[C@H]2[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]2O)c1I |a:19,23,26,28,&1:20|, CN(C(C)=O)c1c(I)c(NC(C)=O)c(I)c(C(=O)N[C@H]2[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]2O)c1I |a:19,23,26,28,&1:20|	BAQCROVBDNBEEB-KSDLJXBFSA-N, BAQCROVBDNBEEB-KSDLJXBFSA-N	Launched
metrizoic-acid	radiopaque medium		radiology	contrast agent	CN(C(C)=O)c1c(I)c(NC(C)=O)c(I)c(C(O)=O)c1I, CN(C(C)=O)c1c(I)c(NC(C)=O)c(I)c(C(O)=O)c1I, CN(C(C)=O)c1c(I)c(NC(C)=O)c(I)c(C(O)=O)c1I	GGGDNPWHMNJRFN-UHFFFAOYSA-N, GGGDNPWHMNJRFN-UHFFFAOYSA-N, GGGDNPWHMNJRFN-UHFFFAOYSA-N	Launched
metronidazole	DNA inhibitor	CYP2C9, CYP3A4	dermatology	rosacea	Cc1ncc(n1CCO)[N+]([O-])=O, Cc1ncc(n1CCO)[N+]([O-])=O	VAOCPAMSLUNLGC-UHFFFAOYSA-N, VAOCPAMSLUNLGC-UHFFFAOYSA-N	Launched
metyrapone	cytochrome P450 inhibitor	CYP11B1	nephrology	adrenal diagnostic agent	CC(C)(C(=O)c1cccnc1)c1cccnc1, CC(C)(C(=O)c1cccnc1)c1cccnc1, CC(C)(C(=O)c1cccnc1)c1cccnc1, CC(C)(C(=O)c1cccnc1)c1cccnc1	FJLBFSROUSIWMA-UHFFFAOYSA-N, FJLBFSROUSIWMA-UHFFFAOYSA-N, FJLBFSROUSIWMA-UHFFFAOYSA-N, FJLBFSROUSIWMA-UHFFFAOYSA-N	Launched
mevastatin	HMGCR inhibitor	HMGCR			CC[C@H](C)C(=O)O[C@H]1CCC=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12 |c:12,t:10|, CC[C@H](C)C(=O)O[C@H]1CCC=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12 |c:12,t:10|, CC[C@H](C)C(=O)O[C@H]1CCC=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12 |c:12,t:10|, CC[C@H](C)C(=O)O[C@H]1CCC=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12 |c:12,t:10|, CC[C@H](C)C(=O)O[C@H]1CCC=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12 |c:12,t:10|, CC[C@H](C)C(=O)O[C@H]1CCC=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12 |c:12,t:10|, CC[C@H](C)C(=O)O[C@H]1CCC=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12 |c:12,t:10|, CC[C@H](C)C(=O)O[C@H]1CCC=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12 |c:12,t:10|, CC[C@H](C)C(=O)O[C@H]1CCC=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12 |c:12,t:10|, CC[C@H](C)C(=O)O[C@H]1CCC=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12 |c:12,t:10|, CC[C@H](C)C(=O)O[C@H]1CCC=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12 |c:12,t:10|, CC[C@H](C)C(=O)O[C@H]1CCC=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12 |c:12,t:10|, CC[C@H](C)C(=O)O[C@H]1CCC=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12 |c:12,t:10|, CC[C@H](C)C(=O)O[C@H]1CCC=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12 |c:12,t:10|	AJLFOPYRIVGYMJ-INTXDZFKSA-N, AJLFOPYRIVGYMJ-INTXDZFKSA-N, AJLFOPYRIVGYMJ-INTXDZFKSA-N, AJLFOPYRIVGYMJ-INTXDZFKSA-N, AJLFOPYRIVGYMJ-INTXDZFKSA-N, AJLFOPYRIVGYMJ-INTXDZFKSA-N, AJLFOPYRIVGYMJ-INTXDZFKSA-N, AJLFOPYRIVGYMJ-INTXDZFKSA-N, AJLFOPYRIVGYMJ-INTXDZFKSA-N, AJLFOPYRIVGYMJ-INTXDZFKSA-N, AJLFOPYRIVGYMJ-INTXDZFKSA-N, AJLFOPYRIVGYMJ-INTXDZFKSA-N, AJLFOPYRIVGYMJ-INTXDZFKSA-N, AJLFOPYRIVGYMJ-INTXDZFKSA-N	Preclinical
mexeneone					COc1ccc(C(=O)c2ccc(C)cc2)c(O)c1, COc1ccc(C(=O)c2ccc(C)cc2)c(O)c1, COc1ccc(C(=O)c2ccc(C)cc2)c(O)c1	MJVGBKJNTFCUJM-UHFFFAOYSA-N, MJVGBKJNTFCUJM-UHFFFAOYSA-N, MJVGBKJNTFCUJM-UHFFFAOYSA-N	Preclinical
mexiletine	sodium channel blocker	PLAU, SCN4A, SCN5A	cardiology	ventricular arrhythmias, ventricular tachycardia (VT)	C[C@@H](N)COc1c(C)cccc1C |&1:1|, C[C@@H](N)COc1c(C)cccc1C |&1:1|, C[C@@H](N)COc1c(C)cccc1C |&1:1|, C[C@@H](N)COc1c(C)cccc1C |&1:1|, C[C@@H](N)COc1c(C)cccc1C |&1:1|, C[C@@H](N)COc1c(C)cccc1C |&1:1|, C[C@@H](N)COc1c(C)cccc1C |&1:1|	VLPIATFUUWWMKC-SNVBAGLBSA-N, VLPIATFUUWWMKC-SNVBAGLBSA-N, VLPIATFUUWWMKC-SNVBAGLBSA-N, VLPIATFUUWWMKC-SNVBAGLBSA-N, VLPIATFUUWWMKC-SNVBAGLBSA-N, VLPIATFUUWWMKC-SNVBAGLBSA-N, VLPIATFUUWWMKC-SNVBAGLBSA-N	Launched
mezlocillin	bacterial cell wall synthesis inhibitor		infectious disease	gram-negative bacterial infections, gram-positive bacterial infections	CC1(C)S[C@H]2[C@@H](NC(=O)[C@@H](NC(=O)N3CCN(C3=O)S(C)(=O)=O)c3ccccc3)C(=O)N2[C@@H]1C(O)=O, CC1(C)S[C@H]2[C@@H](NC(=O)[C@@H](NC(=O)N3CCN(C3=O)S(C)(=O)=O)c3ccccc3)C(=O)N2[C@@H]1C(O)=O, CC1(C)S[C@H]2[C@@H](NC(=O)[C@@H](NC(=O)N3CCN(C3=O)S(C)(=O)=O)c3ccccc3)C(=O)N2[C@@H]1C(O)=O	YPBATNHYBCGSSN-ZJOBFFGXSA-N, YPBATNHYBCGSSN-ZJOBFFGXSA-N, YPBATNHYBCGSSN-ZJOBFFGXSA-N	Launched
ME0328	PARP inhibitor	PARP3			C[C@@H](NC(=O)CCc1nc(=O)c2ccccc2[nH]1)c1ccccc1 |&1:1,r|, C[C@@H](NC(=O)CCc1nc(=O)c2ccccc2[nH]1)c1ccccc1 |&1:1,r|, C[C@@H](NC(=O)CCc1nc(=O)c2ccccc2[nH]1)c1ccccc1 |&1:1,r|	QIHBWVVVRYYYRO-CYBMUJFWSA-N, QIHBWVVVRYYYRO-CYBMUJFWSA-N, QIHBWVVVRYYYRO-CYBMUJFWSA-N	Preclinical
MF-101	estrogen receptor agonist	CYP19A1, XDH			Oc1ccc(cc1)[C@@H]1CC(=O)c2ccc(O)cc2O1, Oc1ccc(cc1)[C@@H]1CC(=O)c2ccc(O)cc2O1	FURUXTVZLHCCNA-AWEZNQCLSA-N, FURUXTVZLHCCNA-AWEZNQCLSA-N	Phase 3
MG-132	proteasome inhibitor	PSMB1			CC(C)C[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)OCc1ccccc1)C=O, CC(C)C[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)OCc1ccccc1)C=O, CC(C)C[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)OCc1ccccc1)C=O, CC(C)C[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)OCc1ccccc1)C=O, CC(C)C[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)OCc1ccccc1)C=O, CC(C)C[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)OCc1ccccc1)C=O, CC(C)C[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)OCc1ccccc1)C=O, CC(C)C[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)OCc1ccccc1)C=O, CC(C)C[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)OCc1ccccc1)C=O	TZYWCYJVHRLUCT-VABKMULXSA-N, TZYWCYJVHRLUCT-VABKMULXSA-N, TZYWCYJVHRLUCT-VABKMULXSA-N, TZYWCYJVHRLUCT-VABKMULXSA-N, TZYWCYJVHRLUCT-VABKMULXSA-N, TZYWCYJVHRLUCT-VABKMULXSA-N, TZYWCYJVHRLUCT-VABKMULXSA-N, TZYWCYJVHRLUCT-VABKMULXSA-N, TZYWCYJVHRLUCT-VABKMULXSA-N	Preclinical
MG-624	acetylcholine receptor antagonist	CHRNA7			CC[N+](CC)(CC)CCOc1ccc(\C=C\c2ccccc2)cc1, CC[N+](CC)(CC)CCOc1ccc(\C=C\c2ccccc2)cc1, CC[N+](CC)(CC)CCOc1ccc(\C=C\c2ccccc2)cc1	YIMFXBPXUPTIEJ-OUKQBFOZSA-N, YIMFXBPXUPTIEJ-OUKQBFOZSA-N, YIMFXBPXUPTIEJ-OUKQBFOZSA-N	Preclinical
MGCD-265	VEGFR inhibitor	AXL, MET			Cn1cnc(c1)-c1cc2nccc(Oc3ccc(NC(=S)NC(=O)Cc4ccccc4)cc3F)c2s1, Cn1cnc(c1)-c1cc2nccc(Oc3ccc(NC(=S)NC(=O)Cc4ccccc4)cc3F)c2s1	UFICVEHDQUKCEA-UHFFFAOYSA-N, UFICVEHDQUKCEA-UHFFFAOYSA-N	Preclinical
MI-14	PI4K inhibitor	PI4KB			CN(C)S(=O)(=O)c1cccc(c1)-c1c(C)nc2c(NCCNC(C)=O)cc(Cl)nn12, CN(C)S(=O)(=O)c1cccc(c1)-c1c(C)nc2c(NCCNC(C)=O)cc(Cl)nn12	PSTAJIONBVMKLA-UHFFFAOYSA-N, PSTAJIONBVMKLA-UHFFFAOYSA-N	Preclinical
mianserin	serotonin receptor antagonist	ADRA1A, ADRA1B, ADRA1D, HRH1, HRH2, HTR2A, HTR2B, HTR2C, HTR6, HTR7	neurology/psychiatry	depression	CN1CCN2C(C1)c1ccccc1Cc1ccccc21, CN1CCN2C(C1)c1ccccc1Cc1ccccc21, CN1CCN2C(C1)c1ccccc1Cc1ccccc21, CN1CCN2C(C1)c1ccccc1Cc1ccccc21	UEQUQVLFIPOEMF-UHFFFAOYSA-N, UEQUQVLFIPOEMF-UHFFFAOYSA-N, UEQUQVLFIPOEMF-UHFFFAOYSA-N, UEQUQVLFIPOEMF-UHFFFAOYSA-N	Launched
mibampator	glutamate receptor modulator	GRIA1			CC(C)S(=O)(=O)NC[C@H](C)c1ccc(cc1)-c1ccc(CCNS(C)(=O)=O)cc1, CC(C)S(=O)(=O)NC[C@H](C)c1ccc(cc1)-c1ccc(CCNS(C)(=O)=O)cc1, CC(C)S(=O)(=O)NC[C@H](C)c1ccc(cc1)-c1ccc(CCNS(C)(=O)=O)cc1, CC(C)S(=O)(=O)NC[C@H](C)c1ccc(cc1)-c1ccc(CCNS(C)(=O)=O)cc1	ULRDYYKSPCRXAJ-KRWDZBQOSA-N, ULRDYYKSPCRXAJ-KRWDZBQOSA-N, ULRDYYKSPCRXAJ-KRWDZBQOSA-N, ULRDYYKSPCRXAJ-KRWDZBQOSA-N	Phase 2
mibefradil	T-type calcium channel blocker	ANO1, CACNA1C, CACNA1D, CACNA1F, CACNA1G, CACNA1H, CACNA1I, CACNA1S, CACNB1, CACNB2, CACNB3, CACNB4, CATSPER1, CATSPER2, CATSPER3, CATSPER4			COCC(=O)O[C@]1(CCN(C)CCCc2nc3ccccc3[nH]2)CCc2cc(F)ccc2[C@@H]1C(C)C, COCC(=O)O[C@]1(CCN(C)CCCc2nc3ccccc3[nH]2)CCc2cc(F)ccc2[C@@H]1C(C)C, COCC(=O)O[C@]1(CCN(C)CCCc2nc3ccccc3[nH]2)CCc2cc(F)ccc2[C@@H]1C(C)C, COCC(=O)O[C@]1(CCN(C)CCCc2nc3ccccc3[nH]2)CCc2cc(F)ccc2[C@@H]1C(C)C, COCC(=O)O[C@]1(CCN(C)CCCc2nc3ccccc3[nH]2)CCc2cc(F)ccc2[C@@H]1C(C)C, COCC(=O)O[C@]1(CCN(C)CCCc2nc3ccccc3[nH]2)CCc2cc(F)ccc2[C@@H]1C(C)C, COCC(=O)O[C@]1(CCN(C)CCCc2nc3ccccc3[nH]2)CCc2cc(F)ccc2[C@@H]1C(C)C	HBNPJJILLOYFJU-VMPREFPWSA-N, HBNPJJILLOYFJU-VMPREFPWSA-N, HBNPJJILLOYFJU-VMPREFPWSA-N, HBNPJJILLOYFJU-VMPREFPWSA-N, HBNPJJILLOYFJU-VMPREFPWSA-N, HBNPJJILLOYFJU-VMPREFPWSA-N, HBNPJJILLOYFJU-VMPREFPWSA-N	Withdrawn
micafungin	fungal 1,3-beta-D-glucan synthase inhibitor		infectious disease	candidemia, peritonitis, esophageal candidiasis	CCCCCOc1ccc(cc1)-c1cc(no1)-c1ccc(cc1)C(=O)N[C@H]1C[C@@H](O)[C@@H](O)NC(=O)[C@@H]2[C@@H](O)[C@@H](C)CN2C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC1=O)[C@@H](C)O)[C@H](O)[C@@H](O)c1ccc(O)c(OS(O)(=O)=O)c1)[C@H](O)CC(N)=O, CCCCCOc1ccc(cc1)-c1cc(no1)-c1ccc(cc1)C(=O)N[C@H]1C[C@@H](O)[C@@H](O)NC(=O)[C@@H]2[C@@H](O)[C@@H](C)CN2C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC1=O)[C@@H](C)O)[C@H](O)[C@@H](O)c1ccc(O)c(OS(O)(=O)=O)c1)[C@H](O)CC(N)=O, CCCCCOc1ccc(cc1)-c1cc(no1)-c1ccc(cc1)C(=O)N[C@H]1C[C@@H](O)[C@@H](O)NC(=O)[C@@H]2[C@@H](O)[C@@H](C)CN2C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC1=O)[C@@H](C)O)[C@H](O)[C@@H](O)c1ccc(O)c(OS(O)(=O)=O)c1)[C@H](O)CC(N)=O	PIEUQSKUWLMALL-YABMTYFHSA-N, PIEUQSKUWLMALL-YABMTYFHSA-N, PIEUQSKUWLMALL-YABMTYFHSA-N	Launched
miconazole	bacterial cell wall synthesis inhibitor	TRPM2, TRPV5	infectious disease, neurology/psychiatry	yeast infection, itching	Clc1ccc(CO[C@@H](Cn2ccnc2)c2ccc(Cl)cc2Cl)c(Cl)c1 |&1:7,r|, Clc1ccc(CO[C@@H](Cn2ccnc2)c2ccc(Cl)cc2Cl)c(Cl)c1 |&1:7,r|	BYBLEWFAAKGYCD-SFHVURJKSA-N, BYBLEWFAAKGYCD-SFHVURJKSA-N	Launched
micronomicin	protein synthesis inhibitor		infectious disease	gram-negative bacterial infections	CNC[C@@H]1CC[C@@H](N)[C@@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3OC[C@](C)(O)[C@H](NC)[C@H]3O)[C@H]2O)O1, CNC[C@@H]1CC[C@@H](N)[C@@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3OC[C@](C)(O)[C@H](NC)[C@H]3O)[C@H]2O)O1	DNYGXMICFMACRA-XHEDQWPISA-N, DNYGXMICFMACRA-XHEDQWPISA-N	Launched
midafotel	glutamate receptor antagonist	GRIN2A, GRIN2B, GRIN2C, GRIN2D			OC(=O)[C@H]1CN(C\C=C\P(O)(O)=O)CCN1, OC(=O)[C@H]1CN(C\C=C\P(O)(O)=O)CCN1	VZXMZMJSGLFKQI-ABVWVHJUSA-N, VZXMZMJSGLFKQI-ABVWVHJUSA-N	Phase 3
midecamycin	protein synthesis inhibitor		infectious disease	respiratory tract infections, ear infections, skin infections	CCC(=O)O[C@H]1[C@H](C)O[C@H](C[C@@]1(C)O)O[C@@H]1[C@@H](C)O[C@@H](O[C@H]2[C@@H](CC=O)C[C@@H](C)[C@@H](O)\C=C\C=C\C[C@@H](C)OC(=O)C[C@@H](OC(=O)CC)[C@@H]2OC)[C@H](O)[C@H]1N(C)C |t:32,34|	DMUAPQTXSSNEDD-RVVOCHMRSA-N	Launched
midodrine	adrenergic receptor agonist		cardiology	hypotension	COc1ccc(OC)c(c1)[C@@H](O)CNC(=O)CN |&1:10|, COc1ccc(OC)c(c1)[C@@H](O)CNC(=O)CN |&1:10|, COc1ccc(OC)c(c1)[C@@H](O)CNC(=O)CN |&1:10|, COc1ccc(OC)c(c1)[C@@H](O)CNC(=O)CN |&1:10|	PTKSEFOSCHHMPD-JTQLQIEISA-N, PTKSEFOSCHHMPD-JTQLQIEISA-N, PTKSEFOSCHHMPD-JTQLQIEISA-N, PTKSEFOSCHHMPD-JTQLQIEISA-N	Launched
midostaurin	FLT3 inhibitor, KIT inhibitor, PKC inhibitor	FLT3, PRKCG	hematologic malignancy	acute myeloid leukemia (AML)	CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)n1c3ccccc3c3c4CNC(=O)c4c4c5ccccc5n2c4c13)N(C)C(=O)c1ccccc1, CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)n1c3ccccc3c3c4CNC(=O)c4c4c5ccccc5n2c4c13)N(C)C(=O)c1ccccc1, CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)n1c3ccccc3c3c4CNC(=O)c4c4c5ccccc5n2c4c13)N(C)C(=O)c1ccccc1, CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)n1c3ccccc3c3c4CNC(=O)c4c4c5ccccc5n2c4c13)N(C)C(=O)c1ccccc1, CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)n1c3ccccc3c3c4CNC(=O)c4c4c5ccccc5n2c4c13)N(C)C(=O)c1ccccc1, CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)n1c3ccccc3c3c4CNC(=O)c4c4c5ccccc5n2c4c13)N(C)C(=O)c1ccccc1, CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)n1c3ccccc3c3c4CNC(=O)c4c4c5ccccc5n2c4c13)N(C)C(=O)c1ccccc1, CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)n1c3ccccc3c3c4CNC(=O)c4c4c5ccccc5n2c4c13)N(C)C(=O)c1ccccc1, CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)n1c3ccccc3c3c4CNC(=O)c4c4c5ccccc5n2c4c13)N(C)C(=O)c1ccccc1, CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)n1c3ccccc3c3c4CNC(=O)c4c4c5ccccc5n2c4c13)N(C)C(=O)c1ccccc1, CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)n1c3ccccc3c3c4CNC(=O)c4c4c5ccccc5n2c4c13)N(C)C(=O)c1ccccc1, CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)n1c3ccccc3c3c4CNC(=O)c4c4c5ccccc5n2c4c13)N(C)C(=O)c1ccccc1	BMGQWWVMWDBQGC-IIFHNQTCSA-N, BMGQWWVMWDBQGC-IIFHNQTCSA-N, BMGQWWVMWDBQGC-IIFHNQTCSA-N, BMGQWWVMWDBQGC-IIFHNQTCSA-N, BMGQWWVMWDBQGC-IIFHNQTCSA-N, BMGQWWVMWDBQGC-IIFHNQTCSA-N, BMGQWWVMWDBQGC-IIFHNQTCSA-N, BMGQWWVMWDBQGC-IIFHNQTCSA-N, BMGQWWVMWDBQGC-IIFHNQTCSA-N, BMGQWWVMWDBQGC-IIFHNQTCSA-N, BMGQWWVMWDBQGC-IIFHNQTCSA-N, BMGQWWVMWDBQGC-IIFHNQTCSA-N	Launched
mifepristone	glucocorticoid receptor antagonist, progesterone receptor antagonist	AR, NR1I2, NR3C1, PGR	endocrinology	hyperglycemia, diabetes mellitus	CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@H](C[C@]12C)c1ccc(cc1)N(C)C |c:18,t:11|, CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@H](C[C@]12C)c1ccc(cc1)N(C)C |c:18,t:11|, CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@H](C[C@]12C)c1ccc(cc1)N(C)C |c:18,t:11|, CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@H](C[C@]12C)c1ccc(cc1)N(C)C |c:18,t:11|, CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@H](C[C@]12C)c1ccc(cc1)N(C)C |c:18,t:11|, CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@H](C[C@]12C)c1ccc(cc1)N(C)C |c:18,t:11|, CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@H](C[C@]12C)c1ccc(cc1)N(C)C |c:18,t:11|, CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@H](C[C@]12C)c1ccc(cc1)N(C)C |c:18,t:11|, CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@H](C[C@]12C)c1ccc(cc1)N(C)C |c:18,t:11|, CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@H](C[C@]12C)c1ccc(cc1)N(C)C |c:18,t:11|, CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@H](C[C@]12C)c1ccc(cc1)N(C)C |c:18,t:11|, CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@H](C[C@]12C)c1ccc(cc1)N(C)C |c:18,t:11|	VKHAHZOOUSRJNA-GCNJZUOMSA-N, VKHAHZOOUSRJNA-GCNJZUOMSA-N, VKHAHZOOUSRJNA-GCNJZUOMSA-N, VKHAHZOOUSRJNA-GCNJZUOMSA-N, VKHAHZOOUSRJNA-GCNJZUOMSA-N, VKHAHZOOUSRJNA-GCNJZUOMSA-N, VKHAHZOOUSRJNA-GCNJZUOMSA-N, VKHAHZOOUSRJNA-GCNJZUOMSA-N, VKHAHZOOUSRJNA-GCNJZUOMSA-N, VKHAHZOOUSRJNA-GCNJZUOMSA-N, VKHAHZOOUSRJNA-GCNJZUOMSA-N, VKHAHZOOUSRJNA-GCNJZUOMSA-N	Launched
mifobate	PPAR receptor antagonist	PPARG			COP(=O)(OC)O[C@@H](c1ccc(Cl)cc1)P(=O)(OC)OC |&1:7,r|	VQHUQHAPWMNBLP-LLVKDONJSA-N	Phase 2
miglitol	glucosidase inhibitor	GAA, GANAB, GANC, MGAM	endocrinology	diabetes mellitus	OCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO, OCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO, OCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO, OCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO	IBAQFPQHRJAVAV-ULAWRXDQSA-N, IBAQFPQHRJAVAV-ULAWRXDQSA-N, IBAQFPQHRJAVAV-ULAWRXDQSA-N, IBAQFPQHRJAVAV-ULAWRXDQSA-N	Launched
miglustat	glycosyl transferase inhibitor	UGCG	hematology	Gaucher disease	CCCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO, CCCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO	UQRORFVVSGFNRO-UTINFBMNSA-N, UQRORFVVSGFNRO-UTINFBMNSA-N	Launched
milacemide	monoamine oxidase inhibitor	MAOB			CCCCCNCC(N)=O, CCCCCNCC(N)=O, CCCCCNCC(N)=O, CCCCCNCC(N)=O	GJNNXIYZWIZFRH-UHFFFAOYSA-N, GJNNXIYZWIZFRH-UHFFFAOYSA-N, GJNNXIYZWIZFRH-UHFFFAOYSA-N, GJNNXIYZWIZFRH-UHFFFAOYSA-N	Phase 3
milademetan	MDM inhibitor				CC1(C)CCC2(CC1)N[C@H]([C@H](c1ccnc(Cl)c1F)[C@]21C(=O)Nc2cc(Cl)ccc12)C(=O)N[C@@H]1CC[C@H](OC1)C(N)=O	RYAYYVTWKAOAJF-QISPRATLSA-N	Phase 1
milnacipran	serotoninnorepinephrine reuptake inhibitor (SNRI)	SLC6A2, SLC6A4	rheumatology	fibromyalgia	CCN(CC)C(=O)[C@]1(C[C@H]1CN)c1ccccc1 |r|	GJJFMKBJSRMPLA-DZGCQCFKSA-N	Launched
milrinone	phosphodiesterase inhibitor	PDE2A, PDE3A, PDE3B, PDE5A	cardiology	congestive heart failure	Cc1[nH]c(=O)c(cc1-c1ccncc1)C#N, Cc1[nH]c(=O)c(cc1-c1ccncc1)C#N, Cc1[nH]c(=O)c(cc1-c1ccncc1)C#N, Cc1[nH]c(=O)c(cc1-c1ccncc1)C#N, Cc1[nH]c(=O)c(cc1-c1ccncc1)C#N, Cc1[nH]c(=O)c(cc1-c1ccncc1)C#N	PZRHRDRVRGEVNW-UHFFFAOYSA-N, PZRHRDRVRGEVNW-UHFFFAOYSA-N, PZRHRDRVRGEVNW-UHFFFAOYSA-N, PZRHRDRVRGEVNW-UHFFFAOYSA-N, PZRHRDRVRGEVNW-UHFFFAOYSA-N, PZRHRDRVRGEVNW-UHFFFAOYSA-N	Launched
miltefosine	membrane integrity inhibitor	PLA2G1B	infectious disease	leishmaniasis	CCCCCCCCCCCCCCCCOP(O)(=O)OCC[N+](C)(C)C |&1:17|	PQLXHQMOHUQAKB-UHFFFAOYSA-O	Launched
mimosine	DNA replication inhibitor	CCL2, SHMT1, SHMT2, TYR			N[C@@H](Cn1ccc(=O)c(O)c1)C(O)=O, N[C@@H](Cn1ccc(=O)c(O)c1)C(O)=O	WZNJWVWKTVETCG-YFKPBYRVSA-N, WZNJWVWKTVETCG-YFKPBYRVSA-N	Preclinical
minaprine	serotonin reuptake inhibitor	ACHE, CHRM1, DRD1, DRD2, HTR2A, HTR2B, HTR2C, MAOA, SLC6A4			Cc1cc(nnc1NCCN1CCOCC1)-c1ccccc1, Cc1cc(nnc1NCCN1CCOCC1)-c1ccccc1	LDMWSLGGVTVJPG-UHFFFAOYSA-N, LDMWSLGGVTVJPG-UHFFFAOYSA-N	Withdrawn
minerval	FAAH inhibitor				CCCCCCCC\C=C/CCCCCC[C@@H](O)C(O)=O |&1:16,r|, CCCCCCCC\C=C/CCCCCC[C@@H](O)C(O)=O |&1:16,r|, CCCCCCCC\C=C/CCCCCC[C@@H](O)C(O)=O |&1:16,r|	JBSOOFITVPOOSY-DOOKAGJSSA-N, JBSOOFITVPOOSY-DOOKAGJSSA-N, JBSOOFITVPOOSY-DOOKAGJSSA-N	Phase 1/Phase 2
minocycline	bacterial 30S ribosomal subunit inhibitor		endocrinology, infectious disease, ophthalmology, urology	fever, respiratory tract infections, psittacosis, trachoma, conjunctivitis, urethritis, chancroid, tularemia, cholera, brucellosis	[H][C@@]12Cc3c(ccc(O)c3C(=O)[C@@H]1C(=O)[C@]1(O)C(=O)[C@H](C(N)=O)C(=O)[C@@H](N(C)C)[C@]1([H])C2)N(C)C |&1:19,&2:12|	ZZZRUAITSXLWBH-NOHUXHDNSA-N	Launched
minodronic-acid	bone resorption inhibitor	FDPS, GGPS1	orthopedics	osteoporosis	OC(Cc1cnc2ccccn12)(P(O)(O)=O)P(O)(O)=O, OC(Cc1cnc2ccccn12)(P(O)(O)=O)P(O)(O)=O, OC(Cc1cnc2ccccn12)(P(O)(O)=O)P(O)(O)=O	VMMKGHQPQIEGSQ-UHFFFAOYSA-N, VMMKGHQPQIEGSQ-UHFFFAOYSA-N, VMMKGHQPQIEGSQ-UHFFFAOYSA-N	Launched
minoxidil	KATP activator, Kir6 channel (KATP) activator, vasodilator	ABCC9, KCNJ1, KCNJ10, KCNJ11, KCNJ8, PTGS1	endocrinology	androgenetic alopecia	Nc1cc(nc(N)[n+]1[O-])N1CCCCC1, Nc1cc(nc(N)[n+]1[O-])N1CCCCC1, Nc1cc(nc(N)[n+]1[O-])N1CCCCC1, Nc1cc(nc(N)[n+]1[O-])N1CCCCC1, Nc1cc(nc(N)[n+]1[O-])N1CCCCC1	ZFMITUMMTDLWHR-UHFFFAOYSA-N, ZFMITUMMTDLWHR-UHFFFAOYSA-N, ZFMITUMMTDLWHR-UHFFFAOYSA-N, ZFMITUMMTDLWHR-UHFFFAOYSA-N, ZFMITUMMTDLWHR-UHFFFAOYSA-N	Launched
miocamycin	other antibiotic		infectious disease	urinary tract infections, chlamydia	CCC(=O)O[C@H]1[C@H](C)O[C@H](C[C@@]1(C)OC(C)=O)O[C@@H]1[C@@H](C)O[C@@H](O[C@H]2[C@@H](CC=O)C[C@@H](C)[C@@H](OC(C)=O)\C=C\C=C\C[C@@H](C)OC(=O)C[C@@H](OC(=O)CC)[C@@H]2OC)[C@H](O)[C@H]1N(C)C |t:38,40|	GQNZGCARKRHPOH-XUDBFGHTSA-N	Launched
MIRA-1	apoptosis stimulant				CCC(=O)OCN1C(=O)C=CC1=O |c:9|	YXEWPGYLMHXLPS-UHFFFAOYSA-N	Preclinical
mirabegron	adrenergic receptor agonist	ADRB1, ADRB2, ADRB3	urology	urinary incontinence	Nc1nc(CC(=O)Nc2ccc(CCNC[C@H](O)c3ccccc3)cc2)cs1, Nc1nc(CC(=O)Nc2ccc(CCNC[C@H](O)c3ccccc3)cc2)cs1, Nc1nc(CC(=O)Nc2ccc(CCNC[C@H](O)c3ccccc3)cc2)cs1, Nc1nc(CC(=O)Nc2ccc(CCNC[C@H](O)c3ccccc3)cc2)cs1, Nc1nc(CC(=O)Nc2ccc(CCNC[C@H](O)c3ccccc3)cc2)cs1	PBAPPPCECJKMCM-IBGZPJMESA-N, PBAPPPCECJKMCM-IBGZPJMESA-N, PBAPPPCECJKMCM-IBGZPJMESA-N, PBAPPPCECJKMCM-IBGZPJMESA-N, PBAPPPCECJKMCM-IBGZPJMESA-N	Launched
miridesap	amyloid protein inhibitor				OC(=O)[C@H]1CCCN1C(=O)CCCCC(=O)N1CCC[C@@H]1C(O)=O	HZLAWYIBLZNRFZ-VXGBXAGGSA-N	Preclinical
mirin	MRE11A exonuclease inhibitor	MRE11A			NC1=NC(=O)\C(S1)=C\c1ccc(O)cc1 |t:1|, NC1=NC(=O)\C(S1)=C\c1ccc(O)cc1 |t:1|	YBHQCJILTOVLHD-YVMONPNESA-N, InChI=1S/C10H8N2O2S/c11-10-12-9(14)8(15-10)5-6-1-3-7(13)4-2-6/h1-5,13H,(H2,11,12,14)/b8-5-	Preclinical
miriplatin	DNA synthesis inhibitor		oncology	hepatocellular carcinoma (HCC)	[Pt++].N[C@H]1CCCC[C@@H]1N.CCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCC(O)=O |&1:2,&2:7,r|, [Pt++].N[C@H]1CCCC[C@@H]1N.CCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCC(O)=O |&1:2,&2:7,r|	BGIHRZPJIYJKAZ-JPLLOCSESA-N, BGIHRZPJIYJKAZ-JPLLOCSESA-N	Launched
mirodenafil	phosphodiesterase inhibitor	PDE5A	urology	erectile dysfunction	CCCOc1ccc(cc1-c1nc2c(CCC)cn(CC)c2c(=O)[nH]1)S(=O)(=O)N1CCN(CCO)CC1, CCCOc1ccc(cc1-c1nc2c(CCC)cn(CC)c2c(=O)[nH]1)S(=O)(=O)N1CCN(CCO)CC1, CCCOc1ccc(cc1-c1nc2c(CCC)cn(CC)c2c(=O)[nH]1)S(=O)(=O)N1CCN(CCO)CC1	MIJFNYMSCFYZNY-UHFFFAOYSA-N, MIJFNYMSCFYZNY-UHFFFAOYSA-N, MIJFNYMSCFYZNY-UHFFFAOYSA-N	Launched
mirogabalin-besylate	calcium channel antagonist				[H][C@@]12C[C@](CN)(CC(O)=O)[C@]1([H])C=C(CC)C2 |t:13|	FTBQORVNHOIASH-CKYFFXLPSA-N	Preclinical
mirtazapine	adrenergic receptor antagonist, serotonin receptor antagonist	ADRA2A, ADRA2B, ADRA2C, HTR2A, HTR2C	neurology/psychiatry	depression	CN1CCN2[C@@H](C1)c1ccccc1Cc1cccnc21 |&1:5,r|, CN1CCN2[C@@H](C1)c1ccccc1Cc1cccnc21 |&1:5,r|, CN1CCN2[C@@H](C1)c1ccccc1Cc1cccnc21 |&1:5,r|, CN1CCN2[C@@H](C1)c1ccccc1Cc1cccnc21 |&1:5,r|, CN1CCN2[C@@H](C1)c1ccccc1Cc1cccnc21 |&1:5,r|	RONZAEMNMFQXRA-INIZCTEOSA-N, RONZAEMNMFQXRA-INIZCTEOSA-N, RONZAEMNMFQXRA-INIZCTEOSA-N, RONZAEMNMFQXRA-INIZCTEOSA-N, RONZAEMNMFQXRA-INIZCTEOSA-N	Launched
misonidazole					COC[C@@H](O)Cn1ccnc1[N+]([O-])=O |&1:3,r|	OBBCSXFCDPPXOL-LURJTMIESA-N	Phase 3
misoprostol	prostanoid receptor agonist	PTGER2, PTGER3, PTGER4, PTGIR	gastroenterology	duodenal ulcer disease	CCCCC(C)(O)C\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(=O)OC |a:10,11,16,&1:4|	OJLOPKGSLYJEMD-URPKTTJQSA-N	Launched
mitapivat	pyruvate kinase isozyme activator				O=C(N1CCN(CC2CC2)CC1)c1ccc(NS(=O)(=O)c2cccc3cccnc23)cc1	XAYGBKHKBBXDAK-UHFFFAOYSA-N	Preclinical
mitiglinide	insulin secretagogue	ABCC8, KCNJ10, PPARG	endocrinology	diabetes mellitus	OC(=O)[C@H](CC(=O)N1C[C@H]2CCCC[C@H]2C1)Cc1ccccc1, OC(=O)[C@H](CC(=O)N1C[C@H]2CCCC[C@H]2C1)Cc1ccccc1	WPGGHFDDFPHPOB-BBWFWOEESA-N, WPGGHFDDFPHPOB-BBWFWOEESA-N	Launched
mitoflaxone	antitumor agent	VWF			OC(=O)Cc1cccc2c1oc(cc2=O)-c1ccccc1	TZZNWMJZDWYJAZ-UHFFFAOYSA-N	Phase 2
mitomycin-C	DNA alkylating agent, DNA synthesis inhibitor		oncology	pancreatic cancer, gastric adenocarcinoma	CO[C@]12[C@H]3N[C@H]3CN1C1=C([C@H]2COC(N)=O)C(=O)C(N)=C(C)C1=O |c:10,t:22|	NWIBSHFKIJFRCO-WUDYKRTCSA-N	Launched
mitoquinone	antioxidant				COC1=C(OC)C(=O)C(CCCCCCCCCC[P+](c2ccccc2)(c2ccccc2)c2ccccc2)=C(C)C1=O |c:2,t:40|, COC1=C(OC)C(=O)C(CCCCCCCCCC[P+](c2ccccc2)(c2ccccc2)c2ccccc2)=C(C)C1=O |c:2,t:40|	OIIMUKXVVLRCAF-UHFFFAOYSA-N, OIIMUKXVVLRCAF-UHFFFAOYSA-N	Launched
mitotane	antineoplastic agent	CYP11A1, CYP11B1, ESR1	oncology	adrenal cortical carcinoma	ClC(Cl)[C@@H](c1ccc(Cl)cc1)c1ccccc1Cl |&1:3,r|, ClC(Cl)[C@@H](c1ccc(Cl)cc1)c1ccccc1Cl |&1:3,r|, ClC(Cl)[C@@H](c1ccc(Cl)cc1)c1ccccc1Cl |&1:3,r|, ClC(Cl)[C@@H](c1ccc(Cl)cc1)c1ccccc1Cl |&1:3,r|, ClC(Cl)[C@@H](c1ccc(Cl)cc1)c1ccccc1Cl |&1:3,r|, ClC(Cl)[C@@H](c1ccc(Cl)cc1)c1ccccc1Cl |&1:3,r|	JWBOIMRXGHLCPP-ZDUSSCGKSA-N, JWBOIMRXGHLCPP-ZDUSSCGKSA-N, JWBOIMRXGHLCPP-ZDUSSCGKSA-N, JWBOIMRXGHLCPP-ZDUSSCGKSA-N, JWBOIMRXGHLCPP-ZDUSSCGKSA-N, JWBOIMRXGHLCPP-ZDUSSCGKSA-N	Launched
mitoxantrone	topoisomerase inhibitor	TOP2A	neurology/psychiatry, oncology, hematologic malignancy	multiple sclerosis, prostate cancer, acute myeloid leukemia (AML)	OCCNCCNc1ccc(NCCNCCO)c2C(=O)c3c(O)ccc(O)c3C(=O)c12, OCCNCCNc1ccc(NCCNCCO)c2C(=O)c3c(O)ccc(O)c3C(=O)c12, OCCNCCNc1ccc(NCCNCCO)c2C(=O)c3c(O)ccc(O)c3C(=O)c12, OCCNCCNc1ccc(NCCNCCO)c2C(=O)c3c(O)ccc(O)c3C(=O)c12, OCCNCCNc1ccc(NCCNCCO)c2C(=O)c3c(O)ccc(O)c3C(=O)c12, OCCNCCNc1ccc(NCCNCCO)c2C(=O)c3c(O)ccc(O)c3C(=O)c12, OCCNCCNc1ccc(NCCNCCO)c2C(=O)c3c(O)ccc(O)c3C(=O)c12, OCCNCCNc1ccc(NCCNCCO)c2C(=O)c3c(O)ccc(O)c3C(=O)c12	KKZJGLLVHKMTCM-UHFFFAOYSA-N, KKZJGLLVHKMTCM-UHFFFAOYSA-N, KKZJGLLVHKMTCM-UHFFFAOYSA-N, KKZJGLLVHKMTCM-UHFFFAOYSA-N, KKZJGLLVHKMTCM-UHFFFAOYSA-N, KKZJGLLVHKMTCM-UHFFFAOYSA-N, KKZJGLLVHKMTCM-UHFFFAOYSA-N, KKZJGLLVHKMTCM-UHFFFAOYSA-N	Launched
mivacurium	acetylcholine receptor antagonist	CHRNA2	critical care, neurology/psychiatry	endotracheal intubation, muscle relaxant	COc1cc2CC[N@@+](C)(CCCOC(=O)CC\C=C\CCC(=O)OCCC[N@@+]3(C)CCc4cc(OC)c(OC)cc4[C@H]3Cc3cc(OC)c(OC)c(OC)c3)[C@H](Cc3cc(OC)c(OC)c(OC)c3)c2cc1OC |a:41,55,&1:7,&2:27|	ILVYCEVXHALBSC-GZICNWBJSA-N	Launched
mivebresib	bromodomain inhibitor				CCS(=O)(=O)Nc1ccc(Oc2ccc(F)cc2F)c(c1)-c1cn(C)c(=O)c2[nH]ccc12, CCS(=O)(=O)Nc1ccc(Oc2ccc(F)cc2F)c(c1)-c1cn(C)c(=O)c2[nH]ccc12	RDONXGFGWSSFMY-UHFFFAOYSA-N, RDONXGFGWSSFMY-UHFFFAOYSA-N	Phase 1
mivobulin	microtubule inhibitor				CCOC(=O)Nc1cc2N=C(C)C(Nc2c(N)n1)c1ccccc1 |t:9|	XOJFFEJRKAIVCH-UHFFFAOYSA-N	Phase 2
MIW-815	interferon inducer				[H][C@]12CO[P@](S)(=O)O[C@@]3([H])[C@@H](O)[C@@H](O[C@]3([H])CO[P@](S)(=O)O[C@@]([H])([C@@H](O1)n1cnc3c(N)ncnc13)[C@]2([H])O)n1cnc2c(N)ncnc12	IZJJFUQKKZFVLH-YBVMPXGUSA-N	Preclinical
mizolastine	histamine receptor antagonist	HRH1	allergy	urticaria, allergic rhinitis	CN(C1CCN(CC1)c1nc2ccccc2n1Cc1ccc(F)cc1)c1nc(=O)cc[nH]1, CN(C1CCN(CC1)c1nc2ccccc2n1Cc1ccc(F)cc1)c1nc(=O)cc[nH]1	PVLJETXTTWAYEW-UHFFFAOYSA-N, PVLJETXTTWAYEW-UHFFFAOYSA-N	Launched
mizoribine	immunosuppressant, inosine monophosphate dehydrogenase inhibitor	IMPDH1	transplant, rheumatology	organ rejection, nephrotic syndrome	NC(=O)C1N=CN([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)C1=O |c:4|, NC(=O)C1N=CN([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)C1=O |c:4|, NC(=O)C1N=CN([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)C1=O |c:4|, NC(=O)C1N=CN([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)C1=O |c:4|	OPMVDWXPLVKNQN-AAXBYFMASA-N, OPMVDWXPLVKNQN-AAXBYFMASA-N, OPMVDWXPLVKNQN-AAXBYFMASA-N, OPMVDWXPLVKNQN-AAXBYFMASA-N	Launched
MJ-15	cannabinoid receptor antagonist	CNR1			Cc1c(nn(c1-c1ccc(Cl)cc1)-c1ccc(Cl)cc1Cl)C(=O)NCc1cccnc1, Cc1c(nn(c1-c1ccc(Cl)cc1)-c1ccc(Cl)cc1Cl)C(=O)NCc1cccnc1	PJEIKJFNEFJFLA-UHFFFAOYSA-N, PJEIKJFNEFJFLA-UHFFFAOYSA-N	Preclinical
MK-0354	niacin receptor agonist	HCAR2, HCAR3			C1Cc2[nH]nc(-c3nn[nH]n3)c2C1	LTQYSJKGRPGMPO-UHFFFAOYSA-N	Phase 2
MK-0557	neuropeptide receptor antagonist				Fc1ccccc1-n1ccc(NC(=O)[C@H]2CC[C@]3(CC2)OC(=O)c2ccncc32)n1 |r|	RMYZIRFUCOMQRH-XLOAEROZSA-N	Phase 3
MK-0608	antiviral				C[C@@]1(O)[C@H](O)[C@@H](CO)O[C@H]1n1ccc2c(N)ncnc12	IRZRJANZDIOOIF-GAJNKVMBSA-N	Phase 1
MK-0752	gamma secretase inhibitor				OC(=O)CC[C@H]1CC[C@@](CC1)(c1cc(F)ccc1F)S(=O)(=O)c1ccc(Cl)cc1 |r|, OC(=O)CC[C@H]1CC[C@@](CC1)(c1cc(F)ccc1F)S(=O)(=O)c1ccc(Cl)cc1 |r|	XCGJIFAKUZNNOR-QCKZDCLWSA-N, XCGJIFAKUZNNOR-QCKZDCLWSA-N	Phase 1/Phase 2
MK-0773	androgen receptor modulator	AR			CN1[C@@H]2CC[C@H]3[C@@H]4CC[C@H](C(=O)NCc5nc6ncccc6[nH]5)[C@@]4(C)CC[C@@H]3[C@@]2(C)C=C(F)C1=O |t:35|, CN1[C@@H]2CC[C@H]3[C@@H]4CC[C@H](C(=O)NCc5nc6ncccc6[nH]5)[C@@]4(C)CC[C@@H]3[C@@]2(C)C=C(F)C1=O |t:35|, CN1[C@@H]2CC[C@H]3[C@@H]4CC[C@H](C(=O)NCc5nc6ncccc6[nH]5)[C@@]4(C)CC[C@@H]3[C@@]2(C)C=C(F)C1=O |t:35|	GBEUKTWTUSPHEE-JWJWXJQQSA-N, GBEUKTWTUSPHEE-JWJWXJQQSA-N, GBEUKTWTUSPHEE-JWJWXJQQSA-N	Phase 2
MK-0812	CC chemokine receptor antagonist	CCR2			CO[C@@H]1COCC[C@@H]1N[C@@H]1CC[C@](C1)(C(C)C)C(=O)N1CCc2ncc(cc2C1)C(F)(F)F, CO[C@@H]1COCC[C@@H]1N[C@@H]1CC[C@](C1)(C(C)C)C(=O)N1CCc2ncc(cc2C1)C(F)(F)F, CO[C@@H]1COCC[C@@H]1N[C@@H]1CC[C@](C1)(C(C)C)C(=O)N1CCc2ncc(cc2C1)C(F)(F)F	MTMDXAIUENDNDL-RJSMDTJLSA-N, MTMDXAIUENDNDL-RJSMDTJLSA-N, MTMDXAIUENDNDL-RJSMDTJLSA-N	Phase 2
MK-0893	glucagon receptor antagonist	GCGR			COc1ccc2cc(ccc2c1)-c1cc(nn1[C@@H](C)c1ccc(cc1)C(=O)NCCC(O)=O)-c1cc(Cl)cc(Cl)c1, COc1ccc2cc(ccc2c1)-c1cc(nn1[C@@H](C)c1ccc(cc1)C(=O)NCCC(O)=O)-c1cc(Cl)cc(Cl)c1, COc1ccc2cc(ccc2c1)-c1cc(nn1[C@@H](C)c1ccc(cc1)C(=O)NCCC(O)=O)-c1cc(Cl)cc(Cl)c1, COc1ccc2cc(ccc2c1)-c1cc(nn1[C@@H](C)c1ccc(cc1)C(=O)NCCC(O)=O)-c1cc(Cl)cc(Cl)c1, COc1ccc2cc(ccc2c1)-c1cc(nn1[C@@H](C)c1ccc(cc1)C(=O)NCCC(O)=O)-c1cc(Cl)cc(Cl)c1	DNTVJEMGHBIUMW-IBGZPJMESA-N, DNTVJEMGHBIUMW-IBGZPJMESA-N, DNTVJEMGHBIUMW-IBGZPJMESA-N, DNTVJEMGHBIUMW-IBGZPJMESA-N, DNTVJEMGHBIUMW-IBGZPJMESA-N	Phase 2
MK-1064	orexin receptor antagonist				COc1ccc(CNC(=O)c2cc(cnc2-c2ccccn2)-c2cncc(Cl)c2)nc1OC	CKTWQGHVNRYNCM-UHFFFAOYSA-N	Phase 1
MK-1775	WEE1 kinase inhibitor	WEE1			CN1CCN(CC1)c1ccc(Nc2ncc3c(n2)n(-c2cccc(n2)C(C)(C)O)n(CC=C)c3=O)cc1, CN1CCN(CC1)c1ccc(Nc2ncc3c(n2)n(-c2cccc(n2)C(C)(C)O)n(CC=C)c3=O)cc1, CN1CCN(CC1)c1ccc(Nc2ncc3c(n2)n(-c2cccc(n2)C(C)(C)O)n(CC=C)c3=O)cc1, CN1CCN(CC1)c1ccc(Nc2ncc3c(n2)n(-c2cccc(n2)C(C)(C)O)n(CC=C)c3=O)cc1	BKWJAKQVGHWELA-UHFFFAOYSA-N, BKWJAKQVGHWELA-UHFFFAOYSA-N, BKWJAKQVGHWELA-UHFFFAOYSA-N, InChI=1S/C27H32N8O2/c1-5-13-34-25(36)21-18-28-26(29-19-9-11-20(12-10-19)33-16-14-32(4)15-17-33)31-24(21)35(34)23-8-6-7-22(30-23)27(2,3)37/h5-12,18,37H,1,13-17H2,2-4H3,(H,28,29,31)	Phase 2
MK-1903	niacin receptor agonist				OC(=O)c1n[nH]c2[C@@H]3C[C@@H]3Cc12	CUTZNERBKDMLAP-QWWZWVQMSA-N	Phase 2
MK-2048	HIV integrase inhibitor				CCN1C[C@H](C)n2c(c(O)c3c2c(nn(Cc2ccc(F)c(Cl)c2)c3=O)C(=O)NC)C1=O, CCN1C[C@H](C)n2c(c(O)c3c2c(nn(Cc2ccc(F)c(Cl)c2)c3=O)C(=O)NC)C1=O, CCN1C[C@H](C)n2c(c(O)c3c2c(nn(Cc2ccc(F)c(Cl)c2)c3=O)C(=O)NC)C1=O	JSRREMIKIHJGAA-JTQLQIEISA-N, JSRREMIKIHJGAA-JTQLQIEISA-N, JSRREMIKIHJGAA-JTQLQIEISA-N	Preclinical
MK-2206	AKT inhibitor	AKT1, AKT2, AKT3			NC1(CCC1)c1ccc(cc1)-c1nc2ccn3c(n[nH]c3=O)c2cc1-c1ccccc1, NC1(CCC1)c1ccc(cc1)-c1nc2ccn3c(n[nH]c3=O)c2cc1-c1ccccc1, NC1(CCC1)c1ccc(cc1)-c1nc2ccn3c(n[nH]c3=O)c2cc1-c1ccccc1, NC1(CCC1)c1ccc(cc1)-c1nc2ccn3c(n[nH]c3=O)c2cc1-c1ccccc1, NC1(CCC1)c1ccc(cc1)-c1nc2ccn3c(n[nH]c3=O)c2cc1-c1ccccc1, NC1(CCC1)c1ccc(cc1)-c1nc2ccn3c(n[nH]c3=O)c2cc1-c1ccccc1, NC1(CCC1)c1ccc(cc1)-c1nc2ccn3c(n[nH]c3=O)c2cc1-c1ccccc1, NC1(CCC1)c1ccc(cc1)-c1nc2ccn3c(n[nH]c3=O)c2cc1-c1ccccc1, NC1(CCC1)c1ccc(cc1)-c1nc2ccn3c(n[nH]c3=O)c2cc1-c1ccccc1, NC1(CCC1)c1ccc(cc1)-c1nc2ccn3c(n[nH]c3=O)c2cc1-c1ccccc1, NC1(CCC1)c1ccc(cc1)-c1nc2ccn3c(n[nH]c3=O)c2cc1-c1ccccc1, NC1(CCC1)c1ccc(cc1)-c1nc2ccn3c(n[nH]c3=O)c2cc1-c1ccccc1	ULDXWLCXEDXJGE-UHFFFAOYSA-N, ULDXWLCXEDXJGE-UHFFFAOYSA-N, ULDXWLCXEDXJGE-UHFFFAOYSA-N, ULDXWLCXEDXJGE-UHFFFAOYSA-N, ULDXWLCXEDXJGE-UHFFFAOYSA-N, ULDXWLCXEDXJGE-UHFFFAOYSA-N, InChI=1S/C25H21N5O/c26-25(12-4-13-25)18-9-7-17(8-10-18)22-19(16-5-2-1-3-6-16)15-20-21(27-22)11-14-30-23(20)28-29-24(30)31/h1-3,5-11,14-15H,4,12-13,26H2,(H,29,31), InChI=1S/C25H21N5O/c26-25(12-4-13-25)18-9-7-17(8-10-18)22-19(16-5-2-1-3-6-16)15-20-21(27-22)11-14-30-23(20)28-29-24(30)31/h1-3,5-11,14-15H,4,12-13,26H2,(H,29,31), InChI=1S/C25H21N5O/c26-25(12-4-13-25)18-9-7-17(8-10-18)22-19(16-5-2-1-3-6-16)15-20-21(27-22)11-14-30-23(20)28-29-24(30)31/h1-3,5-11,14-15H,4,12-13,26H2,(H,29,31), InChI=1S/C25H21N5O/c26-25(12-4-13-25)18-9-7-17(8-10-18)22-19(16-5-2-1-3-6-16)15-20-21(27-22)11-14-30-23(20)28-29-24(30)31/h1-3,5-11,14-15H,4,12-13,26H2,(H,29,31), InChI=1S/C25H21N5O/c26-25(12-4-13-25)18-9-7-17(8-10-18)22-19(16-5-2-1-3-6-16)15-20-21(27-22)11-14-30-23(20)28-29-24(30)31/h1-3,5-11,14-15H,4,12-13,26H2,(H,29,31), InChI=1S/C25H21N5O/c26-25(12-4-13-25)18-9-7-17(8-10-18)22-19(16-5-2-1-3-6-16)15-20-21(27-22)11-14-30-23(20)28-29-24(30)31/h1-3,5-11,14-15H,4,12-13,26H2,(H,29,31)	Phase 2
MK-2295	TRPV antagonist	TRPV1			FC(F)(F)c1ccc(Nc2ncnc3cc(ccc23)-c2ncccc2C(F)(F)F)cc1	VTANGSDRFFLTSQ-UHFFFAOYSA-N	Phase 2
MK-2461	FGFR inhibitor, VEGFR inhibitor	FGFR1, FGFR2, FGFR3, FLT1, FLT3, FLT4, KDR, MERTK, MET, MST1R, NTRK1, NTRK2, PDGFRB			CN(C[C@@H]1COCCO1)S(=O)(=O)Nc1ccc2ccc3ncc(cc3c(=O)c2c1)-c1cnn(C)c1, CN(C[C@@H]1COCCO1)S(=O)(=O)Nc1ccc2ccc3ncc(cc3c(=O)c2c1)-c1cnn(C)c1	JGEBLDKNWBUGRZ-HXUWFJFHSA-N, JGEBLDKNWBUGRZ-HXUWFJFHSA-N	Phase 1/Phase 2
MK-2894	prostaglandin inhibitor	PTGER4			Cc1sc(C)c(C(=O)NC2(CC2)c2ccc(cc2)C(O)=O)c1Cc1ccc(cc1)C(F)(F)F	QJZQFVRFJCGDKF-UHFFFAOYSA-N	Preclinical
MK-3207	calcitonin antagonist	CALCA			Fc1cc(F)cc(c1)[C@@H]1CNC2(CCCC2)C(=O)N1CC(=O)Nc1ccc2C[C@]3(Cc2c1)C(=O)Nc1ncccc31, Fc1cc(F)cc(c1)[C@@H]1CNC2(CCCC2)C(=O)N1CC(=O)Nc1ccc2C[C@]3(Cc2c1)C(=O)Nc1ncccc31, Fc1cc(F)cc(c1)[C@@H]1CNC2(CCCC2)C(=O)N1CC(=O)Nc1ccc2C[C@]3(Cc2c1)C(=O)Nc1ncccc31	AZAANWYREOQRFB-SETSBSEESA-N, AZAANWYREOQRFB-SETSBSEESA-N, AZAANWYREOQRFB-SETSBSEESA-N	Phase 2
MK-3697	orexin receptor antagonist	HCRTR2			COc1ccc(CNC(=O)c2cc(ncc2-c2nccs2)-c2cncc(C)c2)nc1OC, COc1ccc(CNC(=O)c2cc(ncc2-c2nccs2)-c2cncc(C)c2)nc1OC	VSOUDUXMPUHJEU-UHFFFAOYSA-N, VSOUDUXMPUHJEU-UHFFFAOYSA-N	Phase 2
MK-4074	acetyl-CoA carboxylase inhibitor				COc1cc(cc2n(cc(C)c12)C1CC1)C(=O)N1CCC2(CC1)CC(=O)c1cc(ccc1O2)-c1cncc(c1)C(O)=O	WDBNGXLHMZSUEI-UHFFFAOYSA-N	Phase 1
MK-5046	bombesin receptor agonist	BRS3, GRPR, NMBR			O[C@@](Cc1ncc(CC2(CC2)C(F)(F)F)[nH]1)(c1ccc(cc1)-n1cccn1)C(F)(F)F	UJINBEQCDMOAHM-SFHVURJKSA-N	Preclinical
MK-5108	Aurora kinase inhibitor	AURKA, AURKB, AURKC			OC(=O)[C@@]1(Cc2cccc(Nc3nccs3)n2)CC[C@@H](CC1)Oc1cccc(Cl)c1F |r|, OC(=O)[C@@]1(Cc2cccc(Nc3nccs3)n2)CC[C@@H](CC1)Oc1cccc(Cl)c1F |r|, OC(=O)[C@@]1(Cc2cccc(Nc3nccs3)n2)CC[C@@H](CC1)Oc1cccc(Cl)c1F |r|, OC(=O)[C@@]1(Cc2cccc(Nc3nccs3)n2)CC[C@@H](CC1)Oc1cccc(Cl)c1F |r|, OC(=O)[C@@]1(Cc2cccc(Nc3nccs3)n2)CC[C@@H](CC1)Oc1cccc(Cl)c1F |r|, OC(=O)[C@@]1(Cc2cccc(Nc3nccs3)n2)CC[C@@H](CC1)Oc1cccc(Cl)c1F |r|	LCVIRAZGMYMNNT-VVONHTQRSA-N, LCVIRAZGMYMNNT-VVONHTQRSA-N, LCVIRAZGMYMNNT-VVONHTQRSA-N, LCVIRAZGMYMNNT-VVONHTQRSA-N, LCVIRAZGMYMNNT-VVONHTQRSA-N, LCVIRAZGMYMNNT-VVONHTQRSA-N	Phase 1
MK-571	leukotriene receptor antagonist	ABCC2, CYSLTR1			CN(C)C(=O)CCS[C@@H](SCCC(O)=O)c1cccc(\C=C\c2ccc3ccc(Cl)cc3n2)c1 |&1:8|, CN(C)C(=O)CCS[C@@H](SCCC(O)=O)c1cccc(\C=C\c2ccc3ccc(Cl)cc3n2)c1 |&1:8|	AXUZQJFHDNNPFG-JORPFSLRSA-N, AXUZQJFHDNNPFG-JORPFSLRSA-N	Phase 2
MK-6096	orexin receptor antagonist	HCRTR1, HCRTR2			C[C@@H]1CC[C@@H](COc2ccc(F)cn2)CN1C(=O)c1cc(C)ccc1-c1ncccn1	NPFDWHQSDBWQLH-QZTJIDSGSA-N	Phase 2
MK-7246	CRTH receptor antagonist				CN([C@@H]1CCc2c(CC(O)=O)c3ccccc3n2C1)S(=O)(=O)c1ccc(F)cc1	JTCAGRAKUAAYDY-OAHLLOKOSA-N	Preclinical
MK-7622	cholinergic receptor agonist				Cc1ccc(Cc2cc3c(ncn([C@H]4CCCC[C@@H]4O)c3=O)c3ccccc23)cn1	JUVQLZBJFOGEEO-GOTSBHOMSA-N	Phase 2
MK-8033	c-Met inhibitor	MET			Cn1cc(cn1)-c1cnc2ccc3ccc(CS(=O)(=O)NCc4ccccn4)cc3c(=O)c2c1, Cn1cc(cn1)-c1cnc2ccc3ccc(CS(=O)(=O)NCc4ccccn4)cc3c(=O)c2c1, Cn1cc(cn1)-c1cnc2ccc3ccc(CS(=O)(=O)NCc4ccccn4)cc3c(=O)c2c1	VMJFTOSOFDEKTM-UHFFFAOYSA-N, VMJFTOSOFDEKTM-UHFFFAOYSA-N, VMJFTOSOFDEKTM-UHFFFAOYSA-N	Phase 1
MK-8245	stearoyl-CoA desaturase inhibitor	SCD			OC(=O)Cn1nnc(n1)-c1cc(no1)N1CCC(CC1)Oc1cc(F)ccc1Br, OC(=O)Cn1nnc(n1)-c1cc(no1)N1CCC(CC1)Oc1cc(F)ccc1Br, OC(=O)Cn1nnc(n1)-c1cc(no1)N1CCC(CC1)Oc1cc(F)ccc1Br, OC(=O)Cn1nnc(n1)-c1cc(no1)N1CCC(CC1)Oc1cc(F)ccc1Br, OC(=O)Cn1nnc(n1)-c1cc(no1)N1CCC(CC1)Oc1cc(F)ccc1Br	UJEAABFSXKCSGI-UHFFFAOYSA-N, UJEAABFSXKCSGI-UHFFFAOYSA-N, UJEAABFSXKCSGI-UHFFFAOYSA-N, UJEAABFSXKCSGI-UHFFFAOYSA-N, UJEAABFSXKCSGI-UHFFFAOYSA-N	Phase 2
MK-8617	hypoxia inducible factor prolyl hydroxylase inhibitor				COc1ccc(cc1)C(NC(=O)c1cnc(nc1O)-c1cccnn1)c1ccc(OC)cc1	WXLPERVDMILVIF-UHFFFAOYSA-N	Preclinical
MK-8745	Aurora kinase inhibitor	AURKA			Fc1c(Cl)cccc1C(=O)N1CCN(Cc2cccc(Nc3nccs3)n2)CC1, Fc1c(Cl)cccc1C(=O)N1CCN(Cc2cccc(Nc3nccs3)n2)CC1	YCRFPWKUUNKNDN-UHFFFAOYSA-N, YCRFPWKUUNKNDN-UHFFFAOYSA-N	Preclinical
MK-886	lipoxygenase inhibitor				CC(C)c1ccc2n(Cc3ccc(Cl)cc3)c(CC(C)(C)C(O)=O)c(SC(C)(C)C)c2c1	QAOAOVKBIIKRNL-UHFFFAOYSA-N	Preclinical
MK-8998	T-type calcium channel blocker				CC(C)c1ccc(CC(=O)N[C@H](C)c2ccc(OCC(F)(F)F)cn2)cc1	IQIKXZMPPBEWAD-CQSZACIVSA-N	Phase 2
MKT-077	HSP inhibitor				CCn1\c(=C/c2cccc[n+]2CC)s\c(=C2\Sc3ccccc3N2C)c1=O, CCn1\c(=C/c2cccc[n+]2CC)s\c(=C2\Sc3ccccc3N2C)c1=O	QLYHOWIZHHZGPV-XUTLUUPISA-N, QLYHOWIZHHZGPV-XUTLUUPISA-N	Phase 1
MK2-IN-1	MAP kinase inhibitor	MAPKAPK2			Clc1ccc(cc1)-c1ccc(o1)C(=O)N(Cc1ccccn1)c1ccc(cc1)N1CCNCC1	LIPNXDIBECKOMJ-UHFFFAOYSA-N	Preclinical
MLN0128	mTOR inhibitor	MTOR, PIK3CA, PIK3CD, PIK3CG			CC(C)n1nc(-c2ccc3oc(N)nc3c2)c2c(N)ncnc12, CC(C)n1nc(-c2ccc3oc(N)nc3c2)c2c(N)ncnc12, CC(C)n1nc(-c2ccc3oc(N)nc3c2)c2c(N)ncnc12, CC(C)n1nc(-c2ccc3oc(N)nc3c2)c2c(N)ncnc12, CC(C)n1nc(-c2ccc3oc(N)nc3c2)c2c(N)ncnc12	GYLDXIAOMVERTK-UHFFFAOYSA-N, GYLDXIAOMVERTK-UHFFFAOYSA-N, GYLDXIAOMVERTK-UHFFFAOYSA-N, GYLDXIAOMVERTK-UHFFFAOYSA-N, GYLDXIAOMVERTK-UHFFFAOYSA-N	Phase 2
MLN1117	PI3K inhibitor	PIK3CA			Nc1nc2cc(ccc2o1)-c1ccc2ncc(C(=O)N3CCOCC3)n2c1, Nc1nc2cc(ccc2o1)-c1ccc2ncc(C(=O)N3CCOCC3)n2c1	BLGWHBSBBJNKJO-UHFFFAOYSA-N, BLGWHBSBBJNKJO-UHFFFAOYSA-N	Phase 2
MLN2480	RAF inhibitor				C[C@@H](NC(=O)c1ncnc(N)c1Cl)c1ncc(s1)C(=O)Nc1cc(c(Cl)cn1)C(F)(F)F, C[C@@H](NC(=O)c1ncnc(N)c1Cl)c1ncc(s1)C(=O)Nc1cc(c(Cl)cn1)C(F)(F)F	VWMJHAFYPMOMGF-ZCFIWIBFSA-N, VWMJHAFYPMOMGF-ZCFIWIBFSA-N	Phase 1/Phase 2
MLN8054	Aurora kinase inhibitor	AURKA			OC(=O)c1ccc(Nc2ncc3CN=C(c4cc(Cl)ccc4-c3n2)c2c(F)cccc2F)cc1 |c:13|, OC(=O)c1ccc(Nc2ncc3CN=C(c4cc(Cl)ccc4-c3n2)c2c(F)cccc2F)cc1 |c:13|, OC(=O)c1ccc(Nc2ncc3CN=C(c4cc(Cl)ccc4-c3n2)c2c(F)cccc2F)cc1 |c:13|, OC(=O)c1ccc(Nc2ncc3CN=C(c4cc(Cl)ccc4-c3n2)c2c(F)cccc2F)cc1 |c:13|	HHFBDROWDBDFBR-UHFFFAOYSA-N, HHFBDROWDBDFBR-UHFFFAOYSA-N, HHFBDROWDBDFBR-UHFFFAOYSA-N, HHFBDROWDBDFBR-UHFFFAOYSA-N	Phase 1
MLN9708	proteasome inhibitor				CC(C)C[C@H](NC(=O)CNC(=O)c1cc(Cl)ccc1Cl)B1OC(=O)C(CC(O)=O)(CC(O)=O)O1, CC(C)C[C@H](NC(=O)CNC(=O)c1cc(Cl)ccc1Cl)B1OC(=O)C(CC(O)=O)(CC(O)=O)O1	MBOMYENWWXQSNW-AWEZNQCLSA-N, MBOMYENWWXQSNW-AWEZNQCLSA-N	Phase 3
ML10302	serotonin receptor partial agonist	HTR3A, HTR3B, HTR4			COc1cc(N)c(Cl)cc1C(=O)OCCN1CCCCC1, COc1cc(N)c(Cl)cc1C(=O)OCCN1CCCCC1, COc1cc(N)c(Cl)cc1C(=O)OCCN1CCCCC1	RVFIAQAAZUEPPE-UHFFFAOYSA-N, RVFIAQAAZUEPPE-UHFFFAOYSA-N, RVFIAQAAZUEPPE-UHFFFAOYSA-N	Preclinical
ML130	NOD1 inhibitor				Cc1ccc(cc1)S(=O)(=O)n1c(N)nc2ccccc12, Cc1ccc(cc1)S(=O)(=O)n1c(N)nc2ccccc12, Cc1ccc(cc1)S(=O)(=O)n1c(N)nc2ccccc12	SRFABRWQVPCPRG-UHFFFAOYSA-N, SRFABRWQVPCPRG-UHFFFAOYSA-N, SRFABRWQVPCPRG-UHFFFAOYSA-N	Preclinical
ML133	potassium channel blocker				COc1ccc(CNCc2cccc3ccccc23)cc1, COc1ccc(CNCc2cccc3ccccc23)cc1	GIFYKGIODMXYNT-UHFFFAOYSA-N, GIFYKGIODMXYNT-UHFFFAOYSA-N	Preclinical
ML141	GTPase inhibitor	CDC42			COc1ccc(cc1)[C@H]1CC(=NN1c1ccc(cc1)S(N)(=O)=O)c1ccccc1 |&1:8,r,c:11|, COc1ccc(cc1)[C@H]1CC(=NN1c1ccc(cc1)S(N)(=O)=O)c1ccccc1 |&1:8,r,c:11|	QBNZBMVRFYREHK-JOCHJYFZSA-N, QBNZBMVRFYREHK-JOCHJYFZSA-N	Preclinical
ML161	protease-activated receptor inhibitor				CCCC(=O)Nc1cccc(NC(=O)c2ccccc2Br)c1, CCCC(=O)Nc1cccc(NC(=O)c2ccccc2Br)c1	DFOVLSMXPWPCFH-UHFFFAOYSA-N, DFOVLSMXPWPCFH-UHFFFAOYSA-N	Preclinical
ML167	CLK inhibitor, DYRK inhibitor	CLK4, DYRK1B			Cc1ccc(CNc2ncnc3ccc(cc23)-c2ccc(CO)o2)o1, Cc1ccc(CNc2ncnc3ccc(cc23)-c2ccc(CO)o2)o1	ROCFOIBAEVAOLQ-UHFFFAOYSA-N, ROCFOIBAEVAOLQ-UHFFFAOYSA-N	Preclinical
ML179	liver receptor homolog inverse agonist	NR5A2			FC(F)(F)c1cccc(c1)N1CCN(CC1)c1cc(=O)n(C2CCCCC2)c(=O)[nH]1, FC(F)(F)c1cccc(c1)N1CCN(CC1)c1cc(=O)n(C2CCCCC2)c(=O)[nH]1	MFABFKUNLDYKGH-UHFFFAOYSA-N, MFABFKUNLDYKGH-UHFFFAOYSA-N	Preclinical
ML193	G protein-coupled receptor antagonist	GPR55			Cc1noc(NS(=O)(=O)c2ccc(NC(=O)c3cc(nc4c(C)cc(C)cc34)-c3ccccn3)cc2)c1C, Cc1noc(NS(=O)(=O)c2ccc(NC(=O)c3cc(nc4c(C)cc(C)cc34)-c3ccccn3)cc2)c1C, Cc1noc(NS(=O)(=O)c2ccc(NC(=O)c3cc(nc4c(C)cc(C)cc34)-c3ccccn3)cc2)c1C	HTSLEZOTMYUPLU-UHFFFAOYSA-N, HTSLEZOTMYUPLU-UHFFFAOYSA-N, HTSLEZOTMYUPLU-UHFFFAOYSA-N	Preclinical
ML204	transient receptor potential channel antagonist	TRPC4, TRPC5			Cc1cc(nc2ccccc12)N1CCCCC1, Cc1cc(nc2ccccc12)N1CCCCC1	USYRQXDHKXGTCK-UHFFFAOYSA-N, USYRQXDHKXGTCK-UHFFFAOYSA-N	Preclinical
ML213	potassium channel activator	KCNQ4			Cc1cc(C)c(NC(=O)[C@@H]2C[C@H]3CC[C@@H]2C3)c(C)c1 |&1:11,14,&2:9,r|	SIQGKPGBLYKQBB-RRFJBIMHSA-N	Preclinical
ML218	T-type calcium channel blocker	CACNA1G, CACNA1H, CACNA1I			CC(C)(C)CCN1C[C@H]2[C@H](CNC(=O)c3cc(Cl)cc(Cl)c3)[C@H]2C1, CC(C)(C)CCN1C[C@H]2[C@H](CNC(=O)c3cc(Cl)cc(Cl)c3)[C@H]2C1	GSJIGYLGKSBYBC-OSYLJGHBSA-N, GSJIGYLGKSBYBC-OSYLJGHBSA-N	Preclinical
ML228	hypoxia inducible factor activator	HIF1A			C(Nc1nc(nnc1-c1ccccc1)-c1ccccn1)c1ccc(cc1)-c1ccccc1, C(Nc1nc(nnc1-c1ccccc1)-c1ccccn1)c1ccc(cc1)-c1ccccc1, C(Nc1nc(nnc1-c1ccccc1)-c1ccccn1)c1ccc(cc1)-c1ccccc1, C(Nc1nc(nnc1-c1ccccc1)-c1ccccn1)c1ccc(cc1)-c1ccccc1, C(Nc1nc(nnc1-c1ccccc1)-c1ccccn1)c1ccc(cc1)-c1ccccc1, C(Nc1nc(nnc1-c1ccccc1)-c1ccccn1)c1ccc(cc1)-c1ccccc1, C(Nc1nc(nnc1-c1ccccc1)-c1ccccn1)c1ccc(cc1)-c1ccccc1	QNRODODTMXCRKU-UHFFFAOYSA-N, QNRODODTMXCRKU-UHFFFAOYSA-N, InChI=1S/C27H21N5/c1-3-9-21(10-4-1)22-16-14-20(15-17-22)19-29-27-25(23-11-5-2-6-12-23)31-32-26(30-27)24-13-7-8-18-28-24/h1-18H,19H2,(H,29,30,32), InChI=1S/C27H21N5/c1-3-9-21(10-4-1)22-16-14-20(15-17-22)19-29-27-25(23-11-5-2-6-12-23)31-32-26(30-27)24-13-7-8-18-28-24/h1-18H,19H2,(H,29,30,32), InChI=1S/C27H21N5/c1-3-9-21(10-4-1)22-16-14-20(15-17-22)19-29-27-25(23-11-5-2-6-12-23)31-32-26(30-27)24-13-7-8-18-28-24/h1-18H,19H2,(H,29,30,32), InChI=1S/C27H21N5/c1-3-9-21(10-4-1)22-16-14-20(15-17-22)19-29-27-25(23-11-5-2-6-12-23)31-32-26(30-27)24-13-7-8-18-28-24/h1-18H,19H2,(H,29,30,32), InChI=1S/C27H21N5/c1-3-9-21(10-4-1)22-16-14-20(15-17-22)19-29-27-25(23-11-5-2-6-12-23)31-32-26(30-27)24-13-7-8-18-28-24/h1-18H,19H2,(H,29,30,32)	Preclinical
ML277	potassium channel activator	KCNQ1			COc1ccc(cc1)-c1csc(NC(=O)[C@H]2CCCCN2S(=O)(=O)c2ccc(C)cc2)n1, COc1ccc(cc1)-c1csc(NC(=O)[C@H]2CCCCN2S(=O)(=O)c2ccc(C)cc2)n1, COc1ccc(cc1)-c1csc(NC(=O)[C@H]2CCCCN2S(=O)(=O)c2ccc(C)cc2)n1	OXQNLLVUVDAEHC-OAQYLSRUSA-N, OXQNLLVUVDAEHC-OAQYLSRUSA-N, OXQNLLVUVDAEHC-OAQYLSRUSA-N	Preclinical
ML281	serine/threonine kinase inhibitor	STK33			CC(C)c1ccc(NC(=O)c2cccs2)c(c1)-c1nc2ccccc2[nH]c1=O, CC(C)c1ccc(NC(=O)c2cccs2)c(c1)-c1nc2ccccc2[nH]c1=O, CC(C)c1ccc(NC(=O)c2cccs2)c(c1)-c1nc2ccccc2[nH]c1=O, CC(C)c1ccc(NC(=O)c2cccs2)c(c1)-c1nc2ccccc2[nH]c1=O, CC(C)c1ccc(NC(=O)c2cccs2)c(c1)-c1nc2ccccc2[nH]c1=O, CC(C)c1ccc(NC(=O)c2cccs2)c(c1)-c1nc2ccccc2[nH]c1=O, CC(C)c1ccc(NC(=O)c2cccs2)c(c1)-c1nc2ccccc2[nH]c1=O, CC(C)c1ccc(NC(=O)c2cccs2)c(c1)-c1nc2ccccc2[nH]c1=O, CC(C)c1ccc(NC(=O)c2cccs2)c(c1)-c1nc2ccccc2[nH]c1=O	HWOYIOLMBQSTQS-UHFFFAOYSA-N, HWOYIOLMBQSTQS-UHFFFAOYSA-N, HWOYIOLMBQSTQS-UHFFFAOYSA-N, HWOYIOLMBQSTQS-UHFFFAOYSA-N, HWOYIOLMBQSTQS-UHFFFAOYSA-N, HWOYIOLMBQSTQS-UHFFFAOYSA-N, HWOYIOLMBQSTQS-UHFFFAOYSA-N, HWOYIOLMBQSTQS-UHFFFAOYSA-N, HWOYIOLMBQSTQS-UHFFFAOYSA-N	Preclinical
ML297	inward rectifier potassium channel activator	KCNJ3			Cc1cc(NC(=O)Nc2ccc(F)c(F)c2)n(n1)-c1ccccc1, Cc1cc(NC(=O)Nc2ccc(F)c(F)c2)n(n1)-c1ccccc1, Cc1cc(NC(=O)Nc2ccc(F)c(F)c2)n(n1)-c1ccccc1, Cc1cc(NC(=O)Nc2ccc(F)c(F)c2)n(n1)-c1ccccc1, Cc1cc(NC(=O)Nc2ccc(F)c(F)c2)n(n1)-c1ccccc1, Cc1cc(NC(=O)Nc2ccc(F)c(F)c2)n(n1)-c1ccccc1	IEKSMUSSYJUQMY-UHFFFAOYSA-N, InChI=1S/C17H14F2N4O/c1-11-9-16(23(22-11)13-5-3-2-4-6-13)21-17(24)20-12-7-8-14(18)15(19)10-12/h2-10H,1H3,(H2,20,21,24), InChI=1S/C17H14F2N4O/c1-11-9-16(23(22-11)13-5-3-2-4-6-13)21-17(24)20-12-7-8-14(18)15(19)10-12/h2-10H,1H3,(H2,20,21,24), InChI=1S/C17H14F2N4O/c1-11-9-16(23(22-11)13-5-3-2-4-6-13)21-17(24)20-12-7-8-14(18)15(19)10-12/h2-10H,1H3,(H2,20,21,24), InChI=1S/C17H14F2N4O/c1-11-9-16(23(22-11)13-5-3-2-4-6-13)21-17(24)20-12-7-8-14(18)15(19)10-12/h2-10H,1H3,(H2,20,21,24), InChI=1S/C17H14F2N4O/c1-11-9-16(23(22-11)13-5-3-2-4-6-13)21-17(24)20-12-7-8-14(18)15(19)10-12/h2-10H,1H3,(H2,20,21,24)	Preclinical
ML298	phospholipase inhibitor	PLD2			Fc1cccc(c1)N1CNC(=O)C11CCN(CCNC(=O)c2ccc(F)c(F)c2)CC1, Fc1cccc(c1)N1CNC(=O)C11CCN(CCNC(=O)c2ccc(F)c(F)c2)CC1, Fc1cccc(c1)N1CNC(=O)C11CCN(CCNC(=O)c2ccc(F)c(F)c2)CC1	XAPVAKKLQGLNOY-UHFFFAOYSA-N, XAPVAKKLQGLNOY-UHFFFAOYSA-N, XAPVAKKLQGLNOY-UHFFFAOYSA-N	Preclinical
ML314	neurotensin agonist	NTSR1			COc1ccccc1N1CCN(CC1)c1nc(nc2cc(OC)c(OC)cc12)C1CC1	SWEOAXMICIJCQC-UHFFFAOYSA-N	Preclinical
ML323	ubiquitin specific protease inhibitor	USP1			CC(C)c1ccccc1-c1ncc(C)c(NCc2ccc(cc2)-n2ccnn2)n1, CC(C)c1ccccc1-c1ncc(C)c(NCc2ccc(cc2)-n2ccnn2)n1	VUIRVWPJNKZOSS-UHFFFAOYSA-N, VUIRVWPJNKZOSS-UHFFFAOYSA-N	Preclinical
ML324	histone lysine demethylase inhibitor	KDM4A			CN(C)CCCNC(=O)c1ccc(cc1)-c1cc(O)c2ncccc2c1, CN(C)CCCNC(=O)c1ccc(cc1)-c1cc(O)c2ncccc2c1	QDBVSOZTVKXUES-UHFFFAOYSA-N, QDBVSOZTVKXUES-UHFFFAOYSA-N	Preclinical
ML3403	MAP kinase inhibitor	CYP3A4, MAPK11, MAPK12, MAPK14			CSc1nc(c([nH]1)-c1ccc(F)cc1)-c1ccnc(N[C@@H](C)c2ccccc2)c1 |&1:20,r|, CSc1nc(c([nH]1)-c1ccc(F)cc1)-c1ccnc(N[C@@H](C)c2ccccc2)c1 |&1:20,r|, CSc1nc(c([nH]1)-c1ccc(F)cc1)-c1ccnc(N[C@@H](C)c2ccccc2)c1 |&1:20,r|	VXPWQNBKEIVYIS-HNNXBMFYSA-N, VXPWQNBKEIVYIS-HNNXBMFYSA-N, VXPWQNBKEIVYIS-HNNXBMFYSA-N	Preclinical
ML347	ALK tyrosine kinase receptor inhibitor	ACVR1, ACVRL1, BMPR1A			COc1ccc(cc1)-c1cnc2c(cnn2c1)-c1cccc2ncccc12, COc1ccc(cc1)-c1cnc2c(cnn2c1)-c1cccc2ncccc12, COc1ccc(cc1)-c1cnc2c(cnn2c1)-c1cccc2ncccc12, COc1ccc(cc1)-c1cnc2c(cnn2c1)-c1cccc2ncccc12, COc1ccc(cc1)-c1cnc2c(cnn2c1)-c1cccc2ncccc12, COc1ccc(cc1)-c1cnc2c(cnn2c1)-c1cccc2ncccc12	FVRYPYDPKSZGNS-UHFFFAOYSA-N, FVRYPYDPKSZGNS-UHFFFAOYSA-N, FVRYPYDPKSZGNS-UHFFFAOYSA-N, FVRYPYDPKSZGNS-UHFFFAOYSA-N, FVRYPYDPKSZGNS-UHFFFAOYSA-N, FVRYPYDPKSZGNS-UHFFFAOYSA-N	Preclinical
ML348	lysophospholipase inhibitor	LYPLA1			FC(F)(F)c1ccc(Cl)c(NC(=O)CN2CCN(CC2)C(=O)c2ccco2)c1, FC(F)(F)c1ccc(Cl)c(NC(=O)CN2CCN(CC2)C(=O)c2ccco2)c1	OXKNHBBDOIMFFQ-UHFFFAOYSA-N, OXKNHBBDOIMFFQ-UHFFFAOYSA-N	Preclinical
ML365	potassium channel blocker	KCNK3, KCNK9			COc1ccccc1C(=O)Nc1cccc(NC(=O)c2cccc(C)c2)c1, COc1ccccc1C(=O)Nc1cccc(NC(=O)c2cccc(C)c2)c1	UTAJHKSGYJSZBR-UHFFFAOYSA-N, UTAJHKSGYJSZBR-UHFFFAOYSA-N	Preclinical
ML786	RAF inhibitor	BRAF, RAF1			CC(C)(N)c1cc(cc(c1)C(F)(F)F)C(=O)N[C@@H]1CCc2ccc(Oc3ccnc4NC(=O)CCc34)cc2C1, CC(C)(N)c1cc(cc(c1)C(F)(F)F)C(=O)N[C@@H]1CCc2ccc(Oc3ccnc4NC(=O)CCc34)cc2C1	GXEGTVQATHKFDH-OAQYLSRUSA-N, GXEGTVQATHKFDH-OAQYLSRUSA-N	Preclinical
ML9	myosin light chain kinase inhibitor	TRPC6			Clc1cccc2c(cccc12)S(=O)(=O)N1CCCNCC1, Clc1cccc2c(cccc12)S(=O)(=O)N1CCCNCC1, Clc1cccc2c(cccc12)S(=O)(=O)N1CCCNCC1, Clc1cccc2c(cccc12)S(=O)(=O)N1CCCNCC1	OZSMSRIUUDGTEP-UHFFFAOYSA-N, OZSMSRIUUDGTEP-UHFFFAOYSA-N, OZSMSRIUUDGTEP-UHFFFAOYSA-N, OZSMSRIUUDGTEP-UHFFFAOYSA-N	Preclinical
MM-102	WDR5/MLL interaction inhibitor				CCC(CC)(NC(=O)C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NC1(CCCC1)C(=O)NC(c1ccc(F)cc1)c1ccc(F)cc1, CCC(CC)(NC(=O)C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NC1(CCCC1)C(=O)NC(c1ccc(F)cc1)c1ccc(F)cc1	RZKSQRIPRKWVBU-MHZLTWQESA-N, RZKSQRIPRKWVBU-MHZLTWQESA-N	Preclinical
MM-11253	retinoid receptor antagonist	RARG			CC1(C)CCC(C)(C)c2cc(ccc12)C1(SCCS1)c1ccc2cc(ccc2c1)C(O)=O, CC1(C)CCC(C)(C)c2cc(ccc12)C1(SCCS1)c1ccc2cc(ccc2c1)C(O)=O, CC1(C)CCC(C)(C)c2cc(ccc12)C1(SCCS1)c1ccc2cc(ccc2c1)C(O)=O	DPVGXUNWCVEIGT-UHFFFAOYSA-N, DPVGXUNWCVEIGT-UHFFFAOYSA-N, DPVGXUNWCVEIGT-UHFFFAOYSA-N	Preclinical
MM-206	STAT inhibitor				Oc1c(Sc2ccccc2)cc(NS(=O)(=O)c2c(F)c(F)c(F)c(F)c2F)c2ccccc12	ZXJHEANDHXHGMV-UHFFFAOYSA-N	Preclinical
MMPX	phosphodiesterase inhibitor				COCc1nc2n(CC(C)C)c(=O)n(C)c(=O)c2[nH]1, COCc1nc2n(CC(C)C)c(=O)n(C)c(=O)c2[nH]1, COCc1nc2n(CC(C)C)c(=O)n(C)c(=O)c2[nH]1	NBLBCGUCPBXKOV-UHFFFAOYSA-N, NBLBCGUCPBXKOV-UHFFFAOYSA-N, NBLBCGUCPBXKOV-UHFFFAOYSA-N	Preclinical
MMV-390048	PI4K inhibitor				CS(=O)(=O)c1ccc(cc1)-c1cnc(N)c(c1)-c1ccc(nc1)C(F)(F)F	RTJQABCNNLMCJF-UHFFFAOYSA-N	Preclinical
MM77	serotonin receptor antagonist	HTR1A			COc1ccccc1N1CCN(CCCCN2C(=O)CCC2=O)CC1, COc1ccccc1N1CCN(CCCCN2C(=O)CCC2=O)CC1	MQHOGPLXAXSQAJ-UHFFFAOYSA-N, MQHOGPLXAXSQAJ-UHFFFAOYSA-N	Preclinical
MN-64	tankyrase inhibitor	TNKS			CC(C)c1ccc(cc1)-c1cc(=O)c2ccccc2o1, CC(C)c1ccc(cc1)-c1cc(=O)c2ccccc2o1	PYTOHIUBXSJKQH-UHFFFAOYSA-N, PYTOHIUBXSJKQH-UHFFFAOYSA-N	Preclinical
MNITMT	lymphocyte inhibitor				Cn1cnnc1Sc1c(ncn1C)[N+]([O-])=O, Cn1cnnc1Sc1c(ncn1C)[N+]([O-])=O	NMBDIMPYACLUDE-UHFFFAOYSA-N, NMBDIMPYACLUDE-UHFFFAOYSA-N	Preclinical
mocetinostat	HDAC inhibitor	HDAC1, HDAC11, HDAC2, HDAC3			Nc1ccccc1NC(=O)c1ccc(CNc2nccc(n2)-c2cccnc2)cc1, Nc1ccccc1NC(=O)c1ccc(CNc2nccc(n2)-c2cccnc2)cc1, Nc1ccccc1NC(=O)c1ccc(CNc2nccc(n2)-c2cccnc2)cc1, Nc1ccccc1NC(=O)c1ccc(CNc2nccc(n2)-c2cccnc2)cc1, Nc1ccccc1NC(=O)c1ccc(CNc2nccc(n2)-c2cccnc2)cc1, Nc1ccccc1NC(=O)c1ccc(CNc2nccc(n2)-c2cccnc2)cc1	HRNLUBSXIHFDHP-UHFFFAOYSA-N, HRNLUBSXIHFDHP-UHFFFAOYSA-N, HRNLUBSXIHFDHP-UHFFFAOYSA-N, HRNLUBSXIHFDHP-UHFFFAOYSA-N, HRNLUBSXIHFDHP-UHFFFAOYSA-N, HRNLUBSXIHFDHP-UHFFFAOYSA-N	Phase 2
moclobemide	monoamine oxidase inhibitor	MAOA, MAOB	neurology/psychiatry	depression, anxiety	Clc1ccc(cc1)C(=O)NCCN1CCOCC1, Clc1ccc(cc1)C(=O)NCCN1CCOCC1, Clc1ccc(cc1)C(=O)NCCN1CCOCC1, Clc1ccc(cc1)C(=O)NCCN1CCOCC1	YHXISWVBGDMDLQ-UHFFFAOYSA-N, YHXISWVBGDMDLQ-UHFFFAOYSA-N, YHXISWVBGDMDLQ-UHFFFAOYSA-N, YHXISWVBGDMDLQ-UHFFFAOYSA-N	Launched
modaline					Cc1nccnc1N1CCCCC1	BJHCGMHPEKLROM-UHFFFAOYSA-N	Preclinical
moexipril	angiotensin converting enzyme inhibitor	ACE, ACE2	cardiology	hypertension	CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1Cc2cc(OC)c(OC)cc2C[C@H]1C(O)=O, CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1Cc2cc(OC)c(OC)cc2C[C@H]1C(O)=O, CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1Cc2cc(OC)c(OC)cc2C[C@H]1C(O)=O, CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1Cc2cc(OC)c(OC)cc2C[C@H]1C(O)=O, CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1Cc2cc(OC)c(OC)cc2C[C@H]1C(O)=O	UWWDHYUMIORJTA-HSQYWUDLSA-N, UWWDHYUMIORJTA-HSQYWUDLSA-N, UWWDHYUMIORJTA-HSQYWUDLSA-N, UWWDHYUMIORJTA-HSQYWUDLSA-N, UWWDHYUMIORJTA-HSQYWUDLSA-N	Launched
mofegiline	monoamine oxidase inhibitor	MAOA, MAOB			NC\C(CCc1ccc(F)cc1)=C\F, NC\C(CCc1ccc(F)cc1)=C\F, NC\C(CCc1ccc(F)cc1)=C\F	VXLBSYHAEKDUSU-JXMROGBWSA-N, VXLBSYHAEKDUSU-JXMROGBWSA-N, VXLBSYHAEKDUSU-JXMROGBWSA-N	Phase 1
mofezolac	cyclooxygenase inhibitor	PTGS1	rheumatology, orthopedics	rheumatoid arthritis, osteoporosis	COc1ccc(cc1)-c1noc(CC(O)=O)c1-c1ccc(OC)cc1	DJEIHHYCDCTAAH-UHFFFAOYSA-N	Launched
moguisteine	ATP-sensitive potassium channel inhibitor				CCOC(=O)CC(=O)N1CCS[C@@H]1COc1ccccc1OC |&1:12,r|	WSYVIAQNTFPTBI-OAHLLOKOSA-N	Phase 2
molidustat	hypoxia inducible factor inhibitor	EGLN2			O=c1c(c[nH]n1-c1cc(ncn1)N1CCOCC1)-n1ccnn1, O=c1c(c[nH]n1-c1cc(ncn1)N1CCOCC1)-n1ccnn1, O=c1c(c[nH]n1-c1cc(ncn1)N1CCOCC1)-n1ccnn1	IJMBOKOTALXLKS-UHFFFAOYSA-N, IJMBOKOTALXLKS-UHFFFAOYSA-N, IJMBOKOTALXLKS-UHFFFAOYSA-N	Phase 3
molindone	dopamine receptor antagonist	DRD2, HRH1, HTR2A	neurology/psychiatry	schizophrenia	CCc1c(C)[nH]c2CC[C@@H](CN3CCOCC3)C(=O)c12 |r|, CCc1c(C)[nH]c2CC[C@@H](CN3CCOCC3)C(=O)c12 |r|	KLPWJLBORRMFGK-LBPRGKRZSA-N, KLPWJLBORRMFGK-LBPRGKRZSA-N	Launched
molsidomine	guanylate cyclase stimulant	GUCY1A3	cardiology	coronary artery disease (CAD)	CCOC(=O)Nc1c[n+](no1)N1CCOCC1, CCOC(=O)Nc1c[n+](no1)N1CCOCC1, CCOC(=O)Nc1c[n+](no1)N1CCOCC1	XLFWDASMENKTKL-UHFFFAOYSA-O, XLFWDASMENKTKL-UHFFFAOYSA-O, XLFWDASMENKTKL-UHFFFAOYSA-O	Launched
mometasone	glucocorticoid receptor agonist	NR3C1	dermatology	corticosteroid-responsive dermatoses	C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CCl |c:11,t:7|	QLIIKPVHVRXHRI-CXSFZGCWSA-N	Launched
mometasone-furoate	glucocorticoid receptor agonist	NR3C1	dermatology	corticosteroid-responsive dermatoses	C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@@]1(OC(=O)c1ccco1)C(=O)CCl |c:11,t:7|, C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@@]1(OC(=O)c1ccco1)C(=O)CCl |c:11,t:7|, C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@@]1(OC(=O)c1ccco1)C(=O)CCl |c:11,t:7|, C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@@]1(OC(=O)c1ccco1)C(=O)CCl |c:11,t:7|, C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@@]1(OC(=O)c1ccco1)C(=O)CCl |c:11,t:7|, C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@@]1(OC(=O)c1ccco1)C(=O)CCl |c:11,t:7|, C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@@]1(OC(=O)c1ccco1)C(=O)CCl |c:11,t:7|	WOFMFGQZHJDGCX-ZULDAHANSA-N, WOFMFGQZHJDGCX-ZULDAHANSA-N, WOFMFGQZHJDGCX-ZULDAHANSA-N, WOFMFGQZHJDGCX-ZULDAHANSA-N, WOFMFGQZHJDGCX-ZULDAHANSA-N, WOFMFGQZHJDGCX-ZULDAHANSA-N, WOFMFGQZHJDGCX-ZULDAHANSA-N	Launched
monastrol	kinesin inhibitor	KIF11			CCOC(=O)C1=C(C)NC(=S)N[C@@H]1c1cccc(O)c1 |r,c:5|, CCOC(=O)C1=C(C)NC(=S)N[C@@H]1c1cccc(O)c1 |r,c:5|, CCOC(=O)C1=C(C)NC(=S)N[C@@H]1c1cccc(O)c1 |r,c:5|, CCOC(=O)C1=C(C)NC(=S)N[C@@H]1c1cccc(O)c1 |r,c:5|, CCOC(=O)C1=C(C)NC(=S)N[C@@H]1c1cccc(O)c1 |r,c:5|	LOBCDGHHHHGHFA-GFCCVEGCSA-N, LOBCDGHHHHGHFA-GFCCVEGCSA-N, LOBCDGHHHHGHFA-GFCCVEGCSA-N, LOBCDGHHHHGHFA-GFCCVEGCSA-N, LOBCDGHHHHGHFA-GFCCVEGCSA-N	Preclinical
monensin	bacterial permeability inducer		infectious disease	gastrointestinal parasites	CC[C@]1(CC[C@@H](O1)[C@]1(C)CC[C@]2(C[C@H](O)[C@@H](C)[C@H](O2)[C@@H](C)[C@@H](OC)[C@H](C)C(O)=O)O1)[C@@H]1O[C@H](C[C@@H]1C)[C@H]1O[C@@](O)(CO)[C@H](C)C[C@@H]1C	GAOZTHIDHYLHMS-KEOBGNEYSA-N	Launched
monepantel	mTOR inhibitor				C[C@](COc1cc(ccc1C(F)(F)F)C#N)(NC(=O)c1ccc(SC(F)(F)F)cc1)C#N	WTERNLDOAPYGJD-SFHVURJKSA-N	Preclinical
monobenzone	melanin inhibitor	TYR	dermatology	skin depigmentation	Oc1ccc(OCc2ccccc2)cc1, Oc1ccc(OCc2ccccc2)cc1, Oc1ccc(OCc2ccccc2)cc1, Oc1ccc(OCc2ccccc2)cc1, Oc1ccc(OCc2ccccc2)cc1	VYQNWZOUAUKGHI-UHFFFAOYSA-N, VYQNWZOUAUKGHI-UHFFFAOYSA-N, VYQNWZOUAUKGHI-UHFFFAOYSA-N, VYQNWZOUAUKGHI-UHFFFAOYSA-N, VYQNWZOUAUKGHI-UHFFFAOYSA-N	Launched
monocrotaline	antitumor agent				C[C@H]1C(=O)O[C@@H]2CCN3CC=C(COC(=O)[C@](C)(O)[C@]1(C)O)[C@H]23 |t:10|	QVCMHGGNRFRMAD-XFGHUUIASA-N	Preclinical
monoctanoin			gastroenterology	gallstones	CCCCCCCC(=O)OC[C@@H](O)CO |&1:11,r|, CCCCCCCC(=O)OC[C@@H](O)CO |&1:11,r|	GHBFNMLVSPCDGN-JTQLQIEISA-N, GHBFNMLVSPCDGN-JTQLQIEISA-N	Launched
monomethyl-fumarate			neurology/psychiatry	multiple sclerosis	COC(=O)\C=C\C(O)=O	NKHAVTQWNUWKEO-NSCUHMNNSA-N	Launched
monosodium-alpha-luminol					Nc1cccc2c1c(=O)[nH][nH]c2=O, Nc1cccc2c1c(=O)[nH][nH]c2=O, Nc1cccc2c1c(=O)[nH][nH]c2=O, Nc1cccc2c1c(=O)[nH][nH]c2=O	HWYHZTIRURJOHG-UHFFFAOYSA-N, HWYHZTIRURJOHG-UHFFFAOYSA-N, HWYHZTIRURJOHG-UHFFFAOYSA-N, HWYHZTIRURJOHG-UHFFFAOYSA-N	Launched
monostearin					CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)CO |&1:21,r|	VBICKXHEKHSIBG-FQEVSTJZSA-N	Preclinical
montelukast	leukotriene receptor antagonist	ALOX5, CYSLTR1	pulmonary, allergy	asthma, allergic rhinitis, exercise-induced bronchoconstriction (EIB)	CC(C)(O)c1ccccc1CC[C@@H](SCC1(CC(O)=O)CC1)c1cccc(\C=C\c2ccc3ccc(Cl)cc3n2)c1, CC(C)(O)c1ccccc1CC[C@@H](SCC1(CC(O)=O)CC1)c1cccc(\C=C\c2ccc3ccc(Cl)cc3n2)c1, CC(C)(O)c1ccccc1CC[C@@H](SCC1(CC(O)=O)CC1)c1cccc(\C=C\c2ccc3ccc(Cl)cc3n2)c1, CC(C)(O)c1ccccc1CC[C@@H](SCC1(CC(O)=O)CC1)c1cccc(\C=C\c2ccc3ccc(Cl)cc3n2)c1, CC(C)(O)c1ccccc1CC[C@@H](SCC1(CC(O)=O)CC1)c1cccc(\C=C\c2ccc3ccc(Cl)cc3n2)c1, CC(C)(O)c1ccccc1CC[C@@H](SCC1(CC(O)=O)CC1)c1cccc(\C=C\c2ccc3ccc(Cl)cc3n2)c1, CC(C)(O)c1ccccc1CC[C@@H](SCC1(CC(O)=O)CC1)c1cccc(\C=C\c2ccc3ccc(Cl)cc3n2)c1, CC(C)(O)c1ccccc1CC[C@@H](SCC1(CC(O)=O)CC1)c1cccc(\C=C\c2ccc3ccc(Cl)cc3n2)c1	UCHDWCPVSPXUMX-TZIWLTJVSA-N, UCHDWCPVSPXUMX-TZIWLTJVSA-N, UCHDWCPVSPXUMX-TZIWLTJVSA-N, UCHDWCPVSPXUMX-TZIWLTJVSA-N, UCHDWCPVSPXUMX-TZIWLTJVSA-N, UCHDWCPVSPXUMX-TZIWLTJVSA-N, UCHDWCPVSPXUMX-TZIWLTJVSA-N, UCHDWCPVSPXUMX-TZIWLTJVSA-N	Launched
moprolol	adrenergic receptor antagonist		cardiology, ophthalmology, neurology/psychiatry	hypertension, glaucoma, anxiety	COc1ccccc1OC[C@@H](O)CNC(C)C |&1:10|, COc1ccccc1OC[C@@H](O)CNC(C)C |&1:10|	LFTFGCDECFPSQD-NSHDSACASA-N, LFTFGCDECFPSQD-NSHDSACASA-N	Launched
moracizine	sodium channel blocker	SCN5A	cardiology	ventricular arrhythmias	CCOC(=O)Nc1ccc2Sc3ccccc3N(C(=O)CCN3CCOCC3)c2c1, CCOC(=O)Nc1ccc2Sc3ccccc3N(C(=O)CCN3CCOCC3)c2c1, CCOC(=O)Nc1ccc2Sc3ccccc3N(C(=O)CCN3CCOCC3)c2c1	FUBVWMNBEHXPSU-UHFFFAOYSA-N, FUBVWMNBEHXPSU-UHFFFAOYSA-N, FUBVWMNBEHXPSU-UHFFFAOYSA-N	Withdrawn
morantel	acetylcholine receptor agonist		infectious disease	tapeworm	CN1CCCN=C1\C=C\c1sccc1C |c:5|, CN1CCCN=C1\C=C\c1sccc1C |c:5|	NVEPPWDVLBMNMB-SNAWJCMRSA-N, NVEPPWDVLBMNMB-SNAWJCMRSA-N	Launched
morin	cytochrome P450 inhibitor	ADORA2A, ESR2, FASN, MCL1, SLC22A12			Oc1ccc(c(O)c1)-c1oc2cc(O)cc(O)c2c(=O)c1O, Oc1ccc(c(O)c1)-c1oc2cc(O)cc(O)c2c(=O)c1O, Oc1ccc(c(O)c1)-c1oc2cc(O)cc(O)c2c(=O)c1O, Oc1ccc(c(O)c1)-c1oc2cc(O)cc(O)c2c(=O)c1O, Oc1ccc(c(O)c1)-c1oc2cc(O)cc(O)c2c(=O)c1O, Oc1ccc(c(O)c1)-c1oc2cc(O)cc(O)c2c(=O)c1O	YXOLAZRVSSWPPT-UHFFFAOYSA-N, YXOLAZRVSSWPPT-UHFFFAOYSA-N, YXOLAZRVSSWPPT-UHFFFAOYSA-N, YXOLAZRVSSWPPT-UHFFFAOYSA-N, YXOLAZRVSSWPPT-UHFFFAOYSA-N, YXOLAZRVSSWPPT-UHFFFAOYSA-N	Preclinical
morinidazole	other antibiotic	CYP51A1			Cc1ncc(n1C[C@@H](O)CN1CCOCC1)[N+]([O-])=O |&1:7,r|	GAZGHCHCYRSPIV-JTQLQIEISA-N	Launched
morniflumate	anti-inflammatory agent		neurology/psychiatry	pain relief	FC(F)(F)c1cccc(Nc2ncccc2C(=O)OCCN2CCOCC2)c1	LDXSPUSKBDTEKA-UHFFFAOYSA-N	Launched
moroxydine	antiviral		infectious disease	influenza A virus infection	NC(=N)\N=C(/N)N1CCOCC1	KJHOZAZQWVKILO-UHFFFAOYSA-N	Launched
morphothiadin	antiinfective drug				CCOC(=O)C1=C(CN2CCOCC2)NC(=N[C@@H]1c1ccc(F)cc1Br)c1nccs1 |&1:17,r,c:5,16|	SQGRDKSRFFUBBU-GOSISDBHSA-N	Preclinical
mosapride	serotonin receptor agonist	HTR4	gastroenterology	hypertrophic gastritis (GHG), gastroesophageal reflux disease (GERD), dyspepsia, irritable bowel syndrome	CCOc1cc(N)c(Cl)cc1C(=O)NC[C@H]1CN(Cc2ccc(F)cc2)CCO1 |&1:15|, CCOc1cc(N)c(Cl)cc1C(=O)NC[C@H]1CN(Cc2ccc(F)cc2)CCO1 |&1:15|	YPELFRMCRYSPKZ-INIZCTEOSA-N, YPELFRMCRYSPKZ-INIZCTEOSA-N	Launched
motapizone	phosphodiesterase inhibitor				CC1=C(NNC(=O)C1)c1cc(cs1)-n1ccnc1 |t:1|	IQHAKYLSMONFMT-UHFFFAOYSA-N	Preclinical
motesanib	KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	FLT1, FLT4, KDR, KIT			CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12, CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12, CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12, CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12, CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12, CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12, CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12, CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12	RAHBGWKEPAQNFF-UHFFFAOYSA-N, RAHBGWKEPAQNFF-UHFFFAOYSA-N, RAHBGWKEPAQNFF-UHFFFAOYSA-N, RAHBGWKEPAQNFF-UHFFFAOYSA-N, RAHBGWKEPAQNFF-UHFFFAOYSA-N, RAHBGWKEPAQNFF-UHFFFAOYSA-N, RAHBGWKEPAQNFF-UHFFFAOYSA-N, RAHBGWKEPAQNFF-UHFFFAOYSA-N	Phase 3
motolimod	toll-like receptor agonist	TLR8			CCCN(CCC)C(=O)C1=Cc2ccc(cc2N=C(N)C1)-c1ccc(cc1)C(=O)N1CCCC1 |t:9,18|, CCCN(CCC)C(=O)C1=Cc2ccc(cc2N=C(N)C1)-c1ccc(cc1)C(=O)N1CCCC1 |t:9,18|	QSPOQCXMGPDIHI-UHFFFAOYSA-N, QSPOQCXMGPDIHI-UHFFFAOYSA-N	Phase 2
moxalactam	bacterial cell wall synthesis inhibitor		infectious disease	gram-positive bacterial infections, gram-negative bacterial infections, skin infections, bone and joint infections, pneumonia, urinary tract infections, meningitis	CO[C@]1(NC(=O)[C@@H](C(O)=O)c2ccc(O)cc2)[C@H]2OCC(CSc3nnnn3C)=C(N2C1=O)C(O)=O |a:2,17,&1:6,c:30|, CO[C@]1(NC(=O)[C@@H](C(O)=O)c2ccc(O)cc2)[C@H]2OCC(CSc3nnnn3C)=C(N2C1=O)C(O)=O |a:2,17,&1:6,c:30|	JWCSIUVGFCSJCK-UOXRKKOCSA-N, JWCSIUVGFCSJCK-UOXRKKOCSA-N	Launched
moxaverine	phosphodiesterase inhibitor		neurology/psychiatry	spasms	CCc1cc2cc(OC)c(OC)cc2c(Cc2ccccc2)n1, CCc1cc2cc(OC)c(OC)cc2c(Cc2ccccc2)n1	MYCMTMIGRXJNSO-UHFFFAOYSA-N, MYCMTMIGRXJNSO-UHFFFAOYSA-N	Launched
moxidectin	chloride channel antagonist		infectious disease	gastrointestinal parasites	[H][C@@]12OC\C3=C/C=C/[C@H](C)C\C(C)=C\C[C@]4([H])C[C@@]([H])(C[C@]5(C\C(=N/OC)[C@H](C)[C@H](O5)C(\C)=C\C(C)C)O4)OC(=O)[C@]([H])(C=C(C)[C@H]1O)[C@@]23O |c:4,t:6,12,45|	YZBLFMPOMVTDJY-LSGXYNIPSA-N	Launched
moxifloxacin	bacterial DNA gyrase inhibitor	TOP2A	otolaryngology, pulmonary, infectious disease	sinusitis, bronchitis, pneumonia, skin infections, intra-abdominal infections	COc1c(N2C[C@@H]3CCCN[C@@H]3C2)c(F)cc2c1n(cc(C(O)=O)c2=O)C1CC1, COc1c(N2C[C@@H]3CCCN[C@@H]3C2)c(F)cc2c1n(cc(C(O)=O)c2=O)C1CC1, COc1c(N2C[C@@H]3CCCN[C@@H]3C2)c(F)cc2c1n(cc(C(O)=O)c2=O)C1CC1	FABPRXSRWADJSP-MEDUHNTESA-N, FABPRXSRWADJSP-MEDUHNTESA-N, FABPRXSRWADJSP-MEDUHNTESA-N	Launched
moxisylyte	adrenergic receptor antagonist				CC(C)c1cc(OC(C)=O)c(C)cc1OCCN(C)C, CC(C)c1cc(OC(C)=O)c(C)cc1OCCN(C)C	VRYMTAVOXVTQEF-UHFFFAOYSA-N, VRYMTAVOXVTQEF-UHFFFAOYSA-N	Withdrawn
moxonidine	imidazoline receptor agonist	ADRA2A, ADRA2B, ADRA2C	cardiology	hypertension	COc1nc(C)nc(Cl)c1NC1=NCCN1 |t:12|, COc1nc(C)nc(Cl)c1NC1=NCCN1 |t:12|, COc1nc(C)nc(Cl)c1NC1=NCCN1 |t:12|, COc1nc(C)nc(Cl)c1NC1=NCCN1 |t:12|, COc1nc(C)nc(Cl)c1NC1=NCCN1 |t:12|, COc1nc(C)nc(Cl)c1NC1=NCCN1 |t:12|, COc1nc(C)nc(Cl)c1NC1=NCCN1 |t:12|	WPNJAUFVNXKLIM-UHFFFAOYSA-N, WPNJAUFVNXKLIM-UHFFFAOYSA-N, WPNJAUFVNXKLIM-UHFFFAOYSA-N, WPNJAUFVNXKLIM-UHFFFAOYSA-N, WPNJAUFVNXKLIM-UHFFFAOYSA-N, WPNJAUFVNXKLIM-UHFFFAOYSA-N, WPNJAUFVNXKLIM-UHFFFAOYSA-N	Launched
mozavaptan	vasopressin receptor antagonist	AVPR1A, AVPR1B, AVPR2	endocrinology	hyponatremia	CN(C)[C@H]1CCCN(C(=O)c2ccc(NC(=O)c3ccccc3C)cc2)c2ccccc12 |&1:3,r|, CN(C)[C@H]1CCCN(C(=O)c2ccc(NC(=O)c3ccccc3C)cc2)c2ccccc12 |&1:3,r|, CN(C)[C@H]1CCCN(C(=O)c2ccc(NC(=O)c3ccccc3C)cc2)c2ccccc12 |&1:3,r|	WRNXUQJJCIZICJ-DEOSSOPVSA-N, WRNXUQJJCIZICJ-DEOSSOPVSA-N, WRNXUQJJCIZICJ-DEOSSOPVSA-N	Launched
MPEP	glutamate receptor antagonist	GRM1, GRM4, GRM5			Cc1cccc(n1)C#Cc1ccccc1, Cc1cccc(n1)C#Cc1ccccc1, Cc1cccc(n1)C#Cc1ccccc1, Cc1cccc(n1)C#Cc1ccccc1	NEWKHUASLBMWRE-UHFFFAOYSA-N, NEWKHUASLBMWRE-UHFFFAOYSA-N, NEWKHUASLBMWRE-UHFFFAOYSA-N, NEWKHUASLBMWRE-UHFFFAOYSA-N	Preclinical
MPI-0479605	mitotic kinase inhibitor	TTK			Cc1cc(ccc1Nc1nc(NC2CCCCC2)c2[nH]cnc2n1)N1CCOCC1, Cc1cc(ccc1Nc1nc(NC2CCCCC2)c2[nH]cnc2n1)N1CCOCC1, Cc1cc(ccc1Nc1nc(NC2CCCCC2)c2[nH]cnc2n1)N1CCOCC1, Cc1cc(ccc1Nc1nc(NC2CCCCC2)c2[nH]cnc2n1)N1CCOCC1, Cc1cc(ccc1Nc1nc(NC2CCCCC2)c2[nH]cnc2n1)N1CCOCC1, Cc1cc(ccc1Nc1nc(NC2CCCCC2)c2[nH]cnc2n1)N1CCOCC1	OVJBNYKNHXJGSA-UHFFFAOYSA-N, OVJBNYKNHXJGSA-UHFFFAOYSA-N, OVJBNYKNHXJGSA-UHFFFAOYSA-N, OVJBNYKNHXJGSA-UHFFFAOYSA-N, OVJBNYKNHXJGSA-UHFFFAOYSA-N, OVJBNYKNHXJGSA-UHFFFAOYSA-N	Preclinical
Mps-BAY-2a	monopolar spindle 1 kinase inhibitor	TTK			CC(C)CNc1nc(cn2c(cnc12)-c1ccc(cc1)C(=O)NC1CC1)-c1cccc2ncccc12, CC(C)CNc1nc(cn2c(cnc12)-c1ccc(cc1)C(=O)NC1CC1)-c1cccc2ncccc12	MDYKTGNHXNTATG-UHFFFAOYSA-N, MDYKTGNHXNTATG-UHFFFAOYSA-N	Preclinical
Mps1-IN-1	monopolar spindle 1 kinase inhibitor	TTK			COc1cc(ccc1Nc1cc(Nc2ccccc2S(=O)(=O)C(C)C)c2cc[nH]c2n1)N1CCC(O)CC1, COc1cc(ccc1Nc1cc(Nc2ccccc2S(=O)(=O)C(C)C)c2cc[nH]c2n1)N1CCC(O)CC1, COc1cc(ccc1Nc1cc(Nc2ccccc2S(=O)(=O)C(C)C)c2cc[nH]c2n1)N1CCC(O)CC1	NMJMRSQTDLRCRQ-UHFFFAOYSA-N, NMJMRSQTDLRCRQ-UHFFFAOYSA-N, NMJMRSQTDLRCRQ-UHFFFAOYSA-N	Preclinical
Mps1-IN-5	protein kinase inhibitor				COc1cc(ccc1Nc1nc2ccc(cn2n1)-c1ccc(NC(=O)[C@H](C)c2ccc(F)cc2)cc1)S(C)(=O)=O, COc1cc(ccc1Nc1nc2ccc(cn2n1)-c1ccc(NC(=O)[C@H](C)c2ccc(F)cc2)cc1)S(C)(=O)=O	NRJKIOCCERLIDG-GOSISDBHSA-N, NRJKIOCCERLIDG-GOSISDBHSA-N	Phase 1
MR-16728	acetylcholine release enhancer				O=C(NCCCN1CCCCCC1)[C@@H](C1CCCCC1)c1ccccc1 |&1:13|, O=C(NCCCN1CCCCCC1)[C@@H](C1CCCCC1)c1ccccc1 |&1:13|	AGKAAJMNNVUNDK-JOCHJYFZSA-N, AGKAAJMNNVUNDK-JOCHJYFZSA-N	Preclinical
MR-948	thromboxane synthase inhibitor	TBXAS1			OCCc1ccc(OCCn2ccnc2)cc1	LQQIZTXSZOYPPS-UHFFFAOYSA-N	Phase 1
MRK-016	GABA receptor inverse agonist	GABRA1, GABRA2, GABRA3, GABRA5			Cc1cc(no1)-c1nncc2c(c(OCc3ncnn3C)nn12)C(C)(C)C, Cc1cc(no1)-c1nncc2c(c(OCc3ncnn3C)nn12)C(C)(C)C, Cc1cc(no1)-c1nncc2c(c(OCc3ncnn3C)nn12)C(C)(C)C	QYSYOGCIDRANAR-UHFFFAOYSA-N, QYSYOGCIDRANAR-UHFFFAOYSA-N, QYSYOGCIDRANAR-UHFFFAOYSA-N	Phase 1
MRK-409	benzodiazepine receptor agonist				Cn1ncnc1COc1nn2c(nnc2cc1C1CCC1)-c1c(F)cccc1F, Cn1ncnc1COc1nn2c(nnc2cc1C1CCC1)-c1c(F)cccc1F	GOIFCXRIFSYPFG-UHFFFAOYSA-N, GOIFCXRIFSYPFG-UHFFFAOYSA-N	Phase 1
MRK-560	gamma secretase inhibitor	APP			Fc1ccc(F)c(c1)[C@]1(CC[C@@H](CC1)NS(=O)(=O)C(F)(F)F)S(=O)(=O)c1ccc(Cl)cc1 |r|, Fc1ccc(F)c(c1)[C@]1(CC[C@@H](CC1)NS(=O)(=O)C(F)(F)F)S(=O)(=O)c1ccc(Cl)cc1 |r|, Fc1ccc(F)c(c1)[C@]1(CC[C@@H](CC1)NS(=O)(=O)C(F)(F)F)S(=O)(=O)c1ccc(Cl)cc1 |r|, Fc1ccc(F)c(c1)[C@]1(CC[C@@H](CC1)NS(=O)(=O)C(F)(F)F)S(=O)(=O)c1ccc(Cl)cc1 |r|	WDZVWDXOIGQJIO-UJKQEGAGSA-N, WDZVWDXOIGQJIO-UJKQEGAGSA-N, WDZVWDXOIGQJIO-UJKQEGAGSA-N, WDZVWDXOIGQJIO-UJKQEGAGSA-N	Preclinical
MRS-1220	adenosine receptor antagonist	ADORA2B, ADORA3			Clc1ccc2nc(NC(=O)Cc3ccccc3)n3nc(nc3c2c1)-c1ccco1, Clc1ccc2nc(NC(=O)Cc3ccccc3)n3nc(nc3c2c1)-c1ccco1, Clc1ccc2nc(NC(=O)Cc3ccccc3)n3nc(nc3c2c1)-c1ccco1, Clc1ccc2nc(NC(=O)Cc3ccccc3)n3nc(nc3c2c1)-c1ccco1, Clc1ccc2nc(NC(=O)Cc3ccccc3)n3nc(nc3c2c1)-c1ccco1, Clc1ccc2nc(NC(=O)Cc3ccccc3)n3nc(nc3c2c1)-c1ccco1, Clc1ccc2nc(NC(=O)Cc3ccccc3)n3nc(nc3c2c1)-c1ccco1	TWWFAXQOKNBUCR-UHFFFAOYSA-N, TWWFAXQOKNBUCR-UHFFFAOYSA-N, TWWFAXQOKNBUCR-UHFFFAOYSA-N, TWWFAXQOKNBUCR-UHFFFAOYSA-N, TWWFAXQOKNBUCR-UHFFFAOYSA-N, TWWFAXQOKNBUCR-UHFFFAOYSA-N, TWWFAXQOKNBUCR-UHFFFAOYSA-N	Preclinical
MRS-1334	adenosine receptor antagonist	ADORA3			CCOC(=O)C1=C(C)NC(=C([C@@H]1C#Cc1ccccc1)C(=O)OCc1ccc(cc1)[N+]([O-])=O)c1ccccc1 |&1:11,r,c:5,9|, CCOC(=O)C1=C(C)NC(=C([C@@H]1C#Cc1ccccc1)C(=O)OCc1ccc(cc1)[N+]([O-])=O)c1ccccc1 |&1:11,r,c:5,9|, CCOC(=O)C1=C(C)NC(=C([C@@H]1C#Cc1ccccc1)C(=O)OCc1ccc(cc1)[N+]([O-])=O)c1ccccc1 |&1:11,r,c:5,9|	QFLOJAMZLQXHFS-AREMUKBSSA-N, QFLOJAMZLQXHFS-AREMUKBSSA-N, QFLOJAMZLQXHFS-AREMUKBSSA-N	Preclinical
MRS-1845	calcium channel blocker				CCOC(=O)C1=C(C)N(CC#C)C(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OC |&1:15,r,c:5,13|, CCOC(=O)C1=C(C)N(CC#C)C(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OC |&1:15,r,c:5,13|, CCOC(=O)C1=C(C)N(CC#C)C(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OC |&1:15,r,c:5,13|	BITHABUTZRAUGT-IBGZPJMESA-N, BITHABUTZRAUGT-IBGZPJMESA-N, BITHABUTZRAUGT-IBGZPJMESA-N	Preclinical
MRS-2578	purinergic receptor antagonist	P2RY6			S=C=Nc1cccc(NC(=S)NCCCCNC(=S)Nc2cccc(c2)N=C=S)c1, S=C=Nc1cccc(NC(=S)NCCCCNC(=S)Nc2cccc(c2)N=C=S)c1, S=C=Nc1cccc(NC(=S)NCCCCNC(=S)Nc2cccc(c2)N=C=S)c1, S=C=Nc1cccc(NC(=S)NCCCCNC(=S)Nc2cccc(c2)N=C=S)c1	QOHNRGHTJPFMSL-UHFFFAOYSA-N, QOHNRGHTJPFMSL-UHFFFAOYSA-N, QOHNRGHTJPFMSL-UHFFFAOYSA-N, QOHNRGHTJPFMSL-UHFFFAOYSA-N	Preclinical
MRS-3777	adenosine receptor antagonist	ADORA1, ADORA2A, ADORA2B, ADORA3			C1CCC(CC1)Nc1nc(Oc2ccccc2)nc2nc[nH]c12.C1CCC(CC1)Nc1nc(Oc2ccccc2)nc2nc[nH]c12, C1CCC(CC1)Nc1nc(Oc2ccccc2)nc2nc[nH]c12.C1CCC(CC1)Nc1nc(Oc2ccccc2)nc2nc[nH]c12, C1CCC(CC1)Nc1nc(Oc2ccccc2)nc2nc[nH]c12.C1CCC(CC1)Nc1nc(Oc2ccccc2)nc2nc[nH]c12, C1CCC(CC1)Nc1nc(Oc2ccccc2)nc2nc[nH]c12, C1CCC(CC1)Nc1nc(Oc2ccccc2)nc2nc[nH]c12, C1CCC(CC1)Nc1nc(Oc2ccccc2)nc2nc[nH]c12, C1CCC(CC1)Nc1nc(Oc2ccccc2)nc2nc[nH]c12	ZYVKEIQGOGHCFB-UHFFFAOYSA-N, ZYVKEIQGOGHCFB-UHFFFAOYSA-N, ZYVKEIQGOGHCFB-UHFFFAOYSA-N, OGCQBCHLFMBCCE-UHFFFAOYSA-N, OGCQBCHLFMBCCE-UHFFFAOYSA-N, OGCQBCHLFMBCCE-UHFFFAOYSA-N, OGCQBCHLFMBCCE-UHFFFAOYSA-N	Preclinical
MRX-2843	MER tyrosine kinase inhibitor				CN1CCN(Cc2ccc(cc2)-c2cn([C@H]3CC[C@H](O)CC3)c3nc(NCCC4CC4)ncc23)CC1 |r|	LBEJYFVJIPQSNX-SOAUALDESA-N	Phase 1
MS-424	glutamate transporter modulator				C[C@@H]1C=CNN1C(=O)c1cccnc1 |c:2|	AEHLCVKEOAFFJC-MRVPVSSYSA-N	Phase 2
MSDC-0160	insulin sensitizer				CCc1ccc(nc1)C(=O)COc1ccc(C[C@@H]2SC(=O)NC2=O)cc1 |&1:17,r|	IRNJSRAGRIZIHD-KRWDZBQOSA-N	Phase 2
MSDC-0602K	mitochondrial pyruvate carrier modulator				COc1cccc(c1)C(=O)COc1ccc(Cc2sc(O)nc2O)cc1	JIJXYXYLGRAIGV-UHFFFAOYSA-N	Phase 2
MSX-122	CC chemokine receptor antagonist	CXCR4			C(Nc1ncccn1)c1ccc(CNc2ncccn2)cc1, C(Nc1ncccn1)c1ccc(CNc2ncccn2)cc1, C(Nc1ncccn1)c1ccc(CNc2ncccn2)cc1	PXZXYRKDDXKDTK-UHFFFAOYSA-N, PXZXYRKDDXKDTK-UHFFFAOYSA-N, PXZXYRKDDXKDTK-UHFFFAOYSA-N	Phase 2
MTPG	glutamate receptor antagonist	GRM2, GRM3			C[C@@](N)(C(O)=O)c1ccc(cc1)-c1nn[nH]n1 |&1:1|, C[C@@](N)(C(O)=O)c1ccc(cc1)-c1nn[nH]n1 |&1:1|	OZBFBAYESADVDX-JTQLQIEISA-N, OZBFBAYESADVDX-JTQLQIEISA-N	Preclinical
mubritinib	protein tyrosine kinase inhibitor	EGFR, ERBB2			FC(F)(F)c1ccc(\C=C\c2nc(COc3ccc(CCCCn4ccnn4)cc3)co2)cc1, FC(F)(F)c1ccc(\C=C\c2nc(COc3ccc(CCCCn4ccnn4)cc3)co2)cc1, FC(F)(F)c1ccc(\C=C\c2nc(COc3ccc(CCCCn4ccnn4)cc3)co2)cc1, FC(F)(F)c1ccc(\C=C\c2nc(COc3ccc(CCCCn4ccnn4)cc3)co2)cc1	ZTFBIUXIQYRUNT-MDWZMJQESA-N, ZTFBIUXIQYRUNT-MDWZMJQESA-N, ZTFBIUXIQYRUNT-MDWZMJQESA-N, ZTFBIUXIQYRUNT-MDWZMJQESA-N	Phase 1
mupirocin	isoleucyl-tRNA synthetase inhibitor		infectious disease	impetigo	C[C@H](O)[C@H](C)[C@@H]1O[C@H]1C[C@H]1CO[C@@H](C\C(C)=C\C(=O)OCCCCCCCCC(O)=O)[C@H](O)[C@@H]1O, C[C@H](O)[C@H](C)[C@@H]1O[C@H]1C[C@H]1CO[C@@H](C\C(C)=C\C(=O)OCCCCCCCCC(O)=O)[C@H](O)[C@@H]1O, C[C@H](O)[C@H](C)[C@@H]1O[C@H]1C[C@H]1CO[C@@H](C\C(C)=C\C(=O)OCCCCCCCCC(O)=O)[C@H](O)[C@@H]1O	MINDHVHHQZYEEK-HBBNESRFSA-N, MINDHVHHQZYEEK-HBBNESRFSA-N, MINDHVHHQZYEEK-HBBNESRFSA-N	Launched
muscimol	benzodiazepine receptor agonist	GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRR1, GABRR2, GABRR3			NCc1cc(=O)[nH]o1, NCc1cc(=O)[nH]o1	ZJQHPWUVQPJPQT-UHFFFAOYSA-N, ZJQHPWUVQPJPQT-UHFFFAOYSA-N	Phase 1
MUT056399	FABI inhibitor				CCc1cc(O)c(Oc2ccc(cc2F)C(N)=O)cc1F, CCc1cc(O)c(Oc2ccc(cc2F)C(N)=O)cc1F	QUHARGDBJJUOEB-UHFFFAOYSA-N, QUHARGDBJJUOEB-UHFFFAOYSA-N	Phase 1
MY-5445	phosphodiesterase inhibitor, platelet aggregation inhibitor	PDE5A			Clc1cccc(Nc2nnc(-c3ccccc3)c3ccccc23)c1, Clc1cccc(Nc2nnc(-c3ccccc3)c3ccccc23)c1, Clc1cccc(Nc2nnc(-c3ccccc3)c3ccccc23)c1, Clc1cccc(Nc2nnc(-c3ccccc3)c3ccccc23)c1	CEHQLKSLMFIHBF-UHFFFAOYSA-N, CEHQLKSLMFIHBF-UHFFFAOYSA-N, CEHQLKSLMFIHBF-UHFFFAOYSA-N, CEHQLKSLMFIHBF-UHFFFAOYSA-N	Preclinical
mycophenolate-mofetil	dehydrogenase inhibitor, inositol monophosphatase inhibitor	IMPDH1, IMPDH2	transplant	organ rejection	COc1c(C)c2COC(=O)c2c(O)c1C\C=C(/C)CCC(=O)OCCN1CCOCC1, COc1c(C)c2COC(=O)c2c(O)c1C\C=C(/C)CCC(=O)OCCN1CCOCC1, COc1c(C)c2COC(=O)c2c(O)c1C\C=C(/C)CCC(=O)OCCN1CCOCC1, COc1c(C)c2COC(=O)c2c(O)c1C\C=C(/C)CCC(=O)OCCN1CCOCC1, COc1c(C)c2COC(=O)c2c(O)c1C\C=C(/C)CCC(=O)OCCN1CCOCC1, COc1c(C)c2COC(=O)c2c(O)c1C\C=C(/C)CCC(=O)OCCN1CCOCC1	RTGDFNSFWBGLEC-SYZQJQIISA-N, RTGDFNSFWBGLEC-SYZQJQIISA-N, RTGDFNSFWBGLEC-SYZQJQIISA-N, RTGDFNSFWBGLEC-SYZQJQIISA-N, RTGDFNSFWBGLEC-SYZQJQIISA-N, RTGDFNSFWBGLEC-SYZQJQIISA-N	Launched
mycophenolic-acid	dehydrogenase inhibitor, inositol monophosphatase inhibitor	IMPDH1, IMPDH2	transplant	organ rejection	COc1c(C)c2COC(=O)c2c(O)c1C\C=C(/C)CCC(O)=O, COc1c(C)c2COC(=O)c2c(O)c1C\C=C(/C)CCC(O)=O, COc1c(C)c2COC(=O)c2c(O)c1C\C=C(/C)CCC(O)=O, COc1c(C)c2COC(=O)c2c(O)c1C\C=C(/C)CCC(O)=O, COc1c(C)c2COC(=O)c2c(O)c1C\C=C(/C)CCC(O)=O, COc1c(C)c2COC(=O)c2c(O)c1C\C=C(/C)CCC(O)=O, COc1c(C)c2COC(=O)c2c(O)c1C\C=C(/C)CCC(O)=O, COc1c(C)c2COC(=O)c2c(O)c1C\C=C(/C)CCC(O)=O	HPNSFSBZBAHARI-RUDMXATFSA-N, HPNSFSBZBAHARI-RUDMXATFSA-N, HPNSFSBZBAHARI-RUDMXATFSA-N, HPNSFSBZBAHARI-RUDMXATFSA-N, HPNSFSBZBAHARI-RUDMXATFSA-N, HPNSFSBZBAHARI-RUDMXATFSA-N, HPNSFSBZBAHARI-RUDMXATFSA-N, HPNSFSBZBAHARI-RUDMXATFSA-N	Launched
myricetin	androgen receptor agonist, cytochrome P450 inhibitor	PIK3CG			Oc1cc(O)c2c(c1)oc(-c1cc(O)c(O)c(O)c1)c(O)c2=O, Oc1cc(O)c2c(c1)oc(-c1cc(O)c(O)c(O)c1)c(O)c2=O, Oc1cc(O)c2c(c1)oc(-c1cc(O)c(O)c(O)c1)c(O)c2=O	IKMDFBPHZNJCSN-UHFFFAOYSA-N, IKMDFBPHZNJCSN-UHFFFAOYSA-N, IKMDFBPHZNJCSN-UHFFFAOYSA-N	Preclinical
myricitrin	PKC inhibitor	NOS1, PRKCA			C[C@@H]1O[C@@H](Oc2c(oc3cc(O)cc(O)c3c2=O)-c2cc(O)c(O)c(O)c2)[C@H](O)[C@H](O)[C@H]1O	DCYOADKBABEMIQ-OWMUPTOHSA-N	Preclinical
myristyl-nicotinate	topical sunscreen agent				CCCCCCCCCCCCCCOC(=O)c1cccnc1	TVGLGJWCZSCAEM-UHFFFAOYSA-N	Phase 1
M8-B	transient receptor potential channel antagonist	TRPM8			COc1cc(CN(CCN)C(=O)c2cccs2)ccc1OCc1ccccc1, COc1cc(CN(CCN)C(=O)c2cccs2)ccc1OCc1ccccc1, COc1cc(CN(CCN)C(=O)c2cccs2)ccc1OCc1ccccc1	UOGGWHBYFVBUIY-UHFFFAOYSA-N, UOGGWHBYFVBUIY-UHFFFAOYSA-N, UOGGWHBYFVBUIY-UHFFFAOYSA-N	Preclinical
N-(p-amylcinnamoyl)-anthranilic-acid	phospholipase inhibitor				CCCCCc1ccc(\C=C\C(=O)Nc2ccccc2C(O)=O)cc1	GAMRBCZMOOMBSQ-CCEZHUSRSA-N	Preclinical
N-(2-chlorophenyl)-2-({(2E)-2-[1-(2-pyridinyl)ethylidene]hydrazino}carbothioyl)hydrazinecarbothioamide					CC(=NNC(=S)NNC(=S)Nc1ccccc1Cl)c1ccccn1	YYLKOELWSMRYHV-UHFFFAOYSA-N	Preclinical
N-[2-(piperidinylamino)ethyl]-4-iodobenzamide	sigma receptor ligand				Ic1ccc(cc1)C(=O)NCCN1CCCCC1, Ic1ccc(cc1)C(=O)NCCN1CCCCC1, Ic1ccc(cc1)C(=O)NCCN1CCCCC1	WCMWVYQHPUQKHW-UHFFFAOYSA-N, WCMWVYQHPUQKHW-UHFFFAOYSA-N, WCMWVYQHPUQKHW-UHFFFAOYSA-N	Preclinical
N-acetyl-D-glucosamine		B4GALT1, B4GALT2, B4GALT3, B4GALT4, NAGK, NAGLU, NAGPA, RENBP			CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO, CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO	MBLBDJOUHNCFQT-LXGUWJNJSA-N, MBLBDJOUHNCFQT-LXGUWJNJSA-N	Phase 2/Phase 3
N-acetyl-tyrosine					CC(=O)N[C@@H](Cc1ccc(O)cc1)C(O)=O |&1:4,r|, CC(=O)N[C@@H](Cc1ccc(O)cc1)C(O)=O |&1:4,r|	CAHKINHBCWCHCF-JTQLQIEISA-N, CAHKINHBCWCHCF-JTQLQIEISA-N	Launched
N-acetylcarnosine					CC(=O)NCCC(=O)N[C@@H](Cc1cnc[nH]1)C(O)=O	BKAYIFDRRZZKNF-VIFPVBQESA-N	Launched
N-acetylglycyl-D-glutamic-acid	glutamate receptor agonist				CC(=O)NCC(=O)N[C@H](CCC(O)=O)C(O)=O, CC(=O)NCC(=O)N[C@H](CCC(O)=O)C(O)=O	CQTYJLQESPLSOP-ZCFIWIBFSA-N, CQTYJLQESPLSOP-ZCFIWIBFSA-N	Preclinical
N-acetylmannosamine					CC(=O)N[C@H]1[C@@H](O)O[C@@H](CO)[C@@H](O)[C@H]1O |a:5,11,13,&1:4,&2:8|	OVRNDRQMDRJTHS-SHGPDSBTSA-N	Phase 2
N-acetyltryptamine	melatonin receptor agonist				CC(=O)NCCc1c[nH]c2ccccc12, CC(=O)NCCc1c[nH]c2ccccc12, CC(=O)NCCc1c[nH]c2ccccc12, CC(=O)NCCc1c[nH]c2ccccc12	NVUGEQAEQJTCIX-UHFFFAOYSA-N, NVUGEQAEQJTCIX-UHFFFAOYSA-N, NVUGEQAEQJTCIX-UHFFFAOYSA-N, NVUGEQAEQJTCIX-UHFFFAOYSA-N	Preclinical
N-alpha-methylhistamine-dihydrochloride	histamine receptor agonist	HRH4			CNCCc1cnc[nH]1, CNCCc1cnc[nH]1	PHSPJQZRQAJPPF-UHFFFAOYSA-N, PHSPJQZRQAJPPF-UHFFFAOYSA-N	Phase 3
N-benzylnaltrindole	opioid receptor antagonist				Oc1ccc2C[C@H]3N(CC4CC4)CC[C@@]45[C@@H](Oc1c24)c1c(C[C@@]35O)c2ccccc2n1Cc1ccccc1 |TLB:21:22:7.12.13:4.5.18,23:22:7.12.13:4.5.18|	PSPANKCQVWSVHM-OUDZLNJNSA-N	Preclinical
N-cyclohexyl-2-benzothiazolesulfenamide					C1CCC(CC1)NSc1nc2ccccc2s1	DEQZTKGFXNUBJL-UHFFFAOYSA-N	Preclinical
N-hydroxynicotinamide					ONC(=O)c1cccnc1	IYCHDNQCHLMLJZ-UHFFFAOYSA-N	Preclinical
N-methyl-(-)ephedrine-[1R,2S]					C[C@@H]([C@H](O)c1ccccc1)N(C)C, C[C@@H]([C@H](O)c1ccccc1)N(C)C	FMCGSUUBYTWNDP-ONGXEEELSA-N, FMCGSUUBYTWNDP-ONGXEEELSA-N	Preclinical
N-methylformamide					CNC=O	ATHHXGZTWNVVOU-UHFFFAOYSA-N	Phase 2
N-methyllidocaine-iodide	antiarrhythmic medication				CC[N+](C)(CC)CC(=O)Nc1c(C)cccc1C	HFRFLLYLVAKRMZ-UHFFFAOYSA-O	Preclinical
N-methylpyrrolidone					CN1CCCC1=O	SECXISVLQFMRJM-UHFFFAOYSA-N	Phase 1
N-methylquipazine	serotonin receptor agonist				CN1CCN(CC1)c1ccc2ccccc2n1, CN1CCN(CC1)c1ccc2ccccc2n1	HOMWNUXPSJQSSU-UHFFFAOYSA-N, HOMWNUXPSJQSSU-UHFFFAOYSA-N	Preclinical
N-MPPP	opioid receptor agonist				CN([C@H](CN1CCCC1)c1ccccc1)C(=O)Cc1ccccc1, CN([C@H](CN1CCCC1)c1ccccc1)C(=O)Cc1ccccc1, CN([C@H](CN1CCCC1)c1ccccc1)C(=O)Cc1ccccc1, CN([C@H](CN1CCCC1)c1ccccc1)C(=O)Cc1ccccc1	OVZWUDZIAAHNFG-HXUWFJFHSA-N, OVZWUDZIAAHNFG-HXUWFJFHSA-N, OVZWUDZIAAHNFG-HXUWFJFHSA-N, OVZWUDZIAAHNFG-HXUWFJFHSA-N	Preclinical
N-oxydiethylenebenzothiazole-2-sulfenamide					C1CN(CCO1)Sc1nc2ccccc2s1, C1CN(CCO1)Sc1nc2ccccc2s1	MHKLKWCYGIBEQF-UHFFFAOYSA-N, MHKLKWCYGIBEQF-UHFFFAOYSA-N	Preclinical
N-salicoylaminophenol	ribonucleotide reductase inhibitor				Oc1ccc(NC(=O)c2ccccc2O)cc1	LGCMKPRGGJRYGM-UHFFFAOYSA-N	Phase 1/Phase 2
NAB-2	ubiquitin ligase transport promoter	NEDD4			Cc1ccc(C)c(c1)-n1cnc2cc(ccc12)C(=O)NCc1ccccc1Cl, Cc1ccc(C)c(c1)-n1cnc2cc(ccc12)C(=O)NCc1ccccc1Cl, Cc1ccc(C)c(c1)-n1cnc2cc(ccc12)C(=O)NCc1ccccc1Cl	CZSLEMCYYGEGKP-UHFFFAOYSA-N, CZSLEMCYYGEGKP-UHFFFAOYSA-N, CZSLEMCYYGEGKP-UHFFFAOYSA-N	Preclinical
nabumetone	cyclooxygenase inhibitor	PTGS1, PTGS2	rheumatology	rheumatoid arthritis, osteoarthritis	COc1ccc2cc(CCC(C)=O)ccc2c1, COc1ccc2cc(CCC(C)=O)ccc2c1, COc1ccc2cc(CCC(C)=O)ccc2c1, COc1ccc2cc(CCC(C)=O)ccc2c1	BLXXJMDCKKHMKV-UHFFFAOYSA-N, BLXXJMDCKKHMKV-UHFFFAOYSA-N, BLXXJMDCKKHMKV-UHFFFAOYSA-N, BLXXJMDCKKHMKV-UHFFFAOYSA-N	Launched
nadide	free radical scavenger	AHCY, AKR1A1, ALDH2, BLVRA, DHPS, DLD, GALE, HMGCR, HSD17B1, HSD17B4, IMPDH2, MGAM, P2RY11, SORD, TRPM2			NC(=O)c1ccc[n+](c1)[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@H](O)[C@@H]2O)n2cnc3c(N)ncnc23)[C@@H](O)[C@H]1O |a:9,11,23,25,26,28,40,42,&1:14,&2:18|, NC(=O)c1ccc[n+](c1)[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@H](O)[C@@H]2O)n2cnc3c(N)ncnc23)[C@@H](O)[C@H]1O |a:9,11,23,25,26,28,40,42,&1:14,&2:18|, NC(=O)c1ccc[n+](c1)[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@H](O)[C@@H]2O)n2cnc3c(N)ncnc23)[C@@H](O)[C@H]1O |a:9,11,23,25,26,28,40,42,&1:14,&2:18|	BAWFJGJZGIEFAR-NNYOXOHSSA-O, BAWFJGJZGIEFAR-NNYOXOHSSA-O, BAWFJGJZGIEFAR-NNYOXOHSSA-O	Launched
nadifloxacin	bacterial DNA gyrase inhibitor		dermatology, infectious disease	acne vulgaris (AV), skin infections	C[C@H]1CCc2c(N3CCC(O)CC3)c(F)cc3c2n1cc(C(O)=O)c3=O |&1:1,r|, C[C@H]1CCc2c(N3CCC(O)CC3)c(F)cc3c2n1cc(C(O)=O)c3=O |&1:1,r|, C[C@H]1CCc2c(N3CCC(O)CC3)c(F)cc3c2n1cc(C(O)=O)c3=O |&1:1,r|	JYJTVFIEFKZWCJ-JTQLQIEISA-N, JYJTVFIEFKZWCJ-JTQLQIEISA-N, JYJTVFIEFKZWCJ-JTQLQIEISA-N	Launched
nadolol	adrenergic receptor antagonist	ADRB1, ADRB2, ADRB3	cardiology	angina pectoris, hypertension	CC(C)(C)NC[C@@H](O)COc1cccc2C[C@@H](O)[C@@H](O)Cc12 |a:16,18,&1:6|, CC(C)(C)NC[C@@H](O)COc1cccc2C[C@@H](O)[C@@H](O)Cc12 |a:16,18,&1:6|	VWPOSFSPZNDTMJ-YUELXQCFSA-N, VWPOSFSPZNDTMJ-YUELXQCFSA-N	Launched
NADPH		DRD2, DRD3, DRD4, GHSR, HTR2A, HTR2C					Preclinical
nafadotride	dopamine receptor antagonist	DRD2, DRD3, HTR1A			CCCCN1CCC[C@@H]1CNC(=O)c1cc(C#N)c2ccccc2c1OC |&1:8,r|	IDZASIQMRGPBCQ-QGZVFWFLSA-N	Preclinical
nafamostat	serine protease inhibitor	ASIC1, ASIC2, ASIC3, C1R, PRSS1, TPSAB1, TRPM7	cardiology	anticoagulent	NC(=N)Nc1ccc(cc1)C(=O)Oc1ccc2cc(ccc2c1)C(N)=N, NC(=N)Nc1ccc(cc1)C(=O)Oc1ccc2cc(ccc2c1)C(N)=N, NC(=N)Nc1ccc(cc1)C(=O)Oc1ccc2cc(ccc2c1)C(N)=N, NC(=N)Nc1ccc(cc1)C(=O)Oc1ccc2cc(ccc2c1)C(N)=N	MQQNFDZXWVTQEH-UHFFFAOYSA-N, MQQNFDZXWVTQEH-UHFFFAOYSA-N, MQQNFDZXWVTQEH-UHFFFAOYSA-N, MQQNFDZXWVTQEH-UHFFFAOYSA-N	Launched
nafcillin	bacterial cell wall synthesis inhibitor	CYP1A2, CYP3A4, SLC22A6	infectious disease	gram-positive bacterial infections	CCOc1ccc2ccccc2c1C(=O)N[C@H]1[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O, CCOc1ccc2ccccc2c1C(=O)N[C@H]1[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O, CCOc1ccc2ccccc2c1C(=O)N[C@H]1[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O, CCOc1ccc2ccccc2c1C(=O)N[C@H]1[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O	GPXLMGHLHQJAGZ-JTDSTZFVSA-N, GPXLMGHLHQJAGZ-JTDSTZFVSA-N, GPXLMGHLHQJAGZ-JTDSTZFVSA-N, GPXLMGHLHQJAGZ-JTDSTZFVSA-N	Launched
naftidrofuryl	adrenergic receptor antagonist		cardiology	claudication	CCN(CC)CCOC(=O)[C@@H](C[C@H]1CCCO1)Cc1cccc2ccccc12 |&1:10,&2:12|, CCN(CC)CCOC(=O)[C@@H](C[C@H]1CCCO1)Cc1cccc2ccccc12 |&1:10,&2:12|, CCN(CC)CCOC(=O)[C@@H](C[C@H]1CCCO1)Cc1cccc2ccccc12 |&1:10,&2:12|	KBAFPSLPKGSANY-FGZHOGPDSA-N, KBAFPSLPKGSANY-FGZHOGPDSA-N, KBAFPSLPKGSANY-FGZHOGPDSA-N	Launched
naftifine	fungal squalene epoxidase inhibitor		infectious disease	tinea pedis, tinea cruris, tinea corporis	CN(C\C=C\c1ccccc1)Cc1cccc2ccccc12, CN(C\C=C\c1ccccc1)Cc1cccc2ccccc12, CN(C\C=C\c1ccccc1)Cc1cccc2ccccc12, CN(C\C=C\c1ccccc1)Cc1cccc2ccccc12, CN(C\C=C\c1ccccc1)Cc1cccc2ccccc12, CN(C\C=C\c1ccccc1)Cc1cccc2ccccc12	OZGNYLLQHRPOBR-DHZHZOJOSA-N, OZGNYLLQHRPOBR-DHZHZOJOSA-N, OZGNYLLQHRPOBR-DHZHZOJOSA-N, OZGNYLLQHRPOBR-DHZHZOJOSA-N, OZGNYLLQHRPOBR-DHZHZOJOSA-N, OZGNYLLQHRPOBR-DHZHZOJOSA-N	Launched
naftopidil	adrenergic receptor antagonist	ADRA1A	urology	benign prostatic hyperplasia (BPH)	COc1ccccc1N1CCN(C[C@@H](O)COc2cccc3ccccc23)CC1 |&1:13|, COc1ccccc1N1CCN(C[C@@H](O)COc2cccc3ccccc23)CC1 |&1:13|, COc1ccccc1N1CCN(C[C@@H](O)COc2cccc3ccccc23)CC1 |&1:13|	HRRBJVNMSRJFHQ-HXUWFJFHSA-N, HRRBJVNMSRJFHQ-HXUWFJFHSA-N, HRRBJVNMSRJFHQ-HXUWFJFHSA-N	Launched
nalbuphine	opioid receptor agonist, opioid receptor antagonist	OPRD1, OPRK1, OPRM1	neurology/psychiatry	pain relief	O[C@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5O[C@@H]1[C@]2(CCN3CC1CCC1)c45, O[C@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5O[C@@H]1[C@]2(CCN3CC1CCC1)c45, O[C@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5O[C@@H]1[C@]2(CCN3CC1CCC1)c45, O[C@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5O[C@@H]1[C@]2(CCN3CC1CCC1)c45	NETZHAKZCGBWSS-CEDHKZHLSA-N, NETZHAKZCGBWSS-CEDHKZHLSA-N, NETZHAKZCGBWSS-CEDHKZHLSA-N, NETZHAKZCGBWSS-CEDHKZHLSA-N	Launched
nalfurafine	opioid receptor agonist	OPRK1, OPRM1	nephrology	uremic pruritus	CN([C@@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5O[C@@H]1[C@]2(CCN3CC1CC1)c45)C(=O)\C=C\c1ccoc1, CN([C@@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5O[C@@H]1[C@]2(CCN3CC1CC1)c45)C(=O)\C=C\c1ccoc1	XGZZHZMWIXFATA-UEZBDDGYSA-N, XGZZHZMWIXFATA-UEZBDDGYSA-N	Launched
nalidixic-acid	bacterial DNA gyrase inhibitor		infectious disease	urinary tract infections	CCn1cc(C(O)=O)c(=O)c2ccc(C)nc12, CCn1cc(C(O)=O)c(=O)c2ccc(C)nc12, CCn1cc(C(O)=O)c(=O)c2ccc(C)nc12	MHWLWQUZZRMNGJ-UHFFFAOYSA-N, MHWLWQUZZRMNGJ-UHFFFAOYSA-N, MHWLWQUZZRMNGJ-UHFFFAOYSA-N	Launched
nalmefene	opioid receptor antagonist	OPRD1, OPRK1, OPRM1	pulmonary	respiratory depression	Oc1ccc2C[C@H]3N(CC4CC4)CC[C@@]45[C@@H](Oc1c24)C(=C)CC[C@@]35O, Oc1ccc2C[C@H]3N(CC4CC4)CC[C@@]45[C@@H](Oc1c24)C(=C)CC[C@@]35O, Oc1ccc2C[C@H]3N(CC4CC4)CC[C@@]45[C@@H](Oc1c24)C(=C)CC[C@@]35O, Oc1ccc2C[C@H]3N(CC4CC4)CC[C@@]45[C@@H](Oc1c24)C(=C)CC[C@@]35O	WJBLNOPPDWQMCH-MBPVOVBZSA-N, WJBLNOPPDWQMCH-MBPVOVBZSA-N, WJBLNOPPDWQMCH-MBPVOVBZSA-N, WJBLNOPPDWQMCH-MBPVOVBZSA-N	Launched
naloxegol	opioid receptor antagonist	OPRM1	gastroenterology	constipation	COCCOCCOCCOCCOCCOCCOCCO[C@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5O[C@@H]1[C@]2(CCN3CC=C)c45, COCCOCCOCCOCCOCCOCCOCCO[C@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5O[C@@H]1[C@]2(CCN3CC=C)c45	XNKCCCKFOQNXKV-ZRSCBOBOSA-N, XNKCCCKFOQNXKV-ZRSCBOBOSA-N	Launched
naloxone	opioid receptor antagonist	CREB1, ESR1, OPRD1, OPRK1, OPRM1, TLR4	pulmonary	respiratory depression	Oc1ccc2C[C@H]3N(CC=C)CC[C@@]45[C@@H](Oc1c24)C(=O)CC[C@@]35O, Oc1ccc2C[C@H]3N(CC=C)CC[C@@]45[C@@H](Oc1c24)C(=O)CC[C@@]35O, Oc1ccc2C[C@H]3N(CC=C)CC[C@@]45[C@@H](Oc1c24)C(=O)CC[C@@]35O, Oc1ccc2C[C@H]3N(CC=C)CC[C@@]45[C@@H](Oc1c24)C(=O)CC[C@@]35O, Oc1ccc2C[C@H]3N(CC=C)CC[C@@]45[C@@H](Oc1c24)C(=O)CC[C@@]35O, Oc1ccc2C[C@H]3N(CC=C)CC[C@@]45[C@@H](Oc1c24)C(=O)CC[C@@]35O	UZHSEJADLWPNLE-GRGSLBFTSA-N, UZHSEJADLWPNLE-GRGSLBFTSA-N, UZHSEJADLWPNLE-GRGSLBFTSA-N, UZHSEJADLWPNLE-GRGSLBFTSA-N, UZHSEJADLWPNLE-GRGSLBFTSA-N, UZHSEJADLWPNLE-GRGSLBFTSA-N	Launched
naloxone-benzoylhydrazone	opioid receptor antagonist	OPRK1, OPRM1			Oc1ccc2C[C@H]3N(CC=C)CC[C@@]45[C@@H](Oc1c24)\C(CC[C@@]35O)=N\NC(=O)c1ccccc1, Oc1ccc2C[C@H]3N(CC=C)CC[C@@]45[C@@H](Oc1c24)\C(CC[C@@]35O)=N\NC(=O)c1ccccc1, Oc1ccc2C[C@H]3N(CC=C)CC[C@@]45[C@@H](Oc1c24)\C(CC[C@@]35O)=N\NC(=O)c1ccccc1, Oc1ccc2C[C@H]3N(CC=C)CC[C@@]45[C@@H](Oc1c24)\C(CC[C@@]35O)=N\NC(=O)c1ccccc1	AKXCFAYOTIEFOH-XTNAHFASSA-N, AKXCFAYOTIEFOH-XTNAHFASSA-N, AKXCFAYOTIEFOH-XTNAHFASSA-N, AKXCFAYOTIEFOH-XTNAHFASSA-N	Preclinical
naltrexone	opioid receptor antagonist	OPRD1, OPRK1, OPRM1, SIGMAR1	neurology/psychiatry	abstinence from alcohol	Oc1ccc2C[C@H]3N(CC4CC4)CC[C@@]45[C@@H](Oc1c24)C(=O)CC[C@@]35O, Oc1ccc2C[C@H]3N(CC4CC4)CC[C@@]45[C@@H](Oc1c24)C(=O)CC[C@@]35O, Oc1ccc2C[C@H]3N(CC4CC4)CC[C@@]45[C@@H](Oc1c24)C(=O)CC[C@@]35O, Oc1ccc2C[C@H]3N(CC4CC4)CC[C@@]45[C@@H](Oc1c24)C(=O)CC[C@@]35O	DQCKKXVULJGBQN-XFWGSAIBSA-N, DQCKKXVULJGBQN-XFWGSAIBSA-N, DQCKKXVULJGBQN-XFWGSAIBSA-N, DQCKKXVULJGBQN-XFWGSAIBSA-N	Launched
naltriben	opioid receptor antagonist	OPRD1, OPRK1, OPRM1			Oc1ccc2C[C@H]3N(CC4CC4)CC[C@@]45[C@@H](Oc1c24)c1oc2ccccc2c1C[C@@]35O	ZHVWWEYETMPAMX-IFKAHUTRSA-N	Preclinical
naltrindole	opioid receptor antagonist	OPRD1, OPRK1, OPRM1			Oc1ccc2C[C@H]3N(CC4CC4)CC[C@@]45[C@@H](Oc1c24)c1[nH]c2ccccc2c1C[C@@]35O	WIYUZYBFCWCCQJ-IFKAHUTRSA-N	Preclinical
Nampt-IN-1					CC(C)(O)CS(=O)(=O)Nc1ccc2CN(CCc2c1)C(=O)COc1cccnc1	QHHSCLARESIWBH-UHFFFAOYSA-N	Preclinical
NAN-190	serotonin receptor agonist	ADRA1A, ADRA1B, ADRA1D, HTR1A, HTR1F			COc1ccccc1N1CCN(CCCCN2C(=O)c3ccccc3C2=O)CC1, COc1ccccc1N1CCN(CCCCN2C(=O)c3ccccc3C2=O)CC1	SJDOMIRMMUGQQK-UHFFFAOYSA-N, SJDOMIRMMUGQQK-UHFFFAOYSA-N	Preclinical
nanchangmycin	other antibiotic				CO[C@H]1CC[C@@H](O[C@H]2C[C@@H](O[C@]3(O[C@H](C[C@@H]3C)[C@H]3O[C@@](O)(CO)[C@H](C)C[C@@H]3C)[C@@H]2C)[C@]2(C)CC[C@]3(C[C@H](O)[C@@H](C)[C@H](O3)[C@@H](C)\C=C(/C)C(=O)[C@H](C)C[C@H](C)C(O)=O)O2)O[C@@H]1C |a:2,7,11,13,15,19,23,26,28,30,34,36,38,40,42,49,52,59,&1:5,&2:9,&3:17|, CO[C@H]1CC[C@@H](O[C@H]2C[C@@H](O[C@]3(O[C@H](C[C@@H]3C)[C@H]3O[C@@](O)(CO)[C@H](C)C[C@@H]3C)[C@@H]2C)[C@]2(C)CC[C@]3(C[C@H](O)[C@@H](C)[C@H](O3)[C@@H](C)\C=C(/C)C(=O)[C@H](C)C[C@H](C)C(O)=O)O2)O[C@@H]1C |a:2,7,11,13,15,19,23,26,28,30,34,36,38,40,42,49,52,59,&1:5,&2:9,&3:17|, CO[C@H]1CC[C@@H](O[C@H]2C[C@@H](O[C@]3(O[C@H](C[C@@H]3C)[C@H]3O[C@@](O)(CO)[C@H](C)C[C@@H]3C)[C@@H]2C)[C@]2(C)CC[C@]3(C[C@H](O)[C@@H](C)[C@H](O3)[C@@H](C)\C=C(/C)C(=O)[C@H](C)C[C@H](C)C(O)=O)O2)O[C@@H]1C |a:2,7,11,13,15,19,23,26,28,30,34,36,38,40,42,49,52,59,&1:5,&2:9,&3:17|, CO[C@H]1CC[C@@H](O[C@H]2C[C@@H](O[C@]3(O[C@H](C[C@@H]3C)[C@H]3O[C@@](O)(CO)[C@H](C)C[C@@H]3C)[C@@H]2C)[C@]2(C)CC[C@]3(C[C@H](O)[C@@H](C)[C@H](O3)[C@@H](C)\C=C(/C)C(=O)[C@H](C)C[C@H](C)C(O)=O)O2)O[C@@H]1C |a:2,7,11,13,15,19,23,26,28,30,34,36,38,40,42,49,52,59,&1:5,&2:9,&3:17|	FELYAZAWTURXNF-KWJIWYEDSA-N, FELYAZAWTURXNF-KWJIWYEDSA-N, FELYAZAWTURXNF-KWJIWYEDSA-N, FELYAZAWTURXNF-KWJIWYEDSA-N	Preclinical
napabucasin	STAT inhibitor	STAT3			CC(=O)c1cc2c(o1)C(=O)c1ccccc1C2=O, CC(=O)c1cc2c(o1)C(=O)c1ccccc1C2=O, CC(=O)c1cc2c(o1)C(=O)c1ccccc1C2=O, CC(=O)c1cc2c(o1)C(=O)c1ccccc1C2=O	DPHUWDIXHNQOSY-UHFFFAOYSA-N, DPHUWDIXHNQOSY-UHFFFAOYSA-N, DPHUWDIXHNQOSY-UHFFFAOYSA-N, DPHUWDIXHNQOSY-UHFFFAOYSA-N	Phase 3
napamezole	adrenergic receptor antagonist, monoamine reuptake inhibitor				C(C1=NCCN1)C1=Cc2ccccc2CC1 |t:1,7|	WETRBJOSGIDJHQ-UHFFFAOYSA-N	Preclinical
naphazoline	adrenergic receptor agonist	ADRA1A, ADRA2A	ophthalmology	eye irritation	C(C1=NCCN1)c1cccc2ccccc12 |t:1|, C(C1=NCCN1)c1cccc2ccccc12 |t:1|, C(C1=NCCN1)c1cccc2ccccc12 |t:1|, C(C1=NCCN1)c1cccc2ccccc12 |t:1|	CNIIGCLFLJGOGP-UHFFFAOYSA-N, CNIIGCLFLJGOGP-UHFFFAOYSA-N, CNIIGCLFLJGOGP-UHFFFAOYSA-N, CNIIGCLFLJGOGP-UHFFFAOYSA-N	Launched
naphthoquine-phosphate	antimalarial agent		infectious disease	malaria	CC(C)(C)NCc1cc(Nc2ccnc3cc(Cl)ccc23)c2CCCCc2c1O, CC(C)(C)NCc1cc(Nc2ccnc3cc(Cl)ccc23)c2CCCCc2c1O, CC(C)(C)NCc1cc(Nc2ccnc3cc(Cl)ccc23)c2CCCCc2c1O	VEVMYTDOWUQLGI-UHFFFAOYSA-N, VEVMYTDOWUQLGI-UHFFFAOYSA-N, VEVMYTDOWUQLGI-UHFFFAOYSA-N	Launched
napirimus	immunosuppressant				Cn1cc(cc1C(O)=O)C(=O)c1cccc2ccccc12	CNUPQURTHORUGH-UHFFFAOYSA-N	Phase 1
naproxen	cyclooxygenase inhibitor	PTGS1, PTGS2	neurology/psychiatry, rheumatology, dental, otolaryngology, endocrinology	pain relief, rheumatoid arthritis, headache, toothache, backache, muscle pain, common cold, fever	COc1ccc2cc(ccc2c1)[C@H](C)C(O)=O, COc1ccc2cc(ccc2c1)[C@H](C)C(O)=O, COc1ccc2cc(ccc2c1)[C@H](C)C(O)=O, COc1ccc2cc(ccc2c1)[C@H](C)C(O)=O, COc1ccc2cc(ccc2c1)[C@H](C)C(O)=O	CMWTZPSULFXXJA-VIFPVBQESA-N, CMWTZPSULFXXJA-VIFPVBQESA-N, CMWTZPSULFXXJA-VIFPVBQESA-N, CMWTZPSULFXXJA-VIFPVBQESA-N, CMWTZPSULFXXJA-VIFPVBQESA-N	Launched
naquotinib	EGFR inhibitor				CCc1nc(C(N)=O)c(Nc2ccc(cc2)N2CCC(CC2)N2CCN(C)CC2)nc1O[C@@H]1CCN(C1)C(=O)C=C	QKDCLUARMDUUKN-XMMPIXPASA-N	Phase 3
narasin	antiprotozoal agent		infectious disease	coccidiosis	CC[C@H]([C@@H]1O[C@@H]([C@@H](C)[C@H](O)[C@H](C)C(=O)[C@H](CC)[C@H]2O[C@@]3(O[C@@]4(CC[C@](C)(O4)[C@H]4CC[C@](O)(CC)[C@H](C)O4)[C@H](O)C=C3)[C@H](C)C[C@@H]2C)[C@@H](C)C[C@H]1C)C(O)=O |a:2,3,5,6,8,10,14,17,19,21,24,30,34,37,41,44,46,49,&1:27,c:41|, CC[C@H]([C@@H]1O[C@@H]([C@@H](C)[C@H](O)[C@H](C)C(=O)[C@H](CC)[C@H]2O[C@@]3(O[C@@]4(CC[C@](C)(O4)[C@H]4CC[C@](O)(CC)[C@H](C)O4)[C@H](O)C=C3)[C@H](C)C[C@@H]2C)[C@@H](C)C[C@H]1C)C(O)=O |a:2,3,5,6,8,10,14,17,19,21,24,30,34,37,41,44,46,49,&1:27,c:41|, CC[C@H]([C@@H]1O[C@@H]([C@@H](C)[C@H](O)[C@H](C)C(=O)[C@H](CC)[C@H]2O[C@@]3(O[C@@]4(CC[C@](C)(O4)[C@H]4CC[C@](O)(CC)[C@H](C)O4)[C@H](O)C=C3)[C@H](C)C[C@@H]2C)[C@@H](C)C[C@H]1C)C(O)=O |a:2,3,5,6,8,10,14,17,19,21,24,30,34,37,41,44,46,49,&1:27,c:41|, CC[C@H]([C@@H]1O[C@@H]([C@@H](C)[C@H](O)[C@H](C)C(=O)[C@H](CC)[C@H]2O[C@@]3(O[C@@]4(CC[C@](C)(O4)[C@H]4CC[C@](O)(CC)[C@H](C)O4)[C@H](O)C=C3)[C@H](C)C[C@@H]2C)[C@@H](C)C[C@H]1C)C(O)=O |a:2,3,5,6,8,10,14,17,19,21,24,30,34,37,41,44,46,49,&1:27,c:41|	VHKXXVVRRDYCIK-OQMITHEGSA-N, VHKXXVVRRDYCIK-OQMITHEGSA-N, VHKXXVVRRDYCIK-OQMITHEGSA-N, VHKXXVVRRDYCIK-OQMITHEGSA-N	Launched
naratriptan	serotonin receptor agonist	HTR1A, HTR1B, HTR1D, HTR1E, HTR1F	neurology/psychiatry	migraine headache	CNS(=O)(=O)CCc1ccc2[nH]cc(C3CCN(C)CC3)c2c1, CNS(=O)(=O)CCc1ccc2[nH]cc(C3CCN(C)CC3)c2c1, CNS(=O)(=O)CCc1ccc2[nH]cc(C3CCN(C)CC3)c2c1	AMKVXSZCKVJAGH-UHFFFAOYSA-N, AMKVXSZCKVJAGH-UHFFFAOYSA-N, AMKVXSZCKVJAGH-UHFFFAOYSA-N	Launched
naringenin	aromatase inhibitor, TRPV antagonist	CYP19A1, CYP1B1, ESR2, GLO1, HSD17B1			Oc1ccc(cc1)[C@@H]1CC(=O)c2c(O)cc(O)cc2O1, Oc1ccc(cc1)[C@@H]1CC(=O)c2c(O)cc(O)cc2O1	FTVWIRXFELQLPI-ZDUSSCGKSA-N, FTVWIRXFELQLPI-ZDUSSCGKSA-N	Phase 1
naringeninic-acid		HCAR2, PTGR1			OC(=O)\C=C\c1ccc(O)cc1, OC(=O)\C=C\c1ccc(O)cc1	NGSWKAQJJWESNS-ZZXKWVIFSA-N, NGSWKAQJJWESNS-ZZXKWVIFSA-N	Phase 1
naringin	cytochrome P450 inhibitor	SLCO1A2			C[C@@H]1O[C@@H](O[C@@H]2[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]2Oc2cc(O)c3C(=O)C[C@H](Oc3c2)c2ccc(O)cc2)[C@H](O)[C@H](O)[C@H]1O, C[C@@H]1O[C@@H](O[C@@H]2[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]2Oc2cc(O)c3C(=O)C[C@H](Oc3c2)c2ccc(O)cc2)[C@H](O)[C@H](O)[C@H]1O	DFPMSGMNTNDNHN-ZPHOTFPESA-N, DFPMSGMNTNDNHN-ZPHOTFPESA-N	Preclinical
naringin-dihydrochalcone	cytochrome P450 inhibitor				C[C@@H]1O[C@@H](O[C@@H]2[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]2Oc2cc(O)c(C(=O)CCc3ccc(O)cc3)c(O)c2)[C@H](O)[C@H](O)[C@H]1O	CWBZAESOUBENAP-QVNVHUMTSA-N	Preclinical
narlaprevir	HCV inhibitor				CCCC[C@H](NC(=O)[C@@H]1[C@@H]2[C@H](CN1C(=O)[C@@H](NC(=O)NC1(CS(=O)(=O)C(C)(C)C)CCCCC1)C(C)(C)C)C2(C)C)C(=O)C(=O)NC1CC1, CCCC[C@H](NC(=O)[C@@H]1[C@@H]2[C@H](CN1C(=O)[C@@H](NC(=O)NC1(CS(=O)(=O)C(C)(C)C)CCCCC1)C(C)(C)C)C2(C)C)C(=O)C(=O)NC1CC1, CCCC[C@H](NC(=O)[C@@H]1[C@@H]2[C@H](CN1C(=O)[C@@H](NC(=O)NC1(CS(=O)(=O)C(C)(C)C)CCCCC1)C(C)(C)C)C2(C)C)C(=O)C(=O)NC1CC1, CCCC[C@H](NC(=O)[C@@H]1[C@@H]2[C@H](CN1C(=O)[C@@H](NC(=O)NC1(CS(=O)(=O)C(C)(C)C)CCCCC1)C(C)(C)C)C2(C)C)C(=O)C(=O)NC1CC1	RICZEKWVNZFTNZ-LFGITCQGSA-N, RICZEKWVNZFTNZ-LFGITCQGSA-N, RICZEKWVNZFTNZ-LFGITCQGSA-N, RICZEKWVNZFTNZ-LFGITCQGSA-N	Phase 3
NAS-181	serotonin receptor antagonist	HTR1B			C(Oc1cccc2C=C(CN3CCOCC3)COc12)[C@H]1CNCCO1 |t:7|	RTKDBEOSPDFLGD-QGZVFWFLSA-N	Preclinical
nastorazepide	CCK receptor antagonist	CCKBR			CC(C)(C)C(=O)CN1c2ccccc2N(C[C@@H](NC(=O)Nc2cccc(c2)C(O)=O)C1=O)C1CCCCC1, CC(C)(C)C(=O)CN1c2ccccc2N(C[C@@H](NC(=O)Nc2cccc(c2)C(O)=O)C1=O)C1CCCCC1, CC(C)(C)C(=O)CN1c2ccccc2N(C[C@@H](NC(=O)Nc2cccc(c2)C(O)=O)C1=O)C1CCCCC1	VIJCCFFEBCOOIE-JOCHJYFZSA-N, VIJCCFFEBCOOIE-JOCHJYFZSA-N, VIJCCFFEBCOOIE-JOCHJYFZSA-N	Phase 2
natamycin	fungal ergosterol inhibitor		ophthalmology, infectious disease	conjunctivitis, fungal keratosis, blepharitis	C[C@H]1O[C@@H](O[C@@H]2C[C@@H]3O[C@@](O)(C[C@H](O)[C@H]3C(O)=O)C[C@@H](O)C[C@H]3O[C@@H]3\C=C\C(=O)O[C@H](C)C\C=C\C=C\C=C\C=C\2)[C@@H](O)[C@@H](N)[C@@H]1O |t:27,35,37,39,41|, C[C@H]1O[C@@H](O[C@@H]2C[C@@H]3O[C@@](O)(C[C@H](O)[C@H]3C(O)=O)C[C@@H](O)C[C@H]3O[C@@H]3\C=C\C(=O)O[C@H](C)C\C=C\C=C\C=C\C=C\2)[C@@H](O)[C@@H](N)[C@@H]1O |t:27,35,37,39,41|, C[C@H]1O[C@@H](O[C@@H]2C[C@@H]3O[C@@](O)(C[C@H](O)[C@H]3C(O)=O)C[C@@H](O)C[C@H]3O[C@@H]3\C=C\C(=O)O[C@H](C)C\C=C\C=C\C=C\C=C\2)[C@@H](O)[C@@H](N)[C@@H]1O |t:27,35,37,39,41|, C[C@H]1O[C@@H](O[C@@H]2C[C@@H]3O[C@@](O)(C[C@H](O)[C@H]3C(O)=O)C[C@@H](O)C[C@H]3O[C@@H]3\C=C\C(=O)O[C@H](C)C\C=C\C=C\C=C\C=C\2)[C@@H](O)[C@@H](N)[C@@H]1O |t:27,35,37,39,41|, C[C@H]1O[C@@H](O[C@@H]2C[C@@H]3O[C@@](O)(C[C@H](O)[C@H]3C(O)=O)C[C@@H](O)C[C@H]3O[C@@H]3\C=C\C(=O)O[C@H](C)C\C=C\C=C\C=C\C=C\2)[C@@H](O)[C@@H](N)[C@@H]1O |t:27,35,37,39,41|, C[C@H]1O[C@@H](O[C@@H]2C[C@@H]3O[C@@](O)(C[C@H](O)[C@H]3C(O)=O)C[C@@H](O)C[C@H]3O[C@@H]3\C=C\C(=O)O[C@H](C)C\C=C\C=C\C=C\C=C\2)[C@@H](O)[C@@H](N)[C@@H]1O |t:27,35,37,39,41|	NCXMLFZGDNKEPB-FFPOYIOWSA-N, NCXMLFZGDNKEPB-FFPOYIOWSA-N, NCXMLFZGDNKEPB-FFPOYIOWSA-N, NCXMLFZGDNKEPB-FFPOYIOWSA-N, NCXMLFZGDNKEPB-FFPOYIOWSA-N, NCXMLFZGDNKEPB-FFPOYIOWSA-N	Launched
nateglinide	insulin secretagogue	ABCC8, KCNJ10, KCNJ11, PPARG	endocrinology	diabetes mellitus	CC(C)[C@H]1CC[C@@H](CC1)C(=O)N[C@H](Cc1ccccc1)C(O)=O, CC(C)[C@H]1CC[C@@H](CC1)C(=O)N[C@H](Cc1ccccc1)C(O)=O, CC(C)[C@H]1CC[C@@H](CC1)C(=O)N[C@H](Cc1ccccc1)C(O)=O, CC(C)[C@H]1CC[C@@H](CC1)C(=O)N[C@H](Cc1ccccc1)C(O)=O, CC(C)[C@H]1CC[C@@H](CC1)C(=O)N[C@H](Cc1ccccc1)C(O)=O	OELFLUMRDSZNSF-BRWVUGGUSA-N, OELFLUMRDSZNSF-BRWVUGGUSA-N, OELFLUMRDSZNSF-BRWVUGGUSA-N, OELFLUMRDSZNSF-BRWVUGGUSA-N, OELFLUMRDSZNSF-BRWVUGGUSA-N	Launched
NAV-26	voltage-gated sodium channel blocker	SCN9A			FC(F)(F)Oc1ccc(CNC(=O)[C@H]2N(C3CCOCC3)C(=O)c3ccccc23)cc1 |&1:13,r|, FC(F)(F)Oc1ccc(CNC(=O)[C@H]2N(C3CCOCC3)C(=O)c3ccccc23)cc1 |&1:13,r|, FC(F)(F)Oc1ccc(CNC(=O)[C@H]2N(C3CCOCC3)C(=O)c3ccccc23)cc1 |&1:13,r|	ICGMZCVSHDKQTE-IBGZPJMESA-N, ICGMZCVSHDKQTE-IBGZPJMESA-N, ICGMZCVSHDKQTE-IBGZPJMESA-N	Preclinical
navarixin	CC chemokine receptor antagonist	CXCR1, CXCR2			CC[C@@H](Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)c1ccc(C)o1, CC[C@@H](Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)c1ccc(C)o1, CC[C@@H](Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)c1ccc(C)o1	RXIUEIPPLAFSDF-CYBMUJFWSA-N, RXIUEIPPLAFSDF-CYBMUJFWSA-N, RXIUEIPPLAFSDF-CYBMUJFWSA-N	Phase 2
navitoclax	BCL inhibitor	BCL2, BCL2L1, BCL2L2			CC1(C)CCC(=C(CN2CCN(CC2)c2ccc(cc2)C(=O)NS(=O)(=O)c2ccc(N[C@H](CCN3CCOCC3)CSc3ccccc3)c(c2)S(=O)(=O)C(F)(F)F)C1)c1ccc(Cl)cc1 |t:5|, CC1(C)CCC(=C(CN2CCN(CC2)c2ccc(cc2)C(=O)NS(=O)(=O)c2ccc(N[C@H](CCN3CCOCC3)CSc3ccccc3)c(c2)S(=O)(=O)C(F)(F)F)C1)c1ccc(Cl)cc1 |t:5|, CC1(C)CCC(=C(CN2CCN(CC2)c2ccc(cc2)C(=O)NS(=O)(=O)c2ccc(N[C@H](CCN3CCOCC3)CSc3ccccc3)c(c2)S(=O)(=O)C(F)(F)F)C1)c1ccc(Cl)cc1 |t:5|, CC1(C)CCC(=C(CN2CCN(CC2)c2ccc(cc2)C(=O)NS(=O)(=O)c2ccc(N[C@H](CCN3CCOCC3)CSc3ccccc3)c(c2)S(=O)(=O)C(F)(F)F)C1)c1ccc(Cl)cc1 |t:5|, CC1(C)CCC(=C(CN2CCN(CC2)c2ccc(cc2)C(=O)NS(=O)(=O)c2ccc(N[C@H](CCN3CCOCC3)CSc3ccccc3)c(c2)S(=O)(=O)C(F)(F)F)C1)c1ccc(Cl)cc1 |t:5|, CC1(C)CCC(=C(CN2CCN(CC2)c2ccc(cc2)C(=O)NS(=O)(=O)c2ccc(N[C@H](CCN3CCOCC3)CSc3ccccc3)c(c2)S(=O)(=O)C(F)(F)F)C1)c1ccc(Cl)cc1 |t:5|, CC1(C)CCC(=C(CN2CCN(CC2)c2ccc(cc2)C(=O)NS(=O)(=O)c2ccc(N[C@H](CCN3CCOCC3)CSc3ccccc3)c(c2)S(=O)(=O)C(F)(F)F)C1)c1ccc(Cl)cc1 |t:5|, CC1(C)CCC(=C(CN2CCN(CC2)c2ccc(cc2)C(=O)NS(=O)(=O)c2ccc(N[C@H](CCN3CCOCC3)CSc3ccccc3)c(c2)S(=O)(=O)C(F)(F)F)C1)c1ccc(Cl)cc1 |t:5|	JLYAXFNOILIKPP-KXQOOQHDSA-N, JLYAXFNOILIKPP-KXQOOQHDSA-N, JLYAXFNOILIKPP-KXQOOQHDSA-N, JLYAXFNOILIKPP-KXQOOQHDSA-N, JLYAXFNOILIKPP-KXQOOQHDSA-N, JLYAXFNOILIKPP-KXQOOQHDSA-N, JLYAXFNOILIKPP-KXQOOQHDSA-N, JLYAXFNOILIKPP-KXQOOQHDSA-N	Phase 2
naxagolide	dopamine receptor agonist				CCCN1CCO[C@H]2[C@H]1CCc1ccc(O)cc21	JCSREICEMHWFAY-HUUCEWRRSA-N	Phase 3
NB-001	antiviral				Nc1ncnc2n(CCNCCCCCO)cnc12	CVPTTZZCRDVGSU-UHFFFAOYSA-N	Preclinical
NBI-27914	corticotropin releasing factor receptor antagonist	CRHR1			CCCN(CC1CC1)c1nc(C)nc(Nc2c(Cl)cc(Cl)cc2Cl)c1Cl, CCCN(CC1CC1)c1nc(C)nc(Nc2c(Cl)cc(Cl)cc2Cl)c1Cl, CCCN(CC1CC1)c1nc(C)nc(Nc2c(Cl)cc(Cl)cc2Cl)c1Cl, CCCN(CC1CC1)c1nc(C)nc(Nc2c(Cl)cc(Cl)cc2Cl)c1Cl	KNADXBVKFAUMCR-UHFFFAOYSA-N, KNADXBVKFAUMCR-UHFFFAOYSA-N, KNADXBVKFAUMCR-UHFFFAOYSA-N, KNADXBVKFAUMCR-UHFFFAOYSA-N	Preclinical
NBI-74330-(+/-)	CC chemokine receptor antagonist	CXCR3			CCOc1ccc(cc1)-n1c(nc2ncccc2c1=O)[C@@H](C)N(Cc1cccnc1)C(=O)Cc1ccc(F)c(c1)C(F)(F)F |&1:20,r|, CCOc1ccc(cc1)-n1c(nc2ncccc2c1=O)[C@@H](C)N(Cc1cccnc1)C(=O)Cc1ccc(F)c(c1)C(F)(F)F |&1:20,r|	XMRGQUDUVGRCBS-HXUWFJFHSA-N, XMRGQUDUVGRCBS-HXUWFJFHSA-N	Preclinical
NBI-98782	vesicular monoamine transporter inhibitor				COc1cc2CCN3C[C@@H](CC(C)C)[C@H](O)C[C@@H]3c2cc1OC	WEQLWGNDNRARGE-DJIMGWMZSA-N	Preclinical
NBQX	glutamate receptor antagonist	GRIA1, GRIA2, GRIA3, GRIA4, GRIK1, GRIN1, GRIN2A, GRIN2B			NS(=O)(=O)c1cccc2c1c(cc1[nH]c(=O)c(=O)[nH]c21)[N+]([O-])=O, NS(=O)(=O)c1cccc2c1c(cc1[nH]c(=O)c(=O)[nH]c21)[N+]([O-])=O, NS(=O)(=O)c1cccc2c1c(cc1[nH]c(=O)c(=O)[nH]c21)[N+]([O-])=O, NS(=O)(=O)c1cccc2c1c(cc1[nH]c(=O)c(=O)[nH]c21)[N+]([O-])=O, NS(=O)(=O)c1cccc2c1c(cc1[nH]c(=O)c(=O)[nH]c21)[N+]([O-])=O, NS(=O)(=O)c1cccc2c1c(cc1[nH]c(=O)c(=O)[nH]c21)[N+]([O-])=O	UQNAFPHGVPVTAL-UHFFFAOYSA-N, UQNAFPHGVPVTAL-UHFFFAOYSA-N, UQNAFPHGVPVTAL-UHFFFAOYSA-N, UQNAFPHGVPVTAL-UHFFFAOYSA-N, UQNAFPHGVPVTAL-UHFFFAOYSA-N, UQNAFPHGVPVTAL-UHFFFAOYSA-N	Preclinical
NCS-382	GABA receptor antagonist	GABBR1, GABBR2, SLC52A2			O[C@@H]1c2ccccc2CCC\C1=C/C(O)=O |&1:1|	UADPGHINQMWEAG-FROQITRMSA-N	Preclinical
NCX-1015	interleukin sythesis stimulator				C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1CC[C@]2(O)C(=O)COC(=O)c1ccc(CO[N+]([O-])=O)cc1 |c:13,t:9|	MJHYBJOMJPGNMM-KGWLDMEJSA-N	Preclinical
NDD-094					Cc1nccn1Cc1ccccn1	CTUICISGLKIJLG-UHFFFAOYSA-N	Preclinical
NDT-9513727	complement antagonist	C5AR1			CCCCn1c(CN(Cc2ccc3OCOc3c2)Cc2ccc3OCOc3c2)c(nc1-c1ccccc1)-c1ccccc1, CCCCn1c(CN(Cc2ccc3OCOc3c2)Cc2ccc3OCOc3c2)c(nc1-c1ccccc1)-c1ccccc1	ITACCRHKSPSKKL-UHFFFAOYSA-N, ITACCRHKSPSKKL-UHFFFAOYSA-N	Preclinical
NE-100	sigma receptor antagonist	SIGMAR1			CCCN(CCC)CCc1ccc(OC)c(OCCc2ccccc2)c1, CCCN(CCC)CCc1ccc(OC)c(OCCc2ccccc2)c1, CCCN(CCC)CCc1ccc(OC)c(OCCc2ccccc2)c1	YBLIQJGXRLZBCZ-UHFFFAOYSA-N, YBLIQJGXRLZBCZ-UHFFFAOYSA-N, YBLIQJGXRLZBCZ-UHFFFAOYSA-N	Phase 2
nebivolol	adrenergic receptor antagonist	ADRB1	cardiology	hypertension	O[C@H](CNC[C@@H](O)[C@@H]1CCc2cc(F)ccc2O1)[C@H]1CCc2cc(F)ccc2O1 |&1:1,5,7,18|, O[C@H](CNC[C@@H](O)[C@@H]1CCc2cc(F)ccc2O1)[C@H]1CCc2cc(F)ccc2O1 |&1:1,5,7,18|	KOHIRBRYDXPAMZ-YHBROIRLSA-N, KOHIRBRYDXPAMZ-YHBROIRLSA-N	Launched
nebracetam	acetylcholine receptor agonist	CHRM1			NC[C@H]1CN(Cc2ccccc2)C(=O)C1 |&1:2|, NC[C@H]1CN(Cc2ccccc2)C(=O)C1 |&1:2|	LCAFGJGYCUMTGS-NSHDSACASA-N, LCAFGJGYCUMTGS-NSHDSACASA-N	Phase 3
NECA	adenosine receptor agonist	ADORA1, ADORA2A, ADORA2B, ADORA3			CCNC(=O)[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(N)ncnc12, CCNC(=O)[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(N)ncnc12, CCNC(=O)[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(N)ncnc12, CCNC(=O)[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(N)ncnc12	JADDQZYHOWSFJD-FLNNQWSLSA-N, JADDQZYHOWSFJD-FLNNQWSLSA-N, JADDQZYHOWSFJD-FLNNQWSLSA-N, JADDQZYHOWSFJD-FLNNQWSLSA-N	Launched
necrostatin-1	RIPK inhibitor	RIPK1			CN1C(=S)N[C@@H](Cc2c[nH]c3ccccc23)C1=O |r|, CN1C(=S)N[C@@H](Cc2c[nH]c3ccccc23)C1=O |r|, CN1C(=S)N[C@@H](Cc2c[nH]c3ccccc23)C1=O |r|, CN1C(=S)N[C@@H](Cc2c[nH]c3ccccc23)C1=O |r|	TXUWMXQFNYDOEZ-NSHDSACASA-N, TXUWMXQFNYDOEZ-NSHDSACASA-N, TXUWMXQFNYDOEZ-NSHDSACASA-N, TXUWMXQFNYDOEZ-NSHDSACASA-N	Preclinical
necrostatin-2	necroptosis inhibitor, RIPK inhibitor	RIPK2			CN1C(=O)N[C@H](Cc2c[nH]c3c(Cl)cccc23)C1=O, CN1C(=O)N[C@H](Cc2c[nH]c3c(Cl)cccc23)C1=O	WIKGAEMMNQTUGL-SNVBAGLBSA-N, WIKGAEMMNQTUGL-SNVBAGLBSA-N	Preclinical
nedaplatin	DNA inhibitor		oncology	non-small cell lung cancer (NSCLC), small cell lung cancer, esophageal cancer	N[Pt]1(N)OC=C(O)O1 |t:4|, N[Pt]1(N)OC=C(O)O1 |t:4|, N[Pt]1(N)OC=C(O)O1 |t:4|	AUZDMWWRYCUANI-UHFFFAOYSA-L, AUZDMWWRYCUANI-UHFFFAOYSA-L, AUZDMWWRYCUANI-UHFFFAOYSA-L	Launched
nedocromil	histamine receptor antagonist	CYSLTR1, CYSLTR2, FPR1, HSP90AA1, PTGDR	neurology/psychiatry, ophthalmology	itching, conjunctivitis	CCCc1c2oc(cc(=O)c2cc2c1n(CC)c(cc2=O)C(O)=O)C(O)=O, CCCc1c2oc(cc(=O)c2cc2c1n(CC)c(cc2=O)C(O)=O)C(O)=O, CCCc1c2oc(cc(=O)c2cc2c1n(CC)c(cc2=O)C(O)=O)C(O)=O	RQTOOFIXOKYGAN-UHFFFAOYSA-N, RQTOOFIXOKYGAN-UHFFFAOYSA-N, RQTOOFIXOKYGAN-UHFFFAOYSA-N	Launched
nefazodone	adrenergic inhibitor, norepinephrine reuptake inhibitor, serotonin receptor antagonist, serotonin reuptake inhibitor	ADRA1A, ADRA1B, ADRA2A, CYP3A4, HTR1A, HTR2A, HTR2C, SLC6A2, SLC6A3, SLC6A4			CCc1nn(CCCN2CCN(CC2)c2cccc(Cl)c2)c(=O)n1CCOc1ccccc1, CCc1nn(CCCN2CCN(CC2)c2cccc(Cl)c2)c(=O)n1CCOc1ccccc1, CCc1nn(CCCN2CCN(CC2)c2cccc(Cl)c2)c(=O)n1CCOc1ccccc1, CCc1nn(CCCN2CCN(CC2)c2cccc(Cl)c2)c(=O)n1CCOc1ccccc1	VRBKIVRKKCLPHA-UHFFFAOYSA-N, VRBKIVRKKCLPHA-UHFFFAOYSA-N, VRBKIVRKKCLPHA-UHFFFAOYSA-N, VRBKIVRKKCLPHA-UHFFFAOYSA-N	Withdrawn
nefiracetam	acetylcholine receptor agonist, benzodiazepine receptor agonist	CHRM1			Cc1cccc(C)c1NC(=O)CN1CCCC1=O, Cc1cccc(C)c1NC(=O)CN1CCCC1=O, Cc1cccc(C)c1NC(=O)CN1CCCC1=O, Cc1cccc(C)c1NC(=O)CN1CCCC1=O	NGHTXZCKLWZPGK-UHFFFAOYSA-N, NGHTXZCKLWZPGK-UHFFFAOYSA-N, NGHTXZCKLWZPGK-UHFFFAOYSA-N, NGHTXZCKLWZPGK-UHFFFAOYSA-N	Phase 3
nefopam	cyclooxygenase inhibitor		neurology/psychiatry	pain relief	CN1CCO[C@@H](c2ccccc2)c2ccccc2C1 |&1:5|, CN1CCO[C@@H](c2ccccc2)c2ccccc2C1 |&1:5|	RGPDEAGGEXEMMM-KRWDZBQOSA-N, RGPDEAGGEXEMMM-KRWDZBQOSA-N	Launched
nelarabine	DNA synthesis inhibitor, T cell inhibitor	POLA1	hematologic malignancy	acute lymphoblastic leukemia (ALL)	COc1nc(N)nc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O, COc1nc(N)nc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O, COc1nc(N)nc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O	IXOXBSCIXZEQEQ-UHTZMRCNSA-N, IXOXBSCIXZEQEQ-UHTZMRCNSA-N, IXOXBSCIXZEQEQ-UHTZMRCNSA-N	Launched
nelfinavir	HIV protease inhibitor	CYP1A2, CYP2B6, CYP2C19, CYP2C9, CYP2D6, CYP3A4, CYP3A7	infectious disease	human immunodeficiency virus (HIV-1)	Cc1c(O)cccc1C(=O)N[C@@H](CSc1ccccc1)[C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C, Cc1c(O)cccc1C(=O)N[C@@H](CSc1ccccc1)[C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C, Cc1c(O)cccc1C(=O)N[C@@H](CSc1ccccc1)[C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C, Cc1c(O)cccc1C(=O)N[C@@H](CSc1ccccc1)[C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C, Cc1c(O)cccc1C(=O)N[C@@H](CSc1ccccc1)[C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C, Cc1c(O)cccc1C(=O)N[C@@H](CSc1ccccc1)[C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C, Cc1c(O)cccc1C(=O)N[C@@H](CSc1ccccc1)[C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C	QAGYKUNXZHXKMR-HKWSIXNMSA-N, QAGYKUNXZHXKMR-HKWSIXNMSA-N, QAGYKUNXZHXKMR-HKWSIXNMSA-N, QAGYKUNXZHXKMR-HKWSIXNMSA-N, QAGYKUNXZHXKMR-HKWSIXNMSA-N, InChI=1S/C32H45N3O4S/c1-21-25(15-10-16-28(21)36)30(38)33-26(20-40-24-13-6-5-7-14-24)29(37)19-35-18-23-12-9-8-11-22(23)17-27(35)31(39)34-32(2,3)4/h5-7,10,13-16,22-23,26-27,29,36-37H,8-9,11-12,17-20H2,1-4H3,(H,33,38)(H,34,39)/t22-,23+,26-,27-,29+/m0/s1, InChI=1S/C32H45N3O4S/c1-21-25(15-10-16-28(21)36)30(38)33-26(20-40-24-13-6-5-7-14-24)29(37)19-35-18-23-12-9-8-11-22(23)17-27(35)31(39)34-32(2,3)4/h5-7,10,13-16,22-23,26-27,29,36-37H,8-9,11-12,17-20H2,1-4H3,(H,33,38)(H,34,39)/t22-,23+,26-,27-,29+/m0/s1	Launched
nelociguat	guanylate cyclase stimulant				COC(=O)Nc1c(N)nc(nc1N)-c1nn(Cc2ccccc2F)c2ncccc12	FTQHGWIXJSSWOY-UHFFFAOYSA-N	Preclinical
nelotanserin	serotonin receptor inverse agonist				COc1ccc(NC(=O)Nc2ccc(F)cc2F)cc1-c1c(Br)cnn1C	COSPVUFTLGQDQL-UHFFFAOYSA-N	Phase 2
nemazoline	adrenergic receptor agonist, adrenergic receptor antagonist				Nc1c(Cl)cc(C=C2NCCN2)cc1Cl	OEOYJZUHFXEJEI-UHFFFAOYSA-N	Phase 2
nemiralisib					CC(C)N1CCN(Cc2cnc(o2)-c2cc(cc3[nH]ncc23)-c2cccc3[nH]ccc23)CC1	MCIDWGZGWVSZMK-UHFFFAOYSA-N	Phase 2
nemonapride	dopamine receptor antagonist	DRD2, DRD3, DRD4	neurology/psychiatry	schizophrenia	CNc1cc(OC)c(cc1Cl)C(=O)N[C@@H]1CCN(Cc2ccccc2)[C@@H]1C |&1:14,25|	KRVOJOCLBAAKSJ-RDTXWAMCSA-N	Launched
nemorexant	orexin receptor antagonist				COc1ccc(c(c1)C(=O)N1CCC[C@@]1(C)c1nc2ccc(Cl)c(C)c2[nH]1)-n1nccn1	NBGABHGMJVIVBW-QHCPKHFHSA-N	Preclinical
nemorubicin	topoisomerase inhibitor	TOP1, TOP2A			CO[C@@H]1CN(CCO1)[C@H]1C[C@H](O[C@H]2C[C@@](O)(Cc3c(O)c4C(=O)c5cccc(OC)c5C(=O)c4c(O)c23)C(=O)CO)O[C@@H](C)[C@H]1O, CO[C@@H]1CN(CCO1)[C@H]1C[C@H](O[C@H]2C[C@@](O)(Cc3c(O)c4C(=O)c5cccc(OC)c5C(=O)c4c(O)c23)C(=O)CO)O[C@@H](C)[C@H]1O, CO[C@@H]1CN(CCO1)[C@H]1C[C@H](O[C@H]2C[C@@](O)(Cc3c(O)c4C(=O)c5cccc(OC)c5C(=O)c4c(O)c23)C(=O)CO)O[C@@H](C)[C@H]1O, CO[C@@H]1CN(CCO1)[C@H]1C[C@H](O[C@H]2C[C@@](O)(Cc3c(O)c4C(=O)c5cccc(OC)c5C(=O)c4c(O)c23)C(=O)CO)O[C@@H](C)[C@H]1O	CTMCWCONSULRHO-UHQPFXKFSA-N, CTMCWCONSULRHO-UHQPFXKFSA-N, CTMCWCONSULRHO-UHQPFXKFSA-N, CTMCWCONSULRHO-UHQPFXKFSA-N	Phase 2
neo-gilurytmal			cardiology	cardiac arrythmia	CCC[N@@+]12[C@H]3C[C@]45[C@@H](O)[C@@H]3[C@@H](C[C@@H]1[C@@H]4N(C)c1ccccc51)[C@H](CC)[C@H]2O |a:4,6,10,13,22,25,&1:3,&2:7,&3:9,&4:12|, CCC[N@@+]12[C@H]3C[C@]45[C@@H](O)[C@@H]3[C@@H](C[C@@H]1[C@@H]4N(C)c1ccccc51)[C@H](CC)[C@H]2O |a:4,6,10,13,22,25,&1:3,&2:7,&3:9,&4:12|	UAUHEPXILIZYCU-JSQPETPRSA-N, UAUHEPXILIZYCU-JSQPETPRSA-N	Launched
neohesperidin					[H][C@@]1(O[C@@H]2[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]2Oc2cc(O)c3C(=O)C[C@H](Oc3c2)c2ccc(OC)c(O)c2)O[C@@H](C)[C@H](O)[C@@H](O)[C@H]1O	ARGKVCXINMKCAZ-UZRWAPQLSA-N	Preclinical
neohesperidin-dihydrochalcone					COc1ccc(CCC(=O)c2c(O)cc(O[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](O)[C@H]3O)cc2O)cc1O, COc1ccc(CCC(=O)c2c(O)cc(O[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](O)[C@H]3O)cc2O)cc1O, COc1ccc(CCC(=O)c2c(O)cc(O[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](O)[C@H]3O)cc2O)cc1O	ITVGXXMINPYUHD-CUVHLRMHSA-N, ITVGXXMINPYUHD-CUVHLRMHSA-N, ITVGXXMINPYUHD-CUVHLRMHSA-N	Preclinical
neomycin	bacterial 30S ribosomal subunit inhibitor	CXCR4	infectious disease, gastroenterology	first-aid antibiotic, hepatic encephalopathy (HE), intra-abdominal infections	NC[C@@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@@H](O[C@@H]3[C@@H](O)[C@H](N)C[C@H](N)[C@H]3O[C@H]3O[C@H](CN)[C@@H](O)[C@H](O)[C@H]3N)[C@@H]2O)[C@H](N)[C@@H](O)[C@@H]1O, NC[C@@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@@H](O[C@@H]3[C@@H](O)[C@H](N)C[C@H](N)[C@H]3O[C@H]3O[C@H](CN)[C@@H](O)[C@H](O)[C@H]3N)[C@@H]2O)[C@H](N)[C@@H](O)[C@@H]1O, NC[C@@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@@H](O[C@@H]3[C@@H](O)[C@H](N)C[C@H](N)[C@H]3O[C@H]3O[C@H](CN)[C@@H](O)[C@H](O)[C@H]3N)[C@@H]2O)[C@H](N)[C@@H](O)[C@@H]1O, NC[C@@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@@H](O[C@@H]3[C@@H](O)[C@H](N)C[C@H](N)[C@H]3O[C@H]3O[C@H](CN)[C@@H](O)[C@H](O)[C@H]3N)[C@@H]2O)[C@H](N)[C@@H](O)[C@@H]1O, NC[C@@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@@H](O[C@@H]3[C@@H](O)[C@H](N)C[C@H](N)[C@H]3O[C@H]3O[C@H](CN)[C@@H](O)[C@H](O)[C@H]3N)[C@@H]2O)[C@H](N)[C@@H](O)[C@@H]1O, NC[C@@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@@H](O[C@@H]3[C@@H](O)[C@H](N)C[C@H](N)[C@H]3O[C@H]3O[C@H](CN)[C@@H](O)[C@H](O)[C@H]3N)[C@@H]2O)[C@H](N)[C@@H](O)[C@@H]1O	PGBHMTALBVVCIT-VCIWKGPPSA-N, PGBHMTALBVVCIT-VCIWKGPPSA-N, PGBHMTALBVVCIT-VCIWKGPPSA-N, PGBHMTALBVVCIT-VCIWKGPPSA-N, PGBHMTALBVVCIT-VCIWKGPPSA-N, PGBHMTALBVVCIT-VCIWKGPPSA-N	Launched
neostigmine	acetylcholinesterase inhibitor	ACHE	neurology/psychiatry	myasthenia gravis	CN(C)C(=O)Oc1cccc(c1)[N+](C)(C)C, CN(C)C(=O)Oc1cccc(c1)[N+](C)(C)C, CN(C)C(=O)Oc1cccc(c1)[N+](C)(C)C, CN(C)C(=O)Oc1cccc(c1)[N+](C)(C)C, CN(C)C(=O)Oc1cccc(c1)[N+](C)(C)C	ALWKGYPQUAPLQC-UHFFFAOYSA-N, ALWKGYPQUAPLQC-UHFFFAOYSA-N, ALWKGYPQUAPLQC-UHFFFAOYSA-N, ALWKGYPQUAPLQC-UHFFFAOYSA-N, ALWKGYPQUAPLQC-UHFFFAOYSA-N	Launched
nepafenac	cyclooxygenase inhibitor	PTGS1, PTGS2	ophthalmology	eye inflammation	NC(=O)Cc1cccc(C(=O)c2ccccc2)c1N	QEFAQIPZVLVERP-UHFFFAOYSA-N	Launched
nepicastat	dopamine beta hydroxylase inhibitor	DBH			NCc1c[nH]c(=S)n1[C@H]1CCc2c(F)cc(F)cc2C1, NCc1c[nH]c(=S)n1[C@H]1CCc2c(F)cc(F)cc2C1, NCc1c[nH]c(=S)n1[C@H]1CCc2c(F)cc(F)cc2C1	YZZVIKDAOTXDEB-JTQLQIEISA-N, YZZVIKDAOTXDEB-JTQLQIEISA-N, YZZVIKDAOTXDEB-JTQLQIEISA-N	Phase 2
neratinib	EGFR inhibitor	EGFR, ERBB2, KDR	oncology	breast cancer	CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4ccccn4)c(Cl)c3)c2cc1NC(=O)\C=C\CN(C)C, CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4ccccn4)c(Cl)c3)c2cc1NC(=O)\C=C\CN(C)C, CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4ccccn4)c(Cl)c3)c2cc1NC(=O)\C=C\CN(C)C, CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4ccccn4)c(Cl)c3)c2cc1NC(=O)\C=C\CN(C)C, CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4ccccn4)c(Cl)c3)c2cc1NC(=O)\C=C\CN(C)C, CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4ccccn4)c(Cl)c3)c2cc1NC(=O)\C=C\CN(C)C	JWNPDZNEKVCWMY-VQHVLOKHSA-N, JWNPDZNEKVCWMY-VQHVLOKHSA-N, JWNPDZNEKVCWMY-VQHVLOKHSA-N, JWNPDZNEKVCWMY-VQHVLOKHSA-N, JWNPDZNEKVCWMY-VQHVLOKHSA-N, JWNPDZNEKVCWMY-VQHVLOKHSA-N	Launched
nerbacadol	cyclooxygenase inhibitor				Cc1oncc1C(=O)N1CCCCC1	ZWNGSOLJLMBZFZ-UHFFFAOYSA-N	Phase 3
neridronic-acid	bone resorption inhibitor	FDPS	endocrinology	brittle bone disease, Paget's disease	NCCCCCC(O)(P(O)(O)=O)P(O)(O)=O, NCCCCCC(O)(P(O)(O)=O)P(O)(O)=O, NCCCCCC(O)(P(O)(O)=O)P(O)(O)=O	PUUSSSIBPPTKTP-UHFFFAOYSA-N, PUUSSSIBPPTKTP-UHFFFAOYSA-N, PUUSSSIBPPTKTP-UHFFFAOYSA-N	Launched
nesbuvir	RNA polymerase inhibitor				CNC(=O)c1c(oc2cc(N(CCO)S(C)(=O)=O)c(cc12)C1CC1)-c1ccc(F)cc1, CNC(=O)c1c(oc2cc(N(CCO)S(C)(=O)=O)c(cc12)C1CC1)-c1ccc(F)cc1, CNC(=O)c1c(oc2cc(N(CCO)S(C)(=O)=O)c(cc12)C1CC1)-c1ccc(F)cc1	WTDWVLJJJOTABN-UHFFFAOYSA-N, WTDWVLJJJOTABN-UHFFFAOYSA-N, WTDWVLJJJOTABN-UHFFFAOYSA-N	Phase 2
netilmicin	protein synthesis inhibitor		infectious disease	gram-negative bacterial infections	[H][C@]1(O[C@@H]2[C@@H](N)C[C@@H](NCC)[C@H](O[C@@]3([H])OC[C@](C)(O)[C@H](NC)[C@H]3O)[C@H]2O)OC(CN)=CC[C@H]1N |c:32|	CIDUJQMULVCIBT-MQDUPKMGSA-N	Launched
netupitant	tachykinin antagonist	TACR1	gastroenterology	nausea, vomiting	CN(C(=O)C(C)(C)c1cc(cc(c1)C(F)(F)F)C(F)(F)F)c1cnc(cc1-c1ccccc1C)N1CCN(C)CC1, CN(C(=O)C(C)(C)c1cc(cc(c1)C(F)(F)F)C(F)(F)F)c1cnc(cc1-c1ccccc1C)N1CCN(C)CC1, CN(C(=O)C(C)(C)c1cc(cc(c1)C(F)(F)F)C(F)(F)F)c1cnc(cc1-c1ccccc1C)N1CCN(C)CC1, CN(C(=O)C(C)(C)c1cc(cc(c1)C(F)(F)F)C(F)(F)F)c1cnc(cc1-c1ccccc1C)N1CCN(C)CC1	WAXQNWCZJDTGBU-UHFFFAOYSA-N, WAXQNWCZJDTGBU-UHFFFAOYSA-N, WAXQNWCZJDTGBU-UHFFFAOYSA-N, WAXQNWCZJDTGBU-UHFFFAOYSA-N	Launched
neurodazine	neurogenesis of non-pluripotent C2C12 myoblast inducer				COc1ccc(cc1)-c1nc([nH]c1-c1ccc(OC)cc1)-c1ccc(o1)-c1cccc(Cl)c1, COc1ccc(cc1)-c1nc([nH]c1-c1ccc(OC)cc1)-c1ccc(o1)-c1cccc(Cl)c1, COc1ccc(cc1)-c1nc([nH]c1-c1ccc(OC)cc1)-c1ccc(o1)-c1cccc(Cl)c1	FEEOFPAEDSMOTO-UHFFFAOYSA-N, FEEOFPAEDSMOTO-UHFFFAOYSA-N, FEEOFPAEDSMOTO-UHFFFAOYSA-N	Preclinical
neuropathiazol	neural stem cell inducer	BMP2, LIF			CCOC(=O)c1ccc(cc1)N(C)c1csc(n1)-c1ccccc1, CCOC(=O)c1ccc(cc1)N(C)c1csc(n1)-c1ccccc1, CCOC(=O)c1ccc(cc1)N(C)c1csc(n1)-c1ccccc1, CCOC(=O)c1ccc(cc1)N(C)c1csc(n1)-c1ccccc1, CCOC(=O)c1ccc(cc1)N(C)c1csc(n1)-c1ccccc1	MGKYEWWFHSESJN-UHFFFAOYSA-N, InChI=1S/C19H18N2O2S/c1-3-23-19(22)15-9-11-16(12-10-15)21(2)17-13-24-18(20-17)14-7-5-4-6-8-14/h4-13H,3H2,1-2H3, InChI=1S/C19H18N2O2S/c1-3-23-19(22)15-9-11-16(12-10-15)21(2)17-13-24-18(20-17)14-7-5-4-6-8-14/h4-13H,3H2,1-2H3, InChI=1S/C19H18N2O2S/c1-3-23-19(22)15-9-11-16(12-10-15)21(2)17-13-24-18(20-17)14-7-5-4-6-8-14/h4-13H,3H2,1-2H3, InChI=1S/C19H18N2O2S/c1-3-23-19(22)15-9-11-16(12-10-15)21(2)17-13-24-18(20-17)14-7-5-4-6-8-14/h4-13H,3H2,1-2H3	Preclinical
Neu2000	ionotropic glutamate receptor antagonist				OC(=O)c1cc(NCc2c(F)c(F)c(c(F)c2F)C(F)(F)F)ccc1O	HABROHXUHNHQMY-UHFFFAOYSA-N	Phase 2
nevirapine	non-nucleoside reverse transcriptase inhibitor	CYP1A2, CYP2A6, CYP2B6, CYP2C9, CYP2D6, CYP3A4, CYP3A5	infectious disease	human immunodeficiency virus (HIV-1)	Cc1ccnc2N(C3CC3)c3ncccc3C(=O)Nc12, Cc1ccnc2N(C3CC3)c3ncccc3C(=O)Nc12	NQDJXKOVJZTUJA-UHFFFAOYSA-N, NQDJXKOVJZTUJA-UHFFFAOYSA-N	Launched
nexturastat-A	HDAC inhibitor	HDAC1, HDAC6			CCCCN(Cc1ccc(cc1)C(=O)NO)C(=O)Nc1ccccc1, CCCCN(Cc1ccc(cc1)C(=O)NO)C(=O)Nc1ccccc1, CCCCN(Cc1ccc(cc1)C(=O)NO)C(=O)Nc1ccccc1, CCCCN(Cc1ccc(cc1)C(=O)NO)C(=O)Nc1ccccc1, CCCCN(Cc1ccc(cc1)C(=O)NO)C(=O)Nc1ccccc1	JZWXMCPARMXZQV-UHFFFAOYSA-N, JZWXMCPARMXZQV-UHFFFAOYSA-N, JZWXMCPARMXZQV-UHFFFAOYSA-N, JZWXMCPARMXZQV-UHFFFAOYSA-N, JZWXMCPARMXZQV-UHFFFAOYSA-N	Preclinical
NFKB-activation-inhibitor-II	NFkB pathway inhibitor	RELA			Cc1ccc(NCCCc2ccccc2)c(N)c1, Cc1ccc(NCCCc2ccccc2)c(N)c1, Cc1ccc(NCCCc2ccccc2)c(N)c1	YMFNPBSZFWXMAD-UHFFFAOYSA-N, YMFNPBSZFWXMAD-UHFFFAOYSA-N, YMFNPBSZFWXMAD-UHFFFAOYSA-N	Preclinical
NG-nitro-arginine	nitric oxide synthase inhibitor	NOS1, NOS2, NOS3			N[C@@H](CCCNC(N)=N[N+]([O-])=O)C(O)=O, N[C@@H](CCCNC(N)=N[N+]([O-])=O)C(O)=O	MRAUNPAHJZDYCK-BYPYZUCNSA-N, MRAUNPAHJZDYCK-BYPYZUCNSA-N	Phase 1
NGB-2904	dopamine receptor antagonist	DRD3			Clc1cccc(N2CCN(CCCCNC(=O)c3ccc-4c(Cc5ccccc-45)c3)CC2)c1Cl, Clc1cccc(N2CCN(CCCCNC(=O)c3ccc-4c(Cc5ccccc-45)c3)CC2)c1Cl, Clc1cccc(N2CCN(CCCCNC(=O)c3ccc-4c(Cc5ccccc-45)c3)CC2)c1Cl, Clc1cccc(N2CCN(CCCCNC(=O)c3ccc-4c(Cc5ccccc-45)c3)CC2)c1Cl	YJPWVCIGSHWNON-UHFFFAOYSA-N, YJPWVCIGSHWNON-UHFFFAOYSA-N, YJPWVCIGSHWNON-UHFFFAOYSA-N, YJPWVCIGSHWNON-UHFFFAOYSA-N	Preclinical
NGD-94-1	dopamine receptor antagonist	DRD4			C(N1CCN(CC1)c1ncccn1)c1cnc([nH]1)-c1ccccc1, C(N1CCN(CC1)c1ncccn1)c1cnc([nH]1)-c1ccccc1	OTVQCHUIPJYASM-UHFFFAOYSA-N, OTVQCHUIPJYASM-UHFFFAOYSA-N	Phase 1
NGD-98-2	corticotropin releasing factor receptor antagonist	CRHR1			CCC(CC)Nc1nc(C)c(nc1OC)-c1ccc(OC(F)(F)F)cc1OC, CCC(CC)Nc1nc(C)c(nc1OC)-c1ccc(OC(F)(F)F)cc1OC	PSUFQBRCUSJTDO-UHFFFAOYSA-N, PSUFQBRCUSJTDO-UHFFFAOYSA-N	Preclinical
NGP555	gamma secretase modulator				CCc1cc(Nc2nc(cs2)-c2ccc(c(F)c2)-n2cnc(C)c2)c(C)cc1C	WDEKUGNKKOGFOA-UHFFFAOYSA-N	Phase 1
NHI-2	lactate dehydrogenase inhibitor	LDHA			COC(=O)c1cc2c(cc(cc2n1O)-c1ccccc1)C(F)(F)F, COC(=O)c1cc2c(cc(cc2n1O)-c1ccccc1)C(F)(F)F	YPPFWRWCZNXINO-UHFFFAOYSA-N, YPPFWRWCZNXINO-UHFFFAOYSA-N	Preclinical
NH125	eukaryotic translation elongation factor 2 inhibitor				CCCCCCCCCCCCCCCC[n+]1ccn(Cc2ccccc2)c1C, CCCCCCCCCCCCCCCC[n+]1ccn(Cc2ccccc2)c1C, CCCCCCCCCCCCCCCC[n+]1ccn(Cc2ccccc2)c1C, CCCCCCCCCCCCCCCC[n+]1ccn(Cc2ccccc2)c1C, CCCCCCCCCCCCCCCC[n+]1ccn(Cc2ccccc2)c1C	ZZXUNAFAKNKXFW-UHFFFAOYSA-N, ZZXUNAFAKNKXFW-UHFFFAOYSA-N, ZZXUNAFAKNKXFW-UHFFFAOYSA-N, ZZXUNAFAKNKXFW-UHFFFAOYSA-N, ZZXUNAFAKNKXFW-UHFFFAOYSA-N	Preclinical
NI-57	bromodomain inhibitor	BRD1, BRPF1, BRPF3			COc1cc(ccc1S(=O)(=O)Nc1ccc2n(C)c(=O)c(C)cc2c1)C#N, COc1cc(ccc1S(=O)(=O)Nc1ccc2n(C)c(=O)c(C)cc2c1)C#N, COc1cc(ccc1S(=O)(=O)Nc1ccc2n(C)c(=O)c(C)cc2c1)C#N	UEMQPCYDWCSVCU-UHFFFAOYSA-N, UEMQPCYDWCSVCU-UHFFFAOYSA-N, UEMQPCYDWCSVCU-UHFFFAOYSA-N	Preclinical
niacin	NAD precursor, vitamin B	DGAT2, HCAR1, HCAR2, HCAR3, NNMT, QPRT	endocrinology	hypertriglyceridemia	OC(=O)c1cccnc1, OC(=O)c1cccnc1, OC(=O)c1cccnc1, OC(=O)c1cccnc1, OC(=O)c1cccnc1	PVNIIMVLHYAWGP-UHFFFAOYSA-N, PVNIIMVLHYAWGP-UHFFFAOYSA-N, PVNIIMVLHYAWGP-UHFFFAOYSA-N, PVNIIMVLHYAWGP-UHFFFAOYSA-N, PVNIIMVLHYAWGP-UHFFFAOYSA-N	Launched
nialamide	monoamine oxidase inhibitor	COMT, MAOA, MAOB			O=C(CCNNC(=O)c1ccncc1)NCc1ccccc1, O=C(CCNNC(=O)c1ccncc1)NCc1ccccc1, O=C(CCNNC(=O)c1ccncc1)NCc1ccccc1	NOIIUHRQUVNIDD-UHFFFAOYSA-N, NOIIUHRQUVNIDD-UHFFFAOYSA-N, NOIIUHRQUVNIDD-UHFFFAOYSA-N	Withdrawn
nibentan	potassium channel blocker				CCN(CC)CCCC[C@@H](NC(=O)c1ccc(cc1)[N+]([O-])=O)c1ccccc1 |&1:9,r|, CCN(CC)CCCC[C@@H](NC(=O)c1ccc(cc1)[N+]([O-])=O)c1ccccc1 |&1:9,r|	YRFYIORBFFGPPZ-OAQYLSRUSA-N, YRFYIORBFFGPPZ-OAQYLSRUSA-N	Phase 2
nicainoprol	angiotensin converting enzyme inhibitor				CC(C)NC[C@H](O)COc1cccc2CCCN(C(=O)c3cccnc3)c12 |&1:5,r|	AUIHHZBJBKRDIE-SFHVURJKSA-N	Preclinical
nicaraven	free radical scavenger				C[C@@H](CNC(=O)c1cccnc1)NC(=O)c1cccnc1 |&1:1,r|, C[C@@H](CNC(=O)c1cccnc1)NC(=O)c1cccnc1 |&1:1,r|	KTXBOOWDLPUROC-NSHDSACASA-N, KTXBOOWDLPUROC-NSHDSACASA-N	Phase 3
nicardipine	calcium channel blocker	ADORA3	cardiology	chronic stable angina, hypertension	COC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OCCN(C)Cc1ccccc1 |r,c:4,9|, COC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OCCN(C)Cc1ccccc1 |r,c:4,9|, COC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OCCN(C)Cc1ccccc1 |r,c:4,9|, COC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OCCN(C)Cc1ccccc1 |r,c:4,9|	ZBBHBTPTTSWHBA-XMMPIXPASA-N, ZBBHBTPTTSWHBA-XMMPIXPASA-N, ZBBHBTPTTSWHBA-XMMPIXPASA-N, ZBBHBTPTTSWHBA-XMMPIXPASA-N	Launched
nicergoline	adrenergic receptor antagonist	ADRA1A	rheumatology, neurology/psychiatry, cardiology, hematology	Raynaud's disease, migraine headache, atherosclerosis, thrombosis	CO[C@]12C[C@@H](COC(=O)c3cncc(Br)c3)CN(C)[C@@H]1Cc1cn(C)c3cccc2c13, CO[C@]12C[C@@H](COC(=O)c3cncc(Br)c3)CN(C)[C@@H]1Cc1cn(C)c3cccc2c13, CO[C@]12C[C@@H](COC(=O)c3cncc(Br)c3)CN(C)[C@@H]1Cc1cn(C)c3cccc2c13, CO[C@]12C[C@@H](COC(=O)c3cncc(Br)c3)CN(C)[C@@H]1Cc1cn(C)c3cccc2c13	YSEXMKHXIOCEJA-FVFQAYNVSA-N, YSEXMKHXIOCEJA-FVFQAYNVSA-N, YSEXMKHXIOCEJA-FVFQAYNVSA-N, YSEXMKHXIOCEJA-FVFQAYNVSA-N	Launched
niceritrol	NAD precursor		endocrinology	hyperlipidemia	O=C(OCC(COC(=O)c1cccnc1)(COC(=O)c1cccnc1)COC(=O)c1cccnc1)c1cccnc1, O=C(OCC(COC(=O)c1cccnc1)(COC(=O)c1cccnc1)COC(=O)c1cccnc1)c1cccnc1	KUEUWHJGRZKESU-UHFFFAOYSA-N, KUEUWHJGRZKESU-UHFFFAOYSA-N	Launched
niclosamide	DNA replication inhibitor, STAT inhibitor	STAT3	infectious disease	tapeworm	Oc1ccc(Cl)cc1C(=O)Nc1ccc(cc1Cl)[N+]([O-])=O, Oc1ccc(Cl)cc1C(=O)Nc1ccc(cc1Cl)[N+]([O-])=O, Oc1ccc(Cl)cc1C(=O)Nc1ccc(cc1Cl)[N+]([O-])=O, Oc1ccc(Cl)cc1C(=O)Nc1ccc(cc1Cl)[N+]([O-])=O, Oc1ccc(Cl)cc1C(=O)Nc1ccc(cc1Cl)[N+]([O-])=O, Oc1ccc(Cl)cc1C(=O)Nc1ccc(cc1Cl)[N+]([O-])=O	RJMUSRYZPJIFPJ-UHFFFAOYSA-N, RJMUSRYZPJIFPJ-UHFFFAOYSA-N, RJMUSRYZPJIFPJ-UHFFFAOYSA-N, RJMUSRYZPJIFPJ-UHFFFAOYSA-N, RJMUSRYZPJIFPJ-UHFFFAOYSA-N, RJMUSRYZPJIFPJ-UHFFFAOYSA-N	Launched
nicodicosapent	sterol regulatory element binding protein (SREBP) inhibitor				CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)NCCNC(=O)c1cccnc1	YYQALOWPCKMFDQ-JLNKQSITSA-N	Preclinical
nicorandil	nitric oxide donor, potassium channel activator	KCNJ11	cardiology	angina pectoris	[O-][N+](=O)OCCNC(=O)c1cccnc1, [O-][N+](=O)OCCNC(=O)c1cccnc1, [O-][N+](=O)OCCNC(=O)c1cccnc1, [O-][N+](=O)OCCNC(=O)c1cccnc1, [O-][N+](=O)OCCNC(=O)c1cccnc1, [O-][N+](=O)OCCNC(=O)c1cccnc1, [O-][N+](=O)OCCNC(=O)c1cccnc1, [O-][N+](=O)OCCNC(=O)c1cccnc1, [O-][N+](=O)OCCNC(=O)c1cccnc1	LBHIOVVIQHSOQN-UHFFFAOYSA-N, LBHIOVVIQHSOQN-UHFFFAOYSA-N, LBHIOVVIQHSOQN-UHFFFAOYSA-N, LBHIOVVIQHSOQN-UHFFFAOYSA-N, LBHIOVVIQHSOQN-UHFFFAOYSA-N, LBHIOVVIQHSOQN-UHFFFAOYSA-N, LBHIOVVIQHSOQN-UHFFFAOYSA-N, LBHIOVVIQHSOQN-UHFFFAOYSA-N, LBHIOVVIQHSOQN-UHFFFAOYSA-N	Launched
nicotinamide	protein synthesis stimulant	BST1, LDHA, PARP1, SIRT5	dermatology	acne vulgaris (AV)	NC(=O)c1cccnc1, NC(=O)c1cccnc1, NC(=O)c1cccnc1	DFPAKSUCGFBDDF-UHFFFAOYSA-N, DFPAKSUCGFBDDF-UHFFFAOYSA-N, DFPAKSUCGFBDDF-UHFFFAOYSA-N	Launched
nicotine	acetylcholine receptor agonist	CHAT, CHRNA10, CHRNA2, CHRNA3, CHRNA4, CHRNA5, CHRNA6, CHRNA7, CHRNA9, CHRNB2, CHRNB3, CHRNB4, CYP19A1, TBXAS1, TRPA1	neurology/psychiatry	smoking cessation	CN1CCC[C@H]1c1cccnc1	SNICXCGAKADSCV-JTQLQIEISA-N	Launched
nicotinyl-alcohol-tartrate			cardiology, neurology/psychiatry	vascular spasm, vertigo	OCc1cccnc1, OCc1cccnc1	MVQVNTPHUGQQHK-UHFFFAOYSA-N, MVQVNTPHUGQQHK-UHFFFAOYSA-N	Launched
NIDA-41020	cannabinoid receptor antagonist	CNR1			COc1ccc(cc1)-c1c(C)c(nn1-c1ccc(Cl)cc1Cl)C(=O)NN1CCCCC1, COc1ccc(cc1)-c1c(C)c(nn1-c1ccc(Cl)cc1Cl)C(=O)NN1CCCCC1, COc1ccc(cc1)-c1c(C)c(nn1-c1ccc(Cl)cc1Cl)C(=O)NN1CCCCC1	KWDBQJRWPWTGPF-UHFFFAOYSA-N, KWDBQJRWPWTGPF-UHFFFAOYSA-N, KWDBQJRWPWTGPF-UHFFFAOYSA-N	Preclinical
nifedipine	calcium channel blocker	CACNA1C, CACNA1D, CACNA1F, CACNA1H, CACNA1S, CACNA2D1, CACNB2, CALM1, GLRA1, GLRA3, GLRB, KCNA1, KCNA5, NR1I2, TRPM3	cardiology	vasospastic angina, chronic stable angina	COC(=O)C1=C(C)NC(C)=C(C1c1ccccc1[N+]([O-])=O)C(=O)OC |c:4,9|, COC(=O)C1=C(C)NC(C)=C(C1c1ccccc1[N+]([O-])=O)C(=O)OC |c:4,9|, COC(=O)C1=C(C)NC(C)=C(C1c1ccccc1[N+]([O-])=O)C(=O)OC |c:4,9|, COC(=O)C1=C(C)NC(C)=C(C1c1ccccc1[N+]([O-])=O)C(=O)OC |c:4,9|, COC(=O)C1=C(C)NC(C)=C(C1c1ccccc1[N+]([O-])=O)C(=O)OC |c:4,9|, COC(=O)C1=C(C)NC(C)=C(C1c1ccccc1[N+]([O-])=O)C(=O)OC |c:4,9|, COC(=O)C1=C(C)NC(C)=C(C1c1ccccc1[N+]([O-])=O)C(=O)OC |c:4,9|	HYIMSNHJOBLJNT-UHFFFAOYSA-N, HYIMSNHJOBLJNT-UHFFFAOYSA-N, HYIMSNHJOBLJNT-UHFFFAOYSA-N, HYIMSNHJOBLJNT-UHFFFAOYSA-N, HYIMSNHJOBLJNT-UHFFFAOYSA-N, HYIMSNHJOBLJNT-UHFFFAOYSA-N, HYIMSNHJOBLJNT-UHFFFAOYSA-N	Launched
nifekalant	potassium channel blocker		cardiology	ventricular arrhythmias, ventricular tachycardia (VT)	Cn1c(NCCN(CCO)CCCc2ccc(cc2)[N+]([O-])=O)cc(=O)n(C)c1=O, Cn1c(NCCN(CCO)CCCc2ccc(cc2)[N+]([O-])=O)cc(=O)n(C)c1=O	OEBPANQZQGQPHF-UHFFFAOYSA-N, OEBPANQZQGQPHF-UHFFFAOYSA-N	Launched
nifenalol	adrenergic receptor antagonist	ADRB1, ADRB2			CC(C)NC[C@@H](O)c1ccc(cc1)[N+]([O-])=O |&1:5,r|	UAORFCGRZIGNCI-LLVKDONJSA-N	Launched
nifenazone	analgesic agent		neurology/psychiatry	pain relief	Cc1c(NC(=O)c2cccnc2)c(=O)n(-c2ccccc2)n1C, Cc1c(NC(=O)c2cccnc2)c(=O)n(-c2ccccc2)n1C, Cc1c(NC(=O)c2cccnc2)c(=O)n(-c2ccccc2)n1C	BRZANEXCSZCZCI-UHFFFAOYSA-N, BRZANEXCSZCZCI-UHFFFAOYSA-N, BRZANEXCSZCZCI-UHFFFAOYSA-N	Launched
niflumic-acid	cyclooxygenase inhibitor	ANO1, CLCN1, CLCNKA, CLCNKB, KCNQ1, PLA2G1B, PLA2G4A, PTGS1, PTGS2, UGT1A9	rheumatology, neurology/psychiatry	joint pain, muscle pain	OC(=O)c1cccnc1Nc1cccc(c1)C(F)(F)F, OC(=O)c1cccnc1Nc1cccc(c1)C(F)(F)F, OC(=O)c1cccnc1Nc1cccc(c1)C(F)(F)F	JZFPYUNJRRFVQU-UHFFFAOYSA-N, JZFPYUNJRRFVQU-UHFFFAOYSA-N, JZFPYUNJRRFVQU-UHFFFAOYSA-N	Launched
nifuroxazide	bacterial DNA inhibitor		gastroenterology	colitis, diarrhea	Oc1ccc(cc1)C(=O)N\N=C\c1ccc(o1)[N+]([O-])=O, Oc1ccc(cc1)C(=O)N\N=C\c1ccc(o1)[N+]([O-])=O, Oc1ccc(cc1)C(=O)N\N=C\c1ccc(o1)[N+]([O-])=O, Oc1ccc(cc1)C(=O)N\N=C\c1ccc(o1)[N+]([O-])=O, Oc1ccc(cc1)C(=O)N\N=C\c1ccc(o1)[N+]([O-])=O, Oc1ccc(cc1)C(=O)N\N=C\c1ccc(o1)[N+]([O-])=O, Oc1ccc(cc1)C(=O)N\N=C\c1ccc(o1)[N+]([O-])=O	YCWSUKQGVSGXJO-NTUHNPAUSA-N, YCWSUKQGVSGXJO-NTUHNPAUSA-N, YCWSUKQGVSGXJO-NTUHNPAUSA-N, YCWSUKQGVSGXJO-NTUHNPAUSA-N, YCWSUKQGVSGXJO-NTUHNPAUSA-N, YCWSUKQGVSGXJO-NTUHNPAUSA-N, YCWSUKQGVSGXJO-NTUHNPAUSA-N	Launched
nifursol	bacterial DNA inhibitor				Oc1c(cc(cc1[N+]([O-])=O)[N+]([O-])=O)C(=O)N\N=C\c1ccc(o1)[N+]([O-])=O, Oc1c(cc(cc1[N+]([O-])=O)[N+]([O-])=O)C(=O)N\N=C\c1ccc(o1)[N+]([O-])=O, Oc1c(cc(cc1[N+]([O-])=O)[N+]([O-])=O)C(=O)N\N=C\c1ccc(o1)[N+]([O-])=O	XXUXXCZCUGIGPP-WLRTZDKTSA-N, XXUXXCZCUGIGPP-WLRTZDKTSA-N, XXUXXCZCUGIGPP-WLRTZDKTSA-N	Launched
nifurtimox	DNA inhibitor		infectious disease	Chagas disease, African trypanosomiasis	C[C@H]1CS(=O)(=O)CCN1\N=C\c1ccc(o1)[N+]([O-])=O |&1:1,r|	ARFHIAQFJWUCFH-KIFNTFBYSA-N	Launched
niguldipine-(R)-(-)					COC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OCCCN1CCC(CC1)(c1ccccc1)c1ccccc1 |r,c:4,9|	SVJMLYUFVDMUHP-MGBGTMOVSA-N	Preclinical
niguldipine-(S)-(+)	adrenergic receptor antagonist	ADRA1A			COC(=O)C1=C(C)NC(C)=C([C@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OCCCN1CCC(CC1)(c1ccccc1)c1ccccc1 |c:4,9|, COC(=O)C1=C(C)NC(C)=C([C@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OCCCN1CCC(CC1)(c1ccccc1)c1ccccc1 |c:4,9|, COC(=O)C1=C(C)NC(C)=C([C@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OCCCN1CCC(CC1)(c1ccccc1)c1ccccc1 |c:4,9|, COC(=O)C1=C(C)NC(C)=C([C@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OCCCN1CCC(CC1)(c1ccccc1)c1ccccc1 |c:4,9|, COC(=O)C1=C(C)NC(C)=C([C@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OCCCN1CCC(CC1)(c1ccccc1)c1ccccc1 |c:4,9|, COC(=O)C1=C(C)NC(C)=C([C@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OCCCN1CCC(CC1)(c1ccccc1)c1ccccc1 |c:4,9|	SVJMLYUFVDMUHP-XIFFEERXSA-N, SVJMLYUFVDMUHP-XIFFEERXSA-N, SVJMLYUFVDMUHP-XIFFEERXSA-N, SVJMLYUFVDMUHP-XIFFEERXSA-N, SVJMLYUFVDMUHP-XIFFEERXSA-N, SVJMLYUFVDMUHP-XIFFEERXSA-N	Preclinical
nikethamide	immunostimulant				CCN(CC)C(=O)c1cccnc1, CCN(CC)C(=O)c1cccnc1	NCYVXEGFNDZQCU-UHFFFAOYSA-N, NCYVXEGFNDZQCU-UHFFFAOYSA-N	Withdrawn
nilotinib	Abl kinase inhibitor, Bcr-Abl kinase inhibitor	ABL1, KIT	hematologic malignancy	chronic myeloid leukemia (CML)	Cc1cn(cn1)-c1cc(NC(=O)c2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)cc(c1)C(F)(F)F, Cc1cn(cn1)-c1cc(NC(=O)c2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)cc(c1)C(F)(F)F	HHZIURLSWUIHRB-UHFFFAOYSA-N, HHZIURLSWUIHRB-UHFFFAOYSA-N	Launched
nilutamide	androgen receptor antagonist	AR	oncology	prostate cancer	CC1(C)NC(=O)N(C1=O)c1ccc(c(c1)C(F)(F)F)[N+]([O-])=O, CC1(C)NC(=O)N(C1=O)c1ccc(c(c1)C(F)(F)F)[N+]([O-])=O, CC1(C)NC(=O)N(C1=O)c1ccc(c(c1)C(F)(F)F)[N+]([O-])=O	XWXYUMMDTVBTOU-UHFFFAOYSA-N, XWXYUMMDTVBTOU-UHFFFAOYSA-N, XWXYUMMDTVBTOU-UHFFFAOYSA-N	Launched
nilvadipine	calcium channel blocker	CACNA1C, CACNA1D	cardiology	hypertension, cerebral artery occlusion	COC(=O)C1=C(NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OC(C)C)C#N |&1:10,r,c:8,t:4|, COC(=O)C1=C(NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OC(C)C)C#N |&1:10,r,c:8,t:4|, COC(=O)C1=C(NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OC(C)C)C#N |&1:10,r,c:8,t:4|, COC(=O)C1=C(NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OC(C)C)C#N |&1:10,r,c:8,t:4|, COC(=O)C1=C(NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OC(C)C)C#N |&1:10,r,c:8,t:4|, COC(=O)C1=C(NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OC(C)C)C#N |&1:10,r,c:8,t:4|, COC(=O)C1=C(NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OC(C)C)C#N |&1:10,r,c:8,t:4|, COC(=O)C1=C(NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OC(C)C)C#N |&1:10,r,c:8,t:4|	FAIIFDPAEUKBEP-INIZCTEOSA-N, FAIIFDPAEUKBEP-INIZCTEOSA-N, FAIIFDPAEUKBEP-INIZCTEOSA-N, FAIIFDPAEUKBEP-INIZCTEOSA-N, FAIIFDPAEUKBEP-INIZCTEOSA-N, FAIIFDPAEUKBEP-INIZCTEOSA-N, FAIIFDPAEUKBEP-INIZCTEOSA-N, FAIIFDPAEUKBEP-INIZCTEOSA-N	Launched
nimesulide	cyclooxygenase inhibitor	LTF, PLA2G2E, PTGS1, PTGS2	rheumatology, obstetrics/gynecology	osteoarthritis, menstrual pain	CS(=O)(=O)Nc1ccc(cc1Oc1ccccc1)[N+]([O-])=O, CS(=O)(=O)Nc1ccc(cc1Oc1ccccc1)[N+]([O-])=O, CS(=O)(=O)Nc1ccc(cc1Oc1ccccc1)[N+]([O-])=O, CS(=O)(=O)Nc1ccc(cc1Oc1ccccc1)[N+]([O-])=O, CS(=O)(=O)Nc1ccc(cc1Oc1ccccc1)[N+]([O-])=O, CS(=O)(=O)Nc1ccc(cc1Oc1ccccc1)[N+]([O-])=O	HYWYRSMBCFDLJT-UHFFFAOYSA-N, HYWYRSMBCFDLJT-UHFFFAOYSA-N, HYWYRSMBCFDLJT-UHFFFAOYSA-N, HYWYRSMBCFDLJT-UHFFFAOYSA-N, HYWYRSMBCFDLJT-UHFFFAOYSA-N, HYWYRSMBCFDLJT-UHFFFAOYSA-N	Launched
nimodipine	calcium channel blocker	CFTR, NR3C2	hematology	hemorrhage	COCCOC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OC(C)C |r,c:7,12|, COCCOC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OC(C)C |r,c:7,12|, COCCOC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OC(C)C |r,c:7,12|	UIAGMCDKSXEBJQ-LJQANCHMSA-N, UIAGMCDKSXEBJQ-LJQANCHMSA-N, UIAGMCDKSXEBJQ-LJQANCHMSA-N	Launched
nimorazole	bacterial DNA inhibitor		oncology	head and neck squamous cell carcinoma (HNSCC)	[O-][N+](=O)c1cncn1CCN1CCOCC1, [O-][N+](=O)c1cncn1CCN1CCOCC1	MDJFHRLTPRPZLY-UHFFFAOYSA-N, MDJFHRLTPRPZLY-UHFFFAOYSA-N	Launched
nimustine	DNA alkylating agent				Cc1ncc(CNC(=O)N(CCCl)[NH2+][O-])c(N)n1, Cc1ncc(CNC(=O)N(CCCl)[NH2+][O-])c(N)n1	QMAZPCHGABINAB-UHFFFAOYSA-N, QMAZPCHGABINAB-UHFFFAOYSA-N	Launched
NIM811	mitochondrial permeability transition inhibitor				[H][C@]1(NC(=O)[C@]([H])([C@@H](C)CC)N(C)C(=O)CN(C)C(=O)[C@H](CC)NC(=O)[C@]([H])([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@]([H])(C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@]([H])(CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C1=O)C(C)C	RPJPZDVUUKWPGT-FOIHOXPVSA-N	Phase 2
ningetinib-tosylate	protein tyrosine kinase inhibitor				Cc1c(C(=O)Nc2ccc(Oc3ccnc4cc(OCC(C)(C)O)ccc34)c(F)c2)c(=O)n(-c2ccccc2)n1C	VQYYQSZNRVQLIS-UHFFFAOYSA-N	Preclinical
nintedanib	FGFR inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	FGFR1, FGFR2, FGFR3, FGFR4, FLT1, FLT4, KDR, PDGFRA, PDGFRB	pulmonary	idiopathic pulmonary fibrosis (IPF)	COC(=O)c1ccc2\C(=C(\Nc3ccc(cc3)N(C)C(=O)CN3CCN(C)CC3)c3ccccc3)C(=O)Nc2c1, COC(=O)c1ccc2\C(=C(\Nc3ccc(cc3)N(C)C(=O)CN3CCN(C)CC3)c3ccccc3)C(=O)Nc2c1, COC(=O)c1ccc2\C(=C(\Nc3ccc(cc3)N(C)C(=O)CN3CCN(C)CC3)c3ccccc3)C(=O)Nc2c1	XZXHXSATPCNXJR-ZIADKAODSA-N, XZXHXSATPCNXJR-ZIADKAODSA-N, XZXHXSATPCNXJR-ZIADKAODSA-N	Launched
niraparib	PARP inhibitor	PARP1	oncology	primary peritoneal cancer (PPC)	NC(=O)c1cccc2cn(nc12)-c1ccc(cc1)[C@@H]1CCCNC1, NC(=O)c1cccc2cn(nc12)-c1ccc(cc1)[C@@H]1CCCNC1, NC(=O)c1cccc2cn(nc12)-c1ccc(cc1)[C@@H]1CCCNC1, NC(=O)c1cccc2cn(nc12)-c1ccc(cc1)[C@@H]1CCCNC1, NC(=O)c1cccc2cn(nc12)-c1ccc(cc1)[C@@H]1CCCNC1, NC(=O)c1cccc2cn(nc12)-c1ccc(cc1)[C@@H]1CCCNC1, NC(=O)c1cccc2cn(nc12)-c1ccc(cc1)[C@@H]1CCCNC1	PCHKPVIQAHNQLW-CQSZACIVSA-N, PCHKPVIQAHNQLW-CQSZACIVSA-N, PCHKPVIQAHNQLW-CQSZACIVSA-N, PCHKPVIQAHNQLW-CQSZACIVSA-N, PCHKPVIQAHNQLW-CQSZACIVSA-N, PCHKPVIQAHNQLW-CQSZACIVSA-N, PCHKPVIQAHNQLW-CQSZACIVSA-N	Launched
niridazole	phosphofructokinase inhibitor		infectious disease	schistosomiasis	[O-][N+](=O)c1cnc(s1)N1CCNC1=O, [O-][N+](=O)c1cnc(s1)N1CCNC1=O, [O-][N+](=O)c1cnc(s1)N1CCNC1=O	RDXLYGJSWZYTFJ-UHFFFAOYSA-N, RDXLYGJSWZYTFJ-UHFFFAOYSA-N, RDXLYGJSWZYTFJ-UHFFFAOYSA-N	Launched
nisin	bacterial cell wall synthesis inhibitor						Phase 1
nisoldipine	calcium channel blocker	CACNA1C, CACNA1D, CACNA1F, CACNA1S	cardiology	hypertension	COC(=O)C1=C(C)NC(C)=C([C@@H]1c1ccccc1[N+]([O-])=O)C(=O)OCC(C)C |r,c:4,9|, COC(=O)C1=C(C)NC(C)=C([C@@H]1c1ccccc1[N+]([O-])=O)C(=O)OCC(C)C |r,c:4,9|, COC(=O)C1=C(C)NC(C)=C([C@@H]1c1ccccc1[N+]([O-])=O)C(=O)OCC(C)C |r,c:4,9|, COC(=O)C1=C(C)NC(C)=C([C@@H]1c1ccccc1[N+]([O-])=O)C(=O)OCC(C)C |r,c:4,9|, COC(=O)C1=C(C)NC(C)=C([C@@H]1c1ccccc1[N+]([O-])=O)C(=O)OCC(C)C |r,c:4,9|, COC(=O)C1=C(C)NC(C)=C([C@@H]1c1ccccc1[N+]([O-])=O)C(=O)OCC(C)C |r,c:4,9|, COC(=O)C1=C(C)NC(C)=C([C@@H]1c1ccccc1[N+]([O-])=O)C(=O)OCC(C)C |r,c:4,9|, COC(=O)C1=C(C)NC(C)=C([C@@H]1c1ccccc1[N+]([O-])=O)C(=O)OCC(C)C |r,c:4,9|, COC(=O)C1=C(C)NC(C)=C([C@@H]1c1ccccc1[N+]([O-])=O)C(=O)OCC(C)C |r,c:4,9|	VKQFCGNPDRICFG-GOSISDBHSA-N, VKQFCGNPDRICFG-GOSISDBHSA-N, VKQFCGNPDRICFG-GOSISDBHSA-N, VKQFCGNPDRICFG-GOSISDBHSA-N, VKQFCGNPDRICFG-GOSISDBHSA-N, VKQFCGNPDRICFG-GOSISDBHSA-N, VKQFCGNPDRICFG-GOSISDBHSA-N, VKQFCGNPDRICFG-GOSISDBHSA-N, VKQFCGNPDRICFG-GOSISDBHSA-N	Launched
nisoxetine	norepinephrine reuptake inhibitor	SLC6A2, SLC6A3, SLC6A4			CNCC[C@@H](Oc1ccccc1OC)c1ccccc1 |&1:4,r|	ITJNARMNRKSWTA-OAHLLOKOSA-N	Phase 1
nitarsone			dermatology	blackhead disease	O[As](O)(=O)c1ccc(cc1)[N+]([O-])=O, O[As](O)(=O)c1ccc(cc1)[N+]([O-])=O, O[As](O)(=O)c1ccc(cc1)[N+]([O-])=O	FUUFQLXAIUOWML-UHFFFAOYSA-N, FUUFQLXAIUOWML-UHFFFAOYSA-N, FUUFQLXAIUOWML-UHFFFAOYSA-N	Launched
nitazoxanide	pyruvate ferredoxin oxidoreductase inhibitor		gastroenterology	diarrhea	CC(=O)Oc1ccccc1C(=O)Nc1ncc(s1)[N+]([O-])=O, CC(=O)Oc1ccccc1C(=O)Nc1ncc(s1)[N+]([O-])=O, CC(=O)Oc1ccccc1C(=O)Nc1ncc(s1)[N+]([O-])=O, CC(=O)Oc1ccccc1C(=O)Nc1ncc(s1)[N+]([O-])=O, CC(=O)Oc1ccccc1C(=O)Nc1ncc(s1)[N+]([O-])=O, CC(=O)Oc1ccccc1C(=O)Nc1ncc(s1)[N+]([O-])=O	YQNQNVDNTFHQSW-UHFFFAOYSA-N, YQNQNVDNTFHQSW-UHFFFAOYSA-N, YQNQNVDNTFHQSW-UHFFFAOYSA-N, YQNQNVDNTFHQSW-UHFFFAOYSA-N, YQNQNVDNTFHQSW-UHFFFAOYSA-N, YQNQNVDNTFHQSW-UHFFFAOYSA-N	Launched
nitecapone	catechol O methyltransferase inhibitor	COMT			CC(=O)C(=Cc1cc(O)c(O)c(c1)[N+]([O-])=O)C(C)=O	UPMRZALMHVUCIN-UHFFFAOYSA-N	Phase 2
nitenpyram			infectious disease	flea control	CCN(Cc1ccc(Cl)nc1)C(\NC)=C\[N+]([O-])=O	CFRPSFYHXJZSBI-DHZHZOJOSA-N	Launched
nithiamide	bacterial DNA inhibitor				CC(=O)Nc1ncc(s1)[N+]([O-])=O, CC(=O)Nc1ncc(s1)[N+]([O-])=O, CC(=O)Nc1ncc(s1)[N+]([O-])=O	UJRRDDHEMZLWFI-UHFFFAOYSA-N, UJRRDDHEMZLWFI-UHFFFAOYSA-N, UJRRDDHEMZLWFI-UHFFFAOYSA-N	Preclinical
nitisinone	hydroxyphenylpyruvate dioxygenase inhibitor		metabolism	tyrosinemia	OC(=C1C(=O)CCCC1=O)c1ccc(cc1[N+]([O-])=O)C(F)(F)F, OC(=C1C(=O)CCCC1=O)c1ccc(cc1[N+]([O-])=O)C(F)(F)F, OC(=C1C(=O)CCCC1=O)c1ccc(cc1[N+]([O-])=O)C(F)(F)F	PMHVFNYNPNKNRO-UHFFFAOYSA-N, PMHVFNYNPNKNRO-UHFFFAOYSA-N, PMHVFNYNPNKNRO-UHFFFAOYSA-N	Launched
nitrendipine	calcium channel blocker	CACNA1D, CACNA2D1, KCNN4	cardiology	hypertension	CCOC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OC |r,c:5,10|, CCOC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OC |r,c:5,10|, CCOC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OC |r,c:5,10|, CCOC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OC |r,c:5,10|, CCOC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OC |r,c:5,10|, CCOC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OC |r,c:5,10|	PVHUJELLJLJGLN-INIZCTEOSA-N, PVHUJELLJLJGLN-INIZCTEOSA-N, PVHUJELLJLJGLN-INIZCTEOSA-N, PVHUJELLJLJGLN-INIZCTEOSA-N, PVHUJELLJLJGLN-INIZCTEOSA-N, PVHUJELLJLJGLN-INIZCTEOSA-N	Launched
nitrocaramiphen	cholinergic receptor antagonist	CHRM1			CCN(CC)CCOC(=O)C1(CCCC1)c1ccc(cc1)[N+]([O-])=O, CCN(CC)CCOC(=O)C1(CCCC1)c1ccc(cc1)[N+]([O-])=O	NSHMVLOWOAQFTP-UHFFFAOYSA-N, NSHMVLOWOAQFTP-UHFFFAOYSA-N	Preclinical
nitroflurbiprofen	cyclooxygenase inhibitor				C[C@@H](C(=O)OCCCCO[N+]([O-])=O)c1ccc(c(F)c1)-c1ccccc1 |&1:1,r|	DLWSRGHNJVLJAH-CQSZACIVSA-N	Preclinical
nitrofurantoin	DNA inhibitor		infectious disease	urinary tract infections, pyelonephritis	[O-][N+](=O)c1ccc(\C=N\N2CC(=O)NC2=O)o1, [O-][N+](=O)c1ccc(\C=N\N2CC(=O)NC2=O)o1, [O-][N+](=O)c1ccc(\C=N\N2CC(=O)NC2=O)o1	NXFQHRVNIOXGAQ-YCRREMRBSA-N, NXFQHRVNIOXGAQ-YCRREMRBSA-N, NXFQHRVNIOXGAQ-YCRREMRBSA-N	Launched
nitrofurazone	bacterial DNA inhibitor		infectious disease	first-aid antibiotic	NC(=O)N\N=C\c1ccc(o1)[N+]([O-])=O, NC(=O)N\N=C\c1ccc(o1)[N+]([O-])=O, NC(=O)N\N=C\c1ccc(o1)[N+]([O-])=O, NC(=O)N\N=C\c1ccc(o1)[N+]([O-])=O	IAIWVQXQOWNYOU-FPYGCLRLSA-N, IAIWVQXQOWNYOU-FPYGCLRLSA-N, IAIWVQXQOWNYOU-FPYGCLRLSA-N, IAIWVQXQOWNYOU-FPYGCLRLSA-N	Launched
nitromide			infectious disease	coccidiosis	NC(=O)c1cc(cc(c1)[N+]([O-])=O)[N+]([O-])=O, NC(=O)c1cc(cc(c1)[N+]([O-])=O)[N+]([O-])=O, NC(=O)c1cc(cc(c1)[N+]([O-])=O)[N+]([O-])=O	UUKWKUSGGZNXGA-UHFFFAOYSA-N, UUKWKUSGGZNXGA-UHFFFAOYSA-N, UUKWKUSGGZNXGA-UHFFFAOYSA-N	Launched
nitrosodimethylurea	DNA synthesis inhibitor				CNC(=O)N(C)[NH2+][O-]	RCUSTCPNMVCLLN-UHFFFAOYSA-N	Preclinical
nitroxoline	cathepsin inhibitor	METAP2	infectious disease	urinary tract infections	Oc1ccc([N+]([O-])=O)c2cccnc12, Oc1ccc([N+]([O-])=O)c2cccnc12	RJIWZDNTCBHXAL-UHFFFAOYSA-N, RJIWZDNTCBHXAL-UHFFFAOYSA-N	Launched
nizatidine	histamine receptor antagonist	HRH2	gastroenterology	duodenal ulcer disease, erosive esophagitis (EE), ulcerative esophagitis (UE), gastroesophageal reflux disease (GERD)	CN\C(NCCSCc1csc(CN(C)C)n1)=C/[N+]([O-])=O, CN\C(NCCSCc1csc(CN(C)C)n1)=C/[N+]([O-])=O, CN\C(NCCSCc1csc(CN(C)C)n1)=C/[N+]([O-])=O, CN\C(NCCSCc1csc(CN(C)C)n1)=C/[N+]([O-])=O, CN\C(NCCSCc1csc(CN(C)C)n1)=C/[N+]([O-])=O, CN\C(NCCSCc1csc(CN(C)C)n1)=C/[N+]([O-])=O	SGXXNSQHWDMGGP-IZZDOVSWSA-N, SGXXNSQHWDMGGP-IZZDOVSWSA-N, SGXXNSQHWDMGGP-IZZDOVSWSA-N, SGXXNSQHWDMGGP-IZZDOVSWSA-N, SGXXNSQHWDMGGP-IZZDOVSWSA-N, SGXXNSQHWDMGGP-IZZDOVSWSA-N	Launched
nizofenone	ion channel antagonist		neurology/psychiatry	stroke	CCN(CC)Cc1nccn1-c1ccc(cc1C(=O)c1ccccc1Cl)[N+]([O-])=O	WZGBZLHGOVJDET-UHFFFAOYSA-N	Launched
NK-252	nuclear factor erythroid derived, like (NRF2) activator	NFE2L2			O=C(NCc1ccccn1)Nc1nnc(o1)-c1ccco1, O=C(NCc1ccccn1)Nc1nnc(o1)-c1ccco1	FNSCFQXZZNCDAI-UHFFFAOYSA-N, FNSCFQXZZNCDAI-UHFFFAOYSA-N	Preclinical
NKP-1339	HSP inhibitor				Cl[Ru+3](Cl)(Cl)(Cl)([n+]1cc2ccccc2[nH]1)[n+]1cc2ccccc2[nH]1, Cl[Ru+3](Cl)(Cl)(Cl)([n+]1cc2ccccc2[nH]1)[n+]1cc2ccccc2[nH]1	KNLORLKZMHLRBH-UHFFFAOYSA-J, KNLORLKZMHLRBH-UHFFFAOYSA-J	Phase 1
NKY-80	adenylyl cyclase inhibitor	ADCY5			Nc1ncc2C(=O)C[C@@H](Cc2n1)c1ccco1 |&1:8,r|, Nc1ncc2C(=O)C[C@@H](Cc2n1)c1ccco1 |&1:8,r|	SOJUSNIBPPMLCC-SSDOTTSWSA-N, SOJUSNIBPPMLCC-SSDOTTSWSA-N	Preclinical
NLG919	indoleamine 2,3-dioxygenase inhibitor	IDO1			O[C@@H](C[C@H]1c2ccccc2-c2cncn12)C1CCCCC1 |&1:1,&2:3,r|, O[C@@H](C[C@H]1c2ccccc2-c2cncn12)C1CCCCC1 |&1:1,&2:3,r|, O[C@@H](C[C@H]1c2ccccc2-c2cncn12)C1CCCCC1 |&1:1,&2:3,r|, O[C@@H](C[C@H]1c2ccccc2-c2cncn12)C1CCCCC1 |&1:1,&2:3,r|, O[C@@H](C[C@H]1c2ccccc2-c2cncn12)C1CCCCC1 |&1:1,&2:3,r|	YTRRAUACYORZLX-WMZOPIPTSA-N, YTRRAUACYORZLX-WMZOPIPTSA-N, YTRRAUACYORZLX-WMZOPIPTSA-N, YTRRAUACYORZLX-WMZOPIPTSA-N, YTRRAUACYORZLX-WMZOPIPTSA-N	Phase 1
NMDA	glutamate receptor agonist	GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D			CN[C@H](CC(O)=O)C(O)=O, CN[C@H](CC(O)=O)C(O)=O, CN[C@H](CC(O)=O)C(O)=O, CN[C@H](CC(O)=O)C(O)=O, CN[C@H](CC(O)=O)C(O)=O	HOKKHZGPKSLGJE-GSVOUGTGSA-N, HOKKHZGPKSLGJE-GSVOUGTGSA-N, HOKKHZGPKSLGJE-GSVOUGTGSA-N, HOKKHZGPKSLGJE-GSVOUGTGSA-N, HOKKHZGPKSLGJE-GSVOUGTGSA-N	Preclinical
NMS-E973	HSP inhibitor				CN1CCC(CC1)NC(=O)c1cc(on1)-c1c(O)cc(O)cc1Oc1ccc(cc1)[N+]([O-])=O, CN1CCC(CC1)NC(=O)c1cc(on1)-c1c(O)cc(O)cc1Oc1ccc(cc1)[N+]([O-])=O, CN1CCC(CC1)NC(=O)c1cc(on1)-c1c(O)cc(O)cc1Oc1ccc(cc1)[N+]([O-])=O, CN1CCC(CC1)NC(=O)c1cc(on1)-c1c(O)cc(O)cc1Oc1ccc(cc1)[N+]([O-])=O, CN1CCC(CC1)NC(=O)c1cc(on1)-c1c(O)cc(O)cc1Oc1ccc(cc1)[N+]([O-])=O	YLQODGGPIHWTHR-UHFFFAOYSA-N, YLQODGGPIHWTHR-UHFFFAOYSA-N, YLQODGGPIHWTHR-UHFFFAOYSA-N, YLQODGGPIHWTHR-UHFFFAOYSA-N, YLQODGGPIHWTHR-UHFFFAOYSA-N	Preclinical
NMS-P715	protein kinase inhibitor				CCc1cccc(CC)c1NC(=O)c1nn(C)c-2c1CCc1cnc(Nc3ccc(cc3OC(F)(F)F)C(=O)NC3CCN(C)CC3)nc-21	JFOAJUGFHDCBJJ-UHFFFAOYSA-N	Preclinical
NMS-1286937	PLK inhibitor	FLT3, PLK1, PLK2, PLK3			CN1CCN(CC1)c1ccc(OC(F)(F)F)c(Nc2ncc3CCc4c(nn(CCO)c4-c3n2)C(N)=O)c1, CN1CCN(CC1)c1ccc(OC(F)(F)F)c(Nc2ncc3CCc4c(nn(CCO)c4-c3n2)C(N)=O)c1, CN1CCN(CC1)c1ccc(OC(F)(F)F)c(Nc2ncc3CCc4c(nn(CCO)c4-c3n2)C(N)=O)c1, CN1CCN(CC1)c1ccc(OC(F)(F)F)c(Nc2ncc3CCc4c(nn(CCO)c4-c3n2)C(N)=O)c1, CN1CCN(CC1)c1ccc(OC(F)(F)F)c(Nc2ncc3CCc4c(nn(CCO)c4-c3n2)C(N)=O)c1, CN1CCN(CC1)c1ccc(OC(F)(F)F)c(Nc2ncc3CCc4c(nn(CCO)c4-c3n2)C(N)=O)c1, CN1CCN(CC1)c1ccc(OC(F)(F)F)c(Nc2ncc3CCc4c(nn(CCO)c4-c3n2)C(N)=O)c1, CN1CCN(CC1)c1ccc(OC(F)(F)F)c(Nc2ncc3CCc4c(nn(CCO)c4-c3n2)C(N)=O)c1, CN1CCN(CC1)c1ccc(OC(F)(F)F)c(Nc2ncc3CCc4c(nn(CCO)c4-c3n2)C(N)=O)c1	QHLVBNKYJGBCQJ-UHFFFAOYSA-N, QHLVBNKYJGBCQJ-UHFFFAOYSA-N, QHLVBNKYJGBCQJ-UHFFFAOYSA-N, QHLVBNKYJGBCQJ-UHFFFAOYSA-N, QHLVBNKYJGBCQJ-UHFFFAOYSA-N, QHLVBNKYJGBCQJ-UHFFFAOYSA-N, QHLVBNKYJGBCQJ-UHFFFAOYSA-N, QHLVBNKYJGBCQJ-UHFFFAOYSA-N, QHLVBNKYJGBCQJ-UHFFFAOYSA-N	Phase 2
NMS-873	ATPase inhibitor	VCP			Cc1cc(OCc2nnc(SC3CCCC3)n2-c2cccnc2)ccc1-c1ccc(cc1)S(C)(=O)=O, Cc1cc(OCc2nnc(SC3CCCC3)n2-c2cccnc2)ccc1-c1ccc(cc1)S(C)(=O)=O	UJGTUKMAJVCBIS-UHFFFAOYSA-N, UJGTUKMAJVCBIS-UHFFFAOYSA-N	Preclinical
NM107	RNA polymerase inhibitor				C[C@@]1(O)[C@H](O)[C@@H](CO)O[C@H]1n1ccc(N)nc1=O	PPUDLEUZKVJXSZ-VPCXQMTMSA-N	Phase 2
NN-DNJ	glucosidase inhibitor	GBA			CCCCCCCCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO	FTSCEGKYKXESFF-LXTVHRRPSA-N	Preclinical
NNC-05-2090	GABA uptake inhibitor, GAT inhibitor	SLC6A12			COc1ccccc1C1(O)CCN(CCCn2c3ccccc3c3ccccc23)CC1, COc1ccccc1C1(O)CCN(CCCn2c3ccccc3c3ccccc23)CC1, COc1ccccc1C1(O)CCN(CCCn2c3ccccc3c3ccccc23)CC1, COc1ccccc1C1(O)CCN(CCCn2c3ccccc3c3ccccc23)CC1, COc1ccccc1C1(O)CCN(CCCn2c3ccccc3c3ccccc23)CC1, COc1ccccc1C1(O)CCN(CCCn2c3ccccc3c3ccccc23)CC1, COc1ccccc1C1(O)CCN(CCCn2c3ccccc3c3ccccc23)CC1, COc1ccccc1C1(O)CCN(CCCn2c3ccccc3c3ccccc23)CC1, COc1ccccc1C1(O)CCN(CCCn2c3ccccc3c3ccccc23)CC1	XZZYCJOGZYEPPW-UHFFFAOYSA-N, XZZYCJOGZYEPPW-UHFFFAOYSA-N, XZZYCJOGZYEPPW-UHFFFAOYSA-N, XZZYCJOGZYEPPW-UHFFFAOYSA-N, XZZYCJOGZYEPPW-UHFFFAOYSA-N, XZZYCJOGZYEPPW-UHFFFAOYSA-N, XZZYCJOGZYEPPW-UHFFFAOYSA-N, XZZYCJOGZYEPPW-UHFFFAOYSA-N, XZZYCJOGZYEPPW-UHFFFAOYSA-N	Preclinical
NNC-55-0396	T-type calcium channel blocker	CATSPER1, CATSPER2, CATSPER3, CATSPER4			CC(C)[C@H]1c2ccc(F)cc2CC[C@@]1(CCN(C)CCCc1nc2ccccc2[nH]1)OC(=O)C1CC1, CC(C)[C@H]1c2ccc(F)cc2CC[C@@]1(CCN(C)CCCc1nc2ccccc2[nH]1)OC(=O)C1CC1, CC(C)[C@H]1c2ccc(F)cc2CC[C@@]1(CCN(C)CCCc1nc2ccccc2[nH]1)OC(=O)C1CC1, CC(C)[C@H]1c2ccc(F)cc2CC[C@@]1(CCN(C)CCCc1nc2ccccc2[nH]1)OC(=O)C1CC1, CC(C)[C@H]1c2ccc(F)cc2CC[C@@]1(CCN(C)CCCc1nc2ccccc2[nH]1)OC(=O)C1CC1, CC(C)[C@H]1c2ccc(F)cc2CC[C@@]1(CCN(C)CCCc1nc2ccccc2[nH]1)OC(=O)C1CC1, CC(C)[C@H]1c2ccc(F)cc2CC[C@@]1(CCN(C)CCCc1nc2ccccc2[nH]1)OC(=O)C1CC1, CC(C)[C@H]1c2ccc(F)cc2CC[C@@]1(CCN(C)CCCc1nc2ccccc2[nH]1)OC(=O)C1CC1, CC(C)[C@H]1c2ccc(F)cc2CC[C@@]1(CCN(C)CCCc1nc2ccccc2[nH]1)OC(=O)C1CC1	VHHVPDKNKPNKHY-JDXGNMNLSA-N, VHHVPDKNKPNKHY-JDXGNMNLSA-N, VHHVPDKNKPNKHY-JDXGNMNLSA-N, VHHVPDKNKPNKHY-JDXGNMNLSA-N, VHHVPDKNKPNKHY-JDXGNMNLSA-N, VHHVPDKNKPNKHY-JDXGNMNLSA-N, VHHVPDKNKPNKHY-JDXGNMNLSA-N, VHHVPDKNKPNKHY-JDXGNMNLSA-N, VHHVPDKNKPNKHY-JDXGNMNLSA-N	Preclinical
NNC-63-0532	opioid receptor agonist	OPRL1			COC(=O)CN1CN(c2ccccc2)C2(CCN(Cc3cccc4ccccc34)CC2)C1=O, COC(=O)CN1CN(c2ccccc2)C2(CCN(Cc3cccc4ccccc34)CC2)C1=O, COC(=O)CN1CN(c2ccccc2)C2(CCN(Cc3cccc4ccccc34)CC2)C1=O, COC(=O)CN1CN(c2ccccc2)C2(CCN(Cc3cccc4ccccc34)CC2)C1=O, COC(=O)CN1CN(c2ccccc2)C2(CCN(Cc3cccc4ccccc34)CC2)C1=O, COC(=O)CN1CN(c2ccccc2)C2(CCN(Cc3cccc4ccccc34)CC2)C1=O	AQMPIDSGLFVVPL-UHFFFAOYSA-N, AQMPIDSGLFVVPL-UHFFFAOYSA-N, AQMPIDSGLFVVPL-UHFFFAOYSA-N, AQMPIDSGLFVVPL-UHFFFAOYSA-N, AQMPIDSGLFVVPL-UHFFFAOYSA-N, AQMPIDSGLFVVPL-UHFFFAOYSA-N	Preclinical
NNC-711	GABA uptake inhibitor	SIGMAR1, SLC6A1			OC(=O)C1=CCCN(CCON=C(c2ccccc2)c2ccccc2)C1 |t:3|, OC(=O)C1=CCCN(CCON=C(c2ccccc2)c2ccccc2)C1 |t:3|, OC(=O)C1=CCCN(CCON=C(c2ccccc2)c2ccccc2)C1 |t:3|	NGNALWDRPKNJGR-UHFFFAOYSA-N, NGNALWDRPKNJGR-UHFFFAOYSA-N, NGNALWDRPKNJGR-UHFFFAOYSA-N	Preclinical
NO-ASA	cyclooxygenase inhibitor	PTGS2			CC(=O)Oc1ccccc1C(=O)Oc1cccc(CO[N+]([O-])=O)c1, CC(=O)Oc1ccccc1C(=O)Oc1cccc(CO[N+]([O-])=O)c1	IOJUJUOXKXMJNF-UHFFFAOYSA-N, IOJUJUOXKXMJNF-UHFFFAOYSA-N	Phase 2
nobiletin	MEK inhibitor	MAP2K1			COc1ccc(cc1OC)-c1cc(=O)c2c(OC)c(OC)c(OC)c(OC)c2o1, COc1ccc(cc1OC)-c1cc(=O)c2c(OC)c(OC)c(OC)c(OC)c2o1	MRIAQLRQZPPODS-UHFFFAOYSA-N, MRIAQLRQZPPODS-UHFFFAOYSA-N	Preclinical
nocodazole	tubulin polymerization inhibitor	HPGDS			COC(=O)Nc1nc2ccc(cc2[nH]1)C(=O)c1cccs1, COC(=O)Nc1nc2ccc(cc2[nH]1)C(=O)c1cccs1, COC(=O)Nc1nc2ccc(cc2[nH]1)C(=O)c1cccs1, COC(=O)Nc1nc2ccc(cc2[nH]1)C(=O)c1cccs1, COC(=O)Nc1nc2ccc(cc2[nH]1)C(=O)c1cccs1	KYRVNWMVYQXFEU-UHFFFAOYSA-N, KYRVNWMVYQXFEU-UHFFFAOYSA-N, KYRVNWMVYQXFEU-UHFFFAOYSA-N, KYRVNWMVYQXFEU-UHFFFAOYSA-N, KYRVNWMVYQXFEU-UHFFFAOYSA-N	Preclinical
nolatrexed	thymidylate synthase inhibitor	TYMS			Cc1ccc2[nH]c(N)nc(=O)c2c1Sc1ccncc1	XHWRWCSCBDLOLM-UHFFFAOYSA-N	Phase 3
nomegestrol-acetate	progesterone receptor agonist	PGR	endocrinology	contraceptive	CC(=O)O[C@@]1(CC[C@H]2[C@@H]3C=C(C)C4=CC(=O)CC[C@@H]4[C@H]3CC[C@]12C)C(C)=O |t:9,12|, CC(=O)O[C@@]1(CC[C@H]2[C@@H]3C=C(C)C4=CC(=O)CC[C@@H]4[C@H]3CC[C@]12C)C(C)=O |t:9,12|, CC(=O)O[C@@]1(CC[C@H]2[C@@H]3C=C(C)C4=CC(=O)CC[C@@H]4[C@H]3CC[C@]12C)C(C)=O |t:9,12|, CC(=O)O[C@@]1(CC[C@H]2[C@@H]3C=C(C)C4=CC(=O)CC[C@@H]4[C@H]3CC[C@]12C)C(C)=O |t:9,12|	IIVBFTNIGYRNQY-YQLZSBIMSA-N, IIVBFTNIGYRNQY-YQLZSBIMSA-N, IIVBFTNIGYRNQY-YQLZSBIMSA-N, IIVBFTNIGYRNQY-YQLZSBIMSA-N	Launched
nomifensine	dopamine reuptake inhibitor, noradrenaline uptake inhibitor	DRD2, SLC6A2, SLC6A3			CN1C[C@@H](c2ccccc2)c2cccc(N)c2C1 |&1:3|, CN1C[C@@H](c2ccccc2)c2cccc(N)c2C1 |&1:3|, CN1C[C@@H](c2ccccc2)c2cccc(N)c2C1 |&1:3|	XXPANQJNYNUNES-AWEZNQCLSA-N, XXPANQJNYNUNES-AWEZNQCLSA-N, XXPANQJNYNUNES-AWEZNQCLSA-N	Withdrawn
nonivamide	TRPV agonist	TRPV1	rheumatology, neurology/psychiatry	rheumatoid arthritis, muscle pain	CCCCCCCCC(=O)NCc1ccc(O)c(OC)c1, CCCCCCCCC(=O)NCc1ccc(O)c(OC)c1, CCCCCCCCC(=O)NCc1ccc(O)c(OC)c1	RGOVYLWUIBMPGK-UHFFFAOYSA-N, RGOVYLWUIBMPGK-UHFFFAOYSA-N, RGOVYLWUIBMPGK-UHFFFAOYSA-N	Launched
nonoxynol-9	membrane integrity inhibitor		endocrinology	contraceptive	CCCCCCCCCc1ccc(OCCOCCOCCOCCOCCOCCOCCOCCOCCO)cc1, CCCCCCCCCc1ccc(OCCOCCOCCOCCOCCOCCOCCOCCOCCO)cc1, CCCCCCCCCc1ccc(OCCOCCOCCOCCOCCOCCOCCOCCOCCO)cc1, CCCCCCCCCc1ccc(OCCOCCOCCOCCOCCOCCOCCOCCOCCO)cc1, CCCCCCCCCc1ccc(OCCOCCOCCOCCOCCOCCOCCOCCOCCO)cc1	FBWNMEQMRUMQSO-UHFFFAOYSA-N, FBWNMEQMRUMQSO-UHFFFAOYSA-N, FBWNMEQMRUMQSO-UHFFFAOYSA-N, FBWNMEQMRUMQSO-UHFFFAOYSA-N, FBWNMEQMRUMQSO-UHFFFAOYSA-N	Launched
nor-binaltorphimine	opioid receptor antagonist	OPRD1, OPRK1, OPRM1			Oc1ccc2C[C@H]3N(CC4CC4)CC[C@@]45[C@@H](Oc1c24)c1[nH]c2[C@@H]4Oc6c7c(C[C@H]8N(CC9CC9)CC[C@@]47[C@@]8(O)Cc2c1C[C@@]35O)ccc6O, Oc1ccc2C[C@H]3N(CC4CC4)CC[C@@]45[C@@H](Oc1c24)c1[nH]c2[C@@H]4Oc6c7c(C[C@H]8N(CC9CC9)CC[C@@]47[C@@]8(O)Cc2c1C[C@@]35O)ccc6O, Oc1ccc2C[C@H]3N(CC4CC4)CC[C@@]45[C@@H](Oc1c24)c1[nH]c2[C@@H]4Oc6c7c(C[C@H]8N(CC9CC9)CC[C@@]47[C@@]8(O)Cc2c1C[C@@]35O)ccc6O	APSUXPSYBJVPPS-YAUKWVCOSA-N, APSUXPSYBJVPPS-YAUKWVCOSA-N, APSUXPSYBJVPPS-YAUKWVCOSA-N	Preclinical
norcyclobenzaprine	adrenergic receptor agonist, serotonin receptor antagonist				CNCCC=C1c2ccccc2C=Cc2ccccc12 |c:13|, CNCCC=C1c2ccccc2C=Cc2ccccc12 |c:13|, CNCCC=C1c2ccccc2C=Cc2ccccc12 |c:13|, CNCCC=C1c2ccccc2C=Cc2ccccc12 |c:13|	XECQQDXTQRYYBH-UHFFFAOYSA-N, XECQQDXTQRYYBH-UHFFFAOYSA-N, XECQQDXTQRYYBH-UHFFFAOYSA-N, XECQQDXTQRYYBH-UHFFFAOYSA-N	Preclinical
norelgestromin		PGR	endocrinology	contraceptive	CC[C@]12CC[C@H]3[C@@H](CCC4=C\C(CC[C@H]34)=N\O)[C@@H]1CC[C@@]2(O)C#C |t:9|	ISHXLNHNDMZNMC-VTKCIJPMSA-N	Launched
norepinephrine	adrenergic receptor agonist	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3, PAH, SLC18A1, SLC18A2	cardiology, allergy, neurology/psychiatry	hypertension, urticaria, headache, seasonal affective disorder	NC[C@H](O)c1ccc(O)c(O)c1, NC[C@H](O)c1ccc(O)c(O)c1, NC[C@H](O)c1ccc(O)c(O)c1, NC[C@H](O)c1ccc(O)c(O)c1, NC[C@H](O)c1ccc(O)c(O)c1	SFLSHLFXELFNJZ-QMMMGPOBSA-N, SFLSHLFXELFNJZ-QMMMGPOBSA-N, SFLSHLFXELFNJZ-QMMMGPOBSA-N, SFLSHLFXELFNJZ-QMMMGPOBSA-N, SFLSHLFXELFNJZ-QMMMGPOBSA-N	Launched
norethindrone	progesterone receptor agonist	PGR	obstetrics/gynecology	endometriosis	C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C |t:8|, C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C |t:8|, C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C |t:8|, C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C |t:8|, C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C |t:8|, C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C |t:8|, C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C |t:8|	VIKNJXKGJWUCNN-XGXHKTLJSA-N, VIKNJXKGJWUCNN-XGXHKTLJSA-N, VIKNJXKGJWUCNN-XGXHKTLJSA-N, VIKNJXKGJWUCNN-XGXHKTLJSA-N, VIKNJXKGJWUCNN-XGXHKTLJSA-N, VIKNJXKGJWUCNN-XGXHKTLJSA-N, VIKNJXKGJWUCNN-XGXHKTLJSA-N	Launched
norethindrone-acetate	progesterone receptor agonist	PGR	endocrinology, orthopedics, obstetrics/gynecology	menopause, osteoporosis, vaginal atrophy	CC(=O)O[C@]1(CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@@H]4[C@H]3CC[C@]12C)C#C |t:11|	IMONTRJLAWHYGT-ZCPXKWAGSA-N	Launched
norethisterone-enanthate	contraceptive agent		endocrinology	contraceptive	CCCCCCC(=O)O[C@]1(CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@@H]4[C@H]3CC[C@]12C)C#C |t:16|, CCCCCCC(=O)O[C@]1(CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@@H]4[C@H]3CC[C@]12C)C#C |t:16|, CCCCCCC(=O)O[C@]1(CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@@H]4[C@H]3CC[C@]12C)C#C |t:16|	APTGJECXMIKIET-WOSSHHRXSA-N, APTGJECXMIKIET-WOSSHHRXSA-N, APTGJECXMIKIET-WOSSHHRXSA-N	Launched
noretynodrel	progestogen hormone	PGR	endocrinology	contraceptive	C[C@]12CC[C@H]3[C@@H](CCC4=C3CCC(=O)C4)[C@@H]1CC[C@@]2(O)C#C |a:1,18,&1:4,&2:5,&3:15,c:8|, C[C@]12CC[C@H]3[C@@H](CCC4=C3CCC(=O)C4)[C@@H]1CC[C@@]2(O)C#C |a:1,18,&1:4,&2:5,&3:15,c:8|	ICTXHFFSOAJUMG-SLHNCBLASA-N, ICTXHFFSOAJUMG-SLHNCBLASA-N	Launched
norfloxacin	bacterial DNA gyrase inhibitor	TOP2A	infectious disease, urology	urinary tract infections, gonorrhea, prostatitis	CCn1cc(C(O)=O)c(=O)c2cc(F)c(cc12)N1CCNCC1, CCn1cc(C(O)=O)c(=O)c2cc(F)c(cc12)N1CCNCC1, CCn1cc(C(O)=O)c(=O)c2cc(F)c(cc12)N1CCNCC1, CCn1cc(C(O)=O)c(=O)c2cc(F)c(cc12)N1CCNCC1	OGJPXUAPXNRGGI-UHFFFAOYSA-N, OGJPXUAPXNRGGI-UHFFFAOYSA-N, OGJPXUAPXNRGGI-UHFFFAOYSA-N, OGJPXUAPXNRGGI-UHFFFAOYSA-N	Launched
norfluoxetine	selective serotonin reuptake inhibitor (SSRI)	HTR2B			NCC[C@@H](Oc1ccc(cc1)C(F)(F)F)c1ccccc1 |&1:3,r|, NCC[C@@H](Oc1ccc(cc1)C(F)(F)F)c1ccccc1 |&1:3,r|	WIQRCHMSJFFONW-OAHLLOKOSA-N, WIQRCHMSJFFONW-OAHLLOKOSA-N	Phase 1
norgestimate	progesterone receptor agonist	ESR1, PGR	endocrinology	contraceptive	CC[C@]12CC[C@H]3[C@@H](CCC4=C\C(CC[C@H]34)=N\O)[C@@H]1CC[C@@]2(OC(C)=O)C#C |t:9|, CC[C@]12CC[C@H]3[C@@H](CCC4=C\C(CC[C@H]34)=N\O)[C@@H]1CC[C@@]2(OC(C)=O)C#C |t:9|	KIQQMECNKUGGKA-NMYWJIRASA-N, KIQQMECNKUGGKA-NMYWJIRASA-N	Launched
norgestrel	progesterone receptor agonist	AR, ESR1, PGR, SRD5A1	endocrinology	contraceptive	CC[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C |a:2,6,15,16,19,&1:5,t:9|, CC[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C |a:2,6,15,16,19,&1:5,t:9|, CC[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C |a:2,6,15,16,19,&1:5,t:9|	WWYNJERNGUHSAO-XUDSTZEESA-N, WWYNJERNGUHSAO-XUDSTZEESA-N, WWYNJERNGUHSAO-XUDSTZEESA-N	Launched
nornicotine	acetylcholine receptor agonist				C1CN[C@H](C1)c1cccnc1 |r|	MYKUKUCHPMASKF-SECBINFHSA-N	Preclinical
nortriptyline	tricyclic antidepressant	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, DRD2, HRH1, HTR1A, HTR2A, HTR2C, HTR6, KCNJ10, PGRMC1, SIGMAR1, SLC6A2, SLC6A4	neurology/psychiatry	depression	CNCCC=C1c2ccccc2CCc2ccccc12, CNCCC=C1c2ccccc2CCc2ccccc12	PHVGLTMQBUFIQQ-UHFFFAOYSA-N, PHVGLTMQBUFIQQ-UHFFFAOYSA-N	Launched
norvancomycin					[H][C@@]1(C[C@](C)(N)[C@H](O)[C@H](C)O1)O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1Oc1c2Oc3ccc(cc3Cl)[C@@H](O)[C@@H](NC(=O)[C@H](N)CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@]3([H])c(c2)cc1Oc1ccc(cc1Cl)[C@@H](O)[C@]1([H])NC(=O)[C@]([H])(NC3=O)c2ccc(O)c(c2)-c2c(O)cc(O)cc2[C@]([H])(NC1=O)C(O)=O	NUAQIRUAZSJTAI-YRPZDAAMSA-N	Preclinical
noscapine	bradykinin receptor antagonist, tubulin polymerization inhibitor	SIGMAR1	pulmonary	cough suppressant	COc1ccc2[C@H](OC(=O)c2c1OC)[C@@H]1N(C)CCc2cc3OCOc3c(OC)c12, COc1ccc2[C@H](OC(=O)c2c1OC)[C@@H]1N(C)CCc2cc3OCOc3c(OC)c12, COc1ccc2[C@H](OC(=O)c2c1OC)[C@@H]1N(C)CCc2cc3OCOc3c(OC)c12, COc1ccc2[C@H](OC(=O)c2c1OC)[C@@H]1N(C)CCc2cc3OCOc3c(OC)c12, COc1ccc2[C@H](OC(=O)c2c1OC)[C@@H]1N(C)CCc2cc3OCOc3c(OC)c12	AKNNEGZIBPJZJG-MSOLQXFVSA-N, AKNNEGZIBPJZJG-MSOLQXFVSA-N, AKNNEGZIBPJZJG-MSOLQXFVSA-N, AKNNEGZIBPJZJG-MSOLQXFVSA-N, AKNNEGZIBPJZJG-MSOLQXFVSA-N	Launched
NOV-002		GSR			N[C@@H](CCC(=O)N[C@@H](CSSC[C@H](NC(=O)CC[C@@H](N)C(O)=O)C(=O)NCC(O)=O)C(=O)NCC(O)=O)C(O)=O, N[C@@H](CCC(=O)N[C@@H](CSSC[C@H](NC(=O)CC[C@@H](N)C(O)=O)C(=O)NCC(O)=O)C(=O)NCC(O)=O)C(O)=O	YPZRWBKMTBYPTK-USZNOCQGSA-N, YPZRWBKMTBYPTK-USZNOCQGSA-N	Phase 3
novobiocin	bacterial DNA gyrase inhibitor		obstetrics/gynecology	mastitis	CO[C@@H]1[C@@H](OC(N)=O)[C@@H](O)[C@H](Oc2ccc3c(O)c(NC(=O)c4ccc(O)c(CC=C(C)C)c4)c(=O)oc3c2C)OC1(C)C, CO[C@@H]1[C@@H](OC(N)=O)[C@@H](O)[C@H](Oc2ccc3c(O)c(NC(=O)c4ccc(O)c(CC=C(C)C)c4)c(=O)oc3c2C)OC1(C)C, CO[C@@H]1[C@@H](OC(N)=O)[C@@H](O)[C@H](Oc2ccc3c(O)c(NC(=O)c4ccc(O)c(CC=C(C)C)c4)c(=O)oc3c2C)OC1(C)C, CO[C@@H]1[C@@H](OC(N)=O)[C@@H](O)[C@H](Oc2ccc3c(O)c(NC(=O)c4ccc(O)c(CC=C(C)C)c4)c(=O)oc3c2C)OC1(C)C, CO[C@@H]1[C@@H](OC(N)=O)[C@@H](O)[C@H](Oc2ccc3c(O)c(NC(=O)c4ccc(O)c(CC=C(C)C)c4)c(=O)oc3c2C)OC1(C)C, CO[C@@H]1[C@@H](OC(N)=O)[C@@H](O)[C@H](Oc2ccc3c(O)c(NC(=O)c4ccc(O)c(CC=C(C)C)c4)c(=O)oc3c2C)OC1(C)C	YJQPYGGHQPGBLI-KGSXXDOSSA-N, YJQPYGGHQPGBLI-KGSXXDOSSA-N, YJQPYGGHQPGBLI-KGSXXDOSSA-N, YJQPYGGHQPGBLI-KGSXXDOSSA-N, YJQPYGGHQPGBLI-KGSXXDOSSA-N, YJQPYGGHQPGBLI-KGSXXDOSSA-N	Launched
NPC-01	steroid				C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CCC2=O |t:9|, C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CCC2=O |t:9|	WSCUHXPGYUMQEX-KCZNZURUSA-N, WSCUHXPGYUMQEX-KCZNZURUSA-N	Phase 3
NPC-15199	ICAM1 antagonist	PPARG			CC(C)C[C@@H](NC(=O)OCC1c2ccccc2-c2ccccc12)C(O)=O, CC(C)C[C@@H](NC(=O)OCC1c2ccccc2-c2ccccc12)C(O)=O	CBPJQFCAFFNICX-LJQANCHMSA-N, CBPJQFCAFFNICX-LJQANCHMSA-N	Phase 2
NPPB	chloride channel blocker	ANO1, CLCN2, CLCN7, TRPA1			OC(=O)c1cc(ccc1NCCCc1ccccc1)[N+]([O-])=O, OC(=O)c1cc(ccc1NCCCc1ccccc1)[N+]([O-])=O, OC(=O)c1cc(ccc1NCCCc1ccccc1)[N+]([O-])=O, OC(=O)c1cc(ccc1NCCCc1ccccc1)[N+]([O-])=O	WBSMIPAMAXNXFS-UHFFFAOYSA-N, WBSMIPAMAXNXFS-UHFFFAOYSA-N, WBSMIPAMAXNXFS-UHFFFAOYSA-N, WBSMIPAMAXNXFS-UHFFFAOYSA-N	Preclinical
NPS-2143	calcium receptor antagonist	CASR			CC(C)(Cc1ccc2ccccc2c1)NC[C@@H](O)COc1cccc(Cl)c1C#N, CC(C)(Cc1ccc2ccccc2c1)NC[C@@H](O)COc1cccc(Cl)c1C#N, CC(C)(Cc1ccc2ccccc2c1)NC[C@@H](O)COc1cccc(Cl)c1C#N, CC(C)(Cc1ccc2ccccc2c1)NC[C@@H](O)COc1cccc(Cl)c1C#N, CC(C)(Cc1ccc2ccccc2c1)NC[C@@H](O)COc1cccc(Cl)c1C#N, CC(C)(Cc1ccc2ccccc2c1)NC[C@@H](O)COc1cccc(Cl)c1C#N, CC(C)(Cc1ccc2ccccc2c1)NC[C@@H](O)COc1cccc(Cl)c1C#N	PZUJQWHTIRWCID-HXUWFJFHSA-N, PZUJQWHTIRWCID-HXUWFJFHSA-N, PZUJQWHTIRWCID-HXUWFJFHSA-N, PZUJQWHTIRWCID-HXUWFJFHSA-N, PZUJQWHTIRWCID-HXUWFJFHSA-N, PZUJQWHTIRWCID-HXUWFJFHSA-N, PZUJQWHTIRWCID-HXUWFJFHSA-N	Preclinical
NPS-2407	glutamate receptor antagonist				CC(C)(Cc1ccccc1)NC(=O)c1cnc2ccccc2n1	DQEWVIJXZPUPQA-UHFFFAOYSA-N	Preclinical
NPY-5RA972	neuropeptide receptor antagonist	NPY5R			CC(C)n1c2ccccc2c2c(C)c(NC(=O)N3CCOCC3)ccc12, CC(C)n1c2ccccc2c2c(C)c(NC(=O)N3CCOCC3)ccc12, CC(C)n1c2ccccc2c2c(C)c(NC(=O)N3CCOCC3)ccc12	ZNFMHLDBJPAFEQ-UHFFFAOYSA-N, ZNFMHLDBJPAFEQ-UHFFFAOYSA-N, ZNFMHLDBJPAFEQ-UHFFFAOYSA-N	Preclinical
NQDI-1	caspase inhibitor	CASP3			CCOC(=O)c1c2-c3ccccc3C(=O)c3cccc([nH]c1=O)c23, CCOC(=O)c1c2-c3ccccc3C(=O)c3cccc([nH]c1=O)c23	UFJGFNHRMPMALC-UHFFFAOYSA-N, UFJGFNHRMPMALC-UHFFFAOYSA-N	Preclinical
NS-018	JAK inhibitor	JAK1, JAK2, JAK3, TYK2			C[C@H](Nc1cc(cc(Nc2cnccn2)n1)-c1cnn(C)c1)c1ccc(F)cc1, C[C@H](Nc1cc(cc(Nc2cnccn2)n1)-c1cnn(C)c1)c1ccc(F)cc1, C[C@H](Nc1cc(cc(Nc2cnccn2)n1)-c1cnn(C)c1)c1ccc(F)cc1	UQTPDWDAYHAZNT-AWEZNQCLSA-N, UQTPDWDAYHAZNT-AWEZNQCLSA-N, UQTPDWDAYHAZNT-AWEZNQCLSA-N	Phase 1/Phase 2
NS-11021	calcium-activated potassium channel activator	KCNMA1			FC(F)(F)c1cc(NC(=S)Nc2ccc(Br)cc2-c2nn[nH]n2)cc(c1)C(F)(F)F, FC(F)(F)c1cc(NC(=S)Nc2ccc(Br)cc2-c2nn[nH]n2)cc(c1)C(F)(F)F	MDKAFDIKYQMOMF-UHFFFAOYSA-N, MDKAFDIKYQMOMF-UHFFFAOYSA-N	Preclinical
NS-11394	GABA receptor agonist				CC(C)(O)c1ccc2n(cnc2c1)-c1cccc(c1)-c1ccccc1C#N	HLKYSQGBIIIQJN-UHFFFAOYSA-N	Preclinical
NS-1643	voltage-gated potassium channel activator	KCNH2, KCNH6, KCNMA1			Oc1ccc(cc1NC(=O)Nc1cc(ccc1O)C(F)(F)F)C(F)(F)F, Oc1ccc(cc1NC(=O)Nc1cc(ccc1O)C(F)(F)F)C(F)(F)F, Oc1ccc(cc1NC(=O)Nc1cc(ccc1O)C(F)(F)F)C(F)(F)F, Oc1ccc(cc1NC(=O)Nc1cc(ccc1O)C(F)(F)F)C(F)(F)F, Oc1ccc(cc1NC(=O)Nc1cc(ccc1O)C(F)(F)F)C(F)(F)F	NJFVQMRYJZHGME-UHFFFAOYSA-N, NJFVQMRYJZHGME-UHFFFAOYSA-N, NJFVQMRYJZHGME-UHFFFAOYSA-N, NJFVQMRYJZHGME-UHFFFAOYSA-N, NJFVQMRYJZHGME-UHFFFAOYSA-N	Preclinical
NS-19504	calcium-activated potassium channel activator	KCNMA1			Nc1ncc(Cc2ccc(Br)cc2)s1, Nc1ncc(Cc2ccc(Br)cc2)s1, Nc1ncc(Cc2ccc(Br)cc2)s1	HGWLTZOMQZIUBW-UHFFFAOYSA-N, HGWLTZOMQZIUBW-UHFFFAOYSA-N, HGWLTZOMQZIUBW-UHFFFAOYSA-N	Preclinical
NS-309	calcium-activated potassium channel activator	KCNN1, KCNN2, KCNN3, KCNN4			O\N=C1/C(=O)Nc2c1ccc(Cl)c2Cl	CVOUSAVHMDXCKG-UHFFFAOYSA-N	Preclinical
NS-3623	voltage-gated potassium channel activator	KCNH2			FC(F)(F)c1cccc(NC(=O)Nc2ccc(Br)cc2-c2nn[nH]n2)c1, FC(F)(F)c1cccc(NC(=O)Nc2ccc(Br)cc2-c2nn[nH]n2)c1, FC(F)(F)c1cccc(NC(=O)Nc2ccc(Br)cc2-c2nn[nH]n2)c1, FC(F)(F)c1cccc(NC(=O)Nc2ccc(Br)cc2-c2nn[nH]n2)c1, FC(F)(F)c1cccc(NC(=O)Nc2ccc(Br)cc2-c2nn[nH]n2)c1, FC(F)(F)c1cccc(NC(=O)Nc2ccc(Br)cc2-c2nn[nH]n2)c1	JXPULDIATMTIIN-UHFFFAOYSA-N, JXPULDIATMTIIN-UHFFFAOYSA-N, JXPULDIATMTIIN-UHFFFAOYSA-N, JXPULDIATMTIIN-UHFFFAOYSA-N, JXPULDIATMTIIN-UHFFFAOYSA-N, JXPULDIATMTIIN-UHFFFAOYSA-N	Preclinical
NS-3861	acetylcholine receptor agonist	CHRNA3, CHRNB4			CN1[C@@H]2CC[C@H]1C=C(C2)c1sccc1Br |&1:2,5,c:7|	ZJCNRVHZJADROC-VHSXEESVSA-N	Preclinical
NS-5806	voltage-gated potassium channel activator	KCND3			FC(F)(F)c1cc(NC(=O)Nc2c(Br)cc(Br)cc2-c2nn[nH]n2)cc(c1)C(F)(F)F, FC(F)(F)c1cc(NC(=O)Nc2c(Br)cc(Br)cc2-c2nn[nH]n2)cc(c1)C(F)(F)F, FC(F)(F)c1cc(NC(=O)Nc2c(Br)cc(Br)cc2-c2nn[nH]n2)cc(c1)C(F)(F)F	UZWJWROOLOOCPQ-UHFFFAOYSA-N, UZWJWROOLOOCPQ-UHFFFAOYSA-N, UZWJWROOLOOCPQ-UHFFFAOYSA-N	Preclinical
NS-8	potassium channel agonist	KCNMA1			Cc1c([nH]c(N)c1C#N)-c1ccccc1F	KVDWOQGDMAEJLM-UHFFFAOYSA-N	Phase 2
NS-8593	calcium-activated potassium channel modulator	KCNN1, KCNN2, KCNN3			C1C[C@@H](Nc2nc3ccccc3[nH]2)c2ccccc2C1, C1C[C@@H](Nc2nc3ccccc3[nH]2)c2ccccc2C1	XZIZUQSOFMLIIR-CQSZACIVSA-N, XZIZUQSOFMLIIR-CQSZACIVSA-N	Preclinical
NS-9283	acetylcholine receptor allosteric modulator	CHRNA4			N#Cc1cccc(c1)-c1nc(no1)-c1cccnc1, N#Cc1cccc(c1)-c1nc(no1)-c1cccnc1, N#Cc1cccc(c1)-c1nc(no1)-c1cccnc1, N#Cc1cccc(c1)-c1nc(no1)-c1cccnc1	HGFXDSQLRSWUBO-UHFFFAOYSA-N, HGFXDSQLRSWUBO-UHFFFAOYSA-N, HGFXDSQLRSWUBO-UHFFFAOYSA-N, HGFXDSQLRSWUBO-UHFFFAOYSA-N	Preclinical
NSC-23766	Ras GTPase inhibitor				CCN(CC)CCC[C@@H](C)Nc1nc(C)cc(Nc2ccc3nc(C)cc(N)c3c2)n1 |&1:8|, CCN(CC)CCC[C@@H](C)Nc1nc(C)cc(Nc2ccc3nc(C)cc(N)c3c2)n1 |&1:8|, CCN(CC)CCC[C@@H](C)Nc1nc(C)cc(Nc2ccc3nc(C)cc(N)c3c2)n1 |&1:8|, CCN(CC)CCC[C@@H](C)Nc1nc(C)cc(Nc2ccc3nc(C)cc(N)c3c2)n1 |&1:8|	DEFBCZWQLILOJF-MRXNPFEDSA-N, DEFBCZWQLILOJF-MRXNPFEDSA-N, DEFBCZWQLILOJF-MRXNPFEDSA-N, DEFBCZWQLILOJF-MRXNPFEDSA-N	Preclinical
NSC-319726	p53 activator				C\C(=N/NC(=S)N1CCC1)c1ccccn1, C\C(=N/NC(=S)N1CCC1)c1ccccn1, C\C(=N/NC(=S)N1CCC1)c1ccccn1, C\C(=N/NC(=S)N1CCC1)c1ccccn1, C\C(=N/NC(=S)N1CCC1)c1ccccn1, C\C(=N/NC(=S)N1CCC1)c1ccccn1, C\C(=N/NC(=S)N1CCC1)c1ccccn1, C\C(=N/NC(=S)N1CCC1)c1ccccn1, C\C(=N/NC(=S)N1CCC1)c1ccccn1	XDHBUMNIQRLHGO-UKTHLTGXSA-N, XDHBUMNIQRLHGO-UKTHLTGXSA-N, XDHBUMNIQRLHGO-UKTHLTGXSA-N, XDHBUMNIQRLHGO-UKTHLTGXSA-N, XDHBUMNIQRLHGO-UKTHLTGXSA-N, XDHBUMNIQRLHGO-UKTHLTGXSA-N, XDHBUMNIQRLHGO-UKTHLTGXSA-N, XDHBUMNIQRLHGO-UKTHLTGXSA-N, XDHBUMNIQRLHGO-UKTHLTGXSA-N	Preclinical
NSC-3852	HDAC inhibitor	HDAC1			Oc1ccc(N=O)c2cccnc12, Oc1ccc(N=O)c2cccnc12, Oc1ccc(N=O)c2cccnc12, Oc1ccc(N=O)c2cccnc12	RZWRYPGAUIOOMK-UHFFFAOYSA-N, RZWRYPGAUIOOMK-UHFFFAOYSA-N, RZWRYPGAUIOOMK-UHFFFAOYSA-N, RZWRYPGAUIOOMK-UHFFFAOYSA-N	Preclinical
NSC-405020	matrix metalloprotease inhibitor	MMP1			CCC[C@@H](C)NC(=O)c1ccc(Cl)c(Cl)c1 |&1:3,r|, CCC[C@@H](C)NC(=O)c1ccc(Cl)c(Cl)c1 |&1:3,r|, CCC[C@@H](C)NC(=O)c1ccc(Cl)c(Cl)c1 |&1:3,r|, CCC[C@@H](C)NC(=O)c1ccc(Cl)c(Cl)c1 |&1:3,r|, CCC[C@@H](C)NC(=O)c1ccc(Cl)c(Cl)c1 |&1:3,r|, CCC[C@@H](C)NC(=O)c1ccc(Cl)c(Cl)c1 |&1:3,r|	ARDYECYBETXQFD-MRVPVSSYSA-N, ARDYECYBETXQFD-MRVPVSSYSA-N, ARDYECYBETXQFD-MRVPVSSYSA-N, ARDYECYBETXQFD-MRVPVSSYSA-N, ARDYECYBETXQFD-MRVPVSSYSA-N, ARDYECYBETXQFD-MRVPVSSYSA-N	Preclinical
NSC-4644	ACAT inhibitor, sterol regulatory element binding protein (SREBP) inhibitor	PYGM			CC(=C)[C@@H]1CC[C@]2(CO)CC[C@]3(C)[C@H](CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]12, CC(=C)[C@@H]1CC[C@]2(CO)CC[C@]3(C)[C@H](CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]12	FVWJYYTZTCVBKE-ROUWMTJPSA-N, FVWJYYTZTCVBKE-ROUWMTJPSA-N	Phase 2
NSC-5844	CC chemokine receptor agonist	CCR1			Clc1ccc2c(NCCNc3ccnc4cc(Cl)ccc34)ccnc2c1	SSXYXSMMVMVYEV-UHFFFAOYSA-N	Preclinical
NSC-625987	CDK inhibitor	CDK2, CDK4			COc1ccc(OC)c2c1[nH]c1ccccc1c2=S	KFAKESMKRPNZTM-UHFFFAOYSA-N	Preclinical
NSC-632839	ubiquitin specific protease inhibitor	SENP2, USP1, USP2, USP7			Cc1ccc(\C=C2/CNC\C(=C/c3ccc(C)cc3)C2=O)cc1, Cc1ccc(\C=C2/CNC\C(=C/c3ccc(C)cc3)C2=O)cc1, Cc1ccc(\C=C2/CNC\C(=C/c3ccc(C)cc3)C2=O)cc1, Cc1ccc(\C=C2/CNC\C(=C/c3ccc(C)cc3)C2=O)cc1, Cc1ccc(\C=C2/CNC\C(=C/c3ccc(C)cc3)C2=O)cc1	PKCYYPHSCUSQDK-AYKLPDECSA-N, PKCYYPHSCUSQDK-AYKLPDECSA-N, PKCYYPHSCUSQDK-AYKLPDECSA-N, PKCYYPHSCUSQDK-AYKLPDECSA-N, PKCYYPHSCUSQDK-AYKLPDECSA-N	Preclinical
NSC-636819	histone demethylase inhibitor	KDM4A, KDM4B			[O-][N+](=O)c1cc(c(\C=C\c2ccc(Cl)c(Cl)c2)cc1\C=C\c1ccc(Cl)c(Cl)c1)[N+]([O-])=O	YYZPXBXVBQSBDG-IJIVKGSJSA-N	Preclinical
NSC-663284	CDC inhibitor	CDC25A, CDC25B, CDC25C			ClC1=C(NCCN2CCOCC2)C(=O)c2ncccc2C1=O |c:1|, ClC1=C(NCCN2CCOCC2)C(=O)c2ncccc2C1=O |c:1|, ClC1=C(NCCN2CCOCC2)C(=O)c2ncccc2C1=O |c:1|, ClC1=C(NCCN2CCOCC2)C(=O)c2ncccc2C1=O |c:1|, ClC1=C(NCCN2CCOCC2)C(=O)c2ncccc2C1=O |c:1|, ClC1=C(NCCN2CCOCC2)C(=O)c2ncccc2C1=O |c:1|, ClC1=C(NCCN2CCOCC2)C(=O)c2ncccc2C1=O |c:1|	BMKPVDQDJQWBPD-UHFFFAOYSA-N, BMKPVDQDJQWBPD-UHFFFAOYSA-N, BMKPVDQDJQWBPD-UHFFFAOYSA-N, BMKPVDQDJQWBPD-UHFFFAOYSA-N, BMKPVDQDJQWBPD-UHFFFAOYSA-N, BMKPVDQDJQWBPD-UHFFFAOYSA-N, BMKPVDQDJQWBPD-UHFFFAOYSA-N	Preclinical
NSC-697923	ubiquitin-conjugating enzyme inhibitor	UBE2N			Cc1ccc(cc1)S(=O)(=O)c1ccc(o1)[N+]([O-])=O, Cc1ccc(cc1)S(=O)(=O)c1ccc(o1)[N+]([O-])=O, Cc1ccc(cc1)S(=O)(=O)c1ccc(o1)[N+]([O-])=O, Cc1ccc(cc1)S(=O)(=O)c1ccc(o1)[N+]([O-])=O, Cc1ccc(cc1)S(=O)(=O)c1ccc(o1)[N+]([O-])=O	GAUHIPWCDXOLCZ-UHFFFAOYSA-N, GAUHIPWCDXOLCZ-UHFFFAOYSA-N, GAUHIPWCDXOLCZ-UHFFFAOYSA-N, GAUHIPWCDXOLCZ-UHFFFAOYSA-N, GAUHIPWCDXOLCZ-UHFFFAOYSA-N	Preclinical
NSC-95397	CDC inhibitor	CDC25A, CDC25B			OCCSC1=C(SCCO)C(=O)c2ccccc2C1=O |c:4|	MAASHDQFQDDECQ-UHFFFAOYSA-N	Preclinical
NSC-9965	acetylcholine receptor antagonist	CHRNA4, CHRNB2			CO[C@H]1CC=C2CCN3CCC4=C(CC(=O)OC4)[C@]23C1 |t:4,11|, CO[C@H]1CC=C2CCN3CCC4=C(CC(=O)OC4)[C@]23C1 |t:4,11|, CO[C@H]1CC=C2CCN3CCC4=C(CC(=O)OC4)[C@]23C1 |t:4,11|	ALSKYCOJJPXPFS-BBRMVZONSA-N, ALSKYCOJJPXPFS-BBRMVZONSA-N, ALSKYCOJJPXPFS-BBRMVZONSA-N	Preclinical
NSI-189	neurotrophic agent				CC(C)CCNc1ncccc1C(=O)N1CCN(Cc2ccccc2)CC1, CC(C)CCNc1ncccc1C(=O)N1CCN(Cc2ccccc2)CC1	DYTOQURYRYYNOR-UHFFFAOYSA-N, DYTOQURYRYYNOR-UHFFFAOYSA-N	Phase 2
NSP-805	phosphodiesterase inhibitor				CC1=C(CCC1=O)Nc1ccc(cc1)C1=C(C)CC(=O)NN1 |c:16,t:1|	VSEWBFSTIMFCDL-UHFFFAOYSA-N	Preclinical
NTNCB	neuropeptide receptor antagonist	NPY5R			[O-][N+](=O)c1ccccc1S(=O)(=O)NC[C@H]1CC[C@H](CNC[C@H]2CCc3ccccc3C2)CC1 |a:14,17,&1:21|, [O-][N+](=O)c1ccccc1S(=O)(=O)NC[C@H]1CC[C@H](CNC[C@H]2CCc3ccccc3C2)CC1 |a:14,17,&1:21|, [O-][N+](=O)c1ccccc1S(=O)(=O)NC[C@H]1CC[C@H](CNC[C@H]2CCc3ccccc3C2)CC1 |a:14,17,&1:21|, [O-][N+](=O)c1ccccc1S(=O)(=O)NC[C@H]1CC[C@H](CNC[C@H]2CCc3ccccc3C2)CC1 |a:14,17,&1:21|, [O-][N+](=O)c1ccccc1S(=O)(=O)NC[C@H]1CC[C@H](CNC[C@H]2CCc3ccccc3C2)CC1 |a:14,17,&1:21|	ISSSVYKMIIAPTH-ACRUOGEOSA-N, ISSSVYKMIIAPTH-ACRUOGEOSA-N, ISSSVYKMIIAPTH-ACRUOGEOSA-N, ISSSVYKMIIAPTH-ACRUOGEOSA-N, ISSSVYKMIIAPTH-ACRUOGEOSA-N	Preclinical
NTRC-824	neurotensin receptor antagonist	NTSR2			CC(C)C[C@H](NC(=O)Cn1cc(C(=O)C(F)(F)F)c2cc(NS(=O)(=O)c3ccc(C)cc3)ccc12)C(O)=O, CC(C)C[C@H](NC(=O)Cn1cc(C(=O)C(F)(F)F)c2cc(NS(=O)(=O)c3ccc(C)cc3)ccc12)C(O)=O	SOOLLEBJNGCDOZ-FQEVSTJZSA-N, SOOLLEBJNGCDOZ-FQEVSTJZSA-N	Preclinical
nTZDpa	PPAR receptor agonist	PPARG			OC(=O)c1c(Sc2ccccc2)c2cc(Cl)ccc2n1Cc1ccc(Cl)cc1, OC(=O)c1c(Sc2ccccc2)c2cc(Cl)ccc2n1Cc1ccc(Cl)cc1, OC(=O)c1c(Sc2ccccc2)c2cc(Cl)ccc2n1Cc1ccc(Cl)cc1	VUPOTURDKDMIGQ-UHFFFAOYSA-N, VUPOTURDKDMIGQ-UHFFFAOYSA-N, VUPOTURDKDMIGQ-UHFFFAOYSA-N	Preclinical
NT157	IGF-1 inhibitor	IGF1R			Oc1cc(CNC(=S)\C=C\c2cc(O)c(O)c(Br)c2)cc(O)c1O, Oc1cc(CNC(=S)\C=C\c2cc(O)c(O)c(Br)c2)cc(O)c1O	NIPUPOUEGOSAAO-OWOJBTEDSA-N, NIPUPOUEGOSAAO-OWOJBTEDSA-N	Preclinical
NU-1025	PARP inhibitor	PARP1			Cc1nc(=O)c2cccc(O)c2[nH]1, Cc1nc(=O)c2cccc(O)c2[nH]1, Cc1nc(=O)c2cccc(O)c2[nH]1	YJDAOHJWLUNFLX-UHFFFAOYSA-N, YJDAOHJWLUNFLX-UHFFFAOYSA-N, YJDAOHJWLUNFLX-UHFFFAOYSA-N	Preclinical
NU-2058	cyclin D inhibitor	CCNA2, CDK2			Nc1nc(OCC2CCCCC2)c2[nH]cnc2n1	MWGXGTJJAOZBNW-UHFFFAOYSA-N	Preclinical
NU-6027	CDK inhibitor	CCNA2, CDK2			Nc1nc(N)c(N=O)c(OCC2CCCCC2)n1, Nc1nc(N)c(N=O)c(OCC2CCCCC2)n1, Nc1nc(N)c(N=O)c(OCC2CCCCC2)n1	DGWXOLHKVGDQLN-UHFFFAOYSA-N, DGWXOLHKVGDQLN-UHFFFAOYSA-N, DGWXOLHKVGDQLN-UHFFFAOYSA-N	Preclinical
NU-7026	DNA dependent protein kinase inhibitor, mTOR inhibitor, PI3K inhibitor	PRKDC			O=c1cc(oc2c3ccccc3ccc12)N1CCOCC1, O=c1cc(oc2c3ccccc3ccc12)N1CCOCC1, O=c1cc(oc2c3ccccc3ccc12)N1CCOCC1, O=c1cc(oc2c3ccccc3ccc12)N1CCOCC1, O=c1cc(oc2c3ccccc3ccc12)N1CCOCC1	KKTZALUTXUZPSN-UHFFFAOYSA-N, KKTZALUTXUZPSN-UHFFFAOYSA-N, KKTZALUTXUZPSN-UHFFFAOYSA-N, KKTZALUTXUZPSN-UHFFFAOYSA-N, KKTZALUTXUZPSN-UHFFFAOYSA-N	Preclinical
NU-7441	DNA dependent protein kinase inhibitor	PRKDC			O=c1cc(oc2c(cccc12)-c1cccc2c3ccccc3sc12)N1CCOCC1, O=c1cc(oc2c(cccc12)-c1cccc2c3ccccc3sc12)N1CCOCC1, O=c1cc(oc2c(cccc12)-c1cccc2c3ccccc3sc12)N1CCOCC1, O=c1cc(oc2c(cccc12)-c1cccc2c3ccccc3sc12)N1CCOCC1, O=c1cc(oc2c(cccc12)-c1cccc2c3ccccc3sc12)N1CCOCC1, O=c1cc(oc2c(cccc12)-c1cccc2c3ccccc3sc12)N1CCOCC1, O=c1cc(oc2c(cccc12)-c1cccc2c3ccccc3sc12)N1CCOCC1, O=c1cc(oc2c(cccc12)-c1cccc2c3ccccc3sc12)N1CCOCC1	JAMULYFATHSZJM-UHFFFAOYSA-N, JAMULYFATHSZJM-UHFFFAOYSA-N, JAMULYFATHSZJM-UHFFFAOYSA-N, JAMULYFATHSZJM-UHFFFAOYSA-N, JAMULYFATHSZJM-UHFFFAOYSA-N, JAMULYFATHSZJM-UHFFFAOYSA-N, JAMULYFATHSZJM-UHFFFAOYSA-N, InChI=1S/C25H19NO3S/c27-21-15-23(26-11-13-28-14-12-26)29-24-17(6-3-9-20(21)24)19-8-4-7-18-16-5-1-2-10-22(16)30-25(18)19/h1-10,15H,11-14H2	Preclinical
nuclomedone	immunosuppressant				Clc1ccc(C[C@H]2C(=O)N=C3SCCN3C2=O)cc1 |r,t:9|	QSKVYHYMQQQAFS-JTQLQIEISA-N	Phase 3
nutlin-3	MDM inhibitor	MDM2, TP53			COc1ccc(C2=N[C@H]([C@H](N2C(=O)N2CCNC(=O)C2)c2ccc(Cl)cc2)c2ccc(Cl)cc2)c(OC(C)C)c1 |&1:8,9,r,t:6|	BDUHCSBCVGXTJM-WUFINQPMSA-N	Preclinical
nuvenzepine	acetylcholine receptor antagonist				CN1CCC(CC1)C(=O)N1c2ccccc2NC(=O)c2cccnc12	HPKYRXAEGNUARA-UHFFFAOYSA-N	Preclinical
NVP-ADW742	insulin growth factor receptor inhibitor	IGF1R			Nc1ncnc2n(cc(-c3cccc(OCc4ccccc4)c3)c12)[C@H]1C[C@H](CN2CCCC2)C1 |r|, Nc1ncnc2n(cc(-c3cccc(OCc4ccccc4)c3)c12)[C@H]1C[C@H](CN2CCCC2)C1 |r|, Nc1ncnc2n(cc(-c3cccc(OCc4ccccc4)c3)c12)[C@H]1C[C@H](CN2CCCC2)C1 |r|, Nc1ncnc2n(cc(-c3cccc(OCc4ccccc4)c3)c12)[C@H]1C[C@H](CN2CCCC2)C1 |r|, Nc1ncnc2n(cc(-c3cccc(OCc4ccccc4)c3)c12)[C@H]1C[C@H](CN2CCCC2)C1 |r|, Nc1ncnc2n(cc(-c3cccc(OCc4ccccc4)c3)c12)[C@H]1C[C@H](CN2CCCC2)C1 |r|, Nc1ncnc2n(cc(-c3cccc(OCc4ccccc4)c3)c12)[C@H]1C[C@H](CN2CCCC2)C1 |r|, Nc1ncnc2n(cc(-c3cccc(OCc4ccccc4)c3)c12)[C@H]1C[C@H](CN2CCCC2)C1 |r|, Nc1ncnc2n(cc(-c3cccc(OCc4ccccc4)c3)c12)[C@H]1C[C@H](CN2CCCC2)C1 |r|	LSFLAQVDISHMNB-AFARHQOCSA-N, LSFLAQVDISHMNB-AFARHQOCSA-N, LSFLAQVDISHMNB-AFARHQOCSA-N, LSFLAQVDISHMNB-AFARHQOCSA-N, LSFLAQVDISHMNB-AFARHQOCSA-N, LSFLAQVDISHMNB-AFARHQOCSA-N, LSFLAQVDISHMNB-AFARHQOCSA-N, LSFLAQVDISHMNB-AFARHQOCSA-N, LSFLAQVDISHMNB-AFARHQOCSA-N	Preclinical
NVP-AEW541	IGF-1 inhibitor	IGF1R, INSR			Nc1ncnc2n(cc(-c3cccc(OCc4ccccc4)c3)c12)[C@@H]1C[C@H](CN2CCC2)C1 |r|, Nc1ncnc2n(cc(-c3cccc(OCc4ccccc4)c3)c12)[C@@H]1C[C@H](CN2CCC2)C1 |r|, Nc1ncnc2n(cc(-c3cccc(OCc4ccccc4)c3)c12)[C@@H]1C[C@H](CN2CCC2)C1 |r|, Nc1ncnc2n(cc(-c3cccc(OCc4ccccc4)c3)c12)[C@@H]1C[C@H](CN2CCC2)C1 |r|, Nc1ncnc2n(cc(-c3cccc(OCc4ccccc4)c3)c12)[C@@H]1C[C@H](CN2CCC2)C1 |r|	AECDBHGVIIRMOI-GRGXKFILSA-N, AECDBHGVIIRMOI-GRGXKFILSA-N, AECDBHGVIIRMOI-GRGXKFILSA-N, AECDBHGVIIRMOI-GRGXKFILSA-N, AECDBHGVIIRMOI-GRGXKFILSA-N	Preclinical
NVP-AUY922	HSP inhibitor	HSP90AA1, HSP90AB1			CCNC(=O)c1noc(c1-c1ccc(CN2CCOCC2)cc1)-c1cc(C(C)C)c(O)cc1O, CCNC(=O)c1noc(c1-c1ccc(CN2CCOCC2)cc1)-c1cc(C(C)C)c(O)cc1O, CCNC(=O)c1noc(c1-c1ccc(CN2CCOCC2)cc1)-c1cc(C(C)C)c(O)cc1O, CCNC(=O)c1noc(c1-c1ccc(CN2CCOCC2)cc1)-c1cc(C(C)C)c(O)cc1O, CCNC(=O)c1noc(c1-c1ccc(CN2CCOCC2)cc1)-c1cc(C(C)C)c(O)cc1O, CCNC(=O)c1noc(c1-c1ccc(CN2CCOCC2)cc1)-c1cc(C(C)C)c(O)cc1O, CCNC(=O)c1noc(c1-c1ccc(CN2CCOCC2)cc1)-c1cc(C(C)C)c(O)cc1O, CCNC(=O)c1noc(c1-c1ccc(CN2CCOCC2)cc1)-c1cc(C(C)C)c(O)cc1O, CCNC(=O)c1noc(c1-c1ccc(CN2CCOCC2)cc1)-c1cc(C(C)C)c(O)cc1O, CCNC(=O)c1noc(c1-c1ccc(CN2CCOCC2)cc1)-c1cc(C(C)C)c(O)cc1O, CCNC(=O)c1noc(c1-c1ccc(CN2CCOCC2)cc1)-c1cc(C(C)C)c(O)cc1O	NDAZATDQFDPQBD-UHFFFAOYSA-N, NDAZATDQFDPQBD-UHFFFAOYSA-N, NDAZATDQFDPQBD-UHFFFAOYSA-N, NDAZATDQFDPQBD-UHFFFAOYSA-N, NDAZATDQFDPQBD-UHFFFAOYSA-N, NDAZATDQFDPQBD-UHFFFAOYSA-N, NDAZATDQFDPQBD-UHFFFAOYSA-N, NDAZATDQFDPQBD-UHFFFAOYSA-N, NDAZATDQFDPQBD-UHFFFAOYSA-N, NDAZATDQFDPQBD-UHFFFAOYSA-N, NDAZATDQFDPQBD-UHFFFAOYSA-N	Phase 2
NVP-BEZ235	mTOR inhibitor, PI3K inhibitor	ATR, MTOR, PIK3CA, PIK3CD, PIK3CG			Cn1c2cnc3ccc(cc3c2n(-c2ccc(cc2)C(C)(C)C#N)c1=O)-c1cnc2ccccc2c1, Cn1c2cnc3ccc(cc3c2n(-c2ccc(cc2)C(C)(C)C#N)c1=O)-c1cnc2ccccc2c1, Cn1c2cnc3ccc(cc3c2n(-c2ccc(cc2)C(C)(C)C#N)c1=O)-c1cnc2ccccc2c1, Cn1c2cnc3ccc(cc3c2n(-c2ccc(cc2)C(C)(C)C#N)c1=O)-c1cnc2ccccc2c1	JOGKUKXHTYWRGZ-UHFFFAOYSA-N, JOGKUKXHTYWRGZ-UHFFFAOYSA-N, JOGKUKXHTYWRGZ-UHFFFAOYSA-N, JOGKUKXHTYWRGZ-UHFFFAOYSA-N	Phase 3
NVP-BGJ398	FGFR inhibitor	FGFR1, FGFR2, FGFR3, FGFR4, KDR			CCN1CCN(CC1)c1ccc(Nc2cc(ncn2)N(C)C(=O)Nc2c(Cl)c(OC)cc(OC)c2Cl)cc1, CCN1CCN(CC1)c1ccc(Nc2cc(ncn2)N(C)C(=O)Nc2c(Cl)c(OC)cc(OC)c2Cl)cc1, CCN1CCN(CC1)c1ccc(Nc2cc(ncn2)N(C)C(=O)Nc2c(Cl)c(OC)cc(OC)c2Cl)cc1, CCN1CCN(CC1)c1ccc(Nc2cc(ncn2)N(C)C(=O)Nc2c(Cl)c(OC)cc(OC)c2Cl)cc1, CCN1CCN(CC1)c1ccc(Nc2cc(ncn2)N(C)C(=O)Nc2c(Cl)c(OC)cc(OC)c2Cl)cc1, CCN1CCN(CC1)c1ccc(Nc2cc(ncn2)N(C)C(=O)Nc2c(Cl)c(OC)cc(OC)c2Cl)cc1	QADPYRIHXKWUSV-UHFFFAOYSA-N, QADPYRIHXKWUSV-UHFFFAOYSA-N, QADPYRIHXKWUSV-UHFFFAOYSA-N, QADPYRIHXKWUSV-UHFFFAOYSA-N, QADPYRIHXKWUSV-UHFFFAOYSA-N, QADPYRIHXKWUSV-UHFFFAOYSA-N	Phase 3
NVP-BHG712	ephrin inhibitor	EPHB4			Cc1ccc(cc1Nc1nc(nc2n(C)ncc12)-c1cccnc1)C(=O)Nc1cccc(c1)C(F)(F)F, Cc1ccc(cc1Nc1nc(nc2n(C)ncc12)-c1cccnc1)C(=O)Nc1cccc(c1)C(F)(F)F, Cc1ccc(cc1Nc1nc(nc2n(C)ncc12)-c1cccnc1)C(=O)Nc1cccc(c1)C(F)(F)F, Cc1ccc(cc1Nc1nc(nc2n(C)ncc12)-c1cccnc1)C(=O)Nc1cccc(c1)C(F)(F)F	ZCCPLJOKGAACRT-UHFFFAOYSA-N, ZCCPLJOKGAACRT-UHFFFAOYSA-N, ZCCPLJOKGAACRT-UHFFFAOYSA-N, ZCCPLJOKGAACRT-UHFFFAOYSA-N	Preclinical
NVP-BSK805	JAK inhibitor	JAK2			Fc1cc(cc(F)c1CN1CCOCC1)-c1cccc2ncc(nc12)-c1cnn(c1)C1CCNCC1, Fc1cc(cc(F)c1CN1CCOCC1)-c1cccc2ncc(nc12)-c1cnn(c1)C1CCNCC1, Fc1cc(cc(F)c1CN1CCOCC1)-c1cccc2ncc(nc12)-c1cnn(c1)C1CCNCC1, Fc1cc(cc(F)c1CN1CCOCC1)-c1cccc2ncc(nc12)-c1cnn(c1)C1CCNCC1, Fc1cc(cc(F)c1CN1CCOCC1)-c1cccc2ncc(nc12)-c1cnn(c1)C1CCNCC1, Fc1cc(cc(F)c1CN1CCOCC1)-c1cccc2ncc(nc12)-c1cnn(c1)C1CCNCC1	IBPVXAOOVUAOKJ-UHFFFAOYSA-N, IBPVXAOOVUAOKJ-UHFFFAOYSA-N, IBPVXAOOVUAOKJ-UHFFFAOYSA-N, IBPVXAOOVUAOKJ-UHFFFAOYSA-N, IBPVXAOOVUAOKJ-UHFFFAOYSA-N, IBPVXAOOVUAOKJ-UHFFFAOYSA-N	Preclinical
NVP-BVU972	MET inhibitor	MET			Cn1cc(cn1)-c1ccc2ncc(Cc3ccc4ncccc4c3)n2n1, Cn1cc(cn1)-c1ccc2ncc(Cc3ccc4ncccc4c3)n2n1	RNCNPRCUHHDYPC-UHFFFAOYSA-N, RNCNPRCUHHDYPC-UHFFFAOYSA-N	Preclinical
NVP-DPP728	dipeptidyl peptidase inhibitor	DPP4			O=C(CNCCNc1ccc(cn1)C#N)N1CCC[C@H]1C#N, O=C(CNCCNc1ccc(cn1)C#N)N1CCC[C@H]1C#N, O=C(CNCCNc1ccc(cn1)C#N)N1CCC[C@H]1C#N, O=C(CNCCNc1ccc(cn1)C#N)N1CCC[C@H]1C#N, O=C(CNCCNc1ccc(cn1)C#N)N1CCC[C@H]1C#N, O=C(CNCCNc1ccc(cn1)C#N)N1CCC[C@H]1C#N	VFFZWMWTUSXDCB-ZDUSSCGKSA-N, VFFZWMWTUSXDCB-ZDUSSCGKSA-N, VFFZWMWTUSXDCB-ZDUSSCGKSA-N, VFFZWMWTUSXDCB-ZDUSSCGKSA-N, VFFZWMWTUSXDCB-ZDUSSCGKSA-N, VFFZWMWTUSXDCB-ZDUSSCGKSA-N	Phase 2
NVP-HSP990	HSP inhibitor	HSP90AA1, HSP90AB1			COc1cccc(n1)-c1cc(F)ccc1[C@H]1Cc2nc(N)nc(C)c2C(=O)N1, COc1cccc(n1)-c1cc(F)ccc1[C@H]1Cc2nc(N)nc(C)c2C(=O)N1, COc1cccc(n1)-c1cc(F)ccc1[C@H]1Cc2nc(N)nc(C)c2C(=O)N1, COc1cccc(n1)-c1cc(F)ccc1[C@H]1Cc2nc(N)nc(C)c2C(=O)N1	WSMQUUGTQYPVPD-OAHLLOKOSA-N, WSMQUUGTQYPVPD-OAHLLOKOSA-N, WSMQUUGTQYPVPD-OAHLLOKOSA-N, WSMQUUGTQYPVPD-OAHLLOKOSA-N	Phase 1
NVP-TAE226	protein tyrosine kinase inhibitor	PTK2			CNC(=O)c1ccccc1Nc1nc(Nc2ccc(cc2OC)N2CCOCC2)ncc1Cl, CNC(=O)c1ccccc1Nc1nc(Nc2ccc(cc2OC)N2CCOCC2)ncc1Cl, CNC(=O)c1ccccc1Nc1nc(Nc2ccc(cc2OC)N2CCOCC2)ncc1Cl, CNC(=O)c1ccccc1Nc1nc(Nc2ccc(cc2OC)N2CCOCC2)ncc1Cl, CNC(=O)c1ccccc1Nc1nc(Nc2ccc(cc2OC)N2CCOCC2)ncc1Cl, CNC(=O)c1ccccc1Nc1nc(Nc2ccc(cc2OC)N2CCOCC2)ncc1Cl	UYJNQQDJUOUFQJ-UHFFFAOYSA-N, UYJNQQDJUOUFQJ-UHFFFAOYSA-N, UYJNQQDJUOUFQJ-UHFFFAOYSA-N, UYJNQQDJUOUFQJ-UHFFFAOYSA-N, UYJNQQDJUOUFQJ-UHFFFAOYSA-N, UYJNQQDJUOUFQJ-UHFFFAOYSA-N	Preclinical
NVP-TAE684	ALK tyrosine kinase receptor inhibitor	ALK, INSR			COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1)N1CCC(CC1)N1CCN(C)CC1, COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1)N1CCC(CC1)N1CCN(C)CC1, COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1)N1CCC(CC1)N1CCN(C)CC1, COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1)N1CCC(CC1)N1CCN(C)CC1	QQWUGDVOUVUTOY-UHFFFAOYSA-N, QQWUGDVOUVUTOY-UHFFFAOYSA-N, QQWUGDVOUVUTOY-UHFFFAOYSA-N, QQWUGDVOUVUTOY-UHFFFAOYSA-N	Preclinical
NVP-TNKS656	tankyrase inhibitor	TNKS2			COc1ccc(cc1)C(=O)C1CCN(CC(=O)N(CC2CC2)Cc2nc(=O)c3COCCc3[nH]2)CC1	DYGBNAYFDZEYBA-UHFFFAOYSA-N	Preclinical
NVP-231	ceramidase inhibitor	CERK			O=C(Nc1nc2ccc(NC(=O)C34CC5CC(CC(C5)C3)C4)cc2s1)c1ccccc1, O=C(Nc1nc2ccc(NC(=O)C34CC5CC(CC(C5)C3)C4)cc2s1)c1ccccc1, O=C(Nc1nc2ccc(NC(=O)C34CC5CC(CC(C5)C3)C4)cc2s1)c1ccccc1, O=C(Nc1nc2ccc(NC(=O)C34CC5CC(CC(C5)C3)C4)cc2s1)c1ccccc1	MVSSJPGNLQPWSW-UHFFFAOYSA-N, MVSSJPGNLQPWSW-UHFFFAOYSA-N, MVSSJPGNLQPWSW-UHFFFAOYSA-N, MVSSJPGNLQPWSW-UHFFFAOYSA-N	Preclinical
NVS-PAK1-1	p21 activated kinase inhibitor	PAK1			CC(C)NC(=O)N1CC[C@@H](C1)NC1=Nc2cc(F)ccc2N(CC(F)F)c2ccc(Cl)cc12 |t:13|, CC(C)NC(=O)N1CC[C@@H](C1)NC1=Nc2cc(F)ccc2N(CC(F)F)c2ccc(Cl)cc12 |t:13|	OINGHOPGNMYCAB-INIZCTEOSA-N, OINGHOPGNMYCAB-INIZCTEOSA-N	Preclinical
NXY-059	free radical scavenger				CC(C)(C)[N+](\[O-])=C\c1ccc(cc1S(O)(=O)=O)S(O)(=O)=O, CC(C)(C)[N+](\[O-])=C\c1ccc(cc1S(O)(=O)=O)S(O)(=O)=O, CC(C)(C)[N+](\[O-])=C\c1ccc(cc1S(O)(=O)=O)S(O)(=O)=O	OVTCHWSLKGENKP-GHXNOFRVSA-N, OVTCHWSLKGENKP-GHXNOFRVSA-N, OVTCHWSLKGENKP-GHXNOFRVSA-N	Phase 3
nystatin	fungal ergosterol inhibitor		infectious disease	esophageal candidiasis, skin infections, yeast infection	C[C@H]1O[C@@H](O[C@@H]2C[C@@H]3O[C@@](O)(C[C@H](O)[C@H]3C(O)=O)C[C@@H](O)[C@H](O)CC[C@@H](O)C[C@@H](O)C[C@@H](O)CC(=O)O[C@@H](C)[C@H](C)[C@H](O)[C@@H](C)\C=C\C=C\CC\C=C\C=C\C=C\C=C\2)[C@@H](O)[C@@H](N)[C@@H]1O |t:46,48,52,54,56,58|, C[C@H]1O[C@@H](O[C@@H]2C[C@@H]3O[C@@](O)(C[C@H](O)[C@H]3C(O)=O)C[C@@H](O)[C@H](O)CC[C@@H](O)C[C@@H](O)C[C@@H](O)CC(=O)O[C@@H](C)[C@H](C)[C@H](O)[C@@H](C)\C=C\C=C\CC\C=C\C=C\C=C\C=C\2)[C@@H](O)[C@@H](N)[C@@H]1O |t:46,48,52,54,56,58|, C[C@H]1O[C@@H](O[C@@H]2C[C@@H]3O[C@@](O)(C[C@H](O)[C@H]3C(O)=O)C[C@@H](O)[C@H](O)CC[C@@H](O)C[C@@H](O)C[C@@H](O)CC(=O)O[C@@H](C)[C@H](C)[C@H](O)[C@@H](C)\C=C\C=C\CC\C=C\C=C\C=C\C=C\2)[C@@H](O)[C@@H](N)[C@@H]1O |t:46,48,52,54,56,58|	VQOXZBDYSJBXMA-MSHYPYPPSA-N, VQOXZBDYSJBXMA-MSHYPYPPSA-N, VQOXZBDYSJBXMA-MSHYPYPPSA-N	Launched
N20C	glutamate receptor antagonist				NC(=O)CNCCC(c1ccccc1)c1ccccc1, NC(=O)CNCCC(c1ccccc1)c1ccccc1	BYGXICRJQZKUPA-UHFFFAOYSA-N, BYGXICRJQZKUPA-UHFFFAOYSA-N	Preclinical
N6-cyclopentyladenosine	adenosine receptor agonist	ADORA1, ADORA2A, ADORA2B, ADORA3, SLC29A1			OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(NC3CCCC3)ncnc12, OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(NC3CCCC3)ncnc12	SQMWSBKSHWARHU-SDBHATRESA-N, SQMWSBKSHWARHU-SDBHATRESA-N	Preclinical
N6-methyladenosine					CNc1ncnc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O, CNc1ncnc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O	VQAYFKKCNSOZKM-IOSLPCCCSA-N, VQAYFKKCNSOZKM-IOSLPCCCSA-N	Preclinical
N6022	alcohol dehydrogenase inhibitor	ADH5			Cc1cc(ccc1-n1c(CCC(O)=O)ccc1-c1ccc(cc1)-n1ccnc1)C(N)=O, Cc1cc(ccc1-n1c(CCC(O)=O)ccc1-c1ccc(cc1)-n1ccnc1)C(N)=O, Cc1cc(ccc1-n1c(CCC(O)=O)ccc1-c1ccc(cc1)-n1ccnc1)C(N)=O, Cc1cc(ccc1-n1c(CCC(O)=O)ccc1-c1ccc(cc1)-n1ccnc1)C(N)=O, Cc1cc(ccc1-n1c(CCC(O)=O)ccc1-c1ccc(cc1)-n1ccnc1)C(N)=O, Cc1cc(ccc1-n1c(CCC(O)=O)ccc1-c1ccc(cc1)-n1ccnc1)C(N)=O	YVPGZQLRPAGKLA-UHFFFAOYSA-N, YVPGZQLRPAGKLA-UHFFFAOYSA-N, YVPGZQLRPAGKLA-UHFFFAOYSA-N, YVPGZQLRPAGKLA-UHFFFAOYSA-N, YVPGZQLRPAGKLA-UHFFFAOYSA-N, YVPGZQLRPAGKLA-UHFFFAOYSA-N	Phase 1/Phase 2
O-acetyl-L-serine		PTGS1			CC(=O)OC[C@H](N)C(O)=O	VZXPDPZARILFQX-BYPYZUCNSA-N	Preclinical
o-mercapto-benzoic-acid					OC(=O)c1ccccc1S	NBOMNTLFRHMDEZ-UHFFFAOYSA-N	Preclinical
O-1918	cannabinoid receptor antagonist				COc1cc(C)cc(OC)c1[C@@H]1C=C(C)CC[C@H]1C(C)=C |t:13|, COc1cc(C)cc(OC)c1[C@@H]1C=C(C)CC[C@H]1C(C)=C |t:13|, COc1cc(C)cc(OC)c1[C@@H]1C=C(C)CC[C@H]1C(C)=C |t:13|, COc1cc(C)cc(OC)c1[C@@H]1C=C(C)CC[C@H]1C(C)=C |t:13|, COc1cc(C)cc(OC)c1[C@@H]1C=C(C)CC[C@H]1C(C)=C |t:13|	ICHJMVMWPKLUKT-JKSUJKDBSA-N, ICHJMVMWPKLUKT-JKSUJKDBSA-N, ICHJMVMWPKLUKT-JKSUJKDBSA-N, ICHJMVMWPKLUKT-JKSUJKDBSA-N, ICHJMVMWPKLUKT-JKSUJKDBSA-N	Preclinical
o-3M3FBS	phospholipase activator				Cc1cc(C)c(c(C)c1)S(=O)(=O)Nc1ccccc1C(F)(F)F, Cc1cc(C)c(c(C)c1)S(=O)(=O)Nc1ccccc1C(F)(F)F, Cc1cc(C)c(c(C)c1)S(=O)(=O)Nc1ccccc1C(F)(F)F	SKJJIFRWCCSXGL-UHFFFAOYSA-N, SKJJIFRWCCSXGL-UHFFFAOYSA-N, SKJJIFRWCCSXGL-UHFFFAOYSA-N	Preclinical
O-304	AMPK activator				Clc1ccc(Cn2sc(NC(=O)c3ccc(Cl)cc3)nc2=O)cc1	WEDWLYRQKUTOAX-UHFFFAOYSA-N	Preclinical
OAC1	Oct activator				O=C(Nc1cc2cc[nH]c2cn1)c1ccccc1, O=C(Nc1cc2cc[nH]c2cn1)c1ccccc1, O=C(Nc1cc2cc[nH]c2cn1)c1ccccc1	HWJRIFZDXJKJJN-UHFFFAOYSA-N, HWJRIFZDXJKJJN-UHFFFAOYSA-N, HWJRIFZDXJKJJN-UHFFFAOYSA-N	Preclinical
OAC2	Oct activator	POU5F1			O=C(Nc1ccc2[nH]ccc2c1)c1ccccc1, O=C(Nc1ccc2[nH]ccc2c1)c1ccccc1	JCAFGYWSIWYMOX-UHFFFAOYSA-N, JCAFGYWSIWYMOX-UHFFFAOYSA-N	Preclinical
obatoclax	BCL inhibitor	BCL2			COC1=CC(=N\C1=C/c1[nH]c(C)cc1C)c1cc2ccccc2[nH]1 |c:4,t:2|, COC1=CC(=N\C1=C/c1[nH]c(C)cc1C)c1cc2ccccc2[nH]1 |c:4,t:2|, COC1=CC(=N\C1=C/c1[nH]c(C)cc1C)c1cc2ccccc2[nH]1 |c:4,t:2|, COC1=CC(=N\C1=C/c1[nH]c(C)cc1C)c1cc2ccccc2[nH]1 |c:4,t:2|, COC1=CC(=N\C1=C/c1[nH]c(C)cc1C)c1cc2ccccc2[nH]1 |c:4,t:2|, COC1=CC(=N\C1=C/c1[nH]c(C)cc1C)c1cc2ccccc2[nH]1 |c:4,t:2|, COC1=CC(=N\C1=C/c1[nH]c(C)cc1C)c1cc2ccccc2[nH]1 |c:4,t:2|, COC1=CC(=N\C1=C/c1[nH]c(C)cc1C)c1cc2ccccc2[nH]1 |c:4,t:2|, COC1=CC(=N\C1=C/c1[nH]c(C)cc1C)c1cc2ccccc2[nH]1 |c:4,t:2|, COC1=CC(=N\C1=C/c1[nH]c(C)cc1C)c1cc2ccccc2[nH]1 |c:4,t:2|, COC1=CC(=N\C1=C/c1[nH]c(C)cc1C)c1cc2ccccc2[nH]1 |c:4,t:2|	RFTSSZJZXOSICM-GRSHGNNSSA-N, RFTSSZJZXOSICM-GRSHGNNSSA-N, RFTSSZJZXOSICM-GRSHGNNSSA-N, RFTSSZJZXOSICM-GRSHGNNSSA-N, RFTSSZJZXOSICM-GRSHGNNSSA-N, RFTSSZJZXOSICM-GRSHGNNSSA-N, RFTSSZJZXOSICM-GRSHGNNSSA-N, RFTSSZJZXOSICM-GRSHGNNSSA-N, RFTSSZJZXOSICM-GRSHGNNSSA-N, RFTSSZJZXOSICM-GRSHGNNSSA-N, RFTSSZJZXOSICM-GRSHGNNSSA-N	Phase 3
obeticholic-acid	FXR agonist	NR1H4	gastroenterology	primary biliary cholangitis	CC[C@H]1[C@@H](O)[C@H]2[C@H]3CC[C@@H]([C@@H](C)CCC(O)=O)[C@@]3(C)CC[C@@H]2[C@@]2(C)CC[C@@H](O)C[C@@H]12 |&1:2,&2:3,&3:5,&4:6,&5:9,&6:10,&7:17,&8:21,&9:22,&10:26,&11:29,r|	ZXERDUOLZKYMJM-XNNZWSTBSA-N	Launched
obidoxime	cholinesterase reactivator	ACHE	critical care, neurology/psychiatry	poison antidote, nerve gas poisoning	O\N=C\c1cc[n+](COC[n+]2ccc(\C=N\O)cc2)cc1, O\N=C\c1cc[n+](COC[n+]2ccc(\C=N\O)cc2)cc1	HIGRLDNHDGYWQJ-UHFFFAOYSA-P, HIGRLDNHDGYWQJ-UHFFFAOYSA-P	Launched
ocaperidone	serotonin receptor antagonist				Cc1cccn2c1nc(C)c(CCN1CCC(CC1)c1noc3cc(F)ccc13)c2=O	ZZQNEJILGNNOEP-UHFFFAOYSA-N	Preclinical
ochromycinone	STAT inhibitor	STAT3			C[C@@H]1CC(=O)c2c(C1)ccc1C(=O)c3c(O)cccc3C(=O)c21	ZAWXOCUFQSQDJS-VIFPVBQESA-N	Phase 1
ocinaplon	GABA receptor modulator	GABRA1, GABRA2, GABRA3, GABRA5			O=C(c1cnn2c(ccnc12)-c1ccncc1)c1ccccn1	OQJFBUOFGHPMSR-UHFFFAOYSA-N	Phase 3
OCO-1112	cholesterol inhibitor				CC(C)c1ccc(cc1)C(=O)NCCOc1ccc(cc1)C(O)=O, CC(C)c1ccc(cc1)C(=O)NCCOc1ccc(cc1)C(O)=O, CC(C)c1ccc(cc1)C(=O)NCCOc1ccc(cc1)C(O)=O, CC(C)c1ccc(cc1)C(=O)NCCOc1ccc(cc1)C(O)=O, CC(C)c1ccc(cc1)C(=O)NCCOc1ccc(cc1)C(O)=O	ODLDHXPJRGNTPC-UHFFFAOYSA-N, ODLDHXPJRGNTPC-UHFFFAOYSA-N, ODLDHXPJRGNTPC-UHFFFAOYSA-N, ODLDHXPJRGNTPC-UHFFFAOYSA-N, ODLDHXPJRGNTPC-UHFFFAOYSA-N	Phase 2
octadecan-1-ol					CCCCCCCCCCCCCCCCCCO	GLDOVTGHNKAZLK-UHFFFAOYSA-N	Preclinical
octamethyltrisiloxane					C[Si](C)(C)O[Si](C)(C)O[Si](C)(C)C	CXQXSVUQTKDNFP-UHFFFAOYSA-N	Preclinical
octenidine	membrane integrity inhibitor		infectious disease	gram-negative bacterial infections, gram-positive bacterial infections	CCCCCCCCN=c1ccn(CCCCCCCCCCn2ccc(cc2)=NCCCCCCCC)cc1, CCCCCCCCN=c1ccn(CCCCCCCCCCn2ccc(cc2)=NCCCCCCCC)cc1, CCCCCCCCN=c1ccn(CCCCCCCCCCn2ccc(cc2)=NCCCCCCCC)cc1, CCCCCCCCN=c1ccn(CCCCCCCCCCn2ccc(cc2)=NCCCCCCCC)cc1, CCCCCCCCN=c1ccn(CCCCCCCCCCn2ccc(cc2)=NCCCCCCCC)cc1, CCCCCCCCN=c1ccn(CCCCCCCCCCn2ccc(cc2)=NCCCCCCCC)cc1, CCCCCCCCN=c1ccn(CCCCCCCCCCn2ccc(cc2)=NCCCCCCCC)cc1, CCCCCCCCN=c1ccn(CCCCCCCCCCn2ccc(cc2)=NCCCCCCCC)cc1	ZVXNYZWXUADSRV-UHFFFAOYSA-N, ZVXNYZWXUADSRV-UHFFFAOYSA-N, ZVXNYZWXUADSRV-UHFFFAOYSA-N, ZVXNYZWXUADSRV-UHFFFAOYSA-N, ZVXNYZWXUADSRV-UHFFFAOYSA-N, ZVXNYZWXUADSRV-UHFFFAOYSA-N, ZVXNYZWXUADSRV-UHFFFAOYSA-N, ZVXNYZWXUADSRV-UHFFFAOYSA-N	Launched
octinoxate			dermatology	sunscreen lotion	CCCC[C@@H](CC)COC(=O)\C=C\c1ccc(OC)cc1 |&1:4|	YBGZDTIWKVFICR-NRMKIYEFSA-N	Launched
octisalate			dermatology	sunscreen lotion	CCCC[C@@H](CC)COC(=O)c1ccccc1O |&1:4|	FMRHJJZUHUTGKE-GFCCVEGCSA-N	Launched
octocrylene			dermatology	sunscreen lotion	CCCC[C@@H](CC)COC(=O)C(C#N)=C(c1ccccc1)c1ccccc1 |&1:4|	FMJSMJQBSVNSBF-LJQANCHMSA-N	Launched
octodrine	antitumor agent				CC(C)CCC[C@@H](C)N |&1:6,r|, CC(C)CCC[C@@H](C)N |&1:6,r|	QNIVIMYXGGFTAK-MRVPVSSYSA-N, QNIVIMYXGGFTAK-MRVPVSSYSA-N	Preclinical
octopamine	trace amine associated receptor agonist	F10, TAAR1			NCC(O)c1ccc(O)cc1, NCC(O)c1ccc(O)cc1, NCC(O)c1ccc(O)cc1, NCC(O)c1ccc(O)cc1, NCC(O)c1ccc(O)cc1	QHGUCRYDKWKLMG-UHFFFAOYSA-N, QHGUCRYDKWKLMG-UHFFFAOYSA-N, QHGUCRYDKWKLMG-UHFFFAOYSA-N, QHGUCRYDKWKLMG-UHFFFAOYSA-N, QHGUCRYDKWKLMG-UHFFFAOYSA-N	Preclinical
octreotide	somatostatin receptor agonist	SSTR2, SSTR3, SSTR5	gastroenterology, endocrinology, oncology	diarrhea, acromegaly, carcinoid tumors	C[C@@H](O)[C@@H](CO)NC(=O)[C@H]1CSSC[C@@H](NC(=O)[C@@H](N)Cc2ccccc2)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](Cc2c[nH]c3ccccc23)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 |&1:1,&2:3,&3:9,&4:14,&5:18,&6:30,&7:41,&8:55,&9:64,&10:65|, C[C@@H](O)[C@@H](CO)NC(=O)[C@H]1CSSC[C@@H](NC(=O)[C@@H](N)Cc2ccccc2)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](Cc2c[nH]c3ccccc23)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 |&1:1,&2:3,&3:9,&4:14,&5:18,&6:30,&7:41,&8:55,&9:64,&10:65|, C[C@@H](O)[C@@H](CO)NC(=O)[C@H]1CSSC[C@@H](NC(=O)[C@@H](N)Cc2ccccc2)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](Cc2c[nH]c3ccccc23)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 |&1:1,&2:3,&3:9,&4:14,&5:18,&6:30,&7:41,&8:55,&9:64,&10:65|	DEQANNDTNATYII-KWPKQMLXSA-N, DEQANNDTNATYII-KWPKQMLXSA-N, DEQANNDTNATYII-KWPKQMLXSA-N	Launched
OC000459	CRTH receptor antagonist	PTGDR2			Cc1c(Cc2ccc3ccccc3n2)c2cc(F)ccc2n1CC(O)=O, Cc1c(Cc2ccc3ccccc3n2)c2cc(F)ccc2n1CC(O)=O, Cc1c(Cc2ccc3ccccc3n2)c2cc(F)ccc2n1CC(O)=O	FATGTHLOZSXOBC-UHFFFAOYSA-N, FATGTHLOZSXOBC-UHFFFAOYSA-N, FATGTHLOZSXOBC-UHFFFAOYSA-N	Phase 2
odanacatib	cathepsin inhibitor	CTSK			CC(C)(F)C[C@H](N[C@@H](c1ccc(cc1)-c1ccc(cc1)S(C)(=O)=O)C(F)(F)F)C(=O)NC1(CC1)C#N, CC(C)(F)C[C@H](N[C@@H](c1ccc(cc1)-c1ccc(cc1)S(C)(=O)=O)C(F)(F)F)C(=O)NC1(CC1)C#N, CC(C)(F)C[C@H](N[C@@H](c1ccc(cc1)-c1ccc(cc1)S(C)(=O)=O)C(F)(F)F)C(=O)NC1(CC1)C#N, CC(C)(F)C[C@H](N[C@@H](c1ccc(cc1)-c1ccc(cc1)S(C)(=O)=O)C(F)(F)F)C(=O)NC1(CC1)C#N	FWIVDMJALNEADT-SFTDATJTSA-N, FWIVDMJALNEADT-SFTDATJTSA-N, FWIVDMJALNEADT-SFTDATJTSA-N, FWIVDMJALNEADT-SFTDATJTSA-N	Phase 3
ODQ	guanylyl cyclase inhibitor	GUCY1A2, GUCY1A3, GUCY1B3			O=c1onc2cnc3ccccc3n12, O=c1onc2cnc3ccccc3n12	LZMHWZHOZLVYDL-UHFFFAOYSA-N, LZMHWZHOZLVYDL-UHFFFAOYSA-N	Preclinical
OF-1	bromodomain inhibitor	BRD1			COc1cc2n(C)c(=O)n(C)c2cc1NS(=O)(=O)c1ccc(Br)cc1C, COc1cc2n(C)c(=O)n(C)c2cc1NS(=O)(=O)c1ccc(Br)cc1C	YUNQZQREIHWDQT-UHFFFAOYSA-N, YUNQZQREIHWDQT-UHFFFAOYSA-N	Preclinical
ofloxacin	bacterial DNA gyrase inhibitor		infectious disease, otolaryngology, gastroenterology, endocrinology	respiratory tract infections, sinusitis, skin infections, bone and joint infections, intra-abdominal infections, diarrhea, fever, urinary tract infections	C[C@H]1COc2c(N3CCN(C)CC3)c(F)cc3c2n1cc(C(O)=O)c3=O |&1:1|	GSDSWSVVBLHKDQ-JTQLQIEISA-N	Launched
OG-L002	histone lysine demethylase inhibitor	KDM1A			N[C@H]1C[C@@H]1c1ccc(cc1)-c1cccc(O)c1, N[C@H]1C[C@@H]1c1ccc(cc1)-c1cccc(O)c1, N[C@H]1C[C@@H]1c1ccc(cc1)-c1cccc(O)c1, N[C@H]1C[C@@H]1c1ccc(cc1)-c1cccc(O)c1, N[C@H]1C[C@@H]1c1ccc(cc1)-c1cccc(O)c1, N[C@H]1C[C@@H]1c1ccc(cc1)-c1cccc(O)c1	DSOJSZXQRJGBCW-CABCVRRESA-N, DSOJSZXQRJGBCW-CABCVRRESA-N, DSOJSZXQRJGBCW-CABCVRRESA-N, DSOJSZXQRJGBCW-CABCVRRESA-N, DSOJSZXQRJGBCW-CABCVRRESA-N, DSOJSZXQRJGBCW-CABCVRRESA-N	Preclinical
ogerin	G protein-coupled receptor modulator				Nc1nc(NCc2ccccc2)nc(n1)-c1ccccc1CO	MDGIEDNDSFMSLP-UHFFFAOYSA-N	Preclinical
oglemilast	phosphodiesterase inhibitor				CS(=O)(=O)Nc1ccc2oc3c(OC(F)F)ccc(C(=O)Nc4c(Cl)cncc4Cl)c3c2c1, CS(=O)(=O)Nc1ccc2oc3c(OC(F)F)ccc(C(=O)Nc4c(Cl)cncc4Cl)c3c2c1, CS(=O)(=O)Nc1ccc2oc3c(OC(F)F)ccc(C(=O)Nc4c(Cl)cncc4Cl)c3c2c1, CS(=O)(=O)Nc1ccc2oc3c(OC(F)F)ccc(C(=O)Nc4c(Cl)cncc4Cl)c3c2c1, CS(=O)(=O)Nc1ccc2oc3c(OC(F)F)ccc(C(=O)Nc4c(Cl)cncc4Cl)c3c2c1, CS(=O)(=O)Nc1ccc2oc3c(OC(F)F)ccc(C(=O)Nc4c(Cl)cncc4Cl)c3c2c1	OKFDRAHPFKMAJH-UHFFFAOYSA-N, OKFDRAHPFKMAJH-UHFFFAOYSA-N, OKFDRAHPFKMAJH-UHFFFAOYSA-N, OKFDRAHPFKMAJH-UHFFFAOYSA-N, OKFDRAHPFKMAJH-UHFFFAOYSA-N, OKFDRAHPFKMAJH-UHFFFAOYSA-N	Phase 2
oglufanide	VEGF antagonist				N[C@@H](CCC(O)=O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(O)=O	LLEUXCDZPQOJMY-AAEUAGOBSA-N	Phase 2
OICR-9429	WDR5/MLL interaction inhibitor	WDR5			CN1CCN(CC1)c1ccc(cc1NC(=O)c1c[nH]c(=O)cc1C(F)(F)F)-c1cccc(CN2CCOCC2)c1, CN1CCN(CC1)c1ccc(cc1NC(=O)c1c[nH]c(=O)cc1C(F)(F)F)-c1cccc(CN2CCOCC2)c1	DJOVLOYCGXNVPI-UHFFFAOYSA-N, DJOVLOYCGXNVPI-UHFFFAOYSA-N	Preclinical
olanzapine	dopamine receptor antagonist, serotonin receptor antagonist	ADRA1A, ADRA1B, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, DRD1, DRD2, DRD3, DRD4, DRD5, GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, HRH1, HRH2, HRH4, HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2B, HTR2C, HTR3A, HTR5A, HTR6, HTR7	neurology/psychiatry	schizophrenia, bipolar disorder	CN1CCN(CC1)C1=Nc2ccccc2Nc2sc(C)cc12 |t:8|, CN1CCN(CC1)C1=Nc2ccccc2Nc2sc(C)cc12 |t:8|, CN1CCN(CC1)C1=Nc2ccccc2Nc2sc(C)cc12 |t:8|, CN1CCN(CC1)C1=Nc2ccccc2Nc2sc(C)cc12 |t:8|, CN1CCN(CC1)C1=Nc2ccccc2Nc2sc(C)cc12 |t:8|	KVWDHTXUZHCGIO-UHFFFAOYSA-N, KVWDHTXUZHCGIO-UHFFFAOYSA-N, KVWDHTXUZHCGIO-UHFFFAOYSA-N, KVWDHTXUZHCGIO-UHFFFAOYSA-N, KVWDHTXUZHCGIO-UHFFFAOYSA-N	Launched
olaparib	PARP inhibitor	PARP1, PARP2	oncology	ovarian cancer	Fc1ccc(Cc2n[nH]c(=O)c3ccccc23)cc1C(=O)N1CCN(CC1)C(=O)C1CC1, Fc1ccc(Cc2n[nH]c(=O)c3ccccc23)cc1C(=O)N1CCN(CC1)C(=O)C1CC1, Fc1ccc(Cc2n[nH]c(=O)c3ccccc23)cc1C(=O)N1CCN(CC1)C(=O)C1CC1, Fc1ccc(Cc2n[nH]c(=O)c3ccccc23)cc1C(=O)N1CCN(CC1)C(=O)C1CC1, Fc1ccc(Cc2n[nH]c(=O)c3ccccc23)cc1C(=O)N1CCN(CC1)C(=O)C1CC1	FDLYAMZZIXQODN-UHFFFAOYSA-N, FDLYAMZZIXQODN-UHFFFAOYSA-N, FDLYAMZZIXQODN-UHFFFAOYSA-N, FDLYAMZZIXQODN-UHFFFAOYSA-N, FDLYAMZZIXQODN-UHFFFAOYSA-N	Launched
OLDA	TRPV agonist	GPR119			CCCCCCCC\C=C/CCCCCCCC(=O)NCCc1ccc(O)c(O)c1, CCCCCCCC\C=C/CCCCCCCC(=O)NCCc1ccc(O)c(O)c1, CCCCCCCC\C=C/CCCCCCCC(=O)NCCc1ccc(O)c(O)c1, CCCCCCCC\C=C/CCCCCCCC(=O)NCCc1ccc(O)c(O)c1, CCCCCCCC\C=C/CCCCCCCC(=O)NCCc1ccc(O)c(O)c1, CCCCCCCC\C=C/CCCCCCCC(=O)NCCc1ccc(O)c(O)c1	QQBPLXNESPTPNU-KTKRTIGZSA-N, QQBPLXNESPTPNU-KTKRTIGZSA-N, QQBPLXNESPTPNU-KTKRTIGZSA-N, QQBPLXNESPTPNU-KTKRTIGZSA-N, QQBPLXNESPTPNU-KTKRTIGZSA-N, QQBPLXNESPTPNU-KTKRTIGZSA-N	Preclinical
oleamide	cannabinoid receptor agonist	HTR7, PLA2G2A			CCCCCCCC\C=C/CCCCCCCC(N)=O, CCCCCCCC\C=C/CCCCCCCC(N)=O, CCCCCCCC\C=C/CCCCCCCC(N)=O	FATBGEAMYMYZAF-KTKRTIGZSA-N, FATBGEAMYMYZAF-KTKRTIGZSA-N, FATBGEAMYMYZAF-KTKRTIGZSA-N	Preclinical
oleandrin	Na/K-ATPase inhibitor				CO[C@H]1C[C@H](O[C@H]2CC[C@@]3(C)[C@H](CC[C@@H]4[C@@H]3CC[C@]3(C)[C@H]([C@H](C[C@]43O)OC(C)=O)C3=CC(=O)OC3)C2)O[C@@H](C)[C@@H]1O |t:32|, CO[C@H]1C[C@H](O[C@H]2CC[C@@]3(C)[C@H](CC[C@@H]4[C@@H]3CC[C@]3(C)[C@H]([C@H](C[C@]43O)OC(C)=O)C3=CC(=O)OC3)C2)O[C@@H](C)[C@@H]1O |t:32|, CO[C@H]1C[C@H](O[C@H]2CC[C@@]3(C)[C@H](CC[C@@H]4[C@@H]3CC[C@]3(C)[C@H]([C@H](C[C@]43O)OC(C)=O)C3=CC(=O)OC3)C2)O[C@@H](C)[C@@H]1O |t:32|	JLPDBLFIVFSOCC-XYXFTTADSA-N, JLPDBLFIVFSOCC-XYXFTTADSA-N, JLPDBLFIVFSOCC-XYXFTTADSA-N	Phase 1
oleanolic-acid	G protein-coupled receptor agonist	GPBAR1			CC1(C)CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]2C1)C(O)=O |c:10|, CC1(C)CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]2C1)C(O)=O |c:10|, CC1(C)CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]2C1)C(O)=O |c:10|	MIJYXULNPSFWEK-GTOFXWBISA-N, MIJYXULNPSFWEK-GTOFXWBISA-N, MIJYXULNPSFWEK-GTOFXWBISA-N	Preclinical
oleoylethanolamide	cannabinoid receptor agonist, glucose dependent insulinotropic receptor agonist, potassium channel blocker, PPAR receptor agonist	CNR1, GPR119, GPR55, PPARA			CCCCCCCC\C=C/CCCCCCCC(=O)NCCO, CCCCCCCC\C=C/CCCCCCCC(=O)NCCO	BOWVQLFMWHZBEF-KTKRTIGZSA-N, BOWVQLFMWHZBEF-KTKRTIGZSA-N	Preclinical
olesoxime	apoptosis stimulant				CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CCC4=C\C(CC[C@]4(C)[C@H]3CC[C@]12C)=N\O |t:15|, CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CCC4=C\C(CC[C@]4(C)[C@H]3CC[C@]12C)=N\O |t:15|	QNTASHOAVRSLMD-SIWSWZRQSA-N, QNTASHOAVRSLMD-SIWSWZRQSA-N	Phase 2/Phase 3
oleuropein	estrogen receptor agonist	GPER1			COC(=O)C1=CO[C@@H](O[C@H]2O[C@@H](CO)[C@@H](O)[C@@H](O)[C@@H]2O)\C(=C/C)[C@@H]1CC(=O)OCCc1ccc(O)c(O)c1 |&1:7,&2:9,&3:11,&4:14,&5:16,&6:18,&7:23,r,t:4|	RFWGABANNQMHMZ-JIBQERFGSA-N	Phase 2
oligomycin-A	ATP synthase inhibitor, ATPase inhibitor	ATP5A1			[H][C@]12CC[C@@H](CC)\C=C\C=C\C[C@@H](C)[C@H](O)[C@@](C)(O)C(=O)[C@@H](C)[C@H](O)[C@@H](C)C(=O)[C@@H](C)[C@H](O)[C@@H](C)\C=C\C(=O)O[C@]([H])([C@@H]1C)[C@H](C)[C@@]1(CC[C@H](C)[C@H](C[C@@H](C)O)O1)O2 |t:7,9,35|	MNULEGDCPYONBU-BGLGBHOCSA-N	Preclinical
olmesartan	angiotensin receptor antagonist	AGTR1	cardiology	hypertension	CCCc1nc(c(C(O)=O)n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1)C(C)(C)O, CCCc1nc(c(C(O)=O)n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1)C(C)(C)O, CCCc1nc(c(C(O)=O)n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1)C(C)(C)O, CCCc1nc(c(C(O)=O)n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1)C(C)(C)O, CCCc1nc(c(C(O)=O)n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1)C(C)(C)O	VTRAEEWXHOVJFV-UHFFFAOYSA-N, VTRAEEWXHOVJFV-UHFFFAOYSA-N, VTRAEEWXHOVJFV-UHFFFAOYSA-N, VTRAEEWXHOVJFV-UHFFFAOYSA-N, VTRAEEWXHOVJFV-UHFFFAOYSA-N	Launched
olmesartan-medoxomil	angiotensin receptor antagonist	AGTR1	cardiology	hypertension	CCCc1nc(c(C(=O)OCc2oc(=O)oc2C)n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1)C(C)(C)O, CCCc1nc(c(C(=O)OCc2oc(=O)oc2C)n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1)C(C)(C)O, CCCc1nc(c(C(=O)OCc2oc(=O)oc2C)n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1)C(C)(C)O, CCCc1nc(c(C(=O)OCc2oc(=O)oc2C)n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1)C(C)(C)O, CCCc1nc(c(C(=O)OCc2oc(=O)oc2C)n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1)C(C)(C)O, CCCc1nc(c(C(=O)OCc2oc(=O)oc2C)n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1)C(C)(C)O	UQGKUQLKSCSZGY-UHFFFAOYSA-N, UQGKUQLKSCSZGY-UHFFFAOYSA-N, UQGKUQLKSCSZGY-UHFFFAOYSA-N, UQGKUQLKSCSZGY-UHFFFAOYSA-N, UQGKUQLKSCSZGY-UHFFFAOYSA-N, UQGKUQLKSCSZGY-UHFFFAOYSA-N	Launched
olmutinib	Bruton's tyrosine kinase (BTK) inhibitor, EGFR inhibitor	BTK, EGFR	oncology	non-small cell lung cancer (NSCLC)	CN1CCN(CC1)c1ccc(Nc2nc(Oc3cccc(NC(=O)C=C)c3)c3sccc3n2)cc1, CN1CCN(CC1)c1ccc(Nc2nc(Oc3cccc(NC(=O)C=C)c3)c3sccc3n2)cc1, CN1CCN(CC1)c1ccc(Nc2nc(Oc3cccc(NC(=O)C=C)c3)c3sccc3n2)cc1, CN1CCN(CC1)c1ccc(Nc2nc(Oc3cccc(NC(=O)C=C)c3)c3sccc3n2)cc1	FDMQDKQUTRLUBU-UHFFFAOYSA-N, FDMQDKQUTRLUBU-UHFFFAOYSA-N, FDMQDKQUTRLUBU-UHFFFAOYSA-N, FDMQDKQUTRLUBU-UHFFFAOYSA-N	Launched
olodanrigan	angiotensin antagonist				COc1ccc2CN([C@@H](Cc2c1OCc1ccccc1)C(O)=O)C(=O)C(c1ccccc1)c1ccccc1	GHBCIXGRCZIPNQ-MHZLTWQESA-N	Phase 2
olomoucine	CDK inhibitor	CDK1, CDK2, CDK5, MAPK1			Cn1cnc2c(NCc3ccccc3)nc(NCCO)nc12, Cn1cnc2c(NCc3ccccc3)nc(NCCO)nc12	GTVPOLSIJWJJNY-UHFFFAOYSA-N, GTVPOLSIJWJJNY-UHFFFAOYSA-N	Preclinical
olopatadine	histamine receptor antagonist	HRH1, S100A1, S100A12, S100A13, S100A2, S100B	ophthalmology	conjunctivitis	CN(C)CC\C=C1\c2ccccc2COc2ccc(CC(O)=O)cc12, CN(C)CC\C=C1\c2ccccc2COc2ccc(CC(O)=O)cc12, CN(C)CC\C=C1\c2ccccc2COc2ccc(CC(O)=O)cc12	JBIMVDZLSHOPLA-LSCVHKIXSA-N, JBIMVDZLSHOPLA-LSCVHKIXSA-N, JBIMVDZLSHOPLA-LSCVHKIXSA-N	Launched
olprinone	phosphodiesterase inhibitor	PDE3A	cardiology	congestive heart failure	Cc1[nH]c(=O)c(cc1-c1ccc2nccn2c1)C#N, Cc1[nH]c(=O)c(cc1-c1ccc2nccn2c1)C#N, Cc1[nH]c(=O)c(cc1-c1ccc2nccn2c1)C#N	JPAWFIIYTJQOKW-UHFFFAOYSA-N, JPAWFIIYTJQOKW-UHFFFAOYSA-N, JPAWFIIYTJQOKW-UHFFFAOYSA-N	Launched
olsalazine	cyclooxygenase inhibitor	IFNG, TPMT	gastroenterology	ulcerative colitis	OC(=O)c1cc(ccc1O)\N=N\c1ccc(O)c(c1)C(O)=O, OC(=O)c1cc(ccc1O)\N=N\c1ccc(O)c(c1)C(O)=O, OC(=O)c1cc(ccc1O)\N=N\c1ccc(O)c(c1)C(O)=O	QQBDLJCYGRGAKP-FOCLMDBBSA-N, QQBDLJCYGRGAKP-FOCLMDBBSA-N, QQBDLJCYGRGAKP-FOCLMDBBSA-N	Launched
oltipraz	nuclear factor erythroid derived, like (NRF2) activator	ANG			Cc1c(ssc1=S)-c1cnccn1, Cc1c(ssc1=S)-c1cnccn1, Cc1c(ssc1=S)-c1cnccn1, Cc1c(ssc1=S)-c1cnccn1, Cc1c(ssc1=S)-c1cnccn1	CKNAQFVBEHDJQV-UHFFFAOYSA-N, CKNAQFVBEHDJQV-UHFFFAOYSA-N, CKNAQFVBEHDJQV-UHFFFAOYSA-N, CKNAQFVBEHDJQV-UHFFFAOYSA-N, CKNAQFVBEHDJQV-UHFFFAOYSA-N	Phase 3
olumacostat-glasaretil	acetyl-CoA carboxylase inhibitor				CCCCCCCCCCCCCCOc1ccc(o1)C(=O)OCC(=O)N(C)CC(=O)OCC	FYJLDICZGDFWKP-UHFFFAOYSA-N	Phase 3
olvanil	TRPV agonist	CNR1, GPR119, TRPV1			CCCCCCCC\C=C/CCCCCCCC(=O)NCc1ccc(O)c(OC)c1, CCCCCCCC\C=C/CCCCCCCC(=O)NCc1ccc(O)c(OC)c1, CCCCCCCC\C=C/CCCCCCCC(=O)NCc1ccc(O)c(OC)c1, CCCCCCCC\C=C/CCCCCCCC(=O)NCc1ccc(O)c(OC)c1, CCCCCCCC\C=C/CCCCCCCC(=O)NCc1ccc(O)c(OC)c1, CCCCCCCC\C=C/CCCCCCCC(=O)NCc1ccc(O)c(OC)c1	OPZKBPQVWDSATI-KHPPLWFESA-N, OPZKBPQVWDSATI-KHPPLWFESA-N, OPZKBPQVWDSATI-KHPPLWFESA-N, OPZKBPQVWDSATI-KHPPLWFESA-N, OPZKBPQVWDSATI-KHPPLWFESA-N, OPZKBPQVWDSATI-KHPPLWFESA-N	Preclinical
omadacycline	bacterial 30S ribosomal subunit inhibitor		infectious disease	pneumonia	[H][C@@]12Cc3c(cc(CNCC(C)(C)C)c(O)c3C(=O)[C@H]1C(=O)[C@]1(O)C(=O)[C@@H](C(N)=O)C(=O)[C@@H](N(C)C)[C@]1([H])C2)N(C)C |&1:26,&2:19|	OVIWLBQFYMOVOF-NXSZOOMBSA-N	Launched
omapatrilat	metalloproteinase inhibitor	ACE, MME			[H][C@]12CCC[C@H](N1C(=O)[C@H](CCS2)NC(=O)[C@@H](S)Cc1ccccc1)C(O)=O	LVRLSYPNFFBYCZ-VGWMRTNUSA-N	Preclinical
omarigliptin	dipeptidyl peptidase inhibitor	DPP4	endocrinology	diabetes mellitus	CS(=O)(=O)n1cc2CN(Cc2n1)[C@H]1CO[C@@H]([C@@H](N)C1)c1cc(F)ccc1F, CS(=O)(=O)n1cc2CN(Cc2n1)[C@H]1CO[C@@H]([C@@H](N)C1)c1cc(F)ccc1F, CS(=O)(=O)n1cc2CN(Cc2n1)[C@H]1CO[C@@H]([C@@H](N)C1)c1cc(F)ccc1F, CS(=O)(=O)n1cc2CN(Cc2n1)[C@H]1CO[C@@H]([C@@H](N)C1)c1cc(F)ccc1F	MKMPWKUAHLTIBJ-ISTRZQFTSA-N, MKMPWKUAHLTIBJ-ISTRZQFTSA-N, MKMPWKUAHLTIBJ-ISTRZQFTSA-N, MKMPWKUAHLTIBJ-ISTRZQFTSA-N	Launched
ombitasvir	HCV inhibitor		infectious disease	hepatitis C	COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)Nc1ccc(cc1)[C@@H]1CC[C@H](N1c1ccc(cc1)C(C)(C)C)c1ccc(NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)OC)C(C)C)cc1, COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)Nc1ccc(cc1)[C@@H]1CC[C@H](N1c1ccc(cc1)C(C)(C)C)c1ccc(NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)OC)C(C)C)cc1	PIDFDZJZLOTZTM-KHVQSSSXSA-N, PIDFDZJZLOTZTM-KHVQSSSXSA-N	Launched
ombrabulin	tubulin polymerization inhibitor				COc1ccc(\C=C/c2cc(OC)c(OC)c(OC)c2)cc1NC(=O)[C@@H](N)CO	IXWNTLSTOZFSCM-YVACAVLKSA-N	Phase 3
OMDM-2	FAAH inhibitor	GPR119			CCCCCCCC\C=C/CCCCCCCC(=O)N[C@@H](CO)Cc1ccc(O)cc1, CCCCCCCC\C=C/CCCCCCCC(=O)N[C@@H](CO)Cc1ccc(O)cc1, CCCCCCCC\C=C/CCCCCCCC(=O)N[C@@H](CO)Cc1ccc(O)cc1	ICDMLAQPOAVWNH-HAAQQRBASA-N, ICDMLAQPOAVWNH-HAAQQRBASA-N, ICDMLAQPOAVWNH-HAAQQRBASA-N	Preclinical
omecamtiv-mecarbil	cardiac myosin activator	MYBPC3			COC(=O)N1CCN(Cc2cccc(NC(=O)Nc3ccc(C)nc3)c2F)CC1, COC(=O)N1CCN(Cc2cccc(NC(=O)Nc3ccc(C)nc3)c2F)CC1, COC(=O)N1CCN(Cc2cccc(NC(=O)Nc3ccc(C)nc3)c2F)CC1	RFUBTTPMWSKEIW-UHFFFAOYSA-N, RFUBTTPMWSKEIW-UHFFFAOYSA-N, RFUBTTPMWSKEIW-UHFFFAOYSA-N	Phase 3
omega-(4-iodophenyl)pentadecanoic-acid					OC(=O)CCCCCCCCCCCCCCc1ccc(I)cc1	YAONEUNUMVOKNQ-UHFFFAOYSA-N	Preclinical
omega-3-acid-esters	cholesterol inhibitor				CCOC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CC, CCOC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CC, CCOC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CC, CCOC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CC	SSQPWTVBQMWLSZ-AAQCHOMXSA-N, SSQPWTVBQMWLSZ-AAQCHOMXSA-N, SSQPWTVBQMWLSZ-AAQCHOMXSA-N, SSQPWTVBQMWLSZ-AAQCHOMXSA-N	Launched
omeprazole	ATPase inhibitor	ATP4A, CLCN2	gastroenterology	heartburn	COc1ccc2nc([nH]c2c1)[S@@](=O)Cc1ncc(C)c(OC)c1C |r|, COc1ccc2nc([nH]c2c1)[S@@](=O)Cc1ncc(C)c(OC)c1C |r|, COc1ccc2nc([nH]c2c1)[S@@](=O)Cc1ncc(C)c(OC)c1C |r|, COc1ccc2nc([nH]c2c1)[S@@](=O)Cc1ncc(C)c(OC)c1C |r|	SUBDBMMJDZJVOS-DEOSSOPVSA-N, SUBDBMMJDZJVOS-DEOSSOPVSA-N, SUBDBMMJDZJVOS-DEOSSOPVSA-N, SUBDBMMJDZJVOS-DEOSSOPVSA-N	Launched
omeprazole-magnesium	proton pump inhibitor	ATP4A, ATP4B	gastroenterology	gastroesophageal reflux disease (GERD), heartburn	COc1ccc2n([Mg]n3c(nc4cc(OC)ccc34)[S@@](=O)Cc3ncc(C)c(OC)c3C)c(nc2c1)[S@@](=O)Cc1ncc(C)c(OC)c1C |r|	KWORUUGOSLYAGD-YPPDDXJESA-N	Launched
omeprazole-sulfide	ATPase inhibitor				COc1ccc2nc(SCc3ncc(C)c(OC)c3C)[nH]c2c1	XURCIPRUUASYLR-UHFFFAOYSA-N	Phase 1
omtriptolide	ERK1 and ERK2 phosphorylation inhibitor				[H][C@@]12C[C@@H]3O[C@@]33[C@H](OC(=O)CCC(O)=O)[C@]4(O[C@H]4[C@@H]4O[C@]34[C@@]1(C)CCC1=C2COC1=O)C(C)C |c:30|	HROMYAWHLUOUPY-AHCCQAQQSA-N	Preclinical
ON-01500	apoptosis stimulant				COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(N)c2)c(OC)c1, COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(N)c2)c(OC)c1	KUTAVMCJCVADGZ-BQYQJAHWSA-N, KUTAVMCJCVADGZ-BQYQJAHWSA-N	Preclinical
oncrasin-1	apoptosis stimulant				Clc1ccc(Cn2cc(C=O)c3ccccc23)cc1, Clc1ccc(Cn2cc(C=O)c3ccccc23)cc1, Clc1ccc(Cn2cc(C=O)c3ccccc23)cc1, Clc1ccc(Cn2cc(C=O)c3ccccc23)cc1, Clc1ccc(Cn2cc(C=O)c3ccccc23)cc1, Clc1ccc(Cn2cc(C=O)c3ccccc23)cc1, Clc1ccc(Cn2cc(C=O)c3ccccc23)cc1	ZDRQMXCSSAPUMM-UHFFFAOYSA-N, ZDRQMXCSSAPUMM-UHFFFAOYSA-N, ZDRQMXCSSAPUMM-UHFFFAOYSA-N, ZDRQMXCSSAPUMM-UHFFFAOYSA-N, ZDRQMXCSSAPUMM-UHFFFAOYSA-N, ZDRQMXCSSAPUMM-UHFFFAOYSA-N, InChI=1S/C16H12ClNO/c17-14-7-5-12(6-8-14)9-18-10-13(11-19)15-3-1-2-4-16(15)18/h1-8,10-11H,9H2	Preclinical
ONC201	AKT inhibitor, MAP kinase inhibitor	TNFSF10			Cc1ccccc1CN1C2=NCCN2C2=C(CN(Cc3ccccc3)CC2)C1=O |t:10,16|, Cc1ccccc1CN1C2=NCCN2C2=C(CN(Cc3ccccc3)CC2)C1=O |t:10,16|, Cc1ccccc1CN1C2=NCCN2C2=C(CN(Cc3ccccc3)CC2)C1=O |t:10,16|, Cc1ccccc1CN1C2=NCCN2C2=C(CN(Cc3ccccc3)CC2)C1=O |t:10,16|	VLULRUCCHYVXOH-UHFFFAOYSA-N, VLULRUCCHYVXOH-UHFFFAOYSA-N, VLULRUCCHYVXOH-UHFFFAOYSA-N, VLULRUCCHYVXOH-UHFFFAOYSA-N	Phase 2
ondansetron	serotonin receptor antagonist	HTR3A, HTR3B	gastroenterology	nausea, vomiting	Cc1nccn1C[C@H]1CCc2c(C1=O)c1ccccc1n2C |r|, Cc1nccn1C[C@H]1CCc2c(C1=O)c1ccccc1n2C |r|	FELGMEQIXOGIFQ-CYBMUJFWSA-N, FELGMEQIXOGIFQ-CYBMUJFWSA-N	Launched
ONO-AE3-208	prostanoid receptor antagonist	PTGER4			C[C@@H](C(=O)Nc1cc(ccc1CCCC(O)=O)C#N)c1ccc(F)c2ccccc12 |&1:1,r|, C[C@@H](C(=O)Nc1cc(ccc1CCCC(O)=O)C#N)c1ccc(F)c2ccccc12 |&1:1,r|	MTDIMKNAJUQTIO-OAHLLOKOSA-N, MTDIMKNAJUQTIO-OAHLLOKOSA-N	Preclinical
ONO-4059	Bruton's tyrosine kinase (BTK) inhibitor	BTK			CC#CC(=O)N1CC[C@H](C1)n1c2ncnc(N)c2n(-c2ccc(Oc3ccccc3)cc2)c1=O, CC#CC(=O)N1CC[C@H](C1)n1c2ncnc(N)c2n(-c2ccc(Oc3ccccc3)cc2)c1=O	SEJLPXCPMNSRAM-GOSISDBHSA-N, SEJLPXCPMNSRAM-GOSISDBHSA-N	Phase 1
ONO-4817	matrix metalloprotease inhibitor	MMP8			CCOCOC[C@H](C[C@H](C)C(=O)NO)NC(=O)c1ccc(Oc2ccccc2)cc1, CCOCOC[C@H](C[C@H](C)C(=O)NO)NC(=O)c1ccc(Oc2ccccc2)cc1, CCOCOC[C@H](C[C@H](C)C(=O)NO)NC(=O)c1ccc(Oc2ccccc2)cc1	HDWWQELUBWGQGA-WMZOPIPTSA-N, HDWWQELUBWGQGA-WMZOPIPTSA-N, HDWWQELUBWGQGA-WMZOPIPTSA-N	Phase 1
ONO-8130	prostanoid receptor antagonist	PTGER1			CC(C)CN(c1cc2CCCc2cc1OCc1ccc(cc1)C(O)=O)S(=O)(=O)c1nc(C)cs1, CC(C)CN(c1cc2CCCc2cc1OCc1ccc(cc1)C(O)=O)S(=O)(=O)c1nc(C)cs1	IOXMDBQCUCDLAF-UHFFFAOYSA-N, IOXMDBQCUCDLAF-UHFFFAOYSA-N	Preclinical
ONX-0914	proteasome inhibitor				COc1ccc(C[C@H](NC(=O)[C@H](C)NC(=O)CN2CCOCC2)C(=O)N[C@@H](Cc2ccccc2)C(=O)[C@@]2(C)CO2)cc1	WQAVPPWWLLVGFK-VTNASVEKSA-N	Preclinical
ON123300	CDK inhibitor	CDK4, NUAK1, PDGFRB			CN1CCN(CC1)c1ccc(Nc2ncc3cc(C#N)c(=O)n(C4CCCC4)c3n2)cc1, CN1CCN(CC1)c1ccc(Nc2ncc3cc(C#N)c(=O)n(C4CCCC4)c3n2)cc1	VADOZMZXXRBXNY-UHFFFAOYSA-N, VADOZMZXXRBXNY-UHFFFAOYSA-N	Preclinical
OP-0595	beta lactamase inhibitor				NCCONC(=O)[C@@H]1CC[C@@H]2CN1C(=O)N2OS(O)(=O)=O	RSBPYSTVZQAADE-RQJHMYQMSA-N	Preclinical
OPC-21268	vasopressin receptor antagonist	AVPR1A, AVPR2, OXTR			CC(=O)NCCCOc1ccc(cc1)C(=O)N1CCC(CC1)N1C(=O)CCc2ccccc12, CC(=O)NCCCOc1ccc(cc1)C(=O)N1CCC(CC1)N1C(=O)CCc2ccccc12, CC(=O)NCCCOc1ccc(cc1)C(=O)N1CCC(CC1)N1C(=O)CCc2ccccc12, CC(=O)NCCCOc1ccc(cc1)C(=O)N1CCC(CC1)N1C(=O)CCc2ccccc12	KSNUCNRMDYJBKT-UHFFFAOYSA-N, KSNUCNRMDYJBKT-UHFFFAOYSA-N, KSNUCNRMDYJBKT-UHFFFAOYSA-N, KSNUCNRMDYJBKT-UHFFFAOYSA-N	Phase 1
opicapone	catechol O methyltransferase inhibitor	COMT			Cc1c(Cl)c(C)[n+]([O-])c(Cl)c1-c1noc(n1)-c1cc(O)c(O)c(c1)[N+]([O-])=O, Cc1c(Cl)c(C)[n+]([O-])c(Cl)c1-c1noc(n1)-c1cc(O)c(O)c(c1)[N+]([O-])=O	ASOADIZOVZTJSR-UHFFFAOYSA-N, ASOADIZOVZTJSR-UHFFFAOYSA-N	Phase 3
opipramol	sigma receptor agonist		neurology/psychiatry	generalized anxiety disorder (GAD)	OCCN1CCN(CCCN2c3ccccc3C=Cc3ccccc23)CC1 |c:18|, OCCN1CCN(CCCN2c3ccccc3C=Cc3ccccc23)CC1 |c:18|, OCCN1CCN(CCCN2c3ccccc3C=Cc3ccccc23)CC1 |c:18|	YNZFUWZUGRBMHL-UHFFFAOYSA-N, YNZFUWZUGRBMHL-UHFFFAOYSA-N, YNZFUWZUGRBMHL-UHFFFAOYSA-N	Launched
oprozomib	proteasome inhibitor				COC[C@H](NC(=O)[C@H](COC)NC(=O)c1cnc(C)s1)C(=O)N[C@@H](Cc1ccccc1)C(=O)[C@@]1(C)CO1	SWZXEVABPLUDIO-WSZYKNRRSA-N	Phase 1/Phase 2
OR-486	catechol O methyltransferase inhibitor	COMT			Oc1cc(cc(c1O)[N+]([O-])=O)[N+]([O-])=O, Oc1cc(cc(c1O)[N+]([O-])=O)[N+]([O-])=O	VDCDWNDTNSWDFJ-UHFFFAOYSA-N, VDCDWNDTNSWDFJ-UHFFFAOYSA-N	Preclinical
orantinib	FGFR inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	AURKA, AURKB, EGFR, FGFR1, FGFR2, KDR, PDGFRA, PDGFRB			Cc1[nH]c(\C=C2/C(=O)Nc3ccccc23)c(C)c1CCC(O)=O, Cc1[nH]c(\C=C2/C(=O)Nc3ccccc23)c(C)c1CCC(O)=O, Cc1[nH]c(\C=C2/C(=O)Nc3ccccc23)c(C)c1CCC(O)=O, Cc1[nH]c(\C=C2/C(=O)Nc3ccccc23)c(C)c1CCC(O)=O	NHFDRBXTEDBWCZ-ZROIWOOFSA-N, NHFDRBXTEDBWCZ-ZROIWOOFSA-N, NHFDRBXTEDBWCZ-ZROIWOOFSA-N, NHFDRBXTEDBWCZ-ZROIWOOFSA-N	Phase 3
orbifloxacin	bacterial DNA gyrase inhibitor		infectious disease	urinary tract infections	C[C@H]1CN(C[C@@H](C)N1)c1c(F)c(F)c2c(c1F)n(cc(C(O)=O)c2=O)C1CC1, C[C@H]1CN(C[C@@H](C)N1)c1c(F)c(F)c2c(c1F)n(cc(C(O)=O)c2=O)C1CC1, C[C@H]1CN(C[C@@H](C)N1)c1c(F)c(F)c2c(c1F)n(cc(C(O)=O)c2=O)C1CC1, C[C@H]1CN(C[C@@H](C)N1)c1c(F)c(F)c2c(c1F)n(cc(C(O)=O)c2=O)C1CC1, C[C@H]1CN(C[C@@H](C)N1)c1c(F)c(F)c2c(c1F)n(cc(C(O)=O)c2=O)C1CC1, C[C@H]1CN(C[C@@H](C)N1)c1c(F)c(F)c2c(c1F)n(cc(C(O)=O)c2=O)C1CC1	QIPQASLPWJVQMH-DTORHVGOSA-N, QIPQASLPWJVQMH-DTORHVGOSA-N, QIPQASLPWJVQMH-DTORHVGOSA-N, QIPQASLPWJVQMH-DTORHVGOSA-N, QIPQASLPWJVQMH-DTORHVGOSA-N, QIPQASLPWJVQMH-DTORHVGOSA-N	Launched
ORE1001	angiotensin converting enzyme inhibitor	ACE2			CC(C)C[C@H](N[C@@H](Cc1cncn1Cc1cc(Cl)cc(Cl)c1)C(O)=O)C(O)=O, CC(C)C[C@H](N[C@@H](Cc1cncn1Cc1cc(Cl)cc(Cl)c1)C(O)=O)C(O)=O	NTCCRGGIJNDEAB-IRXDYDNUSA-N, NTCCRGGIJNDEAB-IRXDYDNUSA-N	Phase 1/Phase 2
ORG-12962	serotonin receptor agonist	HTR2A, HTR2B, HTR2C			FC(F)(F)c1ccc(nc1Cl)N1CCNCC1	QZYYPQAYSFBKPW-UHFFFAOYSA-N	Phase 2
ORG-25543	glycine transporter inhibitor	GLRB, SLC6A5			COc1cc(cc(OC)c1OCc1ccccc1)C(=O)NCC1(CCCC1)N(C)C, COc1cc(cc(OC)c1OCc1ccccc1)C(=O)NCC1(CCCC1)N(C)C	ZCYOBMASPXQBSZ-UHFFFAOYSA-N, ZCYOBMASPXQBSZ-UHFFFAOYSA-N	Preclinical
ORG-26576	glutamate receptor modulator				O=C1N2CCC[C@H]2COc2ncccc12	FIKUEZUFASUKAH-QMMMGPOBSA-N	Phase 2
ORG-27569	cannabinoid receptor modulator	CNR1			CCc1c([nH]c2ccc(Cl)cc12)C(=O)NCCc1ccc(cc1)N1CCCCC1, CCc1c([nH]c2ccc(Cl)cc12)C(=O)NCCc1ccc(cc1)N1CCCCC1, CCc1c([nH]c2ccc(Cl)cc12)C(=O)NCCc1ccc(cc1)N1CCCCC1, CCc1c([nH]c2ccc(Cl)cc12)C(=O)NCCc1ccc(cc1)N1CCCCC1, CCc1c([nH]c2ccc(Cl)cc12)C(=O)NCCc1ccc(cc1)N1CCCCC1	AHFZDNYNXFMRFQ-UHFFFAOYSA-N, AHFZDNYNXFMRFQ-UHFFFAOYSA-N, AHFZDNYNXFMRFQ-UHFFFAOYSA-N, AHFZDNYNXFMRFQ-UHFFFAOYSA-N, AHFZDNYNXFMRFQ-UHFFFAOYSA-N	Preclinical
ORG-9768	adrenergic receptor antagonist	ADRA2A			CC1(CN)Cc2ccccc2C1, CC1(CN)Cc2ccccc2C1	JOLKQWPKJFRPOU-UHFFFAOYSA-N, JOLKQWPKJFRPOU-UHFFFAOYSA-N	Phase 1
oridonin	BCL inhibitor	BCL2			[H][C@@]1(O)[C@@]2([H])CC[C@]3([H])[C@@]1(C(=O)C2=C)[C@]1(O)OC[C@]32[C@@H](O)CCC(C)(C)[C@@]2([H])[C@@H]1O	SDHTXBWLVGWJFT-XKCURVIJSA-N	Preclinical
oritavancin	bacterial cell wall synthesis inhibitor		infectious disease	skin infections	[H][C@@]1(C[C@](C)(NCc2ccc(cc2)-c2ccc(Cl)cc2)[C@@H](O)[C@H](C)O1)O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1Oc1c2Oc3ccc(cc3Cl)[C@@H](O)[C@@H](NC(=O)[C@@H](CC(C)C)NC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@]3([H])c(c2)cc1Oc1ccc(cc1Cl)[C@@H](O[C@@]1([H])C[C@](C)(N)[C@@H](O)[C@H](C)O1)[C@]1([H])NC(=O)[C@]([H])(NC3=O)c2ccc(O)c(c2)-c2c(O)cc(O)cc2[C@]([H])(NC1=O)C(O)=O	VHFGEBVPHAGQPI-LXKZPTCJSA-N	Launched
orlistat	lipase inhibitor	CNR1, DAGLA, DAGLB, FASN, LIPF, PNLIP	endocrinology	weight-loss aid	CCCCCCCCCCC[C@@H](C[C@@H]1OC(=O)[C@H]1CCCCCC)OC(=O)[C@H](CC(C)C)NC=O, CCCCCCCCCCC[C@@H](C[C@@H]1OC(=O)[C@H]1CCCCCC)OC(=O)[C@H](CC(C)C)NC=O, CCCCCCCCCCC[C@@H](C[C@@H]1OC(=O)[C@H]1CCCCCC)OC(=O)[C@H](CC(C)C)NC=O, CCCCCCCCCCC[C@@H](C[C@@H]1OC(=O)[C@H]1CCCCCC)OC(=O)[C@H](CC(C)C)NC=O, CCCCCCCCCCC[C@@H](C[C@@H]1OC(=O)[C@H]1CCCCCC)OC(=O)[C@H](CC(C)C)NC=O	AHLBNYSZXLDEJQ-FWEHEUNISA-N, AHLBNYSZXLDEJQ-FWEHEUNISA-N, AHLBNYSZXLDEJQ-FWEHEUNISA-N, AHLBNYSZXLDEJQ-FWEHEUNISA-N, AHLBNYSZXLDEJQ-FWEHEUNISA-N	Launched
ormeloxifene	selective estrogen receptor modulator (SERM)		endocrinology	contraceptive	COc1ccc2[C@H]([C@H](c3ccccc3)C(C)(C)Oc2c1)c1ccc(OCCN2CCCC2)cc1	XZEUAXYWNKYKPL-WDYNHAJCSA-N	Launched
ornidazole	antiprotozoal agent		infectious disease	protozoan infection	Cc1ncc(n1C[C@@H](O)CCl)[N+]([O-])=O |&1:7,r|, Cc1ncc(n1C[C@@H](O)CCl)[N+]([O-])=O |&1:7,r|, Cc1ncc(n1C[C@@H](O)CCl)[N+]([O-])=O |&1:7,r|, Cc1ncc(n1C[C@@H](O)CCl)[N+]([O-])=O |&1:7,r|	IPWKIXLWTCNBKN-LURJTMIESA-N, IPWKIXLWTCNBKN-LURJTMIESA-N, IPWKIXLWTCNBKN-LURJTMIESA-N, IPWKIXLWTCNBKN-LURJTMIESA-N	Launched
ornipressin	vasoconstrictor				[H][C@@]1(Cc2ccccc2)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@@H](N)CSSC[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC1=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCN)C(=O)NCC(N)=O	MUNMIGOEDGHVLE-FGJIEJSYSA-N	Preclinical
ornithine	NFkB pathway modulator	GPRC6A			Cl.NCCC[C@@H](N)C(O)=O |&1:5,r|	GGTYBZJRPHEQDG-PGMHMLKASA-N	Launched
orotic-acid		DHODH			OC(=O)c1cc(=O)[nH]c(=O)[nH]1, OC(=O)c1cc(=O)[nH]c(=O)[nH]1	PXQPEWDEAKTCGB-UHFFFAOYSA-N, PXQPEWDEAKTCGB-UHFFFAOYSA-N	Phase 2
orphanin-fq	opioid receptor agonist	OPRL1, OPRM1			CC(C)C[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)CNC(=O)[C@@H](N)Cc1ccccc1)[C@@H](C)O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O, CC(C)C[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)CNC(=O)[C@@H](N)Cc1ccccc1)[C@@H](C)O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O	PULGYDLMFSFVBL-SMFNREODSA-N, PULGYDLMFSFVBL-SMFNREODSA-N	Phase 1
orphenadrine	acetylcholine receptor antagonist		neurology/psychiatry	muscle pain	CN(C)CCO[C@@H](c1ccccc1)c1ccccc1C |&1:6|, CN(C)CCO[C@@H](c1ccccc1)c1ccccc1C |&1:6|, CN(C)CCO[C@@H](c1ccccc1)c1ccccc1C |&1:6|, CN(C)CCO[C@@H](c1ccccc1)c1ccccc1C |&1:6|, CN(C)CCO[C@@H](c1ccccc1)c1ccccc1C |&1:6|	QVYRGXJJSLMXQH-SFHVURJKSA-N, QVYRGXJJSLMXQH-SFHVURJKSA-N, QVYRGXJJSLMXQH-SFHVURJKSA-N, QVYRGXJJSLMXQH-SFHVURJKSA-N, QVYRGXJJSLMXQH-SFHVURJKSA-N	Launched
orteronel	androgen biosynthesis inhibitor, androgen receptor antagonist, cytochrome P450 inhibitor	CYP17A1			CNC(=O)c1ccc2cc(ccc2c1)[C@]1(O)CCn2cncc12, CNC(=O)c1ccc2cc(ccc2c1)[C@]1(O)CCn2cncc12, CNC(=O)c1ccc2cc(ccc2c1)[C@]1(O)CCn2cncc12	OZPFIJIOIVJZMN-GOSISDBHSA-N, OZPFIJIOIVJZMN-GOSISDBHSA-N, OZPFIJIOIVJZMN-GOSISDBHSA-N	Phase 3
ORY-1001	histone lysine demethylase inhibitor	KDM1A			NC1CCC(CC1)N[C@@H]1C[C@H]1c1ccccc1, NC1CCC(CC1)N[C@@H]1C[C@H]1c1ccccc1, NC1CCC(CC1)N[C@@H]1C[C@H]1c1ccccc1	ALHBJBCQLJZYON-PFSRBDOWSA-N, ALHBJBCQLJZYON-PFSRBDOWSA-N, ALHBJBCQLJZYON-PFSRBDOWSA-N	Phase 1/Phase 2
oseltamivir-carboxylate	neuraminidase inhibitor		infectious disease	influenza A virus infection	CCC(CC)O[C@@H]1C=C(C[C@H](N)[C@H]1NC(C)=O)C(O)=O |c:7|, CCC(CC)O[C@@H]1C=C(C[C@H](N)[C@H]1NC(C)=O)C(O)=O |c:7|	NENPYTRHICXVCS-YNEHKIRRSA-N, NENPYTRHICXVCS-YNEHKIRRSA-N	Launched
oseltamivir-phosphate	neuraminidase inhibitor	CES1, NEU1, NEU2	infectious disease	influenza A virus infection	CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1 |t:5|, CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1 |t:5|, CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1 |t:5|, CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1 |t:5|, CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1 |t:5|	VSZGPKBBMSAYNT-RRFJBIMHSA-N, VSZGPKBBMSAYNT-RRFJBIMHSA-N, VSZGPKBBMSAYNT-RRFJBIMHSA-N, VSZGPKBBMSAYNT-RRFJBIMHSA-N, VSZGPKBBMSAYNT-RRFJBIMHSA-N	Launched
osemozotan	serotonin receptor agonist	HTR1A			C(CNC[C@H]1COc2ccccc2O1)COc1ccc2OCOc2c1	MEEQBDCQPIZMLY-HNNXBMFYSA-N	Phase 2/Phase 3
OSI-027	mTOR inhibitor	MTOR			COc1cccc2cc([nH]c12)-c1nc([C@H]2CC[C@@H](CC2)C(O)=O)n2ncnc(N)c12 |r|, COc1cccc2cc([nH]c12)-c1nc([C@H]2CC[C@@H](CC2)C(O)=O)n2ncnc(N)c12 |r|, COc1cccc2cc([nH]c12)-c1nc([C@H]2CC[C@@H](CC2)C(O)=O)n2ncnc(N)c12 |r|	JROFGZPOBKIAEW-HAQNSBGRSA-N, JROFGZPOBKIAEW-HAQNSBGRSA-N, JROFGZPOBKIAEW-HAQNSBGRSA-N	Phase 1
OSI-420	EGFR inhibitor	EGFR			COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCO, COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCO, COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCO	KOQIAZNBAWFSQM-UHFFFAOYSA-N, KOQIAZNBAWFSQM-UHFFFAOYSA-N, KOQIAZNBAWFSQM-UHFFFAOYSA-N	Preclinical
OSI-930	KIT inhibitor, VEGFR inhibitor	FLT1, KDR, KIT			FC(F)(F)Oc1ccc(NC(=O)c2sccc2NCc2ccnc3ccccc23)cc1, FC(F)(F)Oc1ccc(NC(=O)c2sccc2NCc2ccnc3ccccc23)cc1, FC(F)(F)Oc1ccc(NC(=O)c2sccc2NCc2ccnc3ccccc23)cc1, FC(F)(F)Oc1ccc(NC(=O)c2sccc2NCc2ccnc3ccccc23)cc1	FGTCROZDHDSNIO-UHFFFAOYSA-N, FGTCROZDHDSNIO-UHFFFAOYSA-N, FGTCROZDHDSNIO-UHFFFAOYSA-N, FGTCROZDHDSNIO-UHFFFAOYSA-N	Phase 1
osilodrostat	cytochrome P450 inhibitor				Fc1cc(ccc1[C@H]1CCc2cncn12)C#N	USUZGMWDZDXMDG-CYBMUJFWSA-N	Launched
osimertinib	EGFR inhibitor	EGFR	oncology	non-small cell lung cancer (NSCLC)	COc1cc(N(C)CCN(C)C)c(NC(=O)C=C)cc1Nc1nccc(n1)-c1cn(C)c2ccccc12, COc1cc(N(C)CCN(C)C)c(NC(=O)C=C)cc1Nc1nccc(n1)-c1cn(C)c2ccccc12, COc1cc(N(C)CCN(C)C)c(NC(=O)C=C)cc1Nc1nccc(n1)-c1cn(C)c2ccccc12, COc1cc(N(C)CCN(C)C)c(NC(=O)C=C)cc1Nc1nccc(n1)-c1cn(C)c2ccccc12, COc1cc(N(C)CCN(C)C)c(NC(=O)C=C)cc1Nc1nccc(n1)-c1cn(C)c2ccccc12, COc1cc(N(C)CCN(C)C)c(NC(=O)C=C)cc1Nc1nccc(n1)-c1cn(C)c2ccccc12, COc1cc(N(C)CCN(C)C)c(NC(=O)C=C)cc1Nc1nccc(n1)-c1cn(C)c2ccccc12	DUYJMQONPNNFPI-UHFFFAOYSA-N, DUYJMQONPNNFPI-UHFFFAOYSA-N, DUYJMQONPNNFPI-UHFFFAOYSA-N, DUYJMQONPNNFPI-UHFFFAOYSA-N, DUYJMQONPNNFPI-UHFFFAOYSA-N, DUYJMQONPNNFPI-UHFFFAOYSA-N, DUYJMQONPNNFPI-UHFFFAOYSA-N	Launched
ospemifene	selective estrogen receptor modulator (SERM)	ESR1, ESR2	obstetrics/gynecology, endocrinology	vaginal atrophy, dyspareunia, menopause	OCCOc1ccc(cc1)C(=C(\CCCl)c1ccccc1)\c1ccccc1, OCCOc1ccc(cc1)C(=C(\CCCl)c1ccccc1)\c1ccccc1	LUMKNAVTFCDUIE-VHXPQNKSSA-N, LUMKNAVTFCDUIE-VHXPQNKSSA-N	Launched
ostarine	androgen receptor modulator	AR			C[C@](O)(COc1ccc(cc1)C#N)C(=O)Nc1ccc(C#N)c(c1)C(F)(F)F, C[C@](O)(COc1ccc(cc1)C#N)C(=O)Nc1ccc(C#N)c(c1)C(F)(F)F	JNGVJMBLXIUVRD-SFHVURJKSA-N, JNGVJMBLXIUVRD-SFHVURJKSA-N	Phase 3
osthol	calcium channel blocker				COc1ccc2ccc(=O)oc2c1CC=C(C)C, COc1ccc2ccc(=O)oc2c1CC=C(C)C	MBRLOUHOWLUMFF-UHFFFAOYSA-N, MBRLOUHOWLUMFF-UHFFFAOYSA-N	Preclinical
OT-R-antagonist-1	oxytocin receptor antagonist	AVPR1A, OXTR			CO\N=C1\C[C@H](N(C1)C(=O)c1ccc(cc1)-c1ccccc1C)C(=O)NC[C@@H](O)c1ccccc1	IBXGJPAYWMFXSF-UEEONYLUSA-N	Preclinical
otamixaban	coagulation factor inhibitor	F10			COC(=O)[C@H](Cc1cccc(c1)C(N)=N)[C@@H](C)NC(=O)c1ccc(cc1)-c1cc[n+]([O-])cc1, COC(=O)[C@H](Cc1cccc(c1)C(N)=N)[C@@H](C)NC(=O)c1ccc(cc1)-c1cc[n+]([O-])cc1, COC(=O)[C@H](Cc1cccc(c1)C(N)=N)[C@@H](C)NC(=O)c1ccc(cc1)-c1cc[n+]([O-])cc1, COC(=O)[C@H](Cc1cccc(c1)C(N)=N)[C@@H](C)NC(=O)c1ccc(cc1)-c1cc[n+]([O-])cc1	PFGVNLZDWRZPJW-OPAMFIHVSA-N, PFGVNLZDWRZPJW-OPAMFIHVSA-N, PFGVNLZDWRZPJW-OPAMFIHVSA-N, PFGVNLZDWRZPJW-OPAMFIHVSA-N	Phase 3
otenzepad	acetylcholine receptor antagonist	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5			CCN(CC)C[C@H]1CCCCN1CC(=O)N1c2ccccc2C(=O)Nc2cccnc12 |&1:6,r|, CCN(CC)C[C@H]1CCCCN1CC(=O)N1c2ccccc2C(=O)Nc2cccnc12 |&1:6,r|, CCN(CC)C[C@H]1CCCCN1CC(=O)N1c2ccccc2C(=O)Nc2cccnc12 |&1:6,r|	UBRKDAVQCKZSPO-GOSISDBHSA-N, UBRKDAVQCKZSPO-GOSISDBHSA-N, UBRKDAVQCKZSPO-GOSISDBHSA-N	Phase 3
otilonium	acetylcholine receptor antagonist	CACNA1C	gastroenterology	irritable bowel syndrome	CCCCCCCCOc1ccccc1C(=O)Nc1ccc(cc1)C(=O)OCC[N+](C)(CC)CC, CCCCCCCCOc1ccccc1C(=O)Nc1ccc(cc1)C(=O)OCC[N+](C)(CC)CC, CCCCCCCCOc1ccccc1C(=O)Nc1ccc(cc1)C(=O)OCC[N+](C)(CC)CC, CCCCCCCCOc1ccccc1C(=O)Nc1ccc(cc1)C(=O)OCC[N+](C)(CC)CC, CCCCCCCCOc1ccccc1C(=O)Nc1ccc(cc1)C(=O)OCC[N+](C)(CC)CC, CCCCCCCCOc1ccccc1C(=O)Nc1ccc(cc1)C(=O)OCC[N+](C)(CC)CC	NQHNLNLJPDMBFN-UHFFFAOYSA-O, NQHNLNLJPDMBFN-UHFFFAOYSA-O, NQHNLNLJPDMBFN-UHFFFAOYSA-O, NQHNLNLJPDMBFN-UHFFFAOYSA-O, NQHNLNLJPDMBFN-UHFFFAOYSA-O, NQHNLNLJPDMBFN-UHFFFAOYSA-O	Launched
OTS167	maternal embryonic leucine zipper kinase inhibitor	MELK			CN(C)C[C@H]1CC[C@@H](CC1)Nc1c(cnc2ccc(nc12)-c1cc(Cl)c(O)c(Cl)c1)C(C)=O |r|, CN(C)C[C@H]1CC[C@@H](CC1)Nc1c(cnc2ccc(nc12)-c1cc(Cl)c(O)c(Cl)c1)C(C)=O |r|, CN(C)C[C@H]1CC[C@@H](CC1)Nc1c(cnc2ccc(nc12)-c1cc(Cl)c(O)c(Cl)c1)C(C)=O |r|, CN(C)C[C@H]1CC[C@@H](CC1)Nc1c(cnc2ccc(nc12)-c1cc(Cl)c(O)c(Cl)c1)C(C)=O |r|, CN(C)C[C@H]1CC[C@@H](CC1)Nc1c(cnc2ccc(nc12)-c1cc(Cl)c(O)c(Cl)c1)C(C)=O |r|, CN(C)C[C@H]1CC[C@@H](CC1)Nc1c(cnc2ccc(nc12)-c1cc(Cl)c(O)c(Cl)c1)C(C)=O |r|	DKZYXHCYPUVGAF-JCNLHEQBSA-N, DKZYXHCYPUVGAF-JCNLHEQBSA-N, DKZYXHCYPUVGAF-JCNLHEQBSA-N, DKZYXHCYPUVGAF-JCNLHEQBSA-N, DKZYXHCYPUVGAF-JCNLHEQBSA-N, DKZYXHCYPUVGAF-JCNLHEQBSA-N	Phase 1/Phase 2
OTS514	TOPK inhibitor				C[C@@H](CN)c1ccc(cc1)-c1c(O)cc(C)c2[nH]c(=O)c3sccc3c12, C[C@@H](CN)c1ccc(cc1)-c1c(O)cc(C)c2[nH]c(=O)c3sccc3c12, C[C@@H](CN)c1ccc(cc1)-c1c(O)cc(C)c2[nH]c(=O)c3sccc3c12	OETLNMOJNONWOY-LBPRGKRZSA-N, OETLNMOJNONWOY-LBPRGKRZSA-N, OETLNMOJNONWOY-LBPRGKRZSA-N	Preclinical
OTX015	bromodomain inhibitor	BRD2, BRD3, BRD4			Cc1sc-2c(c1C)C(=N[C@@H](CC(=O)Nc1ccc(O)cc1)c1nnc(C)n-21)c1ccc(Cl)cc1 |c:8|, Cc1sc-2c(c1C)C(=N[C@@H](CC(=O)Nc1ccc(O)cc1)c1nnc(C)n-21)c1ccc(Cl)cc1 |c:8|, Cc1sc-2c(c1C)C(=N[C@@H](CC(=O)Nc1ccc(O)cc1)c1nnc(C)n-21)c1ccc(Cl)cc1 |c:8|, Cc1sc-2c(c1C)C(=N[C@@H](CC(=O)Nc1ccc(O)cc1)c1nnc(C)n-21)c1ccc(Cl)cc1 |c:8|, Cc1sc-2c(c1C)C(=N[C@@H](CC(=O)Nc1ccc(O)cc1)c1nnc(C)n-21)c1ccc(Cl)cc1 |c:8|	GNMUEVRJHCWKTO-FQEVSTJZSA-N, GNMUEVRJHCWKTO-FQEVSTJZSA-N, GNMUEVRJHCWKTO-FQEVSTJZSA-N, GNMUEVRJHCWKTO-FQEVSTJZSA-N, GNMUEVRJHCWKTO-FQEVSTJZSA-N	Phase 1/Phase 2
ouabain	ATPase inhibitor	ATP1A1	cardiology	hypertension, cardiac arrythmia	C[C@@H]1O[C@@H](O[C@@H]2C[C@@H](O)[C@]3(CO)[C@H]4[C@H](O)C[C@]5(C)[C@H](CC[C@]5(O)[C@@H]4CC[C@]3(O)C2)C2=CC(=O)OC2)[C@H](O)[C@H](O)[C@H]1O |t:33|, C[C@@H]1O[C@@H](O[C@@H]2C[C@@H](O)[C@]3(CO)[C@H]4[C@H](O)C[C@]5(C)[C@H](CC[C@]5(O)[C@@H]4CC[C@]3(O)C2)C2=CC(=O)OC2)[C@H](O)[C@H](O)[C@H]1O |t:33|, C[C@@H]1O[C@@H](O[C@@H]2C[C@@H](O)[C@]3(CO)[C@H]4[C@H](O)C[C@]5(C)[C@H](CC[C@]5(O)[C@@H]4CC[C@]3(O)C2)C2=CC(=O)OC2)[C@H](O)[C@H](O)[C@H]1O |t:33|, C[C@@H]1O[C@@H](O[C@@H]2C[C@@H](O)[C@]3(CO)[C@H]4[C@H](O)C[C@]5(C)[C@H](CC[C@]5(O)[C@@H]4CC[C@]3(O)C2)C2=CC(=O)OC2)[C@H](O)[C@H](O)[C@H]1O |t:33|, C[C@@H]1O[C@@H](O[C@@H]2C[C@@H](O)[C@]3(CO)[C@H]4[C@H](O)C[C@]5(C)[C@H](CC[C@]5(O)[C@@H]4CC[C@]3(O)C2)C2=CC(=O)OC2)[C@H](O)[C@H](O)[C@H]1O |t:33|, C[C@@H]1O[C@@H](O[C@@H]2C[C@@H](O)[C@]3(CO)[C@H]4[C@H](O)C[C@]5(C)[C@H](CC[C@]5(O)[C@@H]4CC[C@]3(O)C2)C2=CC(=O)OC2)[C@H](O)[C@H](O)[C@H]1O |t:33|, C[C@@H]1O[C@@H](O[C@@H]2C[C@@H](O)[C@]3(CO)[C@H]4[C@H](O)C[C@]5(C)[C@H](CC[C@]5(O)[C@@H]4CC[C@]3(O)C2)C2=CC(=O)OC2)[C@H](O)[C@H](O)[C@H]1O |t:33|, C[C@@H]1O[C@@H](O[C@@H]2C[C@@H](O)[C@]3(CO)[C@H]4[C@H](O)C[C@]5(C)[C@H](CC[C@]5(O)[C@@H]4CC[C@]3(O)C2)C2=CC(=O)OC2)[C@H](O)[C@H](O)[C@H]1O |t:33|, C[C@@H]1O[C@@H](O[C@@H]2C[C@@H](O)[C@]3(CO)[C@H]4[C@H](O)C[C@]5(C)[C@H](CC[C@]5(O)[C@@H]4CC[C@]3(O)C2)C2=CC(=O)OC2)[C@H](O)[C@H](O)[C@H]1O |t:33|, C[C@@H]1O[C@@H](O[C@@H]2C[C@@H](O)[C@]3(CO)[C@H]4[C@H](O)C[C@]5(C)[C@H](CC[C@]5(O)[C@@H]4CC[C@]3(O)C2)C2=CC(=O)OC2)[C@H](O)[C@H](O)[C@H]1O |t:33|, C[C@@H]1O[C@@H](O[C@@H]2C[C@@H](O)[C@]3(CO)[C@H]4[C@H](O)C[C@]5(C)[C@H](CC[C@]5(O)[C@@H]4CC[C@]3(O)C2)C2=CC(=O)OC2)[C@H](O)[C@H](O)[C@H]1O |t:33|, C[C@@H]1O[C@@H](O[C@@H]2C[C@@H](O)[C@]3(CO)[C@H]4[C@H](O)C[C@]5(C)[C@H](CC[C@]5(O)[C@@H]4CC[C@]3(O)C2)C2=CC(=O)OC2)[C@H](O)[C@H](O)[C@H]1O |t:33|	LPMXVESGRSUGHW-VGFRVVOQSA-N, LPMXVESGRSUGHW-VGFRVVOQSA-N, LPMXVESGRSUGHW-VGFRVVOQSA-N, LPMXVESGRSUGHW-VGFRVVOQSA-N, LPMXVESGRSUGHW-VGFRVVOQSA-N, LPMXVESGRSUGHW-VGFRVVOQSA-N, LPMXVESGRSUGHW-VGFRVVOQSA-N, LPMXVESGRSUGHW-VGFRVVOQSA-N, LPMXVESGRSUGHW-VGFRVVOQSA-N, LPMXVESGRSUGHW-VGFRVVOQSA-N, LPMXVESGRSUGHW-VGFRVVOQSA-N, LPMXVESGRSUGHW-VGFRVVOQSA-N	Launched
OXA-06	rho associated kinase inhibitor	ROCK1, ROCK2			Fc1ccccc1CNCc1ccc(cc1)-c1ccnc2[nH]ccc12, Fc1ccccc1CNCc1ccc(cc1)-c1ccnc2[nH]ccc12	XUIUXXQVHPEQNM-UHFFFAOYSA-N, XUIUXXQVHPEQNM-UHFFFAOYSA-N	Preclinical
oxaceprol	anti-inflammatory agent				CC(=O)N1C[C@H](O)C[C@H]1C(O)=O	BAPRUDZDYCKSOQ-RITPCOANSA-N	Preclinical
oxacillin	bacterial cell wall synthesis inhibitor		infectious disease	staphylococcal infections	Cc1onc(c1C(=O)N[C@H]1[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O)-c1ccccc1, Cc1onc(c1C(=O)N[C@H]1[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O)-c1ccccc1, Cc1onc(c1C(=O)N[C@H]1[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O)-c1ccccc1, Cc1onc(c1C(=O)N[C@H]1[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O)-c1ccccc1, Cc1onc(c1C(=O)N[C@H]1[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O)-c1ccccc1, Cc1onc(c1C(=O)N[C@H]1[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O)-c1ccccc1	UWYHMGVUTGAWSP-JKIFEVAISA-N, UWYHMGVUTGAWSP-JKIFEVAISA-N, UWYHMGVUTGAWSP-JKIFEVAISA-N, UWYHMGVUTGAWSP-JKIFEVAISA-N, UWYHMGVUTGAWSP-JKIFEVAISA-N, UWYHMGVUTGAWSP-JKIFEVAISA-N	Launched
oxacyclohexadecan-2-one	protein kinase inhibitor				O=C1CCCCCCCCCCCCCCO1	FKUPPRZPSYCDRS-UHFFFAOYSA-N	Preclinical
oxaliplatin	DNA inhibitor		oncology	colorectal cancer	O=C1O[Pt]2(N[C@@H]3CCCC[C@H]3N2)OC1=O, O=C1O[Pt]2(N[C@@H]3CCCC[C@H]3N2)OC1=O, O=C1O[Pt]2(N[C@@H]3CCCC[C@H]3N2)OC1=O, O=C1O[Pt]2(N[C@@H]3CCCC[C@H]3N2)OC1=O, O=C1O[Pt]2(N[C@@H]3CCCC[C@H]3N2)OC1=O, O=C1O[Pt]2(N[C@@H]3CCCC[C@H]3N2)OC1=O, O=C1O[Pt]2(N[C@@H]3CCCC[C@H]3N2)OC1=O, O=C1O[Pt]2(N[C@@H]3CCCC[C@H]3N2)OC1=O	DWAFYCQODLXJNR-BNTLRKBRSA-L, DWAFYCQODLXJNR-BNTLRKBRSA-L, DWAFYCQODLXJNR-BNTLRKBRSA-L, DWAFYCQODLXJNR-BNTLRKBRSA-L, DWAFYCQODLXJNR-BNTLRKBRSA-L, DWAFYCQODLXJNR-BNTLRKBRSA-L, DWAFYCQODLXJNR-BNTLRKBRSA-L, DWAFYCQODLXJNR-BNTLRKBRSA-L	Launched
oxaloacetate	glutamate release inhibitor				OC(=O)C=C(O)C(O)=O, OC(=O)C=C(O)C(O)=O	UWYVPFMHMJIBHE-UHFFFAOYSA-N, UWYVPFMHMJIBHE-UHFFFAOYSA-N	Phase 2/Phase 3
oxantel	anthelmintic agent		infectious disease	gastrointestinal parasites	CN1CCCN=C1\C=C\c1cccc(O)c1 |c:5|, CN1CCCN=C1\C=C\c1cccc(O)c1 |c:5|	VRYKTHBAWRESFI-VOTSOKGWSA-N, VRYKTHBAWRESFI-VOTSOKGWSA-N	Launched
oxaprozin	cyclooxygenase inhibitor	PTGS1, PTGS2	rheumatology	osteoarthritis, rheumatoid arthritis	OC(=O)CCc1nc(c(o1)-c1ccccc1)-c1ccccc1, OC(=O)CCc1nc(c(o1)-c1ccccc1)-c1ccccc1, OC(=O)CCc1nc(c(o1)-c1ccccc1)-c1ccccc1	OFPXSFXSNFPTHF-UHFFFAOYSA-N, OFPXSFXSNFPTHF-UHFFFAOYSA-N, OFPXSFXSNFPTHF-UHFFFAOYSA-N	Launched
oxatomide	histamine receptor antagonist	HRH1	allergy	allergic rhinitis	O=c1[nH]c2ccccc2n1CCCN1CCN(CC1)C(c1ccccc1)c1ccccc1, O=c1[nH]c2ccccc2n1CCCN1CCN(CC1)C(c1ccccc1)c1ccccc1	BAINIUMDFURPJM-UHFFFAOYSA-N, BAINIUMDFURPJM-UHFFFAOYSA-N	Launched
oxcarbazepine	sodium channel blocker	SCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A	neurology/psychiatry	seizures	NC(=O)N1c2ccccc2CC(=O)c2ccccc12, NC(=O)N1c2ccccc2CC(=O)c2ccccc12, NC(=O)N1c2ccccc2CC(=O)c2ccccc12, NC(=O)N1c2ccccc2CC(=O)c2ccccc12, NC(=O)N1c2ccccc2CC(=O)c2ccccc12	CTRLABGOLIVAIY-UHFFFAOYSA-N, CTRLABGOLIVAIY-UHFFFAOYSA-N, CTRLABGOLIVAIY-UHFFFAOYSA-N, CTRLABGOLIVAIY-UHFFFAOYSA-N, CTRLABGOLIVAIY-UHFFFAOYSA-N	Launched
oxelaidin	antitussive		pulmonary	cough suppressant	CCN(CC)CCOCCOC(=O)C(CC)(CC)c1ccccc1, CCN(CC)CCOCCOC(=O)C(CC)(CC)c1ccccc1, CCN(CC)CCOCCOC(=O)C(CC)(CC)c1ccccc1, CCN(CC)CCOCCOC(=O)C(CC)(CC)c1ccccc1	IQADUMSPOQKAAO-UHFFFAOYSA-N, IQADUMSPOQKAAO-UHFFFAOYSA-N, IQADUMSPOQKAAO-UHFFFAOYSA-N, IQADUMSPOQKAAO-UHFFFAOYSA-N	Launched
oxethazaine	local anesthetic		neurology/psychiatry	local anesthetic	CN(C(=O)CN(CCO)CC(=O)N(C)C(C)(C)Cc1ccccc1)C(C)(C)Cc1ccccc1, CN(C(=O)CN(CCO)CC(=O)N(C)C(C)(C)Cc1ccccc1)C(C)(C)Cc1ccccc1, CN(C(=O)CN(CCO)CC(=O)N(C)C(C)(C)Cc1ccccc1)C(C)(C)Cc1ccccc1	FTLDJPRFCGDUFH-UHFFFAOYSA-N, FTLDJPRFCGDUFH-UHFFFAOYSA-N, FTLDJPRFCGDUFH-UHFFFAOYSA-N	Launched
OXF-BD-02	bromodomain inhibitor	BRD4			Cc1noc(C)c1-c1cc(O)cc(c1)[C@@H](O)c1ccccc1 |&1:14,r|, Cc1noc(C)c1-c1cc(O)cc(c1)[C@@H](O)c1ccccc1 |&1:14,r|	FEQUIPXIENTMJN-SFHVURJKSA-N, FEQUIPXIENTMJN-SFHVURJKSA-N	Preclinical
oxfendazole	anthelmintic agent		infectious disease	lungworms, tapeworm, gastrointestinal roundworms	COC(=O)Nc1nc2ccc(cc2[nH]1)[S@@](=O)c1ccccc1 |r|, COC(=O)Nc1nc2ccc(cc2[nH]1)[S@@](=O)c1ccccc1 |r|	BEZZFPOZAYTVHN-QFIPXVFZSA-N, BEZZFPOZAYTVHN-QFIPXVFZSA-N	Launched
oxfenicine	carnitine palmitoyltransferase inhibitor	CPT1A, CPT1B			N[C@@H](C(O)=O)c1ccc(O)cc1, N[C@@H](C(O)=O)c1ccc(O)cc1	LJCWONGJFPCTTL-SSDOTTSWSA-N, LJCWONGJFPCTTL-SSDOTTSWSA-N	Phase 1
oxibendazole	tubulin polymerization inhibitor	TUBB, TUBB4B	infectious disease	strongyles	CCCOc1ccc2nc(NC(=O)OC)[nH]c2c1, CCCOc1ccc2nc(NC(=O)OC)[nH]c2c1, CCCOc1ccc2nc(NC(=O)OC)[nH]c2c1, CCCOc1ccc2nc(NC(=O)OC)[nH]c2c1	RAOCRURYZCVHMG-UHFFFAOYSA-N, RAOCRURYZCVHMG-UHFFFAOYSA-N, RAOCRURYZCVHMG-UHFFFAOYSA-N, RAOCRURYZCVHMG-UHFFFAOYSA-N	Launched
oxiconazole	bacterial cell wall synthesis inhibitor		infectious disease	tinea pedis, tinea cruris, tinea corporis	Clc1ccc(CO\N=C(/Cn2ccnc2)c2ccc(Cl)cc2Cl)c(Cl)c1, Clc1ccc(CO\N=C(/Cn2ccnc2)c2ccc(Cl)cc2Cl)c(Cl)c1	QRJJEGAJXVEBNE-HKOYGPOVSA-N, QRJJEGAJXVEBNE-HKOYGPOVSA-N	Launched
oxidopamine	neurotoxin				NCCc1cc(O)c(O)cc1O, NCCc1cc(O)c(O)cc1O	DIVDFFZHCJEHGG-UHFFFAOYSA-N, DIVDFFZHCJEHGG-UHFFFAOYSA-N	Preclinical
oxiniacic-acid					OC(=O)c1ccc[n+]([O-])c1, OC(=O)c1ccc[n+]([O-])c1, OC(=O)c1ccc[n+]([O-])c1, OC(=O)c1ccc[n+]([O-])c1	FJCFFCXMEXZEIM-UHFFFAOYSA-N, FJCFFCXMEXZEIM-UHFFFAOYSA-N, FJCFFCXMEXZEIM-UHFFFAOYSA-N, FJCFFCXMEXZEIM-UHFFFAOYSA-N	Preclinical
oxiperomide	dopamine receptor antagonist				O=c1[nH]c2ccccc2n1C1CCN(CCOc2ccccc2)CC1	NVDBBGBUTKLRSN-UHFFFAOYSA-N	Phase 2
oxiracetam	acetylcholine receptor agonist		neurology/psychiatry	senile dementia	NC(=O)CN1C[C@H](O)CC1=O, NC(=O)CN1C[C@H](O)CC1=O, NC(=O)CN1C[C@H](O)CC1=O	IHLAQQPQKRMGSS-SCSAIBSYSA-N, IHLAQQPQKRMGSS-SCSAIBSYSA-N, IHLAQQPQKRMGSS-SCSAIBSYSA-N	Launched
oxolamine	antitussive		pulmonary	cough suppressant	CCN(CC)CCc1nc(no1)-c1ccccc1, CCN(CC)CCc1nc(no1)-c1ccccc1	IDCHQQSVJAAUQQ-UHFFFAOYSA-N, IDCHQQSVJAAUQQ-UHFFFAOYSA-N	Launched
oxolinic-acid	bacterial DNA gyrase inhibitor				CCn1cc(C(O)=O)c(=O)c2cc3OCOc3cc12, CCn1cc(C(O)=O)c(=O)c2cc3OCOc3cc12, CCn1cc(C(O)=O)c(=O)c2cc3OCOc3cc12	KYGZCKSPAKDVKC-UHFFFAOYSA-N, KYGZCKSPAKDVKC-UHFFFAOYSA-N, KYGZCKSPAKDVKC-UHFFFAOYSA-N	Preclinical
oxonic-acid	uricase inhibitor				OC(=O)c1nc(=O)[nH]c(=O)[nH]1, OC(=O)c1nc(=O)[nH]c(=O)[nH]1	RYYCJUAHISIHTL-UHFFFAOYSA-N, RYYCJUAHISIHTL-UHFFFAOYSA-N	Preclinical
oxotremorine-M	acetylcholine receptor agonist	CHRM1, CHRM2, CHRM3, CHRM4			C[N+](C)(C)CC#CCN1CCCC1=O, C[N+](C)(C)CC#CCN1CCCC1=O, C[N+](C)(C)CC#CCN1CCCC1=O, C[N+](C)(C)CC#CCN1CCCC1=O	CANZROMYQDHYHR-UHFFFAOYSA-N, CANZROMYQDHYHR-UHFFFAOYSA-N, CANZROMYQDHYHR-UHFFFAOYSA-N, CANZROMYQDHYHR-UHFFFAOYSA-N	Preclinical
oxotremorine-sesquifumarate	cholinergic receptor agonist	CHRM1, CHRM2, CHRM3, CHRM4			O=C1CCCN1CC#CCN1CCCC1, O=C1CCCN1CC#CCN1CCCC1, O=C1CCCN1CC#CCN1CCCC1	RSDOPYMFZBJHRL-UHFFFAOYSA-N, RSDOPYMFZBJHRL-UHFFFAOYSA-N, RSDOPYMFZBJHRL-UHFFFAOYSA-N	Preclinical
oxprenolol	adrenergic receptor antagonist	ADRB1	cardiology	angina pectoris, hypertension, cardiac arrythmia	CC(C)NC[C@@H](O)COc1ccccc1OCC=C |&1:5|, CC(C)NC[C@@H](O)COc1ccccc1OCC=C |&1:5|	CEMAWMOMDPGJMB-CYBMUJFWSA-N, CEMAWMOMDPGJMB-CYBMUJFWSA-N	Launched
oxybenzone	lipase inhibitor	LIPE	dermatology	sunscreen lotion	COc1ccc(C(=O)c2ccccc2)c(O)c1, COc1ccc(C(=O)c2ccccc2)c(O)c1	DXGLGDHPHMLXJC-UHFFFAOYSA-N, DXGLGDHPHMLXJC-UHFFFAOYSA-N	Launched
oxybuprocaine	local anesthetic	SCN10A	neurology/psychiatry	local anesthetic	CCCCOc1cc(ccc1N)C(=O)OCCN(CC)CC, CCCCOc1cc(ccc1N)C(=O)OCCN(CC)CC, CCCCOc1cc(ccc1N)C(=O)OCCN(CC)CC, CCCCOc1cc(ccc1N)C(=O)OCCN(CC)CC, CCCCOc1cc(ccc1N)C(=O)OCCN(CC)CC	CMHHMUWAYWTMGS-UHFFFAOYSA-N, CMHHMUWAYWTMGS-UHFFFAOYSA-N, CMHHMUWAYWTMGS-UHFFFAOYSA-N, CMHHMUWAYWTMGS-UHFFFAOYSA-N, CMHHMUWAYWTMGS-UHFFFAOYSA-N	Launched
oxybutynin	acetylcholine receptor antagonist	CHRM1, CHRM2, CHRM3	urology	urinary incontinence	CCN(CC)CC#CCOC(=O)[C@@](O)(C1CCCCC1)c1ccccc1 |&1:12,r|, CCN(CC)CC#CCOC(=O)[C@@](O)(C1CCCCC1)c1ccccc1 |&1:12,r|	XIQVNETUBQGFHX-QFIPXVFZSA-N, XIQVNETUBQGFHX-QFIPXVFZSA-N	Launched
oxyclozanide			infectious disease	fascioliasis	Oc1c(Cl)cc(Cl)cc1NC(=O)c1c(O)c(Cl)cc(Cl)c1Cl, Oc1c(Cl)cc(Cl)cc1NC(=O)c1c(O)c(Cl)cc(Cl)c1Cl, Oc1c(Cl)cc(Cl)cc1NC(=O)c1c(O)c(Cl)cc(Cl)c1Cl, Oc1c(Cl)cc(Cl)cc1NC(=O)c1c(O)c(Cl)cc(Cl)c1Cl, Oc1c(Cl)cc(Cl)cc1NC(=O)c1c(O)c(Cl)cc(Cl)c1Cl	JYWIYHUXVMAGLG-UHFFFAOYSA-N, JYWIYHUXVMAGLG-UHFFFAOYSA-N, JYWIYHUXVMAGLG-UHFFFAOYSA-N, JYWIYHUXVMAGLG-UHFFFAOYSA-N, JYWIYHUXVMAGLG-UHFFFAOYSA-N	Launched
oxyfedrine	adrenergic receptor agonist		cardiology	angina pectoris	COc1cccc(c1)C(=O)CCN[C@@H](C)[C@H](O)c1ccccc1, COc1cccc(c1)C(=O)CCN[C@@H](C)[C@H](O)c1ccccc1	GDYUVHBMFVMBAF-LIRRHRJNSA-N, GDYUVHBMFVMBAF-LIRRHRJNSA-N	Launched
oxymatrine					[H][C@]12CCC[N@@+]3([O-])CCC[C@]([H])([C@@]4([H])CCCC(=O)N4C1)[C@]23[H]	XVPBINOPNYFXID-JARXUMMXSA-N	Launched
oxymetazoline	adrenergic receptor agonist	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, HTR1B, HTR1D, HTR2C	otolaryngology	nasal congestion	Cc1cc(c(O)c(C)c1CC1=NCCN1)C(C)(C)C |t:11|, Cc1cc(c(O)c(C)c1CC1=NCCN1)C(C)(C)C |t:11|, Cc1cc(c(O)c(C)c1CC1=NCCN1)C(C)(C)C |t:11|	WYWIFABBXFUGLM-UHFFFAOYSA-N, WYWIFABBXFUGLM-UHFFFAOYSA-N, WYWIFABBXFUGLM-UHFFFAOYSA-N	Launched
oxyphenbutazone	cyclooxygenase inhibitor				CCCC[C@H]1C(=O)N(N(C1=O)c1ccc(O)cc1)c1ccccc1 |r|	HFHZKZSRXITVMK-KRWDZBQOSA-N	Withdrawn
oxyphencyclimine	cholinergic receptor antagonist		gastroenterology	peptic ulcer disease (PUD)	CN1CCCN=C1COC(=O)[C@@](O)(C1CCCCC1)c1ccccc1 |&1:11,c:5|, CN1CCCN=C1COC(=O)[C@@](O)(C1CCCCC1)c1ccccc1 |&1:11,c:5|	DUDKAZCAISNGQN-FQEVSTJZSA-N, DUDKAZCAISNGQN-FQEVSTJZSA-N	Launched
oxyphenonium	cholinergic receptor antagonist	CHRM1, CHRM3	gastroenterology	peptic ulcer disease (PUD)	CC[N+](C)(CC)CCOC(=O)C(O)(C1CCCCC1)c1ccccc1	GFRUPHOKLBPHTQ-UHFFFAOYSA-N	Launched
oxypurinol	xanthine oxidase inhibitor	XDH			O=c1nc2[nH][nH]cc2c(=O)[nH]1, O=c1nc2[nH][nH]cc2c(=O)[nH]1	HXNFUBHNUDHIGC-UHFFFAOYSA-N, HXNFUBHNUDHIGC-UHFFFAOYSA-N	Phase 2/Phase 3
oxyquinoline	chelating agent	METAP2	dermatology	cosmetic	Oc1cccc2cccnc12, Oc1cccc2cccnc12, Oc1cccc2cccnc12, Oc1cccc2cccnc12	MCJGNVYPOGVAJF-UHFFFAOYSA-N, MCJGNVYPOGVAJF-UHFFFAOYSA-N, MCJGNVYPOGVAJF-UHFFFAOYSA-N, MCJGNVYPOGVAJF-UHFFFAOYSA-N	Launched
oxytetracycline	bacterial 30S ribosomal subunit inhibitor		infectious disease, urology	chlamydia, urinary tract infections, skin infections, ear infections, gonorrhea, urethritis, Lyme disease	CN(C)[C@H]1[C@@H]2[C@@H](O)[C@H]3C(=C(O)[C@]2(O)C(O)=C(C(N)=O)C1=O)C(=O)c1c(O)cccc1[C@@]3(C)O |a:3,4,5,7,11,30,&1:8,&2:15,t:8,15|, CN(C)[C@H]1[C@@H]2[C@@H](O)[C@H]3C(=C(O)[C@]2(O)C(O)=C(C(N)=O)C1=O)C(=O)c1c(O)cccc1[C@@]3(C)O |a:3,4,5,7,11,30,&1:8,&2:15,t:8,15|, CN(C)[C@H]1[C@@H]2[C@@H](O)[C@H]3C(=C(O)[C@]2(O)C(O)=C(C(N)=O)C1=O)C(=O)c1c(O)cccc1[C@@]3(C)O |a:3,4,5,7,11,30,&1:8,&2:15,t:8,15|, CN(C)[C@H]1[C@@H]2[C@@H](O)[C@H]3C(=C(O)[C@]2(O)C(O)=C(C(N)=O)C1=O)C(=O)c1c(O)cccc1[C@@]3(C)O |a:3,4,5,7,11,30,&1:8,&2:15,t:8,15|	KTUXFHGUHYRDNF-PXOLEDIWSA-N, KTUXFHGUHYRDNF-PXOLEDIWSA-N, KTUXFHGUHYRDNF-PXOLEDIWSA-N, KTUXFHGUHYRDNF-PXOLEDIWSA-N	Launched
oxytocin	oxytocin receptor agonist	AVPR1A, AVPR1B, AVPR2, OXTR	obstetrics/gynecology	labor induction	CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@@H](N)CSSC[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC1=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O, CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@@H](N)CSSC[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC1=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O	XNOPRXBHLZRZKH-LGMJNFKNSA-N, XNOPRXBHLZRZKH-LGMJNFKNSA-N	Launched
ozagrel	thromboxane synthase inhibitor	TBXAS1	neurology/psychiatry	stroke	OC(=O)\C=C\c1ccc(Cn2ccnc2)cc1, OC(=O)\C=C\c1ccc(Cn2ccnc2)cc1, OC(=O)\C=C\c1ccc(Cn2ccnc2)cc1, OC(=O)\C=C\c1ccc(Cn2ccnc2)cc1, OC(=O)\C=C\c1ccc(Cn2ccnc2)cc1	SHZKQBHERIJWAO-AATRIKPKSA-N, SHZKQBHERIJWAO-AATRIKPKSA-N, SHZKQBHERIJWAO-AATRIKPKSA-N, SHZKQBHERIJWAO-AATRIKPKSA-N, SHZKQBHERIJWAO-AATRIKPKSA-N	Launched
ozanimod	sphingosine 1-phosphate receptor agonist	S1PR1			CC(C)Oc1ccc(cc1C#N)-c1nc(no1)-c1cccc2[C@H](CCc12)NCCO	XRVDGNKRPOAQTN-FQEVSTJZSA-N	Phase 3
ozenoxacin	antiinfective drug				CNc1ncc(cc1C)-c1ccc2c(c1C)n(cc(C(O)=O)c2=O)C1CC1	XPIJWUTXQAGSLK-UHFFFAOYSA-N	Phase 3
ozolinone	diuretic				CN1C(=O)[C@@H](S\C1=C/C(O)=O)N1CCCCC1 |&1:4,r|	NQFBZYYUAFJYNS-SKVAFPRGSA-N	Phase 3
O4I1	Oct inducer	POU5F1			COc1ccc(COc2ccc(CC#N)cc2)cc1, COc1ccc(COc2ccc(CC#N)cc2)cc1	QJEJLARVLKHYFW-UHFFFAOYSA-N, QJEJLARVLKHYFW-UHFFFAOYSA-N	Preclinical
O6-benzylguanine	O6-alkylguanine-DNA alkyltransferase inhibitor	MGMT			Nc1nc(OCc2ccccc2)c2[nH]cnc2n1, Nc1nc(OCc2ccccc2)c2[nH]cnc2n1, Nc1nc(OCc2ccccc2)c2[nH]cnc2n1	KRWMERLEINMZFT-UHFFFAOYSA-N, KRWMERLEINMZFT-UHFFFAOYSA-N, KRWMERLEINMZFT-UHFFFAOYSA-N	Phase 3
p-dimethylinamyl-benzoate					CCCCCOC(=O)c1ccc(cc1)N(C)C, CCCCCOC(=O)c1ccc(cc1)N(C)C	LXTZRIBXKVRLOA-UHFFFAOYSA-N, LXTZRIBXKVRLOA-UHFFFAOYSA-N	Preclinical
PA-452	retinoid receptor antagonist	RXRA			CCCCCCOc1cc2c(cc1N(C)c1ncc(cn1)C(O)=O)C(C)(C)CCC2(C)C, CCCCCCOc1cc2c(cc1N(C)c1ncc(cn1)C(O)=O)C(C)(C)CCC2(C)C, CCCCCCOc1cc2c(cc1N(C)c1ncc(cn1)C(O)=O)C(C)(C)CCC2(C)C, CCCCCCOc1cc2c(cc1N(C)c1ncc(cn1)C(O)=O)C(C)(C)CCC2(C)C	JJUUTJCZMGZJDZ-UHFFFAOYSA-N, JJUUTJCZMGZJDZ-UHFFFAOYSA-N, JJUUTJCZMGZJDZ-UHFFFAOYSA-N, JJUUTJCZMGZJDZ-UHFFFAOYSA-N	Preclinical
PAC-1	caspase activator	CASP3			Oc1c(CC=C)cccc1\C=N\NC(=O)CN1CCN(Cc2ccccc2)CC1, Oc1c(CC=C)cccc1\C=N\NC(=O)CN1CCN(Cc2ccccc2)CC1, Oc1c(CC=C)cccc1\C=N\NC(=O)CN1CCN(Cc2ccccc2)CC1, Oc1c(CC=C)cccc1\C=N\NC(=O)CN1CCN(Cc2ccccc2)CC1, Oc1c(CC=C)cccc1\C=N\NC(=O)CN1CCN(Cc2ccccc2)CC1, Oc1c(CC=C)cccc1\C=N\NC(=O)CN1CCN(Cc2ccccc2)CC1, Oc1c(CC=C)cccc1\C=N\NC(=O)CN1CCN(Cc2ccccc2)CC1, Oc1c(CC=C)cccc1\C=N\NC(=O)CN1CCN(Cc2ccccc2)CC1, Oc1c(CC=C)cccc1\C=N\NC(=O)CN1CCN(Cc2ccccc2)CC1, Oc1c(CC=C)cccc1\C=N\NC(=O)CN1CCN(Cc2ccccc2)CC1, Oc1c(CC=C)cccc1\C=N\NC(=O)CN1CCN(Cc2ccccc2)CC1	YQNRVGJCPCNMKT-LFVJCYFKSA-N, YQNRVGJCPCNMKT-LFVJCYFKSA-N, YQNRVGJCPCNMKT-LFVJCYFKSA-N, YQNRVGJCPCNMKT-LFVJCYFKSA-N, YQNRVGJCPCNMKT-LFVJCYFKSA-N, YQNRVGJCPCNMKT-LFVJCYFKSA-N, YQNRVGJCPCNMKT-LFVJCYFKSA-N, YQNRVGJCPCNMKT-LFVJCYFKSA-N, YQNRVGJCPCNMKT-LFVJCYFKSA-N, YQNRVGJCPCNMKT-LFVJCYFKSA-N, YQNRVGJCPCNMKT-LFVJCYFKSA-N	Phase 1
paclitaxel	tubulin polymerization inhibitor	BCL2, MAP2, MAP4, MAPT, NR1I2, TLR4, TUBA1A, TUBA1B, TUBA1C, TUBA3C, TUBA3D, TUBA3E, TUBA4A, TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8	oncology	ovarian cancer, breast cancer, non-small cell lung cancer (NSCLC)	CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1 |c:5|, CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1 |c:5|, CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1 |c:5|, CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1 |c:5|, CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1 |c:5|, CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1 |c:5|, CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1 |c:5|, CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1 |c:5|, CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1 |c:5|	RCINICONZNJXQF-MZXODVADSA-N, RCINICONZNJXQF-MZXODVADSA-N, RCINICONZNJXQF-MZXODVADSA-N, RCINICONZNJXQF-MZXODVADSA-N, RCINICONZNJXQF-MZXODVADSA-N, RCINICONZNJXQF-MZXODVADSA-N, RCINICONZNJXQF-MZXODVADSA-N, RCINICONZNJXQF-MZXODVADSA-N, RCINICONZNJXQF-MZXODVADSA-N	Launched
PACOCF3	phospholipase inhibitor	PLA2G4A			CCCCCCCCCCCCCCCC(=O)C(F)(F)F, CCCCCCCCCCCCCCCC(=O)C(F)(F)F, CCCCCCCCCCCCCCCC(=O)C(F)(F)F	MAHYXYTYTLCTQD-UHFFFAOYSA-N, MAHYXYTYTLCTQD-UHFFFAOYSA-N, MAHYXYTYTLCTQD-UHFFFAOYSA-N	Preclinical
pacritinib	FLT3 inhibitor, JAK inhibitor	FLT3, JAK1, JAK2, JAK3			C(CN1CCCC1)Oc1ccc2Nc3nccc(n3)-c3cccc(COC\C=C\COCc1c2)c3 |t:29|, C(CN1CCCC1)Oc1ccc2Nc3nccc(n3)-c3cccc(COC\C=C\COCc1c2)c3 |t:29|, C(CN1CCCC1)Oc1ccc2Nc3nccc(n3)-c3cccc(COC\C=C\COCc1c2)c3 |t:29|, C(CN1CCCC1)Oc1ccc2Nc3nccc(n3)-c3cccc(COC\C=C\COCc1c2)c3 |t:29|, C(CN1CCCC1)Oc1ccc2Nc3nccc(n3)-c3cccc(COC\C=C\COCc1c2)c3 |t:29|, C(CN1CCCC1)Oc1ccc2Nc3nccc(n3)-c3cccc(COC\C=C\COCc1c2)c3 |t:29|, C(CN1CCCC1)Oc1ccc2Nc3nccc(n3)-c3cccc(COC\C=C\COCc1c2)c3 |t:29|	HWXVIOGONBBTBY-ONEGZZNKSA-N, HWXVIOGONBBTBY-ONEGZZNKSA-N, HWXVIOGONBBTBY-ONEGZZNKSA-N, HWXVIOGONBBTBY-ONEGZZNKSA-N, HWXVIOGONBBTBY-ONEGZZNKSA-N, HWXVIOGONBBTBY-ONEGZZNKSA-N, HWXVIOGONBBTBY-ONEGZZNKSA-N	Phase 3
padsevonil	antiepileptic				COCc1nn2c(CN3C[C@@H](CC(F)(F)Cl)CC3=O)c(nc2s1)C(F)(F)F	DCXFIOLWWRXEQH-SSDOTTSWSA-N	Phase 3
paeoniflorin	anticonvulsant				C[C@@]12C[C@@]3(O)O[C@@H](O1)[C@]1(COC(=O)c4ccccc4)[C@H]3C[C@]21O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O, C[C@@]12C[C@@]3(O)O[C@@H](O1)[C@]1(COC(=O)c4ccccc4)[C@H]3C[C@]21O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O, C[C@@]12C[C@@]3(O)O[C@@H](O1)[C@]1(COC(=O)c4ccccc4)[C@H]3C[C@]21O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O	YKRGDOXKVOZESV-WRJNSLSBSA-N, YKRGDOXKVOZESV-WRJNSLSBSA-N, YKRGDOXKVOZESV-WRJNSLSBSA-N	Preclinical
paeonol	anti-inflammatory agent				COc1ccc(C(C)=O)c(O)c1, COc1ccc(C(C)=O)c(O)c1	UILPJVPSNHJFIK-UHFFFAOYSA-N, UILPJVPSNHJFIK-UHFFFAOYSA-N	Preclinical
pafuramidine	DNA synthesis inhibitor				CON=C(N)c1ccc(cc1)-c1ccc(o1)-c1ccc(cc1)C(N)=NOC, CON=C(N)c1ccc(cc1)-c1ccc(o1)-c1ccc(cc1)C(N)=NOC	UKOQVLAXCBRRGH-UHFFFAOYSA-N, UKOQVLAXCBRRGH-UHFFFAOYSA-N	Phase 3
pagoclone	GABA receptor agonist				CC(C)CCC(=O)C[C@@H]1N(C(=O)c2ccccc12)c1ccc2ccc(Cl)nc2n1 |&1:8,r|	HIUPRQPBWVEQJJ-IBGZPJMESA-N	Phase 2/Phase 3
palbociclib	CDK inhibitor	CDK4, CDK6	oncology	breast cancer	CC(=O)c1c(C)c2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n(C2CCCC2)c1=O, CC(=O)c1c(C)c2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n(C2CCCC2)c1=O, CC(=O)c1c(C)c2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n(C2CCCC2)c1=O, CC(=O)c1c(C)c2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n(C2CCCC2)c1=O, CC(=O)c1c(C)c2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n(C2CCCC2)c1=O, CC(=O)c1c(C)c2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n(C2CCCC2)c1=O, CC(=O)c1c(C)c2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n(C2CCCC2)c1=O, CC(=O)c1c(C)c2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n(C2CCCC2)c1=O, CC(=O)c1c(C)c2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n(C2CCCC2)c1=O	AHJRHEGDXFFMBM-UHFFFAOYSA-N, AHJRHEGDXFFMBM-UHFFFAOYSA-N, AHJRHEGDXFFMBM-UHFFFAOYSA-N, AHJRHEGDXFFMBM-UHFFFAOYSA-N, AHJRHEGDXFFMBM-UHFFFAOYSA-N, AHJRHEGDXFFMBM-UHFFFAOYSA-N, AHJRHEGDXFFMBM-UHFFFAOYSA-N, InChI=1S/C24H29N7O2/c1-15-19-14-27-24(28-20-8-7-18(13-26-20)30-11-9-25-10-12-30)29-22(19)31(17-5-3-4-6-17)23(33)21(15)16(2)32/h7-8,13-14,17,25H,3-6,9-12H2,1-2H3,(H,26,27,28,29), InChI=1S/C24H29N7O2/c1-15-19-14-27-24(28-20-8-7-18(13-26-20)30-11-9-25-10-12-30)29-22(19)31(17-5-3-4-6-17)23(33)21(15)16(2)32/h7-8,13-14,17,25H,3-6,9-12H2,1-2H3,(H,26,27,28,29)	Launched
palifosfamide	DNA alkylating agent				OP(=O)(NCCCl)NCCCl, OP(=O)(NCCCl)NCCCl	BKCJZNIZRWYHBN-UHFFFAOYSA-N, BKCJZNIZRWYHBN-UHFFFAOYSA-N	Phase 3
paliperidone	dopamine receptor antagonist, serotonin receptor antagonist	DRD2, HTR2A	neurology/psychiatry	schizophrenia	Cc1nc2[C@@H](O)CCCn2c(=O)c1CCN1CCC(CC1)c1noc2cc(F)ccc12 |&1:4,r|, Cc1nc2[C@@H](O)CCCn2c(=O)c1CCN1CCC(CC1)c1noc2cc(F)ccc12 |&1:4,r|, Cc1nc2[C@@H](O)CCCn2c(=O)c1CCN1CCC(CC1)c1noc2cc(F)ccc12 |&1:4,r|, Cc1nc2[C@@H](O)CCCn2c(=O)c1CCN1CCC(CC1)c1noc2cc(F)ccc12 |&1:4,r|	PMXMIIMHBWHSKN-IBGZPJMESA-N, PMXMIIMHBWHSKN-IBGZPJMESA-N, PMXMIIMHBWHSKN-IBGZPJMESA-N, PMXMIIMHBWHSKN-IBGZPJMESA-N	Launched
palmatine-chloride	dopamine synthesis inhibitor	CYP3A4			COc1cc2CC[n+]3cc4c(OC)c(OC)ccc4cc3-c2cc1OC, COc1cc2CC[n+]3cc4c(OC)c(OC)ccc4cc3-c2cc1OC, COc1cc2CC[n+]3cc4c(OC)c(OC)ccc4cc3-c2cc1OC	QUCQEUCGKKTEBI-UHFFFAOYSA-N, QUCQEUCGKKTEBI-UHFFFAOYSA-N, QUCQEUCGKKTEBI-UHFFFAOYSA-N	Preclinical
palmitoleic-acid					CCCCCC\C=C/CCCCCCCC(O)=O, CCCCCC\C=C/CCCCCCCC(O)=O	SECPZKHBENQXJG-FPLPWBNLSA-N, SECPZKHBENQXJG-FPLPWBNLSA-N	Preclinical
palmitoylcarnitine	protein kinase inhibitor				CCCCCCCCCCCCCCCC(=O)O[C@@H](CC(O)=O)C[N+](C)(C)C |&1:18|, CCCCCCCCCCCCCCCC(=O)O[C@@H](CC(O)=O)C[N+](C)(C)C |&1:18|, CCCCCCCCCCCCCCCC(=O)O[C@@H](CC(O)=O)C[N+](C)(C)C |&1:18|	XOMRRQXKHMYMOC-NRFANRHFSA-O, XOMRRQXKHMYMOC-NRFANRHFSA-O, XOMRRQXKHMYMOC-NRFANRHFSA-O	Preclinical
palmitoylethanolamide	cannabinoid receptor agonist	CNR2, GPR119, GPR55			CCCCCCCCCCCCCCCC(=O)NCCO, CCCCCCCCCCCCCCCC(=O)NCCO	HXYVTAGFYLMHSO-UHFFFAOYSA-N, HXYVTAGFYLMHSO-UHFFFAOYSA-N	Launched
palomid-529	AKT inhibitor, mTOR inhibitor	MTOR			COc1ccc(COc2cc3oc(=O)c4cc(ccc4c3cc2OC)[C@@H](C)O)cc1 |&1:25,r|, COc1ccc(COc2cc3oc(=O)c4cc(ccc4c3cc2OC)[C@@H](C)O)cc1 |&1:25,r|, COc1ccc(COc2cc3oc(=O)c4cc(ccc4c3cc2OC)[C@@H](C)O)cc1 |&1:25,r|	YEAHTLOYHVWAKW-CQSZACIVSA-N, YEAHTLOYHVWAKW-CQSZACIVSA-N, YEAHTLOYHVWAKW-CQSZACIVSA-N	Phase 1
palonosetron	serotonin receptor antagonist	HTR3A	gastroenterology	nausea, vomiting	O=C1N(C[C@H]2CCCc3cccc1c23)[C@@H]1CN2CCC1CC2, O=C1N(C[C@H]2CCCc3cccc1c23)[C@@H]1CN2CCC1CC2	CPZBLNMUGSZIPR-NVXWUHKLSA-N, CPZBLNMUGSZIPR-NVXWUHKLSA-N	Launched
palosuran	urotensin receptor antagonist	UTS2R			Cc1cc(NC(=O)NCCN2CCC(O)(Cc3ccccc3)CC2)c2ccccc2n1	WYJCYXOCHXWTHG-UHFFFAOYSA-N	Phase 2
palovarotene	retinoid receptor agonist	RARG			CC1(C)CCC(C)(C)c2cc(\C=C\c3ccc(cc3)C(O)=O)c(Cn3cccn3)cc12, CC1(C)CCC(C)(C)c2cc(\C=C\c3ccc(cc3)C(O)=O)c(Cn3cccn3)cc12, CC1(C)CCC(C)(C)c2cc(\C=C\c3ccc(cc3)C(O)=O)c(Cn3cccn3)cc12, CC1(C)CCC(C)(C)c2cc(\C=C\c3ccc(cc3)C(O)=O)c(Cn3cccn3)cc12, CC1(C)CCC(C)(C)c2cc(\C=C\c3ccc(cc3)C(O)=O)c(Cn3cccn3)cc12	YTFHCXIPDIHOIA-DHZHZOJOSA-N, YTFHCXIPDIHOIA-DHZHZOJOSA-N, YTFHCXIPDIHOIA-DHZHZOJOSA-N, YTFHCXIPDIHOIA-DHZHZOJOSA-N, YTFHCXIPDIHOIA-DHZHZOJOSA-N	Phase 3
pamabrom	diuretic		gastroenterology	bloating	CC(C)(N)CO.Cn1c2nc(Br)[nH]c2c(=O)n(C)c1=O, CC(C)(N)CO.Cn1c2nc(Br)[nH]c2c(=O)n(C)c1=O	ATOTUUBRFJHZQG-UHFFFAOYSA-N, ATOTUUBRFJHZQG-UHFFFAOYSA-N	Launched
pamidronate	bone resorption inhibitor	FDPS	endocrinology, oncology, hematologic malignancy	hypercalcemia, Paget's disease, breast cancer, multiple myeloma	NCCC(O)(P(O)(O)=O)P(O)(O)=O, NCCC(O)(P(O)(O)=O)P(O)(O)=O	WRUUGTRCQOWXEG-UHFFFAOYSA-N, WRUUGTRCQOWXEG-UHFFFAOYSA-N	Launched
pamiparib	PARP inhibitor				C[C@]12CCCN1Cc1n[nH]c(=O)c3cc(F)cc4[nH]c2c1c34	DENYZIUJOTUUNY-MRXNPFEDSA-N	Phase 3
pancuronium	acetylcholine receptor antagonist	CHRM2, CHRM3, CHRNA1, CHRNA2	critical care, neurology/psychiatry	endotracheal intubation, muscle relaxant	CC(=O)O[C@H]1[C@H](C[C@H]2[C@@H]3CC[C@H]4C[C@H](OC(C)=O)[C@H](C[C@]4(C)[C@H]3CC[C@]12C)[N+]1(C)CCCCC1)[N+]1(C)CCCCC1, CC(=O)O[C@H]1[C@H](C[C@H]2[C@@H]3CC[C@H]4C[C@H](OC(C)=O)[C@H](C[C@]4(C)[C@H]3CC[C@]12C)[N+]1(C)CCCCC1)[N+]1(C)CCCCC1, CC(=O)O[C@H]1[C@H](C[C@H]2[C@@H]3CC[C@H]4C[C@H](OC(C)=O)[C@H](C[C@]4(C)[C@H]3CC[C@]12C)[N+]1(C)CCCCC1)[N+]1(C)CCCCC1, CC(=O)O[C@H]1[C@H](C[C@H]2[C@@H]3CC[C@H]4C[C@H](OC(C)=O)[C@H](C[C@]4(C)[C@H]3CC[C@]12C)[N+]1(C)CCCCC1)[N+]1(C)CCCCC1	GVEAYVLWDAFXET-XGHATYIMSA-N, GVEAYVLWDAFXET-XGHATYIMSA-N, GVEAYVLWDAFXET-XGHATYIMSA-N, GVEAYVLWDAFXET-XGHATYIMSA-N	Launched
panipenem	antibacterial 				C[C@@H](O)[C@@H]1[C@H]2CC(S[C@H]3CCN(C3)C(N)=C)=C(N2C1=O)C(O)=O |c:16|	UIWSCWBHZRPIKR-DLYFRVTGSA-N	Preclinical
panobinostat	HDAC inhibitor	HDAC1, HDAC2, HDAC3, HDAC4, HDAC6, HDAC7, HDAC8, HDAC9	hematologic malignancy	multiple myeloma	Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1, Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1, Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1, Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1, Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1, Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1, Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1, Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1, Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1, Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1	FPOHNWQLNRZRFC-ZHACJKMWSA-N, FPOHNWQLNRZRFC-ZHACJKMWSA-N, FPOHNWQLNRZRFC-ZHACJKMWSA-N, FPOHNWQLNRZRFC-ZHACJKMWSA-N, FPOHNWQLNRZRFC-ZHACJKMWSA-N, FPOHNWQLNRZRFC-ZHACJKMWSA-N, FPOHNWQLNRZRFC-ZHACJKMWSA-N, FPOHNWQLNRZRFC-ZHACJKMWSA-N, FPOHNWQLNRZRFC-ZHACJKMWSA-N, FPOHNWQLNRZRFC-ZHACJKMWSA-N	Launched
pantethine	coenzyme A precursor				CC(C)(CO)[C@@H](O)C(=O)NCCC(=O)NCCSSCCNC(=O)CCNC(=O)[C@H](O)C(C)(C)CO, CC(C)(CO)[C@@H](O)C(=O)NCCC(=O)NCCSSCCNC(=O)CCNC(=O)[C@H](O)C(C)(C)CO, CC(C)(CO)[C@@H](O)C(=O)NCCC(=O)NCCSSCCNC(=O)CCNC(=O)[C@H](O)C(C)(C)CO, CC(C)(CO)[C@@H](O)C(=O)NCCC(=O)NCCSSCCNC(=O)CCNC(=O)[C@H](O)C(C)(C)CO, CC(C)(CO)[C@@H](O)C(=O)NCCC(=O)NCCSSCCNC(=O)CCNC(=O)[C@H](O)C(C)(C)CO	DJWYOLJPSHDSAL-ROUUACIJSA-N, DJWYOLJPSHDSAL-ROUUACIJSA-N, DJWYOLJPSHDSAL-ROUUACIJSA-N, DJWYOLJPSHDSAL-ROUUACIJSA-N, DJWYOLJPSHDSAL-ROUUACIJSA-N	Launched
pantoprazole	ATPase inhibitor	ATP4A	gastroenterology	gastroesophageal reflux disease (GERD), erosive esophagitis (EE), Zollinger-Ellison syndrome	COc1ccnc(C[S@@](=O)c2nc3ccc(OC(F)F)cc3[nH]2)c1OC |&1:8|	IQPSEEYGBUAQFF-AREMUKBSSA-N	Launched
pantothenic-acid	coenzyme A precursor				CC(C)(CO)[C@@H](O)C(=O)NCCC(O)=O, CC(C)(CO)[C@@H](O)C(=O)NCCC(O)=O, CC(C)(CO)[C@@H](O)C(=O)NCCC(O)=O, CC(C)(CO)[C@@H](O)C(=O)NCCC(O)=O	GHOKWGTUZJEAQD-ZETCQYMHSA-N, GHOKWGTUZJEAQD-ZETCQYMHSA-N, GHOKWGTUZJEAQD-ZETCQYMHSA-N, GHOKWGTUZJEAQD-ZETCQYMHSA-N	Launched
PAOPA	dopamine receptor modulator	DRD2			NC(=O)CN1CC[C@@H](NC(=O)[C@@H]2CCCN2)C1=O, NC(=O)CN1CC[C@@H](NC(=O)[C@@H]2CCCN2)C1=O	QXHVGEXNEZRSGG-JGVFFNPUSA-N, QXHVGEXNEZRSGG-JGVFFNPUSA-N	Preclinical
papaverine	phosphodiesterase inhibitor	PDE10A, PDE4B, PDE5A	cardiology, hematology, gastroenterology	myocardial infarction, angina pectoris, pulmonary embolism (PE), colitis, vascular spasm	COc1ccc(Cc2nccc3cc(OC)c(OC)cc23)cc1OC, COc1ccc(Cc2nccc3cc(OC)c(OC)cc23)cc1OC, COc1ccc(Cc2nccc3cc(OC)c(OC)cc23)cc1OC	XQYZDYMELSJDRZ-UHFFFAOYSA-N, XQYZDYMELSJDRZ-UHFFFAOYSA-N, XQYZDYMELSJDRZ-UHFFFAOYSA-N	Launched
paquinimod	S100A9 inhibitor				CCN(C(=O)c1c(O)c2c(CC)cccc2n(C)c1=O)c1ccccc1	DIKSYHCCYVYKRO-UHFFFAOYSA-N	Phase 2
para-toluenesulfonamide		CA12, CA2, CA6, CA9			Cc1ccc(cc1)S(N)(=O)=O, Cc1ccc(cc1)S(N)(=O)=O, Cc1ccc(cc1)S(N)(=O)=O	LMYRWZFENFIFIT-UHFFFAOYSA-N, LMYRWZFENFIFIT-UHFFFAOYSA-N, LMYRWZFENFIFIT-UHFFFAOYSA-N	Phase 3
paracetamol	cyclooxygenase inhibitor	FAAH, PTGS1, PTGS2, TRPV1	neurology/psychiatry, endocrinology	pain relief, fever	CC(=O)Nc1ccc(O)cc1, CC(=O)Nc1ccc(O)cc1, CC(=O)Nc1ccc(O)cc1, CC(=O)Nc1ccc(O)cc1, CC(=O)Nc1ccc(O)cc1, CC(=O)Nc1ccc(O)cc1, CC(=O)Nc1ccc(O)cc1	RZVAJINKPMORJF-UHFFFAOYSA-N, RZVAJINKPMORJF-UHFFFAOYSA-N, RZVAJINKPMORJF-UHFFFAOYSA-N, InChI=1S/C8H9NO2/c1-6(10)9-7-2-4-8(11)5-3-7/h2-5,11H,1H3,(H,9,10), InChI=1S/C8H9NO2/c1-6(10)9-7-2-4-8(11)5-3-7/h2-5,11H,1H3,(H,9,10), InChI=1S/C8H9NO2/c1-6(10)9-7-2-4-8(11)5-3-7/h2-5,11H,1H3,(H,9,10), InChI=1S/C8H9NO2/c1-6(10)9-7-2-4-8(11)5-3-7/h2-5,11H,1H3,(H,9,10)	Launched
parachlorophenol	antiinfective drug		infectious disease	first-aid antiseptic	Oc1ccc(Cl)cc1, Oc1ccc(Cl)cc1, Oc1ccc(Cl)cc1, Oc1ccc(Cl)cc1	WXNZTHHGJRFXKQ-UHFFFAOYSA-N, WXNZTHHGJRFXKQ-UHFFFAOYSA-N, WXNZTHHGJRFXKQ-UHFFFAOYSA-N, WXNZTHHGJRFXKQ-UHFFFAOYSA-N	Launched
paramethadione	anticonvulsant	CACNA1G	neurology/psychiatry	seizures	CC[C@@]1(C)OC(=O)N(C)C1=O |&1:2,r|, CC[C@@]1(C)OC(=O)N(C)C1=O |&1:2,r|	VQASKUSHBVDKGU-SSDOTTSWSA-N, VQASKUSHBVDKGU-SSDOTTSWSA-N	Launched
paraxanthine	adenosine receptor antagonist				Cn1cnc2[nH]c(=O)n(C)c(=O)c12, Cn1cnc2[nH]c(=O)n(C)c(=O)c12, Cn1cnc2[nH]c(=O)n(C)c(=O)c12	QUNWUDVFRNGTCO-UHFFFAOYSA-N, QUNWUDVFRNGTCO-UHFFFAOYSA-N, QUNWUDVFRNGTCO-UHFFFAOYSA-N	Phase 1
parbendazole	tubulin polymerization inhibitor	TUBB			CCCCc1ccc2nc(NC(=O)OC)[nH]c2c1, CCCCc1ccc2nc(NC(=O)OC)[nH]c2c1, CCCCc1ccc2nc(NC(=O)OC)[nH]c2c1	YRWLZFXJFBZBEY-UHFFFAOYSA-N, YRWLZFXJFBZBEY-UHFFFAOYSA-N, YRWLZFXJFBZBEY-UHFFFAOYSA-N	Preclinical
parcetasal	anti-inflammatory agent				CC(=O)Nc1ccc(O[C@]2(C)OC(=O)c3ccccc3O2)cc1 |&1:9,r|	ZAPRLADYRFPQSH-KRWDZBQOSA-N	Preclinical
pardoprunox	dopamine receptor agonist, serotonin receptor agonist	DRD2, DRD3, DRD4, HTR1A, HTR7			CN1CCN(CC1)c1cccc2[nH]c(=O)oc12, CN1CCN(CC1)c1cccc2[nH]c(=O)oc12, CN1CCN(CC1)c1cccc2[nH]c(=O)oc12	YVPUUUDAZYFFQT-UHFFFAOYSA-N, YVPUUUDAZYFFQT-UHFFFAOYSA-N, YVPUUUDAZYFFQT-UHFFFAOYSA-N	Phase 3
parecoxib	cyclooxygenase inhibitor	LTF	neurology/psychiatry	pain relief	CCC(=O)NS(=O)(=O)c1ccc(cc1)-c1c(C)onc1-c1ccccc1, CCC(=O)NS(=O)(=O)c1ccc(cc1)-c1c(C)onc1-c1ccccc1, CCC(=O)NS(=O)(=O)c1ccc(cc1)-c1c(C)onc1-c1ccccc1	TZRHLKRLEZJVIJ-UHFFFAOYSA-N, TZRHLKRLEZJVIJ-UHFFFAOYSA-N, TZRHLKRLEZJVIJ-UHFFFAOYSA-N	Launched
parethoxycaine	local anesthetic				CCOc1ccc(cc1)C(=O)OCCN(CC)CC	OWWVHQUOYSPNNE-UHFFFAOYSA-N	Preclinical
pargyline	monoamine oxidase inhibitor	MAOA, MAOB	cardiology	hypertension	CN(CC#C)Cc1ccccc1, CN(CC#C)Cc1ccccc1	DPWPWRLQFGFJFI-UHFFFAOYSA-N, DPWPWRLQFGFJFI-UHFFFAOYSA-N	Launched
paricalcitol	vitamin D receptor agonist	VDR	nephrology, endocrinology	chronic kidney disease (CKD), hyperthyroidism	C[C@H](\C=C\[C@H](C)C(C)(C)O)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1C[C@@H](O)C[C@H](O)C1, C[C@H](\C=C\[C@H](C)C(C)(C)O)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1C[C@@H](O)C[C@H](O)C1, C[C@H](\C=C\[C@H](C)C(C)(C)O)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1C[C@@H](O)C[C@H](O)C1, C[C@H](\C=C\[C@H](C)C(C)(C)O)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1C[C@@H](O)C[C@H](O)C1	BPKAHTKRCLCHEA-UBFJEZKGSA-N, BPKAHTKRCLCHEA-UBFJEZKGSA-N, BPKAHTKRCLCHEA-UBFJEZKGSA-N, BPKAHTKRCLCHEA-UBFJEZKGSA-N	Launched
paritaprevir	HCV inhibitor		infectious disease	hepatitis C	Cc1cnc(cn1)C(=O)N[C@H]1CCCCC\C=C/[C@@H]2C[C@]2(NC(=O)[C@@H]2C[C@H](CN2C1=O)Oc1nc2ccccc2c2ccccc12)C(=O)NS(=O)(=O)C1CC1 |c:17|, Cc1cnc(cn1)C(=O)N[C@H]1CCCCC\C=C/[C@@H]2C[C@]2(NC(=O)[C@@H]2C[C@H](CN2C1=O)Oc1nc2ccccc2c2ccccc12)C(=O)NS(=O)(=O)C1CC1 |c:17|	UAUIUKWPKRJZJV-QPLHLKROSA-N, UAUIUKWPKRJZJV-QPLHLKROSA-N	Launched
paromomycin	bacterial 30S ribosomal subunit inhibitor		infectious disease	amebiasis	NC[C@@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@@H](O[C@@H]3[C@@H](O)[C@H](N)C[C@H](N)[C@H]3O[C@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3N)[C@@H]2O)[C@H](N)[C@@H](O)[C@@H]1O, NC[C@@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@@H](O[C@@H]3[C@@H](O)[C@H](N)C[C@H](N)[C@H]3O[C@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3N)[C@@H]2O)[C@H](N)[C@@H](O)[C@@H]1O, NC[C@@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@@H](O[C@@H]3[C@@H](O)[C@H](N)C[C@H](N)[C@H]3O[C@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3N)[C@@H]2O)[C@H](N)[C@@H](O)[C@@H]1O, NC[C@@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@@H](O[C@@H]3[C@@H](O)[C@H](N)C[C@H](N)[C@H]3O[C@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3N)[C@@H]2O)[C@H](N)[C@@H](O)[C@@H]1O, NC[C@@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@@H](O[C@@H]3[C@@H](O)[C@H](N)C[C@H](N)[C@H]3O[C@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3N)[C@@H]2O)[C@H](N)[C@@H](O)[C@@H]1O	UOZODPSAJZTQNH-LSWIJEOBSA-N, UOZODPSAJZTQNH-LSWIJEOBSA-N, UOZODPSAJZTQNH-LSWIJEOBSA-N, UOZODPSAJZTQNH-LSWIJEOBSA-N, UOZODPSAJZTQNH-LSWIJEOBSA-N	Launched
paroxetine	selective serotonin reuptake inhibitor (SSRI)	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, HTR2A, SLC6A2, SLC6A4	neurology/psychiatry	depression, obsessive compulsive disorder (OCD), generalized anxiety disorder (GAD), panic disorders, posttraumatic stress disorder, social anxiety disorder	Fc1ccc(cc1)[C@@H]1CCNC[C@H]1COc1ccc2OCOc2c1, Fc1ccc(cc1)[C@@H]1CCNC[C@H]1COc1ccc2OCOc2c1, Fc1ccc(cc1)[C@@H]1CCNC[C@H]1COc1ccc2OCOc2c1, Fc1ccc(cc1)[C@@H]1CCNC[C@H]1COc1ccc2OCOc2c1, Fc1ccc(cc1)[C@@H]1CCNC[C@H]1COc1ccc2OCOc2c1, Fc1ccc(cc1)[C@@H]1CCNC[C@H]1COc1ccc2OCOc2c1	AHOUBRCZNHFOSL-YOEHRIQHSA-N, AHOUBRCZNHFOSL-YOEHRIQHSA-N, AHOUBRCZNHFOSL-YOEHRIQHSA-N, AHOUBRCZNHFOSL-YOEHRIQHSA-N, AHOUBRCZNHFOSL-YOEHRIQHSA-N, AHOUBRCZNHFOSL-YOEHRIQHSA-N	Launched
paroxypropione	gonadotropin inhibitor				CCC(=O)c1ccc(O)cc1, CCC(=O)c1ccc(O)cc1	RARSHUDCJQSEFJ-UHFFFAOYSA-N, RARSHUDCJQSEFJ-UHFFFAOYSA-N	Launched
parsaclisib	PI3K inhibitor				CCOc1c(cc(Cl)c(F)c1[C@@H]1CNC(=O)C1)[C@H](C)n1nc(C)c2c(N)ncnc12	ZQPDJCIXJHUERQ-QWRGUYRKSA-N	Phase 2
parthenolide	NFkB pathway inhibitor				C\C1=C/CC[C@@]2(C)O[C@H]2[C@H]2OC(=O)C(=C)[C@@H]2CC1 |c:1|, C\C1=C/CC[C@@]2(C)O[C@H]2[C@H]2OC(=O)C(=C)[C@@H]2CC1 |c:1|, C\C1=C/CC[C@@]2(C)O[C@H]2[C@H]2OC(=O)C(=C)[C@@H]2CC1 |c:1|	KTEXNACQROZXEV-SLXBATTESA-N, KTEXNACQROZXEV-SLXBATTESA-N, KTEXNACQROZXEV-SLXBATTESA-N	Phase 1
parthenolide-(-)	NFkB pathway inhibitor	HDAC1			C\C1=C\CC[C@@]2(C)O[C@H]2[C@H]2OC(=O)C(=C)[C@@H]2CC1 |t:1|, C\C1=C\CC[C@@]2(C)O[C@H]2[C@H]2OC(=O)C(=C)[C@@H]2CC1 |t:1|	KTEXNACQROZXEV-QLIGOWBFSA-N, KTEXNACQROZXEV-QLIGOWBFSA-N	Preclinical
parthenolide-(alternate-stereo)	NFkB pathway inhibitor	IKBKB, RELA			C\C1=C/CC[C@@]2(C)O[C@@H]2[C@H]2OC(=O)C(=C)[C@@H]2CC1 |c:1|, C\C1=C/CC[C@@]2(C)O[C@@H]2[C@H]2OC(=O)C(=C)[C@@H]2CC1 |c:1|, C\C1=C/CC[C@@]2(C)O[C@@H]2[C@H]2OC(=O)C(=C)[C@@H]2CC1 |c:1|, C\C1=C/CC[C@@]2(C)O[C@@H]2[C@H]2OC(=O)C(=C)[C@@H]2CC1 |c:1|, C\C1=C/CC[C@@]2(C)O[C@@H]2[C@H]2OC(=O)C(=C)[C@@H]2CC1 |c:1|	KTEXNACQROZXEV-PVLRGYAZSA-N, KTEXNACQROZXEV-PVLRGYAZSA-N, KTEXNACQROZXEV-PVLRGYAZSA-N, KTEXNACQROZXEV-PVLRGYAZSA-N, KTEXNACQROZXEV-PVLRGYAZSA-N	Preclinical
pasireotide	somatostatin receptor agonist	SSTR1, SSTR2, SSTR3, SSTR5	endocrinology	Cushing's syndrome, acromegaly	NCCCC[C@@H]1NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)[C@@H](NC(=O)[C@@H]2C[C@H](CN2C(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2ccc(OCc3ccccc3)cc2)NC1=O)OC(=O)NCCN)c1ccccc1, NCCCC[C@@H]1NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)[C@@H](NC(=O)[C@@H]2C[C@H](CN2C(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2ccc(OCc3ccccc3)cc2)NC1=O)OC(=O)NCCN)c1ccccc1	VMZMNAABQBOLAK-DBILLSOUSA-N, VMZMNAABQBOLAK-DBILLSOUSA-N	Launched
PAT-1251	lysyl oxidase inhibitor				NCc1cc(Oc2cccc(c2)C(=O)N2C[C@@H](O)[C@H](F)C2)nc(c1)C(F)(F)F	ODGXXYXJORZPHE-ZIAGYGMSSA-N	Phase 1
pavinetant	neurokinin receptor antagonist				CC[C@H](NC(=O)c1c(NS(C)(=O)=O)c(nc2ccccc12)-c1ccccc1)c1ccccc1	QYTBBBAHNIWFOD-NRFANRHFSA-N	Phase 2
pazopanib	KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	CSF1R, FGF1, FGFR1, FGFR3, FLT1, FLT4, ITK, KDR, KIT, PDGFRA, PDGFRB, SH2B3	oncology	renal cell carcinoma (RCC), soft tissue sarcoma (STS)	CN(c1ccc2c(C)n(C)nc2c1)c1ccnc(Nc2ccc(C)c(c2)S(N)(=O)=O)n1, CN(c1ccc2c(C)n(C)nc2c1)c1ccnc(Nc2ccc(C)c(c2)S(N)(=O)=O)n1, CN(c1ccc2c(C)n(C)nc2c1)c1ccnc(Nc2ccc(C)c(c2)S(N)(=O)=O)n1, CN(c1ccc2c(C)n(C)nc2c1)c1ccnc(Nc2ccc(C)c(c2)S(N)(=O)=O)n1, CN(c1ccc2c(C)n(C)nc2c1)c1ccnc(Nc2ccc(C)c(c2)S(N)(=O)=O)n1, CN(c1ccc2c(C)n(C)nc2c1)c1ccnc(Nc2ccc(C)c(c2)S(N)(=O)=O)n1, CN(c1ccc2c(C)n(C)nc2c1)c1ccnc(Nc2ccc(C)c(c2)S(N)(=O)=O)n1	CUIHSIWYWATEQL-UHFFFAOYSA-N, CUIHSIWYWATEQL-UHFFFAOYSA-N, CUIHSIWYWATEQL-UHFFFAOYSA-N, CUIHSIWYWATEQL-UHFFFAOYSA-N, CUIHSIWYWATEQL-UHFFFAOYSA-N, CUIHSIWYWATEQL-UHFFFAOYSA-N, CUIHSIWYWATEQL-UHFFFAOYSA-N	Launched
pazufloxacin	topoisomerase inhibitor		infectious disease	pneumonia, peritonitis, bacterial septicemia	C[C@H]1COc2c(c(F)cc3c2n1cc(C(O)=O)c3=O)C1(N)CC1, C[C@H]1COc2c(c(F)cc3c2n1cc(C(O)=O)c3=O)C1(N)CC1	XAGMUUZPGZWTRP-ZETCQYMHSA-N, XAGMUUZPGZWTRP-ZETCQYMHSA-N	Launched
PBI-4050	free fatty acid receptor agonist				CCCCCc1cccc(CC(O)=O)c1	PEGQOIGYZLJMIB-UHFFFAOYSA-N	Phase 2/Phase 3
PBT-1033	chelating agent				CN(C)Cc1ccc2c(Cl)cc(Cl)c(O)c2n1	YZPOQCQXOSEMAZ-UHFFFAOYSA-N	Preclinical
PCA-4248	platelet activating factor receptor antagonist	PTAFR			COC(=O)C1=C(C)NC(C)=C([C@@H]1C)C(=O)OCCSc1ccccc1 |&1:11,r,c:4,9|, COC(=O)C1=C(C)NC(C)=C([C@@H]1C)C(=O)OCCSc1ccccc1 |&1:11,r,c:4,9|, COC(=O)C1=C(C)NC(C)=C([C@@H]1C)C(=O)OCCSc1ccccc1 |&1:11,r,c:4,9|, COC(=O)C1=C(C)NC(C)=C([C@@H]1C)C(=O)OCCSc1ccccc1 |&1:11,r,c:4,9|	DHCNAWNKZMNTIS-GFCCVEGCSA-N, DHCNAWNKZMNTIS-GFCCVEGCSA-N, DHCNAWNKZMNTIS-GFCCVEGCSA-N, DHCNAWNKZMNTIS-GFCCVEGCSA-N	Phase 1
PCI-24781	HDAC inhibitor	HDAC1, HDAC2, HDAC3, HDAC6			CN(C)Cc1c(oc2ccccc12)C(=O)NCCOc1ccc(cc1)C(=O)NO, CN(C)Cc1c(oc2ccccc12)C(=O)NCCOc1ccc(cc1)C(=O)NO, CN(C)Cc1c(oc2ccccc12)C(=O)NCCOc1ccc(cc1)C(=O)NO, CN(C)Cc1c(oc2ccccc12)C(=O)NCCOc1ccc(cc1)C(=O)NO	MAUCONCHVWBMHK-UHFFFAOYSA-N, MAUCONCHVWBMHK-UHFFFAOYSA-N, MAUCONCHVWBMHK-UHFFFAOYSA-N, MAUCONCHVWBMHK-UHFFFAOYSA-N	Phase 3
PCI-27483	ERK1 and ERK2 phosphorylation inhibitor				NC(=N)c1ccc2nc([nH]c2c1)-c1cc(CC(=O)N[C@@H](CC(O)=O)C(O)=O)cc(c1O)-c1cc(ccc1O)S(N)(=O)=O	WDJHHCAKBRKCLW-IBGZPJMESA-N	Phase 2
PCI-29732	Bruton's tyrosine kinase (BTK) inhibitor	BTK			Nc1ncnc2n(nc(-c3ccc(Oc4ccccc4)cc3)c12)C1CCCC1, Nc1ncnc2n(nc(-c3ccc(Oc4ccccc4)cc3)c12)C1CCCC1	GMJUPMONHWAZCP-UHFFFAOYSA-N, GMJUPMONHWAZCP-UHFFFAOYSA-N	Preclinical
PCI-34051	HDAC inhibitor	HDAC1, HDAC10, HDAC6, HDAC8			COc1ccc(Cn2ccc3ccc(cc23)C(=O)NO)cc1, COc1ccc(Cn2ccc3ccc(cc23)C(=O)NO)cc1, COc1ccc(Cn2ccc3ccc(cc23)C(=O)NO)cc1, COc1ccc(Cn2ccc3ccc(cc23)C(=O)NO)cc1, COc1ccc(Cn2ccc3ccc(cc23)C(=O)NO)cc1	AJRGHIGYPXNABY-UHFFFAOYSA-N, AJRGHIGYPXNABY-UHFFFAOYSA-N, AJRGHIGYPXNABY-UHFFFAOYSA-N, AJRGHIGYPXNABY-UHFFFAOYSA-N, AJRGHIGYPXNABY-UHFFFAOYSA-N	Preclinical
PCO-400	potassium channel activator	KCNJ8			CC1(C)Oc2ccc(cc2[C@@H](OC2=CC(=O)CC2)[C@@H]1O)C#N |t:13|, CC1(C)Oc2ccc(cc2[C@@H](OC2=CC(=O)CC2)[C@@H]1O)C#N |t:13|	WJBHHTPFTVKZCV-CVEARBPZSA-N, WJBHHTPFTVKZCV-CVEARBPZSA-N	Phase 1
PD-0325901	MEK inhibitor	MAP2K1			OC[C@@H](O)CONC(=O)c1ccc(F)c(F)c1Nc1ccc(I)cc1F, OC[C@@H](O)CONC(=O)c1ccc(F)c(F)c1Nc1ccc(I)cc1F	SUDAHWBOROXANE-SECBINFHSA-N, SUDAHWBOROXANE-SECBINFHSA-N	Phase 2
PD-102807	acetylcholine receptor antagonist	CHRM4			CCOC(=O)c1c(C)[nH]c2ccc3O[C@H]4N(CCc5cc(OC)ccc45)Cc3c12 |&1:14,r|, CCOC(=O)c1c(C)[nH]c2ccc3O[C@H]4N(CCc5cc(OC)ccc45)Cc3c12 |&1:14,r|, CCOC(=O)c1c(C)[nH]c2ccc3O[C@H]4N(CCc5cc(OC)ccc45)Cc3c12 |&1:14,r|, CCOC(=O)c1c(C)[nH]c2ccc3O[C@H]4N(CCc5cc(OC)ccc45)Cc3c12 |&1:14,r|	VDDUJINYXKGZLV-JOCHJYFZSA-N, VDDUJINYXKGZLV-JOCHJYFZSA-N, VDDUJINYXKGZLV-JOCHJYFZSA-N, VDDUJINYXKGZLV-JOCHJYFZSA-N	Preclinical
PD-118057	potassium channel activator	KCNH2			OC(=O)c1ccccc1Nc1ccc(CCc2ccc(Cl)c(Cl)c2)cc1, OC(=O)c1ccccc1Nc1ccc(CCc2ccc(Cl)c(Cl)c2)cc1, OC(=O)c1ccccc1Nc1ccc(CCc2ccc(Cl)c(Cl)c2)cc1	ZCQOSCDABPVAFB-UHFFFAOYSA-N, ZCQOSCDABPVAFB-UHFFFAOYSA-N, ZCQOSCDABPVAFB-UHFFFAOYSA-N	Preclinical
PD-123319	angiotensin antagonist	AGTR2			CN(C)c1ccc(Cn2cnc3CN([C@@H](Cc23)C(O)=O)C(=O)C(c2ccccc2)c2ccccc2)cc1C, CN(C)c1ccc(Cn2cnc3CN([C@@H](Cc23)C(O)=O)C(=O)C(c2ccccc2)c2ccccc2)cc1C, CN(C)c1ccc(Cn2cnc3CN([C@@H](Cc23)C(O)=O)C(=O)C(c2ccccc2)c2ccccc2)cc1C, CN(C)c1ccc(Cn2cnc3CN([C@@H](Cc23)C(O)=O)C(=O)C(c2ccccc2)c2ccccc2)cc1C	YSTVFDAKLDMYCR-NDEPHWFRSA-N, YSTVFDAKLDMYCR-NDEPHWFRSA-N, YSTVFDAKLDMYCR-NDEPHWFRSA-N, YSTVFDAKLDMYCR-NDEPHWFRSA-N	Phase 1
PD-128907	dopamine receptor agonist	DRD2, DRD3			CCCN1CCO[C@H]2[C@H]1COc1ccc(O)cc21, CCCN1CCO[C@H]2[C@H]1COc1ccc(O)cc21, CCCN1CCO[C@H]2[C@H]1COc1ccc(O)cc21	YOILXOMTHPUMRG-TZMCWYRMSA-N, YOILXOMTHPUMRG-TZMCWYRMSA-N, YOILXOMTHPUMRG-TZMCWYRMSA-N	Preclinical
PD-153035	EGFR inhibitor	EGFR, KDR			COc1cc2ncnc(Nc3cccc(Br)c3)c2cc1OC, COc1cc2ncnc(Nc3cccc(Br)c3)c2cc1OC	LSPANGZZENHZNJ-UHFFFAOYSA-N, LSPANGZZENHZNJ-UHFFFAOYSA-N	Phase 1
PD-156707	endothelin receptor antagonist	EDNRA, EDNRB			COc1ccc(cc1)C(=O)C(\Cc1cc(OC)c(OC)c(OC)c1)=C(/C(O)=O)c1ccc2OCOc2c1	OFCTYBMKKTVKCR-QQTULTPQSA-N	Preclinical
PD-158780	EGFR inhibitor	EGFR			CNc1cc2c(Nc3cccc(Br)c3)ncnc2cn1, CNc1cc2c(Nc3cccc(Br)c3)ncnc2cn1, CNc1cc2c(Nc3cccc(Br)c3)ncnc2cn1, CNc1cc2c(Nc3cccc(Br)c3)ncnc2cn1, CNc1cc2c(Nc3cccc(Br)c3)ncnc2cn1	KFHMLBXBRCITHF-UHFFFAOYSA-N, KFHMLBXBRCITHF-UHFFFAOYSA-N, InChI=1S/C14H12BrN5/c1-16-13-6-11-12(7-17-13)18-8-19-14(11)20-10-4-2-3-9(15)5-10/h2-8H,1H3,(H,16,17)(H,18,19,20), InChI=1S/C14H12BrN5/c1-16-13-6-11-12(7-17-13)18-8-19-14(11)20-10-4-2-3-9(15)5-10/h2-8H,1H3,(H,16,17)(H,18,19,20), InChI=1S/C14H12BrN5/c1-16-13-6-11-12(7-17-13)18-8-19-14(11)20-10-4-2-3-9(15)5-10/h2-8H,1H3,(H,16,17)(H,18,19,20)	Preclinical
PD-160170	neuropeptide receptor antagonist	NPY1R			CC(C)c1ccccc1S(=O)(=O)c1cc(N)c2ncccc2c1[N+]([O-])=O, CC(C)c1ccccc1S(=O)(=O)c1cc(N)c2ncccc2c1[N+]([O-])=O, CC(C)c1ccccc1S(=O)(=O)c1cc(N)c2ncccc2c1[N+]([O-])=O	YUVNGBZROXQYQH-UHFFFAOYSA-N, YUVNGBZROXQYQH-UHFFFAOYSA-N, YUVNGBZROXQYQH-UHFFFAOYSA-N	Preclinical
PD-161570	FGFR inhibitor	FGFR1			CCN(CC)CCCCNc1ncc2cc(c(NC(=O)NC(C)(C)C)nc2n1)-c1c(Cl)cccc1Cl, CCN(CC)CCCCNc1ncc2cc(c(NC(=O)NC(C)(C)C)nc2n1)-c1c(Cl)cccc1Cl, CCN(CC)CCCCNc1ncc2cc(c(NC(=O)NC(C)(C)C)nc2n1)-c1c(Cl)cccc1Cl, CCN(CC)CCCCNc1ncc2cc(c(NC(=O)NC(C)(C)C)nc2n1)-c1c(Cl)cccc1Cl	MKVMEJKNLUWFSQ-UHFFFAOYSA-N, MKVMEJKNLUWFSQ-UHFFFAOYSA-N, MKVMEJKNLUWFSQ-UHFFFAOYSA-N, MKVMEJKNLUWFSQ-UHFFFAOYSA-N	Preclinical
PD-166285	SRC inhibitor	EGFR, FGFR1, PDGFRB, PKMYT1, SRC, WEE1			CCN(CC)CCOc1ccc(Nc2ncc3cc(-c4c(Cl)cccc4Cl)c(=O)n(C)c3n2)cc1, CCN(CC)CCOc1ccc(Nc2ncc3cc(-c4c(Cl)cccc4Cl)c(=O)n(C)c3n2)cc1, CCN(CC)CCOc1ccc(Nc2ncc3cc(-c4c(Cl)cccc4Cl)c(=O)n(C)c3n2)cc1, CCN(CC)CCOc1ccc(Nc2ncc3cc(-c4c(Cl)cccc4Cl)c(=O)n(C)c3n2)cc1, CCN(CC)CCOc1ccc(Nc2ncc3cc(-c4c(Cl)cccc4Cl)c(=O)n(C)c3n2)cc1, CCN(CC)CCOc1ccc(Nc2ncc3cc(-c4c(Cl)cccc4Cl)c(=O)n(C)c3n2)cc1	IFPPYSWJNWHOLQ-UHFFFAOYSA-N, IFPPYSWJNWHOLQ-UHFFFAOYSA-N, IFPPYSWJNWHOLQ-UHFFFAOYSA-N, IFPPYSWJNWHOLQ-UHFFFAOYSA-N, IFPPYSWJNWHOLQ-UHFFFAOYSA-N, IFPPYSWJNWHOLQ-UHFFFAOYSA-N	Preclinical
PD-166793	collagenase inhibitor, metalloproteinase inhibitor	MMP13, MMP2, MMP3			CC(C)[C@H](NS(=O)(=O)c1ccc(cc1)-c1ccc(Br)cc1)C(O)=O, CC(C)[C@H](NS(=O)(=O)c1ccc(cc1)-c1ccc(Br)cc1)C(O)=O, CC(C)[C@H](NS(=O)(=O)c1ccc(cc1)-c1ccc(Br)cc1)C(O)=O, CC(C)[C@H](NS(=O)(=O)c1ccc(cc1)-c1ccc(Br)cc1)C(O)=O	GJOCABIDMCKCEG-INIZCTEOSA-N, GJOCABIDMCKCEG-INIZCTEOSA-N, GJOCABIDMCKCEG-INIZCTEOSA-N, GJOCABIDMCKCEG-INIZCTEOSA-N	Preclinical
PD-168077	dopamine receptor agonist	DRD2			Cc1cccc(c1)C(=O)NCN1CCN(CC1)c1ccccc1C#N	DNULYRGWTFLJQL-UHFFFAOYSA-N	Preclinical
PD-168393	EGFR inhibitor	EGFR, ERBB2, SRC			Brc1cccc(Nc2ncnc3ccc(NC(=O)C=C)cc23)c1, Brc1cccc(Nc2ncnc3ccc(NC(=O)C=C)cc23)c1, Brc1cccc(Nc2ncnc3ccc(NC(=O)C=C)cc23)c1, Brc1cccc(Nc2ncnc3ccc(NC(=O)C=C)cc23)c1	HTUBKQUPEREOGA-UHFFFAOYSA-N, HTUBKQUPEREOGA-UHFFFAOYSA-N, HTUBKQUPEREOGA-UHFFFAOYSA-N, HTUBKQUPEREOGA-UHFFFAOYSA-N	Preclinical
PD-168568	dopamine receptor antagonist	DRD2, DRD4			Cc1ccc(cc1C)N1CCN(CC[C@H]2NC(=O)c3ccccc23)CC1 |&1:14|, Cc1ccc(cc1C)N1CCN(CC[C@H]2NC(=O)c3ccccc23)CC1 |&1:14|, Cc1ccc(cc1C)N1CCN(CC[C@H]2NC(=O)c3ccccc23)CC1 |&1:14|	WQEPZBNLBWDIRZ-OAQYLSRUSA-N, WQEPZBNLBWDIRZ-OAQYLSRUSA-N, WQEPZBNLBWDIRZ-OAQYLSRUSA-N	Preclinical
PD-173074	FGFR inhibitor, VEGFR inhibitor	FGFR1, FGFR2, FGFR3, FGFR4, FLT1, FLT4, KDR, PDGFRA, PDGFRB			CCN(CC)CCCCNc1ncc2cc(c(NC(=O)NC(C)(C)C)nc2n1)-c1cc(OC)cc(OC)c1, CCN(CC)CCCCNc1ncc2cc(c(NC(=O)NC(C)(C)C)nc2n1)-c1cc(OC)cc(OC)c1, CCN(CC)CCCCNc1ncc2cc(c(NC(=O)NC(C)(C)C)nc2n1)-c1cc(OC)cc(OC)c1, CCN(CC)CCCCNc1ncc2cc(c(NC(=O)NC(C)(C)C)nc2n1)-c1cc(OC)cc(OC)c1, CCN(CC)CCCCNc1ncc2cc(c(NC(=O)NC(C)(C)C)nc2n1)-c1cc(OC)cc(OC)c1, CCN(CC)CCCCNc1ncc2cc(c(NC(=O)NC(C)(C)C)nc2n1)-c1cc(OC)cc(OC)c1	DXCUKNQANPLTEJ-UHFFFAOYSA-N, DXCUKNQANPLTEJ-UHFFFAOYSA-N, DXCUKNQANPLTEJ-UHFFFAOYSA-N, DXCUKNQANPLTEJ-UHFFFAOYSA-N, DXCUKNQANPLTEJ-UHFFFAOYSA-N, DXCUKNQANPLTEJ-UHFFFAOYSA-N	Preclinical
PD-173212	calcium channel blocker	CACNA1B			CC(C)C[C@H](N(C)Cc1ccc(cc1)C(C)(C)C)C(=O)N[C@@H](Cc1ccc(OCc2ccccc2)cc1)C(=O)NC(C)(C)C, CC(C)C[C@H](N(C)Cc1ccc(cc1)C(C)(C)C)C(=O)N[C@@H](Cc1ccc(OCc2ccccc2)cc1)C(=O)NC(C)(C)C, CC(C)C[C@H](N(C)Cc1ccc(cc1)C(C)(C)C)C(=O)N[C@@H](Cc1ccc(OCc2ccccc2)cc1)C(=O)NC(C)(C)C, CC(C)C[C@H](N(C)Cc1ccc(cc1)C(C)(C)C)C(=O)N[C@@H](Cc1ccc(OCc2ccccc2)cc1)C(=O)NC(C)(C)C	GCDHMGROXQUFNR-HEVIKAOCSA-N, GCDHMGROXQUFNR-HEVIKAOCSA-N, GCDHMGROXQUFNR-HEVIKAOCSA-N, GCDHMGROXQUFNR-HEVIKAOCSA-N	Preclinical
PD-184352	MEK inhibitor	MAP2K1, MAP3K1, MAP3K2			Fc1ccc(C(=O)NOCC2CC2)c(Nc2ccc(I)cc2Cl)c1F, Fc1ccc(C(=O)NOCC2CC2)c(Nc2ccc(I)cc2Cl)c1F, Fc1ccc(C(=O)NOCC2CC2)c(Nc2ccc(I)cc2Cl)c1F, Fc1ccc(C(=O)NOCC2CC2)c(Nc2ccc(I)cc2Cl)c1F, Fc1ccc(C(=O)NOCC2CC2)c(Nc2ccc(I)cc2Cl)c1F, Fc1ccc(C(=O)NOCC2CC2)c(Nc2ccc(I)cc2Cl)c1F, Fc1ccc(C(=O)NOCC2CC2)c(Nc2ccc(I)cc2Cl)c1F, Fc1ccc(C(=O)NOCC2CC2)c(Nc2ccc(I)cc2Cl)c1F	GFMMXOIFOQCCGU-UHFFFAOYSA-N, GFMMXOIFOQCCGU-UHFFFAOYSA-N, GFMMXOIFOQCCGU-UHFFFAOYSA-N, GFMMXOIFOQCCGU-UHFFFAOYSA-N, GFMMXOIFOQCCGU-UHFFFAOYSA-N, InChI=1S/C17H14ClF2IN2O2/c18-12-7-10(21)3-6-14(12)22-16-11(4-5-13(19)15(16)20)17(24)23-25-8-9-1-2-9/h3-7,9,22H,1-2,8H2,(H,23,24), InChI=1S/C17H14ClF2IN2O2/c18-12-7-10(21)3-6-14(12)22-16-11(4-5-13(19)15(16)20)17(24)23-25-8-9-1-2-9/h3-7,9,22H,1-2,8H2,(H,23,24), InChI=1S/C17H14ClF2IN2O2/c18-12-7-10(21)3-6-14(12)22-16-11(4-5-13(19)15(16)20)17(24)23-25-8-9-1-2-9/h3-7,9,22H,1-2,8H2,(H,23,24)	Phase 2
PD-198306	MAP kinase inhibitor, MEK inhibitor	MAP2K1, MAP2K2			Cc1cc(I)ccc1Nc1c(F)c(F)c(F)cc1C(=O)NOCC1CC1, Cc1cc(I)ccc1Nc1c(F)c(F)c(F)cc1C(=O)NOCC1CC1, Cc1cc(I)ccc1Nc1c(F)c(F)c(F)cc1C(=O)NOCC1CC1, Cc1cc(I)ccc1Nc1c(F)c(F)c(F)cc1C(=O)NOCC1CC1, Cc1cc(I)ccc1Nc1c(F)c(F)c(F)cc1C(=O)NOCC1CC1, Cc1cc(I)ccc1Nc1c(F)c(F)c(F)cc1C(=O)NOCC1CC1, Cc1cc(I)ccc1Nc1c(F)c(F)c(F)cc1C(=O)NOCC1CC1	UHAXDAKQGVISBZ-UHFFFAOYSA-N, UHAXDAKQGVISBZ-UHFFFAOYSA-N, UHAXDAKQGVISBZ-UHFFFAOYSA-N, UHAXDAKQGVISBZ-UHFFFAOYSA-N, UHAXDAKQGVISBZ-UHFFFAOYSA-N, UHAXDAKQGVISBZ-UHFFFAOYSA-N, UHAXDAKQGVISBZ-UHFFFAOYSA-N	Preclinical
PD-318088	MEK inhibitor				OC[C@@H](O)CONC(=O)c1cc(Br)c(F)c(F)c1Nc1ccc(I)cc1F |&1:2,r|, OC[C@@H](O)CONC(=O)c1cc(Br)c(F)c(F)c1Nc1ccc(I)cc1F |&1:2,r|, OC[C@@H](O)CONC(=O)c1cc(Br)c(F)c(F)c1Nc1ccc(I)cc1F |&1:2,r|, OC[C@@H](O)CONC(=O)c1cc(Br)c(F)c(F)c1Nc1ccc(I)cc1F |&1:2,r|	XXSSGBYXSKOLAM-MRVPVSSYSA-N, XXSSGBYXSKOLAM-MRVPVSSYSA-N, XXSSGBYXSKOLAM-MRVPVSSYSA-N, XXSSGBYXSKOLAM-MRVPVSSYSA-N	Preclinical
PD-407824	PKC inhibitor	WEE1			Oc1ccc2[nH]c3cc(c4C(=O)NC(=O)c4c3c2c1)-c1ccccc1, Oc1ccc2[nH]c3cc(c4C(=O)NC(=O)c4c3c2c1)-c1ccccc1, Oc1ccc2[nH]c3cc(c4C(=O)NC(=O)c4c3c2c1)-c1ccccc1, Oc1ccc2[nH]c3cc(c4C(=O)NC(=O)c4c3c2c1)-c1ccccc1, Oc1ccc2[nH]c3cc(c4C(=O)NC(=O)c4c3c2c1)-c1ccccc1, Oc1ccc2[nH]c3cc(c4C(=O)NC(=O)c4c3c2c1)-c1ccccc1	IAUZTOZLTFSMIE-UHFFFAOYSA-N, IAUZTOZLTFSMIE-UHFFFAOYSA-N, IAUZTOZLTFSMIE-UHFFFAOYSA-N, IAUZTOZLTFSMIE-UHFFFAOYSA-N, IAUZTOZLTFSMIE-UHFFFAOYSA-N, IAUZTOZLTFSMIE-UHFFFAOYSA-N	Preclinical
PD-81723	adenosine receptor agonist	ADORA1			Cc1sc(N)c(C(=O)c2cccc(c2)C(F)(F)F)c1C, Cc1sc(N)c(C(=O)c2cccc(c2)C(F)(F)F)c1C	KKDKAWKYGCUOGR-UHFFFAOYSA-N, KKDKAWKYGCUOGR-UHFFFAOYSA-N	Preclinical
PD-98059	MEK inhibitor	AKT1, CHEK1, GSK3B, LCK, MAP2K1, MAPK1, MAPK11, MAPK12, MAPK14, MAPK8, PRKCA, RAF1, ROCK1, RPS6KB1, SGK1			COc1cccc(c1N)-c1cc(=O)c2ccccc2o1, COc1cccc(c1N)-c1cc(=O)c2ccccc2o1, COc1cccc(c1N)-c1cc(=O)c2ccccc2o1	QFWCYNPOPKQOKV-UHFFFAOYSA-N, QFWCYNPOPKQOKV-UHFFFAOYSA-N, QFWCYNPOPKQOKV-UHFFFAOYSA-N	Preclinical
PDD-00017273	PARG inhibitor				Cc1cc(Cn2c3ccc(cc3c(=O)n(Cc3cnc(C)s3)c2=O)S(=O)(=O)NC2(C)CC2)n(C)n1, Cc1cc(Cn2c3ccc(cc3c(=O)n(Cc3cnc(C)s3)c2=O)S(=O)(=O)NC2(C)CC2)n(C)n1	IFWUBRBMMNTBRZ-UHFFFAOYSA-N, IFWUBRBMMNTBRZ-UHFFFAOYSA-N	Preclinical
PDE10-IN-1	phosphodiesterase inhibitor	PDE10A			Cc1c(nc2c3cccnc3ccn12)[C@@H]1C[C@H]1c1nc2c(C)ncc(C)n2n1	ZLHNYULRKIEGAY-HZPDHXFCSA-N	Preclinical
PDP-EA	FAAH activator	FAAH			CCCCCCCCCCCCCCCc1cccc(OCC(=O)NCCO)c1, CCCCCCCCCCCCCCCc1cccc(OCC(=O)NCCO)c1	BIOVSNWTCKRADD-UHFFFAOYSA-N, BIOVSNWTCKRADD-UHFFFAOYSA-N	Preclinical
PD1-PDL-inhibitor-1	programmed death ligand inhibitor	CD274			COc1cc(OCc2cccc(c2C)-c2ccccc2)cc(OC)c1CN1CCCC[C@H]1C(O)=O, COc1cc(OCc2cccc(c2C)-c2ccccc2)cc(OC)c1CN1CCCC[C@H]1C(O)=O	ZBOYJODMIAUJHH-SANMLTNESA-N, ZBOYJODMIAUJHH-SANMLTNESA-N	Preclinical
peficitinib	JAK inhibitor	JAK1, JAK2, JAK3	rheumatology	rheumatoid arthritis	NC(=O)c1cnc2[nH]ccc2c1N[C@H]1[C@H]2C[C@H]3C[C@@H]1C[C@](O)(C3)C2 |&1:13,14,16,18,20,r|	DREIJXJRTLTGJC-ZKVNVPQCSA-N	Launched
pefloxacin	bacterial DNA gyrase inhibitor	TOP2A	infectious disease, urology	gastrointestinal infections, urethritis, gonorrhea, urinary tract infections	CCn1cc(C(O)=O)c(=O)c2cc(F)c(cc12)N1CCN(C)CC1, CCn1cc(C(O)=O)c(=O)c2cc(F)c(cc12)N1CCN(C)CC1, CCn1cc(C(O)=O)c(=O)c2cc(F)c(cc12)N1CCN(C)CC1	FHFYDNQZQSQIAI-UHFFFAOYSA-N, FHFYDNQZQSQIAI-UHFFFAOYSA-N, FHFYDNQZQSQIAI-UHFFFAOYSA-N	Launched
pelanserin	serotonin receptor antagonist	HTR2A			O=c1[nH]c2ccccc2c(=O)n1CCCN1CCN(CC1)c1ccccc1	WPKPLSFHHBBLRY-UHFFFAOYSA-N	Phase 2
pelitinib	EGFR inhibitor	EGFR			CCOc1cc2ncc(C#N)c(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)\C=C\CN(C)C, CCOc1cc2ncc(C#N)c(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)\C=C\CN(C)C, CCOc1cc2ncc(C#N)c(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)\C=C\CN(C)C, CCOc1cc2ncc(C#N)c(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)\C=C\CN(C)C	WVUNYSQLFKLYNI-AATRIKPKSA-N, WVUNYSQLFKLYNI-AATRIKPKSA-N, WVUNYSQLFKLYNI-AATRIKPKSA-N, WVUNYSQLFKLYNI-AATRIKPKSA-N	Phase 2
pelrinone	phosphodiesterase inhibitor				Cc1nc(=O)c(C#N)c(NCc2cccnc2)[nH]1	NZXHFDXOCVIYLO-UHFFFAOYSA-N	Phase 2
pemafibrate	PPAR receptor agonist				CC[C@@H](Oc1cccc(CN(CCCOc2ccc(OC)cc2)c2nc3ccccc3o2)c1)C(O)=O	ZHKNLJLMDFQVHJ-RUZDIDTESA-N	Phase 3
pemetrexed	dihydrofolate reductase inhibitor, thymidylate synthase inhibitor	ATIC, DHFR, GART, TYMS	oncology	non-small cell lung cancer (NSCLC), mesothelioma	Nc1nc(=O)c2c(CCc3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)c[nH]c2[nH]1, Nc1nc(=O)c2c(CCc3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)c[nH]c2[nH]1, Nc1nc(=O)c2c(CCc3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)c[nH]c2[nH]1, Nc1nc(=O)c2c(CCc3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)c[nH]c2[nH]1, Nc1nc(=O)c2c(CCc3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)c[nH]c2[nH]1, Nc1nc(=O)c2c(CCc3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)c[nH]c2[nH]1, Nc1nc(=O)c2c(CCc3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)c[nH]c2[nH]1, Nc1nc(=O)c2c(CCc3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)c[nH]c2[nH]1, Nc1nc(=O)c2c(CCc3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)c[nH]c2[nH]1, Nc1nc(=O)c2c(CCc3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)c[nH]c2[nH]1, Nc1nc(=O)c2c(CCc3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)c[nH]c2[nH]1	WBXPDJSOTKVWSJ-ZDUSSCGKSA-N, WBXPDJSOTKVWSJ-ZDUSSCGKSA-N, WBXPDJSOTKVWSJ-ZDUSSCGKSA-N, WBXPDJSOTKVWSJ-ZDUSSCGKSA-N, WBXPDJSOTKVWSJ-ZDUSSCGKSA-N, WBXPDJSOTKVWSJ-ZDUSSCGKSA-N, WBXPDJSOTKVWSJ-ZDUSSCGKSA-N, WBXPDJSOTKVWSJ-ZDUSSCGKSA-N, WBXPDJSOTKVWSJ-ZDUSSCGKSA-N, WBXPDJSOTKVWSJ-ZDUSSCGKSA-N, WBXPDJSOTKVWSJ-ZDUSSCGKSA-N	Launched
pemirolast	mediator release inhibitor	HRH1	pulmonary	asthma	Cc1cccn2c1ncc(-c1nn[nH]n1)c2=O, Cc1cccn2c1ncc(-c1nn[nH]n1)c2=O, Cc1cccn2c1ncc(-c1nn[nH]n1)c2=O	HIANJWSAHKJQTH-UHFFFAOYSA-N, HIANJWSAHKJQTH-UHFFFAOYSA-N, HIANJWSAHKJQTH-UHFFFAOYSA-N	Launched
pempidine	ganglionic blocker		cardiology	hypertension	CN1C(C)(C)CCCC1(C)C, CN1C(C)(C)CCCC1(C)C	XULIXFLCVXWHRF-UHFFFAOYSA-N, XULIXFLCVXWHRF-UHFFFAOYSA-N	Launched
penbutolol	adrenergic receptor antagonist	ADRB1, ADRB2, HTR1A, HTR1B	cardiology	hypertension	CC(C)(C)NC[C@H](O)COc1ccccc1C1CCCC1, CC(C)(C)NC[C@H](O)COc1ccccc1C1CCCC1, CC(C)(C)NC[C@H](O)COc1ccccc1C1CCCC1, CC(C)(C)NC[C@H](O)COc1ccccc1C1CCCC1, CC(C)(C)NC[C@H](O)COc1ccccc1C1CCCC1, CC(C)(C)NC[C@H](O)COc1ccccc1C1CCCC1	KQXKVJAGOJTNJS-HNNXBMFYSA-N, KQXKVJAGOJTNJS-HNNXBMFYSA-N, KQXKVJAGOJTNJS-HNNXBMFYSA-N, KQXKVJAGOJTNJS-HNNXBMFYSA-N, KQXKVJAGOJTNJS-HNNXBMFYSA-N, KQXKVJAGOJTNJS-HNNXBMFYSA-N	Launched
penciclovir	DNA directed DNA polymerase inhibitor		dental	cold sore	Nc1nc(=O)c2ncn(CCC(CO)CO)c2[nH]1, Nc1nc(=O)c2ncn(CCC(CO)CO)c2[nH]1, Nc1nc(=O)c2ncn(CCC(CO)CO)c2[nH]1, Nc1nc(=O)c2ncn(CCC(CO)CO)c2[nH]1	JNTOCHDNEULJHD-UHFFFAOYSA-N, JNTOCHDNEULJHD-UHFFFAOYSA-N, JNTOCHDNEULJHD-UHFFFAOYSA-N, JNTOCHDNEULJHD-UHFFFAOYSA-N	Launched
penfluridol	T-type calcium channel blocker	CACNA1G	neurology/psychiatry	schizophrenia	OC1(CCN(CCCC(c2ccc(F)cc2)c2ccc(F)cc2)CC1)c1ccc(Cl)c(c1)C(F)(F)F, OC1(CCN(CCCC(c2ccc(F)cc2)c2ccc(F)cc2)CC1)c1ccc(Cl)c(c1)C(F)(F)F, OC1(CCN(CCCC(c2ccc(F)cc2)c2ccc(F)cc2)CC1)c1ccc(Cl)c(c1)C(F)(F)F, OC1(CCN(CCCC(c2ccc(F)cc2)c2ccc(F)cc2)CC1)c1ccc(Cl)c(c1)C(F)(F)F, OC1(CCN(CCCC(c2ccc(F)cc2)c2ccc(F)cc2)CC1)c1ccc(Cl)c(c1)C(F)(F)F, OC1(CCN(CCCC(c2ccc(F)cc2)c2ccc(F)cc2)CC1)c1ccc(Cl)c(c1)C(F)(F)F	MDLAAYDRRZXJIF-UHFFFAOYSA-N, MDLAAYDRRZXJIF-UHFFFAOYSA-N, MDLAAYDRRZXJIF-UHFFFAOYSA-N, MDLAAYDRRZXJIF-UHFFFAOYSA-N, MDLAAYDRRZXJIF-UHFFFAOYSA-N, MDLAAYDRRZXJIF-UHFFFAOYSA-N	Launched
penicillamine-(D)	chelating agent		metabolism, rheumatology, nephrology	Wilson's disease, rheumatoid arthritis, cystinuria	CC(C)(S)[C@@H](N)C(O)=O, CC(C)(S)[C@@H](N)C(O)=O, CC(C)(S)[C@@H](N)C(O)=O	VVNCNSJFMMFHPL-VKHMYHEASA-N, VVNCNSJFMMFHPL-VKHMYHEASA-N, VVNCNSJFMMFHPL-VKHMYHEASA-N	Launched
penicillamine-(racemic)					CC(C)(S)[C@@H](N)C(O)=O |&1:4|	VVNCNSJFMMFHPL-VKHMYHEASA-N	Launched
penicillin-v-potassium	bacterial cell wall synthesis inhibitor		infectious disease	pneumonia, ear infections, skin infections, throat infections, cholera, scarlet fever	CC1(C)S[C@@H]2[C@H](NC(=O)COc3ccccc3)C(=O)N2[C@H]1C(O)=O, CC1(C)S[C@@H]2[C@H](NC(=O)COc3ccccc3)C(=O)N2[C@H]1C(O)=O	BPLBGHOLXOTWMN-MBNYWOFBSA-N, BPLBGHOLXOTWMN-MBNYWOFBSA-N	Launched
pentacosanoic-acid					CCCCCCCCCCCCCCCCCCCCCCCCC(O)=O, CCCCCCCCCCCCCCCCCCCCCCCCC(O)=O	MWMPEAHGUXCSMY-UHFFFAOYSA-N, MWMPEAHGUXCSMY-UHFFFAOYSA-N	Preclinical
pentagastrin	CCK receptor agonist	CCKBR	gastroenterology	anacidity diagnostic, gastric hypersecretion diagnostic	CSCC[C@H](NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)CCNC(=O)OC(C)(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](Cc1ccccc1)C(N)=O, CSCC[C@H](NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)CCNC(=O)OC(C)(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](Cc1ccccc1)C(N)=O	NEYNJQRKHLUJRU-DZUOILHNSA-N, NEYNJQRKHLUJRU-DZUOILHNSA-N	Launched
pentamidine	anti-pneumocystis agent	TRDMT1	infectious disease	pneumonia	NC(=N)c1ccc(OCCCCCOc2ccc(cc2)C(N)=N)cc1, NC(=N)c1ccc(OCCCCCOc2ccc(cc2)C(N)=N)cc1	XDRYMKDFEDOLFX-UHFFFAOYSA-N, XDRYMKDFEDOLFX-UHFFFAOYSA-N	Launched
pentetic-acid	chelating agent				OC(=O)CN(CCN(CC(O)=O)CC(O)=O)CCN(CC(O)=O)CC(O)=O, OC(=O)CN(CCN(CC(O)=O)CC(O)=O)CCN(CC(O)=O)CC(O)=O	QPCDCPDFJACHGM-UHFFFAOYSA-N, QPCDCPDFJACHGM-UHFFFAOYSA-N	Phase 2
pentolinium	cholinergic receptor antagonist	CHRNA10, CHRNA3, CHRNA4, CHRNB4	cardiology	hypertension	C[N+]1(CCCCC[N+]2(C)CCCC2)CCCC1, C[N+]1(CCCCC[N+]2(C)CCCC2)CCCC1, C[N+]1(CCCCC[N+]2(C)CCCC2)CCCC1	XSBSKEQEUFOSDD-UHFFFAOYSA-N, XSBSKEQEUFOSDD-UHFFFAOYSA-N, XSBSKEQEUFOSDD-UHFFFAOYSA-N	Launched
pentostatin	adenosine deaminase inhibitor, ribonucleotide reductase inhibitor	ADA	hematologic malignancy	hairy cell leukemia	OC[C@H]1O[C@H](C[C@@H]1O)n1cnc2[C@H](O)CN=CNc12 |c:16|, OC[C@H]1O[C@H](C[C@@H]1O)n1cnc2[C@H](O)CN=CNc12 |c:16|, OC[C@H]1O[C@H](C[C@@H]1O)n1cnc2[C@H](O)CN=CNc12 |c:16|	FPVKHBSQESCIEP-JQCXWYLXSA-N, FPVKHBSQESCIEP-JQCXWYLXSA-N, FPVKHBSQESCIEP-JQCXWYLXSA-N	Launched
pentoxifylline	phosphodiesterase inhibitor	ADORA1, ADORA2A, ADORA2B, ADRA2B, NT5E, PDE10A, PDE1A, PDE1B, PDE1C, PDE2A, PDE3A, PDE3B, PDE4A, PDE4B, PDE4C, PDE4D, PDE5A, PDE6A, PDE6B, PDE6C, PDE6D, PDE6G, PDE6H, PDE7A, PDE7B, PDE8A, PDE8B, PDE9A, TNF	cardiology	claudication	CC(=O)CCCCn1c(=O)n(C)c2ncn(C)c2c1=O, CC(=O)CCCCn1c(=O)n(C)c2ncn(C)c2c1=O, CC(=O)CCCCn1c(=O)n(C)c2ncn(C)c2c1=O, CC(=O)CCCCn1c(=O)n(C)c2ncn(C)c2c1=O, CC(=O)CCCCn1c(=O)n(C)c2ncn(C)c2c1=O	BYPFEZZEUUWMEJ-UHFFFAOYSA-N, BYPFEZZEUUWMEJ-UHFFFAOYSA-N, BYPFEZZEUUWMEJ-UHFFFAOYSA-N, BYPFEZZEUUWMEJ-UHFFFAOYSA-N, BYPFEZZEUUWMEJ-UHFFFAOYSA-N	Launched
pentylenetetrazol	GABA receptor antagonist				C1CCc2nnnn2CC1, C1CCc2nnnn2CC1, C1CCc2nnnn2CC1, C1CCc2nnnn2CC1	CWRVKFFCRWGWCS-UHFFFAOYSA-N, CWRVKFFCRWGWCS-UHFFFAOYSA-N, CWRVKFFCRWGWCS-UHFFFAOYSA-N, CWRVKFFCRWGWCS-UHFFFAOYSA-N	Withdrawn
peposertib	DNA dependent protein kinase inhibitor				COc1ccc(nn1)[C@@H](O)c1cc(c(F)cc1Cl)-c1ncnc2cc(ccc12)N1CCOCC1	MOWXJLUYGFNTAL-DEOSSOPVSA-N	Phase 1/Phase 2
pepstatin	aspartic protease inhibitor	CTSB, CTSD, CTSL, REN			CC(C)C[C@H](NC(=O)[C@H](C)NC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)CC(C)C)C(C)C)C(C)C)[C@@H](O)CC(O)=O, CC(C)C[C@H](NC(=O)[C@H](C)NC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)CC(C)C)C(C)C)C(C)C)[C@@H](O)CC(O)=O	FAXGPCHRFPCXOO-LXTPJMTPSA-N, FAXGPCHRFPCXOO-LXTPJMTPSA-N	Preclinical
peramivir	neuraminidase inhibitor		infectious disease	influenza A virus infection	CCC(CC)[C@H](NC(C)=O)[C@@H]1[C@H](O)[C@H](C[C@H]1NC(N)=N)C(O)=O, CCC(CC)[C@H](NC(C)=O)[C@@H]1[C@H](O)[C@H](C[C@H]1NC(N)=N)C(O)=O, CCC(CC)[C@H](NC(C)=O)[C@@H]1[C@H](O)[C@H](C[C@H]1NC(N)=N)C(O)=O	XRQDFNLINLXZLB-CKIKVBCHSA-N, XRQDFNLINLXZLB-CKIKVBCHSA-N, XRQDFNLINLXZLB-CKIKVBCHSA-N	Launched
perchlozone			infectious disease	tuberculosis	NC(=S)N\N=C\c1ccncc1	QTSJJDIDTYFLFC-BJMVGYQFSA-N	Launched
peretinoin	retinoid receptor agonist	RXRA			CC(C)=CCC\C(C)=C\CC\C(C)=C\C=C\C(\C)=C\C(O)=O, CC(C)=CCC\C(C)=C\CC\C(C)=C\C=C\C(\C)=C\C(O)=O, CC(C)=CCC\C(C)=C\CC\C(C)=C\C=C\C(\C)=C\C(O)=O	UUBHZHZSIKRVIV-KCXSXWJSSA-N, UUBHZHZSIKRVIV-KCXSXWJSSA-N, UUBHZHZSIKRVIV-KCXSXWJSSA-N	Phase 3
perfluamine					FC(F)(F)C(F)(F)C(F)(F)N(C(F)(F)C(F)(F)C(F)(F)F)C(F)(F)C(F)(F)C(F)(F)F	JAJLKEVKNDUJBG-UHFFFAOYSA-N	Launched
perflubron	contrast agent		radiology	contrast agent	FC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)Br, FC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)Br	WTWWXOGTJWMJHI-UHFFFAOYSA-N, WTWWXOGTJWMJHI-UHFFFAOYSA-N	Launched
perfluorodecalin			dermatology	cosmetic	FC1(F)C(F)(F)C(F)(F)C2(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C2(F)C1(F)F	UWEYRJFJVCLAGH-UHFFFAOYSA-N	Launched
perfluorohexyloctane					CCCCCCCCC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F	WRYIIOKOQSICTB-UHFFFAOYSA-N	Launched
pergolide	dopamine receptor agonist	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, DRD4, DRD5, HTR1A, HTR1B, HTR1D, HTR2A, HTR2B, HTR2C			CCCN1C[C@H](CSC)C[C@H]2[C@H]1Cc1c[nH]c3cccc2c13, CCCN1C[C@H](CSC)C[C@H]2[C@H]1Cc1c[nH]c3cccc2c13, CCCN1C[C@H](CSC)C[C@H]2[C@H]1Cc1c[nH]c3cccc2c13, CCCN1C[C@H](CSC)C[C@H]2[C@H]1Cc1c[nH]c3cccc2c13, CCCN1C[C@H](CSC)C[C@H]2[C@H]1Cc1c[nH]c3cccc2c13	YEHCICAEULNIGD-MZMPZRCHSA-N, YEHCICAEULNIGD-MZMPZRCHSA-N, YEHCICAEULNIGD-MZMPZRCHSA-N, YEHCICAEULNIGD-MZMPZRCHSA-N, YEHCICAEULNIGD-MZMPZRCHSA-N	Withdrawn
perhexiline	carnitine palmitoyltransferase inhibitor	CPT1A	cardiology	angina pectoris	C(C(C1CCCCC1)C1CCCCC1)[C@H]1CCCCN1 |&1:14|, C(C(C1CCCCC1)C1CCCCC1)[C@H]1CCCCN1 |&1:14|, C(C(C1CCCCC1)C1CCCCC1)[C@H]1CCCCN1 |&1:14|, C(C(C1CCCCC1)C1CCCCC1)[C@H]1CCCCN1 |&1:14|, C(C(C1CCCCC1)C1CCCCC1)[C@H]1CCCCN1 |&1:14|, C(C(C1CCCCC1)C1CCCCC1)[C@H]1CCCCN1 |&1:14|, C(C(C1CCCCC1)C1CCCCC1)[C@H]1CCCCN1 |&1:14|, C(C(C1CCCCC1)C1CCCCC1)[C@H]1CCCCN1 |&1:14|, C(C(C1CCCCC1)C1CCCCC1)[C@H]1CCCCN1 |&1:14|	CYXKNKQEMFBLER-GOSISDBHSA-N, CYXKNKQEMFBLER-GOSISDBHSA-N, CYXKNKQEMFBLER-GOSISDBHSA-N, CYXKNKQEMFBLER-GOSISDBHSA-N, CYXKNKQEMFBLER-GOSISDBHSA-N, CYXKNKQEMFBLER-GOSISDBHSA-N, CYXKNKQEMFBLER-GOSISDBHSA-N, InChI=1S/C19H35N/c1-3-9-16(10-4-1)19(17-11-5-2-6-12-17)15-18-13-7-8-14-20-18/h16-20H,1-15H2/t18-/m1/s1, InChI=1S/C19H35N/c1-3-9-16(10-4-1)19(17-11-5-2-6-12-17)15-18-13-7-8-14-20-18/h16-20H,1-15H2/t18-/m1/s1	Launched
perifosine	AKT inhibitor	AKT1			CCCCCCCCCCCCCCCCCCOP(O)(=O)OC1CC[N+](C)(C)CC1 |&1:19|, CCCCCCCCCCCCCCCCCCOP(O)(=O)OC1CC[N+](C)(C)CC1 |&1:19|, CCCCCCCCCCCCCCCCCCOP(O)(=O)OC1CC[N+](C)(C)CC1 |&1:19|, CCCCCCCCCCCCCCCCCCOP(O)(=O)OC1CC[N+](C)(C)CC1 |&1:19|, CCCCCCCCCCCCCCCCCCOP(O)(=O)OC1CC[N+](C)(C)CC1 |&1:19|	SZFPYBIJACMNJV-UHFFFAOYSA-O, SZFPYBIJACMNJV-UHFFFAOYSA-O, SZFPYBIJACMNJV-UHFFFAOYSA-O, SZFPYBIJACMNJV-UHFFFAOYSA-O, SZFPYBIJACMNJV-UHFFFAOYSA-O	Phase 3
perillyl-alcohol	apoptosis stimulant, farnesyltransferase inhibitor	FNTA			CC(=C)[C@H]1CCC(CO)=CC1 |&1:3,r,c:8|, CC(=C)[C@H]1CCC(CO)=CC1 |&1:3,r,c:8|, CC(=C)[C@H]1CCC(CO)=CC1 |&1:3,r,c:8|, CC(=C)[C@H]1CCC(CO)=CC1 |&1:3,r,c:8|	NDTYTMIUWGWIMO-SNVBAGLBSA-N, NDTYTMIUWGWIMO-SNVBAGLBSA-N, NDTYTMIUWGWIMO-SNVBAGLBSA-N, NDTYTMIUWGWIMO-SNVBAGLBSA-N	Phase 2
perindopril	angiotensin converting enzyme inhibitor	ACE	cardiology	hypertension, myocardial infarction, coronary artery disease (CAD)	CCC[C@H](N[C@@H](C)C(=O)N1[C@H]2CCCC[C@H]2C[C@H]1C(O)=O)C(=O)OCC, CCC[C@H](N[C@@H](C)C(=O)N1[C@H]2CCCC[C@H]2C[C@H]1C(O)=O)C(=O)OCC, CCC[C@H](N[C@@H](C)C(=O)N1[C@H]2CCCC[C@H]2C[C@H]1C(O)=O)C(=O)OCC, CCC[C@H](N[C@@H](C)C(=O)N1[C@H]2CCCC[C@H]2C[C@H]1C(O)=O)C(=O)OCC, CCC[C@H](N[C@@H](C)C(=O)N1[C@H]2CCCC[C@H]2C[C@H]1C(O)=O)C(=O)OCC	IPVQLZZIHOAWMC-QXKUPLGCSA-N, IPVQLZZIHOAWMC-QXKUPLGCSA-N, IPVQLZZIHOAWMC-QXKUPLGCSA-N, IPVQLZZIHOAWMC-QXKUPLGCSA-N, IPVQLZZIHOAWMC-QXKUPLGCSA-N	Launched
perindoprilat	angiotensin converting enzyme inhibitor	ACE			CCC[C@H](N[C@@H](C)C(=O)N1[C@H]2CCCC[C@H]2C[C@H]1C(O)=O)C(O)=O	ODAIHABQVKJNIY-PEDHHIEDSA-N	Phase 2
permethrin			infectious disease	lice	CC1(C)[C@@H](C=C(Cl)Cl)[C@@H]1C(=O)OCc1cccc(Oc2ccccc2)c1 |&1:3,&2:8,r|, CC1(C)[C@@H](C=C(Cl)Cl)[C@@H]1C(=O)OCc1cccc(Oc2ccccc2)c1 |&1:3,&2:8,r|, CC1(C)[C@@H](C=C(Cl)Cl)[C@@H]1C(=O)OCc1cccc(Oc2ccccc2)c1 |&1:3,&2:8,r|	RLLPVAHGXHCWKJ-PKOBYXMFSA-N, RLLPVAHGXHCWKJ-PKOBYXMFSA-N, RLLPVAHGXHCWKJ-PKOBYXMFSA-N	Launched
perospirone	dopamine receptor antagonist, serotonin receptor antagonist	DRD2, DRD3, DRD4	neurology/psychiatry	schizophrenia, bipolar disorder	O=C1[C@H]2CCCC[C@H]2C(=O)N1CCCCN1CCN(CC1)c1nsc2ccccc12, O=C1[C@H]2CCCC[C@H]2C(=O)N1CCCCN1CCN(CC1)c1nsc2ccccc12, O=C1[C@H]2CCCC[C@H]2C(=O)N1CCCCN1CCN(CC1)c1nsc2ccccc12, O=C1[C@H]2CCCC[C@H]2C(=O)N1CCCCN1CCN(CC1)c1nsc2ccccc12, O=C1[C@H]2CCCC[C@H]2C(=O)N1CCCCN1CCN(CC1)c1nsc2ccccc12	FBVFZWUMDDXLLG-HDICACEKSA-N, FBVFZWUMDDXLLG-HDICACEKSA-N, FBVFZWUMDDXLLG-HDICACEKSA-N, FBVFZWUMDDXLLG-HDICACEKSA-N, FBVFZWUMDDXLLG-HDICACEKSA-N	Launched
perphenazine	dopamine receptor antagonist	CALM1, DRD1, DRD2, HRH1, HTR2A, HTR2C, HTR6, HTR7	neurology/psychiatry, gastroenterology	schizophrenia, nausea, vomiting	OCCN1CCN(CCCN2c3ccccc3Sc3ccc(Cl)cc23)CC1, OCCN1CCN(CCCN2c3ccccc3Sc3ccc(Cl)cc23)CC1, OCCN1CCN(CCCN2c3ccccc3Sc3ccc(Cl)cc23)CC1, OCCN1CCN(CCCN2c3ccccc3Sc3ccc(Cl)cc23)CC1	RGCVKNLCSQQDEP-UHFFFAOYSA-N, RGCVKNLCSQQDEP-UHFFFAOYSA-N, RGCVKNLCSQQDEP-UHFFFAOYSA-N, RGCVKNLCSQQDEP-UHFFFAOYSA-N	Launched
peruvoside	cardiac glycoside				CO[C@H]1[C@@H](O)[C@@H](C)O[C@@H](O[C@H]2CC[C@@]3(C=O)[C@H](CC[C@@H]4[C@@H]3CC[C@]3(C)[C@H](CC[C@]43O)C3=CC(=O)OC3)C2)[C@@H]1O |a:2,3,8,10,13,16,19,20,23,25,28,&1:5,&2:37,t:33|	PMTSPAGBAFCORP-BZEWZVDJSA-N	Phase 1
perzinfotel	glutamate receptor antagonist	GRIN1, GRIN2A, GRIN2B			OP(O)(=O)CCN1CCCNc2c1c(=O)c2=O, OP(O)(=O)CCN1CCCNc2c1c(=O)c2=O, OP(O)(=O)CCN1CCCNc2c1c(=O)c2=O	BDABGOLMYNHHTR-UHFFFAOYSA-N, BDABGOLMYNHHTR-UHFFFAOYSA-N, BDABGOLMYNHHTR-UHFFFAOYSA-N	Phase 2
PETCM	caspase activator	CASP3			O[C@@H](Cc1ccncc1)C(Cl)(Cl)Cl |&1:1,r|, O[C@@H](Cc1ccncc1)C(Cl)(Cl)Cl |&1:1,r|	NGTDJJKTGRNNAU-ZETCQYMHSA-N, NGTDJJKTGRNNAU-ZETCQYMHSA-N	Preclinical
pevonedistat	nedd activating enzyme inhibitor	NAE1, UBA3			NS(=O)(=O)OC[C@@H]1C[C@H](C[C@@H]1O)n1ccc2c(N[C@H]3CCc4ccccc34)ncnc12, NS(=O)(=O)OC[C@@H]1C[C@H](C[C@@H]1O)n1ccc2c(N[C@H]3CCc4ccccc34)ncnc12, NS(=O)(=O)OC[C@@H]1C[C@H](C[C@@H]1O)n1ccc2c(N[C@H]3CCc4ccccc34)ncnc12, NS(=O)(=O)OC[C@@H]1C[C@H](C[C@@H]1O)n1ccc2c(N[C@H]3CCc4ccccc34)ncnc12, NS(=O)(=O)OC[C@@H]1C[C@H](C[C@@H]1O)n1ccc2c(N[C@H]3CCc4ccccc34)ncnc12, NS(=O)(=O)OC[C@@H]1C[C@H](C[C@@H]1O)n1ccc2c(N[C@H]3CCc4ccccc34)ncnc12, NS(=O)(=O)OC[C@@H]1C[C@H](C[C@@H]1O)n1ccc2c(N[C@H]3CCc4ccccc34)ncnc12, NS(=O)(=O)OC[C@@H]1C[C@H](C[C@@H]1O)n1ccc2c(N[C@H]3CCc4ccccc34)ncnc12	MPUQHZXIXSTTDU-QXGSTGNESA-N, MPUQHZXIXSTTDU-QXGSTGNESA-N, MPUQHZXIXSTTDU-QXGSTGNESA-N, MPUQHZXIXSTTDU-QXGSTGNESA-N, MPUQHZXIXSTTDU-QXGSTGNESA-N, InChI=1S/C21H25N5O4S/c22-31(28,29)30-11-14-9-15(10-19(14)27)26-8-7-17-20(23-12-24-21(17)26)25-18-6-5-13-3-1-2-4-16(13)18/h1-4,7-8,12,14-15,18-19,27H,5-6,9-11H2,(H2,22,28,29)(H,23,24,25)/t14-,15+,18-,19-/m0/s1, InChI=1S/C21H25N5O4S/c22-31(28,29)30-11-14-9-15(10-19(14)27)26-8-7-17-20(23-12-24-21(17)26)25-18-6-5-13-3-1-2-4-16(13)18/h1-4,7-8,12,14-15,18-19,27H,5-6,9-11H2,(H2,22,28,29)(H,23,24,25)/t14-,15+,18-,19-/m0/s1, InChI=1S/C21H25N5O4S/c22-31(28,29)30-11-14-9-15(10-19(14)27)26-8-7-17-20(23-12-24-21(17)26)25-18-6-5-13-3-1-2-4-16(13)18/h1-4,7-8,12,14-15,18-19,27H,5-6,9-11H2,(H2,22,28,29)(H,23,24,25)/t14-,15+,18-,19-/m0/s1	Phase 3
pexidartinib	tyrosine kinase inhibitor	CSF1R, FLT3, KIT			FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1, FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1, FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1	JGWRKYUXBBNENE-UHFFFAOYSA-N, JGWRKYUXBBNENE-UHFFFAOYSA-N, JGWRKYUXBBNENE-UHFFFAOYSA-N	Launched
pexmetinib	MAP kinase inhibitor, TIE tyrosine kinase inhibitor	MAPK14, TEK			Cc1ccc(cc1)-n1nc(cc1NC(=O)NCc1cc(F)ccc1Oc1ccc2n(CCO)ncc2c1)C(C)(C)C, Cc1ccc(cc1)-n1nc(cc1NC(=O)NCc1cc(F)ccc1Oc1ccc2n(CCO)ncc2c1)C(C)(C)C, Cc1ccc(cc1)-n1nc(cc1NC(=O)NCc1cc(F)ccc1Oc1ccc2n(CCO)ncc2c1)C(C)(C)C, Cc1ccc(cc1)-n1nc(cc1NC(=O)NCc1cc(F)ccc1Oc1ccc2n(CCO)ncc2c1)C(C)(C)C	LNMRSSIMGCDUTP-UHFFFAOYSA-N, LNMRSSIMGCDUTP-UHFFFAOYSA-N, LNMRSSIMGCDUTP-UHFFFAOYSA-N, LNMRSSIMGCDUTP-UHFFFAOYSA-N	Phase 1
PF-02413873	progesterone receptor antagonist				Cc1c(Oc2cc(C)c(C#N)c(C)c2)c(nn1CS(C)(=O)=O)C1CC1	QSFGZNVRVZHUGV-UHFFFAOYSA-N	Phase 1
PF-02545920	phosphodiesterase inhibitor	PDE10A			Cn1cc(c(n1)-c1ccc(OCc2ccc3ccccc3n2)cc1)-c1ccncc1, Cn1cc(c(n1)-c1ccc(OCc2ccc3ccccc3n2)cc1)-c1ccncc1, Cn1cc(c(n1)-c1ccc(OCc2ccc3ccccc3n2)cc1)-c1ccncc1	AZEXWHKOMMASPA-UHFFFAOYSA-N, AZEXWHKOMMASPA-UHFFFAOYSA-N, AZEXWHKOMMASPA-UHFFFAOYSA-N	Phase 2
PF-03049423	phosphodiesterase inhibitor	PDE5A			CCCOCCn1c2cc(ncc2nc(N2CCN(CCO)CC2)c1=O)-c1ccc(OC)nc1, CCCOCCn1c2cc(ncc2nc(N2CCN(CCO)CC2)c1=O)-c1ccc(OC)nc1	MNLNAGRCHNMKKJ-UHFFFAOYSA-N, MNLNAGRCHNMKKJ-UHFFFAOYSA-N	Phase 2
PF-03084014	gamma secretase inhibitor				CCC[C@H](N[C@H]1CCc2cc(F)cc(F)c2C1)C(=O)Nc1cn(cn1)C(C)(C)CNCC(C)(C)C, CCC[C@H](N[C@H]1CCc2cc(F)cc(F)c2C1)C(=O)Nc1cn(cn1)C(C)(C)CNCC(C)(C)C, CCC[C@H](N[C@H]1CCc2cc(F)cc(F)c2C1)C(=O)Nc1cn(cn1)C(C)(C)CNCC(C)(C)C	VFCRKLWBYMDAED-REWPJTCUSA-N, VFCRKLWBYMDAED-REWPJTCUSA-N, VFCRKLWBYMDAED-REWPJTCUSA-N	Phase 3
PF-03758309	p21 activated kinase inhibitor	PAK4			CN(C)C[C@@H](NC(=O)N1Cc2c(Nc3nc(C)nc4ccsc34)[nH]nc2C1(C)C)c1ccccc1, CN(C)C[C@@H](NC(=O)N1Cc2c(Nc3nc(C)nc4ccsc34)[nH]nc2C1(C)C)c1ccccc1, CN(C)C[C@@H](NC(=O)N1Cc2c(Nc3nc(C)nc4ccsc34)[nH]nc2C1(C)C)c1ccccc1, CN(C)C[C@@H](NC(=O)N1Cc2c(Nc3nc(C)nc4ccsc34)[nH]nc2C1(C)C)c1ccccc1, CN(C)C[C@@H](NC(=O)N1Cc2c(Nc3nc(C)nc4ccsc34)[nH]nc2C1(C)C)c1ccccc1, CN(C)C[C@@H](NC(=O)N1Cc2c(Nc3nc(C)nc4ccsc34)[nH]nc2C1(C)C)c1ccccc1, CN(C)C[C@@H](NC(=O)N1Cc2c(Nc3nc(C)nc4ccsc34)[nH]nc2C1(C)C)c1ccccc1, CN(C)C[C@@H](NC(=O)N1Cc2c(Nc3nc(C)nc4ccsc34)[nH]nc2C1(C)C)c1ccccc1, CN(C)C[C@@H](NC(=O)N1Cc2c(Nc3nc(C)nc4ccsc34)[nH]nc2C1(C)C)c1ccccc1, CN(C)C[C@@H](NC(=O)N1Cc2c(Nc3nc(C)nc4ccsc34)[nH]nc2C1(C)C)c1ccccc1, CN(C)C[C@@H](NC(=O)N1Cc2c(Nc3nc(C)nc4ccsc34)[nH]nc2C1(C)C)c1ccccc1, CN(C)C[C@@H](NC(=O)N1Cc2c(Nc3nc(C)nc4ccsc34)[nH]nc2C1(C)C)c1ccccc1	AYCPARAPKDAOEN-LJQANCHMSA-N, AYCPARAPKDAOEN-LJQANCHMSA-N, AYCPARAPKDAOEN-LJQANCHMSA-N, AYCPARAPKDAOEN-LJQANCHMSA-N, InChI=1S/C25H30N8OS/c1-15-26-18-11-12-35-20(18)23(27-15)29-22-17-13-33(25(2,3)21(17)30-31-22)24(34)28-19(14-32(4)5)16-9-7-6-8-10-16/h6-12,19H,13-14H2,1-5H3,(H,28,34)(H2,26,27,29,30,31)/t19-/m1/s1, InChI=1S/C25H30N8OS/c1-15-26-18-11-12-35-20(18)23(27-15)29-22-17-13-33(25(2,3)21(17)30-31-22)24(34)28-19(14-32(4)5)16-9-7-6-8-10-16/h6-12,19H,13-14H2,1-5H3,(H,28,34)(H2,26,27,29,30,31)/t19-/m1/s1, InChI=1S/C25H30N8OS/c1-15-26-18-11-12-35-20(18)23(27-15)29-22-17-13-33(25(2,3)21(17)30-31-22)24(34)28-19(14-32(4)5)16-9-7-6-8-10-16/h6-12,19H,13-14H2,1-5H3,(H,28,34)(H2,26,27,29,30,31)/t19-/m1/s1, InChI=1S/C25H30N8OS/c1-15-26-18-11-12-35-20(18)23(27-15)29-22-17-13-33(25(2,3)21(17)30-31-22)24(34)28-19(14-32(4)5)16-9-7-6-8-10-16/h6-12,19H,13-14H2,1-5H3,(H,28,34)(H2,26,27,29,30,31)/t19-/m1/s1, InChI=1S/C25H30N8OS/c1-15-26-18-11-12-35-20(18)23(27-15)29-22-17-13-33(25(2,3)21(17)30-31-22)24(34)28-19(14-32(4)5)16-9-7-6-8-10-16/h6-12,19H,13-14H2,1-5H3,(H,28,34)(H2,26,27,29,30,31)/t19-/m1/s1, InChI=1S/C25H30N8OS/c1-15-26-18-11-12-35-20(18)23(27-15)29-22-17-13-33(25(2,3)21(17)30-31-22)24(34)28-19(14-32(4)5)16-9-7-6-8-10-16/h6-12,19H,13-14H2,1-5H3,(H,28,34)(H2,26,27,29,30,31)/t19-/m1/s1, InChI=1S/C25H30N8OS/c1-15-26-18-11-12-35-20(18)23(27-15)29-22-17-13-33(25(2,3)21(17)30-31-22)24(34)28-19(14-32(4)5)16-9-7-6-8-10-16/h6-12,19H,13-14H2,1-5H3,(H,28,34)(H2,26,27,29,30,31)/t19-/m1/s1, InChI=1S/C25H30N8OS/c1-15-26-18-11-12-35-20(18)23(27-15)29-22-17-13-33(25(2,3)21(17)30-31-22)24(34)28-19(14-32(4)5)16-9-7-6-8-10-16/h6-12,19H,13-14H2,1-5H3,(H,28,34)(H2,26,27,29,30,31)/t19-/m1/s1	Phase 1
PF-03814735	Aurora kinase inhibitor	AURKA, AURKB			CC(=O)NCC(=O)N1[C@H]2CC[C@@H]1c1cc(Nc3ncc(c(NC4CCC4)n3)C(F)(F)F)ccc21, CC(=O)NCC(=O)N1[C@H]2CC[C@@H]1c1cc(Nc3ncc(c(NC4CCC4)n3)C(F)(F)F)ccc21, CC(=O)NCC(=O)N1[C@H]2CC[C@@H]1c1cc(Nc3ncc(c(NC4CCC4)n3)C(F)(F)F)ccc21, CC(=O)NCC(=O)N1[C@H]2CC[C@@H]1c1cc(Nc3ncc(c(NC4CCC4)n3)C(F)(F)F)ccc21	RYYNGWLOYLRZLK-RBUKOAKNSA-N, RYYNGWLOYLRZLK-RBUKOAKNSA-N, RYYNGWLOYLRZLK-RBUKOAKNSA-N, RYYNGWLOYLRZLK-RBUKOAKNSA-N	Phase 1
PF-03882845	mineralocorticoid receptor antagonist				OC(=O)c1ccc2C3=NN([C@@H](C4CCCC4)C3CCc2c1)c1ccc(C#N)c(Cl)c1 |t:7|, OC(=O)c1ccc2C3=NN([C@@H](C4CCCC4)C3CCc2c1)c1ccc(C#N)c(Cl)c1 |t:7|, OC(=O)c1ccc2C3=NN([C@@H](C4CCCC4)C3CCc2c1)c1ccc(C#N)c(Cl)c1 |t:7|, OC(=O)c1ccc2C3=NN([C@@H](C4CCCC4)C3CCc2c1)c1ccc(C#N)c(Cl)c1 |t:7|	XNULRSOGWPFPBL-AKRCKQFNSA-N, XNULRSOGWPFPBL-AKRCKQFNSA-N, XNULRSOGWPFPBL-AKRCKQFNSA-N, XNULRSOGWPFPBL-AKRCKQFNSA-N	Phase 1
PF-04136309	CC chemokine receptor antagonist				O[C@]1(CC[C@@H](CC1)N[C@H]1CCN(C1)C(=O)CNC(=O)c1cccc(c1)C(F)(F)F)c1ccc(cn1)-c1ncccn1, O[C@]1(CC[C@@H](CC1)N[C@H]1CCN(C1)C(=O)CNC(=O)c1cccc(c1)C(F)(F)F)c1ccc(cn1)-c1ncccn1, O[C@]1(CC[C@@H](CC1)N[C@H]1CCN(C1)C(=O)CNC(=O)c1cccc(c1)C(F)(F)F)c1ccc(cn1)-c1ncccn1, O[C@]1(CC[C@@H](CC1)N[C@H]1CCN(C1)C(=O)CNC(=O)c1cccc(c1)C(F)(F)F)c1ccc(cn1)-c1ncccn1, O[C@]1(CC[C@@H](CC1)N[C@H]1CCN(C1)C(=O)CNC(=O)c1cccc(c1)C(F)(F)F)c1ccc(cn1)-c1ncccn1	ZNSVOHSYDRPBGI-LXWOLXCRSA-N, ZNSVOHSYDRPBGI-LXWOLXCRSA-N, ZNSVOHSYDRPBGI-LXWOLXCRSA-N, ZNSVOHSYDRPBGI-LXWOLXCRSA-N, ZNSVOHSYDRPBGI-LXWOLXCRSA-N	Phase 2
PF-04217903	c-Met inhibitor	MET			OCCn1cc(cn1)-c1cnc2nnn(Cc3ccc4ncccc4c3)c2n1, OCCn1cc(cn1)-c1cnc2nnn(Cc3ccc4ncccc4c3)c2n1, OCCn1cc(cn1)-c1cnc2nnn(Cc3ccc4ncccc4c3)c2n1, OCCn1cc(cn1)-c1cnc2nnn(Cc3ccc4ncccc4c3)c2n1	PDMUGYOXRHVNMO-UHFFFAOYSA-N, PDMUGYOXRHVNMO-UHFFFAOYSA-N, PDMUGYOXRHVNMO-UHFFFAOYSA-N, InChI=1S/C19H16N8O/c28-7-6-26-12-15(9-22-26)17-10-21-18-19(23-17)27(25-24-18)11-13-3-4-16-14(8-13)2-1-5-20-16/h1-5,8-10,12,28H,6-7,11H2	Phase 1
PF-04418948	prostaglandin inhibitor	PTGER2			COc1ccc2cc(OCC3(CN(C3)C(=O)c3ccc(F)cc3)C(O)=O)ccc2c1, COc1ccc2cc(OCC3(CN(C3)C(=O)c3ccc(F)cc3)C(O)=O)ccc2c1, COc1ccc2cc(OCC3(CN(C3)C(=O)c3ccc(F)cc3)C(O)=O)ccc2c1	LWJGMYMNSNVCEM-UHFFFAOYSA-N, LWJGMYMNSNVCEM-UHFFFAOYSA-N, LWJGMYMNSNVCEM-UHFFFAOYSA-N	Phase 1
PF-04447943	phosphodiesterase inhibitor	PDE9A			C[C@@H]1CN(Cc2ncccn2)C[C@H]1c1nc(=O)c2cnn(C3CCOCC3)c2[nH]1, C[C@@H]1CN(Cc2ncccn2)C[C@H]1c1nc(=O)c2cnn(C3CCOCC3)c2[nH]1, C[C@@H]1CN(Cc2ncccn2)C[C@H]1c1nc(=O)c2cnn(C3CCOCC3)c2[nH]1	IWXUVYOOUMLUTQ-CZUORRHYSA-N, IWXUVYOOUMLUTQ-CZUORRHYSA-N, IWXUVYOOUMLUTQ-CZUORRHYSA-N	Phase 2
PF-04457845	FAAH inhibitor	FAAH			FC(F)(F)c1ccc(Oc2cccc(C=C3CCN(CC3)C(=O)Nc3cccnn3)c2)nc1, FC(F)(F)c1ccc(Oc2cccc(C=C3CCN(CC3)C(=O)Nc3cccnn3)c2)nc1, FC(F)(F)c1ccc(Oc2cccc(C=C3CCN(CC3)C(=O)Nc3cccnn3)c2)nc1	BATCTBJIJJEPHM-UHFFFAOYSA-N, BATCTBJIJJEPHM-UHFFFAOYSA-N, BATCTBJIJJEPHM-UHFFFAOYSA-N	Phase 2
PF-04620110	diacylglycerol O acyltransferase inhibitor	DGAT1			Nc1ncnc2OCCN(c3ccc(cc3)[C@H]3CC[C@H](CC(O)=O)CC3)C(=O)c12 |r|, Nc1ncnc2OCCN(c3ccc(cc3)[C@H]3CC[C@H](CC(O)=O)CC3)C(=O)c12 |r|, Nc1ncnc2OCCN(c3ccc(cc3)[C@H]3CC[C@H](CC(O)=O)CC3)C(=O)c12 |r|	GEVVQZHMFVFGLN-HDJSIYSDSA-N, GEVVQZHMFVFGLN-HDJSIYSDSA-N, GEVVQZHMFVFGLN-HDJSIYSDSA-N	Phase 1
PF-04691502	mTOR inhibitor, PI3K inhibitor	MTOR, PIK3CA			COc1ccc(cn1)-c1cc2c(C)nc(N)nc2n([C@H]2CC[C@@H](CC2)OCCO)c1=O |r|, COc1ccc(cn1)-c1cc2c(C)nc(N)nc2n([C@H]2CC[C@@H](CC2)OCCO)c1=O |r|, COc1ccc(cn1)-c1cc2c(C)nc(N)nc2n([C@H]2CC[C@@H](CC2)OCCO)c1=O |r|	XDLYKKIQACFMJG-WKILWMFISA-N, XDLYKKIQACFMJG-WKILWMFISA-N, XDLYKKIQACFMJG-WKILWMFISA-N	Phase 2
PF-04885614	voltage-gated sodium channel blocker	SCN10A			CC(C)(N)c1nc(c[nH]1)-c1ccc(OC(F)(F)F)cc1, CC(C)(N)c1nc(c[nH]1)-c1ccc(OC(F)(F)F)cc1	AGORGFNWYAUYSU-UHFFFAOYSA-N, AGORGFNWYAUYSU-UHFFFAOYSA-N	Preclinical
PF-04937319	glucokinase activator	GCK			CN(C)C(=O)c1ncc(Oc2cc(cc3oc(C)cc23)C(=O)Nc2cnc(C)cn2)cn1	MASKQITXHVYVFL-UHFFFAOYSA-N	Phase 2
PF-04995274	serotonin receptor agonist				OC1(CN2CCC(COc3noc4cccc(O[C@@H]5CCOC5)c34)CC2)CCOCC1	WLLOFQROROXOMO-GOSISDBHSA-N	Phase 1
PF-05089771	sodium channel blocker				Nc1[nH]ncc1-c1cc(Cl)ccc1Oc1cc(F)c(cc1Cl)S(=O)(=O)Nc1cscn1	ZYSCOUXLBXGGIM-UHFFFAOYSA-N	Preclinical
PF-05175157	acetyl-CoA carboxylase inhibitor				[H]n1c(C)nc2ccc(cc12)C(=O)N1CCC2(CC1)Cc1cnn(C(C)C)c1C(=O)C2	BDXXSFOJPYSYOC-UHFFFAOYSA-N	Phase 2
PF-05180999	phosphodiesterase inhibitor				Cc1nc(-c2cnn(C)c2-c2ccc(cn2)C(F)(F)F)c2c(ncnn12)N1CCC1	CLGCHUKGBICQTE-UHFFFAOYSA-N	Phase 1
PF-05190457	growth hormone secretagogue receptor inverse agonist	GHSR			Cc1cn2cc(CC(=O)N3CCC4(CN(C4)[C@@H]4CCc5cc(ccc45)-c4cc(C)ncn4)CC3)nc2s1	ZIUDADZJCKGWKR-AREMUKBSSA-N	Phase 2
PF-05212384	mTOR inhibitor, PI3K inhibitor	MTOR, PIK3CA			CN(C)C1CCN(CC1)C(=O)c1ccc(NC(=O)Nc2ccc(cc2)-c2nc(nc(n2)N2CCOCC2)N2CCOCC2)cc1, CN(C)C1CCN(CC1)C(=O)c1ccc(NC(=O)Nc2ccc(cc2)-c2nc(nc(n2)N2CCOCC2)N2CCOCC2)cc1, CN(C)C1CCN(CC1)C(=O)c1ccc(NC(=O)Nc2ccc(cc2)-c2nc(nc(n2)N2CCOCC2)N2CCOCC2)cc1	DWZAEMINVBZMHQ-UHFFFAOYSA-N, DWZAEMINVBZMHQ-UHFFFAOYSA-N, DWZAEMINVBZMHQ-UHFFFAOYSA-N	Phase 2
PF-06260414	androgen receptor modulator				C[C@@H]1CNS(=O)(=O)N(C1)c1ccc2c(nccc2c1)C#N	ZKAVFOXYJCREBQ-SNVBAGLBSA-N	Phase 1
PF-06273340	tyrosine kinase receptor inhibitor				CC(C)(CO)n1cc(C(=O)c2cncc(NC(=O)Cc3ccc(Cl)cn3)c2)c2cnc(N)nc12	BPIWZDNVMQQBQX-UHFFFAOYSA-N	Phase 1
PF-06282999	myeloperoxidase inhibitor				COc1ccc(Cl)cc1-c1cc(=O)[nH]c(=S)n1CC(N)=O	ICYNYWFGIDGBRD-UHFFFAOYSA-N	Phase 1
PF-06305591	sodium channel blocker				C[C@H]([C@H](N)c1nc2cc(ccc2[nH]1)C(C)(C)C)C(N)=O	APWZIFIAVVFPNT-PELKAZGASA-N	Phase 1
PF-06409577	protein kinase activator				OC(=O)c1c[nH]c2cc(Cl)c(cc12)-c1ccc(cc1)C1(O)CCC1	FHQXLWCFSUSXBF-UHFFFAOYSA-N	Phase 1
PF-06412562	dopamine receptor partial agonist				Cc1cc(Oc2nccc3[nH]ncc23)ccc1-c1c(C)ncnc1C	IDIUJOHYYBNCPC-UHFFFAOYSA-N	Phase 1
PF-06447475	serine/threonine kinase inhibitor	LRRK2			N#Cc1cccc(c1)-c1c[nH]c2ncnc(N3CCOCC3)c12, N#Cc1cccc(c1)-c1c[nH]c2ncnc(N3CCOCC3)c12	BHTWDJBVZQBRKP-UHFFFAOYSA-N, BHTWDJBVZQBRKP-UHFFFAOYSA-N	Preclinical
PF-06459988	receptor tyrosine protein kinase inhibitor				CO[C@H]1CN(C[C@@H]1COc1nc(Nc2cnn(C)c2)nc2[nH]cc(Cl)c12)C(=O)C=C	ODMXWZROLKITMS-RISCZKNCSA-N	Phase 2
PF-06463922	ALK tyrosine kinase receptor inhibitor	ALK, FES, ROS1	oncology	non-small cell lung cancer (NSCLC)	C[C@H]1Oc2cc(cnc2N)-c2c(CN(C)C(=O)c3ccc(F)cc13)nn(C)c2C#N |&1:1,r|	IIXWYSCJSQVBQM-UHFFFAOYSA-N	Launched
PF-06650833	kinase inhibitor				CC[C@H]1[C@@H](COc2nccc3cc(C(N)=O)c(OC)cc23)NC(=O)[C@H]1F	JKDGKIBAOAFRPJ-ZBINZKHDSA-N	Phase 1
PF-06651600	JAK inhibitor				C[C@H]1CC[C@H](CN1C(=O)C=C)Nc1ncnc2[nH]ccc12	CBRJPFGIXUFMTM-WDEREUQCSA-N	Phase 2/Phase 3
PF-06747775	EGFR inhibitor				COc1nn(C)cc1Nc1nc(nc2n(C)cnc12)N1C[C@@H](F)[C@@H](C1)NC(=O)C=C	JYIUNVOCEFIUIU-GHMZBOCLSA-N	Phase 2
PF-06751979	beta secretase inhibitor				C[C@H]1C[C@H]2CSC(N)=N[C@]2(CO1)c1nc(NC(=O)c2ccc(OC(F)F)cn2)cs1 |c:7|	ZLZUHACSRMOLLV-RAALSFIWSA-N	Phase 1
PF-06840003	indoleamine 2,3-dioxygenase inhibitor				Fc1ccc2[nH]cc([C@H]3CC(=O)NC3=O)c2c1 |&1:8,r|	MXKLDYKORJEOPR-MRVPVSSYSA-N	Phase 1
PF-06873600	CDK inhibitor				C[C@@]1(O)CCC[C@H]1n1c2nc(NC3CCN(CC3)S(C)(=O)=O)ncc2cc(C(F)F)c1=O	QIEKHLDZKRQLLN-FOIQADDNSA-N	Phase 2
PF-06928215	cyclic GMP-AMP synthase inhibitor				OC(=O)[C@@H]1CCCC[C@@H]1NC(=O)c1cnn2c(O)cc(nc12)-c1ccccc1	PHGTYMRDHDEHLI-HIFRSBDPSA-N	Preclinical
PF-3274167	oxytocin receptor antagonist	AVPR1A, OXTR			COCc1nnc(N2CC(C2)Oc2ccc(F)cc2Cl)n1-c1ccc(OC)nc1	HNIFCPBQMKPRCX-UHFFFAOYSA-N	Phase 2
PF-3845	FAAH inhibitor	FAAH			FC(F)(F)c1ccc(Oc2cccc(CC3CCN(CC3)C(=O)Nc3cccnc3)c2)nc1, FC(F)(F)c1ccc(Oc2cccc(CC3CCN(CC3)C(=O)Nc3cccnc3)c2)nc1, FC(F)(F)c1ccc(Oc2cccc(CC3CCN(CC3)C(=O)Nc3cccnc3)c2)nc1	NBOJHRYUGLRASX-UHFFFAOYSA-N, NBOJHRYUGLRASX-UHFFFAOYSA-N, NBOJHRYUGLRASX-UHFFFAOYSA-N	Preclinical
PF-4191834	lipoxygenase inhibitor				Cn1nccc1-c1ccc(Sc2cccc(c2)C2(CCOCC2)C(N)=O)cc1	DVNQWYLVSNPCJZ-UHFFFAOYSA-N	Preclinical
PF-429242	SREBP inhibitor	MBTPS1			CCN(CC)Cc1ccc(cc1)C(=O)N(CCc1ccccc1OC)[C@@H]1CCNC1, CCN(CC)Cc1ccc(cc1)C(=O)N(CCc1ccccc1OC)[C@@H]1CCNC1	XKPJTOHUPQWSOJ-HSZRJFAPSA-N, XKPJTOHUPQWSOJ-HSZRJFAPSA-N	Preclinical
PF-431396	focal adhesion kinase inhibitor	PTK2, PTK2B			CN(c1ccccc1CNc1nc(Nc2ccc3NC(=O)Cc3c2)ncc1C(F)(F)F)S(C)(=O)=O, CN(c1ccccc1CNc1nc(Nc2ccc3NC(=O)Cc3c2)ncc1C(F)(F)F)S(C)(=O)=O, CN(c1ccccc1CNc1nc(Nc2ccc3NC(=O)Cc3c2)ncc1C(F)(F)F)S(C)(=O)=O, CN(c1ccccc1CNc1nc(Nc2ccc3NC(=O)Cc3c2)ncc1C(F)(F)F)S(C)(=O)=O	POJZIZBONPAWIV-UHFFFAOYSA-N, POJZIZBONPAWIV-UHFFFAOYSA-N, POJZIZBONPAWIV-UHFFFAOYSA-N, POJZIZBONPAWIV-UHFFFAOYSA-N	Preclinical
PF-4708671	ribosomal protein inhibitor	RPS6KB1			CCc1cncnc1N1CCN(Cc2nc3ccc(cc3[nH]2)C(F)(F)F)CC1, CCc1cncnc1N1CCN(Cc2nc3ccc(cc3[nH]2)C(F)(F)F)CC1, CCc1cncnc1N1CCN(Cc2nc3ccc(cc3[nH]2)C(F)(F)F)CC1	FBLPQCAQRNSVHB-UHFFFAOYSA-N, FBLPQCAQRNSVHB-UHFFFAOYSA-N, FBLPQCAQRNSVHB-UHFFFAOYSA-N	Preclinical
PF-477736	CHK inhibitor	CHEK1, CHEK2			Cn1cc(cn1)-c1[nH]c2cc(NC(=O)[C@H](N)C3CCCCC3)cc3c2c1cn[nH]c3=O, Cn1cc(cn1)-c1[nH]c2cc(NC(=O)[C@H](N)C3CCCCC3)cc3c2c1cn[nH]c3=O, Cn1cc(cn1)-c1[nH]c2cc(NC(=O)[C@H](N)C3CCCCC3)cc3c2c1cn[nH]c3=O, Cn1cc(cn1)-c1[nH]c2cc(NC(=O)[C@H](N)C3CCCCC3)cc3c2c1cn[nH]c3=O, Cn1cc(cn1)-c1[nH]c2cc(NC(=O)[C@H](N)C3CCCCC3)cc3c2c1cn[nH]c3=O, Cn1cc(cn1)-c1[nH]c2cc(NC(=O)[C@H](N)C3CCCCC3)cc3c2c1cn[nH]c3=O, Cn1cc(cn1)-c1[nH]c2cc(NC(=O)[C@H](N)C3CCCCC3)cc3c2c1cn[nH]c3=O, Cn1cc(cn1)-c1[nH]c2cc(NC(=O)[C@H](N)C3CCCCC3)cc3c2c1cn[nH]c3=O	NDEXUOWTGYUVGA-LJQANCHMSA-N, NDEXUOWTGYUVGA-LJQANCHMSA-N, NDEXUOWTGYUVGA-LJQANCHMSA-N, NDEXUOWTGYUVGA-LJQANCHMSA-N, NDEXUOWTGYUVGA-LJQANCHMSA-N, NDEXUOWTGYUVGA-LJQANCHMSA-N, NDEXUOWTGYUVGA-LJQANCHMSA-N, NDEXUOWTGYUVGA-LJQANCHMSA-N	Phase 1
PF-4800567	casein kinase inhibitor	CSNK1D, CSNK1E			Nc1ncnc2n(nc(COc3cccc(Cl)c3)c12)C1CCOCC1, Nc1ncnc2n(nc(COc3cccc(Cl)c3)c12)C1CCOCC1, Nc1ncnc2n(nc(COc3cccc(Cl)c3)c12)C1CCOCC1, Nc1ncnc2n(nc(COc3cccc(Cl)c3)c12)C1CCOCC1, Nc1ncnc2n(nc(COc3cccc(Cl)c3)c12)C1CCOCC1, Nc1ncnc2n(nc(COc3cccc(Cl)c3)c12)C1CCOCC1, Nc1ncnc2n(nc(COc3cccc(Cl)c3)c12)C1CCOCC1, Nc1ncnc2n(nc(COc3cccc(Cl)c3)c12)C1CCOCC1, Nc1ncnc2n(nc(COc3cccc(Cl)c3)c12)C1CCOCC1	AUMDBEHGJRZSOO-UHFFFAOYSA-N, AUMDBEHGJRZSOO-UHFFFAOYSA-N, AUMDBEHGJRZSOO-UHFFFAOYSA-N, AUMDBEHGJRZSOO-UHFFFAOYSA-N, AUMDBEHGJRZSOO-UHFFFAOYSA-N, AUMDBEHGJRZSOO-UHFFFAOYSA-N, AUMDBEHGJRZSOO-UHFFFAOYSA-N, AUMDBEHGJRZSOO-UHFFFAOYSA-N, AUMDBEHGJRZSOO-UHFFFAOYSA-N	Preclinical
PF-4981517	cytochrome P450 inhibitor	CYP3A4			Cc1ccc(cc1)-c1c(cnn1C)-c1nn(C)c2ncnc(N3CC[C@@H](C3)N3CCCCC3)c12, Cc1ccc(cc1)-c1c(cnn1C)-c1nn(C)c2ncnc(N3CC[C@@H](C3)N3CCCCC3)c12	WDWIMDKOXZZYHH-FQEVSTJZSA-N, WDWIMDKOXZZYHH-FQEVSTJZSA-N	Preclinical
PF-514273	cannabinoid receptor antagonist				CC(F)(F)CN1CCOc2c(nn(c2-c2ccc(Cl)cc2)-c2ccccc2Cl)C1=O	FJMQJSUOOGOWBD-UHFFFAOYSA-N	Preclinical
PF-5274857	smoothened receptor antagonist	SMO			Cc1cnc(c(C)c1)-c1cc(ncc1Cl)N1CCN(CC1)C(=O)CCS(C)(=O)=O, Cc1cnc(c(C)c1)-c1cc(ncc1Cl)N1CCN(CC1)C(=O)CCS(C)(=O)=O, Cc1cnc(c(C)c1)-c1cc(ncc1Cl)N1CCN(CC1)C(=O)CCS(C)(=O)=O, Cc1cnc(c(C)c1)-c1cc(ncc1Cl)N1CCN(CC1)C(=O)CCS(C)(=O)=O, Cc1cnc(c(C)c1)-c1cc(ncc1Cl)N1CCN(CC1)C(=O)CCS(C)(=O)=O, Cc1cnc(c(C)c1)-c1cc(ncc1Cl)N1CCN(CC1)C(=O)CCS(C)(=O)=O	BBVNTTZIOTWDSV-UHFFFAOYSA-N, BBVNTTZIOTWDSV-UHFFFAOYSA-N, BBVNTTZIOTWDSV-UHFFFAOYSA-N, BBVNTTZIOTWDSV-UHFFFAOYSA-N, BBVNTTZIOTWDSV-UHFFFAOYSA-N, BBVNTTZIOTWDSV-UHFFFAOYSA-N	Preclinical
PF-562271	focal adhesion kinase inhibitor	PTK2, PTK2B			CN(c1ncccc1CNc1nc(Nc2ccc3NC(=O)Cc3c2)ncc1C(F)(F)F)S(C)(=O)=O, CN(c1ncccc1CNc1nc(Nc2ccc3NC(=O)Cc3c2)ncc1C(F)(F)F)S(C)(=O)=O, CN(c1ncccc1CNc1nc(Nc2ccc3NC(=O)Cc3c2)ncc1C(F)(F)F)S(C)(=O)=O, CN(c1ncccc1CNc1nc(Nc2ccc3NC(=O)Cc3c2)ncc1C(F)(F)F)S(C)(=O)=O, CN(c1ncccc1CNc1nc(Nc2ccc3NC(=O)Cc3c2)ncc1C(F)(F)F)S(C)(=O)=O, CN(c1ncccc1CNc1nc(Nc2ccc3NC(=O)Cc3c2)ncc1C(F)(F)F)S(C)(=O)=O, CN(c1ncccc1CNc1nc(Nc2ccc3NC(=O)Cc3c2)ncc1C(F)(F)F)S(C)(=O)=O, CN(c1ncccc1CNc1nc(Nc2ccc3NC(=O)Cc3c2)ncc1C(F)(F)F)S(C)(=O)=O, CN(c1ncccc1CNc1nc(Nc2ccc3NC(=O)Cc3c2)ncc1C(F)(F)F)S(C)(=O)=O, CN(c1ncccc1CNc1nc(Nc2ccc3NC(=O)Cc3c2)ncc1C(F)(F)F)S(C)(=O)=O	MZDKLVOWGIOKTN-UHFFFAOYSA-N, MZDKLVOWGIOKTN-UHFFFAOYSA-N, MZDKLVOWGIOKTN-UHFFFAOYSA-N, MZDKLVOWGIOKTN-UHFFFAOYSA-N, MZDKLVOWGIOKTN-UHFFFAOYSA-N, MZDKLVOWGIOKTN-UHFFFAOYSA-N, MZDKLVOWGIOKTN-UHFFFAOYSA-N, MZDKLVOWGIOKTN-UHFFFAOYSA-N, MZDKLVOWGIOKTN-UHFFFAOYSA-N, MZDKLVOWGIOKTN-UHFFFAOYSA-N	Phase 1
PF-573228	focal adhesion kinase inhibitor	CDK1, CDK2, CDK7, GSK3B, IKBKB			CS(=O)(=O)c1cccc(CNc2nc(Nc3ccc4NC(=O)CCc4c3)ncc2C(F)(F)F)c1, CS(=O)(=O)c1cccc(CNc2nc(Nc3ccc4NC(=O)CCc4c3)ncc2C(F)(F)F)c1, CS(=O)(=O)c1cccc(CNc2nc(Nc3ccc4NC(=O)CCc4c3)ncc2C(F)(F)F)c1, CS(=O)(=O)c1cccc(CNc2nc(Nc3ccc4NC(=O)CCc4c3)ncc2C(F)(F)F)c1, CS(=O)(=O)c1cccc(CNc2nc(Nc3ccc4NC(=O)CCc4c3)ncc2C(F)(F)F)c1, CS(=O)(=O)c1cccc(CNc2nc(Nc3ccc4NC(=O)CCc4c3)ncc2C(F)(F)F)c1	HESLKTSGTIBHJU-UHFFFAOYSA-N, HESLKTSGTIBHJU-UHFFFAOYSA-N, HESLKTSGTIBHJU-UHFFFAOYSA-N, HESLKTSGTIBHJU-UHFFFAOYSA-N, HESLKTSGTIBHJU-UHFFFAOYSA-N, HESLKTSGTIBHJU-UHFFFAOYSA-N	Preclinical
PF-670462	casein kinase inhibitor	CSNK1D, CSNK1E			Nc1nccc(n1)-c1c(ncn1C1CCCCC1)-c1ccc(F)cc1, Nc1nccc(n1)-c1c(ncn1C1CCCCC1)-c1ccc(F)cc1, Nc1nccc(n1)-c1c(ncn1C1CCCCC1)-c1ccc(F)cc1, Nc1nccc(n1)-c1c(ncn1C1CCCCC1)-c1ccc(F)cc1, Nc1nccc(n1)-c1c(ncn1C1CCCCC1)-c1ccc(F)cc1	WUDBUIUHVNECTM-UHFFFAOYSA-N, WUDBUIUHVNECTM-UHFFFAOYSA-N, WUDBUIUHVNECTM-UHFFFAOYSA-N, WUDBUIUHVNECTM-UHFFFAOYSA-N, WUDBUIUHVNECTM-UHFFFAOYSA-N	Preclinical
PF-750	FAAH inhibitor	FAAH			O=C(Nc1ccccc1)N1CCC(Cc2cnc3ccccc3c2)CC1, O=C(Nc1ccccc1)N1CCC(Cc2cnc3ccccc3c2)CC1	BIODYGOZWZNCAG-UHFFFAOYSA-N, BIODYGOZWZNCAG-UHFFFAOYSA-N	Preclinical
PF-8380	autotaxin inhibitor	ENPP2			Clc1cc(Cl)cc(COC(=O)N2CCN(CCC(=O)c3ccc4[nH]c(=O)oc4c3)CC2)c1, Clc1cc(Cl)cc(COC(=O)N2CCN(CCC(=O)c3ccc4[nH]c(=O)oc4c3)CC2)c1	JMSUDQYHPSNBSN-UHFFFAOYSA-N, JMSUDQYHPSNBSN-UHFFFAOYSA-N	Preclinical
PF-915275	11-beta hydroxysteroid dehydrogenase inhibitor	HSD11B1			Nc1cccc(NS(=O)(=O)c2ccc(cc2)-c2ccc(cc2)C#N)n1, Nc1cccc(NS(=O)(=O)c2ccc(cc2)-c2ccc(cc2)C#N)n1, Nc1cccc(NS(=O)(=O)c2ccc(cc2)-c2ccc(cc2)C#N)n1, Nc1cccc(NS(=O)(=O)c2ccc(cc2)-c2ccc(cc2)C#N)n1	ZESFDAKNYJQYKO-UHFFFAOYSA-N, ZESFDAKNYJQYKO-UHFFFAOYSA-N, ZESFDAKNYJQYKO-UHFFFAOYSA-N, ZESFDAKNYJQYKO-UHFFFAOYSA-N	Phase 1
PFI-1	bromodomain inhibitor	BRD4			COc1ccccc1S(=O)(=O)Nc1ccc2NC(=O)N(C)Cc2c1, COc1ccccc1S(=O)(=O)Nc1ccc2NC(=O)N(C)Cc2c1, COc1ccccc1S(=O)(=O)Nc1ccc2NC(=O)N(C)Cc2c1, COc1ccccc1S(=O)(=O)Nc1ccc2NC(=O)N(C)Cc2c1, COc1ccccc1S(=O)(=O)Nc1ccc2NC(=O)N(C)Cc2c1, COc1ccccc1S(=O)(=O)Nc1ccc2NC(=O)N(C)Cc2c1, COc1ccccc1S(=O)(=O)Nc1ccc2NC(=O)N(C)Cc2c1	TXZPMHLMPKIUGK-UHFFFAOYSA-N, TXZPMHLMPKIUGK-UHFFFAOYSA-N, TXZPMHLMPKIUGK-UHFFFAOYSA-N, TXZPMHLMPKIUGK-UHFFFAOYSA-N, TXZPMHLMPKIUGK-UHFFFAOYSA-N, TXZPMHLMPKIUGK-UHFFFAOYSA-N, TXZPMHLMPKIUGK-UHFFFAOYSA-N	Preclinical
PFI-3	bromodomain inhibitor	PBRM1, SMARCA4			Oc1ccccc1C(=O)\C=C\N1C[C@H]2C[C@@H]1CN2c1ccccn1, Oc1ccccc1C(=O)\C=C\N1C[C@H]2C[C@@H]1CN2c1ccccn1, Oc1ccccc1C(=O)\C=C\N1C[C@H]2C[C@@H]1CN2c1ccccn1	INAICWLVUAKEPB-QSTFCLMHSA-N, INAICWLVUAKEPB-QSTFCLMHSA-N, INAICWLVUAKEPB-QSTFCLMHSA-N	Preclinical
PFI-4	bromodomain inhibitor	BRPF1			COc1ccccc1C(=O)Nc1cc2n(C)c(=O)n(C)c2cc1N1CCCC1, COc1ccccc1C(=O)Nc1cc2n(C)c(=O)n(C)c2cc1N1CCCC1, COc1ccccc1C(=O)Nc1cc2n(C)c(=O)n(C)c2cc1N1CCCC1	QCIJLRJBZDBVDB-UHFFFAOYSA-N, QCIJLRJBZDBVDB-UHFFFAOYSA-N, QCIJLRJBZDBVDB-UHFFFAOYSA-N	Preclinical
PFK-015	phosphofructokinase inhibitor	PFKFB3			O=C(\C=C\c1ccc2ccccc2n1)c1ccncc1, O=C(\C=C\c1ccc2ccccc2n1)c1ccncc1, O=C(\C=C\c1ccc2ccccc2n1)c1ccncc1, O=C(\C=C\c1ccc2ccccc2n1)c1ccncc1, O=C(\C=C\c1ccc2ccccc2n1)c1ccncc1	UJJUKZPBUMCSJZ-BQYQJAHWSA-N, UJJUKZPBUMCSJZ-BQYQJAHWSA-N, UJJUKZPBUMCSJZ-BQYQJAHWSA-N, UJJUKZPBUMCSJZ-BQYQJAHWSA-N, UJJUKZPBUMCSJZ-BQYQJAHWSA-N	Phase 1
PFK-158	phosphofructokinase inhibitor	PFKFB3			FC(F)(F)c1ccc2ccc(\C=C\C(=O)c3ccncc3)nc2c1, FC(F)(F)c1ccc2ccc(\C=C\C(=O)c3ccncc3)nc2c1, FC(F)(F)c1ccc2ccc(\C=C\C(=O)c3ccncc3)nc2c1	IAJOMYABKVAZCN-AATRIKPKSA-N, IAJOMYABKVAZCN-AATRIKPKSA-N, IAJOMYABKVAZCN-AATRIKPKSA-N	Phase 1
PG-9	acetylcholine receptor agonist				C[C@@H](C(=O)O[C@@H]1C[C@@H]2CC[C@H](C1)N2C)c1ccc(Br)cc1 |&1:5,7,10,&2:1,r,TLB:13:12:8.9:5.6.11|	GHDWIFTUSXQYGK-FWYOQMDTSA-N	Preclinical
PGL5001	JNK inhibitor	MAPK10, MAPK8, MAPK9			N#C[C@@H](c1nc2ccccc2s1)c1ccnc(OCc2ccc(CN3CCOCC3)cc2)n1 |&1:2,r|, N#C[C@@H](c1nc2ccccc2s1)c1ccnc(OCc2ccc(CN3CCOCC3)cc2)n1 |&1:2,r|, N#C[C@@H](c1nc2ccccc2s1)c1ccnc(OCc2ccc(CN3CCOCC3)cc2)n1 |&1:2,r|, N#C[C@@H](c1nc2ccccc2s1)c1ccnc(OCc2ccc(CN3CCOCC3)cc2)n1 |&1:2,r|, N#C[C@@H](c1nc2ccccc2s1)c1ccnc(OCc2ccc(CN3CCOCC3)cc2)n1 |&1:2,r|, N#C[C@@H](c1nc2ccccc2s1)c1ccnc(OCc2ccc(CN3CCOCC3)cc2)n1 |&1:2,r|, N#C[C@@H](c1nc2ccccc2s1)c1ccnc(OCc2ccc(CN3CCOCC3)cc2)n1 |&1:2,r|, N#C[C@@H](c1nc2ccccc2s1)c1ccnc(OCc2ccc(CN3CCOCC3)cc2)n1 |&1:2,r|, N#C[C@@H](c1nc2ccccc2s1)c1ccnc(OCc2ccc(CN3CCOCC3)cc2)n1 |&1:2,r|, N#C[C@@H](c1nc2ccccc2s1)c1ccnc(OCc2ccc(CN3CCOCC3)cc2)n1 |&1:2,r|	XCPPIJCBCWUBNT-HXUWFJFHSA-N, XCPPIJCBCWUBNT-HXUWFJFHSA-N, XCPPIJCBCWUBNT-HXUWFJFHSA-N, XCPPIJCBCWUBNT-HXUWFJFHSA-N, XCPPIJCBCWUBNT-HXUWFJFHSA-N, XCPPIJCBCWUBNT-HXUWFJFHSA-N, XCPPIJCBCWUBNT-HXUWFJFHSA-N, XCPPIJCBCWUBNT-HXUWFJFHSA-N, XCPPIJCBCWUBNT-HXUWFJFHSA-N, XCPPIJCBCWUBNT-HXUWFJFHSA-N	Phase 2
PH-797804	p38 MAPK inhibitor	MAPK11, MAPK14			CNC(=O)c1ccc(C)c(c1)-n1c(C)cc(OCc2ccc(F)cc2F)c(Br)c1=O, CNC(=O)c1ccc(C)c(c1)-n1c(C)cc(OCc2ccc(F)cc2F)c(Br)c1=O, CNC(=O)c1ccc(C)c(c1)-n1c(C)cc(OCc2ccc(F)cc2F)c(Br)c1=O	KCAJXIDMCNPGHZ-UHFFFAOYSA-N, KCAJXIDMCNPGHZ-UHFFFAOYSA-N, KCAJXIDMCNPGHZ-UHFFFAOYSA-N	Phase 2
PHA-543613	nicotinic receptor agonist				O=C(N[C@H]1CN2CCC1CC2)c1cc2ccoc2cn1	IPKZCLGGYKRDES-ZDUSSCGKSA-N	Preclinical
PHA-568487	nicotinic receptor agonist	CHRNA7			O=C(N[C@H]1CN2CCC1CC2)c1ccc2OCCOc2c1, O=C(N[C@H]1CN2CCC1CC2)c1ccc2OCCOc2c1	LUVXHMJTVXZFPD-ZDUSSCGKSA-N, LUVXHMJTVXZFPD-ZDUSSCGKSA-N	Preclinical
PHA-665752	c-Met inhibitor	MET			Cc1[nH]c(\C=C2/C(=O)Nc3ccc(cc23)S(=O)(=O)Cc2c(Cl)cccc2Cl)c(C)c1C(=O)N1CCC[C@@H]1CN1CCCC1, Cc1[nH]c(\C=C2/C(=O)Nc3ccc(cc23)S(=O)(=O)Cc2c(Cl)cccc2Cl)c(C)c1C(=O)N1CCC[C@@H]1CN1CCCC1, Cc1[nH]c(\C=C2/C(=O)Nc3ccc(cc23)S(=O)(=O)Cc2c(Cl)cccc2Cl)c(C)c1C(=O)N1CCC[C@@H]1CN1CCCC1, Cc1[nH]c(\C=C2/C(=O)Nc3ccc(cc23)S(=O)(=O)Cc2c(Cl)cccc2Cl)c(C)c1C(=O)N1CCC[C@@H]1CN1CCCC1, Cc1[nH]c(\C=C2/C(=O)Nc3ccc(cc23)S(=O)(=O)Cc2c(Cl)cccc2Cl)c(C)c1C(=O)N1CCC[C@@H]1CN1CCCC1, Cc1[nH]c(\C=C2/C(=O)Nc3ccc(cc23)S(=O)(=O)Cc2c(Cl)cccc2Cl)c(C)c1C(=O)N1CCC[C@@H]1CN1CCCC1	OYONTEXKYJZFHA-SSHUPFPWSA-N, OYONTEXKYJZFHA-SSHUPFPWSA-N, OYONTEXKYJZFHA-SSHUPFPWSA-N, OYONTEXKYJZFHA-SSHUPFPWSA-N, OYONTEXKYJZFHA-SSHUPFPWSA-N, OYONTEXKYJZFHA-SSHUPFPWSA-N	Preclinical
PHA-680632	Aurora kinase inhibitor	AURKA, AURKB, AURKC			CCc1cccc(CC)c1NC(=O)N1Cc2n[nH]c(NC(=O)c3ccc(cc3)N3CCN(C)CC3)c2C1, CCc1cccc(CC)c1NC(=O)N1Cc2n[nH]c(NC(=O)c3ccc(cc3)N3CCN(C)CC3)c2C1, CCc1cccc(CC)c1NC(=O)N1Cc2n[nH]c(NC(=O)c3ccc(cc3)N3CCN(C)CC3)c2C1, CCc1cccc(CC)c1NC(=O)N1Cc2n[nH]c(NC(=O)c3ccc(cc3)N3CCN(C)CC3)c2C1	OBWNXGOQPLDDPS-UHFFFAOYSA-N, OBWNXGOQPLDDPS-UHFFFAOYSA-N, OBWNXGOQPLDDPS-UHFFFAOYSA-N, OBWNXGOQPLDDPS-UHFFFAOYSA-N	Preclinical
PHA-767491	CDC inhibitor	CDK1, RPS6KB1			O=C1NCCc2[nH]c(cc12)-c1ccncc1, O=C1NCCc2[nH]c(cc12)-c1ccncc1, O=C1NCCc2[nH]c(cc12)-c1ccncc1, O=C1NCCc2[nH]c(cc12)-c1ccncc1, O=C1NCCc2[nH]c(cc12)-c1ccncc1	DKXHSOUZPMHNIZ-UHFFFAOYSA-N, DKXHSOUZPMHNIZ-UHFFFAOYSA-N, DKXHSOUZPMHNIZ-UHFFFAOYSA-N, DKXHSOUZPMHNIZ-UHFFFAOYSA-N, DKXHSOUZPMHNIZ-UHFFFAOYSA-N	Preclinical
PHA-793887	CDK inhibitor	CDK1, CDK2, CDK4, CDK5, CDK7, CDK9			CC(C)CC(=O)Nc1[nH]nc2c1CN(C(=O)C1CCN(C)CC1)C2(C)C, CC(C)CC(=O)Nc1[nH]nc2c1CN(C(=O)C1CCN(C)CC1)C2(C)C, CC(C)CC(=O)Nc1[nH]nc2c1CN(C(=O)C1CCN(C)CC1)C2(C)C, CC(C)CC(=O)Nc1[nH]nc2c1CN(C(=O)C1CCN(C)CC1)C2(C)C, CC(C)CC(=O)Nc1[nH]nc2c1CN(C(=O)C1CCN(C)CC1)C2(C)C, CC(C)CC(=O)Nc1[nH]nc2c1CN(C(=O)C1CCN(C)CC1)C2(C)C, CC(C)CC(=O)Nc1[nH]nc2c1CN(C(=O)C1CCN(C)CC1)C2(C)C, CC(C)CC(=O)Nc1[nH]nc2c1CN(C(=O)C1CCN(C)CC1)C2(C)C, CC(C)CC(=O)Nc1[nH]nc2c1CN(C(=O)C1CCN(C)CC1)C2(C)C, CC(C)CC(=O)Nc1[nH]nc2c1CN(C(=O)C1CCN(C)CC1)C2(C)C, CC(C)CC(=O)Nc1[nH]nc2c1CN(C(=O)C1CCN(C)CC1)C2(C)C, CC(C)CC(=O)Nc1[nH]nc2c1CN(C(=O)C1CCN(C)CC1)C2(C)C, CC(C)CC(=O)Nc1[nH]nc2c1CN(C(=O)C1CCN(C)CC1)C2(C)C	HUXYBQXJVXOMKX-UHFFFAOYSA-N, HUXYBQXJVXOMKX-UHFFFAOYSA-N, HUXYBQXJVXOMKX-UHFFFAOYSA-N, HUXYBQXJVXOMKX-UHFFFAOYSA-N, HUXYBQXJVXOMKX-UHFFFAOYSA-N, HUXYBQXJVXOMKX-UHFFFAOYSA-N, HUXYBQXJVXOMKX-UHFFFAOYSA-N, HUXYBQXJVXOMKX-UHFFFAOYSA-N, HUXYBQXJVXOMKX-UHFFFAOYSA-N, HUXYBQXJVXOMKX-UHFFFAOYSA-N, HUXYBQXJVXOMKX-UHFFFAOYSA-N, HUXYBQXJVXOMKX-UHFFFAOYSA-N, HUXYBQXJVXOMKX-UHFFFAOYSA-N	Phase 1
PHA-848125	CDK inhibitor, growth factor receptor inhibitor	CDK2, CDK4, CDK7, NTRK1			CNC(=O)c1nn(C)c-2c1C(C)(C)Cc1cnc(Nc3ccc(cc3)N3CCN(C)CC3)nc-21, CNC(=O)c1nn(C)c-2c1C(C)(C)Cc1cnc(Nc3ccc(cc3)N3CCN(C)CC3)nc-21, CNC(=O)c1nn(C)c-2c1C(C)(C)Cc1cnc(Nc3ccc(cc3)N3CCN(C)CC3)nc-21, CNC(=O)c1nn(C)c-2c1C(C)(C)Cc1cnc(Nc3ccc(cc3)N3CCN(C)CC3)nc-21, CNC(=O)c1nn(C)c-2c1C(C)(C)Cc1cnc(Nc3ccc(cc3)N3CCN(C)CC3)nc-21, CNC(=O)c1nn(C)c-2c1C(C)(C)Cc1cnc(Nc3ccc(cc3)N3CCN(C)CC3)nc-21, CNC(=O)c1nn(C)c-2c1C(C)(C)Cc1cnc(Nc3ccc(cc3)N3CCN(C)CC3)nc-21, CNC(=O)c1nn(C)c-2c1C(C)(C)Cc1cnc(Nc3ccc(cc3)N3CCN(C)CC3)nc-21, CNC(=O)c1nn(C)c-2c1C(C)(C)Cc1cnc(Nc3ccc(cc3)N3CCN(C)CC3)nc-21	RXZMYLDMFYNEIM-UHFFFAOYSA-N, RXZMYLDMFYNEIM-UHFFFAOYSA-N, RXZMYLDMFYNEIM-UHFFFAOYSA-N, RXZMYLDMFYNEIM-UHFFFAOYSA-N, RXZMYLDMFYNEIM-UHFFFAOYSA-N, RXZMYLDMFYNEIM-UHFFFAOYSA-N, RXZMYLDMFYNEIM-UHFFFAOYSA-N, RXZMYLDMFYNEIM-UHFFFAOYSA-N, RXZMYLDMFYNEIM-UHFFFAOYSA-N	Phase 2
PHCCC	glutamate receptor agonist	GRM1, GRM4			O\N=C1/[C@@H]2C[C@@]2(Oc2ccccc12)C(=O)Nc1ccccc1 |&1:3,5|	FPXPIEZPAXSELW-RGNAGUPPSA-N	Preclinical
phenacaine	local anesthetic		neurology/psychiatry	local anesthetic	CCOc1ccc(NC(C)=Nc2ccc(OCC)cc2)cc1, CCOc1ccc(NC(C)=Nc2ccc(OCC)cc2)cc1	QXDAEKSDNVPFJG-UHFFFAOYSA-N, QXDAEKSDNVPFJG-UHFFFAOYSA-N	Launched
phenacemide	sodium channel blocker	SCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A	neurology/psychiatry	epilepsy, seizures	NC(=O)NC(=O)Cc1ccccc1, NC(=O)NC(=O)Cc1ccccc1	XPFRXWCVYUEORT-UHFFFAOYSA-N, XPFRXWCVYUEORT-UHFFFAOYSA-N	Launched
phenacetin	cyclooxygenase inhibitor	PTGS1			CCOc1ccc(NC(C)=O)cc1, CCOc1ccc(NC(C)=O)cc1, CCOc1ccc(NC(C)=O)cc1	CPJSUEIXXCENMM-UHFFFAOYSA-N, CPJSUEIXXCENMM-UHFFFAOYSA-N, CPJSUEIXXCENMM-UHFFFAOYSA-N	Withdrawn
phenazone	cyclooxygenase inhibitor	PTGS1, PTGS2	neurology/psychiatry	pain relief	Cc1cc(=O)n(-c2ccccc2)n1C, Cc1cc(=O)n(-c2ccccc2)n1C, Cc1cc(=O)n(-c2ccccc2)n1C	VEQOALNAAJBPNY-UHFFFAOYSA-N, VEQOALNAAJBPNY-UHFFFAOYSA-N, VEQOALNAAJBPNY-UHFFFAOYSA-N	Launched
phenazopyridine	local anesthetic	SCN1A	infectious disease	urinary tract infections	Nc1ccc(\N=N\c2ccccc2)c(N)n1, Nc1ccc(\N=N\c2ccccc2)c(N)n1, Nc1ccc(\N=N\c2ccccc2)c(N)n1, Nc1ccc(\N=N\c2ccccc2)c(N)n1, Nc1ccc(\N=N\c2ccccc2)c(N)n1	QPFYXYFORQJZEC-FOCLMDBBSA-N, QPFYXYFORQJZEC-FOCLMDBBSA-N, QPFYXYFORQJZEC-FOCLMDBBSA-N, QPFYXYFORQJZEC-FOCLMDBBSA-N, QPFYXYFORQJZEC-FOCLMDBBSA-N	Launched
phenelzine	monoamine oxidase inhibitor	ABAT, AOC3, GAD2, GPT, GPT2, MAOA, MAOB, SLC6A2, SLC6A3, SLC6A4	neurology/psychiatry	depression	NNCCc1ccccc1, NNCCc1ccccc1, NNCCc1ccccc1, NNCCc1ccccc1, NNCCc1ccccc1	RMUCZJUITONUFY-UHFFFAOYSA-N, RMUCZJUITONUFY-UHFFFAOYSA-N, RMUCZJUITONUFY-UHFFFAOYSA-N, RMUCZJUITONUFY-UHFFFAOYSA-N, RMUCZJUITONUFY-UHFFFAOYSA-N	Launched
phenethicillin	bacterial cell wall synthesis inhibitor				C[C@@H](Oc1ccccc1)C(=O)N[C@H]1[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O |a:12,13,18,&1:1|	NONJJLVGHLVQQM-ADGXKJENSA-N	Launched
phenethyl-isothiocyanate	anticancer agent	CYP2E1			S=C=NCCc1ccccc1	IZJDOKYDEWTZSO-UHFFFAOYSA-N	Phase 2
phenformin	AMPK activator	KCNJ8, PRKAA1			NC(N)=NC(=N)NCCc1ccccc1, NC(N)=NC(=N)NCCc1ccccc1, NC(N)=NC(=N)NCCc1ccccc1, NC(N)=NC(=N)NCCc1ccccc1, NC(N)=NC(=N)NCCc1ccccc1	ICFJFFQQTFMIBG-UHFFFAOYSA-N, ICFJFFQQTFMIBG-UHFFFAOYSA-N, ICFJFFQQTFMIBG-UHFFFAOYSA-N, ICFJFFQQTFMIBG-UHFFFAOYSA-N, ICFJFFQQTFMIBG-UHFFFAOYSA-N	Withdrawn
phenindamine	histamine receptor antagonist	HRH1	allergy, otolaryngology	allergic rhinitis, common cold	CN1CCC2=C(C1)[C@@H](c1ccccc21)c1ccccc1 |&1:7,r,c:4|, CN1CCC2=C(C1)[C@@H](c1ccccc21)c1ccccc1 |&1:7,r,c:4|	ISFHAYSTHMVOJR-LJQANCHMSA-N, ISFHAYSTHMVOJR-LJQANCHMSA-N	Launched
phenindione	vitamin K antagonist	VKORC1	hematology	deep vein thrombosis (DVT)	O=C1C(C(=O)c2ccccc12)c1ccccc1, O=C1C(C(=O)c2ccccc12)c1ccccc1, O=C1C(C(=O)c2ccccc12)c1ccccc1, O=C1C(C(=O)c2ccccc12)c1ccccc1, O=C1C(C(=O)c2ccccc12)c1ccccc1, O=C1C(C(=O)c2ccccc12)c1ccccc1, O=C1C(C(=O)c2ccccc12)c1ccccc1, O=C1C(C(=O)c2ccccc12)c1ccccc1	NFBAXHOPROOJAW-UHFFFAOYSA-N, NFBAXHOPROOJAW-UHFFFAOYSA-N, NFBAXHOPROOJAW-UHFFFAOYSA-N, NFBAXHOPROOJAW-UHFFFAOYSA-N, NFBAXHOPROOJAW-UHFFFAOYSA-N, NFBAXHOPROOJAW-UHFFFAOYSA-N, NFBAXHOPROOJAW-UHFFFAOYSA-N, NFBAXHOPROOJAW-UHFFFAOYSA-N	Launched
pheniramine	histamine receptor antagonist	HRH1	allergy	allergic rhinitis, urticaria	CN(C)CC[C@@H](c1ccccc1)c1ccccn1 |&1:5|, CN(C)CC[C@@H](c1ccccc1)c1ccccn1 |&1:5|, CN(C)CC[C@@H](c1ccccc1)c1ccccn1 |&1:5|, CN(C)CC[C@@H](c1ccccc1)c1ccccn1 |&1:5|	IJHNSHDBIRRJRN-HNNXBMFYSA-N, IJHNSHDBIRRJRN-HNNXBMFYSA-N, IJHNSHDBIRRJRN-HNNXBMFYSA-N, IJHNSHDBIRRJRN-HNNXBMFYSA-N	Launched
phenol		CA1, CA12, CA14, CA2, CA4, CA9	otolaryngology	pharyngitis	Oc1ccccc1	ISWSIDIOOBJBQZ-UHFFFAOYSA-N	Preclinical
phenolphthalein	indicator dye	UGT1A9			Oc1ccc(cc1)C1(OC(=O)c2ccccc12)c1ccc(O)cc1, Oc1ccc(cc1)C1(OC(=O)c2ccccc12)c1ccc(O)cc1	KJFMBFZCATUALV-UHFFFAOYSA-N, KJFMBFZCATUALV-UHFFFAOYSA-N	Withdrawn
phenolsulfonphthalein					Oc1ccc(cc1)C1(OS(=O)(=O)c2ccccc12)c1ccc(O)cc1, Oc1ccc(cc1)C1(OS(=O)(=O)c2ccccc12)c1ccc(O)cc1	BELBBZDIHDAJOR-UHFFFAOYSA-N, BELBBZDIHDAJOR-UHFFFAOYSA-N	Launched
phenothiazine	dopamine receptor antagonist				N1c2ccccc2Sc2ccccc12, N1c2ccccc2Sc2ccccc12, N1c2ccccc2Sc2ccccc12, N1c2ccccc2Sc2ccccc12	WJFKNYWRSNBZNX-UHFFFAOYSA-N, WJFKNYWRSNBZNX-UHFFFAOYSA-N, WJFKNYWRSNBZNX-UHFFFAOYSA-N, WJFKNYWRSNBZNX-UHFFFAOYSA-N	Preclinical
phenothrin			infectious disease	lice	CC(C)=C[C@H]1[C@@H](C(=O)OCc2cccc(Oc3ccccc3)c2)C1(C)C |&1:4,&2:5,r|, CC(C)=C[C@H]1[C@@H](C(=O)OCc2cccc(Oc3ccccc3)c2)C1(C)C |&1:4,&2:5,r|, CC(C)=C[C@H]1[C@@H](C(=O)OCc2cccc(Oc3ccccc3)c2)C1(C)C |&1:4,&2:5,r|	SBNFWQZLDJGRLK-SFTDATJTSA-N, SBNFWQZLDJGRLK-SFTDATJTSA-N, SBNFWQZLDJGRLK-SFTDATJTSA-N	Launched
phenoxybenzamine	adrenergic receptor antagonist	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C	cardiology, endocrinology	hypertension, pheochromocytoma	CC(COc1ccccc1)N(CCCl)Cc1ccccc1, CC(COc1ccccc1)N(CCCl)Cc1ccccc1, CC(COc1ccccc1)N(CCCl)Cc1ccccc1, CC(COc1ccccc1)N(CCCl)Cc1ccccc1, CC(COc1ccccc1)N(CCCl)Cc1ccccc1	QZVCTJOXCFMACW-UHFFFAOYSA-N, QZVCTJOXCFMACW-UHFFFAOYSA-N, QZVCTJOXCFMACW-UHFFFAOYSA-N, QZVCTJOXCFMACW-UHFFFAOYSA-N, QZVCTJOXCFMACW-UHFFFAOYSA-N	Launched
phenprobamate	muscle relaxant		neurology/psychiatry	anxiety, muscle relaxant	NC(=O)OCCCc1ccccc1	CAMYKONBWHRPDD-UHFFFAOYSA-N	Launched
phenprocoumon	vitamin K antagonist	VKORC1	hematology	thrombosis, pulmonary embolism (PE)	CC[C@@H](c1ccccc1)c1c(O)c2ccccc2oc1=O |&1:2,r|	DQDAYGNAKTZFIW-ZDUSSCGKSA-N	Launched
phenserine	acetylcholinesterase inhibitor, beta amyloid synthesis inhibitor	ACHE, BCHE			CN1CC[C@]2(C)[C@H]1N(C)c1ccc(OC(=O)Nc3ccccc3)cc21, CN1CC[C@]2(C)[C@H]1N(C)c1ccc(OC(=O)Nc3ccccc3)cc21, CN1CC[C@]2(C)[C@H]1N(C)c1ccc(OC(=O)Nc3ccccc3)cc21	PBHFNBQPZCRWQP-QUCCMNQESA-N, PBHFNBQPZCRWQP-QUCCMNQESA-N, PBHFNBQPZCRWQP-QUCCMNQESA-N	Phase 3
phensuximide	succinimide antiepileptic		neurology/psychiatry	seizures	CN1C(=O)C[C@@H](C1=O)c1ccccc1 |&1:5,r|, CN1C(=O)C[C@@H](C1=O)c1ccccc1 |&1:5,r|	WLWFNJKHKGIJNW-SECBINFHSA-N, WLWFNJKHKGIJNW-SECBINFHSA-N	Launched
phentolamine	adrenergic receptor antagonist	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C	endocrinology, cardiology	pheochromocytoma, hypertension	Cc1ccc(cc1)N(CC1=NCCN1)c1cccc(O)c1 |t:10|, Cc1ccc(cc1)N(CC1=NCCN1)c1cccc(O)c1 |t:10|, Cc1ccc(cc1)N(CC1=NCCN1)c1cccc(O)c1 |t:10|, Cc1ccc(cc1)N(CC1=NCCN1)c1cccc(O)c1 |t:10|, Cc1ccc(cc1)N(CC1=NCCN1)c1cccc(O)c1 |t:10|, Cc1ccc(cc1)N(CC1=NCCN1)c1cccc(O)c1 |t:10|, Cc1ccc(cc1)N(CC1=NCCN1)c1cccc(O)c1 |t:10|	MRBDMNSDAVCSSF-UHFFFAOYSA-N, MRBDMNSDAVCSSF-UHFFFAOYSA-N, MRBDMNSDAVCSSF-UHFFFAOYSA-N, MRBDMNSDAVCSSF-UHFFFAOYSA-N, MRBDMNSDAVCSSF-UHFFFAOYSA-N, MRBDMNSDAVCSSF-UHFFFAOYSA-N, MRBDMNSDAVCSSF-UHFFFAOYSA-N	Launched
phenyl-aminosalicylate			infectious disease	tuberculosis	Nc1ccc(C(=O)Oc2ccccc2)c(O)c1, Nc1ccc(C(=O)Oc2ccccc2)c(O)c1	DNVVZWSVACQWJE-UHFFFAOYSA-N, DNVVZWSVACQWJE-UHFFFAOYSA-N	Launched
phenyl-salicylate	antiseptic		urology	interstitial cystitis (IC)	Oc1ccccc1C(=O)Oc1ccccc1, Oc1ccccc1C(=O)Oc1ccccc1	ZQBAKBUEJOMQEX-UHFFFAOYSA-N, ZQBAKBUEJOMQEX-UHFFFAOYSA-N	Launched
phenylacetylglutamine	DNA methylase inhibitor, protein synthesis inhibitor				NC(=O)CC[C@H](NC(=O)Cc1ccccc1)C(O)=O	JFLIEFSWGNOPJJ-JTQLQIEISA-N	Phase 2
phenylbenzimidazole-sulfonic-acid			dermatology	sunscreen lotion	OS(=O)(=O)c1ccc2nc([nH]c2c1)-c1ccccc1, OS(=O)(=O)c1ccc2nc([nH]c2c1)-c1ccccc1	UVCJGUGAGLDPAA-UHFFFAOYSA-N, UVCJGUGAGLDPAA-UHFFFAOYSA-N	Launched
phenylbutazone	cyclooxygenase inhibitor, prostanoid receptor antagonist	PTGIS, PTGS1, PTGS2			CCCCC1C(=O)N(N(C1=O)c1ccccc1)c1ccccc1, CCCCC1C(=O)N(N(C1=O)c1ccccc1)c1ccccc1, CCCCC1C(=O)N(N(C1=O)c1ccccc1)c1ccccc1, CCCCC1C(=O)N(N(C1=O)c1ccccc1)c1ccccc1	VYMDGNCVAMGZFE-UHFFFAOYSA-N, VYMDGNCVAMGZFE-UHFFFAOYSA-N, VYMDGNCVAMGZFE-UHFFFAOYSA-N, VYMDGNCVAMGZFE-UHFFFAOYSA-N	Withdrawn
phenylbutyrate	HDAC inhibitor	HDAC1	metabolism	urea cycle disorders	OC(=O)CCCc1ccccc1, OC(=O)CCCc1ccccc1, OC(=O)CCCc1ccccc1, OC(=O)CCCc1ccccc1, OC(=O)CCCc1ccccc1, OC(=O)CCCc1ccccc1	OBKXEAXTFZPCHS-UHFFFAOYSA-N, OBKXEAXTFZPCHS-UHFFFAOYSA-N, OBKXEAXTFZPCHS-UHFFFAOYSA-N, OBKXEAXTFZPCHS-UHFFFAOYSA-N, OBKXEAXTFZPCHS-UHFFFAOYSA-N, OBKXEAXTFZPCHS-UHFFFAOYSA-N	Launched
phenylephrine	adrenergic receptor agonist	ADRA1A, ADRA1B, ADRA1D	otolaryngology, gastroenterology, cardiology	nasal congestion, hemorrhoids, hypotension	CNC[C@H](O)c1cccc(O)c1, CNC[C@H](O)c1cccc(O)c1, CNC[C@H](O)c1cccc(O)c1, CNC[C@H](O)c1cccc(O)c1, CNC[C@H](O)c1cccc(O)c1	SONNWYBIRXJNDC-VIFPVBQESA-N, SONNWYBIRXJNDC-VIFPVBQESA-N, SONNWYBIRXJNDC-VIFPVBQESA-N, SONNWYBIRXJNDC-VIFPVBQESA-N, SONNWYBIRXJNDC-VIFPVBQESA-N	Launched
phenylethyl-alcohol					OCCc1ccccc1, OCCc1ccccc1	WRMNZCZEMHIOCP-UHFFFAOYSA-N, WRMNZCZEMHIOCP-UHFFFAOYSA-N	Preclinical
phenylmercuric-acetate	other antifungal				CC(=O)O[Hg]c1ccccc1, CC(=O)O[Hg]c1ccccc1, CC(=O)O[Hg]c1ccccc1, CC(=O)O[Hg]c1ccccc1	XEBWQGVWTUSTLN-UHFFFAOYSA-M, XEBWQGVWTUSTLN-UHFFFAOYSA-M, XEBWQGVWTUSTLN-UHFFFAOYSA-M, XEBWQGVWTUSTLN-UHFFFAOYSA-M	Preclinical
phenylmethylsulfonyl-fluoride	serine protease inhibitor				FS(=O)(=O)Cc1ccccc1, FS(=O)(=O)Cc1ccccc1, FS(=O)(=O)Cc1ccccc1, FS(=O)(=O)Cc1ccccc1	YBYRMVIVWMBXKQ-UHFFFAOYSA-N, YBYRMVIVWMBXKQ-UHFFFAOYSA-N, YBYRMVIVWMBXKQ-UHFFFAOYSA-N, YBYRMVIVWMBXKQ-UHFFFAOYSA-N	Preclinical
phenylpiracetam	noradrenaline uptake inhibitor		neurology/psychiatry	anxiety, fatigue, depression	NC(=O)CN1C[C@@H](CC1=O)c1ccccc1 |&1:6,r|	LYONXVJRBWWGQO-SNVBAGLBSA-N	Launched
phenytoin	hydantoin antiepileptic	SCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A	neurology/psychiatry	seizures	O=C1NC(=O)C(N1)(c1ccccc1)c1ccccc1, O=C1NC(=O)C(N1)(c1ccccc1)c1ccccc1, O=C1NC(=O)C(N1)(c1ccccc1)c1ccccc1	CXOFVDLJLONNDW-UHFFFAOYSA-N, CXOFVDLJLONNDW-UHFFFAOYSA-N, CXOFVDLJLONNDW-UHFFFAOYSA-N	Launched
PhiKan-083	p53 stabilizing agent	TP53			CCn1c2ccccc2c2cc(CNC)ccc12, CCn1c2ccccc2c2cc(CNC)ccc12	LBPNOEAFWYTTEB-UHFFFAOYSA-N, LBPNOEAFWYTTEB-UHFFFAOYSA-N	Preclinical
phloretin	sodium/glucose cotransporter inhibitor	AQP9, CLCN3, SLC23A1			Oc1ccc(CCC(=O)c2c(O)cc(O)cc2O)cc1, Oc1ccc(CCC(=O)c2c(O)cc(O)cc2O)cc1	VGEREEWJJVICBM-UHFFFAOYSA-N, VGEREEWJJVICBM-UHFFFAOYSA-N	Launched
phlorizin	sodium/glucose cotransporter inhibitor	SLC5A1, SLC5A11, SLC5A2, SLC5A3			OC[C@H]1O[C@@H](Oc2cc(O)cc(O)c2C(=O)CCc2ccc(O)cc2)[C@H](O)[C@@H](O)[C@@H]1O	IOUVKUPGCMBWBT-QNDFHXLGSA-N	Preclinical
phloroglucin			neurology/psychiatry	spasms	Oc1cc(O)cc(O)c1, Oc1cc(O)cc(O)c1	QCDYQQDYXPDABM-UHFFFAOYSA-N, QCDYQQDYXPDABM-UHFFFAOYSA-N	Launched
phortress	aryl hydrocarbon receptor ligand	AHR			Cc1cc(ccc1NC(=O)[C@@H](N)CCCCN)-c1nc2cc(F)ccc2s1, Cc1cc(ccc1NC(=O)[C@@H](N)CCCCN)-c1nc2cc(F)ccc2s1, Cc1cc(ccc1NC(=O)[C@@H](N)CCCCN)-c1nc2cc(F)ccc2s1	LFDOEFHQLNGBQQ-HNNXBMFYSA-N, LFDOEFHQLNGBQQ-HNNXBMFYSA-N, LFDOEFHQLNGBQQ-HNNXBMFYSA-N	Phase 1
phosphatidylcholine			infectious disease, dermatology, gastroenterology, cardiology, obstetrics/gynecology	hepatitis B, hepatitis C, eczema, gallbladder disease, cholesterol, premenstrual syndrome	CCCCCCCCCCCCCCCC(=O)OC[C@H](CO[P@](O)(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC |a:19,&1:22|, CCCCCCCCCCCCCCCC(=O)OC[C@H](CO[P@](O)(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC |a:19,&1:22|, CCCCCCCCCCCCCCCC(=O)OC[C@H](CO[P@](O)(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC |a:19,&1:22|	JLPULHDHAOZNQI-ZTIMHPMXSA-O, JLPULHDHAOZNQI-ZTIMHPMXSA-O, JLPULHDHAOZNQI-ZTIMHPMXSA-O	Launched
PHP-501	GABA receptor antagonist	GABRA1, GABRB2, GABRG2			On1ncc(C2CCNCC2)c1-c1cccc(c1)-c1ccccc1, On1ncc(C2CCNCC2)c1-c1cccc(c1)-c1ccccc1, On1ncc(C2CCNCC2)c1-c1cccc(c1)-c1ccccc1	UHEYIOPHTBWBQN-UHFFFAOYSA-N, UHEYIOPHTBWBQN-UHFFFAOYSA-N, UHEYIOPHTBWBQN-UHFFFAOYSA-N	Preclinical
PHT-427	AKT inhibitor, pyruvate dehydrogenase inhibitor	AKT2, PDPK1			CCCCCCCCCCCCc1ccc(cc1)S(=O)(=O)Nc1nncs1, CCCCCCCCCCCCc1ccc(cc1)S(=O)(=O)Nc1nncs1, CCCCCCCCCCCCc1ccc(cc1)S(=O)(=O)Nc1nncs1, CCCCCCCCCCCCc1ccc(cc1)S(=O)(=O)Nc1nncs1, CCCCCCCCCCCCc1ccc(cc1)S(=O)(=O)Nc1nncs1	BYWWNRBKPCPJMG-UHFFFAOYSA-N, BYWWNRBKPCPJMG-UHFFFAOYSA-N, BYWWNRBKPCPJMG-UHFFFAOYSA-N, BYWWNRBKPCPJMG-UHFFFAOYSA-N, BYWWNRBKPCPJMG-UHFFFAOYSA-N	Preclinical
phthalylsulfacetamide					CC(=O)NS(=O)(=O)c1ccc(NC(=O)c2ccccc2C(O)=O)cc1, CC(=O)NS(=O)(=O)c1ccc(NC(=O)c2ccccc2C(O)=O)cc1, CC(=O)NS(=O)(=O)c1ccc(NC(=O)c2ccccc2C(O)=O)cc1, CC(=O)NS(=O)(=O)c1ccc(NC(=O)c2ccccc2C(O)=O)cc1	SNWQKAWITMVCQW-UHFFFAOYSA-N, SNWQKAWITMVCQW-UHFFFAOYSA-N, SNWQKAWITMVCQW-UHFFFAOYSA-N, SNWQKAWITMVCQW-UHFFFAOYSA-N	Preclinical
phthalylsulfathiazole	dihydropteroate synthetase inhibitor		infectious disease, gastroenterology	dysentry, colitis	OC(=O)c1ccccc1C(=O)Nc1ccc(cc1)S(=O)(=O)Nc1nccs1, OC(=O)c1ccccc1C(=O)Nc1ccc(cc1)S(=O)(=O)Nc1nccs1	PBMSWVPMRUJMPE-UHFFFAOYSA-N, PBMSWVPMRUJMPE-UHFFFAOYSA-N	Launched
PHTPP	estrogen receptor antagonist	ESR2			Oc1ccc(cc1)-c1c(nn2c(cc(nc12)C(F)(F)F)C(F)(F)F)-c1ccccc1, Oc1ccc(cc1)-c1c(nn2c(cc(nc12)C(F)(F)F)C(F)(F)F)-c1ccccc1, Oc1ccc(cc1)-c1c(nn2c(cc(nc12)C(F)(F)F)C(F)(F)F)-c1ccccc1	AEZPAUSGTAHLOQ-UHFFFAOYSA-N, AEZPAUSGTAHLOQ-UHFFFAOYSA-N, AEZPAUSGTAHLOQ-UHFFFAOYSA-N	Preclinical
physostigmine	acetylcholinesterase inhibitor, cholinesterase inhibitor	ACHE, BCHE	cardiology, neurology/psychiatry, ophthalmology, gastroenterology	hypotension, Alzheimer's disease, glaucoma, gastroparesis	CNC(=O)Oc1ccc2N(C)[C@H]3N(C)CC[C@@]3(C)c2c1, CNC(=O)Oc1ccc2N(C)[C@H]3N(C)CC[C@@]3(C)c2c1, CNC(=O)Oc1ccc2N(C)[C@H]3N(C)CC[C@@]3(C)c2c1, CNC(=O)Oc1ccc2N(C)[C@H]3N(C)CC[C@@]3(C)c2c1, CNC(=O)Oc1ccc2N(C)[C@H]3N(C)CC[C@@]3(C)c2c1, CNC(=O)Oc1ccc2N(C)[C@H]3N(C)CC[C@@]3(C)c2c1, CNC(=O)Oc1ccc2N(C)[C@H]3N(C)CC[C@@]3(C)c2c1, CNC(=O)Oc1ccc2N(C)[C@H]3N(C)CC[C@@]3(C)c2c1, CNC(=O)Oc1ccc2N(C)[C@H]3N(C)CC[C@@]3(C)c2c1, CNC(=O)Oc1ccc2N(C)[C@H]3N(C)CC[C@@]3(C)c2c1	PIJVFDBKTWXHHD-HIFRSBDPSA-N, PIJVFDBKTWXHHD-HIFRSBDPSA-N, PIJVFDBKTWXHHD-HIFRSBDPSA-N, PIJVFDBKTWXHHD-HIFRSBDPSA-N, PIJVFDBKTWXHHD-HIFRSBDPSA-N, PIJVFDBKTWXHHD-HIFRSBDPSA-N, PIJVFDBKTWXHHD-HIFRSBDPSA-N, PIJVFDBKTWXHHD-HIFRSBDPSA-N, PIJVFDBKTWXHHD-HIFRSBDPSA-N, PIJVFDBKTWXHHD-HIFRSBDPSA-N	Launched
phytonadione		BGLAP, GGCX	hematology	vitamin K deficiency, anticoagulation reversal	CC(C)CCC[C@@H](C)CCC[C@@H](C)CCC\C(C)=C\CC1=C(C)C(=O)c2ccccc2C1=O |c:20|, CC(C)CCC[C@@H](C)CCC[C@@H](C)CCC\C(C)=C\CC1=C(C)C(=O)c2ccccc2C1=O |c:20|	MBWXNTAXLNYFJB-NKFFZRIASA-N, MBWXNTAXLNYFJB-NKFFZRIASA-N	Launched
phytosphingosine					CCCCCCCCCCCCCC[C@@H](O)[C@@H](O)[C@@H](N)CO, CCCCCCCCCCCCCC[C@@H](O)[C@@H](O)[C@@H](N)CO, CCCCCCCCCCCCCC[C@@H](O)[C@@H](O)[C@@H](N)CO, CCCCCCCCCCCCCC[C@@H](O)[C@@H](O)[C@@H](N)CO, CCCCCCCCCCCCCC[C@@H](O)[C@@H](O)[C@@H](N)CO, CCCCCCCCCCCCCC[C@@H](O)[C@@H](O)[C@@H](N)CO	AERBNCYCJBRYDG-KSZLIROESA-N, InChI=1S/C18H39NO3/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-17(21)18(22)16(19)15-20/h16-18,20-22H,2-15,19H2,1H3/t16-,17+,18-/m0/s1, InChI=1S/C18H39NO3/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-17(21)18(22)16(19)15-20/h16-18,20-22H,2-15,19H2,1H3/t16-,17+,18-/m0/s1, InChI=1S/C18H39NO3/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-17(21)18(22)16(19)15-20/h16-18,20-22H,2-15,19H2,1H3/t16-,17+,18-/m0/s1, InChI=1S/C18H39NO3/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-17(21)18(22)16(19)15-20/h16-18,20-22H,2-15,19H2,1H3/t16-,17+,18-/m0/s1, InChI=1S/C18H39NO3/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-17(21)18(22)16(19)15-20/h16-18,20-22H,2-15,19H2,1H3/t16-,17+,18-/m0/s1	Phase 1
PI-103	mTOR inhibitor, PI3K inhibitor	MTOR, PIK3CA, PIK3CB, PIK3CD, PIK3CG, PRKDC			Oc1cccc(c1)-c1nc(N2CCOCC2)c2oc3ncccc3c2n1, Oc1cccc(c1)-c1nc(N2CCOCC2)c2oc3ncccc3c2n1, Oc1cccc(c1)-c1nc(N2CCOCC2)c2oc3ncccc3c2n1, Oc1cccc(c1)-c1nc(N2CCOCC2)c2oc3ncccc3c2n1, Oc1cccc(c1)-c1nc(N2CCOCC2)c2oc3ncccc3c2n1, Oc1cccc(c1)-c1nc(N2CCOCC2)c2oc3ncccc3c2n1, Oc1cccc(c1)-c1nc(N2CCOCC2)c2oc3ncccc3c2n1, Oc1cccc(c1)-c1nc(N2CCOCC2)c2oc3ncccc3c2n1, Oc1cccc(c1)-c1nc(N2CCOCC2)c2oc3ncccc3c2n1	TUVCWJQQGGETHL-UHFFFAOYSA-N, TUVCWJQQGGETHL-UHFFFAOYSA-N, TUVCWJQQGGETHL-UHFFFAOYSA-N, TUVCWJQQGGETHL-UHFFFAOYSA-N, TUVCWJQQGGETHL-UHFFFAOYSA-N, TUVCWJQQGGETHL-UHFFFAOYSA-N, TUVCWJQQGGETHL-UHFFFAOYSA-N, InChI=1S/C19H16N4O3/c24-13-4-1-3-12(11-13)17-21-15-14-5-2-6-20-19(14)26-16(15)18(22-17)23-7-9-25-10-8-23/h1-6,11,24H,7-10H2, InChI=1S/C19H16N4O3/c24-13-4-1-3-12(11-13)17-21-15-14-5-2-6-20-19(14)26-16(15)18(22-17)23-7-9-25-10-8-23/h1-6,11,24H,7-10H2	Preclinical
PI-828	PI3K inhibitor				Nc1ccc(cc1)-c1cccc2c1oc(cc2=O)N1CCOCC1, Nc1ccc(cc1)-c1cccc2c1oc(cc2=O)N1CCOCC1, Nc1ccc(cc1)-c1cccc2c1oc(cc2=O)N1CCOCC1, Nc1ccc(cc1)-c1cccc2c1oc(cc2=O)N1CCOCC1, Nc1ccc(cc1)-c1cccc2c1oc(cc2=O)N1CCOCC1, Nc1ccc(cc1)-c1cccc2c1oc(cc2=O)N1CCOCC1, Nc1ccc(cc1)-c1cccc2c1oc(cc2=O)N1CCOCC1, Nc1ccc(cc1)-c1cccc2c1oc(cc2=O)N1CCOCC1, Nc1ccc(cc1)-c1cccc2c1oc(cc2=O)N1CCOCC1, Nc1ccc(cc1)-c1cccc2c1oc(cc2=O)N1CCOCC1, Nc1ccc(cc1)-c1cccc2c1oc(cc2=O)N1CCOCC1	WUKMIBOGGXMBAC-UHFFFAOYSA-N, WUKMIBOGGXMBAC-UHFFFAOYSA-N, WUKMIBOGGXMBAC-UHFFFAOYSA-N, WUKMIBOGGXMBAC-UHFFFAOYSA-N, WUKMIBOGGXMBAC-UHFFFAOYSA-N, WUKMIBOGGXMBAC-UHFFFAOYSA-N, WUKMIBOGGXMBAC-UHFFFAOYSA-N, WUKMIBOGGXMBAC-UHFFFAOYSA-N, WUKMIBOGGXMBAC-UHFFFAOYSA-N, WUKMIBOGGXMBAC-UHFFFAOYSA-N, WUKMIBOGGXMBAC-UHFFFAOYSA-N	Preclinical
pibenzimol	DNA inhibitor				CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1ccc2nc([nH]c2c1)-c1ccc(O)cc1, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1ccc2nc([nH]c2c1)-c1ccc(O)cc1	INAAIJLSXJJHOZ-UHFFFAOYSA-N, INAAIJLSXJJHOZ-UHFFFAOYSA-N	Phase 2
piboserod	serotonin receptor antagonist	HTR2B, HTR4			CCCCN1CCC(CNC(=O)c2c3OCCCn3c3ccccc23)CC1, CCCCN1CCC(CNC(=O)c2c3OCCCn3c3ccccc23)CC1	KVCSJPATKXABRQ-UHFFFAOYSA-N, KVCSJPATKXABRQ-UHFFFAOYSA-N	Phase 2
picartamide	H+/K+-ATPase inhibitor	ATP4A			CNC(=S)[C@]1(CCCS1)c1ccccn1 |&1:4,r|	ITNLONMDUMHEOK-NSHDSACASA-N	Phase 2
piceatannol	SYK inhibitor	ATP5A1, ATP5B, ATP5C1, IRF3			Oc1cc(O)cc(\C=C\c2ccc(O)c(O)c2)c1, Oc1cc(O)cc(\C=C\c2ccc(O)c(O)c2)c1, Oc1cc(O)cc(\C=C\c2ccc(O)c(O)c2)c1, Oc1cc(O)cc(\C=C\c2ccc(O)c(O)c2)c1, Oc1cc(O)cc(\C=C\c2ccc(O)c(O)c2)c1, Oc1cc(O)cc(\C=C\c2ccc(O)c(O)c2)c1, Oc1cc(O)cc(\C=C\c2ccc(O)c(O)c2)c1, Oc1cc(O)cc(\C=C\c2ccc(O)c(O)c2)c1	CDRPUGZCRXZLFL-OWOJBTEDSA-N, CDRPUGZCRXZLFL-OWOJBTEDSA-N, CDRPUGZCRXZLFL-OWOJBTEDSA-N, CDRPUGZCRXZLFL-OWOJBTEDSA-N, CDRPUGZCRXZLFL-OWOJBTEDSA-N, CDRPUGZCRXZLFL-OWOJBTEDSA-N, CDRPUGZCRXZLFL-OWOJBTEDSA-N, CDRPUGZCRXZLFL-OWOJBTEDSA-N	Preclinical
piclamilast	phosphodiesterase inhibitor	PDE4A, PDE4B, PDE4C, PDE4D			COc1ccc(cc1OC1CCCC1)C(=O)Nc1c(Cl)cncc1Cl, COc1ccc(cc1OC1CCCC1)C(=O)Nc1c(Cl)cncc1Cl, COc1ccc(cc1OC1CCCC1)C(=O)Nc1c(Cl)cncc1Cl, COc1ccc(cc1OC1CCCC1)C(=O)Nc1c(Cl)cncc1Cl	RRRUXBQSQLKHEL-UHFFFAOYSA-N, RRRUXBQSQLKHEL-UHFFFAOYSA-N, RRRUXBQSQLKHEL-UHFFFAOYSA-N, RRRUXBQSQLKHEL-UHFFFAOYSA-N	Phase 2
picolamine					NCc1cccnc1, NCc1cccnc1	HDOUGSFASVGDCS-UHFFFAOYSA-N, HDOUGSFASVGDCS-UHFFFAOYSA-N	Preclinical
picolinic-acid	chelating agent				OC(=O)c1ccccn1, OC(=O)c1ccccn1	SIOXPEMLGUPBBT-UHFFFAOYSA-N, SIOXPEMLGUPBBT-UHFFFAOYSA-N	Phase 2
piconol					OCc1ccccn1, OCc1ccccn1	SHNUBALDGXWUJI-UHFFFAOYSA-N, SHNUBALDGXWUJI-UHFFFAOYSA-N	Preclinical
picotamide	thromboxane receptor antagonist, thromboxane synthase inhibitor	TBXA2R	hematology	thrombosis	COc1ccc(cc1C(=O)NCc1cccnc1)C(=O)NCc1cccnc1, COc1ccc(cc1C(=O)NCc1cccnc1)C(=O)NCc1cccnc1, COc1ccc(cc1C(=O)NCc1cccnc1)C(=O)NCc1cccnc1, COc1ccc(cc1C(=O)NCc1cccnc1)C(=O)NCc1cccnc1, COc1ccc(cc1C(=O)NCc1cccnc1)C(=O)NCc1cccnc1, COc1ccc(cc1C(=O)NCc1cccnc1)C(=O)NCc1cccnc1	KYWCWBXGRWWINE-UHFFFAOYSA-N, KYWCWBXGRWWINE-UHFFFAOYSA-N, KYWCWBXGRWWINE-UHFFFAOYSA-N, KYWCWBXGRWWINE-UHFFFAOYSA-N, KYWCWBXGRWWINE-UHFFFAOYSA-N, KYWCWBXGRWWINE-UHFFFAOYSA-N	Launched
picrotin	GABA receptor antagonist	GLRA1, GLRA2, GLRA3, GLRB			CC(C)(O)[C@H]1[C@H]2OC(=O)[C@@H]1[C@@]1(O)C[C@H]3O[C@]33C(=O)O[C@@H]2[C@@]13C |&1:4,&2:5,&3:9,&4:10,&5:13,&6:15,&7:19,&8:20,r|, CC(C)(O)[C@H]1[C@H]2OC(=O)[C@@H]1[C@@]1(O)C[C@H]3O[C@]33C(=O)O[C@@H]2[C@@]13C |&1:4,&2:5,&3:9,&4:10,&5:13,&6:15,&7:19,&8:20,r|, CC(C)(O)[C@H]1[C@H]2OC(=O)[C@@H]1[C@@]1(O)C[C@H]3O[C@]33C(=O)O[C@@H]2[C@@]13C |&1:4,&2:5,&3:9,&4:10,&5:13,&6:15,&7:19,&8:20,r|, CC(C)(O)[C@H]1[C@H]2OC(=O)[C@@H]1[C@@]1(O)C[C@H]3O[C@]33C(=O)O[C@@H]2[C@@]13C |&1:4,&2:5,&3:9,&4:10,&5:13,&6:15,&7:19,&8:20,r|	RYEFFICCPKWYML-XSVQNFTRSA-N, RYEFFICCPKWYML-XSVQNFTRSA-N, RYEFFICCPKWYML-XSVQNFTRSA-N, RYEFFICCPKWYML-XSVQNFTRSA-N	Phase 2
picrotoxinin	GABA receptor antagonist	GLRA1, GLRA2, GLRA3, GLRB, HTR3A, HTR3B			CC(=C)[C@@H]1[C@H]2OC(=O)[C@H]1[C@]1(O)C[C@H]3O[C@]33C(=O)O[C@H]2[C@]13C, CC(=C)[C@@H]1[C@H]2OC(=O)[C@H]1[C@]1(O)C[C@H]3O[C@]33C(=O)O[C@H]2[C@]13C	PIMZUZSSNYHVCU-KBLUICEQSA-N, PIMZUZSSNYHVCU-KBLUICEQSA-N	Preclinical
pidolic-acid		ADAM28, AMY1A, AMY2A, AMY2B, ANG, CCL8, HCRT, IGLC1, KRTAP5-2, TFF2, VEGFA	dermatology	xerosis cutis	OC(=O)[C@@H]1CCC(=O)N1	ODHCTXKNWHHXJC-VKHMYHEASA-N	Launched
pidotimod	interferon receptor agonist, interleukin receptor agonist		infectious disease	immune adjuvant	OC(=O)[C@@H]1CSCN1C(=O)[C@@H]1CCC(=O)N1, OC(=O)[C@@H]1CSCN1C(=O)[C@@H]1CCC(=O)N1, OC(=O)[C@@H]1CSCN1C(=O)[C@@H]1CCC(=O)N1, OC(=O)[C@@H]1CSCN1C(=O)[C@@H]1CCC(=O)N1	UUTKICFRNVKFRG-WDSKDSINSA-N, UUTKICFRNVKFRG-WDSKDSINSA-N, UUTKICFRNVKFRG-WDSKDSINSA-N, UUTKICFRNVKFRG-WDSKDSINSA-N	Launched
pifithrin-alpha	TP53 inhibitor	TP53			Cc1ccc(cc1)C(=O)Cn1c2CCCCc2sc1=N, Cc1ccc(cc1)C(=O)Cn1c2CCCCc2sc1=N, Cc1ccc(cc1)C(=O)Cn1c2CCCCc2sc1=N	OLTZHXYLLRJLST-UHFFFAOYSA-N, OLTZHXYLLRJLST-UHFFFAOYSA-N, OLTZHXYLLRJLST-UHFFFAOYSA-N	Preclinical
pifithrin-cyclic	TP53 inhibitor	TP53			Cc1ccc(cc1)-c1cn2c3CCCCc3sc2n1, Cc1ccc(cc1)-c1cn2c3CCCCc3sc2n1, Cc1ccc(cc1)-c1cn2c3CCCCc3sc2n1, Cc1ccc(cc1)-c1cn2c3CCCCc3sc2n1	IMUKUMUNZJILCG-UHFFFAOYSA-N, IMUKUMUNZJILCG-UHFFFAOYSA-N, IMUKUMUNZJILCG-UHFFFAOYSA-N, IMUKUMUNZJILCG-UHFFFAOYSA-N	Preclinical
pifithrin-mu	HSP inhibitor	HSPA1A, TP53			NS(=O)(=O)C#Cc1ccccc1, NS(=O)(=O)C#Cc1ccccc1, NS(=O)(=O)C#Cc1ccccc1, NS(=O)(=O)C#Cc1ccccc1, NS(=O)(=O)C#Cc1ccccc1, NS(=O)(=O)C#Cc1ccccc1, NS(=O)(=O)C#Cc1ccccc1, NS(=O)(=O)C#Cc1ccccc1, NS(=O)(=O)C#Cc1ccccc1	ZZUZYEMRHCMVTB-UHFFFAOYSA-N, ZZUZYEMRHCMVTB-UHFFFAOYSA-N, ZZUZYEMRHCMVTB-UHFFFAOYSA-N, ZZUZYEMRHCMVTB-UHFFFAOYSA-N, ZZUZYEMRHCMVTB-UHFFFAOYSA-N, ZZUZYEMRHCMVTB-UHFFFAOYSA-N, ZZUZYEMRHCMVTB-UHFFFAOYSA-N, ZZUZYEMRHCMVTB-UHFFFAOYSA-N, ZZUZYEMRHCMVTB-UHFFFAOYSA-N	Preclinical
PIK-293	PI3K inhibitor	PIK3CA, PIK3CB, PIK3CD, PIK3CG			Cc1ccccc1-n1c(Cn2ncc3c(N)ncnc23)nc2cccc(C)c2c1=O, Cc1ccccc1-n1c(Cn2ncc3c(N)ncnc23)nc2cccc(C)c2c1=O	KQDBVHKNIYROHU-UHFFFAOYSA-N, KQDBVHKNIYROHU-UHFFFAOYSA-N	Preclinical
PIK-294	PI3K inhibitor	PIK3CB, PIK3CD, PIK3CG			Cc1ccccc1-n1c(Cn2nc(-c3cccc(O)c3)c3c(N)ncnc23)nc2cccc(C)c2c1=O, Cc1ccccc1-n1c(Cn2nc(-c3cccc(O)c3)c3c(N)ncnc23)nc2cccc(C)c2c1=O	WFSLJOPRIJSOJR-UHFFFAOYSA-N, WFSLJOPRIJSOJR-UHFFFAOYSA-N	Preclinical
PIK-75	DNA protein kinase inhibitor, PI3K inhibitor	PIK3CA, PIK3CB, PIK3CD, PIK3CG, PRKDC			CN(\N=C\c1cnc2ccc(Br)cn12)S(=O)(=O)c1cc(ccc1C)[N+]([O-])=O, CN(\N=C\c1cnc2ccc(Br)cn12)S(=O)(=O)c1cc(ccc1C)[N+]([O-])=O, CN(\N=C\c1cnc2ccc(Br)cn12)S(=O)(=O)c1cc(ccc1C)[N+]([O-])=O	QTHCAAFKVUWAFI-DJKKODMXSA-N, QTHCAAFKVUWAFI-DJKKODMXSA-N, QTHCAAFKVUWAFI-DJKKODMXSA-N	Preclinical
PIK-93	PI3K inhibitor	PI4KB, PIK3C3, PIK3CG			CC(=O)Nc1nc(C)c(s1)-c1ccc(Cl)c(c1)S(=O)(=O)NCCO, CC(=O)Nc1nc(C)c(s1)-c1ccc(Cl)c(c1)S(=O)(=O)NCCO, CC(=O)Nc1nc(C)c(s1)-c1ccc(Cl)c(c1)S(=O)(=O)NCCO, CC(=O)Nc1nc(C)c(s1)-c1ccc(Cl)c(c1)S(=O)(=O)NCCO	JFVNFXCESCXMBC-UHFFFAOYSA-N, JFVNFXCESCXMBC-UHFFFAOYSA-N, JFVNFXCESCXMBC-UHFFFAOYSA-N, JFVNFXCESCXMBC-UHFFFAOYSA-N	Preclinical
pikamilone					OC(=O)CCCNC(=O)c1cccnc1	NAJVRARAUNYNDX-UHFFFAOYSA-N	Phase 1
piketoprofen	cyclooxygenase inhibitor		neurology/psychiatry	pain relief	C[C@@H](C(=O)Nc1cc(C)ccn1)c1cccc(c1)C(=O)c1ccccc1 |&1:1,r|, C[C@@H](C(=O)Nc1cc(C)ccn1)c1cccc(c1)C(=O)c1ccccc1 |&1:1,r|, C[C@@H](C(=O)Nc1cc(C)ccn1)c1cccc(c1)C(=O)c1ccccc1 |&1:1,r|, C[C@@H](C(=O)Nc1cc(C)ccn1)c1cccc(c1)C(=O)c1ccccc1 |&1:1,r|	ASFKKFRSMGBFRO-MRXNPFEDSA-N, ASFKKFRSMGBFRO-MRXNPFEDSA-N, ASFKKFRSMGBFRO-MRXNPFEDSA-N, ASFKKFRSMGBFRO-MRXNPFEDSA-N	Launched
pilaralisib	PI3K inhibitor				COc1ccc(Cl)c(Nc2nc3ccccc3nc2NS(=O)(=O)c2cccc(NC(=O)C(C)(C)N)c2)c1, COc1ccc(Cl)c(Nc2nc3ccccc3nc2NS(=O)(=O)c2cccc(NC(=O)C(C)(C)N)c2)c1, COc1ccc(Cl)c(Nc2nc3ccccc3nc2NS(=O)(=O)c2cccc(NC(=O)C(C)(C)N)c2)c1, COc1ccc(Cl)c(Nc2nc3ccccc3nc2NS(=O)(=O)c2cccc(NC(=O)C(C)(C)N)c2)c1, COc1ccc(Cl)c(Nc2nc3ccccc3nc2NS(=O)(=O)c2cccc(NC(=O)C(C)(C)N)c2)c1, COc1ccc(Cl)c(Nc2nc3ccccc3nc2NS(=O)(=O)c2cccc(NC(=O)C(C)(C)N)c2)c1	QINPEPAQOBZPOF-UHFFFAOYSA-N, QINPEPAQOBZPOF-UHFFFAOYSA-N, QINPEPAQOBZPOF-UHFFFAOYSA-N, QINPEPAQOBZPOF-UHFFFAOYSA-N, QINPEPAQOBZPOF-UHFFFAOYSA-N, QINPEPAQOBZPOF-UHFFFAOYSA-N	Phase 2
pilocarpine	acetylcholine receptor agonist	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5	ophthalmology, cardiology	glaucoma, hypertension	CC[C@H]1[C@@H](Cc2cncn2C)COC1=O, CC[C@H]1[C@@H](Cc2cncn2C)COC1=O, CC[C@H]1[C@@H](Cc2cncn2C)COC1=O, CC[C@H]1[C@@H](Cc2cncn2C)COC1=O, CC[C@H]1[C@@H](Cc2cncn2C)COC1=O, CC[C@H]1[C@@H](Cc2cncn2C)COC1=O, CC[C@H]1[C@@H](Cc2cncn2C)COC1=O, CC[C@H]1[C@@H](Cc2cncn2C)COC1=O, CC[C@H]1[C@@H](Cc2cncn2C)COC1=O	QCHFTSOMWOSFHM-WPRPVWTQSA-N, QCHFTSOMWOSFHM-WPRPVWTQSA-N, QCHFTSOMWOSFHM-WPRPVWTQSA-N, QCHFTSOMWOSFHM-WPRPVWTQSA-N, QCHFTSOMWOSFHM-WPRPVWTQSA-N, QCHFTSOMWOSFHM-WPRPVWTQSA-N, QCHFTSOMWOSFHM-WPRPVWTQSA-N, QCHFTSOMWOSFHM-WPRPVWTQSA-N, QCHFTSOMWOSFHM-WPRPVWTQSA-N	Launched
pilsicainide	sodium channel blocker	SCN5A	cardiology	cardiac arrythmia	Cc1cccc(C)c1NC(=O)CC12CCCN1CCC2, Cc1cccc(C)c1NC(=O)CC12CCCN1CCC2	BCQTVJKBTWGHCX-UHFFFAOYSA-N, BCQTVJKBTWGHCX-UHFFFAOYSA-N	Launched
PIM-1-Inhibitor-2	Pim kinase inhibitor	PIM1			Nc1nccc(n1)-c1ccc2noc(-c3ccc(Cl)cc3)c2c1, Nc1nccc(n1)-c1ccc2noc(-c3ccc(Cl)cc3)c2c1, Nc1nccc(n1)-c1ccc2noc(-c3ccc(Cl)cc3)c2c1	AQVFETGXIRKVAQ-UHFFFAOYSA-N, AQVFETGXIRKVAQ-UHFFFAOYSA-N, AQVFETGXIRKVAQ-UHFFFAOYSA-N	Preclinical
PIM-447	Pim kinase inhibitor				C[C@@H]1C[C@H](N)C[C@@H](C1)c1ccncc1NC(=O)c1ccc(F)c(n1)-c1c(F)cccc1F	VRQXRVAKPDCRCI-ZNMIVQPWSA-N	Phase 1
pimavanserin	serotonin receptor inverse agonist	DRD2, HTR2A	neurology/psychiatry	Parkinson's Disease	CC(C)COc1ccc(CNC(=O)N(Cc2ccc(F)cc2)C2CCN(C)CC2)cc1, CC(C)COc1ccc(CNC(=O)N(Cc2ccc(F)cc2)C2CCN(C)CC2)cc1	RKEWSXXUOLRFBX-UHFFFAOYSA-N, RKEWSXXUOLRFBX-UHFFFAOYSA-N	Launched
pimecrolimus	calcineurin inhibitor		dermatology	eczema	CC[C@@H]1\C=C(C)\C[C@H](C)C[C@H](OC)[C@H]2O[C@](O)([C@H](C)C[C@@H]2OC)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@@H]([C@H](C)[C@@H](O)CC1=O)C(\C)=C\[C@@H]1CC[C@H](Cl)[C@@H](C1)OC |c:3|, CC[C@@H]1\C=C(C)\C[C@H](C)C[C@H](OC)[C@H]2O[C@](O)([C@H](C)C[C@@H]2OC)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@@H]([C@H](C)[C@@H](O)CC1=O)C(\C)=C\[C@@H]1CC[C@H](Cl)[C@@H](C1)OC |c:3|	KASDHRXLYQOAKZ-YFMQXNBHSA-N, KASDHRXLYQOAKZ-YFMQXNBHSA-N	Launched
pimethixene	antihistamine		neurology/psychiatry, allergy	attention-deficit/hyperactivity disorder (ADHD), anxiety, sleep cycle support, allergic rhinitis	CN1CCC(CC1)=C1c2ccccc2Sc2ccccc12, CN1CCC(CC1)=C1c2ccccc2Sc2ccccc12	NZLVRVYNQYGMAB-UHFFFAOYSA-N, NZLVRVYNQYGMAB-UHFFFAOYSA-N	Launched
pimobendan	calcium sensitizer, phosphodiesterase inhibitor	PDE3A	cardiology	congestive heart failure	COc1ccc(cc1)-c1nc2ccc(cc2[nH]1)C1=NNC(=O)C[C@H]1C |&1:23,t:20|, COc1ccc(cc1)-c1nc2ccc(cc2[nH]1)C1=NNC(=O)C[C@H]1C |&1:23,t:20|	GLBJJMFZWDBELO-LLVKDONJSA-N, GLBJJMFZWDBELO-LLVKDONJSA-N	Launched
pimodivir	antiviral				OC(=O)[C@H]1C2CCC(CC2)[C@@H]1Nc1nc(ncc1F)-c1c[nH]c2ncc(F)cc12	JGPXDNKSIXAZEQ-SBBZOCNPSA-N	Phase 3
pimonidazole					O[C@@H](CN1CCCCC1)Cn1ccnc1[N+]([O-])=O |&1:1,r|, O[C@@H](CN1CCCCC1)Cn1ccnc1[N+]([O-])=O |&1:1,r|	WVWOOAYQYLJEFD-JTQLQIEISA-N, WVWOOAYQYLJEFD-JTQLQIEISA-N	Phase 3
pimozide	dopamine receptor antagonist	CACNA1I, CALM1, DRD1, DRD2, DRD3, DRD4, DRD5, HRH1, HTR1A, HTR2A, KCNA10, KCNH2	neurology/psychiatry	Tourette's disorder	Fc1ccc(cc1)C(CCCN1CCC(CC1)n1c2ccccc2[nH]c1=O)c1ccc(F)cc1, Fc1ccc(cc1)C(CCCN1CCC(CC1)n1c2ccccc2[nH]c1=O)c1ccc(F)cc1, Fc1ccc(cc1)C(CCCN1CCC(CC1)n1c2ccccc2[nH]c1=O)c1ccc(F)cc1, Fc1ccc(cc1)C(CCCN1CCC(CC1)n1c2ccccc2[nH]c1=O)c1ccc(F)cc1	YVUQSNJEYSNKRX-UHFFFAOYSA-N, YVUQSNJEYSNKRX-UHFFFAOYSA-N, YVUQSNJEYSNKRX-UHFFFAOYSA-N, YVUQSNJEYSNKRX-UHFFFAOYSA-N	Launched
pinacidil	ATP channel activator, potassium channel activator	ABCC8, ABCC9	cardiology	hypertension	C[C@@H](NC(Nc1ccncc1)=NC#N)C(C)(C)C |&1:1,r|, C[C@@H](NC(Nc1ccncc1)=NC#N)C(C)(C)C |&1:1,r|, C[C@@H](NC(Nc1ccncc1)=NC#N)C(C)(C)C |&1:1,r|, C[C@@H](NC(Nc1ccncc1)=NC#N)C(C)(C)C |&1:1,r|, C[C@@H](NC(Nc1ccncc1)=NC#N)C(C)(C)C |&1:1,r|	IVVNZDGDKPTYHK-SNVBAGLBSA-N, IVVNZDGDKPTYHK-SNVBAGLBSA-N, IVVNZDGDKPTYHK-SNVBAGLBSA-N, IVVNZDGDKPTYHK-SNVBAGLBSA-N, IVVNZDGDKPTYHK-SNVBAGLBSA-N	Launched
pinanediol					CC1(C)[C@H]2C[C@@H]1[C@](C)(O)[C@H](O)C2	MOILFCKRQFQVFS-OORONAJNSA-N	Preclinical
pinaverium	T-type calcium channel blocker	CACNA1C	gastroenterology	irritable bowel syndrome	COc1cc(Br)c(C[N+]2(CCOCC[C@H]3CC[C@@H]4C[C@H]3C4(C)C)CCOCC2)cc1OC |&1:17,19,&2:14,r|	DDHUTBKXLWCZCO-CEMLEFRQSA-N	Launched
pincainide	antiarrhythmic				Cc1cccc(C)c1NC(=O)CN1CCCCCC1	RJOUHGWLHPOQSA-UHFFFAOYSA-N	Phase 1
pindolol	adrenergic receptor antagonist	ADRB1, ADRB2, HTR1A, HTR2A, HTR2B	cardiology	hypertension	CC(C)NC[C@@H](O)COc1cccc2[nH]ccc12 |&1:5,r|, CC(C)NC[C@@H](O)COc1cccc2[nH]ccc12 |&1:5,r|, CC(C)NC[C@@H](O)COc1cccc2[nH]ccc12 |&1:5,r|, CC(C)NC[C@@H](O)COc1cccc2[nH]ccc12 |&1:5,r|, CC(C)NC[C@@H](O)COc1cccc2[nH]ccc12 |&1:5,r|	JZQKKSLKJUAGIC-LLVKDONJSA-N, JZQKKSLKJUAGIC-LLVKDONJSA-N, JZQKKSLKJUAGIC-LLVKDONJSA-N, JZQKKSLKJUAGIC-LLVKDONJSA-N, JZQKKSLKJUAGIC-LLVKDONJSA-N	Launched
pindolol-(-)	adrenergic receptor antagonist, serotonin receptor antagonist	HTR1A			CC(C)NC[C@H](O)COc1cccc2[nH]ccc12, CC(C)NC[C@H](O)COc1cccc2[nH]ccc12	JZQKKSLKJUAGIC-NSHDSACASA-N, JZQKKSLKJUAGIC-NSHDSACASA-N	Phase 2
pinitol	gamma secretase inhibitor						Phase 2
pinocembrin	cytochrome P450 inhibitor	CYP1B1			Oc1cc(O)c2C(=O)C[C@H](Oc2c1)c1ccccc1, Oc1cc(O)c2C(=O)C[C@H](Oc2c1)c1ccccc1	URFCJEUYXNAHFI-ZDUSSCGKSA-N, URFCJEUYXNAHFI-ZDUSSCGKSA-N	Phase 2
pioglitazone	insulin sensitizer, PPAR receptor agonist	PPARG, TRPM3	endocrinology	diabetes mellitus	CCc1ccc(CCOc2ccc(C[C@H]3SC(=O)NC3=O)cc2)nc1 |&1:14|	HYAFETHFCAUJAY-QGZVFWFLSA-N	Launched
pipamperone	dopamine receptor antagonist	DRD2, HRH1, HTR1A, HTR1B, HTR1D, HTR2A	neurology/psychiatry	schizophrenia	NC(=O)C1(CCN(CCCC(=O)c2ccc(F)cc2)CC1)N1CCCCC1, NC(=O)C1(CCN(CCCC(=O)c2ccc(F)cc2)CC1)N1CCCCC1, NC(=O)C1(CCN(CCCC(=O)c2ccc(F)cc2)CC1)N1CCCCC1	AXKPFOAXAHJUAG-UHFFFAOYSA-N, AXKPFOAXAHJUAG-UHFFFAOYSA-N, AXKPFOAXAHJUAG-UHFFFAOYSA-N	Launched
pipecuronium	neuromuscular blocker	CHRM2, CHRM3, CHRNA2	neurology/psychiatry	anesthetic			Launched
pipemidic-acid	topoisomerase inhibitor		infectious disease	gram-negative bacterial infections	CCn1cc(C(O)=O)c(=O)c2cnc(nc12)N1CCNCC1, CCn1cc(C(O)=O)c(=O)c2cnc(nc12)N1CCNCC1	JOHZPMXAZQZXHR-UHFFFAOYSA-N, JOHZPMXAZQZXHR-UHFFFAOYSA-N	Launched
pipenzolate	cholinergic receptor antagonist	CHRM1	neurology/psychiatry	spasms	CC[N@@+]1(C)CCC[C@@H](C1)OC(=O)C(O)(c1ccccc1)c1ccccc1 |&1:2,&2:7|, CC[N@@+]1(C)CCC[C@@H](C1)OC(=O)C(O)(c1ccccc1)c1ccccc1 |&1:2,&2:7|, CC[N@@+]1(C)CCC[C@@H](C1)OC(=O)C(O)(c1ccccc1)c1ccccc1 |&1:2,&2:7|	WPUKUEMZZRVAKZ-REWPJTCUSA-N, WPUKUEMZZRVAKZ-REWPJTCUSA-N, WPUKUEMZZRVAKZ-REWPJTCUSA-N	Launched
piperacetazine	dopamine receptor antagonist		neurology/psychiatry	schizophrenia	CC(=O)c1ccc2Sc3ccccc3N(CCCN3CCC(CCO)CC3)c2c1, CC(=O)c1ccc2Sc3ccccc3N(CCCN3CCC(CCO)CC3)c2c1	BTFMCMVEUCGQDX-UHFFFAOYSA-N, BTFMCMVEUCGQDX-UHFFFAOYSA-N	Launched
piperacillin	bacterial cell wall synthesis inhibitor		infectious disease	intra-abdominal infections, skin infections, pelvic inflammatory disease, pneumonia	CCN1CCN(C(=O)N[C@@H](C(=O)N[C@H]2[C@H]3SC(C)(C)[C@@H](N3C2=O)C(O)=O)c2ccccc2)C(=O)C1=O, CCN1CCN(C(=O)N[C@@H](C(=O)N[C@H]2[C@H]3SC(C)(C)[C@@H](N3C2=O)C(O)=O)c2ccccc2)C(=O)C1=O, CCN1CCN(C(=O)N[C@@H](C(=O)N[C@H]2[C@H]3SC(C)(C)[C@@H](N3C2=O)C(O)=O)c2ccccc2)C(=O)C1=O, CCN1CCN(C(=O)N[C@@H](C(=O)N[C@H]2[C@H]3SC(C)(C)[C@@H](N3C2=O)C(O)=O)c2ccccc2)C(=O)C1=O, CCN1CCN(C(=O)N[C@@H](C(=O)N[C@H]2[C@H]3SC(C)(C)[C@@H](N3C2=O)C(O)=O)c2ccccc2)C(=O)C1=O, CCN1CCN(C(=O)N[C@@H](C(=O)N[C@H]2[C@H]3SC(C)(C)[C@@H](N3C2=O)C(O)=O)c2ccccc2)C(=O)C1=O, CCN1CCN(C(=O)N[C@@H](C(=O)N[C@H]2[C@H]3SC(C)(C)[C@@H](N3C2=O)C(O)=O)c2ccccc2)C(=O)C1=O	IVBHGBMCVLDMKU-GXNBUGAJSA-N, IVBHGBMCVLDMKU-GXNBUGAJSA-N, IVBHGBMCVLDMKU-GXNBUGAJSA-N, IVBHGBMCVLDMKU-GXNBUGAJSA-N, IVBHGBMCVLDMKU-GXNBUGAJSA-N, IVBHGBMCVLDMKU-GXNBUGAJSA-N, IVBHGBMCVLDMKU-GXNBUGAJSA-N	Launched
piperaquine-phosphate	antimalarial agent		infectious disease	malaria	Clc1ccc2c(ccnc2c1)N1CCN(CCCN2CCN(CC2)c2ccnc3cc(Cl)ccc23)CC1, Clc1ccc2c(ccnc2c1)N1CCN(CCCN2CCN(CC2)c2ccnc3cc(Cl)ccc23)CC1	UCRHFBCYFMIWHC-UHFFFAOYSA-N, UCRHFBCYFMIWHC-UHFFFAOYSA-N	Launched
piperazine	benzodiazepine receptor agonist	GABRB3	infectious disease	gastrointestinal roundworms	C1CNCCN1, C1CNCCN1, C1CNCCN1	GLUUGHFHXGJENI-UHFFFAOYSA-N, GLUUGHFHXGJENI-UHFFFAOYSA-N, GLUUGHFHXGJENI-UHFFFAOYSA-N	Launched
piperazinedione	DNA synthesis inhibitor				O=C1CNC(=O)CN1	BXRNXXXXHLBUKK-UHFFFAOYSA-N	Phase 2
piperidolate	acetylcholine receptor antagonist	CHRM1	neurology/psychiatry	spasms	CCN1CCC[C@@H](C1)OC(=O)C(c1ccccc1)c1ccccc1 |&1:6|, CCN1CCC[C@@H](C1)OC(=O)C(c1ccccc1)c1ccccc1 |&1:6|	KTHVBAZBLKXIHZ-IBGZPJMESA-N, KTHVBAZBLKXIHZ-IBGZPJMESA-N	Launched
piperine	monoamine oxidase inhibitor	MAOA, MAOB, TRPV1			O=C(\C=C\C=C\c1ccc2OCOc2c1)N1CCCCC1, O=C(\C=C\C=C\c1ccc2OCOc2c1)N1CCCCC1, O=C(\C=C\C=C\c1ccc2OCOc2c1)N1CCCCC1, O=C(\C=C\C=C\c1ccc2OCOc2c1)N1CCCCC1, O=C(\C=C\C=C\c1ccc2OCOc2c1)N1CCCCC1, O=C(\C=C\C=C\c1ccc2OCOc2c1)N1CCCCC1	MXXWOMGUGJBKIW-YPCIICBESA-N, MXXWOMGUGJBKIW-YPCIICBESA-N, MXXWOMGUGJBKIW-YPCIICBESA-N, MXXWOMGUGJBKIW-YPCIICBESA-N, MXXWOMGUGJBKIW-YPCIICBESA-N, MXXWOMGUGJBKIW-YPCIICBESA-N	Phase 1
piperonyl-butoxide	cytochrome P450 inhibitor		infectious disease	lice	CCCCOCCOCCOCc1cc2OCOc2cc1CCC, CCCCOCCOCCOCc1cc2OCOc2cc1CCC, CCCCOCCOCCOCc1cc2OCOc2cc1CCC	FIPWRIJSWJWJAI-UHFFFAOYSA-N, FIPWRIJSWJWJAI-UHFFFAOYSA-N, FIPWRIJSWJWJAI-UHFFFAOYSA-N	Launched
pipobroman	DNA alkylating agent		hematology	polycythemia vera, thrombocythemia	BrCCC(=O)N1CCN(CC1)C(=O)CCBr, BrCCC(=O)N1CCN(CC1)C(=O)CCBr, BrCCC(=O)N1CCN(CC1)C(=O)CCBr	NJBFOOCLYDNZJN-UHFFFAOYSA-N, NJBFOOCLYDNZJN-UHFFFAOYSA-N, NJBFOOCLYDNZJN-UHFFFAOYSA-N	Launched
pipofezine	selective serotonin reuptake inhibitor (SSRI)				CN1CCN(CC1)c1cc2N(C)c3ccccc3Oc2nn1	SDYYIRPAZHJOLM-UHFFFAOYSA-N	Preclinical
pipotiazine	dopamine receptor antagonist	DRD1, DRD2, HTR1A, HTR2A	neurology/psychiatry	schizophrenia	CN(C)S(=O)(=O)c1ccc2Sc3ccccc3N(CCCN3CCC(CCO)CC3)c2c1	JOMHSQGEWSNUKU-UHFFFAOYSA-N	Launched
pipotiazine-palmitate	dopamine receptor antagonist, serotonin receptor antagonist	DRD1, DRD2, HTR1A, HTR2A	neurology/psychiatry	schizophrenia	CCCCCCCCCCCCCCCC(=O)OCCC1CCN(CCCN2c3ccccc3Sc3ccc(cc23)S(=O)(=O)N(C)C)CC1	KTOYYUONFQWSMW-UHFFFAOYSA-N	Launched
piracetam	acetylcholine receptor agonist	GRIA1, GRIA2, GRIA3, GRIA4	neurology/psychiatry	senile dementia	NC(=O)CN1CCCC1=O, NC(=O)CN1CCCC1=O, NC(=O)CN1CCCC1=O	GMZVRMREEHBGGF-UHFFFAOYSA-N, GMZVRMREEHBGGF-UHFFFAOYSA-N, GMZVRMREEHBGGF-UHFFFAOYSA-N	Launched
pirarubicin	topoisomerase inhibitor	TOP2A	oncology	breast cancer	COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O[C@@H]6CCCCO6)[C@H](C)O5)c4c(O)c3C(=O)c12)C(=O)CO, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O[C@@H]6CCCCO6)[C@H](C)O5)c4c(O)c3C(=O)c12)C(=O)CO, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O[C@@H]6CCCCO6)[C@H](C)O5)c4c(O)c3C(=O)c12)C(=O)CO, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O[C@@H]6CCCCO6)[C@H](C)O5)c4c(O)c3C(=O)c12)C(=O)CO	KMSKQZKKOZQFFG-YXRRJAAWSA-N, KMSKQZKKOZQFFG-YXRRJAAWSA-N, KMSKQZKKOZQFFG-YXRRJAAWSA-N, KMSKQZKKOZQFFG-YXRRJAAWSA-N	Launched
pirenoxine	AGE inhibitor		ophthalmology	cataracts	OC(=O)c1cc(=O)c2c3nc4ccccc4oc3cc(=O)c2[nH]1	OKPNYGAWTYOBFZ-UHFFFAOYSA-N	Launched
pirenperone	serotonin receptor antagonist	HTR2A, HTR7			Cc1nc2ccccn2c(=O)c1CCN1CCC(CC1)C(=O)c1ccc(F)cc1, Cc1nc2ccccn2c(=O)c1CCN1CCC(CC1)C(=O)c1ccc(F)cc1, Cc1nc2ccccn2c(=O)c1CCN1CCC(CC1)C(=O)c1ccc(F)cc1	HXCNRYXBZNHDNE-UHFFFAOYSA-N, HXCNRYXBZNHDNE-UHFFFAOYSA-N, HXCNRYXBZNHDNE-UHFFFAOYSA-N	Preclinical
pirenzepine	acetylcholine receptor antagonist	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5	gastroenterology	peptic ulcer disease (PUD)	CN1CCN(CC(=O)N2c3ccccc3C(=O)Nc3cccnc23)CC1, CN1CCN(CC(=O)N2c3ccccc3C(=O)Nc3cccnc23)CC1, CN1CCN(CC(=O)N2c3ccccc3C(=O)Nc3cccnc23)CC1	RMHMFHUVIITRHF-UHFFFAOYSA-N, RMHMFHUVIITRHF-UHFFFAOYSA-N, RMHMFHUVIITRHF-UHFFFAOYSA-N	Launched
piretanide	glucocorticoid receptor agonist	SLC12A1, SLC12A2	cardiology	hypertension, edema	NS(=O)(=O)c1cc(cc(N2CCCC2)c1Oc1ccccc1)C(O)=O, NS(=O)(=O)c1cc(cc(N2CCCC2)c1Oc1ccccc1)C(O)=O	UJEWTUDSLQGTOA-UHFFFAOYSA-N, UJEWTUDSLQGTOA-UHFFFAOYSA-N	Launched
pirfenidone	TGF beta receptor inhibitor	FURIN, TNF	pulmonary	idiopathic pulmonary fibrosis (IPF)	Cc1ccc(=O)n(c1)-c1ccccc1, Cc1ccc(=O)n(c1)-c1ccccc1, Cc1ccc(=O)n(c1)-c1ccccc1, Cc1ccc(=O)n(c1)-c1ccccc1	ISWRGOKTTBVCFA-UHFFFAOYSA-N, ISWRGOKTTBVCFA-UHFFFAOYSA-N, ISWRGOKTTBVCFA-UHFFFAOYSA-N, ISWRGOKTTBVCFA-UHFFFAOYSA-N	Launched
piribedil	dopamine receptor agonist	ADRA1A, ADRA2A, ADRA2C, DRD2, DRD3, DRD4, HTR1A, HTR2B	neurology/psychiatry	Parkinson's Disease, dizziness	C(N1CCN(CC1)c1ncccn1)c1ccc2OCOc2c1	OQDPVLVUJFGPGQ-UHFFFAOYSA-N	Launched
piricapiron	dopamine receptor antagonist, serotonin receptor antagonist	HTR2A			CC1(C)[C@@H]2CC[C@@]1(C)C(=O)N(CCCCN1CCN(CC1)c1ccccn1)C2=O |&1:3,6|	NCMIPRCQUMYAEC-JPYJTQIMSA-N	Phase 2
pirinixic-acid	PPAR receptor agonist	PPARA			Cc1cccc(Nc2cc(Cl)nc(SCC(O)=O)n2)c1C, Cc1cccc(Nc2cc(Cl)nc(SCC(O)=O)n2)c1C, Cc1cccc(Nc2cc(Cl)nc(SCC(O)=O)n2)c1C, Cc1cccc(Nc2cc(Cl)nc(SCC(O)=O)n2)c1C, Cc1cccc(Nc2cc(Cl)nc(SCC(O)=O)n2)c1C	SZRPDCCEHVWOJX-UHFFFAOYSA-N, SZRPDCCEHVWOJX-UHFFFAOYSA-N, SZRPDCCEHVWOJX-UHFFFAOYSA-N, SZRPDCCEHVWOJX-UHFFFAOYSA-N, SZRPDCCEHVWOJX-UHFFFAOYSA-N	Preclinical
pirlindole	monoamine oxidase inhibitor	MAOA	neurology/psychiatry	depression	Cc1ccc2n3CCN[C@H]4CCCc(c34)c2c1 |&1:9|	IWVRVEIKCBFZNF-ZDUSSCGKSA-N	Launched
pirmenol	acetylcholine receptor inhibitor				C[C@H]1CCC[C@@H](C)N1CCC[C@@](O)(c1ccccc1)c1ccccn1 |a:1,5,&1:11|	APUDBKTWDCXQJA-XQBPLPMBSA-N	Preclinical
piroctone-olamine			infectious disease	fungal infection	C[C@@H](Cc1cc(C)cc(=O)n1O)CC(C)(C)C |&1:1|	OIQJEQLSYJSNDS-NSHDSACASA-N	Launched
pirodavir					CCOC(=O)c1ccc(OCCC2CCN(CC2)c2ccc(C)nn2)cc1, CCOC(=O)c1ccc(OCCC2CCN(CC2)c2ccc(C)nn2)cc1, CCOC(=O)c1ccc(OCCC2CCN(CC2)c2ccc(C)nn2)cc1	KCHIOGFOPPOUJC-UHFFFAOYSA-N, KCHIOGFOPPOUJC-UHFFFAOYSA-N, KCHIOGFOPPOUJC-UHFFFAOYSA-N	Phase 2
piromidic-acid	bacterial DNA gyrase inhibitor				CCn1cc(C(O)=O)c(=O)c2cnc(nc12)N1CCCC1, CCn1cc(C(O)=O)c(=O)c2cnc(nc12)N1CCCC1, CCn1cc(C(O)=O)c(=O)c2cnc(nc12)N1CCCC1, CCn1cc(C(O)=O)c(=O)c2cnc(nc12)N1CCCC1	RCIMBBZXSXFZBV-UHFFFAOYSA-N, RCIMBBZXSXFZBV-UHFFFAOYSA-N, RCIMBBZXSXFZBV-UHFFFAOYSA-N, RCIMBBZXSXFZBV-UHFFFAOYSA-N	Phase 2
piroxicam	cyclooxygenase inhibitor	PTGS1, PTGS2	rheumatology	osteoarthritis, rheumatoid arthritis	CN1C(C(=O)Nc2ccccn2)=C(O)c2ccccc2S1(=O)=O |t:12|	QYSPLQLAKJAUJT-UHFFFAOYSA-N	Launched
piroximone	phosphodiesterase inhibitor	PDE3A			CCc1[nH]c(=O)[nH]c1C(=O)c1ccncc1, CCc1[nH]c(=O)[nH]c1C(=O)c1ccncc1	OQGWJZOWLHWFME-UHFFFAOYSA-N, OQGWJZOWLHWFME-UHFFFAOYSA-N	Phase 2
pirozadil	hypolipidemic				COc1cc(cc(OC)c1OC)C(=O)OCc1cccc(COC(=O)c2cc(OC)c(OC)c(OC)c2)n1	DIIBXMIIOQXTHW-UHFFFAOYSA-N	Preclinical
pirquinozol	histamine release inhibitor				OCc1cc2c3ccccc3[nH]c(=O)n2n1	XLUKOGNIEDDIMV-UHFFFAOYSA-N	Phase 1
PIT	purinergic receptor antagonist	P2RY1			[O-][N+]1=C(C(=O)c2ccccc12)c1ccccn1 |t:1|, [O-][N+]1=C(C(=O)c2ccccc12)c1ccccn1 |t:1|	LXEZPPZLNVOLDI-UHFFFAOYSA-N, LXEZPPZLNVOLDI-UHFFFAOYSA-N	Preclinical
pitavastatin	HMGCR inhibitor	HMGCR	endocrinology	hyperlipidemia	O[C@H](C[C@H](O)\C=C\c1c(nc2ccccc2c1-c1ccc(F)cc1)C1CC1)CC(O)=O, O[C@H](C[C@H](O)\C=C\c1c(nc2ccccc2c1-c1ccc(F)cc1)C1CC1)CC(O)=O, O[C@H](C[C@H](O)\C=C\c1c(nc2ccccc2c1-c1ccc(F)cc1)C1CC1)CC(O)=O, O[C@H](C[C@H](O)\C=C\c1c(nc2ccccc2c1-c1ccc(F)cc1)C1CC1)CC(O)=O, O[C@H](C[C@H](O)\C=C\c1c(nc2ccccc2c1-c1ccc(F)cc1)C1CC1)CC(O)=O, O[C@H](C[C@H](O)\C=C\c1c(nc2ccccc2c1-c1ccc(F)cc1)C1CC1)CC(O)=O, O[C@H](C[C@H](O)\C=C\c1c(nc2ccccc2c1-c1ccc(F)cc1)C1CC1)CC(O)=O, O[C@H](C[C@H](O)\C=C\c1c(nc2ccccc2c1-c1ccc(F)cc1)C1CC1)CC(O)=O, O[C@H](C[C@H](O)\C=C\c1c(nc2ccccc2c1-c1ccc(F)cc1)C1CC1)CC(O)=O	VGYFMXBACGZSIL-MCBHFWOFSA-N, VGYFMXBACGZSIL-MCBHFWOFSA-N, VGYFMXBACGZSIL-MCBHFWOFSA-N, VGYFMXBACGZSIL-MCBHFWOFSA-N, VGYFMXBACGZSIL-MCBHFWOFSA-N, VGYFMXBACGZSIL-MCBHFWOFSA-N, VGYFMXBACGZSIL-MCBHFWOFSA-N, VGYFMXBACGZSIL-MCBHFWOFSA-N, VGYFMXBACGZSIL-MCBHFWOFSA-N	Launched
pitolisant	histamine receptor antagonist	HRH3			Clc1ccc(CCCOCCCN2CCCCC2)cc1, Clc1ccc(CCCOCCCN2CCCCC2)cc1, Clc1ccc(CCCOCCCN2CCCCC2)cc1, Clc1ccc(CCCOCCCN2CCCCC2)cc1, Clc1ccc(CCCOCCCN2CCCCC2)cc1	NNACHAUCXXVJSP-UHFFFAOYSA-N, NNACHAUCXXVJSP-UHFFFAOYSA-N, NNACHAUCXXVJSP-UHFFFAOYSA-N, NNACHAUCXXVJSP-UHFFFAOYSA-N, NNACHAUCXXVJSP-UHFFFAOYSA-N	Launched
pivagabine	corticotropin releasing factor receptor antagonist	CRHR1, CRHR2	neurology/psychiatry	depression	CC(C)(C)C(=O)NCCCC(O)=O, CC(C)(C)C(=O)NCCCC(O)=O	SRPNQDXRVRCTNK-UHFFFAOYSA-N, SRPNQDXRVRCTNK-UHFFFAOYSA-N	Launched
pivampicillin	bacterial cell wall synthesis inhibitor		pulmonary, infectious disease	bronchitis, pneumonia, gynecologic infections	CC(C)(C)C(=O)OCOC(=O)[C@@H]1N2[C@H](SC1(C)C)[C@H](NC(=O)[C@H](N)c1ccccc1)C2=O	ZEMIJUDPLILVNQ-ZXFNITATSA-N	Launched
pivanex	HDAC inhibitor	HDAC1, HDAC2, HDAC3, HDAC8			CCCC(=O)OCOC(=O)C(C)(C)C, CCCC(=O)OCOC(=O)C(C)(C)C	GYKLFBYWXZYSOW-UHFFFAOYSA-N, GYKLFBYWXZYSOW-UHFFFAOYSA-N	Phase 2
pivmecillinam	bacterial cell wall synthesis inhibitor		infectious disease	urinary tract infections, gram-negative bacterial infections	CC(C)(C)C(=O)OCOC(=O)[C@@H]1N2[C@H](SC1(C)C)[C@H](\N=C\N1CCCCCC1)C2=O, CC(C)(C)C(=O)OCOC(=O)[C@@H]1N2[C@H](SC1(C)C)[C@H](\N=C\N1CCCCCC1)C2=O, CC(C)(C)C(=O)OCOC(=O)[C@@H]1N2[C@H](SC1(C)C)[C@H](\N=C\N1CCCCCC1)C2=O	NPGNOVNWUSPMDP-UTEPHESZSA-N, NPGNOVNWUSPMDP-UTEPHESZSA-N, NPGNOVNWUSPMDP-UTEPHESZSA-N	Launched
pixantrone	topoisomerase inhibitor	TOP2A	hematologic malignancy	non-Hodgkin lymphoma (NHL)	NCCNc1ccc(NCCN)c2C(=O)c3cnccc3C(=O)c12, NCCNc1ccc(NCCN)c2C(=O)c3cnccc3C(=O)c12	PEZPMAYDXJQYRV-UHFFFAOYSA-N, PEZPMAYDXJQYRV-UHFFFAOYSA-N	Launched
pizotifen	serotonin receptor antagonist	HTR1A, HTR2A, HTR2C	neurology/psychiatry	migraine headache	CN1CCC(CC1)=C1c2ccsc2CCc2ccccc12, CN1CCC(CC1)=C1c2ccsc2CCc2ccccc12, CN1CCC(CC1)=C1c2ccsc2CCc2ccccc12, CN1CCC(CC1)=C1c2ccsc2CCc2ccccc12	FIADGNVRKBPQEU-UHFFFAOYSA-N, FIADGNVRKBPQEU-UHFFFAOYSA-N, FIADGNVRKBPQEU-UHFFFAOYSA-N, FIADGNVRKBPQEU-UHFFFAOYSA-N	Launched
PI3K-IN-2	PI3K inhibitor				Nc1cc(c(cn1)-c1nc(nc(n1)N1CCOCC1)N1CCOCC1)C(F)(F)F, Nc1cc(c(cn1)-c1nc(nc(n1)N1CCOCC1)N1CCOCC1)C(F)(F)F, Nc1cc(c(cn1)-c1nc(nc(n1)N1CCOCC1)N1CCOCC1)C(F)(F)F	ADGGYDAFIHSYFI-UHFFFAOYSA-N, ADGGYDAFIHSYFI-UHFFFAOYSA-N, ADGGYDAFIHSYFI-UHFFFAOYSA-N	Phase 2
PI3Kd-IN-2	PI3K inhibitor				COc1ncc(cc1NS(C)(=O)=O)-c1nc(nc2c(CN3CCC(CC3)C(C)(C)O)cc(F)cc12)N1CCOCC1	NVWKNQGHVMMAJW-UHFFFAOYSA-N	Preclinical
PI4KIII-beta-inhibitor-1	PI4K inhibitor	PI4K2B			COc1ccc(cc1S(=O)(=O)Nc1ccc(O)cc1)-c1sc(NC(=O)C(C)(C)C)nc1C, COc1ccc(cc1S(=O)(=O)Nc1ccc(O)cc1)-c1sc(NC(=O)C(C)(C)C)nc1C	PLUYFBRIGUAKBR-UHFFFAOYSA-N, PLUYFBRIGUAKBR-UHFFFAOYSA-N	Preclinical
PJ-34	PARP inhibitor	EEF2, PARP1, PARP15, PARP3			CN(C)CC(=O)Nc1ccc2[nH]c(=O)c3ccccc3c2c1, CN(C)CC(=O)Nc1ccc2[nH]c(=O)c3ccccc3c2c1, CN(C)CC(=O)Nc1ccc2[nH]c(=O)c3ccccc3c2c1, CN(C)CC(=O)Nc1ccc2[nH]c(=O)c3ccccc3c2c1, CN(C)CC(=O)Nc1ccc2[nH]c(=O)c3ccccc3c2c1, CN(C)CC(=O)Nc1ccc2[nH]c(=O)c3ccccc3c2c1, CN(C)CC(=O)Nc1ccc2[nH]c(=O)c3ccccc3c2c1, CN(C)CC(=O)Nc1ccc2[nH]c(=O)c3ccccc3c2c1	UYJZZVDLGDDTCL-UHFFFAOYSA-N, UYJZZVDLGDDTCL-UHFFFAOYSA-N, UYJZZVDLGDDTCL-UHFFFAOYSA-N, UYJZZVDLGDDTCL-UHFFFAOYSA-N, UYJZZVDLGDDTCL-UHFFFAOYSA-N, UYJZZVDLGDDTCL-UHFFFAOYSA-N, UYJZZVDLGDDTCL-UHFFFAOYSA-N, UYJZZVDLGDDTCL-UHFFFAOYSA-N	Preclinical
PK-THPP	potassium channel blocker	KCNK9			CCCC(=O)C1CCN(CC1)c1ncnc2CCN(Cc12)C(=O)c1ccc(cc1)-c1ccccc1, CCCC(=O)C1CCN(CC1)c1ncnc2CCN(Cc12)C(=O)c1ccc(cc1)-c1ccccc1, CCCC(=O)C1CCN(CC1)c1ncnc2CCN(Cc12)C(=O)c1ccc(cc1)-c1ccccc1	CJZGRIRZVHNUSM-UHFFFAOYSA-N, CJZGRIRZVHNUSM-UHFFFAOYSA-N, CJZGRIRZVHNUSM-UHFFFAOYSA-N	Preclinical
PK-11195	benzodiazepine receptor antagonist	TSPO			CC[C@@H](C)N(C)C(=O)c1cc2ccccc2c(n1)-c1ccccc1Cl |&1:2,r|, CC[C@@H](C)N(C)C(=O)c1cc2ccccc2c(n1)-c1ccccc1Cl |&1:2,r|	RAVIZVQZGXBOQO-CQSZACIVSA-N, RAVIZVQZGXBOQO-CQSZACIVSA-N	Phase 1
PK-44	dipeptidyl peptidase inhibitor	DPP4			N[C@@H](CC(=O)N1CCn2c(C1)nnc2C(F)(F)F)Cc1[nH]nc2c(F)c(F)ccc12, N[C@@H](CC(=O)N1CCn2c(C1)nnc2C(F)(F)F)Cc1[nH]nc2c(F)c(F)ccc12	LIPWZZYFIVYJSI-MRVPVSSYSA-N, LIPWZZYFIVYJSI-MRVPVSSYSA-N	Preclinical
PKI-166	EGFR inhibitor	EGFR			C[C@@H](Nc1ncnc2[nH]c(cc12)-c1ccc(O)cc1)c1ccccc1, C[C@@H](Nc1ncnc2[nH]c(cc12)-c1ccc(O)cc1)c1ccccc1	XRYJULCDUUATMC-CYBMUJFWSA-N, XRYJULCDUUATMC-CYBMUJFWSA-N	Phase 1
PKI-179	mTOR inhibitor, PI3K inhibitor	MTOR			O=C(Nc1ccncc1)Nc1ccc(cc1)-c1nc(nc(n1)N1CCOCC1)N1[C@H]2CC[C@@H]1COC2 |&1:29,&2:32|, O=C(Nc1ccncc1)Nc1ccc(cc1)-c1nc(nc(n1)N1CCOCC1)N1[C@H]2CC[C@@H]1COC2 |&1:29,&2:32|, O=C(Nc1ccncc1)Nc1ccc(cc1)-c1nc(nc(n1)N1CCOCC1)N1[C@H]2CC[C@@H]1COC2 |&1:29,&2:32|, O=C(Nc1ccncc1)Nc1ccc(cc1)-c1nc(nc(n1)N1CCOCC1)N1[C@H]2CC[C@@H]1COC2 |&1:29,&2:32|, O=C(Nc1ccncc1)Nc1ccc(cc1)-c1nc(nc(n1)N1CCOCC1)N1[C@H]2CC[C@@H]1COC2 |&1:29,&2:32|	WXUUCRLKXQMWRY-OYRHEFFESA-N, WXUUCRLKXQMWRY-OYRHEFFESA-N, WXUUCRLKXQMWRY-OYRHEFFESA-N, WXUUCRLKXQMWRY-OYRHEFFESA-N, WXUUCRLKXQMWRY-OYRHEFFESA-N	Phase 1
pleconaril					Cc1cc(CCCOc2c(C)cc(cc2C)-c2noc(n2)C(F)(F)F)on1, Cc1cc(CCCOc2c(C)cc(cc2C)-c2noc(n2)C(F)(F)F)on1	KQOXLKOJHVFTRN-UHFFFAOYSA-N, KQOXLKOJHVFTRN-UHFFFAOYSA-N	Phase 3
plerixafor	CC chemokine receptor antagonist	ACKR3, CCR4, CXCR4	hematologic malignancy	non-Hodgkin lymphoma (NHL), multiple myeloma	C(N1CCCNCCNCCCNCC1)c1ccc(CN2CCCNCCNCCCNCC2)cc1, C(N1CCCNCCNCCCNCC1)c1ccc(CN2CCCNCCNCCCNCC2)cc1, C(N1CCCNCCNCCCNCC1)c1ccc(CN2CCCNCCNCCCNCC2)cc1, C(N1CCCNCCNCCCNCC1)c1ccc(CN2CCCNCCNCCCNCC2)cc1, C(N1CCCNCCNCCCNCC1)c1ccc(CN2CCCNCCNCCCNCC2)cc1, C(N1CCCNCCNCCCNCC1)c1ccc(CN2CCCNCCNCCCNCC2)cc1	YIQPUIGJQJDJOS-UHFFFAOYSA-N, YIQPUIGJQJDJOS-UHFFFAOYSA-N, YIQPUIGJQJDJOS-UHFFFAOYSA-N, YIQPUIGJQJDJOS-UHFFFAOYSA-N, YIQPUIGJQJDJOS-UHFFFAOYSA-N, YIQPUIGJQJDJOS-UHFFFAOYSA-N	Launched
plicamycin	alcohol dehydrogenase inhibitor		oncology, endocrinology	testicular carcinoma, Paget's disease, hypercalcemia	CO[C@@H]([C@@H]1Cc2cc3cc(O[C@H]4C[C@@H](O[C@H]5C[C@@H](O)[C@H](O)[C@@H](C)O5)[C@@H](O)[C@@H](C)O4)c(C)c(O)c3c(O)c2C(=O)[C@H]1O[C@H]1C[C@@H](O[C@H]2C[C@@H](O[C@H]3C[C@](C)(O)[C@H](O)[C@@H](C)O3)[C@H](O)[C@@H](C)O2)[C@H](O)[C@@H](C)O1)C(=O)[C@@H](O)[C@@H](C)O, CO[C@@H]([C@@H]1Cc2cc3cc(O[C@H]4C[C@@H](O[C@H]5C[C@@H](O)[C@H](O)[C@@H](C)O5)[C@@H](O)[C@@H](C)O4)c(C)c(O)c3c(O)c2C(=O)[C@H]1O[C@H]1C[C@@H](O[C@H]2C[C@@H](O[C@H]3C[C@](C)(O)[C@H](O)[C@@H](C)O3)[C@H](O)[C@@H](C)O2)[C@H](O)[C@@H](C)O1)C(=O)[C@@H](O)[C@@H](C)O	CFCUWKMKBJTWLW-BGLFSJPPSA-N, CFCUWKMKBJTWLW-BGLFSJPPSA-N	Launched
plinabulin	tubulin polymerization inhibitor				CC(C)(C)c1nc[nH]c1\C=c1/[nH]c(=O)\c(=C\c2ccccc2)[nH]c1=O, CC(C)(C)c1nc[nH]c1\C=c1/[nH]c(=O)\c(=C\c2ccccc2)[nH]c1=O, CC(C)(C)c1nc[nH]c1\C=c1/[nH]c(=O)\c(=C\c2ccccc2)[nH]c1=O	UNRCMCRRFYFGFX-TYPNBTCFSA-N, UNRCMCRRFYFGFX-TYPNBTCFSA-N, UNRCMCRRFYFGFX-TYPNBTCFSA-N	Phase 3
plovamer-acetate		TAT, TH, YARS, YARS2			N[C@@H](Cc1ccc(O)cc1)C(O)=O |&1:1,r|, N[C@@H](Cc1ccc(O)cc1)C(O)=O |&1:1,r|	OUYCCCASQSFEME-QMMMGPOBSA-N, OUYCCCASQSFEME-QMMMGPOBSA-N	Phase 2
plumbagin	anticancer agent				CC1=CC(=O)c2c(O)cccc2C1=O |t:1|	VCMMXZQDRFWYSE-UHFFFAOYSA-N	Preclinical
plurisin-1	stearoyl-CoA desaturase inhibitor	SCD			O=C(NNc1ccccc1)c1ccncc1, O=C(NNc1ccccc1)c1ccncc1, O=C(NNc1ccccc1)c1ccncc1, O=C(NNc1ccccc1)c1ccncc1, O=C(NNc1ccccc1)c1ccncc1, O=C(NNc1ccccc1)c1ccncc1, O=C(NNc1ccccc1)c1ccncc1	HUDWXDLBWRHCKO-UHFFFAOYSA-N, HUDWXDLBWRHCKO-UHFFFAOYSA-N, HUDWXDLBWRHCKO-UHFFFAOYSA-N, HUDWXDLBWRHCKO-UHFFFAOYSA-N, HUDWXDLBWRHCKO-UHFFFAOYSA-N, HUDWXDLBWRHCKO-UHFFFAOYSA-N, HUDWXDLBWRHCKO-UHFFFAOYSA-N	Preclinical
PLX4720	RAF inhibitor	BRAF, KDR			CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(Cl)cc23)c1F, CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(Cl)cc23)c1F	YZDJQTHVDDOVHR-UHFFFAOYSA-N, YZDJQTHVDDOVHR-UHFFFAOYSA-N	Preclinical
PLX51107	bromodomain inhibitor				C[C@@H](c1ccccn1)n1cc(-c2ccc(cc2)C(O)=O)c2ncc(cc12)-c1c(C)noc1C	AMSUHYUVOVCWTP-INIZCTEOSA-N	Phase 1
PLX647	receptor tyrosine protein kinase inhibitor	CSF1R, KIT			FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncccc34)cn2)cc1, FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncccc34)cn2)cc1	NODCQQSEMCESEC-UHFFFAOYSA-N, NODCQQSEMCESEC-UHFFFAOYSA-N	Preclinical
PLX8394	serine/threonine kinase inhibitor	BRAF			F[C@@H]1CCN(C1)S(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(cc23)-c2cnc(nc2)C2CC2)c1F, F[C@@H]1CCN(C1)S(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(cc23)-c2cnc(nc2)C2CC2)c1F	YYACLQUDUDXAPA-MRXNPFEDSA-N, YYACLQUDUDXAPA-MRXNPFEDSA-N	Phase 1/Phase 2
PMPA	glutamate receptor antagonist	FOLH1			OC(=O)CC[C@@H](CP(O)(O)=O)C(O)=O |&1:5,r|, OC(=O)CC[C@@H](CP(O)(O)=O)C(O)=O |&1:5,r|, OC(=O)CC[C@@H](CP(O)(O)=O)C(O)=O |&1:5,r|	ISEYJGQFXSTPMQ-BYPYZUCNSA-N, ISEYJGQFXSTPMQ-BYPYZUCNSA-N, ISEYJGQFXSTPMQ-BYPYZUCNSA-N	Preclinical
PNU-120596	acetylcholine receptor agonist	CHRNA7			COc1cc(OC)c(NC(=O)Nc2cc(C)on2)cc1Cl, COc1cc(OC)c(NC(=O)Nc2cc(C)on2)cc1Cl, COc1cc(OC)c(NC(=O)Nc2cc(C)on2)cc1Cl, COc1cc(OC)c(NC(=O)Nc2cc(C)on2)cc1Cl, COc1cc(OC)c(NC(=O)Nc2cc(C)on2)cc1Cl, COc1cc(OC)c(NC(=O)Nc2cc(C)on2)cc1Cl, COc1cc(OC)c(NC(=O)Nc2cc(C)on2)cc1Cl	CEIIEALEIHQDBX-UHFFFAOYSA-N, CEIIEALEIHQDBX-UHFFFAOYSA-N, CEIIEALEIHQDBX-UHFFFAOYSA-N, CEIIEALEIHQDBX-UHFFFAOYSA-N, CEIIEALEIHQDBX-UHFFFAOYSA-N, CEIIEALEIHQDBX-UHFFFAOYSA-N, CEIIEALEIHQDBX-UHFFFAOYSA-N	Preclinical
PNU-142633	serotonin receptor agonist	HTR1D			CNC(=O)c1ccc2[C@H](CCN3CCN(CC3)c3ccc(cc3)C(N)=O)OCCc2c1	PNTVCCRNJOGKGA-QFIPXVFZSA-N	Phase 2
PNU-177864	dopamine receptor antagonist	DRD3			CCCNCCc1ccc(NS(=O)(=O)c2ccc(OC(F)(F)F)cc2)cc1, CCCNCCc1ccc(NS(=O)(=O)c2ccc(OC(F)(F)F)cc2)cc1	JGGQWSXZZQPZTR-UHFFFAOYSA-N, JGGQWSXZZQPZTR-UHFFFAOYSA-N	Preclinical
PNU-22394	serotonin receptor agonist	HTR2A, HTR2B, HTR2C, MAOA, MAOB			Cn1c2CCNCCc2c2ccccc12, Cn1c2CCNCCc2c2ccccc12	ZBXDOQWPGBISAR-UHFFFAOYSA-N, ZBXDOQWPGBISAR-UHFFFAOYSA-N	Phase 2
PNU-282987	cholinergic receptor agonist	CHRNA7			Clc1ccc(cc1)C(=O)N[C@H]1CN2CCC1CC2, Clc1ccc(cc1)C(=O)N[C@H]1CN2CCC1CC2, Clc1ccc(cc1)C(=O)N[C@H]1CN2CCC1CC2, Clc1ccc(cc1)C(=O)N[C@H]1CN2CCC1CC2	WECKJONDRAUFDD-ZDUSSCGKSA-N, WECKJONDRAUFDD-ZDUSSCGKSA-N, WECKJONDRAUFDD-ZDUSSCGKSA-N, WECKJONDRAUFDD-ZDUSSCGKSA-N	Preclinical
PNU-37883	ATP-sensitive potassium channel antagonist				C1CCC(CC1)N=C(NC12CC3CC(CC(C3)C1)C2)N1CCOCC1	GKCGWXNLOYTUNC-UHFFFAOYSA-N	Preclinical
PNU-74654	beta-catenin inhibitor	CTNNB1, TCF4			Cc1ccc(\C=N\NC(=O)c2ccccc2Oc2ccccc2)o1, Cc1ccc(\C=N\NC(=O)c2ccccc2Oc2ccccc2)o1, Cc1ccc(\C=N\NC(=O)c2ccccc2Oc2ccccc2)o1, Cc1ccc(\C=N\NC(=O)c2ccccc2Oc2ccccc2)o1, Cc1ccc(\C=N\NC(=O)c2ccccc2Oc2ccccc2)o1	JJEDWBQZCRESJL-DEDYPNTBSA-N, JJEDWBQZCRESJL-DEDYPNTBSA-N, JJEDWBQZCRESJL-DEDYPNTBSA-N, JJEDWBQZCRESJL-DEDYPNTBSA-N, JJEDWBQZCRESJL-DEDYPNTBSA-N	Preclinical
PNU-89843	benzodiazepine receptor agonist	GABBR1			Cc1cc2c(nc(nc2n1C)N1CCCC1)N1CCCC1	UADIKEUOAMACNA-UHFFFAOYSA-N	Preclinical
pocapavir	Enterovirus capsid inhibitor				COc1ccc(OCc2ccc(COc3c(Cl)cccc3Cl)cc2)c(Cl)c1	XXMDDBVNWRWNCW-UHFFFAOYSA-N	Preclinical
podophyllotoxin	microtubule inhibitor, tubulin polymerization inhibitor	IGF1R, TOP2A, TUBA4A, TUBB	infectious disease	genital warts	COc1cc(cc(OC)c1OC)[C@H]1[C@@H]2[C@H](COC2=O)[C@@H](O)c2cc3OCOc3cc12, COc1cc(cc(OC)c1OC)[C@H]1[C@@H]2[C@H](COC2=O)[C@@H](O)c2cc3OCOc3cc12, COc1cc(cc(OC)c1OC)[C@H]1[C@@H]2[C@H](COC2=O)[C@@H](O)c2cc3OCOc3cc12, COc1cc(cc(OC)c1OC)[C@H]1[C@@H]2[C@H](COC2=O)[C@@H](O)c2cc3OCOc3cc12, COc1cc(cc(OC)c1OC)[C@H]1[C@@H]2[C@H](COC2=O)[C@@H](O)c2cc3OCOc3cc12	YJGVMLPVUAXIQN-XVVDYKMHSA-N, YJGVMLPVUAXIQN-XVVDYKMHSA-N, YJGVMLPVUAXIQN-XVVDYKMHSA-N, YJGVMLPVUAXIQN-XVVDYKMHSA-N, YJGVMLPVUAXIQN-XVVDYKMHSA-N	Launched
polaprezinc	chelating agent				O=C1CCN[Zn]OC(=O)[C@H](Cc2cnc[nH]2)N1	VBHDYBCWTAXBNA-FJXQXJEOSA-M	Preclinical
polidocanol	local anesthetic		dermatology	varicose veins	CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO	ONJQDTZCDSESIW-UHFFFAOYSA-N	Launched
polydatin	ICAM1 expression inhibitor	ICAM1			OC[C@H]1O[C@@H](Oc2cc(O)cc(\C=C\c3ccc(O)cc3)c2)[C@H](O)[C@@H](O)[C@@H]1O, OC[C@H]1O[C@@H](Oc2cc(O)cc(\C=C\c3ccc(O)cc3)c2)[C@H](O)[C@@H](O)[C@@H]1O	HSTZMXCBWJGKHG-CUYWLFDKSA-N, HSTZMXCBWJGKHG-CUYWLFDKSA-N	Phase 2
polyinosine	immunostimulant	HPRT1, IMPDH2, PYGM			O[C@H]1[C@@H](COP(O)(O)=O)O[C@@H]([C@@H]1O)n1cnc2c1[nH]cnc2=O |&1:1,&2:2,&3:10,&4:11,r|	GRSZFWQUAKGDAV-SQQSDITASA-N	Preclinical
polymyxin-B-sulfate	bacterial permeability inducer		ophthalmology	eye infection	CC[C@@H](C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@@H](NC(=O)[C@@H](CCN)NC(=O)[C@@H](CCN)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@@H](CCN)NC1=O)[C@@H](C)O |&1:2,&2:11,&3:18,&4:19,&5:25,&6:32,&7:38,&8:42,&9:49,&10:56,&11:64,&12:75,&13:82|, CC[C@@H](C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@@H](NC(=O)[C@@H](CCN)NC(=O)[C@@H](CCN)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@@H](CCN)NC1=O)[C@@H](C)O |&1:2,&2:11,&3:18,&4:19,&5:25,&6:32,&7:38,&8:42,&9:49,&10:56,&11:64,&12:75,&13:82|	WQVJHHACXVLGBL-XLCZGQJLSA-N, WQVJHHACXVLGBL-XLCZGQJLSA-N	Launched
polythiazide	sodium/chloride cotransporter inhibitor	SLC12A3	cardiology, gastroenterology, rheumatology, nephrology	edema, congestive heart failure, hepatic cirrhosis, nephrotic syndrome, acute glomerulonephritis (AGN), chronic renal failure, hypertension	CN1[C@@H](CSCC(F)(F)F)Nc2cc(Cl)c(cc2S1(=O)=O)S(N)(=O)=O |&1:2,r|, CN1[C@@H](CSCC(F)(F)F)Nc2cc(Cl)c(cc2S1(=O)=O)S(N)(=O)=O |&1:2,r|	CYLWJCABXYDINA-JTQLQIEISA-N, CYLWJCABXYDINA-JTQLQIEISA-N	Launched
pomalidomide	angiogenesis inhibitor, tumor necrosis factor production inhibitor		hematologic malignancy	multiple myeloma	Nc1cccc2C(=O)N([C@H]3CCC(=O)NC3=O)C(=O)c12 |&1:9,r|, Nc1cccc2C(=O)N([C@H]3CCC(=O)NC3=O)C(=O)c12 |&1:9,r|, Nc1cccc2C(=O)N([C@H]3CCC(=O)NC3=O)C(=O)c12 |&1:9,r|, Nc1cccc2C(=O)N([C@H]3CCC(=O)NC3=O)C(=O)c12 |&1:9,r|	UVSMNLNDYGZFPF-QMMMGPOBSA-N, UVSMNLNDYGZFPF-QMMMGPOBSA-N, UVSMNLNDYGZFPF-QMMMGPOBSA-N, UVSMNLNDYGZFPF-QMMMGPOBSA-N	Launched
ponatinib	Bcr-Abl kinase inhibitor, FLT3 inhibitor, PDGFR tyrosine kinase receptor inhibitor	ABL1, BCR, FGFR1, FGFR2, FGFR3, FGFR4, FLT3, KDR, KIT, LCK, LYN, PDGFRA, RET, SRC, TEK	hematologic malignancy	chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL)	CN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(c3)C#Cc3cnc4cccnn34)cc2C(F)(F)F)CC1, CN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(c3)C#Cc3cnc4cccnn34)cc2C(F)(F)F)CC1, CN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(c3)C#Cc3cnc4cccnn34)cc2C(F)(F)F)CC1, CN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(c3)C#Cc3cnc4cccnn34)cc2C(F)(F)F)CC1, CN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(c3)C#Cc3cnc4cccnn34)cc2C(F)(F)F)CC1, CN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(c3)C#Cc3cnc4cccnn34)cc2C(F)(F)F)CC1, CN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(c3)C#Cc3cnc4cccnn34)cc2C(F)(F)F)CC1, CN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(c3)C#Cc3cnc4cccnn34)cc2C(F)(F)F)CC1, CN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(c3)C#Cc3cnc4cccnn34)cc2C(F)(F)F)CC1	PHXJVRSECIGDHY-UHFFFAOYSA-N, PHXJVRSECIGDHY-UHFFFAOYSA-N, PHXJVRSECIGDHY-UHFFFAOYSA-N, PHXJVRSECIGDHY-UHFFFAOYSA-N, PHXJVRSECIGDHY-UHFFFAOYSA-N, PHXJVRSECIGDHY-UHFFFAOYSA-N, PHXJVRSECIGDHY-UHFFFAOYSA-N, PHXJVRSECIGDHY-UHFFFAOYSA-N, PHXJVRSECIGDHY-UHFFFAOYSA-N	Launched
ponesimod	sphingosine 1-phosphate receptor agonist	S1PR1			CCC\N=C1/S\C(=C/c2ccc(OC[C@H](O)CO)c(Cl)c2)C(=O)N1c1ccccc1C, CCC\N=C1/S\C(=C/c2ccc(OC[C@H](O)CO)c(Cl)c2)C(=O)N1c1ccccc1C	LPAUOXUZGSBGDU-STDDISTJSA-N, LPAUOXUZGSBGDU-STDDISTJSA-N	Phase 3
posaconazole	sterol demethylase inhibitor	CYP3A4	infectious disease	oropharyngeal candidiasis	CC[C@@H]([C@H](C)O)n1ncn(-c2ccc(cc2)N2CCN(CC2)c2ccc(OC[C@@H]3CO[C@](Cn4cncn4)(C3)c3ccc(F)cc3F)cc2)c1=O, CC[C@@H]([C@H](C)O)n1ncn(-c2ccc(cc2)N2CCN(CC2)c2ccc(OC[C@@H]3CO[C@](Cn4cncn4)(C3)c3ccc(F)cc3F)cc2)c1=O, CC[C@@H]([C@H](C)O)n1ncn(-c2ccc(cc2)N2CCN(CC2)c2ccc(OC[C@@H]3CO[C@](Cn4cncn4)(C3)c3ccc(F)cc3F)cc2)c1=O, CC[C@@H]([C@H](C)O)n1ncn(-c2ccc(cc2)N2CCN(CC2)c2ccc(OC[C@@H]3CO[C@](Cn4cncn4)(C3)c3ccc(F)cc3F)cc2)c1=O, CC[C@@H]([C@H](C)O)n1ncn(-c2ccc(cc2)N2CCN(CC2)c2ccc(OC[C@@H]3CO[C@](Cn4cncn4)(C3)c3ccc(F)cc3F)cc2)c1=O, CC[C@@H]([C@H](C)O)n1ncn(-c2ccc(cc2)N2CCN(CC2)c2ccc(OC[C@@H]3CO[C@](Cn4cncn4)(C3)c3ccc(F)cc3F)cc2)c1=O	RAGOYPUPXAKGKH-XAKZXMRKSA-N, RAGOYPUPXAKGKH-XAKZXMRKSA-N, RAGOYPUPXAKGKH-XAKZXMRKSA-N, RAGOYPUPXAKGKH-XAKZXMRKSA-N, RAGOYPUPXAKGKH-XAKZXMRKSA-N, RAGOYPUPXAKGKH-XAKZXMRKSA-N	Launched
potassium-canrenoate	mineralocorticoid receptor antagonist	NR3C2	cardiology	edema	C[C@]12CC[C@H]3[C@@H](C=CC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@@]2(O)CCC(O)=O |c:6,t:8|, C[C@]12CC[C@H]3[C@@H](C=CC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@@]2(O)CCC(O)=O |c:6,t:8|, C[C@]12CC[C@H]3[C@@H](C=CC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@@]2(O)CCC(O)=O |c:6,t:8|, C[C@]12CC[C@H]3[C@@H](C=CC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@@]2(O)CCC(O)=O |c:6,t:8|, C[C@]12CC[C@H]3[C@@H](C=CC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@@]2(O)CCC(O)=O |c:6,t:8|, C[C@]12CC[C@H]3[C@@H](C=CC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@@]2(O)CCC(O)=O |c:6,t:8|, C[C@]12CC[C@H]3[C@@H](C=CC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@@]2(O)CCC(O)=O |c:6,t:8|	PBKZPPIHUVSDNM-WNHSNXHDSA-N, PBKZPPIHUVSDNM-WNHSNXHDSA-N, PBKZPPIHUVSDNM-WNHSNXHDSA-N, PBKZPPIHUVSDNM-WNHSNXHDSA-N, PBKZPPIHUVSDNM-WNHSNXHDSA-N, PBKZPPIHUVSDNM-WNHSNXHDSA-N, PBKZPPIHUVSDNM-WNHSNXHDSA-N	Launched
potassium-iodide			pulmonary	asthma, bronchitis, emphysema	[K].I, [K].I	KIRAUJWBCMCUBY-UHFFFAOYSA-N, KIRAUJWBCMCUBY-UHFFFAOYSA-N	Launched
potassium-p-aminobenzoate			rheumatology, urology	scleroderma, dermatomyositis, Peyronie's disease	Nc1ccc(cc1)C(O)=O, Nc1ccc(cc1)C(O)=O, Nc1ccc(cc1)C(O)=O, Nc1ccc(cc1)C(O)=O	ALYNCZNDIQEVRV-UHFFFAOYSA-N, ALYNCZNDIQEVRV-UHFFFAOYSA-N, ALYNCZNDIQEVRV-UHFFFAOYSA-N, ALYNCZNDIQEVRV-UHFFFAOYSA-N	Launched
pozanicline	acetylcholine receptor antagonist	CHRNA4, CHRNB2			Cc1ncccc1OC[C@@H]1CCCN1	YRVIKLBSVVNSHF-JTQLQIEISA-N	Phase 2
poziotinib	EGFR inhibitor	EGFR, ERBB2, ERBB4			COc1cc2ncnc(Nc3ccc(Cl)c(Cl)c3F)c2cc1OC1CCN(CC1)C(=O)C=C, COc1cc2ncnc(Nc3ccc(Cl)c(Cl)c3F)c2cc1OC1CCN(CC1)C(=O)C=C, COc1cc2ncnc(Nc3ccc(Cl)c(Cl)c3F)c2cc1OC1CCN(CC1)C(=O)C=C, COc1cc2ncnc(Nc3ccc(Cl)c(Cl)c3F)c2cc1OC1CCN(CC1)C(=O)C=C, COc1cc2ncnc(Nc3ccc(Cl)c(Cl)c3F)c2cc1OC1CCN(CC1)C(=O)C=C	LPFWVDIFUFFKJU-UHFFFAOYSA-N, LPFWVDIFUFFKJU-UHFFFAOYSA-N, LPFWVDIFUFFKJU-UHFFFAOYSA-N, LPFWVDIFUFFKJU-UHFFFAOYSA-N, LPFWVDIFUFFKJU-UHFFFAOYSA-N	Phase 2
PP-1	SRC inhibitor	HCK, RET			Cc1ccc(cc1)-c1nn(c2ncnc(N)c12)C(C)(C)C, Cc1ccc(cc1)-c1nn(c2ncnc(N)c12)C(C)(C)C, Cc1ccc(cc1)-c1nn(c2ncnc(N)c12)C(C)(C)C, Cc1ccc(cc1)-c1nn(c2ncnc(N)c12)C(C)(C)C	ZVPDNRVYHLRXLX-UHFFFAOYSA-N, ZVPDNRVYHLRXLX-UHFFFAOYSA-N, ZVPDNRVYHLRXLX-UHFFFAOYSA-N, ZVPDNRVYHLRXLX-UHFFFAOYSA-N	Preclinical
PP-121	protein tyrosine kinase inhibitor	ABL1, EGFR, HCK, KDR, MTOR, PDGFRA, PIK3CA, PIK3CB, PIK3CD, PIK3CG, PRKDC, SRC			Nc1ncnc2n(nc(-c3cnc4[nH]ccc4c3)c12)C1CCCC1, Nc1ncnc2n(nc(-c3cnc4[nH]ccc4c3)c12)C1CCCC1, Nc1ncnc2n(nc(-c3cnc4[nH]ccc4c3)c12)C1CCCC1, Nc1ncnc2n(nc(-c3cnc4[nH]ccc4c3)c12)C1CCCC1	NVRXTLZYXZNATH-UHFFFAOYSA-N, NVRXTLZYXZNATH-UHFFFAOYSA-N, NVRXTLZYXZNATH-UHFFFAOYSA-N, NVRXTLZYXZNATH-UHFFFAOYSA-N	Preclinical
PP-2	SRC inhibitor	ABL1, LCK, RIPK2, SRC			CC(C)(C)n1nc(-c2ccc(Cl)cc2)c2c(N)ncnc12, CC(C)(C)n1nc(-c2ccc(Cl)cc2)c2c(N)ncnc12, CC(C)(C)n1nc(-c2ccc(Cl)cc2)c2c(N)ncnc12, CC(C)(C)n1nc(-c2ccc(Cl)cc2)c2c(N)ncnc12, CC(C)(C)n1nc(-c2ccc(Cl)cc2)c2c(N)ncnc12	PBBRWFOVCUAONR-UHFFFAOYSA-N, PBBRWFOVCUAONR-UHFFFAOYSA-N, PBBRWFOVCUAONR-UHFFFAOYSA-N, PBBRWFOVCUAONR-UHFFFAOYSA-N, PBBRWFOVCUAONR-UHFFFAOYSA-N	Preclinical
PPT	estrogen receptor agonist	ESR1			CCCc1c(nn(c1-c1ccc(O)cc1)-c1ccc(O)cc1)-c1ccc(O)cc1, CCCc1c(nn(c1-c1ccc(O)cc1)-c1ccc(O)cc1)-c1ccc(O)cc1, CCCc1c(nn(c1-c1ccc(O)cc1)-c1ccc(O)cc1)-c1ccc(O)cc1, CCCc1c(nn(c1-c1ccc(O)cc1)-c1ccc(O)cc1)-c1ccc(O)cc1	IOTXSIGGFRQYKW-UHFFFAOYSA-N, IOTXSIGGFRQYKW-UHFFFAOYSA-N, IOTXSIGGFRQYKW-UHFFFAOYSA-N, IOTXSIGGFRQYKW-UHFFFAOYSA-N	Preclinical
PPY-A	Abl kinase inhibitor	ABL1, BCR			COc1ccccc1-c1c[nH]c2ncc(cc12)-c1cncc(c1)C(=O)N(C)C, COc1ccccc1-c1c[nH]c2ncc(cc12)-c1cncc(c1)C(=O)N(C)C, COc1ccccc1-c1c[nH]c2ncc(cc12)-c1cncc(c1)C(=O)N(C)C, COc1ccccc1-c1c[nH]c2ncc(cc12)-c1cncc(c1)C(=O)N(C)C, COc1ccccc1-c1c[nH]c2ncc(cc12)-c1cncc(c1)C(=O)N(C)C	GYQRHHQPEMOLKH-UHFFFAOYSA-N, GYQRHHQPEMOLKH-UHFFFAOYSA-N, GYQRHHQPEMOLKH-UHFFFAOYSA-N, GYQRHHQPEMOLKH-UHFFFAOYSA-N, GYQRHHQPEMOLKH-UHFFFAOYSA-N	Preclinical
PP242	mTOR inhibitor	MTOR, PASK			CC(C)n1nc(-c2cc3cc(O)ccc3[nH]2)c2c(N)ncnc12, CC(C)n1nc(-c2cc3cc(O)ccc3[nH]2)c2c(N)ncnc12, CC(C)n1nc(-c2cc3cc(O)ccc3[nH]2)c2c(N)ncnc12, CC(C)n1nc(-c2cc3cc(O)ccc3[nH]2)c2c(N)ncnc12	MFAQYJIYDMLAIM-UHFFFAOYSA-N, MFAQYJIYDMLAIM-UHFFFAOYSA-N, MFAQYJIYDMLAIM-UHFFFAOYSA-N, MFAQYJIYDMLAIM-UHFFFAOYSA-N	Preclinical
PQ-401	IGF-1 inhibitor	IGF1R			COc1ccc(Cl)cc1NC(=O)Nc1cc(C)nc2ccccc12, COc1ccc(Cl)cc1NC(=O)Nc1cc(C)nc2ccccc12, COc1ccc(Cl)cc1NC(=O)Nc1cc(C)nc2ccccc12, COc1ccc(Cl)cc1NC(=O)Nc1cc(C)nc2ccccc12, COc1ccc(Cl)cc1NC(=O)Nc1cc(C)nc2ccccc12, COc1ccc(Cl)cc1NC(=O)Nc1cc(C)nc2ccccc12, COc1ccc(Cl)cc1NC(=O)Nc1cc(C)nc2ccccc12, COc1ccc(Cl)cc1NC(=O)Nc1cc(C)nc2ccccc12, COc1ccc(Cl)cc1NC(=O)Nc1cc(C)nc2ccccc12, COc1ccc(Cl)cc1NC(=O)Nc1cc(C)nc2ccccc12	YBLWOZUPHDKFOT-UHFFFAOYSA-N, YBLWOZUPHDKFOT-UHFFFAOYSA-N, YBLWOZUPHDKFOT-UHFFFAOYSA-N, YBLWOZUPHDKFOT-UHFFFAOYSA-N, YBLWOZUPHDKFOT-UHFFFAOYSA-N, YBLWOZUPHDKFOT-UHFFFAOYSA-N, YBLWOZUPHDKFOT-UHFFFAOYSA-N, YBLWOZUPHDKFOT-UHFFFAOYSA-N, YBLWOZUPHDKFOT-UHFFFAOYSA-N, YBLWOZUPHDKFOT-UHFFFAOYSA-N	Preclinical
PR-619	DUB inhibitor				Nc1nc(N)c(SC#N)cc1SC#N, Nc1nc(N)c(SC#N)cc1SC#N, Nc1nc(N)c(SC#N)cc1SC#N, Nc1nc(N)c(SC#N)cc1SC#N, Nc1nc(N)c(SC#N)cc1SC#N, Nc1nc(N)c(SC#N)cc1SC#N, Nc1nc(N)c(SC#N)cc1SC#N	ZXOBLNBVNROVLC-UHFFFAOYSA-N, ZXOBLNBVNROVLC-UHFFFAOYSA-N, ZXOBLNBVNROVLC-UHFFFAOYSA-N, ZXOBLNBVNROVLC-UHFFFAOYSA-N, ZXOBLNBVNROVLC-UHFFFAOYSA-N, ZXOBLNBVNROVLC-UHFFFAOYSA-N, ZXOBLNBVNROVLC-UHFFFAOYSA-N	Preclinical
practolol	adrenergic receptor antagonist	ADRB1			CC(C)NC[C@@H](O)COc1ccc(NC(C)=O)cc1 |&1:5,r|, CC(C)NC[C@@H](O)COc1ccc(NC(C)=O)cc1 |&1:5,r|	DURULFYMVIFBIR-CYBMUJFWSA-N, DURULFYMVIFBIR-CYBMUJFWSA-N	Withdrawn
pradefovir	cytochrome P450 activator				Nc1ncnc2n(CCOC[P@@]3(=O)OCC[C@H](O3)c3cccc(Cl)c3)cnc12	GWNHAOBXDGOXRR-HJFSHJIFSA-N	Phase 2
pralatrexate	dihydrofolate reductase inhibitor	DHFR	hematologic malignancy	peripheral T-cell lymphoma (PTCL)	Nc1nc(N)c2nc(C[C@@H](CC#C)c3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)cnc2n1 |a:22,&1:9|, Nc1nc(N)c2nc(C[C@@H](CC#C)c3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)cnc2n1 |a:22,&1:9|, Nc1nc(N)c2nc(C[C@@H](CC#C)c3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)cnc2n1 |a:22,&1:9|, Nc1nc(N)c2nc(C[C@@H](CC#C)c3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)cnc2n1 |a:22,&1:9|, Nc1nc(N)c2nc(C[C@@H](CC#C)c3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)cnc2n1 |a:22,&1:9|, Nc1nc(N)c2nc(C[C@@H](CC#C)c3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)cnc2n1 |a:22,&1:9|, Nc1nc(N)c2nc(C[C@@H](CC#C)c3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)cnc2n1 |a:22,&1:9|	OGSBUKJUDHAQEA-ZBFHGGJFSA-N, OGSBUKJUDHAQEA-ZBFHGGJFSA-N, OGSBUKJUDHAQEA-ZBFHGGJFSA-N, OGSBUKJUDHAQEA-ZBFHGGJFSA-N, OGSBUKJUDHAQEA-ZBFHGGJFSA-N, InChI=1S/C23H23N7O5/c1-2-3-14(10-15-11-26-20-18(27-15)19(24)29-23(25)30-20)12-4-6-13(7-5-12)21(33)28-16(22(34)35)8-9-17(31)32/h1,4-7,11,14,16H,3,8-10H2,(H,28,33)(H,31,32)(H,34,35)(H4,24,25,26,29,30)/t14-,16+/m1/s1, InChI=1S/C23H23N7O5/c1-2-3-14(10-15-11-26-20-18(27-15)19(24)29-23(25)30-20)12-4-6-13(7-5-12)21(33)28-16(22(34)35)8-9-17(31)32/h1,4-7,11,14,16H,3,8-10H2,(H,28,33)(H,31,32)(H,34,35)(H4,24,25,26,29,30)/t14-,16+/m1/s1	Launched
pralidoxime	acetylcholinesterase inhibitor	ACHE, BCHE	critical care	organophosphate poisoning	C[n+]1ccccc1\C=N\O, C[n+]1ccccc1\C=N\O, C[n+]1ccccc1\C=N\O, C[n+]1ccccc1\C=N\O	JBKPUQTUERUYQE-UHFFFAOYSA-O, JBKPUQTUERUYQE-UHFFFAOYSA-O, JBKPUQTUERUYQE-UHFFFAOYSA-O, JBKPUQTUERUYQE-UHFFFAOYSA-O	Launched
pralidoxime-chloride	acetylcholinesterase inhibitor	ACHE, BCHE	pulmonary	respiratory depression	C[n+]1ccccc1CN=O, C[n+]1ccccc1CN=O	MHOAUIZFSQGCNM-UHFFFAOYSA-N, MHOAUIZFSQGCNM-UHFFFAOYSA-N	Launched
pralmorelin	growth hormone releasing peptide ligand agonist				C[C@@H](N)C(=O)N[C@H](Cc1ccc2ccccc2c1)C(=O)N[C@@H](C)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@H](Cc1ccccc1)C(=O)N[C@@H](CCCCN)C(N)=O	HRNLPPBUBKMZMT-RDRUQFPZSA-N	Launched
pramipexole	dopamine receptor agonist	ADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, DRD4, DRD5, HTR1A, HTR1B, HTR1D, HTR2A, HTR2B, HTR2C	neurology/psychiatry	Parkinson's Disease	CCCN[C@H]1CCc2nc(N)sc2C1, CCCN[C@H]1CCc2nc(N)sc2C1, CCCN[C@H]1CCc2nc(N)sc2C1, CCCN[C@H]1CCc2nc(N)sc2C1	FASDKYOPVNHBLU-ZETCQYMHSA-N, FASDKYOPVNHBLU-ZETCQYMHSA-N, FASDKYOPVNHBLU-ZETCQYMHSA-N, FASDKYOPVNHBLU-ZETCQYMHSA-N	Launched
pramiracetam	acetylcholine receptor agonist		neurology/psychiatry	senile dementia	CC(C)N(CCNC(=O)CN1CCCC1=O)C(C)C, CC(C)N(CCNC(=O)CN1CCCC1=O)C(C)C	ZULJGOSFKWFVRX-UHFFFAOYSA-N, ZULJGOSFKWFVRX-UHFFFAOYSA-N	Launched
pramoxine	topical anesthetic		dermatology	corticosteroid-responsive dermatoses	CCCCOc1ccc(OCCCN2CCOCC2)cc1, CCCCOc1ccc(OCCCN2CCOCC2)cc1, CCCCOc1ccc(OCCCN2CCOCC2)cc1	DQKXQSGTHWVTAD-UHFFFAOYSA-N, DQKXQSGTHWVTAD-UHFFFAOYSA-N, DQKXQSGTHWVTAD-UHFFFAOYSA-N	Launched
pranidipine	calcium channel blocker	CACNA1C			COC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OC\C=C\c1ccccc1 |r,c:4,9|, COC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OC\C=C\c1ccccc1 |r,c:4,9|, COC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OC\C=C\c1ccccc1 |r,c:4,9|, COC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OC\C=C\c1ccccc1 |r,c:4,9|, COC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OC\C=C\c1ccccc1 |r,c:4,9|	XTFPDGZNWTZCMF-OXHGWOFKSA-N, XTFPDGZNWTZCMF-OXHGWOFKSA-N, XTFPDGZNWTZCMF-OXHGWOFKSA-N, XTFPDGZNWTZCMF-OXHGWOFKSA-N, XTFPDGZNWTZCMF-OXHGWOFKSA-N	Phase 2
pranlukast	leukotriene receptor antagonist	CYSLTR1, CYSLTR2, IL5, MUC2, NFKB1, RNASE3, TNF	pulmonary	bronchospasm, asthma	O=C(Nc1cccc2c1oc(cc2=O)-c1nn[nH]n1)c1ccc(OCCCCc2ccccc2)cc1, O=C(Nc1cccc2c1oc(cc2=O)-c1nn[nH]n1)c1ccc(OCCCCc2ccccc2)cc1, O=C(Nc1cccc2c1oc(cc2=O)-c1nn[nH]n1)c1ccc(OCCCCc2ccccc2)cc1, O=C(Nc1cccc2c1oc(cc2=O)-c1nn[nH]n1)c1ccc(OCCCCc2ccccc2)cc1, O=C(Nc1cccc2c1oc(cc2=O)-c1nn[nH]n1)c1ccc(OCCCCc2ccccc2)cc1, O=C(Nc1cccc2c1oc(cc2=O)-c1nn[nH]n1)c1ccc(OCCCCc2ccccc2)cc1, O=C(Nc1cccc2c1oc(cc2=O)-c1nn[nH]n1)c1ccc(OCCCCc2ccccc2)cc1, O=C(Nc1cccc2c1oc(cc2=O)-c1nn[nH]n1)c1ccc(OCCCCc2ccccc2)cc1, O=C(Nc1cccc2c1oc(cc2=O)-c1nn[nH]n1)c1ccc(OCCCCc2ccccc2)cc1, O=C(Nc1cccc2c1oc(cc2=O)-c1nn[nH]n1)c1ccc(OCCCCc2ccccc2)cc1, O=C(Nc1cccc2c1oc(cc2=O)-c1nn[nH]n1)c1ccc(OCCCCc2ccccc2)cc1, O=C(Nc1cccc2c1oc(cc2=O)-c1nn[nH]n1)c1ccc(OCCCCc2ccccc2)cc1	NBQKINXMPLXUET-UHFFFAOYSA-N, NBQKINXMPLXUET-UHFFFAOYSA-N, NBQKINXMPLXUET-UHFFFAOYSA-N, NBQKINXMPLXUET-UHFFFAOYSA-N, NBQKINXMPLXUET-UHFFFAOYSA-N, NBQKINXMPLXUET-UHFFFAOYSA-N, NBQKINXMPLXUET-UHFFFAOYSA-N, NBQKINXMPLXUET-UHFFFAOYSA-N, NBQKINXMPLXUET-UHFFFAOYSA-N, NBQKINXMPLXUET-UHFFFAOYSA-N, NBQKINXMPLXUET-UHFFFAOYSA-N, NBQKINXMPLXUET-UHFFFAOYSA-N	Launched
pranoprofen	cyclooxygenase inhibitor		neurology/psychiatry	pain relief	C[C@@H](C(O)=O)c1ccc2Oc3ncccc3Cc2c1 |&1:1,r|, C[C@@H](C(O)=O)c1ccc2Oc3ncccc3Cc2c1 |&1:1,r|, C[C@@H](C(O)=O)c1ccc2Oc3ncccc3Cc2c1 |&1:1,r|, C[C@@H](C(O)=O)c1ccc2Oc3ncccc3Cc2c1 |&1:1,r|	TVQZAMVBTVNYLA-SECBINFHSA-N, TVQZAMVBTVNYLA-SECBINFHSA-N, TVQZAMVBTVNYLA-SECBINFHSA-N, TVQZAMVBTVNYLA-SECBINFHSA-N	Launched
prasterone-acetate					CC(=O)O[C@H]1CC[C@]2(C)[C@H]3CC[C@@]4(C)[C@@H](CCC4=O)[C@@H]3CC=C2C1 |c:23|	NCMZQTLCXHGLOK-ZKHIMWLXSA-N	Preclinical
prasugrel	purinergic receptor antagonist	P2RY12	cardiology	myocardial infarction, acute coronary syndrome (ACS)	CC(=O)Oc1cc2CN(CCc2s1)[C@@H](C(=O)C1CC1)c1ccccc1F |&1:13,r|, CC(=O)Oc1cc2CN(CCc2s1)[C@@H](C(=O)C1CC1)c1ccccc1F |&1:13,r|, CC(=O)Oc1cc2CN(CCc2s1)[C@@H](C(=O)C1CC1)c1ccccc1F |&1:13,r|, CC(=O)Oc1cc2CN(CCc2s1)[C@@H](C(=O)C1CC1)c1ccccc1F |&1:13,r|, CC(=O)Oc1cc2CN(CCc2s1)[C@@H](C(=O)C1CC1)c1ccccc1F |&1:13,r|, CC(=O)Oc1cc2CN(CCc2s1)[C@@H](C(=O)C1CC1)c1ccccc1F |&1:13,r|, CC(=O)Oc1cc2CN(CCc2s1)[C@@H](C(=O)C1CC1)c1ccccc1F |&1:13,r|	DTGLZDAWLRGWQN-LJQANCHMSA-N, DTGLZDAWLRGWQN-LJQANCHMSA-N, DTGLZDAWLRGWQN-LJQANCHMSA-N, DTGLZDAWLRGWQN-LJQANCHMSA-N, DTGLZDAWLRGWQN-LJQANCHMSA-N, DTGLZDAWLRGWQN-LJQANCHMSA-N, DTGLZDAWLRGWQN-LJQANCHMSA-N	Launched
pravadoline	cyclooxygenase inhibitor	CNR1, CNR2			COc1ccc(cc1)C(=O)c1c(C)n(CCN2CCOCC2)c2ccccc12	MEUQWHZOUDZXHH-UHFFFAOYSA-N	Preclinical
pravastatin	HMGCR inhibitor	HMGCR, SLCO1B1	endocrinology, cardiology	hypercholesterolemia, myocardial infarction, hyperlipidemia	CC[C@H](C)C(=O)O[C@H]1C[C@H](O)C=C2C=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@@H]12 |c:13,t:11|, CC[C@H](C)C(=O)O[C@H]1C[C@H](O)C=C2C=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@@H]12 |c:13,t:11|, CC[C@H](C)C(=O)O[C@H]1C[C@H](O)C=C2C=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@@H]12 |c:13,t:11|, CC[C@H](C)C(=O)O[C@H]1C[C@H](O)C=C2C=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@@H]12 |c:13,t:11|, CC[C@H](C)C(=O)O[C@H]1C[C@H](O)C=C2C=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@@H]12 |c:13,t:11|, CC[C@H](C)C(=O)O[C@H]1C[C@H](O)C=C2C=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@@H]12 |c:13,t:11|	TUZYXOIXSAXUGO-PZAWKZKUSA-N, TUZYXOIXSAXUGO-PZAWKZKUSA-N, TUZYXOIXSAXUGO-PZAWKZKUSA-N, TUZYXOIXSAXUGO-PZAWKZKUSA-N, TUZYXOIXSAXUGO-PZAWKZKUSA-N, TUZYXOIXSAXUGO-PZAWKZKUSA-N	Launched
praziquantel	anthelmintic agent		infectious disease	gastrointestinal parasites, cystic hydatid disease, schistosomiasis	O=C(C1CCCCC1)N1C[C@H]2N(CCc3ccccc23)C(=O)C1 |&1:10,r|, O=C(C1CCCCC1)N1C[C@H]2N(CCc3ccccc23)C(=O)C1 |&1:10,r|	FSVJFNAIGNNGKK-QGZVFWFLSA-N, FSVJFNAIGNNGKK-QGZVFWFLSA-N	Launched
prazosin	adrenergic receptor antagonist	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, KCNH2, KCNH6, KCNH7	cardiology	hypertension	COc1cc2nc(nc(N)c2cc1OC)N1CCN(CC1)C(=O)c1ccco1, COc1cc2nc(nc(N)c2cc1OC)N1CCN(CC1)C(=O)c1ccco1, COc1cc2nc(nc(N)c2cc1OC)N1CCN(CC1)C(=O)c1ccco1, COc1cc2nc(nc(N)c2cc1OC)N1CCN(CC1)C(=O)c1ccco1, COc1cc2nc(nc(N)c2cc1OC)N1CCN(CC1)C(=O)c1ccco1, COc1cc2nc(nc(N)c2cc1OC)N1CCN(CC1)C(=O)c1ccco1	IENZQIKPVFGBNW-UHFFFAOYSA-N, IENZQIKPVFGBNW-UHFFFAOYSA-N, IENZQIKPVFGBNW-UHFFFAOYSA-N, IENZQIKPVFGBNW-UHFFFAOYSA-N, IENZQIKPVFGBNW-UHFFFAOYSA-N, IENZQIKPVFGBNW-UHFFFAOYSA-N	Launched
PRE-084	sigma receptor agonist	SIGMAR1			O=C(OCCN1CCOCC1)C1(CCCCC1)c1ccccc1, O=C(OCCN1CCOCC1)C1(CCCCC1)c1ccccc1, O=C(OCCN1CCOCC1)C1(CCCCC1)c1ccccc1, O=C(OCCN1CCOCC1)C1(CCCCC1)c1ccccc1	RQHKZUBCUZVZEF-UHFFFAOYSA-N, RQHKZUBCUZVZEF-UHFFFAOYSA-N, RQHKZUBCUZVZEF-UHFFFAOYSA-N, RQHKZUBCUZVZEF-UHFFFAOYSA-N	Preclinical
preclamol	dopamine receptor agonist	DRD2			CCCN1CCC[C@@H](C1)c1cccc(O)c1, CCCN1CCC[C@@H](C1)c1cccc(O)c1	HTSNFXAICLXZMA-ZDUSSCGKSA-N, HTSNFXAICLXZMA-ZDUSSCGKSA-N	Phase 2
prednicarbate	phospholipase activator	PLA2G1B	dermatology, ophthalmology, neurology/psychiatry	eczema, contact dermatitis, itching	CCOC(=O)O[C@@]1(CC[C@H]2[C@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@H]3[C@@H](O)C[C@]12C)C(=O)COC(=O)CC |a:6,19,22,25,&1:9,&2:10,&3:21,c:17,t:13|	FNPXMHRZILFCKX-HGVFMWMISA-N	Launched
prednisolone	glucocorticoid receptor agonist	NR3C1, NR3C2, SERPINA6	ophthalmology, dermatology, infectious disease	conjunctivitis, rosacea, punctate keratitis, shingles, iritis, cyclitis	C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO |a:1,3,15,20,&1:5,&2:6,&3:17,c:13,t:9|, C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO |a:1,3,15,20,&1:5,&2:6,&3:17,c:13,t:9|, C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO |a:1,3,15,20,&1:5,&2:6,&3:17,c:13,t:9|, C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO |a:1,3,15,20,&1:5,&2:6,&3:17,c:13,t:9|, C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO |a:1,3,15,20,&1:5,&2:6,&3:17,c:13,t:9|	OIGNJSKKLXVSLS-VWUMJDOOSA-N, OIGNJSKKLXVSLS-VWUMJDOOSA-N, OIGNJSKKLXVSLS-VWUMJDOOSA-N, OIGNJSKKLXVSLS-VWUMJDOOSA-N, OIGNJSKKLXVSLS-VWUMJDOOSA-N	Launched
prednisolone-acetate	glucocorticoid receptor agonist	NR3C1	ophthalmology, dermatology, infectious disease	conjunctivitis, rosacea, punctate keratitis, shingles, iritis, cyclitis	CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]12C |c:19,t:15|, CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@H]3CCC4=CC(=O)C=C[C@@]4(C)[C@@H]3[C@@H](O)C[C@]12C |a:7,24,27,&1:11,&2:12,&3:21,&4:23,c:19,t:15|, CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]12C |c:19,t:15|, CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]12C |c:19,t:15|	LRJOMUJRLNCICJ-JZYPGELDSA-N, LRJOMUJRLNCICJ-WXLIAARGSA-N, LRJOMUJRLNCICJ-JZYPGELDSA-N, LRJOMUJRLNCICJ-JZYPGELDSA-N	Launched
prednisolone-hemisuccinate	glucocorticoid receptor agonist	NR3C1			C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1CC[C@]2(O)C(=O)COC(=O)CCC(O)=O |a:1,3,15,20,&1:5,&2:6,&3:17,c:13,t:9|	APGDTXUMTIZLCJ-CGVGKPPMSA-N	Preclinical
prednisolone-sodium-phosphate	glucocorticoid receptor agonist	NR3C1	allergy, pulmonary, ophthalmology, infectious disease, rheumatology, endocrinology, neurology/psychiatry, gastroenterology, hematology	allergic rhinitis, asthma, contact dermatitis, mycosis, lupus, hypercalcemia, thyroiditis, congenital adrenal hyperplasia, multiple sclerosis, ulcerative colitis, enteritis, thrombocythemia, pneumonia, meningitis, psoriatic arthritis, rheumatoid arthritis	[H][C@@]12CC[C@](O)(C(=O)COP(O)(O)=O)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C |c:31,t:27|	JDOZJEUDSLGTLU-VWUMJDOOSA-N	Launched
prednisolone-tebutate	anti-inflammatory agent				CC(C)(C)CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@H]3[C@@H](O)C[C@]12C |a:11,25,28,31,&1:15,&2:16,&3:27,c:23,t:19|	HUMXXHTVHHLNRO-HGVFMWMISA-N	Launched
prednisone	glucocorticoid receptor agonist	HSD11B1, NR3C1	endocrinology, rheumatology, infectious disease, dermatology, ophthalmology, hematology, gastroenterology, neurology/psychiatry	congenital adrenal hyperplasia, hypercalcemia, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, bursitis, osteoarthritis, epicondylitis, dermatomyositis, psoriasis, mycosis, conjunctivitis, anemia, ulcerative colitis, enteritis, multiple sclerosis, meningitis	C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO |c:13,t:9|, C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO |c:13,t:9|, C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO |c:13,t:9|, C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO |c:13,t:9|, C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO |c:13,t:9|	XOFYZVNMUHMLCC-ZPOLXVRWSA-N, XOFYZVNMUHMLCC-ZPOLXVRWSA-N, XOFYZVNMUHMLCC-ZPOLXVRWSA-N, XOFYZVNMUHMLCC-ZPOLXVRWSA-N, XOFYZVNMUHMLCC-ZPOLXVRWSA-N	Launched
pregnenolone	glutamate receptor modulator	SULT2B1	rheumatology	rheumatoid arthritis	CC(=O)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C |t:9|, CC(=O)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C |t:9|, CC(=O)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C |t:9|, CC(=O)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C |t:9|	ORNBQBCIOKFOEO-QGVNFLHTSA-N, ORNBQBCIOKFOEO-QGVNFLHTSA-N, ORNBQBCIOKFOEO-QGVNFLHTSA-N, ORNBQBCIOKFOEO-QGVNFLHTSA-N	Launched
pregnenolone-succinate	GABA receptor negative allosteric modulator	CYP17A1			CC(=O)[C@H]1CC[C@H]2[C@H]3CC=C4C[C@H](CC[C@]4(C)[C@@H]3CC[C@]12C)OC(=O)CCC(O)=O |a:3,12,15,20,&1:6,&2:7,&3:17,t:9|, CC(=O)[C@H]1CC[C@H]2[C@H]3CC=C4C[C@H](CC[C@]4(C)[C@@H]3CC[C@]12C)OC(=O)CCC(O)=O |a:3,12,15,20,&1:6,&2:7,&3:17,t:9|	OZZAYJQNMKMUSD-VQLNUFJUSA-N, OZZAYJQNMKMUSD-VQLNUFJUSA-N	Preclinical
preladenant	adenosine receptor antagonist	ADORA1, ADORA2A, ADORA2B, ADORA3			COCCOc1ccc(cc1)N1CCN(CCn2ncc3c2nc(N)n2nc(nc32)-c2ccco2)CC1, COCCOc1ccc(cc1)N1CCN(CCn2ncc3c2nc(N)n2nc(nc32)-c2ccco2)CC1, COCCOc1ccc(cc1)N1CCN(CCn2ncc3c2nc(N)n2nc(nc32)-c2ccco2)CC1, COCCOc1ccc(cc1)N1CCN(CCn2ncc3c2nc(N)n2nc(nc32)-c2ccco2)CC1, COCCOc1ccc(cc1)N1CCN(CCn2ncc3c2nc(N)n2nc(nc32)-c2ccco2)CC1	DTYWJKSSUANMHD-UHFFFAOYSA-N, DTYWJKSSUANMHD-UHFFFAOYSA-N, DTYWJKSSUANMHD-UHFFFAOYSA-N, DTYWJKSSUANMHD-UHFFFAOYSA-N, DTYWJKSSUANMHD-UHFFFAOYSA-N	Phase 3
prenylamine	calcium channel blocker				C[C@@H](Cc1ccccc1)NCCC(c1ccccc1)c1ccccc1 |&2:1|, C[C@@H](Cc1ccccc1)NCCC(c1ccccc1)c1ccccc1 |&2:1|, C[C@@H](Cc1ccccc1)NCCC(c1ccccc1)c1ccccc1 |&2:1|, C[C@@H](Cc1ccccc1)NCCC(c1ccccc1)c1ccccc1 |&2:1|	IFFPICMESYHZPQ-FQEVSTJZSA-N, IFFPICMESYHZPQ-FQEVSTJZSA-N, IFFPICMESYHZPQ-FQEVSTJZSA-N, IFFPICMESYHZPQ-FQEVSTJZSA-N	Withdrawn
presatovir	RSV fusion inhibitor				Cc1cn2nc(cc2nc1N1CC[C@H](N)C1)[C@@H]1CCCCN1C(=O)c1cc(Cl)ccc1NS(C)(=O)=O, Cc1cn2nc(cc2nc1N1CC[C@H](N)C1)[C@@H]1CCCCN1C(=O)c1cc(Cl)ccc1NS(C)(=O)=O	GOFXWTVKPWJNGD-UWJYYQICSA-N, GOFXWTVKPWJNGD-UWJYYQICSA-N	Phase 2
pretomanid	nitric oxide donor	FASN			[O-][N+](=O)c1cn2C[C@@H](COc2n1)OCc1ccc(OC(F)(F)F)cc1, [O-][N+](=O)c1cn2C[C@@H](COc2n1)OCc1ccc(OC(F)(F)F)cc1	ZLHZLMOSPGACSZ-NSHDSACASA-N, ZLHZLMOSPGACSZ-NSHDSACASA-N	Launched
pridinol	muscle relaxant		neurology/psychiatry	muscle relaxant	OC(CCN1CCCCC1)(c1ccccc1)c1ccccc1, OC(CCN1CCCCC1)(c1ccccc1)c1ccccc1, OC(CCN1CCCCC1)(c1ccccc1)c1ccccc1, OC(CCN1CCCCC1)(c1ccccc1)c1ccccc1	RQXCLMGKHJWMOA-UHFFFAOYSA-N, RQXCLMGKHJWMOA-UHFFFAOYSA-N, RQXCLMGKHJWMOA-UHFFFAOYSA-N, RQXCLMGKHJWMOA-UHFFFAOYSA-N	Launched
pridopidine	dopamine receptor antagonist				CCCN1CCC(CC1)c1cccc(c1)S(C)(=O)=O	YGKUEOZJFIXDGI-UHFFFAOYSA-N	Phase 2
prilocaine	local anesthetic	SCN5A	neurology/psychiatry	anesthetic	CCCN[C@@H](C)C(=O)Nc1ccccc1C |&1:4,r|, CCCN[C@@H](C)C(=O)Nc1ccccc1C |&1:4,r|	MVFGUOIZUNYYSO-NSHDSACASA-N, MVFGUOIZUNYYSO-NSHDSACASA-N	Launched
primaquine	antimalarial agent, DNA inhibitor		infectious disease	malaria	COc1cc(N[C@@H](C)CCCN)c2ncccc2c1 |r|	INDBQLZJXZLFIT-NSHDSACASA-N	Launched
PRIMA1	TP53 inhibitor	ACHE			OCC1(CO)N2CCC(CC2)C1=O, OCC1(CO)N2CCC(CC2)C1=O, OCC1(CO)N2CCC(CC2)C1=O	RFBVBRVVOPAAFS-UHFFFAOYSA-N, RFBVBRVVOPAAFS-UHFFFAOYSA-N, RFBVBRVVOPAAFS-UHFFFAOYSA-N	Preclinical
primidone	GABA receptor antagonist	CHRNA4, CHRNA7, GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, GRIA2, GRIK2, SCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A	neurology/psychiatry	seizures	CCC1(C(=O)NCNC1=O)c1ccccc1, CCC1(C(=O)NCNC1=O)c1ccccc1, CCC1(C(=O)NCNC1=O)c1ccccc1, CCC1(C(=O)NCNC1=O)c1ccccc1, CCC1(C(=O)NCNC1=O)c1ccccc1, CCC1(C(=O)NCNC1=O)c1ccccc1	DQMZLTXERSFNPB-UHFFFAOYSA-N, DQMZLTXERSFNPB-UHFFFAOYSA-N, DQMZLTXERSFNPB-UHFFFAOYSA-N, DQMZLTXERSFNPB-UHFFFAOYSA-N, DQMZLTXERSFNPB-UHFFFAOYSA-N, DQMZLTXERSFNPB-UHFFFAOYSA-N	Launched
prinaberel	estrogen receptor agonist	ESR2, NCOA1			Oc1cc(C=C)c2oc(nc2c1)-c1ccc(O)c(F)c1	MQIMZDXIAHJKQP-UHFFFAOYSA-N	Phase 2
prinomastat	matrix metalloprotease inhibitor				CC1(C)SCCN([C@H]1C(=O)NO)S(=O)(=O)c1ccc(Oc2ccncc2)cc1	YKPYIPVDTNNYCN-INIZCTEOSA-N	Phase 3
priralfinamide	sodium channel blocker	CACNA1B			C[C@H](NCc1ccc(OCc2ccccc2F)cc1)C(N)=O, C[C@H](NCc1ccc(OCc2ccccc2F)cc1)C(N)=O	BHJIBOFHEFDSAU-LBPRGKRZSA-N, BHJIBOFHEFDSAU-LBPRGKRZSA-N	Phase 3
prisotinol					CC(C)N[C@H](C)Cc1ccc(O)cn1 |&1:4,r|	WQRPBKUCJBWQRT-SECBINFHSA-N	Phase 2
pritelivir	helicase primase inhibitor				CN(C(=O)Cc1ccc(cc1)-c1ccccn1)c1nc(C)c(s1)S(N)(=O)=O, CN(C(=O)Cc1ccc(cc1)-c1ccccn1)c1nc(C)c(s1)S(N)(=O)=O	IVZKZONQVYTCKC-UHFFFAOYSA-N, IVZKZONQVYTCKC-UHFFFAOYSA-N	Phase 2
PRLX-93936	voltage-dependent anion selective channel protein inhibitor				CCOc1ccccc1-n1c(CN2CCNCC2)nc2ccccc2c1=O	OBWOSMGNXYUDFB-UHFFFAOYSA-N	Phase 1/Phase 2
PRN1008	Bruton's tyrosine kinase (BTK) inhibitor				CC(C)(\C=C(/C#N)C(=O)N1CCC[C@H](C1)n1nc(-c2ccc(Oc3ccccc3)cc2F)c2c(N)ncnc12)N1CCN(CC1)C1COC1	LCFFREMLXLZNHE-GBOLQPHISA-N	Preclinical
PRN1371	protein tyrosine kinase inhibitor				CNc1ncc2cc(-c3c(Cl)c(OC)cc(OC)c3Cl)c(=O)n(CCCN3CCN(CC3)C(=O)C=C)c2n1	PUIXMSRTTHLNKI-UHFFFAOYSA-N	Phase 1
proacipimox	cholesterol inhibitor				COCc1c[n+]([O-])c(C)cn1, COCc1c[n+]([O-])c(C)cn1	KKKHJYGCTVKQEM-UHFFFAOYSA-N, KKKHJYGCTVKQEM-UHFFFAOYSA-N	Phase 1
proadifen	nitric oxide synthase inhibitor	NOS1			CCCC(C(=O)OCCN(CC)CC)(c1ccccc1)c1ccccc1, CCCC(C(=O)OCCN(CC)CC)(c1ccccc1)c1ccccc1, CCCC(C(=O)OCCN(CC)CC)(c1ccccc1)c1ccccc1	SNTQPLDRUZOSDP-UHFFFAOYSA-N, SNTQPLDRUZOSDP-UHFFFAOYSA-N, SNTQPLDRUZOSDP-UHFFFAOYSA-N	Preclinical
probenecid	uricosuric blocker	PANX1, SLC22A11, SLC22A6, SLC22A8, SLCO1C1	nephrology, rheumatology	hyperuricemia, gout	CCCN(CCC)S(=O)(=O)c1ccc(cc1)C(O)=O, CCCN(CCC)S(=O)(=O)c1ccc(cc1)C(O)=O, CCCN(CCC)S(=O)(=O)c1ccc(cc1)C(O)=O, CCCN(CCC)S(=O)(=O)c1ccc(cc1)C(O)=O, CCCN(CCC)S(=O)(=O)c1ccc(cc1)C(O)=O	DBABZHXKTCFAPX-UHFFFAOYSA-N, DBABZHXKTCFAPX-UHFFFAOYSA-N, DBABZHXKTCFAPX-UHFFFAOYSA-N, DBABZHXKTCFAPX-UHFFFAOYSA-N, DBABZHXKTCFAPX-UHFFFAOYSA-N	Launched
probucol	atherogenesis inhibitor	ABCA1, ABCB11, CES1	cardiology	coronary artery disease (CAD)	CC(C)(Sc1cc(c(O)c(c1)C(C)(C)C)C(C)(C)C)Sc1cc(c(O)c(c1)C(C)(C)C)C(C)(C)C, CC(C)(Sc1cc(c(O)c(c1)C(C)(C)C)C(C)(C)C)Sc1cc(c(O)c(c1)C(C)(C)C)C(C)(C)C, CC(C)(Sc1cc(c(O)c(c1)C(C)(C)C)C(C)(C)C)Sc1cc(c(O)c(c1)C(C)(C)C)C(C)(C)C, CC(C)(Sc1cc(c(O)c(c1)C(C)(C)C)C(C)(C)C)Sc1cc(c(O)c(c1)C(C)(C)C)C(C)(C)C, CC(C)(Sc1cc(c(O)c(c1)C(C)(C)C)C(C)(C)C)Sc1cc(c(O)c(c1)C(C)(C)C)C(C)(C)C	FYPMFJGVHOHGLL-UHFFFAOYSA-N, FYPMFJGVHOHGLL-UHFFFAOYSA-N, FYPMFJGVHOHGLL-UHFFFAOYSA-N, FYPMFJGVHOHGLL-UHFFFAOYSA-N, FYPMFJGVHOHGLL-UHFFFAOYSA-N	Launched
procainamide	sodium channel blocker	DNMT1, SCN5A	cardiology	ventricular arrhythmias, ventricular tachycardia (VT)	CCN(CC)CCNC(=O)c1ccc(N)cc1, CCN(CC)CCNC(=O)c1ccc(N)cc1, CCN(CC)CCNC(=O)c1ccc(N)cc1, CCN(CC)CCNC(=O)c1ccc(N)cc1	REQCZEXYDRLIBE-UHFFFAOYSA-N, REQCZEXYDRLIBE-UHFFFAOYSA-N, REQCZEXYDRLIBE-UHFFFAOYSA-N, REQCZEXYDRLIBE-UHFFFAOYSA-N	Launched
procaine	HMGCR inhibitor	CHRNA2, GRIN3A, HTR3A, KCNMA1, KCNMB1, KCNMB2, KCNMB3, KCNMB4, KCNN1, KCNN2, KCNN3, KCNN4, MAOA, MAOB, RYR1, RYR2, SCN10A, SLC6A3	neurology/psychiatry	anesthetic	CCN(CC)CCOC(=O)c1ccc(N)cc1, CCN(CC)CCOC(=O)c1ccc(N)cc1	MFDFERRIHVXMIY-UHFFFAOYSA-N, MFDFERRIHVXMIY-UHFFFAOYSA-N	Launched
procarbazine	monoamine oxidase inhibitor		hematologic malignancy	Hodgkin's lymphoma	CNNCc1ccc(cc1)C(=O)NC(C)C, CNNCc1ccc(cc1)C(=O)NC(C)C, CNNCc1ccc(cc1)C(=O)NC(C)C, CNNCc1ccc(cc1)C(=O)NC(C)C	CPTBDICYNRMXFX-UHFFFAOYSA-N, CPTBDICYNRMXFX-UHFFFAOYSA-N, CPTBDICYNRMXFX-UHFFFAOYSA-N, CPTBDICYNRMXFX-UHFFFAOYSA-N	Launched
procaterol	adrenergic receptor agonist	ADRB2	pulmonary	asthma	CC[C@H](NC(C)C)[C@H](O)c1ccc(O)c2[nH]c(=O)ccc12, CC[C@H](NC(C)C)[C@H](O)c1ccc(O)c2[nH]c(=O)ccc12, CC[C@H](NC(C)C)[C@H](O)c1ccc(O)c2[nH]c(=O)ccc12, CC[C@H](NC(C)C)[C@H](O)c1ccc(O)c2[nH]c(=O)ccc12	FKNXQNWAXFXVNW-BLLLJJGKSA-N, FKNXQNWAXFXVNW-BLLLJJGKSA-N, FKNXQNWAXFXVNW-BLLLJJGKSA-N, FKNXQNWAXFXVNW-BLLLJJGKSA-N	Launched
prochlorperazine	dopamine receptor antagonist	DRD1, DRD2, DRD3, DRD4	gastroenterology	nausea, vomiting	CN1CCN(CCCN2c3ccccc3Sc3ccc(Cl)cc23)CC1, CN1CCN(CCCN2c3ccccc3Sc3ccc(Cl)cc23)CC1, CN1CCN(CCCN2c3ccccc3Sc3ccc(Cl)cc23)CC1, CN1CCN(CCCN2c3ccccc3Sc3ccc(Cl)cc23)CC1, CN1CCN(CCCN2c3ccccc3Sc3ccc(Cl)cc23)CC1, CN1CCN(CCCN2c3ccccc3Sc3ccc(Cl)cc23)CC1	WIKYUJGCLQQFNW-UHFFFAOYSA-N, WIKYUJGCLQQFNW-UHFFFAOYSA-N, WIKYUJGCLQQFNW-UHFFFAOYSA-N, WIKYUJGCLQQFNW-UHFFFAOYSA-N, WIKYUJGCLQQFNW-UHFFFAOYSA-N, WIKYUJGCLQQFNW-UHFFFAOYSA-N	Launched
procodazole	immunostimulant				OC(=O)CCc1nc2ccccc2[nH]1, OC(=O)CCc1nc2ccccc2[nH]1	XYWJNTOURDMTPI-UHFFFAOYSA-N, XYWJNTOURDMTPI-UHFFFAOYSA-N	Preclinical
procyanidin-B-2					O[C@H]1Cc2c(O)cc(O)c([C@@H]3[C@@H](O)[C@H](Oc4cc(O)cc(O)c34)c3ccc(O)c(O)c3)c2O[C@@H]1c1ccc(O)c(O)c1, O[C@H]1Cc2c(O)cc(O)c([C@@H]3[C@@H](O)[C@H](Oc4cc(O)cc(O)c34)c3ccc(O)c(O)c3)c2O[C@@H]1c1ccc(O)c(O)c1, O[C@H]1Cc2c(O)cc(O)c([C@@H]3[C@@H](O)[C@H](Oc4cc(O)cc(O)c34)c3ccc(O)c(O)c3)c2O[C@@H]1c1ccc(O)c(O)c1	XFZJEEAOWLFHDH-UKWJTHFESA-N, XFZJEEAOWLFHDH-UKWJTHFESA-N, XFZJEEAOWLFHDH-UKWJTHFESA-N	Phase 2
procyclidine	acetylcholine receptor antagonist		neurology/psychiatry	parkinsonism, Parkinson's Disease, akathisia, dystonia	COc1cc(N[C@@H](C)CCCN)c2ncccc2c1 |&1:6|	INDBQLZJXZLFIT-NSHDSACASA-N	Launched
procysteine	glutathione synthase stimulant				OC(=O)[C@@H]1CSC(=O)N1, OC(=O)[C@@H]1CSC(=O)N1	BMLMGCPTLHPWPY-REOHCLBHSA-N, BMLMGCPTLHPWPY-REOHCLBHSA-N	Phase 3
profenamine	butyrylcholinesterase inhibitor, cholinergic receptor antagonist	CHRM1	neurology/psychiatry	Parkinson's Disease	CCN(CC)[C@@H](C)CN1c2ccccc2Sc2ccccc12 |&1:5|, CCN(CC)[C@@H](C)CN1c2ccccc2Sc2ccccc12 |&1:5|	CDOZDBSBBXSXLB-HNNXBMFYSA-N, CDOZDBSBBXSXLB-HNNXBMFYSA-N	Launched
proflavine-hemisulfate	topical anesthetic	F2			Nc1ccc2cc3ccc(N)cc3nc2c1, Nc1ccc2cc3ccc(N)cc3nc2c1, Nc1ccc2cc3ccc(N)cc3nc2c1, Nc1ccc2cc3ccc(N)cc3nc2c1	WDVSHHCDHLJJJR-UHFFFAOYSA-N, WDVSHHCDHLJJJR-UHFFFAOYSA-N, WDVSHHCDHLJJJR-UHFFFAOYSA-N, WDVSHHCDHLJJJR-UHFFFAOYSA-N	Phase 2
progesterone	progesterone receptor agonist	CATSPER1, CATSPER2, CATSPER3, CATSPER4, CYP17A1, ESR1, NR3C2, OPRK1, PGR, TRPC5	obstetrics/gynecology, endocrinology	infertility, amenorrhea	CC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C |t:10|, CC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C |t:10|	RJKFOVLPORLFTN-LEKSSAKUSA-N, RJKFOVLPORLFTN-LEKSSAKUSA-N	Launched
proglumetacin	cyclooxygenase inhibitor	PTGS1, PTGS2	neurology/psychiatry	pain relief	CCCN(CCC)C(=O)[C@@H](CCC(=O)OCCCN1CCN(CCOC(=O)Cc2c(C)n(C(=O)c3ccc(Cl)cc3)c3ccc(OC)cc23)CC1)NC(=O)c1ccccc1 |&1:9,r|	PTXGHCGBYMQQIG-RRHRGVEJSA-N	Launched
proglumide	CCK receptor antagonist	CCKAR, CCKBR			CCCN(CCC)C(=O)[C@@H](CCC(O)=O)NC(=O)c1ccccc1 |&1:9|	DGMKFQYCZXERLX-OAHLLOKOSA-N	Withdrawn
proguanil	dihydrofolate reductase inhibitor	DHFR	infectious disease	malaria	CC(C)NC(=N)N=C(N)Nc1ccc(Cl)cc1, CC(C)NC(=N)N=C(N)Nc1ccc(Cl)cc1	SSOLNOMRVKKSON-UHFFFAOYSA-N, SSOLNOMRVKKSON-UHFFFAOYSA-N	Launched
prolylleucylglycinamide	melanocyte-stimulating hormone release inhibitor				CC(C)C[C@@H](NC(=O)[C@H]1CCCN1)C(=O)NCC(N)=O |&1:4,&2:8,r|	NOOJLZTTWSNHOX-NXEZZACHSA-N	Phase 2
promazine	dopamine receptor antagonist	ADRA1A, ADRA1B, ADRA1D, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, DRD1, DRD2, DRD3, DRD4, HRH1, HTR2A, HTR2C	neurology/psychiatry	schizophrenia	CN(C)CCCN1c2ccccc2Sc2ccccc12, CN(C)CCCN1c2ccccc2Sc2ccccc12	ZGUGWUXLJSTTMA-UHFFFAOYSA-N, ZGUGWUXLJSTTMA-UHFFFAOYSA-N	Launched
promestriene	estrogen receptor agonist	ESR1	endocrinology	androgenetic alopecia	CCCOc1ccc2[C@H]3CC[C@]4(C)[C@H](CC[C@H]4[C@@H]3CCc2c1)OC	IUWKNLFTJBHTSD-AANPDWTMSA-N	Launched
promethazine	histamine receptor antagonist	HRH1	neurology/psychiatry, allergy	sedative, allergic rhinitis	CC(CN1c2ccccc2Sc2ccccc12)N(C)C, CC(CN1c2ccccc2Sc2ccccc12)N(C)C, CC(CN1c2ccccc2Sc2ccccc12)N(C)C, CC(CN1c2ccccc2Sc2ccccc12)N(C)C	PWWVAXIEGOYWEE-UHFFFAOYSA-N, PWWVAXIEGOYWEE-UHFFFAOYSA-N, PWWVAXIEGOYWEE-UHFFFAOYSA-N, PWWVAXIEGOYWEE-UHFFFAOYSA-N	Launched
pronethalol	adrenergic receptor antagonist				CC(C)NC[C@@H](O)c1ccc2ccccc2c1 |&1:5,r|	HRSANNODOVBCST-OAHLLOKOSA-N	Withdrawn
propacetamol	cyclooxygenase inhibitor	PTGS2	endocrinology, neurology/psychiatry	fever, pain relief	CCN(CC)CC(=O)Oc1ccc(NC(C)=O)cc1	QTGAJCQTLIRCFL-UHFFFAOYSA-N	Launched
propafenone	antiarrhythmic	ADRB1, ADRB2, KCNA5, KCNH2	cardiology	atrial fibrillation (AF), ventricular tachycardia (VT), ventricular arrhythmias	CCCNC[C@@H](O)COc1ccccc1C(=O)CCc1ccccc1 |&1:5,r|, CCCNC[C@@H](O)COc1ccccc1C(=O)CCc1ccccc1 |&1:5,r|, CCCNC[C@@H](O)COc1ccccc1C(=O)CCc1ccccc1 |&1:5,r|	JWHAUXFOSRPERK-GOSISDBHSA-N, JWHAUXFOSRPERK-GOSISDBHSA-N, JWHAUXFOSRPERK-GOSISDBHSA-N	Launched
propagermanium	CCR agonist, interferon receptor agonist	CCR2	infectious disease	hepatitis B	OC(=O)CC[Ge](=O)O[Ge](=O)CCC(O)=O	XEABSBMNTNXEJM-UHFFFAOYSA-N	Launched
propantheline	acetylcholine receptor antagonist	CHRM1, CHRM2, CHRM3, CHRM4	gastroenterology	peptic ulcer disease (PUD)	CC(C)[N+](C)(CCOC(=O)C1c2ccccc2Oc2ccccc12)C(C)C, CC(C)[N+](C)(CCOC(=O)C1c2ccccc2Oc2ccccc12)C(C)C, CC(C)[N+](C)(CCOC(=O)C1c2ccccc2Oc2ccccc12)C(C)C	VVWYOYDLCMFIEM-UHFFFAOYSA-N, VVWYOYDLCMFIEM-UHFFFAOYSA-N, VVWYOYDLCMFIEM-UHFFFAOYSA-N	Launched
propatylnitrate			cardiology	angina pectoris	CCC(CO[N+]([O-])=O)(CO[N+]([O-])=O)CO[N+]([O-])=O, CCC(CO[N+]([O-])=O)(CO[N+]([O-])=O)CO[N+]([O-])=O	YZZCJYJBCUJISI-UHFFFAOYSA-N, YZZCJYJBCUJISI-UHFFFAOYSA-N	Launched
propentofylline	adenosine reuptake inhibitor, phosphodiesterase inhibitor	PDE1A	neurology/psychiatry	stroke	CCCn1cnc2n(C)c(=O)n(CCCCC(C)=O)c(=O)c12, CCCn1cnc2n(C)c(=O)n(CCCCC(C)=O)c(=O)c12	RBQOQRRFDPXAGN-UHFFFAOYSA-N, RBQOQRRFDPXAGN-UHFFFAOYSA-N	Launched
propidium-iodide		ACHE			CC[N+](C)(CC)CCC[n+]1c(-c2ccccc2)c2cc(N)ccc2c2ccc(N)cc12, CC[N+](C)(CC)CCC[n+]1c(-c2ccccc2)c2cc(N)ccc2c2ccc(N)cc12	ZDWVWKDAWBGPDN-UHFFFAOYSA-O, ZDWVWKDAWBGPDN-UHFFFAOYSA-O	Preclinical
propiolactone			infectious disease	antiseptic	O=C1CCO1, O=C1CCO1	VEZXCJBBBCKRPI-UHFFFAOYSA-N, VEZXCJBBBCKRPI-UHFFFAOYSA-N	Launched
propiverine	acetylcholine receptor antagonist	CHRM1	urology	urinary incontinence	CCCOC(C(=O)OC1CCN(C)CC1)(c1ccccc1)c1ccccc1	QPCVHQBVMYCJOM-UHFFFAOYSA-N	Launched
propofol	benzodiazepine receptor agonist	FAAH, GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, SCN2A, SCN4A	neurology/psychiatry	anesthetic	CC(C)c1cccc(C(C)C)c1O, CC(C)c1cccc(C(C)C)c1O	OLBCVFGFOZPWHH-UHFFFAOYSA-N, OLBCVFGFOZPWHH-UHFFFAOYSA-N	Launched
propoxur			infectious disease	flea control	CNC(=O)Oc1ccccc1OC(C)C, CNC(=O)Oc1ccccc1OC(C)C	ISRUGXGCCGIOQO-UHFFFAOYSA-N, ISRUGXGCCGIOQO-UHFFFAOYSA-N	Launched
propoxycaine	local anesthetic		neurology/psychiatry	anesthetic	CCCOc1cc(N)ccc1C(=O)OCCN(CC)CC, CCCOc1cc(N)ccc1C(=O)OCCN(CC)CC, CCCOc1cc(N)ccc1C(=O)OCCN(CC)CC, CCCOc1cc(N)ccc1C(=O)OCCN(CC)CC	CAJIGINSTLKQMM-UHFFFAOYSA-N, CAJIGINSTLKQMM-UHFFFAOYSA-N, CAJIGINSTLKQMM-UHFFFAOYSA-N, CAJIGINSTLKQMM-UHFFFAOYSA-N	Launched
propranolol	adrenergic receptor antagonist	ADRB1, ADRB2	cardiology, neurology/psychiatry	hypertension, angina pectoris, migraine headache	CC(C)NCC(O)COc1cccc2ccccc12, CC(C)NCC(O)COc1cccc2ccccc12, CC(C)NCC(O)COc1cccc2ccccc12, CC(C)NCC(O)COc1cccc2ccccc12	AQHHHDLHHXJYJD-UHFFFAOYSA-N, AQHHHDLHHXJYJD-UHFFFAOYSA-N, AQHHHDLHHXJYJD-UHFFFAOYSA-N, AQHHHDLHHXJYJD-UHFFFAOYSA-N	Launched
propranolol-(R)	adrenergic receptor antagonist	ADRB2, ADRB3			CC(C)NC[C@@H](O)COc1cccc2ccccc12, CC(C)NC[C@@H](O)COc1cccc2ccccc12, CC(C)NC[C@@H](O)COc1cccc2ccccc12	AQHHHDLHHXJYJD-CQSZACIVSA-N, AQHHHDLHHXJYJD-CQSZACIVSA-N, AQHHHDLHHXJYJD-CQSZACIVSA-N	Preclinical
propranolol-(S)	adrenergic receptor antagonist	ADRB1, HTR1A, HTR5A, SLC10A1			CC(C)NC[C@H](O)COc1cccc2ccccc12, CC(C)NC[C@H](O)COc1cccc2ccccc12, CC(C)NC[C@H](O)COc1cccc2ccccc12, CC(C)NC[C@H](O)COc1cccc2ccccc12	AQHHHDLHHXJYJD-AWEZNQCLSA-N, AQHHHDLHHXJYJD-AWEZNQCLSA-N, AQHHHDLHHXJYJD-AWEZNQCLSA-N, AQHHHDLHHXJYJD-AWEZNQCLSA-N	Preclinical
propyl-benzoate					CCCOC(=O)c1ccccc1, CCCOC(=O)c1ccccc1	UDEWPOVQBGFNGE-UHFFFAOYSA-N, UDEWPOVQBGFNGE-UHFFFAOYSA-N	Launched
propylene-glycol					C[C@@H](O)CO |&1:1,r|	DNIAPMSPPWPWGF-GSVOUGTGSA-N	Launched
propylhexedrine	adrenergic receptor agonist		otolaryngology, endocrinology, allergy	nasal congestion, fever, allergic rhinitis	CN[C@@H](C)CC1CCCCC1 |&1:2,r|	JCRIVQIOJSSCQD-VIFPVBQESA-N	Launched
propylparaben					CCCOC(=O)c1ccc(O)cc1, CCCOC(=O)c1ccc(O)cc1	QELSKZZBTMNZEB-UHFFFAOYSA-N, QELSKZZBTMNZEB-UHFFFAOYSA-N	Launched
propylthiouracil	thyroid peroxidase inhibitor	DIO1, TPO	endocrinology	hyperthyroidism, Grave's disease, goiter	CCCc1cc(=O)[nH]c(=S)[nH]1, CCCc1cc(=O)[nH]c(=S)[nH]1	KNAHARQHSZJURB-UHFFFAOYSA-N, KNAHARQHSZJURB-UHFFFAOYSA-N	Launched
propyphenazone	anti-inflammatory agent				CC(C)c1c(C)n(C)n(-c2ccccc2)c1=O	PXWLVJLKJGVOKE-UHFFFAOYSA-N	Preclinical
proquazone	cyclooxygenase inhibitor	PTGS1, PTGS2	neurology/psychiatry	pain relief	CC(C)n1c2cc(C)ccc2c(nc1=O)-c1ccccc1, CC(C)n1c2cc(C)ccc2c(nc1=O)-c1ccccc1	JTIGKVIOEQASGT-UHFFFAOYSA-N, JTIGKVIOEQASGT-UHFFFAOYSA-N	Launched
proscillaridin-A			cardiology	congestive heart failure, cardiac arrythmia	C[C@@H]1O[C@@H](O[C@H]2CC[C@]3(C)[C@H]4CC[C@]5(C)[C@H](CC[C@]5(O)[C@@H]4CCC3=C2)c2ccc(=O)oc2)[C@H](O)[C@H](O)[C@H]1O |c:26|, C[C@@H]1O[C@@H](O[C@H]2CC[C@]3(C)[C@H]4CC[C@]5(C)[C@H](CC[C@]5(O)[C@@H]4CCC3=C2)c2ccc(=O)oc2)[C@H](O)[C@H](O)[C@H]1O |c:26|, C[C@@H]1O[C@@H](O[C@H]2CC[C@]3(C)[C@H]4CC[C@]5(C)[C@H](CC[C@]5(O)[C@@H]4CCC3=C2)c2ccc(=O)oc2)[C@H](O)[C@H](O)[C@H]1O |c:26|	MYEJFUXQJGHEQK-ALRJYLEOSA-N, MYEJFUXQJGHEQK-ALRJYLEOSA-N, MYEJFUXQJGHEQK-ALRJYLEOSA-N	Launched
protionamide			infectious disease	tuberculosis	CCCc1cc(ccn1)C(N)=S, CCCc1cc(ccn1)C(N)=S, CCCc1cc(ccn1)C(N)=S	VRDIULHPQTYCLN-UHFFFAOYSA-N, VRDIULHPQTYCLN-UHFFFAOYSA-N, VRDIULHPQTYCLN-UHFFFAOYSA-N	Launched
protirelin	thyrotropin releasing hormone receptor agonist	TRHR	radiology	thyroid function diagnostic	NC(=O)[C@@H]1CCCN1C(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H]1CCC(=O)N1	XNSAINXGIQZQOO-SRVKXCTJSA-N	Launched
protoporphyrin-IX	heme oxygenase inhibitor	HMOX1			Cc1c(C=C)c2cc3[nH]c(cc4[nH]c(cc5nc(cc1n2)c(C=C)c5C)c(C)c4CCC(O)=O)c(CCC(O)=O)c3C, Cc1c(C=C)c2cc3[nH]c(cc4[nH]c(cc5nc(cc1n2)c(C=C)c5C)c(C)c4CCC(O)=O)c(CCC(O)=O)c3C	HGXFBVDWWKPUKZ-UJJXFSCMSA-N, HGXFBVDWWKPUKZ-UJJXFSCMSA-N	Preclinical
protriptyline	tricyclic antidepressant	SLC6A2, SLC6A4	neurology/psychiatry	depression	CNCCCC1c2ccccc2C=Cc2ccccc12 |c:13|, CNCCCC1c2ccccc2C=Cc2ccccc12 |c:13|, CNCCCC1c2ccccc2C=Cc2ccccc12 |c:13|, CNCCCC1c2ccccc2C=Cc2ccccc12 |c:13|	BWPIARFWQZKAIA-UHFFFAOYSA-N, BWPIARFWQZKAIA-UHFFFAOYSA-N, BWPIARFWQZKAIA-UHFFFAOYSA-N, BWPIARFWQZKAIA-UHFFFAOYSA-N	Launched
proxodolol	adrenergic receptor antagonist				Cc1noc(COc2ccccc2OC[C@@H](O)CNC(C)(C)C)n1 |&1:15|, Cc1noc(COc2ccccc2OC[C@@H](O)CNC(C)(C)C)n1 |&1:15|	CEDZURSVVKNCSL-ZDUSSCGKSA-N, CEDZURSVVKNCSL-ZDUSSCGKSA-N	Launched
proxyfan	histamine receptor modulator	HRH3			C(COCc1ccccc1)Cc1cnc[nH]1, C(COCc1ccccc1)Cc1cnc[nH]1, C(COCc1ccccc1)Cc1cnc[nH]1	WNWALBVQAAIULR-UHFFFAOYSA-N, WNWALBVQAAIULR-UHFFFAOYSA-N, WNWALBVQAAIULR-UHFFFAOYSA-N	Preclinical
proxymetacaine	sodium channel blocker	SCN10A, SCN5A	neurology/psychiatry	anesthetic	CCCOc1ccc(cc1N)C(=O)OCCN(CC)CC, CCCOc1ccc(cc1N)C(=O)OCCN(CC)CC, CCCOc1ccc(cc1N)C(=O)OCCN(CC)CC	KCLANYCVBBTKTO-UHFFFAOYSA-N, KCLANYCVBBTKTO-UHFFFAOYSA-N, KCLANYCVBBTKTO-UHFFFAOYSA-N	Launched
Proxyphylline			pulmonary	asthma	C[C@@H](O)Cn1cnc2n(C)c(=O)n(C)c(=O)c12 |&1:1,r|, C[C@@H](O)Cn1cnc2n(C)c(=O)n(C)c(=O)c12 |&1:1,r|	KYHQZNGJUGFTGR-ZCFIWIBFSA-N, KYHQZNGJUGFTGR-ZCFIWIBFSA-N	Launched
PRT062070	JAK inhibitor, SYK inhibitor	SYK			CCS(=O)(=O)N1CCN(CC1)c1ccc(Nc2ncc(C(N)=O)c(NC3CC3)n2)cc1, CCS(=O)(=O)N1CCN(CC1)c1ccc(Nc2ncc(C(N)=O)c(NC3CC3)n2)cc1, CCS(=O)(=O)N1CCN(CC1)c1ccc(Nc2ncc(C(N)=O)c(NC3CC3)n2)cc1, CCS(=O)(=O)N1CCN(CC1)c1ccc(Nc2ncc(C(N)=O)c(NC3CC3)n2)cc1, CCS(=O)(=O)N1CCN(CC1)c1ccc(Nc2ncc(C(N)=O)c(NC3CC3)n2)cc1, CCS(=O)(=O)N1CCN(CC1)c1ccc(Nc2ncc(C(N)=O)c(NC3CC3)n2)cc1	BGLPECHZZQDNCD-UHFFFAOYSA-N, BGLPECHZZQDNCD-UHFFFAOYSA-N, BGLPECHZZQDNCD-UHFFFAOYSA-N, BGLPECHZZQDNCD-UHFFFAOYSA-N, BGLPECHZZQDNCD-UHFFFAOYSA-N, BGLPECHZZQDNCD-UHFFFAOYSA-N	Phase 2/Phase 3
PRT062607	SYK inhibitor	FGR, MAP3K9, SYK			N[C@H]1CCCC[C@H]1Nc1ncc(C(N)=O)c(Nc2cccc(c2)-n2nccn2)n1, N[C@H]1CCCC[C@H]1Nc1ncc(C(N)=O)c(Nc2cccc(c2)-n2nccn2)n1, N[C@H]1CCCC[C@H]1Nc1ncc(C(N)=O)c(Nc2cccc(c2)-n2nccn2)n1, N[C@H]1CCCC[C@H]1Nc1ncc(C(N)=O)c(Nc2cccc(c2)-n2nccn2)n1, N[C@H]1CCCC[C@H]1Nc1ncc(C(N)=O)c(Nc2cccc(c2)-n2nccn2)n1, N[C@H]1CCCC[C@H]1Nc1ncc(C(N)=O)c(Nc2cccc(c2)-n2nccn2)n1, N[C@H]1CCCC[C@H]1Nc1ncc(C(N)=O)c(Nc2cccc(c2)-n2nccn2)n1, N[C@H]1CCCC[C@H]1Nc1ncc(C(N)=O)c(Nc2cccc(c2)-n2nccn2)n1, N[C@H]1CCCC[C@H]1Nc1ncc(C(N)=O)c(Nc2cccc(c2)-n2nccn2)n1, N[C@H]1CCCC[C@H]1Nc1ncc(C(N)=O)c(Nc2cccc(c2)-n2nccn2)n1, N[C@H]1CCCC[C@H]1Nc1ncc(C(N)=O)c(Nc2cccc(c2)-n2nccn2)n1, N[C@H]1CCCC[C@H]1Nc1ncc(C(N)=O)c(Nc2cccc(c2)-n2nccn2)n1	TXGKRVFSSHPBAJ-JKSUJKDBSA-N, TXGKRVFSSHPBAJ-JKSUJKDBSA-N, TXGKRVFSSHPBAJ-JKSUJKDBSA-N, TXGKRVFSSHPBAJ-JKSUJKDBSA-N, TXGKRVFSSHPBAJ-JKSUJKDBSA-N, TXGKRVFSSHPBAJ-JKSUJKDBSA-N, TXGKRVFSSHPBAJ-JKSUJKDBSA-N, TXGKRVFSSHPBAJ-JKSUJKDBSA-N, TXGKRVFSSHPBAJ-JKSUJKDBSA-N, InChI=1S/C19H23N9O/c20-15-6-1-2-7-16(15)26-19-22-11-14(17(21)29)18(27-19)25-12-4-3-5-13(10-12)28-23-8-9-24-28/h3-5,8-11,15-16H,1-2,6-7,20H2,(H2,21,29)(H2,22,25,26,27)/t15-,16+/m0/s1, InChI=1S/C19H23N9O/c20-15-6-1-2-7-16(15)26-19-22-11-14(17(21)29)18(27-19)25-12-4-3-5-13(10-12)28-23-8-9-24-28/h3-5,8-11,15-16H,1-2,6-7,20H2,(H2,21,29)(H2,22,25,26,27)/t15-,16+/m0/s1, InChI=1S/C19H23N9O/c20-15-6-1-2-7-16(15)26-19-22-11-14(17(21)29)18(27-19)25-12-4-3-5-13(10-12)28-23-8-9-24-28/h3-5,8-11,15-16H,1-2,6-7,20H2,(H2,21,29)(H2,22,25,26,27)/t15-,16+/m0/s1	Phase 2
PRT4165	polycomb repressive complex inhibitor	PRC1			O=C1C(=Cc2cccnc2)C(=O)c2ccccc12, O=C1C(=Cc2cccnc2)C(=O)c2ccccc12, O=C1C(=Cc2cccnc2)C(=O)c2ccccc12	OMHZFEWYVFWVLI-UHFFFAOYSA-N, OMHZFEWYVFWVLI-UHFFFAOYSA-N, OMHZFEWYVFWVLI-UHFFFAOYSA-N	Preclinical
prucalopride	serotonin receptor agonist	HTR4	gastroenterology	constipation	COCCCN1CCC(CC1)NC(=O)c1cc(Cl)c(N)c2CCOc12, COCCCN1CCC(CC1)NC(=O)c1cc(Cl)c(N)c2CCOc12, COCCCN1CCC(CC1)NC(=O)c1cc(Cl)c(N)c2CCOc12, COCCCN1CCC(CC1)NC(=O)c1cc(Cl)c(N)c2CCOc12	ZPMNHBXQOOVQJL-UHFFFAOYSA-N, ZPMNHBXQOOVQJL-UHFFFAOYSA-N, ZPMNHBXQOOVQJL-UHFFFAOYSA-N, ZPMNHBXQOOVQJL-UHFFFAOYSA-N	Launched
prulifloxacin	bacterial DNA gyrase inhibitor		infectious disease, pulmonary, gastroenterology	urinary tract infections, bronchitis, diarrhea	C[C@H]1Sc2c(C(O)=O)c(=O)c3cc(F)c(cc3n12)N1CCN(Cc2oc(=O)oc2C)CC1 |&1:1,r|, C[C@H]1Sc2c(C(O)=O)c(=O)c3cc(F)c(cc3n12)N1CCN(Cc2oc(=O)oc2C)CC1 |&1:1,r|	PWNMXPDKBYZCOO-LLVKDONJSA-N, PWNMXPDKBYZCOO-LLVKDONJSA-N	Launched
pruvanserin	serotonin receptor antagonist	HTR2A, HTR2C			Fc1ccc(CCN2CCN(CC2)C(=O)c2cccc3c(c[nH]c23)C#N)cc1, Fc1ccc(CCN2CCN(CC2)C(=O)c2cccc3c(c[nH]c23)C#N)cc1, Fc1ccc(CCN2CCN(CC2)C(=O)c2cccc3c(c[nH]c23)C#N)cc1	AQRLDDAFYYAIJP-UHFFFAOYSA-N, AQRLDDAFYYAIJP-UHFFFAOYSA-N, AQRLDDAFYYAIJP-UHFFFAOYSA-N	Phase 2
PRX-07034	serotonin receptor antagonist				COc1cc(Cl)cc([C@H](C)Nc2cc(ccc2S(C)(=O)=O)N2CCNCC2)c1OC |&1:8,r|	BSLXKMCHXRCBIH-AWEZNQCLSA-N	Phase 1
PRX-08066	serotonin receptor antagonist	HTR2B			Fc1ccc(CN2CCC(CC2)Nc2ncnc3sc(Cl)cc23)cc1C#N, Fc1ccc(CN2CCC(CC2)Nc2ncnc3sc(Cl)cc23)cc1C#N, Fc1ccc(CN2CCC(CC2)Nc2ncnc3sc(Cl)cc23)cc1C#N	IENZFHBNCRQMNP-UHFFFAOYSA-N, IENZFHBNCRQMNP-UHFFFAOYSA-N, IENZFHBNCRQMNP-UHFFFAOYSA-N	Phase 2
PSB-06126	NTPDase inhibitor	ENTPD3			Nc1c2C(=O)c3ccccc3C(=O)c2c(Nc2cccc3ccccc23)cc1S(O)(=O)=O, Nc1c2C(=O)c3ccccc3C(=O)c2c(Nc2cccc3ccccc23)cc1S(O)(=O)=O, Nc1c2C(=O)c3ccccc3C(=O)c2c(Nc2cccc3ccccc23)cc1S(O)(=O)=O, Nc1c2C(=O)c3ccccc3C(=O)c2c(Nc2cccc3ccccc23)cc1S(O)(=O)=O, Nc1c2C(=O)c3ccccc3C(=O)c2c(Nc2cccc3ccccc23)cc1S(O)(=O)=O, Nc1c2C(=O)c3ccccc3C(=O)c2c(Nc2cccc3ccccc23)cc1S(O)(=O)=O, Nc1c2C(=O)c3ccccc3C(=O)c2c(Nc2cccc3ccccc23)cc1S(O)(=O)=O, Nc1c2C(=O)c3ccccc3C(=O)c2c(Nc2cccc3ccccc23)cc1S(O)(=O)=O	ZHQRPIRGSWEALJ-UHFFFAOYSA-N, ZHQRPIRGSWEALJ-UHFFFAOYSA-N, ZHQRPIRGSWEALJ-UHFFFAOYSA-N, ZHQRPIRGSWEALJ-UHFFFAOYSA-N, ZHQRPIRGSWEALJ-UHFFFAOYSA-N, ZHQRPIRGSWEALJ-UHFFFAOYSA-N, ZHQRPIRGSWEALJ-UHFFFAOYSA-N, ZHQRPIRGSWEALJ-UHFFFAOYSA-N	Preclinical
PSB-11	adenosine receptor antagonist	ADORA1, ADORA2A, ADORA3			CC[C@@H]1CN2C(=N1)c1nc([nH]c1N(C)C2=O)-c1ccccc1 |c:5|, CC[C@@H]1CN2C(=N1)c1nc([nH]c1N(C)C2=O)-c1ccccc1 |c:5|, CC[C@@H]1CN2C(=N1)c1nc([nH]c1N(C)C2=O)-c1ccccc1 |c:5|, CC[C@@H]1CN2C(=N1)c1nc([nH]c1N(C)C2=O)-c1ccccc1 |c:5|, CC[C@@H]1CN2C(=N1)c1nc([nH]c1N(C)C2=O)-c1ccccc1 |c:5|	RGDHRCXUMURWBJ-LLVKDONJSA-N, RGDHRCXUMURWBJ-LLVKDONJSA-N, RGDHRCXUMURWBJ-LLVKDONJSA-N, RGDHRCXUMURWBJ-LLVKDONJSA-N, RGDHRCXUMURWBJ-LLVKDONJSA-N	Preclinical
PSB-1115	adenosine receptor antagonist	ADORA1, ADORA2B, ADORA3			CCCn1c(=O)[nH]c2nc([nH]c2c1=O)-c1ccc(cc1)S(O)(=O)=O, CCCn1c(=O)[nH]c2nc([nH]c2c1=O)-c1ccc(cc1)S(O)(=O)=O, CCCn1c(=O)[nH]c2nc([nH]c2c1=O)-c1ccc(cc1)S(O)(=O)=O, CCCn1c(=O)[nH]c2nc([nH]c2c1=O)-c1ccc(cc1)S(O)(=O)=O	UYDRRQPGDSIMNU-UHFFFAOYSA-N, UYDRRQPGDSIMNU-UHFFFAOYSA-N, UYDRRQPGDSIMNU-UHFFFAOYSA-N, UYDRRQPGDSIMNU-UHFFFAOYSA-N	Preclinical
PSB-36	adenosine receptor antagonist	ADORA1, ADORA2A, ADORA2B, ADORA3			[H][C@]12C[C@H]3C[C@]([H])(C[C@]3(C1)c1nc3n(CCCO)c(=O)n(CCCC)c(=O)c3[nH]1)C2 |r,THB:9:1:4:7.8|	CIBIXJYFYPFMTN-FZUGUKJMSA-N	Preclinical
PSB-603	adenosine receptor antagonist	ADORA1, ADORA2A, ADORA2B, ADORA3			CCCn1c(=O)[nH]c2nc([nH]c2c1=O)-c1ccc(cc1)S(=O)(=O)N1CCN(CC1)c1ccc(Cl)cc1, CCCn1c(=O)[nH]c2nc([nH]c2c1=O)-c1ccc(cc1)S(=O)(=O)N1CCN(CC1)c1ccc(Cl)cc1, CCCn1c(=O)[nH]c2nc([nH]c2c1=O)-c1ccc(cc1)S(=O)(=O)N1CCN(CC1)c1ccc(Cl)cc1, CCCn1c(=O)[nH]c2nc([nH]c2c1=O)-c1ccc(cc1)S(=O)(=O)N1CCN(CC1)c1ccc(Cl)cc1	OVHCTHHFOHMNFV-UHFFFAOYSA-N, OVHCTHHFOHMNFV-UHFFFAOYSA-N, OVHCTHHFOHMNFV-UHFFFAOYSA-N, OVHCTHHFOHMNFV-UHFFFAOYSA-N	Preclinical
PSI-6130	RNA polymerase inhibitor				C[C@@]1(F)[C@H](O)[C@@H](CO)O[C@H]1n1ccc(N)nc1=O, C[C@@]1(F)[C@H](O)[C@@H](CO)O[C@H]1n1ccc(N)nc1=O	NYPIRLYMDJMKGW-VPCXQMTMSA-N, NYPIRLYMDJMKGW-VPCXQMTMSA-N	Phase 1
PSI-697	P selectin inhibitor				OC(=O)c1c(O)c(Cc2ccc(Cl)cc2)nc2c3CCCCc3ccc12	DIEPFYNZGUUVHD-UHFFFAOYSA-N	Phase 1
PSI-7976	HCV inhibitor				CC(C)OC(=O)[C@H](C)N[P@@](=O)(OC[C@H]1O[C@@H](n2ccc(=O)[nH]c2=O)[C@](C)(F)[C@@H]1O)Oc1ccccc1, CC(C)OC(=O)[C@H](C)N[P@@](=O)(OC[C@H]1O[C@@H](n2ccc(=O)[nH]c2=O)[C@](C)(F)[C@@H]1O)Oc1ccccc1, CC(C)OC(=O)[C@H](C)N[P@@](=O)(OC[C@H]1O[C@@H](n2ccc(=O)[nH]c2=O)[C@](C)(F)[C@@H]1O)Oc1ccccc1	TTZHDVOVKQGIBA-YBSJRAAASA-N, TTZHDVOVKQGIBA-YBSJRAAASA-N, TTZHDVOVKQGIBA-YBSJRAAASA-N	Preclinical
PSN-375963	glucose dependent insulinotropic receptor agonist	GPR119			CCCCC1CCC(CC1)c1nc(no1)-c1ccncc1, CCCCC1CCC(CC1)c1nc(no1)-c1ccncc1, CCCCC1CCC(CC1)c1nc(no1)-c1ccncc1	OAVLEYPTWABFLF-UHFFFAOYSA-N, OAVLEYPTWABFLF-UHFFFAOYSA-N, OAVLEYPTWABFLF-UHFFFAOYSA-N	Preclinical
PSNCBAM-1	cannabinoid receptor modulator	CNR1			Clc1ccc(NC(=O)Nc2cccc(c2)-c2cccc(n2)N2CCCC2)cc1, Clc1ccc(NC(=O)Nc2cccc(c2)-c2cccc(n2)N2CCCC2)cc1	HDAYFSFWIPRJSO-UHFFFAOYSA-N, HDAYFSFWIPRJSO-UHFFFAOYSA-N	Preclinical
psoralen		MAOA, MAOB	dermatology	psoriasis, eczema, vitiligo	O=c1ccc2cc3ccoc3cc2o1	ZCCUUQDIBDJBTK-UHFFFAOYSA-N	Launched
PS178990	androgen receptor modulator	AR			Cc1c(Cl)c(ccc1N1C(=O)[C@@H]2[C@H](O)CCN2C1=O)C#N, Cc1c(Cl)c(ccc1N1C(=O)[C@@H]2[C@H](O)CCN2C1=O)C#N, Cc1c(Cl)c(ccc1N1C(=O)[C@@H]2[C@H](O)CCN2C1=O)C#N, Cc1c(Cl)c(ccc1N1C(=O)[C@@H]2[C@H](O)CCN2C1=O)C#N, Cc1c(Cl)c(ccc1N1C(=O)[C@@H]2[C@H](O)CCN2C1=O)C#N	KEJORAMIZFOODM-PWSUYJOCSA-N, KEJORAMIZFOODM-PWSUYJOCSA-N, KEJORAMIZFOODM-PWSUYJOCSA-N, KEJORAMIZFOODM-PWSUYJOCSA-N, KEJORAMIZFOODM-PWSUYJOCSA-N	Phase 1
PT-2385	hypoxia inducible factor inhibitor	EPAS1			CS(=O)(=O)c1ccc(Oc2cc(F)cc(c2)C#N)c2CC(F)(F)[C@@H](O)c12, CS(=O)(=O)c1ccc(Oc2cc(F)cc(c2)C#N)c2CC(F)(F)[C@@H](O)c12, CS(=O)(=O)c1ccc(Oc2cc(F)cc(c2)C#N)c2CC(F)(F)[C@@H](O)c12	ONBSHRSJOPSEGS-INIZCTEOSA-N, ONBSHRSJOPSEGS-INIZCTEOSA-N, ONBSHRSJOPSEGS-INIZCTEOSA-N	Phase 1
PTC-028	BMI-1 inhibitor				Cc1nc2cc(F)c(F)cc2n1-c1cncc(Nc2ccc(cc2)C(F)(F)F)n1	JEZGPBWIZWPDHP-UHFFFAOYSA-N	Preclinical
PTC-209	BMI-1 inhibitor				COc1cc(Br)c(Nc2nc(cs2)-c2c(C)nc3ncccn23)c(Br)c1, COc1cc(Br)c(Nc2nc(cs2)-c2c(C)nc3ncccn23)c(Br)c1, COc1cc(Br)c(Nc2nc(cs2)-c2c(C)nc3ncccn23)c(Br)c1, COc1cc(Br)c(Nc2nc(cs2)-c2c(C)nc3ncccn23)c(Br)c1, COc1cc(Br)c(Nc2nc(cs2)-c2c(C)nc3ncccn23)c(Br)c1, COc1cc(Br)c(Nc2nc(cs2)-c2c(C)nc3ncccn23)c(Br)c1	XVOOCQSWCCRVDY-UHFFFAOYSA-N, XVOOCQSWCCRVDY-UHFFFAOYSA-N, XVOOCQSWCCRVDY-UHFFFAOYSA-N, XVOOCQSWCCRVDY-UHFFFAOYSA-N, XVOOCQSWCCRVDY-UHFFFAOYSA-N, XVOOCQSWCCRVDY-UHFFFAOYSA-N	Preclinical
pterostilbene	cyclooxygenase inhibitor, PPAR receptor agonist	PTGS2			COc1cc(OC)cc(\C=C\c2ccc(O)cc2)c1	VLEUZFDZJKSGMX-ONEGZZNKSA-N	Phase 2/Phase 3
PU-H71	HSP inhibitor	HSP90AA1			CC(C)NCCCn1c(Sc2cc3OCOc3cc2I)nc2c(N)ncnc12, CC(C)NCCCn1c(Sc2cc3OCOc3cc2I)nc2c(N)ncnc12, CC(C)NCCCn1c(Sc2cc3OCOc3cc2I)nc2c(N)ncnc12	SUPVGFZUWFMATN-UHFFFAOYSA-N, SUPVGFZUWFMATN-UHFFFAOYSA-N, SUPVGFZUWFMATN-UHFFFAOYSA-N	Phase 1
puerarin	serotonin receptor antagonist				OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)c1c(O)ccc2c1occ(-c1ccc(O)cc1)c2=O, OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)c1c(O)ccc2c1occ(-c1ccc(O)cc1)c2=O, OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)c1c(O)ccc2c1occ(-c1ccc(O)cc1)c2=O	HKEAFJYKMMKDOR-VPRICQMDSA-N, HKEAFJYKMMKDOR-VPRICQMDSA-N, HKEAFJYKMMKDOR-VPRICQMDSA-N	Phase 2
pumosetrag	serotonin receptor agonist	HTR3A, HTR4			O=C(N[C@H]1CN2CCC1CC2)c1c[nH]c2ccsc2c1=O	AFUWQWYPPZFWCO-LBPRGKRZSA-N	Phase 2
purmorphamine	smoothened receptor agonist	SMO			C1CCC(CC1)n1cnc2c(Nc3ccc(cc3)N3CCOCC3)nc(Oc3cccc4ccccc34)nc12, C1CCC(CC1)n1cnc2c(Nc3ccc(cc3)N3CCOCC3)nc(Oc3cccc4ccccc34)nc12, C1CCC(CC1)n1cnc2c(Nc3ccc(cc3)N3CCOCC3)nc(Oc3cccc4ccccc34)nc12, C1CCC(CC1)n1cnc2c(Nc3ccc(cc3)N3CCOCC3)nc(Oc3cccc4ccccc34)nc12, C1CCC(CC1)n1cnc2c(Nc3ccc(cc3)N3CCOCC3)nc(Oc3cccc4ccccc34)nc12, C1CCC(CC1)n1cnc2c(Nc3ccc(cc3)N3CCOCC3)nc(Oc3cccc4ccccc34)nc12	FYBHCRQFSFYWPY-UHFFFAOYSA-N, FYBHCRQFSFYWPY-UHFFFAOYSA-N, FYBHCRQFSFYWPY-UHFFFAOYSA-N, FYBHCRQFSFYWPY-UHFFFAOYSA-N, FYBHCRQFSFYWPY-UHFFFAOYSA-N, FYBHCRQFSFYWPY-UHFFFAOYSA-N	Preclinical
puromycin	protein synthesis inhibitor	NHP2L1, RPL10L, RPL11, RPL13A, RPL15, RPL19, RPL23, RPL23A, RPL26L1, RPL3, RPL37, RPL8, RSL24D1			COc1ccc(C[C@H](N)C(=O)N[C@@H]2[C@@H](CO)O[C@H]([C@@H]2O)n2cnc3c(ncnc23)N(C)C)cc1	RXWNCPJZOCPEPQ-NVWDDTSBSA-N	Preclinical
purvalanol-A	CDK inhibitor	CDK1, CDK2, CDK4, CDK5, CSNK1G3, RPS6KA1, SRC			CC(C)[C@H](CO)Nc1nc(Nc2cccc(Cl)c2)c2ncn(C(C)C)c2n1, CC(C)[C@H](CO)Nc1nc(Nc2cccc(Cl)c2)c2ncn(C(C)C)c2n1, CC(C)[C@H](CO)Nc1nc(Nc2cccc(Cl)c2)c2ncn(C(C)C)c2n1, CC(C)[C@H](CO)Nc1nc(Nc2cccc(Cl)c2)c2ncn(C(C)C)c2n1, CC(C)[C@H](CO)Nc1nc(Nc2cccc(Cl)c2)c2ncn(C(C)C)c2n1	PMXCMJLOPOFPBT-HNNXBMFYSA-N, PMXCMJLOPOFPBT-HNNXBMFYSA-N, PMXCMJLOPOFPBT-HNNXBMFYSA-N, PMXCMJLOPOFPBT-HNNXBMFYSA-N, PMXCMJLOPOFPBT-HNNXBMFYSA-N	Preclinical
purvalanol-B	tyrosine kinase inhibitor	CDK2, CDK4, CDK5, MAPK1, MAPK3, SRPK2			CC(C)[C@H](CO)Nc1nc(Nc2ccc(C(O)=O)c(Cl)c2)c2ncn(C(C)C)c2n1, CC(C)[C@H](CO)Nc1nc(Nc2ccc(C(O)=O)c(Cl)c2)c2ncn(C(C)C)c2n1, CC(C)[C@H](CO)Nc1nc(Nc2ccc(C(O)=O)c(Cl)c2)c2ncn(C(C)C)c2n1, CC(C)[C@H](CO)Nc1nc(Nc2ccc(C(O)=O)c(Cl)c2)c2ncn(C(C)C)c2n1	ZKDXRFMOHZVXSG-HNNXBMFYSA-N, ZKDXRFMOHZVXSG-HNNXBMFYSA-N, ZKDXRFMOHZVXSG-HNNXBMFYSA-N, ZKDXRFMOHZVXSG-HNNXBMFYSA-N	Preclinical
putrescine	tissue transglutaminase inhibitor	AMD1, KCNJ4, ODC1			NCCCCN	KIDHWZJUCRJVML-UHFFFAOYSA-N	Phase 2
PX-12	thioredoxin inhibitor	CNR1, TXN			CC[C@@H](C)SSc1ncc[nH]1 |&1:2,r|	BPBPYQWMFCTCNG-ZCFIWIBFSA-N	Phase 2
PX-478	hypoxia inducible factor inhibitor				N[C@@H](Cc1ccc(cc1)[N+]([O-])(CCCl)CCCl)C(O)=O |&1:1|, N[C@@H](Cc1ccc(cc1)[N+]([O-])(CCCl)CCCl)C(O)=O |&1:1|, N[C@@H](Cc1ccc(cc1)[N+]([O-])(CCCl)CCCl)C(O)=O |&1:1|	GSKQMLGAUOTSKT-LBPRGKRZSA-N, GSKQMLGAUOTSKT-LBPRGKRZSA-N, GSKQMLGAUOTSKT-LBPRGKRZSA-N	Phase 1
PYM50028	neurotrophic agent				C[C@H]1[C@H]2[C@H](C[C@H]3[C@@H]4CC[C@@H]5C[C@@H](O)CC[C@]5(C)[C@H]4CC[C@]23C)O[C@]11CC[C@H](C)CO1, C[C@H]1[C@H]2[C@H](C[C@H]3[C@@H]4CC[C@@H]5C[C@@H](O)CC[C@]5(C)[C@H]4CC[C@]23C)O[C@]11CC[C@H](C)CO1	GMBQZIIUCVWOCD-WWASVFFGSA-N, GMBQZIIUCVWOCD-WWASVFFGSA-N	Phase 2
PYR-41	ubiquitin activating enzyme inhibitor				CCOC(=O)c1ccc(cc1)N1NC(=O)\C(=C\c2ccc(o2)[N+]([O-])=O)C1=O, CCOC(=O)c1ccc(cc1)N1NC(=O)\C(=C\c2ccc(o2)[N+]([O-])=O)C1=O, CCOC(=O)c1ccc(cc1)N1NC(=O)\C(=C\c2ccc(o2)[N+]([O-])=O)C1=O	ARGIPZKQJGFSGQ-LCYFTJDESA-N, ARGIPZKQJGFSGQ-LCYFTJDESA-N, ARGIPZKQJGFSGQ-LCYFTJDESA-N	Preclinical
pyrantel	acetylcholine receptor agonist, nicotinic receptor agonist		infectious disease	gastrointestinal roundworms	OC(=O)c1cc2ccccc2c(Cc2c(O)c(cc3ccccc23)C(O)=O)c1O	WLJNZVDCPSBLRP-UHFFFAOYSA-N	Launched
pyrantel-pamoate	neuromuscular blocker		infectious disease	hookworm, tapeworm	CN1CCCN=C1\C=C\c1cccs1 |c:5|, CN1CCCN=C1\C=C\c1cccs1 |c:5|, CN1CCCN=C1\C=C\c1cccs1 |c:5|, CN1CCCN=C1\C=C\c1cccs1 |c:5|, CN1CCCN=C1\C=C\c1cccs1 |c:5|, CN1CCCN=C1\C=C\c1cccs1 |c:5|	YSAUAVHXTIETRK-AATRIKPKSA-N, YSAUAVHXTIETRK-AATRIKPKSA-N, YSAUAVHXTIETRK-AATRIKPKSA-N, YSAUAVHXTIETRK-AATRIKPKSA-N, YSAUAVHXTIETRK-AATRIKPKSA-N, YSAUAVHXTIETRK-AATRIKPKSA-N	Launched
pyrazinamide	fatty acid synthase inhibitor	FASN	infectious disease	tuberculosis	NC(=O)c1cnccn1, NC(=O)c1cnccn1	IPEHBUMCGVEMRF-UHFFFAOYSA-N, IPEHBUMCGVEMRF-UHFFFAOYSA-N	Launched
pyrazinoylguanidine	diuretic				NC(=N)NC(=O)c1cnccn1	WNBSDCKJFDZMHT-UHFFFAOYSA-N	Phase 1
pyrazolanthrone	JNK inhibitor	MAPK10, MAPK8, MAPK8IP1, MAPK9, TTK			O=C1c2ccccc2-c2[nH]nc3cccc1c23, O=C1c2ccccc2-c2[nH]nc3cccc1c23, O=C1c2ccccc2-c2[nH]nc3cccc1c23, O=C1c2ccccc2-c2[nH]nc3cccc1c23, O=C1c2ccccc2-c2[nH]nc3cccc1c23	ACPOUJIDANTYHO-UHFFFAOYSA-N, ACPOUJIDANTYHO-UHFFFAOYSA-N, ACPOUJIDANTYHO-UHFFFAOYSA-N, ACPOUJIDANTYHO-UHFFFAOYSA-N, ACPOUJIDANTYHO-UHFFFAOYSA-N	Preclinical
pyrazoloacridine	topoisomerase inhibitor	TOP1, TOP2A			COc1ccc2nc3c(ccc4n(CCCN(C)C)[nH]c(c34)c2c1)[N+]([O-])=O	HVRZAFDJOWIDMM-UHFFFAOYSA-N	Phase 2
pyrethrins			infectious disease	flea control	CC(C)=C[C@@H]1[C@@H](C(=O)O[C@H]2CC(=O)C(C\C=C/C=C)=C2C)C1(C)C |c:18|	ROVGZAWFACYCSP-VUMXUWRFSA-N	Launched
pyridoxal		PDXK	neurology/psychiatry	epilepsy	Cc1ncc(CO)c(C=O)c1O	RADKZDMFGJYCBB-UHFFFAOYSA-N	Launched
pyridoxal-isonicotinoyl-hydrazone	apoptosis stimulant				Cc1ncc(CO)c(\C=N\NC(=O)c2ccncc2)c1O, Cc1ncc(CO)c(\C=N\NC(=O)c2ccncc2)c1O	BQYIXOPJPLGCRZ-REZTVBANSA-N, BQYIXOPJPLGCRZ-REZTVBANSA-N	Phase 2
pyridoxamine	AGE inhibitor				Cc1ncc(CO)c(CN)c1O	NHZMQXZHNVQTQA-UHFFFAOYSA-N	Phase 3
pyridoxine	vitamin B	DDC, PDXK	metabolism	vitamin B6 deficiency	Cc1ncc(CO)c(CO)c1O, Cc1ncc(CO)c(CO)c1O	LXNHXLLTXMVWPM-UHFFFAOYSA-N, LXNHXLLTXMVWPM-UHFFFAOYSA-N	Launched
pyrimethamine	dihydrofolate reductase inhibitor	DHFR, SLC47A1	infectious disease	malaria	CCc1nc(N)nc(N)c1-c1ccc(Cl)cc1, CCc1nc(N)nc(N)c1-c1ccc(Cl)cc1, CCc1nc(N)nc(N)c1-c1ccc(Cl)cc1, CCc1nc(N)nc(N)c1-c1ccc(Cl)cc1, CCc1nc(N)nc(N)c1-c1ccc(Cl)cc1, CCc1nc(N)nc(N)c1-c1ccc(Cl)cc1, CCc1nc(N)nc(N)c1-c1ccc(Cl)cc1, CCc1nc(N)nc(N)c1-c1ccc(Cl)cc1	WKSAUQYGYAYLPV-UHFFFAOYSA-N, WKSAUQYGYAYLPV-UHFFFAOYSA-N, WKSAUQYGYAYLPV-UHFFFAOYSA-N, WKSAUQYGYAYLPV-UHFFFAOYSA-N, WKSAUQYGYAYLPV-UHFFFAOYSA-N, WKSAUQYGYAYLPV-UHFFFAOYSA-N, WKSAUQYGYAYLPV-UHFFFAOYSA-N, WKSAUQYGYAYLPV-UHFFFAOYSA-N	Launched
pyrintegrin	integrin signaling activator				Oc1ccc2N(CCCc2c1)c1ccnc(Nc2ccc(cc2)S(=O)(=O)NCC2CC2)n1, Oc1ccc2N(CCCc2c1)c1ccnc(Nc2ccc(cc2)S(=O)(=O)NCC2CC2)n1	QRJTZIJWDLJKQO-UHFFFAOYSA-N, QRJTZIJWDLJKQO-UHFFFAOYSA-N	Preclinical
pyrithione-zinc	ATP synthase inhibitor	KCNQ1, KCNQ2, KCNQ4, KCNQ5	dermatology	dandruff, cosmetic	O1[n+]2ccccc2S[Zn]11O[n+]2ccccc2S1, O1[n+]2ccccc2S[Zn]11O[n+]2ccccc2S1, O1[n+]2ccccc2S[Zn]11O[n+]2ccccc2S1, O1[n+]2ccccc2S[Zn]11O[n+]2ccccc2S1, O1[n+]2ccccc2S[Zn]11O[n+]2ccccc2S1, O1[n+]2ccccc2S[Zn]11O[n+]2ccccc2S1	KTIHEFSORPLWRR-UHFFFAOYSA-L, KTIHEFSORPLWRR-UHFFFAOYSA-L, KTIHEFSORPLWRR-UHFFFAOYSA-L, KTIHEFSORPLWRR-UHFFFAOYSA-L, KTIHEFSORPLWRR-UHFFFAOYSA-L, KTIHEFSORPLWRR-UHFFFAOYSA-L	Launched
pyrithyldione	psychoactive drug				CCC1(CC)C(=O)NC=CC1=O |c:8|	NZASCBIBXNPDMH-UHFFFAOYSA-N	Withdrawn
pyritinol			rheumatology, neurology/psychiatry	rheumatoid arthritis, senile dementia	Cc1ncc(CSSCc2cnc(C)c(O)c2CO)c(CO)c1O, Cc1ncc(CSSCc2cnc(C)c(O)c2CO)c(CO)c1O	SIXLXDIJGIWWFU-UHFFFAOYSA-N, SIXLXDIJGIWWFU-UHFFFAOYSA-N	Launched
pyronaridine	antimalarial agent				COc1ccc2nc3cc(Cl)ccc3c(Nc3cc(CN4CCCC4)c(O)c(CN4CCCC4)c3)c2n1, COc1ccc2nc3cc(Cl)ccc3c(Nc3cc(CN4CCCC4)c(O)c(CN4CCCC4)c3)c2n1	DJUFPMUQJKWIJB-UHFFFAOYSA-N, DJUFPMUQJKWIJB-UHFFFAOYSA-N	Phase 3
pyrotinib	kinase inhibitor				CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4ccccn4)c(Cl)c3)c2cc1NC(=O)\C=C\[C@H]1CCCN1C	SADXACCFNXBCFY-IYNHSRRRSA-N	Phase 3
pyroxamide	HDAC inhibitor	HDAC1			ONC(=O)CCCCCCC(=O)Nc1cccnc1, ONC(=O)CCCCCCC(=O)Nc1cccnc1, ONC(=O)CCCCCCC(=O)Nc1cccnc1, ONC(=O)CCCCCCC(=O)Nc1cccnc1, ONC(=O)CCCCCCC(=O)Nc1cccnc1, ONC(=O)CCCCCCC(=O)Nc1cccnc1, ONC(=O)CCCCCCC(=O)Nc1cccnc1	PTJGLFIIZFVFJV-UHFFFAOYSA-N, PTJGLFIIZFVFJV-UHFFFAOYSA-N, PTJGLFIIZFVFJV-UHFFFAOYSA-N, PTJGLFIIZFVFJV-UHFFFAOYSA-N, PTJGLFIIZFVFJV-UHFFFAOYSA-N, PTJGLFIIZFVFJV-UHFFFAOYSA-N, PTJGLFIIZFVFJV-UHFFFAOYSA-N	Phase 1
pyrrolidine-dithiocarbamate	NFkB pathway inhibitor	HSD11B1, RELA			SC(=S)N1CCCC1, SC(=S)N1CCCC1	VSWDORGPIHIGNW-UHFFFAOYSA-N, VSWDORGPIHIGNW-UHFFFAOYSA-N	Preclinical
pyrvinium-pamoate	androgen receptor antagonist	AR	infectious disease	pinworm	CN(C)c1ccc2[n+](C)c(\C=C\c3cc(C)n(c3C)-c3ccccc3)ccc2c1, CN(C)c1ccc2[n+](C)c(\C=C\c3cc(C)n(c3C)-c3ccccc3)ccc2c1	QMHSXPLYMTVAMK-UHFFFAOYSA-N, QMHSXPLYMTVAMK-UHFFFAOYSA-N	Launched
PZ-2891	pantothenate kinase activator				CC(C)c1ccc(CC(=O)N2CCN(CC2)c2ccc(nn2)C#N)cc1	LGWDVWIZDPGCFG-UHFFFAOYSA-N	Preclinical
P22077	ubiquitin specific protease inhibitor	USP7			CC(=O)c1cc(c(Sc2ccc(F)cc2F)s1)[N+]([O-])=O, CC(=O)c1cc(c(Sc2ccc(F)cc2F)s1)[N+]([O-])=O, CC(=O)c1cc(c(Sc2ccc(F)cc2F)s1)[N+]([O-])=O, CC(=O)c1cc(c(Sc2ccc(F)cc2F)s1)[N+]([O-])=O, CC(=O)c1cc(c(Sc2ccc(F)cc2F)s1)[N+]([O-])=O, CC(=O)c1cc(c(Sc2ccc(F)cc2F)s1)[N+]([O-])=O, CC(=O)c1cc(c(Sc2ccc(F)cc2F)s1)[N+]([O-])=O, CC(=O)c1cc(c(Sc2ccc(F)cc2F)s1)[N+]([O-])=O, CC(=O)c1cc(c(Sc2ccc(F)cc2F)s1)[N+]([O-])=O, CC(=O)c1cc(c(Sc2ccc(F)cc2F)s1)[N+]([O-])=O	RMAMGGNACJHXHO-UHFFFAOYSA-N, RMAMGGNACJHXHO-UHFFFAOYSA-N, RMAMGGNACJHXHO-UHFFFAOYSA-N, RMAMGGNACJHXHO-UHFFFAOYSA-N, RMAMGGNACJHXHO-UHFFFAOYSA-N, RMAMGGNACJHXHO-UHFFFAOYSA-N, RMAMGGNACJHXHO-UHFFFAOYSA-N, RMAMGGNACJHXHO-UHFFFAOYSA-N, RMAMGGNACJHXHO-UHFFFAOYSA-N, RMAMGGNACJHXHO-UHFFFAOYSA-N	Preclinical
P276-00	CDK inhibitor	CDK1, CDK4, CDK9			CN1CC[C@H]([C@@H]1CO)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl, CN1CC[C@H]([C@@H]1CO)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl, CN1CC[C@H]([C@@H]1CO)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl, CN1CC[C@H]([C@@H]1CO)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl	QLUYMIVVAYRECT-OCCSQVGLSA-N, QLUYMIVVAYRECT-OCCSQVGLSA-N, QLUYMIVVAYRECT-OCCSQVGLSA-N, QLUYMIVVAYRECT-OCCSQVGLSA-N	Phase 2
P5091	ubiquitin specific protease inhibitor	USP7			CC(=O)c1cc(c(Sc2cccc(Cl)c2Cl)s1)[N+]([O-])=O, CC(=O)c1cc(c(Sc2cccc(Cl)c2Cl)s1)[N+]([O-])=O, CC(=O)c1cc(c(Sc2cccc(Cl)c2Cl)s1)[N+]([O-])=O, CC(=O)c1cc(c(Sc2cccc(Cl)c2Cl)s1)[N+]([O-])=O, CC(=O)c1cc(c(Sc2cccc(Cl)c2Cl)s1)[N+]([O-])=O, CC(=O)c1cc(c(Sc2cccc(Cl)c2Cl)s1)[N+]([O-])=O, CC(=O)c1cc(c(Sc2cccc(Cl)c2Cl)s1)[N+]([O-])=O, CC(=O)c1cc(c(Sc2cccc(Cl)c2Cl)s1)[N+]([O-])=O	LKZLGMAAKNEGCH-UHFFFAOYSA-N, LKZLGMAAKNEGCH-UHFFFAOYSA-N, LKZLGMAAKNEGCH-UHFFFAOYSA-N, LKZLGMAAKNEGCH-UHFFFAOYSA-N, LKZLGMAAKNEGCH-UHFFFAOYSA-N, LKZLGMAAKNEGCH-UHFFFAOYSA-N, LKZLGMAAKNEGCH-UHFFFAOYSA-N, LKZLGMAAKNEGCH-UHFFFAOYSA-N	Preclinical
P7C3	NAMPT inhibitor	NAMPT			O[C@@H](CNc1ccccc1)Cn1c2ccc(Br)cc2c2cc(Br)ccc12 |&1:1,r|, O[C@@H](CNc1ccccc1)Cn1c2ccc(Br)cc2c2cc(Br)ccc12 |&1:1,r|	FZHHRERIIVOATI-KRWDZBQOSA-N, FZHHRERIIVOATI-KRWDZBQOSA-N	Preclinical
Q-203	ATP synthase inhibitor				CCc1nc2ccc(Cl)cn2c1C(=O)NCc1ccc(cc1)N1CCC(CC1)c1ccc(OC(F)(F)F)cc1, CCc1nc2ccc(Cl)cn2c1C(=O)NCc1ccc(cc1)N1CCC(CC1)c1ccc(OC(F)(F)F)cc1	OJICYBSWSZGRFB-UHFFFAOYSA-N, OJICYBSWSZGRFB-UHFFFAOYSA-N	Phase 2
quazinone	phosphodiesterase inhibitor	PDE3A, PDE3B			CC1N2Cc3c(Cl)cccc3NC2=NC1=O |c:14|, CC1N2Cc3c(Cl)cccc3NC2=NC1=O |c:14|, CC1N2Cc3c(Cl)cccc3NC2=NC1=O |c:14|	BHZFZYLBVSWUMT-UHFFFAOYSA-N, BHZFZYLBVSWUMT-UHFFFAOYSA-N, BHZFZYLBVSWUMT-UHFFFAOYSA-N	Phase 2
quercetin	polar auxin transport inhibitor	ATP5A1, ATP5B, ATP5C1, HCK, HIBCH, PIK3CG, PIM1, STK17B, UGT3A1	neurology/psychiatry, allergy	fatigue, allergic rhinitis, drowsiness	Oc1cc(O)c2c(c1)oc(-c1ccc(O)c(O)c1)c(O)c2=O, Oc1cc(O)c2c(c1)oc(-c1ccc(O)c(O)c1)c(O)c2=O, Oc1cc(O)c2c(c1)oc(-c1ccc(O)c(O)c1)c(O)c2=O, Oc1cc(O)c2c(c1)oc(-c1ccc(O)c(O)c1)c(O)c2=O, Oc1cc(O)c2c(c1)oc(-c1ccc(O)c(O)c1)c(O)c2=O, Oc1cc(O)c2c(c1)oc(-c1ccc(O)c(O)c1)c(O)c2=O, Oc1cc(O)c2c(c1)oc(-c1ccc(O)c(O)c1)c(O)c2=O	REFJWTPEDVJJIY-UHFFFAOYSA-N, REFJWTPEDVJJIY-UHFFFAOYSA-N, REFJWTPEDVJJIY-UHFFFAOYSA-N, REFJWTPEDVJJIY-UHFFFAOYSA-N, REFJWTPEDVJJIY-UHFFFAOYSA-N, REFJWTPEDVJJIY-UHFFFAOYSA-N, REFJWTPEDVJJIY-UHFFFAOYSA-N	Launched
quetiapine	dopamine receptor antagonist, serotonin receptor antagonist	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, DRD1, DRD2, DRD3, DRD4, DRD5, HRH1, HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2C, HTR3A, HTR6, HTR7, SLC6A2	neurology/psychiatry	schizophrenia, bipolar disorder	OCCOCCN1CCN(CC1)C1=Nc2ccccc2Sc2ccccc12 |t:13|, OCCOCCN1CCN(CC1)C1=Nc2ccccc2Sc2ccccc12 |t:13|, OCCOCCN1CCN(CC1)C1=Nc2ccccc2Sc2ccccc12 |t:13|, OCCOCCN1CCN(CC1)C1=Nc2ccccc2Sc2ccccc12 |t:13|	URKOMYMAXPYINW-UHFFFAOYSA-N, URKOMYMAXPYINW-UHFFFAOYSA-N, URKOMYMAXPYINW-UHFFFAOYSA-N, URKOMYMAXPYINW-UHFFFAOYSA-N	Launched
quiflapon	leukotriene synthesis inhibitor	ALOX5, ALOX5AP			CC(C)(C)Sc1c(CC(C)(C)C(O)=O)n(Cc2ccc(Cl)cc2)c2ccc(OCc3ccc4ccccc4n3)cc12	NZOONKHCNQFYCI-UHFFFAOYSA-N	Phase 2
quinagolide	dopamine receptor agonist	DRD2	endocrinology	hyperprolactinemia	CCCN1C[C@H](C[C@@H]2Cc3c(O)cccc3C[C@@H]12)NS(=O)(=O)N(CC)CC	GDFGTRDCCWFXTG-ZIFCJYIRSA-N	Launched
quinapril	angiotensin converting enzyme inhibitor	ACE	cardiology	hypertension, congestive heart failure, angioedema	CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1Cc2ccccc2C[C@H]1C(O)=O, CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1Cc2ccccc2C[C@H]1C(O)=O, CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1Cc2ccccc2C[C@H]1C(O)=O, CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1Cc2ccccc2C[C@H]1C(O)=O, CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1Cc2ccccc2C[C@H]1C(O)=O	JSDRRTOADPPCHY-HSQYWUDLSA-N, JSDRRTOADPPCHY-HSQYWUDLSA-N, JSDRRTOADPPCHY-HSQYWUDLSA-N, JSDRRTOADPPCHY-HSQYWUDLSA-N, JSDRRTOADPPCHY-HSQYWUDLSA-N	Launched
quinaprilat	angiotensin converting enzyme inhibitor	ACE	cardiology	hypertension, angioedema	C[C@H](N[C@@H](CCc1ccccc1)C(O)=O)C(=O)N1Cc2ccccc2C[C@H]1C(O)=O, C[C@H](N[C@@H](CCc1ccccc1)C(O)=O)C(=O)N1Cc2ccccc2C[C@H]1C(O)=O	FLSLEGPOVLMJMN-YSSFQJQWSA-N, FLSLEGPOVLMJMN-YSSFQJQWSA-N	Launched
quinelorane	dopamine receptor agonist	DRD2, DRD3			CCCN1CCC[C@@H]2Cc3nc(N)ncc3C[C@@H]12	TUFADSGTJUOBEH-ZWNOBZJWSA-N	Phase 3
quinestrol	estrogen receptor agonist	ESR1, ESR2	endocrinology	menopause	C[C@]12CC[C@H]3[C@@H](CCc4cc(OC5CCCC5)ccc34)[C@@H]1CC[C@@]2(O)C#C	PWZUUYSISTUNDW-VAFBSOEGSA-N	Launched
quinethazone	thiazide diuretic		cardiology	hypertension	CC[C@H]1NC(=O)c2cc(c(Cl)cc2N1)S(N)(=O)=O |&1:2,r|, CC[C@H]1NC(=O)c2cc(c(Cl)cc2N1)S(N)(=O)=O |&1:2,r|, CC[C@H]1NC(=O)c2cc(c(Cl)cc2N1)S(N)(=O)=O |&1:2,r|, CC[C@H]1NC(=O)c2cc(c(Cl)cc2N1)S(N)(=O)=O |&1:2,r|, CC[C@H]1NC(=O)c2cc(c(Cl)cc2N1)S(N)(=O)=O |&1:2,r|, CC[C@H]1NC(=O)c2cc(c(Cl)cc2N1)S(N)(=O)=O |&1:2,r|, CC[C@H]1NC(=O)c2cc(c(Cl)cc2N1)S(N)(=O)=O |&1:2,r|, CC[C@H]1NC(=O)c2cc(c(Cl)cc2N1)S(N)(=O)=O |&1:2,r|	AGMMTXLNIQSRCG-SECBINFHSA-N, AGMMTXLNIQSRCG-SECBINFHSA-N, AGMMTXLNIQSRCG-SECBINFHSA-N, AGMMTXLNIQSRCG-SECBINFHSA-N, AGMMTXLNIQSRCG-SECBINFHSA-N, AGMMTXLNIQSRCG-SECBINFHSA-N, AGMMTXLNIQSRCG-SECBINFHSA-N, AGMMTXLNIQSRCG-SECBINFHSA-N	Launched
quinidine	sodium channel blocker	KCNA5, KCNA7, KCNH1, KCNH2, KCNH5, KCNK1, KCNK6, SCN5A, SLC29A4	infectious disease, cardiology	malaria, atrial fibrillation (AF), ventricular arrhythmias	COc1ccc2nccc([C@H](O)[C@H]3C[C@@H]4CC[N@]3C[C@@H]4C=C)c2c1, COc1ccc2nccc([C@H](O)[C@H]3C[C@@H]4CC[N@]3C[C@@H]4C=C)c2c1, COc1ccc2nccc([C@H](O)[C@H]3C[C@@H]4CC[N@]3C[C@@H]4C=C)c2c1, COc1ccc2nccc([C@H](O)[C@H]3C[C@@H]4CC[N@]3C[C@@H]4C=C)c2c1	LOUPRKONTZGTKE-LHHVKLHASA-N, LOUPRKONTZGTKE-LHHVKLHASA-N, LOUPRKONTZGTKE-LHHVKLHASA-N, LOUPRKONTZGTKE-LHHVKLHASA-N	Launched
quinine	hemozoin biocrystallization inhibitor	GP9, KCNB2, KCNN4, SLC29A4	infectious disease	malaria	COc1ccc2nccc([C@@H](O)[C@@H]3C[C@@H]4CC[N@]3C[C@@H]4C=C)c2c1, COc1ccc2nccc([C@@H](O)[C@@H]3C[C@@H]4CC[N@]3C[C@@H]4C=C)c2c1, COc1ccc2nccc([C@@H](O)[C@@H]3C[C@@H]4CC[N@]3C[C@@H]4C=C)c2c1	LOUPRKONTZGTKE-WZBLMQSHSA-N, LOUPRKONTZGTKE-WZBLMQSHSA-N, LOUPRKONTZGTKE-WZBLMQSHSA-N	Launched
quinine-ethyl-carbonate			infectious disease	malaria	CCOC(=O)O[C@H]([C@H]1C[C@@H]2CC[N@]1C[C@@H]2C=C)c1ccnc2ccc(OC)cc12	NSBRKSWSLRQPJW-FRMGNDQPSA-N	Launched
quinolinic-acid	glutamate receptor agonist				OC(=O)c1cccnc1C(O)=O	GJAWHXHKYYXBSV-UHFFFAOYSA-N	Preclinical
quinpirol-(-)	dopamine receptor agonist	DRD1, DRD2, DRD3, DRD4, HTR1A, HTR2A, HTR2B, HTR2C			CCCN1CCC[C@@H]2Cc3[nH]ncc3C[C@@H]12, CCCN1CCC[C@@H]2Cc3[nH]ncc3C[C@@H]12, CCCN1CCC[C@@H]2Cc3[nH]ncc3C[C@@H]12, CCCN1CCC[C@@H]2Cc3[nH]ncc3C[C@@H]12, CCCN1CCC[C@@H]2Cc3[nH]ncc3C[C@@H]12	FTSUPYGMFAPCFZ-ZWNOBZJWSA-N, FTSUPYGMFAPCFZ-ZWNOBZJWSA-N, FTSUPYGMFAPCFZ-ZWNOBZJWSA-N, FTSUPYGMFAPCFZ-ZWNOBZJWSA-N, FTSUPYGMFAPCFZ-ZWNOBZJWSA-N	Phase 2
quipazine	serotonin receptor agonist	HTR1A, HTR1D, HTR2A, HTR2B, HTR2C, HTR3A, HTR3B, HTR6, SLC6A4			C1CN(CCN1)c1ccc2ccccc2n1, C1CN(CCN1)c1ccc2ccccc2n1, C1CN(CCN1)c1ccc2ccccc2n1, C1CN(CCN1)c1ccc2ccccc2n1	XRXDAJYKGWNHTQ-UHFFFAOYSA-N, XRXDAJYKGWNHTQ-UHFFFAOYSA-N, XRXDAJYKGWNHTQ-UHFFFAOYSA-N, XRXDAJYKGWNHTQ-UHFFFAOYSA-N	Preclinical
quizartinib	FLT3 inhibitor	CSF1R, FLT3, KIT, PDGFRA, PDGFRB, RET			CC(C)(C)c1cc(NC(=O)Nc2ccc(cc2)-c2cn3c(n2)sc2cc(OCCN4CCOCC4)ccc32)no1, CC(C)(C)c1cc(NC(=O)Nc2ccc(cc2)-c2cn3c(n2)sc2cc(OCCN4CCOCC4)ccc32)no1, CC(C)(C)c1cc(NC(=O)Nc2ccc(cc2)-c2cn3c(n2)sc2cc(OCCN4CCOCC4)ccc32)no1, CC(C)(C)c1cc(NC(=O)Nc2ccc(cc2)-c2cn3c(n2)sc2cc(OCCN4CCOCC4)ccc32)no1, CC(C)(C)c1cc(NC(=O)Nc2ccc(cc2)-c2cn3c(n2)sc2cc(OCCN4CCOCC4)ccc32)no1	CVWXJKQAOSCOAB-UHFFFAOYSA-N, CVWXJKQAOSCOAB-UHFFFAOYSA-N, CVWXJKQAOSCOAB-UHFFFAOYSA-N, CVWXJKQAOSCOAB-UHFFFAOYSA-N, CVWXJKQAOSCOAB-UHFFFAOYSA-N	Phase 3
QX-222	sodium channel blocker				Cc1cccc(C)c1NC(=O)C[N+](C)(C)C	QYUXPWDVDMSTKR-UHFFFAOYSA-O	Preclinical
QX-314	sodium channel blocker	MAPK14, TGFBR1			CC[N+](CC)(CC)CC(=O)Nc1c(C)cccc1C, CC[N+](CC)(CC)CC(=O)Nc1c(C)cccc1C, CC[N+](CC)(CC)CC(=O)Nc1c(C)cccc1C, CC[N+](CC)(CC)CC(=O)Nc1c(C)cccc1C	PYEBKOFMWAMBFV-UHFFFAOYSA-O, PYEBKOFMWAMBFV-UHFFFAOYSA-O, PYEBKOFMWAMBFV-UHFFFAOYSA-O, PYEBKOFMWAMBFV-UHFFFAOYSA-O	Preclinical
R-121919	CRF receptor antagonist				CCCN(CCC)c1cc(C)nc2c(c(C)nn12)-c1cnc(cc1C)N(C)C	ANNRUWYFVIGKHA-UHFFFAOYSA-N	Preclinical
R-1479	HCV inhibitor				Nc1ccn([C@@H]2O[C@@](CO)(N=[N+]=[N-])[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@@](CO)(N=[N+]=[N-])[C@@H](O)[C@H]2O)c(=O)n1	ODLGMSQBFONGNG-JVZYCSMKSA-N, ODLGMSQBFONGNG-JVZYCSMKSA-N	Phase 1
R-1485	serotonin receptor antagonist	HTR6			Fc1ccccc1S(=O)(=O)N1CCOc2c(cccc12)N1CCNCC1, Fc1ccccc1S(=O)(=O)N1CCOc2c(cccc12)N1CCNCC1, Fc1ccccc1S(=O)(=O)N1CCOc2c(cccc12)N1CCNCC1	UPROBLPRPWYJGN-UHFFFAOYSA-N, UPROBLPRPWYJGN-UHFFFAOYSA-N, UPROBLPRPWYJGN-UHFFFAOYSA-N	Phase 1
R-1487	p38 MAPK inhibitor				Cn1c2nc(NC3CCOCC3)ncc2cc(Oc2ccc(F)cc2F)c1=O	KKKRKRMVJRHDMG-UHFFFAOYSA-N	Phase 1
R-268712	serine/threonine kinase inhibitor	TGFBR1			Cc1cccc(n1)-c1n[nH]cc1-c1ccc(F)c(c1)-c1cnn(CCO)c1, Cc1cccc(n1)-c1n[nH]cc1-c1ccc(F)c(c1)-c1cnn(CCO)c1, Cc1cccc(n1)-c1n[nH]cc1-c1ccc(F)c(c1)-c1cnn(CCO)c1, Cc1cccc(n1)-c1n[nH]cc1-c1ccc(F)c(c1)-c1cnn(CCO)c1	JQGOCCALXFSRHZ-UHFFFAOYSA-N, JQGOCCALXFSRHZ-UHFFFAOYSA-N, JQGOCCALXFSRHZ-UHFFFAOYSA-N, JQGOCCALXFSRHZ-UHFFFAOYSA-N	Preclinical
R-428	AXL kinase inhibitor	AXL			Nc1nc(Nc2ccc3CC[C@@H](CCc3c2)N2CCCC2)nn1-c1cc2CCCc3ccccc3-c2nn1, Nc1nc(Nc2ccc3CC[C@@H](CCc3c2)N2CCCC2)nn1-c1cc2CCCc3ccccc3-c2nn1, Nc1nc(Nc2ccc3CC[C@@H](CCc3c2)N2CCCC2)nn1-c1cc2CCCc3ccccc3-c2nn1	KXMZDGSRSGHMMK-VWLOTQADSA-N, KXMZDGSRSGHMMK-VWLOTQADSA-N, KXMZDGSRSGHMMK-VWLOTQADSA-N	Phase 2
R-59022	diacylglycerol kinase inhibitor, protein kinase inhibitor	DGKA			Cc1nc2sccn2c(=O)c1CCN1CCC(CC1)=C(c1ccccc1)c1ccc(F)cc1, Cc1nc2sccn2c(=O)c1CCN1CCC(CC1)=C(c1ccccc1)c1ccc(F)cc1	MFVJXLPANKSLLD-UHFFFAOYSA-N, MFVJXLPANKSLLD-UHFFFAOYSA-N	Preclinical
R-96544	serotonin receptor antagonist	HTR2A			COc1cccc(CCc2ccccc2OCC[C@@H]2C[C@@H](O)CN2C)c1, COc1cccc(CCc2ccccc2OCC[C@@H]2C[C@@H](O)CN2C)c1, COc1cccc(CCc2ccccc2OCC[C@@H]2C[C@@H](O)CN2C)c1	AFZLABYDOCWQBQ-WOJBJXKFSA-N, AFZLABYDOCWQBQ-WOJBJXKFSA-N, AFZLABYDOCWQBQ-WOJBJXKFSA-N	Preclinical
rabeprazole	ATPase inhibitor, gastrin inhibitor	ATP4A	gastroenterology	gastroesophageal reflux disease (GERD), duodenal ulcer disease, Zollinger-Ellison syndrome	COCCCOc1ccnc(C[S@@](=O)c2nc3ccccc3[nH]2)c1C |r|, COCCCOc1ccnc(C[S@@](=O)c2nc3ccccc3[nH]2)c1C |r|, COCCCOc1ccnc(C[S@@](=O)c2nc3ccccc3[nH]2)c1C |r|, COCCCOc1ccnc(C[S@@](=O)c2nc3ccccc3[nH]2)c1C |r|	YREYEVIYCVEVJK-RUZDIDTESA-N, YREYEVIYCVEVJK-RUZDIDTESA-N, YREYEVIYCVEVJK-RUZDIDTESA-N, YREYEVIYCVEVJK-RUZDIDTESA-N	Launched
rac-BHFF	GABA receptor positive allosteric modulator	GABBR1			CC(C)(C)c1cc2c(OC(=O)[C@@]2(O)C(F)(F)F)c(c1)C(C)(C)C |&1:11,r|, CC(C)(C)c1cc2c(OC(=O)[C@@]2(O)C(F)(F)F)c(c1)C(C)(C)C |&1:11,r|	RVNOANDLZIIFHB-MRXNPFEDSA-N, RVNOANDLZIIFHB-MRXNPFEDSA-N	Preclinical
racecadotril	enkephalinase inhibitor	MME	gastroenterology	diarrhea	CC(=O)SC[C@@H](Cc1ccccc1)C(=O)NCC(=O)OCc1ccccc1 |&1:5,r|, CC(=O)SC[C@@H](Cc1ccccc1)C(=O)NCC(=O)OCc1ccccc1 |&1:5,r|, CC(=O)SC[C@@H](Cc1ccccc1)C(=O)NCC(=O)OCc1ccccc1 |&1:5,r|, CC(=O)SC[C@@H](Cc1ccccc1)C(=O)NCC(=O)OCc1ccccc1 |&1:5,r|, CC(=O)SC[C@@H](Cc1ccccc1)C(=O)NCC(=O)OCc1ccccc1 |&1:5,r|, CC(=O)SC[C@@H](Cc1ccccc1)C(=O)NCC(=O)OCc1ccccc1 |&1:5,r|, CC(=O)SC[C@@H](Cc1ccccc1)C(=O)NCC(=O)OCc1ccccc1 |&1:5,r|	ODUOJXZPIYUATO-LJQANCHMSA-N, ODUOJXZPIYUATO-LJQANCHMSA-N, ODUOJXZPIYUATO-LJQANCHMSA-N, ODUOJXZPIYUATO-LJQANCHMSA-N, ODUOJXZPIYUATO-LJQANCHMSA-N, ODUOJXZPIYUATO-LJQANCHMSA-N, ODUOJXZPIYUATO-LJQANCHMSA-N	Launched
raclopride	dopamine receptor antagonist	DRD2, DRD3, HTR1A			CCN1CCC[C@H]1CNC(=O)c1c(O)c(Cl)cc(Cl)c1OC, CCN1CCC[C@H]1CNC(=O)c1c(O)c(Cl)cc(Cl)c1OC, CCN1CCC[C@H]1CNC(=O)c1c(O)c(Cl)cc(Cl)c1OC	WAOQONBSWFLFPE-VIFPVBQESA-N, WAOQONBSWFLFPE-VIFPVBQESA-N, WAOQONBSWFLFPE-VIFPVBQESA-N	Launched
ractopamine	adrenergic receptor agonist		endocrinology	weight-gain aid	C[C@@H](CCc1ccc(O)cc1)NC[C@@H](O)c1ccc(O)cc1 |&1:1,&2:13,r|	YJQZYXCXBBCEAQ-SCLBCKFNSA-N	Launched
radafaxine	dopamine-norepinephrine reuptake inhibitor	SLC6A3			C[C@@H]1NC(C)(C)CO[C@@]1(O)c1cccc(Cl)c1	RCOBKSKAZMVBHT-TVQRCGJNSA-N	Phase 2
radezolid	bacterial 30S ribosomal subunit inhibitor, bacterial 50S ribosomal subunit inhibitor				CC(=O)NC[C@H]1CN(C(=O)O1)c1ccc(c(F)c1)-c1ccc(CNCc2cn[nH]n2)cc1, CC(=O)NC[C@H]1CN(C(=O)O1)c1ccc(c(F)c1)-c1ccc(CNCc2cn[nH]n2)cc1, CC(=O)NC[C@H]1CN(C(=O)O1)c1ccc(c(F)c1)-c1ccc(CNCc2cn[nH]n2)cc1, CC(=O)NC[C@H]1CN(C(=O)O1)c1ccc(c(F)c1)-c1ccc(CNCc2cn[nH]n2)cc1	BTTNOGHPGJANSW-IBGZPJMESA-N, BTTNOGHPGJANSW-IBGZPJMESA-N, BTTNOGHPGJANSW-IBGZPJMESA-N, BTTNOGHPGJANSW-IBGZPJMESA-N	Phase 2
radiprodil	acetylcholine receptor antagonist				Fc1ccc(CC2CCN(CC2)C(=O)C(=O)Nc2ccc3[nH]c(=O)oc3c2)cc1	GKGRZLGAQZPEHO-UHFFFAOYSA-N	Phase 2
radotinib	Bcr-Abl kinase inhibitor				Cc1cn(cn1)-c1cc(NC(=O)c2ccc(C)c(Nc3nccc(n3)-c3cnccn3)c2)cc(c1)C(F)(F)F	DUPWHXBITIZIKZ-UHFFFAOYSA-N	Phase 3
RAD140	androgen receptor modulator				[H][C@@](C)(O)[C@@]([H])(Nc1ccc(C#N)c(Cl)c1C)c1nnc(o1)-c1ccc(cc1)C#N	XMBUPPIEVAFYHO-KPZWWZAWSA-N	Phase 1
RAF265	RAF inhibitor, VEGFR inhibitor	BRAF			Cn1c(Nc2ccc(cc2)C(F)(F)F)nc2cc(Oc3ccnc(c3)-c3ncc([nH]3)C(F)(F)F)ccc12, Cn1c(Nc2ccc(cc2)C(F)(F)F)nc2cc(Oc3ccnc(c3)-c3ncc([nH]3)C(F)(F)F)ccc12, Cn1c(Nc2ccc(cc2)C(F)(F)F)nc2cc(Oc3ccnc(c3)-c3ncc([nH]3)C(F)(F)F)ccc12, Cn1c(Nc2ccc(cc2)C(F)(F)F)nc2cc(Oc3ccnc(c3)-c3ncc([nH]3)C(F)(F)F)ccc12	YABJJWZLRMPFSI-UHFFFAOYSA-N, YABJJWZLRMPFSI-UHFFFAOYSA-N, YABJJWZLRMPFSI-UHFFFAOYSA-N, YABJJWZLRMPFSI-UHFFFAOYSA-N	Phase 2
RAF709	RAF inhibitor				Cc1ncc(NC(=O)c2cccc(c2)C(F)(F)F)cc1-c1cnc(OC2CCOCC2)c(c1)N1CCOCC1	FYNMINFUAIDIFL-UHFFFAOYSA-N	Preclinical
ralinepag	IP1 prostacyclin receptor agonist				OC(=O)COC[C@H]1CC[C@H](COC(=O)N(c2ccccc2)c2ccc(Cl)cc2)CC1 |r|	NPDKXVKJRHPDQT-IYARVYRRSA-N	Phase 3
raloxifene	estrogen receptor antagonist, selective estrogen receptor modulator (SERM)	ESR1, ESR2	orthopedics, oncology	osteoporosis, breast cancer	Oc1ccc(cc1)-c1sc2cc(O)ccc2c1C(=O)c1ccc(OCCN2CCCCC2)cc1, Oc1ccc(cc1)-c1sc2cc(O)ccc2c1C(=O)c1ccc(OCCN2CCCCC2)cc1, Oc1ccc(cc1)-c1sc2cc(O)ccc2c1C(=O)c1ccc(OCCN2CCCCC2)cc1, Oc1ccc(cc1)-c1sc2cc(O)ccc2c1C(=O)c1ccc(OCCN2CCCCC2)cc1, Oc1ccc(cc1)-c1sc2cc(O)ccc2c1C(=O)c1ccc(OCCN2CCCCC2)cc1, Oc1ccc(cc1)-c1sc2cc(O)ccc2c1C(=O)c1ccc(OCCN2CCCCC2)cc1	GZUITABIAKMVPG-UHFFFAOYSA-N, GZUITABIAKMVPG-UHFFFAOYSA-N, GZUITABIAKMVPG-UHFFFAOYSA-N, GZUITABIAKMVPG-UHFFFAOYSA-N, GZUITABIAKMVPG-UHFFFAOYSA-N, GZUITABIAKMVPG-UHFFFAOYSA-N	Launched
raltegravir	HIV integrase inhibitor		infectious disease	human immunodeficiency virus (HIV-1)	Cc1nnc(o1)C(=O)NC(C)(C)c1nc(C(=O)NCc2ccc(F)cc2)c(O)c(=O)n1C, Cc1nnc(o1)C(=O)NC(C)(C)c1nc(C(=O)NCc2ccc(F)cc2)c(O)c(=O)n1C, Cc1nnc(o1)C(=O)NC(C)(C)c1nc(C(=O)NCc2ccc(F)cc2)c(O)c(=O)n1C	CZFFBEXEKNGXKS-UHFFFAOYSA-N, CZFFBEXEKNGXKS-UHFFFAOYSA-N, CZFFBEXEKNGXKS-UHFFFAOYSA-N	Launched
raltitrexed	thymidylate synthase inhibitor	FPGS, TYMS	oncology	mesothelioma	CN(Cc1ccc2[nH]c(C)nc(=O)c2c1)c1ccc(s1)C(=O)N[C@@H](CCC(O)=O)C(O)=O, CN(Cc1ccc2[nH]c(C)nc(=O)c2c1)c1ccc(s1)C(=O)N[C@@H](CCC(O)=O)C(O)=O, CN(Cc1ccc2[nH]c(C)nc(=O)c2c1)c1ccc(s1)C(=O)N[C@@H](CCC(O)=O)C(O)=O, CN(Cc1ccc2[nH]c(C)nc(=O)c2c1)c1ccc(s1)C(=O)N[C@@H](CCC(O)=O)C(O)=O	IVTVGDXNLFLDRM-HNNXBMFYSA-N, IVTVGDXNLFLDRM-HNNXBMFYSA-N, IVTVGDXNLFLDRM-HNNXBMFYSA-N, IVTVGDXNLFLDRM-HNNXBMFYSA-N	Launched
ramatroban	prostanoid receptor antagonist	PTGDR2, TBXA2R	cardiology, pulmonary	coronary artery disease (CAD), asthma	OC(=O)CCn1c2CC[C@H](Cc2c2ccccc12)NS(=O)(=O)c1ccc(F)cc1, OC(=O)CCn1c2CC[C@H](Cc2c2ccccc12)NS(=O)(=O)c1ccc(F)cc1, OC(=O)CCn1c2CC[C@H](Cc2c2ccccc12)NS(=O)(=O)c1ccc(F)cc1, OC(=O)CCn1c2CC[C@H](Cc2c2ccccc12)NS(=O)(=O)c1ccc(F)cc1	LDXDSHIEDAPSSA-OAHLLOKOSA-N, LDXDSHIEDAPSSA-OAHLLOKOSA-N, LDXDSHIEDAPSSA-OAHLLOKOSA-N, LDXDSHIEDAPSSA-OAHLLOKOSA-N	Launched
ramelteon	melatonin receptor agonist	MTNR1A, MTNR1B	neurology/psychiatry	insomnia	CCC(=O)NCC[C@@H]1CCc2ccc3OCCc3c12, CCC(=O)NCC[C@@H]1CCc2ccc3OCCc3c12	YLXDSYKOBKBWJQ-LBPRGKRZSA-N, YLXDSYKOBKBWJQ-LBPRGKRZSA-N	Launched
ramifenazone	cyclooxygenase inhibitor		neurology/psychiatry, endocrinology	pain relief, fever	CC(C)Nc1c(C)n(C)n(-c2ccccc2)c1=O, CC(C)Nc1c(C)n(C)n(-c2ccccc2)c1=O, CC(C)Nc1c(C)n(C)n(-c2ccccc2)c1=O	XOZLRRYPUKAKMU-UHFFFAOYSA-N, XOZLRRYPUKAKMU-UHFFFAOYSA-N, XOZLRRYPUKAKMU-UHFFFAOYSA-N	Launched
ramipril	angiotensin converting enzyme inhibitor	ACE	cardiology	hypertension	CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1[C@H]2CCC[C@H]2C[C@H]1C(O)=O, CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1[C@H]2CCC[C@H]2C[C@H]1C(O)=O, CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1[C@H]2CCC[C@H]2C[C@H]1C(O)=O, CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1[C@H]2CCC[C@H]2C[C@H]1C(O)=O, CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1[C@H]2CCC[C@H]2C[C@H]1C(O)=O	HDACQVRGBOVJII-JBDAPHQKSA-N, HDACQVRGBOVJII-JBDAPHQKSA-N, HDACQVRGBOVJII-JBDAPHQKSA-N, HDACQVRGBOVJII-JBDAPHQKSA-N, HDACQVRGBOVJII-JBDAPHQKSA-N	Launched
ramosetron	serotonin receptor antagonist	HTR3A	gastroenterology	nausea, vomiting, irritable bowel syndrome	Cn1cc(C(=O)[C@@H]2CCc3nc[nH]c3C2)c2ccccc12, Cn1cc(C(=O)[C@@H]2CCc3nc[nH]c3C2)c2ccccc12	NTHPAPBPFQJABD-LLVKDONJSA-N, NTHPAPBPFQJABD-LLVKDONJSA-N	Launched
ranirestat	aldose reductase inhibitor	AKR1B1			Fc1cc(Br)ccc1CN1C(=O)c2cccn2[C@@]2(CC(=O)NC2=O)C1=O, Fc1cc(Br)ccc1CN1C(=O)c2cccn2[C@@]2(CC(=O)NC2=O)C1=O	QCVNMNYRNIMDKV-QGZVFWFLSA-N, QCVNMNYRNIMDKV-QGZVFWFLSA-N	Phase 3
ranitidine	histamine receptor antagonist	HRH2	gastroenterology	heartburn	CN=C(C[N+]([O-])=O)NCCSCc1ccc(CN(C)C)o1	SYNOVMDJYWJCON-UHFFFAOYSA-N	Launched
ranolazine	sodium channel blocker	SCN10A, SCN9A	cardiology	chronic stable angina	COc1ccccc1OC[C@@H](O)CN1CCN(CC(=O)Nc2c(C)cccc2C)CC1 |&1:10|, COc1ccccc1OC[C@@H](O)CN1CCN(CC(=O)Nc2c(C)cccc2C)CC1 |&1:10|, COc1ccccc1OC[C@@H](O)CN1CCN(CC(=O)Nc2c(C)cccc2C)CC1 |&1:10|	XKLMZUWKNUAPSZ-FQEVSTJZSA-N, XKLMZUWKNUAPSZ-FQEVSTJZSA-N, XKLMZUWKNUAPSZ-FQEVSTJZSA-N	Launched
rapastinel	glutamate receptor agonist				C[C@@H](O)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(N)=O	GIBQQARAXHVEGD-BSOLPCOYSA-N	Phase 2
rasagiline	monoamine oxidase inhibitor	BCL2, MAOB	neurology/psychiatry	Parkinson's Disease	C#CCN[C@@H]1CCc2ccccc12, C#CCN[C@@H]1CCc2ccccc12, C#CCN[C@@H]1CCc2ccccc12, C#CCN[C@@H]1CCc2ccccc12, C#CCN[C@@H]1CCc2ccccc12, C#CCN[C@@H]1CCc2ccccc12	RUOKEQAAGRXIBM-GFCCVEGCSA-N, RUOKEQAAGRXIBM-GFCCVEGCSA-N, RUOKEQAAGRXIBM-GFCCVEGCSA-N, RUOKEQAAGRXIBM-GFCCVEGCSA-N, RUOKEQAAGRXIBM-GFCCVEGCSA-N, RUOKEQAAGRXIBM-GFCCVEGCSA-N	Launched
rauwolscine	adrenergic receptor antagonist	ADRA2A, ADRA2B, ADRA2C, HTR1B, HTR1D, HTR1E, HTR2B			COC(=O)[C@@H]1[C@@H](O)CC[C@@H]2CN3CCc4c([nH]c5ccccc45)[C@@H]3C[C@H]12, COC(=O)[C@@H]1[C@@H](O)CC[C@@H]2CN3CCc4c([nH]c5ccccc45)[C@@H]3C[C@H]12, COC(=O)[C@@H]1[C@@H](O)CC[C@@H]2CN3CCc4c([nH]c5ccccc45)[C@@H]3C[C@H]12, COC(=O)[C@@H]1[C@@H](O)CC[C@@H]2CN3CCc4c([nH]c5ccccc45)[C@@H]3C[C@H]12	BLGXFZZNTVWLAY-DIRVCLHFSA-N, BLGXFZZNTVWLAY-DIRVCLHFSA-N, BLGXFZZNTVWLAY-DIRVCLHFSA-N, BLGXFZZNTVWLAY-DIRVCLHFSA-N	Preclinical
ravoxertinib	ERK1 and ERK2 phosphorylation inhibitor	MAPK1, MAPK3			Cn1nccc1Nc1nccc(n1)-c1ccn([C@H](CO)c2ccc(Cl)c(F)c2)c(=O)c1, Cn1nccc1Nc1nccc(n1)-c1ccn([C@H](CO)c2ccc(Cl)c(F)c2)c(=O)c1, Cn1nccc1Nc1nccc(n1)-c1ccn([C@H](CO)c2ccc(Cl)c(F)c2)c(=O)c1, Cn1nccc1Nc1nccc(n1)-c1ccn([C@H](CO)c2ccc(Cl)c(F)c2)c(=O)c1	RZUOCXOYPYGSKL-GOSISDBHSA-N, RZUOCXOYPYGSKL-GOSISDBHSA-N, RZUOCXOYPYGSKL-GOSISDBHSA-N, RZUOCXOYPYGSKL-GOSISDBHSA-N	Phase 1
ravuconazole	sterol demethylase inhibitor				C[C@@H](c1nc(cs1)-c1ccc(cc1)C#N)[C@](O)(Cn1cncn1)c1ccc(F)cc1F, C[C@@H](c1nc(cs1)-c1ccc(cc1)C#N)[C@](O)(Cn1cncn1)c1ccc(F)cc1F, C[C@@H](c1nc(cs1)-c1ccc(cc1)C#N)[C@](O)(Cn1cncn1)c1ccc(F)cc1F	OPAHEYNNJWPQPX-RCDICMHDSA-N, OPAHEYNNJWPQPX-RCDICMHDSA-N, OPAHEYNNJWPQPX-RCDICMHDSA-N	Phase 2
RBC8	Ral GTPase inhibitor	RALA, RALB			COc1ccc(OC)c(c1)[C@@H]1C(C#N)C(=N)Oc2[nH]nc(c12)-c1ccc2ccccc2c1 |&1:10,r|, COc1ccc(OC)c(c1)[C@@H]1C(C#N)C(=N)Oc2[nH]nc(c12)-c1ccc2ccccc2c1 |&1:10,r|, COc1ccc(OC)c(c1)[C@@H]1C(C#N)C(=N)Oc2[nH]nc(c12)-c1ccc2ccccc2c1 |&1:10,r|	RFEAEBNMNYRJFD-VGAJERRHSA-N, RFEAEBNMNYRJFD-VGAJERRHSA-N, RFEAEBNMNYRJFD-VGAJERRHSA-N	Preclinical
rebamipide	free radical scavenger	FPR1	gastroenterology	peptic ulcer disease (PUD), gastritis	OC(=O)[C@@H](Cc1cc(=O)[nH]c2ccccc12)NC(=O)c1ccc(Cl)cc1 |&1:3,r|, OC(=O)[C@@H](Cc1cc(=O)[nH]c2ccccc12)NC(=O)c1ccc(Cl)cc1 |&1:3,r|, OC(=O)[C@@H](Cc1cc(=O)[nH]c2ccccc12)NC(=O)c1ccc(Cl)cc1 |&1:3,r|	ALLWOAVDORUJLA-MRXNPFEDSA-N, ALLWOAVDORUJLA-MRXNPFEDSA-N, ALLWOAVDORUJLA-MRXNPFEDSA-N	Launched
rebastinib	Bcr-Abl kinase inhibitor, TIE tyrosine kinase inhibitor, VEGFR inhibitor	ABL1, BCR, FGR, FLT3, HCK, LYN, SRC			CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3cc(nn3-c3ccc4ncccc4c3)C(C)(C)C)c(F)c2)ccn1, CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3cc(nn3-c3ccc4ncccc4c3)C(C)(C)C)c(F)c2)ccn1, CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3cc(nn3-c3ccc4ncccc4c3)C(C)(C)C)c(F)c2)ccn1, CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3cc(nn3-c3ccc4ncccc4c3)C(C)(C)C)c(F)c2)ccn1, CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3cc(nn3-c3ccc4ncccc4c3)C(C)(C)C)c(F)c2)ccn1, CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3cc(nn3-c3ccc4ncccc4c3)C(C)(C)C)c(F)c2)ccn1, CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3cc(nn3-c3ccc4ncccc4c3)C(C)(C)C)c(F)c2)ccn1	WVXNSAVVKYZVOE-UHFFFAOYSA-N, WVXNSAVVKYZVOE-UHFFFAOYSA-N, WVXNSAVVKYZVOE-UHFFFAOYSA-N, WVXNSAVVKYZVOE-UHFFFAOYSA-N, WVXNSAVVKYZVOE-UHFFFAOYSA-N, WVXNSAVVKYZVOE-UHFFFAOYSA-N, WVXNSAVVKYZVOE-UHFFFAOYSA-N	Phase 1/Phase 2
reboxetine	adrenergic receptor antagonist	SLC6A2	neurology/psychiatry	depression	CCOc1ccccc1O[C@@H]([C@H]1CNCCO1)c1ccccc1 |&1:10,11|, CCOc1ccccc1O[C@@H]([C@H]1CNCCO1)c1ccccc1 |&1:10,11|, CCOc1ccccc1O[C@@H]([C@H]1CNCCO1)c1ccccc1 |&1:10,11|	CBQGYUDMJHNJBX-RTBURBONSA-N, CBQGYUDMJHNJBX-RTBURBONSA-N, CBQGYUDMJHNJBX-RTBURBONSA-N	Launched
Rec-15/2615	adrenergic receptor antagonist	ADRA1A			COc1cc2nc(nc(N)c2cc1OC)N1CCN(CC1)C(=O)COc1c(OC)cccc1C(C)C, COc1cc2nc(nc(N)c2cc1OC)N1CCN(CC1)C(=O)COc1c(OC)cccc1C(C)C	ZZMFJJDBKSYGRM-UHFFFAOYSA-N, ZZMFJJDBKSYGRM-UHFFFAOYSA-N	Phase 2
refametinib	MEK inhibitor	MAP2K1, MAP2K2			COc1cc(F)c(F)c(Nc2ccc(I)cc2F)c1NS(=O)(=O)C1(C[C@H](O)CO)CC1, COc1cc(F)c(F)c(Nc2ccc(I)cc2F)c1NS(=O)(=O)C1(C[C@H](O)CO)CC1, COc1cc(F)c(F)c(Nc2ccc(I)cc2F)c1NS(=O)(=O)C1(C[C@H](O)CO)CC1, COc1cc(F)c(F)c(Nc2ccc(I)cc2F)c1NS(=O)(=O)C1(C[C@H](O)CO)CC1, COc1cc(F)c(F)c(Nc2ccc(I)cc2F)c1NS(=O)(=O)C1(C[C@H](O)CO)CC1, COc1cc(F)c(F)c(Nc2ccc(I)cc2F)c1NS(=O)(=O)C1(C[C@H](O)CO)CC1	RDSACQWTXKSHJT-NSHDSACASA-N, RDSACQWTXKSHJT-NSHDSACASA-N, RDSACQWTXKSHJT-NSHDSACASA-N, RDSACQWTXKSHJT-NSHDSACASA-N, RDSACQWTXKSHJT-NSHDSACASA-N, RDSACQWTXKSHJT-NSHDSACASA-N	Phase 2
regadenoson	adenosine receptor agonist	ADORA1, ADORA2A, ADORA2B, ADORA3	radiology	myocardial perfusion imaging (MPI)	CNC(=O)c1cnn(c1)-c1nc(N)c2ncn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c2n1	LZPZPHGJDAGEJZ-AKAIJSEGSA-N	Launched
regorafenib	FGFR inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RAF inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor	ABL1, BRAF, DDR2, EPHA2, FGFR1, FGFR2, FLT1, FLT4, FRK, KDR, KIT, MAPK11, NTRK1, PDGFRA, PDGFRB, RAF1, RET, TEK	oncology	colorectal cancer, gastrointestinal stromal tumors (GIST)	CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)c(F)c2)ccn1, CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)c(F)c2)ccn1, CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)c(F)c2)ccn1, CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)c(F)c2)ccn1, CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)c(F)c2)ccn1, CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)c(F)c2)ccn1	FNHKPVJBJVTLMP-UHFFFAOYSA-N, FNHKPVJBJVTLMP-UHFFFAOYSA-N, InChI=1S/C21H15ClF4N4O3/c1-27-19(31)18-10-13(6-7-28-18)33-12-3-5-17(16(23)9-12)30-20(32)29-11-2-4-15(22)14(8-11)21(24,25)26/h2-10H,1H3,(H,27,31)(H2,29,30,32), InChI=1S/C21H15ClF4N4O3/c1-27-19(31)18-10-13(6-7-28-18)33-12-3-5-17(16(23)9-12)30-20(32)29-11-2-4-15(22)14(8-11)21(24,25)26/h2-10H,1H3,(H,27,31)(H2,29,30,32), InChI=1S/C21H15ClF4N4O3/c1-27-19(31)18-10-13(6-7-28-18)33-12-3-5-17(16(23)9-12)30-20(32)29-11-2-4-15(22)14(8-11)21(24,25)26/h2-10H,1H3,(H,27,31)(H2,29,30,32), InChI=1S/C21H15ClF4N4O3/c1-27-19(31)18-10-13(6-7-28-18)33-12-3-5-17(16(23)9-12)30-20(32)29-11-2-4-15(22)14(8-11)21(24,25)26/h2-10H,1H3,(H,27,31)(H2,29,30,32)	Launched
relcovaptan	vasopressin receptor antagonist	AVPR1A, AVPR1B, AVPR2, OXTR			COc1ccc(cc1OC)S(=O)(=O)N1[C@@H](C(=O)N2CCC[C@H]2C(N)=O)[C@](O)(c2cc(Cl)ccc12)c1ccccc1Cl, COc1ccc(cc1OC)S(=O)(=O)N1[C@@H](C(=O)N2CCC[C@H]2C(N)=O)[C@](O)(c2cc(Cl)ccc12)c1ccccc1Cl, COc1ccc(cc1OC)S(=O)(=O)N1[C@@H](C(=O)N2CCC[C@H]2C(N)=O)[C@](O)(c2cc(Cl)ccc12)c1ccccc1Cl	CEBYCSRFKCEUSW-NAYZPBBASA-N, CEBYCSRFKCEUSW-NAYZPBBASA-N, CEBYCSRFKCEUSW-NAYZPBBASA-N	Phase 2
relebactam	beta lactamase inhibitor				OS(=O)(=O)ON1[C@H]2CN([C@@H](CC2)C(=O)NC2CCNCC2)C1=O	SMOBCLHAZXOKDQ-ZJUUUORDSA-N	Launched
relugolix	gonadotropin releasing factor hormone receptor antagonist				CONC(=O)Nc1ccc(cc1)-c1sc2n(Cc3c(F)cccc3F)c(=O)n(-c3ccc(OC)nn3)c(=O)c2c1CN(C)C	AOMXMOCNKJTRQP-UHFFFAOYSA-N	Phase 3
remacemide	glutamate receptor antagonist	GRIN1			C[C@@](Cc1ccccc1)(NC(=O)CN)c1ccccc1 |&1:1|, C[C@@](Cc1ccccc1)(NC(=O)CN)c1ccccc1 |&1:1|	YSGASDXSLKIKOD-KRWDZBQOSA-N, YSGASDXSLKIKOD-KRWDZBQOSA-N	Phase 3
remetinostat	HDAC inhibitor				COC(=O)c1ccc(OC(=O)CCCCCCC(=O)NO)cc1	XDZAHHULFQIBFE-UHFFFAOYSA-N	Phase 2
remimazolam	benzodiazepine receptor agonist	GABBR1			COC(=O)CC[C@@H]1N=C(c2ccccn2)c2cc(Br)ccc2-n2c(C)cnc12 |t:7|, COC(=O)CC[C@@H]1N=C(c2ccccn2)c2cc(Br)ccc2-n2c(C)cnc12 |t:7|	CYHWMBVXXDIZNZ-KRWDZBQOSA-N, CYHWMBVXXDIZNZ-KRWDZBQOSA-N	Phase 3
remodelin	transferase inhibitor	NAT10			N#Cc1ccc(cc1)-c1csc(NN=C2CCCC2)n1, N#Cc1ccc(cc1)-c1csc(NN=C2CCCC2)n1	XAEJIFARBQJLML-UHFFFAOYSA-N, XAEJIFARBQJLML-UHFFFAOYSA-N	Preclinical
remoxipride	dopamine receptor antagonist	DRD2, DRD3, DRD4, HTR2A, SIGMAR1			CCN1CCC[C@H]1CNC(=O)c1c(OC)ccc(Br)c1OC, CCN1CCC[C@H]1CNC(=O)c1c(OC)ccc(Br)c1OC, CCN1CCC[C@H]1CNC(=O)c1c(OC)ccc(Br)c1OC, CCN1CCC[C@H]1CNC(=O)c1c(OC)ccc(Br)c1OC, CCN1CCC[C@H]1CNC(=O)c1c(OC)ccc(Br)c1OC	GUJRSXAPGDDABA-NSHDSACASA-N, GUJRSXAPGDDABA-NSHDSACASA-N, GUJRSXAPGDDABA-NSHDSACASA-N, GUJRSXAPGDDABA-NSHDSACASA-N, GUJRSXAPGDDABA-NSHDSACASA-N	Withdrawn
repaglinide	insulin secretagogue	ABCC8, KCNJ11, PPARG	endocrinology	diabetes mellitus	CCOc1cc(CC(=O)N[C@@H](CC(C)C)c2ccccc2N2CCCCC2)ccc1C(O)=O, CCOc1cc(CC(=O)N[C@@H](CC(C)C)c2ccccc2N2CCCCC2)ccc1C(O)=O, CCOc1cc(CC(=O)N[C@@H](CC(C)C)c2ccccc2N2CCCCC2)ccc1C(O)=O, CCOc1cc(CC(=O)N[C@@H](CC(C)C)c2ccccc2N2CCCCC2)ccc1C(O)=O, CCOc1cc(CC(=O)N[C@@H](CC(C)C)c2ccccc2N2CCCCC2)ccc1C(O)=O	FAEKWTJYAYMJKF-QHCPKHFHSA-N, FAEKWTJYAYMJKF-QHCPKHFHSA-N, FAEKWTJYAYMJKF-QHCPKHFHSA-N, FAEKWTJYAYMJKF-QHCPKHFHSA-N, FAEKWTJYAYMJKF-QHCPKHFHSA-N	Launched
reparixin	CC chemokine receptor antagonist	CXCR1, CXCR2			CC(C)Cc1ccc(cc1)[C@@H](C)C(=O)NS(C)(=O)=O, CC(C)Cc1ccc(cc1)[C@@H](C)C(=O)NS(C)(=O)=O, CC(C)Cc1ccc(cc1)[C@@H](C)C(=O)NS(C)(=O)=O, CC(C)Cc1ccc(cc1)[C@@H](C)C(=O)NS(C)(=O)=O	KQDRVXQXKZXMHP-LLVKDONJSA-N, KQDRVXQXKZXMHP-LLVKDONJSA-N, KQDRVXQXKZXMHP-LLVKDONJSA-N, KQDRVXQXKZXMHP-LLVKDONJSA-N	Phase 3
repotrectinib	receptor tyrosine protein kinase inhibitor				C[C@H]1CNC(=O)c2cnn3ccc(N[C@H](C)c4cc(F)ccc4O1)nc23	FIKPXCOQUIZNHB-VUWPPUDQSA-N	Phase 1/Phase 2
repsox	TGF beta receptor inhibitor	TGFBR1			Cc1cccc(n1)-c1n[nH]cc1-c1ccc2ncccc2n1, Cc1cccc(n1)-c1n[nH]cc1-c1ccc2ncccc2n1, Cc1cccc(n1)-c1n[nH]cc1-c1ccc2ncccc2n1, Cc1cccc(n1)-c1n[nH]cc1-c1ccc2ncccc2n1, Cc1cccc(n1)-c1n[nH]cc1-c1ccc2ncccc2n1, Cc1cccc(n1)-c1n[nH]cc1-c1ccc2ncccc2n1, Cc1cccc(n1)-c1n[nH]cc1-c1ccc2ncccc2n1, Cc1cccc(n1)-c1n[nH]cc1-c1ccc2ncccc2n1	LBPKYPYHDKKRFS-UHFFFAOYSA-N, LBPKYPYHDKKRFS-UHFFFAOYSA-N, LBPKYPYHDKKRFS-UHFFFAOYSA-N, LBPKYPYHDKKRFS-UHFFFAOYSA-N, LBPKYPYHDKKRFS-UHFFFAOYSA-N, LBPKYPYHDKKRFS-UHFFFAOYSA-N, LBPKYPYHDKKRFS-UHFFFAOYSA-N, LBPKYPYHDKKRFS-UHFFFAOYSA-N	Preclinical
resatorvid	toll-like receptor inhibitor	TLR4			CCOC(=O)C1=CCCC[C@H]1S(=O)(=O)Nc1ccc(F)cc1Cl |t:5|, CCOC(=O)C1=CCCC[C@H]1S(=O)(=O)Nc1ccc(F)cc1Cl |t:5|, CCOC(=O)C1=CCCC[C@H]1S(=O)(=O)Nc1ccc(F)cc1Cl |t:5|	LEEIJTHMHDMWLJ-CQSZACIVSA-N, LEEIJTHMHDMWLJ-CQSZACIVSA-N, LEEIJTHMHDMWLJ-CQSZACIVSA-N	Phase 3
reserpine	vesicular monoamine transporter inhibitor	SLC18A1, SLC18A2	cardiology	hypertension	CO[C@H]1[C@@H](C[C@@H]2CN3CCc4c([nH]c5cc(OC)ccc45)[C@H]3C[C@@H]2[C@@H]1C(=O)OC)OC(=O)c1cc(OC)c(OC)c(OC)c1, CO[C@H]1[C@@H](C[C@@H]2CN3CCc4c([nH]c5cc(OC)ccc45)[C@H]3C[C@@H]2[C@@H]1C(=O)OC)OC(=O)c1cc(OC)c(OC)c(OC)c1, CO[C@H]1[C@@H](C[C@@H]2CN3CCc4c([nH]c5cc(OC)ccc45)[C@H]3C[C@@H]2[C@@H]1C(=O)OC)OC(=O)c1cc(OC)c(OC)c(OC)c1, CO[C@H]1[C@@H](C[C@@H]2CN3CCc4c([nH]c5cc(OC)ccc45)[C@H]3C[C@@H]2[C@@H]1C(=O)OC)OC(=O)c1cc(OC)c(OC)c(OC)c1, CO[C@H]1[C@@H](C[C@@H]2CN3CCc4c([nH]c5cc(OC)ccc45)[C@H]3C[C@@H]2[C@@H]1C(=O)OC)OC(=O)c1cc(OC)c(OC)c(OC)c1, CO[C@H]1[C@@H](C[C@@H]2CN3CCc4c([nH]c5cc(OC)ccc45)[C@H]3C[C@@H]2[C@@H]1C(=O)OC)OC(=O)c1cc(OC)c(OC)c(OC)c1, CO[C@H]1[C@@H](C[C@@H]2CN3CCc4c([nH]c5cc(OC)ccc45)[C@H]3C[C@@H]2[C@@H]1C(=O)OC)OC(=O)c1cc(OC)c(OC)c(OC)c1	QEVHRUUCFGRFIF-MDEJGZGSSA-N, QEVHRUUCFGRFIF-MDEJGZGSSA-N, QEVHRUUCFGRFIF-MDEJGZGSSA-N, QEVHRUUCFGRFIF-MDEJGZGSSA-N, QEVHRUUCFGRFIF-MDEJGZGSSA-N, QEVHRUUCFGRFIF-MDEJGZGSSA-N, QEVHRUUCFGRFIF-MDEJGZGSSA-N	Launched
resibufogenin	Na/K-ATPase inhibitor				C[C@]12CC[C@H]3[C@@H](CC[C@@H]4C[C@@H](O)CC[C@]34C)[C@]11O[C@@H]1C[C@@H]2c1ccc(=O)oc1	ATLJNLYIJOCWJE-CWMZOUAVSA-N	Phase 2
resiquimod	toll-like receptor agonist	TLR7, TLR8			CCOCc1nc2c(N)nc3ccccc3c2n1CC(C)(C)O, CCOCc1nc2c(N)nc3ccccc3c2n1CC(C)(C)O, CCOCc1nc2c(N)nc3ccccc3c2n1CC(C)(C)O, CCOCc1nc2c(N)nc3ccccc3c2n1CC(C)(C)O	BXNMTOQRYBFHNZ-UHFFFAOYSA-N, BXNMTOQRYBFHNZ-UHFFFAOYSA-N, BXNMTOQRYBFHNZ-UHFFFAOYSA-N, BXNMTOQRYBFHNZ-UHFFFAOYSA-N	Phase 3
resmetirom	thyroid hormone receptor agonist				CC(C)c1cc(Oc2c(Cl)cc(cc2Cl)-n2nc(C#N)c(=O)[nH]c2=O)nnc1O	FDBYIYFVSAHJLY-UHFFFAOYSA-N	Phase 3
resminostat	HDAC inhibitor	HDAC1, HDAC3, HDAC6, HDAC8			CN(C)Cc1ccc(cc1)S(=O)(=O)n1ccc(\C=C\C(=O)NO)c1, CN(C)Cc1ccc(cc1)S(=O)(=O)n1ccc(\C=C\C(=O)NO)c1, CN(C)Cc1ccc(cc1)S(=O)(=O)n1ccc(\C=C\C(=O)NO)c1, CN(C)Cc1ccc(cc1)S(=O)(=O)n1ccc(\C=C\C(=O)NO)c1, CN(C)Cc1ccc(cc1)S(=O)(=O)n1ccc(\C=C\C(=O)NO)c1, CN(C)Cc1ccc(cc1)S(=O)(=O)n1ccc(\C=C\C(=O)NO)c1, CN(C)Cc1ccc(cc1)S(=O)(=O)n1ccc(\C=C\C(=O)NO)c1, CN(C)Cc1ccc(cc1)S(=O)(=O)n1ccc(\C=C\C(=O)NO)c1, CN(C)Cc1ccc(cc1)S(=O)(=O)n1ccc(\C=C\C(=O)NO)c1, CN(C)Cc1ccc(cc1)S(=O)(=O)n1ccc(\C=C\C(=O)NO)c1, CN(C)Cc1ccc(cc1)S(=O)(=O)n1ccc(\C=C\C(=O)NO)c1	FECGNJPYVFEKOD-VMPITWQZSA-N, FECGNJPYVFEKOD-VMPITWQZSA-N, FECGNJPYVFEKOD-VMPITWQZSA-N, FECGNJPYVFEKOD-VMPITWQZSA-N, FECGNJPYVFEKOD-VMPITWQZSA-N, FECGNJPYVFEKOD-VMPITWQZSA-N, FECGNJPYVFEKOD-VMPITWQZSA-N, FECGNJPYVFEKOD-VMPITWQZSA-N, FECGNJPYVFEKOD-VMPITWQZSA-N, FECGNJPYVFEKOD-VMPITWQZSA-N, FECGNJPYVFEKOD-VMPITWQZSA-N	Phase 2
resorcinol	phosphodiesterase inhibitor	CA12, CA14, CA2, PTGS1	dermatology	acne vulgaris (AV), eczema, psoriasis, seborrheic dermatitis	Oc1cccc(O)c1, Oc1cccc(O)c1, Oc1cccc(O)c1	GHMLBKRAJCXXBS-UHFFFAOYSA-N, GHMLBKRAJCXXBS-UHFFFAOYSA-N, GHMLBKRAJCXXBS-UHFFFAOYSA-N	Launched
resorcinol-monoacetate	antiseptic				CC(=O)Oc1cccc(O)c1, CC(=O)Oc1cccc(O)c1	ZZPKZRHERLGEKA-UHFFFAOYSA-N, ZZPKZRHERLGEKA-UHFFFAOYSA-N	Launched
resveratrol	cytochrome P450 inhibitor, SIRT activator	CSNK2A1, NQO2, PTGS1, PTGS2			Oc1ccc(\C=C\c2cc(O)cc(O)c2)cc1, Oc1ccc(\C=C\c2cc(O)cc(O)c2)cc1, Oc1ccc(\C=C\c2cc(O)cc(O)c2)cc1, Oc1ccc(\C=C\c2cc(O)cc(O)c2)cc1, Oc1ccc(\C=C\c2cc(O)cc(O)c2)cc1	LUKBXSAWLPMMSZ-OWOJBTEDSA-N, LUKBXSAWLPMMSZ-OWOJBTEDSA-N, LUKBXSAWLPMMSZ-OWOJBTEDSA-N, LUKBXSAWLPMMSZ-OWOJBTEDSA-N, LUKBXSAWLPMMSZ-OWOJBTEDSA-N	Launched
retagliptin	dipeptidyl peptidase inhibitor				COC(=O)c1nc(n2CCN(Cc12)C(=O)C[C@H](N)Cc1cc(F)c(F)cc1F)C(F)(F)F	WIIAMRXFUJLYEF-SNVBAGLBSA-N	Phase 1
retapamulin	protein synthesis inhibitor		infectious disease	impetigo	C[C@@H]1CC[C@@]23CCC(=O)[C@H]2[C@]1(C)[C@@H](C[C@@](C)(C=C)[C@@H](O)[C@@H]3C)OC(=O)CS[C@H]1C[C@@H]2CC[C@H](C1)N2C	STZYTFJPGGDRJD-NHUWBDDWSA-N	Launched
retaspimycin	HSP inhibitor	HSP90AA1			CO[C@H]1C[C@H](C)Cc2c(O)c(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)cc(O)c2NCC=C |c:17,t:15,28|, CO[C@H]1C[C@H](C)Cc2c(O)c(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)cc(O)c2NCC=C |c:17,t:15,28|	OAKGNIRUXAZDQF-FBDSWQSESA-N, OAKGNIRUXAZDQF-FBDSWQSESA-N	Phase 3
retinaldehyde			dermatology	cosmetic	C\C(\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C)=C/C=O |c:9|	NCYCYZXNIZJOKI-OVSJKPMPSA-N	Launched
retinol	retinoid receptor ligand	ALDH1A1, ALDH1A2, ALDH1A3, DHRS3, DHRS4, LRAT, NR2C2, RBP1, RBP3, RDH11, RDH12, RDH13, RDH14, RDH5, RDH8, RETSAT, RHO, RLBP1, RXRA, RXRB, RXRG	dermatology	cosmetic, acne vulgaris (AV), keratosis	C\C(=C/CO)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C |c:12|, C\C(=C/CO)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C |c:12|	FPIPGXGPPPQFEQ-OVSJKPMPSA-N, FPIPGXGPPPQFEQ-OVSJKPMPSA-N	Launched
retinyl-acetate					CC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C |c:15|, CC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C |c:15|	QGNJRVVDBSJHIZ-QHLGVNSISA-N, QGNJRVVDBSJHIZ-QHLGVNSISA-N	Launched
retinyl-palmitate					CCCCCCCCCCCCCCCC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C |c:29|, CCCCCCCCCCCCCCCC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C |c:29|	VYGQUTWHTHXGQB-FFHKNEKCSA-N, VYGQUTWHTHXGQB-FFHKNEKCSA-N	Launched
REV-5901	leukotriene receptor antagonist, lipoxygenase inhibitor	ALOX5			CCCCC[C@@H](O)c1cccc(OCc2ccc3ccccc3n2)c1 |&1:5,r|, CCCCC[C@@H](O)c1cccc(OCc2ccc3ccccc3n2)c1 |&1:5,r|, CCCCC[C@@H](O)c1cccc(OCc2ccc3ccccc3n2)c1 |&1:5,r|, CCCCC[C@@H](O)c1cccc(OCc2ccc3ccccc3n2)c1 |&1:5,r|	JRLOEMCOOZSCQP-JOCHJYFZSA-N, JRLOEMCOOZSCQP-JOCHJYFZSA-N, JRLOEMCOOZSCQP-JOCHJYFZSA-N, JRLOEMCOOZSCQP-JOCHJYFZSA-N	Phase 2
revaprazan	potassium-competitive acid antagonist	ATP4A	gastroenterology	gastritis	C[C@H]1N(CCc2ccccc12)c1nc(Nc2ccc(F)cc2)nc(C)c1C |&1:1,r|	LECZXZOBEZITCL-MRXNPFEDSA-N	Launched
revefenacin	cholinergic receptor antagonist				CN(CCN1CCC(CC1)OC(=O)Nc1ccccc1-c1ccccc1)C(=O)c1ccc(CN2CCC(CC2)C(N)=O)cc1	FYDWDCIFZSGNBU-UHFFFAOYSA-N	Launched
reversan	MRP inhibitor	ABCC1			O=C(NCCCN1CCOCC1)c1cnn2c(cc(nc12)-c1ccccc1)-c1ccccc1, O=C(NCCCN1CCOCC1)c1cnn2c(cc(nc12)-c1ccccc1)-c1ccccc1, O=C(NCCCN1CCOCC1)c1cnn2c(cc(nc12)-c1ccccc1)-c1ccccc1	JTRXWCLQFAZHGP-UHFFFAOYSA-N, JTRXWCLQFAZHGP-UHFFFAOYSA-N, JTRXWCLQFAZHGP-UHFFFAOYSA-N	Preclinical
reversine	Aurora kinase inhibitor	AURKB, INCENP, MAP2K1			C1CCC(CC1)Nc1nc(Nc2ccc(cc2)N2CCOCC2)nc2nc[nH]c12, C1CCC(CC1)Nc1nc(Nc2ccc(cc2)N2CCOCC2)nc2nc[nH]c12, C1CCC(CC1)Nc1nc(Nc2ccc(cc2)N2CCOCC2)nc2nc[nH]c12	ZFLJHSQHILSNCM-UHFFFAOYSA-N, ZFLJHSQHILSNCM-UHFFFAOYSA-N, ZFLJHSQHILSNCM-UHFFFAOYSA-N	Preclinical
reynoutrin	antioxidant				O[C@@H]1CO[C@@H](Oc2c(oc3cc(O)cc(O)c3c2=O)-c2ccc(O)c(O)c2)[C@H](O)[C@H]1O, O[C@@H]1CO[C@@H](Oc2c(oc3cc(O)cc(O)c3c2=O)-c2ccc(O)c(O)c2)[C@H](O)[C@H]1O	PZZRDJXEMZMZFD-BWYUNELBSA-N, PZZRDJXEMZMZFD-BWYUNELBSA-N	Preclinical
RGB-286638	CDK inhibitor	CDK1, CDK2, CDK3, CDK4, CDK5, CDK6, CDK7, CDK9, FLT3, GSK3B, JAK2, MAP3K7, MAPK9			COCCN1CCN(Cc2ccc(cc2)-c2n[nH]c3-c4cccc(NC(=O)NN5CCOCC5)c4C(=O)c23)CC1, COCCN1CCN(Cc2ccc(cc2)-c2n[nH]c3-c4cccc(NC(=O)NN5CCOCC5)c4C(=O)c23)CC1, COCCN1CCN(Cc2ccc(cc2)-c2n[nH]c3-c4cccc(NC(=O)NN5CCOCC5)c4C(=O)c23)CC1, COCCN1CCN(Cc2ccc(cc2)-c2n[nH]c3-c4cccc(NC(=O)NN5CCOCC5)c4C(=O)c23)CC1	XLSYZSRXVVCHLS-UHFFFAOYSA-N, XLSYZSRXVVCHLS-UHFFFAOYSA-N, XLSYZSRXVVCHLS-UHFFFAOYSA-N, XLSYZSRXVVCHLS-UHFFFAOYSA-N	Phase 1
RGFP966	HDAC inhibitor	HDAC3			Nc1cc(F)ccc1NC(=O)\C=C\c1cnn(C\C=C\c2ccccc2)c1, Nc1cc(F)ccc1NC(=O)\C=C\c1cnn(C\C=C\c2ccccc2)c1, Nc1cc(F)ccc1NC(=O)\C=C\c1cnn(C\C=C\c2ccccc2)c1	BLVQHYHDYFTPDV-VCABWLAWSA-N, BLVQHYHDYFTPDV-VCABWLAWSA-N, BLVQHYHDYFTPDV-VCABWLAWSA-N	Preclinical
RGX-104	LXR agonist				C[C@H](CCOc1cccc(CC(O)=O)c1)N(CC(c1ccccc1)c1ccccc1)Cc1cccc(c1Cl)C(F)(F)F	ZLJZDYOBXVOTSA-XMMPIXPASA-N	Phase 1
RG108	DNA methyltransferase inhibitor	DNMT1, DNMT3B			OC(=O)[C@H](Cc1c[nH]c2ccccc12)N1C(=O)c2ccccc2C1=O, OC(=O)[C@H](Cc1c[nH]c2ccccc12)N1C(=O)c2ccccc2C1=O, OC(=O)[C@H](Cc1c[nH]c2ccccc12)N1C(=O)c2ccccc2C1=O, OC(=O)[C@H](Cc1c[nH]c2ccccc12)N1C(=O)c2ccccc2C1=O	HPTXLHAHLXOAKV-INIZCTEOSA-N, HPTXLHAHLXOAKV-INIZCTEOSA-N, HPTXLHAHLXOAKV-INIZCTEOSA-N, HPTXLHAHLXOAKV-INIZCTEOSA-N	Preclinical
RG1530	FGFR inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	FGFR1, FGFR2			COc1cc2N=C3NN=C(C)C3N=C(c3ccccc3Cl)c2cc1F |t:5,8,13|, COc1cc2N=C3NN=C(C)C3N=C(c3ccccc3Cl)c2cc1F |t:5,8,13|, COc1cc2N=C3NN=C(C)C3N=C(c3ccccc3Cl)c2cc1F |t:5,8,13|, COc1cc2N=C3NN=C(C)C3N=C(c3ccccc3Cl)c2cc1F |t:5,8,13|	XXAKBYBCWYYQTL-UHFFFAOYSA-N, XXAKBYBCWYYQTL-UHFFFAOYSA-N, XXAKBYBCWYYQTL-UHFFFAOYSA-N, XXAKBYBCWYYQTL-UHFFFAOYSA-N	Phase 1
RG2833	HDAC inhibitor	HDAC1, HDAC3			Cc1ccc(cc1)C(=O)NCCCCCC(=O)Nc1ccccc1N, Cc1ccc(cc1)C(=O)NCCCCCC(=O)Nc1ccccc1N, Cc1ccc(cc1)C(=O)NCCCCCC(=O)Nc1ccccc1N, Cc1ccc(cc1)C(=O)NCCCCCC(=O)Nc1ccccc1N, Cc1ccc(cc1)C(=O)NCCCCCC(=O)Nc1ccccc1N	VOPDXHFYDJAYNS-UHFFFAOYSA-N, VOPDXHFYDJAYNS-UHFFFAOYSA-N, VOPDXHFYDJAYNS-UHFFFAOYSA-N, VOPDXHFYDJAYNS-UHFFFAOYSA-N, VOPDXHFYDJAYNS-UHFFFAOYSA-N	Phase 1
RG4733	gamma secretase inhibitor	PSEN1			CC(C)(C(=O)NCC(F)(F)C(F)(F)F)C(=O)N[C@H]1c2ccccc2-c2ccccc2NC1=O, CC(C)(C(=O)NCC(F)(F)C(F)(F)F)C(=O)N[C@H]1c2ccccc2-c2ccccc2NC1=O, CC(C)(C(=O)NCC(F)(F)C(F)(F)F)C(=O)N[C@H]1c2ccccc2-c2ccccc2NC1=O, CC(C)(C(=O)NCC(F)(F)C(F)(F)F)C(=O)N[C@H]1c2ccccc2-c2ccccc2NC1=O	OJPLJFIFUQPSJR-INIZCTEOSA-N, OJPLJFIFUQPSJR-INIZCTEOSA-N, OJPLJFIFUQPSJR-INIZCTEOSA-N, OJPLJFIFUQPSJR-INIZCTEOSA-N	Phase 2
RG7112	MDM inhibitor	MDM2			CCOc1cc(ccc1C1=N[C@@](C)(c2ccc(Cl)cc2)[C@](C)(N1C(=O)N1CCN(CCCS(C)(=O)=O)CC1)c1ccc(Cl)cc1)C(C)(C)C |t:10|	QBGKPEROWUKSBK-QPPIDDCLSA-N	Phase 1
RG7800	RNA splicing modifier				CCc1nc(C)cn2nc(cc12)-c1cc(=O)n2cc(cc(C)c2n1)C1CCN(C)CC1	GYFRQCMDLBNZSF-UHFFFAOYSA-N	Preclinical
RG7834	antiviral				COCCCOc1cc2C[C@@H](C(C)C)n3cc(C(O)=O)c(=O)cc3-c2cc1OC	KBXLMOYQNDMHQT-KRWDZBQOSA-N	Preclinical
RHC-80267	triacylglycerol lipase inhibitor	DAGLA, DAGLB			O=C(NCCCCCCNC(=O)ON=C1CCCCC1)ON=C1CCCCC1, O=C(NCCCCCCNC(=O)ON=C1CCCCC1)ON=C1CCCCC1, O=C(NCCCCCCNC(=O)ON=C1CCCCC1)ON=C1CCCCC1	RXSVYGIGWRDVQC-UHFFFAOYSA-N, RXSVYGIGWRDVQC-UHFFFAOYSA-N, RXSVYGIGWRDVQC-UHFFFAOYSA-N	Preclinical
rhein		HSP90AA1			OC(=O)c1cc(O)c2C(=O)c3c(O)cccc3C(=O)c2c1, OC(=O)c1cc(O)c2C(=O)c3c(O)cccc3C(=O)c2c1, OC(=O)c1cc(O)c2C(=O)c3c(O)cccc3C(=O)c2c1	FCDLCPWAQCPTKC-UHFFFAOYSA-N, FCDLCPWAQCPTKC-UHFFFAOYSA-N, FCDLCPWAQCPTKC-UHFFFAOYSA-N	Phase 1
rheochrysidin	protein tyrosine kinase inhibitor	PTPN1			COc1cc(O)c2C(=O)c3c(O)cc(C)cc3C(=O)c2c1, COc1cc(O)c2C(=O)c3c(O)cc(C)cc3C(=O)c2c1, COc1cc(O)c2C(=O)c3c(O)cc(C)cc3C(=O)c2c1	FFWOKTFYGVYKIR-UHFFFAOYSA-N, FFWOKTFYGVYKIR-UHFFFAOYSA-N, FFWOKTFYGVYKIR-UHFFFAOYSA-N	Preclinical
rhodamine-123					COC(=O)c1ccccc1-c1c2ccc(N)cc2[o+]c2cc(N)ccc12, COC(=O)c1ccccc1-c1c2ccc(N)cc2[o+]c2cc(N)ccc12, COC(=O)c1ccccc1-c1c2ccc(N)cc2[o+]c2cc(N)ccc12	ZWODABSNRKVFCK-UHFFFAOYSA-N, ZWODABSNRKVFCK-UHFFFAOYSA-N, ZWODABSNRKVFCK-UHFFFAOYSA-N	Phase 1
RI-1		RAD51			ClC1=C(N2CCOCC2)C(=O)N(C1=O)c1ccc(Cl)c(Cl)c1 |c:1|, ClC1=C(N2CCOCC2)C(=O)N(C1=O)c1ccc(Cl)c(Cl)c1 |c:1|	MWSUIZKGNWELRF-UHFFFAOYSA-N, MWSUIZKGNWELRF-UHFFFAOYSA-N	Preclinical
ribavirin	antiviral	ADK, ENPP1, IMPDH1, IMPDH2, NT5C2	infectious disease	hepatitis C	NC(=O)c1ncn(n1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O, NC(=O)c1ncn(n1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O, NC(=O)c1ncn(n1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O, NC(=O)c1ncn(n1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O, NC(=O)c1ncn(n1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O	IWUCXVSUMQZMFG-AFCXAGJDSA-N, IWUCXVSUMQZMFG-AFCXAGJDSA-N, IWUCXVSUMQZMFG-AFCXAGJDSA-N, IWUCXVSUMQZMFG-AFCXAGJDSA-N, IWUCXVSUMQZMFG-AFCXAGJDSA-N	Launched
ribitol					OC[C@H](O)[C@H](O)[C@H](O)CO, OC[C@H](O)[C@H](O)[C@H](O)CO	HEBKCHPVOIAQTA-ZXFHETKHSA-N, HEBKCHPVOIAQTA-ZXFHETKHSA-N	Preclinical
ribociclib	CDK inhibitor	CDK4, CDK6	oncology	breast cancer	CN(C)C(=O)c1cc2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n1C1CCCC1, CN(C)C(=O)c1cc2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n1C1CCCC1, CN(C)C(=O)c1cc2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n1C1CCCC1, CN(C)C(=O)c1cc2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n1C1CCCC1, CN(C)C(=O)c1cc2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n1C1CCCC1, CN(C)C(=O)c1cc2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n1C1CCCC1, CN(C)C(=O)c1cc2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n1C1CCCC1, CN(C)C(=O)c1cc2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n1C1CCCC1	RHXHGRAEPCAFML-UHFFFAOYSA-N, RHXHGRAEPCAFML-UHFFFAOYSA-N, RHXHGRAEPCAFML-UHFFFAOYSA-N, RHXHGRAEPCAFML-UHFFFAOYSA-N, RHXHGRAEPCAFML-UHFFFAOYSA-N, RHXHGRAEPCAFML-UHFFFAOYSA-N, RHXHGRAEPCAFML-UHFFFAOYSA-N, RHXHGRAEPCAFML-UHFFFAOYSA-N	Launched
riboflavin	vitamin B	BLVRB, RFK	gastroenterology	jaundice	Cc1cc2nc3c(nc(=O)[nH]c3=O)n(C[C@H](O)[C@H](O)[C@H](O)CO)c2cc1C, Cc1cc2nc3c(nc(=O)[nH]c3=O)n(C[C@H](O)[C@H](O)[C@H](O)CO)c2cc1C, Cc1cc2nc3c(nc(=O)[nH]c3=O)n(C[C@H](O)[C@H](O)[C@H](O)CO)c2cc1C, Cc1cc2nc3c(nc(=O)[nH]c3=O)n(C[C@H](O)[C@H](O)[C@H](O)CO)c2cc1C	AUNGANRZJHBGPY-SCRDCRAPSA-N, AUNGANRZJHBGPY-SCRDCRAPSA-N, AUNGANRZJHBGPY-SCRDCRAPSA-N, AUNGANRZJHBGPY-SCRDCRAPSA-N	Launched
riboflavin-tetrabutyrate	antioxidant				CCCC(=O)OC[C@@H](OC(=O)CCC)[C@@H](OC(=O)CCC)[C@H](Cn1c2cc(C)c(C)cc2nc2c1nc(=O)[nH]c2=O)OC(=O)CCC	MJNIWUJSIGSWKK-BBANNHEPSA-N	Preclinical
riboflavin-5-phosphate-sodium		BLVRB, DHODH, DPYD, HAO1, HAO2, MT-ND1, NOS1, PNPO, POR, PPCDC, RFK, RPS6KA4, SGK1			Cc1cc2nc3c(nc(=O)[nH]c3=O)n(C[C@H](O)[C@H](O)[C@H](O)COP(O)(O)=O)c2cc1C, Cc1cc2nc3c(nc(=O)[nH]c3=O)n(C[C@H](O)[C@H](O)[C@H](O)COP(O)(O)=O)c2cc1C, Cc1cc2nc3c(nc(=O)[nH]c3=O)n(C[C@H](O)[C@H](O)[C@H](O)COP(O)(O)=O)c2cc1C	FVTCRASFADXXNN-SCRDCRAPSA-N, FVTCRASFADXXNN-SCRDCRAPSA-N, FVTCRASFADXXNN-SCRDCRAPSA-N	Launched
ribostamycin	bacterial 30S ribosomal subunit inhibitor	P4HB	infectious disease	human immunodeficiency virus (HIV-1)	NC[C@H]1O[C@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O)[C@H]2O[C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)[C@H](N)[C@@H](O)[C@@H]1O, NC[C@H]1O[C@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O)[C@H]2O[C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)[C@H](N)[C@@H](O)[C@@H]1O, NC[C@H]1O[C@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O)[C@H]2O[C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)[C@H](N)[C@@H](O)[C@@H]1O	NSKGQURZWSPSBC-VVPCINPTSA-N, NSKGQURZWSPSBC-VVPCINPTSA-N, NSKGQURZWSPSBC-VVPCINPTSA-N	Launched
ribostamycin-sulfate	bacterial 30S ribosomal subunit inhibitor		infectious disease	gram-negative bacterial infections	NC[C@H]1O[C@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O)[C@@H]2O[C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)[C@H](N)[C@@H](O)[C@@H]1O |a:2,4,6,7,10,12,16,18,21,23,25,27,29,&1:14|	NSKGQURZWSPSBC-NZJHKTKDSA-N	Launched
ricinoleic-acid	prostanoid receptor agonist	PTGER3			CCCCCC[C@@H](O)C\C=C/CCCCCCCC(O)=O	WBHHMMIMDMUBKC-QJWNTBNXSA-N	Launched
ridinilazole	antibacterial				c1cc(ccn1)-c1nc2ccc(cc2[nH]1)-c1ccc2nc([nH]c2c1)-c1ccncc1	UHQFBTAJFNVZIV-UHFFFAOYSA-N	Phase 3
rifabutin	protein synthesis inhibitor		infectious disease	human immunodeficiency virus (HIV-1)	CO[C@H]1\C=C\O[C@@]2(C)Oc3c(C2=O)c2C4=NC5(CCN(CC(C)C)CC5)NC4=C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C(=O)c2c(O)c3C |c:36,t:3,15,30,38|	ATEBXHFBFRCZMA-DVAZEERGSA-N	Launched
rifampin	RNA polymerase inhibitor	NR1I2, SLCO1A2, SLCO1B1, SLCO1B3	infectious disease	tuberculosis, meningitis	CO[C@H]1\C=C\O[C@@]2(C)Oc3c(C2=O)c2c(O)c(\C=N\N4CCN(C)CC4)c(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)c(O)c2c(O)c3C |c:33,t:3,35|, CO[C@H]1\C=C\O[C@@]2(C)Oc3c(C2=O)c2c(O)c(\C=N\N4CCN(C)CC4)c(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)c(O)c2c(O)c3C |c:33,t:3,35|, CO[C@H]1\C=C\O[C@@]2(C)Oc3c(C2=O)c2c(O)c(\C=N\N4CCN(C)CC4)c(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)c(O)c2c(O)c3C |c:33,t:3,35|, CO[C@H]1\C=C\O[C@@]2(C)Oc3c(C2=O)c2c(O)c(\C=N\N4CCN(C)CC4)c(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)c(O)c2c(O)c3C |c:33,t:3,35|, CO[C@H]1\C=C\O[C@@]2(C)Oc3c(C2=O)c2c(O)c(\C=N\N4CCN(C)CC4)c(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)c(O)c2c(O)c3C |c:33,t:3,35|	JQXXHWHPUNPDRT-YOPQJBRCSA-N, JQXXHWHPUNPDRT-YOPQJBRCSA-N, JQXXHWHPUNPDRT-YOPQJBRCSA-N, JQXXHWHPUNPDRT-YOPQJBRCSA-N, JQXXHWHPUNPDRT-YOPQJBRCSA-N	Launched
rifamycin	DNA directed RNA polymerase inhibitor	SLCO1A2, SLCO1B1, SLCO1B3, SLCO2B1	infectious disease	tuberculosis, leprosy	CO[C@H]1\C=C\O[C@@]2(C)Oc3c(C2=O)c2c(O)cc(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)c(O)c2c(O)c3C |c:23,t:3,25|	HJYYPODYNSCCOU-WURVRSKISA-N	Launched
rifamycin-sv	RNA synthesis inhibitor				CO[C@H]1\C=C\O[C@@]2(C)Oc3c(C2=O)c2c(O)cc(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)c(O)c2c(O)c3C |c:23,t:3,25|	HJYYPODYNSCCOU-WURVRSKISA-N	Phase 3
rifapentine	RNA polymerase inhibitor	CYP2C8, CYP2C9, CYP3A4	infectious disease	tuberculosis	CO[C@H]1\C=C\O[C@@]2(C)Oc3c(C2=O)c2c(O)c(\C=N\N4CCN(CC4)C4CCCC4)c(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)c(O)c2c(O)c3C |c:38,t:3,40|, CO[C@H]1\C=C\O[C@@]2(C)Oc3c(C2=O)c2c(O)c(\C=N\N4CCN(CC4)C4CCCC4)c(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)c(O)c2c(O)c3C |c:38,t:3,40|, CO[C@H]1\C=C\O[C@@]2(C)Oc3c(C2=O)c2c(O)c(\C=N\N4CCN(CC4)C4CCCC4)c(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)c(O)c2c(O)c3C |c:38,t:3,40|, CO[C@H]1\C=C\O[C@@]2(C)Oc3c(C2=O)c2c(O)c(\C=N\N4CCN(CC4)C4CCCC4)c(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)c(O)c2c(O)c3C |c:38,t:3,40|, CO[C@H]1\C=C\O[C@@]2(C)Oc3c(C2=O)c2c(O)c(\C=N\N4CCN(CC4)C4CCCC4)c(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)c(O)c2c(O)c3C |c:38,t:3,40|	WDZCUPBHRAEYDL-NAFQJNKLSA-N, WDZCUPBHRAEYDL-NAFQJNKLSA-N, WDZCUPBHRAEYDL-NAFQJNKLSA-N, WDZCUPBHRAEYDL-NAFQJNKLSA-N, WDZCUPBHRAEYDL-NAFQJNKLSA-N	Launched
rifaximin	RNA synthesis inhibitor		gastroenterology	diarrhea, irritable bowel syndrome, hepatic encephalopathy (HE)	CO[C@H]1\C=C\O[C@@]2(C)Oc3c(C2=O)c2c4nc5cc(C)ccn5c4c(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)c(O)c2c(O)c3C |c:32,t:3,34|, CO[C@H]1\C=C\O[C@@]2(C)Oc3c(C2=O)c2c4nc5cc(C)ccn5c4c(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)c(O)c2c(O)c3C |c:32,t:3,34|	NZCRJKRKKOLAOJ-LGPAXTBISA-N, NZCRJKRKKOLAOJ-LGPAXTBISA-N	Launched
rigosertib	cell cycle inhibitor, PLK inhibitor	PLK1			COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(NCC(O)=O)c2)c(OC)c1, COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(NCC(O)=O)c2)c(OC)c1, COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(NCC(O)=O)c2)c(OC)c1, COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(NCC(O)=O)c2)c(OC)c1, COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(NCC(O)=O)c2)c(OC)c1, COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(NCC(O)=O)c2)c(OC)c1, COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(NCC(O)=O)c2)c(OC)c1	OWBFCJROIKNMGD-BQYQJAHWSA-N, OWBFCJROIKNMGD-BQYQJAHWSA-N, OWBFCJROIKNMGD-BQYQJAHWSA-N, OWBFCJROIKNMGD-BQYQJAHWSA-N, OWBFCJROIKNMGD-BQYQJAHWSA-N, OWBFCJROIKNMGD-BQYQJAHWSA-N, OWBFCJROIKNMGD-BQYQJAHWSA-N	Phase 3
rilapladib	phospholipase inhibitor				COCCN1CCC(CC1)N(Cc1ccc(cc1)-c1ccc(cc1)C(F)(F)F)C(=O)Cn1c(SCc2cccc(F)c2F)cc(=O)c2ccccc12	NNBGCSGCRSCFEA-UHFFFAOYSA-N	Phase 2
rilmenidine	adrenergic receptor agonist, imidazoline receptor agonist	ADRA2A	cardiology	hypertension	C1CC1C(NC1=NCCO1)C1CC1 |t:6|, C1CC1C(NC1=NCCO1)C1CC1 |t:6|, C1CC1C(NC1=NCCO1)C1CC1 |t:6|	CQXADFVORZEARL-UHFFFAOYSA-N, CQXADFVORZEARL-UHFFFAOYSA-N, CQXADFVORZEARL-UHFFFAOYSA-N	Launched
rilpivirine	non-nucleoside reverse transcriptase inhibitor	NR1I2, SCN10A	infectious disease	human immunodeficiency virus (HIV-1)	Cc1cc(\C=C\C#N)cc(C)c1Nc1ccnc(Nc2ccc(cc2)C#N)n1, Cc1cc(\C=C\C#N)cc(C)c1Nc1ccnc(Nc2ccc(cc2)C#N)n1, Cc1cc(\C=C\C#N)cc(C)c1Nc1ccnc(Nc2ccc(cc2)C#N)n1	YIBOMRUWOWDFLG-ONEGZZNKSA-N, YIBOMRUWOWDFLG-ONEGZZNKSA-N, YIBOMRUWOWDFLG-ONEGZZNKSA-N	Launched
riluzole	glutamate inhibitor	KCNK10, KCNK2, KCNK4, KCNN4, SCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A, SLC7A11	neurology/psychiatry	amyotrophic lateral sclerosis (ALS)	Nc1nc2ccc(OC(F)(F)F)cc2s1, Nc1nc2ccc(OC(F)(F)F)cc2s1, Nc1nc2ccc(OC(F)(F)F)cc2s1, Nc1nc2ccc(OC(F)(F)F)cc2s1	FTALBRSUTCGOEG-UHFFFAOYSA-N, FTALBRSUTCGOEG-UHFFFAOYSA-N, FTALBRSUTCGOEG-UHFFFAOYSA-N, FTALBRSUTCGOEG-UHFFFAOYSA-N	Launched
rimantadine	antiviral, RNA synthesis inhibitor		infectious disease	influenza A virus infection	C[C@@H](N)C12CC3CC(CC(C3)C1)C2 |&1:1,r|, C[C@@H](N)C12CC3CC(CC(C3)C1)C2 |&1:1,r|, C[C@@H](N)C12CC3CC(CC(C3)C1)C2 |&1:1,r|	UBCHPRBFMUDMNC-AAWJQDODSA-N, UBCHPRBFMUDMNC-AAWJQDODSA-N, UBCHPRBFMUDMNC-AAWJQDODSA-N	Launched
rimcazole	sigma receptor antagonist	SIGMAR1			C[C@H]1CN(CCCn2c3ccccc3c3ccccc23)C[C@@H](C)N1, C[C@H]1CN(CCCn2c3ccccc3c3ccccc23)C[C@@H](C)N1	GUDVQJXODNJRIJ-CALCHBBNSA-N, GUDVQJXODNJRIJ-CALCHBBNSA-N	Phase 1
rimegepant	calcitonin antagonist	CALCA			N[C@H]1[C@@H](CC[C@@H](OC(=O)N2CCC(CC2)n2c3cccnc3[nH]c2=O)c2ncccc12)c1cccc(F)c1F, N[C@H]1[C@@H](CC[C@@H](OC(=O)N2CCC(CC2)n2c3cccnc3[nH]c2=O)c2ncccc12)c1cccc(F)c1F, N[C@H]1[C@@H](CC[C@@H](OC(=O)N2CCC(CC2)n2c3cccnc3[nH]c2=O)c2ncccc12)c1cccc(F)c1F	KRNAOFGYEFKHPB-ANJVHQHFSA-N, KRNAOFGYEFKHPB-ANJVHQHFSA-N, KRNAOFGYEFKHPB-ANJVHQHFSA-N	Launched
rimeporide	sodium/hydrogen exchanger inhibitor				Cc1cc(c(cc1C(=O)NC(N)=N)S(C)(=O)=O)S(C)(=O)=O	GROMEQPXDKRRIE-UHFFFAOYSA-N	Phase 1
rimexolone	glucocorticoid receptor agonist	NR3C1, SERPINA6	ophthalmology	anterior uveitis	CCC(=O)[C@@]1(C)[C@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]12C |c:17,t:13|, CCC(=O)[C@@]1(C)[C@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]12C |c:17,t:13|, CCC(=O)[C@@]1(C)[C@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]12C |c:17,t:13|	QTTRZHGPGKRAFB-OOKHYKNYSA-N, QTTRZHGPGKRAFB-OOKHYKNYSA-N, QTTRZHGPGKRAFB-OOKHYKNYSA-N	Launched
rimonabant	cannabinoid receptor antagonist	CNR1, GPR55			Cc1c(nn(c1-c1ccc(Cl)cc1)-c1ccc(Cl)cc1Cl)C(=O)NN1CCCCC1, Cc1c(nn(c1-c1ccc(Cl)cc1)-c1ccc(Cl)cc1Cl)C(=O)NN1CCCCC1, Cc1c(nn(c1-c1ccc(Cl)cc1)-c1ccc(Cl)cc1Cl)C(=O)NN1CCCCC1	JZCPYUJPEARBJL-UHFFFAOYSA-N, JZCPYUJPEARBJL-UHFFFAOYSA-N, JZCPYUJPEARBJL-UHFFFAOYSA-N	Withdrawn
riociguat	guanylate cyclase stimulant	GUCY1A2, GUCY1A3, GUCY1B2, GUCY1B3	cardiology	hypertension	COC(=O)N(C)c1c(N)nc(nc1N)-c1nn(Cc2ccccc2F)c2ncccc12, COC(=O)N(C)c1c(N)nc(nc1N)-c1nn(Cc2ccccc2F)c2ncccc12, COC(=O)N(C)c1c(N)nc(nc1N)-c1nn(Cc2ccccc2F)c2ncccc12	WXXSNCNJFUAIDG-UHFFFAOYSA-N, WXXSNCNJFUAIDG-UHFFFAOYSA-N, WXXSNCNJFUAIDG-UHFFFAOYSA-N	Launched
riodipine	calcium channel blocker				COC(=O)C1=C(C)NC(C)=C(C1c1ccccc1OC(F)F)C(=O)OC |c:4,9|, COC(=O)C1=C(C)NC(C)=C(C1c1ccccc1OC(F)F)C(=O)OC |c:4,9|	AZVFIZVKGSPGPK-UHFFFAOYSA-N, AZVFIZVKGSPGPK-UHFFFAOYSA-N	Phase 2
riodoxol	other antibiotic				Oc1c(I)cc(I)c(O)c1I, Oc1c(I)cc(I)c(O)c1I, Oc1c(I)cc(I)c(O)c1I	XKFZYVWWXHCHIX-UHFFFAOYSA-N, XKFZYVWWXHCHIX-UHFFFAOYSA-N, XKFZYVWWXHCHIX-UHFFFAOYSA-N	Launched
ripasudil	rho associated kinase inhibitor	ROCK1, ROCK2	ophthalmology	glaucoma, ocular hypertension	C[C@H]1CNCCCN1S(=O)(=O)c1cccc2cncc(F)c12, C[C@H]1CNCCCN1S(=O)(=O)c1cccc2cncc(F)c12, C[C@H]1CNCCCN1S(=O)(=O)c1cccc2cncc(F)c12, C[C@H]1CNCCCN1S(=O)(=O)c1cccc2cncc(F)c12, C[C@H]1CNCCCN1S(=O)(=O)c1cccc2cncc(F)c12, C[C@H]1CNCCCN1S(=O)(=O)c1cccc2cncc(F)c12	QSKQVZWVLOIIEV-NSHDSACASA-N, QSKQVZWVLOIIEV-NSHDSACASA-N, QSKQVZWVLOIIEV-NSHDSACASA-N, QSKQVZWVLOIIEV-NSHDSACASA-N, QSKQVZWVLOIIEV-NSHDSACASA-N, QSKQVZWVLOIIEV-NSHDSACASA-N	Launched
ripazepam	benzodiazepine receptor agonist	GABRA1			CCn1nc(C)c2NC(=O)CN=C(c12)c1ccccc1 |c:11|, CCn1nc(C)c2NC(=O)CN=C(c12)c1ccccc1 |c:11|	YFHYNLHGFKXAIQ-UHFFFAOYSA-N, YFHYNLHGFKXAIQ-UHFFFAOYSA-N	Phase 2
ripretinib	receptor tyrosine protein kinase inhibitor				CCn1c2cc(NC)ncc2cc(-c2cc(NC(=O)Nc3ccccc3)c(F)cc2Br)c1=O	CEFJVGZHQAGLHS-UHFFFAOYSA-N	Phase 3
risdiplam	RNA splicing inhibitor				Cc1cn2nc(cc(C)c2n1)-c1cc(=O)n2cc(ccc2n1)N1CCNC2(CC2)C1	ASKZRYGFUPSJPN-UHFFFAOYSA-N	Phase 2/Phase 3
risedronate	osteoclast inhibitor	FDPS	orthopedics, endocrinology	osteoporosis, Paget's disease	OC(Cc1cccnc1)(P(O)(O)=O)P(O)(O)=O, OC(Cc1cccnc1)(P(O)(O)=O)P(O)(O)=O, OC(Cc1cccnc1)(P(O)(O)=O)P(O)(O)=O, OC(Cc1cccnc1)(P(O)(O)=O)P(O)(O)=O, OC(Cc1cccnc1)(P(O)(O)=O)P(O)(O)=O	IIDJRNMFWXDHID-UHFFFAOYSA-N, IIDJRNMFWXDHID-UHFFFAOYSA-N, IIDJRNMFWXDHID-UHFFFAOYSA-N, IIDJRNMFWXDHID-UHFFFAOYSA-N, IIDJRNMFWXDHID-UHFFFAOYSA-N	Launched
rislenemdaz	ionotropic glutamate receptor antagonist				Cc1ccc(COC(=O)N2CC[C@H](CNc3ncccn3)[C@H](F)C2)cc1	RECBFDWSXWAXHY-IAGOWNOFSA-N	Preclinical
risperidone	dopamine receptor antagonist, serotonin receptor antagonist	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, DRD4, HRH1, HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2C, HTR6, HTR7	neurology/psychiatry	schizophrenia, bipolar disorder, irritability	Cc1nc2CCCCn2c(=O)c1CCN1CCC(CC1)c1noc2cc(F)ccc12, Cc1nc2CCCCn2c(=O)c1CCN1CCC(CC1)c1noc2cc(F)ccc12	RAPZEAPATHNIPO-UHFFFAOYSA-N, RAPZEAPATHNIPO-UHFFFAOYSA-N	Launched
RITA	MDM inhibitor	MDM2			OCc1ccc(s1)-c1ccc(o1)-c1ccc(CO)s1, OCc1ccc(s1)-c1ccc(o1)-c1ccc(CO)s1, OCc1ccc(s1)-c1ccc(o1)-c1ccc(CO)s1	KZENBFUSKMWCJF-UHFFFAOYSA-N, KZENBFUSKMWCJF-UHFFFAOYSA-N, KZENBFUSKMWCJF-UHFFFAOYSA-N	Preclinical
ritanserin	serotonin receptor antagonist	ADRA1A, ADRA1B, ADRA1D, HTR1A, HTR1B, HTR1D, HTR2A, HTR2B, HTR2C, HTR5A, HTR6, HTR7			Cc1nc2sccn2c(=O)c1CCN1CCC(CC1)=C(c1ccc(F)cc1)c1ccc(F)cc1, Cc1nc2sccn2c(=O)c1CCN1CCC(CC1)=C(c1ccc(F)cc1)c1ccc(F)cc1, Cc1nc2sccn2c(=O)c1CCN1CCC(CC1)=C(c1ccc(F)cc1)c1ccc(F)cc1, Cc1nc2sccn2c(=O)c1CCN1CCC(CC1)=C(c1ccc(F)cc1)c1ccc(F)cc1, Cc1nc2sccn2c(=O)c1CCN1CCC(CC1)=C(c1ccc(F)cc1)c1ccc(F)cc1, Cc1nc2sccn2c(=O)c1CCN1CCC(CC1)=C(c1ccc(F)cc1)c1ccc(F)cc1	JUQLTPCYUFPYKE-UHFFFAOYSA-N, JUQLTPCYUFPYKE-UHFFFAOYSA-N, JUQLTPCYUFPYKE-UHFFFAOYSA-N, JUQLTPCYUFPYKE-UHFFFAOYSA-N, JUQLTPCYUFPYKE-UHFFFAOYSA-N, JUQLTPCYUFPYKE-UHFFFAOYSA-N	Phase 3
ritodrine	adrenergic receptor agonist		obstetrics/gynecology	premature labor	C[C@@H](NCCc1ccc(O)cc1)[C@@H](O)c1ccc(O)cc1 |&1:1,12|, C[C@@H](NCCc1ccc(O)cc1)[C@@H](O)c1ccc(O)cc1 |&1:1,12|, C[C@@H](NCCc1ccc(O)cc1)[C@@H](O)c1ccc(O)cc1 |&1:1,12|, C[C@@H](NCCc1ccc(O)cc1)[C@@H](O)c1ccc(O)cc1 |&1:1,12|	IOVGROKTTNBUGK-SJKOYZFVSA-N, IOVGROKTTNBUGK-SJKOYZFVSA-N, IOVGROKTTNBUGK-SJKOYZFVSA-N, IOVGROKTTNBUGK-SJKOYZFVSA-N	Withdrawn
ritonavir	HIV protease inhibitor	CYP1A2, CYP2B6, CYP2C19, CYP2C8, CYP2C9, CYP2D6, CYP2E1, CYP3A4, CYP3A5, CYP3A7	infectious disease	human immunodeficiency virus (HIV-1)	CC(C)[C@H](NC(=O)N(C)Cc1csc(n1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](Cc1ccccc1)NC(=O)OCc1cncs1)Cc1ccccc1, CC(C)[C@H](NC(=O)N(C)Cc1csc(n1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](Cc1ccccc1)NC(=O)OCc1cncs1)Cc1ccccc1, CC(C)[C@H](NC(=O)N(C)Cc1csc(n1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](Cc1ccccc1)NC(=O)OCc1cncs1)Cc1ccccc1	NCDNCNXCDXHOMX-XGKFQTDJSA-N, NCDNCNXCDXHOMX-XGKFQTDJSA-N, NCDNCNXCDXHOMX-XGKFQTDJSA-N	Launched
rivanicline	acetylcholine receptor agonist	CHRNA4, CHRNB2, CXCL8			CNCC\C=C\c1cccnc1, CNCC\C=C\c1cccnc1	JUOSGGQXEBBCJB-GORDUTHDSA-N, JUOSGGQXEBBCJB-GORDUTHDSA-N	Phase 2
rivaroxaban	coagulation factor inhibitor	F10	neurology/psychiatry, hematology, cardiology	stroke, systemic embolism, atrial fibrillation (AF), deep vein thrombosis (DVT), pulmonary embolism (PE)	Clc1ccc(s1)C(=O)NC[C@H]1CN(C(=O)O1)c1ccc(cc1)N1CCOCC1=O, Clc1ccc(s1)C(=O)NC[C@H]1CN(C(=O)O1)c1ccc(cc1)N1CCOCC1=O, Clc1ccc(s1)C(=O)NC[C@H]1CN(C(=O)O1)c1ccc(cc1)N1CCOCC1=O	KGFYHTZWPPHNLQ-AWEZNQCLSA-N, KGFYHTZWPPHNLQ-AWEZNQCLSA-N, KGFYHTZWPPHNLQ-AWEZNQCLSA-N	Launched
rivastigmine	acetylcholinesterase inhibitor	ACHE, BCHE	neurology/psychiatry	Alzheimer's disease, Parkinson's Disease, senile dementia	CCN(C)C(=O)Oc1cccc(c1)[C@H](C)N(C)C, CCN(C)C(=O)Oc1cccc(c1)[C@H](C)N(C)C, CCN(C)C(=O)Oc1cccc(c1)[C@H](C)N(C)C, CCN(C)C(=O)Oc1cccc(c1)[C@H](C)N(C)C, CCN(C)C(=O)Oc1cccc(c1)[C@H](C)N(C)C, CCN(C)C(=O)Oc1cccc(c1)[C@H](C)N(C)C, CCN(C)C(=O)Oc1cccc(c1)[C@H](C)N(C)C	XSVMFMHYUFZWBK-NSHDSACASA-N, XSVMFMHYUFZWBK-NSHDSACASA-N, XSVMFMHYUFZWBK-NSHDSACASA-N, XSVMFMHYUFZWBK-NSHDSACASA-N, XSVMFMHYUFZWBK-NSHDSACASA-N, XSVMFMHYUFZWBK-NSHDSACASA-N, XSVMFMHYUFZWBK-NSHDSACASA-N	Launched
rizatriptan	serotonin receptor agonist	HTR1A, HTR1B, HTR1D, HTR1E, HTR1F	neurology/psychiatry	migraine headache	CN(C)CCc1c[nH]c2ccc(Cn3cncn3)cc12, CN(C)CCc1c[nH]c2ccc(Cn3cncn3)cc12, CN(C)CCc1c[nH]c2ccc(Cn3cncn3)cc12, CN(C)CCc1c[nH]c2ccc(Cn3cncn3)cc12	ULFRLSNUDGIQQP-UHFFFAOYSA-N, ULFRLSNUDGIQQP-UHFFFAOYSA-N, ULFRLSNUDGIQQP-UHFFFAOYSA-N, ULFRLSNUDGIQQP-UHFFFAOYSA-N	Launched
RKI-1447	rho associated kinase inhibitor	CDC42BPA, DMPK, LIMK1, MYLK, PAK1, PKN1, ROCK1, ROCK2			Oc1cccc(CNC(=O)Nc2nc(cs2)-c2ccncc2)c1, Oc1cccc(CNC(=O)Nc2nc(cs2)-c2ccncc2)c1, Oc1cccc(CNC(=O)Nc2nc(cs2)-c2ccncc2)c1, Oc1cccc(CNC(=O)Nc2nc(cs2)-c2ccncc2)c1	GDVRVPIXWXOKQO-UHFFFAOYSA-N, GDVRVPIXWXOKQO-UHFFFAOYSA-N, GDVRVPIXWXOKQO-UHFFFAOYSA-N, GDVRVPIXWXOKQO-UHFFFAOYSA-N	Preclinical
RLX					O=c1n2CCCCCc2nc2ccccc12, O=c1n2CCCCCc2nc2ccccc12	HTLIIBRHXAULMB-UHFFFAOYSA-N, HTLIIBRHXAULMB-UHFFFAOYSA-N	Preclinical
RMC-4550	SHIP2 phosphatase inhibitor				C[C@@H]1OCC2(CCN(CC2)c2nc(C)c(nc2CO)-c2cccc(Cl)c2Cl)[C@@H]1N, C[C@@H]1OCC2(CCN(CC2)c2nc(C)c(nc2CO)-c2cccc(Cl)c2Cl)[C@@H]1N	IKUYEYLZXGGCRD-ORAYPTAESA-N, IKUYEYLZXGGCRD-ORAYPTAESA-N	Preclinical
RN-1	histone demethylase inhibitor	KDM1A			CN1CCN(CC1)C(=O)CN[C@@H]1C[C@H]1c1ccc(OCc2ccccc2)cc1, CN1CCN(CC1)C(=O)CN[C@@H]1C[C@H]1c1ccc(OCc2ccccc2)cc1	YAMSXCOVJUUMCT-FCHUYYIVSA-N, YAMSXCOVJUUMCT-FCHUYYIVSA-N	Preclinical
RN-1734	TRPV antagonist	TRPV4			CC(C)NCCN(C(C)C)S(=O)(=O)c1ccc(Cl)cc1Cl, CC(C)NCCN(C(C)C)S(=O)(=O)c1ccc(Cl)cc1Cl, CC(C)NCCN(C(C)C)S(=O)(=O)c1ccc(Cl)cc1Cl, CC(C)NCCN(C(C)C)S(=O)(=O)c1ccc(Cl)cc1Cl, CC(C)NCCN(C(C)C)S(=O)(=O)c1ccc(Cl)cc1Cl, CC(C)NCCN(C(C)C)S(=O)(=O)c1ccc(Cl)cc1Cl, CC(C)NCCN(C(C)C)S(=O)(=O)c1ccc(Cl)cc1Cl	IHYZMEAZAIFMTN-UHFFFAOYSA-N, IHYZMEAZAIFMTN-UHFFFAOYSA-N, IHYZMEAZAIFMTN-UHFFFAOYSA-N, IHYZMEAZAIFMTN-UHFFFAOYSA-N, IHYZMEAZAIFMTN-UHFFFAOYSA-N, IHYZMEAZAIFMTN-UHFFFAOYSA-N, IHYZMEAZAIFMTN-UHFFFAOYSA-N	Preclinical
RN-1747	TRPV agonist	TRPV4			[O-][N+](=O)c1cc(Cl)ccc1S(=O)(=O)N1CCN(Cc2ccccc2)CC1, [O-][N+](=O)c1cc(Cl)ccc1S(=O)(=O)N1CCN(Cc2ccccc2)CC1, [O-][N+](=O)c1cc(Cl)ccc1S(=O)(=O)N1CCN(Cc2ccccc2)CC1, [O-][N+](=O)c1cc(Cl)ccc1S(=O)(=O)N1CCN(Cc2ccccc2)CC1	ZNLVYSJQUMALEO-UHFFFAOYSA-N, ZNLVYSJQUMALEO-UHFFFAOYSA-N, ZNLVYSJQUMALEO-UHFFFAOYSA-N, ZNLVYSJQUMALEO-UHFFFAOYSA-N	Preclinical
Ro-04-5595	glutamate receptor antagonist	GRIN2B			COc1cc2CCN(C)[C@@H](CCc3ccc(Cl)cc3)c2cc1O |&1:9|, COc1cc2CCN(C)[C@@H](CCc3ccc(Cl)cc3)c2cc1O |&1:9|, COc1cc2CCN(C)[C@@H](CCc3ccc(Cl)cc3)c2cc1O |&1:9|	DSTWURHEHMZWEI-KRWDZBQOSA-N, DSTWURHEHMZWEI-KRWDZBQOSA-N, DSTWURHEHMZWEI-KRWDZBQOSA-N	Preclinical
Ro-08-2750	NGF binding inhibitor	NGF, NGFR			Cc1cc2nc3c(nc(=O)[nH]c3=O)n(C)c2cc1C=O, Cc1cc2nc3c(nc(=O)[nH]c3=O)n(C)c2cc1C=O, Cc1cc2nc3c(nc(=O)[nH]c3=O)n(C)c2cc1C=O	JDEMVNYMYPJJIM-UHFFFAOYSA-N, JDEMVNYMYPJJIM-UHFFFAOYSA-N, JDEMVNYMYPJJIM-UHFFFAOYSA-N	Preclinical
Ro-10-5824	dopamine receptor agonist	DRD4			Cc1ncc(CN2CCC(=CC2)c2ccccc2)c(N)n1 |c:9|, Cc1ncc(CN2CCC(=CC2)c2ccccc2)c(N)n1 |c:9|, Cc1ncc(CN2CCC(=CC2)c2ccccc2)c(N)n1 |c:9|, Cc1ncc(CN2CCC(=CC2)c2ccccc2)c(N)n1 |c:9|	KABDATZAOUSYES-UHFFFAOYSA-N, KABDATZAOUSYES-UHFFFAOYSA-N, KABDATZAOUSYES-UHFFFAOYSA-N, KABDATZAOUSYES-UHFFFAOYSA-N	Preclinical
Ro-106-9920	NFkB pathway inhibitor				O=[S@@](c1ccccc1)c1ccc2nnnn2n1 |&1:1,r|, O=[S@@](c1ccccc1)c1ccc2nnnn2n1 |&1:1,r|, O=[S@@](c1ccccc1)c1ccc2nnnn2n1 |&1:1,r|, O=[S@@](c1ccccc1)c1ccc2nnnn2n1 |&1:1,r|, O=[S@@](c1ccccc1)c1ccc2nnnn2n1 |&1:1,r|, O=[S@@](c1ccccc1)c1ccc2nnnn2n1 |&1:1,r|, O=[S@@](c1ccccc1)c1ccc2nnnn2n1 |&1:1,r|, O=[S@@](c1ccccc1)c1ccc2nnnn2n1 |&1:1,r|, O=[S@@](c1ccccc1)c1ccc2nnnn2n1 |&1:1,r|	JFSXSNSCPNFCDM-KRWDZBQOSA-N, JFSXSNSCPNFCDM-KRWDZBQOSA-N, JFSXSNSCPNFCDM-KRWDZBQOSA-N, JFSXSNSCPNFCDM-KRWDZBQOSA-N, JFSXSNSCPNFCDM-KRWDZBQOSA-N, JFSXSNSCPNFCDM-KRWDZBQOSA-N, JFSXSNSCPNFCDM-KRWDZBQOSA-N, JFSXSNSCPNFCDM-KRWDZBQOSA-N, JFSXSNSCPNFCDM-KRWDZBQOSA-N	Preclinical
Ro-1138452	prostanoid receptor antagonist	PTGIR			CC(C)Oc1ccc(Cc2ccc(NC3=NCCN3)cc2)cc1 |t:14|, CC(C)Oc1ccc(Cc2ccc(NC3=NCCN3)cc2)cc1 |t:14|, CC(C)Oc1ccc(Cc2ccc(NC3=NCCN3)cc2)cc1 |t:14|, CC(C)Oc1ccc(Cc2ccc(NC3=NCCN3)cc2)cc1 |t:14|	GYYRMJMXXLJZAB-UHFFFAOYSA-N, GYYRMJMXXLJZAB-UHFFFAOYSA-N, GYYRMJMXXLJZAB-UHFFFAOYSA-N, GYYRMJMXXLJZAB-UHFFFAOYSA-N	Preclinical
Ro-15-4513	GABA benzodiazepine site receptor inverse agonist	GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB2, GABRG2			CCOC(=O)c1ncn-2c1CN(C)C(=O)c1cc(ccc-21)N=[N+]=[N-], CCOC(=O)c1ncn-2c1CN(C)C(=O)c1cc(ccc-21)N=[N+]=[N-]	CFSOJZTUTOQNIA-UHFFFAOYSA-N, CFSOJZTUTOQNIA-UHFFFAOYSA-N	Preclinical
Ro-19-4605	GABA benzodiazepine site receptor inverse agonist	GABRA1, GABRA2, GABRA3, GABRA5			CN1Cc2c(ncn2-c2ccsc2C1=O)C(=O)OC(C)(C)C, CN1Cc2c(ncn2-c2ccsc2C1=O)C(=O)OC(C)(C)C, CN1Cc2c(ncn2-c2ccsc2C1=O)C(=O)OC(C)(C)C, CN1Cc2c(ncn2-c2ccsc2C1=O)C(=O)OC(C)(C)C	ZIGMMUKDYCABPW-UHFFFAOYSA-N, ZIGMMUKDYCABPW-UHFFFAOYSA-N, ZIGMMUKDYCABPW-UHFFFAOYSA-N, ZIGMMUKDYCABPW-UHFFFAOYSA-N	Preclinical
Ro-20-1724	phosphodiesterase inhibitor	PDE3A, PDE4A, PDE4B, PDE4C, PDE4D			CCCCOc1cc(C[C@H]2CNC(=O)N2)ccc1OC |&1:9,r|, CCCCOc1cc(C[C@H]2CNC(=O)N2)ccc1OC |&1:9,r|, CCCCOc1cc(C[C@H]2CNC(=O)N2)ccc1OC |&1:9,r|, CCCCOc1cc(C[C@H]2CNC(=O)N2)ccc1OC |&1:9,r|, CCCCOc1cc(C[C@H]2CNC(=O)N2)ccc1OC |&1:9,r|	PDMUULPVBYQBBK-LBPRGKRZSA-N, PDMUULPVBYQBBK-LBPRGKRZSA-N, PDMUULPVBYQBBK-LBPRGKRZSA-N, PDMUULPVBYQBBK-LBPRGKRZSA-N, PDMUULPVBYQBBK-LBPRGKRZSA-N	Preclinical
Ro-25-6981	glutamate receptor antagonist, monamine transporter modulator	GRIN2B			C[C@@H](CN1CCC(Cc2ccccc2)CC1)[C@@H](O)c1ccc(O)cc1, C[C@@H](CN1CCC(Cc2ccccc2)CC1)[C@@H](O)c1ccc(O)cc1, C[C@@H](CN1CCC(Cc2ccccc2)CC1)[C@@H](O)c1ccc(O)cc1, C[C@@H](CN1CCC(Cc2ccccc2)CC1)[C@@H](O)c1ccc(O)cc1	WVZSEUPGUDIELE-HTAPYJJXSA-N, WVZSEUPGUDIELE-HTAPYJJXSA-N, WVZSEUPGUDIELE-HTAPYJJXSA-N, WVZSEUPGUDIELE-HTAPYJJXSA-N	Preclinical
Ro-28-1675	glucokinase activator	GCK			CS(=O)(=O)c1ccc(cc1)[C@@H](CC1CCCC1)C(=O)Nc1nccs1	NEQSWPCDHDQINX-MRXNPFEDSA-N	Preclinical
Ro-3	purinergic receptor antagonist	P2RX3			COc1cc(Cc2cnc(N)nc2N)c(cc1OC)C(C)C, COc1cc(Cc2cnc(N)nc2N)c(cc1OC)C(C)C, COc1cc(Cc2cnc(N)nc2N)c(cc1OC)C(C)C, COc1cc(Cc2cnc(N)nc2N)c(cc1OC)C(C)C	PYNPWUIBJMVRIG-UHFFFAOYSA-N, PYNPWUIBJMVRIG-UHFFFAOYSA-N, PYNPWUIBJMVRIG-UHFFFAOYSA-N, PYNPWUIBJMVRIG-UHFFFAOYSA-N	Preclinical
Ro-3306	CDK inhibitor	CDK1			O=C1N=C(NCc2cccs2)S\C1=C/c1ccc2ncccc2c1 |t:2|, O=C1N=C(NCc2cccs2)S\C1=C/c1ccc2ncccc2c1 |t:2|, O=C1N=C(NCc2cccs2)S\C1=C/c1ccc2ncccc2c1 |t:2|	XOLMRFUGOINFDQ-YBEGLDIGSA-N, XOLMRFUGOINFDQ-YBEGLDIGSA-N, XOLMRFUGOINFDQ-YBEGLDIGSA-N	Preclinical
Ro-48-6791	GABA receptor modulator				CCCN(CCC)Cc1nc(no1)-c1ncn-2c1CN(C)C(=O)c1cc(F)ccc-21	NOQIYRGMEFBZTI-UHFFFAOYSA-N	Preclinical
Ro-48-8071	oxidosqualene cyclase inhibitor	LSS			CN(CCCCCCOc1ccc(C(=O)c2ccc(Br)cc2)c(F)c1)CC=C, CN(CCCCCCOc1ccc(C(=O)c2ccc(Br)cc2)c(F)c1)CC=C, CN(CCCCCCOc1ccc(C(=O)c2ccc(Br)cc2)c(F)c1)CC=C	CMYCCJYVZIMDFU-UHFFFAOYSA-N, CMYCCJYVZIMDFU-UHFFFAOYSA-N, CMYCCJYVZIMDFU-UHFFFAOYSA-N	Preclinical
Ro-4987655	MEK inhibitor	MAP2K1			OCCONC(=O)c1cc(CN2OCCCC2=O)c(F)c(F)c1Nc1ccc(I)cc1F, OCCONC(=O)c1cc(CN2OCCCC2=O)c(F)c(F)c1Nc1ccc(I)cc1F, OCCONC(=O)c1cc(CN2OCCCC2=O)c(F)c(F)c1Nc1ccc(I)cc1F	FIMYFEGKMOCQKT-UHFFFAOYSA-N, FIMYFEGKMOCQKT-UHFFFAOYSA-N, FIMYFEGKMOCQKT-UHFFFAOYSA-N	Phase 1
Ro-5028442	vasopressin receptor antagonist				CN(C)CCn1cc(C(=O)N2CCC3(CC2)OCc2ccccc32)c2ccc(Cl)cc12	QZXVLRCMAHJVIP-UHFFFAOYSA-N	Phase 1
Ro-5126766	MEK inhibitor, RAF inhibitor	BRAF, MAP2K1, MAP2K2, RAF1			CNS(=O)(=O)Nc1nccc(Cc2c(C)c3ccc(Oc4ncccn4)cc3oc2=O)c1F, CNS(=O)(=O)Nc1nccc(Cc2c(C)c3ccc(Oc4ncccn4)cc3oc2=O)c1F, CNS(=O)(=O)Nc1nccc(Cc2c(C)c3ccc(Oc4ncccn4)cc3oc2=O)c1F	LMMJFBMMJUMSJS-UHFFFAOYSA-N, LMMJFBMMJUMSJS-UHFFFAOYSA-N, LMMJFBMMJUMSJS-UHFFFAOYSA-N	Phase 1
Ro-5263397	trace amine associated receptor agonist				Cc1c(F)cccc1[C@H]1COC(N)=N1 |c:13|	IOHOUWIYOVWGHV-SECBINFHSA-N	Preclinical
Ro-60-0175	serotonin receptor agonist	HTR2A, HTR2B, HTR2C			C[C@H](N)Cn1ccc2cc(F)c(Cl)cc12, C[C@H](N)Cn1ccc2cc(F)c(Cl)cc12, C[C@H](N)Cn1ccc2cc(F)c(Cl)cc12, C[C@H](N)Cn1ccc2cc(F)c(Cl)cc12, C[C@H](N)Cn1ccc2cc(F)c(Cl)cc12	XJJZQXUGLLXTHO-ZETCQYMHSA-N, XJJZQXUGLLXTHO-ZETCQYMHSA-N, XJJZQXUGLLXTHO-ZETCQYMHSA-N, XJJZQXUGLLXTHO-ZETCQYMHSA-N, XJJZQXUGLLXTHO-ZETCQYMHSA-N	Preclinical
Ro-61-8048	kynurenine 3-monooxygenase inhibitor	KMO			COc1ccc(cc1OC)S(=O)(=O)Nc1nc(cs1)-c1cccc(c1)[N+]([O-])=O, COc1ccc(cc1OC)S(=O)(=O)Nc1nc(cs1)-c1cccc(c1)[N+]([O-])=O, COc1ccc(cc1OC)S(=O)(=O)Nc1nc(cs1)-c1cccc(c1)[N+]([O-])=O	NDPBMCKQJOZAQX-UHFFFAOYSA-N, NDPBMCKQJOZAQX-UHFFFAOYSA-N, NDPBMCKQJOZAQX-UHFFFAOYSA-N	Preclinical
Ro-67-7476	glutamate receptor positive allosteric modulator	GRM1			Cc1ccc(cc1)S(=O)(=O)N1CCC[C@H]1c1ccc(F)cc1, Cc1ccc(cc1)S(=O)(=O)N1CCC[C@H]1c1ccc(F)cc1	DAEHFYNGSSBGSS-KRWDZBQOSA-N, DAEHFYNGSSBGSS-KRWDZBQOSA-N	Preclinical
Ro-90-7501	beta amyloid protein neurotoxicity inhibitor	APP			Nc1ccc(cc1)-c1nc2ccc(cc2[nH]1)-c1nc2ccc(N)cc2[nH]1, Nc1ccc(cc1)-c1nc2ccc(cc2[nH]1)-c1nc2ccc(N)cc2[nH]1, Nc1ccc(cc1)-c1nc2ccc(cc2[nH]1)-c1nc2ccc(N)cc2[nH]1, Nc1ccc(cc1)-c1nc2ccc(cc2[nH]1)-c1nc2ccc(N)cc2[nH]1	PAGZCEHLFCJSPV-UHFFFAOYSA-N, PAGZCEHLFCJSPV-UHFFFAOYSA-N, PAGZCEHLFCJSPV-UHFFFAOYSA-N, PAGZCEHLFCJSPV-UHFFFAOYSA-N	Preclinical
Ro-9187	HCV inhibitor				Nc1ccn([C@@H]2O[C@@](CO)(N=[N+]=[N-])[C@@H](O)[C@@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@@](CO)(N=[N+]=[N-])[C@@H](O)[C@@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@@](CO)(N=[N+]=[N-])[C@@H](O)[C@@H]2O)c(=O)n1	ODLGMSQBFONGNG-XZMZPDFPSA-N, ODLGMSQBFONGNG-XZMZPDFPSA-N, ODLGMSQBFONGNG-XZMZPDFPSA-N	Preclinical
robalzotan	serotonin receptor antagonist	HTR1A			NC(=O)c1ccc(F)c2OC[C@@H](Cc12)N(C1CCC1)C1CCC1, NC(=O)c1ccc(F)c2OC[C@@H](Cc12)N(C1CCC1)C1CCC1, NC(=O)c1ccc(F)c2OC[C@@H](Cc12)N(C1CCC1)C1CCC1	MQTUXRKNJYPMCG-CYBMUJFWSA-N, MQTUXRKNJYPMCG-CYBMUJFWSA-N, MQTUXRKNJYPMCG-CYBMUJFWSA-N	Phase 2
roblitinib	FGFR inhibitor				COCCNc1cc(NC(=O)N2CCCc3cc(CN4CCN(C)CC4=O)c(C=O)nc23)ncc1C#N	BHKDKKZMPODMIQ-UHFFFAOYSA-N	Preclinical
rociletinib	EGFR inhibitor	EGFR			COc1cc(ccc1Nc1ncc(c(Nc2cccc(NC(=O)C=C)c2)n1)C(F)(F)F)N1CCN(CC1)C(C)=O, COc1cc(ccc1Nc1ncc(c(Nc2cccc(NC(=O)C=C)c2)n1)C(F)(F)F)N1CCN(CC1)C(C)=O, COc1cc(ccc1Nc1ncc(c(Nc2cccc(NC(=O)C=C)c2)n1)C(F)(F)F)N1CCN(CC1)C(C)=O, COc1cc(ccc1Nc1ncc(c(Nc2cccc(NC(=O)C=C)c2)n1)C(F)(F)F)N1CCN(CC1)C(C)=O, COc1cc(ccc1Nc1ncc(c(Nc2cccc(NC(=O)C=C)c2)n1)C(F)(F)F)N1CCN(CC1)C(C)=O, COc1cc(ccc1Nc1ncc(c(Nc2cccc(NC(=O)C=C)c2)n1)C(F)(F)F)N1CCN(CC1)C(C)=O, COc1cc(ccc1Nc1ncc(c(Nc2cccc(NC(=O)C=C)c2)n1)C(F)(F)F)N1CCN(CC1)C(C)=O, COc1cc(ccc1Nc1ncc(c(Nc2cccc(NC(=O)C=C)c2)n1)C(F)(F)F)N1CCN(CC1)C(C)=O, COc1cc(ccc1Nc1ncc(c(Nc2cccc(NC(=O)C=C)c2)n1)C(F)(F)F)N1CCN(CC1)C(C)=O, COc1cc(ccc1Nc1ncc(c(Nc2cccc(NC(=O)C=C)c2)n1)C(F)(F)F)N1CCN(CC1)C(C)=O, COc1cc(ccc1Nc1ncc(c(Nc2cccc(NC(=O)C=C)c2)n1)C(F)(F)F)N1CCN(CC1)C(C)=O, COc1cc(ccc1Nc1ncc(c(Nc2cccc(NC(=O)C=C)c2)n1)C(F)(F)F)N1CCN(CC1)C(C)=O	HUFOZJXAKZVRNJ-UHFFFAOYSA-N, HUFOZJXAKZVRNJ-UHFFFAOYSA-N, HUFOZJXAKZVRNJ-UHFFFAOYSA-N, HUFOZJXAKZVRNJ-UHFFFAOYSA-N, HUFOZJXAKZVRNJ-UHFFFAOYSA-N, InChI=1S/C27H28F3N7O3/c1-4-24(39)32-18-6-5-7-19(14-18)33-25-21(27(28,29)30)16-31-26(35-25)34-22-9-8-20(15-23(22)40-3)37-12-10-36(11-13-37)17(2)38/h4-9,14-16H,1,10-13H2,2-3H3,(H,32,39)(H2,31,33,34,35), InChI=1S/C27H28F3N7O3/c1-4-24(39)32-18-6-5-7-19(14-18)33-25-21(27(28,29)30)16-31-26(35-25)34-22-9-8-20(15-23(22)40-3)37-12-10-36(11-13-37)17(2)38/h4-9,14-16H,1,10-13H2,2-3H3,(H,32,39)(H2,31,33,34,35), InChI=1S/C27H28F3N7O3/c1-4-24(39)32-18-6-5-7-19(14-18)33-25-21(27(28,29)30)16-31-26(35-25)34-22-9-8-20(15-23(22)40-3)37-12-10-36(11-13-37)17(2)38/h4-9,14-16H,1,10-13H2,2-3H3,(H,32,39)(H2,31,33,34,35), InChI=1S/C27H28F3N7O3/c1-4-24(39)32-18-6-5-7-19(14-18)33-25-21(27(28,29)30)16-31-26(35-25)34-22-9-8-20(15-23(22)40-3)37-12-10-36(11-13-37)17(2)38/h4-9,14-16H,1,10-13H2,2-3H3,(H,32,39)(H2,31,33,34,35), InChI=1S/C27H28F3N7O3/c1-4-24(39)32-18-6-5-7-19(14-18)33-25-21(27(28,29)30)16-31-26(35-25)34-22-9-8-20(15-23(22)40-3)37-12-10-36(11-13-37)17(2)38/h4-9,14-16H,1,10-13H2,2-3H3,(H,32,39)(H2,31,33,34,35), InChI=1S/C27H28F3N7O3/c1-4-24(39)32-18-6-5-7-19(14-18)33-25-21(27(28,29)30)16-31-26(35-25)34-22-9-8-20(15-23(22)40-3)37-12-10-36(11-13-37)17(2)38/h4-9,14-16H,1,10-13H2,2-3H3,(H,32,39)(H2,31,33,34,35), InChI=1S/C27H28F3N7O3/c1-4-24(39)32-18-6-5-7-19(14-18)33-25-21(27(28,29)30)16-31-26(35-25)34-22-9-8-20(15-23(22)40-3)37-12-10-36(11-13-37)17(2)38/h4-9,14-16H,1,10-13H2,2-3H3,(H,32,39)(H2,31,33,34,35)	Phase 3
rocuronium	acetylcholine receptor antagonist	CHRM2, CHRNA2, HTR3A	neurology/psychiatry	anesthetic	CC(=O)O[C@H]1[C@H](C[C@H]2[C@@H]3CC[C@H]4C[C@H](O)[C@H](C[C@]4(C)[C@H]3CC[C@]12C)N1CCOCC1)[N+]1(CC=C)CCCC1, CC(=O)O[C@H]1[C@H](C[C@H]2[C@@H]3CC[C@H]4C[C@H](O)[C@H](C[C@]4(C)[C@H]3CC[C@]12C)N1CCOCC1)[N+]1(CC=C)CCCC1, CC(=O)O[C@H]1[C@H](C[C@H]2[C@@H]3CC[C@H]4C[C@H](O)[C@H](C[C@]4(C)[C@H]3CC[C@]12C)N1CCOCC1)[N+]1(CC=C)CCCC1	YXRDKMPIGHSVRX-OOJCLDBCSA-N, YXRDKMPIGHSVRX-OOJCLDBCSA-N, YXRDKMPIGHSVRX-OOJCLDBCSA-N	Launched
rofecoxib	cyclooxygenase inhibitor	ELN, PTGS2			CS(=O)(=O)c1ccc(cc1)C1=C(C(=O)OC1)c1ccccc1 |t:11|, CS(=O)(=O)c1ccc(cc1)C1=C(C(=O)OC1)c1ccccc1 |t:11|, CS(=O)(=O)c1ccc(cc1)C1=C(C(=O)OC1)c1ccccc1 |t:11|, CS(=O)(=O)c1ccc(cc1)C1=C(C(=O)OC1)c1ccccc1 |t:11|, CS(=O)(=O)c1ccc(cc1)C1=C(C(=O)OC1)c1ccccc1 |t:11|, CS(=O)(=O)c1ccc(cc1)C1=C(C(=O)OC1)c1ccccc1 |t:11|	RZJQGNCSTQAWON-UHFFFAOYSA-N, RZJQGNCSTQAWON-UHFFFAOYSA-N, RZJQGNCSTQAWON-UHFFFAOYSA-N, RZJQGNCSTQAWON-UHFFFAOYSA-N, RZJQGNCSTQAWON-UHFFFAOYSA-N, RZJQGNCSTQAWON-UHFFFAOYSA-N	Withdrawn
roflumilast	phosphodiesterase inhibitor	PDE4A, PDE4B, PDE4C, PDE4D	pulmonary	chronic obstructive pulmonary disease (COPD), bronchitis	FC(F)Oc1ccc(cc1OCC1CC1)C(=O)Nc1c(Cl)cncc1Cl, FC(F)Oc1ccc(cc1OCC1CC1)C(=O)Nc1c(Cl)cncc1Cl	MNDBXUUTURYVHR-UHFFFAOYSA-N, MNDBXUUTURYVHR-UHFFFAOYSA-N	Launched
rogaratinib	FGFR inhibitor				COCc1c(CN2CCNC(=O)C2)n2ncnc(N)c2c1-c1cc2cc(C)cc(OC)c2s1	HNLRRJSKGXOYNO-UHFFFAOYSA-N	Phase 2/Phase 3
rolapitant	neurokinin receptor antagonist				[H][C@](C)(OC[C@]1(CC[C@]2(CCC(=O)N2)CN1)c1ccccc1)c1cc(cc(c1)C(F)(F)F)C(F)(F)F	FIVSJYGQAIEMOC-ZGNKEGEESA-N	Phase 3
rolipram	phosphodiesterase inhibitor				COc1ccc(cc1OC1CCCC1)[C@H]1CNC(=O)C1 |&1:14,r|, COc1ccc(cc1OC1CCCC1)[C@H]1CNC(=O)C1 |&1:14,r|, COc1ccc(cc1OC1CCCC1)[C@H]1CNC(=O)C1 |&1:14,r|, COc1ccc(cc1OC1CCCC1)[C@H]1CNC(=O)C1 |&1:14,r|, COc1ccc(cc1OC1CCCC1)[C@H]1CNC(=O)C1 |&1:14,r|	HJORMJIFDVBMOB-GFCCVEGCSA-N, HJORMJIFDVBMOB-GFCCVEGCSA-N, HJORMJIFDVBMOB-GFCCVEGCSA-N, HJORMJIFDVBMOB-GFCCVEGCSA-N, HJORMJIFDVBMOB-GFCCVEGCSA-N	Phase 3
rolitetracycline	bacterial 30S ribosomal subunit inhibitor		infectious disease	gram-negative bacterial infections, gram-positive bacterial infections	CN(C)[C@H]1[C@@H]2C[C@H]3C(=C(O)[C@]2(O)C(O)=C(C(=O)NCN2CCCC2)C1=O)C(=O)c1c(O)cccc1[C@@]3(C)O |a:3,4,6,10,35,&1:7,&2:14,t:7,14|, CN(C)[C@H]1[C@@H]2C[C@H]3C(=C(O)[C@]2(O)C(O)=C(C(=O)NCN2CCCC2)C1=O)C(=O)c1c(O)cccc1[C@@]3(C)O |a:3,4,6,10,35,&1:7,&2:14,t:7,14|, CN(C)[C@H]1[C@@H]2C[C@H]3C(=C(O)[C@]2(O)C(O)=C(C(=O)NCN2CCCC2)C1=O)C(=O)c1c(O)cccc1[C@@]3(C)O |a:3,4,6,10,35,&1:7,&2:14,t:7,14|, CN(C)[C@H]1[C@@H]2C[C@H]3C(=C(O)[C@]2(O)C(O)=C(C(=O)NCN2CCCC2)C1=O)C(=O)c1c(O)cccc1[C@@]3(C)O |a:3,4,6,10,35,&1:7,&2:14,t:7,14|	YEHCEZXUSLIKDU-IAHYZSEUSA-N, YEHCEZXUSLIKDU-IAHYZSEUSA-N, YEHCEZXUSLIKDU-IAHYZSEUSA-N, YEHCEZXUSLIKDU-IAHYZSEUSA-N	Launched
roluperidone					Fc1ccc(cc1)C(=O)CN1CCC(CN2Cc3ccccc3C2=O)CC1	RNRYULFRLCBRQS-UHFFFAOYSA-N	Phase 2
rolziracetam					O=C1CCC2CCC(=O)N12	IEZDOKQWPWZVQF-UHFFFAOYSA-N	Phase 2
romidepsin	HDAC inhibitor	HDAC1, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9	hematologic malignancy	cutaneous T-cell lymphoma (CTCL)	C\C=C1/NC(=O)[C@H]2CSSCC\C=C\[C@H](CC(=O)N[C@H](C(C)C)C(=O)N2)OC(=O)[C@@H](NC1=O)C(C)C |t:12|, C\C=C1/NC(=O)[C@H]2CSSCC\C=C\[C@H](CC(=O)N[C@H](C(C)C)C(=O)N2)OC(=O)[C@@H](NC1=O)C(C)C |t:12|, C\C=C1/NC(=O)[C@H]2CSSCC\C=C\[C@H](CC(=O)N[C@H](C(C)C)C(=O)N2)OC(=O)[C@@H](NC1=O)C(C)C |t:12|, C\C=C1/NC(=O)[C@H]2CSSCC\C=C\[C@H](CC(=O)N[C@H](C(C)C)C(=O)N2)OC(=O)[C@@H](NC1=O)C(C)C |t:12|, C\C=C1/NC(=O)[C@H]2CSSCC\C=C\[C@H](CC(=O)N[C@H](C(C)C)C(=O)N2)OC(=O)[C@@H](NC1=O)C(C)C |t:12|, C\C=C1/NC(=O)[C@H]2CSSCC\C=C\[C@H](CC(=O)N[C@H](C(C)C)C(=O)N2)OC(=O)[C@@H](NC1=O)C(C)C |t:12|, C\C=C1/NC(=O)[C@H]2CSSCC\C=C\[C@H](CC(=O)N[C@H](C(C)C)C(=O)N2)OC(=O)[C@@H](NC1=O)C(C)C |t:12|	OHRURASPPZQGQM-WDCUYUQDSA-N, OHRURASPPZQGQM-WDCUYUQDSA-N, OHRURASPPZQGQM-WDCUYUQDSA-N, OHRURASPPZQGQM-WDCUYUQDSA-N, InChI=1S/C24H36N4O6S2/c1-6-16-21(30)28-20(14(4)5)24(33)34-15-9-7-8-10-35-36-12-17(22(31)25-16)26-23(32)19(13(2)3)27-18(29)11-15/h6-7,9,13-15,17,19-20H,8,10-12H2,1-5H3,(H,25,31)(H,26,32)(H,27,29)(H,28,30)/b9-7+,16-6-/t15-,17-,19-,20?/m1/s1, InChI=1S/C24H36N4O6S2/c1-6-16-21(30)28-20(14(4)5)24(33)34-15-9-7-8-10-35-36-12-17(22(31)25-16)26-23(32)19(13(2)3)27-18(29)11-15/h6-7,9,13-15,17,19-20H,8,10-12H2,1-5H3,(H,25,31)(H,26,32)(H,27,29)(H,28,30)/b9-7+,16-6-/t15-,17-,19-,20?/m1/s1, InChI=1S/C24H36N4O6S2/c1-6-16-21(30)28-20(14(4)5)24(33)34-15-9-7-8-10-35-36-12-17(22(31)25-16)26-23(32)19(13(2)3)27-18(29)11-15/h6-7,9,13-15,17,19-20H,8,10-12H2,1-5H3,(H,25,31)(H,26,32)(H,27,29)(H,28,30)/b9-7+,16-6-/t15-,17-,19-,20?/m1/s1	Launched
ronidazole	antiprotozoal agent		infectious disease	histomoniasis, dysentry	Cn1c(COC(N)=O)ncc1[N+]([O-])=O, Cn1c(COC(N)=O)ncc1[N+]([O-])=O, Cn1c(COC(N)=O)ncc1[N+]([O-])=O	PQFRTXSWDXZRRS-UHFFFAOYSA-N, PQFRTXSWDXZRRS-UHFFFAOYSA-N, PQFRTXSWDXZRRS-UHFFFAOYSA-N	Launched
ropinirole	dopamine receptor agonist	ADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, DRD4, DRD5, HTR1A, HTR1B, HTR1D, HTR2A, HTR2B, HTR2C	neurology/psychiatry	Parkinson's Disease, restless leg syndrome	CCCN(CCC)CCc1cccc2NC(=O)Cc12, CCCN(CCC)CCc1cccc2NC(=O)Cc12, CCCN(CCC)CCc1cccc2NC(=O)Cc12, CCCN(CCC)CCc1cccc2NC(=O)Cc12	UHSKFQJFRQCDBE-UHFFFAOYSA-N, UHSKFQJFRQCDBE-UHFFFAOYSA-N, UHSKFQJFRQCDBE-UHFFFAOYSA-N, UHSKFQJFRQCDBE-UHFFFAOYSA-N	Launched
ropivacaine	sodium channel blocker	SCN10A	neurology/psychiatry	anesthetic	CCCN1CCCC[C@H]1C(=O)Nc1c(C)cccc1C, CCCN1CCCC[C@H]1C(=O)Nc1c(C)cccc1C, CCCN1CCCC[C@H]1C(=O)Nc1c(C)cccc1C	ZKMNUMMKYBVTFN-HNNXBMFYSA-N, ZKMNUMMKYBVTFN-HNNXBMFYSA-N, ZKMNUMMKYBVTFN-HNNXBMFYSA-N	Launched
roquinimex	angiogenesis inhibitor, tumor necrosis factor production inhibitor				CN(C(=O)c1c(O)c2ccccc2n(C)c1=O)c1ccccc1, CN(C(=O)c1c(O)c2ccccc2n(C)c1=O)c1ccccc1, CN(C(=O)c1c(O)c2ccccc2n(C)c1=O)c1ccccc1	SGOOQMRIPALTEL-UHFFFAOYSA-N, SGOOQMRIPALTEL-UHFFFAOYSA-N, SGOOQMRIPALTEL-UHFFFAOYSA-N	Phase 3
rosamicin	protein synthesis inhibitor				CC[C@H]1OC(=O)C[C@@H](O)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@@H](CC=O)C[C@@H](C)C(=O)\C=C\[C@]2(C)O[C@H]2[C@@H]1C |t:34|	IUPCWCLVECYZRV-WMNDRESDSA-N	Phase 2
roscovitine	CDK inhibitor	CDK2, CDK9			CC[C@H](CO)Nc1nc(NCc2ccccc2)c2ncn(C(C)C)c2n1, CC[C@H](CO)Nc1nc(NCc2ccccc2)c2ncn(C(C)C)c2n1, CC[C@H](CO)Nc1nc(NCc2ccccc2)c2ncn(C(C)C)c2n1, CC[C@H](CO)Nc1nc(NCc2ccccc2)c2ncn(C(C)C)c2n1	BTIHMVBBUGXLCJ-OAHLLOKOSA-N, BTIHMVBBUGXLCJ-OAHLLOKOSA-N, BTIHMVBBUGXLCJ-OAHLLOKOSA-N, BTIHMVBBUGXLCJ-OAHLLOKOSA-N	Phase 2
rose-bengal	contrast agent, immunostimulant		radiology	diagnostic agent	OC(=O)c1c(Cl)c(Cl)c(Cl)c(Cl)c1-c1c2cc(I)c(O)c(I)c2oc2c(I)c(=O)c(I)cc12, OC(=O)c1c(Cl)c(Cl)c(Cl)c(Cl)c1-c1c2cc(I)c(O)c(I)c2oc2c(I)c(=O)c(I)cc12, OC(=O)c1c(Cl)c(Cl)c(Cl)c(Cl)c1-c1c2cc(I)c(O)c(I)c2oc2c(I)c(=O)c(I)cc12	VDNLFJGJEQUWRB-UHFFFAOYSA-N, VDNLFJGJEQUWRB-UHFFFAOYSA-N, VDNLFJGJEQUWRB-UHFFFAOYSA-N	Launched
rose-bengal-lactone	coloring agent		ophthalmology	staining agent	Oc1c(I)cc2c(Oc3c(I)c(O)c(I)cc3C22OC(=O)c3c2c(Cl)c(Cl)c(Cl)c3Cl)c1I, Oc1c(I)cc2c(Oc3c(I)c(O)c(I)cc3C22OC(=O)c3c2c(Cl)c(Cl)c(Cl)c3Cl)c1I	IICCLYANAQEHCI-UHFFFAOYSA-N, IICCLYANAQEHCI-UHFFFAOYSA-N	Launched
rosiglitazone	insulin sensitizer, PPAR receptor agonist	FFAR1, PPARG, TRPC5, TRPM3			CN(CCOc1ccc(C[C@H]2SC(=O)NC2=O)cc1)c1ccccn1 |&1:10|, CN(CCOc1ccc(C[C@H]2SC(=O)NC2=O)cc1)c1ccccn1 |&1:10|	YASAKCUCGLMORW-OAHLLOKOSA-N, YASAKCUCGLMORW-OAHLLOKOSA-N	Withdrawn
rosiptor	SHIP1 phosphatase activator				[H][C@@]12CCC(=C)[C@@]1(C)CC[C@@]([H])([C@H]2CN)[C@@]1(C)CC[C@H](O)C[C@@H]1CO	MDEJTPWQNNMAQF-BVMLLJBZSA-N	Phase 2
rosmarinic-acid	GABA transaminase inhibitor	MCL1, TYR			OC(=O)[C@@H](Cc1ccc(O)c(O)c1)OC(=O)\C=C\c1ccc(O)c(O)c1, OC(=O)[C@@H](Cc1ccc(O)c(O)c1)OC(=O)\C=C\c1ccc(O)c(O)c1, OC(=O)[C@@H](Cc1ccc(O)c(O)c1)OC(=O)\C=C\c1ccc(O)c(O)c1, OC(=O)[C@@H](Cc1ccc(O)c(O)c1)OC(=O)\C=C\c1ccc(O)c(O)c1	DOUMFZQKYFQNTF-WUTVXBCWSA-N, DOUMFZQKYFQNTF-WUTVXBCWSA-N, DOUMFZQKYFQNTF-WUTVXBCWSA-N, DOUMFZQKYFQNTF-WUTVXBCWSA-N	Launched
rosoxacin	topoisomerase inhibitor		infectious disease	urinary tract infections	CCn1cc(C(O)=O)c(=O)c2ccc(cc12)-c1ccncc1	XBPZXDSZHPDXQU-UHFFFAOYSA-N	Launched
rostafuroxine	ATPase inhibitor	ATP1A1			C[C@]12CC[C@H]3[C@@H](CC[C@@H]4C[C@@H](O)CC[C@]34C)[C@@]1(O)CC[C@]2(O)c1ccoc1, C[C@]12CC[C@H]3[C@@H](CC[C@@H]4C[C@@H](O)CC[C@]34C)[C@@]1(O)CC[C@]2(O)c1ccoc1, C[C@]12CC[C@H]3[C@@H](CC[C@@H]4C[C@@H](O)CC[C@]34C)[C@@]1(O)CC[C@]2(O)c1ccoc1	AEAPORIZZWBIEX-DTBDINHYSA-N, AEAPORIZZWBIEX-DTBDINHYSA-N, AEAPORIZZWBIEX-DTBDINHYSA-N	Phase 2
rosuvastatin	HMGCR inhibitor	HMGCR	endocrinology, cardiology	hyperlipidemia, dyslipidemia, hypertriglyceridemia, hypercholesterolemia, atherosclerosis	CC(C)c1nc(nc(-c2ccc(F)cc2)c1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)N(C)S(C)(=O)=O, CC(C)c1nc(nc(-c2ccc(F)cc2)c1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)N(C)S(C)(=O)=O, CC(C)c1nc(nc(-c2ccc(F)cc2)c1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)N(C)S(C)(=O)=O, CC(C)c1nc(nc(-c2ccc(F)cc2)c1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)N(C)S(C)(=O)=O, CC(C)c1nc(nc(-c2ccc(F)cc2)c1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)N(C)S(C)(=O)=O, CC(C)c1nc(nc(-c2ccc(F)cc2)c1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)N(C)S(C)(=O)=O, CC(C)c1nc(nc(-c2ccc(F)cc2)c1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)N(C)S(C)(=O)=O	BPRHUIZQVSMCRT-VEUZHWNKSA-N, BPRHUIZQVSMCRT-VEUZHWNKSA-N, BPRHUIZQVSMCRT-VEUZHWNKSA-N, BPRHUIZQVSMCRT-VEUZHWNKSA-N, BPRHUIZQVSMCRT-VEUZHWNKSA-N, BPRHUIZQVSMCRT-VEUZHWNKSA-N, BPRHUIZQVSMCRT-VEUZHWNKSA-N	Launched
rotigotine	dopamine receptor agonist	ADRA2B, DRD1, DRD2, DRD3, DRD4, DRD5, HTR1A	neurology/psychiatry	Parkinson's Disease, restless leg syndrome	CCCN(CCc1cccs1)[C@H]1CCc2c(O)cccc2C1, CCCN(CCc1cccs1)[C@H]1CCc2c(O)cccc2C1, CCCN(CCc1cccs1)[C@H]1CCc2c(O)cccc2C1	KFQYTPMOWPVWEJ-INIZCTEOSA-N, KFQYTPMOWPVWEJ-INIZCTEOSA-N, KFQYTPMOWPVWEJ-INIZCTEOSA-N	Launched
rotundine	serotonin receptor agonist	DRD1, DRD2, DRD3, HTR1A	neurology/psychiatry	anxiety, sedative	COc1cc2CCN3Cc4c(C[C@H]3c2cc1OC)ccc(OC)c4OC, COc1cc2CCN3Cc4c(C[C@H]3c2cc1OC)ccc(OC)c4OC	AEQDJSLRWYMAQI-KRWDZBQOSA-N, AEQDJSLRWYMAQI-KRWDZBQOSA-N	Launched
rovazolac	LXR agonist				CCOC(=O)Cn1nc(cc1-c1ccc(cc1)-c1cccc(c1)S(C)(=O)=O)C(F)(F)F	ZUMNJDGBYXHASJ-UHFFFAOYSA-N	Preclinical
roxarsone	antiprotozoal agent		endocrinology	weight-gain aid	Oc1ccc(cc1[N+]([O-])=O)[As](O)(O)=O, Oc1ccc(cc1[N+]([O-])=O)[As](O)(O)=O, Oc1ccc(cc1[N+]([O-])=O)[As](O)(O)=O	XMVJITFPVVRMHC-UHFFFAOYSA-N, XMVJITFPVVRMHC-UHFFFAOYSA-N, XMVJITFPVVRMHC-UHFFFAOYSA-N	Launched
roxatidine-acetate	histamine receptor antagonist	HRH2	gastroenterology	Zollinger-Ellison syndrome, erosive esophagitis (EE), gastroesophageal reflux disease (GERD), gastritis	CC(=O)OCC(=O)NCCCOc1cccc(CN2CCCCC2)c1, CC(=O)OCC(=O)NCCCOc1cccc(CN2CCCCC2)c1, CC(=O)OCC(=O)NCCCOc1cccc(CN2CCCCC2)c1	SMTZFNFIKUPEJC-UHFFFAOYSA-N, SMTZFNFIKUPEJC-UHFFFAOYSA-N, SMTZFNFIKUPEJC-UHFFFAOYSA-N	Launched
roxithromycin	bacterial 50S ribosomal subunit inhibitor	MLNR	infectious disease	respiratory tract infections, urinary tract infections, skin infections	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)\C(=N/OCOCCOC)[C@H](C)[C@@H](O)[C@]1(C)O, CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)\C(=N/OCOCCOC)[C@H](C)[C@@H](O)[C@]1(C)O, CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)\C(=N/OCOCCOC)[C@H](C)[C@@H](O)[C@]1(C)O	RXZBMPWDPOLZGW-SWCVOMKCSA-N, RXZBMPWDPOLZGW-SWCVOMKCSA-N, RXZBMPWDPOLZGW-SWCVOMKCSA-N	Launched
RP-001	sphingosine 1-phosphate receptor agonist	S1PR1			CC(C)Oc1ccc(cc1C#N)-c1nc(no1)-c1cccc2[C@@H](CCc12)NCCC(O)=O |&1:22|, CC(C)Oc1ccc(cc1C#N)-c1nc(no1)-c1cccc2[C@@H](CCc12)NCCC(O)=O |&1:22|, CC(C)Oc1ccc(cc1C#N)-c1nc(no1)-c1cccc2[C@@H](CCc12)NCCC(O)=O |&1:22|	WNDDDFYFTSGSEC-HXUWFJFHSA-N, WNDDDFYFTSGSEC-HXUWFJFHSA-N, WNDDDFYFTSGSEC-HXUWFJFHSA-N	Preclinical
RP67580					COc1ccccc1CC(=N)N1C[C@H]2[C@@H](C1)C(CCC2=O)(c1ccccc1)c1ccccc1	VWBOQFANCXZMAU-LOSJGSFVSA-N	Preclinical
RQ-00203078	transient receptor potential channel antagonist	TRPM8			OC(=O)c1ccc(cc1)S(=O)(=O)N(Cc1ccc(OC(F)(F)F)cc1)c1ncc(cc1Cl)C(F)(F)F, OC(=O)c1ccc(cc1)S(=O)(=O)N(Cc1ccc(OC(F)(F)F)cc1)c1ncc(cc1Cl)C(F)(F)F	IJGQFZYYEHCCIZ-UHFFFAOYSA-N, IJGQFZYYEHCCIZ-UHFFFAOYSA-N	Preclinical
RRx-001	glucose 6-phosphate dehydrogenase inhibitor	G6PD			[O-][N+](=O)C1(CN(C1)C(=O)CBr)[N+]([O-])=O, [O-][N+](=O)C1(CN(C1)C(=O)CBr)[N+]([O-])=O	JODKFOVZURLVTG-UHFFFAOYSA-N, JODKFOVZURLVTG-UHFFFAOYSA-N	Phase 3
RS-0481	immunostimulant						Phase 2
RS-100329	adrenergic receptor antagonist	ADRA1A, ADRA1D			Cc1c[nH]c(=O)n(CCCN2CCN(CC2)c2ccccc2OCC(F)(F)F)c1=O, Cc1c[nH]c(=O)n(CCCN2CCN(CC2)c2ccccc2OCC(F)(F)F)c1=O	RCOBWVAGWYRNHZ-UHFFFAOYSA-N, RCOBWVAGWYRNHZ-UHFFFAOYSA-N	Preclinical
RS-102221	serotonin receptor antagonist	HTR2A, HTR2B, HTR2C			COc1cc(OC)c(cc1NS(=O)(=O)c1ccc(cc1)C(F)(F)F)C(=O)CCCCN1CCC2(CC1)NC(=O)NC2=O, COc1cc(OC)c(cc1NS(=O)(=O)c1ccc(cc1)C(F)(F)F)C(=O)CCCCN1CCC2(CC1)NC(=O)NC2=O, COc1cc(OC)c(cc1NS(=O)(=O)c1ccc(cc1)C(F)(F)F)C(=O)CCCCN1CCC2(CC1)NC(=O)NC2=O, COc1cc(OC)c(cc1NS(=O)(=O)c1ccc(cc1)C(F)(F)F)C(=O)CCCCN1CCC2(CC1)NC(=O)NC2=O, COc1cc(OC)c(cc1NS(=O)(=O)c1ccc(cc1)C(F)(F)F)C(=O)CCCCN1CCC2(CC1)NC(=O)NC2=O	HZZZZODVDSHQRG-UHFFFAOYSA-N, HZZZZODVDSHQRG-UHFFFAOYSA-N, HZZZZODVDSHQRG-UHFFFAOYSA-N, HZZZZODVDSHQRG-UHFFFAOYSA-N, HZZZZODVDSHQRG-UHFFFAOYSA-N	Preclinical
RS-102895	CCR antagonist	CCR2			FC(F)(F)c1ccc(CCN2CCC3(CC2)OC(=O)Nc2ccccc32)cc1, FC(F)(F)c1ccc(CCN2CCC3(CC2)OC(=O)Nc2ccccc32)cc1, FC(F)(F)c1ccc(CCN2CCC3(CC2)OC(=O)Nc2ccccc32)cc1	HIDWEYPGMLIQSN-UHFFFAOYSA-N, HIDWEYPGMLIQSN-UHFFFAOYSA-N, HIDWEYPGMLIQSN-UHFFFAOYSA-N	Preclinical
RS-127445	serotonin receptor antagonist	HTR2A, HTR2B, HTR2C			CC(C)c1cc(nc(N)n1)-c1ccc(F)c2ccccc12, CC(C)c1cc(nc(N)n1)-c1ccc(F)c2ccccc12, CC(C)c1cc(nc(N)n1)-c1ccc(F)c2ccccc12	ZZZQXCUPAJFVBN-UHFFFAOYSA-N, ZZZQXCUPAJFVBN-UHFFFAOYSA-N, ZZZQXCUPAJFVBN-UHFFFAOYSA-N	Phase 1
RS-16566	serotonin receptor antagonist				CC(C)n1cnc2c(cc(Cl)cc12)C(=O)N[C@H]1C[N@@]2CC[C@H]1CC2	OGXMGJGFLBSEJW-HNNXBMFYSA-N	Preclinical
RS-17053	adrenergic receptor antagonist	ADRA1A, ADRA1D			CC(C)(Cc1c[nH]c2ccc(Cl)cc12)NCCOc1ccccc1OCC1CC1, CC(C)(Cc1c[nH]c2ccc(Cl)cc12)NCCOc1ccccc1OCC1CC1, CC(C)(Cc1c[nH]c2ccc(Cl)cc12)NCCOc1ccccc1OCC1CC1, CC(C)(Cc1c[nH]c2ccc(Cl)cc12)NCCOc1ccccc1OCC1CC1, CC(C)(Cc1c[nH]c2ccc(Cl)cc12)NCCOc1ccccc1OCC1CC1, CC(C)(Cc1c[nH]c2ccc(Cl)cc12)NCCOc1ccccc1OCC1CC1, CC(C)(Cc1c[nH]c2ccc(Cl)cc12)NCCOc1ccccc1OCC1CC1, CC(C)(Cc1c[nH]c2ccc(Cl)cc12)NCCOc1ccccc1OCC1CC1	XLZHXAXXJVKTFM-UHFFFAOYSA-N, XLZHXAXXJVKTFM-UHFFFAOYSA-N, XLZHXAXXJVKTFM-UHFFFAOYSA-N, XLZHXAXXJVKTFM-UHFFFAOYSA-N, XLZHXAXXJVKTFM-UHFFFAOYSA-N, XLZHXAXXJVKTFM-UHFFFAOYSA-N, XLZHXAXXJVKTFM-UHFFFAOYSA-N, XLZHXAXXJVKTFM-UHFFFAOYSA-N	Preclinical
RS-23597-190	serotonin receptor antagonist	HTR4			COc1cc(N)c(Cl)cc1C(=O)OCCCN1CCCCC1	RLSGBCUXLRMTPF-UHFFFAOYSA-N	Preclinical
RS-39604	serotonin receptor antagonist	HTR4			COc1cc(COc2cc(N)c(Cl)cc2C(=O)CCC2CCN(CCNS(C)(=O)=O)CC2)cc(OC)c1, COc1cc(COc2cc(N)c(Cl)cc2C(=O)CCC2CCN(CCNS(C)(=O)=O)CC2)cc(OC)c1, COc1cc(COc2cc(N)c(Cl)cc2C(=O)CCC2CCN(CCNS(C)(=O)=O)CC2)cc(OC)c1, COc1cc(COc2cc(N)c(Cl)cc2C(=O)CCC2CCN(CCNS(C)(=O)=O)CC2)cc(OC)c1	BKVIWGRFRKLFIO-UHFFFAOYSA-N, BKVIWGRFRKLFIO-UHFFFAOYSA-N, BKVIWGRFRKLFIO-UHFFFAOYSA-N, BKVIWGRFRKLFIO-UHFFFAOYSA-N	Preclinical
RS-45041-190	imidazoline receptor agonist				Clc1cccc2CN(Cc12)C1=NCCN1 |t:12|, Clc1cccc2CN(Cc12)C1=NCCN1 |t:12|, Clc1cccc2CN(Cc12)C1=NCCN1 |t:12|	IVCMOOBKRRDNHX-UHFFFAOYSA-N, IVCMOOBKRRDNHX-UHFFFAOYSA-N, IVCMOOBKRRDNHX-UHFFFAOYSA-N	Preclinical
RS-504393	CC chemokine receptor antagonist	CCL2, CCR2			Cc1oc(nc1CCN1CCC2(CC1)OC(=O)Nc1ccc(C)cc21)-c1ccccc1, Cc1oc(nc1CCN1CCC2(CC1)OC(=O)Nc1ccc(C)cc21)-c1ccccc1	ODNICNWASXKNNQ-UHFFFAOYSA-N, ODNICNWASXKNNQ-UHFFFAOYSA-N	Preclinical
RS-56812	serotonin receptor partial agonist	HTR3A			Cn1cc(C(=O)C(=O)N[C@H]2C[N@@]3CC[C@H]2CC3)c2ccccc12	ZNAPADWWBWFMCQ-HNNXBMFYSA-N	Preclinical
RS-67333	serotonin receptor partial agonist	HTR4			CCCCN1CCC(CCC(=O)c2cc(Cl)c(N)cc2OC)CC1, CCCCN1CCC(CCC(=O)c2cc(Cl)c(N)cc2OC)CC1, CCCCN1CCC(CCC(=O)c2cc(Cl)c(N)cc2OC)CC1	JBHLYIVFFLNISJ-UHFFFAOYSA-N, JBHLYIVFFLNISJ-UHFFFAOYSA-N, JBHLYIVFFLNISJ-UHFFFAOYSA-N	Preclinical
RS-67506	serotonin receptor partial agonist	HTR4			COc1cc(N)c(Cl)cc1C(=O)CCC1CCN(CCNS(C)(=O)=O)CC1, COc1cc(N)c(Cl)cc1C(=O)CCC1CCN(CCNS(C)(=O)=O)CC1, COc1cc(N)c(Cl)cc1C(=O)CCC1CCN(CCNS(C)(=O)=O)CC1, COc1cc(N)c(Cl)cc1C(=O)CCC1CCN(CCNS(C)(=O)=O)CC1	UATDVRSFFGFTAI-UHFFFAOYSA-N, UATDVRSFFGFTAI-UHFFFAOYSA-N, UATDVRSFFGFTAI-UHFFFAOYSA-N, UATDVRSFFGFTAI-UHFFFAOYSA-N	Preclinical
RS-79948	adrenergic receptor antagonist	ADRA2A			CCS(=O)(=O)N1CCC[C@@H]2CN3CCc4cc(OC)ccc4[C@@H]3C[C@H]12, CCS(=O)(=O)N1CCC[C@@H]2CN3CCc4cc(OC)ccc4[C@@H]3C[C@H]12	UMGBFFAJXFXOIL-MNEFBYGVSA-N, UMGBFFAJXFXOIL-MNEFBYGVSA-N	Preclinical
RSV604	RSV replication inhibitor				Fc1ccccc1NC(=O)N[C@H]1N=C(c2ccccc2)c2ccccc2NC1=O |t:13|	MTPVBMVUENFFLL-HXUWFJFHSA-N	Phase 2
RTA-408	nitric oxide production inhibitor	NFE2L2			CC(F)(F)C(=O)N[C@]12CCC(C)(C)C[C@H]1[C@H]1C(=O)C=C3[C@@]4(C)C=C(C#N)C(=O)C(C)(C)[C@@H]4CC[C@@]3(C)[C@]1(C)CC2 |t:19,23|, CC(F)(F)C(=O)N[C@]12CCC(C)(C)C[C@H]1[C@H]1C(=O)C=C3[C@@]4(C)C=C(C#N)C(=O)C(C)(C)[C@@H]4CC[C@@]3(C)[C@]1(C)CC2 |t:19,23|, CC(F)(F)C(=O)N[C@]12CCC(C)(C)C[C@H]1[C@H]1C(=O)C=C3[C@@]4(C)C=C(C#N)C(=O)C(C)(C)[C@@H]4CC[C@@]3(C)[C@]1(C)CC2 |t:19,23|	RJCWBNBKOKFWNY-IDPLTSGASA-N, RJCWBNBKOKFWNY-IDPLTSGASA-N, RJCWBNBKOKFWNY-IDPLTSGASA-N	Phase 2
RU-SKI-43	hedgehog pathway inhibitor	HHAT			CC[C@@H](C)CNCC(=O)N1CCc2sccc2[C@@H]1COc1cccc(C)c1 |&1:2,&2:17|, CC[C@@H](C)CNCC(=O)N1CCc2sccc2[C@@H]1COc1cccc(C)c1 |&1:2,&2:17|	AEENEMOEBJOKGN-UZLBHIALSA-N, AEENEMOEBJOKGN-UZLBHIALSA-N	Preclinical
RU-24969	serotonin receptor agonist	HTR1A, HTR1B, HTR1D, HTR2A, HTR2B, HTR2C, HTR5A, HTR6			COc1ccc2[nH]cc(C3=CCNCC3)c2c1 |t:9|, COc1ccc2[nH]cc(C3=CCNCC3)c2c1 |t:9|, COc1ccc2[nH]cc(C3=CCNCC3)c2c1 |t:9|	KRVMLPUDAOWOGN-UHFFFAOYSA-N, KRVMLPUDAOWOGN-UHFFFAOYSA-N, KRVMLPUDAOWOGN-UHFFFAOYSA-N	Phase 1
RU-28318	cytochrome P450 inhibitor	NR3C2			CCC[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@H]2CC[C@@]3(C)[C@@H](CC[C@@]3(O)CCC(O)=O)[C@H]12 |t:5|, CCC[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@H]2CC[C@@]3(C)[C@@H](CC[C@@]3(O)CCC(O)=O)[C@H]12 |t:5|	DNHCHRGCTVRAFT-JEHIOXJOSA-N, DNHCHRGCTVRAFT-JEHIOXJOSA-N	Phase 2
RU-42173	adrenergic receptor agonist	ADRB2			CC(C)N[C@@H]1CCn2c3c(cccc3[nH]c2=O)[C@H]1O	ZSTCZWJCLIRCOJ-DGCLKSJQSA-N	Phase 2
RU-58841	androgen receptor antagonist	AR			CC1(C)N(CCCCO)C(=O)N(C1=O)c1ccc(C#N)c(c1)C(F)(F)F, CC1(C)N(CCCCO)C(=O)N(C1=O)c1ccc(C#N)c(c1)C(F)(F)F	ARBYGDBJECGMGA-UHFFFAOYSA-N, ARBYGDBJECGMGA-UHFFFAOYSA-N	Phase 2
rubitecan	topoisomerase inhibitor	TOP1			CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4cccc([N+]([O-])=O)c4cc3Cn1c2=O, CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4cccc([N+]([O-])=O)c4cc3Cn1c2=O, CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4cccc([N+]([O-])=O)c4cc3Cn1c2=O	VHXNKPBCCMUMSW-FQEVSTJZSA-N, VHXNKPBCCMUMSW-FQEVSTJZSA-N, VHXNKPBCCMUMSW-FQEVSTJZSA-N	Phase 3
ruboxistaurin	PKC inhibitor				CN(C)C[C@@H]1CCn2cc(C3=C(C(=O)NC3=O)c3cn(CCO1)c1ccccc31)c1ccccc21 |t:10|	ZCBUQCWBWNUWSU-SFHVURJKSA-N	Phase 3
rucaparib	PARP inhibitor	PARP1, PARP2			CNCc1ccc(cc1)-c1[nH]c2cc(F)cc3C(=O)NCCc1c23, CNCc1ccc(cc1)-c1[nH]c2cc(F)cc3C(=O)NCCc1c23, CNCc1ccc(cc1)-c1[nH]c2cc(F)cc3C(=O)NCCc1c23, CNCc1ccc(cc1)-c1[nH]c2cc(F)cc3C(=O)NCCc1c23, CNCc1ccc(cc1)-c1[nH]c2cc(F)cc3C(=O)NCCc1c23, CNCc1ccc(cc1)-c1[nH]c2cc(F)cc3C(=O)NCCc1c23, CNCc1ccc(cc1)-c1[nH]c2cc(F)cc3C(=O)NCCc1c23, CNCc1ccc(cc1)-c1[nH]c2cc(F)cc3C(=O)NCCc1c23, CNCc1ccc(cc1)-c1[nH]c2cc(F)cc3C(=O)NCCc1c23, CNCc1ccc(cc1)-c1[nH]c2cc(F)cc3C(=O)NCCc1c23, CNCc1ccc(cc1)-c1[nH]c2cc(F)cc3C(=O)NCCc1c23, CNCc1ccc(cc1)-c1[nH]c2cc(F)cc3C(=O)NCCc1c23	HMABYWSNWIZPAG-UHFFFAOYSA-N, HMABYWSNWIZPAG-UHFFFAOYSA-N, HMABYWSNWIZPAG-UHFFFAOYSA-N, HMABYWSNWIZPAG-UHFFFAOYSA-N, HMABYWSNWIZPAG-UHFFFAOYSA-N, HMABYWSNWIZPAG-UHFFFAOYSA-N, HMABYWSNWIZPAG-UHFFFAOYSA-N, HMABYWSNWIZPAG-UHFFFAOYSA-N, HMABYWSNWIZPAG-UHFFFAOYSA-N, HMABYWSNWIZPAG-UHFFFAOYSA-N, HMABYWSNWIZPAG-UHFFFAOYSA-N, HMABYWSNWIZPAG-UHFFFAOYSA-N	Phase 3
rucinol	tyrosinase inhibitor	TYR			CCCCc1ccc(O)cc1O, CCCCc1ccc(O)cc1O	CSHZYWUPJWVTMQ-UHFFFAOYSA-N, CSHZYWUPJWVTMQ-UHFFFAOYSA-N	Phase 1
rufinamide	voltage-gated sodium channel blocker	GRM5, SCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A	neurology/psychiatry	seizures	NC(=O)c1cn(Cc2c(F)cccc2F)nn1	POGQSBRIGCQNEG-UHFFFAOYSA-N	Launched
rufloxacin	bacterial DNA gyrase inhibitor		infectious disease	gram-negative bacterial infections	CN1CCN(CC1)c1c(F)cc2c3c1SCCn3cc(C(O)=O)c2=O, CN1CCN(CC1)c1c(F)cc2c3c1SCCn3cc(C(O)=O)c2=O, CN1CCN(CC1)c1c(F)cc2c3c1SCCn3cc(C(O)=O)c2=O	NJCJBUHJQLFDSW-UHFFFAOYSA-N, NJCJBUHJQLFDSW-UHFFFAOYSA-N, NJCJBUHJQLFDSW-UHFFFAOYSA-N	Launched
rupatadine	histamine receptor antagonist, platelet activating factor receptor antagonist	HRH1, PTAFR	allergy	allergic rhinitis, urticaria	Cc1cncc(CN2CCC(CC2)=C2c3ccc(Cl)cc3CCc3cccnc23)c1, Cc1cncc(CN2CCC(CC2)=C2c3ccc(Cl)cc3CCc3cccnc23)c1	WUZYKBABMWJHDL-UHFFFAOYSA-N, WUZYKBABMWJHDL-UHFFFAOYSA-N	Launched
rutaecarpine	cyclooxygenase inhibitor	PTGS2			O=c1n2CCc3c([nH]c4ccccc34)-c2nc2ccccc12, O=c1n2CCc3c([nH]c4ccccc34)-c2nc2ccccc12, O=c1n2CCc3c([nH]c4ccccc34)-c2nc2ccccc12	ACVGWSKVRYFWRP-UHFFFAOYSA-N, ACVGWSKVRYFWRP-UHFFFAOYSA-N, ACVGWSKVRYFWRP-UHFFFAOYSA-N	Preclinical
rutin	antioxidant, capillary stabilizing agent, nitric oxide scavenger	AKR1C3	rheumatology, otolaryngology, gastroenterology, neurology/psychiatry, allergy	joint pain, nasal congestion, constipation, irritability, allergic rhinitis	C[C@@H]1O[C@@H](OC[C@H]2O[C@@H](Oc3c(oc4cc(O)cc(O)c4c3=O)-c3ccc(O)c(O)c3)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@H](O)[C@H]1O, C[C@@H]1O[C@@H](OC[C@H]2O[C@@H](Oc3c(oc4cc(O)cc(O)c4c3=O)-c3ccc(O)c(O)c3)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@H](O)[C@H]1O, C[C@@H]1O[C@@H](OC[C@H]2O[C@@H](Oc3c(oc4cc(O)cc(O)c4c3=O)-c3ccc(O)c(O)c3)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@H](O)[C@H]1O, C[C@@H]1O[C@@H](OC[C@H]2O[C@@H](Oc3c(oc4cc(O)cc(O)c4c3=O)-c3ccc(O)c(O)c3)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@H](O)[C@H]1O	IKGXIBQEEMLURG-NVPNHPEKSA-N, IKGXIBQEEMLURG-NVPNHPEKSA-N, IKGXIBQEEMLURG-NVPNHPEKSA-N, IKGXIBQEEMLURG-NVPNHPEKSA-N	Launched
ruxolitinib	JAK inhibitor	JAK1, JAK2, JAK3, TYK2	hematologic malignancy, hematology	myelofibrosis, polycythemia vera	N#CC[C@H](C1CCCC1)n1cc(cn1)-c1ncnc2[nH]ccc12, N#CC[C@H](C1CCCC1)n1cc(cn1)-c1ncnc2[nH]ccc12, N#CC[C@H](C1CCCC1)n1cc(cn1)-c1ncnc2[nH]ccc12, N#CC[C@H](C1CCCC1)n1cc(cn1)-c1ncnc2[nH]ccc12, N#CC[C@H](C1CCCC1)n1cc(cn1)-c1ncnc2[nH]ccc12, N#CC[C@H](C1CCCC1)n1cc(cn1)-c1ncnc2[nH]ccc12, N#CC[C@H](C1CCCC1)n1cc(cn1)-c1ncnc2[nH]ccc12	HFNKQEVNSGCOJV-OAHLLOKOSA-N, HFNKQEVNSGCOJV-OAHLLOKOSA-N, HFNKQEVNSGCOJV-OAHLLOKOSA-N, HFNKQEVNSGCOJV-OAHLLOKOSA-N, HFNKQEVNSGCOJV-OAHLLOKOSA-N, HFNKQEVNSGCOJV-OAHLLOKOSA-N, HFNKQEVNSGCOJV-OAHLLOKOSA-N	Launched
ruxolitinib-(S)	JAK inhibitor	JAK1, JAK2			N#CC[C@@H](C1CCCC1)n1cc(cn1)-c1ncnc2[nH]ccc12, N#CC[C@@H](C1CCCC1)n1cc(cn1)-c1ncnc2[nH]ccc12, N#CC[C@@H](C1CCCC1)n1cc(cn1)-c1ncnc2[nH]ccc12	HFNKQEVNSGCOJV-HNNXBMFYSA-N, HFNKQEVNSGCOJV-HNNXBMFYSA-N, HFNKQEVNSGCOJV-HNNXBMFYSA-N	Preclinical
RV1729	PI3K inhibitor				COCCN(CCOC)C(=O)CCCC#Cc1cccc2nc(Cn3nc(-c4cccc(O)c4)c4c(N)ncnc34)n(Cc3ccccc3Cl)c(=O)c12	UBLOHCIYTDRGJH-UHFFFAOYSA-N	Phase 1
RWJ-21757	toll-like receptor agonist	TLR7			Nc1nc(=O)c2n(CC=C)c(=O)n([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c2[nH]1, Nc1nc(=O)c2n(CC=C)c(=O)n([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c2[nH]1, Nc1nc(=O)c2n(CC=C)c(=O)n([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c2[nH]1, Nc1nc(=O)c2n(CC=C)c(=O)n([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c2[nH]1	VDCRFBBZFHHYGT-IOSLPCCCSA-N, VDCRFBBZFHHYGT-IOSLPCCCSA-N, VDCRFBBZFHHYGT-IOSLPCCCSA-N, VDCRFBBZFHHYGT-IOSLPCCCSA-N	Phase 2
RWJ-50271	integrin inhibitor	ICAM1			Cc1c(cnn1-c1nc(cs1)-c1cccc(c1)C(F)(F)F)C(=O)NCCCO, Cc1c(cnn1-c1nc(cs1)-c1cccc(c1)C(F)(F)F)C(=O)NCCCO, Cc1c(cnn1-c1nc(cs1)-c1cccc(c1)C(F)(F)F)C(=O)NCCCO	HOFGTYCLOKDAES-UHFFFAOYSA-N, HOFGTYCLOKDAES-UHFFFAOYSA-N, HOFGTYCLOKDAES-UHFFFAOYSA-N	Preclinical
RWJ-67657	MAP kinase inhibitor	MAPK14, PTGS2			OCCC#Cc1nc(c(-c2ccncc2)n1CCCc1ccccc1)-c1ccc(F)cc1, OCCC#Cc1nc(c(-c2ccncc2)n1CCCc1ccccc1)-c1ccc(F)cc1, OCCC#Cc1nc(c(-c2ccncc2)n1CCCc1ccccc1)-c1ccc(F)cc1, OCCC#Cc1nc(c(-c2ccncc2)n1CCCc1ccccc1)-c1ccc(F)cc1	QSUSKMBNZQHHPA-UHFFFAOYSA-N, QSUSKMBNZQHHPA-UHFFFAOYSA-N, QSUSKMBNZQHHPA-UHFFFAOYSA-N, QSUSKMBNZQHHPA-UHFFFAOYSA-N	Phase 1
RX-3117	CDK inhibitor, DNA synthesis inhibitor	CDK2, DNMT1			Nc1ccn([C@H]2[C@H](O)[C@H](O)C(CO)=C2F)c(=O)n1 |c:12|, Nc1ccn([C@H]2[C@H](O)[C@H](O)C(CO)=C2F)c(=O)n1 |c:12|, Nc1ccn([C@H]2[C@H](O)[C@H](O)C(CO)=C2F)c(=O)n1 |c:12|	QLLGKCJUPWYJON-HLTSFMKQSA-N, QLLGKCJUPWYJON-HLTSFMKQSA-N, QLLGKCJUPWYJON-HLTSFMKQSA-N	Phase 1/Phase 2
RX-821002	adrenergic receptor antagonist	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C			CO[C@]1(COc2ccccc2O1)C1=NCCN1 |&1:2,t:14|, CO[C@]1(COc2ccccc2O1)C1=NCCN1 |&1:2,t:14|, CO[C@]1(COc2ccccc2O1)C1=NCCN1 |&1:2,t:14|	HQGWKNGAKBPTBX-LBPRGKRZSA-N, HQGWKNGAKBPTBX-LBPRGKRZSA-N, HQGWKNGAKBPTBX-LBPRGKRZSA-N	Preclinical
ryuvidine	histone lysine methyltransferase inhibitor	CDK2, CDK4			Cc1nc2c(s1)C(=O)C=C(Nc1ccc(C)cc1)C2=O |t:9|, Cc1nc2c(s1)C(=O)C=C(Nc1ccc(C)cc1)C2=O |t:9|, Cc1nc2c(s1)C(=O)C=C(Nc1ccc(C)cc1)C2=O |t:9|, Cc1nc2c(s1)C(=O)C=C(Nc1ccc(C)cc1)C2=O |t:9|, Cc1nc2c(s1)C(=O)C=C(Nc1ccc(C)cc1)C2=O |t:9|, Cc1nc2c(s1)C(=O)C=C(Nc1ccc(C)cc1)C2=O |t:9|, Cc1nc2c(s1)C(=O)C=C(Nc1ccc(C)cc1)C2=O |t:9|	HFPLHASLIOXVGS-UHFFFAOYSA-N, HFPLHASLIOXVGS-UHFFFAOYSA-N, HFPLHASLIOXVGS-UHFFFAOYSA-N, HFPLHASLIOXVGS-UHFFFAOYSA-N, HFPLHASLIOXVGS-UHFFFAOYSA-N, HFPLHASLIOXVGS-UHFFFAOYSA-N, HFPLHASLIOXVGS-UHFFFAOYSA-N	Preclinical
R112	SYK inhibitor	SYK			Oc1cccc(Nc2ncc(F)c(Nc3cccc(O)c3)n2)c1, Oc1cccc(Nc2ncc(F)c(Nc3cccc(O)c3)n2)c1, Oc1cccc(Nc2ncc(F)c(Nc3cccc(O)c3)n2)c1, Oc1cccc(Nc2ncc(F)c(Nc3cccc(O)c3)n2)c1, Oc1cccc(Nc2ncc(F)c(Nc3cccc(O)c3)n2)c1	TVKGTSHBQZEFEE-UHFFFAOYSA-N, TVKGTSHBQZEFEE-UHFFFAOYSA-N, TVKGTSHBQZEFEE-UHFFFAOYSA-N, TVKGTSHBQZEFEE-UHFFFAOYSA-N, TVKGTSHBQZEFEE-UHFFFAOYSA-N	Phase 1
R306465	HDAC inhibitor				ONC(=O)c1cnc(nc1)N1CCN(CC1)S(=O)(=O)c1ccc2ccccc2c1, ONC(=O)c1cnc(nc1)N1CCN(CC1)S(=O)(=O)c1ccc2ccccc2c1, ONC(=O)c1cnc(nc1)N1CCN(CC1)S(=O)(=O)c1ccc2ccccc2c1, ONC(=O)c1cnc(nc1)N1CCN(CC1)S(=O)(=O)c1ccc2ccccc2c1	MUTBJZVSRNUIHA-UHFFFAOYSA-N, MUTBJZVSRNUIHA-UHFFFAOYSA-N, MUTBJZVSRNUIHA-UHFFFAOYSA-N, MUTBJZVSRNUIHA-UHFFFAOYSA-N	Phase 1
R406	SYK inhibitor	RET, SYK			COc1cc(Nc2ncc(F)c(Nc3ccc4OC(C)(C)C(=O)Nc4n3)n2)cc(OC)c1OC, COc1cc(Nc2ncc(F)c(Nc3ccc4OC(C)(C)C(=O)Nc4n3)n2)cc(OC)c1OC, COc1cc(Nc2ncc(F)c(Nc3ccc4OC(C)(C)C(=O)Nc4n3)n2)cc(OC)c1OC, COc1cc(Nc2ncc(F)c(Nc3ccc4OC(C)(C)C(=O)Nc4n3)n2)cc(OC)c1OC, COc1cc(Nc2ncc(F)c(Nc3ccc4OC(C)(C)C(=O)Nc4n3)n2)cc(OC)c1OC, COc1cc(Nc2ncc(F)c(Nc3ccc4OC(C)(C)C(=O)Nc4n3)n2)cc(OC)c1OC, COc1cc(Nc2ncc(F)c(Nc3ccc4OC(C)(C)C(=O)Nc4n3)n2)cc(OC)c1OC, COc1cc(Nc2ncc(F)c(Nc3ccc4OC(C)(C)C(=O)Nc4n3)n2)cc(OC)c1OC, COc1cc(Nc2ncc(F)c(Nc3ccc4OC(C)(C)C(=O)Nc4n3)n2)cc(OC)c1OC, COc1cc(Nc2ncc(F)c(Nc3ccc4OC(C)(C)C(=O)Nc4n3)n2)cc(OC)c1OC, COc1cc(Nc2ncc(F)c(Nc3ccc4OC(C)(C)C(=O)Nc4n3)n2)cc(OC)c1OC, COc1cc(Nc2ncc(F)c(Nc3ccc4OC(C)(C)C(=O)Nc4n3)n2)cc(OC)c1OC, COc1cc(Nc2ncc(F)c(Nc3ccc4OC(C)(C)C(=O)Nc4n3)n2)cc(OC)c1OC, COc1cc(Nc2ncc(F)c(Nc3ccc4OC(C)(C)C(=O)Nc4n3)n2)cc(OC)c1OC	NHHQJBCNYHBUSI-UHFFFAOYSA-N, NHHQJBCNYHBUSI-UHFFFAOYSA-N, NHHQJBCNYHBUSI-UHFFFAOYSA-N, NHHQJBCNYHBUSI-UHFFFAOYSA-N, NHHQJBCNYHBUSI-UHFFFAOYSA-N, NHHQJBCNYHBUSI-UHFFFAOYSA-N, NHHQJBCNYHBUSI-UHFFFAOYSA-N, NHHQJBCNYHBUSI-UHFFFAOYSA-N, NHHQJBCNYHBUSI-UHFFFAOYSA-N, NHHQJBCNYHBUSI-UHFFFAOYSA-N, NHHQJBCNYHBUSI-UHFFFAOYSA-N, NHHQJBCNYHBUSI-UHFFFAOYSA-N, NHHQJBCNYHBUSI-UHFFFAOYSA-N, NHHQJBCNYHBUSI-UHFFFAOYSA-N	Phase 1
R547	CDK inhibitor	CDK1, CDK2, CDK4, CDK7			COc1ccc(F)c(F)c1C(=O)c1cnc(NC2CCN(CC2)S(C)(=O)=O)nc1N, COc1ccc(F)c(F)c1C(=O)c1cnc(NC2CCN(CC2)S(C)(=O)=O)nc1N, COc1ccc(F)c(F)c1C(=O)c1cnc(NC2CCN(CC2)S(C)(=O)=O)nc1N, COc1ccc(F)c(F)c1C(=O)c1cnc(NC2CCN(CC2)S(C)(=O)=O)nc1N	JRNJNYBQQYBCLE-UHFFFAOYSA-N, JRNJNYBQQYBCLE-UHFFFAOYSA-N, JRNJNYBQQYBCLE-UHFFFAOYSA-N, JRNJNYBQQYBCLE-UHFFFAOYSA-N	Phase 1
S-isopropylisothiourea	nitric oxide synthase inhibitor	NOS3			CC(C)SC(N)=N, CC(C)SC(N)=N	XSSNABKEYXKKMK-UHFFFAOYSA-N, XSSNABKEYXKKMK-UHFFFAOYSA-N	Preclinical
S-methylcysteine		CTSD, MGMT			CSC[C@H](N)C(O)=O, CSC[C@H](N)C(O)=O, CSC[C@H](N)C(O)=O	IDIDJDIHTAOVLG-VKHMYHEASA-N, IDIDJDIHTAOVLG-VKHMYHEASA-N, IDIDJDIHTAOVLG-VKHMYHEASA-N	Phase 1
S-nitrosoglutathione	nitric oxide stimulant	PTPN1					Phase 1
S-sulfo-L-cysteine	glutamate receptor agonist				N[C@@H](CSS(O)(=O)=O)C(O)=O	NOKPBJYHPHHWAN-REOHCLBHSA-N	Preclinical
S-trityl-L-cysteine	mitotic kinesin inhibitor				N[C@H](CSC(c1ccccc1)(c1ccccc1)c1ccccc1)C(O)=O, N[C@H](CSC(c1ccccc1)(c1ccccc1)c1ccccc1)C(O)=O, N[C@H](CSC(c1ccccc1)(c1ccccc1)c1ccccc1)C(O)=O	DLMYFMLKORXJPO-HXUWFJFHSA-N, DLMYFMLKORXJPO-HXUWFJFHSA-N, DLMYFMLKORXJPO-HXUWFJFHSA-N	Preclinical
S-07662	CAR antagonist	NR1I3			Cc1oc2ccccc2c1CNC(=O)NCc1cccs1, Cc1oc2ccccc2c1CNC(=O)NCc1cccs1, Cc1oc2ccccc2c1CNC(=O)NCc1cccs1, Cc1oc2ccccc2c1CNC(=O)NCc1cccs1	UITFWLJMEZPXOF-UHFFFAOYSA-N, UITFWLJMEZPXOF-UHFFFAOYSA-N, UITFWLJMEZPXOF-UHFFFAOYSA-N, UITFWLJMEZPXOF-UHFFFAOYSA-N	Preclinical
S-111	PARP inhibitor	PARP1			CC(C)=CCC[C@](C)(O)[C@H]1CC[C@]2(C)[C@@H]1[C@H](O)C[C@@H]1[C@@]3(C)CC[C@H](O)C(C)(C)[C@@H]3CC[C@@]21C, CC(C)=CCC[C@](C)(O)[C@H]1CC[C@]2(C)[C@@H]1[C@H](O)C[C@@H]1[C@@]3(C)CC[C@H](O)C(C)(C)[C@@H]3CC[C@@]21C, CC(C)=CCC[C@](C)(O)[C@H]1CC[C@]2(C)[C@@H]1[C@H](O)C[C@@H]1[C@@]3(C)CC[C@H](O)C(C)(C)[C@@H]3CC[C@@]21C, CC(C)=CCC[C@](C)(O)[C@H]1CC[C@]2(C)[C@@H]1[C@H](O)C[C@@H]1[C@@]3(C)CC[C@H](O)C(C)(C)[C@@H]3CC[C@@]21C, CC(C)=CCC[C@](C)(O)[C@H]1CC[C@]2(C)[C@@H]1[C@H](O)C[C@@H]1[C@@]3(C)CC[C@H](O)C(C)(C)[C@@H]3CC[C@@]21C, CC(C)=CCC[C@](C)(O)[C@H]1CC[C@]2(C)[C@@H]1[C@H](O)C[C@@H]1[C@@]3(C)CC[C@H](O)C(C)(C)[C@@H]3CC[C@@]21C	PYXFVCFISTUSOO-HKUCOEKDSA-N, PYXFVCFISTUSOO-HKUCOEKDSA-N, PYXFVCFISTUSOO-HKUCOEKDSA-N, PYXFVCFISTUSOO-HKUCOEKDSA-N, PYXFVCFISTUSOO-HKUCOEKDSA-N, PYXFVCFISTUSOO-HKUCOEKDSA-N	Phase 2
S-14506	serotonin receptor agonist	HTR1A			COc1ccc2cccc(N3CCN(CCNC(=O)c4ccc(F)cc4)CC3)c2c1, COc1ccc2cccc(N3CCN(CCNC(=O)c4ccc(F)cc4)CC3)c2c1, COc1ccc2cccc(N3CCN(CCNC(=O)c4ccc(F)cc4)CC3)c2c1, COc1ccc2cccc(N3CCN(CCNC(=O)c4ccc(F)cc4)CC3)c2c1, COc1ccc2cccc(N3CCN(CCNC(=O)c4ccc(F)cc4)CC3)c2c1, COc1ccc2cccc(N3CCN(CCNC(=O)c4ccc(F)cc4)CC3)c2c1	IFMQODYDAUKKEN-UHFFFAOYSA-N, IFMQODYDAUKKEN-UHFFFAOYSA-N, IFMQODYDAUKKEN-UHFFFAOYSA-N, IFMQODYDAUKKEN-UHFFFAOYSA-N, IFMQODYDAUKKEN-UHFFFAOYSA-N, IFMQODYDAUKKEN-UHFFFAOYSA-N	Preclinical
S-17092	prolyl endopeptidase inhibitor				O=C([C@@H]1C[C@H]1c1ccccc1)N1[C@H]2CCCC[C@H]2C[C@H]1C(=O)N1CCSC1	NXSXRIHXEQSYEZ-KNJMJIDISA-N	Preclinical
S-3304	matrix metalloprotease inhibitor				Cc1ccc(cc1)C#Cc1ccc(s1)S(=O)(=O)N[C@H](Cc1c[nH]c2ccccc12)C(O)=O	YWCLDDLVLSQGSZ-JOCHJYFZSA-N	Phase 1/Phase 2
S-38093	histamine receptor antagonist				NC(=O)c1ccc(OCCCN2C[C@@H]3CCC[C@@H]3C2)cc1 |r|	MRNMYWNBLVJWKG-GASCZTMLSA-N	Preclinical
SA-47	FAAH inhibitor	FAAH			CNC(=O)COC(=O)NCCC1CCN(CC1)c1cccc(C)n1, CNC(=O)COC(=O)NCCC1CCN(CC1)c1cccc(C)n1	HSYCMGWPPRTNKH-UHFFFAOYSA-N, HSYCMGWPPRTNKH-UHFFFAOYSA-N	Preclinical
saccharin	DNA polymerase inhibitor	CA1, CA12, CA2, CA9			O=C1NS(=O)(=O)c2ccccc12	CVHZOJJKTDOEJC-UHFFFAOYSA-N	Launched
saclofen	GABA receptor antagonist	GABBR1, GABBR2, KCTD12, KCTD16, KCTD8			NC[C@@H](CS(O)(=O)=O)c1ccc(Cl)cc1 |&1:2,r|, NC[C@@H](CS(O)(=O)=O)c1ccc(Cl)cc1 |&1:2,r|, NC[C@@H](CS(O)(=O)=O)c1ccc(Cl)cc1 |&1:2,r|	JYLNVJYYQQXNEK-QMMMGPOBSA-N, JYLNVJYYQQXNEK-QMMMGPOBSA-N, JYLNVJYYQQXNEK-QMMMGPOBSA-N	Preclinical
sacubitril	neprilysin inhibitor	MME	cardiology	congestive heart failure	CCOC(=O)[C@H](C)C[C@@H](Cc1ccc(cc1)-c1ccccc1)NC(=O)CCC(O)=O, CCOC(=O)[C@H](C)C[C@@H](Cc1ccc(cc1)-c1ccccc1)NC(=O)CCC(O)=O, CCOC(=O)[C@H](C)C[C@@H](Cc1ccc(cc1)-c1ccccc1)NC(=O)CCC(O)=O, CCOC(=O)[C@H](C)C[C@@H](Cc1ccc(cc1)-c1ccccc1)NC(=O)CCC(O)=O	PYNXFZCZUAOOQC-UTKZUKDTSA-N, PYNXFZCZUAOOQC-UTKZUKDTSA-N, PYNXFZCZUAOOQC-UTKZUKDTSA-N, PYNXFZCZUAOOQC-UTKZUKDTSA-N	Launched
sacubitrilat	neprilysin inhibitor				[H]N([C@@H](C[C@@H](C)C(O)=O)Cc1ccc(cc1)-c1ccccc1)C(=O)CCC(O)=O	DOBNVUFHFMVMDB-BEFAXECRSA-N	Preclinical
safflower-yellow	anti-inflammatory agent				OC[C@H]1O[C@@H]([C@H](O)[C@@H](O)[C@@H]1O)[C@]1(O)C(=O)[C@@H](\C=C2/C(=O)C(=C(O)\C=C\c3ccc(O)cc3)C(=O)[C@@](O)([C@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)C2=O)C(=O)C(=C(O)\C=C\c2ccc(O)cc2)C1=O |a:2,5,7,9,11,34,38,41,43,45,&1:4,&2:15,&3:20,&4:36,&5:51|	HLUBVUICXYRPPM-DVSWWXTKSA-N	Preclinical
safinamide	dopamine reuptake inhibitor, glutamate inhibitor, monoamine oxidase inhibitor	MAOB	neurology/psychiatry	Parkinson's Disease	C[C@H](NCc1ccc(OCc2cccc(F)c2)cc1)C(N)=O, C[C@H](NCc1ccc(OCc2cccc(F)c2)cc1)C(N)=O	NEMGRZFTLSKBAP-LBPRGKRZSA-N, NEMGRZFTLSKBAP-LBPRGKRZSA-N	Launched
safingol	PKC inhibitor	TRPM3			CCCCCCCCCCCCCCC[C@@H](O)[C@@H](N)CO, CCCCCCCCCCCCCCC[C@@H](O)[C@@H](N)CO, CCCCCCCCCCCCCCC[C@@H](O)[C@@H](N)CO	OTKJDMGTUTTYMP-ZWKOTPCHSA-N, OTKJDMGTUTTYMP-ZWKOTPCHSA-N, OTKJDMGTUTTYMP-ZWKOTPCHSA-N	Phase 1
safranal	benzodiazepine receptor agonist	GABBR1			CC1=C(C=O)C(C)(C)CC=C1 |c:1,9|	SGAWOGXMMPSZPB-UHFFFAOYSA-N	Phase 2
SAG	smoothened receptor agonist	SMO, TRPC6			CN[C@H]1CC[C@@H](CC1)N(Cc1cccc(c1)-c1ccncc1)C(=O)c1sc2ccccc2c1Cl |r|, CN[C@H]1CC[C@@H](CC1)N(Cc1cccc(c1)-c1ccncc1)C(=O)c1sc2ccccc2c1Cl |r|, CN[C@H]1CC[C@@H](CC1)N(Cc1cccc(c1)-c1ccncc1)C(=O)c1sc2ccccc2c1Cl |r|, CN[C@H]1CC[C@@H](CC1)N(Cc1cccc(c1)-c1ccncc1)C(=O)c1sc2ccccc2c1Cl |r|, CN[C@H]1CC[C@@H](CC1)N(Cc1cccc(c1)-c1ccncc1)C(=O)c1sc2ccccc2c1Cl |r|	VFSUUTYAEQOIMW-YHBQERECSA-N, VFSUUTYAEQOIMW-YHBQERECSA-N, VFSUUTYAEQOIMW-YHBQERECSA-N, VFSUUTYAEQOIMW-YHBQERECSA-N, VFSUUTYAEQOIMW-YHBQERECSA-N	Preclinical
salazodine					COc1ccc(NS(=O)(=O)c2ccc(cc2)N=Nc2ccc(O)c(c2)C(O)=O)nn1	YFUATOCFMCWUEH-UHFFFAOYSA-N	Phase 2
salicin	anti-inflammatory agent				OC[C@H]1O[C@@H](Oc2ccccc2CO)[C@H](O)[C@@H](O)[C@@H]1O, OC[C@H]1O[C@@H](Oc2ccccc2CO)[C@H](O)[C@@H](O)[C@@H]1O, OC[C@H]1O[C@@H](Oc2ccccc2CO)[C@H](O)[C@@H](O)[C@@H]1O	NGFMICBWJRZIBI-UJPOAAIJSA-N, NGFMICBWJRZIBI-UJPOAAIJSA-N, NGFMICBWJRZIBI-UJPOAAIJSA-N	Phase 1
salicyl-alcohol					OCc1ccccc1O, OCc1ccccc1O, OCc1ccccc1O	CQRYARSYNCAZFO-UHFFFAOYSA-N, CQRYARSYNCAZFO-UHFFFAOYSA-N, CQRYARSYNCAZFO-UHFFFAOYSA-N	Preclinical
salicylamide	analgesic agent		neurology/psychiatry, endocrinology	pain relief, fever	NC(=O)c1ccccc1O, NC(=O)c1ccccc1O	SKZKKFZAGNVIMN-UHFFFAOYSA-N, SKZKKFZAGNVIMN-UHFFFAOYSA-N	Launched
salicylanilide	other antibiotic				Oc1ccccc1C(=O)Nc1ccccc1, Oc1ccccc1C(=O)Nc1ccccc1, Oc1ccccc1C(=O)Nc1ccccc1	WKEDVNSFRWHDNR-UHFFFAOYSA-N, WKEDVNSFRWHDNR-UHFFFAOYSA-N, WKEDVNSFRWHDNR-UHFFFAOYSA-N	Preclinical
salicylic-acid	cyclooxygenase inhibitor, prostanoid receptor antagonist	AKR1C1, ASIC3, PTGS1, PTGS2	dermatology, endocrinology, neurology/psychiatry	acne vulgaris (AV), fever, pain relief	OC(=O)c1ccccc1O, OC(=O)c1ccccc1O, OC(=O)c1ccccc1O, OC(=O)c1ccccc1O, OC(=O)c1ccccc1O	YGSDEFSMJLZEOE-UHFFFAOYSA-N, YGSDEFSMJLZEOE-UHFFFAOYSA-N, YGSDEFSMJLZEOE-UHFFFAOYSA-N, YGSDEFSMJLZEOE-UHFFFAOYSA-N, YGSDEFSMJLZEOE-UHFFFAOYSA-N	Launched
salidroside	beta amyloid protein neurotoxicity inhibitor	APP			OC[C@H]1O[C@@H](OCCc2ccc(O)cc2)[C@H](O)[C@@H](O)[C@@H]1O, OC[C@H]1O[C@@H](OCCc2ccc(O)cc2)[C@H](O)[C@@H](O)[C@@H]1O	ILRCGYURZSFMEG-RKQHYHRCSA-N, ILRCGYURZSFMEG-RKQHYHRCSA-N	Preclinical
salinomycin			infectious disease	coccidiosis	CC[C@H]([C@H]1CC[C@H](C)[C@@H](O1)[C@@H](C)[C@H](O)[C@H](C)C(=O)[C@H](CC)[C@H]1O[C@@]2(O[C@@]3(CC[C@](C)(O3)[C@H]3CC[C@](O)(CC)[C@H](C)O3)[C@H](O)C=C2)[C@H](C)C[C@@H]1C)C(O)=O |c:46|	KQXDHUJYNAXLNZ-XQSDOZFQSA-N	Launched
salirasib	mTOR inhibitor	TRPA1			CC(C)=CCC\C(C)=C\CC\C(C)=C\CSc1ccccc1C(O)=O, CC(C)=CCC\C(C)=C\CC\C(C)=C\CSc1ccccc1C(O)=O, CC(C)=CCC\C(C)=C\CC\C(C)=C\CSc1ccccc1C(O)=O, CC(C)=CCC\C(C)=C\CC\C(C)=C\CSc1ccccc1C(O)=O	WUILNKCFCLNXOK-CFBAGHHKSA-N, WUILNKCFCLNXOK-CFBAGHHKSA-N, WUILNKCFCLNXOK-CFBAGHHKSA-N, WUILNKCFCLNXOK-CFBAGHHKSA-N	Phase 2
salmeterol	adrenergic receptor agonist	ADRB2	pulmonary	asthma, chronic obstructive pulmonary disease (COPD), bronchospasm	OCc1cc(ccc1O)[C@@H](O)CNCCCCCCOCCCCc1ccccc1 |&1:9|, OCc1cc(ccc1O)[C@@H](O)CNCCCCCCOCCCCc1ccccc1 |&1:9|, OCc1cc(ccc1O)[C@@H](O)CNCCCCCCOCCCCc1ccccc1 |&1:9|, OCc1cc(ccc1O)[C@@H](O)CNCCCCCCOCCCCc1ccccc1 |&1:9|, OCc1cc(ccc1O)[C@@H](O)CNCCCCCCOCCCCc1ccccc1 |&1:9|	GIIZNNXWQWCKIB-VWLOTQADSA-N, GIIZNNXWQWCKIB-VWLOTQADSA-N, GIIZNNXWQWCKIB-VWLOTQADSA-N, GIIZNNXWQWCKIB-VWLOTQADSA-N, GIIZNNXWQWCKIB-VWLOTQADSA-N	Launched
salsolinol-1-carboxylic-acid					C[C@]1(NCCc2cc(O)c(O)cc12)C(O)=O |&1:1,r|, C[C@]1(NCCc2cc(O)c(O)cc12)C(O)=O |&1:1,r|	XHGLVMDBZZZXDP-LLVKDONJSA-N, XHGLVMDBZZZXDP-LLVKDONJSA-N	Preclinical
salubrinal	eukaryotic translation initiation factor inhibitor	EIF2S1			ClC(Cl)(Cl)[C@H](NC(=S)Nc1cccc2cccnc12)NC(=O)\C=C\c1ccccc1 |&1:4,r|, ClC(Cl)(Cl)[C@H](NC(=S)Nc1cccc2cccnc12)NC(=O)\C=C\c1ccccc1 |&1:4,r|, ClC(Cl)(Cl)[C@H](NC(=S)Nc1cccc2cccnc12)NC(=O)\C=C\c1ccccc1 |&1:4,r|, ClC(Cl)(Cl)[C@H](NC(=S)Nc1cccc2cccnc12)NC(=O)\C=C\c1ccccc1 |&1:4,r|, ClC(Cl)(Cl)[C@H](NC(=S)Nc1cccc2cccnc12)NC(=O)\C=C\c1ccccc1 |&1:4,r|, ClC(Cl)(Cl)[C@H](NC(=S)Nc1cccc2cccnc12)NC(=O)\C=C\c1ccccc1 |&1:4,r|	LCOIAYJMPKXARU-CVTTXWKISA-N, LCOIAYJMPKXARU-CVTTXWKISA-N, LCOIAYJMPKXARU-CVTTXWKISA-N, LCOIAYJMPKXARU-CVTTXWKISA-N, LCOIAYJMPKXARU-CVTTXWKISA-N, LCOIAYJMPKXARU-CVTTXWKISA-N	Preclinical
salvianolic-acid-A	matrix metalloprotease inhibitor				OC(=O)[C@@H](Cc1ccc(O)c(O)c1)OC(=O)\C=C\c1ccc(O)c(O)c1\C=C\c1ccc(O)c(O)c1	YMGFTDKNIWPMGF-UCPJVGPRSA-N	Phase 1
salvianolic-acid-B	EGFR inhibitor, metalloproteinase inhibitor	MMP9			OC(=O)[C@@H](Cc1ccc(O)c(O)c1)OC(=O)\C=C\c1ccc(O)c2O[C@H]([C@H](C(=O)O[C@H](Cc3ccc(O)c(O)c3)C(O)=O)c12)c1ccc(O)c(O)c1, OC(=O)[C@@H](Cc1ccc(O)c(O)c1)OC(=O)\C=C\c1ccc(O)c2O[C@H]([C@H](C(=O)O[C@H](Cc3ccc(O)c(O)c3)C(O)=O)c12)c1ccc(O)c(O)c1	SNKFFCBZYFGCQN-PDVBOLEISA-N, SNKFFCBZYFGCQN-PDVBOLEISA-N	Phase 2
salvinorin-A	opioid receptor agonist	OPRD1, OPRK1, OPRM1			COC(=O)[C@@H]1C[C@H](OC(C)=O)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@@H](C[C@]21C)c1ccoc1, COC(=O)[C@@H]1C[C@H](OC(C)=O)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@@H](C[C@]21C)c1ccoc1	OBSYBRPAKCASQB-AGQYDFLVSA-N, OBSYBRPAKCASQB-AGQYDFLVSA-N	Phase 1
sal003	eukaryotic translation initiation factor inhibitor	EIF2A			Clc1ccc(NC(=S)N[C@H](NC(=O)\C=C\c2ccccc2)C(Cl)(Cl)Cl)cc1 |&1:9,r|, Clc1ccc(NC(=S)N[C@H](NC(=O)\C=C\c2ccccc2)C(Cl)(Cl)Cl)cc1 |&1:9,r|, Clc1ccc(NC(=S)N[C@H](NC(=O)\C=C\c2ccccc2)C(Cl)(Cl)Cl)cc1 |&1:9,r|, Clc1ccc(NC(=S)N[C@H](NC(=O)\C=C\c2ccccc2)C(Cl)(Cl)Cl)cc1 |&1:9,r|, Clc1ccc(NC(=S)N[C@H](NC(=O)\C=C\c2ccccc2)C(Cl)(Cl)Cl)cc1 |&1:9,r|	TVNBASWNLOIQML-RFKZRZAASA-N, TVNBASWNLOIQML-RFKZRZAASA-N, TVNBASWNLOIQML-RFKZRZAASA-N, TVNBASWNLOIQML-RFKZRZAASA-N, TVNBASWNLOIQML-RFKZRZAASA-N	Preclinical
SAM-315	serotonin receptor antagonist				O=S(=O)(c1n[nH]c2ccc(cc12)N1CCNCC1)c1cccc2ccccc12	FYOVZCDHYOEKDE-UHFFFAOYSA-N	Preclinical
sameridine	opioid receptor modulator				CCCCCCN1CCC(CC1)(C(=O)N(C)CC)c1ccccc1	TYWUGCGYWNSRPS-UHFFFAOYSA-N	Preclinical
sanazole					COCCNC(=O)Cn1cnc(n1)[N+]([O-])=O	YKDRHKCETNMLHL-UHFFFAOYSA-N	Phase 1
sancycline	antitumor agent				[H][C@@]12Cc3cccc(O)c3C(=O)[C@@H]1C(=O)[C@]1(O)C(=O)[C@H](C(N)=O)C(=O)[C@@H](N(C)C)[C@]1([H])C2 |&1:19,&2:12|	CRNIKQQPTHSPBA-IEPLVVIMSA-N	Preclinical
sangivamycin	DNA inhibitor				NC(=O)c1cn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c2ncnc(N)c12, NC(=O)c1cn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c2ncnc(N)c12	OBZJZDHRXBKKTJ-JTFADIMSSA-N, OBZJZDHRXBKKTJ-JTFADIMSSA-N	Phase 1
sanguinarium-chloride	apoptosis stimulant	CASP3			C[n+]1cc2c3OCOc3ccc2c2ccc3cc4OCOc4cc3c12, C[n+]1cc2c3OCOc3ccc2c2ccc3cc4OCOc4cc3c12, C[n+]1cc2c3OCOc3ccc2c2ccc3cc4OCOc4cc3c12, C[n+]1cc2c3OCOc3ccc2c2ccc3cc4OCOc4cc3c12, C[n+]1cc2c3OCOc3ccc2c2ccc3cc4OCOc4cc3c12, C[n+]1cc2c3OCOc3ccc2c2ccc3cc4OCOc4cc3c12, C[n+]1cc2c3OCOc3ccc2c2ccc3cc4OCOc4cc3c12, C[n+]1cc2c3OCOc3ccc2c2ccc3cc4OCOc4cc3c12	INVGWHRKADIJHF-UHFFFAOYSA-N, INVGWHRKADIJHF-UHFFFAOYSA-N, INVGWHRKADIJHF-UHFFFAOYSA-N, INVGWHRKADIJHF-UHFFFAOYSA-N, INVGWHRKADIJHF-UHFFFAOYSA-N, INVGWHRKADIJHF-UHFFFAOYSA-N, INVGWHRKADIJHF-UHFFFAOYSA-N, INVGWHRKADIJHF-UHFFFAOYSA-N	Phase 1
SANT-1	smoothened receptor antagonist	SHH, SMO			Cc1nn(c(C)c1\C=N\N1CCN(Cc2ccccc2)CC1)-c1ccccc1, Cc1nn(c(C)c1\C=N\N1CCN(Cc2ccccc2)CC1)-c1ccccc1, Cc1nn(c(C)c1\C=N\N1CCN(Cc2ccccc2)CC1)-c1ccccc1, Cc1nn(c(C)c1\C=N\N1CCN(Cc2ccccc2)CC1)-c1ccccc1, Cc1nn(c(C)c1\C=N\N1CCN(Cc2ccccc2)CC1)-c1ccccc1, Cc1nn(c(C)c1\C=N\N1CCN(Cc2ccccc2)CC1)-c1ccccc1, Cc1nn(c(C)c1\C=N\N1CCN(Cc2ccccc2)CC1)-c1ccccc1	FOORCIAZMIWALX-JJIBRWJFSA-N, FOORCIAZMIWALX-JJIBRWJFSA-N, FOORCIAZMIWALX-JJIBRWJFSA-N, FOORCIAZMIWALX-JJIBRWJFSA-N, FOORCIAZMIWALX-JJIBRWJFSA-N, FOORCIAZMIWALX-JJIBRWJFSA-N, FOORCIAZMIWALX-JJIBRWJFSA-N	Preclinical
SANT-2	smoothened receptor antagonist	SHH, SMO			CCOc1cc(cc(OCC)c1OCC)C(=O)Nc1ccc(Cl)c(c1)-c1nc2ccccc2[nH]1, CCOc1cc(cc(OCC)c1OCC)C(=O)Nc1ccc(Cl)c(c1)-c1nc2ccccc2[nH]1, CCOc1cc(cc(OCC)c1OCC)C(=O)Nc1ccc(Cl)c(c1)-c1nc2ccccc2[nH]1, CCOc1cc(cc(OCC)c1OCC)C(=O)Nc1ccc(Cl)c(c1)-c1nc2ccccc2[nH]1, CCOc1cc(cc(OCC)c1OCC)C(=O)Nc1ccc(Cl)c(c1)-c1nc2ccccc2[nH]1, CCOc1cc(cc(OCC)c1OCC)C(=O)Nc1ccc(Cl)c(c1)-c1nc2ccccc2[nH]1	VQOJFGFKIVFMDH-UHFFFAOYSA-N, VQOJFGFKIVFMDH-UHFFFAOYSA-N, VQOJFGFKIVFMDH-UHFFFAOYSA-N, VQOJFGFKIVFMDH-UHFFFAOYSA-N, VQOJFGFKIVFMDH-UHFFFAOYSA-N, VQOJFGFKIVFMDH-UHFFFAOYSA-N	Preclinical
sapacitabine	DNA synthesis inhibitor				CCCCCCCCCCCCCCCC(=O)Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2C#N)c(=O)n1	LBGFKUUHOPIEMA-PEARBKPGSA-N	Phase 3
sapropterin	phenylalanine 4-hydroxylase stimulant	NOS3, PAH, TH, TPH1	metabolism	hyperphenylalaninemia (HPA)	C[C@H](O)[C@H](O)[C@H]1CNc2[nH]c(N)nc(=O)c2N1, C[C@H](O)[C@H](O)[C@H]1CNc2[nH]c(N)nc(=O)c2N1, C[C@H](O)[C@H](O)[C@H]1CNc2[nH]c(N)nc(=O)c2N1	FNKQXYHWGSIFBK-RPDRRWSUSA-N, FNKQXYHWGSIFBK-RPDRRWSUSA-N, FNKQXYHWGSIFBK-RPDRRWSUSA-N	Launched
saquinavir	HIV protease inhibitor	CYP3A4	infectious disease	human immunodeficiency virus (HIV-1)	CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(N)=O)NC(=O)c1ccc2ccccc2n1, CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(N)=O)NC(=O)c1ccc2ccccc2n1, CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(N)=O)NC(=O)c1ccc2ccccc2n1, CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(N)=O)NC(=O)c1ccc2ccccc2n1, CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(N)=O)NC(=O)c1ccc2ccccc2n1, CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(N)=O)NC(=O)c1ccc2ccccc2n1	QWAXKHKRTORLEM-UGJKXSETSA-N, QWAXKHKRTORLEM-UGJKXSETSA-N, QWAXKHKRTORLEM-UGJKXSETSA-N, QWAXKHKRTORLEM-UGJKXSETSA-N, QWAXKHKRTORLEM-UGJKXSETSA-N, QWAXKHKRTORLEM-UGJKXSETSA-N	Launched
SAR-245409	PI3K inhibitor	MTOR, PIK3CG			COc1cc(Nc2nc3ccccc3nc2NS(=O)(=O)c2ccc(NC(=O)c3ccc(C)c(OC)c3)cc2)cc(OC)c1	HJSSPYJVWLTYHG-UHFFFAOYSA-N	Phase 1/Phase 2
saracatinib	SRC inhibitor	ABL1, LCK, SRC, YES1			CN1CCN(CCOc2cc(OC3CCOCC3)c3c(Nc4c5OCOc5ccc4Cl)ncnc3c2)CC1, CN1CCN(CCOc2cc(OC3CCOCC3)c3c(Nc4c5OCOc5ccc4Cl)ncnc3c2)CC1, CN1CCN(CCOc2cc(OC3CCOCC3)c3c(Nc4c5OCOc5ccc4Cl)ncnc3c2)CC1, CN1CCN(CCOc2cc(OC3CCOCC3)c3c(Nc4c5OCOc5ccc4Cl)ncnc3c2)CC1, CN1CCN(CCOc2cc(OC3CCOCC3)c3c(Nc4c5OCOc5ccc4Cl)ncnc3c2)CC1, CN1CCN(CCOc2cc(OC3CCOCC3)c3c(Nc4c5OCOc5ccc4Cl)ncnc3c2)CC1, CN1CCN(CCOc2cc(OC3CCOCC3)c3c(Nc4c5OCOc5ccc4Cl)ncnc3c2)CC1, CN1CCN(CCOc2cc(OC3CCOCC3)c3c(Nc4c5OCOc5ccc4Cl)ncnc3c2)CC1, CN1CCN(CCOc2cc(OC3CCOCC3)c3c(Nc4c5OCOc5ccc4Cl)ncnc3c2)CC1, CN1CCN(CCOc2cc(OC3CCOCC3)c3c(Nc4c5OCOc5ccc4Cl)ncnc3c2)CC1, CN1CCN(CCOc2cc(OC3CCOCC3)c3c(Nc4c5OCOc5ccc4Cl)ncnc3c2)CC1, CN1CCN(CCOc2cc(OC3CCOCC3)c3c(Nc4c5OCOc5ccc4Cl)ncnc3c2)CC1, CN1CCN(CCOc2cc(OC3CCOCC3)c3c(Nc4c5OCOc5ccc4Cl)ncnc3c2)CC1, CN1CCN(CCOc2cc(OC3CCOCC3)c3c(Nc4c5OCOc5ccc4Cl)ncnc3c2)CC1, CN1CCN(CCOc2cc(OC3CCOCC3)c3c(Nc4c5OCOc5ccc4Cl)ncnc3c2)CC1, CN1CCN(CCOc2cc(OC3CCOCC3)c3c(Nc4c5OCOc5ccc4Cl)ncnc3c2)CC1	OUKYUETWWIPKQR-UHFFFAOYSA-N, OUKYUETWWIPKQR-UHFFFAOYSA-N, OUKYUETWWIPKQR-UHFFFAOYSA-N, OUKYUETWWIPKQR-UHFFFAOYSA-N, OUKYUETWWIPKQR-UHFFFAOYSA-N, OUKYUETWWIPKQR-UHFFFAOYSA-N, OUKYUETWWIPKQR-UHFFFAOYSA-N, InChI=1S/C27H32ClN5O5/c1-32-6-8-33(9-7-32)10-13-35-19-14-21-24(23(15-19)38-18-4-11-34-12-5-18)27(30-16-29-21)31-25-20(28)2-3-22-26(25)37-17-36-22/h2-3,14-16,18H,4-13,17H2,1H3,(H,29,30,31), InChI=1S/C27H32ClN5O5/c1-32-6-8-33(9-7-32)10-13-35-19-14-21-24(23(15-19)38-18-4-11-34-12-5-18)27(30-16-29-21)31-25-20(28)2-3-22-26(25)37-17-36-22/h2-3,14-16,18H,4-13,17H2,1H3,(H,29,30,31), InChI=1S/C27H32ClN5O5/c1-32-6-8-33(9-7-32)10-13-35-19-14-21-24(23(15-19)38-18-4-11-34-12-5-18)27(30-16-29-21)31-25-20(28)2-3-22-26(25)37-17-36-22/h2-3,14-16,18H,4-13,17H2,1H3,(H,29,30,31), InChI=1S/C27H32ClN5O5/c1-32-6-8-33(9-7-32)10-13-35-19-14-21-24(23(15-19)38-18-4-11-34-12-5-18)27(30-16-29-21)31-25-20(28)2-3-22-26(25)37-17-36-22/h2-3,14-16,18H,4-13,17H2,1H3,(H,29,30,31), InChI=1S/C27H32ClN5O5/c1-32-6-8-33(9-7-32)10-13-35-19-14-21-24(23(15-19)38-18-4-11-34-12-5-18)27(30-16-29-21)31-25-20(28)2-3-22-26(25)37-17-36-22/h2-3,14-16,18H,4-13,17H2,1H3,(H,29,30,31), InChI=1S/C27H32ClN5O5/c1-32-6-8-33(9-7-32)10-13-35-19-14-21-24(23(15-19)38-18-4-11-34-12-5-18)27(30-16-29-21)31-25-20(28)2-3-22-26(25)37-17-36-22/h2-3,14-16,18H,4-13,17H2,1H3,(H,29,30,31), InChI=1S/C27H32ClN5O5/c1-32-6-8-33(9-7-32)10-13-35-19-14-21-24(23(15-19)38-18-4-11-34-12-5-18)27(30-16-29-21)31-25-20(28)2-3-22-26(25)37-17-36-22/h2-3,14-16,18H,4-13,17H2,1H3,(H,29,30,31), InChI=1S/C27H32ClN5O5/c1-32-6-8-33(9-7-32)10-13-35-19-14-21-24(23(15-19)38-18-4-11-34-12-5-18)27(30-16-29-21)31-25-20(28)2-3-22-26(25)37-17-36-22/h2-3,14-16,18H,4-13,17H2,1H3,(H,29,30,31), InChI=1S/C27H32ClN5O5/c1-32-6-8-33(9-7-32)10-13-35-19-14-21-24(23(15-19)38-18-4-11-34-12-5-18)27(30-16-29-21)31-25-20(28)2-3-22-26(25)37-17-36-22/h2-3,14-16,18H,4-13,17H2,1H3,(H,29,30,31)	Phase 2/Phase 3
sarafloxacin	bacterial DNA gyrase inhibitor		infectious disease	gram-negative bacterial infections, gram-positive bacterial infections	OC(=O)c1cn(-c2ccc(F)cc2)c2cc(N3CCNCC3)c(F)cc2c1=O, OC(=O)c1cn(-c2ccc(F)cc2)c2cc(N3CCNCC3)c(F)cc2c1=O, OC(=O)c1cn(-c2ccc(F)cc2)c2cc(N3CCNCC3)c(F)cc2c1=O	XBHBWNFJWIASRO-UHFFFAOYSA-N, XBHBWNFJWIASRO-UHFFFAOYSA-N, XBHBWNFJWIASRO-UHFFFAOYSA-N	Launched
sarcosine	glycine transporter inhibitor	SLC6A9			CNCC(O)=O	FSYKKLYZXJSNPZ-UHFFFAOYSA-N	Phase 2
sardomozide	S-adenosylmethionine decarboxylase inhibitor				NC(=N)N\N=C1/CCc2c1cccc2C(N)=N	CYPGNVSXMAUSJY-CXUHLZMHSA-N	Preclinical
sari-59-801					CCc1noc(C)c1-c1[nH]c2ccccc2c1[C@@H](O)CN(C)C |&1:17,r|, CCc1noc(C)c1-c1[nH]c2ccccc2c1[C@@H](O)CN(C)C |&1:17,r|	GMGOZCSXMVXXRS-HNNXBMFYSA-N, GMGOZCSXMVXXRS-HNNXBMFYSA-N	Phase 1
saroglitazar	PPAR receptor agonist	PPARA, PPARG	endocrinology, cardiology, gastroenterology	diabetes mellitus, dyslipidemia, non-alcoholic steatohepatitis (NASH)	CCO[C@@H](Cc1ccc(OCCn2c(C)ccc2-c2ccc(SC)cc2)cc1)C(O)=O, CCO[C@@H](Cc1ccc(OCCn2c(C)ccc2-c2ccc(SC)cc2)cc1)C(O)=O	MRWFZSLZNUJVQW-DEOSSOPVSA-N, MRWFZSLZNUJVQW-DEOSSOPVSA-N	Launched
sarpogrelate	serotonin receptor antagonist	HTR2A, HTR2B, HTR2C	endocrinology, cardiology, rheumatology	diabetes mellitus, angina pectoris, Raynaud's disease, atherosclerosis, Buerger's disease	COc1cccc(CCc2ccccc2OC[C@@H](CN(C)C)OC(=O)CCC(O)=O)c1 |&1:17|, COc1cccc(CCc2ccccc2OC[C@@H](CN(C)C)OC(=O)CCC(O)=O)c1 |&1:17|, COc1cccc(CCc2ccccc2OC[C@@H](CN(C)C)OC(=O)CCC(O)=O)c1 |&1:17|, COc1cccc(CCc2ccccc2OC[C@@H](CN(C)C)OC(=O)CCC(O)=O)c1 |&1:17|	FFYNAVGJSYHHFO-OAQYLSRUSA-N, FFYNAVGJSYHHFO-OAQYLSRUSA-N, FFYNAVGJSYHHFO-OAQYLSRUSA-N, FFYNAVGJSYHHFO-OAQYLSRUSA-N	Launched
SAR131675	VEGFR inhibitor	FLT4			CCn1c(N)c(C(=O)NC)c(=O)c2ccc(nc12)C#C[C@@](C)(O)COC, CCn1c(N)c(C(=O)NC)c(=O)c2ccc(nc12)C#C[C@@](C)(O)COC	PFMPOBVAYMTUOX-GOSISDBHSA-N, PFMPOBVAYMTUOX-GOSISDBHSA-N	Preclinical
SAR405	PI3K inhibitor	PIK3C3			C[C@@H]1COCCN1c1cc(=O)n2CC[C@H](N(Cc3cncc(Cl)c3)c2n1)C(F)(F)F, C[C@@H]1COCCN1c1cc(=O)n2CC[C@H](N(Cc3cncc(Cl)c3)c2n1)C(F)(F)F, C[C@@H]1COCCN1c1cc(=O)n2CC[C@H](N(Cc3cncc(Cl)c3)c2n1)C(F)(F)F, C[C@@H]1COCCN1c1cc(=O)n2CC[C@H](N(Cc3cncc(Cl)c3)c2n1)C(F)(F)F	SPDQRCUBFSRAFI-DOMZBBRYSA-N, SPDQRCUBFSRAFI-DOMZBBRYSA-N, SPDQRCUBFSRAFI-DOMZBBRYSA-N, SPDQRCUBFSRAFI-DOMZBBRYSA-N	Preclinical
SAR405838	MDM inhibitor	MDM2			CC(C)(C)C[C@@H]1N[C@H]([C@H](c2cccc(Cl)c2F)[C@]11C(=O)Nc2cc(Cl)ccc12)C(=O)N[C@H]1CC[C@H](O)CC1, CC(C)(C)C[C@@H]1N[C@H]([C@H](c2cccc(Cl)c2F)[C@]11C(=O)Nc2cc(Cl)ccc12)C(=O)N[C@H]1CC[C@H](O)CC1, CC(C)(C)C[C@@H]1N[C@H]([C@H](c2cccc(Cl)c2F)[C@]11C(=O)Nc2cc(Cl)ccc12)C(=O)N[C@H]1CC[C@H](O)CC1, CC(C)(C)C[C@@H]1N[C@H]([C@H](c2cccc(Cl)c2F)[C@]11C(=O)Nc2cc(Cl)ccc12)C(=O)N[C@H]1CC[C@H](O)CC1, CC(C)(C)C[C@@H]1N[C@H]([C@H](c2cccc(Cl)c2F)[C@]11C(=O)Nc2cc(Cl)ccc12)C(=O)N[C@H]1CC[C@H](O)CC1, CC(C)(C)C[C@@H]1N[C@H]([C@H](c2cccc(Cl)c2F)[C@]11C(=O)Nc2cc(Cl)ccc12)C(=O)N[C@H]1CC[C@H](O)CC1, CC(C)(C)C[C@@H]1N[C@H]([C@H](c2cccc(Cl)c2F)[C@]11C(=O)Nc2cc(Cl)ccc12)C(=O)N[C@H]1CC[C@H](O)CC1, CC(C)(C)C[C@@H]1N[C@H]([C@H](c2cccc(Cl)c2F)[C@]11C(=O)Nc2cc(Cl)ccc12)C(=O)N[C@H]1CC[C@H](O)CC1	IDKAKZRYYDCJDU-HBMMIIHUSA-N, IDKAKZRYYDCJDU-HBMMIIHUSA-N, IDKAKZRYYDCJDU-HBMMIIHUSA-N, IDKAKZRYYDCJDU-HBMMIIHUSA-N, IDKAKZRYYDCJDU-HBMMIIHUSA-N, IDKAKZRYYDCJDU-HBMMIIHUSA-N, IDKAKZRYYDCJDU-HBMMIIHUSA-N, IDKAKZRYYDCJDU-HBMMIIHUSA-N	Phase 1
SAR407899	rho associated kinase inhibitor	ROCK1			O=c1[nH]ccc2cc(OC3CCNCC3)ccc12, O=c1[nH]ccc2cc(OC3CCNCC3)ccc12, O=c1[nH]ccc2cc(OC3CCNCC3)ccc12	IPEXHQGMTHOKQV-UHFFFAOYSA-N, IPEXHQGMTHOKQV-UHFFFAOYSA-N, IPEXHQGMTHOKQV-UHFFFAOYSA-N	Phase 2
sasapyrine	NFkB pathway inhibitor	PTGS1, PTGS2	rheumatology	osteoarthritis, rheumatoid arthritis	OC(=O)c1ccccc1OC(=O)c1ccccc1O, OC(=O)c1ccccc1OC(=O)c1ccccc1O, OC(=O)c1ccccc1OC(=O)c1ccccc1O	WVYADZUPLLSGPU-UHFFFAOYSA-N, WVYADZUPLLSGPU-UHFFFAOYSA-N, WVYADZUPLLSGPU-UHFFFAOYSA-N	Launched
satraplatin	DNA alkylating agent				CC(=O)O[Pt](N)(Cl)(Cl)(NC1CCCCC1)OC(C)=O, CC(=O)O[Pt](N)(Cl)(Cl)(NC1CCCCC1)OC(C)=O	JWTNVKZACPRKPF-UHFFFAOYSA-J, JWTNVKZACPRKPF-UHFFFAOYSA-J	Phase 3
savolitinib	c-Met inhibitor	MET			C[C@@H](c1ccc2nccn2c1)n1nnc2ncc(nc12)-c1cnn(C)c1, C[C@@H](c1ccc2nccn2c1)n1nnc2ncc(nc12)-c1cnn(C)c1, C[C@@H](c1ccc2nccn2c1)n1nnc2ncc(nc12)-c1cnn(C)c1	XYDNMOZJKOGZLS-NSHDSACASA-N, XYDNMOZJKOGZLS-NSHDSACASA-N, XYDNMOZJKOGZLS-NSHDSACASA-N	Phase 3
saxagliptin	dipeptidyl peptidase inhibitor	DPP4	endocrinology	diabetes mellitus	N[C@H](C(=O)N1[C@H]2C[C@H]2C[C@H]1C#N)[C@]12C[C@H]3C[C@H](C[C@](O)(C3)C1)C2	QGJUIPDUBHWZPV-YQBUGCKMSA-N	Launched
SB-200646	serotonin receptor antagonist	HTR2B, HTR2C			Cn1ccc2cc(NC(=O)Nc3cccnc3)ccc12, Cn1ccc2cc(NC(=O)Nc3cccnc3)ccc12, Cn1ccc2cc(NC(=O)Nc3cccnc3)ccc12, Cn1ccc2cc(NC(=O)Nc3cccnc3)ccc12, Cn1ccc2cc(NC(=O)Nc3cccnc3)ccc12	OJZZJTLBYXHUSJ-UHFFFAOYSA-N, OJZZJTLBYXHUSJ-UHFFFAOYSA-N, OJZZJTLBYXHUSJ-UHFFFAOYSA-N, OJZZJTLBYXHUSJ-UHFFFAOYSA-N, OJZZJTLBYXHUSJ-UHFFFAOYSA-N	Preclinical
SB-202190	p38 MAPK inhibitor	AKT1, ALOX5, CHEK1, GSK3B, LCK, MAPK1, MAPK11, MAPK12, MAPK14, MAPK8, PRKCA, ROCK1, RPS6KB1, SGK1			Oc1ccc(cc1)-c1nc(c([nH]1)-c1ccc(F)cc1)-c1ccncc1, Oc1ccc(cc1)-c1nc(c([nH]1)-c1ccc(F)cc1)-c1ccncc1, Oc1ccc(cc1)-c1nc(c([nH]1)-c1ccc(F)cc1)-c1ccncc1	QHKYPYXTTXKZST-UHFFFAOYSA-N, QHKYPYXTTXKZST-UHFFFAOYSA-N, QHKYPYXTTXKZST-UHFFFAOYSA-N	Preclinical
SB-203186	serotonin receptor antagonist	HTR4			O=C(OCCN1CCCCC1)c1c[nH]c2ccccc12, O=C(OCCN1CCCCC1)c1c[nH]c2ccccc12	YGKPIROTKVQCCU-UHFFFAOYSA-N, YGKPIROTKVQCCU-UHFFFAOYSA-N	Preclinical
SB-203580	p38 MAPK inhibitor	AKT1, ALOX5, CHEK1, CYP2D6, CYP3A4, GAK, GSK3B, LCK, MAPK1, MAPK10, MAPK11, MAPK12, MAPK14, MAPK8, MAPK9, PRKCA, RAF1, RIPK2, ROCK1, RPS6KB1, SGK1, SRC, TNF			C[S@@](=O)c1ccc(cc1)-c1nc(c([nH]1)-c1ccc(F)cc1)-c1ccncc1 |&1:1|, C[S@@](=O)c1ccc(cc1)-c1nc(c([nH]1)-c1ccc(F)cc1)-c1ccncc1 |&1:1|	CDMGBJANTYXAIV-HHHXNRCGSA-N, CDMGBJANTYXAIV-HHHXNRCGSA-N	Preclinical
SB-205384	GABA receptor modulator	GABRA3, GABRA5, GABRA6			CC#CCOC(=O)c1c(C)nc2sc3C[C@@H](O)CCc3c2c1N |&1:15,r|, CC#CCOC(=O)c1c(C)nc2sc3C[C@@H](O)CCc3c2c1N |&1:15,r|, CC#CCOC(=O)c1c(C)nc2sc3C[C@@H](O)CCc3c2c1N |&1:15,r|, CC#CCOC(=O)c1c(C)nc2sc3C[C@@H](O)CCc3c2c1N |&1:15,r|, CC#CCOC(=O)c1c(C)nc2sc3C[C@@H](O)CCc3c2c1N |&1:15,r|, CC#CCOC(=O)c1c(C)nc2sc3C[C@@H](O)CCc3c2c1N |&1:15,r|, CC#CCOC(=O)c1c(C)nc2sc3C[C@@H](O)CCc3c2c1N |&1:15,r|	JDTZAGLGBRRCJT-JTQLQIEISA-N, JDTZAGLGBRRCJT-JTQLQIEISA-N, JDTZAGLGBRRCJT-JTQLQIEISA-N, JDTZAGLGBRRCJT-JTQLQIEISA-N, JDTZAGLGBRRCJT-JTQLQIEISA-N, JDTZAGLGBRRCJT-JTQLQIEISA-N, JDTZAGLGBRRCJT-JTQLQIEISA-N	Preclinical
SB-206553	serotonin receptor antagonist	HTR2A, HTR2B, HTR2C			Cn1ccc2cc3N(CCc3cc12)C(=O)Nc1cccnc1, Cn1ccc2cc3N(CCc3cc12)C(=O)Nc1cccnc1, Cn1ccc2cc3N(CCc3cc12)C(=O)Nc1cccnc1	QJQORSLQNXDVGE-UHFFFAOYSA-N, QJQORSLQNXDVGE-UHFFFAOYSA-N, QJQORSLQNXDVGE-UHFFFAOYSA-N	Preclinical
SB-216641	serotonin receptor antagonist	HTR1A, HTR1B, HTR1D, HTR2A, HTR2B, HTR2C			COc1ccc(NC(=O)c2ccc(cc2)-c2ccc(cc2C)-c2noc(C)n2)cc1OCCN(C)C, COc1ccc(NC(=O)c2ccc(cc2)-c2ccc(cc2C)-c2noc(C)n2)cc1OCCN(C)C	JRNUKVFYILMMLX-UHFFFAOYSA-N, JRNUKVFYILMMLX-UHFFFAOYSA-N	Preclinical
SB-216763	glycogen synthase kinase inhibitor	CCNA2, CDK2, GSK3A, GSK3B			Cn1cc(C2=C(C(=O)NC2=O)c2ccc(Cl)cc2Cl)c2ccccc12 |t:4|, Cn1cc(C2=C(C(=O)NC2=O)c2ccc(Cl)cc2Cl)c2ccccc12 |t:4|	JCSGFHVFHSKIJH-UHFFFAOYSA-N, JCSGFHVFHSKIJH-UHFFFAOYSA-N	Preclinical
SB-218078	CHK inhibitor	CHEK1					Preclinical
SB-218795	tachykinin antagonist	TACR3			COC(=O)[C@H](NC(=O)c1cc(nc2ccccc12)-c1ccccc1)c1ccccc1, COC(=O)[C@H](NC(=O)c1cc(nc2ccccc12)-c1ccccc1)c1ccccc1, COC(=O)[C@H](NC(=O)c1cc(nc2ccccc12)-c1ccccc1)c1ccccc1	IUMQXQJZIHWLIN-HSZRJFAPSA-N, IUMQXQJZIHWLIN-HSZRJFAPSA-N, IUMQXQJZIHWLIN-HSZRJFAPSA-N	Preclinical
SB-221284	serotonin receptor antagonist	HTR2A, HTR2B, HTR2C			CSc1cc2CCN(C(=O)Nc3cccnc3)c2cc1C(F)(F)F, CSc1cc2CCN(C(=O)Nc3cccnc3)c2cc1C(F)(F)F, CSc1cc2CCN(C(=O)Nc3cccnc3)c2cc1C(F)(F)F	OQZOXHCRSXYSPM-UHFFFAOYSA-N, OQZOXHCRSXYSPM-UHFFFAOYSA-N, OQZOXHCRSXYSPM-UHFFFAOYSA-N	Preclinical
SB-222200	tachykinin antagonist	TACR3			CC[C@H](NC(=O)c1c(C)c(nc2ccccc12)-c1ccccc1)c1ccccc1, CC[C@H](NC(=O)c1c(C)c(nc2ccccc12)-c1ccccc1)c1ccccc1, CC[C@H](NC(=O)c1c(C)c(nc2ccccc12)-c1ccccc1)c1ccccc1, CC[C@H](NC(=O)c1c(C)c(nc2ccccc12)-c1ccccc1)c1ccccc1	MQNYRKWJSMQECI-QFIPXVFZSA-N, MQNYRKWJSMQECI-QFIPXVFZSA-N, MQNYRKWJSMQECI-QFIPXVFZSA-N, MQNYRKWJSMQECI-QFIPXVFZSA-N	Preclinical
SB-225002	CC chemokine receptor antagonist	CXCR2			Oc1cc(ccc1NC(=O)Nc1ccccc1Br)[N+]([O-])=O, Oc1cc(ccc1NC(=O)Nc1ccccc1Br)[N+]([O-])=O, Oc1cc(ccc1NC(=O)Nc1ccccc1Br)[N+]([O-])=O, Oc1cc(ccc1NC(=O)Nc1ccccc1Br)[N+]([O-])=O, Oc1cc(ccc1NC(=O)Nc1ccccc1Br)[N+]([O-])=O, Oc1cc(ccc1NC(=O)Nc1ccccc1Br)[N+]([O-])=O, Oc1cc(ccc1NC(=O)Nc1ccccc1Br)[N+]([O-])=O	MQBZVUNNWUIPMK-UHFFFAOYSA-N, MQBZVUNNWUIPMK-UHFFFAOYSA-N, MQBZVUNNWUIPMK-UHFFFAOYSA-N, MQBZVUNNWUIPMK-UHFFFAOYSA-N, MQBZVUNNWUIPMK-UHFFFAOYSA-N, MQBZVUNNWUIPMK-UHFFFAOYSA-N, MQBZVUNNWUIPMK-UHFFFAOYSA-N	Preclinical
SB-228357	serotonin receptor antagonist	HTR2A, HTR2B, HTR2C			COc1cc2CCN(C(=O)Nc3cc(F)cc(c3)-c3cccnc3)c2cc1C(F)(F)F, COc1cc2CCN(C(=O)Nc3cc(F)cc(c3)-c3cccnc3)c2cc1C(F)(F)F, COc1cc2CCN(C(=O)Nc3cc(F)cc(c3)-c3cccnc3)c2cc1C(F)(F)F, COc1cc2CCN(C(=O)Nc3cc(F)cc(c3)-c3cccnc3)c2cc1C(F)(F)F	RRJLJKRFFRZRAF-UHFFFAOYSA-N, RRJLJKRFFRZRAF-UHFFFAOYSA-N, RRJLJKRFFRZRAF-UHFFFAOYSA-N, RRJLJKRFFRZRAF-UHFFFAOYSA-N	Preclinical
SB-2343	mTOR inhibitor, PI3K inhibitor	MTOR, PIK3CA, PIK3CB, PIK3CD, PIK3CG			CC(C)n1c(C)nc2c(nc(nc12)N1CCOCC1)-c1cnc(N)nc1, CC(C)n1c(C)nc2c(nc(nc12)N1CCOCC1)-c1cnc(N)nc1, CC(C)n1c(C)nc2c(nc(nc12)N1CCOCC1)-c1cnc(N)nc1, CC(C)n1c(C)nc2c(nc(nc12)N1CCOCC1)-c1cnc(N)nc1, CC(C)n1c(C)nc2c(nc(nc12)N1CCOCC1)-c1cnc(N)nc1	QYBGBLQCOOISAR-UHFFFAOYSA-N, QYBGBLQCOOISAR-UHFFFAOYSA-N, QYBGBLQCOOISAR-UHFFFAOYSA-N, QYBGBLQCOOISAR-UHFFFAOYSA-N, QYBGBLQCOOISAR-UHFFFAOYSA-N	Phase 1
SB-239063	p38 MAPK inhibitor	MAPK11, MAPK14, PTGS2			COc1nccc(n1)-c1c(ncn1[C@H]1CC[C@H](O)CC1)-c1ccc(F)cc1 |r|, COc1nccc(n1)-c1c(ncn1[C@H]1CC[C@H](O)CC1)-c1ccc(F)cc1 |r|, COc1nccc(n1)-c1c(ncn1[C@H]1CC[C@H](O)CC1)-c1ccc(F)cc1 |r|, COc1nccc(n1)-c1c(ncn1[C@H]1CC[C@H](O)CC1)-c1ccc(F)cc1 |r|, COc1nccc(n1)-c1c(ncn1[C@H]1CC[C@H](O)CC1)-c1ccc(F)cc1 |r|, COc1nccc(n1)-c1c(ncn1[C@H]1CC[C@H](O)CC1)-c1ccc(F)cc1 |r|, COc1nccc(n1)-c1c(ncn1[C@H]1CC[C@H](O)CC1)-c1ccc(F)cc1 |r|	ZQUSFAUAYSEREK-WKILWMFISA-N, ZQUSFAUAYSEREK-WKILWMFISA-N, ZQUSFAUAYSEREK-WKILWMFISA-N, ZQUSFAUAYSEREK-WKILWMFISA-N, ZQUSFAUAYSEREK-WKILWMFISA-N, ZQUSFAUAYSEREK-WKILWMFISA-N, ZQUSFAUAYSEREK-WKILWMFISA-N	Preclinical
SB-242235	p38 MAPK inhibitor	HSPB1, MAPK14			COc1nccc(n1)-c1c(ncn1C1CCNCC1)-c1ccc(F)cc1, COc1nccc(n1)-c1c(ncn1C1CCNCC1)-c1ccc(F)cc1, COc1nccc(n1)-c1c(ncn1C1CCNCC1)-c1ccc(F)cc1, COc1nccc(n1)-c1c(ncn1C1CCNCC1)-c1ccc(F)cc1	PDTYLGXVBIWRIM-UHFFFAOYSA-N, PDTYLGXVBIWRIM-UHFFFAOYSA-N, PDTYLGXVBIWRIM-UHFFFAOYSA-N, PDTYLGXVBIWRIM-UHFFFAOYSA-N	Phase 1
SB-243213	serotonin receptor inverse agonist	HTR2A, HTR2B, HTR2C, HTR6			Cc1cc2CCN(C(=O)Nc3ccc(Oc4cccnc4C)nc3)c2cc1C(F)(F)F, Cc1cc2CCN(C(=O)Nc3ccc(Oc4cccnc4C)nc3)c2cc1C(F)(F)F, Cc1cc2CCN(C(=O)Nc3ccc(Oc4cccnc4C)nc3)c2cc1C(F)(F)F, Cc1cc2CCN(C(=O)Nc3ccc(Oc4cccnc4C)nc3)c2cc1C(F)(F)F	ZETBBVYSBABLHL-UHFFFAOYSA-N, ZETBBVYSBABLHL-UHFFFAOYSA-N, ZETBBVYSBABLHL-UHFFFAOYSA-N, ZETBBVYSBABLHL-UHFFFAOYSA-N	Phase 1
SB-258585	serotonin receptor antagonist	HTR6			COc1ccc(NS(=O)(=O)c2ccc(I)cc2)cc1N1CCN(C)CC1, COc1ccc(NS(=O)(=O)c2ccc(I)cc2)cc1N1CCN(C)CC1	BDHMSYNBSBZCAF-UHFFFAOYSA-N, BDHMSYNBSBZCAF-UHFFFAOYSA-N	Preclinical
SB-268262	calcitonin antagonist	CALCA			CN(C(=O)c1ccc(c(c1)[N+]([O-])=O)[S@@](=O)c1nccs1)c1ccccc1C |&1:13,r|, CN(C(=O)c1ccc(c(c1)[N+]([O-])=O)[S@@](=O)c1nccs1)c1ccccc1C |&1:13,r|, CN(C(=O)c1ccc(c(c1)[N+]([O-])=O)[S@@](=O)c1nccs1)c1ccccc1C |&1:13,r|, CN(C(=O)c1ccc(c(c1)[N+]([O-])=O)[S@@](=O)c1nccs1)c1ccccc1C |&1:13,r|, CN(C(=O)c1ccc(c(c1)[N+]([O-])=O)[S@@](=O)c1nccs1)c1ccccc1C |&1:13,r|	YXHLPJQQPOMPGE-HHHXNRCGSA-N, YXHLPJQQPOMPGE-HHHXNRCGSA-N, YXHLPJQQPOMPGE-HHHXNRCGSA-N, YXHLPJQQPOMPGE-HHHXNRCGSA-N, YXHLPJQQPOMPGE-HHHXNRCGSA-N	Preclinical
SB-269970	serotonin receptor antagonist	HTR7			CC1CCN(CC[C@H]2CCCN2S(=O)(=O)c2cccc(O)c2)CC1, CC1CCN(CC[C@H]2CCCN2S(=O)(=O)c2cccc(O)c2)CC1, CC1CCN(CC[C@H]2CCCN2S(=O)(=O)c2cccc(O)c2)CC1, CC1CCN(CC[C@H]2CCCN2S(=O)(=O)c2cccc(O)c2)CC1, CC1CCN(CC[C@H]2CCCN2S(=O)(=O)c2cccc(O)c2)CC1	HWKROQUZSKPIKQ-MRXNPFEDSA-N, HWKROQUZSKPIKQ-MRXNPFEDSA-N, HWKROQUZSKPIKQ-MRXNPFEDSA-N, HWKROQUZSKPIKQ-MRXNPFEDSA-N, HWKROQUZSKPIKQ-MRXNPFEDSA-N	Preclinical
SB-271046	serotonin receptor antagonist	HTR6			COc1ccc(NS(=O)(=O)c2sc3ccc(Cl)cc3c2C)cc1N1CCNCC1, COc1ccc(NS(=O)(=O)c2sc3ccc(Cl)cc3c2C)cc1N1CCNCC1, COc1ccc(NS(=O)(=O)c2sc3ccc(Cl)cc3c2C)cc1N1CCNCC1, COc1ccc(NS(=O)(=O)c2sc3ccc(Cl)cc3c2C)cc1N1CCNCC1, COc1ccc(NS(=O)(=O)c2sc3ccc(Cl)cc3c2C)cc1N1CCNCC1, COc1ccc(NS(=O)(=O)c2sc3ccc(Cl)cc3c2C)cc1N1CCNCC1, COc1ccc(NS(=O)(=O)c2sc3ccc(Cl)cc3c2C)cc1N1CCNCC1, COc1ccc(NS(=O)(=O)c2sc3ccc(Cl)cc3c2C)cc1N1CCNCC1	LOCQRDBFWSXQQI-UHFFFAOYSA-N, LOCQRDBFWSXQQI-UHFFFAOYSA-N, LOCQRDBFWSXQQI-UHFFFAOYSA-N, LOCQRDBFWSXQQI-UHFFFAOYSA-N, LOCQRDBFWSXQQI-UHFFFAOYSA-N, LOCQRDBFWSXQQI-UHFFFAOYSA-N, LOCQRDBFWSXQQI-UHFFFAOYSA-N, LOCQRDBFWSXQQI-UHFFFAOYSA-N	Phase 1
SB-297006	CC chemokine receptor antagonist	CCR3			CCOC(=O)[C@H](Cc1ccc(cc1)[N+]([O-])=O)NC(=O)c1ccccc1, CCOC(=O)[C@H](Cc1ccc(cc1)[N+]([O-])=O)NC(=O)c1ccccc1	BEZXGSZPWXRHIN-INIZCTEOSA-N, BEZXGSZPWXRHIN-INIZCTEOSA-N	Preclinical
SB-328437	CCR antagonist				COC(=O)[C@H](Cc1ccc(cc1)[N+]([O-])=O)NC(=O)c1cccc2ccccc12, COC(=O)[C@H](Cc1ccc(cc1)[N+]([O-])=O)NC(=O)c1cccc2ccccc12, COC(=O)[C@H](Cc1ccc(cc1)[N+]([O-])=O)NC(=O)c1cccc2ccccc12	VMFGCGRAIBLAFY-IBGZPJMESA-N, VMFGCGRAIBLAFY-IBGZPJMESA-N, VMFGCGRAIBLAFY-IBGZPJMESA-N	Preclinical
SB-334867	orexin receptor antagonist	HCRTR1, HCRTR2			Cc1nc2ccc(NC(=O)Nc3ccnc4cccnc34)cc2o1, Cc1nc2ccc(NC(=O)Nc3ccnc4cccnc34)cc2o1, Cc1nc2ccc(NC(=O)Nc3ccnc4cccnc34)cc2o1, Cc1nc2ccc(NC(=O)Nc3ccnc4cccnc34)cc2o1	AKMNUCBQGHFICM-UHFFFAOYSA-N, AKMNUCBQGHFICM-UHFFFAOYSA-N, AKMNUCBQGHFICM-UHFFFAOYSA-N, AKMNUCBQGHFICM-UHFFFAOYSA-N	Preclinical
SB-366791	TRPV antagonist	TRPV1			COc1cccc(NC(=O)\C=C\c2ccc(Cl)cc2)c1, COc1cccc(NC(=O)\C=C\c2ccc(Cl)cc2)c1, COc1cccc(NC(=O)\C=C\c2ccc(Cl)cc2)c1, COc1cccc(NC(=O)\C=C\c2ccc(Cl)cc2)c1, COc1cccc(NC(=O)\C=C\c2ccc(Cl)cc2)c1	RYAMDQKWNKKFHD-JXMROGBWSA-N, RYAMDQKWNKKFHD-JXMROGBWSA-N, RYAMDQKWNKKFHD-JXMROGBWSA-N, RYAMDQKWNKKFHD-JXMROGBWSA-N, RYAMDQKWNKKFHD-JXMROGBWSA-N	Preclinical
SB-399885	serotonin receptor antagonist	HTR6			COc1ccc(cc1N1CCNCC1)S(=O)(=O)Nc1cc(Cl)cc(Cl)c1OC, COc1ccc(cc1N1CCNCC1)S(=O)(=O)Nc1cc(Cl)cc(Cl)c1OC	ATKZKAYWARYLBW-UHFFFAOYSA-N, ATKZKAYWARYLBW-UHFFFAOYSA-N	Preclinical
SB-408124	orexin receptor antagonist	HCRTR1, HCRTR2			CN(C)c1ccc(NC(=O)Nc2cc(C)nc3c(F)cc(F)cc23)cc1, CN(C)c1ccc(NC(=O)Nc2cc(C)nc3c(F)cc(F)cc23)cc1, CN(C)c1ccc(NC(=O)Nc2cc(C)nc3c(F)cc(F)cc23)cc1, CN(C)c1ccc(NC(=O)Nc2cc(C)nc3c(F)cc(F)cc23)cc1, CN(C)c1ccc(NC(=O)Nc2cc(C)nc3c(F)cc(F)cc23)cc1	JTARFZSNUAGHRB-UHFFFAOYSA-N, JTARFZSNUAGHRB-UHFFFAOYSA-N, JTARFZSNUAGHRB-UHFFFAOYSA-N, JTARFZSNUAGHRB-UHFFFAOYSA-N, JTARFZSNUAGHRB-UHFFFAOYSA-N	Preclinical
SB-415286	glycogen synthase kinase inhibitor	GSK3A, GSK3B, RPS6KB1			Oc1ccc(NC2=C(C(=O)NC2=O)c2ccccc2[N+]([O-])=O)cc1Cl |t:6|, Oc1ccc(NC2=C(C(=O)NC2=O)c2ccccc2[N+]([O-])=O)cc1Cl |t:6|, Oc1ccc(NC2=C(C(=O)NC2=O)c2ccccc2[N+]([O-])=O)cc1Cl |t:6|, Oc1ccc(NC2=C(C(=O)NC2=O)c2ccccc2[N+]([O-])=O)cc1Cl |t:6|, Oc1ccc(NC2=C(C(=O)NC2=O)c2ccccc2[N+]([O-])=O)cc1Cl |t:6|, Oc1ccc(NC2=C(C(=O)NC2=O)c2ccccc2[N+]([O-])=O)cc1Cl |t:6|	PQCXVIPXISBFPN-UHFFFAOYSA-N, PQCXVIPXISBFPN-UHFFFAOYSA-N, PQCXVIPXISBFPN-UHFFFAOYSA-N, PQCXVIPXISBFPN-UHFFFAOYSA-N, PQCXVIPXISBFPN-UHFFFAOYSA-N, PQCXVIPXISBFPN-UHFFFAOYSA-N	Preclinical
SB-431542	TGF beta receptor inhibitor	ACVR1C, TGFBR1			NC(=O)c1ccc(cc1)-c1nc(c([nH]1)-c1ccc2OCOc2c1)-c1ccccn1, NC(=O)c1ccc(cc1)-c1nc(c([nH]1)-c1ccc2OCOc2c1)-c1ccccn1, NC(=O)c1ccc(cc1)-c1nc(c([nH]1)-c1ccc2OCOc2c1)-c1ccccn1, NC(=O)c1ccc(cc1)-c1nc(c([nH]1)-c1ccc2OCOc2c1)-c1ccccn1, NC(=O)c1ccc(cc1)-c1nc(c([nH]1)-c1ccc2OCOc2c1)-c1ccccn1, NC(=O)c1ccc(cc1)-c1nc(c([nH]1)-c1ccc2OCOc2c1)-c1ccccn1	FHYUGAJXYORMHI-UHFFFAOYSA-N, FHYUGAJXYORMHI-UHFFFAOYSA-N, FHYUGAJXYORMHI-UHFFFAOYSA-N, FHYUGAJXYORMHI-UHFFFAOYSA-N, FHYUGAJXYORMHI-UHFFFAOYSA-N, FHYUGAJXYORMHI-UHFFFAOYSA-N	Preclinical
SB-452533	TRPV antagonist	TRPV1			CCN(CCNC(=O)Nc1ccccc1Br)c1cccc(C)c1, CCN(CCNC(=O)Nc1ccccc1Br)c1cccc(C)c1	IFJYEGJUQIBBQV-UHFFFAOYSA-N, IFJYEGJUQIBBQV-UHFFFAOYSA-N	Preclinical
SB-505124	ALK tyrosine kinase receptor inhibitor	TGFBR1			Cc1cccc(n1)-c1nc([nH]c1-c1ccc2OCOc2c1)C(C)(C)C, Cc1cccc(n1)-c1nc([nH]c1-c1ccc2OCOc2c1)C(C)(C)C, Cc1cccc(n1)-c1nc([nH]c1-c1ccc2OCOc2c1)C(C)(C)C	WGZOTBUYUFBEPZ-UHFFFAOYSA-N, WGZOTBUYUFBEPZ-UHFFFAOYSA-N, WGZOTBUYUFBEPZ-UHFFFAOYSA-N	Preclinical
SB-525334	TGF beta receptor inhibitor	TGFBR1			Cc1cccc(n1)-c1nc([nH]c1-c1ccc2nccnc2c1)C(C)(C)C, Cc1cccc(n1)-c1nc([nH]c1-c1ccc2nccnc2c1)C(C)(C)C, Cc1cccc(n1)-c1nc([nH]c1-c1ccc2nccnc2c1)C(C)(C)C, Cc1cccc(n1)-c1nc([nH]c1-c1ccc2nccnc2c1)C(C)(C)C	DKPQHFZUICCZHF-UHFFFAOYSA-N, DKPQHFZUICCZHF-UHFFFAOYSA-N, DKPQHFZUICCZHF-UHFFFAOYSA-N, DKPQHFZUICCZHF-UHFFFAOYSA-N	Preclinical
SB-590885	RAF inhibitor	BRAF			CN(C)CCOc1ccc(cc1)-c1nc(c([nH]1)-c1ccc2\C(CCc2c1)=N\O)-c1ccncc1, CN(C)CCOc1ccc(cc1)-c1nc(c([nH]1)-c1ccc2\C(CCc2c1)=N\O)-c1ccncc1, CN(C)CCOc1ccc(cc1)-c1nc(c([nH]1)-c1ccc2\C(CCc2c1)=N\O)-c1ccncc1, CN(C)CCOc1ccc(cc1)-c1nc(c([nH]1)-c1ccc2\C(CCc2c1)=N\O)-c1ccncc1	MLSAQOINCGAULQ-QFMPWRQOSA-N, MLSAQOINCGAULQ-QFMPWRQOSA-N, MLSAQOINCGAULQ-QFMPWRQOSA-N, MLSAQOINCGAULQ-QFMPWRQOSA-N	Preclinical
SB-612111	nociceptin/orphanin FQ receptor antagonist	OPRL1			Cc1cccc2[C@@H](O)C[C@@H](CN3CCC(CC3)c3c(Cl)cccc3Cl)CCc12, Cc1cccc2[C@@H](O)C[C@@H](CN3CCC(CC3)c3c(Cl)cccc3Cl)CCc12, Cc1cccc2[C@@H](O)C[C@@H](CN3CCC(CC3)c3c(Cl)cccc3Cl)CCc12	OHRDCQFCAWLDBP-SBUREZEXSA-N, OHRDCQFCAWLDBP-SBUREZEXSA-N, OHRDCQFCAWLDBP-SBUREZEXSA-N	Preclinical
SB-649868	orexin receptor antagonist				Cc1nc(C(=O)N2CCCC[C@H]2CNC(=O)c2cccc3occc23)c(s1)-c1ccc(F)cc1	ZJXIUGNEAIHSBI-IBGZPJMESA-N	Phase 2
SB-657510	urotensin receptor antagonist	UTS2R			COc1cc(Br)c(cc1OC)S(=O)(=O)Nc1ccc(Cl)c(O[C@@H]2CCN(C)C2)c1, COc1cc(Br)c(cc1OC)S(=O)(=O)Nc1ccc(Cl)c(O[C@@H]2CCN(C)C2)c1, COc1cc(Br)c(cc1OC)S(=O)(=O)Nc1ccc(Cl)c(O[C@@H]2CCN(C)C2)c1, COc1cc(Br)c(cc1OC)S(=O)(=O)Nc1ccc(Cl)c(O[C@@H]2CCN(C)C2)c1	KQCZCINJGIRLCD-CYBMUJFWSA-N, KQCZCINJGIRLCD-CYBMUJFWSA-N, KQCZCINJGIRLCD-CYBMUJFWSA-N, KQCZCINJGIRLCD-CYBMUJFWSA-N	Preclinical
SB-683698	integrin antagonist	ITGA4, ITGAV, ITGB1, ITGB7			COc1cccc(OC)c1-c1ccc(C[C@H](NC(=O)c2c(Cl)cccc2Cl)C(O)=O)cc1, COc1cccc(OC)c1-c1ccc(C[C@H](NC(=O)c2c(Cl)cccc2Cl)C(O)=O)cc1, COc1cccc(OC)c1-c1ccc(C[C@H](NC(=O)c2c(Cl)cccc2Cl)C(O)=O)cc1, COc1cccc(OC)c1-c1ccc(C[C@H](NC(=O)c2c(Cl)cccc2Cl)C(O)=O)cc1, COc1cccc(OC)c1-c1ccc(C[C@H](NC(=O)c2c(Cl)cccc2Cl)C(O)=O)cc1	DRSJLVGDSNWQBI-SFHVURJKSA-N, DRSJLVGDSNWQBI-SFHVURJKSA-N, DRSJLVGDSNWQBI-SFHVURJKSA-N, DRSJLVGDSNWQBI-SFHVURJKSA-N, DRSJLVGDSNWQBI-SFHVURJKSA-N	Phase 1
SB-705498	TRPV antagonist	TRPV1			FC(F)(F)c1ccc(nc1)N1CC[C@H](C1)NC(=O)Nc1ccccc1Br, FC(F)(F)c1ccc(nc1)N1CC[C@H](C1)NC(=O)Nc1ccccc1Br, FC(F)(F)c1ccc(nc1)N1CC[C@H](C1)NC(=O)Nc1ccccc1Br, FC(F)(F)c1ccc(nc1)N1CC[C@H](C1)NC(=O)Nc1ccccc1Br, FC(F)(F)c1ccc(nc1)N1CC[C@H](C1)NC(=O)Nc1ccccc1Br	JYILLRHXRVTRSH-GFCCVEGCSA-N, JYILLRHXRVTRSH-GFCCVEGCSA-N, JYILLRHXRVTRSH-GFCCVEGCSA-N, JYILLRHXRVTRSH-GFCCVEGCSA-N, JYILLRHXRVTRSH-GFCCVEGCSA-N	Phase 2
SB-706375	urotensin receptor antagonist	UTS2R			COc1cc(Br)c(cc1OC)S(=O)(=O)Nc1ccc(c(O[C@@H]2CCN(C)C2)c1)C(F)(F)F, COc1cc(Br)c(cc1OC)S(=O)(=O)Nc1ccc(c(O[C@@H]2CCN(C)C2)c1)C(F)(F)F	BPOWQJYAMDEAFF-CYBMUJFWSA-N, BPOWQJYAMDEAFF-CYBMUJFWSA-N	Preclinical
SB-742457	serotonin receptor antagonist	HTR6			O=S(=O)(c1ccccc1)c1cnc2c(cccc2c1)N1CCNCC1, O=S(=O)(c1ccccc1)c1cnc2c(cccc2c1)N1CCNCC1, O=S(=O)(c1ccccc1)c1cnc2c(cccc2c1)N1CCNCC1	JJZFWROHYSMCMU-UHFFFAOYSA-N, JJZFWROHYSMCMU-UHFFFAOYSA-N, JJZFWROHYSMCMU-UHFFFAOYSA-N	Phase 3
SB-743921	kinesin-like spindle protein inhibitor	KIF11			CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1oc2cc(Cl)ccc2c(=O)c1Cc1ccccc1, CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1oc2cc(Cl)ccc2c(=O)c1Cc1ccccc1, CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1oc2cc(Cl)ccc2c(=O)c1Cc1ccccc1	PGXYIBJJCLWJST-MUUNZHRXSA-N, PGXYIBJJCLWJST-MUUNZHRXSA-N, PGXYIBJJCLWJST-MUUNZHRXSA-N	Phase 1/Phase 2
SB-747651A	kinase inhibitor	AKT1, AKT3, ROCK1, RPS6KA5, RPS6KB1			CCn1c(nc2cncc(CNC3CCNCC3)c12)-c1nonc1N, CCn1c(nc2cncc(CNC3CCNCC3)c12)-c1nonc1N, CCn1c(nc2cncc(CNC3CCNCC3)c12)-c1nonc1N, CCn1c(nc2cncc(CNC3CCNCC3)c12)-c1nonc1N	MBCJUIJWPYUEBX-UHFFFAOYSA-N, MBCJUIJWPYUEBX-UHFFFAOYSA-N, MBCJUIJWPYUEBX-UHFFFAOYSA-N, MBCJUIJWPYUEBX-UHFFFAOYSA-N	Preclinical
SB-756050	G protein-coupled receptor agonist	GPBAR1			COc1ccc(cc1OC)S(=O)(=O)N1CCCN(CC1)S(=O)(=O)c1ccc(OC)c(OC)c1, COc1ccc(cc1OC)S(=O)(=O)N1CCCN(CC1)S(=O)(=O)c1ccc(OC)c(OC)c1, COc1ccc(cc1OC)S(=O)(=O)N1CCCN(CC1)S(=O)(=O)c1ccc(OC)c(OC)c1	GJUFPAZNBPFNRI-UHFFFAOYSA-N, GJUFPAZNBPFNRI-UHFFFAOYSA-N, GJUFPAZNBPFNRI-UHFFFAOYSA-N	Phase 1
SB-772077B	rho associated kinase inhibitor	ROCK1, ROCK2			CCn1c(nc2cncc(C(=O)N3CC[C@H](N)C3)c12)-c1nonc1N, CCn1c(nc2cncc(C(=O)N3CC[C@H](N)C3)c12)-c1nonc1N	PHWHNHYZZNJPLB-QMMMGPOBSA-N, PHWHNHYZZNJPLB-QMMMGPOBSA-N	Preclinical
SB-939	HDAC inhibitor	HDAC1, HDAC10, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC9			CCCCc1nc2cc(\C=C\C(=O)NO)ccc2n1CCN(CC)CC, CCCCc1nc2cc(\C=C\C(=O)NO)ccc2n1CCN(CC)CC, CCCCc1nc2cc(\C=C\C(=O)NO)ccc2n1CCN(CC)CC, CCCCc1nc2cc(\C=C\C(=O)NO)ccc2n1CCN(CC)CC, CCCCc1nc2cc(\C=C\C(=O)NO)ccc2n1CCN(CC)CC, CCCCc1nc2cc(\C=C\C(=O)NO)ccc2n1CCN(CC)CC, CCCCc1nc2cc(\C=C\C(=O)NO)ccc2n1CCN(CC)CC	JHDKZFFAIZKUCU-ZRDIBKRKSA-N, JHDKZFFAIZKUCU-ZRDIBKRKSA-N, JHDKZFFAIZKUCU-ZRDIBKRKSA-N, JHDKZFFAIZKUCU-ZRDIBKRKSA-N, JHDKZFFAIZKUCU-ZRDIBKRKSA-N, JHDKZFFAIZKUCU-ZRDIBKRKSA-N, JHDKZFFAIZKUCU-ZRDIBKRKSA-N	Phase 3
SBE-13	PLK inhibitor	PLK1			COc1ccc(CCNCc2ccc(OCc3ccc(Cl)nc3)c(OC)c2)cc1OC, COc1ccc(CCNCc2ccc(OCc3ccc(Cl)nc3)c(OC)c2)cc1OC	XNPRQBVQOJZMMA-UHFFFAOYSA-N, XNPRQBVQOJZMMA-UHFFFAOYSA-N	Preclinical
SBHA	HDAC inhibitor	HDAC1, HDAC3			ONC(=O)CCCCCCC(=O)NO, ONC(=O)CCCCCCC(=O)NO, ONC(=O)CCCCCCC(=O)NO	IDQPVOFTURLJPT-UHFFFAOYSA-N, IDQPVOFTURLJPT-UHFFFAOYSA-N, IDQPVOFTURLJPT-UHFFFAOYSA-N	Preclinical
SBI-115	G protein-coupled receptor antagonist				CCS(=O)(=O)c1ncc(Cl)c(n1)C(=O)Oc1cccc(C)c1	IJPXOPBVXVPPEW-UHFFFAOYSA-N	Preclinical
SC-10	protein kinase activator	PRKCA			CCCCCCCNS(=O)(=O)c1cccc2c(Cl)cccc12, CCCCCCCNS(=O)(=O)c1cccc2c(Cl)cccc12	MJMJERJFCHYXEM-UHFFFAOYSA-N, MJMJERJFCHYXEM-UHFFFAOYSA-N	Preclinical
SC-12267	dihydroorotate dehydrogenase inhibitor	IL17A			COc1cccc(c1)-c1ccc(NC(=O)C2=C(CCC2)C(O)=O)c(F)c1 |t:16|, COc1cccc(c1)-c1ccc(NC(=O)C2=C(CCC2)C(O)=O)c(F)c1 |t:16|, COc1cccc(c1)-c1ccc(NC(=O)C2=C(CCC2)C(O)=O)c(F)c1 |t:16|, COc1cccc(c1)-c1ccc(NC(=O)C2=C(CCC2)C(O)=O)c(F)c1 |t:16|, COc1cccc(c1)-c1ccc(NC(=O)C2=C(CCC2)C(O)=O)c(F)c1 |t:16|, COc1cccc(c1)-c1ccc(NC(=O)C2=C(CCC2)C(O)=O)c(F)c1 |t:16|	XPRDUGXOWVXZLL-UHFFFAOYSA-N, XPRDUGXOWVXZLL-UHFFFAOYSA-N, XPRDUGXOWVXZLL-UHFFFAOYSA-N, XPRDUGXOWVXZLL-UHFFFAOYSA-N, XPRDUGXOWVXZLL-UHFFFAOYSA-N, XPRDUGXOWVXZLL-UHFFFAOYSA-N	Phase 2
SC-144	P glycoprotein inhibitor				Fc1ccc2c(c1)nc(NNC(=O)c1cnccn1)c1cccn21, Fc1ccc2c(c1)nc(NNC(=O)c1cnccn1)c1cccn21, Fc1ccc2c(c1)nc(NNC(=O)c1cnccn1)c1cccn21, Fc1ccc2c(c1)nc(NNC(=O)c1cnccn1)c1cccn21, Fc1ccc2c(c1)nc(NNC(=O)c1cnccn1)c1cccn21, Fc1ccc2c(c1)nc(NNC(=O)c1cnccn1)c1cccn21, Fc1ccc2c(c1)nc(NNC(=O)c1cnccn1)c1cccn21	UEADAWQSJOWXBK-UHFFFAOYSA-N, UEADAWQSJOWXBK-UHFFFAOYSA-N, UEADAWQSJOWXBK-UHFFFAOYSA-N, UEADAWQSJOWXBK-UHFFFAOYSA-N, UEADAWQSJOWXBK-UHFFFAOYSA-N, UEADAWQSJOWXBK-UHFFFAOYSA-N, UEADAWQSJOWXBK-UHFFFAOYSA-N	Preclinical
SC-19220	prostanoid receptor antagonist	PTGER1			CC(=O)NNC(=O)N1Cc2ccccc2Oc2ccc(Cl)cc12, CC(=O)NNC(=O)N1Cc2ccccc2Oc2ccc(Cl)cc12, CC(=O)NNC(=O)N1Cc2ccccc2Oc2ccc(Cl)cc12, CC(=O)NNC(=O)N1Cc2ccccc2Oc2ccc(Cl)cc12	KNURFLJTOUGOOQ-UHFFFAOYSA-N, KNURFLJTOUGOOQ-UHFFFAOYSA-N, KNURFLJTOUGOOQ-UHFFFAOYSA-N, KNURFLJTOUGOOQ-UHFFFAOYSA-N	Preclinical
SC-236	cyclooxygenase inhibitor	PTGS2			NS(=O)(=O)c1ccc(cc1)-n1nc(cc1-c1ccc(Cl)cc1)C(F)(F)F, NS(=O)(=O)c1ccc(cc1)-n1nc(cc1-c1ccc(Cl)cc1)C(F)(F)F, NS(=O)(=O)c1ccc(cc1)-n1nc(cc1-c1ccc(Cl)cc1)C(F)(F)F	NSQNZEUFHPTJME-UHFFFAOYSA-N, NSQNZEUFHPTJME-UHFFFAOYSA-N, NSQNZEUFHPTJME-UHFFFAOYSA-N	Preclinical
SC-51089	prostanoid receptor antagonist	PTGER1			Clc1ccc2Oc3ccccc3CN(C(=O)NNC(=O)CCc3ccncc3)c2c1, Clc1ccc2Oc3ccccc3CN(C(=O)NNC(=O)CCc3ccncc3)c2c1	XDJPQOUDGROSEU-UHFFFAOYSA-N, XDJPQOUDGROSEU-UHFFFAOYSA-N	Preclinical
SC-560	cyclooxygenase inhibitor	PTGS1			COc1ccc(cc1)-n1nc(cc1-c1ccc(Cl)cc1)C(F)(F)F, COc1ccc(cc1)-n1nc(cc1-c1ccc(Cl)cc1)C(F)(F)F, COc1ccc(cc1)-n1nc(cc1-c1ccc(Cl)cc1)C(F)(F)F, COc1ccc(cc1)-n1nc(cc1-c1ccc(Cl)cc1)C(F)(F)F	PQUGCKBLVKJMNT-UHFFFAOYSA-N, PQUGCKBLVKJMNT-UHFFFAOYSA-N, PQUGCKBLVKJMNT-UHFFFAOYSA-N, PQUGCKBLVKJMNT-UHFFFAOYSA-N	Preclinical
SC-9	protein tyrosine kinase activator	PRKCA			Clc1cccc2c(cccc12)S(=O)(=O)NCCCCCCc1ccccc1, Clc1cccc2c(cccc12)S(=O)(=O)NCCCCCCc1ccccc1, Clc1cccc2c(cccc12)S(=O)(=O)NCCCCCCc1ccccc1, Clc1cccc2c(cccc12)S(=O)(=O)NCCCCCCc1ccccc1, Clc1cccc2c(cccc12)S(=O)(=O)NCCCCCCc1ccccc1	YUXMTDYHFPRPLG-UHFFFAOYSA-N, YUXMTDYHFPRPLG-UHFFFAOYSA-N, YUXMTDYHFPRPLG-UHFFFAOYSA-N, YUXMTDYHFPRPLG-UHFFFAOYSA-N, YUXMTDYHFPRPLG-UHFFFAOYSA-N	Preclinical
scabertopin	anticancer agent				[H][C@]12C\C(C)=C/[C@@]3([H])OC(=O)C(=C)[C@]3([H])[C@H](CC(=C1)C(=O)O2)OC(=O)C(\C)=C/C |c:4,t:18|	FTPHYXGWMIZVMP-WQYRJXRXSA-N	Preclinical
SCH-202676	G protein-coupled receptor modulator	CHRM1, CHRM2, DRD1, DRD2			CN=c1nc(-c2ccccc2)n(s1)-c1ccccc1, CN=c1nc(-c2ccccc2)n(s1)-c1ccccc1, CN=c1nc(-c2ccccc2)n(s1)-c1ccccc1	FFUBTEITUNMMOK-UHFFFAOYSA-N, FFUBTEITUNMMOK-UHFFFAOYSA-N, FFUBTEITUNMMOK-UHFFFAOYSA-N	Preclinical
SCH-221510	nociceptin/orphanin FQ receptor agonist	OPRL1			Cc1ccccc1C(N1[C@H]2CC[C@@H]1C[C@](O)(C2)c1ccccc1)c1ccccc1C |&1:9,12,14,r|	LOSJNRBXNQTUNT-FOURXJPJSA-N	Preclinical
SCH-23390	dopamine receptor antagonist	DRD1, DRD5, HTR2C, KCNJ4, KCNJ6			CN1CCc2cc(Cl)c(O)cc2[C@H](C1)c1ccccc1, CN1CCc2cc(Cl)c(O)cc2[C@H](C1)c1ccccc1	GOTMKOSCLKVOGG-OAHLLOKOSA-N, GOTMKOSCLKVOGG-OAHLLOKOSA-N	Preclinical
SCH-28080	ATPase inhibitor	ATP4A			Cc1nc2c(OCc3ccccc3)cccn2c1CC#N, Cc1nc2c(OCc3ccccc3)cccn2c1CC#N	PYKJFEPAUKAXNN-UHFFFAOYSA-N, PYKJFEPAUKAXNN-UHFFFAOYSA-N	Phase 1
SCH-51344	MTH1 inhibitor	NUDT1			COc1ccc2nc3n[nH]c(C)c3c(NCCOCCO)c2c1, COc1ccc2nc3n[nH]c(C)c3c(NCCOCCO)c2c1	YWEGXZZAORIRQR-UHFFFAOYSA-N, YWEGXZZAORIRQR-UHFFFAOYSA-N	Preclinical
SCH-58261	adenosine receptor antagonist	ADORA1, ADORA2A, ADORA2B, ADORA3			Nc1nc2n(CCc3ccccc3)ncc2c2nc(nn12)-c1ccco1, Nc1nc2n(CCc3ccccc3)ncc2c2nc(nn12)-c1ccco1, Nc1nc2n(CCc3ccccc3)ncc2c2nc(nn12)-c1ccco1, Nc1nc2n(CCc3ccccc3)ncc2c2nc(nn12)-c1ccco1, Nc1nc2n(CCc3ccccc3)ncc2c2nc(nn12)-c1ccco1, Nc1nc2n(CCc3ccccc3)ncc2c2nc(nn12)-c1ccco1, Nc1nc2n(CCc3ccccc3)ncc2c2nc(nn12)-c1ccco1	UTLPKQYUXOEJIL-UHFFFAOYSA-N, UTLPKQYUXOEJIL-UHFFFAOYSA-N, UTLPKQYUXOEJIL-UHFFFAOYSA-N, UTLPKQYUXOEJIL-UHFFFAOYSA-N, UTLPKQYUXOEJIL-UHFFFAOYSA-N, UTLPKQYUXOEJIL-UHFFFAOYSA-N, UTLPKQYUXOEJIL-UHFFFAOYSA-N	Preclinical
SCH-900776	CHK inhibitor	CDK2, CHEK1			Cn1cc(cn1)-c1cnn2c(N)c(Br)c(nc12)[C@@H]1CCCNC1, Cn1cc(cn1)-c1cnn2c(N)c(Br)c(nc12)[C@@H]1CCCNC1, Cn1cc(cn1)-c1cnn2c(N)c(Br)c(nc12)[C@@H]1CCCNC1, Cn1cc(cn1)-c1cnn2c(N)c(Br)c(nc12)[C@@H]1CCCNC1, Cn1cc(cn1)-c1cnn2c(N)c(Br)c(nc12)[C@@H]1CCCNC1	GMIZZEXBPRLVIV-SECBINFHSA-N, GMIZZEXBPRLVIV-SECBINFHSA-N, GMIZZEXBPRLVIV-SECBINFHSA-N, GMIZZEXBPRLVIV-SECBINFHSA-N, GMIZZEXBPRLVIV-SECBINFHSA-N	Phase 2
schisandrin-B	antioxidant	ATR			COc1cc2C[C@H](C)[C@H](C)Cc3cc4OCOc4c(OC)c3-c2c(OC)c1OC |r|	RTZKSTLPRTWFEV-QWHCGFSZSA-N	Preclinical
schisandrol-B	lipid peroxidase inhibitor				COc1cc2C[C@](C)(O)[C@@H](C)Cc3cc4OCOc4c(OC)c3-c2c(OC)c1OC, COc1cc2C[C@](C)(O)[C@@H](C)Cc3cc4OCOc4c(OC)c3-c2c(OC)c1OC	ZWRRJEICIPUPHZ-MYODQAERSA-N, ZWRRJEICIPUPHZ-MYODQAERSA-N	Phase 3
sclareol					CC(O)(CC[C@H]1[C@](C)(O)CC[C@H]2C(C)(C)CCC[C@]12C)C=C |a:5,6,18,&1:1,&2:11|, CC(O)(CC[C@H]1[C@](C)(O)CC[C@H]2C(C)(C)CCC[C@]12C)C=C |a:5,6,18,&1:1,&2:11|	XVULBTBTFGYVRC-SVPXJYONSA-N, XVULBTBTFGYVRC-SVPXJYONSA-N	Preclinical
sclareolide	other antifungal				C[C@@]12CC[C@H]3C(C)(C)CCC[C@]3(C)[C@H]1CC(=O)O2, C[C@@]12CC[C@H]3C(C)(C)CCC[C@]3(C)[C@H]1CC(=O)O2, C[C@@]12CC[C@H]3C(C)(C)CCC[C@]3(C)[C@H]1CC(=O)O2	IMKJGXCIJJXALX-SHUKQUCYSA-N, IMKJGXCIJJXALX-SHUKQUCYSA-N, IMKJGXCIJJXALX-SHUKQUCYSA-N	Launched
SCMC-Lys	mucolytic agent	GSTP1	pulmonary	chronic obstructive pulmonary disease (COPD)	N[C@@H](CSCC(O)=O)C(O)=O, N[C@@H](CSCC(O)=O)C(O)=O	GBFLZEXEOZUWRN-VKHMYHEASA-N, GBFLZEXEOZUWRN-VKHMYHEASA-N	Launched
scopine					CN1[C@H]2C[C@H](O)C[C@@H]1[C@H]1O[C@@H]21, CN1[C@H]2C[C@H](O)C[C@@H]1[C@H]1O[C@@H]21, CN1[C@H]2C[C@H](O)C[C@@H]1[C@H]1O[C@@H]21, CN1[C@H]2C[C@H](O)C[C@@H]1[C@H]1O[C@@H]21	FIMXSEMBHGTNKT-RZVDLVGDSA-N, FIMXSEMBHGTNKT-RZVDLVGDSA-N, FIMXSEMBHGTNKT-RZVDLVGDSA-N, FIMXSEMBHGTNKT-RZVDLVGDSA-N	Launched
scopolamine	acetylcholine receptor antagonist	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, SI	neurology/psychiatry, gastroenterology	motion sickness, vomiting, nausea	CN1[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)c1ccccc1, CN1[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)c1ccccc1, CN1[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)c1ccccc1, CN1[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)c1ccccc1	STECJAGHUSJQJN-FWXGHANASA-N, STECJAGHUSJQJN-FWXGHANASA-N, STECJAGHUSJQJN-FWXGHANASA-N, STECJAGHUSJQJN-FWXGHANASA-N	Launched
scopolamine-N-oxide	acetylcholine receptor antagonist	CHRM1, CHRM2, CHRM3, CHRM4			C[N@@+]1([O-])[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)c1ccccc1 |a:3,5,7,8,10,14,&1:1,TLB:0:1:4.5.6:8.10,THB:2:1:4.5.6:8.10,9:8:1:4.5.6,9:10:1:4.5.6,11:5:1:8.10|, C[N@@+]1([O-])[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)c1ccccc1 |a:3,5,7,8,10,14,&1:1,TLB:0:1:4.5.6:8.10,THB:2:1:4.5.6:8.10,9:8:1:4.5.6,9:10:1:4.5.6,11:5:1:8.10|	GSYQNAMOFFWAPF-SXWCTKSRSA-N, GSYQNAMOFFWAPF-SXWCTKSRSA-N	Preclinical
SCP-1	analgesic agent				Oc1ccc(NC(=O)CN2C(=O)c3ccccc3S2(=O)=O)cc1, Oc1ccc(NC(=O)CN2C(=O)c3ccccc3S2(=O)=O)cc1	PUPNJSIFIXXJCH-UHFFFAOYSA-N, PUPNJSIFIXXJCH-UHFFFAOYSA-N	Phase 1
scriptaid	HDAC inhibitor	HDAC1, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9			ONC(=O)CCCCCN1C(=O)c2cccc3cccc(C1=O)c23, ONC(=O)CCCCCN1C(=O)c2cccc3cccc(C1=O)c23, ONC(=O)CCCCCN1C(=O)c2cccc3cccc(C1=O)c23	JTDYUFSDZATMKU-UHFFFAOYSA-N, JTDYUFSDZATMKU-UHFFFAOYSA-N, JTDYUFSDZATMKU-UHFFFAOYSA-N	Preclinical
SCS					Oc1ccccc1\C=N\NC(=O)c1ccccc1O, Oc1ccccc1\C=N\NC(=O)c1ccccc1O, Oc1ccccc1\C=N\NC(=O)c1ccccc1O, Oc1ccccc1\C=N\NC(=O)c1ccccc1O	OMCYEZUIYGPHDJ-OQLLNIDSSA-N, OMCYEZUIYGPHDJ-OQLLNIDSSA-N, OMCYEZUIYGPHDJ-OQLLNIDSSA-N, OMCYEZUIYGPHDJ-OQLLNIDSSA-N	Preclinical
SD-0006	p38 MAPK inhibitor				OCC(=O)N1CCC(CC1)c1[nH]nc(c1-c1ccncn1)-c1ccc(Cl)cc1	CATQHDWESBRRQA-UHFFFAOYSA-N	Phase 2
SD-169	p38 MAPK inhibitor	MAPK14			NC(=O)c1ccc2[nH]ccc2c1	GQMYQEAXTITUAE-UHFFFAOYSA-N	Preclinical
SD-208	TGF beta receptor inhibitor	TGFBR1			Fc1ccc(Cl)cc1-c1nc(Nc2ccncc2)c2nccnc2n1, Fc1ccc(Cl)cc1-c1nc(Nc2ccncc2)c2nccnc2n1, Fc1ccc(Cl)cc1-c1nc(Nc2ccncc2)c2nccnc2n1	BERLXWPRSBJFHO-UHFFFAOYSA-N, BERLXWPRSBJFHO-UHFFFAOYSA-N, BERLXWPRSBJFHO-UHFFFAOYSA-N	Preclinical
SD-2590	matrix metalloprotease inhibitor	MMP1, MMP13, MMP2			COCCN1CCC(CC1)(C(=O)NO)S(=O)(=O)c1ccc(Oc2ccc(OC(F)(F)F)cc2)cc1, COCCN1CCC(CC1)(C(=O)NO)S(=O)(=O)c1ccc(Oc2ccc(OC(F)(F)F)cc2)cc1, COCCN1CCC(CC1)(C(=O)NO)S(=O)(=O)c1ccc(Oc2ccc(OC(F)(F)F)cc2)cc1	NXUHVWMBPOFLMA-UHFFFAOYSA-N, NXUHVWMBPOFLMA-UHFFFAOYSA-N, NXUHVWMBPOFLMA-UHFFFAOYSA-N	Preclinical
SDM25N	opioid receptor antagonist	OPRD1			CC(=C)CN1CC[C@@]23[C@H]4Oc5c2c(C[C@@H]1[C@]3(O)Cc1c4[nH]c2ccccc12)ccc5O |a:7,8,15,&1:14,TLB:17:15:4.5.6:11.12.13,THB:16:15:4.5.6:11.12.13|, CC(=C)CN1CC[C@@]23[C@H]4Oc5c2c(C[C@@H]1[C@]3(O)Cc1c4[nH]c2ccccc12)ccc5O |a:7,8,15,&1:14,TLB:17:15:4.5.6:11.12.13,THB:16:15:4.5.6:11.12.13|, CC(=C)CN1CC[C@@]23[C@H]4Oc5c2c(C[C@@H]1[C@]3(O)Cc1c4[nH]c2ccccc12)ccc5O |a:7,8,15,&1:14,TLB:17:15:4.5.6:11.12.13,THB:16:15:4.5.6:11.12.13|, CC(=C)CN1CC[C@@]23[C@H]4Oc5c2c(C[C@@H]1[C@]3(O)Cc1c4[nH]c2ccccc12)ccc5O |a:7,8,15,&1:14,TLB:17:15:4.5.6:11.12.13,THB:16:15:4.5.6:11.12.13|, CC(=C)CN1CC[C@@]23[C@H]4Oc5c2c(C[C@@H]1[C@]3(O)Cc1c4[nH]c2ccccc12)ccc5O |a:7,8,15,&1:14,TLB:17:15:4.5.6:11.12.13,THB:16:15:4.5.6:11.12.13|	ZFMVWAWSKLAVOE-IFKAHUTRSA-N, ZFMVWAWSKLAVOE-IFKAHUTRSA-N, ZFMVWAWSKLAVOE-IFKAHUTRSA-N, ZFMVWAWSKLAVOE-IFKAHUTRSA-N, ZFMVWAWSKLAVOE-IFKAHUTRSA-N	Preclinical
SDZ-NKT-343	tachykinin antagonist	TACR1			CN(Cc1ccccc1)C(=O)[C@H](Cc1ccc2ccccc2c1)NC(=O)[C@@H]1CCCN1C(=O)Nc1ccccc1[N+]([O-])=O, CN(Cc1ccccc1)C(=O)[C@H](Cc1ccc2ccccc2c1)NC(=O)[C@@H]1CCCN1C(=O)Nc1ccccc1[N+]([O-])=O, CN(Cc1ccccc1)C(=O)[C@H](Cc1ccc2ccccc2c1)NC(=O)[C@@H]1CCCN1C(=O)Nc1ccccc1[N+]([O-])=O, CN(Cc1ccccc1)C(=O)[C@H](Cc1ccc2ccccc2c1)NC(=O)[C@@H]1CCCN1C(=O)Nc1ccccc1[N+]([O-])=O, CN(Cc1ccccc1)C(=O)[C@H](Cc1ccc2ccccc2c1)NC(=O)[C@@H]1CCCN1C(=O)Nc1ccccc1[N+]([O-])=O	PCVSIMQAFWRUEC-JDXGNMNLSA-N, PCVSIMQAFWRUEC-JDXGNMNLSA-N, PCVSIMQAFWRUEC-JDXGNMNLSA-N, PCVSIMQAFWRUEC-JDXGNMNLSA-N, PCVSIMQAFWRUEC-JDXGNMNLSA-N	Phase 1
SDZ-SER-082	serotonin receptor antagonist	HTR2A, HTR2B, HTR2C			CN1CC[C@@H]2CN3CCc4cccc([C@@H]2C1)c34, CN1CC[C@@H]2CN3CCc4cccc([C@@H]2C1)c34	YASBOGFWAMXINH-TZMCWYRMSA-N, YASBOGFWAMXINH-TZMCWYRMSA-N	Preclinical
SDZ-WAG-994	adenosine receptor agonist	ADORA1			CO[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1n1cnc2c(NC3CCCCC3)ncnc12, CO[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1n1cnc2c(NC3CCCCC3)ncnc12, CO[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1n1cnc2c(NC3CCCCC3)ncnc12, CO[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1n1cnc2c(NC3CCCCC3)ncnc12	JAKAFSGZUXCHLF-LSCFUAHRSA-N, JAKAFSGZUXCHLF-LSCFUAHRSA-N, JAKAFSGZUXCHLF-LSCFUAHRSA-N, JAKAFSGZUXCHLF-LSCFUAHRSA-N	Phase 2
SDZ-205-557	serotonin receptor antagonist	HTR3A, HTR3B			CCN(CC)CCOC(=O)c1cc(Cl)c(N)cc1OC, CCN(CC)CCOC(=O)c1cc(Cl)c(N)cc1OC	FFNWMBDISAYHDC-UHFFFAOYSA-N, FFNWMBDISAYHDC-UHFFFAOYSA-N	Preclinical
SDZ-21009	adrenergic receptor antagonist, serotonin receptor antagonist	HTR1A, HTR1B			CC(C)OC(=O)c1cc2c(OC[C@@H](O)CNC(C)(C)C)cccc2[nH]1 |&1:12,r|, CC(C)OC(=O)c1cc2c(OC[C@@H](O)CNC(C)(C)C)cccc2[nH]1 |&1:12,r|, CC(C)OC(=O)c1cc2c(OC[C@@H](O)CNC(C)(C)C)cccc2[nH]1 |&1:12,r|	SJYFDORQYYEJLB-ZDUSSCGKSA-N, SJYFDORQYYEJLB-ZDUSSCGKSA-N, SJYFDORQYYEJLB-ZDUSSCGKSA-N	Preclinical
SDZ-220-040	glutamate receptor antagonist	GRIN1			N[C@@H](Cc1cc(cc(CP(O)(O)=O)c1O)-c1ccc(Cl)cc1Cl)C(O)=O, N[C@@H](Cc1cc(cc(CP(O)(O)=O)c1O)-c1ccc(Cl)cc1Cl)C(O)=O	NYZFUZCCDOSQBG-AWEZNQCLSA-N, NYZFUZCCDOSQBG-AWEZNQCLSA-N	Preclinical
SDZ-220-581	glutamate receptor antagonist	GRIN1			N[C@@H](Cc1cc(CP(O)(O)=O)cc(c1)-c1ccccc1Cl)C(O)=O, N[C@@H](Cc1cc(CP(O)(O)=O)cc(c1)-c1ccccc1Cl)C(O)=O, N[C@@H](Cc1cc(CP(O)(O)=O)cc(c1)-c1ccccc1Cl)C(O)=O, N[C@@H](Cc1cc(CP(O)(O)=O)cc(c1)-c1ccccc1Cl)C(O)=O	VBRJFXSFCYEZMQ-HNNXBMFYSA-N, VBRJFXSFCYEZMQ-HNNXBMFYSA-N, VBRJFXSFCYEZMQ-HNNXBMFYSA-N, VBRJFXSFCYEZMQ-HNNXBMFYSA-N	Preclinical
Se-methylselenocysteine					C[Se]C[C@H](N)C(O)=O, C[Se]C[C@H](N)C(O)=O	XDSSPSLGNGIIHP-VKHMYHEASA-N, XDSSPSLGNGIIHP-VKHMYHEASA-N	Phase 2
secalciferol	vitamin D receptor agonist	VDR	critical care	bone fracture	C[C@H](CC[C@@H](O)C(C)(C)O)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)CCC1=C, C[C@H](CC[C@@H](O)C(C)(C)O)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)CCC1=C, C[C@H](CC[C@@H](O)C(C)(C)O)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)CCC1=C, C[C@H](CC[C@@H](O)C(C)(C)O)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)CCC1=C	FCKJYANJHNLEEP-XRWYNYHCSA-N, FCKJYANJHNLEEP-XRWYNYHCSA-N, FCKJYANJHNLEEP-XRWYNYHCSA-N, FCKJYANJHNLEEP-XRWYNYHCSA-N	Launched
seclazone	anti-inflammatory agent				Clc1ccc2O[C@H]3CCON3C(=O)c2c1 |&1:6,r|	XWXVKXXKKLBDDJ-VIFPVBQESA-N	Phase 1
seclidemstat	histone demethylase inhibitor				CN1CCN(CC1)S(=O)(=O)c1cccc(c1)C(=O)N\N=C(/C)c1cc(Cl)ccc1O	MVSQDUZRRVBYLA-HYARGMPZSA-N	Phase 1
secnidazole	acetylcholinesterase inhibitor, microtubule inhibitor		infectious disease	protozoan infection	C[C@@H](O)Cn1c(C)ncc1[N+]([O-])=O |&1:1,r|, C[C@@H](O)Cn1c(C)ncc1[N+]([O-])=O |&1:1,r|, C[C@@H](O)Cn1c(C)ncc1[N+]([O-])=O |&1:1,r|, C[C@@H](O)Cn1c(C)ncc1[N+]([O-])=O |&1:1,r|, C[C@@H](O)Cn1c(C)ncc1[N+]([O-])=O |&1:1,r|	KPQZUUQMTUIKBP-RXMQYKEDSA-N, KPQZUUQMTUIKBP-RXMQYKEDSA-N, KPQZUUQMTUIKBP-RXMQYKEDSA-N, KPQZUUQMTUIKBP-RXMQYKEDSA-N, KPQZUUQMTUIKBP-RXMQYKEDSA-N	Launched
secoisolariciresinol-(-)					COc1cc(C[C@@H](CO)[C@H](CO)Cc2ccc(O)c(OC)c2)ccc1O, COc1cc(C[C@@H](CO)[C@H](CO)Cc2ccc(O)c(OC)c2)ccc1O, COc1cc(C[C@@H](CO)[C@H](CO)Cc2ccc(O)c(OC)c2)ccc1O	PUETUDUXMCLALY-HOTGVXAUSA-N, PUETUDUXMCLALY-HOTGVXAUSA-N, PUETUDUXMCLALY-HOTGVXAUSA-N	Phase 2
secoisolariciresinol-diglucoside	antioxidant				COc1cc(C[C@@H](CO[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@H](CO[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)Cc2ccc(O)c(OC)c2)ccc1O	SBVBJPHMDABKJV-PGCJWIIOSA-N	Phase 2
securinine	GABA receptor antagonist, TP53 activator	GABRA1			O=C1O[C@@]23C[C@@H](C=CC2=C1)N1CCCC[C@H]31 |c:6,9|, O=C1O[C@@]23C[C@@H](C=CC2=C1)N1CCCC[C@H]31 |c:6,9|, O=C1O[C@@]23C[C@@H](C=CC2=C1)N1CCCC[C@H]31 |c:6,9|, O=C1O[C@@]23C[C@@H](C=CC2=C1)N1CCCC[C@H]31 |c:6,9|	SWZMSZQQJRKFBP-WZRBSPASSA-N, SWZMSZQQJRKFBP-WZRBSPASSA-N, SWZMSZQQJRKFBP-WZRBSPASSA-N, SWZMSZQQJRKFBP-WZRBSPASSA-N	Preclinical
segesterone-acetate	progesterone receptor agonist	PGR			[H][C@@]12CC(=C)[C@](OC(C)=O)(C(C)=O)[C@@]1(C)CC[C@]1([H])[C@@]3([H])CCC(=O)C=C3CC[C@@]21[H] |c:26|	CKFBRGLGTWAVLG-GOMYTPFNSA-N	Launched
seladelpar	PPAR receptor agonist				CCO[C@H](COc1ccc(cc1)C(F)(F)F)CSc1ccc(OCC(O)=O)c(C)c1	JWHYSEDOYMYMNM-QGZVFWFLSA-N	Phase 3
selamectin	nematocide		infectious disease	flea control	[H][C@@]12OC\C3=C/C=C/[C@H](C)[C@H](O[C@@]4([H])C[C@H](OC)[C@@H](O)[C@H](C)O4)\C(C)=C\C[C@]4([H])C[C@@]([H])(C[C@]5(CC[C@H](C)[C@H](O5)C5CCCCC5)O4)OC(=O)[C@]([H])(C=C(C)\C1=N\O)[C@@]23O |c:4,t:6,25,56|	AFJYYKSVHJGXSN-XHKIUTQPSA-N	Launched
selegiline	monoamine oxidase inhibitor	MAOA, MAOB	neurology/psychiatry	Parkinson's Disease	C[C@H](Cc1ccccc1)N(C)CC#C	MEZLKOACVSPNER-GFCCVEGCSA-N	Launched
selenomethionine					C[Se]CC[C@H](N)C(O)=O, C[Se]CC[C@H](N)C(O)=O	RJFAYQIBOAGBLC-BYPYZUCNSA-N, RJFAYQIBOAGBLC-BYPYZUCNSA-N	Launched
seletalisib	PI3K inhibitor				[O-][n+]1cccc(c1)-c1nc2c(Cl)cccc2cc1[C@@H](Nc1ncnc2cccnc12)C(F)(F)F	LNLJHGXOFYUARS-OAQYLSRUSA-N	Preclinical
selexipag	IP1 prostacyclin receptor agonist, platelet aggregation inhibitor	PTGIR	pulmonary	pulmonary arterial hypertension (PAH)	CC(C)N(CCCCOCC(=O)NS(C)(=O)=O)c1cnc(-c2ccccc2)c(n1)-c1ccccc1, CC(C)N(CCCCOCC(=O)NS(C)(=O)=O)c1cnc(-c2ccccc2)c(n1)-c1ccccc1	QXWZQTURMXZVHJ-UHFFFAOYSA-N, QXWZQTURMXZVHJ-UHFFFAOYSA-N	Launched
selfotel	glutamate receptor antagonist	GRIN2A, GRIN2B, GRIN2C, GRIN2D			OC(=O)[C@H]1C[C@@H](CP(O)(O)=O)CCN1, OC(=O)[C@H]1C[C@@H](CP(O)(O)=O)CCN1, OC(=O)[C@H]1C[C@@H](CP(O)(O)=O)CCN1	LPMRCCNDNGONCD-NTSWFWBYSA-N, LPMRCCNDNGONCD-NTSWFWBYSA-N, LPMRCCNDNGONCD-NTSWFWBYSA-N	Phase 3
selinexor	exportin antagonist	XPO1	hematologic malignancy	multiple myeloma	FC(F)(F)c1cc(cc(c1)C(F)(F)F)-c1ncn(\C=C/C(=O)NNc2cnccn2)n1, FC(F)(F)c1cc(cc(c1)C(F)(F)F)-c1ncn(\C=C/C(=O)NNc2cnccn2)n1, FC(F)(F)c1cc(cc(c1)C(F)(F)F)-c1ncn(\C=C/C(=O)NNc2cnccn2)n1, FC(F)(F)c1cc(cc(c1)C(F)(F)F)-c1ncn(\C=C/C(=O)NNc2cnccn2)n1, FC(F)(F)c1cc(cc(c1)C(F)(F)F)-c1ncn(\C=C/C(=O)NNc2cnccn2)n1	DEVSOMFAQLZNKR-RJRFIUFISA-N, DEVSOMFAQLZNKR-RJRFIUFISA-N, DEVSOMFAQLZNKR-RJRFIUFISA-N, DEVSOMFAQLZNKR-RJRFIUFISA-N, DEVSOMFAQLZNKR-RJRFIUFISA-N	Launched
selitrectinib	protein tyrosine kinase inhibitor				[H][C@]12CCCN1c1ccn3ncc(C(=O)N[C@H](C)CCc4ncc(F)cc24)c3n1	OEBIHOVSAMBXIB-SJKOYZFVSA-N	Phase 1/Phase 2
selonsertib	MAP kinase activator				CC(C)n1cnnc1-c1cccc(NC(=O)c2cc(c(C)cc2F)-n2cnc(c2)C2CC2)n1	YIDDLAAKOYYGJG-UHFFFAOYSA-N	Phase 2
selumetinib	MEK inhibitor	MAP2K1			Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(cc12)C(=O)NOCCO, Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(cc12)C(=O)NOCCO, Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(cc12)C(=O)NOCCO, Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(cc12)C(=O)NOCCO, Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(cc12)C(=O)NOCCO, Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(cc12)C(=O)NOCCO, Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(cc12)C(=O)NOCCO, Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(cc12)C(=O)NOCCO	CYOHGALHFOKKQC-UHFFFAOYSA-N, CYOHGALHFOKKQC-UHFFFAOYSA-N, CYOHGALHFOKKQC-UHFFFAOYSA-N, CYOHGALHFOKKQC-UHFFFAOYSA-N, CYOHGALHFOKKQC-UHFFFAOYSA-N, CYOHGALHFOKKQC-UHFFFAOYSA-N, CYOHGALHFOKKQC-UHFFFAOYSA-N, CYOHGALHFOKKQC-UHFFFAOYSA-N	Phase 3
semagacestat	gamma secretase inhibitor	PSEN1			CC(C)[C@H](O)C(=O)N[C@@H](C)C(=O)N[C@H]1c2ccccc2CCN(C)C1=O	PKXWXXPNHIWQHW-RCBQFDQVSA-N	Phase 3
semapimod	cytokine production inhibitor, p38 MAPK inhibitor	MAPK14			CC(=NNC(N)=N)c1cc(NC(=O)CCCCCCCCC(=O)Nc2cc(cc(c2)C(C)=NNC(N)=N)C(C)=NNC(N)=N)cc(c1)C(C)=NNC(N)=N, CC(=NNC(N)=N)c1cc(NC(=O)CCCCCCCCC(=O)Nc2cc(cc(c2)C(C)=NNC(N)=N)C(C)=NNC(N)=N)cc(c1)C(C)=NNC(N)=N, CC(=NNC(N)=N)c1cc(NC(=O)CCCCCCCCC(=O)Nc2cc(cc(c2)C(C)=NNC(N)=N)C(C)=NNC(N)=N)cc(c1)C(C)=NNC(N)=N	PWDYHMBTPGXCSN-UHFFFAOYSA-N, PWDYHMBTPGXCSN-UHFFFAOYSA-N, PWDYHMBTPGXCSN-UHFFFAOYSA-N	Phase 2
semaxanib	VEGFR inhibitor	FGFR1, FLT1, KDR, KIT, PDGFRA, PDGFRB, RET			Cc1cc(C)c(\C=C2/C(=O)Nc3ccccc23)[nH]1, Cc1cc(C)c(\C=C2/C(=O)Nc3ccccc23)[nH]1, Cc1cc(C)c(\C=C2/C(=O)Nc3ccccc23)[nH]1, Cc1cc(C)c(\C=C2/C(=O)Nc3ccccc23)[nH]1, Cc1cc(C)c(\C=C2/C(=O)Nc3ccccc23)[nH]1, Cc1cc(C)c(\C=C2/C(=O)Nc3ccccc23)[nH]1, Cc1cc(C)c(\C=C2/C(=O)Nc3ccccc23)[nH]1, Cc1cc(C)c(\C=C2/C(=O)Nc3ccccc23)[nH]1, Cc1cc(C)c(\C=C2/C(=O)Nc3ccccc23)[nH]1	WUWDLXZGHZSWQZ-WQLSENKSSA-N, WUWDLXZGHZSWQZ-WQLSENKSSA-N, WUWDLXZGHZSWQZ-WQLSENKSSA-N, WUWDLXZGHZSWQZ-WQLSENKSSA-N, WUWDLXZGHZSWQZ-WQLSENKSSA-N, WUWDLXZGHZSWQZ-WQLSENKSSA-N, WUWDLXZGHZSWQZ-WQLSENKSSA-N, WUWDLXZGHZSWQZ-WQLSENKSSA-N, WUWDLXZGHZSWQZ-WQLSENKSSA-N	Phase 3
semustine	DNA alkylating agent				CC1CCC(CC1)NC(=O)N(CCCl)[NH2+][O-], CC1CCC(CC1)NC(=O)N(CCCl)[NH2+][O-]	JUUWEJHZVBABHQ-UHFFFAOYSA-N, JUUWEJHZVBABHQ-UHFFFAOYSA-N	Phase 3
SEN-1269	beta amyloid inhibitor	APP			CN(C)c1cccc(Oc2cnc(Nc3cccc(O)c3)nc2)c1, CN(C)c1cccc(Oc2cnc(Nc3cccc(O)c3)nc2)c1	MFPAAKZZUIRMKR-UHFFFAOYSA-N, MFPAAKZZUIRMKR-UHFFFAOYSA-N	Preclinical
senicapoc	intermediate conductance potassium channel blocker	KCNN4			NC(=O)C(c1ccccc1)(c1ccc(F)cc1)c1ccc(F)cc1, NC(=O)C(c1ccccc1)(c1ccc(F)cc1)c1ccc(F)cc1, NC(=O)C(c1ccccc1)(c1ccc(F)cc1)c1ccc(F)cc1	SCTZUZTYRMOMKT-UHFFFAOYSA-N, SCTZUZTYRMOMKT-UHFFFAOYSA-N, SCTZUZTYRMOMKT-UHFFFAOYSA-N	Phase 3
sennoside-A	glycoside agonist		gastroenterology	constipation	OC[C@H]1O[C@H](Oc2cccc3c(-c4c5cccc(O[C@H]6O[C@H](CO)[C@@H](O)[C@H](O)[C@H]6O)c5c(O)c5c(O)cc(cc45)C(O)=O)c4cc(cc(O)c4c(O)c23)C(O)=O)[C@H](O)[C@@H](O)[C@@H]1O |a:2,4,12,19,21,24,26,28,56,58,60,&1:11|, OC[C@H]1O[C@H](Oc2cccc3c(-c4c5cccc(O[C@H]6O[C@H](CO)[C@@H](O)[C@H](O)[C@H]6O)c5c(O)c5c(O)cc(cc45)C(O)=O)c4cc(cc(O)c4c(O)c23)C(O)=O)[C@H](O)[C@@H](O)[C@@H]1O |a:2,4,12,19,21,24,26,28,56,58,60,&1:11|	QFJIQUOMKJNYLI-QSXPFVSBSA-N, QFJIQUOMKJNYLI-QSXPFVSBSA-N	Launched
sennoside-protonated					OC[C@H]1O[C@@H](Oc2cccc3c(-c4c5cccc(O[C@H]6O[C@@H](CO)[C@@H](O)[C@@H](O)[C@@H]6O)c5c(O)c5c(O)cc(cc45)C(O)=O)c4cc(cc(O)c4c(O)c23)C(O)=O)[C@@H](O)[C@@H](O)[C@@H]1O |&1:2,&2:4,&3:19,&4:21,&5:24,&6:26,&7:28,&8:56,&9:58,&10:60,r|, OC[C@H]1O[C@@H](Oc2cccc3c(-c4c5cccc(O[C@H]6O[C@@H](CO)[C@@H](O)[C@@H](O)[C@@H]6O)c5c(O)c5c(O)cc(cc45)C(O)=O)c4cc(cc(O)c4c(O)c23)C(O)=O)[C@@H](O)[C@@H](O)[C@@H]1O |&1:2,&2:4,&3:19,&4:21,&5:24,&6:26,&7:28,&8:56,&9:58,&10:60,r|	QFJIQUOMKJNYLI-NGMZATEOSA-N, QFJIQUOMKJNYLI-NGMZATEOSA-N	Preclinical
seocalcitol	vitamin D receptor agonist	VDR			CCC(O)(CC)\C=C\C=C\[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C, CCC(O)(CC)\C=C\C=C\[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C, CCC(O)(CC)\C=C\C=C\[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C, CCC(O)(CC)\C=C\C=C\[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C, CCC(O)(CC)\C=C\C=C\[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C, CCC(O)(CC)\C=C\C=C\[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C	LVLLALCJVJNGQQ-SEODYNFXSA-N, LVLLALCJVJNGQQ-SEODYNFXSA-N, LVLLALCJVJNGQQ-SEODYNFXSA-N, LVLLALCJVJNGQQ-SEODYNFXSA-N, LVLLALCJVJNGQQ-SEODYNFXSA-N, LVLLALCJVJNGQQ-SEODYNFXSA-N	Phase 3
SEP-227900	D-amino acid oxidase Inhibitor	DAO			OC(=O)c1cc2occc2[nH]1, OC(=O)c1cc2occc2[nH]1	MMAIBGHDBYQYDI-UHFFFAOYSA-N, MMAIBGHDBYQYDI-UHFFFAOYSA-N	Phase 1
seratrodast	prostanoid receptor antagonist	TBXA2R	pulmonary	asthma	CC1=C(C)C(=O)C([C@@H](CCCCCC(O)=O)c2ccccc2)=C(C)C1=O |r,c:1,t:22|, CC1=C(C)C(=O)C([C@@H](CCCCCC(O)=O)c2ccccc2)=C(C)C1=O |r,c:1,t:22|, CC1=C(C)C(=O)C([C@@H](CCCCCC(O)=O)c2ccccc2)=C(C)C1=O |r,c:1,t:22|	ZBVKEHDGYSLCCC-SFHVURJKSA-N, ZBVKEHDGYSLCCC-SFHVURJKSA-N, ZBVKEHDGYSLCCC-SFHVURJKSA-N	Launched
serdemetan	MDM inhibitor	MDM2			C(Cc1c[nH]c2ccccc12)Nc1ccc(Nc2ccncc2)cc1, C(Cc1c[nH]c2ccccc12)Nc1ccc(Nc2ccncc2)cc1, C(Cc1c[nH]c2ccccc12)Nc1ccc(Nc2ccncc2)cc1, C(Cc1c[nH]c2ccccc12)Nc1ccc(Nc2ccncc2)cc1, C(Cc1c[nH]c2ccccc12)Nc1ccc(Nc2ccncc2)cc1, C(Cc1c[nH]c2ccccc12)Nc1ccc(Nc2ccncc2)cc1	CEGSUKYESLWKJP-UHFFFAOYSA-N, CEGSUKYESLWKJP-UHFFFAOYSA-N, CEGSUKYESLWKJP-UHFFFAOYSA-N, CEGSUKYESLWKJP-UHFFFAOYSA-N, CEGSUKYESLWKJP-UHFFFAOYSA-N, CEGSUKYESLWKJP-UHFFFAOYSA-N	Phase 1
serotonin	growth factor receptor activator	DRD1, DRD5, HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2B, HTR2C, HTR3A, HTR3B, HTR4, HTR5A, HTR6, HTR7, SLC36A1	neurology/psychiatry	anxiety, depression, sleeplessness	NCCc1c[nH]c2ccc(O)cc12, NCCc1c[nH]c2ccc(O)cc12, NCCc1c[nH]c2ccc(O)cc12	QZAYGJVTTNCVMB-UHFFFAOYSA-N, QZAYGJVTTNCVMB-UHFFFAOYSA-N, QZAYGJVTTNCVMB-UHFFFAOYSA-N	Launched
sertaconazole	sterol demethylase inhibitor		infectious disease	tinea pedis	Clc1ccc([C@@H](Cn2ccnc2)OCc2csc3c(Cl)cccc23)c(Cl)c1 |&1:5,r|, Clc1ccc([C@@H](Cn2ccnc2)OCc2csc3c(Cl)cccc23)c(Cl)c1 |&1:5,r|, Clc1ccc([C@@H](Cn2ccnc2)OCc2csc3c(Cl)cccc23)c(Cl)c1 |&1:5,r|, Clc1ccc([C@@H](Cn2ccnc2)OCc2csc3c(Cl)cccc23)c(Cl)c1 |&1:5,r|, Clc1ccc([C@@H](Cn2ccnc2)OCc2csc3c(Cl)cccc23)c(Cl)c1 |&1:5,r|	JLGKQTAYUIMGRK-LJQANCHMSA-N, JLGKQTAYUIMGRK-LJQANCHMSA-N, JLGKQTAYUIMGRK-LJQANCHMSA-N, JLGKQTAYUIMGRK-LJQANCHMSA-N, JLGKQTAYUIMGRK-LJQANCHMSA-N	Launched
sertindole	dopamine receptor antagonist, serotonin receptor antagonist	ADRA1A, ADRA1B, ADRA1D, DRD2, DRD3, DRD4, HRH1, HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2C, HTR6, KCNH2			Fc1ccc(cc1)-n1cc(C2CCN(CCN3CCNC3=O)CC2)c2cc(Cl)ccc12, Fc1ccc(cc1)-n1cc(C2CCN(CCN3CCNC3=O)CC2)c2cc(Cl)ccc12, Fc1ccc(cc1)-n1cc(C2CCN(CCN3CCNC3=O)CC2)c2cc(Cl)ccc12, Fc1ccc(cc1)-n1cc(C2CCN(CCN3CCNC3=O)CC2)c2cc(Cl)ccc12, Fc1ccc(cc1)-n1cc(C2CCN(CCN3CCNC3=O)CC2)c2cc(Cl)ccc12	GZKLJWGUPQBVJQ-UHFFFAOYSA-N, GZKLJWGUPQBVJQ-UHFFFAOYSA-N, GZKLJWGUPQBVJQ-UHFFFAOYSA-N, GZKLJWGUPQBVJQ-UHFFFAOYSA-N, GZKLJWGUPQBVJQ-UHFFFAOYSA-N	Withdrawn
sertraline	selective serotonin reuptake inhibitor (SSRI)	SLC6A3, SLC6A4	neurology/psychiatry, obstetrics/gynecology	depression, obsessive compulsive disorder (OCD), panic disorders, posttraumatic stress disorder, premenstrual syndrome, social anxiety disorder	CN[C@H]1CC[C@@H](c2ccc(Cl)c(Cl)c2)c2ccccc12, CN[C@H]1CC[C@@H](c2ccc(Cl)c(Cl)c2)c2ccccc12, CN[C@H]1CC[C@@H](c2ccc(Cl)c(Cl)c2)c2ccccc12, CN[C@H]1CC[C@@H](c2ccc(Cl)c(Cl)c2)c2ccccc12, CN[C@H]1CC[C@@H](c2ccc(Cl)c(Cl)c2)c2ccccc12, CN[C@H]1CC[C@@H](c2ccc(Cl)c(Cl)c2)c2ccccc12, CN[C@H]1CC[C@@H](c2ccc(Cl)c(Cl)c2)c2ccccc12	VGKDLMBJGBXTGI-SJCJKPOMSA-N, VGKDLMBJGBXTGI-SJCJKPOMSA-N, VGKDLMBJGBXTGI-SJCJKPOMSA-N, VGKDLMBJGBXTGI-SJCJKPOMSA-N, VGKDLMBJGBXTGI-SJCJKPOMSA-N, VGKDLMBJGBXTGI-SJCJKPOMSA-N, VGKDLMBJGBXTGI-SJCJKPOMSA-N	Launched
sesamin	NFkB pathway inhibitor				C1Oc2ccc(cc2O1)[C@H]1OC[C@H]2[C@@H]1CO[C@@H]2c1ccc2OCOc2c1, C1Oc2ccc(cc2O1)[C@H]1OC[C@H]2[C@@H]1CO[C@@H]2c1ccc2OCOc2c1, C1Oc2ccc(cc2O1)[C@H]1OC[C@H]2[C@@H]1CO[C@@H]2c1ccc2OCOc2c1	PEYUIKBAABKQKQ-AFHBHXEDSA-N, PEYUIKBAABKQKQ-AFHBHXEDSA-N, PEYUIKBAABKQKQ-AFHBHXEDSA-N	Preclinical
setipiprant	prostaglandin inhibitor	PTGDR2			OC(=O)Cn1c2CCN(Cc2c2cc(F)ccc12)C(=O)c1cccc2ccccc12	IHAXLPDVOWLUOS-UHFFFAOYSA-N	Phase 3
setiptiline	adrenergic receptor antagonist	HRH1, HTR2A, HTR2C	neurology/psychiatry	depression	CN1CCC2=C(C1)c1ccccc1Cc1ccccc21 |c:4|, CN1CCC2=C(C1)c1ccccc1Cc1ccccc21 |c:4|	GVPIXRLYKVFFMK-UHFFFAOYSA-N, GVPIXRLYKVFFMK-UHFFFAOYSA-N	Launched
setmelanotide	melanocortin receptor agonist				[H][C@]1(Cc2ccccc2)NC(=O)[C@H](Cc2cnc[nH]2)NC(=O)[C@@H](C)NC(=O)[C@]([H])(CSSC[C@H](NC(=O)[C@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](CCCNC(N)=N)NC1=O)C(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(C)=O	HDHDTKMUACZDAA-PJHQLSNHSA-N	Phase 3
sevoflurane	membrane integrity inhibitor	ATP2C1, ATP5D, GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, GLRA1, GLRB, GRIA1, KCNA1, KCNK10, KCNK18, KCNK2, KCNK3, KCNK9, MT-ND1	neurology/psychiatry	anesthetic	FCOC(C(F)(F)F)C(F)(F)F, FCOC(C(F)(F)F)C(F)(F)F	DFEYYRMXOJXZRJ-UHFFFAOYSA-N, DFEYYRMXOJXZRJ-UHFFFAOYSA-N	Launched
SEW-2871	lysophospholipid receptor agonist	S1PR1			FC(F)(F)c1sc(cc1-c1ccccc1)-c1nc(no1)-c1cccc(c1)C(F)(F)F, FC(F)(F)c1sc(cc1-c1ccccc1)-c1nc(no1)-c1cccc(c1)C(F)(F)F	OYMNPJXKQVTQTR-UHFFFAOYSA-N, OYMNPJXKQVTQTR-UHFFFAOYSA-N	Preclinical
SF-11	neuropeptide receptor antagonist	MCOLN3, NPY2R			CCOc1ccc(NC(=S)N2CCC(CC2)C(O)(c2ccccc2)c2ccccc2)cc1, CCOc1ccc(NC(=S)N2CCC(CC2)C(O)(c2ccccc2)c2ccccc2)cc1	PMEQBGAGFZDWQX-UHFFFAOYSA-N, PMEQBGAGFZDWQX-UHFFFAOYSA-N	Preclinical
SGC-CBP30	bromodomain inhibitor	CREBBP, EP300			COc1ccc(CCc2nc3cc(ccc3n2C[C@H](C)N2CCOCC2)-c2c(C)noc2C)cc1Cl, COc1ccc(CCc2nc3cc(ccc3n2C[C@H](C)N2CCOCC2)-c2c(C)noc2C)cc1Cl, COc1ccc(CCc2nc3cc(ccc3n2C[C@H](C)N2CCOCC2)-c2c(C)noc2C)cc1Cl, COc1ccc(CCc2nc3cc(ccc3n2C[C@H](C)N2CCOCC2)-c2c(C)noc2C)cc1Cl, COc1ccc(CCc2nc3cc(ccc3n2C[C@H](C)N2CCOCC2)-c2c(C)noc2C)cc1Cl, COc1ccc(CCc2nc3cc(ccc3n2C[C@H](C)N2CCOCC2)-c2c(C)noc2C)cc1Cl	GEPYBHCJBORHCE-SFHVURJKSA-N, GEPYBHCJBORHCE-SFHVURJKSA-N, GEPYBHCJBORHCE-SFHVURJKSA-N, GEPYBHCJBORHCE-SFHVURJKSA-N, GEPYBHCJBORHCE-SFHVURJKSA-N, GEPYBHCJBORHCE-SFHVURJKSA-N	Preclinical
SGC-0946	histone lysine methyltransferase inhibitor				CC(C)N(CCCNC(=O)Nc1ccc(cc1)C(C)(C)C)C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cc(Br)c2c(N)ncnc12, CC(C)N(CCCNC(=O)Nc1ccc(cc1)C(C)(C)C)C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cc(Br)c2c(N)ncnc12, CC(C)N(CCCNC(=O)Nc1ccc(cc1)C(C)(C)C)C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cc(Br)c2c(N)ncnc12, CC(C)N(CCCNC(=O)Nc1ccc(cc1)C(C)(C)C)C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cc(Br)c2c(N)ncnc12, CC(C)N(CCCNC(=O)Nc1ccc(cc1)C(C)(C)C)C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cc(Br)c2c(N)ncnc12	IQCKJUKAQJINMK-HUBRGWSESA-N, IQCKJUKAQJINMK-HUBRGWSESA-N, IQCKJUKAQJINMK-HUBRGWSESA-N, IQCKJUKAQJINMK-HUBRGWSESA-N, IQCKJUKAQJINMK-HUBRGWSESA-N	Preclinical
SGC-707	protein arginine N-methyltransferase inhibitor	PRMT3			O=C(NCC(=O)N1CCCC1)Nc1ccc2cnccc2c1, O=C(NCC(=O)N1CCCC1)Nc1ccc2cnccc2c1, O=C(NCC(=O)N1CCCC1)Nc1ccc2cnccc2c1	DMIDPTCQPIJYFE-UHFFFAOYSA-N, DMIDPTCQPIJYFE-UHFFFAOYSA-N, DMIDPTCQPIJYFE-UHFFFAOYSA-N	Preclinical
SGI-1027	DNA methyltransferase inhibitor	DNMT1, DNMT3A, DNMT3B			Cc1cc(Nc2ccc(NC(=O)c3ccc(Nc4ccnc5ccccc45)cc3)cc2)nc(N)n1, Cc1cc(Nc2ccc(NC(=O)c3ccc(Nc4ccnc5ccccc45)cc3)cc2)nc(N)n1, Cc1cc(Nc2ccc(NC(=O)c3ccc(Nc4ccnc5ccccc45)cc3)cc2)nc(N)n1, Cc1cc(Nc2ccc(NC(=O)c3ccc(Nc4ccnc5ccccc45)cc3)cc2)nc(N)n1	QSYLKMKIVWJAAK-UHFFFAOYSA-N, QSYLKMKIVWJAAK-UHFFFAOYSA-N, QSYLKMKIVWJAAK-UHFFFAOYSA-N, QSYLKMKIVWJAAK-UHFFFAOYSA-N	Preclinical
SGI-1776	Pim kinase inhibitor	FLT3, PIM1, PIM2, PIM3			CN1CCC(CNc2ccc3ncc(-c4cccc(OC(F)(F)F)c4)n3n2)CC1, CN1CCC(CNc2ccc3ncc(-c4cccc(OC(F)(F)F)c4)n3n2)CC1, CN1CCC(CNc2ccc3ncc(-c4cccc(OC(F)(F)F)c4)n3n2)CC1, CN1CCC(CNc2ccc3ncc(-c4cccc(OC(F)(F)F)c4)n3n2)CC1, CN1CCC(CNc2ccc3ncc(-c4cccc(OC(F)(F)F)c4)n3n2)CC1, CN1CCC(CNc2ccc3ncc(-c4cccc(OC(F)(F)F)c4)n3n2)CC1, CN1CCC(CNc2ccc3ncc(-c4cccc(OC(F)(F)F)c4)n3n2)CC1, CN1CCC(CNc2ccc3ncc(-c4cccc(OC(F)(F)F)c4)n3n2)CC1	MHXGEROHKGDZGO-UHFFFAOYSA-N, MHXGEROHKGDZGO-UHFFFAOYSA-N, MHXGEROHKGDZGO-UHFFFAOYSA-N, MHXGEROHKGDZGO-UHFFFAOYSA-N, MHXGEROHKGDZGO-UHFFFAOYSA-N, MHXGEROHKGDZGO-UHFFFAOYSA-N, MHXGEROHKGDZGO-UHFFFAOYSA-N, MHXGEROHKGDZGO-UHFFFAOYSA-N	Phase 1
SGS-742	GABA receptor antagonist	GABBR1, GABBR2			CCCCP(O)(=O)CCCN	ONNMDRQRSGKZCN-UHFFFAOYSA-N	Preclinical
SGX523	hepatocyte growth factor receptor inhibitor	MET			Cn1cc(cn1)-c1ccc2nnc(Sc3ccc4ncccc4c3)n2n1, Cn1cc(cn1)-c1ccc2nnc(Sc3ccc4ncccc4c3)n2n1, Cn1cc(cn1)-c1ccc2nnc(Sc3ccc4ncccc4c3)n2n1	BCZUAADEACICHN-UHFFFAOYSA-N, BCZUAADEACICHN-UHFFFAOYSA-N, BCZUAADEACICHN-UHFFFAOYSA-N	Phase 1
SHA-68	neuropeptide receptor antagonist	NPSR1			Fc1ccc(CNC(=O)N2CCN3[C@@H](C2)C(OC3=O)(c2ccccc2)c2ccccc2)cc1 |&1:13,r|, Fc1ccc(CNC(=O)N2CCN3[C@@H](C2)C(OC3=O)(c2ccccc2)c2ccccc2)cc1 |&1:13,r|	SFRQIPRTNYHJHP-QHCPKHFHSA-N, SFRQIPRTNYHJHP-QHCPKHFHSA-N	Preclinical
shikimic-acid					O[C@@H]1CC(=C[C@@H](O)[C@@H]1O)C(O)=O |a:1,&1:5,&2:7,c:3|, O[C@@H]1CC(=C[C@@H](O)[C@@H]1O)C(O)=O |a:1,&1:5,&2:7,c:3|	JXOHGGNKMLTUBP-PBXRRBTRSA-N, JXOHGGNKMLTUBP-PBXRRBTRSA-N	Preclinical
SHP099	protein tyrosine kinase inhibitor	PTPN11			CC1(N)CCN(CC1)c1cnc(c(N)n1)-c1cccc(Cl)c1Cl, CC1(N)CCN(CC1)c1cnc(c(N)n1)-c1cccc(Cl)c1Cl, CC1(N)CCN(CC1)c1cnc(c(N)n1)-c1cccc(Cl)c1Cl, CC1(N)CCN(CC1)c1cnc(c(N)n1)-c1cccc(Cl)c1Cl	YGUFCDOEKKVKJK-UHFFFAOYSA-N, YGUFCDOEKKVKJK-UHFFFAOYSA-N, YGUFCDOEKKVKJK-UHFFFAOYSA-N, YGUFCDOEKKVKJK-UHFFFAOYSA-N	Preclinical
SIB-1553A	acetylcholine receptor agonist	CHRNB4			CN1CCC[C@@H]1CCSc1ccc(O)cc1 |&1:5|	NVZGJSVPOOILDI-LLVKDONJSA-N	Phase 2
SIB-1757	glutamate receptor antagonist	GRM5			C=C1NC(=NNc2ccccc2)C(=O)C=C1 |c:15|, C=C1NC(=NNc2ccccc2)C(=O)C=C1 |c:15|, C=C1NC(=NNc2ccccc2)C(=O)C=C1 |c:15|, C=C1NC(=NNc2ccccc2)C(=O)C=C1 |c:15|, C=C1NC(=NNc2ccccc2)C(=O)C=C1 |c:15|, C=C1NC(=NNc2ccccc2)C(=O)C=C1 |c:15|	UOJMXHLMOUOGPY-UHFFFAOYSA-N, UOJMXHLMOUOGPY-UHFFFAOYSA-N, UOJMXHLMOUOGPY-UHFFFAOYSA-N, UOJMXHLMOUOGPY-UHFFFAOYSA-N, UOJMXHLMOUOGPY-UHFFFAOYSA-N, UOJMXHLMOUOGPY-UHFFFAOYSA-N	Preclinical
SIB-1893	glutamate receptor antagonist	GRM4, GRM5			Cc1cccc(\C=C\c2ccccc2)n1, Cc1cccc(\C=C\c2ccccc2)n1	SISOFUCTXZKSOQ-ZHACJKMWSA-N, SISOFUCTXZKSOQ-ZHACJKMWSA-N	Preclinical
SID-7969543	steroidogenic factor antagonist	NR5A1			CCOC(=O)[C@@H](C)Oc1cccc2c1ccn(CC(=O)Nc1ccc3OCCOc3c1)c2=O |&1:5,r|, CCOC(=O)[C@@H](C)Oc1cccc2c1ccn(CC(=O)Nc1ccc3OCCOc3c1)c2=O |&1:5,r|, CCOC(=O)[C@@H](C)Oc1cccc2c1ccn(CC(=O)Nc1ccc3OCCOc3c1)c2=O |&1:5,r|	KWMBIIQCLUIHDI-OAHLLOKOSA-N, KWMBIIQCLUIHDI-OAHLLOKOSA-N, KWMBIIQCLUIHDI-OAHLLOKOSA-N	Preclinical
siguazodan	phosphodiesterase inhibitor	PDE3A			CN\C(NC#N)=N/c1ccc(cc1)C1=NNC(=O)C[C@@H]1C |r,t:14|, CN\C(NC#N)=N/c1ccc(cc1)C1=NNC(=O)C[C@@H]1C |r,t:14|, CN\C(NC#N)=N/c1ccc(cc1)C1=NNC(=O)C[C@@H]1C |r,t:14|	NUHPODZZKHQQET-VIFPVBQESA-N, NUHPODZZKHQQET-VIFPVBQESA-N, NUHPODZZKHQQET-VIFPVBQESA-N	Phase 1
sildenafil	phosphodiesterase inhibitor	PDE5A, PDE6G, PDE6H, SLCO1B1, SLCO1B3	urology	erectile dysfunction	CCCc1nn(C)c2c1nc([nH]c2=O)-c1cc(ccc1OCC)S(=O)(=O)N1CCN(C)CC1, CCCc1nn(C)c2c1nc([nH]c2=O)-c1cc(ccc1OCC)S(=O)(=O)N1CCN(C)CC1, CCCc1nn(C)c2c1nc([nH]c2=O)-c1cc(ccc1OCC)S(=O)(=O)N1CCN(C)CC1, CCCc1nn(C)c2c1nc([nH]c2=O)-c1cc(ccc1OCC)S(=O)(=O)N1CCN(C)CC1, CCCc1nn(C)c2c1nc([nH]c2=O)-c1cc(ccc1OCC)S(=O)(=O)N1CCN(C)CC1, CCCc1nn(C)c2c1nc([nH]c2=O)-c1cc(ccc1OCC)S(=O)(=O)N1CCN(C)CC1	BNRNXUUZRGQAQC-UHFFFAOYSA-N, BNRNXUUZRGQAQC-UHFFFAOYSA-N, BNRNXUUZRGQAQC-UHFFFAOYSA-N, BNRNXUUZRGQAQC-UHFFFAOYSA-N, BNRNXUUZRGQAQC-UHFFFAOYSA-N, BNRNXUUZRGQAQC-UHFFFAOYSA-N	Launched
silibinin	cytochrome P450 inhibitor	ALOX5	gastroenterology	hepatic cirrhosis	COc1cc(ccc1O)[C@H]1Oc2cc(ccc2O[C@@H]1CO)[C@H]1Oc2cc(O)cc(O)c2C(=O)[C@@H]1O, COc1cc(ccc1O)[C@H]1Oc2cc(ccc2O[C@@H]1CO)[C@H]1Oc2cc(O)cc(O)c2C(=O)[C@@H]1O, COc1cc(ccc1O)[C@H]1Oc2cc(ccc2O[C@@H]1CO)[C@H]1Oc2cc(O)cc(O)c2C(=O)[C@@H]1O, COc1cc(ccc1O)[C@H]1Oc2cc(ccc2O[C@@H]1CO)[C@H]1Oc2cc(O)cc(O)c2C(=O)[C@@H]1O	SEBFKMXJBCUCAI-HKTJVKLFSA-N, SEBFKMXJBCUCAI-HKTJVKLFSA-N, SEBFKMXJBCUCAI-HKTJVKLFSA-N, SEBFKMXJBCUCAI-HKTJVKLFSA-N	Launched
silodosin	adrenergic receptor antagonist	ADRA1A, ADRA1B, ADRA1D	urology	benign prostatic hyperplasia (BPH)	C[C@H](Cc1cc2CCN(CCCO)c2c(c1)C(N)=O)NCCOc1ccccc1OCC(F)(F)F, C[C@H](Cc1cc2CCN(CCCO)c2c(c1)C(N)=O)NCCOc1ccccc1OCC(F)(F)F, C[C@H](Cc1cc2CCN(CCCO)c2c(c1)C(N)=O)NCCOc1ccccc1OCC(F)(F)F	PNCPYILNMDWPEY-QGZVFWFLSA-N, PNCPYILNMDWPEY-QGZVFWFLSA-N, PNCPYILNMDWPEY-QGZVFWFLSA-N	Launched
silver-sulfadiazine	PABA antagonist		critical care	sepsis	Nc1ccc(cc1)S(=O)(=O)N([Ag])c1ncccn1, Nc1ccc(cc1)S(=O)(=O)N([Ag])c1ncccn1, Nc1ccc(cc1)S(=O)(=O)N([Ag])c1ncccn1	UEJSSZHHYBHCEL-UHFFFAOYSA-N, UEJSSZHHYBHCEL-UHFFFAOYSA-N, UEJSSZHHYBHCEL-UHFFFAOYSA-N	Launched
silymarin					COc1cc(ccc1O)[C@H]1Oc2ccc(cc2O[C@@H]1CO)[C@H]1Oc2cc(O)cc(O)c2C(=O)[C@@H]1O |&1:9,&2:18,&3:21,&4:33,r|, COc1cc(ccc1O)[C@H]1Oc2ccc(cc2O[C@@H]1CO)[C@H]1Oc2cc(O)cc(O)c2C(=O)[C@@H]1O |&1:9,&2:18,&3:21,&4:33,r|, COc1cc(ccc1O)[C@H]1Oc2ccc(cc2O[C@@H]1CO)[C@H]1Oc2cc(O)cc(O)c2C(=O)[C@@H]1O |&1:9,&2:18,&3:21,&4:33,r|	FDQAOULAVFHKBX-HKTJVKLFSA-N, FDQAOULAVFHKBX-HKTJVKLFSA-N, FDQAOULAVFHKBX-HKTJVKLFSA-N	Launched
simeprevir	HCV inhibitor	CYP1A2, CYP3A4	infectious disease	hepatitis C	COc1ccc2c(O[C@@H]3C[C@@H]4[C@@H](C3)C(=O)N(C)CCCC\C=C/[C@@H]3C[C@]3(NC4=O)C(=O)NS(=O)(=O)C3CC3)cc(nc2c1C)-c1nc(cs1)C(C)C |c:22|, COc1ccc2c(O[C@@H]3C[C@@H]4[C@@H](C3)C(=O)N(C)CCCC\C=C/[C@@H]3C[C@]3(NC4=O)C(=O)NS(=O)(=O)C3CC3)cc(nc2c1C)-c1nc(cs1)C(C)C |c:22|	JTZZSQYMACOLNN-VDWJNHBNSA-N, JTZZSQYMACOLNN-VDWJNHBNSA-N	Launched
simurosertib	kinase inhibitor				Cc1n[nH]cc1-c1cc2[nH]c(nc(=O)c2s1)[C@H]1CC2CCN1CC2 |&1:16,r|	XGVXKJKTISMIOW-CYBMUJFWSA-N	Preclinical
simvastatin	HMGCR inhibitor	HMGCR, ITGB2	endocrinology, cardiology, neurology/psychiatry	hypercholesterolemia, coronary heart disease, myocardial infarction, stroke, hyperlipidemia	CCC(C)(C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12 |c:14,t:12|, CCC(C)(C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12 |c:14,t:12|, CCC(C)(C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12 |c:14,t:12|, CCC(C)(C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12 |c:14,t:12|, CCC(C)(C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12 |c:14,t:12|, CCC(C)(C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12 |c:14,t:12|, CCC(C)(C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12 |c:14,t:12|, CCC(C)(C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12 |c:14,t:12|, CCC(C)(C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12 |c:14,t:12|	RYMZZMVNJRMUDD-HGQWONQESA-N, RYMZZMVNJRMUDD-HGQWONQESA-N, RYMZZMVNJRMUDD-HGQWONQESA-N, RYMZZMVNJRMUDD-HGQWONQESA-N, RYMZZMVNJRMUDD-HGQWONQESA-N, RYMZZMVNJRMUDD-HGQWONQESA-N, RYMZZMVNJRMUDD-HGQWONQESA-N, RYMZZMVNJRMUDD-HGQWONQESA-N, RYMZZMVNJRMUDD-HGQWONQESA-N	Launched
sincalide	cholecystokinin agonist				CSCC[C@H](NC(=O)[C@H](Cc1ccc(OS(O)(=O)=O)cc1)NC(=O)[C@@H](N)CC(O)=O)C(=O)NCC(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](Cc1ccccc1)C(N)=O	IZTQOLKUZKXIRV-YRVFCXMDSA-N	Preclinical
sinefungin	DNA methyltransferase inhibitor, RNA synthesis inhibitor	CARM1			N[C@@H](CC[C@H](N)C(O)=O)C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(N)ncnc12, N[C@@H](CC[C@H](N)C(O)=O)C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(N)ncnc12	LMXOHSDXUQEUSF-YECHIGJVSA-N, LMXOHSDXUQEUSF-YECHIGJVSA-N	Preclinical
sinomenine	angiogenesis inhibitor				COC1=C[C@@H]2[C@@H]3Cc4ccc(OC)c(O)c4[C@]2(CCN3C)CC1=O |t:2|, COC1=C[C@@H]2[C@@H]3Cc4ccc(OC)c(O)c4[C@]2(CCN3C)CC1=O |t:2|	INYYVPJSBIVGPH-QHRIQVFBSA-N, INYYVPJSBIVGPH-QHRIQVFBSA-N	Preclinical
sipatrigine	voltage-gated sodium channel blocker	CACNA1D, SCN10A, SCN1A, SCN3A, SCN4A, SCN5A, SCN9A			CN1CCN(CC1)c1ncc(c(N)n1)-c1cc(Cl)cc(Cl)c1Cl, CN1CCN(CC1)c1ncc(c(N)n1)-c1cc(Cl)cc(Cl)c1Cl	PDOCBJADCWMDGL-UHFFFAOYSA-N, PDOCBJADCWMDGL-UHFFFAOYSA-N	Phase 2
siponimod	sphingosine 1-phosphate receptor modulator	S1PR1	neurology/psychiatry	multiple sclerosis	CCc1cc(ccc1CN1CC(C1)C(O)=O)C(\C)=N\OCc1ccc(C2CCCCC2)c(c1)C(F)(F)F, CCc1cc(ccc1CN1CC(C1)C(O)=O)C(\C)=N\OCc1ccc(C2CCCCC2)c(c1)C(F)(F)F, CCc1cc(ccc1CN1CC(C1)C(O)=O)C(\C)=N\OCc1ccc(C2CCCCC2)c(c1)C(F)(F)F, CCc1cc(ccc1CN1CC(C1)C(O)=O)C(\C)=N\OCc1ccc(C2CCCCC2)c(c1)C(F)(F)F, CCc1cc(ccc1CN1CC(C1)C(O)=O)C(\C)=N\OCc1ccc(C2CCCCC2)c(c1)C(F)(F)F	KIHYPELVXPAIDH-HNSNBQBZSA-N, KIHYPELVXPAIDH-HNSNBQBZSA-N, KIHYPELVXPAIDH-HNSNBQBZSA-N, KIHYPELVXPAIDH-HNSNBQBZSA-N, KIHYPELVXPAIDH-HNSNBQBZSA-N	Launched
siramesine	sigma receptor antagonist	ADRA1A, ADRA1B, ADRA1D			Fc1ccc(cc1)-n1cc(CCCCN2CCC3(CC2)OCc2ccccc32)c2ccccc12, Fc1ccc(cc1)-n1cc(CCCCN2CCC3(CC2)OCc2ccccc32)c2ccccc12, Fc1ccc(cc1)-n1cc(CCCCN2CCC3(CC2)OCc2ccccc32)c2ccccc12	XWAONOGAGZNUSF-UHFFFAOYSA-N, XWAONOGAGZNUSF-UHFFFAOYSA-N, XWAONOGAGZNUSF-UHFFFAOYSA-N	Phase 2
siremadlin	MDM inhibitor				COc1ncc(-c2nc3C(=O)N([C@H](c3n2C(C)C)c2ccc(Cl)cc2)c2cc(Cl)cn(C)c2=O)c(OC)n1	AGBSXNCBIWWLHD-FQEVSTJZSA-N	Preclinical
sirolimus	mTOR inhibitor	FKBP1A, MTOR	transplant, pulmonary	organ rejection, lymphangioleiomyomatosis	CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1O |c:14,33,t:29,31|, CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1O |c:14,33,t:29,31|, CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1O |c:14,33,t:29,31|, CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1O |c:14,33,t:29,31|, CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1O |c:14,33,t:29,31|, CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1O |c:14,33,t:29,31|, CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1O |c:14,33,t:29,31|, CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1O |c:14,33,t:29,31|	QFJCIRLUMZQUOT-MHOZHFGWSA-N, QFJCIRLUMZQUOT-MHOZHFGWSA-N, QFJCIRLUMZQUOT-MHOZHFGWSA-N, QFJCIRLUMZQUOT-MHOZHFGWSA-N, QFJCIRLUMZQUOT-MHOZHFGWSA-N, QFJCIRLUMZQUOT-MHOZHFGWSA-N, QFJCIRLUMZQUOT-MHOZHFGWSA-N, QFJCIRLUMZQUOT-MHOZHFGWSA-N	Launched
SirReal-2	SIRT inhibitor	SIRT2			Cc1cc(C)nc(SCC(=O)Nc2ncc(Cc3cccc4ccccc34)s2)n1, Cc1cc(C)nc(SCC(=O)Nc2ncc(Cc3cccc4ccccc34)s2)n1, Cc1cc(C)nc(SCC(=O)Nc2ncc(Cc3cccc4ccccc34)s2)n1	MENNDDDTIIZDDN-UHFFFAOYSA-N, MENNDDDTIIZDDN-UHFFFAOYSA-N, MENNDDDTIIZDDN-UHFFFAOYSA-N	Preclinical
sirtinol	SIRT inhibitor	SIRT1, SIRT2			C[C@@H](NC(=O)c1ccccc1\N=C\c1c(O)ccc2ccccc12)c1ccccc1 |&1:1,r|, C[C@@H](NC(=O)c1ccccc1\N=C\c1c(O)ccc2ccccc12)c1ccccc1 |&1:1,r|, C[C@@H](NC(=O)c1ccccc1\N=C\c1c(O)ccc2ccccc12)c1ccccc1 |&1:1,r|, C[C@@H](NC(=O)c1ccccc1\N=C\c1c(O)ccc2ccccc12)c1ccccc1 |&1:1,r|	UXJFDYIHRJGPFS-OVKKOYPGSA-N, UXJFDYIHRJGPFS-OVKKOYPGSA-N, UXJFDYIHRJGPFS-OVKKOYPGSA-N, UXJFDYIHRJGPFS-OVKKOYPGSA-N	Preclinical
sisomicin	protein synthesis inhibitor		ophthalmology	conjunctivitis, punctate keratitis	CN[C@@H]1[C@@H](O)[C@@H](O[C@H]2[C@H](N)C[C@H](N)[C@@H](O[C@H]3OC(CN)=CC[C@H]3N)[C@@H]2O)OC[C@]1(C)O |c:19|, CN[C@@H]1[C@@H](O)[C@@H](O[C@H]2[C@H](N)C[C@H](N)[C@@H](O[C@H]3OC(CN)=CC[C@H]3N)[C@@H]2O)OC[C@]1(C)O |c:19|, CN[C@@H]1[C@@H](O)[C@@H](O[C@H]2[C@H](N)C[C@H](N)[C@@H](O[C@H]3OC(CN)=CC[C@H]3N)[C@@H]2O)OC[C@]1(C)O |c:19|, CN[C@@H]1[C@@H](O)[C@@H](O[C@H]2[C@H](N)C[C@H](N)[C@@H](O[C@H]3OC(CN)=CC[C@H]3N)[C@@H]2O)OC[C@]1(C)O |c:19|	URWAJWIAIPFPJE-YFMIWBNJSA-N, URWAJWIAIPFPJE-YFMIWBNJSA-N, URWAJWIAIPFPJE-YFMIWBNJSA-N, URWAJWIAIPFPJE-YFMIWBNJSA-N	Launched
sisomicin-sulfate	bacterial 30S ribosomal subunit inhibitor		infectious disease	gram-negative bacterial infections	CN[C@@H]1[C@@H](O)[C@@H](O[C@H]2[C@H](N)C[C@H](N)[C@@H](O[C@H]3OC(CN)=CC[C@H]3N)[C@@H]2O)OC[C@]1(C)O |a:2,5,7,8,11,13,15,22,24,28,&1:3,c:19|	URWAJWIAIPFPJE-YFMIWBNJSA-N	Launched
SIS3	serine/threonine kinase inhibitor	SMAD3, TGFBR1			COc1cc2CCN(Cc2cc1OC)C(=O)\C=C\c1c(-c2ccccc2)n(C)c2ncccc12, COc1cc2CCN(Cc2cc1OC)C(=O)\C=C\c1c(-c2ccccc2)n(C)c2ncccc12	IJYPHMXWKKKHGT-VAWYXSNFSA-N, IJYPHMXWKKKHGT-VAWYXSNFSA-N	Preclinical
sitafloxacin	bacterial DNA gyrase inhibitor		infectious disease	buruli ulcer	N[C@@H]1CN(CC11CC1)c1c(F)cc2c(c1Cl)n(cc(C(O)=O)c2=O)[C@@H]1C[C@@H]1F, N[C@@H]1CN(CC11CC1)c1c(F)cc2c(c1Cl)n(cc(C(O)=O)c2=O)[C@@H]1C[C@@H]1F, N[C@@H]1CN(CC11CC1)c1c(F)cc2c(c1Cl)n(cc(C(O)=O)c2=O)[C@@H]1C[C@@H]1F, N[C@@H]1CN(CC11CC1)c1c(F)cc2c(c1Cl)n(cc(C(O)=O)c2=O)[C@@H]1C[C@@H]1F	PNUZDKCDAWUEGK-CYZMBNFOSA-N, PNUZDKCDAWUEGK-CYZMBNFOSA-N, PNUZDKCDAWUEGK-CYZMBNFOSA-N, PNUZDKCDAWUEGK-CYZMBNFOSA-N	Launched
sitagliptin	dipeptidyl peptidase inhibitor	DPP4	endocrinology	diabetes mellitus	N[C@@H](CC(=O)N1CCn2c(C1)nnc2C(F)(F)F)Cc1cc(F)c(F)cc1F, N[C@@H](CC(=O)N1CCn2c(C1)nnc2C(F)(F)F)Cc1cc(F)c(F)cc1F, N[C@@H](CC(=O)N1CCn2c(C1)nnc2C(F)(F)F)Cc1cc(F)c(F)cc1F	MFFMDFFZMYYVKS-SECBINFHSA-N, MFFMDFFZMYYVKS-SECBINFHSA-N, MFFMDFFZMYYVKS-SECBINFHSA-N	Launched
sitaxentan	endothelin receptor antagonist	EDNRA, EDNRB			Cc1noc(NS(=O)(=O)c2ccsc2C(=O)Cc2cc3OCOc3cc2C)c1Cl, Cc1noc(NS(=O)(=O)c2ccsc2C(=O)Cc2cc3OCOc3cc2C)c1Cl, Cc1noc(NS(=O)(=O)c2ccsc2C(=O)Cc2cc3OCOc3cc2C)c1Cl, Cc1noc(NS(=O)(=O)c2ccsc2C(=O)Cc2cc3OCOc3cc2C)c1Cl, Cc1noc(NS(=O)(=O)c2ccsc2C(=O)Cc2cc3OCOc3cc2C)c1Cl	PHWXUGHIIBDVKD-UHFFFAOYSA-N, PHWXUGHIIBDVKD-UHFFFAOYSA-N, PHWXUGHIIBDVKD-UHFFFAOYSA-N, PHWXUGHIIBDVKD-UHFFFAOYSA-N, PHWXUGHIIBDVKD-UHFFFAOYSA-N	Withdrawn
sitosterol					CC[C@H](CC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)C |t:13|, CC[C@H](CC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)C |t:13|, CC[C@H](CC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)C |t:13|	KZJWDPNRJALLNS-VJSFXXLFSA-N, KZJWDPNRJALLNS-VJSFXXLFSA-N, KZJWDPNRJALLNS-VJSFXXLFSA-N	Preclinical
sitravatinib	receptor tyrosine protein kinase inhibitor				COCCNCc1ccc(nc1)-c1cc2nccc(Oc3ccc(NC(=O)C4(CC4)C(=O)Nc4ccc(F)cc4)cc3F)c2s1	WLAVZAAODLTUSW-UHFFFAOYSA-N	Phase 3
sivelestat	elastase inhibitor	CELA1, ELANE	pulmonary	acute lung injury	CC(C)(C)C(=O)Oc1ccc(cc1)S(=O)(=O)Nc1ccccc1C(=O)NCC(O)=O, CC(C)(C)C(=O)Oc1ccc(cc1)S(=O)(=O)Nc1ccccc1C(=O)NCC(O)=O, CC(C)(C)C(=O)Oc1ccc(cc1)S(=O)(=O)Nc1ccccc1C(=O)NCC(O)=O, CC(C)(C)C(=O)Oc1ccc(cc1)S(=O)(=O)Nc1ccccc1C(=O)NCC(O)=O	BTGNGJJLZOIYID-UHFFFAOYSA-N, BTGNGJJLZOIYID-UHFFFAOYSA-N, BTGNGJJLZOIYID-UHFFFAOYSA-N, BTGNGJJLZOIYID-UHFFFAOYSA-N	Launched
SJ-172550	MDM inhibitor	MDM4			CCOc1cc(\C=C2/C(C)=NN(C2=O)c2ccccc2)cc(Cl)c1OCC(=O)OC |c:9|, CCOc1cc(\C=C2/C(C)=NN(C2=O)c2ccccc2)cc(Cl)c1OCC(=O)OC |c:9|, CCOc1cc(\C=C2/C(C)=NN(C2=O)c2ccccc2)cc(Cl)c1OCC(=O)OC |c:9|	RKKFQJXGAQWHBZ-LICLKQGHSA-N, RKKFQJXGAQWHBZ-LICLKQGHSA-N, RKKFQJXGAQWHBZ-LICLKQGHSA-N	Preclinical
SJ-733	ATPase inhibitor				Fc1ccc(NC(=O)[C@@H]2[C@H](N(CC(F)(F)F)C(=O)c3ccccc23)c2cccnc2)cc1C#N	VKCPFWKTFZAOTO-LEWJYISDSA-N	Phase 1
SJG-136	DNA intercalating agent				COc1cc2c(cc1OCCCOc1cc3N=C[C@@H]4CC(=C)CN4C(=O)c3cc1OC)N=C[C@@H]1CC(=C)CN1C2=O |c:17,35|	RWZVMMQNDHPRQD-SFTDATJTSA-N	Phase 2
SK&F-10047-(+)	sigma receptor agonist	SIGMAR1			C[C@@H]1[C@@H]2Cc3ccc(O)cc3[C@@]1(C)CCN2CC=C, C[C@@H]1[C@@H]2Cc3ccc(O)cc3[C@@]1(C)CCN2CC=C	LGQCVMYAEFTEFN-DQYPLSBCSA-N, LGQCVMYAEFTEFN-DQYPLSBCSA-N	Phase 1
SKA-31	potassium channel activator	KCNN4			Nc1nc2c(ccc3ccccc23)s1, Nc1nc2c(ccc3ccccc23)s1, Nc1nc2c(ccc3ccccc23)s1, Nc1nc2c(ccc3ccccc23)s1	FECQXVPRUCCUIL-UHFFFAOYSA-N, FECQXVPRUCCUIL-UHFFFAOYSA-N, FECQXVPRUCCUIL-UHFFFAOYSA-N, FECQXVPRUCCUIL-UHFFFAOYSA-N	Preclinical
skepinone-L	p38 MAPK inhibitor	MAPK14			OC[C@@H](O)COc1ccc2CCc3cc(Nc4ccc(F)cc4F)ccc3C(=O)c2c1, OC[C@@H](O)COc1ccc2CCc3cc(Nc4ccc(F)cc4F)ccc3C(=O)c2c1, OC[C@@H](O)COc1ccc2CCc3cc(Nc4ccc(F)cc4F)ccc3C(=O)c2c1, OC[C@@H](O)COc1ccc2CCc3cc(Nc4ccc(F)cc4F)ccc3C(=O)c2c1	HXMGCTFLLWPVFM-GOSISDBHSA-N, HXMGCTFLLWPVFM-GOSISDBHSA-N, HXMGCTFLLWPVFM-GOSISDBHSA-N, HXMGCTFLLWPVFM-GOSISDBHSA-N	Preclinical
SKF-38393	dopamine receptor agonist	CALY, DRD1, DRD5			Oc1cc2CCNC[C@@H](c3ccccc3)c2cc1O |&1:8|, Oc1cc2CCNC[C@@H](c3ccccc3)c2cc1O |&1:8|, Oc1cc2CCNC[C@@H](c3ccccc3)c2cc1O |&1:8|, Oc1cc2CCNC[C@@H](c3ccccc3)c2cc1O |&1:8|	JUDKOGFHZYMDMF-AWEZNQCLSA-N, JUDKOGFHZYMDMF-AWEZNQCLSA-N, JUDKOGFHZYMDMF-AWEZNQCLSA-N, JUDKOGFHZYMDMF-AWEZNQCLSA-N	Preclinical
SKF-77434	dopamine receptor agonist	DRD1			Oc1cc2CCN(CC=C)C[C@@H](c3ccccc3)c2cc1O |&1:11|, Oc1cc2CCN(CC=C)C[C@@H](c3ccccc3)c2cc1O |&1:11|, Oc1cc2CCN(CC=C)C[C@@H](c3ccccc3)c2cc1O |&1:11|	QBUVZVXIRYFENV-KRWDZBQOSA-N, QBUVZVXIRYFENV-KRWDZBQOSA-N, QBUVZVXIRYFENV-KRWDZBQOSA-N	Preclinical
SKF-81297	dopamine receptor agonist	DRD1, DRD5			Oc1cc2C(CNCCc2c(Cl)c1O)c1ccccc1, Oc1cc2C(CNCCc2c(Cl)c1O)c1ccccc1, Oc1cc2C(CNCCc2c(Cl)c1O)c1ccccc1, Oc1cc2C(CNCCc2c(Cl)c1O)c1ccccc1, Oc1cc2C(CNCCc2c(Cl)c1O)c1ccccc1	GHWJEDJMOVUXEC-UHFFFAOYSA-N, GHWJEDJMOVUXEC-UHFFFAOYSA-N, GHWJEDJMOVUXEC-UHFFFAOYSA-N, GHWJEDJMOVUXEC-UHFFFAOYSA-N, GHWJEDJMOVUXEC-UHFFFAOYSA-N	Preclinical
SKF-83566	dopamine receptor antagonist	DRD1, DRD5			CN1CCc2cc(Br)c(O)cc2[C@@H](C1)c1ccccc1 |&1:12|, CN1CCc2cc(Br)c(O)cc2[C@@H](C1)c1ccccc1 |&1:12|, CN1CCc2cc(Br)c(O)cc2[C@@H](C1)c1ccccc1 |&1:12|	XFTVOHWWEQGXLS-HNNXBMFYSA-N, XFTVOHWWEQGXLS-HNNXBMFYSA-N, XFTVOHWWEQGXLS-HNNXBMFYSA-N	Preclinical
SKF-86002	p38 MAPK inhibitor	ALOX5, MAPK14			Fc1ccc(cc1)-c1nc2SCCn2c1-c1ccncc1, Fc1ccc(cc1)-c1nc2SCCn2c1-c1ccncc1, Fc1ccc(cc1)-c1nc2SCCn2c1-c1ccncc1	YOELZIQOLWZLQC-UHFFFAOYSA-N, YOELZIQOLWZLQC-UHFFFAOYSA-N, YOELZIQOLWZLQC-UHFFFAOYSA-N	Preclinical
SKF-89976A	GABA uptake inhibitor	SLC6A1			OC(=O)[C@H]1CCCN(CCC=C(c2ccccc2)c2ccccc2)C1 |&1:3|, OC(=O)[C@H]1CCCN(CCC=C(c2ccccc2)c2ccccc2)C1 |&1:3|, OC(=O)[C@H]1CCCN(CCC=C(c2ccccc2)c2ccccc2)C1 |&1:3|, OC(=O)[C@H]1CCCN(CCC=C(c2ccccc2)c2ccccc2)C1 |&1:3|	TXQKSMSLZVKQBI-FQEVSTJZSA-N, TXQKSMSLZVKQBI-FQEVSTJZSA-N, TXQKSMSLZVKQBI-FQEVSTJZSA-N, TXQKSMSLZVKQBI-FQEVSTJZSA-N	Preclinical
SKF-91488	histamine N-methyltransferase inhibitor	HNMT			CN(C)CCCCSC(N)=N, CN(C)CCCCSC(N)=N, CN(C)CCCCSC(N)=N	UFYJLJINUGVUHO-UHFFFAOYSA-N, UFYJLJINUGVUHO-UHFFFAOYSA-N, UFYJLJINUGVUHO-UHFFFAOYSA-N	Preclinical
SKF-96365	calcium channel blocker	CYP3A4, PKD2, TRPC1, TRPC3, TRPC4, TRPC5, TRPV2			COc1ccc(CCCO[C@@H](Cn2ccnc2)c2ccc(OC)cc2)cc1 |&1:10|, COc1ccc(CCCO[C@@H](Cn2ccnc2)c2ccc(OC)cc2)cc1 |&1:10|, COc1ccc(CCCO[C@@H](Cn2ccnc2)c2ccc(OC)cc2)cc1 |&1:10|, COc1ccc(CCCO[C@@H](Cn2ccnc2)c2ccc(OC)cc2)cc1 |&1:10|	HLMBXBGDBBCYII-QFIPXVFZSA-N, HLMBXBGDBBCYII-QFIPXVFZSA-N, HLMBXBGDBBCYII-QFIPXVFZSA-N, HLMBXBGDBBCYII-QFIPXVFZSA-N	Preclinical
SKI-II	sphingosine kinase inhibitor	SPHK1			Oc1ccc(Nc2nc(cs2)-c2ccc(Cl)cc2)cc1, Oc1ccc(Nc2nc(cs2)-c2ccc(Cl)cc2)cc1, Oc1ccc(Nc2nc(cs2)-c2ccc(Cl)cc2)cc1, Oc1ccc(Nc2nc(cs2)-c2ccc(Cl)cc2)cc1, Oc1ccc(Nc2nc(cs2)-c2ccc(Cl)cc2)cc1, Oc1ccc(Nc2nc(cs2)-c2ccc(Cl)cc2)cc1	ZFGXZJKLOFCECI-UHFFFAOYSA-N, ZFGXZJKLOFCECI-UHFFFAOYSA-N, ZFGXZJKLOFCECI-UHFFFAOYSA-N, ZFGXZJKLOFCECI-UHFFFAOYSA-N, ZFGXZJKLOFCECI-UHFFFAOYSA-N, ZFGXZJKLOFCECI-UHFFFAOYSA-N	Preclinical
SKLB-1028	Abl kinase inhibitor, EGFR inhibitor, FLT3 inhibitor				CC(C)n1c(Nc2cccnc2)nc2cnc(Nc3ccc(cc3)N3CCN(C)CC3)nc12	WSOHOUHPUOAXIN-UHFFFAOYSA-N	Preclinical
SKLB1002	VEGFR inhibitor	KDR			COc1cc2ncnc(Sc3nnc(C)s3)c2cc1OC, COc1cc2ncnc(Sc3nnc(C)s3)c2cc1OC, COc1cc2ncnc(Sc3nnc(C)s3)c2cc1OC	RQVGFDBMONQTBC-UHFFFAOYSA-N, RQVGFDBMONQTBC-UHFFFAOYSA-N, RQVGFDBMONQTBC-UHFFFAOYSA-N	Preclinical
SLV-319-(+/-)	cannabinoid receptor antagonist	CNR1, DRD2, HTR1A			C\N=C(\NS(=O)(=O)c1ccc(Cl)cc1)N1C[C@@H](C(=N1)c1ccc(Cl)cc1)c1ccccc1 |&1:16,r,c:18|	AXJQVVLKUYCICH-OAQYLSRUSA-N	Phase 2
SLV-320	adenosine receptor antagonist	ADORA1, ADORA2A, ADORA2B, ADORA3			O[C@H]1CC[C@@H](CC1)Nc1nc(nc2[nH]ccc12)-c1ccccc1 |r|, O[C@H]1CC[C@@H](CC1)Nc1nc(nc2[nH]ccc12)-c1ccccc1 |r|, O[C@H]1CC[C@@H](CC1)Nc1nc(nc2[nH]ccc12)-c1ccccc1 |r|, O[C@H]1CC[C@@H](CC1)Nc1nc(nc2[nH]ccc12)-c1ccccc1 |r|	RBZNJGHIKXAKQE-HDJSIYSDSA-N, RBZNJGHIKXAKQE-HDJSIYSDSA-N, RBZNJGHIKXAKQE-HDJSIYSDSA-N, RBZNJGHIKXAKQE-HDJSIYSDSA-N	Phase 2
SM-108					NC(=O)C1N=CNC1=O |c:4|, NC(=O)C1N=CNC1=O |c:4|	PXQCVBRDIZZRGM-UHFFFAOYSA-N, PXQCVBRDIZZRGM-UHFFFAOYSA-N	Phase 2
SM-164	XIAP inhibitor	BIRC2, BIRC3, XIAP			CN[C@@H](C)C(=O)N[C@H]1CCCC[C@H]2CC[C@H](N2C1=O)C(=O)N[C@H](c1cn(CCCCc2ccc(CCCCn3cc(nn3)[C@@H](NC(=O)[C@@H]3CC[C@@H]4CCCC[C@H](NC(=O)[C@H](C)NC)C(=O)N34)c3ccccc3)cc2)nn1)c1ccccc1, CN[C@@H](C)C(=O)N[C@H]1CCCC[C@H]2CC[C@H](N2C1=O)C(=O)N[C@H](c1cn(CCCCc2ccc(CCCCn3cc(nn3)[C@@H](NC(=O)[C@@H]3CC[C@@H]4CCCC[C@H](NC(=O)[C@H](C)NC)C(=O)N34)c3ccccc3)cc2)nn1)c1ccccc1	LGYDZXNSSLRFJS-IOQQVAQYSA-N, LGYDZXNSSLRFJS-IOQQVAQYSA-N	Preclinical
SM-21	sigma receptor antagonist	PGRMC1			CC[C@H](Oc1ccc(Cl)cc1)C(=O)O[C@@H]1C[C@@H]2CC[C@H](C1)N2C |&1:14,16,19,&2:2,r,TLB:22:21:17.18:14.15.20|	WTPAXDRULIZRDJ-ABFRBSLYSA-N	Preclinical
SMER-28	autophagy inducer	SNCA			Brc1ccc2ncnc(NCC=C)c2c1, Brc1ccc2ncnc(NCC=C)c2c1, Brc1ccc2ncnc(NCC=C)c2c1, Brc1ccc2ncnc(NCC=C)c2c1, Brc1ccc2ncnc(NCC=C)c2c1	BCPOLXUSCUFDGE-UHFFFAOYSA-N, BCPOLXUSCUFDGE-UHFFFAOYSA-N, BCPOLXUSCUFDGE-UHFFFAOYSA-N, BCPOLXUSCUFDGE-UHFFFAOYSA-N, BCPOLXUSCUFDGE-UHFFFAOYSA-N	Preclinical
SMI-4a	Pim kinase inhibitor	PIM1			FC(F)(F)c1cccc(\C=C2/SC(=O)NC2=O)c1	NGJLOFCOEOHFKQ-YVMONPNESA-N	Preclinical
SN-2	transient receptor potential channel agonist	MCOLN3			Cc1cc(C)c(C2=NO[C@@H]3[C@H]4CC[C@H](C4)[C@H]23)c(C)c1 |&1:9,10,13,15,t:6|	WKLZNTYMDOPBSE-IARIHHJXSA-N	Preclinical
SN-38	topoisomerase inhibitor	TOP1	oncology	colorectal cancer	CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(O)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(O)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(O)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(O)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(O)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(O)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(O)cc12	FJHBVJOVLFPMQE-QFIPXVFZSA-N, FJHBVJOVLFPMQE-QFIPXVFZSA-N, FJHBVJOVLFPMQE-QFIPXVFZSA-N, FJHBVJOVLFPMQE-QFIPXVFZSA-N, FJHBVJOVLFPMQE-QFIPXVFZSA-N, FJHBVJOVLFPMQE-QFIPXVFZSA-N, FJHBVJOVLFPMQE-QFIPXVFZSA-N	Launched
SN-6	sodium/calcium exchange inhibitor				CCOC(=O)[C@H]1CS[C@H](Cc2ccc(OCc3ccc(cc3)[N+]([O-])=O)cc2)N1 |&1:5,&2:8,r|, CCOC(=O)[C@H]1CS[C@H](Cc2ccc(OCc3ccc(cc3)[N+]([O-])=O)cc2)N1 |&1:5,&2:8,r|, CCOC(=O)[C@H]1CS[C@H](Cc2ccc(OCc3ccc(cc3)[N+]([O-])=O)cc2)N1 |&1:5,&2:8,r|	ZVYIJXLMBWCGHP-RTBURBONSA-N, ZVYIJXLMBWCGHP-RTBURBONSA-N, ZVYIJXLMBWCGHP-RTBURBONSA-N	Preclinical
SNAP	nitric oxide donor	PTPN1			CC(=O)N[C@@H](C(O)=O)C(C)(C)S[NH2+][O-] |&1:4,r|, CC(=O)N[C@@H](C(O)=O)C(C)(C)S[NH2+][O-] |&1:4,r|	MLXCQEWOIZBBDM-YFKPBYRVSA-N, MLXCQEWOIZBBDM-YFKPBYRVSA-N	Phase 2
SNAP-5089	adrenergic receptor antagonist	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, CACNA1C, CACNA1D			COC(=O)C1=C(C)NC(C)=C([C@@H]1c1ccc(cc1)[N+]([O-])=O)C(=O)NCCCN1CCC(CC1)(c1ccccc1)c1ccccc1 |&1:11,c:4,9|, COC(=O)C1=C(C)NC(C)=C([C@@H]1c1ccc(cc1)[N+]([O-])=O)C(=O)NCCCN1CCC(CC1)(c1ccccc1)c1ccccc1 |&1:11,c:4,9|	FIIXCJGBCCCOQQ-XIFFEERXSA-N, FIIXCJGBCCCOQQ-XIFFEERXSA-N	Preclinical
SNAP-94847		ADRA1A, DRD2			CC(C)C(=O)Nc1ccc(C)c(c1)C1CCN(Cc2ccc(Oc3ccc(F)c(F)c3)cc2)CC1, CC(C)C(=O)Nc1ccc(C)c(c1)C1CCN(Cc2ccc(Oc3ccc(F)c(F)c3)cc2)CC1, CC(C)C(=O)Nc1ccc(C)c(c1)C1CCN(Cc2ccc(Oc3ccc(F)c(F)c3)cc2)CC1, CC(C)C(=O)Nc1ccc(C)c(c1)C1CCN(Cc2ccc(Oc3ccc(F)c(F)c3)cc2)CC1, CC(C)C(=O)Nc1ccc(C)c(c1)C1CCN(Cc2ccc(Oc3ccc(F)c(F)c3)cc2)CC1	VMLZFUVIKCGATC-UHFFFAOYSA-N, VMLZFUVIKCGATC-UHFFFAOYSA-N, VMLZFUVIKCGATC-UHFFFAOYSA-N, VMLZFUVIKCGATC-UHFFFAOYSA-N, VMLZFUVIKCGATC-UHFFFAOYSA-N	Preclinical
SNC-80		OPRD1			CCN(CC)C(=O)c1ccc(cc1)[C@@H](N1C[C@@H](C)N(CC=C)C[C@@H]1C)c1cccc(OC)c1, CCN(CC)C(=O)c1ccc(cc1)[C@@H](N1C[C@@H](C)N(CC=C)C[C@@H]1C)c1cccc(OC)c1, CCN(CC)C(=O)c1ccc(cc1)[C@@H](N1C[C@@H](C)N(CC=C)C[C@@H]1C)c1cccc(OC)c1	KQWVAUSXZDRQPZ-UMTXDNHDSA-N, KQWVAUSXZDRQPZ-UMTXDNHDSA-N, KQWVAUSXZDRQPZ-UMTXDNHDSA-N	Preclinical
SNG-1153	selective estrogen receptor modulator (SERM)	ESR1			CC(C)=CCc1c(O)cc(O)c2c1oc(c(O)c2=O)-c1ccc(cc1)C(F)(F)F, CC(C)=CCc1c(O)cc(O)c2c1oc(c(O)c2=O)-c1ccc(cc1)C(F)(F)F	OXHMDMVBLQNMGP-UHFFFAOYSA-N, OXHMDMVBLQNMGP-UHFFFAOYSA-N	Preclinical
SNS-314	Aurora kinase inhibitor	AURKA, AURKB, AURKC			Clc1cccc(NC(=O)Nc2ncc(CCNc3ncnc4ccsc34)s2)c1, Clc1cccc(NC(=O)Nc2ncc(CCNc3ncnc4ccsc34)s2)c1, Clc1cccc(NC(=O)Nc2ncc(CCNc3ncnc4ccsc34)s2)c1, Clc1cccc(NC(=O)Nc2ncc(CCNc3ncnc4ccsc34)s2)c1	FAYAUAZLLLJJGH-UHFFFAOYSA-N, FAYAUAZLLLJJGH-UHFFFAOYSA-N, FAYAUAZLLLJJGH-UHFFFAOYSA-N, FAYAUAZLLLJJGH-UHFFFAOYSA-N	Phase 1
SNX-2112	HSP inhibitor				CC1(C)Cc2c(c(nn2-c2ccc(C(N)=O)c(N[C@H]3CC[C@H](O)CC3)c2)C(F)(F)F)C(=O)C1 |r|, CC1(C)Cc2c(c(nn2-c2ccc(C(N)=O)c(N[C@H]3CC[C@H](O)CC3)c2)C(F)(F)F)C(=O)C1 |r|	ZFVRYNYOPQZKDG-MQMHXKEQSA-N, ZFVRYNYOPQZKDG-MQMHXKEQSA-N	Phase 1
SNX-5422	HSP inhibitor	HSP90AA1, HSP90AB1			CC1(C)Cc2c(c(nn2-c2ccc(C(N)=O)c(N[C@H]3CC[C@@H](CC3)OC(=O)CN)c2)C(F)(F)F)C(=O)C1 |r|, CC1(C)Cc2c(c(nn2-c2ccc(C(N)=O)c(N[C@H]3CC[C@@H](CC3)OC(=O)CN)c2)C(F)(F)F)C(=O)C1 |r|, CC1(C)Cc2c(c(nn2-c2ccc(C(N)=O)c(N[C@H]3CC[C@@H](CC3)OC(=O)CN)c2)C(F)(F)F)C(=O)C1 |r|, CC1(C)Cc2c(c(nn2-c2ccc(C(N)=O)c(N[C@H]3CC[C@@H](CC3)OC(=O)CN)c2)C(F)(F)F)C(=O)C1 |r|, CC1(C)Cc2c(c(nn2-c2ccc(C(N)=O)c(N[C@H]3CC[C@@H](CC3)OC(=O)CN)c2)C(F)(F)F)C(=O)C1 |r|	AVDSOVJPJZVBTC-CTYIDZIISA-N, AVDSOVJPJZVBTC-CTYIDZIISA-N, AVDSOVJPJZVBTC-CTYIDZIISA-N, AVDSOVJPJZVBTC-CTYIDZIISA-N, AVDSOVJPJZVBTC-CTYIDZIISA-N	Phase 1/Phase 2
sobetirome	thyroid hormone receptor agonist	THRA, THRB			CC(C)c1cc(Cc2c(C)cc(OCC(O)=O)cc2C)ccc1O, CC(C)c1cc(Cc2c(C)cc(OCC(O)=O)cc2C)ccc1O, CC(C)c1cc(Cc2c(C)cc(OCC(O)=O)cc2C)ccc1O, CC(C)c1cc(Cc2c(C)cc(OCC(O)=O)cc2C)ccc1O, CC(C)c1cc(Cc2c(C)cc(OCC(O)=O)cc2C)ccc1O, CC(C)c1cc(Cc2c(C)cc(OCC(O)=O)cc2C)ccc1O, CC(C)c1cc(Cc2c(C)cc(OCC(O)=O)cc2C)ccc1O	QNAZTOHXCZPOSA-UHFFFAOYSA-N, QNAZTOHXCZPOSA-UHFFFAOYSA-N, QNAZTOHXCZPOSA-UHFFFAOYSA-N, QNAZTOHXCZPOSA-UHFFFAOYSA-N, QNAZTOHXCZPOSA-UHFFFAOYSA-N, QNAZTOHXCZPOSA-UHFFFAOYSA-N, QNAZTOHXCZPOSA-UHFFFAOYSA-N	Phase 1/Phase 2
soblidotin	microtubule inhibitor				[H][C@]1(CCCN1C(=O)C[C@@H](OC)[C@H]([C@@H](C)CC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C)C(C)C)[C@H](OC)[C@@H](C)C(=O)NCCc1ccccc1	DZMVCVHATYROOS-ZBFGKEHZSA-N	Phase 2
sobrepin	mucolytic agent		pulmonary	chest congestion	CC1=CC[C@H](C[C@@H]1O)C(C)(C)O |t:1|	OMDMTHRBGUBUCO-BDAKNGLRSA-N	Launched
sobuzoxane	topoisomerase inhibitor		hematologic malignancy	peripheral T-cell lymphoma (PTCL)	CC(C)COC(=O)OCN1C(=O)CN(CCN2CC(=O)N(COC(=O)OCC(C)C)C(=O)C2)CC1=O	OCOKWVBYZHBHLU-UHFFFAOYSA-N	Launched
sodium-ascorbate					OC[C@H](O)[C@H]1OC(=O)[C@@H](O)[C@@H]1O |a:2,4,&1:8,&2:10|, OC[C@H](O)[C@H]1OC(=O)[C@@H](O)[C@@H]1O |a:2,4,&1:8,&2:10|	SXZYCXMUPBBULW-NEEWWZBLSA-N, SXZYCXMUPBBULW-NEEWWZBLSA-N	Launched
sodium-butyrate	HDAC inhibitor	BCHE, FFAR2, FFAR3, HDAC1, HDAC2, HDAC3, HDAC8			CCCC(O)=O, CCCC(O)=O, CCCC(O)=O	FERIUCNNQQJTOY-UHFFFAOYSA-N, FERIUCNNQQJTOY-UHFFFAOYSA-N, FERIUCNNQQJTOY-UHFFFAOYSA-N	Phase 2
sodium-danshensu					O[C@@H](Cc1ccc(O)c(O)c1)C(O)=O |&1:1|, O[C@@H](Cc1ccc(O)c(O)c1)C(O)=O |&1:1|, O[C@@H](Cc1ccc(O)c(O)c1)C(O)=O |&1:1|	PAFLSMZLRSPALU-QMMMGPOBSA-N, PAFLSMZLRSPALU-QMMMGPOBSA-N, PAFLSMZLRSPALU-QMMMGPOBSA-N	Preclinical
sodium-dodecyl-sulfate		ALB			[Na].CCCCCCCCCCCCOS(O)(=O)=O, [Na].CCCCCCCCCCCCOS(O)(=O)=O	ISYOIFGRKUYTGX-UHFFFAOYSA-N, ISYOIFGRKUYTGX-UHFFFAOYSA-N	Launched
sodium-gluconate					OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O, OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O	RGHNJXZEOKUKBD-SQOUGZDYSA-N, RGHNJXZEOKUKBD-SQOUGZDYSA-N	Launched
sodium-gualenate	antacid		gastroenterology, otolaryngology	peptic ulcer disease (PUD), pharyngitis	CC(C)c1ccc(C)c2c(cc(C)c2c1)S(O)(=O)=O	VIZXMHCBZLGUET-UHFFFAOYSA-N	Launched
sodium-monofluorophosphate		PYGM	dental	cavities	OP(O)(F)=O, OP(O)(F)=O, OP(O)(F)=O	DWYMPOCYEZONEA-UHFFFAOYSA-N, DWYMPOCYEZONEA-UHFFFAOYSA-N, DWYMPOCYEZONEA-UHFFFAOYSA-N	Launched
sodium-nitrite	nitric oxide donor		critical care	poison antidote, cyanide poisoning	[O-][NH2+][O-], [O-][NH2+][O-]	ROODZSDSPAHHIS-UHFFFAOYSA-N, ROODZSDSPAHHIS-UHFFFAOYSA-N	Launched
sodium-nitroprusside	nitric oxide donor		cardiology	hypertension, congestive heart failure	[O-][N+][Fe--](C#N)(C#N)(C#N)(C#N)C#N, [O-][N+][Fe--](C#N)(C#N)(C#N)(C#N)C#N	WTISQLWAPBSCSF-UHFFFAOYSA-N, WTISQLWAPBSCSF-UHFFFAOYSA-N	Launched
sodium-orthovanadate					O[V](O)(O)=O, O[V](O)(O)=O	WQEVDHBJGNOKKO-UHFFFAOYSA-K, WQEVDHBJGNOKKO-UHFFFAOYSA-K	Preclinical
sodium-picosulfate			gastroenterology	constipation	OS(=O)(=O)Oc1ccc(cc1)C(c1ccc(OS(O)(=O)=O)cc1)c1ccccn1, OS(=O)(=O)Oc1ccc(cc1)C(c1ccc(OS(O)(=O)=O)cc1)c1ccccn1	UJIDKYTZIQTXPM-UHFFFAOYSA-N, UJIDKYTZIQTXPM-UHFFFAOYSA-N	Launched
sodium-stibogluconate	tyrosine phosphatase inhibitor	PTPN6	infectious disease	leishmaniasis	[H][C@@]1(O[Sb]2(O)(O[Sb]34(O)O[C@H]([C@@H](O3)[C@]([H])(O4)[C@H](O)CO)C(O)=O)O[C@H]([C@H]1O2)C(O)=O)[C@H](O)CO	RPOBPHCDIPHDQL-XCCFGPONSA-L	Launched
sodium-tanshinone-II-A-sulfonate	potassium channel activator				Cc1c2c(oc1S(O)(=O)=O)-c1ccc3c(CCCC3(C)C)c1C(=O)C2=O	UJCACMLMPLLRGW-UHFFFAOYSA-N	Phase 2
sodium-tetradecyl-sulfate		PROC	dermatology	varicose veins	CCCC[C@@H](CC)CC[C@@H](CC(C)C)OS(O)(=O)=O |&1:4,&2:9|, CCCC[C@@H](CC)CC[C@@H](CC(C)C)OS(O)(=O)=O |&1:4,&2:9|, CCCC[C@@H](CC)CC[C@@H](CC(C)C)OS(O)(=O)=O |&1:4,&2:9|	GROJOWHVXQYQGN-KGLIPLIRSA-N, GROJOWHVXQYQGN-KGLIPLIRSA-N, GROJOWHVXQYQGN-KGLIPLIRSA-N	Launched
sofalcone	mucus protecting agent	CBR1	gastroenterology	peptic ulcer disease (PUD)	CC(C)=CCOc1ccc(\C=C\C(=O)c2ccc(OCC=C(C)C)cc2OCC(O)=O)cc1, CC(C)=CCOc1ccc(\C=C\C(=O)c2ccc(OCC=C(C)C)cc2OCC(O)=O)cc1	GFWRVVCDTLRWPK-KPKJPENVSA-N, GFWRVVCDTLRWPK-KPKJPENVSA-N	Launched
sofosbuvir	HCV inhibitor		infectious disease	hepatitis C, hepatitis C	CC(C)OC(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@@H](n2ccc(=O)[nH]c2=O)[C@](C)(F)[C@@H]1O)Oc1ccccc1, CC(C)OC(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@@H](n2ccc(=O)[nH]c2=O)[C@](C)(F)[C@@H]1O)Oc1ccccc1, CC(C)OC(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@@H](n2ccc(=O)[nH]c2=O)[C@](C)(F)[C@@H]1O)Oc1ccccc1	TTZHDVOVKQGIBA-IQWMDFIBSA-N, TTZHDVOVKQGIBA-IQWMDFIBSA-N, TTZHDVOVKQGIBA-IQWMDFIBSA-N	Launched
sofosbuvir-impurity-m	antiviral				CC(C)OC(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@@H](n2ccc(=O)[nH]c2=O)[C@@](C)(O)[C@@H]1O)Oc1ccccc1	WAKQLZVLNOKKHE-BFQGEBBDSA-N	Preclinical
sograzepide	gastrin inhibitor				CNc1cccc(NC(=O)N[C@@H]2N=C(c3ccccn3)c3ccccc3N(CC(=O)C(C)(C)C)C2=O)c1 |t:12|	YDZYKNJZCVIKPP-VWLOTQADSA-N	Phase 2
solamargine	apoptosis inhibitor				C[C@H]1[C@H]2[C@@H](C[C@H]3[C@H]4CC=C5C[C@@H](CC[C@@]5(C)[C@@H]4CC[C@@]23C)O[C@H]2O[C@@H](CO)[C@@H](O[C@H]3O[C@@H](C)[C@@H](O)[C@@H](O)[C@@H]3O)[C@@H](O)[C@@H]2O[C@H]2O[C@@H](C)[C@@H](O)[C@@H](O)[C@@H]2O)O[C@]11CC[C@@H](C)CN1 |&1:1,&2:2,&3:3,&4:5,&5:6,&6:11,&7:14,&8:16,&9:19,&10:22,&11:24,&12:27,&13:29,&14:31,&15:33,&16:35,&17:37,&18:39,&19:41,&20:43,&21:45,&22:47,&23:49,&24:51,&25:54,&26:57,r,t:8|, C[C@H]1[C@H]2[C@@H](C[C@H]3[C@H]4CC=C5C[C@@H](CC[C@@]5(C)[C@@H]4CC[C@@]23C)O[C@H]2O[C@@H](CO)[C@@H](O[C@H]3O[C@@H](C)[C@@H](O)[C@@H](O)[C@@H]3O)[C@@H](O)[C@@H]2O[C@H]2O[C@@H](C)[C@@H](O)[C@@H](O)[C@@H]2O)O[C@]11CC[C@@H](C)CN1 |&1:1,&2:2,&3:3,&4:5,&5:6,&6:11,&7:14,&8:16,&9:19,&10:22,&11:24,&12:27,&13:29,&14:31,&15:33,&16:35,&17:37,&18:39,&19:41,&20:43,&21:45,&22:47,&23:49,&24:51,&25:54,&26:57,r,t:8|, C[C@H]1[C@H]2[C@@H](C[C@H]3[C@H]4CC=C5C[C@@H](CC[C@@]5(C)[C@@H]4CC[C@@]23C)O[C@H]2O[C@@H](CO)[C@@H](O[C@H]3O[C@@H](C)[C@@H](O)[C@@H](O)[C@@H]3O)[C@@H](O)[C@@H]2O[C@H]2O[C@@H](C)[C@@H](O)[C@@H](O)[C@@H]2O)O[C@]11CC[C@@H](C)CN1 |&1:1,&2:2,&3:3,&4:5,&5:6,&6:11,&7:14,&8:16,&9:19,&10:22,&11:24,&12:27,&13:29,&14:31,&15:33,&16:35,&17:37,&18:39,&19:41,&20:43,&21:45,&22:47,&23:49,&24:51,&25:54,&26:57,r,t:8|, C[C@H]1[C@H]2[C@@H](C[C@H]3[C@H]4CC=C5C[C@@H](CC[C@@]5(C)[C@@H]4CC[C@@]23C)O[C@H]2O[C@@H](CO)[C@@H](O[C@H]3O[C@@H](C)[C@@H](O)[C@@H](O)[C@@H]3O)[C@@H](O)[C@@H]2O[C@H]2O[C@@H](C)[C@@H](O)[C@@H](O)[C@@H]2O)O[C@]11CC[C@@H](C)CN1 |&1:1,&2:2,&3:3,&4:5,&5:6,&6:11,&7:14,&8:16,&9:19,&10:22,&11:24,&12:27,&13:29,&14:31,&15:33,&16:35,&17:37,&18:39,&19:41,&20:43,&21:45,&22:47,&23:49,&24:51,&25:54,&26:57,r,t:8|	MBWUSSKCCUMJHO-OXBNUUDKSA-N, MBWUSSKCCUMJHO-OXBNUUDKSA-N, MBWUSSKCCUMJHO-OXBNUUDKSA-N, MBWUSSKCCUMJHO-OXBNUUDKSA-N	Phase 3
solcitinib	JAK inhibitor	JAK1			CC1(C)CN(C1)C(=O)c1ccc(cc1)-c1cccc2nc(NC(=O)C3CC3)nn12, CC1(C)CN(C1)C(=O)c1ccc(cc1)-c1cccc2nc(NC(=O)C3CC3)nn12	MPYACSQFXVMWNO-UHFFFAOYSA-N, MPYACSQFXVMWNO-UHFFFAOYSA-N	Phase 1
solifenacin-succinate	acetylcholine receptor antagonist	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5	urology	urinary incontinence, urinary frequency	[H][C@@]1(C[N@@]2CC[C@H]1CC2)OC(=O)N1CCc2ccccc2[C@@H]1c1ccccc1	FBOUYBDGKBSUES-VXKWHMMOSA-N	Launched
solithromycin	protein synthesis inhibitor				CC[C@H]1OC(=O)[C@@](C)(F)C(=O)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@@](C)(C[C@@H](C)C(=O)[C@H](C)[C@H]2N(CCCCn3cc(nn3)-c3cccc(N)c3)C(=O)O[C@]12C)OC	IXXFZUPTQVDPPK-ALZZPGSQSA-N	Phase 3
solriamfetol	dopamine reuptake inhibitor		neurology/psychiatry	narcolepsy	N[C@@H](COC(N)=O)Cc1ccccc1	UCTRAOBQFUDCSR-SECBINFHSA-N	Launched
somantadine	antiviral				CC(C)(N)CC12CC3CC(CC(C3)C1)C2	OWKXRDQRMTVCEX-UHFFFAOYSA-N	Phase 1
somatostatin	somatostatin receptor agonist	OPRD1, OPRM1, SSTR1, SSTR2, SSTR3, SSTR4, SSTR5	hematology	hemorrhage	C[C@@H](O)[C@@H]1NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CSSC[C@H](NC(=O)[C@H](CO)NC1=O)C(O)=O)NC(=O)CNC(=O)[C@H](C)N)[C@@H](C)O, C[C@@H](O)[C@@H]1NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CSSC[C@H](NC(=O)[C@H](CO)NC1=O)C(O)=O)NC(=O)CNC(=O)[C@H](C)N)[C@@H](C)O	NHXLMOGPVYXJNR-FMFSXUEQSA-N, NHXLMOGPVYXJNR-FMFSXUEQSA-N	Launched
sonepiprazole	dopamine receptor antagonist				NS(=O)(=O)c1ccc(cc1)N1CCN(CC[C@@H]2OCCc3ccccc23)CC1	WNUQCGWXPNGORO-NRFANRHFSA-N	Phase 2
sonidegib	smoothened receptor antagonist	SMO	oncology	basal cell carcinoma (BCC)	C[C@H]1CN(C[C@@H](C)O1)c1ccc(NC(=O)c2cccc(c2C)-c2ccc(OC(F)(F)F)cc2)cn1, C[C@H]1CN(C[C@@H](C)O1)c1ccc(NC(=O)c2cccc(c2C)-c2ccc(OC(F)(F)F)cc2)cn1, C[C@H]1CN(C[C@@H](C)O1)c1ccc(NC(=O)c2cccc(c2C)-c2ccc(OC(F)(F)F)cc2)cn1, C[C@H]1CN(C[C@@H](C)O1)c1ccc(NC(=O)c2cccc(c2C)-c2ccc(OC(F)(F)F)cc2)cn1	VZZJRYRQSPEMTK-CALCHBBNSA-N, VZZJRYRQSPEMTK-CALCHBBNSA-N, VZZJRYRQSPEMTK-CALCHBBNSA-N, VZZJRYRQSPEMTK-CALCHBBNSA-N	Launched
sophocarpine					O=C1C=CC[C@@H]2[C@H]3CCCN4CCC[C@@H](CN12)[C@@H]34 |c:2|, O=C1C=CC[C@@H]2[C@H]3CCCN4CCC[C@@H](CN12)[C@@H]34 |c:2|, O=C1C=CC[C@@H]2[C@H]3CCCN4CCC[C@@H](CN12)[C@@H]34 |c:2|	AAGFPTSOPGCENQ-JLNYLFASSA-N, AAGFPTSOPGCENQ-JLNYLFASSA-N, AAGFPTSOPGCENQ-JLNYLFASSA-N	Phase 3
sorafenib	FLT3 inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RAF inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor	BRAF, DDR2, FGFR1, FLT1, FLT3, FLT4, KDR, KIT, PDGFRB, RAF1, RET	oncology	renal cell carcinoma (RCC), thyroid cancer, hepatocellular carcinoma (HCC)	CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)cc2)ccn1, CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)cc2)ccn1, CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)cc2)ccn1, CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)cc2)ccn1, CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)cc2)ccn1, CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)cc2)ccn1, CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)cc2)ccn1, CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)cc2)ccn1	MLDQJTXFUGDVEO-UHFFFAOYSA-N, MLDQJTXFUGDVEO-UHFFFAOYSA-N, MLDQJTXFUGDVEO-UHFFFAOYSA-N, MLDQJTXFUGDVEO-UHFFFAOYSA-N, MLDQJTXFUGDVEO-UHFFFAOYSA-N, MLDQJTXFUGDVEO-UHFFFAOYSA-N, MLDQJTXFUGDVEO-UHFFFAOYSA-N, MLDQJTXFUGDVEO-UHFFFAOYSA-N	Launched
soraprazan	proton pump inhibitor				COCCO[C@H]1[C@H](O)[C@H](Nc2c1ccn1c(C)c(C)nc21)c1ccccc1	PWILYDZRJORZDR-MISYRCLQSA-N	Preclinical
sorbic-acid					C\C=C\C=C\C(O)=O	WSWCOQWTEOXDQX-MQQKCMAXSA-N	Launched
sorbinil	aldose reductase inhibitor	AKR1B1			Fc1ccc2OCC[C@]3(NC(=O)NC3=O)c2c1 |&1:8,r|, Fc1ccc2OCC[C@]3(NC(=O)NC3=O)c2c1 |&1:8,r|, Fc1ccc2OCC[C@]3(NC(=O)NC3=O)c2c1 |&1:8,r|, Fc1ccc2OCC[C@]3(NC(=O)NC3=O)c2c1 |&1:8,r|, Fc1ccc2OCC[C@]3(NC(=O)NC3=O)c2c1 |&1:8,r|	LXANPKRCLVQAOG-NSHDSACASA-N, LXANPKRCLVQAOG-NSHDSACASA-N, LXANPKRCLVQAOG-NSHDSACASA-N, LXANPKRCLVQAOG-NSHDSACASA-N, LXANPKRCLVQAOG-NSHDSACASA-N	Phase 3
sorbitan-monostearate					CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O |a:23,26,28,&1:21|, CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O |a:23,26,28,&1:21|	HVUMOYIDDBPOLL-XWVZOOPGSA-N, HVUMOYIDDBPOLL-XWVZOOPGSA-N	Preclinical
sorbitol	mucolytic agent		gastroenterology	constipation	OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO, OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO, OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO, OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO	FBPFZTCFMRRESA-JGWLITMVSA-N, FBPFZTCFMRRESA-JGWLITMVSA-N, FBPFZTCFMRRESA-JGWLITMVSA-N, FBPFZTCFMRRESA-JGWLITMVSA-N	Launched
sotagliflozin	sodium/glucose cotransporter inhibitor	SLC5A1, SLC5A2			CCOc1ccc(Cc2cc(ccc2Cl)[C@@H]2O[C@H](SC)[C@@H](O)[C@H](O)[C@H]2O)cc1, CCOc1ccc(Cc2cc(ccc2Cl)[C@@H]2O[C@H](SC)[C@@H](O)[C@H](O)[C@H]2O)cc1, CCOc1ccc(Cc2cc(ccc2Cl)[C@@H]2O[C@H](SC)[C@@H](O)[C@H](O)[C@H]2O)cc1	QKDRXGFQVGOQKS-CRSSMBPESA-N, QKDRXGFQVGOQKS-CRSSMBPESA-N, QKDRXGFQVGOQKS-CRSSMBPESA-N	Phase 3
sotalol	adrenergic receptor antagonist	ADRB1, ADRB2, KCNH2	cardiology	atrial fibrillation (AF), ventricular arrhythmias	CC(C)NCC(O)c1ccc(NS(C)(=O)=O)cc1, CC(C)NCC(O)c1ccc(NS(C)(=O)=O)cc1, CC(C)NCC(O)c1ccc(NS(C)(=O)=O)cc1, CC(C)NCC(O)c1ccc(NS(C)(=O)=O)cc1	ZBMZVLHSJCTVON-UHFFFAOYSA-N, ZBMZVLHSJCTVON-UHFFFAOYSA-N, ZBMZVLHSJCTVON-UHFFFAOYSA-N, ZBMZVLHSJCTVON-UHFFFAOYSA-N	Launched
sotrastaurin	PKC inhibitor	PRKCA, PRKCB, PRKCD, PRKCE, PRKCH, PRKCQ			CN1CCN(CC1)c1nc(C2=C(C(=O)NC2=O)c2c[nH]c3ccccc23)c2ccccc2n1 |t:11|, CN1CCN(CC1)c1nc(C2=C(C(=O)NC2=O)c2c[nH]c3ccccc23)c2ccccc2n1 |t:11|, CN1CCN(CC1)c1nc(C2=C(C(=O)NC2=O)c2c[nH]c3ccccc23)c2ccccc2n1 |t:11|	OAVGBZOFDPFGPJ-UHFFFAOYSA-N, OAVGBZOFDPFGPJ-UHFFFAOYSA-N, OAVGBZOFDPFGPJ-UHFFFAOYSA-N	Phase 2
SP-100030	NFkB pathway inhibitor	JUN, NFKB1			FC(F)(F)c1cc(NC(=O)c2cnc(Cl)nc2C(F)(F)F)cc(c1)C(F)(F)F, FC(F)(F)c1cc(NC(=O)c2cnc(Cl)nc2C(F)(F)F)cc(c1)C(F)(F)F	GHMKQBWHPQMXSH-UHFFFAOYSA-N, GHMKQBWHPQMXSH-UHFFFAOYSA-N	Preclinical
SP-141	ubiquitin ligase inhibitor	MDM2			COc1ccc2[nH]c3c(nccc3c2c1)-c1cccc2ccccc12, COc1ccc2[nH]c3c(nccc3c2c1)-c1cccc2ccccc12, COc1ccc2[nH]c3c(nccc3c2c1)-c1cccc2ccccc12, COc1ccc2[nH]c3c(nccc3c2c1)-c1cccc2ccccc12, COc1ccc2[nH]c3c(nccc3c2c1)-c1cccc2ccccc12	AABFWJDLCCDJJN-UHFFFAOYSA-N, AABFWJDLCCDJJN-UHFFFAOYSA-N, AABFWJDLCCDJJN-UHFFFAOYSA-N, AABFWJDLCCDJJN-UHFFFAOYSA-N, AABFWJDLCCDJJN-UHFFFAOYSA-N	Preclinical
SP-420					COCCOCCOc1ccc(C2=N[C@](C)(CS2)C(O)=O)c(O)c1 |t:12|, COCCOCCOc1ccc(C2=N[C@](C)(CS2)C(O)=O)c(O)c1 |t:12|	YASYAEVZKXPYIZ-MRXNPFEDSA-N, YASYAEVZKXPYIZ-MRXNPFEDSA-N	Phase 1
spaglumic-acid	glutamate receptor antagonist	GRM3	allergy	allergic conjunctivitis, allergic rhinitis	CC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O, CC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O, CC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O, CC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O	OPVPGKGADVGKTG-BQBZGAKWSA-N, OPVPGKGADVGKTG-BQBZGAKWSA-N, OPVPGKGADVGKTG-BQBZGAKWSA-N, OPVPGKGADVGKTG-BQBZGAKWSA-N	Launched
sparfloxacin	bacterial DNA gyrase inhibitor	TOP2A			C[C@H]1CN(C[C@@H](C)N1)c1c(F)c(N)c2c(c1F)n(cc(C(O)=O)c2=O)C1CC1, C[C@H]1CN(C[C@@H](C)N1)c1c(F)c(N)c2c(c1F)n(cc(C(O)=O)c2=O)C1CC1, C[C@H]1CN(C[C@@H](C)N1)c1c(F)c(N)c2c(c1F)n(cc(C(O)=O)c2=O)C1CC1, C[C@H]1CN(C[C@@H](C)N1)c1c(F)c(N)c2c(c1F)n(cc(C(O)=O)c2=O)C1CC1, C[C@H]1CN(C[C@@H](C)N1)c1c(F)c(N)c2c(c1F)n(cc(C(O)=O)c2=O)C1CC1, C[C@H]1CN(C[C@@H](C)N1)c1c(F)c(N)c2c(c1F)n(cc(C(O)=O)c2=O)C1CC1	DZZWHBIBMUVIIW-DTORHVGOSA-N, DZZWHBIBMUVIIW-DTORHVGOSA-N, DZZWHBIBMUVIIW-DTORHVGOSA-N, DZZWHBIBMUVIIW-DTORHVGOSA-N, DZZWHBIBMUVIIW-DTORHVGOSA-N, DZZWHBIBMUVIIW-DTORHVGOSA-N	Withdrawn
sparfosate	aspartate carbamoyltransferase inhibitor	CA2, CA4			OC(=O)C[C@@H](NC(=O)CP(O)(O)=O)C(O)=O |&1:4|	ZZKNRXZVGOYGJT-GSVOUGTGSA-N	Phase 3
sparsentan	angiotensin receptor antagonist				CCCCC1=NC2(CCCC2)C(=O)N1Cc1ccc(c(COCC)c1)-c1ccccc1S(=O)(=O)Nc1noc(C)c1C |t:4|	WRFHGDPIDHPWIQ-UHFFFAOYSA-N	Phase 3
sparteine-(+)					C1CCN2C[C@H]3C[C@H](CN4CCCC[C@H]34)[C@@H]2C1	SLRCCWJSBJZJBV-TUVASFSCSA-N	Launched
sparteine-(-)					C1CCN2C[C@@H]3C[C@@H](CN4CCCC[C@H]34)[C@@H]2C1	SLRCCWJSBJZJBV-ZQDZILKHSA-N	Launched
sparteine-sulfate					C1CCN2C[C@H]3C[C@@H](CN4CCCC[C@H]34)[C@@H]2C1	SLRCCWJSBJZJBV-NMWPEEMBSA-N	Launched
spautin-1	deubiquitinase inhibitor	USP10, USP13			Fc1ccc(CNc2ncnc3ccc(F)cc23)cc1, Fc1ccc(CNc2ncnc3ccc(F)cc23)cc1, Fc1ccc(CNc2ncnc3ccc(F)cc23)cc1	AWIVHRPYFSSVOG-UHFFFAOYSA-N, AWIVHRPYFSSVOG-UHFFFAOYSA-N, AWIVHRPYFSSVOG-UHFFFAOYSA-N	Preclinical
spectinomycin	bacterial 30S ribosomal subunit inhibitor		pulmonary	airsacculitis, chronic respiratory disease	CN[C@@H]1[C@H](O)[C@H](NC)[C@H]2O[C@]3(O)[C@@H](O[C@H](C)CC3=O)O[C@@H]2[C@H]1O, CN[C@@H]1[C@H](O)[C@H](NC)[C@H]2O[C@]3(O)[C@@H](O[C@H](C)CC3=O)O[C@@H]2[C@H]1O, CN[C@@H]1[C@H](O)[C@H](NC)[C@H]2O[C@]3(O)[C@@H](O[C@H](C)CC3=O)O[C@@H]2[C@H]1O, CN[C@@H]1[C@H](O)[C@H](NC)[C@H]2O[C@]3(O)[C@@H](O[C@H](C)CC3=O)O[C@@H]2[C@H]1O, CN[C@@H]1[C@H](O)[C@H](NC)[C@H]2O[C@]3(O)[C@@H](O[C@H](C)CC3=O)O[C@@H]2[C@H]1O	UNFWWIHTNXNPBV-WXKVUWSESA-N, UNFWWIHTNXNPBV-WXKVUWSESA-N, UNFWWIHTNXNPBV-WXKVUWSESA-N, UNFWWIHTNXNPBV-WXKVUWSESA-N, UNFWWIHTNXNPBV-WXKVUWSESA-N	Launched
spermidine	glutamate receptor modulator	KCNJ4, TXNRD1			NCCCCNCCCN, NCCCCNCCCN	ATHGHQPFGPMSJY-UHFFFAOYSA-N, ATHGHQPFGPMSJY-UHFFFAOYSA-N	Preclinical
spermine		CA14, CA4, CA6, CA9, CASR, GRIN1, GRIN2A, KCNJ4, ODC1, SMOX, SMS, TRPM4, TRPM5			NCCCNCCCCNCCCN	PFNFFQXMRSDOHW-UHFFFAOYSA-N	Preclinical
sphingosylphosphorylcholine	gene expression stimulant	GPR12			CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](N)COP(O)(=O)OCC[N+](C)(C)C |a:15,17,&1:21|	JLVSPVFPBBFMBE-HXSWCURESA-O	Preclinical
spiperone	dopamine receptor antagonist	ADRA1A, ADRA1B, ADRA1D, DRD1, DRD2, DRD3, DRD4, DRD5, HTR1A, HTR1D, HTR2A, HTR2B, HTR2C, HTR6, HTR7	neurology/psychiatry	schizophrenia	Fc1ccc(cc1)C(=O)CCCN1CCC2(CC1)N(CNC2=O)c1ccccc1, Fc1ccc(cc1)C(=O)CCCN1CCC2(CC1)N(CNC2=O)c1ccccc1	DKGZKTPJOSAWFA-UHFFFAOYSA-N, DKGZKTPJOSAWFA-UHFFFAOYSA-N	Launched
spiradoline	opioid receptor agonist	OPRK1			CN([C@H]1CC[C@@]2(CCCO2)C[C@@H]1N1CCCC1)C(=O)Cc1ccc(Cl)c(Cl)c1, CN([C@H]1CC[C@@]2(CCCO2)C[C@@H]1N1CCCC1)C(=O)Cc1ccc(Cl)c(Cl)c1, CN([C@H]1CC[C@@]2(CCCO2)C[C@@H]1N1CCCC1)C(=O)Cc1ccc(Cl)c(Cl)c1, CN([C@H]1CC[C@@]2(CCCO2)C[C@@H]1N1CCCC1)C(=O)Cc1ccc(Cl)c(Cl)c1, CN([C@H]1CC[C@@]2(CCCO2)C[C@@H]1N1CCCC1)C(=O)Cc1ccc(Cl)c(Cl)c1	NYKCGQQJNVPOLU-ONTIZHBOSA-N, NYKCGQQJNVPOLU-ONTIZHBOSA-N, NYKCGQQJNVPOLU-ONTIZHBOSA-N, NYKCGQQJNVPOLU-ONTIZHBOSA-N, NYKCGQQJNVPOLU-ONTIZHBOSA-N	Phase 2
spiramycin	bacterial 50S ribosomal subunit inhibitor		infectious disease	toxoplasmosis, soft tissue infection	CO[C@H]1[C@H](O)CC(=O)O[C@H](C)C\C=C\C=C\[C@H](O[C@H]2CC[C@@H]([C@@H](C)O2)N(C)C)[C@H](C)C[C@H](CC=O)[C@@H]1O[C@@H]1O[C@H](C)[C@@H](O[C@H]2C[C@@](C)(O)[C@@H](O)[C@H](C)O2)[C@@H]([C@H]1O)N(C)C |t:12,14|	ACTOXUHEUCPTEW-VTGPZPQGSA-N	Launched
spirobromin					BrCCC(=O)N1CC[N+]2(CC1)CC[N+]1(CCN(CC1)C(=O)CCBr)CC2	JXEICPOBKSQAIU-UHFFFAOYSA-N	Phase 1
spironolactone	mineralocorticoid receptor antagonist	AR, CACNA1A, CACNA1B, CACNA1C, CACNA1D, CACNA1F, CACNA1G, CACNA1H, CACNA1I, CACNA1S, CACNA2D1, CACNA2D2, CACNA2D3, CACNB1, CACNB2, CACNB3, CACNB4, CACNG1, CYP11B2, NR3C1, NR3C2, PGR, SHBG	endocrinology, cardiology, gastroenterology, rheumatology	hyperaldosteronism, congestive heart failure, hepatic cirrhosis, nephrotic syndrome, hypertension, hypokalemia	CC(=O)S[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@H]2CC[C@@]3(C)[C@@H](CC[C@@]33CCC(=O)O3)[C@H]12 |t:6|, CC(=O)S[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@H]2CC[C@@]3(C)[C@@H](CC[C@@]33CCC(=O)O3)[C@H]12 |t:6|, CC(=O)S[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@H]2CC[C@@]3(C)[C@@H](CC[C@@]33CCC(=O)O3)[C@H]12 |t:6|, CC(=O)S[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@H]2CC[C@@]3(C)[C@@H](CC[C@@]33CCC(=O)O3)[C@H]12 |t:6|, CC(=O)S[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@H]2CC[C@@]3(C)[C@@H](CC[C@@]33CCC(=O)O3)[C@H]12 |t:6|, CC(=O)S[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@H]2CC[C@@]3(C)[C@@H](CC[C@@]33CCC(=O)O3)[C@H]12 |t:6|, CC(=O)S[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@H]2CC[C@@]3(C)[C@@H](CC[C@@]33CCC(=O)O3)[C@H]12 |t:6|	LXMSZDCAJNLERA-ZHYRCANASA-N, LXMSZDCAJNLERA-ZHYRCANASA-N, LXMSZDCAJNLERA-ZHYRCANASA-N, LXMSZDCAJNLERA-ZHYRCANASA-N, LXMSZDCAJNLERA-ZHYRCANASA-N, LXMSZDCAJNLERA-ZHYRCANASA-N, LXMSZDCAJNLERA-ZHYRCANASA-N	Launched
spiroxatrine	serotonin receptor antagonist	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, HTR1A, HTR2B			O=C1NCN(c2ccccc2)C11CCN(C[C@H]2COc3ccccc3O2)CC1 |&1:16,r|, O=C1NCN(c2ccccc2)C11CCN(C[C@H]2COc3ccccc3O2)CC1 |&1:16,r|	JVGBTTIJPBFLTE-SFHVURJKSA-N, JVGBTTIJPBFLTE-SFHVURJKSA-N	Preclinical
spizofurone					CC(=O)c1ccc2OC3(CC3)C(=O)c2c1	SETMGIIITGNLAS-UHFFFAOYSA-N	Withdrawn
splitomycin	SIRT inhibitor	SIRT1			O=C1CCc2c(O1)ccc1ccccc21	ISFPDBUKMJDAJH-UHFFFAOYSA-N	Preclinical
SPP301	endothelin receptor antagonist	EDNRA			COc1ccccc1Oc1c(NS(=O)(=O)c2ccc(C)cn2)nc(nc1OC)-c1ccncc1, COc1ccccc1Oc1c(NS(=O)(=O)c2ccc(C)cn2)nc(nc1OC)-c1ccncc1	YBWLTKFZAOSWSM-UHFFFAOYSA-N, YBWLTKFZAOSWSM-UHFFFAOYSA-N	Phase 3
SPP86	receptor tyrosine protein kinase inhibitor	RET			CC(C)n1nc(C#Cc2ccccc2)c2c(N)ncnc12, CC(C)n1nc(C#Cc2ccccc2)c2c(N)ncnc12	JQOIRTDBHMDWMT-UHFFFAOYSA-N, JQOIRTDBHMDWMT-UHFFFAOYSA-N	Preclinical
SQ-109	bacterial cell wall synthesis inhibitor	FDFT1			CC(C)=CCC\C(C)=C\CNCCNC1[C@H]2C[C@@H]3C[C@@H](C[C@H]1C3)C2 |r|, CC(C)=CCC\C(C)=C\CNCCNC1[C@H]2C[C@@H]3C[C@@H](C[C@H]1C3)C2 |r|	JFIBVDBTCDTBRH-UNRAVDGJSA-N, JFIBVDBTCDTBRH-UNRAVDGJSA-N	Phase 3
SQ-22536	adenylyl cyclase inhibitor	ADCY1			Nc1ncnc2n(cnc12)[C@H]1CCCO1 |&1:10,r|, Nc1ncnc2n(cnc12)[C@H]1CCCO1 |&1:10,r|	UKHMZCMKHPHFOT-ZCFIWIBFSA-N, UKHMZCMKHPHFOT-ZCFIWIBFSA-N	Preclinical
squalamine	antiviral				[H][C@@]1(CC[C@@]2([H])[C@]3([H])[C@H](O)C[C@@]4([H])C[C@H](CC[C@]4(C)[C@@]3([H])CC[C@]12C)NCCCNCCCCN)[C@H](C)CC[C@@H](OS(O)(=O)=O)C(C)C	UIRKNQLZZXALBI-MSVGPLKSSA-N	Phase 3
squaric-acid-dibutyl-ester	oxidative stress inducer				CCCCOc1c(OCCCC)c(=O)c1=O	XBRWELTXMQSEIN-UHFFFAOYSA-N	Preclinical
SR-1078	retinoid receptor agonist	RORA, RORC			OC(c1ccc(NC(=O)c2ccc(cc2)C(F)(F)F)cc1)(C(F)(F)F)C(F)(F)F, OC(c1ccc(NC(=O)c2ccc(cc2)C(F)(F)F)cc1)(C(F)(F)F)C(F)(F)F	DUXWIYXHHGNUJU-UHFFFAOYSA-N, DUXWIYXHHGNUJU-UHFFFAOYSA-N	Preclinical
SR-11302					C\C(\C=C\C=C(\C=C\C1=C(C)CCCC1(C)C)/c1ccc(C)cc1)=C/C(O)=O |c:8|, C\C(\C=C\C=C(\C=C\C1=C(C)CCCC1(C)C)/c1ccc(C)cc1)=C/C(O)=O |c:8|	RQANARBNMTXCDM-DKOHIBGUSA-N, RQANARBNMTXCDM-DKOHIBGUSA-N	Preclinical
SR-140333	neurokinin receptor antagonist	TACR1			CC(C)Oc1cccc(CC(=O)N2CCC[C@@](CC[N+]34CCC(CC3)(CC4)c3ccccc3)(C2)c2ccc(Cl)c(Cl)c2)c1, CC(C)Oc1cccc(CC(=O)N2CCC[C@@](CC[N+]34CCC(CC3)(CC4)c3ccccc3)(C2)c2ccc(Cl)c(Cl)c2)c1, CC(C)Oc1cccc(CC(=O)N2CCC[C@@](CC[N+]34CCC(CC3)(CC4)c3ccccc3)(C2)c2ccc(Cl)c(Cl)c2)c1	RPDFDSQFBCJTDY-GAQXSTBRSA-N, RPDFDSQFBCJTDY-GAQXSTBRSA-N, RPDFDSQFBCJTDY-GAQXSTBRSA-N	Phase 2
SR-1664	PPAR receptor ligand	PPARG			C[C@H](NC(=O)c1ccc2n(Cc3ccc(cc3)-c3ccccc3C(O)=O)c(C)c(C)c2c1)c1ccc(cc1)[N+]([O-])=O, C[C@H](NC(=O)c1ccc2n(Cc3ccc(cc3)-c3ccccc3C(O)=O)c(C)c(C)c2c1)c1ccc(cc1)[N+]([O-])=O	IIJDFXNUWZTHIM-NRFANRHFSA-N, IIJDFXNUWZTHIM-NRFANRHFSA-N	Preclinical
SR-2211	retinoid receptor inverse agonist	RORC			OC(c1ccc(c(F)c1)-c1ccc(CN2CCN(Cc3ccncc3)CC2)cc1)(C(F)(F)F)C(F)(F)F, OC(c1ccc(c(F)c1)-c1ccc(CN2CCN(Cc3ccncc3)CC2)cc1)(C(F)(F)F)C(F)(F)F, OC(c1ccc(c(F)c1)-c1ccc(CN2CCN(Cc3ccncc3)CC2)cc1)(C(F)(F)F)C(F)(F)F	KVHKWAZUPPBMLL-UHFFFAOYSA-N, KVHKWAZUPPBMLL-UHFFFAOYSA-N, KVHKWAZUPPBMLL-UHFFFAOYSA-N	Preclinical
SR-2640	leukotriene receptor antagonist	CYSLTR1			OC(=O)c1ccccc1Nc1cccc(OCc2ccc3ccccc3n2)c1, OC(=O)c1ccccc1Nc1cccc(OCc2ccc3ccccc3n2)c1, OC(=O)c1ccccc1Nc1cccc(OCc2ccc3ccccc3n2)c1	LMPZHLXYBWGGNT-UHFFFAOYSA-N, LMPZHLXYBWGGNT-UHFFFAOYSA-N, LMPZHLXYBWGGNT-UHFFFAOYSA-N	Phase 2
SR-27897	CCK receptor antagonist	CCKAR			OC(=O)Cn1c(cc2ccccc12)C(=O)Nc1nc(cs1)-c1ccccc1Cl, OC(=O)Cn1c(cc2ccccc12)C(=O)Nc1nc(cs1)-c1ccccc1Cl, OC(=O)Cn1c(cc2ccccc12)C(=O)Nc1nc(cs1)-c1ccccc1Cl, OC(=O)Cn1c(cc2ccccc12)C(=O)Nc1nc(cs1)-c1ccccc1Cl	ILNRQFBVVQUOLP-UHFFFAOYSA-N, ILNRQFBVVQUOLP-UHFFFAOYSA-N, ILNRQFBVVQUOLP-UHFFFAOYSA-N, ILNRQFBVVQUOLP-UHFFFAOYSA-N	Phase 2
SR-3306	JNK inhibitor	MAPK10, MAPK8, MAPK9			Cc1ccc(cn1)-c1ncn(n1)-c1ccc(Nc2nccc(n2)-c2cccc(c2)N2CCOCC2)cc1, Cc1ccc(cn1)-c1ncn(n1)-c1ccc(Nc2nccc(n2)-c2cccc(c2)N2CCOCC2)cc1, Cc1ccc(cn1)-c1ncn(n1)-c1ccc(Nc2nccc(n2)-c2cccc(c2)N2CCOCC2)cc1, Cc1ccc(cn1)-c1ncn(n1)-c1ccc(Nc2nccc(n2)-c2cccc(c2)N2CCOCC2)cc1	QDMXVKKPYBGIAS-UHFFFAOYSA-N, QDMXVKKPYBGIAS-UHFFFAOYSA-N, QDMXVKKPYBGIAS-UHFFFAOYSA-N, QDMXVKKPYBGIAS-UHFFFAOYSA-N	Preclinical
SR-33805	calcium channel blocker				COc1ccc(CCN(C)CCCOc2ccc(cc2)S(=O)(=O)c2c(C(C)C)c3ccccc3n2C)cc1OC, COc1ccc(CCN(C)CCCOc2ccc(cc2)S(=O)(=O)c2c(C(C)C)c3ccccc3n2C)cc1OC, COc1ccc(CCN(C)CCCOc2ccc(cc2)S(=O)(=O)c2c(C(C)C)c3ccccc3n2C)cc1OC, COc1ccc(CCN(C)CCCOc2ccc(cc2)S(=O)(=O)c2c(C(C)C)c3ccccc3n2C)cc1OC, COc1ccc(CCN(C)CCCOc2ccc(cc2)S(=O)(=O)c2c(C(C)C)c3ccccc3n2C)cc1OC	GCVFQRRBTCHIPK-UHFFFAOYSA-N, GCVFQRRBTCHIPK-UHFFFAOYSA-N, GCVFQRRBTCHIPK-UHFFFAOYSA-N, GCVFQRRBTCHIPK-UHFFFAOYSA-N, GCVFQRRBTCHIPK-UHFFFAOYSA-N	Phase 1
SR-3576	JNK inhibitor	MAPK10			COc1cc(NC(=O)c2cccc(c2)-n2cc(NC(=O)Nc3cccc(C)c3)cn2)cc(OC)c1OC, COc1cc(NC(=O)c2cccc(c2)-n2cc(NC(=O)Nc3cccc(C)c3)cn2)cc(OC)c1OC, COc1cc(NC(=O)c2cccc(c2)-n2cc(NC(=O)Nc3cccc(C)c3)cn2)cc(OC)c1OC	MTFAYLZZDJGFGV-UHFFFAOYSA-N, MTFAYLZZDJGFGV-UHFFFAOYSA-N, MTFAYLZZDJGFGV-UHFFFAOYSA-N	Preclinical
SR-3677	rho associated kinase inhibitor	ROCK2			CN(C)CCOc1cc(ccc1NC(=O)[C@H]1COc2ccccc2O1)-c1cn[nH]c1 |&1:15|, CN(C)CCOc1cc(ccc1NC(=O)[C@H]1COc2ccccc2O1)-c1cn[nH]c1 |&1:15|	OQWZIAVXCYIZNN-OAQYLSRUSA-N, OQWZIAVXCYIZNN-OAQYLSRUSA-N	Preclinical
SR-57227A	serotonin receptor agonist	HTR3A			NC1CCN(CC1)c1cccc(Cl)n1, NC1CCN(CC1)c1cccc(Cl)n1	WPVVMKYQOMJPIN-UHFFFAOYSA-N, WPVVMKYQOMJPIN-UHFFFAOYSA-N	Phase 2
SR-59230A	adrenergic receptor antagonist	ADRB1, ADRB2, ADRB3			CCc1ccccc1OC[C@@H](O)CN[C@H]1CCCc2ccccc12, CCc1ccccc1OC[C@@H](O)CN[C@H]1CCCc2ccccc12, CCc1ccccc1OC[C@@H](O)CN[C@H]1CCCc2ccccc12, CCc1ccccc1OC[C@@H](O)CN[C@H]1CCCc2ccccc12	VFDHMSXXELYMRW-ICSRJNTNSA-N, VFDHMSXXELYMRW-ICSRJNTNSA-N, VFDHMSXXELYMRW-ICSRJNTNSA-N, VFDHMSXXELYMRW-ICSRJNTNSA-N	Preclinical
SR-95639A	acetylcholine receptor agonist	CHRM1			C(CN1CCOCC1)Nc1cc2CCCc3ccccc3-c2nn1, C(CN1CCOCC1)Nc1cc2CCCc3ccccc3-c2nn1	RUTYAHFAKWVMNH-UHFFFAOYSA-N, RUTYAHFAKWVMNH-UHFFFAOYSA-N	Preclinical
SRC-kinase-inhibitor-I	SRC inhibitor	CSK, LCK, RIPK2			COc1cc2ncnc(Nc3ccc(Oc4ccccc4)cc3)c2cc1OC, COc1cc2ncnc(Nc3ccc(Oc4ccccc4)cc3)c2cc1OC, COc1cc2ncnc(Nc3ccc(Oc4ccccc4)cc3)c2cc1OC	DMWVGXGXHPOEPT-UHFFFAOYSA-N, DMWVGXGXHPOEPT-UHFFFAOYSA-N, DMWVGXGXHPOEPT-UHFFFAOYSA-N	Preclinical
SRPIN340	serine arginine protein kinase inhibitor	SRPK1, SRPK2			FC(F)(F)c1ccc(N2CCCCC2)c(NC(=O)c2ccncc2)c1, FC(F)(F)c1ccc(N2CCCCC2)c(NC(=O)c2ccncc2)c1, FC(F)(F)c1ccc(N2CCCCC2)c(NC(=O)c2ccncc2)c1, FC(F)(F)c1ccc(N2CCCCC2)c(NC(=O)c2ccncc2)c1	DWFGGOFPIISJIT-UHFFFAOYSA-N, DWFGGOFPIISJIT-UHFFFAOYSA-N, DWFGGOFPIISJIT-UHFFFAOYSA-N, DWFGGOFPIISJIT-UHFFFAOYSA-N	Preclinical
SRT1720	SIRT activator	SIRT1			O=C(Nc1ccccc1-c1cn2c(CN3CCNCC3)csc2n1)c1cnc2ccccc2n1, O=C(Nc1ccccc1-c1cn2c(CN3CCNCC3)csc2n1)c1cnc2ccccc2n1, O=C(Nc1ccccc1-c1cn2c(CN3CCNCC3)csc2n1)c1cnc2ccccc2n1, O=C(Nc1ccccc1-c1cn2c(CN3CCNCC3)csc2n1)c1cnc2ccccc2n1, O=C(Nc1ccccc1-c1cn2c(CN3CCNCC3)csc2n1)c1cnc2ccccc2n1, O=C(Nc1ccccc1-c1cn2c(CN3CCNCC3)csc2n1)c1cnc2ccccc2n1	IASPBORHOMBZMY-UHFFFAOYSA-N, IASPBORHOMBZMY-UHFFFAOYSA-N, IASPBORHOMBZMY-UHFFFAOYSA-N, IASPBORHOMBZMY-UHFFFAOYSA-N, IASPBORHOMBZMY-UHFFFAOYSA-N, IASPBORHOMBZMY-UHFFFAOYSA-N	Preclinical
SRT2104	SIRT activator	SIRT1			Cc1nc(sc1C(=O)Nc1ccccc1-c1cn2c(CN3CCOCC3)csc2n1)-c1cccnc1, Cc1nc(sc1C(=O)Nc1ccccc1-c1cn2c(CN3CCOCC3)csc2n1)-c1cccnc1	LAMQVIQMVKWXOC-UHFFFAOYSA-N, LAMQVIQMVKWXOC-UHFFFAOYSA-N	Phase 2
SRT3190	CC chemokine receptor antagonist				C[C@H](Nc1cc(NS(=O)(=O)N2CCC2)nc(SCc2cccc(F)c2F)n1)[C@@H](O)CO, C[C@H](Nc1cc(NS(=O)(=O)N2CCC2)nc(SCc2cccc(F)c2F)n1)[C@@H](O)CO, C[C@H](Nc1cc(NS(=O)(=O)N2CCC2)nc(SCc2cccc(F)c2F)n1)[C@@H](O)CO	QVKPEMXUBULFBM-FZMZJTMJSA-N, QVKPEMXUBULFBM-FZMZJTMJSA-N, QVKPEMXUBULFBM-FZMZJTMJSA-N	Preclinical
SSR128129E					COc1c(C)c(C(=O)c2ccc(N)c(c2)C(O)=O)n2ccccc12, COc1c(C)c(C(=O)c2ccc(N)c(c2)C(O)=O)n2ccccc12	SNMCWIDCSPHZRD-UHFFFAOYSA-N, SNMCWIDCSPHZRD-UHFFFAOYSA-N	Preclinical
SSR180711	acetylcholine receptor agonist	CHRNA7			Brc1ccc(OC(=O)N2CC[N@@]3CC[C@H]2CC3)cc1 |r|	RXLOZRCLQMJJLC-UHFFFAOYSA-N	Phase 2
SSR240612	bradykinin receptor antagonist				COc1ccc2cc(ccc2c1)S(=O)(=O)N[C@H](CC(=O)N[C@H](Cc1ccc(CN2[C@@H](C)CCC[C@H]2C)cc1)C(=O)N(C)C(C)C)c1ccc2OCOc2c1	QGWIQIAWOCJRPI-WSCVWKGISA-N	Preclinical
ST-1535	adenosine receptor antagonist				CCCCc1nc(N)c2nc(-n3nccn3)n(C)c2n1	CYYQMAWUIRPCNW-UHFFFAOYSA-N	Preclinical
ST-1859	antiamyloidogenic agent				Oc1ccc2ccccc2c1Cc1c(O)ccc2ccccc12, Oc1ccc2ccccc2c1Cc1c(O)ccc2ccccc12, Oc1ccc2ccccc2c1Cc1c(O)ccc2ccccc12, Oc1ccc2ccccc2c1Cc1c(O)ccc2ccccc12	ZPANWZBSGMDWON-UHFFFAOYSA-N, ZPANWZBSGMDWON-UHFFFAOYSA-N, ZPANWZBSGMDWON-UHFFFAOYSA-N, ZPANWZBSGMDWON-UHFFFAOYSA-N	Phase 1
ST-2825	myeloid differentiation primary response inhibitor	MYD88			NC(=O)[C@H]1CCS[C@@H]2C[C@]3(CCCN3C(=O)Cc3ccc(NC(=O)COc4ccc(Cl)cc4Cl)cc3)C(=O)N12	HBLHLJXFIPCEMW-ZJSFPPFMSA-N	Preclinical
ST-91	adrenergic receptor agonist				CCc1cccc(CC)c1NC1=NCCN1 |t:12|, CCc1cccc(CC)c1NC1=NCCN1 |t:12|, CCc1cccc(CC)c1NC1=NCCN1 |t:12|, CCc1cccc(CC)c1NC1=NCCN1 |t:12|	IALHTUPVRAQZFI-UHFFFAOYSA-N, IALHTUPVRAQZFI-UHFFFAOYSA-N, IALHTUPVRAQZFI-UHFFFAOYSA-N, IALHTUPVRAQZFI-UHFFFAOYSA-N	Preclinical
STA-5326	interleukin synthesis inhibitor	IL12A			Cc1cccc(\C=N\Nc2cc(nc(OCCc3ccccn3)n2)N2CCOCC2)c1, Cc1cccc(\C=N\Nc2cc(nc(OCCc3ccccn3)n2)N2CCOCC2)c1, Cc1cccc(\C=N\Nc2cc(nc(OCCc3ccccn3)n2)N2CCOCC2)c1, Cc1cccc(\C=N\Nc2cc(nc(OCCc3ccccn3)n2)N2CCOCC2)c1, Cc1cccc(\C=N\Nc2cc(nc(OCCc3ccccn3)n2)N2CCOCC2)c1, Cc1cccc(\C=N\Nc2cc(nc(OCCc3ccccn3)n2)N2CCOCC2)c1, Cc1cccc(\C=N\Nc2cc(nc(OCCc3ccccn3)n2)N2CCOCC2)c1	HSKAZIJJKRAJAV-KOEQRZSOSA-N, HSKAZIJJKRAJAV-KOEQRZSOSA-N, HSKAZIJJKRAJAV-KOEQRZSOSA-N, HSKAZIJJKRAJAV-KOEQRZSOSA-N, InChI=1S/C23H26N6O2/c1-18-5-4-6-19(15-18)17-25-28-21-16-22(29-10-13-30-14-11-29)27-23(26-21)31-12-8-20-7-2-3-9-24-20/h2-7,9,15-17H,8,10-14H2,1H3,(H,26,27,28)/b25-17+, InChI=1S/C23H26N6O2/c1-18-5-4-6-19(15-18)17-25-28-21-16-22(29-10-13-30-14-11-29)27-23(26-21)31-12-8-20-7-2-3-9-24-20/h2-7,9,15-17H,8,10-14H2,1H3,(H,26,27,28)/b25-17+, InChI=1S/C23H26N6O2/c1-18-5-4-6-19(15-18)17-25-28-21-16-22(29-10-13-30-14-11-29)27-23(26-21)31-12-8-20-7-2-3-9-24-20/h2-7,9,15-17H,8,10-14H2,1H3,(H,26,27,28)/b25-17+	Phase 2
statil	aldose reductase inhibitor				OC(=O)Cc1nn(Cc2ccc(Br)cc2F)c(=O)c2ccccc12	LKBFFDOJUKLQNY-UHFFFAOYSA-N	Preclinical
stattic					[O-][N+](=O)c1ccc2C=CS(=O)(=O)c2c1 |c:7|	ZRRGOUHITGRLBA-UHFFFAOYSA-N	Preclinical
STAT3-inhibitor-VI	STAT inhibitor	STAT3			Cc1ccc(cc1)S(=O)(=O)OCC(=O)Nc1ccc(C(O)=O)c(O)c1, Cc1ccc(cc1)S(=O)(=O)OCC(=O)Nc1ccc(C(O)=O)c(O)c1, Cc1ccc(cc1)S(=O)(=O)OCC(=O)Nc1ccc(C(O)=O)c(O)c1, Cc1ccc(cc1)S(=O)(=O)OCC(=O)Nc1ccc(C(O)=O)c(O)c1, Cc1ccc(cc1)S(=O)(=O)OCC(=O)Nc1ccc(C(O)=O)c(O)c1, Cc1ccc(cc1)S(=O)(=O)OCC(=O)Nc1ccc(C(O)=O)c(O)c1	HWNUSGNZBAISFM-UHFFFAOYSA-N, HWNUSGNZBAISFM-UHFFFAOYSA-N, HWNUSGNZBAISFM-UHFFFAOYSA-N, HWNUSGNZBAISFM-UHFFFAOYSA-N, HWNUSGNZBAISFM-UHFFFAOYSA-N, HWNUSGNZBAISFM-UHFFFAOYSA-N	Preclinical
stavudine	DNA directed DNA polymerase inhibitor, nucleoside reverse transcriptase inhibitor		infectious disease	human immunodeficiency virus (HIV-1)	Cc1cn([C@@H]2O[C@H](CO)C=C2)c(=O)[nH]c1=O |c:9|, Cc1cn([C@@H]2O[C@H](CO)C=C2)c(=O)[nH]c1=O |c:9|, Cc1cn([C@@H]2O[C@H](CO)C=C2)c(=O)[nH]c1=O |c:9|, Cc1cn([C@@H]2O[C@H](CO)C=C2)c(=O)[nH]c1=O |c:9|, Cc1cn([C@@H]2O[C@H](CO)C=C2)c(=O)[nH]c1=O |c:9|, Cc1cn([C@@H]2O[C@H](CO)C=C2)c(=O)[nH]c1=O |c:9|	XNKLLVCARDGLGL-JGVFFNPUSA-N, XNKLLVCARDGLGL-JGVFFNPUSA-N, XNKLLVCARDGLGL-JGVFFNPUSA-N, XNKLLVCARDGLGL-JGVFFNPUSA-N, XNKLLVCARDGLGL-JGVFFNPUSA-N, XNKLLVCARDGLGL-JGVFFNPUSA-N	Launched
stemregenin-1	aryl hydrocarbon receptor antagonist	AHR			CC(C)n1cnc2c(NCCc3ccc(O)cc3)nc(nc12)-c1csc2ccccc12, CC(C)n1cnc2c(NCCc3ccc(O)cc3)nc(nc12)-c1csc2ccccc12, CC(C)n1cnc2c(NCCc3ccc(O)cc3)nc(nc12)-c1csc2ccccc12	BGFHMYJZJZLMHW-UHFFFAOYSA-N, BGFHMYJZJZLMHW-UHFFFAOYSA-N, BGFHMYJZJZLMHW-UHFFFAOYSA-N	Preclinical
stepronin	mucolytic agent				C[C@@H](SC(=O)c1cccs1)C(=O)NCC(O)=O |&1:1,r|	JNYSEDHQJCOWQU-ZCFIWIBFSA-N	Launched
stetaderm					CC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3[C@H](O)C[C@]12C |t:10|, CC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3[C@H](O)C[C@]12C |t:10|	BFZHCUBIASXHPK-QJSKAATBSA-N, BFZHCUBIASXHPK-QJSKAATBSA-N	Launched
STF-083010	serine/threonine kinase inhibitor	ERN1			Oc1ccc2ccccc2c1\C=N\S(=O)(=O)c1cccs1, Oc1ccc2ccccc2c1\C=N\S(=O)(=O)c1cccs1	TVIVJHZHPKNDAQ-MHWRWJLKSA-N, TVIVJHZHPKNDAQ-MHWRWJLKSA-N	Preclinical
STF-118804	NAMPT inhibitor	NAMPT			Cc1oc(nc1CS(=O)(=O)c1ccc(C)cc1)-c1ccc(cc1)C(=O)NCc1cccnc1, Cc1oc(nc1CS(=O)(=O)c1ccc(C)cc1)-c1ccc(cc1)C(=O)NCc1cccnc1, Cc1oc(nc1CS(=O)(=O)c1ccc(C)cc1)-c1ccc(cc1)C(=O)NCc1cccnc1, Cc1oc(nc1CS(=O)(=O)c1ccc(C)cc1)-c1ccc(cc1)C(=O)NCc1cccnc1, Cc1oc(nc1CS(=O)(=O)c1ccc(C)cc1)-c1ccc(cc1)C(=O)NCc1cccnc1, Cc1oc(nc1CS(=O)(=O)c1ccc(C)cc1)-c1ccc(cc1)C(=O)NCc1cccnc1	DLFCEZOMHBPDGI-UHFFFAOYSA-N, DLFCEZOMHBPDGI-UHFFFAOYSA-N, DLFCEZOMHBPDGI-UHFFFAOYSA-N, DLFCEZOMHBPDGI-UHFFFAOYSA-N, DLFCEZOMHBPDGI-UHFFFAOYSA-N, DLFCEZOMHBPDGI-UHFFFAOYSA-N	Preclinical
STF-31	NAMPT inhibitor	NAMPT, SLC2A1			CC(C)(C)c1ccc(cc1)S(=O)(=O)NCc1ccc(cc1)C(=O)Nc1cccnc1, CC(C)(C)c1ccc(cc1)S(=O)(=O)NCc1ccc(cc1)C(=O)Nc1cccnc1, CC(C)(C)c1ccc(cc1)S(=O)(=O)NCc1ccc(cc1)C(=O)Nc1cccnc1, CC(C)(C)c1ccc(cc1)S(=O)(=O)NCc1ccc(cc1)C(=O)Nc1cccnc1, CC(C)(C)c1ccc(cc1)S(=O)(=O)NCc1ccc(cc1)C(=O)Nc1cccnc1, CC(C)(C)c1ccc(cc1)S(=O)(=O)NCc1ccc(cc1)C(=O)Nc1cccnc1, CC(C)(C)c1ccc(cc1)S(=O)(=O)NCc1ccc(cc1)C(=O)Nc1cccnc1, CC(C)(C)c1ccc(cc1)S(=O)(=O)NCc1ccc(cc1)C(=O)Nc1cccnc1, CC(C)(C)c1ccc(cc1)S(=O)(=O)NCc1ccc(cc1)C(=O)Nc1cccnc1, CC(C)(C)c1ccc(cc1)S(=O)(=O)NCc1ccc(cc1)C(=O)Nc1cccnc1, CC(C)(C)c1ccc(cc1)S(=O)(=O)NCc1ccc(cc1)C(=O)Nc1cccnc1, CC(C)(C)c1ccc(cc1)S(=O)(=O)NCc1ccc(cc1)C(=O)Nc1cccnc1	NGQPRVWTFNBUHA-UHFFFAOYSA-N, NGQPRVWTFNBUHA-UHFFFAOYSA-N, NGQPRVWTFNBUHA-UHFFFAOYSA-N, NGQPRVWTFNBUHA-UHFFFAOYSA-N, NGQPRVWTFNBUHA-UHFFFAOYSA-N, NGQPRVWTFNBUHA-UHFFFAOYSA-N, NGQPRVWTFNBUHA-UHFFFAOYSA-N, NGQPRVWTFNBUHA-UHFFFAOYSA-N, NGQPRVWTFNBUHA-UHFFFAOYSA-N, NGQPRVWTFNBUHA-UHFFFAOYSA-N, NGQPRVWTFNBUHA-UHFFFAOYSA-N, NGQPRVWTFNBUHA-UHFFFAOYSA-N	Preclinical
STF-62247	autophagy inducer				Cc1cccc(Nc2nc(cs2)-c2ccncc2)c1, Cc1cccc(Nc2nc(cs2)-c2ccncc2)c1	KATNUHQNJGNLPW-UHFFFAOYSA-N, KATNUHQNJGNLPW-UHFFFAOYSA-N	Preclinical
stigmasterol					CC[C@H](\C=C\[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)C |t:13|, CC[C@H](\C=C\[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)C |t:13|	HCXVJBMSMIARIN-PHZDYDNGSA-N, HCXVJBMSMIARIN-PHZDYDNGSA-N	Preclinical
stiripentol	GABA uptake inhibitor	GABRA3	neurology/psychiatry	epilepsy	CC(C)(C)[C@@H](O)\C=C\c1ccc2OCOc2c1 |&1:4,r|, CC(C)(C)[C@@H](O)\C=C\c1ccc2OCOc2c1 |&1:4,r|	IBLNKMRFIPWSOY-IYNGYCSASA-N, IBLNKMRFIPWSOY-IYNGYCSASA-N	Launched
stobadine	adrenergic receptor antagonist	ADRA1A			CN1CC[C@H]2Nc3ccc(C)cc3[C@H]2C1	CYJQCYXRNNCURD-DGCLKSJQSA-N	Phase 2
streptomycin	bacterial 30S ribosomal subunit inhibitor		infectious disease	tuberculosis	CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@H]1[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](NC(N)=N)[C@@H](O)[C@@H]2NC(N)=N)O[C@@H](C)[C@]1(O)C=O, CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@H]1[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](NC(N)=N)[C@@H](O)[C@@H]2NC(N)=N)O[C@@H](C)[C@]1(O)C=O, CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@H]1[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](NC(N)=N)[C@@H](O)[C@@H]2NC(N)=N)O[C@@H](C)[C@]1(O)C=O	UCSJYZPVAKXKNQ-HZYVHMACSA-N, UCSJYZPVAKXKNQ-HZYVHMACSA-N, UCSJYZPVAKXKNQ-HZYVHMACSA-N	Launched
streptozotocin	DNA alkylating agent		oncology	pancreatic cancer	CN([NH2+][O-])C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O, CN([NH2+][O-])C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O, CN([NH2+][O-])C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O, CN([NH2+][O-])C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O, CN([NH2+][O-])C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O, CN([NH2+][O-])C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O	BKWHZSFINQBEQH-GKHCUFPYSA-N, BKWHZSFINQBEQH-GKHCUFPYSA-N, BKWHZSFINQBEQH-GKHCUFPYSA-N, BKWHZSFINQBEQH-GKHCUFPYSA-N, BKWHZSFINQBEQH-GKHCUFPYSA-N, BKWHZSFINQBEQH-GKHCUFPYSA-N	Launched
strontium-ranelate	bone formation stimulant, bone resorption inhibitor	CASR	orthopedics, rheumatology	osteoporosis, osteoarthritis	OC1=CN(C=C(O)O[Sr]O1)c1sc2c(CC(=O)O[Sr]OC2=O)c1C#N, OC1=CN(C=C(O)O[Sr]O1)c1sc2c(CC(=O)O[Sr]OC2=O)c1C#N, OC1=CN(C=C(O)O[Sr]O1)c1sc2c(CC(=O)O[Sr]OC2=O)c1C#N, OC1=CN(C=C(O)O[Sr]O1)c1sc2c(CC(=O)O[Sr]OC2=O)c1C#N	TWHPPRXFYWSOQF-UHFFFAOYSA-J, TWHPPRXFYWSOQF-UHFFFAOYSA-J, TWHPPRXFYWSOQF-UHFFFAOYSA-J, TWHPPRXFYWSOQF-UHFFFAOYSA-J	Launched
strychnine	acetylcholine receptor antagonist	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, CHRNA10, CHRNA9, GLRA1, GLRA2, GLRA3, GLRB			O=C1C[C@@H]2OCC=C3CN4CC[C@@]56[C@@H]4C[C@@H]3[C@@H]2[C@@H]5N1c1ccccc61 |t:6|	QMGVPVSNSZLJIA-FVWCLLPLSA-N	Preclinical
substance-P	neurokinin receptor antagonist	TACR1, TACR2, TACR3			CSCC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCN)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CCCNC(N)=N)C(N)=O, CSCC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCN)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CCCNC(N)=N)C(N)=O, CSCC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCN)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CCCNC(N)=N)C(N)=O, CSCC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCN)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CCCNC(N)=N)C(N)=O	ADNPLDHMAVUMIW-CUZNLEPHSA-N, ADNPLDHMAVUMIW-CUZNLEPHSA-N, ADNPLDHMAVUMIW-CUZNLEPHSA-N, ADNPLDHMAVUMIW-CUZNLEPHSA-N	Phase 1
succinic-acid		ALDH5A1, ASPH, BBOX1, HSD17B6, OXCT1, OXCT2, P3H1, P3H2, P3H3, P4HA1, P4HA2, PLOD1, PLOD3, SDHA, SDHB, SDHC, SDHD, SLC13A1, SLC13A2, SLC13A3, SLC25A10, SUCLA2, SUCLG1, SUCLG2, SUCNR1, TMLHE			OC(=O)CCC(O)=O	KDYFGRWQOYBRFD-UHFFFAOYSA-N	Launched
succinobucol	antioxidant	VCAM1			CC(C)(C)c1cc(SC(C)(C)Sc2cc(c(OC(=O)CCC(O)=O)c(c2)C(C)(C)C)C(C)(C)C)cc(c1O)C(C)(C)C	RKSMVPNZHBRNNS-UHFFFAOYSA-N	Phase 2/Phase 3
succinylcholine-chloride		CHRFAM7A, CHRM1, CHRM2, CHRM3, CHRNA1, CHRNA10	neurology/psychiatry	muscle relaxant	C[N+](C)(C)CCOC(=O)CCC(=O)OCC[N+](C)(C)C, C[N+](C)(C)CCOC(=O)CCC(=O)OCC[N+](C)(C)C, C[N+](C)(C)CCOC(=O)CCC(=O)OCC[N+](C)(C)C, C[N+](C)(C)CCOC(=O)CCC(=O)OCC[N+](C)(C)C	AXOIZCJOOAYSMI-UHFFFAOYSA-N, AXOIZCJOOAYSMI-UHFFFAOYSA-N, AXOIZCJOOAYSMI-UHFFFAOYSA-N, AXOIZCJOOAYSMI-UHFFFAOYSA-N	Launched
succinylsulfathiazole	dihydrofolate reductase inhibitor	DHFR			OC(=O)CCC(=O)Nc1ccc(cc1)S(=O)(=O)Nc1nccs1, OC(=O)CCC(=O)Nc1ccc(cc1)S(=O)(=O)Nc1nccs1	SKVLYVHULOWXTD-UHFFFAOYSA-N, SKVLYVHULOWXTD-UHFFFAOYSA-N	Phase 2
sucralfate	antacid		gastroenterology	duodenal ulcer disease	O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)OS(=O)(=O)OC[C@H]1O[C@@](COS(=O)(=O)O[Al](O)O)(O[C@H]2O[C@H](COS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)[C@H](OS(=O)(=O)O[Al](O)O)[C@H]2OS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)[C@@H]1OS(=O)(=O)O[Al](O)O, O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)OS(=O)(=O)OC[C@H]1O[C@@](COS(=O)(=O)O[Al](O)O)(O[C@H]2O[C@H](COS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)[C@H](OS(=O)(=O)O[Al](O)O)[C@H]2OS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)[C@@H]1OS(=O)(=O)O[Al](O)O	DTULOKYBGCTCFP-QRLOXDDHSA-A, DTULOKYBGCTCFP-QRLOXDDHSA-A	Launched
sucralose					OC[C@H]1O[C@H](O[C@]2(CCl)O[C@H](CCl)[C@@H](O)[C@@H]2O)[C@H](O)[C@@H](O)[C@H]1Cl, OC[C@H]1O[C@H](O[C@]2(CCl)O[C@H](CCl)[C@@H](O)[C@@H]2O)[C@H](O)[C@@H](O)[C@H]1Cl, OC[C@H]1O[C@H](O[C@]2(CCl)O[C@H](CCl)[C@@H](O)[C@@H]2O)[C@H](O)[C@@H](O)[C@H]1Cl, OC[C@H]1O[C@H](O[C@]2(CCl)O[C@H](CCl)[C@@H](O)[C@@H]2O)[C@H](O)[C@@H](O)[C@H]1Cl, OC[C@H]1O[C@H](O[C@]2(CCl)O[C@H](CCl)[C@@H](O)[C@@H]2O)[C@H](O)[C@@H](O)[C@H]1Cl	BAQAVOSOZGMPRM-QBMZZYIRSA-N, BAQAVOSOZGMPRM-QBMZZYIRSA-N, BAQAVOSOZGMPRM-QBMZZYIRSA-N, BAQAVOSOZGMPRM-QBMZZYIRSA-N, BAQAVOSOZGMPRM-QBMZZYIRSA-N	Launched
sucrose		ACTA1, ATOX1, C22orf28, LYZ			OC[C@H]1O[C@@](CO)(O[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@@H](O)[C@@H]1O	CZMRCDWAGMRECN-UGDNZRGBSA-N	Launched
sucrose-octaacetate					CC(=O)OC[C@H]1O[C@@](COC(C)=O)(O[C@H]2O[C@H](COC(C)=O)[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H]2OC(C)=O)[C@@H](OC(C)=O)[C@@H]1OC(C)=O	ZIJKGAXBCRWEOL-SAXBRCJISA-N	Preclinical
sudan-IV					Cc1ccccc1\N=N\c1ccc(\N=N\c2c(O)ccc3ccccc23)c(C)c1	RCTGMCJBQGBLKT-PAMTUDGESA-N	Preclinical
sufugolix	gonadotropin releasing factor hormone receptor antagonist				CONC(=O)Nc1ccc(cc1)-c1sc2n(Cc3c(F)cccc3F)c(=O)n(-c3ccccc3)c(=O)c2c1CN(C)Cc1ccccc1	UCQSBGOFELXYIN-UHFFFAOYSA-N	Preclinical
sugammadex	neuromuscular blockade reversal agent				O[C@H]1[C@H](O)[C@H]2O[C@@H]3O[C@@H](CSCCC(O)=O)[C@H](O[C@@H]4O[C@@H](CSCCC(O)=O)[C@H](O[C@@H]5O[C@@H](CSCCC(O)=O)[C@H](O[C@@H]6O[C@@H](CSCCC(O)=O)[C@H](O[C@@H]7O[C@@H](CSCCC(O)=O)[C@H](O[C@@H]8O[C@@H](CSCCC(O)=O)[C@H](O[C@@H]9O[C@@H](CSCCC(O)=O)[C@H](O[C@@H]1O[C@H]2CSCCC(O)=O)[C@@H](O)[C@@H]9O)[C@@H](O)[C@@H]8O)[C@@H](O)[C@@H]7O)[C@@H](O)[C@@H]6O)[C@@H](O)[C@@H]5O)[C@@H](O)[C@@H]4O)[C@@H](O)[C@@H]3O	WHRODDIHRRDWEW-WXUQZJQRSA-N	Launched
sulbactam	beta lactamase inhibitor		infectious disease	skin infections, intra-abdominal infections, gynecologic infections	CC1(C)[C@@H](N2[C@@H](CC2=O)S1(=O)=O)C(O)=O, CC1(C)[C@@H](N2[C@@H](CC2=O)S1(=O)=O)C(O)=O, CC1(C)[C@@H](N2[C@@H](CC2=O)S1(=O)=O)C(O)=O, CC1(C)[C@@H](N2[C@@H](CC2=O)S1(=O)=O)C(O)=O, CC1(C)[C@@H](N2[C@@H](CC2=O)S1(=O)=O)C(O)=O, CC1(C)[C@@H](N2[C@@H](CC2=O)S1(=O)=O)C(O)=O, CC1(C)[C@@H](N2[C@@H](CC2=O)S1(=O)=O)C(O)=O	FKENQMMABCRJMK-RITPCOANSA-N, FKENQMMABCRJMK-RITPCOANSA-N, FKENQMMABCRJMK-RITPCOANSA-N, FKENQMMABCRJMK-RITPCOANSA-N, FKENQMMABCRJMK-RITPCOANSA-N, FKENQMMABCRJMK-RITPCOANSA-N, FKENQMMABCRJMK-RITPCOANSA-N	Launched
sulbactam-pivoxil	beta lactamase inhibitor		infectious disease	skin infections	CC(C)(C)C(=O)OCOC(=O)[C@H]1N2[C@@H](CC2=O)S(=O)(=O)C1(C)C |&1:11,&2:13,r|	OHPVYKXTRACOSQ-NXEZZACHSA-N	Launched
sulbentine	other antifungal				S=C1SCN(Cc2ccccc2)CN1Cc1ccccc1, S=C1SCN(Cc2ccccc2)CN1Cc1ccccc1	QFVAWNPSRQWSDU-UHFFFAOYSA-N, QFVAWNPSRQWSDU-UHFFFAOYSA-N	Preclinical
sulbutiamine	acetylcholine receptor antagonist		neurology/psychiatry	asthenia	CC(C)C(=O)OCC\C(SS\C(CCOC(=O)C(C)C)=C(/C)N(Cc1cnc(C)nc1N)C=O)=C(\C)N(Cc1cnc(C)nc1N)C=O	CKHJPWQVLKHBIH-GPAWKIAZSA-N	Launched
sulconazole	sterol demethylase inhibitor		infectious disease	tinea pedis, tinea cruris, tinea corporis	Clc1ccc(CS[C@@H](Cn2ccnc2)c2ccc(Cl)cc2Cl)cc1 |&1:7|, Clc1ccc(CS[C@@H](Cn2ccnc2)c2ccc(Cl)cc2Cl)cc1 |&1:7|, Clc1ccc(CS[C@@H](Cn2ccnc2)c2ccc(Cl)cc2Cl)cc1 |&1:7|, Clc1ccc(CS[C@@H](Cn2ccnc2)c2ccc(Cl)cc2Cl)cc1 |&1:7|, Clc1ccc(CS[C@@H](Cn2ccnc2)c2ccc(Cl)cc2Cl)cc1 |&1:7|, Clc1ccc(CS[C@@H](Cn2ccnc2)c2ccc(Cl)cc2Cl)cc1 |&1:7|, Clc1ccc(CS[C@@H](Cn2ccnc2)c2ccc(Cl)cc2Cl)cc1 |&1:7|	AFNXATANNDIXLG-SFHVURJKSA-N, AFNXATANNDIXLG-SFHVURJKSA-N, AFNXATANNDIXLG-SFHVURJKSA-N, AFNXATANNDIXLG-SFHVURJKSA-N, AFNXATANNDIXLG-SFHVURJKSA-N, AFNXATANNDIXLG-SFHVURJKSA-N, AFNXATANNDIXLG-SFHVURJKSA-N	Launched
sulfabenzamide	bacterial antifolate		infectious disease	gram-negative bacterial infections, gram-positive bacterial infections	Nc1ccc(cc1)S(=O)(=O)NC(=O)c1ccccc1, Nc1ccc(cc1)S(=O)(=O)NC(=O)c1ccccc1, Nc1ccc(cc1)S(=O)(=O)NC(=O)c1ccccc1	PBCZLFBEBARBBI-UHFFFAOYSA-N, PBCZLFBEBARBBI-UHFFFAOYSA-N, PBCZLFBEBARBBI-UHFFFAOYSA-N	Launched
sulfacarbamide					NC(=O)NS(=O)(=O)c1ccc(N)cc1, NC(=O)NS(=O)(=O)c1ccc(N)cc1	WVAKABMNNSMCDK-UHFFFAOYSA-N, WVAKABMNNSMCDK-UHFFFAOYSA-N	Withdrawn
sulfacetamide	PABA antagonist		ophthalmology	conjunctivitis	CC(=O)NS(=O)(=O)c1ccc(N)cc1, CC(=O)NS(=O)(=O)c1ccc(N)cc1, CC(=O)NS(=O)(=O)c1ccc(N)cc1	SKIVFJLNDNKQPD-UHFFFAOYSA-N, SKIVFJLNDNKQPD-UHFFFAOYSA-N, SKIVFJLNDNKQPD-UHFFFAOYSA-N	Launched
sulfachlorpyridazine	bacterial antifolate		infectious disease	urinary tract infections	Nc1ccc(cc1)S(=O)(=O)Nc1ccc(Cl)nn1, Nc1ccc(cc1)S(=O)(=O)Nc1ccc(Cl)nn1	XOXHILFPRYWFOD-UHFFFAOYSA-N, XOXHILFPRYWFOD-UHFFFAOYSA-N	Launched
sulfadiazine	bacterial antifolate		infectious disease, ophthalmology	malaria, meningitis, urinary tract infections, conjunctivitis, trachoma, chancroid	Nc1ccc(cc1)S(=O)(=O)Nc1ncccn1, Nc1ccc(cc1)S(=O)(=O)Nc1ncccn1, Nc1ccc(cc1)S(=O)(=O)Nc1ncccn1, Nc1ccc(cc1)S(=O)(=O)Nc1ncccn1	SEEPANYCNGTZFQ-UHFFFAOYSA-N, SEEPANYCNGTZFQ-UHFFFAOYSA-N, SEEPANYCNGTZFQ-UHFFFAOYSA-N, SEEPANYCNGTZFQ-UHFFFAOYSA-N	Launched
sulfadoxine	dihydropteroate synthase inhibitor		infectious disease	malaria	COc1ncnc(NS(=O)(=O)c2ccc(N)cc2)c1OC, COc1ncnc(NS(=O)(=O)c2ccc(N)cc2)c1OC, COc1ncnc(NS(=O)(=O)c2ccc(N)cc2)c1OC, COc1ncnc(NS(=O)(=O)c2ccc(N)cc2)c1OC	PJSFRIWCGOHTNF-UHFFFAOYSA-N, PJSFRIWCGOHTNF-UHFFFAOYSA-N, PJSFRIWCGOHTNF-UHFFFAOYSA-N, PJSFRIWCGOHTNF-UHFFFAOYSA-N	Launched
sulfafurazole	bacterial antifolate		infectious disease	urinary tract infections	Cc1noc(NS(=O)(=O)c2ccc(N)cc2)c1C, Cc1noc(NS(=O)(=O)c2ccc(N)cc2)c1C, Cc1noc(NS(=O)(=O)c2ccc(N)cc2)c1C, Cc1noc(NS(=O)(=O)c2ccc(N)cc2)c1C, Cc1noc(NS(=O)(=O)c2ccc(N)cc2)c1C, Cc1noc(NS(=O)(=O)c2ccc(N)cc2)c1C	NHUHCSRWZMLRLA-UHFFFAOYSA-N, NHUHCSRWZMLRLA-UHFFFAOYSA-N, NHUHCSRWZMLRLA-UHFFFAOYSA-N, NHUHCSRWZMLRLA-UHFFFAOYSA-N, NHUHCSRWZMLRLA-UHFFFAOYSA-N, NHUHCSRWZMLRLA-UHFFFAOYSA-N	Launched
sulfaguanidine	bacterial antifolate		infectious disease	urinary tract infections	NC(=N)NS(=O)(=O)c1ccc(N)cc1, NC(=N)NS(=O)(=O)c1ccc(N)cc1, NC(=N)NS(=O)(=O)c1ccc(N)cc1, NC(=N)NS(=O)(=O)c1ccc(N)cc1	BRBKOPJOKNSWSG-UHFFFAOYSA-N, BRBKOPJOKNSWSG-UHFFFAOYSA-N, BRBKOPJOKNSWSG-UHFFFAOYSA-N, BRBKOPJOKNSWSG-UHFFFAOYSA-N	Launched
sulfamerazine	bacterial antifolate		infectious disease	coccidiosis, cholera	Cc1ccnc(NS(=O)(=O)c2ccc(N)cc2)n1, Cc1ccnc(NS(=O)(=O)c2ccc(N)cc2)n1, Cc1ccnc(NS(=O)(=O)c2ccc(N)cc2)n1, Cc1ccnc(NS(=O)(=O)c2ccc(N)cc2)n1	QPPBRPIAZZHUNT-UHFFFAOYSA-N, QPPBRPIAZZHUNT-UHFFFAOYSA-N, QPPBRPIAZZHUNT-UHFFFAOYSA-N, QPPBRPIAZZHUNT-UHFFFAOYSA-N	Launched
sulfameter	dihydrofolate reductase inhibitor	DHFR	infectious disease	urinary tract infections	COc1cnc(NS(=O)(=O)c2ccc(N)cc2)nc1, COc1cnc(NS(=O)(=O)c2ccc(N)cc2)nc1, COc1cnc(NS(=O)(=O)c2ccc(N)cc2)nc1	GPTONYMQFTZPKC-UHFFFAOYSA-N, GPTONYMQFTZPKC-UHFFFAOYSA-N, GPTONYMQFTZPKC-UHFFFAOYSA-N	Launched
sulfamethazine	PABA antagonist		gastroenterology	enteritis	Cc1cc(C)nc(NS(=O)(=O)c2ccc(N)cc2)n1, Cc1cc(C)nc(NS(=O)(=O)c2ccc(N)cc2)n1, Cc1cc(C)nc(NS(=O)(=O)c2ccc(N)cc2)n1, Cc1cc(C)nc(NS(=O)(=O)c2ccc(N)cc2)n1	ASWVTGNCAZCNNR-UHFFFAOYSA-N, ASWVTGNCAZCNNR-UHFFFAOYSA-N, ASWVTGNCAZCNNR-UHFFFAOYSA-N, ASWVTGNCAZCNNR-UHFFFAOYSA-N	Launched
sulfamethizole	bacterial antifolate		infectious disease	urinary tract infections	Cc1nnc(NS(=O)(=O)c2ccc(N)cc2)s1, Cc1nnc(NS(=O)(=O)c2ccc(N)cc2)s1, Cc1nnc(NS(=O)(=O)c2ccc(N)cc2)s1	VACCAVUAMIDAGB-UHFFFAOYSA-N, VACCAVUAMIDAGB-UHFFFAOYSA-N, VACCAVUAMIDAGB-UHFFFAOYSA-N	Launched
sulfamethoxazole	PABA antagonist		infectious disease, gastroenterology	pneumonia, enteritis, urinary tract infections	Cc1cc(NS(=O)(=O)c2ccc(N)cc2)no1, Cc1cc(NS(=O)(=O)c2ccc(N)cc2)no1, Cc1cc(NS(=O)(=O)c2ccc(N)cc2)no1	JLKIGFTWXXRPMT-UHFFFAOYSA-N, JLKIGFTWXXRPMT-UHFFFAOYSA-N, JLKIGFTWXXRPMT-UHFFFAOYSA-N	Launched
sulfamethoxypyridazine	bacterial antifolate				COc1ccc(NS(=O)(=O)c2ccc(N)cc2)nn1, COc1ccc(NS(=O)(=O)c2ccc(N)cc2)nn1, COc1ccc(NS(=O)(=O)c2ccc(N)cc2)nn1	VLYWMPOKSSWJAL-UHFFFAOYSA-N, VLYWMPOKSSWJAL-UHFFFAOYSA-N, VLYWMPOKSSWJAL-UHFFFAOYSA-N	Withdrawn
sulfametopyrazine	PABA antagonist		infectious disease	malaria, urinary tract infections, respiratory tract infections	COc1nccnc1NS(=O)(=O)c1ccc(N)cc1, COc1nccnc1NS(=O)(=O)c1ccc(N)cc1, COc1nccnc1NS(=O)(=O)c1ccc(N)cc1, COc1nccnc1NS(=O)(=O)c1ccc(N)cc1, COc1nccnc1NS(=O)(=O)c1ccc(N)cc1	KXRZBTAEDBELFD-UHFFFAOYSA-N, KXRZBTAEDBELFD-UHFFFAOYSA-N, KXRZBTAEDBELFD-UHFFFAOYSA-N, KXRZBTAEDBELFD-UHFFFAOYSA-N, KXRZBTAEDBELFD-UHFFFAOYSA-N	Launched
sulfamonomethoxine	bacterial antifolate		infectious disease	urinary tract infections	COc1cc(NS(=O)(=O)c2ccc(N)cc2)ncn1, COc1cc(NS(=O)(=O)c2ccc(N)cc2)ncn1	WMPXPUYPYQKQCX-UHFFFAOYSA-N, WMPXPUYPYQKQCX-UHFFFAOYSA-N	Launched
sulfamoxole	PABA antagonist		infectious disease	urinary tract infections	Cc1nc(NS(=O)(=O)c2ccc(N)cc2)oc1C, Cc1nc(NS(=O)(=O)c2ccc(N)cc2)oc1C, Cc1nc(NS(=O)(=O)c2ccc(N)cc2)oc1C	CYFLXLSBHQBMFT-UHFFFAOYSA-N, CYFLXLSBHQBMFT-UHFFFAOYSA-N, CYFLXLSBHQBMFT-UHFFFAOYSA-N	Launched
sulfanilamide	carbonic anhydrase inhibitor	CYP2C19, CYP2C9, CYP2D6, CYP2E1, CYP3A4	infectious disease	vulvovaginal candidiasis	Nc1ccc(cc1)S(N)(=O)=O, Nc1ccc(cc1)S(N)(=O)=O	FDDDEECHVMSUSB-UHFFFAOYSA-N, FDDDEECHVMSUSB-UHFFFAOYSA-N	Launched
sulfanilate-zinc					Nc1ccc(cc1)S(=O)(=O)O[Zn]OS(=O)(=O)c1ccc(N)cc1	RIUORJCWAHCMSA-UHFFFAOYSA-L	Preclinical
sulfanitran			infectious disease	coccidiosis	CC(=O)Nc1ccc(cc1)S(=O)(=O)Nc1ccc(cc1)[N+]([O-])=O, CC(=O)Nc1ccc(cc1)S(=O)(=O)Nc1ccc(cc1)[N+]([O-])=O	GWBPFRGXNGPPMF-UHFFFAOYSA-N, GWBPFRGXNGPPMF-UHFFFAOYSA-N	Launched
sulfaphenazole	dihydropteroate synthetase inhibitor	DHPS	infectious disease	urinary tract infections	Nc1ccc(cc1)S(=O)(=O)Nc1ccnn1-c1ccccc1, Nc1ccc(cc1)S(=O)(=O)Nc1ccnn1-c1ccccc1, Nc1ccc(cc1)S(=O)(=O)Nc1ccnn1-c1ccccc1	QWCJHSGMANYXCW-UHFFFAOYSA-N, QWCJHSGMANYXCW-UHFFFAOYSA-N, QWCJHSGMANYXCW-UHFFFAOYSA-N	Launched
sulfapyridine	PABA antagonist		infectious disease	gram-negative bacterial infections, gram-positive bacterial infections	Nc1ccc(cc1)S(=O)(=O)Nc1ccccn1, Nc1ccc(cc1)S(=O)(=O)Nc1ccccn1, Nc1ccc(cc1)S(=O)(=O)Nc1ccccn1, Nc1ccc(cc1)S(=O)(=O)Nc1ccccn1, Nc1ccc(cc1)S(=O)(=O)Nc1ccccn1, Nc1ccc(cc1)S(=O)(=O)Nc1ccccn1	GECHUMIMRBOMGK-UHFFFAOYSA-N, GECHUMIMRBOMGK-UHFFFAOYSA-N, GECHUMIMRBOMGK-UHFFFAOYSA-N, GECHUMIMRBOMGK-UHFFFAOYSA-N, GECHUMIMRBOMGK-UHFFFAOYSA-N, GECHUMIMRBOMGK-UHFFFAOYSA-N	Launched
sulfaquinoxaline	vitamin K antagonist		infectious disease	coccidiosis	Nc1ccc(cc1)S(=O)(=O)Nc1cnc2ccccc2n1, Nc1ccc(cc1)S(=O)(=O)Nc1cnc2ccccc2n1	NHZLNPMOSADWGC-UHFFFAOYSA-N, NHZLNPMOSADWGC-UHFFFAOYSA-N	Launched
sulfasalazine	cyclooxygenase inhibitor	ACAT1, ALOX5, CHUK, IKBKB, PLA2G1B, PPARG, PTGS1, PTGS2, SLC46A1, SLC7A11, TBXAS1	gastroenterology	ulcerative colitis	OC(=O)c1cc(ccc1O)\N=N\c1ccc(cc1)S(=O)(=O)Nc1ccccn1, OC(=O)c1cc(ccc1O)\N=N\c1ccc(cc1)S(=O)(=O)Nc1ccccn1, OC(=O)c1cc(ccc1O)\N=N\c1ccc(cc1)S(=O)(=O)Nc1ccccn1, OC(=O)c1cc(ccc1O)\N=N\c1ccc(cc1)S(=O)(=O)Nc1ccccn1	NCEXYHBECQHGNR-QZQOTICOSA-N, NCEXYHBECQHGNR-QZQOTICOSA-N, NCEXYHBECQHGNR-QZQOTICOSA-N, NCEXYHBECQHGNR-QZQOTICOSA-N	Launched
sulfathiazole	dihydropteroate synthase inhibitor		infectious disease	gram-negative bacterial infections, gram-positive bacterial infections	Nc1ccc(cc1)S(=O)(=O)Nc1nccs1, Nc1ccc(cc1)S(=O)(=O)Nc1nccs1, Nc1ccc(cc1)S(=O)(=O)Nc1nccs1	JNMRHUJNCSQMMB-UHFFFAOYSA-N, JNMRHUJNCSQMMB-UHFFFAOYSA-N, JNMRHUJNCSQMMB-UHFFFAOYSA-N	Launched
sulfatinib	tyrosine kinase inhibitor				CN(C)CCNS(=O)(=O)Cc1cccc(Nc2nccc(Oc3ccc4[nH]c(C)cc4c3)n2)c1	TTZSNFLLYPYKIL-UHFFFAOYSA-N	Phase 1
sulfinpyrazone	uricosuric blocker	ABCC1, FPR1, SLC22A12	rheumatology	gout	O=C1C(CC[S@](=O)c2ccccc2)C(=O)N(N1c1ccccc1)c1ccccc1 |&1:5,r|	MBGGBVCUIVRRBF-LJAQVGFWSA-N	Launched
sulfisomidin	antibacterial				Cc1cc(NS(=O)(=O)c2ccc(N)cc2)nc(C)n1	YZMCKZRAOLZXAZ-UHFFFAOYSA-N	Preclinical
sulfisoxazole-acetyl	folic acid antagonist		infectious disease, otolaryngology	meningitis, urinary tract infections, otitis, trachoma	CC(=O)N(c1onc(C)c1C)S(=O)(=O)c1ccc(N)cc1	JFNWFXVFBDDWCX-UHFFFAOYSA-N	Launched
sulforaphane	anticancer agent, aryl hydrocarbon receptor antagonist	NFE2L2			C[S@@](=O)CCCCN=C=S |r|, C[S@@](=O)CCCCN=C=S |r|, C[S@@](=O)CCCCN=C=S |r|	SUVMJBTUFCVSAD-SNVBAGLBSA-N, SUVMJBTUFCVSAD-SNVBAGLBSA-N, SUVMJBTUFCVSAD-SNVBAGLBSA-N	Phase 2
sulindac	cyclooxygenase inhibitor	AKR1B1	rheumatology	osteoarthritis, rheumatoid arthritis, ankylosing spondylitis	CC1=C(CC(O)=O)c2cc(F)ccc2\C1=C/c1ccc(cc1)[S@@](C)=O |r,c:1|, CC1=C(CC(O)=O)c2cc(F)ccc2\C1=C/c1ccc(cc1)[S@@](C)=O |r,c:1|, CC1=C(CC(O)=O)c2cc(F)ccc2\C1=C/c1ccc(cc1)[S@@](C)=O |r,c:1|, CC1=C(CC(O)=O)c2cc(F)ccc2\C1=C/c1ccc(cc1)[S@@](C)=O |r,c:1|, CC1=C(CC(O)=O)c2cc(F)ccc2\C1=C/c1ccc(cc1)[S@@](C)=O |r,c:1|	MLKXDPUZXIRXEP-LQVWSKNFSA-N, MLKXDPUZXIRXEP-LQVWSKNFSA-N, MLKXDPUZXIRXEP-LQVWSKNFSA-N, MLKXDPUZXIRXEP-LQVWSKNFSA-N, MLKXDPUZXIRXEP-LQVWSKNFSA-N	Launched
sulisobenzone			dermatology	sunscreen lotion	COc1cc(O)c(cc1S(O)(=O)=O)C(=O)c1ccccc1, COc1cc(O)c(cc1S(O)(=O)=O)C(=O)c1ccccc1, COc1cc(O)c(cc1S(O)(=O)=O)C(=O)c1ccccc1	CXVGEDCSTKKODG-UHFFFAOYSA-N, CXVGEDCSTKKODG-UHFFFAOYSA-N, CXVGEDCSTKKODG-UHFFFAOYSA-N	Launched
sulmazole	adenosine receptor antagonist				COc1cc(ccc1-c1nc2ncccc2[nH]1)[S@@](C)=O |r|, COc1cc(ccc1-c1nc2ncccc2[nH]1)[S@@](C)=O |r|, COc1cc(ccc1-c1nc2ncccc2[nH]1)[S@@](C)=O |r|	XMFCOYRWYYXZMY-HXUWFJFHSA-N, XMFCOYRWYYXZMY-HXUWFJFHSA-N, XMFCOYRWYYXZMY-HXUWFJFHSA-N	Phase 1
sulmetozine	gastrin inhibitor	GAST	gastroenterology	peptic ulcer disease (PUD)	COc1cc(cc(OC)c1OC)C(=S)N1CCOCC1, COc1cc(cc(OC)c1OC)C(=S)N1CCOCC1	MVOUIYUWRXPNKD-UHFFFAOYSA-N, MVOUIYUWRXPNKD-UHFFFAOYSA-N	Launched
suloctidil	adrenergic receptor antagonist				CCCCCCCCN[C@H](C)[C@@H](O)c1ccc(SC(C)C)cc1 |&1:9,11|	BFCDFTHTSVTWOG-YLJYHZDGSA-N	Withdrawn
sulopenem	antibacterial				C[C@@H](O)[C@@H]1[C@H]2SC(S[C@H]3CC[S@@](=O)C3)=C(N2C1=O)C(O)=O |&1:11,c:14|	FLSUCZWOEMTFAQ-PRBGKLEPSA-N	Phase 3
sulphadimethoxine	dihydropteroate synthetase inhibitor		infectious disease	gram-negative bacterial infections, gram-positive bacterial infections	COc1cc(NS(=O)(=O)c2ccc(N)cc2)nc(OC)n1, COc1cc(NS(=O)(=O)c2ccc(N)cc2)nc(OC)n1, COc1cc(NS(=O)(=O)c2ccc(N)cc2)nc(OC)n1, COc1cc(NS(=O)(=O)c2ccc(N)cc2)nc(OC)n1	ZZORFUFYDOWNEF-UHFFFAOYSA-N, ZZORFUFYDOWNEF-UHFFFAOYSA-N, ZZORFUFYDOWNEF-UHFFFAOYSA-N, ZZORFUFYDOWNEF-UHFFFAOYSA-N	Launched
sulpiride	dopamine receptor antagonist		neurology/psychiatry	schizophrenia	CCN1CCC[C@@H]1CNC(=O)c1cc(ccc1OC)S(N)(=O)=O |&1:6,r|, CCN1CCC[C@@H]1CNC(=O)c1cc(ccc1OC)S(N)(=O)=O |&1:6,r|, CCN1CCC[C@@H]1CNC(=O)c1cc(ccc1OC)S(N)(=O)=O |&1:6,r|, CCN1CCC[C@@H]1CNC(=O)c1cc(ccc1OC)S(N)(=O)=O |&1:6,r|, CCN1CCC[C@@H]1CNC(=O)c1cc(ccc1OC)S(N)(=O)=O |&1:6,r|	BGRJTUBHPOOWDU-LLVKDONJSA-N, BGRJTUBHPOOWDU-LLVKDONJSA-N, BGRJTUBHPOOWDU-LLVKDONJSA-N, BGRJTUBHPOOWDU-LLVKDONJSA-N, BGRJTUBHPOOWDU-LLVKDONJSA-N	Launched
sultamicillin	antibacterial 		infectious disease	gram-negative bacterial infections, gram-positive bacterial infections	CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccccc3)C(=O)N2[C@H]1C(=O)OCOC(=O)[C@@H]1N2[C@@H](CC2=O)S(=O)(=O)C1(C)C	OPYGFNJSCUDTBT-PMLPCWDUSA-N	Launched
sultiame	carbonic anhydrase inhibitor	CA2			NS(=O)(=O)c1ccc(cc1)N1CCCCS1(=O)=O	HMHVCUVYZFYAJI-UHFFFAOYSA-N	Phase 3
sultopride	dopamine receptor antagonist				CCN1CCC[C@H]1CNC(=O)c1cc(ccc1OC)S(=O)(=O)CC |&1:6,r|	UNRHXEPDKXPRTM-ZDUSSCGKSA-N	Preclinical
sumanirole	dopamine receptor agonist	DRD2			CN[C@@H]1Cc2cccc3[nH]c(=O)n(C1)c23	RKZSNTNMEFVBDT-MRVPVSSYSA-N	Phase 3
sumatriptan	serotonin receptor agonist	HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR5A, HTR6, HTR7	neurology/psychiatry	migraine headache	CNS(=O)(=O)Cc1ccc2[nH]cc(CCN(C)C)c2c1, CNS(=O)(=O)Cc1ccc2[nH]cc(CCN(C)C)c2c1, CNS(=O)(=O)Cc1ccc2[nH]cc(CCN(C)C)c2c1, CNS(=O)(=O)Cc1ccc2[nH]cc(CCN(C)C)c2c1	KQKPFRSPSRPDEB-UHFFFAOYSA-N, KQKPFRSPSRPDEB-UHFFFAOYSA-N, KQKPFRSPSRPDEB-UHFFFAOYSA-N, KQKPFRSPSRPDEB-UHFFFAOYSA-N	Launched
SUN-B-8155	calcitonin agonist	CALCR			C\C(=N/c1ccccc1N)c1c(C)cc(=O)n(O)c1O, C\C(=N/c1ccccc1N)c1c(C)cc(=O)n(O)c1O, C\C(=N/c1ccccc1N)c1c(C)cc(=O)n(O)c1O	SGJLINMLDNLWOS-CXUHLZMHSA-N, SGJLINMLDNLWOS-CXUHLZMHSA-N, SGJLINMLDNLWOS-CXUHLZMHSA-N	Preclinical
SUN-11602	fibroblast growth factor mimetic	FGFR1			CN(C1CCN(Cc2ccc(cc2)C(N)=O)CC1)C(=O)CNc1c(C)c(C)c(N)c(C)c1C, CN(C1CCN(Cc2ccc(cc2)C(N)=O)CC1)C(=O)CNc1c(C)c(C)c(N)c(C)c1C, CN(C1CCN(Cc2ccc(cc2)C(N)=O)CC1)C(=O)CNc1c(C)c(C)c(N)c(C)c1C	KCODNOOPOPTZMO-UHFFFAOYSA-N, KCODNOOPOPTZMO-UHFFFAOYSA-N, KCODNOOPOPTZMO-UHFFFAOYSA-N	Preclinical
sunitinib	FLT3 inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor	CSF1R, FGFR1, FLT1, FLT3, FLT4, KDR, KIT, PDGFRA, PDGFRB, RET	oncology	gastrointestinal stromal tumors (GIST), renal cell carcinoma (RCC), neuroendocrine tumors of pancreatic origin (PNET)	CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C, CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C, CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C, CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C, CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C, CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C, CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C, CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C, CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C, CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C, CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C, CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C	WINHZLLDWRZWRT-ATVHPVEESA-N, WINHZLLDWRZWRT-ATVHPVEESA-N, WINHZLLDWRZWRT-ATVHPVEESA-N, WINHZLLDWRZWRT-ATVHPVEESA-N, WINHZLLDWRZWRT-ATVHPVEESA-N, WINHZLLDWRZWRT-ATVHPVEESA-N, WINHZLLDWRZWRT-ATVHPVEESA-N, WINHZLLDWRZWRT-ATVHPVEESA-N, WINHZLLDWRZWRT-ATVHPVEESA-N, WINHZLLDWRZWRT-ATVHPVEESA-N, WINHZLLDWRZWRT-ATVHPVEESA-N, WINHZLLDWRZWRT-ATVHPVEESA-N	Launched
suplatast	histamine release inhibitor, immunoglobulin inhibitor		rheumatology	Kimura's disease	CCOC[C@@H](O)COc1ccc(NC(=O)CC[S+](C)C)cc1 |&1:4|, CCOC[C@@H](O)COc1ccc(NC(=O)CC[S+](C)C)cc1 |&1:4|, CCOC[C@@H](O)COc1ccc(NC(=O)CC[S+](C)C)cc1 |&1:4|, CCOC[C@@H](O)COc1ccc(NC(=O)CC[S+](C)C)cc1 |&1:4|, CCOC[C@@H](O)COc1ccc(NC(=O)CC[S+](C)C)cc1 |&1:4|	DYZJXZOQQRXDLE-CQSZACIVSA-O, DYZJXZOQQRXDLE-CQSZACIVSA-O, DYZJXZOQQRXDLE-CQSZACIVSA-O, DYZJXZOQQRXDLE-CQSZACIVSA-O, DYZJXZOQQRXDLE-CQSZACIVSA-O	Launched
suprofen	cyclooxygenase inhibitor	PTGS1, PTGS2			C[C@@H](C(O)=O)c1ccc(cc1)C(=O)c1cccs1 |&1:1,r|, C[C@@H](C(O)=O)c1ccc(cc1)C(=O)c1cccs1 |&1:1,r|, C[C@@H](C(O)=O)c1ccc(cc1)C(=O)c1cccs1 |&1:1,r|	MDKGKXOCJGEUJW-SECBINFHSA-N, MDKGKXOCJGEUJW-SECBINFHSA-N, MDKGKXOCJGEUJW-SECBINFHSA-N	Withdrawn
suramin	DNA synthesis inhibitor	F2, FSHR, P2RY1, P2RY11, P2RY13, P2RY2, PLA2G2A, RYR1, RYR2, SIRT5	infectious disease	African trypanosomiasis, onchocerciasis	Cc1ccc(cc1NC(=O)c1cccc(NC(=O)Nc2cccc(c2)C(=O)Nc2cc(ccc2C)C(=O)Nc2ccc(c3cc(cc(c23)S(O)(=O)=O)S(O)(=O)=O)S(O)(=O)=O)c1)C(=O)Nc1ccc(c2cc(cc(c12)S(O)(=O)=O)S(O)(=O)=O)S(O)(=O)=O, Cc1ccc(cc1NC(=O)c1cccc(NC(=O)Nc2cccc(c2)C(=O)Nc2cc(ccc2C)C(=O)Nc2ccc(c3cc(cc(c23)S(O)(=O)=O)S(O)(=O)=O)S(O)(=O)=O)c1)C(=O)Nc1ccc(c2cc(cc(c12)S(O)(=O)=O)S(O)(=O)=O)S(O)(=O)=O	FIAFUQMPZJWCLV-UHFFFAOYSA-N, FIAFUQMPZJWCLV-UHFFFAOYSA-N	Launched
suritozole	GABA receptor inverse agonist	GABBR1			Cn1nc(-c2cccc(F)c2)n(C)c1=S, Cn1nc(-c2cccc(F)c2)n(C)c1=S	IWDUZEHNLHFBRZ-UHFFFAOYSA-N, IWDUZEHNLHFBRZ-UHFFFAOYSA-N	Phase 2
sutezolid	protein synthesis inhibitor				CC(=O)NC[C@H]1CN(C(=O)O1)c1ccc(N2CCSCC2)c(F)c1	FNDDDNOJWPQCBZ-ZDUSSCGKSA-N	Phase 2
suxibuzone	cyclooxygenase inhibitor		rheumatology, neurology/psychiatry	joint pain, muscle pain	CCCCC1(COC(=O)CCC(O)=O)C(=O)N(N(C1=O)c1ccccc1)c1ccccc1, CCCCC1(COC(=O)CCC(O)=O)C(=O)N(N(C1=O)c1ccccc1)c1ccccc1, CCCCC1(COC(=O)CCC(O)=O)C(=O)N(N(C1=O)c1ccccc1)c1ccccc1, CCCCC1(COC(=O)CCC(O)=O)C(=O)N(N(C1=O)c1ccccc1)c1ccccc1	ONWXNHPOAGOMTG-UHFFFAOYSA-N, ONWXNHPOAGOMTG-UHFFFAOYSA-N, ONWXNHPOAGOMTG-UHFFFAOYSA-N, ONWXNHPOAGOMTG-UHFFFAOYSA-N	Launched
SU014813	PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	KDR			Cc1[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1	CTNPALGJUAXMMC-PMFHANACSA-N	Phase 2
SU11274	hepatocyte growth factor receptor inhibitor, tyrosine kinase inhibitor	MET			CN(c1cccc(Cl)c1)S(=O)(=O)c1ccc2NC(=O)\C(=C/c3[nH]c(C)c(C(=O)N4CCN(C)CC4)c3C)c2c1, CN(c1cccc(Cl)c1)S(=O)(=O)c1ccc2NC(=O)\C(=C/c3[nH]c(C)c(C(=O)N4CCN(C)CC4)c3C)c2c1, CN(c1cccc(Cl)c1)S(=O)(=O)c1ccc2NC(=O)\C(=C/c3[nH]c(C)c(C(=O)N4CCN(C)CC4)c3C)c2c1, CN(c1cccc(Cl)c1)S(=O)(=O)c1ccc2NC(=O)\C(=C/c3[nH]c(C)c(C(=O)N4CCN(C)CC4)c3C)c2c1	FPYJSJDOHRDAMT-KQWNVCNZSA-N, FPYJSJDOHRDAMT-KQWNVCNZSA-N, FPYJSJDOHRDAMT-KQWNVCNZSA-N, FPYJSJDOHRDAMT-KQWNVCNZSA-N	Preclinical
SU16f	PDGFR tyrosine kinase receptor inhibitor	PDGFRB			Cc1[nH]c(\C=C2/C(=O)Nc3cc(ccc23)-c2ccccc2)c(C)c1CCC(O)=O, Cc1[nH]c(\C=C2/C(=O)Nc3cc(ccc23)-c2ccccc2)c(C)c1CCC(O)=O, Cc1[nH]c(\C=C2/C(=O)Nc3cc(ccc23)-c2ccccc2)c(C)c1CCC(O)=O	APYYTEJNOZQZNA-MOSHPQCFSA-N, APYYTEJNOZQZNA-MOSHPQCFSA-N, APYYTEJNOZQZNA-MOSHPQCFSA-N	Preclinical
SU3327	JNK inhibitor	MAPK8			Nc1nnc(Sc2ncc(s2)[N+]([O-])=O)s1, Nc1nnc(Sc2ncc(s2)[N+]([O-])=O)s1, Nc1nnc(Sc2ncc(s2)[N+]([O-])=O)s1, Nc1nnc(Sc2ncc(s2)[N+]([O-])=O)s1, Nc1nnc(Sc2ncc(s2)[N+]([O-])=O)s1, Nc1nnc(Sc2ncc(s2)[N+]([O-])=O)s1	NQQBNZBOOHHVQP-UHFFFAOYSA-N, NQQBNZBOOHHVQP-UHFFFAOYSA-N, NQQBNZBOOHHVQP-UHFFFAOYSA-N, NQQBNZBOOHHVQP-UHFFFAOYSA-N, NQQBNZBOOHHVQP-UHFFFAOYSA-N, NQQBNZBOOHHVQP-UHFFFAOYSA-N	Preclinical
SU4312	PDGFR tyrosine kinase receptor inhibitor, tyrosine kinase inhibitor, VEGFR inhibitor	KDR, PDGFRB			CN(C)c1ccc(\C=C2/C(=O)Nc3ccccc23)cc1, CN(C)c1ccc(\C=C2/C(=O)Nc3ccccc23)cc1	UAKWLVYMKBWHMX-PTNGSMBKSA-N, UAKWLVYMKBWHMX-PTNGSMBKSA-N	Preclinical
SU9516	CDK inhibitor	CDK1, CDK2, CDK4, CDK5			COc1ccc2NC(=O)\C(=C/c3cnc[nH]3)c2c1, COc1ccc2NC(=O)\C(=C/c3cnc[nH]3)c2c1, COc1ccc2NC(=O)\C(=C/c3cnc[nH]3)c2c1	QNUKRWAIZMBVCU-WCIBSUBMSA-N, QNUKRWAIZMBVCU-WCIBSUBMSA-N, QNUKRWAIZMBVCU-WCIBSUBMSA-N	Preclinical
swainsonine	alpha mannosidase inhibitor	MAN2A1			O[C@@H]1CN2CCC[C@@H](O)[C@@H]2[C@@H]1O	FXUAIOOAOAVCGD-WCTZXXKLSA-N	Phase 2
SX-011	MAP kinase inhibitor	MAPK14			CN(C)C(=O)C(=O)c1cn(C)c2cc(Cl)c(cc12)C(=O)N1CCC(Cc2ccc(F)cc2)CC1, CN(C)C(=O)C(=O)c1cn(C)c2cc(Cl)c(cc12)C(=O)N1CCC(Cc2ccc(F)cc2)CC1, CN(C)C(=O)C(=O)c1cn(C)c2cc(Cl)c(cc12)C(=O)N1CCC(Cc2ccc(F)cc2)CC1	GUTYHDCSDBBMGW-UHFFFAOYSA-N, GUTYHDCSDBBMGW-UHFFFAOYSA-N, GUTYHDCSDBBMGW-UHFFFAOYSA-N	Preclinical
SY-640					CN(Cc1ccc2OCOc2c1)C(C)=O	JIWDGIYBLGMPRV-UHFFFAOYSA-N	Phase 2
SYM-2081	kainate receptor antagonist	GRIK1, GRIK2, GRIK3, GRIK4, GRIK5, SLC1A2			C[C@H](C[C@H](N)C(O)=O)C(O)=O, C[C@H](C[C@H](N)C(O)=O)C(O)=O	KRKRAOXTGDJWNI-DMTCNVIQSA-N, KRKRAOXTGDJWNI-DMTCNVIQSA-N	Preclinical
SYM-2206	glutamate receptor antagonist	GRIA1, GRIA2, GRIA3, GRIA4			CCCNC(=O)N1N=C(c2ccc(N)cc2)c2cc3OCOc3cc2[C@@H]1C |r,t:7|, CCCNC(=O)N1N=C(c2ccc(N)cc2)c2cc3OCOc3cc2[C@@H]1C |r,t:7|, CCCNC(=O)N1N=C(c2ccc(N)cc2)c2cc3OCOc3cc2[C@@H]1C |r,t:7|	OFUDZKKOKPGXOH-LBPRGKRZSA-N, OFUDZKKOKPGXOH-LBPRGKRZSA-N, OFUDZKKOKPGXOH-LBPRGKRZSA-N	Preclinical
symclosene					Cln1c(=O)n(Cl)c(=O)n(Cl)c1=O, Cln1c(=O)n(Cl)c(=O)n(Cl)c1=O	YRIZYWQGELRKNT-UHFFFAOYSA-N, YRIZYWQGELRKNT-UHFFFAOYSA-N	Preclinical
synephrine	adrenergic receptor agonist	ADRA1A	otolaryngology	sinusitis	CNC[C@@H](O)c1ccc(O)cc1 |&1:3|, CNC[C@@H](O)c1ccc(O)cc1 |&1:3|	YRCWQPVGYLYSOX-SECBINFHSA-N, YRCWQPVGYLYSOX-SECBINFHSA-N	Launched
S1P1-agonist-III	sphingosine kinase inhibitor	S1PR1			COc1ccncc1C(=O)NC(=O)Nc1ccc(-c2ccccc2)c(c1)C(F)(F)F, COc1ccncc1C(=O)NC(=O)Nc1ccc(-c2ccccc2)c(c1)C(F)(F)F, COc1ccncc1C(=O)NC(=O)Nc1ccc(-c2ccccc2)c(c1)C(F)(F)F, COc1ccncc1C(=O)NC(=O)Nc1ccc(-c2ccccc2)c(c1)C(F)(F)F	MLDQTQOMWDNTNN-UHFFFAOYSA-N, MLDQTQOMWDNTNN-UHFFFAOYSA-N, MLDQTQOMWDNTNN-UHFFFAOYSA-N, MLDQTQOMWDNTNN-UHFFFAOYSA-N	Preclinical
S15535	serotonin receptor agonist				C1C(Cc2ccccc12)N1CCN(CC1)c1cccc2OCCOc12	QJPPEMXOOWNICQ-UHFFFAOYSA-N	Preclinical
S18986	glutamate receptor modulator	GRIA1, GRIA2, GRIA3, GRIA4			O=S1(=O)N[C@H]2CCCN2c2ccccc12, O=S1(=O)N[C@H]2CCCN2c2ccccc12	MNTIJYGEITVWHU-SNVBAGLBSA-N, MNTIJYGEITVWHU-SNVBAGLBSA-N	Phase 2
S26948	PPAR receptor agonist	PPARG			COC(=O)C(Cc1ccc(OCCn2c3ccc(cc3sc2=O)C(=O)c2ccccc2)cc1)C(=O)OC, COC(=O)C(Cc1ccc(OCCn2c3ccc(cc3sc2=O)C(=O)c2ccccc2)cc1)C(=O)OC, COC(=O)C(Cc1ccc(OCCn2c3ccc(cc3sc2=O)C(=O)c2ccccc2)cc1)C(=O)OC	NSMJEHGOMXSLCW-UHFFFAOYSA-N, NSMJEHGOMXSLCW-UHFFFAOYSA-N, NSMJEHGOMXSLCW-UHFFFAOYSA-N	Preclinical
S4	carbonic anhydrase inhibitor	CA12, CA9			Cc1cc(C)cc(NC(=O)Nc2ccc(OS(N)(=O)=O)cc2)c1, Cc1cc(C)cc(NC(=O)Nc2ccc(OS(N)(=O)=O)cc2)c1	HGVHSNXRZYOTPD-UHFFFAOYSA-N, HGVHSNXRZYOTPD-UHFFFAOYSA-N	Preclinical
S49076	tyrosine kinase inhibitor				O=C1CSC(=O)N1Cc1ccc2NC(=O)\C(=C/c3cc(CN4CCOCC4)c[nH]3)c2c1	AREYWCZYVPSHGS-NVMNQCDNSA-N	Preclinical
S63845	MCL1 inhibitor				CN1CCN(CCOc2ccc(-c3c(sc4ncnc(O[C@H](Cc5ccccc5OCc5ccnn5CC(F)(F)F)C(O)=O)c34)-c3ccc(F)o3)c(C)c2Cl)CC1, CN1CCN(CCOc2ccc(-c3c(sc4ncnc(O[C@H](Cc5ccccc5OCc5ccnn5CC(F)(F)F)C(O)=O)c34)-c3ccc(F)o3)c(C)c2Cl)CC1	ZFBHXVOCZBPADE-SSEXGKCCSA-N, ZFBHXVOCZBPADE-SSEXGKCCSA-N	Preclinical
T-0070907	PPAR receptor antagonist	PPARG			[O-][N+](=O)c1ccc(Cl)c(c1)C(=O)Nc1ccncc1, [O-][N+](=O)c1ccc(Cl)c(c1)C(=O)Nc1ccncc1, [O-][N+](=O)c1ccc(Cl)c(c1)C(=O)Nc1ccncc1, [O-][N+](=O)c1ccc(Cl)c(c1)C(=O)Nc1ccncc1, [O-][N+](=O)c1ccc(Cl)c(c1)C(=O)Nc1ccncc1	FRPJSHKMZHWJBE-UHFFFAOYSA-N, FRPJSHKMZHWJBE-UHFFFAOYSA-N, FRPJSHKMZHWJBE-UHFFFAOYSA-N, FRPJSHKMZHWJBE-UHFFFAOYSA-N, FRPJSHKMZHWJBE-UHFFFAOYSA-N	Preclinical
T-0156	phosphodiesterase inhibitor	PDE5A			COC(=O)c1c(-c2cc(OC)c(OC)c(OC)c2)c2ccnc(OCc3ncccn3)c2c(=O)n1Cc1ccnc(C)c1, COC(=O)c1c(-c2cc(OC)c(OC)c(OC)c2)c2ccnc(OCc3ncccn3)c2c(=O)n1Cc1ccnc(C)c1, COC(=O)c1c(-c2cc(OC)c(OC)c(OC)c2)c2ccnc(OCc3ncccn3)c2c(=O)n1Cc1ccnc(C)c1, COC(=O)c1c(-c2cc(OC)c(OC)c(OC)c2)c2ccnc(OCc3ncccn3)c2c(=O)n1Cc1ccnc(C)c1, COC(=O)c1c(-c2cc(OC)c(OC)c(OC)c2)c2ccnc(OCc3ncccn3)c2c(=O)n1Cc1ccnc(C)c1	JEMJAABFSYOLAP-UHFFFAOYSA-N, JEMJAABFSYOLAP-UHFFFAOYSA-N, JEMJAABFSYOLAP-UHFFFAOYSA-N, JEMJAABFSYOLAP-UHFFFAOYSA-N, JEMJAABFSYOLAP-UHFFFAOYSA-N	Preclinical
T-025	CLK inhibitor						Preclinical
T-0901317	LXR agonist	NCOA1, NCOA2, NR1H2, NR1H3, NR1I2, RXRB			OC(c1ccc(cc1)N(CC(F)(F)F)S(=O)(=O)c1ccccc1)(C(F)(F)F)C(F)(F)F, OC(c1ccc(cc1)N(CC(F)(F)F)S(=O)(=O)c1ccccc1)(C(F)(F)F)C(F)(F)F, OC(c1ccc(cc1)N(CC(F)(F)F)S(=O)(=O)c1ccccc1)(C(F)(F)F)C(F)(F)F, OC(c1ccc(cc1)N(CC(F)(F)F)S(=O)(=O)c1ccccc1)(C(F)(F)F)C(F)(F)F, OC(c1ccc(cc1)N(CC(F)(F)F)S(=O)(=O)c1ccccc1)(C(F)(F)F)C(F)(F)F, OC(c1ccc(cc1)N(CC(F)(F)F)S(=O)(=O)c1ccccc1)(C(F)(F)F)C(F)(F)F, OC(c1ccc(cc1)N(CC(F)(F)F)S(=O)(=O)c1ccccc1)(C(F)(F)F)C(F)(F)F, OC(c1ccc(cc1)N(CC(F)(F)F)S(=O)(=O)c1ccccc1)(C(F)(F)F)C(F)(F)F	SGIWFELWJPNFDH-UHFFFAOYSA-N, SGIWFELWJPNFDH-UHFFFAOYSA-N, SGIWFELWJPNFDH-UHFFFAOYSA-N, SGIWFELWJPNFDH-UHFFFAOYSA-N, SGIWFELWJPNFDH-UHFFFAOYSA-N, SGIWFELWJPNFDH-UHFFFAOYSA-N, SGIWFELWJPNFDH-UHFFFAOYSA-N, SGIWFELWJPNFDH-UHFFFAOYSA-N	Preclinical
T-1095	sodium/glucose cotransporter inhibitor				COC(=O)OC[C@H]1O[C@@H](Oc2cc(C)cc(O)c2C(=O)CCc2ccc3occc3c2)[C@H](O)[C@@H](O)[C@@H]1O	BXNCIERBDJYIQT-PRDVQWLOSA-N	Preclinical
T-5224	AP inhibitor	JUN			OC(=O)CCc1cc(ccc1OCc1ccc2c(c1)o[nH]c2=O)C(=O)c1ccc(OC2CCCC2)cc1O, OC(=O)CCc1cc(ccc1OCc1ccc2c(c1)o[nH]c2=O)C(=O)c1ccc(OC2CCCC2)cc1O, OC(=O)CCc1cc(ccc1OCc1ccc2c(c1)o[nH]c2=O)C(=O)c1ccc(OC2CCCC2)cc1O	DALCQQSLNPLQFZ-UHFFFAOYSA-N, DALCQQSLNPLQFZ-UHFFFAOYSA-N, DALCQQSLNPLQFZ-UHFFFAOYSA-N	Phase 2
T-5601640	LIM kinase inhibitor	LIMK2			Cc1cc(on1)C(=O)Nc1cccc(c1)C(=O)Nc1cccc(c1)C(F)(F)F, Cc1cc(on1)C(=O)Nc1cccc(c1)C(=O)Nc1cccc(c1)C(F)(F)F	XVOKFRPKSAWELK-UHFFFAOYSA-N, XVOKFRPKSAWELK-UHFFFAOYSA-N	Preclinical
T-62	adenosine receptor modulator	ADORA2A			Nc1sc2CCCCc2c1C(=O)c1ccc(Cl)cc1, Nc1sc2CCCCc2c1C(=O)c1ccc(Cl)cc1	OTZVBZFYMFTYKH-UHFFFAOYSA-N, OTZVBZFYMFTYKH-UHFFFAOYSA-N	Phase 2
T-807	PET radiotracer				Fc1ccc(cn1)-c1ccc2c(c1)[nH]c1ccncc21	GETAAWDSFUCLBS-UHFFFAOYSA-N	Phase 2
TA-01	casein kinase inhibitor, MAP kinase inhibitor	CSNK1D, CSNK1E, MAPK14			Fc1ccc(cc1)-c1[nH]c(nc1-c1ccncc1)-c1c(F)cccc1F, Fc1ccc(cc1)-c1[nH]c(nc1-c1ccncc1)-c1c(F)cccc1F, Fc1ccc(cc1)-c1[nH]c(nc1-c1ccncc1)-c1c(F)cccc1F, Fc1ccc(cc1)-c1[nH]c(nc1-c1ccncc1)-c1c(F)cccc1F	TWPJJJZCYVFUOA-UHFFFAOYSA-N, TWPJJJZCYVFUOA-UHFFFAOYSA-N, TWPJJJZCYVFUOA-UHFFFAOYSA-N, TWPJJJZCYVFUOA-UHFFFAOYSA-N	Preclinical
tabimorelin	growth hormone secretagogue receptor agonist	GHSR			CNC(=O)[C@@H](Cc1ccccc1)N(C)C(=O)[C@@H](Cc1ccc2ccccc2c1)N(C)C(=O)\C=C\CC(C)(C)N, CNC(=O)[C@@H](Cc1ccccc1)N(C)C(=O)[C@@H](Cc1ccc2ccccc2c1)N(C)C(=O)\C=C\CC(C)(C)N, CNC(=O)[C@@H](Cc1ccccc1)N(C)C(=O)[C@@H](Cc1ccc2ccccc2c1)N(C)C(=O)\C=C\CC(C)(C)N	WURGZWOTGMLDJP-ZCYANPAGSA-N, WURGZWOTGMLDJP-ZCYANPAGSA-N, WURGZWOTGMLDJP-ZCYANPAGSA-N	Phase 2
tacalcitol	vitamin D receptor agonist	VDR	dermatology	psoriasis, chapped lips	CC(C)[C@H](O)CC[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C, CC(C)[C@H](O)CC[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C, CC(C)[C@H](O)CC[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C, CC(C)[C@H](O)CC[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C, CC(C)[C@H](O)CC[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C, CC(C)[C@H](O)CC[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C, CC(C)[C@H](O)CC[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C	BJYLYJCXYAMOFT-RSFVBTMBSA-N, BJYLYJCXYAMOFT-RSFVBTMBSA-N, BJYLYJCXYAMOFT-RSFVBTMBSA-N, BJYLYJCXYAMOFT-RSFVBTMBSA-N, BJYLYJCXYAMOFT-RSFVBTMBSA-N, BJYLYJCXYAMOFT-RSFVBTMBSA-N, BJYLYJCXYAMOFT-RSFVBTMBSA-N	Launched
tacedinaline	HDAC inhibitor	HDAC1			CC(=O)Nc1ccc(cc1)C(=O)Nc1ccccc1N, CC(=O)Nc1ccc(cc1)C(=O)Nc1ccccc1N, CC(=O)Nc1ccc(cc1)C(=O)Nc1ccccc1N, CC(=O)Nc1ccc(cc1)C(=O)Nc1ccccc1N, CC(=O)Nc1ccc(cc1)C(=O)Nc1ccccc1N, CC(=O)Nc1ccc(cc1)C(=O)Nc1ccccc1N, CC(=O)Nc1ccc(cc1)C(=O)Nc1ccccc1N	VAZAPHZUAVEOMC-UHFFFAOYSA-N, VAZAPHZUAVEOMC-UHFFFAOYSA-N, VAZAPHZUAVEOMC-UHFFFAOYSA-N, VAZAPHZUAVEOMC-UHFFFAOYSA-N, VAZAPHZUAVEOMC-UHFFFAOYSA-N, VAZAPHZUAVEOMC-UHFFFAOYSA-N, VAZAPHZUAVEOMC-UHFFFAOYSA-N	Phase 3
tacrine	acetylcholinesterase inhibitor	ACHE, BCHE	neurology/psychiatry	Alzheimer's disease	Nc1c2CCCCc2nc2ccccc12, Nc1c2CCCCc2nc2ccccc12, Nc1c2CCCCc2nc2ccccc12, Nc1c2CCCCc2nc2ccccc12, Nc1c2CCCCc2nc2ccccc12, Nc1c2CCCCc2nc2ccccc12	YLJREFDVOIBQDA-UHFFFAOYSA-N, YLJREFDVOIBQDA-UHFFFAOYSA-N, YLJREFDVOIBQDA-UHFFFAOYSA-N, YLJREFDVOIBQDA-UHFFFAOYSA-N, YLJREFDVOIBQDA-UHFFFAOYSA-N, YLJREFDVOIBQDA-UHFFFAOYSA-N	Launched
tacrolimus	calcineurin inhibitor	FKBP1A	transplant	organ rejection	CO[C@@H]1C[C@@H](CC[C@H]1O)\C=C(/C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@H](C[C@@H](C)C\C(C)=C\[C@@H](CC=C)C(=O)C[C@H](O)[C@H]1C)OC |t:45|, CO[C@@H]1C[C@@H](CC[C@H]1O)\C=C(/C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@H](C[C@@H](C)C\C(C)=C\[C@@H](CC=C)C(=O)C[C@H](O)[C@H]1C)OC |t:45|, CO[C@@H]1C[C@@H](CC[C@H]1O)\C=C(/C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@H](C[C@@H](C)C\C(C)=C\[C@@H](CC=C)C(=O)C[C@H](O)[C@H]1C)OC |t:45|, CO[C@@H]1C[C@@H](CC[C@H]1O)\C=C(/C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@H](C[C@@H](C)C\C(C)=C\[C@@H](CC=C)C(=O)C[C@H](O)[C@H]1C)OC |t:45|, CO[C@@H]1C[C@@H](CC[C@H]1O)\C=C(/C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@H](C[C@@H](C)C\C(C)=C\[C@@H](CC=C)C(=O)C[C@H](O)[C@H]1C)OC |t:45|, CO[C@@H]1C[C@@H](CC[C@H]1O)\C=C(/C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@H](C[C@@H](C)C\C(C)=C\[C@@H](CC=C)C(=O)C[C@H](O)[C@H]1C)OC |t:45|	QJJXYPPXXYFBGM-LFZNUXCKSA-N, QJJXYPPXXYFBGM-LFZNUXCKSA-N, QJJXYPPXXYFBGM-LFZNUXCKSA-N, QJJXYPPXXYFBGM-LFZNUXCKSA-N, QJJXYPPXXYFBGM-LFZNUXCKSA-N, QJJXYPPXXYFBGM-LFZNUXCKSA-N	Launched
tadalafil	phosphodiesterase inhibitor	PDE11A, PDE5A	urology	erectile dysfunction	CN1CC(=O)N2[C@H](Cc3c([nH]c4ccccc34)[C@H]2c2ccc3OCOc3c2)C1=O, CN1CC(=O)N2[C@H](Cc3c([nH]c4ccccc34)[C@H]2c2ccc3OCOc3c2)C1=O, CN1CC(=O)N2[C@H](Cc3c([nH]c4ccccc34)[C@H]2c2ccc3OCOc3c2)C1=O, CN1CC(=O)N2[C@H](Cc3c([nH]c4ccccc34)[C@H]2c2ccc3OCOc3c2)C1=O, CN1CC(=O)N2[C@H](Cc3c([nH]c4ccccc34)[C@H]2c2ccc3OCOc3c2)C1=O, CN1CC(=O)N2[C@H](Cc3c([nH]c4ccccc34)[C@H]2c2ccc3OCOc3c2)C1=O	WOXKDUGGOYFFRN-IIBYNOLFSA-N, WOXKDUGGOYFFRN-IIBYNOLFSA-N, WOXKDUGGOYFFRN-IIBYNOLFSA-N, WOXKDUGGOYFFRN-IIBYNOLFSA-N, WOXKDUGGOYFFRN-IIBYNOLFSA-N, WOXKDUGGOYFFRN-IIBYNOLFSA-N	Launched
tafamidis-meglumine	transthyretin amyloid inhibitor	TTR	neurology/psychiatry	familial amyloid polyneuropathy (FAP)	OC(=O)c1ccc2nc(oc2c1)-c1cc(Cl)cc(Cl)c1, OC(=O)c1ccc2nc(oc2c1)-c1cc(Cl)cc(Cl)c1	TXEIIPDJKFWEEC-UHFFFAOYSA-N, TXEIIPDJKFWEEC-UHFFFAOYSA-N	Launched
tafenoquine	antimalarial agent		infectious disease	malaria	COc1cc(C)c2c(Oc3cccc(c3)C(F)(F)F)c(OC)cc(N[C@@H](C)CCCN)c2n1 |&1:25|	LBHLFPGPEGDCJG-HNNXBMFYSA-N	Launched
tafluprost	prostaglandin inhibitor	PTGFR	ophthalmology	glaucoma, ocular hypertension	CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\C(F)(F)COc1ccccc1	WSNODXPBBALQOF-VEJSHDCNSA-N	Launched
tagatose	phosphorylase inhibitor	PYGL			OC[C@@H](O)[C@H](O)[C@H](O)C(=O)CO	BJHIKXHVCXFQLS-PQLUHFTBSA-N	Launched
TAK-063	phosphodiesterase inhibitor	PDE10A			COc1cn(nc(-c2ccnn2-c2ccccc2)c1=O)-c1ccc(cc1F)-n1cccn1	KVHRYLNQDWXAGI-UHFFFAOYSA-N	Phase 2
TAK-220	CC chemokine receptor antagonist	CCR5			CC(=O)N1CCC(CC1)C(=O)N(CCCN1CCC(Cc2ccc(cc2)C(N)=O)CC1)c1ccc(C)c(Cl)c1, CC(=O)N1CCC(CC1)C(=O)N(CCCN1CCC(Cc2ccc(cc2)C(N)=O)CC1)c1ccc(C)c(Cl)c1, CC(=O)N1CCC(CC1)C(=O)N(CCCN1CCC(Cc2ccc(cc2)C(N)=O)CC1)c1ccc(C)c(Cl)c1	ASSJTMUEFHUKMJ-UHFFFAOYSA-N, ASSJTMUEFHUKMJ-UHFFFAOYSA-N, ASSJTMUEFHUKMJ-UHFFFAOYSA-N	Phase 1
TAK-243	ubiquitin activating enzyme inhibitor				NS(=O)(=O)OC[C@H]1C[C@@H](Nc2ccnc3cc(nn23)-c2cccc(SC(F)(F)F)c2)[C@H](O)[C@@H]1O	KJDAGXLMHXUAGV-DGWLBADLSA-N	Phase 1
TAK-285	EGFR inhibitor	ERBB2			CC(C)(O)CC(=O)NCCn1ccc2ncnc(Nc3ccc(Oc4cccc(c4)C(F)(F)F)c(Cl)c3)c12, CC(C)(O)CC(=O)NCCn1ccc2ncnc(Nc3ccc(Oc4cccc(c4)C(F)(F)F)c(Cl)c3)c12, CC(C)(O)CC(=O)NCCn1ccc2ncnc(Nc3ccc(Oc4cccc(c4)C(F)(F)F)c(Cl)c3)c12, CC(C)(O)CC(=O)NCCn1ccc2ncnc(Nc3ccc(Oc4cccc(c4)C(F)(F)F)c(Cl)c3)c12	ZYQXEVJIFYIBHZ-UHFFFAOYSA-N, ZYQXEVJIFYIBHZ-UHFFFAOYSA-N, ZYQXEVJIFYIBHZ-UHFFFAOYSA-N, ZYQXEVJIFYIBHZ-UHFFFAOYSA-N	Phase 1
TAK-593	VEGFR inhibitor	PDGFRA			Cc1cc(C(=O)Nc2cc(Oc3ccc4nc(NC(=O)C5CC5)cn4n3)ccc2C)n(C)n1, Cc1cc(C(=O)Nc2cc(Oc3ccc4nc(NC(=O)C5CC5)cn4n3)ccc2C)n(C)n1	DZFZXPPHBWCXPQ-UHFFFAOYSA-N, DZFZXPPHBWCXPQ-UHFFFAOYSA-N	Phase 1
TAK-632	RAF inhibitor	BRAF			Fc1ccc(Oc2ccc3nc(NC(=O)C4CC4)sc3c2C#N)cc1NC(=O)Cc1cccc(c1)C(F)(F)F, Fc1ccc(Oc2ccc3nc(NC(=O)C4CC4)sc3c2C#N)cc1NC(=O)Cc1cccc(c1)C(F)(F)F, Fc1ccc(Oc2ccc3nc(NC(=O)C4CC4)sc3c2C#N)cc1NC(=O)Cc1cccc(c1)C(F)(F)F, Fc1ccc(Oc2ccc3nc(NC(=O)C4CC4)sc3c2C#N)cc1NC(=O)Cc1cccc(c1)C(F)(F)F	OJFKUJDRGJSAQB-UHFFFAOYSA-N, OJFKUJDRGJSAQB-UHFFFAOYSA-N, OJFKUJDRGJSAQB-UHFFFAOYSA-N, OJFKUJDRGJSAQB-UHFFFAOYSA-N	Preclinical
TAK-659	spleen associated tyrosine kinase inhibitor				Cn1cc(cn1)-c1nc(N[C@@H]2CCCC[C@@H]2N)c(F)c2CNC(=O)c12, Cn1cc(cn1)-c1nc(N[C@@H]2CCCC[C@@H]2N)c(F)c2CNC(=O)c12	MJHOMTRKVMKCNE-NWDGAFQWSA-N, MJHOMTRKVMKCNE-NWDGAFQWSA-N	Phase 2
TAK-715	p38 MAPK inhibitor	MAPK14			CCc1nc(c(s1)-c1ccnc(NC(=O)c2ccccc2)c1)-c1cccc(C)c1, CCc1nc(c(s1)-c1ccnc(NC(=O)c2ccccc2)c1)-c1cccc(C)c1, CCc1nc(c(s1)-c1ccnc(NC(=O)c2ccccc2)c1)-c1cccc(C)c1, CCc1nc(c(s1)-c1ccnc(NC(=O)c2ccccc2)c1)-c1cccc(C)c1, CCc1nc(c(s1)-c1ccnc(NC(=O)c2ccccc2)c1)-c1cccc(C)c1	HEKAIDKUDLCBRU-UHFFFAOYSA-N, HEKAIDKUDLCBRU-UHFFFAOYSA-N, HEKAIDKUDLCBRU-UHFFFAOYSA-N, HEKAIDKUDLCBRU-UHFFFAOYSA-N, HEKAIDKUDLCBRU-UHFFFAOYSA-N	Phase 2
TAK-733	MEK inhibitor	MAP2K1			Cn1c2ncn(C[C@@H](O)CO)c(=O)c2c(Nc2ccc(I)cc2F)c(F)c1=O, Cn1c2ncn(C[C@@H](O)CO)c(=O)c2c(Nc2ccc(I)cc2F)c(F)c1=O, Cn1c2ncn(C[C@@H](O)CO)c(=O)c2c(Nc2ccc(I)cc2F)c(F)c1=O, Cn1c2ncn(C[C@@H](O)CO)c(=O)c2c(Nc2ccc(I)cc2F)c(F)c1=O	RCLQNICOARASSR-SECBINFHSA-N, RCLQNICOARASSR-SECBINFHSA-N, RCLQNICOARASSR-SECBINFHSA-N, RCLQNICOARASSR-SECBINFHSA-N	Phase 1
TAK-779	CC chemokine receptor antagonist				Cc1ccc(cc1)-c1ccc2CCCC(=Cc2c1)C(=O)Nc1ccc(C[N+](C)(C)C2CCOCC2)cc1 |c:15|	XNHZXMPLVSJQFK-UHFFFAOYSA-O	Preclinical
TAK-875	insulin secretagogue	FFAR1			Cc1cc(OCCCS(C)(=O)=O)cc(C)c1-c1cccc(COc2ccc3[C@H](CC(O)=O)COc3c2)c1, Cc1cc(OCCCS(C)(=O)=O)cc(C)c1-c1cccc(COc2ccc3[C@H](CC(O)=O)COc3c2)c1, Cc1cc(OCCCS(C)(=O)=O)cc(C)c1-c1cccc(COc2ccc3[C@H](CC(O)=O)COc3c2)c1, Cc1cc(OCCCS(C)(=O)=O)cc(C)c1-c1cccc(COc2ccc3[C@H](CC(O)=O)COc3c2)c1, Cc1cc(OCCCS(C)(=O)=O)cc(C)c1-c1cccc(COc2ccc3[C@H](CC(O)=O)COc3c2)c1, Cc1cc(OCCCS(C)(=O)=O)cc(C)c1-c1cccc(COc2ccc3[C@H](CC(O)=O)COc3c2)c1	BZCALJIHZVNMGJ-HSZRJFAPSA-N, BZCALJIHZVNMGJ-HSZRJFAPSA-N, BZCALJIHZVNMGJ-HSZRJFAPSA-N, BZCALJIHZVNMGJ-HSZRJFAPSA-N, BZCALJIHZVNMGJ-HSZRJFAPSA-N, BZCALJIHZVNMGJ-HSZRJFAPSA-N	Phase 3
TAK-901	Aurora kinase inhibitor	AURKB			CCS(=O)(=O)c1cccc(c1)-c1cc(C(=O)NC2CCN(C)CC2)c(C)c2[nH]c3ncc(C)cc3c12, CCS(=O)(=O)c1cccc(c1)-c1cc(C(=O)NC2CCN(C)CC2)c(C)c2[nH]c3ncc(C)cc3c12, CCS(=O)(=O)c1cccc(c1)-c1cc(C(=O)NC2CCN(C)CC2)c(C)c2[nH]c3ncc(C)cc3c12	WKDACQVEJIVHMZ-UHFFFAOYSA-N, WKDACQVEJIVHMZ-UHFFFAOYSA-N, WKDACQVEJIVHMZ-UHFFFAOYSA-N	Phase 1
TAK-960	PLK inhibitor	PLK1			COc1cc(C(=O)NC2CCN(C)CC2)c(F)cc1Nc1ncc2N(C)C(=O)C(F)(F)CN(C3CCCC3)c2n1, COc1cc(C(=O)NC2CCN(C)CC2)c(F)cc1Nc1ncc2N(C)C(=O)C(F)(F)CN(C3CCCC3)c2n1, COc1cc(C(=O)NC2CCN(C)CC2)c(F)cc1Nc1ncc2N(C)C(=O)C(F)(F)CN(C3CCCC3)c2n1, COc1cc(C(=O)NC2CCN(C)CC2)c(F)cc1Nc1ncc2N(C)C(=O)C(F)(F)CN(C3CCCC3)c2n1	GWRSATNRNFYMDI-UHFFFAOYSA-N, GWRSATNRNFYMDI-UHFFFAOYSA-N, GWRSATNRNFYMDI-UHFFFAOYSA-N, GWRSATNRNFYMDI-UHFFFAOYSA-N	Phase 1
talabostat	dipeptidyl peptidase inhibitor, fibroblast activation protein inhibitor	DPP4			CC(C)[C@H](N)C(=O)N1CCC[C@H]1B(O)O, CC(C)[C@H](N)C(=O)N1CCC[C@H]1B(O)O, CC(C)[C@H](N)C(=O)N1CCC[C@H]1B(O)O	FKCMADOPPWWGNZ-YUMQZZPRSA-N, FKCMADOPPWWGNZ-YUMQZZPRSA-N, FKCMADOPPWWGNZ-YUMQZZPRSA-N	Phase 3
taladegib	smoothened receptor antagonist	DHH, IHH, SMO			CN(C1CCN(CC1)c1nnc(-c2ccnn2C)c2ccccc12)C(=O)c1ccc(F)cc1C(F)(F)F, CN(C1CCN(CC1)c1nnc(-c2ccnn2C)c2ccccc12)C(=O)c1ccc(F)cc1C(F)(F)F, CN(C1CCN(CC1)c1nnc(-c2ccnn2C)c2ccccc12)C(=O)c1ccc(F)cc1C(F)(F)F, CN(C1CCN(CC1)c1nnc(-c2ccnn2C)c2ccccc12)C(=O)c1ccc(F)cc1C(F)(F)F, CN(C1CCN(CC1)c1nnc(-c2ccnn2C)c2ccccc12)C(=O)c1ccc(F)cc1C(F)(F)F, CN(C1CCN(CC1)c1nnc(-c2ccnn2C)c2ccccc12)C(=O)c1ccc(F)cc1C(F)(F)F	SZBGQDXLNMELTB-UHFFFAOYSA-N, SZBGQDXLNMELTB-UHFFFAOYSA-N, SZBGQDXLNMELTB-UHFFFAOYSA-N, SZBGQDXLNMELTB-UHFFFAOYSA-N, SZBGQDXLNMELTB-UHFFFAOYSA-N, SZBGQDXLNMELTB-UHFFFAOYSA-N	Phase 2
talampanel	glutamate receptor antagonist	GRIA1, GRIA2, GRIA3, GRIA4			C[C@@H]1Cc2cc3OCOc3cc2C(=NN1C(C)=O)c1ccc(N)cc1 |c:14|, C[C@@H]1Cc2cc3OCOc3cc2C(=NN1C(C)=O)c1ccc(N)cc1 |c:14|, C[C@@H]1Cc2cc3OCOc3cc2C(=NN1C(C)=O)c1ccc(N)cc1 |c:14|	JACAAXNEHGBPOQ-LLVKDONJSA-N, JACAAXNEHGBPOQ-LLVKDONJSA-N, JACAAXNEHGBPOQ-LLVKDONJSA-N	Phase 2
talaporfin	photosensitizing agent				CCc1c(C)c2cc3[nH]c(cc4nc([C@@H](CCC(O)=O)[C@@H]4C)c(CC(=O)N[C@@H](CC(O)=O)C(O)=O)c4nc(cc1[nH]2)c(C)c4C(O)=O)c(C)c3C=C	SIEXFRDYNDREBM-WSUYNKMOSA-N	Phase 3
talarozole	cytochrome P450 inhibitor	CYP26A1			CCC(CC)[C@@H](c1ccc(Nc2nc3ccccc3s2)cc1)n1cncn1 |&1:5,r|, CCC(CC)[C@@H](c1ccc(Nc2nc3ccccc3s2)cc1)n1cncn1 |&1:5,r|, CCC(CC)[C@@H](c1ccc(Nc2nc3ccccc3s2)cc1)n1cncn1 |&1:5,r|	SNFYYXUGUBUECJ-FQEVSTJZSA-N, SNFYYXUGUBUECJ-FQEVSTJZSA-N, SNFYYXUGUBUECJ-FQEVSTJZSA-N	Phase 2
talazoparib	PARP inhibitor	PARP2	oncology	breast cancer	Cn1ncnc1[C@@H]1[C@H](Nc2cc(F)cc3c2c1n[nH]c3=O)c1ccc(F)cc1, Cn1ncnc1[C@@H]1[C@H](Nc2cc(F)cc3c2c1n[nH]c3=O)c1ccc(F)cc1, Cn1ncnc1[C@@H]1[C@H](Nc2cc(F)cc3c2c1n[nH]c3=O)c1ccc(F)cc1, Cn1ncnc1[C@@H]1[C@H](Nc2cc(F)cc3c2c1n[nH]c3=O)c1ccc(F)cc1, Cn1ncnc1[C@@H]1[C@H](Nc2cc(F)cc3c2c1n[nH]c3=O)c1ccc(F)cc1, Cn1ncnc1[C@@H]1[C@H](Nc2cc(F)cc3c2c1n[nH]c3=O)c1ccc(F)cc1, Cn1ncnc1[C@@H]1[C@H](Nc2cc(F)cc3c2c1n[nH]c3=O)c1ccc(F)cc1	HWGQMRYQVZSGDQ-HZPDHXFCSA-N, HWGQMRYQVZSGDQ-HZPDHXFCSA-N, HWGQMRYQVZSGDQ-HZPDHXFCSA-N, HWGQMRYQVZSGDQ-HZPDHXFCSA-N, HWGQMRYQVZSGDQ-HZPDHXFCSA-N, HWGQMRYQVZSGDQ-HZPDHXFCSA-N, HWGQMRYQVZSGDQ-HZPDHXFCSA-N	Launched
talinolol	adrenergic receptor antagonist	ADRB1	cardiology	hypertension	CC(C)(C)NC[C@@H](O)COc1ccc(NC(=O)NC2CCCCC2)cc1 |&1:6,r|, CC(C)(C)NC[C@@H](O)COc1ccc(NC(=O)NC2CCCCC2)cc1 |&1:6,r|, CC(C)(C)NC[C@@H](O)COc1ccc(NC(=O)NC2CCCCC2)cc1 |&1:6,r|	MXFWWQICDIZSOA-QGZVFWFLSA-N, MXFWWQICDIZSOA-QGZVFWFLSA-N, MXFWWQICDIZSOA-QGZVFWFLSA-N	Launched
talipexole	adrenergic receptor agonist, dopamine receptor agonist	ADRA2A, DRD2, HTR3A	infectious disease	genitial herpes	Nc1nc2CCN(CC=C)CCc2s1, Nc1nc2CCN(CC=C)CCc2s1, Nc1nc2CCN(CC=C)CCc2s1, Nc1nc2CCN(CC=C)CCc2s1	DHSSDEDRBUKTQY-UHFFFAOYSA-N, DHSSDEDRBUKTQY-UHFFFAOYSA-N, DHSSDEDRBUKTQY-UHFFFAOYSA-N, DHSSDEDRBUKTQY-UHFFFAOYSA-N	Launched
talmapimod	p38 MAPK inhibitor	IL1B, MAPK11, MAPK14, MT-CO2, TNF			C[C@H]1CN([C@H](C)CN1Cc1ccc(F)cc1)C(=O)c1cc2c(cn(C)c2cc1Cl)C(=O)C(=O)N(C)C, C[C@H]1CN([C@H](C)CN1Cc1ccc(F)cc1)C(=O)c1cc2c(cn(C)c2cc1Cl)C(=O)C(=O)N(C)C, C[C@H]1CN([C@H](C)CN1Cc1ccc(F)cc1)C(=O)c1cc2c(cn(C)c2cc1Cl)C(=O)C(=O)N(C)C, C[C@H]1CN([C@H](C)CN1Cc1ccc(F)cc1)C(=O)c1cc2c(cn(C)c2cc1Cl)C(=O)C(=O)N(C)C, C[C@H]1CN([C@H](C)CN1Cc1ccc(F)cc1)C(=O)c1cc2c(cn(C)c2cc1Cl)C(=O)C(=O)N(C)C, C[C@H]1CN([C@H](C)CN1Cc1ccc(F)cc1)C(=O)c1cc2c(cn(C)c2cc1Cl)C(=O)C(=O)N(C)C, C[C@H]1CN([C@H](C)CN1Cc1ccc(F)cc1)C(=O)c1cc2c(cn(C)c2cc1Cl)C(=O)C(=O)N(C)C, C[C@H]1CN([C@H](C)CN1Cc1ccc(F)cc1)C(=O)c1cc2c(cn(C)c2cc1Cl)C(=O)C(=O)N(C)C, C[C@H]1CN([C@H](C)CN1Cc1ccc(F)cc1)C(=O)c1cc2c(cn(C)c2cc1Cl)C(=O)C(=O)N(C)C	ZMELOYOKMZBMRB-DLBZAZTESA-N, ZMELOYOKMZBMRB-DLBZAZTESA-N, ZMELOYOKMZBMRB-DLBZAZTESA-N, ZMELOYOKMZBMRB-DLBZAZTESA-N, ZMELOYOKMZBMRB-DLBZAZTESA-N, ZMELOYOKMZBMRB-DLBZAZTESA-N, ZMELOYOKMZBMRB-DLBZAZTESA-N, ZMELOYOKMZBMRB-DLBZAZTESA-N, ZMELOYOKMZBMRB-DLBZAZTESA-N	Phase 2
talnetant	tachykinin antagonist	TACR2, TACR3			CC[C@H](NC(=O)c1c(O)c(nc2ccccc12)-c1ccccc1)c1ccccc1, CC[C@H](NC(=O)c1c(O)c(nc2ccccc12)-c1ccccc1)c1ccccc1	BIAVGWDGIJKWRM-FQEVSTJZSA-N, BIAVGWDGIJKWRM-FQEVSTJZSA-N	Phase 2
talniflumate	cyclooxygenase inhibitor	CLCA1	neurology/psychiatry	pain relief	FC(F)(F)c1cccc(Nc2ncccc2C(=O)O[C@H]2OC(=O)c3ccccc23)c1 |&1:19,r|, FC(F)(F)c1cccc(Nc2ncccc2C(=O)O[C@H]2OC(=O)c3ccccc23)c1 |&1:19,r|, FC(F)(F)c1cccc(Nc2ncccc2C(=O)O[C@H]2OC(=O)c3ccccc23)c1 |&1:19,r|, FC(F)(F)c1cccc(Nc2ncccc2C(=O)O[C@H]2OC(=O)c3ccccc23)c1 |&1:19,r|, FC(F)(F)c1cccc(Nc2ncccc2C(=O)O[C@H]2OC(=O)c3ccccc23)c1 |&1:19,r|	ANMLJLFWUCQGKZ-HXUWFJFHSA-N, ANMLJLFWUCQGKZ-HXUWFJFHSA-N, ANMLJLFWUCQGKZ-HXUWFJFHSA-N, ANMLJLFWUCQGKZ-HXUWFJFHSA-N, ANMLJLFWUCQGKZ-HXUWFJFHSA-N	Launched
talopram	adrenergic inhibitor	SLC6A2			CNCCC[C@]1(OC(C)(C)c2ccccc12)c1ccccc1 |&1:5|, CNCCC[C@]1(OC(C)(C)c2ccccc12)c1ccccc1 |&1:5|, CNCCC[C@]1(OC(C)(C)c2ccccc12)c1ccccc1 |&1:5|	LJBBMCNHIUJBDU-FQEVSTJZSA-N, LJBBMCNHIUJBDU-FQEVSTJZSA-N, LJBBMCNHIUJBDU-FQEVSTJZSA-N	Phase 2
talsaclidine	acetylcholine receptor agonist				C#CCO[C@H]1CN2CCC1CC2	XVFJONKUSLSKSW-JTQLQIEISA-N	Phase 2/Phase 3
taltirelin	thyrotropin releasing hormone receptor agonist	TRHR	neurology/psychiatry	spinocerebellar ataxia	CN1C(=O)C[C@H](NC1=O)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N1CCC[C@H]1C(N)=O, CN1C(=O)C[C@H](NC1=O)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N1CCC[C@H]1C(N)=O	LQZAIAZUDWIVPM-SRVKXCTJSA-N, LQZAIAZUDWIVPM-SRVKXCTJSA-N	Launched
taltobulin	tubulin polymerization inhibitor				CN[C@H](C(=O)N[C@H](C(=O)N(C)[C@H](\C=C(/C)C(O)=O)C(C)C)C(C)(C)C)C(C)(C)c1ccccc1, CN[C@H](C(=O)N[C@H](C(=O)N(C)[C@H](\C=C(/C)C(O)=O)C(C)C)C(C)(C)C)C(C)(C)c1ccccc1, CN[C@H](C(=O)N[C@H](C(=O)N(C)[C@H](\C=C(/C)C(O)=O)C(C)C)C(C)(C)C)C(C)(C)c1ccccc1, CN[C@H](C(=O)N[C@H](C(=O)N(C)[C@H](\C=C(/C)C(O)=O)C(C)C)C(C)(C)C)C(C)(C)c1ccccc1, CN[C@H](C(=O)N[C@H](C(=O)N(C)[C@H](\C=C(/C)C(O)=O)C(C)C)C(C)(C)C)C(C)(C)c1ccccc1, CN[C@H](C(=O)N[C@H](C(=O)N(C)[C@H](\C=C(/C)C(O)=O)C(C)C)C(C)(C)C)C(C)(C)c1ccccc1	CNTMOLDWXSVYKD-PSRNMDMQSA-N, CNTMOLDWXSVYKD-PSRNMDMQSA-N, CNTMOLDWXSVYKD-PSRNMDMQSA-N, CNTMOLDWXSVYKD-PSRNMDMQSA-N, CNTMOLDWXSVYKD-PSRNMDMQSA-N, CNTMOLDWXSVYKD-PSRNMDMQSA-N	Phase 1
TAME					COC(=O)[C@H](CCCNC(N)=N)NS(=O)(=O)c1ccc(C)cc1, COC(=O)[C@H](CCCNC(N)=N)NS(=O)(=O)c1ccc(C)cc1	FKMJXALNHKIDOD-LBPRGKRZSA-N, FKMJXALNHKIDOD-LBPRGKRZSA-N	Preclinical
tamibarotene	retinoid receptor agonist	RARA, RARB	hematologic malignancy	acute promyelocytic leukemia (APL)	CC1(C)CCC(C)(C)c2cc(NC(=O)c3ccc(cc3)C(O)=O)ccc12, CC1(C)CCC(C)(C)c2cc(NC(=O)c3ccc(cc3)C(O)=O)ccc12, CC1(C)CCC(C)(C)c2cc(NC(=O)c3ccc(cc3)C(O)=O)ccc12, CC1(C)CCC(C)(C)c2cc(NC(=O)c3ccc(cc3)C(O)=O)ccc12	MUTNCGKQJGXKEM-UHFFFAOYSA-N, MUTNCGKQJGXKEM-UHFFFAOYSA-N, MUTNCGKQJGXKEM-UHFFFAOYSA-N, InChI=1S/C22H25NO3/c1-21(2)11-12-22(3,4)18-13-16(9-10-17(18)21)23-19(24)14-5-7-15(8-6-14)20(25)26/h5-10,13H,11-12H2,1-4H3,(H,23,24)(H,25,26)	Launched
taminadenant	adenosine receptor antagonist				Nc1nc(nc(c1Br)-n1cccn1)-n1cccn1	ATFXVNUWQOXRRU-UHFFFAOYSA-N	Phase 1/Phase 2
tamoxifen	estrogen receptor antagonist, selective estrogen receptor modulator (SERM)	EBP, ESR1, ESR2, GPER1, PRKCA, PRKCB, PRKCD, PRKCE, PRKCG, PRKCI, PRKCQ, PRKCZ	oncology	breast cancer	CC\C(=C(/c1ccccc1)c1ccc(OCCN(C)C)cc1)c1ccccc1, CC\C(=C(/c1ccccc1)c1ccc(OCCN(C)C)cc1)c1ccccc1, CC\C(=C(/c1ccccc1)c1ccc(OCCN(C)C)cc1)c1ccccc1, CC\C(=C(/c1ccccc1)c1ccc(OCCN(C)C)cc1)c1ccccc1, CC\C(=C(/c1ccccc1)c1ccc(OCCN(C)C)cc1)c1ccccc1, CC\C(=C(/c1ccccc1)c1ccc(OCCN(C)C)cc1)c1ccccc1, CC\C(=C(/c1ccccc1)c1ccc(OCCN(C)C)cc1)c1ccccc1	NKANXQFJJICGDU-QPLCGJKRSA-N, NKANXQFJJICGDU-QPLCGJKRSA-N, NKANXQFJJICGDU-QPLCGJKRSA-N, NKANXQFJJICGDU-QPLCGJKRSA-N, NKANXQFJJICGDU-QPLCGJKRSA-N, NKANXQFJJICGDU-QPLCGJKRSA-N, NKANXQFJJICGDU-QPLCGJKRSA-N	Launched
tamsulosin	adrenergic receptor antagonist	ADRA1A, ADRA1B, ADRA1D	urology	benign prostatic hyperplasia (BPH)	CCOc1ccccc1OCCN[C@H](C)Cc1ccc(OC)c(c1)S(N)(=O)=O, CCOc1ccccc1OCCN[C@H](C)Cc1ccc(OC)c(c1)S(N)(=O)=O	DRHKJLXJIQTDTD-OAHLLOKOSA-N, DRHKJLXJIQTDTD-OAHLLOKOSA-N	Launched
tanaproget	progesterone receptor agonist	PGR			Cn1c(ccc1-c1ccc2NC(=S)OC(C)(C)c2c1)C#N, Cn1c(ccc1-c1ccc2NC(=S)OC(C)(C)c2c1)C#N, Cn1c(ccc1-c1ccc2NC(=S)OC(C)(C)c2c1)C#N, Cn1c(ccc1-c1ccc2NC(=S)OC(C)(C)c2c1)C#N, Cn1c(ccc1-c1ccc2NC(=S)OC(C)(C)c2c1)C#N	PYVFWTPEBMRKSR-UHFFFAOYSA-N, PYVFWTPEBMRKSR-UHFFFAOYSA-N, PYVFWTPEBMRKSR-UHFFFAOYSA-N, PYVFWTPEBMRKSR-UHFFFAOYSA-N, PYVFWTPEBMRKSR-UHFFFAOYSA-N	Phase 2
tandospirone	serotonin receptor agonist	HTR1A	neurology/psychiatry	generalized anxiety disorder (GAD), dysthymic disorder	O=C1[C@H]2[C@@H]3CC[C@@H](C3)[C@H]2C(=O)N1CCCCN1CCN(CC1)c1ncccn1, O=C1[C@H]2[C@@H]3CC[C@@H](C3)[C@H]2C(=O)N1CCCCN1CCN(CC1)c1ncccn1, O=C1[C@H]2[C@@H]3CC[C@@H](C3)[C@H]2C(=O)N1CCCCN1CCN(CC1)c1ncccn1, O=C1[C@H]2[C@@H]3CC[C@@H](C3)[C@H]2C(=O)N1CCCCN1CCN(CC1)c1ncccn1	CEIJFEGBUDEYSX-FZDBZEDMSA-N, CEIJFEGBUDEYSX-FZDBZEDMSA-N, CEIJFEGBUDEYSX-FZDBZEDMSA-N, CEIJFEGBUDEYSX-FZDBZEDMSA-N	Launched
tandutinib	FLT3 inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor	CSF1R, FLT3, KIT, PDGFD, PDGFRB			COc1cc2c(ncnc2cc1OCCCN1CCCCC1)N1CCN(CC1)C(=O)Nc1ccc(OC(C)C)cc1, COc1cc2c(ncnc2cc1OCCCN1CCCCC1)N1CCN(CC1)C(=O)Nc1ccc(OC(C)C)cc1, COc1cc2c(ncnc2cc1OCCCN1CCCCC1)N1CCN(CC1)C(=O)Nc1ccc(OC(C)C)cc1, COc1cc2c(ncnc2cc1OCCCN1CCCCC1)N1CCN(CC1)C(=O)Nc1ccc(OC(C)C)cc1, COc1cc2c(ncnc2cc1OCCCN1CCCCC1)N1CCN(CC1)C(=O)Nc1ccc(OC(C)C)cc1, COc1cc2c(ncnc2cc1OCCCN1CCCCC1)N1CCN(CC1)C(=O)Nc1ccc(OC(C)C)cc1	UXXQOJXBIDBUAC-UHFFFAOYSA-N, UXXQOJXBIDBUAC-UHFFFAOYSA-N, UXXQOJXBIDBUAC-UHFFFAOYSA-N, UXXQOJXBIDBUAC-UHFFFAOYSA-N, UXXQOJXBIDBUAC-UHFFFAOYSA-N, UXXQOJXBIDBUAC-UHFFFAOYSA-N	Phase 2
tanespimycin	HSP inhibitor	HSP90AA1			CO[C@H]1C[C@H](C)CC2=C(NCC=C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O |c:7,23,t:15,21,34|, CO[C@H]1C[C@H](C)CC2=C(NCC=C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O |c:7,23,t:15,21,34|, CO[C@H]1C[C@H](C)CC2=C(NCC=C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O |c:7,23,t:15,21,34|, CO[C@H]1C[C@H](C)CC2=C(NCC=C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O |c:7,23,t:15,21,34|, CO[C@H]1C[C@H](C)CC2=C(NCC=C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O |c:7,23,t:15,21,34|, CO[C@H]1C[C@H](C)CC2=C(NCC=C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O |c:7,23,t:15,21,34|, CO[C@H]1C[C@H](C)CC2=C(NCC=C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O |c:7,23,t:15,21,34|, CO[C@H]1C[C@H](C)CC2=C(NCC=C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O |c:7,23,t:15,21,34|, CO[C@H]1C[C@H](C)CC2=C(NCC=C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O |c:7,23,t:15,21,34|	AYUNIORJHRXIBJ-FBDSWQSESA-N, AYUNIORJHRXIBJ-FBDSWQSESA-N, AYUNIORJHRXIBJ-FBDSWQSESA-N, AYUNIORJHRXIBJ-FBDSWQSESA-N, AYUNIORJHRXIBJ-FBDSWQSESA-N, AYUNIORJHRXIBJ-FBDSWQSESA-N, AYUNIORJHRXIBJ-FBDSWQSESA-N, AYUNIORJHRXIBJ-FBDSWQSESA-N, AYUNIORJHRXIBJ-FBDSWQSESA-N	Phase 3
tangeritin	cell cycle inhibitor				COc1ccc(cc1)-c1cc(=O)c2c(OC)c(OC)c(OC)c(OC)c2o1, COc1ccc(cc1)-c1cc(=O)c2c(OC)c(OC)c(OC)c(OC)c2o1	ULSUXBXHSYSGDT-UHFFFAOYSA-N, ULSUXBXHSYSGDT-UHFFFAOYSA-N	Preclinical
tannic-acid	PARG inhibitor	ANO1	gastroenterology	constipation	Oc1cc(cc(O)c1O)C(=O)Oc1cc(cc(O)c1O)C(=O)OC[C@H]1O[C@@H](OC(=O)c2cc(O)c(O)c(OC(=O)c3cc(O)c(O)c(O)c3)c2)[C@H](OC(=O)c2cc(O)c(O)c(OC(=O)c3cc(O)c(O)c(O)c3)c2)[C@@H](OC(=O)c2cc(O)c(O)c(OC(=O)c3cc(O)c(O)c(O)c3)c2)[C@@H]1OC(=O)c1cc(O)c(O)c(OC(=O)c2cc(O)c(O)c(O)c2)c1	LRBQNJMCXXYXIU-PPKXGCFTSA-N	Launched
tanshinone-I	AP inhibitor	IFNG			Cc1coc-2c1C(=O)C(=O)c1c-2ccc2c(C)cccc12, Cc1coc-2c1C(=O)C(=O)c1c-2ccc2c(C)cccc12, Cc1coc-2c1C(=O)C(=O)c1c-2ccc2c(C)cccc12, Cc1coc-2c1C(=O)C(=O)c1c-2ccc2c(C)cccc12	AIGAZQPHXLWMOJ-UHFFFAOYSA-N, AIGAZQPHXLWMOJ-UHFFFAOYSA-N, AIGAZQPHXLWMOJ-UHFFFAOYSA-N, AIGAZQPHXLWMOJ-UHFFFAOYSA-N	Phase 2
tanshinone-IIA	anti-inflammatory agent, interleukin inhibitor	IL1B, NR1I2, TNF			Cc1coc-2c1C(=O)C(=O)c1c3CCCC(C)(C)c3ccc-21, Cc1coc-2c1C(=O)C(=O)c1c3CCCC(C)(C)c3ccc-21, Cc1coc-2c1C(=O)C(=O)c1c3CCCC(C)(C)c3ccc-21, Cc1coc-2c1C(=O)C(=O)c1c3CCCC(C)(C)c3ccc-21	HYXITZLLTYIPOF-UHFFFAOYSA-N, HYXITZLLTYIPOF-UHFFFAOYSA-N, HYXITZLLTYIPOF-UHFFFAOYSA-N, HYXITZLLTYIPOF-UHFFFAOYSA-N	Phase 2/Phase 3
tapinarof	aryl hydrocarbon receptor agonist				CC(C)c1c(O)cc(\C=C\c2ccccc2)cc1O	ZISJNXNHJRQYJO-CMDGGOBGSA-N	Phase 3
taprenepag	prostaglandin receptor agonist	PTGER2			OC(=O)COc1cccc(CN(Cc2ccc(cc2)-n2cccn2)S(=O)(=O)c2cccnc2)c1	MFFBXYNKZHTCEY-UHFFFAOYSA-N	Phase 2
tarafenacin	acetylcholine receptor antagonist	CHRM3			Fc1cccc(c1)N(Cc1cc(F)c(F)c(F)c1)C(=O)O[C@H]1C[N@@]2CC[C@H]1CC2	UXZDMXYRRQJIBJ-IBGZPJMESA-N	Phase 2
taranabant	cannabinoid receptor inverse agonist	CNR1			C[C@H](NC(=O)C(C)(C)Oc1ccc(cn1)C(F)(F)F)[C@@H](Cc1ccc(Cl)cc1)c1cccc(c1)C#N, C[C@H](NC(=O)C(C)(C)Oc1ccc(cn1)C(F)(F)F)[C@@H](Cc1ccc(Cl)cc1)c1cccc(c1)C#N, C[C@H](NC(=O)C(C)(C)Oc1ccc(cn1)C(F)(F)F)[C@@H](Cc1ccc(Cl)cc1)c1cccc(c1)C#N, C[C@H](NC(=O)C(C)(C)Oc1ccc(cn1)C(F)(F)F)[C@@H](Cc1ccc(Cl)cc1)c1cccc(c1)C#N, C[C@H](NC(=O)C(C)(C)Oc1ccc(cn1)C(F)(F)F)[C@@H](Cc1ccc(Cl)cc1)c1cccc(c1)C#N	QLYKJCMUNUWAGO-GAJHUEQPSA-N, QLYKJCMUNUWAGO-GAJHUEQPSA-N, QLYKJCMUNUWAGO-GAJHUEQPSA-N, QLYKJCMUNUWAGO-GAJHUEQPSA-N, QLYKJCMUNUWAGO-GAJHUEQPSA-N	Phase 3
targinine	nitric oxide synthase inhibitor	NOS3			CNC(=N)NCCC[C@H](N)C(O)=O	NTNWOCRCBQPEKQ-YFKPBYRVSA-N	Phase 3
tariquidar	P glycoprotein inhibitor	ABCB1			COc1cc2CCN(CCc3ccc(NC(=O)c4cc(OC)c(OC)cc4NC(=O)c4cnc5ccccc5c4)cc3)Cc2cc1OC, COc1cc2CCN(CCc3ccc(NC(=O)c4cc(OC)c(OC)cc4NC(=O)c4cnc5ccccc5c4)cc3)Cc2cc1OC, COc1cc2CCN(CCc3ccc(NC(=O)c4cc(OC)c(OC)cc4NC(=O)c4cnc5ccccc5c4)cc3)Cc2cc1OC, COc1cc2CCN(CCc3ccc(NC(=O)c4cc(OC)c(OC)cc4NC(=O)c4cnc5ccccc5c4)cc3)Cc2cc1OC, COc1cc2CCN(CCc3ccc(NC(=O)c4cc(OC)c(OC)cc4NC(=O)c4cnc5ccccc5c4)cc3)Cc2cc1OC, COc1cc2CCN(CCc3ccc(NC(=O)c4cc(OC)c(OC)cc4NC(=O)c4cnc5ccccc5c4)cc3)Cc2cc1OC, COc1cc2CCN(CCc3ccc(NC(=O)c4cc(OC)c(OC)cc4NC(=O)c4cnc5ccccc5c4)cc3)Cc2cc1OC	LGGHDPFKSSRQNS-UHFFFAOYSA-N, LGGHDPFKSSRQNS-UHFFFAOYSA-N, LGGHDPFKSSRQNS-UHFFFAOYSA-N, LGGHDPFKSSRQNS-UHFFFAOYSA-N, InChI=1S/C38H38N4O6/c1-45-33-18-25-14-16-42(23-28(25)19-34(33)46-2)15-13-24-9-11-29(12-10-24)40-38(44)30-20-35(47-3)36(48-4)21-32(30)41-37(43)27-17-26-7-5-6-8-31(26)39-22-27/h5-12,17-22H,13-16,23H2,1-4H3,(H,40,44)(H,41,43), InChI=1S/C38H38N4O6/c1-45-33-18-25-14-16-42(23-28(25)19-34(33)46-2)15-13-24-9-11-29(12-10-24)40-38(44)30-20-35(47-3)36(48-4)21-32(30)41-37(43)27-17-26-7-5-6-8-31(26)39-22-27/h5-12,17-22H,13-16,23H2,1-4H3,(H,40,44)(H,41,43), InChI=1S/C38H38N4O6/c1-45-33-18-25-14-16-42(23-28(25)19-34(33)46-2)15-13-24-9-11-29(12-10-24)40-38(44)30-20-35(47-3)36(48-4)21-32(30)41-37(43)27-17-26-7-5-6-8-31(26)39-22-27/h5-12,17-22H,13-16,23H2,1-4H3,(H,40,44)(H,41,43)	Phase 3
tartaric-acid	antioxidant				O[C@H]([C@@H](O)C(O)=O)C(O)=O, O[C@H]([C@@H](O)C(O)=O)C(O)=O	FEWJPZIEWOKRBE-JCYAYHJZSA-N, FEWJPZIEWOKRBE-JCYAYHJZSA-N	Launched
TAS-103	topoisomerase inhibitor	TOP1			CN(C)CCNc1nc2cc(O)ccc2c2-c3ccccc3C(=O)c12, CN(C)CCNc1nc2cc(O)ccc2c2-c3ccccc3C(=O)c12, CN(C)CCNc1nc2cc(O)ccc2c2-c3ccccc3C(=O)c12	ROWSTIYZUWEOMM-UHFFFAOYSA-N, ROWSTIYZUWEOMM-UHFFFAOYSA-N, ROWSTIYZUWEOMM-UHFFFAOYSA-N	Phase 1
taselisib	PI3K inhibitor	PIK3CA			CC(C)n1nc(C)nc1-c1cn2CCOc3cc(ccc3-c2n1)-c1cnn(c1)C(C)(C)C(N)=O, CC(C)n1nc(C)nc1-c1cn2CCOc3cc(ccc3-c2n1)-c1cnn(c1)C(C)(C)C(N)=O, CC(C)n1nc(C)nc1-c1cn2CCOc3cc(ccc3-c2n1)-c1cnn(c1)C(C)(C)C(N)=O, CC(C)n1nc(C)nc1-c1cn2CCOc3cc(ccc3-c2n1)-c1cnn(c1)C(C)(C)C(N)=O, CC(C)n1nc(C)nc1-c1cn2CCOc3cc(ccc3-c2n1)-c1cnn(c1)C(C)(C)C(N)=O, CC(C)n1nc(C)nc1-c1cn2CCOc3cc(ccc3-c2n1)-c1cnn(c1)C(C)(C)C(N)=O, CC(C)n1nc(C)nc1-c1cn2CCOc3cc(ccc3-c2n1)-c1cnn(c1)C(C)(C)C(N)=O, CC(C)n1nc(C)nc1-c1cn2CCOc3cc(ccc3-c2n1)-c1cnn(c1)C(C)(C)C(N)=O, CC(C)n1nc(C)nc1-c1cn2CCOc3cc(ccc3-c2n1)-c1cnn(c1)C(C)(C)C(N)=O, CC(C)n1nc(C)nc1-c1cn2CCOc3cc(ccc3-c2n1)-c1cnn(c1)C(C)(C)C(N)=O, CC(C)n1nc(C)nc1-c1cn2CCOc3cc(ccc3-c2n1)-c1cnn(c1)C(C)(C)C(N)=O	BEUQXVWXFDOSAQ-UHFFFAOYSA-N, BEUQXVWXFDOSAQ-UHFFFAOYSA-N, BEUQXVWXFDOSAQ-UHFFFAOYSA-N, BEUQXVWXFDOSAQ-UHFFFAOYSA-N, BEUQXVWXFDOSAQ-UHFFFAOYSA-N, InChI=1S/C24H28N8O2/c1-14(2)32-22(27-15(3)29-32)19-13-30-8-9-34-20-10-16(6-7-18(20)21(30)28-19)17-11-26-31(12-17)24(4,5)23(25)33/h6-7,10-14H,8-9H2,1-5H3,(H2,25,33), InChI=1S/C24H28N8O2/c1-14(2)32-22(27-15(3)29-32)19-13-30-8-9-34-20-10-16(6-7-18(20)21(30)28-19)17-11-26-31(12-17)24(4,5)23(25)33/h6-7,10-14H,8-9H2,1-5H3,(H2,25,33), InChI=1S/C24H28N8O2/c1-14(2)32-22(27-15(3)29-32)19-13-30-8-9-34-20-10-16(6-7-18(20)21(30)28-19)17-11-26-31(12-17)24(4,5)23(25)33/h6-7,10-14H,8-9H2,1-5H3,(H2,25,33), InChI=1S/C24H28N8O2/c1-14(2)32-22(27-15(3)29-32)19-13-30-8-9-34-20-10-16(6-7-18(20)21(30)28-19)17-11-26-31(12-17)24(4,5)23(25)33/h6-7,10-14H,8-9H2,1-5H3,(H2,25,33), InChI=1S/C24H28N8O2/c1-14(2)32-22(27-15(3)29-32)19-13-30-8-9-34-20-10-16(6-7-18(20)21(30)28-19)17-11-26-31(12-17)24(4,5)23(25)33/h6-7,10-14H,8-9H2,1-5H3,(H2,25,33), InChI=1S/C24H28N8O2/c1-14(2)32-22(27-15(3)29-32)19-13-30-8-9-34-20-10-16(6-7-18(20)21(30)28-19)17-11-26-31(12-17)24(4,5)23(25)33/h6-7,10-14H,8-9H2,1-5H3,(H2,25,33)	Phase 3
tasimelteon	melatonin receptor agonist	MTNR1A, MTNR1B	neurology/psychiatry	Non-24-Hour Sleep-Wake Disorder	CCC(=O)NC[C@@H]1C[C@H]1c1cccc2OCCc12	PTOIAAWZLUQTIO-GXFFZTMASA-N	Launched
tasisulam	apoptosis stimulant				Clc1ccc(C(=O)NS(=O)(=O)c2ccc(Br)s2)c(Cl)c1, Clc1ccc(C(=O)NS(=O)(=O)c2ccc(Br)s2)c(Cl)c1, Clc1ccc(C(=O)NS(=O)(=O)c2ccc(Br)s2)c(Cl)c1, Clc1ccc(C(=O)NS(=O)(=O)c2ccc(Br)s2)c(Cl)c1, Clc1ccc(C(=O)NS(=O)(=O)c2ccc(Br)s2)c(Cl)c1, Clc1ccc(C(=O)NS(=O)(=O)c2ccc(Br)s2)c(Cl)c1, Clc1ccc(C(=O)NS(=O)(=O)c2ccc(Br)s2)c(Cl)c1	WWONFUQGBVOKOF-UHFFFAOYSA-N, WWONFUQGBVOKOF-UHFFFAOYSA-N, WWONFUQGBVOKOF-UHFFFAOYSA-N, WWONFUQGBVOKOF-UHFFFAOYSA-N, WWONFUQGBVOKOF-UHFFFAOYSA-N, WWONFUQGBVOKOF-UHFFFAOYSA-N, WWONFUQGBVOKOF-UHFFFAOYSA-N	Phase 3
tasquinimod	angiogenesis inhibitor, S100A9 inhibitor	HDAC4			COc1cccc2n(C)c(=O)c(C(=O)N(C)c3ccc(cc3)C(F)(F)F)c(O)c12, COc1cccc2n(C)c(=O)c(C(=O)N(C)c3ccc(cc3)C(F)(F)F)c(O)c12, COc1cccc2n(C)c(=O)c(C(=O)N(C)c3ccc(cc3)C(F)(F)F)c(O)c12, COc1cccc2n(C)c(=O)c(C(=O)N(C)c3ccc(cc3)C(F)(F)F)c(O)c12	ONDYALNGTUAJDX-UHFFFAOYSA-N, ONDYALNGTUAJDX-UHFFFAOYSA-N, ONDYALNGTUAJDX-UHFFFAOYSA-N, ONDYALNGTUAJDX-UHFFFAOYSA-N	Phase 3
tasuldine	mucolytic agent				C(Sc1ncccn1)c1cccnc1, C(Sc1ncccn1)c1cccnc1	HMCTXMOKMWELFJ-UHFFFAOYSA-N, HMCTXMOKMWELFJ-UHFFFAOYSA-N	Phase 3
taurine	antioxidant		neurology/psychiatry	anxiety, irritability, sleeplessness	NCCS(O)(=O)=O, NCCS(O)(=O)=O	XOAAWQZATWQOTB-UHFFFAOYSA-N, XOAAWQZATWQOTB-UHFFFAOYSA-N	Launched
taurocholate	G protein-coupled receptor agonist	CEL, FABP6, SLCO1C1			C[C@H](CCC(=O)NCCS(O)(=O)=O)[C@H]1CC[C@H]2[C@@H]3[C@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3C[C@H](O)[C@]12C, C[C@H](CCC(=O)NCCS(O)(=O)=O)[C@H]1CC[C@H]2[C@@H]3[C@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3C[C@H](O)[C@]12C	WBWWGRHZICKQGZ-HZAMXZRMSA-N, WBWWGRHZICKQGZ-HZAMXZRMSA-N	Phase 1
tauroglycocholate	membrane permeability enhancer				[H][C@@]1(CC[C@@]2([H])[C@]3([H])[C@H](O)C[C@]4([H])C[C@H](O)CC[C@]4(C)[C@@]3([H])C[C@H](O)[C@]12C)[C@H](C)CCC(=O)NCC(=O)NCCS(O)(=O)=O	URJQSMIFSMHWSP-VVHBOOHCSA-N	Preclinical
taurolidine	apoptosis stimulant		infectious disease	catheter-related bloodstream infection	O=S1(=O)CCN(CN2CCS(=O)(=O)NC2)CN1	AJKIRUJIDFJUKJ-UHFFFAOYSA-N	Launched
tavaborole	leucyl-tRNA synthetase inhibitor		infectious disease	onychomycosis	OB1OCc2cc(F)ccc12, OB1OCc2cc(F)ccc12, OB1OCc2cc(F)ccc12	LFQDNHWZDQTITF-UHFFFAOYSA-N, LFQDNHWZDQTITF-UHFFFAOYSA-N, LFQDNHWZDQTITF-UHFFFAOYSA-N	Launched
tavilermide	tyrosine kinase partial agonist				NCCCC[C@@H]1NC(=O)[C@H](CCC(O)=O)NC(=O)c2cc(ccc2OCC[C@H](NC1=O)C(=O)NCC(O)=O)[N+]([O-])=O	DVJXNXPFYJIACK-ULQDDVLXSA-N	Phase 3
taxifolin	opioid receptor antagonist	ADIPOR2			O[C@@H]1[C@H](Oc2cc(O)cc(O)c2C1=O)c1ccc(O)c(O)c1, O[C@@H]1[C@H](Oc2cc(O)cc(O)c2C1=O)c1ccc(O)c(O)c1, O[C@@H]1[C@H](Oc2cc(O)cc(O)c2C1=O)c1ccc(O)c(O)c1, O[C@@H]1[C@H](Oc2cc(O)cc(O)c2C1=O)c1ccc(O)c(O)c1, O[C@@H]1[C@H](Oc2cc(O)cc(O)c2C1=O)c1ccc(O)c(O)c1, O[C@@H]1[C@H](Oc2cc(O)cc(O)c2C1=O)c1ccc(O)c(O)c1	CXQWRCVTCMQVQX-LSDHHAIUSA-N, CXQWRCVTCMQVQX-LSDHHAIUSA-N, CXQWRCVTCMQVQX-LSDHHAIUSA-N, CXQWRCVTCMQVQX-LSDHHAIUSA-N, CXQWRCVTCMQVQX-LSDHHAIUSA-N, CXQWRCVTCMQVQX-LSDHHAIUSA-N	Phase 2
tazarotene	retinoid receptor agonist	RARA, RARB, RARG, RXRB	dermatology	cosmetic, sunscreen lotion	CCOC(=O)c1ccc(nc1)C#Cc1ccc2SCCC(C)(C)c2c1, CCOC(=O)c1ccc(nc1)C#Cc1ccc2SCCC(C)(C)c2c1, CCOC(=O)c1ccc(nc1)C#Cc1ccc2SCCC(C)(C)c2c1	OGQICQVSFDPSEI-UHFFFAOYSA-N, OGQICQVSFDPSEI-UHFFFAOYSA-N, OGQICQVSFDPSEI-UHFFFAOYSA-N	Launched
tazemetostat	histone lysine methyltransferase inhibitor	EZH2			CCN(C1CCOCC1)c1cc(cc(C(=O)NCc2c(C)cc(C)[nH]c2=O)c1C)-c1ccc(CN2CCOCC2)cc1, CCN(C1CCOCC1)c1cc(cc(C(=O)NCc2c(C)cc(C)[nH]c2=O)c1C)-c1ccc(CN2CCOCC2)cc1, CCN(C1CCOCC1)c1cc(cc(C(=O)NCc2c(C)cc(C)[nH]c2=O)c1C)-c1ccc(CN2CCOCC2)cc1, CCN(C1CCOCC1)c1cc(cc(C(=O)NCc2c(C)cc(C)[nH]c2=O)c1C)-c1ccc(CN2CCOCC2)cc1	NSQSAUGJQHDYNO-UHFFFAOYSA-N, NSQSAUGJQHDYNO-UHFFFAOYSA-N, NSQSAUGJQHDYNO-UHFFFAOYSA-N, NSQSAUGJQHDYNO-UHFFFAOYSA-N	Launched
tazobactam	beta lactamase inhibitor		infectious disease	pneumonia	C[C@]1(Cn2ccnn2)[C@@H](N2[C@@H](CC2=O)S1(=O)=O)C(O)=O	LPQZKKCYTLCDGQ-WEDXCCLWSA-N	Launched
TBA-354					[O-][N+](=O)c1cn2C[C@@H](COc2n1)OCc1ccc(nc1)-c1ccc(OC(F)(F)F)cc1, [O-][N+](=O)c1cn2C[C@@H](COc2n1)OCc1ccc(nc1)-c1ccc(OC(F)(F)F)cc1	ZXSGSFMORAILEY-HNNXBMFYSA-N, ZXSGSFMORAILEY-HNNXBMFYSA-N	Phase 1
TBOA-(DL)	excitatory amino acid transporter inhibitor	SLC1A1, SLC1A2, SLC1A3, SLC1A6, SLC1A7			N[C@@H]([C@H](OCc1ccccc1)C(O)=O)C(O)=O.N[C@H]([C@@H](OCc1ccccc1)C(O)=O)C(O)=O, N[C@@H]([C@H](OCc1ccccc1)C(O)=O)C(O)=O.N[C@H]([C@@H](OCc1ccccc1)C(O)=O)C(O)=O, N[C@@H]([C@H](OCc1ccccc1)C(O)=O)C(O)=O.N[C@H]([C@@H](OCc1ccccc1)C(O)=O)C(O)=O, N[C@@H]([C@H](OCc1ccccc1)C(O)=O)C(O)=O.N[C@H]([C@@H](OCc1ccccc1)C(O)=O)C(O)=O, N[C@@H]([C@H](OCc1ccccc1)C(O)=O)C(O)=O.N[C@H]([C@@H](OCc1ccccc1)C(O)=O)C(O)=O	CSEZCYBVEGIYNG-MFBWXLJUSA-N, CSEZCYBVEGIYNG-MFBWXLJUSA-N, CSEZCYBVEGIYNG-MFBWXLJUSA-N, CSEZCYBVEGIYNG-MFBWXLJUSA-N, CSEZCYBVEGIYNG-MFBWXLJUSA-N	Preclinical
TC-A-2317	Aurora kinase inhibitor	AURKA			C[C@@H](CCCC(C)(C)O)Nc1nc(Nc2cc(C)n[nH]2)cc(C)c1C#N |&1:1|, C[C@@H](CCCC(C)(C)O)Nc1nc(Nc2cc(C)n[nH]2)cc(C)c1C#N |&1:1|, C[C@@H](CCCC(C)(C)O)Nc1nc(Nc2cc(C)n[nH]2)cc(C)c1C#N |&1:1|, C[C@@H](CCCC(C)(C)O)Nc1nc(Nc2cc(C)n[nH]2)cc(C)c1C#N |&1:1|	XHHRGYCOEVNAKV-ZDUSSCGKSA-N, XHHRGYCOEVNAKV-ZDUSSCGKSA-N, XHHRGYCOEVNAKV-ZDUSSCGKSA-N, XHHRGYCOEVNAKV-ZDUSSCGKSA-N	Preclinical
TC-ASK-10	MAP kinase inhibitor	MAP3K5, MAP3K6			CC(C)(C)c1ccc(cc1)C(=O)Nc1cn2cc(ccc2n1)-n1ccnc1, CC(C)(C)c1ccc(cc1)C(=O)Nc1cn2cc(ccc2n1)-n1ccnc1, CC(C)(C)c1ccc(cc1)C(=O)Nc1cn2cc(ccc2n1)-n1ccnc1, CC(C)(C)c1ccc(cc1)C(=O)Nc1cn2cc(ccc2n1)-n1ccnc1	SMJAMOAYGIVKRI-UHFFFAOYSA-N, SMJAMOAYGIVKRI-UHFFFAOYSA-N, SMJAMOAYGIVKRI-UHFFFAOYSA-N, SMJAMOAYGIVKRI-UHFFFAOYSA-N	Preclinical
TC-E-5002	histone demethylase inhibitor	KDM2A, KDM4A, KDM4C, KDM5A, KDM6A, KDM7A, PHF8			ON(CCC(O)=O)C(=O)CCCCCCCCC1CC1, ON(CCC(O)=O)C(=O)CCCCCCCCC1CC1, ON(CCC(O)=O)C(=O)CCCCCCCCC1CC1	NEHSERYKENINRH-UHFFFAOYSA-N, NEHSERYKENINRH-UHFFFAOYSA-N, NEHSERYKENINRH-UHFFFAOYSA-N	Preclinical
TC-E-5006	gamma secretase modulator	APP			C[C@@H](C(O)=O)c1ccc([C@@H](N2CCC(C)CC2)c2ccc(F)cc2)c(c1)-c1ccc(cc1)C(F)(F)F |&1:1,&2:9,r|, C[C@@H](C(O)=O)c1ccc([C@@H](N2CCC(C)CC2)c2ccc(F)cc2)c(c1)-c1ccc(cc1)C(F)(F)F |&1:1,&2:9,r|, C[C@@H](C(O)=O)c1ccc([C@@H](N2CCC(C)CC2)c2ccc(F)cc2)c(c1)-c1ccc(cc1)C(F)(F)F |&1:1,&2:9,r|, C[C@@H](C(O)=O)c1ccc([C@@H](N2CCC(C)CC2)c2ccc(F)cc2)c(c1)-c1ccc(cc1)C(F)(F)F |&1:1,&2:9,r|	ONYWALXTZFPKAS-WINIVTDRSA-N, ONYWALXTZFPKAS-WINIVTDRSA-N, ONYWALXTZFPKAS-WINIVTDRSA-N, ONYWALXTZFPKAS-WINIVTDRSA-N	Preclinical
TC-F-2	FAAH inhibitor	FAAH			CCn1c2ccccc2n([C@H]2CCCN(C2)c2nccc(n2)-c2cc3ccccc3o2)c1=O, CCn1c2ccccc2n([C@H]2CCCN(C2)c2nccc(n2)-c2cc3ccccc3o2)c1=O	NXTBLPPTZRPJCA-IBGZPJMESA-N, NXTBLPPTZRPJCA-IBGZPJMESA-N	Preclinical
TC-FPR-43	formyl peptide receptor agonist	FPR2			CC(C)c1c(NC(=O)Nc2ccc(Cl)cc2)c(=O)n(-c2ccccc2)n1C, CC(C)c1c(NC(=O)Nc2ccc(Cl)cc2)c(=O)n(-c2ccccc2)n1C	PAEBEUZTAPIOIO-UHFFFAOYSA-N, PAEBEUZTAPIOIO-UHFFFAOYSA-N	Preclinical
TC-G-1000	adrenergic receptor agonist	ADRA2A, ADRA2B, ADRA2C			Cc1sc(C)c2c1CCC=C2c1cnc[nH]1 |c:10|, Cc1sc(C)c2c1CCC=C2c1cnc[nH]1 |c:10|	RLKWQKZPCMICPS-UHFFFAOYSA-N, RLKWQKZPCMICPS-UHFFFAOYSA-N	Preclinical
TC-G-1004	adenosine receptor antagonist	ADORA2A			COC1CCN(CC1)c1cccc(n1)-c1cc(NC(C)=O)nc(n1)-n1nc(C)cc1C, COC1CCN(CC1)c1cccc(n1)-c1cc(NC(C)=O)nc(n1)-n1nc(C)cc1C, COC1CCN(CC1)c1cccc(n1)-c1cc(NC(C)=O)nc(n1)-n1nc(C)cc1C	JENSDTKXNVHSSN-UHFFFAOYSA-N, JENSDTKXNVHSSN-UHFFFAOYSA-N, JENSDTKXNVHSSN-UHFFFAOYSA-N	Preclinical
TC-G-1005	G protein-coupled receptor agonist	GPBAR1			Cc1ccc(C)c(Oc2ccncc2C(=O)N2CCN(C3CC3)c3ccccc23)c1, Cc1ccc(C)c(Oc2ccncc2C(=O)N2CCN(C3CC3)c3ccccc23)c1	JQULIQJSYPZQMA-UHFFFAOYSA-N, JQULIQJSYPZQMA-UHFFFAOYSA-N	Preclinical
TC-G-1008	G protein-coupled receptor agonist	GPR39			CNc1nc(NCc2ccc(NS(C)(=O)=O)cc2Cl)cc(n1)-c1ccccn1, CNc1nc(NCc2ccc(NS(C)(=O)=O)cc2Cl)cc(n1)-c1ccccn1	DRSZMILOMUPIBJ-UHFFFAOYSA-N, DRSZMILOMUPIBJ-UHFFFAOYSA-N	Preclinical
TC-H-106	HDAC inhibitor	HDAC1, HDAC2, HDAC3, HDAC8			Cc1ccc(NC(=O)CCCCCC(=O)Nc2ccccc2N)cc1, Cc1ccc(NC(=O)CCCCCC(=O)Nc2ccccc2N)cc1, Cc1ccc(NC(=O)CCCCCC(=O)Nc2ccccc2N)cc1, Cc1ccc(NC(=O)CCCCCC(=O)Nc2ccccc2N)cc1, Cc1ccc(NC(=O)CCCCCC(=O)Nc2ccccc2N)cc1, Cc1ccc(NC(=O)CCCCCC(=O)Nc2ccccc2N)cc1	WTKBRPXPNAKVEQ-UHFFFAOYSA-N, WTKBRPXPNAKVEQ-UHFFFAOYSA-N, InChI=1S/C20H25N3O2/c1-15-11-13-16(14-12-15)22-19(24)9-3-2-4-10-20(25)23-18-8-6-5-7-17(18)21/h5-8,11-14H,2-4,9-10,21H2,1H3,(H,22,24)(H,23,25), InChI=1S/C20H25N3O2/c1-15-11-13-16(14-12-15)22-19(24)9-3-2-4-10-20(25)23-18-8-6-5-7-17(18)21/h5-8,11-14H,2-4,9-10,21H2,1H3,(H,22,24)(H,23,25), InChI=1S/C20H25N3O2/c1-15-11-13-16(14-12-15)22-19(24)9-3-2-4-10-20(25)23-18-8-6-5-7-17(18)21/h5-8,11-14H,2-4,9-10,21H2,1H3,(H,22,24)(H,23,25), InChI=1S/C20H25N3O2/c1-15-11-13-16(14-12-15)22-19(24)9-3-2-4-10-20(25)23-18-8-6-5-7-17(18)21/h5-8,11-14H,2-4,9-10,21H2,1H3,(H,22,24)(H,23,25)	Preclinical
TC-I-15	integrin inhibitor	ITGA2, ITGB1			CC1(C)SCN([C@@H]1C(=O)N[C@@H](CNC(=O)NCc1ccccc1)C(O)=O)S(=O)(=O)c1ccccc1, CC1(C)SCN([C@@H]1C(=O)N[C@@H](CNC(=O)NCc1ccccc1)C(O)=O)S(=O)(=O)c1ccccc1, CC1(C)SCN([C@@H]1C(=O)N[C@@H](CNC(=O)NCc1ccccc1)C(O)=O)S(=O)(=O)c1ccccc1	XKLHCUGVLCGKKX-RBUKOAKNSA-N, XKLHCUGVLCGKKX-RBUKOAKNSA-N, XKLHCUGVLCGKKX-RBUKOAKNSA-N	Preclinical
TC-I-2000	transient receptor potential channel antagonist	TRPM8			Fc1ccc(NC(=O)N2CCc3ccccc3[C@@H]2c2ccc(cc2)C(F)(F)F)cc1 |&1:17,r|, Fc1ccc(NC(=O)N2CCc3ccccc3[C@@H]2c2ccc(cc2)C(F)(F)F)cc1 |&1:17,r|, Fc1ccc(NC(=O)N2CCc3ccccc3[C@@H]2c2ccc(cc2)C(F)(F)F)cc1 |&1:17,r|, Fc1ccc(NC(=O)N2CCc3ccccc3[C@@H]2c2ccc(cc2)C(F)(F)F)cc1 |&1:17,r|	ADCDUDFEGFKKQH-NRFANRHFSA-N, ADCDUDFEGFKKQH-NRFANRHFSA-N, ADCDUDFEGFKKQH-NRFANRHFSA-N, ADCDUDFEGFKKQH-NRFANRHFSA-N	Preclinical
TC-I-2014	transient receptor potential channel antagonist	TRPM8			FC(F)(F)c1ccccc1-c1cc(c2[nH]c(nc2c1)C1=NOC2(C1)CCCCC2)C(F)(F)F |t:22|, FC(F)(F)c1ccccc1-c1cc(c2[nH]c(nc2c1)C1=NOC2(C1)CCCCC2)C(F)(F)F |t:22|, FC(F)(F)c1ccccc1-c1cc(c2[nH]c(nc2c1)C1=NOC2(C1)CCCCC2)C(F)(F)F |t:22|	VSMFCZZEKTVDHM-UHFFFAOYSA-N, VSMFCZZEKTVDHM-UHFFFAOYSA-N, VSMFCZZEKTVDHM-UHFFFAOYSA-N	Preclinical
TC-LPA5-4	lysophosphatidic acid receptor antagonist	LPAR5			COc1cccc(c1)-n1nc(cc1-c1ccc(C2CCCCC2)c(Cl)c1)C(O)=O, COc1cccc(c1)-n1nc(cc1-c1ccc(C2CCCCC2)c(Cl)c1)C(O)=O, COc1cccc(c1)-n1nc(cc1-c1ccc(C2CCCCC2)c(Cl)c1)C(O)=O, COc1cccc(c1)-n1nc(cc1-c1ccc(C2CCCCC2)c(Cl)c1)C(O)=O, COc1cccc(c1)-n1nc(cc1-c1ccc(C2CCCCC2)c(Cl)c1)C(O)=O	BNALUYKEGYUHQC-UHFFFAOYSA-N, BNALUYKEGYUHQC-UHFFFAOYSA-N, BNALUYKEGYUHQC-UHFFFAOYSA-N, BNALUYKEGYUHQC-UHFFFAOYSA-N, BNALUYKEGYUHQC-UHFFFAOYSA-N	Preclinical
TC-Mps1-12	monopolar spindle 1 kinase inhibitor	TTK			CC(C)(C)Nc1nc(Nc2ccc(cc2)C(N)=O)cc(N)c1C#N, CC(C)(C)Nc1nc(Nc2ccc(cc2)C(N)=O)cc(N)c1C#N	XDEFNAWAKYQBQY-UHFFFAOYSA-N, XDEFNAWAKYQBQY-UHFFFAOYSA-N	Preclinical
TC-N-1752	sodium channel blocker	SCN9A			CC(=O)Nc1cccc(Nc2ncnc(n2)N2CCC(CC2)OCc2ccc(OC(F)(F)F)cc2)c1C, CC(=O)Nc1cccc(Nc2ncnc(n2)N2CCC(CC2)OCc2ccc(OC(F)(F)F)cc2)c1C, CC(=O)Nc1cccc(Nc2ncnc(n2)N2CCC(CC2)OCc2ccc(OC(F)(F)F)cc2)c1C	QLKAFHZJICDACE-UHFFFAOYSA-N, QLKAFHZJICDACE-UHFFFAOYSA-N, QLKAFHZJICDACE-UHFFFAOYSA-N	Preclinical
TC-NTR1-17	neurotensin agonist	NTSR1			COc1cccc(OC)c1-c1cc(nn1-c1ccnc2cc(Cl)ccc12)C(=O)N[C@@H](CC(C)C)C(O)=O, COc1cccc(OC)c1-c1cc(nn1-c1ccnc2cc(Cl)ccc12)C(=O)N[C@@H](CC(C)C)C(O)=O	ZQUSYVORYNBGLG-FQEVSTJZSA-N, ZQUSYVORYNBGLG-FQEVSTJZSA-N	Preclinical
TC-O-9311	G protein-coupled receptor agonist	GPR139			COc1cc(OC)cc(c1)C(=O)NNC(=O)Nc1cccc2ccccc12, COc1cc(OC)cc(c1)C(=O)NNC(=O)Nc1cccc2ccccc12, COc1cc(OC)cc(c1)C(=O)NNC(=O)Nc1cccc2ccccc12	KPTMSQHTGZMEFU-UHFFFAOYSA-N, KPTMSQHTGZMEFU-UHFFFAOYSA-N, KPTMSQHTGZMEFU-UHFFFAOYSA-N	Preclinical
TC-OT-39	oxytocin receptor agonist, vasopressin receptor agonist	AVPR1A, OXT			CN1CCCN(CC1)C(=S)[C@@H]1CCCN1C(=O)NCc1ccc(cc1C)C(=O)N1Cc2cnn(C)c2Nc2ccccc12, CN1CCCN(CC1)C(=S)[C@@H]1CCCN1C(=O)NCc1ccc(cc1C)C(=O)N1Cc2cnn(C)c2Nc2ccccc12, CN1CCCN(CC1)C(=S)[C@@H]1CCCN1C(=O)NCc1ccc(cc1C)C(=O)N1Cc2cnn(C)c2Nc2ccccc12	KSNHHKZYKYNBEI-NDEPHWFRSA-N, KSNHHKZYKYNBEI-NDEPHWFRSA-N, KSNHHKZYKYNBEI-NDEPHWFRSA-N	Preclinical
TC-S-7003	SRC inhibitor	LCK			CN1CCN(CC1)c1ccc(Nc2ncc3c(n2)n2c(nc4ccccc24)n(-c2c(C)cccc2C)c3=O)cc1, CN1CCN(CC1)c1ccc(Nc2ncc3c(n2)n2c(nc4ccccc24)n(-c2c(C)cccc2C)c3=O)cc1	BHJJWVDKNXABFS-UHFFFAOYSA-N, BHJJWVDKNXABFS-UHFFFAOYSA-N	Preclinical
TC-S-7004	DYRK inhibitor	DYRK1A, DYRK1B			COc1ncc2cc(C(=O)Nc3cc(ccc3Cl)C(=O)NCc3cccc(Cl)c3)c(=O)[nH]c2n1, COc1ncc2cc(C(=O)Nc3cc(ccc3Cl)C(=O)NCc3cccc(Cl)c3)c(=O)[nH]c2n1, COc1ncc2cc(C(=O)Nc3cc(ccc3Cl)C(=O)NCc3cccc(Cl)c3)c(=O)[nH]c2n1, COc1ncc2cc(C(=O)Nc3cc(ccc3Cl)C(=O)NCc3cccc(Cl)c3)c(=O)[nH]c2n1	CQKBSRPVZZLCJE-UHFFFAOYSA-N, CQKBSRPVZZLCJE-UHFFFAOYSA-N, CQKBSRPVZZLCJE-UHFFFAOYSA-N, CQKBSRPVZZLCJE-UHFFFAOYSA-N	Preclinical
TC-S-7005	PLK inhibitor	PLK2			C[C@H](Nc1cc2c(noc2cn1)-c1ccc2OCOc2c1)c1ccccc1, C[C@H](Nc1cc2c(noc2cn1)-c1ccc2OCOc2c1)c1ccccc1	DAAGOCSHXCDWDY-ZDUSSCGKSA-N, DAAGOCSHXCDWDY-ZDUSSCGKSA-N	Preclinical
TC-S-7006	MAP kinase inhibitor	MAP3K8			Fc1ccc(Nc2c(cnc3cnc(NCc4cccnc4)cc23)C#N)cc1Cl, Fc1ccc(Nc2c(cnc3cnc(NCc4cccnc4)cc23)C#N)cc1Cl	NMEUKWOOQOHUNA-UHFFFAOYSA-N, NMEUKWOOQOHUNA-UHFFFAOYSA-N	Preclinical
TC-S-7009	hypoxia inducible factor inhibitor	EPAS1			[O-][N+](=O)c1c(Nc2cc(F)cc(Cl)c2)ccc2nonc12, [O-][N+](=O)c1c(Nc2cc(F)cc(Cl)c2)ccc2nonc12	CDQUJZKBRAFWNG-UHFFFAOYSA-N, CDQUJZKBRAFWNG-UHFFFAOYSA-N	Preclinical
TC-SP-14	sphingosine 1-phosphate receptor agonist	S1PR1			OC(=O)C1CN(Cc2ccc(-c3nc4cc(Cc5ccccc5F)ccc4s3)c(F)c2)C1, OC(=O)C1CN(Cc2ccc(-c3nc4cc(Cc5ccccc5F)ccc4s3)c(F)c2)C1	GVXGVDIXINMAAL-UHFFFAOYSA-N, GVXGVDIXINMAAL-UHFFFAOYSA-N	Preclinical
TCID					Clc1c2C(=O)CC(=O)c2c(Cl)c(Cl)c1Cl, Clc1c2C(=O)CC(=O)c2c(Cl)c(Cl)c1Cl, Clc1c2C(=O)CC(=O)c2c(Cl)c(Cl)c1Cl, Clc1c2C(=O)CC(=O)c2c(Cl)c(Cl)c1Cl, Clc1c2C(=O)CC(=O)c2c(Cl)c(Cl)c1Cl	IDLAOWFFKWRNHB-UHFFFAOYSA-N, IDLAOWFFKWRNHB-UHFFFAOYSA-N, IDLAOWFFKWRNHB-UHFFFAOYSA-N, IDLAOWFFKWRNHB-UHFFFAOYSA-N, IDLAOWFFKWRNHB-UHFFFAOYSA-N	Preclinical
TCN201	glutamate receptor antagonist	GRIN2A			Fc1ccc(cc1Cl)S(=O)(=O)NCc1ccc(cc1)C(=O)NNC(=O)c1ccccc1, Fc1ccc(cc1Cl)S(=O)(=O)NCc1ccc(cc1)C(=O)NNC(=O)c1ccccc1, Fc1ccc(cc1Cl)S(=O)(=O)NCc1ccc(cc1)C(=O)NNC(=O)c1ccccc1, Fc1ccc(cc1Cl)S(=O)(=O)NCc1ccc(cc1)C(=O)NNC(=O)c1ccccc1	FYIBXBFDXNPBSF-UHFFFAOYSA-N, FYIBXBFDXNPBSF-UHFFFAOYSA-N, FYIBXBFDXNPBSF-UHFFFAOYSA-N, FYIBXBFDXNPBSF-UHFFFAOYSA-N	Preclinical
TCN238	glutamate receptor positive allosteric modulator	GRM4			Nc1nccc(\C=C\c2ccccc2)n1, Nc1nccc(\C=C\c2ccccc2)n1	LNUXNUNUGIHCPA-VOTSOKGWSA-N, LNUXNUNUGIHCPA-VOTSOKGWSA-N	Preclinical
TCS-HDAC6-20b	HDAC inhibitor	HDAC6			CC(C)C(=O)SCCCCC[C@H](NC(=O)OC(C)(C)C)C(=O)NC12CC3CC(CC(C3)C1)C2, CC(C)C(=O)SCCCCC[C@H](NC(=O)OC(C)(C)C)C(=O)NC12CC3CC(CC(C3)C1)C2, CC(C)C(=O)SCCCCC[C@H](NC(=O)OC(C)(C)C)C(=O)NC12CC3CC(CC(C3)C1)C2	DQZMLPMCOMRJOR-MOVGKWKRSA-N, DQZMLPMCOMRJOR-MOVGKWKRSA-N, DQZMLPMCOMRJOR-MOVGKWKRSA-N	Preclinical
TCS-OX2-29	orexin receptor antagonist	HCRTR2			COc1cc2CCN(Cc2cc1OC)C(=O)[C@@H](NCc1ccncc1)C(C)(C)C, COc1cc2CCN(Cc2cc1OC)C(=O)[C@@H](NCc1ccncc1)C(C)(C)C	COFVZFLCAOUMJT-OAQYLSRUSA-N, InChI=1S/C23H31N3O3/c1-23(2,3)21(25-14-16-6-9-24-10-7-16)22(27)26-11-8-17-12-19(28-4)20(29-5)13-18(17)15-26/h6-7,9-10,12-13,21,25H,8,11,14-15H2,1-5H3/t21-/m1/s1	Preclinical
TCS-PIM-1-1	Pim kinase inhibitor	PIM1			Oc1ccc(Br)cc1-c1cc(-c2ccccc2)c(C#N)c(=O)[nH]1, Oc1ccc(Br)cc1-c1cc(-c2ccccc2)c(C#N)c(=O)[nH]1	SVSYJTYGPLVUOZ-UHFFFAOYSA-N, SVSYJTYGPLVUOZ-UHFFFAOYSA-N	Preclinical
TCS-2002	glycogen synthase kinase inhibitor	GSK3B			Cc1nnc(o1)-c1ccc2occ(-c3ccc(cc3)[S@](C)=O)c2c1 |&1:19,r|	RCKYSTKYIVULEK-DEOSSOPVSA-N	Preclinical
TCS-21311	JAK inhibitor	JAK3			CC(C)(O)C(=O)N1CCN(CC1)c1ccc(c(c1)C1=C(C(=O)NC1=O)c1c[nH]c2ccccc12)C(F)(F)F |t:20|, CC(C)(O)C(=O)N1CCN(CC1)c1ccc(c(c1)C1=C(C(=O)NC1=O)c1c[nH]c2ccccc12)C(F)(F)F |t:20|, CC(C)(O)C(=O)N1CCN(CC1)c1ccc(c(c1)C1=C(C(=O)NC1=O)c1c[nH]c2ccccc12)C(F)(F)F |t:20|, CC(C)(O)C(=O)N1CCN(CC1)c1ccc(c(c1)C1=C(C(=O)NC1=O)c1c[nH]c2ccccc12)C(F)(F)F |t:20|, CC(C)(O)C(=O)N1CCN(CC1)c1ccc(c(c1)C1=C(C(=O)NC1=O)c1c[nH]c2ccccc12)C(F)(F)F |t:20|	CLGRAWDGLMENOD-UHFFFAOYSA-N, CLGRAWDGLMENOD-UHFFFAOYSA-N, CLGRAWDGLMENOD-UHFFFAOYSA-N, CLGRAWDGLMENOD-UHFFFAOYSA-N, CLGRAWDGLMENOD-UHFFFAOYSA-N	Preclinical
TCS-2210	neural stem cell inducer				ONC(=O)c1ccc2[nH]c(=O)c(CCCc3ccccc3)nc2c1, ONC(=O)c1ccc2[nH]c(=O)c(CCCc3ccccc3)nc2c1	ZOFZKGFBKISZRI-UHFFFAOYSA-N, ZOFZKGFBKISZRI-UHFFFAOYSA-N	Preclinical
TCS-2314	integrin inhibitor	ITGA4, ITGB1			Cc1ccccc1NC(=O)Nc1ccc(CC(=O)N2CCOC[C@H]2C(=O)N2CCC(CC(O)=O)CC2)cc1, Cc1ccccc1NC(=O)Nc1ccc(CC(=O)N2CCOC[C@H]2C(=O)N2CCC(CC(O)=O)CC2)cc1, Cc1ccccc1NC(=O)Nc1ccc(CC(=O)N2CCOC[C@H]2C(=O)N2CCC(CC(O)=O)CC2)cc1	ITXAAOWFOURIHK-DEOSSOPVSA-N, ITXAAOWFOURIHK-DEOSSOPVSA-N, ITXAAOWFOURIHK-DEOSSOPVSA-N	Preclinical
TCS-3035	G protein-coupled receptor agonist	GPR35			OC(=O)COc1ccc(\C=C2/SC(=O)NC2=O)cc1, OC(=O)COc1ccc(\C=C2/SC(=O)NC2=O)cc1	WXMCOLGPDOYHNK-UITAMQMPSA-N, WXMCOLGPDOYHNK-UITAMQMPSA-N	Preclinical
TCS-359	FLT3 inhibitor	FLT3			COc1ccc(cc1OC)C(=O)Nc1sc2CCCCc2c1C(N)=O, COc1ccc(cc1OC)C(=O)Nc1sc2CCCCc2c1C(N)=O, COc1ccc(cc1OC)C(=O)Nc1sc2CCCCc2c1C(N)=O, COc1ccc(cc1OC)C(=O)Nc1sc2CCCCc2c1C(N)=O, COc1ccc(cc1OC)C(=O)Nc1sc2CCCCc2c1C(N)=O, COc1ccc(cc1OC)C(=O)Nc1sc2CCCCc2c1C(N)=O, COc1ccc(cc1OC)C(=O)Nc1sc2CCCCc2c1C(N)=O	FSPQCTGGIANIJZ-UHFFFAOYSA-N, FSPQCTGGIANIJZ-UHFFFAOYSA-N, FSPQCTGGIANIJZ-UHFFFAOYSA-N, FSPQCTGGIANIJZ-UHFFFAOYSA-N, FSPQCTGGIANIJZ-UHFFFAOYSA-N, FSPQCTGGIANIJZ-UHFFFAOYSA-N, FSPQCTGGIANIJZ-UHFFFAOYSA-N	Preclinical
TCS-5861528	transient receptor potential channel antagonist	TRPA1			CC[C@@H](C)c1ccc(NC(=O)Cn2cnc3n(C)c(=O)n(C)c(=O)c23)cc1 |&1:2,r|, CC[C@@H](C)c1ccc(NC(=O)Cn2cnc3n(C)c(=O)n(C)c(=O)c23)cc1 |&1:2,r|, CC[C@@H](C)c1ccc(NC(=O)Cn2cnc3n(C)c(=O)n(C)c(=O)c23)cc1 |&1:2,r|, CC[C@@H](C)c1ccc(NC(=O)Cn2cnc3n(C)c(=O)n(C)c(=O)c23)cc1 |&1:2,r|	ZUTUWJYMCADJHD-GFCCVEGCSA-N, ZUTUWJYMCADJHD-GFCCVEGCSA-N, ZUTUWJYMCADJHD-GFCCVEGCSA-N, ZUTUWJYMCADJHD-GFCCVEGCSA-N	Preclinical
TCV-309	platelet activating factor receptor antagonist				CCC[n+]1cc(Br)cc(c1)C(=O)N(CCC(=O)NCCOC(=O)N1CCc2ccccc2C1)c1ccccc1	NWWZMECSQFUIGC-UHFFFAOYSA-O	Preclinical
TC1	beta-secretase inhibitor	BACE1			O[C@@]12[C@H]3[C@H]4[C@H]5[C@@H]3[C@@H]([C@H]3[C@@H]5C[C@@H]4[C@@H]13)N2CCc1cccc(F)c1 |&1:1,&2:2,&3:3,&4:4,&5:5,&6:6,&7:7,&8:8,&9:10,&10:11,r,TLB:13:12:2.5:7.11|, O[C@@]12[C@H]3[C@H]4[C@H]5[C@@H]3[C@@H]([C@H]3[C@@H]5C[C@@H]4[C@@H]13)N2CCc1cccc(F)c1 |&1:1,&2:2,&3:3,&4:4,&5:5,&6:6,&7:7,&8:8,&9:10,&10:11,r,TLB:13:12:2.5:7.11|, O[C@@]12[C@H]3[C@H]4[C@H]5[C@@H]3[C@@H]([C@H]3[C@@H]5C[C@@H]4[C@@H]13)N2CCc1cccc(F)c1 |&1:1,&2:2,&3:3,&4:4,&5:5,&6:6,&7:7,&8:8,&9:10,&10:11,r,TLB:13:12:2.5:7.11|, O[C@@]12[C@H]3[C@H]4[C@H]5[C@@H]3[C@@H]([C@H]3[C@@H]5C[C@@H]4[C@@H]13)N2CCc1cccc(F)c1 |&1:1,&2:2,&3:3,&4:4,&5:5,&6:6,&7:7,&8:8,&9:10,&10:11,r,TLB:13:12:2.5:7.11|, O[C@@]12[C@H]3[C@H]4[C@H]5[C@@H]3[C@@H]([C@H]3[C@@H]5C[C@@H]4[C@@H]13)N2CCc1cccc(F)c1 |&1:1,&2:2,&3:3,&4:4,&5:5,&6:6,&7:7,&8:8,&9:10,&10:11,r,TLB:13:12:2.5:7.11|, O[C@@]12[C@H]3[C@H]4[C@H]5[C@@H]3[C@@H]([C@H]3[C@@H]5C[C@@H]4[C@@H]13)N2CCc1cccc(F)c1 |&1:1,&2:2,&3:3,&4:4,&5:5,&6:6,&7:7,&8:8,&9:10,&10:11,r,TLB:13:12:2.5:7.11|	FYGREZKTJIXWIH-APDWONGJSA-N, FYGREZKTJIXWIH-APDWONGJSA-N, FYGREZKTJIXWIH-APDWONGJSA-N, FYGREZKTJIXWIH-APDWONGJSA-N, FYGREZKTJIXWIH-APDWONGJSA-N, InChI=1S/C19H20FNO/c20-9-3-1-2-8(6-9)4-5-21-18-14-10-7-11-13-12(10)15(18)17(13)19(21,22)16(11)14/h1-3,6,10-18,22H,4-5,7H2/t10-,11+,12+,13-,14+,15+,16-,17+,18-,19-/m1/s1	Preclinical
TC2559	acetylcholine receptor agonist	CHRNA4			CCOc1cncc(\C=C\CCNC)c1, CCOc1cncc(\C=C\CCNC)c1	HFZDMKMXPGRKCK-GQCTYLIASA-N, HFZDMKMXPGRKCK-GQCTYLIASA-N	Preclinical
TD139	anti-inflammatory agent				OC[C@H]1O[C@@H](S[C@@H]2O[C@H](CO)[C@H](O)[C@@H]([C@H]2O)n2cc(nn2)-c2cccc(F)c2)[C@H](O)[C@H]([C@H]1O)n1cc(nn1)-c1cccc(F)c1	YGIDGBAHDZEYMT-MQFIMZJJSA-N	Phase 2
tebipenem	bacterial cell wall synthesis inhibitor	CNR1	infectious disease, otolaryngology	pneumonia, otitis	C[C@@H](O)[C@@H]1[C@H]2[C@@H](C)C(SC3CN(C3)C3=NCCS3)=C(N2C1=O)C(=O)OCOC(=O)C(C)(C)C |c:19,t:14|	SNUDIPVBUUXCDG-QHSBEEBCSA-N	Launched
tecadenoson	adenosine receptor agonist	ADORA1			OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(N[C@@H]3CCOC3)ncnc12	OESBDSFYJMDRJY-BAYCTPFLSA-N	Phase 2
tecalcet	calcium-sensing receptor agonist	CASR			COc1cccc(c1)[C@@H](C)NCCCc1ccccc1Cl, COc1cccc(c1)[C@@H](C)NCCCc1ccccc1Cl	ZVQUCWXZCKWZBP-CQSZACIVSA-N, ZVQUCWXZCKWZBP-CQSZACIVSA-N	Phase 2
tecastemizole	histamine receptor antagonist	KCNH2			Fc1ccc(Cn2c(NC3CCNCC3)nc3ccccc23)cc1, Fc1ccc(Cn2c(NC3CCNCC3)nc3ccccc23)cc1, Fc1ccc(Cn2c(NC3CCNCC3)nc3ccccc23)cc1, Fc1ccc(Cn2c(NC3CCNCC3)nc3ccccc23)cc1	SFOVDSLXFUGAIV-UHFFFAOYSA-N, SFOVDSLXFUGAIV-UHFFFAOYSA-N, SFOVDSLXFUGAIV-UHFFFAOYSA-N, SFOVDSLXFUGAIV-UHFFFAOYSA-N	Phase 3
tecovirimat	orthopoxvirus egress inhibitor		infectious disease	smallpox	FC(F)(F)c1ccc(cc1)C(=O)NN1C(=O)[C@H]2[C@H]([C@H]3C=C[C@@H]2[C@@H]2C[C@H]32)C1=O |c:20|, FC(F)(F)c1ccc(cc1)C(=O)NN1C(=O)[C@H]2[C@H]([C@H]3C=C[C@@H]2[C@@H]2C[C@H]32)C1=O |c:20|	CSKDFZIMJXRJGH-VWLPUNTISA-N, CSKDFZIMJXRJGH-VWLPUNTISA-N	Launched
tedizolid	bacterial 50S ribosomal subunit inhibitor		infectious disease	skin infections	Cn1nnc(n1)-c1ccc(cn1)-c1ccc(cc1F)N1C[C@H](CO)OC1=O, Cn1nnc(n1)-c1ccc(cn1)-c1ccc(cc1F)N1C[C@H](CO)OC1=O, Cn1nnc(n1)-c1ccc(cn1)-c1ccc(cc1F)N1C[C@H](CO)OC1=O, Cn1nnc(n1)-c1ccc(cn1)-c1ccc(cc1F)N1C[C@H](CO)OC1=O, Cn1nnc(n1)-c1ccc(cn1)-c1ccc(cc1F)N1C[C@H](CO)OC1=O	XFALPSLJIHVRKE-GFCCVEGCSA-N, XFALPSLJIHVRKE-GFCCVEGCSA-N, XFALPSLJIHVRKE-GFCCVEGCSA-N, XFALPSLJIHVRKE-GFCCVEGCSA-N, XFALPSLJIHVRKE-GFCCVEGCSA-N	Launched
tedizolid-phosphate	protein synthesis inhibitor		infectious disease	skin infections	Cn1nnc(n1)-c1ccc(cn1)-c1ccc(cc1F)N1C[C@H](COP(O)(O)=O)OC1=O, Cn1nnc(n1)-c1ccc(cn1)-c1ccc(cc1F)N1C[C@H](COP(O)(O)=O)OC1=O, Cn1nnc(n1)-c1ccc(cn1)-c1ccc(cc1F)N1C[C@H](COP(O)(O)=O)OC1=O, Cn1nnc(n1)-c1ccc(cn1)-c1ccc(cc1F)N1C[C@H](COP(O)(O)=O)OC1=O	QCGUSIANLFXSGE-GFCCVEGCSA-N, QCGUSIANLFXSGE-GFCCVEGCSA-N, QCGUSIANLFXSGE-GFCCVEGCSA-N, QCGUSIANLFXSGE-GFCCVEGCSA-N	Launched
tegaserod	serotonin receptor partial agonist	HTR2A, HTR2B, HTR2C, HTR4			CCCCCNC(=N)N\N=C\c1c[nH]c2ccc(OC)cc12, CCCCCNC(=N)N\N=C\c1c[nH]c2ccc(OC)cc12, CCCCCNC(=N)N\N=C\c1c[nH]c2ccc(OC)cc12, CCCCCNC(=N)N\N=C\c1c[nH]c2ccc(OC)cc12	IKBKZGMPCYNSLU-RGVLZGJSSA-N, IKBKZGMPCYNSLU-RGVLZGJSSA-N, IKBKZGMPCYNSLU-RGVLZGJSSA-N, IKBKZGMPCYNSLU-RGVLZGJSSA-N	Withdrawn
tegobuvir	HCV inhibitor, protease inhibitor				Fc1ccccc1-c1nc2ccn(Cc3ccc(nn3)-c3ccc(cc3C(F)(F)F)C(F)(F)F)cc2n1, Fc1ccccc1-c1nc2ccn(Cc3ccc(nn3)-c3ccc(cc3C(F)(F)F)C(F)(F)F)cc2n1	XBEQSQDCBSKCHJ-UHFFFAOYSA-N, XBEQSQDCBSKCHJ-UHFFFAOYSA-N	Phase 3
teicoplanin	bacterial cell wall synthesis inhibitor		infectious disease	gram-positive bacterial infections	CCCCCCCCCC(=O)N[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1Oc1c2Oc3ccc(C[C@H]4NC(=O)[C@@H](N)c5ccc(O)c(Oc6cc(O)cc(c6)[C@H](NC4=O)C(=O)N[C@@H]4c(c2)cc1Oc1ccc(cc1Cl)[C@@H](O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1NC(C)=O)[C@@H]1NC(=O)[C@H](NC4=O)c2ccc(O)c(c2)-c2c(O[C@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]4O)cc(O)cc2[C@@H](NC1=O)C(O)=O)c5)cc3Cl, CCCCCCCCCC(=O)N[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1Oc1c2Oc3ccc(C[C@H]4NC(=O)[C@@H](N)c5ccc(O)c(Oc6cc(O)cc(c6)[C@H](NC4=O)C(=O)N[C@@H]4c(c2)cc1Oc1ccc(cc1Cl)[C@@H](O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1NC(C)=O)[C@@H]1NC(=O)[C@H](NC4=O)c2ccc(O)c(c2)-c2c(O[C@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]4O)cc(O)cc2[C@@H](NC1=O)C(O)=O)c5)cc3Cl	BJNLLBUOHPVGFT-SZRRLYCBSA-N, BJNLLBUOHPVGFT-SZRRLYCBSA-N	Launched
teicoplanin-A2-1	bacterial cell wall synthesis inhibitor		infectious disease	gram-positive bacterial infections	CCCCC\C=C\CCC(=O)N[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1Oc1c2Oc3ccc(C[C@H]4NC(=O)[C@H](N)c5ccc(O)c(Oc6cc(O)cc(c6)[C@H](NC4=O)C(=O)N[C@@H]4c(c2)cc1Oc1ccc(cc1Cl)[C@@H](O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1NC(C)=O)[C@@H]1NC(=O)[C@H](NC4=O)c2ccc(O)c(c2)-c2c(O[C@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]4O)cc(O)cc2[C@H](NC1=O)C(O)=O)c5)cc3Cl |a:12,13,15,17,21,35,51,58,71,73,75,78,80,82,87,91,107,110,112,114,121,&1:31,&2:105|, CCCCC\C=C\CCC(=O)N[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1Oc1c2Oc3ccc(C[C@H]4NC(=O)[C@H](N)c5ccc(O)c(Oc6cc(O)cc(c6)[C@H](NC4=O)C(=O)N[C@@H]4c(c2)cc1Oc1ccc(cc1Cl)[C@@H](O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1NC(C)=O)[C@@H]1NC(=O)[C@H](NC4=O)c2ccc(O)c(c2)-c2c(O[C@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]4O)cc(O)cc2[C@H](NC1=O)C(O)=O)c5)cc3Cl |a:12,13,15,17,21,35,51,58,71,73,75,78,80,82,87,91,107,110,112,114,121,&1:31,&2:105|	YMWQIYMUNZBOOV-FEHVOAPLSA-N, YMWQIYMUNZBOOV-FEHVOAPLSA-N	Launched
teicoplanin-A2-3	bacterial cell wall synthesis inhibitor		infectious disease	gram-positive bacterial infections	CC(C)CCCCCCCC(=O)N[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1Oc1c2Oc3ccc(C[C@H]4NC(=O)[C@H](N)c5ccc(O)c(Oc6cc(O)cc(c6)[C@H](NC4=O)C(=O)N[C@H]4c(c2)cc1Oc1ccc(cc1Cl)[C@@H](O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]1NC(C)=O)[C@@H]1NC(=O)[C@@H](NC4=O)c2ccc(O)c(c2)-c2c(O[C@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]4O)cc(O)cc2[C@@H](NC1=O)C(O)=O)c5)cc3Cl	FHBQKTSCJKPYIO-VHULWTHOSA-N	Launched
teijin-compound-1	CC chemokine receptor antagonist	CCR2			FC(F)(F)c1cccc(c1)C(=O)NCC(=O)N[C@@H]1CCN(Cc2ccc(Cl)cc2)C1, FC(F)(F)c1cccc(c1)C(=O)NCC(=O)N[C@@H]1CCN(Cc2ccc(Cl)cc2)C1	BAOQJSULMWXFRK-GOSISDBHSA-N, BAOQJSULMWXFRK-GOSISDBHSA-N	Preclinical
telaprevir	HCV inhibitor	CTSA, PGR	infectious disease	hepatitis C	CCC[C@H](NC(=O)[C@@H]1[C@H]2CCC[C@H]2CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)c1cnccn1)C1CCCCC1)C(C)(C)C)C(=O)C(=O)NC1CC1, CCC[C@H](NC(=O)[C@@H]1[C@H]2CCC[C@H]2CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)c1cnccn1)C1CCCCC1)C(C)(C)C)C(=O)C(=O)NC1CC1, CCC[C@H](NC(=O)[C@@H]1[C@H]2CCC[C@H]2CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)c1cnccn1)C1CCCCC1)C(C)(C)C)C(=O)C(=O)NC1CC1, CCC[C@H](NC(=O)[C@@H]1[C@H]2CCC[C@H]2CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)c1cnccn1)C1CCCCC1)C(C)(C)C)C(=O)C(=O)NC1CC1, CCC[C@H](NC(=O)[C@@H]1[C@H]2CCC[C@H]2CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)c1cnccn1)C1CCCCC1)C(C)(C)C)C(=O)C(=O)NC1CC1, CCC[C@H](NC(=O)[C@@H]1[C@H]2CCC[C@H]2CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)c1cnccn1)C1CCCCC1)C(C)(C)C)C(=O)C(=O)NC1CC1, CCC[C@H](NC(=O)[C@@H]1[C@H]2CCC[C@H]2CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)c1cnccn1)C1CCCCC1)C(C)(C)C)C(=O)C(=O)NC1CC1	BBAWEDCPNXPBQM-GDEBMMAJSA-N, BBAWEDCPNXPBQM-GDEBMMAJSA-N, BBAWEDCPNXPBQM-GDEBMMAJSA-N, BBAWEDCPNXPBQM-GDEBMMAJSA-N, BBAWEDCPNXPBQM-GDEBMMAJSA-N, BBAWEDCPNXPBQM-GDEBMMAJSA-N, BBAWEDCPNXPBQM-GDEBMMAJSA-N	Launched
telatinib	KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	KDR			CNC(=O)c1cc(COc2nnc(Nc3ccc(Cl)cc3)c3ccoc23)ccn1, CNC(=O)c1cc(COc2nnc(Nc3ccc(Cl)cc3)c3ccoc23)ccn1, CNC(=O)c1cc(COc2nnc(Nc3ccc(Cl)cc3)c3ccoc23)ccn1	QFCXANHHBCGMAS-UHFFFAOYSA-N, QFCXANHHBCGMAS-UHFFFAOYSA-N, QFCXANHHBCGMAS-UHFFFAOYSA-N	Phase 2
telbivudine	DNA polymerase inhibitor		infectious disease	hepatitis B	Cc1cn([C@@H]2C[C@@H](O)[C@H](CO)O2)c(=O)[nH]c1=O, Cc1cn([C@@H]2C[C@@H](O)[C@H](CO)O2)c(=O)[nH]c1=O	IQFYYKKMVGJFEH-CSMHCCOUSA-N, IQFYYKKMVGJFEH-CSMHCCOUSA-N	Launched
telcagepant	calcitonin antagonist	CALCRL, RAMP1			Fc1cccc([C@@H]2CC[C@@H](NC(=O)N3CCC(CC3)n3c4cccnc4[nH]c3=O)C(=O)N(CC(F)(F)F)C2)c1F, Fc1cccc([C@@H]2CC[C@@H](NC(=O)N3CCC(CC3)n3c4cccnc4[nH]c3=O)C(=O)N(CC(F)(F)F)C2)c1F, Fc1cccc([C@@H]2CC[C@@H](NC(=O)N3CCC(CC3)n3c4cccnc4[nH]c3=O)C(=O)N(CC(F)(F)F)C2)c1F, Fc1cccc([C@@H]2CC[C@@H](NC(=O)N3CCC(CC3)n3c4cccnc4[nH]c3=O)C(=O)N(CC(F)(F)F)C2)c1F	CGDZXLJGHVKVIE-DNVCBOLYSA-N, CGDZXLJGHVKVIE-DNVCBOLYSA-N, CGDZXLJGHVKVIE-DNVCBOLYSA-N, CGDZXLJGHVKVIE-DNVCBOLYSA-N	Phase 3
telenzepine	acetylcholine receptor antagonist	CHRM1			CN1CCN(CC(=O)N2c3c(C)scc3C(=O)Nc3ccccc23)CC1, CN1CCN(CC(=O)N2c3c(C)scc3C(=O)Nc3ccccc23)CC1	VSWPGAIWKHPTKX-UHFFFAOYSA-N, VSWPGAIWKHPTKX-UHFFFAOYSA-N	Phase 3
telithromycin	bacterial 30S ribosomal subunit inhibitor, bacterial 50S ribosomal subunit inhibitor	CYP1A2, CYP2D6, CYP3A4, CYP3A5, CYP3A7	infectious disease	pneumonia	CC[C@H]1OC(=O)[C@H](C)C(=O)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@@](C)(C[C@@H](C)C(=O)[C@H](C)[C@H]2N(CCCCn3cnc(c3)-c3cccnc3)C(=O)O[C@]12C)OC, CC[C@H]1OC(=O)[C@H](C)C(=O)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@@](C)(C[C@@H](C)C(=O)[C@H](C)[C@H]2N(CCCCn3cnc(c3)-c3cccnc3)C(=O)O[C@]12C)OC	LJVAJPDWBABPEJ-PIRKDXADSA-N, LJVAJPDWBABPEJ-PIRKDXADSA-N	Launched
telmesteine	mucolytic agent		pulmonary	cough suppressant	CCOC(=O)N1CSC[C@@H]1C(O)=O |&1:9,r|	XBJWOGLKABXFJE-RXMQYKEDSA-N	Launched
telmisartan	angiotensin receptor antagonist	AGTR1, PPARG	cardiology	hypertension	CCCc1nc2c(C)cc(cc2n1Cc1ccc(cc1)-c1ccccc1C(O)=O)-c1nc2ccccc2n1C, CCCc1nc2c(C)cc(cc2n1Cc1ccc(cc1)-c1ccccc1C(O)=O)-c1nc2ccccc2n1C, CCCc1nc2c(C)cc(cc2n1Cc1ccc(cc1)-c1ccccc1C(O)=O)-c1nc2ccccc2n1C, CCCc1nc2c(C)cc(cc2n1Cc1ccc(cc1)-c1ccccc1C(O)=O)-c1nc2ccccc2n1C, CCCc1nc2c(C)cc(cc2n1Cc1ccc(cc1)-c1ccccc1C(O)=O)-c1nc2ccccc2n1C, CCCc1nc2c(C)cc(cc2n1Cc1ccc(cc1)-c1ccccc1C(O)=O)-c1nc2ccccc2n1C, CCCc1nc2c(C)cc(cc2n1Cc1ccc(cc1)-c1ccccc1C(O)=O)-c1nc2ccccc2n1C, CCCc1nc2c(C)cc(cc2n1Cc1ccc(cc1)-c1ccccc1C(O)=O)-c1nc2ccccc2n1C, CCCc1nc2c(C)cc(cc2n1Cc1ccc(cc1)-c1ccccc1C(O)=O)-c1nc2ccccc2n1C	RMMXLENWKUUMAY-UHFFFAOYSA-N, RMMXLENWKUUMAY-UHFFFAOYSA-N, RMMXLENWKUUMAY-UHFFFAOYSA-N, RMMXLENWKUUMAY-UHFFFAOYSA-N, RMMXLENWKUUMAY-UHFFFAOYSA-N, RMMXLENWKUUMAY-UHFFFAOYSA-N, RMMXLENWKUUMAY-UHFFFAOYSA-N, RMMXLENWKUUMAY-UHFFFAOYSA-N, RMMXLENWKUUMAY-UHFFFAOYSA-N	Launched
telotristat	tryptophan hydroxylase inhibitor	TPH1	gastroenterology	diarrhea	Cc1ccn(n1)-c1cc(Cl)ccc1[C@@H](Oc1cc(nc(N)n1)-c1ccc(C[C@H](N)C(O)=O)cc1)C(F)(F)F, Cc1ccn(n1)-c1cc(Cl)ccc1[C@@H](Oc1cc(nc(N)n1)-c1ccc(C[C@H](N)C(O)=O)cc1)C(F)(F)F	NCLGDOBQAWBXRA-PGRDOPGGSA-N, NCLGDOBQAWBXRA-PGRDOPGGSA-N	Launched
telotristat-ethyl	tryptophan hydroxylase inhibitor	TPH1	gastroenterology	diarrhea	CCOC(=O)[C@@H](N)Cc1ccc(cc1)-c1cc(O[C@H](c2ccc(Cl)cc2-n2ccc(C)n2)C(F)(F)F)nc(N)n1, CCOC(=O)[C@@H](N)Cc1ccc(cc1)-c1cc(O[C@H](c2ccc(Cl)cc2-n2ccc(C)n2)C(F)(F)F)nc(N)n1, CCOC(=O)[C@@H](N)Cc1ccc(cc1)-c1cc(O[C@H](c2ccc(Cl)cc2-n2ccc(C)n2)C(F)(F)F)nc(N)n1, CCOC(=O)[C@@H](N)Cc1ccc(cc1)-c1cc(O[C@H](c2ccc(Cl)cc2-n2ccc(C)n2)C(F)(F)F)nc(N)n1	MDSQOJYHHZBZKA-GBXCKJPGSA-N, MDSQOJYHHZBZKA-GBXCKJPGSA-N, MDSQOJYHHZBZKA-GBXCKJPGSA-N, MDSQOJYHHZBZKA-GBXCKJPGSA-N	Launched
telratolimod	toll-like receptor agonist				CCCCCCCCCCCCCCCCCC(=O)NCCCCOn1c(CCCC)nc2c(N)nc3ccccc3c12	RRTPWQXEERTRRK-UHFFFAOYSA-N	Preclinical
temanogrel	serotonin receptor antagonist				COc1cccc(c1)C(=O)Nc1ccc(OCCN2CCOCC2)c(c1)-c1ccnn1C	ZEOQUKRCASTCFR-UHFFFAOYSA-N	Preclinical
temefos	cholinesterase inhibitor				COP(=S)(OC)Oc1ccc(Sc2ccc(OP(=S)(OC)OC)cc2)cc1, COP(=S)(OC)Oc1ccc(Sc2ccc(OP(=S)(OC)OC)cc2)cc1	WWJZWCUNLNYYAU-UHFFFAOYSA-N, WWJZWCUNLNYYAU-UHFFFAOYSA-N	Launched
temocapril	angiotensin converting enzyme inhibitor	ACE	cardiology, nephrology	hypertension, congestive heart failure, diabetic nephropathy, coronary artery disease (CAD)	CCOC(=O)[C@H](CCc1ccccc1)N[C@H]1CS[C@@H](CN(CC(O)=O)C1=O)c1cccs1, CCOC(=O)[C@H](CCc1ccccc1)N[C@H]1CS[C@@H](CN(CC(O)=O)C1=O)c1cccs1, CCOC(=O)[C@H](CCc1ccccc1)N[C@H]1CS[C@@H](CN(CC(O)=O)C1=O)c1cccs1, CCOC(=O)[C@H](CCc1ccccc1)N[C@H]1CS[C@@H](CN(CC(O)=O)C1=O)c1cccs1	FIQOFIRCTOWDOW-BJLQDIEVSA-N, FIQOFIRCTOWDOW-BJLQDIEVSA-N, FIQOFIRCTOWDOW-BJLQDIEVSA-N, FIQOFIRCTOWDOW-BJLQDIEVSA-N	Launched
temoporfin	radical formation stimulant		oncology	head and neck squamous cell carcinoma (HNSCC)	Oc1cccc(c1)-c1c2CCc([nH]2)c(-c2cccc(O)c2)c2ccc([nH]2)c(-c2cccc(O)c2)c2ccc(n2)c(-c2cccc(O)c2)c2ccc1n2, Oc1cccc(c1)-c1c2CCc([nH]2)c(-c2cccc(O)c2)c2ccc([nH]2)c(-c2cccc(O)c2)c2ccc(n2)c(-c2cccc(O)c2)c2ccc1n2, Oc1cccc(c1)-c1c2CCc([nH]2)c(-c2cccc(O)c2)c2ccc([nH]2)c(-c2cccc(O)c2)c2ccc(n2)c(-c2cccc(O)c2)c2ccc1n2	JGLSWAGTNWZKQU-WWMKMEMESA-N, JGLSWAGTNWZKQU-WWMKMEMESA-N, JGLSWAGTNWZKQU-WWMKMEMESA-N	Launched
temozolomide	DNA alkylating agent	MGMT	oncology	glioblastoma, astrocytoma	Cn1nnc2c(ncn2c1=O)C(N)=O, Cn1nnc2c(ncn2c1=O)C(N)=O, Cn1nnc2c(ncn2c1=O)C(N)=O, Cn1nnc2c(ncn2c1=O)C(N)=O	BPEGJWRSRHCHSN-UHFFFAOYSA-N, BPEGJWRSRHCHSN-UHFFFAOYSA-N, BPEGJWRSRHCHSN-UHFFFAOYSA-N, BPEGJWRSRHCHSN-UHFFFAOYSA-N	Launched
tempol	free radical scavenger				CC1(C)CC(O)CC(C)(C)N1O, CC1(C)CC(O)CC(C)(C)N1O, CC1(C)CC(O)CC(C)(C)N1O	CSGAUKGQUCHWDP-UHFFFAOYSA-N, CSGAUKGQUCHWDP-UHFFFAOYSA-N, CSGAUKGQUCHWDP-UHFFFAOYSA-N	Phase 2
temsirolimus	mTOR inhibitor	MTOR	oncology	renal cell carcinoma (RCC)	CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1OC(=O)C(C)(CO)CO |c:14,33,t:29,31|, CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1OC(=O)C(C)(CO)CO |c:14,33,t:29,31|	CBPNZQVSJQDFBE-NRNHWJPGSA-N, CBPNZQVSJQDFBE-NRNHWJPGSA-N	Launched
TEN-010	bromodomain inhibitor				CN1CCN(CCCNC(=O)C[C@@H]2N=C(c3c(C)c(C)sc3-n3c(C)nnc23)c2ccc(Cl)cc2)CC1 |c:13|	PKQXLRYFPSZKDU-QFIPXVFZSA-N	Preclinical
tenalisib	PI3K inhibitor				CC[C@H](Nc1ncnc2nc[nH]c12)c1oc2ccccc2c(=O)c1-c1cccc(F)c1	HDXDQPRPFRKGKZ-INIZCTEOSA-N	Phase 2
tenapanor	sodium/hydrogen exchanger inhibitor				CN1C[C@@H](c2cccc(c2)S(=O)(=O)NCCOCCOCCNC(=O)NCCCCNC(=O)NCCOCCOCCNS(=O)(=O)c2cccc(c2)[C@@H]2CN(C)Cc3c(Cl)cc(Cl)cc23)c2cc(Cl)cc(Cl)c2C1	DNHPDWGIXIMXSA-CXNSMIOJSA-N	Launched
tenatoprazole	ATPase inhibitor	IDO1			COc1ccc2[nH]c(nc2n1)[S@@](=O)Cc1ncc(C)c(OC)c1C |r|	ZBFDAUIVDSSISP-DEOSSOPVSA-N	Phase 2
teneligliptin	dipeptidyl peptidase inhibitor	DPP4	endocrinology	diabetes mellitus	Cc1cc(N2CCN(CC2)[C@@H]2CN[C@@H](C2)C(=O)N2CCSC2)n(n1)-c1ccccc1, Cc1cc(N2CCN(CC2)[C@@H]2CN[C@@H](C2)C(=O)N2CCSC2)n(n1)-c1ccccc1, Cc1cc(N2CCN(CC2)[C@@H]2CN[C@@H](C2)C(=O)N2CCSC2)n(n1)-c1ccccc1, Cc1cc(N2CCN(CC2)[C@@H]2CN[C@@H](C2)C(=O)N2CCSC2)n(n1)-c1ccccc1, Cc1cc(N2CCN(CC2)[C@@H]2CN[C@@H](C2)C(=O)N2CCSC2)n(n1)-c1ccccc1, Cc1cc(N2CCN(CC2)[C@@H]2CN[C@@H](C2)C(=O)N2CCSC2)n(n1)-c1ccccc1	WGRQANOPCQRCME-PMACEKPBSA-N, WGRQANOPCQRCME-PMACEKPBSA-N, WGRQANOPCQRCME-PMACEKPBSA-N, WGRQANOPCQRCME-PMACEKPBSA-N, WGRQANOPCQRCME-PMACEKPBSA-N, WGRQANOPCQRCME-PMACEKPBSA-N	Launched
tenidap	cyclooxygenase inhibitor	KCNJ4, PTGS1			NC(=O)N1C(=O)[C@@H](C(=O)c2cccs2)c2cc(Cl)ccc12 |&1:6,r|	IGPDWKCUDHIIRL-LLVKDONJSA-N	Phase 3
tenilsetam	AGE inhibitor				O=C1NCCN[C@@H]1c1cccs1 |&1:6,r|, O=C1NCCN[C@@H]1c1cccs1 |&1:6,r|	BBACKDMGYMXYLE-SSDOTTSWSA-N, BBACKDMGYMXYLE-SSDOTTSWSA-N	Phase 3
teniposide	topoisomerase inhibitor	TOP2A, TOP2B	hematologic malignancy	acute lymphoblastic leukemia (ALL)	COc1cc(cc(OC)c1O)[C@H]1[C@@H]2[C@H](COC2=O)[C@H](O[C@@H]2O[C@@H]3CO[C@H](O[C@H]3[C@H](O)[C@H]2O)c2cccs2)c2cc3OCOc3cc12, COc1cc(cc(OC)c1O)[C@H]1[C@@H]2[C@H](COC2=O)[C@H](O[C@@H]2O[C@@H]3CO[C@H](O[C@H]3[C@H](O)[C@H]2O)c2cccs2)c2cc3OCOc3cc12, COc1cc(cc(OC)c1O)[C@H]1[C@@H]2[C@H](COC2=O)[C@H](O[C@@H]2O[C@@H]3CO[C@H](O[C@H]3[C@H](O)[C@H]2O)c2cccs2)c2cc3OCOc3cc12, COc1cc(cc(OC)c1O)[C@H]1[C@@H]2[C@H](COC2=O)[C@H](O[C@@H]2O[C@@H]3CO[C@H](O[C@H]3[C@H](O)[C@H]2O)c2cccs2)c2cc3OCOc3cc12	NRUKOCRGYNPUPR-QBPJDGROSA-N, NRUKOCRGYNPUPR-QBPJDGROSA-N, NRUKOCRGYNPUPR-QBPJDGROSA-N, NRUKOCRGYNPUPR-QBPJDGROSA-N	Launched
tenofovir	HIV integrase inhibitor, nucleoside reverse transcriptase inhibitor		infectious disease	human immunodeficiency virus (HIV-1), hepatitis B	C[C@H](Cn1cnc2c(N)ncnc12)OCP(O)(O)=O, C[C@H](Cn1cnc2c(N)ncnc12)OCP(O)(O)=O, C[C@H](Cn1cnc2c(N)ncnc12)OCP(O)(O)=O	SGOIRFVFHAKUTI-ZCFIWIBFSA-N, SGOIRFVFHAKUTI-ZCFIWIBFSA-N, SGOIRFVFHAKUTI-ZCFIWIBFSA-N	Launched
tenofovir-alafenamide	nucleoside reverse transcriptase inhibitor		infectious disease	hepatitis B	CC(C)OC(=O)[C@@H](C)NP(=O)(CO[C@@H](C)Cn1cnc2c(N)ncnc12)Oc1ccccc1 |&1:6,&2:9,&3:13,r|	LDEKQSIMHVQZJK-FOCZCJQRSA-N	Launched
tenofovir-disoproxil	nucleoside reverse transcriptase inhibitor	CYP1A2	infectious disease	human immunodeficiency virus (HIV-1), hepatitis B	CC(C)OC(=O)OCOP(=O)(CO[C@H](C)Cn1cnc2c(N)ncnc12)OCOC(=O)OC(C)C, CC(C)OC(=O)OCOP(=O)(CO[C@H](C)Cn1cnc2c(N)ncnc12)OCOC(=O)OC(C)C, CC(C)OC(=O)OCOP(=O)(CO[C@H](C)Cn1cnc2c(N)ncnc12)OCOC(=O)OC(C)C, CC(C)OC(=O)OCOP(=O)(CO[C@H](C)Cn1cnc2c(N)ncnc12)OCOC(=O)OC(C)C	JFVZFKDSXNQEJW-CQSZACIVSA-N, JFVZFKDSXNQEJW-CQSZACIVSA-N, JFVZFKDSXNQEJW-CQSZACIVSA-N, JFVZFKDSXNQEJW-CQSZACIVSA-N	Launched
tenovin-1	SIRT inhibitor, TP53 activator	SIRT1			CC(=O)Nc1ccc(NC(=S)NC(=O)c2ccc(cc2)C(C)(C)C)cc1, CC(=O)Nc1ccc(NC(=S)NC(=O)c2ccc(cc2)C(C)(C)C)cc1, CC(=O)Nc1ccc(NC(=S)NC(=O)c2ccc(cc2)C(C)(C)C)cc1, CC(=O)Nc1ccc(NC(=S)NC(=O)c2ccc(cc2)C(C)(C)C)cc1, CC(=O)Nc1ccc(NC(=S)NC(=O)c2ccc(cc2)C(C)(C)C)cc1, CC(=O)Nc1ccc(NC(=S)NC(=O)c2ccc(cc2)C(C)(C)C)cc1, CC(=O)Nc1ccc(NC(=S)NC(=O)c2ccc(cc2)C(C)(C)C)cc1	WOWJIWFCOPZFGV-UHFFFAOYSA-N, WOWJIWFCOPZFGV-UHFFFAOYSA-N, WOWJIWFCOPZFGV-UHFFFAOYSA-N, WOWJIWFCOPZFGV-UHFFFAOYSA-N, WOWJIWFCOPZFGV-UHFFFAOYSA-N, WOWJIWFCOPZFGV-UHFFFAOYSA-N, WOWJIWFCOPZFGV-UHFFFAOYSA-N	Preclinical
tenovin-6	SIRT inhibitor	SIRT1, SIRT2, SIRT3			CN(C)CCCCC(=O)Nc1ccc(NC(=S)NC(=O)c2ccc(cc2)C(C)(C)C)cc1, CN(C)CCCCC(=O)Nc1ccc(NC(=S)NC(=O)c2ccc(cc2)C(C)(C)C)cc1, CN(C)CCCCC(=O)Nc1ccc(NC(=S)NC(=O)c2ccc(cc2)C(C)(C)C)cc1, CN(C)CCCCC(=O)Nc1ccc(NC(=S)NC(=O)c2ccc(cc2)C(C)(C)C)cc1, CN(C)CCCCC(=O)Nc1ccc(NC(=S)NC(=O)c2ccc(cc2)C(C)(C)C)cc1	BVJSXSQRIUSRCO-UHFFFAOYSA-N, BVJSXSQRIUSRCO-UHFFFAOYSA-N, BVJSXSQRIUSRCO-UHFFFAOYSA-N, BVJSXSQRIUSRCO-UHFFFAOYSA-N, BVJSXSQRIUSRCO-UHFFFAOYSA-N	Preclinical
tenoxicam	cyclooxygenase inhibitor	PTGS1, PTGS2	rheumatology, orthopedics	rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, tendinitis, bursitis, periarthritis	CN1C(C(=O)Nc2ccccn2)=C(O)c2sccc2S1(=O)=O |t:12|, CN1C(C(=O)Nc2ccccn2)=C(O)c2sccc2S1(=O)=O |t:12|, CN1C(C(=O)Nc2ccccn2)=C(O)c2sccc2S1(=O)=O |t:12|	LZNWYQJJBLGYLT-UHFFFAOYSA-N, LZNWYQJJBLGYLT-UHFFFAOYSA-N, LZNWYQJJBLGYLT-UHFFFAOYSA-N	Launched
tenylidone					O=C1\C(CCC\C1=C/c1cccs1)=C\c1cccs1, O=C1\C(CCC\C1=C/c1cccs1)=C\c1cccs1	KHXBULXCCPIELT-DCIPZJNNSA-N, KHXBULXCCPIELT-DCIPZJNNSA-N	Preclinical
tepoxalin	cyclooxygenase inhibitor, lipoxygenase inhibitor	ALOX5	rheumatology, orthopedics	rheumatoid arthritis, hip dysplasia	COc1ccc(cc1)-n1nc(CCC(=O)N(C)O)cc1-c1ccc(Cl)cc1, COc1ccc(cc1)-n1nc(CCC(=O)N(C)O)cc1-c1ccc(Cl)cc1, COc1ccc(cc1)-n1nc(CCC(=O)N(C)O)cc1-c1ccc(Cl)cc1, COc1ccc(cc1)-n1nc(CCC(=O)N(C)O)cc1-c1ccc(Cl)cc1, COc1ccc(cc1)-n1nc(CCC(=O)N(C)O)cc1-c1ccc(Cl)cc1	XYKWNRUXCOIMFZ-UHFFFAOYSA-N, XYKWNRUXCOIMFZ-UHFFFAOYSA-N, XYKWNRUXCOIMFZ-UHFFFAOYSA-N, XYKWNRUXCOIMFZ-UHFFFAOYSA-N, XYKWNRUXCOIMFZ-UHFFFAOYSA-N	Launched
TEPP-46	pyruvate kinase isozyme activator	PKM			Cn1c2cc(sc2c2cnn(Cc3cccc(N)c3)c(=O)c12)[S@@](C)=O |r|, Cn1c2cc(sc2c2cnn(Cc3cccc(N)c3)c(=O)c12)[S@@](C)=O |r|, Cn1c2cc(sc2c2cnn(Cc3cccc(N)c3)c(=O)c12)[S@@](C)=O |r|	ZWKJWVSEDISQIS-RUZDIDTESA-N, ZWKJWVSEDISQIS-RUZDIDTESA-N, ZWKJWVSEDISQIS-RUZDIDTESA-N	Preclinical
teprenone	mucus protecting agent		dermatology	cosmetic	CC(C)=CCC\C(C)=C\CC\C(C)=C\CC\C(C)=C\CCC(C)=O, CC(C)=CCC\C(C)=C\CC\C(C)=C\CC\C(C)=C\CCC(C)=O, CC(C)=CCC\C(C)=C\CC\C(C)=C\CC\C(C)=C\CCC(C)=O, CC(C)=CCC\C(C)=C\CC\C(C)=C\CC\C(C)=C\CCC(C)=O	HUCXKZBETONXFO-NJFMWZAGSA-N, HUCXKZBETONXFO-NJFMWZAGSA-N, HUCXKZBETONXFO-NJFMWZAGSA-N, HUCXKZBETONXFO-NJFMWZAGSA-N	Launched
terameprocol	lipoxygenase inhibitor	BIRC5, CDK1			COc1ccc(C[C@H](C)[C@H](C)Cc2ccc(OC)c(OC)c2)cc1OC	ORQFDHFZSMXRLM-IYBDPMFKSA-N	Phase 1/Phase 2
terazosin	adrenergic receptor antagonist	ADRA1A, ADRA1B, ADRA1D	urology, cardiology	benign prostatic hyperplasia (BPH), hypertension	COc1cc2nc(nc(N)c2cc1OC)N1CCN(CC1)C(=O)[C@H]1CCCO1 |&1:23,r|, COc1cc2nc(nc(N)c2cc1OC)N1CCN(CC1)C(=O)[C@H]1CCCO1 |&1:23,r|	VCKUSRYTPJJLNI-CQSZACIVSA-N, VCKUSRYTPJJLNI-CQSZACIVSA-N	Launched
terbinafine	fungal squalene epoxidase inhibitor	SQLE	infectious disease	tinea pedis, tinea cruris, tinea corporis	CN(C\C=C\C#CC(C)(C)C)Cc1cccc2ccccc12, CN(C\C=C\C#CC(C)(C)C)Cc1cccc2ccccc12, CN(C\C=C\C#CC(C)(C)C)Cc1cccc2ccccc12, CN(C\C=C\C#CC(C)(C)C)Cc1cccc2ccccc12, CN(C\C=C\C#CC(C)(C)C)Cc1cccc2ccccc12	DOMXUEMWDBAQBQ-WEVVVXLNSA-N, DOMXUEMWDBAQBQ-WEVVVXLNSA-N, DOMXUEMWDBAQBQ-WEVVVXLNSA-N, DOMXUEMWDBAQBQ-WEVVVXLNSA-N, DOMXUEMWDBAQBQ-WEVVVXLNSA-N	Launched
terbutaline	adrenergic receptor agonist	ADRB2	pulmonary	bronchospasm, bronchitis, emphysema	CC(C)(C)NC[C@@H](O)c1cc(O)cc(O)c1 |&1:6|, CC(C)(C)NC[C@@H](O)c1cc(O)cc(O)c1 |&1:6|, CC(C)(C)NC[C@@H](O)c1cc(O)cc(O)c1 |&1:6|	XWTYSIMOBUGWOL-LLVKDONJSA-N, XWTYSIMOBUGWOL-LLVKDONJSA-N, XWTYSIMOBUGWOL-LLVKDONJSA-N	Launched
terciprazine					O[C@@H](COC1(CCCCC1)C#C)CN1CCN(CC1)c1cccc(c1)C(F)(F)F |&1:1,r|, O[C@@H](COC1(CCCCC1)C#C)CN1CCN(CC1)c1cccc(c1)C(F)(F)F |&1:1,r|	SDKXUWMRKYQIFU-HXUWFJFHSA-N, SDKXUWMRKYQIFU-HXUWFJFHSA-N	Phase 1
terconazole	sterol demethylase inhibitor		infectious disease	vulvovaginal candidiasis	CC(C)N1CCN(CC1)c1ccc(OC[C@H]2CO[C@@](Cn3cncn3)(O2)c2ccc(Cl)cc2Cl)cc1, CC(C)N1CCN(CC1)c1ccc(OC[C@H]2CO[C@@](Cn3cncn3)(O2)c2ccc(Cl)cc2Cl)cc1	BLSQLHNBWJLIBQ-OZXSUGGESA-N, BLSQLHNBWJLIBQ-OZXSUGGESA-N	Launched
terfenadine	histamine receptor antagonist	HRH1, KCNH1, KCNH2			CC(C)(C)c1ccc(cc1)[C@@H](O)CCCN1CCC(CC1)C(O)(c1ccccc1)c1ccccc1 |&1:10,r|, CC(C)(C)c1ccc(cc1)[C@@H](O)CCCN1CCC(CC1)C(O)(c1ccccc1)c1ccccc1 |&1:10,r|, CC(C)(C)c1ccc(cc1)[C@@H](O)CCCN1CCC(CC1)C(O)(c1ccccc1)c1ccccc1 |&1:10,r|, CC(C)(C)c1ccc(cc1)[C@@H](O)CCCN1CCC(CC1)C(O)(c1ccccc1)c1ccccc1 |&1:10,r|, CC(C)(C)c1ccc(cc1)[C@@H](O)CCCN1CCC(CC1)C(O)(c1ccccc1)c1ccccc1 |&1:10,r|, CC(C)(C)c1ccc(cc1)[C@@H](O)CCCN1CCC(CC1)C(O)(c1ccccc1)c1ccccc1 |&1:10,r|	GUGOEEXESWIERI-PMERELPUSA-N, GUGOEEXESWIERI-PMERELPUSA-N, GUGOEEXESWIERI-PMERELPUSA-N, GUGOEEXESWIERI-PMERELPUSA-N, GUGOEEXESWIERI-PMERELPUSA-N, GUGOEEXESWIERI-PMERELPUSA-N	Withdrawn
terguride	dopamine receptor agonist, serotonin receptor antagonist	ADRA1A, ADRA2A, ADRA2B, ADRA2C, DRD2, DRD3, DRD4, HTR1A, HTR1B, HTR1D, HTR2A, HTR2B, HTR2C	neurology/psychiatry	Parkinson's Disease	CCN(CC)C(=O)N[C@H]1C[C@H]2[C@@H](Cc3c[nH]c4cccc2c34)N(C)C1 |a:8,&1:10,&2:11|	JOAHPSVPXZTVEP-YXJHDRRASA-N	Launched
teriflunomide	dihydroorotate dehydrogenase inhibitor	DHODH	neurology/psychiatry	multiple sclerosis	CC(=O)[C@@H](C#N)C(=O)Nc1ccc(cc1)C(F)(F)F |&1:3,r|, CC(=O)[C@@H](C#N)C(=O)Nc1ccc(cc1)C(F)(F)F |&1:3,r|, CC(=O)[C@@H](C#N)C(=O)Nc1ccc(cc1)C(F)(F)F |&1:3,r|	NABQBYDEMLGCEO-SNVBAGLBSA-N, NABQBYDEMLGCEO-SNVBAGLBSA-N, NABQBYDEMLGCEO-SNVBAGLBSA-N	Launched
terlipressin	vasopressin receptor agonist	AVPR1A	cardiology	hypotension	NCCCC[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@@H]1CSSC[C@H](NC(=O)CNC(=O)CNC(=O)CN)C(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N1)C(=O)NCC(N)=O, NCCCC[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@@H]1CSSC[C@H](NC(=O)CNC(=O)CNC(=O)CN)C(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N1)C(=O)NCC(N)=O	BENFXAYNYRLAIU-WBNRJDGRSA-N, BENFXAYNYRLAIU-WBNRJDGRSA-N	Launched
terodiline	cholinergic receptor antagonist				C[C@@H](CC(c1ccccc1)c1ccccc1)NC(C)(C)C |&1:1|	UISARWKNNNHPGI-INIZCTEOSA-N	Withdrawn
teroxirone	DNA inhibitor				O=c1n(C[C@H]2CO2)c(=O)n(C[C@H]2CO2)c(=O)n1C[C@H]1CO1 |&1:4,&2:11,&3:18,r|, O=c1n(C[C@H]2CO2)c(=O)n(C[C@H]2CO2)c(=O)n1C[C@H]1CO1 |&1:4,&2:11,&3:18,r|, O=c1n(C[C@H]2CO2)c(=O)n(C[C@H]2CO2)c(=O)n1C[C@H]1CO1 |&1:4,&2:11,&3:18,r|	OUPZKGBUJRBPGC-CIUDSAMLSA-N, OUPZKGBUJRBPGC-CIUDSAMLSA-N, OUPZKGBUJRBPGC-CIUDSAMLSA-N	Phase 1
terpene					CC(C)(O)[C@H]1CC[C@](C)(O)CC1 |&1:7,&2:4|	RBNWAMSGVWEHFP-CZMCAQCFSA-N	Preclinical
terreic-acid-(-)	Bruton's tyrosine kinase (BTK) inhibitor	BTK					Preclinical
terutroban	prostanoid receptor antagonist	TBXA2R			Cc1ccc2C[C@@H](CCc2c1CCC(O)=O)NS(=O)(=O)c1ccc(Cl)cc1, Cc1ccc2C[C@@H](CCc2c1CCC(O)=O)NS(=O)(=O)c1ccc(Cl)cc1	HWEOXFSBSQIWSY-MRXNPFEDSA-N, HWEOXFSBSQIWSY-MRXNPFEDSA-N	Phase 3
tesaglitazar	insulin sensitizer, PPAR receptor agonist	PPARA, PPARG			CCO[C@@H](Cc1ccc(OCCc2ccc(OS(C)(=O)=O)cc2)cc1)C(O)=O, CCO[C@@H](Cc1ccc(OCCc2ccc(OS(C)(=O)=O)cc2)cc1)C(O)=O	CXGTZJYQWSUFET-IBGZPJMESA-N, CXGTZJYQWSUFET-IBGZPJMESA-N	Phase 3
tetomilast	phosphodiesterase inhibitor	PDE4D			CCOc1ccc(cc1OCC)-c1nc(cs1)-c1cccc(n1)C(O)=O	XDBHURGONHZNJF-UHFFFAOYSA-N	Phase 2
tetrabenazine	vesicular monoamine transporter inhibitor	SLC18A1, SLC18A2	infectious disease, neurology/psychiatry	cholera, Huntington's disease	COc1cc2CCN3C[C@H](CC(C)C)C(=O)C[C@H]3c2cc1OC, COc1cc2CCN3C[C@H](CC(C)C)C(=O)C[C@H]3c2cc1OC, COc1cc2CCN3C[C@H](CC(C)C)C(=O)C[C@H]3c2cc1OC, COc1cc2CCN3C[C@H](CC(C)C)C(=O)C[C@H]3c2cc1OC, COc1cc2CCN3C[C@H](CC(C)C)C(=O)C[C@H]3c2cc1OC	MKJIEFSOBYUXJB-HOCLYGCPSA-N, MKJIEFSOBYUXJB-HOCLYGCPSA-N, MKJIEFSOBYUXJB-HOCLYGCPSA-N, MKJIEFSOBYUXJB-HOCLYGCPSA-N, MKJIEFSOBYUXJB-HOCLYGCPSA-N	Launched
tetracaine	membrane integrity inhibitor	SCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A	neurology/psychiatry	anesthetic	CCCCNc1ccc(cc1)C(=O)OCCN(C)C, CCCCNc1ccc(cc1)C(=O)OCCN(C)C	GKCBAIGFKIBETG-UHFFFAOYSA-N, GKCBAIGFKIBETG-UHFFFAOYSA-N	Launched
tetracycline	bacterial 30S ribosomal subunit inhibitor		infectious disease, dermatology	respiratory tract infections, pneumonia, skin infections, urinary tract infections, acne vulgaris (AV), plague, psittacosis	[H][C@@]12C[C@@]3([H])[C@@H](C(=O)c4c(O)cccc4[C@@]3(C)O)C(=O)[C@]1(O)C(=O)[C@@H](C(N)=O)C(=O)[C@H]2N(C)C |&1:24,&2:5|	MUHBBHLZPHKTTR-VHOYBAKPSA-N	Launched
tetradecylthioacetic-acid	lipid peroxidase inhibitor				CCCCCCCCCCCCCCSCC(O)=O, CCCCCCCCCCCCCCSCC(O)=O, CCCCCCCCCCCCCCSCC(O)=O	IPBCWPPBAWQYOO-UHFFFAOYSA-N, IPBCWPPBAWQYOO-UHFFFAOYSA-N, IPBCWPPBAWQYOO-UHFFFAOYSA-N	Phase 2
tetraethylenepentamine	superoxide dismutase inhibitor	SOD1, SOD2			NCCNCCNCCNCCN, NCCNCCNCCNCCN, NCCNCCNCCNCCN, NCCNCCNCCNCCN, NCCNCCNCCNCCN	FAGUFWYHJQFNRV-UHFFFAOYSA-N, FAGUFWYHJQFNRV-UHFFFAOYSA-N, FAGUFWYHJQFNRV-UHFFFAOYSA-N, FAGUFWYHJQFNRV-UHFFFAOYSA-N, FAGUFWYHJQFNRV-UHFFFAOYSA-N	Phase 2/Phase 3
tetrahydrofolic-acid		FOLR2			Nc1nc(=O)c2N[C@@H](CNc3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)CNc2[nH]1 |a:19,&1:7|	MSTNYGQPCMXVAQ-RYUDHWBXSA-N	Launched
tetrahydropapaverine					COc1ccc(C[C@H]2NCCc3cc(OC)c(OC)cc23)cc1OC |&1:7|, COc1ccc(C[C@H]2NCCc3cc(OC)c(OC)cc23)cc1OC |&1:7|	YXWQTVWJNHKSCC-MRXNPFEDSA-N, YXWQTVWJNHKSCC-MRXNPFEDSA-N	Preclinical
tetrahydrouridine	cytidine deaminase inhibitor	CDA			OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)N1CC[C@@H](O)NC1=O |a:2,4,5,7,&1:12|	UCKYOOZPSJFJIZ-FMDGEEDCSA-N	Phase 2
tetrahydrozoline	adrenergic receptor agonist		ophthalmology	eye irritation	C1CN=C(N1)[C@H]1CCCc2ccccc12 |&1:5,c:2|, C1CN=C(N1)[C@H]1CCCc2ccccc12 |&1:5,c:2|, C1CN=C(N1)[C@H]1CCCc2ccccc12 |&1:5,c:2|, C1CN=C(N1)[C@H]1CCCc2ccccc12 |&1:5,c:2|	BYJAVTDNIXVSPW-LBPRGKRZSA-N, BYJAVTDNIXVSPW-LBPRGKRZSA-N, BYJAVTDNIXVSPW-LBPRGKRZSA-N, BYJAVTDNIXVSPW-LBPRGKRZSA-N	Launched
tetramethylthiuram-monosulfide					CN(C)C(=S)SC(=S)N(C)C	REQPQFUJGGOFQL-UHFFFAOYSA-N	Preclinical
tetramisole	immunostimulant	ALPPL2, CHRNA3	infectious disease	gastrointestinal parasites	C1CN2C[C@@H](N=C2S1)c1ccccc1 |&1:4,c:5|, C1CN2C[C@@H](N=C2S1)c1ccccc1 |&1:4,c:5|, C1CN2C[C@@H](N=C2S1)c1ccccc1 |&1:4,c:5|, C1CN2C[C@@H](N=C2S1)c1ccccc1 |&1:4,c:5|	HLFSDGLLUJUHTE-SNVBAGLBSA-N, HLFSDGLLUJUHTE-SNVBAGLBSA-N, HLFSDGLLUJUHTE-SNVBAGLBSA-N, HLFSDGLLUJUHTE-SNVBAGLBSA-N	Launched
tetrandrine	calcium channel blocker	SLC6A3			COc1ccc2C[C@@H]3N(C)CCc4cc(OC)c(OC)c(Oc5cc6[C@H](Cc7ccc(Oc1c2)cc7)N(C)CCc6cc5OC)c34, COc1ccc2C[C@@H]3N(C)CCc4cc(OC)c(OC)c(Oc5cc6[C@H](Cc7ccc(Oc1c2)cc7)N(C)CCc6cc5OC)c34, COc1ccc2C[C@@H]3N(C)CCc4cc(OC)c(OC)c(Oc5cc6[C@H](Cc7ccc(Oc1c2)cc7)N(C)CCc6cc5OC)c34, COc1ccc2C[C@@H]3N(C)CCc4cc(OC)c(OC)c(Oc5cc6[C@H](Cc7ccc(Oc1c2)cc7)N(C)CCc6cc5OC)c34	WVTKBKWTSCPRNU-KYJUHHDHSA-N, WVTKBKWTSCPRNU-KYJUHHDHSA-N, WVTKBKWTSCPRNU-KYJUHHDHSA-N, WVTKBKWTSCPRNU-KYJUHHDHSA-N	Preclinical
tetrazol-5-yl-glycine-(RS)	glutamate receptor agonist	GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D			N[C@@H](C(O)=O)c1nn[nH]n1 |&1:1,r|, N[C@@H](C(O)=O)c1nn[nH]n1 |&1:1,r|	UKBRUIZWQZHXFL-PVQJCKRUSA-N, UKBRUIZWQZHXFL-PVQJCKRUSA-N	Preclinical
tetrindole	monoamine oxidase inhibitor	MAOA			C1CCC(CC1)c1ccc2n3CCNC4CCCc(c34)c2c1, C1CCC(CC1)c1ccc2n3CCNC4CCCc(c34)c2c1, C1CCC(CC1)c1ccc2n3CCNC4CCCc(c34)c2c1, C1CCC(CC1)c1ccc2n3CCNC4CCCc(c34)c2c1, C1CCC(CC1)c1ccc2n3CCNC4CCCc(c34)c2c1, C1CCC(CC1)c1ccc2n3CCNC4CCCc(c34)c2c1, C1CCC(CC1)c1ccc2n3CCNC4CCCc(c34)c2c1	AUXCHYJDVJZEPG-UHFFFAOYSA-N, AUXCHYJDVJZEPG-UHFFFAOYSA-N, AUXCHYJDVJZEPG-UHFFFAOYSA-N, AUXCHYJDVJZEPG-UHFFFAOYSA-N, AUXCHYJDVJZEPG-UHFFFAOYSA-N, AUXCHYJDVJZEPG-UHFFFAOYSA-N, AUXCHYJDVJZEPG-UHFFFAOYSA-N	Phase 3
tetroquinone					OC1C(=O)C(=O)C(O)C(=O)C1=O, OC1C(=O)C(=O)C(O)C(=O)C1=O, OC1C(=O)C(=O)C(O)C(=O)C1=O	GQPHQLHUIDOQTA-UHFFFAOYSA-N, GQPHQLHUIDOQTA-UHFFFAOYSA-N, GQPHQLHUIDOQTA-UHFFFAOYSA-N	Preclinical
tezacaftor	CFTR channel agonist		pulmonary	cystic fibrosis	CC(C)(CO)c1cc2cc(NC(=O)C3(CC3)c3ccc4OC(F)(F)Oc4c3)c(F)cc2n1C[C@@H](O)CO, CC(C)(CO)c1cc2cc(NC(=O)C3(CC3)c3ccc4OC(F)(F)Oc4c3)c(F)cc2n1C[C@@H](O)CO	MJUVRTYWUMPBTR-MRXNPFEDSA-N, MJUVRTYWUMPBTR-MRXNPFEDSA-N	Launched
TFC-007	prostaglandin inhibitor	HPGDS			O=C(Nc1ccc(cc1)N1CCC(CC1)C(=O)N1CCOCC1)c1cnc(Oc2ccccc2)nc1, O=C(Nc1ccc(cc1)N1CCC(CC1)C(=O)N1CCOCC1)c1cnc(Oc2ccccc2)nc1, O=C(Nc1ccc(cc1)N1CCC(CC1)C(=O)N1CCOCC1)c1cnc(Oc2ccccc2)nc1	NLSSUSRERAMBTA-UHFFFAOYSA-N, NLSSUSRERAMBTA-UHFFFAOYSA-N, NLSSUSRERAMBTA-UHFFFAOYSA-N	Preclinical
TG-003	CLK inhibitor	CLK1, CLK4, DYRK1A, DYRK1B			CCN1\C(Sc2ccc(OC)cc12)=C\C(C)=O, CCN1\C(Sc2ccc(OC)cc12)=C\C(C)=O, CCN1\C(Sc2ccc(OC)cc12)=C\C(C)=O	BGVLELSCIHASRV-QPEQYQDCSA-N, BGVLELSCIHASRV-QPEQYQDCSA-N, BGVLELSCIHASRV-QPEQYQDCSA-N	Preclinical
TG-02	CDK inhibitor, FLT3 inhibitor, JAK inhibitor	CDK1, CDK2, CDK7, CDK9, FLT3, JAK2			CN1C\C=C\CCOc2cccc(c2)-c2ccnc(Nc3cccc(C1)c3)n2 |t:3|, CN1C\C=C\CCOc2cccc(c2)-c2ccnc(Nc3cccc(C1)c3)n2 |t:3|, CN1C\C=C\CCOc2cccc(c2)-c2ccnc(Nc3cccc(C1)c3)n2 |t:3|, CN1C\C=C\CCOc2cccc(c2)-c2ccnc(Nc3cccc(C1)c3)n2 |t:3|, CN1C\C=C\CCOc2cccc(c2)-c2ccnc(Nc3cccc(C1)c3)n2 |t:3|, CN1C\C=C\CCOc2cccc(c2)-c2ccnc(Nc3cccc(C1)c3)n2 |t:3|, CN1C\C=C\CCOc2cccc(c2)-c2ccnc(Nc3cccc(C1)c3)n2 |t:3|, CN1C\C=C\CCOc2cccc(c2)-c2ccnc(Nc3cccc(C1)c3)n2 |t:3|	VXBAJLGYBMTJCY-NSCUHMNNSA-N, VXBAJLGYBMTJCY-NSCUHMNNSA-N, VXBAJLGYBMTJCY-NSCUHMNNSA-N, VXBAJLGYBMTJCY-NSCUHMNNSA-N, VXBAJLGYBMTJCY-NSCUHMNNSA-N, VXBAJLGYBMTJCY-NSCUHMNNSA-N, VXBAJLGYBMTJCY-NSCUHMNNSA-N, VXBAJLGYBMTJCY-NSCUHMNNSA-N	Phase 1/Phase 2
TG-100572	SRC inhibitor, VEGFR inhibitor	KDR, SRC			Cc1cc(cc2nnc(Nc3ccc(OCCN4CCCC4)cc3)nc12)-c1cc(O)ccc1Cl, Cc1cc(cc2nnc(Nc3ccc(OCCN4CCCC4)cc3)nc12)-c1cc(O)ccc1Cl, Cc1cc(cc2nnc(Nc3ccc(OCCN4CCCC4)cc3)nc12)-c1cc(O)ccc1Cl, Cc1cc(cc2nnc(Nc3ccc(OCCN4CCCC4)cc3)nc12)-c1cc(O)ccc1Cl, Cc1cc(cc2nnc(Nc3ccc(OCCN4CCCC4)cc3)nc12)-c1cc(O)ccc1Cl	AQSSMEORRLJZLU-UHFFFAOYSA-N, AQSSMEORRLJZLU-UHFFFAOYSA-N, AQSSMEORRLJZLU-UHFFFAOYSA-N, AQSSMEORRLJZLU-UHFFFAOYSA-N, AQSSMEORRLJZLU-UHFFFAOYSA-N	Preclinical
TG-100713	PI3K inhibitor				Nc1nc(N)c2nc(cnc2n1)-c1cccc(O)c1, Nc1nc(N)c2nc(cnc2n1)-c1cccc(O)c1	UOORQSPLBHUQDQ-UHFFFAOYSA-N, UOORQSPLBHUQDQ-UHFFFAOYSA-N	Preclinical
TG-100801	SRC inhibitor, VEGFR inhibitor	CSK, FGFR1, FLT1, FLT4, KDR, SRC			Cc1cc(cc2nnc(Nc3ccc(OCCN4CCCC4)cc3)nc12)-c1cc(OC(=O)c2ccccc2)ccc1Cl, Cc1cc(cc2nnc(Nc3ccc(OCCN4CCCC4)cc3)nc12)-c1cc(OC(=O)c2ccccc2)ccc1Cl, Cc1cc(cc2nnc(Nc3ccc(OCCN4CCCC4)cc3)nc12)-c1cc(OC(=O)c2ccccc2)ccc1Cl	JMGXJHWTVBGOKG-UHFFFAOYSA-N, JMGXJHWTVBGOKG-UHFFFAOYSA-N, JMGXJHWTVBGOKG-UHFFFAOYSA-N	Phase 2
TG-101209	JAK inhibitor	JAK2, JAK3			CN1CCN(CC1)c1ccc(Nc2ncc(C)c(Nc3cccc(c3)S(=O)(=O)NC(C)(C)C)n2)cc1, CN1CCN(CC1)c1ccc(Nc2ncc(C)c(Nc3cccc(c3)S(=O)(=O)NC(C)(C)C)n2)cc1, CN1CCN(CC1)c1ccc(Nc2ncc(C)c(Nc3cccc(c3)S(=O)(=O)NC(C)(C)C)n2)cc1, CN1CCN(CC1)c1ccc(Nc2ncc(C)c(Nc3cccc(c3)S(=O)(=O)NC(C)(C)C)n2)cc1, CN1CCN(CC1)c1ccc(Nc2ncc(C)c(Nc3cccc(c3)S(=O)(=O)NC(C)(C)C)n2)cc1, CN1CCN(CC1)c1ccc(Nc2ncc(C)c(Nc3cccc(c3)S(=O)(=O)NC(C)(C)C)n2)cc1, CN1CCN(CC1)c1ccc(Nc2ncc(C)c(Nc3cccc(c3)S(=O)(=O)NC(C)(C)C)n2)cc1	JVDOKQYTTYUYDV-UHFFFAOYSA-N, JVDOKQYTTYUYDV-UHFFFAOYSA-N, JVDOKQYTTYUYDV-UHFFFAOYSA-N, JVDOKQYTTYUYDV-UHFFFAOYSA-N, JVDOKQYTTYUYDV-UHFFFAOYSA-N, JVDOKQYTTYUYDV-UHFFFAOYSA-N, JVDOKQYTTYUYDV-UHFFFAOYSA-N	Preclinical
TGR-1202	PI3K inhibitor				CC(C)Oc1ccc(cc1F)-c1nn([C@@H](C)c2oc3ccc(F)cc3c(=O)c2-c2cccc(F)c2)c2ncnc(N)c12, CC(C)Oc1ccc(cc1F)-c1nn([C@@H](C)c2oc3ccc(F)cc3c(=O)c2-c2cccc(F)c2)c2ncnc(N)c12	IUVCFHHAEHNCFT-INIZCTEOSA-N, IUVCFHHAEHNCFT-INIZCTEOSA-N	Phase 3
TGX-221	PI3K inhibitor	PIK3CB, PIK3CD			C[C@@H](Nc1ccccc1)c1cc(C)cn2c1nc(cc2=O)N1CCOCC1 |&1:1,r|, C[C@@H](Nc1ccccc1)c1cc(C)cn2c1nc(cc2=O)N1CCOCC1 |&1:1,r|, C[C@@H](Nc1ccccc1)c1cc(C)cn2c1nc(cc2=O)N1CCOCC1 |&1:1,r|	CPRAGQJXBLMUEL-MRXNPFEDSA-N, CPRAGQJXBLMUEL-MRXNPFEDSA-N, CPRAGQJXBLMUEL-MRXNPFEDSA-N	Preclinical
TG100-115	PI3K inhibitor	PIK3CA, PIK3CB, PIK3CD, PIK3CG			Nc1nc(N)c2nc(-c3cccc(O)c3)c(nc2n1)-c1cccc(O)c1	UJIAQDJKSXQLIT-UHFFFAOYSA-N	Phase 1/Phase 2
TH-302	DNA alkylating agent				Cn1c(COP(=O)(NCCBr)NCCBr)cnc1[N+]([O-])=O, Cn1c(COP(=O)(NCCBr)NCCBr)cnc1[N+]([O-])=O, Cn1c(COP(=O)(NCCBr)NCCBr)cnc1[N+]([O-])=O	UGJWRPJDTDGERK-UHFFFAOYSA-N, UGJWRPJDTDGERK-UHFFFAOYSA-N, UGJWRPJDTDGERK-UHFFFAOYSA-N	Phase 3
TH-588	MTH1 inhibitor	NUDT1			Nc1nc(NC2CC2)cc(n1)-c1cccc(Cl)c1Cl, Nc1nc(NC2CC2)cc(n1)-c1cccc(Cl)c1Cl, Nc1nc(NC2CC2)cc(n1)-c1cccc(Cl)c1Cl, Nc1nc(NC2CC2)cc(n1)-c1cccc(Cl)c1Cl, Nc1nc(NC2CC2)cc(n1)-c1cccc(Cl)c1Cl, Nc1nc(NC2CC2)cc(n1)-c1cccc(Cl)c1Cl	PNMYJIOQIAEYQL-UHFFFAOYSA-N, PNMYJIOQIAEYQL-UHFFFAOYSA-N, PNMYJIOQIAEYQL-UHFFFAOYSA-N, PNMYJIOQIAEYQL-UHFFFAOYSA-N, PNMYJIOQIAEYQL-UHFFFAOYSA-N, PNMYJIOQIAEYQL-UHFFFAOYSA-N	Preclinical
thaliblastine	DNA inhibitor				COc1cc(C[C@@H]2N(C)CCc3cc(OC)c(OC)cc23)c(Oc2cc3C[C@@H]4N(C)CCc5cc(OC)c(OC)c(-c3cc2OC)c45)cc1OC	ZCTJIMXXSXQXRI-KYJUHHDHSA-N	Phase 2
thalidomide	tumor necrosis factor production inhibitor	TNF	oncology	myeloma	O=C1N([C@H]2CCC(=O)NC2=O)C(=O)c2ccccc12 |&1:3,r|, O=C1N([C@H]2CCC(=O)NC2=O)C(=O)c2ccccc12 |&1:3,r|, O=C1N([C@H]2CCC(=O)NC2=O)C(=O)c2ccccc12 |&1:3,r|	UEJJHQNACJXSKW-VIFPVBQESA-N, UEJJHQNACJXSKW-VIFPVBQESA-N, UEJJHQNACJXSKW-VIFPVBQESA-N	Launched
theaflavin	antiviral				O[C@@H]1Cc2c(O)cc(O)cc2O[C@@H]1c1cc(O)c(=O)c2c(O)c(O)cc(cc12)[C@H]1Oc2cc(O)cc(O)c2C[C@H]1O	SPQUOZYCYRJYJU-ZKSIBHASSA-N	Preclinical
theobromine	phosphodiesterase inhibitor	ADORA1, ADORA2A, PDE4B			Cn1cnc2n(C)c(=O)[nH]c(=O)c12, Cn1cnc2n(C)c(=O)[nH]c(=O)c12, Cn1cnc2n(C)c(=O)[nH]c(=O)c12, Cn1cnc2n(C)c(=O)[nH]c(=O)c12, Cn1cnc2n(C)c(=O)[nH]c(=O)c12	YAPQBXQYLJRXSA-UHFFFAOYSA-N, YAPQBXQYLJRXSA-UHFFFAOYSA-N, YAPQBXQYLJRXSA-UHFFFAOYSA-N, YAPQBXQYLJRXSA-UHFFFAOYSA-N, YAPQBXQYLJRXSA-UHFFFAOYSA-N	Launched
thiamet-g	GLCNAC phosphotransferase inhibitor	MGEA5			CCNC1=N[C@H]2[C@H](O[C@H](CO)[C@@H](O)[C@@H]2O)S1 |t:3|, CCNC1=N[C@H]2[C@H](O[C@H](CO)[C@@H](O)[C@@H]2O)S1 |t:3|, CCNC1=N[C@H]2[C@H](O[C@H](CO)[C@@H](O)[C@@H]2O)S1 |t:3|	PPAIMZHKIXDJRN-FMDGEEDCSA-N, PPAIMZHKIXDJRN-FMDGEEDCSA-N, PPAIMZHKIXDJRN-FMDGEEDCSA-N	Preclinical
thiamine	vitamin B	SLC19A2, SLC19A3, TPK1	metabolism	thiamine deficiency	Cc1c(CCO)sc[n+]1Cc1cnc(C)nc1N, Cc1c(CCO)sc[n+]1Cc1cnc(C)nc1N, Cc1c(CCO)sc[n+]1Cc1cnc(C)nc1N	JZRWCGZRTZMZEH-UHFFFAOYSA-N, JZRWCGZRTZMZEH-UHFFFAOYSA-N, JZRWCGZRTZMZEH-UHFFFAOYSA-N	Launched
thiamine-pyrophosphate			hematology	anemia	Cc1c(CCOP(O)(=O)OP(O)(O)=O)sc[n+]1Cc1cnc(C)nc1N |&1:6|	AYEKOFBPNLCAJY-UHFFFAOYSA-O	Launched
thiamphenicol	bacterial 50S ribosomal subunit inhibitor		infectious disease	pelvic inflammatory disease	CS(=O)(=O)c1ccc(cc1)[C@@H](O)[C@@H](CO)NC(=O)C(Cl)Cl, CS(=O)(=O)c1ccc(cc1)[C@@H](O)[C@@H](CO)NC(=O)C(Cl)Cl, CS(=O)(=O)c1ccc(cc1)[C@@H](O)[C@@H](CO)NC(=O)C(Cl)Cl	OTVAEFIXJLOWRX-NXEZZACHSA-N, OTVAEFIXJLOWRX-NXEZZACHSA-N, OTVAEFIXJLOWRX-NXEZZACHSA-N	Launched
thiamylal	glutamate receptor antagonist	GABRA1	neurology/psychiatry	sedative	CCC[C@@H](C)C1(CC=C)C(=O)NC(=S)NC1=O |&1:3,&2:5|	XLOMZPUITCYLMJ-MRVPVSSYSA-N	Launched
thiazovivin	rho associated kinase inhibitor				O=C(NCc1ccccc1)c1csc(Nc2ccncn2)n1, O=C(NCc1ccccc1)c1csc(Nc2ccncn2)n1, O=C(NCc1ccccc1)c1csc(Nc2ccncn2)n1, O=C(NCc1ccccc1)c1csc(Nc2ccncn2)n1	DOBKQCZBPPCLEG-UHFFFAOYSA-N, DOBKQCZBPPCLEG-UHFFFAOYSA-N, DOBKQCZBPPCLEG-UHFFFAOYSA-N, DOBKQCZBPPCLEG-UHFFFAOYSA-N	Preclinical
thiethylperazine	dopamine receptor antagonist	DRD1, DRD2, DRD4	gastroenterology	nausea	CCSc1ccc2Sc3ccccc3N(CCCN3CCN(C)CC3)c2c1, CCSc1ccc2Sc3ccccc3N(CCCN3CCN(C)CC3)c2c1, CCSc1ccc2Sc3ccccc3N(CCCN3CCN(C)CC3)c2c1, CCSc1ccc2Sc3ccccc3N(CCCN3CCN(C)CC3)c2c1, CCSc1ccc2Sc3ccccc3N(CCCN3CCN(C)CC3)c2c1	XCTYLCDETUVOIP-UHFFFAOYSA-N, XCTYLCDETUVOIP-UHFFFAOYSA-N, XCTYLCDETUVOIP-UHFFFAOYSA-N, XCTYLCDETUVOIP-UHFFFAOYSA-N, XCTYLCDETUVOIP-UHFFFAOYSA-N	Launched
thiocolchicoside	GABA receptor antagonist	GABRA1, GABRB2, GABRG2, GLRA1, GLRB	neurology/psychiatry	muscle relaxant	COc1c(O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)cc2CC[C@H](NC(C)=O)c3cc(=O)c(SC)ccc3-c2c1OC, COc1c(O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)cc2CC[C@H](NC(C)=O)c3cc(=O)c(SC)ccc3-c2c1OC, COc1c(O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)cc2CC[C@H](NC(C)=O)c3cc(=O)c(SC)ccc3-c2c1OC, COc1c(O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)cc2CC[C@H](NC(C)=O)c3cc(=O)c(SC)ccc3-c2c1OC, COc1c(O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)cc2CC[C@H](NC(C)=O)c3cc(=O)c(SC)ccc3-c2c1OC	LEQAKWQJCITZNK-AXHKHJLKSA-N, LEQAKWQJCITZNK-AXHKHJLKSA-N, LEQAKWQJCITZNK-AXHKHJLKSA-N, LEQAKWQJCITZNK-AXHKHJLKSA-N, LEQAKWQJCITZNK-AXHKHJLKSA-N	Launched
thioctic-acid	reducing agent	ACHE, PTGS2	nephrology	diabetic nephropathy	OC(=O)CCCC[C@H]1CCSS1 |&1:7,r|	AGBQKNBQESQNJD-ZETCQYMHSA-N	Launched
thiodiglycol					OCCSCCO, OCCSCCO	YODZTKMDCQEPHD-UHFFFAOYSA-N, YODZTKMDCQEPHD-UHFFFAOYSA-N	Preclinical
thioguanine	purine antagonist	IMPDH1, IMPDH2	hematologic malignancy	acute myeloid leukemia (AML)	Nc1nc2nc[nH]c2c(=S)[nH]1, Nc1nc2nc[nH]c2c(=S)[nH]1, Nc1nc2nc[nH]c2c(=S)[nH]1, Nc1nc2nc[nH]c2c(=S)[nH]1	WYWHKKSPHMUBEB-UHFFFAOYSA-N, WYWHKKSPHMUBEB-UHFFFAOYSA-N, WYWHKKSPHMUBEB-UHFFFAOYSA-N, WYWHKKSPHMUBEB-UHFFFAOYSA-N	Launched
thiomersal	other antibiotic	OXCT1	infectious disease	preservative	CC[Hg]Sc1ccccc1C(O)=O, CC[Hg]Sc1ccccc1C(O)=O, CC[Hg]Sc1ccccc1C(O)=O, CC[Hg]Sc1ccccc1C(O)=O, CC[Hg]Sc1ccccc1C(O)=O, CC[Hg]Sc1ccccc1C(O)=O, CC[Hg]Sc1ccccc1C(O)=O, CC[Hg]Sc1ccccc1C(O)=O	HXQVQGWHFRNKMS-UHFFFAOYSA-M, HXQVQGWHFRNKMS-UHFFFAOYSA-M, HXQVQGWHFRNKMS-UHFFFAOYSA-M, HXQVQGWHFRNKMS-UHFFFAOYSA-M, HXQVQGWHFRNKMS-UHFFFAOYSA-M, HXQVQGWHFRNKMS-UHFFFAOYSA-M, HXQVQGWHFRNKMS-UHFFFAOYSA-M, HXQVQGWHFRNKMS-UHFFFAOYSA-M	Launched
thiopental	GABA receptor antagonist	FAAH	neurology/psychiatry	anesthetic	CCC[C@@H](C)C1(CC)C(=O)NC(=S)NC1=O |&1:3,&2:5|, CCC[C@@H](C)C1(CC)C(=O)NC(=S)NC1=O |&1:3,&2:5|	IUJDSEJGGMCXSG-SSDOTTSWSA-N, IUJDSEJGGMCXSG-SSDOTTSWSA-N	Launched
thioperamide	histamine receptor antagonist	HRH3, HRH4			S=C(NC1CCCCC1)N1CCC(CC1)[C@H]1C=NC=N1 |r,c:18,20|	JFAYRTHYLOZRNL-CQSZACIVSA-N	Preclinical
thiophanate					COC(=O)NC(=S)Nc1ccccc1NC(=S)NC(=O)OC, COC(=O)NC(=S)Nc1ccccc1NC(=S)NC(=O)OC, COC(=O)NC(=S)Nc1ccccc1NC(=S)NC(=O)OC, COC(=O)NC(=S)Nc1ccccc1NC(=S)NC(=O)OC	QGHREAKMXXNCOA-UHFFFAOYSA-N, QGHREAKMXXNCOA-UHFFFAOYSA-N, QGHREAKMXXNCOA-UHFFFAOYSA-N, QGHREAKMXXNCOA-UHFFFAOYSA-N	Preclinical
thioproperazine	dopamine receptor antagonist	ADRA1A, ADRA1B, DRD1, DRD2, HTR1A, HTR2A	neurology/psychiatry	schizophrenia	CN(C)S(=O)(=O)c1ccc2Sc3ccccc3N(CCCN3CCN(C)CC3)c2c1, CN(C)S(=O)(=O)c1ccc2Sc3ccccc3N(CCCN3CCN(C)CC3)c2c1	VZYCZNZBPPHOFY-UHFFFAOYSA-N, VZYCZNZBPPHOFY-UHFFFAOYSA-N	Launched
thioridazine	dopamine receptor antagonist	DRD1, DRD2, DRD3, DRD4, DRD5, HRH1, HTR1A, HTR2A, HTR2C, HTR6, HTR7			CSc1ccc2Sc3ccccc3N(CCC3CCCCN3C)c2c1, CSc1ccc2Sc3ccccc3N(CCC3CCCCN3C)c2c1, CSc1ccc2Sc3ccccc3N(CCC3CCCCN3C)c2c1, CSc1ccc2Sc3ccccc3N(CCC3CCCCN3C)c2c1	KLBQZWRITKRQQV-UHFFFAOYSA-N, KLBQZWRITKRQQV-UHFFFAOYSA-N, KLBQZWRITKRQQV-UHFFFAOYSA-N, KLBQZWRITKRQQV-UHFFFAOYSA-N	Withdrawn
thiorphan	membrane metalloendopeptidase inhibitor	MME			OC(=O)CNC(=O)[C@@H](CS)Cc1ccccc1 |&1:7,r|, OC(=O)CNC(=O)[C@@H](CS)Cc1ccccc1 |&1:7,r|	LJJKNPQAGWVLDQ-SNVBAGLBSA-N, LJJKNPQAGWVLDQ-SNVBAGLBSA-N	Phase 1
thiostrepton	FOXM1 inhibitor, protein synthesis inhibitor	FOXM1	obstetrics/gynecology	mastitis	CC[C@H](C)[C@@H]1N[C@@H]2C=Cc3c(cc(nc3[C@H]2O)C(=O)O[C@H](C)[C@@H]2NC(=O)c3csc(n3)[C@@H](NC(=O)[C@H]3CSC(=N3)\C(NC(=O)[C@@H](NC(=O)c3csc(n3)[C@]3(CCC(=N[C@@H]3c3csc2n3)c2nc(cs2)C(=O)NC(=C)C(=O)NC(=C)C(N)=O)NC(=O)[C@H](C)NC(=O)C(=C)NC(=O)[C@H](C)NC1=O)[C@@H](C)O)=C\C)[C@](C)(O)[C@@H](C)O)[C@H](C)O |c:7,41,61|, CC[C@H](C)[C@@H]1N[C@@H]2C=Cc3c(cc(nc3[C@H]2O)C(=O)O[C@H](C)[C@@H]2NC(=O)c3csc(n3)[C@@H](NC(=O)[C@H]3CSC(=N3)\C(NC(=O)[C@@H](NC(=O)c3csc(n3)[C@]3(CCC(=N[C@@H]3c3csc2n3)c2nc(cs2)C(=O)NC(=C)C(=O)NC(=C)C(N)=O)NC(=O)[C@H](C)NC(=O)C(=C)NC(=O)[C@H](C)NC1=O)[C@@H](C)O)=C\C)[C@](C)(O)[C@@H](C)O)[C@H](C)O |c:7,41,61|, CC[C@H](C)[C@@H]1N[C@@H]2C=Cc3c(cc(nc3[C@H]2O)C(=O)O[C@H](C)[C@@H]2NC(=O)c3csc(n3)[C@@H](NC(=O)[C@H]3CSC(=N3)\C(NC(=O)[C@@H](NC(=O)c3csc(n3)[C@]3(CCC(=N[C@@H]3c3csc2n3)c2nc(cs2)C(=O)NC(=C)C(=O)NC(=C)C(N)=O)NC(=O)[C@H](C)NC(=O)C(=C)NC(=O)[C@H](C)NC1=O)[C@@H](C)O)=C\C)[C@](C)(O)[C@@H](C)O)[C@H](C)O |c:7,41,61|, CC[C@H](C)[C@@H]1N[C@@H]2C=Cc3c(cc(nc3[C@H]2O)C(=O)O[C@H](C)[C@@H]2NC(=O)c3csc(n3)[C@@H](NC(=O)[C@H]3CSC(=N3)\C(NC(=O)[C@@H](NC(=O)c3csc(n3)[C@]3(CCC(=N[C@@H]3c3csc2n3)c2nc(cs2)C(=O)NC(=C)C(=O)NC(=C)C(N)=O)NC(=O)[C@H](C)NC(=O)C(=C)NC(=O)[C@H](C)NC1=O)[C@@H](C)O)=C\C)[C@](C)(O)[C@@H](C)O)[C@H](C)O |c:7,41,61|, CC[C@H](C)[C@@H]1N[C@@H]2C=Cc3c(cc(nc3[C@H]2O)C(=O)O[C@H](C)[C@@H]2NC(=O)c3csc(n3)[C@@H](NC(=O)[C@H]3CSC(=N3)\C(NC(=O)[C@@H](NC(=O)c3csc(n3)[C@]3(CCC(=N[C@@H]3c3csc2n3)c2nc(cs2)C(=O)NC(=C)C(=O)NC(=C)C(N)=O)NC(=O)[C@H](C)NC(=O)C(=C)NC(=O)[C@H](C)NC1=O)[C@@H](C)O)=C\C)[C@](C)(O)[C@@H](C)O)[C@H](C)O |c:7,41,61|, CC[C@H](C)[C@@H]1N[C@@H]2C=Cc3c(cc(nc3[C@H]2O)C(=O)O[C@H](C)[C@@H]2NC(=O)c3csc(n3)[C@@H](NC(=O)[C@H]3CSC(=N3)\C(NC(=O)[C@@H](NC(=O)c3csc(n3)[C@]3(CCC(=N[C@@H]3c3csc2n3)c2nc(cs2)C(=O)NC(=C)C(=O)NC(=C)C(N)=O)NC(=O)[C@H](C)NC(=O)C(=C)NC(=O)[C@H](C)NC1=O)[C@@H](C)O)=C\C)[C@](C)(O)[C@@H](C)O)[C@H](C)O |c:7,41,61|, CC[C@H](C)[C@@H]1N[C@@H]2C=Cc3c(cc(nc3[C@H]2O)C(=O)O[C@H](C)[C@@H]2NC(=O)c3csc(n3)[C@@H](NC(=O)[C@H]3CSC(=N3)\C(NC(=O)[C@@H](NC(=O)c3csc(n3)[C@]3(CCC(=N[C@@H]3c3csc2n3)c2nc(cs2)C(=O)NC(=C)C(=O)NC(=C)C(N)=O)NC(=O)[C@H](C)NC(=O)C(=C)NC(=O)[C@H](C)NC1=O)[C@@H](C)O)=C\C)[C@](C)(O)[C@@H](C)O)[C@H](C)O |c:7,41,61|	NSFFHOGKXHRQEW-AIHSUZKVSA-N, NSFFHOGKXHRQEW-AIHSUZKVSA-N, NSFFHOGKXHRQEW-AIHSUZKVSA-N, NSFFHOGKXHRQEW-AIHSUZKVSA-N, NSFFHOGKXHRQEW-AIHSUZKVSA-N, NSFFHOGKXHRQEW-AIHSUZKVSA-N, NSFFHOGKXHRQEW-AIHSUZKVSA-N	Launched
thiotepa	cytochrome P450 inhibitor	CYP2B6, CYP3A4	oncology	breast cancer, ovarian cancer, bladder cancer	S=P(N1CC1)(N1CC1)N1CC1, S=P(N1CC1)(N1CC1)N1CC1, S=P(N1CC1)(N1CC1)N1CC1, S=P(N1CC1)(N1CC1)N1CC1	FOCVUCIESVLUNU-UHFFFAOYSA-N, FOCVUCIESVLUNU-UHFFFAOYSA-N, FOCVUCIESVLUNU-UHFFFAOYSA-N, FOCVUCIESVLUNU-UHFFFAOYSA-N	Launched
thiothixene	dopamine receptor antagonist	DRD1, DRD2, HRH1, HTR2A	neurology/psychiatry	schizophrenia	CN(C)S(=O)(=O)c1ccc2Sc3ccccc3\C(=C\CCN3CCN(C)CC3)c2c1	GFBKORZTTCHDGY-UWVJOHFNSA-N	Launched
thiram		JAK2	ophthalmology	contact dermatitis	CN(C)C(=S)SSC(=S)N(C)C, CN(C)C(=S)SSC(=S)N(C)C	KUAZQDVKQLNFPE-UHFFFAOYSA-N, KUAZQDVKQLNFPE-UHFFFAOYSA-N	Launched
THK5351	PET radiotracer 				CNc1ccc(cn1)-c1ccc2cc(OC[C@H](O)CF)ccc2n1	DLVXFZWSPCOWSN-CQSZACIVSA-N	Phase 2
thonzonium	ATPase inhibitor		infectious disease	ear infections	CCCCCCCCCCCCCCCC[N+](C)(C)CCN(Cc1ccc(OC)cc1)c1ncccn1, CCCCCCCCCCCCCCCC[N+](C)(C)CCN(Cc1ccc(OC)cc1)c1ncccn1, CCCCCCCCCCCCCCCC[N+](C)(C)CCN(Cc1ccc(OC)cc1)c1ncccn1, CCCCCCCCCCCCCCCC[N+](C)(C)CCN(Cc1ccc(OC)cc1)c1ncccn1, CCCCCCCCCCCCCCCC[N+](C)(C)CCN(Cc1ccc(OC)cc1)c1ncccn1, CCCCCCCCCCCCCCCC[N+](C)(C)CCN(Cc1ccc(OC)cc1)c1ncccn1, CCCCCCCCCCCCCCCC[N+](C)(C)CCN(Cc1ccc(OC)cc1)c1ncccn1	IOYZYMQFUSNATM-UHFFFAOYSA-N, IOYZYMQFUSNATM-UHFFFAOYSA-N, IOYZYMQFUSNATM-UHFFFAOYSA-N, IOYZYMQFUSNATM-UHFFFAOYSA-N, IOYZYMQFUSNATM-UHFFFAOYSA-N, IOYZYMQFUSNATM-UHFFFAOYSA-N, IOYZYMQFUSNATM-UHFFFAOYSA-N	Launched
thonzylamine	antihistamine		neurology/psychiatry	itching	COc1ccc(CN(CCN(C)C)c2ncccn2)cc1	GULNIHOSWFYMRN-UHFFFAOYSA-N	Launched
threo-2-methylisocitrate-(DL)	isocitrate lyase substrate				[NaH].[NaH].[NaH].[NaH].[NaH].[NaH].CC(O)([C@@H](CC(O)=O)C(O)=O)C(O)=O.CC(O)([C@H](CC(O)=O)C(O)=O)C(O)=O |a:9,23,&1:7,&2:21|, [NaH].[NaH].[NaH].[NaH].[NaH].[NaH].CC(O)([C@@H](CC(O)=O)C(O)=O)C(O)=O.CC(O)([C@H](CC(O)=O)C(O)=O)C(O)=O |a:9,23,&1:7,&2:21|	ZSOGGZWFKNMGJN-WREOTHMNSA-N, ZSOGGZWFKNMGJN-WREOTHMNSA-N	Preclinical
thymalfasin	immune response modulator		infectious disease	hepatitis B, hepatitis C	CC[C@H](C)[C@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(C)=O)C(C)C)[C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O	NZVYCXVTEHPMHE-ZSUJOUNUSA-N	Launched
thymol	GABA receptor positive allosteric modulator	TRPA1	infectious disease	ringworm, antiseptic	CC(C)c1ccc(C)cc1O, CC(C)c1ccc(C)cc1O	MGSRCZKZVOBKFT-UHFFFAOYSA-N, MGSRCZKZVOBKFT-UHFFFAOYSA-N	Launched
thymol-iodide					CC(C)c1cc(c(C)cc1OI)-c1cc(C(C)C)c(OI)cc1C	SHOKWSLXDAIZPP-UHFFFAOYSA-N	Preclinical
thymopentin	immune response stimulator				CC(C)[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(O)=O	PSWFFKRAVBDQEG-YGQNSOCVSA-N	Launched
THZ1	CDK inhibitor	CDK7			CN(C)C\C=C\C(=O)Nc1ccc(cc1)C(=O)Nc1cccc(Nc2ncc(Cl)c(n2)-c2c[nH]c3ccccc23)c1, CN(C)C\C=C\C(=O)Nc1ccc(cc1)C(=O)Nc1cccc(Nc2ncc(Cl)c(n2)-c2c[nH]c3ccccc23)c1, CN(C)C\C=C\C(=O)Nc1ccc(cc1)C(=O)Nc1cccc(Nc2ncc(Cl)c(n2)-c2c[nH]c3ccccc23)c1, CN(C)C\C=C\C(=O)Nc1ccc(cc1)C(=O)Nc1cccc(Nc2ncc(Cl)c(n2)-c2c[nH]c3ccccc23)c1, CN(C)C\C=C\C(=O)Nc1ccc(cc1)C(=O)Nc1cccc(Nc2ncc(Cl)c(n2)-c2c[nH]c3ccccc23)c1, CN(C)C\C=C\C(=O)Nc1ccc(cc1)C(=O)Nc1cccc(Nc2ncc(Cl)c(n2)-c2c[nH]c3ccccc23)c1, CN(C)C\C=C\C(=O)Nc1ccc(cc1)C(=O)Nc1cccc(Nc2ncc(Cl)c(n2)-c2c[nH]c3ccccc23)c1, CN(C)C\C=C\C(=O)Nc1ccc(cc1)C(=O)Nc1cccc(Nc2ncc(Cl)c(n2)-c2c[nH]c3ccccc23)c1	OBJNFLYHUXWUPF-IZZDOVSWSA-N, OBJNFLYHUXWUPF-IZZDOVSWSA-N, OBJNFLYHUXWUPF-IZZDOVSWSA-N, OBJNFLYHUXWUPF-IZZDOVSWSA-N, OBJNFLYHUXWUPF-IZZDOVSWSA-N, OBJNFLYHUXWUPF-IZZDOVSWSA-N, OBJNFLYHUXWUPF-IZZDOVSWSA-N, OBJNFLYHUXWUPF-IZZDOVSWSA-N	Preclinical
THZ1-R	CDK inhibitor	CDK7			CN(C)CCCC(=O)Nc1ccc(cc1)C(=O)Nc1cccc(Nc2ncc(Cl)c(n2)-c2c[nH]c3ccccc23)c1, CN(C)CCCC(=O)Nc1ccc(cc1)C(=O)Nc1cccc(Nc2ncc(Cl)c(n2)-c2c[nH]c3ccccc23)c1	TUERFPPIPKZNKE-UHFFFAOYSA-N, TUERFPPIPKZNKE-UHFFFAOYSA-N	Preclinical
THZ2	CDK inhibitor	CDK7			CN(C)C\C=C\C(=O)Nc1cccc(c1)C(=O)Nc1cccc(Nc2ncc(Cl)c(n2)-c2c[nH]c3ccccc23)c1, CN(C)C\C=C\C(=O)Nc1cccc(c1)C(=O)Nc1cccc(Nc2ncc(Cl)c(n2)-c2c[nH]c3ccccc23)c1, CN(C)C\C=C\C(=O)Nc1cccc(c1)C(=O)Nc1cccc(Nc2ncc(Cl)c(n2)-c2c[nH]c3ccccc23)c1, CN(C)C\C=C\C(=O)Nc1cccc(c1)C(=O)Nc1cccc(Nc2ncc(Cl)c(n2)-c2c[nH]c3ccccc23)c1, CN(C)C\C=C\C(=O)Nc1cccc(c1)C(=O)Nc1cccc(Nc2ncc(Cl)c(n2)-c2c[nH]c3ccccc23)c1	FONRCZUZCHXWBD-VGOFMYFVSA-N, FONRCZUZCHXWBD-VGOFMYFVSA-N, FONRCZUZCHXWBD-VGOFMYFVSA-N, FONRCZUZCHXWBD-VGOFMYFVSA-N, FONRCZUZCHXWBD-VGOFMYFVSA-N	Preclinical
tiabendazole	angiogenesis inhibitor		infectious disease	gastrointestinal roundworms, hookworm	c1nc(cs1)-c1nc2ccccc2[nH]1, c1nc(cs1)-c1nc2ccccc2[nH]1, c1nc(cs1)-c1nc2ccccc2[nH]1, c1nc(cs1)-c1nc2ccccc2[nH]1	WJCNZQLZVWNLKY-UHFFFAOYSA-N, WJCNZQLZVWNLKY-UHFFFAOYSA-N, WJCNZQLZVWNLKY-UHFFFAOYSA-N, WJCNZQLZVWNLKY-UHFFFAOYSA-N	Launched
tiagabine	GABA uptake inhibitor	SLC6A1	neurology/psychiatry	seizures	Cc1ccsc1C(=CCCN1CCC[C@H](C1)C(O)=O)c1sccc1C, Cc1ccsc1C(=CCCN1CCC[C@H](C1)C(O)=O)c1sccc1C, Cc1ccsc1C(=CCCN1CCC[C@H](C1)C(O)=O)c1sccc1C	PBJUNZJWGZTSKL-MRXNPFEDSA-N, PBJUNZJWGZTSKL-MRXNPFEDSA-N, PBJUNZJWGZTSKL-MRXNPFEDSA-N	Launched
tianeptine	selective serotonin reuptake enhancer (SSRE)	OPRD1, OPRK1, OPRM1	neurology/psychiatry, pulmonary, gastroenterology	depression, asthma, irritable bowel syndrome	CN1c2ccccc2[C@@H](NCCCCCCC(O)=O)c2ccc(Cl)cc2S1(=O)=O |&1:8,r|, CN1c2ccccc2[C@@H](NCCCCCCC(O)=O)c2ccc(Cl)cc2S1(=O)=O |&1:8,r|	JICJBGPOMZQUBB-OAQYLSRUSA-N, JICJBGPOMZQUBB-OAQYLSRUSA-N	Launched
tiapride	dopamine receptor antagonist	DRD2, DRD3	neurology/psychiatry	dyskinesia, abstinence from alcohol, psychosis	CCN(CC)CCNC(=O)c1cc(ccc1OC)S(C)(=O)=O, CCN(CC)CCNC(=O)c1cc(ccc1OC)S(C)(=O)=O, CCN(CC)CCNC(=O)c1cc(ccc1OC)S(C)(=O)=O	JTVPZMFULRWINT-UHFFFAOYSA-N, JTVPZMFULRWINT-UHFFFAOYSA-N, JTVPZMFULRWINT-UHFFFAOYSA-N	Launched
tiaprofenic-acid	cyclooxygenase inhibitor	PTGS2	rheumatology	rheumatoid arthritis	C[C@@H](C(O)=O)c1ccc(s1)C(=O)c1ccccc1 |&1:1,r|, C[C@@H](C(O)=O)c1ccc(s1)C(=O)c1ccccc1 |&1:1,r|, C[C@@H](C(O)=O)c1ccc(s1)C(=O)c1ccccc1 |&1:1,r|	GUHPRPJDBZHYCJ-SECBINFHSA-N, GUHPRPJDBZHYCJ-SECBINFHSA-N, GUHPRPJDBZHYCJ-SECBINFHSA-N	Launched
tiaramide	anti-inflammatory agent		pulmonary	asthma	OCCN1CCN(CC1)C(=O)Cn1c2cc(Cl)ccc2sc1=O	HTJXMOGUGMSZOG-UHFFFAOYSA-N	Launched
tibolone	androgen receptor agonist, estrogen receptor agonist, progesterone receptor agonist	ESR1	obstetrics/gynecology	endometriosis	C[C@@H]1CC2=C(CCC(=O)C2)[C@H]2CC[C@@]3(C)[C@H](CC[C@@]3(O)C#C)[C@@H]12 |a:1,10,13,15,18,&1:22,t:3|, C[C@@H]1CC2=C(CCC(=O)C2)[C@H]2CC[C@@]3(C)[C@H](CC[C@@]3(O)C#C)[C@@H]12 |a:1,10,13,15,18,&1:22,t:3|, C[C@@H]1CC2=C(CCC(=O)C2)[C@H]2CC[C@@]3(C)[C@H](CC[C@@]3(O)C#C)[C@@H]12 |a:1,10,13,15,18,&1:22,t:3|	WZDGZWOAQTVYBX-TZTUDTKPSA-N, WZDGZWOAQTVYBX-TZTUDTKPSA-N, WZDGZWOAQTVYBX-TZTUDTKPSA-N	Launched
ticagrelor	purinergic receptor antagonist	P2RY12	cardiology	acute coronary syndrome (ACS), myocardial infarction	CCCSc1nc(N[C@@H]2C[C@H]2c2ccc(F)c(F)c2)c2nnn([C@@H]3C[C@H](OCCO)[C@@H](O)[C@H]3O)c2n1, CCCSc1nc(N[C@@H]2C[C@H]2c2ccc(F)c(F)c2)c2nnn([C@@H]3C[C@H](OCCO)[C@@H](O)[C@H]3O)c2n1	OEKWJQXRCDYSHL-FNOIDJSQSA-N, OEKWJQXRCDYSHL-FNOIDJSQSA-N	Launched
ticarcillin	lactamase inhibitor		infectious disease	gram-negative bacterial infections	CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](C(O)=O)c3ccsc3)C(=O)N2[C@H]1C(O)=O, CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](C(O)=O)c3ccsc3)C(=O)N2[C@H]1C(O)=O, CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](C(O)=O)c3ccsc3)C(=O)N2[C@H]1C(O)=O, CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](C(O)=O)c3ccsc3)C(=O)N2[C@H]1C(O)=O, CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](C(O)=O)c3ccsc3)C(=O)N2[C@H]1C(O)=O	OHKOGUYZJXTSFX-KZFFXBSXSA-N, OHKOGUYZJXTSFX-KZFFXBSXSA-N, OHKOGUYZJXTSFX-KZFFXBSXSA-N, OHKOGUYZJXTSFX-KZFFXBSXSA-N, OHKOGUYZJXTSFX-KZFFXBSXSA-N	Launched
ticlopidine	purinergic receptor antagonist	P2RY12	hematology, neurology/psychiatry	thrombosis, stroke	Clc1ccccc1CN1CCc2sccc2C1, Clc1ccccc1CN1CCc2sccc2C1, Clc1ccccc1CN1CCc2sccc2C1, Clc1ccccc1CN1CCc2sccc2C1, Clc1ccccc1CN1CCc2sccc2C1	PHWBOXQYWZNQIN-UHFFFAOYSA-N, PHWBOXQYWZNQIN-UHFFFAOYSA-N, PHWBOXQYWZNQIN-UHFFFAOYSA-N, PHWBOXQYWZNQIN-UHFFFAOYSA-N, PHWBOXQYWZNQIN-UHFFFAOYSA-N	Launched
TIC10	AKT inhibitor, TRAIL modulator	AKT1, MAPK1			Cc1ccccc1CN1C2=NCCN2C(=O)C2=C1CCN(Cc1ccccc1)C2 |c:18,t:10|, Cc1ccccc1CN1C2=NCCN2C(=O)C2=C1CCN(Cc1ccccc1)C2 |c:18,t:10|	RSAQARAFWMUYLL-UHFFFAOYSA-N, RSAQARAFWMUYLL-UHFFFAOYSA-N	Phase 2
tideglusib	glycogen synthase kinase inhibitor	GSK3B			O=c1sn(-c2cccc3ccccc23)c(=O)n1Cc1ccccc1, O=c1sn(-c2cccc3ccccc23)c(=O)n1Cc1ccccc1, O=c1sn(-c2cccc3ccccc23)c(=O)n1Cc1ccccc1, O=c1sn(-c2cccc3ccccc23)c(=O)n1Cc1ccccc1, O=c1sn(-c2cccc3ccccc23)c(=O)n1Cc1ccccc1, O=c1sn(-c2cccc3ccccc23)c(=O)n1Cc1ccccc1	PMJIHLSCWIDGMD-UHFFFAOYSA-N, PMJIHLSCWIDGMD-UHFFFAOYSA-N, PMJIHLSCWIDGMD-UHFFFAOYSA-N, PMJIHLSCWIDGMD-UHFFFAOYSA-N, PMJIHLSCWIDGMD-UHFFFAOYSA-N, PMJIHLSCWIDGMD-UHFFFAOYSA-N	Phase 2
tienilic-acid	cytochrome P450 inhibitor, sodium/potassium/chloride transporter inhibitor	CYP2C9, SLC12A1			OC(=O)COc1ccc(C(=O)c2cccs2)c(Cl)c1Cl, OC(=O)COc1ccc(C(=O)c2cccs2)c(Cl)c1Cl	AGHANLSBXUWXTB-UHFFFAOYSA-N, AGHANLSBXUWXTB-UHFFFAOYSA-N	Withdrawn
tie2-kinase-inhibitor	TIE tyrosine kinase inhibitor	KDR, MAPK14			COc1ccc2cc(ccc2c1)-c1[nH]c(nc1-c1ccncc1)-c1ccc(cc1)[S@@](C)=O |r|, COc1ccc2cc(ccc2c1)-c1[nH]c(nc1-c1ccncc1)-c1ccc(cc1)[S@@](C)=O |r|, COc1ccc2cc(ccc2c1)-c1[nH]c(nc1-c1ccncc1)-c1ccc(cc1)[S@@](C)=O |r|	SINQIEAULQKUPD-JGCGQSQUSA-N, SINQIEAULQKUPD-JGCGQSQUSA-N, SINQIEAULQKUPD-JGCGQSQUSA-N	Preclinical
tifenazoxide	ATP-sensitive potassium channel agonist	ABCC8, KCNJ11			CC1(CC1)NC1=NS(=O)(=O)c2sc(Cl)cc2N1 |t:6|, CC1(CC1)NC1=NS(=O)(=O)c2sc(Cl)cc2N1 |t:6|, CC1(CC1)NC1=NS(=O)(=O)c2sc(Cl)cc2N1 |t:6|	KYSFUHHFTIGRJN-UHFFFAOYSA-N, KYSFUHHFTIGRJN-UHFFFAOYSA-N, KYSFUHHFTIGRJN-UHFFFAOYSA-N	Phase 1
tigecycline	bacterial 30S ribosomal subunit inhibitor		infectious disease	skin infections, pneumonia, intra-abdominal infections	[H][C@@]12Cc3c(cc(NC(=O)CNC(C)(C)C)c(O)c3C(=O)[C@@H]1C(=O)[C@]1(O)C(=O)[C@H](C(N)=O)C(=O)[C@@H](N(C)C)[C@]1([H])C2)N(C)C |&1:28,&2:21|	CGZOGNUFXMNYEI-PBZRBWFISA-N	Launched
tilmicosin	bacterial 50S ribosomal subunit inhibitor		pulmonary	bovine respiratory disease (BRD)	CC[C@H]1OC(=O)C[C@@H](O)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)[C@@H](O)[C@@H]([C@H]2O)N(C)C)[C@@H](CCN2C[C@@H](C)C[C@@H](C)C2)C[C@@H](C)C(=O)\C=C\C(\C)=C\[C@@H]1CO[C@@H]1O[C@H](C)[C@@H](O)[C@@H](OC)[C@H]1OC |t:43,46|	JTSDBFGMPLKDCD-UYPDHHONSA-N	Launched
tilorone	interferon inducer		infectious disease, gastroenterology, neurology/psychiatry	influenza A virus infection, diarrhea, hepatitis B, multiple sclerosis, urinary tract infections, virus herpes simplex (HSV), hepatitis C	CCN(CC)CCOc1ccc2-c3ccc(OCCN(CC)CC)cc3C(=O)c2c1, CCN(CC)CCOc1ccc2-c3ccc(OCCN(CC)CC)cc3C(=O)c2c1, CCN(CC)CCOc1ccc2-c3ccc(OCCN(CC)CC)cc3C(=O)c2c1	MPMFCABZENCRHV-UHFFFAOYSA-N, MPMFCABZENCRHV-UHFFFAOYSA-N, MPMFCABZENCRHV-UHFFFAOYSA-N	Launched
tiludronate	bone resorption inhibitor, osteoclast inhibitor	ATP6V1A, MMP2, PTPN1	orthopedics	navicular syndrome	OP(O)(=O)C(Sc1ccc(Cl)cc1)P(O)(O)=O, OP(O)(=O)C(Sc1ccc(Cl)cc1)P(O)(O)=O	DKJJVAGXPKPDRL-UHFFFAOYSA-N, DKJJVAGXPKPDRL-UHFFFAOYSA-N	Launched
timofibrate	cholesterol inhibitor, lipase clearing factor inhibitor	LPL			CC(C)(Oc1ccc(Cl)cc1)C(=O)N1CSC[C@@H]1C(O)=O |&1:17,r|, CC(C)(Oc1ccc(Cl)cc1)C(=O)N1CSC[C@@H]1C(O)=O |&1:17,r|, CC(C)(Oc1ccc(Cl)cc1)C(=O)N1CSC[C@@H]1C(O)=O |&1:17,r|, CC(C)(Oc1ccc(Cl)cc1)C(=O)N1CSC[C@@H]1C(O)=O |&1:17,r|, CC(C)(Oc1ccc(Cl)cc1)C(=O)N1CSC[C@@H]1C(O)=O |&1:17,r|	QSNOWCXXECLALL-LLVKDONJSA-N, QSNOWCXXECLALL-LLVKDONJSA-N, QSNOWCXXECLALL-LLVKDONJSA-N, QSNOWCXXECLALL-LLVKDONJSA-N, QSNOWCXXECLALL-LLVKDONJSA-N	Phase 2
timolol	adrenergic receptor antagonist	ADRB1, ADRB2	ophthalmology	ocular hypertension, glaucoma	CC(C)(C)NC[C@H](O)COc1nsnc1N1CCOCC1, CC(C)(C)NC[C@H](O)COc1nsnc1N1CCOCC1, CC(C)(C)NC[C@H](O)COc1nsnc1N1CCOCC1	BLJRIMJGRPQVNF-JTQLQIEISA-N, BLJRIMJGRPQVNF-JTQLQIEISA-N, BLJRIMJGRPQVNF-JTQLQIEISA-N	Launched
timonacic	antioxidant				OC(=O)[C@H]1CSCN1 |&1:3|	DZLNHFMRPBPULJ-GSVOUGTGSA-N	Launched
tinazoline	adrenergic receptor agonist				C1CN=C(N1)Sc1c[nH]c2ccccc12 |c:2|	JENBDJGHNIOHAJ-UHFFFAOYSA-N	Launched
tinidazole	antiprotozoal agent		infectious disease, obstetrics/gynecology	giardiasis, amebiasis, bacterial vaginosis, trichomoniasis	CCS(=O)(=O)CCn1c(C)ncc1[N+]([O-])=O, CCS(=O)(=O)CCn1c(C)ncc1[N+]([O-])=O, CCS(=O)(=O)CCn1c(C)ncc1[N+]([O-])=O, CCS(=O)(=O)CCn1c(C)ncc1[N+]([O-])=O, CCS(=O)(=O)CCn1c(C)ncc1[N+]([O-])=O	HJLSLZFTEKNLFI-UHFFFAOYSA-N, HJLSLZFTEKNLFI-UHFFFAOYSA-N, HJLSLZFTEKNLFI-UHFFFAOYSA-N, HJLSLZFTEKNLFI-UHFFFAOYSA-N, HJLSLZFTEKNLFI-UHFFFAOYSA-N	Launched
tinoridine	anti-inflammatory agent		neurology/psychiatry	pain relief	CCOC(=O)c1c(N)sc2CN(Cc3ccccc3)CCc12	PFENFDGYVLAFBR-UHFFFAOYSA-N	Launched
tioconazole	sterol demethylase inhibitor		infectious disease	yeast infection	Clc1sccc1CO[C@@H](Cn1ccnc1)c1ccc(Cl)cc1Cl |&1:8|	QXHHHPZILQDDPS-HNNXBMFYSA-N	Launched
tioguanine	purine antagonist		hematologic malignancy	acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), chronic myeloid leukemia (CML)	Nc1nc(=S)c2ncn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c2[nH]1, Nc1nc(=S)c2ncn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c2[nH]1, Nc1nc(=S)c2ncn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c2[nH]1, Nc1nc(=S)c2ncn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c2[nH]1, Nc1nc(=S)c2ncn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c2[nH]1	OTDJAMXESTUWLO-UUOKFMHZSA-N, OTDJAMXESTUWLO-UUOKFMHZSA-N, OTDJAMXESTUWLO-UUOKFMHZSA-N, OTDJAMXESTUWLO-UUOKFMHZSA-N, OTDJAMXESTUWLO-UUOKFMHZSA-N	Launched
tiopronin	chelating agent, reducing agent		urology	kidney stones	C[C@@H](S)C(=O)NCC(O)=O |&1:1,r|, C[C@@H](S)C(=O)NCC(O)=O |&1:1,r|, C[C@@H](S)C(=O)NCC(O)=O |&1:1,r|, C[C@@H](S)C(=O)NCC(O)=O |&1:1,r|, C[C@@H](S)C(=O)NCC(O)=O |&1:1,r|	YTGJWQPHMWSCST-GSVOUGTGSA-N, YTGJWQPHMWSCST-GSVOUGTGSA-N, YTGJWQPHMWSCST-GSVOUGTGSA-N, YTGJWQPHMWSCST-GSVOUGTGSA-N, YTGJWQPHMWSCST-GSVOUGTGSA-N	Launched
tiotidine	histamine receptor antagonist	HRH2			CN=C(NCCSCc1csc(NC(N)=N)n1)NC#N	YDDXVAXDYKBWDX-UHFFFAOYSA-N	Phase 2
tiotropium	acetylcholine receptor antagonist	CHRM1, CHRM2, CHRM3	pulmonary	chronic obstructive pulmonary disease (COPD), bronchitis, emphysema	C[N+]1(C)[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)C(O)(c1cccs1)c1cccs1, C[N+]1(C)[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)C(O)(c1cccs1)c1cccs1	LERNTVKEWCAPOY-DZZGSBJMSA-N, LERNTVKEWCAPOY-DZZGSBJMSA-N	Launched
tioxolone	carbonic anhydrase inhibitor	CA2			Oc1ccc2sc(=O)oc2c1, Oc1ccc2sc(=O)oc2c1, Oc1ccc2sc(=O)oc2c1	SLYPOVJCSQHITR-UHFFFAOYSA-N, SLYPOVJCSQHITR-UHFFFAOYSA-N, SLYPOVJCSQHITR-UHFFFAOYSA-N	Preclinical
tipelukast	leukotriene receptor antagonist				CCCc1c(O)c(ccc1SCCCOc1ccc(C(C)=O)c(OCCCC(O)=O)c1CCC)C(C)=O	KPWYNAGOBXLMSE-UHFFFAOYSA-N	Phase 2
tipifarnib	farnesyltransferase inhibitor	FNTA, FNTB			Cn1cncc1[C@@](N)(c1ccc(Cl)cc1)c1ccc2n(C)c(=O)cc(-c3cccc(Cl)c3)c2c1, Cn1cncc1[C@@](N)(c1ccc(Cl)cc1)c1ccc2n(C)c(=O)cc(-c3cccc(Cl)c3)c2c1, Cn1cncc1[C@@](N)(c1ccc(Cl)cc1)c1ccc2n(C)c(=O)cc(-c3cccc(Cl)c3)c2c1, Cn1cncc1[C@@](N)(c1ccc(Cl)cc1)c1ccc2n(C)c(=O)cc(-c3cccc(Cl)c3)c2c1, Cn1cncc1[C@@](N)(c1ccc(Cl)cc1)c1ccc2n(C)c(=O)cc(-c3cccc(Cl)c3)c2c1, Cn1cncc1[C@@](N)(c1ccc(Cl)cc1)c1ccc2n(C)c(=O)cc(-c3cccc(Cl)c3)c2c1	PLHJCIYEEKOWNM-HHHXNRCGSA-N, PLHJCIYEEKOWNM-HHHXNRCGSA-N, PLHJCIYEEKOWNM-HHHXNRCGSA-N, PLHJCIYEEKOWNM-HHHXNRCGSA-N, PLHJCIYEEKOWNM-HHHXNRCGSA-N, InChI=1S/C27H22Cl2N4O/c1-32-16-31-15-25(32)27(30,18-6-9-20(28)10-7-18)19-8-11-24-23(13-19)22(14-26(34)33(24)2)17-4-3-5-21(29)12-17/h3-16H,30H2,1-2H3/t27-/m1/s1	Phase 3
tipiracil	thymidine phosphorylase inhibitor		oncology	colorectal cancer	Clc1c(CN2CCCC2=N)[nH]c(=O)[nH]c1=O, Clc1c(CN2CCCC2=N)[nH]c(=O)[nH]c1=O, Clc1c(CN2CCCC2=N)[nH]c(=O)[nH]c1=O	QQHMKNYGKVVGCZ-UHFFFAOYSA-N, QQHMKNYGKVVGCZ-UHFFFAOYSA-N, QQHMKNYGKVVGCZ-UHFFFAOYSA-N	Launched
tiplaxtinin	plasminogen activator inhibitor	SERPINE1			OC(=O)C(=O)c1cn(Cc2ccccc2)c2ccc(cc12)-c1ccc(OC(F)(F)F)cc1, OC(=O)C(=O)c1cn(Cc2ccccc2)c2ccc(cc12)-c1ccc(OC(F)(F)F)cc1, OC(=O)C(=O)c1cn(Cc2ccccc2)c2ccc(cc12)-c1ccc(OC(F)(F)F)cc1, OC(=O)C(=O)c1cn(Cc2ccccc2)c2ccc(cc12)-c1ccc(OC(F)(F)F)cc1	ODXQFEWQSHNQNI-UHFFFAOYSA-N, ODXQFEWQSHNQNI-UHFFFAOYSA-N, ODXQFEWQSHNQNI-UHFFFAOYSA-N, ODXQFEWQSHNQNI-UHFFFAOYSA-N	Phase 1
tipranavir	HIV protease inhibitor		infectious disease	human immunodeficiency virus (HIV-1)	CCC[C@@]1(CCc2ccccc2)CC(=O)[C@@H]([C@H](CC)c2cccc(NS(=O)(=O)c3ccc(cn3)C(F)(F)F)c2)C(=O)O1 |a:3,16,&1:15|, CCC[C@@]1(CCc2ccccc2)CC(=O)[C@@H]([C@H](CC)c2cccc(NS(=O)(=O)c3ccc(cn3)C(F)(F)F)c2)C(=O)O1 |a:3,16,&1:15|, CCC[C@@]1(CCc2ccccc2)CC(=O)[C@@H]([C@H](CC)c2cccc(NS(=O)(=O)c3ccc(cn3)C(F)(F)F)c2)C(=O)O1 |a:3,16,&1:15|, CCC[C@@]1(CCc2ccccc2)CC(=O)[C@@H]([C@H](CC)c2cccc(NS(=O)(=O)c3ccc(cn3)C(F)(F)F)c2)C(=O)O1 |a:3,16,&1:15|	MYXACKZCYFKMTE-WWKQIGMOSA-N, MYXACKZCYFKMTE-WWKQIGMOSA-N, MYXACKZCYFKMTE-WWKQIGMOSA-N, MYXACKZCYFKMTE-WWKQIGMOSA-N	Launched
tiprenolol	adrenergic receptor antagonist	ADRB1, ADRB2, ADRB3			CSc1ccccc1OC[C@@H](O)CNC(C)C |&1:10,r|	CSUNLSYSEQIDMO-NSHDSACASA-N	Phase 2
tiquizium	acetylcholine receptor antagonist		neurology/psychiatry	spasms	C[N@+]12CCCC[C@@H]1CCC(C2)=C(c1cccs1)c1cccs1	ZGSDGGRVFIYKKE-OXQOHEQNSA-N	Launched
tiracizine	sodium channel blocker	SCN5A			CCOC(=O)Nc1ccc2CCc3ccccc3N(C(=O)CN(C)C)c2c1	KJAMZCVTJDTESW-UHFFFAOYSA-N	Withdrawn
tirapazamine	DNA inhibitor				Nc1n[n+]([O-])c2ccccc2[n+]1[O-], Nc1n[n+]([O-])c2ccccc2[n+]1[O-], Nc1n[n+]([O-])c2ccccc2[n+]1[O-], Nc1n[n+]([O-])c2ccccc2[n+]1[O-], Nc1n[n+]([O-])c2ccccc2[n+]1[O-]	ORYDPOVDJJZGHQ-UHFFFAOYSA-N, ORYDPOVDJJZGHQ-UHFFFAOYSA-N, ORYDPOVDJJZGHQ-UHFFFAOYSA-N, ORYDPOVDJJZGHQ-UHFFFAOYSA-N, ORYDPOVDJJZGHQ-UHFFFAOYSA-N	Phase 3
tirasemtiv	troponin activator				CCC(CC)n1c2nc(cnc2[nH]c1=O)C#C, CCC(CC)n1c2nc(cnc2[nH]c1=O)C#C	RSQGZEAXODVTOL-UHFFFAOYSA-N, RSQGZEAXODVTOL-UHFFFAOYSA-N	Phase 2
tiratricol	thyroid hormone stimulant	THRA, THRB	endocrinology	Refetoff syndrome	OC(=O)Cc1cc(I)c(Oc2ccc(O)c(I)c2)c(I)c1, OC(=O)Cc1cc(I)c(Oc2ccc(O)c(I)c2)c(I)c1, OC(=O)Cc1cc(I)c(Oc2ccc(O)c(I)c2)c(I)c1	UOWZUVNAGUAEQC-UHFFFAOYSA-N, UOWZUVNAGUAEQC-UHFFFAOYSA-N, UOWZUVNAGUAEQC-UHFFFAOYSA-N	Launched
tirofiban	platelet aggregation inhibitor, structural glycoprotein antagonist	ITGA2B, ITGB3	cardiology	myocardial infarction, refactory angina	CCCCS(=O)(=O)N[C@@H](Cc1ccc(OCCCCC2CCNCC2)cc1)C(O)=O, CCCCS(=O)(=O)N[C@@H](Cc1ccc(OCCCCC2CCNCC2)cc1)C(O)=O	COKMIXFXJJXBQG-NRFANRHFSA-N, COKMIXFXJJXBQG-NRFANRHFSA-N	Launched
titanocene-dichloride	apoptosis stimulant				Cl[Ti](Cl)(C1C=CC=C1)C1C=CC=C1 |c:4,6,10,12|, Cl[Ti](Cl)(C1C=CC=C1)C1C=CC=C1 |c:4,6,10,12|	XKLWATAZDMHTSH-UHFFFAOYSA-L, XKLWATAZDMHTSH-UHFFFAOYSA-L	Phase 2
tivantinib	tyrosine kinase inhibitor	MET			O=C1NC(=O)[C@H]([C@@H]1c1c[nH]c2ccccc12)c1cn2CCCc3cccc1c23, O=C1NC(=O)[C@H]([C@@H]1c1c[nH]c2ccccc12)c1cn2CCCc3cccc1c23, O=C1NC(=O)[C@H]([C@@H]1c1c[nH]c2ccccc12)c1cn2CCCc3cccc1c23, O=C1NC(=O)[C@H]([C@@H]1c1c[nH]c2ccccc12)c1cn2CCCc3cccc1c23	UCEQXRCJXIVODC-PMACEKPBSA-N, UCEQXRCJXIVODC-PMACEKPBSA-N, UCEQXRCJXIVODC-PMACEKPBSA-N, UCEQXRCJXIVODC-PMACEKPBSA-N	Phase 3
tivozanib	VEGFR inhibitor	FLT1, FLT4, KDR, KIT, PDGFRA, PDGFRB	oncology	renal cell carcinoma (RCC)	COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC, COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC, COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC, COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC, COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC, COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC	SPMVMDHWKHCIDT-UHFFFAOYSA-N, SPMVMDHWKHCIDT-UHFFFAOYSA-N, SPMVMDHWKHCIDT-UHFFFAOYSA-N, SPMVMDHWKHCIDT-UHFFFAOYSA-N, SPMVMDHWKHCIDT-UHFFFAOYSA-N, SPMVMDHWKHCIDT-UHFFFAOYSA-N	Launched
tizanidine	adrenergic receptor agonist	ADRA2A, ADRA2B, ADRA2C, NISCH	neurology/psychiatry	spasms	Clc1ccc2nsnc2c1NC1=NCCN1 |t:13|, Clc1ccc2nsnc2c1NC1=NCCN1 |t:13|, Clc1ccc2nsnc2c1NC1=NCCN1 |t:13|, Clc1ccc2nsnc2c1NC1=NCCN1 |t:13|, Clc1ccc2nsnc2c1NC1=NCCN1 |t:13|	XFYDIVBRZNQMJC-UHFFFAOYSA-N, XFYDIVBRZNQMJC-UHFFFAOYSA-N, XFYDIVBRZNQMJC-UHFFFAOYSA-N, XFYDIVBRZNQMJC-UHFFFAOYSA-N, XFYDIVBRZNQMJC-UHFFFAOYSA-N	Launched
TMC-353121	RSV fusion inhibitor				Cc1ccc(CCCO)c(NCc2ccc3nc(NCCCN4CCOCC4)n(Cc4nc(C)ccc4O)c3c2)c1, Cc1ccc(CCCO)c(NCc2ccc3nc(NCCCN4CCOCC4)n(Cc4nc(C)ccc4O)c3c2)c1	DKORMNNYNRPTBJ-UHFFFAOYSA-N, DKORMNNYNRPTBJ-UHFFFAOYSA-N	Phase 2
TMC647055	RNA polymerase inhibitor				COc1ccc2-c3c(C4CCCCC4)c4ccc5cc4n3CC(=Cc2c1)C(=O)N(C)CCOCCN(C)S(=O)(=O)NC5=O |c:25|	UOBYJVFBFSLCTQ-UHFFFAOYSA-N	Phase 2
TMN-355	cyclophilin inhibitor	PPIA			Fc1cccc(Cl)c1C(=O)NC(=O)NC1c2ccccc2-c2ccccc12, Fc1cccc(Cl)c1C(=O)NC(=O)NC1c2ccccc2-c2ccccc12	SFNLLCUAISZNRV-UHFFFAOYSA-N, SFNLLCUAISZNRV-UHFFFAOYSA-N	Preclinical
TMPH					CCCCCCC(=O)OC1CC(C)(C)NC(C)(C)C1, CCCCCCC(=O)OC1CC(C)(C)NC(C)(C)C1, CCCCCCC(=O)OC1CC(C)(C)NC(C)(C)C1	PWWKJRFUJIFGGD-UHFFFAOYSA-N, PWWKJRFUJIFGGD-UHFFFAOYSA-N, PWWKJRFUJIFGGD-UHFFFAOYSA-N	Preclinical
TMS					COc1ccc(\C=C\c2cc(OC)cc(OC)c2)c(OC)c1, COc1ccc(\C=C\c2cc(OC)cc(OC)c2)c(OC)c1, COc1ccc(\C=C\c2cc(OC)cc(OC)c2)c(OC)c1, COc1ccc(\C=C\c2cc(OC)cc(OC)c2)c(OC)c1, COc1ccc(\C=C\c2cc(OC)cc(OC)c2)c(OC)c1	JDBCWSHYEQUBLW-AATRIKPKSA-N, JDBCWSHYEQUBLW-AATRIKPKSA-N, JDBCWSHYEQUBLW-AATRIKPKSA-N, JDBCWSHYEQUBLW-AATRIKPKSA-N, JDBCWSHYEQUBLW-AATRIKPKSA-N	Preclinical
TNP-470	methionine aminopeptidase inhibitor	METAP2			CO[C@@H]1[C@@H](CC[C@]2(CO2)[C@H]1[C@@]1(C)O[C@@H]1CC=C(C)C)OC(=O)NC(=O)CCl, CO[C@@H]1[C@@H](CC[C@]2(CO2)[C@H]1[C@@]1(C)O[C@@H]1CC=C(C)C)OC(=O)NC(=O)CCl, CO[C@@H]1[C@@H](CC[C@]2(CO2)[C@H]1[C@@]1(C)O[C@@H]1CC=C(C)C)OC(=O)NC(=O)CCl	MSHZHSPISPJWHW-PVDLLORBSA-N, MSHZHSPISPJWHW-PVDLLORBSA-N, MSHZHSPISPJWHW-PVDLLORBSA-N	Phase 2
tobramycin	bacterial 30S ribosomal subunit inhibitor		infectious disease	bacterial septicemia, respiratory tract infections, meningitis, skin infections, urinary tract infections	NC[C@H]1O[C@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O)[C@H]2O)[C@H](N)C[C@@H]1O, NC[C@H]1O[C@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O)[C@H]2O)[C@H](N)C[C@@H]1O, NC[C@H]1O[C@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O)[C@H]2O)[C@H](N)C[C@@H]1O	NLVFBUXFDBBNBW-PBSUHMDJSA-N, NLVFBUXFDBBNBW-PBSUHMDJSA-N, NLVFBUXFDBBNBW-PBSUHMDJSA-N	Launched
tocainide	sodium channel blocker	SCN5A	cardiology	cardiac arrythmia	C[C@@H](N)C(=O)Nc1c(C)cccc1C |&1:1,r|, C[C@@H](N)C(=O)Nc1c(C)cccc1C |&1:1,r|	BUJAGSGYPOAWEI-SECBINFHSA-N, BUJAGSGYPOAWEI-SECBINFHSA-N	Launched
toceranib	protein tyrosine kinase inhibitor	FLT1, FLT3, KDR, PDGFRA, PDGFRB	oncology	cutaneous mast cell tumors	Cc1[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c(C)c1C(=O)NCCN1CCCC1, Cc1[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c(C)c1C(=O)NCCN1CCCC1, Cc1[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c(C)c1C(=O)NCCN1CCCC1, Cc1[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c(C)c1C(=O)NCCN1CCCC1	SRSGVKWWVXWSJT-ATVHPVEESA-N, SRSGVKWWVXWSJT-ATVHPVEESA-N, SRSGVKWWVXWSJT-ATVHPVEESA-N, SRSGVKWWVXWSJT-ATVHPVEESA-N	Launched
tocofersolan	antioxidant		cardiology	cerebral cholesterosis	CC(C)CCC[C@@H](C)CCC[C@@H](C)CCC[C@]1(C)CCc2c(C)c(OC(=O)CCC(=O)OCCO)c(C)c(C)c2O1, CC(C)CCC[C@@H](C)CCC[C@@H](C)CCC[C@]1(C)CCc2c(C)c(OC(=O)CCC(=O)OCCO)c(C)c(C)c2O1	AOBORMOPSGHCAX-AZAGJHQNSA-N, AOBORMOPSGHCAX-AZAGJHQNSA-N	Launched
todralazine	antihypertensive agent		cardiology	hypertension	CCOC(=O)NNc1nncc2ccccc12	WGZDBVOTUVNQFP-UHFFFAOYSA-N	Launched
tofacitinib	JAK inhibitor	JAK1, JAK2, JAK3	rheumatology	rheumatoid arthritis	C[C@@H]1CCN(C[C@@H]1N(C)c1ncnc2[nH]ccc12)C(=O)CC#N, C[C@@H]1CCN(C[C@@H]1N(C)c1ncnc2[nH]ccc12)C(=O)CC#N, C[C@@H]1CCN(C[C@@H]1N(C)c1ncnc2[nH]ccc12)C(=O)CC#N, C[C@@H]1CCN(C[C@@H]1N(C)c1ncnc2[nH]ccc12)C(=O)CC#N, C[C@@H]1CCN(C[C@@H]1N(C)c1ncnc2[nH]ccc12)C(=O)CC#N, C[C@@H]1CCN(C[C@@H]1N(C)c1ncnc2[nH]ccc12)C(=O)CC#N, C[C@@H]1CCN(C[C@@H]1N(C)c1ncnc2[nH]ccc12)C(=O)CC#N, C[C@@H]1CCN(C[C@@H]1N(C)c1ncnc2[nH]ccc12)C(=O)CC#N	UJLAWZDWDVHWOW-YPMHNXCESA-N, UJLAWZDWDVHWOW-YPMHNXCESA-N, UJLAWZDWDVHWOW-YPMHNXCESA-N, UJLAWZDWDVHWOW-YPMHNXCESA-N, UJLAWZDWDVHWOW-YPMHNXCESA-N, UJLAWZDWDVHWOW-YPMHNXCESA-N, UJLAWZDWDVHWOW-YPMHNXCESA-N, UJLAWZDWDVHWOW-YPMHNXCESA-N	Launched
tofisopam	cytochrome P450 inhibitor, phosphodiesterase inhibitor	CYP3A4	neurology/psychiatry	anxiety, abstinence from alcohol	CCC1=C(C)NN=C(c2ccc(OC)c(OC)c2)c2cc(OC)c(OC)cc12 |c:2,t:6|, CCC1=C(C)NN=C(c2ccc(OC)c(OC)c2)c2cc(OC)c(OC)cc12 |c:2,t:6|	LOUZDJSQOFXLAP-UHFFFAOYSA-N, LOUZDJSQOFXLAP-UHFFFAOYSA-N	Launched
tofogliflozin	sodium/glucose cotransporter inhibitor	GCK	endocrinology	diabetes mellitus	CCc1ccc(Cc2ccc3CO[C@]4(O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)c3c2)cc1, CCc1ccc(Cc2ccc3CO[C@]4(O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)c3c2)cc1, CCc1ccc(Cc2ccc3CO[C@]4(O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)c3c2)cc1, CCc1ccc(Cc2ccc3CO[C@]4(O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)c3c2)cc1, CCc1ccc(Cc2ccc3CO[C@]4(O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)c3c2)cc1	VWVKUNOPTJGDOB-BDHVOXNPSA-N, VWVKUNOPTJGDOB-BDHVOXNPSA-N, VWVKUNOPTJGDOB-BDHVOXNPSA-N, VWVKUNOPTJGDOB-BDHVOXNPSA-N, VWVKUNOPTJGDOB-BDHVOXNPSA-N	Launched
tolamolol	adrenergic receptor antagonist	ADRB1, ADRB2, ADRB3			Cc1ccccc1OC[C@@H](O)CNCCOc1ccc(cc1)C(N)=O |&1:9,r|	SKQDKFOTIPJUSV-INIZCTEOSA-N	Phase 3
tolazamide	ATP channel blocker	ABCC8, KCNJ1, KCNJ10, KCNJ11	endocrinology	diabetes mellitus	Cc1ccc(cc1)S(=O)(=O)NC(=O)NN1CCCCCC1, Cc1ccc(cc1)S(=O)(=O)NC(=O)NN1CCCCCC1, Cc1ccc(cc1)S(=O)(=O)NC(=O)NN1CCCCCC1	OUDSBRTVNLOZBN-UHFFFAOYSA-N, OUDSBRTVNLOZBN-UHFFFAOYSA-N, OUDSBRTVNLOZBN-UHFFFAOYSA-N	Launched
tolazoline	adrenergic receptor antagonist	ADRA1A, ADRA2A, ADRA2B, ADRA2C, HRH1, HRH2	neurology/psychiatry	reverse sedative	C(C1=NCCN1)c1ccccc1 |t:1|, C(C1=NCCN1)c1ccccc1 |t:1|, C(C1=NCCN1)c1ccccc1 |t:1|	JIVZKJJQOZQXQB-UHFFFAOYSA-N, JIVZKJJQOZQXQB-UHFFFAOYSA-N, JIVZKJJQOZQXQB-UHFFFAOYSA-N	Launched
tolbutamide	ATP channel blocker	ABCC8, KCNJ1, KCNJ11, KCNJ8	endocrinology	diabetes mellitus	CCCCNC(=O)NS(=O)(=O)c1ccc(C)cc1, CCCCNC(=O)NS(=O)(=O)c1ccc(C)cc1, CCCCNC(=O)NS(=O)(=O)c1ccc(C)cc1	JLRGJRBPOGGCBT-UHFFFAOYSA-N, JLRGJRBPOGGCBT-UHFFFAOYSA-N, JLRGJRBPOGGCBT-UHFFFAOYSA-N	Launched
tolcapone	catechol O methyltransferase inhibitor	COMT			Cc1ccc(cc1)C(=O)c1cc(O)c(O)c(c1)[N+]([O-])=O, Cc1ccc(cc1)C(=O)c1cc(O)c(O)c(c1)[N+]([O-])=O, Cc1ccc(cc1)C(=O)c1cc(O)c(O)c(c1)[N+]([O-])=O, Cc1ccc(cc1)C(=O)c1cc(O)c(O)c(c1)[N+]([O-])=O, Cc1ccc(cc1)C(=O)c1cc(O)c(O)c(c1)[N+]([O-])=O, Cc1ccc(cc1)C(=O)c1cc(O)c(O)c(c1)[N+]([O-])=O, Cc1ccc(cc1)C(=O)c1cc(O)c(O)c(c1)[N+]([O-])=O	MIQPIUSUKVNLNT-UHFFFAOYSA-N, MIQPIUSUKVNLNT-UHFFFAOYSA-N, MIQPIUSUKVNLNT-UHFFFAOYSA-N, MIQPIUSUKVNLNT-UHFFFAOYSA-N, MIQPIUSUKVNLNT-UHFFFAOYSA-N, MIQPIUSUKVNLNT-UHFFFAOYSA-N, MIQPIUSUKVNLNT-UHFFFAOYSA-N	Withdrawn
tolfenamic-acid	cyclooxygenase inhibitor, prostanoid receptor antagonist		neurology/psychiatry	migraine headache	Cc1c(Cl)cccc1Nc1ccccc1C(O)=O, Cc1c(Cl)cccc1Nc1ccccc1C(O)=O, Cc1c(Cl)cccc1Nc1ccccc1C(O)=O	YEZNLOUZAIOMLT-UHFFFAOYSA-N, YEZNLOUZAIOMLT-UHFFFAOYSA-N, YEZNLOUZAIOMLT-UHFFFAOYSA-N	Launched
tolimidone	SRC activator	LYN, SRC			Cc1cccc(Oc2cnc(=O)[nH]c2)c1, Cc1cccc(Oc2cnc(=O)[nH]c2)c1, Cc1cccc(Oc2cnc(=O)[nH]c2)c1	HJQILFPVRNHTIG-UHFFFAOYSA-N, HJQILFPVRNHTIG-UHFFFAOYSA-N, HJQILFPVRNHTIG-UHFFFAOYSA-N	Phase 2
tolmetin	cyclooxygenase inhibitor	PTGS1, PTGS2	rheumatology	rheumatoid arthritis, osteoarthritis	Cc1ccc(cc1)C(=O)c1ccc(CC(O)=O)n1C, Cc1ccc(cc1)C(=O)c1ccc(CC(O)=O)n1C, Cc1ccc(cc1)C(=O)c1ccc(CC(O)=O)n1C	UPSPUYADGBWSHF-UHFFFAOYSA-N, UPSPUYADGBWSHF-UHFFFAOYSA-N, UPSPUYADGBWSHF-UHFFFAOYSA-N	Launched
tolnaftate	fungal squalene epoxidase inhibitor		infectious disease	tinea pedis, tinea corporis	CN(C(=S)Oc1ccc2ccccc2c1)c1cccc(C)c1, CN(C(=S)Oc1ccc2ccccc2c1)c1cccc(C)c1, CN(C(=S)Oc1ccc2ccccc2c1)c1cccc(C)c1	FUSNMLFNXJSCDI-UHFFFAOYSA-N, FUSNMLFNXJSCDI-UHFFFAOYSA-N, FUSNMLFNXJSCDI-UHFFFAOYSA-N	Launched
tolonidine	adrenergic receptor antagonist	ADRA2A			Cc1ccc(NC2=NCCN2)c(Cl)c1 |t:6|	KWBTZIFLQYYPTH-UHFFFAOYSA-N	Launched
tolonium			hematology	methemoglobinemia	Cc1cc2nc3ccc(cc3sc2cc1N)=[N+](C)C, Cc1cc2nc3ccc(cc3sc2cc1N)=[N+](C)C	KZEUBCUXBNEMSQ-UHFFFAOYSA-O, KZEUBCUXBNEMSQ-UHFFFAOYSA-O	Launched
toloxatone	monoamine oxidase inhibitor	MAOA, MAOB	neurology/psychiatry	depression	Cc1cccc(c1)N1C[C@@H](CO)OC1=O |&1:9,r|, Cc1cccc(c1)N1C[C@@H](CO)OC1=O |&1:9,r|	MXUNKHLAEDCYJL-JTQLQIEISA-N, MXUNKHLAEDCYJL-JTQLQIEISA-N	Launched
tolperisone	voltage-gated sodium channel blocker	CYP2C19, CYP2D6	neurology/psychiatry, infectious disease, rheumatology, cardiology	muscle relaxant, multiple sclerosis, encephalomyelitis, ankylosing spondylitis, atherosclerosis, Raynaud's disease	C[C@@H](CN1CCCCC1)C(=O)c1ccc(C)cc1 |r|, C[C@@H](CN1CCCCC1)C(=O)c1ccc(C)cc1 |r|, C[C@@H](CN1CCCCC1)C(=O)c1ccc(C)cc1 |r|, C[C@@H](CN1CCCCC1)C(=O)c1ccc(C)cc1 |r|	FSKFPVLPFLJRQB-AWEZNQCLSA-N, FSKFPVLPFLJRQB-AWEZNQCLSA-N, FSKFPVLPFLJRQB-AWEZNQCLSA-N, FSKFPVLPFLJRQB-AWEZNQCLSA-N	Launched
tolrestat	aldose reductase inhibitor	AKR1A1, AKR1B1, AKR1B10			COc1ccc2c(cccc2c1C(F)(F)F)C(=S)N(C)CC(O)=O, COc1ccc2c(cccc2c1C(F)(F)F)C(=S)N(C)CC(O)=O, COc1ccc2c(cccc2c1C(F)(F)F)C(=S)N(C)CC(O)=O, COc1ccc2c(cccc2c1C(F)(F)F)C(=S)N(C)CC(O)=O, COc1ccc2c(cccc2c1C(F)(F)F)C(=S)N(C)CC(O)=O	LUBHDINQXIHVLS-UHFFFAOYSA-N, LUBHDINQXIHVLS-UHFFFAOYSA-N, LUBHDINQXIHVLS-UHFFFAOYSA-N, LUBHDINQXIHVLS-UHFFFAOYSA-N, LUBHDINQXIHVLS-UHFFFAOYSA-N	Withdrawn
tolterodine	acetylcholine receptor antagonist	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5	urology	urinary incontinence, urinary frequency	CC(C)N(CC[C@H](c1ccccc1)c1cc(C)ccc1O)C(C)C, CC(C)N(CC[C@H](c1ccccc1)c1cc(C)ccc1O)C(C)C, CC(C)N(CC[C@H](c1ccccc1)c1cc(C)ccc1O)C(C)C, CC(C)N(CC[C@H](c1ccccc1)c1cc(C)ccc1O)C(C)C	OOGJQPCLVADCPB-HXUWFJFHSA-N, OOGJQPCLVADCPB-HXUWFJFHSA-N, OOGJQPCLVADCPB-HXUWFJFHSA-N, OOGJQPCLVADCPB-HXUWFJFHSA-N	Launched
toltrazuril	antiprotozoal agent		infectious disease	coccidiosis	Cc1cc(ccc1Oc1ccc(SC(F)(F)F)cc1)-n1c(=O)[nH]c(=O)n(C)c1=O, Cc1cc(ccc1Oc1ccc(SC(F)(F)F)cc1)-n1c(=O)[nH]c(=O)n(C)c1=O, Cc1cc(ccc1Oc1ccc(SC(F)(F)F)cc1)-n1c(=O)[nH]c(=O)n(C)c1=O, Cc1cc(ccc1Oc1ccc(SC(F)(F)F)cc1)-n1c(=O)[nH]c(=O)n(C)c1=O	OCINXEZVIIVXFU-UHFFFAOYSA-N, OCINXEZVIIVXFU-UHFFFAOYSA-N, OCINXEZVIIVXFU-UHFFFAOYSA-N, OCINXEZVIIVXFU-UHFFFAOYSA-N	Launched
tolvaptan	vasopressin receptor antagonist	AVPR1A, AVPR2	endocrinology, cardiology, gastroenterology	hyponatremia, congestive heart failure, hepatic cirrhosis	Cc1ccccc1C(=O)Nc1ccc(C(=O)N2CCC[C@@H](O)c3cc(Cl)ccc23)c(C)c1 |&1:20,r|, Cc1ccccc1C(=O)Nc1ccc(C(=O)N2CCC[C@@H](O)c3cc(Cl)ccc23)c(C)c1 |&1:20,r|, Cc1ccccc1C(=O)Nc1ccc(C(=O)N2CCC[C@@H](O)c3cc(Cl)ccc23)c(C)c1 |&1:20,r|, Cc1ccccc1C(=O)Nc1ccc(C(=O)N2CCC[C@@H](O)c3cc(Cl)ccc23)c(C)c1 |&1:20,r|	GYHCTFXIZSNGJT-XMMPIXPASA-N, GYHCTFXIZSNGJT-XMMPIXPASA-N, GYHCTFXIZSNGJT-XMMPIXPASA-N, GYHCTFXIZSNGJT-XMMPIXPASA-N	Launched
tomeglovir	antiviral				CN(C)c1cccc2c(cccc12)S(=O)(=O)Nc1ccc(NC(=O)C(C)(C)CO)cc1	OSQAKHSYTKBSPB-UHFFFAOYSA-N	Preclinical
tomelukast	leukotriene receptor antagonist	CYSLTR1			CCCc1c(OCCCCc2nn[nH]n2)ccc(C(C)=O)c1O	MWYHLEQJTQJHSS-UHFFFAOYSA-N	Phase 3
tomivosertib	MAPK-interacting kinase inhibitor				Cc1cc(Nc2cc(N)ncn2)c(=O)n2c1C(=O)NC21CCCCC1	HKTBYUWLRDZAJK-UHFFFAOYSA-N	Phase 2
tonabersat	gap junction modulator, nitric oxide production inhibitor				CC(=O)c1ccc2OC(C)(C)[C@@H](O)[C@@H](NC(=O)c3ccc(F)c(Cl)c3)c2c1, CC(=O)c1ccc2OC(C)(C)[C@@H](O)[C@@H](NC(=O)c3ccc(F)c(Cl)c3)c2c1	XLIIRNOPGJTBJD-ROUUACIJSA-N, XLIIRNOPGJTBJD-ROUUACIJSA-N	Phase 2
topilutamide	androgen receptor antagonist				C[C@](O)(CNC(=O)C(F)(F)F)C(=O)Nc1ccc(c(c1)C(F)(F)F)[N+]([O-])=O |&1:1,r|	YCNCRLKXSLARFT-NSHDSACASA-N	Preclinical
topiramate	carbonic anhydrase inhibitor, glutamate receptor antagonist, kainate receptor antagonist	CA1, CA12, CA2, CA4, CA7, GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, GRIA1, GRIA2, GRIA3, GRIA4, GRIK1, GRIK2, GRIK3, GRIK4, GRIK5, SCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A	neurology/psychiatry	epilepsy, migraine headache	CC1(C)O[C@@H]2CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@H]3[C@@H]2O1, CC1(C)O[C@@H]2CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@H]3[C@@H]2O1, CC1(C)O[C@@H]2CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@H]3[C@@H]2O1, CC1(C)O[C@@H]2CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@H]3[C@@H]2O1, CC1(C)O[C@@H]2CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@H]3[C@@H]2O1, CC1(C)O[C@@H]2CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@H]3[C@@H]2O1	KJADKKWYZYXHBB-XBWDGYHZSA-N, KJADKKWYZYXHBB-XBWDGYHZSA-N, KJADKKWYZYXHBB-XBWDGYHZSA-N, KJADKKWYZYXHBB-XBWDGYHZSA-N, KJADKKWYZYXHBB-XBWDGYHZSA-N, KJADKKWYZYXHBB-XBWDGYHZSA-N	Launched
topiroxostat	xanthine oxidase inhibitor	XDH	rheumatology, nephrology	gout, hyperuricemia	N#Cc1cc(ccn1)-c1nnc([nH]1)-c1ccncc1, N#Cc1cc(ccn1)-c1nnc([nH]1)-c1ccncc1, N#Cc1cc(ccn1)-c1nnc([nH]1)-c1ccncc1, N#Cc1cc(ccn1)-c1nnc([nH]1)-c1ccncc1, N#Cc1cc(ccn1)-c1nnc([nH]1)-c1ccncc1	UBVZQGOVTLIHLH-UHFFFAOYSA-N, UBVZQGOVTLIHLH-UHFFFAOYSA-N, UBVZQGOVTLIHLH-UHFFFAOYSA-N, UBVZQGOVTLIHLH-UHFFFAOYSA-N, UBVZQGOVTLIHLH-UHFFFAOYSA-N	Launched
topotecan	topoisomerase inhibitor	TOP1, TOP1MT	oncology	small cell lung cancer, cervical cancer	CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccc(O)c(CN(C)C)c4cc3Cn1c2=O, CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccc(O)c(CN(C)C)c4cc3Cn1c2=O, CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccc(O)c(CN(C)C)c4cc3Cn1c2=O, CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccc(O)c(CN(C)C)c4cc3Cn1c2=O, CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccc(O)c(CN(C)C)c4cc3Cn1c2=O, CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccc(O)c(CN(C)C)c4cc3Cn1c2=O, CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccc(O)c(CN(C)C)c4cc3Cn1c2=O	UCFGDBYHRUNTLO-QHCPKHFHSA-N, UCFGDBYHRUNTLO-QHCPKHFHSA-N, UCFGDBYHRUNTLO-QHCPKHFHSA-N, UCFGDBYHRUNTLO-QHCPKHFHSA-N, UCFGDBYHRUNTLO-QHCPKHFHSA-N, UCFGDBYHRUNTLO-QHCPKHFHSA-N, UCFGDBYHRUNTLO-QHCPKHFHSA-N	Launched
torasemide	electrolyte reabsorption inhibitor, thromboxane receptor antagonist	SLC12A1	cardiology	edema, congestive heart failure, hypertension	CC(C)NC(=O)NS(=O)(=O)c1cnccc1Nc1cccc(C)c1, CC(C)NC(=O)NS(=O)(=O)c1cnccc1Nc1cccc(C)c1, CC(C)NC(=O)NS(=O)(=O)c1cnccc1Nc1cccc(C)c1, CC(C)NC(=O)NS(=O)(=O)c1cnccc1Nc1cccc(C)c1	NGBFQHCMQULJNZ-UHFFFAOYSA-N, NGBFQHCMQULJNZ-UHFFFAOYSA-N, NGBFQHCMQULJNZ-UHFFFAOYSA-N, NGBFQHCMQULJNZ-UHFFFAOYSA-N	Launched
torcetrapib	cholesteryl ester transfer protein inhibitor	CETP			CCOC(=O)N1[C@H](CC)C[C@H](N(Cc2cc(cc(c2)C(F)(F)F)C(F)(F)F)C(=O)OC)c2cc(ccc12)C(F)(F)F, CCOC(=O)N1[C@H](CC)C[C@H](N(Cc2cc(cc(c2)C(F)(F)F)C(F)(F)F)C(=O)OC)c2cc(ccc12)C(F)(F)F, CCOC(=O)N1[C@H](CC)C[C@H](N(Cc2cc(cc(c2)C(F)(F)F)C(F)(F)F)C(=O)OC)c2cc(ccc12)C(F)(F)F, CCOC(=O)N1[C@H](CC)C[C@H](N(Cc2cc(cc(c2)C(F)(F)F)C(F)(F)F)C(=O)OC)c2cc(ccc12)C(F)(F)F	CMSGWTNRGKRWGS-NQIIRXRSSA-N, CMSGWTNRGKRWGS-NQIIRXRSSA-N, CMSGWTNRGKRWGS-NQIIRXRSSA-N, CMSGWTNRGKRWGS-NQIIRXRSSA-N	Phase 3
torcitabine	DNA polymerase inhibitor	DCK, TK2			Nc1ccn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1, Nc1ccn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1	CKTSBUTUHBMZGZ-SHYZEUOFSA-N, CKTSBUTUHBMZGZ-SHYZEUOFSA-N	Phase 2
toremifene	estrogen receptor antagonist, selective estrogen receptor modulator (SERM)	ESR1	oncology	breast cancer	CN(C)CCOc1ccc(cc1)C(=C(\CCCl)c1ccccc1)\c1ccccc1, CN(C)CCOc1ccc(cc1)C(=C(\CCCl)c1ccccc1)\c1ccccc1, CN(C)CCOc1ccc(cc1)C(=C(\CCCl)c1ccccc1)\c1ccccc1, CN(C)CCOc1ccc(cc1)C(=C(\CCCl)c1ccccc1)\c1ccccc1, CN(C)CCOc1ccc(cc1)C(=C(\CCCl)c1ccccc1)\c1ccccc1, CN(C)CCOc1ccc(cc1)C(=C(\CCCl)c1ccccc1)\c1ccccc1, CN(C)CCOc1ccc(cc1)C(=C(\CCCl)c1ccccc1)\c1ccccc1, CN(C)CCOc1ccc(cc1)C(=C(\CCCl)c1ccccc1)\c1ccccc1, CN(C)CCOc1ccc(cc1)C(=C(\CCCl)c1ccccc1)\c1ccccc1, CN(C)CCOc1ccc(cc1)C(=C(\CCCl)c1ccccc1)\c1ccccc1	XFCLJVABOIYOMF-QPLCGJKRSA-N, XFCLJVABOIYOMF-QPLCGJKRSA-N, XFCLJVABOIYOMF-QPLCGJKRSA-N, XFCLJVABOIYOMF-QPLCGJKRSA-N, XFCLJVABOIYOMF-QPLCGJKRSA-N, XFCLJVABOIYOMF-QPLCGJKRSA-N, XFCLJVABOIYOMF-QPLCGJKRSA-N, XFCLJVABOIYOMF-QPLCGJKRSA-N, XFCLJVABOIYOMF-QPLCGJKRSA-N, XFCLJVABOIYOMF-QPLCGJKRSA-N	Launched
torin-1	mTOR inhibitor	MTOR			CCC(=O)N1CCN(CC1)c1ccc(cc1C(F)(F)F)-n1c2c(ccc1=O)cnc1ccc(cc21)-c1cnc2ccccc2c1, CCC(=O)N1CCN(CC1)c1ccc(cc1C(F)(F)F)-n1c2c(ccc1=O)cnc1ccc(cc21)-c1cnc2ccccc2c1, CCC(=O)N1CCN(CC1)c1ccc(cc1C(F)(F)F)-n1c2c(ccc1=O)cnc1ccc(cc21)-c1cnc2ccccc2c1, CCC(=O)N1CCN(CC1)c1ccc(cc1C(F)(F)F)-n1c2c(ccc1=O)cnc1ccc(cc21)-c1cnc2ccccc2c1, CCC(=O)N1CCN(CC1)c1ccc(cc1C(F)(F)F)-n1c2c(ccc1=O)cnc1ccc(cc21)-c1cnc2ccccc2c1	AKCRNFFTGXBONI-UHFFFAOYSA-N, AKCRNFFTGXBONI-UHFFFAOYSA-N, AKCRNFFTGXBONI-UHFFFAOYSA-N, AKCRNFFTGXBONI-UHFFFAOYSA-N, AKCRNFFTGXBONI-UHFFFAOYSA-N	Preclinical
torin-2	mTOR inhibitor	MTOR			Nc1ccc(cn1)-c1ccc2ncc3ccc(=O)n(-c4cccc(c4)C(F)(F)F)c3c2c1, Nc1ccc(cn1)-c1ccc2ncc3ccc(=O)n(-c4cccc(c4)C(F)(F)F)c3c2c1, Nc1ccc(cn1)-c1ccc2ncc3ccc(=O)n(-c4cccc(c4)C(F)(F)F)c3c2c1, Nc1ccc(cn1)-c1ccc2ncc3ccc(=O)n(-c4cccc(c4)C(F)(F)F)c3c2c1, Nc1ccc(cn1)-c1ccc2ncc3ccc(=O)n(-c4cccc(c4)C(F)(F)F)c3c2c1, Nc1ccc(cn1)-c1ccc2ncc3ccc(=O)n(-c4cccc(c4)C(F)(F)F)c3c2c1	GUXXEUUYCAYESJ-UHFFFAOYSA-N, GUXXEUUYCAYESJ-UHFFFAOYSA-N, GUXXEUUYCAYESJ-UHFFFAOYSA-N, GUXXEUUYCAYESJ-UHFFFAOYSA-N, GUXXEUUYCAYESJ-UHFFFAOYSA-N, GUXXEUUYCAYESJ-UHFFFAOYSA-N	Preclinical
tosedostat	peptidase inhibitor	ANPEP, LAP3, NPEPPS			CC(C)C[C@H]([C@H](O)C(=O)NO)C(=O)N[C@H](C(=O)OC1CCCC1)c1ccccc1, CC(C)C[C@H]([C@H](O)C(=O)NO)C(=O)N[C@H](C(=O)OC1CCCC1)c1ccccc1, CC(C)C[C@H]([C@H](O)C(=O)NO)C(=O)N[C@H](C(=O)OC1CCCC1)c1ccccc1, CC(C)C[C@H]([C@H](O)C(=O)NO)C(=O)N[C@H](C(=O)OC1CCCC1)c1ccccc1, CC(C)C[C@H]([C@H](O)C(=O)NO)C(=O)N[C@H](C(=O)OC1CCCC1)c1ccccc1, CC(C)C[C@H]([C@H](O)C(=O)NO)C(=O)N[C@H](C(=O)OC1CCCC1)c1ccccc1, CC(C)C[C@H]([C@H](O)C(=O)NO)C(=O)N[C@H](C(=O)OC1CCCC1)c1ccccc1, CC(C)C[C@H]([C@H](O)C(=O)NO)C(=O)N[C@H](C(=O)OC1CCCC1)c1ccccc1	FWFGIHPGRQZWIW-SQNIBIBYSA-N, FWFGIHPGRQZWIW-SQNIBIBYSA-N, FWFGIHPGRQZWIW-SQNIBIBYSA-N, FWFGIHPGRQZWIW-SQNIBIBYSA-N, FWFGIHPGRQZWIW-SQNIBIBYSA-N, FWFGIHPGRQZWIW-SQNIBIBYSA-N, FWFGIHPGRQZWIW-SQNIBIBYSA-N, FWFGIHPGRQZWIW-SQNIBIBYSA-N	Phase 2
tosufloxacin	bacterial DNA gyrase inhibitor		infectious disease	gram-negative bacterial infections	N[C@H]1CCN(C1)c1nc2n(cc(C(O)=O)c(=O)c2cc1F)-c1ccc(F)cc1F |&1:1|	WUWFMDMBOJLQIV-JTQLQIEISA-N	Launched
toyocamycin	serine/threonine kinase inhibitor	ERN1			Nc1ncnc2n(cc(C#N)c12)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O, Nc1ncnc2n(cc(C#N)c12)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O, Nc1ncnc2n(cc(C#N)c12)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O	XOKJUSAYZUAMGJ-WOUKDFQISA-N, XOKJUSAYZUAMGJ-WOUKDFQISA-N, XOKJUSAYZUAMGJ-WOUKDFQISA-N	Phase 1
tozadenant	adenosine receptor antagonist	ADORA2A			COc1ccc(N2CCOCC2)c2sc(NC(=O)N3CCC(C)(O)CC3)nc12, COc1ccc(N2CCOCC2)c2sc(NC(=O)N3CCC(C)(O)CC3)nc12, COc1ccc(N2CCOCC2)c2sc(NC(=O)N3CCC(C)(O)CC3)nc12, COc1ccc(N2CCOCC2)c2sc(NC(=O)N3CCC(C)(O)CC3)nc12	XNBRWUQWSKXMPW-UHFFFAOYSA-N, XNBRWUQWSKXMPW-UHFFFAOYSA-N, XNBRWUQWSKXMPW-UHFFFAOYSA-N, XNBRWUQWSKXMPW-UHFFFAOYSA-N	Phase 3
tozasertib	Aurora kinase inhibitor, Bcr-Abl kinase inhibitor, FLT3 inhibitor, JAK inhibitor	AURKA, AURKB, AURKC, LCK			CN1CCN(CC1)c1cc(Nc2cc(C)n[nH]2)nc(Sc2ccc(NC(=O)C3CC3)cc2)n1, CN1CCN(CC1)c1cc(Nc2cc(C)n[nH]2)nc(Sc2ccc(NC(=O)C3CC3)cc2)n1, CN1CCN(CC1)c1cc(Nc2cc(C)n[nH]2)nc(Sc2ccc(NC(=O)C3CC3)cc2)n1, CN1CCN(CC1)c1cc(Nc2cc(C)n[nH]2)nc(Sc2ccc(NC(=O)C3CC3)cc2)n1, CN1CCN(CC1)c1cc(Nc2cc(C)n[nH]2)nc(Sc2ccc(NC(=O)C3CC3)cc2)n1	GCIKSSRWRFVXBI-UHFFFAOYSA-N, GCIKSSRWRFVXBI-UHFFFAOYSA-N, GCIKSSRWRFVXBI-UHFFFAOYSA-N, GCIKSSRWRFVXBI-UHFFFAOYSA-N, GCIKSSRWRFVXBI-UHFFFAOYSA-N	Phase 2
TP-003	GABA receptor inverse agonist	GABRA1, GABRA2, GABRA3, GABRA5			CC(C)(O)c1ccn2c(cnc2c1F)-c1ccc(F)c(c1)-c1ccc(F)cc1C#N, CC(C)(O)c1ccn2c(cnc2c1F)-c1ccc(F)c(c1)-c1ccc(F)cc1C#N	SJMMDWXJSSJHOQ-UHFFFAOYSA-N, SJMMDWXJSSJHOQ-UHFFFAOYSA-N	Preclinical
TP-0903	AXL kinase inhibitor	AXL			CN(C)S(=O)(=O)c1ccccc1Nc1nc(Nc2ccc(CN3CCN(C)CC3)cc2)ncc1Cl, CN(C)S(=O)(=O)c1ccccc1Nc1nc(Nc2ccc(CN3CCN(C)CC3)cc2)ncc1Cl, CN(C)S(=O)(=O)c1ccccc1Nc1nc(Nc2ccc(CN3CCN(C)CC3)cc2)ncc1Cl, CN(C)S(=O)(=O)c1ccccc1Nc1nc(Nc2ccc(CN3CCN(C)CC3)cc2)ncc1Cl, CN(C)S(=O)(=O)c1ccccc1Nc1nc(Nc2ccc(CN3CCN(C)CC3)cc2)ncc1Cl	YUAALFPUEOYPNX-UHFFFAOYSA-N, YUAALFPUEOYPNX-UHFFFAOYSA-N, YUAALFPUEOYPNX-UHFFFAOYSA-N, YUAALFPUEOYPNX-UHFFFAOYSA-N, YUAALFPUEOYPNX-UHFFFAOYSA-N	Phase 1/Phase 2
TP-3654	1,4,5-trisphosphate inhibitor				CC(C)(O)[C@H]1CC[C@@H](CC1)Nc1ccc2ncc(-c3cccc(c3)C(F)(F)F)n2n1 |r|	XRNVABDYQLHODA-JCNLHEQBSA-N	Phase 1
TPCA-1	IKK inhibitor	IKBKB			NC(=O)Nc1sc(cc1C(N)=O)-c1ccc(F)cc1, NC(=O)Nc1sc(cc1C(N)=O)-c1ccc(F)cc1, NC(=O)Nc1sc(cc1C(N)=O)-c1ccc(F)cc1, NC(=O)Nc1sc(cc1C(N)=O)-c1ccc(F)cc1, NC(=O)Nc1sc(cc1C(N)=O)-c1ccc(F)cc1, NC(=O)Nc1sc(cc1C(N)=O)-c1ccc(F)cc1	SAYGKHKXGCPTLX-UHFFFAOYSA-N, SAYGKHKXGCPTLX-UHFFFAOYSA-N, SAYGKHKXGCPTLX-UHFFFAOYSA-N, SAYGKHKXGCPTLX-UHFFFAOYSA-N, SAYGKHKXGCPTLX-UHFFFAOYSA-N, SAYGKHKXGCPTLX-UHFFFAOYSA-N	Preclinical
TPPS4					OS(=O)(=O)c1ccc(cc1)-c1c2ccc(n2)c(-c2ccc(cc2)S(O)(=O)=O)c2ccc([nH]2)c(-c2ccc(cc2)S(O)(=O)=O)c2ccc(n2)c(-c2ccc(cc2)S(O)(=O)=O)c2ccc1[nH]2	PBHVCRIXMXQXPD-LWQDQPMZSA-N	Phase 1
trabectedin	antitumor agent				[H][C@@]12Cc3cc(C)c(OC)c(O)c3[C@@]([H])(N1C)[C@@]1([H])N([C@H]2O)[C@@]2([H])COC(=O)[C@]3(CS[C@]1([H])c1c(OC(C)=O)c(C)c4OCOc4c21)NCCc1cc(O)c(OC)cc31 |THB:16:15:2.3.12:17.19.20|	PKVRCIRHQMSYJX-AIFWHQITSA-N	Phase 3
trabodenoson	adenosine receptor agonist				O[C@@H]1[C@@H](CO[N+]([O-])=O)O[C@H]([C@@H]1O)n1cnc2c(NC3CCCC3)ncnc12	AQLVRTWKJDTWQQ-SDBHATRESA-N	Phase 3
tracazolate	GABA receptor modulator	GABRA1			CCCCNc1c(C(=O)OCC)c(C)nc2n(CC)ncc12, CCCCNc1c(C(=O)OCC)c(C)nc2n(CC)ncc12, CCCCNc1c(C(=O)OCC)c(C)nc2n(CC)ncc12, CCCCNc1c(C(=O)OCC)c(C)nc2n(CC)ncc12	PCTRYMLLRKWXGF-UHFFFAOYSA-N, PCTRYMLLRKWXGF-UHFFFAOYSA-N, PCTRYMLLRKWXGF-UHFFFAOYSA-N, PCTRYMLLRKWXGF-UHFFFAOYSA-N	Phase 2
tradipitant	neurokinin receptor antagonist				FC(F)(F)c1cc(Cn2nnc(c2-c2ccncc2)-c2ncccc2C(=O)c2ccccc2Cl)cc(c1)C(F)(F)F	CAVRKWRKTNINFF-UHFFFAOYSA-N	Phase 3
TRAM-34	potassium channel antagonist	KCNN4			Clc1ccccc1C(c1ccccc1)(c1ccccc1)n1cccn1, Clc1ccccc1C(c1ccccc1)(c1ccccc1)n1cccn1	KBFUQFVFYYBHBT-UHFFFAOYSA-N, KBFUQFVFYYBHBT-UHFFFAOYSA-N	Preclinical
TRAM-39	calcium-activated potassium channel activator	KCNN4			Clc1ccccc1C(C#N)(c1ccccc1)c1ccccc1, Clc1ccccc1C(C#N)(c1ccccc1)c1ccccc1, Clc1ccccc1C(C#N)(c1ccccc1)c1ccccc1	JHNRTPKGSCVKKC-UHFFFAOYSA-N, JHNRTPKGSCVKKC-UHFFFAOYSA-N, JHNRTPKGSCVKKC-UHFFFAOYSA-N	Preclinical
trametinib	MEK inhibitor	MAP2K1, MAP2K2	oncology	melanoma	CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O, CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O, CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O, CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O, CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O, CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O, CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O, CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O, CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O, CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O, CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O	LIRYPHYGHXZJBZ-UHFFFAOYSA-N, LIRYPHYGHXZJBZ-UHFFFAOYSA-N, LIRYPHYGHXZJBZ-UHFFFAOYSA-N, LIRYPHYGHXZJBZ-UHFFFAOYSA-N, LIRYPHYGHXZJBZ-UHFFFAOYSA-N, LIRYPHYGHXZJBZ-UHFFFAOYSA-N, LIRYPHYGHXZJBZ-UHFFFAOYSA-N, LIRYPHYGHXZJBZ-UHFFFAOYSA-N, LIRYPHYGHXZJBZ-UHFFFAOYSA-N, LIRYPHYGHXZJBZ-UHFFFAOYSA-N, LIRYPHYGHXZJBZ-UHFFFAOYSA-N	Launched
tramiprosate	beta amyloid protein neurotoxicity inhibitor	APP			NCCCS(O)(=O)=O, NCCCS(O)(=O)=O	SNKZJIOFVMKAOJ-UHFFFAOYSA-N, SNKZJIOFVMKAOJ-UHFFFAOYSA-N	Phase 3
trandolapril	angiotensin converting enzyme inhibitor	ACE	cardiology	hypertension, myocardial infarction	CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1[C@H]2CCCC[C@@H]2C[C@H]1C(O)=O, CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1[C@H]2CCCC[C@@H]2C[C@H]1C(O)=O	VXFJYXUZANRPDJ-WTNASJBWSA-N, VXFJYXUZANRPDJ-WTNASJBWSA-N	Launched
tranexamic-acid	antifibrinolytic, plasminogen activator inhibitor	PLG	hematology	hemophilia	NC[C@H]1CC[C@@H](CC1)C(O)=O |r|, NC[C@H]1CC[C@@H](CC1)C(O)=O |r|, NC[C@H]1CC[C@@H](CC1)C(O)=O |r|, NC[C@H]1CC[C@@H](CC1)C(O)=O |r|, NC[C@H]1CC[C@@H](CC1)C(O)=O |r|	GYDJEQRTZSCIOI-LJGSYFOKSA-N, GYDJEQRTZSCIOI-LJGSYFOKSA-N, GYDJEQRTZSCIOI-LJGSYFOKSA-N, GYDJEQRTZSCIOI-LJGSYFOKSA-N, GYDJEQRTZSCIOI-LJGSYFOKSA-N	Launched
tranilast	angiogenesis inhibitor	HPGDS, HRH1	pulmonary	asthma	COc1ccc(\C=C\C(=O)Nc2ccccc2C(O)=O)cc1OC, COc1ccc(\C=C\C(=O)Nc2ccccc2C(O)=O)cc1OC, COc1ccc(\C=C\C(=O)Nc2ccccc2C(O)=O)cc1OC, COc1ccc(\C=C\C(=O)Nc2ccccc2C(O)=O)cc1OC, COc1ccc(\C=C\C(=O)Nc2ccccc2C(O)=O)cc1OC, COc1ccc(\C=C\C(=O)Nc2ccccc2C(O)=O)cc1OC	NZHGWWWHIYHZNX-CSKARUKUSA-N, NZHGWWWHIYHZNX-CSKARUKUSA-N, NZHGWWWHIYHZNX-CSKARUKUSA-N, NZHGWWWHIYHZNX-CSKARUKUSA-N, NZHGWWWHIYHZNX-CSKARUKUSA-N, NZHGWWWHIYHZNX-CSKARUKUSA-N	Launched
trans-10,cis-12-conjugated-linoleic-acid					CCCCC\C=C/C=C/CCCCCCCCC(O)=O, CCCCC\C=C/C=C/CCCCCCCCC(O)=O	GKJZMAHZJGSBKD-NMMTYZSQSA-N, GKJZMAHZJGSBKD-NMMTYZSQSA-N	Launched
trans-2-undecenoic-acid					CCCCCCCC\C=C\C(O)=O	IGBBVTAVILYDIO-MDZDMXLPSA-N	Preclinical
trans-4-[8-(3-fluorophenyl)-1,7-naphthyridin-6-yl]cyclohexanecarboxylic-acid					OC(=O)C1CCC(CC1)c1cc2cccnc2c(n1)-c1cccc(F)c1, OC(=O)C1CCC(CC1)c1cc2cccnc2c(n1)-c1cccc(F)c1	XWVBOPKUSVZZPJ-UHFFFAOYSA-N, XWVBOPKUSVZZPJ-UHFFFAOYSA-N	Preclinical
trans-4-hydroxycrotonic-acid	gamma hydroxybutyric acid ligand				OC\C=C\C(O)=O, OC\C=C\C(O)=O	RMQJECWPWQIIPW-OWOJBTEDSA-N, RMQJECWPWQIIPW-OWOJBTEDSA-N	Preclinical
trans-4-methoxycinnamic-acid					COc1ccc(\C=C\C(O)=O)cc1, COc1ccc(\C=C\C(O)=O)cc1, COc1ccc(\C=C\C(O)=O)cc1	AFDXODALSZRGIH-QPJJXVBHSA-N, AFDXODALSZRGIH-QPJJXVBHSA-N, AFDXODALSZRGIH-QPJJXVBHSA-N	Preclinical
transcrocetinate	glutamate receptor antagonist				C\C(\C=C\C=C(/C)C(O)=O)=C/C=C/C=C(\C)/C=C/C=C(\C)C(O)=O	PANKHBYNKQNAHN-MQQNZMFNSA-N	Preclinical
tranylcypromine	monoamine oxidase inhibitor	KDM1A, MAOA, MAOB	neurology/psychiatry	depression	N[C@H]1C[C@@H]1c1ccccc1 |&1:1,3|	AELCINSCMGFISI-BDAKNGLRSA-N	Launched
trap-101	nociceptin/orphanin FQ receptor antagonist, opioid receptor antagonist	OPRL1			CCn1c2ccccc2n(C2=C(CO)CN(CC3CCCCCCC3)CC2)c1=O |c:11|, CCn1c2ccccc2n(C2=C(CO)CN(CC3CCCCCCC3)CC2)c1=O |c:11|, CCn1c2ccccc2n(C2=C(CO)CN(CC3CCCCCCC3)CC2)c1=O |c:11|, CCn1c2ccccc2n(C2=C(CO)CN(CC3CCCCCCC3)CC2)c1=O |c:11|	DCRGHMJXEBSRQG-UHFFFAOYSA-N, DCRGHMJXEBSRQG-UHFFFAOYSA-N, DCRGHMJXEBSRQG-UHFFFAOYSA-N, DCRGHMJXEBSRQG-UHFFFAOYSA-N	Preclinical
trapidil	PDGFR tyrosine kinase receptor inhibitor	PDGFRA	cardiology	coronary artery disease (CAD)	CCN(CC)c1cc(C)nc2ncnn12, CCN(CC)c1cc(C)nc2ncnn12, CCN(CC)c1cc(C)nc2ncnn12	GSNOZLZNQMLSKJ-UHFFFAOYSA-N, GSNOZLZNQMLSKJ-UHFFFAOYSA-N, GSNOZLZNQMLSKJ-UHFFFAOYSA-N	Launched
travoprost	prostanoid receptor agonist	PTGFR	ophthalmology	ocular hypertension, glaucoma	CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\[C@@H](O)COc1cccc(c1)C(F)(F)F, CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\[C@@H](O)COc1cccc(c1)C(F)(F)F	MKPLKVHSHYCHOC-AHTXBMBWSA-N, MKPLKVHSHYCHOC-AHTXBMBWSA-N	Launched
traxoprodil	glutamate receptor antagonist	GRIN2B			C[C@@H]([C@@H](O)c1ccc(O)cc1)N1CCC(O)(CC1)c1ccccc1, C[C@@H]([C@@H](O)c1ccc(O)cc1)N1CCC(O)(CC1)c1ccccc1	QEMSVZNTSXPFJA-HNAYVOBHSA-N, QEMSVZNTSXPFJA-HNAYVOBHSA-N	Phase 2
trazodone	adrenergic receptor antagonist, serotonin receptor antagonist, serotonin reuptake inhibitor	ADRA1A, ADRA2A, HRH1, HTR1A, HTR2A, HTR2B, HTR2C, SLC6A4	neurology/psychiatry	depression	Clc1cccc(c1)N1CCN(CCCn2nc3ccccn3c2=O)CC1, Clc1cccc(c1)N1CCN(CCCn2nc3ccccn3c2=O)CC1	PHLBKPHSAVXXEF-UHFFFAOYSA-N, PHLBKPHSAVXXEF-UHFFFAOYSA-N	Launched
trebenzomine					C[C@H]1Oc2ccccc2C[C@@H]1N(C)C |&1:1,&2:10,r|	FDJAKSHVOONYHX-KOLCDFICSA-N	Phase 2
trelagliptin	dipeptidyl peptidase inhibitor	DPP4	endocrinology	diabetes mellitus	Cn1c(=O)cc(N2CCC[C@@H](N)C2)n(Cc2cc(F)ccc2C#N)c1=O	IWYJYHUNXVAVAA-OAHLLOKOSA-N	Launched
tremorine	acetylcholine receptor agonist				C(C#CCN1CCCC1)N1CCCC1, C(C#CCN1CCCC1)N1CCCC1, C(C#CCN1CCCC1)N1CCCC1	JSUAJTLKVREZHV-UHFFFAOYSA-N, JSUAJTLKVREZHV-UHFFFAOYSA-N, JSUAJTLKVREZHV-UHFFFAOYSA-N	Preclinical
treosulfan	DNA synthesis inhibitor		oncology	ovarian cancer	CS(=O)(=O)OC[C@H](O)[C@@H](O)COS(C)(=O)=O, CS(=O)(=O)OC[C@H](O)[C@@H](O)COS(C)(=O)=O	YCPOZVAOBBQLRI-WDSKDSINSA-N, YCPOZVAOBBQLRI-WDSKDSINSA-N	Launched
trepibutone	cholinergic receptor antagonist	CHRM1, CHRM2, CHRM3, CHRM4	gastroenterology	irritable bowel syndrome	CCOc1cc(OCC)c(cc1OCC)C(=O)CCC(O)=O	YPTFHLJNWSJXKG-UHFFFAOYSA-N	Launched
treprostinil	prostanoid receptor agonist	P2RY12, PPARD, PTGIR	pulmonary	pulmonary arterial hypertension (PAH)	CCCCC[C@H](O)CC[C@H]1[C@H](O)C[C@@H]2Cc3c(C[C@H]12)cccc3OCC(O)=O	PAJMKGZZBBTTOY-ZFORQUDYSA-N	Launched
trequinsin	phosphodiesterase inhibitor	PDE5A			COc1cc2CCn3c(c\c(=N/c4c(C)cc(C)cc4C)n(C)c3=O)-c2cc1OC, COc1cc2CCn3c(c\c(=N/c4c(C)cc(C)cc4C)n(C)c3=O)-c2cc1OC, COc1cc2CCn3c(c\c(=N/c4c(C)cc(C)cc4C)n(C)c3=O)-c2cc1OC, COc1cc2CCn3c(c\c(=N/c4c(C)cc(C)cc4C)n(C)c3=O)-c2cc1OC	MCMSJVMUSBZUCN-YYDJUVGSSA-N, MCMSJVMUSBZUCN-YYDJUVGSSA-N, MCMSJVMUSBZUCN-YYDJUVGSSA-N, MCMSJVMUSBZUCN-YYDJUVGSSA-N	Phase 1
tretazicar	DNA replication inhibitor	NQO2			NC(=O)c1cc(N2CC2)c(cc1[N+]([O-])=O)[N+]([O-])=O, NC(=O)c1cc(N2CC2)c(cc1[N+]([O-])=O)[N+]([O-])=O, NC(=O)c1cc(N2CC2)c(cc1[N+]([O-])=O)[N+]([O-])=O	WOCXQMCIOTUMJV-UHFFFAOYSA-N, WOCXQMCIOTUMJV-UHFFFAOYSA-N, WOCXQMCIOTUMJV-UHFFFAOYSA-N	Phase 2
tretinoin	retinoid receptor agonist, retinoid receptor ligand	ALDH1A1, ALDH1A2, GPRC5A, NR0B1, NR2C2, PPARD, RARA, RARB, RARG, RARRES1, RORB, RORC, RXRB, RXRG	hematologic malignancy	acute promyelocytic leukemia (APL)	C\C(\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C/C(O)=O |c:4|, C\C(\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C/C(O)=O |c:4|, C\C(\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C/C(O)=O |c:4|, C\C(\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C/C(O)=O |c:4|, C\C(\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C/C(O)=O |c:4|, C\C(\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C/C(O)=O |c:4|, C\C(\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C/C(O)=O |c:4|, C\C(\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C/C(O)=O |c:4|, C\C(\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C/C(O)=O |c:4|	SHGAZHPCJJPHSC-YCNIQYBTSA-N, SHGAZHPCJJPHSC-YCNIQYBTSA-N, SHGAZHPCJJPHSC-YCNIQYBTSA-N, SHGAZHPCJJPHSC-YCNIQYBTSA-N, SHGAZHPCJJPHSC-YCNIQYBTSA-N, SHGAZHPCJJPHSC-YCNIQYBTSA-N, SHGAZHPCJJPHSC-YCNIQYBTSA-N, SHGAZHPCJJPHSC-YCNIQYBTSA-N, SHGAZHPCJJPHSC-YCNIQYBTSA-N	Launched
triacetin					CC(=O)OCC(COC(C)=O)OC(C)=O, CC(=O)OCC(COC(C)=O)OC(C)=O	URAYPUMNDPQOKB-UHFFFAOYSA-N, URAYPUMNDPQOKB-UHFFFAOYSA-N	Launched
triamcinolone	glucocorticoid receptor agonist	NR3C1	dermatology	corticosteroid-responsive dermatoses	C[C@]12C[C@H](O)[C@@]3(F)[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1C[C@@H](O)[C@]2(O)C(=O)CO |c:14,t:10|, C[C@]12C[C@H](O)[C@@]3(F)[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1C[C@@H](O)[C@]2(O)C(=O)CO |c:14,t:10|, C[C@]12C[C@H](O)[C@@]3(F)[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1C[C@@H](O)[C@]2(O)C(=O)CO |c:14,t:10|, C[C@]12C[C@H](O)[C@@]3(F)[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1C[C@@H](O)[C@]2(O)C(=O)CO |c:14,t:10|, C[C@]12C[C@H](O)[C@@]3(F)[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1C[C@@H](O)[C@]2(O)C(=O)CO |c:14,t:10|, C[C@]12C[C@H](O)[C@@]3(F)[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1C[C@@H](O)[C@]2(O)C(=O)CO |c:14,t:10|, C[C@]12C[C@H](O)[C@@]3(F)[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1C[C@@H](O)[C@]2(O)C(=O)CO |c:14,t:10|, C[C@]12C[C@H](O)[C@@]3(F)[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1C[C@@H](O)[C@]2(O)C(=O)CO |c:14,t:10|, C[C@]12C[C@H](O)[C@@]3(F)[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1C[C@@H](O)[C@]2(O)C(=O)CO |c:14,t:10|, C[C@]12C[C@H](O)[C@@]3(F)[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1C[C@@H](O)[C@]2(O)C(=O)CO |c:14,t:10|, C[C@]12C[C@H](O)[C@@]3(F)[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1C[C@@H](O)[C@]2(O)C(=O)CO |c:14,t:10|	GFNANZIMVAIWHM-OBYCQNJPSA-N, GFNANZIMVAIWHM-OBYCQNJPSA-N, GFNANZIMVAIWHM-OBYCQNJPSA-N, GFNANZIMVAIWHM-OBYCQNJPSA-N, GFNANZIMVAIWHM-OBYCQNJPSA-N, GFNANZIMVAIWHM-OBYCQNJPSA-N, GFNANZIMVAIWHM-OBYCQNJPSA-N, GFNANZIMVAIWHM-OBYCQNJPSA-N, GFNANZIMVAIWHM-OBYCQNJPSA-N, GFNANZIMVAIWHM-OBYCQNJPSA-N, GFNANZIMVAIWHM-OBYCQNJPSA-N	Launched
triamcinolone-acetonide	glucocorticoid receptor agonist, immunosuppressant	NR3C1, SERPINA6	dermatology	corticosteroid-responsive dermatoses	CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO |c:14,t:10|	YNDXUCZADRHECN-JNQJZLCISA-N	Launched
triamcinolone-hexacetonide	anti-inflammatory agent				[H][C@@]12C[C@@]3([H])[C@]4([H])CCC5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@@]1(OC(C)(C)O2)C(=O)COC(=O)CC(C)(C)C |c:13,t:9|	TZIZWYVVGLXXFV-FLRHRWPCSA-N	Launched
triamterene	sodium channel blocker	SCNN1A, SCNN1B, SCNN1D, SCNN1G	endocrinology, cardiology	hypokalemia, hypertension, edema	Nc1nc(N)c2nc(c(N)nc2n1)-c1ccccc1, Nc1nc(N)c2nc(c(N)nc2n1)-c1ccccc1, Nc1nc(N)c2nc(c(N)nc2n1)-c1ccccc1, Nc1nc(N)c2nc(c(N)nc2n1)-c1ccccc1, Nc1nc(N)c2nc(c(N)nc2n1)-c1ccccc1, Nc1nc(N)c2nc(c(N)nc2n1)-c1ccccc1, Nc1nc(N)c2nc(c(N)nc2n1)-c1ccccc1	FNYLWPVRPXGIIP-UHFFFAOYSA-N, FNYLWPVRPXGIIP-UHFFFAOYSA-N, FNYLWPVRPXGIIP-UHFFFAOYSA-N, FNYLWPVRPXGIIP-UHFFFAOYSA-N, FNYLWPVRPXGIIP-UHFFFAOYSA-N, FNYLWPVRPXGIIP-UHFFFAOYSA-N, FNYLWPVRPXGIIP-UHFFFAOYSA-N	Launched
triapine	ribonucleotide reductase inhibitor	RRM1, RRM2			NC(=S)N\N=C\c1ncccc1N, NC(=S)N\N=C\c1ncccc1N, NC(=S)N\N=C\c1ncccc1N	XMYKNCNAZKMVQN-NYYWCZLTSA-N, XMYKNCNAZKMVQN-NYYWCZLTSA-N, XMYKNCNAZKMVQN-NYYWCZLTSA-N	Phase 2
tribenoside	anti-inflammatory agent, capillary stabilizing agent				CCO[C@H]1O[C@H]([C@@H](COCc2ccccc2)OCc2ccccc2)[C@H](OCc2ccccc2)[C@H]1O |a:5,6,24,33,&1:3|, CCO[C@H]1O[C@H]([C@@H](COCc2ccccc2)OCc2ccccc2)[C@H](OCc2ccccc2)[C@H]1O |a:5,6,24,33,&1:3|	ULLNJSBQMBKOJH-JPHCZMGXSA-N, ULLNJSBQMBKOJH-JPHCZMGXSA-N	Launched
tribomsalan					Oc1c(Br)cc(Br)cc1C(=O)Nc1ccc(Br)cc1, Oc1c(Br)cc(Br)cc1C(=O)Nc1ccc(Br)cc1, Oc1c(Br)cc(Br)cc1C(=O)Nc1ccc(Br)cc1, Oc1c(Br)cc(Br)cc1C(=O)Nc1ccc(Br)cc1	KVSKGMLNBAPGKH-UHFFFAOYSA-N, KVSKGMLNBAPGKH-UHFFFAOYSA-N, KVSKGMLNBAPGKH-UHFFFAOYSA-N, KVSKGMLNBAPGKH-UHFFFAOYSA-N	Preclinical
tribromoethanol	analgesic agent				OCC(Br)(Br)Br, OCC(Br)(Br)Br	YFDSDPIBEUFTMI-UHFFFAOYSA-N, YFDSDPIBEUFTMI-UHFFFAOYSA-N	Preclinical
tributyrin	HDAC inhibitor				CCCC(=O)OCC(COC(=O)CCC)OC(=O)CCC, CCCC(=O)OCC(COC(=O)CCC)OC(=O)CCC	UYXTWWCETRIEDR-UHFFFAOYSA-N, UYXTWWCETRIEDR-UHFFFAOYSA-N	Phase 1
tricaprylin			dermatology	cosmetic	CCCCCCCC(=O)OCC(COC(=O)CCCCCCC)OC(=O)CCCCCCC, CCCCCCCC(=O)OCC(COC(=O)CCCCCCC)OC(=O)CCCCCCC	VLPFTAMPNXLGLX-UHFFFAOYSA-N, VLPFTAMPNXLGLX-UHFFFAOYSA-N	Launched
trichlormethiazide	chloride channel blocker	PTGS1, PTGS2, SLC12A1	cardiology	hypertension, edema	NS(=O)(=O)c1cc2c(N[C@@H](NS2(=O)=O)C(Cl)Cl)cc1Cl |&1:9,r|, NS(=O)(=O)c1cc2c(N[C@@H](NS2(=O)=O)C(Cl)Cl)cc1Cl |&1:9,r|, NS(=O)(=O)c1cc2c(N[C@@H](NS2(=O)=O)C(Cl)Cl)cc1Cl |&1:9,r|, NS(=O)(=O)c1cc2c(N[C@@H](NS2(=O)=O)C(Cl)Cl)cc1Cl |&1:9,r|, NS(=O)(=O)c1cc2c(N[C@@H](NS2(=O)=O)C(Cl)Cl)cc1Cl |&1:9,r|	LMJSLTNSBFUCMU-QMMMGPOBSA-N, LMJSLTNSBFUCMU-QMMMGPOBSA-N, LMJSLTNSBFUCMU-QMMMGPOBSA-N, LMJSLTNSBFUCMU-QMMMGPOBSA-N, LMJSLTNSBFUCMU-QMMMGPOBSA-N	Launched
trichloroacetic-acid			dermatology	warts	OC(=O)C(Cl)(Cl)Cl, OC(=O)C(Cl)(Cl)Cl, OC(=O)C(Cl)(Cl)Cl	YNJBWRMUSHSURL-UHFFFAOYSA-N, YNJBWRMUSHSURL-UHFFFAOYSA-N, YNJBWRMUSHSURL-UHFFFAOYSA-N	Launched
trichloroethylene					ClC=C(Cl)Cl, ClC=C(Cl)Cl	XSTXAVWGXDQKEL-UHFFFAOYSA-N, XSTXAVWGXDQKEL-UHFFFAOYSA-N	Preclinical
trichostatin-a	HDAC inhibitor	HDAC1, HDAC10, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9			C[C@H](\C=C(/C)\C=C\C(=O)NO)C(=O)c1ccc(cc1)N(C)C, C[C@H](\C=C(/C)\C=C\C(=O)NO)C(=O)c1ccc(cc1)N(C)C, C[C@H](\C=C(/C)\C=C\C(=O)NO)C(=O)c1ccc(cc1)N(C)C, C[C@H](\C=C(/C)\C=C\C(=O)NO)C(=O)c1ccc(cc1)N(C)C, C[C@H](\C=C(/C)\C=C\C(=O)NO)C(=O)c1ccc(cc1)N(C)C, C[C@H](\C=C(/C)\C=C\C(=O)NO)C(=O)c1ccc(cc1)N(C)C	RTKIYFITIVXBLE-QEQCGCAPSA-N, RTKIYFITIVXBLE-QEQCGCAPSA-N, RTKIYFITIVXBLE-QEQCGCAPSA-N, RTKIYFITIVXBLE-QEQCGCAPSA-N, RTKIYFITIVXBLE-QEQCGCAPSA-N, RTKIYFITIVXBLE-QEQCGCAPSA-N	Phase 1
triciribine	AKT inhibitor	AKT1, AKT2, AKT3			Cn1nc(N)c2cn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c3ncnc1c23, Cn1nc(N)c2cn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c3ncnc1c23, Cn1nc(N)c2cn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c3ncnc1c23, Cn1nc(N)c2cn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c3ncnc1c23, Cn1nc(N)c2cn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c3ncnc1c23, Cn1nc(N)c2cn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c3ncnc1c23, Cn1nc(N)c2cn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c3ncnc1c23, Cn1nc(N)c2cn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c3ncnc1c23, Cn1nc(N)c2cn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c3ncnc1c23	HOGVTUZUJGHKPL-HTVVRFAVSA-N, HOGVTUZUJGHKPL-HTVVRFAVSA-N, HOGVTUZUJGHKPL-HTVVRFAVSA-N, HOGVTUZUJGHKPL-HTVVRFAVSA-N, HOGVTUZUJGHKPL-HTVVRFAVSA-N, HOGVTUZUJGHKPL-HTVVRFAVSA-N, HOGVTUZUJGHKPL-HTVVRFAVSA-N, HOGVTUZUJGHKPL-HTVVRFAVSA-N, HOGVTUZUJGHKPL-HTVVRFAVSA-N	Phase 1/Phase 2
triciribine-phosphate	AKT inhibitor				Cn1nc(N)c2cn([C@@H]3O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]3O)c3ncnc1c23	URLYINUFLXOMHP-HTVVRFAVSA-N	Phase 1/Phase 2
triclabendazole	microtubule inhibitor	DNMT1	infectious disease	tapeworm	CSc1nc2cc(Cl)c(Oc3cccc(Cl)c3Cl)cc2[nH]1, CSc1nc2cc(Cl)c(Oc3cccc(Cl)c3Cl)cc2[nH]1, CSc1nc2cc(Cl)c(Oc3cccc(Cl)c3Cl)cc2[nH]1, CSc1nc2cc(Cl)c(Oc3cccc(Cl)c3Cl)cc2[nH]1, CSc1nc2cc(Cl)c(Oc3cccc(Cl)c3Cl)cc2[nH]1, CSc1nc2cc(Cl)c(Oc3cccc(Cl)c3Cl)cc2[nH]1, CSc1nc2cc(Cl)c(Oc3cccc(Cl)c3Cl)cc2[nH]1, CSc1nc2cc(Cl)c(Oc3cccc(Cl)c3Cl)cc2[nH]1, CSc1nc2cc(Cl)c(Oc3cccc(Cl)c3Cl)cc2[nH]1	NQPDXQQQCQDHHW-UHFFFAOYSA-N, NQPDXQQQCQDHHW-UHFFFAOYSA-N, NQPDXQQQCQDHHW-UHFFFAOYSA-N, NQPDXQQQCQDHHW-UHFFFAOYSA-N, NQPDXQQQCQDHHW-UHFFFAOYSA-N, NQPDXQQQCQDHHW-UHFFFAOYSA-N, NQPDXQQQCQDHHW-UHFFFAOYSA-N, NQPDXQQQCQDHHW-UHFFFAOYSA-N, NQPDXQQQCQDHHW-UHFFFAOYSA-N	Launched
triclocarban	other antibiotic		infectious disease	first-aid antiseptic	Clc1ccc(NC(=O)Nc2ccc(Cl)c(Cl)c2)cc1, Clc1ccc(NC(=O)Nc2ccc(Cl)c(Cl)c2)cc1, Clc1ccc(NC(=O)Nc2ccc(Cl)c(Cl)c2)cc1, Clc1ccc(NC(=O)Nc2ccc(Cl)c(Cl)c2)cc1, Clc1ccc(NC(=O)Nc2ccc(Cl)c(Cl)c2)cc1, Clc1ccc(NC(=O)Nc2ccc(Cl)c(Cl)c2)cc1	ICUTUKXCWQYESQ-UHFFFAOYSA-N, ICUTUKXCWQYESQ-UHFFFAOYSA-N, ICUTUKXCWQYESQ-UHFFFAOYSA-N, ICUTUKXCWQYESQ-UHFFFAOYSA-N, ICUTUKXCWQYESQ-UHFFFAOYSA-N, ICUTUKXCWQYESQ-UHFFFAOYSA-N	Launched
triclosan	antibacterial agent	DNMT1	infectious disease	first-aid antiseptic	Oc1cc(Cl)ccc1Oc1ccc(Cl)cc1Cl, Oc1cc(Cl)ccc1Oc1ccc(Cl)cc1Cl, Oc1cc(Cl)ccc1Oc1ccc(Cl)cc1Cl, Oc1cc(Cl)ccc1Oc1ccc(Cl)cc1Cl	XEFQLINVKFYRCS-UHFFFAOYSA-N, XEFQLINVKFYRCS-UHFFFAOYSA-N, XEFQLINVKFYRCS-UHFFFAOYSA-N, XEFQLINVKFYRCS-UHFFFAOYSA-N	Launched
tridihexethyl	acetylcholine receptor antagonist		gastroenterology, ophthalmology	peptic ulcer disease (PUD), nystagmus	CC[N+](CC)(CC)CC[C@@](O)(C1CCCCC1)c1ccccc1 |&1:9|	NPRHVSBSZMAEIN-NRFANRHFSA-N	Launched
trientine	chelating agent	CA14	metabolism	Wilson's disease	NCCNCCNCCN, NCCNCCNCCN	VILCJCGEZXAXTO-UHFFFAOYSA-N, VILCJCGEZXAXTO-UHFFFAOYSA-N	Launched
trifloxystrobin	mitochondrial electron transport inhibitor				CO\N=C(\C(=O)OC)c1ccccc1CO\N=C(/C)c1cccc(c1)C(F)(F)F	ONCZDRURRATYFI-TVJDWZFNSA-N	Preclinical
trifluoperazine	dopamine receptor antagonist	ADRA1A, CALM1, CALY, DRD2, DRD4, HRH1, HTR2A, HTR2C, S100A4, TNNC1	neurology/psychiatry	schizophrenia	CN1CCN(CCCN2c3ccccc3Sc3ccc(cc23)C(F)(F)F)CC1, CN1CCN(CCCN2c3ccccc3Sc3ccc(cc23)C(F)(F)F)CC1, CN1CCN(CCCN2c3ccccc3Sc3ccc(cc23)C(F)(F)F)CC1, CN1CCN(CCCN2c3ccccc3Sc3ccc(cc23)C(F)(F)F)CC1, CN1CCN(CCCN2c3ccccc3Sc3ccc(cc23)C(F)(F)F)CC1, CN1CCN(CCCN2c3ccccc3Sc3ccc(cc23)C(F)(F)F)CC1, CN1CCN(CCCN2c3ccccc3Sc3ccc(cc23)C(F)(F)F)CC1	ZEWQUBUPAILYHI-UHFFFAOYSA-N, ZEWQUBUPAILYHI-UHFFFAOYSA-N, ZEWQUBUPAILYHI-UHFFFAOYSA-N, ZEWQUBUPAILYHI-UHFFFAOYSA-N, ZEWQUBUPAILYHI-UHFFFAOYSA-N, ZEWQUBUPAILYHI-UHFFFAOYSA-N, ZEWQUBUPAILYHI-UHFFFAOYSA-N	Launched
triflupromazine	dopamine receptor antagonist	CHRM1, CHRM2, DRD1, DRD2, HTR2B	neurology/psychiatry, gastroenterology	psychosis, nausea, vomiting	CN(C)CCCN1c2ccccc2Sc2ccc(cc12)C(F)(F)F, CN(C)CCCN1c2ccccc2Sc2ccc(cc12)C(F)(F)F, CN(C)CCCN1c2ccccc2Sc2ccc(cc12)C(F)(F)F, CN(C)CCCN1c2ccccc2Sc2ccc(cc12)C(F)(F)F, CN(C)CCCN1c2ccccc2Sc2ccc(cc12)C(F)(F)F, CN(C)CCCN1c2ccccc2Sc2ccc(cc12)C(F)(F)F, CN(C)CCCN1c2ccccc2Sc2ccc(cc12)C(F)(F)F	XSCGXQMFQXDFCW-UHFFFAOYSA-N, XSCGXQMFQXDFCW-UHFFFAOYSA-N, XSCGXQMFQXDFCW-UHFFFAOYSA-N, XSCGXQMFQXDFCW-UHFFFAOYSA-N, XSCGXQMFQXDFCW-UHFFFAOYSA-N, XSCGXQMFQXDFCW-UHFFFAOYSA-N, XSCGXQMFQXDFCW-UHFFFAOYSA-N	Launched
trifluridine	DNA directed DNA polymerase inhibitor, thymidylate synthase inhibitor	TYMS	infectious disease	virus herpes simplex (HSV)	OC[C@H]1O[C@H](C[C@@H]1O)n1cc(c(=O)[nH]c1=O)C(F)(F)F, OC[C@H]1O[C@H](C[C@@H]1O)n1cc(c(=O)[nH]c1=O)C(F)(F)F, OC[C@H]1O[C@H](C[C@@H]1O)n1cc(c(=O)[nH]c1=O)C(F)(F)F, OC[C@H]1O[C@H](C[C@@H]1O)n1cc(c(=O)[nH]c1=O)C(F)(F)F, OC[C@H]1O[C@H](C[C@@H]1O)n1cc(c(=O)[nH]c1=O)C(F)(F)F, OC[C@H]1O[C@H](C[C@@H]1O)n1cc(c(=O)[nH]c1=O)C(F)(F)F, OC[C@H]1O[C@H](C[C@@H]1O)n1cc(c(=O)[nH]c1=O)C(F)(F)F, OC[C@H]1O[C@H](C[C@@H]1O)n1cc(c(=O)[nH]c1=O)C(F)(F)F, OC[C@H]1O[C@H](C[C@@H]1O)n1cc(c(=O)[nH]c1=O)C(F)(F)F	VSQQQLOSPVPRAZ-RRKCRQDMSA-N, VSQQQLOSPVPRAZ-RRKCRQDMSA-N, VSQQQLOSPVPRAZ-RRKCRQDMSA-N, VSQQQLOSPVPRAZ-RRKCRQDMSA-N, VSQQQLOSPVPRAZ-RRKCRQDMSA-N, VSQQQLOSPVPRAZ-RRKCRQDMSA-N, VSQQQLOSPVPRAZ-RRKCRQDMSA-N, VSQQQLOSPVPRAZ-RRKCRQDMSA-N, VSQQQLOSPVPRAZ-RRKCRQDMSA-N	Launched
triflusal	cyclooxygenase inhibitor, platelet aggregation inhibitor, thromboxane synthase inhibitor	NFKB1, NOS2, PDE10A, PTGS1	neurology/psychiatry, cardiology	stroke, myocardial infarction, atrial fibrillation (AF)	CC(=O)Oc1cc(ccc1C(O)=O)C(F)(F)F, CC(=O)Oc1cc(ccc1C(O)=O)C(F)(F)F, CC(=O)Oc1cc(ccc1C(O)=O)C(F)(F)F, CC(=O)Oc1cc(ccc1C(O)=O)C(F)(F)F, CC(=O)Oc1cc(ccc1C(O)=O)C(F)(F)F, CC(=O)Oc1cc(ccc1C(O)=O)C(F)(F)F, CC(=O)Oc1cc(ccc1C(O)=O)C(F)(F)F	RMWVZGDJPAKBDE-UHFFFAOYSA-N, RMWVZGDJPAKBDE-UHFFFAOYSA-N, RMWVZGDJPAKBDE-UHFFFAOYSA-N, RMWVZGDJPAKBDE-UHFFFAOYSA-N, RMWVZGDJPAKBDE-UHFFFAOYSA-N, RMWVZGDJPAKBDE-UHFFFAOYSA-N, RMWVZGDJPAKBDE-UHFFFAOYSA-N	Launched
trigonelline					C[n+]1cccc(c1)C(O)=O, C[n+]1cccc(c1)C(O)=O	WWNNZCOKKKDOPX-UHFFFAOYSA-O, WWNNZCOKKKDOPX-UHFFFAOYSA-O	Phase 1
trihexyphenidyl	acetylcholine receptor antagonist	CHRM1	neurology/psychiatry	parkinsonism	O[C@@](CCN1CCCCC1)(C1CCCCC1)c1ccccc1 |&1:1|	HWHLPVGTWGOCJO-HXUWFJFHSA-N	Launched
trilaciclib	CDK inhibitor				CN1CCN(CC1)c1ccc(Nc2ncc3cc4C(=O)NCC5(CCCCC5)n4c3n2)nc1	PDGKHKMBHVFCMG-UHFFFAOYSA-N	Phase 2
trilostane	3beta-hydroxy-delta5-steroid dehydrogenase inhibitor		endocrinology	Cushing's syndrome	C[C@]12CC[C@H]3[C@@H](CC[C@@]45O[C@@H]4C(=O)[C@@H](C[C@]35C)C#N)[C@@H]1CC[C@@H]2O |a:1,4,5,8,10,15,19,22,&1:13|, C[C@]12CC[C@H]3[C@@H](CC[C@@]45O[C@@H]4C(=O)[C@@H](C[C@]35C)C#N)[C@@H]1CC[C@@H]2O |a:1,4,5,8,10,15,19,22,&1:13|, C[C@]12CC[C@H]3[C@@H](CC[C@@]45O[C@@H]4C(=O)[C@@H](C[C@]35C)C#N)[C@@H]1CC[C@@H]2O |a:1,4,5,8,10,15,19,22,&1:13|	RLQVKDVIBJCQGE-PORJLZOZSA-N, RLQVKDVIBJCQGE-PORJLZOZSA-N, RLQVKDVIBJCQGE-PORJLZOZSA-N	Launched
TRIM					FC(F)(F)c1ccccc1-n1ccnc1	WZBWBNCQUTXYEL-UHFFFAOYSA-N	Preclinical
trimebutine	opioid receptor agonist	OPRD1, OPRK1, OPRM1	gastroenterology	irritable bowel syndrome	CC[C@](COC(=O)c1cc(OC)c(OC)c(OC)c1)(N(C)C)c1ccccc1 |&1:2|	LORDFXWUHHSAQU-JOCHJYFZSA-N	Launched
trimetazidine	3-ketoacyl CoA thiolase inhibitor	ACAA2	cardiology	angina pectoris	COc1ccc(CN2CCNCC2)c(OC)c1OC, COc1ccc(CN2CCNCC2)c(OC)c1OC, COc1ccc(CN2CCNCC2)c(OC)c1OC	UHWVSEOVJBQKBE-UHFFFAOYSA-N, UHWVSEOVJBQKBE-UHFFFAOYSA-N, UHWVSEOVJBQKBE-UHFFFAOYSA-N	Launched
trimethadione	oxazolidine antiepileptic	CACNA1G, CACNA1H, CACNA1I	neurology/psychiatry	seizures	CN1C(=O)OC(C)(C)C1=O, CN1C(=O)OC(C)(C)C1=O, CN1C(=O)OC(C)(C)C1=O, CN1C(=O)OC(C)(C)C1=O	IRYJRGCIQBGHIV-UHFFFAOYSA-N, IRYJRGCIQBGHIV-UHFFFAOYSA-N, IRYJRGCIQBGHIV-UHFFFAOYSA-N, IRYJRGCIQBGHIV-UHFFFAOYSA-N	Launched
trimethobenzamide	histamine receptor antagonist	DRD2	gastroenterology	vomiting, nausea, gastroenteritis	COc1cc(cc(OC)c1OC)C(=O)NCc1ccc(OCCN(C)C)cc1, COc1cc(cc(OC)c1OC)C(=O)NCc1ccc(OCCN(C)C)cc1, COc1cc(cc(OC)c1OC)C(=O)NCc1ccc(OCCN(C)C)cc1, COc1cc(cc(OC)c1OC)C(=O)NCc1ccc(OCCN(C)C)cc1	FEZBIKUBAYAZIU-UHFFFAOYSA-N, FEZBIKUBAYAZIU-UHFFFAOYSA-N, FEZBIKUBAYAZIU-UHFFFAOYSA-N, FEZBIKUBAYAZIU-UHFFFAOYSA-N	Launched
trimethoprim	dihydrofolate reductase inhibitor	DHFR, TYMS	infectious disease, gastroenterology	urinary tract infections, ear infections, diarrhea	COc1cc(Cc2cnc(N)nc2N)cc(OC)c1OC, COc1cc(Cc2cnc(N)nc2N)cc(OC)c1OC	IEDVJHCEMCRBQM-UHFFFAOYSA-N, IEDVJHCEMCRBQM-UHFFFAOYSA-N	Launched
trimethoquinol	adrenergic receptor antagonist	ADRB2, ADRB3	pulmonary	asthma	COc1cc(C[C@H]2NCCc3cc(O)c(O)cc23)cc(OC)c1OC |&1:6|	RGVPOXRFEPSFGH-CQSZACIVSA-N	Launched
trimethylolpropane-triacrylate					CCC(COC(=O)C=C)(COC(=O)C=C)COC(=O)C=C	DAKWPKUUDNSNPN-UHFFFAOYSA-N	Preclinical
trimetozine	sedative		neurology/psychiatry	sedative	COc1cc(cc(OC)c1OC)C(=O)N1CCOCC1, COc1cc(cc(OC)c1OC)C(=O)N1CCOCC1	XWVOEFLBOSSYGM-UHFFFAOYSA-N, XWVOEFLBOSSYGM-UHFFFAOYSA-N	Launched
trimetrexate	dihydrofolate reductase inhibitor	DHFR			COc1cc(NCc2ccc3nc(N)nc(N)c3c2C)cc(OC)c1OC	NOYPYLRCIDNJJB-UHFFFAOYSA-N	Phase 3
trimipramine	norepinephrine reputake inhibitor, tricyclic antidepressant	SLC6A2, SLC6A3, SLC6A4	neurology/psychiatry	depression	C[C@@H](CN(C)C)CN1c2ccccc2CCc2ccccc12 |&1:1|	ZSCDBOWYZJWBIY-INIZCTEOSA-N	Launched
trioxsalen	DNA synthesis inhibitor		dermatology	vitiligo, eczema	Cc1cc2cc3c(C)cc(=O)oc3c(C)c2o1, Cc1cc2cc3c(C)cc(=O)oc3c(C)c2o1	FMHHVULEAZTJMA-UHFFFAOYSA-N, FMHHVULEAZTJMA-UHFFFAOYSA-N	Launched
tripelennamine	histamine receptor antagonist	HRH1	pulmonary, allergy	asthma, allergic rhinitis, urticaria	CN(C)CCN(Cc1ccccc1)c1ccccn1, CN(C)CCN(Cc1ccccc1)c1ccccn1, CN(C)CCN(Cc1ccccc1)c1ccccn1	UFLGIAIHIAPJJC-UHFFFAOYSA-N, UFLGIAIHIAPJJC-UHFFFAOYSA-N, UFLGIAIHIAPJJC-UHFFFAOYSA-N	Launched
triprolidine	histamine receptor antagonist	HRH1	allergy	allergic rhinitis	Cc1ccc(cc1)C(=C/CN1CCCC1)\c1ccccn1, Cc1ccc(cc1)C(=C/CN1CCCC1)\c1ccccn1	CBEQULMOCCWAQT-WOJGMQOQSA-N, CBEQULMOCCWAQT-WOJGMQOQSA-N	Launched
triptan	serotonin receptor agonist	HTR1B, HTR1D			CC(C)C(C)(C)C	ZISSAWUMDACLOM-UHFFFAOYSA-N	Phase 1
triptolide	RNA polymerase inhibitor	RELA			CC(C)[C@]12O[C@H]1[C@@H]1O[C@]11[C@]3(O[C@H]3C[C@H]3C4=C(CC[C@]13C)C(=O)OC4)[C@@H]2O |c:17|, CC(C)[C@]12O[C@H]1[C@@H]1O[C@]11[C@]3(O[C@H]3C[C@H]3C4=C(CC[C@]13C)C(=O)OC4)[C@@H]2O |c:17|, CC(C)[C@]12O[C@H]1[C@@H]1O[C@]11[C@]3(O[C@H]3C[C@H]3C4=C(CC[C@]13C)C(=O)OC4)[C@@H]2O |c:17|, CC(C)[C@]12O[C@H]1[C@@H]1O[C@]11[C@]3(O[C@H]3C[C@H]3C4=C(CC[C@]13C)C(=O)OC4)[C@@H]2O |c:17|, CC(C)[C@]12O[C@H]1[C@@H]1O[C@]11[C@]3(O[C@H]3C[C@H]3C4=C(CC[C@]13C)C(=O)OC4)[C@@H]2O |c:17|, CC(C)[C@]12O[C@H]1[C@@H]1O[C@]11[C@]3(O[C@H]3C[C@H]3C4=C(CC[C@]13C)C(=O)OC4)[C@@H]2O |c:17|, CC(C)[C@]12O[C@H]1[C@@H]1O[C@]11[C@]3(O[C@H]3C[C@H]3C4=C(CC[C@]13C)C(=O)OC4)[C@@H]2O |c:17|	DFBIRQPKNDILPW-CIVMWXNOSA-N, DFBIRQPKNDILPW-CIVMWXNOSA-N, DFBIRQPKNDILPW-CIVMWXNOSA-N, DFBIRQPKNDILPW-CIVMWXNOSA-N, DFBIRQPKNDILPW-CIVMWXNOSA-N, InChI=1S/C20H24O6/c1-8(2)18-13(25-18)14-20(26-14)17(3)5-4-9-10(7-23-15(9)21)11(17)6-12-19(20,24-12)16(18)22/h8,11-14,16,22H,4-7H2,1-3H3/t11-,12-,13-,14-,16+,17-,18-,19+,20+/m0/s1, InChI=1S/C20H24O6/c1-8(2)18-13(25-18)14-20(26-14)17(3)5-4-9-10(7-23-15(9)21)11(17)6-12-19(20,24-12)16(18)22/h8,11-14,16,22H,4-7H2,1-3H3/t11-,12-,13-,14-,16+,17-,18-,19+,20+/m0/s1	Phase 3
triptorelin	gonadotropin releasing factor hormone receptor agonist	GNRHR	oncology, endocrinology, obstetrics/gynecology	prostate cancer, breast cancer, precocious puberty, endometriosis, myoma, gender dysphoria	CC(C)C[C@H](NC(=O)[C@@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)NCC(N)=O, CC(C)C[C@H](NC(=O)[C@@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)NCC(N)=O	VXKHXGOKWPXYNA-PGBVPBMZSA-N, VXKHXGOKWPXYNA-PGBVPBMZSA-N	Launched
troclosene					Cln1c(=O)[nH]c(=O)n(Cl)c1=O, Cln1c(=O)[nH]c(=O)n(Cl)c1=O	CEJLBZWIKQJOAT-UHFFFAOYSA-N, CEJLBZWIKQJOAT-UHFFFAOYSA-N	Launched
trodusquemine	tyrosine phosphatase inhibitor				[H][C@@]1(CC[C@@]2([H])[C@]3([H])[C@H](O)C[C@@]4([H])C[C@H](CC[C@]4(C)[C@@]3([H])CC[C@]12C)NCCCNCCCCNCCCN)[C@H](C)CC[C@@H](OS(O)(=O)=O)C(C)C	WUJVPODXELZABP-FWJXURDUSA-N	Phase 1
trofinetide	cytokine production inhibitor	IFNG, IL6, TNF			NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(O)=O	JJGBXTYGTKWGAT-YUMQZZPRSA-N	Phase 2
trofosfamide	DNA alkylating agent		oncology	medulloblastoma	ClCCN(CCCl)[P@@]1(=O)OCCCN1CCCl |&1:7,r|	UMKFEPPTGMDVMI-KRWDZBQOSA-N	Launched
troglitazone	insulin sensitizer, PPAR receptor agonist	CYP2C8, PPARG, TRPM3			Cc1c(C)c2O[C@@](C)(COc3ccc(C[C@H]4SC(=O)NC4=O)cc3)CCc2c(C)c1O |&1:6,r|, Cc1c(C)c2O[C@@](C)(COc3ccc(C[C@H]4SC(=O)NC4=O)cc3)CCc2c(C)c1O |&1:6,r|, Cc1c(C)c2O[C@@](C)(COc3ccc(C[C@H]4SC(=O)NC4=O)cc3)CCc2c(C)c1O |&1:6,r|	GXPHKUHSUJUWKP-NTKDMRAZSA-N, GXPHKUHSUJUWKP-NTKDMRAZSA-N, GXPHKUHSUJUWKP-NTKDMRAZSA-N	Withdrawn
troleandomycin	protein synthesis inhibitor		infectious disease, pulmonary, otolaryngology	pneumonia, bronchitis, tonsillitis, sinusitis	CO[C@H]1C[C@H](O[C@H]2[C@H](C)[C@@H](O[C@@H]3O[C@H](C)C[C@@H]([C@H]3OC(C)=O)N(C)C)[C@@H](C)C[C@@]3(CO3)C(=O)[C@H](C)[C@@H](OC(C)=O)[C@@H](C)[C@@H](C)OC(=O)[C@@H]2C)O[C@@H](C)[C@@H]1OC(C)=O	LQCLVBQBTUVCEQ-FBZTUZAPSA-N	Launched
trolox	antioxidant				Cc1c(C)c2O[C@@](C)(CCc2c(C)c1O)C(O)=O |&1:6,r|, Cc1c(C)c2O[C@@](C)(CCc2c(C)c1O)C(O)=O |&1:6,r|, Cc1c(C)c2O[C@@](C)(CCc2c(C)c1O)C(O)=O |&1:6,r|	GLEVLJDDWXEYCO-AWEZNQCLSA-N, GLEVLJDDWXEYCO-AWEZNQCLSA-N, GLEVLJDDWXEYCO-AWEZNQCLSA-N	Launched
tromaril	prostanoid receptor antagonist		ophthalmology	eye inflammation	OC(=O)c1ccccc1NCCc1ccccc1, OC(=O)c1ccccc1NCCc1ccccc1, OC(=O)c1ccccc1NCCc1ccccc1, OC(=O)c1ccccc1NCCc1ccccc1	HLNLBEFKHHCAMV-UHFFFAOYSA-N, HLNLBEFKHHCAMV-UHFFFAOYSA-N, HLNLBEFKHHCAMV-UHFFFAOYSA-N, HLNLBEFKHHCAMV-UHFFFAOYSA-N	Launched
trometamol		AMD1, CANT1, DCN, NEIL1, VEGFA			NC(CO)(CO)CO, NC(CO)(CO)CO, NC(CO)(CO)CO, NC(CO)(CO)CO	LENZDBCJOHFCAS-UHFFFAOYSA-N, LENZDBCJOHFCAS-UHFFFAOYSA-N, LENZDBCJOHFCAS-UHFFFAOYSA-N, LENZDBCJOHFCAS-UHFFFAOYSA-N	Launched
tropanyl-3,5-dimethylbenzoate	serotonin receptor antagonist	HTR3A, HTR3B			CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)c1cc(C)cc(C)c1 |&1:2,&2:5,&3:7,r,TLB:0:1:3.4:6.7.8|	HDDNYFLPWFSBLN-ZSHCYNCHSA-N	Preclinical
tropesin	cyclooxygenase inhibitor	PTGS1, PTGS2			COc1ccc2n(C(=O)c3ccc(Cl)cc3)c(C)c(CC(=O)OC[C@@H](C(O)=O)c3ccccc3)c2c1 |&1:24,r|	UCCJWNPWWPJKGL-XMMPIXPASA-N	Launched
tropicamide	acetylcholine receptor antagonist	CHRM3, CHRM4	ophthalmology	mydriasis diagnostic, cycloplegia diagnostic	CCN(Cc1ccncc1)C(=O)[C@@H](CO)c1ccccc1 |&1:12,r|, CCN(Cc1ccncc1)C(=O)[C@@H](CO)c1ccccc1 |&1:12,r|, CCN(Cc1ccncc1)C(=O)[C@@H](CO)c1ccccc1 |&1:12,r|, CCN(Cc1ccncc1)C(=O)[C@@H](CO)c1ccccc1 |&1:12,r|, CCN(Cc1ccncc1)C(=O)[C@@H](CO)c1ccccc1 |&1:12,r|, CCN(Cc1ccncc1)C(=O)[C@@H](CO)c1ccccc1 |&1:12,r|	BGDKAVGWHJFAGW-INIZCTEOSA-N, BGDKAVGWHJFAGW-INIZCTEOSA-N, BGDKAVGWHJFAGW-INIZCTEOSA-N, BGDKAVGWHJFAGW-INIZCTEOSA-N, BGDKAVGWHJFAGW-INIZCTEOSA-N, BGDKAVGWHJFAGW-INIZCTEOSA-N	Launched
tropifexor	FXR agonist				OC(=O)c1cc(F)c2nc(sc2c1)N1[C@H]2CC[C@@H]1C[C@@H](C2)OCc1c(onc1-c1ccccc1OC(F)(F)F)C1CC1 |TLB:9:13:16.15:19.20.18|	VYLOOGHLKSNNEK-PIIMJCKOSA-N	Phase 2
tropisetron	serotonin receptor antagonist	GLRA1, GLRA2, GLRB, HTR3A, HTR4	gastroenterology	nausea, vomiting	CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)c1c[nH]c2ccccc12, CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)c1c[nH]c2ccccc12, CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)c1c[nH]c2ccccc12, CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)c1c[nH]c2ccccc12	ZNRGQMMCGHDTEI-ITGUQSILSA-N, ZNRGQMMCGHDTEI-ITGUQSILSA-N, ZNRGQMMCGHDTEI-ITGUQSILSA-N, ZNRGQMMCGHDTEI-ITGUQSILSA-N	Launched
trospium	acetylcholine receptor antagonist	CHRM1	urology	urinary incontinence, urinary frequency	[H][C@]12CC[C@]([H])(C[C@@H](C1)OC(=O)C(O)(c1ccccc1)c1ccccc1)[N+]21CCCC1 |&1:1,4,7|	OYYDSUSKLWTMMQ-JKHIJQBDSA-N	Launched
trovafloxacin	bacterial DNA gyrase inhibitor	TOP2A			N[C@H]1[C@@H]2CN(C[C@H]12)c1nc2n(cc(C(O)=O)c(=O)c2cc1F)-c1ccc(F)cc1F, N[C@H]1[C@@H]2CN(C[C@H]12)c1nc2n(cc(C(O)=O)c(=O)c2cc1F)-c1ccc(F)cc1F, N[C@H]1[C@@H]2CN(C[C@H]12)c1nc2n(cc(C(O)=O)c(=O)c2cc1F)-c1ccc(F)cc1F, N[C@H]1[C@@H]2CN(C[C@H]12)c1nc2n(cc(C(O)=O)c(=O)c2cc1F)-c1ccc(F)cc1F, N[C@H]1[C@@H]2CN(C[C@H]12)c1nc2n(cc(C(O)=O)c(=O)c2cc1F)-c1ccc(F)cc1F	WVPSKSLAZQPAKQ-CDMJZVDBSA-N, WVPSKSLAZQPAKQ-CDMJZVDBSA-N, WVPSKSLAZQPAKQ-CDMJZVDBSA-N, WVPSKSLAZQPAKQ-CDMJZVDBSA-N, WVPSKSLAZQPAKQ-CDMJZVDBSA-N	Withdrawn
troventol					CCC(CO)(C(=O)OC1C[C@@H]2CC[C@H](C1)[N+]2(C)C)c1ccccc1 |&1:2,&2:13,&3:10,TLB:7:8:11.12:15|	QFWSRMACUIYPGS-ZVBHREPYSA-N	Phase 1
trovirdine	non-nucleoside reverse transcriptase inhibitor				Brc1ccc(NC(=S)NCCc2ccccn2)nc1, Brc1ccc(NC(=S)NCCc2ccccn2)nc1, Brc1ccc(NC(=S)NCCc2ccccn2)nc1	HOCFDYZWQYGULA-UHFFFAOYSA-N, HOCFDYZWQYGULA-UHFFFAOYSA-N, HOCFDYZWQYGULA-UHFFFAOYSA-N	Phase 1
troxerutin	antioxidant				C[C@@H]1O[C@@H](OC[C@H]2O[C@@H](Oc3c(oc4cc(OCCO)cc(O)c4c3=O)-c3ccc(OCCO)c(OCCO)c3)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@H](O)[C@H]1O, C[C@@H]1O[C@@H](OC[C@H]2O[C@@H](Oc3c(oc4cc(OCCO)cc(O)c4c3=O)-c3ccc(OCCO)c(OCCO)c3)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@H](O)[C@H]1O, C[C@@H]1O[C@@H](OC[C@H]2O[C@@H](Oc3c(oc4cc(OCCO)cc(O)c4c3=O)-c3ccc(OCCO)c(OCCO)c3)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@H](O)[C@H]1O, C[C@@H]1O[C@@H](OC[C@H]2O[C@@H](Oc3c(oc4cc(OCCO)cc(O)c4c3=O)-c3ccc(OCCO)c(OCCO)c3)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@H](O)[C@H]1O	IYVFNTXFRYQLRP-VVSTWUKXSA-N, IYVFNTXFRYQLRP-VVSTWUKXSA-N, IYVFNTXFRYQLRP-VVSTWUKXSA-N, IYVFNTXFRYQLRP-VVSTWUKXSA-N	Launched
troxipide	glucosamine synthetase stimulant		gastroenterology	gastroesophageal reflux disease (GERD)	COc1cc(cc(OC)c1OC)C(=O)N[C@H]1CCCNC1 |&1:15,r|, COc1cc(cc(OC)c1OC)C(=O)N[C@H]1CCCNC1 |&1:15,r|, COc1cc(cc(OC)c1OC)C(=O)N[C@H]1CCCNC1 |&1:15,r|, COc1cc(cc(OC)c1OC)C(=O)N[C@H]1CCCNC1 |&1:15,r|	YSIITVVESCNIPR-NSHDSACASA-N, YSIITVVESCNIPR-NSHDSACASA-N, YSIITVVESCNIPR-NSHDSACASA-N, YSIITVVESCNIPR-NSHDSACASA-N	Launched
TRV130	opioid receptor agonist	OPRM1			COc1ccsc1CNCC[C@]1(CCOC2(CCCC2)C1)c1ccccn1	DMNOVGJWPASQDL-OAQYLSRUSA-N	Phase 3
tryptanthrin	cyclooxygenase inhibitor	IDO1			O=C1c2ccccc2-n2c1nc1ccccc1c2=O, O=C1c2ccccc2-n2c1nc1ccccc1c2=O	VQQVWGVXDIPORV-UHFFFAOYSA-N, VQQVWGVXDIPORV-UHFFFAOYSA-N	Preclinical
tryptophan	serotonin receptor partial agonist	CASR, IDO1, SLC36A1, WARS, WARS2	neurology/psychiatry, gastroenterology	anxiety, bloating, constipation, fatigue, sleeplessness	N[C@@H](Cc1c[nH]c2ccccc12)C(O)=O, N[C@@H](Cc1c[nH]c2ccccc12)C(O)=O, N[C@@H](Cc1c[nH]c2ccccc12)C(O)=O	QIVBCDIJIAJPQS-VIFPVBQESA-N, QIVBCDIJIAJPQS-VIFPVBQESA-N, QIVBCDIJIAJPQS-VIFPVBQESA-N	Launched
TS-011	delayed vasospasm antagonist				[O-][N+]CNc1ccc(N2CCOCC2)c(Cl)c1	CQMCOBQPZDLWIX-UHFFFAOYSA-N	Preclinical
TTNPB	retinoid receptor agonist	RARA, RARB, RARG			C\C(=C/c1ccc(cc1)C(O)=O)c1ccc2c(c1)C(C)(C)CCC2(C)C, C\C(=C/c1ccc(cc1)C(O)=O)c1ccc2c(c1)C(C)(C)CCC2(C)C, C\C(=C/c1ccc(cc1)C(O)=O)c1ccc2c(c1)C(C)(C)CCC2(C)C	FOIVPCKZDPCJJY-JQIJEIRASA-N, FOIVPCKZDPCJJY-JQIJEIRASA-N, FOIVPCKZDPCJJY-JQIJEIRASA-N	Phase 1
TTP-22	casein kinase inhibitor	CSNK2A1			Cc1ccc(cc1)-c1csc2ncnc(SCCC(O)=O)c12, Cc1ccc(cc1)-c1csc2ncnc(SCCC(O)=O)c12	RAOULLCLLOGTDA-UHFFFAOYSA-N, RAOULLCLLOGTDA-UHFFFAOYSA-N	Preclinical
TU-2100					CCOC(=O)c1ccccc1OC(=O)CCCCCCCC(=O)Oc1ccccc1C(=O)OCC, CCOC(=O)c1ccccc1OC(=O)CCCCCCCC(=O)Oc1ccccc1C(=O)OCC	LIBAUACOIKWWKP-UHFFFAOYSA-N, LIBAUACOIKWWKP-UHFFFAOYSA-N	Phase 2
tuaminoheptane			otolaryngology	nasal congestion	CCCCC[C@@H](C)N |&1:5|, CCCCC[C@@H](C)N |&1:5|	VSRBKQFNFZQRBM-SSDOTTSWSA-N, VSRBKQFNFZQRBM-SSDOTTSWSA-N	Launched
tubastatin-A	HDAC inhibitor	HDAC6			CN1CCc2c(C1)c1ccccc1n2Cc1ccc(cc1)C(=O)NO, CN1CCc2c(C1)c1ccccc1n2Cc1ccc(cc1)C(=O)NO, CN1CCc2c(C1)c1ccccc1n2Cc1ccc(cc1)C(=O)NO, CN1CCc2c(C1)c1ccccc1n2Cc1ccc(cc1)C(=O)NO, CN1CCc2c(C1)c1ccccc1n2Cc1ccc(cc1)C(=O)NO, CN1CCc2c(C1)c1ccccc1n2Cc1ccc(cc1)C(=O)NO	GOVYBPLHWIEHEJ-UHFFFAOYSA-N, GOVYBPLHWIEHEJ-UHFFFAOYSA-N, GOVYBPLHWIEHEJ-UHFFFAOYSA-N, GOVYBPLHWIEHEJ-UHFFFAOYSA-N, GOVYBPLHWIEHEJ-UHFFFAOYSA-N, GOVYBPLHWIEHEJ-UHFFFAOYSA-N	Preclinical
tubocurarine	acetylcholine receptor antagonist	ACHE, CHRNA2, HTR3A, HTR3B, KCNN1, KCNN2, KCNN3, ZACN	neurology/psychiatry	anesthetic	COc1cc2CC[N+](C)(C)[C@@H]3Cc4ccc(O)c(Oc5cc6[C@H](Cc7ccc(Oc(c1O)c23)cc7)N(C)CCc6cc5OC)c4, COc1cc2CC[N+](C)(C)[C@@H]3Cc4ccc(O)c(Oc5cc6[C@H](Cc7ccc(Oc(c1O)c23)cc7)N(C)CCc6cc5OC)c4, COc1cc2CC[N+](C)(C)[C@@H]3Cc4ccc(O)c(Oc5cc6[C@H](Cc7ccc(Oc(c1O)c23)cc7)N(C)CCc6cc5OC)c4	JFJZZMVDLULRGK-URLMMPGGSA-O, JFJZZMVDLULRGK-URLMMPGGSA-O, JFJZZMVDLULRGK-URLMMPGGSA-O	Launched
tucatinib	EGFR inhibitor	ERBB2			Cc1cc(Nc2ncnc3ccc(NC4=NC(C)(C)CO4)cc23)ccc1Oc1ccn2ncnc2c1 |t:14|, Cc1cc(Nc2ncnc3ccc(NC4=NC(C)(C)CO4)cc23)ccc1Oc1ccn2ncnc2c1 |t:14|, Cc1cc(Nc2ncnc3ccc(NC4=NC(C)(C)CO4)cc23)ccc1Oc1ccn2ncnc2c1 |t:14|, Cc1cc(Nc2ncnc3ccc(NC4=NC(C)(C)CO4)cc23)ccc1Oc1ccn2ncnc2c1 |t:14|	SDEAXTCZPQIFQM-UHFFFAOYSA-N, SDEAXTCZPQIFQM-UHFFFAOYSA-N, SDEAXTCZPQIFQM-UHFFFAOYSA-N, SDEAXTCZPQIFQM-UHFFFAOYSA-N	Phase 3
tucidinostat	HDAC inhibitor				Nc1cc(F)ccc1NC(=O)c1ccc(CNC(=O)\C=C\c2cccnc2)cc1	SZMJVTADHFNAIS-BJMVGYQFSA-N	Phase 3
tuftsin	macrophage activator				C[C@@H](O)[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(O)=O	IESDGNYHXIOKRW-YXMSTPNBSA-N	Preclinical
TUG-770	free fatty acid receptor agonist	FFAR1			OC(=O)CCc1ccc(cc1F)C#Cc1ccccc1CC#N	KIZUBVPJNPVIIN-UHFFFAOYSA-N	Preclinical
TUG-891	free fatty acid receptor agonist	FFAR4			Cc1ccc(cc1)-c1ccc(F)cc1COc1ccc(CCC(O)=O)cc1, Cc1ccc(cc1)-c1ccc(F)cc1COc1ccc(CCC(O)=O)cc1, Cc1ccc(cc1)-c1ccc(F)cc1COc1ccc(CCC(O)=O)cc1, Cc1ccc(cc1)-c1ccc(F)cc1COc1ccc(CCC(O)=O)cc1	LPGBXHWIQNZEJB-UHFFFAOYSA-N, LPGBXHWIQNZEJB-UHFFFAOYSA-N, LPGBXHWIQNZEJB-UHFFFAOYSA-N, LPGBXHWIQNZEJB-UHFFFAOYSA-N	Preclinical
tulobuterol	adrenergic receptor agonist	ADRB2	pulmonary	asthma	CC(C)(C)NC[C@H](O)c1ccccc1Cl |&1:6|	YREYLAVBNPACJM-NSHDSACASA-N	Launched
tulrampator	antidepressant 				Fc1cccc(CCn2nnc3cc4C(=O)N(COc4cc3c2=O)C2CC2)c1	JHCFQXNWYDLBOG-UHFFFAOYSA-N	Phase 2
TW-37	BCL inhibitor	BCL2, BCL2L1, MCL1			CC(C)c1ccccc1Cc1cc(C(=O)Nc2ccc(cc2)S(=O)(=O)c2ccccc2C(C)(C)C)c(O)c(O)c1O, CC(C)c1ccccc1Cc1cc(C(=O)Nc2ccc(cc2)S(=O)(=O)c2ccccc2C(C)(C)C)c(O)c(O)c1O, CC(C)c1ccccc1Cc1cc(C(=O)Nc2ccc(cc2)S(=O)(=O)c2ccccc2C(C)(C)C)c(O)c(O)c1O, CC(C)c1ccccc1Cc1cc(C(=O)Nc2ccc(cc2)S(=O)(=O)c2ccccc2C(C)(C)C)c(O)c(O)c1O	PQAPVTKIEGUPRN-UHFFFAOYSA-N, PQAPVTKIEGUPRN-UHFFFAOYSA-N, PQAPVTKIEGUPRN-UHFFFAOYSA-N, PQAPVTKIEGUPRN-UHFFFAOYSA-N	Preclinical
TWS-119	glycogen synthase kinase inhibitor	GSK3B, JUN, MYC			Nc1cccc(c1)-c1cc2c(Oc3cccc(O)c3)ncnc2[nH]1, Nc1cccc(c1)-c1cc2c(Oc3cccc(O)c3)ncnc2[nH]1, Nc1cccc(c1)-c1cc2c(Oc3cccc(O)c3)ncnc2[nH]1, Nc1cccc(c1)-c1cc2c(Oc3cccc(O)c3)ncnc2[nH]1, Nc1cccc(c1)-c1cc2c(Oc3cccc(O)c3)ncnc2[nH]1	VPVLEBIVXZSOMQ-UHFFFAOYSA-N, VPVLEBIVXZSOMQ-UHFFFAOYSA-N, VPVLEBIVXZSOMQ-UHFFFAOYSA-N, VPVLEBIVXZSOMQ-UHFFFAOYSA-N, VPVLEBIVXZSOMQ-UHFFFAOYSA-N	Preclinical
TXA127	angiotensin receptor agonist				CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N1CCC[C@H]1C(O)=O, CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N1CCC[C@H]1C(O)=O, CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N1CCC[C@H]1C(O)=O	PVHLMTREZMEJCG-GDTLVBQBSA-N, PVHLMTREZMEJCG-GDTLVBQBSA-N, PVHLMTREZMEJCG-GDTLVBQBSA-N	Phase 2
TY-52156	sphingosine 1-phosphate receptor antagonist	S1PR3			CC(C)(C)C(=O)C(Nc1ccc(Cl)cc1)=NNc1ccc(Cl)cc1, CC(C)(C)C(=O)C(Nc1ccc(Cl)cc1)=NNc1ccc(Cl)cc1, CC(C)(C)C(=O)C(Nc1ccc(Cl)cc1)=NNc1ccc(Cl)cc1	XONRRGIRSGNWFP-UHFFFAOYSA-N, XONRRGIRSGNWFP-UHFFFAOYSA-N, XONRRGIRSGNWFP-UHFFFAOYSA-N	Preclinical
tylosin	protein synthesis inhibitor		infectious disease, gastroenterology	gram-positive bacterial infections, colitis	CC[C@H]1OC(=O)C[C@@H](O)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)[C@@H](O[C@H]3C[C@@](C)(O)[C@@H](O)[C@H](C)O3)[C@@H]([C@H]2O)N(C)C)[C@@H](CC=O)C[C@@H](C)C(=O)\C=C\C(\C)=C\[C@@H]1CO[C@@H]1O[C@H](C)[C@@H](O)[C@@H](OC)[C@H]1OC |t:46,49|, CC[C@H]1OC(=O)C[C@@H](O)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)[C@@H](O[C@H]3C[C@@](C)(O)[C@@H](O)[C@H](C)O3)[C@@H]([C@H]2O)N(C)C)[C@@H](CC=O)C[C@@H](C)C(=O)\C=C\C(\C)=C\[C@@H]1CO[C@@H]1O[C@H](C)[C@@H](O)[C@@H](OC)[C@H]1OC |t:46,49|, CC[C@H]1OC(=O)C[C@@H](O)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)[C@@H](O[C@H]3C[C@@](C)(O)[C@@H](O)[C@H](C)O3)[C@@H]([C@H]2O)N(C)C)[C@@H](CC=O)C[C@@H](C)C(=O)\C=C\C(\C)=C\[C@@H]1CO[C@@H]1O[C@H](C)[C@@H](O)[C@@H](OC)[C@H]1OC |t:46,49|	WBPYTXDJUQJLPQ-CQICKBAWSA-N, WBPYTXDJUQJLPQ-CQICKBAWSA-N, WBPYTXDJUQJLPQ-CQICKBAWSA-N	Launched
tymazoline			allergy	allergic rhinitis	CC(C)c1ccc(C)cc1OCC1=NCCN1 |t:13|	QRORCRWSRPKEHR-UHFFFAOYSA-N	Launched
tyrphostin-AG-1296	FLT3 inhibitor	FLT3			COc1cc2ncc(nc2cc1OC)-c1ccccc1, COc1cc2ncc(nc2cc1OC)-c1ccccc1, COc1cc2ncc(nc2cc1OC)-c1ccccc1, COc1cc2ncc(nc2cc1OC)-c1ccccc1, COc1cc2ncc(nc2cc1OC)-c1ccccc1, COc1cc2ncc(nc2cc1OC)-c1ccccc1	QNOXYUNHIGOWNY-UHFFFAOYSA-N, QNOXYUNHIGOWNY-UHFFFAOYSA-N, QNOXYUNHIGOWNY-UHFFFAOYSA-N, QNOXYUNHIGOWNY-UHFFFAOYSA-N, QNOXYUNHIGOWNY-UHFFFAOYSA-N, QNOXYUNHIGOWNY-UHFFFAOYSA-N	Preclinical
tyrphostin-AG-1478	EGFR inhibitor	EGFR, MAPK14			COc1cc2ncnc(Nc3cccc(Cl)c3)c2cc1OC, COc1cc2ncnc(Nc3cccc(Cl)c3)c2cc1OC	GFNNBHLJANVSQV-UHFFFAOYSA-N, GFNNBHLJANVSQV-UHFFFAOYSA-N	Preclinical
tyrphostin-AG-18	EGFR inhibitor, tyrosine kinase inhibitor	EGFR			Oc1ccc(C=C(C#N)C#N)cc1O, Oc1ccc(C=C(C#N)C#N)cc1O, Oc1ccc(C=C(C#N)C#N)cc1O, Oc1ccc(C=C(C#N)C#N)cc1O	VTJXFTPMFYAJJU-UHFFFAOYSA-N, VTJXFTPMFYAJJU-UHFFFAOYSA-N, VTJXFTPMFYAJJU-UHFFFAOYSA-N, VTJXFTPMFYAJJU-UHFFFAOYSA-N	Preclinical
tyrphostin-AG-494	EGFR inhibitor	EGFR			Oc1ccc(\C=C(/C#N)C(=O)Nc2ccccc2)cc1O, Oc1ccc(\C=C(/C#N)C(=O)Nc2ccccc2)cc1O, Oc1ccc(\C=C(/C#N)C(=O)Nc2ccccc2)cc1O, Oc1ccc(\C=C(/C#N)C(=O)Nc2ccccc2)cc1O	HKHOVJYOELRGMV-XYOKQWHBSA-N, HKHOVJYOELRGMV-XYOKQWHBSA-N, HKHOVJYOELRGMV-XYOKQWHBSA-N, HKHOVJYOELRGMV-XYOKQWHBSA-N	Preclinical
tyrphostin-AG-825	protein tyrosine kinase inhibitor	ERBB2			COc1cc(\C=C(/C#N)C(N)=O)cc(CSc2nc3ccccc3s2)c1O, COc1cc(\C=C(/C#N)C(N)=O)cc(CSc2nc3ccccc3s2)c1O	KXDONFLNGBQLTN-WUXMJOGZSA-N, KXDONFLNGBQLTN-WUXMJOGZSA-N	Preclinical
tyrphostin-AG-835	protein tyrosine kinase inhibitor	EGFR			C[C@H](NC(=O)C(=C\c1ccc(O)c(O)c1)\C#N)c1ccccc1, C[C@H](NC(=O)C(=C\c1ccc(O)c(O)c1)\C#N)c1ccccc1	UMGQVUWXNOJOSJ-DGGAMASNSA-N, UMGQVUWXNOJOSJ-DGGAMASNSA-N	Preclinical
tyrphostin-AG-879	tyrosine kinase inhibitor	ERBB2, KDR, NTRK1			CC(C)(C)c1cc(\C=C(/C#N)C(N)=S)cc(c1O)C(C)(C)C, CC(C)(C)c1cc(\C=C(/C#N)C(N)=S)cc(c1O)C(C)(C)C, CC(C)(C)c1cc(\C=C(/C#N)C(N)=S)cc(c1O)C(C)(C)C, CC(C)(C)c1cc(\C=C(/C#N)C(N)=S)cc(c1O)C(C)(C)C, CC(C)(C)c1cc(\C=C(/C#N)C(N)=S)cc(c1O)C(C)(C)C, CC(C)(C)c1cc(\C=C(/C#N)C(N)=S)cc(c1O)C(C)(C)C, CC(C)(C)c1cc(\C=C(/C#N)C(N)=S)cc(c1O)C(C)(C)C, CC(C)(C)c1cc(\C=C(/C#N)C(N)=S)cc(c1O)C(C)(C)C, CC(C)(C)c1cc(\C=C(/C#N)C(N)=S)cc(c1O)C(C)(C)C, CC(C)(C)c1cc(\C=C(/C#N)C(N)=S)cc(c1O)C(C)(C)C	XRZYELWZLNAXGE-KPKJPENVSA-N, XRZYELWZLNAXGE-KPKJPENVSA-N, XRZYELWZLNAXGE-KPKJPENVSA-N, XRZYELWZLNAXGE-KPKJPENVSA-N, XRZYELWZLNAXGE-KPKJPENVSA-N, XRZYELWZLNAXGE-KPKJPENVSA-N, XRZYELWZLNAXGE-KPKJPENVSA-N, XRZYELWZLNAXGE-KPKJPENVSA-N, XRZYELWZLNAXGE-KPKJPENVSA-N, XRZYELWZLNAXGE-KPKJPENVSA-N	Preclinical
tyrphostin-AG-99	tyrosine kinase inhibitor	EGFR			NC(=O)C(=C\c1ccc(O)c(O)c1)\C#N, NC(=O)C(=C\c1ccc(O)c(O)c1)\C#N, NC(=O)C(=C\c1ccc(O)c(O)c1)\C#N	USOXQZNJFMKTKJ-XVNBXDOJSA-N, USOXQZNJFMKTKJ-XVNBXDOJSA-N, USOXQZNJFMKTKJ-XVNBXDOJSA-N	Preclinical
tyrphostin-A9	protein tyrosine kinase inhibitor, tyrosine kinase inhibitor				CC(C)(C)c1cc(C=C(C#N)C#N)cc(c1O)C(C)(C)C, CC(C)(C)c1cc(C=C(C#N)C#N)cc(c1O)C(C)(C)C, CC(C)(C)c1cc(C=C(C#N)C#N)cc(c1O)C(C)(C)C, CC(C)(C)c1cc(C=C(C#N)C#N)cc(c1O)C(C)(C)C, CC(C)(C)c1cc(C=C(C#N)C#N)cc(c1O)C(C)(C)C, CC(C)(C)c1cc(C=C(C#N)C#N)cc(c1O)C(C)(C)C, CC(C)(C)c1cc(C=C(C#N)C#N)cc(c1O)C(C)(C)C, CC(C)(C)c1cc(C=C(C#N)C#N)cc(c1O)C(C)(C)C, CC(C)(C)c1cc(C=C(C#N)C#N)cc(c1O)C(C)(C)C	MZOPWQKISXCCTP-UHFFFAOYSA-N, MZOPWQKISXCCTP-UHFFFAOYSA-N, MZOPWQKISXCCTP-UHFFFAOYSA-N, MZOPWQKISXCCTP-UHFFFAOYSA-N, MZOPWQKISXCCTP-UHFFFAOYSA-N, MZOPWQKISXCCTP-UHFFFAOYSA-N, MZOPWQKISXCCTP-UHFFFAOYSA-N, MZOPWQKISXCCTP-UHFFFAOYSA-N, InChI=1S/C18H22N2O/c1-17(2,3)14-8-12(7-13(10-19)11-20)9-15(16(14)21)18(4,5)6/h7-9,21H,1-6H3	Preclinical
U-0124	MEK inhibitor				CSC(=N)C(C#N)C(C#N)C(=N)SC, CSC(=N)C(C#N)C(C#N)C(=N)SC	GXGXSVFKGDVBMD-UHFFFAOYSA-N, GXGXSVFKGDVBMD-UHFFFAOYSA-N	Preclinical
U-0126	MEK inhibitor	AKT1, CHEK1, GSK3B, LCK, MAP2K1, MAP2K2, MAP2K7, MAPK1, MAPK11, MAPK12, MAPK14, MAPK8, PRKCA, RAF1, ROCK1, RPS6KB1, SGK1			Nc1ccccc1SC(=N)C(C#N)C(C#N)C(=N)Sc1ccccc1N, Nc1ccccc1SC(=N)C(C#N)C(C#N)C(=N)Sc1ccccc1N, Nc1ccccc1SC(=N)C(C#N)C(C#N)C(=N)Sc1ccccc1N, Nc1ccccc1SC(=N)C(C#N)C(C#N)C(=N)Sc1ccccc1N, Nc1ccccc1SC(=N)C(C#N)C(C#N)C(=N)Sc1ccccc1N, Nc1ccccc1SC(=N)C(C#N)C(C#N)C(=N)Sc1ccccc1N	ZCHZSBUNJOCWCW-UHFFFAOYSA-N, ZCHZSBUNJOCWCW-UHFFFAOYSA-N, ZCHZSBUNJOCWCW-UHFFFAOYSA-N, ZCHZSBUNJOCWCW-UHFFFAOYSA-N, ZCHZSBUNJOCWCW-UHFFFAOYSA-N, ZCHZSBUNJOCWCW-UHFFFAOYSA-N	Preclinical
U-0521	catechol O methyltransferase inhibitor	COMT			CC(C)C(=O)c1ccc(O)c(O)c1	VDQLKIBLTMPAHI-UHFFFAOYSA-N	Preclinical
U-104	carbonic anhydrase inhibitor	CA1, CA12, CA2, CA9			NS(=O)(=O)c1ccc(NC(=O)Nc2ccc(F)cc2)cc1, NS(=O)(=O)c1ccc(NC(=O)Nc2ccc(F)cc2)cc1, NS(=O)(=O)c1ccc(NC(=O)Nc2ccc(F)cc2)cc1, NS(=O)(=O)c1ccc(NC(=O)Nc2ccc(F)cc2)cc1, NS(=O)(=O)c1ccc(NC(=O)Nc2ccc(F)cc2)cc1	YJQZNWPYLCNRLP-UHFFFAOYSA-N, YJQZNWPYLCNRLP-UHFFFAOYSA-N, YJQZNWPYLCNRLP-UHFFFAOYSA-N, YJQZNWPYLCNRLP-UHFFFAOYSA-N, YJQZNWPYLCNRLP-UHFFFAOYSA-N	Phase 1/Phase 2
U-18666A	oxidosqualene cyclase inhibitor				CCN(CC)CCO[C@H]1CC[C@]2(C)[C@H]3CC[C@@]4(C)[C@@H](CCC4=O)[C@@H]3CC=C2C1 |c:27|, CCN(CC)CCO[C@H]1CC[C@]2(C)[C@H]3CC[C@@]4(C)[C@@H](CCC4=O)[C@@H]3CC=C2C1 |c:27|, CCN(CC)CCO[C@H]1CC[C@]2(C)[C@H]3CC[C@@]4(C)[C@@H](CCC4=O)[C@@H]3CC=C2C1 |c:27|, CCN(CC)CCO[C@H]1CC[C@]2(C)[C@H]3CC[C@@]4(C)[C@@H](CCC4=O)[C@@H]3CC=C2C1 |c:27|, CCN(CC)CCO[C@H]1CC[C@]2(C)[C@H]3CC[C@@]4(C)[C@@H](CCC4=O)[C@@H]3CC=C2C1 |c:27|	DMZCCFMMPHJWQY-BKWLFHPQSA-N, DMZCCFMMPHJWQY-BKWLFHPQSA-N, DMZCCFMMPHJWQY-BKWLFHPQSA-N, DMZCCFMMPHJWQY-BKWLFHPQSA-N, DMZCCFMMPHJWQY-BKWLFHPQSA-N	Preclinical
U-50488-(-)	opioid receptor agonist	OPRK1			CN([C@H]1CCCC[C@@H]1N1CCCC1)C(=O)Cc1ccc(Cl)c(Cl)c1, CN([C@H]1CCCC[C@@H]1N1CCCC1)C(=O)Cc1ccc(Cl)c(Cl)c1, CN([C@H]1CCCC[C@@H]1N1CCCC1)C(=O)Cc1ccc(Cl)c(Cl)c1, CN([C@H]1CCCC[C@@H]1N1CCCC1)C(=O)Cc1ccc(Cl)c(Cl)c1, CN([C@H]1CCCC[C@@H]1N1CCCC1)C(=O)Cc1ccc(Cl)c(Cl)c1, CN([C@H]1CCCC[C@@H]1N1CCCC1)C(=O)Cc1ccc(Cl)c(Cl)c1	VQLPLYSROCPWFF-ROUUACIJSA-N, VQLPLYSROCPWFF-ROUUACIJSA-N, VQLPLYSROCPWFF-ROUUACIJSA-N, VQLPLYSROCPWFF-ROUUACIJSA-N, VQLPLYSROCPWFF-ROUUACIJSA-N, VQLPLYSROCPWFF-ROUUACIJSA-N	Preclinical
U-54494A	opioid receptor agonist	OPRK1			CN([C@@H]1CCCC[C@@H]1N1CCCC1)C(=O)c1ccc(Cl)c(Cl)c1, CN([C@@H]1CCCC[C@@H]1N1CCCC1)C(=O)c1ccc(Cl)c(Cl)c1	JUBNVWGVNWIXMB-SJORKVTESA-N, JUBNVWGVNWIXMB-SJORKVTESA-N	Preclinical
U-75799E	growth hormone releasing factor agonist	GHSR			C[C@H](NC(=O)[C@@H](Cc1c[nH]c2ccccc12)NC(=O)[C@@H](N)Cc1cnc[nH]1)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@H](Cc1ccccc1)C(=O)N[C@@H](CCCCN)C(N)=O, C[C@H](NC(=O)[C@@H](Cc1c[nH]c2ccccc12)NC(=O)[C@@H](N)Cc1cnc[nH]1)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@H](Cc1ccccc1)C(=O)N[C@@H](CCCCN)C(N)=O, C[C@H](NC(=O)[C@@H](Cc1c[nH]c2ccccc12)NC(=O)[C@@H](N)Cc1cnc[nH]1)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@H](Cc1ccccc1)C(=O)N[C@@H](CCCCN)C(N)=O	WZHKXNSOCOQYQX-FUAFALNISA-N, WZHKXNSOCOQYQX-FUAFALNISA-N, WZHKXNSOCOQYQX-FUAFALNISA-N	Phase 1
U-99194	dopamine receptor antagonist	DRD3			CCCN(CCC)C1Cc2cc(OC)c(OC)cc2C1	UOLJKAPABHXFRE-UHFFFAOYSA-N	Preclinical
UAMC-00039	dipeptidyl peptidase inhibitor	DPP4, DPP7			N[C@@H](CCNCc1ccc(Cl)cc1)C(=O)N1CCCCC1, N[C@@H](CCNCc1ccc(Cl)cc1)C(=O)N1CCCCC1	DNVZYSMOLXCOLY-HNNXBMFYSA-N, DNVZYSMOLXCOLY-HNNXBMFYSA-N	Preclinical
UB-165	acetylcholine receptor agonist	CHRNA3, CHRNA4, CHRNB2			Clc1ccc(cn1)C1=CCC[C@H]2CC[C@@H]1N2 |&1:11,&2:14,t:8,THB:4:7:12.13:15|, Clc1ccc(cn1)C1=CCC[C@H]2CC[C@@H]1N2 |&1:11,&2:14,t:8,THB:4:7:12.13:15|, Clc1ccc(cn1)C1=CCC[C@H]2CC[C@@H]1N2 |&1:11,&2:14,t:8,THB:4:7:12.13:15|	TVSNVPGPFGAKPT-JQWIXIFHSA-N, TVSNVPGPFGAKPT-JQWIXIFHSA-N, TVSNVPGPFGAKPT-JQWIXIFHSA-N	Preclinical
ubenimex	leukotriene synthesis inhibitor	LTA4H, RNPEP	hematologic malignancy	acute myeloid leukemia (AML)	CC(C)C[C@H](NC(=O)[C@@H](O)[C@H](N)Cc1ccccc1)C(O)=O, CC(C)C[C@H](NC(=O)[C@@H](O)[C@H](N)Cc1ccccc1)C(O)=O, CC(C)C[C@H](NC(=O)[C@@H](O)[C@H](N)Cc1ccccc1)C(O)=O, CC(C)C[C@H](NC(=O)[C@@H](O)[C@H](N)Cc1ccccc1)C(O)=O	VGGGPCQERPFHOB-RDBSUJKOSA-N, VGGGPCQERPFHOB-RDBSUJKOSA-N, VGGGPCQERPFHOB-RDBSUJKOSA-N, VGGGPCQERPFHOB-RDBSUJKOSA-N	Launched
UBP-296	glutamate receptor antagonist	GRIK1			N[C@@H](Cn1ccc(=O)n(Cc2ccccc2C(O)=O)c1=O)C(O)=O |&1:1,r|, N[C@@H](Cn1ccc(=O)n(Cc2ccccc2C(O)=O)c1=O)C(O)=O |&1:1,r|, N[C@@H](Cn1ccc(=O)n(Cc2ccccc2C(O)=O)c1=O)C(O)=O |&1:1,r|	UUIYULWYHDSXHL-NSHDSACASA-N, UUIYULWYHDSXHL-NSHDSACASA-N, UUIYULWYHDSXHL-NSHDSACASA-N	Preclinical
UBP-302	glutamate receptor antagonist	GRIK1			N[C@@H](Cn1ccc(=O)n(Cc2ccccc2C(O)=O)c1=O)C(O)=O, N[C@@H](Cn1ccc(=O)n(Cc2ccccc2C(O)=O)c1=O)C(O)=O, N[C@@H](Cn1ccc(=O)n(Cc2ccccc2C(O)=O)c1=O)C(O)=O, N[C@@H](Cn1ccc(=O)n(Cc2ccccc2C(O)=O)c1=O)C(O)=O	UUIYULWYHDSXHL-NSHDSACASA-N, UUIYULWYHDSXHL-NSHDSACASA-N, UUIYULWYHDSXHL-NSHDSACASA-N, UUIYULWYHDSXHL-NSHDSACASA-N	Preclinical
UBP-310	glutamate receptor antagonist	GRIK1, GRIK5			Cc1cn(C[C@H](N)C(O)=O)c(=O)n(Cc2ccsc2C(O)=O)c1=O, Cc1cn(C[C@H](N)C(O)=O)c(=O)n(Cc2ccsc2C(O)=O)c1=O	ZTAZUCRXCRXNSU-VIFPVBQESA-N, ZTAZUCRXCRXNSU-VIFPVBQESA-N	Preclinical
UC-112	XIAP inhibitor	XIAP			Oc1c(CN2CCCC2)cc(COCc2ccccc2)c2cccnc12, Oc1c(CN2CCCC2)cc(COCc2ccccc2)c2cccnc12, Oc1c(CN2CCCC2)cc(COCc2ccccc2)c2cccnc12	LTGLGIQQZXSLLF-UHFFFAOYSA-N, LTGLGIQQZXSLLF-UHFFFAOYSA-N, LTGLGIQQZXSLLF-UHFFFAOYSA-N	Preclinical
UCL-2077	slow afterhyperpolarization channel blocker				C(NC(c1ccccc1)(c1ccccc1)c1ccccc1)c1cccnc1, C(NC(c1ccccc1)(c1ccccc1)c1ccccc1)c1cccnc1, C(NC(c1ccccc1)(c1ccccc1)c1ccccc1)c1cccnc1	PQFNWDHABGBCHB-UHFFFAOYSA-N, PQFNWDHABGBCHB-UHFFFAOYSA-N, PQFNWDHABGBCHB-UHFFFAOYSA-N	Preclinical
udenafil	phosphodiesterase inhibitor		urology	erectile dysfunction	CCCOc1ccc(cc1-c1nc2c(CCC)nn(C)c2c(=O)[nH]1)S(=O)(=O)NCC[C@@H]1CCCN1C |&1:30,r|	IYFNEFQTYQPVOC-KRWDZBQOSA-N	Launched
UF-010	HDAC inhibitor	HDAC1, HDAC2, HDAC3, HDAC8			CCCCNNC(=O)c1ccc(Br)cc1, CCCCNNC(=O)c1ccc(Br)cc1, CCCCNNC(=O)c1ccc(Br)cc1	BVQCFCYPFJOOAV-UHFFFAOYSA-N, BVQCFCYPFJOOAV-UHFFFAOYSA-N, BVQCFCYPFJOOAV-UHFFFAOYSA-N	Preclinical
ufenamate	cyclooxygenase inhibitor	PTGS1, PTGS2	dermatology	eczema, dermatitis	CCCCOC(=O)c1ccccc1Nc1cccc(c1)C(F)(F)F, CCCCOC(=O)c1ccccc1Nc1cccc(c1)C(F)(F)F	JDLSRXWHEBFHNC-UHFFFAOYSA-N, JDLSRXWHEBFHNC-UHFFFAOYSA-N	Launched
UH-232-(+)	dopamine receptor antagonist	DRD2, DRD3, DRD4, HTR1A			CCCN(CCC)[C@@H]1CCc2c(OC)cccc2[C@@H]1C, CCCN(CCC)[C@@H]1CCc2c(OC)cccc2[C@@H]1C	BTOJYCTUJJHANF-WMLDXEAASA-N, BTOJYCTUJJHANF-WMLDXEAASA-N	Preclinical
UK-356618	metalloproteinase inhibitor	MMP13, MMP14, MMP2, MMP3, MMP9			C[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CCCc1ccc(c(C)c1)-c1ccccc1)CC(=O)NO)C(C)(C)C)c1ccccc1, C[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CCCc1ccc(c(C)c1)-c1ccccc1)CC(=O)NO)C(C)(C)C)c1ccccc1, C[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CCCc1ccc(c(C)c1)-c1ccccc1)CC(=O)NO)C(C)(C)C)c1ccccc1, C[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CCCc1ccc(c(C)c1)-c1ccccc1)CC(=O)NO)C(C)(C)C)c1ccccc1, C[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CCCc1ccc(c(C)c1)-c1ccccc1)CC(=O)NO)C(C)(C)C)c1ccccc1	JJHRUUKMPWUYIB-HVOSOHGQSA-N, JJHRUUKMPWUYIB-HVOSOHGQSA-N, JJHRUUKMPWUYIB-HVOSOHGQSA-N, InChI=1S/C34H43N3O4/c1-23-21-25(19-20-29(23)27-16-10-7-11-17-27)13-12-18-28(22-30(38)37-41)32(39)36-31(34(3,4)5)33(40)35-24(2)26-14-8-6-9-15-26/h6-11,14-17,19-21,24,28,31,41H,12-13,18,22H2,1-5H3,(H,35,40)(H,36,39)(H,37,38)/t24-,28-,31-/m1/s1, InChI=1S/C34H43N3O4/c1-23-21-25(19-20-29(23)27-16-10-7-11-17-27)13-12-18-28(22-30(38)37-41)32(39)36-31(34(3,4)5)33(40)35-24(2)26-14-8-6-9-15-26/h6-11,14-17,19-21,24,28,31,41H,12-13,18,22H2,1-5H3,(H,35,40)(H,36,39)(H,37,38)/t24-,28-,31-/m1/s1	Preclinical
UK-383367	procollagen C-endopeptidase inhibitor	BMP1			NC(=O)c1noc(n1)[C@H](CCCC1CCCCC1)CC(=O)NO, NC(=O)c1noc(n1)[C@H](CCCC1CCCCC1)CC(=O)NO, NC(=O)c1noc(n1)[C@H](CCCC1CCCCC1)CC(=O)NO, NC(=O)c1noc(n1)[C@H](CCCC1CCCCC1)CC(=O)NO, NC(=O)c1noc(n1)[C@H](CCCC1CCCCC1)CC(=O)NO, NC(=O)c1noc(n1)[C@H](CCCC1CCCCC1)CC(=O)NO	ARJCBSRIPGJMAD-LLVKDONJSA-N, ARJCBSRIPGJMAD-LLVKDONJSA-N, ARJCBSRIPGJMAD-LLVKDONJSA-N, ARJCBSRIPGJMAD-LLVKDONJSA-N, ARJCBSRIPGJMAD-LLVKDONJSA-N, ARJCBSRIPGJMAD-LLVKDONJSA-N	Phase 1
UK-5099	monocarboxylate transporter inhibitor	SLC16A1			OC(=O)C(=C\c1cn(-c2ccccc2)c2ccccc12)\C#N, OC(=O)C(=C\c1cn(-c2ccccc2)c2ccccc12)\C#N, OC(=O)C(=C\c1cn(-c2ccccc2)c2ccccc12)\C#N	BIZNHCWFGNKBBZ-JLHYYAGUSA-N, BIZNHCWFGNKBBZ-JLHYYAGUSA-N, BIZNHCWFGNKBBZ-JLHYYAGUSA-N	Preclinical
uki-1	urokinase inhibitor				CCOC(=O)N1CCN(CC1)C(=O)[C@H](Cc1cccc(c1)C(N)=N)NS(=O)(=O)c1c(cc(cc1C(C)C)C(C)C)C(C)C	ISJSHQTWOHGCMM-NDEPHWFRSA-N	Preclinical
ulifloxacin			infectious disease	gram-negative bacterial infections, gram-positive bacterial infections	C[C@H]1Sc2c(C(O)=O)c(=O)c3cc(F)c(cc3n12)N1CCNCC1 |&1:1,r|, C[C@H]1Sc2c(C(O)=O)c(=O)c3cc(F)c(cc3n12)N1CCNCC1 |&1:1,r|	SUXQDLLXIBLQHW-MRVPVSSYSA-N, SUXQDLLXIBLQHW-MRVPVSSYSA-N	Launched
ulipristal	progesterone receptor antagonist	PGR	endocrinology	contraceptive	CN(C)c1ccc(cc1)[C@H]1C[C@@]2(C)[C@@H](CC[C@]2(OC(C)=O)C(C)=O)[C@@H]2CCC3=CC(=O)CCC3=C12 |t:29,36|, CN(C)c1ccc(cc1)[C@H]1C[C@@]2(C)[C@@H](CC[C@]2(OC(C)=O)C(C)=O)[C@@H]2CCC3=CC(=O)CCC3=C12 |t:29,36|, CN(C)c1ccc(cc1)[C@H]1C[C@@]2(C)[C@@H](CC[C@]2(OC(C)=O)C(C)=O)[C@@H]2CCC3=CC(=O)CCC3=C12 |t:29,36|, CN(C)c1ccc(cc1)[C@H]1C[C@@]2(C)[C@@H](CC[C@]2(OC(C)=O)C(C)=O)[C@@H]2CCC3=CC(=O)CCC3=C12 |t:29,36|, CN(C)c1ccc(cc1)[C@H]1C[C@@]2(C)[C@@H](CC[C@]2(OC(C)=O)C(C)=O)[C@@H]2CCC3=CC(=O)CCC3=C12 |t:29,36|	OOLLAFOLCSJHRE-ZHAKMVSLSA-N, OOLLAFOLCSJHRE-ZHAKMVSLSA-N, OOLLAFOLCSJHRE-ZHAKMVSLSA-N, OOLLAFOLCSJHRE-ZHAKMVSLSA-N, OOLLAFOLCSJHRE-ZHAKMVSLSA-N	Launched
umeclidinium	acetylcholine receptor antagonist	CHRM1, CHRM2, CHRM3	pulmonary	chronic obstructive pulmonary disease (COPD), bronchitis, emphysema	OC(c1ccccc1)(c1ccccc1)C12CC[N+](CCOCc3ccccc3)(CC1)CC2, OC(c1ccccc1)(c1ccccc1)C12CC[N+](CCOCc3ccccc3)(CC1)CC2, OC(c1ccccc1)(c1ccccc1)C12CC[N+](CCOCc3ccccc3)(CC1)CC2, OC(c1ccccc1)(c1ccccc1)C12CC[N+](CCOCc3ccccc3)(CC1)CC2	FVTWTVQXNAJTQP-UHFFFAOYSA-N, FVTWTVQXNAJTQP-UHFFFAOYSA-N, FVTWTVQXNAJTQP-UHFFFAOYSA-N, FVTWTVQXNAJTQP-UHFFFAOYSA-N	Launched
unbs-5162	CC chemokine receptor antagonist				CN(C)CCN1C(=O)c2cccc3cc(NC(N)=O)cc(C1=O)c23, CN(C)CCN1C(=O)c2cccc3cc(NC(N)=O)cc(C1=O)c23, CN(C)CCN1C(=O)c2cccc3cc(NC(N)=O)cc(C1=O)c23	WCKZRLOUKYFJDY-UHFFFAOYSA-N, WCKZRLOUKYFJDY-UHFFFAOYSA-N, WCKZRLOUKYFJDY-UHFFFAOYSA-N	Phase 1
UNC0224	histone lysine methyltransferase inhibitor	EHMT1, EHMT2			COc1cc2c(NC3CCN(C)CC3)nc(nc2cc1OCCCN(C)C)N1CCCN(C)CC1, COc1cc2c(NC3CCN(C)CC3)nc(nc2cc1OCCCN(C)C)N1CCCN(C)CC1, COc1cc2c(NC3CCN(C)CC3)nc(nc2cc1OCCCN(C)C)N1CCCN(C)CC1, COc1cc2c(NC3CCN(C)CC3)nc(nc2cc1OCCCN(C)C)N1CCCN(C)CC1	XIVUGRBSBIXXJE-UHFFFAOYSA-N, XIVUGRBSBIXXJE-UHFFFAOYSA-N, XIVUGRBSBIXXJE-UHFFFAOYSA-N, XIVUGRBSBIXXJE-UHFFFAOYSA-N	Preclinical
UNC0321	histone lysine methyltransferase inhibitor	EHMT2			COc1cc2c(NC3CCN(C)CC3)nc(nc2cc1OCCOCCN(C)C)N1CCCN(C)CC1, COc1cc2c(NC3CCN(C)CC3)nc(nc2cc1OCCOCCN(C)C)N1CCCN(C)CC1, COc1cc2c(NC3CCN(C)CC3)nc(nc2cc1OCCOCCN(C)C)N1CCCN(C)CC1	AULLUGALUBVBDD-UHFFFAOYSA-N, AULLUGALUBVBDD-UHFFFAOYSA-N, AULLUGALUBVBDD-UHFFFAOYSA-N	Preclinical
UNC0631	histone lysine methyltransferase inhibitor	EHMT2			COc1cc2c(NC3CCN(CC4CCCCC4)CC3)nc(nc2cc1OCCCN1CCCCC1)N1CCCN(CC1)C(C)C, COc1cc2c(NC3CCN(CC4CCCCC4)CC3)nc(nc2cc1OCCCN1CCCCC1)N1CCCN(CC1)C(C)C, COc1cc2c(NC3CCN(CC4CCCCC4)CC3)nc(nc2cc1OCCCN1CCCCC1)N1CCCN(CC1)C(C)C, COc1cc2c(NC3CCN(CC4CCCCC4)CC3)nc(nc2cc1OCCCN1CCCCC1)N1CCCN(CC1)C(C)C, COc1cc2c(NC3CCN(CC4CCCCC4)CC3)nc(nc2cc1OCCCN1CCCCC1)N1CCCN(CC1)C(C)C, COc1cc2c(NC3CCN(CC4CCCCC4)CC3)nc(nc2cc1OCCCN1CCCCC1)N1CCCN(CC1)C(C)C, COc1cc2c(NC3CCN(CC4CCCCC4)CC3)nc(nc2cc1OCCCN1CCCCC1)N1CCCN(CC1)C(C)C	XFAXSWXKPQWHDW-UHFFFAOYSA-N, XFAXSWXKPQWHDW-UHFFFAOYSA-N, XFAXSWXKPQWHDW-UHFFFAOYSA-N, XFAXSWXKPQWHDW-UHFFFAOYSA-N, XFAXSWXKPQWHDW-UHFFFAOYSA-N, XFAXSWXKPQWHDW-UHFFFAOYSA-N, XFAXSWXKPQWHDW-UHFFFAOYSA-N	Preclinical
UNC0638	histone lysine methyltransferase inhibitor	EHMT1, EHMT2			COc1cc2c(NC3CCN(CC3)C(C)C)nc(nc2cc1OCCCN1CCCC1)C1CCCCC1, COc1cc2c(NC3CCN(CC3)C(C)C)nc(nc2cc1OCCCN1CCCC1)C1CCCCC1, COc1cc2c(NC3CCN(CC3)C(C)C)nc(nc2cc1OCCCN1CCCC1)C1CCCCC1, COc1cc2c(NC3CCN(CC3)C(C)C)nc(nc2cc1OCCCN1CCCC1)C1CCCCC1	QOECJCJVIMVJGX-UHFFFAOYSA-N, QOECJCJVIMVJGX-UHFFFAOYSA-N, QOECJCJVIMVJGX-UHFFFAOYSA-N, QOECJCJVIMVJGX-UHFFFAOYSA-N	Preclinical
UNC0642	histone lysine methyltransferase inhibitor	EHMT1, EHMT2			COc1cc2c(NC3CCN(CC3)C(C)C)nc(nc2cc1OCCCN1CCCC1)N1CCC(F)(F)CC1, COc1cc2c(NC3CCN(CC3)C(C)C)nc(nc2cc1OCCCN1CCCC1)N1CCC(F)(F)CC1, COc1cc2c(NC3CCN(CC3)C(C)C)nc(nc2cc1OCCCN1CCCC1)N1CCC(F)(F)CC1, COc1cc2c(NC3CCN(CC3)C(C)C)nc(nc2cc1OCCCN1CCCC1)N1CCC(F)(F)CC1	RNAMYOYQYRYFQY-UHFFFAOYSA-N, RNAMYOYQYRYFQY-UHFFFAOYSA-N, RNAMYOYQYRYFQY-UHFFFAOYSA-N, RNAMYOYQYRYFQY-UHFFFAOYSA-N	Preclinical
UNC0646	histone lysine methyltransferase inhibitor	EHMT2			COc1cc2c(NC3CCN(CC3)C3CCCCC3)nc(nc2cc1OCCCN1CCCCC1)N1CCCN(CC1)C(C)C, COc1cc2c(NC3CCN(CC3)C3CCCCC3)nc(nc2cc1OCCCN1CCCCC1)N1CCCN(CC1)C(C)C, COc1cc2c(NC3CCN(CC3)C3CCCCC3)nc(nc2cc1OCCCN1CCCCC1)N1CCCN(CC1)C(C)C	OUKWLRHRXOPODD-UHFFFAOYSA-N, OUKWLRHRXOPODD-UHFFFAOYSA-N, OUKWLRHRXOPODD-UHFFFAOYSA-N	Preclinical
UNC0737	histone lysine methyltransferase inhibitor	EHMT1, EHMT2			COc1cc2c(nc(nc2cc1OCCCN1CCCC1)C1CCCCC1)N(C)C1CCN(CC1)C(C)C	ATORKVYCKKBNTF-UHFFFAOYSA-N	Preclinical
UNC1215	L3MBTL antagonist	L3MBTL3			O=C(N1CCC(CC1)N1CCCC1)c1ccc(C(=O)N2CCC(CC2)N2CCCC2)c(Nc2ccccc2)c1, O=C(N1CCC(CC1)N1CCCC1)c1ccc(C(=O)N2CCC(CC2)N2CCCC2)c(Nc2ccccc2)c1, O=C(N1CCC(CC1)N1CCCC1)c1ccc(C(=O)N2CCC(CC2)N2CCCC2)c(Nc2ccccc2)c1	PQOOIERVZAXHBP-UHFFFAOYSA-N, PQOOIERVZAXHBP-UHFFFAOYSA-N, PQOOIERVZAXHBP-UHFFFAOYSA-N	Preclinical
UNC1999	histone lysine methyltransferase inhibitor	EZH2			CCCc1cc(C)[nH]c(=O)c1CNC(=O)c1cc(cc2n(ncc12)C(C)C)-c1ccc(nc1)N1CCN(CC1)C(C)C, CCCc1cc(C)[nH]c(=O)c1CNC(=O)c1cc(cc2n(ncc12)C(C)C)-c1ccc(nc1)N1CCN(CC1)C(C)C, CCCc1cc(C)[nH]c(=O)c1CNC(=O)c1cc(cc2n(ncc12)C(C)C)-c1ccc(nc1)N1CCN(CC1)C(C)C, CCCc1cc(C)[nH]c(=O)c1CNC(=O)c1cc(cc2n(ncc12)C(C)C)-c1ccc(nc1)N1CCN(CC1)C(C)C, CCCc1cc(C)[nH]c(=O)c1CNC(=O)c1cc(cc2n(ncc12)C(C)C)-c1ccc(nc1)N1CCN(CC1)C(C)C, CCCc1cc(C)[nH]c(=O)c1CNC(=O)c1cc(cc2n(ncc12)C(C)C)-c1ccc(nc1)N1CCN(CC1)C(C)C, CCCc1cc(C)[nH]c(=O)c1CNC(=O)c1cc(cc2n(ncc12)C(C)C)-c1ccc(nc1)N1CCN(CC1)C(C)C	DPJNKUOXBZSZAI-UHFFFAOYSA-N, DPJNKUOXBZSZAI-UHFFFAOYSA-N, DPJNKUOXBZSZAI-UHFFFAOYSA-N, DPJNKUOXBZSZAI-UHFFFAOYSA-N, DPJNKUOXBZSZAI-UHFFFAOYSA-N, DPJNKUOXBZSZAI-UHFFFAOYSA-N, DPJNKUOXBZSZAI-UHFFFAOYSA-N	Preclinical
UNC2025	FLT3 inhibitor, MER tyrosine kinase inhibitor	FLT3, MERTK			CCCCNc1ncc2c(cn([C@H]3CC[C@H](O)CC3)c2n1)-c1ccc(CN2CCN(C)CC2)cc1 |r|, CCCCNc1ncc2c(cn([C@H]3CC[C@H](O)CC3)c2n1)-c1ccc(CN2CCN(C)CC2)cc1 |r|	MJSHVHLADKXCML-RQNOJGIXSA-N, MJSHVHLADKXCML-RQNOJGIXSA-N	Preclinical
UNC2250	MER tyrosine kinase inhibitor	MERTK			CCCCNc1ncc(c(N[C@H]2CC[C@H](O)CC2)n1)-c1ccc(CN2CCOCC2)cn1 |r|, CCCCNc1ncc(c(N[C@H]2CC[C@H](O)CC2)n1)-c1ccc(CN2CCOCC2)cn1 |r|, CCCCNc1ncc(c(N[C@H]2CC[C@H](O)CC2)n1)-c1ccc(CN2CCOCC2)cn1 |r|, CCCCNc1ncc(c(N[C@H]2CC[C@H](O)CC2)n1)-c1ccc(CN2CCOCC2)cn1 |r|	HSYSSKFCQHXOBP-MXVIHJGJSA-N, HSYSSKFCQHXOBP-MXVIHJGJSA-N, HSYSSKFCQHXOBP-MXVIHJGJSA-N, HSYSSKFCQHXOBP-MXVIHJGJSA-N	Preclinical
UNC2327	protein arginine N-methyltransferase inhibitor	PRMT3			O=C(NCC(=O)N1CCCCC1)Nc1ccc2nnsc2c1, O=C(NCC(=O)N1CCCCC1)Nc1ccc2nnsc2c1, O=C(NCC(=O)N1CCCCC1)Nc1ccc2nnsc2c1	MYTRGTBDVGKKRO-UHFFFAOYSA-N, MYTRGTBDVGKKRO-UHFFFAOYSA-N, MYTRGTBDVGKKRO-UHFFFAOYSA-N	Preclinical
UNC3230	phosphatidyl-inositol activator	PIP5K1C			NC(=O)c1nc(Nc2ccccc2)sc1NC(=O)C1CCCCC1, NC(=O)c1nc(Nc2ccccc2)sc1NC(=O)C1CCCCC1	RZCNASHHHSKTGP-UHFFFAOYSA-N, RZCNASHHHSKTGP-UHFFFAOYSA-N	Preclinical
UNC669	L3MBTL antagonist	L3MBTL1			Brc1cncc(c1)C(=O)N1CCC(CC1)N1CCCC1, Brc1cncc(c1)C(=O)N1CCC(CC1)N1CCCC1, Brc1cncc(c1)C(=O)N1CCC(CC1)N1CCCC1	CQERVFFAOOUFEQ-UHFFFAOYSA-N, CQERVFFAOOUFEQ-UHFFFAOYSA-N, CQERVFFAOOUFEQ-UHFFFAOYSA-N	Preclinical
UNC926	MBT inhibitor	L3MBTL1			Brc1cccc(c1)C(=O)N1CCC(CC1)N1CCCC1, Brc1cccc(c1)C(=O)N1CCC(CC1)N1CCCC1, Brc1cccc(c1)C(=O)N1CCC(CC1)N1CCCC1	OWGLFIKZKQOYHZ-UHFFFAOYSA-N, OWGLFIKZKQOYHZ-UHFFFAOYSA-N, OWGLFIKZKQOYHZ-UHFFFAOYSA-N	Preclinical
undecylenic-acid	other antifungal		infectious disease	tinea pedis, tinea corporis	OC(=O)CCCCCCCCC=C, OC(=O)CCCCCCCCC=C	FRPZMMHWLSIFAZ-UHFFFAOYSA-N, FRPZMMHWLSIFAZ-UHFFFAOYSA-N	Launched
upadacitinib	JAK inhibitor				CC[C@@H]1CN(C[C@@H]1c1cnc2cnc3[nH]ccc3n12)C(=O)NCC(F)(F)F	WYQFJHHDOKWSHR-MNOVXSKESA-N	Launched
upamostat	serine protease inhibitor				CCOC(=O)N1CCN(CC1)C(=O)[C@H](Cc1cccc(c1)C(=N)NO)NS(=O)(=O)c1c(cc(cc1C(C)C)C(C)C)C(C)C	HUASEDVYRABWCV-NDEPHWFRSA-N	Phase 2
UPF-1069	PARP inhibitor	PARP2			O=C(COc1cccc2c1cc[nH]c2=O)c1ccccc1, O=C(COc1cccc2c1cc[nH]c2=O)c1ccccc1, O=C(COc1cccc2c1cc[nH]c2=O)c1ccccc1, O=C(COc1cccc2c1cc[nH]c2=O)c1ccccc1, O=C(COc1cccc2c1cc[nH]c2=O)c1ccccc1	JJWMRRNGWSITSQ-UHFFFAOYSA-N, JJWMRRNGWSITSQ-UHFFFAOYSA-N, JJWMRRNGWSITSQ-UHFFFAOYSA-N, JJWMRRNGWSITSQ-UHFFFAOYSA-N, JJWMRRNGWSITSQ-UHFFFAOYSA-N	Preclinical
uprifosbuvir	antiviral				CC(C)OC(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@@H](n2ccc(=O)[nH]c2=O)[C@](C)(Cl)[C@@H]1O)Oc1ccccc1	SFPFZQKYPOWCSI-IQWMDFIBSA-N	Preclinical
uprosertib	AKT inhibitor	AKT1, AKT2, AKT3			Cn1ncc(Cl)c1-c1cc(oc1Cl)C(=O)N[C@H](CN)Cc1ccc(F)c(F)c1, Cn1ncc(Cl)c1-c1cc(oc1Cl)C(=O)N[C@H](CN)Cc1ccc(F)c(F)c1, Cn1ncc(Cl)c1-c1cc(oc1Cl)C(=O)N[C@H](CN)Cc1ccc(F)c(F)c1, Cn1ncc(Cl)c1-c1cc(oc1Cl)C(=O)N[C@H](CN)Cc1ccc(F)c(F)c1	AXTAPYRUEKNRBA-JTQLQIEISA-N, AXTAPYRUEKNRBA-JTQLQIEISA-N, AXTAPYRUEKNRBA-JTQLQIEISA-N, AXTAPYRUEKNRBA-JTQLQIEISA-N	Phase 2
uracil		DPYD, UCKL1			O=c1cc[nH]c(=O)[nH]1, O=c1cc[nH]c(=O)[nH]1, O=c1cc[nH]c(=O)[nH]1, O=c1cc[nH]c(=O)[nH]1	ISAKRJDGNUQOIC-UHFFFAOYSA-N, ISAKRJDGNUQOIC-UHFFFAOYSA-N, ISAKRJDGNUQOIC-UHFFFAOYSA-N, ISAKRJDGNUQOIC-UHFFFAOYSA-N	Launched
uracil-mustard	DNA synthesis inhibitor		hematologic malignancy	non-Hodgkin lymphoma (NHL)	ClCCN(CCCl)c1c[nH]c(=O)[nH]c1=O, ClCCN(CCCl)c1c[nH]c(=O)[nH]c1=O, ClCCN(CCCl)c1c[nH]c(=O)[nH]c1=O	IDPUKCWIGUEADI-UHFFFAOYSA-N, IDPUKCWIGUEADI-UHFFFAOYSA-N, IDPUKCWIGUEADI-UHFFFAOYSA-N	Launched
urapidil	adrenergic receptor antagonist	HTR1A	cardiology	hypertension	COc1ccccc1N1CCN(CCCNc2cc(=O)n(C)c(=O)n2C)CC1, COc1ccccc1N1CCN(CCCNc2cc(=O)n(C)c(=O)n2C)CC1, COc1ccccc1N1CCN(CCCNc2cc(=O)n(C)c(=O)n2C)CC1, COc1ccccc1N1CCN(CCCNc2cc(=O)n(C)c(=O)n2C)CC1, COc1ccccc1N1CCN(CCCNc2cc(=O)n(C)c(=O)n2C)CC1, COc1ccccc1N1CCN(CCCNc2cc(=O)n(C)c(=O)n2C)CC1	ICMGLRUYEQNHPF-UHFFFAOYSA-N, ICMGLRUYEQNHPF-UHFFFAOYSA-N, ICMGLRUYEQNHPF-UHFFFAOYSA-N, ICMGLRUYEQNHPF-UHFFFAOYSA-N, ICMGLRUYEQNHPF-UHFFFAOYSA-N, ICMGLRUYEQNHPF-UHFFFAOYSA-N	Launched
URB597	FAAH inhibitor	FAAH, FAAH2, TRPA1			NC(=O)c1cccc(c1)-c1cccc(OC(=O)NC2CCCCC2)c1, NC(=O)c1cccc(c1)-c1cccc(OC(=O)NC2CCCCC2)c1, NC(=O)c1cccc(c1)-c1cccc(OC(=O)NC2CCCCC2)c1, NC(=O)c1cccc(c1)-c1cccc(OC(=O)NC2CCCCC2)c1, NC(=O)c1cccc(c1)-c1cccc(OC(=O)NC2CCCCC2)c1, NC(=O)c1cccc(c1)-c1cccc(OC(=O)NC2CCCCC2)c1, NC(=O)c1cccc(c1)-c1cccc(OC(=O)NC2CCCCC2)c1	ROFVXGGUISEHAM-UHFFFAOYSA-N, ROFVXGGUISEHAM-UHFFFAOYSA-N, ROFVXGGUISEHAM-UHFFFAOYSA-N, ROFVXGGUISEHAM-UHFFFAOYSA-N, ROFVXGGUISEHAM-UHFFFAOYSA-N, ROFVXGGUISEHAM-UHFFFAOYSA-N, ROFVXGGUISEHAM-UHFFFAOYSA-N	Phase 1
urea	hydroxy radical formation stimulant	ARG1, CA2, CTNNB1	dermatology	psoriasis, xerosis cutis, ichthyosis vulgaris, eczema, keratosis, dermatitis	NC(N)=O, NC(N)=O, NC(N)=O	XSQUKJJJFZCRTK-UHFFFAOYSA-N, XSQUKJJJFZCRTK-UHFFFAOYSA-N, XSQUKJJJFZCRTK-UHFFFAOYSA-N	Launched
urethane	local anesthetic				CCOC(N)=O, CCOC(N)=O	JOYRKODLDBILNP-UHFFFAOYSA-N, JOYRKODLDBILNP-UHFFFAOYSA-N	Preclinical
uric-acid		PYGL			O=c1[nH]c2[nH]c(=O)[nH]c(=O)c2[nH]1	LEHOTFFKMJEONL-UHFFFAOYSA-N	Phase 3
uridine	dopamine receptor agonist	LSM6, TYMP			OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1ccc(=O)[nH]c1=O, OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1ccc(=O)[nH]c1=O, OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1ccc(=O)[nH]c1=O	DRTQHJPVMGBUCF-XVFCMESISA-N, DRTQHJPVMGBUCF-XVFCMESISA-N, DRTQHJPVMGBUCF-XVFCMESISA-N	Phase 2
uridine-triacetate			nephrology	orotic aciduria	CC(=O)OC[C@H]1O[C@H]([C@H](OC(C)=O)[C@@H]1OC(C)=O)n1ccc(=O)[nH]c1=O	AUFUWRKPQLGTGF-FMKGYKFTSA-N	Launched
uridine-5'-triphosphate	purinergic receptor activator	P2RY11, P2RY2, P2RY4, P2RY6, UCK2			O[C@@H]1[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O[C@H]([C@@H]1O)n1ccc(=O)[nH]c1=O |a:1,2,18,19,&1:5,&2:9|	PGAVKCOVUIYSFO-XVFCMESISA-N	Launched
URMC-099	mixed lineage kinase inhibitor	CDKL2, DAPK3, FLT3, LRRK2, MAP3K10, MAP3K11, MAP3K2, MAP3K9, SRPK2			CN1CCN(Cc2ccc(cc2)-c2cnc3[nH]cc(-c4ccc5[nH]ccc5c4)c3c2)CC1, CN1CCN(Cc2ccc(cc2)-c2cnc3[nH]cc(-c4ccc5[nH]ccc5c4)c3c2)CC1	QKKIWEILHCXECO-UHFFFAOYSA-N, QKKIWEILHCXECO-UHFFFAOYSA-N	Preclinical
urolithin-A	antioxidant				Oc1ccc2c(c1)oc(=O)c1cc(O)ccc21	RIUPLDUFZCXCHM-UHFFFAOYSA-N	Phase 3
ursodeoxycholyltaurine	cholesterol inhibitor				C[C@H](CCC(=O)NCCS(O)(=O)=O)[C@H]1CC[C@H]2[C@@H]3[C@@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C, C[C@H](CCC(=O)NCCS(O)(=O)=O)[C@H]1CC[C@H]2[C@@H]3[C@@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C, C[C@H](CCC(=O)NCCS(O)(=O)=O)[C@H]1CC[C@H]2[C@@H]3[C@@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C	BHTRKEVKTKCXOH-LBSADWJPSA-N, BHTRKEVKTKCXOH-LBSADWJPSA-N, BHTRKEVKTKCXOH-LBSADWJPSA-N	Phase 3
ursodiol	nuclear factor erythroid derived, like (NRF2) activator	AKR1C2, NR1H4	gastroenterology	gallstones	C[C@H](CCC(O)=O)[C@H]1CC[C@H]2[C@@H]3[C@@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C, C[C@H](CCC(O)=O)[C@H]1CC[C@H]2[C@@H]3[C@@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C	RUDATBOHQWOJDD-UZVSRGJWSA-N, RUDATBOHQWOJDD-UZVSRGJWSA-N	Launched
ursolic-acid	ATPase inhibitor, NFkB pathway inhibitor, STAT inhibitor	HSD11B1, PLA2G1B, PTPN1, PYGM			C[C@@H]1CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]2[C@H]1C)C(O)=O |c:9|, C[C@@H]1CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]2[C@H]1C)C(O)=O |c:9|, C[C@@H]1CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]2[C@H]1C)C(O)=O |c:9|, C[C@@H]1CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]2[C@H]1C)C(O)=O |c:9|, C[C@@H]1CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]2[C@H]1C)C(O)=O |c:9|	WCGUUGGRBIKTOS-GPOJBZKASA-N, WCGUUGGRBIKTOS-GPOJBZKASA-N, WCGUUGGRBIKTOS-GPOJBZKASA-N, WCGUUGGRBIKTOS-GPOJBZKASA-N, WCGUUGGRBIKTOS-GPOJBZKASA-N	Phase 2/Phase 3
usniacin-(+)	MAP kinase activator	PTPN1			CC(O)=C1C(=O)C=C2Oc3c(c(O)c(C)c(O)c3C(C)=O)[C@]2(C)C1=O |a:21,&1:3,t:6|, CC(O)=C1C(=O)C=C2Oc3c(c(O)c(C)c(O)c3C(C)=O)[C@@]2(C)C1=O |a:21,&1:3,t:6|, CC(O)=C1C(=O)C=C2Oc3c(c(O)c(C)c(O)c3C(C)=O)[C@@]2(C)C1=O |a:21,&1:3,t:6|	ZQHDVMCIDXEICF-GOSISDBHSA-N, ZQHDVMCIDXEICF-SFHVURJKSA-N, ZQHDVMCIDXEICF-SFHVURJKSA-N	Preclinical
V-51	adrenergic receptor antagonist				COc1cc(CN2CCN(CC2)c2ccc(F)cc2)cc(OC)c1OC, COc1cc(CN2CCN(CC2)c2ccc(F)cc2)cc(OC)c1OC	KKCOGNFFBYOKMA-UHFFFAOYSA-N, KKCOGNFFBYOKMA-UHFFFAOYSA-N	Phase 1
vaborbactam	beta lactamase inhibitor				OB1O[C@H](CC(O)=O)CC[C@@H]1NC(=O)Cc1cccs1	IOOWNWLVCOUUEX-WPRPVWTQSA-N	Launched
vadadustat	hypoxia inducible factor prolyl hydroxylase inhibitor				OC(=O)CNC(=O)c1ncc(cc1O)-c1cccc(Cl)c1	JGRXMPYUTJLTKT-UHFFFAOYSA-N	Phase 3
val-tyr	angiotensin converting enzyme inhibitor				CC(C)[C@H](N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(O)=O	VEYJKJORLPYVLO-RYUDHWBXSA-N	Preclinical
valaciclovir	DNA polymerase inhibitor		infectious disease	shingles, virus herpes simplex (HSV)	CC(C)[C@H](N)C(=O)OCCOCn1cnc2c1[nH]c(N)nc2=O, CC(C)[C@H](N)C(=O)OCCOCn1cnc2c1[nH]c(N)nc2=O, CC(C)[C@H](N)C(=O)OCCOCn1cnc2c1[nH]c(N)nc2=O	HDOVUKNUBWVHOX-QMMMGPOBSA-N, HDOVUKNUBWVHOX-QMMMGPOBSA-N, HDOVUKNUBWVHOX-QMMMGPOBSA-N	Launched
valbenazine	vesicular monoamine transporter inhibitor		neurology/psychiatry	dyskinesia	[H][C@]12C[C@@H](OC(=O)[C@@H](N)C(C)C)[C@H](CC(C)C)CN1CCc1cc(OC)c(OC)cc21	GEJDGVNQKABXKG-CFKGEZKQSA-N	Launched
valdecoxib	cyclooxygenase inhibitor	CA12, PTGS2			Cc1onc(c1-c1ccc(cc1)S(N)(=O)=O)-c1ccccc1, Cc1onc(c1-c1ccc(cc1)S(N)(=O)=O)-c1ccccc1, Cc1onc(c1-c1ccc(cc1)S(N)(=O)=O)-c1ccccc1	LNPDTQAFDNKSHK-UHFFFAOYSA-N, LNPDTQAFDNKSHK-UHFFFAOYSA-N, LNPDTQAFDNKSHK-UHFFFAOYSA-N	Withdrawn
valethamate	acetylcholine receptor antagonist	CHRM1, CHRM4, CHRM5	obstetrics/gynecology	labor induction	CC[C@@H](C)[C@@H](C(=O)OCC[N+](C)(CC)CC)c1ccccc1 |&1:2,&2:4|	UPPMZCXMQRVMME-SJLPKXTDSA-N	Launched
valganciclovir	DNA synthesis inhibitor		infectious disease	cytomegalovirus (CMV)	CC(C)[C@H](N)C(=O)OC[C@@H](CO)OCn1cnc2c1[nH]c(N)nc2=O |a:3,&1:9|	WPVFJKSGQUFQAP-BDAKNGLRSA-N	Launched
valnemulin	bacterial 50S ribosomal subunit inhibitor		infectious disease, gastroenterology	dysentry, colitis, pneumonia	CC(C)[C@@H](N)C(=O)NCC(C)(C)SCC(=O)O[C@@H]1C[C@@](C)(C=C)[C@@H](O)[C@H](C)[C@]23CCC(=O)[C@H]2[C@@]1(C)[C@H](C)CC3	LLYYNOVSVPBRGV-MVNKZKPCSA-N	Launched
valnoctamide	arachidonic acid acylation inhibitor, benzodiazepine receptor agonist		neurology/psychiatry	sleeplessness	CC[C@@H](C)[C@@H](CC)C(N)=O |&1:2,&2:4,r|	QRCJOCOSPZMDJY-RNFRBKRXSA-N	Launched
valproic-acid	benzodiazepine receptor agonist, HDAC inhibitor	ABAT, ACADSB, ALDH5A1, HDAC1, HDAC2, HDAC9, OGDH, SCN10A, SCN11A, SCN1A, SCN1B, SCN2A, SCN2B, SCN3A, SCN3B, SCN4A, SCN4B, SCN5A, SCN7A, SCN8A, SCN9A	neurology/psychiatry	epilepsy, seizures, seizures	CCCC(CCC)C(O)=O, CCCC(CCC)C(O)=O, CCCC(CCC)C(O)=O, CCCC(CCC)C(O)=O, CCCC(CCC)C(O)=O, CCCC(CCC)C(O)=O, CCCC(CCC)C(O)=O, CCCC(CCC)C(O)=O, CCCC(CCC)C(O)=O, CCCC(CCC)C(O)=O	NIJJYAXOARWZEE-UHFFFAOYSA-N, NIJJYAXOARWZEE-UHFFFAOYSA-N, NIJJYAXOARWZEE-UHFFFAOYSA-N, NIJJYAXOARWZEE-UHFFFAOYSA-N, NIJJYAXOARWZEE-UHFFFAOYSA-N, NIJJYAXOARWZEE-UHFFFAOYSA-N, NIJJYAXOARWZEE-UHFFFAOYSA-N, NIJJYAXOARWZEE-UHFFFAOYSA-N, NIJJYAXOARWZEE-UHFFFAOYSA-N, NIJJYAXOARWZEE-UHFFFAOYSA-N	Launched
valpromide	epoxide hydolase inhibitor		neurology/psychiatry	epilepsy	CCCC(CCC)C(N)=O	OMOMUFTZPTXCHP-UHFFFAOYSA-N	Launched
valrocemide					CCCC(CCC)C(=O)NCC(N)=O	RALGCAOVRLYSMA-UHFFFAOYSA-N	Phase 2
valrubicin	DNA inhibitor, topoisomerase inhibitor	TOP2A	oncology	bladder cancer	CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1, CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1, CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1, CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1	ZOCKGBMQLCSHFP-KQRAQHLDSA-N, ZOCKGBMQLCSHFP-KQRAQHLDSA-N, ZOCKGBMQLCSHFP-KQRAQHLDSA-N, ZOCKGBMQLCSHFP-KQRAQHLDSA-N	Launched
valsartan	angiotensin receptor antagonist	AGTR1	cardiology	hypertension, congestive heart failure, congestive heart failure	CCCCC(=O)N(Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1)[C@@H](C(C)C)C(O)=O, CCCCC(=O)N(Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1)[C@@H](C(C)C)C(O)=O, CCCCC(=O)N(Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1)[C@@H](C(C)C)C(O)=O, CCCCC(=O)N(Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1)[C@@H](C(C)C)C(O)=O, CCCCC(=O)N(Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1)[C@@H](C(C)C)C(O)=O, CCCCC(=O)N(Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1)[C@@H](C(C)C)C(O)=O, CCCCC(=O)N(Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1)[C@@H](C(C)C)C(O)=O, CCCCC(=O)N(Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1)[C@@H](C(C)C)C(O)=O	ACWBQPMHZXGDFX-QFIPXVFZSA-N, ACWBQPMHZXGDFX-QFIPXVFZSA-N, ACWBQPMHZXGDFX-QFIPXVFZSA-N, ACWBQPMHZXGDFX-QFIPXVFZSA-N, ACWBQPMHZXGDFX-QFIPXVFZSA-N, ACWBQPMHZXGDFX-QFIPXVFZSA-N, ACWBQPMHZXGDFX-QFIPXVFZSA-N, ACWBQPMHZXGDFX-QFIPXVFZSA-N	Launched
valspodar	P glycoprotein inhibitor	ABCB1			C\C=C\C[C@@H](C)C(=O)[C@@H]1N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C(=O)[C@@H](NC1=O)C(C)C)C(C)C, C\C=C\C[C@@H](C)C(=O)[C@@H]1N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C(=O)[C@@H](NC1=O)C(C)C)C(C)C, C\C=C\C[C@@H](C)C(=O)[C@@H]1N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C(=O)[C@@H](NC1=O)C(C)C)C(C)C	YJDYDFNKCBANTM-QCWCSKBGSA-N, YJDYDFNKCBANTM-QCWCSKBGSA-N, YJDYDFNKCBANTM-QCWCSKBGSA-N	Phase 3
vancomycin	bacterial cell wall synthesis inhibitor		infectious disease	endocarditis	CN[C@H](CC(C)C)C(=O)N[C@@H]1[C@H](O)c2ccc(Oc3cc4cc(Oc5ccc(cc5Cl)[C@@H](O)[C@@H]5NC(=O)[C@H](NC(=O)[C@@H]4NC(=O)[C@H](CC(N)=O)NC1=O)c1ccc(O)c(c1)-c1c(O)cc(O)cc1[C@H](NC5=O)C(O)=O)c3O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1)c(Cl)c2, CN[C@H](CC(C)C)C(=O)N[C@@H]1[C@H](O)c2ccc(Oc3cc4cc(Oc5ccc(cc5Cl)[C@@H](O)[C@@H]5NC(=O)[C@H](NC(=O)[C@@H]4NC(=O)[C@H](CC(N)=O)NC1=O)c1ccc(O)c(c1)-c1c(O)cc(O)cc1[C@H](NC5=O)C(O)=O)c3O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1)c(Cl)c2, CN[C@H](CC(C)C)C(=O)N[C@@H]1[C@H](O)c2ccc(Oc3cc4cc(Oc5ccc(cc5Cl)[C@@H](O)[C@@H]5NC(=O)[C@H](NC(=O)[C@@H]4NC(=O)[C@H](CC(N)=O)NC1=O)c1ccc(O)c(c1)-c1c(O)cc(O)cc1[C@H](NC5=O)C(O)=O)c3O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1)c(Cl)c2, CN[C@H](CC(C)C)C(=O)N[C@@H]1[C@H](O)c2ccc(Oc3cc4cc(Oc5ccc(cc5Cl)[C@@H](O)[C@@H]5NC(=O)[C@H](NC(=O)[C@@H]4NC(=O)[C@H](CC(N)=O)NC1=O)c1ccc(O)c(c1)-c1c(O)cc(O)cc1[C@H](NC5=O)C(O)=O)c3O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1)c(Cl)c2, CN[C@H](CC(C)C)C(=O)N[C@@H]1[C@H](O)c2ccc(Oc3cc4cc(Oc5ccc(cc5Cl)[C@@H](O)[C@@H]5NC(=O)[C@H](NC(=O)[C@@H]4NC(=O)[C@H](CC(N)=O)NC1=O)c1ccc(O)c(c1)-c1c(O)cc(O)cc1[C@H](NC5=O)C(O)=O)c3O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1)c(Cl)c2, CN[C@H](CC(C)C)C(=O)N[C@@H]1[C@H](O)c2ccc(Oc3cc4cc(Oc5ccc(cc5Cl)[C@@H](O)[C@@H]5NC(=O)[C@H](NC(=O)[C@@H]4NC(=O)[C@H](CC(N)=O)NC1=O)c1ccc(O)c(c1)-c1c(O)cc(O)cc1[C@H](NC5=O)C(O)=O)c3O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1)c(Cl)c2	MYPYJXKWCTUITO-LYRMYLQWSA-N, MYPYJXKWCTUITO-LYRMYLQWSA-N, MYPYJXKWCTUITO-LYRMYLQWSA-N, MYPYJXKWCTUITO-LYRMYLQWSA-N, MYPYJXKWCTUITO-LYRMYLQWSA-N, MYPYJXKWCTUITO-LYRMYLQWSA-N	Launched
vandetanib	EGFR inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor	EGFR, EPHA1, EPHA10, EPHA2, EPHA3, EPHA4, EPHA5, EPHA6, EPHA7, EPHA8, EPHB1, EPHB2, EPHB3, EPHB4, EPHB6, ERBB2, ERBB3, ERBB4, FLT1, FLT4, KDR, PTK6, RET, SRC, TEK, VEGFA	oncology	medullary thyroid cancer (MTC)	COc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCC1CCN(C)CC1, COc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCC1CCN(C)CC1, COc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCC1CCN(C)CC1, COc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCC1CCN(C)CC1, COc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCC1CCN(C)CC1, COc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCC1CCN(C)CC1, COc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCC1CCN(C)CC1, COc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCC1CCN(C)CC1	UHTHHESEBZOYNR-UHFFFAOYSA-N, UHTHHESEBZOYNR-UHFFFAOYSA-N, UHTHHESEBZOYNR-UHFFFAOYSA-N, UHTHHESEBZOYNR-UHFFFAOYSA-N, UHTHHESEBZOYNR-UHFFFAOYSA-N, UHTHHESEBZOYNR-UHFFFAOYSA-N, UHTHHESEBZOYNR-UHFFFAOYSA-N, UHTHHESEBZOYNR-UHFFFAOYSA-N	Launched
vanillin		ABAT, ALDH5A1			COc1cc(C=O)ccc1O, COc1cc(C=O)ccc1O, COc1cc(C=O)ccc1O	MWOOGOJBHIARFG-UHFFFAOYSA-N, MWOOGOJBHIARFG-UHFFFAOYSA-N, MWOOGOJBHIARFG-UHFFFAOYSA-N	Preclinical
vanillylacetone					COc1cc(CCC(C)=O)ccc1O, COc1cc(CCC(C)=O)ccc1O	OJYLAHXKWMRDGS-UHFFFAOYSA-N, OJYLAHXKWMRDGS-UHFFFAOYSA-N	Preclinical
vaniprevir	serine protease inhibitor				CC[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@H]2CN1C(=O)[C@@H](NC(=O)OCC(C)(C)CCCCc1cccc3CN(Cc13)C(=O)O2)C(C)(C)C)C(=O)NS(=O)(=O)C1CC1, CC[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@H]2CN1C(=O)[C@@H](NC(=O)OCC(C)(C)CCCCc1cccc3CN(Cc13)C(=O)O2)C(C)(C)C)C(=O)NS(=O)(=O)C1CC1	KUQWGLQLLVFLSM-ONAXAZCASA-N, KUQWGLQLLVFLSM-ONAXAZCASA-N	Phase 3
vanitiolide					COc1cc(ccc1O)C(=S)N1CCOCC1, COc1cc(ccc1O)C(=S)N1CCOCC1	WQYRHRAZNNRDIA-UHFFFAOYSA-N, WQYRHRAZNNRDIA-UHFFFAOYSA-N	Preclinical
vanoxerine	dopamine reuptake inhibitor	SLC6A3			Fc1ccc(cc1)C(OCCN1CCN(CCCc2ccccc2)CC1)c1ccc(F)cc1, Fc1ccc(cc1)C(OCCN1CCN(CCCc2ccccc2)CC1)c1ccc(F)cc1, Fc1ccc(cc1)C(OCCN1CCN(CCCc2ccccc2)CC1)c1ccc(F)cc1, Fc1ccc(cc1)C(OCCN1CCN(CCCc2ccccc2)CC1)c1ccc(F)cc1, Fc1ccc(cc1)C(OCCN1CCN(CCCc2ccccc2)CC1)c1ccc(F)cc1, Fc1ccc(cc1)C(OCCN1CCN(CCCc2ccccc2)CC1)c1ccc(F)cc1	NAUWTFJOPJWYOT-UHFFFAOYSA-N, NAUWTFJOPJWYOT-UHFFFAOYSA-N, NAUWTFJOPJWYOT-UHFFFAOYSA-N, NAUWTFJOPJWYOT-UHFFFAOYSA-N, NAUWTFJOPJWYOT-UHFFFAOYSA-N, NAUWTFJOPJWYOT-UHFFFAOYSA-N	Phase 3
vapendavir	antiviral				CCOc1noc2cc(OCCC3CCN(CC3)c3ccc(C)nn3)ccc12	DKSVBVKHUICELN-UHFFFAOYSA-N	Phase 2
vardenafil	phosphodiesterase inhibitor	PDE5A, PDE6G, PDE6H	urology	erectile dysfunction	CCCc1nc(C)c2n1[nH]c(nc2=O)-c1cc(ccc1OCC)S(=O)(=O)N1CCN(CC)CC1, CCCc1nc(C)c2n1[nH]c(nc2=O)-c1cc(ccc1OCC)S(=O)(=O)N1CCN(CC)CC1, CCCc1nc(C)c2n1[nH]c(nc2=O)-c1cc(ccc1OCC)S(=O)(=O)N1CCN(CC)CC1, CCCc1nc(C)c2n1[nH]c(nc2=O)-c1cc(ccc1OCC)S(=O)(=O)N1CCN(CC)CC1	SECKRCOLJRRGGV-UHFFFAOYSA-N, SECKRCOLJRRGGV-UHFFFAOYSA-N, SECKRCOLJRRGGV-UHFFFAOYSA-N, SECKRCOLJRRGGV-UHFFFAOYSA-N	Launched
varenicline	acetylcholine receptor agonist	CHRNA3, CHRNA4, CHRNA6, CHRNA7	neurology/psychiatry	smoking cessation	C1[C@H]2CNC[C@@H]1c1cc3nccnc3cc21 |&1:1,5|	JQSHBVHOMNKWFT-DTORHVGOSA-N	Launched
varespladib	secretory phospholipase inhibitor	PLA2G2A			CCc1c(C(=O)C(N)=O)c2c(OCC(O)=O)cccc2n1Cc1ccccc1	BHLXTPHDSZUFHR-UHFFFAOYSA-N	Phase 3
vasopressin	vasopressin receptor agonist	AVPR1A, AVPR1B, AVPR2, OXTR	gastroenterology	abdominal distension	N[C@H]1CSSC[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2ccc(O)cc2)NC1=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(N)=O	KBZOIRJILGZLEJ-PLCMWKKKSA-N	Launched
vatalanib	KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	EGFR, FLT1, FLT4, KDR, PDGFRB			Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1, Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1, Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1	YCOYDOIWSSHVCK-UHFFFAOYSA-N, YCOYDOIWSSHVCK-UHFFFAOYSA-N, YCOYDOIWSSHVCK-UHFFFAOYSA-N	Phase 3
vatinoxan	adrenergic receptor antagonist				[H][C@@]12C[C@@]3(CNC(=O)N3CCNS(C)(=O)=O)CCN1CCc1c2oc2ccccc12	GTBKISRCRQUFNL-OXJNMPFZSA-N	Preclinical
VBY-825	cathepsin inhibitor	CTSB, CTSL, CTSS			CC[C@H](NC(=O)[C@H](CS(=O)(=O)CC1CC1)N[C@@H](c1ccc(F)cc1)C(F)(F)F)C(=O)C(=O)NC1CC1, CC[C@H](NC(=O)[C@H](CS(=O)(=O)CC1CC1)N[C@@H](c1ccc(F)cc1)C(F)(F)F)C(=O)C(=O)NC1CC1, CC[C@H](NC(=O)[C@H](CS(=O)(=O)CC1CC1)N[C@@H](c1ccc(F)cc1)C(F)(F)F)C(=O)C(=O)NC1CC1, CC[C@H](NC(=O)[C@H](CS(=O)(=O)CC1CC1)N[C@@H](c1ccc(F)cc1)C(F)(F)F)C(=O)C(=O)NC1CC1	PPUXXDKQNAHHON-BJLQDIEVSA-N, PPUXXDKQNAHHON-BJLQDIEVSA-N, PPUXXDKQNAHHON-BJLQDIEVSA-N, PPUXXDKQNAHHON-BJLQDIEVSA-N	Preclinical
VCH-916	HCV inhibitor				CO[C@H]1CC[C@@H](CC1)N(C(=O)[C@H]1CC[C@H](C)CC1)c1cc(sc1C(O)=O)C1=CCCCC1 |r,t:29|, CO[C@H]1CC[C@@H](CC1)N(C(=O)[C@H]1CC[C@H](C)CC1)c1cc(sc1C(O)=O)C1=CCCCC1 |r,t:29|, CO[C@H]1CC[C@@H](CC1)N(C(=O)[C@H]1CC[C@H](C)CC1)c1cc(sc1C(O)=O)C1=CCCCC1 |r,t:29|	LNYKGELUODVSNS-YSXIEMCBSA-N, LNYKGELUODVSNS-YSXIEMCBSA-N, LNYKGELUODVSNS-YSXIEMCBSA-N	Phase 1
VE-821	ATR kinase inhibitor	ATR			CS(=O)(=O)c1ccc(cc1)-c1cnc(N)c(n1)C(=O)Nc1ccccc1, CS(=O)(=O)c1ccc(cc1)-c1cnc(N)c(n1)C(=O)Nc1ccccc1, CS(=O)(=O)c1ccc(cc1)-c1cnc(N)c(n1)C(=O)Nc1ccccc1, CS(=O)(=O)c1ccc(cc1)-c1cnc(N)c(n1)C(=O)Nc1ccccc1	DUIHHZKTCSNTGM-UHFFFAOYSA-N, DUIHHZKTCSNTGM-UHFFFAOYSA-N, DUIHHZKTCSNTGM-UHFFFAOYSA-N, DUIHHZKTCSNTGM-UHFFFAOYSA-N	Preclinical
VE-822	ATR kinase inhibitor	ATM, ATR, MTOR, PIK3CG			CNCc1ccc(cc1)-c1cc(on1)-c1nc(cnc1N)-c1ccc(cc1)S(=O)(=O)C(C)C, CNCc1ccc(cc1)-c1cc(on1)-c1nc(cnc1N)-c1ccc(cc1)S(=O)(=O)C(C)C, CNCc1ccc(cc1)-c1cc(on1)-c1nc(cnc1N)-c1ccc(cc1)S(=O)(=O)C(C)C, CNCc1ccc(cc1)-c1cc(on1)-c1nc(cnc1N)-c1ccc(cc1)S(=O)(=O)C(C)C, CNCc1ccc(cc1)-c1cc(on1)-c1nc(cnc1N)-c1ccc(cc1)S(=O)(=O)C(C)C, CNCc1ccc(cc1)-c1cc(on1)-c1nc(cnc1N)-c1ccc(cc1)S(=O)(=O)C(C)C, CNCc1ccc(cc1)-c1cc(on1)-c1nc(cnc1N)-c1ccc(cc1)S(=O)(=O)C(C)C, CNCc1ccc(cc1)-c1cc(on1)-c1nc(cnc1N)-c1ccc(cc1)S(=O)(=O)C(C)C	JZCWLJDSIRUGIN-UHFFFAOYSA-N, JZCWLJDSIRUGIN-UHFFFAOYSA-N, JZCWLJDSIRUGIN-UHFFFAOYSA-N, JZCWLJDSIRUGIN-UHFFFAOYSA-N, JZCWLJDSIRUGIN-UHFFFAOYSA-N, JZCWLJDSIRUGIN-UHFFFAOYSA-N, JZCWLJDSIRUGIN-UHFFFAOYSA-N, JZCWLJDSIRUGIN-UHFFFAOYSA-N	Phase 2
vecabrutinib	Bruton's tyrosine kinase (BTK) inhibitor				NC(=O)[C@H]1CCN(C[C@@H]1N1CCC[C@@H](Nc2cc(Cl)cc(c2)C(F)(F)F)C1=O)c1ncnc(N)c1F	QLRRJMOBVVGXEJ-XHSDSOJGSA-N	Phase 1/Phase 2
vecuronium	acetylcholine receptor antagonist	CHRNA2	neurology/psychiatry	muscle relaxant	CC(=O)O[C@H]1[C@H](C[C@H]2[C@@H]3CC[C@H]4C[C@H](OC(C)=O)[C@H](C[C@]4(C)[C@H]3CC[C@]12C)N1CCCCC1)[N+]1(C)CCCCC1, CC(=O)O[C@H]1[C@H](C[C@H]2[C@@H]3CC[C@H]4C[C@H](OC(C)=O)[C@H](C[C@]4(C)[C@H]3CC[C@]12C)N1CCCCC1)[N+]1(C)CCCCC1, CC(=O)O[C@H]1[C@H](C[C@H]2[C@@H]3CC[C@H]4C[C@H](OC(C)=O)[C@H](C[C@]4(C)[C@H]3CC[C@]12C)N1CCCCC1)[N+]1(C)CCCCC1	BGSZAXLLHYERSY-XQIGCQGXSA-N, BGSZAXLLHYERSY-XQIGCQGXSA-N, BGSZAXLLHYERSY-XQIGCQGXSA-N	Launched
vedaprofen	anti-inflammatory agent	PTGS2	neurology/psychiatry, endocrinology	pain relief, fever	C[C@H](C(O)=O)c1ccc(C2CCCCC2)c2ccccc12 |&1:1,r|	VZUGVMQFWFVFBX-ZDUSSCGKSA-N	Launched
velaresol					OC(=O)CCCCOc1cccc(O)c1C=O	NSUDGNLOXMLAEB-UHFFFAOYSA-N	Preclinical
veledimex	cytochrome P450 inhibitor				CCC[C@@H](N(NC(=O)c1cccc(OC)c1CC)C(=O)c1cc(C)cc(C)c1)C(C)(C)C	LZWZPGLVHLSWQX-XMMPIXPASA-N	Phase 2
veliflapon	leukotriene synthesis inhibitor	ALOX5AP			OC(=O)[C@H](C1CCCC1)c1ccc(OCc2ccc3ccccc3n2)cc1	ZEYYDOLCHFETHQ-JOCHJYFZSA-N	Phase 3
veliparib	PARP inhibitor	PARP1, PARP2			C[C@@]1(CCCN1)c1nc2cccc(C(N)=O)c2[nH]1	JNAHVYVRKWKWKQ-CYBMUJFWSA-N	Phase 3
velneperit	neuropeptide receptor antagonist	NPY5R			CC(C)(C)S(=O)(=O)N[C@H]1CC[C@@H](CC1)C(=O)Nc1ccc(cn1)C(F)(F)F |r|, CC(C)(C)S(=O)(=O)N[C@H]1CC[C@@H](CC1)C(=O)Nc1ccc(cn1)C(F)(F)F |r|	WGEWUYACXPEFPO-AULYBMBSSA-N, WGEWUYACXPEFPO-AULYBMBSSA-N	Phase 2
velpatasvir	antiviral		infectious disease	hepatitis C	COC[C@H]1C[C@H](N(C1)C(=O)[C@H](NC(=O)OC)c1ccccc1)c1nc(c[nH]1)-c1ccc-2c(COc3cc4c5nc([nH]c5ccc4cc-23)[C@@H]2CC[C@H](C)N2C(=O)[C@@H](NC(=O)OC)C(C)C)c1	FHCUMDQMBHQXKK-CDIODLITSA-N	Launched
vemurafenib	RAF inhibitor	BRAF, RAF1	oncology	melanoma	CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(cc23)-c2ccc(Cl)cc2)c1F, CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(cc23)-c2ccc(Cl)cc2)c1F, CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(cc23)-c2ccc(Cl)cc2)c1F, CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(cc23)-c2ccc(Cl)cc2)c1F, CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(cc23)-c2ccc(Cl)cc2)c1F, CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(cc23)-c2ccc(Cl)cc2)c1F, CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(cc23)-c2ccc(Cl)cc2)c1F, CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(cc23)-c2ccc(Cl)cc2)c1F, CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(cc23)-c2ccc(Cl)cc2)c1F, CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(cc23)-c2ccc(Cl)cc2)c1F, CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(cc23)-c2ccc(Cl)cc2)c1F	GPXBXXGIAQBQNI-UHFFFAOYSA-N, GPXBXXGIAQBQNI-UHFFFAOYSA-N, GPXBXXGIAQBQNI-UHFFFAOYSA-N, GPXBXXGIAQBQNI-UHFFFAOYSA-N, GPXBXXGIAQBQNI-UHFFFAOYSA-N, GPXBXXGIAQBQNI-UHFFFAOYSA-N, GPXBXXGIAQBQNI-UHFFFAOYSA-N, GPXBXXGIAQBQNI-UHFFFAOYSA-N, GPXBXXGIAQBQNI-UHFFFAOYSA-N, GPXBXXGIAQBQNI-UHFFFAOYSA-N, GPXBXXGIAQBQNI-UHFFFAOYSA-N	Launched
venetoclax	BCL inhibitor	BCL2	hematologic malignancy	chronic lymphocytic leukemia (CLL)	CC1(C)CCC(CN2CCN(CC2)c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c(c3)[N+]([O-])=O)c(Oc3cnc4[nH]ccc4c3)c2)=C(C1)c1ccc(Cl)cc1 |c:57|, CC1(C)CCC(CN2CCN(CC2)c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c(c3)[N+]([O-])=O)c(Oc3cnc4[nH]ccc4c3)c2)=C(C1)c1ccc(Cl)cc1 |c:57|, CC1(C)CCC(CN2CCN(CC2)c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c(c3)[N+]([O-])=O)c(Oc3cnc4[nH]ccc4c3)c2)=C(C1)c1ccc(Cl)cc1 |c:57|, CC1(C)CCC(CN2CCN(CC2)c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c(c3)[N+]([O-])=O)c(Oc3cnc4[nH]ccc4c3)c2)=C(C1)c1ccc(Cl)cc1 |c:57|, CC1(C)CCC(CN2CCN(CC2)c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c(c3)[N+]([O-])=O)c(Oc3cnc4[nH]ccc4c3)c2)=C(C1)c1ccc(Cl)cc1 |c:57|, CC1(C)CCC(CN2CCN(CC2)c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c(c3)[N+]([O-])=O)c(Oc3cnc4[nH]ccc4c3)c2)=C(C1)c1ccc(Cl)cc1 |c:57|, CC1(C)CCC(CN2CCN(CC2)c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c(c3)[N+]([O-])=O)c(Oc3cnc4[nH]ccc4c3)c2)=C(C1)c1ccc(Cl)cc1 |c:57|, CC1(C)CCC(CN2CCN(CC2)c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c(c3)[N+]([O-])=O)c(Oc3cnc4[nH]ccc4c3)c2)=C(C1)c1ccc(Cl)cc1 |c:57|, CC1(C)CCC(CN2CCN(CC2)c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c(c3)[N+]([O-])=O)c(Oc3cnc4[nH]ccc4c3)c2)=C(C1)c1ccc(Cl)cc1 |c:57|, CC1(C)CCC(CN2CCN(CC2)c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c(c3)[N+]([O-])=O)c(Oc3cnc4[nH]ccc4c3)c2)=C(C1)c1ccc(Cl)cc1 |c:57|, CC1(C)CCC(CN2CCN(CC2)c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c(c3)[N+]([O-])=O)c(Oc3cnc4[nH]ccc4c3)c2)=C(C1)c1ccc(Cl)cc1 |c:57|, CC1(C)CCC(CN2CCN(CC2)c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c(c3)[N+]([O-])=O)c(Oc3cnc4[nH]ccc4c3)c2)=C(C1)c1ccc(Cl)cc1 |c:57|	LQBVNQSMGBZMKD-UHFFFAOYSA-N, LQBVNQSMGBZMKD-UHFFFAOYSA-N, LQBVNQSMGBZMKD-UHFFFAOYSA-N, LQBVNQSMGBZMKD-UHFFFAOYSA-N, LQBVNQSMGBZMKD-UHFFFAOYSA-N, LQBVNQSMGBZMKD-UHFFFAOYSA-N, LQBVNQSMGBZMKD-UHFFFAOYSA-N, LQBVNQSMGBZMKD-UHFFFAOYSA-N, LQBVNQSMGBZMKD-UHFFFAOYSA-N, LQBVNQSMGBZMKD-UHFFFAOYSA-N, LQBVNQSMGBZMKD-UHFFFAOYSA-N, LQBVNQSMGBZMKD-UHFFFAOYSA-N	Launched
venlafaxine	adrenergic inhibitor, norepinephrine reuptake inhibitor, serotoninnorepinephrine reuptake inhibitor (SNRI)	SLC6A2, SLC6A4	neurology/psychiatry	depression, generalized anxiety disorder (GAD), panic disorders, social anxiety disorder	COc1ccc(cc1)[C@@H](CN(C)C)C1(O)CCCCC1 |&1:8|, COc1ccc(cc1)[C@@H](CN(C)C)C1(O)CCCCC1 |&1:8|, COc1ccc(cc1)[C@@H](CN(C)C)C1(O)CCCCC1 |&1:8|, COc1ccc(cc1)[C@@H](CN(C)C)C1(O)CCCCC1 |&1:8|	PNVNVHUZROJLTJ-MRXNPFEDSA-N, PNVNVHUZROJLTJ-MRXNPFEDSA-N, PNVNVHUZROJLTJ-MRXNPFEDSA-N, PNVNVHUZROJLTJ-MRXNPFEDSA-N	Launched
VER-155008	HSP inhibitor	HSPA1A			Nc1ncnc2n([C@@H]3O[C@H](COCc4ccc(cc4)C#N)[C@@H](O)[C@H]3O)c(NCc3ccc(Cl)c(Cl)c3)nc12, Nc1ncnc2n([C@@H]3O[C@H](COCc4ccc(cc4)C#N)[C@@H](O)[C@H]3O)c(NCc3ccc(Cl)c(Cl)c3)nc12, Nc1ncnc2n([C@@H]3O[C@H](COCc4ccc(cc4)C#N)[C@@H](O)[C@H]3O)c(NCc3ccc(Cl)c(Cl)c3)nc12, Nc1ncnc2n([C@@H]3O[C@H](COCc4ccc(cc4)C#N)[C@@H](O)[C@H]3O)c(NCc3ccc(Cl)c(Cl)c3)nc12, Nc1ncnc2n([C@@H]3O[C@H](COCc4ccc(cc4)C#N)[C@@H](O)[C@H]3O)c(NCc3ccc(Cl)c(Cl)c3)nc12, Nc1ncnc2n([C@@H]3O[C@H](COCc4ccc(cc4)C#N)[C@@H](O)[C@H]3O)c(NCc3ccc(Cl)c(Cl)c3)nc12, Nc1ncnc2n([C@@H]3O[C@H](COCc4ccc(cc4)C#N)[C@@H](O)[C@H]3O)c(NCc3ccc(Cl)c(Cl)c3)nc12, Nc1ncnc2n([C@@H]3O[C@H](COCc4ccc(cc4)C#N)[C@@H](O)[C@H]3O)c(NCc3ccc(Cl)c(Cl)c3)nc12, Nc1ncnc2n([C@@H]3O[C@H](COCc4ccc(cc4)C#N)[C@@H](O)[C@H]3O)c(NCc3ccc(Cl)c(Cl)c3)nc12, Nc1ncnc2n([C@@H]3O[C@H](COCc4ccc(cc4)C#N)[C@@H](O)[C@H]3O)c(NCc3ccc(Cl)c(Cl)c3)nc12, Nc1ncnc2n([C@@H]3O[C@H](COCc4ccc(cc4)C#N)[C@@H](O)[C@H]3O)c(NCc3ccc(Cl)c(Cl)c3)nc12, Nc1ncnc2n([C@@H]3O[C@H](COCc4ccc(cc4)C#N)[C@@H](O)[C@H]3O)c(NCc3ccc(Cl)c(Cl)c3)nc12	ZXGGCBQORXDVTE-UMCMBGNQSA-N, ZXGGCBQORXDVTE-UMCMBGNQSA-N, ZXGGCBQORXDVTE-UMCMBGNQSA-N, ZXGGCBQORXDVTE-UMCMBGNQSA-N, ZXGGCBQORXDVTE-UMCMBGNQSA-N, ZXGGCBQORXDVTE-UMCMBGNQSA-N, ZXGGCBQORXDVTE-UMCMBGNQSA-N, ZXGGCBQORXDVTE-UMCMBGNQSA-N, ZXGGCBQORXDVTE-UMCMBGNQSA-N, ZXGGCBQORXDVTE-UMCMBGNQSA-N, ZXGGCBQORXDVTE-UMCMBGNQSA-N, ZXGGCBQORXDVTE-UMCMBGNQSA-N	Preclinical
VER-49009	HSP inhibitor	HSP90AA1			CCNC(=O)c1[nH]nc(c1-c1ccc(OC)cc1)-c1cc(Cl)c(O)cc1O, CCNC(=O)c1[nH]nc(c1-c1ccc(OC)cc1)-c1cc(Cl)c(O)cc1O, CCNC(=O)c1[nH]nc(c1-c1ccc(OC)cc1)-c1cc(Cl)c(O)cc1O, CCNC(=O)c1[nH]nc(c1-c1ccc(OC)cc1)-c1cc(Cl)c(O)cc1O, CCNC(=O)c1[nH]nc(c1-c1ccc(OC)cc1)-c1cc(Cl)c(O)cc1O	HUNAOTXNHVALTN-UHFFFAOYSA-N, HUNAOTXNHVALTN-UHFFFAOYSA-N, HUNAOTXNHVALTN-UHFFFAOYSA-N, HUNAOTXNHVALTN-UHFFFAOYSA-N, HUNAOTXNHVALTN-UHFFFAOYSA-N	Preclinical
veralipride	dopamine receptor antagonist				COc1cc(cc(C(=O)NC[C@@H]2CCCN2CC=C)c1OC)S(N)(=O)=O |&1:11,r|	RYJXBGGBZJGVQF-LBPRGKRZSA-N	Preclinical
verapamil	calcium channel blocker	CACNA1A, CACNA1B, CACNA1C, CACNA1D, CACNA1F, CACNA1G, CACNA1I, CACNA1S, CACNB1, CACNB2, CACNB3, CACNB4, CYP3A4, KCNA10, KCNA7, KCNH2, KCNJ11, NALCN, SCN5A, SLC29A4, SLC6A4	cardiology	hypertension	COc1ccc(CCN(C)CCCC(C#N)(C(C)C)c2ccc(OC)c(OC)c2)cc1OC |&1:13|, COc1ccc(CCN(C)CCCC(C#N)(C(C)C)c2ccc(OC)c(OC)c2)cc1OC |&1:13|, COc1ccc(CCN(C)CCCC(C#N)(C(C)C)c2ccc(OC)c(OC)c2)cc1OC |&1:13|, COc1ccc(CCN(C)CCCC(C#N)(C(C)C)c2ccc(OC)c(OC)c2)cc1OC |&1:13|	SGTNSNPWRIOYBX-UHFFFAOYSA-N, SGTNSNPWRIOYBX-UHFFFAOYSA-N, SGTNSNPWRIOYBX-UHFFFAOYSA-N, SGTNSNPWRIOYBX-UHFFFAOYSA-N	Launched
verbascoside	NFkB pathway inhibitor, PKC inhibitor				C[C@@H]1O[C@@H](O[C@@H]2[C@@H](O)[C@H](OCCc3ccc(O)c(O)c3)O[C@H](CO)[C@H]2OC(=O)\C=C\c2ccc(O)c(O)c2)[C@H](O)[C@H](O)[C@H]1O, C[C@@H]1O[C@@H](O[C@@H]2[C@@H](O)[C@H](OCCc3ccc(O)c(O)c3)O[C@H](CO)[C@H]2OC(=O)\C=C\c2ccc(O)c(O)c2)[C@H](O)[C@H](O)[C@H]1O	FBSKJMQYURKNSU-ZLSOWSIRSA-N, FBSKJMQYURKNSU-ZLSOWSIRSA-N	Phase 2/Phase 3
vercirnon	CC chemokine receptor antagonist	CCR9			CC(C)(C)c1ccc(cc1)S(=O)(=O)Nc1ccc(Cl)cc1C(=O)c1cc[n+]([O-])cc1, CC(C)(C)c1ccc(cc1)S(=O)(=O)Nc1ccc(Cl)cc1C(=O)c1cc[n+]([O-])cc1	JRWROCIMSDXGOZ-UHFFFAOYSA-N, JRWROCIMSDXGOZ-UHFFFAOYSA-N	Phase 3
verdinexor	exportin antagonist				FC(F)(F)c1cc(cc(c1)C(F)(F)F)-c1ncn(\C=C/C(=O)NNc2ccccn2)n1	OPAKEJZFFCECPN-XQRVVYSFSA-N	Preclinical
verdiperstat	myeloperoxidase inhibitor				CC(C)OCCn1c2cc[nH]c2c(=O)[nH]c1=S	FVJCUZCRPIMVLB-UHFFFAOYSA-N	Phase 3
vericiguat	guanylate cyclase stimulant				COC(=O)Nc1c(N)nc(nc1N)-c1nn(Cc2ccccc2F)c2ncc(F)cc12	QZFHIXARHDBPBY-UHFFFAOYSA-N	Phase 3
verinurad	urate transporter inhibitor	SLC22A12			CC(C)(Sc1ccncc1-c1ccc(C#N)c2ccccc12)C(O)=O	YYBOLPLTQDKXPM-UHFFFAOYSA-N	Phase 2
vernakalant	potassium channel blocker	KCNA5	cardiology	atrial fibrillation (AF)	COc1ccc(CCO[C@@H]2CCCC[C@H]2N2CC[C@@H](O)C2)cc1OC, COc1ccc(CCO[C@@H]2CCCC[C@H]2N2CC[C@@H](O)C2)cc1OC, COc1ccc(CCO[C@@H]2CCCC[C@H]2N2CC[C@@H](O)C2)cc1OC, COc1ccc(CCO[C@@H]2CCCC[C@H]2N2CC[C@@H](O)C2)cc1OC	VBHQKCBVWWUUKN-KZNAEPCWSA-N, VBHQKCBVWWUUKN-KZNAEPCWSA-N, VBHQKCBVWWUUKN-KZNAEPCWSA-N, VBHQKCBVWWUUKN-KZNAEPCWSA-N	Launched
verteporfin	photosensitizing agent		ophthalmology	macular degeneration	COC(=O)CCc1c(C)c2cc3[nH]c(cc4nc(cc5nc(cc1[nH]2)c(CCC(O)=O)c5C)c(C=C)c4C)C1=CC=C([C@@H](C(=O)OC)[C@@]31C)C(=O)OC |c:44,t:42|, COC(=O)CCc1c(C)c2cc3[nH]c(cc4nc(cc5nc(cc1[nH]2)c(CCC(O)=O)c5C)c(C=C)c4C)C1=CC=C([C@@H](C(=O)OC)[C@@]31C)C(=O)OC |c:44,t:42|, COC(=O)CCc1c(C)c2cc3[nH]c(cc4nc(cc5nc(cc1[nH]2)c(CCC(O)=O)c5C)c(C=C)c4C)C1=CC=C([C@@H](C(=O)OC)[C@@]31C)C(=O)OC |c:44,t:42|, COC(=O)CCc1c(C)c2cc3[nH]c(cc4nc(cc5nc(cc1[nH]2)c(CCC(O)=O)c5C)c(C=C)c4C)C1=CC=C([C@@H](C(=O)OC)[C@@]31C)C(=O)OC |c:44,t:42|, COC(=O)CCc1c(C)c2cc3[nH]c(cc4nc(cc5nc(cc1[nH]2)c(CCC(O)=O)c5C)c(C=C)c4C)C1=CC=C([C@@H](C(=O)OC)[C@@]31C)C(=O)OC |c:44,t:42|, COC(=O)CCc1c(C)c2cc3[nH]c(cc4nc(cc5nc(cc1[nH]2)c(CCC(O)=O)c5C)c(C=C)c4C)C1=CC=C([C@@H](C(=O)OC)[C@@]31C)C(=O)OC |c:44,t:42|, COC(=O)CCc1c(C)c2cc3[nH]c(cc4nc(cc5nc(cc1[nH]2)c(CCC(O)=O)c5C)c(C=C)c4C)C1=CC=C([C@@H](C(=O)OC)[C@@]31C)C(=O)OC |c:44,t:42|	VLGTZPSSBIXGAI-SUPIZNKRSA-N, VLGTZPSSBIXGAI-SUPIZNKRSA-N, VLGTZPSSBIXGAI-SUPIZNKRSA-N, VLGTZPSSBIXGAI-SUPIZNKRSA-N, VLGTZPSSBIXGAI-SUPIZNKRSA-N, VLGTZPSSBIXGAI-SUPIZNKRSA-N, VLGTZPSSBIXGAI-SUPIZNKRSA-N	Launched
verubecestat	beta secretase inhibitor				CN1C(N)=N[C@@](C)(CS1(=O)=O)c1cc(NC(=O)c2ccc(F)cn2)ccc1F |c:3|	YHYKUSGACIYRML-KRWDZBQOSA-N	Phase 3
verubulin	tubulin polymerization inhibitor	TUBB			COc1ccc(cc1)N(C)c1nc(C)nc2ccccc12, COc1ccc(cc1)N(C)c1nc(C)nc2ccccc12, COc1ccc(cc1)N(C)c1nc(C)nc2ccccc12, COc1ccc(cc1)N(C)c1nc(C)nc2ccccc12	SNHCRNMVYDHVDT-UHFFFAOYSA-N, SNHCRNMVYDHVDT-UHFFFAOYSA-N, SNHCRNMVYDHVDT-UHFFFAOYSA-N, SNHCRNMVYDHVDT-UHFFFAOYSA-N	Phase 2
verucerfont	corticotropin releasing factor receptor antagonist				CC[C@H](Nc1cc(C)nc2c(c(C)nn12)-c1ccc(OC)cc1C)c1nc(C)no1	VKHVAUKFLBBZFJ-SFHVURJKSA-N	Phase 2
vesamicol	acetylcholinesterase inhibitor	SLC18A3			O[C@@H]1CCCC[C@H]1N1CCC(CC1)c1ccccc1, O[C@@H]1CCCC[C@H]1N1CCC(CC1)c1ccccc1, O[C@@H]1CCCC[C@H]1N1CCC(CC1)c1ccccc1, O[C@@H]1CCCC[C@H]1N1CCC(CC1)c1ccccc1, O[C@@H]1CCCC[C@H]1N1CCC(CC1)c1ccccc1	YSSBJODGIYRAMI-IAGOWNOFSA-N, YSSBJODGIYRAMI-IAGOWNOFSA-N, YSSBJODGIYRAMI-IAGOWNOFSA-N, YSSBJODGIYRAMI-IAGOWNOFSA-N, YSSBJODGIYRAMI-IAGOWNOFSA-N	Preclinical
vesnarinone	phosphodiesterase inhibitor	KCNH2, PDE3A	cardiology	congestive heart failure	COc1ccc(cc1OC)C(=O)N1CCN(CC1)c1ccc2NC(=O)CCc2c1, COc1ccc(cc1OC)C(=O)N1CCN(CC1)c1ccc2NC(=O)CCc2c1, COc1ccc(cc1OC)C(=O)N1CCN(CC1)c1ccc2NC(=O)CCc2c1	ZVNYJIZDIRKMBF-UHFFFAOYSA-N, ZVNYJIZDIRKMBF-UHFFFAOYSA-N, ZVNYJIZDIRKMBF-UHFFFAOYSA-N	Launched
VGX-1027	tumor necrosis factor receptor antagonist	TLR4			OC(=O)C[C@H]1CC(=NO1)c1ccccc1 |&1:4,r,c:6|, OC(=O)C[C@H]1CC(=NO1)c1ccccc1 |&1:4,r,c:6|, OC(=O)C[C@H]1CC(=NO1)c1ccccc1 |&1:4,r,c:6|	MUFJHYRCIHHATF-SECBINFHSA-N, MUFJHYRCIHHATF-SECBINFHSA-N, MUFJHYRCIHHATF-SECBINFHSA-N	Phase 1
vicriviroc	CC chemokine receptor antagonist	CCR5			COC[C@H](N1CCN(C[C@@H]1C)C1(C)CCN(CC1)C(=O)c1c(C)ncnc1C)c1ccc(cc1)C(F)(F)F, COC[C@H](N1CCN(C[C@@H]1C)C1(C)CCN(CC1)C(=O)c1c(C)ncnc1C)c1ccc(cc1)C(F)(F)F, COC[C@H](N1CCN(C[C@@H]1C)C1(C)CCN(CC1)C(=O)c1c(C)ncnc1C)c1ccc(cc1)C(F)(F)F	CNPVJJQCETWNEU-CYFREDJKSA-N, CNPVJJQCETWNEU-CYFREDJKSA-N, CNPVJJQCETWNEU-CYFREDJKSA-N	Phase 3
vidarabine	antiviral	ADA	infectious disease	virus herpes simplex (HSV), varicella-zoster virus (VZV)	Nc1ncnc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O, Nc1ncnc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O	OIRDTQYFTABQOQ-UHTZMRCNSA-N, OIRDTQYFTABQOQ-UHTZMRCNSA-N	Launched
vigabatrin	GABA aminotransferase inhibitor	ABAT, SLC32A1	neurology/psychiatry	seizures, spasms	N[C@@H](CCC(O)=O)C=C |&1:1|, N[C@@H](CCC(O)=O)C=C |&1:1|	PJDFLNIOAUIZSL-RXMQYKEDSA-N, PJDFLNIOAUIZSL-RXMQYKEDSA-N	Launched
vilanterol	adrenergic receptor agonist	ADRB2	pulmonary	chronic obstructive pulmonary disease (COPD)			Launched
vilazodone	serotonin reuptake inhibitor	DRD2, DRD3, HRH1, HTR1A, HTR4, SLC6A4	neurology/psychiatry	depression	NC(=O)c1cc2cc(ccc2o1)N1CCN(CCCCc2c[nH]c3ccc(cc23)C#N)CC1, NC(=O)c1cc2cc(ccc2o1)N1CCN(CCCCc2c[nH]c3ccc(cc23)C#N)CC1, NC(=O)c1cc2cc(ccc2o1)N1CCN(CCCCc2c[nH]c3ccc(cc23)C#N)CC1, NC(=O)c1cc2cc(ccc2o1)N1CCN(CCCCc2c[nH]c3ccc(cc23)C#N)CC1, NC(=O)c1cc2cc(ccc2o1)N1CCN(CCCCc2c[nH]c3ccc(cc23)C#N)CC1	SGEGOXDYSFKCPT-UHFFFAOYSA-N, SGEGOXDYSFKCPT-UHFFFAOYSA-N, SGEGOXDYSFKCPT-UHFFFAOYSA-N, SGEGOXDYSFKCPT-UHFFFAOYSA-N, SGEGOXDYSFKCPT-UHFFFAOYSA-N	Launched
vildagliptin	dipeptidyl peptidase inhibitor	DPP4	endocrinology	diabetes mellitus	O[C@]12C[C@@H]3C[C@H](C1)C[C@@](C3)(C2)NCC(=O)N1CCC[C@H]1C#N	SYOKIDBDQMKNDQ-NHMCJKAESA-N	Launched
viloxazine	norepinephrine reuptake inhibitor	SLC6A2	neurology/psychiatry	depression	CCOc1ccccc1OC[C@H]1CNCCO1 |&1:11|, CCOc1ccccc1OC[C@H]1CNCCO1 |&1:11|, CCOc1ccccc1OC[C@H]1CNCCO1 |&1:11|	YWPHCCPCQOJSGZ-LLVKDONJSA-N, YWPHCCPCQOJSGZ-LLVKDONJSA-N, YWPHCCPCQOJSGZ-LLVKDONJSA-N	Launched
vinblastine	microtubule inhibitor, tubulin polymerization inhibitor	JUN, TUBA1A, TUBB, TUBD1, TUBE1, TUBG1	hematologic malignancy, infectious disease, oncology	Hodgkin's lymphoma, true histiocytic lymphoma (THL), mycosis, small lymphocytic lymphoma (SLL), testicular carcinoma, Kaposi sarcoma	CC[C@]1(O)C[C@@H]2C[N@](C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC |c:48|, CC[C@]1(O)C[C@@H]2C[N@](C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC |c:48|, CC[C@]1(O)C[C@@H]2C[N@](C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC |c:48|, CC[C@]1(O)C[C@@H]2C[N@](C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC |c:48|, CC[C@]1(O)C[C@@H]2C[N@](C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC |c:48|, CC[C@]1(O)C[C@@H]2C[N@](C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC |c:48|, CC[C@]1(O)C[C@@H]2C[N@](C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC |c:48|, CC[C@]1(O)C[C@@H]2C[N@](C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC |c:48|, CC[C@]1(O)C[C@@H]2C[N@](C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC |c:48|, CC[C@]1(O)C[C@@H]2C[N@](C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC |c:48|, CC[C@]1(O)C[C@@H]2C[N@](C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC |c:48|	JXLYSJRDGCGARV-CFWMRBGOSA-N, JXLYSJRDGCGARV-CFWMRBGOSA-N, JXLYSJRDGCGARV-CFWMRBGOSA-N, JXLYSJRDGCGARV-CFWMRBGOSA-N, JXLYSJRDGCGARV-CFWMRBGOSA-N, JXLYSJRDGCGARV-CFWMRBGOSA-N, JXLYSJRDGCGARV-CFWMRBGOSA-N, JXLYSJRDGCGARV-CFWMRBGOSA-N, JXLYSJRDGCGARV-CFWMRBGOSA-N, JXLYSJRDGCGARV-CFWMRBGOSA-N, JXLYSJRDGCGARV-CFWMRBGOSA-N	Launched
vinburnine	adrenergic receptor antagonist	CHRM1, CHRM2, CHRM3, CHRM4	neurology/psychiatry	stroke	CC[C@@]12CCCN3CCc4c([C@H]13)n(C(=O)C2)c1ccccc41, CC[C@@]12CCCN3CCc4c([C@H]13)n(C(=O)C2)c1ccccc41	WYJAPUKIYAZSEM-MOPGFXCFSA-N, WYJAPUKIYAZSEM-MOPGFXCFSA-N	Launched
vincamine	adrenergic receptor antagonist	CHRM1, CHRM2, CHRM3, CHRM4			CC[C@@]12CCCN3CCc4c([C@H]13)n(c1ccccc41)[C@](O)(C2)C(=O)OC	RXPRRQLKFXBCSJ-GIVPXCGWSA-N	Withdrawn
vincristine	tubulin polymerization inhibitor	TUBA4A, TUBB	hematologic malignancy	acute lymphoblastic leukemia (ALL)	CC[C@]1(O)C[C@@H]2C[N@](C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C=O)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC |c:49|, CC[C@]1(O)C[C@@H]2C[N@](C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C=O)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC |c:49|, CC[C@]1(O)C[C@@H]2C[N@](C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C=O)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC |c:49|, CC[C@]1(O)C[C@@H]2C[N@](C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C=O)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC |c:49|, CC[C@]1(O)C[C@@H]2C[N@](C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C=O)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC |c:49|, CC[C@]1(O)C[C@@H]2C[N@](C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C=O)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC |c:49|, CC[C@]1(O)C[C@@H]2C[N@](C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C=O)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC |c:49|	OGWKCGZFUXNPDA-CFWMRBGOSA-N, OGWKCGZFUXNPDA-CFWMRBGOSA-N, OGWKCGZFUXNPDA-CFWMRBGOSA-N, OGWKCGZFUXNPDA-CFWMRBGOSA-N, OGWKCGZFUXNPDA-CFWMRBGOSA-N, OGWKCGZFUXNPDA-CFWMRBGOSA-N, OGWKCGZFUXNPDA-CFWMRBGOSA-N	Launched
vindesine	tubulin polymerization inhibitor	TUBB, TUBB1	oncology	breast cancer, non-small cell lung cancer (NSCLC), melanoma	CC[C@]1(O)C[C@H]2CN(C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](O)[C@]1(O)C(N)=O |c:48|, CC[C@]1(O)C[C@H]2CN(C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](O)[C@]1(O)C(N)=O |c:48|, CC[C@]1(O)C[C@H]2CN(C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](O)[C@]1(O)C(N)=O |c:48|, CC[C@]1(O)C[C@H]2CN(C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](O)[C@]1(O)C(N)=O |c:48|	HHJUWIANJFBDHT-KOTLKJBCSA-N, HHJUWIANJFBDHT-KOTLKJBCSA-N, HHJUWIANJFBDHT-KOTLKJBCSA-N, HHJUWIANJFBDHT-KOTLKJBCSA-N	Launched
vinflunine	microtubule inhibitor		oncology	bladder cancer	CC[C@@]12C=CCN3CC[C@@]4([C@H]13)[C@@H](N(C)c1cc(OC)c(cc41)[C@]1(C[C@@H]3C[C@H](C[N@@](C3)CCc3c1[nH]c1ccccc31)C(C)(F)F)C(=O)OC)[C@](O)([C@@H]2OC(C)=O)C(=O)OC |c:3|, CC[C@@]12C=CCN3CC[C@@]4([C@H]13)[C@@H](N(C)c1cc(OC)c(cc41)[C@]1(C[C@@H]3C[C@H](C[N@@](C3)CCc3c1[nH]c1ccccc31)C(C)(F)F)C(=O)OC)[C@](O)([C@@H]2OC(C)=O)C(=O)OC |c:3|, CC[C@@]12C=CCN3CC[C@@]4([C@H]13)[C@@H](N(C)c1cc(OC)c(cc41)[C@]1(C[C@@H]3C[C@H](C[N@@](C3)CCc3c1[nH]c1ccccc31)C(C)(F)F)C(=O)OC)[C@](O)([C@@H]2OC(C)=O)C(=O)OC |c:3|, CC[C@@]12C=CCN3CC[C@@]4([C@H]13)[C@@H](N(C)c1cc(OC)c(cc41)[C@]1(C[C@@H]3C[C@H](C[N@@](C3)CCc3c1[nH]c1ccccc31)C(C)(F)F)C(=O)OC)[C@](O)([C@@H]2OC(C)=O)C(=O)OC |c:3|	NOSAJPUYIASWEH-USRBKURZSA-N, NOSAJPUYIASWEH-USRBKURZSA-N, NOSAJPUYIASWEH-USRBKURZSA-N, NOSAJPUYIASWEH-USRBKURZSA-N	Launched
vinorelbine	tubulin polymerization inhibitor	TUBA1A, TUBA1B, TUBA1C, TUBA3C, TUBA3D, TUBA3E, TUBA4A, TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8	oncology	non-small cell lung cancer (NSCLC)	CCC1=C[C@@H]2C[N@](C1)Cc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC |c:46,t:2|, CCC1=C[C@@H]2C[N@](C1)Cc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC |c:46,t:2|	GBABOYUKABKIAF-IELIFDKJSA-N, GBABOYUKABKIAF-IELIFDKJSA-N	Launched
vinpocetine	phosphodiesterase inhibitor, sodium channel blocker	PDE1A, PDE1C	neurology/psychiatry	stroke, senile dementia	CCOC(=O)C1=C[C@]2(CC)CCCN3CCc4c([C@H]23)n1c1ccccc41 |t:5|, CCOC(=O)C1=C[C@]2(CC)CCCN3CCc4c([C@H]23)n1c1ccccc41 |t:5|, CCOC(=O)C1=C[C@]2(CC)CCCN3CCc4c([C@H]23)n1c1ccccc41 |t:5|, CCOC(=O)C1=C[C@]2(CC)CCCN3CCc4c([C@H]23)n1c1ccccc41 |t:5|, CCOC(=O)C1=C[C@]2(CC)CCCN3CCc4c([C@H]23)n1c1ccccc41 |t:5|	DDNCQMVWWZOMLN-IRLDBZIGSA-N, DDNCQMVWWZOMLN-IRLDBZIGSA-N, DDNCQMVWWZOMLN-IRLDBZIGSA-N, DDNCQMVWWZOMLN-IRLDBZIGSA-N, DDNCQMVWWZOMLN-IRLDBZIGSA-N	Launched
viomycin	protein synthesis inhibitor		infectious disease	tuberculosis	NCCC[C@H](N)CC(=O)N[C@H]1CNC(=O)[C@@H](NC(=O)C(NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC1=O)C=NC(N)=O)[C@H]1C[C@H](O)N=C(N)N1 |a:4,10,15,23,29,42,&1:40,&2:35,w:35.35,t:45|	NSWGELWYFNCPHU-RWOORDGESA-N	Launched
vipadenant	adenosine receptor antagonist	ADORA1, ADORA2A, ADORA2B, ADORA3			Cc1cc(Cn2nnc3c(nc(N)nc23)-c2ccco2)ccc1N, Cc1cc(Cn2nnc3c(nc(N)nc23)-c2ccco2)ccc1N, Cc1cc(Cn2nnc3c(nc(N)nc23)-c2ccco2)ccc1N, Cc1cc(Cn2nnc3c(nc(N)nc23)-c2ccco2)ccc1N	HQSBCDPYXDGTCL-UHFFFAOYSA-N, HQSBCDPYXDGTCL-UHFFFAOYSA-N, HQSBCDPYXDGTCL-UHFFFAOYSA-N, HQSBCDPYXDGTCL-UHFFFAOYSA-N	Phase 1
vismodegib	hedgehog pathway inhibitor, smoothened receptor antagonist	SMO	oncology	basal cell carcinoma (BCC)	CS(=O)(=O)c1ccc(C(=O)Nc2ccc(Cl)c(c2)-c2ccccn2)c(Cl)c1, CS(=O)(=O)c1ccc(C(=O)Nc2ccc(Cl)c(c2)-c2ccccn2)c(Cl)c1, CS(=O)(=O)c1ccc(C(=O)Nc2ccc(Cl)c(c2)-c2ccccn2)c(Cl)c1, CS(=O)(=O)c1ccc(C(=O)Nc2ccc(Cl)c(c2)-c2ccccn2)c(Cl)c1	BPQMGSKTAYIVFO-UHFFFAOYSA-N, BPQMGSKTAYIVFO-UHFFFAOYSA-N, BPQMGSKTAYIVFO-UHFFFAOYSA-N, InChI=1S/C19H14Cl2N2O3S/c1-27(25,26)13-6-7-14(17(21)11-13)19(24)23-12-5-8-16(20)15(10-12)18-4-2-3-9-22-18/h2-11H,1H3,(H,23,24)	Launched
visomitin	antioxidant				CC1=C(C)C(=O)C(CCCCCCCCCC[P+](c2ccccc2)(c2ccccc2)c2ccccc2)=CC1=O |c:1,38|, CC1=C(C)C(=O)C(CCCCCCCCCC[P+](c2ccccc2)(c2ccccc2)c2ccccc2)=CC1=O |c:1,38|	ZFUDULLGKXSPPH-UHFFFAOYSA-N, ZFUDULLGKXSPPH-UHFFFAOYSA-N	Preclinical
vitamin-B12			hematology	megaloblastic anemia	C[C@H](CNC(=O)CC[C@]1(C)[C@@H](CC(N)=O)[C@H]2N=C1\C(C)=C1/N=C(/C=C3\N=C(\C(\C)=C4\[C@@H](CCC(N)=O)[C@](C)(CC(N)=O)[C@@]2(C)N4[Co+]C#N)[C@@](C)(CC(N)=O)[C@@H]3CCC(N)=O)C(C)(C)[C@@H]1CCC(N)=O)OP(O)(=O)O[C@@H]1[C@@H](CO)O[C@@H]([C@@H]1O)n1cnc2cc(C)c(C)cc12 |c:16,20,24,t:22,26,29|	RMRCNWBMXRMIRW-WZHZPDAFSA-M	Launched
vitamin-E	LDL oxidation inhibitor, PKC inhibitor	ALOX5, DGKA, NR1I2, PPP2CA, PPP2CB, PRKCA, PRKCB, SEC14L2, SEC14L3, SEC14L4			CC(C)CCC[C@@H](C)CCC[C@@H](C)CCC[C@]1(C)CCc2c(C)c(O)c(C)c(C)c2O1	GVJHHUAWPYXKBD-IEOSBIPESA-N	Launched
vixotrigine	sodium channel blocker				NC(=O)[C@@H]1CC[C@@H](N1)c1ccc(OCc2ccccc2F)cc1	JESCETIFNOFKEU-SJORKVTESA-N	Phase 2
VLX1570	deubiquitinase inhibitor				[O-][N+](=O)c1cc(\C=C2/CCN(C\C(=C/c3ccc(F)c(c3)[N+]([O-])=O)C2=O)C(=O)C=C)ccc1F	SCKXBVLYWLLALY-CZCYGEDCSA-N	Phase 1/Phase 2
VLX600	antitumor agent, ubiquitin C-terminal hydrolase inhibitor	TP53, USP14			CC(=NNc1nnc2c(n1)[nH]c1c(C)cccc21)c1ccccn1, CC(=NNc1nnc2c(n1)[nH]c1c(C)cccc21)c1ccccn1, C\C(=N\Nc1nnc2c(n1)[nH]c1c(C)cccc21)c1ccccn1, C\C(=N\Nc1nnc2c(n1)[nH]c1c(C)cccc21)c1ccccn1, C\C(=N\Nc1nnc2c(n1)[nH]c1c(C)cccc21)c1ccccn1, C\C(=N\Nc1nnc2c(n1)[nH]c1c(C)cccc21)c1ccccn1	UQOSBPRTQFFUOA-UHFFFAOYSA-N, UQOSBPRTQFFUOA-UHFFFAOYSA-N, UQOSBPRTQFFUOA-NHDPSOOVSA-N, UQOSBPRTQFFUOA-NHDPSOOVSA-N, UQOSBPRTQFFUOA-NHDPSOOVSA-N, UQOSBPRTQFFUOA-NHDPSOOVSA-N	Phase 1
VL285	PROTAC				CC(C)[C@H](N1Cc2ccccc2C1=O)C(=O)N1C[C@H](O)C[C@H]1C(=O)NCc1ccc(cc1)-c1scnc1C	HEDFFPYRFJKXQP-VJTSUQJLSA-N	Preclinical
voclosporin	calcineurin inhibitor				[H][C@@]1(CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@]([H])(NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C(=O)[C@H](CC)NC(=O)[C@]([H])([C@H](O)[C@H](C)C\C=C\C=C)N(C)C(=O)[C@]([H])(C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C1=O)C(C)C	BICRTLVBTLFLRD-PTWUADNWSA-N	Phase 3
voglibose	glucosidase inhibitor	MGAM	endocrinology	diabetes mellitus, hyperglycemia	OCC(CO)N[C@H]1C[C@](O)(CO)[C@@H](O)[C@H](O)[C@H]1O, OCC(CO)N[C@H]1C[C@](O)(CO)[C@@H](O)[C@H](O)[C@H]1O, OCC(CO)N[C@H]1C[C@](O)(CO)[C@@H](O)[C@H](O)[C@H]1O	FZNCGRZWXLXZSZ-CIQUZCHMSA-N, FZNCGRZWXLXZSZ-CIQUZCHMSA-N, FZNCGRZWXLXZSZ-CIQUZCHMSA-N	Launched
volasertib	PLK inhibitor	PLK1			CC[C@H]1N(C(C)C)c2nc(Nc3ccc(cc3OC)C(=O)N[C@H]3CC[C@@H](CC3)N3CCN(CC4CC4)CC3)ncc2N(C)C1=O, CC[C@H]1N(C(C)C)c2nc(Nc3ccc(cc3OC)C(=O)N[C@H]3CC[C@@H](CC3)N3CCN(CC4CC4)CC3)ncc2N(C)C1=O, CC[C@H]1N(C(C)C)c2nc(Nc3ccc(cc3OC)C(=O)N[C@H]3CC[C@@H](CC3)N3CCN(CC4CC4)CC3)ncc2N(C)C1=O, CC[C@H]1N(C(C)C)c2nc(Nc3ccc(cc3OC)C(=O)N[C@H]3CC[C@@H](CC3)N3CCN(CC4CC4)CC3)ncc2N(C)C1=O, CC[C@H]1N(C(C)C)c2nc(Nc3ccc(cc3OC)C(=O)N[C@H]3CC[C@@H](CC3)N3CCN(CC4CC4)CC3)ncc2N(C)C1=O, CC[C@H]1N(C(C)C)c2nc(Nc3ccc(cc3OC)C(=O)N[C@H]3CC[C@@H](CC3)N3CCN(CC4CC4)CC3)ncc2N(C)C1=O, CC[C@H]1N(C(C)C)c2nc(Nc3ccc(cc3OC)C(=O)N[C@H]3CC[C@@H](CC3)N3CCN(CC4CC4)CC3)ncc2N(C)C1=O, CC[C@H]1N(C(C)C)c2nc(Nc3ccc(cc3OC)C(=O)N[C@H]3CC[C@@H](CC3)N3CCN(CC4CC4)CC3)ncc2N(C)C1=O	SXNJFOWDRLKDSF-STROYTFGSA-N, SXNJFOWDRLKDSF-STROYTFGSA-N, SXNJFOWDRLKDSF-STROYTFGSA-N, SXNJFOWDRLKDSF-STROYTFGSA-N, SXNJFOWDRLKDSF-STROYTFGSA-N, InChI=1S/C34H50N8O3/c1-6-28-33(44)39(4)29-20-35-34(38-31(29)42(28)22(2)3)37-27-14-9-24(19-30(27)45-5)32(43)36-25-10-12-26(13-11-25)41-17-15-40(16-18-41)21-23-7-8-23/h9,14,19-20,22-23,25-26,28H,6-8,10-13,15-18,21H2,1-5H3,(H,36,43)(H,35,37,38)/t25-,26-,28-/m1/s1, InChI=1S/C34H50N8O3/c1-6-28-33(44)39(4)29-20-35-34(38-31(29)42(28)22(2)3)37-27-14-9-24(19-30(27)45-5)32(43)36-25-10-12-26(13-11-25)41-17-15-40(16-18-41)21-23-7-8-23/h9,14,19-20,22-23,25-26,28H,6-8,10-13,15-18,21H2,1-5H3,(H,36,43)(H,35,37,38)/t25-,26-,28-/m1/s1, InChI=1S/C34H50N8O3/c1-6-28-33(44)39(4)29-20-35-34(38-31(29)42(28)22(2)3)37-27-14-9-24(19-30(27)45-5)32(43)36-25-10-12-26(13-11-25)41-17-15-40(16-18-41)21-23-7-8-23/h9,14,19-20,22-23,25-26,28H,6-8,10-13,15-18,21H2,1-5H3,(H,36,43)(H,35,37,38)/t25-,26-,28-/m1/s1	Phase 3
volinanserin	serotonin receptor antagonist	HTR2A, HTR2B, HTR2C, KCNH2			COc1cccc([C@H](O)C2CCN(CCc3ccc(F)cc3)CC2)c1OC, COc1cccc([C@H](O)C2CCN(CCc3ccc(F)cc3)CC2)c1OC	HXTGXYRHXAGCFP-OAQYLSRUSA-N, HXTGXYRHXAGCFP-OAQYLSRUSA-N	Phase 3
vonoprazan	potassium-competitive acid antagonist	ATP4A	gastroenterology	peptic ulcer disease (PUD)	CNCc1cc(-c2ccccc2F)n(c1)S(=O)(=O)c1cccnc1, CNCc1cc(-c2ccccc2F)n(c1)S(=O)(=O)c1cccnc1, CNCc1cc(-c2ccccc2F)n(c1)S(=O)(=O)c1cccnc1, CNCc1cc(-c2ccccc2F)n(c1)S(=O)(=O)c1cccnc1, CNCc1cc(-c2ccccc2F)n(c1)S(=O)(=O)c1cccnc1	BFDBKMOZYNOTPK-UHFFFAOYSA-N, BFDBKMOZYNOTPK-UHFFFAOYSA-N, BFDBKMOZYNOTPK-UHFFFAOYSA-N, BFDBKMOZYNOTPK-UHFFFAOYSA-N, BFDBKMOZYNOTPK-UHFFFAOYSA-N	Launched
vorapaxar	thrombin inhibitor	F2R	cardiology	myocardial infarction, peripheral artery disease (PAD)	CCOC(=O)N[C@@H]1CC[C@@H]2[C@H](C[C@@H]3[C@@H]([C@@H](C)OC3=O)[C@H]2\C=C\c2ccc(cn2)-c2cccc(F)c2)C1, CCOC(=O)N[C@@H]1CC[C@@H]2[C@H](C[C@@H]3[C@@H]([C@@H](C)OC3=O)[C@H]2\C=C\c2ccc(cn2)-c2cccc(F)c2)C1, CCOC(=O)N[C@@H]1CC[C@@H]2[C@H](C[C@@H]3[C@@H]([C@@H](C)OC3=O)[C@H]2\C=C\c2ccc(cn2)-c2cccc(F)c2)C1, CCOC(=O)N[C@@H]1CC[C@@H]2[C@H](C[C@@H]3[C@@H]([C@@H](C)OC3=O)[C@H]2\C=C\c2ccc(cn2)-c2cccc(F)c2)C1	ZBGXUVOIWDMMJE-QHNZEKIYSA-N, ZBGXUVOIWDMMJE-QHNZEKIYSA-N, ZBGXUVOIWDMMJE-QHNZEKIYSA-N, ZBGXUVOIWDMMJE-QHNZEKIYSA-N	Launched
vorasidenib	isocitrate dehydrogenase inhibitor				C[C@@H](Nc1nc(N[C@H](C)C(F)(F)F)nc(n1)-c1cccc(Cl)n1)C(F)(F)F	QCZAWDGAVJMPTA-RNFRBKRXSA-N	Preclinical
voreloxin	topoisomerase inhibitor	TOP2A			CN[C@H]1CN(C[C@@H]1OC)c1ccc2c(n1)n(cc(C(O)=O)c2=O)-c1nccs1, CN[C@H]1CN(C[C@@H]1OC)c1ccc2c(n1)n(cc(C(O)=O)c2=O)-c1nccs1, CN[C@H]1CN(C[C@@H]1OC)c1ccc2c(n1)n(cc(C(O)=O)c2=O)-c1nccs1	XZAFZXJXZHRNAQ-STQMWFEESA-N, XZAFZXJXZHRNAQ-STQMWFEESA-N, XZAFZXJXZHRNAQ-STQMWFEESA-N	Phase 3
voriconazole	cytochrome P450 inhibitor	CYP2C19, CYP2C9, CYP3A4, CYP3A5, PTGS1	infectious disease	esophageal candidiasis, aspergillosis, skin infections	C[C@@H](c1ncncc1F)[C@](O)(Cn1cncn1)c1ccc(F)cc1F, C[C@@H](c1ncncc1F)[C@](O)(Cn1cncn1)c1ccc(F)cc1F, C[C@@H](c1ncncc1F)[C@](O)(Cn1cncn1)c1ccc(F)cc1F, C[C@@H](c1ncncc1F)[C@](O)(Cn1cncn1)c1ccc(F)cc1F, C[C@@H](c1ncncc1F)[C@](O)(Cn1cncn1)c1ccc(F)cc1F	BCEHBSKCWLPMDN-MGPLVRAMSA-N, BCEHBSKCWLPMDN-MGPLVRAMSA-N, BCEHBSKCWLPMDN-MGPLVRAMSA-N, BCEHBSKCWLPMDN-MGPLVRAMSA-N, BCEHBSKCWLPMDN-MGPLVRAMSA-N	Launched
vorinostat	HDAC inhibitor	HDAC1, HDAC10, HDAC11, HDAC2, HDAC3, HDAC5, HDAC6, HDAC8, HDAC9	hematologic malignancy	cutaneous T-cell lymphoma (CTCL)	ONC(=O)CCCCCCC(=O)Nc1ccccc1, ONC(=O)CCCCCCC(=O)Nc1ccccc1, ONC(=O)CCCCCCC(=O)Nc1ccccc1, ONC(=O)CCCCCCC(=O)Nc1ccccc1, ONC(=O)CCCCCCC(=O)Nc1ccccc1, ONC(=O)CCCCCCC(=O)Nc1ccccc1, ONC(=O)CCCCCCC(=O)Nc1ccccc1, ONC(=O)CCCCCCC(=O)Nc1ccccc1, ONC(=O)CCCCCCC(=O)Nc1ccccc1, ONC(=O)CCCCCCC(=O)Nc1ccccc1, ONC(=O)CCCCCCC(=O)Nc1ccccc1, ONC(=O)CCCCCCC(=O)Nc1ccccc1, ONC(=O)CCCCCCC(=O)Nc1ccccc1, ONC(=O)CCCCCCC(=O)Nc1ccccc1, ONC(=O)CCCCCCC(=O)Nc1ccccc1	WAEXFXRVDQXREF-UHFFFAOYSA-N, WAEXFXRVDQXREF-UHFFFAOYSA-N, WAEXFXRVDQXREF-UHFFFAOYSA-N, WAEXFXRVDQXREF-UHFFFAOYSA-N, WAEXFXRVDQXREF-UHFFFAOYSA-N, WAEXFXRVDQXREF-UHFFFAOYSA-N, WAEXFXRVDQXREF-UHFFFAOYSA-N, WAEXFXRVDQXREF-UHFFFAOYSA-N, WAEXFXRVDQXREF-UHFFFAOYSA-N, WAEXFXRVDQXREF-UHFFFAOYSA-N, WAEXFXRVDQXREF-UHFFFAOYSA-N, WAEXFXRVDQXREF-UHFFFAOYSA-N, WAEXFXRVDQXREF-UHFFFAOYSA-N, WAEXFXRVDQXREF-UHFFFAOYSA-N, WAEXFXRVDQXREF-UHFFFAOYSA-N	Launched
vortioxetine	serotonin receptor agonist, serotonin receptor antagonist	HTR1A, HTR1B, HTR2A, HTR2C, HTR3A, HTR5A, HTR6, HTR7, SLC6A4	neurology/psychiatry	depression	Cc1ccc(Sc2ccccc2N2CCNCC2)c(C)c1, Cc1ccc(Sc2ccccc2N2CCNCC2)c(C)c1, Cc1ccc(Sc2ccccc2N2CCNCC2)c(C)c1, Cc1ccc(Sc2ccccc2N2CCNCC2)c(C)c1, Cc1ccc(Sc2ccccc2N2CCNCC2)c(C)c1	YQNWZWMKLDQSAC-UHFFFAOYSA-N, YQNWZWMKLDQSAC-UHFFFAOYSA-N, YQNWZWMKLDQSAC-UHFFFAOYSA-N, YQNWZWMKLDQSAC-UHFFFAOYSA-N, YQNWZWMKLDQSAC-UHFFFAOYSA-N	Launched
voruciclib	CDK9 inhibitor				CN1CC[C@H]([C@@H]1CO)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccc(cc1Cl)C(F)(F)F	MRPGRAKIAJJGMM-OCCSQVGLSA-N	Phase 1
voxelotor	hemoglobin modulator				CC(C)n1nccc1-c1ncccc1COc1cccc(O)c1C=O, CC(C)n1nccc1-c1ncccc1COc1cccc(O)c1C=O	FWCVZAQENIZVMY-UHFFFAOYSA-N, FWCVZAQENIZVMY-UHFFFAOYSA-N	Launched
voxtalisib	mTOR inhibitor, PI3K inhibitor	MTOR, PIK3CA			CCn1c2nc(N)nc(C)c2cc(-c2cc[nH]n2)c1=O, CCn1c2nc(N)nc(C)c2cc(-c2cc[nH]n2)c1=O, CCn1c2nc(N)nc(C)c2cc(-c2cc[nH]n2)c1=O	RGHYDLZMTYDBDT-UHFFFAOYSA-N, RGHYDLZMTYDBDT-UHFFFAOYSA-N, RGHYDLZMTYDBDT-UHFFFAOYSA-N	Phase 2
VP-20629	beta amyloid antagonist	PLA2G2E, SLC36A1			OC(=O)CCc1c[nH]c2ccccc12	GOLXRNDWAUTYKT-UHFFFAOYSA-N	Phase 1
VS-4718	focal adhesion kinase inhibitor				CNC(=O)c1ccccc1Nc1cc(Nc2ccc(cc2OC)N2CCOCC2)ncc1C(F)(F)F, CNC(=O)c1ccccc1Nc1cc(Nc2ccc(cc2OC)N2CCOCC2)ncc1C(F)(F)F, CNC(=O)c1ccccc1Nc1cc(Nc2ccc(cc2OC)N2CCOCC2)ncc1C(F)(F)F, CNC(=O)c1ccccc1Nc1cc(Nc2ccc(cc2OC)N2CCOCC2)ncc1C(F)(F)F, CNC(=O)c1ccccc1Nc1cc(Nc2ccc(cc2OC)N2CCOCC2)ncc1C(F)(F)F, CNC(=O)c1ccccc1Nc1cc(Nc2ccc(cc2OC)N2CCOCC2)ncc1C(F)(F)F, CNC(=O)c1ccccc1Nc1cc(Nc2ccc(cc2OC)N2CCOCC2)ncc1C(F)(F)F, CNC(=O)c1ccccc1Nc1cc(Nc2ccc(cc2OC)N2CCOCC2)ncc1C(F)(F)F	IGUBBWJDMLCRIK-UHFFFAOYSA-N, IGUBBWJDMLCRIK-UHFFFAOYSA-N, IGUBBWJDMLCRIK-UHFFFAOYSA-N, IGUBBWJDMLCRIK-UHFFFAOYSA-N, IGUBBWJDMLCRIK-UHFFFAOYSA-N, IGUBBWJDMLCRIK-UHFFFAOYSA-N, IGUBBWJDMLCRIK-UHFFFAOYSA-N, IGUBBWJDMLCRIK-UHFFFAOYSA-N	Phase 1
VT-464	cytochrome P450 inhibitor	CYP17A1			CC(C)[C@@](O)(c1cn[nH]n1)c1ccc2cc(OC(F)F)c(OC(F)F)cc2c1, CC(C)[C@@](O)(c1cn[nH]n1)c1ccc2cc(OC(F)F)c(OC(F)F)cc2c1, CC(C)[C@@](O)(c1cn[nH]n1)c1ccc2cc(OC(F)F)c(OC(F)F)cc2c1, CC(C)[C@@](O)(c1cn[nH]n1)c1ccc2cc(OC(F)F)c(OC(F)F)cc2c1, CC(C)[C@@](O)(c1cn[nH]n1)c1ccc2cc(OC(F)F)c(OC(F)F)cc2c1	ZBRAJOQFSNYJMF-SFHVURJKSA-N, ZBRAJOQFSNYJMF-SFHVURJKSA-N, ZBRAJOQFSNYJMF-SFHVURJKSA-N, ZBRAJOQFSNYJMF-SFHVURJKSA-N, ZBRAJOQFSNYJMF-SFHVURJKSA-N	Phase 2
VTP-27999	renin inhibitor	REN			CN[C@H](CNC(=O)N1CCC[C@H](C1)[C@@H](OCCNC(=O)OC)c1cccc(Cl)c1)C[C@H]1CCCOC1, CN[C@H](CNC(=O)N1CCC[C@H](C1)[C@@H](OCCNC(=O)OC)c1cccc(Cl)c1)C[C@H]1CCCOC1	NXWASIVXQMMPLM-ZXMXYHOLSA-N, NXWASIVXQMMPLM-ZXMXYHOLSA-N	Phase 1
VUF10166	serotonin receptor antagonist	HTR3A, HTR3B			CN1CCN(CC1)c1nc2ccccc2nc1Cl, CN1CCN(CC1)c1nc2ccccc2nc1Cl	FFXVTQDGTKEXHF-UHFFFAOYSA-N, FFXVTQDGTKEXHF-UHFFFAOYSA-N	Preclinical
VUF10460	histamine receptor agonist	HRH4			CN1CCN(CC1)c1cc(nc(N)n1)-c1ccccc1, CN1CCN(CC1)c1cc(nc(N)n1)-c1ccccc1, CN1CCN(CC1)c1cc(nc(N)n1)-c1ccccc1	NIJGWJIOMPHDBP-UHFFFAOYSA-N, NIJGWJIOMPHDBP-UHFFFAOYSA-N, NIJGWJIOMPHDBP-UHFFFAOYSA-N	Preclinical
VUF11207	CC chemokine receptor agonist	ACKR3			COc1cc(cc(OC)c1OC)C(=O)N(CC[C@H]1CCCN1C)C\C(C)=C\c1ccccc1F |&1:17|, COc1cc(cc(OC)c1OC)C(=O)N(CC[C@H]1CCCN1C)C\C(C)=C\c1ccccc1F |&1:17|	JVRRRKAXHMGUHZ-JIKIWWBOSA-N, JVRRRKAXHMGUHZ-JIKIWWBOSA-N	Preclinical
VU0155069	phospholipase inhibitor	PLD1			C[C@@H](CN1CCC(CC1)n1c2ccc(Cl)cc2[nH]c1=O)NC(=O)c1ccc2ccccc2c1, C[C@@H](CN1CCC(CC1)n1c2ccc(Cl)cc2[nH]c1=O)NC(=O)c1ccc2ccccc2c1, C[C@@H](CN1CCC(CC1)n1c2ccc(Cl)cc2[nH]c1=O)NC(=O)c1ccc2ccccc2c1, C[C@@H](CN1CCC(CC1)n1c2ccc(Cl)cc2[nH]c1=O)NC(=O)c1ccc2ccccc2c1	DRIMIUYGTDAQOX-KRWDZBQOSA-N, DRIMIUYGTDAQOX-KRWDZBQOSA-N, DRIMIUYGTDAQOX-KRWDZBQOSA-N, DRIMIUYGTDAQOX-KRWDZBQOSA-N	Preclinical
VU0238429	acetylcholine receptor allosteric modulator	CHRM5			COc1ccc(CN2C(=O)C(=O)c3cc(OC(F)(F)F)ccc23)cc1, COc1ccc(CN2C(=O)C(=O)c3cc(OC(F)(F)F)ccc23)cc1, COc1ccc(CN2C(=O)C(=O)c3cc(OC(F)(F)F)ccc23)cc1, COc1ccc(CN2C(=O)C(=O)c3cc(OC(F)(F)F)ccc23)cc1, COc1ccc(CN2C(=O)C(=O)c3cc(OC(F)(F)F)ccc23)cc1, COc1ccc(CN2C(=O)C(=O)c3cc(OC(F)(F)F)ccc23)cc1	CKLGZXFOLMHCMC-UHFFFAOYSA-N, CKLGZXFOLMHCMC-UHFFFAOYSA-N, CKLGZXFOLMHCMC-UHFFFAOYSA-N, CKLGZXFOLMHCMC-UHFFFAOYSA-N, CKLGZXFOLMHCMC-UHFFFAOYSA-N, CKLGZXFOLMHCMC-UHFFFAOYSA-N	Preclinical
VU0240551	potassium/chloride cotransporter inhibitor	SLC12A5			Cc1csc(NC(=O)CSc2ccc(nn2)-c2ccccc2)n1	WJRWSLORVIHRNX-UHFFFAOYSA-N	Preclinical
VU0357121	glutamate receptor positive allosteric modulator	GRM5			CCCCOc1ccc(cc1)C(=O)Nc1ccc(F)cc1F, CCCCOc1ccc(cc1)C(=O)Nc1ccc(F)cc1F, CCCCOc1ccc(cc1)C(=O)Nc1ccc(F)cc1F, CCCCOc1ccc(cc1)C(=O)Nc1ccc(F)cc1F, CCCCOc1ccc(cc1)C(=O)Nc1ccc(F)cc1F, CCCCOc1ccc(cc1)C(=O)Nc1ccc(F)cc1F, CCCCOc1ccc(cc1)C(=O)Nc1ccc(F)cc1F	AHCYOTLTLQTPSU-UHFFFAOYSA-N, AHCYOTLTLQTPSU-UHFFFAOYSA-N, AHCYOTLTLQTPSU-UHFFFAOYSA-N, AHCYOTLTLQTPSU-UHFFFAOYSA-N, AHCYOTLTLQTPSU-UHFFFAOYSA-N, AHCYOTLTLQTPSU-UHFFFAOYSA-N, AHCYOTLTLQTPSU-UHFFFAOYSA-N	Preclinical
VU0360172	glutamate receptor positive allosteric modulator	GRM5			Fc1cccc(c1)C#Cc1ccc(cn1)C(=O)NC1CCC1, Fc1cccc(c1)C#Cc1ccc(cn1)C(=O)NC1CCC1	NEMHWVUKNWAKTM-UHFFFAOYSA-N, NEMHWVUKNWAKTM-UHFFFAOYSA-N	Preclinical
VU0361737	glutamate receptor positive allosteric modulator	GRM4			COc1cc(NC(=O)c2ccccn2)ccc1Cl, COc1cc(NC(=O)c2ccccn2)ccc1Cl, COc1cc(NC(=O)c2ccccn2)ccc1Cl, COc1cc(NC(=O)c2ccccn2)ccc1Cl, COc1cc(NC(=O)c2ccccn2)ccc1Cl	ARYUXFNGXHNNDM-UHFFFAOYSA-N, ARYUXFNGXHNNDM-UHFFFAOYSA-N, ARYUXFNGXHNNDM-UHFFFAOYSA-N, ARYUXFNGXHNNDM-UHFFFAOYSA-N, ARYUXFNGXHNNDM-UHFFFAOYSA-N	Preclinical
VU0364439	glutamate receptor positive allosteric modulator	GRM4			Clc1ccccc1NS(=O)(=O)c1ccc(NC(=O)c2ccccn2)cc1Cl, Clc1ccccc1NS(=O)(=O)c1ccc(NC(=O)c2ccccn2)cc1Cl, Clc1ccccc1NS(=O)(=O)c1ccc(NC(=O)c2ccccn2)cc1Cl	IXHCGJXBIHHIEF-UHFFFAOYSA-N, IXHCGJXBIHHIEF-UHFFFAOYSA-N, IXHCGJXBIHHIEF-UHFFFAOYSA-N	Preclinical
VU0364739	phospholipase inhibitor	PLD2			Fc1cccc(c1)N1CNC(=O)C11CCN(CCNC(=O)c2ccc3ccccc3c2)CC1, Fc1cccc(c1)N1CNC(=O)C11CCN(CCNC(=O)c2ccc3ccccc3c2)CC1, Fc1cccc(c1)N1CNC(=O)C11CCN(CCNC(=O)c2ccc3ccccc3c2)CC1	MSTXJJGAXXJCBY-UHFFFAOYSA-N, MSTXJJGAXXJCBY-UHFFFAOYSA-N, MSTXJJGAXXJCBY-UHFFFAOYSA-N	Preclinical
VU0364770	glutamate receptor positive allosteric modulator	GRM4			Clc1cccc(NC(=O)c2ccccn2)c1, Clc1cccc(NC(=O)c2ccccn2)c1, Clc1cccc(NC(=O)c2ccccn2)c1	SUYUTNCKIOLMAJ-UHFFFAOYSA-N, SUYUTNCKIOLMAJ-UHFFFAOYSA-N, SUYUTNCKIOLMAJ-UHFFFAOYSA-N	Preclinical
VU0422288	glutamate receptor positive allosteric modulator	GRM3			Clc1ccc(Oc2ccc(NC(=O)c3ccccn3)cc2Cl)nc1, Clc1ccc(Oc2ccc(NC(=O)c3ccccn3)cc2Cl)nc1, Clc1ccc(Oc2ccc(NC(=O)c3ccccn3)cc2Cl)nc1	MZRLPXFGQKQHST-UHFFFAOYSA-N, MZRLPXFGQKQHST-UHFFFAOYSA-N, MZRLPXFGQKQHST-UHFFFAOYSA-N	Preclinical
VU10010	acetylcholine receptor allosteric modulator	CHRM4			Cc1cc(C)c2c(N)c(sc2n1)C(=O)NCc1ccc(Cl)cc1, Cc1cc(C)c2c(N)c(sc2n1)C(=O)NCc1ccc(Cl)cc1, Cc1cc(C)c2c(N)c(sc2n1)C(=O)NCc1ccc(Cl)cc1, Cc1cc(C)c2c(N)c(sc2n1)C(=O)NCc1ccc(Cl)cc1	FPRULFHDSFKYBV-UHFFFAOYSA-N, FPRULFHDSFKYBV-UHFFFAOYSA-N, FPRULFHDSFKYBV-UHFFFAOYSA-N, FPRULFHDSFKYBV-UHFFFAOYSA-N	Preclinical
VU152100	acetylcholine receptor allosteric modulator	CHRM4			COc1ccc(CNC(=O)c2sc3nc(C)cc(C)c3c2N)cc1, COc1ccc(CNC(=O)c2sc3nc(C)cc(C)c3c2N)cc1, COc1ccc(CNC(=O)c2sc3nc(C)cc(C)c3c2N)cc1	MDNWGCQSCGNTKH-UHFFFAOYSA-N, MDNWGCQSCGNTKH-UHFFFAOYSA-N, MDNWGCQSCGNTKH-UHFFFAOYSA-N	Preclinical
VU1545	glutamate receptor positive allosteric modulator	GRM5			[O-][N+](=O)c1ccc(cc1)C(=O)Nc1cc(nn1-c1ccccc1F)-c1ccccc1, [O-][N+](=O)c1ccc(cc1)C(=O)Nc1cc(nn1-c1ccccc1F)-c1ccccc1, [O-][N+](=O)c1ccc(cc1)C(=O)Nc1cc(nn1-c1ccccc1F)-c1ccccc1	BRAZLURTFMCAHU-UHFFFAOYSA-N, BRAZLURTFMCAHU-UHFFFAOYSA-N, BRAZLURTFMCAHU-UHFFFAOYSA-N	Preclinical
VU29	glutamate receptor potentiator	GRM5			[O-][N+](=O)c1ccc(cc1)C(=O)Nc1cc(nn1-c1ccccc1)-c1ccccc1, [O-][N+](=O)c1ccc(cc1)C(=O)Nc1cc(nn1-c1ccccc1)-c1ccccc1, [O-][N+](=O)c1ccc(cc1)C(=O)Nc1cc(nn1-c1ccccc1)-c1ccccc1	KIALCSMRIHRFPL-UHFFFAOYSA-N, KIALCSMRIHRFPL-UHFFFAOYSA-N, KIALCSMRIHRFPL-UHFFFAOYSA-N	Preclinical
VU591	potassium channel blocker	KCNJ1			[O-][N+](=O)c1ccc2nc(COCc3nc4ccc(cc4[nH]3)[N+]([O-])=O)[nH]c2c1, [O-][N+](=O)c1ccc2nc(COCc3nc4ccc(cc4[nH]3)[N+]([O-])=O)[nH]c2c1, [O-][N+](=O)c1ccc2nc(COCc3nc4ccc(cc4[nH]3)[N+]([O-])=O)[nH]c2c1, [O-][N+](=O)c1ccc2nc(COCc3nc4ccc(cc4[nH]3)[N+]([O-])=O)[nH]c2c1	ZQPXNYLXYNRFNP-UHFFFAOYSA-N, ZQPXNYLXYNRFNP-UHFFFAOYSA-N, ZQPXNYLXYNRFNP-UHFFFAOYSA-N, ZQPXNYLXYNRFNP-UHFFFAOYSA-N	Preclinical
VX-11e	MAP kinase inhibitor	MAPK1			Cc1cnc(Nc2ccc(F)cc2Cl)nc1-c1c[nH]c(c1)C(=O)N[C@H](CO)c1cccc(Cl)c1, Cc1cnc(Nc2ccc(F)cc2Cl)nc1-c1c[nH]c(c1)C(=O)N[C@H](CO)c1cccc(Cl)c1, Cc1cnc(Nc2ccc(F)cc2Cl)nc1-c1c[nH]c(c1)C(=O)N[C@H](CO)c1cccc(Cl)c1	WUTVMXLIGHTZJC-OAQYLSRUSA-N, WUTVMXLIGHTZJC-OAQYLSRUSA-N, WUTVMXLIGHTZJC-OAQYLSRUSA-N	Preclinical
VX-222	HCV inhibitor				C[C@H]1CC[C@@H](CC1)C(=O)N([C@@H]1CC[C@H](O)CC1)c1cc(sc1C(O)=O)C#CC(C)(C)C |r|, C[C@H]1CC[C@@H](CC1)C(=O)N([C@@H]1CC[C@H](O)CC1)c1cc(sc1C(O)=O)C#CC(C)(C)C |r|	WPMJNLCLKAKMLA-UGLKCIBTSA-N, WPMJNLCLKAKMLA-UGLKCIBTSA-N	Phase 2
VX-702	p38 MAPK inhibitor	IL1B, IL6, MAPK11, MAPK12, MAPK14, TNF			NC(=O)N(c1ccc(C(N)=O)c(n1)-c1ccc(F)cc1F)c1c(F)cccc1F, NC(=O)N(c1ccc(C(N)=O)c(n1)-c1ccc(F)cc1F)c1c(F)cccc1F, NC(=O)N(c1ccc(C(N)=O)c(n1)-c1ccc(F)cc1F)c1c(F)cccc1F, NC(=O)N(c1ccc(C(N)=O)c(n1)-c1ccc(F)cc1F)c1c(F)cccc1F, NC(=O)N(c1ccc(C(N)=O)c(n1)-c1ccc(F)cc1F)c1c(F)cccc1F, NC(=O)N(c1ccc(C(N)=O)c(n1)-c1ccc(F)cc1F)c1c(F)cccc1F	FYSRKRZDBHOFAY-UHFFFAOYSA-N, FYSRKRZDBHOFAY-UHFFFAOYSA-N, FYSRKRZDBHOFAY-UHFFFAOYSA-N, FYSRKRZDBHOFAY-UHFFFAOYSA-N, FYSRKRZDBHOFAY-UHFFFAOYSA-N, FYSRKRZDBHOFAY-UHFFFAOYSA-N	Phase 2
VX-745	p38 MAPK inhibitor	MAPK11, MAPK12, MAPK14			Fc1ccc(Sc2ccc3c(-c4c(Cl)cccc4Cl)c(=O)ncn3n2)c(F)c1, Fc1ccc(Sc2ccc3c(-c4c(Cl)cccc4Cl)c(=O)ncn3n2)c(F)c1, Fc1ccc(Sc2ccc3c(-c4c(Cl)cccc4Cl)c(=O)ncn3n2)c(F)c1, Fc1ccc(Sc2ccc3c(-c4c(Cl)cccc4Cl)c(=O)ncn3n2)c(F)c1, Fc1ccc(Sc2ccc3c(-c4c(Cl)cccc4Cl)c(=O)ncn3n2)c(F)c1, Fc1ccc(Sc2ccc3c(-c4c(Cl)cccc4Cl)c(=O)ncn3n2)c(F)c1	VEPKQEUBKLEPRA-UHFFFAOYSA-N, VEPKQEUBKLEPRA-UHFFFAOYSA-N, VEPKQEUBKLEPRA-UHFFFAOYSA-N, VEPKQEUBKLEPRA-UHFFFAOYSA-N, VEPKQEUBKLEPRA-UHFFFAOYSA-N, VEPKQEUBKLEPRA-UHFFFAOYSA-N	Phase 2
VX-765	caspase inhibitor	CASP1			CCO[C@@H]1OC(=O)C[C@@H]1NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)c1ccc(N)c(Cl)c1)C(C)(C)C	SJDDOCKBXFJEJB-MOKWFATOSA-N	Phase 2
W-54011	anaphylatoxin chemotactic receptor antagonist	C5AR1			COc1ccc2CCC[C@@H](C(=O)N(Cc3ccc(cc3)N(C)C)c3ccc(cc3)C(C)C)c2c1 |&1:9|, COc1ccc2CCC[C@@H](C(=O)N(Cc3ccc(cc3)N(C)C)c3ccc(cc3)C(C)C)c2c1 |&1:9|	DVYASSBBADJRAS-MUUNZHRXSA-N, DVYASSBBADJRAS-MUUNZHRXSA-N	Preclinical
walrycin-B	transcriptional regulatory protein WalR				Cn1nc(nc2c1nc(=O)n(C)c2=O)-c1ccc(cc1)C(F)(F)F, Cn1nc(nc2c1nc(=O)n(C)c2=O)-c1ccc(cc1)C(F)(F)F, Cn1nc(nc2c1nc(=O)n(C)c2=O)-c1ccc(cc1)C(F)(F)F, Cn1nc(nc2c1nc(=O)n(C)c2=O)-c1ccc(cc1)C(F)(F)F	XRVMPTWWKLKLPB-UHFFFAOYSA-N, XRVMPTWWKLKLPB-UHFFFAOYSA-N, XRVMPTWWKLKLPB-UHFFFAOYSA-N, XRVMPTWWKLKLPB-UHFFFAOYSA-N	Preclinical
warfarin	vitamin K antagonist	VKORC1	hematology, cardiology	deep vein thrombosis (DVT), pulmonary embolism (PE), atrial fibrillation (AF), myocardial infarction	CC(=O)C[C@@H](c1ccccc1)c1c(O)c2ccccc2oc1=O |&1:4|, CC(=O)C[C@@H](c1ccccc1)c1c(O)c2ccccc2oc1=O |&1:4|	PJVWKTKQMONHTI-HNNXBMFYSA-N, PJVWKTKQMONHTI-HNNXBMFYSA-N	Launched
WAY-100635	serotonin receptor antagonist	HTR1A			COc1ccccc1N1CCN(CCN(C(=O)C2CCCCC2)c2ccccn2)CC1, COc1ccccc1N1CCN(CCN(C(=O)C2CCCCC2)c2ccccn2)CC1, COc1ccccc1N1CCN(CCN(C(=O)C2CCCCC2)c2ccccn2)CC1	SBPRIAGPYFYCRT-UHFFFAOYSA-N, SBPRIAGPYFYCRT-UHFFFAOYSA-N, SBPRIAGPYFYCRT-UHFFFAOYSA-N	Phase 1
WAY-161503	serotonin receptor agonist	HTR2C			Clc1cc2NC(=O)[C@H]3CNCCN3c2cc1Cl |&1:7|, Clc1cc2NC(=O)[C@H]3CNCCN3c2cc1Cl |&1:7|, Clc1cc2NC(=O)[C@H]3CNCCN3c2cc1Cl |&1:7|, Clc1cc2NC(=O)[C@H]3CNCCN3c2cc1Cl |&1:7|	PHGWDAICBXUJDU-SNVBAGLBSA-N, PHGWDAICBXUJDU-SNVBAGLBSA-N, PHGWDAICBXUJDU-SNVBAGLBSA-N, PHGWDAICBXUJDU-SNVBAGLBSA-N	Preclinical
WAY-170523	metalloproteinase inhibitor	MMP13			Cc1cc(C)c(N(Cc2ccccc2)S(=O)(=O)c2ccc(OCCNC(=O)c3cc4ccccc4o3)cc2)c(c1)C(=O)NO, Cc1cc(C)c(N(Cc2ccccc2)S(=O)(=O)c2ccc(OCCNC(=O)c3cc4ccccc4o3)cc2)c(c1)C(=O)NO, Cc1cc(C)c(N(Cc2ccccc2)S(=O)(=O)c2ccc(OCCNC(=O)c3cc4ccccc4o3)cc2)c(c1)C(=O)NO, Cc1cc(C)c(N(Cc2ccccc2)S(=O)(=O)c2ccc(OCCNC(=O)c3cc4ccccc4o3)cc2)c(c1)C(=O)NO, Cc1cc(C)c(N(Cc2ccccc2)S(=O)(=O)c2ccc(OCCNC(=O)c3cc4ccccc4o3)cc2)c(c1)C(=O)NO	FARMEEAGJWMFSZ-UHFFFAOYSA-N, FARMEEAGJWMFSZ-UHFFFAOYSA-N, FARMEEAGJWMFSZ-UHFFFAOYSA-N, FARMEEAGJWMFSZ-UHFFFAOYSA-N, FARMEEAGJWMFSZ-UHFFFAOYSA-N	Preclinical
WAY-200070	estrogen receptor agonist	ERBB2, ERBB3, ERBB4, ESR2			Oc1ccc(cc1)-c1nc2cc(O)cc(Br)c2o1, Oc1ccc(cc1)-c1nc2cc(O)cc(Br)c2o1, Oc1ccc(cc1)-c1nc2cc(O)cc(Br)c2o1	BAAILVWEAXFTSF-UHFFFAOYSA-N, BAAILVWEAXFTSF-UHFFFAOYSA-N, BAAILVWEAXFTSF-UHFFFAOYSA-N	Preclinical
WAY-207024	gonadotropin releasing factor hormone receptor antagonist	GNRHR, HRH2, TACR2			CC(C)(C)c1ccc(cc1)-c1nc2c(cccc2[nH]1)N1CCN(Cc2ccc3nccnc3c2)CC1, CC(C)(C)c1ccc(cc1)-c1nc2c(cccc2[nH]1)N1CCN(Cc2ccc3nccnc3c2)CC1, CC(C)(C)c1ccc(cc1)-c1nc2c(cccc2[nH]1)N1CCN(Cc2ccc3nccnc3c2)CC1, CC(C)(C)c1ccc(cc1)-c1nc2c(cccc2[nH]1)N1CCN(Cc2ccc3nccnc3c2)CC1, CC(C)(C)c1ccc(cc1)-c1nc2c(cccc2[nH]1)N1CCN(Cc2ccc3nccnc3c2)CC1	AVEVJMZJJJDOCI-UHFFFAOYSA-N, AVEVJMZJJJDOCI-UHFFFAOYSA-N, AVEVJMZJJJDOCI-UHFFFAOYSA-N, AVEVJMZJJJDOCI-UHFFFAOYSA-N, AVEVJMZJJJDOCI-UHFFFAOYSA-N	Preclinical
WAY-208466	serotonin receptor agonist	DRD2, HTR2A, HTR2C, HTR6, HTR7			CN(C)CCn1cc(c2cccnc12)S(=O)(=O)c1cccc(F)c1, CN(C)CCn1cc(c2cccnc12)S(=O)(=O)c1cccc(F)c1, CN(C)CCn1cc(c2cccnc12)S(=O)(=O)c1cccc(F)c1	SFSFIDVAEMDPIP-UHFFFAOYSA-N, SFSFIDVAEMDPIP-UHFFFAOYSA-N, SFSFIDVAEMDPIP-UHFFFAOYSA-N	Preclinical
WAY-213613	glutamate inhibitor	SLC1A2			N[C@@H](CC(=O)Nc1ccc(Oc2cc(F)c(F)cc2Br)cc1)C(O)=O, N[C@@H](CC(=O)Nc1ccc(Oc2cc(F)c(F)cc2Br)cc1)C(O)=O, N[C@@H](CC(=O)Nc1ccc(Oc2cc(F)c(F)cc2Br)cc1)C(O)=O, N[C@@H](CC(=O)Nc1ccc(Oc2cc(F)c(F)cc2Br)cc1)C(O)=O	BNYDDAAZMBUFRG-ZDUSSCGKSA-N, BNYDDAAZMBUFRG-ZDUSSCGKSA-N, BNYDDAAZMBUFRG-ZDUSSCGKSA-N, BNYDDAAZMBUFRG-ZDUSSCGKSA-N	Preclinical
WAY-255348	progesterone receptor antagonist				Cn1c(ccc1-c1cc2c(NC(=O)C2(C)C)c(F)c1)C#N	KIOOLNRTWPFVHX-UHFFFAOYSA-N	Preclinical
WAY-316606	secreted frizzled related protein inhibitor	SFRP1			FC(F)(F)c1ccc(cc1S(=O)(=O)NC1CCNCC1)S(=O)(=O)c1ccccc1, FC(F)(F)c1ccc(cc1S(=O)(=O)NC1CCNCC1)S(=O)(=O)c1ccccc1, FC(F)(F)c1ccc(cc1S(=O)(=O)NC1CCNCC1)S(=O)(=O)c1ccccc1	ITBGJNVZJBVPLJ-UHFFFAOYSA-N, ITBGJNVZJBVPLJ-UHFFFAOYSA-N, ITBGJNVZJBVPLJ-UHFFFAOYSA-N	Preclinical
WAY-362450	FXR agonist	NR1H4			CC(C)OC(=O)C1=CN(CC(C)(C)c2c1[nH]c1ccccc21)C(=O)c1ccc(F)c(F)c1 |t:6|, CC(C)OC(=O)C1=CN(CC(C)(C)c2c1[nH]c1ccccc21)C(=O)c1ccc(F)c(F)c1 |t:6|	INASOKQDNHHMRE-UHFFFAOYSA-N, INASOKQDNHHMRE-UHFFFAOYSA-N	Phase 1
WAY-600	mTOR inhibitor	MTOR			C(N1CCC(CC1)n1ncc2c(nc(nc12)-c1ccc2[nH]ccc2c1)N1CCOCC1)c1cccnc1, C(N1CCC(CC1)n1ncc2c(nc(nc12)-c1ccc2[nH]ccc2c1)N1CCOCC1)c1cccnc1, C(N1CCC(CC1)n1ncc2c(nc(nc12)-c1ccc2[nH]ccc2c1)N1CCOCC1)c1cccnc1	FPEIJQLXFHKLJV-UHFFFAOYSA-N, FPEIJQLXFHKLJV-UHFFFAOYSA-N, FPEIJQLXFHKLJV-UHFFFAOYSA-N	Preclinical
WAY-629	serotonin receptor agonist	HTR2C			C1CCc2c(C1)n1CCNCc3cccc2c13, C1CCc2c(C1)n1CCNCc3cccc2c13	OIGHTPDWPMLMGT-UHFFFAOYSA-N, OIGHTPDWPMLMGT-UHFFFAOYSA-N	Preclinical
WB-4101	adrenergic receptor antagonist	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, HTR1A			COc1cccc(OC)c1OCCNC[C@H]1COc2ccccc2O1 |&1:15|, COc1cccc(OC)c1OCCNC[C@H]1COc2ccccc2O1 |&1:15|, COc1cccc(OC)c1OCCNC[C@H]1COc2ccccc2O1 |&1:15|	GYSZUJHYXCZAKI-AWEZNQCLSA-N, GYSZUJHYXCZAKI-AWEZNQCLSA-N, GYSZUJHYXCZAKI-AWEZNQCLSA-N	Preclinical
WDR5-0103	histone lysine methyltransferase inhibitor	WDR5			COC(=O)c1ccc(N2CCN(C)CC2)c(NC(=O)c2cccc(OC)c2)c1, COC(=O)c1ccc(N2CCN(C)CC2)c(NC(=O)c2cccc(OC)c2)c1, COC(=O)c1ccc(N2CCN(C)CC2)c(NC(=O)c2cccc(OC)c2)c1	ZPLBXOVTSNRBFB-UHFFFAOYSA-N, ZPLBXOVTSNRBFB-UHFFFAOYSA-N, ZPLBXOVTSNRBFB-UHFFFAOYSA-N	Preclinical
WEHI-345-analog	SRC inhibitor				Cc1ccc(cc1)-c1nn(c2ncnc(N)c12)C(C)(C)CNC(=O)c1ncccc1C, Cc1ccc(cc1)-c1nn(c2ncnc(N)c12)C(C)(C)CNC(=O)c1ncccc1C	ZCZGSEXBXXYQQC-UHFFFAOYSA-N, ZCZGSEXBXXYQQC-UHFFFAOYSA-N	Preclinical
WH-4-023	SRC inhibitor	LCK, SRC			COc1ccc(N(C(=O)Oc2c(C)cccc2C)c2ccnc(Nc3ccc(cc3)N3CCN(C)CC3)n2)c(OC)c1, COc1ccc(N(C(=O)Oc2c(C)cccc2C)c2ccnc(Nc3ccc(cc3)N3CCN(C)CC3)n2)c(OC)c1, COc1ccc(N(C(=O)Oc2c(C)cccc2C)c2ccnc(Nc3ccc(cc3)N3CCN(C)CC3)n2)c(OC)c1	NBTNHSGBRGTFJS-UHFFFAOYSA-N, NBTNHSGBRGTFJS-UHFFFAOYSA-N, NBTNHSGBRGTFJS-UHFFFAOYSA-N	Preclinical
WHI-P154	JAK inhibitor	EGFR, JAK1, JAK2, JAK3			COc1cc2ncnc(Nc3ccc(O)c(Br)c3)c2cc1OC, COc1cc2ncnc(Nc3ccc(O)c(Br)c3)c2cc1OC, COc1cc2ncnc(Nc3ccc(O)c(Br)c3)c2cc1OC, COc1cc2ncnc(Nc3ccc(O)c(Br)c3)c2cc1OC, COc1cc2ncnc(Nc3ccc(O)c(Br)c3)c2cc1OC	CBIAKDAYHRWZCU-UHFFFAOYSA-N, CBIAKDAYHRWZCU-UHFFFAOYSA-N, CBIAKDAYHRWZCU-UHFFFAOYSA-N, CBIAKDAYHRWZCU-UHFFFAOYSA-N, CBIAKDAYHRWZCU-UHFFFAOYSA-N	Preclinical
WIKI4	tankyrase inhibitor, WNT pathway inhibitor	TNKS2			COc1ccc(cc1)-n1c(SCCCN2C(=O)c3cccc4cccc(C2=O)c34)nnc1-c1ccncc1	RNUXIZKXJOGYQP-UHFFFAOYSA-N	Preclinical
WIN-18446	aldehyde dehydrogenase inhibitor	ALDH1A2			ClC(Cl)C(=O)NCCCCCCCCNC(=O)C(Cl)Cl	FAOMZVDZARKPFJ-UHFFFAOYSA-N	Preclinical
WIN-64338	bradykinin receptor antagonist	BDKRB2			CCCC[P+](CCCC)(CCCC)Cc1ccc(NC(=O)[C@H](Cc2ccc3ccccc3c2)N\C(NC2CCCCC2)=N\C2CCCCC2)cc1, CCCC[P+](CCCC)(CCCC)Cc1ccc(NC(=O)[C@H](Cc2ccc3ccccc3c2)N\C(NC2CCCCC2)=N\C2CCCCC2)cc1, CCCC[P+](CCCC)(CCCC)Cc1ccc(NC(=O)[C@H](Cc2ccc3ccccc3c2)N\C(NC2CCCCC2)=N\C2CCCCC2)cc1, CCCC[P+](CCCC)(CCCC)Cc1ccc(NC(=O)[C@H](Cc2ccc3ccccc3c2)N\C(NC2CCCCC2)=N\C2CCCCC2)cc1, CCCC[P+](CCCC)(CCCC)Cc1ccc(NC(=O)[C@H](Cc2ccc3ccccc3c2)N\C(NC2CCCCC2)=N\C2CCCCC2)cc1	UKMJWGFHXMGRNG-QLKFWGTOSA-O, UKMJWGFHXMGRNG-QLKFWGTOSA-O, UKMJWGFHXMGRNG-QLKFWGTOSA-O, UKMJWGFHXMGRNG-QLKFWGTOSA-O, UKMJWGFHXMGRNG-QLKFWGTOSA-O	Preclinical
wiskostatin	actin related protein inhibitor, neural Wiskott-Aldrich syndrome protein inhibitor	WASL			CN(C)C[C@@H](O)Cn1c2ccc(Br)cc2c2cc(Br)ccc12 |&1:4,r|, CN(C)C[C@@H](O)Cn1c2ccc(Br)cc2c2cc(Br)ccc12 |&1:4,r|, CN(C)C[C@@H](O)Cn1c2ccc(Br)cc2c2cc(Br)ccc12 |&1:4,r|	XUBJEDZHBUPBKL-CYBMUJFWSA-N, XUBJEDZHBUPBKL-CYBMUJFWSA-N, XUBJEDZHBUPBKL-CYBMUJFWSA-N	Preclinical
wnt-c59	porcupine inhibitor	PORCN			Cc1cc(ccn1)-c1ccc(CC(=O)Nc2ccc(cc2)-c2cccnc2)cc1, Cc1cc(ccn1)-c1ccc(CC(=O)Nc2ccc(cc2)-c2cccnc2)cc1, Cc1cc(ccn1)-c1ccc(CC(=O)Nc2ccc(cc2)-c2cccnc2)cc1, Cc1cc(ccn1)-c1ccc(CC(=O)Nc2ccc(cc2)-c2cccnc2)cc1, Cc1cc(ccn1)-c1ccc(CC(=O)Nc2ccc(cc2)-c2cccnc2)cc1, Cc1cc(ccn1)-c1ccc(CC(=O)Nc2ccc(cc2)-c2cccnc2)cc1, Cc1cc(ccn1)-c1ccc(CC(=O)Nc2ccc(cc2)-c2cccnc2)cc1, Cc1cc(ccn1)-c1ccc(CC(=O)Nc2ccc(cc2)-c2cccnc2)cc1	KHZOJCQBHJUJFY-UHFFFAOYSA-N, KHZOJCQBHJUJFY-UHFFFAOYSA-N, KHZOJCQBHJUJFY-UHFFFAOYSA-N, KHZOJCQBHJUJFY-UHFFFAOYSA-N, KHZOJCQBHJUJFY-UHFFFAOYSA-N, KHZOJCQBHJUJFY-UHFFFAOYSA-N, KHZOJCQBHJUJFY-UHFFFAOYSA-N, KHZOJCQBHJUJFY-UHFFFAOYSA-N	Preclinical
wortmannin	PI3K inhibitor	PI4KA, PI4KB, PIK3CA, PIK3CD, PIK3CG, PIK3R1, PLK1, PRKDC			COC[C@H]1OC(=O)c2coc3c2[C@@]1(C)C1=C([C@@H]2CCC(=O)[C@@]2(C)C[C@H]1OC(C)=O)C3=O |t:16|, COC[C@H]1OC(=O)c2coc3c2[C@@]1(C)C1=C([C@@H]2CCC(=O)[C@@]2(C)C[C@H]1OC(C)=O)C3=O |t:16|, COC[C@H]1OC(=O)c2coc3c2[C@@]1(C)C1=C([C@@H]2CCC(=O)[C@@]2(C)C[C@H]1OC(C)=O)C3=O |t:16|	QDLHCMPXEPAAMD-QAIWCSMKSA-N, QDLHCMPXEPAAMD-QAIWCSMKSA-N, QDLHCMPXEPAAMD-QAIWCSMKSA-N	Preclinical
WP1066	STAT inhibitor	STAT3			C[C@H](NC(=O)C(=C\c1cccc(Br)n1)\C#N)c1ccccc1, C[C@H](NC(=O)C(=C\c1cccc(Br)n1)\C#N)c1ccccc1, C[C@H](NC(=O)C(=C\c1cccc(Br)n1)\C#N)c1ccccc1, C[C@H](NC(=O)C(=C\c1cccc(Br)n1)\C#N)c1ccccc1, C[C@H](NC(=O)C(=C\c1cccc(Br)n1)\C#N)c1ccccc1	VFUAJMPDXIRPKO-LQELWAHVSA-N, VFUAJMPDXIRPKO-LQELWAHVSA-N, VFUAJMPDXIRPKO-LQELWAHVSA-N, VFUAJMPDXIRPKO-LQELWAHVSA-N, VFUAJMPDXIRPKO-LQELWAHVSA-N	Phase 1
WP1130	deubiquitinase inhibitor	JAK2, UCHL5, USP14, USP9X			CCC[C@H](NC(=O)C(=C\c1cccc(Br)n1)\C#N)c1ccccc1, CCC[C@H](NC(=O)C(=C\c1cccc(Br)n1)\C#N)c1ccccc1, CCC[C@H](NC(=O)C(=C\c1cccc(Br)n1)\C#N)c1ccccc1, CCC[C@H](NC(=O)C(=C\c1cccc(Br)n1)\C#N)c1ccccc1, CCC[C@H](NC(=O)C(=C\c1cccc(Br)n1)\C#N)c1ccccc1, CCC[C@H](NC(=O)C(=C\c1cccc(Br)n1)\C#N)c1ccccc1, CCC[C@H](NC(=O)C(=C\c1cccc(Br)n1)\C#N)c1ccccc1	LIDOPKHSVQTSJY-VMEIHUARSA-N, LIDOPKHSVQTSJY-VMEIHUARSA-N, LIDOPKHSVQTSJY-VMEIHUARSA-N, LIDOPKHSVQTSJY-VMEIHUARSA-N, LIDOPKHSVQTSJY-VMEIHUARSA-N, LIDOPKHSVQTSJY-VMEIHUARSA-N, LIDOPKHSVQTSJY-VMEIHUARSA-N	Preclinical
WP921					OC(=O)Cn1nnnc1-c1ccsc1	DDVAZOPRCKAYOV-UHFFFAOYSA-N	Preclinical
WR99210	dihydrofolate reductase inhibitor	TYMS	infectious disease	malaria	CC1(C)N=C(N)N=C(N)N1OCCCOc1cc(Cl)c(Cl)cc1Cl |t:3,6|	MJZJYWCQPMNPRM-UHFFFAOYSA-N	Preclinical
WWL-113	carboxylesterase inhibitor	CES3			CCOC(=O)c1ccc(cc1)-c1ccc(OC(=O)N(C)Cc2cccc(c2)-c2ccncc2)cc1, CCOC(=O)c1ccc(cc1)-c1ccc(OC(=O)N(C)Cc2cccc(c2)-c2ccncc2)cc1	AKIIPHDGVCFVCC-UHFFFAOYSA-N, AKIIPHDGVCFVCC-UHFFFAOYSA-N	Preclinical
WWL-123	monoacylglycerol lipase inhibitor	ABHD6			CN(Cc1cccc(c1)-c1ccccc1)C(=O)Oc1ccc(cc1)-c1ccc(cc1)C(N)=O, CN(Cc1cccc(c1)-c1ccccc1)C(=O)Oc1ccc(cc1)-c1ccc(cc1)C(N)=O, CN(Cc1cccc(c1)-c1ccccc1)C(=O)Oc1ccc(cc1)-c1ccc(cc1)C(N)=O, CN(Cc1cccc(c1)-c1ccccc1)C(=O)Oc1ccc(cc1)-c1ccc(cc1)C(N)=O	UUJGYRHAOHORFC-UHFFFAOYSA-N, UUJGYRHAOHORFC-UHFFFAOYSA-N, UUJGYRHAOHORFC-UHFFFAOYSA-N, UUJGYRHAOHORFC-UHFFFAOYSA-N	Preclinical
WY-16922	histamine release inhibitor				CCOC(=O)C(=O)Nc1cccc(OC)c1C(N)=O	GGLRYZACPLNCKB-UHFFFAOYSA-N	Phase 1
WYE-125132	mTOR inhibitor	MTOR			CNC(=O)Nc1ccc(cc1)-c1nc(N2C[C@@H]3CC[C@H](C2)O3)c2cnn(C3CCC4(CC3)OCCO4)c2n1 |&1:16,19|	QLHHRYZMBGPBJG-OYRHEFFESA-N	Preclinical
WYE-354	mTOR inhibitor	MTOR			COC(=O)Nc1ccc(cc1)-c1nc(N2CCOCC2)c2cnn(C3CCN(CC3)C(=O)OC)c2n1, COC(=O)Nc1ccc(cc1)-c1nc(N2CCOCC2)c2cnn(C3CCN(CC3)C(=O)OC)c2n1	IMXHGCRIEAKIBU-UHFFFAOYSA-N, IMXHGCRIEAKIBU-UHFFFAOYSA-N	Preclinical
WYE-687	mTOR inhibitor	MTOR			COC(=O)Nc1ccc(cc1)-c1nc(N2CCOCC2)c2cnn(C3CCN(Cc4cccnc4)CC3)c2n1, COC(=O)Nc1ccc(cc1)-c1nc(N2CCOCC2)c2cnn(C3CCN(Cc4cccnc4)CC3)c2n1	VDOCQQKGPJENHJ-UHFFFAOYSA-N, VDOCQQKGPJENHJ-UHFFFAOYSA-N	Preclinical
WZ-3146	EGFR inhibitor	EGFR			CN1CCN(CC1)c1ccc(Nc2ncc(Cl)c(Oc3cccc(NC(=O)C=C)c3)n2)cc1, CN1CCN(CC1)c1ccc(Nc2ncc(Cl)c(Oc3cccc(NC(=O)C=C)c3)n2)cc1	APHGZZPEOCCYNO-UHFFFAOYSA-N, APHGZZPEOCCYNO-UHFFFAOYSA-N	Preclinical
WZ-4002	EGFR inhibitor	EGFR, ERBB2			COc1cc(ccc1Nc1ncc(Cl)c(Oc2cccc(NC(=O)C=C)c2)n1)N1CCN(C)CC1, COc1cc(ccc1Nc1ncc(Cl)c(Oc2cccc(NC(=O)C=C)c2)n1)N1CCN(C)CC1, COc1cc(ccc1Nc1ncc(Cl)c(Oc2cccc(NC(=O)C=C)c2)n1)N1CCN(C)CC1	ITTRLTNMFYIYPA-UHFFFAOYSA-N, ITTRLTNMFYIYPA-UHFFFAOYSA-N, ITTRLTNMFYIYPA-UHFFFAOYSA-N	Preclinical
WZ4003	AMPK inhibitor	NUAK1, NUAK2			CCC(=O)Nc1cccc(Oc2nc(Nc3ccc(cc3OC)N3CCN(C)CC3)ncc2Cl)c1, CCC(=O)Nc1cccc(Oc2nc(Nc3ccc(cc3OC)N3CCN(C)CC3)ncc2Cl)c1, CCC(=O)Nc1cccc(Oc2nc(Nc3ccc(cc3OC)N3CCN(C)CC3)ncc2Cl)c1, CCC(=O)Nc1cccc(Oc2nc(Nc3ccc(cc3OC)N3CCN(C)CC3)ncc2Cl)c1	SDGJBAUIGHSMRI-UHFFFAOYSA-N, SDGJBAUIGHSMRI-UHFFFAOYSA-N, SDGJBAUIGHSMRI-UHFFFAOYSA-N, SDGJBAUIGHSMRI-UHFFFAOYSA-N	Preclinical
WZ8040	EGFR inhibitor	EGFR			CN1CCN(CC1)c1ccc(Nc2ncc(Cl)c(Sc3cccc(NC(=O)C=C)c3)n2)cc1, CN1CCN(CC1)c1ccc(Nc2ncc(Cl)c(Sc3cccc(NC(=O)C=C)c3)n2)cc1, CN1CCN(CC1)c1ccc(Nc2ncc(Cl)c(Sc3cccc(NC(=O)C=C)c3)n2)cc1	KIISCIGBPUVZBF-UHFFFAOYSA-N, KIISCIGBPUVZBF-UHFFFAOYSA-N, KIISCIGBPUVZBF-UHFFFAOYSA-N	Preclinical
WZ811	CC chemokine receptor antagonist	CXCR4			C(Nc1ccccn1)c1ccc(CNc2ccccn2)cc1, C(Nc1ccccn1)c1ccc(CNc2ccccn2)cc1, C(Nc1ccccn1)c1ccc(CNc2ccccn2)cc1, C(Nc1ccccn1)c1ccc(CNc2ccccn2)cc1, C(Nc1ccccn1)c1ccc(CNc2ccccn2)cc1	KBVFRXIGQQRMEF-UHFFFAOYSA-N, KBVFRXIGQQRMEF-UHFFFAOYSA-N, KBVFRXIGQQRMEF-UHFFFAOYSA-N, KBVFRXIGQQRMEF-UHFFFAOYSA-N, KBVFRXIGQQRMEF-UHFFFAOYSA-N	Preclinical
xaliproden	serotonin receptor agonist	HTR1A			FC(F)(F)c1cccc(c1)C1=CCN(CCc2ccc3ccccc3c2)CC1 |t:11|, FC(F)(F)c1cccc(c1)C1=CCN(CCc2ccc3ccccc3c2)CC1 |t:11|, FC(F)(F)c1cccc(c1)C1=CCN(CCc2ccc3ccccc3c2)CC1 |t:11|, FC(F)(F)c1cccc(c1)C1=CCN(CCc2ccc3ccccc3c2)CC1 |t:11|	WJJYZXPHLSLMGE-UHFFFAOYSA-N, WJJYZXPHLSLMGE-UHFFFAOYSA-N, WJJYZXPHLSLMGE-UHFFFAOYSA-N, WJJYZXPHLSLMGE-UHFFFAOYSA-N	Phase 3
xamoterol	adrenergic receptor agonist	ADRB1			OC(CNCCNC(=O)N1CCOCC1)COc1ccc(O)cc1, OC(CNCCNC(=O)N1CCOCC1)COc1ccc(O)cc1, OC(CNCCNC(=O)N1CCOCC1)COc1ccc(O)cc1, OC(CNCCNC(=O)N1CCOCC1)COc1ccc(O)cc1	DXPOSRCHIDYWHW-UHFFFAOYSA-N, DXPOSRCHIDYWHW-UHFFFAOYSA-N, DXPOSRCHIDYWHW-UHFFFAOYSA-N, DXPOSRCHIDYWHW-UHFFFAOYSA-N	Phase 3
xanomeline	acetylcholine receptor agonist	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2B, HTR2C, HTR6, HTR7			CCCCCCOc1nsnc1C1=CCCN(C)C1 |t:13|, CCCCCCOc1nsnc1C1=CCCN(C)C1 |t:13|	JOLJIIDDOBNFHW-UHFFFAOYSA-N, JOLJIIDDOBNFHW-UHFFFAOYSA-N	Phase 3
xanthone	antimalarial agent				O=c1c2ccccc2oc2ccccc12, O=c1c2ccccc2oc2ccccc12	JNELGWHKGNBSMD-UHFFFAOYSA-N, JNELGWHKGNBSMD-UHFFFAOYSA-N	Preclinical
XAV-939	tankyrase inhibitor	TNKS, TNKS2			FC(F)(F)c1ccc(cc1)-c1nc(=O)c2CSCCc2[nH]1, FC(F)(F)c1ccc(cc1)-c1nc(=O)c2CSCCc2[nH]1, FC(F)(F)c1ccc(cc1)-c1nc(=O)c2CSCCc2[nH]1, FC(F)(F)c1ccc(cc1)-c1nc(=O)c2CSCCc2[nH]1	KLGQSVMIPOVQAX-UHFFFAOYSA-N, KLGQSVMIPOVQAX-UHFFFAOYSA-N, KLGQSVMIPOVQAX-UHFFFAOYSA-N, KLGQSVMIPOVQAX-UHFFFAOYSA-N	Preclinical
XBD173	benzodiazepine receptor ligand	TSPO			CCN(Cc1ccccc1)C(=O)Cn1c2nc(ncc2n(C)c1=O)-c1ccccc1, CCN(Cc1ccccc1)C(=O)Cn1c2nc(ncc2n(C)c1=O)-c1ccccc1, CCN(Cc1ccccc1)C(=O)Cn1c2nc(ncc2n(C)c1=O)-c1ccccc1	NBMBIEOUVBHEBM-UHFFFAOYSA-N, NBMBIEOUVBHEBM-UHFFFAOYSA-N, NBMBIEOUVBHEBM-UHFFFAOYSA-N	Phase 2
XD-14	bromodomain inhibitor	BRD2, BRD3, BRD4, BRDT			CCN(CC)S(=O)(=O)c1ccc(O)c(NC(=O)c2[nH]c(C)c(C(C)=O)c2CC)c1, CCN(CC)S(=O)(=O)c1ccc(O)c(NC(=O)c2[nH]c(C)c(C(C)=O)c2CC)c1	DPBKLIVPNYGQQG-UHFFFAOYSA-N, DPBKLIVPNYGQQG-UHFFFAOYSA-N	Preclinical
XE-991	potassium channel blocker	KCNQ1, KCNQ2, KCNQ3, KCNQ4, KCNQ5			O=C1c2ccccc2C(Cc2ccncc2)(Cc2ccncc2)c2ccccc12, O=C1c2ccccc2C(Cc2ccncc2)(Cc2ccncc2)c2ccccc12	KHJFBUUFMUBONL-UHFFFAOYSA-N, KHJFBUUFMUBONL-UHFFFAOYSA-N	Preclinical
xenalipin					OC(=O)c1ccccc1-c1ccc(cc1)C(F)(F)F	IQOMYCGTGFGDFN-UHFFFAOYSA-N	Phase 2
xibenolol	adrenergic receptor antagonist				Cc1cccc(OC[C@@H](O)CNC(C)(C)C)c1C |&1:8,r|	RKUQLAPSGZJLGP-ZDUSSCGKSA-N	Phase 3
xilobam					CN1CCC\C1=N\C(=O)Nc1c(C)cccc1C	PAXRPWSXCPTPCA-QINSGFPZSA-N	Phase 1
xipamide	carbonic anhydrase inhibitor	SLC12A3	cardiology	edema, hypertension	Cc1cccc(C)c1NC(=O)c1cc(c(Cl)cc1O)S(N)(=O)=O, Cc1cccc(C)c1NC(=O)c1cc(c(Cl)cc1O)S(N)(=O)=O	MTZBBNMLMNBNJL-UHFFFAOYSA-N, MTZBBNMLMNBNJL-UHFFFAOYSA-N	Launched
XL019	JAK inhibitor	JAK1, JAK2, JAK3			O=C(Nc1ccc(cc1)-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1)[C@@H]1CCCN1, O=C(Nc1ccc(cc1)-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1)[C@@H]1CCCN1, O=C(Nc1ccc(cc1)-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1)[C@@H]1CCCN1, O=C(Nc1ccc(cc1)-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1)[C@@H]1CCCN1, O=C(Nc1ccc(cc1)-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1)[C@@H]1CCCN1	ISOCDPQFIXDIMS-QHCPKHFHSA-N, ISOCDPQFIXDIMS-QHCPKHFHSA-N, ISOCDPQFIXDIMS-QHCPKHFHSA-N, ISOCDPQFIXDIMS-QHCPKHFHSA-N, ISOCDPQFIXDIMS-QHCPKHFHSA-N	Phase 1
XL041	LXR agonist				CC(C)(O)c1cn(c(n1)C(C)(C)c1c(Cl)cccc1Cl)-c1ccc(cc1F)-c1cc(F)c(CO)c(c1)S(C)(=O)=O	HNAJDMYOTDNOBK-UHFFFAOYSA-N	Preclinical
XL147	PI3K inhibitor	PIK3CA, PIK3CD, PIK3CG			Cc1ccc(cc1)S(=O)(=O)Nc1nc2ccccc2nc1Nc1ccc2nsnc2c1, Cc1ccc(cc1)S(=O)(=O)Nc1nc2ccccc2nc1Nc1ccc2nsnc2c1	MQMKRQLTIWPEDM-UHFFFAOYSA-N, MQMKRQLTIWPEDM-UHFFFAOYSA-N	Phase 2
XL228	Abl kinase inhibitor, insulin growth factor receptor inhibitor, SRC inhibitor	IGF1R, SRC			CC(C)c1cc(CNc2nc(Nc3cc(n[nH]3)C3CC3)cc(n2)N2CCN(C)CC2)on1, CC(C)c1cc(CNc2nc(Nc3cc(n[nH]3)C3CC3)cc(n2)N2CCN(C)CC2)on1, CC(C)c1cc(CNc2nc(Nc3cc(n[nH]3)C3CC3)cc(n2)N2CCN(C)CC2)on1, CC(C)c1cc(CNc2nc(Nc3cc(n[nH]3)C3CC3)cc(n2)N2CCN(C)CC2)on1	ALKJNCZNEOTEMP-UHFFFAOYSA-N, ALKJNCZNEOTEMP-UHFFFAOYSA-N, ALKJNCZNEOTEMP-UHFFFAOYSA-N, ALKJNCZNEOTEMP-UHFFFAOYSA-N	Phase 1
XL388	mTOR inhibitor	MTOR			Cc1c(F)c(ccc1C(=O)N1CCOc2ccc(cc2C1)-c1ccc(N)nc1)S(C)(=O)=O, Cc1c(F)c(ccc1C(=O)N1CCOc2ccc(cc2C1)-c1ccc(N)nc1)S(C)(=O)=O	LNFBAYSBVQBKFR-UHFFFAOYSA-N, LNFBAYSBVQBKFR-UHFFFAOYSA-N	Preclinical
XL647	EGFR inhibitor, VEGFR inhibitor	EGFR, EPHB4, ERBB2, FLT4, KDR			COc1cc2c(Nc3ccc(Cl)c(Cl)c3F)ncnc2cc1OC[C@H]1C[C@H]2CN(C)C[C@H]2C1, COc1cc2c(Nc3ccc(Cl)c(Cl)c3F)ncnc2cc1OC[C@H]1C[C@H]2CN(C)C[C@H]2C1, COc1cc2c(Nc3ccc(Cl)c(Cl)c3F)ncnc2cc1OC[C@H]1C[C@H]2CN(C)C[C@H]2C1, COc1cc2c(Nc3ccc(Cl)c(Cl)c3F)ncnc2cc1OC[C@H]1C[C@H]2CN(C)C[C@H]2C1	HVXKQKFEHMGHSL-QKDCVEJESA-N, HVXKQKFEHMGHSL-QKDCVEJESA-N, HVXKQKFEHMGHSL-QKDCVEJESA-N, HVXKQKFEHMGHSL-QKDCVEJESA-N	Phase 3
XL888	HSP inhibitor				[H][C@]1(C[C@@H]2CC[C@H](C1)N2c1ccc(cn1)C(=O)C1CC1)NC(=O)c1cc(N[C@H](C)CC)c(cc1C)C(N)=O |TLB:9:8:4.5:1.2.7|	LHGWWAFKVCIILM-HLRQEUIKSA-N	Phase 1
XMD17-109	MAP kinase inhibitor	MAPK7			CCOc1cc(ccc1Nc1ncc2N(C)C(=O)c3ccccc3N(C3CCCC3)c2n1)C(=O)N1CCC(CC1)N1CCN(C)CC1, CCOc1cc(ccc1Nc1ncc2N(C)C(=O)c3ccccc3N(C3CCCC3)c2n1)C(=O)N1CCC(CC1)N1CCN(C)CC1, CCOc1cc(ccc1Nc1ncc2N(C)C(=O)c3ccccc3N(C3CCCC3)c2n1)C(=O)N1CCC(CC1)N1CCN(C)CC1, CCOc1cc(ccc1Nc1ncc2N(C)C(=O)c3ccccc3N(C3CCCC3)c2n1)C(=O)N1CCC(CC1)N1CCN(C)CC1, CCOc1cc(ccc1Nc1ncc2N(C)C(=O)c3ccccc3N(C3CCCC3)c2n1)C(=O)N1CCC(CC1)N1CCN(C)CC1	XVBGRTMNFNMINE-UHFFFAOYSA-N, XVBGRTMNFNMINE-UHFFFAOYSA-N, XVBGRTMNFNMINE-UHFFFAOYSA-N, XVBGRTMNFNMINE-UHFFFAOYSA-N, XVBGRTMNFNMINE-UHFFFAOYSA-N	Preclinical
XMD8-92	MAP kinase inhibitor	DCLK2, MAPK7, PLK4, TNK1			CCOc1cc(ccc1Nc1ncc2N(C)C(=O)c3ccccc3N(C)c2n1)N1CCC(O)CC1, CCOc1cc(ccc1Nc1ncc2N(C)C(=O)c3ccccc3N(C)c2n1)N1CCC(O)CC1, CCOc1cc(ccc1Nc1ncc2N(C)C(=O)c3ccccc3N(C)c2n1)N1CCC(O)CC1	QAPAJIZPZGWAND-UHFFFAOYSA-N, QAPAJIZPZGWAND-UHFFFAOYSA-N, QAPAJIZPZGWAND-UHFFFAOYSA-N	Preclinical
xylazine	adrenergic receptor agonist	ADRA2A, ADRA2B, ADRA2C	neurology/psychiatry	anesthetic	Cc1cccc(C)c1NC1=NCCCS1 |t:10|, Cc1cccc(C)c1NC1=NCCCS1 |t:10|, Cc1cccc(C)c1NC1=NCCCS1 |t:10|	BPICBUSOMSTKRF-UHFFFAOYSA-N, BPICBUSOMSTKRF-UHFFFAOYSA-N, BPICBUSOMSTKRF-UHFFFAOYSA-N	Launched
xylometazoline	adrenergic receptor agonist	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C	otolaryngology, allergy	nasal congestion, allergic rhinitis	Cc1cc(cc(C)c1CC1=NCCN1)C(C)(C)C |t:10|, Cc1cc(cc(C)c1CC1=NCCN1)C(C)(C)C |t:10|, Cc1cc(cc(C)c1CC1=NCCN1)C(C)(C)C |t:10|	HUCJFAOMUPXHDK-UHFFFAOYSA-N, HUCJFAOMUPXHDK-UHFFFAOYSA-N, HUCJFAOMUPXHDK-UHFFFAOYSA-N	Launched
xylose					OC[C@@H](O)[C@H](O)[C@@H](O)C=O, OC[C@@H](O)[C@H](O)[C@@H](O)C=O	PYMYPHUHKUWMLA-VPENINKCSA-N, PYMYPHUHKUWMLA-VPENINKCSA-N	Launched
Y-11	focal adhesion kinase inhibitor	PTK2			OCC[N+]12CN3CN(CN(C3)C1)C2, OCC[N+]12CN3CN(CN(C3)C1)C2	SQWGHMPVSMSPNY-UHFFFAOYSA-N, SQWGHMPVSMSPNY-UHFFFAOYSA-N	Preclinical
Y-134	estrogen receptor antagonist	ESR1, ESR2			CC(C)N1CCN(CC1)c1ccc(cc1)C(=O)c1c(sc2cc(O)ccc12)-c1ccc(O)cc1, CC(C)N1CCN(CC1)c1ccc(cc1)C(=O)c1c(sc2cc(O)ccc12)-c1ccc(O)cc1, CC(C)N1CCN(CC1)c1ccc(cc1)C(=O)c1c(sc2cc(O)ccc12)-c1ccc(O)cc1, CC(C)N1CCN(CC1)c1ccc(cc1)C(=O)c1c(sc2cc(O)ccc12)-c1ccc(O)cc1, CC(C)N1CCN(CC1)c1ccc(cc1)C(=O)c1c(sc2cc(O)ccc12)-c1ccc(O)cc1	LQEOPHGPHCWOAC-UHFFFAOYSA-N, LQEOPHGPHCWOAC-UHFFFAOYSA-N, LQEOPHGPHCWOAC-UHFFFAOYSA-N, LQEOPHGPHCWOAC-UHFFFAOYSA-N, LQEOPHGPHCWOAC-UHFFFAOYSA-N	Preclinical
Y-26763	potassium channel activator	KCNJ8			CC(=O)N(O)[C@H]1[C@H](O)C(C)(C)Oc2ccc(cc12)C#N, CC(=O)N(O)[C@H]1[C@H](O)C(C)(C)Oc2ccc(cc12)C#N, CC(=O)N(O)[C@H]1[C@H](O)C(C)(C)Oc2ccc(cc12)C#N	IWTCFIIOUXJOOV-OLZOCXBDSA-N, IWTCFIIOUXJOOV-OLZOCXBDSA-N, IWTCFIIOUXJOOV-OLZOCXBDSA-N	Phase 1
Y-27152	potassium channel activator	KCNJ8			CC(=O)N(OCc1ccccc1)[C@H]1[C@H](O)C(C)(C)Oc2ccc(cc12)C#N, CC(=O)N(OCc1ccccc1)[C@H]1[C@H](O)C(C)(C)Oc2ccc(cc12)C#N	RHFUXPCCELGMFC-UXHICEINSA-N, RHFUXPCCELGMFC-UXHICEINSA-N	Phase 1
Y-27632	rho associated kinase inhibitor	PKIA, PKN2, PRKACA, PRKCE, ROCK1, ROCK2			C[C@@H](N)[C@H]1CC[C@@H](CC1)C(=O)Nc1ccncc1, C[C@@H](N)[C@H]1CC[C@@H](CC1)C(=O)Nc1ccncc1, C[C@@H](N)[C@H]1CC[C@@H](CC1)C(=O)Nc1ccncc1, C[C@@H](N)[C@H]1CC[C@@H](CC1)C(=O)Nc1ccncc1, C[C@@H](N)[C@H]1CC[C@@H](CC1)C(=O)Nc1ccncc1	IYOZTVGMEWJPKR-IJLUTSLNSA-N, IYOZTVGMEWJPKR-IJLUTSLNSA-N, IYOZTVGMEWJPKR-IJLUTSLNSA-N, IYOZTVGMEWJPKR-IJLUTSLNSA-N, IYOZTVGMEWJPKR-IJLUTSLNSA-N	Preclinical
Y-29794	prolyl endopeptidase inhibitor	PREP			CC(C)c1ccc(C(=O)c2cccs2)c(SCCCCCCCCN(C)C)n1, CC(C)c1ccc(C(=O)c2cccs2)c(SCCCCCCCCN(C)C)n1	HAGHKJDWBDSFKC-UHFFFAOYSA-N, HAGHKJDWBDSFKC-UHFFFAOYSA-N	Preclinical
Y-320	interleukin inhibitor	IL17A			Cc1c(cnn1-c1ccc(Cl)cc1)C(=O)Nc1ccc(N2CCC(CC2)N2CCOCC2)c(c1)C#N, Cc1c(cnn1-c1ccc(Cl)cc1)C(=O)Nc1ccc(N2CCC(CC2)N2CCOCC2)c(c1)C#N	BWZNJVZTAWBIFG-UHFFFAOYSA-N, BWZNJVZTAWBIFG-UHFFFAOYSA-N	Preclinical
Y-39983	rho associated kinase inhibitor	ROCK1, ROCK2			C[C@@H](N)c1ccc(cc1)C(=O)Nc1ccnc2[nH]ccc12, C[C@@H](N)c1ccc(cc1)C(=O)Nc1ccnc2[nH]ccc12, C[C@@H](N)c1ccc(cc1)C(=O)Nc1ccnc2[nH]ccc12, C[C@@H](N)c1ccc(cc1)C(=O)Nc1ccnc2[nH]ccc12, C[C@@H](N)c1ccc(cc1)C(=O)Nc1ccnc2[nH]ccc12, C[C@@H](N)c1ccc(cc1)C(=O)Nc1ccnc2[nH]ccc12, C[C@@H](N)c1ccc(cc1)C(=O)Nc1ccnc2[nH]ccc12	JTVBXQAYBIJXRP-SNVBAGLBSA-N, JTVBXQAYBIJXRP-SNVBAGLBSA-N, JTVBXQAYBIJXRP-SNVBAGLBSA-N, JTVBXQAYBIJXRP-SNVBAGLBSA-N, JTVBXQAYBIJXRP-SNVBAGLBSA-N, JTVBXQAYBIJXRP-SNVBAGLBSA-N, JTVBXQAYBIJXRP-SNVBAGLBSA-N	Phase 2
YC-1	guanylyl cyclase activator	GUCY1A2, GUCY1A3, GUCY1B3, HIF1A			OCc1ccc(o1)-c1nn(Cc2ccccc2)c2ccccc12, OCc1ccc(o1)-c1nn(Cc2ccccc2)c2ccccc12	OQQVFCKUDYMWGV-UHFFFAOYSA-N, OQQVFCKUDYMWGV-UHFFFAOYSA-N	Preclinical
YIL-781	ghrelin receptor antagonist	GHSR			CC(C)N1CCC[C@H](Cn2c(C)nc3ccc(Oc4ccc(F)cc4)cc3c2=O)C1, CC(C)N1CCC[C@H](Cn2c(C)nc3ccc(Oc4ccc(F)cc4)cc3c2=O)C1	FRKXOBMDEXCHHD-SFHVURJKSA-N, FRKXOBMDEXCHHD-SFHVURJKSA-N	Preclinical
YK-4-279	apoptosis inhibitor	EWSR1, FLI1			COc1ccc(cc1)C(=O)C[C@@]1(O)C(=O)Nc2c1c(Cl)ccc2Cl |&1:11,r|, COc1ccc(cc1)C(=O)C[C@@]1(O)C(=O)Nc2c1c(Cl)ccc2Cl |&1:11,r|	HLXSCTYHLQHQDJ-KRWDZBQOSA-N, HLXSCTYHLQHQDJ-KRWDZBQOSA-N	Preclinical
YL0919	selective serotonin reuptake inhibitor (SSRI)				OC1(Cn2ccccc2=O)CCN(Cc2ccccc2)CC1	BGMVOROUOUVVRV-UHFFFAOYSA-N	Preclinical
YM-022	CCK receptor antagonist	CCKBR			Cc1cccc(NC(=O)N[C@@H]2N=C(c3ccccc3)c3ccccc3N(CC(=O)c3ccccc3C)C2=O)c1 |t:11|	YCXFHPUBGMMWJQ-PMERELPUSA-N	Phase 2
YM-155	survivin inhibitor	BIRC5			COCCn1c(C)[n+](Cc2cnccn2)c2c1C(=O)c1ccccc1C2=O, COCCn1c(C)[n+](Cc2cnccn2)c2c1C(=O)c1ccccc1C2=O, COCCn1c(C)[n+](Cc2cnccn2)c2c1C(=O)c1ccccc1C2=O, COCCn1c(C)[n+](Cc2cnccn2)c2c1C(=O)c1ccccc1C2=O, COCCn1c(C)[n+](Cc2cnccn2)c2c1C(=O)c1ccccc1C2=O	OTSOOHRUMBRSHZ-UHFFFAOYSA-N, OTSOOHRUMBRSHZ-UHFFFAOYSA-N, OTSOOHRUMBRSHZ-UHFFFAOYSA-N, OTSOOHRUMBRSHZ-UHFFFAOYSA-N, OTSOOHRUMBRSHZ-UHFFFAOYSA-N	Phase 2
YM-201636	PI3K inhibitor				Nc1ccc(cn1)C(=O)Nc1cccc(c1)-c1nc(N2CCOCC2)c2oc3ncccc3c2n1, Nc1ccc(cn1)C(=O)Nc1cccc(c1)-c1nc(N2CCOCC2)c2oc3ncccc3c2n1, Nc1ccc(cn1)C(=O)Nc1cccc(c1)-c1nc(N2CCOCC2)c2oc3ncccc3c2n1	YBPIBGNBHHGLEB-UHFFFAOYSA-N, YBPIBGNBHHGLEB-UHFFFAOYSA-N, YBPIBGNBHHGLEB-UHFFFAOYSA-N	Preclinical
YM-244769	sodium/calcium exchange inhibitor				Nc1cccc(CNC(=O)c2ccc(Oc3ccc(OCc4cccc(F)c4)cc3)nc2)c1, Nc1cccc(CNC(=O)c2ccc(Oc3ccc(OCc4cccc(F)c4)cc3)nc2)c1	JZMLHJRKSJXARY-UHFFFAOYSA-N, JZMLHJRKSJXARY-UHFFFAOYSA-N	Preclinical
YM-298198	glutamate receptor antagonist	GRM1			CN(C1CCCCC1)C(=O)c1sc2nc3ccc(N)cc3n2c1C, CN(C1CCCCC1)C(=O)c1sc2nc3ccc(N)cc3n2c1C, CN(C1CCCCC1)C(=O)c1sc2nc3ccc(N)cc3n2c1C	KCBXOMYXOBVLED-UHFFFAOYSA-N, KCBXOMYXOBVLED-UHFFFAOYSA-N, KCBXOMYXOBVLED-UHFFFAOYSA-N	Preclinical
YM-298198-desmethyl	glutamate receptor antagonist	GRM1			Cc1c(sc2nc3ccc(N)cc3n12)C(=O)NC1CCCCC1, Cc1c(sc2nc3ccc(N)cc3n12)C(=O)NC1CCCCC1	VWOMTTIMBHBPBI-UHFFFAOYSA-N, VWOMTTIMBHBPBI-UHFFFAOYSA-N	Preclinical
YM-511	aromatase inhibitor	CYP19A1			Brc1ccc(CN(c2ccc(cc2)C#N)n2cnnc2)cc1	GGPPBTSXFROGAE-UHFFFAOYSA-N	Phase 2
YM-58483	calcium channel blocker	TRPC3, TRPC5, TRPM4			Cc1nnsc1C(=O)Nc1ccc(cc1)-n1nc(cc1C(F)(F)F)C(F)(F)F, Cc1nnsc1C(=O)Nc1ccc(cc1)-n1nc(cc1C(F)(F)F)C(F)(F)F, Cc1nnsc1C(=O)Nc1ccc(cc1)-n1nc(cc1C(F)(F)F)C(F)(F)F, Cc1nnsc1C(=O)Nc1ccc(cc1)-n1nc(cc1C(F)(F)F)C(F)(F)F, Cc1nnsc1C(=O)Nc1ccc(cc1)-n1nc(cc1C(F)(F)F)C(F)(F)F, Cc1nnsc1C(=O)Nc1ccc(cc1)-n1nc(cc1C(F)(F)F)C(F)(F)F, Cc1nnsc1C(=O)Nc1ccc(cc1)-n1nc(cc1C(F)(F)F)C(F)(F)F, Cc1nnsc1C(=O)Nc1ccc(cc1)-n1nc(cc1C(F)(F)F)C(F)(F)F, Cc1nnsc1C(=O)Nc1ccc(cc1)-n1nc(cc1C(F)(F)F)C(F)(F)F	XPRZIORDEVHURQ-UHFFFAOYSA-N, XPRZIORDEVHURQ-UHFFFAOYSA-N, XPRZIORDEVHURQ-UHFFFAOYSA-N, XPRZIORDEVHURQ-UHFFFAOYSA-N, XPRZIORDEVHURQ-UHFFFAOYSA-N, XPRZIORDEVHURQ-UHFFFAOYSA-N, XPRZIORDEVHURQ-UHFFFAOYSA-N, XPRZIORDEVHURQ-UHFFFAOYSA-N, XPRZIORDEVHURQ-UHFFFAOYSA-N	Preclinical
YM-750	ACAT inhibitor	SOAT1			Cc1cc(C)c(NC(=O)N(Cc2ccc-3c(Cc4ccccc-34)c2)C2CCCCCC2)c(C)c1, Cc1cc(C)c(NC(=O)N(Cc2ccc-3c(Cc4ccccc-34)c2)C2CCCCCC2)c(C)c1	FMLJREWZCZHGGW-UHFFFAOYSA-N, FMLJREWZCZHGGW-UHFFFAOYSA-N	Phase 1
YM-90709	IL5 inhibitor	CSF2RB, IL5RA			COc1cc2CC(C)(C)n3c(cc4nc5ccccc5nc34)-c2cc1OC, COc1cc2CC(C)(C)n3c(cc4nc5ccccc5nc34)-c2cc1OC, COc1cc2CC(C)(C)n3c(cc4nc5ccccc5nc34)-c2cc1OC	HIXSPVQXXDULHS-UHFFFAOYSA-N, HIXSPVQXXDULHS-UHFFFAOYSA-N, HIXSPVQXXDULHS-UHFFFAOYSA-N	Preclinical
YM-976	phosphodiesterase inhibitor	PDE4A			CCc1ccc2c(nc(=O)n(CC)c2n1)-c1cccc(Cl)c1, CCc1ccc2c(nc(=O)n(CC)c2n1)-c1cccc(Cl)c1, CCc1ccc2c(nc(=O)n(CC)c2n1)-c1cccc(Cl)c1, CCc1ccc2c(nc(=O)n(CC)c2n1)-c1cccc(Cl)c1	MNHXYNNKDDXKNP-UHFFFAOYSA-N, MNHXYNNKDDXKNP-UHFFFAOYSA-N, MNHXYNNKDDXKNP-UHFFFAOYSA-N, MNHXYNNKDDXKNP-UHFFFAOYSA-N	Phase 1
YO-01027	gamma secretase inhibitor				C[C@H](NC(=O)Cc1cc(F)cc(F)c1)C(=O)N[C@H]1c2ccccc2-c2ccccc2N(C)C1=O, C[C@H](NC(=O)Cc1cc(F)cc(F)c1)C(=O)N[C@H]1c2ccccc2-c2ccccc2N(C)C1=O, C[C@H](NC(=O)Cc1cc(F)cc(F)c1)C(=O)N[C@H]1c2ccccc2-c2ccccc2N(C)C1=O	QSHGISMANBKLQL-OWJWWREXSA-N, QSHGISMANBKLQL-OWJWWREXSA-N, QSHGISMANBKLQL-OWJWWREXSA-N	Preclinical
yoda-1	piezo channel activator	PIEZO1			Clc1cccc(Cl)c1CSc1nnc(s1)-c1cnccn1, Clc1cccc(Cl)c1CSc1nnc(s1)-c1cnccn1, Clc1cccc(Cl)c1CSc1nnc(s1)-c1cnccn1	BQNXBSYSQXSXPT-UHFFFAOYSA-N, BQNXBSYSQXSXPT-UHFFFAOYSA-N, BQNXBSYSQXSXPT-UHFFFAOYSA-N	Preclinical
yohimbine	adrenergic receptor antagonist	ADRA2A, ADRA2B, ADRA2C, DRD2, DRD3, HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2B, HTR2C, HTR5A, HTR7, KCNJ1, KCNJ10, KCNJ11, KCNJ12, KCNJ14, KCNJ15, KCNJ8	cardiology	cardiac arrythmia, bradycardia	COC(=O)[C@H]1[C@@H](O)CC[C@H]2CN3CCc4c([nH]c5ccccc45)[C@@H]3C[C@H]12, COC(=O)[C@H]1[C@@H](O)CC[C@H]2CN3CCc4c([nH]c5ccccc45)[C@@H]3C[C@H]12, COC(=O)[C@H]1[C@@H](O)CC[C@H]2CN3CCc4c([nH]c5ccccc45)[C@@H]3C[C@H]12, COC(=O)[C@H]1[C@@H](O)CC[C@H]2CN3CCc4c([nH]c5ccccc45)[C@@H]3C[C@H]12	BLGXFZZNTVWLAY-SCYLSFHTSA-N, BLGXFZZNTVWLAY-SCYLSFHTSA-N, BLGXFZZNTVWLAY-SCYLSFHTSA-N, BLGXFZZNTVWLAY-SCYLSFHTSA-N	Launched
YS-035	calcium channel blocker				COc1ccc(CCN(C)CCc2ccc(OC)c(OC)c2)cc1OC, COc1ccc(CCN(C)CCc2ccc(OC)c(OC)c2)cc1OC	OXZMQFKVNVQMLI-UHFFFAOYSA-N, OXZMQFKVNVQMLI-UHFFFAOYSA-N	Preclinical
YS-201	calcium receptor antagonist				CCOC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OCCN1CCCCC1 |&1:12,r,c:5,10|	LBSRZVRITCRLIU-JOCHJYFZSA-N	Preclinical
YZ9	phosphofructokinase inhibitor	MIF, PFKFB3			CCOC(=O)c1cc2ccc(O)cc2oc1=O, CCOC(=O)c1cc2ccc(O)cc2oc1=O, CCOC(=O)c1cc2ccc(O)cc2oc1=O	IETDBZQIWIJQJG-UHFFFAOYSA-N, IETDBZQIWIJQJG-UHFFFAOYSA-N, IETDBZQIWIJQJG-UHFFFAOYSA-N	Preclinical
Y16	rho associated kinase inhibitor	RHOA			Cc1cccc(COc2cccc(\C=C3/C(=O)NN(C3=O)c3ccccc3)c2)c1, Cc1cccc(COc2cccc(\C=C3/C(=O)NN(C3=O)c3ccccc3)c2)c1	ITMLWGWTDWJSRZ-PXLXIMEGSA-N, ITMLWGWTDWJSRZ-PXLXIMEGSA-N	Preclinical
zacopride	serotonin receptor antagonist	HTR3A, HTR3B, HTR4, HTR5A			COc1cc(N)c(Cl)cc1C(=O)N[C@H]1CN2CCC1CC2 |&1:13,THB:12:13:16.17:19.20|, COc1cc(N)c(Cl)cc1C(=O)N[C@H]1CN2CCC1CC2 |&1:13,THB:12:13:16.17:19.20|	FEROPKNOYKURCJ-ZDUSSCGKSA-N, FEROPKNOYKURCJ-ZDUSSCGKSA-N	Phase 2
zafirlukast	leukotriene receptor antagonist	CYSLTR1, CYSLTR2	pulmonary	asthma	COc1cc(ccc1Cc1cn(C)c2ccc(NC(=O)OC3CCCC3)cc12)C(=O)NS(=O)(=O)c1ccccc1C, COc1cc(ccc1Cc1cn(C)c2ccc(NC(=O)OC3CCCC3)cc12)C(=O)NS(=O)(=O)c1ccccc1C, COc1cc(ccc1Cc1cn(C)c2ccc(NC(=O)OC3CCCC3)cc12)C(=O)NS(=O)(=O)c1ccccc1C	YEEZWCHGZNKEEK-UHFFFAOYSA-N, YEEZWCHGZNKEEK-UHFFFAOYSA-N, YEEZWCHGZNKEEK-UHFFFAOYSA-N	Launched
zalcitabine	nucleoside reverse transcriptase inhibitor		infectious disease	human immunodeficiency virus (HIV-1)	Nc1ccn([C@H]2CC[C@@H](CO)O2)c(=O)n1, Nc1ccn([C@H]2CC[C@@H](CO)O2)c(=O)n1, Nc1ccn([C@H]2CC[C@@H](CO)O2)c(=O)n1, Nc1ccn([C@H]2CC[C@@H](CO)O2)c(=O)n1, Nc1ccn([C@H]2CC[C@@H](CO)O2)c(=O)n1	WREGKURFCTUGRC-POYBYMJQSA-N, WREGKURFCTUGRC-POYBYMJQSA-N, WREGKURFCTUGRC-POYBYMJQSA-N, WREGKURFCTUGRC-POYBYMJQSA-N, WREGKURFCTUGRC-POYBYMJQSA-N	Launched
zaldaride	calmodulin antagonist	CALM1			C[C@@]1(CN2CCC(CC2)n2c3ccccc3[nH]c2=O)OCc2ccccc2-n2cccc12 |&1:1|, C[C@@]1(CN2CCC(CC2)n2c3ccccc3[nH]c2=O)OCc2ccccc2-n2cccc12 |&1:1|, C[C@@]1(CN2CCC(CC2)n2c3ccccc3[nH]c2=O)OCc2ccccc2-n2cccc12 |&1:1|, C[C@@]1(CN2CCC(CC2)n2c3ccccc3[nH]c2=O)OCc2ccccc2-n2cccc12 |&1:1|	HTGCJAAPDHZCHL-SANMLTNESA-N, HTGCJAAPDHZCHL-SANMLTNESA-N, HTGCJAAPDHZCHL-SANMLTNESA-N, HTGCJAAPDHZCHL-SANMLTNESA-N	Phase 3
zaltidine	histamine receptor antagonist	HRH2			Cc1nc(c[nH]1)-c1csc(NC(N)=N)n1, Cc1nc(c[nH]1)-c1csc(NC(N)=N)n1	GIMNAEMRNXUAQP-UHFFFAOYSA-N, GIMNAEMRNXUAQP-UHFFFAOYSA-N	Phase 3
zaltoprofen	cyclooxygenase inhibitor		endocrinology, neurology/psychiatry	fever, pain relief	C[C@@H](C(O)=O)c1ccc2Sc3ccccc3C(=O)Cc2c1 |&1:1,r|, C[C@@H](C(O)=O)c1ccc2Sc3ccccc3C(=O)Cc2c1 |&1:1,r|	MUXFZBHBYYYLTH-SNVBAGLBSA-N, MUXFZBHBYYYLTH-SNVBAGLBSA-N	Launched
ZAMI-633	urease inhibitor				CCC(=O)NO	RSIPQHOWTCNEBI-UHFFFAOYSA-N	Phase 3
zamifenacin	acetylcholine receptor antagonist	CHRM3			C(Cc1ccc2OCOc2c1)N1CCC[C@H](C1)OC(c1ccccc1)c1ccccc1, C(Cc1ccc2OCOc2c1)N1CCC[C@H](C1)OC(c1ccccc1)c1ccccc1, C(Cc1ccc2OCOc2c1)N1CCC[C@H](C1)OC(c1ccccc1)c1ccccc1	BDNFQGRSKSQXRI-XMMPIXPASA-N, BDNFQGRSKSQXRI-XMMPIXPASA-N, BDNFQGRSKSQXRI-XMMPIXPASA-N	Phase 3
zanamivir	neuraminidase inhibitor	NEU2	infectious disease	influenza A virus infection	CC(=O)N[C@@H]1[C@@H](NC(N)=N)C=C(O[C@H]1[C@H](O)[C@H](O)CO)C(O)=O |c:10|, CC(=O)N[C@@H]1[C@@H](NC(N)=N)C=C(O[C@H]1[C@H](O)[C@H](O)CO)C(O)=O |c:10|, CC(=O)N[C@@H]1[C@@H](NC(N)=N)C=C(O[C@H]1[C@H](O)[C@H](O)CO)C(O)=O |c:10|	ARAIBEBZBOPLMB-UFGQHTETSA-N, ARAIBEBZBOPLMB-UFGQHTETSA-N, ARAIBEBZBOPLMB-UFGQHTETSA-N	Launched
zanubrutinib	Bruton's tyrosine kinase (BTK) inhibitor				NC(=O)c1c2NCC[C@@H](C3CCN(CC3)C(=O)C=C)n2nc1-c1ccc(Oc2ccccc2)cc1	RNOAOAWBMHREKO-QFIPXVFZSA-N	Launched
ZAPA					NC(=N)S\C=C/C(O)=O, NC(=N)S\C=C/C(O)=O	QEYNZJBVNYDZKZ-UPHRSURJSA-N, QEYNZJBVNYDZKZ-UPHRSURJSA-N	Preclinical
zaprinast	phosphodiesterase inhibitor	GPR35, PDE1A, PDE4D, PDE5A, PDE9A			CCCOc1ccccc1-c1nc(=O)c2n[nH]nc2[nH]1, CCCOc1ccccc1-c1nc(=O)c2n[nH]nc2[nH]1, CCCOc1ccccc1-c1nc(=O)c2n[nH]nc2[nH]1, CCCOc1ccccc1-c1nc(=O)c2n[nH]nc2[nH]1, CCCOc1ccccc1-c1nc(=O)c2n[nH]nc2[nH]1	REZGGXNDEMKIQB-UHFFFAOYSA-N, REZGGXNDEMKIQB-UHFFFAOYSA-N, REZGGXNDEMKIQB-UHFFFAOYSA-N, REZGGXNDEMKIQB-UHFFFAOYSA-N, REZGGXNDEMKIQB-UHFFFAOYSA-N	Phase 2
zardaverine	phosphodiesterase inhibitor	PDE4D			COc1cc(ccc1OC(F)F)-c1ccc(=O)[nH]n1, COc1cc(ccc1OC(F)F)-c1ccc(=O)[nH]n1, COc1cc(ccc1OC(F)F)-c1ccc(=O)[nH]n1, COc1cc(ccc1OC(F)F)-c1ccc(=O)[nH]n1, COc1cc(ccc1OC(F)F)-c1ccc(=O)[nH]n1, COc1cc(ccc1OC(F)F)-c1ccc(=O)[nH]n1, COc1cc(ccc1OC(F)F)-c1ccc(=O)[nH]n1, COc1cc(ccc1OC(F)F)-c1ccc(=O)[nH]n1	HJMQDJPMQIHLPB-UHFFFAOYSA-N, HJMQDJPMQIHLPB-UHFFFAOYSA-N, HJMQDJPMQIHLPB-UHFFFAOYSA-N, HJMQDJPMQIHLPB-UHFFFAOYSA-N, HJMQDJPMQIHLPB-UHFFFAOYSA-N, HJMQDJPMQIHLPB-UHFFFAOYSA-N, HJMQDJPMQIHLPB-UHFFFAOYSA-N, HJMQDJPMQIHLPB-UHFFFAOYSA-N	Phase 2
zatebradine	HCN channel blocker	HCN1, HCN2, HCN3, HCN4			COc1ccc(CCN(C)CCCN2CCc3cc(OC)c(OC)cc3CC2=O)cc1OC, COc1ccc(CCN(C)CCCN2CCc3cc(OC)c(OC)cc3CC2=O)cc1OC, COc1ccc(CCN(C)CCCN2CCc3cc(OC)c(OC)cc3CC2=O)cc1OC	KEDQCFRVSHYKLR-UHFFFAOYSA-N, KEDQCFRVSHYKLR-UHFFFAOYSA-N, KEDQCFRVSHYKLR-UHFFFAOYSA-N	Phase 3
ZCL-278	CDC inhibitor	CDC42			Cc1cc(C)nc(NS(=O)(=O)c2ccc(NC(=S)NC(=O)COc3ccc(Br)cc3Cl)cc2)n1, Cc1cc(C)nc(NS(=O)(=O)c2ccc(NC(=S)NC(=O)COc3ccc(Br)cc3Cl)cc2)n1, Cc1cc(C)nc(NS(=O)(=O)c2ccc(NC(=S)NC(=O)COc3ccc(Br)cc3Cl)cc2)n1, Cc1cc(C)nc(NS(=O)(=O)c2ccc(NC(=S)NC(=O)COc3ccc(Br)cc3Cl)cc2)n1	XKZDWYDHEBCGCG-UHFFFAOYSA-N, XKZDWYDHEBCGCG-UHFFFAOYSA-N, XKZDWYDHEBCGCG-UHFFFAOYSA-N, XKZDWYDHEBCGCG-UHFFFAOYSA-N	Preclinical
ZD-0947	potassium channel activator				FC(F)(F)C1=C[C@H](C2=C(CCCC2=O)N1)c1cccc(c1)C#N |t:4,7|	RUVMMEREJMHLOS-LBPRGKRZSA-N	Preclinical
ZD-2079	adrenergic receptor agonist	ADRB3			O[C@@H](CNCCOc1ccc(CC(O)=O)cc1)c1ccccc1, O[C@@H](CNCCOc1ccc(CC(O)=O)cc1)c1ccccc1	SRBPKVWITYPHQR-KRWDZBQOSA-N, SRBPKVWITYPHQR-KRWDZBQOSA-N	Phase 2
ZD-7114	adrenergic receptor agonist	ADRB3			COCCNC(=O)COc1ccc(OCCNC[C@H](O)COc2ccccc2)cc1, COCCNC(=O)COc1ccc(OCCNC[C@H](O)COc2ccccc2)cc1, COCCNC(=O)COc1ccc(OCCNC[C@H](O)COc2ccccc2)cc1, COCCNC(=O)COc1ccc(OCCNC[C@H](O)COc2ccccc2)cc1	RVMBDLSFFNKKLG-SFHVURJKSA-N, RVMBDLSFFNKKLG-SFHVURJKSA-N, RVMBDLSFFNKKLG-SFHVURJKSA-N, RVMBDLSFFNKKLG-SFHVURJKSA-N	Phase 1
ZD-7155	angiotensin receptor antagonist	AGTR1			CCc1cc2N(Cc3ccc(cc3)-c3ccccc3-c3nn[nH]n3)C(=O)CCc2c(CC)n1, CCc1cc2N(Cc3ccc(cc3)-c3ccccc3-c3nn[nH]n3)C(=O)CCc2c(CC)n1, CCc1cc2N(Cc3ccc(cc3)-c3ccccc3-c3nn[nH]n3)C(=O)CCc2c(CC)n1, CCc1cc2N(Cc3ccc(cc3)-c3ccccc3-c3nn[nH]n3)C(=O)CCc2c(CC)n1, CCc1cc2N(Cc3ccc(cc3)-c3ccccc3-c3nn[nH]n3)C(=O)CCc2c(CC)n1	BFVNEYDCFJNLGN-UHFFFAOYSA-N, BFVNEYDCFJNLGN-UHFFFAOYSA-N, BFVNEYDCFJNLGN-UHFFFAOYSA-N, BFVNEYDCFJNLGN-UHFFFAOYSA-N, BFVNEYDCFJNLGN-UHFFFAOYSA-N	Preclinical
ZD-7288	HCN channel blocker	HCN1, HCN2, HCN3, HCN4			CCN(c1ccccc1)c1cc(=NC)n(C)c(C)n1, CCN(c1ccccc1)c1cc(=NC)n(C)c(C)n1, CCN(c1ccccc1)c1cc(=NC)n(C)c(C)n1, CCN(c1ccccc1)c1cc(=NC)n(C)c(C)n1, CCN(c1ccccc1)c1cc(=NC)n(C)c(C)n1, CCN(c1ccccc1)c1cc(=NC)n(C)c(C)n1	JABSKGQQWUDVRU-UHFFFAOYSA-N, JABSKGQQWUDVRU-UHFFFAOYSA-N, JABSKGQQWUDVRU-UHFFFAOYSA-N, JABSKGQQWUDVRU-UHFFFAOYSA-N, JABSKGQQWUDVRU-UHFFFAOYSA-N, JABSKGQQWUDVRU-UHFFFAOYSA-N	Phase 2
zeatin					C\C(CO)=C/CNc1ncnc2nc[nH]c12	UZKQTCBAMSWPJD-FARCUNLSSA-N	Phase 1
zebularine	DNA methyltransferase inhibitor	CDA, DNMT1			OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cccnc1=O, OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cccnc1=O, OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cccnc1=O, OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cccnc1=O, OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cccnc1=O	RPQZTTQVRYEKCR-WCTZXXKLSA-N, RPQZTTQVRYEKCR-WCTZXXKLSA-N, RPQZTTQVRYEKCR-WCTZXXKLSA-N, RPQZTTQVRYEKCR-WCTZXXKLSA-N, RPQZTTQVRYEKCR-WCTZXXKLSA-N	Preclinical
zibotentan	endothelin receptor antagonist	EDNRA			COc1nc(C)cnc1NS(=O)(=O)c1cccnc1-c1ccc(cc1)-c1nnco1, COc1nc(C)cnc1NS(=O)(=O)c1cccnc1-c1ccc(cc1)-c1nnco1, COc1nc(C)cnc1NS(=O)(=O)c1cccnc1-c1ccc(cc1)-c1nnco1	FJHHZXWJVIEFGJ-UHFFFAOYSA-N, FJHHZXWJVIEFGJ-UHFFFAOYSA-N, FJHHZXWJVIEFGJ-UHFFFAOYSA-N	Phase 3
zidovudine	nucleoside reverse transcriptase inhibitor	TERT	infectious disease	human immunodeficiency virus (HIV-1), acquired immunodeficiency syndrome (AIDS)	Cc1cn([C@H]2C[C@H](N=[N+]=[N-])[C@@H](CO)O2)c(=O)[nH]c1=O, Cc1cn([C@H]2C[C@H](N=[N+]=[N-])[C@@H](CO)O2)c(=O)[nH]c1=O, Cc1cn([C@H]2C[C@H](N=[N+]=[N-])[C@@H](CO)O2)c(=O)[nH]c1=O	HBOMLICNUCNMMY-XLPZGREQSA-N, HBOMLICNUCNMMY-XLPZGREQSA-N, HBOMLICNUCNMMY-XLPZGREQSA-N	Launched
zileuton	leukotriene synthesis inhibitor, lipoxygenase inhibitor	ALOX5	pulmonary	asthma	C[C@@H](N(O)C(N)=O)c1cc2ccccc2s1 |&1:1,r|, C[C@@H](N(O)C(N)=O)c1cc2ccccc2s1 |&1:1,r|, C[C@@H](N(O)C(N)=O)c1cc2ccccc2s1 |&1:1,r|, C[C@@H](N(O)C(N)=O)c1cc2ccccc2s1 |&1:1,r|, C[C@@H](N(O)C(N)=O)c1cc2ccccc2s1 |&1:1,r|	MWLSOWXNZPKENC-SSDOTTSWSA-N, MWLSOWXNZPKENC-SSDOTTSWSA-N, MWLSOWXNZPKENC-SSDOTTSWSA-N, MWLSOWXNZPKENC-SSDOTTSWSA-N, MWLSOWXNZPKENC-SSDOTTSWSA-N	Launched
zilpaterol	adrenergic receptor agonist	ADRB2	endocrinology	weight-gain aid	CC(C)N[C@H]1CCn2c3c(cccc3[nH]c2=O)[C@@H]1O	ZSTCZWJCLIRCOJ-AAEUAGOBSA-N	Launched
zimelidine	selective serotonin reuptake inhibitor (SSRI)	MAOA, MAOB, SLC6A4			CN(C)C\C=C(\c1ccc(Br)cc1)c1cccnc1, CN(C)C\C=C(\c1ccc(Br)cc1)c1cccnc1	OYPPVKRFBIWMSX-SXGWCWSVSA-N, OYPPVKRFBIWMSX-SXGWCWSVSA-N	Withdrawn
zinc-undecylenate	other antifungal		infectious disease	tinea pedis	C=CCCCCCCCCC(=O)O[Zn]OC(=O)CCCCCCCCC=C, C=CCCCCCCCCC(=O)O[Zn]OC(=O)CCCCCCCCC=C	YMCOHQVWOBMDCZ-UHFFFAOYSA-L, YMCOHQVWOBMDCZ-UHFFFAOYSA-L	Launched
zindotrine	phosphodiesterase inhibitor				Cc1cc(nn2cnnc12)N1CCCCC1	YYHWOTFWBVRTQD-UHFFFAOYSA-N	Phase 2
ziprasidone	dopamine receptor antagonist, serotonin receptor antagonist	ADRA1A, ADRA1B, ADRA2A, ADRA2B, ADRA2C, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, DRD1, DRD2, DRD3, DRD4, DRD5, HRH1, HTR1A, HTR1B, HTR1D, HTR1E, HTR2A, HTR2C, HTR3A, HTR6, HTR7, SLC6A4	neurology/psychiatry	schizophrenia, bipolar disorder	Clc1cc2NC(=O)Cc2cc1CCN1CCN(CC1)c1nsc2ccccc12, Clc1cc2NC(=O)Cc2cc1CCN1CCN(CC1)c1nsc2ccccc12	MVWVFYHBGMAFLY-UHFFFAOYSA-N, MVWVFYHBGMAFLY-UHFFFAOYSA-N	Launched
ziritaxestat	autotaxin inhibitor				CCc1nc2c(C)cc(cn2c1N(C)c1nc(c(s1)C#N)-c1ccc(F)cc1)N1CCN(CC(=O)N2CC(O)C2)CC1	REQQVBGILUTQNN-UHFFFAOYSA-N	Phase 3
ZK-164015	estrogen receptor antagonist	ESR1, ESR2			CCCCCS(=O)(=O)CCCCCCCCCCn1c(c(C)c2cc(O)ccc12)-c1ccc(O)cc1, CCCCCS(=O)(=O)CCCCCCCCCCn1c(c(C)c2cc(O)ccc12)-c1ccc(O)cc1, CCCCCS(=O)(=O)CCCCCCCCCCn1c(c(C)c2cc(O)ccc12)-c1ccc(O)cc1	LYJSJVYJLZOMCD-UHFFFAOYSA-N, LYJSJVYJLZOMCD-UHFFFAOYSA-N, LYJSJVYJLZOMCD-UHFFFAOYSA-N	Preclinical
ZK-200775	kainate receptor antagonist				OP(O)(=O)Cn1c2cc(N3CCOCC3)c(cc2[nH]c(=O)c1=O)C(F)(F)F, OP(O)(=O)Cn1c2cc(N3CCOCC3)c(cc2[nH]c(=O)c1=O)C(F)(F)F, OP(O)(=O)Cn1c2cc(N3CCOCC3)c(cc2[nH]c(=O)c1=O)C(F)(F)F, OP(O)(=O)Cn1c2cc(N3CCOCC3)c(cc2[nH]c(=O)c1=O)C(F)(F)F	WZMQMKNCWDCCMT-UHFFFAOYSA-N, WZMQMKNCWDCCMT-UHFFFAOYSA-N, WZMQMKNCWDCCMT-UHFFFAOYSA-N, WZMQMKNCWDCCMT-UHFFFAOYSA-N	Phase 2
ZK-811752	CC chemokine receptor antagonist	CCR1			C[C@@H]1CN(Cc2ccc(F)cc2)CCN1C(=O)COc1ccc(Cl)cc1NC(N)=O, C[C@@H]1CN(Cc2ccc(F)cc2)CCN1C(=O)COc1ccc(Cl)cc1NC(N)=O, C[C@@H]1CN(Cc2ccc(F)cc2)CCN1C(=O)COc1ccc(Cl)cc1NC(N)=O, C[C@@H]1CN(Cc2ccc(F)cc2)CCN1C(=O)COc1ccc(Cl)cc1NC(N)=O, C[C@@H]1CN(Cc2ccc(F)cc2)CCN1C(=O)COc1ccc(Cl)cc1NC(N)=O, C[C@@H]1CN(Cc2ccc(F)cc2)CCN1C(=O)COc1ccc(Cl)cc1NC(N)=O, C[C@@H]1CN(Cc2ccc(F)cc2)CCN1C(=O)COc1ccc(Cl)cc1NC(N)=O	XQYASZNUFDVMFH-CQSZACIVSA-N, XQYASZNUFDVMFH-CQSZACIVSA-N, XQYASZNUFDVMFH-CQSZACIVSA-N, XQYASZNUFDVMFH-CQSZACIVSA-N, XQYASZNUFDVMFH-CQSZACIVSA-N, XQYASZNUFDVMFH-CQSZACIVSA-N, XQYASZNUFDVMFH-CQSZACIVSA-N	Phase 2
ZK-93423	benzodiazepine receptor agonist	GABRA1, GABRA2, GABRA3, GABRA5, GABRB2, GABRG2			CCOC(=O)c1ncc2[nH]c3ccc(OCc4ccccc4)cc3c2c1COC, CCOC(=O)c1ncc2[nH]c3ccc(OCc4ccccc4)cc3c2c1COC, CCOC(=O)c1ncc2[nH]c3ccc(OCc4ccccc4)cc3c2c1COC, CCOC(=O)c1ncc2[nH]c3ccc(OCc4ccccc4)cc3c2c1COC, CCOC(=O)c1ncc2[nH]c3ccc(OCc4ccccc4)cc3c2c1COC, CCOC(=O)c1ncc2[nH]c3ccc(OCc4ccccc4)cc3c2c1COC, CCOC(=O)c1ncc2[nH]c3ccc(OCc4ccccc4)cc3c2c1COC	ALBKMJDFBZVHAK-UHFFFAOYSA-N, ALBKMJDFBZVHAK-UHFFFAOYSA-N, ALBKMJDFBZVHAK-UHFFFAOYSA-N, ALBKMJDFBZVHAK-UHFFFAOYSA-N, ALBKMJDFBZVHAK-UHFFFAOYSA-N, ALBKMJDFBZVHAK-UHFFFAOYSA-N, ALBKMJDFBZVHAK-UHFFFAOYSA-N	Phase 3
ZK-93426	benzodiazepine receptor antagonist	GABRA1, GABRA2, GABRA3, GABRA5			CCOC(=O)c1ncc2[nH]c3cccc(OC(C)C)c3c2c1C, CCOC(=O)c1ncc2[nH]c3cccc(OC(C)C)c3c2c1C, CCOC(=O)c1ncc2[nH]c3cccc(OC(C)C)c3c2c1C, CCOC(=O)c1ncc2[nH]c3cccc(OC(C)C)c3c2c1C	VMDUABMKBUKKPG-UHFFFAOYSA-N, VMDUABMKBUKKPG-UHFFFAOYSA-N, VMDUABMKBUKKPG-UHFFFAOYSA-N, VMDUABMKBUKKPG-UHFFFAOYSA-N	Phase 1
ZLN005					CC(C)(C)c1ccc(cc1)-c1nc2ccccc2[nH]1, CC(C)(C)c1ccc(cc1)-c1nc2ccccc2[nH]1, CC(C)(C)c1ccc(cc1)-c1nc2ccccc2[nH]1, CC(C)(C)c1ccc(cc1)-c1nc2ccccc2[nH]1, CC(C)(C)c1ccc(cc1)-c1nc2ccccc2[nH]1	LQUNNCQSFFKSSK-UHFFFAOYSA-N, LQUNNCQSFFKSSK-UHFFFAOYSA-N, LQUNNCQSFFKSSK-UHFFFAOYSA-N, LQUNNCQSFFKSSK-UHFFFAOYSA-N, LQUNNCQSFFKSSK-UHFFFAOYSA-N	Preclinical
ZLN024	AMPK activator	PRKAA1, PRKAB1, PRKAG1			Cc1ccc(OCCSc2ncccn2)c(Br)c1, Cc1ccc(OCCSc2ncccn2)c(Br)c1, Cc1ccc(OCCSc2ncccn2)c(Br)c1	KWJRSHZSULRJHE-UHFFFAOYSA-N, KWJRSHZSULRJHE-UHFFFAOYSA-N, KWJRSHZSULRJHE-UHFFFAOYSA-N	Preclinical
ZM-226600	Kir6 channel (KATP) activator				C[C@@](O)(C(=O)Nc1ccc(cc1)S(=O)(=O)c1ccccc1)C(F)(F)F |&1:1|, C[C@@](O)(C(=O)Nc1ccc(cc1)S(=O)(=O)c1ccccc1)C(F)(F)F |&1:1|	LJLXQHHFAKVTNP-OAHLLOKOSA-N, LJLXQHHFAKVTNP-OAHLLOKOSA-N	Preclinical
ZM-241385	adenosine receptor antagonist	ADORA1, ADORA2A, ADORA2B, ADORA3			Nc1nc(NCCc2ccc(O)cc2)nc2nc(nn12)-c1ccco1, Nc1nc(NCCc2ccc(O)cc2)nc2nc(nn12)-c1ccco1, Nc1nc(NCCc2ccc(O)cc2)nc2nc(nn12)-c1ccco1, Nc1nc(NCCc2ccc(O)cc2)nc2nc(nn12)-c1ccco1, Nc1nc(NCCc2ccc(O)cc2)nc2nc(nn12)-c1ccco1, Nc1nc(NCCc2ccc(O)cc2)nc2nc(nn12)-c1ccco1	PWTBZOIUWZOPFT-UHFFFAOYSA-N, PWTBZOIUWZOPFT-UHFFFAOYSA-N, PWTBZOIUWZOPFT-UHFFFAOYSA-N, PWTBZOIUWZOPFT-UHFFFAOYSA-N, PWTBZOIUWZOPFT-UHFFFAOYSA-N, PWTBZOIUWZOPFT-UHFFFAOYSA-N	Preclinical
ZM-306416	Abl kinase inhibitor, SRC inhibitor, VEGFR inhibitor	EGFR, FLT1, FLT4, KDR			COc1cc2ncnc(Nc3ccc(Cl)cc3F)c2cc1OC, COc1cc2ncnc(Nc3ccc(Cl)cc3F)c2cc1OC, COc1cc2ncnc(Nc3ccc(Cl)cc3F)c2cc1OC, COc1cc2ncnc(Nc3ccc(Cl)cc3F)c2cc1OC, COc1cc2ncnc(Nc3ccc(Cl)cc3F)c2cc1OC, COc1cc2ncnc(Nc3ccc(Cl)cc3F)c2cc1OC	YHUIUSRCUKUUQA-UHFFFAOYSA-N, YHUIUSRCUKUUQA-UHFFFAOYSA-N, YHUIUSRCUKUUQA-UHFFFAOYSA-N, YHUIUSRCUKUUQA-UHFFFAOYSA-N, YHUIUSRCUKUUQA-UHFFFAOYSA-N, YHUIUSRCUKUUQA-UHFFFAOYSA-N	Preclinical
ZM-323881	VEGFR inhibitor	KDR			Cc1cc(F)c(Nc2ncnc3cc(OCc4ccccc4)ccc23)cc1O, Cc1cc(F)c(Nc2ncnc3cc(OCc4ccccc4)ccc23)cc1O, Cc1cc(F)c(Nc2ncnc3cc(OCc4ccccc4)ccc23)cc1O, Cc1cc(F)c(Nc2ncnc3cc(OCc4ccccc4)ccc23)cc1O, Cc1cc(F)c(Nc2ncnc3cc(OCc4ccccc4)ccc23)cc1O	NVBNDZZLJRYRPD-UHFFFAOYSA-N, NVBNDZZLJRYRPD-UHFFFAOYSA-N, NVBNDZZLJRYRPD-UHFFFAOYSA-N, NVBNDZZLJRYRPD-UHFFFAOYSA-N, NVBNDZZLJRYRPD-UHFFFAOYSA-N	Preclinical
ZM-336372	RAF inhibitor	BRAF, LCK, MAPK14, RAF1			CN(C)c1cccc(c1)C(=O)Nc1ccc(C)c(NC(=O)c2ccc(O)cc2)c1, CN(C)c1cccc(c1)C(=O)Nc1ccc(C)c(NC(=O)c2ccc(O)cc2)c1, CN(C)c1cccc(c1)C(=O)Nc1ccc(C)c(NC(=O)c2ccc(O)cc2)c1, CN(C)c1cccc(c1)C(=O)Nc1ccc(C)c(NC(=O)c2ccc(O)cc2)c1	PYEFPDQFAZNXLI-UHFFFAOYSA-N, PYEFPDQFAZNXLI-UHFFFAOYSA-N, PYEFPDQFAZNXLI-UHFFFAOYSA-N, PYEFPDQFAZNXLI-UHFFFAOYSA-N	Preclinical
ZM-39923	JAK inhibitor	JAK1, JAK3			CC(C)N(CCC(=O)c1ccc2ccccc2c1)Cc1ccccc1, CC(C)N(CCC(=O)c1ccc2ccccc2c1)Cc1ccccc1, CC(C)N(CCC(=O)c1ccc2ccccc2c1)Cc1ccccc1, CC(C)N(CCC(=O)c1ccc2ccccc2c1)Cc1ccccc1, CC(C)N(CCC(=O)c1ccc2ccccc2c1)Cc1ccccc1	JSASWRWALCMOQP-UHFFFAOYSA-N, JSASWRWALCMOQP-UHFFFAOYSA-N, JSASWRWALCMOQP-UHFFFAOYSA-N, JSASWRWALCMOQP-UHFFFAOYSA-N, JSASWRWALCMOQP-UHFFFAOYSA-N	Preclinical
ZM-447439	Aurora kinase inhibitor	AURKA, AURKB			COc1cc2c(Nc3ccc(NC(=O)c4ccccc4)cc3)ncnc2cc1OCCCN1CCOCC1, COc1cc2c(Nc3ccc(NC(=O)c4ccccc4)cc3)ncnc2cc1OCCCN1CCOCC1, COc1cc2c(Nc3ccc(NC(=O)c4ccccc4)cc3)ncnc2cc1OCCCN1CCOCC1, COc1cc2c(Nc3ccc(NC(=O)c4ccccc4)cc3)ncnc2cc1OCCCN1CCOCC1	OGNYUTNQZVRGMN-UHFFFAOYSA-N, OGNYUTNQZVRGMN-UHFFFAOYSA-N, OGNYUTNQZVRGMN-UHFFFAOYSA-N, OGNYUTNQZVRGMN-UHFFFAOYSA-N	Preclinical
zofenopril-calcium	angiotensin converting enzyme inhibitor	ACE	cardiology	hypertension	C[C@H](CSC(=O)c1ccccc1)C(=O)N1C[C@H](C[C@H]1C(O)=O)Sc1ccccc1, C[C@H](CSC(=O)c1ccccc1)C(=O)N1C[C@H](C[C@H]1C(O)=O)Sc1ccccc1, C[C@H](CSC(=O)c1ccccc1)C(=O)N1C[C@H](C[C@H]1C(O)=O)Sc1ccccc1, C[C@H](CSC(=O)c1ccccc1)C(=O)N1C[C@H](C[C@H]1C(O)=O)Sc1ccccc1, C[C@H](CSC(=O)c1ccccc1)C(=O)N1C[C@H](C[C@H]1C(O)=O)Sc1ccccc1	IAIDUHCBNLFXEF-MNEFBYGVSA-N, IAIDUHCBNLFXEF-MNEFBYGVSA-N, IAIDUHCBNLFXEF-MNEFBYGVSA-N, IAIDUHCBNLFXEF-MNEFBYGVSA-N, IAIDUHCBNLFXEF-MNEFBYGVSA-N	Launched
zolantidine	histamine receptor antagonist				C(CNc1nc2ccccc2s1)COc1cccc(CN2CCCCC2)c1, C(CNc1nc2ccccc2s1)COc1cccc(CN2CCCCC2)c1	KUBONGDXTUOOLM-UHFFFAOYSA-N, KUBONGDXTUOOLM-UHFFFAOYSA-N	Preclinical
zoledronic-acid	bone resorption inhibitor	FDPS, GGPS1	endocrinology	Paget's disease	OC(Cn1ccnc1)(P(O)(O)=O)P(O)(O)=O, OC(Cn1ccnc1)(P(O)(O)=O)P(O)(O)=O, OC(Cn1ccnc1)(P(O)(O)=O)P(O)(O)=O	XRASPMIURGNCCH-UHFFFAOYSA-N, XRASPMIURGNCCH-UHFFFAOYSA-N, XRASPMIURGNCCH-UHFFFAOYSA-N	Launched
zoliflodacin	antibacterial 				[H][C@]12[C@H](C)O[C@H](C)CN1c1c(CC22C(=O)NC(=O)NC2=O)cc2c(noc2c1F)N1[C@@H](C)COC1=O	ZSWMIFNWDQEXDT-ZESJGQACSA-N	Phase 3
zolimidine	mucus protecting agent		gastroenterology	peptic ulcer disease (PUD), gastroesophageal reflux disease (GERD)	CS(=O)(=O)c1ccc(cc1)-c1cn2ccccc2n1	VSLIUWLPFRVCDL-UHFFFAOYSA-N	Launched
zolmitriptan	serotonin receptor agonist	HTR1A, HTR1B, HTR1D, HTR1E, HTR1F	neurology/psychiatry	migraine headache	CN(C)CCc1c[nH]c2ccc(C[C@H]3COC(=O)N3)cc12, CN(C)CCc1c[nH]c2ccc(C[C@H]3COC(=O)N3)cc12, CN(C)CCc1c[nH]c2ccc(C[C@H]3COC(=O)N3)cc12, CN(C)CCc1c[nH]c2ccc(C[C@H]3COC(=O)N3)cc12	ULSDMUVEXKOYBU-ZDUSSCGKSA-N, ULSDMUVEXKOYBU-ZDUSSCGKSA-N, ULSDMUVEXKOYBU-ZDUSSCGKSA-N, ULSDMUVEXKOYBU-ZDUSSCGKSA-N	Launched
zomepirac	prostaglandin synthesis inhibitor	PTGDR2			Cc1cc(CC(O)=O)n(C)c1C(=O)c1ccc(Cl)cc1, Cc1cc(CC(O)=O)n(C)c1C(=O)c1ccc(Cl)cc1, Cc1cc(CC(O)=O)n(C)c1C(=O)c1ccc(Cl)cc1	ZXVNMYWKKDOREA-UHFFFAOYSA-N, ZXVNMYWKKDOREA-UHFFFAOYSA-N, ZXVNMYWKKDOREA-UHFFFAOYSA-N	Withdrawn
zometapine					Cc1nn(C)c2NCCN=C(c12)c1cccc(Cl)c1 |c:9|	YCWROMXNZZIJDQ-UHFFFAOYSA-N	Phase 2
zoniporide	sodium/hydrogen exchanger inhibitor	SLC9A1			NC(N)=NC(=O)c1cnn(c1C1CC1)-c1cccc2ncccc12, NC(N)=NC(=O)c1cnn(c1C1CC1)-c1cccc2ncccc12	GDXBRVCQGGKXJY-UHFFFAOYSA-N, GDXBRVCQGGKXJY-UHFFFAOYSA-N	Phase 3
zonisamide	sodium channel blocker, T-type calcium channel blocker	CA1, CA10, CA11, CA12, CA13, CA14, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA8, CA9, CACNA1G, CACNA1H, CACNA1I, MAOA, MAOB, SCN10A, SCN11A, SCN1A, SCN1B, SCN2A, SCN2B, SCN3A, SCN3B, SCN4A, SCN4B, SCN5A, SCN7A, SCN8A, SCN9A	neurology/psychiatry	seizures, epilepsy	NS(=O)(=O)Cc1noc2ccccc12, NS(=O)(=O)Cc1noc2ccccc12, NS(=O)(=O)Cc1noc2ccccc12, NS(=O)(=O)Cc1noc2ccccc12	UBQNRHZMVUUOMG-UHFFFAOYSA-N, UBQNRHZMVUUOMG-UHFFFAOYSA-N, UBQNRHZMVUUOMG-UHFFFAOYSA-N, UBQNRHZMVUUOMG-UHFFFAOYSA-N	Launched
zopolrestat		AKR1B1, AKR1B10			OC(=O)Cc1nn(Cc2nc3cc(ccc3s2)C(F)(F)F)c(=O)c2ccccc12, OC(=O)Cc1nn(Cc2nc3cc(ccc3s2)C(F)(F)F)c(=O)c2ccccc12	BCSVCWVQNOXFGL-UHFFFAOYSA-N, BCSVCWVQNOXFGL-UHFFFAOYSA-N	Phase 2
zosuquidar	P glycoprotein inhibitor	ABCB1, ABCB4			O[C@@H](COc1cccc2ncccc12)CN1CCN(CC1)[C@@H]1c2ccccc2[C@@H]2[C@H](c3ccccc13)C2(F)F, O[C@@H](COc1cccc2ncccc12)CN1CCN(CC1)[C@@H]1c2ccccc2[C@@H]2[C@H](c3ccccc13)C2(F)F	IHOVFYSQUDPMCN-DBEBIPAYSA-N, IHOVFYSQUDPMCN-DBEBIPAYSA-N	Phase 3
zotarolimus	mTOR inhibitor	FKBP1A	cardiology	coronary artery restenosis	CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@@H]1n1cnnn1 |c:14,33,t:29,31|, CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@@H]1n1cnnn1 |c:14,33,t:29,31|, CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@@H]1n1cnnn1 |c:14,33,t:29,31|	CGTADGCBEXYWNE-GYKXXMIGSA-N, CGTADGCBEXYWNE-GYKXXMIGSA-N, CGTADGCBEXYWNE-GYKXXMIGSA-N	Launched
zotepine	dopamine receptor antagonist, serotonin receptor antagonist	ADRA2B, DRD2, DRD3, DRD4, HRH1, HTR1A, HTR1B, HTR1D, HTR1E, HTR2A, HTR2C, HTR6, HTR7, SLC6A2, SLC6A4	neurology/psychiatry	schizophrenia	CN(C)CCOC1=Cc2ccccc2Sc2ccc(Cl)cc12 |t:6|, CN(C)CCOC1=Cc2ccccc2Sc2ccc(Cl)cc12 |t:6|, CN(C)CCOC1=Cc2ccccc2Sc2ccc(Cl)cc12 |t:6|, CN(C)CCOC1=Cc2ccccc2Sc2ccc(Cl)cc12 |t:6|	HDOZVRUNCMBHFH-UHFFFAOYSA-N, HDOZVRUNCMBHFH-UHFFFAOYSA-N, HDOZVRUNCMBHFH-UHFFFAOYSA-N, HDOZVRUNCMBHFH-UHFFFAOYSA-N	Launched
zoxazolamine	myorelaxant				Nc1nc2cc(Cl)ccc2o1, Nc1nc2cc(Cl)ccc2o1, Nc1nc2cc(Cl)ccc2o1	YGCODSQDUUUKIV-UHFFFAOYSA-N, YGCODSQDUUUKIV-UHFFFAOYSA-N, YGCODSQDUUUKIV-UHFFFAOYSA-N	Phase 2
ZSET1446	nicotinic receptor agonist				O=C1N=C2C=CC=CN2C11Cc2ccccc2C1 |c:4,6,t:2|	QZWYXEBIQWJXAR-UHFFFAOYSA-N	Preclinical
ZSTK-474	PI3K inhibitor	PIK3CB, PIK3CD, PIK3CG			FC(F)c1nc2ccccc2n1-c1nc(nc(n1)N1CCOCC1)N1CCOCC1, FC(F)c1nc2ccccc2n1-c1nc(nc(n1)N1CCOCC1)N1CCOCC1	HGVNLRPZOWWDKD-UHFFFAOYSA-N, HGVNLRPZOWWDKD-UHFFFAOYSA-N	Phase 1/Phase 2
zuclopenthixol	dopamine receptor antagonist	ADRA1A, ADRA2A, DRD1, DRD2, DRD5, HRH1, HTR2A	neurology/psychiatry	schizophrenia, bipolar disorder	OCCN1CCN(CC\C=C2\c3ccccc3Sc3ccc(Cl)cc23)CC1, OCCN1CCN(CC\C=C2\c3ccccc3Sc3ccc(Cl)cc23)CC1, OCCN1CCN(CC\C=C2\c3ccccc3Sc3ccc(Cl)cc23)CC1	WFPIAZLQTJBIFN-DVZOWYKESA-N, WFPIAZLQTJBIFN-DVZOWYKESA-N, WFPIAZLQTJBIFN-DVZOWYKESA-N	Launched
zuranolone	GABA receptor agonist				[H][C@@]12CC[C@H](C(=O)Cn3cc(cn3)C#N)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@]2([H])C[C@](C)(O)CC[C@]12[H]	HARRKNSQXBRBGZ-GVKWWOCJSA-N	Phase 3
Z160	N-type calcium channel blocker	CACNA2D1			O=C(CC(c1ccccc1)c1ccccc1)N1CCN(CC1)C(c1ccccc1)c1ccccc1, O=C(CC(c1ccccc1)c1ccccc1)N1CCN(CC1)C(c1ccccc1)c1ccccc1, O=C(CC(c1ccccc1)c1ccccc1)N1CCN(CC1)C(c1ccccc1)c1ccccc1	VCPMZDWBEWTGNW-UHFFFAOYSA-N, VCPMZDWBEWTGNW-UHFFFAOYSA-N, VCPMZDWBEWTGNW-UHFFFAOYSA-N	Phase 2
1,12-Besm	polyamine biosynthesis inhibitor				CCNCCCNCCCCNCCCNCC	PGMIWVSHZMWSSI-UHFFFAOYSA-N	Phase 2
1,2,3,4,5,6-hexabromocyclohexane	JAK inhibitor	JAK2			BrC1C(Br)C(Br)C(Br)C(Br)C1Br, BrC1C(Br)C(Br)C(Br)C(Br)C1Br, BrC1C(Br)C(Br)C(Br)C(Br)C1Br	QFQZKISCBJKVHI-UHFFFAOYSA-N, QFQZKISCBJKVHI-UHFFFAOYSA-N, QFQZKISCBJKVHI-UHFFFAOYSA-N	Preclinical
1,3-dipropyl-8-phenylxanthine	adenosine receptor antagonist				CCCn1c2nc([nH]c2c(=O)n(CCC)c1=O)-c1ccccc1, CCCn1c2nc([nH]c2c(=O)n(CCC)c1=O)-c1ccccc1	CLIGSMOZKDCDRZ-UHFFFAOYSA-N, CLIGSMOZKDCDRZ-UHFFFAOYSA-N	Preclinical
1,4-butanediol	benzodiazepine receptor agonist, gamma hydroxybutyric acid agonist	MAN1B1, PLA2G2A, PLA2G2E			OCCCCO	WERYXYBDKMZEQL-UHFFFAOYSA-N	Phase 1
1,5-dicaffeoylquinic-acid					O[C@@H]1C[C@@](C[C@@H](OC(=O)\C=C\c2ccc(O)c(O)c2)[C@@H]1O)(OC(=O)\C=C\c1ccc(O)c(O)c1)C(O)=O, O[C@@H]1C[C@@](C[C@@H](OC(=O)\C=C\c2ccc(O)c(O)c2)[C@@H]1O)(OC(=O)\C=C\c1ccc(O)c(O)c1)C(O)=O	YDDUMTOHNYZQPO-PSEXTPKNSA-N, YDDUMTOHNYZQPO-PSEXTPKNSA-N	Phase 1
1-((Z)-3-chloroallyl)-1,3,5,7-tetraazaadamantan-1-ium					Cl\C=C/C[N+]12CN3CN(CN(C3)C1)C2	LDLCEGCJYSDJLX-UPHRSURJSA-N	Preclinical
1-(1,2-diphenylethyl)piperidine-(+/-)	glutamate receptor antagonist				C([C@@H](N1CCCCC1)c1ccccc1)c1ccccc1 |&1:1|, C([C@@H](N1CCCCC1)c1ccccc1)c1ccccc1 |&1:1|	JQWJJJYHVHNXJH-LJQANCHMSA-N, JQWJJJYHVHNXJH-LJQANCHMSA-N	Preclinical
1-(2-chloro-5-methylphenoxy)-3-(isopropylamino)-2-propanol					CC(C)NC[C@@H](O)COc1cc(C)ccc1Cl |&1:5,r|	NJEIOWSBPCZKTL-LLVKDONJSA-N	Preclinical
1-acetyl-4-methylpiperazine	acetylcholine receptor agonist				CN1CCN(CC1)C(C)=O, CN1CCN(CC1)C(C)=O	YSDBJKNOEWSFGA-UHFFFAOYSA-N, YSDBJKNOEWSFGA-UHFFFAOYSA-N	Preclinical
1-azakenpaullone	glycogen synthase kinase inhibitor	CCNB1, CDK1, CDK5, GSK3B			Brc1ccc2[nH]c-3c(CC(=O)Nc4cccnc-34)c2c1, Brc1ccc2[nH]c-3c(CC(=O)Nc4cccnc-34)c2c1, Brc1ccc2[nH]c-3c(CC(=O)Nc4cccnc-34)c2c1, Brc1ccc2[nH]c-3c(CC(=O)Nc4cccnc-34)c2c1, Brc1ccc2[nH]c-3c(CC(=O)Nc4cccnc-34)c2c1, Brc1ccc2[nH]c-3c(CC(=O)Nc4cccnc-34)c2c1	NTSBZVCEIVPKBJ-UHFFFAOYSA-N, NTSBZVCEIVPKBJ-UHFFFAOYSA-N, NTSBZVCEIVPKBJ-UHFFFAOYSA-N, NTSBZVCEIVPKBJ-UHFFFAOYSA-N, NTSBZVCEIVPKBJ-UHFFFAOYSA-N, NTSBZVCEIVPKBJ-UHFFFAOYSA-N	Preclinical
1-deoxymannojirimycin	alpha mannosidase inhibitor	MAN2A1			OC[C@H]1NC[C@@H](O)[C@@H](O)[C@@H]1O, OC[C@H]1NC[C@@H](O)[C@@H](O)[C@@H]1O	LXBIFEVIBLOUGU-KVTDHHQDSA-N, LXBIFEVIBLOUGU-KVTDHHQDSA-N	Preclinical
1-EBIO	potassium channel activator	KCNN1, KCNN2, KCNN3, KCNN4			CCn1c2ccccc2[nH]c1=O, CCn1c2ccccc2[nH]c1=O, CCn1c2ccccc2[nH]c1=O, CCn1c2ccccc2[nH]c1=O	CXUCKELNYMZTRT-UHFFFAOYSA-N, CXUCKELNYMZTRT-UHFFFAOYSA-N, CXUCKELNYMZTRT-UHFFFAOYSA-N, CXUCKELNYMZTRT-UHFFFAOYSA-N	Preclinical
1-ethyl-2-pyrrolidone	transdermal absorption-enhancing compound				CCN1CCCC1=O	ZFPGARUNNKGOBB-UHFFFAOYSA-N	Preclinical
1-hexadecanal	sphingosine 1-phosphate receptor substrate	DBI, RHO			CCCCCCCCCCCCCCCC=O	NIOYUNMRJMEDGI-UHFFFAOYSA-N	Preclinical
1-hexadecanol			dermatology	cosmetic	CCCCCCCCCCCCCCCCO, CCCCCCCCCCCCCCCCO, CCCCCCCCCCCCCCCCO	BXWNKGSJHAJOGX-UHFFFAOYSA-N, BXWNKGSJHAJOGX-UHFFFAOYSA-N, BXWNKGSJHAJOGX-UHFFFAOYSA-N	Launched
1-naphthyl-PP1	SRC inhibitor	SRC			CC(C)(C)n1nc(-c2cccc3ccccc23)c2c(N)ncnc12, CC(C)(C)n1nc(-c2cccc3ccccc23)c2c(N)ncnc12, CC(C)(C)n1nc(-c2cccc3ccccc23)c2c(N)ncnc12, CC(C)(C)n1nc(-c2cccc3ccccc23)c2c(N)ncnc12, CC(C)(C)n1nc(-c2cccc3ccccc23)c2c(N)ncnc12, CC(C)(C)n1nc(-c2cccc3ccccc23)c2c(N)ncnc12	XSHQBIXMLULFEV-UHFFFAOYSA-N, XSHQBIXMLULFEV-UHFFFAOYSA-N, XSHQBIXMLULFEV-UHFFFAOYSA-N, XSHQBIXMLULFEV-UHFFFAOYSA-N, XSHQBIXMLULFEV-UHFFFAOYSA-N, XSHQBIXMLULFEV-UHFFFAOYSA-N	Preclinical
1-octacosanol					CCCCCCCCCCCCCCCCCCCCCCCCCCCCO	CNNRPFQICPFDPO-UHFFFAOYSA-N	Phase 2
1-octanol		GJA1, GJA10, GJA3, GJA4, GJA5, GJA8, GJA9, GJB1, GJB2, GJB3, GJB4, GJB5, GJB6, GJB7, GJC1, GJC2, GJC3, GJD2, GJD3, GJD4, GJE1			CCCCCCCCO, CCCCCCCCO	KBPLFHHGFOOTCA-UHFFFAOYSA-N, KBPLFHHGFOOTCA-UHFFFAOYSA-N	Phase 2
1-phenylbiguanide	serotonin receptor agonist	HTR3A, HTR3B			NC(N)=NC(=N)Nc1ccccc1, NC(N)=NC(=N)Nc1ccccc1	CUQCMXFWIMOWRP-UHFFFAOYSA-N, CUQCMXFWIMOWRP-UHFFFAOYSA-N	Preclinical
1E-1-(2-hydroxy-5-methylphenyl)-1-dodecanone-oxime					CCCCCCCCCCC[C@@H](N=O)c1cc(C)ccc1O |r|, CCCCCCCCCCC[C@@H](N=O)c1cc(C)ccc1O |r|, CCCCCCCCCCC[C@@H](N=O)c1cc(C)ccc1O |r|, CCCCCCCCCCC[C@@H](N=O)c1cc(C)ccc1O |r|	NFONIVRMILHYLH-GOSISDBHSA-N, NFONIVRMILHYLH-GOSISDBHSA-N, NFONIVRMILHYLH-GOSISDBHSA-N, NFONIVRMILHYLH-GOSISDBHSA-N	Preclinical
1S,2R-phenylpropanolamine	adrenergic receptor agonist				C[C@@H](N)[C@@H](O)c1ccccc1	DLNKOYKMWOXYQA-VXNVDRBHSA-N	Withdrawn
10-deacetylbaccatin	antitumor agent				CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](O)C(C)=C([C@@H](O)C1=O)C2(C)C |t:33|, CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](O)C(C)=C([C@@H](O)C1=O)C2(C)C |t:33|, CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](O)C(C)=C([C@@H](O)C1=O)C2(C)C |t:33|, CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](O)C(C)=C([C@@H](O)C1=O)C2(C)C |t:33|	YWLXLRUDGLRYDR-ZHPRIASZSA-N, YWLXLRUDGLRYDR-ZHPRIASZSA-N, YWLXLRUDGLRYDR-ZHPRIASZSA-N, YWLXLRUDGLRYDR-ZHPRIASZSA-N	Preclinical
10-DEBC	AKT inhibitor	PIM1			CCN(CC)CCCCN1c2ccccc2Oc2ccc(Cl)cc12, CCN(CC)CCCCN1c2ccccc2Oc2ccc(Cl)cc12, CCN(CC)CCCCN1c2ccccc2Oc2ccc(Cl)cc12, CCN(CC)CCCCN1c2ccccc2Oc2ccc(Cl)cc12	GYBXAGDWMCJZJK-UHFFFAOYSA-N, GYBXAGDWMCJZJK-UHFFFAOYSA-N, GYBXAGDWMCJZJK-UHFFFAOYSA-N, GYBXAGDWMCJZJK-UHFFFAOYSA-N	Preclinical
10-hydroxycamptothecin	topoisomerase inhibitor	TOP1			CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccc(O)cc4cc3Cn1c2=O, CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccc(O)cc4cc3Cn1c2=O, CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccc(O)cc4cc3Cn1c2=O, CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccc(O)cc4cc3Cn1c2=O, CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccc(O)cc4cc3Cn1c2=O	HAWSQZCWOQZXHI-FQEVSTJZSA-N, HAWSQZCWOQZXHI-FQEVSTJZSA-N, HAWSQZCWOQZXHI-FQEVSTJZSA-N, HAWSQZCWOQZXHI-FQEVSTJZSA-N, HAWSQZCWOQZXHI-FQEVSTJZSA-N	Preclinical
10058-F4	c-Myc inhibitor				CCc1ccc(\C=C2\SC(=S)NC2=O)cc1, CCc1ccc(\C=C2\SC(=S)NC2=O)cc1, CCc1ccc(\C=C2\SC(=S)NC2=O)cc1, CCc1ccc(\C=C2\SC(=S)NC2=O)cc1, CCc1ccc(\C=C2\SC(=S)NC2=O)cc1	SVXDHPADAXBMFB-JXMROGBWSA-N, SVXDHPADAXBMFB-JXMROGBWSA-N, SVXDHPADAXBMFB-JXMROGBWSA-N, SVXDHPADAXBMFB-JXMROGBWSA-N, SVXDHPADAXBMFB-JXMROGBWSA-N	Preclinical
12-O-tetradecanoylphorbol-13-acetate	PKC activator	KCNT2, TRPV4			CCCCCCCCCCCCCC(=O)O[C@@H]1[C@@H](C)[C@]2(O)[C@@H]3C=C(C)C(=O)[C@@]3(O)CC(CO)=C[C@H]2[C@@H]2C(C)(C)[C@]12OC(C)=O |c:33,t:22|, CCCCCCCCCCCCCC(=O)O[C@@H]1[C@@H](C)[C@]2(O)[C@@H]3C=C(C)C(=O)[C@@]3(O)CC(CO)=C[C@H]2[C@@H]2C(C)(C)[C@]12OC(C)=O |c:33,t:22|, CCCCCCCCCCCCCC(=O)O[C@@H]1[C@@H](C)[C@]2(O)[C@@H]3C=C(C)C(=O)[C@@]3(O)CC(CO)=C[C@H]2[C@@H]2C(C)(C)[C@]12OC(C)=O |c:33,t:22|, CCCCCCCCCCCCCC(=O)O[C@@H]1[C@@H](C)[C@]2(O)[C@@H]3C=C(C)C(=O)[C@@]3(O)CC(CO)=C[C@H]2[C@@H]2C(C)(C)[C@]12OC(C)=O |c:33,t:22|, CCCCCCCCCCCCCC(=O)O[C@@H]1[C@@H](C)[C@]2(O)[C@@H]3C=C(C)C(=O)[C@@]3(O)CC(CO)=C[C@H]2[C@@H]2C(C)(C)[C@]12OC(C)=O |c:33,t:22|, CCCCCCCCCCCCCC(=O)O[C@@H]1[C@@H](C)[C@]2(O)[C@@H]3C=C(C)C(=O)[C@@]3(O)CC(CO)=C[C@H]2[C@@H]2C(C)(C)[C@]12OC(C)=O |c:33,t:22|	PHEDXBVPIONUQT-RGYGYFBISA-N, PHEDXBVPIONUQT-RGYGYFBISA-N, PHEDXBVPIONUQT-RGYGYFBISA-N, PHEDXBVPIONUQT-RGYGYFBISA-N, PHEDXBVPIONUQT-RGYGYFBISA-N, PHEDXBVPIONUQT-RGYGYFBISA-N	Phase 2
1400W	nitric oxide synthase inhibitor	NOS1, NOS2, NOS3			CC(=N)NCc1cccc(CN)c1, CC(=N)NCc1cccc(CN)c1	RODUKNYOEVZQPR-UHFFFAOYSA-N, RODUKNYOEVZQPR-UHFFFAOYSA-N	Preclinical
16,16-dimethylprostaglandin-e2	prostanoid receptor agonist	HPGD			CCCCC(C)(C)[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O, CCCCC(C)(C)[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O, CCCCC(C)(C)[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O	QAOBBBBDJSWHMU-WMBBNPMCSA-N, QAOBBBBDJSWHMU-WMBBNPMCSA-N, QAOBBBBDJSWHMU-WMBBNPMCSA-N	Phase 2
17-hydroxyprogesterone-caproate	progesterone receptor agonist	AR, ESR1, ESR2, NR1H4, NR1I2, NR3C1, PGR	obstetrics/gynecology	spontaneous preterm birth	CCCCCC(=O)O[C@@]1(CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)=O |t:15|	DOMWKUIIPQCAJU-LJHIYBGHSA-N	Launched
17-PA	glucocorticoid receptor agonist				C[C@]12CC[C@H]3[C@@H](CC[C@H]4C[C@H](O)CC[C@]34C)[C@@H]1CC=C2c1ccccc1 |c:21|, C[C@]12CC[C@H]3[C@@H](CC[C@H]4C[C@H](O)CC[C@]34C)[C@@H]1CC=C2c1ccccc1 |c:21|	SINAMTXBCYKFDL-WBJZGETLSA-N, SINAMTXBCYKFDL-WBJZGETLSA-N	Preclinical
2'-C-methylguanosine	HCV inhibitor				C[C@@]1(O)[C@H](O)[C@@H](CO)O[C@H]1n1cnc2c1[nH]c(N)nc2=O	NVKAMPJSWMHVDK-GITKWUPZSA-N	Preclinical
2'-MeCCPA	adenosine receptor agonist	ADORA1			C[C@@]1(O)[C@H](O)[C@@H](CO)O[C@H]1n1cnc2c(NC3CCCC3)nc(Cl)nc12, C[C@@]1(O)[C@H](O)[C@@H](CO)O[C@H]1n1cnc2c(NC3CCCC3)nc(Cl)nc12, C[C@@]1(O)[C@H](O)[C@@H](CO)O[C@H]1n1cnc2c(NC3CCCC3)nc(Cl)nc12, C[C@@]1(O)[C@H](O)[C@@H](CO)O[C@H]1n1cnc2c(NC3CCCC3)nc(Cl)nc12, C[C@@]1(O)[C@H](O)[C@@H](CO)O[C@H]1n1cnc2c(NC3CCCC3)nc(Cl)nc12	MMPAUXMIDJWGFO-ROMFRFKVSA-N, MMPAUXMIDJWGFO-ROMFRFKVSA-N, MMPAUXMIDJWGFO-ROMFRFKVSA-N, MMPAUXMIDJWGFO-ROMFRFKVSA-N, MMPAUXMIDJWGFO-ROMFRFKVSA-N	Preclinical
2,3-cis/exo-camphanediol					CC1(C)[C@@H]2CC[C@@]1(C)[C@H](O)[C@@H]2O	AYEOSGBMQHXVER-DQUBFYRCSA-N	Phase 1
2,3-cis/exo-pinanediol					CC1(C)C2CC1[C@](C)(O)[C@H](O)C2	MOILFCKRQFQVFS-VUMZSGCYSA-N	Phase 1
2,3-DCPE	BCL-XL downregulator	BCL2L1			OCCNCCCOc1cccc(Cl)c1Cl, OCCNCCCOc1cccc(Cl)c1Cl, OCCNCCCOc1cccc(Cl)c1Cl, OCCNCCCOc1cccc(Cl)c1Cl	QVEIRCZEBQRCTR-UHFFFAOYSA-N, QVEIRCZEBQRCTR-UHFFFAOYSA-N, QVEIRCZEBQRCTR-UHFFFAOYSA-N, QVEIRCZEBQRCTR-UHFFFAOYSA-N	Preclinical
2,4-dinitrochlorobenzene	thioredoxin inhibitor	TXN			[O-][N+](=O)c1ccc(Cl)c(c1)[N+]([O-])=O	VYZAHLCBVHPDDF-UHFFFAOYSA-N	Phase 2
2,4-dinitrophenol	ATP synthase inhibitor	APP			Oc1ccc(cc1[N+]([O-])=O)[N+]([O-])=O	UFBJCMHMOXMLKC-UHFFFAOYSA-N	Preclinical
2,5-furandimethanol	hemoglobin modulator	HBB			OCc1ccc(CO)o1	DSLRVRBSNLHVBH-UHFFFAOYSA-N	Phase 2
2,6-dimethylpiperidine					C[C@H]1CCC[C@@H](C)N1 |&1:1,&2:5,r|, C[C@H]1CCC[C@@H](C)N1 |&1:1,&2:5,r|	SDGKUVSVPIIUCF-KNVOCYPGSA-N, SDGKUVSVPIIUCF-KNVOCYPGSA-N	Preclinical
2-(chloromethyl)-5,6,7,8-tetrahydro[1]benzothieno[2,3-d]pyrimidin-4(3H)-one					ClC=C1Nc2sc3CCCCc3c2C(=O)N1	UTWSZXBGTLNPOV-UHFFFAOYSA-N	Preclinical
2-(1-adamantylamino)benzoic-acid					OC(=O)c1ccccc1NC(=O)C12CC3CC(CC(C3)C1)C2	XKZLSYWCDJZTMW-UHFFFAOYSA-N	Preclinical
2-(3-mercaptopropyl)pentanedioic-acid	glutamate carboxypeptidase inhibitor	FOLH1			OC(=O)CC[C@@H](CCCS)C(O)=O |&1:5,r|, OC(=O)CC[C@@H](CCCS)C(O)=O |&1:5,r|	FNLNSQHJKVQCBP-ZCFIWIBFSA-N, FNLNSQHJKVQCBP-ZCFIWIBFSA-N	Phase 1
2-[1-(4-piperonyl)piperazinyl]benzothiazole	serotonin receptor agonist	HTR4			C(N1CCN(CC1)c1nc2ccccc2s1)c1ccc2OCOc2c1, C(N1CCN(CC1)c1nc2ccccc2s1)c1ccc2OCOc2c1	BYHKGNWKJMGHGE-UHFFFAOYSA-N, BYHKGNWKJMGHGE-UHFFFAOYSA-N	Preclinical
2-aminobenzenesulfonamide	carbonic anhydrase inhibitor	CA12, CA14, CA2, CA6, CA9			Nc1ccccc1S(N)(=O)=O	YAZSBRQTAHVVGE-UHFFFAOYSA-N	Preclinical
2-APB	1,4,5-trisphosphate inhibitor	TRPC1, TRPC3, TRPC4, TRPC5, TRPC6, TRPC7, TRPM2, TRPM3, TRPM6, TRPV1, TRPV6			NCCOB(c1ccccc1)c1ccccc1, NCCOB(c1ccccc1)c1ccccc1	BLZVCIGGICSWIG-UHFFFAOYSA-N, BLZVCIGGICSWIG-UHFFFAOYSA-N	Preclinical
2-BFI	imidazoline receptor ligand	ADRA2A, ADRA2B, ADRA2C, MAOA, MAOB			C1CN=C(N1)c1cc2ccccc2o1 |c:2|	YTJOHEUHUVBKSB-UHFFFAOYSA-N	Preclinical
2-chloro-N6-cyclopentyladenosine	adenosine receptor agonist	ADORA1, ADORA2A, ADORA2B, ADORA3			OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(NC3CCCC3)nc(Cl)nc12, OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(NC3CCCC3)nc(Cl)nc12, OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(NC3CCCC3)nc(Cl)nc12, OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(NC3CCCC3)nc(Cl)nc12	XSMYYYQVWPZWIZ-IDTAVKCVSA-N, XSMYYYQVWPZWIZ-IDTAVKCVSA-N, XSMYYYQVWPZWIZ-IDTAVKCVSA-N, XSMYYYQVWPZWIZ-IDTAVKCVSA-N	Preclinical
2-chloroadenosine	adenosine receptor agonist	ADORA1, ADORA2A, ADORA2B			Nc1nc(Cl)nc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O, Nc1nc(Cl)nc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O, Nc1nc(Cl)nc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O	BIXYYZIIJIXVFW-UUOKFMHZSA-N, BIXYYZIIJIXVFW-UUOKFMHZSA-N, BIXYYZIIJIXVFW-UUOKFMHZSA-N	Preclinical
2-chloropyrazine					Clc1cnccn1, Clc1cnccn1	GELVZYOEQVJIRR-UHFFFAOYSA-N, GELVZYOEQVJIRR-UHFFFAOYSA-N	Preclinical
2-CMDO	dopamine receptor antagonist	DRD2, DRD4			CN1CCN(CC1)C1=Cc2ccccc2Oc2ccc(Cl)cc12 |t:8|, CN1CCN(CC1)C1=Cc2ccccc2Oc2ccc(Cl)cc12 |t:8|, CN1CCN(CC1)C1=Cc2ccccc2Oc2ccc(Cl)cc12 |t:8|, CN1CCN(CC1)C1=Cc2ccccc2Oc2ccc(Cl)cc12 |t:8|	OTKUTGIVEREJLL-UHFFFAOYSA-N, OTKUTGIVEREJLL-UHFFFAOYSA-N, OTKUTGIVEREJLL-UHFFFAOYSA-N, OTKUTGIVEREJLL-UHFFFAOYSA-N	Preclinical
2-deoxy-2-([methyl(nitroso)carbamoyl]amino)hexose			oncology, endocrinology	pancreatic cancer, hypoglycemia	CN([NH2+][O-])C(=O)N[C@@H](C=O)[C@@H](O)[C@@H](O)[C@@H](O)CO |&1:7,&2:10,&3:12,&4:14,r|	VUVHIMLGTHRGQZ-YTLHQDLWSA-N	Preclinical
2-deoxyglucose	glycolysis inhibitor	SLC2A1, SLC2A2, SLC2A3, SLC2A4			OC[C@H]1O[C@H](O)C[C@@H](O)[C@@H]1O, OC[C@H]1O[C@H](O)C[C@@H](O)[C@@H]1O, OC[C@H]1O[C@H](O)C[C@@H](O)[C@@H]1O	PMMURAAUARKVCB-ZXXMMSQZSA-N, PMMURAAUARKVCB-ZXXMMSQZSA-N, PMMURAAUARKVCB-ZXXMMSQZSA-N	Phase 2
2-ethoxybenzoic-acid	analgesic agent				CCOc1ccccc1C(O)=O	XDZMPRGFOOFSBL-UHFFFAOYSA-N	Phase 1
2-ethyl-1,3-hexanediol					CCC[C@@H](O)[C@@H](CC)CO |&1:3,&2:5,r|, CCC[C@@H](O)[C@@H](CC)CO |&1:3,&2:5,r|, CCC[C@@H](O)[C@@H](CC)CO |&1:3,&2:5,r|	RWLALWYNXFYRGW-JGVFFNPUSA-N, RWLALWYNXFYRGW-JGVFFNPUSA-N, RWLALWYNXFYRGW-JGVFFNPUSA-N	Preclinical
2-fluoro-2-deoxy-D-galactose		LCT			OC[C@H]1O[C@@H](O)[C@@H](F)[C@@H](O)[C@@H]1O |&1:2,&2:4,&3:6,&4:8,&5:10,r|	ZCXUVYAZINUVJD-AIECOIEWSA-N	Phase 1
2-fluorofucose					C[C@@H]1O[C@H](O)[C@@H](F)[C@H](O)[C@@H]1O |&1:3|	IRKXGKIPOMIQOD-QYESYBIKSA-N	Phase 1
2-hydroxy-4-((E)-3-(4-hydroxyphenyl)acryloyl)-2-((2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)-6-((2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)cyclohexane-1,3,5-trione					OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)[C@H]1C(=O)C(=C(O)\C=C\c2ccc(O)cc2)C(=O)[C@@](O)([C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)C1=O |a:2,4,5,7,9,30,32,35,37,39,&1:11,&2:14,&3:28|, OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)[C@H]1C(=O)C(=C(O)\C=C\c2ccc(O)cc2)C(=O)[C@@](O)([C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)C1=O |a:2,4,5,7,9,30,32,35,37,39,&1:11,&2:14,&3:28|	BWKBPVRNWJFLSC-FROSJQSHSA-N, BWKBPVRNWJFLSC-FROSJQSHSA-N	Preclinical
2-hydroxyethyl-salicylate			neurology/psychiatry	pain relief	OCCOC(=O)c1ccccc1O	LVYLCBNXHHHPSB-UHFFFAOYSA-N	Launched
2-hydroxyflutamide	androgen receptor antagonist	AR			CC(C)(O)C(=O)Nc1ccc(c(c1)C(F)(F)F)[N+]([O-])=O, CC(C)(O)C(=O)Nc1ccc(c(c1)C(F)(F)F)[N+]([O-])=O	YPQLFJODEKMJEF-UHFFFAOYSA-N, YPQLFJODEKMJEF-UHFFFAOYSA-N	Phase 2
2-hydroxysaclofen	GABA receptor antagonist	GABBR1, GABBR2			NC[C@@](O)(CS(O)(=O)=O)c1ccc(Cl)cc1 |&1:2,r|, NC[C@@](O)(CS(O)(=O)=O)c1ccc(Cl)cc1 |&1:2,r|, NC[C@@](O)(CS(O)(=O)=O)c1ccc(Cl)cc1 |&1:2,r|, NC[C@@](O)(CS(O)(=O)=O)c1ccc(Cl)cc1 |&1:2,r|, NC[C@@](O)(CS(O)(=O)=O)c1ccc(Cl)cc1 |&1:2,r|, NC[C@@](O)(CS(O)(=O)=O)c1ccc(Cl)cc1 |&1:2,r|, NC[C@@](O)(CS(O)(=O)=O)c1ccc(Cl)cc1 |&1:2,r|	WBSMZVIMANOCNX-SECBINFHSA-N, WBSMZVIMANOCNX-SECBINFHSA-N, WBSMZVIMANOCNX-SECBINFHSA-N, WBSMZVIMANOCNX-SECBINFHSA-N, WBSMZVIMANOCNX-SECBINFHSA-N, WBSMZVIMANOCNX-SECBINFHSA-N, WBSMZVIMANOCNX-SECBINFHSA-N	Preclinical
2-iminobiotin	nitric oxide synthase inhibitor	NOS1, NOS2			NC1=N[C@H]2CS[C@@H](CCCCC(O)=O)[C@H]2N1 |t:1|, NC1=N[C@H]2CS[C@@H](CCCCC(O)=O)[C@H]2N1 |t:1|	WWVANQJRLPIHNS-ZKWXMUAHSA-N, WWVANQJRLPIHNS-ZKWXMUAHSA-N	Phase 2
2-iodohippuric-acid					OC(=O)CNC(=O)c1ccccc1I, OC(=O)CNC(=O)c1ccccc1I	CORFWQGVBFFZHF-UHFFFAOYSA-N, CORFWQGVBFFZHF-UHFFFAOYSA-N	Preclinical
2-iodomelatonin	melatonin receptor agonist	MTNR1A, MTNR1B, NQO2			COc1ccc2[nH]c(I)c(CCNC(C)=O)c2c1, COc1ccc2[nH]c(I)c(CCNC(C)=O)c2c1	FJDDSMSDZHURBJ-UHFFFAOYSA-N, FJDDSMSDZHURBJ-UHFFFAOYSA-N	Preclinical
2-methoxyestradiol	hypoxia inducible factor inhibitor	COMT, CYP19A1, CYP1A1, CYP1B1, HIF1A, TUBB			COc1cc2[C@H]3CC[C@]4(C)[C@@H](O)CC[C@H]4[C@@H]3CCc2cc1O, COc1cc2[C@H]3CC[C@]4(C)[C@@H](O)CC[C@H]4[C@@H]3CCc2cc1O, COc1cc2[C@H]3CC[C@]4(C)[C@@H](O)CC[C@H]4[C@@H]3CCc2cc1O, COc1cc2[C@H]3CC[C@]4(C)[C@@H](O)CC[C@H]4[C@@H]3CCc2cc1O, COc1cc2[C@H]3CC[C@]4(C)[C@@H](O)CC[C@H]4[C@@H]3CCc2cc1O, COc1cc2[C@H]3CC[C@]4(C)[C@@H](O)CC[C@H]4[C@@H]3CCc2cc1O, COc1cc2[C@H]3CC[C@]4(C)[C@@H](O)CC[C@H]4[C@@H]3CCc2cc1O, COc1cc2[C@H]3CC[C@]4(C)[C@@H](O)CC[C@H]4[C@@H]3CCc2cc1O	CQOQDQWUFQDJMK-SSTWWWIQSA-N, CQOQDQWUFQDJMK-SSTWWWIQSA-N, CQOQDQWUFQDJMK-SSTWWWIQSA-N, CQOQDQWUFQDJMK-SSTWWWIQSA-N, CQOQDQWUFQDJMK-SSTWWWIQSA-N, CQOQDQWUFQDJMK-SSTWWWIQSA-N, CQOQDQWUFQDJMK-SSTWWWIQSA-N, CQOQDQWUFQDJMK-SSTWWWIQSA-N	Phase 2
2-methyl-5-hydroxytryptamine	serotonin receptor agonist	HTR1B, HTR1D, HTR1E, HTR1F, HTR3A, HTR3B, HTR6			Cc1[nH]c2ccc(O)cc2c1CCN, Cc1[nH]c2ccc(O)cc2c1CCN, Cc1[nH]c2ccc(O)cc2c1CCN	WYWNEDARFVJQSG-UHFFFAOYSA-N, WYWNEDARFVJQSG-UHFFFAOYSA-N, WYWNEDARFVJQSG-UHFFFAOYSA-N	Preclinical
2-methyl-5-nitrophenol					Cc1ccc(cc1O)[N+]([O-])=O, Cc1ccc(cc1O)[N+]([O-])=O	UMFDLIXUUJMPSI-UHFFFAOYSA-N, UMFDLIXUUJMPSI-UHFFFAOYSA-N	Preclinical
2-methylimidazole	cholesterol inhibitor				Cc1ncc[nH]1	LXBGSDVWAMZHDD-UHFFFAOYSA-N	Preclinical
2-octyldodecan-1-ol					CCCCCCCCCC[C@@H](CO)CCCCCCCC |&1:10,r|, CCCCCCCCCC[C@@H](CO)CCCCCCCC |&1:10,r|, CCCCCCCCCC[C@@H](CO)CCCCCCCC |&1:10,r|	LEACJMVNYZDSKR-FQEVSTJZSA-N, LEACJMVNYZDSKR-FQEVSTJZSA-N, LEACJMVNYZDSKR-FQEVSTJZSA-N	Preclinical
2-oleoylglycerol	glucose dependent insulinotropic receptor ligand	GPR119			CCCCCCCC\C=C/CCCCCCCC(=O)OC(CO)CO, CCCCCCCC\C=C/CCCCCCCC(=O)OC(CO)CO	UPWGQKDVAURUGE-KTKRTIGZSA-N, UPWGQKDVAURUGE-KTKRTIGZSA-N	Phase 1
2-oxoglutaric-acid		OXGR1			OC(=O)CCC(=O)C(O)=O, OC(=O)CCC(=O)C(O)=O	KPGXRSRHYNQIFN-UHFFFAOYSA-N, KPGXRSRHYNQIFN-UHFFFAOYSA-N	Preclinical
2-oxopropanoate	pyruvate dehydrogenase kinase inhibitor	ABAT			OC(=C)C(O)=O	FEWFXBUNENSNBQ-UHFFFAOYSA-N	Preclinical
2-phenylmelatonin	melatonin receptor agonist	MTNR1A, MTNR1B			COc1ccc2[nH]c(c(CCNC(C)=O)c2c1)-c1ccccc1, COc1ccc2[nH]c(c(CCNC(C)=O)c2c1)-c1ccccc1, COc1ccc2[nH]c(c(CCNC(C)=O)c2c1)-c1ccccc1, COc1ccc2[nH]c(c(CCNC(C)=O)c2c1)-c1ccccc1, COc1ccc2[nH]c(c(CCNC(C)=O)c2c1)-c1ccccc1	OFCLARYYBGKCHN-UHFFFAOYSA-N, OFCLARYYBGKCHN-UHFFFAOYSA-N, OFCLARYYBGKCHN-UHFFFAOYSA-N, OFCLARYYBGKCHN-UHFFFAOYSA-N, OFCLARYYBGKCHN-UHFFFAOYSA-N	Preclinical
2-PMDQ	adrenergic receptor antagonist	ADRA1A			O=C1Nc2ccccc2C2=N[C@@H](CN3CCN(CC3)c3ccccc3)CN12 |&1:11,r,t:10|, O=C1Nc2ccccc2C2=N[C@@H](CN3CCN(CC3)c3ccccc3)CN12 |&1:11,r,t:10|	ONSOQRPYFKDOEB-INIZCTEOSA-N, ONSOQRPYFKDOEB-INIZCTEOSA-N	Preclinical
2-pyridylethylamine	histamine receptor agonist	HRH1			NCCc1ccccn1, NCCc1ccccn1, NCCc1ccccn1	XPQIPUZPSLAZDV-UHFFFAOYSA-N, XPQIPUZPSLAZDV-UHFFFAOYSA-N, XPQIPUZPSLAZDV-UHFFFAOYSA-N	Preclinical
2-TEDC	lipoxygenase inhibitor	ALOX12			Oc1ccc(\C=C(/C#N)C(=O)OCCc2cccs2)cc1O, Oc1ccc(\C=C(/C#N)C(=O)OCCc2cccs2)cc1O	KCGLTUBCAGZLHP-XYOKQWHBSA-N, KCGLTUBCAGZLHP-XYOKQWHBSA-N	Preclinical
2-thiouracil					O=c1cc[nH]c(=S)[nH]1, O=c1cc[nH]c(=S)[nH]1, O=c1cc[nH]c(=S)[nH]1	ZEMGGZBWXRYJHK-UHFFFAOYSA-N, ZEMGGZBWXRYJHK-UHFFFAOYSA-N, ZEMGGZBWXRYJHK-UHFFFAOYSA-N	Preclinical
20-HETE	ion channel antagonist				OCCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O	NNDIXBJHNLFJJP-DTLRTWKJSA-N	Preclinical
20-hydroxyecdysone	ecdysone receptor modulator				CC(C)(O)CC[C@@H](O)[C@](C)(O)[C@@H]1CC[C@@]2(O)C3=CC(=O)[C@@H]4C[C@@H](O)[C@@H](O)C[C@]4(C)[C@@H]3CC[C@]12C |t:16|	NKDFYOWSKOHCCO-HMIIXLFTSA-N	Phase 2
3'-fluorobenzylspiperone	dopamine receptor ligand	DRD2			Fc1ccc(cc1)C(=O)CCCN1CCC2(CC1)N(CN(Cc1cccc(F)c1)C2=O)c1ccccc1, Fc1ccc(cc1)C(=O)CCCN1CCC2(CC1)N(CN(Cc1cccc(F)c1)C2=O)c1ccccc1, Fc1ccc(cc1)C(=O)CCCN1CCC2(CC1)N(CN(Cc1cccc(F)c1)C2=O)c1ccccc1, Fc1ccc(cc1)C(=O)CCCN1CCC2(CC1)N(CN(Cc1cccc(F)c1)C2=O)c1ccccc1	DXZKTRNEOISOCA-UHFFFAOYSA-N, DXZKTRNEOISOCA-UHFFFAOYSA-N, DXZKTRNEOISOCA-UHFFFAOYSA-N, DXZKTRNEOISOCA-UHFFFAOYSA-N	Preclinical
3,3'-dichlorobenzaldazine	glutamate receptor modulator	GRM5			Clc1cccc(\C=N\N=C\c2cccc(Cl)c2)c1, Clc1cccc(\C=N\N=C\c2cccc(Cl)c2)c1	XMOVWXSCYLINBJ-BEQMOXJMSA-N, XMOVWXSCYLINBJ-BEQMOXJMSA-N	Preclinical
3,3'-diindolylmethane	CHK inhibitor, cytochrome P450 activator, indoleamine 2,3-dioxygenase inhibitor	AR, HIF1A, IFNG, PI3			C(c1c[nH]c2ccccc12)c1c[nH]c2ccccc12, C(c1c[nH]c2ccccc12)c1c[nH]c2ccccc12, C(c1c[nH]c2ccccc12)c1c[nH]c2ccccc12	VFTRKSBEFQDZKX-UHFFFAOYSA-N, VFTRKSBEFQDZKX-UHFFFAOYSA-N, VFTRKSBEFQDZKX-UHFFFAOYSA-N	Phase 3
3,4-DCPG-(+/-)	glutamate receptor agonist	GRM8			N[C@@H](C(O)=O)c1ccc(C(O)=O)c(c1)C(O)=O |&1:1,r|, N[C@@H](C(O)=O)c1ccc(C(O)=O)c(c1)C(O)=O |&1:1,r|	IJVMOGKBEVRBPP-SSDOTTSWSA-N, IJVMOGKBEVRBPP-SSDOTTSWSA-N	Preclinical
3,4-DCPG-(R)	glutamate receptor antagonist				N[C@@H](C(O)=O)c1ccc(C(O)=O)c(c1)C(O)=O, N[C@@H](C(O)=O)c1ccc(C(O)=O)c(c1)C(O)=O	IJVMOGKBEVRBPP-SSDOTTSWSA-N, IJVMOGKBEVRBPP-SSDOTTSWSA-N	Preclinical
3,4-DCPG-(S)	glutamate receptor agonist	GRM8			N[C@H](C(O)=O)c1ccc(C(O)=O)c(c1)C(O)=O, N[C@H](C(O)=O)c1ccc(C(O)=O)c(c1)C(O)=O, N[C@H](C(O)=O)c1ccc(C(O)=O)c(c1)C(O)=O	IJVMOGKBEVRBPP-ZETCQYMHSA-N, IJVMOGKBEVRBPP-ZETCQYMHSA-N, IJVMOGKBEVRBPP-ZETCQYMHSA-N	Preclinical
3,4-methylenedioxy-beta-nitrostyrene	SRC inhibitor, SYK inhibitor	SRC, SYK			[O-][N+](=O)\C=C\c1ccc2OCOc2c1, [O-][N+](=O)\C=C\c1ccc2OCOc2c1, [O-][N+](=O)\C=C\c1ccc2OCOc2c1, [O-][N+](=O)\C=C\c1ccc2OCOc2c1, [O-][N+](=O)\C=C\c1ccc2OCOc2c1, [O-][N+](=O)\C=C\c1ccc2OCOc2c1	KFLWBZPSJQPRDD-ONEGZZNKSA-N, KFLWBZPSJQPRDD-ONEGZZNKSA-N, KFLWBZPSJQPRDD-ONEGZZNKSA-N, KFLWBZPSJQPRDD-ONEGZZNKSA-N, KFLWBZPSJQPRDD-ONEGZZNKSA-N, KFLWBZPSJQPRDD-ONEGZZNKSA-N	Preclinical
3,5-DHPG-(S)	glutamate receptor agonist	GRM1			N[C@H](C(O)=O)c1cc(O)cc(O)c1, N[C@H](C(O)=O)c1cc(O)cc(O)c1, N[C@H](C(O)=O)c1cc(O)cc(O)c1	HOOWCUZPEFNHDT-ZETCQYMHSA-N, HOOWCUZPEFNHDT-ZETCQYMHSA-N, HOOWCUZPEFNHDT-ZETCQYMHSA-N	Preclinical
3-(4-methylbenzylidene)camphor	endocrine disruptor		dermatology	sunscreen lotion	Cc1ccc(\C=C2\[C@H]3CC[C@@](C)(C2=O)C3(C)C)cc1 |&1:7,&2:10,r|, Cc1ccc(\C=C2\[C@H]3CC[C@@](C)(C2=O)C3(C)C)cc1 |&1:7,&2:10,r|	HEOCBCNFKCOKBX-LBONJMQPSA-N, HEOCBCNFKCOKBX-LBONJMQPSA-N	Launched
3-alpha-bis-(4-fluorophenyl)-methoxytropane	dopamine uptake inhibitor	CHRM1, SLC6A2, SLC6A3, SLC6A4			CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(c1ccc(F)cc1)c1ccc(F)cc1 |&1:2,5,7|	MHNSOBBJZCWUGS-PMOLBWCYSA-N	Preclinical
3-alpha-hydroxy-5-beta-androstan-17-one		HSD17B11, IGHG2, SULT2A1			C[C@]12CC[C@H]3[C@@H](CC[C@@H]4C[C@H](O)CC[C@]34C)[C@@H]1CCC2=O |a:1,5,8,10,14,16,&1:4|	QGXBDMJGAMFCBF-BNSUEQOYSA-N	Preclinical
3-amino-benzamide	PARP inhibitor	PARP1			NC(=O)c1cccc(N)c1, NC(=O)c1cccc(N)c1, NC(=O)c1cccc(N)c1	GSCPDZHWVNUUFI-UHFFFAOYSA-N, GSCPDZHWVNUUFI-UHFFFAOYSA-N, GSCPDZHWVNUUFI-UHFFFAOYSA-N	Phase 2
3-anilinopropan-1-ol					OCCCNc1ccccc1, OCCCNc1ccccc1	GZYBSURBYCLNSM-UHFFFAOYSA-N, GZYBSURBYCLNSM-UHFFFAOYSA-N	Preclinical
3-AQC	serotonin receptor agonist	HTR3A			C=CCN1CCN(CC1)c1nc2ccccc2nc1C#N, C=CCN1CCN(CC1)c1nc2ccccc2nc1C#N, C=CCN1CCN(CC1)c1nc2ccccc2nc1C#N	IDOXKFDPDOIUMG-UHFFFAOYSA-N, IDOXKFDPDOIUMG-UHFFFAOYSA-N, IDOXKFDPDOIUMG-UHFFFAOYSA-N	Preclinical
3-bromo-7-nitroindazole	nitric oxide synthase inhibitor	NOS1, NOS2, NOS3			[O-][N+](=O)c1cccc2c(Br)[nH]nc12, [O-][N+](=O)c1cccc2c(Br)[nH]nc12, [O-][N+](=O)c1cccc2c(Br)[nH]nc12, [O-][N+](=O)c1cccc2c(Br)[nH]nc12	NFSTZPMYAZRZPC-UHFFFAOYSA-N, NFSTZPMYAZRZPC-UHFFFAOYSA-N, NFSTZPMYAZRZPC-UHFFFAOYSA-N, NFSTZPMYAZRZPC-UHFFFAOYSA-N	Preclinical
3-bromocamphor					[H][C@]1(Br)[C@@H]2CC[C@@](C)(C1=O)C2(C)C |&1:1,3,6|	NJQADTYRAYFBJN-BYULHYEWSA-N	Launched
3-bromopyruvate	hexokinase inhibitor	HK2			OC(=O)C(O)=CBr, OC(=O)C(O)=CBr, OC(=O)C(O)=CBr	CHNJCELMWMIDSC-UHFFFAOYSA-N, CHNJCELMWMIDSC-UHFFFAOYSA-N, CHNJCELMWMIDSC-UHFFFAOYSA-N	Preclinical
3-carboxy-4-hydroxyphenylglycine-(R)	glutamate receptor antagonist	GRIN1, GRIN2A, GRIN2B, GRIN2C			N[C@@H](C(O)=O)c1ccc(O)c(c1)C(O)=O, N[C@@H](C(O)=O)c1ccc(O)c(c1)C(O)=O	CHZBCZTXSTWCIG-SSDOTTSWSA-N, CHZBCZTXSTWCIG-SSDOTTSWSA-N	Preclinical
3-carboxy-4-hydroxyphenylglycine-(S)	glutamate receptor antagonist	GRM1, GRM5			N[C@H](C(O)=O)c1ccc(O)c(c1)C(O)=O, N[C@H](C(O)=O)c1ccc(O)c(c1)C(O)=O	CHZBCZTXSTWCIG-ZETCQYMHSA-N, CHZBCZTXSTWCIG-ZETCQYMHSA-N	Preclinical
3-CPMT	dopamine reuptake inhibitor				CN1[C@H]2CC[C@@H]1C[C@@H](C2)O[C@H](c1ccccc1)c1ccc(Cl)cc1 |&1:2,5,7,&2:10,r,THB:0:1:3.4:6.7.8|	OCAXFDULERPAJM-IVAOSVALSA-N	Preclinical
3-deazaadenosine	adenosylhomocysteinase inhibitor	AHCY			Nc1nccc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O |a:10,12,&1:15,&2:17|	DBZQFUNLCALWDY-GPUHXXMPSA-N	Phase 2
3-deazaneplanocin-A	histone lysine methyltransferase inhibitor	EZH2			Nc1nccc2n(cnc12)[C@@H]1C=C(CO)[C@@H](O)[C@H]1O |t:13|, Nc1nccc2n(cnc12)[C@@H]1C=C(CO)[C@@H](O)[C@H]1O |t:13|, Nc1nccc2n(cnc12)[C@@H]1C=C(CO)[C@@H](O)[C@H]1O |t:13|, Nc1nccc2n(cnc12)[C@@H]1C=C(CO)[C@@H](O)[C@H]1O |t:13|	OMKHWTRUYNAGFG-IEBDPFPHSA-N, OMKHWTRUYNAGFG-IEBDPFPHSA-N, OMKHWTRUYNAGFG-IEBDPFPHSA-N, OMKHWTRUYNAGFG-IEBDPFPHSA-N	Preclinical
3-deazauridine	cytidine deaminase inhibitor				OC[C@H]1O[C@@H]([C@@H](O)[C@@H]1O)n1ccc(O)cc1=O |&1:2,&2:4,&3:5,&4:7,r|	CBOKZNLSFMZJJA-PRQTWWFRSA-N	Preclinical
3-hydroxy-3-phenylpentanamide	GABA receptor modulator				CC[C@@](O)(CC(N)=O)c1ccccc1 |&1:2,r|, CC[C@@](O)(CC(N)=O)c1ccccc1 |&1:2,r|	MOHYRCCDARWQRM-LLVKDONJSA-N, MOHYRCCDARWQRM-LLVKDONJSA-N	Phase 1
3-indolebutyric-acid		B2M, HLA-A, TRAC, TRBC1			OC(=O)CCCc1c[nH]c2ccccc12	JTEDVYBZBROSJT-UHFFFAOYSA-N	Preclinical
3-MATIDA	glutamate receptor antagonist	GRM1			Cc1cc(sc1[C@@H](N)C(O)=O)C(O)=O |&1:6,r|, Cc1cc(sc1[C@@H](N)C(O)=O)C(O)=O |&1:6,r|	KOMWRBFEDDEWEP-RXMQYKEDSA-N, KOMWRBFEDDEWEP-RXMQYKEDSA-N	Preclinical
3-methyl-GABA	GABA aminotransferase activator	ABAT			C[C@@H](CN)CC(O)=O |&1:1|, C[C@@H](CN)CC(O)=O |&1:1|	CZGLBWZXGIAIBU-SCSAIBSYSA-N, CZGLBWZXGIAIBU-SCSAIBSYSA-N	Preclinical
3-methyladenine	PI3K inhibitor	PI3			Cn1cnc(=N)c2[nH]cnc12, Cn1cnc(=N)c2[nH]cnc12, Cn1cnc(=N)c2[nH]cnc12	ZPBYVFQJHWLTFB-UHFFFAOYSA-N, ZPBYVFQJHWLTFB-UHFFFAOYSA-N, ZPBYVFQJHWLTFB-UHFFFAOYSA-N	Preclinical
3-MPPI	adrenergic receptor ligand	ADRA1A			COc1ccccc1N1CCN(CCn2c(=O)[nH]c3c4ccccc4[nH]c3c2=O)CC1, COc1ccccc1N1CCN(CCn2c(=O)[nH]c3c4ccccc4[nH]c3c2=O)CC1, COc1ccccc1N1CCN(CCn2c(=O)[nH]c3c4ccccc4[nH]c3c2=O)CC1	AQASGOHUMGAWJJ-UHFFFAOYSA-N, AQASGOHUMGAWJJ-UHFFFAOYSA-N, AQASGOHUMGAWJJ-UHFFFAOYSA-N	Preclinical
3PO	phosphofructokinase inhibitor	PFKFB3			O=C(\C=C\c1cccnc1)c1ccncc1, O=C(\C=C\c1cccnc1)c1ccncc1	UOWGYMNWMDNSTL-ONEGZZNKSA-N, UOWGYMNWMDNSTL-ONEGZZNKSA-N	Preclinical
4,4'-DDT					Clc1ccc(cc1)C(c1ccc(Cl)cc1)C(Cl)(Cl)Cl	YVGGHNCTFXOJCH-UHFFFAOYSA-N	Preclinical
4,4-pentamethylenepiperidine	M2 channel blocker				C1CCC2(CC1)CCNCC2, C1CCC2(CC1)CCNCC2	LIZKZVQBLDHKCY-UHFFFAOYSA-N, LIZKZVQBLDHKCY-UHFFFAOYSA-N	Preclinical
4,5,6,7-tetrabromobenzotriazole	casein kinase inhibitor	AKT1, CHEK1, CSNK2A1, GSK3B, LCK, MAP2K1, MAPK1, MAPK11, MAPK12, MAPK14, MAPK8, PRKCA, ROCK1, RPS6KB1, SGK1			Brc1c(Br)c(Br)c2n[nH]nc2c1Br, Brc1c(Br)c(Br)c2n[nH]nc2c1Br, Brc1c(Br)c(Br)c2n[nH]nc2c1Br, Brc1c(Br)c(Br)c2n[nH]nc2c1Br	OMZYUVOATZSGJY-UHFFFAOYSA-N, OMZYUVOATZSGJY-UHFFFAOYSA-N, OMZYUVOATZSGJY-UHFFFAOYSA-N, OMZYUVOATZSGJY-UHFFFAOYSA-N	Preclinical
4-(aminomethyl)benzoic-acid	hemostatic agent				NCc1ccc(cc1)C(O)=O	QCTBMLYLENLHLA-UHFFFAOYSA-N	Preclinical
4-(4-fluorobenzoyl)-1-(4-phenylbutyl)-piperidine	serotonin receptor antagonist	HTR2A			Fc1ccc(cc1)C(=O)C1CCN(CCCCc2ccccc2)CC1, Fc1ccc(cc1)C(=O)C1CCN(CCCCc2ccccc2)CC1, Fc1ccc(cc1)C(=O)C1CCN(CCCCc2ccccc2)CC1, Fc1ccc(cc1)C(=O)C1CCN(CCCCc2ccccc2)CC1	FTJXZACAQRDRNT-UHFFFAOYSA-N, FTJXZACAQRDRNT-UHFFFAOYSA-N, FTJXZACAQRDRNT-UHFFFAOYSA-N, FTJXZACAQRDRNT-UHFFFAOYSA-N	Preclinical
4-acetyl-1,1-dimethylpiperazinium	acetylcholine receptor agonist				CC(=O)N1CC[N+](C)(C)CC1, CC(=O)N1CC[N+](C)(C)CC1	MSBLMBWXUVQCDY-UHFFFAOYSA-N, MSBLMBWXUVQCDY-UHFFFAOYSA-N	Preclinical
4-aminohippuric-acid		SLC22A6	nephrology	renal diagnostic agent	Nc1ccc(cc1)C(=O)NCC(O)=O, Nc1ccc(cc1)C(=O)NCC(O)=O, Nc1ccc(cc1)C(=O)NCC(O)=O, Nc1ccc(cc1)C(=O)NCC(O)=O, Nc1ccc(cc1)C(=O)NCC(O)=O	HSMNQINEKMPTIC-UHFFFAOYSA-N, HSMNQINEKMPTIC-UHFFFAOYSA-N, HSMNQINEKMPTIC-UHFFFAOYSA-N, HSMNQINEKMPTIC-UHFFFAOYSA-N, HSMNQINEKMPTIC-UHFFFAOYSA-N	Launched
4-carboxy-3-hydroxyphenylglycine-(RS)	glutamate receptor agonist, glutamate receptor antagonist	GRM1			N[C@@H](C(O)=O)c1ccc(C(O)=O)c(O)c1 |&1:1,r|, N[C@@H](C(O)=O)c1ccc(C(O)=O)c(O)c1 |&1:1,r|	GXZSAQLJWLCLOX-SSDOTTSWSA-N, GXZSAQLJWLCLOX-SSDOTTSWSA-N	Preclinical
4-carboxy-3-hydroxyphenylglycine-(S)	glutamate receptor agonist, glutamate receptor antagonist	GRM1, GRM2			N[C@H](C(O)=O)c1ccc(C(O)=O)c(O)c1, N[C@H](C(O)=O)c1ccc(C(O)=O)c(O)c1	GXZSAQLJWLCLOX-ZETCQYMHSA-N, GXZSAQLJWLCLOX-ZETCQYMHSA-N	Preclinical
4-chlorophenylguanidine	urokinase inhibitor	PLAUR			NC(=N)Nc1ccc(Cl)cc1, NC(=N)Nc1ccc(Cl)cc1	ZSJNJAJDBNFVCA-UHFFFAOYSA-N, ZSJNJAJDBNFVCA-UHFFFAOYSA-N	Preclinical
4-CMTB	free fatty acid receptor agonist	FFAR2			CC(C)[C@@H](C(=O)Nc1nccs1)c1ccc(Cl)cc1 |&1:3,r|, CC(C)[C@@H](C(=O)Nc1nccs1)c1ccc(Cl)cc1 |&1:3,r|, CC(C)[C@@H](C(=O)Nc1nccs1)c1ccc(Cl)cc1 |&1:3,r|	AZYDQCGCBQYFSE-GFCCVEGCSA-N, AZYDQCGCBQYFSE-GFCCVEGCSA-N, AZYDQCGCBQYFSE-GFCCVEGCSA-N	Preclinical
4-DAMP	cholinergic receptor antagonist	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5			C[N+]1(C)CCC(CC1)OC(=O)C(c1ccccc1)c1ccccc1, C[N+]1(C)CCC(CC1)OC(=O)C(c1ccccc1)c1ccccc1	HYJRTXSYDAFGJK-UHFFFAOYSA-N, HYJRTXSYDAFGJK-UHFFFAOYSA-N	Preclinical
4-galactosyllactose					OC[C@H]1O[C@@H](O[C@@H]2[C@H](O)[C@@H](O)[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)O[C@@H]3CO)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O |a:2,4,6,7,9,11,13,14,16,21,25,28,30,32,&1:18|	FYGDTMLNYKFZSV-QGAOIPDPSA-N	Preclinical
4-HQN	PARP inhibitor	PARP1			O=c1nc[nH]c2ccccc12, O=c1nc[nH]c2ccccc12	QMNUDYFKZYBWQX-UHFFFAOYSA-N, QMNUDYFKZYBWQX-UHFFFAOYSA-N	Preclinical
4-hydroxy-phenazone					Cc1c(O)c(=O)n(-c2ccccc2)n1C, Cc1c(O)c(=O)n(-c2ccccc2)n1C, Cc1c(O)c(=O)n(-c2ccccc2)n1C	SKVPTPMWXJSBTF-UHFFFAOYSA-N, SKVPTPMWXJSBTF-UHFFFAOYSA-N, SKVPTPMWXJSBTF-UHFFFAOYSA-N	Preclinical
4-IBP	sigma receptor agonist	SIGMAR1			Ic1ccc(cc1)C(=O)NC1CCN(Cc2ccccc2)CC1	HELCSESNNDZLFM-UHFFFAOYSA-N	Preclinical
4-iodo-L-phenylalanine		DPP4			N[C@H](Cc1ccc(I)cc1)C(O)=O, N[C@H](Cc1ccc(I)cc1)C(O)=O	PZNQZSRPDOEBMS-MRVPVSSYSA-N, PZNQZSRPDOEBMS-MRVPVSSYSA-N	Preclinical
4-iodo-6-phenylpyrimidine	macrophage migration inhibiting factor inhibitor	MIF			Ic1cc(ncn1)-c1ccccc1	ZTCJXHNJVLUUMR-UHFFFAOYSA-N	Preclinical
4-methylgenistein	protein tyrosine kinase inhibitor	CYP19A1, ESRRA, ESRRB, ESRRG, FASN			COc1ccc(cc1)-c1coc2cc(O)cc(O)c2c1=O	WUADCCWRTIWANL-UHFFFAOYSA-N	Preclinical
4-methylhistamine	histamine receptor agonist	HRH4			Cc1nc[nH]c1CCN	UGYXPZQILZRKJJ-UHFFFAOYSA-N	Preclinical
4-mu-8C	IRE1 inhibitor	ERN1			Cc1cc(=O)oc2c(C=O)c(O)ccc12, Cc1cc(=O)oc2c(C=O)c(O)ccc12, Cc1cc(=O)oc2c(C=O)c(O)ccc12, Cc1cc(=O)oc2c(C=O)c(O)ccc12, Cc1cc(=O)oc2c(C=O)c(O)ccc12	RTHHSXOVIJWFQP-UHFFFAOYSA-N, RTHHSXOVIJWFQP-UHFFFAOYSA-N, RTHHSXOVIJWFQP-UHFFFAOYSA-N, RTHHSXOVIJWFQP-UHFFFAOYSA-N, RTHHSXOVIJWFQP-UHFFFAOYSA-N	Preclinical
4-P-PDOT	melatonin receptor antagonist	MTNR1A, MTNR1B			CCC(=O)N[C@H]1C[C@@H](c2ccccc2)c2ccccc2C1 |&1:5,7|	RCYLUNPFECYGDW-AEFFLSMTSA-N	Preclinical
4-phenolsulfonic-acid					Oc1ccc(cc1)S(O)(=O)=O	FEPBITJSIHRMRT-UHFFFAOYSA-N	Preclinical
4-phenyl-1,2,3,4-tetrahydroisoquinoline	dopamine release inhibitor				C1NCc2ccccc2[C@@H]1c1ccccc1 |&1:9,r|, C1NCc2ccccc2[C@@H]1c1ccccc1 |&1:9,r|	OSZMNJRKIPAVOS-HNNXBMFYSA-N, OSZMNJRKIPAVOS-HNNXBMFYSA-N	Preclinical
4-PPBP	sigma receptor ligand	SIGMAR1			C(CCc1ccccc1)CN1CCC(CC1)c1ccccc1, C(CCc1ccccc1)CN1CCC(CC1)c1ccccc1, C(CCc1ccccc1)CN1CCC(CC1)c1ccccc1	HQGDPZPNAXRCSA-UHFFFAOYSA-N, HQGDPZPNAXRCSA-UHFFFAOYSA-N, HQGDPZPNAXRCSA-UHFFFAOYSA-N	Preclinical
4-propylbenzoic-acid					CCCc1ccc(cc1)C(O)=O	ATZHGRNFEFVDDJ-UHFFFAOYSA-N	Preclinical
4-pyrimidinecarbonitrile					N#Cc1ccncn1	ZIEWSZYVEDTXGH-UHFFFAOYSA-N	Preclinical
4-tert-butylphenol					CC(C)(C)c1ccc(O)cc1, CC(C)(C)c1ccc(O)cc1	QHPQWRBYOIRBIT-UHFFFAOYSA-N, QHPQWRBYOIRBIT-UHFFFAOYSA-N	Preclinical
4BP-TQS	nicotinic receptor agonist	CHRNA7			NS(=O)(=O)c1ccc2N[C@@H]([C@H]3CC=C[C@@H]3c2c1)c1ccc(Br)cc1 |&1:9,&2:10,&3:14,r,c:12|, NS(=O)(=O)c1ccc2N[C@@H]([C@H]3CC=C[C@@H]3c2c1)c1ccc(Br)cc1 |&1:9,&2:10,&3:14,r,c:12|	YNCXHXYZTLIZTO-RLFYNMQTSA-N, YNCXHXYZTLIZTO-RLFYNMQTSA-N	Preclinical
4EGI-1	protein synthesis inhibitor	EIF4E			OC(=O)C(Cc1ccccc1[N+]([O-])=O)=NNc1nc(cs1)-c1ccc(Cl)c(Cl)c1	KFRKRECSIYXARE-UHFFFAOYSA-N	Preclinical
4E1RCat	protein synthesis inhibitor	EIF4E, EIF4G1			OC(=O)c1ccc(cc1)N1C(=O)\C(=C\c2ccc(o2)-c2ccc(cc2)[N+]([O-])=O)C=C1c1ccccc1 |c:31|, OC(=O)c1ccc(cc1)N1C(=O)\C(=C\c2ccc(o2)-c2ccc(cc2)[N+]([O-])=O)C=C1c1ccccc1 |c:31|, OC(=O)c1ccc(cc1)N1C(=O)\C(=C\c2ccc(o2)-c2ccc(cc2)[N+]([O-])=O)C=C1c1ccccc1 |c:31|, OC(=O)c1ccc(cc1)N1C(=O)\C(=C\c2ccc(o2)-c2ccc(cc2)[N+]([O-])=O)C=C1c1ccccc1 |c:31|, OC(=O)c1ccc(cc1)N1C(=O)\C(=C\c2ccc(o2)-c2ccc(cc2)[N+]([O-])=O)C=C1c1ccccc1 |c:31|	BBQRBOIMSKMFFO-LTGZKZEYSA-N, BBQRBOIMSKMFFO-LTGZKZEYSA-N, BBQRBOIMSKMFFO-LTGZKZEYSA-N, BBQRBOIMSKMFFO-LTGZKZEYSA-N, BBQRBOIMSKMFFO-LTGZKZEYSA-N	Preclinical
4SC-202	HDAC inhibitor	HDAC1			Cn1cc(cn1)-c1ccc(cc1)S(=O)(=O)n1ccc(\C=C\C(=O)Nc2ccccc2N)c1, Cn1cc(cn1)-c1ccc(cc1)S(=O)(=O)n1ccc(\C=C\C(=O)Nc2ccccc2N)c1, Cn1cc(cn1)-c1ccc(cc1)S(=O)(=O)n1ccc(\C=C\C(=O)Nc2ccccc2N)c1, Cn1cc(cn1)-c1ccc(cc1)S(=O)(=O)n1ccc(\C=C\C(=O)Nc2ccccc2N)c1, Cn1cc(cn1)-c1ccc(cc1)S(=O)(=O)n1ccc(\C=C\C(=O)Nc2ccccc2N)c1, Cn1cc(cn1)-c1ccc(cc1)S(=O)(=O)n1ccc(\C=C\C(=O)Nc2ccccc2N)c1, Cn1cc(cn1)-c1ccc(cc1)S(=O)(=O)n1ccc(\C=C\C(=O)Nc2ccccc2N)c1, Cn1cc(cn1)-c1ccc(cc1)S(=O)(=O)n1ccc(\C=C\C(=O)Nc2ccccc2N)c1	PRXXYMVLYKJITB-IZZDOVSWSA-N, PRXXYMVLYKJITB-IZZDOVSWSA-N, PRXXYMVLYKJITB-IZZDOVSWSA-N, PRXXYMVLYKJITB-IZZDOVSWSA-N, PRXXYMVLYKJITB-IZZDOVSWSA-N, PRXXYMVLYKJITB-IZZDOVSWSA-N, PRXXYMVLYKJITB-IZZDOVSWSA-N, PRXXYMVLYKJITB-IZZDOVSWSA-N	Phase 1
5'-chloro-5'-deoxy-ENBA-(+/-)	adenosine receptor agonist	ADORA1			O[C@@H]1[C@@H](CCl)O[C@H]([C@@H]1O)n1cnc2c(N[C@H]3C[C@@H]4CC[C@H]3C4)ncnc12 |a:1,2,6,7,&1:17,20,&2:15|	PVJGDYDNVNCGBT-CYDCOVMPSA-N	Preclinical
5,7-dichlorokynurenic-acid	glutamate receptor antagonist	GLRA2, GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D			OC(=O)c1cc(=O)c2c(Cl)cc(Cl)cc2[nH]1, OC(=O)c1cc(=O)c2c(Cl)cc(Cl)cc2[nH]1, OC(=O)c1cc(=O)c2c(Cl)cc(Cl)cc2[nH]1	BGKFPRIGXAVYNX-UHFFFAOYSA-N, BGKFPRIGXAVYNX-UHFFFAOYSA-N, BGKFPRIGXAVYNX-UHFFFAOYSA-N	Preclinical
5-(4chlorophenyl)-4-ethyl-2,4-dihydro-3H-1,2,4-triazol-3-one					CCn1c(n[nH]c1=O)-c1ccc(Cl)cc1	PXINDYJACXPZIN-UHFFFAOYSA-N	Preclinical
5-amino-3-D-ribofuranosylthiazolo[4,5-d]pyrimidin-2,7(3H,6H)-dione		TLR7			Nc1nc(=O)c2sc(=O)n([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c2[nH]1	TZYVRXZQAWPIAB-FCLHUMLKSA-N	Preclinical
5-aminolevulinic-acid	oxidizing agent	ALAD	oncology, dermatology	glioma, actinic keratosis (AK)	NCC(=O)CCC(O)=O, NCC(=O)CCC(O)=O	ZGXJTSGNIOSYLO-UHFFFAOYSA-N, ZGXJTSGNIOSYLO-UHFFFAOYSA-N	Launched
5-BDBD	purinergic receptor antagonist	P2RX4			Brc1cccc(c1)C1=NCC(=O)Nc2c1oc1ccccc21 |t:8|, Brc1cccc(c1)C1=NCC(=O)Nc2c1oc1ccccc21 |t:8|, Brc1cccc(c1)C1=NCC(=O)Nc2c1oc1ccccc21 |t:8|, Brc1cccc(c1)C1=NCC(=O)Nc2c1oc1ccccc21 |t:8|, Brc1cccc(c1)C1=NCC(=O)Nc2c1oc1ccccc21 |t:8|, Brc1cccc(c1)C1=NCC(=O)Nc2c1oc1ccccc21 |t:8|	NKYMVQPXXTZHSF-UHFFFAOYSA-N, NKYMVQPXXTZHSF-UHFFFAOYSA-N, NKYMVQPXXTZHSF-UHFFFAOYSA-N, NKYMVQPXXTZHSF-UHFFFAOYSA-N, NKYMVQPXXTZHSF-UHFFFAOYSA-N, NKYMVQPXXTZHSF-UHFFFAOYSA-N	Preclinical
5-carboxamidotryptamine	serotonin receptor agonist	HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2B, HTR2C, HTR5A, HTR6, HTR7			NCCc1c[nH]c2ccc(cc12)C(N)=O, NCCc1c[nH]c2ccc(cc12)C(N)=O	WKZLNEWVIAGNAW-UHFFFAOYSA-N, WKZLNEWVIAGNAW-UHFFFAOYSA-N	Preclinical
5-fluoro-3-pyridyl-methanol					OCc1cncc(F)c1	GGGJYJXAFSEWNM-UHFFFAOYSA-N	Preclinical
5-fluoropyrimidine	kinase inhibitor				Fc1cncnc1	KSPDSMOWMQFPBL-UHFFFAOYSA-N	Phase 3
5-fluorouracil	thymidylate synthase inhibitor	DPYD, TYMS	oncology	colorectal cancer, breast cancer, pancreatic cancer, gastric adenocarcinoma	Fc1c[nH]c(=O)[nH]c1=O, Fc1c[nH]c(=O)[nH]c1=O, Fc1c[nH]c(=O)[nH]c1=O, Fc1c[nH]c(=O)[nH]c1=O, Fc1c[nH]c(=O)[nH]c1=O	GHASVSINZRGABV-UHFFFAOYSA-N, GHASVSINZRGABV-UHFFFAOYSA-N, GHASVSINZRGABV-UHFFFAOYSA-N, GHASVSINZRGABV-UHFFFAOYSA-N, GHASVSINZRGABV-UHFFFAOYSA-N	Launched
5-FP	thymidylate synthase inhibitor	TYMS			Fc1cnc(=O)[nH]c1, Fc1cnc(=O)[nH]c1	HPABFFGQPLJKBP-UHFFFAOYSA-N, HPABFFGQPLJKBP-UHFFFAOYSA-N	Phase 1
5-HMF					OCc1ccc(C=O)o1, OCc1ccc(C=O)o1, OCc1ccc(C=O)o1	NOEGNKMFWQHSLB-UHFFFAOYSA-N, NOEGNKMFWQHSLB-UHFFFAOYSA-N, NOEGNKMFWQHSLB-UHFFFAOYSA-N	Phase 2
5-hydroxydecanoic-acid					CCCCC[C@@H](O)CCCC(O)=O |&1:5|	LMHJFKYQYDSOQO-SECBINFHSA-N	Preclinical
5-hydroxyectoine					CC1=NC[C@H](O)[C@H](N1)C(O)=O |t:1|, CC1=NC[C@H](O)[C@H](N1)C(O)=O |t:1|, CC1=NC[C@H](O)[C@H](N1)C(O)=O |t:1|	KIIBBJKLKFTNQO-WHFBIAKZSA-N, KIIBBJKLKFTNQO-WHFBIAKZSA-N, KIIBBJKLKFTNQO-WHFBIAKZSA-N	Preclinical
5-hydroxymethyl-tolterodine	acetylcholine receptor antagonist	CHRM3			CC(C)N(CC[C@H](c1ccccc1)c1cc(CO)ccc1O)C(C)C, CC(C)N(CC[C@H](c1ccccc1)c1cc(CO)ccc1O)C(C)C, CC(C)N(CC[C@H](c1ccccc1)c1cc(CO)ccc1O)C(C)C, CC(C)N(CC[C@H](c1ccccc1)c1cc(CO)ccc1O)C(C)C	DUXZAXCGJSBGDW-HXUWFJFHSA-N, DUXZAXCGJSBGDW-HXUWFJFHSA-N, DUXZAXCGJSBGDW-HXUWFJFHSA-N, DUXZAXCGJSBGDW-HXUWFJFHSA-N	Phase 1
5-hydroxytryptophan	neurotransmitter	SLC36A1, SLC36A2	neurology/psychiatry	insomnia	N[C@@H](Cc1c[nH]c2ccc(O)cc12)C(O)=O |&1:1,r|, N[C@@H](Cc1c[nH]c2ccc(O)cc12)C(O)=O |&1:1,r|, N[C@@H](Cc1c[nH]c2ccc(O)cc12)C(O)=O |&1:1,r|	LDCYZAJDBXYCGN-VIFPVBQESA-N, LDCYZAJDBXYCGN-VIFPVBQESA-N, LDCYZAJDBXYCGN-VIFPVBQESA-N	Launched
5-iodo-A-85380	acetylcholine receptor agonist				Ic1cncc(OC[C@@H]2CCN2)c1, Ic1cncc(OC[C@@H]2CCN2)c1	RKVRGRXOYDTUEY-QMMMGPOBSA-N, RKVRGRXOYDTUEY-QMMMGPOBSA-N	Phase 2
5-methylfurmethiodide	acetylcholine receptor agonist	CHRM1, CHRM2, CHRM3, CHRM4			Cc1ccc(C[N+](C)(C)C)o1, Cc1ccc(C[N+](C)(C)C)o1	KOWVJDFMEZKDDT-UHFFFAOYSA-N, KOWVJDFMEZKDDT-UHFFFAOYSA-N	Preclinical
5-methylhydantoin-(D)					C[C@H]1NC(=O)NC1=O, C[C@H]1NC(=O)NC1=O	VMAQYKGITHDWKL-UWTATZPHSA-N, VMAQYKGITHDWKL-UWTATZPHSA-N	Preclinical
5-methylhydantoin-(L)					C[C@@H]1NC(=O)NC1=O	VMAQYKGITHDWKL-REOHCLBHSA-N	Preclinical
5-octanoylsalicylic-acid	protein kinase activator				CCCCCCCC(=O)c1ccc(O)c(c1)C(O)=O	IXIGWKNBFPKCCD-UHFFFAOYSA-N	Preclinical
6,7-dehydro-17-acetoxy-progesterone	steroidal progestin				CC(=O)O[C@@]1(CC[C@H]2[C@@H]3C=CC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)=O |c:9,t:11|, CC(=O)O[C@@]1(CC[C@H]2[C@@H]3C=CC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)=O |c:9,t:11|, CC(=O)O[C@@]1(CC[C@H]2[C@@H]3C=CC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)=O |c:9,t:11|	URXWVWVPMJSAJD-KOORYGTMSA-N, URXWVWVPMJSAJD-KOORYGTMSA-N, URXWVWVPMJSAJD-KOORYGTMSA-N	Preclinical
6-aminochrysene	transferase inhibitor				Nc1cc2c3ccccc3ccc2c2ccccc12	KIVUHCNVDWYUNP-UHFFFAOYSA-N	Phase 2
6-aminopenicillanic-acid					CC1(C)S[C@@H]2[C@H](N)C(=O)N2[C@H]1C(O)=O, CC1(C)S[C@@H]2[C@H](N)C(=O)N2[C@H]1C(O)=O	NGHVIOIJCVXTGV-ALEPSDHESA-N, NGHVIOIJCVXTGV-ALEPSDHESA-N	Preclinical
6-benzylaminopurine	purinergic receptor activator				C(Nc1ncnc2nc[nH]c12)c1ccccc1, C(Nc1ncnc2nc[nH]c12)c1ccccc1, C(Nc1ncnc2nc[nH]c12)c1ccccc1	NWBJYWHLCVSVIJ-UHFFFAOYSA-N, NWBJYWHLCVSVIJ-UHFFFAOYSA-N, NWBJYWHLCVSVIJ-UHFFFAOYSA-N	Preclinical
6-chloromelatonin	melatonin receptor agonist	MTNR1A, MTNR1B			COc1cc2c(CCNC(C)=O)c[nH]c2cc1Cl, COc1cc2c(CCNC(C)=O)c[nH]c2cc1Cl, COc1cc2c(CCNC(C)=O)c[nH]c2cc1Cl, COc1cc2c(CCNC(C)=O)c[nH]c2cc1Cl	LUINDDOUWHRIPW-UHFFFAOYSA-N, LUINDDOUWHRIPW-UHFFFAOYSA-N, LUINDDOUWHRIPW-UHFFFAOYSA-N, LUINDDOUWHRIPW-UHFFFAOYSA-N	Preclinical
6-diazo-5-oxo-L-norleucine	glutamate receptor antagonist, glutaminase inhibitor				N[C@@H](CCC(=O)C[N+]#N)C(O)=O, N[C@@H](CCC(=O)C[N+]#N)C(O)=O	UUTYCZUIECRVAL-YFKPBYRVSA-O, UUTYCZUIECRVAL-YFKPBYRVSA-O	Preclinical
6-iodo-nordihydrocapsaicin	TRPV antagonist	TRPV1			CCCCCCCCC(=O)NCc1cc(OC)c(O)cc1I, CCCCCCCCC(=O)NCc1cc(OC)c(O)cc1I	AAORACFZMYMFCG-UHFFFAOYSA-N, AAORACFZMYMFCG-UHFFFAOYSA-N	Preclinical
7,8,9,10-tetrahydroazepino[2,1-b]quinazolin-12(6H)-one					O=C1N2CCCCC=C2Nc2ccccc12 |c:7|	HBEJFHWHFIAMAI-UHFFFAOYSA-N	Preclinical
7-aminocephalosporanic-acid	beta lactamase inhibitor				CC(=O)OCC1=C(N2[C@H](SC1)[C@H](N)C2=O)C(O)=O |t:5|, CC(=O)OCC1=C(N2[C@H](SC1)[C@H](N)C2=O)C(O)=O |t:5|	HSHGZXNAXBPPDL-HZGVNTEJSA-N, HSHGZXNAXBPPDL-HZGVNTEJSA-N	Preclinical
7-chlorokynurenic-acid	glutamate receptor antagonist	GRIN1, GRIN2A, GRIN2B, GRIN2C			OC(=O)c1cc(=O)c2ccc(Cl)cc2[nH]1, OC(=O)c1cc(=O)c2ccc(Cl)cc2[nH]1, OC(=O)c1cc(=O)c2ccc(Cl)cc2[nH]1, OC(=O)c1cc(=O)c2ccc(Cl)cc2[nH]1	UAWVRVFHMOSAPU-UHFFFAOYSA-N, UAWVRVFHMOSAPU-UHFFFAOYSA-N, UAWVRVFHMOSAPU-UHFFFAOYSA-N, UAWVRVFHMOSAPU-UHFFFAOYSA-N	Preclinical
7-hydroxy-DPAT	dopamine receptor agonist	DRD2, DRD3			CCCN(CCC)[C@H]1CCc2ccc(O)cc2C1 |&1:7|, CCCN(CCC)[C@H]1CCc2ccc(O)cc2C1 |&1:7|, CCCN(CCC)[C@H]1CCc2ccc(O)cc2C1 |&1:7|, CCCN(CCC)[C@H]1CCc2ccc(O)cc2C1 |&1:7|	BLYMJBIZMIGWFK-HNNXBMFYSA-N, BLYMJBIZMIGWFK-HNNXBMFYSA-N, BLYMJBIZMIGWFK-HNNXBMFYSA-N, BLYMJBIZMIGWFK-HNNXBMFYSA-N	Preclinical
7-hydroxy-PIPAT	dopamine receptor ligand	DRD3			CCCN(C\C=C\I)[C@H]1CCc2ccc(O)cc2C1 |&1:8|	RTMIJLQPWFKAFE-GZTQLTBSSA-N	Preclinical
7-hydroxystaurosporine	CDK inhibitor, CHK inhibitor, PKC inhibitor	CDK1, CHEK1, CHEK2, GSK3B, LCK, MAPK14, MARK1, MARK3, PDPK1, PRKCA, PRKCB, PRKCD, PRKCE, PRKCG			CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4[C@H](O)NC(=O)c4c4c5ccccc5n2c4c13, CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4[C@H](O)NC(=O)c4c4c5ccccc5n2c4c13, CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4[C@H](O)NC(=O)c4c4c5ccccc5n2c4c13	PBCZSGKMGDDXIJ-KRUBCLEUSA-N, PBCZSGKMGDDXIJ-KRUBCLEUSA-N, PBCZSGKMGDDXIJ-KRUBCLEUSA-N	Phase 2
7-keto-DHEA	steroid				CC(=O)O[C@H]1CC[C@]2(C)[C@H]3CC[C@@]4(C)[C@@H](CCC4=O)[C@@H]3C(=O)C=C2C1 |c:24|	VVSMJVQHDZUPIL-XFKPDKBWSA-N	Launched
7-methoxytacrine	acetylcholinesterase inhibitor	ACHE			COc1ccc2nc3CCCCc3c(N)c2c1, COc1ccc2nc3CCCCc3c(N)c2c1	APQPVVOYBLOJDY-UHFFFAOYSA-N, APQPVVOYBLOJDY-UHFFFAOYSA-N	Phase 2
7-methylxanthine	adenosine receptor antagonist				Cn1cnc2[nH]c(=O)[nH]c(=O)c12, Cn1cnc2[nH]c(=O)[nH]c(=O)c12, Cn1cnc2[nH]c(=O)[nH]c(=O)c12	PFWLFWPASULGAN-UHFFFAOYSA-N, PFWLFWPASULGAN-UHFFFAOYSA-N, PFWLFWPASULGAN-UHFFFAOYSA-N	Phase 2
7-nitroindazole	nitric oxide synthase inhibitor	NOS1, NOS2, NOS3			[O-][N+](=O)c1cccc2c[nH]nc12, [O-][N+](=O)c1cccc2c[nH]nc12, [O-][N+](=O)c1cccc2c[nH]nc12	PQCAUHUKTBHUSA-UHFFFAOYSA-N, PQCAUHUKTBHUSA-UHFFFAOYSA-N, PQCAUHUKTBHUSA-UHFFFAOYSA-N	Preclinical
8-bromo-cAMP	PKA activator				Nc1ncnc2n([C@@H]3O[C@@H]4CO[P@](O)(=O)O[C@H]4[C@H]3O)c(Br)nc12 |a:7,9,16,17,&1:12|, Nc1ncnc2n([C@@H]3O[C@@H]4CO[P@](O)(=O)O[C@H]4[C@H]3O)c(Br)nc12 |a:7,9,16,17,&1:12|, Nc1ncnc2n([C@@H]3O[C@@H]4CO[P@](O)(=O)O[C@H]4[C@H]3O)c(Br)nc12 |a:7,9,16,17,&1:12|, Nc1ncnc2n([C@@H]3O[C@@H]4CO[P@](O)(=O)O[C@H]4[C@H]3O)c(Br)nc12 |a:7,9,16,17,&1:12|, Nc1ncnc2n([C@@H]3O[C@@H]4CO[P@](O)(=O)O[C@H]4[C@H]3O)c(Br)nc12 |a:7,9,16,17,&1:12|	DVKQVRZMKBDMDH-UUOKFMHZSA-N, DVKQVRZMKBDMDH-UUOKFMHZSA-N, DVKQVRZMKBDMDH-UUOKFMHZSA-N, DVKQVRZMKBDMDH-UUOKFMHZSA-N, DVKQVRZMKBDMDH-UUOKFMHZSA-N	Preclinical
8-bromo-cGMP	PKA activator	PRKG1			Nc1nc(=O)c2nc(Br)n([C@@H]3O[C@@H]4CO[P@](O)(=O)O[C@H]4[C@H]3O)c2[nH]1 |a:10,12,19,20,&1:15|, Nc1nc(=O)c2nc(Br)n([C@@H]3O[C@@H]4CO[P@](O)(=O)O[C@H]4[C@H]3O)c2[nH]1 |a:10,12,19,20,&1:15|, Nc1nc(=O)c2nc(Br)n([C@@H]3O[C@@H]4CO[P@](O)(=O)O[C@H]4[C@H]3O)c2[nH]1 |a:10,12,19,20,&1:15|, Nc1nc(=O)c2nc(Br)n([C@@H]3O[C@@H]4CO[P@](O)(=O)O[C@H]4[C@H]3O)c2[nH]1 |a:10,12,19,20,&1:15|	YUFCOOWNNHGGOD-UMMCILCDSA-N, YUFCOOWNNHGGOD-UMMCILCDSA-N, YUFCOOWNNHGGOD-UMMCILCDSA-N, YUFCOOWNNHGGOD-UMMCILCDSA-N	Preclinical
8-hydroxy-DPAT	serotonin receptor agonist	HTR5A, HTR7			CCCN(CCC)[C@H]1CCc2cccc(O)c2C1 |&1:7|, CCCN(CCC)[C@H]1CCc2cccc(O)c2C1 |&1:7|	ASXGJMSKWNBENU-AWEZNQCLSA-N, ASXGJMSKWNBENU-AWEZNQCLSA-N	Preclinical
8-hydroxy-PIPAT	dopamine receptor ligand	DRD2, DRD3			CCCN(C\C=C\I)[C@H]1CCc2cccc(O)c2C1 |&1:8|, CCCN(C\C=C\I)[C@H]1CCc2cccc(O)c2C1 |&1:8|	QBXHUZJZYDSLRH-MDDUGHTDSA-N, QBXHUZJZYDSLRH-MDDUGHTDSA-N	Preclinical
8-M-PDOT	melatonin receptor agonist	MTNR1A, MTNR1B			CCC(=O)N[C@H]1CCc2cccc(OC)c2C1 |&1:5,r|, CCC(=O)N[C@H]1CCc2cccc(OC)c2C1 |&1:5,r|	RVIGBTUDFAGRTQ-NSHDSACASA-N, RVIGBTUDFAGRTQ-NSHDSACASA-N	Preclinical
80841-78-7					Cc1oc(=O)oc1CCl	QCLFSYYUWPUWQR-UHFFFAOYSA-N	Preclinical
9-aminoacridine					Nc1c2ccccc2nc2ccccc12, Nc1c2ccccc2nc2ccccc12, Nc1c2ccccc2nc2ccccc12, Nc1c2ccccc2nc2ccccc12, Nc1c2ccccc2nc2ccccc12	XJGFWWJLMVZSIG-UHFFFAOYSA-N, XJGFWWJLMVZSIG-UHFFFAOYSA-N, XJGFWWJLMVZSIG-UHFFFAOYSA-N, XJGFWWJLMVZSIG-UHFFFAOYSA-N, XJGFWWJLMVZSIG-UHFFFAOYSA-N	Preclinical
9-aminocamptothecin	topoisomerase inhibitor	TOP1			CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4cccc(N)c4cc3Cn1c2=O, CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4cccc(N)c4cc3Cn1c2=O	FUXVKZWTXQUGMW-FQEVSTJZSA-N, FUXVKZWTXQUGMW-FQEVSTJZSA-N	Phase 2
9-anthracenecarboxylic-acid		ANO1, CLCN1			OC(=O)c1c2ccccc2cc2ccccc12, OC(=O)c1c2ccccc2cc2ccccc12	XGWFJBFNAQHLEF-UHFFFAOYSA-N, XGWFJBFNAQHLEF-UHFFFAOYSA-N	Preclinical
